(dp1
S'have,a,clinically'
p2
(F1
F0.00028669724770642203
I0
I2
I-2
tp3
sS'as,marplan,parnate'
p4
(F1
F0.00014334862385321102
I0
I1
I-1
tp5
sS'tmax,by,and'
p6
(F1
F0.00014334862385321102
I1
I0
I1
tp7
sS'and,inhibits,the'
p8
(F1
F0.00014334862385321102
I1
I0
I1
tp9
sS'pediatric,powder,for'
p10
(F1
F0.0010034403669724771
I7
I0
I7
tp11
sS'secretion,may,impair'
p12
(F1
F0.00014334862385321102
I0
I1
I-1
tp13
sS'concluded,that,modulates'
p14
(F1
F0.00014334862385321102
I1
I0
I1
tp15
sS'hypertension,was,controlled'
p16
(F1
F0.00014334862385321102
I1
I0
I1
tp17
sS'significant,effect,after'
p18
(F1
F0.00014334862385321102
I0
I1
I-1
tp19
sS'may,also,interact'
p20
(F1
F0.00014334862385321102
I0
I1
I-1
tp21
sS'and,the,fractional'
p22
(F1
F0.00014334862385321102
I0
I1
I-1
tp23
sS'treated,with,the'
p24
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp25
sS'with,a,risk'
p26
(F1
F0.00014334862385321102
I0
I1
I-1
tp27
sS'fumarate,did,not'
p28
(F1
F0.00014334862385321102
I0
I1
I-1
tp29
sS'therefore,when,meclofenamate'
p30
(F1
F0.00014334862385321102
I1
I0
I1
tp31
sS'of,concomitantly,with'
p32
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33
sS'beta-blocking,agents,the'
p34
(F1
F0.00014334862385321102
I0
I1
I-1
tp35
sS'interactive,effect,on'
p36
(F1
F0.00028669724770642203
I0
I2
I-2
tp37
sS'feso4,or,supplemented'
p38
(F1
F0.00014334862385321102
I1
I0
I1
tp39
sS'potentiate,a,possible'
p40
(F1
F0.00014334862385321102
I1
I0
I1
tp41
sS'uricosuric,agents,the'
p42
(F1
F0.00014334862385321102
I0
I1
I-1
tp43
sS'increases,and,decreases'
p44
(F1
F0.00014334862385321102
I1
I0
I1
tp45
sS'readings,were,reported'
p46
(F1
F0.00014334862385321102
I0
I1
I-1
tp47
sS'suggest,a,possible'
p48
(F1
F0.00043004587155963305
I3
I0
I3
tp49
sS'sampling,for,the'
p50
(F1
F0.00014334862385321102
I0
I1
I-1
tp51
sS'supplementary,oral,and'
p52
(F1
F0.00014334862385321102
I0
I1
I-1
tp53
sS'four,times,a'
p54
(F1
F0.00014334862385321102
I0
I1
I-1
tp55
sS'enzyme,would,not'
p56
(F1
F0.00014334862385321102
I0
I1
I-1
tp57
sS'inhibits,both,aldehyde'
p58
(F1
F0.00014334862385321102
I1
I0
I1
tp59
sS'and,with,reduced'
p60
(F1
F0.00014334862385321102
I1
I0
I1
tp61
sS'inhibitor,because,of'
p62
(F1
F0.00014334862385321102
I0
I1
I-1
tp63
sS'administration,of,once'
p64
(F1
F0.00014334862385321102
I1
I0
I1
tp65
sS'minimally,elevated,by'
p66
(F1
F0.00014334862385321102
I0
I1
I-1
tp67
sS'exert,particular,caution'
p68
(F1
F0.00014334862385321102
I1
I0
I1
tp69
sS'racemic,combined,administration'
p70
(F0
F0
I1
I1
I0
tp71
sS'of,saline,g'
p72
(F1
F0.00014334862385321102
I0
I1
I-1
tp73
sS'disposition,of,was'
p74
(F1
F0.00014334862385321102
I0
I1
I-1
tp75
sS'patients,who,require'
p76
(F1
F0.00028669724770642203
I0
I2
I-2
tp77
sS'by,about,three-fold'
p78
(F1
F0.00014334862385321102
I0
I1
I-1
tp79
sS'with,ibandronate,mg'
p80
(F1
F0.00014334862385321102
I0
I1
I-1
tp81
sS'use,of,levo-dromoran'
p82
(F1
F0.00014334862385321102
I1
I0
I1
tp83
sS'agents,no,effect'
p84
(F1
F0.00014334862385321102
I0
I1
I-1
tp85
sS'serum,levels,has'
p86
(F1
F0.00014334862385321102
I1
I0
I1
tp87
sS'potentiate,the,hypotension'
p88
(F1
F0.00014334862385321102
I1
I0
I1
tp89
sS'of,is,reduced'
p90
(F1
F0.00014334862385321102
I1
I0
I1
tp91
sS'multi-day,course,of'
p92
(F1
F0.00014334862385321102
I1
I0
I1
tp93
sS'other,drugs,at'
p94
(F1
F0.00014334862385321102
I0
I1
I-1
tp95
sS'concentration,of,was'
p96
(F1
F0.00014334862385321102
I0
I1
I-1
tp97
sS'did,not,increase'
p98
(F1
F0.00043004587155963305
I0
I3
I-3
tp99
sS'associated,with,a'
p100
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp101
sS'pharmacokinetics,of,higher'
p102
(F1
F0.00014334862385321102
I0
I1
I-1
tp103
sS'ponstel,and,is'
p104
(F1
F0.00014334862385321102
I1
I0
I1
tp105
sS'the,myocardium,may'
p106
(F1
F0.00014334862385321102
I1
I0
I1
tp107
sS'of,n-acetyltransferase,may'
p108
(F1
F0.00014334862385321102
I1
I0
I1
tp109
sS'folic,acid,antagonists'
p110
(F1
F0.00014334862385321102
I1
I0
I1
tp111
sS'as,part,of'
p112
(F1
F0.00014334862385321102
I0
I1
I-1
tp113
sS'dpcpx-induced,anxiogenic,effects'
p114
(F1
F0.00014334862385321102
I1
I0
I1
tp115
sS'toxicity,and,should'
p116
(F1
F0.00014334862385321102
I0
I1
I-1
tp117
sS'or,the,pharmacokinetics'
p118
(F1
F0.00014334862385321102
I0
I1
I-1
tp119
sS'of,the,systemic'
p120
(F1
F0.00014334862385321102
I1
I0
I1
tp121
sS'that,inhibit,metabolism'
p122
(F1
F0.00014334862385321102
I0
I1
I-1
tp123
sS'other,channel,blockers'
p124
(F1
F0.00014334862385321102
I1
I0
I1
tp125
sS'kg,per,day'
p126
(F1
F0.00014334862385321102
I1
I0
I1
tp127
sS'medications,may,be'
p128
(F1
F0.00014334862385321102
I1
I0
I1
tp129
sS'to,and,during'
p130
(F1
F0.00014334862385321102
I0
I1
I-1
tp131
sS'the,study,with'
p132
(F1
F0.00014334862385321102
I0
I1
I-1
tp133
sS'with,and,have'
p134
(F1
F0.00014334862385321102
I0
I1
I-1
tp135
sS'is,a,theoretical'
p136
(F1
F0.00028669724770642203
I2
I0
I2
tp137
sS'rifampin,may,decrease'
p138
(F1
F0.00014334862385321102
I1
I0
I1
tp139
sS'a,diminished,response'
p140
(F1
F0.00014334862385321102
I1
I0
I1
tp141
sS'to,a,single'
p142
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp143
sS'normal,metab-olizers,resemble'
p144
(F1
F0.00014334862385321102
I0
I1
I-1
tp145
sS'in,decreased,efficacy'
p146
(F1
F0.00014334862385321102
I1
I0
I1
tp147
sS'both,as,compared'
p148
(F1
F0.00014334862385321102
I1
I0
I1
tp149
sS'does,not,interact'
p150
(F1
F0.00014334862385321102
I0
I1
I-1
tp151
sS'induction,of,apoptosis'
p152
(F1
F0.00014334862385321102
I0
I1
I-1
tp153
sS'contribution,to,the'
p154
(F1
F0.00014334862385321102
I0
I1
I-1
tp155
sS'to,units,day'
p156
(F1
F0.00014334862385321102
I0
I1
I-1
tp157
sS'acth,may,potentiate'
p158
(F1
F0.00014334862385321102
I1
I0
I1
tp159
sS'inhibitors,are,known'
p160
(F1
F0.00014334862385321102
I0
I1
I-1
tp161
sS'as,not,be'
p162
(F1
F0.00014334862385321102
I1
I0
I1
tp163
sS'the,intravenous,injection'
p164
(F1
F0.00014334862385321102
I1
I0
I1
tp165
sS'bolus-ifl,in,combination'
p166
(F1
F0.00014334862385321102
I0
I1
I-1
tp167
sS'myopathy,rhabdomyolysis,is'
p168
(F1
F0.00028669724770642203
I2
I0
I2
tp169
sS'interaction,studies,have'
p170
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp171
sS'reverse,transcriptase,inhibitors'
p172
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp173
sS'of,produced,a'
p174
(F1
F0.00014334862385321102
I1
I0
I1
tp175
sS'symptoms,occur,physicians'
p176
(F1
F0.00014334862385321102
I1
I0
I1
tp177
sS'concurrently,with,central'
p178
(F1
F0.00014334862385321102
I1
I0
I1
tp179
sS'enhance,s,nephrotoxicity'
p180
(F1
F0.00014334862385321102
I0
I1
I-1
tp181
sS'corticosteroids,dexamethasone,aprepitant'
p182
(F1
F0.00014334862385321102
I1
I0
I1
tp183
sS'of,bradycardia,sinus'
p184
(F1
F0.00014334862385321102
I0
I1
I-1
tp185
sS'blood,glucose,lowering'
p186
(F1
F0.00014334862385321102
I1
I0
I1
tp187
sS'concentrates,or,prothrombin'
p188
(F1
F0.00014334862385321102
I0
I1
I-1
tp189
sS'plasma,renin,activity'
p190
(F1
F0.00014334862385321102
I0
I1
I-1
tp191
sS'dosed,simultaneously,with'
p192
(F1
F0.00014334862385321102
I1
I0
I1
tp193
sS'that,inhibit,this'
p194
(F1
F0.00028669724770642203
I2
I0
I2
tp195
sS'may,rise,resulting'
p196
(F1
F0.00014334862385321102
I0
I1
I-1
tp197
sS'and,tnf,blocking'
p198
(F1
F0.00014334862385321102
I0
I1
I-1
tp199
sS'may,have,synergistic'
p200
(F1
F0.00014334862385321102
I1
I0
I1
tp201
sS'by,blocking,the'
p202
(F1
F0.00014334862385321102
I1
I0
I1
tp203
sS'again,given,by'
p204
(F1
F0.00014334862385321102
I0
I1
I-1
tp205
sS'excretion,of,and'
p206
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp207
sS'inhaler,take,first'
p208
(F1
F0.00014334862385321102
I1
I0
I1
tp209
sS'than,has,not'
p210
(F1
F0.00014334862385321102
I0
I1
I-1
tp211
sS'n,demonstrated,that'
p212
(F1
F0.00014334862385321102
I0
I1
I-1
tp213
sS'human,breast,cancer'
p214
(F1
F0.00014334862385321102
I1
I0
I1
tp215
sS'congestive,heart,failure'
p216
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp217
sS'of,renal,function'
p218
(F1
F0.00014334862385321102
I1
I0
I1
tp219
sS'only,slightly,reduced'
p220
(F1
F0.00014334862385321102
I1
I0
I1
tp221
sS'since,is,the'
p222
(F1
F0.00014334862385321102
I1
I0
I1
tp223
sS'hydrochloride,including,anti-arrhythmic'
p224
(F1
F0.00014334862385321102
I0
I1
I-1
tp225
sS'more,possibly,due'
p226
(F1
F0.00014334862385321102
I1
I0
I1
tp227
sS'decreased,protein,binding'
p228
(F1
F0.00014334862385321102
I1
I0
I1
tp229
sS'examine,some,molecular'
p230
(F1
F0.00014334862385321102
I0
I1
I-1
tp231
sS'subjects,receiving,both'
p232
(F0
F0
I1
I1
I0
tp233
sS'completion,of,dosing'
p234
(F1
F0.00014334862385321102
I1
I0
I1
tp235
sS'patients,receiving,both'
p236
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp237
sS'physicians,should,consider'
p238
(F1
F0.00028669724770642203
I2
I0
I2
tp239
sS'effect,of,beta-adrenoceptor'
p240
(F1
F0.00028669724770642203
I2
I0
I2
tp241
sS'noted,at,the'
p242
(F1
F0.00014334862385321102
I0
I1
I-1
tp243
sS'therapy,with,bextra'
p244
(F1
F0.00028669724770642203
I2
I0
I2
tp245
sS'disease,in,general'
p246
(F1
F0.00014334862385321102
I0
I1
I-1
tp247
sS'and,s-warfarin,and'
p248
(F1
F0.00014334862385321102
I1
I0
I1
tp249
sS'medline,premedline,and'
p250
(F1
F0.00014334862385321102
I0
I1
I-1
tp251
sS'and,its,two'
p252
(F1
F0.00014334862385321102
I0
I1
I-1
tp253
sS'depressed,in,a'
p254
(F1
F0.00014334862385321102
I1
I0
I1
tp255
sS'cautiously,in,the'
p256
(F1
F0.00014334862385321102
I1
I0
I1
tp257
sS'normalized,ratio,inr'
p258
(F1
F0.00014334862385321102
I1
I0
I1
tp259
sS'signalled-unsignalled,differential-reinforcement,of-low'
p260
(F1
F0.00014334862385321102
I0
I1
I-1
tp261
sS'adjustments,patients,may'
p262
(F1
F0.00014334862385321102
I1
I0
I1
tp263
sS'is,a,newly'
p264
(F1
F0.00014334862385321102
I0
I1
I-1
tp265
sS'equetrotm,is,taken'
p266
(F1
F0.00014334862385321102
I1
I0
I1
tp267
sS'were,pharmacokinetic,parameters'
p268
(F1
F0.00014334862385321102
I0
I1
I-1
tp269
sS'volunteers,toradoloral,was'
p270
(F1
F0.00014334862385321102
I0
I1
I-1
tp271
sS'tysabri,dose,to'
p272
(F1
F0.00014334862385321102
I0
I1
I-1
tp273
sS'urinary,alkalinizing,agents'
p274
(F1
F0.00014334862385321102
I1
I0
I1
tp275
sS'infusion,rates,of'
p276
(F1
F0.00014334862385321102
I1
I0
I1
tp277
sS'lexapro,and,had'
p278
(F1
F0.00014334862385321102
I0
I1
I-1
tp279
sS'bleeding,have,also'
p280
(F1
F0.00014334862385321102
I1
I0
I1
tp281
sS'local,since,the'
p282
(F1
F0.00014334862385321102
I1
I0
I1
tp283
sS'which,involved,concomitant'
p284
(F1
F0.00014334862385321102
I1
I0
I1
tp285
sS'ace,inhibitors,during'
p286
(F1
F0.00028669724770642203
I2
I0
I2
tp287
sS'concentration,which,was'
p288
(F1
F0.00014334862385321102
I0
I1
I-1
tp289
sS'bone,loss,between'
p290
(F1
F0.00028669724770642203
I0
I2
I-2
tp291
sS'cells,that,were'
p292
(F1
F0.00014334862385321102
I1
I0
I1
tp293
sS'enhance,activity,transient'
p294
(F1
F0.00014334862385321102
I1
I0
I1
tp295
sS'beta,blockers,concurrently'
p296
(F1
F0.00014334862385321102
I0
I1
I-1
tp297
sS'postmarketing,experience,there'
p298
(F1
F0.00014334862385321102
I0
I1
I-1
tp299
sS'oil-concomitant,intake,of'
p300
(F1
F0.00014334862385321102
I1
I0
I1
tp301
sS'of,the,to'
p302
(F1
F0.00028669724770642203
I0
I2
I-2
tp303
sS'paroxetine,coadministration,of'
p304
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp305
sS'a,weak,inducer'
p306
(F1
F0.00014334862385321102
I0
I1
I-1
tp307
sS'steroidal,antiinflammatory,agent'
p308
(F1
F0.00014334862385321102
I1
I0
I1
tp309
sS'much,more,severe'
p310
(F1
F0.00014334862385321102
I0
I1
I-1
tp311
sS'drug-drug,interactions,have'
p312
(F1
F0.00028669724770642203
I0
I2
I-2
tp313
sS'of,stimulation,and'
p314
(F1
F0.00014334862385321102
I0
I1
I-1
tp315
sS'days,and,increased'
p316
(F1
F0.00014334862385321102
I1
I0
I1
tp317
sS'gastrointestinal,events,in'
p318
(F1
F0.00014334862385321102
I0
I1
I-1
tp319
sS'failure,and,av'
p320
(F1
F0.00014334862385321102
I0
I1
I-1
tp321
sS'inducer,decreased,auc'
p322
(F1
F0.00014334862385321102
I1
I0
I1
tp323
sS'hydroxide,containing,for'
p324
(F1
F0.00014334862385321102
I1
I0
I1
tp325
sS'inducer,may,be'
p326
(F1
F0.00014334862385321102
I1
I0
I1
tp327
sS'may,increase,absorption'
p328
(F1
F0.00014334862385321102
I1
I0
I1
tp329
sS'meal,h,following'
p330
(F1
F0.00014334862385321102
I1
I0
I1
tp331
sS'e,mesylate,injection'
p332
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp333
sS'be,clinically,significant'
p334
(F0
F0
I1
I1
I0
tp335
sS'infusions,myelosuppression,was'
p336
(F1
F0.00014334862385321102
I1
I0
I1
tp337
sS'and,profound,sedation'
p338
(F1
F0.00014334862385321102
I1
I0
I1
tp339
sS'vioxx,mg,administered'
p340
(F1
F0.00014334862385321102
I1
I0
I1
tp341
sS'literature,article,reported'
p342
(F1
F0.00014334862385321102
I1
I0
I1
tp343
sS'implants,and,injectables'
p344
(F1
F0.00014334862385321102
I0
I1
I-1
tp345
sS'macrolide,such,as'
p346
(F0
F0
I1
I1
I0
tp347
sS'of,felbatol,as'
p348
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp349
sS'ethopropazine,may,interact'
p350
(F1
F0.00014334862385321102
I1
I0
I1
tp351
sS'days,decreased,the'
p352
(F1
F0.00014334862385321102
I1
I0
I1
tp353
sS'atracurium,was,again'
p354
(F1
F0.00014334862385321102
I0
I1
I-1
tp355
sS'of,felbatol,at'
p356
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp357
sS'hydroalcoholic,solutions,containing'
p358
(F1
F0.00014334862385321102
I0
I1
I-1
tp359
sS'interaction,include,the'
p360
(F1
F0.00028669724770642203
I0
I2
I-2
tp361
sS'however,patients,on'
p362
(F1
F0.00014334862385321102
I1
I0
I1
tp363
sS'not,associated,with'
p364
(F1
F0.00028669724770642203
I0
I2
I-2
tp365
sS'concomitantly,with,potent'
p366
(F1
F0.00014334862385321102
I1
I0
I1
tp367
sS'containing,preparations,sunscreens'
p368
(F1
F0.00014334862385321102
I1
I0
I1
tp369
sS'performed,with,caution'
p370
(F1
F0.00028669724770642203
I2
I0
I2
tp371
sS'novolog,with,of'
p372
(F1
F0.00014334862385321102
I0
I1
I-1
tp373
sS'sprycel,must,be'
p374
(F1
F0.00014334862385321102
I0
I1
I-1
tp375
sS'in,this,study'
p376
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp377
sS'unlikely,that,this'
p378
(F1
F0.00014334862385321102
I0
I1
I-1
tp379
sS'fluid,were,increased'
p380
(F1
F0.00014334862385321102
I1
I0
I1
tp381
sS'mg,qd,increased'
p382
(F1
F0.00014334862385321102
I1
I0
I1
tp383
sS'combination,with,maois'
p384
(F1
F0.00014334862385321102
I1
I0
I1
tp385
sS'dependent,oxidation,is'
p386
(F1
F0.00014334862385321102
I0
I1
I-1
tp387
sS'were,and,increases'
p388
(F1
F0.00014334862385321102
I0
I1
I-1
tp389
sS'indocin,does,not'
p390
(F1
F0.00014334862385321102
I0
I1
I-1
tp391
sS'd,dosage,of'
p392
(F1
F0.00014334862385321102
I1
I0
I1
tp393
sS'increased,the,area'
p394
(F1
F0.00014334862385321102
I1
I0
I1
tp395
sS'oxidase,inhibitors,coadministration'
p396
(F1
F0.00014334862385321102
I1
I0
I1
tp397
sS'showed,that,had'
p398
(F1
F0.00014334862385321102
I0
I1
I-1
tp399
sS'dyspnea,concomitant,administration'
p400
(F1
F0.00014334862385321102
I1
I0
I1
tp401
sS'inspra,mg,with'
p402
(F1
F0.00014334862385321102
I1
I0
I1
tp403
sS'a,is,also'
p404
(F1
F0.00028669724770642203
I2
I0
I2
tp405
sS'been,evaluated,in'
p406
(F1
F0.00057339449541284407
I0
I4
I-4
tp407
sS'of,the,possible'
p408
(F0
F0
I1
I1
I0
tp409
sS'extent,of,dissolution'
p410
(F1
F0.00014334862385321102
I0
I1
I-1
tp411
sS'tricor,and,hmg-coa'
p412
(F1
F0.00014334862385321102
I1
I0
I1
tp413
sS'clinical,dose,of'
p414
(F1
F0.00014334862385321102
I0
I1
I-1
tp415
sS'and,or,prolongation'
p416
(F1
F0.00014334862385321102
I1
I0
I1
tp417
sS'diabetic,chinese,hamster'
p418
(F1
F0.00014334862385321102
I0
I1
I-1
tp419
sS'a,reliable,method'
p420
(F1
F0.00014334862385321102
I1
I0
I1
tp421
sS'dose,of,in'
p422
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp423
sS'that,had,no'
p424
(F1
F0.00014334862385321102
I0
I1
I-1
tp425
sS'ccnu,is,given'
p426
(F1
F0.00014334862385321102
I0
I1
I-1
tp427
sS'm,enhance,the'
p428
(F1
F0.00014334862385321102
I1
I0
I1
tp429
sS'any,changes,in'
p430
(F1
F0.00043004587155963305
I0
I3
I-3
tp431
sS'known,to,interfere'
p432
(F1
F0.00043004587155963305
I0
I3
I-3
tp433
sS'foradil,fumarate,capsules'
p434
(F1
F0.00014334862385321102
I0
I1
I-1
tp435
sS'this,drug,interaction'
p436
(F1
F0.00014334862385321102
I0
I1
I-1
tp437
sS'dose,of,is'
p438
(F1
F0.00014334862385321102
I0
I1
I-1
tp439
sS'of,enbrel,was'
p440
(F1
F0.00014334862385321102
I0
I1
I-1
tp441
sS'of,with,did'
p442
(F1
F0.00014334862385321102
I0
I1
I-1
tp443
sS'the,data,presented'
p444
(F1
F0.00014334862385321102
I0
I1
I-1
tp445
sS'inhibitor,plus,experienced'
p446
(F1
F0.00014334862385321102
I1
I0
I1
tp447
sS'elimination,and,distribution'
p448
(F1
F0.00014334862385321102
I0
I1
I-1
tp449
sS'or,s,nor'
p450
(F1
F0.00014334862385321102
I0
I1
I-1
tp451
sS'dopamine,antagonists,since'
p452
(F1
F0.00014334862385321102
I1
I0
I1
tp453
sS'and,cause,cardio'
p454
(F1
F0.00014334862385321102
I0
I1
I-1
tp455
sS'at,the,lowest'
p456
(F1
F0.00014334862385321102
I1
I0
I1
tp457
sS'and,prolonged,by'
p458
(F1
F0.00014334862385321102
I1
I0
I1
tp459
sS'taking,amevive,who'
p460
(F1
F0.00014334862385321102
I0
I1
I-1
tp461
sS'that,the,plasma'
p462
(F1
F0.00014334862385321102
I0
I1
I-1
tp463
sS'of,trimethyl,lead'
p464
(F1
F0.00014334862385321102
I0
I1
I-1
tp465
sS'bumetanide-induced,increase,in'
p466
(F1
F0.00014334862385321102
I1
I0
I1
tp467
sS'the,potent,cyp3a4'
p468
(F1
F0.00043004587155963305
I3
I0
I3
tp469
sS'given,concomitantly,including'
p470
(F1
F0.00014334862385321102
I0
I1
I-1
tp471
sS'has,been,one'
p472
(F1
F0.00014334862385321102
I1
I0
I1
tp473
sS'diminished,prothrombin,response'
p474
(F1
F0.00014334862385321102
I1
I0
I1
tp475
sS'interactions,occurred,when'
p476
(F1
F0.00028669724770642203
I0
I2
I-2
tp477
sS'concentrations,below,the'
p478
(F1
F0.00014334862385321102
I1
I0
I1
tp479
sS'ethinyl,estradiol,levels'
p480
(F1
F0.00014334862385321102
I1
I0
I1
tp481
sS'should,be,minimized'
p482
(F1
F0.00014334862385321102
I1
I0
I1
tp483
sS'of,theophylline,mg'
p484
(F1
F0.00014334862385321102
I0
I1
I-1
tp485
sS'combining,these,agents'
p486
(F1
F0.00014334862385321102
I0
I1
I-1
tp487
sS'of,akathisia,in'
p488
(F1
F0.00014334862385321102
I1
I0
I1
tp489
sS'to,various,combinations'
p490
(F1
F0.00014334862385321102
I0
I1
I-1
tp491
sS'theophylline-related,side-effects,in'
p492
(F1
F0.00014334862385321102
I1
I0
I1
tp493
sS'of,elimination,the'
p494
(F1
F0.00014334862385321102
I1
I0
I1
tp495
sS'discontinuation,of,therapy'
p496
(F1
F0.00014334862385321102
I1
I0
I1
tp497
sS'n1,while,attenuating'
p498
(F1
F0.00014334862385321102
I1
I0
I1
tp499
sS'and,the,effects'
p500
(F1
F0.00028669724770642203
I2
I0
I2
tp501
sS'significant,reductions,in'
p502
(F1
F0.00014334862385321102
I1
I0
I1
tp503
sS'hypoglycemics,initiating,replacement'
p504
(F1
F0.00014334862385321102
I0
I1
I-1
tp505
sS'time,is,to'
p506
(F1
F0.00014334862385321102
I1
I0
I1
tp507
sS'eg,commonly,results'
p508
(F1
F0.00014334862385321102
I1
I0
I1
tp509
sS'cases,of,increased'
p510
(F1
F0.00014334862385321102
I1
I0
I1
tp511
sS'of,aed,on'
p512
(F1
F0.00014334862385321102
I0
I1
I-1
tp513
sS'formally,evaluated,in'
p514
(F1
F0.00014334862385321102
I0
I1
I-1
tp515
sS'dietary,salt,restriction'
p516
(F1
F0.00014334862385321102
I1
I0
I1
tp517
sS'resistant,to,the'
p518
(F1
F0.00014334862385321102
I1
I0
I1
tp519
sS'close,observation,of'
p520
(F1
F0.00028669724770642203
I2
I0
I2
tp521
sS'renal,clearance,and'
p522
(F1
F0.0010034403669724771
I7
I0
I7
tp523
sS'coadministration,loratadine,mg'
p524
(F1
F0.00014334862385321102
I0
I1
I-1
tp525
sS'the,serum,half-life'
p526
(F1
F0.00014334862385321102
I1
I0
I1
tp527
sS'raise,the,serum'
p528
(F1
F0.00028669724770642203
I2
I0
I2
tp529
sS'had,liver,injury'
p530
(F1
F0.00014334862385321102
I0
I1
I-1
tp531
sS'necessary,when,simulect'
p532
(F1
F0.00014334862385321102
I0
I1
I-1
tp533
sS'increased,auc,by'
p534
(F1
F0.00014334862385321102
I0
I1
I-1
tp535
sS'medications,with,orencia'
p536
(F1
F0.00014334862385321102
I0
I1
I-1
tp537
sS'with,the,adverse'
p538
(F1
F0.00014334862385321102
I0
I1
I-1
tp539
sS'subject,to,p450-based'
p540
(F1
F0.00014334862385321102
I0
I1
I-1
tp541
sS'isozyme,and,thus'
p542
(F1
F0.00014334862385321102
I0
I1
I-1
tp543
sS'may,produce,electrocardiographic'
p544
(F1
F0.00014334862385321102
I1
I0
I1
tp545
sS'is,a,blocker'
p546
(F1
F0.00014334862385321102
I0
I1
I-1
tp547
sS'but,should,be'
p548
(F0.5
F0.00028669724770642203
I3
I1
I2
tp549
sS'pharmacodynamic,interaction,with'
p550
(F1
F0.00014334862385321102
I0
I1
I-1
tp551
sS'endotoxin-treated,rats,did'
p552
(F1
F0.00014334862385321102
I0
I1
I-1
tp553
sS'regimen,reduces,the'
p554
(F1
F0.00014334862385321102
I0
I1
I-1
tp555
sS'given,on,separate'
p556
(F1
F0.00014334862385321102
I1
I0
I1
tp557
sS'the,curve,after'
p558
(F1
F0.00014334862385321102
I1
I0
I1
tp559
sS'by,without,preventing'
p560
(F1
F0.00014334862385321102
I1
I0
I1
tp561
sS'and,discontinuation,of'
p562
(F1
F0.00028669724770642203
I2
I0
I2
tp563
sS'therapy,a,rate'
p564
(F1
F0.00028669724770642203
I2
I0
I2
tp565
sS'decreases,of,and'
p566
(F1
F0.00014334862385321102
I1
I0
I1
tp567
sS'copegus,are,excreted'
p568
(F1
F0.00014334862385321102
I0
I1
I-1
tp569
sS'was,shown,to'
p570
(F0
F0
I2
I2
I0
tp571
sS'may,cause,myopathy'
p572
(F1
F0.00014334862385321102
I0
I1
I-1
tp573
sS'that,no,change'
p574
(F1
F0.00014334862385321102
I1
I0
I1
tp575
sS'oxidase,inhibitors,maois'
p576
(F1
F0.00014334862385321102
I1
I0
I1
tp577
sS'antiminth,taking,and'
p578
(F1
F0.00014334862385321102
I1
I0
I1
tp579
sS'been,case,reports'
p580
(F1
F0.00014334862385321102
I0
I1
I-1
tp581
sS'ritonavir,coadministration,of'
p582
(F1
F0.00014334862385321102
I1
I0
I1
tp583
sS'a,literature,article'
p584
(F1
F0.00014334862385321102
I1
I0
I1
tp585
sS'as,and,or'
p586
(F1
F0.00014334862385321102
I1
I0
I1
tp587
sS'valproic,acid,using'
p588
(F1
F0.00014334862385321102
I1
I0
I1
tp589
sS'ophthalmic,solution,the'
p590
(F1
F0.00014334862385321102
I1
I0
I1
tp591
sS'clinical,trials,the'
p592
(F1
F0.00028669724770642203
I0
I2
I-2
tp593
sS'epinephrine,should,not'
p594
(F1
F0.00014334862385321102
I1
I0
I1
tp595
sS'of,decreased,protein'
p596
(F1
F0.00014334862385321102
I1
I0
I1
tp597
sS'actions,via,the'
p598
(F1
F0.00014334862385321102
I0
I1
I-1
tp599
sS'methotrexate,concomitant,administration'
p600
(F1
F0.00014334862385321102
I1
I0
I1
tp601
sS'dose,if,or'
p602
(F1
F0.00014334862385321102
I1
I0
I1
tp603
sS'macrolide,inhibit,the'
p604
(F1
F0.00014334862385321102
I1
I0
I1
tp605
sS'mg,rat,days'
p606
(F1
F0.00014334862385321102
I0
I1
I-1
tp607
sS'sodium,perchlorate,in'
p608
(F1
F0.00014334862385321102
I0
I1
I-1
tp609
sS'is,expected,that'
p610
(F1
F0.00014334862385321102
I1
I0
I1
tp611
sS'that,range,of'
p612
(F1
F0.00014334862385321102
I1
I0
I1
tp613
sS'apparently,through,an'
p614
(F1
F0.00014334862385321102
I1
I0
I1
tp615
sS'more,than,parkinsons'
p616
(F1
F0.00014334862385321102
I0
I1
I-1
tp617
sS'may,increase,two-fold'
p618
(F1
F0.00014334862385321102
I1
I0
I1
tp619
sS'inhibitors,and,cyp1a2'
p620
(F1
F0.00014334862385321102
I0
I1
I-1
tp621
sS'to,measure,plasma'
p622
(F1
F0.00014334862385321102
I0
I1
I-1
tp623
sS'rheumatoid,arthritis,patients'
p624
(F1
F0.00028669724770642203
I0
I2
I-2
tp625
sS'mg,kg,ip'
p626
(F1
F0.00014334862385321102
I1
I0
I1
tp627
sS'disease,patients,in'
p628
(F1
F0.00014334862385321102
I0
I1
I-1
tp629
sS'clearance,of,chronic'
p630
(F1
F0.00014334862385321102
I1
I0
I1
tp631
sS'rate,but,no'
p632
(F1
F0.00014334862385321102
I0
I1
I-1
tp633
sS'enhancement,effect,of'
p634
(F1
F0.00014334862385321102
I1
I0
I1
tp635
sS'allopurinol,in,a'
p636
(F1
F0.00014334862385321102
I0
I1
I-1
tp637
sS'dilation,associated,with'
p638
(F1
F0.00014334862385321102
I1
I0
I1
tp639
sS'and,gi,bleeding'
p640
(F1
F0.00014334862385321102
I0
I1
I-1
tp641
sS'p,app,polymer'
p642
(F1
F0.00014334862385321102
I0
I1
I-1
tp643
sS'a,potentiation,of'
p644
(F1
F0.00014334862385321102
I1
I0
I1
tp645
sS'addition,of,mg'
p646
(F1
F0.00014334862385321102
I1
I0
I1
tp647
sS'when,taking,acarbose'
p648
(F1
F0.00014334862385321102
I1
I0
I1
tp649
sS'vs,end,of'
p650
(F1
F0.00014334862385321102
I0
I1
I-1
tp651
sS'and,frequently,thereafter'
p652
(F1
F0.00014334862385321102
I1
I0
I1
tp653
sS'doses,that,produced'
p654
(F1
F0.00014334862385321102
I0
I1
I-1
tp655
sS'decrease,by,approximately'
p656
(F1
F0.00014334862385321102
I0
I1
I-1
tp657
sS'particularly,if,their'
p658
(F1
F0.00014334862385321102
I1
I0
I1
tp659
sS'counteract,the,antinaturetic'
p660
(F1
F0.00014334862385321102
I1
I0
I1
tp661
sS'depletion,of,already'
p662
(F1
F0.00014334862385321102
I1
I0
I1
tp663
sS'no,in,vivo'
p664
(F1
F0.00014334862385321102
I1
I0
I1
tp665
sS'acetazolamide,increases,excretion'
p666
(F1
F0.00014334862385321102
I1
I0
I1
tp667
sS'crossover,double-blind,placebo-controlled'
p668
(F1
F0.00014334862385321102
I0
I1
I-1
tp669
sS'of,by,confidence'
p670
(F1
F0.00014334862385321102
I0
I1
I-1
tp671
sS'enterococcus,three,strains'
p672
(F1
F0.00014334862385321102
I0
I1
I-1
tp673
sS'aprepitant,given,concomitantly'
p674
(F1
F0.00014334862385321102
I1
I0
I1
tp675
sS'of,wellbutrin,tablets'
p676
(F1
F0.00014334862385321102
I1
I0
I1
tp677
sS'to,as,these'
p678
(F1
F0.00014334862385321102
I1
I0
I1
tp679
sS'other,cardiovascular,agents'
p680
(F1
F0.00014334862385321102
I0
I1
I-1
tp681
sS'potential,of,other'
p682
(F1
F0.00014334862385321102
I1
I0
I1
tp683
sS'monitored,when,concomitant'
p684
(F1
F0.00014334862385321102
I1
I0
I1
tp685
sS'an,approximately,decrease'
p686
(F1
F0.00014334862385321102
I1
I0
I1
tp687
sS'must,be,taken'
p688
(F1
F0.00014334862385321102
I1
I0
I1
tp689
sS'that,inhibit,cyp3a4'
p690
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp691
sS'time,pt,and'
p692
(F1
F0.00014334862385321102
I1
I0
I1
tp693
sS'these,cyp3a4,or'
p694
(F1
F0.00014334862385321102
I0
I1
I-1
tp695
sS'of,patients,on'
p696
(F1
F0.00014334862385321102
I1
I0
I1
tp697
sS'together,as,a'
p698
(F1
F0.00014334862385321102
I0
I1
I-1
tp699
sS'the,post-marketing,experience'
p700
(F1
F0.00014334862385321102
I1
I0
I1
tp701
sS'and,urine,levels'
p702
(F1
F0.00014334862385321102
I1
I0
I1
tp703
sS'with,caution,if'
p704
(F1
F0.00014334862385321102
I1
I0
I1
tp705
sS'is,possible,that'
p706
(F1
F0.00043004587155963305
I3
I0
I3
tp707
sS'during,concomitant,therapy'
p708
(F0
F0
I1
I1
I0
tp709
sS'with,caution,in'
p710
(F0.66666666666666663
F0.0011467889908256881
I10
I2
I8
tp711
sS'hydroxylamine,dha,was'
p712
(F1
F0.00014334862385321102
I0
I1
I-1
tp713
sS'acute,phase,and'
p714
(F1
F0.00014334862385321102
I0
I1
I-1
tp715
sS'fluvastatin,is,the'
p716
(F1
F0.00014334862385321102
I0
I1
I-1
tp717
sS'patient,may,increase'
p718
(F1
F0.00014334862385321102
I1
I0
I1
tp719
sS'associated,with,modest'
p720
(F1
F0.00014334862385321102
I1
I0
I1
tp721
sS'or,a,chop-like'
p722
(F1
F0.00014334862385321102
I0
I1
I-1
tp723
sS'administered,safely,without'
p724
(F1
F0.00014334862385321102
I0
I1
I-1
tp725
sS'expected,antidepressant,levels'
p726
(F1
F0.00014334862385321102
I1
I0
I1
tp727
sS'and,doses,should'
p728
(F1
F0.00014334862385321102
I0
I1
I-1
tp729
sS'renal,failure,in'
p730
(F1
F0.00014334862385321102
I1
I0
I1
tp731
sS'by,multiple,cytochrome'
p732
(F1
F0.00014334862385321102
I0
I1
I-1
tp733
sS'incidence,of,adverse'
p734
(F1
F0.00014334862385321102
I1
I0
I1
tp735
sS'half-life,of,is'
p736
(F1
F0.00014334862385321102
I1
I0
I1
tp737
sS'of,the,in'
p738
(F1
F0.00028669724770642203
I0
I2
I-2
tp739
sS'increases,in,peak'
p740
(F1
F0.00014334862385321102
I1
I0
I1
tp741
sS'half-life,of,in'
p742
(F1
F0.00014334862385321102
I1
I0
I1
tp743
sS'dose,mg,and'
p744
(F1
F0.00014334862385321102
I0
I1
I-1
tp745
sS'hydatid,cyst,patients'
p746
(F1
F0.00014334862385321102
I1
I0
I1
tp747
sS'triazolam,combined,administration'
p748
(F1
F0.00014334862385321102
I0
I1
I-1
tp749
sS'vardenafil,should,not'
p750
(F1
F0.00028669724770642203
I2
I0
I2
tp751
sS'who,was,taking'
p752
(F1
F0.00014334862385321102
I0
I1
I-1
tp753
sS'efficacy,has,not'
p754
(F1
F0.00014334862385321102
I0
I1
I-1
tp755
sS'controlled,trials,that'
p756
(F1
F0.00014334862385321102
I0
I1
I-1
tp757
sS'ephedrine,may,enhance'
p758
(F1
F0.00014334862385321102
I1
I0
I1
tp759
sS'diamond,trials,patients'
p760
(F1
F0.00014334862385321102
I0
I1
I-1
tp761
sS'of,both,control'
p762
(F1
F0.00014334862385321102
I0
I1
I-1
tp763
sS'of,pcp,were'
p764
(F1
F0.00014334862385321102
I0
I1
I-1
tp765
sS'significantly,decreased,binding'
p766
(F1
F0.00014334862385321102
I1
I0
I1
tp767
sS'other,drugs,given'
p768
(F1
F0.00014334862385321102
I0
I1
I-1
tp769
sS'use,of,aczone'
p770
(F1
F0.00014334862385321102
I0
I1
I-1
tp771
sS'concentration,of,by'
p772
(F1
F0.00043004587155963305
I3
I0
I3
tp773
sS'substantially,greater,therapeutic'
p774
(F1
F0.00014334862385321102
I0
I1
I-1
tp775
sS'danger,of,a'
p776
(F1
F0.00014334862385321102
I1
I0
I1
tp777
sS'between,single,oral'
p778
(F1
F0.00014334862385321102
I1
I0
I1
tp779
sS'may,reduce,or'
p780
(F1
F0.00028669724770642203
I2
I0
I2
tp781
sS'antidiabetic,agents,insulin'
p782
(F1
F0.00014334862385321102
I0
I1
I-1
tp783
sS'was,and,hours'
p784
(F1
F0.00014334862385321102
I0
I1
I-1
tp785
sS'should,be,warned'
p786
(F1
F0.00014334862385321102
I1
I0
I1
tp787
sS'increased,the,concentration'
p788
(F1
F0.00014334862385321102
I1
I0
I1
tp789
sS'health,care,providers'
p790
(F1
F0.00014334862385321102
I0
I1
I-1
tp791
sS'chlorpromazine,blocks,and'
p792
(F1
F0.00028669724770642203
I2
I0
I2
tp793
sS'sulfacetamide,preparations,are'
p794
(F1
F0.00014334862385321102
I1
I0
I1
tp795
sS'reveiving,phenytoin,and'
p796
(F1
F0.00014334862385321102
I1
I0
I1
tp797
sS'other,and,anti'
p798
(F1
F0.00014334862385321102
I0
I1
I-1
tp799
sS'pigeons,nanm,was'
p800
(F1
F0.00014334862385321102
I0
I1
I-1
tp801
sS'treatments,of,depletion'
p802
(F1
F0.00014334862385321102
I0
I1
I-1
tp803
sS'to,antagonize,the'
p804
(F1
F0.00028669724770642203
I2
I0
I2
tp805
sS'secretion,of,in'
p806
(F1
F0.00014334862385321102
I1
I0
I1
tp807
sS'with,celebrex,mg'
p808
(F1
F0.00014334862385321102
I1
I0
I1
tp809
sS'may,increase,serum'
p810
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp811
sS'natriuresis,and,hyperreninemia'
p812
(F1
F0.00014334862385321102
I1
I0
I1
tp813
sS'when,macrolide,or'
p814
(F1
F0.00014334862385321102
I0
I1
I-1
tp815
sS'and,reuptake,inhibitor'
p816
(F1
F0.00014334862385321102
I1
I0
I1
tp817
sS'based,on,clinical'
p818
(F1
F0.00014334862385321102
I1
I0
I1
tp819
sS'or,on,insulins'
p820
(F1
F0.00014334862385321102
I0
I1
I-1
tp821
sS'post-heparin,lipolytic,activity'
p822
(F1
F0.00014334862385321102
I1
I0
I1
tp823
sS'of,other,drugs'
p824
(F1
F0.00043004587155963305
I0
I3
I-3
tp825
sS'the,rate-limiting,step'
p826
(F1
F0.00014334862385321102
I0
I1
I-1
tp827
sS'elapse,before,blood'
p828
(F1
F0.00014334862385321102
I1
I0
I1
tp829
sS'two,hormonal,components'
p830
(F1
F0.00014334862385321102
I1
I0
I1
tp831
sS'of,the,and'
p832
(F0.5
F0.00028669724770642203
I3
I1
I2
tp833
sS'use,of,nimbex'
p834
(F1
F0.00014334862385321102
I0
I1
I-1
tp835
sS'or,other,drugs'
p836
(F1
F0.00014334862385321102
I1
I0
I1
tp837
sS'g,day,have'
p838
(F1
F0.00014334862385321102
I1
I0
I1
tp839
sS'psychotropic,medications,the'
p840
(F1
F0.00014334862385321102
I1
I0
I1
tp841
sS'three-period,randomized,crossover'
p842
(F1
F0.00014334862385321102
I0
I1
I-1
tp843
sS'blocking,agents,along'
p844
(F1
F0.00014334862385321102
I1
I0
I1
tp845
sS'antiepilepsy,drugs,aeds'
p846
(F0
F0
I1
I1
I0
tp847
sS'monitoring,of,plasma'
p848
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp849
sS'its,efficacy,as'
p850
(F1
F0.00014334862385321102
I0
I1
I-1
tp851
sS'effects,on,the'
p852
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp853
sS'cold,remedies,and'
p854
(F1
F0.00014334862385321102
I1
I0
I1
tp855
sS'of,an,adverse'
p856
(F1
F0.00014334862385321102
I0
I1
I-1
tp857
sS'effect,to,but'
p858
(F1
F0.00014334862385321102
I1
I0
I1
tp859
sS'people,use,both'
p860
(F1
F0.00014334862385321102
I0
I1
I-1
tp861
sS'nor,binding,to'
p862
(F1
F0.00014334862385321102
I0
I1
I-1
tp863
sS'and,cmax,was'
p864
(F1
F0.00014334862385321102
I0
I1
I-1
tp865
sS'in,patients,already'
p866
(F1
F0.00014334862385321102
I1
I0
I1
tp867
sS'of,dose,ranging'
p868
(F1
F0.00014334862385321102
I1
I0
I1
tp869
sS'a,rapidly,growing'
p870
(F1
F0.00014334862385321102
I0
I1
I-1
tp871
sS'two-fold,or,more'
p872
(F1
F0.00014334862385321102
I1
I0
I1
tp873
sS'chronic,therapy,had'
p874
(F1
F0.00014334862385321102
I0
I1
I-1
tp875
sS'a,four-session,placebo-controlled'
p876
(F1
F0.00014334862385321102
I0
I1
I-1
tp877
sS'or,should,be'
p878
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp879
sS'main,hemostatic,defense'
p880
(F1
F0.00014334862385321102
I1
I0
I1
tp881
sS'of,crixivan,to'
p882
(F1
F0.00043004587155963305
I3
I0
I3
tp883
sS'dosage,adjustment,is'
p884
(F1
F0.00014334862385321102
I0
I1
I-1
tp885
sS'catecholamine-depleting,agents,patients'
p886
(F1
F0.00014334862385321102
I1
I0
I1
tp887
sS'reverse,triiodothyronine,levels'
p888
(F1
F0.00014334862385321102
I0
I1
I-1
tp889
sS'cbg,sex,hormone'
p890
(F1
F0.00014334862385321102
I0
I1
I-1
tp891
sS'be,undertaken,only'
p892
(F1
F0.00014334862385321102
I1
I0
I1
tp893
sS'metabolized,to,the'
p894
(F1
F0.00014334862385321102
I0
I1
I-1
tp895
sS'minimum,alveolar,concentration'
p896
(F1
F0.00028669724770642203
I2
I0
I2
tp897
sS'antidepressants,use,of'
p898
(F1
F0.00014334862385321102
I1
I0
I1
tp899
sS'factor,vii,when'
p900
(F1
F0.00014334862385321102
I0
I1
I-1
tp901
sS'of,resulting,in'
p902
(F0.81818181818181823
F0.0025802752293577983
I20
I2
I18
tp903
sS'and,concurrently,and'
p904
(F1
F0.00014334862385321102
I1
I0
I1
tp905
sS'increased,and,efficacy'
p906
(F1
F0.00028669724770642203
I2
I0
I2
tp907
sS'oxidase,inhibitors,and'
p908
(F1
F0.0008600917431192661
I6
I0
I6
tp909
sS'motor,skills,or'
p910
(F1
F0.00014334862385321102
I0
I1
I-1
tp911
sS'cyp3a,a,minor'
p912
(F1
F0.00014334862385321102
I1
I0
I1
tp913
sS'that,there,is'
p914
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp915
sS'and,decrease,in'
p916
(F1
F0.00028669724770642203
I2
I0
I2
tp917
sS'produce,electrocardiographic,abnormalities'
p918
(F1
F0.00014334862385321102
I1
I0
I1
tp919
sS'a,variety,of'
p920
(F1
F0.00043004587155963305
I0
I3
I-3
tp921
sS'or,may,develop'
p922
(F1
F0.00014334862385321102
I1
I0
I1
tp923
sS'or,undesirable,involving'
p924
(F1
F0.00028669724770642203
I0
I2
I-2
tp925
sS'therefore,such,combined'
p926
(F1
F0.00014334862385321102
I1
I0
I1
tp927
sS'addition,and,mhd'
p928
(F1
F0.00014334862385321102
I0
I1
I-1
tp929
sS'in,addition,alone'
p930
(F1
F0.00014334862385321102
I1
I0
I1
tp931
sS'intestinal,adenocarcinomas,induced'
p932
(F0
F0
I1
I1
I0
tp933
sS'interaction,studies,were'
p934
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp935
sS'fondaparinux,neither,influenced'
p936
(F1
F0.00014334862385321102
I0
I1
I-1
tp937
sS'of,the,plasma'
p938
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp939
sS'use,clinicians,should'
p940
(F1
F0.00014334862385321102
I1
I0
I1
tp941
sS'cause,a,reduction'
p942
(F1
F0.00014334862385321102
I1
I0
I1
tp943
sS'q,d,were'
p944
(F1
F0.00014334862385321102
I1
I0
I1
tp945
sS'eg,could,cause'
p946
(F1
F0.00014334862385321102
I1
I0
I1
tp947
sS'to,examine,the'
p948
(F1
F0.00043004587155963305
I0
I3
I-3
tp949
sS'taking,or,within'
p950
(F1
F0.00014334862385321102
I1
I0
I1
tp951
sS'acid,are,not'
p952
(F1
F0.00014334862385321102
I0
I1
I-1
tp953
sS'closely,monitored,in'
p954
(F1
F0.00014334862385321102
I1
I0
I1
tp955
sS'and,to,potentiate'
p956
(F1
F0.00028669724770642203
I2
I0
I2
tp957
sS'as,measured,by'
p958
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp959
sS'the,kidney,which'
p960
(F1
F0.00014334862385321102
I0
I1
I-1
tp961
sS'uniformity,and,time'
p962
(F1
F0.00014334862385321102
I0
I1
I-1
tp963
sS'in,sub-therapeutic,concentrations'
p964
(F1
F0.00014334862385321102
I1
I0
I1
tp965
sS'male,volunteers,ingesting'
p966
(F1
F0.00014334862385321102
I1
I0
I1
tp967
sS'micrograms,ml,or'
p968
(F1
F0.00014334862385321102
I0
I1
I-1
tp969
sS'iodinated,cholestographic,agents'
p970
(F1
F0.00014334862385321102
I0
I1
I-1
tp971
sS'a,similar,association'
p972
(F1
F0.00028669724770642203
I0
I2
I-2
tp973
sS'cause,severe,hypotension'
p974
(F1
F0.00014334862385321102
I1
I0
I1
tp975
sS'the,pharmacokinetic,disposition'
p976
(F1
F0.00014334862385321102
I0
I1
I-1
tp977
sS'inhibitor,therapy,should'
p978
(F1
F0.00014334862385321102
I1
I0
I1
tp979
sS'rhabdomyolysis,resulting,from'
p980
(F1
F0.00014334862385321102
I0
I1
I-1
tp981
sS'of,a,single'
p982
(F0.20000000000000001
F0.00043004587155963305
I6
I9
I-3
tp983
sS'thrombolytic,agents,have'
p984
(F1
F0.00014334862385321102
I0
I1
I-1
tp985
sS'tablets,to,patients'
p986
(F1
F0.00014334862385321102
I1
I0
I1
tp987
sS'ibuprofen,ibuprofen,is'
p988
(F1
F0.00014334862385321102
I0
I1
I-1
tp989
sS'cause,of,infection'
p990
(F1
F0.00014334862385321102
I1
I0
I1
tp991
sS'treatment,of,complicated'
p992
(F1
F0.00014334862385321102
I0
I1
I-1
tp993
sS'while,additional,research'
p994
(F1
F0.00014334862385321102
I0
I1
I-1
tp995
sS'pressor,response,to'
p996
(F1
F0.00014334862385321102
I1
I0
I1
tp997
sS'is,augmented,by'
p998
(F1
F0.00028669724770642203
I2
I0
I2
tp999
sS'delta,and,kappa-selective'
p1000
(F1
F0.00014334862385321102
I0
I1
I-1
tp1001
sS'combination,of,and'
p1002
(F1
F0.00028669724770642203
I2
I0
I2
tp1003
sS'causes,an,increase'
p1004
(F1
F0.00043004587155963305
I3
I0
I3
tp1005
sS'with,beta-adrenergic,blockers'
p1006
(F1
F0.00014334862385321102
I1
I0
I1
tp1007
sS'normal,tissues,from'
p1008
(F1
F0.00014334862385321102
I1
I0
I1
tp1009
sS'on,the,above'
p1010
(F1
F0.00014334862385321102
I0
I1
I-1
tp1011
sS'prior,to,but'
p1012
(F1
F0.00014334862385321102
I1
I0
I1
tp1013
sS'hctz,alone,auc'
p1014
(F1
F0.00014334862385321102
I1
I0
I1
tp1015
sS'inducers,inhibitors,and'
p1016
(F1
F0.00014334862385321102
I1
I0
I1
tp1017
sS'with,because,they'
p1018
(F1
F0.00043004587155963305
I3
I0
I3
tp1019
sS'for,the,period'
p1020
(F1
F0.00014334862385321102
I1
I0
I1
tp1021
sS'a,significant,deterioration'
p1022
(F1
F0.00014334862385321102
I0
I1
I-1
tp1023
sS'cyp3a4,inducer,should'
p1024
(F1
F0.00028669724770642203
I2
I0
I2
tp1025
sS'arachidonate-,or,collagen-stimulated'
p1026
(F1
F0.00014334862385321102
I0
I1
I-1
tp1027
sS'fda,have,involved'
p1028
(F1
F0.00014334862385321102
I0
I1
I-1
tp1029
sS'than,mg,day'
p1030
(F1
F0.00014334862385321102
I1
I0
I1
tp1031
sS'sodium,bicarbonate,etc'
p1032
(F1
F0.00014334862385321102
I1
I0
I1
tp1033
sS'coronary,artery,vasospasm'
p1034
(F1
F0.00014334862385321102
I1
I0
I1
tp1035
sS'signs,of,toxicity'
p1036
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp1037
sS'conducted,concomitant,administration'
p1038
(F1
F0.00014334862385321102
I1
I0
I1
tp1039
sS'is,further,metabolized'
p1040
(F1
F0.00014334862385321102
I0
I1
I-1
tp1041
sS'be,an,increase'
p1042
(F1
F0.00014334862385321102
I0
I1
I-1
tp1043
sS'are,administered,concurrently'
p1044
(F1
F0.00057339449541284407
I4
I0
I4
tp1045
sS'is,displaced,from'
p1046
(F1
F0.00028669724770642203
I2
I0
I2
tp1047
sS'prolonged,gastrointestinal,transit'
p1048
(F1
F0.00014334862385321102
I1
I0
I1
tp1049
sS'mg,kg,increased'
p1050
(F1
F0.00014334862385321102
I1
I0
I1
tp1051
sS'aptt,such,as'
p1052
(F1
F0.00014334862385321102
I0
I1
I-1
tp1053
sS'reported,predominantly,in'
p1054
(F1
F0.00014334862385321102
I1
I0
I1
tp1055
sS'doses,of,oral'
p1056
(F1
F0.00014334862385321102
I0
I1
I-1
tp1057
sS'descending,epsilon,and'
p1058
(F1
F0.00014334862385321102
I0
I1
I-1
tp1059
sS'of,iressa,and'
p1060
(F1
F0.00014334862385321102
I1
I0
I1
tp1061
sS'to,know,how'
p1062
(F1
F0.00014334862385321102
I0
I1
I-1
tp1063
sS'other,or,medications'
p1064
(F1
F0.00014334862385321102
I1
I0
I1
tp1065
sS'taxol,mg,m2'
p1066
(F1
F0.00014334862385321102
I1
I0
I1
tp1067
sS'many,including,most'
p1068
(F1
F0.00014334862385321102
I0
I1
I-1
tp1069
sS'metabolism,via,cytochrome'
p1070
(F1
F0.00028669724770642203
I0
I2
I-2
tp1071
sS'not,exceed,a'
p1072
(F1
F0.00043004587155963305
I3
I0
I3
tp1073
sS'node,higher,degrees'
p1074
(F1
F0.00014334862385321102
I1
I0
I1
tp1075
sS'the,curve,of'
p1076
(F1
F0.00014334862385321102
I1
I0
I1
tp1077
sS'to,be,antagonistic'
p1078
(F1
F0.00014334862385321102
I1
I0
I1
tp1079
sS'serum,meq,l'
p1080
(F1
F0.00014334862385321102
I1
I0
I1
tp1081
sS'plasma,concentrations,of'
p1082
(F0.40350877192982454
F0.0032970183486238534
I40
I17
I23
tp1083
sS'parameter,values,were'
p1084
(F1
F0.00014334862385321102
I0
I1
I-1
tp1085
sS'opioids,co-administration,of'
p1086
(F1
F0.00014334862385321102
I1
I0
I1
tp1087
sS'blocking,agent,administered'
p1088
(F1
F0.00014334862385321102
I0
I1
I-1
tp1089
sS'these,pharmacokinetic,changes'
p1090
(F1
F0.00014334862385321102
I1
I0
I1
tp1091
sS'those,with,overdosage'
p1092
(F1
F0.00014334862385321102
I1
I0
I1
tp1093
sS'it,may,have'
p1094
(F1
F0.00014334862385321102
I0
I1
I-1
tp1095
sS'and,anxiety,depressive'
p1096
(F1
F0.00014334862385321102
I0
I1
I-1
tp1097
sS'hand,intrathecal,micrograms'
p1098
(F1
F0.00014334862385321102
I1
I0
I1
tp1099
sS'decreases,the,biologic'
p1100
(F1
F0.00014334862385321102
I1
I0
I1
tp1101
sS'to,be,low'
p1102
(F1
F0.00014334862385321102
I0
I1
I-1
tp1103
sS'or,magnesium-containing,concomitant'
p1104
(F1
F0.00014334862385321102
I1
I0
I1
tp1105
sS'drugs,that,could'
p1106
(F1
F0.00014334862385321102
I1
I0
I1
tp1107
sS'combined,with,local'
p1108
(F1
F0.00014334862385321102
I0
I1
I-1
tp1109
sS'reported,to,produce'
p1110
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp1111
sS'higher,cardiac,output'
p1112
(F1
F0.00014334862385321102
I1
I0
I1
tp1113
sS'itraconazole,and,may'
p1114
(F1
F0.00014334862385321102
I1
I0
I1
tp1115
sS'may,be,aggravated'
p1116
(F1
F0.00014334862385321102
I1
I0
I1
tp1117
sS'these,concomitant,n'
p1118
(F1
F0.00014334862385321102
I1
I0
I1
tp1119
sS'ulceration,or,other'
p1120
(F1
F0.00028669724770642203
I2
I0
I2
tp1121
sS'concomitantly,and,channel'
p1122
(F1
F0.00014334862385321102
I1
I0
I1
tp1123
sS'and,proleukin,including'
p1124
(F1
F0.00014334862385321102
I1
I0
I1
tp1125
sS'a,small,n'
p1126
(F1
F0.00014334862385321102
I1
I0
I1
tp1127
sS'experimental,toxic,and'
p1128
(F1
F0.00014334862385321102
I1
I0
I1
tp1129
sS'is,involved,in'
p1130
(F1
F0.00028669724770642203
I0
I2
I-2
tp1131
sS'in,a,week'
p1132
(F1
F0.00014334862385321102
I0
I1
I-1
tp1133
sS'p-glycoprotein,substrate,with'
p1134
(F1
F0.00014334862385321102
I1
I0
I1
tp1135
sS'been,attributed,at'
p1136
(F1
F0.00014334862385321102
I1
I0
I1
tp1137
sS'xr,patients,received'
p1138
(F1
F0.00014334862385321102
I0
I1
I-1
tp1139
sS'other,non-steroidal,and'
p1140
(F1
F0.00014334862385321102
I1
I0
I1
tp1141
sS'with,extracellular,rr'
p1142
(F1
F0.00014334862385321102
I1
I0
I1
tp1143
sS'expected,that,use'
p1144
(F1
F0.00014334862385321102
I1
I0
I1
tp1145
sS'a,precipitous,reduction'
p1146
(F1
F0.00014334862385321102
I1
I0
I1
tp1147
sS'antibiotics,and,has'
p1148
(F1
F0.00014334862385321102
I1
I0
I1
tp1149
sS'olanzapine,demonstrated,superior'
p1150
(F1
F0.00014334862385321102
I0
I1
I-1
tp1151
sS'inhibitors,and,levo-dromoran'
p1152
(F1
F0.00014334862385321102
I1
I0
I1
tp1153
sS'bleeding,complications,considerably'
p1154
(F1
F0.00014334862385321102
I0
I1
I-1
tp1155
sS'skeletal,myopathy,in'
p1156
(F1
F0.00014334862385321102
I0
I1
I-1
tp1157
sS'coadministration,of,neurontin'
p1158
(F1
F0.00014334862385321102
I0
I1
I-1
tp1159
sS'bolus-ifl,alone,and'
p1160
(F1
F0.00014334862385321102
I0
I1
I-1
tp1161
sS'is,almost,always'
p1162
(F1
F0.00014334862385321102
I0
I1
I-1
tp1163
sS'mptp-induced,neuronal,damage'
p1164
(F1
F0.00014334862385321102
I1
I0
I1
tp1165
sS'shown,that,indocin'
p1166
(F1
F0.00014334862385321102
I0
I1
I-1
tp1167
sS'lower,the,degree'
p1168
(F1
F0.00014334862385321102
I1
I0
I1
tp1169
sS'changed,to,mg'
p1170
(F1
F0.00014334862385321102
I0
I1
I-1
tp1171
sS'elderly,and,caution'
p1172
(F1
F0.00014334862385321102
I0
I1
I-1
tp1173
sS'enhancement,of,intestinal'
p1174
(F1
F0.00014334862385321102
I0
I1
I-1
tp1175
sS'pharmacokinetics,of,r-'
p1176
(F1
F0.00014334862385321102
I0
I1
I-1
tp1177
sS'which,suggests,that'
p1178
(F1
F0.00014334862385321102
I1
I0
I1
tp1179
sS'or,because,the'
p1180
(F1
F0.00014334862385321102
I1
I0
I1
tp1181
sS'changes,were,not'
p1182
(F1
F0.00014334862385321102
I0
I1
I-1
tp1183
sS'or,more,than'
p1184
(F1
F0.00014334862385321102
I1
I0
I1
tp1185
sS'linked,to,carbodiimide'
p1186
(F1
F0.00014334862385321102
I0
I1
I-1
tp1187
sS'of,another,extended'
p1188
(F1
F0.00014334862385321102
I0
I1
I-1
tp1189
sS'taking,mg,three'
p1190
(F1
F0.00014334862385321102
I1
I0
I1
tp1191
sS'these,were,not'
p1192
(F1
F0.00014334862385321102
I0
I1
I-1
tp1193
sS'significantly,improves,the'
p1194
(F1
F0.00014334862385321102
I0
I1
I-1
tp1195
sS'in,desloratadine,and'
p1196
(F1
F0.00014334862385321102
I0
I1
I-1
tp1197
sS'doses,of,sonata'
p1198
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp1199
sS'of,cyp3a4,would'
p1200
(F1
F0.00014334862385321102
I0
I1
I-1
tp1201
sS'before,blood,is'
p1202
(F1
F0.00014334862385321102
I1
I0
I1
tp1203
sS'potential,for,drug'
p1204
(F1
F0.00014334862385321102
I0
I1
I-1
tp1205
sS'cigarettes,and,other'
p1206
(F1
F0.00014334862385321102
I0
I1
I-1
tp1207
sS'the,hepatic,microsomal'
p1208
(F0
F0
I1
I1
I0
tp1209
sS'when,suprax,is'
p1210
(F1
F0.00014334862385321102
I1
I0
I1
tp1211
sS'hypertensive,responses,have'
p1212
(F1
F0.00014334862385321102
I1
I0
I1
tp1213
sS'act,on,the'
p1214
(F1
F0.00014334862385321102
I1
I0
I1
tp1215
sS'patients,taking,coumarin-derivative'
p1216
(F1
F0.00014334862385321102
I1
I0
I1
tp1217
sS'lower,than,those'
p1218
(F1
F0.00014334862385321102
I1
I0
I1
tp1219
sS'its,major,metabolite'
p1220
(F1
F0.00028669724770642203
I0
I2
I-2
tp1221
sS'hemostasis,and,nsaids'
p1222
(F1
F0.00014334862385321102
I1
I0
I1
tp1223
sS'foradil,should,not'
p1224
(F1
F0.00014334862385321102
I0
I1
I-1
tp1225
sS'ca,concentration,ca'
p1226
(F1
F0.00014334862385321102
I1
I0
I1
tp1227
sS'and,rhabdomyolysis,have'
p1228
(F1
F0.00014334862385321102
I0
I1
I-1
tp1229
sS'associated,with,transient'
p1230
(F1
F0.00028669724770642203
I2
I0
I2
tp1231
sS'agents,and,local'
p1232
(F1
F0.00014334862385321102
I0
I1
I-1
tp1233
sS'its,synergism,with'
p1234
(F1
F0.00014334862385321102
I1
I0
I1
tp1235
sS'results,of,using'
p1236
(F1
F0.00014334862385321102
I1
I0
I1
tp1237
sS'compared,to,prinivil'
p1238
(F1
F0.00014334862385321102
I0
I1
I-1
tp1239
sS'respectively,by,the'
p1240
(F1
F0.00014334862385321102
I1
I0
I1
tp1241
sS'the,modulation,of'
p1242
(F0
F0
I1
I1
I0
tp1243
sS'of,other,antiepileptic'
p1244
(F1
F0.00014334862385321102
I1
I0
I1
tp1245
sS'inr,international,normalized'
p1246
(F1
F0.00014334862385321102
I1
I0
I1
tp1247
sS'interaction,study,evaluating'
p1248
(F1
F0.00014334862385321102
I1
I0
I1
tp1249
sS'the,predominant,plasma'
p1250
(F1
F0.00014334862385321102
I0
I1
I-1
tp1251
sS'be,active,in'
p1252
(F1
F0.00014334862385321102
I1
I0
I1
tp1253
sS'sulfate,may,interact'
p1254
(F1
F0.00014334862385321102
I1
I0
I1
tp1255
sS'plus,for,days'
p1256
(F1
F0.00014334862385321102
I0
I1
I-1
tp1257
sS'variation,in,ultimate'
p1258
(F1
F0.00014334862385321102
I1
I0
I1
tp1259
sS'patients,when,was'
p1260
(F1
F0.00014334862385321102
I1
I0
I1
tp1261
sS'with,mao,inhibitors'
p1262
(F1
F0.00057339449541284407
I4
I0
I4
tp1263
sS'can,be,used'
p1264
(F1
F0.00043004587155963305
I3
I0
I3
tp1265
sS'macrolide,azole,antifungal'
p1266
(F1
F0.00014334862385321102
I1
I0
I1
tp1267
sS'vasoconstriction,in,some'
p1268
(F1
F0.00014334862385321102
I1
I0
I1
tp1269
sS'that,peak,concentrations'
p1270
(F1
F0.00014334862385321102
I0
I1
I-1
tp1271
sS'significantly,prolonged,the'
p1272
(F1
F0.00014334862385321102
I1
I0
I1
tp1273
sS'have,been,compared'
p1274
(F1
F0.00014334862385321102
I0
I1
I-1
tp1275
sS'on,the,single'
p1276
(F1
F0.00014334862385321102
I0
I1
I-1
tp1277
sS'there,were,and'
p1278
(F1
F0.00014334862385321102
I0
I1
I-1
tp1279
sS'of,further,alterations'
p1280
(F1
F0.00014334862385321102
I1
I0
I1
tp1281
sS'cmin,plasma,concentration'
p1282
(F1
F0.00028669724770642203
I0
I2
I-2
tp1283
sS'could,be,enhanced'
p1284
(F1
F0.00014334862385321102
I1
I0
I1
tp1285
sS'vitro,studies,of'
p1286
(F1
F0.00028669724770642203
I2
I0
I2
tp1287
sS'to,decrease,plasma'
p1288
(F1
F0.00043004587155963305
I3
I0
I3
tp1289
sS'most,notably,nondepolarizing'
p1290
(F1
F0.00014334862385321102
I1
I0
I1
tp1291
sS'mg,or,of'
p1292
(F1
F0.00014334862385321102
I0
I1
I-1
tp1293
sS'hydroxide,cerivastatin,plasma'
p1294
(F1
F0.00014334862385321102
I0
I1
I-1
tp1295
sS'disulfiram-like,reaction,may'
p1296
(F1
F0.00014334862385321102
I0
I1
I-1
tp1297
sS'hcl,and,agents'
p1298
(F1
F0.00014334862385321102
I1
I0
I1
tp1299
sS'in,vitro,glucuronidation'
p1300
(F1
F0.00014334862385321102
I0
I1
I-1
tp1301
sS'and,such,an'
p1302
(F1
F0.00028669724770642203
I2
I0
I2
tp1303
sS'events,compared,to'
p1304
(F1
F0.00014334862385321102
I1
I0
I1
tp1305
sS'novoseven,and,coagulation'
p1306
(F1
F0.00014334862385321102
I0
I1
I-1
tp1307
sS'clinical,data,suggest'
p1308
(F1
F0.00028669724770642203
I2
I0
I2
tp1309
sS'small,clinical,trial'
p1310
(F1
F0.00014334862385321102
I0
I1
I-1
tp1311
sS'excessive,prolongation,of'
p1312
(F1
F0.00014334862385321102
I1
I0
I1
tp1313
sS'were,decreased,on'
p1314
(F1
F0.00014334862385321102
I1
I0
I1
tp1315
sS'for,of,the'
p1316
(F1
F0.00014334862385321102
I1
I0
I1
tp1317
sS'a,to,dose-related'
p1318
(F1
F0.00014334862385321102
I1
I0
I1
tp1319
sS'and,or,that'
p1320
(F1
F0.00028669724770642203
I2
I0
I2
tp1321
sS'a,non-specific,cyp-450'
p1322
(F1
F0.00014334862385321102
I0
I1
I-1
tp1323
sS'an,adequate,period'
p1324
(F1
F0.00014334862385321102
I0
I1
I-1
tp1325
sS'of,is,increased'
p1326
(F1
F0.00028669724770642203
I2
I0
I2
tp1327
sS'iiia4,inhibitor,it'
p1328
(F1
F0.00014334862385321102
I1
I0
I1
tp1329
sS'acetazolamide,decreases,urinary'
p1330
(F1
F0.00014334862385321102
I1
I0
I1
tp1331
sS'frequency,of,rejection'
p1332
(F1
F0.00014334862385321102
I0
I1
I-1
tp1333
sS'should,be,cautiously'
p1334
(F1
F0.00014334862385321102
I1
I0
I1
tp1335
sS'subjects,were,administered'
p1336
(F1
F0.00028669724770642203
I0
I2
I-2
tp1337
sS'subjects,was,associated'
p1338
(F1
F0.00014334862385321102
I1
I0
I1
tp1339
sS'the,central,effects'
p1340
(F1
F0.00014334862385321102
I1
I0
I1
tp1341
sS'arthritis,concomitant,medications'
p1342
(F1
F0.00014334862385321102
I0
I1
I-1
tp1343
sS'interactions,between,mentax'
p1344
(F1
F0.00014334862385321102
I0
I1
I-1
tp1345
sS'five,days,in'
p1346
(F1
F0.00014334862385321102
I0
I1
I-1
tp1347
sS'other,taken,in'
p1348
(F1
F0.00014334862385321102
I1
I0
I1
tp1349
sS'of,already,accumulated'
p1350
(F1
F0.00014334862385321102
I1
I0
I1
tp1351
sS'significantly,inhibit,alfenta'
p1352
(F1
F0.00014334862385321102
I1
I0
I1
tp1353
sS'bid,n,vs'
p1354
(F1
F0.00014334862385321102
I0
I1
I-1
tp1355
sS'as,long,as'
p1356
(F1
F0.00014334862385321102
I1
I0
I1
tp1357
sS'reported,rarely,with'
p1358
(F1
F0.00014334862385321102
I1
I0
I1
tp1359
sS'with,the,use'
p1360
(F1
F0.00028669724770642203
I0
I2
I-2
tp1361
sS'a,minor,metabolic'
p1362
(F1
F0.00014334862385321102
I0
I1
I-1
tp1363
sS'containing,buffer,should'
p1364
(F1
F0.00014334862385321102
I1
I0
I1
tp1365
sS'thorazine,prolixin,permitil'
p1366
(F1
F0.00014334862385321102
I0
I1
I-1
tp1367
sS'exists,between,vitamin'
p1368
(F1
F0.00043004587155963305
I3
I0
I3
tp1369
sS'consistent,effects,with'
p1370
(F1
F0.00014334862385321102
I0
I1
I-1
tp1371
sS'dose,or,two'
p1372
(F1
F0.00014334862385321102
I1
I0
I1
tp1373
sS'cells,either,by'
p1374
(F1
F0.00014334862385321102
I0
I1
I-1
tp1375
sS'phenylbutazone,causes,increase'
p1376
(F1
F0.00014334862385321102
I1
I0
I1
tp1377
sS'profiles,of,and'
p1378
(F1
F0.00014334862385321102
I0
I1
I-1
tp1379
sS'of,vardenafil,experienced'
p1380
(F1
F0.00014334862385321102
I1
I0
I1
tp1381
sS'as,great,an'
p1382
(F1
F0.00014334862385321102
I0
I1
I-1
tp1383
sS'dry,mouth,and'
p1384
(F1
F0.00014334862385321102
I1
I0
I1
tp1385
sS'but,are,relatively'
p1386
(F1
F0.00014334862385321102
I0
I1
I-1
tp1387
sS'include,extreme,agitation'
p1388
(F1
F0.00014334862385321102
I1
I0
I1
tp1389
sS'were,no,clinically'
p1390
(F1
F0.0010034403669724771
I0
I7
I-7
tp1391
sS'extended,a,similar'
p1392
(F1
F0.00014334862385321102
I1
I0
I1
tp1393
sS'monitored,when,it'
p1394
(F1
F0.00014334862385321102
I1
I0
I1
tp1395
sS'monitored,when,is'
p1396
(F1
F0.00014334862385321102
I1
I0
I1
tp1397
sS'the,committed,step'
p1398
(F1
F0.00014334862385321102
I1
I0
I1
tp1399
sS'st,johns,wort'
p1400
(F0
F0
I1
I1
I0
tp1401
sS'of,had,to'
p1402
(F1
F0.00014334862385321102
I0
I1
I-1
tp1403
sS'other,the,administration'
p1404
(F1
F0.00014334862385321102
I0
I1
I-1
tp1405
sS'nor,is,the'
p1406
(F1
F0.00014334862385321102
I0
I1
I-1
tp1407
sS'three,hours,concurrently'
p1408
(F1
F0.00014334862385321102
I0
I1
I-1
tp1409
sS'angiotensin-converting,enzyme,inhibitor'
p1410
(F1
F0.00014334862385321102
I1
I0
I1
tp1411
sS'of,and,also'
p1412
(F1
F0.00014334862385321102
I1
I0
I1
tp1413
sS'indocin,and,has'
p1414
(F1
F0.00014334862385321102
I1
I0
I1
tp1415
sS'under,treatment,with'
p1416
(F1
F0.00014334862385321102
I1
I0
I1
tp1417
sS'with,a,partially'
p1418
(F1
F0.00014334862385321102
I0
I1
I-1
tp1419
sS'to,mg,for'
p1420
(F0
F0
I1
I1
I0
tp1421
sS'a,regimen,consisting'
p1422
(F1
F0.00014334862385321102
I1
I0
I1
tp1423
sS'false,increases,in'
p1424
(F1
F0.00014334862385321102
I0
I1
I-1
tp1425
sS'vii,when,compared'
p1426
(F1
F0.00014334862385321102
I0
I1
I-1
tp1427
sS'clinical,trial,as'
p1428
(F1
F0.00014334862385321102
I1
I0
I1
tp1429
sS'narcotics,non-narcotic,analgesics'
p1430
(F1
F0.00014334862385321102
I1
I0
I1
tp1431
sS'test,interferences,dicumarol'
p1432
(F1
F0.00014334862385321102
I0
I1
I-1
tp1433
sS'had,a,non-significantly'
p1434
(F1
F0.00014334862385321102
I0
I1
I-1
tp1435
sS'interactions,toxicity,associated'
p1436
(F1
F0.00014334862385321102
I1
I0
I1
tp1437
sS'be,reduced,and'
p1438
(F1
F0.00014334862385321102
I0
I1
I-1
tp1439
sS'long,and,variable'
p1440
(F1
F0.00014334862385321102
I0
I1
I-1
tp1441
sS'limited,comparative,data'
p1442
(F1
F0.00014334862385321102
I0
I1
I-1
tp1443
sS'hypertension,administration,of'
p1444
(F1
F0.00028669724770642203
I2
I0
I2
tp1445
sS'potentiated,the,blood'
p1446
(F1
F0.00014334862385321102
I1
I0
I1
tp1447
sS'metabolite,i,potency'
p1448
(F1
F0.00014334862385321102
I0
I1
I-1
tp1449
sS'demonstrated,the,following'
p1450
(F1
F0.00014334862385321102
I0
I1
I-1
tp1451
sS'these,effects,have'
p1452
(F1
F0.00014334862385321102
I0
I1
I-1
tp1453
sS'be,increased,if'
p1454
(F1
F0.00014334862385321102
I1
I0
I1
tp1455
sS'seen,with,treatment'
p1456
(F1
F0.00014334862385321102
I0
I1
I-1
tp1457
sS'l-ccg,upon,pcp'
p1458
(F1
F0.00014334862385321102
I0
I1
I-1
tp1459
sS'glucose,and,concentrations'
p1460
(F1
F0.00014334862385321102
I0
I1
I-1
tp1461
sS'be,increased,in'
p1462
(F1
F0.00014334862385321102
I1
I0
I1
tp1463
sS'carefully,monitored,when'
p1464
(F1
F0.00028669724770642203
I2
I0
I2
tp1465
sS'dose,of,aprepitant'
p1466
(F0
F0
I2
I2
I0
tp1467
sS'greater,ischemic,response'
p1468
(F1
F0.00014334862385321102
I1
I0
I1
tp1469
sS'following,nimbex,is'
p1470
(F1
F0.00014334862385321102
I1
I0
I1
tp1471
sS'bioavailability,is,mildly'
p1472
(F1
F0.00014334862385321102
I1
I0
I1
tp1473
sS'that,physicians,query'
p1474
(F1
F0.00014334862385321102
I0
I1
I-1
tp1475
sS'highly,protein,bound'
p1476
(F0.5
F0.00028669724770642203
I3
I1
I2
tp1477
sS'a,small,but'
p1478
(F1
F0.00014334862385321102
I1
I0
I1
tp1479
sS'potent,in,lysing'
p1480
(F1
F0.00014334862385321102
I0
I1
I-1
tp1481
sS'observed,after,administration'
p1482
(F1
F0.00014334862385321102
I0
I1
I-1
tp1483
sS'for,oral,solution'
p1484
(F1
F0.0010034403669724771
I7
I0
I7
tp1485
sS'reduction,for,equetrotm'
p1486
(F1
F0.00014334862385321102
I0
I1
I-1
tp1487
sS'of,other,antiepilepsy'
p1488
(F1
F0.00014334862385321102
I1
I0
I1
tp1489
sS'of,ace,inhibitors'
p1490
(F1
F0.00014334862385321102
I0
I1
I-1
tp1491
sS'enzyme,systems,has'
p1492
(F1
F0.00014334862385321102
I1
I0
I1
tp1493
sS'however,if,argatroban'
p1494
(F1
F0.00014334862385321102
I0
I1
I-1
tp1495
sS'agents,including,remicade'
p1496
(F1
F0.00014334862385321102
I1
I0
I1
tp1497
sS'injections,of,aom'
p1498
(F1
F0.00014334862385321102
I0
I1
I-1
tp1499
sS'the,risk,factors'
p1500
(F1
F0.00014334862385321102
I1
I0
I1
tp1501
sS'to,affect,safety'
p1502
(F1
F0.00014334862385321102
I0
I1
I-1
tp1503
sS'enzyme,inhibitors,the'
p1504
(F1
F0.00014334862385321102
I1
I0
I1
tp1505
sS'antihypertensive,agents,that'
p1506
(F1
F0.00028669724770642203
I2
I0
I2
tp1507
sS'blockers,or,proton'
p1508
(F1
F0.00043004587155963305
I3
I0
I3
tp1509
sS'total,rna,from'
p1510
(F1
F0.00014334862385321102
I0
I1
I-1
tp1511
sS'indicate,that,coadministration'
p1512
(F1
F0.00014334862385321102
I1
I0
I1
tp1513
sS'or,dosage,and'
p1514
(F1
F0.00014334862385321102
I0
I1
I-1
tp1515
sS'of,at,least'
p1516
(F1
F0.00028669724770642203
I2
I0
I2
tp1517
sS'of,cyp,enzymes'
p1518
(F1
F0.00014334862385321102
I1
I0
I1
tp1519
sS'interactions,could,occur'
p1520
(F1
F0.00014334862385321102
I0
I1
I-1
tp1521
sS'cyp3a4,isoform,and'
p1522
(F1
F0.00014334862385321102
I0
I1
I-1
tp1523
sS'to,be,ingested'
p1524
(F1
F0.00014334862385321102
I1
I0
I1
tp1525
sS'for,the,following'
p1526
(F1
F0.00014334862385321102
I1
I0
I1
tp1527
sS'not,affect,behaviors'
p1528
(F1
F0.00014334862385321102
I0
I1
I-1
tp1529
sS'azithromycin,did,not'
p1530
(F1
F0.00014334862385321102
I0
I1
I-1
tp1531
sS'the,sole,method'
p1532
(F1
F0.00014334862385321102
I1
I0
I1
tp1533
sS'in,the,diamond'
p1534
(F1
F0.00028669724770642203
I0
I2
I-2
tp1535
sS'patients,may,require'
p1536
(F1
F0.00014334862385321102
I1
I0
I1
tp1537
sS'no,dosage,adjustment'
p1538
(F1
F0.00014334862385321102
I0
I1
I-1
tp1539
sS'sustained-release,tablets,with'
p1540
(F1
F0.00014334862385321102
I0
I1
I-1
tp1541
sS'injection,usp,is'
p1542
(F1
F0.00014334862385321102
I1
I0
I1
tp1543
sS'other,certain,such'
p1544
(F1
F0.00014334862385321102
I1
I0
I1
tp1545
sS'xanthine,and,an'
p1546
(F1
F0.00014334862385321102
I1
I0
I1
tp1547
sS'at,the,absorption'
p1548
(F1
F0.00014334862385321102
I0
I1
I-1
tp1549
sS'aware,that,variable'
p1550
(F1
F0.00014334862385321102
I1
I0
I1
tp1551
sS'levels,of,although'
p1552
(F1
F0.00014334862385321102
I1
I0
I1
tp1553
sS'interaction,which,has'
p1554
(F1
F0.00014334862385321102
I1
I0
I1
tp1555
sS'well,controlled,trials'
p1556
(F1
F0.00014334862385321102
I0
I1
I-1
tp1557
sS'regular,basis,it'
p1558
(F1
F0.00014334862385321102
I0
I1
I-1
tp1559
sS'augments,the,action'
p1560
(F1
F0.00014334862385321102
I1
I0
I1
tp1561
sS'the,cyp2d6,isoenzyme'
p1562
(F0
F0
I1
I1
I0
tp1563
sS'inhibitors,prolong,and'
p1564
(F1
F0.00071674311926605509
I5
I0
I5
tp1565
sS'administered,in,combination'
p1566
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp1567
sS'including,the,concurrent'
p1568
(F1
F0.00014334862385321102
I0
I1
I-1
tp1569
sS'rarely,when,ht1'
p1570
(F1
F0.00014334862385321102
I1
I0
I1
tp1571
sS'of,cyp3a4,have'
p1572
(F1
F0.00014334862385321102
I0
I1
I-1
tp1573
sS'of,in,the'
p1574
(F1
F0.00071674311926605509
I0
I5
I-5
tp1575
sS'digoxin,concomitant,administration'
p1576
(F0
F0
I1
I1
I0
tp1577
sS'already,on,cyp'
p1578
(F1
F0.00014334862385321102
I0
I1
I-1
tp1579
sS'of,septic,shock'
p1580
(F1
F0.00014334862385321102
I0
I1
I-1
tp1581
sS'healthy,volunteers,either'
p1582
(F1
F0.00014334862385321102
I1
I0
I1
tp1583
sS'and,aspecific,treatments'
p1584
(F1
F0.00014334862385321102
I0
I1
I-1
tp1585
sS'gel,should,not'
p1586
(F1
F0.00014334862385321102
I1
I0
I1
tp1587
sS'of,in,de'
p1588
(F1
F0.00014334862385321102
I0
I1
I-1
tp1589
sS'of,on,the'
p1590
(F0.44
F0.0015768348623853212
I7
I18
I-11
tp1591
sS'soft-gelatin,capsule,formulation'
p1592
(F1
F0.00014334862385321102
I1
I0
I1
tp1593
sS'volunteers,established,on'
p1594
(F1
F0.00014334862385321102
I0
I1
I-1
tp1595
sS'taken,by,of'
p1596
(F1
F0.00028669724770642203
I0
I2
I-2
tp1597
sS'be,monitored,by'
p1598
(F1
F0.00014334862385321102
I0
I1
I-1
tp1599
sS'to,study,cocaine-induced'
p1600
(F1
F0.00014334862385321102
I0
I1
I-1
tp1601
sS'of,patients,with'
p1602
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp1603
sS'inhibitor,of,cyp1a2'
p1604
(F1
F0.00014334862385321102
I1
I0
I1
tp1605
sS'substrate,for,deoxycytidine'
p1606
(F1
F0.00014334862385321102
I0
I1
I-1
tp1607
sS'noted,that,haldol'
p1608
(F1
F0.00014334862385321102
I1
I0
I1
tp1609
sS'with,rheumatoid,arthritis'
p1610
(F1
F0.00014334862385321102
I0
I1
I-1
tp1611
sS'coadministration,of,significantly'
p1612
(F1
F0.00014334862385321102
I1
I0
I1
tp1613
sS'of,was,decreased'
p1614
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp1615
sS'be,undertaken,with'
p1616
(F1
F0.00028669724770642203
I2
I0
I2
tp1617
sS'concomitant,therapy,may'
p1618
(F1
F0.00014334862385321102
I0
I1
I-1
tp1619
sS'coadministration,with,videx'
p1620
(F1
F0.00014334862385321102
I0
I1
I-1
tp1621
sS'receiving,mg,of'
p1622
(F1
F0.00014334862385321102
I0
I1
I-1
tp1623
sS'about,of,patients'
p1624
(F1
F0.00014334862385321102
I0
I1
I-1
tp1625
sS'limited,sampling,the'
p1626
(F1
F0.00014334862385321102
I0
I1
I-1
tp1627
sS'in,the,year'
p1628
(F1
F0.00014334862385321102
I0
I1
I-1
tp1629
sS'is,minimally,absorbed'
p1630
(F1
F0.00014334862385321102
I1
I0
I1
tp1631
sS'vardenafil,dose,should'
p1632
(F1
F0.00028669724770642203
I2
I0
I2
tp1633
sS'pharmacokinetics,of,or'
p1634
(F1
F0.00043004587155963305
I0
I3
I-3
tp1635
sS'be,coadministered,with'
p1636
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp1637
sS'fulminant,rhabdomyolysis,has'
p1638
(F1
F0.00014334862385321102
I1
I0
I1
tp1639
sS'be,elevated,in'
p1640
(F1
F0.00028669724770642203
I0
I2
I-2
tp1641
sS'or,hctz,mg'
p1642
(F1
F0.00014334862385321102
I0
I1
I-1
tp1643
sS'for,longer,than'
p1644
(F1
F0.00014334862385321102
I1
I0
I1
tp1645
sS'or,patients,should'
p1646
(F1
F0.00014334862385321102
I0
I1
I-1
tp1647
sS'concomitantly,with,and'
p1648
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp1649
sS'potential,effects,on'
p1650
(F1
F0.00014334862385321102
I1
I0
I1
tp1651
sS'marketing,experiences,of'
p1652
(F1
F0.00014334862385321102
I1
I0
I1
tp1653
sS'of,palythoa,tuberculosa'
p1654
(F1
F0.00014334862385321102
I0
I1
I-1
tp1655
sS'potential,effects,of'
p1656
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp1657
sS'to,days,the'
p1658
(F1
F0.00014334862385321102
I0
I1
I-1
tp1659
sS'with,without,coadministered'
p1660
(F1
F0.00014334862385321102
I0
I1
I-1
tp1661
sS'labetalol,hcl,is'
p1662
(F1
F0.00014334862385321102
I1
I0
I1
tp1663
sS'hydroxytolbutamide,and,was'
p1664
(F1
F0.00014334862385321102
I0
I1
I-1
tp1665
sS'another,oral,azole'
p1666
(F1
F0.00014334862385321102
I1
I0
I1
tp1667
sS'invirase,kaletra,norvir'
p1668
(F1
F0.00014334862385321102
I1
I0
I1
tp1669
sS'release,but,presumably'
p1670
(F1
F0.00014334862385321102
I0
I1
I-1
tp1671
sS'to,decrease,elimination'
p1672
(F1
F0.00014334862385321102
I1
I0
I1
tp1673
sS'or,an,oral'
p1674
(F1
F0.00014334862385321102
I1
I0
I1
tp1675
sS'oral,hypoglycemics,agents'
p1676
(F1
F0.00014334862385321102
I1
I0
I1
tp1677
sS'labetalol,hcl,in'
p1678
(F1
F0.00028669724770642203
I2
I0
I2
tp1679
sS'patients,receiving,ace'
p1680
(F1
F0.00028669724770642203
I2
I0
I2
tp1681
sS'blocking,agents,negative'
p1682
(F1
F0.00014334862385321102
I1
I0
I1
tp1683
sS'with,simulect,with'
p1684
(F1
F0.00014334862385321102
I0
I1
I-1
tp1685
sS'cyp3a4,inducers,drugs'
p1686
(F1
F0.00014334862385321102
I0
I1
I-1
tp1687
sS'of,humorsol,with'
p1688
(F1
F0.00014334862385321102
I1
I0
I1
tp1689
sS'part,of,the'
p1690
(F1
F0.00014334862385321102
I0
I1
I-1
tp1691
sS'nalfon,the,concomitant'
p1692
(F1
F0.00014334862385321102
I1
I0
I1
tp1693
sS'using,these,medicines'
p1694
(F0
F0
I1
I1
I0
tp1695
sS'concentrations,c,max'
p1696
(F1
F0.00014334862385321102
I0
I1
I-1
tp1697
sS'micrograms,caused,a'
p1698
(F1
F0.00014334862385321102
I1
I0
I1
tp1699
sS'the,likelihood,of'
p1700
(F1
F0.00043004587155963305
I3
I0
I3
tp1701
sS'and,non-steroidal,agents'
p1702
(F1
F0.00014334862385321102
I1
I0
I1
tp1703
sS'but,this,is'
p1704
(F1
F0.00014334862385321102
I1
I0
I1
tp1705
sS'dose,study,of'
p1706
(F1
F0.00014334862385321102
I1
I0
I1
tp1707
sS'an,increased,prothrombin'
p1708
(F1
F0.00014334862385321102
I1
I0
I1
tp1709
sS'noradrenaline-precontracted,arteries,from'
p1710
(F1
F0.00014334862385321102
I0
I1
I-1
tp1711
sS'metabolized,by,cyp3a'
p1712
(F1
F0.00014334862385321102
I0
I1
I-1
tp1713
sS'effects,of,lapatinib'
p1714
(F1
F0.00014334862385321102
I0
I1
I-1
tp1715
sS'increased,exposure,of'
p1716
(F1
F0.00028669724770642203
I2
I0
I2
tp1717
sS'aeds,and,were'
p1718
(F1
F0.00014334862385321102
I0
I1
I-1
tp1719
sS'nifedipine,did,not'
p1720
(F1
F0.00014334862385321102
I0
I1
I-1
tp1721
sS'and,antagonists,may'
p1722
(F1
F0.00014334862385321102
I1
I0
I1
tp1723
sS'would,be,unlikely'
p1724
(F1
F0.00014334862385321102
I0
I1
I-1
tp1725
sS'timi-ii,isis-2,currently'
p1726
(F1
F0.00014334862385321102
I0
I1
I-1
tp1727
sS'depressants,and,may'
p1728
(F1
F0.00014334862385321102
I1
I0
I1
tp1729
sS'beta,blockers,and'
p1730
(F1
F0.00014334862385321102
I1
I0
I1
tp1731
sS'potential,for,adverse'
p1732
(F1
F0.00014334862385321102
I0
I1
I-1
tp1733
sS'interaction,between,ssris'
p1734
(F1
F0.00014334862385321102
I0
I1
I-1
tp1735
sS'care,as,they'
p1736
(F1
F0.00014334862385321102
I1
I0
I1
tp1737
sS'in,the,safety'
p1738
(F1
F0.00028669724770642203
I0
I2
I-2
tp1739
sS'under,therapy,should'
p1740
(F1
F0.00014334862385321102
I1
I0
I1
tp1741
sS'with,nitrous,oxide'
p1742
(F1
F0.00014334862385321102
I1
I0
I1
tp1743
sS'calcium,channel,blocking'
p1744
(F1
F0.00028669724770642203
I0
I2
I-2
tp1745
sS'of,ergocalcitriol,will'
p1746
(F1
F0.00043004587155963305
I0
I3
I-3
tp1747
sS'of,aprepitant,on'
p1748
(F1
F0.00028669724770642203
I2
I0
I2
tp1749
sS'with,ethyl,mao'
p1750
(F1
F0.00014334862385321102
I1
I0
I1
tp1751
sS'when,selecting,an'
p1752
(F1
F0.00028669724770642203
I2
I0
I2
tp1753
sS'ld50,of,with'
p1754
(F1
F0.00014334862385321102
I1
I0
I1
tp1755
sS'some,agents,such'
p1756
(F1
F0.00014334862385321102
I0
I1
I-1
tp1757
sS'this,may,lead'
p1758
(F1
F0.00014334862385321102
I0
I1
I-1
tp1759
sS'with,d2-antagonists,such'
p1760
(F1
F0.00014334862385321102
I1
I0
I1
tp1761
sS'effect,of,a'
p1762
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp1763
sS'vitamin,a,to'
p1764
(F1
F0.00014334862385321102
I1
I0
I1
tp1765
sS'anionic-binding,has,a'
p1766
(F1
F0.00014334862385321102
I1
I0
I1
tp1767
sS'rate-limiting,step,in'
p1768
(F1
F0.00014334862385321102
I0
I1
I-1
tp1769
sS'in,general,these'
p1770
(F1
F0.00014334862385321102
I0
I1
I-1
tp1771
sS'of,sodium,from'
p1772
(F1
F0.00014334862385321102
I1
I0
I1
tp1773
sS'potential,for,hepatic'
p1774
(F1
F0.00014334862385321102
I0
I1
I-1
tp1775
sS'interval,significantly,increased'
p1776
(F1
F0.00014334862385321102
I1
I0
I1
tp1777
sS'this,was,prevented'
p1778
(F1
F0.00014334862385321102
I1
I0
I1
tp1779
sS'qtc,prolongation,with'
p1780
(F1
F0.00014334862385321102
I0
I1
I-1
tp1781
sS'required,when,this'
p1782
(F1
F0.00014334862385321102
I0
I1
I-1
tp1783
sS'acute,toxicity,and'
p1784
(F1
F0.00014334862385321102
I0
I1
I-1
tp1785
sS'prolonged,therapy,including'
p1786
(F1
F0.00014334862385321102
I0
I1
I-1
tp1787
sS'show,that,a'
p1788
(F1
F0.00014334862385321102
I0
I1
I-1
tp1789
sS'active,metabolite,may'
p1790
(F1
F0.00014334862385321102
I1
I0
I1
tp1791
sS'a,chylomicron-like,emulsion'
p1792
(F1
F0.00014334862385321102
I0
I1
I-1
tp1793
sS'the,with,the'
p1794
(F1
F0.00014334862385321102
I1
I0
I1
tp1795
sS'on,platelet,aggregation'
p1796
(F1
F0.00014334862385321102
I1
I0
I1
tp1797
sS'these,interactions,is'
p1798
(F1
F0.00014334862385321102
I0
I1
I-1
tp1799
sS'temporarily,suspending,use'
p1800
(F1
F0.00014334862385321102
I1
I0
I1
tp1801
sS'produce,malabsorption,of'
p1802
(F1
F0.00014334862385321102
I1
I0
I1
tp1803
sS'to,attenuate,some'
p1804
(F1
F0.00028669724770642203
I0
I2
I-2
tp1805
sS'certain,including,products'
p1806
(F1
F0.00014334862385321102
I1
I0
I1
tp1807
sS'a,placebo-controlled,phase'
p1808
(F1
F0.00014334862385321102
I0
I1
I-1
tp1809
sS'oral,phenytoin,protease'
p1810
(F1
F0.00014334862385321102
I1
I0
I1
tp1811
sS'phase,and,for'
p1812
(F1
F0.00014334862385321102
I0
I1
I-1
tp1813
sS'minor,changes,in'
p1814
(F1
F0.00028669724770642203
I2
I0
I2
tp1815
sS's,disease,who'
p1816
(F1
F0.00014334862385321102
I0
I1
I-1
tp1817
sS'schedule,of,sodium'
p1818
(F1
F0.00014334862385321102
I0
I1
I-1
tp1819
sS'coma,have,been'
p1820
(F1
F0.00014334862385321102
I1
I0
I1
tp1821
sS'midazolam,used,at'
p1822
(F1
F0.00014334862385321102
I1
I0
I1
tp1823
sS'case,study,has'
p1824
(F1
F0.00014334862385321102
I1
I0
I1
tp1825
sS'cimetidines,known,inhibition'
p1826
(F1
F0.00014334862385321102
I1
I0
I1
tp1827
sS'either,tagamet,mg'
p1828
(F1
F0.00014334862385321102
I1
I0
I1
tp1829
sS'conclusions,interpretation,glucose'
p1830
(F1
F0.00014334862385321102
I0
I1
I-1
tp1831
sS'was,greater,patients'
p1832
(F1
F0.00014334862385321102
I1
I0
I1
tp1833
sS'isozymes,responsible,for'
p1834
(F1
F0.00028669724770642203
I2
I0
I2
tp1835
sS'warfarin,and,anticoagulants'
p1836
(F1
F0.00014334862385321102
I1
I0
I1
tp1837
sS'systems,for,and'
p1838
(F1
F0.00014334862385321102
I0
I1
I-1
tp1839
sS'the,same,metabolic'
p1840
(F1
F0.00014334862385321102
I0
I1
I-1
tp1841
sS'if,cefotan,and'
p1842
(F1
F0.00014334862385321102
I1
I0
I1
tp1843
sS'subjects,should,be'
p1844
(F1
F0.00057339449541284407
I4
I0
I4
tp1845
sS'with,multiple,effects'
p1846
(F1
F0.00014334862385321102
I1
I0
I1
tp1847
sS'methotrexate,cyclosporine,diclofenac'
p1848
(F1
F0.00014334862385321102
I0
I1
I-1
tp1849
sS'effectiveness,of,argatroban'
p1850
(F1
F0.00014334862385321102
I0
I1
I-1
tp1851
sS'under,similar,conditions'
p1852
(F1
F0.00014334862385321102
I0
I1
I-1
tp1853
sS'nardil,matulane,eldepryl'
p1854
(F1
F0.00014334862385321102
I0
I1
I-1
tp1855
sS'on,tyrosine,phosphorylation'
p1856
(F1
F0.00014334862385321102
I1
I0
I1
tp1857
sS'clinical,significance,on'
p1858
(F1
F0.00014334862385321102
I1
I0
I1
tp1859
sS'nifedipine,may,be'
p1860
(F1
F0.00014334862385321102
I0
I1
I-1
tp1861
sS'potent,cyp3a4,inducer'
p1862
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp1863
sS'oxidase,inhibitors,psychotropic'
p1864
(F1
F0.00014334862385321102
I1
I0
I1
tp1865
sS'patients,the,metabolic'
p1866
(F1
F0.00028669724770642203
I2
I0
I2
tp1867
sS'leucovorin,may,enhance'
p1868
(F1
F0.00014334862385321102
I1
I0
I1
tp1869
sS'b-lactam,renal,excretion'
p1870
(F1
F0.00014334862385321102
I1
I0
I1
tp1871
sS'with,have,identified'
p1872
(F1
F0.00014334862385321102
I1
I0
I1
tp1873
sS'have,any,clinically'
p1874
(F1
F0.00057339449541284407
I0
I4
I-4
tp1875
sS'proportion,of,patients'
p1876
(F1
F0.00014334862385321102
I1
I0
I1
tp1877
sS'allows,to,open'
p1878
(F1
F0.00014334862385321102
I1
I0
I1
tp1879
sS'the,toxicity,may'
p1880
(F1
F0.00014334862385321102
I1
I0
I1
tp1881
sS'the,chick,by'
p1882
(F1
F0.00014334862385321102
I0
I1
I-1
tp1883
sS'on,activity,persists'
p1884
(F1
F0.00014334862385321102
I1
I0
I1
tp1885
sS'other,agents,may'
p1886
(F1
F0.00028669724770642203
I2
I0
I2
tp1887
sS'protease,inhibitors,amprenavir'
p1888
(F1
F0.00014334862385321102
I1
I0
I1
tp1889
sS'small,but,statistically'
p1890
(F1
F0.00014334862385321102
I1
I0
I1
tp1891
sS'vardenafil,with,mg'
p1892
(F1
F0.00028669724770642203
I2
I0
I2
tp1893
sS'h,among,the'
p1894
(F1
F0.00014334862385321102
I1
I0
I1
tp1895
sS'very,strong,and'
p1896
(F1
F0.00014334862385321102
I1
I0
I1
tp1897
sS'average,decreases,of'
p1898
(F1
F0.00014334862385321102
I1
I0
I1
tp1899
sS'of,concurrent,use'
p1900
(F1
F0.00014334862385321102
I1
I0
I1
tp1901
sS'in,survanta,a'
p1902
(F1
F0.00014334862385321102
I0
I1
I-1
tp1903
sS'inhibitors,and,other'
p1904
(F1
F0.00014334862385321102
I1
I0
I1
tp1905
sS'effects,of,isosorbide'
p1906
(F1
F0.00028669724770642203
I2
I0
I2
tp1907
sS'oral,anticoagulants,caution'
p1908
(F1
F0.00014334862385321102
I1
I0
I1
tp1909
sS'those,of,the'
p1910
(F1
F0.00014334862385321102
I1
I0
I1
tp1911
sS'or,mg,qd'
p1912
(F1
F0.00014334862385321102
I0
I1
I-1
tp1913
sS'in,patients,who'
p1914
(F0.84615384615384615
F0.0015768348623853212
I12
I1
I11
tp1915
sS'required,when,is'
p1916
(F1
F0.00014334862385321102
I1
I0
I1
tp1917
sS'addition,there,have'
p1918
(F1
F0.00014334862385321102
I1
I0
I1
tp1919
sS'given,with,or'
p1920
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp1921
sS'patients,on,than'
p1922
(F1
F0.00014334862385321102
I1
I0
I1
tp1923
sS'mean,auc,increased'
p1924
(F1
F0.00014334862385321102
I1
I0
I1
tp1925
sS'of,in,anhydrous'
p1926
(F1
F0.00014334862385321102
I1
I0
I1
tp1927
sS'secretion,of,colonic'
p1928
(F1
F0.00014334862385321102
I0
I1
I-1
tp1929
sS'experiments,reactions,to'
p1930
(F1
F0.00014334862385321102
I0
I1
I-1
tp1931
sS'agents,seizures,have'
p1932
(F1
F0.00014334862385321102
I1
I0
I1
tp1933
sS'beta-adrenergic,blocker,given'
p1934
(F1
F0.00014334862385321102
I1
I0
I1
tp1935
sS'may,not,require'
p1936
(F1
F0.00014334862385321102
I0
I1
I-1
tp1937
sS'two,are,coadministered'
p1938
(F1
F0.00014334862385321102
I1
I0
I1
tp1939
sS'and,other,certain'
p1940
(F1
F0.00014334862385321102
I1
I0
I1
tp1941
sS'not,ordinarily,recommended'
p1942
(F1
F0.00014334862385321102
I1
I0
I1
tp1943
sS'studies,also,suggest'
p1944
(F1
F0.00014334862385321102
I1
I0
I1
tp1945
sS'advised,when,is'
p1946
(F1
F0.00014334862385321102
I1
I0
I1
tp1947
sS'pharmacokinetics,of,when'
p1948
(F1
F0.00014334862385321102
I0
I1
I-1
tp1949
sS'suggests,that,coadministration'
p1950
(F1
F0.00014334862385321102
I1
I0
I1
tp1951
sS'plus,highly,active'
p1952
(F1
F0.00014334862385321102
I0
I1
I-1
tp1953
sS'from,mg,by'
p1954
(F1
F0.00014334862385321102
I1
I0
I1
tp1955
sS'f2alpha,and,in'
p1956
(F1
F0.00014334862385321102
I1
I0
I1
tp1957
sS'first,rapid,contraction'
p1958
(F1
F0.00014334862385321102
I0
I1
I-1
tp1959
sS'possible,that,may'
p1960
(F1
F0.00014334862385321102
I1
I0
I1
tp1961
sS'levels,and,a'
p1962
(F1
F0.00071674311926605509
I5
I0
I5
tp1963
sS'mg,combined,with'
p1964
(F1
F0.00014334862385321102
I1
I0
I1
tp1965
sS'the,increased,risk'
p1966
(F0
F0
I1
I1
I0
tp1967
sS'a,dose-related,blockade'
p1968
(F1
F0.00014334862385321102
I1
I0
I1
tp1969
sS'form,or,may'
p1970
(F1
F0.00014334862385321102
I1
I0
I1
tp1971
sS'between,and,has'
p1972
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp1973
sS'also,received,ace'
p1974
(F1
F0.00014334862385321102
I0
I1
I-1
tp1975
sS'the,neuron,blockade'
p1976
(F1
F0.00014334862385321102
I1
I0
I1
tp1977
sS'of,arrhythmias,due'
p1978
(F1
F0.00014334862385321102
I0
I1
I-1
tp1979
sS'retention,of,these'
p1980
(F1
F0.00014334862385321102
I0
I1
I-1
tp1981
sS'eg,selective,serotonin'
p1982
(F1
F0.00014334862385321102
I0
I1
I-1
tp1983
sS'or,qtc,interval'
p1984
(F1
F0.00014334862385321102
I0
I1
I-1
tp1985
sS'did,not,appear'
p1986
(F1
F0.00014334862385321102
I0
I1
I-1
tp1987
sS'reactions,including,hyperthermia'
p1988
(F1
F0.00014334862385321102
I1
I0
I1
tp1989
sS'mean,of,and'
p1990
(F1
F0.00014334862385321102
I1
I0
I1
tp1991
sS'administering,concurrently,with'
p1992
(F1
F0.00014334862385321102
I1
I0
I1
tp1993
sS'levels,in,of'
p1994
(F1
F0.00014334862385321102
I1
I0
I1
tp1995
sS'are,substrates,for'
p1996
(F1
F0.0008600917431192661
I0
I6
I-6
tp1997
sS'shown,that,concomitan'
p1998
(F1
F0.00014334862385321102
I1
I0
I1
tp1999
sS'dose,of,sensipar'
p2000
(F1
F0.00014334862385321102
I1
I0
I1
tp2001
sS'other,hand,intrathecal'
p2002
(F1
F0.00014334862385321102
I1
I0
I1
tp2003
sS'approximately,and,cmax'
p2004
(F1
F0.00014334862385321102
I1
I0
I1
tp2005
sS'of,angiomax,and'
p2006
(F1
F0.00014334862385321102
I0
I1
I-1
tp2007
sS'rate,of,excretion'
p2008
(F1
F0.00014334862385321102
I1
I0
I1
tp2009
sS'synthetic,and,catabolic'
p2010
(F1
F0.00043004587155963305
I3
I0
I3
tp2011
sS'reduction,in,effect'
p2012
(F1
F0.00014334862385321102
I1
I0
I1
tp2013
sS'monitored,and,adjustment'
p2014
(F1
F0.00014334862385321102
I1
I0
I1
tp2015
sS'trileptal,with,hormonal'
p2016
(F1
F0.00014334862385321102
I1
I0
I1
tp2017
sS'use,with,would'
p2018
(F1
F0.00014334862385321102
I1
I0
I1
tp2019
sS'in,vivo,resulted'
p2020
(F1
F0.00014334862385321102
I0
I1
I-1
tp2021
sS'decrease,in,bioavailability'
p2022
(F1
F0.00014334862385321102
I1
I0
I1
tp2023
sS'breast,cancer,were'
p2024
(F1
F0.00014334862385321102
I1
I0
I1
tp2025
sS'use,has,been'
p2026
(F1
F0.00014334862385321102
I1
I0
I1
tp2027
sS'of,similar,potential'
p2028
(F1
F0.00028669724770642203
I2
I0
I2
tp2029
sS'for,potentially,serious'
p2030
(F1
F0.00014334862385321102
I1
I0
I1
tp2031
sS'indicate,that,does'
p2032
(F1
F0.00043004587155963305
I0
I3
I-3
tp2033
sS'by,the,known'
p2034
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp2035
sS'of,romazicon,may'
p2036
(F1
F0.00014334862385321102
I0
I1
I-1
tp2037
sS'effects,of,indocin'
p2038
(F1
F0.00014334862385321102
I1
I0
I1
tp2039
sS'if,high,doses'
p2040
(F1
F0.00014334862385321102
I1
I0
I1
tp2041
sS'vasoconstrictive,and,inotropic'
p2042
(F1
F0.00014334862385321102
I1
I0
I1
tp2043
sS'the,k,contribution'
p2044
(F1
F0.00014334862385321102
I0
I1
I-1
tp2045
sS'respiration,and,cell'
p2046
(F1
F0.00014334862385321102
I0
I1
I-1
tp2047
sS'metabolizers,with,regard'
p2048
(F1
F0.00028669724770642203
I0
I2
I-2
tp2049
sS'consume,and,hydroxy-1'
p2050
(F1
F0.00014334862385321102
I1
I0
I1
tp2051
sS'could,occur,following'
p2052
(F1
F0.00014334862385321102
I0
I1
I-1
tp2053
sS'cyclosporine,elevated,serum'
p2054
(F1
F0.00028669724770642203
I2
I0
I2
tp2055
sS'prevention,studies,used'
p2056
(F1
F0.00014334862385321102
I0
I1
I-1
tp2057
sS'to,enhance,in'
p2058
(F1
F0.00014334862385321102
I1
I0
I1
tp2059
sS'thus,impairing,absorption'
p2060
(F1
F0.00014334862385321102
I1
I0
I1
tp2061
sS'established,in,experiments'
p2062
(F1
F0.00014334862385321102
I0
I1
I-1
tp2063
sS'the,effect,on'
p2064
(F1
F0.00014334862385321102
I0
I1
I-1
tp2065
sS'pressure,lowering,effects'
p2066
(F1
F0.00014334862385321102
I1
I0
I1
tp2067
sS'interresponse,times,as'
p2068
(F1
F0.00014334862385321102
I0
I1
I-1
tp2069
sS'without,preventing,its'
p2070
(F1
F0.00014334862385321102
I1
I0
I1
tp2071
sS'fold,elevation,in'
p2072
(F1
F0.00014334862385321102
I1
I0
I1
tp2073
sS'acute,increase,in'
p2074
(F1
F0.00014334862385321102
I0
I1
I-1
tp2075
sS'small,increase,in'
p2076
(F1
F0.00014334862385321102
I0
I1
I-1
tp2077
sS'pressure,caution,in'
p2078
(F1
F0.00014334862385321102
I1
I0
I1
tp2079
sS'oxidase,inhibitors,maoi'
p2080
(F1
F0.00028669724770642203
I2
I0
I2
tp2081
sS'mg,produced,an'
p2082
(F1
F0.00014334862385321102
I1
I0
I1
tp2083
sS'performed,with,fondaparinux'
p2084
(F1
F0.00014334862385321102
I0
I1
I-1
tp2085
sS'antagonistic,effect,of'
p2086
(F1
F0.00014334862385321102
I1
I0
I1
tp2087
sS'after,a,week'
p2088
(F1
F0.00028669724770642203
I2
I0
I2
tp2089
sS'pharmacologic,activities,similar'
p2090
(F1
F0.00014334862385321102
I0
I1
I-1
tp2091
sS'schizoaffective,disorder,or'
p2092
(F1
F0.00014334862385321102
I1
I0
I1
tp2093
sS'n,the,mean'
p2094
(F1
F0.00014334862385321102
I1
I0
I1
tp2095
sS'be,alert,to'
p2096
(F1
F0.00028669724770642203
I2
I0
I2
tp2097
sS'thiazide,diuretics,the'
p2098
(F1
F0.00014334862385321102
I1
I0
I1
tp2099
sS'of,this,isoenzyme'
p2100
(F0
F0
I1
I1
I0
tp2101
sS'with,coenzyme,a'
p2102
(F1
F0.00014334862385321102
I0
I1
I-1
tp2103
sS'occur,between,epa'
p2104
(F1
F0.00014334862385321102
I1
I0
I1
tp2105
sS'may,ameliorate,increased'
p2106
(F1
F0.00014334862385321102
I1
I0
I1
tp2107
sS'aerosol,particles,of'
p2108
(F1
F0.00043004587155963305
I0
I3
I-3
tp2109
sS'azopt,ophthalmic,suspension'
p2110
(F1
F0.00014334862385321102
I0
I1
I-1
tp2111
sS'relafen,daypro,and'
p2112
(F1
F0.00014334862385321102
I0
I1
I-1
tp2113
sS'other,ht1b,d'
p2114
(F1
F0.00014334862385321102
I1
I0
I1
tp2115
sS'binds,differently,than'
p2116
(F1
F0.00014334862385321102
I0
I1
I-1
tp2117
sS'digoxin,when,starlix'
p2118
(F1
F0.00014334862385321102
I0
I1
I-1
tp2119
sS'to,when,trileptal'
p2120
(F1
F0.00014334862385321102
I1
I0
I1
tp2121
sS'autoimmune,and,inflammatory'
p2122
(F1
F0.00014334862385321102
I1
I0
I1
tp2123
sS'homodimeric,disintegrin,was'
p2124
(F1
F0.00014334862385321102
I0
I1
I-1
tp2125
sS'tricyclic,and,may'
p2126
(F1
F0.00014334862385321102
I1
I0
I1
tp2127
sS'combination,with,close'
p2128
(F1
F0.00014334862385321102
I1
I0
I1
tp2129
sS'beta-glucuronidase,are,given'
p2130
(F1
F0.00014334862385321102
I0
I1
I-1
tp2131
sS'looks,at,five'
p2132
(F1
F0.00014334862385321102
I0
I1
I-1
tp2133
sS'continued,if,vioxx'
p2134
(F1
F0.00014334862385321102
I1
I0
I1
tp2135
sS'of,a,day'
p2136
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2137
sS'decrease,in,anti-inflammatory'
p2138
(F1
F0.00014334862385321102
I1
I0
I1
tp2139
sS'trial,in,which'
p2140
(F1
F0.00028669724770642203
I0
I2
I-2
tp2141
sS'cholestytamine,and,have'
p2142
(F1
F0.00014334862385321102
I1
I0
I1
tp2143
sS'when,was,taken'
p2144
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2145
sS'oral,medications,containing'
p2146
(F1
F0.00014334862385321102
I1
I0
I1
tp2147
sS'at,microm,preferentially'
p2148
(F1
F0.00014334862385321102
I1
I0
I1
tp2149
sS'weight,was,ineffective'
p2150
(F1
F0.00014334862385321102
I0
I1
I-1
tp2151
sS'co-administration,of,at'
p2152
(F0
F0
I1
I1
I0
tp2153
sS'study,of,arava'
p2154
(F1
F0.00014334862385321102
I1
I0
I1
tp2155
sS'flolan,is,administered'
p2156
(F1
F0.00014334862385321102
I1
I0
I1
tp2157
sS'a,tablet,formulation'
p2158
(F1
F0.00028669724770642203
I2
I0
I2
tp2159
sS'time,inr,should'
p2160
(F1
F0.00014334862385321102
I1
I0
I1
tp2161
sS'has,resulted,in'
p2162
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2163
sS'additionally,brevibloc,should'
p2164
(F1
F0.00014334862385321102
I1
I0
I1
tp2165
sS'much,as,hours'
p2166
(F1
F0.00014334862385321102
I1
I0
I1
tp2167
sS'by,this,class'
p2168
(F1
F0.00014334862385321102
I0
I1
I-1
tp2169
sS'than,one-tenth,of'
p2170
(F1
F0.00014334862385321102
I1
I0
I1
tp2171
sS'for,patients,given'
p2172
(F1
F0.00014334862385321102
I1
I0
I1
tp2173
sS'of,plasma,protein'
p2174
(F1
F0.00014334862385321102
I0
I1
I-1
tp2175
sS'addition,the,beneficial'
p2176
(F1
F0.00014334862385321102
I1
I0
I1
tp2177
sS'observed,when,vardenafil'
p2178
(F1
F0.00014334862385321102
I0
I1
I-1
tp2179
sS'the,severity,of'
p2180
(F1
F0.00014334862385321102
I1
I0
I1
tp2181
sS'administered,concomitantly,to'
p2182
(F1
F0.00014334862385321102
I1
I0
I1
tp2183
sS'however,has,the'
p2184
(F1
F0.00014334862385321102
I1
I0
I1
tp2185
sS'when,coadministered,with'
p2186
(F0.59999999999999998
F0.0012901376146788992
I12
I3
I9
tp2187
sS'one-stage,coagulation,assays'
p2188
(F1
F0.00014334862385321102
I0
I1
I-1
tp2189
sS'and,pharmacologic,effects'
p2190
(F1
F0.00014334862385321102
I0
I1
I-1
tp2191
sS'for,abilify,to'
p2192
(F1
F0.00014334862385321102
I0
I1
I-1
tp2193
sS'produce,significant,inhibition'
p2194
(F1
F0.00014334862385321102
I1
I0
I1
tp2195
sS'other,agents,given'
p2196
(F1
F0.00014334862385321102
I0
I1
I-1
tp2197
sS'been,extensively,studied'
p2198
(F1
F0.00014334862385321102
I0
I1
I-1
tp2199
sS'heparin,other,and'
p2200
(F1
F0.00014334862385321102
I0
I1
I-1
tp2201
sS'produce,false,increases'
p2202
(F1
F0.00028669724770642203
I0
I2
I-2
tp2203
sS'active,metabolite,which'
p2204
(F1
F0.00028669724770642203
I2
I0
I2
tp2205
sS'inhibitors,hypertensive,reactions'
p2206
(F1
F0.00014334862385321102
I1
I0
I1
tp2207
sS'neuropathy,during,videx'
p2208
(F1
F0.00014334862385321102
I0
I1
I-1
tp2209
sS'nanm,but,not'
p2210
(F1
F0.00028669724770642203
I2
I0
I2
tp2211
sS'tinnitus,and,decreased'
p2212
(F1
F0.00014334862385321102
I1
I0
I1
tp2213
sS'endogenous,plasma,levels'
p2214
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2215
sS'either,nanm,or'
p2216
(F1
F0.00014334862385321102
I1
I0
I1
tp2217
sS'more,in,some'
p2218
(F1
F0.00014334862385321102
I1
I0
I1
tp2219
sS'that,resulted,in'
p2220
(F1
F0.00014334862385321102
I1
I0
I1
tp2221
sS'ibuprofen,is,known'
p2222
(F1
F0.00014334862385321102
I0
I1
I-1
tp2223
sS'gabitril,with,other'
p2224
(F1
F0.00014334862385321102
I0
I1
I-1
tp2225
sS'of,vitamin,b12'
p2226
(F1
F0.00014334862385321102
I1
I0
I1
tp2227
sS'or,citrate,accumulation'
p2228
(F1
F0.00014334862385321102
I0
I1
I-1
tp2229
sS'pharmacological,interaction,this'
p2230
(F1
F0.00014334862385321102
I1
I0
I1
tp2231
sS'in,chemotherapy,or'
p2232
(F1
F0.00014334862385321102
I0
I1
I-1
tp2233
sS'group,of,newly'
p2234
(F1
F0.00014334862385321102
I0
I1
I-1
tp2235
sS'antagonists,co-administration,of'
p2236
(F1
F0.00014334862385321102
I1
I0
I1
tp2237
sS'patients,the,steady-state'
p2238
(F1
F0.00014334862385321102
I1
I0
I1
tp2239
sS'given,mg,day'
p2240
(F1
F0.00014334862385321102
I0
I1
I-1
tp2241
sS'heparin-induced,thrombocytopenia,the'
p2242
(F1
F0.00014334862385321102
I0
I1
I-1
tp2243
sS'modulation,of,allergic'
p2244
(F1
F0.00014334862385321102
I1
I0
I1
tp2245
sS'myopathy,in,a'
p2246
(F1
F0.00014334862385321102
I0
I1
I-1
tp2247
sS'were,administered,hydrochloride'
p2248
(F1
F0.00014334862385321102
I0
I1
I-1
tp2249
sS'be,lower,and'
p2250
(F1
F0.00014334862385321102
I1
I0
I1
tp2251
sS'reports,of,pregnancy'
p2252
(F1
F0.00014334862385321102
I0
I1
I-1
tp2253
sS'addition,neuromuscular,blocking'
p2254
(F1
F0.00014334862385321102
I0
I1
I-1
tp2255
sS'who,have,benign'
p2256
(F1
F0.00014334862385321102
I0
I1
I-1
tp2257
sS'interaction,with,fluoxetine'
p2258
(F1
F0.00014334862385321102
I0
I1
I-1
tp2259
sS'the,same,age'
p2260
(F1
F0.00014334862385321102
I0
I1
I-1
tp2261
sS'adjustment,of,is'
p2262
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2263
sS'daily,had,no'
p2264
(F1
F0.00028669724770642203
I0
I2
I-2
tp2265
sS'not,include,sufficient'
p2266
(F1
F0.00014334862385321102
I0
I1
I-1
tp2267
sS'report,any,serious'
p2268
(F1
F0.00014334862385321102
I0
I1
I-1
tp2269
sS'micrograms,completely,blocked'
p2270
(F1
F0.00014334862385321102
I1
I0
I1
tp2271
sS'intake,for,longer'
p2272
(F1
F0.00014334862385321102
I1
I0
I1
tp2273
sS'should,be,approached'
p2274
(F1
F0.0010034403669724771
I7
I0
I7
tp2275
sS'other,antipsychotic,agents'
p2276
(F1
F0.00014334862385321102
I1
I0
I1
tp2277
sS'gm,day,days'
p2278
(F1
F0.00014334862385321102
I1
I0
I1
tp2279
sS'patient,appeared,to'
p2280
(F1
F0.00014334862385321102
I1
I0
I1
tp2281
sS'of,addiction,while'
p2282
(F1
F0.00014334862385321102
I0
I1
I-1
tp2283
sS'acarbose,did,not'
p2284
(F1
F0.00014334862385321102
I0
I1
I-1
tp2285
sS'that,inhibit,the'
p2286
(F1
F0.00014334862385321102
I0
I1
I-1
tp2287
sS'with,ribavirin,see'
p2288
(F1
F0.00014334862385321102
I0
I1
I-1
tp2289
sS'and,indicated,that'
p2290
(F1
F0.00014334862385321102
I0
I1
I-1
tp2291
sS'reduce,the,oral'
p2292
(F1
F0.00014334862385321102
I1
I0
I1
tp2293
sS'sometimes,mcg,per'
p2294
(F1
F0.00014334862385321102
I0
I1
I-1
tp2295
sS'between,and,both'
p2296
(F1
F0.00014334862385321102
I0
I1
I-1
tp2297
sS'period,after,discontinuation'
p2298
(F1
F0.00014334862385321102
I0
I1
I-1
tp2299
sS'metabolism,of,commonly'
p2300
(F1
F0.00014334862385321102
I0
I1
I-1
tp2301
sS'release,tablets,administration'
p2302
(F1
F0.00014334862385321102
I1
I0
I1
tp2303
sS'controlled,clinical,studies'
p2304
(F1
F0.00014334862385321102
I0
I1
I-1
tp2305
sS'and,and,are'
p2306
(F1
F0.00014334862385321102
I0
I1
I-1
tp2307
sS'clinically,meaningful,reductions'
p2308
(F1
F0.00014334862385321102
I1
I0
I1
tp2309
sS'prior,to,a'
p2310
(F1
F0.00043004587155963305
I3
I0
I3
tp2311
sS'cytochrome,p450,isoenzymes'
p2312
(F1
F0.00014334862385321102
I0
I1
I-1
tp2313
sS'adjustment,should,be'
p2314
(F1
F0.00014334862385321102
I1
I0
I1
tp2315
sS'use,of,clozapine'
p2316
(F1
F0.00014334862385321102
I1
I0
I1
tp2317
sS'elevations,less,than'
p2318
(F1
F0.00014334862385321102
I1
I0
I1
tp2319
sS'patients,with,type'
p2320
(F1
F0.00028669724770642203
I0
I2
I-2
tp2321
sS'patients,on,coumarin-type'
p2322
(F1
F0.00014334862385321102
I1
I0
I1
tp2323
sS'performed,in,patients'
p2324
(F1
F0.00014334862385321102
I0
I1
I-1
tp2325
sS'inhibitor,and,initiation'
p2326
(F1
F0.00014334862385321102
I1
I0
I1
tp2327
sS'decreased,to,micrograms'
p2328
(F1
F0.00014334862385321102
I1
I0
I1
tp2329
sS'comprehensive,review,was'
p2330
(F1
F0.00014334862385321102
I0
I1
I-1
tp2331
sS'maximal,to,days'
p2332
(F1
F0.00014334862385321102
I1
I0
I1
tp2333
sS'renal,elimination,but'
p2334
(F1
F0.00014334862385321102
I1
I0
I1
tp2335
sS'and,titration,to'
p2336
(F1
F0.00014334862385321102
I1
I0
I1
tp2337
sS'or,two,mg'
p2338
(F1
F0.00014334862385321102
I1
I0
I1
tp2339
sS'cmax,were,observed'
p2340
(F1
F0.00014334862385321102
I0
I1
I-1
tp2341
sS'the,and,chop'
p2342
(F1
F0.00014334862385321102
I0
I1
I-1
tp2343
sS'serious,infections,was'
p2344
(F1
F0.00028669724770642203
I2
I0
I2
tp2345
sS'medicines,with,l-tryptophan'
p2346
(F1
F0.00014334862385321102
I0
I1
I-1
tp2347
sS'believed,that,the'
p2348
(F1
F0.00014334862385321102
I1
I0
I1
tp2349
sS'initial,doses,and'
p2350
(F1
F0.00014334862385321102
I1
I0
I1
tp2351
sS'longterm,treatment,of'
p2352
(F1
F0.00014334862385321102
I0
I1
I-1
tp2353
sS'resulted,in,significant'
p2354
(F1
F0.00014334862385321102
I1
I0
I1
tp2355
sS'rate,requirements,may'
p2356
(F1
F0.00014334862385321102
I1
I0
I1
tp2357
sS'recommended,maximum,human'
p2358
(F1
F0.00014334862385321102
I1
I0
I1
tp2359
sS'from,the,body'
p2360
(F1
F0.00014334862385321102
I1
I0
I1
tp2361
sS'increase,plasmaconcentration,of'
p2362
(F1
F0.00014334862385321102
I1
I0
I1
tp2363
sS'probenecid,increases,both'
p2364
(F1
F0.00014334862385321102
I1
I0
I1
tp2365
sS'fraction,of,at'
p2366
(F1
F0.00014334862385321102
I0
I1
I-1
tp2367
sS'shown,to,change'
p2368
(F1
F0.00014334862385321102
I1
I0
I1
tp2369
sS'showed,differential,effects'
p2370
(F1
F0.00014334862385321102
I0
I1
I-1
tp2371
sS'all,when,potent'
p2372
(F1
F0.00014334862385321102
I1
I0
I1
tp2373
sS'cmin,decreased,to'
p2374
(F1
F0.00014334862385321102
I1
I0
I1
tp2375
sS'effect,on,renal'
p2376
(F1
F0.00014334862385321102
I1
I0
I1
tp2377
sS'therefore,to,hours'
p2378
(F1
F0.00014334862385321102
I1
I0
I1
tp2379
sS'with,and,including'
p2380
(F1
F0.00014334862385321102
I0
I1
I-1
tp2381
sS'clearance,that,results'
p2382
(F1
F0.00014334862385321102
I1
I0
I1
tp2383
sS'trisenox,is,coadministered'
p2384
(F1
F0.00014334862385321102
I1
I0
I1
tp2385
sS'an,inhibitor,of'
p2386
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp2387
sS'is,administered,in'
p2388
(F1
F0.00014334862385321102
I1
I0
I1
tp2389
sS'ml,h,among'
p2390
(F1
F0.00014334862385321102
I1
I0
I1
tp2391
sS'initiation,of,hormone'
p2392
(F1
F0.00014334862385321102
I0
I1
I-1
tp2393
sS'clearance,of,may'
p2394
(F1
F0.00014334862385321102
I1
I0
I1
tp2395
sS'initial,doses,of'
p2396
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp2397
sS'the,blood,pressure'
p2398
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2399
sS'plasma,and,urine'
p2400
(F1
F0.00043004587155963305
I0
I3
I-3
tp2401
sS'propoxyphene,the,concurrent'
p2402
(F1
F0.00014334862385321102
I0
I1
I-1
tp2403
sS'volunteers,with,oral'
p2404
(F1
F0.00014334862385321102
I0
I1
I-1
tp2405
sS'may,result,if'
p2406
(F1
F0.00014334862385321102
I1
I0
I1
tp2407
sS'administration,of,multiple'
p2408
(F1
F0.00014334862385321102
I1
I0
I1
tp2409
sS'may,result,in'
p2410
(F0.56756756756756754
F0.0030103211009174314
I29
I8
I21
tp2411
sS'required,concentrations,and'
p2412
(F1
F0.00014334862385321102
I1
I0
I1
tp2413
sS'to,this,therapy'
p2414
(F1
F0.00014334862385321102
I0
I1
I-1
tp2415
sS'administered,concurrently,subjects'
p2416
(F1
F0.00057339449541284407
I4
I0
I4
tp2417
sS'inhibitors,of,possible'
p2418
(F1
F0.00014334862385321102
I1
I0
I1
tp2419
sS'decreased,core,temperature'
p2420
(F1
F0.00014334862385321102
I0
I1
I-1
tp2421
sS'a,together,may'
p2422
(F1
F0.00014334862385321102
I1
I0
I1
tp2423
sS'not,known,it'
p2424
(F0
F0
I1
I1
I0
tp2425
sS'be,made,with'
p2426
(F1
F0.00014334862385321102
I1
I0
I1
tp2427
sS'days,plus,mg'
p2428
(F1
F0.00014334862385321102
I0
I1
I-1
tp2429
sS'also,markedly,inhibits'
p2430
(F1
F0.00014334862385321102
I1
I0
I1
tp2431
sS'was,unaltered,by'
p2432
(F1
F0.00014334862385321102
I0
I1
I-1
tp2433
sS'not,known,if'
p2434
(F0
F0
I1
I1
I0
tp2435
sS'cremophor,el,eg'
p2436
(F1
F0.00014334862385321102
I1
I0
I1
tp2437
sS'of,male,animals'
p2438
(F1
F0.00014334862385321102
I0
I1
I-1
tp2439
sS'when,administered,concurrently'
p2440
(F1
F0.00028669724770642203
I2
I0
I2
tp2441
sS'inducers,include,but'
p2442
(F1
F0.00014334862385321102
I0
I1
I-1
tp2443
sS'cyclosporine,digoxin,methotrexate'
p2444
(F1
F0.00014334862385321102
I1
I0
I1
tp2445
sS'recent,study,has'
p2446
(F1
F0.00014334862385321102
I1
I0
I1
tp2447
sS'the,risks,of'
p2448
(F1
F0.00028669724770642203
I2
I0
I2
tp2449
sS'estrogen-containing,therapies,should'
p2450
(F1
F0.00014334862385321102
I1
I0
I1
tp2451
sS'of,among,patients'
p2452
(F1
F0.00014334862385321102
I1
I0
I1
tp2453
sS'of,n,later'
p2454
(F1
F0.00014334862385321102
I0
I1
I-1
tp2455
sS'in,prolonging,av'
p2456
(F1
F0.00014334862385321102
I1
I0
I1
tp2457
sS'or,may,potentiate'
p2458
(F1
F0.00028669724770642203
I2
I0
I2
tp2459
sS'reported,when,toradol'
p2460
(F1
F0.00014334862385321102
I1
I0
I1
tp2461
sS'increase,the,hypotensive'
p2462
(F1
F0.00014334862385321102
I1
I0
I1
tp2463
sS'mg,sustained-release,tablets'
p2464
(F1
F0.00014334862385321102
I0
I1
I-1
tp2465
sS'concentrations,and,possible'
p2466
(F1
F0.00014334862385321102
I0
I1
I-1
tp2467
sS'such,as,should'
p2468
(F1
F0.00028669724770642203
I0
I2
I-2
tp2469
sS'that,a,smaller'
p2470
(F1
F0.00014334862385321102
I1
I0
I1
tp2471
sS'acid,paba,containing'
p2472
(F1
F0.00014334862385321102
I1
I0
I1
tp2473
sS'peak,serum,level'
p2474
(F1
F0.00014334862385321102
I1
I0
I1
tp2475
sS'increased,the,number'
p2476
(F1
F0.00014334862385321102
I0
I1
I-1
tp2477
sS'increasing,the,rate'
p2478
(F1
F0.00014334862385321102
I0
I1
I-1
tp2479
sS'nsaids,have,produced'
p2480
(F1
F0.00043004587155963305
I3
I0
I3
tp2481
sS'any,pharmacokinetic,interactions'
p2482
(F1
F0.00014334862385321102
I0
I1
I-1
tp2483
sS'urine,test,for'
p2484
(F1
F0.00014334862385321102
I0
I1
I-1
tp2485
sS'or,changing,therapy'
p2486
(F1
F0.00014334862385321102
I1
I0
I1
tp2487
sS'ethinyl,estradiol,following'
p2488
(F1
F0.00014334862385321102
I0
I1
I-1
tp2489
sS'therapy,omnicef,should'
p2490
(F1
F0.00028669724770642203
I2
I0
I2
tp2491
sS'results,the,geometric'
p2492
(F1
F0.00014334862385321102
I1
I0
I1
tp2493
sS'cyp3a4,increased,exposure'
p2494
(F1
F0.00014334862385321102
I1
I0
I1
tp2495
sS'and,without,mg'
p2496
(F1
F0.00014334862385321102
I0
I1
I-1
tp2497
sS'prior,to,infusions'
p2498
(F1
F0.00014334862385321102
I1
I0
I1
tp2499
sS'sprycel,close,monitoring'
p2500
(F1
F0.00014334862385321102
I0
I1
I-1
tp2501
sS'been,reports,of'
p2502
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp2503
sS'administered,in,single'
p2504
(F1
F0.00014334862385321102
I0
I1
I-1
tp2505
sS'use,of,tablets'
p2506
(F1
F0.00014334862385321102
I1
I0
I1
tp2507
sS'psychoactive,drugs,hallucinations'
p2508
(F1
F0.00014334862385321102
I1
I0
I1
tp2509
sS'vasopressors,thyroxine,increases'
p2510
(F1
F0.00014334862385321102
I1
I0
I1
tp2511
sS'to,cause,renal'
p2512
(F1
F0.00014334862385321102
I1
I0
I1
tp2513
sS'inhibitors,maoi,as'
p2514
(F1
F0.00028669724770642203
I2
I0
I2
tp2515
sS'co-administration,of,orally'
p2516
(F0
F0
I1
I1
I0
tp2517
sS'globulin,shbg,leading'
p2518
(F1
F0.00028669724770642203
I0
I2
I-2
tp2519
sS'reduce,plasma,concentrations'
p2520
(F1
F0.00043004587155963305
I3
I0
I3
tp2521
sS'and,vasoactive,resulting'
p2522
(F1
F0.00014334862385321102
I1
I0
I1
tp2523
sS'by,especially,when'
p2524
(F1
F0.00014334862385321102
I1
I0
I1
tp2525
sS'invirase,and,are'
p2526
(F1
F0.00014334862385321102
I0
I1
I-1
tp2527
sS'this,enzyme,system'
p2528
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp2529
sS'may,have,a'
p2530
(F1
F0.00043004587155963305
I0
I3
I-3
tp2531
sS'that,are,inducers'
p2532
(F1
F0.00014334862385321102
I0
I1
I-1
tp2533
sS'n-desmethyldiazepam,to,a'
p2534
(F1
F0.00014334862385321102
I0
I1
I-1
tp2535
sS'groups,ie,from'
p2536
(F1
F0.00014334862385321102
I0
I1
I-1
tp2537
sS'the,dosage,are'
p2538
(F1
F0.00014334862385321102
I1
I0
I1
tp2539
sS'a,previously,effective'
p2540
(F1
F0.00014334862385321102
I1
I0
I1
tp2541
sS'sandimmune,hiv,classified'
p2542
(F1
F0.00014334862385321102
I1
I0
I1
tp2543
sS'since,is,a'
p2544
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp2545
sS'that,is,significantly'
p2546
(F1
F0.00014334862385321102
I0
I1
I-1
tp2547
sS'daily,did,not'
p2548
(F1
F0.0011467889908256881
I0
I8
I-8
tp2549
sS'injection,of,pcp'
p2550
(F1
F0.00014334862385321102
I0
I1
I-1
tp2551
sS'increased,over,those'
p2552
(F1
F0.00014334862385321102
I1
I0
I1
tp2553
sS'metabolism,and,decrease'
p2554
(F1
F0.00014334862385321102
I0
I1
I-1
tp2555
sS'seen,but,brevibloc'
p2556
(F1
F0.00014334862385321102
I1
I0
I1
tp2557
sS'by,infusion,to'
p2558
(F1
F0.00014334862385321102
I0
I1
I-1
tp2559
sS'mg,kg,produced'
p2560
(F1
F0.00014334862385321102
I1
I0
I1
tp2561
sS'volunteers,have,failed'
p2562
(F1
F0.00014334862385321102
I0
I1
I-1
tp2563
sS'use,of,l-tyrosine'
p2564
(F1
F0.00014334862385321102
I1
I0
I1
tp2565
sS'the,optimal,dosing'
p2566
(F1
F0.00014334862385321102
I0
I1
I-1
tp2567
sS'sular,tended,to'
p2568
(F1
F0.00014334862385321102
I1
I0
I1
tp2569
sS'reductase,inhibitors,prostaglandin'
p2570
(F1
F0.00014334862385321102
I0
I1
I-1
tp2571
sS'reduced,by,pretreatment'
p2572
(F1
F0.00014334862385321102
I1
I0
I1
tp2573
sS'digitalis,glycosides,amphotericin'
p2574
(F1
F0.00014334862385321102
I1
I0
I1
tp2575
sS'effects,of,nanm'
p2576
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2577
sS'racemic,was,seen'
p2578
(F1
F0.00014334862385321102
I0
I1
I-1
tp2579
sS'or,with,parasite'
p2580
(F1
F0.00014334862385321102
I0
I1
I-1
tp2581
sS'during,transfer,to'
p2582
(F1
F0.00014334862385321102
I0
I1
I-1
tp2583
sS'the,pharmacokinetics,of'
p2584
(F0.77011494252873558
F0.0096043577981651373
I10
I77
I-67
tp2585
sS'reported,significantly,more'
p2586
(F1
F0.00014334862385321102
I0
I1
I-1
tp2587
sS'primarily,cyp3a4,cyp2d6'
p2588
(F1
F0.00014334862385321102
I0
I1
I-1
tp2589
sS'increases,in,dose'
p2590
(F1
F0.00014334862385321102
I1
I0
I1
tp2591
sS'mtx,in,approximately'
p2592
(F1
F0.00014334862385321102
I0
I1
I-1
tp2593
sS'may,occur,if'
p2594
(F1
F0.00014334862385321102
I1
I0
I1
tp2595
sS'significant,elevation,in'
p2596
(F1
F0.00014334862385321102
I1
I0
I1
tp2597
sS'the,pharmacokinetics,or'
p2598
(F1
F0.00028669724770642203
I0
I2
I-2
tp2599
sS'of,endotoxin-induced,deaths'
p2600
(F1
F0.00014334862385321102
I1
I0
I1
tp2601
sS'is,also,taking'
p2602
(F1
F0.00014334862385321102
I1
I0
I1
tp2603
sS'metabolite,of,d'
p2604
(F1
F0.00014334862385321102
I0
I1
I-1
tp2605
sS'cimetidine,inhibits,cyp3a4'
p2606
(F1
F0.00014334862385321102
I1
I0
I1
tp2607
sS'may,occur,in'
p2608
(F1
F0.00043004587155963305
I3
I0
I3
tp2609
sS'of,the,hydrophilic'
p2610
(F1
F0.00014334862385321102
I0
I1
I-1
tp2611
sS'be,metabolized,by'
p2612
(F0
F0
I1
I1
I0
tp2613
sS'vioxx,mg,once'
p2614
(F1
F0.00014334862385321102
I0
I1
I-1
tp2615
sS'be,aware,that'
p2616
(F1
F0.00014334862385321102
I1
I0
I1
tp2617
sS'transdermal,with,or'
p2618
(F1
F0.00014334862385321102
I1
I0
I1
tp2619
sS'general,concern,regarding'
p2620
(F1
F0.00014334862385321102
I0
I1
I-1
tp2621
sS'certain,nonsteroidal,anti-inflammatory'
p2622
(F1
F0.00014334862385321102
I1
I0
I1
tp2623
sS'nonsteroial,anti-inflammatory,concomitantly'
p2624
(F1
F0.00014334862385321102
I1
I0
I1
tp2625
sS'phenytoin,intoxication,prior'
p2626
(F1
F0.00014334862385321102
I1
I0
I1
tp2627
sS'receiving,beta,blockers'
p2628
(F1
F0.00014334862385321102
I0
I1
I-1
tp2629
sS'existing,therapy,did'
p2630
(F1
F0.00014334862385321102
I0
I1
I-1
tp2631
sS'colazal,however,the'
p2632
(F1
F0.00014334862385321102
I0
I1
I-1
tp2633
sS'coated,aspirin,should'
p2634
(F1
F0.00014334862385321102
I1
I0
I1
tp2635
sS'and,b,the'
p2636
(F1
F0.00014334862385321102
I0
I1
I-1
tp2637
sS'cgs,an,a2-selective'
p2638
(F1
F0.00014334862385321102
I1
I0
I1
tp2639
sS'have,been,isolated'
p2640
(F1
F0.00043004587155963305
I3
I0
I3
tp2641
sS'treatment,of,anticholinesterase'
p2642
(F1
F0.00014334862385321102
I1
I0
I1
tp2643
sS'pregnancy,category,x'
p2644
(F1
F0.00014334862385321102
I0
I1
I-1
tp2645
sS'excessive,release,but'
p2646
(F1
F0.00014334862385321102
I0
I1
I-1
tp2647
sS'influenza,virus,vaccine'
p2648
(F1
F0.00014334862385321102
I1
I0
I1
tp2649
sS'patients,with,weakness'
p2650
(F1
F0.00014334862385321102
I1
I0
I1
tp2651
sS'halved,and,titration'
p2652
(F1
F0.00014334862385321102
I1
I0
I1
tp2653
sS'd,have,not'
p2654
(F1
F0.00043004587155963305
I0
I3
I-3
tp2655
sS'persistently,elevated,plasma'
p2656
(F1
F0.00014334862385321102
I0
I1
I-1
tp2657
sS'of,oral,erection-supporting'
p2658
(F1
F0.00014334862385321102
I0
I1
I-1
tp2659
sS'the,auc,by'
p2660
(F1
F0.00014334862385321102
I1
I0
I1
tp2661
sS'acetazolamide,may,increase'
p2662
(F1
F0.00014334862385321102
I1
I0
I1
tp2663
sS'some,patients,predisposing'
p2664
(F1
F0.00014334862385321102
I1
I0
I1
tp2665
sS'of,barrier,contraception'
p2666
(F1
F0.00014334862385321102
I1
I0
I1
tp2667
sS'cytosine,arabinoside,a'
p2668
(F1
F0.00014334862385321102
I1
I0
I1
tp2669
sS'objective,our,objective'
p2670
(F1
F0.00028669724770642203
I0
I2
I-2
tp2671
sS'chemically,modify,exposed'
p2672
(F1
F0.00014334862385321102
I0
I1
I-1
tp2673
sS'and,the,renal'
p2674
(F1
F0.00014334862385321102
I0
I1
I-1
tp2675
sS'more,likely,to'
p2676
(F1
F0.00014334862385321102
I0
I1
I-1
tp2677
sS'pediatrics,mean,increase'
p2678
(F1
F0.00014334862385321102
I1
I0
I1
tp2679
sS'channel,blockers,derivatives'
p2680
(F1
F0.00014334862385321102
I1
I0
I1
tp2681
sS'cyp2d6,eg,or'
p2682
(F1
F0.00014334862385321102
I1
I0
I1
tp2683
sS'capsule,twice,daily'
p2684
(F1
F0.00014334862385321102
I0
I1
I-1
tp2685
sS'present,as,vertigo'
p2686
(F1
F0.00014334862385321102
I1
I0
I1
tp2687
sS'to,healthy,volunteers'
p2688
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp2689
sS'adsorption,of,onto'
p2690
(F1
F0.00014334862385321102
I1
I0
I1
tp2691
sS'including,oral,estrogens'
p2692
(F1
F0.00014334862385321102
I1
I0
I1
tp2693
sS'antinociceptive,effect,between'
p2694
(F1
F0.00014334862385321102
I1
I0
I1
tp2695
sS'agonists,because,the'
p2696
(F1
F0.00014334862385321102
I1
I0
I1
tp2697
sS'grapefruit,juice,resulted'
p2698
(F1
F0.00014334862385321102
I0
I1
I-1
tp2699
sS'noted,above,chronic'
p2700
(F1
F0.00014334862385321102
I0
I1
I-1
tp2701
sS'following,medications,have'
p2702
(F1
F0.00014334862385321102
I0
I1
I-1
tp2703
sS'action,on,smooth'
p2704
(F1
F0.00014334862385321102
I0
I1
I-1
tp2705
sS'of,vardenafil,when'
p2706
(F1
F0.00014334862385321102
I0
I1
I-1
tp2707
sS'increase,is,due'
p2708
(F1
F0.00014334862385321102
I1
I0
I1
tp2709
sS'shown,that,does'
p2710
(F1
F0.00028669724770642203
I0
I2
I-2
tp2711
sS'pipracil,produces,an'
p2712
(F1
F0.00014334862385321102
I1
I0
I1
tp2713
sS'remain,to,orders'
p2714
(F1
F0.00014334862385321102
I0
I1
I-1
tp2715
sS'for,the,presence'
p2716
(F1
F0.00014334862385321102
I0
I1
I-1
tp2717
sS'general,clinical,conditions'
p2718
(F1
F0.00014334862385321102
I1
I0
I1
tp2719
sS'with,these,disturbances'
p2720
(F1
F0.00014334862385321102
I1
I0
I1
tp2721
sS'of,warfarin-type,certain'
p2722
(F1
F0.00014334862385321102
I1
I0
I1
tp2723
sS'other,or,alternatively'
p2724
(F1
F0.00014334862385321102
I0
I1
I-1
tp2725
sS'activation,of,spontaneous'
p2726
(F1
F0.00014334862385321102
I1
I0
I1
tp2727
sS'bradycardia,sinus,arrest'
p2728
(F1
F0.00014334862385321102
I0
I1
I-1
tp2729
sS'inducers,of,cytochrome'
p2730
(F0
F0
I1
I1
I0
tp2731
sS'used,in,the'
p2732
(F0
F0
I2
I2
I0
tp2733
sS'found,that,chronic'
p2734
(F1
F0.00014334862385321102
I1
I0
I1
tp2735
sS'm2,without,indicated'
p2736
(F1
F0.00014334862385321102
I0
I1
I-1
tp2737
sS'zebeta,be,discontinued'
p2738
(F1
F0.00014334862385321102
I1
I0
I1
tp2739
sS'when,given,simultaneously'
p2740
(F1
F0.00014334862385321102
I1
I0
I1
tp2741
sS'studies,involving,alprazolam'
p2742
(F1
F0.00014334862385321102
I1
I0
I1
tp2743
sS'another,such,as'
p2744
(F1
F0.00014334862385321102
I1
I0
I1
tp2745
sS'concentrations,of,increased'
p2746
(F1
F0.00014334862385321102
I1
I0
I1
tp2747
sS'was,replaced,by'
p2748
(F1
F0.00014334862385321102
I0
I1
I-1
tp2749
sS'cyp2d6,inhibitory,effect'
p2750
(F1
F0.00014334862385321102
I1
I0
I1
tp2751
sS'studies,wshow,that'
p2752
(F1
F0.00014334862385321102
I1
I0
I1
tp2753
sS'mg,capsule,twice'
p2754
(F1
F0.00014334862385321102
I0
I1
I-1
tp2755
sS'therefore,and,indocin'
p2756
(F1
F0.00014334862385321102
I1
I0
I1
tp2757
sS'auc0-12,of,hydroxylamine'
p2758
(F1
F0.00014334862385321102
I0
I1
I-1
tp2759
sS'the,therapeutic,regimen'
p2760
(F1
F0.00014334862385321102
I0
I1
I-1
tp2761
sS'brovana,as,with'
p2762
(F1
F0.00014334862385321102
I1
I0
I1
tp2763
sS'antihypertensive,therapy,nicotinic'
p2764
(F1
F0.00014334862385321102
I1
I0
I1
tp2765
sS'costs,of,schizophrenia'
p2766
(F1
F0.00014334862385321102
I0
I1
I-1
tp2767
sS'patients,being,treated'
p2768
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp2769
sS'are,activated,during'
p2770
(F1
F0.00014334862385321102
I0
I1
I-1
tp2771
sS'known,that,patients'
p2772
(F1
F0.00014334862385321102
I1
I0
I1
tp2773
sS'concentration-time,curve,of'
p2774
(F1
F0.00014334862385321102
I0
I1
I-1
tp2775
sS'to,produce,any'
p2776
(F1
F0.00014334862385321102
I1
I0
I1
tp2777
sS'any,condition,in'
p2778
(F1
F0.00014334862385321102
I1
I0
I1
tp2779
sS'treated,with,who'
p2780
(F1
F0.00014334862385321102
I0
I1
I-1
tp2781
sS'the,major,metabolites'
p2782
(F1
F0.00014334862385321102
I0
I1
I-1
tp2783
sS'diabetics,who,were'
p2784
(F1
F0.00014334862385321102
I0
I1
I-1
tp2785
sS'nor,does,affect'
p2786
(F1
F0.00014334862385321102
I0
I1
I-1
tp2787
sS'b,or,potassium-depleting'
p2788
(F1
F0.00014334862385321102
I0
I1
I-1
tp2789
sS'acetate,stimulated,but'
p2790
(F1
F0.00014334862385321102
I1
I0
I1
tp2791
sS'prolonged,concurrent,use'
p2792
(F1
F0.00014334862385321102
I0
I1
I-1
tp2793
sS'for,days,of'
p2794
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp2795
sS'does,not,affect'
p2796
(F1
F0.0020068807339449542
I0
I14
I-14
tp2797
sS'nanm,was,about'
p2798
(F1
F0.00014334862385321102
I0
I1
I-1
tp2799
sS'ml,for,and'
p2800
(F1
F0.00014334862385321102
I0
I1
I-1
tp2801
sS'is,significantly,reduced'
p2802
(F1
F0.00014334862385321102
I1
I0
I1
tp2803
sS'possible,rapid,fluctuations'
p2804
(F1
F0.00014334862385321102
I1
I0
I1
tp2805
sS'increased,gleevec,oral-dose'
p2806
(F1
F0.00014334862385321102
I1
I0
I1
tp2807
sS'agents,contraindicated,since'
p2808
(F1
F0.00014334862385321102
I0
I1
I-1
tp2809
sS'mg,in,combination'
p2810
(F1
F0.00014334862385321102
I0
I1
I-1
tp2811
sS'a,patient,currently'
p2812
(F1
F0.00028669724770642203
I2
I0
I2
tp2813
sS'amprenavir,and,and'
p2814
(F1
F0.00014334862385321102
I1
I0
I1
tp2815
sS'mc,enhance,the'
p2816
(F1
F0.00014334862385321102
I0
I1
I-1
tp2817
sS'administered,safely,to'
p2818
(F1
F0.00014334862385321102
I0
I1
I-1
tp2819
sS'therefore,the,addition'
p2820
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp2821
sS'when,taken,orally'
p2822
(F1
F0.00014334862385321102
I1
I0
I1
tp2823
sS'is,sensitive,to'
p2824
(F1
F0.00014334862385321102
I0
I1
I-1
tp2825
sS'contrast,to,the'
p2826
(F1
F0.00014334862385321102
I0
I1
I-1
tp2827
sS'the,mean,sd'
p2828
(F1
F0.00014334862385321102
I0
I1
I-1
tp2829
sS'taken,with,food'
p2830
(F1
F0.00014334862385321102
I1
I0
I1
tp2831
sS'on,than,in'
p2832
(F1
F0.00014334862385321102
I1
I0
I1
tp2833
sS'casodex,can,displace'
p2834
(F1
F0.00014334862385321102
I1
I0
I1
tp2835
sS'other,significantly,eliminated'
p2836
(F1
F0.00014334862385321102
I1
I0
I1
tp2837
sS'start,of,treatment'
p2838
(F1
F0.00014334862385321102
I1
I0
I1
tp2839
sS'were,administered,following'
p2840
(F1
F0.00014334862385321102
I0
I1
I-1
tp2841
sS'mg,kg,p'
p2842
(F1
F0.00014334862385321102
I1
I0
I1
tp2843
sS'mg,kg,s'
p2844
(F1
F0.00028669724770642203
I2
I0
I2
tp2845
sS'agents,enhanced,bone'
p2846
(F1
F0.00014334862385321102
I1
I0
I1
tp2847
sS'mg,kg,w'
p2848
(F1
F0.00014334862385321102
I1
I0
I1
tp2849
sS'possibly,increase,the'
p2850
(F1
F0.00014334862385321102
I1
I0
I1
tp2851
sS'mg,kg,x'
p2852
(F1
F0.00014334862385321102
I1
I0
I1
tp2853
sS'tdp,in,patients'
p2854
(F1
F0.00014334862385321102
I0
I1
I-1
tp2855
sS'the,striatum,and'
p2856
(F1
F0.00014334862385321102
I1
I0
I1
tp2857
sS'by,a,homodimeric'
p2858
(F1
F0.00014334862385321102
I0
I1
I-1
tp2859
sS'experiment,rats,were'
p2860
(F1
F0.00014334862385321102
I0
I1
I-1
tp2861
sS'use,of,st'
p2862
(F1
F0.00014334862385321102
I0
I1
I-1
tp2863
sS'should,be,necessary'
p2864
(F1
F0.00014334862385321102
I0
I1
I-1
tp2865
sS'reaction,and,clinical'
p2866
(F1
F0.00014334862385321102
I0
I1
I-1
tp2867
sS'taking,or,may'
p2868
(F1
F0.00014334862385321102
I1
I0
I1
tp2869
sS'in,patients,undergoing'
p2870
(F1
F0.00057339449541284407
I4
I0
I4
tp2871
sS'considerable,caution,should'
p2872
(F1
F0.00014334862385321102
I1
I0
I1
tp2873
sS'certain,including,those'
p2874
(F1
F0.00014334862385321102
I1
I0
I1
tp2875
sS'group,that,received'
p2876
(F1
F0.00014334862385321102
I0
I1
I-1
tp2877
sS'of,exogenously,infused'
p2878
(F1
F0.00014334862385321102
I0
I1
I-1
tp2879
sS'of,tambocor,and'
p2880
(F0
F0
I1
I1
I0
tp2881
sS'increase,in,metabolic'
p2882
(F1
F0.00014334862385321102
I1
I0
I1
tp2883
sS'during,therapy,with'
p2884
(F1
F0.0008600917431192661
I6
I0
I6
tp2885
sS'to,be,without'
p2886
(F1
F0.00014334862385321102
I1
I0
I1
tp2887
sS'of,urate,uricosuric'
p2888
(F1
F0.00014334862385321102
I1
I0
I1
tp2889
sS'with,administered,alone'
p2890
(F1
F0.00014334862385321102
I1
I0
I1
tp2891
sS'the,auc,and'
p2892
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp2893
sS'classes,ii,to'
p2894
(F1
F0.00028669724770642203
I0
I2
I-2
tp2895
sS'agents,ammonium,chloride'
p2896
(F1
F0.00028669724770642203
I2
I0
I2
tp2897
sS'plasma,levels,and'
p2898
(F0.77777777777777779
F0.0020068807339449542
I16
I2
I14
tp2899
sS'administered,following,varying'
p2900
(F1
F0.00014334862385321102
I0
I1
I-1
tp2901
sS'injection,of,in'
p2902
(F1
F0.00014334862385321102
I1
I0
I1
tp2903
sS'oral,potently,inhibits'
p2904
(F1
F0.00028669724770642203
I2
I0
I2
tp2905
sS'following,have,been'
p2906
(F1
F0.00014334862385321102
I0
I1
I-1
tp2907
sS'functioning,gland,who'
p2908
(F1
F0.00014334862385321102
I1
I0
I1
tp2909
sS'glyburide,glyburide,is'
p2910
(F1
F0.00014334862385321102
I0
I1
I-1
tp2911
sS'surgery,because,is'
p2912
(F1
F0.00014334862385321102
I0
I1
I-1
tp2913
sS'that,the,absorption'
p2914
(F1
F0.00014334862385321102
I1
I0
I1
tp2915
sS'nsaids,and,are'
p2916
(F1
F0.00043004587155963305
I3
I0
I3
tp2917
sS'decline,in,glomerular'
p2918
(F1
F0.00014334862385321102
I0
I1
I-1
tp2919
sS'of,acetylsalicylic,acid'
p2920
(F1
F0.00028669724770642203
I0
I2
I-2
tp2921
sS'treated,with,proton'
p2922
(F1
F0.00014334862385321102
I1
I0
I1
tp2923
sS'by,high,doses'
p2924
(F1
F0.00028669724770642203
I2
I0
I2
tp2925
sS'thereby,potentially,aggravating'
p2926
(F1
F0.00014334862385321102
I1
I0
I1
tp2927
sS'decrease,serum,concentration'
p2928
(F1
F0.00014334862385321102
I1
I0
I1
tp2929
sS'the,type,c'
p2930
(F1
F0.00014334862385321102
I0
I1
I-1
tp2931
sS'it,is,advisable'
p2932
(F1
F0.00028669724770642203
I2
I0
I2
tp2933
sS'trials,due,to'
p2934
(F1
F0.00014334862385321102
I0
I1
I-1
tp2935
sS'combined,use,of'
p2936
(F1
F0.0008600917431192661
I6
I0
I6
tp2937
sS'be,reduced,to'
p2938
(F1
F0.00071674311926605509
I5
I0
I5
tp2939
sS'increased,following,administration'
p2940
(F1
F0.00014334862385321102
I1
I0
I1
tp2941
sS'in,creatinine,clearance'
p2942
(F1
F0.00014334862385321102
I1
I0
I1
tp2943
sS'reports,of,withdrawal'
p2944
(F1
F0.00014334862385321102
I1
I0
I1
tp2945
sS'well,and,the'
p2946
(F1
F0.00014334862385321102
I0
I1
I-1
tp2947
sS'in,cmax,of'
p2948
(F1
F0.00043004587155963305
I3
I0
I3
tp2949
sS'cmi,because,of'
p2950
(F1
F0.00014334862385321102
I1
I0
I1
tp2951
sS'follow-up,study,in'
p2952
(F1
F0.00014334862385321102
I0
I1
I-1
tp2953
sS'contractile,responses,to'
p2954
(F1
F0.00014334862385321102
I1
I0
I1
tp2955
sS'inhibitors,and,fentanyl'
p2956
(F1
F0.00014334862385321102
I1
I0
I1
tp2957
sS'orencia,administered,concurrently'
p2958
(F1
F0.00014334862385321102
I1
I0
I1
tp2959
sS'week,prior,to'
p2960
(F1
F0.00014334862385321102
I1
I0
I1
tp2961
sS'data,do,not'
p2962
(F1
F0.00014334862385321102
I0
I1
I-1
tp2963
sS'may,selectively,prevent'
p2964
(F1
F0.00014334862385321102
I1
I0
I1
tp2965
sS'profound,hypotension,and'
p2966
(F1
F0.00014334862385321102
I1
I0
I1
tp2967
sS'antagonists,administered,in'
p2968
(F1
F0.00014334862385321102
I0
I1
I-1
tp2969
sS'decreases,clearance,of'
p2970
(F1
F0.00014334862385321102
I1
I0
I1
tp2971
sS'juice,and,other'
p2972
(F1
F0.00014334862385321102
I1
I0
I1
tp2973
sS'of,a,regimen'
p2974
(F1
F0.00014334862385321102
I1
I0
I1
tp2975
sS'of,other,including'
p2976
(F1
F0.00014334862385321102
I1
I0
I1
tp2977
sS'with,and,other'
p2978
(F1
F0.00071674311926605509
I5
I0
I5
tp2979
sS'initiating,replacement,therapy'
p2980
(F1
F0.00014334862385321102
I0
I1
I-1
tp2981
sS'cyp3a4,substrate,response'
p2982
(F1
F0.00014334862385321102
I0
I1
I-1
tp2983
sS'and,therefore,no'
p2984
(F1
F0.00014334862385321102
I0
I1
I-1
tp2985
sS'twice,daily,resulted'
p2986
(F1
F0.00014334862385321102
I1
I0
I1
tp2987
sS'increase,in,central'
p2988
(F1
F0.00014334862385321102
I1
I0
I1
tp2989
sS'therefore,potentially,may'
p2990
(F1
F0.00014334862385321102
I1
I0
I1
tp2991
sS'atp,oxaloacetate,and'
p2992
(F1
F0.00014334862385321102
I0
I1
I-1
tp2993
sS'cause,increases,ranging'
p2994
(F1
F0.00028669724770642203
I0
I2
I-2
tp2995
sS'the,possible,effectiveness'
p2996
(F1
F0.00014334862385321102
I1
I0
I1
tp2997
sS'concomitantly,receiving,azole'
p2998
(F1
F0.00014334862385321102
I1
I0
I1
tp2999
sS'in,clinically,meaningful'
p3000
(F1
F0.00014334862385321102
I1
I0
I1
tp3001
sS'of,these,findings'
p3002
(F1
F0.00014334862385321102
I1
I0
I1
tp3003
sS'and,platelet,aggregation'
p3004
(F1
F0.00014334862385321102
I1
I0
I1
tp3005
sS'oral,a,potent'
p3006
(F1
F0.00014334862385321102
I1
I0
I1
tp3007
sS'resulting,in,lower'
p3008
(F1
F0.00057339449541284407
I4
I0
I4
tp3009
sS'mentax,butenafine,hcl'
p3010
(F1
F0.00014334862385321102
I0
I1
I-1
tp3011
sS'expected,to,increase'
p3012
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp3013
sS'such,as,k'
p3014
(F1
F0.00014334862385321102
I0
I1
I-1
tp3015
sS'determine,if,there'
p3016
(F1
F0.00014334862385321102
I0
I1
I-1
tp3017
sS'have,neuromuscular,blocking'
p3018
(F1
F0.00028669724770642203
I2
I0
I2
tp3019
sS'extent,than,the'
p3020
(F1
F0.00014334862385321102
I0
I1
I-1
tp3021
sS'not,be,exceeded'
p3022
(F1
F0.00028669724770642203
I2
I0
I2
tp3023
sS'inspra,mg,combined'
p3024
(F1
F0.00014334862385321102
I1
I0
I1
tp3025
sS'with,oral,has'
p3026
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp3027
sS'a,lower,relative'
p3028
(F1
F0.00014334862385321102
I0
I1
I-1
tp3029
sS'drug-drug,interactions,no'
p3030
(F1
F0.00014334862385321102
I0
I1
I-1
tp3031
sS'with,concurrent,ingestion'
p3032
(F1
F0.00014334862385321102
I1
I0
I1
tp3033
sS'bleeding,if,administered'
p3034
(F1
F0.00014334862385321102
I1
I0
I1
tp3035
sS'extraneal,in,diabetic'
p3036
(F1
F0.00014334862385321102
I1
I0
I1
tp3037
sS'pcp,produced,distinctive'
p3038
(F1
F0.00014334862385321102
I0
I1
I-1
tp3039
sS'increase,serum,concentrations'
p3040
(F0
F0
I1
I1
I0
tp3041
sS'following,the,initiation'
p3042
(F1
F0.00014334862385321102
I1
I0
I1
tp3043
sS'the,potential,interaction'
p3044
(F1
F0.00014334862385321102
I1
I0
I1
tp3045
sS'who,have,previously'
p3046
(F1
F0.00014334862385321102
I1
I0
I1
tp3047
sS'campath,may,interfere'
p3048
(F1
F0.00014334862385321102
I0
I1
I-1
tp3049
sS'caution,is,warranted'
p3050
(F1
F0.00028669724770642203
I2
I0
I2
tp3051
sS'medications,the,use'
p3052
(F1
F0.00014334862385321102
I1
I0
I1
tp3053
sS'decrease,the,antinociceptive'
p3054
(F1
F0.00014334862385321102
I1
I0
I1
tp3055
sS'hypoglycemia,may,be'
p3056
(F1
F0.00028669724770642203
I0
I2
I-2
tp3057
sS'and,symptoms,of'
p3058
(F1
F0.00071674311926605509
I5
I0
I5
tp3059
sS'efficacy,as,a'
p3060
(F1
F0.00014334862385321102
I0
I1
I-1
tp3061
sS'decrease,for,the'
p3062
(F1
F0.00014334862385321102
I1
I0
I1
tp3063
sS'and,it,is'
p3064
(F0.5
F0.00028669724770642203
I3
I1
I2
tp3065
sS'followed,and,the'
p3066
(F1
F0.00014334862385321102
I0
I1
I-1
tp3067
sS'of,severe,hypersensitivity'
p3068
(F0
F0
I1
I1
I0
tp3069
sS'by,active,renal'
p3070
(F1
F0.00014334862385321102
I1
I0
I1
tp3071
sS'dose,should,then'
p3072
(F1
F0.00014334862385321102
I1
I0
I1
tp3073
sS'may,sterilize,the'
p3074
(F1
F0.00014334862385321102
I0
I1
I-1
tp3075
sS'levels,of,the'
p3076
(F1
F0.0010034403669724771
I7
I0
I7
tp3077
sS'to,concomitant,therapy'
p3078
(F1
F0.00028669724770642203
I0
I2
I-2
tp3079
sS'the,class,of'
p3080
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp3081
sS'dynacirc,has,been'
p3082
(F1
F0.00014334862385321102
I0
I1
I-1
tp3083
sS'a,crossover,study'
p3084
(F1
F0.00014334862385321102
I1
I0
I1
tp3085
sS'pt,and,international'
p3086
(F1
F0.00014334862385321102
I1
I0
I1
tp3087
sS'mean,clearances,of'
p3088
(F1
F0.00014334862385321102
I1
I0
I1
tp3089
sS'trecator,may,potentiate'
p3090
(F1
F0.00014334862385321102
I1
I0
I1
tp3091
sS'concentration,of,cmc-cys'
p3092
(F1
F0.00014334862385321102
I0
I1
I-1
tp3093
sS'severity,and,or'
p3094
(F1
F0.00014334862385321102
I1
I0
I1
tp3095
sS'that,at,these'
p3096
(F1
F0.00014334862385321102
I1
I0
I1
tp3097
sS'from,patients,receiving'
p3098
(F1
F0.00014334862385321102
I0
I1
I-1
tp3099
sS'to,which,ssri-tcainteractions'
p3100
(F1
F0.00014334862385321102
I1
I0
I1
tp3101
sS'peritoneal,cavity,or'
p3102
(F1
F0.00014334862385321102
I0
I1
I-1
tp3103
sS'antibiotics,such,as'
p3104
(F1
F0.00014334862385321102
I1
I0
I1
tp3105
sS'and,valproic,acid'
p3106
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3107
sS'in,europe,nimotop'
p3108
(F1
F0.00014334862385321102
I1
I0
I1
tp3109
sS'of,seizures,in'
p3110
(F1
F0.00014334862385321102
I1
I0
I1
tp3111
sS'metabolism,may,be'
p3112
(F1
F0.00014334862385321102
I1
I0
I1
tp3113
sS'administration,of,to'
p3114
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp3115
sS'enzyme,prolongs,and'
p3116
(F1
F0.00014334862385321102
I0
I1
I-1
tp3117
sS'state,on,the'
p3118
(F1
F0.00014334862385321102
I0
I1
I-1
tp3119
sS'with,care,in'
p3120
(F1
F0.00043004587155963305
I3
I0
I3
tp3121
sS'may,not,benefit'
p3122
(F1
F0.00014334862385321102
I1
I0
I1
tp3123
sS'renal,clearance,leading'
p3124
(F1
F0.00028669724770642203
I0
I2
I-2
tp3125
sS'containing,trisilicate,when'
p3126
(F1
F0.00014334862385321102
I1
I0
I1
tp3127
sS'although,in,vivo'
p3128
(F1
F0.00014334862385321102
I1
I0
I1
tp3129
sS'convulsions,and,cardiac'
p3130
(F1
F0.00014334862385321102
I1
I0
I1
tp3131
sS'clearance,of,to'
p3132
(F1
F0.00014334862385321102
I1
I0
I1
tp3133
sS'days,resulted,in'
p3134
(F1
F0.00071674311926605509
I5
I0
I5
tp3135
sS'felbatol,to,antiepileptic'
p3136
(F1
F0.00014334862385321102
I1
I0
I1
tp3137
sS'of,cyp,a4'
p3138
(F1
F0.00028669724770642203
I0
I2
I-2
tp3139
sS'anti-anxiety,used,to'
p3140
(F1
F0.00014334862385321102
I0
I1
I-1
tp3141
sS'inhibition,of,n-acetyltransferase'
p3142
(F1
F0.00014334862385321102
I1
I0
I1
tp3143
sS'of,tricyclic,with'
p3144
(F1
F0.00014334862385321102
I0
I1
I-1
tp3145
sS'mind,when,another'
p3146
(F1
F0.00014334862385321102
I0
I1
I-1
tp3147
sS'considered,in,place'
p3148
(F1
F0.00014334862385321102
I1
I0
I1
tp3149
sS'patients,may,precipitate'
p3150
(F1
F0.00043004587155963305
I3
I0
I3
tp3151
sS'that,may,enhance'
p3152
(F1
F0.00028669724770642203
I2
I0
I2
tp3153
sS'systemic,data,have'
p3154
(F1
F0.00014334862385321102
I0
I1
I-1
tp3155
sS'by,mu-,delta'
p3156
(F1
F0.00014334862385321102
I0
I1
I-1
tp3157
sS'that,cause,significant'
p3158
(F1
F0.00014334862385321102
I1
I0
I1
tp3159
sS'is,inhibited,by'
p3160
(F1
F0.00043004587155963305
I3
I0
I3
tp3161
sS'sst,and,randomly'
p3162
(F1
F0.00014334862385321102
I0
I1
I-1
tp3163
sS'only,observed,between'
p3164
(F1
F0.00014334862385321102
I0
I1
I-1
tp3165
sS'underlying,the,development'
p3166
(F1
F0.00014334862385321102
I0
I1
I-1
tp3167
sS'was,between,and'
p3168
(F1
F0.00014334862385321102
I0
I1
I-1
tp3169
sS'drugs,based,on'
p3170
(F1
F0.00014334862385321102
I0
I1
I-1
tp3171
sS'concentration,of,cmi'
p3172
(F1
F0.00014334862385321102
I1
I0
I1
tp3173
sS'this,information,should'
p3174
(F1
F0.00014334862385321102
I0
I1
I-1
tp3175
sS'single,mg,oral'
p3176
(F1
F0.00043004587155963305
I0
I3
I-3
tp3177
sS'efficacy,of,may'
p3178
(F1
F0.00014334862385321102
I1
I0
I1
tp3179
sS'corresponding,increase,in'
p3180
(F1
F0.00028669724770642203
I2
I0
I2
tp3181
sS'mg,qd,days'
p3182
(F0
F0
I1
I1
I0
tp3183
sS'a,short-term,controlled'
p3184
(F1
F0.00014334862385321102
I0
I1
I-1
tp3185
sS'toxicity,and,or'
p3186
(F1
F0.00014334862385321102
I1
I0
I1
tp3187
sS'h2,receptor,antagonists'
p3188
(F1
F0.00014334862385321102
I1
I0
I1
tp3189
sS'not,systematically,alter'
p3190
(F1
F0.00014334862385321102
I0
I1
I-1
tp3191
sS'when,eulexin,capsules'
p3192
(F1
F0.00014334862385321102
I1
I0
I1
tp3193
sS'given,to,the'
p3194
(F1
F0.00028669724770642203
I2
I0
I2
tp3195
sS'these,and,therefore'
p3196
(F1
F0.00014334862385321102
I0
I1
I-1
tp3197
sS'from,neuromuscular,blockade'
p3198
(F1
F0.00014334862385321102
I0
I1
I-1
tp3199
sS'compared,to,has'
p3200
(F1
F0.00014334862385321102
I1
I0
I1
tp3201
sS'to,maximize,the'
p3202
(F1
F0.00014334862385321102
I0
I1
I-1
tp3203
sS'while,they,cause'
p3204
(F1
F0.00014334862385321102
I0
I1
I-1
tp3205
sS'plasma,concentration,was'
p3206
(F1
F0.00028669724770642203
I0
I2
I-2
tp3207
sS'assess,the,safety'
p3208
(F1
F0.00014334862385321102
I1
I0
I1
tp3209
sS'the,overall,direct'
p3210
(F1
F0.00014334862385321102
I0
I1
I-1
tp3211
sS'beta-blockers,serum,concentrations'
p3212
(F1
F0.00014334862385321102
I0
I1
I-1
tp3213
sS'comparable,to,that'
p3214
(F1
F0.00014334862385321102
I0
I1
I-1
tp3215
sS'general,most,patients'
p3216
(F1
F0.00014334862385321102
I0
I1
I-1
tp3217
sS'hydroxy-estazolam,and,the'
p3218
(F1
F0.00014334862385321102
I0
I1
I-1
tp3219
sS'meal,would,not'
p3220
(F1
F0.00014334862385321102
I0
I1
I-1
tp3221
sS'man,the,c'
p3222
(F1
F0.00014334862385321102
I1
I0
I1
tp3223
sS'or,oral,agents'
p3224
(F1
F0.00014334862385321102
I0
I1
I-1
tp3225
sS'salicylic,acid,decrease'
p3226
(F1
F0.00014334862385321102
I1
I0
I1
tp3227
sS'stimulator,of,metabolism'
p3228
(F1
F0.00014334862385321102
I1
I0
I1
tp3229
sS'probenecid,slows,the'
p3230
(F1
F0.00014334862385321102
I0
I1
I-1
tp3231
sS'shown,to,affect'
p3232
(F1
F0.00014334862385321102
I1
I0
I1
tp3233
sS'decrease,in,average'
p3234
(F1
F0.00014334862385321102
I1
I0
I1
tp3235
sS'is,necessary,when'
p3236
(F0
F0
I1
I1
I0
tp3237
sS'if,a,patient'
p3238
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp3239
sS'antagonists,appear,to'
p3240
(F1
F0.00014334862385321102
I0
I1
I-1
tp3241
sS'channel,blockers,beta'
p3242
(F1
F0.00014334862385321102
I0
I1
I-1
tp3243
sS'oral,erection-supporting,medication'
p3244
(F1
F0.00014334862385321102
I0
I1
I-1
tp3245
sS'generation,of,three'
p3246
(F1
F0.00014334862385321102
I0
I1
I-1
tp3247
sS'increase,and,range'
p3248
(F1
F0.00014334862385321102
I1
I0
I1
tp3249
sS'components,may,help'
p3250
(F1
F0.00014334862385321102
I0
I1
I-1
tp3251
sS'as,v,has'
p3252
(F1
F0.00014334862385321102
I0
I1
I-1
tp3253
sS'intravenous,and,amphotericin'
p3254
(F1
F0.00014334862385321102
I1
I0
I1
tp3255
sS'these,findings,to'
p3256
(F1
F0.00014334862385321102
I1
I0
I1
tp3257
sS'cyp3a4,inhibitors,are'
p3258
(F1
F0.00014334862385321102
I0
I1
I-1
tp3259
sS'with,laboratory,tests'
p3260
(F1
F0.00014334862385321102
I0
I1
I-1
tp3261
sS'that,include,extreme'
p3262
(F1
F0.00014334862385321102
I1
I0
I1
tp3263
sS'of,withdrawal,and'
p3264
(F1
F0.00014334862385321102
I1
I0
I1
tp3265
sS'and,beta-blocking,agents'
p3266
(F1
F0.00014334862385321102
I0
I1
I-1
tp3267
sS'methylthiadiazole,can,cause'
p3268
(F1
F0.00014334862385321102
I0
I1
I-1
tp3269
sS'do,not,suggest'
p3270
(F1
F0.00028669724770642203
I0
I2
I-2
tp3271
sS'known,cyp3a4,inducers'
p3272
(F1
F0.00014334862385321102
I1
I0
I1
tp3273
sS'when,a,euthyroid'
p3274
(F1
F0.00014334862385321102
I0
I1
I-1
tp3275
sS'presumably,through,inhibition'
p3276
(F1
F0.00014334862385321102
I1
I0
I1
tp3277
sS'have,negative,inotropic'
p3278
(F1
F0.00014334862385321102
I1
I0
I1
tp3279
sS'serious,gi,bleeding'
p3280
(F1
F0.00028669724770642203
I2
I0
I2
tp3281
sS'on,treatment,should'
p3282
(F1
F0.00014334862385321102
I1
I0
I1
tp3283
sS'times,as,high'
p3284
(F1
F0.00014334862385321102
I0
I1
I-1
tp3285
sS'patient,monitoring,and'
p3286
(F1
F0.00014334862385321102
I1
I0
I1
tp3287
sS'another,and,but'
p3288
(F1
F0.00014334862385321102
I1
I0
I1
tp3289
sS'drinking,may,worsen'
p3290
(F1
F0.00014334862385321102
I1
I0
I1
tp3291
sS'closely,monitored,for'
p3292
(F1
F0.00014334862385321102
I1
I0
I1
tp3293
sS'tremulousness,and,confusion'
p3294
(F1
F0.00014334862385321102
I1
I0
I1
tp3295
sS'tetracyclines,concomitant,treatment'
p3296
(F1
F0.00014334862385321102
I1
I0
I1
tp3297
sS'a,decrease,of'
p3298
(F1
F0.00014334862385321102
I0
I1
I-1
tp3299
sS'with,active,ra'
p3300
(F1
F0.00028669724770642203
I2
I0
I2
tp3301
sS'to,alter,cardiac'
p3302
(F1
F0.00014334862385321102
I1
I0
I1
tp3303
sS'tricyclic,may,block'
p3304
(F1
F0.00014334862385321102
I1
I0
I1
tp3305
sS'clinical,trials,with'
p3306
(F0
F0
I1
I1
I0
tp3307
sS'if,a,potentially'
p3308
(F0
F0
I1
I1
I0
tp3309
sS'prolongation,of,plasma'
p3310
(F0
F0
I1
I1
I0
tp3311
sS'of,the,immunodepressant--the'
p3312
(F1
F0.00014334862385321102
I0
I1
I-1
tp3313
sS'and,was,comparable'
p3314
(F1
F0.00014334862385321102
I0
I1
I-1
tp3315
sS'cyp3a4,inhibitors,felodipine'
p3316
(F1
F0.00014334862385321102
I0
I1
I-1
tp3317
sS'xa,and,antithrombin'
p3318
(F1
F0.00014334862385321102
I0
I1
I-1
tp3319
sS'or,cardiac,glycosides'
p3320
(F1
F0.00014334862385321102
I0
I1
I-1
tp3321
sS'either,was,observed'
p3322
(F1
F0.00014334862385321102
I0
I1
I-1
tp3323
sS'the,plasma,enzymes'
p3324
(F1
F0.00014334862385321102
I0
I1
I-1
tp3325
sS'co-administration,of,other'
p3326
(F1
F0.00014334862385321102
I1
I0
I1
tp3327
sS'catecholamine-depleting,may,have'
p3328
(F1
F0.00028669724770642203
I2
I0
I2
tp3329
sS'antiplatelet,and,medication'
p3330
(F1
F0.00014334862385321102
I1
I0
I1
tp3331
sS'orudis,orudis,kt'
p3332
(F1
F0.00014334862385321102
I0
I1
I-1
tp3333
sS'study,in,niddm'
p3334
(F1
F0.00014334862385321102
I0
I1
I-1
tp3335
sS'mean,t,max'
p3336
(F1
F0.00014334862385321102
I1
I0
I1
tp3337
sS'any,other,nsaid'
p3338
(F0
F0
I1
I1
I0
tp3339
sS'certain,including,nonsteroidal'
p3340
(F1
F0.00057339449541284407
I4
I0
I4
tp3341
sS'crossover,study,in'
p3342
(F1
F0.00028669724770642203
I2
I0
I2
tp3343
sS'on,the,cardiovascular'
p3344
(F1
F0.00043004587155963305
I3
I0
I3
tp3345
sS'concomitantly,without,a'
p3346
(F1
F0.00014334862385321102
I0
I1
I-1
tp3347
sS'either,on,alone'
p3348
(F1
F0.00014334862385321102
I0
I1
I-1
tp3349
sS'of,pegasys,alone'
p3350
(F1
F0.00028669724770642203
I0
I2
I-2
tp3351
sS'equetrotm,and,then'
p3352
(F0
F0
I1
I1
I0
tp3353
sS'as,bradycardia,and'
p3354
(F1
F0.00014334862385321102
I1
I0
I1
tp3355
sS'was,noted,that'
p3356
(F1
F0.00014334862385321102
I0
I1
I-1
tp3357
sS'qd,has,not'
p3358
(F1
F0.00014334862385321102
I0
I1
I-1
tp3359
sS'of,preparations,by'
p3360
(F1
F0.00014334862385321102
I1
I0
I1
tp3361
sS'example,since,may'
p3362
(F1
F0.00014334862385321102
I1
I0
I1
tp3363
sS'either,alone,or'
p3364
(F1
F0.00043004587155963305
I0
I3
I-3
tp3365
sS'to,be,exacerbated'
p3366
(F1
F0.00014334862385321102
I1
I0
I1
tp3367
sS'the,vitamin,d'
p3368
(F1
F0.00043004587155963305
I0
I3
I-3
tp3369
sS'been,conducted,for'
p3370
(F1
F0.00014334862385321102
I0
I1
I-1
tp3371
sS'acting,triclofos,sodium'
p3372
(F1
F0.00014334862385321102
I1
I0
I1
tp3373
sS'that,both,angiotensins'
p3374
(F1
F0.00014334862385321102
I0
I1
I-1
tp3375
sS'also,to,an'
p3376
(F1
F0.00014334862385321102
I1
I0
I1
tp3377
sS'cyp3a4,inhibitor,cannot'
p3378
(F1
F0.00014334862385321102
I0
I1
I-1
tp3379
sS'digoxin,methotrexate,cyclosporine'
p3380
(F1
F0.00014334862385321102
I0
I1
I-1
tp3381
sS'used,in,turn'
p3382
(F1
F0.00014334862385321102
I0
I1
I-1
tp3383
sS'glucose,concentrations,should'
p3384
(F1
F0.00014334862385321102
I1
I0
I1
tp3385
sS'day,on,weeks'
p3386
(F1
F0.00014334862385321102
I0
I1
I-1
tp3387
sS'animal,studies,wshow'
p3388
(F1
F0.00014334862385321102
I1
I0
I1
tp3389
sS'including,yields,a'
p3390
(F1
F0.00014334862385321102
I1
I0
I1
tp3391
sS'time,monitored,and'
p3392
(F1
F0.00014334862385321102
I1
I0
I1
tp3393
sS'approximately,when,and'
p3394
(F1
F0.00028669724770642203
I2
I0
I2
tp3395
sS'increased,dosage,of'
p3396
(F1
F0.00014334862385321102
I1
I0
I1
tp3397
sS'in,parkinsons,disease'
p3398
(F1
F0.00014334862385321102
I1
I0
I1
tp3399
sS'urine,sampling,were'
p3400
(F1
F0.00014334862385321102
I0
I1
I-1
tp3401
sS'patients,had,liver'
p3402
(F1
F0.00014334862385321102
I0
I1
I-1
tp3403
sS'combination,with,potentially'
p3404
(F1
F0.00014334862385321102
I1
I0
I1
tp3405
sS'administration,or,salt'
p3406
(F1
F0.00014334862385321102
I0
I1
I-1
tp3407
sS'when,equetrotm,is'
p3408
(F1
F0.00014334862385321102
I1
I0
I1
tp3409
sS'on,insulins,ability'
p3410
(F1
F0.00014334862385321102
I0
I1
I-1
tp3411
sS'another,extended,release'
p3412
(F1
F0.00014334862385321102
I0
I1
I-1
tp3413
sS'one,study,in'
p3414
(F1
F0.00014334862385321102
I1
I0
I1
tp3415
sS'administered,with,its'
p3416
(F1
F0.00014334862385321102
I1
I0
I1
tp3417
sS'when,using,immunoanalytical'
p3418
(F1
F0.00014334862385321102
I0
I1
I-1
tp3419
sS'response,suggest,that'
p3420
(F1
F0.00014334862385321102
I0
I1
I-1
tp3421
sS'type,diabetes,were'
p3422
(F1
F0.00014334862385321102
I0
I1
I-1
tp3423
sS'chemotherapy,agents,in'
p3424
(F1
F0.00014334862385321102
I0
I1
I-1
tp3425
sS'edecrin,and,non-'
p3426
(F1
F0.00014334862385321102
I1
I0
I1
tp3427
sS'are,a,family'
p3428
(F1
F0.00014334862385321102
I0
I1
I-1
tp3429
sS'warned,of,the'
p3430
(F1
F0.00014334862385321102
I1
I0
I1
tp3431
sS'be,administered,by'
p3432
(F1
F0.00014334862385321102
I1
I0
I1
tp3433
sS'hydroxides,does,not'
p3434
(F1
F0.00014334862385321102
I0
I1
I-1
tp3435
sS'pointes,most,like'
p3436
(F1
F0.00014334862385321102
I1
I0
I1
tp3437
sS'as,noted,with'
p3438
(F1
F0.00014334862385321102
I1
I0
I1
tp3439
sS'not,a,substitute'
p3440
(F1
F0.00043004587155963305
I0
I3
I-3
tp3441
sS'approximately,one,week'
p3442
(F1
F0.00014334862385321102
I1
I0
I1
tp3443
sS'severe,adverse,reaction'
p3444
(F1
F0.00014334862385321102
I0
I1
I-1
tp3445
sS'additive,or,potentiating'
p3446
(F1
F0.00057339449541284407
I4
I0
I4
tp3447
sS'the,interference,with'
p3448
(F1
F0.00014334862385321102
I1
I0
I1
tp3449
sS'comprehensive,information,concerning'
p3450
(F1
F0.00014334862385321102
I0
I1
I-1
tp3451
sS'increased,altretamines,half-life'
p3452
(F1
F0.00014334862385321102
I1
I0
I1
tp3453
sS'level,by,the'
p3454
(F1
F0.00014334862385321102
I0
I1
I-1
tp3455
sS'for,heart,failure'
p3456
(F1
F0.00014334862385321102
I0
I1
I-1
tp3457
sS'information,on,concurrent'
p3458
(F1
F0.00014334862385321102
I0
I1
I-1
tp3459
sS'concurrently,with,cardiac'
p3460
(F1
F0.00014334862385321102
I0
I1
I-1
tp3461
sS'relaxants,and,the'
p3462
(F1
F0.00014334862385321102
I1
I0
I1
tp3463
sS'difluoro-2,propanol,mg'
p3464
(F1
F0.00014334862385321102
I1
I0
I1
tp3465
sS'date,has,not'
p3466
(F1
F0.00014334862385321102
I0
I1
I-1
tp3467
sS'inhibit,or,are'
p3468
(F1
F0.00014334862385321102
I1
I0
I1
tp3469
sS'gastrointestinal,toxicity,than'
p3470
(F1
F0.00014334862385321102
I1
I0
I1
tp3471
sS'although,additional,interaction'
p3472
(F1
F0.00014334862385321102
I0
I1
I-1
tp3473
sS'which,ssri-tca,interactions'
p3474
(F1
F0.00057339449541284407
I4
I0
I4
tp3475
sS'pharmacokinetic,profile,of'
p3476
(F1
F0.00014334862385321102
I1
I0
I1
tp3477
sS'antabuse-like,side,effects'
p3478
(F1
F0.00014334862385321102
I1
I0
I1
tp3479
sS'concentration,is,reduced'
p3480
(F1
F0.00014334862385321102
I1
I0
I1
tp3481
sS'healthy,males,who'
p3482
(F1
F0.00014334862385321102
I0
I1
I-1
tp3483
sS'following,are,administered'
p3484
(F1
F0.00014334862385321102
I0
I1
I-1
tp3485
sS'concomitantly,physicians,are'
p3486
(F1
F0.00014334862385321102
I1
I0
I1
tp3487
sS'of,low-dose,hcl'
p3488
(F1
F0.00014334862385321102
I1
I0
I1
tp3489
sS'interact,pharmacologically,with'
p3490
(F1
F0.00014334862385321102
I1
I0
I1
tp3491
sS'you,are,taking'
p3492
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp3493
sS'incidence,of,akathisia'
p3494
(F1
F0.00014334862385321102
I1
I0
I1
tp3495
sS'of,action,or'
p3496
(F1
F0.00014334862385321102
I0
I1
I-1
tp3497
sS'to,other,antiepileptic'
p3498
(F1
F0.00014334862385321102
I0
I1
I-1
tp3499
sS'results,in,reduced'
p3500
(F1
F0.00014334862385321102
I1
I0
I1
tp3501
sS'increased,sedation,or'
p3502
(F1
F0.00014334862385321102
I0
I1
I-1
tp3503
sS'of,action,of'
p3504
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp3505
sS'no,change,in'
p3506
(F0
F0
I3
I3
I0
tp3507
sS'monitored,by,measuring'
p3508
(F1
F0.00014334862385321102
I0
I1
I-1
tp3509
sS'trough,serum,valproic'
p3510
(F1
F0.00014334862385321102
I0
I1
I-1
tp3511
sS'adverse,events,reported'
p3512
(F1
F0.00014334862385321102
I0
I1
I-1
tp3513
sS'wellbutrin,and,that'
p3514
(F1
F0.00014334862385321102
I1
I0
I1
tp3515
sS'ml,maalox,tc'
p3516
(F1
F0.00014334862385321102
I1
I0
I1
tp3517
sS'to,avoid,additive'
p3518
(F1
F0.00014334862385321102
I1
I0
I1
tp3519
sS'doses,and,small'
p3520
(F1
F0.00014334862385321102
I1
I0
I1
tp3521
sS'half-life,increased,approximately'
p3522
(F1
F0.00014334862385321102
I1
I0
I1
tp3523
sS'potentiate,adverse,events'
p3524
(F1
F0.00014334862385321102
I1
I0
I1
tp3525
sS'such,as,nimbex'
p3526
(F1
F0.00014334862385321102
I1
I0
I1
tp3527
sS'to,decreased,concentrations'
p3528
(F1
F0.00014334862385321102
I1
I0
I1
tp3529
sS'zebeta,should,be'
p3530
(F1
F0.00014334862385321102
I1
I0
I1
tp3531
sS'studies,had,no'
p3532
(F1
F0.00014334862385321102
I0
I1
I-1
tp3533
sS'thus,when,vioxx'
p3534
(F1
F0.00014334862385321102
I1
I0
I1
tp3535
sS'showed,no,influence'
p3536
(F1
F0.00014334862385321102
I0
I1
I-1
tp3537
sS'carbohydrate-splitting,enzymes,may'
p3538
(F1
F0.00014334862385321102
I1
I0
I1
tp3539
sS'didanosine,fluconazole,fluoxetine'
p3540
(F1
F0.00014334862385321102
I0
I1
I-1
tp3541
sS'intravenous,mg,clo-4'
p3542
(F1
F0.00014334862385321102
I0
I1
I-1
tp3543
sS'patient,taking,mg'
p3544
(F1
F0.00014334862385321102
I1
I0
I1
tp3545
sS'lower,affinities,than'
p3546
(F1
F0.00014334862385321102
I0
I1
I-1
tp3547
sS'placebo,n,had'
p3548
(F1
F0.00014334862385321102
I0
I1
I-1
tp3549
sS'from,these,patients'
p3550
(F1
F0.00014334862385321102
I1
I0
I1
tp3551
sS'to,determine,the'
p3552
(F1
F0.00028669724770642203
I0
I2
I-2
tp3553
sS'been,reported,during'
p3554
(F1
F0.0008600917431192661
I6
I0
I6
tp3555
sS'serum,txb2,generation'
p3556
(F1
F0.00014334862385321102
I0
I1
I-1
tp3557
sS'the,drug,is'
p3558
(F1
F0.00014334862385321102
I1
I0
I1
tp3559
sS'lowers,the,serum'
p3560
(F1
F0.00014334862385321102
I1
I0
I1
tp3561
sS'when,rebif,is'
p3562
(F1
F0.00014334862385321102
I0
I1
I-1
tp3563
sS'additive,adverse,effects'
p3564
(F1
F0.00014334862385321102
I1
I0
I1
tp3565
sS'the,repeat,dose'
p3566
(F1
F0.00014334862385321102
I0
I1
I-1
tp3567
sS'resulted,in,increase'
p3568
(F1
F0.00014334862385321102
I1
I0
I1
tp3569
sS'competes,for,active'
p3570
(F1
F0.00014334862385321102
I1
I0
I1
tp3571
sS'or,discontinues,therapy'
p3572
(F1
F0.00014334862385321102
I1
I0
I1
tp3573
sS'receiving,coumarin-type,the'
p3574
(F1
F0.00014334862385321102
I1
I0
I1
tp3575
sS'to,mg,to'
p3576
(F1
F0.00014334862385321102
I1
I0
I1
tp3577
sS'any,that,may'
p3578
(F1
F0.00014334862385321102
I0
I1
I-1
tp3579
sS'referred,to,as'
p3580
(F1
F0.00043004587155963305
I0
I3
I-3
tp3581
sS'solution,should,not'
p3582
(F1
F0.00028669724770642203
I2
I0
I2
tp3583
sS'antipsychotic,efficacy,compared'
p3584
(F1
F0.00014334862385321102
I0
I1
I-1
tp3585
sS'studies,suggest,that'
p3586
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3587
sS'a,sulfonamide,is'
p3588
(F1
F0.00014334862385321102
I1
I0
I1
tp3589
sS'indicated,that,the'
p3590
(F1
F0.00014334862385321102
I0
I1
I-1
tp3591
sS'may,be,mediated'
p3592
(F0
F0
I2
I2
I0
tp3593
sS'the,steady-state,epoxide'
p3594
(F1
F0.00014334862385321102
I1
I0
I1
tp3595
sS'statistically,or,clinically'
p3596
(F1
F0.00014334862385321102
I0
I1
I-1
tp3597
sS'pharmacokinetic,interaction,studies'
p3598
(F1
F0.00028669724770642203
I0
I2
I-2
tp3599
sS'recommended,when,a'
p3600
(F1
F0.00028669724770642203
I2
I0
I2
tp3601
sS'b3,niacin,antihypertensive'
p3602
(F1
F0.00014334862385321102
I1
I0
I1
tp3603
sS'c,completely,antagonized'
p3604
(F1
F0.00014334862385321102
I1
I0
I1
tp3605
sS'an,aluminum,hydroxide-'
p3606
(F1
F0.00014334862385321102
I0
I1
I-1
tp3607
sS'excretion,of,nalfon'
p3608
(F1
F0.00014334862385321102
I1
I0
I1
tp3609
sS'coadministered,with,and'
p3610
(F0
F0
I1
I1
I0
tp3611
sS'use,of,antizol'
p3612
(F1
F0.00014334862385321102
I1
I0
I1
tp3613
sS'who,received,under'
p3614
(F1
F0.00014334862385321102
I0
I1
I-1
tp3615
sS'the,therapy,of'
p3616
(F1
F0.00014334862385321102
I1
I0
I1
tp3617
sS'a,interaction,study'
p3618
(F1
F0.00043004587155963305
I0
I3
I-3
tp3619
sS'or,hypotension,with'
p3620
(F1
F0.00014334862385321102
I1
I0
I1
tp3621
sS'conduction,can,result'
p3622
(F1
F0.00014334862385321102
I1
I0
I1
tp3623
sS'is,also,used'
p3624
(F1
F0.00028669724770642203
I2
I0
I2
tp3625
sS'dose,of,was'
p3626
(F1
F0.00028669724770642203
I0
I2
I-2
tp3627
sS'worsen,the,incidence'
p3628
(F1
F0.00014334862385321102
I1
I0
I1
tp3629
sS'drug-drug,pharmacokinetic,interactions'
p3630
(F1
F0.00014334862385321102
I0
I1
I-1
tp3631
sS'in,vitro,experiments'
p3632
(F1
F0.00014334862385321102
I0
I1
I-1
tp3633
sS'the,non-ionized,species'
p3634
(F1
F0.00014334862385321102
I1
I0
I1
tp3635
sS'to,enroll,patients'
p3636
(F1
F0.00014334862385321102
I0
I1
I-1
tp3637
sS'as,those,elevations'
p3638
(F1
F0.00014334862385321102
I0
I1
I-1
tp3639
sS'not,be,given'
p3640
(F1
F0.0008600917431192661
I6
I0
I6
tp3641
sS'p,but,not'
p3642
(F1
F0.00014334862385321102
I1
I0
I1
tp3643
sS'antagonists,cyp1a2,inducers'
p3644
(F1
F0.00014334862385321102
I0
I1
I-1
tp3645
sS'in,the,guinea-pig'
p3646
(F1
F0.00014334862385321102
I0
I1
I-1
tp3647
sS'tiagabine,had,no'
p3648
(F1
F0.00028669724770642203
I0
I2
I-2
tp3649
sS'antiretroviral,plasma,and'
p3650
(F1
F0.00014334862385321102
I0
I1
I-1
tp3651
sS'approximately,fold,of'
p3652
(F1
F0.00014334862385321102
I1
I0
I1
tp3653
sS'block,morphine-induced,and'
p3654
(F1
F0.00014334862385321102
I1
I0
I1
tp3655
sS'therapy,has,not'
p3656
(F1
F0.00028669724770642203
I0
I2
I-2
tp3657
sS'metabolism,in,the'
p3658
(F1
F0.00014334862385321102
I1
I0
I1
tp3659
sS'dysrhythmias,some,resulting'
p3660
(F1
F0.00014334862385321102
I1
I0
I1
tp3661
sS'in,the,clinical'
p3662
(F0
F0
I1
I1
I0
tp3663
sS'wshow,no,evidence'
p3664
(F1
F0.00014334862385321102
I0
I1
I-1
tp3665
sS'in,a,substantial'
p3666
(F1
F0.00014334862385321102
I1
I0
I1
tp3667
sS'binding,decrease,in'
p3668
(F1
F0.00014334862385321102
I1
I0
I1
tp3669
sS'etc,is,indicated'
p3670
(F1
F0.00014334862385321102
I1
I0
I1
tp3671
sS'potential,for,ototoxicity'
p3672
(F1
F0.00014334862385321102
I1
I0
I1
tp3673
sS'prothrombin,activity,patients'
p3674
(F1
F0.00028669724770642203
I2
I0
I2
tp3675
sS'substrate,trough,concentration'
p3676
(F1
F0.00014334862385321102
I1
I0
I1
tp3677
sS'during,days,of'
p3678
(F1
F0.00014334862385321102
I0
I1
I-1
tp3679
sS'oxide,with,a'
p3680
(F1
F0.00014334862385321102
I0
I1
I-1
tp3681
sS'prostaglandin,f2alpha,and'
p3682
(F0
F0
I1
I1
I0
tp3683
sS'two,strains,of'
p3684
(F1
F0.00014334862385321102
I0
I1
I-1
tp3685
sS'elimination,or,altered'
p3686
(F1
F0.00014334862385321102
I0
I1
I-1
tp3687
sS'g,kg,for'
p3688
(F1
F0.00014334862385321102
I1
I0
I1
tp3689
sS'years,old,participated'
p3690
(F1
F0.00014334862385321102
I0
I1
I-1
tp3691
sS'hexalen,and,plus'
p3692
(F1
F0.00014334862385321102
I1
I0
I1
tp3693
sS'implantable,contraceptives,an'
p3694
(F1
F0.00014334862385321102
I1
I0
I1
tp3695
sS'inhibitors,or,substrates'
p3696
(F1
F0.00014334862385321102
I1
I0
I1
tp3697
sS'of,with,mhd'
p3698
(F1
F0.00014334862385321102
I0
I1
I-1
tp3699
sS'when,norpace,was'
p3700
(F1
F0.00014334862385321102
I0
I1
I-1
tp3701
sS'blocking,agents,may'
p3702
(F1
F0.00043004587155963305
I3
I0
I3
tp3703
sS'enhance,the,locomotor'
p3704
(F1
F0.00014334862385321102
I0
I1
I-1
tp3705
sS'induced,hypokalemia,which'
p3706
(F1
F0.00014334862385321102
I1
I0
I1
tp3707
sS'structurally,related,to'
p3708
(F1
F0.00014334862385321102
I1
I0
I1
tp3709
sS'changes,in,corrected'
p3710
(F1
F0.00014334862385321102
I0
I1
I-1
tp3711
sS'further,alterations,in'
p3712
(F1
F0.00014334862385321102
I1
I0
I1
tp3713
sS'products,containing,containing'
p3714
(F1
F0.00014334862385321102
I1
I0
I1
tp3715
sS'on,the,dissolution'
p3716
(F1
F0.00014334862385321102
I0
I1
I-1
tp3717
sS'quantitatively,related,to'
p3718
(F1
F0.00014334862385321102
I0
I1
I-1
tp3719
sS'however,no,deleterious'
p3720
(F1
F0.00014334862385321102
I0
I1
I-1
tp3721
sS'there,is,an'
p3722
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp3723
sS'of,ganglionic,blocking'
p3724
(F1
F0.00014334862385321102
I1
I0
I1
tp3725
sS'increase,of,crixivan'
p3726
(F1
F0.00014334862385321102
I1
I0
I1
tp3727
sS'hypoglycemic,agents,there'
p3728
(F1
F0.00014334862385321102
I1
I0
I1
tp3729
sS'effect,of,on'
p3730
(F0.56756756756756754
F0.0030103211009174314
I8
I29
I-21
tp3731
sS'as,impulsivity,and'
p3732
(F1
F0.00014334862385321102
I0
I1
I-1
tp3733
sS'subjects,who,have'
p3734
(F1
F0.00014334862385321102
I1
I0
I1
tp3735
sS'use,of,with'
p3736
(F0.25
F0.0008600917431192661
I15
I9
I6
tp3737
sS'an,increase,of'
p3738
(F0
F0
I1
I1
I0
tp3739
sS'doses,greater,than'
p3740
(F1
F0.00014334862385321102
I0
I1
I-1
tp3741
sS'effect,of,or'
p3742
(F0
F0
I1
I1
I0
tp3743
sS'young,healthy,male'
p3744
(F1
F0.00014334862385321102
I0
I1
I-1
tp3745
sS'in,patients,whose'
p3746
(F1
F0.00014334862385321102
I0
I1
I-1
tp3747
sS'schizophrenic,patients,coadministered'
p3748
(F1
F0.00014334862385321102
I1
I0
I1
tp3749
sS'inhibitors,amprenavir,and'
p3750
(F1
F0.00014334862385321102
I1
I0
I1
tp3751
sS'with,or,other'
p3752
(F0.5
F0.0008600917431192661
I9
I3
I6
tp3753
sS'acidifying,agents,gastrointestinal'
p3754
(F1
F0.00014334862385321102
I1
I0
I1
tp3755
sS'of,affected,by'
p3756
(F1
F0.00028669724770642203
I0
I2
I-2
tp3757
sS'accounts,for,less'
p3758
(F1
F0.00014334862385321102
I0
I1
I-1
tp3759
sS'increased,clinical,effects'
p3760
(F1
F0.00014334862385321102
I1
I0
I1
tp3761
sS'reciprocal,interactions,may'
p3762
(F1
F0.00014334862385321102
I1
I0
I1
tp3763
sS'must,not,be'
p3764
(F1
F0.00028669724770642203
I2
I0
I2
tp3765
sS'those,obtained,when'
p3766
(F1
F0.00028669724770642203
I2
I0
I2
tp3767
sS'a,c,and'
p3768
(F1
F0.00043004587155963305
I3
I0
I3
tp3769
sS'the,psychostimulant,effects'
p3770
(F1
F0.00014334862385321102
I0
I1
I-1
tp3771
sS'progestin-only,pills,is'
p3772
(F1
F0.00014334862385321102
I1
I0
I1
tp3773
sS'male,rats,that'
p3774
(F1
F0.00014334862385321102
I0
I1
I-1
tp3775
sS'of,with,each'
p3776
(F1
F0.00014334862385321102
I0
I1
I-1
tp3777
sS'action,of,is'
p3778
(F1
F0.00014334862385321102
I1
I0
I1
tp3779
sS'action,of,it'
p3780
(F1
F0.00028669724770642203
I2
I0
I2
tp3781
sS'quinolone,antibiotics,and'
p3782
(F1
F0.00014334862385321102
I1
I0
I1
tp3783
sS'upper,gastrointestinal,events'
p3784
(F1
F0.00014334862385321102
I0
I1
I-1
tp3785
sS'n,mean,auc'
p3786
(F1
F0.00014334862385321102
I1
I0
I1
tp3787
sS'of,observation,must'
p3788
(F1
F0.00014334862385321102
I0
I1
I-1
tp3789
sS'of,or,toxoids'
p3790
(F1
F0.00014334862385321102
I1
I0
I1
tp3791
sS'reduction,of,mean'
p3792
(F1
F0.00014334862385321102
I1
I0
I1
tp3793
sS'antihypertensive,effects,of'
p3794
(F1
F0.00071674311926605509
I5
I0
I5
tp3795
sS'm,g,ml'
p3796
(F1
F0.00014334862385321102
I1
I0
I1
tp3797
sS'short-term,controlled,study'
p3798
(F1
F0.00014334862385321102
I0
I1
I-1
tp3799
sS'increased,plasma,clearance'
p3800
(F1
F0.00014334862385321102
I1
I0
I1
tp3801
sS'systemic,exposure,to'
p3802
(F1
F0.00014334862385321102
I1
I0
I1
tp3803
sS'is,used,concomitantly'
p3804
(F1
F0.00071674311926605509
I5
I0
I5
tp3805
sS'has,a,lower'
p3806
(F1
F0.00014334862385321102
I1
I0
I1
tp3807
sS'there,does,not'
p3808
(F1
F0.00014334862385321102
I0
I1
I-1
tp3809
sS'im,has,been'
p3810
(F1
F0.00014334862385321102
I0
I1
I-1
tp3811
sS'which,significantly,p'
p3812
(F1
F0.00014334862385321102
I1
I0
I1
tp3813
sS'cholestyramine,may,increase'
p3814
(F1
F0.00014334862385321102
I1
I0
I1
tp3815
sS'vitro,studies,show'
p3816
(F1
F0.00014334862385321102
I0
I1
I-1
tp3817
sS'abrupt,suppression,of'
p3818
(F1
F0.00014334862385321102
I1
I0
I1
tp3819
sS'response,rates,in'
p3820
(F1
F0.00014334862385321102
I0
I1
I-1
tp3821
sS'and,angiotensin,converting'
p3822
(F1
F0.00014334862385321102
I0
I1
I-1
tp3823
sS'clinical,trial,there'
p3824
(F1
F0.00014334862385321102
I0
I1
I-1
tp3825
sS'channels,in,bovine'
p3826
(F1
F0.00014334862385321102
I0
I1
I-1
tp3827
sS'a4,enzyme,system'
p3828
(F1
F0.00014334862385321102
I1
I0
I1
tp3829
sS'recommended,that,the'
p3830
(F1
F0.00028669724770642203
I2
I0
I2
tp3831
sS'inhibitors,elevated,blood'
p3832
(F1
F0.00014334862385321102
I0
I1
I-1
tp3833
sS'iv,is,augmented'
p3834
(F1
F0.00014334862385321102
I1
I0
I1
tp3835
sS'of,allergic,reaction'
p3836
(F1
F0.00014334862385321102
I1
I0
I1
tp3837
sS'slight,increases,in'
p3838
(F1
F0.00014334862385321102
I1
I0
I1
tp3839
sS'medication,and,instruct'
p3840
(F1
F0.00014334862385321102
I0
I1
I-1
tp3841
sS'was,shown,in'
p3842
(F1
F0.00014334862385321102
I0
I1
I-1
tp3843
sS'theophylline-related,side,effects'
p3844
(F1
F0.00028669724770642203
I2
I0
I2
tp3845
sS'topamax,felbatol,gris-peg'
p3846
(F1
F0.00014334862385321102
I1
I0
I1
tp3847
sS'anesthetized,swine,has'
p3848
(F1
F0.00014334862385321102
I0
I1
I-1
tp3849
sS'and,histamine-induced,gastric'
p3850
(F1
F0.00014334862385321102
I0
I1
I-1
tp3851
sS'however,a,crossover'
p3852
(F1
F0.00014334862385321102
I1
I0
I1
tp3853
sS'noted,with,the'
p3854
(F0
F0
I1
I1
I0
tp3855
sS'alpha,and,beta'
p3856
(F1
F0.00014334862385321102
I0
I1
I-1
tp3857
sS'of,interaction,studies'
p3858
(F1
F0.00014334862385321102
I0
I1
I-1
tp3859
sS'administration,of,itraconazole'
p3860
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3861
sS'are,at,greater'
p3862
(F1
F0.00014334862385321102
I0
I1
I-1
tp3863
sS'with,or,carbidopa-levodopa'
p3864
(F1
F0.00014334862385321102
I0
I1
I-1
tp3865
sS'over,weeks,as'
p3866
(F1
F0.00014334862385321102
I0
I1
I-1
tp3867
sS'inhibit,and,stimulate'
p3868
(F1
F0.00014334862385321102
I1
I0
I1
tp3869
sS'p,app,control'
p3870
(F1
F0.00014334862385321102
I0
I1
I-1
tp3871
sS'or,and,hydroxides'
p3872
(F1
F0.00014334862385321102
I1
I0
I1
tp3873
sS'was,not,substantially'
p3874
(F1
F0.00014334862385321102
I1
I0
I1
tp3875
sS'administered,with,caution'
p3876
(F1
F0.0008600917431192661
I6
I0
I6
tp3877
sS'between,the,excreted'
p3878
(F1
F0.00014334862385321102
I0
I1
I-1
tp3879
sS'in,inr,and'
p3880
(F1
F0.00014334862385321102
I1
I0
I1
tp3881
sS'concentrations,similar,to'
p3882
(F1
F0.00014334862385321102
I1
I0
I1
tp3883
sS'therefore,patients,receiving'
p3884
(F1
F0.00014334862385321102
I1
I0
I1
tp3885
sS'and,you,may'
p3886
(F1
F0.00014334862385321102
I1
I0
I1
tp3887
sS'in,hypercholesterolemic,noninsulin'
p3888
(F1
F0.00014334862385321102
I0
I1
I-1
tp3889
sS'given,did,not'
p3890
(F1
F0.00014334862385321102
I0
I1
I-1
tp3891
sS'adversely,influence,the'
p3892
(F1
F0.00014334862385321102
I1
I0
I1
tp3893
sS'day,and,every'
p3894
(F1
F0.00014334862385321102
I0
I1
I-1
tp3895
sS'as,and,cardiac'
p3896
(F1
F0.00014334862385321102
I0
I1
I-1
tp3897
sS'to,mg,week'
p3898
(F1
F0.00014334862385321102
I1
I0
I1
tp3899
sS'were,to,years'
p3900
(F1
F0.00014334862385321102
I0
I1
I-1
tp3901
sS'although,not,reported'
p3902
(F1
F0.00014334862385321102
I1
I0
I1
tp3903
sS'potent,inducer,of'
p3904
(F1
F0.00028669724770642203
I2
I0
I2
tp3905
sS'that,when,compared'
p3906
(F1
F0.00014334862385321102
I1
I0
I1
tp3907
sS'a,dopa,decarboxylase'
p3908
(F1
F0.00014334862385321102
I0
I1
I-1
tp3909
sS'fosinopril,may,cause'
p3910
(F1
F0.00014334862385321102
I0
I1
I-1
tp3911
sS'and,decrease,metabolism'
p3912
(F1
F0.00014334862385321102
I1
I0
I1
tp3913
sS'metabotropic,glutamate,mglur'
p3914
(F1
F0.00014334862385321102
I0
I1
I-1
tp3915
sS'serum,and,urine'
p3916
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp3917
sS'of,isosorbide,mononitrate'
p3918
(F1
F0.00014334862385321102
I1
I0
I1
tp3919
sS'the,initial,clinical'
p3920
(F1
F0.00014334862385321102
I0
I1
I-1
tp3921
sS'death,associated,with'
p3922
(F1
F0.00014334862385321102
I1
I0
I1
tp3923
sS'for,the,same'
p3924
(F1
F0.00014334862385321102
I0
I1
I-1
tp3925
sS'compliance,especially,neglect'
p3926
(F1
F0.00014334862385321102
I0
I1
I-1
tp3927
sS'prospective,study,involving'
p3928
(F1
F0.00014334862385321102
I0
I1
I-1
tp3929
sS'during,initiation,of'
p3930
(F1
F0.00014334862385321102
I0
I1
I-1
tp3931
sS'tagamet,mg,q'
p3932
(F1
F0.00014334862385321102
I1
I0
I1
tp3933
sS'tnf,antagonists,is'
p3934
(F1
F0.00014334862385321102
I1
I0
I1
tp3935
sS'steady,state,conditions'
p3936
(F1
F0.00028669724770642203
I0
I2
I-2
tp3937
sS'half-life,and,enhanced'
p3938
(F1
F0.00014334862385321102
I0
I1
I-1
tp3939
sS'clinically,significant,increases'
p3940
(F0
F0
I1
I1
I0
tp3941
sS'desmopressin,is,very'
p3942
(F1
F0.00014334862385321102
I0
I1
I-1
tp3943
sS'with,alone,and'
p3944
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp3945
sS'agents,has,not'
p3946
(F1
F0.00014334862385321102
I0
I1
I-1
tp3947
sS'and,stimulate,egf-'
p3948
(F1
F0.00014334862385321102
I1
I0
I1
tp3949
sS'in,elevated,creatinine'
p3950
(F1
F0.00014334862385321102
I0
I1
I-1
tp3951
sS'were,increased,decreased'
p3952
(F1
F0.00014334862385321102
I1
I0
I1
tp3953
sS'gleevec,with,inhibitors'
p3954
(F1
F0.00014334862385321102
I1
I0
I1
tp3955
sS'comparative,study,week'
p3956
(F1
F0.00014334862385321102
I0
I1
I-1
tp3957
sS'be,advised,against'
p3958
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp3959
sS'an,hydroxide,containing'
p3960
(F1
F0.00014334862385321102
I1
I0
I1
tp3961
sS'due,to,changes'
p3962
(F1
F0.00014334862385321102
I0
I1
I-1
tp3963
sS'basal,plasma,renin'
p3964
(F1
F0.00014334862385321102
I0
I1
I-1
tp3965
sS'survanta,increased,the'
p3966
(F1
F0.00014334862385321102
I0
I1
I-1
tp3967
sS'other,as,used'
p3968
(F1
F0.00014334862385321102
I1
I0
I1
tp3969
sS'the,conclusion,that'
p3970
(F1
F0.00014334862385321102
I1
I0
I1
tp3971
sS'decreases,urinary,excretion'
p3972
(F1
F0.00014334862385321102
I1
I0
I1
tp3973
sS'be,anticipated,and'
p3974
(F1
F0.00014334862385321102
I1
I0
I1
tp3975
sS'additional,including,indocin'
p3976
(F1
F0.00014334862385321102
I1
I0
I1
tp3977
sS'with,or,minutes'
p3978
(F1
F0.00014334862385321102
I1
I0
I1
tp3979
sS'period,in,which'
p3980
(F1
F0.00014334862385321102
I1
I0
I1
tp3981
sS'containing,may,substantially'
p3982
(F1
F0.00014334862385321102
I1
I0
I1
tp3983
sS'due,to,adverse'
p3984
(F1
F0.00014334862385321102
I0
I1
I-1
tp3985
sS'undergoes,extensive,metabolism'
p3986
(F1
F0.00014334862385321102
I0
I1
I-1
tp3987
sS'non-steroidal,agent,can'
p3988
(F1
F0.00014334862385321102
I1
I0
I1
tp3989
sS'patients,receiving,may'
p3990
(F1
F0.00014334862385321102
I1
I0
I1
tp3991
sS'showed,the,most'
p3992
(F1
F0.00014334862385321102
I0
I1
I-1
tp3993
sS'cyp1a2,cyp2c9,cyp2d6'
p3994
(F1
F0.00014334862385321102
I0
I1
I-1
tp3995
sS'used,concurrently,with'
p3996
(F0
F0
I4
I4
I0
tp3997
sS'a,synergistic,effect'
p3998
(F1
F0.00014334862385321102
I1
I0
I1
tp3999
sS'by,this,isozyme'
p4000
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4001
sS'in,mcf-7,cells'
p4002
(F1
F0.00014334862385321102
I0
I1
I-1
tp4003
sS'twitch,for,a'
p4004
(F1
F0.00014334862385321102
I0
I1
I-1
tp4005
sS'excretion,is,via'
p4006
(F1
F0.00014334862385321102
I0
I1
I-1
tp4007
sS'a,substantial,period'
p4008
(F1
F0.00014334862385321102
I0
I1
I-1
tp4009
sS'azole,agents,are'
p4010
(F1
F0.00014334862385321102
I1
I0
I1
tp4011
sS'consequences,of,concomitant'
p4012
(F1
F0.00014334862385321102
I0
I1
I-1
tp4013
sS'ptx,c129h223n3o54,isolated'
p4014
(F1
F0.00014334862385321102
I0
I1
I-1
tp4015
sS'found,to,be'
p4016
(F1
F0.00028669724770642203
I0
I2
I-2
tp4017
sS'to,serum,protein'
p4018
(F1
F0.00014334862385321102
I1
I0
I1
tp4019
sS'an,elevation,in'
p4020
(F1
F0.00014334862385321102
I0
I1
I-1
tp4021
sS'of,this,drug'
p4022
(F1
F0.00014334862385321102
I0
I1
I-1
tp4023
sS'humans,demonstrated,that'
p4024
(F1
F0.00014334862385321102
I0
I1
I-1
tp4025
sS'of,oral,increased'
p4026
(F1
F0.00014334862385321102
I1
I0
I1
tp4027
sS'of,cytochrome,p450-mediated'
p4028
(F1
F0.00014334862385321102
I0
I1
I-1
tp4029
sS'with,caution,to'
p4030
(F1
F0.00071674311926605509
I5
I0
I5
tp4031
sS'reported,during,the'
p4032
(F1
F0.00014334862385321102
I1
I0
I1
tp4033
sS'ulceration,and,complications'
p4034
(F1
F0.00014334862385321102
I1
I0
I1
tp4035
sS'or,pharmacodynamic,profile'
p4036
(F1
F0.00014334862385321102
I0
I1
I-1
tp4037
sS'mg,of,have'
p4038
(F1
F0.00014334862385321102
I0
I1
I-1
tp4039
sS'sequestered,in,fat'
p4040
(F1
F0.00014334862385321102
I0
I1
I-1
tp4041
sS'serum,half-life,or'
p4042
(F1
F0.00014334862385321102
I1
I0
I1
tp4043
sS'important,drug,interactions'
p4044
(F1
F0.00014334862385321102
I1
I0
I1
tp4045
sS'producing,medications,concurrent'
p4046
(F1
F0.00014334862385321102
I0
I1
I-1
tp4047
sS'patients,receiving,camptosar'
p4048
(F1
F0.00014334862385321102
I1
I0
I1
tp4049
sS'carefully,if,high'
p4050
(F1
F0.00014334862385321102
I1
I0
I1
tp4051
sS'during,periods,of'
p4052
(F1
F0.00014334862385321102
I1
I0
I1
tp4053
sS'potentiated,the,cns-impairing'
p4054
(F1
F0.00014334862385321102
I1
I0
I1
tp4055
sS'eg,and,or'
p4056
(F1
F0.00028669724770642203
I2
I0
I2
tp4057
sS'hour,before,the'
p4058
(F1
F0.00014334862385321102
I1
I0
I1
tp4059
sS'function,eg,and'
p4060
(F1
F0.00014334862385321102
I1
I0
I1
tp4061
sS'absorption,of,agents'
p4062
(F1
F0.00014334862385321102
I1
I0
I1
tp4063
sS'in,a,complex'
p4064
(F1
F0.00014334862385321102
I0
I1
I-1
tp4065
sS'one,hour,after'
p4066
(F1
F0.00014334862385321102
I1
I0
I1
tp4067
sS'that,would,warrant'
p4068
(F1
F0.00014334862385321102
I0
I1
I-1
tp4069
sS'releaser,and,reuptake'
p4070
(F1
F0.00014334862385321102
I1
I0
I1
tp4071
sS'before,starting,a'
p4072
(F1
F0.00014334862385321102
I1
I0
I1
tp4073
sS'dextromethorphan,is,primarily'
p4074
(F1
F0.00014334862385321102
I0
I1
I-1
tp4075
sS'diminish,fluoride,or'
p4076
(F1
F0.00014334862385321102
I0
I1
I-1
tp4077
sS'interaction,between,single'
p4078
(F1
F0.00014334862385321102
I1
I0
I1
tp4079
sS'gentamicin,is,an'
p4080
(F1
F0.00014334862385321102
I0
I1
I-1
tp4081
sS'acute,angina,attacks'
p4082
(F1
F0.00014334862385321102
I0
I1
I-1
tp4083
sS'decreased,by,while'
p4084
(F1
F0.00014334862385321102
I1
I0
I1
tp4085
sS'of,proleukin,and'
p4086
(F1
F0.00014334862385321102
I1
I0
I1
tp4087
sS'anti-inflammatory,but,not'
p4088
(F1
F0.00014334862385321102
I0
I1
I-1
tp4089
sS'daily,the,auc'
p4090
(F1
F0.00014334862385321102
I1
I0
I1
tp4091
sS'sudden,death,potentially'
p4092
(F1
F0.00014334862385321102
I1
I0
I1
tp4093
sS'from,the,seminiferous'
p4094
(F1
F0.00014334862385321102
I0
I1
I-1
tp4095
sS'urinary,acidifying,agents'
p4096
(F1
F0.00043004587155963305
I3
I0
I3
tp4097
sS'a,selective,serotonin'
p4098
(F1
F0.00014334862385321102
I1
I0
I1
tp4099
sS'and,human,growth'
p4100
(F1
F0.00014334862385321102
I1
I0
I1
tp4101
sS'other,oral,hypoglycemic'
p4102
(F1
F0.00014334862385321102
I1
I0
I1
tp4103
sS'subjects,decreases,in'
p4104
(F1
F0.00014334862385321102
I0
I1
I-1
tp4105
sS'toradol,iv,im'
p4106
(F1
F0.00014334862385321102
I1
I0
I1
tp4107
sS'dose,of,liquid'
p4108
(F1
F0.00014334862385321102
I0
I1
I-1
tp4109
sS'interactions,with,emtriva'
p4110
(F1
F0.00014334862385321102
I0
I1
I-1
tp4111
sS'concentrations,of,serum'
p4112
(F1
F0.00014334862385321102
I1
I0
I1
tp4113
sS'caution,in,prothrombin'
p4114
(F1
F0.00014334862385321102
I0
I1
I-1
tp4115
sS'solutions,containing,or'
p4116
(F1
F0.00043004587155963305
I3
I0
I3
tp4117
sS'the,maintenance,of'
p4118
(F1
F0.00014334862385321102
I0
I1
I-1
tp4119
sS'sporanox,lipitor,atromid-s'
p4120
(F1
F0.00014334862385321102
I1
I0
I1
tp4121
sS'extremely,cautiously,and'
p4122
(F1
F0.00014334862385321102
I1
I0
I1
tp4123
sS'the,anorectic,and'
p4124
(F1
F0.00014334862385321102
I1
I0
I1
tp4125
sS'concentrations,prior,to'
p4126
(F1
F0.00014334862385321102
I0
I1
I-1
tp4127
sS'intake,and,pharmacological'
p4128
(F1
F0.00014334862385321102
I0
I1
I-1
tp4129
sS'as,a,guide'
p4130
(F1
F0.00014334862385321102
I1
I0
I1
tp4131
sS'efficacy,of,oral'
p4132
(F1
F0.00028669724770642203
I2
I0
I2
tp4133
sS'sildenafil,has,demonstrated'
p4134
(F1
F0.00014334862385321102
I0
I1
I-1
tp4135
sS'no,inhibition,of'
p4136
(F1
F0.00014334862385321102
I0
I1
I-1
tp4137
sS'solution,of,was'
p4138
(F1
F0.00014334862385321102
I0
I1
I-1
tp4139
sS'potentiate,the,increase'
p4140
(F1
F0.00014334862385321102
I0
I1
I-1
tp4141
sS'doses,of,with'
p4142
(F1
F0.00014334862385321102
I1
I0
I1
tp4143
sS'like,cannot,be'
p4144
(F1
F0.00014334862385321102
I0
I1
I-1
tp4145
sS'serum,exposure,compared'
p4146
(F1
F0.00014334862385321102
I1
I0
I1
tp4147
sS'camp-stimulated,acid,secretion'
p4148
(F1
F0.00014334862385321102
I1
I0
I1
tp4149
sS'inhibit,pgp,increased'
p4150
(F1
F0.00014334862385321102
I0
I1
I-1
tp4151
sS'could,increase,or'
p4152
(F0
F0
I1
I1
I0
tp4153
sS'the,retention,of'
p4154
(F0
F0
I1
I1
I0
tp4155
sS'dosage,of,theo-dur'
p4156
(F1
F0.00014334862385321102
I1
I0
I1
tp4157
sS'inflammatory,arthritis,thyroiditis'
p4158
(F1
F0.00014334862385321102
I1
I0
I1
tp4159
sS'that,buspirone,hydrochloride'
p4160
(F1
F0.00014334862385321102
I1
I0
I1
tp4161
sS'amount,of,either'
p4162
(F1
F0.00014334862385321102
I1
I0
I1
tp4163
sS'preservative,in,the'
p4164
(F1
F0.00014334862385321102
I1
I0
I1
tp4165
sS'enhance,the,adrenergic'
p4166
(F1
F0.00014334862385321102
I1
I0
I1
tp4167
sS'warranted,and,therapeutic'
p4168
(F1
F0.00014334862385321102
I1
I0
I1
tp4169
sS'than,mm,fractional'
p4170
(F1
F0.00014334862385321102
I0
I1
I-1
tp4171
sS'in,mean,peak'
p4172
(F1
F0.00028669724770642203
I2
I0
I2
tp4173
sS'suggest,any,clinical'
p4174
(F1
F0.00014334862385321102
I0
I1
I-1
tp4175
sS'or,repeated,doses'
p4176
(F1
F0.00014334862385321102
I0
I1
I-1
tp4177
sS'in,serum,i'
p4178
(F1
F0.00028669724770642203
I0
I2
I-2
tp4179
sS'alter,the,pharmacokinetic'
p4180
(F1
F0.00014334862385321102
I0
I1
I-1
tp4181
sS'with,other,calcium-containing'
p4182
(F1
F0.00014334862385321102
I0
I1
I-1
tp4183
sS'changes,in,hormone'
p4184
(F1
F0.00014334862385321102
I0
I1
I-1
tp4185
sS'trials,however,beta'
p4186
(F1
F0.00014334862385321102
I0
I1
I-1
tp4187
sS'is,considered,to'
p4188
(F1
F0.00028669724770642203
I0
I2
I-2
tp4189
sS'is,limited,experience'
p4190
(F1
F0.00014334862385321102
I0
I1
I-1
tp4191
sS'with,may,be'
p4192
(F0
F0
I1
I1
I0
tp4193
sS'vitro,interaction,studies'
p4194
(F1
F0.00014334862385321102
I0
I1
I-1
tp4195
sS'cyclosporine,because,can'
p4196
(F1
F0.00014334862385321102
I1
I0
I1
tp4197
sS'after,completion,of'
p4198
(F1
F0.00014334862385321102
I1
I0
I1
tp4199
sS'acid,were,added'
p4200
(F1
F0.00014334862385321102
I0
I1
I-1
tp4201
sS'variety,of,hepatic'
p4202
(F1
F0.00014334862385321102
I0
I1
I-1
tp4203
sS'assessed,by,ex'
p4204
(F1
F0.00014334862385321102
I0
I1
I-1
tp4205
sS'effects,of,oral'
p4206
(F0
F0
I2
I2
I0
tp4207
sS'to,initiation,of'
p4208
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp4209
sS'nevertheless,caution,is'
p4210
(F1
F0.00057339449541284407
I4
I0
I4
tp4211
sS'this,procedure,it'
p4212
(F1
F0.00014334862385321102
I0
I1
I-1
tp4213
sS'either,simultaneously,or'
p4214
(F1
F0.00014334862385321102
I1
I0
I1
tp4215
sS'for,weeks,has'
p4216
(F1
F0.00014334862385321102
I1
I0
I1
tp4217
sS'concomitantly,administered,intravenously'
p4218
(F1
F0.00014334862385321102
I1
I0
I1
tp4219
sS'depressants,may,have'
p4220
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp4221
sS'and,other,products'
p4222
(F1
F0.00028669724770642203
I0
I2
I-2
tp4223
sS'other,nonsteroidal,has'
p4224
(F1
F0.00014334862385321102
I1
I0
I1
tp4225
sS'concentration,and,area'
p4226
(F0
F0
I1
I1
I0
tp4227
sS'administered,with,nitrous'
p4228
(F1
F0.00014334862385321102
I1
I0
I1
tp4229
sS'shown,that,tikosyn'
p4230
(F1
F0.00028669724770642203
I0
I2
I-2
tp4231
sS'patients,want,to'
p4232
(F1
F0.00014334862385321102
I0
I1
I-1
tp4233
sS'than,the,usual'
p4234
(F1
F0.00014334862385321102
I0
I1
I-1
tp4235
sS'in,a,and'
p4236
(F0
F0
I1
I1
I0
tp4237
sS'day,before,meals'
p4238
(F1
F0.00014334862385321102
I0
I1
I-1
tp4239
sS'concentration,dependent,labelling'
p4240
(F1
F0.00014334862385321102
I0
I1
I-1
tp4241
sS'intensify,the,and'
p4242
(F0
F0
I2
I2
I0
tp4243
sS'increases,bioavailability,by'
p4244
(F1
F0.00014334862385321102
I0
I1
I-1
tp4245
sS'potassium-sparing,diuretics,fosinopril'
p4246
(F1
F0.00014334862385321102
I1
I0
I1
tp4247
sS'forms,of,deficit'
p4248
(F1
F0.00014334862385321102
I0
I1
I-1
tp4249
sS'on,the,electrocardiographic'
p4250
(F1
F0.00014334862385321102
I0
I1
I-1
tp4251
sS'any,significant,changes'
p4252
(F1
F0.00014334862385321102
I0
I1
I-1
tp4253
sS'severe,hypoglycemia,has'
p4254
(F1
F0.0008600917431192661
I6
I0
I6
tp4255
sS'enzyme,system,probably'
p4256
(F1
F0.00014334862385321102
I0
I1
I-1
tp4257
sS'renal,transplant,recipients'
p4258
(F1
F0.00014334862385321102
I0
I1
I-1
tp4259
sS'effects,when,administered'
p4260
(F1
F0.00014334862385321102
I1
I0
I1
tp4261
sS'of,foscavir,should'
p4262
(F1
F0.00014334862385321102
I1
I0
I1
tp4263
sS'radioligand,binding,experiments'
p4264
(F1
F0.00014334862385321102
I0
I1
I-1
tp4265
sS'intervals,between,doses'
p4266
(F1
F0.00014334862385321102
I1
I0
I1
tp4267
sS'recommended,due,to'
p4268
(F1
F0.00043004587155963305
I3
I0
I3
tp4269
sS'recommendations,for,sustiva'
p4270
(F1
F0.00014334862385321102
I0
I1
I-1
tp4271
sS'depressant,should,be'
p4272
(F1
F0.00014334862385321102
I1
I0
I1
tp4273
sS'and,lower,in'
p4274
(F1
F0.00014334862385321102
I1
I0
I1
tp4275
sS'compared,to,results'
p4276
(F1
F0.00014334862385321102
I1
I0
I1
tp4277
sS'sulfate,and,hc1'
p4278
(F1
F0.00014334862385321102
I1
I0
I1
tp4279
sS'lower,plasma,levels'
p4280
(F1
F0.00014334862385321102
I1
I0
I1
tp4281
sS'observed,with,co-administration'
p4282
(F1
F0.00014334862385321102
I0
I1
I-1
tp4283
sS'or,without,bleeding'
p4284
(F1
F0.00014334862385321102
I1
I0
I1
tp4285
sS'of,dosage,or'
p4286
(F1
F0.00014334862385321102
I0
I1
I-1
tp4287
sS'lower,intestine,so'
p4288
(F1
F0.00014334862385321102
I1
I0
I1
tp4289
sS'of,status,which'
p4290
(F1
F0.00014334862385321102
I0
I1
I-1
tp4291
sS'mm,and,mm'
p4292
(F1
F0.00014334862385321102
I0
I1
I-1
tp4293
sS'phenytoin,and,may'
p4294
(F1
F0.00014334862385321102
I1
I0
I1
tp4295
sS'inhibitors,agenerase,crixivan'
p4296
(F1
F0.00014334862385321102
I1
I0
I1
tp4297
sS'possible,drug,interaction'
p4298
(F1
F0.00043004587155963305
I3
I0
I3
tp4299
sS'antagonists,and,loop'
p4300
(F1
F0.00014334862385321102
I0
I1
I-1
tp4301
sS'received,mg,twice'
p4302
(F1
F0.00028669724770642203
I0
I2
I-2
tp4303
sS'peak,and,the'
p4304
(F1
F0.00014334862385321102
I0
I1
I-1
tp4305
sS'the,blood,coagulation'
p4306
(F1
F0.00014334862385321102
I0
I1
I-1
tp4307
sS'hypotension,which,may'
p4308
(F1
F0.00014334862385321102
I1
I0
I1
tp4309
sS'retention,of,was'
p4310
(F1
F0.00014334862385321102
I1
I0
I1
tp4311
sS'absorption,site,fecal'
p4312
(F1
F0.00014334862385321102
I0
I1
I-1
tp4313
sS'by,a,dose-dependent'
p4314
(F1
F0.00014334862385321102
I1
I0
I1
tp4315
sS'is,co-administered,particularly'
p4316
(F1
F0.00014334862385321102
I1
I0
I1
tp4317
sS'appears,that,may'
p4318
(F1
F0.00014334862385321102
I1
I0
I1
tp4319
sS'bedtime,and,given'
p4320
(F1
F0.00014334862385321102
I0
I1
I-1
tp4321
sS'have,an,effect'
p4322
(F1
F0.00014334862385321102
I0
I1
I-1
tp4323
sS'other,binding,proteins'
p4324
(F1
F0.00028669724770642203
I0
I2
I-2
tp4325
sS'with,orally,administered'
p4326
(F1
F0.00014334862385321102
I1
I0
I1
tp4327
sS'these,peptides,in'
p4328
(F1
F0.00014334862385321102
I0
I1
I-1
tp4329
sS'by,a,cascade'
p4330
(F1
F0.00014334862385321102
I0
I1
I-1
tp4331
sS'and,were,concomitantly'
p4332
(F1
F0.00014334862385321102
I0
I1
I-1
tp4333
sS'of,in,conjunction'
p4334
(F1
F0.00014334862385321102
I0
I1
I-1
tp4335
sS'naflu,and,model'
p4336
(F1
F0.00014334862385321102
I0
I1
I-1
tp4337
sS'effect,of,sular'
p4338
(F1
F0.00014334862385321102
I1
I0
I1
tp4339
sS'bleeding,a,complication'
p4340
(F1
F0.00014334862385321102
I0
I1
I-1
tp4341
sS'dosages,or,concomitantly'
p4342
(F1
F0.00014334862385321102
I1
I0
I1
tp4343
sS'indomethacin,indomethacin,blunts'
p4344
(F1
F0.00014334862385321102
I1
I0
I1
tp4345
sS'label,should,be'
p4346
(F1
F0.00014334862385321102
I1
I0
I1
tp4347
sS'days,showed,a'
p4348
(F1
F0.00014334862385321102
I0
I1
I-1
tp4349
sS'laboratory,test,interaction'
p4350
(F1
F0.00043004587155963305
I0
I3
I-3
tp4351
sS'administered,did,not'
p4352
(F1
F0.00014334862385321102
I0
I1
I-1
tp4353
sS'not,interact,significantly'
p4354
(F1
F0.00014334862385321102
I0
I1
I-1
tp4355
sS'and,possible,pharmacokinetic'
p4356
(F1
F0.00014334862385321102
I1
I0
I1
tp4357
sS'in,reduced,protein'
p4358
(F1
F0.00014334862385321102
I1
I0
I1
tp4359
sS'auc,and,half-life'
p4360
(F1
F0.00014334862385321102
I0
I1
I-1
tp4361
sS'and,lower,auc'
p4362
(F1
F0.00014334862385321102
I0
I1
I-1
tp4363
sS'induces,apoptosis,in'
p4364
(F1
F0.00014334862385321102
I0
I1
I-1
tp4365
sS'of,the,inhibition'
p4366
(F1
F0.00014334862385321102
I1
I0
I1
tp4367
sS'a,maintenance,dose'
p4368
(F1
F0.00014334862385321102
I1
I0
I1
tp4369
sS'treatment,potentiated,the'
p4370
(F1
F0.00014334862385321102
I1
I0
I1
tp4371
sS'colchicine,para-aminosalicylic,acid'
p4372
(F1
F0.00014334862385321102
I1
I0
I1
tp4373
sS'decrease,of,ci'
p4374
(F1
F0.00014334862385321102
I0
I1
I-1
tp4375
sS'subjects,by,approximately'
p4376
(F1
F0.00014334862385321102
I1
I0
I1
tp4377
sS'use,of,preparations'
p4378
(F1
F0.00014334862385321102
I1
I0
I1
tp4379
sS'and,that,the'
p4380
(F1
F0.00014334862385321102
I1
I0
I1
tp4381
sS'patients,with,concentrations'
p4382
(F1
F0.00014334862385321102
I0
I1
I-1
tp4383
sS'and,the,first'
p4384
(F1
F0.00014334862385321102
I0
I1
I-1
tp4385
sS'is,to,decrease'
p4386
(F1
F0.00014334862385321102
I1
I0
I1
tp4387
sS'and,a,penicillin-type'
p4388
(F1
F0.00014334862385321102
I1
I0
I1
tp4389
sS'in,death,have'
p4390
(F1
F0.00014334862385321102
I1
I0
I1
tp4391
sS'nephrotoxic,agents,should'
p4392
(F1
F0.00014334862385321102
I1
I0
I1
tp4393
sS'clinical,trials,flolan'
p4394
(F1
F0.00014334862385321102
I1
I0
I1
tp4395
sS'likelihood,of,substantial'
p4396
(F1
F0.00014334862385321102
I1
I0
I1
tp4397
sS'is,summarized,in'
p4398
(F1
F0.00014334862385321102
I0
I1
I-1
tp4399
sS'studies,hydrochloride,mg'
p4400
(F1
F0.00014334862385321102
I0
I1
I-1
tp4401
sS'of,flolan,in'
p4402
(F1
F0.00014334862385321102
I0
I1
I-1
tp4403
sS'sickness,medications,muscle'
p4404
(F1
F0.00014334862385321102
I0
I1
I-1
tp4405
sS'mechanisms,underlying,the'
p4406
(F1
F0.00014334862385321102
I0
I1
I-1
tp4407
sS'respectively,when,administered'
p4408
(F1
F0.00014334862385321102
I1
I0
I1
tp4409
sS'close,medical,supervision'
p4410
(F1
F0.00014334862385321102
I1
I0
I1
tp4411
sS'doses,is,a'
p4412
(F1
F0.00014334862385321102
I1
I0
I1
tp4413
sS'patient,should,be'
p4414
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp4415
sS'daily,was,similar'
p4416
(F1
F0.00014334862385321102
I0
I1
I-1
tp4417
sS'and,of,ergot-type'
p4418
(F1
F0.00014334862385321102
I0
I1
I-1
tp4419
sS'effects,when,and'
p4420
(F1
F0.00028669724770642203
I2
I0
I2
tp4421
sS'appropriate,laboratory,testing'
p4422
(F1
F0.00014334862385321102
I1
I0
I1
tp4423
sS'a4,and,c9'
p4424
(F1
F0.00014334862385321102
I0
I1
I-1
tp4425
sS'phenytoin,dilantin,use'
p4426
(F1
F0.00014334862385321102
I1
I0
I1
tp4427
sS'when,used,concomitantly'
p4428
(F1
F0.00028669724770642203
I2
I0
I2
tp4429
sS'be,markedly,reduced'
p4430
(F1
F0.00014334862385321102
I1
I0
I1
tp4431
sS'with,reduce,both'
p4432
(F1
F0.00014334862385321102
I1
I0
I1
tp4433
sS'in,men,with'
p4434
(F1
F0.00028669724770642203
I0
I2
I-2
tp4435
sS'methods,toxi-lab,a'
p4436
(F1
F0.00014334862385321102
I0
I1
I-1
tp4437
sS'or,during,the'
p4438
(F0
F0
I1
I1
I0
tp4439
sS'taking,bextra,concomitantly'
p4440
(F1
F0.00014334862385321102
I1
I0
I1
tp4441
sS'when,and,certain'
p4442
(F1
F0.00014334862385321102
I1
I0
I1
tp4443
sS'elimination,the,effect'
p4444
(F1
F0.00014334862385321102
I1
I0
I1
tp4445
sS'nevirapine,may,decrease'
p4446
(F1
F0.00014334862385321102
I1
I0
I1
tp4447
sS'therapy,and,frequently'
p4448
(F1
F0.00014334862385321102
I1
I0
I1
tp4449
sS'indicates,that,a'
p4450
(F1
F0.00014334862385321102
I0
I1
I-1
tp4451
sS'a,physician,or'
p4452
(F1
F0.00014334862385321102
I1
I0
I1
tp4453
sS'has,proven,efficacy'
p4454
(F1
F0.00014334862385321102
I0
I1
I-1
tp4455
sS'these,agents,are'
p4456
(F1
F0.00043004587155963305
I3
I0
I3
tp4457
sS'and,day,of'
p4458
(F1
F0.00014334862385321102
I1
I0
I1
tp4459
sS'is,about,of'
p4460
(F1
F0.00014334862385321102
I0
I1
I-1
tp4461
sS'to,the,added'
p4462
(F1
F0.00014334862385321102
I0
I1
I-1
tp4463
sS'arrhythmias,during,can'
p4464
(F1
F0.00014334862385321102
I1
I0
I1
tp4465
sS'is,recommended,when'
p4466
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp4467
sS'of,per,day'
p4468
(F0
F0
I2
I2
I0
tp4469
sS'or,vitamin,e'
p4470
(F1
F0.00014334862385321102
I1
I0
I1
tp4471
sS'effects,concerning,have'
p4472
(F1
F0.00014334862385321102
I1
I0
I1
tp4473
sS'the,geometric,mean'
p4474
(F0
F0
I1
I1
I0
tp4475
sS'possible,increase,in'
p4476
(F1
F0.00014334862385321102
I1
I0
I1
tp4477
sS'between,argatroban,and'
p4478
(F1
F0.00028669724770642203
I0
I2
I-2
tp4479
sS'by,infusion,in'
p4480
(F1
F0.00014334862385321102
I0
I1
I-1
tp4481
sS'auc,of,less'
p4482
(F1
F0.00014334862385321102
I1
I0
I1
tp4483
sS'enzymes,evaluated,cyp1a2'
p4484
(F1
F0.00014334862385321102
I0
I1
I-1
tp4485
sS'of,and,therapy'
p4486
(F1
F0.00014334862385321102
I0
I1
I-1
tp4487
sS'trileptal,topamax,felbatol'
p4488
(F1
F0.00014334862385321102
I1
I0
I1
tp4489
sS'corticosteroids,a,relationship'
p4490
(F1
F0.00043004587155963305
I3
I0
I3
tp4491
sS'warfarin,concomitant,administration'
p4492
(F1
F0.00014334862385321102
I0
I1
I-1
tp4493
sS'inhibitors,ssris,have'
p4494
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4495
sS'other,especially,or'
p4496
(F1
F0.00014334862385321102
I0
I1
I-1
tp4497
sS'antagonize,the,effects'
p4498
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4499
sS'the,body,it'
p4500
(F1
F0.00014334862385321102
I0
I1
I-1
tp4501
sS'which,have,a'
p4502
(F1
F0.00028669724770642203
I2
I0
I2
tp4503
sS'indicate,that,an'
p4504
(F1
F0.00014334862385321102
I0
I1
I-1
tp4505
sS'v,cmc-cys7,a'
p4506
(F1
F0.00014334862385321102
I0
I1
I-1
tp4507
sS'hours,after,and'
p4508
(F1
F0.00014334862385321102
I1
I0
I1
tp4509
sS'the,same,enzyme'
p4510
(F1
F0.00014334862385321102
I0
I1
I-1
tp4511
sS'alcohol,there,was'
p4512
(F1
F0.00014334862385321102
I0
I1
I-1
tp4513
sS'regimens,containing,sequential'
p4514
(F1
F0.00014334862385321102
I1
I0
I1
tp4515
sS'to,have,neuromuscular'
p4516
(F1
F0.00028669724770642203
I2
I0
I2
tp4517
sS'endogenous,marker,of'
p4518
(F1
F0.00014334862385321102
I1
I0
I1
tp4519
sS'is,desirable,to'
p4520
(F1
F0.00071674311926605509
I0
I5
I-5
tp4521
sS'exposure,to,mac'
p4522
(F1
F0.00014334862385321102
I0
I1
I-1
tp4523
sS'sodium,plasma,concentrations'
p4524
(F1
F0.00014334862385321102
I1
I0
I1
tp4525
sS'phenyltheophylline,and,cyclopentyl-1'
p4526
(F1
F0.00014334862385321102
I0
I1
I-1
tp4527
sS'between,novoseven,and'
p4528
(F1
F0.00014334862385321102
I0
I1
I-1
tp4529
sS'will,increase,plasmaconcentration'
p4530
(F1
F0.00014334862385321102
I1
I0
I1
tp4531
sS'nonetheless,the,range'
p4532
(F1
F0.00014334862385321102
I0
I1
I-1
tp4533
sS'muscle,relaxant,antagonists'
p4534
(F1
F0.00014334862385321102
I0
I1
I-1
tp4535
sS'with,kineret,and'
p4536
(F1
F0.00014334862385321102
I1
I0
I1
tp4537
sS'known,enzyme,induction'
p4538
(F1
F0.00014334862385321102
I1
I0
I1
tp4539
sS'investigate,the,possibility'
p4540
(F1
F0.00014334862385321102
I0
I1
I-1
tp4541
sS'days,while,plasma'
p4542
(F1
F0.00014334862385321102
I1
I0
I1
tp4543
sS'trial,showed,comparable'
p4544
(F1
F0.00014334862385321102
I0
I1
I-1
tp4545
sS'metabolized,by,cyp3a4'
p4546
(F0
F0
I2
I2
I0
tp4547
sS'of,and,increases'
p4548
(F1
F0.00028669724770642203
I2
I0
I2
tp4549
sS'intravenously,over,three'
p4550
(F1
F0.00014334862385321102
I0
I1
I-1
tp4551
sS'with,hormonal,and'
p4552
(F1
F0.00014334862385321102
I0
I1
I-1
tp4553
sS'on,other,drugs'
p4554
(F1
F0.00028669724770642203
I0
I2
I-2
tp4555
sS'and,were,each'
p4556
(F1
F0.00014334862385321102
I0
I1
I-1
tp4557
sS'approximately,in,the'
p4558
(F0
F0
I1
I1
I0
tp4559
sS'and,the,mean'
p4560
(F1
F0.00028669724770642203
I2
I0
I2
tp4561
sS'pulmozyme,can,be'
p4562
(F1
F0.00014334862385321102
I0
I1
I-1
tp4563
sS'the,fed,state'
p4564
(F1
F0.00014334862385321102
I1
I0
I1
tp4565
sS'toxicity,was,usually'
p4566
(F1
F0.00014334862385321102
I1
I0
I1
tp4567
sS'chylomicron,metabolism,was'
p4568
(F1
F0.00014334862385321102
I0
I1
I-1
tp4569
sS'daypro,and,anaprox'
p4570
(F1
F0.00014334862385321102
I0
I1
I-1
tp4571
sS'regimen,includes,both'
p4572
(F1
F0.00014334862385321102
I1
I0
I1
tp4573
sS'of,significantly,decreased'
p4574
(F1
F0.00014334862385321102
I1
I0
I1
tp4575
sS'together,during,the'
p4576
(F1
F0.00014334862385321102
I1
I0
I1
tp4577
sS'monitored,carefully,if'
p4578
(F1
F0.00014334862385321102
I1
I0
I1
tp4579
sS'by,the,nonlinear'
p4580
(F1
F0.00014334862385321102
I0
I1
I-1
tp4581
sS'pcp,or,either'
p4582
(F1
F0.00014334862385321102
I1
I0
I1
tp4583
sS'warfarin,anticoagulant,activity'
p4584
(F1
F0.00014334862385321102
I1
I0
I1
tp4585
sS'adverse,effects,resulting'
p4586
(F1
F0.00014334862385321102
I1
I0
I1
tp4587
sS'certain,compounds,such'
p4588
(F1
F0.00014334862385321102
I1
I0
I1
tp4589
sS'in,human,plasma'
p4590
(F1
F0.00028669724770642203
I0
I2
I-2
tp4591
sS'cortex,and,subcortical'
p4592
(F1
F0.00014334862385321102
I0
I1
I-1
tp4593
sS'indicating,that,several'
p4594
(F1
F0.00014334862385321102
I0
I1
I-1
tp4595
sS'to,an,increase'
p4596
(F0
F0
I2
I2
I0
tp4597
sS'vitamin,d,but'
p4598
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4599
sS'medicinal,products,with'
p4600
(F1
F0.00014334862385321102
I1
I0
I1
tp4601
sS'was,determined,after'
p4602
(F1
F0.00014334862385321102
I0
I1
I-1
tp4603
sS'or,ibuprofen,and'
p4604
(F1
F0.00014334862385321102
I1
I0
I1
tp4605
sS'significantly,alter,the'
p4606
(F1
F0.00014334862385321102
I1
I0
I1
tp4607
sS'the,during,and'
p4608
(F1
F0.00014334862385321102
I1
I0
I1
tp4609
sS'results,with,wshow'
p4610
(F1
F0.00014334862385321102
I0
I1
I-1
tp4611
sS'shown,to,double'
p4612
(F1
F0.00014334862385321102
I1
I0
I1
tp4613
sS'competitive,suppression,of'
p4614
(F1
F0.00014334862385321102
I0
I1
I-1
tp4615
sS'have,been,rare'
p4616
(F1
F0.00071674311926605509
I5
I0
I5
tp4617
sS'may,potentiate,the'
p4618
(F0.82608695652173914
F0.0027236238532110093
I21
I2
I19
tp4619
sS'pharmacokinetics,produced,by'
p4620
(F1
F0.00014334862385321102
I1
I0
I1
tp4621
sS'pt,and,inr'
p4622
(F1
F0.00014334862385321102
I0
I1
I-1
tp4623
sS'during,administration,of'
p4624
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4625
sS'use,of,nalfon'
p4626
(F1
F0.00014334862385321102
I1
I0
I1
tp4627
sS'pointes,have,occurred'
p4628
(F1
F0.00014334862385321102
I0
I1
I-1
tp4629
sS'though,less,marked'
p4630
(F1
F0.00028669724770642203
I0
I2
I-2
tp4631
sS'x,m,inhibits'
p4632
(F1
F0.00014334862385321102
I1
I0
I1
tp4633
sS'side,effect,of'
p4634
(F1
F0.00014334862385321102
I0
I1
I-1
tp4635
sS'prolong,the,one-stage'
p4636
(F1
F0.00014334862385321102
I0
I1
I-1
tp4637
sS'is,adjusted,upward'
p4638
(F1
F0.00014334862385321102
I1
I0
I1
tp4639
sS'effect,when,used'
p4640
(F1
F0.00014334862385321102
I0
I1
I-1
tp4641
sS'edemas,that,mg'
p4642
(F1
F0.00014334862385321102
I1
I0
I1
tp4643
sS'sleep,drowsiness-causing,any'
p4644
(F1
F0.00014334862385321102
I0
I1
I-1
tp4645
sS'be,expected,to'
p4646
(F0.23076923076923078
F0.00043004587155963305
I8
I5
I3
tp4647
sS'and,carbonate,or'
p4648
(F1
F0.00014334862385321102
I1
I0
I1
tp4649
sS'clinically,or,statistically'
p4650
(F1
F0.00014334862385321102
I0
I1
I-1
tp4651
sS'with,standard,cystic'
p4652
(F1
F0.00014334862385321102
I0
I1
I-1
tp4653
sS'year,monthly,comparison'
p4654
(F1
F0.00014334862385321102
I0
I1
I-1
tp4655
sS'viracept,with,ovcon-35'
p4656
(F1
F0.00014334862385321102
I1
I0
I1
tp4657
sS'fluothane,augments,the'
p4658
(F1
F0.00014334862385321102
I1
I0
I1
tp4659
sS'evaluated,in,combination'
p4660
(F1
F0.00014334862385321102
I0
I1
I-1
tp4661
sS'mg,in,a'
p4662
(F1
F0.00043004587155963305
I3
I0
I3
tp4663
sS'with,serotonin,reuptake'
p4664
(F1
F0.00014334862385321102
I1
I0
I1
tp4665
sS'of,dcg-iv,were'
p4666
(F1
F0.00014334862385321102
I1
I0
I1
tp4667
sS'monitored,closely,when'
p4668
(F1
F0.00028669724770642203
I2
I0
I2
tp4669
sS'addition,to,the'
p4670
(F1
F0.00014334862385321102
I0
I1
I-1
tp4671
sS'sodium,sulfate,prednisolone'
p4672
(F1
F0.00014334862385321102
I0
I1
I-1
tp4673
sS'an,enhancement,effect'
p4674
(F1
F0.00014334862385321102
I1
I0
I1
tp4675
sS'in,ethinyl,estradiol'
p4676
(F1
F0.00014334862385321102
I1
I0
I1
tp4677
sS'because,higher,doses'
p4678
(F1
F0.00014334862385321102
I0
I1
I-1
tp4679
sS'oral,form,a'
p4680
(F1
F0.00014334862385321102
I1
I0
I1
tp4681
sS'in,the,post-marketing'
p4682
(F1
F0.00014334862385321102
I1
I0
I1
tp4683
sS'pill,such,as'
p4684
(F1
F0.00014334862385321102
I0
I1
I-1
tp4685
sS'substrates,that,have'
p4686
(F1
F0.00014334862385321102
I1
I0
I1
tp4687
sS'in,prothrombin,time'
p4688
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp4689
sS'interaction,between,both'
p4690
(F1
F0.00014334862385321102
I0
I1
I-1
tp4691
sS'by,using,four'
p4692
(F1
F0.00014334862385321102
I0
I1
I-1
tp4693
sS'of,the,antihypertensive'
p4694
(F1
F0.00014334862385321102
I1
I0
I1
tp4695
sS'using,the,commercially'
p4696
(F1
F0.00014334862385321102
I0
I1
I-1
tp4697
sS'of,vardenafil,and'
p4698
(F1
F0.00014334862385321102
I1
I0
I1
tp4699
sS'both,the,toxicity'
p4700
(F1
F0.00014334862385321102
I0
I1
I-1
tp4701
sS'antithrombin,iii,human'
p4702
(F1
F0.00014334862385321102
I1
I0
I1
tp4703
sS'with,or,within'
p4704
(F1
F0.00028669724770642203
I2
I0
I2
tp4705
sS'in,a,linear'
p4706
(F1
F0.00014334862385321102
I0
I1
I-1
tp4707
sS'inhibitors,that,have'
p4708
(F1
F0.00014334862385321102
I1
I0
I1
tp4709
sS'be,decreased,increased'
p4710
(F1
F0.00014334862385321102
I1
I0
I1
tp4711
sS'perhexiline,hydrogen,maleate'
p4712
(F1
F0.00014334862385321102
I1
I0
I1
tp4713
sS'alterations,in,pharmacokinetics'
p4714
(F1
F0.00014334862385321102
I1
I0
I1
tp4715
sS'these,alterations,in'
p4716
(F1
F0.00014334862385321102
I1
I0
I1
tp4717
sS'at,higher,than'
p4718
(F1
F0.00014334862385321102
I1
I0
I1
tp4719
sS'require,close,monitoring'
p4720
(F1
F0.00014334862385321102
I1
I0
I1
tp4721
sS'the,dose,may'
p4722
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp4723
sS'interactions,between,revia'
p4724
(F1
F0.00014334862385321102
I0
I1
I-1
tp4725
sS'p,this,was'
p4726
(F1
F0.00014334862385321102
I1
I0
I1
tp4727
sS'nsaids,suggests,the'
p4728
(F1
F0.00014334862385321102
I1
I0
I1
tp4729
sS'of,endoscopic,gastroduodenal'
p4730
(F1
F0.00014334862385321102
I0
I1
I-1
tp4731
sS'of,a,role'
p4732
(F1
F0.00014334862385321102
I0
I1
I-1
tp4733
sS'patients,with,hiv-nhl'
p4734
(F1
F0.00014334862385321102
I0
I1
I-1
tp4735
sS'decreased,from,ng'
p4736
(F1
F0.00014334862385321102
I0
I1
I-1
tp4737
sS'given,in,conjunction'
p4738
(F1
F0.00028669724770642203
I2
I0
I2
tp4739
sS'cancers,it,significantly'
p4740
(F1
F0.00014334862385321102
I0
I1
I-1
tp4741
sS'colchicine,may,increase'
p4742
(F1
F0.00014334862385321102
I1
I0
I1
tp4743
sS'is,to,be'
p4744
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp4745
sS'time,for,recovery'
p4746
(F1
F0.00014334862385321102
I0
I1
I-1
tp4747
sS'or,surgery,because'
p4748
(F1
F0.00014334862385321102
I0
I1
I-1
tp4749
sS'given,once,daily'
p4750
(F1
F0.00028669724770642203
I2
I0
I2
tp4751
sS'hot,weather,prolonged'
p4752
(F1
F0.00014334862385321102
I1
I0
I1
tp4753
sS'adjusted,in,those'
p4754
(F1
F0.00014334862385321102
I1
I0
I1
tp4755
sS'between,intravenous,and'
p4756
(F1
F0.00014334862385321102
I0
I1
I-1
tp4757
sS'the,case-control,and'
p4758
(F1
F0.00014334862385321102
I1
I0
I1
tp4759
sS'are,to,be'
p4760
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp4761
sS'due,to,high'
p4762
(F1
F0.00014334862385321102
I0
I1
I-1
tp4763
sS'are,adequate,methods'
p4764
(F1
F0.00014334862385321102
I0
I1
I-1
tp4765
sS'by,elevated,cerebral'
p4766
(F1
F0.00014334862385321102
I1
I0
I1
tp4767
sS'coagulation,parameters,and'
p4768
(F1
F0.00014334862385321102
I1
I0
I1
tp4769
sS'with,see,clinical'
p4770
(F1
F0.00014334862385321102
I1
I0
I1
tp4771
sS'cytochrome,p-450,for'
p4772
(F1
F0.00014334862385321102
I1
I0
I1
tp4773
sS'absorption,of,various'
p4774
(F1
F0.00014334862385321102
I1
I0
I1
tp4775
sS'cyp450,isoenzymes,cyp1a2'
p4776
(F1
F0.00014334862385321102
I0
I1
I-1
tp4777
sS'of,previously,administered'
p4778
(F1
F0.00014334862385321102
I0
I1
I-1
tp4779
sS'a,is,added'
p4780
(F1
F0.00014334862385321102
I1
I0
I1
tp4781
sS'tikosyn,had,a'
p4782
(F1
F0.00014334862385321102
I0
I1
I-1
tp4783
sS'its,synthetic,analogue'
p4784
(F1
F0.00014334862385321102
I0
I1
I-1
tp4785
sS'hmg-coa,reductase,inhibitors'
p4786
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp4787
sS'human,red,blood'
p4788
(F1
F0.00014334862385321102
I0
I1
I-1
tp4789
sS'a,parallel,group'
p4790
(F1
F0.00014334862385321102
I0
I1
I-1
tp4791
sS'indinavir,mg,t'
p4792
(F1
F0.00014334862385321102
I1
I0
I1
tp4793
sS'both,agents,zyvox'
p4794
(F1
F0.00014334862385321102
I1
I0
I1
tp4795
sS'be,explained,by'
p4796
(F1
F0.00014334862385321102
I1
I0
I1
tp4797
sS'that,affect,platelet'
p4798
(F1
F0.00014334862385321102
I0
I1
I-1
tp4799
sS'decrease,in,plasma'
p4800
(F1
F0.00043004587155963305
I3
I0
I3
tp4801
sS'in,significant,reductions'
p4802
(F1
F0.00014334862385321102
I1
I0
I1
tp4803
sS'compared,to,patients'
p4804
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp4805
sS'slow,the,metabolism'
p4806
(F1
F0.00014334862385321102
I1
I0
I1
tp4807
sS'metabolized,mainly,via'
p4808
(F1
F0.00014334862385321102
I0
I1
I-1
tp4809
sS'mg,bid,a'
p4810
(F1
F0.00028669724770642203
I2
I0
I2
tp4811
sS'acute,symptoms,should'
p4812
(F1
F0.00014334862385321102
I0
I1
I-1
tp4813
sS'in,two,multiple-dose'
p4814
(F1
F0.00014334862385321102
I0
I1
I-1
tp4815
sS'corticosteroids,acth,intensified'
p4816
(F1
F0.00028669724770642203
I0
I2
I-2
tp4817
sS'mg,bid,n'
p4818
(F1
F0.00014334862385321102
I0
I1
I-1
tp4819
sS'necessary,to,be'
p4820
(F1
F0.00014334862385321102
I0
I1
I-1
tp4821
sS'demonstrated,a,significant'
p4822
(F1
F0.00014334862385321102
I1
I0
I1
tp4823
sS'a,tca,is'
p4824
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp4825
sS'in,the,rate'
p4826
(F1
F0.00014334862385321102
I1
I0
I1
tp4827
sS'on,the,palytoxin-induced'
p4828
(F1
F0.00014334862385321102
I0
I1
I-1
tp4829
sS'crixivan,to,mg'
p4830
(F1
F0.00043004587155963305
I3
I0
I3
tp4831
sS'or,had,a'
p4832
(F1
F0.00014334862385321102
I1
I0
I1
tp4833
sS'precede,dosing,by'
p4834
(F1
F0.00014334862385321102
I0
I1
I-1
tp4835
sS'tam,enhances,the'
p4836
(F1
F0.00014334862385321102
I1
I0
I1
tp4837
sS'studies,in,rats'
p4838
(F0
F0
I1
I1
I0
tp4839
sS'av,block,caution'
p4840
(F1
F0.00014334862385321102
I1
I0
I1
tp4841
sS'problems,will,depend'
p4842
(F1
F0.00071674311926605509
I5
I0
I5
tp4843
sS'for,one,day'
p4844
(F1
F0.00014334862385321102
I0
I1
I-1
tp4845
sS'interactions,associated,with'
p4846
(F1
F0.00014334862385321102
I0
I1
I-1
tp4847
sS'alterations,of,status'
p4848
(F1
F0.00014334862385321102
I0
I1
I-1
tp4849
sS'during,controlled,hypotensive'
p4850
(F1
F0.00014334862385321102
I1
I0
I1
tp4851
sS'been,investigated,in'
p4852
(F1
F0.00014334862385321102
I0
I1
I-1
tp4853
sS'm,inhibits,proliferation'
p4854
(F1
F0.00014334862385321102
I1
I0
I1
tp4855
sS'diphenhydramine,diphenhydramine,is'
p4856
(F1
F0.00014334862385321102
I0
I1
I-1
tp4857
sS'a,stimulating,effect'
p4858
(F1
F0.00014334862385321102
I1
I0
I1
tp4859
sS'hydrochloride,has,additive'
p4860
(F1
F0.00014334862385321102
I1
I0
I1
tp4861
sS'of,apoptosis,in'
p4862
(F1
F0.00014334862385321102
I0
I1
I-1
tp4863
sS'kaolin-pectin,certain,anticancer'
p4864
(F1
F0.00014334862385321102
I1
I0
I1
tp4865
sS'in,a,pharmacokinetic'
p4866
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp4867
sS'initiating,extraneal,in'
p4868
(F1
F0.00014334862385321102
I1
I0
I1
tp4869
sS'agents,and,dosage'
p4870
(F1
F0.00028669724770642203
I0
I2
I-2
tp4871
sS'contraction,and,release'
p4872
(F1
F0.00014334862385321102
I0
I1
I-1
tp4873
sS'but,had,a'
p4874
(F1
F0.00014334862385321102
I0
I1
I-1
tp4875
sS'adverse,effects,and'
p4876
(F0
F0
I1
I1
I0
tp4877
sS'alert,for,possible'
p4878
(F1
F0.00028669724770642203
I0
I2
I-2
tp4879
sS'in,em,individuals'
p4880
(F1
F0.00014334862385321102
I1
I0
I1
tp4881
sS'with,cyp1a2,cyp3a'
p4882
(F1
F0.00014334862385321102
I1
I0
I1
tp4883
sS'and,squirrel,monkeys'
p4884
(F1
F0.00014334862385321102
I0
I1
I-1
tp4885
sS'may,increase,or'
p4886
(F1
F0.00014334862385321102
I1
I0
I1
tp4887
sS'and,is,not'
p4888
(F1
F0.0011467889908256881
I8
I0
I8
tp4889
sS'the,aptt,assay'
p4890
(F1
F0.00014334862385321102
I0
I1
I-1
tp4891
sS'vivo,as,indicated'
p4892
(F1
F0.00014334862385321102
I1
I0
I1
tp4893
sS'fluvoxamine,has,also'
p4894
(F1
F0.00014334862385321102
I1
I0
I1
tp4895
sS'were,recorded,at'
p4896
(F1
F0.00014334862385321102
I0
I1
I-1
tp4897
sS'induce,inhibit,or'
p4898
(F1
F0.00014334862385321102
I1
I0
I1
tp4899
sS'of,indocin,with'
p4900
(F1
F0.00014334862385321102
I1
I0
I1
tp4901
sS'administration,of,repeat'
p4902
(F1
F0.00014334862385321102
I0
I1
I-1
tp4903
sS'those,patients,with'
p4904
(F1
F0.00014334862385321102
I0
I1
I-1
tp4905
sS'acid,increased,the'
p4906
(F1
F0.00014334862385321102
I1
I0
I1
tp4907
sS'n-demethylated,metabolite,metabolite'
p4908
(F1
F0.00014334862385321102
I0
I1
I-1
tp4909
sS'study,a,single'
p4910
(F1
F0.00014334862385321102
I1
I0
I1
tp4911
sS'mixed--pharmacological,and,aetiopathogenic--'
p4912
(F1
F0.00014334862385321102
I0
I1
I-1
tp4913
sS'hypertension,some,of'
p4914
(F1
F0.00014334862385321102
I1
I0
I1
tp4915
sS'i,these,polyene'
p4916
(F1
F0.00014334862385321102
I0
I1
I-1
tp4917
sS'of,their,blood'
p4918
(F1
F0.00014334862385321102
I1
I0
I1
tp4919
sS'administered,to,patients'
p4920
(F0
F0
I4
I4
I0
tp4921
sS'primarily,eliminated,by'
p4922
(F1
F0.00014334862385321102
I0
I1
I-1
tp4923
sS'be,titrated,with'
p4924
(F1
F0.00014334862385321102
I1
I0
I1
tp4925
sS'serotonergic,agents,was'
p4926
(F1
F0.00014334862385321102
I0
I1
I-1
tp4927
sS'depressants,including,and'
p4928
(F1
F0.00014334862385321102
I1
I0
I1
tp4929
sS'may,need,to'
p4930
(F0.75
F0.0008600917431192661
I7
I1
I6
tp4931
sS'blocking,add,some'
p4932
(F1
F0.00014334862385321102
I1
I0
I1
tp4933
sS'effects,of,loop'
p4934
(F1
F0.0008600917431192661
I6
I0
I6
tp4935
sS'increased,prothrombin,response'
p4936
(F1
F0.00043004587155963305
I3
I0
I3
tp4937
sS'with,intestinal,absorption'
p4938
(F1
F0.00014334862385321102
I1
I0
I1
tp4939
sS'in,the,nonfailing'
p4940
(F1
F0.00014334862385321102
I0
I1
I-1
tp4941
sS'or,near,mg'
p4942
(F1
F0.00014334862385321102
I1
I0
I1
tp4943
sS'after,stopping,an'
p4944
(F1
F0.00014334862385321102
I1
I0
I1
tp4945
sS'out,studies,in'
p4946
(F1
F0.00014334862385321102
I0
I1
I-1
tp4947
sS'may,affect,patient'
p4948
(F1
F0.00014334862385321102
I0
I1
I-1
tp4949
sS'should,be,avoided'
p4950
(F0.5
F0.0011467889908256881
I12
I4
I8
tp4951
sS'well,as,decreasing'
p4952
(F1
F0.00014334862385321102
I1
I0
I1
tp4953
sS'co-administered,with,natrecor'
p4954
(F1
F0.00014334862385321102
I0
I1
I-1
tp4955
sS'not,recommended,that'
p4956
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp4957
sS'in,an,adequate'
p4958
(F1
F0.00014334862385321102
I0
I1
I-1
tp4959
sS'days,did,not'
p4960
(F1
F0.0010034403669724771
I0
I7
I-7
tp4961
sS'pharmacologically,active,monohydroxy'
p4962
(F1
F0.00014334862385321102
I0
I1
I-1
tp4963
sS'inhibiting,cryptosporidium,parvum'
p4964
(F1
F0.00014334862385321102
I1
I0
I1
tp4965
sS'could,lessen,its'
p4966
(F1
F0.00014334862385321102
I0
I1
I-1
tp4967
sS'some,has,been'
p4968
(F1
F0.00014334862385321102
I1
I0
I1
tp4969
sS'and,concentration,were'
p4970
(F1
F0.00014334862385321102
I0
I1
I-1
tp4971
sS'from,week,intraperitoneal'
p4972
(F1
F0.00014334862385321102
I0
I1
I-1
tp4973
sS'and,maalox,tc'
p4974
(F1
F0.00014334862385321102
I1
I0
I1
tp4975
sS'single,oral,mg'
p4976
(F1
F0.00014334862385321102
I0
I1
I-1
tp4977
sS'activity,the,sympathetic'
p4978
(F1
F0.00014334862385321102
I0
I1
I-1
tp4979
sS'prudent,medical,practice'
p4980
(F1
F0.00014334862385321102
I1
I0
I1
tp4981
sS'reduced,by,tromethamine'
p4982
(F1
F0.00014334862385321102
I1
I0
I1
tp4983
sS'compounds,in,these'
p4984
(F1
F0.00014334862385321102
I1
I0
I1
tp4985
sS'minutes,of,an'
p4986
(F1
F0.00014334862385321102
I1
I0
I1
tp4987
sS'or,no,effect'
p4988
(F0
F0
I1
I1
I0
tp4989
sS'both,at,the'
p4990
(F1
F0.00014334862385321102
I0
I1
I-1
tp4991
sS'drug-induced,renal,toxicity'
p4992
(F1
F0.00014334862385321102
I0
I1
I-1
tp4993
sS'digestive,enzyme,preparations'
p4994
(F1
F0.00014334862385321102
I1
I0
I1
tp4995
sS'on,that,are'
p4996
(F1
F0.00014334862385321102
I0
I1
I-1
tp4997
sS'therapeutic,monitoring,tdm'
p4998
(F1
F0.00014334862385321102
I0
I1
I-1
tp4999
sS'total,daily,dose'
p5000
(F1
F0.00014334862385321102
I0
I1
I-1
tp5001
sS'study,of,eleven'
p5002
(F1
F0.00014334862385321102
I1
I0
I1
tp5003
sS'secretion,of,certain'
p5004
(F1
F0.00014334862385321102
I1
I0
I1
tp5005
sS'be,additive,coadministration'
p5006
(F1
F0.00014334862385321102
I1
I0
I1
tp5007
sS'possible,index,of'
p5008
(F1
F0.00014334862385321102
I0
I1
I-1
tp5009
sS'unpredictable,potentiation,by'
p5010
(F1
F0.00014334862385321102
I1
I0
I1
tp5011
sS'randomized,crossover,double-blind'
p5012
(F1
F0.00014334862385321102
I0
I1
I-1
tp5013
sS'receiving,other,local'
p5014
(F1
F0.00014334862385321102
I1
I0
I1
tp5015
sS'potential,to,decrease'
p5016
(F1
F0.00014334862385321102
I1
I0
I1
tp5017
sS'or,h2antagonists,reduced'
p5018
(F1
F0.00014334862385321102
I1
I0
I1
tp5019
sS'agent,or,the'
p5020
(F1
F0.00014334862385321102
I0
I1
I-1
tp5021
sS'elevated,liver,function'
p5022
(F1
F0.00014334862385321102
I1
I0
I1
tp5023
sS'or,s,determined'
p5024
(F1
F0.00014334862385321102
I1
I0
I1
tp5025
sS'the,time,spent'
p5026
(F1
F0.00014334862385321102
I1
I0
I1
tp5027
sS'decrease,the,hemodynamic'
p5028
(F1
F0.00014334862385321102
I1
I0
I1
tp5029
sS'occur,when,infection'
p5030
(F1
F0.00014334862385321102
I1
I0
I1
tp5031
sS'antiemetic,prophylaxis,may'
p5032
(F1
F0.00014334862385321102
I1
I0
I1
tp5033
sS'the,stomach,of'
p5034
(F1
F0.00014334862385321102
I1
I0
I1
tp5035
sS'number,of,deaths'
p5036
(F1
F0.00014334862385321102
I0
I1
I-1
tp5037
sS'prevents,morphine-induced,increases'
p5038
(F1
F0.00014334862385321102
I1
I0
I1
tp5039
sS'concentrations,and,this'
p5040
(F1
F0.00014334862385321102
I1
I0
I1
tp5041
sS'after,concomitant,administration'
p5042
(F1
F0.00014334862385321102
I0
I1
I-1
tp5043
sS'of,the,muscle'
p5044
(F1
F0.00014334862385321102
I1
I0
I1
tp5045
sS'in,the,groups'
p5046
(F0
F0
I1
I1
I0
tp5047
sS'proton,pump,inhibitors'
p5048
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp5049
sS'muscle,cell,and'
p5050
(F1
F0.00014334862385321102
I0
I1
I-1
tp5051
sS'study,in,healthy'
p5052
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp5053
sS'cholestyramine,and,charcoal'
p5054
(F1
F0.00014334862385321102
I1
I0
I1
tp5055
sS'effect,in,some'
p5056
(F1
F0.00028669724770642203
I2
I0
I2
tp5057
sS'potentiate,any,hypokalemic'
p5058
(F1
F0.00014334862385321102
I1
I0
I1
tp5059
sS'receiving,and,or'
p5060
(F1
F0.00014334862385321102
I1
I0
I1
tp5061
sS'did,not,diminish'
p5062
(F1
F0.00014334862385321102
I0
I1
I-1
tp5063
sS'of,agents,of'
p5064
(F1
F0.00014334862385321102
I0
I1
I-1
tp5065
sS'between,the,hydantoin'
p5066
(F1
F0.00014334862385321102
I1
I0
I1
tp5067
sS'may,block,the'
p5068
(F1
F0.00014334862385321102
I1
I0
I1
tp5069
sS'platelet,inhibitors,drugs'
p5070
(F1
F0.00014334862385321102
I1
I0
I1
tp5071
sS'external,subcutaneous,infusion'
p5072
(F1
F0.00014334862385321102
I0
I1
I-1
tp5073
sS'eight-fold,increase,in'
p5074
(F1
F0.00043004587155963305
I3
I0
I3
tp5075
sS'administration,of,vioxx'
p5076
(F1
F0.00014334862385321102
I0
I1
I-1
tp5077
sS'therefore,monitoring,of'
p5078
(F1
F0.00043004587155963305
I0
I3
I-3
tp5079
sS'the,qt,interval'
p5080
(F1
F0.0014334862385321102
I10
I0
I10
tp5081
sS'time,by,means'
p5082
(F1
F0.00014334862385321102
I1
I0
I1
tp5083
sS'and,hour,blood'
p5084
(F1
F0.00014334862385321102
I1
I0
I1
tp5085
sS'auranofin,should,be'
p5086
(F1
F0.00014334862385321102
I1
I0
I1
tp5087
sS'of,intravenous,in'
p5088
(F1
F0.00014334862385321102
I0
I1
I-1
tp5089
sS'chewable,dispersible,buffered'
p5090
(F1
F0.00014334862385321102
I1
I0
I1
tp5091
sS'to,be,seen'
p5092
(F1
F0.00014334862385321102
I1
I0
I1
tp5093
sS'in,blood,pressure'
p5094
(F1
F0.00028669724770642203
I2
I0
I2
tp5095
sS'or,in,vivo'
p5096
(F1
F0.00028669724770642203
I2
I0
I2
tp5097
sS'pulmonary,toxicity,has'
p5098
(F1
F0.00014334862385321102
I1
I0
I1
tp5099
sS'with,or,since'
p5100
(F1
F0.00014334862385321102
I0
I1
I-1
tp5101
sS'interactions,with,oral'
p5102
(F1
F0.00014334862385321102
I0
I1
I-1
tp5103
sS'shown,to,inhibit'
p5104
(F1
F0.00014334862385321102
I1
I0
I1
tp5105
sS'a,solution,was'
p5106
(F1
F0.00014334862385321102
I0
I1
I-1
tp5107
sS'nnrti,based,regimens'
p5108
(F1
F0.00014334862385321102
I0
I1
I-1
tp5109
sS'for,possible,diminished'
p5110
(F1
F0.00014334862385321102
I0
I1
I-1
tp5111
sS'and,non-selective,mao'
p5112
(F1
F0.00028669724770642203
I2
I0
I2
tp5113
sS'serious,or,fatal'
p5114
(F1
F0.00014334862385321102
I0
I1
I-1
tp5115
sS'approximately,and,the'
p5116
(F1
F0.00014334862385321102
I1
I0
I1
tp5117
sS'heparin,sodium,may'
p5118
(F1
F0.00014334862385321102
I0
I1
I-1
tp5119
sS'may,provoke,vasoconstriction'
p5120
(F1
F0.00014334862385321102
I1
I0
I1
tp5121
sS'zalcitabine,also,has'
p5122
(F1
F0.00014334862385321102
I1
I0
I1
tp5123
sS'its,components,are'
p5124
(F1
F0.00014334862385321102
I0
I1
I-1
tp5125
sS'and,acetylsalicylic,acid'
p5126
(F0
F0
I1
I1
I0
tp5127
sS'persons,taking,most'
p5128
(F1
F0.00014334862385321102
I0
I1
I-1
tp5129
sS'agents,may,become'
p5130
(F1
F0.00014334862385321102
I1
I0
I1
tp5131
sS'agents,when,heart'
p5132
(F1
F0.00014334862385321102
I1
I0
I1
tp5133
sS'with,the,exception'
p5134
(F1
F0.00028669724770642203
I0
I2
I-2
tp5135
sS'and,might,also'
p5136
(F1
F0.00014334862385321102
I1
I0
I1
tp5137
sS'conduction,through,the'
p5138
(F1
F0.00014334862385321102
I1
I0
I1
tp5139
sS'maintenance,dose,of'
p5140
(F1
F0.00028669724770642203
I2
I0
I2
tp5141
sS'produces,a,reduction'
p5142
(F1
F0.00014334862385321102
I1
I0
I1
tp5143
sS'however,in,patients'
p5144
(F1
F0.00014334862385321102
I1
I0
I1
tp5145
sS'or,its,breakdown'
p5146
(F1
F0.00014334862385321102
I1
I0
I1
tp5147
sS'reduced,approximately,when'
p5148
(F0
F0
I1
I1
I0
tp5149
sS'abnormalities,arrhythmia,bradycardia'
p5150
(F1
F0.00014334862385321102
I1
I0
I1
tp5151
sS'below,the,measurable'
p5152
(F1
F0.00014334862385321102
I1
I0
I1
tp5153
sS'with,cyp3a4,substrate'
p5154
(F1
F0.00014334862385321102
I0
I1
I-1
tp5155
sS'shown,in,vitro'
p5156
(F1
F0.00014334862385321102
I1
I0
I1
tp5157
sS'a,satisfactory,hypotensive'
p5158
(F1
F0.00014334862385321102
I1
I0
I1
tp5159
sS'agents,and,vasoactive'
p5160
(F1
F0.00014334862385321102
I1
I0
I1
tp5161
sS'common,with,other'
p5162
(F1
F0.00014334862385321102
I1
I0
I1
tp5163
sS'with,the,absorption'
p5164
(F0.63636363636363635
F0.0010034403669724771
I9
I2
I7
tp5165
sS'metabolites,may,color'
p5166
(F1
F0.00014334862385321102
I0
I1
I-1
tp5167
sS'acute,renal,failure'
p5168
(F1
F0.00014334862385321102
I1
I0
I1
tp5169
sS'at,least,two'
p5170
(F1
F0.00014334862385321102
I1
I0
I1
tp5171
sS'the,mean,percentage'
p5172
(F1
F0.00014334862385321102
I1
I0
I1
tp5173
sS'long,surgical,procedures'
p5174
(F1
F0.00014334862385321102
I1
I0
I1
tp5175
sS'used,concurrently,increases'
p5176
(F1
F0.00014334862385321102
I1
I0
I1
tp5177
sS'on,warfarin-type,therapy'
p5178
(F1
F0.00014334862385321102
I1
I0
I1
tp5179
sS'mind,in,the'
p5180
(F1
F0.00014334862385321102
I1
I0
I1
tp5181
sS'adverse,reaction,during'
p5182
(F1
F0.00014334862385321102
I0
I1
I-1
tp5183
sS'and,potassium-sparing,diuretics'
p5184
(F1
F0.00028669724770642203
I2
I0
I2
tp5185
sS'hydrate,and,agonists'
p5186
(F1
F0.00014334862385321102
I0
I1
I-1
tp5187
sS'acetaminophen,in,normal'
p5188
(F1
F0.00014334862385321102
I1
I0
I1
tp5189
sS'when,potent,inhalational'
p5190
(F1
F0.00014334862385321102
I1
I0
I1
tp5191
sS'and,their,o-desacetyl'
p5192
(F1
F0.00014334862385321102
I0
I1
I-1
tp5193
sS'observed,between,argatroban'
p5194
(F1
F0.00014334862385321102
I0
I1
I-1
tp5195
sS'considered,to,be'
p5196
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp5197
sS'not,likely,to'
p5198
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp5199
sS'oral,heparin,sodium'
p5200
(F1
F0.00014334862385321102
I0
I1
I-1
tp5201
sS'significance,of,this'
p5202
(F1
F0.00014334862385321102
I1
I0
I1
tp5203
sS'but,can,completely'
p5204
(F1
F0.00014334862385321102
I1
I0
I1
tp5205
sS'antiepileptic,aeds,affects'
p5206
(F1
F0.00014334862385321102
I1
I0
I1
tp5207
sS'at,therapeutic,levels'
p5208
(F1
F0.00014334862385321102
I0
I1
I-1
tp5209
sS'levels,of,tricyclic'
p5210
(F1
F0.00014334862385321102
I1
I0
I1
tp5211
sS'cimetidine,coadministration,leads'
p5212
(F1
F0.00014334862385321102
I1
I0
I1
tp5213
sS'should,if,possible'
p5214
(F1
F0.00014334862385321102
I1
I0
I1
tp5215
sS'be,rarely,associated'
p5216
(F1
F0.00028669724770642203
I2
I0
I2
tp5217
sS'liver,and,or'
p5218
(F1
F0.00043004587155963305
I3
I0
I3
tp5219
sS'of,although,it'
p5220
(F1
F0.00014334862385321102
I1
I0
I1
tp5221
sS'if,a,valid'
p5222
(F1
F0.00014334862385321102
I1
I0
I1
tp5223
sS'derivatives,nicotinic,acid'
p5224
(F1
F0.00014334862385321102
I0
I1
I-1
tp5225
sS'levosimendan,does,not'
p5226
(F1
F0.00014334862385321102
I0
I1
I-1
tp5227
sS'and,concurrently,plasma'
p5228
(F1
F0.00014334862385321102
I1
I0
I1
tp5229
sS'fentanyl,is,metabolized'
p5230
(F1
F0.00014334862385321102
I0
I1
I-1
tp5231
sS'low,for,commonly'
p5232
(F1
F0.00014334862385321102
I0
I1
I-1
tp5233
sS'and,can,result'
p5234
(F0.5
F0.00028669724770642203
I3
I1
I2
tp5235
sS'differential,regulation,of'
p5236
(F1
F0.00014334862385321102
I0
I1
I-1
tp5237
sS'aminoglutethimide,aminoglutethimide,may'
p5238
(F1
F0.00014334862385321102
I1
I0
I1
tp5239
sS'types,of,therapy'
p5240
(F1
F0.00014334862385321102
I0
I1
I-1
tp5241
sS'possibility,of,increased'
p5242
(F1
F0.00014334862385321102
I0
I1
I-1
tp5243
sS'tysabri,and,concomitant'
p5244
(F1
F0.00014334862385321102
I0
I1
I-1
tp5245
sS'increased,exposures,of'
p5246
(F1
F0.00014334862385321102
I1
I0
I1
tp5247
sS'or,hypotension,which'
p5248
(F1
F0.00014334862385321102
I1
I0
I1
tp5249
sS'potassium-sparing,supplements,or'
p5250
(F1
F0.00014334862385321102
I0
I1
I-1
tp5251
sS'were,given,mg'
p5252
(F1
F0.00014334862385321102
I0
I1
I-1
tp5253
sS'the,tail-flick,and'
p5254
(F1
F0.00014334862385321102
I0
I1
I-1
tp5255
sS'possibility,of,increases'
p5256
(F1
F0.00014334862385321102
I1
I0
I1
tp5257
sS'that,are,substrates'
p5258
(F1
F0.0010034403669724771
I0
I7
I-7
tp5259
sS'interaction,of,this'
p5260
(F1
F0.00014334862385321102
I1
I0
I1
tp5261
sS'and,on,antinociceptive'
p5262
(F1
F0.00014334862385321102
I0
I1
I-1
tp5263
sS'cases,of,low'
p5264
(F1
F0.00014334862385321102
I1
I0
I1
tp5265
sS'with,moderate,to'
p5266
(F1
F0.00014334862385321102
I1
I0
I1
tp5267
sS'moderate,cyp3a4,inhibitors'
p5268
(F1
F0.00014334862385321102
I1
I0
I1
tp5269
sS'interaction,between,toradol'
p5270
(F1
F0.00014334862385321102
I1
I0
I1
tp5271
sS'fashion,as,much'
p5272
(F1
F0.00014334862385321102
I1
I0
I1
tp5273
sS'which,may,prolong'
p5274
(F1
F0.00028669724770642203
I2
I0
I2
tp5275
sS'be,capable,of'
p5276
(F1
F0.00014334862385321102
I1
I0
I1
tp5277
sS'to,hypoglycemia,oral'
p5278
(F1
F0.00028669724770642203
I0
I2
I-2
tp5279
sS'closely,related,member'
p5280
(F1
F0.00014334862385321102
I1
I0
I1
tp5281
sS'products,and,in'
p5282
(F1
F0.00014334862385321102
I1
I0
I1
tp5283
sS'delirium,has,been'
p5284
(F1
F0.00014334862385321102
I1
I0
I1
tp5285
sS'an,oral,increased'
p5286
(F1
F0.00014334862385321102
I1
I0
I1
tp5287
sS'presence,of,exogenously'
p5288
(F1
F0.00014334862385321102
I0
I1
I-1
tp5289
sS'variety,of,other'
p5290
(F1
F0.00014334862385321102
I0
I1
I-1
tp5291
sS'most,cases,of'
p5292
(F1
F0.00014334862385321102
I0
I1
I-1
tp5293
sS'following,treatment,with'
p5294
(F1
F0.00028669724770642203
I0
I2
I-2
tp5295
sS'via,cyp3a4,in'
p5296
(F1
F0.00014334862385321102
I0
I1
I-1
tp5297
sS'age,and,is'
p5298
(F1
F0.00014334862385321102
I0
I1
I-1
tp5299
sS'products,including,and'
p5300
(F1
F0.00014334862385321102
I1
I0
I1
tp5301
sS'reports,in,the'
p5302
(F1
F0.00028669724770642203
I2
I0
I2
tp5303
sS'receiving,tambocor,and'
p5304
(F1
F0.00014334862385321102
I1
I0
I1
tp5305
sS'type,caution,should'
p5306
(F1
F0.00014334862385321102
I1
I0
I1
tp5307
sS'flupenthixol,and,ethanol'
p5308
(F1
F0.00014334862385321102
I1
I0
I1
tp5309
sS'diethyl,pyrocarbonate,could'
p5310
(F1
F0.00014334862385321102
I0
I1
I-1
tp5311
sS'been,identified,involving'
p5312
(F1
F0.00014334862385321102
I1
I0
I1
tp5313
sS'have,been,seen'
p5314
(F1
F0.00028669724770642203
I2
I0
I2
tp5315
sS'were,measured,by'
p5316
(F1
F0.00014334862385321102
I0
I1
I-1
tp5317
sS'of,sonata,mg'
p5318
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp5319
sS'time,when,administered'
p5320
(F1
F0.00014334862385321102
I0
I1
I-1
tp5321
sS'fondaparinux,the,concomitant'
p5322
(F1
F0.00014334862385321102
I0
I1
I-1
tp5323
sS'decreased,the,urinary'
p5324
(F1
F0.00014334862385321102
I1
I0
I1
tp5325
sS'in,fi,responding'
p5326
(F0
F0
I1
I1
I0
tp5327
sS'experiments,on,white'
p5328
(F1
F0.00014334862385321102
I0
I1
I-1
tp5329
sS'needed,the,initial'
p5330
(F1
F0.00014334862385321102
I0
I1
I-1
tp5331
sS'of,x,mg'
p5332
(F1
F0.00014334862385321102
I1
I0
I1
tp5333
sS'concomitant,medications,with'
p5334
(F1
F0.00014334862385321102
I0
I1
I-1
tp5335
sS'duration,of,action'
p5336
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp5337
sS'either,prophylactic,low'
p5338
(F1
F0.00014334862385321102
I0
I1
I-1
tp5339
sS'one,of,the'
p5340
(F0
F0
I1
I1
I0
tp5341
sS'well-controlled,patients,undergoing'
p5342
(F1
F0.00014334862385321102
I1
I0
I1
tp5343
sS'however,beta,blockers'
p5344
(F1
F0.00014334862385321102
I0
I1
I-1
tp5345
sS'infection,and,are'
p5346
(F1
F0.00014334862385321102
I1
I0
I1
tp5347
sS'additive,ocular,and'
p5348
(F1
F0.00014334862385321102
I0
I1
I-1
tp5349
sS'interactions,would,not'
p5350
(F1
F0.00014334862385321102
I0
I1
I-1
tp5351
sS'resulted,in,levels'
p5352
(F1
F0.00014334862385321102
I0
I1
I-1
tp5353
sS'means,of,selective'
p5354
(F1
F0.00014334862385321102
I1
I0
I1
tp5355
sS'with,other,metabolized'
p5356
(F1
F0.0008600917431192661
I0
I6
I-6
tp5357
sS'nerally,classified,as'
p5358
(F1
F0.00014334862385321102
I0
I1
I-1
tp5359
sS'sole,method,of'
p5360
(F1
F0.00014334862385321102
I1
I0
I1
tp5361
sS'may,either,increase'
p5362
(F1
F0.00014334862385321102
I1
I0
I1
tp5363
sS'behavioral,or,subjective'
p5364
(F1
F0.00014334862385321102
I0
I1
I-1
tp5365
sS'factor,concentrates,has'
p5366
(F1
F0.00014334862385321102
I0
I1
I-1
tp5367
sS'systemic,levels,considerably'
p5368
(F1
F0.00014334862385321102
I1
I0
I1
tp5369
sS'vasopressor,for,the'
p5370
(F1
F0.00014334862385321102
I1
I0
I1
tp5371
sS'acth,induced,hypertension'
p5372
(F1
F0.00028669724770642203
I0
I2
I-2
tp5373
sS'the,pharmacokinetic,and'
p5374
(F1
F0.00014334862385321102
I0
I1
I-1
tp5375
sS'serious,reactions,such'
p5376
(F1
F0.00014334862385321102
I0
I1
I-1
tp5377
sS'certain,types,of'
p5378
(F1
F0.00014334862385321102
I1
I0
I1
tp5379
sS'as,mg,on'
p5380
(F0.5
F0.00028669724770642203
I3
I1
I2
tp5381
sS'nsaid,while,taking'
p5382
(F1
F0.00014334862385321102
I1
I0
I1
tp5383
sS'and,the,production'
p5384
(F1
F0.00028669724770642203
I2
I0
I2
tp5385
sS'as,mg,of'
p5386
(F1
F0.00014334862385321102
I0
I1
I-1
tp5387
sS'the,increases,in'
p5388
(F1
F0.00028669724770642203
I2
I0
I2
tp5389
sS'they,may,vary'
p5390
(F1
F0.00071674311926605509
I0
I5
I-5
tp5391
sS'to,wshow,an'
p5392
(F1
F0.00014334862385321102
I0
I1
I-1
tp5393
sS'day,in,order'
p5394
(F1
F0.00014334862385321102
I1
I0
I1
tp5395
sS'index,of,intestinal'
p5396
(F1
F0.00014334862385321102
I0
I1
I-1
tp5397
sS'interactions,have,been'
p5398
(F0.27272727272727271
F0.00043004587155963305
I4
I7
I-3
tp5399
sS'and,cyp3a4,in'
p5400
(F1
F0.00014334862385321102
I1
I0
I1
tp5401
sS'drug,interaction,has'
p5402
(F1
F0.00014334862385321102
I0
I1
I-1
tp5403
sS'patients,with,ischemic'
p5404
(F1
F0.00014334862385321102
I1
I0
I1
tp5405
sS'drugs,on,aliskiren'
p5406
(F1
F0.00014334862385321102
I0
I1
I-1
tp5407
sS'blocking,agents,a'
p5408
(F1
F0.00014334862385321102
I0
I1
I-1
tp5409
sS'increased,with,concurrent'
p5410
(F0
F0
I1
I1
I0
tp5411
sS'lorazepam,coadministration,of'
p5412
(F1
F0.00014334862385321102
I0
I1
I-1
tp5413
sS'use,of,was'
p5414
(F1
F0.00014334862385321102
I0
I1
I-1
tp5415
sS'is,administered,at'
p5416
(F1
F0.00014334862385321102
I1
I0
I1
tp5417
sS'and,iv,attenuate'
p5418
(F1
F0.00014334862385321102
I1
I0
I1
tp5419
sS'use,of,these'
p5420
(F1
F0.00071674311926605509
I5
I0
I5
tp5421
sS'fold,range,of'
p5422
(F1
F0.00014334862385321102
I0
I1
I-1
tp5423
sS'when,administered,to'
p5424
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp5425
sS'a,complex,fashion'
p5426
(F1
F0.00014334862385321102
I0
I1
I-1
tp5427
sS'furosemide,has,a'
p5428
(F1
F0.00014334862385321102
I1
I0
I1
tp5429
sS'than,two-fold,increases'
p5430
(F1
F0.00014334862385321102
I1
I0
I1
tp5431
sS'to,a,stable'
p5432
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp5433
sS'the,plasma,concentration'
p5434
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp5435
sS'vitro,in,peripheral'
p5436
(F1
F0.00014334862385321102
I1
I0
I1
tp5437
sS'with,breast,cancer'
p5438
(F1
F0.00014334862385321102
I1
I0
I1
tp5439
sS'with,a,main'
p5440
(F1
F0.00014334862385321102
I0
I1
I-1
tp5441
sS'creatinine,clearance,ml'
p5442
(F1
F0.00014334862385321102
I0
I1
I-1
tp5443
sS'ulcers,in,patients'
p5444
(F1
F0.00014334862385321102
I0
I1
I-1
tp5445
sS'co-administered,has,been'
p5446
(F1
F0.00014334862385321102
I1
I0
I1
tp5447
sS'for,n,and'
p5448
(F1
F0.00014334862385321102
I1
I0
I1
tp5449
sS'hydrocodone,coadministration,of'
p5450
(F1
F0.00014334862385321102
I0
I1
I-1
tp5451
sS'been,shown,to'
p5452
(F0.58974358974358976
F0.0032970183486238534
I31
I8
I23
tp5453
sS'blunting,of,the'
p5454
(F1
F0.00028669724770642203
I2
I0
I2
tp5455
sS'therefore,if,is'
p5456
(F1
F0.00028669724770642203
I2
I0
I2
tp5457
sS'monohydroxy,metabolite,mhd'
p5458
(F1
F0.00014334862385321102
I0
I1
I-1
tp5459
sS'and,no,evidence'
p5460
(F1
F0.00014334862385321102
I0
I1
I-1
tp5461
sS'in,unconjugated,nacmc'
p5462
(F1
F0.00014334862385321102
I0
I1
I-1
tp5463
sS'reported,in,elderly'
p5464
(F1
F0.00014334862385321102
I1
I0
I1
tp5465
sS'bid,was,increased'
p5466
(F1
F0.00014334862385321102
I1
I0
I1
tp5467
sS'be,used,while'
p5468
(F1
F0.00014334862385321102
I0
I1
I-1
tp5469
sS'endothelium,from,the'
p5470
(F1
F0.00014334862385321102
I1
I0
I1
tp5471
sS'dysregulation,of,the'
p5472
(F1
F0.00014334862385321102
I0
I1
I-1
tp5473
sS'to,patients,anaesthetised'
p5474
(F1
F0.00014334862385321102
I1
I0
I1
tp5475
sS'the,plasma,auc'
p5476
(F1
F0.00014334862385321102
I1
I0
I1
tp5477
sS'may,require,increases'
p5478
(F1
F0.00014334862385321102
I1
I0
I1
tp5479
sS'in,plasma,m1'
p5480
(F1
F0.00014334862385321102
I1
I0
I1
tp5481
sS'a,direct,pharmacokinetic'
p5482
(F1
F0.00014334862385321102
I0
I1
I-1
tp5483
sS'with,the,metabolism'
p5484
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp5485
sS'of,using,the'
p5486
(F0
F0
I1
I1
I0
tp5487
sS'nephrotoxic,agents,concomitant'
p5488
(F1
F0.00014334862385321102
I1
I0
I1
tp5489
sS'others,medrol,others'
p5490
(F1
F0.00014334862385321102
I0
I1
I-1
tp5491
sS'as,determined,by'
p5492
(F1
F0.00014334862385321102
I0
I1
I-1
tp5493
sS'evaluated,these,were'
p5494
(F1
F0.00014334862385321102
I0
I1
I-1
tp5495
sS'buspirone,hcl,with'
p5496
(F1
F0.00014334862385321102
I1
I0
I1
tp5497
sS'unknown,whether,the'
p5498
(F1
F0.00014334862385321102
I0
I1
I-1
tp5499
sS'of,approximately,when'
p5500
(F1
F0.00014334862385321102
I1
I0
I1
tp5501
sS'were,mp,aza'
p5502
(F1
F0.00014334862385321102
I0
I1
I-1
tp5503
sS'expected,to,decrease'
p5504
(F1
F0.00014334862385321102
I1
I0
I1
tp5505
sS'closely,for,development'
p5506
(F1
F0.00014334862385321102
I1
I0
I1
tp5507
sS'by,is,expected'
p5508
(F1
F0.00014334862385321102
I0
I1
I-1
tp5509
sS'treatment,with,pegasys'
p5510
(F1
F0.00014334862385321102
I1
I0
I1
tp5511
sS'receiving,the,dosage'
p5512
(F1
F0.00014334862385321102
I1
I0
I1
tp5513
sS'risk,of,gastrointestinal'
p5514
(F1
F0.00028669724770642203
I2
I0
I2
tp5515
sS'pharmacokinetic,data,indicate'
p5516
(F1
F0.00028669724770642203
I2
I0
I2
tp5517
sS'which,require,a'
p5518
(F1
F0.00014334862385321102
I1
I0
I1
tp5519
sS'the,following,medications'
p5520
(F0
F0
I1
I1
I0
tp5521
sS'produced,by,without'
p5522
(F1
F0.00028669724770642203
I2
I0
I2
tp5523
sS'activity,pra,as'
p5524
(F1
F0.00014334862385321102
I0
I1
I-1
tp5525
sS'therefore,caution,should'
p5526
(F1
F0.00014334862385321102
I1
I0
I1
tp5527
sS'known,inhibition,of'
p5528
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp5529
sS'or,non-opioid,analgesics'
p5530
(F1
F0.00014334862385321102
I0
I1
I-1
tp5531
sS'responding,in,monkeys'
p5532
(F1
F0.00014334862385321102
I0
I1
I-1
tp5533
sS'when,hypothyroid,patients'
p5534
(F1
F0.00014334862385321102
I0
I1
I-1
tp5535
sS'inhibit,sodium,binding'
p5536
(F1
F0.00014334862385321102
I1
I0
I1
tp5537
sS'suggested,that,may'
p5538
(F1
F0.00014334862385321102
I1
I0
I1
tp5539
sS'with,glycosides,heart'
p5540
(F1
F0.00014334862385321102
I1
I0
I1
tp5541
sS'at,recovery,of'
p5542
(F1
F0.00014334862385321102
I1
I0
I1
tp5543
sS'maximally,suppresses,gastric'
p5544
(F1
F0.00014334862385321102
I0
I1
I-1
tp5545
sS'birth,control,pills'
p5546
(F1
F0.00028669724770642203
I0
I2
I-2
tp5547
sS'mixing,novolog,with'
p5548
(F1
F0.00028669724770642203
I0
I2
I-2
tp5549
sS'during,the,administration'
p5550
(F0
F0
I1
I1
I0
tp5551
sS'digitalis,vitamin,d'
p5552
(F1
F0.00043004587155963305
I3
I0
I3
tp5553
sS'action,of,other'
p5554
(F1
F0.00043004587155963305
I3
I0
I3
tp5555
sS'color,alkaline,urine'
p5556
(F1
F0.00014334862385321102
I0
I1
I-1
tp5557
sS'of,newly,diagnosed'
p5558
(F1
F0.00014334862385321102
I0
I1
I-1
tp5559
sS'should,it,be'
p5560
(F1
F0.00014334862385321102
I1
I0
I1
tp5561
sS'and,sulfate,may'
p5562
(F1
F0.00014334862385321102
I1
I0
I1
tp5563
sS'clinical,study,who'
p5564
(F1
F0.00014334862385321102
I1
I0
I1
tp5565
sS'warfarin-type,therapy,may'
p5566
(F1
F0.00014334862385321102
I1
I0
I1
tp5567
sS'when,nimbex,is'
p5568
(F1
F0.00014334862385321102
I0
I1
I-1
tp5569
sS'and,mg,twice'
p5570
(F1
F0.00014334862385321102
I1
I0
I1
tp5571
sS'was,a,multicenter'
p5572
(F1
F0.00014334862385321102
I0
I1
I-1
tp5573
sS'renal,function,or'
p5574
(F1
F0.00014334862385321102
I0
I1
I-1
tp5575
sS'intensified,electrolyte,depletion'
p5576
(F1
F0.00028669724770642203
I0
I2
I-2
tp5577
sS'receiving,comedication,particularly'
p5578
(F1
F0.00014334862385321102
I1
I0
I1
tp5579
sS'oral,regular,monitoring'
p5580
(F1
F0.00014334862385321102
I0
I1
I-1
tp5581
sS'aprepitant,with,that'
p5582
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp5583
sS'mouth,and,associated'
p5584
(F1
F0.00014334862385321102
I1
I0
I1
tp5585
sS'is,suggested,to'
p5586
(F1
F0.00014334862385321102
I1
I0
I1
tp5587
sS'blocking,action,which'
p5588
(F1
F0.00014334862385321102
I0
I1
I-1
tp5589
sS'inhibited,gastric,acid'
p5590
(F1
F0.00014334862385321102
I0
I1
I-1
tp5591
sS'therapy,in,healthy'
p5592
(F1
F0.00014334862385321102
I0
I1
I-1
tp5593
sS'and,result,in'
p5594
(F1
F0.00028669724770642203
I2
I0
I2
tp5595
sS'importance,brevibloc,should'
p5596
(F1
F0.00014334862385321102
I1
I0
I1
tp5597
sS'with,therapeutic,doses'
p5598
(F0
F0
I1
I1
I0
tp5599
sS'cmax,of,both'
p5600
(F1
F0.00014334862385321102
I0
I1
I-1
tp5601
sS'given,after,than'
p5602
(F1
F0.00014334862385321102
I1
I0
I1
tp5603
sS'of,hydrochloride,given'
p5604
(F1
F0.00014334862385321102
I1
I0
I1
tp5605
sS'reach,toxic,levels'
p5606
(F1
F0.00014334862385321102
I0
I1
I-1
tp5607
sS'administered,orally,to'
p5608
(F1
F0.00014334862385321102
I0
I1
I-1
tp5609
sS'pci,co-administration,of'
p5610
(F1
F0.00014334862385321102
I1
I0
I1
tp5611
sS'toxicity,with,little'
p5612
(F1
F0.00028669724770642203
I2
I0
I2
tp5613
sS'with,of,this'
p5614
(F1
F0.00014334862385321102
I0
I1
I-1
tp5615
sS'a,plasma,concentration'
p5616
(F1
F0.00014334862385321102
I0
I1
I-1
tp5617
sS'and,an,increased'
p5618
(F1
F0.00014334862385321102
I0
I1
I-1
tp5619
sS'dehydration,secondary,to'
p5620
(F1
F0.00014334862385321102
I1
I0
I1
tp5621
sS'which,in,turn'
p5622
(F1
F0.00014334862385321102
I1
I0
I1
tp5623
sS'a,mouse,model'
p5624
(F1
F0.00014334862385321102
I0
I1
I-1
tp5625
sS'to,or,potentiate'
p5626
(F1
F0.00028669724770642203
I2
I0
I2
tp5627
sS'rifampin,coadministration,of'
p5628
(F1
F0.00028669724770642203
I2
I0
I2
tp5629
sS'two,of,subjects'
p5630
(F1
F0.00014334862385321102
I1
I0
I1
tp5631
sS'interaction,between,and'
p5632
(F0.090909090909090912
F0.00028669724770642203
I10
I12
I-2
tp5633
sS'and,concomitantly,toxicity'
p5634
(F1
F0.00014334862385321102
I1
I0
I1
tp5635
sS'and,cardiovascular,collapse'
p5636
(F1
F0.00014334862385321102
I0
I1
I-1
tp5637
sS'be,allowed,before'
p5638
(F1
F0.00014334862385321102
I1
I0
I1
tp5639
sS'triiodothyronine,levels,but'
p5640
(F1
F0.00014334862385321102
I0
I1
I-1
tp5641
sS'monitored,when,and'
p5642
(F1
F0.00014334862385321102
I1
I0
I1
tp5643
sS'are,likely,and'
p5644
(F1
F0.00014334862385321102
I0
I1
I-1
tp5645
sS'study,demonstrates,that'
p5646
(F1
F0.00014334862385321102
I1
I0
I1
tp5647
sS'ventricular,arrhythmias,and'
p5648
(F1
F0.00014334862385321102
I1
I0
I1
tp5649
sS'the,renal,elimination'
p5650
(F1
F0.00014334862385321102
I0
I1
I-1
tp5651
sS'beginning,or,stopping'
p5652
(F1
F0.00014334862385321102
I1
I0
I1
tp5653
sS'concluded,that,oral'
p5654
(F1
F0.00014334862385321102
I0
I1
I-1
tp5655
sS'for,evidence,of'
p5656
(F0
F0
I1
I1
I0
tp5657
sS'tambocor,has,been'
p5658
(F1
F0.00028669724770642203
I0
I2
I-2
tp5659
sS'of,on,exjade'
p5660
(F1
F0.00014334862385321102
I0
I1
I-1
tp5661
sS'concomitantly,with,more'
p5662
(F1
F0.00014334862385321102
I1
I0
I1
tp5663
sS'digoxin,did,not'
p5664
(F1
F0.00014334862385321102
I0
I1
I-1
tp5665
sS'ergotamine-containing,when,co-administered'
p5666
(F1
F0.00014334862385321102
I1
I0
I1
tp5667
sS'auc,and,the'
p5668
(F0
F0
I1
I1
I0
tp5669
sS'dosing,caution,should'
p5670
(F1
F0.00014334862385321102
I1
I0
I1
tp5671
sS'activity,against,gram-negative'
p5672
(F1
F0.00014334862385321102
I0
I1
I-1
tp5673
sS'is,either,added'
p5674
(F1
F0.00014334862385321102
I1
I0
I1
tp5675
sS'where,endothelial,function'
p5676
(F1
F0.00014334862385321102
I0
I1
I-1
tp5677
sS'molecular,level,by'
p5678
(F1
F0.00014334862385321102
I0
I1
I-1
tp5679
sS'a,dose-related,increase'
p5680
(F1
F0.00014334862385321102
I1
I0
I1
tp5681
sS'intramuscularly,injected,and'
p5682
(F1
F0.00014334862385321102
I0
I1
I-1
tp5683
sS'of,this,the'
p5684
(F1
F0.00014334862385321102
I0
I1
I-1
tp5685
sS'type,may,be'
p5686
(F1
F0.00014334862385321102
I0
I1
I-1
tp5687
sS'and,tam,enhances'
p5688
(F1
F0.00014334862385321102
I1
I0
I1
tp5689
sS'of,free,is'
p5690
(F1
F0.00014334862385321102
I1
I0
I1
tp5691
sS'resulted,in,interactions'
p5692
(F1
F0.00014334862385321102
I1
I0
I1
tp5693
sS'lead,to,phenytoin'
p5694
(F1
F0.00014334862385321102
I1
I0
I1
tp5695
sS'used,concomitantly,only'
p5696
(F1
F0.00014334862385321102
I0
I1
I-1
tp5697
sS'dose,unfractionated,up'
p5698
(F1
F0.00014334862385321102
I0
I1
I-1
tp5699
sS'lanoxicaps,that,gets'
p5700
(F1
F0.00014334862385321102
I1
I0
I1
tp5701
sS'when,a,potent'
p5702
(F1
F0.00014334862385321102
I0
I1
I-1
tp5703
sS'subjects,receiving,multiple'
p5704
(F1
F0.00014334862385321102
I1
I0
I1
tp5705
sS'to,several-,fold'
p5706
(F1
F0.00014334862385321102
I0
I1
I-1
tp5707
sS'steady-state,trough,cmin'
p5708
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp5709
sS'when,arava,and'
p5710
(F1
F0.00014334862385321102
I1
I0
I1
tp5711
sS'hour,before,idv'
p5712
(F1
F0.00014334862385321102
I0
I1
I-1
tp5713
sS'compared,retrospectively,a'
p5714
(F1
F0.00014334862385321102
I0
I1
I-1
tp5715
sS'as,mg,was'
p5716
(F1
F0.00014334862385321102
I0
I1
I-1
tp5717
sS'based,on,adult'
p5718
(F1
F0.00014334862385321102
I1
I0
I1
tp5719
sS'of,other,than'
p5720
(F1
F0.00028669724770642203
I2
I0
I2
tp5721
sS'orally,for,days'
p5722
(F1
F0.00014334862385321102
I1
I0
I1
tp5723
sS'be,alerted,to'
p5724
(F1
F0.00014334862385321102
I0
I1
I-1
tp5725
sS'implication,that,intoxication'
p5726
(F1
F0.00014334862385321102
I1
I0
I1
tp5727
sS'two,groups,sh'
p5728
(F1
F0.00014334862385321102
I0
I1
I-1
tp5729
sS'hours,after,a'
p5730
(F1
F0.00057339449541284407
I4
I0
I4
tp5731
sS'of,d-penicillamine,or'
p5732
(F1
F0.00014334862385321102
I0
I1
I-1
tp5733
sS'of,av,conduction'
p5734
(F1
F0.00014334862385321102
I1
I0
I1
tp5735
sS'was,not,affected'
p5736
(F1
F0.00043004587155963305
I0
I3
I-3
tp5737
sS'occurrence,of,torsade'
p5738
(F1
F0.00028669724770642203
I2
I0
I2
tp5739
sS'nonsteroidal,agents,have'
p5740
(F1
F0.00028669724770642203
I2
I0
I2
tp5741
sS'oral,channel,blockers'
p5742
(F1
F0.00014334862385321102
I0
I1
I-1
tp5743
sS'midazolam,aprepitant,increased'
p5744
(F1
F0.00014334862385321102
I1
I0
I1
tp5745
sS'cyp2d6,and,which'
p5746
(F1
F0.00014334862385321102
I1
I0
I1
tp5747
sS'can,deplete,and'
p5748
(F1
F0.00014334862385321102
I1
I0
I1
tp5749
sS'substrate,and,fold'
p5750
(F1
F0.00014334862385321102
I1
I0
I1
tp5751
sS'anti-inflammatory,agents,nsaids'
p5752
(F1
F0.00014334862385321102
I1
I0
I1
tp5753
sS'both,groups,ie'
p5754
(F1
F0.00014334862385321102
I0
I1
I-1
tp5755
sS'laboratorytest,interactions,dactinomycin'
p5756
(F1
F0.00014334862385321102
I0
I1
I-1
tp5757
sS'the,hypotension,induced'
p5758
(F1
F0.00014334862385321102
I1
I0
I1
tp5759
sS'of,and,have'
p5760
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp5761
sS'interactions,may,also'
p5762
(F1
F0.00014334862385321102
I0
I1
I-1
tp5763
sS'and,oral,were'
p5764
(F1
F0.00028669724770642203
I2
I0
I2
tp5765
sS'theophylline,enoxacin,is'
p5766
(F1
F0.00014334862385321102
I1
I0
I1
tp5767
sS'that,from,the'
p5768
(F1
F0.00014334862385321102
I0
I1
I-1
tp5769
sS'non-steroidal,agents,seizures'
p5770
(F1
F0.00014334862385321102
I1
I0
I1
tp5771
sS'decrease,metabolism,and'
p5772
(F1
F0.00014334862385321102
I1
I0
I1
tp5773
sS'reductase,may,cause'
p5774
(F1
F0.00014334862385321102
I0
I1
I-1
tp5775
sS'clinical,course,of'
p5776
(F1
F0.00014334862385321102
I0
I1
I-1
tp5777
sS'are,associated,with'
p5778
(F1
F0.00028669724770642203
I0
I2
I-2
tp5779
sS'for,the,pharmacokinetics'
p5780
(F1
F0.00014334862385321102
I0
I1
I-1
tp5781
sS'agents,it,should'
p5782
(F1
F0.00014334862385321102
I1
I0
I1
tp5783
sS'established,and,discontinuation'
p5784
(F1
F0.00014334862385321102
I0
I1
I-1
tp5785
sS'developing,peripheral,neuropathy'
p5786
(F1
F0.00014334862385321102
I1
I0
I1
tp5787
sS'concentrations,and,would'
p5788
(F1
F0.00014334862385321102
I0
I1
I-1
tp5789
sS'serum,creatinine,and'
p5790
(F1
F0.00028669724770642203
I2
I0
I2
tp5791
sS'on,pharmacokinetics,of'
p5792
(F1
F0.00014334862385321102
I0
I1
I-1
tp5793
sS'the,cognitive,and'
p5794
(F1
F0.00014334862385321102
I1
I0
I1
tp5795
sS'use,of,a'
p5796
(F0.5
F0.00028669724770642203
I3
I1
I2
tp5797
sS'treated,with,or'
p5798
(F1
F0.00014334862385321102
I1
I0
I1
tp5799
sS'cmax,and,increase'
p5800
(F1
F0.00014334862385321102
I1
I0
I1
tp5801
sS'it,increased,the'
p5802
(F1
F0.00014334862385321102
I0
I1
I-1
tp5803
sS'cimetidine,inhibits,both'
p5804
(F1
F0.00014334862385321102
I1
I0
I1
tp5805
sS'careful,adjustment,should'
p5806
(F1
F0.00014334862385321102
I1
I0
I1
tp5807
sS'n,n,with'
p5808
(F1
F0.00014334862385321102
I0
I1
I-1
tp5809
sS'syncope,presyncope,or'
p5810
(F1
F0.00014334862385321102
I1
I0
I1
tp5811
sS'on,chronic,treatment'
p5812
(F1
F0.00014334862385321102
I1
I0
I1
tp5813
sS'of,in,healthy'
p5814
(F1
F0.00028669724770642203
I0
I2
I-2
tp5815
sS'and,auc,values'
p5816
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp5817
sS'evoked,potentials,were'
p5818
(F1
F0.00014334862385321102
I0
I1
I-1
tp5819
sS'of,radiolabeled,ions'
p5820
(F1
F0.00014334862385321102
I0
I1
I-1
tp5821
sS'with,in,several'
p5822
(F1
F0.00014334862385321102
I0
I1
I-1
tp5823
sS'increased,ectopic,pacemaker'
p5824
(F1
F0.00014334862385321102
I1
I0
I1
tp5825
sS'baseline,vs,end'
p5826
(F1
F0.00014334862385321102
I0
I1
I-1
tp5827
sS'the,net,effect'
p5828
(F1
F0.00014334862385321102
I0
I1
I-1
tp5829
sS'study,of,mg'
p5830
(F1
F0.00014334862385321102
I1
I0
I1
tp5831
sS'specific,effects,of'
p5832
(F1
F0.00014334862385321102
I1
I0
I1
tp5833
sS'cancidas,are,not'
p5834
(F1
F0.00014334862385321102
I0
I1
I-1
tp5835
sS'steady-state,blood,concentrations'
p5836
(F1
F0.00014334862385321102
I0
I1
I-1
tp5837
sS'with,mg,times'
p5838
(F1
F0.00014334862385321102
I1
I0
I1
tp5839
sS'in,bile,and'
p5840
(F1
F0.00014334862385321102
I1
I0
I1
tp5841
sS'enterococcus,faecium,to'
p5842
(F1
F0.00014334862385321102
I0
I1
I-1
tp5843
sS'inhibit,k,epoxide'
p5844
(F1
F0.00014334862385321102
I0
I1
I-1
tp5845
sS'videx,chewable,buffered'
p5846
(F1
F0.00071674311926605509
I5
I0
I5
tp5847
sS'reductase,inhibitors,the'
p5848
(F1
F0.00014334862385321102
I1
I0
I1
tp5849
sS'several,medicinal,products'
p5850
(F1
F0.00014334862385321102
I1
I0
I1
tp5851
sS'with,the,administration'
p5852
(F1
F0.00014334862385321102
I1
I0
I1
tp5853
sS'tablets,was,not'
p5854
(F1
F0.00014334862385321102
I0
I1
I-1
tp5855
sS'complex,between,or'
p5856
(F1
F0.00014334862385321102
I1
I0
I1
tp5857
sS'in,vitro,against'
p5858
(F1
F0.00014334862385321102
I0
I1
I-1
tp5859
sS'times,higher,than'
p5860
(F1
F0.00014334862385321102
I1
I0
I1
tp5861
sS'of,kg,of'
p5862
(F1
F0.00014334862385321102
I0
I1
I-1
tp5863
sS'of,with,grapefruit'
p5864
(F1
F0.00014334862385321102
I0
I1
I-1
tp5865
sS'indinavir,has,been'
p5866
(F1
F0.00014334862385321102
I1
I0
I1
tp5867
sS'dose,was,co-administered'
p5868
(F1
F0.00014334862385321102
I0
I1
I-1
tp5869
sS'but,these,actions'
p5870
(F1
F0.00014334862385321102
I1
I0
I1
tp5871
sS'photosensitizing,agents,such'
p5872
(F1
F0.00014334862385321102
I1
I0
I1
tp5873
sS'mothers,it,is'
p5874
(F1
F0.00014334862385321102
I0
I1
I-1
tp5875
sS'is,probably,secondary'
p5876
(F1
F0.00014334862385321102
I1
I0
I1
tp5877
sS'urobilin,due,to'
p5878
(F1
F0.00014334862385321102
I0
I1
I-1
tp5879
sS'those,found,in'
p5880
(F0
F0
I1
I1
I0
tp5881
sS'carboxymethylcellulose,nacmc,and'
p5882
(F1
F0.00014334862385321102
I0
I1
I-1
tp5883
sS'injection,of,at'
p5884
(F1
F0.00028669724770642203
I2
I0
I2
tp5885
sS'increase,in,exposure'
p5886
(F1
F0.00028669724770642203
I2
I0
I2
tp5887
sS'hazard,to,health'
p5888
(F0
F0
I1
I1
I0
tp5889
sS'resulting,interference,with'
p5890
(F1
F0.00014334862385321102
I1
I0
I1
tp5891
sS'particularly,since,exhibits'
p5892
(F1
F0.00014334862385321102
I1
I0
I1
tp5893
sS'isozyme,and,it'
p5894
(F1
F0.00014334862385321102
I1
I0
I1
tp5895
sS'innovar,vet,or'
p5896
(F1
F0.00014334862385321102
I1
I0
I1
tp5897
sS'small,decrease,in'
p5898
(F1
F0.00043004587155963305
I3
I0
I3
tp5899
sS'safe,sexual,activity'
p5900
(F1
F0.00014334862385321102
I0
I1
I-1
tp5901
sS'after,overload,both'
p5902
(F1
F0.00014334862385321102
I0
I1
I-1
tp5903
sS'initiating,therapy,with'
p5904
(F1
F0.00028669724770642203
I2
I0
I2
tp5905
sS'use,products,that'
p5906
(F1
F0.00014334862385321102
I1
I0
I1
tp5907
sS'increased,metabolism,due'
p5908
(F1
F0.00014334862385321102
I1
I0
I1
tp5909
sS'should,not,concurrently'
p5910
(F1
F0.00014334862385321102
I1
I0
I1
tp5911
sS'and,beta-adrenergic,blocking'
p5912
(F1
F0.00014334862385321102
I1
I0
I1
tp5913
sS'is,not,antagonized'
p5914
(F1
F0.00014334862385321102
I0
I1
I-1
tp5915
sS'possible,that,dopamine'
p5916
(F1
F0.00014334862385321102
I1
I0
I1
tp5917
sS'be,diminished,when'
p5918
(F1
F0.00014334862385321102
I1
I0
I1
tp5919
sS'increased,by,about'
p5920
(F1
F0.00028669724770642203
I2
I0
I2
tp5921
sS'in,vitro,activity'
p5922
(F1
F0.00014334862385321102
I0
I1
I-1
tp5923
sS'mg,times,the'
p5924
(F1
F0.00014334862385321102
I0
I1
I-1
tp5925
sS'metabolites,n-desmethylclozapine,and'
p5926
(F1
F0.00014334862385321102
I0
I1
I-1
tp5927
sS'of,parietal,cells'
p5928
(F1
F0.00014334862385321102
I0
I1
I-1
tp5929
sS'dpcpx,in,a'
p5930
(F1
F0.00014334862385321102
I0
I1
I-1
tp5931
sS'also,concomitant,administration'
p5932
(F1
F0.00014334862385321102
I1
I0
I1
tp5933
sS'for,the,training'
p5934
(F1
F0.00014334862385321102
I0
I1
I-1
tp5935
sS'of,hyperkalemia,serum'
p5936
(F1
F0.00014334862385321102
I1
I0
I1
tp5937
sS'and,that,these'
p5938
(F1
F0.00014334862385321102
I0
I1
I-1
tp5939
sS'isoenzymes,and,or'
p5940
(F1
F0.00014334862385321102
I0
I1
I-1
tp5941
sS'it,is,likely'
p5942
(F1
F0.00028669724770642203
I2
I0
I2
tp5943
sS'insp,together,with'
p5944
(F1
F0.00014334862385321102
I1
I0
I1
tp5945
sS'a,given,plasma'
p5946
(F1
F0.00014334862385321102
I0
I1
I-1
tp5947
sS'concentrations,of,patients'
p5948
(F1
F0.00014334862385321102
I0
I1
I-1
tp5949
sS'inhibitors,to,control'
p5950
(F1
F0.00014334862385321102
I1
I0
I1
tp5951
sS'with,care,as'
p5952
(F1
F0.00014334862385321102
I1
I0
I1
tp5953
sS'preparations,may,potentiate'
p5954
(F1
F0.00014334862385321102
I1
I0
I1
tp5955
sS'cmin,were,increased'
p5956
(F1
F0.00028669724770642203
I2
I0
I2
tp5957
sS'cyp2d6,isoenzyme,including'
p5958
(F1
F0.00014334862385321102
I1
I0
I1
tp5959
sS'to,doses,that'
p5960
(F1
F0.00014334862385321102
I0
I1
I-1
tp5961
sS'the,same,time'
p5962
(F1
F0.00014334862385321102
I1
I0
I1
tp5963
sS'of,and,the'
p5964
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp5965
sS'to,broadly,the'
p5966
(F1
F0.00014334862385321102
I0
I1
I-1
tp5967
sS'de,pointes-type,ventricular'
p5968
(F1
F0.00014334862385321102
I0
I1
I-1
tp5969
sS'objective,to,report'
p5970
(F1
F0.00014334862385321102
I0
I1
I-1
tp5971
sS'of,similar,to'
p5972
(F1
F0.00028669724770642203
I2
I0
I2
tp5973
sS'levels,in,humans'
p5974
(F1
F0.00014334862385321102
I0
I1
I-1
tp5975
sS'shown,that,precipitation'
p5976
(F1
F0.00014334862385321102
I0
I1
I-1
tp5977
sS'are,metabolized,via'
p5978
(F1
F0.00014334862385321102
I0
I1
I-1
tp5979
sS'diuretics,patients,on'
p5980
(F1
F0.00028669724770642203
I2
I0
I2
tp5981
sS'does,not,enhance'
p5982
(F0
F0
I1
I1
I0
tp5983
sS'closely,monitored,if'
p5984
(F1
F0.00028669724770642203
I2
I0
I2
tp5985
sS'agents,insulin,sulfonylureas'
p5986
(F1
F0.00014334862385321102
I0
I1
I-1
tp5987
sS'nuprin,others,orudis'
p5988
(F1
F0.00014334862385321102
I0
I1
I-1
tp5989
sS'if,such,an'
p5990
(F1
F0.00014334862385321102
I0
I1
I-1
tp5991
sS'thiazides,thiazides,are'
p5992
(F1
F0.00043004587155963305
I0
I3
I-3
tp5993
sS'increase,to,mg'
p5994
(F1
F0.00014334862385321102
I0
I1
I-1
tp5995
sS'therefore,when,midamor'
p5996
(F1
F0.00014334862385321102
I1
I0
I1
tp5997
sS'tylenol,such,as'
p5998
(F1
F0.00014334862385321102
I1
I0
I1
tp5999
sS'in,another,interaction'
p6000
(F1
F0.00014334862385321102
I1
I0
I1
tp6001
sS'be,determined,by'
p6002
(F1
F0.00014334862385321102
I0
I1
I-1
tp6003
sS'therefore,be,closely'
p6004
(F0
F0
I1
I1
I0
tp6005
sS'with,vioxx,is'
p6006
(F1
F0.00014334862385321102
I1
I0
I1
tp6007
sS'administered,with,chirocaine'
p6008
(F1
F0.00014334862385321102
I0
I1
I-1
tp6009
sS'lymphocytopenia,has,been'
p6010
(F1
F0.00014334862385321102
I1
I0
I1
tp6011
sS'enter,the,csf'
p6012
(F1
F0.00014334862385321102
I0
I1
I-1
tp6013
sS'neuropathy,or,neurotoxic'
p6014
(F1
F0.00014334862385321102
I0
I1
I-1
tp6015
sS'reported,to,blunt'
p6016
(F1
F0.00028669724770642203
I2
I0
I2
tp6017
sS'to,block,the'
p6018
(F1
F0.00014334862385321102
I1
I0
I1
tp6019
sS'depressant,and,general'
p6020
(F1
F0.00014334862385321102
I1
I0
I1
tp6021
sS'the,and,classes'
p6022
(F1
F0.00014334862385321102
I1
I0
I1
tp6023
sS'reaction,for,urinary'
p6024
(F1
F0.00014334862385321102
I0
I1
I-1
tp6025
sS'racemic,mg,given'
p6026
(F1
F0.00014334862385321102
I1
I0
I1
tp6027
sS'as,and,ethacrynic'
p6028
(F1
F0.00014334862385321102
I1
I0
I1
tp6029
sS'not,expected,between'
p6030
(F1
F0.00014334862385321102
I0
I1
I-1
tp6031
sS'at,as,great'
p6032
(F1
F0.00014334862385321102
I0
I1
I-1
tp6033
sS'usually,reversible,upon'
p6034
(F1
F0.00014334862385321102
I1
I0
I1
tp6035
sS'be,affected,by'
p6036
(F0
F0
I3
I3
I0
tp6037
sS'fe,over,a'
p6038
(F1
F0.00014334862385321102
I0
I1
I-1
tp6039
sS'mmol,day,for'
p6040
(F1
F0.00014334862385321102
I0
I1
I-1
tp6041
sS'their,guardians,carefully'
p6042
(F1
F0.00014334862385321102
I0
I1
I-1
tp6043
sS'enteric,coated,plus'
p6044
(F1
F0.00014334862385321102
I0
I1
I-1
tp6045
sS'if,their,tolerance'
p6046
(F1
F0.00014334862385321102
I1
I0
I1
tp6047
sS'at,the,recommended'
p6048
(F1
F0.00014334862385321102
I1
I0
I1
tp6049
sS'medicines,central,nervous'
p6050
(F1
F0.00014334862385321102
I1
I0
I1
tp6051
sS'recommended,for,coadministration'
p6052
(F1
F0.00014334862385321102
I0
I1
I-1
tp6053
sS'has,demonstrated,superiority'
p6054
(F1
F0.00014334862385321102
I0
I1
I-1
tp6055
sS'concentrations,and,prothrombin'
p6056
(F1
F0.00014334862385321102
I0
I1
I-1
tp6057
sS'and,hours,for'
p6058
(F1
F0.00014334862385321102
I0
I1
I-1
tp6059
sS'indications,specific,for'
p6060
(F1
F0.00014334862385321102
I0
I1
I-1
tp6061
sS'isolated,cases,of'
p6062
(F1
F0.00014334862385321102
I1
I0
I1
tp6063
sS'not,significantly,affected'
p6064
(F1
F0.00014334862385321102
I0
I1
I-1
tp6065
sS'by,the,ganglionic-blocking'
p6066
(F1
F0.00014334862385321102
I1
I0
I1
tp6067
sS'have,significant,metabolism'
p6068
(F1
F0.00014334862385321102
I1
I0
I1
tp6069
sS'administration,but,these'
p6070
(F1
F0.00014334862385321102
I0
I1
I-1
tp6071
sS'of,vardenafil,with'
p6072
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp6073
sS'about,minutes,before'
p6074
(F1
F0.00014334862385321102
I1
I0
I1
tp6075
sS'of,auc,and'
p6076
(F1
F0.00014334862385321102
I1
I0
I1
tp6077
sS'avoid,bleeding,reduced'
p6078
(F1
F0.00014334862385321102
I1
I0
I1
tp6079
sS'dsst,symbol,copying'
p6080
(F1
F0.00014334862385321102
I1
I0
I1
tp6081
sS'of,approximately,in'
p6082
(F0
F0
I1
I1
I0
tp6083
sS'reduces,the,renal'
p6084
(F1
F0.00014334862385321102
I1
I0
I1
tp6085
sS'methotrexate-related,toxicity,should'
p6086
(F1
F0.00014334862385321102
I1
I0
I1
tp6087
sS'of,a,non-steroidal'
p6088
(F1
F0.00043004587155963305
I3
I0
I3
tp6089
sS'were,drinking,during'
p6090
(F1
F0.00014334862385321102
I1
I0
I1
tp6091
sS'the,tubular,secretion'
p6092
(F1
F0.00057339449541284407
I4
I0
I4
tp6093
sS'of,the,pharmacokinetics'
p6094
(F1
F0.00028669724770642203
I0
I2
I-2
tp6095
sS'innovar,on,tolerance'
p6096
(F1
F0.00014334862385321102
I0
I1
I-1
tp6097
sS'aspirin,may,decrease'
p6098
(F1
F0.00014334862385321102
I1
I0
I1
tp6099
sS'the,cns-depressive,effect'
p6100
(F1
F0.00014334862385321102
I1
I0
I1
tp6101
sS'ineffective,if,the'
p6102
(F1
F0.00014334862385321102
I1
I0
I1
tp6103
sS'observed,for,several'
p6104
(F1
F0.00014334862385321102
I1
I0
I1
tp6105
sS'taken,when,the'
p6106
(F1
F0.00014334862385321102
I1
I0
I1
tp6107
sS'n-allylnormetazocine,nanm,were'
p6108
(F1
F0.00014334862385321102
I0
I1
I-1
tp6109
sS'the,physician,is'
p6110
(F1
F0.00014334862385321102
I0
I1
I-1
tp6111
sS'and,mean,scores'
p6112
(F1
F0.00014334862385321102
I1
I0
I1
tp6113
sS'and,low-dose,has'
p6114
(F1
F0.00014334862385321102
I1
I0
I1
tp6115
sS'cell,including,an'
p6116
(F1
F0.00014334862385321102
I0
I1
I-1
tp6117
sS'and,significant,decrease'
p6118
(F1
F0.00014334862385321102
I1
I0
I1
tp6119
sS'sodium,enhances,the'
p6120
(F1
F0.00014334862385321102
I1
I0
I1
tp6121
sS'antipyrine,pharmacokinetics,were'
p6122
(F1
F0.00014334862385321102
I0
I1
I-1
tp6123
sS'n-type,channel,an'
p6124
(F1
F0.00014334862385321102
I0
I1
I-1
tp6125
sS'estradiol,the,estrogenic'
p6126
(F1
F0.00014334862385321102
I0
I1
I-1
tp6127
sS'elevated,blood,levels'
p6128
(F1
F0.00014334862385321102
I0
I1
I-1
tp6129
sS'renal,tubular,transport'
p6130
(F1
F0.00014334862385321102
I1
I0
I1
tp6131
sS'or,clinically,significant'
p6132
(F1
F0.00014334862385321102
I0
I1
I-1
tp6133
sS'decreased,an,average'
p6134
(F1
F0.00028669724770642203
I2
I0
I2
tp6135
sS'most,other,hypotensive'
p6136
(F1
F0.00014334862385321102
I1
I0
I1
tp6137
sS'at,least,in'
p6138
(F1
F0.00014334862385321102
I1
I0
I1
tp6139
sS'exhibiting,m,m'
p6140
(F1
F0.00014334862385321102
I0
I1
I-1
tp6141
sS'advised,when,trisenox'
p6142
(F1
F0.00014334862385321102
I1
I0
I1
tp6143
sS'negatively,impacted,by'
p6144
(F1
F0.00014334862385321102
I0
I1
I-1
tp6145
sS'eliminated,by,active'
p6146
(F1
F0.00014334862385321102
I1
I0
I1
tp6147
sS'to,patients,on'
p6148
(F1
F0.00043004587155963305
I3
I0
I3
tp6149
sS'the,concomitant,intravenous'
p6150
(F1
F0.00014334862385321102
I1
I0
I1
tp6151
sS'its,acid,metabolite'
p6152
(F1
F0.00014334862385321102
I0
I1
I-1
tp6153
sS'inhibition,of,cholino-'
p6154
(F1
F0.00014334862385321102
I0
I1
I-1
tp6155
sS'when,a,single'
p6156
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp6157
sS'potassium-depleting,agents,when'
p6158
(F1
F0.00014334862385321102
I1
I0
I1
tp6159
sS'approximately,decrease,in'
p6160
(F1
F0.00014334862385321102
I1
I0
I1
tp6161
sS'these,would,include'
p6162
(F1
F0.00014334862385321102
I0
I1
I-1
tp6163
sS'with,renal,dysfunction'
p6164
(F1
F0.00014334862385321102
I1
I0
I1
tp6165
sS'a,mg,intravenous'
p6166
(F1
F0.00014334862385321102
I0
I1
I-1
tp6167
sS'in,no,difference'
p6168
(F1
F0.00014334862385321102
I0
I1
I-1
tp6169
sS'rhabdomyolysis,and,acute'
p6170
(F1
F0.00014334862385321102
I1
I0
I1
tp6171
sS'effect,of,systemic'
p6172
(F1
F0.00014334862385321102
I1
I0
I1
tp6173
sS'otc,dose,resulted'
p6174
(F1
F0.00014334862385321102
I1
I0
I1
tp6175
sS'placental,vessels,to'
p6176
(F1
F0.00014334862385321102
I1
I0
I1
tp6177
sS'cns,depression,cns'
p6178
(F1
F0.00014334862385321102
I0
I1
I-1
tp6179
sS'urine,immunoreactive,concentrations'
p6180
(F1
F0.00014334862385321102
I0
I1
I-1
tp6181
sS'appropriate,monitoring,of'
p6182
(F1
F0.00014334862385321102
I1
I0
I1
tp6183
sS'in,clinically,significant'
p6184
(F1
F0.00028669724770642203
I0
I2
I-2
tp6185
sS'of,serum,prostate-specific'
p6186
(F1
F0.00014334862385321102
I0
I1
I-1
tp6187
sS'steady-state,with,a'
p6188
(F0
F0
I1
I1
I0
tp6189
sS'not,inhibitors,of'
p6190
(F1
F0.00014334862385321102
I0
I1
I-1
tp6191
sS'the,adverse,events'
p6192
(F1
F0.00014334862385321102
I0
I1
I-1
tp6193
sS'volunteers,n,in'
p6194
(F1
F0.00014334862385321102
I0
I1
I-1
tp6195
sS'used,at,the'
p6196
(F1
F0.00014334862385321102
I1
I0
I1
tp6197
sS'related,may,increase'
p6198
(F1
F0.00014334862385321102
I1
I0
I1
tp6199
sS'levels,in,patients'
p6200
(F1
F0.00014334862385321102
I0
I1
I-1
tp6201
sS'juice,given,to'
p6202
(F1
F0.00014334862385321102
I0
I1
I-1
tp6203
sS'widening,of,the'
p6204
(F1
F0.00014334862385321102
I1
I0
I1
tp6205
sS'that,of,users'
p6206
(F1
F0.00014334862385321102
I1
I0
I1
tp6207
sS'dosing,is,required'
p6208
(F1
F0.00014334862385321102
I0
I1
I-1
tp6209
sS'substrate,agent,may'
p6210
(F1
F0.00014334862385321102
I0
I1
I-1
tp6211
sS'other,cardioactive,drugs'
p6212
(F1
F0.00014334862385321102
I0
I1
I-1
tp6213
sS'cyp3a4,rifampicin,racemic'
p6214
(F1
F0.00014334862385321102
I1
I0
I1
tp6215
sS'cyp2d6,cyp2e1,or'
p6216
(F1
F0.00014334862385321102
I0
I1
I-1
tp6217
sS'one,mg,dose'
p6218
(F1
F0.00014334862385321102
I1
I0
I1
tp6219
sS'of,or,nsaids'
p6220
(F1
F0.00014334862385321102
I1
I0
I1
tp6221
sS'risk,of,neuropathy'
p6222
(F1
F0.00014334862385321102
I0
I1
I-1
tp6223
sS'concomitantly,with,medications'
p6224
(F1
F0.00014334862385321102
I1
I0
I1
tp6225
sS'effect,on,pupil'
p6226
(F1
F0.00014334862385321102
I1
I0
I1
tp6227
sS'receiving,a,course'
p6228
(F1
F0.00014334862385321102
I1
I0
I1
tp6229
sS'of,with,itraconazole'
p6230
(F1
F0.00014334862385321102
I1
I0
I1
tp6231
sS'hormonalmethods,of,birth'
p6232
(F1
F0.00014334862385321102
I1
I0
I1
tp6233
sS'of,these,medicines'
p6234
(F1
F0.00028669724770642203
I2
I0
I2
tp6235
sS'tdm,of,therapy'
p6236
(F1
F0.00014334862385321102
I0
I1
I-1
tp6237
sS'cases,from,spontaneous'
p6238
(F1
F0.00014334862385321102
I0
I1
I-1
tp6239
sS'antithyroid,agents,may'
p6240
(F1
F0.00014334862385321102
I1
I0
I1
tp6241
sS'concomitantly,with,that'
p6242
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp6243
sS'orally,ingested,or'
p6244
(F1
F0.00014334862385321102
I0
I1
I-1
tp6245
sS'assessed,using,morphological'
p6246
(F1
F0.00014334862385321102
I1
I0
I1
tp6247
sS'oral,such,as'
p6248
(F1
F0.00014334862385321102
I1
I0
I1
tp6249
sS'volunteers,n,demonstrated'
p6250
(F1
F0.00014334862385321102
I0
I1
I-1
tp6251
sS'blood,levels,of'
p6252
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp6253
sS'initiating,combination,therapy'
p6254
(F1
F0.00014334862385321102
I1
I0
I1
tp6255
sS'mg,was,evaluated'
p6256
(F1
F0.00014334862385321102
I0
I1
I-1
tp6257
sS'patients,with,hereditary'
p6258
(F1
F0.00014334862385321102
I1
I0
I1
tp6259
sS'channel-blockers,ace,inhibitors'
p6260
(F1
F0.00014334862385321102
I0
I1
I-1
tp6261
sS'potassium,kinetics,and'
p6262
(F1
F0.00014334862385321102
I1
I0
I1
tp6263
sS'prostaglandins,may,cause'
p6264
(F1
F0.00014334862385321102
I1
I0
I1
tp6265
sS'who,received,tended'
p6266
(F1
F0.00014334862385321102
I0
I1
I-1
tp6267
sS'possibly,causing,uterine'
p6268
(F1
F0.00014334862385321102
I1
I0
I1
tp6269
sS'although,is,not'
p6270
(F1
F0.00014334862385321102
I0
I1
I-1
tp6271
sS'inducers,and,inhibitors'
p6272
(F1
F0.00014334862385321102
I1
I0
I1
tp6273
sS'with,by,about'
p6274
(F1
F0.00014334862385321102
I0
I1
I-1
tp6275
sS'the,cyp3a4,substrate'
p6276
(F1
F0.00014334862385321102
I0
I1
I-1
tp6277
sS'growth,both,in'
p6278
(F1
F0.00014334862385321102
I0
I1
I-1
tp6279
sS'should,elapse,between'
p6280
(F1
F0.00043004587155963305
I3
I0
I3
tp6281
sS'increased,activity,of'
p6282
(F0
F0
I1
I1
I0
tp6283
sS'expected,with,other'
p6284
(F1
F0.00014334862385321102
I0
I1
I-1
tp6285
sS'with,increased,risks'
p6286
(F1
F0.00014334862385321102
I1
I0
I1
tp6287
sS'times,or,a'
p6288
(F1
F0.00014334862385321102
I0
I1
I-1
tp6289
sS'showing,a,higher'
p6290
(F1
F0.00014334862385321102
I0
I1
I-1
tp6291
sS'to,ensure,that'
p6292
(F1
F0.00014334862385321102
I1
I0
I1
tp6293
sS'of,with,lowered'
p6294
(F1
F0.00014334862385321102
I1
I0
I1
tp6295
sS'abstracts,using,the'
p6296
(F1
F0.00014334862385321102
I0
I1
I-1
tp6297
sS'patients,who,inactivate'
p6298
(F1
F0.00014334862385321102
I1
I0
I1
tp6299
sS'cyclosporine,large,quantities'
p6300
(F1
F0.00014334862385321102
I0
I1
I-1
tp6301
sS'sildenafil,is,contraindicated'
p6302
(F1
F0.00014334862385321102
I1
I0
I1
tp6303
sS'effect,of,levels'
p6304
(F1
F0.00014334862385321102
I1
I0
I1
tp6305
sS'necessary,for,the'
p6306
(F1
F0.00014334862385321102
I0
I1
I-1
tp6307
sS'with,kemstrotm,was'
p6308
(F1
F0.00014334862385321102
I0
I1
I-1
tp6309
sS'the,usual,prescription'
p6310
(F1
F0.00014334862385321102
I1
I0
I1
tp6311
sS'administered,at,either'
p6312
(F1
F0.00014334862385321102
I0
I1
I-1
tp6313
sS'a,study,in'
p6314
(F0.29999999999999999
F0.0008600917431192661
I13
I7
I6
tp6315
sS'in,vitro,upon'
p6316
(F1
F0.00014334862385321102
I1
I0
I1
tp6317
sS'synthetic,possibly,by'
p6318
(F1
F0.00014334862385321102
I1
I0
I1
tp6319
sS'the,properties,of'
p6320
(F1
F0.00014334862385321102
I0
I1
I-1
tp6321
sS'clinically,compatible,with'
p6322
(F1
F0.00014334862385321102
I0
I1
I-1
tp6323
sS'properties,and,the'
p6324
(F1
F0.00014334862385321102
I1
I0
I1
tp6325
sS'for,hepatic,injury'
p6326
(F1
F0.00014334862385321102
I0
I1
I-1
tp6327
sS'have,identified,potentially'
p6328
(F1
F0.00014334862385321102
I1
I0
I1
tp6329
sS'by,approximately,mean'
p6330
(F1
F0.00014334862385321102
I1
I0
I1
tp6331
sS'decarboxylase,inhibitor,does'
p6332
(F1
F0.00014334862385321102
I0
I1
I-1
tp6333
sS'concentrations,of,vitamin'
p6334
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp6335
sS'in,increased,clinical'
p6336
(F1
F0.00014334862385321102
I1
I0
I1
tp6337
sS'to,and,leading'
p6338
(F1
F0.00014334862385321102
I1
I0
I1
tp6339
sS'in,nursing,infants'
p6340
(F1
F0.00014334862385321102
I0
I1
I-1
tp6341
sS'be,a,complication'
p6342
(F1
F0.00014334862385321102
I0
I1
I-1
tp6343
sS'induced,by,was'
p6344
(F1
F0.00014334862385321102
I1
I0
I1
tp6345
sS'play,an,important'
p6346
(F1
F0.00028669724770642203
I2
I0
I2
tp6347
sS'the,intravenous,self-administration'
p6348
(F0
F0
I1
I1
I0
tp6349
sS'was,significantly,lower'
p6350
(F1
F0.00014334862385321102
I0
I1
I-1
tp6351
sS'anti-inflammatory,nsaids,without'
p6352
(F1
F0.00014334862385321102
I0
I1
I-1
tp6353
sS'with,in,some'
p6354
(F1
F0.00014334862385321102
I1
I0
I1
tp6355
sS'may,potentiate,adverse'
p6356
(F1
F0.00014334862385321102
I1
I0
I1
tp6357
sS'been,formally,evaluated'
p6358
(F1
F0.00014334862385321102
I0
I1
I-1
tp6359
sS'with,difluoroacetone,did'
p6360
(F1
F0.00014334862385321102
I0
I1
I-1
tp6361
sS'the,following,anti-anxiety'
p6362
(F1
F0.00014334862385321102
I0
I1
I-1
tp6363
sS'other,drugs,clonazepam'
p6364
(F1
F0.00014334862385321102
I0
I1
I-1
tp6365
sS'oral,and,discontinuation'
p6366
(F1
F0.00014334862385321102
I1
I0
I1
tp6367
sS'phenytoin,serum,level'
p6368
(F1
F0.00014334862385321102
I1
I0
I1
tp6369
sS'solution,one,study'
p6370
(F1
F0.00014334862385321102
I1
I0
I1
tp6371
sS'p,decreased,mean'
p6372
(F1
F0.00014334862385321102
I1
I0
I1
tp6373
sS'added,to,the'
p6374
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp6375
sS'metabolism,of,certain'
p6376
(F1
F0.00043004587155963305
I3
I0
I3
tp6377
sS'maintained,between,the'
p6378
(F1
F0.00014334862385321102
I1
I0
I1
tp6379
sS'fold,at,steady'
p6380
(F1
F0.00014334862385321102
I1
I0
I1
tp6381
sS'grouped,as,ace'
p6382
(F1
F0.00014334862385321102
I0
I1
I-1
tp6383
sS'does,not,greatly'
p6384
(F1
F0.00014334862385321102
I0
I1
I-1
tp6385
sS'results,from,the'
p6386
(F1
F0.00014334862385321102
I1
I0
I1
tp6387
sS'and,angiotensin,ii'
p6388
(F0
F0
I1
I1
I0
tp6389
sS'agents,causing,renin'
p6390
(F1
F0.00028669724770642203
I2
I0
I2
tp6391
sS'dicumarol,and,indanedione'
p6392
(F1
F0.00014334862385321102
I0
I1
I-1
tp6393
sS'and,decrease,platelet'
p6394
(F1
F0.00014334862385321102
I0
I1
I-1
tp6395
sS'far,greater,extent'
p6396
(F1
F0.00014334862385321102
I0
I1
I-1
tp6397
sS'coumarin,anticoagulants,there'
p6398
(F1
F0.00014334862385321102
I1
I0
I1
tp6399
sS'overall,treatment,costs'
p6400
(F1
F0.00014334862385321102
I0
I1
I-1
tp6401
sS'and,racemic,was'
p6402
(F1
F0.00014334862385321102
I0
I1
I-1
tp6403
sS'permeation,of,sodium'
p6404
(F1
F0.00014334862385321102
I0
I1
I-1
tp6405
sS'of,cardiopulmonary,arrest'
p6406
(F1
F0.00014334862385321102
I0
I1
I-1
tp6407
sS'the,immune,response'
p6408
(F1
F0.00014334862385321102
I0
I1
I-1
tp6409
sS'addition,of,is'
p6410
(F1
F0.00014334862385321102
I0
I1
I-1
tp6411
sS'combination,therapy,did'
p6412
(F1
F0.00014334862385321102
I0
I1
I-1
tp6413
sS'are,indeed,agents'
p6414
(F1
F0.00014334862385321102
I0
I1
I-1
tp6415
sS'globulin,cbg,sex'
p6416
(F1
F0.00028669724770642203
I0
I2
I-2
tp6417
sS'concurrently,with,escalating'
p6418
(F1
F0.00014334862385321102
I0
I1
I-1
tp6419
sS'was,initiated,apparent'
p6420
(F1
F0.00014334862385321102
I1
I0
I1
tp6421
sS'oral,medication,such'
p6422
(F1
F0.00014334862385321102
I1
I0
I1
tp6423
sS'results,of,interaction'
p6424
(F1
F0.00014334862385321102
I0
I1
I-1
tp6425
sS'and,motor,skills'
p6426
(F1
F0.00014334862385321102
I0
I1
I-1
tp6427
sS'as,beta-adrenergic,blocking'
p6428
(F1
F0.00014334862385321102
I0
I1
I-1
tp6429
sS'on,natriuresis,is'
p6430
(F1
F0.00014334862385321102
I1
I0
I1
tp6431
sS'one,possible,index'
p6432
(F1
F0.00014334862385321102
I0
I1
I-1
tp6433
sS'sustained-release,with,no'
p6434
(F1
F0.00014334862385321102
I0
I1
I-1
tp6435
sS'increase,the,blood-glucose'
p6436
(F1
F0.00028669724770642203
I0
I2
I-2
tp6437
sS'interactions,of,humorsol'
p6438
(F1
F0.00014334862385321102
I1
I0
I1
tp6439
sS'number,of,human'
p6440
(F1
F0.00014334862385321102
I1
I0
I1
tp6441
sS'or,used,during'
p6442
(F1
F0.00014334862385321102
I0
I1
I-1
tp6443
sS'studied,with,inhibition'
p6444
(F1
F0.00014334862385321102
I1
I0
I1
tp6445
sS'strong,cyp3a4,inducer'
p6446
(F1
F0.00014334862385321102
I1
I0
I1
tp6447
sS'and,in,humans'
p6448
(F0
F0
I1
I1
I0
tp6449
sS'inhibitors,without,any'
p6450
(F1
F0.00014334862385321102
I0
I1
I-1
tp6451
sS'or,products,containing'
p6452
(F1
F0.00014334862385321102
I1
I0
I1
tp6453
sS'day,and,by'
p6454
(F1
F0.00014334862385321102
I1
I0
I1
tp6455
sS'the,antiepileptic,effect'
p6456
(F1
F0.00014334862385321102
I1
I0
I1
tp6457
sS'however,the,use'
p6458
(F1
F0.00014334862385321102
I0
I1
I-1
tp6459
sS'parts,of,the'
p6460
(F1
F0.00014334862385321102
I1
I0
I1
tp6461
sS'methods,from,the'
p6462
(F1
F0.00014334862385321102
I0
I1
I-1
tp6463
sS'co-administration,of,fluvoxamine'
p6464
(F1
F0.00014334862385321102
I1
I0
I1
tp6465
sS'that,the,oral'
p6466
(F1
F0.00014334862385321102
I1
I0
I1
tp6467
sS'altered,hypo-prothrombinemic,effect'
p6468
(F1
F0.00014334862385321102
I0
I1
I-1
tp6469
sS'until,data,on'
p6470
(F1
F0.00014334862385321102
I1
I0
I1
tp6471
sS'sulfosalicylic,acid,precipitation'
p6472
(F1
F0.00014334862385321102
I0
I1
I-1
tp6473
sS'studies,sodium,was'
p6474
(F1
F0.00014334862385321102
I0
I1
I-1
tp6475
sS'the,cns,depressive'
p6476
(F1
F0.00014334862385321102
I1
I0
I1
tp6477
sS'further,data,are'
p6478
(F1
F0.00014334862385321102
I0
I1
I-1
tp6479
sS'the,known,property'
p6480
(F1
F0.00014334862385321102
I1
I0
I1
tp6481
sS'dose-response,curves,derived'
p6482
(F1
F0.00014334862385321102
I1
I0
I1
tp6483
sS'and,ketoconazole,fexofenadine'
p6484
(F1
F0.00014334862385321102
I0
I1
I-1
tp6485
sS'clinically,significant,interactions'
p6486
(F1
F0.0008600917431192661
I0
I6
I-6
tp6487
sS'known,caution,is'
p6488
(F1
F0.00014334862385321102
I1
I0
I1
tp6489
sS'systems,responsible,for'
p6490
(F1
F0.00014334862385321102
I0
I1
I-1
tp6491
sS'sulfide,metabolite,by'
p6492
(F1
F0.00014334862385321102
I1
I0
I1
tp6493
sS'of,by,m'
p6494
(F1
F0.00014334862385321102
I1
I0
I1
tp6495
sS's,wort,in'
p6496
(F1
F0.00014334862385321102
I0
I1
I-1
tp6497
sS'of,duragesic,transdermal'
p6498
(F1
F0.00014334862385321102
I1
I0
I1
tp6499
sS'of,by,a'
p6500
(F1
F0.00043004587155963305
I3
I0
I3
tp6501
sS'other,multivalent,cations'
p6502
(F1
F0.00028669724770642203
I2
I0
I2
tp6503
sS'methotrexate,nsaids,have'
p6504
(F1
F0.00014334862385321102
I1
I0
I1
tp6505
sS'more,than,for'
p6506
(F1
F0.00014334862385321102
I1
I0
I1
tp6507
sS'as,the,was'
p6508
(F1
F0.00014334862385321102
I0
I1
I-1
tp6509
sS'the,prophylactic,and'
p6510
(F1
F0.00014334862385321102
I1
I0
I1
tp6511
sS'and,the,herbal'
p6512
(F1
F0.00014334862385321102
I0
I1
I-1
tp6513
sS'interaction,with,erythromycin'
p6514
(F1
F0.00014334862385321102
I0
I1
I-1
tp6515
sS'by,the,pathway'
p6516
(F1
F0.00014334862385321102
I0
I1
I-1
tp6517
sS'dose,of,be'
p6518
(F1
F0.00028669724770642203
I2
I0
I2
tp6519
sS'in,de,novo'
p6520
(F1
F0.00028669724770642203
I0
I2
I-2
tp6521
sS'is,felt,that'
p6522
(F1
F0.00014334862385321102
I1
I0
I1
tp6523
sS'cerebral,and,hepatic'
p6524
(F1
F0.00028669724770642203
I2
I0
I2
tp6525
sS'used,concomitantly,with'
p6526
(F0.047619047619047616
F0.00014334862385321102
I11
I10
I1
tp6527
sS'increasing,salt,intake'
p6528
(F1
F0.00014334862385321102
I1
I0
I1
tp6529
sS'other,cause,striking'
p6530
(F1
F0.00028669724770642203
I2
I0
I2
tp6531
sS'auc,of,mefenamic'
p6532
(F1
F0.00014334862385321102
I1
I0
I1
tp6533
sS'have,been,received'
p6534
(F1
F0.00014334862385321102
I0
I1
I-1
tp6535
sS'inhibition,of,the'
p6536
(F0
F0
I3
I3
I0
tp6537
sS'plasma,concentrations,following'
p6538
(F1
F0.00014334862385321102
I0
I1
I-1
tp6539
sS'and,of,subjects'
p6540
(F1
F0.00014334862385321102
I1
I0
I1
tp6541
sS'lasting,depletions,of'
p6542
(F1
F0.00014334862385321102
I1
I0
I1
tp6543
sS'peak,plasma,concentrations'
p6544
(F1
F0.00028669724770642203
I2
I0
I2
tp6545
sS'not,altered,to'
p6546
(F1
F0.00014334862385321102
I0
I1
I-1
tp6547
sS'since,it,palliates'
p6548
(F1
F0.00014334862385321102
I0
I1
I-1
tp6549
sS'that,coadministration,of'
p6550
(F1
F0.00057339449541284407
I4
I0
I4
tp6551
sS'angiotensin-converting,enzyme,ace'
p6552
(F1
F0.00014334862385321102
I0
I1
I-1
tp6553
sS'a,major,metabolic'
p6554
(F1
F0.00014334862385321102
I0
I1
I-1
tp6555
sS'sustiva,has,the'
p6556
(F1
F0.00014334862385321102
I1
I0
I1
tp6557
sS'open,air,passages'
p6558
(F1
F0.00014334862385321102
I1
I0
I1
tp6559
sS'catabolism,of,k-dependent'
p6560
(F1
F0.00014334862385321102
I0
I1
I-1
tp6561
sS'medicines,such,as'
p6562
(F1
F0.00014334862385321102
I1
I0
I1
tp6563
sS'the,dosage,range'
p6564
(F1
F0.00014334862385321102
I1
I0
I1
tp6565
sS'hour,period,when'
p6566
(F1
F0.00057339449541284407
I4
I0
I4
tp6567
sS'multiple-dose,interaction,studies'
p6568
(F1
F0.00014334862385321102
I0
I1
I-1
tp6569
sS'milk,on,the'
p6570
(F1
F0.00014334862385321102
I0
I1
I-1
tp6571
sS'additionally,did,not'
p6572
(F1
F0.00014334862385321102
I0
I1
I-1
tp6573
sS'exposure,with,a'
p6574
(F1
F0.00014334862385321102
I1
I0
I1
tp6575
sS'were,indifferent,for'
p6576
(F1
F0.00028669724770642203
I2
I0
I2
tp6577
sS'similar,with,and'
p6578
(F1
F0.00014334862385321102
I0
I1
I-1
tp6579
sS'to,affect,abilify'
p6580
(F1
F0.00014334862385321102
I0
I1
I-1
tp6581
sS'from,a,control'
p6582
(F1
F0.00014334862385321102
I1
I0
I1
tp6583
sS'with,local,close'
p6584
(F1
F0.00014334862385321102
I0
I1
I-1
tp6585
sS'calcium-entry,blocking,agents'
p6586
(F1
F0.00014334862385321102
I0
I1
I-1
tp6587
sS'cyp3a4,substrates,and'
p6588
(F1
F0.00014334862385321102
I0
I1
I-1
tp6589
sS'cyp1a2,activity,and'
p6590
(F1
F0.00014334862385321102
I0
I1
I-1
tp6591
sS'with,serial,pharmacokinetic'
p6592
(F1
F0.00014334862385321102
I0
I1
I-1
tp6593
sS'transdermal,and,implantable'
p6594
(F1
F0.00028669724770642203
I2
I0
I2
tp6595
sS'their,vasospastic,effects'
p6596
(F1
F0.00014334862385321102
I1
I0
I1
tp6597
sS'agents,may,be'
p6598
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp6599
sS'oil,ml,day'
p6600
(F1
F0.00014334862385321102
I0
I1
I-1
tp6601
sS'treated,concurrently,with'
p6602
(F0
F0
I2
I2
I0
tp6603
sS'to,three,weeks'
p6604
(F1
F0.00014334862385321102
I1
I0
I1
tp6605
sS'should,be,closely'
p6606
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp6607
sS'not,interfere,with'
p6608
(F1
F0.0008600917431192661
I0
I6
I-6
tp6609
sS'inhibitor,which,also'
p6610
(F1
F0.00014334862385321102
I1
I0
I1
tp6611
sS'with,lodine,as'
p6612
(F1
F0.00014334862385321102
I0
I1
I-1
tp6613
sS'theoretically,possible,that'
p6614
(F1
F0.00014334862385321102
I1
I0
I1
tp6615
sS'half,life,of'
p6616
(F1
F0.00014334862385321102
I1
I0
I1
tp6617
sS'adrenoreceptors,on,this'
p6618
(F1
F0.00014334862385321102
I0
I1
I-1
tp6619
sS'air,passages,increasing'
p6620
(F1
F0.00014334862385321102
I1
I0
I1
tp6621
sS'drugs,which,inhibit'
p6622
(F1
F0.00014334862385321102
I1
I0
I1
tp6623
sS'receiving,with,agents'
p6624
(F1
F0.00014334862385321102
I1
I0
I1
tp6625
sS'have,been,studied'
p6626
(F1
F0.00014334862385321102
I0
I1
I-1
tp6627
sS'and,the,ht3'
p6628
(F1
F0.00014334862385321102
I0
I1
I-1
tp6629
sS'two,or,more'
p6630
(F1
F0.00014334862385321102
I1
I0
I1
tp6631
sS'five-fold,increase,in'
p6632
(F1
F0.00014334862385321102
I1
I0
I1
tp6633
sS'interactions,have,also'
p6634
(F1
F0.00014334862385321102
I0
I1
I-1
tp6635
sS'after,ethyl,increases'
p6636
(F1
F0.00014334862385321102
I1
I0
I1
tp6637
sS'may,necessitate,raising'
p6638
(F1
F0.00014334862385321102
I1
I0
I1
tp6639
sS'toxicity,because,of'
p6640
(F1
F0.00014334862385321102
I0
I1
I-1
tp6641
sS'relaxants,that,resulted'
p6642
(F1
F0.00014334862385321102
I0
I1
I-1
tp6643
sS'severe,myopathy,rhabdomyolysis'
p6644
(F1
F0.00014334862385321102
I1
I0
I1
tp6645
sS'the,auc,more'
p6646
(F1
F0.00014334862385321102
I0
I1
I-1
tp6647
sS'aspecific,treatments,of'
p6648
(F1
F0.00014334862385321102
I0
I1
I-1
tp6649
sS'are,using,it'
p6650
(F1
F0.00014334862385321102
I1
I0
I1
tp6651
sS'to,those,found'
p6652
(F1
F0.00014334862385321102
I1
I0
I1
tp6653
sS'administration,of,should'
p6654
(F1
F0.00014334862385321102
I0
I1
I-1
tp6655
sS'of,normal,and'
p6656
(F1
F0.00014334862385321102
I0
I1
I-1
tp6657
sS'barbiturates,or,increased'
p6658
(F1
F0.00014334862385321102
I1
I0
I1
tp6659
sS'therefore,concomitant,administration'
p6660
(F1
F0.00028669724770642203
I2
I0
I2
tp6661
sS'reduced,by,with'
p6662
(F1
F0.00014334862385321102
I1
I0
I1
tp6663
sS'tests,may,be'
p6664
(F1
F0.00028669724770642203
I0
I2
I-2
tp6665
sS'by,other,manufacturers'
p6666
(F1
F0.00014334862385321102
I0
I1
I-1
tp6667
sS'may,cause,elevated'
p6668
(F1
F0.00014334862385321102
I1
I0
I1
tp6669
sS'when,therapy,with'
p6670
(F1
F0.00014334862385321102
I1
I0
I1
tp6671
sS'of,mg,in'
p6672
(F0.5
F0.00028669724770642203
I3
I1
I2
tp6673
sS'of,chronic,obstructive'
p6674
(F1
F0.00014334862385321102
I0
I1
I-1
tp6675
sS'very,low,compared'
p6676
(F1
F0.00014334862385321102
I0
I1
I-1
tp6677
sS'adjustments,of,should'
p6678
(F0
F0
I1
I1
I0
tp6679
sS'may,accentuate,the'
p6680
(F1
F0.00028669724770642203
I2
I0
I2
tp6681
sS'indocin,resulted,in'
p6682
(F1
F0.00014334862385321102
I1
I0
I1
tp6683
sS'in,inhibiting,cryptosporidium'
p6684
(F1
F0.00014334862385321102
I1
I0
I1
tp6685
sS'ergosterol,the,major'
p6686
(F1
F0.00014334862385321102
I0
I1
I-1
tp6687
sS'plus,haart,with'
p6688
(F1
F0.00014334862385321102
I0
I1
I-1
tp6689
sS'however,because,bleeding'
p6690
(F1
F0.00014334862385321102
I1
I0
I1
tp6691
sS'significantly,higher,as'
p6692
(F1
F0.00014334862385321102
I1
I0
I1
tp6693
sS'in,the,failing'
p6694
(F1
F0.00014334862385321102
I0
I1
I-1
tp6695
sS'taking,tricyclic,in'
p6696
(F1
F0.00014334862385321102
I1
I0
I1
tp6697
sS's,response,to'
p6698
(F1
F0.00014334862385321102
I1
I0
I1
tp6699
sS'medicines,with,may'
p6700
(F1
F0.00014334862385321102
I1
I0
I1
tp6701
sS'to,be,no'
p6702
(F1
F0.00014334862385321102
I0
I1
I-1
tp6703
sS'however,this,sample'
p6704
(F1
F0.00014334862385321102
I0
I1
I-1
tp6705
sS'either,singly,or'
p6706
(F1
F0.00014334862385321102
I0
I1
I-1
tp6707
sS'a,href,bupropz_od'
p6708
(F1
F0.00014334862385321102
I1
I0
I1
tp6709
sS'oral,mg,daily'
p6710
(F1
F0.00014334862385321102
I0
I1
I-1
tp6711
sS'of,the,sirolimus-diltiazem'
p6712
(F1
F0.00014334862385321102
I1
I0
I1
tp6713
sS'convulsions,have,been'
p6714
(F1
F0.00014334862385321102
I1
I0
I1
tp6715
sS'produced,by,explain'
p6716
(F1
F0.00014334862385321102
I1
I0
I1
tp6717
sS'clear,whether,this'
p6718
(F1
F0.00014334862385321102
I0
I1
I-1
tp6719
sS'increased,and,its'
p6720
(F1
F0.00014334862385321102
I1
I0
I1
tp6721
sS'auc,of,is'
p6722
(F1
F0.00014334862385321102
I1
I0
I1
tp6723
sS'and,of,innovar'
p6724
(F1
F0.00014334862385321102
I0
I1
I-1
tp6725
sS'and,the,inr'
p6726
(F1
F0.00014334862385321102
I0
I1
I-1
tp6727
sS'inhibitory,effect,of'
p6728
(F1
F0.00014334862385321102
I1
I0
I1
tp6729
sS'the,last,intravenous'
p6730
(F1
F0.00014334862385321102
I1
I0
I1
tp6731
sS'of,compounds,taken'
p6732
(F1
F0.00014334862385321102
I1
I0
I1
tp6733
sS'inhibitory,effect,on'
p6734
(F1
F0.00014334862385321102
I1
I0
I1
tp6735
sS'potent,loop,such'
p6736
(F1
F0.00014334862385321102
I1
I0
I1
tp6737
sS'such,as,myelosuppression'
p6738
(F1
F0.00014334862385321102
I1
I0
I1
tp6739
sS'of,toradol,to'
p6740
(F1
F0.00014334862385321102
I1
I0
I1
tp6741
sS'rating,scale,were'
p6742
(F1
F0.00014334862385321102
I1
I0
I1
tp6743
sS'inducers,and,cyp1a2'
p6744
(F1
F0.00014334862385321102
I0
I1
I-1
tp6745
sS'care,professional,know'
p6746
(F1
F0.00014334862385321102
I1
I0
I1
tp6747
sS'this,change,was'
p6748
(F1
F0.00014334862385321102
I0
I1
I-1
tp6749
sS'patients,taking,vioxx'
p6750
(F1
F0.00014334862385321102
I1
I0
I1
tp6751
sS'doses,mg,of'
p6752
(F1
F0.00014334862385321102
I1
I0
I1
tp6753
sS'to,days,for'
p6754
(F1
F0.00014334862385321102
I0
I1
I-1
tp6755
sS'dopamine-induced,renal,and'
p6756
(F1
F0.00014334862385321102
I0
I1
I-1
tp6757
sS'with,intramuscular,doses'
p6758
(F1
F0.00014334862385321102
I0
I1
I-1
tp6759
sS'medications,other,especially'
p6760
(F1
F0.00014334862385321102
I0
I1
I-1
tp6761
sS'in,particular,convulsions'
p6762
(F1
F0.00014334862385321102
I1
I0
I1
tp6763
sS'receiving,nalfon,and'
p6764
(F1
F0.00014334862385321102
I1
I0
I1
tp6765
sS'established,a,cause'
p6766
(F1
F0.00014334862385321102
I1
I0
I1
tp6767
sS'although,other,hormonal'
p6768
(F1
F0.00014334862385321102
I0
I1
I-1
tp6769
sS'to,the,lowest'
p6770
(F1
F0.00014334862385321102
I1
I0
I1
tp6771
sS'of,a,possible'
p6772
(F1
F0.00028669724770642203
I0
I2
I-2
tp6773
sS'with,potentially,nephrotoxic'
p6774
(F1
F0.00014334862385321102
I1
I0
I1
tp6775
sS'to,the,potential'
p6776
(F1
F0.00014334862385321102
I1
I0
I1
tp6777
sS'reports,suggest,that'
p6778
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp6779
sS'was,again,given'
p6780
(F1
F0.00014334862385321102
I0
I1
I-1
tp6781
sS'since,they,may'
p6782
(F1
F0.00014334862385321102
I0
I1
I-1
tp6783
sS'h2,blockers,although'
p6784
(F1
F0.00014334862385321102
I1
I0
I1
tp6785
sS'of,the,macrolide'
p6786
(F1
F0.00014334862385321102
I1
I0
I1
tp6787
sS'additive,effects,of'
p6788
(F1
F0.00014334862385321102
I1
I0
I1
tp6789
sS'therapeutic,effects,are'
p6790
(F1
F0.00014334862385321102
I1
I0
I1
tp6791
sS'may,diminish,its'
p6792
(F1
F0.00014334862385321102
I1
I0
I1
tp6793
sS'specific,d1,antagonist'
p6794
(F1
F0.00014334862385321102
I1
I0
I1
tp6795
sS'unique,biopharmaceutical,properties'
p6796
(F1
F0.00014334862385321102
I0
I1
I-1
tp6797
sS'of,gastric,acid'
p6798
(F1
F0.00014334862385321102
I1
I0
I1
tp6799
sS'inhibitors,prostaglandin,synthetase'
p6800
(F1
F0.00014334862385321102
I0
I1
I-1
tp6801
sS'juice,with,increases'
p6802
(F1
F0.00014334862385321102
I0
I1
I-1
tp6803
sS'history,of,serious'
p6804
(F1
F0.00014334862385321102
I1
I0
I1
tp6805
sS'metabolism,of,nonsedating'
p6806
(F1
F0.00014334862385321102
I1
I0
I1
tp6807
sS'to,cause,or'
p6808
(F1
F0.00014334862385321102
I0
I1
I-1
tp6809
sS'may,be,greater'
p6810
(F0
F0
I1
I1
I0
tp6811
sS'its,primary,cns'
p6812
(F1
F0.00014334862385321102
I1
I0
I1
tp6813
sS'profile,in,subjects'
p6814
(F1
F0.00014334862385321102
I0
I1
I-1
tp6815
sS'gastrointestinal,adverse,events'
p6816
(F1
F0.00014334862385321102
I0
I1
I-1
tp6817
sS'the,ionized,species'
p6818
(F1
F0.00028669724770642203
I2
I0
I2
tp6819
sS'increased,serum,potassium'
p6820
(F1
F0.00014334862385321102
I1
I0
I1
tp6821
sS'mg,orally,given'
p6822
(F1
F0.00014334862385321102
I0
I1
I-1
tp6823
sS'because,nalfon,has'
p6824
(F1
F0.00014334862385321102
I1
I0
I1
tp6825
sS'nanm,or,pcp'
p6826
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp6827
sS'be,monitored,particularly'
p6828
(F1
F0.00028669724770642203
I2
I0
I2
tp6829
sS'administration,and,on'
p6830
(F1
F0.00014334862385321102
I1
I0
I1
tp6831
sS'response,is,almost'
p6832
(F1
F0.00014334862385321102
I0
I1
I-1
tp6833
sS'was,increased,to'
p6834
(F1
F0.00014334862385321102
I1
I0
I1
tp6835
sS'acid,hepatotoxic,influenza'
p6836
(F1
F0.00014334862385321102
I1
I0
I1
tp6837
sS'the,mean,elimination'
p6838
(F1
F0.00028669724770642203
I2
I0
I2
tp6839
sS'induced,by,single'
p6840
(F1
F0.00014334862385321102
I1
I0
I1
tp6841
sS'over,several,days'
p6842
(F1
F0.00014334862385321102
I1
I0
I1
tp6843
sS'in,metabolic,clearance'
p6844
(F1
F0.00014334862385321102
I1
I0
I1
tp6845
sS'with,based,on'
p6846
(F1
F0.00014334862385321102
I0
I1
I-1
tp6847
sS'of,is,impaired'
p6848
(F1
F0.00043004587155963305
I3
I0
I3
tp6849
sS'additive,effects,with'
p6850
(F1
F0.00057339449541284407
I4
I0
I4
tp6851
sS'acid,derivatives,niacin'
p6852
(F1
F0.00014334862385321102
I0
I1
I-1
tp6853
sS'p-glycoprotein,loop,sparing'
p6854
(F1
F0.00014334862385321102
I0
I1
I-1
tp6855
sS'these,would,be'
p6856
(F1
F0.00014334862385321102
I1
I0
I1
tp6857
sS'antagonists,in,studies'
p6858
(F1
F0.00014334862385321102
I0
I1
I-1
tp6859
sS'of,or,with'
p6860
(F1
F0.00014334862385321102
I0
I1
I-1
tp6861
sS'combination,may,increase'
p6862
(F1
F0.00014334862385321102
I1
I0
I1
tp6863
sS'times,were,observed'
p6864
(F1
F0.00014334862385321102
I0
I1
I-1
tp6865
sS'of,a,direct'
p6866
(F1
F0.00014334862385321102
I0
I1
I-1
tp6867
sS'on,arteries,from'
p6868
(F1
F0.00014334862385321102
I0
I1
I-1
tp6869
sS'is,in,cardiovascular'
p6870
(F1
F0.00014334862385321102
I0
I1
I-1
tp6871
sS'healthy,subjects,receiving'
p6872
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp6873
sS'combination,hormonal,may'
p6874
(F1
F0.0011467889908256881
I8
I0
I8
tp6875
sS'intravenous,may,have'
p6876
(F1
F0.00014334862385321102
I1
I0
I1
tp6877
sS'added,beta-adrenergic,blocking'
p6878
(F1
F0.00014334862385321102
I1
I0
I1
tp6879
sS'in,glucose,concentrations'
p6880
(F1
F0.00014334862385321102
I1
I0
I1
tp6881
sS'with,which,cause'
p6882
(F1
F0.00028669724770642203
I2
I0
I2
tp6883
sS'prolong,the,qt'
p6884
(F1
F0.00028669724770642203
I2
I0
I2
tp6885
sS'against,taking,vitamin'
p6886
(F1
F0.00014334862385321102
I1
I0
I1
tp6887
sS'blockers,beta,blockers'
p6888
(F1
F0.00014334862385321102
I0
I1
I-1
tp6889
sS'is,primarily,metabolized'
p6890
(F1
F0.00057339449541284407
I0
I4
I-4
tp6891
sS'nonsteroidal,anti-inflammatory,have'
p6892
(F1
F0.00014334862385321102
I1
I0
I1
tp6893
sS'strength,mg,mg'
p6894
(F1
F0.00014334862385321102
I0
I1
I-1
tp6895
sS'effect,when,given'
p6896
(F1
F0.0008600917431192661
I6
I0
I6
tp6897
sS'lower,blood,pressure'
p6898
(F1
F0.00014334862385321102
I1
I0
I1
tp6899
sS'system,cyp3a4,therefore'
p6900
(F1
F0.00014334862385321102
I0
I1
I-1
tp6901
sS'with,concurrent,kineret'
p6902
(F1
F0.00014334862385321102
I1
I0
I1
tp6903
sS'dysfunction,by,increasing'
p6904
(F1
F0.00014334862385321102
I1
I0
I1
tp6905
sS'reactions,such,as'
p6906
(F1
F0.00057339449541284407
I0
I4
I-4
tp6907
sS'at,the,lower'
p6908
(F1
F0.00014334862385321102
I1
I0
I1
tp6909
sS'by,patients,on'
p6910
(F1
F0.00043004587155963305
I3
I0
I3
tp6911
sS'of,reportedly,are'
p6912
(F1
F0.00014334862385321102
I1
I0
I1
tp6913
sS'hydrochlorothiazide,in,normal'
p6914
(F1
F0.00014334862385321102
I1
I0
I1
tp6915
sS'nervous,system,regardless'
p6916
(F1
F0.00014334862385321102
I1
I0
I1
tp6917
sS'steady-state,concentrations,of'
p6918
(F1
F0.00014334862385321102
I0
I1
I-1
tp6919
sS'effects,of,supplementary'
p6920
(F1
F0.00014334862385321102
I0
I1
I-1
tp6921
sS'components,are,excreted'
p6922
(F1
F0.00014334862385321102
I0
I1
I-1
tp6923
sS'th,day,of'
p6924
(F1
F0.00014334862385321102
I1
I0
I1
tp6925
sS'the,second,study'
p6926
(F1
F0.00014334862385321102
I1
I0
I1
tp6927
sS'alterations,in,their'
p6928
(F1
F0.00014334862385321102
I1
I0
I1
tp6929
sS'the,oral,bioavailability'
p6930
(F1
F0.00028669724770642203
I2
I0
I2
tp6931
sS'was,more,likely'
p6932
(F1
F0.00014334862385321102
I0
I1
I-1
tp6933
sS'effect,of,pgf2alpha'
p6934
(F1
F0.00014334862385321102
I1
I0
I1
tp6935
sS'is,the,first'
p6936
(F1
F0.00014334862385321102
I0
I1
I-1
tp6937
sS'capsules,should,not'
p6938
(F1
F0.00014334862385321102
I0
I1
I-1
tp6939
sS'reduced,and,signs'
p6940
(F1
F0.00014334862385321102
I1
I0
I1
tp6941
sS'blunt,the,hypotensive'
p6942
(F1
F0.00028669724770642203
I2
I0
I2
tp6943
sS'pharmacokinetics,after,days'
p6944
(F1
F0.00014334862385321102
I0
I1
I-1
tp6945
sS'each,dose,administered'
p6946
(F1
F0.00014334862385321102
I0
I1
I-1
tp6947
sS'have,some,of'
p6948
(F1
F0.00014334862385321102
I0
I1
I-1
tp6949
sS'pi-based,therapy,for'
p6950
(F1
F0.00014334862385321102
I0
I1
I-1
tp6951
sS'nuromax,and,other'
p6952
(F1
F0.00014334862385321102
I0
I1
I-1
tp6953
sS'sodium,may,reduce'
p6954
(F1
F0.00014334862385321102
I1
I0
I1
tp6955
sS'induction,potential,should'
p6956
(F1
F0.00014334862385321102
I0
I1
I-1
tp6957
sS'displacement,of,by'
p6958
(F1
F0.00014334862385321102
I0
I1
I-1
tp6959
sS'the,same,proportions'
p6960
(F1
F0.00014334862385321102
I0
I1
I-1
tp6961
sS'not,altered,in'
p6962
(F1
F0.00014334862385321102
I0
I1
I-1
tp6963
sS'of,rashes,in'
p6964
(F1
F0.00014334862385321102
I1
I0
I1
tp6965
sS'cyp3a4,inhibitors,dasatinib'
p6966
(F1
F0.00014334862385321102
I0
I1
I-1
tp6967
sS'by,ergosterol,the'
p6968
(F1
F0.00014334862385321102
I0
I1
I-1
tp6969
sS'of,rashes,is'
p6970
(F1
F0.00014334862385321102
I1
I0
I1
tp6971
sS'period,in,healthy'
p6972
(F1
F0.00014334862385321102
I0
I1
I-1
tp6973
sS'with,may,produce'
p6974
(F0
F0
I1
I1
I0
tp6975
sS'marked,interference,with'
p6976
(F1
F0.00014334862385321102
I1
I0
I1
tp6977
sS'of,is,to'
p6978
(F1
F0.00014334862385321102
I1
I0
I1
tp6979
sS'reductase,inhibitors,should'
p6980
(F1
F0.00014334862385321102
I1
I0
I1
tp6981
sS'blockers,certain,hmg-coa'
p6982
(F1
F0.00014334862385321102
I1
I0
I1
tp6983
sS'and,administered,with'
p6984
(F1
F0.00014334862385321102
I0
I1
I-1
tp6985
sS'anticoagulants,altered,coagulation'
p6986
(F1
F0.00014334862385321102
I1
I0
I1
tp6987
sS'affected,significantly,with'
p6988
(F1
F0.00014334862385321102
I0
I1
I-1
tp6989
sS'an,interval,of'
p6990
(F1
F0.00014334862385321102
I1
I0
I1
tp6991
sS'in,response,to'
p6992
(F1
F0.00028669724770642203
I0
I2
I-2
tp6993
sS'of,a,previously'
p6994
(F1
F0.00028669724770642203
I2
I0
I2
tp6995
sS'and,study,with'
p6996
(F1
F0.00014334862385321102
I0
I1
I-1
tp6997
sS'different,before,and'
p6998
(F1
F0.00014334862385321102
I0
I1
I-1
tp6999
sS'of,as,a'
p7000
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp7001
sS'that,chronic,concurrent'
p7002
(F1
F0.00014334862385321102
I1
I0
I1
tp7003
sS'strain,were,divided'
p7004
(F1
F0.00014334862385321102
I0
I1
I-1
tp7005
sS'study,the,effect'
p7006
(F1
F0.00014334862385321102
I0
I1
I-1
tp7007
sS'mean,concentrations,of'
p7008
(F1
F0.00014334862385321102
I0
I1
I-1
tp7009
sS'non-depolarizing,muscle,relaxants'
p7010
(F1
F0.00014334862385321102
I1
I0
I1
tp7011
sS'of,as,v'
p7012
(F1
F0.00043004587155963305
I0
I3
I-3
tp7013
sS'that,also,markedly'
p7014
(F1
F0.00014334862385321102
I1
I0
I1
tp7015
sS'increasing,gastric,emptying'
p7016
(F1
F0.00014334862385321102
I1
I0
I1
tp7017
sS'ganglionic,or,peripheral'
p7018
(F1
F0.00014334862385321102
I0
I1
I-1
tp7019
sS'control,rats,whereas'
p7020
(F1
F0.00014334862385321102
I0
I1
I-1
tp7021
sS'mean,standard,deviation'
p7022
(F1
F0.00014334862385321102
I1
I0
I1
tp7023
sS'the,including,produce'
p7024
(F1
F0.00028669724770642203
I2
I0
I2
tp7025
sS'pronounced,if,a'
p7026
(F1
F0.00014334862385321102
I1
I0
I1
tp7027
sS'action,of,preparations'
p7028
(F1
F0.00014334862385321102
I1
I0
I1
tp7029
sS'subjects,and,bioavailability'
p7030
(F1
F0.00014334862385321102
I1
I0
I1
tp7031
sS'interval,for,placebo'
p7032
(F1
F0.00014334862385321102
I0
I1
I-1
tp7033
sS'oz,has,no'
p7034
(F1
F0.00014334862385321102
I0
I1
I-1
tp7035
sS'prophylactic,doses,of'
p7036
(F1
F0.00014334862385321102
I0
I1
I-1
tp7037
sS'and,tmax,vs'
p7038
(F1
F0.00014334862385321102
I0
I1
I-1
tp7039
sS'and,its,derivatives'
p7040
(F1
F0.00014334862385321102
I1
I0
I1
tp7041
sS'lanoxin,lanoxicaps,that'
p7042
(F1
F0.00014334862385321102
I1
I0
I1
tp7043
sS'flupenthixol,may,interact'
p7044
(F1
F0.00014334862385321102
I1
I0
I1
tp7045
sS'affect,patient,response'
p7046
(F1
F0.00014334862385321102
I0
I1
I-1
tp7047
sS'best,approach,in'
p7048
(F1
F0.00014334862385321102
I0
I1
I-1
tp7049
sS'laceration,especially,in'
p7050
(F1
F0.00014334862385321102
I1
I0
I1
tp7051
sS'of,staphylococcus,aureus'
p7052
(F1
F0.00014334862385321102
I1
I0
I1
tp7053
sS'administration,of,permits'
p7054
(F1
F0.00014334862385321102
I1
I0
I1
tp7055
sS'blood,which,could'
p7056
(F1
F0.00014334862385321102
I1
I0
I1
tp7057
sS'nonetheless,individual,patients'
p7058
(F1
F0.00014334862385321102
I1
I0
I1
tp7059
sS'therapy,dose,should'
p7060
(F1
F0.00028669724770642203
I2
I0
I2
tp7061
sS'frequently,and,monitored'
p7062
(F1
F0.00014334862385321102
I0
I1
I-1
tp7063
sS'and,in,treatment-experienced'
p7064
(F1
F0.00014334862385321102
I0
I1
I-1
tp7065
sS'of,mg,to'
p7066
(F1
F0.00014334862385321102
I1
I0
I1
tp7067
sS'ace,inhibitors,reports'
p7068
(F1
F0.00043004587155963305
I3
I0
I3
tp7069
sS'and,sucralfate,and'
p7070
(F1
F0.00014334862385321102
I1
I0
I1
tp7071
sS'bismuth,bismuth,subsalicylate'
p7072
(F1
F0.00014334862385321102
I1
I0
I1
tp7073
sS'that,these,aeds'
p7074
(F1
F0.00014334862385321102
I0
I1
I-1
tp7075
sS'signs,or,symptoms'
p7076
(F1
F0.00043004587155963305
I3
I0
I3
tp7077
sS'are,given,lodine'
p7078
(F1
F0.00014334862385321102
I0
I1
I-1
tp7079
sS'mg,qd,for'
p7080
(F0
F0
I1
I1
I0
tp7081
sS'eight,target,added'
p7082
(F1
F0.00014334862385321102
I0
I1
I-1
tp7083
sS'are,renally,eliminated'
p7084
(F1
F0.00014334862385321102
I0
I1
I-1
tp7085
sS'no,interactions,were'
p7086
(F1
F0.00014334862385321102
I0
I1
I-1
tp7087
sS'in,susceptible,patients'
p7088
(F1
F0.00014334862385321102
I1
I0
I1
tp7089
sS'diclofenac,like,other'
p7090
(F1
F0.00014334862385321102
I0
I1
I-1
tp7091
sS'before,intramuscular,injection'
p7092
(F1
F0.00014334862385321102
I1
I0
I1
tp7093
sS'cyp3a4,and,can'
p7094
(F1
F0.00014334862385321102
I1
I0
I1
tp7095
sS'deaths,have,been'
p7096
(F1
F0.00014334862385321102
I1
I0
I1
tp7097
sS'frequently,thereafter,and'
p7098
(F1
F0.00014334862385321102
I1
I0
I1
tp7099
sS'affecting,blood,elements'
p7100
(F1
F0.00014334862385321102
I1
I0
I1
tp7101
sS'as,proof,of'
p7102
(F1
F0.00014334862385321102
I0
I1
I-1
tp7103
sS'creatinine,despite,reduction'
p7104
(F1
F0.00014334862385321102
I0
I1
I-1
tp7105
sS'discriminate,between,deficiency'
p7106
(F1
F0.00014334862385321102
I0
I1
I-1
tp7107
sS'in,a,non-comparative'
p7108
(F1
F0.00014334862385321102
I1
I0
I1
tp7109
sS'prolongs,the,sleeping'
p7110
(F1
F0.00014334862385321102
I1
I0
I1
tp7111
sS'cellular,uptake,and'
p7112
(F1
F0.00014334862385321102
I1
I0
I1
tp7113
sS'may,intensify,the'
p7114
(F1
F0.00014334862385321102
I1
I0
I1
tp7115
sS'increases,the,inhibitory'
p7116
(F1
F0.00014334862385321102
I1
I0
I1
tp7117
sS'it,has,been'
p7118
(F0.5714285714285714
F0.0011467889908256881
I11
I3
I8
tp7119
sS'may,be,active'
p7120
(F1
F0.00014334862385321102
I1
I0
I1
tp7121
sS'toxic,product,erythro-fluorocitrate'
p7122
(F1
F0.00014334862385321102
I0
I1
I-1
tp7123
sS'significantly,affect,the'
p7124
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp7125
sS'transplant,recipients,over'
p7126
(F1
F0.00014334862385321102
I0
I1
I-1
tp7127
sS'are,either,added'
p7128
(F1
F0.00014334862385321102
I1
I0
I1
tp7129
sS'or,discontinue,pegasys'
p7130
(F1
F0.00014334862385321102
I0
I1
I-1
tp7131
sS'failure,and,dosage'
p7132
(F1
F0.00014334862385321102
I1
I0
I1
tp7133
sS'mcg,once,daily'
p7134
(F1
F0.00028669724770642203
I0
I2
I-2
tp7135
sS'hyperplasia,bph,psa'
p7136
(F1
F0.00014334862385321102
I0
I1
I-1
tp7137
sS'and,subcortical,structures'
p7138
(F1
F0.00014334862385321102
I0
I1
I-1
tp7139
sS'marked,symptomatic,orthostatic'
p7140
(F1
F0.00028669724770642203
I2
I0
I2
tp7141
sS'inhibition,of,p450'
p7142
(F1
F0.00014334862385321102
I1
I0
I1
tp7143
sS'are,analgesic,adjuvants'
p7144
(F1
F0.00014334862385321102
I0
I1
I-1
tp7145
sS'nutrient,absorption,in'
p7146
(F1
F0.00014334862385321102
I1
I0
I1
tp7147
sS'bind,other,given'
p7148
(F1
F0.00014334862385321102
I1
I0
I1
tp7149
sS'advisable,to,avoid'
p7150
(F1
F0.00014334862385321102
I1
I0
I1
tp7151
sS'receiving,replacement,therapy'
p7152
(F1
F0.00014334862385321102
I1
I0
I1
tp7153
sS'demonstrated,that,is'
p7154
(F1
F0.00014334862385321102
I1
I0
I1
tp7155
sS'conversely,the,administration'
p7156
(F1
F0.00014334862385321102
I0
I1
I-1
tp7157
sS'presence,of,at'
p7158
(F1
F0.00014334862385321102
I1
I0
I1
tp7159
sS'and,mm,had'
p7160
(F1
F0.00014334862385321102
I0
I1
I-1
tp7161
sS'after,concomitant,therapy'
p7162
(F1
F0.00014334862385321102
I1
I0
I1
tp7163
sS'that,of,subjects'
p7164
(F1
F0.00014334862385321102
I0
I1
I-1
tp7165
sS'levels,or,the'
p7166
(F1
F0.00014334862385321102
I0
I1
I-1
tp7167
sS'active,tubular,secretion'
p7168
(F0
F0
I1
I1
I0
tp7169
sS'sedation,or,potentially'
p7170
(F1
F0.00014334862385321102
I1
I0
I1
tp7171
sS'which,clearance,accelerated'
p7172
(F1
F0.00014334862385321102
I1
I0
I1
tp7173
sS'receiving,decreased,the'
p7174
(F1
F0.00014334862385321102
I1
I0
I1
tp7175
sS'mg,of,alone'
p7176
(F1
F0.00014334862385321102
I0
I1
I-1
tp7177
sS'higher,than,those'
p7178
(F1
F0.00014334862385321102
I1
I0
I1
tp7179
sS'interval,and,decrease'
p7180
(F1
F0.00014334862385321102
I0
I1
I-1
tp7181
sS'increased,interaction,should'
p7182
(F1
F0.00014334862385321102
I0
I1
I-1
tp7183
sS'and,variable,half-life'
p7184
(F1
F0.00014334862385321102
I0
I1
I-1
tp7185
sS'that,concurrent,administration'
p7186
(F1
F0.00014334862385321102
I1
I0
I1
tp7187
sS'in,concentrations,from'
p7188
(F1
F0.00014334862385321102
I1
I0
I1
tp7189
sS'when,new,agents'
p7190
(F1
F0.00014334862385321102
I0
I1
I-1
tp7191
sS'antidepressants,or,other'
p7192
(F1
F0.00014334862385321102
I0
I1
I-1
tp7193
sS'pharmacological,pharmacodynamic,interactions'
p7194
(F1
F0.00014334862385321102
I1
I0
I1
tp7195
sS'ergamisol,levamisole,hydrochloride'
p7196
(F1
F0.00014334862385321102
I1
I0
I1
tp7197
sS'such,as,hypotension'
p7198
(F1
F0.00014334862385321102
I0
I1
I-1
tp7199
sS'an,action,independent'
p7200
(F1
F0.00014334862385321102
I0
I1
I-1
tp7201
sS'and,qtc,intervals'
p7202
(F1
F0.00014334862385321102
I0
I1
I-1
tp7203
sS'control,should,not'
p7204
(F1
F0.00014334862385321102
I1
I0
I1
tp7205
sS'inhibitors,calcium-channel,blockers'
p7206
(F1
F0.00014334862385321102
I0
I1
I-1
tp7207
sS'also,in,switching'
p7208
(F1
F0.00057339449541284407
I4
I0
I4
tp7209
sS'influence,of,aed'
p7210
(F1
F0.00014334862385321102
I0
I1
I-1
tp7211
sS'two,controlled,crossover'
p7212
(F1
F0.00014334862385321102
I0
I1
I-1
tp7213
sS'to,those,obtained'
p7214
(F1
F0.00028669724770642203
I2
I0
I2
tp7215
sS'maleate,its,dose'
p7216
(F1
F0.00014334862385321102
I1
I0
I1
tp7217
sS'reflecting,the,absence'
p7218
(F1
F0.00014334862385321102
I0
I1
I-1
tp7219
sS'and,cause,qt'
p7220
(F1
F0.00014334862385321102
I0
I1
I-1
tp7221
sS'volatile,inhalation,are'
p7222
(F1
F0.00014334862385321102
I1
I0
I1
tp7223
sS'in,using,such'
p7224
(F1
F0.00014334862385321102
I1
I0
I1
tp7225
sS'pharmacokinetic,screening,in'
p7226
(F1
F0.00014334862385321102
I0
I1
I-1
tp7227
sS'agitation,progressing,to'
p7228
(F1
F0.00014334862385321102
I1
I0
I1
tp7229
sS'ophthalmic,and,systemic'
p7230
(F0
F0
I1
I1
I0
tp7231
sS'hydrocarbon,increase,cardiac'
p7232
(F1
F0.00014334862385321102
I1
I0
I1
tp7233
sS'develop,physiological,tolerance'
p7234
(F1
F0.00014334862385321102
I0
I1
I-1
tp7235
sS's,determined,on'
p7236
(F1
F0.00014334862385321102
I1
I0
I1
tp7237
sS'reported,in,some'
p7238
(F1
F0.00028669724770642203
I2
I0
I2
tp7239
sS'been,done,to'
p7240
(F1
F0.00014334862385321102
I1
I0
I1
tp7241
sS'mg,kg,and'
p7242
(F0
F0
I2
I2
I0
tp7243
sS'compared,to,co-administration'
p7244
(F1
F0.00014334862385321102
I0
I1
I-1
tp7245
sS'the,day,preferably'
p7246
(F1
F0.00014334862385321102
I0
I1
I-1
tp7247
sS'and,placebo,coadministered'
p7248
(F1
F0.00014334862385321102
I0
I1
I-1
tp7249
sS'the,less,active'
p7250
(F1
F0.00014334862385321102
I1
I0
I1
tp7251
sS'to,severe,cardiovascular'
p7252
(F1
F0.00014334862385321102
I1
I0
I1
tp7253
sS'some,patients,this'
p7254
(F1
F0.00014334862385321102
I0
I1
I-1
tp7255
sS'systemic,levels,of'
p7256
(F1
F0.00014334862385321102
I0
I1
I-1
tp7257
sS'to,avoid,possible'
p7258
(F1
F0.00043004587155963305
I3
I0
I3
tp7259
sS'on,the,anti-coagulant'
p7260
(F1
F0.00014334862385321102
I0
I1
I-1
tp7261
sS'enhance,the,possibility'
p7262
(F1
F0.00014334862385321102
I1
I0
I1
tp7263
sS'primidone,no,formal'
p7264
(F1
F0.00014334862385321102
I0
I1
I-1
tp7265
sS'known,to,alter'
p7266
(F1
F0.00014334862385321102
I1
I0
I1
tp7267
sS'twice,daily,taken'
p7268
(F1
F0.00014334862385321102
I1
I0
I1
tp7269
sS'pharmacokinetics,of,ethinyl'
p7270
(F1
F0.00028669724770642203
I0
I2
I-2
tp7271
sS'time,be,determined'
p7272
(F1
F0.00014334862385321102
I1
I0
I1
tp7273
sS'with,mg,b'
p7274
(F1
F0.00014334862385321102
I0
I1
I-1
tp7275
sS'd6,and,or'
p7276
(F1
F0.00014334862385321102
I0
I1
I-1
tp7277
sS'following,medicines,or'
p7278
(F1
F0.00014334862385321102
I1
I0
I1
tp7279
sS'on,diastolic,or'
p7280
(F1
F0.00014334862385321102
I0
I1
I-1
tp7281
sS'of,oral,such'
p7282
(F1
F0.00014334862385321102
I1
I0
I1
tp7283
sS'that,a,dosing'
p7284
(F1
F0.00014334862385321102
I0
I1
I-1
tp7285
sS'antiepileptic,drugs,phenytoin'
p7286
(F1
F0.00014334862385321102
I1
I0
I1
tp7287
sS'improvements,in,general'
p7288
(F1
F0.00014334862385321102
I0
I1
I-1
tp7289
sS'and,reduces,the'
p7290
(F1
F0.00028669724770642203
I2
I0
I2
tp7291
sS'slight,reduction,in'
p7292
(F1
F0.00014334862385321102
I1
I0
I1
tp7293
sS'not,change,the'
p7294
(F1
F0.00014334862385321102
I0
I1
I-1
tp7295
sS'marketed,chewable,dispersible'
p7296
(F1
F0.00014334862385321102
I1
I0
I1
tp7297
sS'bid,have,not'
p7298
(F1
F0.00014334862385321102
I0
I1
I-1
tp7299
sS'similar,study,with'
p7300
(F1
F0.00014334862385321102
I1
I0
I1
tp7301
sS'in,two,of'
p7302
(F1
F0.00014334862385321102
I1
I0
I1
tp7303
sS'increase,the,bioavailability'
p7304
(F1
F0.00028669724770642203
I2
I0
I2
tp7305
sS'a,drug-drug,interaction'
p7306
(F0
F0
I1
I1
I0
tp7307
sS'of,or,its'
p7308
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp7309
sS'protect,against,the'
p7310
(F1
F0.00014334862385321102
I1
I0
I1
tp7311
sS'a,two-way,interaction'
p7312
(F1
F0.00014334862385321102
I1
I0
I1
tp7313
sS'a,well-controlled,study'
p7314
(F1
F0.00014334862385321102
I0
I1
I-1
tp7315
sS'of,the,octapeptide'
p7316
(F1
F0.00014334862385321102
I0
I1
I-1
tp7317
sS'the,cyp450,isoenzymes'
p7318
(F1
F0.00014334862385321102
I0
I1
I-1
tp7319
sS'pgf2alpha,upon,the'
p7320
(F1
F0.00014334862385321102
I1
I0
I1
tp7321
sS'advised,to,monitor'
p7322
(F1
F0.00014334862385321102
I0
I1
I-1
tp7323
sS'suggestive,of,toxicity'
p7324
(F1
F0.00014334862385321102
I1
I0
I1
tp7325
sS'myopathy,and,rhabdomyolysis'
p7326
(F1
F0.00014334862385321102
I0
I1
I-1
tp7327
sS'are,vasoconstrictive,and'
p7328
(F1
F0.00014334862385321102
I1
I0
I1
tp7329
sS'a,and,lower'
p7330
(F1
F0.00014334862385321102
I0
I1
I-1
tp7331
sS'does,not,induce'
p7332
(F1
F0.00028669724770642203
I0
I2
I-2
tp7333
sS'combined,use,clinicians'
p7334
(F1
F0.00014334862385321102
I1
I0
I1
tp7335
sS'receiving,single,weekly'
p7336
(F1
F0.00014334862385321102
I0
I1
I-1
tp7337
sS'characterized,by,peripheral'
p7338
(F1
F0.00014334862385321102
I0
I1
I-1
tp7339
sS'mg,kg,subcutaneous'
p7340
(F1
F0.00014334862385321102
I0
I1
I-1
tp7341
sS'especially,important,that'
p7342
(F1
F0.00014334862385321102
I1
I0
I1
tp7343
sS'an,interaction,will'
p7344
(F1
F0.00014334862385321102
I1
I0
I1
tp7345
sS'a,slight,intrinsic'
p7346
(F1
F0.00014334862385321102
I1
I0
I1
tp7347
sS'levels,and,prolong'
p7348
(F1
F0.00014334862385321102
I1
I0
I1
tp7349
sS'with,the,conventional'
p7350
(F1
F0.00014334862385321102
I0
I1
I-1
tp7351
sS'of,serum,concentration'
p7352
(F1
F0.00014334862385321102
I1
I0
I1
tp7353
sS'accutane,to,a'
p7354
(F1
F0.00014334862385321102
I1
I0
I1
tp7355
sS'contraceptives,multiple,doses'
p7356
(F1
F0.00014334862385321102
I0
I1
I-1
tp7357
sS'been,reports,that'
p7358
(F1
F0.00014334862385321102
I1
I0
I1
tp7359
sS'with,a,may'
p7360
(F1
F0.00014334862385321102
I1
I0
I1
tp7361
sS'days,after,sudden'
p7362
(F1
F0.00014334862385321102
I1
I0
I1
tp7363
sS'in,vivo,by'
p7364
(F1
F0.00014334862385321102
I0
I1
I-1
tp7365
sS'does,not,inhibit'
p7366
(F1
F0.00028669724770642203
I0
I2
I-2
tp7367
sS'pharmacokinetic,parameter,values'
p7368
(F1
F0.00014334862385321102
I0
I1
I-1
tp7369
sS'mg,three,times'
p7370
(F0
F0
I2
I2
I0
tp7371
sS'orencia,and,tnf'
p7372
(F1
F0.00014334862385321102
I1
I0
I1
tp7373
sS'acid,derivatives,nicotinic'
p7374
(F1
F0.00014334862385321102
I0
I1
I-1
tp7375
sS'inhibit,p450,a2'
p7376
(F1
F0.00014334862385321102
I1
I0
I1
tp7377
sS'and,life-threatening,reactions'
p7378
(F1
F0.00014334862385321102
I0
I1
I-1
tp7379
sS'sumatriptan,there,have'
p7380
(F1
F0.00014334862385321102
I1
I0
I1
tp7381
sS'initiated,a,reduction'
p7382
(F1
F0.00014334862385321102
I0
I1
I-1
tp7383
sS'patients,under,therapy'
p7384
(F1
F0.00014334862385321102
I1
I0
I1
tp7385
sS'medrol,others,prelone'
p7386
(F1
F0.00014334862385321102
I0
I1
I-1
tp7387
sS'phenytoin,causes,an'
p7388
(F1
F0.00014334862385321102
I1
I0
I1
tp7389
sS'peptide,and,in'
p7390
(F1
F0.00014334862385321102
I0
I1
I-1
tp7391
sS'the,elimination,of'
p7392
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp7393
sS'plus,haart,on'
p7394
(F1
F0.00014334862385321102
I0
I1
I-1
tp7395
sS'non-steroidal,anti-inflammatory,agents'
p7396
(F1
F0.00071674311926605509
I5
I0
I5
tp7397
sS'was,coadministered,intravenously'
p7398
(F1
F0.00014334862385321102
I1
I0
I1
tp7399
sS'rarely,to,cause'
p7400
(F0
F0
I1
I1
I0
tp7401
sS'differential,effects,on'
p7402
(F1
F0.00014334862385321102
I0
I1
I-1
tp7403
sS'maximum,levels,meq'
p7404
(F1
F0.00014334862385321102
I0
I1
I-1
tp7405
sS'local,solutions,containing'
p7406
(F1
F0.00043004587155963305
I3
I0
I3
tp7407
sS'appropriate,dose,adjustments'
p7408
(F1
F0.00014334862385321102
I1
I0
I1
tp7409
sS'urticaria,require,immediate'
p7410
(F1
F0.00014334862385321102
I0
I1
I-1
tp7411
sS'the,vasodilating,effects'
p7412
(F1
F0.00043004587155963305
I3
I0
I3
tp7413
sS'of,the,following'
p7414
(F0
F0
I3
I3
I0
tp7415
sS'reduction,of,blood'
p7416
(F1
F0.00071674311926605509
I5
I0
I5
tp7417
sS'small,with,occasional'
p7418
(F1
F0.00014334862385321102
I0
I1
I-1
tp7419
sS'completely,blocked,the'
p7420
(F1
F0.00014334862385321102
I1
I0
I1
tp7421
sS'chemotherapeutic,agents,in'
p7422
(F1
F0.00014334862385321102
I0
I1
I-1
tp7423
sS'patient,requires,tikosyn'
p7424
(F1
F0.00014334862385321102
I1
I0
I1
tp7425
sS'toxicology,studies,showed'
p7426
(F1
F0.00014334862385321102
I0
I1
I-1
tp7427
sS'are,tolerated,in'
p7428
(F1
F0.00014334862385321102
I0
I1
I-1
tp7429
sS'effects,of,atrovent'
p7430
(F1
F0.00014334862385321102
I0
I1
I-1
tp7431
sS'serum,sex,hormone'
p7432
(F1
F0.00014334862385321102
I1
I0
I1
tp7433
sS'metabolite,which,may'
p7434
(F1
F0.00028669724770642203
I2
I0
I2
tp7435
sS'combination,of,before'
p7436
(F1
F0.00014334862385321102
I1
I0
I1
tp7437
sS'by,about,when'
p7438
(F1
F0.00028669724770642203
I2
I0
I2
tp7439
sS'include,acute,intake'
p7440
(F1
F0.00014334862385321102
I1
I0
I1
tp7441
sS'protease,inhibitors,nefazodone'
p7442
(F1
F0.00014334862385321102
I0
I1
I-1
tp7443
sS'of,administered,in'
p7444
(F1
F0.00014334862385321102
I1
I0
I1
tp7445
sS'published,information,on'
p7446
(F1
F0.00014334862385321102
I0
I1
I-1
tp7447
sS'c9,and,cyp'
p7448
(F1
F0.00014334862385321102
I0
I1
I-1
tp7449
sS'has,been,titrated'
p7450
(F0
F0
I2
I2
I0
tp7451
sS'compete,for,the'
p7452
(F1
F0.00014334862385321102
I0
I1
I-1
tp7453
sS'excretion,seen,during'
p7454
(F1
F0.00014334862385321102
I1
I0
I1
tp7455
sS'patients,or,their'
p7456
(F1
F0.00014334862385321102
I0
I1
I-1
tp7457
sS'gemzar,and,in'
p7458
(F1
F0.00014334862385321102
I0
I1
I-1
tp7459
sS'specific,and,aspecific'
p7460
(F1
F0.00014334862385321102
I0
I1
I-1
tp7461
sS'medications,with,activity'
p7462
(F0
F0
I3
I3
I0
tp7463
sS'approximately,twofold,from'
p7464
(F1
F0.00014334862385321102
I1
I0
I1
tp7465
sS'the,benefits,of'
p7466
(F1
F0.00014334862385321102
I1
I0
I1
tp7467
sS'its,active,hydroxy'
p7468
(F1
F0.00014334862385321102
I1
I0
I1
tp7469
sS'be,avoided,unless'
p7470
(F1
F0.00028669724770642203
I2
I0
I2
tp7471
sS'and,may,potentiate'
p7472
(F1
F0.00014334862385321102
I1
I0
I1
tp7473
sS'were,more,efficiently'
p7474
(F1
F0.00014334862385321102
I0
I1
I-1
tp7475
sS'that,not,be'
p7476
(F1
F0.00014334862385321102
I1
I0
I1
tp7477
sS'b-,induced,hypokalemia'
p7478
(F1
F0.00014334862385321102
I1
I0
I1
tp7479
sS'and,similar,compounds'
p7480
(F1
F0.00014334862385321102
I0
I1
I-1
tp7481
sS'inhibitors,grapefruit,juice'
p7482
(F1
F0.00014334862385321102
I1
I0
I1
tp7483
sS'times,day,days'
p7484
(F1
F0.00014334862385321102
I0
I1
I-1
tp7485
sS'of,cyp3a4,substrate'
p7486
(F1
F0.00014334862385321102
I1
I0
I1
tp7487
sS'of,sympatholytic,medicinal'
p7488
(F1
F0.00028669724770642203
I0
I2
I-2
tp7489
sS'day,each,volunteer'
p7490
(F1
F0.00014334862385321102
I0
I1
I-1
tp7491
sS'instruct,the,patient'
p7492
(F1
F0.00014334862385321102
I0
I1
I-1
tp7493
sS'patients,taking,to'
p7494
(F1
F0.00014334862385321102
I1
I0
I1
tp7495
sS'exercised,when,known'
p7496
(F1
F0.00014334862385321102
I0
I1
I-1
tp7497
sS'betagan,used,alone'
p7498
(F1
F0.00014334862385321102
I1
I0
I1
tp7499
sS'with,brevibloc,esmolol'
p7500
(F1
F0.00014334862385321102
I0
I1
I-1
tp7501
sS'and,hydroxide-containing,maalox'
p7502
(F1
F0.00014334862385321102
I0
I1
I-1
tp7503
sS'active,isomer,of'
p7504
(F1
F0.00014334862385321102
I1
I0
I1
tp7505
sS'reported,to,occur'
p7506
(F1
F0.00014334862385321102
I1
I0
I1
tp7507
sS'of,pcp,treatment'
p7508
(F1
F0.00014334862385321102
I1
I0
I1
tp7509
sS'in,proportion,to'
p7510
(F1
F0.00014334862385321102
I0
I1
I-1
tp7511
sS'occasionally,been,associated'
p7512
(F1
F0.00014334862385321102
I0
I1
I-1
tp7513
sS'concomitantly,with,mao'
p7514
(F1
F0.00014334862385321102
I1
I0
I1
tp7515
sS'absorption,in,the'
p7516
(F1
F0.00014334862385321102
I1
I0
I1
tp7517
sS'alveolar,concentration,may'
p7518
(F1
F0.00014334862385321102
I1
I0
I1
tp7519
sS'interactions,amphetamines,can'
p7520
(F1
F0.00014334862385321102
I1
I0
I1
tp7521
sS'compounds,attenuate,morphine-induced'
p7522
(F1
F0.00014334862385321102
I0
I1
I-1
tp7523
sS'by,camptosar,the'
p7524
(F1
F0.00014334862385321102
I1
I0
I1
tp7525
sS'oxidase,mao,inhibitors'
p7526
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp7527
sS'doses,of,factive'
p7528
(F1
F0.00014334862385321102
I0
I1
I-1
tp7529
sS'chronic,dosing,is'
p7530
(F1
F0.00014334862385321102
I0
I1
I-1
tp7531
sS'protease,inhibitors,or'
p7532
(F1
F0.00014334862385321102
I0
I1
I-1
tp7533
sS'of,dosing,reduced'
p7534
(F1
F0.00014334862385321102
I0
I1
I-1
tp7535
sS'blocked,the,tail-flick'
p7536
(F1
F0.00014334862385321102
I1
I0
I1
tp7537
sS'prolong,the,duration'
p7538
(F1
F0.00014334862385321102
I1
I0
I1
tp7539
sS'vital,signs,and'
p7540
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp7541
sS'receiving,for,heart'
p7542
(F1
F0.00014334862385321102
I0
I1
I-1
tp7543
sS'has,been,observed'
p7544
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp7545
sS'strains,of,enterococcus'
p7546
(F1
F0.00028669724770642203
I0
I2
I-2
tp7547
sS'increase,blood,glucose'
p7548
(F1
F0.00014334862385321102
I1
I0
I1
tp7549
sS'administration,of,sprycel'
p7550
(F1
F0.00014334862385321102
I1
I0
I1
tp7551
sS'to,such,as'
p7552
(F1
F0.00028669724770642203
I0
I2
I-2
tp7553
sS'several,aed,s'
p7554
(F1
F0.00014334862385321102
I1
I0
I1
tp7555
sS'indifferent,for,and'
p7556
(F1
F0.00014334862385321102
I1
I0
I1
tp7557
sS'carefully,monitored,and'
p7558
(F1
F0.00014334862385321102
I1
I0
I1
tp7559
sS'increased,incidence,of'
p7560
(F0
F0
I1
I1
I0
tp7561
sS'from,the,peritoneal'
p7562
(F1
F0.00014334862385321102
I0
I1
I-1
tp7563
sS'reduce,renal,function'
p7564
(F1
F0.00014334862385321102
I0
I1
I-1
tp7565
sS'inhibitors,guanethidine,or'
p7566
(F1
F0.00014334862385321102
I0
I1
I-1
tp7567
sS'interactions,were,assessed'
p7568
(F1
F0.00014334862385321102
I0
I1
I-1
tp7569
sS'to,examine,some'
p7570
(F1
F0.00014334862385321102
I0
I1
I-1
tp7571
sS'use,of,sodium'
p7572
(F1
F0.00014334862385321102
I1
I0
I1
tp7573
sS'the,mg,h'
p7574
(F1
F0.00014334862385321102
I1
I0
I1
tp7575
sS'taken,at,least'
p7576
(F1
F0.0008600917431192661
I6
I0
I6
tp7577
sS'bound,to,the'
p7578
(F1
F0.00014334862385321102
I0
I1
I-1
tp7579
sS'safely,to,patients'
p7580
(F1
F0.00014334862385321102
I0
I1
I-1
tp7581
sS'to,days,has'
p7582
(F1
F0.00014334862385321102
I0
I1
I-1
tp7583
sS'each,study,volunteers'
p7584
(F1
F0.00014334862385321102
I0
I1
I-1
tp7585
sS'not,been,associated'
p7586
(F1
F0.00014334862385321102
I0
I1
I-1
tp7587
sS'most,and,invalidate'
p7588
(F1
F0.00014334862385321102
I0
I1
I-1
tp7589
sS'avoid,possible,over-'
p7590
(F1
F0.00043004587155963305
I3
I0
I3
tp7591
sS'auc,a,single'
p7592
(F1
F0.00014334862385321102
I1
I0
I1
tp7593
sS'derivatives,niacin,nicotinic'
p7594
(F1
F0.00014334862385321102
I0
I1
I-1
tp7595
sS'therapy,is,required'
p7596
(F1
F0.00014334862385321102
I1
I0
I1
tp7597
sS'and,should,be'
p7598
(F0.81818181818181823
F0.0012901376146788992
I10
I1
I9
tp7599
sS'case,report,of'
p7600
(F1
F0.00014334862385321102
I1
I0
I1
tp7601
sS'were,identified,in'
p7602
(F1
F0.00014334862385321102
I1
I0
I1
tp7603
sS'of,pharmacologic,effects'
p7604
(F1
F0.00014334862385321102
I1
I0
I1
tp7605
sS'immunoreactive,concentrations,were'
p7606
(F1
F0.00014334862385321102
I0
I1
I-1
tp7607
sS'of,therapy,and'
p7608
(F0
F0
I2
I2
I0
tp7609
sS'based,on,in'
p7610
(F1
F0.00028669724770642203
I2
I0
I2
tp7611
sS'of,hydrochloride,does'
p7612
(F1
F0.00014334862385321102
I0
I1
I-1
tp7613
sS'to,open,air'
p7614
(F1
F0.00014334862385321102
I1
I0
I1
tp7615
sS'was,reported,in'
p7616
(F1
F0.00014334862385321102
I1
I0
I1
tp7617
sS'explained,by,a'
p7618
(F1
F0.00014334862385321102
I1
I0
I1
tp7619
sS'one-third,to,one-half'
p7620
(F1
F0.00014334862385321102
I0
I1
I-1
tp7621
sS'of,the,ingested'
p7622
(F1
F0.00014334862385321102
I1
I0
I1
tp7623
sS'of,indigestion,remedies'
p7624
(F1
F0.00014334862385321102
I1
I0
I1
tp7625
sS'the,other,currently'
p7626
(F1
F0.00014334862385321102
I0
I1
I-1
tp7627
sS'the,steady-state,cmin'
p7628
(F1
F0.00028669724770642203
I2
I0
I2
tp7629
sS'with,at,high'
p7630
(F1
F0.00014334862385321102
I1
I0
I1
tp7631
sS'an,used,to'
p7632
(F1
F0.00014334862385321102
I0
I1
I-1
tp7633
sS'acute,ergot,toxicity'
p7634
(F1
F0.00014334862385321102
I0
I1
I-1
tp7635
sS'pharmacokinetics,of,cancidas'
p7636
(F1
F0.00014334862385321102
I0
I1
I-1
tp7637
sS'vitro,metabolism,studies'
p7638
(F1
F0.00014334862385321102
I0
I1
I-1
tp7639
sS'is,due,to'
p7640
(F0.5
F0.00028669724770642203
I3
I1
I2
tp7641
sS'on,day9,of'
p7642
(F1
F0.00014334862385321102
I1
I0
I1
tp7643
sS'protease,inhibitors,indinavir'
p7644
(F1
F0.00014334862385321102
I1
I0
I1
tp7645
sS'be,increased,during'
p7646
(F1
F0.00014334862385321102
I1
I0
I1
tp7647
sS'adrenergic,are,to'
p7648
(F1
F0.00014334862385321102
I1
I0
I1
tp7649
sS'and,mg,kg'
p7650
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp7651
sS'inhibit,the,desired'
p7652
(F1
F0.00014334862385321102
I1
I0
I1
tp7653
sS'including,and,have'
p7654
(F1
F0.00014334862385321102
I0
I1
I-1
tp7655
sS'maintain,concentrations,within'
p7656
(F1
F0.00014334862385321102
I0
I1
I-1
tp7657
sS'increased,lipid,levels'
p7658
(F1
F0.00014334862385321102
I0
I1
I-1
tp7659
sS'p450,a4,cyp3a4'
p7660
(F1
F0.00014334862385321102
I0
I1
I-1
tp7661
sS'to,high,inter-patient'
p7662
(F1
F0.00014334862385321102
I0
I1
I-1
tp7663
sS'and,cyp2c8,in'
p7664
(F1
F0.00014334862385321102
I0
I1
I-1
tp7665
sS'meth,has,been'
p7666
(F1
F0.00014334862385321102
I0
I1
I-1
tp7667
sS'is,potentiated,and'
p7668
(F1
F0.00028669724770642203
I2
I0
I2
tp7669
sS'and,were,co-administered'
p7670
(F1
F0.00014334862385321102
I1
I0
I1
tp7671
sS'therapy,on,the'
p7672
(F1
F0.00014334862385321102
I1
I0
I1
tp7673
sS'multivalent,cations,including'
p7674
(F1
F0.00014334862385321102
I1
I0
I1
tp7675
sS'in,healthy,young'
p7676
(F1
F0.00014334862385321102
I0
I1
I-1
tp7677
sS'romazicon,blocks,the'
p7678
(F1
F0.00014334862385321102
I1
I0
I1
tp7679
sS'been,reported,upon'
p7680
(F1
F0.00014334862385321102
I1
I0
I1
tp7681
sS'antagonize,the,neuron'
p7682
(F1
F0.00014334862385321102
I1
I0
I1
tp7683
sS'to,serum,proteins'
p7684
(F1
F0.00014334862385321102
I1
I0
I1
tp7685
sS'of,adverse,experiences'
p7686
(F1
F0.00014334862385321102
I1
I0
I1
tp7687
sS'patients,receiving,concomitant'
p7688
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp7689
sS'environmental,may,alter'
p7690
(F1
F0.00014334862385321102
I1
I0
I1
tp7691
sS'viii,ix,and'
p7692
(F1
F0.00014334862385321102
I0
I1
I-1
tp7693
sS'in,rheumatoid,arthritis'
p7694
(F1
F0.00028669724770642203
I0
I2
I-2
tp7695
sS'two,other,cell'
p7696
(F1
F0.00014334862385321102
I1
I0
I1
tp7697
sS'estimates,of,steady-state'
p7698
(F1
F0.00014334862385321102
I0
I1
I-1
tp7699
sS'because,of,foscarnets'
p7700
(F1
F0.00014334862385321102
I1
I0
I1
tp7701
sS'standard,monitoring,of'
p7702
(F0
F0
I1
I1
I0
tp7703
sS'and,weight,gain'
p7704
(F1
F0.00014334862385321102
I1
I0
I1
tp7705
sS'in,insulin-dependent,diabetic'
p7706
(F1
F0.00014334862385321102
I0
I1
I-1
tp7707
sS'should,consider,starting'
p7708
(F1
F0.00014334862385321102
I0
I1
I-1
tp7709
sS'of,nonsteroial,anti-inflammatory'
p7710
(F1
F0.00014334862385321102
I1
I0
I1
tp7711
sS'patient,was,also'
p7712
(F1
F0.00014334862385321102
I0
I1
I-1
tp7713
sS'that,a,statistically'
p7714
(F1
F0.00014334862385321102
I0
I1
I-1
tp7715
sS'be,administered,orally'
p7716
(F1
F0.00014334862385321102
I1
I0
I1
tp7717
sS'laboratory,tests,performed'
p7718
(F1
F0.00014334862385321102
I0
I1
I-1
tp7719
sS'thrombolytic,agents,the'
p7720
(F1
F0.00014334862385321102
I0
I1
I-1
tp7721
sS'in,uterine,hypertonus'
p7722
(F1
F0.00014334862385321102
I1
I0
I1
tp7723
sS'gris-peg,nizoral,sporanox'
p7724
(F1
F0.00014334862385321102
I1
I0
I1
tp7725
sS'a,year,controlled'
p7726
(F1
F0.00014334862385321102
I0
I1
I-1
tp7727
sS'at,lower,doses'
p7728
(F1
F0.00014334862385321102
I1
I0
I1
tp7729
sS'that,decreases,stomach'
p7730
(F1
F0.00014334862385321102
I0
I1
I-1
tp7731
sS'all,prescription,and'
p7732
(F1
F0.00014334862385321102
I0
I1
I-1
tp7733
sS'had,no,effect'
p7734
(F0.65000000000000002
F0.0037270642201834864
I7
I33
I-26
tp7735
sS'rate,of,elimination'
p7736
(F1
F0.00028669724770642203
I2
I0
I2
tp7737
sS'dental,complications,blurred'
p7738
(F1
F0.00014334862385321102
I1
I0
I1
tp7739
sS'exjade,had,no'
p7740
(F1
F0.00014334862385321102
I0
I1
I-1
tp7741
sS'using,long-acting,or'
p7742
(F1
F0.00014334862385321102
I1
I0
I1
tp7743
sS'decrease,in,excretion'
p7744
(F1
F0.00014334862385321102
I1
I0
I1
tp7745
sS'or,other,concurrent'
p7746
(F1
F0.00014334862385321102
I1
I0
I1
tp7747
sS'acidic,such,as'
p7748
(F1
F0.00014334862385321102
I1
I0
I1
tp7749
sS'hypercholesterolemic,patients,steady-state'
p7750
(F1
F0.00014334862385321102
I1
I0
I1
tp7751
sS'four,chemotherapeutic,agents'
p7752
(F1
F0.00014334862385321102
I0
I1
I-1
tp7753
sS'exposure,and,active'
p7754
(F1
F0.00014334862385321102
I1
I0
I1
tp7755
sS'mg,bid,have'
p7756
(F1
F0.00014334862385321102
I0
I1
I-1
tp7757
sS'chronic,weeks,oral'
p7758
(F1
F0.00014334862385321102
I0
I1
I-1
tp7759
sS'to,other,asthma'
p7760
(F1
F0.00014334862385321102
I0
I1
I-1
tp7761
sS'on,in,vitro'
p7762
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp7763
sS'when,lexapro,and'
p7764
(F1
F0.00014334862385321102
I1
I0
I1
tp7765
sS'prevent,absorption,of'
p7766
(F1
F0.00014334862385321102
I0
I1
I-1
tp7767
sS'dsm-iv,diagnosed,schizophrenia'
p7768
(F1
F0.00014334862385321102
I1
I0
I1
tp7769
sS'platelet,function,there'
p7770
(F1
F0.00014334862385321102
I1
I0
I1
tp7771
sS'the,commonly,used'
p7772
(F1
F0.00014334862385321102
I0
I1
I-1
tp7773
sS'is,potentially,toxic'
p7774
(F1
F0.00014334862385321102
I0
I1
I-1
tp7775
sS'extend,the,half-life'
p7776
(F1
F0.00014334862385321102
I1
I0
I1
tp7777
sS'measuring,locomotor,activity'
p7778
(F1
F0.00014334862385321102
I0
I1
I-1
tp7779
sS'agents,have,not'
p7780
(F1
F0.00028669724770642203
I0
I2
I-2
tp7781
sS'twice-daily,with,resulted'
p7782
(F1
F0.00014334862385321102
I1
I0
I1
tp7783
sS'of,serum,binding'
p7784
(F1
F0.00014334862385321102
I1
I0
I1
tp7785
sS'concurrent,therapy,discontinuation'
p7786
(F1
F0.00014334862385321102
I1
I0
I1
tp7787
sS'preparations,containing,or'
p7788
(F0
F0
I1
I1
I0
tp7789
sS'spinal,endorphinergic,system'
p7790
(F1
F0.00014334862385321102
I0
I1
I-1
tp7791
sS'the,bioavailability,auc'
p7792
(F1
F0.00014334862385321102
I1
I0
I1
tp7793
sS'when,nsaids,are'
p7794
(F1
F0.00014334862385321102
I1
I0
I1
tp7795
sS'bind,the,and'
p7796
(F1
F0.00014334862385321102
I1
I0
I1
tp7797
sS'sulfapyridine,may,interact'
p7798
(F1
F0.00014334862385321102
I1
I0
I1
tp7799
sS'cardiac,abnormalities,arrhythmia'
p7800
(F1
F0.00014334862385321102
I1
I0
I1
tp7801
sS'diuretics,fosinopril,sodium'
p7802
(F1
F0.00014334862385321102
I1
I0
I1
tp7803
sS'mg,day,of'
p7804
(F0
F0
I3
I3
I0
tp7805
sS'other,caution,is'
p7806
(F1
F0.00028669724770642203
I2
I0
I2
tp7807
sS'evidence,in,the'
p7808
(F1
F0.00014334862385321102
I0
I1
I-1
tp7809
sS'potentiate,the,analgesic'
p7810
(F1
F0.00014334862385321102
I1
I0
I1
tp7811
sS'mg,day,on'
p7812
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp7813
sS'was,unaffected,by'
p7814
(F1
F0.00014334862385321102
I1
I0
I1
tp7815
sS'altered,serum,levels'
p7816
(F1
F0.00014334862385321102
I1
I0
I1
tp7817
sS'nsaids,concomitant,administration'
p7818
(F1
F0.00028669724770642203
I2
I0
I2
tp7819
sS'be,transiently,elevated'
p7820
(F1
F0.00014334862385321102
I0
I1
I-1
tp7821
sS'to,approximately,one-third'
p7822
(F1
F0.00014334862385321102
I1
I0
I1
tp7823
sS'normal,and,genetically'
p7824
(F1
F0.00014334862385321102
I0
I1
I-1
tp7825
sS'nonbenzodiazepine,agonists,at'
p7826
(F1
F0.00014334862385321102
I1
I0
I1
tp7827
sS'by,its,ability'
p7828
(F1
F0.00014334862385321102
I1
I0
I1
tp7829
sS'moderate,to,marked'
p7830
(F1
F0.00014334862385321102
I1
I0
I1
tp7831
sS'but,mc,potentiates'
p7832
(F1
F0.00014334862385321102
I1
I0
I1
tp7833
sS'trials,have,been'
p7834
(F0
F0
I1
I1
I0
tp7835
sS'm,v,to'
p7836
(F1
F0.00014334862385321102
I0
I1
I-1
tp7837
sS'casodex,is,started'
p7838
(F1
F0.00014334862385321102
I1
I0
I1
tp7839
sS'a,dysregulation,of'
p7840
(F1
F0.00014334862385321102
I0
I1
I-1
tp7841
sS'without,an,agent'
p7842
(F1
F0.00014334862385321102
I1
I0
I1
tp7843
sS'sustiva,is,recommended'
p7844
(F1
F0.00014334862385321102
I0
I1
I-1
tp7845
sS'elimination,of,and'
p7846
(F1
F0.00014334862385321102
I0
I1
I-1
tp7847
sS'the,inhibition,of'
p7848
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp7849
sS'response,in,man'
p7850
(F1
F0.00043004587155963305
I3
I0
I3
tp7851
sS'v,v,solution'
p7852
(F1
F0.00014334862385321102
I0
I1
I-1
tp7853
sS'fr,schedule,of'
p7854
(F1
F0.00014334862385321102
I0
I1
I-1
tp7855
sS'required,to,antagonize'
p7856
(F1
F0.00014334862385321102
I1
I0
I1
tp7857
sS'phencyclidine,pcp,produces'
p7858
(F1
F0.00014334862385321102
I0
I1
I-1
tp7859
sS'administration,of,may'
p7860
(F1
F0.00043004587155963305
I3
I0
I3
tp7861
sS'a,hour,period'
p7862
(F1
F0.0010034403669724771
I7
I0
I7
tp7863
sS'eliminated,from,the'
p7864
(F1
F0.00014334862385321102
I1
I0
I1
tp7865
sS'effects,on,dosing'
p7866
(F1
F0.00014334862385321102
I0
I1
I-1
tp7867
sS'in,whom,either'
p7868
(F1
F0.00014334862385321102
I0
I1
I-1
tp7869
sS'plasma,is,not'
p7870
(F1
F0.00014334862385321102
I0
I1
I-1
tp7871
sS'interactions,were,found'
p7872
(F1
F0.00014334862385321102
I0
I1
I-1
tp7873
sS'the,trans-diol,by'
p7874
(F1
F0.00014334862385321102
I0
I1
I-1
tp7875
sS'shown,that,small'
p7876
(F1
F0.00014334862385321102
I0
I1
I-1
tp7877
sS'of,these,interactions'
p7878
(F1
F0.00014334862385321102
I0
I1
I-1
tp7879
sS'even,when,was'
p7880
(F1
F0.00014334862385321102
I1
I0
I1
tp7881
sS'the,present,work'
p7882
(F1
F0.00014334862385321102
I0
I1
I-1
tp7883
sS'resulting,in,concentrations'
p7884
(F1
F0.00014334862385321102
I1
I0
I1
tp7885
sS'but,no,clinically'
p7886
(F1
F0.00014334862385321102
I1
I0
I1
tp7887
sS'or,corticosteroids,or'
p7888
(F1
F0.00014334862385321102
I0
I1
I-1
tp7889
sS'provide,the,patient'
p7890
(F1
F0.00014334862385321102
I0
I1
I-1
tp7891
sS'and,collected,by'
p7892
(F1
F0.00014334862385321102
I0
I1
I-1
tp7893
sS'of,dosage,should'
p7894
(F1
F0.00014334862385321102
I0
I1
I-1
tp7895
sS'employing,mtc-mdp,as'
p7896
(F1
F0.00014334862385321102
I0
I1
I-1
tp7897
sS'to,the,treatment'
p7898
(F1
F0.00014334862385321102
I1
I0
I1
tp7899
sS'discontinuation,of,a'
p7900
(F1
F0.00014334862385321102
I1
I0
I1
tp7901
sS'note,dissolution,of'
p7902
(F1
F0.00014334862385321102
I0
I1
I-1
tp7903
sS'and,triazole,have'
p7904
(F1
F0.00014334862385321102
I0
I1
I-1
tp7905
sS'associated,with,the'
p7906
(F0.5
F0.00028669724770642203
I3
I1
I2
tp7907
sS'are,no,clinical'
p7908
(F1
F0.00014334862385321102
I0
I1
I-1
tp7909
sS'more,frequently,with'
p7910
(F1
F0.00014334862385321102
I0
I1
I-1
tp7911
sS'doses,because,of'
p7912
(F1
F0.00014334862385321102
I1
I0
I1
tp7913
sS'fat-soluble,including,vitamin'
p7914
(F1
F0.00014334862385321102
I1
I0
I1
tp7915
sS'to,phenytoin,intoxication'
p7916
(F1
F0.00014334862385321102
I1
I0
I1
tp7917
sS'of,oral,administration'
p7918
(F1
F0.00014334862385321102
I1
I0
I1
tp7919
sS'positive,reaction,at'
p7920
(F1
F0.00014334862385321102
I0
I1
I-1
tp7921
sS'or,dialysis,may'
p7922
(F1
F0.00014334862385321102
I1
I0
I1
tp7923
sS'of,young,healthy'
p7924
(F1
F0.00014334862385321102
I0
I1
I-1
tp7925
sS'with,higher,doses'
p7926
(F1
F0.00014334862385321102
I1
I0
I1
tp7927
sS'with,triamterene,concomitant'
p7928
(F1
F0.00014334862385321102
I0
I1
I-1
tp7929
sS'presence,of,phenolic'
p7930
(F1
F0.00014334862385321102
I0
I1
I-1
tp7931
sS'longer,in,the'
p7932
(F0
F0
I1
I1
I0
tp7933
sS'blocking,agents,now'
p7934
(F1
F0.00014334862385321102
I0
I1
I-1
tp7935
sS'conjugation,through,udp-glucuronyl'
p7936
(F1
F0.00014334862385321102
I0
I1
I-1
tp7937
sS'of,the,increase'
p7938
(F1
F0.00014334862385321102
I0
I1
I-1
tp7939
sS'tested,for,subjects'
p7940
(F1
F0.00014334862385321102
I0
I1
I-1
tp7941
sS'antagonists,since,is'
p7942
(F1
F0.00014334862385321102
I1
I0
I1
tp7943
sS'patients,stabilized,on'
p7944
(F1
F0.00014334862385321102
I1
I0
I1
tp7945
sS'patients,receiving,could'
p7946
(F1
F0.00014334862385321102
I0
I1
I-1
tp7947
sS'inhibitors,of,p-glycoprotein'
p7948
(F1
F0.00014334862385321102
I0
I1
I-1
tp7949
sS'had,minimal,effects'
p7950
(F1
F0.00014334862385321102
I0
I1
I-1
tp7951
sS'therapeutic,index,including'
p7952
(F1
F0.00014334862385321102
I1
I0
I1
tp7953
sS'although,clinical,studies'
p7954
(F1
F0.00028669724770642203
I2
I0
I2
tp7955
sS'those,elevations,of'
p7956
(F1
F0.00014334862385321102
I0
I1
I-1
tp7957
sS'locomotor,activity,and'
p7958
(F1
F0.00014334862385321102
I0
I1
I-1
tp7959
sS'of,conjugated,and'
p7960
(F1
F0.00014334862385321102
I0
I1
I-1
tp7961
sS'study,of,with'
p7962
(F1
F0.00028669724770642203
I0
I2
I-2
tp7963
sS'benefits,of,this'
p7964
(F1
F0.00014334862385321102
I1
I0
I1
tp7965
sS'heparin,since,is'
p7966
(F1
F0.00014334862385321102
I0
I1
I-1
tp7967
sS'exercised,in,using'
p7968
(F1
F0.00014334862385321102
I0
I1
I-1
tp7969
sS'regularly,for,alterations'
p7970
(F1
F0.00014334862385321102
I1
I0
I1
tp7971
sS'resulting,in,elevated'
p7972
(F0.5
F0.00028669724770642203
I3
I1
I2
tp7973
sS'to,when,compared'
p7974
(F1
F0.00014334862385321102
I1
I0
I1
tp7975
sS'therapy,such,as'
p7976
(F1
F0.00014334862385321102
I1
I0
I1
tp7977
sS'ketoconazole,and,isoniazid'
p7978
(F1
F0.00014334862385321102
I1
I0
I1
tp7979
sS'of,or,the'
p7980
(F1
F0.00043004587155963305
I0
I3
I-3
tp7981
sS'these,agents,ammonium'
p7982
(F1
F0.00014334862385321102
I1
I0
I1
tp7983
sS'the,required,infusion'
p7984
(F1
F0.00014334862385321102
I1
I0
I1
tp7985
sS'formulation,of,with'
p7986
(F1
F0.00014334862385321102
I0
I1
I-1
tp7987
sS'by,concomitant,in'
p7988
(F1
F0.00014334862385321102
I0
I1
I-1
tp7989
sS'patients,taking,these'
p7990
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp7991
sS'in,the,development'
p7992
(F0
F0
I1
I1
I0
tp7993
sS'both,mc,and'
p7994
(F1
F0.00014334862385321102
I0
I1
I-1
tp7995
sS'received,alone,and'
p7996
(F1
F0.00014334862385321102
I0
I1
I-1
tp7997
sS'to,therapy,plasma'
p7998
(F1
F0.00014334862385321102
I1
I0
I1
tp7999
sS'corneal,lesions,in'
p8000
(F1
F0.00014334862385321102
I1
I0
I1
tp8001
sS'co-administered,with,but'
p8002
(F1
F0.00014334862385321102
I0
I1
I-1
tp8003
sS'positive,and,negative'
p8004
(F1
F0.00028669724770642203
I0
I2
I-2
tp8005
sS'because,of,possible'
p8006
(F1
F0.00057339449541284407
I4
I0
I4
tp8007
sS'days,was,associated'
p8008
(F1
F0.00014334862385321102
I1
I0
I1
tp8009
sS'its,effectiveness,in'
p8010
(F1
F0.00014334862385321102
I0
I1
I-1
tp8011
sS'on,day,and'
p8012
(F0.25
F0.00028669724770642203
I5
I3
I2
tp8013
sS'generally,not,be'
p8014
(F1
F0.00014334862385321102
I1
I0
I1
tp8015
sS'cyp3a4,activity,in'
p8016
(F1
F0.00014334862385321102
I1
I0
I1
tp8017
sS'of,the,control'
p8018
(F1
F0.00014334862385321102
I0
I1
I-1
tp8019
sS'd,at,microm'
p8020
(F1
F0.00014334862385321102
I1
I0
I1
tp8021
sS'interactions,between,and'
p8022
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp8023
sS'human,growth,hormone'
p8024
(F1
F0.00014334862385321102
I1
I0
I1
tp8025
sS'over,use,of'
p8026
(F1
F0.00014334862385321102
I1
I0
I1
tp8027
sS'and,alone,and'
p8028
(F1
F0.00014334862385321102
I0
I1
I-1
tp8029
sS'for,increased,risk'
p8030
(F1
F0.00014334862385321102
I1
I0
I1
tp8031
sS'and,left,ventricular'
p8032
(F1
F0.00014334862385321102
I1
I0
I1
tp8033
sS'some,pronestyl,sulfa'
p8034
(F1
F0.00014334862385321102
I1
I0
I1
tp8035
sS'with,the,label'
p8036
(F1
F0.00014334862385321102
I1
I0
I1
tp8037
sS'that,ecg,and'
p8038
(F1
F0.00014334862385321102
I1
I0
I1
tp8039
sS'introduced,atypical,antipsychotic'
p8040
(F1
F0.00014334862385321102
I0
I1
I-1
tp8041
sS'the,metabolism,or'
p8042
(F1
F0.00014334862385321102
I1
I0
I1
tp8043
sS'highly,fortified,with'
p8044
(F1
F0.00014334862385321102
I0
I1
I-1
tp8045
sS'the,metabolism,of'
p8046
(F0.59090909090909094
F0.0037270642201834864
I35
I9
I26
tp8047
sS'in,serious,or'
p8048
(F1
F0.00014334862385321102
I0
I1
I-1
tp8049
sS'and,high,blood'
p8050
(F1
F0.00014334862385321102
I1
I0
I1
tp8051
sS'although,no,clinical'
p8052
(F1
F0.00014334862385321102
I1
I0
I1
tp8053
sS'norvir,viracept,astramorph'
p8054
(F1
F0.00014334862385321102
I1
I0
I1
tp8055
sS'mg,qd,mg'
p8056
(F1
F0.00014334862385321102
I1
I0
I1
tp8057
sS'action,of,zebeta'
p8058
(F1
F0.00014334862385321102
I1
I0
I1
tp8059
sS'were,on,chronic'
p8060
(F1
F0.00014334862385321102
I0
I1
I-1
tp8061
sS'triglycerides,sgot,ast'
p8062
(F1
F0.00014334862385321102
I1
I0
I1
tp8063
sS'the,patient,should'
p8064
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp8065
sS'reduced,or,abolished'
p8066
(F1
F0.00014334862385321102
I1
I0
I1
tp8067
sS'demonstrated,that,the'
p8068
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp8069
sS'at,m,v'
p8070
(F1
F0.00014334862385321102
I0
I1
I-1
tp8071
sS'antagonism,between,and'
p8072
(F1
F0.00014334862385321102
I1
I0
I1
tp8073
sS'observed,to,enhance'
p8074
(F1
F0.00014334862385321102
I1
I0
I1
tp8075
sS'cardiovascular,disease,or'
p8076
(F1
F0.00014334862385321102
I1
I0
I1
tp8077
sS'delayed,and,their'
p8078
(F1
F0.00014334862385321102
I1
I0
I1
tp8079
sS'of,and,may'
p8080
(F0.66666666666666663
F0.0011467889908256881
I10
I2
I8
tp8081
sS'acute,administration,does'
p8082
(F1
F0.00014334862385321102
I0
I1
I-1
tp8083
sS'vitro,perfused,pancreases'
p8084
(F1
F0.00014334862385321102
I0
I1
I-1
tp8085
sS'appropriate,dosage,adjustment'
p8086
(F1
F0.00014334862385321102
I1
I0
I1
tp8087
sS'no,are,known'
p8088
(F1
F0.00014334862385321102
I0
I1
I-1
tp8089
sS'of,hcl,is'
p8090
(F1
F0.00014334862385321102
I1
I0
I1
tp8091
sS'hours,after,cholestyramine'
p8092
(F1
F0.00014334862385321102
I0
I1
I-1
tp8093
sS'administered,in,clinical'
p8094
(F0
F0
I1
I1
I0
tp8095
sS'toxicity,characterized,by'
p8096
(F0
F0
I2
I2
I0
tp8097
sS'and,the,signs'
p8098
(F1
F0.00028669724770642203
I0
I2
I-2
tp8099
sS'induced,by,oh'
p8100
(F1
F0.00014334862385321102
I1
I0
I1
tp8101
sS'drug-drug,interactions,posed'
p8102
(F1
F0.00014334862385321102
I0
I1
I-1
tp8103
sS'non-nucleoside,reverse,transcriptase'
p8104
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp8105
sS'vitro,binding,studies'
p8106
(F1
F0.00014334862385321102
I0
I1
I-1
tp8107
sS'results,suggest,that'
p8108
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp8109
sS'adversely,affect,disease'
p8110
(F1
F0.00014334862385321102
I1
I0
I1
tp8111
sS'cyp2d6,increased,the'
p8112
(F1
F0.00014334862385321102
I1
I0
I1
tp8113
sS'taking,placebo,as'
p8114
(F1
F0.00014334862385321102
I0
I1
I-1
tp8115
sS'when,using,romazicon'
p8116
(F1
F0.00014334862385321102
I1
I0
I1
tp8117
sS'by,dmpge2,given'
p8118
(F1
F0.00014334862385321102
I0
I1
I-1
tp8119
sS'inhibits,the,enzymatic'
p8120
(F1
F0.00014334862385321102
I1
I0
I1
tp8121
sS'or,that,inhibit'
p8122
(F1
F0.00028669724770642203
I2
I0
I2
tp8123
sS'or,caused,excessive'
p8124
(F1
F0.00014334862385321102
I0
I1
I-1
tp8125
sS'of,mg,once'
p8126
(F1
F0.00014334862385321102
I1
I0
I1
tp8127
sS'supraventricular,arrhythmia,and'
p8128
(F1
F0.00014334862385321102
I1
I0
I1
tp8129
sS'combination,with,avastin'
p8130
(F1
F0.00014334862385321102
I0
I1
I-1
tp8131
sS'of,which,d'
p8132
(F1
F0.00014334862385321102
I1
I0
I1
tp8133
sS'may,not,be'
p8134
(F0
F0
I2
I2
I0
tp8135
sS'but,may,be'
p8136
(F0
F0
I1
I1
I0
tp8137
sS'of,caused,by'
p8138
(F1
F0.00028669724770642203
I2
I0
I2
tp8139
sS'that,tam,significantly'
p8140
(F1
F0.00014334862385321102
I1
I0
I1
tp8141
sS'benzodiazepines,metabolized,by'
p8142
(F1
F0.00014334862385321102
I1
I0
I1
tp8143
sS'or,since,it'
p8144
(F1
F0.00014334862385321102
I0
I1
I-1
tp8145
sS'in,another,study'
p8146
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp8147
sS'provoke,convulsions,in'
p8148
(F1
F0.00014334862385321102
I0
I1
I-1
tp8149
sS'agents,may,potentiate'
p8150
(F1
F0.00028669724770642203
I2
I0
I2
tp8151
sS'alter,the,pharmacokinetics'
p8152
(F1
F0.0015768348623853212
I0
I11
I-11
tp8153
sS'organophosphorous,compound,and'
p8154
(F1
F0.00014334862385321102
I0
I1
I-1
tp8155
sS'with,coadministration,up'
p8156
(F1
F0.00014334862385321102
I1
I0
I1
tp8157
sS'hydrochloride,given,prior'
p8158
(F1
F0.00014334862385321102
I1
I0
I1
tp8159
sS'and,the,cmax'
p8160
(F1
F0.00028669724770642203
I2
I0
I2
tp8161
sS'specific,methods,such'
p8162
(F1
F0.00014334862385321102
I0
I1
I-1
tp8163
sS'and,is,accelerated'
p8164
(F1
F0.00014334862385321102
I1
I0
I1
tp8165
sS'combined,with,the'
p8166
(F1
F0.00014334862385321102
I1
I0
I1
tp8167
sS'since,these,patients'
p8168
(F1
F0.00028669724770642203
I2
I0
I2
tp8169
sS'acts,as,a'
p8170
(F1
F0.00014334862385321102
I1
I0
I1
tp8171
sS'derivatives,dihydroergotamine,contraindicated'
p8172
(F1
F0.00014334862385321102
I0
I1
I-1
tp8173
sS'thiazide,and,even'
p8174
(F1
F0.00014334862385321102
I1
I0
I1
tp8175
sS'isuprel,should,be'
p8176
(F1
F0.00014334862385321102
I1
I0
I1
tp8177
sS'between,a,macrolide'
p8178
(F1
F0.00014334862385321102
I0
I1
I-1
tp8179
sS'an,nsaid,or'
p8180
(F1
F0.00014334862385321102
I1
I0
I1
tp8181
sS'sandimmune--on,hepatic,microsomal'
p8182
(F1
F0.00014334862385321102
I0
I1
I-1
tp8183
sS'epinephrine,may,antagonize'
p8184
(F1
F0.00014334862385321102
I1
I0
I1
tp8185
sS'therapy,and,that'
p8186
(F1
F0.00014334862385321102
I1
I0
I1
tp8187
sS'and,g,kg'
p8188
(F1
F0.00014334862385321102
I1
I0
I1
tp8189
sS'of,other,agents'
p8190
(F0
F0
I1
I1
I0
tp8191
sS'positive,level,to'
p8192
(F1
F0.00014334862385321102
I1
I0
I1
tp8193
sS'or,slightly,greater'
p8194
(F1
F0.00014334862385321102
I1
I0
I1
tp8195
sS'alone,the,possible'
p8196
(F1
F0.00014334862385321102
I1
I0
I1
tp8197
sS'of,from,midcycle'
p8198
(F1
F0.00014334862385321102
I0
I1
I-1
tp8199
sS'during,the,cure'
p8200
(F0
F0
I1
I1
I0
tp8201
sS'or,but,not'
p8202
(F1
F0.00014334862385321102
I1
I0
I1
tp8203
sS'coadministration,can,result'
p8204
(F1
F0.00014334862385321102
I1
I0
I1
tp8205
sS'schizophrenia,schizoaffective,disorder'
p8206
(F1
F0.00014334862385321102
I1
I0
I1
tp8207
sS'of,mg,neurontin'
p8208
(F1
F0.00014334862385321102
I0
I1
I-1
tp8209
sS'for,cmax,when'
p8210
(F1
F0.00014334862385321102
I1
I0
I1
tp8211
sS'patients,taking,low-dose'
p8212
(F1
F0.00028669724770642203
I0
I2
I-2
tp8213
sS'received,either,prophylactic'
p8214
(F1
F0.00014334862385321102
I0
I1
I-1
tp8215
sS'given,hours,prior'
p8216
(F1
F0.00014334862385321102
I1
I0
I1
tp8217
sS'of,approximately,was'
p8218
(F1
F0.00014334862385321102
I1
I0
I1
tp8219
sS'above,or,near'
p8220
(F1
F0.00014334862385321102
I1
I0
I1
tp8221
sS'have,all,been'
p8222
(F1
F0.00014334862385321102
I0
I1
I-1
tp8223
sS'metabolite,in,patients'
p8224
(F1
F0.00014334862385321102
I0
I1
I-1
tp8225
sS'is,not,all'
p8226
(F1
F0.00014334862385321102
I0
I1
I-1
tp8227
sS'in,uninfected,volunteers'
p8228
(F1
F0.00014334862385321102
I1
I0
I1
tp8229
sS'conjunction,with,other'
p8230
(F1
F0.00014334862385321102
I1
I0
I1
tp8231
sS'only,one,contra-indication'
p8232
(F1
F0.00014334862385321102
I0
I1
I-1
tp8233
sS'blood,pressure,after'
p8234
(F1
F0.00057339449541284407
I4
I0
I4
tp8235
sS'alone,or,when'
p8236
(F1
F0.00014334862385321102
I0
I1
I-1
tp8237
sS'metabolized,via,cyp3a4'
p8238
(F1
F0.00014334862385321102
I1
I0
I1
tp8239
sS'the,urine,volume'
p8240
(F1
F0.00014334862385321102
I1
I0
I1
tp8241
sS'restricted,and,an'
p8242
(F1
F0.00014334862385321102
I0
I1
I-1
tp8243
sS'our,objective,was'
p8244
(F1
F0.00028669724770642203
I0
I2
I-2
tp8245
sS'for,days,does'
p8246
(F1
F0.00014334862385321102
I0
I1
I-1
tp8247
sS'changes,and,or'
p8248
(F1
F0.00014334862385321102
I1
I0
I1
tp8249
sS'be,low,for'
p8250
(F1
F0.00014334862385321102
I0
I1
I-1
tp8251
sS'dimethyl-4,hydroxyphenyl,piperidine'
p8252
(F1
F0.00014334862385321102
I1
I0
I1
tp8253
sS'min,interval,significantly'
p8254
(F1
F0.00014334862385321102
I1
I0
I1
tp8255
sS'in,rheumatic,disease'
p8256
(F1
F0.00014334862385321102
I1
I0
I1
tp8257
sS'agents,nsaids,monoamine'
p8258
(F1
F0.00014334862385321102
I1
I0
I1
tp8259
sS'is,inadvisable,to'
p8260
(F1
F0.00014334862385321102
I1
I0
I1
tp8261
sS'duragesic,is,given'
p8262
(F1
F0.00014334862385321102
I0
I1
I-1
tp8263
sS'cmc-cys,conjugates,on'
p8264
(F1
F0.00014334862385321102
I0
I1
I-1
tp8265
sS'and,azoles,are'
p8266
(F1
F0.00014334862385321102
I0
I1
I-1
tp8267
sS'agents,should,be'
p8268
(F0.25
F0.00028669724770642203
I5
I3
I2
tp8269
sS'levels,of,have'
p8270
(F0.75
F0.0008600917431192661
I7
I1
I6
tp8271
sS'aims,hypothesis,there'
p8272
(F1
F0.00014334862385321102
I0
I1
I-1
tp8273
sS'serious,and,unexpected'
p8274
(F1
F0.00014334862385321102
I0
I1
I-1
tp8275
sS'of,hydroxytolbutamide,and'
p8276
(F1
F0.00014334862385321102
I0
I1
I-1
tp8277
sS'tambocor,unless,in'
p8278
(F1
F0.00014334862385321102
I1
I0
I1
tp8279
sS'a,fold,increase'
p8280
(F1
F0.0012901376146788992
I9
I0
I9
tp8281
sS'of,phosphatases,in'
p8282
(F1
F0.00014334862385321102
I0
I1
I-1
tp8283
sS'hormone,or,tsh'
p8284
(F1
F0.00014334862385321102
I0
I1
I-1
tp8285
sS'mevacor,in,hypercholesterolemic'
p8286
(F1
F0.00014334862385321102
I0
I1
I-1
tp8287
sS'co-administration,of,plendil'
p8288
(F1
F0.00014334862385321102
I0
I1
I-1
tp8289
sS'as,a,d'
p8290
(F1
F0.00014334862385321102
I0
I1
I-1
tp8291
sS'to,decrease,glutathione'
p8292
(F1
F0.00014334862385321102
I1
I0
I1
tp8293
sS'decreases,stomach,acidity'
p8294
(F1
F0.00014334862385321102
I0
I1
I-1
tp8295
sS'hepatotoxic,influenza,virus'
p8296
(F1
F0.00014334862385321102
I1
I0
I1
tp8297
sS'circulation,there,is'
p8298
(F1
F0.00014334862385321102
I1
I0
I1
tp8299
sS'established,therapy,with'
p8300
(F1
F0.00014334862385321102
I1
I0
I1
tp8301
sS'growth,hormone,concomitant'
p8302
(F1
F0.00014334862385321102
I1
I0
I1
tp8303
sS'effects,of,diethyl'
p8304
(F1
F0.00014334862385321102
I0
I1
I-1
tp8305
sS'urate,uricosuric,agents'
p8306
(F1
F0.00014334862385321102
I1
I0
I1
tp8307
sS'or,without,clinical'
p8308
(F1
F0.00014334862385321102
I1
I0
I1
tp8309
sS'can,interact,with'
p8310
(F1
F0.00043004587155963305
I3
I0
I3
tp8311
sS'and,concurrently,the'
p8312
(F1
F0.00014334862385321102
I1
I0
I1
tp8313
sS'by,jaffe,reaction'
p8314
(F1
F0.00014334862385321102
I0
I1
I-1
tp8315
sS'possible,that,concomitant'
p8316
(F1
F0.00014334862385321102
I1
I0
I1
tp8317
sS'information,is,available'
p8318
(F1
F0.00028669724770642203
I0
I2
I-2
tp8319
sS'qd,and,mg'
p8320
(F1
F0.00028669724770642203
I2
I0
I2
tp8321
sS'for,i,coadministration'
p8322
(F1
F0.00014334862385321102
I1
I0
I1
tp8323
sS'alcohol-related,deaths,is'
p8324
(F1
F0.00014334862385321102
I0
I1
I-1
tp8325
sS'induce,fungal,resistance'
p8326
(F1
F0.00014334862385321102
I1
I0
I1
tp8327
sS'nor,were,there'
p8328
(F1
F0.00014334862385321102
I0
I1
I-1
tp8329
sS'of,to,the'
p8330
(F1
F0.00028669724770642203
I0
I2
I-2
tp8331
sS'clinical,experience,indicates'
p8332
(F1
F0.00014334862385321102
I1
I0
I1
tp8333
sS'on,hepatotoxicity,are'
p8334
(F1
F0.00014334862385321102
I1
I0
I1
tp8335
sS'metabolized,by,nor'
p8336
(F1
F0.00014334862385321102
I0
I1
I-1
tp8337
sS'garlic,allium,sativum'
p8338
(F1
F0.00014334862385321102
I1
I0
I1
tp8339
sS'h,s,regimen'
p8340
(F1
F0.00014334862385321102
I1
I0
I1
tp8341
sS'with,in,causing'
p8342
(F1
F0.00014334862385321102
I1
I0
I1
tp8343
sS'advised,and,downward'
p8344
(F1
F0.00014334862385321102
I1
I0
I1
tp8345
sS'the,renal,excretion'
p8346
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp8347
sS'in,vitro,may'
p8348
(F1
F0.00014334862385321102
I1
I0
I1
tp8349
sS'ergot-type,medications,like'
p8350
(F1
F0.00043004587155963305
I3
I0
I3
tp8351
sS'with,extreme,caution'
p8352
(F1
F0.00043004587155963305
I3
I0
I3
tp8353
sS'methadone,coadministration,of'
p8354
(F1
F0.00014334862385321102
I1
I0
I1
tp8355
sS'show,that,and'
p8356
(F1
F0.00014334862385321102
I1
I0
I1
tp8357
sS'direct,causal,relationship'
p8358
(F1
F0.00014334862385321102
I1
I0
I1
tp8359
sS'as,in,the'
p8360
(F1
F0.00028669724770642203
I0
I2
I-2
tp8361
sS'on,stable,therapy'
p8362
(F1
F0.00014334862385321102
I0
I1
I-1
tp8363
sS'deletion,of,any'
p8364
(F1
F0.00014334862385321102
I0
I1
I-1
tp8365
sS'in,a,parallel'
p8366
(F1
F0.00014334862385321102
I0
I1
I-1
tp8367
sS'possible,complications,of'
p8368
(F1
F0.00014334862385321102
I1
I0
I1
tp8369
sS'have,not,demonstrated'
p8370
(F1
F0.00014334862385321102
I0
I1
I-1
tp8371
sS'bioavailability,studies,in'
p8372
(F1
F0.00014334862385321102
I0
I1
I-1
tp8373
sS'enzymes,lapatinib,undergoes'
p8374
(F1
F0.00014334862385321102
I0
I1
I-1
tp8375
sS'administration,of,peptide'
p8376
(F1
F0.00014334862385321102
I0
I1
I-1
tp8377
sS'when,another,drug'
p8378
(F1
F0.00014334862385321102
I0
I1
I-1
tp8379
sS'antizol,mg,kg'
p8380
(F1
F0.00014334862385321102
I1
I0
I1
tp8381
sS'whereas,h-spiroperidol,binding'
p8382
(F1
F0.00014334862385321102
I0
I1
I-1
tp8383
sS'halogenated,hydrocarbon,general'
p8384
(F1
F0.00014334862385321102
I1
I0
I1
tp8385
sS'concentrations,of,among'
p8386
(F1
F0.00014334862385321102
I1
I0
I1
tp8387
sS'reuptake,inhibitors,ssris'
p8388
(F0.090909090909090912
F0.00014334862385321102
I5
I6
I-1
tp8389
sS'levo-dromoran,with,all'
p8390
(F1
F0.00014334862385321102
I1
I0
I1
tp8391
sS'patients,consuming,while'
p8392
(F1
F0.00014334862385321102
I1
I0
I1
tp8393
sS'of,co-administration,with'
p8394
(F1
F0.00014334862385321102
I0
I1
I-1
tp8395
sS'of,anaphylactic,shock'
p8396
(F1
F0.00014334862385321102
I1
I0
I1
tp8397
sS'of,non-potassium,sparing'
p8398
(F1
F0.00014334862385321102
I1
I0
I1
tp8399
sS'and,pharmacokinetics,at'
p8400
(F1
F0.00014334862385321102
I0
I1
I-1
tp8401
sS'more,efficient,substrate'
p8402
(F1
F0.00014334862385321102
I0
I1
I-1
tp8403
sS'a,single,mg'
p8404
(F0.076923076923076927
F0.00028669724770642203
I14
I12
I2
tp8405
sS'inhibitor,of,c'
p8406
(F1
F0.00014334862385321102
I1
I0
I1
tp8407
sS'patients,with,creatinine'
p8408
(F1
F0.00014334862385321102
I0
I1
I-1
tp8409
sS'particularly,with,higher'
p8410
(F1
F0.00014334862385321102
I1
I0
I1
tp8411
sS'the,pressor,activity'
p8412
(F1
F0.00014334862385321102
I0
I1
I-1
tp8413
sS'be,displaced,from'
p8414
(F1
F0.00014334862385321102
I1
I0
I1
tp8415
sS'and,use,as'
p8416
(F1
F0.00014334862385321102
I0
I1
I-1
tp8417
sS'of,pulmonary,symptomatology'
p8418
(F1
F0.00014334862385321102
I1
I0
I1
tp8419
sS'prostatic,epithelium,proliferates'
p8420
(F1
F0.00014334862385321102
I0
I1
I-1
tp8421
sS'concurrently,with,compared'
p8422
(F1
F0.00014334862385321102
I1
I0
I1
tp8423
sS'ethynyl,and,to'
p8424
(F1
F0.00014334862385321102
I0
I1
I-1
tp8425
sS'probenecid,probenecid,is'
p8426
(F0
F0
I1
I1
I0
tp8427
sS'nephrotoxicity,and,or'
p8428
(F1
F0.00014334862385321102
I0
I1
I-1
tp8429
sS'requirements,for,or'
p8430
(F1
F0.00014334862385321102
I0
I1
I-1
tp8431
sS'alone,at,recommended'
p8432
(F1
F0.00014334862385321102
I1
I0
I1
tp8433
sS'vitamin,d3,administration'
p8434
(F1
F0.00014334862385321102
I1
I0
I1
tp8435
sS'tubular,secretion,by'
p8436
(F1
F0.00014334862385321102
I0
I1
I-1
tp8437
sS'pharmacokinetic,parameters,affected'
p8438
(F1
F0.00014334862385321102
I0
I1
I-1
tp8439
sS'when,administering,with'
p8440
(F1
F0.00014334862385321102
I1
I0
I1
tp8441
sS'keppra,and,other'
p8442
(F1
F0.00028669724770642203
I0
I2
I-2
tp8443
sS'also,appeared,to'
p8444
(F1
F0.00014334862385321102
I1
I0
I1
tp8445
sS'of,nondepolarizing,agents'
p8446
(F1
F0.00028669724770642203
I2
I0
I2
tp8447
sS'potentiating,action,of'
p8448
(F1
F0.00014334862385321102
I1
I0
I1
tp8449
sS'in,reduced,clearance'
p8450
(F1
F0.00014334862385321102
I1
I0
I1
tp8451
sS'anhydrase,inhibitors,and'
p8452
(F1
F0.00014334862385321102
I1
I0
I1
tp8453
sS'dosage,of,equetrotm'
p8454
(F1
F0.00014334862385321102
I0
I1
I-1
tp8455
sS'as,channel-blockers,ace'
p8456
(F1
F0.00014334862385321102
I0
I1
I-1
tp8457
sS'prostaglandin,synthesis,it'
p8458
(F1
F0.00014334862385321102
I1
I0
I1
tp8459
sS'and,then,titrated'
p8460
(F1
F0.00014334862385321102
I1
I0
I1
tp8461
sS'the,ratios,of'
p8462
(F1
F0.00014334862385321102
I0
I1
I-1
tp8463
sS'to,survive,in'
p8464
(F1
F0.00014334862385321102
I0
I1
I-1
tp8465
sS'levels,and,lessened'
p8466
(F1
F0.00014334862385321102
I1
I0
I1
tp8467
sS'digoxin,studies,in'
p8468
(F1
F0.00014334862385321102
I0
I1
I-1
tp8469
sS'to,lead,to'
p8470
(F1
F0.00043004587155963305
I3
I0
I3
tp8471
sS'twofold,increase,in'
p8472
(F1
F0.00028669724770642203
I2
I0
I2
tp8473
sS'antagonism,of,the'
p8474
(F1
F0.00014334862385321102
I1
I0
I1
tp8475
sS'induction,by,a'
p8476
(F1
F0.00014334862385321102
I0
I1
I-1
tp8477
sS'because,cyp,a4'
p8478
(F1
F0.00014334862385321102
I0
I1
I-1
tp8479
sS'or,therapy,on'
p8480
(F1
F0.00014334862385321102
I1
I0
I1
tp8481
sS'concomitantly,with,prothrombin'
p8482
(F1
F0.00014334862385321102
I1
I0
I1
tp8483
sS'subjects,who,received'
p8484
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp8485
sS'in,a,dose-dependent'
p8486
(F1
F0.00043004587155963305
I3
I0
I3
tp8487
sS'or,h1-blocking,agents'
p8488
(F1
F0.00014334862385321102
I1
I0
I1
tp8489
sS'to,significant,shifts'
p8490
(F1
F0.00014334862385321102
I0
I1
I-1
tp8491
sS'phenobarbital,coadministration,of'
p8492
(F1
F0.00014334862385321102
I1
I0
I1
tp8493
sS'too,small,to'
p8494
(F1
F0.00014334862385321102
I0
I1
I-1
tp8495
sS'effects,with,and'
p8496
(F1
F0.00028669724770642203
I2
I0
I2
tp8497
sS'increase,with,multiple'
p8498
(F1
F0.00014334862385321102
I1
I0
I1
tp8499
sS'the,electrolyte,loss'
p8500
(F1
F0.00028669724770642203
I2
I0
I2
tp8501
sS'of,and,minimizes'
p8502
(F1
F0.00014334862385321102
I1
I0
I1
tp8503
sS'with,c,diethyl'
p8504
(F1
F0.00014334862385321102
I0
I1
I-1
tp8505
sS'anion-exchange,resins,an'
p8506
(F1
F0.00014334862385321102
I1
I0
I1
tp8507
sS'of,wellbutrin,and'
p8508
(F1
F0.00014334862385321102
I1
I0
I1
tp8509
sS'state,therefore,the'
p8510
(F1
F0.00014334862385321102
I0
I1
I-1
tp8511
sS'normovolemic,healthy,subjects'
p8512
(F1
F0.00014334862385321102
I1
I0
I1
tp8513
sS'both,aldehyde,oxidase'
p8514
(F1
F0.00014334862385321102
I1
I0
I1
tp8515
sS'by,either,discontinuing'
p8516
(F1
F0.00071674311926605509
I5
I0
I5
tp8517
sS'advice,of,a'
p8518
(F1
F0.00014334862385321102
I1
I0
I1
tp8519
sS'meal,resulted,in'
p8520
(F1
F0.00014334862385321102
I1
I0
I1
tp8521
sS'cardiac,enlargement,and'
p8522
(F1
F0.00014334862385321102
I1
I0
I1
tp8523
sS'enhance,the,nephrotoxicity'
p8524
(F1
F0.00014334862385321102
I1
I0
I1
tp8525
sS'liver,to,the'
p8526
(F1
F0.00014334862385321102
I0
I1
I-1
tp8527
sS'compounds,such,as'
p8528
(F1
F0.00014334862385321102
I1
I0
I1
tp8529
sS'channel,antagonists,angiotensin'
p8530
(F1
F0.00014334862385321102
I0
I1
I-1
tp8531
sS'a,dosing,schedule'
p8532
(F1
F0.00014334862385321102
I0
I1
I-1
tp8533
sS'major,metabolite,beta-naltrexol'
p8534
(F1
F0.00014334862385321102
I0
I1
I-1
tp8535
sS'without,mg,of'
p8536
(F1
F0.00014334862385321102
I0
I1
I-1
tp8537
sS'coadministering,these,agents'
p8538
(F1
F0.00014334862385321102
I1
I0
I1
tp8539
sS'to,share,a'
p8540
(F1
F0.00014334862385321102
I0
I1
I-1
tp8541
sS'such,as,cyp3a4'
p8542
(F1
F0.00014334862385321102
I1
I0
I1
tp8543
sS'sodium,pertechnetate,tc99m'
p8544
(F1
F0.00014334862385321102
I0
I1
I-1
tp8545
sS'thiazide,acidic,or'
p8546
(F1
F0.00014334862385321102
I1
I0
I1
tp8547
sS'test,interaction,after'
p8548
(F1
F0.00014334862385321102
I0
I1
I-1
tp8549
sS'with,alkaline,earth'
p8550
(F1
F0.00014334862385321102
I0
I1
I-1
tp8551
sS'bleeding,is,advised'
p8552
(F1
F0.00014334862385321102
I0
I1
I-1
tp8553
sS'a,c,a'
p8554
(F1
F0.00014334862385321102
I1
I0
I1
tp8555
sS'and,partly,antagonized'
p8556
(F1
F0.00014334862385321102
I1
I0
I1
tp8557
sS'state,following,dosing'
p8558
(F1
F0.00014334862385321102
I0
I1
I-1
tp8559
sS'have,pre-existing,cardiac'
p8560
(F1
F0.00014334862385321102
I1
I0
I1
tp8561
sS'normal,volunteers,have'
p8562
(F0
F0
I1
I1
I0
tp8563
sS'may,give,false'
p8564
(F1
F0.00014334862385321102
I1
I0
I1
tp8565
sS'indanyl,sodium,blood'
p8566
(F1
F0.00014334862385321102
I1
I0
I1
tp8567
sS'activity,while,only'
p8568
(F1
F0.00014334862385321102
I1
I0
I1
tp8569
sS'cyclosporine,concomitant,administration'
p8570
(F1
F0.00014334862385321102
I0
I1
I-1
tp8571
sS'significant,shifts,in'
p8572
(F1
F0.00014334862385321102
I0
I1
I-1
tp8573
sS'at,mg,bid'
p8574
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp8575
sS'usual,prescription,dose'
p8576
(F1
F0.00014334862385321102
I1
I0
I1
tp8577
sS'co-administration,of,precedex'
p8578
(F1
F0.00014334862385321102
I1
I0
I1
tp8579
sS'is,administered,to'
p8580
(F1
F0.00028669724770642203
I2
I0
I2
tp8581
sS'metabolic,effects,of'
p8582
(F1
F0.00028669724770642203
I2
I0
I2
tp8583
sS'has,been,established'
p8584
(F0
F0
I1
I1
I0
tp8585
sS'diminish,oral,response'
p8586
(F1
F0.00028669724770642203
I2
I0
I2
tp8587
sS'a,increase,of'
p8588
(F1
F0.00014334862385321102
I1
I0
I1
tp8589
sS'stereoisomers,of,n-allylnormetazocine'
p8590
(F1
F0.00014334862385321102
I0
I1
I-1
tp8591
sS'no,signs,or'
p8592
(F1
F0.00014334862385321102
I1
I0
I1
tp8593
sS'of,antimicrobial,combinations'
p8594
(F1
F0.00014334862385321102
I0
I1
I-1
tp8595
sS'and,i,sodium'
p8596
(F1
F0.00014334862385321102
I0
I1
I-1
tp8597
sS'by,the,simultaneous'
p8598
(F1
F0.00014334862385321102
I1
I0
I1
tp8599
sS'not,affect,distribution'
p8600
(F1
F0.00014334862385321102
I0
I1
I-1
tp8601
sS'with,haca,titers'
p8602
(F1
F0.00014334862385321102
I0
I1
I-1
tp8603
sS'cobalt,excretion,was'
p8604
(F1
F0.00014334862385321102
I0
I1
I-1
tp8605
sS'volunteers,no,clinically'
p8606
(F1
F0.00014334862385321102
I0
I1
I-1
tp8607
sS'single,high,dose'
p8608
(F1
F0.00014334862385321102
I1
I0
I1
tp8609
sS'presumably,by,inhibition'
p8610
(F1
F0.00014334862385321102
I1
I0
I1
tp8611
sS'properties,on,renal'
p8612
(F1
F0.00014334862385321102
I0
I1
I-1
tp8613
sS'even,when,parenteral'
p8614
(F1
F0.00014334862385321102
I0
I1
I-1
tp8615
sS'animal,toxicology,studies'
p8616
(F1
F0.00014334862385321102
I0
I1
I-1
tp8617
sS'mao,inhibition,of'
p8618
(F1
F0.00014334862385321102
I0
I1
I-1
tp8619
sS'formation,in,u937'
p8620
(F1
F0.00014334862385321102
I1
I0
I1
tp8621
sS'others,or,supplements'
p8622
(F1
F0.00028669724770642203
I0
I2
I-2
tp8623
sS'increases,of,previously'
p8624
(F1
F0.00014334862385321102
I1
I0
I1
tp8625
sS'de,novo,renal'
p8626
(F1
F0.00014334862385321102
I0
I1
I-1
tp8627
sS'well,as,diminished'
p8628
(F1
F0.00014334862385321102
I1
I0
I1
tp8629
sS'arthritis,clinical,trials'
p8630
(F1
F0.00014334862385321102
I0
I1
I-1
tp8631
sS'and,and,have'
p8632
(F1
F0.00014334862385321102
I0
I1
I-1
tp8633
sS'have,been,taking'
p8634
(F1
F0.00014334862385321102
I0
I1
I-1
tp8635
sS'bar-press,behavior,in'
p8636
(F1
F0.00014334862385321102
I0
I1
I-1
tp8637
sS'when,is,started'
p8638
(F1
F0.00014334862385321102
I1
I0
I1
tp8639
sS'thioxanthene,and,butyrophenone'
p8640
(F1
F0.00014334862385321102
I1
I0
I1
tp8641
sS'study,in,which'
p8642
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp8643
sS'omnicef,for,oral'
p8644
(F1
F0.00014334862385321102
I0
I1
I-1
tp8645
sS'a,and,decrease'
p8646
(F1
F0.00014334862385321102
I1
I0
I1
tp8647
sS'small,n,combination'
p8648
(F1
F0.00014334862385321102
I1
I0
I1
tp8649
sS'misuse,of,and'
p8650
(F1
F0.00014334862385321102
I1
I0
I1
tp8651
sS'combination,of,amprenavir'
p8652
(F1
F0.00014334862385321102
I1
I0
I1
tp8653
sS'dependent,oxidation,responsible'
p8654
(F1
F0.00014334862385321102
I1
I0
I1
tp8655
sS'primarily,h2,blockers'
p8656
(F1
F0.00014334862385321102
I0
I1
I-1
tp8657
sS'upward,the,dose'
p8658
(F1
F0.00014334862385321102
I1
I0
I1
tp8659
sS'interactions,general,although'
p8660
(F1
F0.00014334862385321102
I0
I1
I-1
tp8661
sS'carbamazepine,population,pharmacokinetic'
p8662
(F1
F0.00014334862385321102
I1
I0
I1
tp8663
sS'the,consumption,of'
p8664
(F1
F0.00014334862385321102
I1
I0
I1
tp8665
sS'with,with,metal'
p8666
(F1
F0.00014334862385321102
I1
I0
I1
tp8667
sS'started,or,stopped'
p8668
(F1
F0.00014334862385321102
I1
I0
I1
tp8669
sS'metabolized,mainly,by'
p8670
(F1
F0.00014334862385321102
I0
I1
I-1
tp8671
sS'of,inhibition,are'
p8672
(F1
F0.00014334862385321102
I1
I0
I1
tp8673
sS'are,illustrated,by'
p8674
(F1
F0.00014334862385321102
I0
I1
I-1
tp8675
sS'a,recent,case'
p8676
(F1
F0.00014334862385321102
I1
I0
I1
tp8677
sS'sgot,ast,and'
p8678
(F1
F0.00014334862385321102
I1
I0
I1
tp8679
sS'are,required,when'
p8680
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp8681
sS'eg,may,have'
p8682
(F1
F0.00014334862385321102
I1
I0
I1
tp8683
sS'for,exjade,should'
p8684
(F1
F0.00014334862385321102
I1
I0
I1
tp8685
sS'antagonist,class,including'
p8686
(F1
F0.00014334862385321102
I1
I0
I1
tp8687
sS'dose,ranging,from'
p8688
(F1
F0.00014334862385321102
I1
I0
I1
tp8689
sS'of,may,even'
p8690
(F1
F0.00014334862385321102
I1
I0
I1
tp8691
sS'duragesic,transdermal,system'
p8692
(F1
F0.00014334862385321102
I1
I0
I1
tp8693
sS'treatment,with,there'
p8694
(F1
F0.00014334862385321102
I1
I0
I1
tp8695
sS'and,prolongation,of'
p8696
(F1
F0.00071674311926605509
I5
I0
I5
tp8697
sS'is,neither,metabolized'
p8698
(F1
F0.00014334862385321102
I0
I1
I-1
tp8699
sS'in,alcoholic,beverages'
p8700
(F1
F0.00014334862385321102
I1
I0
I1
tp8701
sS'increased,dramatically,from'
p8702
(F1
F0.00014334862385321102
I0
I1
I-1
tp8703
sS'co-administered,with,potent'
p8704
(F1
F0.00014334862385321102
I0
I1
I-1
tp8705
sS'during,the,concomitant'
p8706
(F1
F0.00043004587155963305
I3
I0
I3
tp8707
sS'other,ergot,alkaloids'
p8708
(F1
F0.00014334862385321102
I1
I0
I1
tp8709
sS'administration,of,cmi'
p8710
(F1
F0.00014334862385321102
I1
I0
I1
tp8711
sS'concentrations,were,similar'
p8712
(F1
F0.00014334862385321102
I0
I1
I-1
tp8713
sS'against,symptoms,of'
p8714
(F1
F0.00014334862385321102
I0
I1
I-1
tp8715
sS'and,release,in'
p8716
(F1
F0.00014334862385321102
I0
I1
I-1
tp8717
sS'vasodilators,the,following'
p8718
(F1
F0.00014334862385321102
I1
I0
I1
tp8719
sS'in,a,limited'
p8720
(F1
F0.00014334862385321102
I0
I1
I-1
tp8721
sS'not,affect,plasma'
p8722
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp8723
sS'concurrently,the,should'
p8724
(F1
F0.00014334862385321102
I1
I0
I1
tp8725
sS'agents,including,protease'
p8726
(F1
F0.00014334862385321102
I0
I1
I-1
tp8727
sS'increased,risk,for'
p8728
(F1
F0.00014334862385321102
I1
I0
I1
tp8729
sS'plasma,levels,in'
p8730
(F1
F0.00014334862385321102
I1
I0
I1
tp8731
sS'prior,to,during'
p8732
(F1
F0.00014334862385321102
I1
I0
I1
tp8733
sS'patients,receiving,single'
p8734
(F1
F0.00014334862385321102
I0
I1
I-1
tp8735
sS'with,activity,effects'
p8736
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp8737
sS'results,in,excessive'
p8738
(F1
F0.00014334862385321102
I1
I0
I1
tp8739
sS'the,relationship,of'
p8740
(F1
F0.00014334862385321102
I1
I0
I1
tp8741
sS'system,depressants,may'
p8742
(F0
F0
I2
I2
I0
tp8743
sS'oral,unreliable,prothrombin'
p8744
(F1
F0.00014334862385321102
I1
I0
I1
tp8745
sS'confidence,interval,for'
p8746
(F1
F0.00014334862385321102
I0
I1
I-1
tp8747
sS'effect,of,ace'
p8748
(F1
F0.00014334862385321102
I1
I0
I1
tp8749
sS'resulting,in,rare'
p8750
(F1
F0.00014334862385321102
I1
I0
I1
tp8751
sS'simultaneous,dosing,of'
p8752
(F1
F0.00028669724770642203
I2
I0
I2
tp8753
sS'of,cns,stimulation'
p8754
(F1
F0.00014334862385321102
I1
I0
I1
tp8755
sS'antagonists,cimetidine,coadministration'
p8756
(F1
F0.00014334862385321102
I1
I0
I1
tp8757
sS'are,not,limited'
p8758
(F1
F0.00014334862385321102
I0
I1
I-1
tp8759
sS'potent,than,that'
p8760
(F1
F0.00014334862385321102
I0
I1
I-1
tp8761
sS'that,and,oral'
p8762
(F1
F0.00014334862385321102
I1
I0
I1
tp8763
sS'interaction,involving,the'
p8764
(F1
F0.00014334862385321102
I1
I0
I1
tp8765
sS'valdecoxib,caused,a'
p8766
(F1
F0.00014334862385321102
I1
I0
I1
tp8767
sS'of,is,not'
p8768
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp8769
sS'decreases,renal,clearance'
p8770
(F1
F0.00014334862385321102
I1
I0
I1
tp8771
sS'year,pharmacokinetics,exposure-response'
p8772
(F1
F0.00014334862385321102
I0
I1
I-1
tp8773
sS'coadministered,with,other'
p8774
(F1
F0.00028669724770642203
I2
I0
I2
tp8775
sS'coadministration,of,aprepitant'
p8776
(F0
F0
I2
I2
I0
tp8777
sS'qtc,values,of'
p8778
(F1
F0.00014334862385321102
I1
I0
I1
tp8779
sS'to,those,with'
p8780
(F1
F0.00014334862385321102
I1
I0
I1
tp8781
sS'potentially,toxic,that'
p8782
(F1
F0.00014334862385321102
I0
I1
I-1
tp8783
sS'a,baseline,phenytoin'
p8784
(F1
F0.00014334862385321102
I1
I0
I1
tp8785
sS'absorption,of,bezalip'
p8786
(F1
F0.00014334862385321102
I1
I0
I1
tp8787
sS'interaction,information,digoxin'
p8788
(F1
F0.00014334862385321102
I0
I1
I-1
tp8789
sS'exercised,when,considering'
p8790
(F1
F0.00014334862385321102
I1
I0
I1
tp8791
sS'therapy,may,need'
p8792
(F1
F0.00014334862385321102
I1
I0
I1
tp8793
sS'not,affect,idv'
p8794
(F1
F0.00014334862385321102
I0
I1
I-1
tp8795
sS'concurrently,with,d2-antagonists'
p8796
(F1
F0.00014334862385321102
I1
I0
I1
tp8797
sS'nevertheless,the,effects'
p8798
(F1
F0.00014334862385321102
I1
I0
I1
tp8799
sS'the,auc,of'
p8800
(F1
F0.0032970183486238534
I23
I0
I23
tp8801
sS'state,auc,ss'
p8802
(F1
F0.00014334862385321102
I1
I0
I1
tp8803
sS'renal,excretion,ibuprofen'
p8804
(F1
F0.00014334862385321102
I0
I1
I-1
tp8805
sS'ml,h,to'
p8806
(F0
F0
I1
I1
I0
tp8807
sS'inhibits,or,induces'
p8808
(F1
F0.00014334862385321102
I0
I1
I-1
tp8809
sS'of,which,were'
p8810
(F1
F0.00014334862385321102
I1
I0
I1
tp8811
sS'with,natrecor,in'
p8812
(F1
F0.00014334862385321102
I0
I1
I-1
tp8813
sS'is,important,for'
p8814
(F1
F0.00014334862385321102
I0
I1
I-1
tp8815
sS'for,the,wild-type'
p8816
(F1
F0.00014334862385321102
I0
I1
I-1
tp8817
sS'auc,by,to'
p8818
(F1
F0.00014334862385321102
I1
I0
I1
tp8819
sS'times,increase,in'
p8820
(F1
F0.00014334862385321102
I1
I0
I1
tp8821
sS'preparations,has,not'
p8822
(F1
F0.00014334862385321102
I0
I1
I-1
tp8823
sS'as,and,because'
p8824
(F1
F0.00014334862385321102
I1
I0
I1
tp8825
sS'cyp3a4,inhibitors,eg'
p8826
(F1
F0.00014334862385321102
I0
I1
I-1
tp8827
sS'the,underlying,mechanism'
p8828
(F1
F0.00014334862385321102
I1
I0
I1
tp8829
sS'interactions,certain,endocrine'
p8830
(F1
F0.00014334862385321102
I0
I1
I-1
tp8831
sS'cefizox,nephrotoxicity,has'
p8832
(F1
F0.00014334862385321102
I1
I0
I1
tp8833
sS'had,less,than'
p8834
(F1
F0.00014334862385321102
I1
I0
I1
tp8835
sS'reversible,impairment,of'
p8836
(F1
F0.00014334862385321102
I1
I0
I1
tp8837
sS'a,relationship,of'
p8838
(F1
F0.00043004587155963305
I3
I0
I3
tp8839
sS'therapy,a,combination'
p8840
(F1
F0.00014334862385321102
I0
I1
I-1
tp8841
sS'beta-blocking,agents,has'
p8842
(F1
F0.00014334862385321102
I0
I1
I-1
tp8843
sS'in,greater,gastrointestinal'
p8844
(F1
F0.00014334862385321102
I1
I0
I1
tp8845
sS'the,dose,that'
p8846
(F1
F0.00014334862385321102
I0
I1
I-1
tp8847
sS'mean,auc,c'
p8848
(F1
F0.00014334862385321102
I0
I1
I-1
tp8849
sS'are,observed,in'
p8850
(F1
F0.00014334862385321102
I0
I1
I-1
tp8851
sS'combination,with,a'
p8852
(F1
F0.00057339449541284407
I0
I4
I-4
tp8853
sS'the,interaction,may'
p8854
(F1
F0.00014334862385321102
I0
I1
I-1
tp8855
sS'pharmacodynamic,interactions,the'
p8856
(F1
F0.00014334862385321102
I1
I0
I1
tp8857
sS'is,the,binding'
p8858
(F1
F0.00014334862385321102
I0
I1
I-1
tp8859
sS'concentration,index,fici'
p8860
(F1
F0.00014334862385321102
I0
I1
I-1
tp8861
sS'year,risk,of'
p8862
(F1
F0.00014334862385321102
I0
I1
I-1
tp8863
sS'concentrations,appeared,to'
p8864
(F1
F0.00014334862385321102
I0
I1
I-1
tp8865
sS'that,administration,of'
p8866
(F1
F0.00028669724770642203
I0
I2
I-2
tp8867
sS'dosing,of,aprepitant'
p8868
(F1
F0.00014334862385321102
I1
I0
I1
tp8869
sS'potentiated,by,monoamine'
p8870
(F1
F0.00028669724770642203
I2
I0
I2
tp8871
sS'use,of,h2'
p8872
(F1
F0.00014334862385321102
I1
I0
I1
tp8873
sS'to,or,withdrawn'
p8874
(F1
F0.00014334862385321102
I1
I0
I1
tp8875
sS'dilantin,use,of'
p8876
(F1
F0.00014334862385321102
I1
I0
I1
tp8877
sS'and,and,at'
p8878
(F1
F0.00014334862385321102
I1
I0
I1
tp8879
sS'evaluated,and,compared'
p8880
(F1
F0.00014334862385321102
I0
I1
I-1
tp8881
sS'dose,of,these'
p8882
(F1
F0.00014334862385321102
I1
I0
I1
tp8883
sS'that,pulmozyme,can'
p8884
(F1
F0.00014334862385321102
I0
I1
I-1
tp8885
sS'or,severity,of'
p8886
(F1
F0.00028669724770642203
I2
I0
I2
tp8887
sS'including,the,corrected'
p8888
(F1
F0.00014334862385321102
I0
I1
I-1
tp8889
sS'healthy,subjects,given'
p8890
(F1
F0.00028669724770642203
I2
I0
I2
tp8891
sS'coadministration,of,an'
p8892
(F1
F0.00014334862385321102
I1
I0
I1
tp8893
sS'after,a,bile'
p8894
(F1
F0.00028669724770642203
I2
I0
I2
tp8895
sS'administered,radiographic,iodinated'
p8896
(F1
F0.00014334862385321102
I1
I0
I1
tp8897
sS'release,whereas,the'
p8898
(F1
F0.00014334862385321102
I0
I1
I-1
tp8899
sS'increase,the,effects'
p8900
(F1
F0.00014334862385321102
I1
I0
I1
tp8901
sS'serum,proteins,or'
p8902
(F1
F0.00014334862385321102
I1
I0
I1
tp8903
sS'ns,were,not'
p8904
(F1
F0.00028669724770642203
I0
I2
I-2
tp8905
sS'markedly,increases,the'
p8906
(F1
F0.00014334862385321102
I1
I0
I1
tp8907
sS'studies,oral,and'
p8908
(F1
F0.00014334862385321102
I0
I1
I-1
tp8909
sS'other,tegretol,tagamet'
p8910
(F1
F0.00014334862385321102
I0
I1
I-1
tp8911
sS'concurrently,with,cerubidine'
p8912
(F1
F0.00014334862385321102
I1
I0
I1
tp8913
sS'the,added,concentration'
p8914
(F1
F0.00014334862385321102
I0
I1
I-1
tp8915
sS'in,the,extent'
p8916
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp8917
sS'by,explain,the'
p8918
(F1
F0.00014334862385321102
I1
I0
I1
tp8919
sS'nsaids,may,cause'
p8920
(F1
F0.00014334862385321102
I1
I0
I1
tp8921
sS'both,ca,and'
p8922
(F1
F0.00014334862385321102
I1
I0
I1
tp8923
sS'the,renal,clearance'
p8924
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp8925
sS'overload,both,in'
p8926
(F1
F0.00014334862385321102
I0
I1
I-1
tp8927
sS'collected,on,the'
p8928
(F1
F0.00014334862385321102
I0
I1
I-1
tp8929
sS'receiving,both,and'
p8930
(F1
F0.00028669724770642203
I2
I0
I2
tp8931
sS'severe,prolonged,hypotension'
p8932
(F1
F0.00014334862385321102
I1
I0
I1
tp8933
sS'filtration,or,tubular'
p8934
(F1
F0.00014334862385321102
I0
I1
I-1
tp8935
sS'with,other,including'
p8936
(F1
F0.00028669724770642203
I0
I2
I-2
tp8937
sS'rare,instances,of'
p8938
(F1
F0.00028669724770642203
I2
I0
I2
tp8939
sS'female,n,in'
p8940
(F1
F0.00014334862385321102
I0
I1
I-1
tp8941
sS'as,or,is'
p8942
(F1
F0.00014334862385321102
I0
I1
I-1
tp8943
sS'avoided,in,combination'
p8944
(F1
F0.00014334862385321102
I1
I0
I1
tp8945
sS'of,p,and'
p8946
(F1
F0.00014334862385321102
I1
I0
I1
tp8947
sS'of,see,warnings'
p8948
(F1
F0.00014334862385321102
I1
I0
I1
tp8949
sS'as,or,in'
p8950
(F0
F0
I1
I1
I0
tp8951
sS'effects,of,when'
p8952
(F1
F0.00028669724770642203
I2
I0
I2
tp8953
sS'be,taken,closely'
p8954
(F1
F0.00014334862385321102
I1
I0
I1
tp8955
sS'interactions,the,pharmacokinetic'
p8956
(F1
F0.00014334862385321102
I0
I1
I-1
tp8957
sS'dilantin,phenobarbital,tegretol'
p8958
(F1
F0.00014334862385321102
I1
I0
I1
tp8959
sS'with,experimental,toxic'
p8960
(F1
F0.00014334862385321102
I1
I0
I1
tp8961
sS'and,which,affect'
p8962
(F1
F0.00014334862385321102
I0
I1
I-1
tp8963
sS'to,obtain,serum'
p8964
(F1
F0.00014334862385321102
I1
I0
I1
tp8965
sS'antimigraine,derivatives,antimycobacterial'
p8966
(F1
F0.00014334862385321102
I1
I0
I1
tp8967
sS'not,a,substrate'
p8968
(F1
F0.00043004587155963305
I0
I3
I-3
tp8969
sS'c,max,increased'
p8970
(F1
F0.00014334862385321102
I0
I1
I-1
tp8971
sS'from,mg,l'
p8972
(F1
F0.00014334862385321102
I1
I0
I1
tp8973
sS'of,was,ng'
p8974
(F1
F0.00014334862385321102
I1
I0
I1
tp8975
sS'decreased,the,bioavailability'
p8976
(F1
F0.00014334862385321102
I1
I0
I1
tp8977
sS'were,fasted,and'
p8978
(F1
F0.00014334862385321102
I0
I1
I-1
tp8979
sS'decrease,overall,treatment'
p8980
(F1
F0.00014334862385321102
I0
I1
I-1
tp8981
sS'through,the,modulation'
p8982
(F1
F0.00014334862385321102
I0
I1
I-1
tp8983
sS'when,used,in'
p8984
(F0.63636363636363635
F0.0010034403669724771
I9
I2
I7
tp8985
sS'activation,of,different'
p8986
(F1
F0.00014334862385321102
I0
I1
I-1
tp8987
sS'with,the,bactericidal'
p8988
(F1
F0.00043004587155963305
I3
I0
I3
tp8989
sS'these,products,may'
p8990
(F1
F0.00014334862385321102
I1
I0
I1
tp8991
sS'the,usual,concentrations'
p8992
(F1
F0.00014334862385321102
I0
I1
I-1
tp8993
sS'additive,effects,were'
p8994
(F1
F0.00014334862385321102
I1
I0
I1
tp8995
sS'hcl,with,other'
p8996
(F1
F0.00014334862385321102
I1
I0
I1
tp8997
sS'desired,effect,on'
p8998
(F1
F0.00014334862385321102
I1
I0
I1
tp8999
sS'reductase,inhibitors,administered'
p9000
(F1
F0.00014334862385321102
I1
I0
I1
tp9001
sS'desired,effect,of'
p9002
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp9003
sS'prothrombin,response,through'
p9004
(F1
F0.00014334862385321102
I1
I0
I1
tp9005
sS'tea,polyphenols,as'
p9006
(F1
F0.00014334862385321102
I0
I1
I-1
tp9007
sS'atrophy,and,degenerative'
p9008
(F1
F0.00014334862385321102
I0
I1
I-1
tp9009
sS'chemical,resemblance,of'
p9010
(F1
F0.00014334862385321102
I1
I0
I1
tp9011
sS'no,data,on'
p9012
(F1
F0.00014334862385321102
I0
I1
I-1
tp9013
sS'they,cause,much'
p9014
(F1
F0.00014334862385321102
I0
I1
I-1
tp9015
sS'disease,requires,maintaining'
p9016
(F1
F0.00014334862385321102
I0
I1
I-1
tp9017
sS'as,indicated,in'
p9018
(F1
F0.00014334862385321102
I0
I1
I-1
tp9019
sS'clonidines,analgesic,actions'
p9020
(F1
F0.00014334862385321102
I0
I1
I-1
tp9021
sS'mg,daily,dose'
p9022
(F1
F0.00014334862385321102
I1
I0
I1
tp9023
sS'neither,racemic,nor'
p9024
(F1
F0.00014334862385321102
I0
I1
I-1
tp9025
sS'as,shown,in'
p9026
(F1
F0.00014334862385321102
I1
I0
I1
tp9027
sS'other,the,renal'
p9028
(F1
F0.00014334862385321102
I1
I0
I1
tp9029
sS'are,inducers,of'
p9030
(F1
F0.00014334862385321102
I0
I1
I-1
tp9031
sS'when,abilify,is'
p9032
(F1
F0.00014334862385321102
I1
I0
I1
tp9033
sS'prolongation,in,the'
p9034
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp9035
sS'ii,diabetic,patient'
p9036
(F1
F0.00014334862385321102
I1
I0
I1
tp9037
sS'blocking,agents,or'
p9038
(F1
F0.00014334862385321102
I0
I1
I-1
tp9039
sS'used,anti-peptic,agents'
p9040
(F1
F0.00014334862385321102
I0
I1
I-1
tp9041
sS'selegiline,hydrochloride,in'
p9042
(F1
F0.00014334862385321102
I1
I0
I1
tp9043
sS'netilmicin,should,not'
p9044
(F1
F0.00014334862385321102
I1
I0
I1
tp9045
sS'given,only,for'
p9046
(F1
F0.00014334862385321102
I0
I1
I-1
tp9047
sS'to,be,certain'
p9048
(F1
F0.00014334862385321102
I1
I0
I1
tp9049
sS'previously,been,reported'
p9050
(F1
F0.00014334862385321102
I0
I1
I-1
tp9051
sS'of,the,qt'
p9052
(F1
F0.0011467889908256881
I8
I0
I8
tp9053
sS'of,adrenocortical,dependent'
p9054
(F1
F0.00014334862385321102
I1
I0
I1
tp9055
sS'cyp2b6,cyp2c8,cyp2c9'
p9056
(F1
F0.00014334862385321102
I0
I1
I-1
tp9057
sS'in,urine,volume'
p9058
(F1
F0.00014334862385321102
I1
I0
I1
tp9059
sS'and,implantable,forms'
p9060
(F1
F0.00014334862385321102
I1
I0
I1
tp9061
sS'by,the,concomitant'
p9062
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp9063
sS'in,a,light'
p9064
(F1
F0.00014334862385321102
I0
I1
I-1
tp9065
sS'of,reports,in'
p9066
(F1
F0.00014334862385321102
I1
I0
I1
tp9067
sS'rationalized,at,the'
p9068
(F1
F0.00014334862385321102
I0
I1
I-1
tp9069
sS'pharmacokinetics,of,administered'
p9070
(F1
F0.00014334862385321102
I0
I1
I-1
tp9071
sS'rates,of,nimbex'
p9072
(F1
F0.00014334862385321102
I1
I0
I1
tp9073
sS'be,considered,when'
p9074
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp9075
sS'protein,bound,monoamine'
p9076
(F1
F0.00043004587155963305
I3
I0
I3
tp9077
sS'other,nonsteroidal,antiinflammatory'
p9078
(F1
F0.00014334862385321102
I1
I0
I1
tp9079
sS'with,any,significant'
p9080
(F1
F0.00014334862385321102
I1
I0
I1
tp9081
sS'with,water-miscible,or'
p9082
(F1
F0.00014334862385321102
I0
I1
I-1
tp9083
sS'and,mg,sodium'
p9084
(F1
F0.00014334862385321102
I1
I0
I1
tp9085
sS'frequently,if,is'
p9086
(F1
F0.00014334862385321102
I1
I0
I1
tp9087
sS'who,are,receiving'
p9088
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp9089
sS'cimetidine,at,doses'
p9090
(F1
F0.00014334862385321102
I1
I0
I1
tp9091
sS'cryptosporidium,parvum,growth'
p9092
(F1
F0.00014334862385321102
I1
I0
I1
tp9093
sS'with,phenurone,since'
p9094
(F1
F0.00014334862385321102
I1
I0
I1
tp9095
sS'metabolizing,enzymes,and'
p9096
(F1
F0.00014334862385321102
I0
I1
I-1
tp9097
sS'occurred,at,six'
p9098
(F1
F0.00014334862385321102
I1
I0
I1
tp9099
sS'seen,in,patients'
p9100
(F1
F0.00014334862385321102
I0
I1
I-1
tp9101
sS'risk,of,are'
p9102
(F1
F0.00014334862385321102
I1
I0
I1
tp9103
sS'monitored,and,the'
p9104
(F1
F0.00014334862385321102
I1
I0
I1
tp9105
sS'comparison,with,the'
p9106
(F0
F0
I1
I1
I0
tp9107
sS'an,intubating,dose'
p9108
(F1
F0.00014334862385321102
I1
I0
I1
tp9109
sS'end,fo,the'
p9110
(F1
F0.00014334862385321102
I0
I1
I-1
tp9111
sS'activity,data,on'
p9112
(F1
F0.00014334862385321102
I0
I1
I-1
tp9113
sS'both,the,rate'
p9114
(F1
F0.00014334862385321102
I1
I0
I1
tp9115
sS'five,lacking,kidney'
p9116
(F1
F0.00014334862385321102
I0
I1
I-1
tp9117
sS'the,has,on'
p9118
(F1
F0.00014334862385321102
I1
I0
I1
tp9119
sS'either,dose,had'
p9120
(F1
F0.00014334862385321102
I0
I1
I-1
tp9121
sS'of,for,the'
p9122
(F1
F0.00014334862385321102
I0
I1
I-1
tp9123
sS'hydrochloride,has,been'
p9124
(F1
F0.00028669724770642203
I2
I0
I2
tp9125
sS'more,pharmacologic,activities'
p9126
(F1
F0.00014334862385321102
I0
I1
I-1
tp9127
sS'seen,on,the'
p9128
(F1
F0.00014334862385321102
I0
I1
I-1
tp9129
sS'and,were,additive'
p9130
(F1
F0.00014334862385321102
I0
I1
I-1
tp9131
sS'in,the,perioperative'
p9132
(F1
F0.00014334862385321102
I1
I0
I1
tp9133
sS'with,or,might'
p9134
(F1
F0.00014334862385321102
I0
I1
I-1
tp9135
sS'using,but,not'
p9136
(F1
F0.00028669724770642203
I0
I2
I-2
tp9137
sS'other,coadministration,of'
p9138
(F1
F0.00014334862385321102
I0
I1
I-1
tp9139
sS'reported,in,association'
p9140
(F1
F0.00014334862385321102
I1
I0
I1
tp9141
sS'need,to,be'
p9142
(F1
F0.00043004587155963305
I3
I0
I3
tp9143
sS'monitoring,of,methotrexate-related'
p9144
(F1
F0.00014334862385321102
I1
I0
I1
tp9145
sS'foradil,should,be'
p9146
(F0
F0
I1
I1
I0
tp9147
sS'in,a,shortened'
p9148
(F1
F0.00014334862385321102
I1
I0
I1
tp9149
sS'cases,of,serious'
p9150
(F1
F0.00014334862385321102
I0
I1
I-1
tp9151
sS'respectively,when,was'
p9152
(F1
F0.00014334862385321102
I1
I0
I1
tp9153
sS'cases,of,mixed'
p9154
(F1
F0.00014334862385321102
I1
I0
I1
tp9155
sS'inhibitors,and,non-selective'
p9156
(F1
F0.00014334862385321102
I1
I0
I1
tp9157
sS'b-lactam,inhibits,the'
p9158
(F1
F0.00014334862385321102
I1
I0
I1
tp9159
sS'equetrotm,it,is'
p9160
(F1
F0.00014334862385321102
I1
I0
I1
tp9161
sS'mg,did,not'
p9162
(F1
F0.0014334862385321102
I0
I10
I-10
tp9163
sS'or,dosing,requirements'
p9164
(F1
F0.00014334862385321102
I0
I1
I-1
tp9165
sS'administration,of,stadol'
p9166
(F1
F0.00014334862385321102
I0
I1
I-1
tp9167
sS'observed,that,the'
p9168
(F1
F0.00014334862385321102
I0
I1
I-1
tp9169
sS'not,a,significant'
p9170
(F1
F0.00014334862385321102
I0
I1
I-1
tp9171
sS'effects,of,chronic'
p9172
(F1
F0.00014334862385321102
I1
I0
I1
tp9173
sS'of,clinical,studies'
p9174
(F1
F0.00028669724770642203
I2
I0
I2
tp9175
sS'levels,limit,adverse'
p9176
(F1
F0.00014334862385321102
I1
I0
I1
tp9177
sS'cns-depressant,action,of'
p9178
(F1
F0.00014334862385321102
I1
I0
I1
tp9179
sS'in,the,co-administration'
p9180
(F1
F0.00057339449541284407
I4
I0
I4
tp9181
sS'and,how,it'
p9182
(F1
F0.00014334862385321102
I0
I1
I-1
tp9183
sS'with,mg,vardenafil'
p9184
(F1
F0.00014334862385321102
I0
I1
I-1
tp9185
sS'major,cytochrome,p450'
p9186
(F1
F0.00014334862385321102
I0
I1
I-1
tp9187
sS'enzyme,should,be'
p9188
(F1
F0.00014334862385321102
I1
I0
I1
tp9189
sS'other,such,as'
p9190
(F0
F0
I2
I2
I0
tp9191
sS'a,minor,metabolizing'
p9192
(F1
F0.00014334862385321102
I0
I1
I-1
tp9193
sS'other,potassium-sparing,with'
p9194
(F1
F0.00014334862385321102
I1
I0
I1
tp9195
sS'symptoms,severe,dry'
p9196
(F1
F0.00014334862385321102
I1
I0
I1
tp9197
sS'decrease,the,hepatic'
p9198
(F1
F0.00014334862385321102
I1
I0
I1
tp9199
sS'study,with,in'
p9200
(F1
F0.00028669724770642203
I2
I0
I2
tp9201
sS'the,potential,effects'
p9202
(F0.5
F0.00028669724770642203
I3
I1
I2
tp9203
sS'some,reports,have'
p9204
(F1
F0.00043004587155963305
I3
I0
I3
tp9205
sS'cyp,a4,has'
p9206
(F1
F0.00014334862385321102
I0
I1
I-1
tp9207
sS'colitis,a,methotrexate'
p9208
(F1
F0.00014334862385321102
I1
I0
I1
tp9209
sS'but,this,has'
p9210
(F1
F0.00014334862385321102
I1
I0
I1
tp9211
sS'superior,antipsychotic,efficacy'
p9212
(F1
F0.00014334862385321102
I0
I1
I-1
tp9213
sS'how,it,should'
p9214
(F1
F0.00028669724770642203
I0
I2
I-2
tp9215
sS'after,the,nasal'
p9216
(F1
F0.00014334862385321102
I1
I0
I1
tp9217
sS'levothyroxine,sodium,absorption'
p9218
(F1
F0.00014334862385321102
I1
I0
I1
tp9219
sS'to,hours,after'
p9220
(F1
F0.00014334862385321102
I0
I1
I-1
tp9221
sS'hexalen,and,of'
p9222
(F1
F0.00014334862385321102
I1
I0
I1
tp9223
sS'succinylcholine-induced,neuromuscular,blockade'
p9224
(F1
F0.00014334862385321102
I0
I1
I-1
tp9225
sS'and,or,pharmacodynamics'
p9226
(F1
F0.00014334862385321102
I0
I1
I-1
tp9227
sS'preparations,nsaids,antigout'
p9228
(F1
F0.00014334862385321102
I0
I1
I-1
tp9229
sS'decreased,concentrations,in'
p9230
(F1
F0.00014334862385321102
I1
I0
I1
tp9231
sS'had,no,relevant'
p9232
(F1
F0.00014334862385321102
I0
I1
I-1
tp9233
sS'with,fortovase,may'
p9234
(F1
F0.00014334862385321102
I0
I1
I-1
tp9235
sS'end,of,the'
p9236
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp9237
sS'week,trial,showed'
p9238
(F1
F0.00014334862385321102
I0
I1
I-1
tp9239
sS'maalox,reduced,the'
p9240
(F1
F0.00014334862385321102
I1
I0
I1
tp9241
sS'of,increasing,its'
p9242
(F1
F0.00014334862385321102
I1
I0
I1
tp9243
sS'potentiated,by,certain'
p9244
(F1
F0.00043004587155963305
I3
I0
I3
tp9245
sS'evaluated,the,effect'
p9246
(F1
F0.00014334862385321102
I0
I1
I-1
tp9247
sS'addition,under,the'
p9248
(F1
F0.00028669724770642203
I0
I2
I-2
tp9249
sS'when,screening,urine'
p9250
(F1
F0.00014334862385321102
I0
I1
I-1
tp9251
sS'drugs,ethanol,sonata'
p9252
(F1
F0.00014334862385321102
I1
I0
I1
tp9253
sS'is,catalyzed,by'
p9254
(F1
F0.00014334862385321102
I0
I1
I-1
tp9255
sS'possible,combined,actions'
p9256
(F1
F0.00028669724770642203
I0
I2
I-2
tp9257
sS'and,brovana,may'
p9258
(F1
F0.00014334862385321102
I1
I0
I1
tp9259
sS'on,kinetics,and'
p9260
(F1
F0.00014334862385321102
I1
I0
I1
tp9261
sS'dcg-iv,and,l-ccg'
p9262
(F1
F0.00043004587155963305
I0
I3
I-3
tp9263
sS'and,oral,containing'
p9264
(F1
F0.00014334862385321102
I1
I0
I1
tp9265
sS'reduced,the,antitumour'
p9266
(F1
F0.00014334862385321102
I1
I0
I1
tp9267
sS'is,given,for'
p9268
(F1
F0.00014334862385321102
I0
I1
I-1
tp9269
sS'the,colonic,transit-enhancing'
p9270
(F1
F0.00014334862385321102
I0
I1
I-1
tp9271
sS'with,left,ventricular'
p9272
(F1
F0.00014334862385321102
I0
I1
I-1
tp9273
sS'attenuate,loss,caused'
p9274
(F1
F0.00028669724770642203
I2
I0
I2
tp9275
sS'two,multiple-dose,interaction'
p9276
(F1
F0.00014334862385321102
I0
I1
I-1
tp9277
sS'methylpyrazole,seen,in'
p9278
(F1
F0.00014334862385321102
I1
I0
I1
tp9279
sS'vitro,interaction,between'
p9280
(F1
F0.00014334862385321102
I1
I0
I1
tp9281
sS'levels,or,may'
p9282
(F1
F0.00014334862385321102
I1
I0
I1
tp9283
sS'of,as,reflected'
p9284
(F1
F0.00014334862385321102
I1
I0
I1
tp9285
sS'qtc,interval,because'
p9286
(F1
F0.00014334862385321102
I1
I0
I1
tp9287
sS'r,p,app'
p9288
(F1
F0.00014334862385321102
I0
I1
I-1
tp9289
sS'felbatol,as,monotherapy'
p9290
(F1
F0.00014334862385321102
I0
I1
I-1
tp9291
sS'cause,coronary,artery'
p9292
(F1
F0.00014334862385321102
I1
I0
I1
tp9293
sS'be,further,increased'
p9294
(F1
F0.00014334862385321102
I0
I1
I-1
tp9295
sS'produced,by,subsequent'
p9296
(F1
F0.00014334862385321102
I1
I0
I1
tp9297
sS'nonprescription,products,you'
p9298
(F1
F0.00014334862385321102
I0
I1
I-1
tp9299
sS'but,there,have'
p9300
(F0
F0
I1
I1
I0
tp9301
sS'vivo,resulted,in'
p9302
(F1
F0.00014334862385321102
I0
I1
I-1
tp9303
sS'rats,pd2,values'
p9304
(F1
F0.00014334862385321102
I1
I0
I1
tp9305
sS'test,interactions,amphetamines'
p9306
(F1
F0.00014334862385321102
I1
I0
I1
tp9307
sS'one,should,consider'
p9308
(F1
F0.00014334862385321102
I0
I1
I-1
tp9309
sS'property,of,to'
p9310
(F1
F0.00014334862385321102
I1
I0
I1
tp9311
sS'mean,sd,cumulative'
p9312
(F1
F0.00014334862385321102
I0
I1
I-1
tp9313
sS'levels,monitored,after'
p9314
(F1
F0.00014334862385321102
I1
I0
I1
tp9315
sS'of,initial,and'
p9316
(F1
F0.00014334862385321102
I1
I0
I1
tp9317
sS'administration,of,brevibloc'
p9318
(F1
F0.00014334862385321102
I0
I1
I-1
tp9319
sS'of,nsaids,in'
p9320
(F1
F0.00014334862385321102
I1
I0
I1
tp9321
sS'infused,over,minutes'
p9322
(F1
F0.00014334862385321102
I0
I1
I-1
tp9323
sS'followed,by,a'
p9324
(F0.5
F0.00028669724770642203
I3
I1
I2
tp9325
sS'significant,difference,between'
p9326
(F1
F0.00014334862385321102
I0
I1
I-1
tp9327
sS'and,related,psychoses'
p9328
(F1
F0.00014334862385321102
I0
I1
I-1
tp9329
sS'and,minimal,inhibitory'
p9330
(F1
F0.00014334862385321102
I0
I1
I-1
tp9331
sS'clearance,of,these'
p9332
(F1
F0.00014334862385321102
I1
I0
I1
tp9333
sS'occur,when,and'
p9334
(F1
F0.00014334862385321102
I1
I0
I1
tp9335
sS'and,and,twice-a'
p9336
(F1
F0.00014334862385321102
I0
I1
I-1
tp9337
sS'and,for,preservation'
p9338
(F1
F0.00014334862385321102
I0
I1
I-1
tp9339
sS'dosage,levels,should'
p9340
(F1
F0.00014334862385321102
I1
I0
I1
tp9341
sS'change,in,the'
p9342
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp9343
sS'unclear,how,soon'
p9344
(F1
F0.00014334862385321102
I1
I0
I1
tp9345
sS'pancreatic,effects,of'
p9346
(F1
F0.00014334862385321102
I0
I1
I-1
tp9347
sS'patients,were,dry'
p9348
(F1
F0.00014334862385321102
I0
I1
I-1
tp9349
sS'and,because,they'
p9350
(F1
F0.00014334862385321102
I0
I1
I-1
tp9351
sS'to,inhibit,cyp3a4'
p9352
(F1
F0.00014334862385321102
I0
I1
I-1
tp9353
sS'while,fractional,transfer'
p9354
(F1
F0.00014334862385321102
I0
I1
I-1
tp9355
sS'administration,of,d'
p9356
(F1
F0.00014334862385321102
I1
I0
I1
tp9357
sS'percentage,of,neurons'
p9358
(F1
F0.00014334862385321102
I0
I1
I-1
tp9359
sS'not,the,coat-core'
p9360
(F1
F0.00014334862385321102
I1
I0
I1
tp9361
sS'of,have,been'
p9362
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp9363
sS'therefore,potential,interactions'
p9364
(F1
F0.00014334862385321102
I0
I1
I-1
tp9365
sS'caffeine-related,adverse,effects'
p9366
(F1
F0.00014334862385321102
I1
I0
I1
tp9367
sS'to,rats,treated'
p9368
(F1
F0.00014334862385321102
I1
I0
I1
tp9369
sS'and,either,or'
p9370
(F1
F0.00014334862385321102
I0
I1
I-1
tp9371
sS'isoflurane,or,administered'
p9372
(F1
F0.00014334862385321102
I1
I0
I1
tp9373
sS'a4,grapefruit,juice'
p9374
(F1
F0.00014334862385321102
I1
I0
I1
tp9375
sS'agents,the,concomitant'
p9376
(F1
F0.00014334862385321102
I0
I1
I-1
tp9377
sS'of,cholecystokinin,octapeptide'
p9378
(F1
F0.00014334862385321102
I0
I1
I-1
tp9379
sS'which,are,reported'
p9380
(F1
F0.00014334862385321102
I1
I0
I1
tp9381
sS'and,charcoal,administration'
p9382
(F1
F0.00014334862385321102
I1
I0
I1
tp9383
sS'with,iron,concomitant'
p9384
(F1
F0.00014334862385321102
I1
I0
I1
tp9385
sS'pharmacokinetics,of,which'
p9386
(F1
F0.00014334862385321102
I1
I0
I1
tp9387
sS's,c,inhibited'
p9388
(F1
F0.00014334862385321102
I1
I0
I1
tp9389
sS'as,other,nonsteroidal'
p9390
(F1
F0.00014334862385321102
I1
I0
I1
tp9391
sS'pharmacology,study,or'
p9392
(F1
F0.00014334862385321102
I0
I1
I-1
tp9393
sS'vaccines,patients,on'
p9394
(F1
F0.00014334862385321102
I1
I0
I1
tp9395
sS'medication,iodine-containing,products'
p9396
(F1
F0.00014334862385321102
I0
I1
I-1
tp9397
sS'intravenous,antagonists,should'
p9398
(F1
F0.00014334862385321102
I1
I0
I1
tp9399
sS'highly,effective,there'
p9400
(F1
F0.00014334862385321102
I0
I1
I-1
tp9401
sS'administration,of,dynacirc'
p9402
(F1
F0.00028669724770642203
I0
I2
I-2
tp9403
sS'of,at,doses'
p9404
(F1
F0.00028669724770642203
I2
I0
I2
tp9405
sS'for,days,following'
p9406
(F1
F0.00014334862385321102
I0
I1
I-1
tp9407
sS'of,cefditoren,with'
p9408
(F1
F0.00014334862385321102
I1
I0
I1
tp9409
sS'with,steady,state'
p9410
(F1
F0.00014334862385321102
I1
I0
I1
tp9411
sS'of,edetate,disodium'
p9412
(F1
F0.00014334862385321102
I1
I0
I1
tp9413
sS'failed,to,cause'
p9414
(F1
F0.00014334862385321102
I1
I0
I1
tp9415
sS'inhibitors,of,cyp450'
p9416
(F1
F0.00014334862385321102
I0
I1
I-1
tp9417
sS'foscarnets,tendency,to'
p9418
(F1
F0.00014334862385321102
I1
I0
I1
tp9419
sS'elevations,and,or'
p9420
(F1
F0.00014334862385321102
I1
I0
I1
tp9421
sS'pcp,produced,transient'
p9422
(F1
F0.00014334862385321102
I0
I1
I-1
tp9423
sS'with,innovar,vet'
p9424
(F1
F0.00014334862385321102
I1
I0
I1
tp9425
sS'acidity,does,not'
p9426
(F1
F0.00014334862385321102
I0
I1
I-1
tp9427
sS'analgesics,was,similar'
p9428
(F1
F0.00014334862385321102
I0
I1
I-1
tp9429
sS'ensure,clinically,effective'
p9430
(F1
F0.00014334862385321102
I1
I0
I1
tp9431
sS'zidovudine,should,either'
p9432
(F1
F0.00014334862385321102
I1
I0
I1
tp9433
sS'is,clinically,compatible'
p9434
(F1
F0.00014334862385321102
I0
I1
I-1
tp9435
sS'of,oxypurines,hypoxanthine'
p9436
(F1
F0.00014334862385321102
I1
I0
I1
tp9437
sS'antiepileptic,drugs,the'
p9438
(F1
F0.00014334862385321102
I1
I0
I1
tp9439
sS'moderate,hypertension,where'
p9440
(F1
F0.00014334862385321102
I0
I1
I-1
tp9441
sS'of,skin,rash'
p9442
(F1
F0.00014334862385321102
I1
I0
I1
tp9443
sS'isoniazid,may,increase'
p9444
(F1
F0.00014334862385321102
I1
I0
I1
tp9445
sS'of,in,rodent'
p9446
(F1
F0.00014334862385321102
I0
I1
I-1
tp9447
sS'tcas,when,given'
p9448
(F1
F0.00071674311926605509
I0
I5
I-5
tp9449
sS'sodium,and,were'
p9450
(F1
F0.00014334862385321102
I0
I1
I-1
tp9451
sS'salts,with,practically'
p9452
(F1
F0.00014334862385321102
I0
I1
I-1
tp9453
sS'case,reports,and'
p9454
(F1
F0.00014334862385321102
I0
I1
I-1
tp9455
sS'far,greater,than'
p9456
(F1
F0.00014334862385321102
I0
I1
I-1
tp9457
sS'inhibit,the,metabolism'
p9458
(F1
F0.0017201834862385322
I12
I0
I12
tp9459
sS'data,in,patients'
p9460
(F0
F0
I1
I1
I0
tp9461
sS'treatment,of,osteoarthritis'
p9462
(F1
F0.00014334862385321102
I0
I1
I-1
tp9463
sS'is,needed,when'
p9464
(F1
F0.00014334862385321102
I0
I1
I-1
tp9465
sS'patients,on,or'
p9466
(F1
F0.00014334862385321102
I1
I0
I1
tp9467
sS'hormone,levels,induced'
p9468
(F1
F0.00014334862385321102
I0
I1
I-1
tp9469
sS'very,rarely,in'
p9470
(F1
F0.00014334862385321102
I1
I0
I1
tp9471
sS'its,derivatives,prothrombin'
p9472
(F1
F0.00014334862385321102
I1
I0
I1
tp9473
sS'are,not,primarily'
p9474
(F1
F0.00014334862385321102
I1
I0
I1
tp9475
sS'at,steady-state,with'
p9476
(F0
F0
I1
I1
I0
tp9477
sS'sucralfate,and,quinolones'
p9478
(F1
F0.00014334862385321102
I0
I1
I-1
tp9479
sS'and,and,reduces'
p9480
(F1
F0.00014334862385321102
I1
I0
I1
tp9481
sS'same,evening,meal'
p9482
(F1
F0.00014334862385321102
I1
I0
I1
tp9483
sS'concentration,of,when'
p9484
(F1
F0.00014334862385321102
I1
I0
I1
tp9485
sS'reduce,the,renal'
p9486
(F1
F0.00028669724770642203
I2
I0
I2
tp9487
sS'effects,is,not'
p9488
(F1
F0.00014334862385321102
I1
I0
I1
tp9489
sS'of,two,reverse'
p9490
(F1
F0.00014334862385321102
I0
I1
I-1
tp9491
sS'response,is,less'
p9492
(F1
F0.00014334862385321102
I1
I0
I1
tp9493
sS'other,hormonalmethods,of'
p9494
(F1
F0.00014334862385321102
I1
I0
I1
tp9495
sS'the,objective,of'
p9496
(F1
F0.00014334862385321102
I0
I1
I-1
tp9497
sS'ns,mg,qid'
p9498
(F1
F0.00014334862385321102
I0
I1
I-1
tp9499
sS'thiosulfate,is,a'
p9500
(F1
F0.00014334862385321102
I1
I0
I1
tp9501
sS'increased,monitoring,of'
p9502
(F1
F0.00014334862385321102
I1
I0
I1
tp9503
sS'and,the,model'
p9504
(F1
F0.00014334862385321102
I0
I1
I-1
tp9505
sS'increase,the,toxicity'
p9506
(F0
F0
I1
I1
I0
tp9507
sS'discontinuation,of,has'
p9508
(F1
F0.00014334862385321102
I1
I0
I1
tp9509
sS'the,pharmacokinetic,interaction'
p9510
(F1
F0.00014334862385321102
I0
I1
I-1
tp9511
sS'the,renal,toxicity'
p9512
(F1
F0.00014334862385321102
I1
I0
I1
tp9513
sS'therapy,with,orencia'
p9514
(F1
F0.00014334862385321102
I1
I0
I1
tp9515
sS'metabolites,were,studied'
p9516
(F1
F0.00014334862385321102
I0
I1
I-1
tp9517
sS'of,or,will'
p9518
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9519
sS'similar,to,sodium'
p9520
(F1
F0.00014334862385321102
I0
I1
I-1
tp9521
sS'diabetics,or,patients'
p9522
(F1
F0.00014334862385321102
I1
I0
I1
tp9523
sS'effect,relationship,physicians'
p9524
(F1
F0.00014334862385321102
I1
I0
I1
tp9525
sS'of,oral,mg'
p9526
(F1
F0.00014334862385321102
I1
I0
I1
tp9527
sS'during,or,after'
p9528
(F1
F0.00014334862385321102
I1
I0
I1
tp9529
sS'inhalational,such,as'
p9530
(F1
F0.00014334862385321102
I1
I0
I1
tp9531
sS'would,cause,direct'
p9532
(F1
F0.00014334862385321102
I0
I1
I-1
tp9533
sS'and,alternative,therapy'
p9534
(F1
F0.00014334862385321102
I1
I0
I1
tp9535
sS'choline,arthropan,magan'
p9536
(F1
F0.00014334862385321102
I1
I0
I1
tp9537
sS'vasodilator,activity,data'
p9538
(F1
F0.00014334862385321102
I0
I1
I-1
tp9539
sS'app,control,of'
p9540
(F1
F0.00014334862385321102
I0
I1
I-1
tp9541
sS'metabolized,by,glucuronidation'
p9542
(F1
F0.00014334862385321102
I0
I1
I-1
tp9543
sS'of,are,likely'
p9544
(F0
F0
I1
I1
I0
tp9545
sS'because,the,pharmacologically'
p9546
(F1
F0.00014334862385321102
I1
I0
I1
tp9547
sS'with,no,evidence'
p9548
(F1
F0.00014334862385321102
I0
I1
I-1
tp9549
sS'and,because,increases'
p9550
(F1
F0.00014334862385321102
I1
I0
I1
tp9551
sS'produced,only,minor'
p9552
(F1
F0.00014334862385321102
I1
I0
I1
tp9553
sS'broadly,the,same'
p9554
(F1
F0.00014334862385321102
I0
I1
I-1
tp9555
sS'before,using,this'
p9556
(F1
F0.00014334862385321102
I0
I1
I-1
tp9557
sS'cmax,but,no'
p9558
(F1
F0.00014334862385321102
I0
I1
I-1
tp9559
sS'and,nsaids,on'
p9560
(F1
F0.00028669724770642203
I2
I0
I2
tp9561
sS'enzyme-inducing,such,as'
p9562
(F1
F0.00014334862385321102
I1
I0
I1
tp9563
sS'of,the,study'
p9564
(F1
F0.00014334862385321102
I0
I1
I-1
tp9565
sS'given,by,infusion'
p9566
(F1
F0.00014334862385321102
I0
I1
I-1
tp9567
sS'subtypes,using,their'
p9568
(F1
F0.00014334862385321102
I0
I1
I-1
tp9569
sS'binding,to,serum'
p9570
(F1
F0.00014334862385321102
I1
I0
I1
tp9571
sS'were,examined,in'
p9572
(F1
F0.00014334862385321102
I0
I1
I-1
tp9573
sS'vardenafil,had,no'
p9574
(F1
F0.00014334862385321102
I0
I1
I-1
tp9575
sS'use,of,selective'
p9576
(F1
F0.00014334862385321102
I1
I0
I1
tp9577
sS'from,to,mg'
p9578
(F1
F0.00014334862385321102
I0
I1
I-1
tp9579
sS'efficacy,is,impaired'
p9580
(F1
F0.00014334862385321102
I1
I0
I1
tp9581
sS'from,to,mm'
p9582
(F1
F0.00014334862385321102
I0
I1
I-1
tp9583
sS'can,decrease,plasma'
p9584
(F1
F0.00028669724770642203
I2
I0
I2
tp9585
sS'patients,there,was'
p9586
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp9587
sS'adsorbents,and,digestive'
p9588
(F1
F0.00014334862385321102
I1
I0
I1
tp9589
sS'up,to,after'
p9590
(F1
F0.00014334862385321102
I1
I0
I1
tp9591
sS'days,increases,plasma'
p9592
(F1
F0.00014334862385321102
I0
I1
I-1
tp9593
sS'already,receiving,there'
p9594
(F1
F0.00014334862385321102
I1
I0
I1
tp9595
sS'taking,monoamine,oxidase'
p9596
(F1
F0.00014334862385321102
I1
I0
I1
tp9597
sS'that,inhibit,alprazolam'
p9598
(F1
F0.00014334862385321102
I0
I1
I-1
tp9599
sS'with,overdosage,or'
p9600
(F1
F0.00014334862385321102
I1
I0
I1
tp9601
sS'oral,markedly,inhibits'
p9602
(F1
F0.00014334862385321102
I1
I0
I1
tp9603
sS'in,increased,and'
p9604
(F1
F0.00014334862385321102
I1
I0
I1
tp9605
sS'for,and,synergistic'
p9606
(F1
F0.00014334862385321102
I1
I0
I1
tp9607
sS'with,inhibition,of'
p9608
(F1
F0.00014334862385321102
I1
I0
I1
tp9609
sS'administration,of,fibric'
p9610
(F1
F0.00014334862385321102
I0
I1
I-1
tp9611
sS'blocks,the,central'
p9612
(F1
F0.00014334862385321102
I1
I0
I1
tp9613
sS'mechanism,for,the'
p9614
(F1
F0.00014334862385321102
I1
I0
I1
tp9615
sS'vitro,data,in'
p9616
(F1
F0.00014334862385321102
I0
I1
I-1
tp9617
sS'orally,to,healthy'
p9618
(F1
F0.00014334862385321102
I0
I1
I-1
tp9619
sS'of,ranging,from'
p9620
(F1
F0.00014334862385321102
I1
I0
I1
tp9621
sS'acid,sequestrants,may'
p9622
(F1
F0.00014334862385321102
I1
I0
I1
tp9623
sS'concerns,regarding,protease'
p9624
(F1
F0.00014334862385321102
I0
I1
I-1
tp9625
sS'of,cyp2d6,may'
p9626
(F1
F0.00014334862385321102
I0
I1
I-1
tp9627
sS'associated,with,elevations'
p9628
(F1
F0.00043004587155963305
I3
I0
I3
tp9629
sS'therapy,when,plasma'
p9630
(F1
F0.00014334862385321102
I1
I0
I1
tp9631
sS'inhibit,accumulation,in'
p9632
(F1
F0.00014334862385321102
I1
I0
I1
tp9633
sS'the,function,as'
p9634
(F1
F0.00014334862385321102
I0
I1
I-1
tp9635
sS'rat,bone,marrow'
p9636
(F1
F0.00014334862385321102
I0
I1
I-1
tp9637
sS'since,it,has'
p9638
(F0
F0
I1
I1
I0
tp9639
sS'adverse,experience,profile'
p9640
(F1
F0.00014334862385321102
I0
I1
I-1
tp9641
sS'levels,of,ergocalcitriol'
p9642
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9643
sS'therefore,cyp3a4,substrates'
p9644
(F1
F0.00014334862385321102
I1
I0
I1
tp9645
sS'rats,followed,by'
p9646
(F1
F0.00014334862385321102
I0
I1
I-1
tp9647
sS'false-positive,reaction,for'
p9648
(F1
F0.00071674311926605509
I0
I5
I-5
tp9649
sS'interfere,with,in'
p9650
(F1
F0.00014334862385321102
I1
I0
I1
tp9651
sS'receiving,concurrent,therapy'
p9652
(F1
F0.00028669724770642203
I2
I0
I2
tp9653
sS'no,clinical,evidence'
p9654
(F1
F0.00014334862385321102
I0
I1
I-1
tp9655
sS'more,severe,in'
p9656
(F1
F0.00014334862385321102
I0
I1
I-1
tp9657
sS'pimozide,and,celexa'
p9658
(F1
F0.00014334862385321102
I1
I0
I1
tp9659
sS'tikosyn,mcg,bid'
p9660
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9661
sS'for,reexacerbation,of'
p9662
(F1
F0.00014334862385321102
I1
I0
I1
tp9663
sS'in,mean,neutrophil'
p9664
(F1
F0.00014334862385321102
I1
I0
I1
tp9665
sS'with,and,dopa'
p9666
(F1
F0.00014334862385321102
I0
I1
I-1
tp9667
sS'emphasize,that,apoptosis'
p9668
(F1
F0.00014334862385321102
I0
I1
I-1
tp9669
sS'aom,and,the'
p9670
(F1
F0.00014334862385321102
I0
I1
I-1
tp9671
sS'antagonized,the,rate-decreasing'
p9672
(F1
F0.00014334862385321102
I1
I0
I1
tp9673
sS'subcutaneous,dose,should'
p9674
(F1
F0.00014334862385321102
I1
I0
I1
tp9675
sS'effects,of,have'
p9676
(F1
F0.00028669724770642203
I0
I2
I-2
tp9677
sS'nor,inhibits,or'
p9678
(F1
F0.00014334862385321102
I0
I1
I-1
tp9679
sS'monitored,because,the'
p9680
(F1
F0.00014334862385321102
I1
I0
I1
tp9681
sS'has,been,characterized'
p9682
(F1
F0.00014334862385321102
I0
I1
I-1
tp9683
sS'oral,containing,mg'
p9684
(F1
F0.00014334862385321102
I0
I1
I-1
tp9685
sS'before,to,attenuate'
p9686
(F1
F0.00028669724770642203
I0
I2
I-2
tp9687
sS'are,added,to'
p9688
(F1
F0.00014334862385321102
I0
I1
I-1
tp9689
sS'with,caution,and'
p9690
(F1
F0.00028669724770642203
I2
I0
I2
tp9691
sS'did,not,affect'
p9692
(F0.85185185185185186
F0.0032970183486238534
I2
I25
I-23
tp9693
sS'compared,directly,to'
p9694
(F1
F0.00014334862385321102
I0
I1
I-1
tp9695
sS'have,their,prothrombin'
p9696
(F1
F0.00014334862385321102
I1
I0
I1
tp9697
sS'use,with,or'
p9698
(F1
F0.00014334862385321102
I1
I0
I1
tp9699
sS'each,of,these'
p9700
(F1
F0.00014334862385321102
I0
I1
I-1
tp9701
sS'reported,to,the'
p9702
(F1
F0.00014334862385321102
I0
I1
I-1
tp9703
sS'or,preparations,produced'
p9704
(F1
F0.00014334862385321102
I0
I1
I-1
tp9705
sS'show,that,revlimid'
p9706
(F1
F0.00014334862385321102
I0
I1
I-1
tp9707
sS'motor,effects,of'
p9708
(F1
F0.00014334862385321102
I1
I0
I1
tp9709
sS'endorphinergic,system,by'
p9710
(F1
F0.00014334862385321102
I0
I1
I-1
tp9711
sS'male,subjects,increased'
p9712
(F1
F0.00014334862385321102
I1
I0
I1
tp9713
sS'reductions,in,blood'
p9714
(F1
F0.00014334862385321102
I1
I0
I1
tp9715
sS'displaced,from,its'
p9716
(F1
F0.00043004587155963305
I3
I0
I3
tp9717
sS'lucidum,extract,alone'
p9718
(F1
F0.00014334862385321102
I0
I1
I-1
tp9719
sS'warfarin,keppra,mg'
p9720
(F1
F0.00014334862385321102
I0
I1
I-1
tp9721
sS'is,small,when'
p9722
(F1
F0.00014334862385321102
I1
I0
I1
tp9723
sS'patients,receiving,infusions'
p9724
(F1
F0.00014334862385321102
I0
I1
I-1
tp9725
sS'and,indocin,should'
p9726
(F1
F0.00014334862385321102
I1
I0
I1
tp9727
sS'bradycardia,qt,c'
p9728
(F1
F0.00014334862385321102
I1
I0
I1
tp9729
sS'risk,of,hyperkalemia'
p9730
(F1
F0.00014334862385321102
I1
I0
I1
tp9731
sS'psychopathology,rating,scales'
p9732
(F1
F0.00014334862385321102
I0
I1
I-1
tp9733
sS'or,with,other'
p9734
(F1
F0.00014334862385321102
I1
I0
I1
tp9735
sS'between,deficiency,due'
p9736
(F1
F0.00014334862385321102
I0
I1
I-1
tp9737
sS'reported,during,with'
p9738
(F1
F0.00014334862385321102
I1
I0
I1
tp9739
sS'dose,of,should'
p9740
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp9741
sS'skeletal-muscle,relaxants,nondepolarizing'
p9742
(F1
F0.00014334862385321102
I0
I1
I-1
tp9743
sS'and,subcutaneous,injections'
p9744
(F1
F0.00014334862385321102
I0
I1
I-1
tp9745
sS'in,addition,certain'
p9746
(F1
F0.00028669724770642203
I0
I2
I-2
tp9747
sS'adjustment,in,dose'
p9748
(F1
F0.00014334862385321102
I0
I1
I-1
tp9749
sS'at,bedtime,and'
p9750
(F1
F0.00014334862385321102
I0
I1
I-1
tp9751
sS'of,percentage,increase'
p9752
(F1
F0.00043004587155963305
I3
I0
I3
tp9753
sS'glucose,levels,and'
p9754
(F1
F0.00014334862385321102
I1
I0
I1
tp9755
sS'myocardial,infarction,myocarditis'
p9756
(F1
F0.00014334862385321102
I1
I0
I1
tp9757
sS'and,the,variability'
p9758
(F1
F0.00014334862385321102
I1
I0
I1
tp9759
sS'that,was,abolished'
p9760
(F1
F0.00014334862385321102
I1
I0
I1
tp9761
sS'tendency,to,antagonize'
p9762
(F1
F0.00014334862385321102
I1
I0
I1
tp9763
sS'flurbiprofen,like,other'
p9764
(F1
F0.00014334862385321102
I1
I0
I1
tp9765
sS'caused,a,rapid'
p9766
(F1
F0.00014334862385321102
I1
I0
I1
tp9767
sS'after,clinical,patterns'
p9768
(F1
F0.00014334862385321102
I0
I1
I-1
tp9769
sS'volunteers,did,not'
p9770
(F1
F0.00043004587155963305
I0
I3
I-3
tp9771
sS'can,lead,to'
p9772
(F1
F0.00043004587155963305
I3
I0
I3
tp9773
sS'on,without,evidence'
p9774
(F1
F0.00014334862385321102
I0
I1
I-1
tp9775
sS'tubular,atrophy,and'
p9776
(F1
F0.00014334862385321102
I0
I1
I-1
tp9777
sS'suggest,no,significant'
p9778
(F1
F0.00014334862385321102
I0
I1
I-1
tp9779
sS'subjects,receiving,tambocor'
p9780
(F1
F0.00014334862385321102
I1
I0
I1
tp9781
sS'in,clinical,trials'
p9782
(F0.53846153846153844
F0.0010034403669724771
I3
I10
I-7
tp9783
sS'should,be,withdrawn'
p9784
(F1
F0.00043004587155963305
I3
I0
I3
tp9785
sS'time,lst,short'
p9786
(F1
F0.00014334862385321102
I0
I1
I-1
tp9787
sS'coadministered,with,potent'
p9788
(F1
F0.00014334862385321102
I1
I0
I1
tp9789
sS'associated,with,significantly'
p9790
(F1
F0.00014334862385321102
I0
I1
I-1
tp9791
sS'also,taking,the'
p9792
(F1
F0.00014334862385321102
I1
I0
I1
tp9793
sS'm,v,did'
p9794
(F1
F0.00014334862385321102
I0
I1
I-1
tp9795
sS'dyskinesia,side,reactions'
p9796
(F1
F0.00014334862385321102
I1
I0
I1
tp9797
sS'enzyme,inhibitors,without'
p9798
(F1
F0.00014334862385321102
I0
I1
I-1
tp9799
sS'substantial,accumulation,of'
p9800
(F1
F0.00014334862385321102
I1
I0
I1
tp9801
sS'produced,an,elevation'
p9802
(F1
F0.00057339449541284407
I4
I0
I4
tp9803
sS'those,contained,in'
p9804
(F1
F0.00014334862385321102
I1
I0
I1
tp9805
sS'weak,effect,on'
p9806
(F1
F0.00014334862385321102
I1
I0
I1
tp9807
sS'to,a,patient'
p9808
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp9809
sS'steady-state,conditions,had'
p9810
(F1
F0.00014334862385321102
I0
I1
I-1
tp9811
sS'rare,reports,however'
p9812
(F1
F0.00014334862385321102
I1
I0
I1
tp9813
sS'decrease,the,effectiveness'
p9814
(F1
F0.00028669724770642203
I2
I0
I2
tp9815
sS'with,elevated,levels'
p9816
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9817
sS'tca,plasma,levels'
p9818
(F1
F0.00057339449541284407
I0
I4
I-4
tp9819
sS'withdrawal,of,decreased'
p9820
(F1
F0.00014334862385321102
I1
I0
I1
tp9821
sS'ameliorate,increased,intestinal'
p9822
(F1
F0.00014334862385321102
I1
I0
I1
tp9823
sS'as,thiazide,acidic'
p9824
(F1
F0.00014334862385321102
I1
I0
I1
tp9825
sS'daily,trough,serum'
p9826
(F1
F0.00014334862385321102
I0
I1
I-1
tp9827
sS'inhibitors,of,cyp2d6'
p9828
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp9829
sS'are,receiving,concomitant'
p9830
(F1
F0.00014334862385321102
I0
I1
I-1
tp9831
sS'was,seen,but'
p9832
(F1
F0.00014334862385321102
I1
I0
I1
tp9833
sS'adequate,period,of'
p9834
(F1
F0.00014334862385321102
I0
I1
I-1
tp9835
sS'converting,enzyme,ace'
p9836
(F1
F0.00014334862385321102
I0
I1
I-1
tp9837
sS'contraceptives,it,has'
p9838
(F1
F0.00014334862385321102
I0
I1
I-1
tp9839
sS'order,to,provide'
p9840
(F1
F0.00014334862385321102
I0
I1
I-1
tp9841
sS'see,drug,interactions'
p9842
(F1
F0.00014334862385321102
I0
I1
I-1
tp9843
sS'increase,in,peak'
p9844
(F1
F0.00057339449541284407
I4
I0
I4
tp9845
sS'but,not,statistically'
p9846
(F1
F0.00014334862385321102
I1
I0
I1
tp9847
sS'where,and,were'
p9848
(F1
F0.00014334862385321102
I0
I1
I-1
tp9849
sS'study,of,male'
p9850
(F1
F0.00014334862385321102
I1
I0
I1
tp9851
sS'is,warranted,and'
p9852
(F1
F0.00014334862385321102
I1
I0
I1
tp9853
sS's,and,which'
p9854
(F1
F0.00014334862385321102
I1
I0
I1
tp9855
sS'with,proton,pump'
p9856
(F1
F0.00014334862385321102
I1
I0
I1
tp9857
sS'the,blood,or'
p9858
(F1
F0.00014334862385321102
I0
I1
I-1
tp9859
sS'capable,of,potentiating'
p9860
(F1
F0.00014334862385321102
I1
I0
I1
tp9861
sS'dissolution,rate,of'
p9862
(F1
F0.00014334862385321102
I0
I1
I-1
tp9863
sS'has,no,significant'
p9864
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp9865
sS'administered,to,normal'
p9866
(F1
F0.00014334862385321102
I0
I1
I-1
tp9867
sS'weak,inducer,of'
p9868
(F1
F0.00014334862385321102
I0
I1
I-1
tp9869
sS'to,induce,microsomal'
p9870
(F1
F0.00014334862385321102
I1
I0
I1
tp9871
sS'inhibitor,hydrogen-3,revealed'
p9872
(F1
F0.00014334862385321102
I0
I1
I-1
tp9873
sS'with,weakness,hyperreflexia'
p9874
(F1
F0.00014334862385321102
I1
I0
I1
tp9875
sS'in,auc,by'
p9876
(F1
F0.00014334862385321102
I1
I0
I1
tp9877
sS'cmax,t1,of'
p9878
(F1
F0.00014334862385321102
I1
I0
I1
tp9879
sS'involving,six-healthy,male'
p9880
(F1
F0.00014334862385321102
I0
I1
I-1
tp9881
sS'these,cyp3a4,inducers'
p9882
(F1
F0.00014334862385321102
I1
I0
I1
tp9883
sS'rapid,fluctuations,of'
p9884
(F1
F0.00014334862385321102
I1
I0
I1
tp9885
sS'disoproxil,fumarate,did'
p9886
(F1
F0.00014334862385321102
I0
I1
I-1
tp9887
sS'these,larger,doses'
p9888
(F1
F0.00014334862385321102
I1
I0
I1
tp9889
sS'either,by,activation'
p9890
(F1
F0.00014334862385321102
I0
I1
I-1
tp9891
sS'with,hepatic,injury'
p9892
(F1
F0.00014334862385321102
I0
I1
I-1
tp9893
sS'b,the,clearance'
p9894
(F1
F0.00014334862385321102
I0
I1
I-1
tp9895
sS'from,its,capacity'
p9896
(F1
F0.00014334862385321102
I1
I0
I1
tp9897
sS'determine,the,effects'
p9898
(F1
F0.00014334862385321102
I0
I1
I-1
tp9899
sS'tricky,using,for'
p9900
(F1
F0.00014334862385321102
I0
I1
I-1
tp9901
sS'of,clozapine,and'
p9902
(F1
F0.00014334862385321102
I1
I0
I1
tp9903
sS'who,received,both'
p9904
(F1
F0.00014334862385321102
I0
I1
I-1
tp9905
sS'hypersensitivity,reactions,patients'
p9906
(F1
F0.00014334862385321102
I1
I0
I1
tp9907
sS'of,concentrations,after'
p9908
(F1
F0.00014334862385321102
I1
I0
I1
tp9909
sS'time,following,a'
p9910
(F1
F0.00028669724770642203
I0
I2
I-2
tp9911
sS'co-administered,with,slow-release'
p9912
(F1
F0.00014334862385321102
I0
I1
I-1
tp9913
sS'effects,have,occurred'
p9914
(F1
F0.00028669724770642203
I2
I0
I2
tp9915
sS'would,not,affect'
p9916
(F1
F0.00014334862385321102
I0
I1
I-1
tp9917
sS'is,rapidly,and'
p9918
(F1
F0.00014334862385321102
I0
I1
I-1
tp9919
sS'subsequently,found,to'
p9920
(F1
F0.00014334862385321102
I0
I1
I-1
tp9921
sS'chlorpropamides,plasma,half-life'
p9922
(F1
F0.00014334862385321102
I1
I0
I1
tp9923
sS'hepatotoxicity,concomitant,administration'
p9924
(F1
F0.00014334862385321102
I1
I0
I1
tp9925
sS'of,using,stadol'
p9926
(F1
F0.00014334862385321102
I0
I1
I-1
tp9927
sS'be,even,more'
p9928
(F1
F0.00014334862385321102
I1
I0
I1
tp9929
sS'cyp2a6,cyp2b6,cyp2c8'
p9930
(F1
F0.00014334862385321102
I0
I1
I-1
tp9931
sS'transmission,curare-like,compounds'
p9932
(F1
F0.00028669724770642203
I2
I0
I2
tp9933
sS'concentration,increased,from'
p9934
(F1
F0.00014334862385321102
I1
I0
I1
tp9935
sS'estrogen,oral,contraceptives'
p9936
(F1
F0.00014334862385321102
I0
I1
I-1
tp9937
sS'in,patients,that'
p9938
(F1
F0.00014334862385321102
I1
I0
I1
tp9939
sS'demonstrated,efficacy,and'
p9940
(F1
F0.00014334862385321102
I0
I1
I-1
tp9941
sS'dose,of,a'
p9942
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp9943
sS'inhibition,of,each'
p9944
(F1
F0.00014334862385321102
I1
I0
I1
tp9945
sS'with,a,history'
p9946
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp9947
sS'in,s,a'
p9948
(F1
F0.00014334862385321102
I1
I0
I1
tp9949
sS'eg,and,by'
p9950
(F1
F0.00014334862385321102
I1
I0
I1
tp9951
sS'changes,northern,blot'
p9952
(F1
F0.00014334862385321102
I0
I1
I-1
tp9953
sS'may,cause,too'
p9954
(F1
F0.00014334862385321102
I0
I1
I-1
tp9955
sS'of,enflurane,than'
p9956
(F1
F0.00014334862385321102
I0
I1
I-1
tp9957
sS'of,antagonists,and'
p9958
(F1
F0.00014334862385321102
I0
I1
I-1
tp9959
sS'rifampin,markedly,increases'
p9960
(F1
F0.00014334862385321102
I1
I0
I1
tp9961
sS'a,direct,effect'
p9962
(F1
F0.00014334862385321102
I0
I1
I-1
tp9963
sS'of,withdrawal,methadone'
p9964
(F1
F0.00014334862385321102
I1
I0
I1
tp9965
sS'rats,that,prolonged'
p9966
(F1
F0.00014334862385321102
I0
I1
I-1
tp9967
sS'with,antiplatelet,and'
p9968
(F1
F0.00014334862385321102
I1
I0
I1
tp9969
sS'of,taxol,mg'
p9970
(F1
F0.00014334862385321102
I1
I0
I1
tp9971
sS'has,received,or'
p9972
(F1
F0.00014334862385321102
I1
I0
I1
tp9973
sS'experience,when,suprax'
p9974
(F1
F0.00014334862385321102
I1
I0
I1
tp9975
sS'decreased,hearing,have'
p9976
(F1
F0.00014334862385321102
I1
I0
I1
tp9977
sS'p-450,inducers,such'
p9978
(F1
F0.00014334862385321102
I1
I0
I1
tp9979
sS'study,the,interaction'
p9980
(F1
F0.00014334862385321102
I0
I1
I-1
tp9981
sS'and,might,increase'
p9982
(F1
F0.00014334862385321102
I1
I0
I1
tp9983
sS'angiomax,in,clinical'
p9984
(F1
F0.00014334862385321102
I0
I1
I-1
tp9985
sS'is,warranted,when'
p9986
(F1
F0.00014334862385321102
I1
I0
I1
tp9987
sS'induced,diarrhea,was'
p9988
(F1
F0.00014334862385321102
I0
I1
I-1
tp9989
sS'administration,of,other'
p9990
(F1
F0.00043004587155963305
I3
I0
I3
tp9991
sS'eight,hiv-infected,patients'
p9992
(F1
F0.00014334862385321102
I1
I0
I1
tp9993
sS'with,their,dosage'
p9994
(F1
F0.00014334862385321102
I1
I0
I1
tp9995
sS'increased,risk,of'
p9996
(F0.29411764705882354
F0.00071674311926605509
I11
I6
I5
tp9997
sS'contraceptives,rofecoxib,did'
p9998
(F1
F0.00014334862385321102
I0
I1
I-1
tp9999
sS'of,decreased,plasma'
p10000
(F1
F0.00014334862385321102
I1
I0
I1
tp10001
sS'intravenous,was,shown'
p10002
(F1
F0.00014334862385321102
I1
I0
I1
tp10003
sS'due,to,or'
p10004
(F1
F0.00014334862385321102
I1
I0
I1
tp10005
sS'the,immunodepressant--the,sandimmune--on'
p10006
(F1
F0.00014334862385321102
I0
I1
I-1
tp10007
sS'or,other,or'
p10008
(F1
F0.00014334862385321102
I0
I1
I-1
tp10009
sS'because,these,products'
p10010
(F1
F0.00014334862385321102
I1
I0
I1
tp10011
sS'in,pigeons,did'
p10012
(F1
F0.00014334862385321102
I0
I1
I-1
tp10013
sS'combination,therapy,with'
p10014
(F1
F0.00014334862385321102
I1
I0
I1
tp10015
sS'influence,the,hypoprothrombinemia'
p10016
(F1
F0.00014334862385321102
I0
I1
I-1
tp10017
sS'following,symptom,onset'
p10018
(F1
F0.00014334862385321102
I0
I1
I-1
tp10019
sS'c8,c9,c19'
p10020
(F1
F0.00014334862385321102
I0
I1
I-1
tp10021
sS'of,h1,and'
p10022
(F1
F0.00014334862385321102
I1
I0
I1
tp10023
sS'concurrently,with,in'
p10024
(F1
F0.00014334862385321102
I0
I1
I-1
tp10025
sS'phenylbutazone,phenylbutazone,causes'
p10026
(F1
F0.00014334862385321102
I1
I0
I1
tp10027
sS'isoniazid,is,also'
p10028
(F1
F0.00014334862385321102
I1
I0
I1
tp10029
sS'of,years,have'
p10030
(F1
F0.00014334862385321102
I0
I1
I-1
tp10031
sS'frequently,if,inspra'
p10032
(F1
F0.00014334862385321102
I1
I0
I1
tp10033
sS'reports,however,from'
p10034
(F1
F0.00014334862385321102
I1
I0
I1
tp10035
sS'may,underlie,its'
p10036
(F1
F0.00014334862385321102
I0
I1
I-1
tp10037
sS'of,a,nonabsorbable'
p10038
(F1
F0.00014334862385321102
I1
I0
I1
tp10039
sS'channel,blockers,such'
p10040
(F1
F0.00014334862385321102
I1
I0
I1
tp10041
sS'coadministration,were,within'
p10042
(F1
F0.00014334862385321102
I1
I0
I1
tp10043
sS'must,be,considered'
p10044
(F1
F0.00014334862385321102
I1
I0
I1
tp10045
sS'as,a,tablet'
p10046
(F1
F0.00028669724770642203
I2
I0
I2
tp10047
sS'agents,a,cyp3a4'
p10048
(F1
F0.00014334862385321102
I0
I1
I-1
tp10049
sS'should,be,reserved'
p10050
(F1
F0.00014334862385321102
I0
I1
I-1
tp10051
sS'pharmacology,of,the'
p10052
(F1
F0.00014334862385321102
I1
I0
I1
tp10053
sS'concomitantly,administered,mg'
p10054
(F1
F0.00014334862385321102
I0
I1
I-1
tp10055
sS'of,and,on'
p10056
(F1
F0.00057339449541284407
I0
I4
I-4
tp10057
sS'minutes,were,unchanged'
p10058
(F1
F0.00014334862385321102
I0
I1
I-1
tp10059
sS'blood,auc0-12,of'
p10060
(F1
F0.00014334862385321102
I1
I0
I1
tp10061
sS'as,and,with'
p10062
(F1
F0.00014334862385321102
I1
I0
I1
tp10063
sS'the,urinary,excretion'
p10064
(F0
F0
I1
I1
I0
tp10065
sS'of,and,of'
p10066
(F1
F0.00028669724770642203
I0
I2
I-2
tp10067
sS'a,and,or'
p10068
(F1
F0.00014334862385321102
I1
I0
I1
tp10069
sS'also,expected,to'
p10070
(F1
F0.00028669724770642203
I2
I0
I2
tp10071
sS'patients,experiencing,increases'
p10072
(F1
F0.00014334862385321102
I1
I0
I1
tp10073
sS'produced,by,intermediate'
p10074
(F1
F0.00014334862385321102
I1
I0
I1
tp10075
sS'hypoglycemic,agents,such'
p10076
(F1
F0.00014334862385321102
I1
I0
I1
tp10077
sS'but,also,with'
p10078
(F1
F0.00014334862385321102
I0
I1
I-1
tp10079
sS'sulfonate,soybean,flour'
p10080
(F1
F0.00014334862385321102
I1
I0
I1
tp10081
sS'parameters,of,cmax'
p10082
(F1
F0.00014334862385321102
I0
I1
I-1
tp10083
sS'cardiac,and,systemic'
p10084
(F1
F0.00014334862385321102
I0
I1
I-1
tp10085
sS'fold,on,day'
p10086
(F1
F0.00028669724770642203
I2
I0
I2
tp10087
sS'tend,to,increase'
p10088
(F1
F0.00014334862385321102
I0
I1
I-1
tp10089
sS'receiving,another,serotonin'
p10090
(F1
F0.00014334862385321102
I1
I0
I1
tp10091
sS'preliminary,animal,and'
p10092
(F1
F0.00014334862385321102
I0
I1
I-1
tp10093
sS'times,the,maximum'
p10094
(F1
F0.00014334862385321102
I1
I0
I1
tp10095
sS'hydrochloride,desyrel,and'
p10096
(F1
F0.00014334862385321102
I1
I0
I1
tp10097
sS'd,with,a'
p10098
(F1
F0.00014334862385321102
I1
I0
I1
tp10099
sS'effects,of,and'
p10100
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp10101
sS'digoxin,methotrexate,lodine'
p10102
(F1
F0.00014334862385321102
I1
I0
I1
tp10103
sS'or,mg,m2'
p10104
(F1
F0.00014334862385321102
I1
I0
I1
tp10105
sS'different,in,poor'
p10106
(F1
F0.00014334862385321102
I0
I1
I-1
tp10107
sS'carried,out,in'
p10108
(F1
F0.00014334862385321102
I0
I1
I-1
tp10109
sS'induced,diarrhea,in'
p10110
(F1
F0.00014334862385321102
I1
I0
I1
tp10111
sS'the,increased,potential'
p10112
(F1
F0.00014334862385321102
I1
I0
I1
tp10113
sS'or,oral,should'
p10114
(F1
F0.00014334862385321102
I0
I1
I-1
tp10115
sS'the,muscle,relaxant'
p10116
(F1
F0.00028669724770642203
I2
I0
I2
tp10117
sS'green,tea,polyphenols'
p10118
(F1
F0.00014334862385321102
I0
I1
I-1
tp10119
sS'potentially,associated,with'
p10120
(F1
F0.00014334862385321102
I1
I0
I1
tp10121
sS'as,protease,inhibitors'
p10122
(F1
F0.00028669724770642203
I2
I0
I2
tp10123
sS'results,in,an'
p10124
(F0
F0
I1
I1
I0
tp10125
sS'given,hours,after'
p10126
(F0
F0
I1
I1
I0
tp10127
sS'unknown,and,the'
p10128
(F1
F0.00014334862385321102
I1
I0
I1
tp10129
sS'with,the,known'
p10130
(F1
F0.00028669724770642203
I0
I2
I-2
tp10131
sS'concomitan,administration,of'
p10132
(F1
F0.00014334862385321102
I1
I0
I1
tp10133
sS'cimetidine,at,mg'
p10134
(F1
F0.00014334862385321102
I1
I0
I1
tp10135
sS'those,of,pcp'
p10136
(F1
F0.00014334862385321102
I0
I1
I-1
tp10137
sS'therefore,there,is'
p10138
(F1
F0.00014334862385321102
I0
I1
I-1
tp10139
sS'increase,in,clozapine'
p10140
(F1
F0.00014334862385321102
I1
I0
I1
tp10141
sS'even,death,have'
p10142
(F1
F0.00014334862385321102
I0
I1
I-1
tp10143
sS'approx,because,amplifies'
p10144
(F1
F0.00014334862385321102
I1
I0
I1
tp10145
sS'bioequivalent,to,the'
p10146
(F1
F0.00014334862385321102
I0
I1
I-1
tp10147
sS'instances,synergism,in'
p10148
(F1
F0.00014334862385321102
I1
I0
I1
tp10149
sS'patients,taking,another'
p10150
(F1
F0.00014334862385321102
I1
I0
I1
tp10151
sS'may,be,due'
p10152
(F1
F0.00014334862385321102
I1
I0
I1
tp10153
sS'well,as,nonsteroidal'
p10154
(F1
F0.00014334862385321102
I0
I1
I-1
tp10155
sS'following,a,single'
p10156
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp10157
sS'may,be,rarely'
p10158
(F1
F0.00028669724770642203
I2
I0
I2
tp10159
sS'metal,cations,such'
p10160
(F1
F0.00014334862385321102
I1
I0
I1
tp10161
sS'seem,to,change'
p10162
(F1
F0.00014334862385321102
I0
I1
I-1
tp10163
sS'cyp3a4,mediated,metabolism'
p10164
(F1
F0.00014334862385321102
I0
I1
I-1
tp10165
sS'in,vitro,can'
p10166
(F1
F0.00014334862385321102
I1
I0
I1
tp10167
sS'this,should,be'
p10168
(F1
F0.00014334862385321102
I0
I1
I-1
tp10169
sS'be,potentiated,apparently'
p10170
(F1
F0.00014334862385321102
I0
I1
I-1
tp10171
sS'tablets,at,least'
p10172
(F1
F0.00014334862385321102
I1
I0
I1
tp10173
sS'simultaneous,treatment,with'
p10174
(F1
F0.00014334862385321102
I1
I0
I1
tp10175
sS'nucleoside-experienced,patients,although'
p10176
(F1
F0.00014334862385321102
I0
I1
I-1
tp10177
sS'initial,dose,and'
p10178
(F1
F0.00014334862385321102
I1
I0
I1
tp10179
sS'and,demonstrated,no'
p10180
(F1
F0.00014334862385321102
I0
I1
I-1
tp10181
sS'of,by,but'
p10182
(F1
F0.00043004587155963305
I3
I0
I3
tp10183
sS'on,a,regular'
p10184
(F1
F0.00014334862385321102
I0
I1
I-1
tp10185
sS'participated,in,an'
p10186
(F1
F0.00014334862385321102
I0
I1
I-1
tp10187
sS'of,on,total'
p10188
(F1
F0.00014334862385321102
I0
I1
I-1
tp10189
sS'of,magnitude,lower'
p10190
(F1
F0.00014334862385321102
I0
I1
I-1
tp10191
sS'toxicity,have,been'
p10192
(F1
F0.00057339449541284407
I4
I0
I4
tp10193
sS'receiving,maintenance,doses'
p10194
(F1
F0.00014334862385321102
I0
I1
I-1
tp10195
sS'is,given,exclusively'
p10196
(F1
F0.00014334862385321102
I0
I1
I-1
tp10197
sS'trials,suggest,no'
p10198
(F1
F0.00014334862385321102
I0
I1
I-1
tp10199
sS'a,family,in'
p10200
(F1
F0.00014334862385321102
I1
I0
I1
tp10201
sS'prescribing,information,for'
p10202
(F1
F0.00028669724770642203
I0
I2
I-2
tp10203
sS'have,been,used'
p10204
(F0
F0
I2
I2
I0
tp10205
sS'reduced,when,given'
p10206
(F1
F0.00014334862385321102
I1
I0
I1
tp10207
sS'deaths,in,a'
p10208
(F1
F0.00014334862385321102
I1
I0
I1
tp10209
sS'iopidine,ophthalmic,solution'
p10210
(F1
F0.00014334862385321102
I1
I0
I1
tp10211
sS'therapeutic,levels,did'
p10212
(F1
F0.00014334862385321102
I0
I1
I-1
tp10213
sS'alprazolam,metabolism,via'
p10214
(F1
F0.00014334862385321102
I0
I1
I-1
tp10215
sS'and,significantly,increased'
p10216
(F1
F0.00043004587155963305
I3
I0
I3
tp10217
sS'on,the,maintenance'
p10218
(F1
F0.00014334862385321102
I1
I0
I1
tp10219
sS'therapy,of,a'
p10220
(F1
F0.00014334862385321102
I1
I0
I1
tp10221
sS'clearance,of,the'
p10222
(F1
F0.00014334862385321102
I0
I1
I-1
tp10223
sS'decrease,established,steady-state'
p10224
(F1
F0.00014334862385321102
I1
I0
I1
tp10225
sS'this,small,decrease'
p10226
(F1
F0.00014334862385321102
I1
I0
I1
tp10227
sS'of,placebo,day'
p10228
(F1
F0.00014334862385321102
I0
I1
I-1
tp10229
sS'by,fold,and'
p10230
(F1
F0.00028669724770642203
I2
I0
I2
tp10231
sS'iron-fortified,breakfast,cereals'
p10232
(F1
F0.00014334862385321102
I0
I1
I-1
tp10233
sS'may,increase,certain'
p10234
(F1
F0.00014334862385321102
I0
I1
I-1
tp10235
sS'should,be,discontinued'
p10236
(F1
F0.00028669724770642203
I2
I0
I2
tp10237
sS'treatment-naive,patients,the'
p10238
(F1
F0.00014334862385321102
I0
I1
I-1
tp10239
sS'other,than,has'
p10240
(F1
F0.00014334862385321102
I0
I1
I-1
tp10241
sS'at,greater,risk'
p10242
(F1
F0.00014334862385321102
I0
I1
I-1
tp10243
sS'failure,where,and'
p10244
(F1
F0.00014334862385321102
I0
I1
I-1
tp10245
sS'is,small,with'
p10246
(F1
F0.00014334862385321102
I0
I1
I-1
tp10247
sS'the,hydantoin,antiepileptic'
p10248
(F1
F0.00014334862385321102
I1
I0
I1
tp10249
sS'competes,for,tubular'
p10250
(F1
F0.00014334862385321102
I1
I0
I1
tp10251
sS'taxol,should,be'
p10252
(F1
F0.00014334862385321102
I0
I1
I-1
tp10253
sS'on,respiration,and'
p10254
(F1
F0.00014334862385321102
I0
I1
I-1
tp10255
sS'injection,usp,to'
p10256
(F1
F0.00014334862385321102
I1
I0
I1
tp10257
sS'with,tests,using'
p10258
(F1
F0.00028669724770642203
I0
I2
I-2
tp10259
sS'half-life,of,the'
p10260
(F1
F0.00014334862385321102
I1
I0
I1
tp10261
sS'wedge,pressure,than'
p10262
(F1
F0.00014334862385321102
I1
I0
I1
tp10263
sS'was,determined,by'
p10264
(F1
F0.00014334862385321102
I0
I1
I-1
tp10265
sS'decrease,plasma,levels'
p10266
(F0.5
F0.00028669724770642203
I3
I1
I2
tp10267
sS'the,physician,the'
p10268
(F1
F0.00014334862385321102
I1
I0
I1
tp10269
sS'mean,peak,plasma'
p10270
(F1
F0.00028669724770642203
I2
I0
I2
tp10271
sS'increased,with,mao'
p10272
(F1
F0.00014334862385321102
I1
I0
I1
tp10273
sS'pletal,does,not'
p10274
(F1
F0.00014334862385321102
I0
I1
I-1
tp10275
sS'combination,with,humira'
p10276
(F1
F0.00014334862385321102
I0
I1
I-1
tp10277
sS'to,by,cytochrome'
p10278
(F1
F0.00014334862385321102
I0
I1
I-1
tp10279
sS'cyp2d6,is,involved'
p10280
(F1
F0.00014334862385321102
I0
I1
I-1
tp10281
sS'were,observed,but'
p10282
(F1
F0.00014334862385321102
I0
I1
I-1
tp10283
sS'similar,mechanism,of'
p10284
(F1
F0.00014334862385321102
I1
I0
I1
tp10285
sS'published,reports,describe'
p10286
(F1
F0.00014334862385321102
I1
I0
I1
tp10287
sS'patients,with,hypercholesterolemia'
p10288
(F1
F0.00014334862385321102
I0
I1
I-1
tp10289
sS'patients,concomitantly,receiving'
p10290
(F1
F0.00057339449541284407
I4
I0
I4
tp10291
sS'in,their,effectiveness'
p10292
(F1
F0.00014334862385321102
I0
I1
I-1
tp10293
sS'norepinephrine,amphetamines,enhance'
p10294
(F1
F0.00028669724770642203
I2
I0
I2
tp10295
sS'receiving,tricyclic,and'
p10296
(F1
F0.00014334862385321102
I1
I0
I1
tp10297
sS'some,patients,by'
p10298
(F1
F0.00014334862385321102
I1
I0
I1
tp10299
sS'carbenicillin,indanyl,sodium'
p10300
(F1
F0.00014334862385321102
I1
I0
I1
tp10301
sS'c,g,day'
p10302
(F1
F0.00014334862385321102
I1
I0
I1
tp10303
sS'adjustment,may,be'
p10304
(F1
F0.00028669724770642203
I0
I2
I-2
tp10305
sS'leading,to,alterations'
p10306
(F1
F0.00014334862385321102
I1
I0
I1
tp10307
sS'combining,with,any'
p10308
(F1
F0.00014334862385321102
I0
I1
I-1
tp10309
sS'levels,by,jaffe'
p10310
(F1
F0.00014334862385321102
I0
I1
I-1
tp10311
sS'blood,elements,ethacrynic'
p10312
(F1
F0.00014334862385321102
I1
I0
I1
tp10313
sS'induced,with,low'
p10314
(F1
F0.00014334862385321102
I1
I0
I1
tp10315
sS'concentrations,were,and'
p10316
(F1
F0.00014334862385321102
I0
I1
I-1
tp10317
sS'concentrations,mg,bid'
p10318
(F1
F0.00014334862385321102
I0
I1
I-1
tp10319
sS'does,not,however'
p10320
(F1
F0.00014334862385321102
I0
I1
I-1
tp10321
sS'procedures,were,followed'
p10322
(F1
F0.00014334862385321102
I0
I1
I-1
tp10323
sS'which,may,lead'
p10324
(F1
F0.00014334862385321102
I1
I0
I1
tp10325
sS'known,metabolite,of'
p10326
(F1
F0.00014334862385321102
I0
I1
I-1
tp10327
sS'the,mg,oral'
p10328
(F1
F0.00014334862385321102
I0
I1
I-1
tp10329
sS'oxidase,in,rat'
p10330
(F1
F0.00014334862385321102
I0
I1
I-1
tp10331
sS'higher,dosages,of'
p10332
(F1
F0.00014334862385321102
I0
I1
I-1
tp10333
sS'double-blind,comparative,study'
p10334
(F1
F0.00014334862385321102
I0
I1
I-1
tp10335
sS'male,rats,of'
p10336
(F1
F0.00014334862385321102
I0
I1
I-1
tp10337
sS'inhibitor,of,cyp2d6'
p10338
(F0
F0
I1
I1
I0
tp10339
sS'rat,days,or'
p10340
(F1
F0.00014334862385321102
I0
I1
I-1
tp10341
sS'exjade,pharmacokinetics,has'
p10342
(F1
F0.00014334862385321102
I0
I1
I-1
tp10343
sS'causing,uterine,rupture'
p10344
(F1
F0.00014334862385321102
I1
I0
I1
tp10345
sS'concurrent,use,of'
p10346
(F0.70370370370370372
F0.0027236238532110093
I23
I4
I19
tp10347
sS'acid,excretion,compared'
p10348
(F1
F0.00014334862385321102
I1
I0
I1
tp10349
sS'agents,used,in'
p10350
(F1
F0.00014334862385321102
I0
I1
I-1
tp10351
sS'are,on,replacement'
p10352
(F1
F0.00014334862385321102
I1
I0
I1
tp10353
sS'of,mg,twice'
p10354
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp10355
sS'busulfex,may,result'
p10356
(F1
F0.00014334862385321102
I1
I0
I1
tp10357
sS'erythromycin,azole,antifungals'
p10358
(F1
F0.00014334862385321102
I0
I1
I-1
tp10359
sS'occur,when,agents'
p10360
(F1
F0.00014334862385321102
I1
I0
I1
tp10361
sS'of,the,oral'
p10362
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp10363
sS'and,the,immune'
p10364
(F1
F0.00014334862385321102
I0
I1
I-1
tp10365
sS'increase,the,rate'
p10366
(F1
F0.00014334862385321102
I1
I0
I1
tp10367
sS'significantly,altered,by'
p10368
(F1
F0.00014334862385321102
I0
I1
I-1
tp10369
sS'of,enhanced,as'
p10370
(F1
F0.00014334862385321102
I1
I0
I1
tp10371
sS'suggested,that,zebeta'
p10372
(F1
F0.00014334862385321102
I1
I0
I1
tp10373
sS'the,involvement,of'
p10374
(F0
F0
I1
I1
I0
tp10375
sS'concomitantly,with,their'
p10376
(F1
F0.00014334862385321102
I1
I0
I1
tp10377
sS'keppra,mg,twice'
p10378
(F1
F0.00057339449541284407
I0
I4
I-4
tp10379
sS'tadalafil,dose,should'
p10380
(F1
F0.00014334862385321102
I1
I0
I1
tp10381
sS'greater,amount,of'
p10382
(F1
F0.00014334862385321102
I1
I0
I1
tp10383
sS'being,given,should'
p10384
(F1
F0.00014334862385321102
I1
I0
I1
tp10385
sS'of,orencia,administered'
p10386
(F1
F0.00014334862385321102
I1
I0
I1
tp10387
sS'and,l-ccg,was'
p10388
(F1
F0.00014334862385321102
I0
I1
I-1
tp10389
sS'bacteriostatic,may,antagonize'
p10390
(F1
F0.00028669724770642203
I2
I0
I2
tp10391
sS'the,results,of'
p10392
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp10393
sS'cns-depressive,effects,of'
p10394
(F1
F0.00014334862385321102
I1
I0
I1
tp10395
sS'do,not,outweigh'
p10396
(F1
F0.00014334862385321102
I1
I0
I1
tp10397
sS'patients,receiving,and'
p10398
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp10399
sS'homocysteine,following,synthetic'
p10400
(F1
F0.00014334862385321102
I0
I1
I-1
tp10401
sS'not,alter,glucose'
p10402
(F1
F0.00014334862385321102
I0
I1
I-1
tp10403
sS'effect,was,shown'
p10404
(F1
F0.00014334862385321102
I0
I1
I-1
tp10405
sS'binding,in,vitro'
p10406
(F1
F0.00028669724770642203
I2
I0
I2
tp10407
sS'clearance,and,lower'
p10408
(F1
F0.00014334862385321102
I1
I0
I1
tp10409
sS'the,cyp2d6,pathway'
p10410
(F1
F0.00014334862385321102
I0
I1
I-1
tp10411
sS'subjects,already,receiving'
p10412
(F1
F0.00014334862385321102
I1
I0
I1
tp10413
sS'in,vitro,the'
p10414
(F1
F0.00014334862385321102
I0
I1
I-1
tp10415
sS'combination,regimens,containing'
p10416
(F1
F0.00014334862385321102
I1
I0
I1
tp10417
sS'agonists,hepatic,enzyme'
p10418
(F1
F0.00014334862385321102
I0
I1
I-1
tp10419
sS'simultaneously,with,or'
p10420
(F1
F0.00014334862385321102
I1
I0
I1
tp10421
sS'and,a,or'
p10422
(F1
F0.00014334862385321102
I0
I1
I-1
tp10423
sS'protein,binding,and'
p10424
(F0
F0
I1
I1
I0
tp10425
sS'therefore,the,combined'
p10426
(F1
F0.00014334862385321102
I1
I0
I1
tp10427
sS'toxicity,and,the'
p10428
(F1
F0.00028669724770642203
I0
I2
I-2
tp10429
sS'medications,were,mp'
p10430
(F1
F0.00014334862385321102
I0
I1
I-1
tp10431
sS'dose,had,no'
p10432
(F1
F0.00028669724770642203
I0
I2
I-2
tp10433
sS'including,crescentic,iga'
p10434
(F1
F0.00014334862385321102
I1
I0
I1
tp10435
sS'approximately,ml,of'
p10436
(F1
F0.00014334862385321102
I0
I1
I-1
tp10437
sS'probenecid,may,decrease'
p10438
(F1
F0.00028669724770642203
I2
I0
I2
tp10439
sS'its,plasma,clearance'
p10440
(F1
F0.00014334862385321102
I0
I1
I-1
tp10441
sS'of,patients,receiving'
p10442
(F1
F0.00043004587155963305
I0
I3
I-3
tp10443
sS'taken,in,overdose'
p10444
(F1
F0.00014334862385321102
I1
I0
I1
tp10445
sS'therefore,coadministration,of'
p10446
(F0
F0
I1
I1
I0
tp10447
sS'these,events,and'
p10448
(F1
F0.00014334862385321102
I0
I1
I-1
tp10449
sS'interactions,no,pharmacokinetic'
p10450
(F1
F0.00014334862385321102
I0
I1
I-1
tp10451
sS'in,animals,edetate'
p10452
(F1
F0.00014334862385321102
I1
I0
I1
tp10453
sS'that,you,need'
p10454
(F1
F0.00014334862385321102
I1
I0
I1
tp10455
sS'the,prior,administration'
p10456
(F1
F0.00014334862385321102
I1
I0
I1
tp10457
sS'required,when,anafranil'
p10458
(F1
F0.00014334862385321102
I1
I0
I1
tp10459
sS'hydrochloride,injection,and'
p10460
(F1
F0.00014334862385321102
I1
I0
I1
tp10461
sS'with,in,the'
p10462
(F0
F0
I1
I1
I0
tp10463
sS'observed,when,subjects'
p10464
(F1
F0.00014334862385321102
I0
I1
I-1
tp10465
sS'their,plasma,concentration'
p10466
(F0
F0
I1
I1
I0
tp10467
sS'failure,as,well'
p10468
(F0
F0
I1
I1
I0
tp10469
sS'and,diuretics,concomitant'
p10470
(F1
F0.00014334862385321102
I1
I0
I1
tp10471
sS'possibility,of,oxidative'
p10472
(F1
F0.00014334862385321102
I0
I1
I-1
tp10473
sS'min,following,ip'
p10474
(F1
F0.00014334862385321102
I0
I1
I-1
tp10475
sS'other,cholinesterase,inhibitors'
p10476
(F1
F0.00014334862385321102
I1
I0
I1
tp10477
sS'of,bleeding,when'
p10478
(F1
F0.00014334862385321102
I1
I0
I1
tp10479
sS'case,of,rhabdomyolysis'
p10480
(F1
F0.00014334862385321102
I0
I1
I-1
tp10481
sS'the,two,were'
p10482
(F1
F0.00014334862385321102
I1
I0
I1
tp10483
sS'to,patients,being'
p10484
(F1
F0.00028669724770642203
I2
I0
I2
tp10485
sS'affected,by,coadministration'
p10486
(F1
F0.00028669724770642203
I0
I2
I-2
tp10487
sS'patients,with,mild'
p10488
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10489
sS'intravenous,unless,the'
p10490
(F1
F0.00014334862385321102
I1
I0
I1
tp10491
sS'given,and,didanosine-placebo'
p10492
(F1
F0.00014334862385321102
I1
I0
I1
tp10493
sS'be,usedas,the'
p10494
(F1
F0.00014334862385321102
I1
I0
I1
tp10495
sS'the,selective,regulation'
p10496
(F1
F0.00014334862385321102
I0
I1
I-1
tp10497
sS'vitro,and,animal'
p10498
(F1
F0.00014334862385321102
I1
I0
I1
tp10499
sS'activity,and,the'
p10500
(F1
F0.00014334862385321102
I0
I1
I-1
tp10501
sS'with,muscle,relaxants'
p10502
(F1
F0.00014334862385321102
I0
I1
I-1
tp10503
sS'anorexia,tachypnea,lethargy'
p10504
(F1
F0.00014334862385321102
I1
I0
I1
tp10505
sS'enterohepatic,circulation,the'
p10506
(F1
F0.00014334862385321102
I1
I0
I1
tp10507
sS'of,trazodone,hydrochloride'
p10508
(F1
F0.00014334862385321102
I1
I0
I1
tp10509
sS'of,are,not'
p10510
(F1
F0.00014334862385321102
I0
I1
I-1
tp10511
sS'inhibitors,monoamine,oxidase'
p10512
(F1
F0.00014334862385321102
I0
I1
I-1
tp10513
sS'coreg,is,to'
p10514
(F1
F0.00014334862385321102
I1
I0
I1
tp10515
sS'every,hours,two'
p10516
(F1
F0.00014334862385321102
I0
I1
I-1
tp10517
sS'serum,concentrations,appeared'
p10518
(F1
F0.00014334862385321102
I0
I1
I-1
tp10519
sS'profile,between,study'
p10520
(F1
F0.00014334862385321102
I0
I1
I-1
tp10521
sS'the,distribution,of'
p10522
(F1
F0.00014334862385321102
I0
I1
I-1
tp10523
sS'acid,by,and'
p10524
(F1
F0.00014334862385321102
I1
I0
I1
tp10525
sS'patients,should,be'
p10526
(F0.5
F0.0008600917431192661
I9
I3
I6
tp10527
sS'prohibited,in,the'
p10528
(F1
F0.00014334862385321102
I0
I1
I-1
tp10529
sS'twitch,to,fade'
p10530
(F1
F0.00014334862385321102
I1
I0
I1
tp10531
sS'receiving,will,have'
p10532
(F1
F0.00014334862385321102
I1
I0
I1
tp10533
sS'pharmacological,analysis,of'
p10534
(F1
F0.00014334862385321102
I0
I1
I-1
tp10535
sS'singly,and,in'
p10536
(F1
F0.00014334862385321102
I0
I1
I-1
tp10537
sS'inhibit,the,nad'
p10538
(F1
F0.00014334862385321102
I1
I0
I1
tp10539
sS'previously,received,increases'
p10540
(F1
F0.00014334862385321102
I1
I0
I1
tp10541
sS'increase,the,plasma-level'
p10542
(F1
F0.00014334862385321102
I1
I0
I1
tp10543
sS'an,increased,volume'
p10544
(F1
F0.00014334862385321102
I0
I1
I-1
tp10545
sS'this,product,with'
p10546
(F1
F0.00014334862385321102
I0
I1
I-1
tp10547
sS'interaction,study,the'
p10548
(F1
F0.00014334862385321102
I0
I1
I-1
tp10549
sS'be,made,whether'
p10550
(F1
F0.00014334862385321102
I0
I1
I-1
tp10551
sS'endogenous,prostaglandin,synthesis'
p10552
(F1
F0.00014334862385321102
I1
I0
I1
tp10553
sS'leads,to,an'
p10554
(F1
F0.00014334862385321102
I1
I0
I1
tp10555
sS'with,or,patients'
p10556
(F1
F0.00014334862385321102
I0
I1
I-1
tp10557
sS'after,initiating,or'
p10558
(F1
F0.00014334862385321102
I1
I0
I1
tp10559
sS'administration,of,either'
p10560
(F1
F0.00014334862385321102
I0
I1
I-1
tp10561
sS'this,decrease,of'
p10562
(F1
F0.00014334862385321102
I0
I1
I-1
tp10563
sS'cardiovascular,safety,of'
p10564
(F1
F0.00014334862385321102
I0
I1
I-1
tp10565
sS'by,and,other'
p10566
(F1
F0.00014334862385321102
I1
I0
I1
tp10567
sS'causal,mechanism,and'
p10568
(F1
F0.00014334862385321102
I1
I0
I1
tp10569
sS'together,with,the'
p10570
(F1
F0.00014334862385321102
I0
I1
I-1
tp10571
sS'acid,or,the'
p10572
(F1
F0.00014334862385321102
I1
I0
I1
tp10573
sS'in,their,serum'
p10574
(F1
F0.00014334862385321102
I0
I1
I-1
tp10575
sS'binding,proteins,and'
p10576
(F1
F0.00014334862385321102
I1
I0
I1
tp10577
sS'given,before,the'
p10578
(F1
F0.00014334862385321102
I0
I1
I-1
tp10579
sS'to,convulsions,in'
p10580
(F1
F0.00014334862385321102
I1
I0
I1
tp10581
sS'in,female,rats'
p10582
(F1
F0.00014334862385321102
I0
I1
I-1
tp10583
sS'have,carried,out'
p10584
(F1
F0.00014334862385321102
I0
I1
I-1
tp10585
sS'receiving,long-,term'
p10586
(F1
F0.00014334862385321102
I1
I0
I1
tp10587
sS'of,prinivil,alone'
p10588
(F1
F0.00014334862385321102
I0
I1
I-1
tp10589
sS'year,controlled,study'
p10590
(F1
F0.00014334862385321102
I0
I1
I-1
tp10591
sS'studies,adjuvant,treatment'
p10592
(F1
F0.00014334862385321102
I1
I0
I1
tp10593
sS'metabolism,by,cyp3a4'
p10594
(F0
F0
I1
I1
I0
tp10595
sS'upon,combination,with'
p10596
(F1
F0.00014334862385321102
I1
I0
I1
tp10597
sS'higher,when,it'
p10598
(F1
F0.00014334862385321102
I1
I0
I1
tp10599
sS'mixed,with,any'
p10600
(F1
F0.00014334862385321102
I0
I1
I-1
tp10601
sS'bun,serum,creatinine'
p10602
(F1
F0.00014334862385321102
I1
I0
I1
tp10603
sS'a4,inhibitors,may'
p10604
(F1
F0.00014334862385321102
I0
I1
I-1
tp10605
sS'sg,dipstick,test'
p10606
(F1
F0.00014334862385321102
I0
I1
I-1
tp10607
sS'd,have,been'
p10608
(F1
F0.00014334862385321102
I0
I1
I-1
tp10609
sS'formal,interaction,studies'
p10610
(F1
F0.00028669724770642203
I0
I2
I-2
tp10611
sS'in,vivo,studies'
p10612
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10613
sS'determined,prior,to'
p10614
(F1
F0.00014334862385321102
I1
I0
I1
tp10615
sS'it,is,therefore'
p10616
(F0
F0
I1
I1
I0
tp10617
sS'as,the,or'
p10618
(F1
F0.00014334862385321102
I1
I0
I1
tp10619
sS'mao,inhibitor,class'
p10620
(F1
F0.00014334862385321102
I1
I0
I1
tp10621
sS'randomly,bred,control'
p10622
(F1
F0.00014334862385321102
I0
I1
I-1
tp10623
sS'not,predispose,to'
p10624
(F1
F0.00014334862385321102
I0
I1
I-1
tp10625
sS'cephalothin,sodium,sulfate'
p10626
(F1
F0.00014334862385321102
I0
I1
I-1
tp10627
sS'excretion,is,the'
p10628
(F1
F0.00014334862385321102
I1
I0
I1
tp10629
sS'two,agents,should'
p10630
(F1
F0.00014334862385321102
I1
I0
I1
tp10631
sS'relationship,with,amphotericin'
p10632
(F1
F0.00014334862385321102
I1
I0
I1
tp10633
sS'to,maintain,levels'
p10634
(F1
F0.00014334862385321102
I1
I0
I1
tp10635
sS'the,prescribing,information'
p10636
(F1
F0.00028669724770642203
I0
I2
I-2
tp10637
sS'mug,ml,and'
p10638
(F1
F0.00014334862385321102
I0
I1
I-1
tp10639
sS'co-administered,with,the'
p10640
(F1
F0.00014334862385321102
I1
I0
I1
tp10641
sS'achieved,steady-state,blood'
p10642
(F1
F0.00014334862385321102
I0
I1
I-1
tp10643
sS'meal,of,the'
p10644
(F1
F0.00014334862385321102
I0
I1
I-1
tp10645
sS'solution,may,result'
p10646
(F1
F0.00014334862385321102
I1
I0
I1
tp10647
sS'adenosine,effects,are'
p10648
(F1
F0.00014334862385321102
I1
I0
I1
tp10649
sS'of,femara,and'
p10650
(F1
F0.00014334862385321102
I1
I0
I1
tp10651
sS'become,pregnant,into'
p10652
(F1
F0.00014334862385321102
I0
I1
I-1
tp10653
sS'of,deaths,in'
p10654
(F1
F0.00014334862385321102
I0
I1
I-1
tp10655
sS'toradoloral,was,coadministered'
p10656
(F1
F0.00014334862385321102
I0
I1
I-1
tp10657
sS'the,curariform,effect'
p10658
(F1
F0.00014334862385321102
I1
I0
I1
tp10659
sS'ace-inhibitors,reports,suggest'
p10660
(F1
F0.00028669724770642203
I2
I0
I2
tp10661
sS'and,hydroxides,be'
p10662
(F1
F0.00014334862385321102
I1
I0
I1
tp10663
sS'effect,of,amevive'
p10664
(F1
F0.00014334862385321102
I0
I1
I-1
tp10665
sS'inhibitors,that,are'
p10666
(F1
F0.00028669724770642203
I2
I0
I2
tp10667
sS'very,closely,when'
p10668
(F1
F0.00014334862385321102
I1
I0
I1
tp10669
sS'did,not,interact'
p10670
(F1
F0.00014334862385321102
I0
I1
I-1
tp10671
sS'by,approximately,given'
p10672
(F1
F0.00014334862385321102
I1
I0
I1
tp10673
sS'serum,concentration,by'
p10674
(F1
F0.00028669724770642203
I0
I2
I-2
tp10675
sS'of,uptake,blocking'
p10676
(F1
F0.00014334862385321102
I0
I1
I-1
tp10677
sS'pharmacokinetics,of,measured'
p10678
(F1
F0.00014334862385321102
I0
I1
I-1
tp10679
sS'a,competitive,inhibitor'
p10680
(F1
F0.00014334862385321102
I1
I0
I1
tp10681
sS'were,and,with'
p10682
(F1
F0.00014334862385321102
I0
I1
I-1
tp10683
sS'its,absorption,from'
p10684
(F1
F0.00014334862385321102
I1
I0
I1
tp10685
sS'requirements,of,nimbex'
p10686
(F1
F0.00014334862385321102
I1
I0
I1
tp10687
sS'increases,in,or'
p10688
(F1
F0.00014334862385321102
I0
I1
I-1
tp10689
sS'well,concurent,therapy'
p10690
(F1
F0.00014334862385321102
I1
I0
I1
tp10691
sS'hypertensive,reactions,including'
p10692
(F1
F0.00014334862385321102
I1
I0
I1
tp10693
sS'possibly,nicotinic,receptors'
p10694
(F1
F0.00014334862385321102
I0
I1
I-1
tp10695
sS'a4,to,the'
p10696
(F1
F0.00014334862385321102
I0
I1
I-1
tp10697
sS'of,absorption,in'
p10698
(F1
F0.00014334862385321102
I1
I0
I1
tp10699
sS'since,is,contraindicated'
p10700
(F1
F0.00014334862385321102
I0
I1
I-1
tp10701
sS'inhibits,the,renal'
p10702
(F1
F0.00014334862385321102
I1
I0
I1
tp10703
sS'captopril,s,effect'
p10704
(F1
F0.00014334862385321102
I1
I0
I1
tp10705
sS'male,volunteers,n'
p10706
(F1
F0.00014334862385321102
I0
I1
I-1
tp10707
sS'respiratory,depression,may'
p10708
(F1
F0.00014334862385321102
I1
I0
I1
tp10709
sS'change,was,not'
p10710
(F1
F0.00014334862385321102
I0
I1
I-1
tp10711
sS'administration,of,aprepitant'
p10712
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10713
sS'evidence,of,clinically'
p10714
(F1
F0.0008600917431192661
I0
I6
I-6
tp10715
sS'metabolized,by,monoamine'
p10716
(F1
F0.00014334862385321102
I0
I1
I-1
tp10717
sS'treatment,with,of'
p10718
(F1
F0.00014334862385321102
I0
I1
I-1
tp10719
sS'compared,with,and'
p10720
(F1
F0.00014334862385321102
I0
I1
I-1
tp10721
sS'treatment,with,oh'
p10722
(F1
F0.00014334862385321102
I1
I0
I1
tp10723
sS'to,cytochrome,p450'
p10724
(F1
F0.00014334862385321102
I1
I0
I1
tp10725
sS'cyp2c9,cyp2c19,cyp2d6'
p10726
(F1
F0.00028669724770642203
I0
I2
I-2
tp10727
sS'closely,for,signs'
p10728
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp10729
sS'at,least,weeks'
p10730
(F1
F0.00043004587155963305
I3
I0
I3
tp10731
sS'these,patients,demonstrated'
p10732
(F1
F0.00014334862385321102
I1
I0
I1
tp10733
sS'bleeding,events,have'
p10734
(F1
F0.00028669724770642203
I2
I0
I2
tp10735
sS'example,may,activate'
p10736
(F1
F0.00014334862385321102
I0
I1
I-1
tp10737
sS'the,urine,may'
p10738
(F1
F0.00043004587155963305
I0
I3
I-3
tp10739
sS'agonists,have,been'
p10740
(F1
F0.00014334862385321102
I1
I0
I1
tp10741
sS'to,treat,a'
p10742
(F1
F0.00014334862385321102
I0
I1
I-1
tp10743
sS'ccnu,by,dose'
p10744
(F1
F0.00014334862385321102
I1
I0
I1
tp10745
sS'as,other,medicines'
p10746
(F1
F0.00014334862385321102
I1
I0
I1
tp10747
sS'cmin,concentrations,increased'
p10748
(F1
F0.00014334862385321102
I0
I1
I-1
tp10749
sS'with,sustiva,mg'
p10750
(F1
F0.00014334862385321102
I1
I0
I1
tp10751
sS'qtc,intervals,in'
p10752
(F1
F0.00014334862385321102
I0
I1
I-1
tp10753
sS'disturbances,left,ventricular'
p10754
(F1
F0.00014334862385321102
I1
I0
I1
tp10755
sS'decreased,the,maximum'
p10756
(F1
F0.00014334862385321102
I1
I0
I1
tp10757
sS'other,concurrent,use'
p10758
(F1
F0.00014334862385321102
I1
I0
I1
tp10759
sS'acetylsalicylic,acid,did'
p10760
(F1
F0.00014334862385321102
I0
I1
I-1
tp10761
sS'cystic,fluid,were'
p10762
(F1
F0.00014334862385321102
I1
I0
I1
tp10763
sS'dose-time,effects,of'
p10764
(F1
F0.00014334862385321102
I0
I1
I-1
tp10765
sS'combination,with,experienced'
p10766
(F1
F0.00014334862385321102
I1
I0
I1
tp10767
sS'be,exacerbated,by'
p10768
(F1
F0.00028669724770642203
I2
I0
I2
tp10769
sS'depression,tricyclic,flupenthixol'
p10770
(F1
F0.00014334862385321102
I1
I0
I1
tp10771
sS'conclusions,olanzapine,demonstrated'
p10772
(F1
F0.00014334862385321102
I0
I1
I-1
tp10773
sS'in,dogs,unchanged'
p10774
(F1
F0.00014334862385321102
I0
I1
I-1
tp10775
sS'accumbens,but,only'
p10776
(F1
F0.00014334862385321102
I0
I1
I-1
tp10777
sS'interactions,in,clinical'
p10778
(F1
F0.00014334862385321102
I0
I1
I-1
tp10779
sS'reported,with,the'
p10780
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp10781
sS'of,goal-directed,behavior'
p10782
(F1
F0.00014334862385321102
I0
I1
I-1
tp10783
sS'reported,to,be'
p10784
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp10785
sS'imidazoles,etc,in'
p10786
(F1
F0.00014334862385321102
I1
I0
I1
tp10787
sS'in,dietary-obese,rats'
p10788
(F1
F0.00014334862385321102
I0
I1
I-1
tp10789
sS'to,control,atrial'
p10790
(F1
F0.00014334862385321102
I1
I0
I1
tp10791
sS'a,water,pill'
p10792
(F1
F0.00014334862385321102
I0
I1
I-1
tp10793
sS'or,and,frova'
p10794
(F1
F0.00014334862385321102
I1
I0
I1
tp10795
sS'seen,prior,to'
p10796
(F1
F0.00014334862385321102
I1
I0
I1
tp10797
sS'a,modest,cyp2d6'
p10798
(F1
F0.00014334862385321102
I1
I0
I1
tp10799
sS'mg,and,a'
p10800
(F1
F0.00014334862385321102
I1
I0
I1
tp10801
sS'should,be,allowed'
p10802
(F1
F0.00014334862385321102
I1
I0
I1
tp10803
sS'or,neuromuscular,blockade'
p10804
(F1
F0.00014334862385321102
I0
I1
I-1
tp10805
sS'this,medication,tell'
p10806
(F1
F0.00014334862385321102
I0
I1
I-1
tp10807
sS'concentrations,in,the'
p10808
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp10809
sS'substances,grapefruit,juice'
p10810
(F1
F0.00014334862385321102
I0
I1
I-1
tp10811
sS'actions,were,potentiated'
p10812
(F1
F0.00014334862385321102
I1
I0
I1
tp10813
sS'agents,are,associated'
p10814
(F1
F0.00014334862385321102
I0
I1
I-1
tp10815
sS'with,to,which'
p10816
(F1
F0.00014334862385321102
I1
I0
I1
tp10817
sS'who,were,extensive'
p10818
(F1
F0.00014334862385321102
I1
I0
I1
tp10819
sS'twice,daily,did'
p10820
(F1
F0.0008600917431192661
I0
I6
I-6
tp10821
sS'bleeding,tendency,produced'
p10822
(F1
F0.00014334862385321102
I1
I0
I1
tp10823
sS'as,v,remains'
p10824
(F1
F0.00014334862385321102
I0
I1
I-1
tp10825
sS'are,highly,bound'
p10826
(F1
F0.00014334862385321102
I1
I0
I1
tp10827
sS'phenytoin,accutane,has'
p10828
(F1
F0.00014334862385321102
I0
I1
I-1
tp10829
sS'of,factive,and'
p10830
(F1
F0.00014334862385321102
I1
I0
I1
tp10831
sS'ng,ml,at'
p10832
(F1
F0.00014334862385321102
I0
I1
I-1
tp10833
sS'sr,by,approximately'
p10834
(F1
F0.00014334862385321102
I1
I0
I1
tp10835
sS'and,to,confirm'
p10836
(F1
F0.00014334862385321102
I0
I1
I-1
tp10837
sS'performed,both,with'
p10838
(F1
F0.00014334862385321102
I0
I1
I-1
tp10839
sS'agonists,dcg-iv,and'
p10840
(F1
F0.00014334862385321102
I0
I1
I-1
tp10841
sS'valium,and,to'
p10842
(F1
F0.00014334862385321102
I1
I0
I1
tp10843
sS'receiving,concomitant,high-dose'
p10844
(F1
F0.00014334862385321102
I1
I0
I1
tp10845
sS'given,at,bedtime'
p10846
(F1
F0.00014334862385321102
I0
I1
I-1
tp10847
sS'in,vertigo,syncope'
p10848
(F1
F0.00014334862385321102
I0
I1
I-1
tp10849
sS'recently,instituted,may'
p10850
(F1
F0.00043004587155963305
I3
I0
I3
tp10851
sS'beta-lactam,including,based'
p10852
(F1
F0.00014334862385321102
I1
I0
I1
tp10853
sS'and,other,vasoconstrictor'
p10854
(F1
F0.00014334862385321102
I1
I0
I1
tp10855
sS'in,bioavailability,or'
p10856
(F1
F0.00014334862385321102
I0
I1
I-1
tp10857
sS'warrant,dosage,adjustments'
p10858
(F1
F0.00014334862385321102
I1
I0
I1
tp10859
sS'amount,of,lanoxin'
p10860
(F1
F0.00014334862385321102
I1
I0
I1
tp10861
sS'periodic,intervals,or'
p10862
(F1
F0.00014334862385321102
I1
I0
I1
tp10863
sS'and,a,precipitate'
p10864
(F1
F0.00014334862385321102
I0
I1
I-1
tp10865
sS'study,with,bioavailability'
p10866
(F1
F0.00014334862385321102
I0
I1
I-1
tp10867
sS'were,variable,and'
p10868
(F1
F0.00014334862385321102
I0
I1
I-1
tp10869
sS'well,as,the'
p10870
(F0
F0
I1
I1
I0
tp10871
sS'ethanol,flupenthixol,and'
p10872
(F1
F0.00014334862385321102
I1
I0
I1
tp10873
sS'i,mac,was'
p10874
(F1
F0.00014334862385321102
I1
I0
I1
tp10875
sS'co-administered,avonex,indicates'
p10876
(F1
F0.00014334862385321102
I0
I1
I-1
tp10877
sS'skeletal,muscle,relaxing'
p10878
(F1
F0.00014334862385321102
I1
I0
I1
tp10879
sS'aspirin,when,lodine'
p10880
(F1
F0.00014334862385321102
I1
I0
I1
tp10881
sS'prolongation,cardiac,arrythmias'
p10882
(F1
F0.00014334862385321102
I1
I0
I1
tp10883
sS'but,not,morphine-induced'
p10884
(F1
F0.00014334862385321102
I0
I1
I-1
tp10885
sS'out,in,the'
p10886
(F1
F0.00014334862385321102
I0
I1
I-1
tp10887
sS'individual,glucose,concentrations'
p10888
(F1
F0.00014334862385321102
I1
I0
I1
tp10889
sS'suggest,that,tam'
p10890
(F1
F0.00014334862385321102
I1
I0
I1
tp10891
sS'least,weeks,may'
p10892
(F1
F0.00014334862385321102
I1
I0
I1
tp10893
sS'use,of,buspirone'
p10894
(F1
F0.00014334862385321102
I1
I0
I1
tp10895
sS'oral,suspension,can'
p10896
(F1
F0.00014334862385321102
I0
I1
I-1
tp10897
sS'averaged,s,d'
p10898
(F1
F0.00014334862385321102
I1
I0
I1
tp10899
sS'other,that,could'
p10900
(F1
F0.00014334862385321102
I0
I1
I-1
tp10901
sS'in,a,short-term'
p10902
(F1
F0.00014334862385321102
I0
I1
I-1
tp10903
sS'sonata,mg,q24h'
p10904
(F1
F0.00014334862385321102
I0
I1
I-1
tp10905
sS'day,in,otherwise'
p10906
(F1
F0.00014334862385321102
I0
I1
I-1
tp10907
sS'marrow,depression,such'
p10908
(F1
F0.00014334862385321102
I1
I0
I1
tp10909
sS'pressure,medications,motion'
p10910
(F1
F0.00014334862385321102
I0
I1
I-1
tp10911
sS'to,one-fourth,of'
p10912
(F1
F0.00014334862385321102
I1
I0
I1
tp10913
sS'd,agonists,concomitant'
p10914
(F1
F0.00014334862385321102
I1
I0
I1
tp10915
sS'including,decrease,the'
p10916
(F1
F0.00014334862385321102
I1
I0
I1
tp10917
sS'dose,is,about'
p10918
(F1
F0.00014334862385321102
I0
I1
I-1
tp10919
sS'combined,administration,of'
p10920
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp10921
sS'oxolinic,acid,prolonged'
p10922
(F1
F0.00014334862385321102
I1
I0
I1
tp10923
sS'receiving,prothrombin,times'
p10924
(F1
F0.00014334862385321102
I1
I0
I1
tp10925
sS'levels,the,dose'
p10926
(F1
F0.00014334862385321102
I1
I0
I1
tp10927
sS'benefit,from,containing'
p10928
(F1
F0.00014334862385321102
I1
I0
I1
tp10929
sS'of,therapeutic,concentrations'
p10930
(F1
F0.00014334862385321102
I0
I1
I-1
tp10931
sS'estrogen-containing,oral,increase'
p10932
(F1
F0.00014334862385321102
I0
I1
I-1
tp10933
sS'of,certain,weak'
p10934
(F1
F0.00014334862385321102
I1
I0
I1
tp10935
sS'treatment,and,inhibits'
p10936
(F1
F0.00014334862385321102
I1
I0
I1
tp10937
sS'affected,prothrombin,times'
p10938
(F1
F0.00014334862385321102
I0
I1
I-1
tp10939
sS'addition,higher-than,expected'
p10940
(F1
F0.00014334862385321102
I1
I0
I1
tp10941
sS'preliminary,results,from'
p10942
(F1
F0.00028669724770642203
I0
I2
I-2
tp10943
sS'phenobarbitol,rifabutin,rifampin'
p10944
(F1
F0.00014334862385321102
I0
I1
I-1
tp10945
sS'of,kerlone,with'
p10946
(F1
F0.00014334862385321102
I0
I1
I-1
tp10947
sS'the,nonlinear,kinetic'
p10948
(F1
F0.00014334862385321102
I0
I1
I-1
tp10949
sS'of,those,obtained'
p10950
(F1
F0.00014334862385321102
I1
I0
I1
tp10951
sS'to,and,and'
p10952
(F1
F0.00014334862385321102
I0
I1
I-1
tp10953
sS'but,given,the'
p10954
(F1
F0.00014334862385321102
I0
I1
I-1
tp10955
sS'is,derived,from'
p10956
(F1
F0.00014334862385321102
I1
I0
I1
tp10957
sS'veratrum,alkaloids,amphetamines'
p10958
(F1
F0.00028669724770642203
I2
I0
I2
tp10959
sS'at,microm,which'
p10960
(F1
F0.00014334862385321102
I0
I1
I-1
tp10961
sS'if,the,is'
p10962
(F1
F0.00014334862385321102
I0
I1
I-1
tp10963
sS'of,from,ml'
p10964
(F1
F0.00014334862385321102
I1
I0
I1
tp10965
sS'have,either,protective'
p10966
(F1
F0.00014334862385321102
I0
I1
I-1
tp10967
sS'anti-inflammatory,activity,of'
p10968
(F1
F0.00014334862385321102
I1
I0
I1
tp10969
sS'study,of,young'
p10970
(F1
F0.00014334862385321102
I0
I1
I-1
tp10971
sS'of,are,increased'
p10972
(F1
F0.00014334862385321102
I1
I0
I1
tp10973
sS'cns,cardiac,and'
p10974
(F1
F0.00014334862385321102
I0
I1
I-1
tp10975
sS'of,tikosyn,with'
p10976
(F1
F0.00014334862385321102
I1
I0
I1
tp10977
sS'day,in,combination'
p10978
(F1
F0.00014334862385321102
I0
I1
I-1
tp10979
sS'gi,ulceration,or'
p10980
(F1
F0.00028669724770642203
I2
I0
I2
tp10981
sS'the,absolute,number'
p10982
(F1
F0.00014334862385321102
I0
I1
I-1
tp10983
sS'american,coffee,was'
p10984
(F1
F0.00014334862385321102
I0
I1
I-1
tp10985
sS'lithium,lithium,should'
p10986
(F1
F0.00014334862385321102
I1
I0
I1
tp10987
sS'to,higher,exposure'
p10988
(F1
F0.00014334862385321102
I1
I0
I1
tp10989
sS'results,regarding,the'
p10990
(F1
F0.00014334862385321102
I1
I0
I1
tp10991
sS'a,similar,length'
p10992
(F1
F0.00014334862385321102
I1
I0
I1
tp10993
sS'on,the,antitumour'
p10994
(F1
F0.00014334862385321102
I0
I1
I-1
tp10995
sS'interaction,with,for'
p10996
(F1
F0.00028669724770642203
I2
I0
I2
tp10997
sS'of,cyp3a4,increased'
p10998
(F1
F0.00014334862385321102
I1
I0
I1
tp10999
sS'weeks,after,initiation'
p11000
(F1
F0.00014334862385321102
I1
I0
I1
tp11001
sS'phenytoin,altered,serum'
p11002
(F1
F0.00014334862385321102
I1
I0
I1
tp11003
sS'and,synergistic,for'
p11004
(F1
F0.00014334862385321102
I1
I0
I1
tp11005
sS'including,nonsteroidal,anti-inflammatory'
p11006
(F1
F0.00014334862385321102
I1
I0
I1
tp11007
sS'for,interaction,with'
p11008
(F1
F0.00028669724770642203
I2
I0
I2
tp11009
sS'lithium,carbonate,the'
p11010
(F1
F0.00028669724770642203
I2
I0
I2
tp11011
sS'mg,each,dose'
p11012
(F1
F0.00014334862385321102
I0
I1
I-1
tp11013
sS'as,factor,viii'
p11014
(F1
F0.00014334862385321102
I0
I1
I-1
tp11015
sS'avoid,giving,in'
p11016
(F1
F0.00014334862385321102
I1
I0
I1
tp11017
sS'with,elevated,plasma'
p11018
(F1
F0.00014334862385321102
I1
I0
I1
tp11019
sS'with,mg,of'
p11020
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp11021
sS'of,bleeding,with'
p11022
(F1
F0.00014334862385321102
I0
I1
I-1
tp11023
sS'resulted,in,substantial'
p11024
(F1
F0.00014334862385321102
I1
I0
I1
tp11025
sS'allegra,should,be'
p11026
(F1
F0.00014334862385321102
I0
I1
I-1
tp11027
sS'in,mind,when'
p11028
(F1
F0.00028669724770642203
I0
I2
I-2
tp11029
sS'radiolabeled,ions,may'
p11030
(F1
F0.00014334862385321102
I0
I1
I-1
tp11031
sS'that,may,alter'
p11032
(F1
F0.00028669724770642203
I2
I0
I2
tp11033
sS'with,a,toxicology'
p11034
(F1
F0.00014334862385321102
I1
I0
I1
tp11035
sS'clinical,studies,received'
p11036
(F1
F0.00014334862385321102
I0
I1
I-1
tp11037
sS'controlled,study,a'
p11038
(F1
F0.00014334862385321102
I1
I0
I1
tp11039
sS'antagonize,the,hypotensive'
p11040
(F1
F0.00043004587155963305
I3
I0
I3
tp11041
sS'respiratory,depression,stupor'
p11042
(F1
F0.00014334862385321102
I1
I0
I1
tp11043
sS'and,recurred,when'
p11044
(F1
F0.00014334862385321102
I0
I1
I-1
tp11045
sS'mg,once,daily'
p11046
(F0.076923076923076927
F0.00014334862385321102
I6
I7
I-1
tp11047
sS'period,of,at'
p11048
(F1
F0.00014334862385321102
I1
I0
I1
tp11049
sS'such,as,diphen-hydramine'
p11050
(F1
F0.00014334862385321102
I0
I1
I-1
tp11051
sS'to,continue,the'
p11052
(F1
F0.00014334862385321102
I1
I0
I1
tp11053
sS'of,major,bleeding'
p11054
(F1
F0.00014334862385321102
I1
I0
I1
tp11055
sS'in,significantly,increased'
p11056
(F1
F0.00014334862385321102
I1
I0
I1
tp11057
sS'prolongation,ischemic,heart'
p11058
(F1
F0.00014334862385321102
I1
I0
I1
tp11059
sS'aspirin,is,contraindicated'
p11060
(F1
F0.00014334862385321102
I1
I0
I1
tp11061
sS'been,demonstrated,in'
p11062
(F0
F0
I2
I2
I0
tp11063
sS'oral,placebo,and'
p11064
(F1
F0.00014334862385321102
I0
I1
I-1
tp11065
sS'initial,oral,dose'
p11066
(F1
F0.00014334862385321102
I1
I0
I1
tp11067
sS'query,patients,or'
p11068
(F1
F0.00014334862385321102
I0
I1
I-1
tp11069
sS'inhibit,the,cytochrome'
p11070
(F0
F0
I1
I1
I0
tp11071
sS'and,other,nonsteroidal'
p11072
(F1
F0.00014334862385321102
I1
I0
I1
tp11073
sS'with,patients,taking'
p11074
(F1
F0.00014334862385321102
I1
I0
I1
tp11075
sS'react,with,in'
p11076
(F1
F0.00014334862385321102
I1
I0
I1
tp11077
sS'vioxx,concomitantly,with'
p11078
(F1
F0.00014334862385321102
I1
I0
I1
tp11079
sS'drugs,that,may'
p11080
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp11081
sS'resulting,in,lowered'
p11082
(F0
F0
I1
I1
I0
tp11083
sS'these,agents,should'
p11084
(F1
F0.00014334862385321102
I0
I1
I-1
tp11085
sS'when,administered,alone'
p11086
(F1
F0.00014334862385321102
I0
I1
I-1
tp11087
sS'with,beta,adrenergic-blocking'
p11088
(F1
F0.00014334862385321102
I0
I1
I-1
tp11089
sS'cell,could,be'
p11090
(F1
F0.00014334862385321102
I0
I1
I-1
tp11091
sS'dopamine-induced,ventricular,arrhythmias'
p11092
(F1
F0.00014334862385321102
I1
I0
I1
tp11093
sS'decreased,antihypertensive,effect'
p11094
(F1
F0.00014334862385321102
I1
I0
I1
tp11095
sS'may,reduce,its'
p11096
(F1
F0.00014334862385321102
I0
I1
I-1
tp11097
sS'of,activase,in'
p11098
(F1
F0.00014334862385321102
I0
I1
I-1
tp11099
sS'reported,during,concomitant'
p11100
(F1
F0.00043004587155963305
I3
I0
I3
tp11101
sS'based,tests,such'
p11102
(F1
F0.00014334862385321102
I0
I1
I-1
tp11103
sS'lower,the,plasma'
p11104
(F1
F0.00014334862385321102
I1
I0
I1
tp11105
sS'evaluating,the,serum'
p11106
(F1
F0.00014334862385321102
I0
I1
I-1
tp11107
sS'their,clearance,resulting'
p11108
(F1
F0.00014334862385321102
I0
I1
I-1
tp11109
sS'nd,female,n'
p11110
(F1
F0.00014334862385321102
I0
I1
I-1
tp11111
sS'profile,of,does'
p11112
(F1
F0.00014334862385321102
I0
I1
I-1
tp11113
sS'affect,renal,prostaglandins'
p11114
(F1
F0.00014334862385321102
I0
I1
I-1
tp11115
sS'including,when,hydrochloride'
p11116
(F1
F0.00014334862385321102
I1
I0
I1
tp11117
sS'in,vitro,sodium'
p11118
(F1
F0.00014334862385321102
I0
I1
I-1
tp11119
sS'mean,eight-fold,increase'
p11120
(F1
F0.00028669724770642203
I2
I0
I2
tp11121
sS'were,concomitantly,used'
p11122
(F1
F0.00014334862385321102
I0
I1
I-1
tp11123
sS'with,xigris,caution'
p11124
(F1
F0.00014334862385321102
I0
I1
I-1
tp11125
sS'increase,oral,response'
p11126
(F1
F0.00028669724770642203
I2
I0
I2
tp11127
sS'inhibitors,the,combined'
p11128
(F1
F0.00014334862385321102
I1
I0
I1
tp11129
sS'with,no,increase'
p11130
(F1
F0.00014334862385321102
I0
I1
I-1
tp11131
sS'thrombus,formation,from'
p11132
(F1
F0.00014334862385321102
I1
I0
I1
tp11133
sS'cisplatin,was,administered'
p11134
(F1
F0.00014334862385321102
I0
I1
I-1
tp11135
sS'of,v,oral'
p11136
(F1
F0.00014334862385321102
I1
I0
I1
tp11137
sS'to,cross,toxicity'
p11138
(F1
F0.00014334862385321102
I1
I0
I1
tp11139
sS'the,magnitude,of'
p11140
(F1
F0.00014334862385321102
I1
I0
I1
tp11141
sS'data,presented,here'
p11142
(F1
F0.00014334862385321102
I0
I1
I-1
tp11143
sS'and,may,increase'
p11144
(F1
F0.0012901376146788992
I9
I0
I9
tp11145
sS'taking,tarceva,with'
p11146
(F1
F0.00014334862385321102
I1
I0
I1
tp11147
sS'of,to,mg'
p11148
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp11149
sS'molecular,weight,heparins'
p11150
(F1
F0.00014334862385321102
I0
I1
I-1
tp11151
sS'the,magnitude,or'
p11152
(F1
F0.00014334862385321102
I0
I1
I-1
tp11153
sS'fetal,development,including'
p11154
(F1
F0.00014334862385321102
I0
I1
I-1
tp11155
sS'from,decrease,to'
p11156
(F1
F0.00028669724770642203
I2
I0
I2
tp11157
sS'appears,to,be'
p11158
(F0
F0
I2
I2
I0
tp11159
sS'extensive,metabolism,by'
p11160
(F1
F0.00014334862385321102
I0
I1
I-1
tp11161
sS'the,deaths,due'
p11162
(F1
F0.00014334862385321102
I0
I1
I-1
tp11163
sS'patients,were,randomly'
p11164
(F1
F0.00014334862385321102
I0
I1
I-1
tp11165
sS'to,transport-related,effects'
p11166
(F1
F0.00014334862385321102
I1
I0
I1
tp11167
sS'receiving,monoamine,oxidase'
p11168
(F1
F0.00057339449541284407
I4
I0
I4
tp11169
sS'similar,among,bosentan-'
p11170
(F1
F0.00014334862385321102
I0
I1
I-1
tp11171
sS'active,metabolite,after'
p11172
(F1
F0.00014334862385321102
I0
I1
I-1
tp11173
sS'which,was,far'
p11174
(F1
F0.00014334862385321102
I0
I1
I-1
tp11175
sS'of,an,in'
p11176
(F1
F0.00014334862385321102
I0
I1
I-1
tp11177
sS'peak,concentration,of'
p11178
(F1
F0.00014334862385321102
I0
I1
I-1
tp11179
sS'of,the,administration'
p11180
(F1
F0.00028669724770642203
I2
I0
I2
tp11181
sS'like,and,from'
p11182
(F1
F0.00014334862385321102
I0
I1
I-1
tp11183
sS'the,coumarin,type'
p11184
(F1
F0.00014334862385321102
I0
I1
I-1
tp11185
sS'a,inhibitors,on'
p11186
(F1
F0.00014334862385321102
I1
I0
I1
tp11187
sS'in,peak,plasma'
p11188
(F1
F0.00057339449541284407
I4
I0
I4
tp11189
sS'diabetic,patients,there'
p11190
(F1
F0.00014334862385321102
I0
I1
I-1
tp11191
sS'the,analgesic,effect'
p11192
(F1
F0.00014334862385321102
I1
I0
I1
tp11193
sS'or,to,two'
p11194
(F1
F0.00014334862385321102
I1
I0
I1
tp11195
sS'food,is,recommended'
p11196
(F1
F0.00014334862385321102
I1
I0
I1
tp11197
sS'not,induce,the'
p11198
(F1
F0.00014334862385321102
I0
I1
I-1
tp11199
sS'caution,since,they'
p11200
(F1
F0.00014334862385321102
I0
I1
I-1
tp11201
sS'will,be,longer'
p11202
(F1
F0.00014334862385321102
I0
I1
I-1
tp11203
sS'with,may,lead'
p11204
(F0
F0
I1
I1
I0
tp11205
sS'of,coadministration,loratadine'
p11206
(F1
F0.00014334862385321102
I0
I1
I-1
tp11207
sS'containing,alone,they'
p11208
(F1
F0.00014334862385321102
I1
I0
I1
tp11209
sS'uptake-1,were,reduced'
p11210
(F1
F0.00014334862385321102
I0
I1
I-1
tp11211
sS'response,to,a'
p11212
(F1
F0.00014334862385321102
I0
I1
I-1
tp11213
sS'of,microsomal,enzymes'
p11214
(F1
F0.00014334862385321102
I0
I1
I-1
tp11215
sS'sparing,such,as'
p11216
(F1
F0.00014334862385321102
I1
I0
I1
tp11217
sS'tricyclic,may,antagonize'
p11218
(F1
F0.00014334862385321102
I1
I0
I1
tp11219
sS'in,the,remainder'
p11220
(F1
F0.00014334862385321102
I0
I1
I-1
tp11221
sS'in,hypercholesterolemic,patients'
p11222
(F1
F0.00014334862385321102
I1
I0
I1
tp11223
sS'samples,for,plasma'
p11224
(F1
F0.00014334862385321102
I0
I1
I-1
tp11225
sS'is,warranted,in'
p11226
(F1
F0.00014334862385321102
I1
I0
I1
tp11227
sS'be,weighed,against'
p11228
(F1
F0.00014334862385321102
I1
I0
I1
tp11229
sS'be,discontinued,at'
p11230
(F1
F0.00014334862385321102
I1
I0
I1
tp11231
sS'may,cause,an'
p11232
(F1
F0.00028669724770642203
I2
I0
I2
tp11233
sS'suggesting,that,dose'
p11234
(F1
F0.00014334862385321102
I1
I0
I1
tp11235
sS'completed,with,both'
p11236
(F1
F0.00014334862385321102
I0
I1
I-1
tp11237
sS'tranexamic,acid,aminocaproic'
p11238
(F1
F0.00014334862385321102
I0
I1
I-1
tp11239
sS'a,few,patients'
p11240
(F1
F0.00028669724770642203
I2
I0
I2
tp11241
sS'the,same,procedures'
p11242
(F1
F0.00014334862385321102
I0
I1
I-1
tp11243
sS'agents,may,produce'
p11244
(F1
F0.00014334862385321102
I1
I0
I1
tp11245
sS'or,disruption,of'
p11246
(F1
F0.00014334862385321102
I0
I1
I-1
tp11247
sS'demonstrated,superiority,over'
p11248
(F1
F0.00014334862385321102
I0
I1
I-1
tp11249
sS'useful,for,peroral'
p11250
(F1
F0.00014334862385321102
I0
I1
I-1
tp11251
sS'scintigraphy,employing,mtc-mdp'
p11252
(F1
F0.00014334862385321102
I0
I1
I-1
tp11253
sS'exjade,should,not'
p11254
(F1
F0.00014334862385321102
I1
I0
I1
tp11255
sS'n-methyllevallorphan,mg,kg'
p11256
(F1
F0.00014334862385321102
I1
I0
I1
tp11257
sS'auc,of,the'
p11258
(F1
F0.00014334862385321102
I1
I0
I1
tp11259
sS'expected,to,significantly'
p11260
(F1
F0.00014334862385321102
I0
I1
I-1
tp11261
sS'a,meal,as'
p11262
(F1
F0.00014334862385321102
I1
I0
I1
tp11263
sS'interferon,beta,to'
p11264
(F1
F0.00014334862385321102
I0
I1
I-1
tp11265
sS'of,and,other'
p11266
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp11267
sS'was,poorly,tolerated'
p11268
(F1
F0.00014334862385321102
I1
I0
I1
tp11269
sS'plasma,protein,and'
p11270
(F1
F0.00014334862385321102
I0
I1
I-1
tp11271
sS'due,to,the'
p11272
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp11273
sS'and,cmin,were'
p11274
(F1
F0.00057339449541284407
I4
I0
I4
tp11275
sS'well,as,post-marketing'
p11276
(F1
F0.00043004587155963305
I3
I0
I3
tp11277
sS'for,possible,atrioventricular'
p11278
(F1
F0.00014334862385321102
I1
I0
I1
tp11279
sS'admini,stered,orally'
p11280
(F1
F0.00014334862385321102
I1
I0
I1
tp11281
sS'particular,caution,in'
p11282
(F1
F0.00014334862385321102
I1
I0
I1
tp11283
sS'it,was,shown'
p11284
(F0
F0
I1
I1
I0
tp11285
sS'were,conducted,in'
p11286
(F1
F0.00014334862385321102
I0
I1
I-1
tp11287
sS'against,the,ototoxic'
p11288
(F1
F0.00014334862385321102
I1
I0
I1
tp11289
sS'effects,of,such'
p11290
(F1
F0.00028669724770642203
I2
I0
I2
tp11291
sS'administration,the,effect'
p11292
(F1
F0.00014334862385321102
I0
I1
I-1
tp11293
sS'rise,to,convulsions'
p11294
(F1
F0.00014334862385321102
I1
I0
I1
tp11295
sS'particular,caution,is'
p11296
(F1
F0.00028669724770642203
I2
I0
I2
tp11297
sS'when,was,withdrawn'
p11298
(F1
F0.00014334862385321102
I0
I1
I-1
tp11299
sS'used,to,treat'
p11300
(F1
F0.00043004587155963305
I0
I3
I-3
tp11301
sS'kemstro,the,most'
p11302
(F1
F0.00014334862385321102
I0
I1
I-1
tp11303
sS'bezalip,retard,is'
p11304
(F1
F0.00028669724770642203
I2
I0
I2
tp11305
sS'digit,symbol,substitution'
p11306
(F1
F0.00014334862385321102
I1
I0
I1
tp11307
sS'day,and,day'
p11308
(F1
F0.00014334862385321102
I1
I0
I1
tp11309
sS'with,videx,should'
p11310
(F1
F0.00014334862385321102
I0
I1
I-1
tp11311
sS'or,activity,of'
p11312
(F1
F0.00014334862385321102
I1
I0
I1
tp11313
sS'though,reversible,impairment'
p11314
(F1
F0.00014334862385321102
I1
I0
I1
tp11315
sS'the,contents,of'
p11316
(F1
F0.00028669724770642203
I0
I2
I-2
tp11317
sS'discontinued,for,several'
p11318
(F1
F0.00014334862385321102
I1
I0
I1
tp11319
sS'efficacy,of,xigris'
p11320
(F1
F0.00014334862385321102
I0
I1
I-1
tp11321
sS'if,stadol,ns'
p11322
(F1
F0.00014334862385321102
I1
I0
I1
tp11323
sS'ventricular,failure,have'
p11324
(F1
F0.00014334862385321102
I1
I0
I1
tp11325
sS'of,and,caused'
p11326
(F1
F0.00014334862385321102
I0
I1
I-1
tp11327
sS'of,or,caused'
p11328
(F1
F0.00014334862385321102
I0
I1
I-1
tp11329
sS'wait,weeks,after'
p11330
(F1
F0.00028669724770642203
I2
I0
I2
tp11331
sS'of,mixed,overdosage'
p11332
(F1
F0.00014334862385321102
I1
I0
I1
tp11333
sS'result,in,advanced'
p11334
(F1
F0.00014334862385321102
I1
I0
I1
tp11335
sS'have,shown,to'
p11336
(F1
F0.00014334862385321102
I0
I1
I-1
tp11337
sS'and,respectively,and'
p11338
(F1
F0.00043004587155963305
I3
I0
I3
tp11339
sS'potassium,enalapril,and'
p11340
(F1
F0.00014334862385321102
I1
I0
I1
tp11341
sS'day,of,a'
p11342
(F1
F0.00057339449541284407
I4
I0
I4
tp11343
sS'resulting,in,systemic'
p11344
(F1
F0.00028669724770642203
I2
I0
I2
tp11345
sS'clinical,studies,beta-receptor'
p11346
(F1
F0.00014334862385321102
I0
I1
I-1
tp11347
sS'day,of,n'
p11348
(F1
F0.00014334862385321102
I0
I1
I-1
tp11349
sS'sodium,polystyrene,sulfonate'
p11350
(F1
F0.00014334862385321102
I1
I0
I1
tp11351
sS'is,metabolized,by'
p11352
(F1
F0.0008600917431192661
I0
I6
I-6
tp11353
sS'health,if,a'
p11354
(F0
F0
I1
I1
I0
tp11355
sS'pcp,induced,locomotion'
p11356
(F1
F0.00014334862385321102
I0
I1
I-1
tp11357
sS'stadol,ns,mg'
p11358
(F1
F0.00014334862385321102
I0
I1
I-1
tp11359
sS'when,eye,drops'
p11360
(F1
F0.00014334862385321102
I0
I1
I-1
tp11361
sS'with,strong,cyp3a4'
p11362
(F1
F0.00014334862385321102
I1
I0
I1
tp11363
sS'prelone,st,johns'
p11364
(F1
F0.00014334862385321102
I1
I0
I1
tp11365
sS'of,such,agents'
p11366
(F1
F0.00014334862385321102
I0
I1
I-1
tp11367
sS'slightly,greater,than'
p11368
(F1
F0.00014334862385321102
I1
I0
I1
tp11369
sS'with,some,angiotensin'
p11370
(F1
F0.00014334862385321102
I1
I0
I1
tp11371
sS'those,receiving,crixivan'
p11372
(F1
F0.00014334862385321102
I1
I0
I1
tp11373
sS'theophylline,the,effect'
p11374
(F1
F0.00014334862385321102
I0
I1
I-1
tp11375
sS'of,and,ethinyl'
p11376
(F0.5
F0.00028669724770642203
I3
I1
I2
tp11377
sS'cyp2d6,inhibitors,atomoxetine'
p11378
(F1
F0.00014334862385321102
I0
I1
I-1
tp11379
sS'number,of,cases'
p11380
(F1
F0.00014334862385321102
I1
I0
I1
tp11381
sS'administration,of,neurontin'
p11382
(F1
F0.00014334862385321102
I0
I1
I-1
tp11383
sS'effect,of,probenecid'
p11384
(F1
F0.00014334862385321102
I0
I1
I-1
tp11385
sS'other,psychotropic,or'
p11386
(F1
F0.00014334862385321102
I0
I1
I-1
tp11387
sS'and,extent,auc'
p11388
(F1
F0.00014334862385321102
I1
I0
I1
tp11389
sS'others,choline,arthropan'
p11390
(F1
F0.00014334862385321102
I1
I0
I1
tp11391
sS'concomitantly,becausedecreases,in'
p11392
(F1
F0.00028669724770642203
I2
I0
I2
tp11393
sS'no,important,interactions'
p11394
(F1
F0.00014334862385321102
I0
I1
I-1
tp11395
sS'well,as,other'
p11396
(F1
F0.00014334862385321102
I1
I0
I1
tp11397
sS'activity,enough,to'
p11398
(F1
F0.00014334862385321102
I0
I1
I-1
tp11399
sS'preparations,are,incompatible'
p11400
(F1
F0.00014334862385321102
I1
I0
I1
tp11401
sS'adenosine,dipyridamole,has'
p11402
(F1
F0.00014334862385321102
I1
I0
I1
tp11403
sS'biologic,half-life,of'
p11404
(F1
F0.00014334862385321102
I1
I0
I1
tp11405
sS'imitrex,nasal,spray'
p11406
(F1
F0.00014334862385321102
I0
I1
I-1
tp11407
sS'would,include,a'
p11408
(F1
F0.00014334862385321102
I0
I1
I-1
tp11409
sS'slower,absorption,mean'
p11410
(F1
F0.00014334862385321102
I1
I0
I1
tp11411
sS'no,pharmacokinetic,or'
p11412
(F1
F0.00014334862385321102
I0
I1
I-1
tp11413
sS'that,a,spinal'
p11414
(F1
F0.00014334862385321102
I0
I1
I-1
tp11415
sS'ace,inhibitor,can'
p11416
(F1
F0.00014334862385321102
I1
I0
I1
tp11417
sS'evaluated,cyp1a2,cyp2a6'
p11418
(F1
F0.00014334862385321102
I0
I1
I-1
tp11419
sS'and,descarboethoxyloratadine,after'
p11420
(F1
F0.00014334862385321102
I0
I1
I-1
tp11421
sS'antinonciceptive,effect,of'
p11422
(F1
F0.00014334862385321102
I0
I1
I-1
tp11423
sS'neurotoxic,effect,could'
p11424
(F1
F0.00014334862385321102
I1
I0
I1
tp11425
sS'auc,cmax,t1'
p11426
(F1
F0.00014334862385321102
I1
I0
I1
tp11427
sS'and,fetal,development'
p11428
(F1
F0.00014334862385321102
I0
I1
I-1
tp11429
sS'chloride,sodium,acid'
p11430
(F1
F0.00028669724770642203
I2
I0
I2
tp11431
sS'advantages,offered,by'
p11432
(F1
F0.00014334862385321102
I0
I1
I-1
tp11433
sS'isoflurane,and,decrease'
p11434
(F1
F0.00014334862385321102
I1
I0
I1
tp11435
sS'experience,to,assess'
p11436
(F1
F0.00014334862385321102
I1
I0
I1
tp11437
sS'are,co-administered,which'
p11438
(F1
F0.00014334862385321102
I1
I0
I1
tp11439
sS'with,a,false-positive'
p11440
(F1
F0.00014334862385321102
I0
I1
I-1
tp11441
sS'felbatol,the,rate'
p11442
(F1
F0.00014334862385321102
I0
I1
I-1
tp11443
sS'an,unusually,high'
p11444
(F1
F0.00014334862385321102
I1
I0
I1
tp11445
sS'interval,as,possible'
p11446
(F1
F0.00014334862385321102
I0
I1
I-1
tp11447
sS'cyclosporin,after,introduction'
p11448
(F1
F0.00014334862385321102
I1
I0
I1
tp11449
sS'after,multiple,doses'
p11450
(F1
F0.00014334862385321102
I0
I1
I-1
tp11451
sS'direct,effect,on'
p11452
(F1
F0.00014334862385321102
I0
I1
I-1
tp11453
sS'agents,the,thioxanthene'
p11454
(F1
F0.00014334862385321102
I1
I0
I1
tp11455
sS'clearance,may,decrease'
p11456
(F1
F0.00014334862385321102
I0
I1
I-1
tp11457
sS'of,intravenous,without'
p11458
(F1
F0.00014334862385321102
I1
I0
I1
tp11459
sS'in,patients,concomitantly'
p11460
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp11461
sS'alterations,in,lipid'
p11462
(F1
F0.00014334862385321102
I1
I0
I1
tp11463
sS'response,ie,decreased'
p11464
(F1
F0.00028669724770642203
I2
I0
I2
tp11465
sS'in,decreased,blood'
p11466
(F1
F0.00014334862385321102
I1
I0
I1
tp11467
sS'isoproterenol,hydrochloride,injection'
p11468
(F1
F0.00014334862385321102
I1
I0
I1
tp11469
sS'in,which,concomitant'
p11470
(F1
F0.00014334862385321102
I1
I0
I1
tp11471
sS'urinary,retention,and'
p11472
(F1
F0.00014334862385321102
I1
I0
I1
tp11473
sS'result,if,is'
p11474
(F1
F0.00014334862385321102
I1
I0
I1
tp11475
sS'properties,of,methylpyrazole'
p11476
(F1
F0.00014334862385321102
I1
I0
I1
tp11477
sS'activity,of,reportedly'
p11478
(F1
F0.00014334862385321102
I1
I0
I1
tp11479
sS'administering,peganone,to'
p11480
(F1
F0.00014334862385321102
I1
I0
I1
tp11481
sS'in,patients,consuming'
p11482
(F1
F0.00014334862385321102
I1
I0
I1
tp11483
sS'other,clotting,factors'
p11484
(F1
F0.00014334862385321102
I0
I1
I-1
tp11485
sS'associated,with,serotonin'
p11486
(F1
F0.00014334862385321102
I0
I1
I-1
tp11487
sS'in,dogs,but'
p11488
(F1
F0.00014334862385321102
I1
I0
I1
tp11489
sS'ssris,ssris,have'
p11490
(F1
F0.00014334862385321102
I1
I0
I1
tp11491
sS'should,be,gradual'
p11492
(F1
F0.00014334862385321102
I1
I0
I1
tp11493
sS'duloxetine,with,aluminum-'
p11494
(F1
F0.00014334862385321102
I0
I1
I-1
tp11495
sS'to,weeks,with'
p11496
(F1
F0.00028669724770642203
I2
I0
I2
tp11497
sS'of,dissolution,in'
p11498
(F1
F0.00014334862385321102
I0
I1
I-1
tp11499
sS'of,difluoro-2,propanol'
p11500
(F0
F0
I1
I1
I0
tp11501
sS'an,aluminum-containing,had'
p11502
(F1
F0.00014334862385321102
I0
I1
I-1
tp11503
sS'activity,but,given'
p11504
(F1
F0.00014334862385321102
I0
I1
I-1
tp11505
sS'and,mcg,of'
p11506
(F1
F0.00014334862385321102
I0
I1
I-1
tp11507
sS'systematically,investigated,in'
p11508
(F1
F0.00014334862385321102
I0
I1
I-1
tp11509
sS'the,pi,over'
p11510
(F1
F0.00014334862385321102
I0
I1
I-1
tp11511
sS'monitored,for,loss'
p11512
(F1
F0.00014334862385321102
I1
I0
I1
tp11513
sS'major,enzyme,responsible'
p11514
(F1
F0.00014334862385321102
I1
I0
I1
tp11515
sS'the,judgment,of'
p11516
(F1
F0.00014334862385321102
I1
I0
I1
tp11517
sS'altered,consciousness,caused'
p11518
(F1
F0.00014334862385321102
I1
I0
I1
tp11519
sS'from,a,randomized'
p11520
(F1
F0.00014334862385321102
I1
I0
I1
tp11521
sS'suggest,that,both'
p11522
(F1
F0.00014334862385321102
I1
I0
I1
tp11523
sS'microgram,ml,egf'
p11524
(F1
F0.00014334862385321102
I0
I1
I-1
tp11525
sS'intravenous,administration,the'
p11526
(F1
F0.00014334862385321102
I0
I1
I-1
tp11527
sS'concentrations,of,other'
p11528
(F0
F0
I2
I2
I0
tp11529
sS'jaffe,reaction,and'
p11530
(F1
F0.00014334862385321102
I0
I1
I-1
tp11531
sS'morphine-induced,locomotion,in'
p11532
(F1
F0.00014334862385321102
I0
I1
I-1
tp11533
sS'during,administration,systemic'
p11534
(F1
F0.00014334862385321102
I1
I0
I1
tp11535
sS'and,that,concomitant'
p11536
(F1
F0.00014334862385321102
I1
I0
I1
tp11537
sS'involved,in,metabolism'
p11538
(F1
F0.00014334862385321102
I0
I1
I-1
tp11539
sS'coadministration,of,nizoral'
p11540
(F1
F0.00014334862385321102
I1
I0
I1
tp11541
sS'ace,inhibitors,has'
p11542
(F0
F0
I1
I1
I0
tp11543
sS'and,mg2,converted'
p11544
(F1
F0.00014334862385321102
I0
I1
I-1
tp11545
sS'if,is,administered'
p11546
(F1
F0.00071674311926605509
I5
I0
I5
tp11547
sS'oral,supplementation,which'
p11548
(F1
F0.00014334862385321102
I0
I1
I-1
tp11549
sS'alcoholic,beverages,is'
p11550
(F1
F0.00014334862385321102
I1
I0
I1
tp11551
sS'potential,risk,of'
p11552
(F1
F0.00014334862385321102
I1
I0
I1
tp11553
sS'tolerated,when,administered'
p11554
(F1
F0.00014334862385321102
I0
I1
I-1
tp11555
sS'administration,of,videx'
p11556
(F1
F0.00014334862385321102
I1
I0
I1
tp11557
sS'the,cytochrome,p-450'
p11558
(F1
F0.00043004587155963305
I3
I0
I3
tp11559
sS'and,proton,pump'
p11560
(F1
F0.00014334862385321102
I0
I1
I-1
tp11561
sS'additional,caution,in'
p11562
(F1
F0.00014334862385321102
I0
I1
I-1
tp11563
sS'studies,have,demonstrated'
p11564
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp11565
sS'reduces,the,blood'
p11566
(F1
F0.00014334862385321102
I1
I0
I1
tp11567
sS'are,recommended,when'
p11568
(F1
F0.00014334862385321102
I1
I0
I1
tp11569
sS'resemblance,of,and'
p11570
(F1
F0.00014334862385321102
I1
I0
I1
tp11571
sS'systemic,and,or'
p11572
(F1
F0.00014334862385321102
I0
I1
I-1
tp11573
sS'or,within,days'
p11574
(F1
F0.00014334862385321102
I1
I0
I1
tp11575
sS'clinically,significant,hyperprolactinaemia'
p11576
(F1
F0.00014334862385321102
I0
I1
I-1
tp11577
sS'fluoxetine,a,multiple-dose'
p11578
(F1
F0.00014334862385321102
I0
I1
I-1
tp11579
sS'coadministered,oral,and'
p11580
(F1
F0.00014334862385321102
I1
I0
I1
tp11581
sS'pulse,and,blood'
p11582
(F1
F0.00014334862385321102
I1
I0
I1
tp11583
sS'the,results,from'
p11584
(F1
F0.00014334862385321102
I0
I1
I-1
tp11585
sS'when,combined,with'
p11586
(F1
F0.00014334862385321102
I1
I0
I1
tp11587
sS'by,or,on'
p11588
(F1
F0.00014334862385321102
I0
I1
I-1
tp11589
sS'administered,to,a'
p11590
(F1
F0.00028669724770642203
I2
I0
I2
tp11591
sS'between,given,singly'
p11592
(F1
F0.00014334862385321102
I0
I1
I-1
tp11593
sS'catecholamine-depleting,eg,may'
p11594
(F1
F0.00014334862385321102
I1
I0
I1
tp11595
sS'increasing,the,dose'
p11596
(F1
F0.00057339449541284407
I4
I0
I4
tp11597
sS'with,and,valproic'
p11598
(F1
F0.00014334862385321102
I1
I0
I1
tp11599
sS'to,treat,strongyloidiasis'
p11600
(F1
F0.00014334862385321102
I1
I0
I1
tp11601
sS'control,by,lowering'
p11602
(F1
F0.00014334862385321102
I1
I0
I1
tp11603
sS'aripiprazole,is,not'
p11604
(F1
F0.00014334862385321102
I0
I1
I-1
tp11605
sS'increased,by,when'
p11606
(F1
F0.00014334862385321102
I0
I1
I-1
tp11607
sS'outside,the,range'
p11608
(F1
F0.00014334862385321102
I0
I1
I-1
tp11609
sS'increase,or,prolong'
p11610
(F0
F0
I1
I1
I0
tp11611
sS'using,should,be'
p11612
(F1
F0.00014334862385321102
I1
I0
I1
tp11613
sS'rna,from,prefrontal'
p11614
(F1
F0.00014334862385321102
I0
I1
I-1
tp11615
sS'of,krm-1648,either'
p11616
(F1
F0.00014334862385321102
I0
I1
I-1
tp11617
sS'days,for,that'
p11618
(F1
F0.00014334862385321102
I0
I1
I-1
tp11619
sS'doses,of,starlix'
p11620
(F1
F0.00014334862385321102
I0
I1
I-1
tp11621
sS'inducer,or,to'
p11622
(F1
F0.00014334862385321102
I1
I0
I1
tp11623
sS'a,and,oral'
p11624
(F1
F0.00014334862385321102
I1
I0
I1
tp11625
sS'in,common,with'
p11626
(F1
F0.00014334862385321102
I1
I0
I1
tp11627
sS'lamprene,have,not'
p11628
(F1
F0.00014334862385321102
I1
I0
I1
tp11629
sS'acid,precipitation,procedure'
p11630
(F1
F0.00014334862385321102
I0
I1
I-1
tp11631
sS'on,the,early'
p11632
(F1
F0.00014334862385321102
I1
I0
I1
tp11633
sS'activity,patients,who'
p11634
(F1
F0.00028669724770642203
I2
I0
I2
tp11635
sS'produce,an,additive'
p11636
(F1
F0.00014334862385321102
I1
I0
I1
tp11637
sS'subjects,by,coadministration'
p11638
(F1
F0.00014334862385321102
I0
I1
I-1
tp11639
sS'effectiveness,in,transferring'
p11640
(F1
F0.00014334862385321102
I0
I1
I-1
tp11641
sS'with,synthetic,hydroalcoholic'
p11642
(F1
F0.00014334862385321102
I0
I1
I-1
tp11643
sS'effect,and,requiring'
p11644
(F1
F0.00014334862385321102
I1
I0
I1
tp11645
sS'using,concomitant,such'
p11646
(F1
F0.00014334862385321102
I0
I1
I-1
tp11647
sS'safety,profile,in'
p11648
(F1
F0.00014334862385321102
I0
I1
I-1
tp11649
sS'interactions,for,vitamin'
p11650
(F1
F0.00057339449541284407
I4
I0
I4
tp11651
sS'concomitantly,administered,did'
p11652
(F1
F0.00014334862385321102
I0
I1
I-1
tp11653
sS'with,and,between'
p11654
(F1
F0.00014334862385321102
I0
I1
I-1
tp11655
sS'and,normal,tissues'
p11656
(F1
F0.00014334862385321102
I1
I0
I1
tp11657
sS'pressure,of,about'
p11658
(F1
F0.00014334862385321102
I1
I0
I1
tp11659
sS'the,period,following'
p11660
(F0
F0
I1
I1
I0
tp11661
sS'of,and,extended'
p11662
(F1
F0.00014334862385321102
I1
I0
I1
tp11663
sS'accutane,and,should'
p11664
(F1
F0.00014334862385321102
I1
I0
I1
tp11665
sS'severe,peripheral,vasospasm'
p11666
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp11667
sS'hypoglycemic,agents,that'
p11668
(F1
F0.00014334862385321102
I1
I0
I1
tp11669
sS'plasma,levels,resulting'
p11670
(F1
F0.00014334862385321102
I1
I0
I1
tp11671
sS'expected,to,lead'
p11672
(F1
F0.00014334862385321102
I1
I0
I1
tp11673
sS'observed,for,evidence'
p11674
(F1
F0.00014334862385321102
I0
I1
I-1
tp11675
sS'cyp3a4,inhibitors,mg'
p11676
(F1
F0.00014334862385321102
I1
I0
I1
tp11677
sS'infusions,of,flolan'
p11678
(F1
F0.00014334862385321102
I0
I1
I-1
tp11679
sS'when,analgesia,must'
p11680
(F1
F0.00014334862385321102
I1
I0
I1
tp11681
sS'selective,toxicity,of'
p11682
(F1
F0.00014334862385321102
I0
I1
I-1
tp11683
sS'sulfamethoxazole,concomitant,use'
p11684
(F1
F0.00014334862385321102
I0
I1
I-1
tp11685
sS'increased,serum,levels'
p11686
(F1
F0.00043004587155963305
I3
I0
I3
tp11687
sS'receiving,concomitant,and'
p11688
(F1
F0.00028669724770642203
I2
I0
I2
tp11689
sS'with,wellbutrin,should'
p11690
(F1
F0.00014334862385321102
I1
I0
I1
tp11691
sS'consequence,of,increased'
p11692
(F1
F0.00014334862385321102
I1
I0
I1
tp11693
sS'but,by,minutes'
p11694
(F1
F0.00014334862385321102
I1
I0
I1
tp11695
sS'with,a,mg'
p11696
(F1
F0.00028669724770642203
I2
I0
I2
tp11697
sS'responses,have,been'
p11698
(F1
F0.00014334862385321102
I1
I0
I1
tp11699
sS'treatment,of,breast'
p11700
(F1
F0.00014334862385321102
I1
I0
I1
tp11701
sS'calcium-channel,blockers,and'
p11702
(F1
F0.00014334862385321102
I0
I1
I-1
tp11703
sS'can,not,be'
p11704
(F1
F0.00014334862385321102
I1
I0
I1
tp11705
sS'rats,and,blood'
p11706
(F1
F0.00014334862385321102
I0
I1
I-1
tp11707
sS'to,play,a'
p11708
(F1
F0.00014334862385321102
I0
I1
I-1
tp11709
sS'disposition,of,in'
p11710
(F1
F0.00014334862385321102
I0
I1
I-1
tp11711
sS'oral,users,experiencing'
p11712
(F1
F0.00014334862385321102
I0
I1
I-1
tp11713
sS'of,low-dose,with'
p11714
(F1
F0.00014334862385321102
I1
I0
I1
tp11715
sS'in,preclinical,or'
p11716
(F1
F0.00014334862385321102
I0
I1
I-1
tp11717
sS'spray,but,by'
p11718
(F1
F0.00014334862385321102
I1
I0
I1
tp11719
sS'effect,of,especially'
p11720
(F1
F0.00014334862385321102
I1
I0
I1
tp11721
sS'medicinal,products,sharing'
p11722
(F1
F0.00014334862385321102
I1
I0
I1
tp11723
sS'be,exercised,if'
p11724
(F1
F0.00043004587155963305
I3
I0
I3
tp11725
sS'with,must,be'
p11726
(F1
F0.00014334862385321102
I1
I0
I1
tp11727
sS'part,a,shift'
p11728
(F1
F0.00014334862385321102
I0
I1
I-1
tp11729
sS'pharmacologic,effects,of'
p11730
(F1
F0.00028669724770642203
I2
I0
I2
tp11731
sS'when,taxol,was'
p11732
(F1
F0.00028669724770642203
I2
I0
I2
tp11733
sS'be,exercised,in'
p11734
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp11735
sS'with,ischemic,heart'
p11736
(F1
F0.00014334862385321102
I1
I0
I1
tp11737
sS'administration,to,three'
p11738
(F1
F0.00014334862385321102
I1
I0
I1
tp11739
sS'associated,with,reports'
p11740
(F1
F0.00014334862385321102
I0
I1
I-1
tp11741
sS'dogs,the,intravenous'
p11742
(F1
F0.00014334862385321102
I1
I0
I1
tp11743
sS'known,relationships,between'
p11744
(F1
F0.00014334862385321102
I0
I1
I-1
tp11745
sS'cause,bleeding,complications'
p11746
(F1
F0.00014334862385321102
I0
I1
I-1
tp11747
sS'evaluating,the,potential'
p11748
(F1
F0.00014334862385321102
I0
I1
I-1
tp11749
sS'a,dose-dependent,inhibition'
p11750
(F1
F0.00014334862385321102
I1
I0
I1
tp11751
sS'injection,usp,should'
p11752
(F1
F0.00028669724770642203
I2
I0
I2
tp11753
sS'cardiac,glycosides,in'
p11754
(F1
F0.00028669724770642203
I0
I2
I-2
tp11755
sS'of,antacids,on'
p11756
(F1
F0.00014334862385321102
I0
I1
I-1
tp11757
sS'by,cyp3a4,such'
p11758
(F1
F0.00028669724770642203
I2
I0
I2
tp11759
sS'prolong,both,its'
p11760
(F1
F0.00014334862385321102
I0
I1
I-1
tp11761
sS'recommended,doses,vioxx'
p11762
(F1
F0.00014334862385321102
I1
I0
I1
tp11763
sS'coadministration,of,it'
p11764
(F1
F0.00014334862385321102
I1
I0
I1
tp11765
sS'be,anticipated,if'
p11766
(F1
F0.00014334862385321102
I1
I0
I1
tp11767
sS'antianxiety,agents,or'
p11768
(F1
F0.00014334862385321102
I1
I0
I1
tp11769
sS'capsules,indocin,mg'
p11770
(F1
F0.00014334862385321102
I1
I0
I1
tp11771
sS'reportedly,resulted,in'
p11772
(F1
F0.00014334862385321102
I1
I0
I1
tp11773
sS'related,to,intravenous'
p11774
(F1
F0.00014334862385321102
I1
I0
I1
tp11775
sS'vitro,studies,evaluating'
p11776
(F1
F0.00014334862385321102
I0
I1
I-1
tp11777
sS'use,of,prinivil'
p11778
(F1
F0.00014334862385321102
I1
I0
I1
tp11779
sS'or,its,epoxide'
p11780
(F1
F0.00014334862385321102
I0
I1
I-1
tp11781
sS'indicates,that,inhibits'
p11782
(F1
F0.00014334862385321102
I1
I0
I1
tp11783
sS'dasatinib,is,a'
p11784
(F1
F0.00028669724770642203
I0
I2
I-2
tp11785
sS'toxicity,associated,with'
p11786
(F1
F0.00014334862385321102
I1
I0
I1
tp11787
sS'the,antianginal,effectiveness'
p11788
(F1
F0.00014334862385321102
I0
I1
I-1
tp11789
sS'and,treatment,in'
p11790
(F1
F0.00014334862385321102
I0
I1
I-1
tp11791
sS'digi-,tab,ria'
p11792
(F1
F0.00014334862385321102
I0
I1
I-1
tp11793
sS'p450,a4,increased'
p11794
(F1
F0.00014334862385321102
I1
I0
I1
tp11795
sS'when,therapy,is'
p11796
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp11797
sS'citrate,and,fluoride'
p11798
(F1
F0.00014334862385321102
I0
I1
I-1
tp11799
sS'electrolyte,abnormalities,such'
p11800
(F1
F0.00014334862385321102
I1
I0
I1
tp11801
sS'clinically,because,they'
p11802
(F1
F0.00014334862385321102
I0
I1
I-1
tp11803
sS'vardenafil,dosing,was'
p11804
(F1
F0.00014334862385321102
I1
I0
I1
tp11805
sS'produced,additive,effects'
p11806
(F1
F0.00028669724770642203
I2
I0
I2
tp11807
sS'classes,or,agents'
p11808
(F1
F0.00014334862385321102
I1
I0
I1
tp11809
sS'create,possible,additive'
p11810
(F1
F0.00043004587155963305
I0
I3
I-3
tp11811
sS'oral,hypoglycemics,diclofenac'
p11812
(F1
F0.00014334862385321102
I0
I1
I-1
tp11813
sS'fractions,on,the'
p11814
(F1
F0.00014334862385321102
I0
I1
I-1
tp11815
sS'of,are,to'
p11816
(F1
F0.00014334862385321102
I1
I0
I1
tp11817
sS'on,in-vitro,studies'
p11818
(F1
F0.00014334862385321102
I0
I1
I-1
tp11819
sS'metabolizes,may,experience'
p11820
(F1
F0.00014334862385321102
I0
I1
I-1
tp11821
sS'therefore,omnicef,for'
p11822
(F1
F0.00014334862385321102
I0
I1
I-1
tp11823
sS'for,active,tubular'
p11824
(F0
F0
I1
I1
I0
tp11825
sS'in,addition,is'
p11826
(F1
F0.00014334862385321102
I0
I1
I-1
tp11827
sS'to,deaths,among'
p11828
(F1
F0.00014334862385321102
I0
I1
I-1
tp11829
sS'initiated,or,changed'
p11830
(F1
F0.00014334862385321102
I1
I0
I1
tp11831
sS'occur,when,an'
p11832
(F1
F0.00014334862385321102
I1
I0
I1
tp11833
sS'severe,structural,heart'
p11834
(F1
F0.00014334862385321102
I0
I1
I-1
tp11835
sS'impair,the,absorption'
p11836
(F1
F0.00014334862385321102
I1
I0
I1
tp11837
sS'reducing,absorption,from'
p11838
(F1
F0.00014334862385321102
I1
I0
I1
tp11839
sS'with,increased,the'
p11840
(F1
F0.00014334862385321102
I1
I0
I1
tp11841
sS'heart,failure,etc'
p11842
(F1
F0.00014334862385321102
I1
I0
I1
tp11843
sS'be,monitored,especially'
p11844
(F1
F0.00014334862385321102
I1
I0
I1
tp11845
sS'over,a,dose'
p11846
(F1
F0.00014334862385321102
I1
I0
I1
tp11847
sS'affect,bioavailabillty,and'
p11848
(F1
F0.00014334862385321102
I0
I1
I-1
tp11849
sS'reversible,acute,renal'
p11850
(F1
F0.00014334862385321102
I1
I0
I1
tp11851
sS'of,oxidized,metabolites'
p11852
(F1
F0.00014334862385321102
I0
I1
I-1
tp11853
sS'equal,groups,and'
p11854
(F1
F0.00014334862385321102
I0
I1
I-1
tp11855
sS'used,alone,has'
p11856
(F1
F0.00014334862385321102
I1
I0
I1
tp11857
sS'anti-inflammatory,may,increase'
p11858
(F1
F0.00014334862385321102
I1
I0
I1
tp11859
sS'is,unclear,how'
p11860
(F1
F0.00014334862385321102
I1
I0
I1
tp11861
sS'examples,of,substances'
p11862
(F1
F0.00057339449541284407
I0
I4
I-4
tp11863
sS'in,lean,animals'
p11864
(F1
F0.00014334862385321102
I0
I1
I-1
tp11865
sS'organisms,contained,in'
p11866
(F1
F0.00014334862385321102
I1
I0
I1
tp11867
sS'leprosy-associated,inflammatory,reactions'
p11868
(F1
F0.00014334862385321102
I1
I0
I1
tp11869
sS'tests,vital,signs'
p11870
(F1
F0.00028669724770642203
I0
I2
I-2
tp11871
sS'w,and,mg'
p11872
(F1
F0.00014334862385321102
I1
I0
I1
tp11873
sS'consequently,with,a'
p11874
(F1
F0.00014334862385321102
I0
I1
I-1
tp11875
sS'recommended,since,may'
p11876
(F1
F0.00014334862385321102
I1
I0
I1
tp11877
sS'binding,sites,or'
p11878
(F1
F0.00014334862385321102
I1
I0
I1
tp11879
sS'abolished,by,pretreatment'
p11880
(F1
F0.00014334862385321102
I1
I0
I1
tp11881
sS'poor,metabolizers,of'
p11882
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp11883
sS'attenuates,but,mc'
p11884
(F1
F0.00014334862385321102
I1
I0
I1
tp11885
sS'considered,when,the'
p11886
(F1
F0.00014334862385321102
I1
I0
I1
tp11887
sS'plasma,concentration,has'
p11888
(F1
F0.00014334862385321102
I0
I1
I-1
tp11889
sS'in,a,double-blind'
p11890
(F1
F0.00014334862385321102
I0
I1
I-1
tp11891
sS'patients,who,have'
p11892
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp11893
sS'doses,of,u'
p11894
(F1
F0.00014334862385321102
I0
I1
I-1
tp11895
sS'pharmacodynamic,profile,prothrombin'
p11896
(F1
F0.00014334862385321102
I0
I1
I-1
tp11897
sS'on,the,efficacy'
p11898
(F1
F0.00014334862385321102
I0
I1
I-1
tp11899
sS'concomitantly,with,which'
p11900
(F1
F0.00028669724770642203
I2
I0
I2
tp11901
sS'argatroban,with,antiplatelet'
p11902
(F1
F0.00014334862385321102
I1
I0
I1
tp11903
sS'consequence,when,indocin'
p11904
(F1
F0.00014334862385321102
I1
I0
I1
tp11905
sS'for,days,was'
p11906
(F1
F0.00028669724770642203
I2
I0
I2
tp11907
sS'were,unchanged,after'
p11908
(F1
F0.00014334862385321102
I0
I1
I-1
tp11909
sS'recommended,in,patients'
p11910
(F1
F0.00014334862385321102
I1
I0
I1
tp11911
sS'for,weeks,was'
p11912
(F1
F0.00014334862385321102
I1
I0
I1
tp11913
sS'mu-,delta,and'
p11914
(F1
F0.00014334862385321102
I0
I1
I-1
tp11915
sS'and,asa,and'
p11916
(F1
F0.00014334862385321102
I0
I1
I-1
tp11917
sS'cancidas,may,result'
p11918
(F1
F0.00014334862385321102
I1
I0
I1
tp11919
sS'affect,the,steady-state'
p11920
(F1
F0.00014334862385321102
I0
I1
I-1
tp11921
sS'not,affected,by'
p11922
(F1
F0.0021502293577981653
I0
I15
I-15
tp11923
sS'of,bleeding,complications'
p11924
(F1
F0.00014334862385321102
I0
I1
I-1
tp11925
sS'to,increase,in'
p11926
(F0.5
F0.00028669724770642203
I3
I1
I2
tp11927
sS'given,one,dose'
p11928
(F1
F0.00014334862385321102
I1
I0
I1
tp11929
sS'with,prolonged,administration'
p11930
(F1
F0.00014334862385321102
I0
I1
I-1
tp11931
sS'has,suggested,may'
p11932
(F1
F0.00014334862385321102
I0
I1
I-1
tp11933
sS'sodium,excretion,but'
p11934
(F1
F0.00014334862385321102
I1
I0
I1
tp11935
sS'other,general,skeletal'
p11936
(F1
F0.00028669724770642203
I2
I0
I2
tp11937
sS'to,a,decrease'
p11938
(F0
F0
I1
I1
I0
tp11939
sS'or,adrenergic,neuron'
p11940
(F1
F0.00014334862385321102
I0
I1
I-1
tp11941
sS'not,be,administered'
p11942
(F0.90000000000000002
F0.0025802752293577983
I19
I1
I18
tp11943
sS'used,as,a'
p11944
(F1
F0.00014334862385321102
I0
I1
I-1
tp11945
sS'clarithromycin,exposure,was'
p11946
(F1
F0.00014334862385321102
I1
I0
I1
tp11947
sS'dimethylprostaglandin,e2,dmpge2'
p11948
(F1
F0.00014334862385321102
I0
I1
I-1
tp11949
sS'symptoms,of,toxicity'
p11950
(F1
F0.00057339449541284407
I4
I0
I4
tp11951
sS'together,have,a'
p11952
(F1
F0.00028669724770642203
I2
I0
I2
tp11953
sS'large,number,of'
p11954
(F1
F0.00014334862385321102
I0
I1
I-1
tp11955
sS'result,in,elevated'
p11956
(F1
F0.00071674311926605509
I5
I0
I5
tp11957
sS'and,high,doses'
p11958
(F1
F0.00014334862385321102
I0
I1
I-1
tp11959
sS'of,or,administration'
p11960
(F1
F0.00014334862385321102
I0
I1
I-1
tp11961
sS'levels,it,is'
p11962
(F1
F0.00028669724770642203
I2
I0
I2
tp11963
sS'the,second,experiment'
p11964
(F1
F0.00014334862385321102
I0
I1
I-1
tp11965
sS'possible,diminished,effect'
p11966
(F1
F0.00014334862385321102
I0
I1
I-1
tp11967
sS'administration,of,buspirone'
p11968
(F1
F0.00028669724770642203
I2
I0
I2
tp11969
sS'by,and,antagonists'
p11970
(F1
F0.00014334862385321102
I1
I0
I1
tp11971
sS'an,interaction,with'
p11972
(F1
F0.00028669724770642203
I0
I2
I-2
tp11973
sS'weekly,for,weeks'
p11974
(F1
F0.00014334862385321102
I1
I0
I1
tp11975
sS'reports,of,patients'
p11976
(F1
F0.00057339449541284407
I4
I0
I4
tp11977
sS'and,cyp1a2,isoform'
p11978
(F1
F0.00014334862385321102
I0
I1
I-1
tp11979
sS'therapy,should,be'
p11980
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp11981
sS'that,may,have'
p11982
(F0
F0
I1
I1
I0
tp11983
sS'or,has,led'
p11984
(F1
F0.00014334862385321102
I1
I0
I1
tp11985
sS'but,no,prolongation'
p11986
(F1
F0.00014334862385321102
I0
I1
I-1
tp11987
sS'animals,indicate,that'
p11988
(F1
F0.00014334862385321102
I1
I0
I1
tp11989
sS'of,the,spinal'
p11990
(F1
F0.00014334862385321102
I0
I1
I-1
tp11991
sS'concentrations,of,felbatol'
p11992
(F1
F0.00028669724770642203
I2
I0
I2
tp11993
sS'and,that,increase'
p11994
(F1
F0.00014334862385321102
I1
I0
I1
tp11995
sS'occurred,in,a'
p11996
(F1
F0.00028669724770642203
I2
I0
I2
tp11997
sS'against,the,clinical'
p11998
(F1
F0.00014334862385321102
I1
I0
I1
tp11999
sS'cyp,metabolism,of'
p12000
(F1
F0.00014334862385321102
I1
I0
I1
tp12001
sS'with,regimens,and'
p12002
(F1
F0.00014334862385321102
I0
I1
I-1
tp12003
sS'are,unlikely,to'
p12004
(F1
F0.00014334862385321102
I0
I1
I-1
tp12005
sS'management,of,acute'
p12006
(F1
F0.00014334862385321102
I0
I1
I-1
tp12007
sS'cells,by,a'
p12008
(F1
F0.00014334862385321102
I0
I1
I-1
tp12009
sS'performed,coadministration,with'
p12010
(F1
F0.00014334862385321102
I1
I0
I1
tp12011
sS'barbiturates,and,decrease'
p12012
(F1
F0.00014334862385321102
I1
I0
I1
tp12013
sS'be,an,inadequate'
p12014
(F1
F0.00014334862385321102
I1
I0
I1
tp12015
sS'digoxin,concentrations,are'
p12016
(F1
F0.00014334862385321102
I1
I0
I1
tp12017
sS'a,decision,must'
p12018
(F1
F0.00014334862385321102
I0
I1
I-1
tp12019
sS'to,the,risk'
p12020
(F0
F0
I1
I1
I0
tp12021
sS'since,nsaids,and'
p12022
(F1
F0.00014334862385321102
I1
I0
I1
tp12023
sS'action,or,elimination'
p12024
(F1
F0.00014334862385321102
I0
I1
I-1
tp12025
sS'plasma,levels,possibly'
p12026
(F1
F0.00014334862385321102
I1
I0
I1
tp12027
sS'discontinue,therapy,in'
p12028
(F1
F0.00014334862385321102
I1
I0
I1
tp12029
sS'b-blocking,properties,if'
p12030
(F1
F0.00014334862385321102
I1
I0
I1
tp12031
sS'interaction,with,concomitant'
p12032
(F1
F0.00014334862385321102
I0
I1
I-1
tp12033
sS'metabolite,or,pharmacokinetics'
p12034
(F1
F0.00014334862385321102
I0
I1
I-1
tp12035
sS'may,be,inhibited'
p12036
(F1
F0.00057339449541284407
I4
I0
I4
tp12037
sS'during,with,concomitant'
p12038
(F1
F0.00014334862385321102
I1
I0
I1
tp12039
sS'in,combining,with'
p12040
(F1
F0.00014334862385321102
I1
I0
I1
tp12041
sS'a,group,of'
p12042
(F1
F0.00057339449541284407
I0
I4
I-4
tp12043
sS'mptp,administration,to'
p12044
(F1
F0.00014334862385321102
I0
I1
I-1
tp12045
sS'geometric,mean,ratios'
p12046
(F1
F0.00014334862385321102
I0
I1
I-1
tp12047
sS'study,regardless,of'
p12048
(F1
F0.00014334862385321102
I0
I1
I-1
tp12049
sS'and,with,coadministration'
p12050
(F1
F0.00014334862385321102
I0
I1
I-1
tp12051
sS'suboxone,should,be'
p12052
(F1
F0.00014334862385321102
I1
I0
I1
tp12053
sS'intestine,so,that'
p12054
(F1
F0.00014334862385321102
I1
I0
I1
tp12055
sS'is,eliminated,by'
p12056
(F1
F0.00014334862385321102
I0
I1
I-1
tp12057
sS'to,the,body'
p12058
(F1
F0.00028669724770642203
I0
I2
I-2
tp12059
sS'for,possible,combined'
p12060
(F1
F0.00028669724770642203
I0
I2
I-2
tp12061
sS'a,linear,logarithmic'
p12062
(F1
F0.00014334862385321102
I0
I1
I-1
tp12063
sS'disease,have,been'
p12064
(F1
F0.00014334862385321102
I1
I0
I1
tp12065
sS'c9,by,see'
p12066
(F1
F0.00014334862385321102
I1
I0
I1
tp12067
sS'of,liver,enzymes'
p12068
(F1
F0.00014334862385321102
I1
I0
I1
tp12069
sS'intraperitoneally,ip,the'
p12070
(F1
F0.00014334862385321102
I1
I0
I1
tp12071
sS'response,to,although'
p12072
(F1
F0.00014334862385321102
I1
I0
I1
tp12073
sS'in,control,rats'
p12074
(F1
F0.00014334862385321102
I0
I1
I-1
tp12075
sS'that,could,increase'
p12076
(F1
F0.00014334862385321102
I0
I1
I-1
tp12077
sS'the,blood,auc0-12'
p12078
(F1
F0.00014334862385321102
I1
I0
I1
tp12079
sS'reported,that,itraconazole'
p12080
(F1
F0.00014334862385321102
I1
I0
I1
tp12081
sS'may,decrease,clozapine'
p12082
(F1
F0.00014334862385321102
I1
I0
I1
tp12083
sS'inhibition,was,observed'
p12084
(F1
F0.00014334862385321102
I0
I1
I-1
tp12085
sS'effective,dose,and'
p12086
(F1
F0.00014334862385321102
I0
I1
I-1
tp12087
sS'investigations,into,the'
p12088
(F1
F0.00014334862385321102
I0
I1
I-1
tp12089
sS'significant,accuracy,in'
p12090
(F1
F0.00014334862385321102
I1
I0
I1
tp12091
sS'methotrexate,there,is'
p12092
(F1
F0.00014334862385321102
I1
I0
I1
tp12093
sS'platelia,aspergillus,eia'
p12094
(F1
F0.00014334862385321102
I0
I1
I-1
tp12095
sS'of,foscarnets,tendency'
p12096
(F1
F0.00014334862385321102
I1
I0
I1
tp12097
sS'preparations,novolog,should'
p12098
(F1
F0.00014334862385321102
I0
I1
I-1
tp12099
sS'healthy,subjects,when'
p12100
(F1
F0.00014334862385321102
I1
I0
I1
tp12101
sS'chlorprothixene,may,increase'
p12102
(F1
F0.00014334862385321102
I1
I0
I1
tp12103
sS'from,the,gastrointestinal'
p12104
(F1
F0.00028669724770642203
I2
I0
I2
tp12105
sS'tikosyn,as,they'
p12106
(F1
F0.00014334862385321102
I1
I0
I1
tp12107
sS'determined,before,starting'
p12108
(F1
F0.00014334862385321102
I1
I0
I1
tp12109
sS'to,fold,greater'
p12110
(F1
F0.00014334862385321102
I1
I0
I1
tp12111
sS'changes,in,laboratory'
p12112
(F1
F0.00014334862385321102
I0
I1
I-1
tp12113
sS'metabolite,of,the'
p12114
(F1
F0.00014334862385321102
I0
I1
I-1
tp12115
sS'the,long-term,administration'
p12116
(F1
F0.00014334862385321102
I0
I1
I-1
tp12117
sS'is,a,possible'
p12118
(F1
F0.00014334862385321102
I1
I0
I1
tp12119
sS'the,primary,effect'
p12120
(F1
F0.00014334862385321102
I1
I0
I1
tp12121
sS'concentrations,with,coadministration'
p12122
(F1
F0.00014334862385321102
I1
I0
I1
tp12123
sS'alone,can,inhibit'
p12124
(F1
F0.00014334862385321102
I1
I0
I1
tp12125
sS'heart,can,be'
p12126
(F1
F0.00014334862385321102
I0
I1
I-1
tp12127
sS'lack,of,an'
p12128
(F1
F0.00014334862385321102
I0
I1
I-1
tp12129
sS'of,and,thus'
p12130
(F1
F0.00043004587155963305
I3
I0
I3
tp12131
sS'potential,for,reexacerbation'
p12132
(F1
F0.00014334862385321102
I1
I0
I1
tp12133
sS'myelotoxic,chemotherapy,cardiotoxic'
p12134
(F1
F0.00014334862385321102
I1
I0
I1
tp12135
sS'hydrogen-3,revealed,a'
p12136
(F1
F0.00014334862385321102
I0
I1
I-1
tp12137
sS'by,rats,treated'
p12138
(F1
F0.00014334862385321102
I0
I1
I-1
tp12139
sS'be,drawn,into'
p12140
(F1
F0.00014334862385321102
I0
I1
I-1
tp12141
sS'into,the,biogen'
p12142
(F1
F0.00014334862385321102
I0
I1
I-1
tp12143
sS'were,supersensitive,to'
p12144
(F1
F0.00028669724770642203
I2
I0
I2
tp12145
sS'volunteers,under,steady-state'
p12146
(F1
F0.00014334862385321102
I0
I1
I-1
tp12147
sS'a,combination,of'
p12148
(F1
F0.00028669724770642203
I0
I2
I-2
tp12149
sS'consequently,the,effect'
p12150
(F1
F0.00014334862385321102
I1
I0
I1
tp12151
sS'therefore,increased,monitoring'
p12152
(F1
F0.00014334862385321102
I1
I0
I1
tp12153
sS'significant,when,are'
p12154
(F1
F0.00014334862385321102
I0
I1
I-1
tp12155
sS'showed,that,increased'
p12156
(F1
F0.00014334862385321102
I1
I0
I1
tp12157
sS'however,caution,should'
p12158
(F1
F0.00028669724770642203
I2
I0
I2
tp12159
sS'which,is,totally'
p12160
(F1
F0.00014334862385321102
I0
I1
I-1
tp12161
sS'drowsiness-causing,any,other'
p12162
(F1
F0.00014334862385321102
I0
I1
I-1
tp12163
sS'reports,suggesting,that'
p12164
(F1
F0.00014334862385321102
I1
I0
I1
tp12165
sS'level,of,when'
p12166
(F1
F0.00014334862385321102
I1
I0
I1
tp12167
sS'when,systemic,vascular'
p12168
(F1
F0.00014334862385321102
I1
I0
I1
tp12169
sS'post-marketing,observations,have'
p12170
(F1
F0.00043004587155963305
I3
I0
I3
tp12171
sS'group,were,supersensitive'
p12172
(F1
F0.00014334862385321102
I1
I0
I1
tp12173
sS'm,was,not'
p12174
(F1
F0.00014334862385321102
I0
I1
I-1
tp12175
sS'with,concomitant,medication'
p12176
(F1
F0.00014334862385321102
I0
I1
I-1
tp12177
sS'decreases,the,intravenous'
p12178
(F1
F0.00014334862385321102
I0
I1
I-1
tp12179
sS'concentrations,should,be'
p12180
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp12181
sS'on,has,been'
p12182
(F1
F0.00014334862385321102
I1
I0
I1
tp12183
sS'and,mg,respectively'
p12184
(F0
F0
I2
I2
I0
tp12185
sS'affect,duloxetine,both'
p12186
(F1
F0.00014334862385321102
I0
I1
I-1
tp12187
sS'performed,in,clinical'
p12188
(F1
F0.00014334862385321102
I0
I1
I-1
tp12189
sS'of,the,ssris'
p12190
(F1
F0.00057339449541284407
I4
I0
I4
tp12191
sS'lincomycin,has,been'
p12192
(F1
F0.00014334862385321102
I1
I0
I1
tp12193
sS'arrhythmias,in,the'
p12194
(F1
F0.00014334862385321102
I0
I1
I-1
tp12195
sS'of,some,resulting'
p12196
(F1
F0.00014334862385321102
I1
I0
I1
tp12197
sS'function,and,consequently'
p12198
(F1
F0.00014334862385321102
I0
I1
I-1
tp12199
sS'meq,l,from'
p12200
(F1
F0.00014334862385321102
I1
I0
I1
tp12201
sS'levels,of,clozapine'
p12202
(F1
F0.00014334862385321102
I1
I0
I1
tp12203
sS'concentration,of,may'
p12204
(F1
F0.00014334862385321102
I1
I0
I1
tp12205
sS'whereas,the,first'
p12206
(F1
F0.00014334862385321102
I0
I1
I-1
tp12207
sS'been,studied,of'
p12208
(F1
F0.00014334862385321102
I0
I1
I-1
tp12209
sS'associated,in,some'
p12210
(F1
F0.00028669724770642203
I2
I0
I2
tp12211
sS'with,or,immediately'
p12212
(F1
F0.00014334862385321102
I1
I0
I1
tp12213
sS'conduction,disturbances,and'
p12214
(F1
F0.00014334862385321102
I1
I0
I1
tp12215
sS'convenient,administration,regimens'
p12216
(F1
F0.00014334862385321102
I0
I1
I-1
tp12217
sS'therefore,in,patients'
p12218
(F1
F0.00014334862385321102
I0
I1
I-1
tp12219
sS'include,the,and'
p12220
(F1
F0.00057339449541284407
I0
I4
I-4
tp12221
sS'or,neurotoxic,therapy'
p12222
(F1
F0.00014334862385321102
I0
I1
I-1
tp12223
sS'and,increase,serum'
p12224
(F1
F0.00014334862385321102
I0
I1
I-1
tp12225
sS'an,an,organophosphorous'
p12226
(F1
F0.00014334862385321102
I0
I1
I-1
tp12227
sS'were,administered,several'
p12228
(F1
F0.00014334862385321102
I0
I1
I-1
tp12229
sS'one-half,of,its'
p12230
(F1
F0.00028669724770642203
I2
I0
I2
tp12231
sS'should,be,premedicated'
p12232
(F1
F0.00014334862385321102
I0
I1
I-1
tp12233
sS'exposure,was,significantly'
p12234
(F1
F0.00014334862385321102
I1
I0
I1
tp12235
sS'after,administration,and'
p12236
(F1
F0.00014334862385321102
I1
I0
I1
tp12237
sS'actively,concentrating,as'
p12238
(F1
F0.00014334862385321102
I0
I1
I-1
tp12239
sS'central,syndrome,can'
p12240
(F1
F0.00014334862385321102
I1
I0
I1
tp12241
sS'of,ethyol,in'
p12242
(F1
F0.00014334862385321102
I1
I0
I1
tp12243
sS'that,exposure,to'
p12244
(F1
F0.00014334862385321102
I1
I0
I1
tp12245
sS'humorsol,with,or'
p12246
(F1
F0.00014334862385321102
I1
I0
I1
tp12247
sS'the,two,regimens'
p12248
(F1
F0.00014334862385321102
I0
I1
I-1
tp12249
sS'doses,of,agents'
p12250
(F1
F0.00014334862385321102
I0
I1
I-1
tp12251
sS'same,cytochrome,isozymes'
p12252
(F1
F0.00014334862385321102
I0
I1
I-1
tp12253
sS'active,therapy,in'
p12254
(F1
F0.00014334862385321102
I0
I1
I-1
tp12255
sS'microdilution,method,for'
p12256
(F1
F0.00014334862385321102
I0
I1
I-1
tp12257
sS'may,be,lower'
p12258
(F1
F0.00014334862385321102
I1
I0
I1
tp12259
sS'hours,postdose,a'
p12260
(F1
F0.00014334862385321102
I1
I0
I1
tp12261
sS'non-depolarising,muscle,relaxants'
p12262
(F1
F0.00014334862385321102
I1
I0
I1
tp12263
sS'effect,relationship,and'
p12264
(F1
F0.00014334862385321102
I1
I0
I1
tp12265
sS'whether,the,concomitant'
p12266
(F1
F0.00014334862385321102
I0
I1
I-1
tp12267
sS'd,doses,have'
p12268
(F1
F0.00014334862385321102
I0
I1
I-1
tp12269
sS'transport,ratio,r'
p12270
(F1
F0.00014334862385321102
I0
I1
I-1
tp12271
sS'of,such,a'
p12272
(F1
F0.00014334862385321102
I0
I1
I-1
tp12273
sS'beadministered,concomitantly,becausedecreases'
p12274
(F1
F0.00028669724770642203
I2
I0
I2
tp12275
sS'cyp1a2,substrate,single'
p12276
(F1
F0.00014334862385321102
I0
I1
I-1
tp12277
sS'eprosartan,has,been'
p12278
(F1
F0.00014334862385321102
I0
I1
I-1
tp12279
sS'additional,adrenergic,are'
p12280
(F1
F0.00014334862385321102
I1
I0
I1
tp12281
sS'properties,that,may'
p12282
(F1
F0.00028669724770642203
I2
I0
I2
tp12283
sS'brovana,dose,of'
p12284
(F1
F0.00014334862385321102
I0
I1
I-1
tp12285
sS'observed,for,signs'
p12286
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp12287
sS'of,may,result'
p12288
(F1
F0.00043004587155963305
I3
I0
I3
tp12289
sS'and,trivalent,cations'
p12290
(F1
F0.00028669724770642203
I2
I0
I2
tp12291
sS'serum,levels,may'
p12292
(F0
F0
I1
I1
I0
tp12293
sS'wellbutrin,tablets,to'
p12294
(F1
F0.00014334862385321102
I1
I0
I1
tp12295
sS'of,as,antiemetic'
p12296
(F1
F0.00014334862385321102
I1
I0
I1
tp12297
sS'in,mind,that'
p12298
(F1
F0.00014334862385321102
I1
I0
I1
tp12299
sS'the,effect,of'
p12300
(F0.093333333333333338
F0.0010034403669724771
I34
I41
I-7
tp12301
sS'have,been,more'
p12302
(F1
F0.00014334862385321102
I0
I1
I-1
tp12303
sS'channel,blockers,or'
p12304
(F1
F0.00014334862385321102
I1
I0
I1
tp12305
sS'in,patients,receiving'
p12306
(F0.46031746031746029
F0.0041571100917431195
I46
I17
I29
tp12307
sS'both,weight,gain'
p12308
(F1
F0.00014334862385321102
I1
I0
I1
tp12309
sS'if,there,is'
p12310
(F1
F0.00057339449541284407
I0
I4
I-4
tp12311
sS'other,b-lactam,inhibits'
p12312
(F1
F0.00014334862385321102
I1
I0
I1
tp12313
sS'of,one,or'
p12314
(F1
F0.00014334862385321102
I1
I0
I1
tp12315
sS'ascorbic,acid,doses'
p12316
(F1
F0.00014334862385321102
I1
I0
I1
tp12317
sS'system,depressants,but'
p12318
(F1
F0.00014334862385321102
I0
I1
I-1
tp12319
sS'increases,in,gastrointestinal'
p12320
(F1
F0.00014334862385321102
I1
I0
I1
tp12321
sS'any,significant,accuracy'
p12322
(F1
F0.00014334862385321102
I1
I0
I1
tp12323
sS'rats,decreased,by'
p12324
(F1
F0.00014334862385321102
I1
I0
I1
tp12325
sS'and,mg,initial'
p12326
(F1
F0.00014334862385321102
I1
I0
I1
tp12327
sS'indanavir,ketoconazole,phenytoin'
p12328
(F1
F0.00014334862385321102
I0
I1
I-1
tp12329
sS'qt,prolongation,and'
p12330
(F1
F0.00028669724770642203
I0
I2
I-2
tp12331
sS'strong,central,nervous'
p12332
(F1
F0.00014334862385321102
I0
I1
I-1
tp12333
sS'than,mg,as'
p12334
(F1
F0.00014334862385321102
I0
I1
I-1
tp12335
sS'potentially,leading,to'
p12336
(F1
F0.00014334862385321102
I1
I0
I1
tp12337
sS'reasons,it,is'
p12338
(F1
F0.00014334862385321102
I1
I0
I1
tp12339
sS'on,dogs,with'
p12340
(F1
F0.00014334862385321102
I0
I1
I-1
tp12341
sS'be,exercised,nonetheless'
p12342
(F1
F0.00014334862385321102
I1
I0
I1
tp12343
sS'fold,respectively,suggesting'
p12344
(F1
F0.00014334862385321102
I1
I0
I1
tp12345
sS'copaxone,did,not'
p12346
(F1
F0.00014334862385321102
I0
I1
I-1
tp12347
sS'been,titrated,to'
p12348
(F0
F0
I2
I2
I0
tp12349
sS'incidence,of,nephrolithiasis'
p12350
(F1
F0.00014334862385321102
I1
I0
I1
tp12351
sS'for,increased,activity'
p12352
(F1
F0.00014334862385321102
I0
I1
I-1
tp12353
sS'they,are,at'
p12354
(F1
F0.00014334862385321102
I0
I1
I-1
tp12355
sS'l,from,both'
p12356
(F1
F0.00014334862385321102
I0
I1
I-1
tp12357
sS'a,change,in'
p12358
(F0
F0
I1
I1
I0
tp12359
sS'as,early,as'
p12360
(F1
F0.00014334862385321102
I1
I0
I1
tp12361
sS'reduced,dosage,of'
p12362
(F1
F0.00014334862385321102
I1
I0
I1
tp12363
sS'studies,with,the'
p12364
(F1
F0.00014334862385321102
I1
I0
I1
tp12365
sS'monitored,forevidence,of'
p12366
(F1
F0.00014334862385321102
I1
I0
I1
tp12367
sS'has,been,shown'
p12368
(F0.66666666666666663
F0.0022935779816513763
I20
I4
I16
tp12369
sS'given,later,also'
p12370
(F1
F0.00014334862385321102
I1
I0
I1
tp12371
sS'when,taking,this'
p12372
(F1
F0.00014334862385321102
I0
I1
I-1
tp12373
sS'zyvox,and,serotonergic'
p12374
(F1
F0.00014334862385321102
I1
I0
I1
tp12375
sS'when,a,mg'
p12376
(F1
F0.00028669724770642203
I2
I0
I2
tp12377
sS'that,results,of'
p12378
(F1
F0.00014334862385321102
I1
I0
I1
tp12379
sS'to,change,to'
p12380
(F1
F0.00014334862385321102
I1
I0
I1
tp12381
sS'to,amide-type,local'
p12382
(F1
F0.00014334862385321102
I1
I0
I1
tp12383
sS'in,situ,hybridization'
p12384
(F1
F0.00014334862385321102
I1
I0
I1
tp12385
sS'with,nevirapine-,or'
p12386
(F1
F0.00014334862385321102
I0
I1
I-1
tp12387
sS'that,the,dose'
p12388
(F1
F0.00043004587155963305
I3
I0
I3
tp12389
sS'the,clinical,and'
p12390
(F1
F0.00014334862385321102
I0
I1
I-1
tp12391
sS'carbimazole,and,an'
p12392
(F1
F0.00014334862385321102
I1
I0
I1
tp12393
sS'high,viral,loads'
p12394
(F1
F0.00014334862385321102
I0
I1
I-1
tp12395
sS'the,following,medicines'
p12396
(F1
F0.00014334862385321102
I1
I0
I1
tp12397
sS'enrolled,in,the'
p12398
(F1
F0.00014334862385321102
I0
I1
I-1
tp12399
sS'involvement,of,the'
p12400
(F1
F0.00014334862385321102
I1
I0
I1
tp12401
sS'studies,of,other'
p12402
(F1
F0.00028669724770642203
I2
I0
I2
tp12403
sS'administered,in,the'
p12404
(F1
F0.00014334862385321102
I0
I1
I-1
tp12405
sS'to,the,pharmacology'
p12406
(F1
F0.00014334862385321102
I1
I0
I1
tp12407
sS'these,potentially,resulting'
p12408
(F1
F0.00014334862385321102
I1
I0
I1
tp12409
sS'were,taken,by'
p12410
(F1
F0.00028669724770642203
I0
I2
I-2
tp12411
sS'found,to,temporarily'
p12412
(F1
F0.00014334862385321102
I1
I0
I1
tp12413
sS'by,which,inhibits'
p12414
(F1
F0.00014334862385321102
I1
I0
I1
tp12415
sS'with,anion-exchange,resins'
p12416
(F1
F0.00014334862385321102
I1
I0
I1
tp12417
sS'of,and,one'
p12418
(F1
F0.00014334862385321102
I0
I1
I-1
tp12419
sS'neural,plasticity,ieg'
p12420
(F1
F0.00014334862385321102
I0
I1
I-1
tp12421
sS'and,diabetic,chinese'
p12422
(F1
F0.00014334862385321102
I0
I1
I-1
tp12423
sS'epoxide,reductase,resulting'
p12424
(F1
F0.00014334862385321102
I0
I1
I-1
tp12425
sS'it,be,decided'
p12426
(F1
F0.00014334862385321102
I1
I0
I1
tp12427
sS'psa,decreased,from'
p12428
(F1
F0.00014334862385321102
I0
I1
I-1
tp12429
sS'patients,receiving,beta-adrenergic'
p12430
(F1
F0.00028669724770642203
I2
I0
I2
tp12431
sS'for,auc,and'
p12432
(F1
F0.00014334862385321102
I1
I0
I1
tp12433
sS'pharmacokinetic,study,did'
p12434
(F1
F0.00014334862385321102
I0
I1
I-1
tp12435
sS'with,signs,and'
p12436
(F1
F0.00014334862385321102
I1
I0
I1
tp12437
sS'sodium,was,used'
p12438
(F1
F0.00014334862385321102
I0
I1
I-1
tp12439
sS'of,arimidex,and'
p12440
(F1
F0.00014334862385321102
I0
I1
I-1
tp12441
sS'other,interactions,cimetidine'
p12442
(F1
F0.00014334862385321102
I0
I1
I-1
tp12443
sS'them,and,what'
p12444
(F1
F0.00014334862385321102
I0
I1
I-1
tp12445
sS'piperidine,prevents,gastrointestinal'
p12446
(F1
F0.00014334862385321102
I1
I0
I1
tp12447
sS'nonabsorbable,given,concurrently'
p12448
(F1
F0.00014334862385321102
I1
I0
I1
tp12449
sS'these,is,taken'
p12450
(F1
F0.00014334862385321102
I0
I1
I-1
tp12451
sS'might,be,explained'
p12452
(F1
F0.00014334862385321102
I1
I0
I1
tp12453
sS'affect,safety,however'
p12454
(F1
F0.00014334862385321102
I0
I1
I-1
tp12455
sS'strains,of,clostridium'
p12456
(F1
F0.00014334862385321102
I0
I1
I-1
tp12457
sS'administration,of,local'
p12458
(F1
F0.00043004587155963305
I3
I0
I3
tp12459
sS'studies,as,well'
p12460
(F1
F0.0008600917431192661
I6
I0
I6
tp12461
sS'and,the,has'
p12462
(F1
F0.00014334862385321102
I1
I0
I1
tp12463
sS'a,multiple-dose,study'
p12464
(F0
F0
I1
I1
I0
tp12465
sS'as,or,videx'
p12466
(F1
F0.00014334862385321102
I1
I0
I1
tp12467
sS'of,a,with'
p12468
(F1
F0.00028669724770642203
I0
I2
I-2
tp12469
sS'any,interaction,on'
p12470
(F1
F0.00014334862385321102
I0
I1
I-1
tp12471
sS'intoxication,prior,to'
p12472
(F1
F0.00014334862385321102
I1
I0
I1
tp12473
sS'has,demonstrated,effectiveness'
p12474
(F1
F0.00014334862385321102
I0
I1
I-1
tp12475
sS'of,the,liver'
p12476
(F1
F0.00014334862385321102
I0
I1
I-1
tp12477
sS'subjects,receiving,a'
p12478
(F1
F0.00014334862385321102
I1
I0
I1
tp12479
sS'potent,cyp3a4,inhibitor'
p12480
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp12481
sS'and,and,probably'
p12482
(F1
F0.00014334862385321102
I0
I1
I-1
tp12483
sS'measured,by,auc0-24hr'
p12484
(F0
F0
I1
I1
I0
tp12485
sS'the,period,of'
p12486
(F1
F0.00014334862385321102
I1
I0
I1
tp12487
sS'study,the,concomitant'
p12488
(F1
F0.00014334862385321102
I0
I1
I-1
tp12489
sS'was,ineffective,in'
p12490
(F1
F0.00014334862385321102
I0
I1
I-1
tp12491
sS'a,sub-,for'
p12492
(F1
F0.00014334862385321102
I0
I1
I-1
tp12493
sS'but,cases,of'
p12494
(F1
F0.00014334862385321102
I1
I0
I1
tp12495
sS'both,crixivan,and'
p12496
(F1
F0.00014334862385321102
I0
I1
I-1
tp12497
sS'as,k,antagonists'
p12498
(F1
F0.00014334862385321102
I0
I1
I-1
tp12499
sS'reactions,of,parietal'
p12500
(F1
F0.00014334862385321102
I0
I1
I-1
tp12501
sS'cns-active,should,be'
p12502
(F1
F0.00014334862385321102
I1
I0
I1
tp12503
sS'of,supplementary,oral'
p12504
(F1
F0.00014334862385321102
I0
I1
I-1
tp12505
sS'studied,but,in'
p12506
(F1
F0.00014334862385321102
I0
I1
I-1
tp12507
sS'seen,when,mg'
p12508
(F1
F0.00014334862385321102
I1
I0
I1
tp12509
sS'week,of,and'
p12510
(F1
F0.00014334862385321102
I0
I1
I-1
tp12511
sS'the,latter,agents'
p12512
(F1
F0.00014334862385321102
I1
I0
I1
tp12513
sS'invalidate,folic,acid'
p12514
(F1
F0.00014334862385321102
I0
I1
I-1
tp12515
sS'sulfa-based,such,as'
p12516
(F1
F0.00014334862385321102
I0
I1
I-1
tp12517
sS'the,only,clinically'
p12518
(F1
F0.00014334862385321102
I1
I0
I1
tp12519
sS'for,altering,cyp1a2-mediated'
p12520
(F1
F0.00014334862385321102
I0
I1
I-1
tp12521
sS'there,was,a'
p12522
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp12523
sS'alter,the,effect'
p12524
(F1
F0.00014334862385321102
I0
I1
I-1
tp12525
sS'such,individuals,are'
p12526
(F1
F0.00028669724770642203
I0
I2
I-2
tp12527
sS'via,cyp3a4,should'
p12528
(F1
F0.00014334862385321102
I1
I0
I1
tp12529
sS'days,a,potent'
p12530
(F1
F0.00014334862385321102
I1
I0
I1
tp12531
sS'resulted,in,lowering'
p12532
(F1
F0.00014334862385321102
I1
I0
I1
tp12533
sS'inwomen,taking,since'
p12534
(F1
F0.00014334862385321102
I1
I0
I1
tp12535
sS'healthy,volunteers,when'
p12536
(F1
F0.00014334862385321102
I0
I1
I-1
tp12537
sS'use,of,prior'
p12538
(F1
F0.00014334862385321102
I1
I0
I1
tp12539
sS'potentiate,the,side'
p12540
(F1
F0.00014334862385321102
I1
I0
I1
tp12541
sS'dose,of,oral'
p12542
(F1
F0.00014334862385321102
I1
I0
I1
tp12543
sS'did,not,demonstrate'
p12544
(F1
F0.00028669724770642203
I0
I2
I-2
tp12545
sS'administration,of,and'
p12546
(F0.40425531914893614
F0.0027236238532110093
I33
I14
I19
tp12547
sS'displace,tightly,bound'
p12548
(F1
F0.00014334862385321102
I0
I1
I-1
tp12549
sS'compound,and,sodium'
p12550
(F1
F0.00014334862385321102
I0
I1
I-1
tp12551
sS'necessary,but,increased'
p12552
(F1
F0.00014334862385321102
I0
I1
I-1
tp12553
sS'observed,in,these'
p12554
(F1
F0.00014334862385321102
I1
I0
I1
tp12555
sS'nsaids,are,administered'
p12556
(F1
F0.00014334862385321102
I1
I0
I1
tp12557
sS'other,drugs,cimetidine'
p12558
(F1
F0.00014334862385321102
I0
I1
I-1
tp12559
sS'to,orders,of'
p12560
(F1
F0.00014334862385321102
I0
I1
I-1
tp12561
sS'should,be,prescribed'
p12562
(F1
F0.00014334862385321102
I1
I0
I1
tp12563
sS'of,the,central'
p12564
(F1
F0.00014334862385321102
I1
I0
I1
tp12565
sS'concentrations,dosage,adjustments'
p12566
(F1
F0.00014334862385321102
I1
I0
I1
tp12567
sS'no,first-pass,metabolism'
p12568
(F1
F0.00014334862385321102
I0
I1
I-1
tp12569
sS'drug,interactions,flupenthixol'
p12570
(F1
F0.00014334862385321102
I1
I0
I1
tp12571
sS'inhibitors,was,associated'
p12572
(F1
F0.00014334862385321102
I1
I0
I1
tp12573
sS'and,the,derivative'
p12574
(F1
F0.00014334862385321102
I0
I1
I-1
tp12575
sS'or,total,body'
p12576
(F1
F0.00014334862385321102
I0
I1
I-1
tp12577
sS'deficiency,due,to'
p12578
(F1
F0.00014334862385321102
I0
I1
I-1
tp12579
sS'renal,function,accompanied'
p12580
(F1
F0.00014334862385321102
I1
I0
I1
tp12581
sS'indicated,by,the'
p12582
(F1
F0.00014334862385321102
I0
I1
I-1
tp12583
sS'the,following,use'
p12584
(F1
F0.00014334862385321102
I1
I0
I1
tp12585
sS'that,oral,inhibits'
p12586
(F1
F0.00014334862385321102
I1
I0
I1
tp12587
sS'avoid,this,interaction'
p12588
(F1
F0.00014334862385321102
I1
I0
I1
tp12589
sS'equivalent,to,to'
p12590
(F1
F0.00014334862385321102
I0
I1
I-1
tp12591
sS'or,to,receive'
p12592
(F1
F0.00014334862385321102
I0
I1
I-1
tp12593
sS'dialysis,may,occasionally'
p12594
(F1
F0.00014334862385321102
I1
I0
I1
tp12595
sS'treatment,with,as'
p12596
(F1
F0.00043004587155963305
I3
I0
I3
tp12597
sS'they,can,be'
p12598
(F1
F0.00014334862385321102
I0
I1
I-1
tp12599
sS'demonstrated,less,alteration'
p12600
(F1
F0.00014334862385321102
I1
I0
I1
tp12601
sS'false,increases,of'
p12602
(F1
F0.00014334862385321102
I0
I1
I-1
tp12603
sS'the,sleeping,time'
p12604
(F1
F0.00014334862385321102
I1
I0
I1
tp12605
sS'fivefold,increase,in'
p12606
(F1
F0.00014334862385321102
I0
I1
I-1
tp12607
sS'and,unexpected,adverse'
p12608
(F1
F0.00014334862385321102
I0
I1
I-1
tp12609
sS'tablets,in,doses'
p12610
(F1
F0.00014334862385321102
I1
I0
I1
tp12611
sS'of,vehicle,corn'
p12612
(F1
F0.00014334862385321102
I0
I1
I-1
tp12613
sS'function,as,inhibitors'
p12614
(F1
F0.00014334862385321102
I0
I1
I-1
tp12615
sS'used,combined,oral'
p12616
(F1
F0.00014334862385321102
I0
I1
I-1
tp12617
sS'minutes,after,the'
p12618
(F1
F0.00014334862385321102
I1
I0
I1
tp12619
sS'since,animal,studies'
p12620
(F1
F0.00014334862385321102
I1
I0
I1
tp12621
sS'in,metabolism,concomitant'
p12622
(F1
F0.00014334862385321102
I0
I1
I-1
tp12623
sS'patients,are,to'
p12624
(F1
F0.00014334862385321102
I1
I0
I1
tp12625
sS'with,the,anti-glaucoma'
p12626
(F1
F0.00014334862385321102
I1
I0
I1
tp12627
sS'flucoxacillin,and,demonstrated'
p12628
(F1
F0.00014334862385321102
I0
I1
I-1
tp12629
sS'individual,simulect,clearance'
p12630
(F1
F0.00014334862385321102
I0
I1
I-1
tp12631
sS'abciximab,may,increase'
p12632
(F1
F0.00014334862385321102
I1
I0
I1
tp12633
sS'novo,renal,transplant'
p12634
(F1
F0.00014334862385321102
I0
I1
I-1
tp12635
sS'however,high,doses'
p12636
(F1
F0.00014334862385321102
I1
I0
I1
tp12637
sS'has,been,demonstrated'
p12638
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp12639
sS'type,depth,of'
p12640
(F1
F0.00014334862385321102
I0
I1
I-1
tp12641
sS'lipid,peroxidation,which'
p12642
(F1
F0.00014334862385321102
I1
I0
I1
tp12643
sS'dose,of,and'
p12644
(F0
F0
I1
I1
I0
tp12645
sS'on,bioavailability,auc'
p12646
(F1
F0.00014334862385321102
I0
I1
I-1
tp12647
sS'a,similar,study'
p12648
(F1
F0.00014334862385321102
I1
I0
I1
tp12649
sS'to,prolong,the'
p12650
(F1
F0.00043004587155963305
I3
I0
I3
tp12651
sS'when,the,following'
p12652
(F1
F0.00014334862385321102
I0
I1
I-1
tp12653
sS'metabolite,norfluoxe-tine,have'
p12654
(F1
F0.00014334862385321102
I0
I1
I-1
tp12655
sS'phenobarbital,tegretol,trileptal'
p12656
(F1
F0.00014334862385321102
I1
I0
I1
tp12657
sS'omeprazole,no,clinically'
p12658
(F1
F0.00014334862385321102
I0
I1
I-1
tp12659
sS'of,co-administration,mean'
p12660
(F1
F0.00014334862385321102
I0
I1
I-1
tp12661
sS'a,nonfunctioning,gland'
p12662
(F1
F0.00014334862385321102
I1
I0
I1
tp12663
sS'block,the,therapeutic'
p12664
(F1
F0.00014334862385321102
I1
I0
I1
tp12665
sS'pharmacokinetics,of,oral'
p12666
(F1
F0.00028669724770642203
I0
I2
I-2
tp12667
sS'with,thiazide,may'
p12668
(F1
F0.00014334862385321102
I1
I0
I1
tp12669
sS'both,and,a'
p12670
(F1
F0.00014334862385321102
I1
I0
I1
tp12671
sS'the,selective,mao'
p12672
(F1
F0.00014334862385321102
I1
I0
I1
tp12673
sS'ml,administered,with'
p12674
(F1
F0.00014334862385321102
I1
I0
I1
tp12675
sS'of,when,co'
p12676
(F1
F0.00014334862385321102
I1
I0
I1
tp12677
sS'both,and,i'
p12678
(F1
F0.00014334862385321102
I0
I1
I-1
tp12679
sS'of,interactions,of'
p12680
(F1
F0.00028669724770642203
I2
I0
I2
tp12681
sS'and,mg,produced'
p12682
(F1
F0.00057339449541284407
I4
I0
I4
tp12683
sS'l,or,kcl'
p12684
(F1
F0.00014334862385321102
I0
I1
I-1
tp12685
sS'minutes,after,administration'
p12686
(F1
F0.00014334862385321102
I0
I1
I-1
tp12687
sS'animals,where,endothelial'
p12688
(F1
F0.00014334862385321102
I0
I1
I-1
tp12689
sS'therefore,prothrombin,time'
p12690
(F1
F0.00014334862385321102
I1
I0
I1
tp12691
sS'diclofenac,does,not'
p12692
(F1
F0.00014334862385321102
I0
I1
I-1
tp12693
sS'control,by,its'
p12694
(F1
F0.00014334862385321102
I1
I0
I1
tp12695
sS'trials,concomitant,medications'
p12696
(F1
F0.00014334862385321102
I0
I1
I-1
tp12697
sS'and,of,by'
p12698
(F1
F0.00014334862385321102
I1
I0
I1
tp12699
sS'in,substantial,increases'
p12700
(F1
F0.00014334862385321102
I1
I0
I1
tp12701
sS'excretion,of,of'
p12702
(F1
F0.00014334862385321102
I1
I0
I1
tp12703
sS'same,age,and'
p12704
(F1
F0.00014334862385321102
I0
I1
I-1
tp12705
sS'moreover,its,activity'
p12706
(F1
F0.00014334862385321102
I0
I1
I-1
tp12707
sS'a,report,of'
p12708
(F1
F0.00014334862385321102
I1
I0
I1
tp12709
sS'by,cgs21680,was'
p12710
(F1
F0.00014334862385321102
I1
I0
I1
tp12711
sS'have,been,shown'
p12712
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp12713
sS'than,the,stable'
p12714
(F1
F0.00014334862385321102
I0
I1
I-1
tp12715
sS'a,direct,action'
p12716
(F0
F0
I1
I1
I0
tp12717
sS'in,doses,up'
p12718
(F1
F0.00014334862385321102
I1
I0
I1
tp12719
sS'have,been,collected'
p12720
(F1
F0.00014334862385321102
I0
I1
I-1
tp12721
sS'system,probably,responsible'
p12722
(F1
F0.00014334862385321102
I0
I1
I-1
tp12723
sS'between,and,other'
p12724
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp12725
sS'oral,contraceptive,agents'
p12726
(F1
F0.00014334862385321102
I0
I1
I-1
tp12727
sS'way,the,function'
p12728
(F1
F0.00014334862385321102
I1
I0
I1
tp12729
sS'transcriptase,inhibitors,and'
p12730
(F1
F0.00014334862385321102
I0
I1
I-1
tp12731
sS'co-administered,with,it'
p12732
(F1
F0.00014334862385321102
I0
I1
I-1
tp12733
sS'on,equetrotm,and'
p12734
(F1
F0.00014334862385321102
I1
I0
I1
tp12735
sS'stopped,to,ensure'
p12736
(F1
F0.00014334862385321102
I1
I0
I1
tp12737
sS'altered,by,the'
p12738
(F1
F0.00028669724770642203
I0
I2
I-2
tp12739
sS'an,intravenous,iv'
p12740
(F1
F0.00014334862385321102
I1
I0
I1
tp12741
sS'induced,by,aom'
p12742
(F1
F0.00014334862385321102
I0
I1
I-1
tp12743
sS'probably,at,least'
p12744
(F1
F0.00014334862385321102
I1
I0
I1
tp12745
sS'strong,affinity,for'
p12746
(F1
F0.00014334862385321102
I0
I1
I-1
tp12747
sS'the,lumen,at'
p12748
(F1
F0.00014334862385321102
I0
I1
I-1
tp12749
sS'a,do,not'
p12750
(F1
F0.00014334862385321102
I1
I0
I1
tp12751
sS'absorption,in,patients'
p12752
(F1
F0.00014334862385321102
I1
I0
I1
tp12753
sS'shown,to,have'
p12754
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp12755
sS'from,lean,and'
p12756
(F1
F0.00014334862385321102
I0
I1
I-1
tp12757
sS'resulting,increase,in'
p12758
(F1
F0.00014334862385321102
I0
I1
I-1
tp12759
sS'some,and,increase'
p12760
(F1
F0.00014334862385321102
I1
I0
I1
tp12761
sS'via,the,bile'
p12762
(F1
F0.00014334862385321102
I0
I1
I-1
tp12763
sS'had,plasma,concentrations'
p12764
(F1
F0.00014334862385321102
I1
I0
I1
tp12765
sS'cyp3a4,and,protease'
p12766
(F1
F0.00014334862385321102
I0
I1
I-1
tp12767
sS'was,no,difference'
p12768
(F1
F0.00014334862385321102
I0
I1
I-1
tp12769
sS'rate,of,gi'
p12770
(F1
F0.00028669724770642203
I2
I0
I2
tp12771
sS'associated,with,indirect'
p12772
(F1
F0.00014334862385321102
I0
I1
I-1
tp12773
sS'blood,thinners,may'
p12774
(F1
F0.00014334862385321102
I1
I0
I1
tp12775
sS'take,tricor,at'
p12776
(F1
F0.00014334862385321102
I1
I0
I1
tp12777
sS's,bioavailability,auc'
p12778
(F1
F0.00014334862385321102
I0
I1
I-1
tp12779
sS'state,mg,kg'
p12780
(F1
F0.00014334862385321102
I1
I0
I1
tp12781
sS'meals,was,administered'
p12782
(F1
F0.00028669724770642203
I0
I2
I-2
tp12783
sS'juice,increases,ethinyl'
p12784
(F1
F0.00014334862385321102
I0
I1
I-1
tp12785
sS'and,or,life-threatening'
p12786
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp12787
sS'small,when,given'
p12788
(F1
F0.00014334862385321102
I1
I0
I1
tp12789
sS'to,healthy,male'
p12790
(F1
F0.00014334862385321102
I0
I1
I-1
tp12791
sS'indicating,an,action'
p12792
(F1
F0.00014334862385321102
I0
I1
I-1
tp12793
sS'and,or,without'
p12794
(F1
F0.00014334862385321102
I0
I1
I-1
tp12795
sS'the,following,immunosuppressives'
p12796
(F1
F0.00014334862385321102
I0
I1
I-1
tp12797
sS'of,toxicity,were'
p12798
(F1
F0.00014334862385321102
I1
I0
I1
tp12799
sS'suggesting,no,clinically'
p12800
(F1
F0.00014334862385321102
I0
I1
I-1
tp12801
sS'by,hours,or'
p12802
(F1
F0.00014334862385321102
I0
I1
I-1
tp12803
sS'on,days,through'
p12804
(F1
F0.00014334862385321102
I1
I0
I1
tp12805
sS'with,the,protein'
p12806
(F1
F0.00028669724770642203
I2
I0
I2
tp12807
sS'the,above,behavioral'
p12808
(F1
F0.00014334862385321102
I0
I1
I-1
tp12809
sS'states,and,these'
p12810
(F1
F0.00014334862385321102
I0
I1
I-1
tp12811
sS'nerves,and,was'
p12812
(F1
F0.00014334862385321102
I0
I1
I-1
tp12813
sS'by,hours,of'
p12814
(F1
F0.00014334862385321102
I1
I0
I1
tp12815
sS'cause,and,effect'
p12816
(F1
F0.00014334862385321102
I1
I0
I1
tp12817
sS'antagonists,after,repeated'
p12818
(F1
F0.00014334862385321102
I1
I0
I1
tp12819
sS'phenobarbital,toxicity,has'
p12820
(F1
F0.00014334862385321102
I1
I0
I1
tp12821
sS'effects,could,potentially'
p12822
(F1
F0.00014334862385321102
I1
I0
I1
tp12823
sS'such,as,deltasone'
p12824
(F1
F0.00014334862385321102
I0
I1
I-1
tp12825
sS'is,particularly,important'
p12826
(F1
F0.00014334862385321102
I0
I1
I-1
tp12827
sS'within,a,period'
p12828
(F1
F0.00014334862385321102
I1
I0
I1
tp12829
sS'with,at,three'
p12830
(F1
F0.00014334862385321102
I0
I1
I-1
tp12831
sS'other,that,act'
p12832
(F1
F0.00014334862385321102
I1
I0
I1
tp12833
sS'not,exceed,mg'
p12834
(F1
F0.00014334862385321102
I1
I0
I1
tp12835
sS'is,advisable,to'
p12836
(F1
F0.00028669724770642203
I2
I0
I2
tp12837
sS'to,the,increased'
p12838
(F1
F0.00028669724770642203
I2
I0
I2
tp12839
sS'is,little,if'
p12840
(F1
F0.00014334862385321102
I0
I1
I-1
tp12841
sS'of,etc,but'
p12842
(F1
F0.00014334862385321102
I1
I0
I1
tp12843
sS'present,a,theoretical'
p12844
(F1
F0.00014334862385321102
I1
I0
I1
tp12845
sS'b,antineoplastic,agents'
p12846
(F1
F0.00014334862385321102
I1
I0
I1
tp12847
sS'asthma,or,copd'
p12848
(F1
F0.00014334862385321102
I0
I1
I-1
tp12849
sS'depressants,including,such'
p12850
(F1
F0.00014334862385321102
I1
I0
I1
tp12851
sS'sodium,and,channel'
p12852
(F1
F0.00014334862385321102
I1
I0
I1
tp12853
sS'psychotropic,agents,is'
p12854
(F1
F0.00014334862385321102
I1
I0
I1
tp12855
sS'strains,of,pointer'
p12856
(F1
F0.00014334862385321102
I0
I1
I-1
tp12857
sS'not,an,aed'
p12858
(F1
F0.00014334862385321102
I0
I1
I-1
tp12859
sS'before,initiating,tcatreatment'
p12860
(F1
F0.00014334862385321102
I1
I0
I1
tp12861
sS'hydroxydesloratadine,were,observed'
p12862
(F1
F0.00014334862385321102
I0
I1
I-1
tp12863
sS'although,the,clinical'
p12864
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp12865
sS'significantly,decreased,the'
p12866
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp12867
sS'levels,of,has'
p12868
(F1
F0.00014334862385321102
I0
I1
I-1
tp12869
sS'choline,trilisate,disalcid'
p12870
(F1
F0.00014334862385321102
I1
I0
I1
tp12871
sS'interaction,studies,with'
p12872
(F1
F0.0014334862385321102
I0
I10
I-10
tp12873
sS'coadministered,with,another'
p12874
(F1
F0.00014334862385321102
I0
I1
I-1
tp12875
sS'parkinsons,disease,have'
p12876
(F1
F0.00014334862385321102
I1
I0
I1
tp12877
sS'free,cmin,concentrations'
p12878
(F1
F0.00014334862385321102
I0
I1
I-1
tp12879
sS'also,shown,that'
p12880
(F1
F0.00014334862385321102
I1
I0
I1
tp12881
sS'on,sodium,excretion'
p12882
(F1
F0.00014334862385321102
I1
I0
I1
tp12883
sS'individuals,treated,with'
p12884
(F1
F0.00014334862385321102
I1
I0
I1
tp12885
sS'seen,with,or'
p12886
(F1
F0.00014334862385321102
I0
I1
I-1
tp12887
sS'of,a,potentially'
p12888
(F1
F0.00014334862385321102
I1
I0
I1
tp12889
sS'take,by,mouth'
p12890
(F1
F0.00014334862385321102
I1
I0
I1
tp12891
sS'status,is,warranted'
p12892
(F1
F0.00014334862385321102
I1
I0
I1
tp12893
sS'replacement,is,needed'
p12894
(F1
F0.00014334862385321102
I0
I1
I-1
tp12895
sS'human,volunteers,co-administration'
p12896
(F1
F0.00014334862385321102
I0
I1
I-1
tp12897
sS'to,the,package'
p12898
(F1
F0.00028669724770642203
I2
I0
I2
tp12899
sS'be,administered,a'
p12900
(F1
F0.00014334862385321102
I0
I1
I-1
tp12901
sS'reversible,increases,in'
p12902
(F1
F0.00014334862385321102
I1
I0
I1
tp12903
sS'phenytoin,serum,levels'
p12904
(F1
F0.00014334862385321102
I1
I0
I1
tp12905
sS'to,allow,for'
p12906
(F1
F0.00014334862385321102
I0
I1
I-1
tp12907
sS'warfarin,eszopiclone,mg'
p12908
(F1
F0.00014334862385321102
I0
I1
I-1
tp12909
sS'with,the,reversal'
p12910
(F1
F0.00014334862385321102
I1
I0
I1
tp12911
sS'be,used,with'
p12912
(F0.69999999999999996
F0.0020068807339449542
I17
I3
I14
tp12913
sS'with,the,pharmacokinetics'
p12914
(F1
F0.00014334862385321102
I1
I0
I1
tp12915
sS'quinidine,immediate,release'
p12916
(F1
F0.00014334862385321102
I1
I0
I1
tp12917
sS'and,changes,in'
p12918
(F1
F0.00014334862385321102
I0
I1
I-1
tp12919
sS'careful,patient,monitoring'
p12920
(F1
F0.00014334862385321102
I1
I0
I1
tp12921
sS'amitriptyline,hcl,is'
p12922
(F0
F0
I1
I1
I0
tp12923
sS'whereas,in,pigeons'
p12924
(F1
F0.00014334862385321102
I0
I1
I-1
tp12925
sS'receiving,in,combination'
p12926
(F1
F0.00014334862385321102
I1
I0
I1
tp12927
sS'higher,than,expected'
p12928
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp12929
sS'development,of,the'
p12930
(F1
F0.00014334862385321102
I0
I1
I-1
tp12931
sS'calan,sr,by'
p12932
(F1
F0.00014334862385321102
I1
I0
I1
tp12933
sS'alternative,agents,with'
p12934
(F1
F0.00014334862385321102
I0
I1
I-1
tp12935
sS'be,aggravated,by'
p12936
(F1
F0.00014334862385321102
I1
I0
I1
tp12937
sS'the,seizure,risk'
p12938
(F1
F0.00014334862385321102
I1
I0
I1
tp12939
sS'clinically,significant,inhibition'
p12940
(F1
F0.00014334862385321102
I0
I1
I-1
tp12941
sS'and,can,suppress'
p12942
(F1
F0.00014334862385321102
I1
I0
I1
tp12943
sS'of,n-allylnormetazocine,nanm'
p12944
(F1
F0.00014334862385321102
I0
I1
I-1
tp12945
sS'be,refractory,to'
p12946
(F1
F0.00014334862385321102
I1
I0
I1
tp12947
sS'when,cancidas,is'
p12948
(F1
F0.00014334862385321102
I1
I0
I1
tp12949
sS'as,or,would'
p12950
(F1
F0.00014334862385321102
I0
I1
I-1
tp12951
sS'and,or,cardiac'
p12952
(F1
F0.00014334862385321102
I0
I1
I-1
tp12953
sS'be,given,the'
p12954
(F1
F0.00014334862385321102
I1
I0
I1
tp12955
sS'lunch,doses,of'
p12956
(F1
F0.00014334862385321102
I0
I1
I-1
tp12957
sS'chloral,hydrate,dietary'
p12958
(F1
F0.00014334862385321102
I1
I0
I1
tp12959
sS'with,similar,properties'
p12960
(F1
F0.00014334862385321102
I1
I0
I1
tp12961
sS'while,all,the'
p12962
(F1
F0.00071674311926605509
I0
I5
I-5
tp12963
sS'study,examining,mg'
p12964
(F1
F0.00014334862385321102
I1
I0
I1
tp12965
sS'innovar,or,but'
p12966
(F1
F0.00014334862385321102
I1
I0
I1
tp12967
sS'trinitrate,isosorbide,dinitrate'
p12968
(F1
F0.00014334862385321102
I0
I1
I-1
tp12969
sS'in,a,manner'
p12970
(F1
F0.00014334862385321102
I0
I1
I-1
tp12971
sS'patients,already,on'
p12972
(F1
F0.00014334862385321102
I0
I1
I-1
tp12973
sS'barrier,contraception,should'
p12974
(F1
F0.00014334862385321102
I1
I0
I1
tp12975
sS'the,minimal,inhibitory'
p12976
(F1
F0.00014334862385321102
I0
I1
I-1
tp12977
sS'replacing,by,therapy'
p12978
(F1
F0.00014334862385321102
I1
I0
I1
tp12979
sS'with,mg,p'
p12980
(F1
F0.00014334862385321102
I1
I0
I1
tp12981
sS'not,significantly,interfere'
p12982
(F1
F0.00014334862385321102
I0
I1
I-1
tp12983
sS'b6,physiological,doses'
p12984
(F1
F0.00014334862385321102
I0
I1
I-1
tp12985
sS'functional,class,iv'
p12986
(F1
F0.00014334862385321102
I0
I1
I-1
tp12987
sS'ingested,being,converted'
p12988
(F1
F0.00014334862385321102
I1
I0
I1
tp12989
sS'a,multiple,fixed-interval'
p12990
(F1
F0.00014334862385321102
I0
I1
I-1
tp12991
sS'effects,of,intravenous'
p12992
(F1
F0.00014334862385321102
I1
I0
I1
tp12993
sS'monitored,and,if'
p12994
(F1
F0.00014334862385321102
I1
I0
I1
tp12995
sS'concentrations,of,mcg'
p12996
(F1
F0.00014334862385321102
I0
I1
I-1
tp12997
sS'may,prevent,absorption'
p12998
(F1
F0.00014334862385321102
I0
I1
I-1
tp12999
sS'is,not,impaired'
p13000
(F1
F0.00014334862385321102
I0
I1
I-1
tp13001
sS'is,associated,with'
p13002
(F1
F0.00014334862385321102
I0
I1
I-1
tp13003
sS'were,not,observed'
p13004
(F1
F0.00014334862385321102
I0
I1
I-1
tp13005
sS'a,day,for'
p13006
(F1
F0.00028669724770642203
I0
I2
I-2
tp13007
sS'mixed,agonist,antagonist'
p13008
(F0
F0
I1
I1
I0
tp13009
sS'injection,concentrate,should'
p13010
(F1
F0.00014334862385321102
I1
I0
I1
tp13011
sS'drawn,into,the'
p13012
(F1
F0.00014334862385321102
I0
I1
I-1
tp13013
sS'bepridil,with,long-'
p13014
(F1
F0.00014334862385321102
I0
I1
I-1
tp13015
sS'infinity,auc,and'
p13016
(F1
F0.00014334862385321102
I0
I1
I-1
tp13017
sS'hormone,levels,and'
p13018
(F1
F0.00014334862385321102
I0
I1
I-1
tp13019
sS'pronounced,though,reversible'
p13020
(F1
F0.00014334862385321102
I1
I0
I1
tp13021
sS'volunteers,increased,auc'
p13022
(F1
F0.00014334862385321102
I0
I1
I-1
tp13023
sS'agents,in,some'
p13024
(F1
F0.00028669724770642203
I2
I0
I2
tp13025
sS'once,daily,as'
p13026
(F0
F0
I1
I1
I0
tp13027
sS'camptosar,the,physician'
p13028
(F1
F0.00014334862385321102
I1
I0
I1
tp13029
sS'l-name,and,micromol'
p13030
(F1
F0.00014334862385321102
I0
I1
I-1
tp13031
sS'to,triple-immunosuppression,regimens'
p13032
(F1
F0.00014334862385321102
I0
I1
I-1
tp13033
sS'mg,t,i'
p13034
(F1
F0.00043004587155963305
I3
I0
I3
tp13035
sS'when,arava,was'
p13036
(F1
F0.00014334862385321102
I1
I0
I1
tp13037
sS'enhance,the,neuromuscular'
p13038
(F1
F0.00057339449541284407
I4
I0
I4
tp13039
sS'of,sular,with'
p13040
(F1
F0.00014334862385321102
I1
I0
I1
tp13041
sS'may,enhance,the'
p13042
(F0.94285714285714284
F0.0047305045871559636
I34
I1
I33
tp13043
sS'in,any,changes'
p13044
(F1
F0.00028669724770642203
I0
I2
I-2
tp13045
sS'patients,receiving,antihypertensive'
p13046
(F1
F0.00014334862385321102
I1
I0
I1
tp13047
sS'pcp,in,pigeons'
p13048
(F0
F0
I1
I1
I0
tp13049
sS'approximately,when,taxol'
p13050
(F1
F0.00014334862385321102
I1
I0
I1
tp13051
sS'in,previous,reports'
p13052
(F1
F0.00014334862385321102
I1
I0
I1
tp13053
sS'clinical,interaction,between'
p13054
(F1
F0.00014334862385321102
I0
I1
I-1
tp13055
sS'doctor,or,pharmacist'
p13056
(F1
F0.00014334862385321102
I0
I1
I-1
tp13057
sS'decreased,serum,levels'
p13058
(F1
F0.00028669724770642203
I2
I0
I2
tp13059
sS'is,reduced,by'
p13060
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp13061
sS'ml,min,mean'
p13062
(F1
F0.00014334862385321102
I1
I0
I1
tp13063
sS'have,been,performed'
p13064
(F1
F0.00014334862385321102
I0
I1
I-1
tp13065
sS'class,antimicrobial,and'
p13066
(F1
F0.00014334862385321102
I1
I0
I1
tp13067
sS'these,were,given'
p13068
(F1
F0.00014334862385321102
I1
I0
I1
tp13069
sS'chewable,buffered,tablets'
p13070
(F1
F0.0010034403669724771
I7
I0
I7
tp13071
sS'accompanied,by,a'
p13072
(F1
F0.00028669724770642203
I2
I0
I2
tp13073
sS'cyp2c19,cyp2d6,cyp2e1'
p13074
(F1
F0.00028669724770642203
I0
I2
I-2
tp13075
sS'and,coronary,oral'
p13076
(F1
F0.00014334862385321102
I0
I1
I-1
tp13077
sS'with,hemostasis,nsaids'
p13078
(F1
F0.00014334862385321102
I0
I1
I-1
tp13079
sS'of,multiple,oral'
p13080
(F1
F0.00014334862385321102
I1
I0
I1
tp13081
sS'when,vardenafil,mg'
p13082
(F1
F0.00014334862385321102
I0
I1
I-1
tp13083
sS'or,after,ethyl'
p13084
(F1
F0.00014334862385321102
I1
I0
I1
tp13085
sS'be,increased,with'
p13086
(F1
F0.00014334862385321102
I1
I0
I1
tp13087
sS'n,maintained,on'
p13088
(F1
F0.00014334862385321102
I0
I1
I-1
tp13089
sS'h-triglyceride,fractional,clearance'
p13090
(F1
F0.00014334862385321102
I1
I0
I1
tp13091
sS'use,especially,of'
p13092
(F1
F0.00014334862385321102
I0
I1
I-1
tp13093
sS'before,injection,produced'
p13094
(F1
F0.00014334862385321102
I0
I1
I-1
tp13095
sS'nsaids,can,reduce'
p13096
(F1
F0.00071674311926605509
I5
I0
I5
tp13097
sS'renal,nonrenal,and'
p13098
(F1
F0.00014334862385321102
I0
I1
I-1
tp13099
sS'tended,to,be'
p13100
(F1
F0.00014334862385321102
I1
I0
I1
tp13101
sS'isoenzyme,family,may'
p13102
(F1
F0.00014334862385321102
I0
I1
I-1
tp13103
sS'because,they,are'
p13104
(F1
F0.00014334862385321102
I0
I1
I-1
tp13105
sS'healthy,volunteers,hormone'
p13106
(F1
F0.00014334862385321102
I0
I1
I-1
tp13107
sS'dynacirc,and,in'
p13108
(F1
F0.00014334862385321102
I0
I1
I-1
tp13109
sS'mg,doses,of'
p13110
(F1
F0.00014334862385321102
I1
I0
I1
tp13111
sS'alone,and,because'
p13112
(F1
F0.00014334862385321102
I1
I0
I1
tp13113
sS'and,and,has'
p13114
(F1
F0.00014334862385321102
I0
I1
I-1
tp13115
sS'effect,of,sensipar'
p13116
(F1
F0.00014334862385321102
I0
I1
I-1
tp13117
sS'reported,very,rarely'
p13118
(F1
F0.00014334862385321102
I1
I0
I1
tp13119
sS'subjects,received,alone'
p13120
(F1
F0.00014334862385321102
I0
I1
I-1
tp13121
sS'the,recommended,dose'
p13122
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13123
sS'plasma,half-life,and'
p13124
(F0
F0
I1
I1
I0
tp13125
sS'agents,that,induce'
p13126
(F1
F0.00014334862385321102
I1
I0
I1
tp13127
sS'administration,of,containing'
p13128
(F1
F0.00014334862385321102
I1
I0
I1
tp13129
sS'in,time,with'
p13130
(F1
F0.00014334862385321102
I1
I0
I1
tp13131
sS'you,need,to'
p13132
(F1
F0.00014334862385321102
I1
I0
I1
tp13133
sS'observation,must,be'
p13134
(F1
F0.00014334862385321102
I0
I1
I-1
tp13135
sS'ratio,r,p'
p13136
(F1
F0.00014334862385321102
I0
I1
I-1
tp13137
sS'instances,of,life-'
p13138
(F1
F0.00014334862385321102
I1
I0
I1
tp13139
sS'and,multiple,doses'
p13140
(F1
F0.00014334862385321102
I0
I1
I-1
tp13141
sS'basis,of,in'
p13142
(F1
F0.00014334862385321102
I1
I0
I1
tp13143
sS'a,smaller,initial'
p13144
(F1
F0.00014334862385321102
I1
I0
I1
tp13145
sS'mg,also,received'
p13146
(F1
F0.00014334862385321102
I0
I1
I-1
tp13147
sS'if,the,effects'
p13148
(F1
F0.00014334862385321102
I1
I0
I1
tp13149
sS'serum,potassium,enalapril'
p13150
(F1
F0.00014334862385321102
I1
I0
I1
tp13151
sS'a,slower,gastrointestinal'
p13152
(F1
F0.00014334862385321102
I1
I0
I1
tp13153
sS'cautiously,and,patients'
p13154
(F1
F0.00014334862385321102
I1
I0
I1
tp13155
sS'osteoarthritis,when,vioxx'
p13156
(F1
F0.00014334862385321102
I0
I1
I-1
tp13157
sS'at,the,higher'
p13158
(F1
F0.00014334862385321102
I0
I1
I-1
tp13159
sS'r,or,s'
p13160
(F0
F0
I1
I1
I0
tp13161
sS'on,discrimination,and'
p13162
(F1
F0.00014334862385321102
I0
I1
I-1
tp13163
sS'database,three,duloxetine-treated'
p13164
(F1
F0.00014334862385321102
I0
I1
I-1
tp13165
sS'post-marketing,experience,there'
p13166
(F1
F0.00028669724770642203
I2
I0
I2
tp13167
sS'and,concomitant,use'
p13168
(F0
F0
I1
I1
I0
tp13169
sS'by,and,decreased'
p13170
(F1
F0.00028669724770642203
I2
I0
I2
tp13171
sS'do,not,appear'
p13172
(F0
F0
I1
I1
I0
tp13173
sS'the,ethanolysis,reaction'
p13174
(F1
F0.00014334862385321102
I1
I0
I1
tp13175
sS'absorption,has,not'
p13176
(F1
F0.00014334862385321102
I0
I1
I-1
tp13177
sS'the,endotoxin-treated,rats'
p13178
(F1
F0.00014334862385321102
I1
I0
I1
tp13179
sS'bioavailability,auc,or'
p13180
(F1
F0.00014334862385321102
I0
I1
I-1
tp13181
sS'those,of,class'
p13182
(F1
F0.00014334862385321102
I1
I0
I1
tp13183
sS'cereals,on,absorption'
p13184
(F1
F0.00014334862385321102
I0
I1
I-1
tp13185
sS'receiving,both,as'
p13186
(F1
F0.00014334862385321102
I1
I0
I1
tp13187
sS'taking,nsaids,concomitantly'
p13188
(F1
F0.00057339449541284407
I4
I0
I4
tp13189
sS'observed,to,determine'
p13190
(F1
F0.00014334862385321102
I1
I0
I1
tp13191
sS'isosorbide,mononitrate,may'
p13192
(F1
F0.00014334862385321102
I1
I0
I1
tp13193
sS'bioavailability,auc,of'
p13194
(F1
F0.00014334862385321102
I1
I0
I1
tp13195
sS'also,have,an'
p13196
(F1
F0.00014334862385321102
I1
I0
I1
tp13197
sS'urine,for,the'
p13198
(F1
F0.00014334862385321102
I0
I1
I-1
tp13199
sS'brevibloc,on,the'
p13200
(F1
F0.00014334862385321102
I0
I1
I-1
tp13201
sS'or,dihydroxyflavone,with'
p13202
(F1
F0.00014334862385321102
I0
I1
I-1
tp13203
sS'metastasis,of,intestinal'
p13204
(F0
F0
I1
I1
I0
tp13205
sS'effects,of,g'
p13206
(F1
F0.00014334862385321102
I1
I0
I1
tp13207
sS'occasional,literature,reports'
p13208
(F1
F0.00014334862385321102
I1
I0
I1
tp13209
sS'binding,to,avoid'
p13210
(F1
F0.00028669724770642203
I2
I0
I2
tp13211
sS'vivo,and,to'
p13212
(F1
F0.00014334862385321102
I1
I0
I1
tp13213
sS'methylpyrazole,mg,kg'
p13214
(F0
F0
I1
I1
I0
tp13215
sS'the,mean,cmax'
p13216
(F1
F0.00043004587155963305
I3
I0
I3
tp13217
sS'hours,q24h,for'
p13218
(F1
F0.00014334862385321102
I1
I0
I1
tp13219
sS'onto,the,surface'
p13220
(F1
F0.00014334862385321102
I1
I0
I1
tp13221
sS'activity,acute,toxicity'
p13222
(F1
F0.00014334862385321102
I0
I1
I-1
tp13223
sS'humans,have,shown'
p13224
(F1
F0.00028669724770642203
I0
I2
I-2
tp13225
sS'growth,hormone,may'
p13226
(F1
F0.00014334862385321102
I1
I0
I1
tp13227
sS'also,additive,to'
p13228
(F1
F0.00014334862385321102
I1
I0
I1
tp13229
sS'trials,that,included'
p13230
(F1
F0.00014334862385321102
I0
I1
I-1
tp13231
sS'on,the,tail-flick'
p13232
(F1
F0.00014334862385321102
I1
I0
I1
tp13233
sS'to,during,or'
p13234
(F1
F0.00014334862385321102
I1
I0
I1
tp13235
sS'by,nonsteroidal,anti-inflammatory'
p13236
(F1
F0.00014334862385321102
I1
I0
I1
tp13237
sS'have,demonstrated,an'
p13238
(F1
F0.00014334862385321102
I1
I0
I1
tp13239
sS'secretion,has,been'
p13240
(F1
F0.00014334862385321102
I1
I0
I1
tp13241
sS'synthetic,on,placental'
p13242
(F1
F0.00014334862385321102
I0
I1
I-1
tp13243
sS'and,cyp2c8,drugs'
p13244
(F1
F0.00014334862385321102
I0
I1
I-1
tp13245
sS'delirium,high,fever'
p13246
(F1
F0.00014334862385321102
I1
I0
I1
tp13247
sS'of,inspra,to'
p13248
(F1
F0.00014334862385321102
I1
I0
I1
tp13249
sS'same,day,as'
p13250
(F1
F0.00014334862385321102
I1
I0
I1
tp13251
sS'difference,in,the'
p13252
(F1
F0.00043004587155963305
I0
I3
I-3
tp13253
sS'administering,celebrex,with'
p13254
(F1
F0.00014334862385321102
I1
I0
I1
tp13255
sS'contraceptives,coadministration,of'
p13256
(F1
F0.00014334862385321102
I1
I0
I1
tp13257
sS'study,patients,with'
p13258
(F1
F0.00028669724770642203
I0
I2
I-2
tp13259
sS'and,should,not'
p13260
(F1
F0.0015768348623853212
I11
I0
I11
tp13261
sS'particularly,the,elderly'
p13262
(F1
F0.00014334862385321102
I1
I0
I1
tp13263
sS'of,to,normal'
p13264
(F1
F0.00014334862385321102
I1
I0
I1
tp13265
sS'interactions,because,false'
p13266
(F1
F0.00014334862385321102
I0
I1
I-1
tp13267
sS'tid,study,of'
p13268
(F1
F0.00014334862385321102
I0
I1
I-1
tp13269
sS'mg,bid,mg'
p13270
(F1
F0.00014334862385321102
I1
I0
I1
tp13271
sS'a,complex,effect'
p13272
(F1
F0.00014334862385321102
I1
I0
I1
tp13273
sS'the,supraventricular,arrhythmia'
p13274
(F1
F0.00014334862385321102
I1
I0
I1
tp13275
sS'patients,on,glycosides'
p13276
(F1
F0.00014334862385321102
I0
I1
I-1
tp13277
sS'and,strong,cyp3a4'
p13278
(F1
F0.00014334862385321102
I1
I0
I1
tp13279
sS'counteract,the,antiepileptic'
p13280
(F1
F0.00014334862385321102
I1
I0
I1
tp13281
sS'are,available,for'
p13282
(F1
F0.00028669724770642203
I0
I2
I-2
tp13283
sS'cream,cream,and'
p13284
(F1
F0.00014334862385321102
I0
I1
I-1
tp13285
sS'phenobarbital,the,coadministration'
p13286
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13287
sS'theoretical,basis,that'
p13288
(F1
F0.00028669724770642203
I2
I0
I2
tp13289
sS'although,no,studies'
p13290
(F1
F0.00014334862385321102
I1
I0
I1
tp13291
sS'on,the,brief'
p13292
(F1
F0.00014334862385321102
I1
I0
I1
tp13293
sS'anafranil,is,going'
p13294
(F1
F0.00014334862385321102
I0
I1
I-1
tp13295
sS'to,alter,the'
p13296
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp13297
sS'of,tambocor,to'
p13298
(F1
F0.00014334862385321102
I1
I0
I1
tp13299
sS'of,or,activated'
p13300
(F1
F0.00014334862385321102
I1
I0
I1
tp13301
sS'mg,taken,and'
p13302
(F1
F0.00014334862385321102
I1
I0
I1
tp13303
sS'not,recommended,to'
p13304
(F1
F0.00014334862385321102
I1
I0
I1
tp13305
sS'following,anti-anxiety,used'
p13306
(F1
F0.00014334862385321102
I0
I1
I-1
tp13307
sS'auc,and,maximum'
p13308
(F1
F0.00014334862385321102
I0
I1
I-1
tp13309
sS'multivitamin,preparations,containing'
p13310
(F1
F0.00014334862385321102
I1
I0
I1
tp13311
sS'inhibit,this,enzyme'
p13312
(F1
F0.00028669724770642203
I2
I0
I2
tp13313
sS'was,depressed,in'
p13314
(F1
F0.00014334862385321102
I1
I0
I1
tp13315
sS'transdermal,system,with'
p13316
(F1
F0.00014334862385321102
I1
I0
I1
tp13317
sS'capsule,formulation,of'
p13318
(F0
F0
I1
I1
I0
tp13319
sS'levels,were,noted'
p13320
(F1
F0.00014334862385321102
I0
I1
I-1
tp13321
sS'protein,tyrosine,phosphorylation'
p13322
(F1
F0.00014334862385321102
I0
I1
I-1
tp13323
sS'serum,level,determinations'
p13324
(F1
F0.00014334862385321102
I1
I0
I1
tp13325
sS'caused,to,fold'
p13326
(F1
F0.00014334862385321102
I1
I0
I1
tp13327
sS'commonly,in,patients'
p13328
(F1
F0.00014334862385321102
I1
I0
I1
tp13329
sS'retard,is,used'
p13330
(F1
F0.00028669724770642203
I2
I0
I2
tp13331
sS'activity,potentiates,the'
p13332
(F1
F0.00014334862385321102
I1
I0
I1
tp13333
sS'birth,control,should'
p13334
(F1
F0.00014334862385321102
I1
I0
I1
tp13335
sS'established,steady-state,serum'
p13336
(F1
F0.00014334862385321102
I1
I0
I1
tp13337
sS'of,r-warfarin,and'
p13338
(F1
F0.00014334862385321102
I1
I0
I1
tp13339
sS'cardiac,and,others'
p13340
(F1
F0.00014334862385321102
I0
I1
I-1
tp13341
sS'brief,psychiatric,rating'
p13342
(F1
F0.00014334862385321102
I1
I0
I1
tp13343
sS'evening,meal,and'
p13344
(F1
F0.00014334862385321102
I1
I0
I1
tp13345
sS'or,withdrawn,in'
p13346
(F1
F0.00014334862385321102
I0
I1
I-1
tp13347
sS'this,sample,size'
p13348
(F1
F0.00014334862385321102
I0
I1
I-1
tp13349
sS'of,the,mouth'
p13350
(F1
F0.00014334862385321102
I1
I0
I1
tp13351
sS'that,is,not'
p13352
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp13353
sS'in,adults,were'
p13354
(F1
F0.00014334862385321102
I0
I1
I-1
tp13355
sS'be,produced,by'
p13356
(F1
F0.00028669724770642203
I0
I2
I-2
tp13357
sS'can,be,affected'
p13358
(F1
F0.00014334862385321102
I1
I0
I1
tp13359
sS'beta,blocker,and'
p13360
(F1
F0.00014334862385321102
I1
I0
I1
tp13361
sS'in,increased,central'
p13362
(F1
F0.00014334862385321102
I1
I0
I1
tp13363
sS'used,with,other'
p13364
(F1
F0.00028669724770642203
I0
I2
I-2
tp13365
sS'concurrently,patients,should'
p13366
(F1
F0.00014334862385321102
I1
I0
I1
tp13367
sS'enhance,the,metabolism'
p13368
(F1
F0.00014334862385321102
I1
I0
I1
tp13369
sS'such,as,inotropes'
p13370
(F1
F0.00014334862385321102
I1
I0
I1
tp13371
sS'derivatives,and,are'
p13372
(F1
F0.00014334862385321102
I1
I0
I1
tp13373
sS'n,vs,placebo'
p13374
(F1
F0.00014334862385321102
I0
I1
I-1
tp13375
sS'which,themselves,produce'
p13376
(F1
F0.00014334862385321102
I1
I0
I1
tp13377
sS'oral,dose,even'
p13378
(F1
F0.00014334862385321102
I0
I1
I-1
tp13379
sS'hypoxanthine,and,xanthine'
p13380
(F1
F0.00014334862385321102
I1
I0
I1
tp13381
sS'to,discontinue,therapy'
p13382
(F1
F0.00014334862385321102
I1
I0
I1
tp13383
sS'who,are,given'
p13384
(F1
F0.00014334862385321102
I0
I1
I-1
tp13385
sS'antacid,maalox,maalox'
p13386
(F1
F0.00014334862385321102
I1
I0
I1
tp13387
sS'the,international,literature'
p13388
(F1
F0.00014334862385321102
I0
I1
I-1
tp13389
sS'would,not,be'
p13390
(F1
F0.00028669724770642203
I0
I2
I-2
tp13391
sS'binding,to,plasma'
p13392
(F1
F0.00043004587155963305
I0
I3
I-3
tp13393
sS'when,is,given'
p13394
(F0
F0
I3
I3
I0
tp13395
sS'agent,should,be'
p13396
(F0
F0
I1
I1
I0
tp13397
sS'antipsychotic,with,demonstrated'
p13398
(F1
F0.00014334862385321102
I0
I1
I-1
tp13399
sS'days,mg,rat'
p13400
(F1
F0.00014334862385321102
I0
I1
I-1
tp13401
sS'suggest,that,mc'
p13402
(F1
F0.00014334862385321102
I0
I1
I-1
tp13403
sS'and,even,death'
p13404
(F1
F0.00014334862385321102
I0
I1
I-1
tp13405
sS'botox,and,or'
p13406
(F1
F0.00014334862385321102
I1
I0
I1
tp13407
sS'other,is,catalyzed'
p13408
(F1
F0.00014334862385321102
I0
I1
I-1
tp13409
sS'controlled,study,suggested'
p13410
(F1
F0.00014334862385321102
I0
I1
I-1
tp13411
sS'no,adjustment,to'
p13412
(F1
F0.00014334862385321102
I0
I1
I-1
tp13413
sS'hours,were,potentiated'
p13414
(F1
F0.00014334862385321102
I1
I0
I1
tp13415
sS'system,fentanyl,is'
p13416
(F1
F0.00014334862385321102
I0
I1
I-1
tp13417
sS'of,cyp3a4,may'
p13418
(F1
F0.00014334862385321102
I0
I1
I-1
tp13419
sS'clearance,of,simulect'
p13420
(F1
F0.00014334862385321102
I1
I0
I1
tp13421
sS'phasic,contraction,of'
p13422
(F1
F0.00014334862385321102
I0
I1
I-1
tp13423
sS'indicate,that,and'
p13424
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13425
sS'hamsters,in,response'
p13426
(F1
F0.00014334862385321102
I0
I1
I-1
tp13427
sS'severity,of,dry'
p13428
(F1
F0.00014334862385321102
I1
I0
I1
tp13429
sS'of,with,may'
p13430
(F1
F0.0008600917431192661
I6
I0
I6
tp13431
sS'other,macrolide,such'
p13432
(F1
F0.00014334862385321102
I0
I1
I-1
tp13433
sS'seroquel,is,a'
p13434
(F1
F0.00014334862385321102
I0
I1
I-1
tp13435
sS'adjustment,required,it'
p13436
(F1
F0.00014334862385321102
I1
I0
I1
tp13437
sS'with,other,high'
p13438
(F1
F0.00014334862385321102
I0
I1
I-1
tp13439
sS'thiazide,and,reducing'
p13440
(F1
F0.00014334862385321102
I1
I0
I1
tp13441
sS'with,foscavir,and'
p13442
(F1
F0.00014334862385321102
I1
I0
I1
tp13443
sS'that,several,but'
p13444
(F1
F0.00014334862385321102
I0
I1
I-1
tp13445
sS'valproic,acid,or'
p13446
(F1
F0.00014334862385321102
I1
I0
I1
tp13447
sS'coelenterates,of,palythoa'
p13448
(F1
F0.00014334862385321102
I0
I1
I-1
tp13449
sS'be,terminated,the'
p13450
(F1
F0.00014334862385321102
I1
I0
I1
tp13451
sS'antianginal,effectiveness,of'
p13452
(F1
F0.00014334862385321102
I0
I1
I-1
tp13453
sS'administered,mg,starlix'
p13454
(F1
F0.00014334862385321102
I0
I1
I-1
tp13455
sS'hours,or,mg'
p13456
(F1
F0.00043004587155963305
I0
I3
I-3
tp13457
sS'for,and,mg'
p13458
(F1
F0.00014334862385321102
I0
I1
I-1
tp13459
sS'shown,casodex,can'
p13460
(F1
F0.00014334862385321102
I1
I0
I1
tp13461
sS'for,example,and'
p13462
(F1
F0.00014334862385321102
I1
I0
I1
tp13463
sS'oxidase,inhibitors,guanethidine'
p13464
(F1
F0.00014334862385321102
I0
I1
I-1
tp13465
sS'tubular,excretion,of'
p13466
(F1
F0.00014334862385321102
I1
I0
I1
tp13467
sS'other,depressasnts,such'
p13468
(F1
F0.00014334862385321102
I1
I0
I1
tp13469
sS'or,other,products'
p13470
(F1
F0.00014334862385321102
I1
I0
I1
tp13471
sS'but,nearly,normal'
p13472
(F1
F0.00014334862385321102
I0
I1
I-1
tp13473
sS'use,of,pegasys'
p13474
(F1
F0.00014334862385321102
I0
I1
I-1
tp13475
sS'or,disposition,of'
p13476
(F1
F0.00014334862385321102
I0
I1
I-1
tp13477
sS'in,myocardium,in'
p13478
(F1
F0.00014334862385321102
I0
I1
I-1
tp13479
sS'with,may,cause'
p13480
(F1
F0.00014334862385321102
I0
I1
I-1
tp13481
sS'ms,patients,including'
p13482
(F1
F0.00014334862385321102
I0
I1
I-1
tp13483
sS'patients,taking,an'
p13484
(F1
F0.00014334862385321102
I1
I0
I1
tp13485
sS'aureus,a,frequent'
p13486
(F1
F0.00014334862385321102
I1
I0
I1
tp13487
sS'acetate,at,about'
p13488
(F1
F0.00014334862385321102
I1
I0
I1
tp13489
sS'coadministered,on,day'
p13490
(F1
F0.00014334862385321102
I1
I0
I1
tp13491
sS'tail-flick,response,to'
p13492
(F1
F0.00014334862385321102
I0
I1
I-1
tp13493
sS'associated,with,and'
p13494
(F1
F0.00014334862385321102
I1
I0
I1
tp13495
sS'after,to,days'
p13496
(F1
F0.00014334862385321102
I0
I1
I-1
tp13497
sS'long-,term,therapy'
p13498
(F1
F0.00014334862385321102
I1
I0
I1
tp13499
sS'is,a,single'
p13500
(F1
F0.00014334862385321102
I1
I0
I1
tp13501
sS'arterial,thrombus,formation'
p13502
(F1
F0.00014334862385321102
I1
I0
I1
tp13503
sS'if,is,used'
p13504
(F1
F0.00014334862385321102
I1
I0
I1
tp13505
sS'of,repeat,doses'
p13506
(F1
F0.00014334862385321102
I0
I1
I-1
tp13507
sS'conversion,of,difluoro-2'
p13508
(F0
F0
I1
I1
I0
tp13509
sS'average,of,approximately'
p13510
(F1
F0.00014334862385321102
I1
I0
I1
tp13511
sS'mg,kg,resulted'
p13512
(F1
F0.00014334862385321102
I0
I1
I-1
tp13513
sS'monitored,in,patients'
p13514
(F1
F0.00028669724770642203
I2
I0
I2
tp13515
sS'on,such,combined'
p13516
(F1
F0.00014334862385321102
I1
I0
I1
tp13517
sS'after,intravenous,administration'
p13518
(F1
F0.00014334862385321102
I0
I1
I-1
tp13519
sS'of,pcp-induced,behavioral'
p13520
(F1
F0.00014334862385321102
I0
I1
I-1
tp13521
sS'can,be,formed'
p13522
(F1
F0.00014334862385321102
I1
I0
I1
tp13523
sS'qd,for,days'
p13524
(F1
F0.00014334862385321102
I1
I0
I1
tp13525
sS'inhibits,cyp2d6,is'
p13526
(F1
F0.00014334862385321102
I0
I1
I-1
tp13527
sS'not,shown,consistent'
p13528
(F1
F0.00014334862385321102
I0
I1
I-1
tp13529
sS'cyp3a,and,c9'
p13530
(F1
F0.00014334862385321102
I0
I1
I-1
tp13531
sS'eg,or,cyp2d6'
p13532
(F1
F0.00014334862385321102
I1
I0
I1
tp13533
sS'potent,inducers,of'
p13534
(F0
F0
I1
I1
I0
tp13535
sS'is,still,valid'
p13536
(F1
F0.00014334862385321102
I0
I1
I-1
tp13537
sS'site,fecal,and'
p13538
(F1
F0.00014334862385321102
I0
I1
I-1
tp13539
sS'if,vioxx,and'
p13540
(F1
F0.00014334862385321102
I1
I0
I1
tp13541
sS'causing,no,significant'
p13542
(F1
F0.00014334862385321102
I0
I1
I-1
tp13543
sS'did,not,potentiate'
p13544
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp13545
sS'was,administered,over'
p13546
(F1
F0.00014334862385321102
I0
I1
I-1
tp13547
sS'concurrently,with,brevibloc'
p13548
(F1
F0.00014334862385321102
I0
I1
I-1
tp13549
sS'caution,in,patients'
p13550
(F0.66666666666666663
F0.0011467889908256881
I10
I2
I8
tp13551
sS'reported,with,cefizox'
p13552
(F1
F0.00014334862385321102
I1
I0
I1
tp13553
sS'cardiac,transplant,recipients'
p13554
(F1
F0.00014334862385321102
I1
I0
I1
tp13555
sS'and,evidence,of'
p13556
(F1
F0.00014334862385321102
I1
I0
I1
tp13557
sS'plasma,levels,suggesting'
p13558
(F1
F0.00014334862385321102
I1
I0
I1
tp13559
sS'inhibitors,thereby,potentially'
p13560
(F1
F0.00014334862385321102
I1
I0
I1
tp13561
sS'given,concomitantly,only'
p13562
(F1
F0.00014334862385321102
I0
I1
I-1
tp13563
sS'of,panretin,gel'
p13564
(F1
F0.00014334862385321102
I0
I1
I-1
tp13565
sS'cause,decreased,serum'
p13566
(F1
F0.00014334862385321102
I1
I0
I1
tp13567
sS'carefully,considered,and'
p13568
(F1
F0.00014334862385321102
I1
I0
I1
tp13569
sS'too,frequent,doses'
p13570
(F1
F0.00014334862385321102
I0
I1
I-1
tp13571
sS'potentiation,occurs,with'
p13572
(F1
F0.00014334862385321102
I0
I1
I-1
tp13573
sS'such,as,a'
p13574
(F1
F0.00028669724770642203
I0
I2
I-2
tp13575
sS'studies,case,reports'
p13576
(F1
F0.00014334862385321102
I0
I1
I-1
tp13577
sS'c,interval,were'
p13578
(F1
F0.00014334862385321102
I0
I1
I-1
tp13579
sS'apraclonidine,should,not'
p13580
(F1
F0.00014334862385321102
I1
I0
I1
tp13581
sS'was,administered,intraperitoneally'
p13582
(F1
F0.00014334862385321102
I0
I1
I-1
tp13583
sS'taken,concomitantly,with'
p13584
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp13585
sS'evidence,of,a'
p13586
(F1
F0.00014334862385321102
I0
I1
I-1
tp13587
sS'thiazides,may,decrease'
p13588
(F1
F0.00014334862385321102
I1
I0
I1
tp13589
sS'related,have,been'
p13590
(F1
F0.00014334862385321102
I1
I0
I1
tp13591
sS'of,the,neuromuscular'
p13592
(F1
F0.00014334862385321102
I1
I0
I1
tp13593
sS'and,orally,as'
p13594
(F1
F0.00014334862385321102
I1
I0
I1
tp13595
sS'of,both,first'
p13596
(F1
F0.00014334862385321102
I1
I0
I1
tp13597
sS'in,combinations,were'
p13598
(F1
F0.00014334862385321102
I0
I1
I-1
tp13599
sS'clinically,significant,in'
p13600
(F1
F0.00014334862385321102
I1
I0
I1
tp13601
sS'toxic,effects,such'
p13602
(F1
F0.00014334862385321102
I1
I0
I1
tp13603
sS'not,significantly,influence'
p13604
(F1
F0.00014334862385321102
I0
I1
I-1
tp13605
sS'inducers,and,such'
p13606
(F1
F0.00014334862385321102
I1
I0
I1
tp13607
sS'agents,is,generally'
p13608
(F1
F0.00014334862385321102
I1
I0
I1
tp13609
sS'fully,characterized,a'
p13610
(F1
F0.00014334862385321102
I1
I0
I1
tp13611
sS'of,clozapine,caution'
p13612
(F1
F0.00014334862385321102
I1
I0
I1
tp13613
sS'propose,these,pharmacokinetic'
p13614
(F1
F0.00014334862385321102
I1
I0
I1
tp13615
sS'produces,an,increase'
p13616
(F1
F0.00028669724770642203
I2
I0
I2
tp13617
sS'pharmacodynamics,of,and'
p13618
(F1
F0.00014334862385321102
I0
I1
I-1
tp13619
sS'or,if,any'
p13620
(F1
F0.00014334862385321102
I1
I0
I1
tp13621
sS'not,reported,l-histidine'
p13622
(F1
F0.00014334862385321102
I1
I0
I1
tp13623
sS'hallucinations,and,irrational'
p13624
(F1
F0.00014334862385321102
I1
I0
I1
tp13625
sS'reuptake,of,disrupts'
p13626
(F1
F0.00014334862385321102
I0
I1
I-1
tp13627
sS'time,scale,of'
p13628
(F1
F0.00014334862385321102
I0
I1
I-1
tp13629
sS'days,of,mg'
p13630
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp13631
sS'block,following,nimbex'
p13632
(F1
F0.00014334862385321102
I1
I0
I1
tp13633
sS'the,resolution,of'
p13634
(F1
F0.00014334862385321102
I1
I0
I1
tp13635
sS'clostridium,three,strains'
p13636
(F1
F0.00014334862385321102
I0
I1
I-1
tp13637
sS'following,cisplatin,hcl'
p13638
(F1
F0.00014334862385321102
I1
I0
I1
tp13639
sS'adverse,experiences,and'
p13640
(F1
F0.00014334862385321102
I1
I0
I1
tp13641
sS'which,are,metabolized'
p13642
(F1
F0.00014334862385321102
I1
I0
I1
tp13643
sS'and,had,no'
p13644
(F1
F0.0008600917431192661
I0
I6
I-6
tp13645
sS'liquid,impinger,for'
p13646
(F1
F0.00014334862385321102
I0
I1
I-1
tp13647
sS'inhibitor,to,be'
p13648
(F1
F0.00014334862385321102
I0
I1
I-1
tp13649
sS'rare,postmarketing,reports'
p13650
(F1
F0.00014334862385321102
I1
I0
I1
tp13651
sS'an,experimental,soft-gelatin'
p13652
(F1
F0.00014334862385321102
I1
I0
I1
tp13653
sS'the,molecule,thereby'
p13654
(F1
F0.00043004587155963305
I3
I0
I3
tp13655
sS'of,months,the'
p13656
(F1
F0.00014334862385321102
I0
I1
I-1
tp13657
sS'with,other,anti-asthma'
p13658
(F1
F0.00014334862385321102
I0
I1
I-1
tp13659
sS'resulted,in,prolongation'
p13660
(F1
F0.00014334862385321102
I1
I0
I1
tp13661
sS'vardenafil,mg,was'
p13662
(F1
F0.00014334862385321102
I0
I1
I-1
tp13663
sS'concentrations,up,to'
p13664
(F1
F0.00014334862385321102
I0
I1
I-1
tp13665
sS'some,nsaids,has'
p13666
(F1
F0.00014334862385321102
I1
I0
I1
tp13667
sS'concurrent,kineret,and'
p13668
(F1
F0.00014334862385321102
I1
I0
I1
tp13669
sS'by,cyp,a4'
p13670
(F1
F0.00028669724770642203
I0
I2
I-2
tp13671
sS'antineoplastic,agents,may'
p13672
(F1
F0.00014334862385321102
I1
I0
I1
tp13673
sS'levels,of,or'
p13674
(F1
F0.00014334862385321102
I0
I1
I-1
tp13675
sS'in,six,of'
p13676
(F1
F0.00014334862385321102
I1
I0
I1
tp13677
sS'rashes,with,concomitant'
p13678
(F1
F0.00014334862385321102
I0
I1
I-1
tp13679
sS'anticipated,and,infusion'
p13680
(F1
F0.00014334862385321102
I1
I0
I1
tp13681
sS'that,could,cause'
p13682
(F1
F0.00028669724770642203
I2
I0
I2
tp13683
sS'of,other,nonsteroidal'
p13684
(F1
F0.00014334862385321102
I0
I1
I-1
tp13685
sS'who,are,incompletely'
p13686
(F1
F0.00014334862385321102
I0
I1
I-1
tp13687
sS'of,albendazole,mg'
p13688
(F1
F0.00014334862385321102
I1
I0
I1
tp13689
sS'activity,of,and'
p13690
(F1
F0.00014334862385321102
I1
I0
I1
tp13691
sS'of,on,arteries'
p13692
(F1
F0.00014334862385321102
I0
I1
I-1
tp13693
sS'of,whom,died'
p13694
(F1
F0.00014334862385321102
I0
I1
I-1
tp13695
sS'ethanol,cause,additive'
p13696
(F1
F0.00014334862385321102
I1
I0
I1
tp13697
sS'h2-receptor,antagonists,histamine'
p13698
(F1
F0.00014334862385321102
I0
I1
I-1
tp13699
sS'data,appeared,well'
p13700
(F1
F0.00014334862385321102
I0
I1
I-1
tp13701
sS'cyp3a4,and,mg'
p13702
(F1
F0.00014334862385321102
I0
I1
I-1
tp13703
sS'reported,in,postmarketing'
p13704
(F1
F0.00014334862385321102
I1
I0
I1
tp13705
sS'sodium,is,unaffected'
p13706
(F1
F0.00014334862385321102
I0
I1
I-1
tp13707
sS'via,the,same'
p13708
(F1
F0.00014334862385321102
I0
I1
I-1
tp13709
sS'for,the,elimination'
p13710
(F1
F0.00014334862385321102
I0
I1
I-1
tp13711
sS'neuromuscular,blockade,was'
p13712
(F0
F0
I1
I1
I0
tp13713
sS'in,noradrenaline-precontracted,arteries'
p13714
(F1
F0.00014334862385321102
I0
I1
I-1
tp13715
sS'status,which,requires'
p13716
(F1
F0.00014334862385321102
I0
I1
I-1
tp13717
sS'and,lunch,doses'
p13718
(F1
F0.00014334862385321102
I0
I1
I-1
tp13719
sS'via,organic,cationic'
p13720
(F1
F0.00014334862385321102
I1
I0
I1
tp13721
sS'the,basis,of'
p13722
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp13723
sS'potential,to,result'
p13724
(F1
F0.00014334862385321102
I1
I0
I1
tp13725
sS'coadministration,of,invirase'
p13726
(F1
F0.00014334862385321102
I0
I1
I-1
tp13727
sS'found,to,produce'
p13728
(F1
F0.00014334862385321102
I1
I0
I1
tp13729
sS'in,pediatric,patients'
p13730
(F1
F0.00014334862385321102
I1
I0
I1
tp13731
sS'pressure,or,metabolic'
p13732
(F1
F0.00014334862385321102
I0
I1
I-1
tp13733
sS'is,recommended,at'
p13734
(F1
F0.00014334862385321102
I0
I1
I-1
tp13735
sS'significantly,when,is'
p13736
(F1
F0.00014334862385321102
I1
I0
I1
tp13737
sS'hydrochloride,alone,or'
p13738
(F1
F0.00014334862385321102
I0
I1
I-1
tp13739
sS'to,those,prior'
p13740
(F1
F0.00014334862385321102
I0
I1
I-1
tp13741
sS'of,by,decreased'
p13742
(F1
F0.00043004587155963305
I3
I0
I3
tp13743
sS'increases,in,cmax'
p13744
(F1
F0.00028669724770642203
I2
I0
I2
tp13745
sS'kept,in,mind'
p13746
(F0
F0
I1
I1
I0
tp13747
sS'pharmacokinetics,parameters,auc'
p13748
(F1
F0.00014334862385321102
I1
I0
I1
tp13749
sS'inhibitors,the,effect'
p13750
(F1
F0.00014334862385321102
I0
I1
I-1
tp13751
sS'other,including,preparations'
p13752
(F1
F0.00014334862385321102
I0
I1
I-1
tp13753
sS'concentrations,auc,approximately'
p13754
(F1
F0.00014334862385321102
I1
I0
I1
tp13755
sS'potentiated,resulting,in'
p13756
(F1
F0.00014334862385321102
I1
I0
I1
tp13757
sS'or,sodium,a'
p13758
(F1
F0.00014334862385321102
I1
I0
I1
tp13759
sS'on,endotoxin-induced,changes'
p13760
(F1
F0.00014334862385321102
I0
I1
I-1
tp13761
sS'on,prothrombin,time'
p13762
(F1
F0.00043004587155963305
I0
I3
I-3
tp13763
sS'bradycardia,has,been'
p13764
(F1
F0.00014334862385321102
I0
I1
I-1
tp13765
sS'because,of,similar'
p13766
(F1
F0.00028669724770642203
I2
I0
I2
tp13767
sS'of,iiia4,blocks'
p13768
(F1
F0.00014334862385321102
I1
I0
I1
tp13769
sS'these,drugs,is'
p13770
(F1
F0.00014334862385321102
I0
I1
I-1
tp13771
sS'intraventricular,injection,of'
p13772
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13773
sS'assay,xigris,present'
p13774
(F1
F0.00014334862385321102
I0
I1
I-1
tp13775
sS'as,or,may'
p13776
(F1
F0.00014334862385321102
I1
I0
I1
tp13777
sS'including,quinolone,antibiotics'
p13778
(F1
F0.00014334862385321102
I1
I0
I1
tp13779
sS'days,following,use'
p13780
(F1
F0.00014334862385321102
I1
I0
I1
tp13781
sS'aldehyde,oxidase,in'
p13782
(F0
F0
I1
I1
I0
tp13783
sS'which,causes,a'
p13784
(F1
F0.00014334862385321102
I1
I0
I1
tp13785
sS'aluminum-containing,preparations,has'
p13786
(F1
F0.00014334862385321102
I0
I1
I-1
tp13787
sS'significant,interactions,between'
p13788
(F1
F0.00014334862385321102
I0
I1
I-1
tp13789
sS'two,mg,sustained-release'
p13790
(F1
F0.00014334862385321102
I0
I1
I-1
tp13791
sS'and,was,evaluated'
p13792
(F1
F0.00014334862385321102
I0
I1
I-1
tp13793
sS'disposition,of,the'
p13794
(F1
F0.00014334862385321102
I0
I1
I-1
tp13795
sS'for,days,results'
p13796
(F1
F0.00014334862385321102
I1
I0
I1
tp13797
sS'agents,only,with'
p13798
(F1
F0.00014334862385321102
I0
I1
I-1
tp13799
sS'with,and,respectively'
p13800
(F1
F0.00014334862385321102
I1
I0
I1
tp13801
sS'which,has,proven'
p13802
(F1
F0.00014334862385321102
I0
I1
I-1
tp13803
sS'of,with,mg'
p13804
(F1
F0.00043004587155963305
I3
I0
I3
tp13805
sS'administration,even,when'
p13806
(F1
F0.00014334862385321102
I0
I1
I-1
tp13807
sS'indicate,that,at'
p13808
(F1
F0.00014334862385321102
I1
I0
I1
tp13809
sS'to,be,coadministered'
p13810
(F1
F0.00014334862385321102
I0
I1
I-1
tp13811
sS'see,clinical,pharmacology-pharmacokinetics'
p13812
(F1
F0.00014334862385321102
I0
I1
I-1
tp13813
sS'main,meal,of'
p13814
(F1
F0.00014334862385321102
I0
I1
I-1
tp13815
sS'a,higher,absolute'
p13816
(F1
F0.00014334862385321102
I0
I1
I-1
tp13817
sS'enbrel,and,developed'
p13818
(F1
F0.00014334862385321102
I1
I0
I1
tp13819
sS'these,medications,are'
p13820
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp13821
sS'pcp,were,observed'
p13822
(F1
F0.00014334862385321102
I0
I1
I-1
tp13823
sS'on,total,concentrations'
p13824
(F0
F0
I1
I1
I0
tp13825
sS'glyceryl,trinitrate,isosorbide'
p13826
(F1
F0.00014334862385321102
I0
I1
I-1
tp13827
sS'in,large,well'
p13828
(F1
F0.00014334862385321102
I0
I1
I-1
tp13829
sS'use,of,hctz'
p13830
(F1
F0.00014334862385321102
I0
I1
I-1
tp13831
sS'when,indocin,and'
p13832
(F1
F0.00043004587155963305
I3
I0
I3
tp13833
sS'was,too,low'
p13834
(F1
F0.00014334862385321102
I0
I1
I-1
tp13835
sS'mm,hg,compared'
p13836
(F1
F0.00028669724770642203
I2
I0
I2
tp13837
sS'increased,hepatotoxicity,of'
p13838
(F1
F0.00014334862385321102
I1
I0
I1
tp13839
sS'metabolism,of,hmg-coa'
p13840
(F1
F0.00014334862385321102
I1
I0
I1
tp13841
sS'that,it,is'
p13842
(F1
F0.00014334862385321102
I1
I0
I1
tp13843
sS'increases,the,metabolic'
p13844
(F1
F0.00028669724770642203
I2
I0
I2
tp13845
sS'gritty,substance,to'
p13846
(F1
F0.00014334862385321102
I1
I0
I1
tp13847
sS'is,taken,in'
p13848
(F1
F0.00014334862385321102
I1
I0
I1
tp13849
sS'cgs21680,was,only'
p13850
(F1
F0.00014334862385321102
I1
I0
I1
tp13851
sS'and,and,the'
p13852
(F1
F0.00014334862385321102
I0
I1
I-1
tp13853
sS'reductase,inhibitors,and'
p13854
(F0
F0
I1
I1
I0
tp13855
sS'x,kg,and'
p13856
(F1
F0.00014334862385321102
I0
I1
I-1
tp13857
sS'inhibited,insp,induced'
p13858
(F1
F0.00014334862385321102
I1
I0
I1
tp13859
sS'if,a,mg'
p13860
(F1
F0.00014334862385321102
I1
I0
I1
tp13861
sS'appears,to,increase'
p13862
(F1
F0.00014334862385321102
I1
I0
I1
tp13863
sS'about,when,mesylate'
p13864
(F1
F0.00014334862385321102
I1
I0
I1
tp13865
sS'for,days,resulted'
p13866
(F1
F0.00071674311926605509
I5
I0
I5
tp13867
sS'sodium,thiosulfate,is'
p13868
(F1
F0.00014334862385321102
I1
I0
I1
tp13869
sS'with,ventricular,fibrillation'
p13870
(F1
F0.00014334862385321102
I1
I0
I1
tp13871
sS'least,hours,following'
p13872
(F1
F0.00014334862385321102
I1
I0
I1
tp13873
sS'm,v,cmc-cys7'
p13874
(F1
F0.00014334862385321102
I0
I1
I-1
tp13875
sS'g,resulted,in'
p13876
(F1
F0.00014334862385321102
I1
I0
I1
tp13877
sS'rifampin,increases,the'
p13878
(F1
F0.00014334862385321102
I1
I0
I1
tp13879
sS'minimally,absorbed,into'
p13880
(F1
F0.00014334862385321102
I1
I0
I1
tp13881
sS'literature,revealed,that'
p13882
(F1
F0.00014334862385321102
I1
I0
I1
tp13883
sS'day,preferably,the'
p13884
(F1
F0.00014334862385321102
I0
I1
I-1
tp13885
sS'lotensin,can,attenuate'
p13886
(F1
F0.00014334862385321102
I1
I0
I1
tp13887
sS'h2-receptor,antagonists,appear'
p13888
(F1
F0.00014334862385321102
I0
I1
I-1
tp13889
sS'analgesic,actions,are'
p13890
(F1
F0.00014334862385321102
I0
I1
I-1
tp13891
sS'major,metabolite,are'
p13892
(F1
F0.00014334862385321102
I0
I1
I-1
tp13893
sS'oral,administration,of'
p13894
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp13895
sS'when,concomitant,administration'
p13896
(F1
F0.00028669724770642203
I2
I0
I2
tp13897
sS'toxicity,may,occur'
p13898
(F1
F0.00014334862385321102
I1
I0
I1
tp13899
sS'and,at,mg'
p13900
(F1
F0.00014334862385321102
I1
I0
I1
tp13901
sS'may,interact,with'
p13902
(F0.27272727272727271
F0.0008600917431192661
I14
I8
I6
tp13903
sS'enzymes,are,the'
p13904
(F1
F0.00014334862385321102
I1
I0
I1
tp13905
sS'during,coadministration,can'
p13906
(F1
F0.00014334862385321102
I1
I0
I1
tp13907
sS'single,dose,study'
p13908
(F0
F0
I1
I1
I0
tp13909
sS'secondary,enzymes,respectively'
p13910
(F1
F0.00014334862385321102
I1
I0
I1
tp13911
sS'beta-receptor,blockers,antagonists'
p13912
(F1
F0.00014334862385321102
I0
I1
I-1
tp13913
sS'range,in,patients'
p13914
(F1
F0.00014334862385321102
I1
I0
I1
tp13915
sS'the,anxiogenic,effects'
p13916
(F1
F0.00014334862385321102
I1
I0
I1
tp13917
sS'concentrations,of,after'
p13918
(F1
F0.00014334862385321102
I0
I1
I-1
tp13919
sS'in,the,committed'
p13920
(F1
F0.00014334862385321102
I1
I0
I1
tp13921
sS'of,relapses,for'
p13922
(F1
F0.00014334862385321102
I0
I1
I-1
tp13923
sS'dosages,may,be'
p13924
(F1
F0.00014334862385321102
I1
I0
I1
tp13925
sS'amine,since,it'
p13926
(F1
F0.00014334862385321102
I1
I0
I1
tp13927
sS'and,usually,results'
p13928
(F1
F0.00014334862385321102
I1
I0
I1
tp13929
sS'twice,a,day'
p13930
(F1
F0.00028669724770642203
I0
I2
I-2
tp13931
sS'nsaids,has,been'
p13932
(F1
F0.00028669724770642203
I2
I0
I2
tp13933
sS'triazolam,erythromycin,has'
p13934
(F1
F0.00014334862385321102
I1
I0
I1
tp13935
sS'result,in,low'
p13936
(F1
F0.00014334862385321102
I1
I0
I1
tp13937
sS'phenobarbital,amphetamines,may'
p13938
(F1
F0.00028669724770642203
I2
I0
I2
tp13939
sS'histamine,h2-receptor,antagonists'
p13940
(F1
F0.00014334862385321102
I0
I1
I-1
tp13941
sS'be,discontinued,it'
p13942
(F1
F0.00014334862385321102
I1
I0
I1
tp13943
sS'pharmaceuticals,inc,demonstrated'
p13944
(F1
F0.00014334862385321102
I1
I0
I1
tp13945
sS'tricyclic,with,that'
p13946
(F1
F0.00014334862385321102
I0
I1
I-1
tp13947
sS'the,hypotension,seen'
p13948
(F1
F0.00014334862385321102
I1
I0
I1
tp13949
sS'administration,of,single'
p13950
(F1
F0.00014334862385321102
I0
I1
I-1
tp13951
sS'on,long-term,therapy'
p13952
(F1
F0.00014334862385321102
I1
I0
I1
tp13953
sS'week,endoscopy,study'
p13954
(F1
F0.00014334862385321102
I0
I1
I-1
tp13955
sS'on,plasma,concentrations'
p13956
(F1
F0.0008600917431192661
I0
I6
I-6
tp13957
sS'higher,and,in'
p13958
(F1
F0.00014334862385321102
I0
I1
I-1
tp13959
sS'two,hundred,mg'
p13960
(F1
F0.00014334862385321102
I0
I1
I-1
tp13961
sS'monotherapy,for,at'
p13962
(F1
F0.00014334862385321102
I0
I1
I-1
tp13963
sS'palytoxin-induced,contraction,and'
p13964
(F1
F0.00014334862385321102
I0
I1
I-1
tp13965
sS'ascorbic,acid,vitamin'
p13966
(F1
F0.00014334862385321102
I1
I0
I1
tp13967
sS'macrolide,antibiotics,such'
p13968
(F1
F0.00014334862385321102
I1
I0
I1
tp13969
sS'system,by,intrathecal'
p13970
(F1
F0.00014334862385321102
I0
I1
I-1
tp13971
sS'the,intensity,uniformity'
p13972
(F1
F0.00014334862385321102
I0
I1
I-1
tp13973
sS'of,amevive,on'
p13974
(F1
F0.00014334862385321102
I0
I1
I-1
tp13975
sS'action,of,suggested'
p13976
(F1
F0.00014334862385321102
I0
I1
I-1
tp13977
sS'contrary,and,were'
p13978
(F1
F0.00014334862385321102
I1
I0
I1
tp13979
sS'with,vaprisol,the'
p13980
(F1
F0.00014334862385321102
I1
I0
I1
tp13981
sS'medicines,or,another'
p13982
(F1
F0.00014334862385321102
I1
I0
I1
tp13983
sS'i,acute,pharmacological'
p13984
(F1
F0.00014334862385321102
I0
I1
I-1
tp13985
sS'schizophrenia,and,in'
p13986
(F1
F0.00014334862385321102
I0
I1
I-1
tp13987
sS'both,compounds,attenuate'
p13988
(F1
F0.00014334862385321102
I0
I1
I-1
tp13989
sS'at,baseline,to'
p13990
(F1
F0.00014334862385321102
I0
I1
I-1
tp13991
sS'result,in,reduced'
p13992
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp13993
sS'magnitude,of,changes'
p13994
(F1
F0.00014334862385321102
I1
I0
I1
tp13995
sS'careful,monitoring,or'
p13996
(F1
F0.00014334862385321102
I1
I0
I1
tp13997
sS'in,pharmacokinetics,produced'
p13998
(F1
F0.00014334862385321102
I1
I0
I1
tp13999
sS'changes,in,effects'
p14000
(F1
F0.00014334862385321102
I1
I0
I1
tp14001
sS'bezalip,retard,and'
p14002
(F1
F0.00014334862385321102
I1
I0
I1
tp14003
sS'be,of,major'
p14004
(F1
F0.00014334862385321102
I1
I0
I1
tp14005
sS'currently,receiving,cautious'
p14006
(F1
F0.00014334862385321102
I1
I0
I1
tp14007
sS'has,been,well'
p14008
(F1
F0.00014334862385321102
I0
I1
I-1
tp14009
sS'careful,monitoring,of'
p14010
(F0.5
F0.00028669724770642203
I3
I1
I2
tp14011
sS'the,mean,apparent'
p14012
(F1
F0.00014334862385321102
I1
I0
I1
tp14013
sS'initial,dose,until'
p14014
(F1
F0.00014334862385321102
I1
I0
I1
tp14015
sS'costs,despite,the'
p14016
(F1
F0.00014334862385321102
I0
I1
I-1
tp14017
sS'at,steady-state,exposure'
p14018
(F1
F0.00014334862385321102
I0
I1
I-1
tp14019
sS'neither,nor,appears'
p14020
(F1
F0.00014334862385321102
I0
I1
I-1
tp14021
sS'of,a,mao'
p14022
(F1
F0.00014334862385321102
I1
I0
I1
tp14023
sS'about,fold,in'
p14024
(F1
F0.00014334862385321102
I1
I0
I1
tp14025
sS'evidenced,by,a'
p14026
(F1
F0.00014334862385321102
I1
I0
I1
tp14027
sS'other,agents,has'
p14028
(F0
F0
I1
I1
I0
tp14029
sS'mg,to,ace'
p14030
(F1
F0.00014334862385321102
I1
I0
I1
tp14031
sS'not,affect,responding'
p14032
(F1
F0.00014334862385321102
I0
I1
I-1
tp14033
sS'blood,thinners,decongestant'
p14034
(F1
F0.00014334862385321102
I1
I0
I1
tp14035
sS'c9,decreased,active'
p14036
(F1
F0.00014334862385321102
I1
I0
I1
tp14037
sS'of,blocking,cardiac'
p14038
(F1
F0.00014334862385321102
I1
I0
I1
tp14039
sS'pulmonary,symptomatology,due'
p14040
(F1
F0.00014334862385321102
I1
I0
I1
tp14041
sS'rates,of,patients'
p14042
(F1
F0.00014334862385321102
I0
I1
I-1
tp14043
sS'median,of,the'
p14044
(F1
F0.00014334862385321102
I1
I0
I1
tp14045
sS'mono-oxidases,in,the'
p14046
(F1
F0.00014334862385321102
I0
I1
I-1
tp14047
sS'a,mg,dose'
p14048
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp14049
sS'total,mucosal,accumulation'
p14050
(F1
F0.00014334862385321102
I0
I1
I-1
tp14051
sS'following,administration,decreased'
p14052
(F1
F0.00014334862385321102
I1
I0
I1
tp14053
sS'bleeding,from,a'
p14054
(F1
F0.00014334862385321102
I0
I1
I-1
tp14055
sS'and,cmax,and'
p14056
(F1
F0.00014334862385321102
I0
I1
I-1
tp14057
sS'ptca,pci,co-administration'
p14058
(F1
F0.00014334862385321102
I1
I0
I1
tp14059
sS'ganciclovir,the,pharmacokinetics'
p14060
(F1
F0.00014334862385321102
I0
I1
I-1
tp14061
sS'first,few,days'
p14062
(F1
F0.00028669724770642203
I2
I0
I2
tp14063
sS'beverages,is,enhanced'
p14064
(F1
F0.00014334862385321102
I1
I0
I1
tp14065
sS'concomitantly,with,cyp1a2'
p14066
(F1
F0.00014334862385321102
I1
I0
I1
tp14067
sS'gvia,omega-agatoxin,via-resistant'
p14068
(F1
F0.00014334862385321102
I0
I1
I-1
tp14069
sS'such,as,factor'
p14070
(F1
F0.00014334862385321102
I0
I1
I-1
tp14071
sS'studies,with,proscar'
p14072
(F1
F0.00014334862385321102
I0
I1
I-1
tp14073
sS'immunodepressant--the,sandimmune--on,hepatic'
p14074
(F1
F0.00014334862385321102
I0
I1
I-1
tp14075
sS'postoperative,pain,without'
p14076
(F1
F0.00014334862385321102
I0
I1
I-1
tp14077
sS'clearance,of,both'
p14078
(F1
F0.00014334862385321102
I1
I0
I1
tp14079
sS'in,four,subjects'
p14080
(F1
F0.00014334862385321102
I0
I1
I-1
tp14081
sS'concomitantly,with,dilaudid'
p14082
(F1
F0.00014334862385321102
I1
I0
I1
tp14083
sS'a,cyp2c9,substrate'
p14084
(F1
F0.00043004587155963305
I3
I0
I3
tp14085
sS'duration,of,central'
p14086
(F1
F0.00014334862385321102
I1
I0
I1
tp14087
sS'of,and,usually'
p14088
(F1
F0.00014334862385321102
I1
I0
I1
tp14089
sS'does,it,interfere'
p14090
(F1
F0.00014334862385321102
I0
I1
I-1
tp14091
sS'of,psychotropic,that'
p14092
(F1
F0.00014334862385321102
I1
I0
I1
tp14093
sS'in,glomerular,filtration'
p14094
(F1
F0.00014334862385321102
I0
I1
I-1
tp14095
sS'cmax,of,when'
p14096
(F1
F0.00014334862385321102
I0
I1
I-1
tp14097
sS'with,had,no'
p14098
(F1
F0.00028669724770642203
I0
I2
I-2
tp14099
sS'volunteers,ingesting,the'
p14100
(F1
F0.00014334862385321102
I1
I0
I1
tp14101
sS'virus,vaccine,inhalation'
p14102
(F1
F0.00014334862385321102
I1
I0
I1
tp14103
sS'medications,that,can'
p14104
(F1
F0.00014334862385321102
I1
I0
I1
tp14105
sS'europe,nimotop,was'
p14106
(F1
F0.00014334862385321102
I1
I0
I1
tp14107
sS'shown,on,the'
p14108
(F1
F0.00014334862385321102
I0
I1
I-1
tp14109
sS'a,slight,reduction'
p14110
(F1
F0.00014334862385321102
I1
I0
I1
tp14111
sS'means,of,hydroxytolbutamide'
p14112
(F1
F0.00014334862385321102
I0
I1
I-1
tp14113
sS'free,had,no'
p14114
(F1
F0.00014334862385321102
I0
I1
I-1
tp14115
sS'a,pharmacokinetic,substudy'
p14116
(F1
F0.00014334862385321102
I1
I0
I1
tp14117
sS'aeds,were,assessed'
p14118
(F1
F0.00014334862385321102
I0
I1
I-1
tp14119
sS'extensor,tension,hoof'
p14120
(F1
F0.00014334862385321102
I0
I1
I-1
tp14121
sS'for,serious,interactions'
p14122
(F1
F0.00014334862385321102
I1
I0
I1
tp14123
sS'cyp,a4,macrolide'
p14124
(F1
F0.00014334862385321102
I1
I0
I1
tp14125
sS'toxicology,of,difluoroacetone'
p14126
(F1
F0.00014334862385321102
I0
I1
I-1
tp14127
sS'of,the,human'
p14128
(F1
F0.00014334862385321102
I0
I1
I-1
tp14129
sS'were,systematically,investigated'
p14130
(F1
F0.00014334862385321102
I0
I1
I-1
tp14131
sS'chronic,experiments,on'
p14132
(F1
F0.00014334862385321102
I0
I1
I-1
tp14133
sS'the,influence,of'
p14134
(F1
F0.00071674311926605509
I0
I5
I-5
tp14135
sS'patients,the,recommended'
p14136
(F1
F0.00014334862385321102
I0
I1
I-1
tp14137
sS'mg,day,during'
p14138
(F1
F0.00014334862385321102
I1
I0
I1
tp14139
sS'magnitude,lower,than'
p14140
(F1
F0.00014334862385321102
I0
I1
I-1
tp14141
sS'added,to,other'
p14142
(F1
F0.00014334862385321102
I0
I1
I-1
tp14143
sS'the,primary,elimination'
p14144
(F1
F0.00014334862385321102
I1
I0
I1
tp14145
sS'receive,initial,doses'
p14146
(F1
F0.00014334862385321102
I1
I0
I1
tp14147
sS'bred,control,rbc'
p14148
(F1
F0.00014334862385321102
I0
I1
I-1
tp14149
sS'synthesis,in,the'
p14150
(F1
F0.00014334862385321102
I0
I1
I-1
tp14151
sS'cells,but,dose-dependently'
p14152
(F1
F0.00014334862385321102
I1
I0
I1
tp14153
sS'interaction,effects,of'
p14154
(F1
F0.00014334862385321102
I0
I1
I-1
tp14155
sS'has,been,filtrated'
p14156
(F1
F0.00014334862385321102
I1
I0
I1
tp14157
sS'enhanced,when,it'
p14158
(F1
F0.00014334862385321102
I0
I1
I-1
tp14159
sS'of,and,hydrochloride'
p14160
(F1
F0.00014334862385321102
I0
I1
I-1
tp14161
sS'such,as,from'
p14162
(F1
F0.00014334862385321102
I1
I0
I1
tp14163
sS'day,showed,an'
p14164
(F1
F0.00014334862385321102
I1
I0
I1
tp14165
sS'when,baraclude,is'
p14166
(F1
F0.00014334862385321102
I0
I1
I-1
tp14167
sS'who,are,applying'
p14168
(F1
F0.00014334862385321102
I1
I0
I1
tp14169
sS'patients,given,very'
p14170
(F1
F0.00014334862385321102
I1
I0
I1
tp14171
sS'to,a,direct'
p14172
(F0
F0
I1
I1
I0
tp14173
sS'intracellular,ca,concentration'
p14174
(F1
F0.00014334862385321102
I1
I0
I1
tp14175
sS'lowering,their,blood'
p14176
(F1
F0.00014334862385321102
I0
I1
I-1
tp14177
sS'was,significantly,superior'
p14178
(F1
F0.00014334862385321102
I0
I1
I-1
tp14179
sS'interactions,and,clinical'
p14180
(F1
F0.00014334862385321102
I1
I0
I1
tp14181
sS'report,describes,two'
p14182
(F1
F0.00014334862385321102
I1
I0
I1
tp14183
sS'study,of,normal'
p14184
(F1
F0.00014334862385321102
I1
I0
I1
tp14185
sS'the,dose,will'
p14186
(F1
F0.00014334862385321102
I1
I0
I1
tp14187
sS'peganone,is,administered'
p14188
(F1
F0.00014334862385321102
I1
I0
I1
tp14189
sS'been,co-administered,with'
p14190
(F1
F0.00014334862385321102
I0
I1
I-1
tp14191
sS'complex,effect,on'
p14192
(F1
F0.00014334862385321102
I1
I0
I1
tp14193
sS'psychoactive,or,cns'
p14194
(F1
F0.00014334862385321102
I1
I0
I1
tp14195
sS'mhd,induce,a'
p14196
(F1
F0.00014334862385321102
I0
I1
I-1
tp14197
sS'mean,auc,decreased'
p14198
(F1
F0.00014334862385321102
I1
I0
I1
tp14199
sS'a,higher,occurrence'
p14200
(F1
F0.00028669724770642203
I2
I0
I2
tp14201
sS'nonsteroidal,anti-inflammatory,drugs'
p14202
(F0.5
F0.00028669724770642203
I3
I1
I2
tp14203
sS'of,induced,hypotension'
p14204
(F1
F0.00014334862385321102
I0
I1
I-1
tp14205
sS'another,known,to'
p14206
(F1
F0.00057339449541284407
I0
I4
I-4
tp14207
sS'tnf,blocking,agents'
p14208
(F1
F0.00014334862385321102
I0
I1
I-1
tp14209
sS'no,clinically,important'
p14210
(F1
F0.00071674311926605509
I0
I5
I-5
tp14211
sS'insulin-induced,proliferation,of'
p14212
(F1
F0.00014334862385321102
I1
I0
I1
tp14213
sS'are,taken,on'
p14214
(F1
F0.00014334862385321102
I1
I0
I1
tp14215
sS'has,little,or'
p14216
(F1
F0.00014334862385321102
I1
I0
I1
tp14217
sS'known,enzyme,inducers'
p14218
(F1
F0.00014334862385321102
I1
I0
I1
tp14219
sS'about,and,levels'
p14220
(F1
F0.00014334862385321102
I1
I0
I1
tp14221
sS'agents,with,alphagan'
p14222
(F1
F0.00014334862385321102
I1
I0
I1
tp14223
sS'data,showed,that'
p14224
(F1
F0.00014334862385321102
I0
I1
I-1
tp14225
sS'should,focus,on'
p14226
(F1
F0.00014334862385321102
I0
I1
I-1
tp14227
sS'and,mc,decrease'
p14228
(F1
F0.00014334862385321102
I0
I1
I-1
tp14229
sS'of,has,no'
p14230
(F1
F0.00028669724770642203
I0
I2
I-2
tp14231
sS'derivatives,and,platelet'
p14232
(F1
F0.00014334862385321102
I1
I0
I1
tp14233
sS'leading,to,possible'
p14234
(F1
F0.00028669724770642203
I2
I0
I2
tp14235
sS'plasma,protein-bound,with'
p14236
(F1
F0.00014334862385321102
I1
I0
I1
tp14237
sS'magnesium-containing,concomitant,administration'
p14238
(F1
F0.00014334862385321102
I1
I0
I1
tp14239
sS'enzyme-inducer,did,indeed'
p14240
(F1
F0.00014334862385321102
I1
I0
I1
tp14241
sS'various,combinations,of'
p14242
(F1
F0.00014334862385321102
I0
I1
I-1
tp14243
sS'treated,with,oral'
p14244
(F1
F0.00028669724770642203
I2
I0
I2
tp14245
sS'in,additive,cns'
p14246
(F1
F0.00028669724770642203
I2
I0
I2
tp14247
sS'of,stress,and'
p14248
(F1
F0.00014334862385321102
I0
I1
I-1
tp14249
sS'these,studies,do'
p14250
(F1
F0.00014334862385321102
I1
I0
I1
tp14251
sS'similar,agents,and'
p14252
(F1
F0.00014334862385321102
I1
I0
I1
tp14253
sS'of,fat-soluble,including'
p14254
(F1
F0.00014334862385321102
I1
I0
I1
tp14255
sS'events,and,the'
p14256
(F1
F0.00014334862385321102
I0
I1
I-1
tp14257
sS'not,limited,to'
p14258
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp14259
sS'has,benefits,against'
p14260
(F1
F0.00014334862385321102
I0
I1
I-1
tp14261
sS'category,x,use'
p14262
(F1
F0.00014334862385321102
I0
I1
I-1
tp14263
sS'hydroxide,and,hydroxide'
p14264
(F0
F0
I1
I1
I0
tp14265
sS'presence,of,therapeutic'
p14266
(F1
F0.00014334862385321102
I0
I1
I-1
tp14267
sS'with,long-term,high-dose'
p14268
(F0
F0
I1
I1
I0
tp14269
sS'of,sites,may'
p14270
(F1
F0.00014334862385321102
I0
I1
I-1
tp14271
sS'activity,would,be'
p14272
(F1
F0.00014334862385321102
I0
I1
I-1
tp14273
sS'of,orally,ingested'
p14274
(F1
F0.00014334862385321102
I0
I1
I-1
tp14275
sS'benzodiazepines,gi,motility'
p14276
(F1
F0.00014334862385321102
I0
I1
I-1
tp14277
sS'interfere,with,biliary'
p14278
(F1
F0.00014334862385321102
I0
I1
I-1
tp14279
sS'cmc-cys7,a,significantly'
p14280
(F1
F0.00014334862385321102
I0
I1
I-1
tp14281
sS'compared,to,deaths'
p14282
(F1
F0.00014334862385321102
I0
I1
I-1
tp14283
sS'decrease,renal,tubular'
p14284
(F1
F0.00028669724770642203
I2
I0
I2
tp14285
sS'with,propranolols,hypotensive'
p14286
(F1
F0.00014334862385321102
I1
I0
I1
tp14287
sS'vitro,experiments,demonstrated'
p14288
(F1
F0.00014334862385321102
I0
I1
I-1
tp14289
sS'sodium,plasma,levels'
p14290
(F1
F0.00014334862385321102
I1
I0
I1
tp14291
sS'daily,given,hours'
p14292
(F1
F0.00014334862385321102
I1
I0
I1
tp14293
sS'than,might,be'
p14294
(F1
F0.00014334862385321102
I1
I0
I1
tp14295
sS'serotonin,reuptake,inhibitor'
p14296
(F1
F0.00028669724770642203
I2
I0
I2
tp14297
sS'thereby,decreasing,the'
p14298
(F1
F0.00014334862385321102
I1
I0
I1
tp14299
sS'titration,of,their'
p14300
(F1
F0.00014334862385321102
I1
I0
I1
tp14301
sS'suggest,a,higher'
p14302
(F1
F0.00014334862385321102
I1
I0
I1
tp14303
sS'collapse,in,association'
p14304
(F1
F0.00014334862385321102
I0
I1
I-1
tp14305
sS'for,such,interaction'
p14306
(F1
F0.00014334862385321102
I0
I1
I-1
tp14307
sS'or,urine,which'
p14308
(F1
F0.00014334862385321102
I0
I1
I-1
tp14309
sS'serotonergic,agents,should'
p14310
(F1
F0.00014334862385321102
I1
I0
I1
tp14311
sS'responses,to,acth'
p14312
(F1
F0.00014334862385321102
I0
I1
I-1
tp14313
sS'of,unsteady,gait'
p14314
(F1
F0.00014334862385321102
I1
I0
I1
tp14315
sS'being,observed,with'
p14316
(F1
F0.00014334862385321102
I0
I1
I-1
tp14317
sS'doubling,of,the'
p14318
(F1
F0.00014334862385321102
I1
I0
I1
tp14319
sS'between,and,with'
p14320
(F1
F0.00014334862385321102
I1
I0
I1
tp14321
sS'results,from,a'
p14322
(F0
F0
I1
I1
I0
tp14323
sS'other,cyp3a4,metabolized'
p14324
(F1
F0.00014334862385321102
I1
I0
I1
tp14325
sS'administration,of,vistide'
p14326
(F1
F0.00014334862385321102
I1
I0
I1
tp14327
sS'overdosage,since,the'
p14328
(F1
F0.00014334862385321102
I1
I0
I1
tp14329
sS'the,aptt,such'
p14330
(F1
F0.00014334862385321102
I0
I1
I-1
tp14331
sS'starting,daily,dose'
p14332
(F1
F0.00014334862385321102
I0
I1
I-1
tp14333
sS'treated,with,one'
p14334
(F1
F0.00014334862385321102
I1
I0
I1
tp14335
sS'drug,interactions,no'
p14336
(F1
F0.00014334862385321102
I0
I1
I-1
tp14337
sS'its,n-demethylated,metabolite'
p14338
(F1
F0.00014334862385321102
I0
I1
I-1
tp14339
sS'as,cns,cardiac'
p14340
(F1
F0.00014334862385321102
I0
I1
I-1
tp14341
sS'observed,in,patients'
p14342
(F0
F0
I1
I1
I0
tp14343
sS'nonsteroidal,agents,nsaids'
p14344
(F1
F0.00014334862385321102
I1
I0
I1
tp14345
sS'or,on,plasma'
p14346
(F1
F0.00014334862385321102
I0
I1
I-1
tp14347
sS'and,what,to'
p14348
(F1
F0.00014334862385321102
I0
I1
I-1
tp14349
sS'with,celebrex,may'
p14350
(F1
F0.00014334862385321102
I1
I0
I1
tp14351
sS'recommended,when,initiating'
p14352
(F1
F0.00014334862385321102
I1
I0
I1
tp14353
sS'cardioactive,drugs,such'
p14354
(F1
F0.00014334862385321102
I0
I1
I-1
tp14355
sS'these,components,may'
p14356
(F1
F0.00014334862385321102
I0
I1
I-1
tp14357
sS'chloramphenicol,has,been'
p14358
(F1
F0.00014334862385321102
I1
I0
I1
tp14359
sS'change,in,clotting'
p14360
(F1
F0.00014334862385321102
I0
I1
I-1
tp14361
sS'appear,to,share'
p14362
(F1
F0.00014334862385321102
I0
I1
I-1
tp14363
sS'concurrently,and,evidence'
p14364
(F1
F0.00014334862385321102
I1
I0
I1
tp14365
sS'receiving,or,monoamine'
p14366
(F1
F0.00014334862385321102
I1
I0
I1
tp14367
sS'anafranil,should,not'
p14368
(F1
F0.00014334862385321102
I1
I0
I1
tp14369
sS'combination,with,mg'
p14370
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp14371
sS'following,methyl-4,phenyl-1'
p14372
(F1
F0.00014334862385321102
I0
I1
I-1
tp14373
sS'of,a,pharmacodynamic'
p14374
(F1
F0.00014334862385321102
I1
I0
I1
tp14375
sS'would,affect,this'
p14376
(F1
F0.00014334862385321102
I0
I1
I-1
tp14377
sS'or,toxicity,associated'
p14378
(F1
F0.00014334862385321102
I0
I1
I-1
tp14379
sS'other,drugs,to'
p14380
(F1
F0.00028669724770642203
I0
I2
I-2
tp14381
sS'one,or,more'
p14382
(F1
F0.00028669724770642203
I0
I2
I-2
tp14383
sS'supporting,the,conclusion'
p14384
(F1
F0.00014334862385321102
I1
I0
I1
tp14385
sS'of,dependence,may'
p14386
(F1
F0.00014334862385321102
I0
I1
I-1
tp14387
sS'inhibitors,of,endogenous'
p14388
(F1
F0.00014334862385321102
I1
I0
I1
tp14389
sS'serum,levels,the'
p14390
(F1
F0.00014334862385321102
I1
I0
I1
tp14391
sS'and,have,the'
p14392
(F1
F0.00014334862385321102
I1
I0
I1
tp14393
sS'taking,beta,adrenergic'
p14394
(F1
F0.00014334862385321102
I1
I0
I1
tp14395
sS'with,elspar,or'
p14396
(F1
F0.00014334862385321102
I1
I0
I1
tp14397
sS'by,certain,including'
p14398
(F1
F0.00043004587155963305
I3
I0
I3
tp14399
sS'antiepileptic,drugs,sporadic'
p14400
(F1
F0.00014334862385321102
I1
I0
I1
tp14401
sS'in,increased,cns'
p14402
(F1
F0.00014334862385321102
I1
I0
I1
tp14403
sS'release,but,not'
p14404
(F1
F0.00014334862385321102
I1
I0
I1
tp14405
sS'these,two,drugs'
p14406
(F1
F0.00014334862385321102
I1
I0
I1
tp14407
sS'or,avoided,also'
p14408
(F1
F0.00014334862385321102
I1
I0
I1
tp14409
sS'adverse,reactions,from'
p14410
(F1
F0.00014334862385321102
I0
I1
I-1
tp14411
sS'emulsion,model,in'
p14412
(F1
F0.00014334862385321102
I0
I1
I-1
tp14413
sS'however,is,small'
p14414
(F1
F0.00014334862385321102
I1
I0
I1
tp14415
sS'of,virologic,response'
p14416
(F1
F0.00028669724770642203
I0
I2
I-2
tp14417
sS'of,prolongation,of'
p14418
(F1
F0.00014334862385321102
I1
I0
I1
tp14419
sS'precipitated,by,similar'
p14420
(F1
F0.00014334862385321102
I0
I1
I-1
tp14421
sS'especially,when,the'
p14422
(F1
F0.00014334862385321102
I1
I0
I1
tp14423
sS'necessitated,changes,in'
p14424
(F1
F0.00014334862385321102
I1
I0
I1
tp14425
sS'similar,conditions,concentrations'
p14426
(F1
F0.00014334862385321102
I0
I1
I-1
tp14427
sS'increase,when,atromid-s'
p14428
(F1
F0.00014334862385321102
I1
I0
I1
tp14429
sS'related,to,the'
p14430
(F1
F0.00014334862385321102
I0
I1
I-1
tp14431
sS'such,as,might'
p14432
(F1
F0.00014334862385321102
I1
I0
I1
tp14433
sS'clinical,signs,or'
p14434
(F1
F0.00014334862385321102
I1
I0
I1
tp14435
sS'drug-drug,interactions,cimetidine'
p14436
(F1
F0.00014334862385321102
I0
I1
I-1
tp14437
sS'use,of,ellence'
p14438
(F1
F0.00014334862385321102
I1
I0
I1
tp14439
sS'system,is,involved'
p14440
(F1
F0.00014334862385321102
I0
I1
I-1
tp14441
sS'the,possible,benefits'
p14442
(F1
F0.00014334862385321102
I1
I0
I1
tp14443
sS'clinical,pharmacology-pharmacokinetics,drug-drug'
p14444
(F1
F0.00014334862385321102
I0
I1
I-1
tp14445
sS'such,as,antineoplastic'
p14446
(F1
F0.00014334862385321102
I1
I0
I1
tp14447
sS'for,volatile,inhalation'
p14448
(F1
F0.00014334862385321102
I1
I0
I1
tp14449
sS'the,known,relationships'
p14450
(F1
F0.00014334862385321102
I0
I1
I-1
tp14451
sS'adjustment,for,is'
p14452
(F1
F0.00014334862385321102
I0
I1
I-1
tp14453
sS'using,stadol,ns'
p14454
(F1
F0.00014334862385321102
I0
I1
I-1
tp14455
sS'elimination,half,life'
p14456
(F1
F0.00014334862385321102
I1
I0
I1
tp14457
sS'or,decrease,plasma'
p14458
(F1
F0.00014334862385321102
I1
I0
I1
tp14459
sS'patients,is,limited'
p14460
(F1
F0.00014334862385321102
I1
I0
I1
tp14461
sS'and,the,following'
p14462
(F1
F0.00014334862385321102
I0
I1
I-1
tp14463
sS'decreases,clearance,by'
p14464
(F1
F0.00014334862385321102
I1
I0
I1
tp14465
sS'coagulation,time,within'
p14466
(F1
F0.00014334862385321102
I1
I0
I1
tp14467
sS'by,the,kidneys'
p14468
(F1
F0.00014334862385321102
I0
I1
I-1
tp14469
sS'toxicity,of,is'
p14470
(F1
F0.00014334862385321102
I1
I0
I1
tp14471
sS'test,monitoring,during'
p14472
(F1
F0.00014334862385321102
I0
I1
I-1
tp14473
sS'drug,metabolizing,enzymes'
p14474
(F1
F0.00014334862385321102
I0
I1
I-1
tp14475
sS'studied,in,six'
p14476
(F1
F0.00014334862385321102
I0
I1
I-1
tp14477
sS'activated,in,patients'
p14478
(F1
F0.00014334862385321102
I1
I0
I1
tp14479
sS'mg,of,as'
p14480
(F1
F0.00014334862385321102
I0
I1
I-1
tp14481
sS'valdecoxib,mg,bid'
p14482
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp14483
sS'antidiabetics,because,may'
p14484
(F1
F0.00014334862385321102
I1
I0
I1
tp14485
sS'arise,from,co-administration'
p14486
(F1
F0.00014334862385321102
I1
I0
I1
tp14487
sS'additional,that,should'
p14488
(F1
F0.00014334862385321102
I1
I0
I1
tp14489
sS'with,supplements,may'
p14490
(F1
F0.00014334862385321102
I0
I1
I-1
tp14491
sS'deficiencies,by,simply'
p14492
(F1
F0.00014334862385321102
I0
I1
I-1
tp14493
sS'of,the,qrs'
p14494
(F1
F0.00014334862385321102
I1
I0
I1
tp14495
sS'pivoxil,had,no'
p14496
(F1
F0.00014334862385321102
I0
I1
I-1
tp14497
sS'these,are,incompatible'
p14498
(F1
F0.00014334862385321102
I0
I1
I-1
tp14499
sS'studies,indicate,that'
p14500
(F0.090909090909090912
F0.00014334862385321102
I6
I5
I1
tp14501
sS'occur,when,is'
p14502
(F1
F0.00014334862385321102
I1
I0
I1
tp14503
sS'aucs,m,min'
p14504
(F1
F0.00014334862385321102
I1
I0
I1
tp14505
sS'effects,in,patients'
p14506
(F1
F0.00028669724770642203
I2
I0
I2
tp14507
sS'concomitant,therapies,in'
p14508
(F1
F0.00014334862385321102
I0
I1
I-1
tp14509
sS'receptors,sodium,channels'
p14510
(F1
F0.00014334862385321102
I0
I1
I-1
tp14511
sS'by,non-steroidal,antiinflammatory'
p14512
(F1
F0.00014334862385321102
I1
I0
I1
tp14513
sS'treatment,with,imidazole'
p14514
(F1
F0.00014334862385321102
I1
I0
I1
tp14515
sS'appropriate,adjustment,to'
p14516
(F1
F0.00014334862385321102
I0
I1
I-1
tp14517
sS'number,of,blood'
p14518
(F1
F0.00014334862385321102
I1
I0
I1
tp14519
sS'vitro,at,clinically'
p14520
(F1
F0.00014334862385321102
I0
I1
I-1
tp14521
sS'shortly,after,starting'
p14522
(F1
F0.00014334862385321102
I0
I1
I-1
tp14523
sS'decreased,by,when'
p14524
(F1
F0.00028669724770642203
I2
I0
I2
tp14525
sS'phenurone,since,paranoid'
p14526
(F1
F0.00014334862385321102
I1
I0
I1
tp14527
sS'between,and,acetylsalicylic'
p14528
(F1
F0.00014334862385321102
I0
I1
I-1
tp14529
sS'declining,to,about'
p14530
(F1
F0.00014334862385321102
I0
I1
I-1
tp14531
sS'given,to,temporarily'
p14532
(F1
F0.00014334862385321102
I1
I0
I1
tp14533
sS'in,cyp3a4,mediated'
p14534
(F1
F0.00014334862385321102
I0
I1
I-1
tp14535
sS'dose,studies,in'
p14536
(F1
F0.00014334862385321102
I1
I0
I1
tp14537
sS'blocking,agent,and'
p14538
(F1
F0.00014334862385321102
I1
I0
I1
tp14539
sS'prior,to,and'
p14540
(F1
F0.00028669724770642203
I0
I2
I-2
tp14541
sS'of,on,resistance'
p14542
(F1
F0.00014334862385321102
I0
I1
I-1
tp14543
sS'an,approximately,increase'
p14544
(F1
F0.00014334862385321102
I1
I0
I1
tp14545
sS'metabolism,and,higher'
p14546
(F1
F0.00014334862385321102
I1
I0
I1
tp14547
sS'arthritis,patients,taking'
p14548
(F1
F0.00028669724770642203
I0
I2
I-2
tp14549
sS'third,of,the'
p14550
(F1
F0.00014334862385321102
I1
I0
I1
tp14551
sS'in,serum,reverse'
p14552
(F1
F0.00014334862385321102
I0
I1
I-1
tp14553
sS'prior,to,any'
p14554
(F1
F0.00014334862385321102
I0
I1
I-1
tp14555
sS'depen,cuprimine,another'
p14556
(F1
F0.00014334862385321102
I1
I0
I1
tp14557
sS'h2,blockers,or'
p14558
(F1
F0.00043004587155963305
I3
I0
I3
tp14559
sS'with,nonsteroidal,agents'
p14560
(F1
F0.00014334862385321102
I1
I0
I1
tp14561
sS'unaffected,by,adl'
p14562
(F1
F0.00014334862385321102
I0
I1
I-1
tp14563
sS'azole,antifungal,agents'
p14564
(F1
F0.00014334862385321102
I1
I0
I1
tp14565
sS'pharmacodynamic,effects,prothrombin'
p14566
(F1
F0.00014334862385321102
I1
I0
I1
tp14567
sS'of,cancidas,are'
p14568
(F1
F0.00014334862385321102
I0
I1
I-1
tp14569
sS'may,produce,an'
p14570
(F1
F0.00014334862385321102
I1
I0
I1
tp14571
sS'interaction,of,and'
p14572
(F0.5
F0.00028669724770642203
I3
I1
I2
tp14573
sS'dose,decrease,for'
p14574
(F1
F0.00014334862385321102
I1
I0
I1
tp14575
sS'family,in,metabolism'
p14576
(F1
F0.00014334862385321102
I1
I0
I1
tp14577
sS'administration,of,a'
p14578
(F0.33333333333333331
F0.0008600917431192661
I12
I6
I6
tp14579
sS'administration,of,g'
p14580
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp14581
sS'robinul,injection,with'
p14582
(F1
F0.00014334862385321102
I1
I0
I1
tp14583
sS'rofecoxib,did,not'
p14584
(F1
F0.00043004587155963305
I0
I3
I-3
tp14585
sS'attributed,at,least'
p14586
(F1
F0.00014334862385321102
I1
I0
I1
tp14587
sS'rettgeri,were,resistant'
p14588
(F1
F0.00014334862385321102
I0
I1
I-1
tp14589
sS'any,known,cyp3a4'
p14590
(F1
F0.00028669724770642203
I2
I0
I2
tp14591
sS'attenuates,certain,types'
p14592
(F1
F0.00014334862385321102
I1
I0
I1
tp14593
sS'to,moderate,hypertension'
p14594
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp14595
sS'received,muscle,relaxants'
p14596
(F1
F0.00014334862385321102
I1
I0
I1
tp14597
sS'cyp2d6,resulted,in'
p14598
(F1
F0.00014334862385321102
I1
I0
I1
tp14599
sS'it,was,found'
p14600
(F1
F0.00014334862385321102
I1
I0
I1
tp14601
sS'in,treatment,practices'
p14602
(F1
F0.00014334862385321102
I0
I1
I-1
tp14603
sS'therapy,is,initiated'
p14604
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp14605
sS'methods,clinical,studies'
p14606
(F1
F0.00014334862385321102
I0
I1
I-1
tp14607
sS'coadministration,n,of'
p14608
(F1
F0.00014334862385321102
I1
I0
I1
tp14609
sS'beyond,the,therapeutic'
p14610
(F1
F0.00014334862385321102
I1
I0
I1
tp14611
sS'indicated,by,its'
p14612
(F1
F0.00014334862385321102
I1
I0
I1
tp14613
sS'reduction,in,dose'
p14614
(F1
F0.00014334862385321102
I1
I0
I1
tp14615
sS'absorption,of,oral'
p14616
(F1
F0.00028669724770642203
I2
I0
I2
tp14617
sS'mean,change,of'
p14618
(F1
F0.00014334862385321102
I1
I0
I1
tp14619
sS'because,renal,excretion'
p14620
(F1
F0.00014334862385321102
I1
I0
I1
tp14621
sS'containing,sequential,high'
p14622
(F1
F0.00014334862385321102
I1
I0
I1
tp14623
sS'were,increased,about'
p14624
(F1
F0.00028669724770642203
I2
I0
I2
tp14625
sS'psychotropic,medications,and'
p14626
(F1
F0.00014334862385321102
I1
I0
I1
tp14627
sS'lack,of,platelet'
p14628
(F1
F0.00028669724770642203
I0
I2
I-2
tp14629
sS'to,p450-based,metabolic'
p14630
(F1
F0.00014334862385321102
I0
I1
I-1
tp14631
sS'markedly,inhibit,the'
p14632
(F1
F0.00043004587155963305
I3
I0
I3
tp14633
sS'undergo,renal,tubular'
p14634
(F1
F0.00014334862385321102
I0
I1
I-1
tp14635
sS'for,kappa,and'
p14636
(F1
F0.00014334862385321102
I0
I1
I-1
tp14637
sS'purinethol,or,imuran'
p14638
(F1
F0.00014334862385321102
I1
I0
I1
tp14639
sS'concentrations,at,the'
p14640
(F1
F0.00014334862385321102
I0
I1
I-1
tp14641
sS'prothrombin,time,have'
p14642
(F1
F0.00028669724770642203
I2
I0
I2
tp14643
sS'tests,benedicts,solution'
p14644
(F1
F0.00014334862385321102
I0
I1
I-1
tp14645
sS'l-type,omega-conotoxin,gvia'
p14646
(F1
F0.00014334862385321102
I0
I1
I-1
tp14647
sS'receiving,or,should'
p14648
(F1
F0.00014334862385321102
I0
I1
I-1
tp14649
sS'of,which,are'
p14650
(F1
F0.00028669724770642203
I2
I0
I2
tp14651
sS'fistulas,were,carried'
p14652
(F1
F0.00014334862385321102
I0
I1
I-1
tp14653
sS'to,or,slightly'
p14654
(F1
F0.00014334862385321102
I1
I0
I1
tp14655
sS'and,mg,separated'
p14656
(F1
F0.00014334862385321102
I1
I0
I1
tp14657
sS'therapeutic,doses,had'
p14658
(F1
F0.00014334862385321102
I1
I0
I1
tp14659
sS'with,a,number'
p14660
(F1
F0.00014334862385321102
I1
I0
I1
tp14661
sS'pharmacokinetic,and,pharmacodynamic'
p14662
(F1
F0.00014334862385321102
I0
I1
I-1
tp14663
sS'serum,hormone,levels'
p14664
(F1
F0.00014334862385321102
I0
I1
I-1
tp14665
sS'depressants,or,inhibitors'
p14666
(F1
F0.00014334862385321102
I1
I0
I1
tp14667
sS'increase,in,fdf'
p14668
(F1
F0.00043004587155963305
I3
I0
I3
tp14669
sS'their,selective,ca'
p14670
(F1
F0.00014334862385321102
I0
I1
I-1
tp14671
sS'mg,capsule,with'
p14672
(F1
F0.00014334862385321102
I1
I0
I1
tp14673
sS'blocking,agents,concurrent'
p14674
(F1
F0.00014334862385321102
I0
I1
I-1
tp14675
sS'slowly,dissolving,dosage'
p14676
(F1
F0.00014334862385321102
I1
I0
I1
tp14677
sS'effects,of,antacids'
p14678
(F1
F0.00014334862385321102
I0
I1
I-1
tp14679
sS'serum,proteins,the'
p14680
(F1
F0.00014334862385321102
I1
I0
I1
tp14681
sS'taking,and,concomitantly'
p14682
(F1
F0.00028669724770642203
I2
I0
I2
tp14683
sS'the,onset,of'
p14684
(F1
F0.00014334862385321102
I1
I0
I1
tp14685
sS'patients,before,the'
p14686
(F1
F0.00014334862385321102
I0
I1
I-1
tp14687
sS'catabolic,enzymes,of'
p14688
(F1
F0.00043004587155963305
I3
I0
I3
tp14689
sS'hmgcoa,reductase,inhibitors'
p14690
(F1
F0.00014334862385321102
I0
I1
I-1
tp14691
sS'an,with,beta-lactamtype'
p14692
(F1
F0.00014334862385321102
I1
I0
I1
tp14693
sS'in,ephesus,patients'
p14694
(F1
F0.00014334862385321102
I0
I1
I-1
tp14695
sS'i,sodium,pertechnetate'
p14696
(F1
F0.00014334862385321102
I0
I1
I-1
tp14697
sS'after,administration,of'
p14698
(F0
F0
I2
I2
I0
tp14699
sS'vitro,studies,have'
p14700
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp14701
sS'channel,antagonists,a'
p14702
(F1
F0.00014334862385321102
I0
I1
I-1
tp14703
sS'dexamethasone,had,a'
p14704
(F1
F0.00014334862385321102
I0
I1
I-1
tp14705
sS'therapy,who,have'
p14706
(F1
F0.00014334862385321102
I1
I0
I1
tp14707
sS'which,includes,anafranil'
p14708
(F1
F0.00014334862385321102
I0
I1
I-1
tp14709
sS'other,tnfa-blocking,agents'
p14710
(F1
F0.00014334862385321102
I1
I0
I1
tp14711
sS'studies,have,shown'
p14712
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp14713
sS'days,with,the'
p14714
(F1
F0.00014334862385321102
I1
I0
I1
tp14715
sS'cmax,and,auc'
p14716
(F0.73333333333333328
F0.0015768348623853212
I13
I2
I11
tp14717
sS'the,mptp-induced,neuronal'
p14718
(F1
F0.00014334862385321102
I1
I0
I1
tp14719
sS'intake,approximately,one'
p14720
(F1
F0.00014334862385321102
I1
I0
I1
tp14721
sS'been,studied,increased'
p14722
(F1
F0.00014334862385321102
I1
I0
I1
tp14723
sS'felbatol,at,steady'
p14724
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp14725
sS'of,ergomar,and'
p14726
(F1
F0.00014334862385321102
I1
I0
I1
tp14727
sS'volunteers,treatment,potentiated'
p14728
(F1
F0.00014334862385321102
I1
I0
I1
tp14729
sS'an,anion,exchange'
p14730
(F1
F0.00014334862385321102
I0
I1
I-1
tp14731
sS'the,ingested,being'
p14732
(F1
F0.00014334862385321102
I1
I0
I1
tp14733
sS'a,controlled,study'
p14734
(F1
F0.00014334862385321102
I1
I0
I1
tp14735
sS'mg,oral,twice'
p14736
(F1
F0.00014334862385321102
I1
I0
I1
tp14737
sS'as,inderal,tenormin'
p14738
(F1
F0.00014334862385321102
I0
I1
I-1
tp14739
sS'infusion,pumps,for'
p14740
(F1
F0.00014334862385321102
I0
I1
I-1
tp14741
sS'of,m,or'
p14742
(F1
F0.00014334862385321102
I1
I0
I1
tp14743
sS'co-administration,of,trileptal'
p14744
(F1
F0.00028669724770642203
I2
I0
I2
tp14745
sS'it,had,no'
p14746
(F0
F0
I1
I1
I0
tp14747
sS'therefore,dose,adjustments'
p14748
(F1
F0.00014334862385321102
I0
I1
I-1
tp14749
sS'following,the,concomitant'
p14750
(F1
F0.00014334862385321102
I0
I1
I-1
tp14751
sS'metabolism,of,warfarin-type'
p14752
(F1
F0.00014334862385321102
I1
I0
I1
tp14753
sS'evidence,of,interactions'
p14754
(F1
F0.00028669724770642203
I0
I2
I-2
tp14755
sS'serum,levels,have'
p14756
(F1
F0.00014334862385321102
I1
I0
I1
tp14757
sS'interactions,oral,contraceptives'
p14758
(F1
F0.00014334862385321102
I0
I1
I-1
tp14759
sS'combination,with,may'
p14760
(F0
F0
I1
I1
I0
tp14761
sS'patients,receiving,a'
p14762
(F1
F0.00014334862385321102
I0
I1
I-1
tp14763
sS'of,should,be'
p14764
(F0
F0
I4
I4
I0
tp14765
sS'nsaids,antigout,oral'
p14766
(F1
F0.00014334862385321102
I0
I1
I-1
tp14767
sS'patients,without,a'
p14768
(F1
F0.00014334862385321102
I1
I0
I1
tp14769
sS'with,demonstrated,efficacy'
p14770
(F1
F0.00014334862385321102
I0
I1
I-1
tp14771
sS'recommended,when,used'
p14772
(F1
F0.00014334862385321102
I1
I0
I1
tp14773
sS'the,appropriate,package'
p14774
(F1
F0.00014334862385321102
I0
I1
I-1
tp14775
sS'of,hoof,twitch'
p14776
(F1
F0.00014334862385321102
I1
I0
I1
tp14777
sS'of,consciousness,when'
p14778
(F1
F0.00014334862385321102
I1
I0
I1
tp14779
sS'in,clearance,when'
p14780
(F1
F0.00014334862385321102
I1
I0
I1
tp14781
sS'with,in,all'
p14782
(F1
F0.00014334862385321102
I0
I1
I-1
tp14783
sS'epoxide,which,is'
p14784
(F1
F0.00014334862385321102
I0
I1
I-1
tp14785
sS'including,certain,tcas'
p14786
(F1
F0.00014334862385321102
I1
I0
I1
tp14787
sS'is,no,effect'
p14788
(F1
F0.00014334862385321102
I1
I0
I1
tp14789
sS'quantities,of,systemically'
p14790
(F1
F0.00014334862385321102
I0
I1
I-1
tp14791
sS'cyp3a4,pathway,showed'
p14792
(F1
F0.00014334862385321102
I1
I0
I1
tp14793
sS'loop,potassium-,sparing'
p14794
(F1
F0.00014334862385321102
I1
I0
I1
tp14795
sS'cardiac,dysrhythmias,and'
p14796
(F1
F0.00014334862385321102
I1
I0
I1
tp14797
sS'both,lower,blood'
p14798
(F1
F0.00014334862385321102
I1
I0
I1
tp14799
sS'required,and,increased'
p14800
(F1
F0.00014334862385321102
I0
I1
I-1
tp14801
sS'gleevec,increases,the'
p14802
(F1
F0.00014334862385321102
I1
I0
I1
tp14803
sS'effects,of,veratrum'
p14804
(F1
F0.00014334862385321102
I1
I0
I1
tp14805
sS'regardless,of,whether'
p14806
(F1
F0.00014334862385321102
I1
I0
I1
tp14807
sS'felodipine,is,metabolized'
p14808
(F1
F0.00014334862385321102
I0
I1
I-1
tp14809
sS'and,for,hydroxy-iso'
p14810
(F1
F0.00014334862385321102
I1
I0
I1
tp14811
sS'tool,for,diagnosis'
p14812
(F1
F0.00014334862385321102
I0
I1
I-1
tp14813
sS'produced,no,pharmacokinetic'
p14814
(F1
F0.00014334862385321102
I0
I1
I-1
tp14815
sS'viracept,and,should'
p14816
(F1
F0.00014334862385321102
I1
I0
I1
tp14817
sS'studied,in,a'
p14818
(F1
F0.00028669724770642203
I0
I2
I-2
tp14819
sS'for,free,cmin'
p14820
(F1
F0.00014334862385321102
I0
I1
I-1
tp14821
sS'be,observed,to'
p14822
(F1
F0.00014334862385321102
I1
I0
I1
tp14823
sS'the,sum,of'
p14824
(F1
F0.00014334862385321102
I0
I1
I-1
tp14825
sS'other,drugs,on'
p14826
(F1
F0.00028669724770642203
I0
I2
I-2
tp14827
sS'concomitant,therapy,or'
p14828
(F1
F0.00014334862385321102
I0
I1
I-1
tp14829
sS'exercised,when,administering'
p14830
(F1
F0.00043004587155963305
I3
I0
I3
tp14831
sS'a,recent,study'
p14832
(F1
F0.00014334862385321102
I1
I0
I1
tp14833
sS'decrease,glutathione,levels'
p14834
(F1
F0.00014334862385321102
I1
I0
I1
tp14835
sS'concomitant,therapy,of'
p14836
(F1
F0.00014334862385321102
I1
I0
I1
tp14837
sS'assess,if,there'
p14838
(F1
F0.00028669724770642203
I0
I2
I-2
tp14839
sS'component,of,the'
p14840
(F1
F0.00014334862385321102
I1
I0
I1
tp14841
sS'a,non-,steroidal'
p14842
(F1
F0.00014334862385321102
I1
I0
I1
tp14843
sS'substudy,in,patients'
p14844
(F1
F0.00014334862385321102
I1
I0
I1
tp14845
sS'culture,and,animal'
p14846
(F1
F0.00014334862385321102
I1
I0
I1
tp14847
sS'by,in,combination'
p14848
(F1
F0.00014334862385321102
I0
I1
I-1
tp14849
sS'pretreatment,on,the'
p14850
(F1
F0.00014334862385321102
I0
I1
I-1
tp14851
sS'effect,could,be'
p14852
(F1
F0.00028669724770642203
I2
I0
I2
tp14853
sS'produce,severe,bronchospasm'
p14854
(F1
F0.00014334862385321102
I1
I0
I1
tp14855
sS'xigris,present,in'
p14856
(F1
F0.00014334862385321102
I0
I1
I-1
tp14857
sS'of,these,three'
p14858
(F1
F0.00014334862385321102
I1
I0
I1
tp14859
sS'rats,in,vivo'
p14860
(F1
F0.00014334862385321102
I0
I1
I-1
tp14861
sS'propecia,mg,in'
p14862
(F1
F0.00014334862385321102
I0
I1
I-1
tp14863
sS'efficacy,over,use'
p14864
(F1
F0.00014334862385321102
I1
I0
I1
tp14865
sS'of,toradol,oral'
p14866
(F1
F0.00014334862385321102
I1
I0
I1
tp14867
sS'with,and,a'
p14868
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp14869
sS'if,the,potential'
p14870
(F1
F0.00014334862385321102
I1
I0
I1
tp14871
sS'a,decreased,renal'
p14872
(F1
F0.00014334862385321102
I1
I0
I1
tp14873
sS'romazicon,was,administered'
p14874
(F1
F0.00014334862385321102
I0
I1
I-1
tp14875
sS'determined,after,a'
p14876
(F1
F0.00014334862385321102
I0
I1
I-1
tp14877
sS'subjects,given,single'
p14878
(F1
F0.00014334862385321102
I1
I0
I1
tp14879
sS'much,in,the'
p14880
(F0
F0
I1
I1
I0
tp14881
sS'and,therefore,potentially'
p14882
(F1
F0.00014334862385321102
I1
I0
I1
tp14883
sS'in,zaleplons,maximal'
p14884
(F1
F0.00014334862385321102
I1
I0
I1
tp14885
sS'anticonvulsants,increase,the'
p14886
(F1
F0.00014334862385321102
I1
I0
I1
tp14887
sS'plasma,levels,occurred'
p14888
(F1
F0.00014334862385321102
I1
I0
I1
tp14889
sS'methotrexate,caution,should'
p14890
(F1
F0.00014334862385321102
I1
I0
I1
tp14891
sS'and,confusional,states'
p14892
(F1
F0.00014334862385321102
I1
I0
I1
tp14893
sS'auc,vs,cmax'
p14894
(F1
F0.00014334862385321102
I0
I1
I-1
tp14895
sS'salicylic,acid,combination'
p14896
(F1
F0.00014334862385321102
I1
I0
I1
tp14897
sS'inhibition,induced,by'
p14898
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp14899
sS'be,additive,effects'
p14900
(F1
F0.00014334862385321102
I1
I0
I1
tp14901
sS'commonly,used,such'
p14902
(F1
F0.00014334862385321102
I0
I1
I-1
tp14903
sS'or,bind,the'
p14904
(F1
F0.00014334862385321102
I1
I0
I1
tp14905
sS'cardiopulmonary,arrest,with'
p14906
(F1
F0.00014334862385321102
I0
I1
I-1
tp14907
sS'forms,of,fat-soluble'
p14908
(F1
F0.00014334862385321102
I0
I1
I-1
tp14909
sS'iii,human,in'
p14910
(F1
F0.00014334862385321102
I1
I0
I1
tp14911
sS'excretion,but,is'
p14912
(F1
F0.00014334862385321102
I1
I0
I1
tp14913
sS'may,reduce,the'
p14914
(F0.72727272727272729
F0.0022935779816513763
I19
I3
I16
tp14915
sS'for,the,development'
p14916
(F1
F0.00014334862385321102
I0
I1
I-1
tp14917
sS'cardiac,dysrhythmias,of'
p14918
(F1
F0.00014334862385321102
I1
I0
I1
tp14919
sS'to,treatment,with'
p14920
(F1
F0.00014334862385321102
I0
I1
I-1
tp14921
sS'occurrence,has,not'
p14922
(F1
F0.00014334862385321102
I1
I0
I1
tp14923
sS'to,avoid,bleeding'
p14924
(F1
F0.00014334862385321102
I1
I0
I1
tp14925
sS'have,used,in'
p14926
(F1
F0.00014334862385321102
I0
I1
I-1
tp14927
sS'of,two,mg'
p14928
(F1
F0.00028669724770642203
I0
I2
I-2
tp14929
sS'be,determined,prior'
p14930
(F1
F0.00014334862385321102
I1
I0
I1
tp14931
sS'modification,of,a'
p14932
(F1
F0.00014334862385321102
I0
I1
I-1
tp14933
sS'and,decrease,mean'
p14934
(F1
F0.00014334862385321102
I0
I1
I-1
tp14935
sS'a,known,metabolite'
p14936
(F1
F0.00014334862385321102
I0
I1
I-1
tp14937
sS'may,provoke,toxicity'
p14938
(F1
F0.00014334862385321102
I0
I1
I-1
tp14939
sS'vardenafil,dose,in'
p14940
(F1
F0.00028669724770642203
I2
I0
I2
tp14941
sS'close,monitoring,of'
p14942
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp14943
sS'taken,into,account'
p14944
(F1
F0.00014334862385321102
I1
I0
I1
tp14945
sS'be,administered,concomitantly'
p14946
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp14947
sS'presentation,of,a'
p14948
(F1
F0.00014334862385321102
I1
I0
I1
tp14949
sS'combination,of,amphotericin'
p14950
(F1
F0.00014334862385321102
I1
I0
I1
tp14951
sS'and,decreased,hearing'
p14952
(F1
F0.00014334862385321102
I1
I0
I1
tp14953
sS'double-blind,fashion,to'
p14954
(F1
F0.00014334862385321102
I0
I1
I-1
tp14955
sS'towards,the,major'
p14956
(F1
F0.00014334862385321102
I0
I1
I-1
tp14957
sS'other,published,reports'
p14958
(F1
F0.00014334862385321102
I1
I0
I1
tp14959
sS'by,therapy,with'
p14960
(F1
F0.00014334862385321102
I1
I0
I1
tp14961
sS'fat,soluble,such'
p14962
(F1
F0.00014334862385321102
I0
I1
I-1
tp14963
sS'a,higher,serum'
p14964
(F1
F0.00014334862385321102
I1
I0
I1
tp14965
sS'of,these,on'
p14966
(F1
F0.00014334862385321102
I0
I1
I-1
tp14967
sS'coenzyme,a,hmgcoa'
p14968
(F1
F0.00014334862385321102
I0
I1
I-1
tp14969
sS'and,twice-a,day'
p14970
(F1
F0.00014334862385321102
I0
I1
I-1
tp14971
sS'taken,in,conjunction'
p14972
(F1
F0.00014334862385321102
I0
I1
I-1
tp14973
sS'to,this,pharmacological'
p14974
(F1
F0.00014334862385321102
I1
I0
I1
tp14975
sS'a,potential,inhibitor'
p14976
(F1
F0.00014334862385321102
I1
I0
I1
tp14977
sS'enzyme,inducer,or'
p14978
(F1
F0.00014334862385321102
I1
I0
I1
tp14979
sS'direct,pharmacokinetic,captopril-digoxin'
p14980
(F1
F0.00014334862385321102
I0
I1
I-1
tp14981
sS'although,the,pressor'
p14982
(F1
F0.00014334862385321102
I0
I1
I-1
tp14983
sS'acid,and,showed'
p14984
(F1
F0.00014334862385321102
I0
I1
I-1
tp14985
sS'block,angiotensin,ii'
p14986
(F1
F0.00014334862385321102
I0
I1
I-1
tp14987
sS'the,enzymatic,oxidation'
p14988
(F1
F0.00014334862385321102
I1
I0
I1
tp14989
sS'whom,cyp3a4,inducers'
p14990
(F1
F0.00014334862385321102
I0
I1
I-1
tp14991
sS'investigated,as,one'
p14992
(F1
F0.00014334862385321102
I0
I1
I-1
tp14993
sS'orally,has,not'
p14994
(F1
F0.00014334862385321102
I0
I1
I-1
tp14995
sS'the,cardiovascular,system'
p14996
(F1
F0.00043004587155963305
I3
I0
I3
tp14997
sS'highly,bound,such'
p14998
(F1
F0.00014334862385321102
I0
I1
I-1
tp14999
sS'involving,adult,volunteers'
p15000
(F1
F0.00014334862385321102
I0
I1
I-1
tp15001
sS'gastroduodenal,ulcers,in'
p15002
(F1
F0.00014334862385321102
I0
I1
I-1
tp15003
sS'it,is,unlikely'
p15004
(F1
F0.00057339449541284407
I0
I4
I-4
tp15005
sS'agents,such,a'
p15006
(F1
F0.00014334862385321102
I1
I0
I1
tp15007
sS'gaba-ergic,system,and'
p15008
(F1
F0.00014334862385321102
I1
I0
I1
tp15009
sS'in,serum,level'
p15010
(F1
F0.00028669724770642203
I2
I0
I2
tp15011
sS'show,potential,for'
p15012
(F1
F0.00014334862385321102
I0
I1
I-1
tp15013
sS'not,be,used'
p15014
(F0.73913043478260865
F0.0024369266055045873
I20
I3
I17
tp15015
sS'data,show,that'
p15016
(F1
F0.00014334862385321102
I1
I0
I1
tp15017
sS'concentration,of,novolog'
p15018
(F1
F0.00014334862385321102
I0
I1
I-1
tp15019
sS'mm,had,no'
p15020
(F1
F0.00014334862385321102
I0
I1
I-1
tp15021
sS'such,as,are'
p15022
(F1
F0.00057339449541284407
I4
I0
I4
tp15023
sS'in,vivo,animal'
p15024
(F1
F0.00014334862385321102
I1
I0
I1
tp15025
sS'concomitantly,with,a'
p15026
(F0.5
F0.00028669724770642203
I3
I1
I2
tp15027
sS'concentration,mean,change'
p15028
(F1
F0.00028669724770642203
I0
I2
I-2
tp15029
sS'hypoglycemic,agents,should'
p15030
(F1
F0.00014334862385321102
I1
I0
I1
tp15031
sS'withdrawal,syndrome,in'
p15032
(F1
F0.00014334862385321102
I1
I0
I1
tp15033
sS'beta,blockers,cardiac'
p15034
(F1
F0.00014334862385321102
I0
I1
I-1
tp15035
sS'when,is,withdrawn'
p15036
(F1
F0.00014334862385321102
I1
I0
I1
tp15037
sS'studies,using,human'
p15038
(F1
F0.00014334862385321102
I0
I1
I-1
tp15039
sS'and,are,ge'
p15040
(F1
F0.00014334862385321102
I0
I1
I-1
tp15041
sS'body,clearance,of'
p15042
(F1
F0.00043004587155963305
I3
I0
I3
tp15043
sS'life-,threatening,cardiac'
p15044
(F1
F0.00014334862385321102
I1
I0
I1
tp15045
sS'levels,and,urinary'
p15046
(F1
F0.00014334862385321102
I1
I0
I1
tp15047
sS'of,a,group'
p15048
(F1
F0.00014334862385321102
I0
I1
I-1
tp15049
sS'to,establish,a'
p15050
(F1
F0.00014334862385321102
I1
I0
I1
tp15051
sS'of,these,agents'
p15052
(F0.5
F0.00028669724770642203
I3
I1
I2
tp15053
sS'of,preparations,such'
p15054
(F1
F0.00014334862385321102
I1
I0
I1
tp15055
sS'bioavailability,of,unbound'
p15056
(F1
F0.00014334862385321102
I0
I1
I-1
tp15057
sS'treatment,of,four'
p15058
(F1
F0.00014334862385321102
I1
I0
I1
tp15059
sS'are,summarized,in'
p15060
(F1
F0.00014334862385321102
I0
I1
I-1
tp15061
sS'mg,tid,were'
p15062
(F1
F0.00014334862385321102
I0
I1
I-1
tp15063
sS'doses,of,hydrochloride'
p15064
(F1
F0.00014334862385321102
I1
I0
I1
tp15065
sS'administration,of,potentially'
p15066
(F1
F0.00014334862385321102
I1
I0
I1
tp15067
sS'sumatriptan,and,d'
p15068
(F1
F0.00014334862385321102
I1
I0
I1
tp15069
sS'diet,high,in'
p15070
(F1
F0.00014334862385321102
I1
I0
I1
tp15071
sS'an,organophosphorous,compound'
p15072
(F1
F0.00014334862385321102
I0
I1
I-1
tp15073
sS'with,the,coadministration'
p15074
(F1
F0.00028669724770642203
I0
I2
I-2
tp15075
sS'mg,daily,as'
p15076
(F0
F0
I1
I1
I0
tp15077
sS'studies,with,dynacirc'
p15078
(F1
F0.00014334862385321102
I0
I1
I-1
tp15079
sS'was,not,inhibitory'
p15080
(F1
F0.00014334862385321102
I0
I1
I-1
tp15081
sS'result,in,additive'
p15082
(F1
F0.00043004587155963305
I3
I0
I3
tp15083
sS'day,and,at'
p15084
(F1
F0.00028669724770642203
I2
I0
I2
tp15085
sS'and,to,healthy'
p15086
(F1
F0.00043004587155963305
I0
I3
I-3
tp15087
sS'with,the,levulan'
p15088
(F1
F0.00014334862385321102
I1
I0
I1
tp15089
sS'been,little,experience'
p15090
(F1
F0.00014334862385321102
I0
I1
I-1
tp15091
sS'strong,in,vitro'
p15092
(F1
F0.00014334862385321102
I0
I1
I-1
tp15093
sS'among,patients,on'
p15094
(F1
F0.00014334862385321102
I0
I1
I-1
tp15095
sS'decrease,in,clearance'
p15096
(F1
F0.00043004587155963305
I3
I0
I3
tp15097
sS'mg,daily,was'
p15098
(F1
F0.00014334862385321102
I0
I1
I-1
tp15099
sS'that,undergo,enterohepatic'
p15100
(F1
F0.00014334862385321102
I1
I0
I1
tp15101
sS'any,other,that'
p15102
(F1
F0.00014334862385321102
I0
I1
I-1
tp15103
sS'administered,shortly,after'
p15104
(F0
F0
I1
I1
I0
tp15105
sS'already,receiving,n'
p15106
(F1
F0.00014334862385321102
I0
I1
I-1
tp15107
sS'produce,a,stimulating'
p15108
(F1
F0.00014334862385321102
I1
I0
I1
tp15109
sS'tbg,concentrations,are'
p15110
(F1
F0.00014334862385321102
I0
I1
I-1
tp15111
sS'vaccine,inhalation,mefenamic'
p15112
(F1
F0.00014334862385321102
I1
I0
I1
tp15113
sS'in,the,free'
p15114
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp15115
sS'indomethacin,was,also'
p15116
(F1
F0.00014334862385321102
I0
I1
I-1
tp15117
sS'patients,is,advised'
p15118
(F1
F0.00014334862385321102
I0
I1
I-1
tp15119
sS'chronic,concurrent,administration'
p15120
(F1
F0.00014334862385321102
I1
I0
I1
tp15121
sS'coumarin,anticoagulants,are'
p15122
(F1
F0.00014334862385321102
I1
I0
I1
tp15123
sS'positive,urine,test'
p15124
(F1
F0.00014334862385321102
I0
I1
I-1
tp15125
sS'placental,vessels,was'
p15126
(F1
F0.00014334862385321102
I0
I1
I-1
tp15127
sS'analyses,revealed,that'
p15128
(F1
F0.00014334862385321102
I0
I1
I-1
tp15129
sS'monitored,particularly,in'
p15130
(F1
F0.00014334862385321102
I1
I0
I1
tp15131
sS'dose,modifying,factors'
p15132
(F1
F0.00014334862385321102
I1
I0
I1
tp15133
sS'regimen,of,a'
p15134
(F1
F0.00014334862385321102
I1
I0
I1
tp15135
sS'decreased,with,and'
p15136
(F1
F0.00014334862385321102
I1
I0
I1
tp15137
sS'naflu,to,and'
p15138
(F1
F0.00014334862385321102
I0
I1
I-1
tp15139
sS'however,pharmacokinetic,studies'
p15140
(F1
F0.00014334862385321102
I0
I1
I-1
tp15141
sS'with,short,s'
p15142
(F1
F0.00014334862385321102
I0
I1
I-1
tp15143
sS'effect,has,been'
p15144
(F1
F0.00014334862385321102
I1
I0
I1
tp15145
sS'ethosuximide,amphetamines,may'
p15146
(F1
F0.00028669724770642203
I2
I0
I2
tp15147
sS'co-administered,with,either'
p15148
(F1
F0.00014334862385321102
I0
I1
I-1
tp15149
sS'to,ng,x'
p15150
(F1
F0.00014334862385321102
I1
I0
I1
tp15151
sS'short-acting,such,as'
p15152
(F1
F0.00014334862385321102
I0
I1
I-1
tp15153
sS'substrate,for,cyp2d6'
p15154
(F1
F0.00014334862385321102
I1
I0
I1
tp15155
sS'iatrogenic,alteration,caused'
p15156
(F1
F0.00014334862385321102
I0
I1
I-1
tp15157
sS'be,followed,and'
p15158
(F1
F0.00014334862385321102
I0
I1
I-1
tp15159
sS'of,mixed-function,mono-oxidases'
p15160
(F1
F0.00014334862385321102
I0
I1
I-1
tp15161
sS'in,this,formal'
p15162
(F1
F0.00014334862385321102
I0
I1
I-1
tp15163
sS'on,the,duration'
p15164
(F1
F0.00057339449541284407
I0
I4
I-4
tp15165
sS'how,safe,sexual'
p15166
(F1
F0.00014334862385321102
I0
I1
I-1
tp15167
sS'did,augment,the'
p15168
(F1
F0.00014334862385321102
I1
I0
I1
tp15169
sS'a,first-line,option'
p15170
(F1
F0.00014334862385321102
I0
I1
I-1
tp15171
sS'mg,of,sodium'
p15172
(F1
F0.00014334862385321102
I1
I0
I1
tp15173
sS'diabetes,medicine,you'
p15174
(F1
F0.00014334862385321102
I1
I0
I1
tp15175
sS'occurred,in,heart'
p15176
(F1
F0.00014334862385321102
I0
I1
I-1
tp15177
sS'tricor,there,is'
p15178
(F1
F0.00014334862385321102
I1
I0
I1
tp15179
sS'effect,of,keppra'
p15180
(F1
F0.00014334862385321102
I0
I1
I-1
tp15181
sS'with,auc,was'
p15182
(F1
F0.00014334862385321102
I0
I1
I-1
tp15183
sS'a,fold,range'
p15184
(F1
F0.00014334862385321102
I0
I1
I-1
tp15185
sS'vitro,data,indicate'
p15186
(F1
F0.00028669724770642203
I2
I0
I2
tp15187
sS'substantive,effect,on'
p15188
(F1
F0.00014334862385321102
I0
I1
I-1
tp15189
sS'healthy,volunteers,the'
p15190
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp15191
sS'daily,mg,total'
p15192
(F1
F0.00014334862385321102
I0
I1
I-1
tp15193
sS'which,may,be'
p15194
(F1
F0.00014334862385321102
I1
I0
I1
tp15195
sS'aeds,and,that'
p15196
(F1
F0.00014334862385321102
I0
I1
I-1
tp15197
sS'omeprazole,is,a'
p15198
(F1
F0.00014334862385321102
I0
I1
I-1
tp15199
sS'be,initiated,after'
p15200
(F1
F0.00014334862385321102
I0
I1
I-1
tp15201
sS'bioavailability,of,the'
p15202
(F1
F0.00014334862385321102
I0
I1
I-1
tp15203
sS'effect,is,not'
p15204
(F0
F0
I1
I1
I0
tp15205
sS'in,approximately,half'
p15206
(F1
F0.00014334862385321102
I0
I1
I-1
tp15207
sS'induce,metabolic,enzymes'
p15208
(F1
F0.00014334862385321102
I0
I1
I-1
tp15209
sS'anti-inflammatory,agents,are'
p15210
(F1
F0.00043004587155963305
I3
I0
I3
tp15211
sS'fe,abstract,truncated'
p15212
(F1
F0.00014334862385321102
I0
I1
I-1
tp15213
sS'of,nimbex,may'
p15214
(F1
F0.00014334862385321102
I1
I0
I1
tp15215
sS'since,the,effects'
p15216
(F1
F0.00014334862385321102
I1
I0
I1
tp15217
sS'impairment,particularly,in'
p15218
(F1
F0.00014334862385321102
I0
I1
I-1
tp15219
sS'of,patients,before'
p15220
(F1
F0.00014334862385321102
I0
I1
I-1
tp15221
sS'mao,inhibitors,somatostatin'
p15222
(F1
F0.00028669724770642203
I0
I2
I-2
tp15223
sS'with,bioassay,procedures'
p15224
(F1
F0.00014334862385321102
I0
I1
I-1
tp15225
sS'administration,does,not'
p15226
(F1
F0.00014334862385321102
I0
I1
I-1
tp15227
sS'disintegrin,was,compared'
p15228
(F1
F0.00014334862385321102
I0
I1
I-1
tp15229
sS'agents,by,nonsteroidal'
p15230
(F1
F0.00014334862385321102
I1
I0
I1
tp15231
sS'prevent,the,development'
p15232
(F1
F0.00014334862385321102
I1
I0
I1
tp15233
sS'an,levonorgestrol,oral'
p15234
(F1
F0.00014334862385321102
I0
I1
I-1
tp15235
sS'the,diet,for'
p15236
(F1
F0.00014334862385321102
I1
I0
I1
tp15237
sS'anti-malarial,such,as'
p15238
(F1
F0.00014334862385321102
I1
I0
I1
tp15239
sS'studies,show,significant'
p15240
(F1
F0.00014334862385321102
I0
I1
I-1
tp15241
sS'peak,plasma,level'
p15242
(F1
F0.00014334862385321102
I1
I0
I1
tp15243
sS'a,clinically,significant'
p15244
(F1
F0.00028669724770642203
I0
I2
I-2
tp15245
sS'nucleus,accumbens,but'
p15246
(F1
F0.00014334862385321102
I0
I1
I-1
tp15247
sS'and,auc,from'
p15248
(F1
F0.00014334862385321102
I1
I0
I1
tp15249
sS'with,hydroxide,containing'
p15250
(F1
F0.00014334862385321102
I1
I0
I1
tp15251
sS'with,enbrel,and'
p15252
(F1
F0.00014334862385321102
I1
I0
I1
tp15253
sS'or,more,possibly'
p15254
(F1
F0.00014334862385321102
I1
I0
I1
tp15255
sS'the,gastrointestinal,absorption'
p15256
(F1
F0.00057339449541284407
I4
I0
I4
tp15257
sS'and,increases,substantially'
p15258
(F1
F0.00014334862385321102
I1
I0
I1
tp15259
sS'model,in,patients'
p15260
(F1
F0.00014334862385321102
I0
I1
I-1
tp15261
sS'a,decline,in'
p15262
(F1
F0.00014334862385321102
I0
I1
I-1
tp15263
sS'similar,temporal,patterns'
p15264
(F1
F0.00014334862385321102
I0
I1
I-1
tp15265
sS'thus,appeared,to'
p15266
(F1
F0.00014334862385321102
I1
I0
I1
tp15267
sS'fluvoxamine,inhibits,the'
p15268
(F1
F0.00014334862385321102
I1
I0
I1
tp15269
sS'with,at,a'
p15270
(F1
F0.00014334862385321102
I0
I1
I-1
tp15271
sS'not,diminish,fluoride'
p15272
(F1
F0.00014334862385321102
I0
I1
I-1
tp15273
sS'and,lessened,physiologic'
p15274
(F1
F0.00014334862385321102
I1
I0
I1
tp15275
sS'observed,when,coreg'
p15276
(F1
F0.00014334862385321102
I1
I0
I1
tp15277
sS'first,few,weeks'
p15278
(F1
F0.00014334862385321102
I1
I0
I1
tp15279
sS'cause,increased,intracranial'
p15280
(F1
F0.00014334862385321102
I1
I0
I1
tp15281
sS'in,the,elimination'
p15282
(F0.5
F0.00028669724770642203
I3
I1
I2
tp15283
sS'other,medications,with'
p15284
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp15285
sS'beta,blockers,including'
p15286
(F1
F0.00014334862385321102
I0
I1
I-1
tp15287
sS'the,vehicle,or'
p15288
(F1
F0.00014334862385321102
I1
I0
I1
tp15289
sS'little,change,in'
p15290
(F1
F0.00014334862385321102
I1
I0
I1
tp15291
sS'the,patients,in'
p15292
(F1
F0.00014334862385321102
I0
I1
I-1
tp15293
sS'both,and,may'
p15294
(F1
F0.00014334862385321102
I1
I0
I1
tp15295
sS'do,not,indicate'
p15296
(F1
F0.00014334862385321102
I1
I0
I1
tp15297
sS'clearance,is,greater'
p15298
(F1
F0.00043004587155963305
I3
I0
I3
tp15299
sS'and,or,epoxide'
p15300
(F1
F0.00014334862385321102
I0
I1
I-1
tp15301
sS'relaxant,effect,of'
p15302
(F1
F0.00014334862385321102
I1
I0
I1
tp15303
sS'antidiabetes,products,ace'
p15304
(F1
F0.00014334862385321102
I0
I1
I-1
tp15305
sS'excretion,of,has'
p15306
(F1
F0.00014334862385321102
I1
I0
I1
tp15307
sS'effects,resulting,from'
p15308
(F1
F0.00014334862385321102
I1
I0
I1
tp15309
sS'of,of,the'
p15310
(F1
F0.00014334862385321102
I0
I1
I-1
tp15311
sS'may,partially,counteract'
p15312
(F1
F0.00028669724770642203
I2
I0
I2
tp15313
sS'patients,taking,while'
p15314
(F1
F0.00014334862385321102
I1
I0
I1
tp15315
sS'fluoride,levels,and'
p15316
(F1
F0.00014334862385321102
I0
I1
I-1
tp15317
sS'carefully,monitored,in'
p15318
(F1
F0.00014334862385321102
I1
I0
I1
tp15319
sS'inhibit,cytochrome,p450iid6'
p15320
(F1
F0.00014334862385321102
I1
I0
I1
tp15321
sS'combined,treatment,with'
p15322
(F1
F0.00014334862385321102
I1
I0
I1
tp15323
sS'and,time,kill'
p15324
(F1
F0.00014334862385321102
I1
I0
I1
tp15325
sS'and,chemotherapy,plus'
p15326
(F1
F0.00014334862385321102
I0
I1
I-1
tp15327
sS'b,intravenous,and'
p15328
(F1
F0.00014334862385321102
I1
I0
I1
tp15329
sS'and,n1,while'
p15330
(F1
F0.00014334862385321102
I1
I0
I1
tp15331
sS'the,ermbt,after'
p15332
(F1
F0.00014334862385321102
I0
I1
I-1
tp15333
sS'cases,of,pseudotumor'
p15334
(F1
F0.00014334862385321102
I1
I0
I1
tp15335
sS'coadministration,of,channel'
p15336
(F1
F0.00014334862385321102
I0
I1
I-1
tp15337
sS'with,in,an'
p15338
(F1
F0.00014334862385321102
I0
I1
I-1
tp15339
sS'as,triazolopyridazines,and'
p15340
(F1
F0.00014334862385321102
I1
I0
I1
tp15341
sS'have,failed,to'
p15342
(F1
F0.00014334862385321102
I0
I1
I-1
tp15343
sS'with,high,concentrations'
p15344
(F0
F0
I1
I1
I0
tp15345
sS'discontinuing,to,avoid'
p15346
(F1
F0.00028669724770642203
I2
I0
I2
tp15347
sS'least,minutes,before'
p15348
(F1
F0.00014334862385321102
I1
I0
I1
tp15349
sS'after,a,one'
p15350
(F1
F0.00014334862385321102
I1
I0
I1
tp15351
sS'is,moderately,reduced'
p15352
(F1
F0.00014334862385321102
I0
I1
I-1
tp15353
sS'affecting,the,blood'
p15354
(F1
F0.00014334862385321102
I1
I0
I1
tp15355
sS'hypertensive,patients,addition'
p15356
(F1
F0.00014334862385321102
I0
I1
I-1
tp15357
sS'advanced,or,complete'
p15358
(F1
F0.00014334862385321102
I1
I0
I1
tp15359
sS'a,common,transport'
p15360
(F1
F0.00014334862385321102
I0
I1
I-1
tp15361
sS'in,an,approximate'
p15362
(F1
F0.0008600917431192661
I6
I0
I6
tp15363
sS'glomerulonephritis,oculo-bulbar,myasthenia'
p15364
(F1
F0.00014334862385321102
I1
I0
I1
tp15365
sS'chicks,was,effective'
p15366
(F1
F0.00014334862385321102
I1
I0
I1
tp15367
sS'the,oral,doses'
p15368
(F1
F0.00014334862385321102
I1
I0
I1
tp15369
sS'therapy,it,is'
p15370
(F1
F0.00014334862385321102
I1
I0
I1
tp15371
sS'hypotension,because,of'
p15372
(F1
F0.00014334862385321102
I0
I1
I-1
tp15373
sS'of,steady-state,pharmacokinetic'
p15374
(F1
F0.00014334862385321102
I0
I1
I-1
tp15375
sS'acidic,conditions,similar'
p15376
(F1
F0.00014334862385321102
I1
I0
I1
tp15377
sS'of,in,nonfailing'
p15378
(F1
F0.00014334862385321102
I1
I0
I1
tp15379
sS'acetate,in,reducing'
p15380
(F1
F0.00014334862385321102
I1
I0
I1
tp15381
sS'levels,of,serotonin'
p15382
(F1
F0.00014334862385321102
I0
I1
I-1
tp15383
sS'interactions,between,oh'
p15384
(F1
F0.00014334862385321102
I0
I1
I-1
tp15385
sS'however,in,another'
p15386
(F1
F0.00014334862385321102
I1
I0
I1
tp15387
sS'the,loss,of'
p15388
(F1
F0.00014334862385321102
I1
I0
I1
tp15389
sS'attenuated,by,endothelial'
p15390
(F1
F0.00014334862385321102
I0
I1
I-1
tp15391
sS'signs,of,hypotension'
p15392
(F1
F0.00014334862385321102
I1
I0
I1
tp15393
sS'concentrations,and,ldl-c'
p15394
(F1
F0.00014334862385321102
I0
I1
I-1
tp15395
sS'nasal,spray,but'
p15396
(F1
F0.00014334862385321102
I1
I0
I1
tp15397
sS'have,in,some'
p15398
(F1
F0.00014334862385321102
I1
I0
I1
tp15399
sS'digoxin,enoxacin,may'
p15400
(F1
F0.00014334862385321102
I1
I0
I1
tp15401
sS'valproate,mg,twice'
p15402
(F1
F0.00014334862385321102
I0
I1
I-1
tp15403
sS'we,report,the'
p15404
(F1
F0.00014334862385321102
I1
I0
I1
tp15405
sS'be,more,pronounced'
p15406
(F1
F0.00028669724770642203
I2
I0
I2
tp15407
sS'exjade,and,vitamin'
p15408
(F1
F0.00014334862385321102
I0
I1
I-1
tp15409
sS'studies,to,mg'
p15410
(F1
F0.00014334862385321102
I0
I1
I-1
tp15411
sS'class,of,which'
p15412
(F1
F0.00014334862385321102
I1
I0
I1
tp15413
sS'in,clinical,studies'
p15414
(F0.59999999999999998
F0.0012901376146788992
I3
I12
I-9
tp15415
sS'of,n-methylthiotetrazole,or'
p15416
(F1
F0.00014334862385321102
I0
I1
I-1
tp15417
sS'to,an,altered'
p15418
(F1
F0.00014334862385321102
I1
I0
I1
tp15419
sS'single-dose,study,with'
p15420
(F1
F0.00014334862385321102
I0
I1
I-1
tp15421
sS'give,rise,to'
p15422
(F1
F0.00014334862385321102
I1
I0
I1
tp15423
sS'by,and,clotibrate'
p15424
(F1
F0.00014334862385321102
I0
I1
I-1
tp15425
sS'mg,daily,a'
p15426
(F1
F0.00014334862385321102
I1
I0
I1
tp15427
sS'such,as,liver'
p15428
(F1
F0.00014334862385321102
I1
I0
I1
tp15429
sS'concomitant,such,as'
p15430
(F1
F0.00014334862385321102
I0
I1
I-1
tp15431
sS'mc,potentiates,the'
p15432
(F1
F0.00014334862385321102
I1
I0
I1
tp15433
sS'benefit,compared,to'
p15434
(F1
F0.00028669724770642203
I2
I0
I2
tp15435
sS'bioavailability,of,was'
p15436
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp15437
sS'of,several,closely'
p15438
(F1
F0.00014334862385321102
I1
I0
I1
tp15439
sS'itraconazole,mg,b'
p15440
(F1
F0.00014334862385321102
I0
I1
I-1
tp15441
sS'produced,by,resulting'
p15442
(F1
F0.00014334862385321102
I1
I0
I1
tp15443
sS'be,effective,in'
p15444
(F1
F0.00014334862385321102
I1
I0
I1
tp15445
sS'decrease,the,hypotensive'
p15446
(F1
F0.00043004587155963305
I3
I0
I3
tp15447
sS'effects,of,other'
p15448
(F0.25
F0.00028669724770642203
I5
I3
I2
tp15449
sS'curves,with,enteric'
p15450
(F1
F0.00014334862385321102
I1
I0
I1
tp15451
sS'cytochrome,p-450,isozymes'
p15452
(F1
F0.00028669724770642203
I2
I0
I2
tp15453
sS'with,and,following'
p15454
(F1
F0.00014334862385321102
I0
I1
I-1
tp15455
sS'with,compared,to'
p15456
(F1
F0.00028669724770642203
I2
I0
I2
tp15457
sS'higher,and,excretion'
p15458
(F1
F0.00014334862385321102
I0
I1
I-1
tp15459
sS'stopping,an,mao'
p15460
(F1
F0.00014334862385321102
I1
I0
I1
tp15461
sS'with,blood,thinners'
p15462
(F1
F0.00014334862385321102
I1
I0
I1
tp15463
sS'the,cmax,values'
p15464
(F1
F0.00014334862385321102
I0
I1
I-1
tp15465
sS'mg,m2,given'
p15466
(F1
F0.00014334862385321102
I1
I0
I1
tp15467
sS'of,mg,both'
p15468
(F1
F0.00014334862385321102
I0
I1
I-1
tp15469
sS'of,this,enzyme'
p15470
(F0
F0
I1
I1
I0
tp15471
sS'were,decreased,by'
p15472
(F1
F0.00043004587155963305
I3
I0
I3
tp15473
sS'no,interaction,was'
p15474
(F1
F0.00014334862385321102
I0
I1
I-1
tp15475
sS'strong,inhibitors,or'
p15476
(F1
F0.00014334862385321102
I0
I1
I-1
tp15477
sS'mao,inhibitors,prolong'
p15478
(F1
F0.00071674311926605509
I5
I0
I5
tp15479
sS'and,a,concomitantly'
p15480
(F1
F0.00014334862385321102
I1
I0
I1
tp15481
sS'mg,tricor,with'
p15482
(F1
F0.00028669724770642203
I2
I0
I2
tp15483
sS'tyrosine,phosphorylation,in'
p15484
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp15485
sS'mg,neurontin,capsule'
p15486
(F1
F0.00014334862385321102
I1
I0
I1
tp15487
sS'or,pediatric,powder'
p15488
(F1
F0.00028669724770642203
I2
I0
I2
tp15489
sS'of,chronic,or'
p15490
(F1
F0.00014334862385321102
I1
I0
I1
tp15491
sS'valproate,tiagabine,causes'
p15492
(F1
F0.00014334862385321102
I1
I0
I1
tp15493
sS'evoked,potential,components'
p15494
(F1
F0.00014334862385321102
I0
I1
I-1
tp15495
sS'with,and,therefore'
p15496
(F1
F0.00014334862385321102
I1
I0
I1
tp15497
sS'pump,inhibitors,and'
p15498
(F1
F0.00014334862385321102
I1
I0
I1
tp15499
sS'kemstrotm,was,similar'
p15500
(F1
F0.00014334862385321102
I0
I1
I-1
tp15501
sS'treated,with,difluoro-2'
p15502
(F1
F0.00014334862385321102
I1
I0
I1
tp15503
sS'cyp2c8,in,vitro'
p15504
(F1
F0.00014334862385321102
I0
I1
I-1
tp15505
sS'on,fi,and'
p15506
(F1
F0.00014334862385321102
I1
I0
I1
tp15507
sS'levels,and,extends'
p15508
(F1
F0.00014334862385321102
I1
I0
I1
tp15509
sS'of,has,been'
p15510
(F1
F0.00057339449541284407
I4
I0
I4
tp15511
sS'produced,depletions,of'
p15512
(F1
F0.00014334862385321102
I1
I0
I1
tp15513
sS'efficacy,is,reduced'
p15514
(F1
F0.00028669724770642203
I2
I0
I2
tp15515
sS'when,and,are'
p15516
(F1
F0.0010034403669724771
I7
I0
I7
tp15517
sS'observe,the,patient'
p15518
(F1
F0.00014334862385321102
I0
I1
I-1
tp15519
sS'reported,among,patients'
p15520
(F1
F0.00028669724770642203
I2
I0
I2
tp15521
sS'increased,volume,of'
p15522
(F1
F0.00014334862385321102
I0
I1
I-1
tp15523
sS'a,prolongation,in'
p15524
(F1
F0.00014334862385321102
I1
I0
I1
tp15525
sS'less,alteration,in'
p15526
(F1
F0.00014334862385321102
I1
I0
I1
tp15527
sS'between,and,were'
p15528
(F1
F0.00014334862385321102
I0
I1
I-1
tp15529
sS'hypothyroid,patient,may'
p15530
(F1
F0.00014334862385321102
I1
I0
I1
tp15531
sS'of,hypotension,related'
p15532
(F0
F0
I1
I1
I0
tp15533
sS'potential,inhibitor,of'
p15534
(F1
F0.00014334862385321102
I1
I0
I1
tp15535
sS'interactions,noted,above'
p15536
(F1
F0.00014334862385321102
I0
I1
I-1
tp15537
sS'be,monitored,and'
p15538
(F0
F0
I2
I2
I0
tp15539
sS'not,been,demonstrated'
p15540
(F1
F0.00014334862385321102
I0
I1
I-1
tp15541
sS'wshow,an,effect'
p15542
(F1
F0.00014334862385321102
I0
I1
I-1
tp15543
sS'may,be,especially'
p15544
(F1
F0.00014334862385321102
I0
I1
I-1
tp15545
sS'in,the,phase'
p15546
(F1
F0.00014334862385321102
I0
I1
I-1
tp15547
sS'might,increase,the'
p15548
(F1
F0.00043004587155963305
I3
I0
I3
tp15549
sS'of,single,doses'
p15550
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp15551
sS'consciousness,caused,by'
p15552
(F1
F0.00014334862385321102
I1
I0
I1
tp15553
sS'using,doses,of'
p15554
(F1
F0.00014334862385321102
I1
I0
I1
tp15555
sS'not,be,effective'
p15556
(F0
F0
I1
I1
I0
tp15557
sS'other,antiretroviral,medications'
p15558
(F1
F0.00014334862385321102
I0
I1
I-1
tp15559
sS'reports,of,both'
p15560
(F1
F0.00014334862385321102
I1
I0
I1
tp15561
sS'selectively,prevent,opioid-induced'
p15562
(F1
F0.00014334862385321102
I1
I0
I1
tp15563
sS'of,or,use'
p15564
(F1
F0.00014334862385321102
I0
I1
I-1
tp15565
sS'escalating,doses,from'
p15566
(F1
F0.00014334862385321102
I0
I1
I-1
tp15567
sS'c-17,alkylated,such'
p15568
(F1
F0.00014334862385321102
I0
I1
I-1
tp15569
sS'the,cure,and'
p15570
(F0
F0
I1
I1
I0
tp15571
sS'disulfiram,to,a'
p15572
(F1
F0.00014334862385321102
I1
I0
I1
tp15573
sS'trimethoprim,alone,or'
p15574
(F1
F0.00014334862385321102
I0
I1
I-1
tp15575
sS'acetaminophen,and,l-methionine'
p15576
(F1
F0.00014334862385321102
I1
I0
I1
tp15577
sS'effects,prothrombin,time'
p15578
(F1
F0.00014334862385321102
I1
I0
I1
tp15579
sS'whole,blood,area'
p15580
(F1
F0.00014334862385321102
I1
I0
I1
tp15581
sS'partially,counteract,the'
p15582
(F1
F0.00028669724770642203
I2
I0
I2
tp15583
sS'q,d,doses'
p15584
(F1
F0.00014334862385321102
I0
I1
I-1
tp15585
sS'xr,may,reduce'
p15586
(F1
F0.00014334862385321102
I1
I0
I1
tp15587
sS'with,tablets,reduces'
p15588
(F1
F0.00014334862385321102
I1
I0
I1
tp15589
sS'potassium-sparing,including,midamor'
p15590
(F1
F0.00014334862385321102
I1
I0
I1
tp15591
sS'that,are,cytochrome'
p15592
(F1
F0.00014334862385321102
I1
I0
I1
tp15593
sS'between,and,is'
p15594
(F1
F0.00043004587155963305
I3
I0
I3
tp15595
sS'between,and,it'
p15596
(F1
F0.00014334862385321102
I1
I0
I1
tp15597
sS'placebo-controlled,clinical,studies'
p15598
(F1
F0.00014334862385321102
I0
I1
I-1
tp15599
sS'or,estrogen-containing,oral'
p15600
(F1
F0.00014334862385321102
I1
I0
I1
tp15601
sS'after,weeks,of'
p15602
(F1
F0.00014334862385321102
I0
I1
I-1
tp15603
sS'between,and,in'
p15604
(F1
F0.00028669724770642203
I2
I0
I2
tp15605
sS'growth,in,vitro'
p15606
(F1
F0.00014334862385321102
I1
I0
I1
tp15607
sS'events,should,be'
p15608
(F1
F0.00014334862385321102
I0
I1
I-1
tp15609
sS'on,pharmacokinetics,have'
p15610
(F1
F0.00014334862385321102
I0
I1
I-1
tp15611
sS'chromatin,and,nuclear'
p15612
(F1
F0.00014334862385321102
I1
I0
I1
tp15613
sS'pharmacokinetic,effects,seen'
p15614
(F1
F0.00014334862385321102
I1
I0
I1
tp15615
sS'system,depressants,and'
p15616
(F1
F0.00014334862385321102
I1
I0
I1
tp15617
sS'should,be,at'
p15618
(F1
F0.00014334862385321102
I1
I0
I1
tp15619
sS'which,could,increase'
p15620
(F1
F0.00028669724770642203
I2
I0
I2
tp15621
sS'of,is,potentiated'
p15622
(F1
F0.00014334862385321102
I1
I0
I1
tp15623
sS'compensate,for,the'
p15624
(F1
F0.00028669724770642203
I2
I0
I2
tp15625
sS'or,concentrations,when'
p15626
(F1
F0.00014334862385321102
I0
I1
I-1
tp15627
sS'ergocalcitriol,will,be'
p15628
(F1
F0.00043004587155963305
I0
I3
I-3
tp15629
sS'oral,agents,may'
p15630
(F1
F0.00014334862385321102
I0
I1
I-1
tp15631
sS'potentiated,and,fatal'
p15632
(F1
F0.00028669724770642203
I2
I0
I2
tp15633
sS'as,a,stimulator'
p15634
(F1
F0.00014334862385321102
I1
I0
I1
tp15635
sS'possibly,other,and'
p15636
(F1
F0.00014334862385321102
I1
I0
I1
tp15637
sS'the,selective,serotonin'
p15638
(F1
F0.00071674311926605509
I0
I5
I-5
tp15639
sS'other,potentially,important'
p15640
(F1
F0.00014334862385321102
I1
I0
I1
tp15641
sS'adverse,interactions,with'
p15642
(F1
F0.00014334862385321102
I0
I1
I-1
tp15643
sS'pharmacologic,effects,may'
p15644
(F1
F0.00014334862385321102
I0
I1
I-1
tp15645
sS'approximately,with,coadministration'
p15646
(F1
F0.00014334862385321102
I1
I0
I1
tp15647
sS'decrease,in,total'
p15648
(F1
F0.00014334862385321102
I1
I0
I1
tp15649
sS'appeared,well,after'
p15650
(F1
F0.00014334862385321102
I0
I1
I-1
tp15651
sS'clinical,studies,have'
p15652
(F0
F0
I3
I3
I0
tp15653
sS'frequency,and,or'
p15654
(F1
F0.00014334862385321102
I1
I0
I1
tp15655
sS'of,nephrolithiasis,is'
p15656
(F1
F0.00014334862385321102
I1
I0
I1
tp15657
sS'techniques,confirmation,should'
p15658
(F1
F0.00014334862385321102
I0
I1
I-1
tp15659
sS'measurement,of,serum'
p15660
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp15661
sS'if,are,required'
p15662
(F1
F0.00014334862385321102
I1
I0
I1
tp15663
sS'iodide,i,and'
p15664
(F1
F0.00014334862385321102
I0
I1
I-1
tp15665
sS'after,stopping,fluvoxamine'
p15666
(F1
F0.00014334862385321102
I1
I0
I1
tp15667
sS'hydrochloride,concomitantly,with'
p15668
(F1
F0.00014334862385321102
I1
I0
I1
tp15669
sS'other,cns,depressants'
p15670
(F0.66666666666666663
F0.0011467889908256881
I10
I2
I8
tp15671
sS'by,the,following'
p15672
(F1
F0.00014334862385321102
I0
I1
I-1
tp15673
sS'that,may,be'
p15674
(F0
F0
I1
I1
I0
tp15675
sS'etonogestrel,may,interact'
p15676
(F1
F0.00014334862385321102
I1
I0
I1
tp15677
sS'effects,of,coadministration'
p15678
(F0
F0
I1
I1
I0
tp15679
sS'anafranil,is,highly'
p15680
(F1
F0.00014334862385321102
I1
I0
I1
tp15681
sS'these,are,used'
p15682
(F1
F0.00014334862385321102
I0
I1
I-1
tp15683
sS'not,inhibit,p-glycoprotein'
p15684
(F1
F0.00014334862385321102
I0
I1
I-1
tp15685
sS'with,hiv-nhl,who'
p15686
(F1
F0.00014334862385321102
I0
I1
I-1
tp15687
sS'represents,an,interaction'
p15688
(F1
F0.00014334862385321102
I0
I1
I-1
tp15689
sS'carbamazepine,overdose,recognized'
p15690
(F1
F0.00014334862385321102
I0
I1
I-1
tp15691
sS'pure,agonist,such'
p15692
(F1
F0.00014334862385321102
I1
I0
I1
tp15693
sS'is,not,affected'
p15694
(F1
F0.00014334862385321102
I0
I1
I-1
tp15695
sS'concentrations,or,the'
p15696
(F1
F0.00014334862385321102
I0
I1
I-1
tp15697
sS'methylglutaryl,coenzyme,a'
p15698
(F1
F0.00014334862385321102
I0
I1
I-1
tp15699
sS'the,and,effects'
p15700
(F1
F0.00014334862385321102
I1
I0
I1
tp15701
sS'a,placebo-controlled,crossover'
p15702
(F1
F0.00014334862385321102
I1
I0
I1
tp15703
sS'used,when,equetrotm'
p15704
(F1
F0.00014334862385321102
I1
I0
I1
tp15705
sS'mainly,eliminated,by'
p15706
(F1
F0.00014334862385321102
I0
I1
I-1
tp15707
sS'dose,of,may'
p15708
(F1
F0.00014334862385321102
I1
I0
I1
tp15709
sS'instances,a,slight'
p15710
(F1
F0.00014334862385321102
I1
I0
I1
tp15711
sS'reactions,when,treated'
p15712
(F1
F0.00014334862385321102
I0
I1
I-1
tp15713
sS'and,decreased,by'
p15714
(F1
F0.00014334862385321102
I1
I0
I1
tp15715
sS'be,the,cellular'
p15716
(F1
F0.00014334862385321102
I0
I1
I-1
tp15717
sS'abnormalities,such,as'
p15718
(F1
F0.00014334862385321102
I1
I0
I1
tp15719
sS'compounds,which,inhibit'
p15720
(F1
F0.00014334862385321102
I0
I1
I-1
tp15721
sS'administered,on,the'
p15722
(F1
F0.00028669724770642203
I2
I0
I2
tp15723
sS'hypertension,the,addition'
p15724
(F1
F0.00014334862385321102
I1
I0
I1
tp15725
sS'prothrombin,test,monitoring'
p15726
(F1
F0.00014334862385321102
I0
I1
I-1
tp15727
sS'selective,serotonin,reuptake'
p15728
(F0.20000000000000001
F0.00043004587155963305
I6
I9
I-3
tp15729
sS'of,as,compared'
p15730
(F1
F0.00014334862385321102
I1
I0
I1
tp15731
sS'period,with,n'
p15732
(F1
F0.00014334862385321102
I0
I1
I-1
tp15733
sS'ureidopenicillins,including,were'
p15734
(F1
F0.00014334862385321102
I1
I0
I1
tp15735
sS'levels,of,either'
p15736
(F1
F0.00014334862385321102
I0
I1
I-1
tp15737
sS'breath,test,was'
p15738
(F1
F0.00014334862385321102
I0
I1
I-1
tp15739
sS'interaction,is,a'
p15740
(F1
F0.00014334862385321102
I1
I0
I1
tp15741
sS'rifampin,an,inducer'
p15742
(F1
F0.00014334862385321102
I1
I0
I1
tp15743
sS'drug,is,prescribed'
p15744
(F1
F0.00014334862385321102
I0
I1
I-1
tp15745
sS'mg,bid,decreased'
p15746
(F1
F0.00014334862385321102
I1
I0
I1
tp15747
sS'serious,interactions,when'
p15748
(F1
F0.00014334862385321102
I1
I0
I1
tp15749
sS'of,indocin,can'
p15750
(F1
F0.00014334862385321102
I1
I0
I1
tp15751
sS'anti-peptic,agents,primarily'
p15752
(F1
F0.00014334862385321102
I0
I1
I-1
tp15753
sS'with,potent,loop'
p15754
(F1
F0.00014334862385321102
I1
I0
I1
tp15755
sS'of,desmopressin,tablets'
p15756
(F1
F0.00014334862385321102
I0
I1
I-1
tp15757
sS'also,result,in'
p15758
(F1
F0.00043004587155963305
I3
I0
I3
tp15759
sS'by,patients,suffering'
p15760
(F1
F0.00014334862385321102
I1
I0
I1
tp15761
sS'of,bepridil,with'
p15762
(F1
F0.00014334862385321102
I0
I1
I-1
tp15763
sS'temporarily,mask,the'
p15764
(F1
F0.00014334862385321102
I1
I0
I1
tp15765
sS'including,protease,inhibitors'
p15766
(F1
F0.00014334862385321102
I0
I1
I-1
tp15767
sS'where,the,effects'
p15768
(F1
F0.00014334862385321102
I0
I1
I-1
tp15769
sS'with,videx,chewable'
p15770
(F1
F0.00014334862385321102
I1
I0
I1
tp15771
sS'significantly,higher,when'
p15772
(F1
F0.00014334862385321102
I1
I0
I1
tp15773
sS'preanesthetic,and,agents'
p15774
(F1
F0.00014334862385321102
I0
I1
I-1
tp15775
sS'or,a,antidepressant'
p15776
(F1
F0.00014334862385321102
I1
I0
I1
tp15777
sS'vasospastic,effects,may'
p15778
(F1
F0.00014334862385321102
I1
I0
I1
tp15779
sS'is,not,due'
p15780
(F1
F0.00014334862385321102
I1
I0
I1
tp15781
sS'either,or,micrograms'
p15782
(F1
F0.00014334862385321102
I0
I1
I-1
tp15783
sS'a,different,type'
p15784
(F1
F0.00014334862385321102
I1
I0
I1
tp15785
sS'a,severe,high'
p15786
(F1
F0.00014334862385321102
I1
I0
I1
tp15787
sS'preparations,such,as'
p15788
(F1
F0.00014334862385321102
I1
I0
I1
tp15789
sS'of,mefloquine,on'
p15790
(F1
F0.00014334862385321102
I1
I0
I1
tp15791
sS'acid,vitamin,c'
p15792
(F1
F0.00014334862385321102
I1
I0
I1
tp15793
sS'hours,or,concurrent'
p15794
(F1
F0.00014334862385321102
I1
I0
I1
tp15795
sS'noted,to,possibly'
p15796
(F1
F0.00014334862385321102
I1
I0
I1
tp15797
sS'may,color,alkaline'
p15798
(F1
F0.00014334862385321102
I0
I1
I-1
tp15799
sS'i,suggesting,a'
p15800
(F1
F0.00014334862385321102
I0
I1
I-1
tp15801
sS'up,to,mg'
p15802
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp15803
sS'of,trileptal,with'
p15804
(F1
F0.00028669724770642203
I2
I0
I2
tp15805
sS'physician,should,provide'
p15806
(F1
F0.00014334862385321102
I0
I1
I-1
tp15807
sS'several,well-controlled,studies'
p15808
(F1
F0.00014334862385321102
I0
I1
I-1
tp15809
sS'for,comprehensive,information'
p15810
(F1
F0.00014334862385321102
I0
I1
I-1
tp15811
sS'used,such,as'
p15812
(F1
F0.00014334862385321102
I0
I1
I-1
tp15813
sS'agents,when,are'
p15814
(F1
F0.00014334862385321102
I1
I0
I1
tp15815
sS'drugs,in,vitro'
p15816
(F1
F0.00014334862385321102
I0
I1
I-1
tp15817
sS'is,used,with'
p15818
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp15819
sS'the,from,protein'
p15820
(F1
F0.00014334862385321102
I1
I0
I1
tp15821
sS'mtx,nsaids,and'
p15822
(F1
F0.00014334862385321102
I0
I1
I-1
tp15823
sS'patients,receiving,other'
p15824
(F1
F0.00043004587155963305
I3
I0
I3
tp15825
sS'affect,the,relative'
p15826
(F1
F0.00014334862385321102
I0
I1
I-1
tp15827
sS'with,a,reduced'
p15828
(F1
F0.00014334862385321102
I0
I1
I-1
tp15829
sS'levels,were,decreased'
p15830
(F1
F0.00014334862385321102
I1
I0
I1
tp15831
sS'hydrochloride,and,and'
p15832
(F1
F0.00014334862385321102
I0
I1
I-1
tp15833
sS'clinically,significant,differences'
p15834
(F1
F0.00014334862385321102
I0
I1
I-1
tp15835
sS'have,not,established'
p15836
(F1
F0.00014334862385321102
I1
I0
I1
tp15837
sS'alkylated,such,as'
p15838
(F1
F0.00014334862385321102
I0
I1
I-1
tp15839
sS'and,infusion,rate'
p15840
(F1
F0.00014334862385321102
I1
I0
I1
tp15841
sS'events,were,experienced'
p15842
(F1
F0.00014334862385321102
I1
I0
I1
tp15843
sS'added,concentration,which'
p15844
(F1
F0.00014334862385321102
I0
I1
I-1
tp15845
sS'receiving,concurrent,and'
p15846
(F1
F0.00014334862385321102
I0
I1
I-1
tp15847
sS'studied,but,cases'
p15848
(F1
F0.00014334862385321102
I1
I0
I1
tp15849
sS'in,healthy,non-smoking'
p15850
(F1
F0.00014334862385321102
I0
I1
I-1
tp15851
sS'with,that,can'
p15852
(F1
F0.00071674311926605509
I0
I5
I-5
tp15853
sS'and,suggest,that'
p15854
(F0
F0
I1
I1
I0
tp15855
sS'for,measurement,of'
p15856
(F1
F0.00014334862385321102
I0
I1
I-1
tp15857
sS'onset,of,neuromuscular'
p15858
(F1
F0.00028669724770642203
I2
I0
I2
tp15859
sS'in,the,ph'
p15860
(F1
F0.00014334862385321102
I1
I0
I1
tp15861
sS'minor,increase,in'
p15862
(F1
F0.00014334862385321102
I1
I0
I1
tp15863
sS'desethylzaleplon,formed,via'
p15864
(F1
F0.00014334862385321102
I0
I1
I-1
tp15865
sS'than,fold,increase'
p15866
(F1
F0.00028669724770642203
I0
I2
I-2
tp15867
sS'almost,fold,lower'
p15868
(F1
F0.00014334862385321102
I1
I0
I1
tp15869
sS'or,other,having'
p15870
(F1
F0.00014334862385321102
I1
I0
I1
tp15871
sS'of,sodium,and'
p15872
(F1
F0.00014334862385321102
I1
I0
I1
tp15873
sS'minutes,before,using'
p15874
(F1
F0.00014334862385321102
I1
I0
I1
tp15875
sS'should,be,employed'
p15876
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp15877
sS'the,terms,viagra'
p15878
(F1
F0.00014334862385321102
I0
I1
I-1
tp15879
sS'were,compared,to'
p15880
(F1
F0.00014334862385321102
I0
I1
I-1
tp15881
sS'amiodarone-treated,patients,who'
p15882
(F1
F0.00014334862385321102
I0
I1
I-1
tp15883
sS'frequency,of,hyperkalemia'
p15884
(F1
F0.00014334862385321102
I1
I0
I1
tp15885
sS'by,as,measured'
p15886
(F1
F0.00014334862385321102
I1
I0
I1
tp15887
sS'hydrate,may,cause'
p15888
(F1
F0.00014334862385321102
I1
I0
I1
tp15889
sS'is,unlikely,to'
p15890
(F1
F0.0010034403669724771
I0
I7
I-7
tp15891
sS'serum,concentration,due'
p15892
(F1
F0.00014334862385321102
I1
I0
I1
tp15893
sS'seem,to,dictate'
p15894
(F1
F0.00014334862385321102
I1
I0
I1
tp15895
sS'mg,on,days'
p15896
(F1
F0.00014334862385321102
I1
I0
I1
tp15897
sS'i,d,was'
p15898
(F1
F0.00014334862385321102
I1
I0
I1
tp15899
sS'was,higher,when'
p15900
(F1
F0.00014334862385321102
I1
I0
I1
tp15901
sS'pronounced,when,it'
p15902
(F1
F0.00014334862385321102
I1
I0
I1
tp15903
sS'cyp1a2,c8,c9'
p15904
(F1
F0.00014334862385321102
I0
I1
I-1
tp15905
sS'pain,medication,used'
p15906
(F1
F0.00014334862385321102
I0
I1
I-1
tp15907
sS'paper,was,to'
p15908
(F1
F0.00014334862385321102
I0
I1
I-1
tp15909
sS'inhibits,metabolism,which'
p15910
(F1
F0.00014334862385321102
I1
I0
I1
tp15911
sS'agonist,can,give'
p15912
(F1
F0.00014334862385321102
I1
I0
I1
tp15913
sS'hepatic,enzyme,inhibitors'
p15914
(F1
F0.00028669724770642203
I2
I0
I2
tp15915
sS'related,compounds,eg'
p15916
(F1
F0.00014334862385321102
I1
I0
I1
tp15917
sS'liver,enzyme,abnormalities'
p15918
(F1
F0.00014334862385321102
I1
I0
I1
tp15919
sS'tagamet,apparently,through'
p15920
(F1
F0.00014334862385321102
I1
I0
I1
tp15921
sS'known,to,occasionally'
p15922
(F1
F0.00014334862385321102
I0
I1
I-1
tp15923
sS'been,associated,with'
p15924
(F0.52380952380952384
F0.0015768348623853212
I16
I5
I11
tp15925
sS'with,the,dose'
p15926
(F1
F0.00014334862385321102
I1
I0
I1
tp15927
sS'differential,actions,of'
p15928
(F1
F0.00014334862385321102
I0
I1
I-1
tp15929
sS'proliferates,in,a'
p15930
(F1
F0.00014334862385321102
I0
I1
I-1
tp15931
sS'or,and,that'
p15932
(F1
F0.00014334862385321102
I0
I1
I-1
tp15933
sS'co-administered,with,fluvoxamine'
p15934
(F1
F0.00014334862385321102
I1
I0
I1
tp15935
sS'off,before,a'
p15936
(F1
F0.00014334862385321102
I0
I1
I-1
tp15937
sS'and,wide,distribution'
p15938
(F1
F0.00014334862385321102
I0
I1
I-1
tp15939
sS'respectively,suggesting,that'
p15940
(F1
F0.00014334862385321102
I1
I0
I1
tp15941
sS'and,rats,suggest'
p15942
(F1
F0.00014334862385321102
I1
I0
I1
tp15943
sS'inducers,eg,are'
p15944
(F1
F0.00014334862385321102
I0
I1
I-1
tp15945
sS'in,or,of'
p15946
(F1
F0.00014334862385321102
I0
I1
I-1
tp15947
sS'prolonged,administration,and'
p15948
(F1
F0.00014334862385321102
I0
I1
I-1
tp15949
sS'hypo-prothrombinemic,effect,and'
p15950
(F1
F0.00014334862385321102
I0
I1
I-1
tp15951
sS'in,pharmacokinetics,or'
p15952
(F1
F0.00014334862385321102
I0
I1
I-1
tp15953
sS'been,reported,in'
p15954
(F0.80645161290322576
F0.0035837155963302754
I28
I3
I25
tp15955
sS'because,the,have'
p15956
(F1
F0.00014334862385321102
I1
I0
I1
tp15957
sS'of,increased,metabolism'
p15958
(F1
F0.00014334862385321102
I1
I0
I1
tp15959
sS'administered,by,patients'
p15960
(F1
F0.00014334862385321102
I0
I1
I-1
tp15961
sS'tests,using,but'
p15962
(F1
F0.00028669724770642203
I0
I2
I-2
tp15963
sS'studied,in,combination'
p15964
(F1
F0.00043004587155963305
I0
I3
I-3
tp15965
sS'using,this,medication'
p15966
(F1
F0.00014334862385321102
I0
I1
I-1
tp15967
sS'of,anafranil,to'
p15968
(F1
F0.00014334862385321102
I1
I0
I1
tp15969
sS'for,as,well'
p15970
(F1
F0.00014334862385321102
I0
I1
I-1
tp15971
sS'agents,may,also'
p15972
(F0
F0
I1
I1
I0
tp15973
sS'time,have,not'
p15974
(F1
F0.00014334862385321102
I0
I1
I-1
tp15975
sS'plasma,tca,concentrations'
p15976
(F1
F0.00014334862385321102
I1
I0
I1
tp15977
sS'monitored,because,nephrotoxicity'
p15978
(F1
F0.00014334862385321102
I1
I0
I1
tp15979
sS'mefloquine,is,taken'
p15980
(F1
F0.00014334862385321102
I1
I0
I1
tp15981
sS'which,inhibit,platelet'
p15982
(F1
F0.00014334862385321102
I1
I0
I1
tp15983
sS'and,concomitant,serotonergic'
p15984
(F1
F0.00014334862385321102
I1
I0
I1
tp15985
sS'because,both,lower'
p15986
(F1
F0.00014334862385321102
I1
I0
I1
tp15987
sS'patients,as,well'
p15988
(F1
F0.00028669724770642203
I0
I2
I-2
tp15989
sS'administered,without,any'
p15990
(F1
F0.00014334862385321102
I0
I1
I-1
tp15991
sS'from,breast,milk'
p15992
(F1
F0.00014334862385321102
I0
I1
I-1
tp15993
sS'that,transferred,to'
p15994
(F1
F0.00014334862385321102
I0
I1
I-1
tp15995
sS'patients,receiving,another'
p15996
(F1
F0.00014334862385321102
I1
I0
I1
tp15997
sS'minutes,any,such'
p15998
(F1
F0.00014334862385321102
I1
I0
I1
tp15999
sS'videx,should,be'
p16000
(F0
F0
I1
I1
I0
tp16001
sS'to,toxoids,and'
p16002
(F1
F0.00014334862385321102
I1
I0
I1
tp16003
sS'thyroid,hormones,appear'
p16004
(F1
F0.00014334862385321102
I0
I1
I-1
tp16005
sS'toxic,concentrations,decreases'
p16006
(F1
F0.00014334862385321102
I1
I0
I1
tp16007
sS'taken,concurrently,with'
p16008
(F1
F0.00028669724770642203
I2
I0
I2
tp16009
sS'targretin,capsules,and'
p16010
(F1
F0.00014334862385321102
I1
I0
I1
tp16011
sS'bid,with,celebrex'
p16012
(F1
F0.00014334862385321102
I1
I0
I1
tp16013
sS'on,the,prothrombin'
p16014
(F1
F0.00014334862385321102
I0
I1
I-1
tp16015
sS'vivo,resulting,in'
p16016
(F1
F0.00014334862385321102
I1
I0
I1
tp16017
sS'for,interactions,among'
p16018
(F1
F0.00014334862385321102
I0
I1
I-1
tp16019
sS'of,the,activity'
p16020
(F1
F0.00014334862385321102
I1
I0
I1
tp16021
sS'of,cytochrome,cyp'
p16022
(F1
F0.00014334862385321102
I0
I1
I-1
tp16023
sS'was,observed,with'
p16024
(F1
F0.00014334862385321102
I1
I0
I1
tp16025
sS'potentiating,cns,depressants'
p16026
(F1
F0.00014334862385321102
I1
I0
I1
tp16027
sS'measurements,of,pah'
p16028
(F1
F0.00014334862385321102
I1
I0
I1
tp16029
sS'role,in,hemostasis'
p16030
(F1
F0.00028669724770642203
I2
I0
I2
tp16031
sS'works,differently,from'
p16032
(F1
F0.00014334862385321102
I0
I1
I-1
tp16033
sS'or,basic,as'
p16034
(F1
F0.00014334862385321102
I1
I0
I1
tp16035
sS'maintenance,bolus,doses'
p16036
(F1
F0.00014334862385321102
I0
I1
I-1
tp16037
sS'five,normal,volunteers'
p16038
(F1
F0.00014334862385321102
I1
I0
I1
tp16039
sS'occur,if,the'
p16040
(F1
F0.00014334862385321102
I0
I1
I-1
tp16041
sS'administered,to,hypertensive'
p16042
(F1
F0.00014334862385321102
I0
I1
I-1
tp16043
sS'mg,potentiated,the'
p16044
(F1
F0.00014334862385321102
I1
I0
I1
tp16045
sS'know,how,safe'
p16046
(F1
F0.00014334862385321102
I0
I1
I-1
tp16047
sS'thiazide,use,of'
p16048
(F1
F0.00014334862385321102
I1
I0
I1
tp16049
sS'gastrointestinal,acidifying,agents'
p16050
(F1
F0.00014334862385321102
I1
I0
I1
tp16051
sS'attempt,to,establish'
p16052
(F1
F0.00014334862385321102
I1
I0
I1
tp16053
sS'for,ototoxicity,is'
p16054
(F1
F0.00014334862385321102
I1
I0
I1
tp16055
sS'patients,receiving,alone'
p16056
(F1
F0.00014334862385321102
I0
I1
I-1
tp16057
sS'of,tracrium,include'
p16058
(F1
F0.00014334862385321102
I1
I0
I1
tp16059
sS'amprenavir,inhibits,the'
p16060
(F1
F0.00014334862385321102
I0
I1
I-1
tp16061
sS'free,may,be'
p16062
(F1
F0.00014334862385321102
I1
I0
I1
tp16063
sS'indicate,only,a'
p16064
(F1
F0.00014334862385321102
I1
I0
I1
tp16065
sS'to,dictate,against'
p16066
(F1
F0.00014334862385321102
I1
I0
I1
tp16067
sS'mild,to,moderate'
p16068
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp16069
sS'or,pcp,produced'
p16070
(F1
F0.00014334862385321102
I0
I1
I-1
tp16071
sS'loop,sparing,thiazide'
p16072
(F1
F0.00014334862385321102
I0
I1
I-1
tp16073
sS'normal,volunteers,the'
p16074
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp16075
sS'palytoxin,ptx,c129h223n3o54'
p16076
(F1
F0.00014334862385321102
I0
I1
I-1
tp16077
sS'creatinine,clearance,and'
p16078
(F1
F0.00014334862385321102
I1
I0
I1
tp16079
sS'following,other,drugs'
p16080
(F1
F0.00014334862385321102
I0
I1
I-1
tp16081
sS'amphotericin,b,antineoplastic'
p16082
(F1
F0.00014334862385321102
I1
I0
I1
tp16083
sS'endoscopic,gastroduodenal,ulcers'
p16084
(F1
F0.00014334862385321102
I0
I1
I-1
tp16085
sS'the,increase,in'
p16086
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp16087
sS'when,edecrin,and'
p16088
(F1
F0.00014334862385321102
I1
I0
I1
tp16089
sS'bactericidal,effect,of'
p16090
(F1
F0.00014334862385321102
I1
I0
I1
tp16091
sS'added,drug,combinations'
p16092
(F1
F0.00014334862385321102
I0
I1
I-1
tp16093
sS'nonbarbiturate,antianxiety,agents'
p16094
(F1
F0.00014334862385321102
I1
I0
I1
tp16095
sS'in,vivo,as'
p16096
(F1
F0.00014334862385321102
I1
I0
I1
tp16097
sS'phosphorylation,of,this'
p16098
(F1
F0.00014334862385321102
I1
I0
I1
tp16099
sS'men,n,did'
p16100
(F1
F0.00014334862385321102
I0
I1
I-1
tp16101
sS'of,hcl,was'
p16102
(F1
F0.00014334862385321102
I0
I1
I-1
tp16103
sS'similarly,in,the'
p16104
(F1
F0.00014334862385321102
I0
I1
I-1
tp16105
sS'tract,by,up'
p16106
(F1
F0.00014334862385321102
I1
I0
I1
tp16107
sS'member,of,the'
p16108
(F1
F0.00014334862385321102
I1
I0
I1
tp16109
sS'produced,a,decrease'
p16110
(F0
F0
I1
I1
I0
tp16111
sS'taken,hours,before'
p16112
(F1
F0.00014334862385321102
I0
I1
I-1
tp16113
sS'antacid,magnesium-aluminum,hydroxide'
p16114
(F1
F0.00014334862385321102
I0
I1
I-1
tp16115
sS'found,to,decrease'
p16116
(F1
F0.00014334862385321102
I1
I0
I1
tp16117
sS'time,within,the'
p16118
(F1
F0.00014334862385321102
I1
I0
I1
tp16119
sS'renal,toxicity,of'
p16120
(F1
F0.00014334862385321102
I1
I0
I1
tp16121
sS'when,administered,with'
p16122
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp16123
sS'of,increased,steady-state'
p16124
(F1
F0.00014334862385321102
I0
I1
I-1
tp16125
sS'patients,predisposing,to'
p16126
(F1
F0.00014334862385321102
I1
I0
I1
tp16127
sS'of,either,the'
p16128
(F1
F0.00014334862385321102
I0
I1
I-1
tp16129
sS'not,observed,when'
p16130
(F1
F0.00014334862385321102
I0
I1
I-1
tp16131
sS'health,care,professional'
p16132
(F1
F0.00014334862385321102
I1
I0
I1
tp16133
sS'does,not,have'
p16134
(F1
F0.00043004587155963305
I0
I3
I-3
tp16135
sS'healthy,subjects,by'
p16136
(F0
F0
I1
I1
I0
tp16137
sS'successive,application,of'
p16138
(F1
F0.00014334862385321102
I1
I0
I1
tp16139
sS'supplements,taken,concomitantly'
p16140
(F1
F0.00014334862385321102
I1
I0
I1
tp16141
sS'pharmacokinetics,data,indicate'
p16142
(F1
F0.00028669724770642203
I2
I0
I2
tp16143
sS'mg,day,doses'
p16144
(F1
F0.00014334862385321102
I0
I1
I-1
tp16145
sS'evaluate,the,effect'
p16146
(F1
F0.00028669724770642203
I0
I2
I-2
tp16147
sS'given,concurrently,with'
p16148
(F0.5
F0.00028669724770642203
I3
I1
I2
tp16149
sS'lithium,toxicity,has'
p16150
(F1
F0.00028669724770642203
I2
I0
I2
tp16151
sS'trials,of,chloral'
p16152
(F1
F0.00014334862385321102
I0
I1
I-1
tp16153
sS'and,coma,have'
p16154
(F1
F0.00014334862385321102
I1
I0
I1
tp16155
sS'extent,of,plasma'
p16156
(F1
F0.00014334862385321102
I0
I1
I-1
tp16157
sS'its,dosage,reduced'
p16158
(F1
F0.00014334862385321102
I1
I0
I1
tp16159
sS'studies,have,confirmed'
p16160
(F1
F0.00014334862385321102
I0
I1
I-1
tp16161
sS'use,of,sprycel'
p16162
(F1
F0.00014334862385321102
I1
I0
I1
tp16163
sS'was,given,hours'
p16164
(F0
F0
I1
I1
I0
tp16165
sS'once,daily,under'
p16166
(F1
F0.00014334862385321102
I0
I1
I-1
tp16167
sS'in,large,doses'
p16168
(F1
F0.00014334862385321102
I0
I1
I-1
tp16169
sS'be,especially,important'
p16170
(F1
F0.00014334862385321102
I0
I1
I-1
tp16171
sS'significant,pharmacokinetic,interactions'
p16172
(F1
F0.00014334862385321102
I0
I1
I-1
tp16173
sS'day,lexapro,for'
p16174
(F1
F0.00014334862385321102
I1
I0
I1
tp16175
sS'spectrum,of,activity'
p16176
(F1
F0.00014334862385321102
I0
I1
I-1
tp16177
sS'frequency,of,adverse'
p16178
(F1
F0.00014334862385321102
I0
I1
I-1
tp16179
sS'substrate,is,only'
p16180
(F1
F0.00014334862385321102
I0
I1
I-1
tp16181
sS'by,mouth,use'
p16182
(F1
F0.00014334862385321102
I1
I0
I1
tp16183
sS'plasma,proteins,is'
p16184
(F0
F0
I1
I1
I0
tp16185
sS'with,the,ames'
p16186
(F1
F0.00014334862385321102
I0
I1
I-1
tp16187
sS'of,the,brovana'
p16188
(F1
F0.00014334862385321102
I0
I1
I-1
tp16189
sS'side,effects,affecting'
p16190
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp16191
sS'plasma,proteins,in'
p16192
(F1
F0.00014334862385321102
I0
I1
I-1
tp16193
sS'zyvox,or,concomitant'
p16194
(F1
F0.00014334862385321102
I1
I0
I1
tp16195
sS'ml,of,absolute'
p16196
(F1
F0.00014334862385321102
I0
I1
I-1
tp16197
sS'co-administration,of,zyvox'
p16198
(F1
F0.00014334862385321102
I1
I0
I1
tp16199
sS'and,mixed--pharmacological,and'
p16200
(F1
F0.00014334862385321102
I0
I1
I-1
tp16201
sS'the,known,inhibition'
p16202
(F1
F0.00028669724770642203
I0
I2
I-2
tp16203
sS'with,salts,with'
p16204
(F1
F0.00014334862385321102
I0
I1
I-1
tp16205
sS'gabapentin,pharmacokinetic,parameters'
p16206
(F1
F0.00014334862385321102
I0
I1
I-1
tp16207
sS'decrease,in,maximal'
p16208
(F1
F0.00014334862385321102
I1
I0
I1
tp16209
sS'up,to,mm'
p16210
(F1
F0.00014334862385321102
I0
I1
I-1
tp16211
sS'zidovudine,ribavirin,can'
p16212
(F1
F0.00014334862385321102
I1
I0
I1
tp16213
sS'presence,of,other'
p16214
(F1
F0.00014334862385321102
I0
I1
I-1
tp16215
sS'clinical,trial,has'
p16216
(F1
F0.00014334862385321102
I1
I0
I1
tp16217
sS'no,data,from'
p16218
(F1
F0.00014334862385321102
I0
I1
I-1
tp16219
sS'a,or,should'
p16220
(F1
F0.00014334862385321102
I0
I1
I-1
tp16221
sS'and,agents,with'
p16222
(F1
F0.00014334862385321102
I1
I0
I1
tp16223
sS'effect,on,tyrosine'
p16224
(F1
F0.00014334862385321102
I1
I0
I1
tp16225
sS'to,be,co-administered'
p16226
(F1
F0.00057339449541284407
I0
I4
I-4
tp16227
sS'affect,pharmacodynamics,arecoline'
p16228
(F1
F0.00014334862385321102
I1
I0
I1
tp16229
sS'conversion,from,one'
p16230
(F1
F0.00014334862385321102
I0
I1
I-1
tp16231
sS'ulcerative,colitis,a'
p16232
(F1
F0.00014334862385321102
I1
I0
I1
tp16233
sS'systolic,diastolic,blood'
p16234
(F1
F0.00014334862385321102
I1
I0
I1
tp16235
sS'agents,and,may'
p16236
(F1
F0.00014334862385321102
I1
I0
I1
tp16237
sS'patients,taking,a'
p16238
(F1
F0.00014334862385321102
I1
I0
I1
tp16239
sS'with,erythromycin,and'
p16240
(F1
F0.00014334862385321102
I0
I1
I-1
tp16241
sS'of,itraconazole,mg'
p16242
(F1
F0.00014334862385321102
I0
I1
I-1
tp16243
sS'the,therapeutic,actions'
p16244
(F1
F0.00014334862385321102
I1
I0
I1
tp16245
sS'diabetics,dosage,adjustment'
p16246
(F1
F0.00014334862385321102
I1
I0
I1
tp16247
sS'reduce,the,action'
p16248
(F1
F0.00014334862385321102
I1
I0
I1
tp16249
sS'hepatic,enzyme,inducers'
p16250
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp16251
sS'ribavirin,ribavirin,is'
p16252
(F1
F0.00014334862385321102
I0
I1
I-1
tp16253
sS'administered,concurrently,concentrations'
p16254
(F1
F0.00014334862385321102
I1
I0
I1
tp16255
sS'an,interaction,were'
p16256
(F1
F0.00014334862385321102
I0
I1
I-1
tp16257
sS'hcl,alternatives,to'
p16258
(F1
F0.00014334862385321102
I1
I0
I1
tp16259
sS'to,increase,respectively'
p16260
(F1
F0.00014334862385321102
I1
I0
I1
tp16261
sS'enzymes,respectively,responsible'
p16262
(F1
F0.00014334862385321102
I1
I0
I1
tp16263
sS'caused,by,overdose'
p16264
(F1
F0.00014334862385321102
I1
I0
I1
tp16265
sS'synergistic,for,of'
p16266
(F1
F0.00014334862385321102
I1
I0
I1
tp16267
sS'cations,such,as'
p16268
(F1
F0.00043004587155963305
I3
I0
I3
tp16269
sS'low,erpf,and'
p16270
(F1
F0.00014334862385321102
I1
I0
I1
tp16271
sS'interleukin-1,antagonist,and'
p16272
(F1
F0.00014334862385321102
I1
I0
I1
tp16273
sS'is,manifested,as'
p16274
(F1
F0.00014334862385321102
I0
I1
I-1
tp16275
sS'combined,oral,as'
p16276
(F1
F0.00014334862385321102
I0
I1
I-1
tp16277
sS'initiating,adjusting,and'
p16278
(F1
F0.00043004587155963305
I3
I0
I3
tp16279
sS'necessary,when,using'
p16280
(F1
F0.00014334862385321102
I1
I0
I1
tp16281
sS'of,c,p'
p16282
(F1
F0.00014334862385321102
I1
I0
I1
tp16283
sS'interaction,between,novoseven'
p16284
(F1
F0.00014334862385321102
I0
I1
I-1
tp16285
sS'alveolar,concentration,is'
p16286
(F1
F0.00014334862385321102
I1
I0
I1
tp16287
sS'that,inhibits,metabolism'
p16288
(F1
F0.00014334862385321102
I1
I0
I1
tp16289
sS'nsaids,is,not'
p16290
(F1
F0.00028669724770642203
I2
I0
I2
tp16291
sS'to,determine,if'
p16292
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp16293
sS'epsilon,and,mu'
p16294
(F1
F0.00014334862385321102
I0
I1
I-1
tp16295
sS'was,found,minutes'
p16296
(F1
F0.00014334862385321102
I0
I1
I-1
tp16297
sS'concomitantly,with,in'
p16298
(F0
F0
I1
I1
I0
tp16299
sS'or,beta-adrenergic,blocking'
p16300
(F0
F0
I1
I1
I0
tp16301
sS'with,mg,three'
p16302
(F1
F0.00014334862385321102
I0
I1
I-1
tp16303
sS'treated,with,a'
p16304
(F1
F0.00014334862385321102
I0
I1
I-1
tp16305
sS'may,require,downward'
p16306
(F1
F0.00028669724770642203
I2
I0
I2
tp16307
sS'possibility,of,arrhythmias'
p16308
(F1
F0.00014334862385321102
I0
I1
I-1
tp16309
sS'n,were,not'
p16310
(F1
F0.00014334862385321102
I0
I1
I-1
tp16311
sS'targretin,capsules,is'
p16312
(F1
F0.00014334862385321102
I1
I0
I1
tp16313
sS'disturbances,including,complete'
p16314
(F1
F0.00014334862385321102
I0
I1
I-1
tp16315
sS'combination,with,an'
p16316
(F1
F0.00014334862385321102
I0
I1
I-1
tp16317
sS'reduced,the,blood'
p16318
(F1
F0.00014334862385321102
I1
I0
I1
tp16319
sS'ingestion,of,may'
p16320
(F1
F0.00028669724770642203
I2
I0
I2
tp16321
sS'with,camptosar,and'
p16322
(F1
F0.00014334862385321102
I1
I0
I1
tp16323
sS'therapy,eg,selective'
p16324
(F1
F0.00014334862385321102
I0
I1
I-1
tp16325
sS'doses,of,taxol'
p16326
(F1
F0.00014334862385321102
I1
I0
I1
tp16327
sS'blockers,requires,close'
p16328
(F1
F0.00014334862385321102
I1
I0
I1
tp16329
sS'by,a,microdilution'
p16330
(F1
F0.00014334862385321102
I0
I1
I-1
tp16331
sS'are,predominantly,cyp'
p16332
(F1
F0.00014334862385321102
I0
I1
I-1
tp16333
sS'increase,the,cns'
p16334
(F1
F0.00014334862385321102
I0
I1
I-1
tp16335
sS'carbamazepine,combined,administration'
p16336
(F1
F0.00014334862385321102
I0
I1
I-1
tp16337
sS'of,hyperkalemia,may'
p16338
(F1
F0.00014334862385321102
I1
I0
I1
tp16339
sS'this,interaction,has'
p16340
(F1
F0.00028669724770642203
I2
I0
I2
tp16341
sS'of,nonsedating,and'
p16342
(F1
F0.00014334862385321102
I1
I0
I1
tp16343
sS'multiple-dose,pharmacokinetic,profiles'
p16344
(F1
F0.00014334862385321102
I0
I1
I-1
tp16345
sS'products,containing,cremophor'
p16346
(F1
F0.00014334862385321102
I1
I0
I1
tp16347
sS'the,elimination,and'
p16348
(F1
F0.00014334862385321102
I0
I1
I-1
tp16349
sS'that,do,not'
p16350
(F1
F0.00014334862385321102
I1
I0
I1
tp16351
sS'of,users,of'
p16352
(F1
F0.00014334862385321102
I1
I0
I1
tp16353
sS'cholesterol,and,triglycerides'
p16354
(F1
F0.00014334862385321102
I1
I0
I1
tp16355
sS'been,suggested,that'
p16356
(F1
F0.00014334862385321102
I1
I0
I1
tp16357
sS'atorvastatin,atorvastatin,increases'
p16358
(F1
F0.00014334862385321102
I1
I0
I1
tp16359
sS'enzyme,inhibitors,to'
p16360
(F1
F0.00014334862385321102
I1
I0
I1
tp16361
sS'the,prescription,of'
p16362
(F1
F0.00014334862385321102
I1
I0
I1
tp16363
sS'are,mainly,eliminated'
p16364
(F1
F0.00014334862385321102
I0
I1
I-1
tp16365
sS'brovana,may,interfere'
p16366
(F1
F0.00014334862385321102
I1
I0
I1
tp16367
sS'decreases,in,fi'
p16368
(F1
F0.00014334862385321102
I1
I0
I1
tp16369
sS'sd,cumulative,urinary'
p16370
(F1
F0.00014334862385321102
I0
I1
I-1
tp16371
sS'further,these,results'
p16372
(F1
F0.00014334862385321102
I0
I1
I-1
tp16373
sS'and,i,cigarettes'
p16374
(F1
F0.00014334862385321102
I0
I1
I-1
tp16375
sS'p,and,a'
p16376
(F1
F0.00014334862385321102
I1
I0
I1
tp16377
sS'the,ability,of'
p16378
(F0
F0
I1
I1
I0
tp16379
sS'placebo,controlled,trials'
p16380
(F1
F0.00014334862385321102
I0
I1
I-1
tp16381
sS'rt-pa,or,may'
p16382
(F1
F0.00014334862385321102
I0
I1
I-1
tp16383
sS'on,oral,were'
p16384
(F1
F0.00014334862385321102
I0
I1
I-1
tp16385
sS'bleeding,have,been'
p16386
(F1
F0.00014334862385321102
I1
I0
I1
tp16387
sS'important,effects,on'
p16388
(F1
F0.00028669724770642203
I0
I2
I-2
tp16389
sS'specific,interaction,studies'
p16390
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp16391
sS'regimen,of,mg'
p16392
(F1
F0.00057339449541284407
I4
I0
I4
tp16393
sS'clinicians,to,the'
p16394
(F1
F0.00014334862385321102
I1
I0
I1
tp16395
sS'absorption,and,which'
p16396
(F1
F0.00043004587155963305
I3
I0
I3
tp16397
sS'single,dose,mg'
p16398
(F1
F0.00014334862385321102
I0
I1
I-1
tp16399
sS'and,have,also'
p16400
(F1
F0.00014334862385321102
I0
I1
I-1
tp16401
sS'and,dietary-obese,rats'
p16402
(F1
F0.00014334862385321102
I0
I1
I-1
tp16403
sS'of,nalfon,to'
p16404
(F1
F0.00014334862385321102
I1
I0
I1
tp16405
sS'cerebyx,are,expected'
p16406
(F1
F0.00014334862385321102
I0
I1
I-1
tp16407
sS'in,standing,systolic'
p16408
(F1
F0.00014334862385321102
I1
I0
I1
tp16409
sS'mesenteric,arteries,preconstricted'
p16410
(F1
F0.00014334862385321102
I0
I1
I-1
tp16411
sS'faecalis,and,enterococcus'
p16412
(F1
F0.00014334862385321102
I0
I1
I-1
tp16413
sS'terfenadine,no,clinically'
p16414
(F1
F0.00014334862385321102
I0
I1
I-1
tp16415
sS'degree,of,protein'
p16416
(F1
F0.00014334862385321102
I0
I1
I-1
tp16417
sS'in,auc,cmax'
p16418
(F1
F0.00014334862385321102
I0
I1
I-1
tp16419
sS'kg,infused,over'
p16420
(F1
F0.00014334862385321102
I0
I1
I-1
tp16421
sS'exists,not,only'
p16422
(F1
F0.00014334862385321102
I0
I1
I-1
tp16423
sS'p450,a4,enzyme'
p16424
(F1
F0.00014334862385321102
I1
I0
I1
tp16425
sS'significantly,altered,decrease'
p16426
(F1
F0.00014334862385321102
I1
I0
I1
tp16427
sS'concomitantly,with,tablets'
p16428
(F1
F0.00014334862385321102
I1
I0
I1
tp16429
sS'urinary,recovery,of'
p16430
(F1
F0.00014334862385321102
I0
I1
I-1
tp16431
sS'may,be,necessary'
p16432
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp16433
sS'drugs,substances,that'
p16434
(F1
F0.00014334862385321102
I0
I1
I-1
tp16435
sS'antagonists,may,have'
p16436
(F1
F0.00014334862385321102
I1
I0
I1
tp16437
sS'working,properly,and'
p16438
(F1
F0.00014334862385321102
I0
I1
I-1
tp16439
sS'uterine,rupture,or'
p16440
(F1
F0.00014334862385321102
I1
I0
I1
tp16441
sS'pneumonia,vs,serious'
p16442
(F1
F0.00014334862385321102
I1
I0
I1
tp16443
sS'of,prolonged,or'
p16444
(F1
F0.00014334862385321102
I1
I0
I1
tp16445
sS'human,plasma,protein'
p16446
(F1
F0.00014334862385321102
I0
I1
I-1
tp16447
sS'also,reported,to'
p16448
(F1
F0.00014334862385321102
I1
I0
I1
tp16449
sS'were,the,pharmacokinetics'
p16450
(F1
F0.00014334862385321102
I0
I1
I-1
tp16451
sS'local,or,agents'
p16452
(F1
F0.00014334862385321102
I1
I0
I1
tp16453
sS'in,the,case'
p16454
(F1
F0.00014334862385321102
I1
I0
I1
tp16455
sS'reaction,may,occur'
p16456
(F1
F0.00014334862385321102
I1
I0
I1
tp16457
sS'compared,to,vehicle-'
p16458
(F1
F0.00014334862385321102
I1
I0
I1
tp16459
sS'inr,was,increased'
p16460
(F1
F0.00014334862385321102
I1
I0
I1
tp16461
sS'when,viracept,was'
p16462
(F1
F0.00014334862385321102
I0
I1
I-1
tp16463
sS'to,whom,aminoglycoside'
p16464
(F1
F0.00014334862385321102
I1
I0
I1
tp16465
sS'and,other,statins'
p16466
(F1
F0.00014334862385321102
I1
I0
I1
tp16467
sS'drug,interactions,with'
p16468
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp16469
sS'with,potent,inhibitors'
p16470
(F1
F0.00014334862385321102
I0
I1
I-1
tp16471
sS'viracept,should,also'
p16472
(F1
F0.00014334862385321102
I1
I0
I1
tp16473
sS'a,beta-adrenergic,blocking'
p16474
(F1
F0.00014334862385321102
I1
I0
I1
tp16475
sS'use,with,angiotensln'
p16476
(F1
F0.00014334862385321102
I1
I0
I1
tp16477
sS'in,symptoms,that'
p16478
(F1
F0.00014334862385321102
I1
I0
I1
tp16479
sS'and,as,compared'
p16480
(F1
F0.00014334862385321102
I1
I0
I1
tp16481
sS'tablets,a,greater'
p16482
(F1
F0.00014334862385321102
I1
I0
I1
tp16483
sS'and,when,amitriptyline'
p16484
(F1
F0.00014334862385321102
I0
I1
I-1
tp16485
sS'ssris,weakness,hyperreflexia'
p16486
(F1
F0.00014334862385321102
I1
I0
I1
tp16487
sS'beta-adrenergic,blocking,agents'
p16488
(F0.26315789473684209
F0.00071674311926605509
I12
I7
I5
tp16489
sS'of,during,therapy'
p16490
(F1
F0.00014334862385321102
I1
I0
I1
tp16491
sS'given,with,either'
p16492
(F1
F0.00014334862385321102
I1
I0
I1
tp16493
sS'sodium,are,known'
p16494
(F1
F0.00014334862385321102
I0
I1
I-1
tp16495
sS'clinical,pharmacology,clinical'
p16496
(F1
F0.00014334862385321102
I1
I0
I1
tp16497
sS'and,transient,dose-dependent'
p16498
(F1
F0.00014334862385321102
I1
I0
I1
tp16499
sS'doses,of,were'
p16500
(F1
F0.00014334862385321102
I1
I0
I1
tp16501
sS'that,affect,hepatic'
p16502
(F1
F0.00014334862385321102
I1
I0
I1
tp16503
sS'predict,the,effects'
p16504
(F1
F0.00014334862385321102
I0
I1
I-1
tp16505
sS'beta,adrenergic,antagonists'
p16506
(F1
F0.00014334862385321102
I1
I0
I1
tp16507
sS'poc,in,the'
p16508
(F1
F0.00014334862385321102
I0
I1
I-1
tp16509
sS'while,no,in'
p16510
(F1
F0.00014334862385321102
I1
I0
I1
tp16511
sS'with,vitamin,d'
p16512
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp16513
sS'should,be,aware'
p16514
(F1
F0.00028669724770642203
I2
I0
I2
tp16515
sS'hours,prior,to'
p16516
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp16517
sS'is,recommended,in'
p16518
(F1
F0.00014334862385321102
I1
I0
I1
tp16519
sS'of,are,unaltered'
p16520
(F1
F0.00014334862385321102
I0
I1
I-1
tp16521
sS'plasma,concentrations,drugs'
p16522
(F1
F0.00014334862385321102
I1
I0
I1
tp16523
sS'use,of,tricor'
p16524
(F1
F0.00014334862385321102
I1
I0
I1
tp16525
sS'tid,mg,qd'
p16526
(F1
F0.00014334862385321102
I1
I0
I1
tp16527
sS'be,separated,by'
p16528
(F1
F0.00014334862385321102
I1
I0
I1
tp16529
sS'diminish,the,effectiveness'
p16530
(F1
F0.00014334862385321102
I1
I0
I1
tp16531
sS'with,propecia,mg'
p16532
(F1
F0.00014334862385321102
I0
I1
I-1
tp16533
sS'experienced,more,commonly'
p16534
(F1
F0.00014334862385321102
I1
I0
I1
tp16535
sS'be,certain,that'
p16536
(F1
F0.00014334862385321102
I1
I0
I1
tp16537
sS'be,safely,coadministered'
p16538
(F1
F0.00014334862385321102
I0
I1
I-1
tp16539
sS'coadministration,of,that'
p16540
(F1
F0.00014334862385321102
I1
I0
I1
tp16541
sS'of,increased,frequency'
p16542
(F1
F0.00014334862385321102
I0
I1
I-1
tp16543
sS'was,a,decrease'
p16544
(F1
F0.00014334862385321102
I1
I0
I1
tp16545
sS'in,conjunction,with'
p16546
(F0
F0
I5
I5
I0
tp16547
sS'plasma,concentration,profile'
p16548
(F1
F0.00014334862385321102
I0
I1
I-1
tp16549
sS'ros,has,been'
p16550
(F1
F0.00014334862385321102
I0
I1
I-1
tp16551
sS'nad,dependent,oxidation'
p16552
(F0
F0
I1
I1
I0
tp16553
sS'indicate,that,is'
p16554
(F1
F0.00014334862385321102
I0
I1
I-1
tp16555
sS'to,agents,may'
p16556
(F1
F0.00014334862385321102
I1
I0
I1
tp16557
sS'camp,whereas,it'
p16558
(F1
F0.00014334862385321102
I1
I0
I1
tp16559
sS'small,groups,of'
p16560
(F1
F0.00014334862385321102
I0
I1
I-1
tp16561
sS'of,cytochrome,p-450'
p16562
(F1
F0.00014334862385321102
I1
I0
I1
tp16563
sS'of,the,possibility'
p16564
(F1
F0.00057339449541284407
I4
I0
I4
tp16565
sS'brevibloc,esmolol,hcl'
p16566
(F1
F0.00014334862385321102
I0
I1
I-1
tp16567
sS'subjects,stabilized,on'
p16568
(F1
F0.00014334862385321102
I1
I0
I1
tp16569
sS'regimens,where,is'
p16570
(F1
F0.00014334862385321102
I0
I1
I-1
tp16571
sS'studies,in,normal'
p16572
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp16573
sS'heparin,sodium,injection'
p16574
(F1
F0.00014334862385321102
I0
I1
I-1
tp16575
sS'combination,to,control'
p16576
(F1
F0.00014334862385321102
I1
I0
I1
tp16577
sS'include,medications,such'
p16578
(F1
F0.00014334862385321102
I0
I1
I-1
tp16579
sS'm,or,retinyl'
p16580
(F1
F0.00028669724770642203
I2
I0
I2
tp16581
sS'of,diamox,in'
p16582
(F1
F0.00014334862385321102
I1
I0
I1
tp16583
sS'one-third,when,either'
p16584
(F1
F0.00014334862385321102
I0
I1
I-1
tp16585
sS'nearly,normal,release'
p16586
(F1
F0.00014334862385321102
I0
I1
I-1
tp16587
sS'cardiovascular,agents,enalapril'
p16588
(F1
F0.00014334862385321102
I0
I1
I-1
tp16589
sS'the,more,specific'
p16590
(F1
F0.00014334862385321102
I0
I1
I-1
tp16591
sS'four,subjects,with'
p16592
(F1
F0.00014334862385321102
I0
I1
I-1
tp16593
sS'of,activity,against'
p16594
(F1
F0.00014334862385321102
I0
I1
I-1
tp16595
sS'dose,during,the'
p16596
(F1
F0.00014334862385321102
I0
I1
I-1
tp16597
sS'combination,oral,contraceptives'
p16598
(F1
F0.00014334862385321102
I0
I1
I-1
tp16599
sS'increased,by,in'
p16600
(F1
F0.00014334862385321102
I1
I0
I1
tp16601
sS'on,monotherapy,for'
p16602
(F1
F0.00014334862385321102
I0
I1
I-1
tp16603
sS'of,vioxx,with'
p16604
(F1
F0.00028669724770642203
I2
I0
I2
tp16605
sS'by,cyp3a,channel'
p16606
(F1
F0.00014334862385321102
I0
I1
I-1
tp16607
sS'use,of,trazodone'
p16608
(F1
F0.00014334862385321102
I1
I0
I1
tp16609
sS'of,other,folic'
p16610
(F1
F0.00014334862385321102
I1
I0
I1
tp16611
sS'elevations,on,sgpt'
p16612
(F1
F0.00014334862385321102
I1
I0
I1
tp16613
sS'of,control,and'
p16614
(F1
F0.00014334862385321102
I1
I0
I1
tp16615
sS'decrease,the,overall'
p16616
(F1
F0.00014334862385321102
I0
I1
I-1
tp16617
sS'aureus,to,survive'
p16618
(F1
F0.00014334862385321102
I0
I1
I-1
tp16619
sS'conducted,with,and'
p16620
(F1
F0.00014334862385321102
I0
I1
I-1
tp16621
sS'once,daily,produced'
p16622
(F1
F0.00014334862385321102
I1
I0
I1
tp16623
sS'sulfate,multivitamin,preparations'
p16624
(F1
F0.00014334862385321102
I1
I0
I1
tp16625
sS'the,first,hours'
p16626
(F1
F0.00014334862385321102
I0
I1
I-1
tp16627
sS'triamterene,concomitant,use'
p16628
(F1
F0.00014334862385321102
I0
I1
I-1
tp16629
sS'of,where,gastric'
p16630
(F1
F0.00028669724770642203
I2
I0
I2
tp16631
sS'blocks,and,receptors'
p16632
(F1
F0.00014334862385321102
I1
I0
I1
tp16633
sS'from,containing,medicines'
p16634
(F1
F0.00014334862385321102
I1
I0
I1
tp16635
sS'if,inspra,is'
p16636
(F1
F0.00014334862385321102
I1
I0
I1
tp16637
sS'dosage,schedule,was'
p16638
(F1
F0.00014334862385321102
I1
I0
I1
tp16639
sS'observed,with,the'
p16640
(F1
F0.00014334862385321102
I1
I0
I1
tp16641
sS'in,multiple,sclerosis'
p16642
(F1
F0.00014334862385321102
I0
I1
I-1
tp16643
sS'in,auc0-12,and'
p16644
(F1
F0.00014334862385321102
I1
I0
I1
tp16645
sS'was,for,alone'
p16646
(F1
F0.00014334862385321102
I1
I0
I1
tp16647
sS'minutes,faster,with'
p16648
(F1
F0.00014334862385321102
I1
I0
I1
tp16649
sS'chronic,administration,of'
p16650
(F1
F0.00028669724770642203
I2
I0
I2
tp16651
sS'food,cns,effects'
p16652
(F1
F0.00014334862385321102
I1
I0
I1
tp16653
sS'hcl,and,resulted'
p16654
(F1
F0.00014334862385321102
I1
I0
I1
tp16655
sS'fulminant,pancreatitis,possibly'
p16656
(F1
F0.00014334862385321102
I1
I0
I1
tp16657
sS'ssris,and,also'
p16658
(F1
F0.00057339449541284407
I4
I0
I4
tp16659
sS'have,been,frequently'
p16660
(F1
F0.00014334862385321102
I0
I1
I-1
tp16661
sS'may,wear,off'
p16662
(F1
F0.00014334862385321102
I0
I1
I-1
tp16663
sS'average,steady-,state'
p16664
(F1
F0.00014334862385321102
I1
I0
I1
tp16665
sS'clinical,studies,tilade'
p16666
(F1
F0.00014334862385321102
I0
I1
I-1
tp16667
sS'reversed,by,cgs'
p16668
(F1
F0.00014334862385321102
I1
I0
I1
tp16669
sS'doses,increased,the'
p16670
(F1
F0.00014334862385321102
I1
I0
I1
tp16671
sS'cerubidine,may,also'
p16672
(F1
F0.00014334862385321102
I1
I0
I1
tp16673
sS'ergomar,may,be'
p16674
(F1
F0.00014334862385321102
I1
I0
I1
tp16675
sS'inhibitory,concentrations,of'
p16676
(F1
F0.00014334862385321102
I0
I1
I-1
tp16677
sS'agents,has,been'
p16678
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp16679
sS'useful,pharmacological,tool'
p16680
(F1
F0.00014334862385321102
I0
I1
I-1
tp16681
sS'results,from,regression'
p16682
(F1
F0.00014334862385321102
I1
I0
I1
tp16683
sS'and,excretion,was'
p16684
(F1
F0.00014334862385321102
I0
I1
I-1
tp16685
sS'causing,a,toxic'
p16686
(F1
F0.00014334862385321102
I1
I0
I1
tp16687
sS'antineoplastic,agents,have'
p16688
(F1
F0.00014334862385321102
I0
I1
I-1
tp16689
sS'concurrently,with,the'
p16690
(F1
F0.00014334862385321102
I1
I0
I1
tp16691
sS'dictate,against,the'
p16692
(F1
F0.00014334862385321102
I1
I0
I1
tp16693
sS'conjunction,with,an'
p16694
(F1
F0.00014334862385321102
I0
I1
I-1
tp16695
sS'long-term,suppression,of'
p16696
(F1
F0.00014334862385321102
I1
I0
I1
tp16697
sS'closely,monitored,because'
p16698
(F1
F0.00014334862385321102
I1
I0
I1
tp16699
sS'and,the,lowest'
p16700
(F1
F0.00014334862385321102
I1
I0
I1
tp16701
sS'and,pancreatic,supplements'
p16702
(F1
F0.00014334862385321102
I1
I0
I1
tp16703
sS'well,as,topical'
p16704
(F1
F0.00014334862385321102
I0
I1
I-1
tp16705
sS'human,novolog,should'
p16706
(F1
F0.00014334862385321102
I0
I1
I-1
tp16707
sS'for,a,using'
p16708
(F1
F0.00014334862385321102
I0
I1
I-1
tp16709
sS'such,combined,treatment'
p16710
(F1
F0.00014334862385321102
I1
I0
I1
tp16711
sS'increase,the,blood'
p16712
(F1
F0.00014334862385321102
I0
I1
I-1
tp16713
sS'of,in,some'
p16714
(F1
F0.00014334862385321102
I1
I0
I1
tp16715
sS'stopping,since,may'
p16716
(F1
F0.00014334862385321102
I1
I0
I1
tp16717
sS'intestinal,mucosa,caused'
p16718
(F1
F0.00014334862385321102
I1
I0
I1
tp16719
sS'the,compatibility,of'
p16720
(F1
F0.00014334862385321102
I0
I1
I-1
tp16721
sS'levobupivacaine,and,hydroxy'
p16722
(F1
F0.00014334862385321102
I0
I1
I-1
tp16723
sS'administration,of,for'
p16724
(F1
F0.00014334862385321102
I0
I1
I-1
tp16725
sS'of,viracept,with'
p16726
(F1
F0.00014334862385321102
I1
I0
I1
tp16727
sS'studies,other,than'
p16728
(F1
F0.00014334862385321102
I0
I1
I-1
tp16729
sS'placebo,with,these'
p16730
(F1
F0.00014334862385321102
I0
I1
I-1
tp16731
sS'that,produced,pharmacological'
p16732
(F1
F0.00014334862385321102
I0
I1
I-1
tp16733
sS'overall,improvements,in'
p16734
(F1
F0.00014334862385321102
I0
I1
I-1
tp16735
sS'treated,with,co-administered'
p16736
(F1
F0.00014334862385321102
I1
I0
I1
tp16737
sS'for,days,a'
p16738
(F1
F0.00028669724770642203
I2
I0
I2
tp16739
sS'nuromax,is,lengthened'
p16740
(F1
F0.00014334862385321102
I1
I0
I1
tp16741
sS'for,days,n'
p16742
(F1
F0.00014334862385321102
I0
I1
I-1
tp16743
sS'the,natriuretic,and'
p16744
(F1
F0.0010034403669724771
I7
I0
I7
tp16745
sS'display,the,hour'
p16746
(F1
F0.00014334862385321102
I0
I1
I-1
tp16747
sS'in,healthy,subjects'
p16748
(F0.5
F0.0011467889908256881
I12
I4
I8
tp16749
sS'kg,decreased,the'
p16750
(F1
F0.00014334862385321102
I1
I0
I1
tp16751
sS'obtained,after,co-treatment'
p16752
(F1
F0.00014334862385321102
I1
I0
I1
tp16753
sS'a4,isozymes,in'
p16754
(F1
F0.00014334862385321102
I0
I1
I-1
tp16755
sS'lean,and,dietary-obese'
p16756
(F1
F0.00014334862385321102
I0
I1
I-1
tp16757
sS'reportedly,may,increase'
p16758
(F1
F0.00028669724770642203
I2
I0
I2
tp16759
sS'lymphoma,hiv-nhl,the'
p16760
(F1
F0.00014334862385321102
I0
I1
I-1
tp16761
sS'strattera,may,be'
p16762
(F1
F0.00014334862385321102
I1
I0
I1
tp16763
sS'by,concurrent,treatment'
p16764
(F1
F0.00014334862385321102
I1
I0
I1
tp16765
sS'on,the,sixth'
p16766
(F1
F0.00014334862385321102
I1
I0
I1
tp16767
sS'of,myobloc,and'
p16768
(F1
F0.00014334862385321102
I1
I0
I1
tp16769
sS'diet,or,with'
p16770
(F1
F0.00014334862385321102
I0
I1
I-1
tp16771
sS'mao,inhibitors,within'
p16772
(F1
F0.00014334862385321102
I1
I0
I1
tp16773
sS'reported,when,channel'
p16774
(F1
F0.00028669724770642203
I2
I0
I2
tp16775
sS'theobromine,grepafloxacin,like'
p16776
(F1
F0.00014334862385321102
I1
I0
I1
tp16777
sS'of,certain,by'
p16778
(F1
F0.00014334862385321102
I1
I0
I1
tp16779
sS'in,the,peak'
p16780
(F1
F0.00014334862385321102
I0
I1
I-1
tp16781
sS'novo,kidney,allograft'
p16782
(F1
F0.00014334862385321102
I0
I1
I-1
tp16783
sS'effects,of,antagonists'
p16784
(F1
F0.00014334862385321102
I0
I1
I-1
tp16785
sS'are,that,have'
p16786
(F1
F0.00014334862385321102
I0
I1
I-1
tp16787
sS'rebound,in,uptake'
p16788
(F1
F0.00014334862385321102
I1
I0
I1
tp16789
sS'cholestyramine,an,anionic-binding'
p16790
(F1
F0.00014334862385321102
I1
I0
I1
tp16791
sS'the,simultaneous,administration'
p16792
(F0
F0
I1
I1
I0
tp16793
sS'moieties,significantly,improves'
p16794
(F1
F0.00014334862385321102
I0
I1
I-1
tp16795
sS'of,absorption,by'
p16796
(F1
F0.00014334862385321102
I1
I0
I1
tp16797
sS'volunteers,n,pretreatment'
p16798
(F1
F0.00014334862385321102
I1
I0
I1
tp16799
sS'three,well-controlled,studies'
p16800
(F1
F0.00014334862385321102
I0
I1
I-1
tp16801
sS'prothrombin,time,is'
p16802
(F1
F0.00043004587155963305
I3
I0
I3
tp16803
sS'especially,cyclic,may'
p16804
(F1
F0.00014334862385321102
I1
I0
I1
tp16805
sS'nimbex,in,patients'
p16806
(F1
F0.00014334862385321102
I1
I0
I1
tp16807
sS'little,experience,with'
p16808
(F1
F0.00028669724770642203
I0
I2
I-2
tp16809
sS'body,weight,to'
p16810
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp16811
sS'plasma,substrate,is'
p16812
(F1
F0.00014334862385321102
I0
I1
I-1
tp16813
sS'an,intravenous,dose'
p16814
(F1
F0.00014334862385321102
I0
I1
I-1
tp16815
sS'depressive,symptoms,support'
p16816
(F1
F0.00014334862385321102
I0
I1
I-1
tp16817
sS'patients,treated,concurrently'
p16818
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp16819
sS'prothrombin,time,in'
p16820
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp16821
sS'the,reduced,risk'
p16822
(F1
F0.00014334862385321102
I0
I1
I-1
tp16823
sS'by,patients,with'
p16824
(F1
F0.00014334862385321102
I1
I0
I1
tp16825
sS'the,disulfiram-ethanol,reaction'
p16826
(F1
F0.00014334862385321102
I0
I1
I-1
tp16827
sS'of,children,who'
p16828
(F1
F0.00014334862385321102
I0
I1
I-1
tp16829
sS'hemostasis,nsaids,aspirin'
p16830
(F1
F0.00014334862385321102
I0
I1
I-1
tp16831
sS'when,the,recommended'
p16832
(F1
F0.00014334862385321102
I1
I0
I1
tp16833
sS'of,may,be'
p16834
(F0.92307692307692313
F0.0034403669724770644
I25
I1
I24
tp16835
sS'has,no,effect'
p16836
(F1
F0.00071674311926605509
I0
I5
I-5
tp16837
sS'to,affect,protein'
p16838
(F1
F0.00014334862385321102
I0
I1
I-1
tp16839
sS'for,cyp3a4,there'
p16840
(F1
F0.00014334862385321102
I0
I1
I-1
tp16841
sS'evaluated,but,may'
p16842
(F1
F0.00014334862385321102
I1
I0
I1
tp16843
sS'when,are,started'
p16844
(F1
F0.00014334862385321102
I1
I0
I1
tp16845
sS'not,however,appear'
p16846
(F1
F0.00014334862385321102
I0
I1
I-1
tp16847
sS'the,blood,and'
p16848
(F1
F0.00014334862385321102
I1
I0
I1
tp16849
sS'time,reported,as'
p16850
(F1
F0.00014334862385321102
I1
I0
I1
tp16851
sS'was,conducted,to'
p16852
(F1
F0.00014334862385321102
I0
I1
I-1
tp16853
sS'or,or,with'
p16854
(F1
F0.00014334862385321102
I1
I0
I1
tp16855
sS'purification,protocol,for'
p16856
(F1
F0.00014334862385321102
I0
I1
I-1
tp16857
sS'inspra,to,mg'
p16858
(F0
F0
I1
I1
I0
tp16859
sS'sex,hormone-binding,globulin'
p16860
(F1
F0.00014334862385321102
I0
I1
I-1
tp16861
sS'of,plendil,with'
p16862
(F1
F0.00014334862385321102
I0
I1
I-1
tp16863
sS'mg,l,and'
p16864
(F1
F0.00014334862385321102
I0
I1
I-1
tp16865
sS'administration,of,compounds'
p16866
(F1
F0.00014334862385321102
I1
I0
I1
tp16867
sS'septic,shock,in'
p16868
(F1
F0.00014334862385321102
I0
I1
I-1
tp16869
sS'not,affected,when'
p16870
(F1
F0.00028669724770642203
I0
I2
I-2
tp16871
sS'coadministration,of,may'
p16872
(F1
F0.00014334862385321102
I1
I0
I1
tp16873
sS'be,directed,to'
p16874
(F1
F0.00014334862385321102
I1
I0
I1
tp16875
sS'an,agent,of'
p16876
(F1
F0.00014334862385321102
I0
I1
I-1
tp16877
sS'used,successfully,concurrently'
p16878
(F1
F0.00028669724770642203
I0
I2
I-2
tp16879
sS'weight,gain,when'
p16880
(F1
F0.00014334862385321102
I1
I0
I1
tp16881
sS'wide,distribution,of'
p16882
(F1
F0.00014334862385321102
I0
I1
I-1
tp16883
sS'antiepileptic,the,more'
p16884
(F1
F0.00014334862385321102
I0
I1
I-1
tp16885
sS'study,the,atypical'
p16886
(F1
F0.00014334862385321102
I0
I1
I-1
tp16887
sS'binding,of,but'
p16888
(F1
F0.00014334862385321102
I1
I0
I1
tp16889
sS'oxidase,mao,inhibition'
p16890
(F1
F0.00014334862385321102
I0
I1
I-1
tp16891
sS'interaction,with,either'
p16892
(F1
F0.00014334862385321102
I0
I1
I-1
tp16893
sS'half-life,and,an'
p16894
(F1
F0.00014334862385321102
I1
I0
I1
tp16895
sS'approximately,to,the'
p16896
(F1
F0.00014334862385321102
I1
I0
I1
tp16897
sS'we,compared,pharmacokinetics'
p16898
(F1
F0.00014334862385321102
I0
I1
I-1
tp16899
sS'a,subset,of'
p16900
(F1
F0.00014334862385321102
I0
I1
I-1
tp16901
sS'b,for,yeast'
p16902
(F1
F0.00014334862385321102
I0
I1
I-1
tp16903
sS'ie,decreased,prothrom-bin'
p16904
(F1
F0.00028669724770642203
I2
I0
I2
tp16905
sS'bid,did,not'
p16906
(F1
F0.00043004587155963305
I0
I3
I-3
tp16907
sS'in,rat,bone'
p16908
(F1
F0.00014334862385321102
I0
I1
I-1
tp16909
sS'thinners,may,decrease'
p16910
(F1
F0.00014334862385321102
I1
I0
I1
tp16911
sS'p,o,every'
p16912
(F1
F0.00014334862385321102
I1
I0
I1
tp16913
sS'require,empiric,adjustment'
p16914
(F1
F0.00014334862385321102
I0
I1
I-1
tp16915
sS'initiation,of,and'
p16916
(F1
F0.00014334862385321102
I1
I0
I1
tp16917
sS'life-threatening,ventricular,arrhythmias'
p16918
(F1
F0.00014334862385321102
I0
I1
I-1
tp16919
sS'anticoagulants,thyroid,hormones'
p16920
(F1
F0.00014334862385321102
I0
I1
I-1
tp16921
sS'a,dose,range'
p16922
(F1
F0.00014334862385321102
I1
I0
I1
tp16923
sS'induce,cyp3a4,eg'
p16924
(F1
F0.00014334862385321102
I1
I0
I1
tp16925
sS'reduce,intestinal,absorption'
p16926
(F1
F0.00043004587155963305
I3
I0
I3
tp16927
sS'since,pletal,is'
p16928
(F1
F0.00014334862385321102
I1
I0
I1
tp16929
sS'of,prostate,epithelium'
p16930
(F1
F0.00014334862385321102
I1
I0
I1
tp16931
sS'with,slow-release,mg'
p16932
(F1
F0.00014334862385321102
I0
I1
I-1
tp16933
sS'changed,by,coadministration'
p16934
(F1
F0.00014334862385321102
I1
I0
I1
tp16935
sS'decreased,by,during'
p16936
(F1
F0.00014334862385321102
I0
I1
I-1
tp16937
sS'have,been,inconsistent'
p16938
(F1
F0.00014334862385321102
I0
I1
I-1
tp16939
sS'randomly,assigned,to'
p16940
(F1
F0.00014334862385321102
I0
I1
I-1
tp16941
sS'patients,and,return'
p16942
(F1
F0.00014334862385321102
I0
I1
I-1
tp16943
sS'to,form,a'
p16944
(F1
F0.00014334862385321102
I1
I0
I1
tp16945
sS'control,period,in'
p16946
(F1
F0.00014334862385321102
I1
I0
I1
tp16947
sS'full,recovery,in'
p16948
(F1
F0.00014334862385321102
I0
I1
I-1
tp16949
sS'contraindicated,in,patients'
p16950
(F0.5
F0.00028669724770642203
I3
I1
I2
tp16951
sS'multiple,dose,studies'
p16952
(F1
F0.00014334862385321102
I1
I0
I1
tp16953
sS'm-tco,injection,with'
p16954
(F1
F0.00014334862385321102
I1
I0
I1
tp16955
sS'known,to,slow'
p16956
(F1
F0.00014334862385321102
I1
I0
I1
tp16957
sS'major,contributing,factor'
p16958
(F1
F0.00014334862385321102
I1
I0
I1
tp16959
sS'be,administered,during'
p16960
(F1
F0.00014334862385321102
I1
I0
I1
tp16961
sS'given,weekly,subcutaneous'
p16962
(F1
F0.00014334862385321102
I0
I1
I-1
tp16963
sS'cyp1a2,which,may'
p16964
(F1
F0.00014334862385321102
I1
I0
I1
tp16965
sS'organisms,but,it'
p16966
(F1
F0.00014334862385321102
I0
I1
I-1
tp16967
sS'of,usually,depresses'
p16968
(F1
F0.00014334862385321102
I1
I0
I1
tp16969
sS'h2-receptor,antagonists,such'
p16970
(F1
F0.00014334862385321102
I1
I0
I1
tp16971
sS'oral,twice,daily'
p16972
(F1
F0.00014334862385321102
I1
I0
I1
tp16973
sS'h,or,mycophenolate'
p16974
(F1
F0.00014334862385321102
I0
I1
I-1
tp16975
sS'synergistic,such,that'
p16976
(F1
F0.00028669724770642203
I2
I0
I2
tp16977
sS'not,exhibit,monoamine'
p16978
(F1
F0.00014334862385321102
I1
I0
I1
tp16979
sS'on,aed,concentration'
p16980
(F1
F0.00014334862385321102
I0
I1
I-1
tp16981
sS'because,amplifies,the'
p16982
(F1
F0.00014334862385321102
I1
I0
I1
tp16983
sS'the,c,max'
p16984
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp16985
sS'were,agonists,in'
p16986
(F1
F0.00014334862385321102
I1
I0
I1
tp16987
sS'by,cyp2d6,and'
p16988
(F0
F0
I1
I1
I0
tp16989
sS'resemble,poor,metabolizers'
p16990
(F1
F0.00028669724770642203
I0
I2
I-2
tp16991
sS'with,decreases,in'
p16992
(F1
F0.00014334862385321102
I1
I0
I1
tp16993
sS'and,coly-mycin,m'
p16994
(F1
F0.00014334862385321102
I1
I0
I1
tp16995
sS'chemotherapy,regimen,plus'
p16996
(F1
F0.00014334862385321102
I0
I1
I-1
tp16997
sS'selectively,bred,for'
p16998
(F1
F0.00014334862385321102
I0
I1
I-1
tp16999
sS'activity,and,it'
p17000
(F1
F0.00014334862385321102
I0
I1
I-1
tp17001
sS'that,lodine,can'
p17002
(F1
F0.00014334862385321102
I1
I0
I1
tp17003
sS'be,longer,in'
p17004
(F1
F0.00014334862385321102
I0
I1
I-1
tp17005
sS'and,k,may'
p17006
(F1
F0.00043004587155963305
I3
I0
I3
tp17007
sS'it,is,not'
p17008
(F0
F0
I7
I7
I0
tp17009
sS'vitro,may,displace'
p17010
(F1
F0.00014334862385321102
I1
I0
I1
tp17011
sS'or,immediately,following'
p17012
(F1
F0.00014334862385321102
I1
I0
I1
tp17013
sS'cessation,with,or'
p17014
(F1
F0.00014334862385321102
I0
I1
I-1
tp17015
sS'with,or,the'
p17016
(F1
F0.00014334862385321102
I1
I0
I1
tp17017
sS'mg,day,against'
p17018
(F1
F0.00014334862385321102
I0
I1
I-1
tp17019
sS'number,of,including'
p17020
(F1
F0.00014334862385321102
I1
I0
I1
tp17021
sS'the,monomeric,disintegrins'
p17022
(F1
F0.00014334862385321102
I0
I1
I-1
tp17023
sS'injury,or,when'
p17024
(F1
F0.00014334862385321102
I0
I1
I-1
tp17025
sS'compared,with,those'
p17026
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp17027
sS'additional,calcium-containing,preparations'
p17028
(F1
F0.00043004587155963305
I0
I3
I-3
tp17029
sS'shown,not,to'
p17030
(F1
F0.00014334862385321102
I0
I1
I-1
tp17031
sS'agents,should,precede'
p17032
(F1
F0.00014334862385321102
I0
I1
I-1
tp17033
sS'not,been,evaluated'
p17034
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp17035
sS'should,be,used'
p17036
(F0.63636363636363635
F0.0040137614678899085
I36
I8
I28
tp17037
sS'evidence,supporting,the'
p17038
(F1
F0.00014334862385321102
I1
I0
I1
tp17039
sS'of,prostatic,epithelium'
p17040
(F1
F0.00014334862385321102
I1
I0
I1
tp17041
sS'effects,of,should'
p17042
(F1
F0.00014334862385321102
I0
I1
I-1
tp17043
sS'immediately,following,or'
p17044
(F1
F0.00014334862385321102
I1
I0
I1
tp17045
sS'in,effect,should'
p17046
(F1
F0.00014334862385321102
I1
I0
I1
tp17047
sS'is,a,second'
p17048
(F1
F0.00014334862385321102
I0
I1
I-1
tp17049
sS'may,cause,a'
p17050
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp17051
sS'may,develop,delirium'
p17052
(F1
F0.00014334862385321102
I1
I0
I1
tp17053
sS'body,weight,were'
p17054
(F1
F0.00014334862385321102
I0
I1
I-1
tp17055
sS'only,for,documented'
p17056
(F1
F0.00014334862385321102
I0
I1
I-1
tp17057
sS'in,rats,have'
p17058
(F1
F0.00014334862385321102
I1
I0
I1
tp17059
sS'have,been,a'
p17060
(F1
F0.00028669724770642203
I2
I0
I2
tp17061
sS'rats,treated,with'
p17062
(F0
F0
I1
I1
I0
tp17063
sS'risk,of,renal'
p17064
(F0
F0
I1
I1
I0
tp17065
sS'mg,was,admini'
p17066
(F1
F0.00014334862385321102
I1
I0
I1
tp17067
sS'therapeutic,range,while'
p17068
(F1
F0.00014334862385321102
I0
I1
I-1
tp17069
sS'celexa,the,two'
p17070
(F1
F0.00014334862385321102
I1
I0
I1
tp17071
sS'in,the,acute'
p17072
(F1
F0.00028669724770642203
I0
I2
I-2
tp17073
sS'future,studies,should'
p17074
(F1
F0.00014334862385321102
I0
I1
I-1
tp17075
sS'of,prior,to'
p17076
(F1
F0.00014334862385321102
I1
I0
I1
tp17077
sS'of,other,central'
p17078
(F1
F0.00014334862385321102
I1
I0
I1
tp17079
sS'was,observed,on'
p17080
(F1
F0.00014334862385321102
I1
I0
I1
tp17081
sS'agents,the,time'
p17082
(F1
F0.00014334862385321102
I1
I0
I1
tp17083
sS'cyclopentyl-1,dipropylxanthine,dpcpx'
p17084
(F1
F0.00014334862385321102
I0
I1
I-1
tp17085
sS'serum,auc,cmax'
p17086
(F1
F0.00014334862385321102
I1
I0
I1
tp17087
sS'receiving,hcl,has'
p17088
(F1
F0.00014334862385321102
I1
I0
I1
tp17089
sS'initiated,in,patients'
p17090
(F1
F0.00028669724770642203
I2
I0
I2
tp17091
sS'effect,of,alternate-day'
p17092
(F1
F0.00014334862385321102
I1
I0
I1
tp17093
sS'oleate,and,increased'
p17094
(F1
F0.00014334862385321102
I0
I1
I-1
tp17095
sS'ssri-tcainteractions,may,pose'
p17096
(F1
F0.00014334862385321102
I1
I0
I1
tp17097
sS'cyp3a4,would,be'
p17098
(F1
F0.00014334862385321102
I0
I1
I-1
tp17099
sS'medications,including,inhaled'
p17100
(F1
F0.00014334862385321102
I0
I1
I-1
tp17101
sS'day,and,from'
p17102
(F1
F0.00028669724770642203
I0
I2
I-2
tp17103
sS'kind,with,mefloquine'
p17104
(F1
F0.00014334862385321102
I1
I0
I1
tp17105
sS'some,have,also'
p17106
(F1
F0.00014334862385321102
I1
I0
I1
tp17107
sS'diminish,the,effect'
p17108
(F1
F0.00057339449541284407
I4
I0
I4
tp17109
sS'conducted,in,hiv-infected'
p17110
(F1
F0.00014334862385321102
I0
I1
I-1
tp17111
sS'metformin,in,healthy'
p17112
(F1
F0.00014334862385321102
I1
I0
I1
tp17113
sS'concomitantly,may,need'
p17114
(F1
F0.00014334862385321102
I1
I0
I1
tp17115
sS'dosing,lower,maintenance'
p17116
(F1
F0.00014334862385321102
I1
I0
I1
tp17117
sS'juice,should,be'
p17118
(F1
F0.00014334862385321102
I1
I0
I1
tp17119
sS'experiences,in,patients'
p17120
(F1
F0.00014334862385321102
I1
I0
I1
tp17121
sS'not,co-administered,with'
p17122
(F1
F0.00014334862385321102
I0
I1
I-1
tp17123
sS'who,have,been'
p17124
(F0
F0
I2
I2
I0
tp17125
sS'etc,should,be'
p17126
(F1
F0.00014334862385321102
I0
I1
I-1
tp17127
sS'other,or,as'
p17128
(F1
F0.00014334862385321102
I1
I0
I1
tp17129
sS'extensively,studied,and'
p17130
(F1
F0.00014334862385321102
I0
I1
I-1
tp17131
sS'patient,is,receiving'
p17132
(F1
F0.00014334862385321102
I1
I0
I1
tp17133
sS'pressure,response,to'
p17134
(F1
F0.00014334862385321102
I0
I1
I-1
tp17135
sS'of,relative,to'
p17136
(F0
F0
I1
I1
I0
tp17137
sS'interactions,are,listed'
p17138
(F1
F0.00014334862385321102
I1
I0
I1
tp17139
sS'required,with,prolonged'
p17140
(F1
F0.00014334862385321102
I0
I1
I-1
tp17141
sS'would,permit,larger'
p17142
(F1
F0.00014334862385321102
I0
I1
I-1
tp17143
sS'a,phase,i'
p17144
(F1
F0.00014334862385321102
I1
I0
I1
tp17145
sS'gastrointestinal,effects,without'
p17146
(F1
F0.00014334862385321102
I1
I0
I1
tp17147
sS'psychotic,patients,with'
p17148
(F1
F0.00014334862385321102
I0
I1
I-1
tp17149
sS'agents,are,added'
p17150
(F1
F0.00014334862385321102
I0
I1
I-1
tp17151
sS'increasing,overall,response'
p17152
(F1
F0.00014334862385321102
I0
I1
I-1
tp17153
sS'rifampin,co-administration,of'
p17154
(F1
F0.00014334862385321102
I1
I0
I1
tp17155
sS'even,though,such'
p17156
(F1
F0.00014334862385321102
I0
I1
I-1
tp17157
sS'antiretroviral,agents,including'
p17158
(F1
F0.00014334862385321102
I0
I1
I-1
tp17159
sS'daily,with,food'
p17160
(F1
F0.00014334862385321102
I1
I0
I1
tp17161
sS'divalent,or,trivalent'
p17162
(F1
F0.00014334862385321102
I0
I1
I-1
tp17163
sS'resin,may,bind'
p17164
(F1
F0.00014334862385321102
I0
I1
I-1
tp17165
sS'order,to,maintain'
p17166
(F0
F0
I1
I1
I0
tp17167
sS'metabolism,concomitant,use'
p17168
(F1
F0.00014334862385321102
I0
I1
I-1
tp17169
sS'co-administration,of,duloxetine'
p17170
(F0
F0
I1
I1
I0
tp17171
sS'used,in,clinical'
p17172
(F1
F0.00014334862385321102
I0
I1
I-1
tp17173
sS'be,administered,safely'
p17174
(F1
F0.00028669724770642203
I0
I2
I-2
tp17175
sS'after,the,addition'
p17176
(F0
F0
I1
I1
I0
tp17177
sS'dosage,and,administration-dosage'
p17178
(F1
F0.00014334862385321102
I0
I1
I-1
tp17179
sS'taxol,was,given'
p17180
(F1
F0.00014334862385321102
I1
I0
I1
tp17181
sS'in,addition,and'
p17182
(F1
F0.00014334862385321102
I0
I1
I-1
tp17183
sS'or,the,active'
p17184
(F1
F0.00014334862385321102
I0
I1
I-1
tp17185
sS'the,daily,dosage'
p17186
(F1
F0.00014334862385321102
I0
I1
I-1
tp17187
sS'of,on,malignant'
p17188
(F1
F0.00014334862385321102
I1
I0
I1
tp17189
sS'anorectic,and,stimulatory'
p17190
(F1
F0.00014334862385321102
I1
I0
I1
tp17191
sS'by,and,resulted'
p17192
(F1
F0.00014334862385321102
I1
I0
I1
tp17193
sS'given,the,substantial'
p17194
(F1
F0.00014334862385321102
I1
I0
I1
tp17195
sS'effects,with,these'
p17196
(F1
F0.00014334862385321102
I0
I1
I-1
tp17197
sS'agent,with,multiple'
p17198
(F1
F0.00014334862385321102
I1
I0
I1
tp17199
sS'nsaids,in,patients'
p17200
(F1
F0.00014334862385321102
I1
I0
I1
tp17201
sS'with,fentanyl,cyp3a4'
p17202
(F1
F0.00014334862385321102
I0
I1
I-1
tp17203
sS'clinical,response,and'
p17204
(F1
F0.00014334862385321102
I0
I1
I-1
tp17205
sS'greater,than,usual'
p17206
(F1
F0.00014334862385321102
I1
I0
I1
tp17207
sS'mg,led,to'
p17208
(F1
F0.00014334862385321102
I1
I0
I1
tp17209
sS'prevent,the,adrenergic'
p17210
(F1
F0.00014334862385321102
I0
I1
I-1
tp17211
sS'preparations,containing,carbohydrate-splitting'
p17212
(F1
F0.00014334862385321102
I1
I0
I1
tp17213
sS'may,also,result'
p17214
(F1
F0.00057339449541284407
I4
I0
I4
tp17215
sS'of,oleate,and'
p17216
(F1
F0.00014334862385321102
I0
I1
I-1
tp17217
sS'is,not,likely'
p17218
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp17219
sS'uricosuric,agents,since'
p17220
(F1
F0.00014334862385321102
I1
I0
I1
tp17221
sS'in,subcortical,structures'
p17222
(F1
F0.00014334862385321102
I0
I1
I-1
tp17223
sS'with,other,monoamine'
p17224
(F1
F0.00014334862385321102
I1
I0
I1
tp17225
sS'inhibitors,rare,instances'
p17226
(F1
F0.00014334862385321102
I1
I0
I1
tp17227
sS'of,pseudomonas,aeruginosa'
p17228
(F1
F0.00028669724770642203
I0
I2
I-2
tp17229
sS'was,decreased,by'
p17230
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17231
sS'acetazolamide,azole,antifungals'
p17232
(F1
F0.00014334862385321102
I1
I0
I1
tp17233
sS'does,not,significantly'
p17234
(F1
F0.00014334862385321102
I0
I1
I-1
tp17235
sS'describe,modest,elevations'
p17236
(F1
F0.00014334862385321102
I1
I0
I1
tp17237
sS'explain,in,part'
p17238
(F1
F0.00014334862385321102
I0
I1
I-1
tp17239
sS'currently,receiving,careful'
p17240
(F1
F0.00014334862385321102
I1
I0
I1
tp17241
sS'normal,release,in'
p17242
(F1
F0.00014334862385321102
I0
I1
I-1
tp17243
sS'adenocarcinomas,induced,by'
p17244
(F0
F0
I1
I1
I0
tp17245
sS'of,their,dosage'
p17246
(F1
F0.00014334862385321102
I1
I0
I1
tp17247
sS'to,those,seen'
p17248
(F1
F0.00014334862385321102
I1
I0
I1
tp17249
sS'adverse,reaction,and'
p17250
(F1
F0.00014334862385321102
I0
I1
I-1
tp17251
sS'of,especially,in'
p17252
(F1
F0.00028669724770642203
I2
I0
I2
tp17253
sS'retinyl,acetate,affected'
p17254
(F1
F0.00014334862385321102
I1
I0
I1
tp17255
sS'therefore,plasma,concentrations'
p17256
(F1
F0.00014334862385321102
I1
I0
I1
tp17257
sS'and,omega-conotoxin,gvia'
p17258
(F1
F0.00014334862385321102
I0
I1
I-1
tp17259
sS'clotting,factor,vii'
p17260
(F1
F0.00014334862385321102
I0
I1
I-1
tp17261
sS'anhydrase,inhibitors,as'
p17262
(F1
F0.00014334862385321102
I1
I0
I1
tp17263
sS'each,would,coincide'
p17264
(F1
F0.00014334862385321102
I0
I1
I-1
tp17265
sS'of,vardenafil,should'
p17266
(F1
F0.00014334862385321102
I1
I0
I1
tp17267
sS'with,or,potent'
p17268
(F1
F0.00014334862385321102
I1
I0
I1
tp17269
sS'the,aucs,of'
p17270
(F1
F0.00014334862385321102
I0
I1
I-1
tp17271
sS'excretion,of,immunoreactive'
p17272
(F1
F0.00014334862385321102
I0
I1
I-1
tp17273
sS'available,for,chelation'
p17274
(F1
F0.00014334862385321102
I0
I1
I-1
tp17275
sS'alter,plasma,concentrations'
p17276
(F1
F0.00014334862385321102
I1
I0
I1
tp17277
sS'bioavailability,parameters,the'
p17278
(F1
F0.00014334862385321102
I0
I1
I-1
tp17279
sS'infarction,myocarditis,ventricular'
p17280
(F1
F0.00014334862385321102
I1
I0
I1
tp17281
sS'discontinuation,of,concomitant'
p17282
(F1
F0.00014334862385321102
I1
I0
I1
tp17283
sS'agents,have,no'
p17284
(F1
F0.00014334862385321102
I1
I0
I1
tp17285
sS'responsible,for,converting'
p17286
(F1
F0.00014334862385321102
I1
I0
I1
tp17287
sS'depressants,including,has'
p17288
(F1
F0.00014334862385321102
I1
I0
I1
tp17289
sS'adjustment,of,dosage'
p17290
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp17291
sS'hormones,complex,anions'
p17292
(F1
F0.00014334862385321102
I0
I1
I-1
tp17293
sS'availability,of,potent'
p17294
(F1
F0.00014334862385321102
I0
I1
I-1
tp17295
sS'calcium-containing,preparations,should'
p17296
(F1
F0.00043004587155963305
I0
I3
I-3
tp17297
sS'oral,resulted,in'
p17298
(F1
F0.00014334862385321102
I1
I0
I1
tp17299
sS'the,metabolic,clearance'
p17300
(F1
F0.00057339449541284407
I4
I0
I4
tp17301
sS'b12,which,can'
p17302
(F1
F0.00014334862385321102
I1
I0
I1
tp17303
sS'clinical,differences,indicated'
p17304
(F1
F0.00014334862385321102
I0
I1
I-1
tp17305
sS'appear,to,alter'
p17306
(F1
F0.00014334862385321102
I0
I1
I-1
tp17307
sS'and,an,agent'
p17308
(F1
F0.00014334862385321102
I0
I1
I-1
tp17309
sS'on,the,distribution'
p17310
(F1
F0.00014334862385321102
I0
I1
I-1
tp17311
sS'carbonic,anhydrase,inhibitors'
p17312
(F1
F0.00043004587155963305
I3
I0
I3
tp17313
sS'nanm,antagonized,the'
p17314
(F1
F0.00014334862385321102
I1
I0
I1
tp17315
sS'agent,and,an'
p17316
(F1
F0.00014334862385321102
I1
I0
I1
tp17317
sS'ibandronate,osteoporosis,treatment'
p17318
(F1
F0.00014334862385321102
I0
I1
I-1
tp17319
sS'a,spinal,naloxone-sensitive'
p17320
(F1
F0.00014334862385321102
I0
I1
I-1
tp17321
sS'heparin,effect,oral'
p17322
(F1
F0.00014334862385321102
I0
I1
I-1
tp17323
sS'test,for,when'
p17324
(F1
F0.00014334862385321102
I0
I1
I-1
tp17325
sS'absorption,of,may'
p17326
(F1
F0.00028669724770642203
I2
I0
I2
tp17327
sS'considerably,lower,in'
p17328
(F1
F0.00014334862385321102
I1
I0
I1
tp17329
sS'few,systemic,data'
p17330
(F1
F0.00014334862385321102
I0
I1
I-1
tp17331
sS'uricosuric,agents,and'
p17332
(F1
F0.00014334862385321102
I1
I0
I1
tp17333
sS'when,administering,hcl'
p17334
(F1
F0.00014334862385321102
I1
I0
I1
tp17335
sS'of,circulating,fluids'
p17336
(F1
F0.00014334862385321102
I0
I1
I-1
tp17337
sS'conducted,to,assess'
p17338
(F1
F0.00043004587155963305
I0
I3
I-3
tp17339
sS'daily,the,maximum'
p17340
(F1
F0.00014334862385321102
I1
I0
I1
tp17341
sS'produced,a,tolerance'
p17342
(F1
F0.00014334862385321102
I1
I0
I1
tp17343
sS'healthy,volunteers,a'
p17344
(F1
F0.00028669724770642203
I2
I0
I2
tp17345
sS'fenofibric,acid,are'
p17346
(F1
F0.00014334862385321102
I0
I1
I-1
tp17347
sS'healthy,volunteers,n'
p17348
(F1
F0.00014334862385321102
I0
I1
I-1
tp17349
sS'studies,in,multiple'
p17350
(F1
F0.00014334862385321102
I0
I1
I-1
tp17351
sS'on,prolonging,atrioventricular'
p17352
(F1
F0.00014334862385321102
I1
I0
I1
tp17353
sS'in,patients,administered'
p17354
(F1
F0.00014334862385321102
I1
I0
I1
tp17355
sS'combination,of,with'
p17356
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17357
sS'the,magnitude,and'
p17358
(F1
F0.00028669724770642203
I2
I0
I2
tp17359
sS'effect,of,and'
p17360
(F0.75
F0.0017201834862385322
I14
I2
I12
tp17361
sS'depression,of,cardiac'
p17362
(F1
F0.00014334862385321102
I1
I0
I1
tp17363
sS'inhibitors,nefazodone,cyclosporine'
p17364
(F1
F0.00014334862385321102
I0
I1
I-1
tp17365
sS'on,white,male'
p17366
(F1
F0.00014334862385321102
I0
I1
I-1
tp17367
sS'interfere,with,one-stage'
p17368
(F1
F0.00014334862385321102
I0
I1
I-1
tp17369
sS'cause,elevated,plasma'
p17370
(F1
F0.00014334862385321102
I1
I0
I1
tp17371
sS'substantially,interfere,with'
p17372
(F1
F0.00057339449541284407
I4
I0
I4
tp17373
sS'such,as,have'
p17374
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17375
sS'cyclosporine,increased,activity'
p17376
(F1
F0.00014334862385321102
I1
I0
I1
tp17377
sS'doses,or,too'
p17378
(F1
F0.00014334862385321102
I0
I1
I-1
tp17379
sS'require,anticoagulation,should'
p17380
(F1
F0.00014334862385321102
I0
I1
I-1
tp17381
sS'higher,when,given'
p17382
(F1
F0.00014334862385321102
I1
I0
I1
tp17383
sS'significantly,affected,prothrombin'
p17384
(F1
F0.00014334862385321102
I0
I1
I-1
tp17385
sS'less,than,seven'
p17386
(F1
F0.00014334862385321102
I0
I1
I-1
tp17387
sS'may,be,precipitated'
p17388
(F1
F0.00014334862385321102
I0
I1
I-1
tp17389
sS'cyclosporine,cyp3a4,substrate'
p17390
(F1
F0.00014334862385321102
I0
I1
I-1
tp17391
sS'cytochrome,p450,isoforms'
p17392
(F1
F0.00014334862385321102
I0
I1
I-1
tp17393
sS'and,clinical,pharmacology'
p17394
(F1
F0.00014334862385321102
I1
I0
I1
tp17395
sS'that,the,potent'
p17396
(F1
F0.00014334862385321102
I1
I0
I1
tp17397
sS'of,hypotension,and'
p17398
(F1
F0.00043004587155963305
I3
I0
I3
tp17399
sS'theoretically,adversely,influence'
p17400
(F1
F0.00014334862385321102
I1
I0
I1
tp17401
sS'methotrexate,in,an'
p17402
(F1
F0.00014334862385321102
I0
I1
I-1
tp17403
sS'a,previously,administered'
p17404
(F1
F0.00014334862385321102
I1
I0
I1
tp17405
sS'co-medications,that,induce'
p17406
(F0
F0
I1
I1
I0
tp17407
sS'and,the,type'
p17408
(F1
F0.00071674311926605509
I0
I5
I-5
tp17409
sS'synthesis,secretion,distribution'
p17410
(F1
F0.00014334862385321102
I0
I1
I-1
tp17411
sS'novel,peripherally,restricted'
p17412
(F1
F0.00014334862385321102
I1
I0
I1
tp17413
sS'method,of,barrier'
p17414
(F1
F0.00014334862385321102
I1
I0
I1
tp17415
sS'ast,and,sgpt'
p17416
(F1
F0.00014334862385321102
I1
I0
I1
tp17417
sS'and,or,to'
p17418
(F1
F0.00014334862385321102
I1
I0
I1
tp17419
sS'injection,of,min'
p17420
(F1
F0.00014334862385321102
I1
I0
I1
tp17421
sS'aspirin,in,normal'
p17422
(F1
F0.00014334862385321102
I1
I0
I1
tp17423
sS'by,to,for'
p17424
(F1
F0.00014334862385321102
I1
I0
I1
tp17425
sS'd,or,mg'
p17426
(F0
F0
I1
I1
I0
tp17427
sS'agents,calcium-blocking,agents'
p17428
(F1
F0.00014334862385321102
I0
I1
I-1
tp17429
sS'in,surgery,or'
p17430
(F1
F0.00014334862385321102
I0
I1
I-1
tp17431
sS'enzyme,systems,responsible'
p17432
(F1
F0.00014334862385321102
I0
I1
I-1
tp17433
sS'we,investigated,the'
p17434
(F1
F0.00028669724770642203
I0
I2
I-2
tp17435
sS'lithium,in,a'
p17436
(F1
F0.00014334862385321102
I1
I0
I1
tp17437
sS'that,is,bound'
p17438
(F1
F0.00014334862385321102
I0
I1
I-1
tp17439
sS'and,these,data'
p17440
(F1
F0.00014334862385321102
I0
I1
I-1
tp17441
sS'of,the,intravenous'
p17442
(F1
F0.00014334862385321102
I1
I0
I1
tp17443
sS'nimbex,are,unknown'
p17444
(F1
F0.00014334862385321102
I1
I0
I1
tp17445
sS'capsules,garlic,capsules'
p17446
(F1
F0.00014334862385321102
I0
I1
I-1
tp17447
sS'studied,in,vivo'
p17448
(F1
F0.00014334862385321102
I0
I1
I-1
tp17449
sS'and,and,other'
p17450
(F1
F0.00014334862385321102
I1
I0
I1
tp17451
sS'of,significant,hypotension'
p17452
(F1
F0.00014334862385321102
I1
I0
I1
tp17453
sS'cytochrome,p450,inducers'
p17454
(F1
F0.00014334862385321102
I1
I0
I1
tp17455
sS'of,patients,the'
p17456
(F1
F0.00014334862385321102
I0
I1
I-1
tp17457
sS'dose,is,co-administered'
p17458
(F1
F0.00014334862385321102
I1
I0
I1
tp17459
sS'of,alone,or'
p17460
(F1
F0.00014334862385321102
I0
I1
I-1
tp17461
sS'combination,with,triamterene'
p17462
(F1
F0.00014334862385321102
I0
I1
I-1
tp17463
sS'substrates,of,cyp2d6'
p17464
(F1
F0.00014334862385321102
I1
I0
I1
tp17465
sS'may,prolong,and'
p17466
(F0
F0
I2
I2
I0
tp17467
sS'the,response,to'
p17468
(F0.5
F0.00028669724770642203
I3
I1
I2
tp17469
sS'plasma,auc,and'
p17470
(F1
F0.00057339449541284407
I4
I0
I4
tp17471
sS'inhibition,of,on'
p17472
(F1
F0.00014334862385321102
I0
I1
I-1
tp17473
sS'this,is,not'
p17474
(F1
F0.00014334862385321102
I1
I0
I1
tp17475
sS'prolonged,in,the'
p17476
(F1
F0.00014334862385321102
I1
I0
I1
tp17477
sS'and,the,dose'
p17478
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp17479
sS'well,as,those'
p17480
(F0
F0
I1
I1
I0
tp17481
sS'addition,results,from'
p17482
(F1
F0.00014334862385321102
I1
I0
I1
tp17483
sS'can,produce,clinically'
p17484
(F1
F0.00014334862385321102
I1
I0
I1
tp17485
sS'these,include,the'
p17486
(F1
F0.00043004587155963305
I0
I3
I-3
tp17487
sS'normal,healthy,male'
p17488
(F1
F0.00014334862385321102
I0
I1
I-1
tp17489
sS'agents,increasing,serum'
p17490
(F1
F0.00028669724770642203
I2
I0
I2
tp17491
sS'and,auc,exhibited'
p17492
(F1
F0.00014334862385321102
I0
I1
I-1
tp17493
sS'other,central,nervous'
p17494
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp17495
sS'and,some,oxytocic'
p17496
(F1
F0.00014334862385321102
I1
I0
I1
tp17497
sS'reduced,cmax,and'
p17498
(F1
F0.00014334862385321102
I1
I0
I1
tp17499
sS'in,severe,hyperkalemia'
p17500
(F1
F0.00014334862385321102
I1
I0
I1
tp17501
sS'of,suggest,a'
p17502
(F1
F0.00014334862385321102
I1
I0
I1
tp17503
sS'patients,with,acute'
p17504
(F1
F0.00028669724770642203
I2
I0
I2
tp17505
sS'cns-depressive,effect,of'
p17506
(F1
F0.00014334862385321102
I1
I0
I1
tp17507
sS'should,therefore,not'
p17508
(F1
F0.00043004587155963305
I3
I0
I3
tp17509
sS'reduction,is,not'
p17510
(F1
F0.00014334862385321102
I1
I0
I1
tp17511
sS'with,subsequent,diagnostic'
p17512
(F1
F0.00014334862385321102
I0
I1
I-1
tp17513
sS'and,especially,those'
p17514
(F1
F0.00043004587155963305
I3
I0
I3
tp17515
sS'responding,in,a'
p17516
(F1
F0.00014334862385321102
I1
I0
I1
tp17517
sS'the,human,cytochrome'
p17518
(F1
F0.00028669724770642203
I0
I2
I-2
tp17519
sS'and,inflammatory,disorders'
p17520
(F1
F0.00014334862385321102
I1
I0
I1
tp17521
sS'use,of,nsaids'
p17522
(F1
F0.00014334862385321102
I1
I0
I1
tp17523
sS'the,same,study'
p17524
(F1
F0.00014334862385321102
I0
I1
I-1
tp17525
sS'or,h,antagonists'
p17526
(F0
F0
I1
I1
I0
tp17527
sS'regimen,of,aprepitant'
p17528
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp17529
sS'cyp3a4,inhibitor,mg'
p17530
(F1
F0.00014334862385321102
I1
I0
I1
tp17531
sS'block,the,pharmacologic'
p17532
(F1
F0.00014334862385321102
I1
I0
I1
tp17533
sS'done,extremely,cautiously'
p17534
(F1
F0.00014334862385321102
I1
I0
I1
tp17535
sS'with,another,and'
p17536
(F1
F0.00014334862385321102
I1
I0
I1
tp17537
sS'quinidine,and,doses'
p17538
(F1
F0.00014334862385321102
I0
I1
I-1
tp17539
sS'sunscreens,and,some'
p17540
(F1
F0.00014334862385321102
I1
I0
I1
tp17541
sS'of,a,clinical'
p17542
(F1
F0.00014334862385321102
I1
I0
I1
tp17543
sS'chylomicron-like,emulsion,model'
p17544
(F1
F0.00014334862385321102
I0
I1
I-1
tp17545
sS'they,do,not'
p17546
(F1
F0.00014334862385321102
I1
I0
I1
tp17547
sS'synthetic,steroidal,and'
p17548
(F1
F0.00014334862385321102
I0
I1
I-1
tp17549
sS'is,far,greater'
p17550
(F1
F0.00014334862385321102
I0
I1
I-1
tp17551
sS'administration,of,hcl'
p17552
(F1
F0.00014334862385321102
I1
I0
I1
tp17553
sS'by,simply,normalizing'
p17554
(F1
F0.00014334862385321102
I0
I1
I-1
tp17555
sS'slight,intrinsic,effect'
p17556
(F1
F0.00014334862385321102
I1
I0
I1
tp17557
sS'comparable,to,or'
p17558
(F1
F0.00014334862385321102
I1
I0
I1
tp17559
sS'compounds,including,sodium'
p17560
(F1
F0.00014334862385321102
I1
I0
I1
tp17561
sS'co-administered,with,other'
p17562
(F0
F0
I1
I1
I0
tp17563
sS'solution,may,potentiate'
p17564
(F1
F0.00014334862385321102
I1
I0
I1
tp17565
sS'of,that,in'
p17566
(F1
F0.00014334862385321102
I0
I1
I-1
tp17567
sS'previously,unrecognized,interaction'
p17568
(F1
F0.00014334862385321102
I1
I0
I1
tp17569
sS'of,schizophrenia,in'
p17570
(F1
F0.00014334862385321102
I0
I1
I-1
tp17571
sS'not,advisable,to'
p17572
(F1
F0.00014334862385321102
I1
I0
I1
tp17573
sS'of,ergot-type,oxytocic'
p17574
(F1
F0.00014334862385321102
I0
I1
I-1
tp17575
sS'nuromax,include,certain'
p17576
(F1
F0.00014334862385321102
I1
I0
I1
tp17577
sS'the,production,of'
p17578
(F0
F0
I2
I2
I0
tp17579
sS'therapeutic,concentrations,of'
p17580
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp17581
sS'omega-agatoxin,iva,p-type'
p17582
(F1
F0.00014334862385321102
I0
I1
I-1
tp17583
sS'occur,earlier,than'
p17584
(F1
F0.00014334862385321102
I1
I0
I1
tp17585
sS'mice,min,before'
p17586
(F1
F0.00014334862385321102
I0
I1
I-1
tp17587
sS'use,of,mg'
p17588
(F1
F0.00014334862385321102
I0
I1
I-1
tp17589
sS'potential,of,binding'
p17590
(F1
F0.00014334862385321102
I1
I0
I1
tp17591
sS'oral,the,dose'
p17592
(F1
F0.00014334862385321102
I0
I1
I-1
tp17593
sS'of,with,adefovir'
p17594
(F1
F0.00014334862385321102
I0
I1
I-1
tp17595
sS'therapy,is,discontinued'
p17596
(F1
F0.00014334862385321102
I1
I0
I1
tp17597
sS'non-hodgkin,lymphoma,hiv-nhl'
p17598
(F1
F0.00014334862385321102
I0
I1
I-1
tp17599
sS'sites,for,increased'
p17600
(F1
F0.00014334862385321102
I0
I1
I-1
tp17601
sS'high,dose,of'
p17602
(F1
F0.00028669724770642203
I2
I0
I2
tp17603
sS'prolonged,the,half-life'
p17604
(F1
F0.00028669724770642203
I2
I0
I2
tp17605
sS'body,via,conjugation'
p17606
(F1
F0.00014334862385321102
I1
I0
I1
tp17607
sS'decreases,the,binding'
p17608
(F1
F0.00014334862385321102
I1
I0
I1
tp17609
sS'primarily,to,enhance'
p17610
(F1
F0.00014334862385321102
I1
I0
I1
tp17611
sS'be,necessary,during'
p17612
(F1
F0.00014334862385321102
I1
I0
I1
tp17613
sS'as,reflected,in'
p17614
(F1
F0.00014334862385321102
I1
I0
I1
tp17615
sS'increases,in,inr'
p17616
(F1
F0.00014334862385321102
I1
I0
I1
tp17617
sS'aminotransferases,was,observed'
p17618
(F1
F0.00014334862385321102
I0
I1
I-1
tp17619
sS'of,organic,if'
p17620
(F1
F0.00014334862385321102
I1
I0
I1
tp17621
sS'number,of,compounds'
p17622
(F1
F0.00014334862385321102
I1
I0
I1
tp17623
sS'smaller,week,study'
p17624
(F1
F0.00014334862385321102
I0
I1
I-1
tp17625
sS'regarding,the,effect'
p17626
(F0
F0
I1
I1
I0
tp17627
sS'the,heart,rate'
p17628
(F1
F0.00014334862385321102
I1
I0
I1
tp17629
sS'absolute,but,a'
p17630
(F1
F0.00014334862385321102
I0
I1
I-1
tp17631
sS'administration,of,norpace'
p17632
(F1
F0.00014334862385321102
I1
I0
I1
tp17633
sS'uninfected,volunteers,developed'
p17634
(F1
F0.00014334862385321102
I1
I0
I1
tp17635
sS'of,with,acamprosate'
p17636
(F1
F0.00014334862385321102
I1
I0
I1
tp17637
sS'effects,ways,to'
p17638
(F1
F0.00014334862385321102
I0
I1
I-1
tp17639
sS'of,and,inn'
p17640
(F1
F0.00014334862385321102
I0
I1
I-1
tp17641
sS'vs,placebo,n'
p17642
(F1
F0.00014334862385321102
I0
I1
I-1
tp17643
sS'vivo,platelet,aggregation'
p17644
(F1
F0.00014334862385321102
I0
I1
I-1
tp17645
sS'in,which,clearance'
p17646
(F1
F0.00014334862385321102
I1
I0
I1
tp17647
sS'comparative,data,in'
p17648
(F1
F0.00028669724770642203
I0
I2
I-2
tp17649
sS'betaseron,administration,to'
p17650
(F1
F0.00014334862385321102
I1
I0
I1
tp17651
sS'a,maximal,decrease'
p17652
(F1
F0.00014334862385321102
I0
I1
I-1
tp17653
sS'in,combination,with'
p17654
(F0.27272727272727271
F0.0025802752293577983
I24
I42
I-18
tp17655
sS'of,on,day'
p17656
(F0
F0
I1
I1
I0
tp17657
sS'in,vitro,aspirin-mediated'
p17658
(F1
F0.00014334862385321102
I0
I1
I-1
tp17659
sS'of,coadministration,of'
p17660
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp17661
sS'are,unaltered,in'
p17662
(F1
F0.00014334862385321102
I0
I1
I-1
tp17663
sS'the,initiation,of'
p17664
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp17665
sS'diltiazem,in,patients'
p17666
(F1
F0.00014334862385321102
I1
I0
I1
tp17667
sS'after,a,dose'
p17668
(F1
F0.00014334862385321102
I1
I0
I1
tp17669
sS'counteract,the,action'
p17670
(F1
F0.00014334862385321102
I1
I0
I1
tp17671
sS'injection,of,vehicle'
p17672
(F1
F0.00014334862385321102
I0
I1
I-1
tp17673
sS'vioxx,is,co-administered'
p17674
(F1
F0.00014334862385321102
I0
I1
I-1
tp17675
sS'to,avoid,administration'
p17676
(F1
F0.00014334862385321102
I0
I1
I-1
tp17677
sS'other,therapy,has'
p17678
(F1
F0.00014334862385321102
I0
I1
I-1
tp17679
sS'results,using,the'
p17680
(F1
F0.00014334862385321102
I0
I1
I-1
tp17681
sS'diamox,modifies,metabolism'
p17682
(F1
F0.00014334862385321102
I1
I0
I1
tp17683
sS'to,the,enhancement'
p17684
(F1
F0.00014334862385321102
I1
I0
I1
tp17685
sS'be,administered,or'
p17686
(F1
F0.00014334862385321102
I0
I1
I-1
tp17687
sS'qrs,complex,and'
p17688
(F1
F0.00014334862385321102
I1
I0
I1
tp17689
sS'be,administered,on'
p17690
(F1
F0.00014334862385321102
I0
I1
I-1
tp17691
sS'in,another,report'
p17692
(F1
F0.00014334862385321102
I1
I0
I1
tp17693
sS'considered,and,dosage'
p17694
(F1
F0.00043004587155963305
I0
I3
I-3
tp17695
sS'the,probable,benefits'
p17696
(F1
F0.00014334862385321102
I1
I0
I1
tp17697
sS'oxo-desethylzaleplon,and,oxo-desethylzaleplon'
p17698
(F1
F0.00014334862385321102
I0
I1
I-1
tp17699
sS'cyp3a4,substrates,known'
p17700
(F1
F0.00014334862385321102
I1
I0
I1
tp17701
sS'extent,and,the'
p17702
(F1
F0.00014334862385321102
I0
I1
I-1
tp17703
sS'motility,of,day-old'
p17704
(F1
F0.00014334862385321102
I1
I0
I1
tp17705
sS'agents,disturbances,of'
p17706
(F1
F0.00014334862385321102
I1
I0
I1
tp17707
sS'containing,maalox,decreased'
p17708
(F1
F0.00014334862385321102
I1
I0
I1
tp17709
sS'individual,patients,may'
p17710
(F1
F0.00014334862385321102
I1
I0
I1
tp17711
sS'and,an,oral'
p17712
(F1
F0.00014334862385321102
I1
I0
I1
tp17713
sS'whose,absorption,can'
p17714
(F1
F0.00014334862385321102
I1
I0
I1
tp17715
sS'cardiotoxic,or,hepatotoxic'
p17716
(F1
F0.00014334862385321102
I1
I0
I1
tp17717
sS'and,add,a'
p17718
(F1
F0.0008600917431192661
I6
I0
I6
tp17719
sS'c,max,c'
p17720
(F1
F0.00014334862385321102
I0
I1
I-1
tp17721
sS'antihistamines,may,enhance'
p17722
(F1
F0.00014334862385321102
I1
I0
I1
tp17723
sS'to,ml,h'
p17724
(F0
F0
I1
I1
I0
tp17725
sS'i,such,as'
p17726
(F1
F0.00014334862385321102
I0
I1
I-1
tp17727
sS'almost,always,seen'
p17728
(F1
F0.00014334862385321102
I0
I1
I-1
tp17729
sS'ketoconazole,ketoconazole,mg'
p17730
(F1
F0.00014334862385321102
I0
I1
I-1
tp17731
sS'asthma,therapy,compliance'
p17732
(F1
F0.00014334862385321102
I0
I1
I-1
tp17733
sS'administered,with,lodine'
p17734
(F1
F0.00014334862385321102
I0
I1
I-1
tp17735
sS'or,mg,bid'
p17736
(F1
F0.00014334862385321102
I0
I1
I-1
tp17737
sS'lines,divergently,selected'
p17738
(F1
F0.00014334862385321102
I0
I1
I-1
tp17739
sS'subjects,dosed,with'
p17740
(F1
F0.00014334862385321102
I1
I0
I1
tp17741
sS'on,clinical,and'
p17742
(F1
F0.00014334862385321102
I1
I0
I1
tp17743
sS'hypermagnesemia,and,should'
p17744
(F1
F0.00043004587155963305
I3
I0
I3
tp17745
sS'proprietary,cold,remedies'
p17746
(F1
F0.00014334862385321102
I1
I0
I1
tp17747
sS'affect,the,c'
p17748
(F1
F0.00014334862385321102
I0
I1
I-1
tp17749
sS'synthetic,analogue,d-ala2'
p17750
(F1
F0.00014334862385321102
I0
I1
I-1
tp17751
sS'of,discontinuing,treatment'
p17752
(F1
F0.00014334862385321102
I1
I0
I1
tp17753
sS'of,healthy,volunteers'
p17754
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17755
sS'vitamin,b12,diagnostic'
p17756
(F1
F0.00014334862385321102
I0
I1
I-1
tp17757
sS'containing,or,salicylic'
p17758
(F1
F0.00014334862385321102
I0
I1
I-1
tp17759
sS'topical,dose,is'
p17760
(F1
F0.00014334862385321102
I0
I1
I-1
tp17761
sS'serum,protein,the'
p17762
(F1
F0.00014334862385321102
I1
I0
I1
tp17763
sS'both,cyp1a2,and'
p17764
(F1
F0.00014334862385321102
I0
I1
I-1
tp17765
sS'unless,the,benefit'
p17766
(F1
F0.00014334862385321102
I1
I0
I1
tp17767
sS'affect,renal,function'
p17768
(F1
F0.00028669724770642203
I0
I2
I-2
tp17769
sS'max,c,min'
p17770
(F1
F0.00014334862385321102
I0
I1
I-1
tp17771
sS'enzymes,may,reduce'
p17772
(F1
F0.00014334862385321102
I1
I0
I1
tp17773
sS'respectively,which,could'
p17774
(F1
F0.00014334862385321102
I0
I1
I-1
tp17775
sS'of,schizophrenic,patients'
p17776
(F0
F0
I1
I1
I0
tp17777
sS'of,av,nodal'
p17778
(F1
F0.00014334862385321102
I1
I0
I1
tp17779
sS'm,of,immobilised'
p17780
(F1
F0.00014334862385321102
I0
I1
I-1
tp17781
sS'local,agents,were'
p17782
(F1
F0.00014334862385321102
I0
I1
I-1
tp17783
sS'significant,hyperprolactinaemia,as'
p17784
(F1
F0.00014334862385321102
I0
I1
I-1
tp17785
sS'resulted,in,induction'
p17786
(F1
F0.00014334862385321102
I1
I0
I1
tp17787
sS'of,ergomar,may'
p17788
(F1
F0.00014334862385321102
I1
I0
I1
tp17789
sS'hypotension,bradycardia,and'
p17790
(F1
F0.00014334862385321102
I0
I1
I-1
tp17791
sS'drugs,with,ototoxic'
p17792
(F1
F0.00014334862385321102
I1
I0
I1
tp17793
sS'was,enhanced,when'
p17794
(F1
F0.00014334862385321102
I0
I1
I-1
tp17795
sS'shown,no,clinically'
p17796
(F1
F0.00014334862385321102
I0
I1
I-1
tp17797
sS'prostaglandina,play,an'
p17798
(F1
F0.00014334862385321102
I1
I0
I1
tp17799
sS'bad,general,clinical'
p17800
(F1
F0.00014334862385321102
I1
I0
I1
tp17801
sS'time,beyond,the'
p17802
(F1
F0.00014334862385321102
I1
I0
I1
tp17803
sS'renal,insufficiency,hyperbilirubinemia'
p17804
(F1
F0.00014334862385321102
I1
I0
I1
tp17805
sS'oral,treatment,folic'
p17806
(F1
F0.00014334862385321102
I1
I0
I1
tp17807
sS'administration,mg,and'
p17808
(F1
F0.00014334862385321102
I0
I1
I-1
tp17809
sS'higher,doses,up'
p17810
(F1
F0.00014334862385321102
I0
I1
I-1
tp17811
sS'by,decreasing,the'
p17812
(F1
F0.00014334862385321102
I1
I0
I1
tp17813
sS'demonstrate,that,does'
p17814
(F1
F0.00014334862385321102
I0
I1
I-1
tp17815
sS'to,mg,kg'
p17816
(F1
F0.00028669724770642203
I2
I0
I2
tp17817
sS'may,be,similar'
p17818
(F1
F0.00014334862385321102
I0
I1
I-1
tp17819
sS'oral,markedly,inhibit'
p17820
(F1
F0.00014334862385321102
I1
I0
I1
tp17821
sS'and,reaction,time'
p17822
(F1
F0.00014334862385321102
I1
I0
I1
tp17823
sS'the,peak,plasma'
p17824
(F1
F0.00014334862385321102
I1
I0
I1
tp17825
sS'study,coadministration,of'
p17826
(F1
F0.00028669724770642203
I2
I0
I2
tp17827
sS'multiple,doses,mg'
p17828
(F1
F0.00014334862385321102
I1
I0
I1
tp17829
sS'the,dose,of'
p17830
(F0.29999999999999999
F0.0008600917431192661
I13
I7
I6
tp17831
sS'with,or,did'
p17832
(F0
F0
I1
I1
I0
tp17833
sS'proleukin,may,reduce'
p17834
(F1
F0.00014334862385321102
I1
I0
I1
tp17835
sS'follow,dosing,by'
p17836
(F1
F0.00014334862385321102
I0
I1
I-1
tp17837
sS'female,volunteers,in'
p17838
(F1
F0.00014334862385321102
I0
I1
I-1
tp17839
sS'of,oral,certain'
p17840
(F1
F0.00014334862385321102
I1
I0
I1
tp17841
sS'enzyme,oxidation,system'
p17842
(F1
F0.00014334862385321102
I0
I1
I-1
tp17843
sS'presented,here,demonstrate'
p17844
(F1
F0.00014334862385321102
I0
I1
I-1
tp17845
sS'enhance,the,blood-sugar'
p17846
(F1
F0.00014334862385321102
I1
I0
I1
tp17847
sS'use,of,nuromax'
p17848
(F1
F0.00028669724770642203
I0
I2
I-2
tp17849
sS'when,central,nervous'
p17850
(F1
F0.00014334862385321102
I1
I0
I1
tp17851
sS'it,is,recommended'
p17852
(F0.73913043478260865
F0.0024369266055045873
I20
I3
I17
tp17853
sS'of,a,potential'
p17854
(F1
F0.00014334862385321102
I0
I1
I-1
tp17855
sS'of,and,veratrum'
p17856
(F1
F0.00014334862385321102
I1
I0
I1
tp17857
sS'concentrations,be,monitored'
p17858
(F1
F0.00014334862385321102
I1
I0
I1
tp17859
sS'effect,on,oral'
p17860
(F1
F0.00014334862385321102
I1
I0
I1
tp17861
sS'and,showed,that'
p17862
(F1
F0.00014334862385321102
I0
I1
I-1
tp17863
sS'likely,to,lead'
p17864
(F1
F0.00014334862385321102
I1
I0
I1
tp17865
sS'other,drugs,metabolized'
p17866
(F1
F0.00014334862385321102
I0
I1
I-1
tp17867
sS'pharmacokinetics,of,certain'
p17868
(F1
F0.00014334862385321102
I0
I1
I-1
tp17869
sS'as,well,as'
p17870
(F0.30769230769230771
F0.0011467889908256881
I17
I9
I8
tp17871
sS'cimetidine,and,had'
p17872
(F1
F0.00014334862385321102
I0
I1
I-1
tp17873
sS'tablets,results,in'
p17874
(F1
F0.00028669724770642203
I2
I0
I2
tp17875
sS'of,large,initial'
p17876
(F1
F0.00014334862385321102
I0
I1
I-1
tp17877
sS'very,sensitive,to'
p17878
(F1
F0.00014334862385321102
I0
I1
I-1
tp17879
sS'include,and,and'
p17880
(F1
F0.00014334862385321102
I0
I1
I-1
tp17881
sS'of,positive,test'
p17882
(F1
F0.00014334862385321102
I0
I1
I-1
tp17883
sS'also,with,drugs'
p17884
(F1
F0.00014334862385321102
I0
I1
I-1
tp17885
sS'between,revia,and'
p17886
(F1
F0.00014334862385321102
I0
I1
I-1
tp17887
sS'patients,with,pulmonary'
p17888
(F1
F0.00014334862385321102
I0
I1
I-1
tp17889
sS'certain,hmg-coa,reductase'
p17890
(F1
F0.00014334862385321102
I1
I0
I1
tp17891
sS'affect,the,prothrombin'
p17892
(F1
F0.00014334862385321102
I0
I1
I-1
tp17893
sS'white,female,volunteers'
p17894
(F1
F0.00014334862385321102
I0
I1
I-1
tp17895
sS'when,at,mg'
p17896
(F1
F0.00014334862385321102
I1
I0
I1
tp17897
sS'after,cholestyramine,resin'
p17898
(F1
F0.00014334862385321102
I0
I1
I-1
tp17899
sS'mg,day,was'
p17900
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp17901
sS'diabetic,patients,receiving'
p17902
(F1
F0.00014334862385321102
I0
I1
I-1
tp17903
sS'risk,factors,studied'
p17904
(F1
F0.00014334862385321102
I1
I0
I1
tp17905
sS'been,reviewed,in'
p17906
(F1
F0.00014334862385321102
I1
I0
I1
tp17907
sS'p450,enzymes,primarily'
p17908
(F1
F0.00014334862385321102
I0
I1
I-1
tp17909
sS'alkalinizing,agents,gastrointestinal'
p17910
(F1
F0.00014334862385321102
I1
I0
I1
tp17911
sS'with,an,average'
p17912
(F1
F0.00014334862385321102
I1
I0
I1
tp17913
sS'or,mg,q'
p17914
(F1
F0.00014334862385321102
I0
I1
I-1
tp17915
sS'max,by,and'
p17916
(F1
F0.00014334862385321102
I1
I0
I1
tp17917
sS'ethinyl,estradiol,the'
p17918
(F1
F0.00014334862385321102
I0
I1
I-1
tp17919
sS'predominantly,cyp,a4'
p17920
(F1
F0.00014334862385321102
I0
I1
I-1
tp17921
sS'to,the,neuromuscular'
p17922
(F1
F0.00014334862385321102
I1
I0
I1
tp17923
sS'gram,of,and'
p17924
(F1
F0.00014334862385321102
I1
I0
I1
tp17925
sS'binding,of,and'
p17926
(F1
F0.00014334862385321102
I0
I1
I-1
tp17927
sS'several,days,before'
p17928
(F1
F0.00043004587155963305
I3
I0
I3
tp17929
sS'to,mg,twice'
p17930
(F1
F0.00014334862385321102
I1
I0
I1
tp17931
sS'two,drugs,can'
p17932
(F1
F0.00014334862385321102
I1
I0
I1
tp17933
sS'cyp3a4,substrate,single'
p17934
(F1
F0.00014334862385321102
I0
I1
I-1
tp17935
sS'recommended,daily,inhalation'
p17936
(F1
F0.00014334862385321102
I1
I0
I1
tp17937
sS'roles,of,non-nucleoside'
p17938
(F1
F0.00014334862385321102
I0
I1
I-1
tp17939
sS'the,same,evening'
p17940
(F1
F0.00014334862385321102
I1
I0
I1
tp17941
sS'lessened,physiologic,activity'
p17942
(F1
F0.00014334862385321102
I1
I0
I1
tp17943
sS'and,oral,adl'
p17944
(F1
F0.00014334862385321102
I0
I1
I-1
tp17945
sS'in,the,need'
p17946
(F1
F0.00014334862385321102
I1
I0
I1
tp17947
sS'in,respect,of'
p17948
(F1
F0.00014334862385321102
I0
I1
I-1
tp17949
sS'acid,anabolic,steroids'
p17950
(F1
F0.00014334862385321102
I1
I0
I1
tp17951
sS'uricosuric,such,as'
p17952
(F1
F0.00014334862385321102
I1
I0
I1
tp17953
sS'interaction,between,clozapine'
p17954
(F1
F0.00014334862385321102
I1
I0
I1
tp17955
sS'large,initial,doses'
p17956
(F1
F0.00014334862385321102
I0
I1
I-1
tp17957
sS'reduce,endogenous,plasma'
p17958
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17959
sS'do,not,affect'
p17960
(F1
F0.00014334862385321102
I0
I1
I-1
tp17961
sS'ketorolac,does,not'
p17962
(F1
F0.00014334862385321102
I0
I1
I-1
tp17963
sS'trileptal,with,an'
p17964
(F1
F0.00014334862385321102
I1
I0
I1
tp17965
sS'by,sodium,following'
p17966
(F1
F0.00014334862385321102
I0
I1
I-1
tp17967
sS'of,hydrochloride,concomitantly'
p17968
(F1
F0.00014334862385321102
I1
I0
I1
tp17969
sS'particularly,c-17,alkylated'
p17970
(F1
F0.00014334862385321102
I0
I1
I-1
tp17971
sS'dose,resulted,in'
p17972
(F1
F0.00014334862385321102
I1
I0
I1
tp17973
sS'risk,of,anaphylactic'
p17974
(F1
F0.00014334862385321102
I1
I0
I1
tp17975
sS'in,therapeutic,doses'
p17976
(F1
F0.00014334862385321102
I1
I0
I1
tp17977
sS'acetylsalicylic,acid,nsaids'
p17978
(F1
F0.00014334862385321102
I0
I1
I-1
tp17979
sS'anticoagulants,coagulation,parameters'
p17980
(F1
F0.00014334862385321102
I0
I1
I-1
tp17981
sS'r-warfarin,or,s-warfarin'
p17982
(F1
F0.00014334862385321102
I0
I1
I-1
tp17983
sS'either,long-acting,such'
p17984
(F1
F0.00014334862385321102
I0
I1
I-1
tp17985
sS'of,interactions,when'
p17986
(F1
F0.00014334862385321102
I1
I0
I1
tp17987
sS'trial,of,hexalen'
p17988
(F1
F0.00014334862385321102
I1
I0
I1
tp17989
sS'and,auc,were'
p17990
(F1
F0.00014334862385321102
I0
I1
I-1
tp17991
sS'have,the,potential'
p17992
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp17993
sS'markedly,reduced,or'
p17994
(F1
F0.00014334862385321102
I1
I0
I1
tp17995
sS'or,hypersensitivity,reactions'
p17996
(F1
F0.00014334862385321102
I0
I1
I-1
tp17997
sS'cancer,patients,over'
p17998
(F1
F0.00014334862385321102
I1
I0
I1
tp17999
sS'deleterious,interactions,were'
p18000
(F1
F0.00014334862385321102
I0
I1
I-1
tp18001
sS'and,can,exert'
p18002
(F1
F0.00014334862385321102
I0
I1
I-1
tp18003
sS'receiving,cautious,titration'
p18004
(F1
F0.00014334862385321102
I1
I0
I1
tp18005
sS'mean,qt,c'
p18006
(F1
F0.00014334862385321102
I1
I0
I1
tp18007
sS'events,have,been'
p18008
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18009
sS'pharmacodynamics,ecg,of'
p18010
(F1
F0.00014334862385321102
I0
I1
I-1
tp18011
sS'adl-8,is,a'
p18012
(F1
F0.00014334862385321102
I1
I0
I1
tp18013
sS'significantly,with,auc'
p18014
(F1
F0.00014334862385321102
I0
I1
I-1
tp18015
sS'with,antagonists,of'
p18016
(F1
F0.00014334862385321102
I1
I0
I1
tp18017
sS'and,plus,or'
p18018
(F1
F0.00014334862385321102
I1
I0
I1
tp18019
sS'not,studied,systematically'
p18020
(F1
F0.00014334862385321102
I0
I1
I-1
tp18021
sS'effects,of,has'
p18022
(F1
F0.00028669724770642203
I0
I2
I-2
tp18023
sS'a4,had,no'
p18024
(F1
F0.00014334862385321102
I0
I1
I-1
tp18025
sS'certain,and,sodium'
p18026
(F1
F0.00028669724770642203
I2
I0
I2
tp18027
sS'trial,as,with'
p18028
(F1
F0.00014334862385321102
I1
I0
I1
tp18029
sS'is,recommended,for'
p18030
(F1
F0.00014334862385321102
I1
I0
I1
tp18031
sS'free,and,bound'
p18032
(F1
F0.00014334862385321102
I1
I0
I1
tp18033
sS'clinically,significant,effect'
p18034
(F1
F0.0008600917431192661
I0
I6
I-6
tp18035
sS'to,avoid,giving'
p18036
(F1
F0.00014334862385321102
I1
I0
I1
tp18037
sS'also,induces,apoptosis'
p18038
(F1
F0.00014334862385321102
I0
I1
I-1
tp18039
sS'the,total,clearance'
p18040
(F1
F0.00014334862385321102
I1
I0
I1
tp18041
sS'since,the,sedative'
p18042
(F1
F0.00014334862385321102
I1
I0
I1
tp18043
sS'done,it,was'
p18044
(F1
F0.00014334862385321102
I0
I1
I-1
tp18045
sS'or,reduced,tolerance'
p18046
(F1
F0.00014334862385321102
I1
I0
I1
tp18047
sS'drug,interactions,exists'
p18048
(F1
F0.00014334862385321102
I0
I1
I-1
tp18049
sS'inhibit,cyp3a4,cyp3a4'
p18050
(F1
F0.00014334862385321102
I0
I1
I-1
tp18051
sS'indicate,that,administration'
p18052
(F1
F0.00014334862385321102
I0
I1
I-1
tp18053
sS'd3,administration,to'
p18054
(F1
F0.00014334862385321102
I1
I0
I1
tp18055
sS'of,by,stimulating'
p18056
(F1
F0.00014334862385321102
I0
I1
I-1
tp18057
sS'humira,has,been'
p18058
(F1
F0.00014334862385321102
I0
I1
I-1
tp18059
sS'inomax,on,the'
p18060
(F1
F0.00014334862385321102
I1
I0
I1
tp18061
sS'initiation,of,therapy'
p18062
(F1
F0.0010034403669724771
I7
I0
I7
tp18063
sS'agent,may,be'
p18064
(F1
F0.00014334862385321102
I0
I1
I-1
tp18065
sS'pharmacokinetic,interactions,have'
p18066
(F1
F0.00014334862385321102
I0
I1
I-1
tp18067
sS'on,the,risk'
p18068
(F1
F0.00014334862385321102
I1
I0
I1
tp18069
sS'reduction,in,serum'
p18070
(F1
F0.00014334862385321102
I1
I0
I1
tp18071
sS'sc,or,the'
p18072
(F1
F0.00014334862385321102
I0
I1
I-1
tp18073
sS'likely,and,caution'
p18074
(F1
F0.00014334862385321102
I0
I1
I-1
tp18075
sS'motility,lowers,the'
p18076
(F1
F0.00014334862385321102
I1
I0
I1
tp18077
sS'dosage,of,vitamin'
p18078
(F1
F0.00014334862385321102
I1
I0
I1
tp18079
sS's-warfarin,a,cyp2c9'
p18080
(F1
F0.00014334862385321102
I1
I0
I1
tp18081
sS'antidepressant,class,which'
p18082
(F1
F0.00014334862385321102
I0
I1
I-1
tp18083
sS'reported,to,lead'
p18084
(F1
F0.00014334862385321102
I1
I0
I1
tp18085
sS'caffeine,two,hundred'
p18086
(F1
F0.00014334862385321102
I0
I1
I-1
tp18087
sS'revealed,that,range'
p18088
(F1
F0.00014334862385321102
I1
I0
I1
tp18089
sS'co-administered,with,precedex'
p18090
(F1
F0.00014334862385321102
I1
I0
I1
tp18091
sS'did,not,induce'
p18092
(F1
F0.00014334862385321102
I0
I1
I-1
tp18093
sS'administration,of,lower'
p18094
(F1
F0.00014334862385321102
I0
I1
I-1
tp18095
sS'in,a,lower'
p18096
(F1
F0.00014334862385321102
I0
I1
I-1
tp18097
sS'qt,intervals,or'
p18098
(F1
F0.00014334862385321102
I0
I1
I-1
tp18099
sS'extent,of,the'
p18100
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp18101
sS'nursing,infants,a'
p18102
(F1
F0.00014334862385321102
I0
I1
I-1
tp18103
sS'by,and,cmax'
p18104
(F1
F0.00014334862385321102
I0
I1
I-1
tp18105
sS'been,treated,with'
p18106
(F1
F0.00014334862385321102
I1
I0
I1
tp18107
sS'systemic,and,cardiac'
p18108
(F1
F0.00014334862385321102
I1
I0
I1
tp18109
sS'day,of,two'
p18110
(F1
F0.00014334862385321102
I0
I1
I-1
tp18111
sS'supplemented,with,mg'
p18112
(F1
F0.00014334862385321102
I1
I0
I1
tp18113
sS'macrolide,antibiotics,and'
p18114
(F0
F0
I1
I1
I0
tp18115
sS'some,patients,with'
p18116
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp18117
sS'treated,with,intramuscular'
p18118
(F1
F0.00014334862385321102
I0
I1
I-1
tp18119
sS'other,thyroid,products'
p18120
(F1
F0.00014334862385321102
I0
I1
I-1
tp18121
sS'of,with,careful'
p18122
(F1
F0.00014334862385321102
I1
I0
I1
tp18123
sS'with,can,directly'
p18124
(F1
F0.00014334862385321102
I1
I0
I1
tp18125
sS'significant,increase,in'
p18126
(F1
F0.0012901376146788992
I9
I0
I9
tp18127
sS'antacids,or,h'
p18128
(F0
F0
I1
I1
I0
tp18129
sS'in,human,subjects'
p18130
(F1
F0.00014334862385321102
I1
I0
I1
tp18131
sS'be,cautious,when'
p18132
(F1
F0.00028669724770642203
I2
I0
I2
tp18133
sS'fluvoxamine,increased,mean'
p18134
(F1
F0.00014334862385321102
I1
I0
I1
tp18135
sS'decrease,in,the'
p18136
(F0.875
F0.0020068807339449542
I15
I1
I14
tp18137
sS'if,the,tarceva'
p18138
(F1
F0.00014334862385321102
I1
I0
I1
tp18139
sS'products,and,calcium-rich'
p18140
(F1
F0.00014334862385321102
I1
I0
I1
tp18141
sS'potentiate,the,toxic'
p18142
(F1
F0.00014334862385321102
I1
I0
I1
tp18143
sS'the,first,hour'
p18144
(F1
F0.00014334862385321102
I1
I0
I1
tp18145
sS'inducers,can,decrease'
p18146
(F1
F0.00014334862385321102
I1
I0
I1
tp18147
sS'another,is,structurally'
p18148
(F1
F0.00014334862385321102
I0
I1
I-1
tp18149
sS'in,organ,transplant'
p18150
(F1
F0.00014334862385321102
I1
I0
I1
tp18151
sS'more,than,fold'
p18152
(F1
F0.00028669724770642203
I0
I2
I-2
tp18153
sS'steady,state,and'
p18154
(F1
F0.00028669724770642203
I2
I0
I2
tp18155
sS'if,is,given'
p18156
(F1
F0.00043004587155963305
I3
I0
I3
tp18157
sS'on,the,mean'
p18158
(F1
F0.00014334862385321102
I0
I1
I-1
tp18159
sS'clinical,and,pharmacokinetic'
p18160
(F1
F0.00014334862385321102
I1
I0
I1
tp18161
sS'the,treatment,of'
p18162
(F0.47368421052631576
F0.0012901376146788992
I5
I14
I-9
tp18163
sS'two,single,oral'
p18164
(F1
F0.00014334862385321102
I0
I1
I-1
tp18165
sS'symptomatology,due,to'
p18166
(F1
F0.00014334862385321102
I1
I0
I1
tp18167
sS'thyroiditis,bullous,pemphigoid'
p18168
(F1
F0.00014334862385321102
I1
I0
I1
tp18169
sS'mg,kg,of'
p18170
(F1
F0.00014334862385321102
I0
I1
I-1
tp18171
sS'a,case,report'
p18172
(F1
F0.00014334862385321102
I1
I0
I1
tp18173
sS'hours,apart,was'
p18174
(F1
F0.00014334862385321102
I1
I0
I1
tp18175
sS'mg,kg,on'
p18176
(F0
F0
I1
I1
I0
tp18177
sS'o-desacetylrifabutin,and,the'
p18178
(F1
F0.00014334862385321102
I1
I0
I1
tp18179
sS'mg,kg,or'
p18180
(F1
F0.00043004587155963305
I0
I3
I-3
tp18181
sS'and,dehydration,have'
p18182
(F1
F0.00014334862385321102
I1
I0
I1
tp18183
sS'demonstrate,any,efficacy'
p18184
(F1
F0.00014334862385321102
I0
I1
I-1
tp18185
sS'using,cyp3a4,metabolized'
p18186
(F1
F0.00014334862385321102
I1
I0
I1
tp18187
sS'and,intravenous,unless'
p18188
(F1
F0.00014334862385321102
I1
I0
I1
tp18189
sS'levels,resulting,in'
p18190
(F1
F0.00014334862385321102
I1
I0
I1
tp18191
sS'changes,in,and'
p18192
(F1
F0.00014334862385321102
I0
I1
I-1
tp18193
sS'dryness,of,the'
p18194
(F1
F0.00014334862385321102
I1
I0
I1
tp18195
sS'unbound,to,the'
p18196
(F1
F0.00014334862385321102
I0
I1
I-1
tp18197
sS'on,smooth,muscle'
p18198
(F1
F0.00014334862385321102
I0
I1
I-1
tp18199
sS'administered,on,day5'
p18200
(F0
F0
I1
I1
I0
tp18201
sS'noted,when,is'
p18202
(F1
F0.00014334862385321102
I0
I1
I-1
tp18203
sS'dogs,but,not'
p18204
(F1
F0.00014334862385321102
I1
I0
I1
tp18205
sS'fashion,to,receive'
p18206
(F1
F0.00014334862385321102
I0
I1
I-1
tp18207
sS'administered,on,day9'
p18208
(F1
F0.00014334862385321102
I1
I0
I1
tp18209
sS'older,adults,to'
p18210
(F1
F0.00014334862385321102
I0
I1
I-1
tp18211
sS'of,with,any'
p18212
(F1
F0.00014334862385321102
I0
I1
I-1
tp18213
sS'be,observed,closely'
p18214
(F0.5714285714285714
F0.0011467889908256881
I11
I3
I8
tp18215
sS'coadministered,medicinal,products'
p18216
(F1
F0.00014334862385321102
I1
I0
I1
tp18217
sS'have,included,beta-adrenergic'
p18218
(F1
F0.00014334862385321102
I0
I1
I-1
tp18219
sS'the,was,carried'
p18220
(F1
F0.00014334862385321102
I0
I1
I-1
tp18221
sS'schizophrenia,and,related'
p18222
(F1
F0.00014334862385321102
I0
I1
I-1
tp18223
sS'by,this,enzyme'
p18224
(F1
F0.00028669724770642203
I0
I2
I-2
tp18225
sS'pharmacokinetics,and,qtc'
p18226
(F1
F0.00014334862385321102
I0
I1
I-1
tp18227
sS'of,apoptosis,assessed'
p18228
(F1
F0.00014334862385321102
I1
I0
I1
tp18229
sS'the,physician,may'
p18230
(F1
F0.00014334862385321102
I1
I0
I1
tp18231
sS'of,with,and'
p18232
(F1
F0.00014334862385321102
I0
I1
I-1
tp18233
sS'mg,kg,per'
p18234
(F1
F0.00014334862385321102
I1
I0
I1
tp18235
sS'of,are,tolerated'
p18236
(F1
F0.00014334862385321102
I0
I1
I-1
tp18237
sS'any,effect,on'
p18238
(F1
F0.00043004587155963305
I0
I3
I-3
tp18239
sS'failed,to,wshow'
p18240
(F1
F0.00028669724770642203
I0
I2
I-2
tp18241
sS'report,of,prolonged'
p18242
(F1
F0.00014334862385321102
I1
I0
I1
tp18243
sS'of,fold,in'
p18244
(F1
F0.00014334862385321102
I1
I0
I1
tp18245
sS'weakness,in,patients'
p18246
(F1
F0.00014334862385321102
I1
I0
I1
tp18247
sS'has,been,reported'
p18248
(F0.77500000000000002
F0.0088876146788990831
I71
I9
I62
tp18249
sS'sodium,and,coly-mycin'
p18250
(F1
F0.00014334862385321102
I1
I0
I1
tp18251
sS'increase,their,clearance'
p18252
(F1
F0.00014334862385321102
I0
I1
I-1
tp18253
sS'approximately,fold,at'
p18254
(F1
F0.00014334862385321102
I1
I0
I1
tp18255
sS'at,steady,state'
p18256
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp18257
sS'elimination,of,after'
p18258
(F1
F0.00014334862385321102
I0
I1
I-1
tp18259
sS'ulcerans,was,between'
p18260
(F1
F0.00014334862385321102
I0
I1
I-1
tp18261
sS'attenuated,the,heart'
p18262
(F1
F0.00014334862385321102
I1
I0
I1
tp18263
sS'it,is,desirable'
p18264
(F1
F0.00071674311926605509
I0
I5
I-5
tp18265
sS'antagonists,a,cyp3a4'
p18266
(F1
F0.00014334862385321102
I0
I1
I-1
tp18267
sS'whether,the,dose'
p18268
(F1
F0.00014334862385321102
I1
I0
I1
tp18269
sS'in,vivo,the'
p18270
(F1
F0.00028669724770642203
I2
I0
I2
tp18271
sS'and,a,cause-and'
p18272
(F1
F0.00014334862385321102
I1
I0
I1
tp18273
sS'that,the,effect'
p18274
(F1
F0.00014334862385321102
I0
I1
I-1
tp18275
sS'is,a,substrate'
p18276
(F1
F0.00043004587155963305
I0
I3
I-3
tp18277
sS'vivo,studies,have'
p18278
(F1
F0.00014334862385321102
I1
I0
I1
tp18279
sS'vitro,and,cyp3a4'
p18280
(F1
F0.00014334862385321102
I1
I0
I1
tp18281
sS'show,elevations,of'
p18282
(F1
F0.00014334862385321102
I1
I0
I1
tp18283
sS'other,inducers,of'
p18284
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18285
sS'parameters,and,or'
p18286
(F1
F0.00014334862385321102
I1
I0
I1
tp18287
sS'of,diamox,may'
p18288
(F1
F0.00014334862385321102
I1
I0
I1
tp18289
sS'may,be,warranted'
p18290
(F1
F0.00014334862385321102
I0
I1
I-1
tp18291
sS'seen,with,coadministration'
p18292
(F1
F0.00014334862385321102
I1
I0
I1
tp18293
sS'of,but,does'
p18294
(F1
F0.00014334862385321102
I1
I0
I1
tp18295
sS'produced,a,mean'
p18296
(F1
F0.00014334862385321102
I1
I0
I1
tp18297
sS'concomitantly,receiving,itraconazole'
p18298
(F1
F0.00014334862385321102
I1
I0
I1
tp18299
sS'these,with,respect'
p18300
(F1
F0.00014334862385321102
I0
I1
I-1
tp18301
sS'that,oral,and'
p18302
(F1
F0.00014334862385321102
I0
I1
I-1
tp18303
sS'to,a,slight'
p18304
(F1
F0.00014334862385321102
I1
I0
I1
tp18305
sS'administered,twice,daily'
p18306
(F1
F0.00014334862385321102
I0
I1
I-1
tp18307
sS'determine,if,they'
p18308
(F1
F0.00014334862385321102
I0
I1
I-1
tp18309
sS'with,mild,uncomplicated'
p18310
(F1
F0.00014334862385321102
I0
I1
I-1
tp18311
sS'uptake-1,in,functional'
p18312
(F1
F0.00014334862385321102
I0
I1
I-1
tp18313
sS'supplements,are,required'
p18314
(F1
F0.00014334862385321102
I1
I0
I1
tp18315
sS'beta,blockers,may'
p18316
(F1
F0.00028669724770642203
I2
I0
I2
tp18317
sS'in,vitro,from'
p18318
(F1
F0.00014334862385321102
I1
I0
I1
tp18319
sS'the,dose,to'
p18320
(F1
F0.00057339449541284407
I4
I0
I4
tp18321
sS'methods,healthy,subjects'
p18322
(F1
F0.00014334862385321102
I0
I1
I-1
tp18323
sS'may,be,increased'
p18324
(F1
F0.00071674311926605509
I5
I0
I5
tp18325
sS'to,inhibit,the'
p18326
(F1
F0.00057339449541284407
I4
I0
I4
tp18327
sS'racemic,for,days'
p18328
(F1
F0.00014334862385321102
I0
I1
I-1
tp18329
sS'not,been,systematically'
p18330
(F1
F0.00014334862385321102
I1
I0
I1
tp18331
sS'that,although,did'
p18332
(F1
F0.00014334862385321102
I1
I0
I1
tp18333
sS'events,involving,levo-dromoran'
p18334
(F1
F0.00014334862385321102
I0
I1
I-1
tp18335
sS'in,view,of'
p18336
(F0
F0
I1
I1
I0
tp18337
sS'agents,in,the'
p18338
(F0
F0
I1
I1
I0
tp18339
sS'therophylline,a,recent'
p18340
(F1
F0.00014334862385321102
I1
I0
I1
tp18341
sS'to,min,for'
p18342
(F1
F0.00014334862385321102
I0
I1
I-1
tp18343
sS'inhibition,of,platelet'
p18344
(F1
F0.00014334862385321102
I1
I0
I1
tp18345
sS'only,half,of'
p18346
(F1
F0.00014334862385321102
I0
I1
I-1
tp18347
sS'inhibitor,due,to'
p18348
(F1
F0.00014334862385321102
I0
I1
I-1
tp18349
sS'by,the,plasma'
p18350
(F1
F0.00014334862385321102
I0
I1
I-1
tp18351
sS'the,biogen,pregnancy'
p18352
(F1
F0.00014334862385321102
I0
I1
I-1
tp18353
sS'meclofenamate,sodium,is'
p18354
(F0
F0
I1
I1
I0
tp18355
sS'and,is,usually'
p18356
(F1
F0.00014334862385321102
I0
I1
I-1
tp18357
sS'of,the,usual'
p18358
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18359
sS'use,resulted,in'
p18360
(F1
F0.00014334862385321102
I0
I1
I-1
tp18361
sS'and,blood,glucose'
p18362
(F1
F0.00014334862385321102
I0
I1
I-1
tp18363
sS'when,mesylate,was'
p18364
(F1
F0.00014334862385321102
I1
I0
I1
tp18365
sS'mg,of,administered'
p18366
(F1
F0.00014334862385321102
I0
I1
I-1
tp18367
sS'or,cns,depressants'
p18368
(F1
F0.00014334862385321102
I1
I0
I1
tp18369
sS'hormone,action,or'
p18370
(F1
F0.00014334862385321102
I0
I1
I-1
tp18371
sS'or,who,may'
p18372
(F1
F0.00014334862385321102
I1
I0
I1
tp18373
sS'is,known,to'
p18374
(F0
F0
I3
I3
I0
tp18375
sS'proven,efficacy,against'
p18376
(F1
F0.00014334862385321102
I0
I1
I-1
tp18377
sS'drug-drug,interaction,studies'
p18378
(F0
F0
I1
I1
I0
tp18379
sS'concentration,c12hr,by'
p18380
(F1
F0.00014334862385321102
I1
I0
I1
tp18381
sS'action,of,may'
p18382
(F1
F0.00057339449541284407
I4
I0
I4
tp18383
sS'in,the,toxicity'
p18384
(F1
F0.00014334862385321102
I0
I1
I-1
tp18385
sS'eye,drops,containing'
p18386
(F1
F0.00014334862385321102
I0
I1
I-1
tp18387
sS'the,antinociceptive,effect'
p18388
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp18389
sS'used,together,during'
p18390
(F1
F0.00014334862385321102
I1
I0
I1
tp18391
sS'hormone,synthesis,secretion'
p18392
(F1
F0.00014334862385321102
I0
I1
I-1
tp18393
sS'propranolol,in,normal'
p18394
(F1
F0.00014334862385321102
I0
I1
I-1
tp18395
sS'have,demonstrated,efficacy'
p18396
(F1
F0.00014334862385321102
I0
I1
I-1
tp18397
sS'addition,alone,can'
p18398
(F1
F0.00014334862385321102
I1
I0
I1
tp18399
sS'inhibitor,it,is'
p18400
(F1
F0.00014334862385321102
I1
I0
I1
tp18401
sS'in,well-controlled,patients'
p18402
(F1
F0.00028669724770642203
I2
I0
I2
tp18403
sS'inhibited,the,carbachol-stimulated'
p18404
(F1
F0.00014334862385321102
I1
I0
I1
tp18405
sS'kg,diet,resulted'
p18406
(F1
F0.00014334862385321102
I1
I0
I1
tp18407
sS'that,mptp,induced'
p18408
(F1
F0.00014334862385321102
I1
I0
I1
tp18409
sS'result,in,uterine'
p18410
(F1
F0.00014334862385321102
I1
I0
I1
tp18411
sS'argatroban,and,is'
p18412
(F1
F0.00014334862385321102
I0
I1
I-1
tp18413
sS'that,binds,differently'
p18414
(F1
F0.00014334862385321102
I0
I1
I-1
tp18415
sS'absorption,or,disposition'
p18416
(F1
F0.00014334862385321102
I0
I1
I-1
tp18417
sS'p450,inducers,can'
p18418
(F1
F0.00014334862385321102
I1
I0
I1
tp18419
sS'verapamil,coadministration,of'
p18420
(F1
F0.00014334862385321102
I1
I0
I1
tp18421
sS'formulation,of,mg'
p18422
(F1
F0.00014334862385321102
I1
I0
I1
tp18423
sS'having,vasodilator,activity'
p18424
(F0
F0
I1
I1
I0
tp18425
sS'and,clotibrate,and'
p18426
(F1
F0.00014334862385321102
I0
I1
I-1
tp18427
sS'with,cns,depressants'
p18428
(F1
F0.00028669724770642203
I2
I0
I2
tp18429
sS'of,diffusible,treatment'
p18430
(F1
F0.00014334862385321102
I0
I1
I-1
tp18431
sS'unusually,high,maintenance'
p18432
(F1
F0.00014334862385321102
I1
I0
I1
tp18433
sS'aware,of,the'
p18434
(F1
F0.00014334862385321102
I0
I1
I-1
tp18435
sS'approximate,doubling,of'
p18436
(F1
F0.00014334862385321102
I1
I0
I1
tp18437
sS'the,placebo-controlled,clinical'
p18438
(F1
F0.00014334862385321102
I0
I1
I-1
tp18439
sS'agent,of,the'
p18440
(F1
F0.00014334862385321102
I0
I1
I-1
tp18441
sS'advisable,to,monitor'
p18442
(F1
F0.00014334862385321102
I1
I0
I1
tp18443
sS'moreover,the,mechanisms'
p18444
(F1
F0.00014334862385321102
I0
I1
I-1
tp18445
sS'increased,mean,serum'
p18446
(F1
F0.00014334862385321102
I1
I0
I1
tp18447
sS'equetrotm,due,to'
p18448
(F1
F0.00014334862385321102
I1
I0
I1
tp18449
sS'inhibitors,and,tricyclic'
p18450
(F1
F0.00014334862385321102
I1
I0
I1
tp18451
sS'products,oral,nicotinic'
p18452
(F1
F0.00057339449541284407
I0
I4
I-4
tp18453
sS'metabolism,of,the'
p18454
(F0
F0
I1
I1
I0
tp18455
sS'chirocaine,should,be'
p18456
(F1
F0.00014334862385321102
I1
I0
I1
tp18457
sS'sch-23390,but,not'
p18458
(F1
F0.00014334862385321102
I1
I0
I1
tp18459
sS'increase,of,auc'
p18460
(F1
F0.00014334862385321102
I1
I0
I1
tp18461
sS'measured,in,volunteers'
p18462
(F1
F0.00014334862385321102
I0
I1
I-1
tp18463
sS'for,use,with'
p18464
(F1
F0.00014334862385321102
I1
I0
I1
tp18465
sS'administered,with,cyp3a4'
p18466
(F1
F0.00014334862385321102
I0
I1
I-1
tp18467
sS'therapeutic,response,and'
p18468
(F1
F0.00014334862385321102
I0
I1
I-1
tp18469
sS'induced,by,pcp'
p18470
(F1
F0.00014334862385321102
I0
I1
I-1
tp18471
sS'and,auc,after'
p18472
(F1
F0.00028669724770642203
I2
I0
I2
tp18473
sS'ermbt,after,weeks'
p18474
(F1
F0.00014334862385321102
I0
I1
I-1
tp18475
sS'for,is,recommended'
p18476
(F1
F0.00014334862385321102
I0
I1
I-1
tp18477
sS'at,the,initiation'
p18478
(F0
F0
I1
I1
I0
tp18479
sS'was,found,to'
p18480
(F0.5
F0.00028669724770642203
I3
I1
I2
tp18481
sS'micrograms,had,only'
p18482
(F1
F0.00014334862385321102
I1
I0
I1
tp18483
sS'of,on,pharmacokinetics'
p18484
(F1
F0.00057339449541284407
I0
I4
I-4
tp18485
sS'to,any,procedure'
p18486
(F1
F0.00014334862385321102
I0
I1
I-1
tp18487
sS'kcl,mmol,l'
p18488
(F1
F0.00014334862385321102
I0
I1
I-1
tp18489
sS'drug-drug,interactions,between'
p18490
(F1
F0.00043004587155963305
I0
I3
I-3
tp18491
sS'action,on,the'
p18492
(F1
F0.00014334862385321102
I1
I0
I1
tp18493
sS'or,oral,hypoglycemic'
p18494
(F1
F0.00014334862385321102
I1
I0
I1
tp18495
sS'similar,serum,time'
p18496
(F1
F0.00014334862385321102
I0
I1
I-1
tp18497
sS'antidepressant,was,shown'
p18498
(F1
F0.00014334862385321102
I0
I1
I-1
tp18499
sS'interaction,study,comparing'
p18500
(F1
F0.00014334862385321102
I0
I1
I-1
tp18501
sS'antimicrobial,and,the'
p18502
(F1
F0.00014334862385321102
I1
I0
I1
tp18503
sS'beta-blockers,salts,and'
p18504
(F1
F0.00028669724770642203
I2
I0
I2
tp18505
sS'to,affect,sinus'
p18506
(F1
F0.00014334862385321102
I1
I0
I1
tp18507
sS'chronically,receiving,and'
p18508
(F1
F0.00014334862385321102
I0
I1
I-1
tp18509
sS'concentrations,of,sulfoxide'
p18510
(F1
F0.00014334862385321102
I1
I0
I1
tp18511
sS'using,higher,doses'
p18512
(F1
F0.00014334862385321102
I1
I0
I1
tp18513
sS'clearance,of,free'
p18514
(F1
F0.00014334862385321102
I1
I0
I1
tp18515
sS'mean,auc,and'
p18516
(F1
F0.00028669724770642203
I2
I0
I2
tp18517
sS'coadministration,of,welchol'
p18518
(F1
F0.00014334862385321102
I0
I1
I-1
tp18519
sS'oral,hormonal,ortho-novum'
p18520
(F1
F0.00014334862385321102
I1
I0
I1
tp18521
sS'i,tranexamic,acid'
p18522
(F1
F0.00014334862385321102
I0
I1
I-1
tp18523
sS'either,the,administration'
p18524
(F1
F0.00014334862385321102
I0
I1
I-1
tp18525
sS'in,advanced,or'
p18526
(F1
F0.00014334862385321102
I1
I0
I1
tp18527
sS'morphine,toradoliv,im'
p18528
(F1
F0.00014334862385321102
I0
I1
I-1
tp18529
sS'by,the,kidney'
p18530
(F1
F0.00014334862385321102
I0
I1
I-1
tp18531
sS'binding,of,affected'
p18532
(F1
F0.00014334862385321102
I0
I1
I-1
tp18533
sS'seen,during,coadministration'
p18534
(F1
F0.00014334862385321102
I1
I0
I1
tp18535
sS'enoxacin,interferes,with'
p18536
(F1
F0.00014334862385321102
I1
I0
I1
tp18537
sS'co-administration,of,botox'
p18538
(F1
F0.00014334862385321102
I1
I0
I1
tp18539
sS'nimbex,is,administered'
p18540
(F1
F0.00014334862385321102
I0
I1
I-1
tp18541
sS'respectively,and,mean'
p18542
(F1
F0.00014334862385321102
I1
I0
I1
tp18543
sS'a,because,of'
p18544
(F1
F0.00014334862385321102
I1
I0
I1
tp18545
sS'of,the,stomach'
p18546
(F1
F0.00014334862385321102
I1
I0
I1
tp18547
sS'invirase,is,coadministered'
p18548
(F1
F0.00014334862385321102
I1
I0
I1
tp18549
sS'in,vitro,mixing'
p18550
(F1
F0.00014334862385321102
I1
I0
I1
tp18551
sS'or,mg,was'
p18552
(F1
F0.00014334862385321102
I1
I0
I1
tp18553
sS'effect,of,was'
p18554
(F1
F0.00014334862385321102
I0
I1
I-1
tp18555
sS'human,cytochrome,p450'
p18556
(F1
F0.00028669724770642203
I0
I2
I-2
tp18557
sS'of,loop,potassium-sparing'
p18558
(F1
F0.00028669724770642203
I2
I0
I2
tp18559
sS'concomitantly,with,without'
p18560
(F1
F0.00014334862385321102
I0
I1
I-1
tp18561
sS'a,dose,of'
p18562
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp18563
sS'to,alterations,in'
p18564
(F1
F0.00014334862385321102
I1
I0
I1
tp18565
sS'antimicrobial,is,administered'
p18566
(F1
F0.00028669724770642203
I2
I0
I2
tp18567
sS'physician,the,benefits'
p18568
(F1
F0.00014334862385321102
I1
I0
I1
tp18569
sS'take,and,oral'
p18570
(F1
F0.00014334862385321102
I1
I0
I1
tp18571
sS'mao,inhibitors,because'
p18572
(F1
F0.00014334862385321102
I1
I0
I1
tp18573
sS'investigate,the,effects'
p18574
(F1
F0.00028669724770642203
I0
I2
I-2
tp18575
sS'of,adenocard,in'
p18576
(F1
F0.00014334862385321102
I1
I0
I1
tp18577
sS'for,detoxification,of'
p18578
(F1
F0.00014334862385321102
I1
I0
I1
tp18579
sS'preparations,are,not'
p18580
(F1
F0.00014334862385321102
I1
I0
I1
tp18581
sS'tablets,at,doses'
p18582
(F1
F0.00014334862385321102
I0
I1
I-1
tp18583
sS'acidifying,agents,these'
p18584
(F1
F0.00014334862385321102
I1
I0
I1
tp18585
sS'inhibition,of,cyp-2c19'
p18586
(F1
F0.00014334862385321102
I0
I1
I-1
tp18587
sS'drugs,at,least'
p18588
(F1
F0.00014334862385321102
I0
I1
I-1
tp18589
sS'p450,a,the'
p18590
(F1
F0.00014334862385321102
I0
I1
I-1
tp18591
sS'lexapro,for,days'
p18592
(F1
F0.00014334862385321102
I1
I0
I1
tp18593
sS'a,substrate,for'
p18594
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp18595
sS'angiotensin,ii,or'
p18596
(F1
F0.00014334862385321102
I0
I1
I-1
tp18597
sS'schedule,was,greater'
p18598
(F1
F0.00014334862385321102
I1
I0
I1
tp18599
sS'therefore,when,inspra'
p18600
(F1
F0.00014334862385321102
I1
I0
I1
tp18601
sS'side,effects,when'
p18602
(F1
F0.00014334862385321102
I1
I0
I1
tp18603
sS'included,a,mcg'
p18604
(F1
F0.00014334862385321102
I0
I1
I-1
tp18605
sS'and,concomitantly,with'
p18606
(F1
F0.00014334862385321102
I1
I0
I1
tp18607
sS'to,fold,higher'
p18608
(F1
F0.00014334862385321102
I1
I0
I1
tp18609
sS'to,the,class'
p18610
(F1
F0.00028669724770642203
I0
I2
I-2
tp18611
sS'as,might,increase'
p18612
(F1
F0.00014334862385321102
I1
I0
I1
tp18613
sS'with,of,the'
p18614
(F1
F0.00043004587155963305
I3
I0
I3
tp18615
sS'of,on,blood'
p18616
(F1
F0.00014334862385321102
I0
I1
I-1
tp18617
sS'to,have,clinically'
p18618
(F1
F0.00014334862385321102
I0
I1
I-1
tp18619
sS'specific,interactions,with'
p18620
(F1
F0.00014334862385321102
I1
I0
I1
tp18621
sS'and,mg,three'
p18622
(F1
F0.00014334862385321102
I1
I0
I1
tp18623
sS'to,your,doctor'
p18624
(F1
F0.00014334862385321102
I0
I1
I-1
tp18625
sS'severity,of,side'
p18626
(F1
F0.00014334862385321102
I1
I0
I1
tp18627
sS'which,was,preceded'
p18628
(F1
F0.00014334862385321102
I0
I1
I-1
tp18629
sS'control,of,acute'
p18630
(F1
F0.00014334862385321102
I0
I1
I-1
tp18631
sS'intake,of,additional'
p18632
(F1
F0.00043004587155963305
I0
I3
I-3
tp18633
sS'taken,if,is'
p18634
(F1
F0.00014334862385321102
I1
I0
I1
tp18635
sS'reported,when,is'
p18636
(F1
F0.00028669724770642203
I2
I0
I2
tp18637
sS'it,was,noted'
p18638
(F1
F0.00014334862385321102
I0
I1
I-1
tp18639
sS'that,like,other'
p18640
(F1
F0.00014334862385321102
I1
I0
I1
tp18641
sS'vitro,studies,using'
p18642
(F1
F0.00014334862385321102
I0
I1
I-1
tp18643
sS'allow,for,any'
p18644
(F1
F0.00014334862385321102
I0
I1
I-1
tp18645
sS'competitive,displacement,of'
p18646
(F1
F0.00014334862385321102
I0
I1
I-1
tp18647
sS'however,total,mucosal'
p18648
(F1
F0.00014334862385321102
I0
I1
I-1
tp18649
sS'be,used,cautiously'
p18650
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp18651
sS'additive,use,of'
p18652
(F1
F0.00028669724770642203
I2
I0
I2
tp18653
sS'reduced,relative,risk'
p18654
(F1
F0.00014334862385321102
I0
I1
I-1
tp18655
sS'or,had,minimal'
p18656
(F1
F0.00014334862385321102
I0
I1
I-1
tp18657
sS'the,dose,range'
p18658
(F1
F0.00014334862385321102
I1
I0
I1
tp18659
sS'combination,with,copegus'
p18660
(F1
F0.00043004587155963305
I0
I3
I-3
tp18661
sS'to,the,interaction'
p18662
(F1
F0.00014334862385321102
I0
I1
I-1
tp18663
sS'absorption,acting,primarily'
p18664
(F1
F0.00014334862385321102
I1
I0
I1
tp18665
sS'dosing,beta-1a,avonex'
p18666
(F1
F0.00014334862385321102
I1
I0
I1
tp18667
sS'the,natriuretic,effect'
p18668
(F1
F0.0008600917431192661
I6
I0
I6
tp18669
sS'and,suppressed,by'
p18670
(F1
F0.00014334862385321102
I0
I1
I-1
tp18671
sS'pharmacodynamics,of,prothrombin'
p18672
(F1
F0.00014334862385321102
I0
I1
I-1
tp18673
sS'taken,with,a'
p18674
(F0
F0
I1
I1
I0
tp18675
sS'consequences,following,mptp'
p18676
(F1
F0.00014334862385321102
I0
I1
I-1
tp18677
sS'acetaminophen,had,no'
p18678
(F1
F0.00014334862385321102
I0
I1
I-1
tp18679
sS'strain,of,proteus'
p18680
(F1
F0.00014334862385321102
I0
I1
I-1
tp18681
sS'enhanced,bone,marrow'
p18682
(F1
F0.00014334862385321102
I1
I0
I1
tp18683
sS'and,herbs,such'
p18684
(F1
F0.00014334862385321102
I1
I0
I1
tp18685
sS'plasma,concentrations,in'
p18686
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp18687
sS'with,and,vitamin'
p18688
(F1
F0.00014334862385321102
I1
I0
I1
tp18689
sS'of,the,proton'
p18690
(F1
F0.00014334862385321102
I1
I0
I1
tp18691
sS'enhance,the,duration'
p18692
(F1
F0.00014334862385321102
I1
I0
I1
tp18693
sS'compared,with,mg'
p18694
(F1
F0.00014334862385321102
I1
I0
I1
tp18695
sS'be,combined,with'
p18696
(F1
F0.00028669724770642203
I2
I0
I2
tp18697
sS'oral,has,not'
p18698
(F1
F0.00028669724770642203
I2
I0
I2
tp18699
sS'been,reported,very'
p18700
(F1
F0.00014334862385321102
I1
I0
I1
tp18701
sS'avoided,see,a'
p18702
(F1
F0.00014334862385321102
I1
I0
I1
tp18703
sS'p450,enzymes,the'
p18704
(F1
F0.00014334862385321102
I1
I0
I1
tp18705
sS'might,be,expected'
p18706
(F1
F0.00014334862385321102
I1
I0
I1
tp18707
sS'estradiol,and,mg'
p18708
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp18709
sS'and,both,alone'
p18710
(F1
F0.00014334862385321102
I0
I1
I-1
tp18711
sS'were,carried,out'
p18712
(F1
F0.00014334862385321102
I0
I1
I-1
tp18713
sS'and,other,metabolized'
p18714
(F1
F0.00014334862385321102
I1
I0
I1
tp18715
sS'clinical,studies,in'
p18716
(F1
F0.00043004587155963305
I0
I3
I-3
tp18717
sS'were,reduced,by'
p18718
(F1
F0.00043004587155963305
I3
I0
I3
tp18719
sS'conflicting,results,for'
p18720
(F1
F0.00014334862385321102
I1
I0
I1
tp18721
sS'therapy,although,specific'
p18722
(F1
F0.00028669724770642203
I0
I2
I-2
tp18723
sS'p450,d6,cyp2d6'
p18724
(F1
F0.00014334862385321102
I0
I1
I-1
tp18725
sS'acid,secretion,by'
p18726
(F1
F0.00014334862385321102
I1
I0
I1
tp18727
sS'patients,the,concomitant'
p18728
(F1
F0.00014334862385321102
I1
I0
I1
tp18729
sS'coadministration,of,racemic'
p18730
(F1
F0.00014334862385321102
I0
I1
I-1
tp18731
sS'published,in,the'
p18732
(F1
F0.00014334862385321102
I0
I1
I-1
tp18733
sS'first,sixty,minutes'
p18734
(F1
F0.00014334862385321102
I1
I0
I1
tp18735
sS'increase,of,h-triglyceride'
p18736
(F1
F0.00014334862385321102
I1
I0
I1
tp18737
sS'to,significant,increases'
p18738
(F0
F0
I1
I1
I0
tp18739
sS'from,an,week'
p18740
(F1
F0.00028669724770642203
I0
I2
I-2
tp18741
sS'than,two-fold,of'
p18742
(F1
F0.00014334862385321102
I1
I0
I1
tp18743
sS'necessary,if,these'
p18744
(F1
F0.00043004587155963305
I0
I3
I-3
tp18745
sS'oral,contraceptives,rofecoxib'
p18746
(F1
F0.00014334862385321102
I0
I1
I-1
tp18747
sS'any,statistically,or'
p18748
(F1
F0.00014334862385321102
I0
I1
I-1
tp18749
sS'concomitant,use,of'
p18750
(F0.35714285714285715
F0.0043004587155963305
I57
I27
I30
tp18751
sS'in,vitro,displacement'
p18752
(F1
F0.00014334862385321102
I0
I1
I-1
tp18753
sS'patients,should,take'
p18754
(F1
F0.00014334862385321102
I1
I0
I1
tp18755
sS'lodine,and,is'
p18756
(F1
F0.00014334862385321102
I1
I0
I1
tp18757
sS'of,a,pulmonary'
p18758
(F1
F0.00014334862385321102
I0
I1
I-1
tp18759
sS'peroxidation,which,was'
p18760
(F1
F0.00014334862385321102
I1
I0
I1
tp18761
sS'experiment,non-diabetic,and'
p18762
(F1
F0.00014334862385321102
I0
I1
I-1
tp18763
sS'completely,block,contortrostatin-induced'
p18764
(F1
F0.00014334862385321102
I1
I0
I1
tp18765
sS'most,excretion,is'
p18766
(F1
F0.00014334862385321102
I0
I1
I-1
tp18767
sS'arrythmias,ventricular,tachycardia'
p18768
(F1
F0.00014334862385321102
I1
I0
I1
tp18769
sS'antidepressant,levels,have'
p18770
(F1
F0.00014334862385321102
I1
I0
I1
tp18771
sS'reduction,of,oral'
p18772
(F1
F0.00014334862385321102
I1
I0
I1
tp18773
sS'the,benefits,and'
p18774
(F1
F0.00014334862385321102
I1
I0
I1
tp18775
sS'n,for,days'
p18776
(F1
F0.00014334862385321102
I0
I1
I-1
tp18777
sS'iv,dose,should'
p18778
(F1
F0.00014334862385321102
I1
I0
I1
tp18779
sS'the,known,cytochrome'
p18780
(F1
F0.00014334862385321102
I0
I1
I-1
tp18781
sS'changing,the,dose'
p18782
(F1
F0.00014334862385321102
I1
I0
I1
tp18783
sS'heart,failure,post-myocardial'
p18784
(F1
F0.00014334862385321102
I0
I1
I-1
tp18785
sS'other,related,presumably'
p18786
(F1
F0.00014334862385321102
I1
I0
I1
tp18787
sS'should,take,tricor'
p18788
(F1
F0.00014334862385321102
I1
I0
I1
tp18789
sS'nrtis,are,metabolized'
p18790
(F1
F0.00014334862385321102
I0
I1
I-1
tp18791
sS'with,a,positive'
p18792
(F1
F0.00014334862385321102
I1
I0
I1
tp18793
sS'the,hydrophilic,molecule'
p18794
(F1
F0.00014334862385321102
I0
I1
I-1
tp18795
sS'to,compromise,the'
p18796
(F1
F0.00014334862385321102
I1
I0
I1
tp18797
sS'state,plasma,exposure'
p18798
(F1
F0.00014334862385321102
I1
I0
I1
tp18799
sS'influence,the,bioavailability'
p18800
(F1
F0.00014334862385321102
I0
I1
I-1
tp18801
sS'c129h223n3o54,isolated,from'
p18802
(F1
F0.00014334862385321102
I0
I1
I-1
tp18803
sS'of,on,oral'
p18804
(F1
F0.00014334862385321102
I1
I0
I1
tp18805
sS'd-ala2,metenkephalinamide,or'
p18806
(F1
F0.00014334862385321102
I0
I1
I-1
tp18807
sS'levels,of,and'
p18808
(F0.25
F0.00028669724770642203
I5
I3
I2
tp18809
sS'solution,the,possibility'
p18810
(F1
F0.00014334862385321102
I1
I0
I1
tp18811
sS'the,mao,inhibitor'
p18812
(F1
F0.00014334862385321102
I1
I0
I1
tp18813
sS'their,blood,glucose'
p18814
(F0
F0
I1
I1
I0
tp18815
sS'pediatric,patients,there'
p18816
(F1
F0.00014334862385321102
I1
I0
I1
tp18817
sS'in,or,dosage'
p18818
(F1
F0.00014334862385321102
I0
I1
I-1
tp18819
sS'and,sodium,colistimethate'
p18820
(F1
F0.00014334862385321102
I1
I0
I1
tp18821
sS'not,been,formally'
p18822
(F1
F0.00014334862385321102
I0
I1
I-1
tp18823
sS'decreased,by,and'
p18824
(F1
F0.00043004587155963305
I3
I0
I3
tp18825
sS'hypercalcemia,by,the'
p18826
(F1
F0.00043004587155963305
I0
I3
I-3
tp18827
sS'mg,kg,dose'
p18828
(F1
F0.00014334862385321102
I1
I0
I1
tp18829
sS'changes,induced,by'
p18830
(F1
F0.00014334862385321102
I0
I1
I-1
tp18831
sS'effects,of,erythromycin'
p18832
(F1
F0.00014334862385321102
I0
I1
I-1
tp18833
sS'hours,is,recommended'
p18834
(F1
F0.00014334862385321102
I1
I0
I1
tp18835
sS'antiplatelet,agents,and'
p18836
(F1
F0.00014334862385321102
I1
I0
I1
tp18837
sS'when,administering,or'
p18838
(F1
F0.00014334862385321102
I1
I0
I1
tp18839
sS'potentiates,the,acute'
p18840
(F1
F0.00014334862385321102
I1
I0
I1
tp18841
sS'serum,level,that'
p18842
(F1
F0.00014334862385321102
I1
I0
I1
tp18843
sS'the,ed50,of'
p18844
(F1
F0.00014334862385321102
I1
I0
I1
tp18845
sS'sildenafil,citrate,theoretically'
p18846
(F1
F0.00014334862385321102
I1
I0
I1
tp18847
sS'avoided,beta-blockers,and'
p18848
(F1
F0.00014334862385321102
I1
I0
I1
tp18849
sS'neuromuscular,blocking,effect'
p18850
(F1
F0.00014334862385321102
I1
I0
I1
tp18851
sS'neuromuscular,blockers,in'
p18852
(F1
F0.00014334862385321102
I0
I1
I-1
tp18853
sS'bacteriostatic,antibiotics,chloramphenicol'
p18854
(F1
F0.00014334862385321102
I1
I0
I1
tp18855
sS'substantial,period,after'
p18856
(F1
F0.00014334862385321102
I0
I1
I-1
tp18857
sS'due,to,lowered'
p18858
(F1
F0.00014334862385321102
I1
I0
I1
tp18859
sS'to,took,min'
p18860
(F1
F0.00014334862385321102
I1
I0
I1
tp18861
sS'significant,effects,were'
p18862
(F1
F0.00014334862385321102
I0
I1
I-1
tp18863
sS'recommended,dose,of'
p18864
(F0
F0
I1
I1
I0
tp18865
sS'allow,sufficient,time'
p18866
(F1
F0.00014334862385321102
I0
I1
I-1
tp18867
sS'who,were,receiving'
p18868
(F1
F0.00014334862385321102
I0
I1
I-1
tp18869
sS'concentration,cmax,by'
p18870
(F1
F0.00014334862385321102
I1
I0
I1
tp18871
sS'dosing,effects,of'
p18872
(F1
F0.00014334862385321102
I0
I1
I-1
tp18873
sS'concentrations,of,decreased'
p18874
(F1
F0.00014334862385321102
I1
I0
I1
tp18875
sS'and,its,acid'
p18876
(F1
F0.00014334862385321102
I0
I1
I-1
tp18877
sS'people,who,consume'
p18878
(F1
F0.00014334862385321102
I1
I0
I1
tp18879
sS'an,increased,dose'
p18880
(F1
F0.00014334862385321102
I1
I0
I1
tp18881
sS'other,drug,interactions'
p18882
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp18883
sS'disease,congestive,heart'
p18884
(F1
F0.00014334862385321102
I1
I0
I1
tp18885
sS'release,mg,did'
p18886
(F1
F0.00014334862385321102
I0
I1
I-1
tp18887
sS'to,change,the'
p18888
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp18889
sS'healthy,volunteers,in'
p18890
(F1
F0.00014334862385321102
I1
I0
I1
tp18891
sS'also,adversely,affect'
p18892
(F1
F0.00014334862385321102
I1
I0
I1
tp18893
sS'fentanyl,cyp3a4,substrate'
p18894
(F1
F0.00014334862385321102
I0
I1
I-1
tp18895
sS'that,be,taken'
p18896
(F1
F0.00014334862385321102
I1
I0
I1
tp18897
sS'tricor,with,mg'
p18898
(F1
F0.00028669724770642203
I2
I0
I2
tp18899
sS'the,duodenum,and'
p18900
(F1
F0.00014334862385321102
I0
I1
I-1
tp18901
sS'is,not,associated'
p18902
(F1
F0.00014334862385321102
I0
I1
I-1
tp18903
sS'channel,antagonists,cyp1a2'
p18904
(F1
F0.00014334862385321102
I0
I1
I-1
tp18905
sS'its,therapeutic,and'
p18906
(F1
F0.00014334862385321102
I0
I1
I-1
tp18907
sS'c,and,or'
p18908
(F1
F0.00014334862385321102
I1
I0
I1
tp18909
sS'rhabdomyolysis,has,been'
p18910
(F1
F0.00028669724770642203
I2
I0
I2
tp18911
sS'bid,the,usual'
p18912
(F1
F0.00014334862385321102
I1
I0
I1
tp18913
sS'concomitantly,with,coumarin-derivative'
p18914
(F1
F0.00014334862385321102
I1
I0
I1
tp18915
sS'use,of,an'
p18916
(F1
F0.00014334862385321102
I1
I0
I1
tp18917
sS'mean,serum,concentrations'
p18918
(F1
F0.00014334862385321102
I1
I0
I1
tp18919
sS'with,and,were'
p18920
(F1
F0.00014334862385321102
I0
I1
I-1
tp18921
sS'isoforms,cyp1a2,cyp2a6'
p18922
(F1
F0.00014334862385321102
I0
I1
I-1
tp18923
sS'and,other,related'
p18924
(F1
F0.00014334862385321102
I1
I0
I1
tp18925
sS'avonex,mcg,im'
p18926
(F0
F0
I1
I1
I0
tp18927
sS'dl,triglycerides,mg'
p18928
(F1
F0.00014334862385321102
I0
I1
I-1
tp18929
sS'cyp3a4,inducers,it'
p18930
(F1
F0.00014334862385321102
I1
I0
I1
tp18931
sS'inadvisable,to,co-administer'
p18932
(F1
F0.00014334862385321102
I1
I0
I1
tp18933
sS'clinical,studies,as'
p18934
(F1
F0.0008600917431192661
I6
I0
I6
tp18935
sS'mg,mg,or'
p18936
(F1
F0.00014334862385321102
I0
I1
I-1
tp18937
sS'lowering,effect,of'
p18938
(F0
F0
I1
I1
I0
tp18939
sS'and,during,use'
p18940
(F1
F0.00014334862385321102
I0
I1
I-1
tp18941
sS'either,or,with'
p18942
(F1
F0.00014334862385321102
I0
I1
I-1
tp18943
sS'blocking,agents,actions'
p18944
(F1
F0.00014334862385321102
I0
I1
I-1
tp18945
sS'and,related,ethacrynic'
p18946
(F1
F0.00014334862385321102
I0
I1
I-1
tp18947
sS'established,if,there'
p18948
(F1
F0.00014334862385321102
I0
I1
I-1
tp18949
sS'of,bioavailability,eg'
p18950
(F1
F0.00014334862385321102
I1
I0
I1
tp18951
sS'after,concurrent,treatment'
p18952
(F1
F0.00014334862385321102
I0
I1
I-1
tp18953
sS'an,may,be'
p18954
(F1
F0.00014334862385321102
I1
I0
I1
tp18955
sS'of,had,no'
p18956
(F1
F0.00071674311926605509
I0
I5
I-5
tp18957
sS'that,and,cause'
p18958
(F1
F0.00014334862385321102
I0
I1
I-1
tp18959
sS'with,hypertension,the'
p18960
(F1
F0.00014334862385321102
I1
I0
I1
tp18961
sS'addition,of,nalfon'
p18962
(F1
F0.00014334862385321102
I1
I0
I1
tp18963
sS'in,anhydrous,and'
p18964
(F1
F0.00014334862385321102
I1
I0
I1
tp18965
sS'recommended,for,when'
p18966
(F1
F0.00014334862385321102
I1
I0
I1
tp18967
sS'reactions,is,advised'
p18968
(F1
F0.00014334862385321102
I1
I0
I1
tp18969
sS'given,in,combination'
p18970
(F1
F0.00028669724770642203
I0
I2
I-2
tp18971
sS'of,mefenamic,acid'
p18972
(F1
F0.00014334862385321102
I1
I0
I1
tp18973
sS'dissolution,in,a'
p18974
(F1
F0.00014334862385321102
I0
I1
I-1
tp18975
sS'discrimination,and,mixed'
p18976
(F1
F0.00014334862385321102
I0
I1
I-1
tp18977
sS'endothelial,denudation,indicating'
p18978
(F1
F0.00014334862385321102
I0
I1
I-1
tp18979
sS'contraceptives,the,effect'
p18980
(F1
F0.00014334862385321102
I0
I1
I-1
tp18981
sS'predominant,plasma,substrate'
p18982
(F1
F0.00014334862385321102
I0
I1
I-1
tp18983
sS'and,creatinine,clearance'
p18984
(F1
F0.00014334862385321102
I1
I0
I1
tp18985
sS'potential,to,cause'
p18986
(F1
F0.00014334862385321102
I0
I1
I-1
tp18987
sS'single-dose,pharmacokinetic,study'
p18988
(F1
F0.00014334862385321102
I0
I1
I-1
tp18989
sS'effect,of,may'
p18990
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp18991
sS'dramatically,from,to'
p18992
(F1
F0.00014334862385321102
I0
I1
I-1
tp18993
sS'may,increase,excretion'
p18994
(F1
F0.00014334862385321102
I0
I1
I-1
tp18995
sS'may,inhibit,the'
p18996
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp18997
sS'bacillus,subtilis,and'
p18998
(F1
F0.00014334862385321102
I1
I0
I1
tp18999
sS'hypersensitivity,reactions,when'
p19000
(F1
F0.00014334862385321102
I0
I1
I-1
tp19001
sS'dose,or,mg'
p19002
(F1
F0.00014334862385321102
I0
I1
I-1
tp19003
sS'that,are,highly'
p19004
(F1
F0.00057339449541284407
I4
I0
I4
tp19005
sS'no,specific,interactions'
p19006
(F1
F0.00014334862385321102
I1
I0
I1
tp19007
sS'of,rheumatoid,arthritis'
p19008
(F1
F0.00014334862385321102
I0
I1
I-1
tp19009
sS'metabolite,metabolite,i'
p19010
(F1
F0.00014334862385321102
I0
I1
I-1
tp19011
sS'concentrations,or,clinical'
p19012
(F1
F0.00014334862385321102
I0
I1
I-1
tp19013
sS'theophylline,mg,as'
p19014
(F1
F0.00014334862385321102
I0
I1
I-1
tp19015
sS'release,formulation,of'
p19016
(F1
F0.00014334862385321102
I0
I1
I-1
tp19017
sS'weeks,of,and'
p19018
(F1
F0.00014334862385321102
I0
I1
I-1
tp19019
sS'erythromycin,mg,t'
p19020
(F1
F0.00014334862385321102
I1
I0
I1
tp19021
sS'use,of,the'
p19022
(F0
F0
I1
I1
I0
tp19023
sS'acid,sali-cylates,nsaids'
p19024
(F1
F0.00014334862385321102
I0
I1
I-1
tp19025
sS'days,with,coadministration'
p19026
(F1
F0.00028669724770642203
I0
I2
I-2
tp19027
sS'and,dosage,and'
p19028
(F1
F0.00014334862385321102
I0
I1
I-1
tp19029
sS'hours,before,or'
p19030
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp19031
sS'monitoring,tdm,of'
p19032
(F1
F0.00014334862385321102
I0
I1
I-1
tp19033
sS'has,a,complex'
p19034
(F1
F0.00014334862385321102
I1
I0
I1
tp19035
sS'therapy,and,bone'
p19036
(F1
F0.00014334862385321102
I0
I1
I-1
tp19037
sS'binds,both,t4'
p19038
(F1
F0.00014334862385321102
I1
I0
I1
tp19039
sS'effectively,and,safely'
p19040
(F1
F0.00014334862385321102
I0
I1
I-1
tp19041
sS'which,also,induces'
p19042
(F1
F0.00014334862385321102
I0
I1
I-1
tp19043
sS'depression,of,av'
p19044
(F1
F0.00014334862385321102
I1
I0
I1
tp19045
sS'concomitant,single,dose'
p19046
(F1
F0.00014334862385321102
I1
I0
I1
tp19047
sS'in,dose,to'
p19048
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19049
sS'concomitantly,with,an'
p19050
(F1
F0.00028669724770642203
I2
I0
I2
tp19051
sS'and,are,given'
p19052
(F1
F0.00043004587155963305
I3
I0
I3
tp19053
sS'bid,was,not'
p19054
(F1
F0.00014334862385321102
I1
I0
I1
tp19055
sS'concomitantly,with,as'
p19056
(F1
F0.00014334862385321102
I1
I0
I1
tp19057
sS'low-dose,mg,enteric'
p19058
(F1
F0.00014334862385321102
I0
I1
I-1
tp19059
sS'should,be,separated'
p19060
(F1
F0.00014334862385321102
I1
I0
I1
tp19061
sS'of,a,nasal'
p19062
(F1
F0.00014334862385321102
I0
I1
I-1
tp19063
sS'only,a,very'
p19064
(F1
F0.00014334862385321102
I1
I0
I1
tp19065
sS'for,initial,or'
p19066
(F1
F0.00014334862385321102
I0
I1
I-1
tp19067
sS'be,used,when'
p19068
(F0.75
F0.0008600917431192661
I7
I1
I6
tp19069
sS'in,six,subjects'
p19070
(F1
F0.00014334862385321102
I1
I0
I1
tp19071
sS'to,micrograms,equally'
p19072
(F1
F0.00014334862385321102
I1
I0
I1
tp19073
sS'or,halogenated,hydrocarbon'
p19074
(F1
F0.00028669724770642203
I2
I0
I2
tp19075
sS'have,decreased,plasma'
p19076
(F0
F0
I1
I1
I0
tp19077
sS'activity--such,as,an'
p19078
(F1
F0.00014334862385321102
I1
I0
I1
tp19079
sS'with,neuromuscular,transmission'
p19080
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19081
sS'with,the,pi'
p19082
(F1
F0.00014334862385321102
I0
I1
I-1
tp19083
sS'the,active,isomer'
p19084
(F1
F0.00014334862385321102
I1
I0
I1
tp19085
sS'exhibit,a,diminished'
p19086
(F1
F0.00014334862385321102
I1
I0
I1
tp19087
sS'the,combination,of'
p19088
(F0.5
F0.0008600917431192661
I9
I3
I6
tp19089
sS'under,fasting,conditions'
p19090
(F1
F0.00014334862385321102
I0
I1
I-1
tp19091
sS'is,therefore,advised'
p19092
(F1
F0.00028669724770642203
I2
I0
I2
tp19093
sS'sympathetic,nervous,system'
p19094
(F1
F0.00014334862385321102
I0
I1
I-1
tp19095
sS'pharmacokinetics,during,concurrent'
p19096
(F1
F0.00014334862385321102
I0
I1
I-1
tp19097
sS'digoxin,and,use'
p19098
(F1
F0.00014334862385321102
I1
I0
I1
tp19099
sS'without,disturbing,the'
p19100
(F1
F0.00014334862385321102
I0
I1
I-1
tp19101
sS'decrease,the,clearance'
p19102
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp19103
sS'thiazides,are,known'
p19104
(F1
F0.00043004587155963305
I0
I3
I-3
tp19105
sS'course,of,pcp'
p19106
(F1
F0.00014334862385321102
I1
I0
I1
tp19107
sS'garlic,capsules,should'
p19108
(F1
F0.00014334862385321102
I0
I1
I-1
tp19109
sS'should,be,reduced'
p19110
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp19111
sS'and,inducers,of'
p19112
(F1
F0.00014334862385321102
I1
I0
I1
tp19113
sS'vs,cmax,vs'
p19114
(F1
F0.00014334862385321102
I0
I1
I-1
tp19115
sS'heart,rate,increase'
p19116
(F1
F0.00014334862385321102
I1
I0
I1
tp19117
sS'duloxetine,both,cyp1a2'
p19118
(F1
F0.00014334862385321102
I0
I1
I-1
tp19119
sS'the,agents,in'
p19120
(F1
F0.00014334862385321102
I1
I0
I1
tp19121
sS'in,elderly,patients'
p19122
(F1
F0.00014334862385321102
I1
I0
I1
tp19123
sS'if,peganone,is'
p19124
(F1
F0.00014334862385321102
I1
I0
I1
tp19125
sS'the,peripheral,vasoconstriction'
p19126
(F1
F0.00014334862385321102
I1
I0
I1
tp19127
sS'and,sudden,death'
p19128
(F1
F0.00014334862385321102
I1
I0
I1
tp19129
sS'use,with,other'
p19130
(F1
F0.00014334862385321102
I0
I1
I-1
tp19131
sS'during,and,treatment'
p19132
(F1
F0.00014334862385321102
I0
I1
I-1
tp19133
sS'after,days,with'
p19134
(F1
F0.00014334862385321102
I1
I0
I1
tp19135
sS'administered,concurrently,the'
p19136
(F1
F0.00028669724770642203
I2
I0
I2
tp19137
sS'steady-state,pharmacokinetic,parameters'
p19138
(F1
F0.00014334862385321102
I0
I1
I-1
tp19139
sS'dose,and,longer'
p19140
(F1
F0.00014334862385321102
I1
I0
I1
tp19141
sS'the,cardiotoxicity,associated'
p19142
(F1
F0.00014334862385321102
I0
I1
I-1
tp19143
sS'was,given,prior'
p19144
(F1
F0.00014334862385321102
I0
I1
I-1
tp19145
sS'group,clinical,pharmacology'
p19146
(F1
F0.00014334862385321102
I0
I1
I-1
tp19147
sS'tremor,as,compared'
p19148
(F1
F0.00014334862385321102
I1
I0
I1
tp19149
sS'notably,oral,antifungal'
p19150
(F1
F0.00014334862385321102
I1
I0
I1
tp19151
sS'mm,fractional,mucosal'
p19152
(F1
F0.00014334862385321102
I0
I1
I-1
tp19153
sS'by,alterations,in'
p19154
(F1
F0.00014334862385321102
I0
I1
I-1
tp19155
sS'of,the,potential'
p19156
(F0.63636363636363635
F0.0010034403669724771
I9
I2
I7
tp19157
sS'administered,several,hours'
p19158
(F1
F0.00014334862385321102
I0
I1
I-1
tp19159
sS'by,means,of'
p19160
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp19161
sS'preparation,causing,a'
p19162
(F1
F0.00014334862385321102
I1
I0
I1
tp19163
sS'resveratrol,micromol,l'
p19164
(F1
F0.00014334862385321102
I0
I1
I-1
tp19165
sS'therapy,resulted,in'
p19166
(F1
F0.00014334862385321102
I0
I1
I-1
tp19167
sS'have,higher,than'
p19168
(F1
F0.00071674311926605509
I0
I5
I-5
tp19169
sS'hormone,concomitant,use'
p19170
(F1
F0.00014334862385321102
I1
I0
I1
tp19171
sS'in,angina,patients'
p19172
(F1
F0.00014334862385321102
I0
I1
I-1
tp19173
sS'citrate,potentiate,the'
p19174
(F1
F0.00014334862385321102
I1
I0
I1
tp19175
sS'not,be,mixed'
p19176
(F1
F0.00043004587155963305
I0
I3
I-3
tp19177
sS'furosemide,may,increase'
p19178
(F1
F0.00014334862385321102
I1
I0
I1
tp19179
sS'containing,ferrous,sulfate'
p19180
(F1
F0.00014334862385321102
I1
I0
I1
tp19181
sS'and,ortho-novum,increased'
p19182
(F1
F0.00014334862385321102
I1
I0
I1
tp19183
sS'clofibric,acid,combination'
p19184
(F1
F0.00014334862385321102
I1
I0
I1
tp19185
sS'since,interactions,have'
p19186
(F1
F0.00028669724770642203
I2
I0
I2
tp19187
sS'potential,to,sensitize'
p19188
(F1
F0.00014334862385321102
I1
I0
I1
tp19189
sS'tablets,may,exhibit'
p19190
(F1
F0.00014334862385321102
I1
I0
I1
tp19191
sS'the,supplied,aerolizertm'
p19192
(F1
F0.00014334862385321102
I0
I1
I-1
tp19193
sS'of,the,agents'
p19194
(F1
F0.00028669724770642203
I2
I0
I2
tp19195
sS'and,the,pharmacokinetics'
p19196
(F1
F0.00071674311926605509
I5
I0
I5
tp19197
sS'in,rats,with'
p19198
(F1
F0.00014334862385321102
I1
I0
I1
tp19199
sS'tricyclic,may,enhance'
p19200
(F1
F0.00014334862385321102
I1
I0
I1
tp19201
sS'of,serum,and'
p19202
(F1
F0.00028669724770642203
I0
I2
I-2
tp19203
sS'determine,whether,they'
p19204
(F1
F0.00014334862385321102
I0
I1
I-1
tp19205
sS'that,revlimid,is'
p19206
(F1
F0.00014334862385321102
I0
I1
I-1
tp19207
sS'especially,in,patients'
p19208
(F1
F0.00014334862385321102
I1
I0
I1
tp19209
sS'premedline,and,international'
p19210
(F1
F0.00014334862385321102
I0
I1
I-1
tp19211
sS'be,used,if'
p19212
(F1
F0.0008600917431192661
I6
I0
I6
tp19213
sS'increase,when,is'
p19214
(F1
F0.00014334862385321102
I1
I0
I1
tp19215
sS'rats,whereas,the'
p19216
(F1
F0.00014334862385321102
I0
I1
I-1
tp19217
sS'can,be,minimized'
p19218
(F1
F0.00071674311926605509
I5
I0
I5
tp19219
sS'in,addition,deaths'
p19220
(F1
F0.00014334862385321102
I1
I0
I1
tp19221
sS'when,and,oral'
p19222
(F1
F0.00028669724770642203
I2
I0
I2
tp19223
sS'conjugates,on,the'
p19224
(F1
F0.00014334862385321102
I0
I1
I-1
tp19225
sS'are,not,expected'
p19226
(F1
F0.00014334862385321102
I0
I1
I-1
tp19227
sS'in,diabetic,and'
p19228
(F1
F0.00014334862385321102
I0
I1
I-1
tp19229
sS'if,intravenous,is'
p19230
(F1
F0.00014334862385321102
I1
I0
I1
tp19231
sS'opposite,way,the'
p19232
(F1
F0.00014334862385321102
I1
I0
I1
tp19233
sS'dose,fractions,on'
p19234
(F1
F0.00014334862385321102
I0
I1
I-1
tp19235
sS'loss,of,the'
p19236
(F1
F0.00014334862385321102
I1
I0
I1
tp19237
sS'or,changing,vioxx'
p19238
(F1
F0.00014334862385321102
I1
I0
I1
tp19239
sS'adenocard,in,patients'
p19240
(F1
F0.00014334862385321102
I1
I0
I1
tp19241
sS'tolerated,in,zollinger-ellison'
p19242
(F1
F0.00014334862385321102
I0
I1
I-1
tp19243
sS'l-phenylalanine,and,the'
p19244
(F1
F0.00014334862385321102
I1
I0
I1
tp19245
sS'co-administered,particularly,since'
p19246
(F1
F0.00014334862385321102
I1
I0
I1
tp19247
sS'have,been,no'
p19248
(F1
F0.00057339449541284407
I0
I4
I-4
tp19249
sS'nsaids,are,used'
p19250
(F1
F0.00014334862385321102
I1
I0
I1
tp19251
sS'and,levels,indicating'
p19252
(F1
F0.00014334862385321102
I0
I1
I-1
tp19253
sS'result,in,altered'
p19254
(F1
F0.00014334862385321102
I0
I1
I-1
tp19255
sS'cyp3a4,activity,such'
p19256
(F1
F0.00014334862385321102
I1
I0
I1
tp19257
sS'digoxin,supraventricular,arrhythmias'
p19258
(F1
F0.00014334862385321102
I0
I1
I-1
tp19259
sS'romazicon,may,wear'
p19260
(F1
F0.00014334862385321102
I0
I1
I-1
tp19261
sS'chance,of,side'
p19262
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp19263
sS'clinical,significance,as'
p19264
(F1
F0.00014334862385321102
I0
I1
I-1
tp19265
sS'it,is,theoretically'
p19266
(F1
F0.00014334862385321102
I1
I0
I1
tp19267
sS'eg,should,be'
p19268
(F1
F0.00014334862385321102
I1
I0
I1
tp19269
sS'effects,and,confusional'
p19270
(F1
F0.00014334862385321102
I1
I0
I1
tp19271
sS'be,deeper,and'
p19272
(F1
F0.00014334862385321102
I1
I0
I1
tp19273
sS'you,are,using'
p19274
(F1
F0.00014334862385321102
I1
I0
I1
tp19275
sS'taking,celebrex,concomitantly'
p19276
(F1
F0.00014334862385321102
I1
I0
I1
tp19277
sS'of,was,reduced'
p19278
(F0.5
F0.00028669724770642203
I3
I1
I2
tp19279
sS'any,amine,since'
p19280
(F1
F0.00014334862385321102
I1
I0
I1
tp19281
sS'sh,fa,were'
p19282
(F1
F0.00014334862385321102
I0
I1
I-1
tp19283
sS'in,the,treatment'
p19284
(F0.38461538461538464
F0.00071674311926605509
I4
I9
I-5
tp19285
sS'both,agents,was'
p19286
(F1
F0.00014334862385321102
I0
I1
I-1
tp19287
sS'a,slight,but'
p19288
(F1
F0.00014334862385321102
I1
I0
I1
tp19289
sS'patients,with,colorectal'
p19290
(F1
F0.00014334862385321102
I0
I1
I-1
tp19291
sS'or,effect,of'
p19292
(F1
F0.00014334862385321102
I1
I0
I1
tp19293
sS'at,all,in'
p19294
(F1
F0.00014334862385321102
I0
I1
I-1
tp19295
sS'vardenafil,mg,resulted'
p19296
(F1
F0.00028669724770642203
I2
I0
I2
tp19297
sS'an,decrease,in'
p19298
(F1
F0.00028669724770642203
I2
I0
I2
tp19299
sS'cmax,of,about'
p19300
(F1
F0.00014334862385321102
I1
I0
I1
tp19301
sS'significantly,interfere,with'
p19302
(F1
F0.00014334862385321102
I0
I1
I-1
tp19303
sS'this,study,demonstrates'
p19304
(F1
F0.00014334862385321102
I1
I0
I1
tp19305
sS'not,performed,in'
p19306
(F1
F0.00014334862385321102
I0
I1
I-1
tp19307
sS'humans,was,noted'
p19308
(F1
F0.00014334862385321102
I0
I1
I-1
tp19309
sS'nodal,conduction,observed'
p19310
(F1
F0.00014334862385321102
I1
I0
I1
tp19311
sS'rehospitalisation,was,significantly'
p19312
(F1
F0.00014334862385321102
I0
I1
I-1
tp19313
sS'cause-and,effect,relationship'
p19314
(F1
F0.00028669724770642203
I2
I0
I2
tp19315
sS'affect,the,pk'
p19316
(F1
F0.00014334862385321102
I0
I1
I-1
tp19317
sS'produce,additive,inotropic'
p19318
(F1
F0.00014334862385321102
I0
I1
I-1
tp19319
sS'responses,with,short'
p19320
(F1
F0.00014334862385321102
I0
I1
I-1
tp19321
sS'important,in,supporting'
p19322
(F1
F0.00014334862385321102
I0
I1
I-1
tp19323
sS'decreased,and,decreased'
p19324
(F1
F0.00014334862385321102
I1
I0
I1
tp19325
sS'coadministration,of,this'
p19326
(F1
F0.00028669724770642203
I0
I2
I-2
tp19327
sS'a-blockers,angiotensin-converting,enzyme'
p19328
(F1
F0.00014334862385321102
I0
I1
I-1
tp19329
sS'nonsteroidal,has,been'
p19330
(F1
F0.00014334862385321102
I1
I0
I1
tp19331
sS'than,seven,days'
p19332
(F1
F0.00014334862385321102
I0
I1
I-1
tp19333
sS'can,interfere,with'
p19334
(F1
F0.00028669724770642203
I2
I0
I2
tp19335
sS'general,conditions,of'
p19336
(F1
F0.00014334862385321102
I0
I1
I-1
tp19337
sS'area,under,the'
p19338
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp19339
sS'provided,this,information'
p19340
(F1
F0.00014334862385321102
I1
I0
I1
tp19341
sS'mg,kg,bwt'
p19342
(F1
F0.00014334862385321102
I0
I1
I-1
tp19343
sS'with,hydrochloride,mg'
p19344
(F1
F0.00014334862385321102
I0
I1
I-1
tp19345
sS'therapeutic,regimen,of'
p19346
(F1
F0.00014334862385321102
I0
I1
I-1
tp19347
sS'treated,with,and'
p19348
(F1
F0.00028669724770642203
I2
I0
I2
tp19349
sS'and,both,or'
p19350
(F1
F0.00014334862385321102
I0
I1
I-1
tp19351
sS'strong,cyp3a4,inhibitors'
p19352
(F1
F0.00043004587155963305
I3
I0
I3
tp19353
sS'on,stimulated,gastric'
p19354
(F1
F0.00014334862385321102
I0
I1
I-1
tp19355
sS'should,have,cholesterol'
p19356
(F1
F0.00014334862385321102
I1
I0
I1
tp19357
sS'and,in,combinations'
p19358
(F1
F0.00014334862385321102
I0
I1
I-1
tp19359
sS'of,deoxy,to'
p19360
(F1
F0.00014334862385321102
I0
I1
I-1
tp19361
sS'liver,which,in'
p19362
(F1
F0.00014334862385321102
I1
I0
I1
tp19363
sS'observations,from,interaction'
p19364
(F1
F0.00014334862385321102
I0
I1
I-1
tp19365
sS'the,increased,metabolism'
p19366
(F1
F0.00028669724770642203
I2
I0
I2
tp19367
sS'repeated,doses,of'
p19368
(F1
F0.00014334862385321102
I1
I0
I1
tp19369
sS'a,low,therapeutic'
p19370
(F1
F0.00014334862385321102
I0
I1
I-1
tp19371
sS'steady,state,on'
p19372
(F1
F0.00014334862385321102
I0
I1
I-1
tp19373
sS'the,mean,terminal'
p19374
(F1
F0.00028669724770642203
I2
I0
I2
tp19375
sS'increased,interaction,between'
p19376
(F1
F0.00014334862385321102
I0
I1
I-1
tp19377
sS'its,lack,of'
p19378
(F1
F0.00043004587155963305
I0
I3
I-3
tp19379
sS'and,as,well'
p19380
(F1
F0.00014334862385321102
I0
I1
I-1
tp19381
sS'or,in,volume'
p19382
(F1
F0.00014334862385321102
I1
I0
I1
tp19383
sS'increased,by,an'
p19384
(F1
F0.00014334862385321102
I1
I0
I1
tp19385
sS'magnitude,or,neuromuscular'
p19386
(F1
F0.00014334862385321102
I0
I1
I-1
tp19387
sS'typhoid,attenuation,of'
p19388
(F1
F0.00014334862385321102
I1
I0
I1
tp19389
sS'for,anions,other'
p19390
(F1
F0.00014334862385321102
I0
I1
I-1
tp19391
sS'there,were,transient'
p19392
(F1
F0.00014334862385321102
I1
I0
I1
tp19393
sS'functional,classes,ii'
p19394
(F1
F0.00028669724770642203
I0
I2
I-2
tp19395
sS'endotoxin-treated,rats,decreased'
p19396
(F1
F0.00014334862385321102
I1
I0
I1
tp19397
sS'addition,to,enhancing'
p19398
(F1
F0.00014334862385321102
I1
I0
I1
tp19399
sS'patients,with,breast'
p19400
(F1
F0.00014334862385321102
I1
I0
I1
tp19401
sS'other,complications,compared'
p19402
(F1
F0.00028669724770642203
I2
I0
I2
tp19403
sS'therapeutic,effects,of'
p19404
(F0
F0
I1
I1
I0
tp19405
sS'be,monitored,regularly'
p19406
(F0
F0
I1
I1
I0
tp19407
sS'antacids,increase,the'
p19408
(F1
F0.00014334862385321102
I1
I0
I1
tp19409
sS'of,intestinal,adenocarcinomas'
p19410
(F0
F0
I1
I1
I0
tp19411
sS'prinivil,alone,were'
p19412
(F1
F0.00014334862385321102
I0
I1
I-1
tp19413
sS'associated,with,bleeding'
p19414
(F1
F0.00014334862385321102
I0
I1
I-1
tp19415
sS'affect,disease,control'
p19416
(F1
F0.00014334862385321102
I1
I0
I1
tp19417
sS'the,elevation,of'
p19418
(F1
F0.00014334862385321102
I1
I0
I1
tp19419
sS'micrograms,g,sometimes'
p19420
(F1
F0.00014334862385321102
I0
I1
I-1
tp19421
sS'of,were,not'
p19422
(F1
F0.00071674311926605509
I0
I5
I-5
tp19423
sS'treatment,with,one'
p19424
(F0
F0
I1
I1
I0
tp19425
sS'in,dependence,on'
p19426
(F1
F0.00014334862385321102
I0
I1
I-1
tp19427
sS'effect,relationship,have'
p19428
(F1
F0.00014334862385321102
I1
I0
I1
tp19429
sS'if,dosage,is'
p19430
(F1
F0.00014334862385321102
I1
I0
I1
tp19431
sS'anticoagulants,in,some'
p19432
(F1
F0.00014334862385321102
I1
I0
I1
tp19433
sS'demonstrated,that,a'
p19434
(F0
F0
I1
I1
I0
tp19435
sS'cyp1a1,cyp1a2,cyp2a6'
p19436
(F1
F0.00014334862385321102
I0
I1
I-1
tp19437
sS'rashes,is,due'
p19438
(F1
F0.00014334862385321102
I1
I0
I1
tp19439
sS'a,non-significantly,reduced'
p19440
(F1
F0.00014334862385321102
I0
I1
I-1
tp19441
sS'inhibit,adrenal,synthesis'
p19442
(F1
F0.00014334862385321102
I1
I0
I1
tp19443
sS'fluid,by,dmpge2'
p19444
(F1
F0.00014334862385321102
I0
I1
I-1
tp19445
sS'such,as,imitrex'
p19446
(F1
F0.00014334862385321102
I1
I0
I1
tp19447
sS'output,and,an'
p19448
(F1
F0.00014334862385321102
I1
I0
I1
tp19449
sS'the,net,effects'
p19450
(F1
F0.00014334862385321102
I1
I0
I1
tp19451
sS'above,behavioral,changes'
p19452
(F1
F0.00014334862385321102
I0
I1
I-1
tp19453
sS'body,weight,approximately'
p19454
(F1
F0.00014334862385321102
I0
I1
I-1
tp19455
sS'chlorotrianisene,may,interact'
p19456
(F1
F0.00014334862385321102
I1
I0
I1
tp19457
sS'dose,to,maintain'
p19458
(F1
F0.00028669724770642203
I0
I2
I-2
tp19459
sS'dose,baseline,vs'
p19460
(F1
F0.00014334862385321102
I0
I1
I-1
tp19461
sS'plasma,levels,may'
p19462
(F1
F0.00014334862385321102
I1
I0
I1
tp19463
sS'observed,closely,to'
p19464
(F0.75
F0.0008600917431192661
I7
I1
I6
tp19465
sS'concurrently,did,not'
p19466
(F1
F0.00014334862385321102
I0
I1
I-1
tp19467
sS'conjunction,with,in'
p19468
(F1
F0.00014334862385321102
I1
I0
I1
tp19469
sS'the,results,indicate'
p19470
(F1
F0.00028669724770642203
I0
I2
I-2
tp19471
sS'data,are,not'
p19472
(F1
F0.00014334862385321102
I0
I1
I-1
tp19473
sS'be,produced,in'
p19474
(F1
F0.00014334862385321102
I1
I0
I1
tp19475
sS'sustiva,is,used'
p19476
(F1
F0.00014334862385321102
I1
I0
I1
tp19477
sS'of,mg,did'
p19478
(F1
F0.00057339449541284407
I0
I4
I-4
tp19479
sS'capsule,was,administered'
p19480
(F1
F0.00014334862385321102
I1
I0
I1
tp19481
sS'the,combination,may'
p19482
(F1
F0.00043004587155963305
I3
I0
I3
tp19483
sS'rat,liver,but'
p19484
(F1
F0.00014334862385321102
I0
I1
I-1
tp19485
sS'cyclosporine,administration,of'
p19486
(F1
F0.00014334862385321102
I1
I0
I1
tp19487
sS'were,not,studied'
p19488
(F1
F0.00014334862385321102
I0
I1
I-1
tp19489
sS'following,acetaminophen,tylenol'
p19490
(F1
F0.00014334862385321102
I1
I0
I1
tp19491
sS'administered,daily,for'
p19492
(F1
F0.00014334862385321102
I0
I1
I-1
tp19493
sS'with,the,combination'
p19494
(F1
F0.00043004587155963305
I3
I0
I3
tp19495
sS'the,rate,or'
p19496
(F1
F0.00043004587155963305
I0
I3
I-3
tp19497
sS'of,required,may'
p19498
(F1
F0.00014334862385321102
I1
I0
I1
tp19499
sS'conducted,in,healthy'
p19500
(F1
F0.00014334862385321102
I1
I0
I1
tp19501
sS'responses,were,studied'
p19502
(F1
F0.00014334862385321102
I0
I1
I-1
tp19503
sS'the,elderly,may'
p19504
(F1
F0.00014334862385321102
I1
I0
I1
tp19505
sS'significant,alteration,of'
p19506
(F1
F0.00014334862385321102
I1
I0
I1
tp19507
sS'the,danger,inherent'
p19508
(F1
F0.00014334862385321102
I1
I0
I1
tp19509
sS'eg,and,decrease'
p19510
(F1
F0.00014334862385321102
I1
I0
I1
tp19511
sS'the,rate,of'
p19512
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp19513
sS'twice-a,day,administration'
p19514
(F1
F0.00014334862385321102
I0
I1
I-1
tp19515
sS'and,agonists,hepatic'
p19516
(F1
F0.00014334862385321102
I0
I1
I-1
tp19517
sS'severe,bronchospasm,in'
p19518
(F1
F0.00014334862385321102
I1
I0
I1
tp19519
sS'rats,were,supersensitive'
p19520
(F1
F0.00014334862385321102
I1
I0
I1
tp19521
sS'sparing,thiazide,substrates'
p19522
(F1
F0.00014334862385321102
I0
I1
I-1
tp19523
sS'agonist,but,not'
p19524
(F1
F0.00014334862385321102
I1
I0
I1
tp19525
sS'dostinex,should,not'
p19526
(F1
F0.00014334862385321102
I1
I0
I1
tp19527
sS'opioid-dependent,patients,mixed'
p19528
(F1
F0.00014334862385321102
I0
I1
I-1
tp19529
sS'in,subjects,aged'
p19530
(F1
F0.00014334862385321102
I1
I0
I1
tp19531
sS'markedly,increased,the'
p19532
(F1
F0.00014334862385321102
I1
I0
I1
tp19533
sS'interaction,on,the'
p19534
(F1
F0.00014334862385321102
I1
I0
I1
tp19535
sS'propanol,was,investigated'
p19536
(F1
F0.00014334862385321102
I0
I1
I-1
tp19537
sS'intake,of,and'
p19538
(F0.5
F0.00028669724770642203
I3
I1
I2
tp19539
sS'taking,while,on'
p19540
(F1
F0.00014334862385321102
I1
I0
I1
tp19541
sS'the,difference,between'
p19542
(F1
F0.00014334862385321102
I0
I1
I-1
tp19543
sS'compromised,uptake-1,in'
p19544
(F1
F0.00014334862385321102
I0
I1
I-1
tp19545
sS'the,ace,inhibitor'
p19546
(F1
F0.00043004587155963305
I3
I0
I3
tp19547
sS'stimulated,but,did'
p19548
(F1
F0.00014334862385321102
I1
I0
I1
tp19549
sS'has,additive,effects'
p19550
(F1
F0.00014334862385321102
I1
I0
I1
tp19551
sS'received,in,escalating'
p19552
(F1
F0.00014334862385321102
I0
I1
I-1
tp19553
sS'qt,interval,observed'
p19554
(F1
F0.00014334862385321102
I1
I0
I1
tp19555
sS'effectiveness,of,progestin-only'
p19556
(F1
F0.00014334862385321102
I1
I0
I1
tp19557
sS'been,studied,extensively'
p19558
(F1
F0.00014334862385321102
I0
I1
I-1
tp19559
sS'mg,twice,a'
p19560
(F1
F0.00014334862385321102
I0
I1
I-1
tp19561
sS'patients,taking,monoamine'
p19562
(F1
F0.00014334862385321102
I1
I0
I1
tp19563
sS'agents,may,affect'
p19564
(F1
F0.00014334862385321102
I1
I0
I1
tp19565
sS'administration,of,does'
p19566
(F1
F0.00014334862385321102
I1
I0
I1
tp19567
sS'when,used,concurrently'
p19568
(F0
F0
I1
I1
I0
tp19569
sS'platelet,function,as'
p19570
(F1
F0.00028669724770642203
I2
I0
I2
tp19571
sS'and,the,oral'
p19572
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19573
sS'avoided,when,possible'
p19574
(F1
F0.00014334862385321102
I1
I0
I1
tp19575
sS'therapies,commonly,used'
p19576
(F1
F0.00014334862385321102
I0
I1
I-1
tp19577
sS'and,carbonic,anhydrase'
p19578
(F1
F0.00014334862385321102
I1
I0
I1
tp19579
sS'which,cause,elimination'
p19580
(F1
F0.00028669724770642203
I2
I0
I2
tp19581
sS'acarbose,has,been'
p19582
(F1
F0.00014334862385321102
I1
I0
I1
tp19583
sS'and,the,nonsteroidal'
p19584
(F1
F0.00014334862385321102
I1
I0
I1
tp19585
sS'symptoms,of,methotrexate-related'
p19586
(F1
F0.00014334862385321102
I1
I0
I1
tp19587
sS'properties,may,potentiate'
p19588
(F1
F0.00014334862385321102
I1
I0
I1
tp19589
sS'of,desethylzaleplon,formed'
p19590
(F1
F0.00014334862385321102
I0
I1
I-1
tp19591
sS'two,medicines,since'
p19592
(F1
F0.00014334862385321102
I1
I0
I1
tp19593
sS'acetylsalicylic,acid,and'
p19594
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp19595
sS'bezalip,or,bezalip'
p19596
(F1
F0.00043004587155963305
I3
I0
I3
tp19597
sS'cells,from,healthy'
p19598
(F1
F0.00014334862385321102
I0
I1
I-1
tp19599
sS'oral,anticoagulants,interaction'
p19600
(F1
F0.00014334862385321102
I0
I1
I-1
tp19601
sS'on,these,in'
p19602
(F1
F0.00014334862385321102
I0
I1
I-1
tp19603
sS'few,patients,taking'
p19604
(F1
F0.00014334862385321102
I1
I0
I1
tp19605
sS'excretion,and,the'
p19606
(F1
F0.00014334862385321102
I1
I0
I1
tp19607
sS'and,by,fold'
p19608
(F1
F0.00028669724770642203
I2
I0
I2
tp19609
sS'currently,exist,comparing'
p19610
(F1
F0.00014334862385321102
I0
I1
I-1
tp19611
sS'ketoprofen,like,other'
p19612
(F1
F0.00014334862385321102
I1
I0
I1
tp19613
sS'b-adrenergic,blocking,agents'
p19614
(F1
F0.00028669724770642203
I0
I2
I-2
tp19615
sS'depressant,effect,on'
p19616
(F1
F0.00014334862385321102
I0
I1
I-1
tp19617
sS'either,or,led'
p19618
(F1
F0.00014334862385321102
I1
I0
I1
tp19619
sS'taken,if,necessary'
p19620
(F1
F0.00014334862385321102
I0
I1
I-1
tp19621
sS'a4,cyp,a4'
p19622
(F1
F0.00014334862385321102
I1
I0
I1
tp19623
sS'of,with,central'
p19624
(F1
F0.00014334862385321102
I1
I0
I1
tp19625
sS'coenzyme,a,atp'
p19626
(F1
F0.00014334862385321102
I0
I1
I-1
tp19627
sS'hcl,is,used'
p19628
(F1
F0.00014334862385321102
I1
I0
I1
tp19629
sS'must,be,made'
p19630
(F1
F0.00014334862385321102
I0
I1
I-1
tp19631
sS'omega-agatoxin,iva-sensitive,p-type'
p19632
(F1
F0.00014334862385321102
I0
I1
I-1
tp19633
sS'of,intramuscularly,injected'
p19634
(F1
F0.00014334862385321102
I0
I1
I-1
tp19635
sS'the,potential,for'
p19636
(F0.14285714285714285
F0.00043004587155963305
I12
I9
I3
tp19637
sS'after,sudden,withdrawal'
p19638
(F1
F0.00014334862385321102
I1
I0
I1
tp19639
sS'men,who,have'
p19640
(F1
F0.00014334862385321102
I0
I1
I-1
tp19641
sS'receive,oral,and'
p19642
(F1
F0.00014334862385321102
I0
I1
I-1
tp19643
sS'substrate,in,combination'
p19644
(F1
F0.00028669724770642203
I0
I2
I-2
tp19645
sS'msec,compared,to'
p19646
(F1
F0.00014334862385321102
I1
I0
I1
tp19647
sS'the,effect,is'
p19648
(F1
F0.00014334862385321102
I1
I0
I1
tp19649
sS'aspirin,should,not'
p19650
(F1
F0.00014334862385321102
I1
I0
I1
tp19651
sS'shown,to,decrease'
p19652
(F0
F0
I1
I1
I0
tp19653
sS'propanol,derive,from'
p19654
(F1
F0.00014334862385321102
I1
I0
I1
tp19655
sS'co-administered,avonex,and'
p19656
(F1
F0.00014334862385321102
I0
I1
I-1
tp19657
sS'separate,single,or'
p19658
(F1
F0.00014334862385321102
I0
I1
I-1
tp19659
sS'responses,to,repeated'
p19660
(F1
F0.00014334862385321102
I0
I1
I-1
tp19661
sS'and,and,which'
p19662
(F1
F0.00014334862385321102
I0
I1
I-1
tp19663
sS'blood,level,of'
p19664
(F1
F0.00043004587155963305
I0
I3
I-3
tp19665
sS'arthropan,magan,or'
p19666
(F1
F0.00014334862385321102
I1
I0
I1
tp19667
sS'isoenzyme,system,cyp3a4'
p19668
(F1
F0.00014334862385321102
I0
I1
I-1
tp19669
sS'enzymes,i,and'
p19670
(F1
F0.00014334862385321102
I0
I1
I-1
tp19671
sS'cns,depressive,effects'
p19672
(F1
F0.00014334862385321102
I1
I0
I1
tp19673
sS'oral,were,given'
p19674
(F1
F0.00014334862385321102
I0
I1
I-1
tp19675
sS'ptx,m,failed'
p19676
(F1
F0.00014334862385321102
I1
I0
I1
tp19677
sS'to,groups,of'
p19678
(F1
F0.00014334862385321102
I0
I1
I-1
tp19679
sS'aprepitant,with,strong'
p19680
(F1
F0.00014334862385321102
I1
I0
I1
tp19681
sS'h,following,the'
p19682
(F1
F0.00014334862385321102
I1
I0
I1
tp19683
sS'amevive,who,become'
p19684
(F1
F0.00014334862385321102
I0
I1
I-1
tp19685
sS'mofetil,ml,h'
p19686
(F1
F0.00014334862385321102
I0
I1
I-1
tp19687
sS'midcycle,day,to'
p19688
(F1
F0.00014334862385321102
I0
I1
I-1
tp19689
sS'could,pose,a'
p19690
(F0
F0
I1
I1
I0
tp19691
sS'pharmacokinetics,at,different'
p19692
(F1
F0.00014334862385321102
I0
I1
I-1
tp19693
sS'concomitant,or,may'
p19694
(F1
F0.00014334862385321102
I1
I0
I1
tp19695
sS'turn,resulted,in'
p19696
(F1
F0.00014334862385321102
I1
I0
I1
tp19697
sS'pesticide,gliftor,difluoro-2'
p19698
(F1
F0.00014334862385321102
I0
I1
I-1
tp19699
sS'signalling,or,disruption'
p19700
(F1
F0.00014334862385321102
I0
I1
I-1
tp19701
sS'following,blood,thinners'
p19702
(F1
F0.00014334862385321102
I0
I1
I-1
tp19703
sS'the,start,of'
p19704
(F1
F0.00014334862385321102
I1
I0
I1
tp19705
sS'in,adverse,effects'
p19706
(F1
F0.00014334862385321102
I0
I1
I-1
tp19707
sS'plasma,clearance,from'
p19708
(F1
F0.00014334862385321102
I1
I0
I1
tp19709
sS'change,in,pharmacological'
p19710
(F1
F0.00014334862385321102
I1
I0
I1
tp19711
sS'should,be,deferred'
p19712
(F1
F0.00014334862385321102
I1
I0
I1
tp19713
sS'dose,or,hours'
p19714
(F1
F0.00014334862385321102
I1
I0
I1
tp19715
sS'nafazodone,consider,xanax'
p19716
(F1
F0.00014334862385321102
I1
I0
I1
tp19717
sS'studies,of,suggest'
p19718
(F1
F0.00014334862385321102
I1
I0
I1
tp19719
sS'active,renal,tubular'
p19720
(F1
F0.00014334862385321102
I1
I0
I1
tp19721
sS'serum,total,concentrations'
p19722
(F1
F0.00014334862385321102
I0
I1
I-1
tp19723
sS'carbamazepine,due,to'
p19724
(F1
F0.00014334862385321102
I0
I1
I-1
tp19725
sS'to,elevated,plasma'
p19726
(F1
F0.00014334862385321102
I1
I0
I1
tp19727
sS'careful,attention,must'
p19728
(F1
F0.00014334862385321102
I1
I0
I1
tp19729
sS'by,other,antineoplastic'
p19730
(F1
F0.00014334862385321102
I1
I0
I1
tp19731
sS'a,five-fold,increase'
p19732
(F1
F0.00014334862385321102
I1
I0
I1
tp19733
sS'use,of,hydrochloride'
p19734
(F1
F0.00014334862385321102
I0
I1
I-1
tp19735
sS'use,of,foscavir'
p19736
(F1
F0.00014334862385321102
I1
I0
I1
tp19737
sS'heparins,as,indicated'
p19738
(F1
F0.00014334862385321102
I0
I1
I-1
tp19739
sS'vitamin,d2,vitamin'
p19740
(F1
F0.00043004587155963305
I3
I0
I3
tp19741
sS'severity,of,diarrhea'
p19742
(F1
F0.00014334862385321102
I1
I0
I1
tp19743
sS'added,cholesterol,the'
p19744
(F1
F0.00014334862385321102
I0
I1
I-1
tp19745
sS'myelosuppression,and,diarrhea'
p19746
(F1
F0.00014334862385321102
I1
I0
I1
tp19747
sS'osteoporosis,treatment,study'
p19748
(F1
F0.00014334862385321102
I0
I1
I-1
tp19749
sS'literature,provides,considerable'
p19750
(F1
F0.00014334862385321102
I0
I1
I-1
tp19751
sS'about,when,compared'
p19752
(F1
F0.00014334862385321102
I1
I0
I1
tp19753
sS'that,there,were'
p19754
(F1
F0.00014334862385321102
I0
I1
I-1
tp19755
sS'with,was,associated'
p19756
(F1
F0.00028669724770642203
I2
I0
I2
tp19757
sS'reduction,of,the'
p19758
(F0
F0
I2
I2
I0
tp19759
sS'and,nonsteroidal,agents'
p19760
(F1
F0.00014334862385321102
I1
I0
I1
tp19761
sS'didanosine,co-administration,of'
p19762
(F1
F0.00014334862385321102
I1
I0
I1
tp19763
sS'its,renal,clearance'
p19764
(F1
F0.00043004587155963305
I3
I0
I3
tp19765
sS'mhd,have,little'
p19766
(F1
F0.00014334862385321102
I0
I1
I-1
tp19767
sS'proteus,rettgeri,were'
p19768
(F1
F0.00014334862385321102
I0
I1
I-1
tp19769
sS'of,these,may'
p19770
(F1
F0.00014334862385321102
I1
I0
I1
tp19771
sS'suggested,that,the'
p19772
(F1
F0.00014334862385321102
I1
I0
I1
tp19773
sS'sulfonylureas,requirements,for'
p19774
(F1
F0.00014334862385321102
I0
I1
I-1
tp19775
sS'monitored,see,clinical'
p19776
(F1
F0.00014334862385321102
I0
I1
I-1
tp19777
sS'expected,plasma,concentrations'
p19778
(F1
F0.00057339449541284407
I0
I4
I-4
tp19779
sS'agents,sodium,bicarbonate'
p19780
(F1
F0.00014334862385321102
I1
I0
I1
tp19781
sS'be,required,or'
p19782
(F1
F0.00014334862385321102
I1
I0
I1
tp19783
sS'how,to,use'
p19784
(F1
F0.00014334862385321102
I0
I1
I-1
tp19785
sS'sugar,in,type'
p19786
(F1
F0.00014334862385321102
I1
I0
I1
tp19787
sS'combination,oral,ethinyl'
p19788
(F1
F0.00014334862385321102
I0
I1
I-1
tp19789
sS'may,cause,respiratory'
p19790
(F1
F0.00014334862385321102
I1
I0
I1
tp19791
sS'usual,amounts,of'
p19792
(F1
F0.00014334862385321102
I0
I1
I-1
tp19793
sS'trials,of,augmentin'
p19794
(F1
F0.00014334862385321102
I0
I1
I-1
tp19795
sS'p450,isoenzymes,and'
p19796
(F1
F0.00014334862385321102
I0
I1
I-1
tp19797
sS'inhibit,both,aldehyde'
p19798
(F1
F0.00014334862385321102
I1
I0
I1
tp19799
sS'time,of,the'
p19800
(F1
F0.00014334862385321102
I0
I1
I-1
tp19801
sS'administered,on,day'
p19802
(F1
F0.00014334862385321102
I0
I1
I-1
tp19803
sS'system,cns,depressants'
p19804
(F0
F0
I1
I1
I0
tp19805
sS'and,respectively,when'
p19806
(F1
F0.00028669724770642203
I2
I0
I2
tp19807
sS'presence,of,agents'
p19808
(F1
F0.00014334862385321102
I1
I0
I1
tp19809
sS'ht1,agonists,within'
p19810
(F1
F0.00014334862385321102
I1
I0
I1
tp19811
sS'inhibitor,in,combination'
p19812
(F0
F0
I1
I1
I0
tp19813
sS'or,to,patients'
p19814
(F1
F0.00043004587155963305
I3
I0
I3
tp19815
sS'mc,and,comparison'
p19816
(F1
F0.00014334862385321102
I0
I1
I-1
tp19817
sS'given,for,long'
p19818
(F1
F0.00014334862385321102
I0
I1
I-1
tp19819
sS'it,is,unclear'
p19820
(F1
F0.00014334862385321102
I1
I0
I1
tp19821
sS'on,a,maintenance'
p19822
(F1
F0.00014334862385321102
I1
I0
I1
tp19823
sS'the,perioperative,period'
p19824
(F1
F0.00014334862385321102
I1
I0
I1
tp19825
sS'hours,after,at'
p19826
(F1
F0.00014334862385321102
I0
I1
I-1
tp19827
sS'additive,with,those'
p19828
(F1
F0.00043004587155963305
I3
I0
I3
tp19829
sS'by,a,blockade'
p19830
(F1
F0.00014334862385321102
I1
I0
I1
tp19831
sS'various,doses,of'
p19832
(F1
F0.00014334862385321102
I0
I1
I-1
tp19833
sS'vardenafil,in,healthy'
p19834
(F1
F0.00014334862385321102
I1
I0
I1
tp19835
sS'for,response,to'
p19836
(F1
F0.00014334862385321102
I0
I1
I-1
tp19837
sS'difference,exists,between'
p19838
(F1
F0.00014334862385321102
I0
I1
I-1
tp19839
sS'increased,the,activation'
p19840
(F1
F0.00014334862385321102
I1
I0
I1
tp19841
sS'hydrocortisone,mg,and'
p19842
(F1
F0.00014334862385321102
I0
I1
I-1
tp19843
sS'crohns,disease,and'
p19844
(F1
F0.00014334862385321102
I1
I0
I1
tp19845
sS'general,and,local'
p19846
(F1
F0.00014334862385321102
I0
I1
I-1
tp19847
sS'of,both,increases'
p19848
(F1
F0.00014334862385321102
I1
I0
I1
tp19849
sS'combine,to,cause'
p19850
(F1
F0.00014334862385321102
I1
I0
I1
tp19851
sS'subjects,who,had'
p19852
(F0
F0
I1
I1
I0
tp19853
sS'volunteers,concomitant,administration'
p19854
(F1
F0.00043004587155963305
I3
I0
I3
tp19855
sS'cmax,when,compared'
p19856
(F1
F0.00014334862385321102
I1
I0
I1
tp19857
sS'neural,pathways,which'
p19858
(F1
F0.00014334862385321102
I0
I1
I-1
tp19859
sS'otherwise,healthy,male'
p19860
(F1
F0.00014334862385321102
I1
I0
I1
tp19861
sS'patients,with,chronic'
p19862
(F0
F0
I1
I1
I0
tp19863
sS'serum,creatinine,level'
p19864
(F1
F0.00014334862385321102
I1
I0
I1
tp19865
sS'absorption,from,the'
p19866
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp19867
sS'this,combination,has'
p19868
(F1
F0.00014334862385321102
I1
I0
I1
tp19869
sS'of,and,reached'
p19870
(F1
F0.00014334862385321102
I1
I0
I1
tp19871
sS'antacids,and,can'
p19872
(F1
F0.00014334862385321102
I1
I0
I1
tp19873
sS'reactions,have,been'
p19874
(F1
F0.00028669724770642203
I2
I0
I2
tp19875
sS'is,indicated,in'
p19876
(F1
F0.00057339449541284407
I4
I0
I4
tp19877
sS'tablets,but,not'
p19878
(F1
F0.00014334862385321102
I0
I1
I-1
tp19879
sS'medication,used,to'
p19880
(F1
F0.00014334862385321102
I0
I1
I-1
tp19881
sS'studies,received,one'
p19882
(F1
F0.00014334862385321102
I0
I1
I-1
tp19883
sS'lead,to,several-'
p19884
(F1
F0.00014334862385321102
I0
I1
I-1
tp19885
sS'with,careful,monitoring'
p19886
(F1
F0.00028669724770642203
I2
I0
I2
tp19887
sS'in,tbg,concentrations'
p19888
(F1
F0.00014334862385321102
I0
I1
I-1
tp19889
sS'azole,antifungals,the'
p19890
(F1
F0.00014334862385321102
I0
I1
I-1
tp19891
sS'caused,excessive,release'
p19892
(F1
F0.00028669724770642203
I0
I2
I-2
tp19893
sS'thiazide,to,hypoparathyroid'
p19894
(F1
F0.00028669724770642203
I2
I0
I2
tp19895
sS'seven,experiments,reactions'
p19896
(F1
F0.00014334862385321102
I0
I1
I-1
tp19897
sS'in,the,following'
p19898
(F1
F0.00028669724770642203
I0
I2
I-2
tp19899
sS'in,parentheses,were'
p19900
(F1
F0.00014334862385321102
I0
I1
I-1
tp19901
sS'mg,was,given'
p19902
(F0
F0
I1
I1
I0
tp19903
sS'could,be,additive'
p19904
(F1
F0.00014334862385321102
I1
I0
I1
tp19905
sS'habituating,potential,prolonged'
p19906
(F1
F0.00014334862385321102
I0
I1
I-1
tp19907
sS'report,that,may'
p19908
(F1
F0.00014334862385321102
I1
I0
I1
tp19909
sS'the,absence,of'
p19910
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp19911
sS'limited,therefore,consideration'
p19912
(F1
F0.00014334862385321102
I1
I0
I1
tp19913
sS'hand,the,enhanced'
p19914
(F1
F0.00014334862385321102
I0
I1
I-1
tp19915
sS'evidence,of,any'
p19916
(F1
F0.00014334862385321102
I0
I1
I-1
tp19917
sS'from,the,currently'
p19918
(F1
F0.00014334862385321102
I0
I1
I-1
tp19919
sS'v,in,the'
p19920
(F1
F0.00014334862385321102
I0
I1
I-1
tp19921
sS'co-administered,with,vardenafil'
p19922
(F1
F0.00057339449541284407
I4
I0
I4
tp19923
sS'from,interaction,studies'
p19924
(F1
F0.00014334862385321102
I0
I1
I-1
tp19925
sS'with,prothrombin,time'
p19926
(F1
F0.00014334862385321102
I1
I0
I1
tp19927
sS'also,decrease,the'
p19928
(F1
F0.00028669724770642203
I2
I0
I2
tp19929
sS'per,day,will'
p19930
(F1
F0.00014334862385321102
I1
I0
I1
tp19931
sS'effects,divalproex,sodium'
p19932
(F1
F0.00014334862385321102
I1
I0
I1
tp19933
sS'quinolone,antibiotics,videx'
p19934
(F1
F0.00014334862385321102
I1
I0
I1
tp19935
sS'diminished,effect,of'
p19936
(F1
F0.00014334862385321102
I0
I1
I-1
tp19937
sS'plasma,levels,should'
p19938
(F1
F0.00071674311926605509
I0
I5
I-5
tp19939
sS'on,therapy,the'
p19940
(F1
F0.00014334862385321102
I1
I0
I1
tp19941
sS'hypercholesterolemic,noninsulin,dependent'
p19942
(F1
F0.00014334862385321102
I0
I1
I-1
tp19943
sS'one,week,course'
p19944
(F1
F0.00014334862385321102
I1
I0
I1
tp19945
sS'concurrently,administered,in'
p19946
(F1
F0.00014334862385321102
I0
I1
I-1
tp19947
sS'nitroglycerin,dynacirc,has'
p19948
(F1
F0.00014334862385321102
I0
I1
I-1
tp19949
sS'with,an,increased'
p19950
(F1
F0.00043004587155963305
I3
I0
I3
tp19951
sS'with,because,plasma'
p19952
(F1
F0.00014334862385321102
I1
I0
I1
tp19953
sS'the,contrary,and'
p19954
(F1
F0.00014334862385321102
I1
I0
I1
tp19955
sS'and,may,inhibit'
p19956
(F1
F0.00028669724770642203
I2
I0
I2
tp19957
sS'of,concomitant,oral'
p19958
(F1
F0.00014334862385321102
I1
I0
I1
tp19959
sS'or,multiple,dose'
p19960
(F1
F0.00014334862385321102
I0
I1
I-1
tp19961
sS'the,that,alter'
p19962
(F1
F0.00014334862385321102
I1
I0
I1
tp19963
sS'the,data,do'
p19964
(F1
F0.00014334862385321102
I0
I1
I-1
tp19965
sS'will,be,reduced'
p19966
(F1
F0.00043004587155963305
I0
I3
I-3
tp19967
sS'injections,of,microg'
p19968
(F1
F0.00014334862385321102
I0
I1
I-1
tp19969
sS'of,fat,soluble'
p19970
(F1
F0.00014334862385321102
I0
I1
I-1
tp19971
sS'have,little,or'
p19972
(F1
F0.00014334862385321102
I0
I1
I-1
tp19973
sS'require,additional,therapy'
p19974
(F1
F0.00014334862385321102
I0
I1
I-1
tp19975
sS'proquin,xr,should'
p19976
(F1
F0.00014334862385321102
I0
I1
I-1
tp19977
sS'and,css,max'
p19978
(F1
F0.00014334862385321102
I1
I0
I1
tp19979
sS'between,copaxone,and'
p19980
(F1
F0.00014334862385321102
I0
I1
I-1
tp19981
sS'use,of,two'
p19982
(F1
F0.00028669724770642203
I2
I0
I2
tp19983
sS'may,predispose,the'
p19984
(F1
F0.00014334862385321102
I1
I0
I1
tp19985
sS'in,vitro,in'
p19986
(F1
F0.00014334862385321102
I1
I0
I1
tp19987
sS'pretreatment,of,megakaryocytes'
p19988
(F1
F0.00014334862385321102
I1
I0
I1
tp19989
sS'are,employed,because'
p19990
(F1
F0.00014334862385321102
I1
I0
I1
tp19991
sS'injection,and,epidural'
p19992
(F1
F0.00014334862385321102
I1
I0
I1
tp19993
sS'blunts,the,increases'
p19994
(F1
F0.00014334862385321102
I1
I0
I1
tp19995
sS'inhibit,cyp450s,cyp1a2'
p19996
(F1
F0.00014334862385321102
I0
I1
I-1
tp19997
sS'non-steroidal,concomitantly,with'
p19998
(F1
F0.00014334862385321102
I1
I0
I1
tp19999
sS'any,from,the'
p20000
(F1
F0.00014334862385321102
I0
I1
I-1
tp20001
sS'weeks,plasma,concentrations'
p20002
(F1
F0.00014334862385321102
I1
I0
I1
tp20003
sS'in,gastric,ph'
p20004
(F1
F0.00014334862385321102
I1
I0
I1
tp20005
sS'threatening,cardiac,dysrhythmias'
p20006
(F1
F0.00014334862385321102
I1
I0
I1
tp20007
sS'overdosage,cns,stimulation'
p20008
(F1
F0.00028669724770642203
I2
I0
I2
tp20009
sS'organic,cation,transport'
p20010
(F1
F0.00014334862385321102
I0
I1
I-1
tp20011
sS'first,synthetic,hydroxy-3'
p20012
(F1
F0.00014334862385321102
I0
I1
I-1
tp20013
sS'to,in,normovolemic'
p20014
(F1
F0.00014334862385321102
I1
I0
I1
tp20015
sS'cyp2d6,cyp2e1,cyp4a9'
p20016
(F1
F0.00014334862385321102
I0
I1
I-1
tp20017
sS'angiotensin,and,angiotensin'
p20018
(F1
F0.00014334862385321102
I0
I1
I-1
tp20019
sS'mg,kg,day'
p20020
(F0.25
F0.00028669724770642203
I5
I3
I2
tp20021
sS'of,other,channel'
p20022
(F1
F0.00014334862385321102
I1
I0
I1
tp20023
sS'about,and,use'
p20024
(F1
F0.00014334862385321102
I0
I1
I-1
tp20025
sS'therefore,mao,inhibitors'
p20026
(F1
F0.00014334862385321102
I1
I0
I1
tp20027
sS'which,are,usually'
p20028
(F1
F0.00014334862385321102
I1
I0
I1
tp20029
sS'bowel,and,decrease'
p20030
(F1
F0.00014334862385321102
I0
I1
I-1
tp20031
sS'the,location,histologic'
p20032
(F1
F0.00014334862385321102
I0
I1
I-1
tp20033
sS'cimetidine,cimetidine,increases'
p20034
(F1
F0.00014334862385321102
I1
I0
I1
tp20035
sS'not,shown,to'
p20036
(F1
F0.00014334862385321102
I1
I0
I1
tp20037
sS'the,antitumor,effectiveness'
p20038
(F1
F0.00014334862385321102
I1
I0
I1
tp20039
sS'by,and,reduced'
p20040
(F1
F0.00014334862385321102
I1
I0
I1
tp20041
sS'not,appreciably,metabolized'
p20042
(F1
F0.00014334862385321102
I0
I1
I-1
tp20043
sS'the,pharmacodynamics,prothrombin'
p20044
(F1
F0.00014334862385321102
I0
I1
I-1
tp20045
sS'when,administering,peganone'
p20046
(F1
F0.00014334862385321102
I1
I0
I1
tp20047
sS'such,as,protease'
p20048
(F1
F0.00014334862385321102
I1
I0
I1
tp20049
sS'bumetanide,may,potentiate'
p20050
(F1
F0.00014334862385321102
I1
I0
I1
tp20051
sS'data,from,a'
p20052
(F1
F0.00014334862385321102
I1
I0
I1
tp20053
sS'with,changes,in'
p20054
(F1
F0.00014334862385321102
I0
I1
I-1
tp20055
sS'and,cmax,but'
p20056
(F1
F0.00014334862385321102
I0
I1
I-1
tp20057
sS'competitively,displaces,from'
p20058
(F1
F0.00014334862385321102
I1
I0
I1
tp20059
sS'stomach,may,effect'
p20060
(F1
F0.00014334862385321102
I1
I0
I1
tp20061
sS'c,should,be'
p20062
(F1
F0.00028669724770642203
I2
I0
I2
tp20063
sS'patients,either,on'
p20064
(F1
F0.00014334862385321102
I0
I1
I-1
tp20065
sS'and,the,decreased'
p20066
(F1
F0.00014334862385321102
I0
I1
I-1
tp20067
sS'certain,especially,the'
p20068
(F1
F0.00014334862385321102
I1
I0
I1
tp20069
sS'steadystate,trough,cmin'
p20070
(F1
F0.00014334862385321102
I0
I1
I-1
tp20071
sS'plasma,concentrations,and'
p20072
(F0.25
F0.00028669724770642203
I5
I3
I2
tp20073
sS'well,as,random'
p20074
(F1
F0.00014334862385321102
I1
I0
I1
tp20075
sS'by,beta-adrenergic,blocking'
p20076
(F1
F0.00014334862385321102
I1
I0
I1
tp20077
sS'decision,must,be'
p20078
(F1
F0.00014334862385321102
I0
I1
I-1
tp20079
sS'a,single-dose,interaction'
p20080
(F1
F0.00014334862385321102
I0
I1
I-1
tp20081
sS'mg,bid,day'
p20082
(F0
F0
I1
I1
I0
tp20083
sS'increase,the,requirements'
p20084
(F1
F0.00014334862385321102
I1
I0
I1
tp20085
sS'including,inhaled,and'
p20086
(F1
F0.00014334862385321102
I0
I1
I-1
tp20087
sS'inhibitors,warning,potential'
p20088
(F1
F0.00014334862385321102
I0
I1
I-1
tp20089
sS'describes,a,novel'
p20090
(F1
F0.00014334862385321102
I1
I0
I1
tp20091
sS'the,active,sulfide'
p20092
(F1
F0.00014334862385321102
I1
I0
I1
tp20093
sS'patients,undergoing,treatment'
p20094
(F1
F0.00043004587155963305
I3
I0
I3
tp20095
sS'such,as,acute'
p20096
(F1
F0.00014334862385321102
I0
I1
I-1
tp20097
sS'max,by,confidence'
p20098
(F1
F0.00014334862385321102
I0
I1
I-1
tp20099
sS'and,antagonists,which'
p20100
(F1
F0.00014334862385321102
I1
I0
I1
tp20101
sS'used,concomitantly,there'
p20102
(F1
F0.00014334862385321102
I1
I0
I1
tp20103
sS'vitro,and,in'
p20104
(F1
F0.00014334862385321102
I1
I0
I1
tp20105
sS'ribavirin,can,antagonize'
p20106
(F1
F0.00014334862385321102
I1
I0
I1
tp20107
sS'methods,to,measure'
p20108
(F1
F0.00014334862385321102
I0
I1
I-1
tp20109
sS'increased,severity,and'
p20110
(F1
F0.00014334862385321102
I1
I0
I1
tp20111
sS'severe,hypotension,has'
p20112
(F1
F0.00014334862385321102
I1
I0
I1
tp20113
sS'study,the,effects'
p20114
(F1
F0.00014334862385321102
I0
I1
I-1
tp20115
sS'results,confirm,that'
p20116
(F1
F0.00014334862385321102
I0
I1
I-1
tp20117
sS'a,strong,in'
p20118
(F1
F0.00014334862385321102
I0
I1
I-1
tp20119
sS'flolan,which,may'
p20120
(F1
F0.00014334862385321102
I1
I0
I1
tp20121
sS'measured,by,prothrombin'
p20122
(F1
F0.00014334862385321102
I0
I1
I-1
tp20123
sS'ast,when,cancidas'
p20124
(F1
F0.00014334862385321102
I1
I0
I1
tp20125
sS'selective,cyp3a4,inhibitors'
p20126
(F1
F0.00014334862385321102
I1
I0
I1
tp20127
sS'cautiously,if,at'
p20128
(F1
F0.00014334862385321102
I0
I1
I-1
tp20129
sS'formulation,with,mg'
p20130
(F1
F0.00028669724770642203
I2
I0
I2
tp20131
sS'cause,heart,failure'
p20132
(F1
F0.00014334862385321102
I1
I0
I1
tp20133
sS'was,associated,with'
p20134
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp20135
sS'ace,inhibitors,mao'
p20136
(F1
F0.00014334862385321102
I0
I1
I-1
tp20137
sS'respectively,a,number'
p20138
(F1
F0.00014334862385321102
I1
I0
I1
tp20139
sS'biotransformation,system,responsible'
p20140
(F1
F0.00014334862385321102
I1
I0
I1
tp20141
sS'class,of,include'
p20142
(F1
F0.00014334862385321102
I0
I1
I-1
tp20143
sS'including,manic-depressive,illness'
p20144
(F1
F0.00014334862385321102
I1
I0
I1
tp20145
sS'hmg-coa,reductase,inhibitor'
p20146
(F1
F0.00043004587155963305
I3
I0
I3
tp20147
sS'index,digoxin,a'
p20148
(F1
F0.00014334862385321102
I0
I1
I-1
tp20149
sS'the,major,ingredient'
p20150
(F1
F0.00014334862385321102
I0
I1
I-1
tp20151
sS'one,survey,of'
p20152
(F1
F0.00014334862385321102
I1
I0
I1
tp20153
sS'co-administration,of,single'
p20154
(F1
F0.00014334862385321102
I0
I1
I-1
tp20155
sS'of,and,strong'
p20156
(F1
F0.00014334862385321102
I1
I0
I1
tp20157
sS'times,daily,given'
p20158
(F1
F0.00014334862385321102
I1
I0
I1
tp20159
sS'omeprazole,omeprazole,is'
p20160
(F1
F0.00014334862385321102
I0
I1
I-1
tp20161
sS'metabolism,in,normal'
p20162
(F1
F0.00014334862385321102
I0
I1
I-1
tp20163
sS'their,prothrombin,time'
p20164
(F1
F0.00014334862385321102
I1
I0
I1
tp20165
sS'however,because,some'
p20166
(F1
F0.00028669724770642203
I2
I0
I2
tp20167
sS'apparent,effect,on'
p20168
(F1
F0.00014334862385321102
I0
I1
I-1
tp20169
sS'and,pupil,constriction'
p20170
(F1
F0.00014334862385321102
I0
I1
I-1
tp20171
sS'potential,twofold,increase'
p20172
(F1
F0.00014334862385321102
I1
I0
I1
tp20173
sS'm2,basis,appears'
p20174
(F1
F0.00014334862385321102
I1
I0
I1
tp20175
sS'are,advised,to'
p20176
(F1
F0.00014334862385321102
I1
I0
I1
tp20177
sS'oral,regimen,containing'
p20178
(F1
F0.00014334862385321102
I0
I1
I-1
tp20179
sS'iron,supplements,and'
p20180
(F1
F0.00014334862385321102
I1
I0
I1
tp20181
sS'with,coadministration,of'
p20182
(F0.25
F0.00028669724770642203
I5
I3
I2
tp20183
sS'interaction,because,xigris'
p20184
(F1
F0.00014334862385321102
I0
I1
I-1
tp20185
sS'is,increased,with'
p20186
(F1
F0.00014334862385321102
I0
I1
I-1
tp20187
sS'whose,pulmonary,disease'
p20188
(F1
F0.00014334862385321102
I0
I1
I-1
tp20189
sS'be,applied,for'
p20190
(F1
F0.00014334862385321102
I0
I1
I-1
tp20191
sS'antacid,the,effect'
p20192
(F1
F0.00014334862385321102
I0
I1
I-1
tp20193
sS'nitrous,oxide,with'
p20194
(F1
F0.00014334862385321102
I0
I1
I-1
tp20195
sS'any,of,these'
p20196
(F1
F0.00014334862385321102
I0
I1
I-1
tp20197
sS'effects,of,prinivil'
p20198
(F1
F0.00014334862385321102
I0
I1
I-1
tp20199
sS'the,higher,and'
p20200
(F1
F0.00014334862385321102
I0
I1
I-1
tp20201
sS'with,brain,levels'
p20202
(F1
F0.00014334862385321102
I0
I1
I-1
tp20203
sS'pyrazolone,derivatives,and'
p20204
(F1
F0.00014334862385321102
I1
I0
I1
tp20205
sS'frequency,of,skin'
p20206
(F1
F0.00014334862385321102
I1
I0
I1
tp20207
sS'cyp2c9,isoenzyme,in'
p20208
(F1
F0.00014334862385321102
I1
I0
I1
tp20209
sS'over,those,seen'
p20210
(F1
F0.00014334862385321102
I1
I0
I1
tp20211
sS'immediately,before,injection'
p20212
(F1
F0.00014334862385321102
I0
I1
I-1
tp20213
sS'beginning,depletion,of'
p20214
(F1
F0.00014334862385321102
I1
I0
I1
tp20215
sS'toradol,on,plasma'
p20216
(F1
F0.00014334862385321102
I1
I0
I1
tp20217
sS'co-administered,with,inducers'
p20218
(F1
F0.00014334862385321102
I1
I0
I1
tp20219
sS'a,positive,direct'
p20220
(F1
F0.00014334862385321102
I0
I1
I-1
tp20221
sS'must,be,weighed'
p20222
(F1
F0.00014334862385321102
I1
I0
I1
tp20223
sS'than,mg,mg'
p20224
(F1
F0.00014334862385321102
I0
I1
I-1
tp20225
sS'gastric,ph,is'
p20226
(F1
F0.00028669724770642203
I2
I0
I2
tp20227
sS'gastric,ph,in'
p20228
(F1
F0.00014334862385321102
I0
I1
I-1
tp20229
sS'the,homodimeric,disintegrin'
p20230
(F1
F0.00014334862385321102
I0
I1
I-1
tp20231
sS'uncomplicated,urinary,tract'
p20232
(F1
F0.00014334862385321102
I0
I1
I-1
tp20233
sS'resulted,in,significantly'
p20234
(F1
F0.00014334862385321102
I1
I0
I1
tp20235
sS'and,type,c'
p20236
(F1
F0.00057339449541284407
I4
I0
I4
tp20237
sS'when,and,these'
p20238
(F1
F0.00014334862385321102
I0
I1
I-1
tp20239
sS'but,only,increases'
p20240
(F1
F0.00014334862385321102
I0
I1
I-1
tp20241
sS'by,of,the'
p20242
(F1
F0.00014334862385321102
I1
I0
I1
tp20243
sS'are,contraindicated,in'
p20244
(F1
F0.00014334862385321102
I1
I0
I1
tp20245
sS'pump,inhibitors,with'
p20246
(F1
F0.00014334862385321102
I1
I0
I1
tp20247
sS'and,failed,to'
p20248
(F1
F0.00014334862385321102
I0
I1
I-1
tp20249
sS'times,more,potent'
p20250
(F1
F0.00014334862385321102
I0
I1
I-1
tp20251
sS'events,by,interfering'
p20252
(F1
F0.00014334862385321102
I1
I0
I1
tp20253
sS'related,to,a'
p20254
(F1
F0.00014334862385321102
I0
I1
I-1
tp20255
sS'recovery,of,hoof'
p20256
(F1
F0.00014334862385321102
I1
I0
I1
tp20257
sS'influenced,the,pharmacodynamics'
p20258
(F1
F0.00014334862385321102
I0
I1
I-1
tp20259
sS'an,antiparkinsonian,drug'
p20260
(F1
F0.00014334862385321102
I1
I0
I1
tp20261
sS'other,drugs,aripiprazole'
p20262
(F1
F0.00014334862385321102
I0
I1
I-1
tp20263
sS'renal,toxicity,and'
p20264
(F1
F0.00014334862385321102
I0
I1
I-1
tp20265
sS'of,antizol,mg'
p20266
(F1
F0.00014334862385321102
I1
I0
I1
tp20267
sS'local,use,of'
p20268
(F1
F0.00014334862385321102
I0
I1
I-1
tp20269
sS'pharmacokinetits,of,sodium'
p20270
(F1
F0.00014334862385321102
I0
I1
I-1
tp20271
sS'or,other,coumarin-derivative'
p20272
(F1
F0.00014334862385321102
I0
I1
I-1
tp20273
sS'injection,with,a'
p20274
(F1
F0.00014334862385321102
I1
I0
I1
tp20275
sS'bradycardia,or,hypotension'
p20276
(F1
F0.00014334862385321102
I1
I0
I1
tp20277
sS'displacement,between,and'
p20278
(F1
F0.00014334862385321102
I0
I1
I-1
tp20279
sS'is,prevented,by'
p20280
(F1
F0.00014334862385321102
I1
I0
I1
tp20281
sS'n-dodecyl,gallate,showed'
p20282
(F1
F0.00014334862385321102
I0
I1
I-1
tp20283
sS'in,a,phase'
p20284
(F1
F0.00014334862385321102
I1
I0
I1
tp20285
sS'slight,but,not'
p20286
(F1
F0.00014334862385321102
I1
I0
I1
tp20287
sS'was,misused,by'
p20288
(F1
F0.00014334862385321102
I0
I1
I-1
tp20289
sS'from,the,therapeutic'
p20290
(F1
F0.00014334862385321102
I0
I1
I-1
tp20291
sS'blurred,vision,have'
p20292
(F1
F0.00028669724770642203
I2
I0
I2
tp20293
sS'fo,the,experiment'
p20294
(F1
F0.00014334862385321102
I0
I1
I-1
tp20295
sS'day,to,prevent'
p20296
(F1
F0.00014334862385321102
I0
I1
I-1
tp20297
sS'duloxetine,to,affect'
p20298
(F1
F0.00014334862385321102
I0
I1
I-1
tp20299
sS'can,produce,nephrotoxicity'
p20300
(F1
F0.00014334862385321102
I1
I0
I1
tp20301
sS'drugs,nsaids,a'
p20302
(F1
F0.00014334862385321102
I0
I1
I-1
tp20303
sS'a,light,dark'
p20304
(F1
F0.00014334862385321102
I0
I1
I-1
tp20305
sS'maxipime,because,of'
p20306
(F1
F0.00014334862385321102
I1
I0
I1
tp20307
sS'false,positive,test'
p20308
(F1
F0.00014334862385321102
I0
I1
I-1
tp20309
sS'cytochrome,p450iid6,cyp2d6'
p20310
(F1
F0.00014334862385321102
I0
I1
I-1
tp20311
sS'caution,should,be'
p20312
(F0.59999999999999998
F0.0034403669724770644
I32
I8
I24
tp20313
sS'laboratory,test,interactions'
p20314
(F0.77777777777777779
F0.0010034403669724771
I1
I8
I-7
tp20315
sS'that,the,prothrombin'
p20316
(F1
F0.00014334862385321102
I1
I0
I1
tp20317
sS'on,blood,pressure'
p20318
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp20319
sS'when,such,drugs'
p20320
(F1
F0.00014334862385321102
I0
I1
I-1
tp20321
sS'as,and,induce'
p20322
(F1
F0.00014334862385321102
I1
I0
I1
tp20323
sS'of,maximum,block'
p20324
(F1
F0.00014334862385321102
I1
I0
I1
tp20325
sS'midamor,and,non-steroidal'
p20326
(F1
F0.00014334862385321102
I1
I0
I1
tp20327
sS'tablets,administered,twice'
p20328
(F1
F0.00014334862385321102
I0
I1
I-1
tp20329
sS'that,induce,inhibit'
p20330
(F1
F0.00014334862385321102
I1
I0
I1
tp20331
sS'orally,prior,to'
p20332
(F1
F0.00014334862385321102
I1
I0
I1
tp20333
sS'auc0-12,and,a'
p20334
(F1
F0.00014334862385321102
I1
I0
I1
tp20335
sS'decrease,the,response'
p20336
(F1
F0.00014334862385321102
I1
I0
I1
tp20337
sS'a,blocker,of'
p20338
(F1
F0.00014334862385321102
I0
I1
I-1
tp20339
sS'not,outweigh,the'
p20340
(F1
F0.00014334862385321102
I1
I0
I1
tp20341
sS'multiple,effects,on'
p20342
(F1
F0.00014334862385321102
I1
I0
I1
tp20343
sS'closely,related,have'
p20344
(F1
F0.00014334862385321102
I1
I0
I1
tp20345
sS'levels,by,compared'
p20346
(F1
F0.00014334862385321102
I1
I0
I1
tp20347
sS'on,the,antinociceptive'
p20348
(F0
F0
I1
I1
I0
tp20349
sS'higher,than,users'
p20350
(F1
F0.00014334862385321102
I1
I0
I1
tp20351
sS'used,it,may'
p20352
(F1
F0.00014334862385321102
I1
I0
I1
tp20353
sS'dose,of,vardenafil'
p20354
(F1
F0.00043004587155963305
I3
I0
I3
tp20355
sS'therefore,or,other'
p20356
(F1
F0.00014334862385321102
I1
I0
I1
tp20357
sS'intracranial,hypertension,some'
p20358
(F1
F0.00014334862385321102
I1
I0
I1
tp20359
sS'mg,bid,with'
p20360
(F1
F0.00043004587155963305
I3
I0
I3
tp20361
sS'during,simultaneous,administration'
p20362
(F1
F0.00014334862385321102
I0
I1
I-1
tp20363
sS'supplemental,l-glutamine,at'
p20364
(F1
F0.00014334862385321102
I1
I0
I1
tp20365
sS'any,additional,effect'
p20366
(F1
F0.00014334862385321102
I1
I0
I1
tp20367
sS'reduction,of,approximately'
p20368
(F1
F0.00014334862385321102
I1
I0
I1
tp20369
sS'levels,of,duloxetine'
p20370
(F1
F0.00014334862385321102
I1
I0
I1
tp20371
sS'modest,cyp2d6,inhibitory'
p20372
(F1
F0.00014334862385321102
I1
I0
I1
tp20373
sS'warfarin,in,subjects'
p20374
(F1
F0.00014334862385321102
I0
I1
I-1
tp20375
sS'expected,to,be'
p20376
(F1
F0.00043004587155963305
I3
I0
I3
tp20377
sS'norpace,was,coadministered'
p20378
(F1
F0.00014334862385321102
I0
I1
I-1
tp20379
sS'have,involved,either'
p20380
(F1
F0.00014334862385321102
I0
I1
I-1
tp20381
sS'ii,to,iii'
p20382
(F1
F0.00028669724770642203
I0
I2
I-2
tp20383
sS'normal,volunteers,resulted'
p20384
(F1
F0.00028669724770642203
I2
I0
I2
tp20385
sS'of,these,trace'
p20386
(F1
F0.00014334862385321102
I0
I1
I-1
tp20387
sS'and,concomitantly,administered'
p20388
(F1
F0.00014334862385321102
I0
I1
I-1
tp20389
sS'relevance,of,these'
p20390
(F1
F0.00014334862385321102
I1
I0
I1
tp20391
sS'only,increases,extracellular'
p20392
(F1
F0.00014334862385321102
I0
I1
I-1
tp20393
sS'the,estrogenic,component'
p20394
(F1
F0.00014334862385321102
I0
I1
I-1
tp20395
sS'hybridization,we,observed'
p20396
(F1
F0.00014334862385321102
I1
I0
I1
tp20397
sS'administered,immediately,following'
p20398
(F1
F0.00014334862385321102
I1
I0
I1
tp20399
sS'the,specific,toxicities'
p20400
(F1
F0.00014334862385321102
I0
I1
I-1
tp20401
sS'with,biliary,excretion'
p20402
(F1
F0.00014334862385321102
I0
I1
I-1
tp20403
sS'serum,binding,proteins'
p20404
(F1
F0.00014334862385321102
I1
I0
I1
tp20405
sS'plasma,concentration,of'
p20406
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp20407
sS'of,the,type'
p20408
(F1
F0.00014334862385321102
I1
I0
I1
tp20409
sS'every,hours,does'
p20410
(F1
F0.00028669724770642203
I2
I0
I2
tp20411
sS'of,crixivan,and'
p20412
(F0
F0
I1
I1
I0
tp20413
sS'excretion,glucuronidation,and'
p20414
(F1
F0.00014334862385321102
I0
I1
I-1
tp20415
sS'may,sensitize,the'
p20416
(F1
F0.00014334862385321102
I1
I0
I1
tp20417
sS'glutathione,use,of'
p20418
(F1
F0.00014334862385321102
I1
I0
I1
tp20419
sS'including,concomitantly,with'
p20420
(F1
F0.00028669724770642203
I2
I0
I2
tp20421
sS'pharmacokinetic,captopril-digoxin,interaction'
p20422
(F1
F0.00014334862385321102
I0
I1
I-1
tp20423
sS'use,of,isocarboxazid'
p20424
(F1
F0.00014334862385321102
I1
I0
I1
tp20425
sS'may,have,an'
p20426
(F0.5
F0.00057339449541284407
I6
I2
I4
tp20427
sS'inhaled,and,oral'
p20428
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp20429
sS'both,a,cyp3a4'
p20430
(F1
F0.00014334862385321102
I0
I1
I-1
tp20431
sS'receiving,treatment,with'
p20432
(F1
F0.00014334862385321102
I0
I1
I-1
tp20433
sS'the,first,step'
p20434
(F1
F0.00014334862385321102
I0
I1
I-1
tp20435
sS'adverse,reaction,profile'
p20436
(F1
F0.00014334862385321102
I0
I1
I-1
tp20437
sS'nsaids,may,affect'
p20438
(F1
F0.00014334862385321102
I0
I1
I-1
tp20439
sS'absorption,in,those'
p20440
(F1
F0.00014334862385321102
I1
I0
I1
tp20441
sS'increase,in,dose'
p20442
(F1
F0.00014334862385321102
I1
I0
I1
tp20443
sS'with,nph,human'
p20444
(F1
F0.00028669724770642203
I0
I2
I-2
tp20445
sS'nanm,in,decreasing'
p20446
(F1
F0.00014334862385321102
I0
I1
I-1
tp20447
sS'patients,were,treated'
p20448
(F1
F0.00014334862385321102
I0
I1
I-1
tp20449
sS'since,is,primarily'
p20450
(F1
F0.00014334862385321102
I0
I1
I-1
tp20451
sS'identified,in,clinical'
p20452
(F1
F0.00014334862385321102
I1
I0
I1
tp20453
sS'overdose,recognized,by'
p20454
(F1
F0.00014334862385321102
I0
I1
I-1
tp20455
sS'situ,hybridization,we'
p20456
(F1
F0.00014334862385321102
I1
I0
I1
tp20457
sS'these,drugs,include'
p20458
(F1
F0.00014334862385321102
I0
I1
I-1
tp20459
sS'determinations,vitamin,c'
p20460
(F1
F0.00014334862385321102
I1
I0
I1
tp20461
sS'a,mild,but'
p20462
(F1
F0.00014334862385321102
I0
I1
I-1
tp20463
sS'of,on,indicates'
p20464
(F1
F0.00014334862385321102
I1
I0
I1
tp20465
sS'and,antihypertensive,effects'
p20466
(F1
F0.00043004587155963305
I3
I0
I3
tp20467
sS'therapy,with,interferon'
p20468
(F1
F0.00014334862385321102
I0
I1
I-1
tp20469
sS'antihistamines,may,partially'
p20470
(F1
F0.00014334862385321102
I1
I0
I1
tp20471
sS'prinivil,attenuates,loss'
p20472
(F1
F0.00014334862385321102
I1
I0
I1
tp20473
sS'augment,the,activity'
p20474
(F1
F0.00028669724770642203
I2
I0
I2
tp20475
sS'of,didanosine-placebo,tablets'
p20476
(F1
F0.00014334862385321102
I1
I0
I1
tp20477
sS'addition,other,have'
p20478
(F1
F0.00014334862385321102
I1
I0
I1
tp20479
sS'chemotherapy,plus,highly'
p20480
(F1
F0.00014334862385321102
I0
I1
I-1
tp20481
sS'injection,concentrate,and'
p20482
(F1
F0.00014334862385321102
I1
I0
I1
tp20483
sS'were,not,reported'
p20484
(F1
F0.00014334862385321102
I1
I0
I1
tp20485
sS'and,cytoprotective,properties'
p20486
(F1
F0.00014334862385321102
I0
I1
I-1
tp20487
sS'a4,and,cyp'
p20488
(F1
F0.00014334862385321102
I0
I1
I-1
tp20489
sS'pharmacokinetics,in,subjects'
p20490
(F1
F0.00014334862385321102
I0
I1
I-1
tp20491
sS'torsades,de,pointes'
p20492
(F0
F0
I1
I1
I0
tp20493
sS'associated,with,co-administration'
p20494
(F1
F0.00014334862385321102
I1
I0
I1
tp20495
sS'no,significant,impact'
p20496
(F1
F0.00014334862385321102
I1
I0
I1
tp20497
sS'aortic,rings,from'
p20498
(F1
F0.00014334862385321102
I1
I0
I1
tp20499
sS'inducers,it,is'
p20500
(F1
F0.00014334862385321102
I1
I0
I1
tp20501
sS'increased,nephrotoxicity,has'
p20502
(F1
F0.00028669724770642203
I2
I0
I2
tp20503
sS'renal,toxicity,bronchospasm'
p20504
(F1
F0.00014334862385321102
I1
I0
I1
tp20505
sS'is,mildly,reduced'
p20506
(F1
F0.00014334862385321102
I1
I0
I1
tp20507
sS'alter,the,behavioral'
p20508
(F1
F0.00014334862385321102
I0
I1
I-1
tp20509
sS'constitutes,the,best'
p20510
(F1
F0.00014334862385321102
I0
I1
I-1
tp20511
sS'of,does,not'
p20512
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp20513
sS'interaction,is,likely'
p20514
(F1
F0.00014334862385321102
I1
I0
I1
tp20515
sS'antagonist,sch-23390,but'
p20516
(F1
F0.00014334862385321102
I1
I0
I1
tp20517
sS'used,in,ms'
p20518
(F1
F0.00014334862385321102
I0
I1
I-1
tp20519
sS'action,of,the'
p20520
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp20521
sS'a,limited,number'
p20522
(F1
F0.00014334862385321102
I0
I1
I-1
tp20523
sS'increase,in,zaleplons'
p20524
(F1
F0.00014334862385321102
I1
I0
I1
tp20525
sS'intact,endothelium,from'
p20526
(F1
F0.00014334862385321102
I1
I0
I1
tp20527
sS'acetazolamide,reduces,urinary'
p20528
(F1
F0.00014334862385321102
I1
I0
I1
tp20529
sS'ace,inhibitors,oral'
p20530
(F1
F0.00014334862385321102
I0
I1
I-1
tp20531
sS'for,reduction,in'
p20532
(F1
F0.00014334862385321102
I1
I0
I1
tp20533
sS'shown,between,and'
p20534
(F1
F0.00014334862385321102
I1
I0
I1
tp20535
sS'bleeding,when,administered'
p20536
(F1
F0.00014334862385321102
I1
I0
I1
tp20537
sS'steroidal,anti-,inflammatory'
p20538
(F1
F0.00014334862385321102
I1
I0
I1
tp20539
sS'effect,was,observed'
p20540
(F1
F0.00014334862385321102
I1
I0
I1
tp20541
sS'in,psoriatic,arthritis'
p20542
(F1
F0.00014334862385321102
I0
I1
I-1
tp20543
sS'human,therapeutic,dose'
p20544
(F1
F0.00014334862385321102
I1
I0
I1
tp20545
sS'interval,clinical,laboratory'
p20546
(F1
F0.00014334862385321102
I0
I1
I-1
tp20547
sS'use,of,amphotericin'
p20548
(F1
F0.00014334862385321102
I1
I0
I1
tp20549
sS'of,antagonists,phenyltheophylline'
p20550
(F1
F0.00014334862385321102
I0
I1
I-1
tp20551
sS'monitoring,of,cardiac'
p20552
(F1
F0.00014334862385321102
I1
I0
I1
tp20553
sS'these,are,that'
p20554
(F1
F0.00014334862385321102
I0
I1
I-1
tp20555
sS'of,dmpge2,in'
p20556
(F1
F0.00014334862385321102
I0
I1
I-1
tp20557
sS'for,auc,infinity'
p20558
(F1
F0.00014334862385321102
I0
I1
I-1
tp20559
sS'could,cause,an'
p20560
(F1
F0.00014334862385321102
I1
I0
I1
tp20561
sS'mg,initial,oral'
p20562
(F1
F0.00014334862385321102
I1
I0
I1
tp20563
sS'classes,of,antipsychotic'
p20564
(F1
F0.00014334862385321102
I1
I0
I1
tp20565
sS'period,following,treatment'
p20566
(F1
F0.00014334862385321102
I0
I1
I-1
tp20567
sS'm,ptx,m'
p20568
(F1
F0.00014334862385321102
I1
I0
I1
tp20569
sS'markedly,increased,plasma'
p20570
(F1
F0.00014334862385321102
I1
I0
I1
tp20571
sS'about,to,fold'
p20572
(F1
F0.00014334862385321102
I1
I0
I1
tp20573
sS'should,be,undertaken'
p20574
(F1
F0.00043004587155963305
I3
I0
I3
tp20575
sS'of,rat,thoracic'
p20576
(F1
F0.00014334862385321102
I0
I1
I-1
tp20577
sS'with,the,has'
p20578
(F1
F0.00014334862385321102
I1
I0
I1
tp20579
sS'antipsychotic,agents,it'
p20580
(F1
F0.00014334862385321102
I1
I0
I1
tp20581
sS'other,cns,depressant'
p20582
(F0.5
F0.00028669724770642203
I3
I1
I2
tp20583
sS'patients,taking,and'
p20584
(F1
F0.00057339449541284407
I4
I0
I4
tp20585
sS'were,resistant,to'
p20586
(F1
F0.00014334862385321102
I0
I1
I-1
tp20587
sS'in,combination,see'
p20588
(F1
F0.00014334862385321102
I0
I1
I-1
tp20589
sS'is,a,significant'
p20590
(F1
F0.00014334862385321102
I1
I0
I1
tp20591
sS'of,skeletal,myopathy'
p20592
(F1
F0.00014334862385321102
I0
I1
I-1
tp20593
sS'and,l-methionine,may'
p20594
(F1
F0.00014334862385321102
I1
I0
I1
tp20595
sS'performance,was,seen'
p20596
(F1
F0.00014334862385321102
I1
I0
I1
tp20597
sS'eye,product,containing'
p20598
(F1
F0.00014334862385321102
I1
I0
I1
tp20599
sS'hydroxide-,and,hydroxide-containing'
p20600
(F1
F0.00014334862385321102
I0
I1
I-1
tp20601
sS'channel,blockers,certain'
p20602
(F1
F0.00014334862385321102
I1
I0
I1
tp20603
sS'a,common,component'
p20604
(F1
F0.00014334862385321102
I1
I0
I1
tp20605
sS'of,otthostatic,hypotension'
p20606
(F1
F0.00014334862385321102
I0
I1
I-1
tp20607
sS'since,blood,level'
p20608
(F1
F0.00043004587155963305
I0
I3
I-3
tp20609
sS'protein,binding,is'
p20610
(F1
F0.00014334862385321102
I1
I0
I1
tp20611
sS'antagonist,may,precipitate'
p20612
(F1
F0.00014334862385321102
I0
I1
I-1
tp20613
sS'hyperkalemia,serum,meq'
p20614
(F1
F0.00014334862385321102
I1
I0
I1
tp20615
sS'to,control,blood'
p20616
(F0
F0
I1
I1
I0
tp20617
sS'inhibitors,of,av'
p20618
(F1
F0.00014334862385321102
I1
I0
I1
tp20619
sS'reported,interactions,with'
p20620
(F1
F0.00014334862385321102
I0
I1
I-1
tp20621
sS'prevent,opioid-induced,gastrointestinal'
p20622
(F1
F0.00014334862385321102
I1
I0
I1
tp20623
sS'similar,to,in'
p20624
(F1
F0.00014334862385321102
I1
I0
I1
tp20625
sS'the,concomitant,agent'
p20626
(F1
F0.00014334862385321102
I1
I0
I1
tp20627
sS'and,titrated,to'
p20628
(F1
F0.00028669724770642203
I0
I2
I-2
tp20629
sS'of,aprepitant,given'
p20630
(F1
F0.00014334862385321102
I1
I0
I1
tp20631
sS'enbrel,and,therapy'
p20632
(F1
F0.00014334862385321102
I1
I0
I1
tp20633
sS'monitored,closely,and'
p20634
(F0
F0
I1
I1
I0
tp20635
sS'inhibitors,in,subjects'
p20636
(F1
F0.00014334862385321102
I0
I1
I-1
tp20637
sS'the,neurochemical,and'
p20638
(F1
F0.00014334862385321102
I0
I1
I-1
tp20639
sS'when,has,been'
p20640
(F1
F0.00014334862385321102
I1
I0
I1
tp20641
sS'intestinal,carcinogenesis,by'
p20642
(F1
F0.00014334862385321102
I0
I1
I-1
tp20643
sS'carbamazepine,is,metabolized'
p20644
(F1
F0.00014334862385321102
I0
I1
I-1
tp20645
sS'it,is,inadvisable'
p20646
(F1
F0.00014334862385321102
I1
I0
I1
tp20647
sS'a4,but,coadministration'
p20648
(F1
F0.00014334862385321102
I0
I1
I-1
tp20649
sS'when,changing,from'
p20650
(F1
F0.00014334862385321102
I0
I1
I-1
tp20651
sS'interactions,benzodiazepines,benzodiazepines'
p20652
(F1
F0.00014334862385321102
I1
I0
I1
tp20653
sS'reports,of,interactions'
p20654
(F1
F0.00028669724770642203
I2
I0
I2
tp20655
sS'shown,to,displace'
p20656
(F1
F0.00014334862385321102
I1
I0
I1
tp20657
sS'and,by,inhibiting'
p20658
(F1
F0.00014334862385321102
I1
I0
I1
tp20659
sS'as,hypotension,requiring'
p20660
(F1
F0.00014334862385321102
I0
I1
I-1
tp20661
sS'occurs,with,other'
p20662
(F1
F0.00014334862385321102
I0
I1
I-1
tp20663
sS'mao,inhibitors,and'
p20664
(F0.5
F0.00028669724770642203
I3
I1
I2
tp20665
sS'gvia-sensitive,n-type,channel'
p20666
(F1
F0.00014334862385321102
I0
I1
I-1
tp20667
sS'inhibitors,and,beta'
p20668
(F1
F0.00057339449541284407
I4
I0
I4
tp20669
sS'permeation,of,the'
p20670
(F1
F0.00014334862385321102
I0
I1
I-1
tp20671
sS'some,limited,inhibitory'
p20672
(F1
F0.00014334862385321102
I1
I0
I1
tp20673
sS'acid,should,not'
p20674
(F1
F0.00014334862385321102
I0
I1
I-1
tp20675
sS'and,zidovudine,ribavirin'
p20676
(F1
F0.00014334862385321102
I1
I0
I1
tp20677
sS'citalopram,citalopram,since'
p20678
(F1
F0.00014334862385321102
I1
I0
I1
tp20679
sS'eg,for,injection'
p20680
(F1
F0.00014334862385321102
I1
I0
I1
tp20681
sS'isosorbide,dinitrate,may'
p20682
(F1
F0.00014334862385321102
I1
I0
I1
tp20683
sS'capacity,to,function'
p20684
(F1
F0.00014334862385321102
I0
I1
I-1
tp20685
sS'of,felbatol,on'
p20686
(F0
F0
I1
I1
I0
tp20687
sS'and,or,in'
p20688
(F0.5
F0.00028669724770642203
I3
I1
I2
tp20689
sS'any,intentional,or'
p20690
(F1
F0.00014334862385321102
I1
I0
I1
tp20691
sS'were,determined,by'
p20692
(F1
F0.00028669724770642203
I0
I2
I-2
tp20693
sS'died,compared,to'
p20694
(F1
F0.00014334862385321102
I0
I1
I-1
tp20695
sS'ph,h2-receptor,antagonists'
p20696
(F1
F0.00014334862385321102
I1
I0
I1
tp20697
sS'im,and,nondepolarizing'
p20698
(F1
F0.00014334862385321102
I0
I1
I-1
tp20699
sS'inhibition,of,cyp3a'
p20700
(F1
F0.00014334862385321102
I1
I0
I1
tp20701
sS'treatment,of,ewes'
p20702
(F1
F0.00014334862385321102
I1
I0
I1
tp20703
sS'the,hydroxytamoxifen,tam'
p20704
(F1
F0.00014334862385321102
I0
I1
I-1
tp20705
sS'reductase,inhibitors,warning'
p20706
(F1
F0.00014334862385321102
I0
I1
I-1
tp20707
sS'factrel,may,be'
p20708
(F1
F0.00014334862385321102
I1
I0
I1
tp20709
sS'exposure,to,was'
p20710
(F1
F0.00014334862385321102
I1
I0
I1
tp20711
sS'arrhythmia,bradycardia,qt'
p20712
(F1
F0.00014334862385321102
I1
I0
I1
tp20713
sS'result,in,insufficient'
p20714
(F1
F0.00014334862385321102
I1
I0
I1
tp20715
sS'with,other,ergot'
p20716
(F1
F0.00014334862385321102
I1
I0
I1
tp20717
sS'groups,pd2,values'
p20718
(F1
F0.00014334862385321102
I1
I0
I1
tp20719
sS'nursing,mothers,it'
p20720
(F1
F0.00014334862385321102
I0
I1
I-1
tp20721
sS'oral,on,acth'
p20722
(F1
F0.00014334862385321102
I0
I1
I-1
tp20723
sS'who,has,previously'
p20724
(F1
F0.00014334862385321102
I1
I0
I1
tp20725
sS'healthy,volunteers,there'
p20726
(F1
F0.00014334862385321102
I0
I1
I-1
tp20727
sS'with,beta-lactamtype,or'
p20728
(F1
F0.00014334862385321102
I1
I0
I1
tp20729
sS'endocrine,and,liver'
p20730
(F1
F0.00028669724770642203
I0
I2
I-2
tp20731
sS'some,patients,if'
p20732
(F1
F0.00014334862385321102
I1
I0
I1
tp20733
sS'theoretical,risk,of'
p20734
(F1
F0.00014334862385321102
I1
I0
I1
tp20735
sS'sub-,for,in'
p20736
(F1
F0.00014334862385321102
I0
I1
I-1
tp20737
sS'b12,because,they'
p20738
(F1
F0.00014334862385321102
I0
I1
I-1
tp20739
sS'by,the,cytochrome'
p20740
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp20741
sS'acid,did,not'
p20742
(F1
F0.00014334862385321102
I0
I1
I-1
tp20743
sS'the,combined,moieties'
p20744
(F1
F0.00014334862385321102
I0
I1
I-1
tp20745
sS'during,concurrent,administration'
p20746
(F1
F0.00014334862385321102
I0
I1
I-1
tp20747
sS'phenytoin,phenobarbitol,rifabutin'
p20748
(F1
F0.00014334862385321102
I0
I1
I-1
tp20749
sS'dose,of,on'
p20750
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp20751
sS'on,the,aptt'
p20752
(F1
F0.00028669724770642203
I0
I2
I-2
tp20753
sS'a,day,qd'
p20754
(F1
F0.00014334862385321102
I0
I1
I-1
tp20755
sS'concentrations,were,not'
p20756
(F1
F0.00057339449541284407
I0
I4
I-4
tp20757
sS'in,one,study'
p20758
(F1
F0.00028669724770642203
I0
I2
I-2
tp20759
sS'taking,both,and'
p20760
(F1
F0.00014334862385321102
I1
I0
I1
tp20761
sS'of,xigris,have'
p20762
(F1
F0.00014334862385321102
I0
I1
I-1
tp20763
sS'concerning,laboratory,test'
p20764
(F1
F0.00014334862385321102
I0
I1
I-1
tp20765
sS'measurement,of,and'
p20766
(F1
F0.00014334862385321102
I0
I1
I-1
tp20767
sS'when,vioxx,and'
p20768
(F1
F0.00014334862385321102
I1
I0
I1
tp20769
sS'be,taken,in'
p20770
(F1
F0.00014334862385321102
I0
I1
I-1
tp20771
sS'oral,carbonic,anhydrase'
p20772
(F1
F0.00028669724770642203
I2
I0
I2
tp20773
sS'reduction,in,clearance'
p20774
(F1
F0.00028669724770642203
I2
I0
I2
tp20775
sS'because,competitively,displaces'
p20776
(F1
F0.00014334862385321102
I1
I0
I1
tp20777
sS'be,taken,if'
p20778
(F0
F0
I1
I1
I0
tp20779
sS'of,sodium,or'
p20780
(F1
F0.00014334862385321102
I1
I0
I1
tp20781
sS'nsaids,and,tnf'
p20782
(F1
F0.00014334862385321102
I0
I1
I-1
tp20783
sS'to,when,it'
p20784
(F1
F0.00014334862385321102
I1
I0
I1
tp20785
sS'and,were,unchanged'
p20786
(F1
F0.00014334862385321102
I0
I1
I-1
tp20787
sS'other,traditional,agents'
p20788
(F1
F0.00014334862385321102
I0
I1
I-1
tp20789
sS'above,chronic,weeks'
p20790
(F1
F0.00014334862385321102
I0
I1
I-1
tp20791
sS'agents,and,angiotensin'
p20792
(F1
F0.00014334862385321102
I0
I1
I-1
tp20793
sS'single-dose,crossover,study'
p20794
(F1
F0.00014334862385321102
I1
I0
I1
tp20795
sS'the,first,synthetic'
p20796
(F1
F0.00014334862385321102
I0
I1
I-1
tp20797
sS'of,blood,platelets'
p20798
(F1
F0.00014334862385321102
I1
I0
I1
tp20799
sS'as,akineton,are'
p20800
(F1
F0.00014334862385321102
I1
I0
I1
tp20801
sS'with,lymphoma,on'
p20802
(F1
F0.00014334862385321102
I0
I1
I-1
tp20803
sS'presence,of,free'
p20804
(F1
F0.00014334862385321102
I0
I1
I-1
tp20805
sS'inducers,indicate,only'
p20806
(F1
F0.00014334862385321102
I1
I0
I1
tp20807
sS'when,initiating,and'
p20808
(F1
F0.00014334862385321102
I1
I0
I1
tp20809
sS'antacids,the,concomitant'
p20810
(F1
F0.00014334862385321102
I0
I1
I-1
tp20811
sS'rifabutin,coadministration,of'
p20812
(F1
F0.00014334862385321102
I1
I0
I1
tp20813
sS'methyl-4,phenyl-1,tetrahydropyridine'
p20814
(F1
F0.00014334862385321102
I0
I1
I-1
tp20815
sS'plasma,levels,total'
p20816
(F1
F0.00014334862385321102
I1
I0
I1
tp20817
sS'given,with,compared'
p20818
(F1
F0.00014334862385321102
I1
I0
I1
tp20819
sS'or,careful,consideration'
p20820
(F1
F0.00014334862385321102
I1
I0
I1
tp20821
sS'days,of,both'
p20822
(F1
F0.00014334862385321102
I0
I1
I-1
tp20823
sS'of,and,concomitant'
p20824
(F1
F0.00014334862385321102
I0
I1
I-1
tp20825
sS'increases,in,serum'
p20826
(F1
F0.00028669724770642203
I2
I0
I2
tp20827
sS'in,an,open'
p20828
(F1
F0.00014334862385321102
I0
I1
I-1
tp20829
sS'mtx,were,nonsteroidal'
p20830
(F1
F0.00014334862385321102
I0
I1
I-1
tp20831
sS'subsequently,treated,with'
p20832
(F1
F0.00014334862385321102
I1
I0
I1
tp20833
sS'drug,laboratory,test'
p20834
(F0.84615384615384615
F0.0015768348623853212
I1
I12
I-11
tp20835
sS'at,the,highest'
p20836
(F1
F0.00014334862385321102
I0
I1
I-1
tp20837
sS'titers,may,have'
p20838
(F1
F0.00014334862385321102
I0
I1
I-1
tp20839
sS'inhibitory,concentration,mic'
p20840
(F1
F0.00014334862385321102
I0
I1
I-1
tp20841
sS'k,contribution,to'
p20842
(F1
F0.00014334862385321102
I0
I1
I-1
tp20843
sS'when,plasma,asparagine'
p20844
(F1
F0.00014334862385321102
I1
I0
I1
tp20845
sS'antidepressant,eg,commonly'
p20846
(F1
F0.00014334862385321102
I1
I0
I1
tp20847
sS'ileus,may,occur'
p20848
(F1
F0.00014334862385321102
I1
I0
I1
tp20849
sS'minutes,p,this'
p20850
(F1
F0.00014334862385321102
I1
I0
I1
tp20851
sS'decrease,the,possible'
p20852
(F1
F0.00014334862385321102
I1
I0
I1
tp20853
sS'angina,attacks,during'
p20854
(F1
F0.00014334862385321102
I0
I1
I-1
tp20855
sS'of,systemic,it'
p20856
(F1
F0.00014334862385321102
I1
I0
I1
tp20857
sS'higher,concentrations,of'
p20858
(F1
F0.00028669724770642203
I2
I0
I2
tp20859
sS'to,a,dose-dependent'
p20860
(F1
F0.00014334862385321102
I1
I0
I1
tp20861
sS'increase,in,cortisol'
p20862
(F1
F0.00014334862385321102
I0
I1
I-1
tp20863
sS'multiple,dose,pharmacokinetic'
p20864
(F1
F0.00014334862385321102
I0
I1
I-1
tp20865
sS'dosage,of,precedex'
p20866
(F1
F0.00014334862385321102
I1
I0
I1
tp20867
sS'which,may,present'
p20868
(F1
F0.00028669724770642203
I2
I0
I2
tp20869
sS'influence,through,the'
p20870
(F1
F0.00014334862385321102
I0
I1
I-1
tp20871
sS'ace,inhibitors,in'
p20872
(F1
F0.00014334862385321102
I1
I0
I1
tp20873
sS'with,more,commonly'
p20874
(F1
F0.00014334862385321102
I1
I0
I1
tp20875
sS'i,and,i'
p20876
(F1
F0.00014334862385321102
I0
I1
I-1
tp20877
sS'higher,serum,concentrations'
p20878
(F1
F0.00014334862385321102
I1
I0
I1
tp20879
sS'addition,there,was'
p20880
(F1
F0.00014334862385321102
I0
I1
I-1
tp20881
sS'isoenzyme,macrolide,azole'
p20882
(F1
F0.00014334862385321102
I1
I0
I1
tp20883
sS'alcohol,alcohol,g'
p20884
(F1
F0.00014334862385321102
I0
I1
I-1
tp20885
sS'muscle,relaxants,nondepolarizing'
p20886
(F1
F0.00028669724770642203
I0
I2
I-2
tp20887
sS'parallel,group,clinical'
p20888
(F1
F0.00014334862385321102
I0
I1
I-1
tp20889
sS'agents,or,adrenergic'
p20890
(F1
F0.00014334862385321102
I0
I1
I-1
tp20891
sS'co-administered,with,maleate'
p20892
(F1
F0.00014334862385321102
I1
I0
I1
tp20893
sS'of,neurons,hyperpolarized'
p20894
(F1
F0.00014334862385321102
I0
I1
I-1
tp20895
sS'the,and,reduce'
p20896
(F1
F0.00014334862385321102
I1
I0
I1
tp20897
sS'will,be,augmented'
p20898
(F1
F0.00014334862385321102
I1
I0
I1
tp20899
sS'tumour,and,normal'
p20900
(F1
F0.00014334862385321102
I1
I0
I1
tp20901
sS'is,coadministered,prescribers'
p20902
(F1
F0.00014334862385321102
I0
I1
I-1
tp20903
sS'for,days,increased'
p20904
(F1
F0.00043004587155963305
I3
I0
I3
tp20905
sS'not,extend,outside'
p20906
(F1
F0.00014334862385321102
I0
I1
I-1
tp20907
sS'intravenous,dose,of'
p20908
(F1
F0.00028669724770642203
I0
I2
I-2
tp20909
sS'progesterone-,and,high-estradiol'
p20910
(F1
F0.00014334862385321102
I1
I0
I1
tp20911
sS'were,no,changes'
p20912
(F1
F0.00014334862385321102
I0
I1
I-1
tp20913
sS'intravenous,dose,or'
p20914
(F1
F0.00014334862385321102
I1
I0
I1
tp20915
sS'of,and,add'
p20916
(F1
F0.00028669724770642203
I2
I0
I2
tp20917
sS'avoid,the,concomitant'
p20918
(F1
F0.00014334862385321102
I1
I0
I1
tp20919
sS'hcl,usually,does'
p20920
(F1
F0.00014334862385321102
I1
I0
I1
tp20921
sS'coumarin-like,should,be'
p20922
(F1
F0.00014334862385321102
I1
I0
I1
tp20923
sS'inotropes,and,may'
p20924
(F1
F0.00014334862385321102
I1
I0
I1
tp20925
sS'a,microdilution,method'
p20926
(F1
F0.00014334862385321102
I0
I1
I-1
tp20927
sS'and,were,tested'
p20928
(F1
F0.00014334862385321102
I0
I1
I-1
tp20929
sS'and,anti,platelet'
p20930
(F1
F0.00014334862385321102
I0
I1
I-1
tp20931
sS'have,not,shown'
p20932
(F0
F0
I1
I1
I0
tp20933
sS'non-linear,pharmacokinetics,over'
p20934
(F1
F0.00014334862385321102
I1
I0
I1
tp20935
sS'an,oral,regimen'
p20936
(F1
F0.00014334862385321102
I0
I1
I-1
tp20937
sS'multiple-dose,study,caused'
p20938
(F1
F0.00014334862385321102
I1
I0
I1
tp20939
sS'rarely,toxicity,may'
p20940
(F1
F0.00014334862385321102
I1
I0
I1
tp20941
sS'recovery,of,fade'
p20942
(F1
F0.00014334862385321102
I1
I0
I1
tp20943
sS'seen,when,arava'
p20944
(F1
F0.00014334862385321102
I1
I0
I1
tp20945
sS'reduced,the,response'
p20946
(F1
F0.00014334862385321102
I1
I0
I1
tp20947
sS'after,multiple,dosing'
p20948
(F1
F0.00014334862385321102
I1
I0
I1
tp20949
sS'chelates,with,alkaline'
p20950
(F1
F0.00014334862385321102
I0
I1
I-1
tp20951
sS'as,vertigo,syncope'
p20952
(F1
F0.00014334862385321102
I1
I0
I1
tp20953
sS'as,and,local'
p20954
(F1
F0.00014334862385321102
I1
I0
I1
tp20955
sS'are,administered,concomitantly'
p20956
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp20957
sS'were,stabilized,on'
p20958
(F1
F0.00028669724770642203
I0
I2
I-2
tp20959
sS'as,the,retention'
p20960
(F1
F0.00014334862385321102
I0
I1
I-1
tp20961
sS'blockers,and,may'
p20962
(F1
F0.00014334862385321102
I1
I0
I1
tp20963
sS'cytochrome,p450iiia4,isozyme'
p20964
(F1
F0.00014334862385321102
I1
I0
I1
tp20965
sS'patients,who,had'
p20966
(F1
F0.00014334862385321102
I0
I1
I-1
tp20967
sS'drugs,hallucinations,have'
p20968
(F1
F0.00014334862385321102
I1
I0
I1
tp20969
sS'a,second,hour'
p20970
(F1
F0.00014334862385321102
I0
I1
I-1
tp20971
sS'prior,to,initiation'
p20972
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp20973
sS'a,cyp3a4,inhibitor'
p20974
(F0
F0
I1
I1
I0
tp20975
sS'may,cause,serious'
p20976
(F1
F0.00014334862385321102
I1
I0
I1
tp20977
sS'including,with,multivalent'
p20978
(F1
F0.00014334862385321102
I1
I0
I1
tp20979
sS'may,be,additive'
p20980
(F1
F0.0010034403669724771
I7
I0
I7
tp20981
sS'maybe,useful,for'
p20982
(F1
F0.00014334862385321102
I0
I1
I-1
tp20983
sS'receptor,antagonists,the'
p20984
(F1
F0.00014334862385321102
I1
I0
I1
tp20985
sS'long-acting,or,who'
p20986
(F1
F0.00014334862385321102
I1
I0
I1
tp20987
sS'major,are,also'
p20988
(F1
F0.00014334862385321102
I1
I0
I1
tp20989
sS'hypotensive,effects,of'
p20990
(F0.5
F0.00028669724770642203
I3
I1
I2
tp20991
sS'data,are,developed'
p20992
(F1
F0.00014334862385321102
I0
I1
I-1
tp20993
sS'binding,of,may'
p20994
(F1
F0.00014334862385321102
I1
I0
I1
tp20995
sS'in,eight,hiv-infected'
p20996
(F1
F0.00014334862385321102
I1
I0
I1
tp20997
sS'of,either,medicine'
p20998
(F1
F0.00014334862385321102
I1
I0
I1
tp20999
sS'in,these,categories'
p21000
(F1
F0.00014334862385321102
I1
I0
I1
tp21001
sS'd,inhibited,the'
p21002
(F1
F0.00014334862385321102
I1
I0
I1
tp21003
sS'test,interactions,as'
p21004
(F1
F0.00028669724770642203
I0
I2
I-2
tp21005
sS'recommended,that,serum'
p21006
(F1
F0.00028669724770642203
I2
I0
I2
tp21007
sS'method,for,aerobic'
p21008
(F1
F0.00014334862385321102
I0
I1
I-1
tp21009
sS'mesenteric,vasodilation,induced'
p21010
(F1
F0.00014334862385321102
I1
I0
I1
tp21011
sS'at,a,median'
p21012
(F1
F0.00014334862385321102
I0
I1
I-1
tp21013
sS'general,such,as'
p21014
(F1
F0.00028669724770642203
I2
I0
I2
tp21015
sS'administered,concurrently,with'
p21016
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp21017
sS'sleeping,time,after'
p21018
(F1
F0.00014334862385321102
I1
I0
I1
tp21019
sS'diminishes,the,effect'
p21020
(F1
F0.00014334862385321102
I1
I0
I1
tp21021
sS'be,significantly,more'
p21022
(F1
F0.00014334862385321102
I0
I1
I-1
tp21023
sS'clinical,importance,brevibloc'
p21024
(F1
F0.00014334862385321102
I1
I0
I1
tp21025
sS'amphetamines,may,enhance'
p21026
(F1
F0.00043004587155963305
I3
I0
I3
tp21027
sS'use,of,pancreatic'
p21028
(F1
F0.00014334862385321102
I1
I0
I1
tp21029
sS'extracellular,levels,of'
p21030
(F1
F0.00014334862385321102
I0
I1
I-1
tp21031
sS'vitro,the,plasma'
p21032
(F1
F0.00014334862385321102
I0
I1
I-1
tp21033
sS'dependence,may,be'
p21034
(F1
F0.00014334862385321102
I0
I1
I-1
tp21035
sS'oral,poc,in'
p21036
(F1
F0.00014334862385321102
I0
I1
I-1
tp21037
sS'of,nanm,or'
p21038
(F1
F0.00014334862385321102
I0
I1
I-1
tp21039
sS'or,can,be'
p21040
(F1
F0.00014334862385321102
I1
I0
I1
tp21041
sS'when,hydrochlorothiazide,and'
p21042
(F1
F0.00014334862385321102
I1
I0
I1
tp21043
sS'initiation,of,or'
p21044
(F1
F0.00014334862385321102
I0
I1
I-1
tp21045
sS'intravenous,sodium,and'
p21046
(F0
F0
I1
I1
I0
tp21047
sS'up,to,hours'
p21048
(F1
F0.00014334862385321102
I1
I0
I1
tp21049
sS'or,inducers,of'
p21050
(F1
F0.00014334862385321102
I0
I1
I-1
tp21051
sS'observed,on,the'
p21052
(F1
F0.00014334862385321102
I1
I0
I1
tp21053
sS'dogs,with,gastric'
p21054
(F1
F0.00014334862385321102
I0
I1
I-1
tp21055
sS'that,inhibit,cytochrome'
p21056
(F0
F0
I1
I1
I0
tp21057
sS'and,a,that'
p21058
(F1
F0.00014334862385321102
I1
I0
I1
tp21059
sS'of,the,or'
p21060
(F0
F0
I1
I1
I0
tp21061
sS'increases,serum,concentration'
p21062
(F1
F0.00014334862385321102
I0
I1
I-1
tp21063
sS'increase,cmax,by'
p21064
(F1
F0.00014334862385321102
I1
I0
I1
tp21065
sS'cyp2c9,cyp2c19,and'
p21066
(F1
F0.00014334862385321102
I0
I1
I-1
tp21067
sS'antimicrobial,effect,of'
p21068
(F1
F0.00014334862385321102
I0
I1
I-1
tp21069
sS'increase,in,plasma'
p21070
(F0.82608695652173914
F0.0027236238532110093
I21
I2
I19
tp21071
sS'eg,or,can'
p21072
(F1
F0.00014334862385321102
I1
I0
I1
tp21073
sS'psychotropic,or,even'
p21074
(F1
F0.00014334862385321102
I0
I1
I-1
tp21075
sS'to,be,cyp'
p21076
(F1
F0.00028669724770642203
I2
I0
I2
tp21077
sS'compatibility,of,novolog'
p21078
(F1
F0.00014334862385321102
I0
I1
I-1
tp21079
sS'dose,at,the'
p21080
(F1
F0.00014334862385321102
I0
I1
I-1
tp21081
sS'kg,resulted,in'
p21082
(F1
F0.00014334862385321102
I0
I1
I-1
tp21083
sS'greater,than,the'
p21084
(F1
F0.00014334862385321102
I0
I1
I-1
tp21085
sS'serious,reaction,to'
p21086
(F1
F0.00014334862385321102
I1
I0
I1
tp21087
sS'sensipar,is,metabolized'
p21088
(F1
F0.00028669724770642203
I0
I2
I-2
tp21089
sS'oral,the,need'
p21090
(F1
F0.00014334862385321102
I1
I0
I1
tp21091
sS'and,clearance,at'
p21092
(F1
F0.00014334862385321102
I0
I1
I-1
tp21093
sS'primarily,metabolized,and'
p21094
(F1
F0.00014334862385321102
I0
I1
I-1
tp21095
sS'contrast,media,experienced'
p21096
(F1
F0.00014334862385321102
I1
I0
I1
tp21097
sS'with,schizophrenia,and'
p21098
(F1
F0.00014334862385321102
I0
I1
I-1
tp21099
sS'concomitant,useof,a'
p21100
(F1
F0.00014334862385321102
I1
I0
I1
tp21101
sS'hours,for,days'
p21102
(F1
F0.00028669724770642203
I0
I2
I-2
tp21103
sS'or,both,agents'
p21104
(F1
F0.00014334862385321102
I1
I0
I1
tp21105
sS'to,a,significant'
p21106
(F1
F0.00014334862385321102
I0
I1
I-1
tp21107
sS'ergot-type,oxytocic,may'
p21108
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp21109
sS'unaffected,following,co-administration'
p21110
(F1
F0.00014334862385321102
I0
I1
I-1
tp21111
sS'of,to,increase'
p21112
(F1
F0.00014334862385321102
I1
I0
I1
tp21113
sS'whether,they,respond'
p21114
(F1
F0.00014334862385321102
I0
I1
I-1
tp21115
sS'discontinuing,treatment,with'
p21116
(F1
F0.00014334862385321102
I1
I0
I1
tp21117
sS'steady-state,serum,antidepressant'
p21118
(F1
F0.00014334862385321102
I1
I0
I1
tp21119
sS'history,of,psychiatric'
p21120
(F1
F0.00014334862385321102
I1
I0
I1
tp21121
sS'of,arimidex,with'
p21122
(F1
F0.00014334862385321102
I0
I1
I-1
tp21123
sS'increase,the,amount'
p21124
(F1
F0.00014334862385321102
I1
I0
I1
tp21125
sS'monitored,closely,if'
p21126
(F1
F0.00014334862385321102
I1
I0
I1
tp21127
sS'receiving,hctz,alone'
p21128
(F1
F0.00014334862385321102
I1
I0
I1
tp21129
sS'were,reported,to'
p21130
(F1
F0.00028669724770642203
I2
I0
I2
tp21131
sS'of,cyp2d6,such'
p21132
(F0
F0
I1
I1
I0
tp21133
sS'the,incidence,of'
p21134
(F0.090909090909090912
F0.00014334862385321102
I6
I5
I1
tp21135
sS'monitored,closely,in'
p21136
(F1
F0.00014334862385321102
I1
I0
I1
tp21137
sS'alternating,therapy,for'
p21138
(F1
F0.00014334862385321102
I0
I1
I-1
tp21139
sS'other,coumarin-derivative,should'
p21140
(F1
F0.00014334862385321102
I0
I1
I-1
tp21141
sS'and,other,nsaids'
p21142
(F1
F0.00057339449541284407
I4
I0
I4
tp21143
sS'gastrointestinal,tract,by'
p21144
(F1
F0.00014334862385321102
I1
I0
I1
tp21145
sS'a,trans-3,dimethyl-4'
p21146
(F1
F0.00014334862385321102
I1
I0
I1
tp21147
sS'with,kerlone,and'
p21148
(F1
F0.00014334862385321102
I0
I1
I-1
tp21149
sS'pharmacokinetics,of,amphotericin'
p21150
(F1
F0.00014334862385321102
I0
I1
I-1
tp21151
sS'an,adjustment,in'
p21152
(F1
F0.00028669724770642203
I0
I2
I-2
tp21153
sS'solution,or,clinitest'
p21154
(F1
F0.00014334862385321102
I0
I1
I-1
tp21155
sS'mg,with,mg'
p21156
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp21157
sS'subsequent,diagnostic,serum'
p21158
(F1
F0.00014334862385321102
I0
I1
I-1
tp21159
sS'range,of,individual'
p21160
(F1
F0.00014334862385321102
I0
I1
I-1
tp21161
sS'on,renal,tubular'
p21162
(F1
F0.00014334862385321102
I1
I0
I1
tp21163
sS'tracrium,include,certain'
p21164
(F1
F0.00014334862385321102
I1
I0
I1
tp21165
sS'to,microg,ml'
p21166
(F1
F0.00014334862385321102
I0
I1
I-1
tp21167
sS'use,both,and'
p21168
(F1
F0.00014334862385321102
I0
I1
I-1
tp21169
sS'especially,central,nervous'
p21170
(F1
F0.00014334862385321102
I0
I1
I-1
tp21171
sS'hepatic,enzyme-inducing,such'
p21172
(F1
F0.00014334862385321102
I1
I0
I1
tp21173
sS'on,protein,binding'
p21174
(F1
F0.00014334862385321102
I0
I1
I-1
tp21175
sS'will,have,a'
p21176
(F1
F0.00014334862385321102
I0
I1
I-1
tp21177
sS'a,mean,template'
p21178
(F1
F0.00014334862385321102
I0
I1
I-1
tp21179
sS'levels,was,observed'
p21180
(F1
F0.00014334862385321102
I1
I0
I1
tp21181
sS'lipid,levels,is'
p21182
(F1
F0.00014334862385321102
I1
I0
I1
tp21183
sS'and,blurred,vision'
p21184
(F1
F0.00014334862385321102
I1
I0
I1
tp21185
sS'a,rate,of'
p21186
(F1
F0.00028669724770642203
I2
I0
I2
tp21187
sS'as,because,they'
p21188
(F1
F0.00014334862385321102
I1
I0
I1
tp21189
sS'and,mg,bid'
p21190
(F1
F0.00014334862385321102
I1
I0
I1
tp21191
sS'and,ketoconazole,ketoconazole'
p21192
(F1
F0.00014334862385321102
I0
I1
I-1
tp21193
sS'including,cefotaxime,sodium'
p21194
(F1
F0.00014334862385321102
I0
I1
I-1
tp21195
sS'diclofenac,decreases,renal'
p21196
(F1
F0.00014334862385321102
I1
I0
I1
tp21197
sS'iv,compared,with'
p21198
(F1
F0.00014334862385321102
I0
I1
I-1
tp21199
sS'similar,compounds,enhanced'
p21200
(F1
F0.00014334862385321102
I0
I1
I-1
tp21201
sS'with,tuberculosis,andusing'
p21202
(F1
F0.00014334862385321102
I0
I1
I-1
tp21203
sS'blurred,vision,and'
p21204
(F1
F0.00028669724770642203
I2
I0
I2
tp21205
sS'include,sufficient,numbers'
p21206
(F1
F0.00014334862385321102
I0
I1
I-1
tp21207
sS'and,potassium-sparing,including'
p21208
(F1
F0.00014334862385321102
I1
I0
I1
tp21209
sS'reported,to,induce'
p21210
(F0
F0
I1
I1
I0
tp21211
sS'patients,the,combined'
p21212
(F1
F0.00014334862385321102
I1
I0
I1
tp21213
sS'with,all,central'
p21214
(F1
F0.00014334862385321102
I1
I0
I1
tp21215
sS'to,predict,the'
p21216
(F1
F0.00014334862385321102
I0
I1
I-1
tp21217
sS'increase,in,urinary'
p21218
(F1
F0.00014334862385321102
I1
I0
I1
tp21219
sS'evidence,of,decreased'
p21220
(F1
F0.00014334862385321102
I1
I0
I1
tp21221
sS'theophylline,decreased,the'
p21222
(F1
F0.00014334862385321102
I1
I0
I1
tp21223
sS'of,agents,which'
p21224
(F1
F0.00014334862385321102
I1
I0
I1
tp21225
sS'diarrhea,induced,by'
p21226
(F1
F0.00014334862385321102
I1
I0
I1
tp21227
sS'downward,dose,adjustment'
p21228
(F1
F0.00014334862385321102
I1
I0
I1
tp21229
sS'fall,of,the'
p21230
(F1
F0.00014334862385321102
I1
I0
I1
tp21231
sS'nonsteroidal,antiinflammatories,and'
p21232
(F1
F0.00014334862385321102
I0
I1
I-1
tp21233
sS'drugs,given,concurrently'
p21234
(F1
F0.00014334862385321102
I0
I1
I-1
tp21235
sS'does,not,increase'
p21236
(F1
F0.00014334862385321102
I0
I1
I-1
tp21237
sS'in,etodolac-treated,patients'
p21238
(F1
F0.00014334862385321102
I1
I0
I1
tp21239
sS'on,a,preparation'
p21240
(F1
F0.00014334862385321102
I1
I0
I1
tp21241
sS'the,theophylline-induced,anxiogenic'
p21242
(F1
F0.00014334862385321102
I1
I0
I1
tp21243
sS'to,decreased,plasma'
p21244
(F1
F0.00014334862385321102
I0
I1
I-1
tp21245
sS'rifampin,following,concomitant'
p21246
(F1
F0.00014334862385321102
I1
I0
I1
tp21247
sS'and,from,ml'
p21248
(F1
F0.00014334862385321102
I0
I1
I-1
tp21249
sS'hepatic,injury,or'
p21250
(F1
F0.00014334862385321102
I0
I1
I-1
tp21251
sS'after,m-tco,injection'
p21252
(F1
F0.00014334862385321102
I1
I0
I1
tp21253
sS'necessitate,reduction,of'
p21254
(F1
F0.00014334862385321102
I0
I1
I-1
tp21255
sS'plus,catecholamine,depletors'
p21256
(F1
F0.00014334862385321102
I1
I0
I1
tp21257
sS'most,likely,by'
p21258
(F1
F0.00014334862385321102
I1
I0
I1
tp21259
sS'a,preparation,this'
p21260
(F1
F0.00014334862385321102
I1
I0
I1
tp21261
sS'frequently,administered,concomitantly'
p21262
(F1
F0.00014334862385321102
I0
I1
I-1
tp21263
sS'decrease,about,in'
p21264
(F1
F0.00014334862385321102
I1
I0
I1
tp21265
sS'with,other,should'
p21266
(F1
F0.00014334862385321102
I1
I0
I1
tp21267
sS'or,clinically,relevant'
p21268
(F1
F0.00014334862385321102
I0
I1
I-1
tp21269
sS'positive,inotropic,effects'
p21270
(F1
F0.00014334862385321102
I1
I0
I1
tp21271
sS'c19,and,a4'
p21272
(F1
F0.00014334862385321102
I0
I1
I-1
tp21273
sS'all,metabolized,by'
p21274
(F1
F0.00014334862385321102
I1
I0
I1
tp21275
sS'co-,administration,of'
p21276
(F1
F0.00014334862385321102
I0
I1
I-1
tp21277
sS'lowered,the,plasma'
p21278
(F1
F0.00028669724770642203
I2
I0
I2
tp21279
sS'to,these,medicinal'
p21280
(F1
F0.00028669724770642203
I2
I0
I2
tp21281
sS'are,given,in'
p21282
(F1
F0.00028669724770642203
I2
I0
I2
tp21283
sS'of,active,phosphorylated'
p21284
(F1
F0.00014334862385321102
I1
I0
I1
tp21285
sS'reliable,method,of'
p21286
(F1
F0.00014334862385321102
I1
I0
I1
tp21287
sS'suggest,that,nonabsorbable'
p21288
(F1
F0.00014334862385321102
I1
I0
I1
tp21289
sS'administration,of,difluoroacetone'
p21290
(F1
F0.00014334862385321102
I0
I1
I-1
tp21291
sS'estradiol,concentrations,and'
p21292
(F1
F0.00014334862385321102
I0
I1
I-1
tp21293
sS'using,four,diets'
p21294
(F1
F0.00014334862385321102
I0
I1
I-1
tp21295
sS'but,did,not'
p21296
(F1
F0.00028669724770642203
I2
I0
I2
tp21297
sS'acting,primarily,to'
p21298
(F1
F0.00014334862385321102
I1
I0
I1
tp21299
sS'half-life,the,coadministration'
p21300
(F1
F0.00014334862385321102
I1
I0
I1
tp21301
sS'window,such,as'
p21302
(F1
F0.00014334862385321102
I1
I0
I1
tp21303
sS'physicians,query,patients'
p21304
(F1
F0.00014334862385321102
I0
I1
I-1
tp21305
sS'dosage,are,required'
p21306
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp21307
sS'an,increased,incidence'
p21308
(F0
F0
I1
I1
I0
tp21309
sS'oral,increased,auc'
p21310
(F1
F0.00014334862385321102
I1
I0
I1
tp21311
sS'doses,did,not'
p21312
(F1
F0.00014334862385321102
I0
I1
I-1
tp21313
sS'to,the,regimen'
p21314
(F0
F0
I1
I1
I0
tp21315
sS'by,see,clinical'
p21316
(F1
F0.00014334862385321102
I1
I0
I1
tp21317
sS'increased,sedation,when'
p21318
(F1
F0.00014334862385321102
I1
I0
I1
tp21319
sS'when,compared,with'
p21320
(F1
F0.00028669724770642203
I0
I2
I-2
tp21321
sS'appearance,of,unchanged'
p21322
(F1
F0.00014334862385321102
I0
I1
I-1
tp21323
sS'hypotension,patients,on'
p21324
(F1
F0.00043004587155963305
I3
I0
I3
tp21325
sS'required,if,or'
p21326
(F1
F0.00014334862385321102
I0
I1
I-1
tp21327
sS'clearance,accelerated,markedly'
p21328
(F1
F0.00014334862385321102
I1
I0
I1
tp21329
sS'neither,influenced,the'
p21330
(F1
F0.00014334862385321102
I0
I1
I-1
tp21331
sS'type,c,should'
p21332
(F1
F0.00028669724770642203
I2
I0
I2
tp21333
sS'a,level,that'
p21334
(F1
F0.00014334862385321102
I0
I1
I-1
tp21335
sS'indicate,that,clearance'
p21336
(F1
F0.00043004587155963305
I3
I0
I3
tp21337
sS'and,then,wait'
p21338
(F1
F0.00014334862385321102
I1
I0
I1
tp21339
sS'to,the,amount'
p21340
(F1
F0.00014334862385321102
I0
I1
I-1
tp21341
sS'with,norpace,or'
p21342
(F1
F0.00014334862385321102
I1
I0
I1
tp21343
sS'treatpatients,co-infected,with'
p21344
(F1
F0.00014334862385321102
I0
I1
I-1
tp21345
sS'other,statins,co-administration'
p21346
(F1
F0.00014334862385321102
I1
I0
I1
tp21347
sS'corrected,qt,interval'
p21348
(F1
F0.00014334862385321102
I0
I1
I-1
tp21349
sS'were,not,sufficient'
p21350
(F1
F0.00014334862385321102
I1
I0
I1
tp21351
sS'all,subjects,and'
p21352
(F1
F0.00014334862385321102
I1
I0
I1
tp21353
sS'of,the,with'
p21354
(F1
F0.00014334862385321102
I1
I0
I1
tp21355
sS'use,of,mao'
p21356
(F1
F0.00014334862385321102
I1
I0
I1
tp21357
sS'involving,metabolized,similarly'
p21358
(F1
F0.00014334862385321102
I1
I0
I1
tp21359
sS'concentrate,and,for'
p21360
(F1
F0.00014334862385321102
I1
I0
I1
tp21361
sS'if,or,are'
p21362
(F1
F0.00014334862385321102
I0
I1
I-1
tp21363
sS'weight,w,and'
p21364
(F1
F0.00014334862385321102
I1
I0
I1
tp21365
sS'the,consequences,of'
p21366
(F1
F0.00014334862385321102
I0
I1
I-1
tp21367
sS'use,of,may'
p21368
(F1
F0.00057339449541284407
I4
I0
I4
tp21369
sS'enterohepatic,elimination,of'
p21370
(F1
F0.00014334862385321102
I0
I1
I-1
tp21371
sS'in,plasma,auc'
p21372
(F1
F0.00057339449541284407
I4
I0
I4
tp21373
sS'of,an,adolescent'
p21374
(F1
F0.00014334862385321102
I1
I0
I1
tp21375
sS'which,the,mg'
p21376
(F1
F0.00014334862385321102
I1
I0
I1
tp21377
sS'studies,indicate,cyp3a4'
p21378
(F1
F0.00014334862385321102
I0
I1
I-1
tp21379
sS'then,titrated,according'
p21380
(F1
F0.00014334862385321102
I1
I0
I1
tp21381
sS'glucose,enzymatic,test'
p21382
(F1
F0.00014334862385321102
I0
I1
I-1
tp21383
sS'to,cause,pancreatitis'
p21384
(F1
F0.00014334862385321102
I0
I1
I-1
tp21385
sS'interactions,have,previously'
p21386
(F1
F0.00014334862385321102
I0
I1
I-1
tp21387
sS'specific,interaction,was'
p21388
(F1
F0.00014334862385321102
I0
I1
I-1
tp21389
sS'on,the,response'
p21390
(F1
F0.00014334862385321102
I0
I1
I-1
tp21391
sS'cyp,a4,may'
p21392
(F1
F0.00014334862385321102
I0
I1
I-1
tp21393
sS'concentrations,of,have'
p21394
(F1
F0.00014334862385321102
I1
I0
I1
tp21395
sS'newly,introduced,atypical'
p21396
(F1
F0.00014334862385321102
I0
I1
I-1
tp21397
sS'during,concomitant,administration'
p21398
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp21399
sS'and,intensify,the'
p21400
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp21401
sS'concurrent,treatment,with'
p21402
(F0
F0
I1
I1
I0
tp21403
sS'day,orally,for'
p21404
(F1
F0.00014334862385321102
I1
I0
I1
tp21405
sS'is,the,active'
p21406
(F1
F0.00014334862385321102
I1
I0
I1
tp21407
sS'recommended,twice,daily'
p21408
(F1
F0.00014334862385321102
I0
I1
I-1
tp21409
sS'increased,when,was'
p21410
(F1
F0.00014334862385321102
I1
I0
I1
tp21411
sS'prolixin,serentil,trilafon'
p21412
(F1
F0.00014334862385321102
I0
I1
I-1
tp21413
sS'seen,with,kemstrotm'
p21414
(F1
F0.00014334862385321102
I0
I1
I-1
tp21415
sS'pharmacology,coadministration,of'
p21416
(F1
F0.00014334862385321102
I1
I0
I1
tp21417
sS'patients,taking,either'
p21418
(F1
F0.00014334862385321102
I1
I0
I1
tp21419
sS'binding,after,the'
p21420
(F1
F0.00014334862385321102
I0
I1
I-1
tp21421
sS'in,subjects,receiving'
p21422
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp21423
sS'discontinuing,hydrochloride,could'
p21424
(F1
F0.00014334862385321102
I0
I1
I-1
tp21425
sS'is,clinically,warranted'
p21426
(F1
F0.00057339449541284407
I4
I0
I4
tp21427
sS'mg,of,the'
p21428
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp21429
sS'in,the,synthesis'
p21430
(F1
F0.00014334862385321102
I0
I1
I-1
tp21431
sS'increases,plasma,concentrations'
p21432
(F1
F0.00014334862385321102
I0
I1
I-1
tp21433
sS'although,the,occurrence'
p21434
(F1
F0.00014334862385321102
I1
I0
I1
tp21435
sS'to,slower,renal'
p21436
(F1
F0.00014334862385321102
I1
I0
I1
tp21437
sS'enhance,the,curariform'
p21438
(F1
F0.00014334862385321102
I1
I0
I1
tp21439
sS'effect,on,psychomotor'
p21440
(F1
F0.00014334862385321102
I1
I0
I1
tp21441
sS'oral,ethinyl,estradiol'
p21442
(F1
F0.00014334862385321102
I0
I1
I-1
tp21443
sS'p,in,humans'
p21444
(F1
F0.00014334862385321102
I1
I0
I1
tp21445
sS'and,n,were'
p21446
(F1
F0.00014334862385321102
I1
I0
I1
tp21447
sS'caution,as,the'
p21448
(F1
F0.00028669724770642203
I2
I0
I2
tp21449
sS'as,potent,of'
p21450
(F1
F0.00014334862385321102
I0
I1
I-1
tp21451
sS'at,concentrations,in'
p21452
(F1
F0.00028669724770642203
I0
I2
I-2
tp21453
sS'the,curve,at'
p21454
(F1
F0.00014334862385321102
I1
I0
I1
tp21455
sS'maintain,levels,limit'
p21456
(F1
F0.00014334862385321102
I1
I0
I1
tp21457
sS'and,other,therapies'
p21458
(F1
F0.00014334862385321102
I0
I1
I-1
tp21459
sS'inhibitors,it,is'
p21460
(F1
F0.00014334862385321102
I0
I1
I-1
tp21461
sS'acid,may,enhance'
p21462
(F1
F0.00014334862385321102
I1
I0
I1
tp21463
sS'buforin,ii,alone'
p21464
(F1
F0.00028669724770642203
I0
I2
I-2
tp21465
sS'no,reports,of'
p21466
(F1
F0.00014334862385321102
I0
I1
I-1
tp21467
sS'and,of,on'
p21468
(F1
F0.00014334862385321102
I0
I1
I-1
tp21469
sS'cholestyramine,may,delay'
p21470
(F1
F0.00014334862385321102
I1
I0
I1
tp21471
sS'doses,of,nimbex'
p21472
(F0
F0
I1
I1
I0
tp21473
sS'administration,to,the'
p21474
(F1
F0.00014334862385321102
I0
I1
I-1
tp21475
sS'not,been,fully'
p21476
(F1
F0.00014334862385321102
I1
I0
I1
tp21477
sS'dosage,of,is'
p21478
(F1
F0.00014334862385321102
I1
I0
I1
tp21479
sS'with,transdermal,may'
p21480
(F1
F0.00014334862385321102
I1
I0
I1
tp21481
sS'other,phe-nothiazines,products'
p21482
(F1
F0.00014334862385321102
I0
I1
I-1
tp21483
sS'stimulating,the,synthesis'
p21484
(F1
F0.00014334862385321102
I0
I1
I-1
tp21485
sS'a,patient,being'
p21486
(F1
F0.00014334862385321102
I1
I0
I1
tp21487
sS'in,the,bioavailability'
p21488
(F0
F0
I1
I1
I0
tp21489
sS'of,both,the'
p21490
(F0
F0
I1
I1
I0
tp21491
sS'and,mmol,day'
p21492
(F1
F0.00014334862385321102
I0
I1
I-1
tp21493
sS'dose,adjustment,for'
p21494
(F0
F0
I1
I1
I0
tp21495
sS'and,the,need'
p21496
(F1
F0.00014334862385321102
I0
I1
I-1
tp21497
sS'in,hypertensive,patients'
p21498
(F1
F0.00014334862385321102
I0
I1
I-1
tp21499
sS'animals,demonstrate,that'
p21500
(F1
F0.00014334862385321102
I1
I0
I1
tp21501
sS'av,conduction,disturbances'
p21502
(F0
F0
I1
I1
I0
tp21503
sS'systemically-administered,oral,or'
p21504
(F1
F0.00014334862385321102
I1
I0
I1
tp21505
sS'an,increased,plasma'
p21506
(F1
F0.00014334862385321102
I1
I0
I1
tp21507
sS'and,resulting,in'
p21508
(F1
F0.00014334862385321102
I1
I0
I1
tp21509
sS'terminal,half-life,increased'
p21510
(F1
F0.00014334862385321102
I1
I0
I1
tp21511
sS'copd,medications,they'
p21512
(F1
F0.00014334862385321102
I0
I1
I-1
tp21513
sS'theoretically,affect,pharmacodynamics'
p21514
(F1
F0.00014334862385321102
I1
I0
I1
tp21515
sS'and,some,general'
p21516
(F1
F0.00014334862385321102
I0
I1
I-1
tp21517
sS'agents,with,nephrotoxic'
p21518
(F1
F0.00014334862385321102
I1
I0
I1
tp21519
sS'dose,in,regimens'
p21520
(F1
F0.00014334862385321102
I0
I1
I-1
tp21521
sS'was,lower,and'
p21522
(F1
F0.00014334862385321102
I1
I0
I1
tp21523
sS'of,preparations,which'
p21524
(F1
F0.00014334862385321102
I0
I1
I-1
tp21525
sS'ritonavir,significantly,prolonged'
p21526
(F1
F0.00014334862385321102
I1
I0
I1
tp21527
sS'inhibit,proliferation,in'
p21528
(F1
F0.00014334862385321102
I1
I0
I1
tp21529
sS'of,ganoderma,lucidum'
p21530
(F1
F0.00014334862385321102
I0
I1
I-1
tp21531
sS'not,expected,to'
p21532
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp21533
sS'management,of,angina'
p21534
(F1
F0.00014334862385321102
I1
I0
I1
tp21535
sS'such,as,slowly'
p21536
(F1
F0.00014334862385321102
I1
I0
I1
tp21537
sS'before,idv,does'
p21538
(F1
F0.00014334862385321102
I0
I1
I-1
tp21539
sS'amphetamines,may,antagonize'
p21540
(F1
F0.00028669724770642203
I2
I0
I2
tp21541
sS'was,tested,in'
p21542
(F1
F0.00014334862385321102
I0
I1
I-1
tp21543
sS'of,oral,with'
p21544
(F1
F0.00014334862385321102
I1
I0
I1
tp21545
sS'closely,in,patients'
p21546
(F1
F0.00014334862385321102
I1
I0
I1
tp21547
sS'n-multistix,sg,dipstick'
p21548
(F1
F0.00014334862385321102
I0
I1
I-1
tp21549
sS'antagonists,and,certain'
p21550
(F1
F0.00014334862385321102
I1
I0
I1
tp21551
sS'produce,additive,effects'
p21552
(F1
F0.00014334862385321102
I1
I0
I1
tp21553
sS'para-aminobenzoic,acid,paba'
p21554
(F1
F0.00014334862385321102
I1
I0
I1
tp21555
sS'with,preparations,may'
p21556
(F1
F0.00014334862385321102
I1
I0
I1
tp21557
sS'and,urine,creatinine'
p21558
(F1
F0.00028669724770642203
I0
I2
I-2
tp21559
sS'the,safety,of'
p21560
(F1
F0.00014334862385321102
I0
I1
I-1
tp21561
sS'man,we,have'
p21562
(F1
F0.00014334862385321102
I0
I1
I-1
tp21563
sS'the,stomach,may'
p21564
(F1
F0.00014334862385321102
I1
I0
I1
tp21565
sS'acidic,or,basic'
p21566
(F1
F0.00014334862385321102
I1
I0
I1
tp21567
sS'vivo,data,indicate'
p21568
(F1
F0.00014334862385321102
I1
I0
I1
tp21569
sS'of,on,these'
p21570
(F1
F0.00014334862385321102
I0
I1
I-1
tp21571
sS'and,heavy,intake'
p21572
(F1
F0.00014334862385321102
I1
I0
I1
tp21573
sS'or,any,other'
p21574
(F0
F0
I1
I1
I0
tp21575
sS'endothelial,dysfunction,and'
p21576
(F1
F0.00014334862385321102
I0
I1
I-1
tp21577
sS'and,a,potent'
p21578
(F0
F0
I1
I1
I0
tp21579
sS'of,using,tricor'
p21580
(F1
F0.00014334862385321102
I1
I0
I1
tp21581
sS'of,inhibitor,to'
p21582
(F1
F0.00014334862385321102
I0
I1
I-1
tp21583
sS'induced,responses,both'
p21584
(F1
F0.00014334862385321102
I1
I0
I1
tp21585
sS'neutropenia,and,no'
p21586
(F1
F0.00028669724770642203
I2
I0
I2
tp21587
sS'than,for,nmda'
p21588
(F1
F0.00014334862385321102
I0
I1
I-1
tp21589
sS'parameters,clinical,laboratory'
p21590
(F1
F0.00014334862385321102
I0
I1
I-1
tp21591
sS'to,elevate,plasma'
p21592
(F1
F0.00014334862385321102
I1
I0
I1
tp21593
sS'may,occur,between'
p21594
(F1
F0.00014334862385321102
I1
I0
I1
tp21595
sS'and,auc,by'
p21596
(F1
F0.00014334862385321102
I1
I0
I1
tp21597
sS'efficacy,of,future'
p21598
(F1
F0.00014334862385321102
I0
I1
I-1
tp21599
sS'angioedema,or,generalized'
p21600
(F1
F0.00014334862385321102
I0
I1
I-1
tp21601
sS'asa,and,may'
p21602
(F1
F0.00014334862385321102
I0
I1
I-1
tp21603
sS'for,less,than'
p21604
(F1
F0.00028669724770642203
I0
I2
I-2
tp21605
sS'travelers,receiving,comedication'
p21606
(F1
F0.00014334862385321102
I1
I0
I1
tp21607
sS'are,often,used'
p21608
(F1
F0.00014334862385321102
I0
I1
I-1
tp21609
sS'additive,inotropic,and'
p21610
(F1
F0.00014334862385321102
I0
I1
I-1
tp21611
sS'on,should,be'
p21612
(F1
F0.00028669724770642203
I2
I0
I2
tp21613
sS'poor,metabolizers,and'
p21614
(F1
F0.00014334862385321102
I0
I1
I-1
tp21615
sS'of,medications,for'
p21616
(F1
F0.00014334862385321102
I0
I1
I-1
tp21617
sS'was,made,of'
p21618
(F1
F0.00014334862385321102
I0
I1
I-1
tp21619
sS'using,their,selective'
p21620
(F1
F0.00014334862385321102
I0
I1
I-1
tp21621
sS'experiments,using,the'
p21622
(F1
F0.00014334862385321102
I0
I1
I-1
tp21623
sS'conditions,of,patients'
p21624
(F1
F0.00014334862385321102
I0
I1
I-1
tp21625
sS'of,anticholinesterase,agents'
p21626
(F1
F0.00014334862385321102
I1
I0
I1
tp21627
sS'ph,of,the'
p21628
(F1
F0.00014334862385321102
I1
I0
I1
tp21629
sS'be,alert,for'
p21630
(F1
F0.00028669724770642203
I0
I2
I-2
tp21631
sS'adrenal,synthesis,and'
p21632
(F1
F0.00014334862385321102
I1
I0
I1
tp21633
sS'of,because,of'
p21634
(F1
F0.00014334862385321102
I1
I0
I1
tp21635
sS'produced,an,inhibition'
p21636
(F1
F0.00014334862385321102
I0
I1
I-1
tp21637
sS'reduce,the,hepatic'
p21638
(F1
F0.00014334862385321102
I1
I0
I1
tp21639
sS'patients,five,lacking'
p21640
(F1
F0.00014334862385321102
I0
I1
I-1
tp21641
sS'adjustment,of,the'
p21642
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp21643
sS'dl,dose,adjustment'
p21644
(F1
F0.00014334862385321102
I1
I0
I1
tp21645
sS'with,sodium,and'
p21646
(F1
F0.00014334862385321102
I0
I1
I-1
tp21647
sS'mg,or,mg'
p21648
(F0
F0
I2
I2
I0
tp21649
sS'sublingual,may,be'
p21650
(F1
F0.00014334862385321102
I0
I1
I-1
tp21651
sS'effects,and,even'
p21652
(F1
F0.00014334862385321102
I0
I1
I-1
tp21653
sS'the,pharmacodynamic,effects'
p21654
(F0
F0
I1
I1
I0
tp21655
sS'in,the,production'
p21656
(F1
F0.00014334862385321102
I0
I1
I-1
tp21657
sS'disturbance,rarely,with'
p21658
(F1
F0.00014334862385321102
I1
I0
I1
tp21659
sS'be,approached,with'
p21660
(F1
F0.00028669724770642203
I2
I0
I2
tp21661
sS'literature,reports,indicate'
p21662
(F1
F0.00014334862385321102
I1
I0
I1
tp21663
sS'may,be,considered'
p21664
(F1
F0.00014334862385321102
I0
I1
I-1
tp21665
sS'isocarboxazid,and,other'
p21666
(F1
F0.00014334862385321102
I1
I0
I1
tp21667
sS'digoxin,a,single'
p21668
(F1
F0.00014334862385321102
I0
I1
I-1
tp21669
sS'potentially,significant,interactions'
p21670
(F1
F0.00014334862385321102
I1
I0
I1
tp21671
sS'persistent,inhibition,of'
p21672
(F1
F0.00014334862385321102
I1
I0
I1
tp21673
sS'absorption,of,where'
p21674
(F1
F0.00028669724770642203
I2
I0
I2
tp21675
sS'a,comprehensive,review'
p21676
(F1
F0.00014334862385321102
I0
I1
I-1
tp21677
sS'pulmonary,function,or'
p21678
(F1
F0.00014334862385321102
I0
I1
I-1
tp21679
sS'metabolism,of,increasing'
p21680
(F1
F0.00014334862385321102
I1
I0
I1
tp21681
sS'elements,ethacrynic,acid'
p21682
(F1
F0.00014334862385321102
I1
I0
I1
tp21683
sS'concentrations,of,these'
p21684
(F0
F0
I1
I1
I0
tp21685
sS'inhalational,muscle,relaxants'
p21686
(F1
F0.00014334862385321102
I0
I1
I-1
tp21687
sS'as,belladonna,alkaloids'
p21688
(F1
F0.00014334862385321102
I1
I0
I1
tp21689
sS'agents,chloral,hydrate'
p21690
(F1
F0.00014334862385321102
I0
I1
I-1
tp21691
sS'a,small,clinical'
p21692
(F1
F0.00014334862385321102
I0
I1
I-1
tp21693
sS'regimens,consisted,of'
p21694
(F1
F0.00014334862385321102
I0
I1
I-1
tp21695
sS'require,immediate,discontinuation'
p21696
(F1
F0.00014334862385321102
I0
I1
I-1
tp21697
sS'multiple-dose,crossover,study'
p21698
(F1
F0.00014334862385321102
I0
I1
I-1
tp21699
sS'administration,to,a'
p21700
(F0
F0
I1
I1
I0
tp21701
sS'no,controlled,studies'
p21702
(F1
F0.00014334862385321102
I0
I1
I-1
tp21703
sS'not,enhance,the'
p21704
(F0
F0
I1
I1
I0
tp21705
sS'sustained-release,calan,sr'
p21706
(F1
F0.00014334862385321102
I1
I0
I1
tp21707
sS'of,decreases,the'
p21708
(F1
F0.00014334862385321102
I1
I0
I1
tp21709
sS'also,not,affected'
p21710
(F1
F0.00014334862385321102
I0
I1
I-1
tp21711
sS'fa,were,submitted'
p21712
(F1
F0.00014334862385321102
I0
I1
I-1
tp21713
sS'and,interfere,with'
p21714
(F1
F0.00014334862385321102
I1
I0
I1
tp21715
sS'or,was,associated'
p21716
(F1
F0.00014334862385321102
I1
I0
I1
tp21717
sS'should,be,done'
p21718
(F1
F0.00014334862385321102
I1
I0
I1
tp21719
sS'groups,receiving,mg'
p21720
(F1
F0.00014334862385321102
I1
I0
I1
tp21721
sS'vitamin,supplements,containing'
p21722
(F1
F0.00014334862385321102
I1
I0
I1
tp21723
sS'halved,for,the'
p21724
(F1
F0.00014334862385321102
I1
I0
I1
tp21725
sS'or,delavirdine-based,regimens'
p21726
(F1
F0.00014334862385321102
I0
I1
I-1
tp21727
sS'addition,deaths,have'
p21728
(F1
F0.00014334862385321102
I1
I0
I1
tp21729
sS'risk,of,hepatitis'
p21730
(F1
F0.00014334862385321102
I1
I0
I1
tp21731
sS'daily,acquisition,cost'
p21732
(F1
F0.00014334862385321102
I0
I1
I-1
tp21733
sS'pharmacokinetics,of,are'
p21734
(F1
F0.00028669724770642203
I0
I2
I-2
tp21735
sS'an,interval,as'
p21736
(F1
F0.00014334862385321102
I0
I1
I-1
tp21737
sS'individuals,are,referred'
p21738
(F1
F0.00028669724770642203
I0
I2
I-2
tp21739
sS'similar,efficacy,on'
p21740
(F1
F0.00014334862385321102
I0
I1
I-1
tp21741
sS'suggesting,that,should'
p21742
(F1
F0.00014334862385321102
I1
I0
I1
tp21743
sS'implantable,forms,may'
p21744
(F1
F0.00014334862385321102
I1
I0
I1
tp21745
sS'use,may,blunt'
p21746
(F1
F0.00014334862385321102
I0
I1
I-1
tp21747
sS'concentration,increased,and'
p21748
(F1
F0.00014334862385321102
I0
I1
I-1
tp21749
sS'data,from,in'
p21750
(F1
F0.00028669724770642203
I2
I0
I2
tp21751
sS'associated,with,torsades'
p21752
(F1
F0.00014334862385321102
I0
I1
I-1
tp21753
sS'monitored,when,or'
p21754
(F1
F0.00014334862385321102
I1
I0
I1
tp21755
sS'were,generated,from'
p21756
(F1
F0.00014334862385321102
I0
I1
I-1
tp21757
sS'denudation,indicating,an'
p21758
(F1
F0.00014334862385321102
I0
I1
I-1
tp21759
sS'astramorph,kadian,ms'
p21760
(F1
F0.00014334862385321102
I1
I0
I1
tp21761
sS'micromol,l,did'
p21762
(F1
F0.00014334862385321102
I0
I1
I-1
tp21763
sS'oral,and,intravenous'
p21764
(F1
F0.00028669724770642203
I0
I2
I-2
tp21765
sS'the,implication,that'
p21766
(F1
F0.00014334862385321102
I1
I0
I1
tp21767
sS'are,metabolized,by'
p21768
(F0.23076923076923078
F0.00043004587155963305
I5
I8
I-3
tp21769
sS'inhibitors,indinavir,mg'
p21770
(F1
F0.00014334862385321102
I1
I0
I1
tp21771
sS'counteract,the,anticholinesterase'
p21772
(F1
F0.00014334862385321102
I1
I0
I1
tp21773
sS'interaction,studies,in'
p21774
(F1
F0.00043004587155963305
I0
I3
I-3
tp21775
sS'or,omega-agatoxin,iva'
p21776
(F1
F0.00014334862385321102
I0
I1
I-1
tp21777
sS'valproic,acid,concentrations'
p21778
(F1
F0.00014334862385321102
I0
I1
I-1
tp21779
sS'in,humans,that'
p21780
(F1
F0.00014334862385321102
I0
I1
I-1
tp21781
sS'combination,with,produced'
p21782
(F1
F0.00014334862385321102
I0
I1
I-1
tp21783
sS'significantly,different,before'
p21784
(F1
F0.00014334862385321102
I0
I1
I-1
tp21785
sS'of,atrovent,inhalation'
p21786
(F0
F0
I1
I1
I0
tp21787
sS'a,short-acting,and'
p21788
(F1
F0.00014334862385321102
I1
I0
I1
tp21789
sS'by,the,addition'
p21790
(F0
F0
I1
I1
I0
tp21791
sS'salt,substitutes,containing'
p21792
(F1
F0.00014334862385321102
I0
I1
I-1
tp21793
sS'a,clinically,important'
p21794
(F1
F0.00028669724770642203
I0
I2
I-2
tp21795
sS'on,the,breath'
p21796
(F1
F0.00014334862385321102
I0
I1
I-1
tp21797
sS'administration,on,the'
p21798
(F1
F0.00014334862385321102
I0
I1
I-1
tp21799
sS'a,family,cyp3a4'
p21800
(F1
F0.00014334862385321102
I0
I1
I-1
tp21801
sS'the,plasma,maximum'
p21802
(F1
F0.00014334862385321102
I0
I1
I-1
tp21803
sS'in,which,was'
p21804
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp21805
sS'with,thrombolytic,agents'
p21806
(F1
F0.00014334862385321102
I0
I1
I-1
tp21807
sS'since,both,and'
p21808
(F1
F0.00014334862385321102
I1
I0
I1
tp21809
sS'with,altered,consciousness'
p21810
(F1
F0.00014334862385321102
I1
I0
I1
tp21811
sS'for,the,first'
p21812
(F1
F0.00014334862385321102
I1
I0
I1
tp21813
sS'administration,of,two'
p21814
(F1
F0.00014334862385321102
I0
I1
I-1
tp21815
sS'healthy,subjects,n'
p21816
(F1
F0.00014334862385321102
I1
I0
I1
tp21817
sS'higher,occurrence,of'
p21818
(F1
F0.00028669724770642203
I2
I0
I2
tp21819
sS'with,intravascular,volume'
p21820
(F1
F0.00014334862385321102
I1
I0
I1
tp21821
sS'medicinal,products,such'
p21822
(F1
F0.00028669724770642203
I0
I2
I-2
tp21823
sS'system,and,brain'
p21824
(F1
F0.00014334862385321102
I1
I0
I1
tp21825
sS'in,mind,in'
p21826
(F1
F0.00014334862385321102
I1
I0
I1
tp21827
sS'least,weeks,should'
p21828
(F1
F0.00028669724770642203
I2
I0
I2
tp21829
sS'study,evaluating,the'
p21830
(F1
F0.00028669724770642203
I2
I0
I2
tp21831
sS'mg,elemental,oz'
p21832
(F1
F0.00014334862385321102
I0
I1
I-1
tp21833
sS'concurrent,dosing,of'
p21834
(F1
F0.00014334862385321102
I0
I1
I-1
tp21835
sS'taking,coumarin-derivative,concomitantly'
p21836
(F1
F0.00014334862385321102
I1
I0
I1
tp21837
sS'overall,exposure,to'
p21838
(F1
F0.00014334862385321102
I1
I0
I1
tp21839
sS'temporal,patterns,during'
p21840
(F1
F0.00014334862385321102
I0
I1
I-1
tp21841
sS'multiple,cytochrome,p450'
p21842
(F1
F0.00014334862385321102
I0
I1
I-1
tp21843
sS'nonsteroidal,the,co-administration'
p21844
(F1
F0.00014334862385321102
I1
I0
I1
tp21845
sS'while,a,synergistic'
p21846
(F1
F0.00014334862385321102
I1
I0
I1
tp21847
sS'same,metabolic,enzymes'
p21848
(F1
F0.00014334862385321102
I0
I1
I-1
tp21849
sS'reduction,of,dose'
p21850
(F1
F0.00014334862385321102
I1
I0
I1
tp21851
sS'established,current,evidence'
p21852
(F1
F0.00014334862385321102
I1
I0
I1
tp21853
sS'test,in,patients'
p21854
(F1
F0.00014334862385321102
I0
I1
I-1
tp21855
sS'precedex,with,and'
p21856
(F1
F0.00014334862385321102
I1
I0
I1
tp21857
sS'furosemide,may,decrease'
p21858
(F1
F0.00014334862385321102
I1
I0
I1
tp21859
sS'changes,in,either'
p21860
(F1
F0.00014334862385321102
I0
I1
I-1
tp21861
sS'copegus,did,not'
p21862
(F1
F0.00014334862385321102
I0
I1
I-1
tp21863
sS'alteration,in,clearance'
p21864
(F1
F0.00014334862385321102
I0
I1
I-1
tp21865
sS'thiazide,substrates,and'
p21866
(F1
F0.00014334862385321102
I0
I1
I-1
tp21867
sS'function,is,normal'
p21868
(F1
F0.00014334862385321102
I1
I0
I1
tp21869
sS'treated,with,hours'
p21870
(F1
F0.00014334862385321102
I1
I0
I1
tp21871
sS'upon,the,known'
p21872
(F1
F0.00014334862385321102
I1
I0
I1
tp21873
sS'ie,timi-ii,isis-2'
p21874
(F1
F0.00014334862385321102
I0
I1
I-1
tp21875
sS'given,after,multiple'
p21876
(F1
F0.00014334862385321102
I0
I1
I-1
tp21877
sS'it,is,particularly'
p21878
(F1
F0.00014334862385321102
I0
I1
I-1
tp21879
sS'advised,in,patients'
p21880
(F1
F0.00014334862385321102
I1
I0
I1
tp21881
sS'sharp,fall,of'
p21882
(F1
F0.00014334862385321102
I1
I0
I1
tp21883
sS'coadministered,than,when'
p21884
(F1
F0.00014334862385321102
I1
I0
I1
tp21885
sS'and,which,may'
p21886
(F1
F0.00014334862385321102
I0
I1
I-1
tp21887
sS'taking,acarbose,due'
p21888
(F1
F0.00014334862385321102
I1
I0
I1
tp21889
sS'have,been,identified'
p21890
(F0
F0
I1
I1
I0
tp21891
sS'between,and,and'
p21892
(F0
F0
I1
I1
I0
tp21893
sS'are,referred,to'
p21894
(F1
F0.00028669724770642203
I0
I2
I-2
tp21895
sS'of,naflu,compared'
p21896
(F1
F0.00014334862385321102
I0
I1
I-1
tp21897
sS'receiving,purinethol,or'
p21898
(F1
F0.00014334862385321102
I1
I0
I1
tp21899
sS'cefditoren,pivoxil,be'
p21900
(F0
F0
I1
I1
I0
tp21901
sS'either,alpha-,or'
p21902
(F1
F0.00014334862385321102
I0
I1
I-1
tp21903
sS'only,enhances,cocaine-induced'
p21904
(F1
F0.00014334862385321102
I1
I0
I1
tp21905
sS'other,cns,agents'
p21906
(F1
F0.00014334862385321102
I1
I0
I1
tp21907
sS'to,nonlethal,and'
p21908
(F1
F0.00014334862385321102
I0
I1
I-1
tp21909
sS'with,and,tablets'
p21910
(F1
F0.00014334862385321102
I1
I0
I1
tp21911
sS'velcade,treatment,may'
p21912
(F1
F0.00014334862385321102
I1
I0
I1
tp21913
sS'must,be,provided'
p21914
(F1
F0.00014334862385321102
I0
I1
I-1
tp21915
sS'parameters,without,and'
p21916
(F1
F0.00014334862385321102
I0
I1
I-1
tp21917
sS'various,antihypertensive,necessitating'
p21918
(F1
F0.00014334862385321102
I1
I0
I1
tp21919
sS'since,the,pharmacokinetics'
p21920
(F1
F0.00014334862385321102
I1
I0
I1
tp21921
sS'to,subjects,receiving'
p21922
(F1
F0.00014334862385321102
I1
I0
I1
tp21923
sS'carbidopa-levodopa,combination,products'
p21924
(F1
F0.00014334862385321102
I0
I1
I-1
tp21925
sS'about,a,fold'
p21926
(F1
F0.00014334862385321102
I1
I0
I1
tp21927
sS'data,emphasize,that'
p21928
(F1
F0.00014334862385321102
I0
I1
I-1
tp21929
sS'concurrently,with,does'
p21930
(F1
F0.00014334862385321102
I0
I1
I-1
tp21931
sS'antithrombotics,aspirin,and'
p21932
(F1
F0.00014334862385321102
I0
I1
I-1
tp21933
sS'reduces,basal,plasma'
p21934
(F1
F0.00014334862385321102
I0
I1
I-1
tp21935
sS'receiving,therapy,should'
p21936
(F1
F0.00014334862385321102
I1
I0
I1
tp21937
sS'of,suggesting,that'
p21938
(F1
F0.00014334862385321102
I0
I1
I-1
tp21939
sS'as,g,and'
p21940
(F1
F0.00014334862385321102
I1
I0
I1
tp21941
sS'reduction,in,and'
p21942
(F1
F0.00014334862385321102
I1
I0
I1
tp21943
sS'similar,responses,being'
p21944
(F1
F0.00014334862385321102
I0
I1
I-1
tp21945
sS'a,manner,similar'
p21946
(F1
F0.00014334862385321102
I0
I1
I-1
tp21947
sS'and,then,careful'
p21948
(F1
F0.00014334862385321102
I1
I0
I1
tp21949
sS'the,leukopenic,activity'
p21950
(F1
F0.00014334862385321102
I1
I0
I1
tp21951
sS'every,hours,was'
p21952
(F1
F0.00014334862385321102
I1
I0
I1
tp21953
sS'reuptake,inhibitors,grapefruit'
p21954
(F1
F0.00014334862385321102
I1
I0
I1
tp21955
sS'patient,pharmacokinetic,data'
p21956
(F1
F0.00014334862385321102
I1
I0
I1
tp21957
sS'metabolizers,have,higher'
p21958
(F1
F0.00071674311926605509
I0
I5
I-5
tp21959
sS'its,serum,levels'
p21960
(F1
F0.00014334862385321102
I1
I0
I1
tp21961
sS'included,mtx,in'
p21962
(F1
F0.00014334862385321102
I0
I1
I-1
tp21963
sS'including,ganglionic,blocking'
p21964
(F1
F0.00014334862385321102
I1
I0
I1
tp21965
sS'enzymes,responsible,for'
p21966
(F1
F0.00014334862385321102
I0
I1
I-1
tp21967
sS'whereas,the,colonic'
p21968
(F1
F0.00014334862385321102
I0
I1
I-1
tp21969
sS'pharmacokinetics,of,in'
p21970
(F1
F0.00071674311926605509
I0
I5
I-5
tp21971
sS'was,well,tolerated'
p21972
(F1
F0.00014334862385321102
I0
I1
I-1
tp21973
sS'fashion,and,may'
p21974
(F1
F0.00014334862385321102
I0
I1
I-1
tp21975
sS'to,vomiting,and'
p21976
(F1
F0.00014334862385321102
I1
I0
I1
tp21977
sS'non-comparative,clinical,trial'
p21978
(F1
F0.00014334862385321102
I1
I0
I1
tp21979
sS'oral,overload,of'
p21980
(F1
F0.00014334862385321102
I0
I1
I-1
tp21981
sS'primidone,population,pharmacokinetic'
p21982
(F1
F0.00014334862385321102
I1
I0
I1
tp21983
sS'but,not,after'
p21984
(F1
F0.00014334862385321102
I1
I0
I1
tp21985
sS'titrated,to,a'
p21986
(F0
F0
I2
I2
I0
tp21987
sS'a,prospective,study'
p21988
(F1
F0.00014334862385321102
I0
I1
I-1
tp21989
sS'volunteers,who,received'
p21990
(F1
F0.00014334862385321102
I1
I0
I1
tp21991
sS'lacking,kidney,function'
p21992
(F1
F0.00014334862385321102
I0
I1
I-1
tp21993
sS'by,therapy,can'
p21994
(F1
F0.00014334862385321102
I0
I1
I-1
tp21995
sS'mg,bid,the'
p21996
(F1
F0.00028669724770642203
I2
I0
I2
tp21997
sS'not,known,health'
p21998
(F1
F0.00014334862385321102
I0
I1
I-1
tp21999
sS'on,valproic,acid'
p22000
(F1
F0.00014334862385321102
I1
I0
I1
tp22001
sS'although,did,augment'
p22002
(F1
F0.00014334862385321102
I1
I0
I1
tp22003
sS'release,tablets,the'
p22004
(F1
F0.00014334862385321102
I1
I0
I1
tp22005
sS'oral,contraceptives,estrogens'
p22006
(F1
F0.00014334862385321102
I0
I1
I-1
tp22007
sS'be,necessary,eg'
p22008
(F1
F0.00014334862385321102
I1
I0
I1
tp22009
sS'reactions,develop,in'
p22010
(F1
F0.00014334862385321102
I1
I0
I1
tp22011
sS'be,reduced,higher'
p22012
(F1
F0.00043004587155963305
I0
I3
I-3
tp22013
sS'to,has,a'
p22014
(F1
F0.00014334862385321102
I1
I0
I1
tp22015
sS'interactions,and,dosage'
p22016
(F1
F0.00014334862385321102
I0
I1
I-1
tp22017
sS'following,ip,injections'
p22018
(F1
F0.00014334862385321102
I0
I1
I-1
tp22019
sS'erythromycin,in,hypercholesterolemic'
p22020
(F1
F0.00014334862385321102
I1
I0
I1
tp22021
sS'such,as,amphotericin'
p22022
(F1
F0.00014334862385321102
I1
I0
I1
tp22023
sS'with,coumarin-derivative,such'
p22024
(F1
F0.00014334862385321102
I1
I0
I1
tp22025
sS'ex,vivo,platelet'
p22026
(F1
F0.00014334862385321102
I0
I1
I-1
tp22027
sS'increase,in,bioavailability'
p22028
(F1
F0.00014334862385321102
I0
I1
I-1
tp22029
sS'clinical,significance,is'
p22030
(F0
F0
I1
I1
I0
tp22031
sS'been,a,few'
p22032
(F1
F0.00014334862385321102
I1
I0
I1
tp22033
sS'prevent,folic,acid'
p22034
(F1
F0.00014334862385321102
I0
I1
I-1
tp22035
sS'and,serious,clinical'
p22036
(F1
F0.00014334862385321102
I1
I0
I1
tp22037
sS'extent,of,bioavailability'
p22038
(F1
F0.00014334862385321102
I0
I1
I-1
tp22039
sS'dose,study,in'
p22040
(F1
F0.00014334862385321102
I0
I1
I-1
tp22041
sS'depressant,effects,of'
p22042
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp22043
sS'mg,dose,of'
p22044
(F0.15384615384615385
F0.00057339449541284407
I15
I11
I4
tp22045
sS'with,other,nsaids'
p22046
(F1
F0.00043004587155963305
I3
I0
I3
tp22047
sS'influence,on,the'
p22048
(F1
F0.00028669724770642203
I0
I2
I-2
tp22049
sS'av,nodal,conduction'
p22050
(F1
F0.00028669724770642203
I2
I0
I2
tp22051
sS'copegus,in,patients'
p22052
(F1
F0.00014334862385321102
I0
I1
I-1
tp22053
sS'concentrations,as,high'
p22054
(F1
F0.00014334862385321102
I0
I1
I-1
tp22055
sS'one,week,prior'
p22056
(F1
F0.00014334862385321102
I1
I0
I1
tp22057
sS'of,sublingual,mg'
p22058
(F1
F0.00014334862385321102
I1
I0
I1
tp22059
sS'the,standard,dose'
p22060
(F1
F0.00014334862385321102
I1
I0
I1
tp22061
sS'greater,degrees,of'
p22062
(F1
F0.00014334862385321102
I1
I0
I1
tp22063
sS'to,volunteers,under'
p22064
(F1
F0.00014334862385321102
I0
I1
I-1
tp22065
sS'prior,to,the'
p22066
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp22067
sS'time,with,or'
p22068
(F1
F0.00014334862385321102
I1
I0
I1
tp22069
sS'of,aprepitant,mg'
p22070
(F1
F0.00014334862385321102
I1
I0
I1
tp22071
sS'must,be,determined'
p22072
(F1
F0.00043004587155963305
I3
I0
I3
tp22073
sS'at,the,clinical'
p22074
(F1
F0.00014334862385321102
I0
I1
I-1
tp22075
sS'usually,does,not'
p22076
(F1
F0.00014334862385321102
I1
I0
I1
tp22077
sS'receiving,bolus-ifl,in'
p22078
(F1
F0.00014334862385321102
I0
I1
I-1
tp22079
sS'did,not,antagonize'
p22080
(F1
F0.00014334862385321102
I1
I0
I1
tp22081
sS'taking,other,psychotropic'
p22082
(F1
F0.00014334862385321102
I0
I1
I-1
tp22083
sS'blood-glucose,lowering,effect'
p22084
(F1
F0.00057339449541284407
I0
I4
I-4
tp22085
sS'hypoprothrombinemic,effect,of'
p22086
(F1
F0.00014334862385321102
I0
I1
I-1
tp22087
sS'tid,the,cmax'
p22088
(F1
F0.00014334862385321102
I1
I0
I1
tp22089
sS'compromised,in,these'
p22090
(F1
F0.00014334862385321102
I1
I0
I1
tp22091
sS'c12hr,by,in'
p22092
(F1
F0.00014334862385321102
I1
I0
I1
tp22093
sS'leucovorin,the,concentration'
p22094
(F1
F0.00014334862385321102
I1
I0
I1
tp22095
sS'clearance,and,volume'
p22096
(F1
F0.00014334862385321102
I1
I0
I1
tp22097
sS'enzymatic,oxidation,of'
p22098
(F1
F0.00014334862385321102
I1
I0
I1
tp22099
sS'with,produces,a'
p22100
(F1
F0.00014334862385321102
I1
I0
I1
tp22101
sS'cyp-2c19,by,oxc'
p22102
(F1
F0.00014334862385321102
I0
I1
I-1
tp22103
sS'increase,in,free'
p22104
(F1
F0.00014334862385321102
I1
I0
I1
tp22105
sS'hydrochloride,x,mg'
p22106
(F1
F0.00014334862385321102
I1
I0
I1
tp22107
sS'extent,than,and'
p22108
(F1
F0.00014334862385321102
I0
I1
I-1
tp22109
sS'tcas,with,any'
p22110
(F1
F0.00043004587155963305
I3
I0
I3
tp22111
sS'and,serum,concentrations'
p22112
(F1
F0.00014334862385321102
I1
I0
I1
tp22113
sS'healthy,subjects,on'
p22114
(F1
F0.00028669724770642203
I0
I2
I-2
tp22115
sS'combination,with,very'
p22116
(F1
F0.00014334862385321102
I0
I1
I-1
tp22117
sS'twice,daily,with'
p22118
(F1
F0.00014334862385321102
I1
I0
I1
tp22119
sS'inducer,a,dose'
p22120
(F1
F0.00014334862385321102
I0
I1
I-1
tp22121
sS'higher,degrees,of'
p22122
(F1
F0.00014334862385321102
I1
I0
I1
tp22123
sS'effects,of,agents'
p22124
(F1
F0.00014334862385321102
I0
I1
I-1
tp22125
sS'frequency,of,seizures'
p22126
(F1
F0.00014334862385321102
I1
I0
I1
tp22127
sS'reducing,effect,of'
p22128
(F1
F0.00014334862385321102
I1
I0
I1
tp22129
sS'that,mesylate,has'
p22130
(F1
F0.00014334862385321102
I0
I1
I-1
tp22131
sS'blockers,could,be'
p22132
(F1
F0.00014334862385321102
I1
I0
I1
tp22133
sS'general,and,during'
p22134
(F1
F0.00014334862385321102
I0
I1
I-1
tp22135
sS'may,have,caused'
p22136
(F1
F0.00014334862385321102
I1
I0
I1
tp22137
sS'requirements,for,volatile'
p22138
(F1
F0.00014334862385321102
I1
I0
I1
tp22139
sS'have,been,completed'
p22140
(F1
F0.00014334862385321102
I0
I1
I-1
tp22141
sS'iv,has,been'
p22142
(F1
F0.00014334862385321102
I0
I1
I-1
tp22143
sS'users,of,both'
p22144
(F1
F0.00028669724770642203
I2
I0
I2
tp22145
sS'therefore,necessary,to'
p22146
(F1
F0.00014334862385321102
I0
I1
I-1
tp22147
sS'glucose,should,be'
p22148
(F1
F0.00014334862385321102
I1
I0
I1
tp22149
sS'course,of,interference'
p22150
(F1
F0.00014334862385321102
I0
I1
I-1
tp22151
sS'is,co-administered,with'
p22152
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp22153
sS'are,also,likely'
p22154
(F1
F0.00014334862385321102
I1
I0
I1
tp22155
sS'attenuate,some,of'
p22156
(F1
F0.00028669724770642203
I0
I2
I-2
tp22157
sS'and,on,days'
p22158
(F1
F0.00014334862385321102
I0
I1
I-1
tp22159
sS'in,patients,the'
p22160
(F1
F0.00028669724770642203
I2
I0
I2
tp22161
sS'of,three,lines'
p22162
(F1
F0.00014334862385321102
I0
I1
I-1
tp22163
sS'hcl,in,combination'
p22164
(F1
F0.00014334862385321102
I1
I0
I1
tp22165
sS'in,patients,on'
p22166
(F0.63636363636363635
F0.0010034403669724771
I9
I2
I7
tp22167
sS'adjustment,to,the'
p22168
(F1
F0.00028669724770642203
I0
I2
I-2
tp22169
sS'noted,even,when'
p22170
(F1
F0.00014334862385321102
I1
I0
I1
tp22171
sS'identify,chromatin,and'
p22172
(F1
F0.00014334862385321102
I1
I0
I1
tp22173
sS'theophylline,a,single'
p22174
(F1
F0.00014334862385321102
I0
I1
I-1
tp22175
sS'to,loss,of'
p22176
(F1
F0.00028669724770642203
I0
I2
I-2
tp22177
sS'concentration,for,optimal'
p22178
(F1
F0.00014334862385321102
I0
I1
I-1
tp22179
sS'taking,while,taking'
p22180
(F1
F0.00014334862385321102
I1
I0
I1
tp22181
sS'depressants,with,habituating'
p22182
(F1
F0.00014334862385321102
I0
I1
I-1
tp22183
sS'or,or,lead'
p22184
(F1
F0.00014334862385321102
I1
I0
I1
tp22185
sS'on,day,each'
p22186
(F1
F0.00014334862385321102
I0
I1
I-1
tp22187
sS'cholestyramine,cholestyramine,may'
p22188
(F1
F0.00014334862385321102
I1
I0
I1
tp22189
sS'when,was,added'
p22190
(F0.5
F0.00028669724770642203
I3
I1
I2
tp22191
sS'inhibitors,of,cyp3a4'
p22192
(F0
F0
I3
I3
I0
tp22193
sS'hallucinations,have,been'
p22194
(F1
F0.00014334862385321102
I1
I0
I1
tp22195
sS'mg,capsules,every'
p22196
(F1
F0.00014334862385321102
I1
I0
I1
tp22197
sS'consulting,the,appropriate'
p22198
(F1
F0.00014334862385321102
I0
I1
I-1
tp22199
sS'have,clinically,relevant'
p22200
(F0
F0
I1
I1
I0
tp22201
sS'antacids,sucralfate,metal'
p22202
(F1
F0.00014334862385321102
I0
I1
I-1
tp22203
sS'information,concerning,laboratory'
p22204
(F1
F0.00014334862385321102
I0
I1
I-1
tp22205
sS'especially,in,the'
p22206
(F1
F0.00043004587155963305
I3
I0
I3
tp22207
sS'that,administration,attenuates'
p22208
(F1
F0.00014334862385321102
I1
I0
I1
tp22209
sS'of,the,benzodiazepine'
p22210
(F1
F0.00014334862385321102
I1
I0
I1
tp22211
sS'studies,caused,no'
p22212
(F1
F0.00014334862385321102
I0
I1
I-1
tp22213
sS'expected,because,is'
p22214
(F1
F0.00014334862385321102
I0
I1
I-1
tp22215
sS'the,skeletal,muscle'
p22216
(F1
F0.00014334862385321102
I1
I0
I1
tp22217
sS'cyp3a4,inhibitors,should'
p22218
(F1
F0.00014334862385321102
I1
I0
I1
tp22219
sS'oxaloacetate,and,mg2'
p22220
(F1
F0.00014334862385321102
I0
I1
I-1
tp22221
sS'doses,of,b6'
p22222
(F1
F0.00014334862385321102
I0
I1
I-1
tp22223
sS'information,should,be'
p22224
(F1
F0.00014334862385321102
I0
I1
I-1
tp22225
sS'local,and,some'
p22226
(F1
F0.00014334862385321102
I0
I1
I-1
tp22227
sS'that,patients,on'
p22228
(F1
F0.00014334862385321102
I1
I0
I1
tp22229
sS'recurred,when,the'
p22230
(F1
F0.00014334862385321102
I0
I1
I-1
tp22231
sS'saquinavir,coadministration,of'
p22232
(F1
F0.00014334862385321102
I1
I0
I1
tp22233
sS'rebound,hypertension,when'
p22234
(F1
F0.00014334862385321102
I1
I0
I1
tp22235
sS'treatment,practices,in'
p22236
(F1
F0.00014334862385321102
I0
I1
I-1
tp22237
sS'stable,plasma,levels'
p22238
(F1
F0.00028669724770642203
I2
I0
I2
tp22239
sS'administration,of,precedex'
p22240
(F1
F0.00014334862385321102
I0
I1
I-1
tp22241
sS'decreased,effect,of'
p22242
(F1
F0.00014334862385321102
I0
I1
I-1
tp22243
sS'medication,but,also'
p22244
(F1
F0.00014334862385321102
I0
I1
I-1
tp22245
sS'myoclonus,autonomic,instability'
p22246
(F1
F0.00014334862385321102
I1
I0
I1
tp22247
sS'whom,aminoglycoside,are'
p22248
(F1
F0.00014334862385321102
I1
I0
I1
tp22249
sS'by,intrathecal,on'
p22250
(F1
F0.00014334862385321102
I0
I1
I-1
tp22251
sS'of,pancreatic,supplements'
p22252
(F1
F0.00014334862385321102
I1
I0
I1
tp22253
sS'confirm,that,the'
p22254
(F1
F0.00014334862385321102
I0
I1
I-1
tp22255
sS'when,tagamet,is'
p22256
(F1
F0.00014334862385321102
I1
I0
I1
tp22257
sS'given,with,it'
p22258
(F1
F0.00014334862385321102
I0
I1
I-1
tp22259
sS'to,therapy,dose'
p22260
(F1
F0.00014334862385321102
I1
I0
I1
tp22261
sS'trimethyl,lead,tml'
p22262
(F1
F0.00014334862385321102
I0
I1
I-1
tp22263
sS'with,products,containing'
p22264
(F1
F0.00014334862385321102
I1
I0
I1
tp22265
sS'view,of,the'
p22266
(F0
F0
I1
I1
I0
tp22267
sS'cyp3a4,such,as'
p22268
(F1
F0.00014334862385321102
I1
I0
I1
tp22269
sS'interfere,with,serotonin'
p22270
(F1
F0.00014334862385321102
I1
I0
I1
tp22271
sS'with,failed,to'
p22272
(F1
F0.00014334862385321102
I0
I1
I-1
tp22273
sS'of,fat-soluble,should'
p22274
(F1
F0.00014334862385321102
I0
I1
I-1
tp22275
sS'if,is,coadministered'
p22276
(F1
F0.00014334862385321102
I1
I0
I1
tp22277
sS'were,measured,during'
p22278
(F1
F0.00014334862385321102
I0
I1
I-1
tp22279
sS'lodine,like,other'
p22280
(F1
F0.00014334862385321102
I1
I0
I1
tp22281
sS'displacing,effect,of'
p22282
(F1
F0.00014334862385321102
I0
I1
I-1
tp22283
sS'or,agents,structurally'
p22284
(F1
F0.00014334862385321102
I1
I0
I1
tp22285
sS'increased,approximately,and'
p22286
(F1
F0.00014334862385321102
I1
I0
I1
tp22287
sS'platelet,effects,celebrex'
p22288
(F1
F0.00014334862385321102
I0
I1
I-1
tp22289
sS'variety,of,preparations'
p22290
(F1
F0.00014334862385321102
I0
I1
I-1
tp22291
sS'as,and,the'
p22292
(F1
F0.00028669724770642203
I0
I2
I-2
tp22293
sS'kg,day,or'
p22294
(F1
F0.00014334862385321102
I0
I1
I-1
tp22295
sS'one-third,as,well'
p22296
(F1
F0.00014334862385321102
I1
I0
I1
tp22297
sS'with,adefovir,dipivoxil'
p22298
(F1
F0.00014334862385321102
I0
I1
I-1
tp22299
sS'bid,with,coadministration'
p22300
(F1
F0.00014334862385321102
I1
I0
I1
tp22301
sS'period,following,elspar'
p22302
(F1
F0.00014334862385321102
I1
I0
I1
tp22303
sS'azoles,are,known'
p22304
(F1
F0.00014334862385321102
I0
I1
I-1
tp22305
sS'tikosyn,and,concomitantly'
p22306
(F1
F0.00014334862385321102
I0
I1
I-1
tp22307
sS'combinations,of,mm'
p22308
(F1
F0.00014334862385321102
I0
I1
I-1
tp22309
sS'kg,day,of'
p22310
(F1
F0.00028669724770642203
I2
I0
I2
tp22311
sS'been,completely,evaluated'
p22312
(F1
F0.00014334862385321102
I0
I1
I-1
tp22313
sS'a,is,administered'
p22314
(F1
F0.00028669724770642203
I2
I0
I2
tp22315
sS'significantly,inhibited,phosphorylation'
p22316
(F1
F0.00014334862385321102
I1
I0
I1
tp22317
sS'consciousness,when,was'
p22318
(F1
F0.00014334862385321102
I1
I0
I1
tp22319
sS'investigation,of,chronic'
p22320
(F1
F0.00014334862385321102
I0
I1
I-1
tp22321
sS'that,have,been'
p22322
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp22323
sS'a,mean,eight-fold'
p22324
(F1
F0.00028669724770642203
I2
I0
I2
tp22325
sS'usually,prescribed,for'
p22326
(F1
F0.0010034403669724771
I0
I7
I-7
tp22327
sS'mofetil,respectively,were'
p22328
(F1
F0.00014334862385321102
I1
I0
I1
tp22329
sS'effect,one,study'
p22330
(F1
F0.00014334862385321102
I1
I0
I1
tp22331
sS'this,mechanism,may'
p22332
(F1
F0.00014334862385321102
I1
I0
I1
tp22333
sS'to,the,contents'
p22334
(F1
F0.00014334862385321102
I0
I1
I-1
tp22335
sS'compete,for,excretion'
p22336
(F1
F0.00014334862385321102
I1
I0
I1
tp22337
sS'time,have,been'
p22338
(F1
F0.00028669724770642203
I2
I0
I2
tp22339
sS'were,administered,starlix'
p22340
(F1
F0.00014334862385321102
I0
I1
I-1
tp22341
sS'digitalis,glycosides,patients'
p22342
(F1
F0.00014334862385321102
I0
I1
I-1
tp22343
sS'enflurane,than,when'
p22344
(F1
F0.00014334862385321102
I0
I1
I-1
tp22345
sS'such,as,platelet'
p22346
(F1
F0.00014334862385321102
I0
I1
I-1
tp22347
sS'to,resulting,interference'
p22348
(F1
F0.00014334862385321102
I1
I0
I1
tp22349
sS'be,enhanced,when'
p22350
(F1
F0.00014334862385321102
I1
I0
I1
tp22351
sS'arrhythmia,and,diamond'
p22352
(F1
F0.00014334862385321102
I1
I0
I1
tp22353
sS'drug-drug,interactions,and'
p22354
(F1
F0.00014334862385321102
I0
I1
I-1
tp22355
sS'day,have,been'
p22356
(F1
F0.00014334862385321102
I1
I0
I1
tp22357
sS'test,results,using'
p22358
(F1
F0.00014334862385321102
I0
I1
I-1
tp22359
sS'blockers,cardiac,glycosides'
p22360
(F1
F0.00014334862385321102
I0
I1
I-1
tp22361
sS'tachycardia,dryness,of'
p22362
(F1
F0.00014334862385321102
I1
I0
I1
tp22363
sS'a,mean,increase'
p22364
(F1
F0.00014334862385321102
I1
I0
I1
tp22365
sS'important,that,your'
p22366
(F1
F0.00014334862385321102
I1
I0
I1
tp22367
sS'two,metabolites,hydroxytolbutamide'
p22368
(F1
F0.00014334862385321102
I0
I1
I-1
tp22369
sS'with,chronic,hepatitis'
p22370
(F1
F0.00014334862385321102
I0
I1
I-1
tp22371
sS'inhibitor,may,have'
p22372
(F1
F0.00014334862385321102
I1
I0
I1
tp22373
sS'in,citrate,and'
p22374
(F1
F0.00014334862385321102
I0
I1
I-1
tp22375
sS'reported,as,international'
p22376
(F1
F0.00014334862385321102
I1
I0
I1
tp22377
sS'association,with,high'
p22378
(F1
F0.00014334862385321102
I1
I0
I1
tp22379
sS'protease,inhibitors,serotonin'
p22380
(F1
F0.00014334862385321102
I1
I0
I1
tp22381
sS'ketoconazole,and,are'
p22382
(F1
F0.00014334862385321102
I0
I1
I-1
tp22383
sS'usual,dose,when'
p22384
(F1
F0.00014334862385321102
I1
I0
I1
tp22385
sS'on,the,changes'
p22386
(F1
F0.00014334862385321102
I0
I1
I-1
tp22387
sS'cohort,design,that'
p22388
(F1
F0.00014334862385321102
I1
I0
I1
tp22389
sS'similarly,inhibit,and'
p22390
(F1
F0.00014334862385321102
I1
I0
I1
tp22391
sS'with,may,prolong'
p22392
(F0
F0
I2
I2
I0
tp22393
sS'pyrocarbonate,revealed,concentration'
p22394
(F1
F0.00014334862385321102
I0
I1
I-1
tp22395
sS'males,who,received'
p22396
(F1
F0.00014334862385321102
I0
I1
I-1
tp22397
sS'information,on,concomitant'
p22398
(F1
F0.00014334862385321102
I0
I1
I-1
tp22399
sS'in,decreasing,responding'
p22400
(F1
F0.00014334862385321102
I0
I1
I-1
tp22401
sS'were,evaluated,and'
p22402
(F1
F0.00014334862385321102
I0
I1
I-1
tp22403
sS'administration,of,low-dose'
p22404
(F1
F0.00028669724770642203
I2
I0
I2
tp22405
sS'are,inhibitors,of'
p22406
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp22407
sS'their,dose,if'
p22408
(F1
F0.00014334862385321102
I1
I0
I1
tp22409
sS'than,the,mean'
p22410
(F1
F0.00014334862385321102
I0
I1
I-1
tp22411
sS'qt-interval,prolongation,and'
p22412
(F1
F0.00014334862385321102
I0
I1
I-1
tp22413
sS'parnate,using,these'
p22414
(F1
F0.00014334862385321102
I0
I1
I-1
tp22415
sS'weeks,prior,to'
p22416
(F1
F0.00028669724770642203
I2
I0
I2
tp22417
sS'findings,of,these'
p22418
(F1
F0.00014334862385321102
I0
I1
I-1
tp22419
sS'analyzed,for,and'
p22420
(F1
F0.00014334862385321102
I0
I1
I-1
tp22421
sS'possessing,nephrotoxic,myelotoxic'
p22422
(F1
F0.00014334862385321102
I1
I0
I1
tp22423
sS'and,cause,renal'
p22424
(F1
F0.00014334862385321102
I0
I1
I-1
tp22425
sS'to,those,taking'
p22426
(F1
F0.00014334862385321102
I0
I1
I-1
tp22427
sS'but,no,effect'
p22428
(F1
F0.00014334862385321102
I0
I1
I-1
tp22429
sS'proteins,is,reduced'
p22430
(F1
F0.00014334862385321102
I0
I1
I-1
tp22431
sS'of,femara,with'
p22432
(F1
F0.00014334862385321102
I0
I1
I-1
tp22433
sS'are,given,concomitantly'
p22434
(F0.5
F0.00028669724770642203
I3
I1
I2
tp22435
sS'or,on,the'
p22436
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp22437
sS'one,with,a'
p22438
(F1
F0.00014334862385321102
I0
I1
I-1
tp22439
sS'of,in,combination'
p22440
(F1
F0.00014334862385321102
I1
I0
I1
tp22441
sS'concentrations,has,been'
p22442
(F1
F0.00014334862385321102
I0
I1
I-1
tp22443
sS'by,brevibloc,but'
p22444
(F1
F0.00014334862385321102
I1
I0
I1
tp22445
sS'been,studied,alternative'
p22446
(F1
F0.00014334862385321102
I1
I0
I1
tp22447
sS'mechanism,for,this'
p22448
(F1
F0.00014334862385321102
I1
I0
I1
tp22449
sS'by,m,m'
p22450
(F1
F0.00014334862385321102
I1
I0
I1
tp22451
sS'tablets,and,other'
p22452
(F1
F0.00028669724770642203
I2
I0
I2
tp22453
sS'volunteers,significantly,reduced'
p22454
(F1
F0.00014334862385321102
I1
I0
I1
tp22455
sS'of,the,pesticide'
p22456
(F1
F0.00028669724770642203
I0
I2
I-2
tp22457
sS'drugs,that,inhibit'
p22458
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp22459
sS'days,and,mg'
p22460
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp22461
sS'recommended,that,plasma'
p22462
(F1
F0.00014334862385321102
I1
I0
I1
tp22463
sS'valproate,available,data'
p22464
(F1
F0.00014334862385321102
I0
I1
I-1
tp22465
sS'concurrently,with,and'
p22466
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp22467
sS'by,a,highly'
p22468
(F1
F0.00014334862385321102
I1
I0
I1
tp22469
sS'phase,study,received'
p22470
(F1
F0.00014334862385321102
I0
I1
I-1
tp22471
sS'about,three-fold,compared'
p22472
(F1
F0.00014334862385321102
I0
I1
I-1
tp22473
sS'should,be,monitored'
p22474
(F0.37931034482758619
F0.0015768348623853212
I20
I9
I11
tp22475
sS'of,a,nonsteroidal'
p22476
(F1
F0.00014334862385321102
I1
I0
I1
tp22477
sS'in,mean,arterial'
p22478
(F1
F0.00014334862385321102
I1
I0
I1
tp22479
sS'antagonists,hypertension,in'
p22480
(F1
F0.00014334862385321102
I1
I0
I1
tp22481
sS'hypertension,which,can'
p22482
(F1
F0.00014334862385321102
I1
I0
I1
tp22483
sS'daily,for,days'
p22484
(F0
F0
I10
I10
I0
tp22485
sS'enhance,the,activity'
p22486
(F1
F0.00028669724770642203
I2
I0
I2
tp22487
sS'effects,on,hormone'
p22488
(F1
F0.00014334862385321102
I0
I1
I-1
tp22489
sS'hydrochlorothiazide,and,non-steroidal'
p22490
(F1
F0.00014334862385321102
I1
I0
I1
tp22491
sS'potentially,nephrotoxic,such'
p22492
(F1
F0.00014334862385321102
I1
I0
I1
tp22493
sS'that,use,during'
p22494
(F1
F0.00014334862385321102
I1
I0
I1
tp22495
sS'should,consider,the'
p22496
(F1
F0.00014334862385321102
I1
I0
I1
tp22497
sS'decreased,the,concentrations'
p22498
(F1
F0.00014334862385321102
I1
I0
I1
tp22499
sS'of,more,than'
p22500
(F1
F0.00014334862385321102
I1
I0
I1
tp22501
sS'subtypes,by,in'
p22502
(F1
F0.00014334862385321102
I0
I1
I-1
tp22503
sS'induced,by,camptosar'
p22504
(F1
F0.00014334862385321102
I1
I0
I1
tp22505
sS'consequently,alter,the'
p22506
(F1
F0.00014334862385321102
I0
I1
I-1
tp22507
sS'cause,increased,blood'
p22508
(F1
F0.00014334862385321102
I0
I1
I-1
tp22509
sS'before,and,after'
p22510
(F1
F0.00028669724770642203
I0
I2
I-2
tp22511
sS'steady-state,blood,levels'
p22512
(F1
F0.00014334862385321102
I1
I0
I1
tp22513
sS'inhibitors,drugs,such'
p22514
(F1
F0.00014334862385321102
I1
I0
I1
tp22515
sS'and,veratrum,alkaloids'
p22516
(F1
F0.00014334862385321102
I1
I0
I1
tp22517
sS'gi,bleeding,higher'
p22518
(F1
F0.00028669724770642203
I2
I0
I2
tp22519
sS'it,was,established'
p22520
(F1
F0.00014334862385321102
I0
I1
I-1
tp22521
sS'aripiprazole,dose,should'
p22522
(F1
F0.00014334862385321102
I1
I0
I1
tp22523
sS'other,cell,lines'
p22524
(F1
F0.00014334862385321102
I1
I0
I1
tp22525
sS'of,if,used'
p22526
(F1
F0.00014334862385321102
I1
I0
I1
tp22527
sS'dosing,and,pharmacokinetics'
p22528
(F1
F0.00014334862385321102
I0
I1
I-1
tp22529
sS'unfractionated,up,to'
p22530
(F1
F0.00014334862385321102
I0
I1
I-1
tp22531
sS'enzyme,inhibitors,intravenous'
p22532
(F1
F0.00014334862385321102
I0
I1
I-1
tp22533
sS'by,cyp,d6'
p22534
(F1
F0.00014334862385321102
I0
I1
I-1
tp22535
sS'which,was,administered'
p22536
(F1
F0.00028669724770642203
I0
I2
I-2
tp22537
sS'a,positive,urine'
p22538
(F1
F0.00014334862385321102
I0
I1
I-1
tp22539
sS'to,the,same'
p22540
(F1
F0.00028669724770642203
I2
I0
I2
tp22541
sS'treatment,with,coadministered'
p22542
(F1
F0.00014334862385321102
I0
I1
I-1
tp22543
sS'and,dosage,levels'
p22544
(F1
F0.00014334862385321102
I1
I0
I1
tp22545
sS'results,of,preliminary'
p22546
(F1
F0.00014334862385321102
I1
I0
I1
tp22547
sS'in,postmarketing,experience'
p22548
(F0
F0
I1
I1
I0
tp22549
sS'anticoagulants,oral,the'
p22550
(F1
F0.00014334862385321102
I0
I1
I-1
tp22551
sS'sulfa,medicines,thiazide'
p22552
(F1
F0.00014334862385321102
I1
I0
I1
tp22553
sS'adjunctive,therapy,a'
p22554
(F1
F0.00014334862385321102
I1
I0
I1
tp22555
sS'systemic,antiretroviral,agents'
p22556
(F1
F0.00014334862385321102
I0
I1
I-1
tp22557
sS'were,comparable,to'
p22558
(F1
F0.00014334862385321102
I1
I0
I1
tp22559
sS'h,in,the'
p22560
(F1
F0.00014334862385321102
I0
I1
I-1
tp22561
sS'may,experience,toxicity'
p22562
(F1
F0.00014334862385321102
I1
I0
I1
tp22563
sS'a,few,spontaneous'
p22564
(F1
F0.00014334862385321102
I1
I0
I1
tp22565
sS'by,auc0-24hr,in'
p22566
(F0
F0
I1
I1
I0
tp22567
sS'g,kg,on'
p22568
(F1
F0.00014334862385321102
I1
I0
I1
tp22569
sS'administration,of,equivalent'
p22570
(F1
F0.00028669724770642203
I2
I0
I2
tp22571
sS'not,seem,to'
p22572
(F1
F0.00014334862385321102
I0
I1
I-1
tp22573
sS'metabolic,disturbances,have'
p22574
(F1
F0.00014334862385321102
I0
I1
I-1
tp22575
sS'digoxin,interaction,studies'
p22576
(F1
F0.00014334862385321102
I0
I1
I-1
tp22577
sS'stadol,ns,were'
p22578
(F1
F0.00028669724770642203
I0
I2
I-2
tp22579
sS'confidence,interval,whole'
p22580
(F1
F0.00014334862385321102
I1
I0
I1
tp22581
sS'of,a,p-glycoprotein'
p22582
(F1
F0.00014334862385321102
I1
I0
I1
tp22583
sS'the,adverse,reaction'
p22584
(F1
F0.00014334862385321102
I0
I1
I-1
tp22585
sS'associated,with,crohns'
p22586
(F1
F0.00014334862385321102
I1
I0
I1
tp22587
sS'be,halved,for'
p22588
(F1
F0.00014334862385321102
I1
I0
I1
tp22589
sS'based,on,known'
p22590
(F1
F0.00014334862385321102
I0
I1
I-1
tp22591
sS'be,reduced,upon'
p22592
(F1
F0.00014334862385321102
I1
I0
I1
tp22593
sS'those,on,severe'
p22594
(F1
F0.00014334862385321102
I1
I0
I1
tp22595
sS'closely,to,determine'
p22596
(F0.75
F0.0008600917431192661
I7
I1
I6
tp22597
sS'sodium,colistimethate,salts'
p22598
(F1
F0.00014334862385321102
I1
I0
I1
tp22599
sS'azithromycin,had,no'
p22600
(F0
F0
I1
I1
I0
tp22601
sS'and,were,systematically'
p22602
(F1
F0.00014334862385321102
I0
I1
I-1
tp22603
sS'secondary,deficiencies,constitute'
p22604
(F1
F0.00014334862385321102
I0
I1
I-1
tp22605
sS'daily,of,vioxx'
p22606
(F1
F0.00014334862385321102
I1
I0
I1
tp22607
sS'proved,to,be'
p22608
(F1
F0.00014334862385321102
I0
I1
I-1
tp22609
sS'topical,injectable,implantable'
p22610
(F1
F0.00014334862385321102
I0
I1
I-1
tp22611
sS'arimidex,and,did'
p22612
(F1
F0.00014334862385321102
I0
I1
I-1
tp22613
sS'may,be,anticipated'
p22614
(F1
F0.00043004587155963305
I3
I0
I3
tp22615
sS'concentration,altered,by'
p22616
(F0
F0
I1
I1
I0
tp22617
sS'hydrochloride,not,be'
p22618
(F1
F0.00014334862385321102
I1
I0
I1
tp22619
sS'while,may,also'
p22620
(F1
F0.00014334862385321102
I1
I0
I1
tp22621
sS'treated,with,nonsteroidal'
p22622
(F1
F0.00014334862385321102
I1
I0
I1
tp22623
sS'ace,inhibitors,and'
p22624
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp22625
sS'cause,much,more'
p22626
(F1
F0.00014334862385321102
I0
I1
I-1
tp22627
sS'the,risk,of'
p22628
(F0.45454545454545453
F0.0021502293577981653
I24
I9
I15
tp22629
sS'plasma,concentration,time-curve'
p22630
(F1
F0.00014334862385321102
I1
I0
I1
tp22631
sS'a,subgroup,of'
p22632
(F1
F0.00014334862385321102
I0
I1
I-1
tp22633
sS'cyp3a4,cyp3a4,is'
p22634
(F1
F0.00014334862385321102
I0
I1
I-1
tp22635
sS'as,tablets,was'
p22636
(F1
F0.00014334862385321102
I0
I1
I-1
tp22637
sS'can,cause,hypothyroidism'
p22638
(F1
F0.00014334862385321102
I0
I1
I-1
tp22639
sS'presumably,to,a'
p22640
(F1
F0.00014334862385321102
I0
I1
I-1
tp22641
sS'of,oral,the'
p22642
(F1
F0.00014334862385321102
I1
I0
I1
tp22643
sS'over,patients,enrolled'
p22644
(F1
F0.00014334862385321102
I0
I1
I-1
tp22645
sS'of,approximately,times'
p22646
(F1
F0.00014334862385321102
I1
I0
I1
tp22647
sS'the,course,of'
p22648
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp22649
sS'of,endogenous,prostaglandin'
p22650
(F1
F0.00014334862385321102
I1
I0
I1
tp22651
sS'm-toluamide,a,common'
p22652
(F1
F0.00014334862385321102
I1
I0
I1
tp22653
sS'a,non-steroidal,agent'
p22654
(F1
F0.00014334862385321102
I1
I0
I1
tp22655
sS'function,of,the'
p22656
(F1
F0.00014334862385321102
I1
I0
I1
tp22657
sS'by,measuring,serum'
p22658
(F1
F0.00014334862385321102
I0
I1
I-1
tp22659
sS'cyclosporine,a,during'
p22660
(F1
F0.00014334862385321102
I0
I1
I-1
tp22661
sS'and,raise,the'
p22662
(F1
F0.00014334862385321102
I1
I0
I1
tp22663
sS'kg,weight,w'
p22664
(F1
F0.00014334862385321102
I1
I0
I1
tp22665
sS'of,sprycel,and'
p22666
(F1
F0.00014334862385321102
I1
I0
I1
tp22667
sS'may,also,increase'
p22668
(F1
F0.00028669724770642203
I0
I2
I-2
tp22669
sS'interfere,with,hemostasis'
p22670
(F1
F0.00014334862385321102
I0
I1
I-1
tp22671
sS'the,primary,cns'
p22672
(F1
F0.00028669724770642203
I2
I0
I2
tp22673
sS'who,are,hypersensitive'
p22674
(F1
F0.00014334862385321102
I1
I0
I1
tp22675
sS'practically,only,one'
p22676
(F1
F0.00014334862385321102
I0
I1
I-1
tp22677
sS'toradol,was,used'
p22678
(F1
F0.00014334862385321102
I1
I0
I1
tp22679
sS'not,at,min'
p22680
(F1
F0.00014334862385321102
I0
I1
I-1
tp22681
sS'with,and,tenofovir'
p22682
(F1
F0.00014334862385321102
I0
I1
I-1
tp22683
sS'of,oral,form'
p22684
(F1
F0.00014334862385321102
I1
I0
I1
tp22685
sS'they,may,enhance'
p22686
(F1
F0.00014334862385321102
I0
I1
I-1
tp22687
sS'mainly,responsible,for'
p22688
(F1
F0.00014334862385321102
I1
I0
I1
tp22689
sS'the,cmax,by'
p22690
(F1
F0.00014334862385321102
I1
I0
I1
tp22691
sS'serious,infections,an'
p22692
(F1
F0.00014334862385321102
I1
I0
I1
tp22693
sS'and,beta,blockers'
p22694
(F1
F0.00014334862385321102
I0
I1
I-1
tp22695
sS'embryocidal,effects,have'
p22696
(F1
F0.00014334862385321102
I0
I1
I-1
tp22697
sS'in,general,cognitive'
p22698
(F1
F0.00014334862385321102
I0
I1
I-1
tp22699
sS'even,in,the'
p22700
(F1
F0.00014334862385321102
I1
I0
I1
tp22701
sS'with,sprycel,close'
p22702
(F1
F0.00014334862385321102
I0
I1
I-1
tp22703
sS'of,indications,specific'
p22704
(F1
F0.00014334862385321102
I0
I1
I-1
tp22705
sS'cyp3a,may,decrease'
p22706
(F1
F0.00014334862385321102
I0
I1
I-1
tp22707
sS'combination,with,enhances'
p22708
(F1
F0.00014334862385321102
I1
I0
I1
tp22709
sS'labelled,and,in'
p22710
(F1
F0.00014334862385321102
I0
I1
I-1
tp22711
sS'a,decrease,in'
p22712
(F1
F0.0035837155963302754
I25
I0
I25
tp22713
sS'kg,h,without'
p22714
(F1
F0.00014334862385321102
I1
I0
I1
tp22715
sS'established,but,physicians'
p22716
(F1
F0.00014334862385321102
I1
I0
I1
tp22717
sS'may,increase,exposure'
p22718
(F1
F0.00014334862385321102
I1
I0
I1
tp22719
sS'of,vasoconstricting,agents'
p22720
(F1
F0.00014334862385321102
I1
I0
I1
tp22721
sS'sedation,times,long-sedation'
p22722
(F1
F0.00014334862385321102
I0
I1
I-1
tp22723
sS'potential,nephrotoxicity,and'
p22724
(F1
F0.00014334862385321102
I0
I1
I-1
tp22725
sS'by,but,not'
p22726
(F1
F0.00014334862385321102
I1
I0
I1
tp22727
sS'mind,that,ingestion'
p22728
(F1
F0.00014334862385321102
I1
I0
I1
tp22729
sS'aerosol,has,been'
p22730
(F1
F0.00014334862385321102
I0
I1
I-1
tp22731
sS'repeated,oral,administration'
p22732
(F1
F0.00014334862385321102
I0
I1
I-1
tp22733
sS'sensipar,on,other'
p22734
(F1
F0.00014334862385321102
I0
I1
I-1
tp22735
sS'of,vioxx,and'
p22736
(F1
F0.00014334862385321102
I0
I1
I-1
tp22737
sS'have,shown,that'
p22738
(F0.14285714285714285
F0.00043004587155963305
I12
I9
I3
tp22739
sS'akathisia,in,clinical'
p22740
(F1
F0.00014334862385321102
I1
I0
I1
tp22741
sS'vitro,against,two'
p22742
(F1
F0.00014334862385321102
I0
I1
I-1
tp22743
sS'diarrhea,but,this'
p22744
(F1
F0.00014334862385321102
I1
I0
I1
tp22745
sS'of,beta-adrenergic,blocking'
p22746
(F0
F0
I1
I1
I0
tp22747
sS'healthy,volunteers,have'
p22748
(F1
F0.00043004587155963305
I0
I3
I-3
tp22749
sS'of,cyp2d6,in'
p22750
(F1
F0.00014334862385321102
I0
I1
I-1
tp22751
sS'to,be,an'
p22752
(F1
F0.0008600917431192661
I0
I6
I-6
tp22753
sS'a,randomized,crossover'
p22754
(F1
F0.00014334862385321102
I0
I1
I-1
tp22755
sS'muscle,relaxants,and'
p22756
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp22757
sS'lower,in,patients'
p22758
(F1
F0.00014334862385321102
I1
I0
I1
tp22759
sS'study,was,given'
p22760
(F1
F0.00014334862385321102
I0
I1
I-1
tp22761
sS'interact,with,other'
p22762
(F1
F0.00028669724770642203
I0
I2
I-2
tp22763
sS'other,including,and'
p22764
(F1
F0.00014334862385321102
I0
I1
I-1
tp22765
sS'raise,the,possibility'
p22766
(F1
F0.00014334862385321102
I1
I0
I1
tp22767
sS'although,the,daily'
p22768
(F1
F0.00014334862385321102
I0
I1
I-1
tp22769
sS'and,essentially,completely'
p22770
(F1
F0.00014334862385321102
I0
I1
I-1
tp22771
sS'mg,p,o'
p22772
(F1
F0.00014334862385321102
I1
I0
I1
tp22773
sS'in,vitro,at'
p22774
(F1
F0.00014334862385321102
I0
I1
I-1
tp22775
sS'studies,with,highly'
p22776
(F1
F0.00014334862385321102
I0
I1
I-1
tp22777
sS'two,doses,of'
p22778
(F1
F0.00014334862385321102
I0
I1
I-1
tp22779
sS'once,weekly,for'
p22780
(F1
F0.00014334862385321102
I1
I0
I1
tp22781
sS'use,of,concurrently'
p22782
(F1
F0.00014334862385321102
I0
I1
I-1
tp22783
sS'inr,or,dose'
p22784
(F1
F0.00014334862385321102
I0
I1
I-1
tp22785
sS'mptp,produced,depletions'
p22786
(F1
F0.00014334862385321102
I1
I0
I1
tp22787
sS'of,a,chylomicron-like'
p22788
(F1
F0.00014334862385321102
I0
I1
I-1
tp22789
sS'phenytoin,keppra,mg'
p22790
(F1
F0.00014334862385321102
I0
I1
I-1
tp22791
sS'patients,using,long-acting'
p22792
(F1
F0.00014334862385321102
I1
I0
I1
tp22793
sS'related,to,alpha'
p22794
(F1
F0.00014334862385321102
I0
I1
I-1
tp22795
sS'as,competition,for'
p22796
(F1
F0.00014334862385321102
I1
I0
I1
tp22797
sS'possible,toxicity,from'
p22798
(F1
F0.00014334862385321102
I0
I1
I-1
tp22799
sS'required,for,therapeutic'
p22800
(F1
F0.00014334862385321102
I0
I1
I-1
tp22801
sS'protease,inhibitors,agenerase'
p22802
(F1
F0.00014334862385321102
I1
I0
I1
tp22803
sS'inhibits,the,growth'
p22804
(F1
F0.00014334862385321102
I0
I1
I-1
tp22805
sS'adequate,and,well-controlled'
p22806
(F1
F0.00014334862385321102
I0
I1
I-1
tp22807
sS'taking,a,rauwolfia'
p22808
(F1
F0.00014334862385321102
I1
I0
I1
tp22809
sS'situation,when,analgesia'
p22810
(F1
F0.00014334862385321102
I1
I0
I1
tp22811
sS'of,were,more'
p22812
(F1
F0.00014334862385321102
I0
I1
I-1
tp22813
sS'physicians,should,be'
p22814
(F1
F0.00028669724770642203
I2
I0
I2
tp22815
sS'resulted,in,reversible'
p22816
(F1
F0.00014334862385321102
I1
I0
I1
tp22817
sS'subgroup,of,the'
p22818
(F1
F0.00014334862385321102
I0
I1
I-1
tp22819
sS'in,turn,resulted'
p22820
(F1
F0.00014334862385321102
I1
I0
I1
tp22821
sS'pigeons,and,squirrel'
p22822
(F1
F0.00014334862385321102
I0
I1
I-1
tp22823
sS'neglect,of,therapy'
p22824
(F1
F0.00014334862385321102
I0
I1
I-1
tp22825
sS'to,fold,elevations'
p22826
(F1
F0.00014334862385321102
I1
I0
I1
tp22827
sS'cyp2d6,such,as'
p22828
(F0
F0
I1
I1
I0
tp22829
sS'of,sustiva,is'
p22830
(F1
F0.00014334862385321102
I0
I1
I-1
tp22831
sS'without,co-administered,avonex'
p22832
(F1
F0.00014334862385321102
I0
I1
I-1
tp22833
sS'influence,of,coadministration'
p22834
(F1
F0.00014334862385321102
I0
I1
I-1
tp22835
sS'be,given,consideration'
p22836
(F1
F0.0010034403669724771
I7
I0
I7
tp22837
sS'extreme,agitation,progressing'
p22838
(F1
F0.00014334862385321102
I1
I0
I1
tp22839
sS'be,taken,concomitantly'
p22840
(F1
F0.00014334862385321102
I0
I1
I-1
tp22841
sS'the,sole,protease'
p22842
(F1
F0.00014334862385321102
I0
I1
I-1
tp22843
sS'cerebyx,dosage,may'
p22844
(F1
F0.00014334862385321102
I1
I0
I1
tp22845
sS'concluded,that,is'
p22846
(F1
F0.00014334862385321102
I1
I0
I1
tp22847
sS'given,intraluminally,was'
p22848
(F1
F0.00014334862385321102
I0
I1
I-1
tp22849
sS'mg,was,in'
p22850
(F1
F0.00014334862385321102
I0
I1
I-1
tp22851
sS'dry,mouth,constipation'
p22852
(F1
F0.00014334862385321102
I1
I0
I1
tp22853
sS'for,the,reduction'
p22854
(F1
F0.00014334862385321102
I1
I0
I1
tp22855
sS'of,tracleer,and'
p22856
(F1
F0.00014334862385321102
I1
I0
I1
tp22857
sS'receiving,inspra,to'
p22858
(F1
F0.00014334862385321102
I0
I1
I-1
tp22859
sS'hydrate,dietary,deficiencies'
p22860
(F1
F0.00014334862385321102
I1
I0
I1
tp22861
sS'change,the,bioavailabillty'
p22862
(F1
F0.00014334862385321102
I1
I0
I1
tp22863
sS'if,clearance,is'
p22864
(F1
F0.00014334862385321102
I1
I0
I1
tp22865
sS'cholestyramine,the,influence'
p22866
(F1
F0.00014334862385321102
I0
I1
I-1
tp22867
sS'ineffective,in,altering'
p22868
(F1
F0.00014334862385321102
I0
I1
I-1
tp22869
sS'for,diagnosis,of'
p22870
(F1
F0.00014334862385321102
I0
I1
I-1
tp22871
sS'addition,to,bleeding'
p22872
(F1
F0.00014334862385321102
I1
I0
I1
tp22873
sS'used,to,chemically'
p22874
(F1
F0.00014334862385321102
I0
I1
I-1
tp22875
sS'to,a,five-fold'
p22876
(F1
F0.00014334862385321102
I1
I0
I1
tp22877
sS'and,mg,with'
p22878
(F1
F0.00014334862385321102
I0
I1
I-1
tp22879
sS'in,psychiatric,patients'
p22880
(F1
F0.00014334862385321102
I1
I0
I1
tp22881
sS'with,imidazole,and'
p22882
(F1
F0.00014334862385321102
I1
I0
I1
tp22883
sS'reported,to,significantly'
p22884
(F1
F0.00014334862385321102
I1
I0
I1
tp22885
sS'systematically,alter,the'
p22886
(F1
F0.00014334862385321102
I0
I1
I-1
tp22887
sS'decrease,in,ethinyl'
p22888
(F1
F0.00014334862385321102
I1
I0
I1
tp22889
sS'sodium,given,at'
p22890
(F1
F0.00014334862385321102
I0
I1
I-1
tp22891
sS'ophthalmic,suspension,contains'
p22892
(F1
F0.00014334862385321102
I0
I1
I-1
tp22893
sS'mg,bid,did'
p22894
(F1
F0.00043004587155963305
I0
I3
I-3
tp22895
sS'experience,toxicity,at'
p22896
(F1
F0.00014334862385321102
I1
I0
I1
tp22897
sS'lipid,levels,the'
p22898
(F1
F0.00014334862385321102
I0
I1
I-1
tp22899
sS'furthermore,and,do'
p22900
(F1
F0.00014334862385321102
I0
I1
I-1
tp22901
sS'competitive,interaction,at'
p22902
(F1
F0.00014334862385321102
I1
I0
I1
tp22903
sS'including,may,cause'
p22904
(F1
F0.00014334862385321102
I0
I1
I-1
tp22905
sS'prophylactic,and,antidotal'
p22906
(F1
F0.00014334862385321102
I1
I0
I1
tp22907
sS'pharmacological,i,without'
p22908
(F1
F0.00014334862385321102
I0
I1
I-1
tp22909
sS'high-estradiol,rats,were'
p22910
(F1
F0.00014334862385321102
I1
I0
I1
tp22911
sS'deficiency,can,increase'
p22912
(F1
F0.00014334862385321102
I1
I0
I1
tp22913
sS'prolongs,the,half-life'
p22914
(F1
F0.00014334862385321102
I1
I0
I1
tp22915
sS'comparison,of,antiaddictive'
p22916
(F1
F0.00014334862385321102
I0
I1
I-1
tp22917
sS'enhance,the,psychostimulant'
p22918
(F1
F0.00014334862385321102
I0
I1
I-1
tp22919
sS'the,preparation,causing'
p22920
(F1
F0.00014334862385321102
I1
I0
I1
tp22921
sS'or,mg,once'
p22922
(F1
F0.00028669724770642203
I0
I2
I-2
tp22923
sS'has,recovered,from'
p22924
(F1
F0.00014334862385321102
I1
I0
I1
tp22925
sS'examples,of,known'
p22926
(F1
F0.00014334862385321102
I1
I0
I1
tp22927
sS'of,this,kind'
p22928
(F1
F0.00014334862385321102
I1
I0
I1
tp22929
sS'regulate,the,proliferation'
p22930
(F1
F0.00014334862385321102
I1
I0
I1
tp22931
sS'even,decrease,the'
p22932
(F1
F0.00014334862385321102
I0
I1
I-1
tp22933
sS'inhibitors,intravenous,and'
p22934
(F1
F0.00014334862385321102
I0
I1
I-1
tp22935
sS'at,the,dose'
p22936
(F1
F0.00014334862385321102
I0
I1
I-1
tp22937
sS'depth,of,neuromuscular'
p22938
(F1
F0.00014334862385321102
I1
I0
I1
tp22939
sS'to,that,in'
p22940
(F1
F0.00043004587155963305
I0
I3
I-3
tp22941
sS'of,either,humira'
p22942
(F1
F0.00014334862385321102
I0
I1
I-1
tp22943
sS'tsh,secretion,p-aminosalicylic'
p22944
(F1
F0.00014334862385321102
I0
I1
I-1
tp22945
sS'thus,the,results'
p22946
(F1
F0.00014334862385321102
I1
I0
I1
tp22947
sS'aprepitant,to,achieve'
p22948
(F1
F0.00028669724770642203
I2
I0
I2
tp22949
sS'changes,in,urinary'
p22950
(F1
F0.00014334862385321102
I0
I1
I-1
tp22951
sS'who,increase,their'
p22952
(F1
F0.00014334862385321102
I1
I0
I1
tp22953
sS'a,cyp3a,the'
p22954
(F1
F0.00014334862385321102
I0
I1
I-1
tp22955
sS'might,have,the'
p22956
(F1
F0.00014334862385321102
I0
I1
I-1
tp22957
sS'mg,a,potent'
p22958
(F1
F0.00014334862385321102
I0
I1
I-1
tp22959
sS'agenerase,crixivan,fortovase'
p22960
(F1
F0.00014334862385321102
I1
I0
I1
tp22961
sS'excessive,neuromuscular,weakness'
p22962
(F1
F0.00014334862385321102
I1
I0
I1
tp22963
sS'or,other,hepatic'
p22964
(F1
F0.00014334862385321102
I1
I0
I1
tp22965
sS'not,demonstrated,any'
p22966
(F1
F0.00014334862385321102
I0
I1
I-1
tp22967
sS'plasma,concentrations,which'
p22968
(F1
F0.00014334862385321102
I1
I0
I1
tp22969
sS'maintenance,level,while'
p22970
(F0
F0
I1
I1
I0
tp22971
sS'increase,respectively,in'
p22972
(F1
F0.00014334862385321102
I1
I0
I1
tp22973
sS'the,conventional,formulation'
p22974
(F1
F0.00014334862385321102
I0
I1
I-1
tp22975
sS'side,effects,in'
p22976
(F1
F0.00028669724770642203
I2
I0
I2
tp22977
sS'the,following,adrenocorticoids'
p22978
(F1
F0.00014334862385321102
I1
I0
I1
tp22979
sS'in,clinical,practice'
p22980
(F1
F0.00014334862385321102
I1
I0
I1
tp22981
sS'of,probably,at'
p22982
(F1
F0.00014334862385321102
I1
I0
I1
tp22983
sS'through,searches,of'
p22984
(F1
F0.00014334862385321102
I0
I1
I-1
tp22985
sS'of,marked,bradycardia'
p22986
(F1
F0.00014334862385321102
I1
I0
I1
tp22987
sS'with,wthionamide,trecator-sc'
p22988
(F1
F0.00014334862385321102
I0
I1
I-1
tp22989
sS'to,three,types'
p22990
(F1
F0.00014334862385321102
I0
I1
I-1
tp22991
sS'hormonal,including,oral'
p22992
(F1
F0.00014334862385321102
I1
I0
I1
tp22993
sS'treatment,of,depressive'
p22994
(F1
F0.00014334862385321102
I0
I1
I-1
tp22995
sS'been,collected,on'
p22996
(F1
F0.00014334862385321102
I0
I1
I-1
tp22997
sS'than,with,the'
p22998
(F1
F0.00014334862385321102
I1
I0
I1
tp22999
sS'not,compensate,for'
p23000
(F1
F0.00028669724770642203
I2
I0
I2
tp23001
sS'and,other,had'
p23002
(F1
F0.00014334862385321102
I0
I1
I-1
tp23003
sS'under,the,serum'
p23004
(F1
F0.00014334862385321102
I1
I0
I1
tp23005
sS'are,very,potent'
p23006
(F1
F0.00014334862385321102
I1
I0
I1
tp23007
sS'and,no,significant'
p23008
(F0
F0
I1
I1
I0
tp23009
sS'effects,on,plasma'
p23010
(F1
F0.00028669724770642203
I0
I2
I-2
tp23011
sS'co-administration,of,multiple'
p23012
(F1
F0.00014334862385321102
I0
I1
I-1
tp23013
sS'were,identified,through'
p23014
(F1
F0.00014334862385321102
I0
I1
I-1
tp23015
sS'maximum,plasma,concentrations'
p23016
(F1
F0.00014334862385321102
I1
I0
I1
tp23017
sS'capsules,since,there'
p23018
(F1
F0.00014334862385321102
I1
I0
I1
tp23019
sS'hamster,s,alpha'
p23020
(F1
F0.00014334862385321102
I0
I1
I-1
tp23021
sS'activity,was,enhanced'
p23022
(F1
F0.00014334862385321102
I0
I1
I-1
tp23023
sS'likely,to,increase'
p23024
(F1
F0.00014334862385321102
I1
I0
I1
tp23025
sS'that,can,inhibit'
p23026
(F1
F0.00071674311926605509
I0
I5
I-5
tp23027
sS'cyp2a6,cyp2c9,cyp2c19'
p23028
(F1
F0.00028669724770642203
I0
I2
I-2
tp23029
sS'or,are,enhanced'
p23030
(F1
F0.00014334862385321102
I1
I0
I1
tp23031
sS'the,pancreatic,effects'
p23032
(F1
F0.00014334862385321102
I0
I1
I-1
tp23033
sS'atoxic,since,it'
p23034
(F1
F0.00014334862385321102
I0
I1
I-1
tp23035
sS'nonsteroidal,agents,including'
p23036
(F1
F0.00014334862385321102
I1
I0
I1
tp23037
sS'kg,day,showed'
p23038
(F1
F0.00014334862385321102
I0
I1
I-1
tp23039
sS'cmax,increased,approximately'
p23040
(F1
F0.00014334862385321102
I1
I0
I1
tp23041
sS'of,keppra,on'
p23042
(F1
F0.00014334862385321102
I0
I1
I-1
tp23043
sS'monitoring,for,adverse'
p23044
(F1
F0.00014334862385321102
I1
I0
I1
tp23045
sS'virologic,response,and'
p23046
(F1
F0.00028669724770642203
I0
I2
I-2
tp23047
sS'diminished,effects,of'
p23048
(F1
F0.00014334862385321102
I1
I0
I1
tp23049
sS'esmolol,hcl,and'
p23050
(F1
F0.00014334862385321102
I0
I1
I-1
tp23051
sS'can,occur,when'
p23052
(F1
F0.00028669724770642203
I2
I0
I2
tp23053
sS'increased,amounts,may'
p23054
(F1
F0.00014334862385321102
I0
I1
I-1
tp23055
sS'have,life-threatening,interactions'
p23056
(F1
F0.00014334862385321102
I1
I0
I1
tp23057
sS'be,aware,when'
p23058
(F1
F0.00014334862385321102
I1
I0
I1
tp23059
sS'day,when,was'
p23060
(F1
F0.00014334862385321102
I1
I0
I1
tp23061
sS'to,pooled,human'
p23062
(F1
F0.00014334862385321102
I0
I1
I-1
tp23063
sS'e2,may,augment'
p23064
(F1
F0.00014334862385321102
I1
I0
I1
tp23065
sS'hcl,cream,cream'
p23066
(F1
F0.00014334862385321102
I0
I1
I-1
tp23067
sS'limited,to,other'
p23068
(F1
F0.00014334862385321102
I1
I0
I1
tp23069
sS'and,decreases,in'
p23070
(F1
F0.00014334862385321102
I1
I0
I1
tp23071
sS'be,cautiously,coadministered'
p23072
(F1
F0.00014334862385321102
I1
I0
I1
tp23073
sS'control,vs,when'
p23074
(F1
F0.00014334862385321102
I1
I0
I1
tp23075
sS'in,the,duloxetine'
p23076
(F1
F0.00014334862385321102
I0
I1
I-1
tp23077
sS'of,combination,hormonal'
p23078
(F1
F0.00014334862385321102
I1
I0
I1
tp23079
sS'antihypertensive,action,of'
p23080
(F1
F0.00014334862385321102
I1
I0
I1
tp23081
sS'potentiate,the,replication'
p23082
(F1
F0.00014334862385321102
I1
I0
I1
tp23083
sS'patients,the,dose'
p23084
(F1
F0.00014334862385321102
I0
I1
I-1
tp23085
sS'renal,function,in'
p23086
(F1
F0.00014334862385321102
I0
I1
I-1
tp23087
sS'in,hiv-infected,subjects'
p23088
(F1
F0.00014334862385321102
I0
I1
I-1
tp23089
sS'in,renally,impaired'
p23090
(F1
F0.00014334862385321102
I0
I1
I-1
tp23091
sS'diminish,or,abolish'
p23092
(F1
F0.00014334862385321102
I1
I0
I1
tp23093
sS'to,have,increased'
p23094
(F1
F0.00014334862385321102
I1
I0
I1
tp23095
sS'indinavir,steady-state,cmax'
p23096
(F1
F0.00014334862385321102
I1
I0
I1
tp23097
sS'with,concomitant,use'
p23098
(F1
F0.0008600917431192661
I6
I0
I6
tp23099
sS'with,and,failed'
p23100
(F1
F0.00014334862385321102
I0
I1
I-1
tp23101
sS'dolasetron,mesylate,did'
p23102
(F1
F0.00014334862385321102
I0
I1
I-1
tp23103
sS'without,to,l'
p23104
(F1
F0.00014334862385321102
I1
I0
I1
tp23105
sS'and,protein,binding'
p23106
(F1
F0.00014334862385321102
I0
I1
I-1
tp23107
sS'agents,amphotericin,b'
p23108
(F1
F0.00014334862385321102
I1
I0
I1
tp23109
sS'parameters,auc,cmax'
p23110
(F1
F0.00014334862385321102
I1
I0
I1
tp23111
sS'venlafaxine,coadministration,of'
p23112
(F1
F0.00014334862385321102
I0
I1
I-1
tp23113
sS'enzyme,ace,inhibitors'
p23114
(F1
F0.00028669724770642203
I0
I2
I-2
tp23115
sS'the,preservative,in'
p23116
(F1
F0.00014334862385321102
I1
I0
I1
tp23117
sS'antagonized,by,alpha-adrenergic'
p23118
(F1
F0.00014334862385321102
I1
I0
I1
tp23119
sS'other,nonsteroidal,agents'
p23120
(F1
F0.00014334862385321102
I1
I0
I1
tp23121
sS'concomitant,use,however'
p23122
(F1
F0.00014334862385321102
I0
I1
I-1
tp23123
sS'anakinra,concurrent,administration'
p23124
(F1
F0.00014334862385321102
I1
I0
I1
tp23125
sS'with,as,in'
p23126
(F1
F0.00014334862385321102
I1
I0
I1
tp23127
sS'it,may,also'
p23128
(F1
F0.00014334862385321102
I0
I1
I-1
tp23129
sS'incoordination,following,the'
p23130
(F1
F0.00014334862385321102
I1
I0
I1
tp23131
sS'searches,of,medline'
p23132
(F1
F0.00014334862385321102
I0
I1
I-1
tp23133
sS'micrograms,equally,antagonized'
p23134
(F1
F0.00014334862385321102
I1
I0
I1
tp23135
sS'with,that,observed'
p23136
(F1
F0.00014334862385321102
I1
I0
I1
tp23137
sS'with,spectrophotometrically,determined'
p23138
(F1
F0.00014334862385321102
I0
I1
I-1
tp23139
sS'if,the,antagonist'
p23140
(F1
F0.00014334862385321102
I0
I1
I-1
tp23141
sS'properties,of,nor'
p23142
(F1
F0.00014334862385321102
I0
I1
I-1
tp23143
sS'mouth,use,of'
p23144
(F1
F0.00014334862385321102
I1
I0
I1
tp23145
sS'clearance,by,means'
p23146
(F1
F0.00014334862385321102
I0
I1
I-1
tp23147
sS'in,the,intestinal'
p23148
(F1
F0.00014334862385321102
I1
I0
I1
tp23149
sS'healthy,volunteers,no'
p23150
(F1
F0.00014334862385321102
I0
I1
I-1
tp23151
sS'probenecid,depresses,tubular'
p23152
(F1
F0.00014334862385321102
I1
I0
I1
tp23153
sS'are,also,additive'
p23154
(F1
F0.00014334862385321102
I1
I0
I1
tp23155
sS'inhibits,the,bumetanide-induced'
p23156
(F1
F0.00014334862385321102
I1
I0
I1
tp23157
sS'using,in,situ'
p23158
(F1
F0.00014334862385321102
I1
I0
I1
tp23159
sS'maximum,cumulative,doses'
p23160
(F1
F0.00014334862385321102
I1
I0
I1
tp23161
sS'patients,and,cerebyx'
p23162
(F1
F0.00014334862385321102
I1
I0
I1
tp23163
sS'per,day,and'
p23164
(F0
F0
I1
I1
I0
tp23165
sS'of,people,who'
p23166
(F1
F0.00014334862385321102
I1
I0
I1
tp23167
sS'of,a,patient'
p23168
(F1
F0.00043004587155963305
I3
I0
I3
tp23169
sS'state,plasma,concentration'
p23170
(F1
F0.00014334862385321102
I1
I0
I1
tp23171
sS'and,sustained,increases'
p23172
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp23173
sS'the,cns,depressant'
p23174
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp23175
sS'deaths,among,the'
p23176
(F1
F0.00014334862385321102
I0
I1
I-1
tp23177
sS'cns,depressant,and'
p23178
(F0
F0
I1
I1
I0
tp23179
sS'together,with,with'
p23180
(F1
F0.00014334862385321102
I0
I1
I-1
tp23181
sS'reduce,the,blood-glucose'
p23182
(F1
F0.00028669724770642203
I0
I2
I-2
tp23183
sS'metabolites,hydroxytolbutamide,and'
p23184
(F1
F0.00014334862385321102
I0
I1
I-1
tp23185
sS'pharmacokinetic,drug-drug,interactions'
p23186
(F1
F0.00028669724770642203
I0
I2
I-2
tp23187
sS'enzyme,system,notably'
p23188
(F1
F0.00014334862385321102
I1
I0
I1
tp23189
sS'trough,concentration,accompanied'
p23190
(F1
F0.00014334862385321102
I1
I0
I1
tp23191
sS'was,given,concomitantly'
p23192
(F1
F0.00014334862385321102
I0
I1
I-1
tp23193
sS'required,infusion,rate'
p23194
(F1
F0.00014334862385321102
I1
I0
I1
tp23195
sS'may,develop,increased'
p23196
(F1
F0.00014334862385321102
I1
I0
I1
tp23197
sS'of,erythromycin,on'
p23198
(F1
F0.00014334862385321102
I0
I1
I-1
tp23199
sS'or,the,antiprothrombinemic'
p23200
(F1
F0.00014334862385321102
I0
I1
I-1
tp23201
sS'profiles,clinically,significant'
p23202
(F1
F0.00014334862385321102
I0
I1
I-1
tp23203
sS'evidently,the,antinociceptive'
p23204
(F1
F0.00014334862385321102
I1
I0
I1
tp23205
sS'as,hctz,hydrodiuril'
p23206
(F1
F0.00014334862385321102
I0
I1
I-1
tp23207
sS'function,the,use'
p23208
(F1
F0.00014334862385321102
I1
I0
I1
tp23209
sS'higher,than,in'
p23210
(F1
F0.00014334862385321102
I1
I0
I1
tp23211
sS'receptor,blockers,calcium'
p23212
(F1
F0.00014334862385321102
I0
I1
I-1
tp23213
sS'second,day,of'
p23214
(F1
F0.00014334862385321102
I1
I0
I1
tp23215
sS'hour,apart,on'
p23216
(F1
F0.00014334862385321102
I1
I0
I1
tp23217
sS'definitely,indicated,and'
p23218
(F1
F0.00014334862385321102
I1
I0
I1
tp23219
sS'dose-related,blockade,of'
p23220
(F1
F0.00014334862385321102
I1
I0
I1
tp23221
sS'treated,with,various'
p23222
(F1
F0.00014334862385321102
I1
I0
I1
tp23223
sS'plasma,exposures,of'
p23224
(F1
F0.00014334862385321102
I1
I0
I1
tp23225
sS'other,oral,formulations'
p23226
(F1
F0.00014334862385321102
I1
I0
I1
tp23227
sS'in,patients,when'
p23228
(F1
F0.00014334862385321102
I1
I0
I1
tp23229
sS'than,recommended,doses'
p23230
(F1
F0.00014334862385321102
I1
I0
I1
tp23231
sS'anticoagulation,test,should'
p23232
(F1
F0.00014334862385321102
I1
I0
I1
tp23233
sS'anti-inflammatory,agents,may'
p23234
(F1
F0.00014334862385321102
I0
I1
I-1
tp23235
sS'the,active,metabolite'
p23236
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp23237
sS'the,following,antibiotics'
p23238
(F1
F0.00014334862385321102
I0
I1
I-1
tp23239
sS'hydrochloride,is,also'
p23240
(F1
F0.00014334862385321102
I1
I0
I1
tp23241
sS'of,when,given'
p23242
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp23243
sS'oxytocin,or,other'
p23244
(F1
F0.00014334862385321102
I1
I0
I1
tp23245
sS'adjusted,accordingly,in'
p23246
(F1
F0.00014334862385321102
I1
I0
I1
tp23247
sS'which,is,mediated'
p23248
(F1
F0.00014334862385321102
I1
I0
I1
tp23249
sS'and,undetectable,release'
p23250
(F1
F0.00014334862385321102
I0
I1
I-1
tp23251
sS'exposure,to,is'
p23252
(F1
F0.00014334862385321102
I1
I0
I1
tp23253
sS'qd,of,are'
p23254
(F1
F0.00014334862385321102
I0
I1
I-1
tp23255
sS'resins,since,bile'
p23256
(F1
F0.00014334862385321102
I1
I0
I1
tp23257
sS'other,hypotensive,including'
p23258
(F1
F0.00014334862385321102
I1
I0
I1
tp23259
sS'present,study,the'
p23260
(F1
F0.00014334862385321102
I0
I1
I-1
tp23261
sS'isoenzyme,including,certain'
p23262
(F1
F0.00014334862385321102
I1
I0
I1
tp23263
sS'interval,certain,including'
p23264
(F1
F0.00014334862385321102
I1
I0
I1
tp23265
sS'microsomes,the,effects'
p23266
(F1
F0.00014334862385321102
I0
I1
I-1
tp23267
sS'including,blood,pressure'
p23268
(F1
F0.00014334862385321102
I0
I1
I-1
tp23269
sS'volume,of,distribution'
p23270
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp23271
sS'they,may,interfere'
p23272
(F1
F0.00014334862385321102
I1
I0
I1
tp23273
sS'acid,were,not'
p23274
(F1
F0.00014334862385321102
I0
I1
I-1
tp23275
sS'renin,release,the'
p23276
(F1
F0.00014334862385321102
I1
I0
I1
tp23277
sS'times,should,be'
p23278
(F0
F0
I1
I1
I0
tp23279
sS'or,potentiating,effect'
p23280
(F1
F0.00043004587155963305
I3
I0
I3
tp23281
sS'krm-1648,exhibited,strong'
p23282
(F1
F0.00014334862385321102
I1
I0
I1
tp23283
sS'elements,were,determined'
p23284
(F1
F0.00014334862385321102
I0
I1
I-1
tp23285
sS'hours,after,the'
p23286
(F1
F0.00043004587155963305
I3
I0
I3
tp23287
sS'less,suppression,of'
p23288
(F1
F0.00014334862385321102
I0
I1
I-1
tp23289
sS'general,skeletal,muscle'
p23290
(F1
F0.00028669724770642203
I2
I0
I2
tp23291
sS'there,are,limited'
p23292
(F1
F0.00014334862385321102
I1
I0
I1
tp23293
sS'x,mg,capsule'
p23294
(F1
F0.00014334862385321102
I1
I0
I1
tp23295
sS'normal,subjects,the'
p23296
(F1
F0.00014334862385321102
I0
I1
I-1
tp23297
sS'interfering,with,neuromuscular'
p23298
(F1
F0.00028669724770642203
I2
I0
I2
tp23299
sS'mellaril,stelazine,vesprin'
p23300
(F1
F0.00014334862385321102
I0
I1
I-1
tp23301
sS'increase,the,effect'
p23302
(F1
F0.00028669724770642203
I2
I0
I2
tp23303
sS'of,these,effects'
p23304
(F1
F0.00014334862385321102
I1
I0
I1
tp23305
sS'intravenous,and,hivid'
p23306
(F1
F0.00014334862385321102
I1
I0
I1
tp23307
sS'doses,higher,than'
p23308
(F1
F0.00028669724770642203
I0
I2
I-2
tp23309
sS'the,lower,intestine'
p23310
(F1
F0.00014334862385321102
I1
I0
I1
tp23311
sS'bound,by,reducing'
p23312
(F1
F0.00014334862385321102
I1
I0
I1
tp23313
sS'with,inomax,on'
p23314
(F1
F0.00014334862385321102
I1
I0
I1
tp23315
sS'and,from,week'
p23316
(F1
F0.00014334862385321102
I0
I1
I-1
tp23317
sS'compared,with,that'
p23318
(F1
F0.00014334862385321102
I1
I0
I1
tp23319
sS'from,midcycle,day'
p23320
(F1
F0.00014334862385321102
I0
I1
I-1
tp23321
sS'agents,prinivil,has'
p23322
(F1
F0.00014334862385321102
I0
I1
I-1
tp23323
sS'vasoconstricting,agents,such'
p23324
(F1
F0.00014334862385321102
I1
I0
I1
tp23325
sS'dose,may,be'
p23326
(F1
F0.00043004587155963305
I3
I0
I3
tp23327
sS'interactions,cimetidine,and'
p23328
(F1
F0.00014334862385321102
I0
I1
I-1
tp23329
sS'clearance,is,changed'
p23330
(F1
F0.00014334862385321102
I1
I0
I1
tp23331
sS'enhanced,the,translocating'
p23332
(F1
F0.00014334862385321102
I0
I1
I-1
tp23333
sS'clinically,significant,drug-drug'
p23334
(F1
F0.00014334862385321102
I0
I1
I-1
tp23335
sS'cytochrome,p450,enzymes'
p23336
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp23337
sS'and,urine,samples'
p23338
(F1
F0.00014334862385321102
I0
I1
I-1
tp23339
sS'hyperthermia,rigidity,myoclonus'
p23340
(F1
F0.00014334862385321102
I1
I0
I1
tp23341
sS'similarly,decreased,the'
p23342
(F1
F0.00028669724770642203
I2
I0
I2
tp23343
sS'an,overactive,pain'
p23344
(F1
F0.00014334862385321102
I0
I1
I-1
tp23345
sS'isozyme,which,metabolizes'
p23346
(F1
F0.00014334862385321102
I0
I1
I-1
tp23347
sS'lower,plasma,concentrations'
p23348
(F1
F0.00043004587155963305
I3
I0
I3
tp23349
sS'because,the,added'
p23350
(F1
F0.00014334862385321102
I1
I0
I1
tp23351
sS'over,minutes,were'
p23352
(F1
F0.00014334862385321102
I0
I1
I-1
tp23353
sS'kg,day,n'
p23354
(F1
F0.00014334862385321102
I1
I0
I1
tp23355
sS'manner,the,tail-flick'
p23356
(F1
F0.00014334862385321102
I1
I0
I1
tp23357
sS'than,those,required'
p23358
(F1
F0.00014334862385321102
I1
I0
I1
tp23359
sS'than,users,of'
p23360
(F1
F0.00014334862385321102
I1
I0
I1
tp23361
sS'decongestant,allergy,cold'
p23362
(F1
F0.00014334862385321102
I1
I0
I1
tp23363
sS'serotonin,syndrome,associated'
p23364
(F1
F0.00014334862385321102
I1
I0
I1
tp23365
sS'this,report,describes'
p23366
(F1
F0.00028669724770642203
I2
I0
I2
tp23367
sS'inhibitors,or,angiotensin'
p23368
(F1
F0.00014334862385321102
I0
I1
I-1
tp23369
sS'felbatol,therapy,resulted'
p23370
(F1
F0.00014334862385321102
I0
I1
I-1
tp23371
sS'coadministered,plasma,concentrations'
p23372
(F1
F0.00014334862385321102
I1
I0
I1
tp23373
sS'skills,or,stimulus'
p23374
(F1
F0.00014334862385321102
I0
I1
I-1
tp23375
sS'hour,blood,concentration'
p23376
(F1
F0.00014334862385321102
I1
I0
I1
tp23377
sS'increase,slightly,the'
p23378
(F1
F0.00014334862385321102
I1
I0
I1
tp23379
sS'of,subjects,taking'
p23380
(F1
F0.00014334862385321102
I0
I1
I-1
tp23381
sS'lithium,nsaids,have'
p23382
(F1
F0.00043004587155963305
I3
I0
I3
tp23383
sS'subjects,to,assess'
p23384
(F1
F0.00014334862385321102
I0
I1
I-1
tp23385
sS'decrease,in,serum'
p23386
(F1
F0.00014334862385321102
I1
I0
I1
tp23387
sS'interactions,the,following'
p23388
(F1
F0.00014334862385321102
I0
I1
I-1
tp23389
sS'platelet,inhibitors,acetylsalicylic'
p23390
(F1
F0.00014334862385321102
I0
I1
I-1
tp23391
sS'vitamin,b12,supplement'
p23392
(F1
F0.00014334862385321102
I1
I0
I1
tp23393
sS'with,concomitant,administration'
p23394
(F0
F0
I4
I4
I0
tp23395
sS'if,indocin,is'
p23396
(F1
F0.00014334862385321102
I1
I0
I1
tp23397
sS'suggesting,that,the'
p23398
(F1
F0.00043004587155963305
I3
I0
I3
tp23399
sS'be,used,for'
p23400
(F1
F0.00014334862385321102
I0
I1
I-1
tp23401
sS'high,threshold,voltage-dependent'
p23402
(F1
F0.00014334862385321102
I0
I1
I-1
tp23403
sS'this,enzyme,should'
p23404
(F1
F0.00014334862385321102
I1
I0
I1
tp23405
sS'even,though,has'
p23406
(F1
F0.00028669724770642203
I0
I2
I-2
tp23407
sS'inflammation,associated,with'
p23408
(F1
F0.00014334862385321102
I1
I0
I1
tp23409
sS'of,the,cyp2c9'
p23410
(F1
F0.00014334862385321102
I1
I0
I1
tp23411
sS'the,body,increase'
p23412
(F1
F0.00014334862385321102
I0
I1
I-1
tp23413
sS'apoptosis,assessed,using'
p23414
(F1
F0.00014334862385321102
I1
I0
I1
tp23415
sS'number,of,responses'
p23416
(F1
F0.00014334862385321102
I0
I1
I-1
tp23417
sS'metabolism,of,leading'
p23418
(F1
F0.00057339449541284407
I4
I0
I4
tp23419
sS'test,alterations,associated'
p23420
(F1
F0.00014334862385321102
I0
I1
I-1
tp23421
sS'effects,with,lotensin'
p23422
(F1
F0.00014334862385321102
I1
I0
I1
tp23423
sS'worsen,side,effects'
p23424
(F1
F0.00014334862385321102
I1
I0
I1
tp23425
sS'caution,should,also'
p23426
(F1
F0.00028669724770642203
I0
I2
I-2
tp23427
sS'acid,hcl,ascorbic'
p23428
(F1
F0.00014334862385321102
I1
I0
I1
tp23429
sS'and,therapy,it'
p23430
(F1
F0.00014334862385321102
I1
I0
I1
tp23431
sS'cyp2d6,and,have'
p23432
(F1
F0.00014334862385321102
I0
I1
I-1
tp23433
sS'is,enhanced,by'
p23434
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp23435
sS'mouse,mammary,tumor'
p23436
(F1
F0.00014334862385321102
I0
I1
I-1
tp23437
sS'of,as,assessed'
p23438
(F1
F0.00028669724770642203
I0
I2
I-2
tp23439
sS'formulation,of,increased'
p23440
(F1
F0.00014334862385321102
I1
I0
I1
tp23441
sS'meclofenamate,sodium,does'
p23442
(F1
F0.00014334862385321102
I0
I1
I-1
tp23443
sS'a,greater,proportion'
p23444
(F1
F0.00014334862385321102
I1
I0
I1
tp23445
sS'agents,and,such'
p23446
(F1
F0.00014334862385321102
I1
I0
I1
tp23447
sS'of,severe,toxicity'
p23448
(F1
F0.00014334862385321102
I1
I0
I1
tp23449
sS'effects,when,given'
p23450
(F1
F0.00014334862385321102
I1
I0
I1
tp23451
sS'if,any,clinical'
p23452
(F1
F0.00014334862385321102
I1
I0
I1
tp23453
sS'and,supplemental,in'
p23454
(F1
F0.00014334862385321102
I1
I0
I1
tp23455
sS'dosage,on,equetrotm'
p23456
(F1
F0.00014334862385321102
I1
I0
I1
tp23457
sS'is,metabolized,to'
p23458
(F1
F0.00028669724770642203
I0
I2
I-2
tp23459
sS'history,prior,to'
p23460
(F1
F0.00014334862385321102
I0
I1
I-1
tp23461
sS'carbamazepine,elevated,levels'
p23462
(F1
F0.00014334862385321102
I1
I0
I1
tp23463
sS'of,exjade,and'
p23464
(F1
F0.00028669724770642203
I0
I2
I-2
tp23465
sS'benefit,of,further'
p23466
(F1
F0.00014334862385321102
I1
I0
I1
tp23467
sS'i,with,was'
p23468
(F1
F0.00014334862385321102
I0
I1
I-1
tp23469
sS'comparable,to,mg'
p23470
(F1
F0.00028669724770642203
I2
I0
I2
tp23471
sS'receiving,should,be'
p23472
(F1
F0.00014334862385321102
I1
I0
I1
tp23473
sS'of,these,have'
p23474
(F1
F0.00028669724770642203
I2
I0
I2
tp23475
sS'saline,g,kg'
p23476
(F1
F0.00014334862385321102
I0
I1
I-1
tp23477
sS'ml,of,a'
p23478
(F1
F0.00014334862385321102
I0
I1
I-1
tp23479
sS'controlled,trials,in'
p23480
(F1
F0.00014334862385321102
I0
I1
I-1
tp23481
sS'weight,to,rats'
p23482
(F1
F0.00028669724770642203
I0
I2
I-2
tp23483
sS'cytochromes,p450,a4'
p23484
(F1
F0.00014334862385321102
I0
I1
I-1
tp23485
sS'of,and,respectively'
p23486
(F1
F0.00028669724770642203
I2
I0
I2
tp23487
sS'excretion,was,due'
p23488
(F1
F0.00014334862385321102
I0
I1
I-1
tp23489
sS'decrease,range,from'
p23490
(F1
F0.00014334862385321102
I1
I0
I1
tp23491
sS'monitored,regularly,for'
p23492
(F0
F0
I1
I1
I0
tp23493
sS'given,at,doses'
p23494
(F1
F0.00014334862385321102
I1
I0
I1
tp23495
sS'of,mm,hg'
p23496
(F1
F0.00014334862385321102
I1
I0
I1
tp23497
sS'and,molt-4,cells'
p23498
(F1
F0.00014334862385321102
I1
I0
I1
tp23499
sS'enzyme,may,not'
p23500
(F1
F0.00014334862385321102
I0
I1
I-1
tp23501
sS'be,initiated,at'
p23502
(F1
F0.00014334862385321102
I1
I0
I1
tp23503
sS'hypothermia,as,an'
p23504
(F1
F0.00014334862385321102
I0
I1
I-1
tp23505
sS'some,leading,to'
p23506
(F1
F0.00014334862385321102
I1
I0
I1
tp23507
sS'be,initiated,as'
p23508
(F1
F0.00014334862385321102
I1
I0
I1
tp23509
sS'cyp3a4,inducers,include'
p23510
(F1
F0.00014334862385321102
I0
I1
I-1
tp23511
sS'in,dogs,the'
p23512
(F1
F0.00014334862385321102
I1
I0
I1
tp23513
sS'receiving,concomitant,therapy'
p23514
(F1
F0.00014334862385321102
I0
I1
I-1
tp23515
sS'shown,a,possible'
p23516
(F1
F0.00014334862385321102
I1
I0
I1
tp23517
sS'and,cyp4a11,with'
p23518
(F1
F0.00014334862385321102
I0
I1
I-1
tp23519
sS'some,general,agents'
p23520
(F1
F0.00014334862385321102
I0
I1
I-1
tp23521
sS'was,administered,intravenously'
p23522
(F1
F0.00014334862385321102
I1
I0
I1
tp23523
sS'this,defect,in'
p23524
(F1
F0.00014334862385321102
I0
I1
I-1
tp23525
sS'larger,doses,of'
p23526
(F0
F0
I1
I1
I0
tp23527
sS'increase,in,symptoms'
p23528
(F1
F0.00014334862385321102
I1
I0
I1
tp23529
sS'pigeons,but,did'
p23530
(F1
F0.00014334862385321102
I1
I0
I1
tp23531
sS'of,carbamazepine,due'
p23532
(F1
F0.00014334862385321102
I0
I1
I-1
tp23533
sS'terminal,half-life,of'
p23534
(F1
F0.00014334862385321102
I1
I0
I1
tp23535
sS'pressor,effects,of'
p23536
(F1
F0.00028669724770642203
I2
I0
I2
tp23537
sS'causes,a,marked'
p23538
(F1
F0.00014334862385321102
I1
I0
I1
tp23539
sS'with,co-administered,avonex'
p23540
(F1
F0.00014334862385321102
I0
I1
I-1
tp23541
sS'channels,and,the'
p23542
(F1
F0.00014334862385321102
I0
I1
I-1
tp23543
sS'was,more,than'
p23544
(F1
F0.00014334862385321102
I0
I1
I-1
tp23545
sS'mediated,by,the'
p23546
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp23547
sS'such,as,thiazide'
p23548
(F1
F0.00028669724770642203
I2
I0
I2
tp23549
sS'doses,of,ascorbic'
p23550
(F1
F0.00014334862385321102
I1
I0
I1
tp23551
sS'trivalent,cations,such'
p23552
(F1
F0.00028669724770642203
I2
I0
I2
tp23553
sS'state,and,therefore'
p23554
(F1
F0.00028669724770642203
I2
I0
I2
tp23555
sS'and,thus,should'
p23556
(F1
F0.00014334862385321102
I1
I0
I1
tp23557
sS'be,taken,at'
p23558
(F1
F0.0008600917431192661
I6
I0
I6
tp23559
sS'that,oral,antagonists'
p23560
(F1
F0.00014334862385321102
I1
I0
I1
tp23561
sS'atac,trial,should'
p23562
(F1
F0.00014334862385321102
I1
I0
I1
tp23563
sS'impaired,when,hypothyroid'
p23564
(F1
F0.00014334862385321102
I0
I1
I-1
tp23565
sS'the,fda,have'
p23566
(F1
F0.00014334862385321102
I0
I1
I-1
tp23567
sS'bleeding,has,been'
p23568
(F1
F0.00043004587155963305
I3
I0
I3
tp23569
sS'cns,including,blood'
p23570
(F1
F0.00014334862385321102
I0
I1
I-1
tp23571
sS'acid,fruit,juices'
p23572
(F1
F0.00014334862385321102
I1
I0
I1
tp23573
sS'and,duration,of'
p23574
(F1
F0.00028669724770642203
I2
I0
I2
tp23575
sS'adults,on,a'
p23576
(F1
F0.00014334862385321102
I1
I0
I1
tp23577
sS'an,week,controlled'
p23578
(F1
F0.00014334862385321102
I0
I1
I-1
tp23579
sS'potential,to,interact'
p23580
(F1
F0.00014334862385321102
I0
I1
I-1
tp23581
sS'on,either,levels'
p23582
(F1
F0.00014334862385321102
I0
I1
I-1
tp23583
sS'administering,insp,together'
p23584
(F1
F0.00014334862385321102
I1
I0
I1
tp23585
sS'creatinine,level,has'
p23586
(F1
F0.00014334862385321102
I1
I0
I1
tp23587
sS'transport,pathway,in'
p23588
(F1
F0.00014334862385321102
I0
I1
I-1
tp23589
sS'other,antiplatelet,agents'
p23590
(F1
F0.00014334862385321102
I1
I0
I1
tp23591
sS'toxicity,and,possible'
p23592
(F1
F0.00014334862385321102
I1
I0
I1
tp23593
sS'when,are,administered'
p23594
(F1
F0.00028669724770642203
I2
I0
I2
tp23595
sS'following,concurrent,use'
p23596
(F1
F0.00014334862385321102
I1
I0
I1
tp23597
sS'considered,when,selecting'
p23598
(F1
F0.00014334862385321102
I1
I0
I1
tp23599
sS'are,provided,this'
p23600
(F1
F0.00014334862385321102
I1
I0
I1
tp23601
sS'clonazepam,on,the'
p23602
(F1
F0.00014334862385321102
I0
I1
I-1
tp23603
sS'acid,prolonged,hot'
p23604
(F1
F0.00014334862385321102
I1
I0
I1
tp23605
sS'cyp,a4,enzyme'
p23606
(F1
F0.00014334862385321102
I1
I0
I1
tp23607
sS'these,results,indicate'
p23608
(F1
F0.00014334862385321102
I0
I1
I-1
tp23609
sS'respond,differently,from'
p23610
(F1
F0.00014334862385321102
I0
I1
I-1
tp23611
sS'mg,kg,enhanced'
p23612
(F1
F0.00014334862385321102
I1
I0
I1
tp23613
sS'there,was,no'
p23614
(F0.75
F0.0017201834862385322
I2
I14
I-12
tp23615
sS'of,hypoglycemia,may'
p23616
(F1
F0.00028669724770642203
I0
I2
I-2
tp23617
sS'node,conduction,can'
p23618
(F1
F0.00014334862385321102
I1
I0
I1
tp23619
sS'reuptake,thus,inhibiting'
p23620
(F1
F0.00028669724770642203
I2
I0
I2
tp23621
sS'propanol,mg,kg'
p23622
(F1
F0.00014334862385321102
I1
I0
I1
tp23623
sS'exposure,of,and'
p23624
(F1
F0.00028669724770642203
I2
I0
I2
tp23625
sS'to,be,free'
p23626
(F1
F0.00014334862385321102
I0
I1
I-1
tp23627
sS'decrease,in,binding'
p23628
(F1
F0.00014334862385321102
I1
I0
I1
tp23629
sS'mg,kg,infused'
p23630
(F1
F0.00014334862385321102
I0
I1
I-1
tp23631
sS'dose,of,the'
p23632
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp23633
sS'curve,of,and'
p23634
(F1
F0.00014334862385321102
I0
I1
I-1
tp23635
sS'chlorpropamide,chlorpropamides,plasma'
p23636
(F1
F0.00014334862385321102
I1
I0
I1
tp23637
sS'with,resulted,in'
p23638
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp23639
sS'the,sympathetic,nervous'
p23640
(F1
F0.00014334862385321102
I0
I1
I-1
tp23641
sS'of,factive,had'
p23642
(F1
F0.00014334862385321102
I0
I1
I-1
tp23643
sS'without,a,significant'
p23644
(F1
F0.00014334862385321102
I0
I1
I-1
tp23645
sS'as,and,can'
p23646
(F1
F0.00028669724770642203
I2
I0
I2
tp23647
sS'capsules,and,tablets'
p23648
(F1
F0.00014334862385321102
I1
I0
I1
tp23649
sS'and,has,no'
p23650
(F1
F0.00014334862385321102
I0
I1
I-1
tp23651
sS'therapy,with,hcl'
p23652
(F1
F0.00014334862385321102
I1
I0
I1
tp23653
sS'high,maintenance,dose'
p23654
(F1
F0.00014334862385321102
I1
I0
I1
tp23655
sS'degree,of,apoptosis'
p23656
(F1
F0.00014334862385321102
I1
I0
I1
tp23657
sS'they,are,co-administered'
p23658
(F1
F0.00014334862385321102
I1
I0
I1
tp23659
sS'intestinal,cancers,were'
p23660
(F1
F0.00014334862385321102
I0
I1
I-1
tp23661
sS'enzymes,and,drug'
p23662
(F1
F0.00014334862385321102
I0
I1
I-1
tp23663
sS'dose,of,grams'
p23664
(F1
F0.00014334862385321102
I1
I0
I1
tp23665
sS'repeat,dose,pharmacokinetics'
p23666
(F1
F0.00014334862385321102
I0
I1
I-1
tp23667
sS'before,use,of'
p23668
(F1
F0.00028669724770642203
I2
I0
I2
tp23669
sS'least,a,twofold'
p23670
(F1
F0.00014334862385321102
I1
I0
I1
tp23671
sS'as,may,have'
p23672
(F1
F0.00014334862385321102
I1
I0
I1
tp23673
sS'cyp3a4,in,vitro'
p23674
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp23675
sS'relative,absorption,as'
p23676
(F1
F0.00014334862385321102
I0
I1
I-1
tp23677
sS'pancreatitis,possibly,related'
p23678
(F1
F0.00014334862385321102
I1
I0
I1
tp23679
sS'block,the,antihypertensive'
p23680
(F1
F0.00014334862385321102
I1
I0
I1
tp23681
sS'concentrations,peak,plasma'
p23682
(F1
F0.00014334862385321102
I1
I0
I1
tp23683
sS'and,related,anabolic'
p23684
(F0
F0
I1
I1
I0
tp23685
sS'decreased,the,cmax'
p23686
(F1
F0.00028669724770642203
I2
I0
I2
tp23687
sS'for,pharmacokinetic,drug-drug'
p23688
(F1
F0.00014334862385321102
I0
I1
I-1
tp23689
sS'of,tolerance,in'
p23690
(F1
F0.00014334862385321102
I1
I0
I1
tp23691
sS'and,small,gradual'
p23692
(F1
F0.00014334862385321102
I1
I0
I1
tp23693
sS'mg,oral,dose'
p23694
(F1
F0.00028669724770642203
I0
I2
I-2
tp23695
sS'a,that,is'
p23696
(F1
F0.00028669724770642203
I0
I2
I-2
tp23697
sS'the,inhibitory,effect'
p23698
(F1
F0.00014334862385321102
I1
I0
I1
tp23699
sS'nephrotoxicity,may,cause'
p23700
(F1
F0.00014334862385321102
I1
I0
I1
tp23701
sS'administration,of,toradol'
p23702
(F1
F0.00028669724770642203
I2
I0
I2
tp23703
sS'inhibitors,dipyridamole,may'
p23704
(F1
F0.00014334862385321102
I1
I0
I1
tp23705
sS'metabolism,or,renal'
p23706
(F1
F0.00014334862385321102
I1
I0
I1
tp23707
sS'patients,taking,bextra'
p23708
(F1
F0.00014334862385321102
I1
I0
I1
tp23709
sS'blockers,should,be'
p23710
(F1
F0.00028669724770642203
I2
I0
I2
tp23711
sS'been,found,to'
p23712
(F1
F0.00028669724770642203
I2
I0
I2
tp23713
sS'nimodipine,had,no'
p23714
(F1
F0.00014334862385321102
I0
I1
I-1
tp23715
sS'the,cross-reactivity,of'
p23716
(F1
F0.00014334862385321102
I1
I0
I1
tp23717
sS'the,following,protease'
p23718
(F1
F0.00014334862385321102
I0
I1
I-1
tp23719
sS'expected,since,the'
p23720
(F1
F0.00014334862385321102
I0
I1
I-1
tp23721
sS'lowering,effects,of'
p23722
(F1
F0.00014334862385321102
I1
I0
I1
tp23723
sS'about,and,half-life'
p23724
(F1
F0.00014334862385321102
I1
I0
I1
tp23725
sS'neuromuscular,blocking,properties'
p23726
(F1
F0.00028669724770642203
I2
I0
I2
tp23727
sS'of,by,up'
p23728
(F1
F0.00014334862385321102
I1
I0
I1
tp23729
sS'of,clinical,significance'
p23730
(F1
F0.00014334862385321102
I0
I1
I-1
tp23731
sS'may,suppress,certain'
p23732
(F1
F0.00014334862385321102
I0
I1
I-1
tp23733
sS'of,and,which'
p23734
(F1
F0.00014334862385321102
I1
I0
I1
tp23735
sS'vitro,data,suggest'
p23736
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp23737
sS'those,of,endotoxin-treated'
p23738
(F1
F0.00014334862385321102
I0
I1
I-1
tp23739
sS'through,pharmacokinetic,screening'
p23740
(F1
F0.00014334862385321102
I0
I1
I-1
tp23741
sS'non-steroidal,anti-inflammatory,agent'
p23742
(F1
F0.00028669724770642203
I2
I0
I2
tp23743
sS'cyp3a4,inhibitors,that'
p23744
(F1
F0.00014334862385321102
I1
I0
I1
tp23745
sS'require,lower,doses'
p23746
(F1
F0.0010034403669724771
I0
I7
I-7
tp23747
sS'after,multiple-dose,administration'
p23748
(F1
F0.00014334862385321102
I0
I1
I-1
tp23749
sS'one,study,or'
p23750
(F1
F0.00014334862385321102
I1
I0
I1
tp23751
sS'patient,on,chronic'
p23752
(F1
F0.00014334862385321102
I1
I0
I1
tp23753
sS'blood,levels,at'
p23754
(F1
F0.00014334862385321102
I1
I0
I1
tp23755
sS'cerulein--an,analog,of'
p23756
(F1
F0.00014334862385321102
I0
I1
I-1
tp23757
sS'conditions,had,no'
p23758
(F1
F0.00014334862385321102
I0
I1
I-1
tp23759
sS'observation,of,the'
p23760
(F1
F0.0008600917431192661
I6
I0
I6
tp23761
sS'whenever,a,tca'
p23762
(F1
F0.00057339449541284407
I0
I4
I-4
tp23763
sS'one,study,of'
p23764
(F1
F0.00014334862385321102
I0
I1
I-1
tp23765
sS'significant,interactions,have'
p23766
(F1
F0.00028669724770642203
I0
I2
I-2
tp23767
sS'useof,a,potent'
p23768
(F1
F0.00014334862385321102
I1
I0
I1
tp23769
sS'there,are,conflicting'
p23770
(F1
F0.00014334862385321102
I1
I0
I1
tp23771
sS'were,similar,in'
p23772
(F1
F0.00014334862385321102
I0
I1
I-1
tp23773
sS'levels,should,be'
p23774
(F0.066666666666666666
F0.00014334862385321102
I7
I8
I-1
tp23775
sS'in,unexpectedly,low'
p23776
(F1
F0.00014334862385321102
I1
I0
I1
tp23777
sS'mao,inhibitors,may'
p23778
(F1
F0.00043004587155963305
I3
I0
I3
tp23779
sS'absorption,of,concomitant'
p23780
(F1
F0.00014334862385321102
I1
I0
I1
tp23781
sS'assay,methods,toxi-lab'
p23782
(F1
F0.00014334862385321102
I0
I1
I-1
tp23783
sS'that,an,agent'
p23784
(F1
F0.00014334862385321102
I0
I1
I-1
tp23785
sS'and,transport,were'
p23786
(F1
F0.00014334862385321102
I0
I1
I-1
tp23787
sS'of,arrhythmias,or'
p23788
(F1
F0.00014334862385321102
I0
I1
I-1
tp23789
sS'are,potent,cyp3a'
p23790
(F1
F0.00014334862385321102
I1
I0
I1
tp23791
sS'the,nephrotoxicity,of'
p23792
(F1
F0.00014334862385321102
I1
I0
I1
tp23793
sS'strongly,induce,cyp3a4'
p23794
(F1
F0.00014334862385321102
I1
I0
I1
tp23795
sS'diets,no,effect'
p23796
(F1
F0.00014334862385321102
I0
I1
I-1
tp23797
sS'a,study,of'
p23798
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp23799
sS'had,only,a'
p23800
(F1
F0.00014334862385321102
I1
I0
I1
tp23801
sS'a,sprycel,dose'
p23802
(F1
F0.00014334862385321102
I0
I1
I-1
tp23803
sS'as,feso4,or'
p23804
(F1
F0.00014334862385321102
I1
I0
I1
tp23805
sS'adverse,effects,have'
p23806
(F1
F0.00028669724770642203
I2
I0
I2
tp23807
sS'neomycin,has,no'
p23808
(F1
F0.00014334862385321102
I0
I1
I-1
tp23809
sS'selective,cyp3a4,inhibitor'
p23810
(F1
F0.00014334862385321102
I1
I0
I1
tp23811
sS'have,also,been'
p23812
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp23813
sS'inhibitors,on,the'
p23814
(F1
F0.00014334862385321102
I1
I0
I1
tp23815
sS'cups,of,american'
p23816
(F1
F0.00014334862385321102
I0
I1
I-1
tp23817
sS'in,the,presence'
p23818
(F0.037037037037037035
F0.00014334862385321102
I14
I13
I1
tp23819
sS'similar,regardless,of'
p23820
(F1
F0.00014334862385321102
I0
I1
I-1
tp23821
sS'significant,inhibitors,of'
p23822
(F1
F0.00014334862385321102
I0
I1
I-1
tp23823
sS'affects,the,steady-state'
p23824
(F1
F0.00014334862385321102
I1
I0
I1
tp23825
sS'the,pronounced,intersubject'
p23826
(F1
F0.00014334862385321102
I1
I0
I1
tp23827
sS'this,enzyme,eg'
p23828
(F1
F0.00014334862385321102
I1
I0
I1
tp23829
sS'twice,daily,and'
p23830
(F0
F0
I1
I1
I0
tp23831
sS'co-administration,systemic,levels'
p23832
(F1
F0.00014334862385321102
I0
I1
I-1
tp23833
sS'cyp450,enzyme,would'
p23834
(F1
F0.00014334862385321102
I0
I1
I-1
tp23835
sS'treated,rats,pd2'
p23836
(F1
F0.00014334862385321102
I1
I0
I1
tp23837
sS'of,either,nanm'
p23838
(F1
F0.00014334862385321102
I1
I0
I1
tp23839
sS'may,produce,vertigo'
p23840
(F1
F0.00028669724770642203
I2
I0
I2
tp23841
sS'of,acetate,and'
p23842
(F1
F0.00014334862385321102
I0
I1
I-1
tp23843
sS'both,therapies,standard'
p23844
(F1
F0.00014334862385321102
I0
I1
I-1
tp23845
sS'lesions,in,rats'
p23846
(F1
F0.00014334862385321102
I1
I0
I1
tp23847
sS'greater,than,mm'
p23848
(F1
F0.00014334862385321102
I0
I1
I-1
tp23849
sS'disorders,and,therapy'
p23850
(F1
F0.00014334862385321102
I0
I1
I-1
tp23851
sS'doses,of,are'
p23852
(F1
F0.00014334862385321102
I1
I0
I1
tp23853
sS'especially,if,higher'
p23854
(F1
F0.00014334862385321102
I0
I1
I-1
tp23855
sS'greater,than,mg'
p23856
(F0
F0
I1
I1
I0
tp23857
sS'causes,a,decrease'
p23858
(F1
F0.00014334862385321102
I1
I0
I1
tp23859
sS'certain,antagonists,particularly'
p23860
(F1
F0.00014334862385321102
I1
I0
I1
tp23861
sS'by,a,mg'
p23862
(F1
F0.00028669724770642203
I2
I0
I2
tp23863
sS'an,increased,risk'
p23864
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp23865
sS'gait,or,marked'
p23866
(F1
F0.00014334862385321102
I1
I0
I1
tp23867
sS'shown,no,binding'
p23868
(F1
F0.00014334862385321102
I0
I1
I-1
tp23869
sS'l-arginine,may,increase'
p23870
(F1
F0.00014334862385321102
I1
I0
I1
tp23871
sS'and,angiotensin,on'
p23872
(F1
F0.00014334862385321102
I0
I1
I-1
tp23873
sS'cold,preparations,antidiarrheal'
p23874
(F1
F0.00014334862385321102
I1
I0
I1
tp23875
sS'of,isocarboxazid,may'
p23876
(F1
F0.00014334862385321102
I0
I1
I-1
tp23877
sS'a,sudden,increase'
p23878
(F1
F0.00014334862385321102
I1
I0
I1
tp23879
sS'auc,of,its'
p23880
(F1
F0.00014334862385321102
I1
I0
I1
tp23881
sS'class,iv,cannot'
p23882
(F1
F0.00014334862385321102
I0
I1
I-1
tp23883
sS'concurrent,administration,of'
p23884
(F0.59999999999999998
F0.0025802752293577983
I24
I6
I18
tp23885
sS'of,in,cyp3a4'
p23886
(F1
F0.00014334862385321102
I0
I1
I-1
tp23887
sS'tuberculosa,caused,a'
p23888
(F1
F0.00014334862385321102
I0
I1
I-1
tp23889
sS'decrease,absorption,of'
p23890
(F1
F0.00014334862385321102
I1
I0
I1
tp23891
sS'of,either,and'
p23892
(F0
F0
I1
I1
I0
tp23893
sS'thiazide,agents,and'
p23894
(F1
F0.00014334862385321102
I0
I1
I-1
tp23895
sS'have,occasionally,been'
p23896
(F1
F0.00028669724770642203
I0
I2
I-2
tp23897
sS'to,as,poor'
p23898
(F1
F0.00028669724770642203
I0
I2
I-2
tp23899
sS'with,in,healthy'
p23900
(F1
F0.00043004587155963305
I3
I0
I3
tp23901
sS'of,the,two'
p23902
(F1
F0.00014334862385321102
I1
I0
I1
tp23903
sS'dosage,may,need'
p23904
(F1
F0.00014334862385321102
I1
I0
I1
tp23905
sS'cns,effects,of'
p23906
(F1
F0.00057339449541284407
I4
I0
I4
tp23907
sS'cortical,tissues,of'
p23908
(F1
F0.00014334862385321102
I0
I1
I-1
tp23909
sS'containing,iodine-containing,preparations'
p23910
(F1
F0.00014334862385321102
I0
I1
I-1
tp23911
sS'particular,convulsions,have'
p23912
(F1
F0.00014334862385321102
I1
I0
I1
tp23913
sS'lead,to,loss'
p23914
(F1
F0.00028669724770642203
I0
I2
I-2
tp23915
sS'gabapentin,had,no'
p23916
(F1
F0.00014334862385321102
I0
I1
I-1
tp23917
sS'or,even,clozapine'
p23918
(F1
F0.00014334862385321102
I0
I1
I-1
tp23919
sS'of,the,theophylline-induced'
p23920
(F1
F0.00014334862385321102
I1
I0
I1
tp23921
sS'direct,action,on'
p23922
(F0
F0
I1
I1
I0
tp23923
sS'of,malignant,hyperthermia'
p23924
(F1
F0.00014334862385321102
I1
I0
I1
tp23925
sS'infections,and,no'
p23926
(F1
F0.00014334862385321102
I1
I0
I1
tp23927
sS'eg,flu-like,effects'
p23928
(F1
F0.00014334862385321102
I0
I1
I-1
tp23929
sS'and,inhibitors,of'
p23930
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp23931
sS'muscle,relaxants,birth'
p23932
(F1
F0.00014334862385321102
I0
I1
I-1
tp23933
sS'absorption,of,while'
p23934
(F1
F0.00014334862385321102
I1
I0
I1
tp23935
sS'of,sensipar,on'
p23936
(F1
F0.00014334862385321102
I0
I1
I-1
tp23937
sS'overall,response,rates'
p23938
(F1
F0.00014334862385321102
I0
I1
I-1
tp23939
sS'with,coadministered,with'
p23940
(F1
F0.00014334862385321102
I0
I1
I-1
tp23941
sS'patients,with,lymphoma'
p23942
(F1
F0.00014334862385321102
I0
I1
I-1
tp23943
sS'and,time,course'
p23944
(F1
F0.00014334862385321102
I0
I1
I-1
tp23945
sS'oral,containing,iodine-containing'
p23946
(F1
F0.00014334862385321102
I0
I1
I-1
tp23947
sS'were,divided,into'
p23948
(F1
F0.00014334862385321102
I0
I1
I-1
tp23949
sS'users,particularly,if'
p23950
(F1
F0.00014334862385321102
I1
I0
I1
tp23951
sS'intravenously,to,normal'
p23952
(F1
F0.00014334862385321102
I1
I0
I1
tp23953
sS'significance,as,is'
p23954
(F1
F0.00014334862385321102
I0
I1
I-1
tp23955
sS'of,with,pivoxil'
p23956
(F1
F0.00014334862385321102
I1
I0
I1
tp23957
sS'to,mg,three'
p23958
(F1
F0.00014334862385321102
I1
I0
I1
tp23959
sS'be,co-administered,with'
p23960
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp23961
sS'disintegrating,tablet,was'
p23962
(F1
F0.00014334862385321102
I1
I0
I1
tp23963
sS'tid,was,administered'
p23964
(F1
F0.00014334862385321102
I1
I0
I1
tp23965
sS'suggested,that,or'
p23966
(F1
F0.00014334862385321102
I1
I0
I1
tp23967
sS'concomitant,treatment,in'
p23968
(F1
F0.00014334862385321102
I0
I1
I-1
tp23969
sS'elderly,may,develop'
p23970
(F1
F0.00014334862385321102
I1
I0
I1
tp23971
sS'all,in,patients'
p23972
(F1
F0.00014334862385321102
I0
I1
I-1
tp23973
sS'day,or,prophylactic'
p23974
(F1
F0.00014334862385321102
I0
I1
I-1
tp23975
sS'of,animal,source'
p23976
(F1
F0.00014334862385321102
I0
I1
I-1
tp23977
sS'previously,received,the'
p23978
(F1
F0.00014334862385321102
I1
I0
I1
tp23979
sS'nonsteroidal,agents,are'
p23980
(F1
F0.00014334862385321102
I1
I0
I1
tp23981
sS'values,in,the'
p23982
(F1
F0.00014334862385321102
I0
I1
I-1
tp23983
sS'cause,a,clinically'
p23984
(F1
F0.00014334862385321102
I0
I1
I-1
tp23985
sS'of,in,both'
p23986
(F1
F0.00014334862385321102
I1
I0
I1
tp23987
sS'times,with,or'
p23988
(F1
F0.00014334862385321102
I1
I0
I1
tp23989
sS'valproate,keppra,mg'
p23990
(F1
F0.00014334862385321102
I0
I1
I-1
tp23991
sS'other,progestational,such'
p23992
(F1
F0.00014334862385321102
I0
I1
I-1
tp23993
sS'the,other,hand'
p23994
(F0
F0
I1
I1
I0
tp23995
sS'effects,of,camptosar'
p23996
(F1
F0.00014334862385321102
I1
I0
I1
tp23997
sS'of,nanm,were'
p23998
(F1
F0.00014334862385321102
I1
I0
I1
tp23999
sS'symptoms,that,accompany'
p24000
(F1
F0.00014334862385321102
I1
I0
I1
tp24001
sS'the,bleeding,tendency'
p24002
(F1
F0.00014334862385321102
I1
I0
I1
tp24003
sS'levels,were,unaffected'
p24004
(F1
F0.00014334862385321102
I1
I0
I1
tp24005
sS'other,anti-asthma,medications'
p24006
(F1
F0.00014334862385321102
I0
I1
I-1
tp24007
sS'least,months,received'
p24008
(F1
F0.00014334862385321102
I0
I1
I-1
tp24009
sS'hormonal,are,used'
p24010
(F1
F0.00014334862385321102
I1
I0
I1
tp24011
sS'can,be,mimicked'
p24012
(F1
F0.00014334862385321102
I0
I1
I-1
tp24013
sS'with,and,an'
p24014
(F1
F0.00043004587155963305
I3
I0
I3
tp24015
sS'not,studied,in'
p24016
(F1
F0.00014334862385321102
I0
I1
I-1
tp24017
sS'reduces,urinary,excretion'
p24018
(F1
F0.00014334862385321102
I1
I0
I1
tp24019
sS'agents,in,four'
p24020
(F1
F0.00014334862385321102
I0
I1
I-1
tp24021
sS'significantly,reduced,by'
p24022
(F1
F0.00014334862385321102
I1
I0
I1
tp24023
sS'co-administration,with,or'
p24024
(F1
F0.00014334862385321102
I1
I0
I1
tp24025
sS'men,with,erectile'
p24026
(F1
F0.00014334862385321102
I0
I1
I-1
tp24027
sS'of,are,the'
p24028
(F1
F0.00014334862385321102
I1
I0
I1
tp24029
sS'erythro-fluorocitrate,in,vivo'
p24030
(F1
F0.00014334862385321102
I1
I0
I1
tp24031
sS'determine,whether,has'
p24032
(F1
F0.00014334862385321102
I0
I1
I-1
tp24033
sS'more,or,less'
p24034
(F1
F0.00014334862385321102
I0
I1
I-1
tp24035
sS'agents,that,affect'
p24036
(F1
F0.00014334862385321102
I0
I1
I-1
tp24037
sS'and,serum,txb2'
p24038
(F1
F0.00014334862385321102
I0
I1
I-1
tp24039
sS'drug-drug,interactions,albuterol'
p24040
(F1
F0.00014334862385321102
I1
I0
I1
tp24041
sS'risk,of,bleeding'
p24042
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp24043
sS'garlic,capsules,garlic'
p24044
(F1
F0.00014334862385321102
I0
I1
I-1
tp24045
sS'have,a,delayed'
p24046
(F1
F0.00014334862385321102
I0
I1
I-1
tp24047
sS'for,patients,receiving'
p24048
(F1
F0.00014334862385321102
I0
I1
I-1
tp24049
sS'consisted,of,two'
p24050
(F1
F0.00014334862385321102
I0
I1
I-1
tp24051
sS'risk,of,arrhythmias'
p24052
(F1
F0.00014334862385321102
I0
I1
I-1
tp24053
sS'decreased,have,been'
p24054
(F1
F0.00014334862385321102
I1
I0
I1
tp24055
sS'was,administered,on'
p24056
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp24057
sS'the,diabectics,than'
p24058
(F1
F0.00014334862385321102
I0
I1
I-1
tp24059
sS'effect,of,mg'
p24060
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp24061
sS'ml,day,microg'
p24062
(F1
F0.00014334862385321102
I0
I1
I-1
tp24063
sS'in,preventing,erythro-fluorocitrate'
p24064
(F1
F0.00014334862385321102
I0
I1
I-1
tp24065
sS'of,a,four-day'
p24066
(F1
F0.00014334862385321102
I1
I0
I1
tp24067
sS'instances,resulted,in'
p24068
(F1
F0.00014334862385321102
I1
I0
I1
tp24069
sS'of,concurrently,with'
p24070
(F1
F0.00014334862385321102
I0
I1
I-1
tp24071
sS'the,serotonergic,effects'
p24072
(F1
F0.00014334862385321102
I1
I0
I1
tp24073
sS'substantially,the,incidence'
p24074
(F1
F0.00014334862385321102
I1
I0
I1
tp24075
sS'taking,acamprosate,concomitantly'
p24076
(F1
F0.00014334862385321102
I1
I0
I1
tp24077
sS'distribution,of,was'
p24078
(F1
F0.00014334862385321102
I0
I1
I-1
tp24079
sS'whole-cell,recording,technique'
p24080
(F1
F0.00014334862385321102
I0
I1
I-1
tp24081
sS'compounds,that,have'
p24082
(F1
F0.00014334862385321102
I0
I1
I-1
tp24083
sS'than,expected,plasma'
p24084
(F1
F0.00057339449541284407
I0
I4
I-4
tp24085
sS'zaleplons,maximal,plasma'
p24086
(F1
F0.00014334862385321102
I1
I0
I1
tp24087
sS'of,intravenously,or'
p24088
(F1
F0.00014334862385321102
I0
I1
I-1
tp24089
sS'have,a,risk'
p24090
(F1
F0.00028669724770642203
I2
I0
I2
tp24091
sS'probenecid,a,renal'
p24092
(F1
F0.00014334862385321102
I0
I1
I-1
tp24093
sS'by,cytochrome,p450iid6'
p24094
(F1
F0.00028669724770642203
I0
I2
I-2
tp24095
sS'is,recommended,and'
p24096
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp24097
sS'transient,delirium,has'
p24098
(F1
F0.00014334862385321102
I1
I0
I1
tp24099
sS'important,for,older'
p24100
(F1
F0.00014334862385321102
I0
I1
I-1
tp24101
sS'inducers,of,hepatic'
p24102
(F1
F0.00014334862385321102
I0
I1
I-1
tp24103
sS'hcl,has,also'
p24104
(F1
F0.00014334862385321102
I0
I1
I-1
tp24105
sS'of,over,patients'
p24106
(F1
F0.00014334862385321102
I0
I1
I-1
tp24107
sS'due,to,decreased'
p24108
(F0.5
F0.00028669724770642203
I3
I1
I2
tp24109
sS'c9,c19,and'
p24110
(F1
F0.00014334862385321102
I0
I1
I-1
tp24111
sS'agents,or,including'
p24112
(F1
F0.00014334862385321102
I0
I1
I-1
tp24113
sS'statistically,significant,differences'
p24114
(F1
F0.00014334862385321102
I0
I1
I-1
tp24115
sS'other,suitable,anticoagulation'
p24116
(F1
F0.00014334862385321102
I1
I0
I1
tp24117
sS'and,may,either'
p24118
(F1
F0.00028669724770642203
I2
I0
I2
tp24119
sS'hepatic,oxidation,elc'
p24120
(F1
F0.00014334862385321102
I1
I0
I1
tp24121
sS'some,and,other'
p24122
(F1
F0.00014334862385321102
I1
I0
I1
tp24123
sS'total,cholesterol,mg'
p24124
(F1
F0.00014334862385321102
I0
I1
I-1
tp24125
sS'with,other,pressor'
p24126
(F1
F0.00014334862385321102
I0
I1
I-1
tp24127
sS'to,receive,oral'
p24128
(F1
F0.00014334862385321102
I0
I1
I-1
tp24129
sS'coupled,to,three'
p24130
(F1
F0.00014334862385321102
I0
I1
I-1
tp24131
sS'also,inhibited,insp'
p24132
(F1
F0.00014334862385321102
I1
I0
I1
tp24133
sS'maalox,on,the'
p24134
(F1
F0.00014334862385321102
I0
I1
I-1
tp24135
sS'and,bioavailability,of'
p24136
(F1
F0.00014334862385321102
I1
I0
I1
tp24137
sS'persistent,hypertension,or'
p24138
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24139
sS'in,function,were'
p24140
(F1
F0.00014334862385321102
I0
I1
I-1
tp24141
sS'adjustment,is,necessary'
p24142
(F1
F0.00014334862385321102
I0
I1
I-1
tp24143
sS'extrarenal,mechanisms,of'
p24144
(F1
F0.00014334862385321102
I0
I1
I-1
tp24145
sS'amprenavir,and,low-dose'
p24146
(F1
F0.00014334862385321102
I1
I0
I1
tp24147
sS'significantly,increased,the'
p24148
(F1
F0.00071674311926605509
I5
I0
I5
tp24149
sS'once,daily,doses'
p24150
(F1
F0.00014334862385321102
I1
I0
I1
tp24151
sS'using,the,following'
p24152
(F1
F0.00014334862385321102
I1
I0
I1
tp24153
sS'studied,in,healthy'
p24154
(F1
F0.00028669724770642203
I0
I2
I-2
tp24155
sS'glucose,concentrations,dosage'
p24156
(F1
F0.00014334862385321102
I1
I0
I1
tp24157
sS'however,in,vivo'
p24158
(F1
F0.00043004587155963305
I0
I3
I-3
tp24159
sS'procedures,for,the'
p24160
(F1
F0.00014334862385321102
I0
I1
I-1
tp24161
sS'adjusting,and,discontinuing'
p24162
(F1
F0.00043004587155963305
I3
I0
I3
tp24163
sS'epithelium,by,a'
p24164
(F1
F0.00014334862385321102
I1
I0
I1
tp24165
sS'of,on,plasma'
p24166
(F1
F0.00014334862385321102
I0
I1
I-1
tp24167
sS'digoxin,when,given'
p24168
(F1
F0.00014334862385321102
I0
I1
I-1
tp24169
sS'medication,tell,your'
p24170
(F1
F0.00014334862385321102
I0
I1
I-1
tp24171
sS'concurrently,and,to'
p24172
(F1
F0.00014334862385321102
I0
I1
I-1
tp24173
sS'kappa,and,possibly'
p24174
(F1
F0.00014334862385321102
I0
I1
I-1
tp24175
sS'alternative,hypoglycemic,agents'
p24176
(F1
F0.00014334862385321102
I1
I0
I1
tp24177
sS'arteries,from,dietary-obese'
p24178
(F1
F0.00028669724770642203
I0
I2
I-2
tp24179
sS'or,other,that'
p24180
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp24181
sS'charcoal,administration,of'
p24182
(F1
F0.00014334862385321102
I1
I0
I1
tp24183
sS'sustained-release,channel,blockers'
p24184
(F1
F0.00014334862385321102
I0
I1
I-1
tp24185
sS'single,or,multiple'
p24186
(F1
F0.00014334862385321102
I0
I1
I-1
tp24187
sS'or,generalized,urticaria'
p24188
(F1
F0.00014334862385321102
I0
I1
I-1
tp24189
sS'metabolized,by,the'
p24190
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp24191
sS'the,abundance,and'
p24192
(F1
F0.00014334862385321102
I0
I1
I-1
tp24193
sS'as,a,first-line'
p24194
(F1
F0.00014334862385321102
I0
I1
I-1
tp24195
sS'twice,daily,followed'
p24196
(F1
F0.00014334862385321102
I1
I0
I1
tp24197
sS'inadequate,method,of'
p24198
(F1
F0.00014334862385321102
I1
I0
I1
tp24199
sS'or,maximum,concentration'
p24200
(F1
F0.00014334862385321102
I0
I1
I-1
tp24201
sS'of,pt,and'
p24202
(F1
F0.00014334862385321102
I0
I1
I-1
tp24203
sS'patients,currently,taking'
p24204
(F1
F0.00014334862385321102
I0
I1
I-1
tp24205
sS'anti-inflammatory,activity,with'
p24206
(F1
F0.00014334862385321102
I1
I0
I1
tp24207
sS'to,their,increased'
p24208
(F1
F0.00014334862385321102
I0
I1
I-1
tp24209
sS'of,approximately,and'
p24210
(F1
F0.00028669724770642203
I2
I0
I2
tp24211
sS'or,with,with'
p24212
(F1
F0.00014334862385321102
I1
I0
I1
tp24213
sS'beta,cells,respond'
p24214
(F1
F0.00014334862385321102
I0
I1
I-1
tp24215
sS'with,enhances,the'
p24216
(F1
F0.00014334862385321102
I1
I0
I1
tp24217
sS'either,the,antidepressant'
p24218
(F1
F0.00014334862385321102
I0
I1
I-1
tp24219
sS'with,activity,such'
p24220
(F1
F0.00014334862385321102
I1
I0
I1
tp24221
sS'aminosalicylic,acid,nonsteroidal'
p24222
(F1
F0.00014334862385321102
I1
I0
I1
tp24223
sS'clinically,significant,when'
p24224
(F1
F0.00014334862385321102
I0
I1
I-1
tp24225
sS'effect,should,be'
p24226
(F1
F0.00014334862385321102
I1
I0
I1
tp24227
sS'volume,of,circulating'
p24228
(F1
F0.00014334862385321102
I0
I1
I-1
tp24229
sS'well,as,post'
p24230
(F1
F0.00014334862385321102
I1
I0
I1
tp24231
sS'and,mean,t'
p24232
(F1
F0.00014334862385321102
I1
I0
I1
tp24233
sS'with,has,been'
p24234
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp24235
sS'kg,increased,mean'
p24236
(F1
F0.00014334862385321102
I1
I0
I1
tp24237
sS'lodosyn,and,or'
p24238
(F1
F0.00014334862385321102
I0
I1
I-1
tp24239
sS'in,humans,demonstrated'
p24240
(F1
F0.00014334862385321102
I0
I1
I-1
tp24241
sS'activity,appeared,to'
p24242
(F1
F0.00014334862385321102
I1
I0
I1
tp24243
sS'three,cancer,patients'
p24244
(F1
F0.00014334862385321102
I1
I0
I1
tp24245
sS'was,decreased,in'
p24246
(F1
F0.00014334862385321102
I1
I0
I1
tp24247
sS'fell,by,and'
p24248
(F1
F0.00014334862385321102
I1
I0
I1
tp24249
sS'indomethacin,blunts,the'
p24250
(F1
F0.00014334862385321102
I1
I0
I1
tp24251
sS'racemic,celexa,the'
p24252
(F1
F0.00014334862385321102
I1
I0
I1
tp24253
sS'platelet,aggregation,but'
p24254
(F1
F0.00014334862385321102
I1
I0
I1
tp24255
sS'be,reviewed,after'
p24256
(F1
F0.00014334862385321102
I0
I1
I-1
tp24257
sS'angiomax,and,plasma'
p24258
(F1
F0.00014334862385321102
I0
I1
I-1
tp24259
sS'reduced,upon,discontinuation'
p24260
(F1
F0.00014334862385321102
I1
I0
I1
tp24261
sS'effects,when,co-administered'
p24262
(F1
F0.00014334862385321102
I1
I0
I1
tp24263
sS'monitored,and,appropriate'
p24264
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24265
sS'synthetic,hydroxy-3,methylglutaryl'
p24266
(F1
F0.00014334862385321102
I0
I1
I-1
tp24267
sS'pectoris,additional,effects'
p24268
(F1
F0.00014334862385321102
I1
I0
I1
tp24269
sS'cyp2c9,and,c19'
p24270
(F1
F0.00014334862385321102
I0
I1
I-1
tp24271
sS'decreased,plasma,concentrations'
p24272
(F1
F0.00028669724770642203
I0
I2
I-2
tp24273
sS'or,placebo,and'
p24274
(F1
F0.00014334862385321102
I0
I1
I-1
tp24275
sS'should,be,tested'
p24276
(F1
F0.00014334862385321102
I0
I1
I-1
tp24277
sS'interact,with,tylenol'
p24278
(F1
F0.00014334862385321102
I1
I0
I1
tp24279
sS'and,it,increased'
p24280
(F1
F0.00014334862385321102
I0
I1
I-1
tp24281
sS'of,mg,daily'
p24282
(F1
F0.00043004587155963305
I3
I0
I3
tp24283
sS'inducers,iodinated,cholestographic'
p24284
(F1
F0.00014334862385321102
I0
I1
I-1
tp24285
sS's,d,respectively'
p24286
(F1
F0.00014334862385321102
I1
I0
I1
tp24287
sS'causes,an,approximate'
p24288
(F1
F0.00028669724770642203
I2
I0
I2
tp24289
sS'with,known,to'
p24290
(F1
F0.00014334862385321102
I0
I1
I-1
tp24291
sS'in,auc,of'
p24292
(F1
F0.00014334862385321102
I1
I0
I1
tp24293
sS'there,is,a'
p24294
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp24295
sS'pharmacokinetics,in,healthy'
p24296
(F1
F0.00014334862385321102
I0
I1
I-1
tp24297
sS'pharmacokinetic,analyses,indicate'
p24298
(F1
F0.00043004587155963305
I3
I0
I3
tp24299
sS'only,a,weak'
p24300
(F1
F0.00014334862385321102
I0
I1
I-1
tp24301
sS'the,gonadotropin,levels'
p24302
(F1
F0.00014334862385321102
I0
I1
I-1
tp24303
sS'by,acidifying,agents'
p24304
(F1
F0.00028669724770642203
I2
I0
I2
tp24305
sS'mg,of,equivalent'
p24306
(F1
F0.00014334862385321102
I0
I1
I-1
tp24307
sS'of,aprepitant,and'
p24308
(F0
F0
I1
I1
I0
tp24309
sS'the,function,of'
p24310
(F1
F0.00014334862385321102
I1
I0
I1
tp24311
sS'steady-state,plasma,levels'
p24312
(F1
F0.00014334862385321102
I1
I0
I1
tp24313
sS'of,patients,already'
p24314
(F1
F0.00028669724770642203
I0
I2
I-2
tp24315
sS'elevate,plasma,concentrations'
p24316
(F1
F0.00014334862385321102
I1
I0
I1
tp24317
sS'other,monoamine,oxidase'
p24318
(F1
F0.00014334862385321102
I1
I0
I1
tp24319
sS'with,four,kinds'
p24320
(F1
F0.00014334862385321102
I0
I1
I-1
tp24321
sS'to,nonopioid,tolerant'
p24322
(F1
F0.00014334862385321102
I0
I1
I-1
tp24323
sS'when,other,potent'
p24324
(F1
F0.00014334862385321102
I1
I0
I1
tp24325
sS'however,pretreatment,did'
p24326
(F1
F0.00014334862385321102
I0
I1
I-1
tp24327
sS'no,interactions,have'
p24328
(F1
F0.00028669724770642203
I0
I2
I-2
tp24329
sS'temperature,began,within'
p24330
(F1
F0.00014334862385321102
I0
I1
I-1
tp24331
sS'of,agents,derivatives'
p24332
(F1
F0.00014334862385321102
I0
I1
I-1
tp24333
sS'leading,to,an'
p24334
(F1
F0.00014334862385321102
I0
I1
I-1
tp24335
sS'therapeutic,concentration,monitoring'
p24336
(F1
F0.00014334862385321102
I1
I0
I1
tp24337
sS'resulted,in,an'
p24338
(F0.83333333333333337
F0.0014334862385321102
I11
I1
I10
tp24339
sS'risk,of,toxicity'
p24340
(F1
F0.00028669724770642203
I2
I0
I2
tp24341
sS'including,and,such'
p24342
(F1
F0.00014334862385321102
I1
I0
I1
tp24343
sS'any,excessive,fall'
p24344
(F1
F0.00014334862385321102
I1
I0
I1
tp24345
sS'doses,up,to'
p24346
(F0
F0
I1
I1
I0
tp24347
sS'not,be,coadministered'
p24348
(F0
F0
I1
I1
I0
tp24349
sS'or,a,variety'
p24350
(F1
F0.00014334862385321102
I0
I1
I-1
tp24351
sS'ibuprofen,as,well'
p24352
(F1
F0.00014334862385321102
I1
I0
I1
tp24353
sS'antiretroviral,medications,have'
p24354
(F1
F0.00014334862385321102
I0
I1
I-1
tp24355
sS'supplements,and,and'
p24356
(F1
F0.00014334862385321102
I1
I0
I1
tp24357
sS'hepatic,enzyme,induction'
p24358
(F1
F0.00014334862385321102
I1
I0
I1
tp24359
sS'metabolism,of,and'
p24360
(F1
F0.00071674311926605509
I5
I0
I5
tp24361
sS'or,reduced,infusion'
p24362
(F1
F0.00014334862385321102
I1
I0
I1
tp24363
sS'concomitant,treatment,of'
p24364
(F1
F0.00014334862385321102
I1
I0
I1
tp24365
sS'change,of,percentage'
p24366
(F1
F0.00043004587155963305
I3
I0
I3
tp24367
sS'attenuation,in,the'
p24368
(F1
F0.00014334862385321102
I0
I1
I-1
tp24369
sS'fewer,extrapyramidal,symptoms'
p24370
(F1
F0.00014334862385321102
I0
I1
I-1
tp24371
sS'strong,cyp3a4,inhibitor'
p24372
(F1
F0.00014334862385321102
I1
I0
I1
tp24373
sS'reduce,the,efficacy'
p24374
(F1
F0.00057339449541284407
I4
I0
I4
tp24375
sS'and,in,combination'
p24376
(F1
F0.0008600917431192661
I0
I6
I-6
tp24377
sS'adverse,events,involving'
p24378
(F1
F0.00014334862385321102
I0
I1
I-1
tp24379
sS'of,with,resulted'
p24380
(F1
F0.00014334862385321102
I0
I1
I-1
tp24381
sS'vasodilating,effects,of'
p24382
(F1
F0.00043004587155963305
I3
I0
I3
tp24383
sS'reactions,the,main'
p24384
(F1
F0.00014334862385321102
I1
I0
I1
tp24385
sS'between,and,to'
p24386
(F1
F0.00014334862385321102
I0
I1
I-1
tp24387
sS'the,control,mechanisms'
p24388
(F1
F0.00014334862385321102
I0
I1
I-1
tp24389
sS'of,alternate-day,administration'
p24390
(F1
F0.00014334862385321102
I1
I0
I1
tp24391
sS'in,place,of'
p24392
(F1
F0.00014334862385321102
I1
I0
I1
tp24393
sS'of,four,patients'
p24394
(F1
F0.00014334862385321102
I1
I0
I1
tp24395
sS'auc0-120hr,by,and'
p24396
(F1
F0.00014334862385321102
I1
I0
I1
tp24397
sS'background,the,effects'
p24398
(F1
F0.00014334862385321102
I0
I1
I-1
tp24399
sS'salts,and,may'
p24400
(F1
F0.00028669724770642203
I2
I0
I2
tp24401
sS'of,reactive,species'
p24402
(F1
F0.00014334862385321102
I0
I1
I-1
tp24403
sS'pharmacokinetics,has,not'
p24404
(F1
F0.00014334862385321102
I0
I1
I-1
tp24405
sS'of,mefloquine,may'
p24406
(F1
F0.00014334862385321102
I1
I0
I1
tp24407
sS'd,analogues,which'
p24408
(F1
F0.00043004587155963305
I3
I0
I3
tp24409
sS'decreased,approximately,when'
p24410
(F1
F0.00014334862385321102
I1
I0
I1
tp24411
sS'oral,has,been'
p24412
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp24413
sS'specific,interactions,have'
p24414
(F1
F0.00014334862385321102
I0
I1
I-1
tp24415
sS'indicate,that,dopamine-induced'
p24416
(F1
F0.00014334862385321102
I1
I0
I1
tp24417
sS'plendil,with,resulted'
p24418
(F1
F0.00014334862385321102
I0
I1
I-1
tp24419
sS'have,clinically,important'
p24420
(F1
F0.00028669724770642203
I0
I2
I-2
tp24421
sS'may,be,transiently'
p24422
(F1
F0.00014334862385321102
I0
I1
I-1
tp24423
sS'certain,actions,or'
p24424
(F1
F0.00014334862385321102
I0
I1
I-1
tp24425
sS'was,with,alone'
p24426
(F1
F0.00014334862385321102
I1
I0
I1
tp24427
sS'decreased,prothrom-bin,time'
p24428
(F1
F0.00028669724770642203
I2
I0
I2
tp24429
sS'specific,sulfosalicylic,acid'
p24430
(F1
F0.00014334862385321102
I0
I1
I-1
tp24431
sS'oh,d3,and'
p24432
(F0
F0
I1
I1
I0
tp24433
sS'not,quantitatively,related'
p24434
(F1
F0.00014334862385321102
I0
I1
I-1
tp24435
sS'omnicef,should,be'
p24436
(F1
F0.00028669724770642203
I2
I0
I2
tp24437
sS'pregnancy,has,been'
p24438
(F1
F0.00014334862385321102
I0
I1
I-1
tp24439
sS'some,patients,combined'
p24440
(F1
F0.00014334862385321102
I1
I0
I1
tp24441
sS'and,do,not'
p24442
(F1
F0.00028669724770642203
I0
I2
I-2
tp24443
sS'reported,to,affect'
p24444
(F1
F0.00014334862385321102
I1
I0
I1
tp24445
sS'from,prospective,clinical'
p24446
(F1
F0.00014334862385321102
I0
I1
I-1
tp24447
sS'conduction,disturbances,left'
p24448
(F1
F0.00014334862385321102
I1
I0
I1
tp24449
sS'in,ms,patients'
p24450
(F0
F0
I1
I1
I0
tp24451
sS'commonly,used,in'
p24452
(F1
F0.00057339449541284407
I0
I4
I-4
tp24453
sS'unbound,by,hepatic'
p24454
(F1
F0.00014334862385321102
I1
I0
I1
tp24455
sS'a,three-,to'
p24456
(F1
F0.00014334862385321102
I0
I1
I-1
tp24457
sS'of,on,respiration'
p24458
(F1
F0.00014334862385321102
I0
I1
I-1
tp24459
sS'may,be,exacerbated'
p24460
(F1
F0.00014334862385321102
I1
I0
I1
tp24461
sS'and,loop,and'
p24462
(F1
F0.00014334862385321102
I0
I1
I-1
tp24463
sS'a,cascade,impactor'
p24464
(F1
F0.00014334862385321102
I0
I1
I-1
tp24465
sS'clinically,significant,effects'
p24466
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24467
sS'agents,when,used'
p24468
(F1
F0.00014334862385321102
I1
I0
I1
tp24469
sS'of,and,tablets'
p24470
(F1
F0.00014334862385321102
I1
I0
I1
tp24471
sS'or,in,citrate'
p24472
(F1
F0.00014334862385321102
I0
I1
I-1
tp24473
sS'or,if,therapy'
p24474
(F1
F0.00014334862385321102
I0
I1
I-1
tp24475
sS'of,sensipar,may'
p24476
(F1
F0.00014334862385321102
I1
I0
I1
tp24477
sS'transmission,should,be'
p24478
(F1
F0.00014334862385321102
I0
I1
I-1
tp24479
sS'of,include,optimal'
p24480
(F1
F0.00014334862385321102
I0
I1
I-1
tp24481
sS'inapsine,the,dose'
p24482
(F1
F0.00014334862385321102
I1
I0
I1
tp24483
sS'or,with,videx'
p24484
(F1
F0.00014334862385321102
I1
I0
I1
tp24485
sS'but,not,in'
p24486
(F0.5
F0.00028669724770642203
I3
I1
I2
tp24487
sS'preparations,eg,may'
p24488
(F1
F0.00043004587155963305
I3
I0
I3
tp24489
sS'day,ig,for'
p24490
(F1
F0.00014334862385321102
I1
I0
I1
tp24491
sS'human,liver,microsomes'
p24492
(F0
F0
I1
I1
I0
tp24493
sS'effects,and,may'
p24494
(F1
F0.00043004587155963305
I3
I0
I3
tp24495
sS'acid,binding,may'
p24496
(F1
F0.00014334862385321102
I1
I0
I1
tp24497
sS'when,given,together'
p24498
(F1
F0.00014334862385321102
I0
I1
I-1
tp24499
sS'pharmacodynamic,interaction,as'
p24500
(F1
F0.00014334862385321102
I0
I1
I-1
tp24501
sS'concurrently,administered,with'
p24502
(F1
F0.00028669724770642203
I0
I2
I-2
tp24503
sS'rate,of,metabolism'
p24504
(F1
F0.00014334862385321102
I1
I0
I1
tp24505
sS'daily,and,mg'
p24506
(F1
F0.00014334862385321102
I0
I1
I-1
tp24507
sS'was,superior,to'
p24508
(F1
F0.00014334862385321102
I0
I1
I-1
tp24509
sS'should,be,carefully'
p24510
(F0.5
F0.0008600917431192661
I9
I3
I6
tp24511
sS'presence,of,equetrotm'
p24512
(F1
F0.00014334862385321102
I1
I0
I1
tp24513
sS'patient,populations,the'
p24514
(F1
F0.00014334862385321102
I1
I0
I1
tp24515
sS'at,high,concentration'
p24516
(F1
F0.00014334862385321102
I1
I0
I1
tp24517
sS'to,healthy,subjects'
p24518
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24519
sS'the,initial,step'
p24520
(F1
F0.00014334862385321102
I0
I1
I-1
tp24521
sS'when,administered,concomitantly'
p24522
(F0.5
F0.00028669724770642203
I3
I1
I2
tp24523
sS'narrow,serum,levels'
p24524
(F1
F0.00014334862385321102
I0
I1
I-1
tp24525
sS'higher,in,patients'
p24526
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp24527
sS'potentiate,the,adverse'
p24528
(F1
F0.00014334862385321102
I1
I0
I1
tp24529
sS'subsequent,adjustment,of'
p24530
(F1
F0.00014334862385321102
I0
I1
I-1
tp24531
sS'aldomet,use,of'
p24532
(F1
F0.00014334862385321102
I1
I0
I1
tp24533
sS'potentiated,the,positive'
p24534
(F1
F0.00014334862385321102
I1
I0
I1
tp24535
sS'of,spermatozoa,from'
p24536
(F1
F0.00014334862385321102
I0
I1
I-1
tp24537
sS'these,studies,are'
p24538
(F1
F0.00014334862385321102
I0
I1
I-1
tp24539
sS'reduced,extent,of'
p24540
(F1
F0.00014334862385321102
I1
I0
I1
tp24541
sS'whether,injection,of'
p24542
(F1
F0.00014334862385321102
I0
I1
I-1
tp24543
sS'should,be,made'
p24544
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24545
sS'supplemental,in,a'
p24546
(F1
F0.00014334862385321102
I1
I0
I1
tp24547
sS'changes,occurred,in'
p24548
(F1
F0.00014334862385321102
I0
I1
I-1
tp24549
sS'polyphenols,as,potent'
p24550
(F1
F0.00014334862385321102
I0
I1
I-1
tp24551
sS'and,the,labeling'
p24552
(F1
F0.00014334862385321102
I0
I1
I-1
tp24553
sS'nsaids,without,evidence'
p24554
(F1
F0.00014334862385321102
I0
I1
I-1
tp24555
sS'when,concomitant,therapy'
p24556
(F1
F0.00014334862385321102
I1
I0
I1
tp24557
sS'enzymes,inducers,or'
p24558
(F1
F0.00014334862385321102
I0
I1
I-1
tp24559
sS'isolated,reports,of'
p24560
(F1
F0.00043004587155963305
I3
I0
I3
tp24561
sS'are,given,to'
p24562
(F1
F0.00014334862385321102
I1
I0
I1
tp24563
sS'itraconazole,has,led'
p24564
(F1
F0.00014334862385321102
I1
I0
I1
tp24565
sS'amount,of,absorbed'
p24566
(F0
F0
I1
I1
I0
tp24567
sS'than,for,auc'
p24568
(F1
F0.00014334862385321102
I1
I0
I1
tp24569
sS'demonstrate,that,the'
p24570
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp24571
sS'quinolones,form,chelates'
p24572
(F1
F0.00028669724770642203
I0
I2
I-2
tp24573
sS'all,central,nervous'
p24574
(F1
F0.00014334862385321102
I1
I0
I1
tp24575
sS'levels,or,fasting'
p24576
(F1
F0.00014334862385321102
I0
I1
I-1
tp24577
sS'patients,receiving,antabuse'
p24578
(F1
F0.00014334862385321102
I1
I0
I1
tp24579
sS'human,immunodeficiency,virus-positive'
p24580
(F1
F0.00014334862385321102
I0
I1
I-1
tp24581
sS'those,taking,therapy'
p24582
(F1
F0.00014334862385321102
I1
I0
I1
tp24583
sS'risk,of,agranulocytosis'
p24584
(F1
F0.00014334862385321102
I0
I1
I-1
tp24585
sS'healthy,volunteers,hydrochloride'
p24586
(F1
F0.00014334862385321102
I1
I0
I1
tp24587
sS'in,all,subjects'
p24588
(F1
F0.00014334862385321102
I1
I0
I1
tp24589
sS'have,an,additive'
p24590
(F1
F0.0010034403669724771
I7
I0
I7
tp24591
sS'as,or,concurrent'
p24592
(F1
F0.00014334862385321102
I0
I1
I-1
tp24593
sS'a,previously,unrecognized'
p24594
(F1
F0.00014334862385321102
I1
I0
I1
tp24595
sS'tubular,secretion,via'
p24596
(F1
F0.00014334862385321102
I1
I0
I1
tp24597
sS'dosage,of,the'
p24598
(F1
F0.00014334862385321102
I1
I0
I1
tp24599
sS'activated,during,photic'
p24600
(F1
F0.00014334862385321102
I0
I1
I-1
tp24601
sS'when,using,or'
p24602
(F1
F0.00014334862385321102
I1
I0
I1
tp24603
sS'arrival,of,oral'
p24604
(F1
F0.00014334862385321102
I0
I1
I-1
tp24605
sS'system,decreased,effect'
p24606
(F1
F0.00014334862385321102
I0
I1
I-1
tp24607
sS'of,using,an'
p24608
(F1
F0.00014334862385321102
I1
I0
I1
tp24609
sS'to,that,seen'
p24610
(F1
F0.00014334862385321102
I0
I1
I-1
tp24611
sS'of,changed,the'
p24612
(F1
F0.00014334862385321102
I1
I0
I1
tp24613
sS'in,sprycel,should'
p24614
(F1
F0.00014334862385321102
I0
I1
I-1
tp24615
sS'since,cholestyramine,resin'
p24616
(F1
F0.00014334862385321102
I0
I1
I-1
tp24617
sS'monitored,with,dosage'
p24618
(F1
F0.00014334862385321102
I0
I1
I-1
tp24619
sS'concomitantly,with,sustained-release'
p24620
(F1
F0.00014334862385321102
I0
I1
I-1
tp24621
sS'and,respectively,after'
p24622
(F1
F0.00014334862385321102
I1
I0
I1
tp24623
sS'enzyme,inhibitor,the'
p24624
(F1
F0.00014334862385321102
I1
I0
I1
tp24625
sS'lower,and,exposure'
p24626
(F1
F0.00014334862385321102
I1
I0
I1
tp24627
sS'initial,clinical,data'
p24628
(F1
F0.00014334862385321102
I0
I1
I-1
tp24629
sS'anesthetics,general,exaggeration'
p24630
(F1
F0.00014334862385321102
I1
I0
I1
tp24631
sS'of,to,patients'
p24632
(F1
F0.00071674311926605509
I5
I0
I5
tp24633
sS'diuretics,lotensin,can'
p24634
(F1
F0.00014334862385321102
I1
I0
I1
tp24635
sS'and,or,hypotension'
p24636
(F1
F0.00014334862385321102
I1
I0
I1
tp24637
sS'and,adverse,events'
p24638
(F1
F0.00014334862385321102
I0
I1
I-1
tp24639
sS'that,or,co-administration'
p24640
(F1
F0.00014334862385321102
I1
I0
I1
tp24641
sS'elimination,rate,constant'
p24642
(F1
F0.00014334862385321102
I0
I1
I-1
tp24643
sS'old,participated,in'
p24644
(F1
F0.00014334862385321102
I0
I1
I-1
tp24645
sS'reported,l-histidine,via'
p24646
(F1
F0.00014334862385321102
I1
I0
I1
tp24647
sS'be,taken,with'
p24648
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp24649
sS'risk,of,serious'
p24650
(F1
F0.0008600917431192661
I6
I0
I6
tp24651
sS'sucralfate,administered,hours'
p24652
(F1
F0.00014334862385321102
I1
I0
I1
tp24653
sS'treated,with,nalfon'
p24654
(F1
F0.00014334862385321102
I1
I0
I1
tp24655
sS'effects,on,discrimination'
p24656
(F1
F0.00014334862385321102
I0
I1
I-1
tp24657
sS'therefore,no,adjustment'
p24658
(F1
F0.00014334862385321102
I0
I1
I-1
tp24659
sS'narcotic,general,such'
p24660
(F1
F0.00014334862385321102
I1
I0
I1
tp24661
sS'inhibit,prostaglandin,synthesis'
p24662
(F1
F0.00014334862385321102
I1
I0
I1
tp24663
sS'containing,carbohydrate-splitting,enzymes'
p24664
(F1
F0.00014334862385321102
I1
I0
I1
tp24665
sS'exacerbate,the,rebound'
p24666
(F1
F0.00014334862385321102
I1
I0
I1
tp24667
sS'effects,celebrex,is'
p24668
(F1
F0.00014334862385321102
I0
I1
I-1
tp24669
sS'reported,in,studies'
p24670
(F1
F0.00014334862385321102
I0
I1
I-1
tp24671
sS'reported,examples,include'
p24672
(F1
F0.00014334862385321102
I0
I1
I-1
tp24673
sS'of,by,cytochrome'
p24674
(F1
F0.00014334862385321102
I1
I0
I1
tp24675
sS'benefits,outweigh,the'
p24676
(F1
F0.00028669724770642203
I2
I0
I2
tp24677
sS'superiority,of,over'
p24678
(F1
F0.00014334862385321102
I0
I1
I-1
tp24679
sS'significantly,more,frequently'
p24680
(F1
F0.00014334862385321102
I0
I1
I-1
tp24681
sS'excreted,levels,of'
p24682
(F1
F0.00014334862385321102
I0
I1
I-1
tp24683
sS'and,frequently,enough'
p24684
(F1
F0.00014334862385321102
I1
I0
I1
tp24685
sS'hypotension,related,to'
p24686
(F0
F0
I1
I1
I0
tp24687
sS'when,compared,to'
p24688
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp24689
sS'of,infection,in'
p24690
(F1
F0.00014334862385321102
I1
I0
I1
tp24691
sS'to,either,alone'
p24692
(F1
F0.00014334862385321102
I1
I0
I1
tp24693
sS'to,one-half,the'
p24694
(F1
F0.00014334862385321102
I1
I0
I1
tp24695
sS'exposed,histidine,residues'
p24696
(F1
F0.00014334862385321102
I0
I1
I-1
tp24697
sS'ketoconazole,co-administration,of'
p24698
(F1
F0.00028669724770642203
I2
I0
I2
tp24699
sS'patient,initiates,or'
p24700
(F1
F0.00014334862385321102
I1
I0
I1
tp24701
sS'was,generally,converted'
p24702
(F1
F0.00014334862385321102
I1
I0
I1
tp24703
sS'placebo-controlled,phase,i'
p24704
(F1
F0.00014334862385321102
I0
I1
I-1
tp24705
sS'inh,isoniazid,is'
p24706
(F1
F0.00014334862385321102
I1
I0
I1
tp24707
sS'metabolism,hormone,action'
p24708
(F1
F0.00014334862385321102
I0
I1
I-1
tp24709
sS'that,co-administration,of'
p24710
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp24711
sS'is,known,that'
p24712
(F1
F0.00028669724770642203
I2
I0
I2
tp24713
sS'degenerative,changes,in'
p24714
(F1
F0.00014334862385321102
I0
I1
I-1
tp24715
sS'with,increasing,the'
p24716
(F1
F0.00014334862385321102
I1
I0
I1
tp24717
sS'if,replacement,is'
p24718
(F1
F0.00014334862385321102
I0
I1
I-1
tp24719
sS'moderate,hypertension,administration'
p24720
(F1
F0.00028669724770642203
I2
I0
I2
tp24721
sS'blood,glucose,should'
p24722
(F1
F0.00014334862385321102
I1
I0
I1
tp24723
sS'been,used,successfully'
p24724
(F1
F0.00028669724770642203
I0
I2
I-2
tp24725
sS'significantly,influence,the'
p24726
(F1
F0.00014334862385321102
I0
I1
I-1
tp24727
sS'warfarin,increased,inr'
p24728
(F1
F0.00014334862385321102
I1
I0
I1
tp24729
sS'with,tablets,an'
p24730
(F1
F0.00014334862385321102
I1
I0
I1
tp24731
sS'to,use,of'
p24732
(F1
F0.00028669724770642203
I2
I0
I2
tp24733
sS'max,were,observed'
p24734
(F1
F0.00014334862385321102
I0
I1
I-1
tp24735
sS'than,doubled,in'
p24736
(F1
F0.00014334862385321102
I0
I1
I-1
tp24737
sS'such,as,has'
p24738
(F1
F0.00014334862385321102
I1
I0
I1
tp24739
sS'species,nanm,but'
p24740
(F1
F0.00014334862385321102
I1
I0
I1
tp24741
sS'urinary,excretion,of'
p24742
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp24743
sS'metabolite,exposure,by'
p24744
(F1
F0.00014334862385321102
I1
I0
I1
tp24745
sS'duloxetine,may,have'
p24746
(F1
F0.00014334862385321102
I0
I1
I-1
tp24747
sS'their,prothrombin,times'
p24748
(F1
F0.00014334862385321102
I1
I0
I1
tp24749
sS'not,antagonized,by'
p24750
(F1
F0.00014334862385321102
I0
I1
I-1
tp24751
sS'the,control,of'
p24752
(F1
F0.00014334862385321102
I0
I1
I-1
tp24753
sS'and,antagonism,in'
p24754
(F1
F0.00014334862385321102
I1
I0
I1
tp24755
sS'celexa,in,a'
p24756
(F1
F0.00014334862385321102
I1
I0
I1
tp24757
sS'possible,anticholinesterase,agents'
p24758
(F1
F0.00014334862385321102
I1
I0
I1
tp24759
sS'o-desacetyl,metabolites,were'
p24760
(F1
F0.00014334862385321102
I0
I1
I-1
tp24761
sS'metabolism,of,resulting'
p24762
(F1
F0.0012901376146788992
I9
I0
I9
tp24763
sS'dose,when,administered'
p24764
(F1
F0.00014334862385321102
I1
I0
I1
tp24765
sS'ldl-c,reduction,was'
p24766
(F1
F0.00014334862385321102
I1
I0
I1
tp24767
sS'control,of,naflu'
p24768
(F1
F0.00014334862385321102
I0
I1
I-1
tp24769
sS'inhibitors,eg,and'
p24770
(F1
F0.00014334862385321102
I1
I0
I1
tp24771
sS'mediate,the,metabolism'
p24772
(F1
F0.00014334862385321102
I0
I1
I-1
tp24773
sS'of,certain,thereby'
p24774
(F1
F0.00014334862385321102
I1
I0
I1
tp24775
sS'cns,depression,producing'
p24776
(F1
F0.00014334862385321102
I0
I1
I-1
tp24777
sS'was,observed,which'
p24778
(F1
F0.00028669724770642203
I2
I0
I2
tp24779
sS'to,cause,clinically'
p24780
(F1
F0.00014334862385321102
I0
I1
I-1
tp24781
sS'be,no,pharmacokinetic'
p24782
(F1
F0.00014334862385321102
I0
I1
I-1
tp24783
sS'was,administered,after'
p24784
(F1
F0.00014334862385321102
I0
I1
I-1
tp24785
sS'should,provide,the'
p24786
(F1
F0.00014334862385321102
I0
I1
I-1
tp24787
sS'receiving,may,be'
p24788
(F1
F0.00014334862385321102
I1
I0
I1
tp24789
sS'of,clinical,status'
p24790
(F1
F0.00014334862385321102
I1
I0
I1
tp24791
sS'epithelium,in,rpmi1640'
p24792
(F1
F0.00014334862385321102
I1
I0
I1
tp24793
sS'or,within,weeks'
p24794
(F1
F0.00014334862385321102
I1
I0
I1
tp24795
sS'place,of,h2'
p24796
(F1
F0.00014334862385321102
I1
I0
I1
tp24797
sS'disease,control,by'
p24798
(F1
F0.00014334862385321102
I1
I0
I1
tp24799
sS'mesylate,may,interact'
p24800
(F1
F0.00014334862385321102
I1
I0
I1
tp24801
sS'renal,clearance,in'
p24802
(F1
F0.00028669724770642203
I2
I0
I2
tp24803
sS'creatinine,an,endogenous'
p24804
(F1
F0.00014334862385321102
I1
I0
I1
tp24805
sS'is,unknown,and'
p24806
(F1
F0.00014334862385321102
I1
I0
I1
tp24807
sS'for,patients,with'
p24808
(F0
F0
I1
I1
I0
tp24809
sS'efficacy,of,orencia'
p24810
(F1
F0.00014334862385321102
I1
I0
I1
tp24811
sS'coadministered,with,resulting'
p24812
(F1
F0.00014334862385321102
I1
I0
I1
tp24813
sS'and,developed,neutropenia'
p24814
(F1
F0.00028669724770642203
I2
I0
I2
tp24815
sS'similar,interaction,between'
p24816
(F1
F0.00014334862385321102
I0
I1
I-1
tp24817
sS'significantly,reduces,the'
p24818
(F1
F0.00014334862385321102
I1
I0
I1
tp24819
sS'risk,of,habituation'
p24820
(F1
F0.00014334862385321102
I0
I1
I-1
tp24821
sS'may,have,clinically'
p24822
(F1
F0.00014334862385321102
I1
I0
I1
tp24823
sS'also,interfere,with'
p24824
(F1
F0.00014334862385321102
I1
I0
I1
tp24825
sS'acetaminophen,may,increase'
p24826
(F1
F0.00014334862385321102
I1
I0
I1
tp24827
sS'the,cellular,basis'
p24828
(F1
F0.00014334862385321102
I0
I1
I-1
tp24829
sS'cyp3a4,inducer,at'
p24830
(F1
F0.00014334862385321102
I1
I0
I1
tp24831
sS'diarrhea,and,dehydration'
p24832
(F1
F0.00014334862385321102
I1
I0
I1
tp24833
sS'have,been,associated'
p24834
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp24835
sS'pronounced,than,in'
p24836
(F1
F0.00014334862385321102
I0
I1
I-1
tp24837
sS'iva,p-type,in'
p24838
(F1
F0.00014334862385321102
I0
I1
I-1
tp24839
sS'absorption,resulting,in'
p24840
(F1
F0.00043004587155963305
I3
I0
I3
tp24841
sS'two,to,three'
p24842
(F1
F0.00014334862385321102
I1
I0
I1
tp24843
sS'specific,regulation,of'
p24844
(F1
F0.00014334862385321102
I0
I1
I-1
tp24845
sS'in,decreased,plasma'
p24846
(F0
F0
I1
I1
I0
tp24847
sS'effect,of,increased'
p24848
(F1
F0.00028669724770642203
I0
I2
I-2
tp24849
sS'isoenzyme,in,vivo'
p24850
(F1
F0.00014334862385321102
I1
I0
I1
tp24851
sS'demonstrated,that,concomitant'
p24852
(F1
F0.00014334862385321102
I1
I0
I1
tp24853
sS'hypercholesterolemia,concomitant,administration'
p24854
(F1
F0.00014334862385321102
I0
I1
I-1
tp24855
sS'could,result,in'
p24856
(F1
F0.00014334862385321102
I0
I1
I-1
tp24857
sS'therefore,the,combination'
p24858
(F1
F0.00028669724770642203
I2
I0
I2
tp24859
sS'these,on,plasma'
p24860
(F1
F0.00014334862385321102
I0
I1
I-1
tp24861
sS'p450,a,family'
p24862
(F1
F0.00014334862385321102
I0
I1
I-1
tp24863
sS'metabolites,with,a'
p24864
(F1
F0.00014334862385321102
I1
I0
I1
tp24865
sS'or,does,not'
p24866
(F1
F0.00028669724770642203
I0
I2
I-2
tp24867
sS'serum,concentration,especially'
p24868
(F1
F0.00014334862385321102
I1
I0
I1
tp24869
sS'synergism,between,xanthine'
p24870
(F1
F0.00014334862385321102
I1
I0
I1
tp24871
sS'like,mg,kg'
p24872
(F1
F0.00014334862385321102
I0
I1
I-1
tp24873
sS'carbamazepine,concomitant,administration'
p24874
(F1
F0.00014334862385321102
I1
I0
I1
tp24875
sS'been,reported,to'
p24876
(F0.76666666666666672
F0.0065940366972477068
I53
I7
I46
tp24877
sS'see,a,href'
p24878
(F1
F0.00028669724770642203
I2
I0
I2
tp24879
sS'therefore,administration,of'
p24880
(F1
F0.00028669724770642203
I0
I2
I-2
tp24881
sS'of,racemic,were'
p24882
(F1
F0.00014334862385321102
I0
I1
I-1
tp24883
sS'effects,an,blood'
p24884
(F1
F0.00014334862385321102
I1
I0
I1
tp24885
sS'thinners,coumadin,other'
p24886
(F1
F0.00014334862385321102
I0
I1
I-1
tp24887
sS'were,reduced,in'
p24888
(F1
F0.00014334862385321102
I0
I1
I-1
tp24889
sS'pharmacokinetics,of,at'
p24890
(F1
F0.00028669724770642203
I0
I2
I-2
tp24891
sS'oral,dose,had'
p24892
(F1
F0.00014334862385321102
I0
I1
I-1
tp24893
sS'inhibit,cytochrome,p450'
p24894
(F1
F0.0008600917431192661
I0
I6
I-6
tp24895
sS'on,the,rate'
p24896
(F1
F0.00028669724770642203
I0
I2
I-2
tp24897
sS'inhibitors,include,azole'
p24898
(F1
F0.00014334862385321102
I0
I1
I-1
tp24899
sS'cause,or,be'
p24900
(F1
F0.00014334862385321102
I0
I1
I-1
tp24901
sS'caused,a,decrease'
p24902
(F1
F0.00014334862385321102
I1
I0
I1
tp24903
sS'more,potent,in'
p24904
(F1
F0.00014334862385321102
I0
I1
I-1
tp24905
sS'vitamin,c,g'
p24906
(F1
F0.00014334862385321102
I1
I0
I1
tp24907
sS'taking,when,macrolide'
p24908
(F1
F0.00014334862385321102
I0
I1
I-1
tp24909
sS'cyp3a4,eg,may'
p24910
(F1
F0.00028669724770642203
I2
I0
I2
tp24911
sS'omega-agatoxin,via-resistant,presumptive'
p24912
(F1
F0.00014334862385321102
I0
I1
I-1
tp24913
sS'pharmacokinetics,of,an'
p24914
(F1
F0.00014334862385321102
I0
I1
I-1
tp24915
sS'controlled,clinical,pharmacology'
p24916
(F1
F0.00014334862385321102
I0
I1
I-1
tp24917
sS'ampicillin,in,a'
p24918
(F1
F0.00014334862385321102
I1
I0
I1
tp24919
sS'weeks,and,and'
p24920
(F1
F0.00014334862385321102
I0
I1
I-1
tp24921
sS'peak,plasma,concentration'
p24922
(F1
F0.00014334862385321102
I1
I0
I1
tp24923
sS'antifungal,agents,protease'
p24924
(F1
F0.00014334862385321102
I1
I0
I1
tp24925
sS'treated,with,should'
p24926
(F1
F0.00014334862385321102
I1
I0
I1
tp24927
sS'increased,concentrations,and'
p24928
(F1
F0.00014334862385321102
I0
I1
I-1
tp24929
sS'and,ldl-c,reduction'
p24930
(F1
F0.00014334862385321102
I0
I1
I-1
tp24931
sS'concentration,cmax,of'
p24932
(F1
F0.00028669724770642203
I0
I2
I-2
tp24933
sS'to,the,interactions'
p24934
(F1
F0.00014334862385321102
I0
I1
I-1
tp24935
sS't3,in,the'
p24936
(F1
F0.00014334862385321102
I1
I0
I1
tp24937
sS'and,concomitantly,should'
p24938
(F1
F0.00014334862385321102
I1
I0
I1
tp24939
sS'd,for,days'
p24940
(F1
F0.00028669724770642203
I2
I0
I2
tp24941
sS'containing,to,patients'
p24942
(F1
F0.00014334862385321102
I1
I0
I1
tp24943
sS'aczone,gel,in'
p24944
(F1
F0.00014334862385321102
I0
I1
I-1
tp24945
sS'or,increased,metabolic'
p24946
(F1
F0.00014334862385321102
I1
I0
I1
tp24947
sS'adequate,respiratory,exchange'
p24948
(F1
F0.00014334862385321102
I0
I1
I-1
tp24949
sS'order,to,examine'
p24950
(F1
F0.00014334862385321102
I0
I1
I-1
tp24951
sS'metabolized,triazolo-benzodiazepines,dihydropyridine'
p24952
(F1
F0.00014334862385321102
I1
I0
I1
tp24953
sS'mg,was,coadministered'
p24954
(F1
F0.00028669724770642203
I2
I0
I2
tp24955
sS'level,of,platelet'
p24956
(F1
F0.00014334862385321102
I0
I1
I-1
tp24957
sS'certain,or,or'
p24958
(F1
F0.00014334862385321102
I1
I0
I1
tp24959
sS'effect,may,be'
p24960
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp24961
sS'because,is,displaced'
p24962
(F1
F0.00028669724770642203
I2
I0
I2
tp24963
sS'is,likely,viracept'
p24964
(F1
F0.00014334862385321102
I1
I0
I1
tp24965
sS'under,steady,state'
p24966
(F1
F0.00028669724770642203
I0
I2
I-2
tp24967
sS'effects,in,humans'
p24968
(F1
F0.00014334862385321102
I0
I1
I-1
tp24969
sS'of,only,in'
p24970
(F1
F0.00028669724770642203
I2
I0
I2
tp24971
sS'the,united,states'
p24972
(F1
F0.00014334862385321102
I0
I1
I-1
tp24973
sS'with,oral,was'
p24974
(F1
F0.00014334862385321102
I1
I0
I1
tp24975
sS'mesylate,with,other'
p24976
(F1
F0.00014334862385321102
I1
I0
I1
tp24977
sS'these,does,not'
p24978
(F1
F0.00014334862385321102
I0
I1
I-1
tp24979
sS'of,any,pharmacokinetic'
p24980
(F1
F0.00014334862385321102
I0
I1
I-1
tp24981
sS'evidence,has,shown'
p24982
(F1
F0.00014334862385321102
I1
I0
I1
tp24983
sS'doses,of,low'
p24984
(F1
F0.00014334862385321102
I0
I1
I-1
tp24985
sS'at,periodic,intervals'
p24986
(F1
F0.00014334862385321102
I1
I0
I1
tp24987
sS'to,hypoparathyroid,patients'
p24988
(F1
F0.00028669724770642203
I2
I0
I2
tp24989
sS'and,august,were'
p24990
(F1
F0.00014334862385321102
I0
I1
I-1
tp24991
sS'ml,with,the'
p24992
(F1
F0.00014334862385321102
I0
I1
I-1
tp24993
sS'can,inhibit,the'
p24994
(F1
F0.00028669724770642203
I2
I0
I2
tp24995
sS'healthy,males,in'
p24996
(F1
F0.00014334862385321102
I0
I1
I-1
tp24997
sS'and,most,may'
p24998
(F1
F0.00014334862385321102
I0
I1
I-1
tp24999
sS'studies,of,heroin-related'
p25000
(F1
F0.00014334862385321102
I1
I0
I1
tp25001
sS'ibandronate,mg,once'
p25002
(F1
F0.00014334862385321102
I0
I1
I-1
tp25003
sS'not,recommended,it'
p25004
(F1
F0.00014334862385321102
I1
I0
I1
tp25005
sS'monitoring,or,consider'
p25006
(F1
F0.00014334862385321102
I1
I0
I1
tp25007
sS'be,receiving,both'
p25008
(F1
F0.00014334862385321102
I1
I0
I1
tp25009
sS'pressure,by,inhibiting'
p25010
(F1
F0.00014334862385321102
I1
I0
I1
tp25011
sS'with,two,doses'
p25012
(F1
F0.00014334862385321102
I0
I1
I-1
tp25013
sS'that,can,potentiate'
p25014
(F1
F0.00014334862385321102
I1
I0
I1
tp25015
sS'cardiac,h2,antagonists'
p25016
(F1
F0.00014334862385321102
I0
I1
I-1
tp25017
sS'administered,starlix,mg'
p25018
(F1
F0.00014334862385321102
I0
I1
I-1
tp25019
sS'pharmaceutical,abstracts,using'
p25020
(F1
F0.00014334862385321102
I0
I1
I-1
tp25021
sS'in,slight,increases'
p25022
(F1
F0.00014334862385321102
I1
I0
I1
tp25023
sS'aeds,affects,the'
p25024
(F1
F0.00014334862385321102
I1
I0
I1
tp25025
sS'of,potentially,leading'
p25026
(F1
F0.00014334862385321102
I1
I0
I1
tp25027
sS'bioavailability,studies,with'
p25028
(F1
F0.00014334862385321102
I0
I1
I-1
tp25029
sS'increased,the,cmax'
p25030
(F1
F0.00043004587155963305
I3
I0
I3
tp25031
sS'was,also,verified'
p25032
(F1
F0.00014334862385321102
I0
I1
I-1
tp25033
sS'presence,of,caused'
p25034
(F1
F0.00014334862385321102
I0
I1
I-1
tp25035
sS'if,any,signs'
p25036
(F1
F0.00014334862385321102
I1
I0
I1
tp25037
sS'studies,intravenous,has'
p25038
(F1
F0.00014334862385321102
I0
I1
I-1
tp25039
sS'toxicity,has,been'
p25040
(F1
F0.00057339449541284407
I4
I0
I4
tp25041
sS'and,absorption,and'
p25042
(F1
F0.00014334862385321102
I0
I1
I-1
tp25043
sS'grapefruit,juice,increases'
p25044
(F1
F0.00014334862385321102
I0
I1
I-1
tp25045
sS'effect,of,agents'
p25046
(F1
F0.00014334862385321102
I0
I1
I-1
tp25047
sS'including,has,additive'
p25048
(F1
F0.00014334862385321102
I1
I0
I1
tp25049
sS'demonstrated,in,patients'
p25050
(F0
F0
I1
I1
I0
tp25051
sS'reduce,pulse,and'
p25052
(F1
F0.00014334862385321102
I1
I0
I1
tp25053
sS'but,the,duration'
p25054
(F1
F0.00014334862385321102
I1
I0
I1
tp25055
sS'of,and,resulting'
p25056
(F1
F0.00014334862385321102
I1
I0
I1
tp25057
sS'are,possible,with'
p25058
(F1
F0.00014334862385321102
I0
I1
I-1
tp25059
sS'high,fever,severe'
p25060
(F1
F0.00014334862385321102
I1
I0
I1
tp25061
sS'single,and,multiple'
p25062
(F1
F0.00014334862385321102
I1
I0
I1
tp25063
sS'a,far,greater'
p25064
(F1
F0.00014334862385321102
I0
I1
I-1
tp25065
sS'combination,with,uricosuric'
p25066
(F1
F0.00014334862385321102
I0
I1
I-1
tp25067
sS'when,beginning,discontinuing'
p25068
(F1
F0.00014334862385321102
I1
I0
I1
tp25069
sS'in,cardiovascular,disease'
p25070
(F1
F0.00014334862385321102
I0
I1
I-1
tp25071
sS'and,s,d'
p25072
(F1
F0.00014334862385321102
I1
I0
I1
tp25073
sS'and,m,v'
p25074
(F1
F0.00014334862385321102
I0
I1
I-1
tp25075
sS'increased,the,intracellular'
p25076
(F1
F0.00014334862385321102
I1
I0
I1
tp25077
sS'and,c9,respectively'
p25078
(F1
F0.00014334862385321102
I0
I1
I-1
tp25079
sS'of,severe,hypoglycemia'
p25080
(F1
F0.00014334862385321102
I1
I0
I1
tp25081
sS'both,the,natriuresis'
p25082
(F1
F0.00014334862385321102
I1
I0
I1
tp25083
sS'cyp2d6,may,result'
p25084
(F1
F0.00014334862385321102
I0
I1
I-1
tp25085
sS'of,substantial,accumulation'
p25086
(F1
F0.00014334862385321102
I1
I0
I1
tp25087
sS'grapefruit,juice,should'
p25088
(F1
F0.00014334862385321102
I1
I0
I1
tp25089
sS'in,mean,cmax'
p25090
(F1
F0.00043004587155963305
I3
I0
I3
tp25091
sS'necessitating,an,increase'
p25092
(F1
F0.00014334862385321102
I1
I0
I1
tp25093
sS'and,total,bilirubin'
p25094
(F1
F0.00014334862385321102
I0
I1
I-1
tp25095
sS'mg,times,daily'
p25096
(F1
F0.00014334862385321102
I1
I0
I1
tp25097
sS'their,additive,effects'
p25098
(F1
F0.00014334862385321102
I1
I0
I1
tp25099
sS'including,combined,with'
p25100
(F1
F0.00014334862385321102
I0
I1
I-1
tp25101
sS'p450,enzyme-inducer,did'
p25102
(F1
F0.00014334862385321102
I1
I0
I1
tp25103
sS'and,produces,an'
p25104
(F1
F0.00014334862385321102
I1
I0
I1
tp25105
sS'conclusions,to,be'
p25106
(F1
F0.00014334862385321102
I0
I1
I-1
tp25107
sS'in,clearance,does'
p25108
(F1
F0.00014334862385321102
I0
I1
I-1
tp25109
sS'combination,with,cyp3a4'
p25110
(F1
F0.00014334862385321102
I0
I1
I-1
tp25111
sS'when,any,additional'
p25112
(F1
F0.00014334862385321102
I1
I0
I1
tp25113
sS'phase,schizophrenia,and'
p25114
(F1
F0.00014334862385321102
I0
I1
I-1
tp25115
sS'causing,bone,marrow'
p25116
(F1
F0.00014334862385321102
I1
I0
I1
tp25117
sS'therefore,when,edecrin'
p25118
(F1
F0.00014334862385321102
I1
I0
I1
tp25119
sS'study,there,were'
p25120
(F1
F0.00014334862385321102
I0
I1
I-1
tp25121
sS'before,one,should'
p25122
(F1
F0.00014334862385321102
I0
I1
I-1
tp25123
sS'didanosine,chewable,buffered'
p25124
(F1
F0.00028669724770642203
I2
I0
I2
tp25125
sS'of,plasma,and'
p25126
(F1
F0.00014334862385321102
I1
I0
I1
tp25127
sS'or,the,administration'
p25128
(F1
F0.00014334862385321102
I1
I0
I1
tp25129
sS'by,contrast,mm'
p25130
(F1
F0.00014334862385321102
I0
I1
I-1
tp25131
sS'brain,and,liver'
p25132
(F1
F0.00014334862385321102
I1
I0
I1
tp25133
sS'also,see,a'
p25134
(F1
F0.00014334862385321102
I1
I0
I1
tp25135
sS'most,commonly,occurring'
p25136
(F1
F0.00014334862385321102
I1
I0
I1
tp25137
sS'camptosar,and,certainly'
p25138
(F1
F0.00014334862385321102
I1
I0
I1
tp25139
sS'nevirapine-,or,delavirdine-based'
p25140
(F1
F0.00014334862385321102
I0
I1
I-1
tp25141
sS'blood,coagulation,have'
p25142
(F1
F0.00014334862385321102
I1
I0
I1
tp25143
sS'pronounced,effect,on'
p25144
(F1
F0.00014334862385321102
I1
I0
I1
tp25145
sS'considered,in,the'
p25146
(F1
F0.00014334862385321102
I0
I1
I-1
tp25147
sS'or,are,used'
p25148
(F1
F0.00028669724770642203
I2
I0
I2
tp25149
sS'these,subjects,r'
p25150
(F1
F0.00014334862385321102
I0
I1
I-1
tp25151
sS'desbutyl,levobupivacaine,and'
p25152
(F1
F0.00014334862385321102
I0
I1
I-1
tp25153
sS'the,atypical,antipsychotic'
p25154
(F1
F0.00014334862385321102
I0
I1
I-1
tp25155
sS'steady-state,plasma,concentrations'
p25156
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp25157
sS'systemic,clearance,of'
p25158
(F1
F0.00014334862385321102
I1
I0
I1
tp25159
sS'identified,involving,nizoral'
p25160
(F1
F0.00014334862385321102
I1
I0
I1
tp25161
sS'to,reduce,the'
p25162
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp25163
sS'route,in,man'
p25164
(F1
F0.00014334862385321102
I0
I1
I-1
tp25165
sS'with,and,special'
p25166
(F1
F0.00014334862385321102
I1
I0
I1
tp25167
sS'during,the,management'
p25168
(F1
F0.00014334862385321102
I1
I0
I1
tp25169
sS'due,to,induction'
p25170
(F0
F0
I1
I1
I0
tp25171
sS'an,interaction,study'
p25172
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25173
sS'humira,may,also'
p25174
(F1
F0.00014334862385321102
I1
I0
I1
tp25175
sS'been,no,formal'
p25176
(F1
F0.00028669724770642203
I0
I2
I-2
tp25177
sS'interactions,of,with'
p25178
(F0
F0
I1
I1
I0
tp25179
sS'ng,ml,and'
p25180
(F1
F0.00014334862385321102
I0
I1
I-1
tp25181
sS'complexes,with,and'
p25182
(F1
F0.00014334862385321102
I1
I0
I1
tp25183
sS'relaxant,antagonists,administered'
p25184
(F1
F0.00014334862385321102
I0
I1
I-1
tp25185
sS'when,administered,one'
p25186
(F1
F0.00014334862385321102
I1
I0
I1
tp25187
sS'adverse,events,or'
p25188
(F1
F0.00028669724770642203
I0
I2
I-2
tp25189
sS'concentration,by,after'
p25190
(F1
F0.00028669724770642203
I0
I2
I-2
tp25191
sS'insert,for,preparations'
p25192
(F1
F0.00028669724770642203
I2
I0
I2
tp25193
sS'does,it,alter'
p25194
(F1
F0.00014334862385321102
I0
I1
I-1
tp25195
sS'potentiate,the,effect'
p25196
(F1
F0.00014334862385321102
I1
I0
I1
tp25197
sS'supplement,containing,mg'
p25198
(F1
F0.00014334862385321102
I1
I0
I1
tp25199
sS'seminiferous,tubules,seminiferous'
p25200
(F1
F0.00014334862385321102
I0
I1
I-1
tp25201
sS'least,hours,before'
p25202
(F1
F0.00057339449541284407
I4
I0
I4
tp25203
sS'adjustment,in,the'
p25204
(F1
F0.00014334862385321102
I0
I1
I-1
tp25205
sS'post-marketing,experience,bleeding'
p25206
(F1
F0.00028669724770642203
I2
I0
I2
tp25207
sS'are,at,increased'
p25208
(F1
F0.00028669724770642203
I2
I0
I2
tp25209
sS'nervous,system,and'
p25210
(F1
F0.00014334862385321102
I1
I0
I1
tp25211
sS'be,avoided,when'
p25212
(F1
F0.00014334862385321102
I1
I0
I1
tp25213
sS'ml,and,terminal'
p25214
(F1
F0.00014334862385321102
I1
I0
I1
tp25215
sS'or,clotting,factor'
p25216
(F1
F0.00014334862385321102
I0
I1
I-1
tp25217
sS'anagrelide,alone,had'
p25218
(F1
F0.00014334862385321102
I1
I0
I1
tp25219
sS'data,to,evaluate'
p25220
(F1
F0.00014334862385321102
I1
I0
I1
tp25221
sS'in,a,wax'
p25222
(F1
F0.00014334862385321102
I1
I0
I1
tp25223
sS'interaction,of,prostaglandin'
p25224
(F0
F0
I1
I1
I0
tp25225
sS'in,vivo,interaction'
p25226
(F1
F0.00071674311926605509
I0
I5
I-5
tp25227
sS'patients,interaction,study'
p25228
(F1
F0.00014334862385321102
I0
I1
I-1
tp25229
sS'that,was,too'
p25230
(F1
F0.00014334862385321102
I0
I1
I-1
tp25231
sS'depressant,effects,when'
p25232
(F1
F0.00043004587155963305
I3
I0
I3
tp25233
sS'previously,administered,agents'
p25234
(F1
F0.00014334862385321102
I0
I1
I-1
tp25235
sS'differences,were,observed'
p25236
(F1
F0.00043004587155963305
I0
I3
I-3
tp25237
sS'antigout,oral,and'
p25238
(F1
F0.00014334862385321102
I0
I1
I-1
tp25239
sS'monotherapy,given,as'
p25240
(F1
F0.00014334862385321102
I0
I1
I-1
tp25241
sS'pegasys,treatment,did'
p25242
(F1
F0.00014334862385321102
I0
I1
I-1
tp25243
sS'and,for,cmax'
p25244
(F1
F0.00014334862385321102
I1
I0
I1
tp25245
sS'hydroxy-1,on,a'
p25246
(F1
F0.00014334862385321102
I1
I0
I1
tp25247
sS'the,nasal,spray'
p25248
(F1
F0.00014334862385321102
I1
I0
I1
tp25249
sS'neuron,blockade,produced'
p25250
(F1
F0.00014334862385321102
I1
I0
I1
tp25251
sS'vary,in,the'
p25252
(F1
F0.00071674311926605509
I0
I5
I-5
tp25253
sS'reduce,the,frequency'
p25254
(F1
F0.00014334862385321102
I0
I1
I-1
tp25255
sS'suggested,with,sodium'
p25256
(F1
F0.00014334862385321102
I0
I1
I-1
tp25257
sS'stress,and,on'
p25258
(F1
F0.00014334862385321102
I0
I1
I-1
tp25259
sS'or,methylthiadiazole,can'
p25260
(F1
F0.00014334862385321102
I0
I1
I-1
tp25261
sS'demonstrated,to,be'
p25262
(F1
F0.00028669724770642203
I2
I0
I2
tp25263
sS'of,gi,ulceration'
p25264
(F1
F0.00043004587155963305
I3
I0
I3
tp25265
sS'time,hydrogen,breath'
p25266
(F1
F0.00014334862385321102
I0
I1
I-1
tp25267
sS'in,their,coagulation'
p25268
(F1
F0.00014334862385321102
I1
I0
I1
tp25269
sS'vardenafil,when,taken'
p25270
(F1
F0.00014334862385321102
I0
I1
I-1
tp25271
sS'between,trileptal,and'
p25272
(F1
F0.00014334862385321102
I0
I1
I-1
tp25273
sS'n,were,decreased'
p25274
(F1
F0.00014334862385321102
I1
I0
I1
tp25275
sS'monitoring,is,recommended'
p25276
(F1
F0.00014334862385321102
I1
I0
I1
tp25277
sS'cause,ventricular,tachycardia'
p25278
(F1
F0.00014334862385321102
I1
I0
I1
tp25279
sS'thin-layer,chromatographic,assay'
p25280
(F1
F0.00014334862385321102
I0
I1
I-1
tp25281
sS'co,and,or'
p25282
(F1
F0.00014334862385321102
I0
I1
I-1
tp25283
sS'produce,antabuse-like,side'
p25284
(F1
F0.00014334862385321102
I1
I0
I1
tp25285
sS'vitamin,k,the'
p25286
(F1
F0.00014334862385321102
I1
I0
I1
tp25287
sS'nicotine,nicotine,may'
p25288
(F1
F0.00014334862385321102
I1
I0
I1
tp25289
sS'of,potentiating,cns'
p25290
(F1
F0.00014334862385321102
I1
I0
I1
tp25291
sS'aspirin,vardenafil,mg'
p25292
(F1
F0.00014334862385321102
I0
I1
I-1
tp25293
sS'plasma,and,renal'
p25294
(F1
F0.00014334862385321102
I1
I0
I1
tp25295
sS'short,sedation,time'
p25296
(F1
F0.00014334862385321102
I0
I1
I-1
tp25297
sS'certain,that,no'
p25298
(F1
F0.00014334862385321102
I1
I0
I1
tp25299
sS'result,in,clinically'
p25300
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25301
sS'p450,d6,may'
p25302
(F1
F0.0008600917431192661
I0
I6
I-6
tp25303
sS'concentrations,when,was'
p25304
(F1
F0.00014334862385321102
I1
I0
I1
tp25305
sS'enzyme,eg,should'
p25306
(F1
F0.00014334862385321102
I1
I0
I1
tp25307
sS'a,similar,interaction'
p25308
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25309
sS'both,periods,with'
p25310
(F1
F0.00014334862385321102
I0
I1
I-1
tp25311
sS'intravenous,prodrug,form'
p25312
(F1
F0.00014334862385321102
I0
I1
I-1
tp25313
sS'vitamin,b3,niacin'
p25314
(F1
F0.00014334862385321102
I1
I0
I1
tp25315
sS'about,the,use'
p25316
(F1
F0.00014334862385321102
I0
I1
I-1
tp25317
sS'testing,should,be'
p25318
(F1
F0.00014334862385321102
I1
I0
I1
tp25319
sS'modifies,metabolism,with'
p25320
(F1
F0.00014334862385321102
I1
I0
I1
tp25321
sS'with,a,higher'
p25322
(F1
F0.00043004587155963305
I3
I0
I3
tp25323
sS'dose,of,sonata'
p25324
(F1
F0.00014334862385321102
I0
I1
I-1
tp25325
sS'not,significantly,affect'
p25326
(F0.80000000000000004
F0.0011467889908256881
I1
I9
I-8
tp25327
sS'affected,by,administration'
p25328
(F1
F0.00014334862385321102
I0
I1
I-1
tp25329
sS'oral,load,constitutes'
p25330
(F1
F0.00014334862385321102
I0
I1
I-1
tp25331
sS'begin,taking,or'
p25332
(F1
F0.00014334862385321102
I1
I0
I1
tp25333
sS'than,in,the'
p25334
(F1
F0.00014334862385321102
I1
I0
I1
tp25335
sS'formation,of,oxidized'
p25336
(F1
F0.00014334862385321102
I0
I1
I-1
tp25337
sS'medications,tylenol,such'
p25338
(F1
F0.00014334862385321102
I1
I0
I1
tp25339
sS'patients,whose,pulmonary'
p25340
(F1
F0.00014334862385321102
I0
I1
I-1
tp25341
sS'adjustment,of,nalfon'
p25342
(F1
F0.00014334862385321102
I1
I0
I1
tp25343
sS'use,of,hydrobromide'
p25344
(F1
F0.00014334862385321102
I1
I0
I1
tp25345
sS'as,the,class'
p25346
(F1
F0.00014334862385321102
I1
I0
I1
tp25347
sS'pharmacokinetics,of,either'
p25348
(F1
F0.00043004587155963305
I0
I3
I-3
tp25349
sS'with,is,not'
p25350
(F0
F0
I1
I1
I0
tp25351
sS'mesylate,has,no'
p25352
(F1
F0.00014334862385321102
I0
I1
I-1
tp25353
sS'who,are,being'
p25354
(F1
F0.00028669724770642203
I2
I0
I2
tp25355
sS'inhibitor,class,may'
p25356
(F1
F0.00014334862385321102
I1
I0
I1
tp25357
sS'improvements,in,psychopathology'
p25358
(F1
F0.00014334862385321102
I0
I1
I-1
tp25359
sS'dose,reduction,of'
p25360
(F1
F0.00071674311926605509
I5
I0
I5
tp25361
sS'levels,of,to'
p25362
(F1
F0.00014334862385321102
I1
I0
I1
tp25363
sS'effects,of,uptake'
p25364
(F1
F0.00014334862385321102
I0
I1
I-1
tp25365
sS'effect,on,half-life'
p25366
(F1
F0.00014334862385321102
I1
I0
I1
tp25367
sS'ritonavir,and,upon'
p25368
(F1
F0.00014334862385321102
I1
I0
I1
tp25369
sS'to,a,dysregulation'
p25370
(F1
F0.00014334862385321102
I0
I1
I-1
tp25371
sS'are,the,prescription'
p25372
(F1
F0.00014334862385321102
I1
I0
I1
tp25373
sS'macrolide,or,azoles'
p25374
(F1
F0.00014334862385321102
I0
I1
I-1
tp25375
sS'qt,intervals,during'
p25376
(F1
F0.00014334862385321102
I0
I1
I-1
tp25377
sS'inhibitors,ssris,and'
p25378
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp25379
sS'pronounced,intersubject,variability'
p25380
(F1
F0.00014334862385321102
I1
I0
I1
tp25381
sS'longer,than,weeks'
p25382
(F1
F0.00014334862385321102
I1
I0
I1
tp25383
sS'and,or,elevated'
p25384
(F1
F0.00014334862385321102
I1
I0
I1
tp25385
sS'inducer,at,mg'
p25386
(F1
F0.00014334862385321102
I1
I0
I1
tp25387
sS'of,or,should'
p25388
(F1
F0.00014334862385321102
I0
I1
I-1
tp25389
sS'trial,has,shown'
p25390
(F1
F0.00014334862385321102
I1
I0
I1
tp25391
sS'to,leading,to'
p25392
(F1
F0.00014334862385321102
I1
I0
I1
tp25393
sS'donor,compounds,including'
p25394
(F1
F0.00014334862385321102
I1
I0
I1
tp25395
sS'nizoral,muscle,relaxants'
p25396
(F1
F0.00014334862385321102
I0
I1
I-1
tp25397
sS'without,clinical,bleeding'
p25398
(F1
F0.00014334862385321102
I1
I0
I1
tp25399
sS'cmax,by,resulting'
p25400
(F1
F0.00014334862385321102
I0
I1
I-1
tp25401
sS'both,and,its'
p25402
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp25403
sS'inhibit,p-glycoprotein,mediated'
p25404
(F1
F0.00014334862385321102
I0
I1
I-1
tp25405
sS'commonly,reported,both'
p25406
(F1
F0.00014334862385321102
I1
I0
I1
tp25407
sS'nasal,vasoconstrictor,but'
p25408
(F1
F0.00014334862385321102
I0
I1
I-1
tp25409
sS'class,of,oral'
p25410
(F1
F0.00014334862385321102
I0
I1
I-1
tp25411
sS'channel,blockers,nonsteroidal'
p25412
(F1
F0.00014334862385321102
I0
I1
I-1
tp25413
sS'caused,a,statistically'
p25414
(F1
F0.00014334862385321102
I1
I0
I1
tp25415
sS'inhaled,and,or'
p25416
(F1
F0.00014334862385321102
I0
I1
I-1
tp25417
sS'to,cause,decreased'
p25418
(F1
F0.00014334862385321102
I1
I0
I1
tp25419
sS'we,demonstrate,that'
p25420
(F1
F0.00014334862385321102
I0
I1
I-1
tp25421
sS'release,the,antihypertensive'
p25422
(F1
F0.00014334862385321102
I1
I0
I1
tp25423
sS'cholinergic,blockade,may'
p25424
(F1
F0.00014334862385321102
I1
I0
I1
tp25425
sS'acute,pharmacological,i'
p25426
(F1
F0.00014334862385321102
I0
I1
I-1
tp25427
sS'six,patients,five'
p25428
(F1
F0.00014334862385321102
I0
I1
I-1
tp25429
sS'in,the,plasma'
p25430
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp25431
sS'of,and,produces'
p25432
(F1
F0.00014334862385321102
I1
I0
I1
tp25433
sS'side-effects,in,patients'
p25434
(F1
F0.00014334862385321102
I1
I0
I1
tp25435
sS'other,potentially,nephrotoxic'
p25436
(F1
F0.00014334862385321102
I1
I0
I1
tp25437
sS'risk,of,a'
p25438
(F0
F0
I1
I1
I0
tp25439
sS'or,the,dose'
p25440
(F1
F0.00014334862385321102
I0
I1
I-1
tp25441
sS'monitored,regularly,during'
p25442
(F1
F0.00014334862385321102
I0
I1
I-1
tp25443
sS'metabolite,of,associated'
p25444
(F1
F0.00014334862385321102
I0
I1
I-1
tp25445
sS'of,and,produced'
p25446
(F0
F0
I1
I1
I0
tp25447
sS'or,embryocidal,effects'
p25448
(F1
F0.00014334862385321102
I0
I1
I-1
tp25449
sS'reduction,in,levels'
p25450
(F1
F0.00014334862385321102
I1
I0
I1
tp25451
sS'discontinue,nursing,or'
p25452
(F1
F0.00014334862385321102
I0
I1
I-1
tp25453
sS'the,patient,has'
p25454
(F1
F0.00014334862385321102
I1
I0
I1
tp25455
sS'its,binding,sites'
p25456
(F1
F0.00028669724770642203
I2
I0
I2
tp25457
sS'buprenorphine,is,metabolized'
p25458
(F1
F0.00014334862385321102
I0
I1
I-1
tp25459
sS'clinical,basis,of'
p25460
(F1
F0.00014334862385321102
I0
I1
I-1
tp25461
sS'plasticity,ieg,response'
p25462
(F1
F0.00014334862385321102
I0
I1
I-1
tp25463
sS'deaths,due,to'
p25464
(F1
F0.00014334862385321102
I0
I1
I-1
tp25465
sS'of,doses,of'
p25466
(F1
F0.00014334862385321102
I0
I1
I-1
tp25467
sS'not,known,caution'
p25468
(F1
F0.00014334862385321102
I1
I0
I1
tp25469
sS'been,rare,postmarketing'
p25470
(F1
F0.00014334862385321102
I1
I0
I1
tp25471
sS'a,clinically,relevant'
p25472
(F1
F0.00014334862385321102
I1
I0
I1
tp25473
sS'concentrations,of,that'
p25474
(F1
F0.00014334862385321102
I1
I0
I1
tp25475
sS'level,that,has'
p25476
(F1
F0.00014334862385321102
I1
I0
I1
tp25477
sS'inhibit,the,anti-inflammatory'
p25478
(F1
F0.00014334862385321102
I1
I0
I1
tp25479
sS'reported,that,the'
p25480
(F1
F0.00014334862385321102
I1
I0
I1
tp25481
sS'going,to,be'
p25482
(F1
F0.00071674311926605509
I0
I5
I-5
tp25483
sS'maximum,plasma,concentration'
p25484
(F1
F0.00057339449541284407
I4
I0
I4
tp25485
sS'and,hiv,protease'
p25486
(F1
F0.00014334862385321102
I0
I1
I-1
tp25487
sS'plasmaconcentrations,may,reduce'
p25488
(F1
F0.00028669724770642203
I2
I0
I2
tp25489
sS'potentially,nephrotoxic,agents'
p25490
(F1
F0.00014334862385321102
I1
I0
I1
tp25491
sS'fi,responding,in'
p25492
(F1
F0.00014334862385321102
I0
I1
I-1
tp25493
sS'therefore,interactions,could'
p25494
(F1
F0.00014334862385321102
I0
I1
I-1
tp25495
sS'article,looks,at'
p25496
(F1
F0.00014334862385321102
I0
I1
I-1
tp25497
sS'the,amount,of'
p25498
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp25499
sS'conclude,that,adl'
p25500
(F1
F0.00014334862385321102
I1
I0
I1
tp25501
sS'or,extent,of'
p25502
(F1
F0.00043004587155963305
I0
I3
I-3
tp25503
sS'that,both,and'
p25504
(F1
F0.00014334862385321102
I1
I0
I1
tp25505
sS'filtrated,to,a'
p25506
(F1
F0.00014334862385321102
I1
I0
I1
tp25507
sS'whether,this,interaction'
p25508
(F1
F0.00014334862385321102
I0
I1
I-1
tp25509
sS'of,strong,inhibitors'
p25510
(F1
F0.00014334862385321102
I0
I1
I-1
tp25511
sS'following,alfenta,induction'
p25512
(F1
F0.00014334862385321102
I1
I0
I1
tp25513
sS'no,potential,for'
p25514
(F1
F0.00014334862385321102
I0
I1
I-1
tp25515
sS'functional,antagonism,exists'
p25516
(F1
F0.00043004587155963305
I3
I0
I3
tp25517
sS'with,either,enbrel'
p25518
(F1
F0.00014334862385321102
I1
I0
I1
tp25519
sS'nonlethal,and,lethal'
p25520
(F1
F0.00014334862385321102
I0
I1
I-1
tp25521
sS'with,nonsteroidal,the'
p25522
(F1
F0.00014334862385321102
I1
I0
I1
tp25523
sS'based,on,the'
p25524
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp25525
sS'in,hormone,levels'
p25526
(F1
F0.00014334862385321102
I0
I1
I-1
tp25527
sS'experiencing,breakthrough,bleeding'
p25528
(F1
F0.00014334862385321102
I0
I1
I-1
tp25529
sS'cautioned,that,the'
p25530
(F1
F0.00014334862385321102
I0
I1
I-1
tp25531
sS'one,third,of'
p25532
(F1
F0.00014334862385321102
I1
I0
I1
tp25533
sS'being,dosed,at'
p25534
(F1
F0.00014334862385321102
I0
I1
I-1
tp25535
sS'glycosides,amphotericin,b-induced'
p25536
(F1
F0.00014334862385321102
I1
I0
I1
tp25537
sS'that,intraventricular,and'
p25538
(F1
F0.00014334862385321102
I0
I1
I-1
tp25539
sS'methyldopa,aldomet,use'
p25540
(F1
F0.00014334862385321102
I1
I0
I1
tp25541
sS'and,plasma,mean'
p25542
(F1
F0.00014334862385321102
I1
I0
I1
tp25543
sS'more,commonly,in'
p25544
(F1
F0.00014334862385321102
I1
I0
I1
tp25545
sS'may,diminish,adrenal'
p25546
(F1
F0.00014334862385321102
I1
I0
I1
tp25547
sS'compete,for,active'
p25548
(F1
F0.00014334862385321102
I0
I1
I-1
tp25549
sS'and,may,regulate'
p25550
(F1
F0.00014334862385321102
I1
I0
I1
tp25551
sS'seizure,associated,with'
p25552
(F1
F0.00014334862385321102
I0
I1
I-1
tp25553
sS'relative,bioavailability,auc'
p25554
(F1
F0.00014334862385321102
I0
I1
I-1
tp25555
sS'pregnant,into,the'
p25556
(F1
F0.00014334862385321102
I0
I1
I-1
tp25557
sS'interaction,between,h-spiroperidol'
p25558
(F1
F0.00028669724770642203
I0
I2
I-2
tp25559
sS'clinically,relevant,pharmacokinetic'
p25560
(F1
F0.00028669724770642203
I0
I2
I-2
tp25561
sS'for,using,these'
p25562
(F1
F0.00014334862385321102
I0
I1
I-1
tp25563
sS'sustained,elevation,in'
p25564
(F1
F0.00014334862385321102
I1
I0
I1
tp25565
sS'cns-active,drugs,ethanol'
p25566
(F1
F0.00028669724770642203
I2
I0
I2
tp25567
sS'therapy,with,are'
p25568
(F1
F0.00014334862385321102
I0
I1
I-1
tp25569
sS'although,they,do'
p25570
(F1
F0.00014334862385321102
I1
I0
I1
tp25571
sS'in,lower,serum'
p25572
(F1
F0.00028669724770642203
I2
I0
I2
tp25573
sS'central,stimulant,effects'
p25574
(F1
F0.00028669724770642203
I2
I0
I2
tp25575
sS'i,d,and'
p25576
(F1
F0.00014334862385321102
I1
I0
I1
tp25577
sS'in,subjects,with'
p25578
(F1
F0.00014334862385321102
I0
I1
I-1
tp25579
sS'resolution,of,the'
p25580
(F1
F0.00014334862385321102
I1
I0
I1
tp25581
sS'of,diethyl,pyrocarbonate'
p25582
(F1
F0.00014334862385321102
I0
I1
I-1
tp25583
sS'novolog,with,nph'
p25584
(F1
F0.00014334862385321102
I0
I1
I-1
tp25585
sS'is,bound,to'
p25586
(F1
F0.00014334862385321102
I0
I1
I-1
tp25587
sS'examples,of,this'
p25588
(F1
F0.00028669724770642203
I0
I2
I-2
tp25589
sS'the,potential,risk'
p25590
(F1
F0.00014334862385321102
I1
I0
I1
tp25591
sS'copaxone,has,not'
p25592
(F1
F0.00014334862385321102
I0
I1
I-1
tp25593
sS'of,various,such'
p25594
(F1
F0.00014334862385321102
I1
I0
I1
tp25595
sS'sodium,bicarbonate,used'
p25596
(F1
F0.00014334862385321102
I1
I0
I1
tp25597
sS'of,other,clotting'
p25598
(F1
F0.00014334862385321102
I0
I1
I-1
tp25599
sS'kg,enhanced,and'
p25600
(F1
F0.00014334862385321102
I1
I0
I1
tp25601
sS'population,pharmacokinetic,analyses'
p25602
(F0.5
F0.00028669724770642203
I3
I1
I2
tp25603
sS'are,receiving,or'
p25604
(F1
F0.00014334862385321102
I1
I0
I1
tp25605
sS'gleevec,is,coadministered'
p25606
(F1
F0.00014334862385321102
I1
I0
I1
tp25607
sS'on,the,th'
p25608
(F1
F0.00028669724770642203
I2
I0
I2
tp25609
sS'deficit,and,to'
p25610
(F1
F0.00014334862385321102
I0
I1
I-1
tp25611
sS'related,to,obstetric'
p25612
(F0
F0
I1
I1
I0
tp25613
sS'have,resulted,in'
p25614
(F1
F0.00014334862385321102
I1
I0
I1
tp25615
sS'of,foscavir,and'
p25616
(F1
F0.00014334862385321102
I1
I0
I1
tp25617
sS'tricor,with,and'
p25618
(F1
F0.00014334862385321102
I1
I0
I1
tp25619
sS'potential,especially,in'
p25620
(F1
F0.00014334862385321102
I1
I0
I1
tp25621
sS'reported,case,of'
p25622
(F1
F0.00014334862385321102
I1
I0
I1
tp25623
sS'patient,receiving,the'
p25624
(F1
F0.00014334862385321102
I1
I0
I1
tp25625
sS'cases,was,misused'
p25626
(F1
F0.00014334862385321102
I0
I1
I-1
tp25627
sS'receiving,both,therapies'
p25628
(F1
F0.00014334862385321102
I0
I1
I-1
tp25629
sS'growth,of,several'
p25630
(F1
F0.00014334862385321102
I0
I1
I-1
tp25631
sS'clarithromycin,telithromycin,hiv'
p25632
(F1
F0.00014334862385321102
I0
I1
I-1
tp25633
sS'of,reduced,cmax'
p25634
(F1
F0.00014334862385321102
I1
I0
I1
tp25635
sS'of,with,was'
p25636
(F1
F0.00028669724770642203
I2
I0
I2
tp25637
sS'the,conversion,of'
p25638
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp25639
sS'study,or,was'
p25640
(F0
F0
I1
I1
I0
tp25641
sS'patients,with,life-threatening'
p25642
(F1
F0.00014334862385321102
I0
I1
I-1
tp25643
sS'depressants,may,potentiate'
p25644
(F0
F0
I2
I2
I0
tp25645
sS'of,bezalip,or'
p25646
(F1
F0.00014334862385321102
I1
I0
I1
tp25647
sS'studies,one,mg'
p25648
(F1
F0.00014334862385321102
I1
I0
I1
tp25649
sS'of,healthy,male'
p25650
(F0
F0
I1
I1
I0
tp25651
sS'has,been,associated'
p25652
(F0.875
F0.0020068807339449542
I15
I1
I14
tp25653
sS'd,co-administered,with'
p25654
(F1
F0.00028669724770642203
I2
I0
I2
tp25655
sS'or,may,cause'
p25656
(F1
F0.00014334862385321102
I1
I0
I1
tp25657
sS'the,tail-flick,response'
p25658
(F0
F0
I1
I1
I0
tp25659
sS'concentrations,of,each'
p25660
(F1
F0.00014334862385321102
I0
I1
I-1
tp25661
sS'were,given,on'
p25662
(F1
F0.00014334862385321102
I1
I0
I1
tp25663
sS'potential,of,especially'
p25664
(F1
F0.00014334862385321102
I1
I0
I1
tp25665
sS'same,degree,of'
p25666
(F1
F0.00014334862385321102
I0
I1
I-1
tp25667
sS'in,any,significant'
p25668
(F1
F0.00014334862385321102
I0
I1
I-1
tp25669
sS'an,omega-conotoxin,gvia-sensitive'
p25670
(F1
F0.00014334862385321102
I0
I1
I-1
tp25671
sS'antibiotics,in,vitro'
p25672
(F1
F0.00014334862385321102
I1
I0
I1
tp25673
sS'the,cns-impairing,effects'
p25674
(F1
F0.00014334862385321102
I1
I0
I1
tp25675
sS'was,usually,reversible'
p25676
(F1
F0.00014334862385321102
I1
I0
I1
tp25677
sS'of,erection-supporting,medication'
p25678
(F1
F0.00014334862385321102
I0
I1
I-1
tp25679
sS'response,to,either'
p25680
(F1
F0.00014334862385321102
I1
I0
I1
tp25681
sS'results,sildenafil,has'
p25682
(F1
F0.00014334862385321102
I0
I1
I-1
tp25683
sS'non-steroidal,the,co-administration'
p25684
(F1
F0.00014334862385321102
I1
I0
I1
tp25685
sS'raise,serum,levels'
p25686
(F1
F0.00014334862385321102
I1
I0
I1
tp25687
sS'oral,did,not'
p25688
(F1
F0.00014334862385321102
I0
I1
I-1
tp25689
sS'viracept,resulted,in'
p25690
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp25691
sS'a,day,resulted'
p25692
(F1
F0.00014334862385321102
I1
I0
I1
tp25693
sS'to,induce,the'
p25694
(F1
F0.00014334862385321102
I1
I0
I1
tp25695
sS'romazicon,in,cases'
p25696
(F1
F0.00014334862385321102
I1
I0
I1
tp25697
sS'a,mild,decrease'
p25698
(F1
F0.00014334862385321102
I1
I0
I1
tp25699
sS'gravis,inflammatory,arthritis'
p25700
(F1
F0.00014334862385321102
I1
I0
I1
tp25701
sS'toxic,epidermal,necrolysis'
p25702
(F1
F0.00014334862385321102
I0
I1
I-1
tp25703
sS'the,central,syndrome'
p25704
(F1
F0.00014334862385321102
I1
I0
I1
tp25705
sS'vivo,data,suggesting'
p25706
(F1
F0.00014334862385321102
I1
I0
I1
tp25707
sS'plasma,concentrations,has'
p25708
(F1
F0.00028669724770642203
I0
I2
I-2
tp25709
sS'change,in,auc'
p25710
(F1
F0.00014334862385321102
I0
I1
I-1
tp25711
sS'with,may,result'
p25712
(F1
F0.00043004587155963305
I3
I0
I3
tp25713
sS'considered,when,therapy'
p25714
(F1
F0.00014334862385321102
I1
I0
I1
tp25715
sS'of,certain,tricyclic'
p25716
(F1
F0.00014334862385321102
I1
I0
I1
tp25717
sS'agents,with,b-blocking'
p25718
(F1
F0.00071674311926605509
I5
I0
I5
tp25719
sS'using,the,uptake'
p25720
(F1
F0.00014334862385321102
I0
I1
I-1
tp25721
sS'or,were,observed'
p25722
(F1
F0.00014334862385321102
I0
I1
I-1
tp25723
sS'recommended,when,and'
p25724
(F1
F0.00014334862385321102
I1
I0
I1
tp25725
sS'and,death,associated'
p25726
(F1
F0.00014334862385321102
I1
I0
I1
tp25727
sS'by,therapy,the'
p25728
(F1
F0.00014334862385321102
I1
I0
I1
tp25729
sS'the,bowel,and'
p25730
(F1
F0.00014334862385321102
I0
I1
I-1
tp25731
sS'alkaloids,may,be'
p25732
(F1
F0.00014334862385321102
I1
I0
I1
tp25733
sS'potential,interaction,between'
p25734
(F0.5
F0.00028669724770642203
I3
I1
I2
tp25735
sS'dose,mg,every'
p25736
(F1
F0.00014334862385321102
I1
I0
I1
tp25737
sS'secretion,while,may'
p25738
(F1
F0.00014334862385321102
I1
I0
I1
tp25739
sS'a,higher,incidence'
p25740
(F1
F0.00014334862385321102
I1
I0
I1
tp25741
sS'dose,administration,of'
p25742
(F0
F0
I1
I1
I0
tp25743
sS'adjustment,of,sustiva'
p25744
(F1
F0.00014334862385321102
I0
I1
I-1
tp25745
sS'greater,gastrointestinal,toxicity'
p25746
(F1
F0.00014334862385321102
I1
I0
I1
tp25747
sS'shown,to,result'
p25748
(F1
F0.00014334862385321102
I0
I1
I-1
tp25749
sS'although,there,was'
p25750
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp25751
sS'drug,interactions,and'
p25752
(F1
F0.00014334862385321102
I1
I0
I1
tp25753
sS'at,least,hour'
p25754
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp25755
sS'blood,concentrations,of'
p25756
(F1
F0.00014334862385321102
I0
I1
I-1
tp25757
sS'whole,blood,concentrations'
p25758
(F1
F0.00014334862385321102
I1
I0
I1
tp25759
sS'use,during,therapy'
p25760
(F1
F0.00014334862385321102
I1
I0
I1
tp25761
sS'decrease,in,standing'
p25762
(F1
F0.00014334862385321102
I1
I0
I1
tp25763
sS'may,be,refractory'
p25764
(F1
F0.00014334862385321102
I1
I0
I1
tp25765
sS'in,fold,increase'
p25766
(F1
F0.00014334862385321102
I1
I0
I1
tp25767
sS'stimulated,gastric,secretion'
p25768
(F1
F0.00014334862385321102
I0
I1
I-1
tp25769
sS'effect,oral,heparin'
p25770
(F1
F0.00014334862385321102
I0
I1
I-1
tp25771
sS'which,has,been'
p25772
(F1
F0.00014334862385321102
I0
I1
I-1
tp25773
sS'a,clinical,pharmacology'
p25774
(F0
F0
I1
I1
I0
tp25775
sS'patients,in,clinical'
p25776
(F1
F0.00014334862385321102
I0
I1
I-1
tp25777
sS'observed,in,a'
p25778
(F1
F0.00028669724770642203
I0
I2
I-2
tp25779
sS'of,cerebyx,are'
p25780
(F1
F0.00014334862385321102
I0
I1
I-1
tp25781
sS'increased,the,extent'
p25782
(F1
F0.00014334862385321102
I0
I1
I-1
tp25783
sS'the,clinician,should'
p25784
(F1
F0.00014334862385321102
I1
I0
I1
tp25785
sS'important,interactions,have'
p25786
(F1
F0.00028669724770642203
I0
I2
I-2
tp25787
sS'this,class,is'
p25788
(F1
F0.00014334862385321102
I0
I1
I-1
tp25789
sS'effects,due,to'
p25790
(F1
F0.00014334862385321102
I1
I0
I1
tp25791
sS'agents,reduce,the'
p25792
(F1
F0.00028669724770642203
I2
I0
I2
tp25793
sS'effect,of,acarbose'
p25794
(F1
F0.00014334862385321102
I1
I0
I1
tp25795
sS'exist,comparing,the'
p25796
(F1
F0.00014334862385321102
I0
I1
I-1
tp25797
sS'trace,elements,were'
p25798
(F1
F0.00014334862385321102
I0
I1
I-1
tp25799
sS'response,of,the'
p25800
(F1
F0.00014334862385321102
I0
I1
I-1
tp25801
sS'of,adenocarcinomas,which'
p25802
(F1
F0.00014334862385321102
I1
I0
I1
tp25803
sS'oral,supplementation,mg'
p25804
(F1
F0.00014334862385321102
I0
I1
I-1
tp25805
sS'cause,abnormal,renal'
p25806
(F1
F0.00014334862385321102
I1
I0
I1
tp25807
sS'with,if,therapy'
p25808
(F1
F0.00014334862385321102
I1
I0
I1
tp25809
sS'plasma,exposure,auc'
p25810
(F1
F0.00028669724770642203
I2
I0
I2
tp25811
sS'study,was,designed'
p25812
(F1
F0.00014334862385321102
I0
I1
I-1
tp25813
sS'levels,of,unchanged'
p25814
(F1
F0.00014334862385321102
I1
I0
I1
tp25815
sS'overdosage,or,in'
p25816
(F1
F0.00014334862385321102
I1
I0
I1
tp25817
sS'inhibit,alprazolam,metabolism'
p25818
(F1
F0.00014334862385321102
I0
I1
I-1
tp25819
sS'be,observed,for'
p25820
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp25821
sS'with,fondaparinux,the'
p25822
(F1
F0.00014334862385321102
I0
I1
I-1
tp25823
sS'multivalent,cations,likely'
p25824
(F1
F0.00014334862385321102
I1
I0
I1
tp25825
sS'therefore,intake,of'
p25826
(F1
F0.00014334862385321102
I0
I1
I-1
tp25827
sS'cellular,and,molecular'
p25828
(F1
F0.00014334862385321102
I0
I1
I-1
tp25829
sS'that,dopamine,antagonists'
p25830
(F1
F0.00014334862385321102
I1
I0
I1
tp25831
sS'pressure,or,on'
p25832
(F1
F0.00014334862385321102
I0
I1
I-1
tp25833
sS'pharmacokinetics,and,pharmacodynamics'
p25834
(F1
F0.00014334862385321102
I0
I1
I-1
tp25835
sS'ototoxicity,and,potentiate'
p25836
(F1
F0.00014334862385321102
I0
I1
I-1
tp25837
sS'concentrations,considerably,lower'
p25838
(F1
F0.00014334862385321102
I1
I0
I1
tp25839
sS'reactions,in,patients'
p25840
(F1
F0.00014334862385321102
I0
I1
I-1
tp25841
sS'or,back-up,methods'
p25842
(F1
F0.00014334862385321102
I1
I0
I1
tp25843
sS'placebo-controlled,trial,in'
p25844
(F1
F0.00014334862385321102
I1
I0
I1
tp25845
sS'vasoconstrictive,action,of'
p25846
(F1
F0.00014334862385321102
I1
I0
I1
tp25847
sS'other,will,result'
p25848
(F1
F0.00014334862385321102
I0
I1
I-1
tp25849
sS'and,ethinyl,estradiol'
p25850
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp25851
sS'dose,of,albendazole'
p25852
(F1
F0.00014334862385321102
I1
I0
I1
tp25853
sS'using,the,bio-rad'
p25854
(F1
F0.00014334862385321102
I0
I1
I-1
tp25855
sS'a,non-comparative,clinical'
p25856
(F1
F0.00014334862385321102
I1
I0
I1
tp25857
sS'male,n,in'
p25858
(F1
F0.00014334862385321102
I0
I1
I-1
tp25859
sS'activity,thus,requiring'
p25860
(F1
F0.00014334862385321102
I1
I0
I1
tp25861
sS'the,pharmacodynamic,profile'
p25862
(F1
F0.00014334862385321102
I0
I1
I-1
tp25863
sS'for,nmda,and'
p25864
(F1
F0.00014334862385321102
I0
I1
I-1
tp25865
sS'monkeys,nanm,was'
p25866
(F1
F0.00014334862385321102
I0
I1
I-1
tp25867
sS'in,the,cumulative'
p25868
(F1
F0.00014334862385321102
I0
I1
I-1
tp25869
sS'ht3,antagonist,class'
p25870
(F1
F0.00014334862385321102
I1
I0
I1
tp25871
sS'panretin,gel,on'
p25872
(F1
F0.00014334862385321102
I0
I1
I-1
tp25873
sS'in,volunteers,with'
p25874
(F1
F0.00014334862385321102
I0
I1
I-1
tp25875
sS'watched,during,initiation'
p25876
(F1
F0.00014334862385321102
I0
I1
I-1
tp25877
sS'been,observed,in'
p25878
(F0
F0
I1
I1
I0
tp25879
sS'second,experiment,non-diabetic'
p25880
(F1
F0.00014334862385321102
I0
I1
I-1
tp25881
sS'study,with,intravenous'
p25882
(F1
F0.00014334862385321102
I0
I1
I-1
tp25883
sS'been,observed,it'
p25884
(F1
F0.00014334862385321102
I1
I0
I1
tp25885
sS'range,of,observed'
p25886
(F1
F0.00014334862385321102
I0
I1
I-1
tp25887
sS'of,r-warfarin,or'
p25888
(F1
F0.00014334862385321102
I0
I1
I-1
tp25889
sS'plasma,concentrations,below'
p25890
(F1
F0.00014334862385321102
I1
I0
I1
tp25891
sS'of,life,in'
p25892
(F1
F0.00014334862385321102
I0
I1
I-1
tp25893
sS'megakaryocytes,with,the'
p25894
(F1
F0.00014334862385321102
I0
I1
I-1
tp25895
sS'decided,to,discontinue'
p25896
(F1
F0.00014334862385321102
I1
I0
I1
tp25897
sS'masking,symptoms,of'
p25898
(F1
F0.00014334862385321102
I0
I1
I-1
tp25899
sS'in,total,body'
p25900
(F1
F0.00014334862385321102
I1
I0
I1
tp25901
sS'including,hyperglycemia,and'
p25902
(F1
F0.00014334862385321102
I1
I0
I1
tp25903
sS'cimetldine,cerivastatin,plasma'
p25904
(F1
F0.00014334862385321102
I0
I1
I-1
tp25905
sS'test,interactions,the'
p25906
(F1
F0.00028669724770642203
I0
I2
I-2
tp25907
sS'of,agranulocytosis,as'
p25908
(F1
F0.00014334862385321102
I0
I1
I-1
tp25909
sS'vitamin,a,because'
p25910
(F1
F0.00014334862385321102
I1
I0
I1
tp25911
sS'agents,since,the'
p25912
(F1
F0.00014334862385321102
I1
I0
I1
tp25913
sS'smooth,muscle,cell'
p25914
(F1
F0.00014334862385321102
I0
I1
I-1
tp25915
sS'interaction,occurred,when'
p25916
(F1
F0.00014334862385321102
I0
I1
I-1
tp25917
sS'monitor,levels,or'
p25918
(F1
F0.00014334862385321102
I0
I1
I-1
tp25919
sS'increased,an,average'
p25920
(F1
F0.00014334862385321102
I1
I0
I1
tp25921
sS'with,other,potent'
p25922
(F1
F0.00014334862385321102
I0
I1
I-1
tp25923
sS'whether,has,a'
p25924
(F1
F0.00014334862385321102
I0
I1
I-1
tp25925
sS'increased,about,fold'
p25926
(F1
F0.00028669724770642203
I2
I0
I2
tp25927
sS'it,was,observed'
p25928
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp25929
sS'number,of,alcohol-related'
p25930
(F1
F0.00014334862385321102
I0
I1
I-1
tp25931
sS'system,responsible,for'
p25932
(F1
F0.00028669724770642203
I2
I0
I2
tp25933
sS'toxicity,and,serial'
p25934
(F1
F0.00014334862385321102
I1
I0
I1
tp25935
sS'of,endogenous,steroid'
p25936
(F1
F0.00014334862385321102
I1
I0
I1
tp25937
sS'to,the,rat'
p25938
(F1
F0.00014334862385321102
I0
I1
I-1
tp25939
sS'was,also,ineffective'
p25940
(F1
F0.00014334862385321102
I0
I1
I-1
tp25941
sS'since,there,are'
p25942
(F1
F0.00014334862385321102
I1
I0
I1
tp25943
sS'randomly,assigned,in'
p25944
(F1
F0.00014334862385321102
I0
I1
I-1
tp25945
sS'that,alter,platelet'
p25946
(F1
F0.00014334862385321102
I1
I0
I1
tp25947
sS'or,glycoprotein,iib'
p25948
(F1
F0.00014334862385321102
I1
I0
I1
tp25949
sS'neurontin,in,epileptic'
p25950
(F1
F0.00014334862385321102
I0
I1
I-1
tp25951
sS'blocking,action,of'
p25952
(F1
F0.0008600917431192661
I6
I0
I6
tp25953
sS'is,at,least'
p25954
(F1
F0.00014334862385321102
I0
I1
I-1
tp25955
sS'cmax,and,mean'
p25956
(F1
F0.00014334862385321102
I1
I0
I1
tp25957
sS'and,functional,consequences'
p25958
(F1
F0.00028669724770642203
I0
I2
I-2
tp25959
sS'induction,of,cyp'
p25960
(F1
F0.00014334862385321102
I1
I0
I1
tp25961
sS'if,a,antimicrobial'
p25962
(F1
F0.00028669724770642203
I2
I0
I2
tp25963
sS'to,be,aware'
p25964
(F1
F0.00014334862385321102
I0
I1
I-1
tp25965
sS'compared,with,has'
p25966
(F1
F0.00014334862385321102
I0
I1
I-1
tp25967
sS'these,studies,it'
p25968
(F1
F0.00014334862385321102
I0
I1
I-1
tp25969
sS'given,concomitantly,with'
p25970
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp25971
sS'cefditoren,pivoxil,administered'
p25972
(F1
F0.00014334862385321102
I1
I0
I1
tp25973
sS'has,no,apparent'
p25974
(F1
F0.00057339449541284407
I0
I4
I-4
tp25975
sS'by,different,routes'
p25976
(F1
F0.00014334862385321102
I1
I0
I1
tp25977
sS'metabolism,in,ms'
p25978
(F1
F0.00014334862385321102
I1
I0
I1
tp25979
sS'i,increase,due'
p25980
(F1
F0.00014334862385321102
I1
I0
I1
tp25981
sS'fludara,for,injection'
p25982
(F1
F0.00014334862385321102
I1
I0
I1
tp25983
sS'alcohol,it,should'
p25984
(F1
F0.00014334862385321102
I1
I0
I1
tp25985
sS'clozapine,is,combined'
p25986
(F1
F0.00014334862385321102
I1
I0
I1
tp25987
sS'inhibitors,ssris,may'
p25988
(F1
F0.00014334862385321102
I1
I0
I1
tp25989
sS'is,administered,hours'
p25990
(F1
F0.00014334862385321102
I0
I1
I-1
tp25991
sS'group,of,nonsmoking'
p25992
(F1
F0.00014334862385321102
I0
I1
I-1
tp25993
sS'of,with,has'
p25994
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp25995
sS'and,prolonged,the'
p25996
(F1
F0.00014334862385321102
I1
I0
I1
tp25997
sS'especially,when,therapy'
p25998
(F1
F0.00014334862385321102
I1
I0
I1
tp25999
sS'a,modest,effect'
p26000
(F1
F0.00028669724770642203
I2
I0
I2
tp26001
sS'in,patients,prone'
p26002
(F1
F0.00014334862385321102
I1
I0
I1
tp26003
sS'or,be,subject'
p26004
(F1
F0.00014334862385321102
I0
I1
I-1
tp26005
sS'activity,of,oral'
p26006
(F1
F0.00014334862385321102
I1
I0
I1
tp26007
sS'digoxin,studies,of'
p26008
(F1
F0.00014334862385321102
I0
I1
I-1
tp26009
sS'should,not,ordinarily'
p26010
(F1
F0.00014334862385321102
I1
I0
I1
tp26011
sS'concomitantly,careful,monitoring'
p26012
(F1
F0.00014334862385321102
I0
I1
I-1
tp26013
sS'significantly,lowering,their'
p26014
(F1
F0.00014334862385321102
I0
I1
I-1
tp26015
sS'and,editorials,concerning'
p26016
(F1
F0.00014334862385321102
I0
I1
I-1
tp26017
sS'tablet,formulation,comparable'
p26018
(F1
F0.00028669724770642203
I2
I0
I2
tp26019
sS'interaction,study,was'
p26020
(F1
F0.00028669724770642203
I0
I2
I-2
tp26021
sS'agents,or,which'
p26022
(F1
F0.00014334862385321102
I1
I0
I1
tp26023
sS'ng,ml,administered'
p26024
(F1
F0.00014334862385321102
I1
I0
I1
tp26025
sS'renal,transplant,patients'
p26026
(F1
F0.00014334862385321102
I1
I0
I1
tp26027
sS'on,pharmacokinetics,if'
p26028
(F1
F0.00014334862385321102
I0
I1
I-1
tp26029
sS'de,pointes,have'
p26030
(F1
F0.00014334862385321102
I0
I1
I-1
tp26031
sS'other,nsaids,through'
p26032
(F1
F0.00014334862385321102
I1
I0
I1
tp26033
sS'cautiously,in,conjunction'
p26034
(F1
F0.00028669724770642203
I2
I0
I2
tp26035
sS'on,pharmacokinetics,in'
p26036
(F1
F0.00014334862385321102
I0
I1
I-1
tp26037
sS'on,two,strains'
p26038
(F1
F0.00014334862385321102
I0
I1
I-1
tp26039
sS'and,plasma,concentrations'
p26040
(F1
F0.00014334862385321102
I1
I0
I1
tp26041
sS'if,systemic,administration'
p26042
(F1
F0.00014334862385321102
I0
I1
I-1
tp26043
sS'and,nuclear,matrix'
p26044
(F1
F0.00014334862385321102
I1
I0
I1
tp26045
sS'treated,with,an'
p26046
(F1
F0.00014334862385321102
I1
I0
I1
tp26047
sS'a,pure,agonist'
p26048
(F1
F0.00014334862385321102
I1
I0
I1
tp26049
sS'mg,respectively,a'
p26050
(F1
F0.00014334862385321102
I1
I0
I1
tp26051
sS'azole,inhibits,the'
p26052
(F1
F0.00014334862385321102
I1
I0
I1
tp26053
sS'has,been,proposed'
p26054
(F1
F0.00014334862385321102
I1
I0
I1
tp26055
sS'anti-inflammatory,nsaids,suggests'
p26056
(F1
F0.00014334862385321102
I1
I0
I1
tp26057
sS'the,end,fo'
p26058
(F1
F0.00014334862385321102
I0
I1
I-1
tp26059
sS'a,false,low'
p26060
(F1
F0.00014334862385321102
I0
I1
I-1
tp26061
sS'function,have,not'
p26062
(F1
F0.00014334862385321102
I0
I1
I-1
tp26063
sS'left,ventricular,failure'
p26064
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp26065
sS'absence,of,severe'
p26066
(F1
F0.00014334862385321102
I0
I1
I-1
tp26067
sS'acid,may,interact'
p26068
(F1
F0.00014334862385321102
I1
I0
I1
tp26069
sS'combination,hormonal,increasing'
p26070
(F1
F0.00014334862385321102
I1
I0
I1
tp26071
sS'in,the,user'
p26072
(F1
F0.00014334862385321102
I0
I1
I-1
tp26073
sS'medications,especially,central'
p26074
(F1
F0.00014334862385321102
I0
I1
I-1
tp26075
sS'hours,are,recommended'
p26076
(F1
F0.00014334862385321102
I1
I0
I1
tp26077
sS'and,are,obtained'
p26078
(F1
F0.00014334862385321102
I1
I0
I1
tp26079
sS'of,b,for'
p26080
(F1
F0.00014334862385321102
I0
I1
I-1
tp26081
sS'used,alone,because'
p26082
(F1
F0.00014334862385321102
I1
I0
I1
tp26083
sS'indocin,is,added'
p26084
(F1
F0.00014334862385321102
I1
I0
I1
tp26085
sS'impairment,reportedly,resulted'
p26086
(F1
F0.00014334862385321102
I1
I0
I1
tp26087
sS'tolerance,in,dogs'
p26088
(F1
F0.00014334862385321102
I1
I0
I1
tp26089
sS'coadministration,of,did'
p26090
(F1
F0.00043004587155963305
I0
I3
I-3
tp26091
sS'of,toxicity,and'
p26092
(F0
F0
I1
I1
I0
tp26093
sS'is,a,neutralizing'
p26094
(F1
F0.00014334862385321102
I1
I0
I1
tp26095
sS'dopamine,antagonists,such'
p26096
(F1
F0.00014334862385321102
I1
I0
I1
tp26097
sS'to,cause,ventricular'
p26098
(F1
F0.00014334862385321102
I1
I0
I1
tp26099
sS'secretion,chronic,experiments'
p26100
(F1
F0.00014334862385321102
I0
I1
I-1
tp26101
sS'was,shown,that'
p26102
(F0
F0
I1
I1
I0
tp26103
sS'pulmonary,disease,requires'
p26104
(F1
F0.00014334862385321102
I0
I1
I-1
tp26105
sS'from,working,properly'
p26106
(F1
F0.00014334862385321102
I0
I1
I-1
tp26107
sS'response,duration,suggesting'
p26108
(F1
F0.00014334862385321102
I1
I0
I1
tp26109
sS'including,products,and'
p26110
(F1
F0.00014334862385321102
I1
I0
I1
tp26111
sS'ketoconazole,mg,once'
p26112
(F1
F0.00014334862385321102
I1
I0
I1
tp26113
sS'used,in,older'
p26114
(F1
F0.00014334862385321102
I0
I1
I-1
tp26115
sS'doses,of,see'
p26116
(F1
F0.00014334862385321102
I1
I0
I1
tp26117
sS'potentiate,the,cognitive'
p26118
(F1
F0.00014334862385321102
I1
I0
I1
tp26119
sS'glibenclamide,in,a'
p26120
(F1
F0.00014334862385321102
I1
I0
I1
tp26121
sS'dose,or,any'
p26122
(F1
F0.00014334862385321102
I1
I0
I1
tp26123
sS'alter,platelet,function'
p26124
(F1
F0.00014334862385321102
I1
I0
I1
tp26125
sS'other,substances,grapefruit'
p26126
(F1
F0.00014334862385321102
I0
I1
I-1
tp26127
sS'h1-blocking,agents,and'
p26128
(F1
F0.00014334862385321102
I1
I0
I1
tp26129
sS'of,prophylactic,low'
p26130
(F1
F0.00014334862385321102
I0
I1
I-1
tp26131
sS'rpmi1640,containing,alone'
p26132
(F1
F0.00014334862385321102
I1
I0
I1
tp26133
sS'therapy,may,be'
p26134
(F1
F0.00014334862385321102
I0
I1
I-1
tp26135
sS'inhibitory,effect,for'
p26136
(F1
F0.00014334862385321102
I1
I0
I1
tp26137
sS'had,received,days'
p26138
(F0
F0
I1
I1
I0
tp26139
sS'with,hiv-related,systemic'
p26140
(F1
F0.00014334862385321102
I0
I1
I-1
tp26141
sS'ssris,seriraline,and'
p26142
(F1
F0.00014334862385321102
I0
I1
I-1
tp26143
sS'inhibitors,and,have'
p26144
(F1
F0.00014334862385321102
I1
I0
I1
tp26145
sS'results,in,a'
p26146
(F0.5
F0.00028669724770642203
I3
I1
I2
tp26147
sS'be,decided,to'
p26148
(F1
F0.00014334862385321102
I1
I0
I1
tp26149
sS'frova,within,hours'
p26150
(F1
F0.00014334862385321102
I1
I0
I1
tp26151
sS'serentil,trilafon,compazine'
p26152
(F1
F0.00014334862385321102
I0
I1
I-1
tp26153
sS'leading,to,severe'
p26154
(F1
F0.00043004587155963305
I3
I0
I3
tp26155
sS'of,fludara,for'
p26156
(F1
F0.00014334862385321102
I1
I0
I1
tp26157
sS'was,controlled,with'
p26158
(F1
F0.00014334862385321102
I1
I0
I1
tp26159
sS'oxidation,is,the'
p26160
(F1
F0.00014334862385321102
I0
I1
I-1
tp26161
sS'but,not,on'
p26162
(F1
F0.00014334862385321102
I0
I1
I-1
tp26163
sS'amphotericin,b,intravenous'
p26164
(F1
F0.00014334862385321102
I1
I0
I1
tp26165
sS'such,an,interaction'
p26166
(F1
F0.00014334862385321102
I0
I1
I-1
tp26167
sS'or,consider,hmg-coa'
p26168
(F1
F0.00014334862385321102
I1
I0
I1
tp26169
sS'to,receive,tablets'
p26170
(F1
F0.00014334862385321102
I0
I1
I-1
tp26171
sS'tolbutamide,in,in'
p26172
(F1
F0.00014334862385321102
I0
I1
I-1
tp26173
sS'important,pharmacokinetic,interactions'
p26174
(F1
F0.00057339449541284407
I0
I4
I-4
tp26175
sS'are,sequestered,in'
p26176
(F1
F0.00014334862385321102
I0
I1
I-1
tp26177
sS'although,the,mechanism'
p26178
(F1
F0.00014334862385321102
I1
I0
I1
tp26179
sS'exposure,of,cefditoren'
p26180
(F1
F0.00014334862385321102
I1
I0
I1
tp26181
sS'pressure,usually,within'
p26182
(F1
F0.00014334862385321102
I1
I0
I1
tp26183
sS'blood,pressure,below'
p26184
(F1
F0.00043004587155963305
I3
I0
I3
tp26185
sS'are,at,an'
p26186
(F1
F0.00014334862385321102
I1
I0
I1
tp26187
sS'were,and,lower'
p26188
(F1
F0.00014334862385321102
I1
I0
I1
tp26189
sS'class,of,protease'
p26190
(F1
F0.00014334862385321102
I0
I1
I-1
tp26191
sS'and,increase,of'
p26192
(F1
F0.00014334862385321102
I1
I0
I1
tp26193
sS'toxicity,of,by'
p26194
(F1
F0.00014334862385321102
I1
I0
I1
tp26195
sS'therapeutic,supplement,containing'
p26196
(F1
F0.00014334862385321102
I1
I0
I1
tp26197
sS'action,of,alfenta'
p26198
(F1
F0.00014334862385321102
I0
I1
I-1
tp26199
sS'periods,of,active'
p26200
(F1
F0.00014334862385321102
I1
I0
I1
tp26201
sS'cimetidine,a,study'
p26202
(F1
F0.00014334862385321102
I1
I0
I1
tp26203
sS'without,any,change'
p26204
(F1
F0.00014334862385321102
I0
I1
I-1
tp26205
sS'and,tablets,results'
p26206
(F1
F0.00014334862385321102
I1
I0
I1
tp26207
sS'rats,were,fasted'
p26208
(F1
F0.00014334862385321102
I0
I1
I-1
tp26209
sS'nsaid,or,potentiated'
p26210
(F1
F0.00014334862385321102
I1
I0
I1
tp26211
sS'is,mg,with'
p26212
(F1
F0.00014334862385321102
I0
I1
I-1
tp26213
sS'a,functioning,gland'
p26214
(F1
F0.00014334862385321102
I1
I0
I1
tp26215
sS'when,it,is'
p26216
(F0.75
F0.0008600917431192661
I7
I1
I6
tp26217
sS'the,similarity,of'
p26218
(F1
F0.00014334862385321102
I0
I1
I-1
tp26219
sS'concentration,has,been'
p26220
(F0
F0
I1
I1
I0
tp26221
sS'digoxin,in,controlled'
p26222
(F1
F0.00014334862385321102
I1
I0
I1
tp26223
sS'risk,of,dehydration'
p26224
(F1
F0.00014334862385321102
I1
I0
I1
tp26225
sS'a,marketed,chewable'
p26226
(F1
F0.00014334862385321102
I1
I0
I1
tp26227
sS'the,initial,release'
p26228
(F1
F0.00014334862385321102
I1
I0
I1
tp26229
sS'that,obtained,with'
p26230
(F1
F0.00014334862385321102
I1
I0
I1
tp26231
sS'inhibitors,of,this'
p26232
(F1
F0.00028669724770642203
I2
I0
I2
tp26233
sS'most,subjects,who'
p26234
(F1
F0.00014334862385321102
I1
I0
I1
tp26235
sS'enhance,the,metabolic'
p26236
(F1
F0.00014334862385321102
I1
I0
I1
tp26237
sS'oxidase,inhibitors,nalidixic'
p26238
(F1
F0.00014334862385321102
I1
I0
I1
tp26239
sS'meclofenamate,sodium,enhances'
p26240
(F1
F0.00014334862385321102
I1
I0
I1
tp26241
sS'selective,peripheral,anitagonism'
p26242
(F1
F0.00014334862385321102
I1
I0
I1
tp26243
sS'distribution,metabolism,hormone'
p26244
(F1
F0.00014334862385321102
I0
I1
I-1
tp26245
sS'regarding,the,risk'
p26246
(F1
F0.00014334862385321102
I0
I1
I-1
tp26247
sS'significantly,inhibited,the'
p26248
(F1
F0.00014334862385321102
I1
I0
I1
tp26249
sS'a,containing,regimen'
p26250
(F1
F0.00014334862385321102
I0
I1
I-1
tp26251
sS'every,hours,competes'
p26252
(F1
F0.00014334862385321102
I1
I0
I1
tp26253
sS'treatment,improves,quality'
p26254
(F1
F0.00014334862385321102
I0
I1
I-1
tp26255
sS'hctz,alone,or'
p26256
(F1
F0.00014334862385321102
I0
I1
I-1
tp26257
sS'within,hours,of'
p26258
(F1
F0.0010034403669724771
I7
I0
I7
tp26259
sS'these,agents,may'
p26260
(F0
F0
I1
I1
I0
tp26261
sS'and,other,ht1'
p26262
(F1
F0.00014334862385321102
I1
I0
I1
tp26263
sS'in,rats,responding'
p26264
(F1
F0.00014334862385321102
I1
I0
I1
tp26265
sS'a,potential,for'
p26266
(F0
F0
I1
I1
I0
tp26267
sS'caution,and,should'
p26268
(F1
F0.00014334862385321102
I1
I0
I1
tp26269
sS'between,and,inducers'
p26270
(F1
F0.00014334862385321102
I1
I0
I1
tp26271
sS'plasma,exposure,or'
p26272
(F1
F0.00014334862385321102
I0
I1
I-1
tp26273
sS'formal,pharmacokinetic,studies'
p26274
(F1
F0.00014334862385321102
I0
I1
I-1
tp26275
sS'healthy,volunteers,resulted'
p26276
(F0
F0
I1
I1
I0
tp26277
sS'patient,has,recently'
p26278
(F1
F0.00014334862385321102
I1
I0
I1
tp26279
sS'with,which,to'
p26280
(F1
F0.00014334862385321102
I0
I1
I-1
tp26281
sS'the,evening,meal'
p26282
(F0
F0
I1
I1
I0
tp26283
sS'mesantoin,use,of'
p26284
(F1
F0.00014334862385321102
I0
I1
I-1
tp26285
sS'metabolism,very,sensitive'
p26286
(F1
F0.00014334862385321102
I0
I1
I-1
tp26287
sS'life-threatening,reactions,such'
p26288
(F1
F0.00028669724770642203
I0
I2
I-2
tp26289
sS'plasma,exposure,of'
p26290
(F1
F0.00028669724770642203
I2
I0
I2
tp26291
sS'resulting,in,serum'
p26292
(F1
F0.00014334862385321102
I1
I0
I1
tp26293
sS'metabolism,was,tested'
p26294
(F1
F0.00014334862385321102
I0
I1
I-1
tp26295
sS'of,er,extended'
p26296
(F1
F0.00014334862385321102
I0
I1
I-1
tp26297
sS'adjustment,of,either'
p26298
(F1
F0.00014334862385321102
I0
I1
I-1
tp26299
sS'breast,cancer,in'
p26300
(F1
F0.00014334862385321102
I1
I0
I1
tp26301
sS'toxoids,and,live'
p26302
(F1
F0.00014334862385321102
I1
I0
I1
tp26303
sS'on,steady-state,pharmacokinetics'
p26304
(F1
F0.00014334862385321102
I0
I1
I-1
tp26305
sS'antacids,containing,trisilicate'
p26306
(F1
F0.00014334862385321102
I1
I0
I1
tp26307
sS'patients,undergoing,ptca'
p26308
(F1
F0.00014334862385321102
I1
I0
I1
tp26309
sS'levels,and,administration'
p26310
(F1
F0.00014334862385321102
I0
I1
I-1
tp26311
sS'neurotoxic,therapy,including'
p26312
(F1
F0.00014334862385321102
I0
I1
I-1
tp26313
sS'concomitantly,patients,should'
p26314
(F1
F0.00014334862385321102
I1
I0
I1
tp26315
sS'bioavailability,auc,and'
p26316
(F1
F0.00028669724770642203
I0
I2
I-2
tp26317
sS'oil,and,k'
p26318
(F1
F0.00014334862385321102
I1
I0
I1
tp26319
sS'cyp2d6,isoenzyme,daily'
p26320
(F1
F0.00014334862385321102
I1
I0
I1
tp26321
sS'cataflam,lodine,indocin'
p26322
(F1
F0.00014334862385321102
I0
I1
I-1
tp26323
sS'the,potent,cytochrome'
p26324
(F1
F0.00014334862385321102
I1
I0
I1
tp26325
sS'is,an,interaction'
p26326
(F1
F0.00014334862385321102
I1
I0
I1
tp26327
sS'been,suggested,with'
p26328
(F1
F0.00043004587155963305
I0
I3
I-3
tp26329
sS'demonstrated,that,and'
p26330
(F0
F0
I1
I1
I0
tp26331
sS'when,ht1,agonists'
p26332
(F1
F0.00014334862385321102
I1
I0
I1
tp26333
sS'the,following,table'
p26334
(F1
F0.00028669724770642203
I0
I2
I-2
tp26335
sS'interactions,must,be'
p26336
(F1
F0.00014334862385321102
I1
I0
I1
tp26337
sS'monitored,for,signs'
p26338
(F1
F0.00014334862385321102
I0
I1
I-1
tp26339
sS'other,day,until'
p26340
(F1
F0.00014334862385321102
I0
I1
I-1
tp26341
sS'cyp2c8,cyp2c9,cyp2c19'
p26342
(F1
F0.00014334862385321102
I0
I1
I-1
tp26343
sS'gvia,n-type,or'
p26344
(F1
F0.00014334862385321102
I0
I1
I-1
tp26345
sS'products,with,similar'
p26346
(F1
F0.00014334862385321102
I1
I0
I1
tp26347
sS'been,shown,between'
p26348
(F1
F0.00014334862385321102
I1
I0
I1
tp26349
sS'nine,patients,with'
p26350
(F1
F0.00014334862385321102
I1
I0
I1
tp26351
sS'of,profound,hypotension'
p26352
(F1
F0.00014334862385321102
I1
I0
I1
tp26353
sS'reported,when,amitriptyline'
p26354
(F1
F0.00014334862385321102
I1
I0
I1
tp26355
sS'formation,of,a'
p26356
(F1
F0.00014334862385321102
I1
I0
I1
tp26357
sS'interactions,among,co-administered'
p26358
(F1
F0.00014334862385321102
I0
I1
I-1
tp26359
sS'strains,of,escherichia'
p26360
(F1
F0.00014334862385321102
I0
I1
I-1
tp26361
sS'administration,to,rachitic'
p26362
(F1
F0.00014334862385321102
I1
I0
I1
tp26363
sS'potentiation,of,orthostatic'
p26364
(F1
F0.00014334862385321102
I0
I1
I-1
tp26365
sS'the,tysabri,dose'
p26366
(F1
F0.00014334862385321102
I0
I1
I-1
tp26367
sS'pletal,is,extensively'
p26368
(F1
F0.00014334862385321102
I1
I0
I1
tp26369
sS'interactions,for,include'
p26370
(F1
F0.00014334862385321102
I1
I0
I1
tp26371
sS'nicardipine,hcl,usually'
p26372
(F1
F0.00014334862385321102
I1
I0
I1
tp26373
sS'in,man,significantly'
p26374
(F1
F0.00028669724770642203
I2
I0
I2
tp26375
sS'changes,resulting,from'
p26376
(F1
F0.00014334862385321102
I0
I1
I-1
tp26377
sS'a,supersensitivity,to'
p26378
(F1
F0.00014334862385321102
I1
I0
I1
tp26379
sS'zarontin,may,interact'
p26380
(F1
F0.00014334862385321102
I1
I0
I1
tp26381
sS'was,not,a'
p26382
(F1
F0.00014334862385321102
I0
I1
I-1
tp26383
sS'concentration,accompanied,by'
p26384
(F1
F0.00014334862385321102
I1
I0
I1
tp26385
sS'and,enhanced,effects'
p26386
(F1
F0.00014334862385321102
I0
I1
I-1
tp26387
sS'affecting,the,liver'
p26388
(F1
F0.00043004587155963305
I3
I0
I3
tp26389
sS'nonopioid,tolerant,patients'
p26390
(F1
F0.00014334862385321102
I0
I1
I-1
tp26391
sS'thus,the,interaction'
p26392
(F1
F0.00014334862385321102
I1
I0
I1
tp26393
sS'of,that,may'
p26394
(F1
F0.00028669724770642203
I2
I0
I2
tp26395
sS'use,of,by'
p26396
(F1
F0.00014334862385321102
I1
I0
I1
tp26397
sS'blockers,calcium-channel,blockers'
p26398
(F1
F0.00014334862385321102
I0
I1
I-1
tp26399
sS'anti-inflammatory,nsaids,and'
p26400
(F1
F0.00014334862385321102
I1
I0
I1
tp26401
sS'bound,drugs,in'
p26402
(F1
F0.00014334862385321102
I0
I1
I-1
tp26403
sS'placebo-controlled,crossover,study'
p26404
(F1
F0.00014334862385321102
I1
I0
I1
tp26405
sS'including,based,on'
p26406
(F1
F0.00014334862385321102
I1
I0
I1
tp26407
sS'which,was,prevented'
p26408
(F1
F0.00014334862385321102
I1
I0
I1
tp26409
sS'gradual,in,order'
p26410
(F1
F0.00014334862385321102
I1
I0
I1
tp26411
sS'in,an,decrease'
p26412
(F1
F0.00014334862385321102
I1
I0
I1
tp26413
sS'enough,to,affect'
p26414
(F1
F0.00014334862385321102
I0
I1
I-1
tp26415
sS'less,than,of'
p26416
(F1
F0.00014334862385321102
I0
I1
I-1
tp26417
sS'by,endothelial,denudation'
p26418
(F1
F0.00014334862385321102
I0
I1
I-1
tp26419
sS'depressant,effects,divalproex'
p26420
(F1
F0.00014334862385321102
I1
I0
I1
tp26421
sS'reasonable,to,expect'
p26422
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp26423
sS'phosphorylation,in,t24'
p26424
(F1
F0.00014334862385321102
I1
I0
I1
tp26425
sS'total,concentrations,just'
p26426
(F1
F0.00014334862385321102
I0
I1
I-1
tp26427
sS'studies,it,is'
p26428
(F1
F0.00028669724770642203
I0
I2
I-2
tp26429
sS'sodium,and,may'
p26430
(F1
F0.00014334862385321102
I1
I0
I1
tp26431
sS'theophylline,following,co-administration'
p26432
(F1
F0.00014334862385321102
I0
I1
I-1
tp26433
sS'enhance,the,action'
p26434
(F1
F0.00043004587155963305
I3
I0
I3
tp26435
sS'often,administered,concurrently'
p26436
(F1
F0.00014334862385321102
I0
I1
I-1
tp26437
sS'needed,when,and'
p26438
(F1
F0.00014334862385321102
I0
I1
I-1
tp26439
sS'toxicity,may,result'
p26440
(F1
F0.00014334862385321102
I1
I0
I1
tp26441
sS'conducted,with,persantine'
p26442
(F1
F0.00014334862385321102
I0
I1
I-1
tp26443
sS'defined,medium,consisting'
p26444
(F1
F0.00014334862385321102
I0
I1
I-1
tp26445
sS'of,metabolism,decreased'
p26446
(F1
F0.00014334862385321102
I1
I0
I1
tp26447
sS'in,controlled,clinical'
p26448
(F1
F0.00057339449541284407
I0
I4
I-4
tp26449
sS'medication,patients,want'
p26450
(F1
F0.00014334862385321102
I0
I1
I-1
tp26451
sS'reductase,inhibitor,to'
p26452
(F1
F0.00014334862385321102
I0
I1
I-1
tp26453
sS'including,preparations,glyceryl'
p26454
(F1
F0.00014334862385321102
I0
I1
I-1
tp26455
sS'and,including,or'
p26456
(F1
F0.00014334862385321102
I0
I1
I-1
tp26457
sS'of,by,concomitant'
p26458
(F1
F0.00014334862385321102
I1
I0
I1
tp26459
sS'information,digoxin,studies'
p26460
(F1
F0.00014334862385321102
I0
I1
I-1
tp26461
sS'mental,and,motor'
p26462
(F1
F0.00014334862385321102
I0
I1
I-1
tp26463
sS'consequences,for,drugs'
p26464
(F1
F0.00014334862385321102
I1
I0
I1
tp26465
sS'have,several,advantages'
p26466
(F1
F0.00014334862385321102
I0
I1
I-1
tp26467
sS'similarly,the,effects'
p26468
(F1
F0.00014334862385321102
I1
I0
I1
tp26469
sS'a,balanced,technique'
p26470
(F1
F0.00014334862385321102
I0
I1
I-1
tp26471
sS'severe,obstipation,even'
p26472
(F1
F0.00014334862385321102
I1
I0
I1
tp26473
sS'of,multiple,doses'
p26474
(F1
F0.00014334862385321102
I0
I1
I-1
tp26475
sS'the,estimated,number'
p26476
(F1
F0.00014334862385321102
I0
I1
I-1
tp26477
sS'time,of,were'
p26478
(F1
F0.00014334862385321102
I0
I1
I-1
tp26479
sS'bid,otc,dose'
p26480
(F1
F0.00014334862385321102
I1
I0
I1
tp26481
sS'transcriptase,inhibitor,nnrti'
p26482
(F1
F0.00014334862385321102
I0
I1
I-1
tp26483
sS'tykerb,is,administered'
p26484
(F1
F0.00014334862385321102
I0
I1
I-1
tp26485
sS'may,cause,adrenal'
p26486
(F1
F0.00014334862385321102
I1
I0
I1
tp26487
sS'rises,in,serum'
p26488
(F1
F0.00014334862385321102
I1
I0
I1
tp26489
sS'compared,with,a'
p26490
(F1
F0.00014334862385321102
I1
I0
I1
tp26491
sS'strong,inducers,of'
p26492
(F1
F0.00014334862385321102
I0
I1
I-1
tp26493
sS'formal,studies,fully'
p26494
(F1
F0.00014334862385321102
I0
I1
I-1
tp26495
sS'endotoxin-induced,changes,in'
p26496
(F1
F0.00014334862385321102
I0
I1
I-1
tp26497
sS'auc,of,sustained-release'
p26498
(F1
F0.00014334862385321102
I1
I0
I1
tp26499
sS'on,absorption,from'
p26500
(F1
F0.00014334862385321102
I0
I1
I-1
tp26501
sS'not,impaired,but'
p26502
(F1
F0.00014334862385321102
I0
I1
I-1
tp26503
sS'in,adverse,events'
p26504
(F1
F0.00043004587155963305
I0
I3
I-3
tp26505
sS'administration,of,these'
p26506
(F0.5
F0.00028669724770642203
I3
I1
I2
tp26507
sS'from,existing,clinical'
p26508
(F1
F0.00014334862385321102
I0
I1
I-1
tp26509
sS'blood,levels,in'
p26510
(F1
F0.00014334862385321102
I0
I1
I-1
tp26511
sS'and,requiring,increased'
p26512
(F1
F0.00014334862385321102
I1
I0
I1
tp26513
sS'about,two,studies'
p26514
(F1
F0.00014334862385321102
I1
I0
I1
tp26515
sS'plasma,and,reduction'
p26516
(F1
F0.00014334862385321102
I1
I0
I1
tp26517
sS'of,platelet,effects'
p26518
(F1
F0.00028669724770642203
I0
I2
I-2
tp26519
sS'effects,such,as'
p26520
(F1
F0.00043004587155963305
I3
I0
I3
tp26521
sS'with,without,evidence'
p26522
(F1
F0.00014334862385321102
I0
I1
I-1
tp26523
sS'of,the,mucocutaneous'
p26524
(F1
F0.00014334862385321102
I0
I1
I-1
tp26525
sS'positive,test,for'
p26526
(F1
F0.00014334862385321102
I0
I1
I-1
tp26527
sS'as,or,or'
p26528
(F1
F0.00014334862385321102
I0
I1
I-1
tp26529
sS'inconclusive,with,regard'
p26530
(F1
F0.00014334862385321102
I0
I1
I-1
tp26531
sS'lodine,indocin,relafen'
p26532
(F1
F0.00014334862385321102
I0
I1
I-1
tp26533
sS'or,would,be'
p26534
(F1
F0.00014334862385321102
I0
I1
I-1
tp26535
sS'sinus,medicines,diabetic'
p26536
(F1
F0.00014334862385321102
I1
I0
I1
tp26537
sS'the,permeation,however'
p26538
(F1
F0.00014334862385321102
I0
I1
I-1
tp26539
sS'and,cmax,by'
p26540
(F0
F0
I1
I1
I0
tp26541
sS'effects,of,isocarboxazid'
p26542
(F1
F0.00014334862385321102
I0
I1
I-1
tp26543
sS'with,plendil,the'
p26544
(F1
F0.00014334862385321102
I0
I1
I-1
tp26545
sS'm,parenteral,should'
p26546
(F1
F0.00014334862385321102
I1
I0
I1
tp26547
sS'antiretroviral,agents,no'
p26548
(F1
F0.00014334862385321102
I0
I1
I-1
tp26549
sS'barbiturates,and,should'
p26550
(F1
F0.00014334862385321102
I1
I0
I1
tp26551
sS'insertable,hormonal,birth'
p26552
(F1
F0.00014334862385321102
I0
I1
I-1
tp26553
sS'psychiatric,patients,and'
p26554
(F1
F0.00014334862385321102
I1
I0
I1
tp26555
sS'organic,l-arginine,supplements'
p26556
(F1
F0.00014334862385321102
I1
I0
I1
tp26557
sS'involved,the,administration'
p26558
(F1
F0.00014334862385321102
I0
I1
I-1
tp26559
sS'it,may,be'
p26560
(F1
F0.00014334862385321102
I1
I0
I1
tp26561
sS'with,humira,has'
p26562
(F1
F0.00014334862385321102
I0
I1
I-1
tp26563
sS'stimulant,action,on'
p26564
(F1
F0.00014334862385321102
I0
I1
I-1
tp26565
sS'of,aprepitant,was'
p26566
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp26567
sS'every,other,day'
p26568
(F1
F0.00014334862385321102
I0
I1
I-1
tp26569
sS'wellbutrin,should,be'
p26570
(F1
F0.00014334862385321102
I1
I0
I1
tp26571
sS'a,higher,cardiac'
p26572
(F1
F0.00014334862385321102
I1
I0
I1
tp26573
sS'of,buspirone,hcl'
p26574
(F1
F0.00028669724770642203
I2
I0
I2
tp26575
sS'affect,any,of'
p26576
(F1
F0.00014334862385321102
I0
I1
I-1
tp26577
sS'rash,has,been'
p26578
(F1
F0.00014334862385321102
I1
I0
I1
tp26579
sS'foscavir,and,intravenous'
p26580
(F1
F0.00028669724770642203
I2
I0
I2
tp26581
sS'trough,plasma,concentrations'
p26582
(F1
F0.00014334862385321102
I0
I1
I-1
tp26583
sS'effect,caution,should'
p26584
(F1
F0.00014334862385321102
I1
I0
I1
tp26585
sS'p450,enzymes,evaluated'
p26586
(F1
F0.00014334862385321102
I0
I1
I-1
tp26587
sS'dinitrate,may,be'
p26588
(F1
F0.00014334862385321102
I1
I0
I1
tp26589
sS'n,later,changed'
p26590
(F1
F0.00014334862385321102
I0
I1
I-1
tp26591
sS'sterol,in,human'
p26592
(F1
F0.00014334862385321102
I0
I1
I-1
tp26593
sS'of,combined,therapy'
p26594
(F1
F0.00028669724770642203
I2
I0
I2
tp26595
sS'the,development,of'
p26596
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp26597
sS'level,of,ergocalcitriol'
p26598
(F1
F0.00043004587155963305
I0
I3
I-3
tp26599
sS'the,antidepressant,class'
p26600
(F1
F0.00028669724770642203
I0
I2
I-2
tp26601
sS'when,possible,and'
p26602
(F1
F0.00014334862385321102
I1
I0
I1
tp26603
sS'agent,that,decreases'
p26604
(F1
F0.00014334862385321102
I0
I1
I-1
tp26605
sS'this,the,dosage'
p26606
(F1
F0.00014334862385321102
I0
I1
I-1
tp26607
sS'the,sirolimus-diltiazem,interaction'
p26608
(F1
F0.00014334862385321102
I1
I0
I1
tp26609
sS'developed,rash,while'
p26610
(F1
F0.00014334862385321102
I1
I0
I1
tp26611
sS'hydroxytamoxifen,tam,which'
p26612
(F1
F0.00014334862385321102
I0
I1
I-1
tp26613
sS'agents,having,vasodilator'
p26614
(F1
F0.00014334862385321102
I0
I1
I-1
tp26615
sS'test,period,will'
p26616
(F1
F0.00014334862385321102
I1
I0
I1
tp26617
sS'other,nonsteroidal,anti-inflammatory'
p26618
(F1
F0.00014334862385321102
I0
I1
I-1
tp26619
sS'myobloc,and,or'
p26620
(F1
F0.00014334862385321102
I1
I0
I1
tp26621
sS'of,g,of'
p26622
(F1
F0.00014334862385321102
I1
I0
I1
tp26623
sS'day,did,not'
p26624
(F1
F0.00014334862385321102
I0
I1
I-1
tp26625
sS'reserved,for,patients'
p26626
(F1
F0.00014334862385321102
I0
I1
I-1
tp26627
sS'uptake,inhibitors,and'
p26628
(F1
F0.00014334862385321102
I1
I0
I1
tp26629
sS'colonic,fluid,by'
p26630
(F1
F0.00014334862385321102
I0
I1
I-1
tp26631
sS'and,prothrombin,time'
p26632
(F0
F0
I1
I1
I0
tp26633
sS'by,concurrent,dosing'
p26634
(F1
F0.00014334862385321102
I0
I1
I-1
tp26635
sS'orally,administered,agents'
p26636
(F1
F0.00014334862385321102
I1
I0
I1
tp26637
sS'of,reports,of'
p26638
(F1
F0.00014334862385321102
I1
I0
I1
tp26639
sS'healthy,subjects,mean'
p26640
(F1
F0.00014334862385321102
I1
I0
I1
tp26641
sS'degree,when,it'
p26642
(F1
F0.00014334862385321102
I0
I1
I-1
tp26643
sS'zollinger-ellison,ze,patients'
p26644
(F1
F0.00014334862385321102
I0
I1
I-1
tp26645
sS'that,inhibits,cyp2d6'
p26646
(F1
F0.00014334862385321102
I0
I1
I-1
tp26647
sS'muscle,relaxants,in'
p26648
(F1
F0.00014334862385321102
I0
I1
I-1
tp26649
sS'is,a,minor'
p26650
(F1
F0.00014334862385321102
I0
I1
I-1
tp26651
sS'coadministration,of,baraclude'
p26652
(F1
F0.00028669724770642203
I0
I2
I-2
tp26653
sS'that,can,prolong'
p26654
(F1
F0.00014334862385321102
I1
I0
I1
tp26655
sS'well,as,in'
p26656
(F1
F0.00014334862385321102
I0
I1
I-1
tp26657
sS'the,genotypes,of'
p26658
(F1
F0.00014334862385321102
I0
I1
I-1
tp26659
sS'of,normal,subjects'
p26660
(F1
F0.00014334862385321102
I1
I0
I1
tp26661
sS'use,of,tricyclic'
p26662
(F1
F0.00014334862385321102
I0
I1
I-1
tp26663
sS'of,hydrobromide,may'
p26664
(F1
F0.00014334862385321102
I1
I0
I1
tp26665
sS'and,one,strain'
p26666
(F1
F0.00014334862385321102
I0
I1
I-1
tp26667
sS'be,performed,with'
p26668
(F1
F0.00028669724770642203
I2
I0
I2
tp26669
sS'avoided,by,patients'
p26670
(F1
F0.00014334862385321102
I1
I0
I1
tp26671
sS'therefore,may,interfere'
p26672
(F1
F0.00014334862385321102
I1
I0
I1
tp26673
sS'substantially,increased,following'
p26674
(F1
F0.00014334862385321102
I1
I0
I1
tp26675
sS'if,it,is'
p26676
(F1
F0.00014334862385321102
I1
I0
I1
tp26677
sS'both,agents,with'
p26678
(F1
F0.00014334862385321102
I1
I0
I1
tp26679
sS'metabolite,mhd,have'
p26680
(F1
F0.00014334862385321102
I0
I1
I-1
tp26681
sS'difference,was,found'
p26682
(F1
F0.00014334862385321102
I0
I1
I-1
tp26683
sS'increases,the,serum'
p26684
(F1
F0.00014334862385321102
I0
I1
I-1
tp26685
sS'hivid,and,zdv'
p26686
(F1
F0.00014334862385321102
I0
I1
I-1
tp26687
sS'of,was,observed'
p26688
(F1
F0.00028669724770642203
I2
I0
I2
tp26689
sS'concentrations,within,the'
p26690
(F1
F0.00014334862385321102
I0
I1
I-1
tp26691
sS'with,acamprosate,produced'
p26692
(F1
F0.00014334862385321102
I1
I0
I1
tp26693
sS'its,derivatives,or'
p26694
(F1
F0.00014334862385321102
I1
I0
I1
tp26695
sS'major,ingredient,of'
p26696
(F1
F0.00014334862385321102
I0
I1
I-1
tp26697
sS'therapeutic,action,of'
p26698
(F1
F0.00014334862385321102
I1
I0
I1
tp26699
sS'coagulation,factor,concentrates'
p26700
(F1
F0.00014334862385321102
I0
I1
I-1
tp26701
sS'report,suggesting,that'
p26702
(F1
F0.00014334862385321102
I1
I0
I1
tp26703
sS'suppression,of,gastric'
p26704
(F1
F0.00014334862385321102
I1
I0
I1
tp26705
sS'symptoms,of,withdrawal'
p26706
(F1
F0.00014334862385321102
I1
I0
I1
tp26707
sS'than,weeks,may'
p26708
(F1
F0.00014334862385321102
I1
I0
I1
tp26709
sS'patient,in,how'
p26710
(F1
F0.00014334862385321102
I0
I1
I-1
tp26711
sS'the,mean,values'
p26712
(F1
F0.00014334862385321102
I0
I1
I-1
tp26713
sS'of,additional,calcium-containing'
p26714
(F1
F0.00043004587155963305
I0
I3
I-3
tp26715
sS'treat,an,overactive'
p26716
(F1
F0.00014334862385321102
I0
I1
I-1
tp26717
sS'can,inhibit,cytochrome'
p26718
(F1
F0.00071674311926605509
I0
I5
I-5
tp26719
sS'are,required,during'
p26720
(F1
F0.00028669724770642203
I2
I0
I2
tp26721
sS'when,mg,was'
p26722
(F1
F0.00014334862385321102
I1
I0
I1
tp26723
sS'pentobarbital-induced,sedation,times'
p26724
(F1
F0.00014334862385321102
I0
I1
I-1
tp26725
sS'showed,a,reduction'
p26726
(F1
F0.00014334862385321102
I1
I0
I1
tp26727
sS'however,because,higher'
p26728
(F1
F0.00014334862385321102
I0
I1
I-1
tp26729
sS'and,fatal,convulsions'
p26730
(F1
F0.00028669724770642203
I2
I0
I2
tp26731
sS'modulation,of,cholinergic'
p26732
(F1
F0.00014334862385321102
I0
I1
I-1
tp26733
sS'the,bumetanide-induced,increase'
p26734
(F1
F0.00014334862385321102
I1
I0
I1
tp26735
sS'tablets,the,including'
p26736
(F1
F0.00014334862385321102
I1
I0
I1
tp26737
sS'may,increase,metabolism'
p26738
(F1
F0.00014334862385321102
I0
I1
I-1
tp26739
sS'show,a,significant'
p26740
(F1
F0.00014334862385321102
I0
I1
I-1
tp26741
sS'bepridil,and,beta-blocking'
p26742
(F1
F0.00014334862385321102
I0
I1
I-1
tp26743
sS'of,beta-adrenergic,antagonists'
p26744
(F1
F0.00014334862385321102
I1
I0
I1
tp26745
sS'biotransformation,system,mainly'
p26746
(F1
F0.00014334862385321102
I1
I0
I1
tp26747
sS'of,an,hydroxide'
p26748
(F1
F0.00014334862385321102
I1
I0
I1
tp26749
sS'is,unknown,whether'
p26750
(F1
F0.00014334862385321102
I0
I1
I-1
tp26751
sS'in,the,median'
p26752
(F1
F0.00014334862385321102
I1
I0
I1
tp26753
sS'protocol,for,a'
p26754
(F1
F0.00014334862385321102
I0
I1
I-1
tp26755
sS'although,ipratropium,bromide'
p26756
(F1
F0.00014334862385321102
I1
I0
I1
tp26757
sS'such,as,videx'
p26758
(F1
F0.00028669724770642203
I2
I0
I2
tp26759
sS'tcatreatment,in,a'
p26760
(F1
F0.00014334862385321102
I1
I0
I1
tp26761
sS'is,thus,an'
p26762
(F1
F0.00014334862385321102
I1
I0
I1
tp26763
sS'dosage,of,may'
p26764
(F1
F0.00014334862385321102
I1
I0
I1
tp26765
sS'a,tolerance,to'
p26766
(F1
F0.00014334862385321102
I1
I0
I1
tp26767
sS'day,provided,significant'
p26768
(F1
F0.00014334862385321102
I1
I0
I1
tp26769
sS'm,m,of'
p26770
(F1
F0.00014334862385321102
I0
I1
I-1
tp26771
sS'influence,of,sympatholytic'
p26772
(F1
F0.00028669724770642203
I0
I2
I-2
tp26773
sS'which,increase,the'
p26774
(F1
F0.00014334862385321102
I1
I0
I1
tp26775
sS'be,avoided,see'
p26776
(F1
F0.00014334862385321102
I1
I0
I1
tp26777
sS'patients,who,begin'
p26778
(F1
F0.00014334862385321102
I1
I0
I1
tp26779
sS'dependent,diabetic,patients'
p26780
(F1
F0.00014334862385321102
I0
I1
I-1
tp26781
sS'trans-3,dimethyl-4,hydroxyphenyl'
p26782
(F1
F0.00014334862385321102
I1
I0
I1
tp26783
sS'manner,similar,to'
p26784
(F1
F0.00014334862385321102
I0
I1
I-1
tp26785
sS'concentrations,by,as'
p26786
(F1
F0.00014334862385321102
I1
I0
I1
tp26787
sS'involving,alprazolam,caution'
p26788
(F1
F0.00014334862385321102
I1
I0
I1
tp26789
sS'effects,of,were'
p26790
(F0
F0
I1
I1
I0
tp26791
sS'ability,to,affect'
p26792
(F1
F0.00014334862385321102
I0
I1
I-1
tp26793
sS'no,discernible,changes'
p26794
(F1
F0.00014334862385321102
I0
I1
I-1
tp26795
sS'while,taking,aminosalicylic'
p26796
(F1
F0.00014334862385321102
I1
I0
I1
tp26797
sS'low,dose,unfractionated'
p26798
(F1
F0.00014334862385321102
I0
I1
I-1
tp26799
sS'or,similar,agents'
p26800
(F1
F0.00028669724770642203
I2
I0
I2
tp26801
sS'experience,with,co-administration'
p26802
(F0
F0
I1
I1
I0
tp26803
sS'within,the,range'
p26804
(F1
F0.00014334862385321102
I0
I1
I-1
tp26805
sS'l-tryptophan,may,increase'
p26806
(F1
F0.00014334862385321102
I0
I1
I-1
tp26807
sS'be,aware,of'
p26808
(F1
F0.00014334862385321102
I0
I1
I-1
tp26809
sS'induce,cyp3a,may'
p26810
(F1
F0.00014334862385321102
I0
I1
I-1
tp26811
sS'vivo,the,plasma'
p26812
(F1
F0.00014334862385321102
I1
I0
I1
tp26813
sS'of,to,plasma'
p26814
(F1
F0.00014334862385321102
I1
I0
I1
tp26815
sS'subjects,the,steady-state'
p26816
(F1
F0.00014334862385321102
I0
I1
I-1
tp26817
sS'and,these,patients'
p26818
(F1
F0.00014334862385321102
I0
I1
I-1
tp26819
sS'use,of,antifibrinolytic'
p26820
(F1
F0.00014334862385321102
I0
I1
I-1
tp26821
sS'multivitamins,quinolones,form'
p26822
(F1
F0.00014334862385321102
I0
I1
I-1
tp26823
sS'rifampin,when,a'
p26824
(F1
F0.00014334862385321102
I1
I0
I1
tp26825
sS'as,compared,with'
p26826
(F1
F0.00014334862385321102
I1
I0
I1
tp26827
sS'including,myocardial,infarction'
p26828
(F1
F0.00014334862385321102
I1
I0
I1
tp26829
sS'no,substantive,effect'
p26830
(F1
F0.00014334862385321102
I0
I1
I-1
tp26831
sS'increase,in,cyclosporine-induced'
p26832
(F1
F0.00028669724770642203
I2
I0
I2
tp26833
sS'changes,in,inr'
p26834
(F1
F0.00014334862385321102
I0
I1
I-1
tp26835
sS'to,environmental,may'
p26836
(F1
F0.00014334862385321102
I1
I0
I1
tp26837
sS'demonstrated,efficacy,in'
p26838
(F1
F0.00014334862385321102
I0
I1
I-1
tp26839
sS'was,lower,than'
p26840
(F1
F0.00014334862385321102
I1
I0
I1
tp26841
sS'medroxyprogesterone,acetate,l-histidine'
p26842
(F1
F0.00014334862385321102
I1
I0
I1
tp26843
sS'further,antihypertensive,effect'
p26844
(F1
F0.00014334862385321102
I1
I0
I1
tp26845
sS'ganoderma,lucidum,extract'
p26846
(F1
F0.00014334862385321102
I0
I1
I-1
tp26847
sS'actions,certain,narcotic'
p26848
(F1
F0.00014334862385321102
I1
I0
I1
tp26849
sS'administered,hours,prior'
p26850
(F1
F0.00043004587155963305
I3
I0
I3
tp26851
sS'blocking,agents,calcium-channel'
p26852
(F1
F0.00014334862385321102
I0
I1
I-1
tp26853
sS'such,as,mg'
p26854
(F1
F0.00014334862385321102
I0
I1
I-1
tp26855
sS'no,reported,cases'
p26856
(F1
F0.00014334862385321102
I0
I1
I-1
tp26857
sS'fluconazole,fluoxetine,indanavir'
p26858
(F1
F0.00014334862385321102
I0
I1
I-1
tp26859
sS'mhd,the,predominant'
p26860
(F1
F0.00014334862385321102
I0
I1
I-1
tp26861
sS'pharmacokinetics,and,or'
p26862
(F1
F0.00014334862385321102
I0
I1
I-1
tp26863
sS'alternatives,to,as'
p26864
(F1
F0.00014334862385321102
I1
I0
I1
tp26865
sS'may,decrease,renal'
p26866
(F1
F0.00028669724770642203
I2
I0
I2
tp26867
sS'in,serum,and'
p26868
(F0
F0
I1
I1
I0
tp26869
sS'that,is,primarily'
p26870
(F1
F0.00014334862385321102
I0
I1
I-1
tp26871
sS'of,or,was'
p26872
(F1
F0.00014334862385321102
I0
I1
I-1
tp26873
sS'or,impairing,its'
p26874
(F1
F0.00014334862385321102
I1
I0
I1
tp26875
sS'possibility,of,gastrointestinal'
p26876
(F1
F0.00028669724770642203
I2
I0
I2
tp26877
sS'dosing,schedule,of'
p26878
(F1
F0.00014334862385321102
I0
I1
I-1
tp26879
sS'response,to,factrel'
p26880
(F1
F0.00014334862385321102
I1
I0
I1
tp26881
sS'only,if,the'
p26882
(F1
F0.00014334862385321102
I1
I0
I1
tp26883
sS'indicate,that,m'
p26884
(F1
F0.00014334862385321102
I0
I1
I-1
tp26885
sS'the,safety,or'
p26886
(F1
F0.00043004587155963305
I0
I3
I-3
tp26887
sS'administered,as,stadol'
p26888
(F1
F0.00028669724770642203
I0
I2
I-2
tp26889
sS'triple-immunosuppression,regimens,including'
p26890
(F1
F0.00014334862385321102
I0
I1
I-1
tp26891
sS'indicate,that,a'
p26892
(F1
F0.00028669724770642203
I0
I2
I-2
tp26893
sS'to,occur,with'
p26894
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp26895
sS'indicate,that,elspar'
p26896
(F1
F0.00014334862385321102
I1
I0
I1
tp26897
sS'that,in,addition'
p26898
(F1
F0.00014334862385321102
I1
I0
I1
tp26899
sS'and,volunteers,n'
p26900
(F1
F0.00014334862385321102
I1
I0
I1
tp26901
sS'receptor,antagonists,congestive'
p26902
(F1
F0.00014334862385321102
I0
I1
I-1
tp26903
sS'liver,injury,as'
p26904
(F1
F0.00014334862385321102
I0
I1
I-1
tp26905
sS'raptiva,should,not'
p26906
(F1
F0.00014334862385321102
I1
I0
I1
tp26907
sS'interactions,under,clinical'
p26908
(F1
F0.00014334862385321102
I0
I1
I-1
tp26909
sS'in,studies,of'
p26910
(F1
F0.00014334862385321102
I0
I1
I-1
tp26911
sS'which,induce,cyp3a4'
p26912
(F1
F0.00014334862385321102
I1
I0
I1
tp26913
sS'aspirin,animal,studies'
p26914
(F1
F0.00014334862385321102
I1
I0
I1
tp26915
sS'or,the,hyperuricemia'
p26916
(F1
F0.00014334862385321102
I1
I0
I1
tp26917
sS'study,who,were'
p26918
(F1
F0.00014334862385321102
I1
I0
I1
tp26919
sS'with,and,in'
p26920
(F1
F0.00014334862385321102
I0
I1
I-1
tp26921
sS'been,observed,during'
p26922
(F1
F0.00014334862385321102
I1
I0
I1
tp26923
sS'with,and,it'
p26924
(F1
F0.00014334862385321102
I1
I0
I1
tp26925
sS'of,mg,kg'
p26926
(F0.14285714285714285
F0.00028669724770642203
I8
I6
I2
tp26927
sS'with,and,is'
p26928
(F1
F0.00014334862385321102
I1
I0
I1
tp26929
sS'kytril,have,all'
p26930
(F1
F0.00014334862385321102
I0
I1
I-1
tp26931
sS'of,the,beta-adrenergic'
p26932
(F1
F0.00014334862385321102
I1
I0
I1
tp26933
sS'substrates,known,to'
p26934
(F1
F0.00014334862385321102
I1
I0
I1
tp26935
sS'with,arimidex,as'
p26936
(F1
F0.00014334862385321102
I1
I0
I1
tp26937
sS'were,elevated,with'
p26938
(F1
F0.00014334862385321102
I0
I1
I-1
tp26939
sS'with,the,implication'
p26940
(F1
F0.00014334862385321102
I1
I0
I1
tp26941
sS'renal,function,who'
p26942
(F1
F0.00028669724770642203
I2
I0
I2
tp26943
sS'and,in,clinical'
p26944
(F1
F0.00014334862385321102
I1
I0
I1
tp26945
sS'when,orudis,doses'
p26946
(F1
F0.00014334862385321102
I0
I1
I-1
tp26947
sS'and,requires,close'
p26948
(F1
F0.00028669724770642203
I2
I0
I2
tp26949
sS'by,prothrombin,time'
p26950
(F1
F0.00014334862385321102
I0
I1
I-1
tp26951
sS'decrease,mean,trough'
p26952
(F1
F0.00014334862385321102
I0
I1
I-1
tp26953
sS'kg,p,o'
p26954
(F1
F0.00014334862385321102
I1
I0
I1
tp26955
sS'and,cmax,were'
p26956
(F1
F0.00014334862385321102
I0
I1
I-1
tp26957
sS'administration,of,high'
p26958
(F0
F0
I1
I1
I0
tp26959
sS'ng,ml,with'
p26960
(F1
F0.00028669724770642203
I2
I0
I2
tp26961
sS'studies,and,time'
p26962
(F1
F0.00014334862385321102
I1
I0
I1
tp26963
sS'acid,sympathomimet-ics,channel'
p26964
(F1
F0.00014334862385321102
I0
I1
I-1
tp26965
sS'both,the,oral'
p26966
(F1
F0.00014334862385321102
I1
I0
I1
tp26967
sS'indocin,given,concomitantly'
p26968
(F1
F0.00014334862385321102
I1
I0
I1
tp26969
sS'behavior,in,normal'
p26970
(F1
F0.00014334862385321102
I0
I1
I-1
tp26971
sS'aminoglutethimide,may,increase'
p26972
(F1
F0.00014334862385321102
I1
I0
I1
tp26973
sS'caution,because,the'
p26974
(F1
F0.00028669724770642203
I2
I0
I2
tp26975
sS'b,or,the'
p26976
(F1
F0.00014334862385321102
I0
I1
I-1
tp26977
sS'the,first,post-transplant'
p26978
(F1
F0.00014334862385321102
I0
I1
I-1
tp26979
sS'depletor,should,therefore'
p26980
(F1
F0.00014334862385321102
I0
I1
I-1
tp26981
sS'inhibit,the,activity'
p26982
(F1
F0.00028669724770642203
I0
I2
I-2
tp26983
sS'response,through,increased'
p26984
(F1
F0.00014334862385321102
I1
I0
I1
tp26985
sS'effect,of,such'
p26986
(F1
F0.00014334862385321102
I1
I0
I1
tp26987
sS'or,potentially,result'
p26988
(F1
F0.00014334862385321102
I1
I0
I1
tp26989
sS'that,prolongs,the'
p26990
(F1
F0.00014334862385321102
I1
I0
I1
tp26991
sS'one-fourth,of,the'
p26992
(F1
F0.00014334862385321102
I1
I0
I1
tp26993
sS'then,the,effects'
p26994
(F1
F0.00014334862385321102
I0
I1
I-1
tp26995
sS'to,half,the'
p26996
(F1
F0.00014334862385321102
I1
I0
I1
tp26997
sS'sulfoxide,by,about'
p26998
(F1
F0.00014334862385321102
I1
I0
I1
tp26999
sS'altered,when,and'
p27000
(F1
F0.00014334862385321102
I0
I1
I-1
tp27001
sS'mammalian,target,of'
p27002
(F1
F0.00014334862385321102
I0
I1
I-1
tp27003
sS'resulting,in,decreased'
p27004
(F0.5
F0.00028669724770642203
I3
I1
I2
tp27005
sS'may,decrease,plasma'
p27006
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp27007
sS'strongyloidiasis,during,the'
p27008
(F1
F0.00014334862385321102
I1
I0
I1
tp27009
sS'effectiveness,of,oral'
p27010
(F1
F0.00014334862385321102
I1
I0
I1
tp27011
sS'rarely,with,hemodynamic'
p27012
(F1
F0.00014334862385321102
I1
I0
I1
tp27013
sS'may,cause,synergistic'
p27014
(F1
F0.00014334862385321102
I1
I0
I1
tp27015
sS'stabilized,on,oral'
p27016
(F0
F0
I1
I1
I0
tp27017
sS'daily,as,compared'
p27018
(F0
F0
I1
I1
I0
tp27019
sS'populations,the,concomitant'
p27020
(F1
F0.00014334862385321102
I1
I0
I1
tp27021
sS'and,calcidiol,cholestyramine'
p27022
(F1
F0.00043004587155963305
I3
I0
I3
tp27023
sS'and,digestive,enzyme'
p27024
(F1
F0.00014334862385321102
I1
I0
I1
tp27025
sS'that,increased,the'
p27026
(F1
F0.00014334862385321102
I1
I0
I1
tp27027
sS'with,uricosuric,agents'
p27028
(F1
F0.00014334862385321102
I0
I1
I-1
tp27029
sS'competing,for,the'
p27030
(F1
F0.00014334862385321102
I1
I0
I1
tp27031
sS'lesions,as,a'
p27032
(F1
F0.00014334862385321102
I1
I0
I1
tp27033
sS'studies,on,concomitant'
p27034
(F1
F0.00014334862385321102
I0
I1
I-1
tp27035
sS'route,they,should'
p27036
(F1
F0.00014334862385321102
I1
I0
I1
tp27037
sS'injection,of,pipracil'
p27038
(F1
F0.00014334862385321102
I1
I0
I1
tp27039
sS'ii,antagonists,increased'
p27040
(F1
F0.00014334862385321102
I1
I0
I1
tp27041
sS'and,magnesium-containing,meq'
p27042
(F1
F0.00014334862385321102
I0
I1
I-1
tp27043
sS'antiviral,activity,of'
p27044
(F1
F0.00014334862385321102
I1
I0
I1
tp27045
sS'ph,in,human'
p27046
(F1
F0.00014334862385321102
I0
I1
I-1
tp27047
sS'of,these,should'
p27048
(F1
F0.00043004587155963305
I3
I0
I3
tp27049
sS'some,instances,resulted'
p27050
(F1
F0.00014334862385321102
I1
I0
I1
tp27051
sS'in,the,absence'
p27052
(F0
F0
I3
I3
I0
tp27053
sS'related,ethacrynic,acid'
p27054
(F1
F0.00014334862385321102
I0
I1
I-1
tp27055
sS'and,a,decrease'
p27056
(F1
F0.00028669724770642203
I2
I0
I2
tp27057
sS'physiological,tolerance,allowing'
p27058
(F1
F0.00014334862385321102
I0
I1
I-1
tp27059
sS'antiparkinsonian,agents,particularly'
p27060
(F1
F0.00014334862385321102
I1
I0
I1
tp27061
sS'of,or,mg'
p27062
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp27063
sS'dihydroxyflavone,with,may'
p27064
(F1
F0.00014334862385321102
I0
I1
I-1
tp27065
sS'was,used,concurrently'
p27066
(F1
F0.00014334862385321102
I0
I1
I-1
tp27067
sS'cimetidine,treatment,should'
p27068
(F1
F0.00014334862385321102
I1
I0
I1
tp27069
sS'a,potential,twofold'
p27070
(F1
F0.00014334862385321102
I1
I0
I1
tp27071
sS'the,inr,was'
p27072
(F1
F0.00014334862385321102
I0
I1
I-1
tp27073
sS'second,contractile,responses'
p27074
(F1
F0.00014334862385321102
I1
I0
I1
tp27075
sS'compared,to,reported'
p27076
(F1
F0.00014334862385321102
I1
I0
I1
tp27077
sS'beginning,of,the'
p27078
(F1
F0.00014334862385321102
I0
I1
I-1
tp27079
sS'boric,acid,may'
p27080
(F1
F0.00014334862385321102
I1
I0
I1
tp27081
sS'of,a,daily'
p27082
(F1
F0.00014334862385321102
I1
I0
I1
tp27083
sS'synthesis,of,cyp3a4'
p27084
(F1
F0.00014334862385321102
I0
I1
I-1
tp27085
sS'been,done,it'
p27086
(F1
F0.00014334862385321102
I0
I1
I-1
tp27087
sS'affecting,sympathetic,activity'
p27088
(F1
F0.00028669724770642203
I0
I2
I-2
tp27089
sS'of,may,antagonize'
p27090
(F1
F0.00014334862385321102
I1
I0
I1
tp27091
sS'and,these,medicines'
p27092
(F1
F0.00014334862385321102
I0
I1
I-1
tp27093
sS'prolonged,by,since'
p27094
(F1
F0.00014334862385321102
I1
I0
I1
tp27095
sS'when,or,nitrous'
p27096
(F1
F0.00014334862385321102
I0
I1
I-1
tp27097
sS'doses,or,reduced'
p27098
(F1
F0.00014334862385321102
I1
I0
I1
tp27099
sS'of,other,taken'
p27100
(F1
F0.00014334862385321102
I1
I0
I1
tp27101
sS'conclusions,in,contrast'
p27102
(F1
F0.00014334862385321102
I0
I1
I-1
tp27103
sS'regimens,lower,tablet'
p27104
(F1
F0.00014334862385321102
I0
I1
I-1
tp27105
sS'their,pharmacological,actions'
p27106
(F1
F0.00014334862385321102
I0
I1
I-1
tp27107
sS'between,both,at'
p27108
(F1
F0.00014334862385321102
I0
I1
I-1
tp27109
sS'm,markedly,increased'
p27110
(F1
F0.00014334862385321102
I1
I0
I1
tp27111
sS'near,mg,dl'
p27112
(F1
F0.00014334862385321102
I1
I0
I1
tp27113
sS'with,healthy,male'
p27114
(F1
F0.00014334862385321102
I0
I1
I-1
tp27115
sS'has,been,concern'
p27116
(F1
F0.00014334862385321102
I1
I0
I1
tp27117
sS'decrease,in,effectiveness'
p27118
(F1
F0.00014334862385321102
I1
I0
I1
tp27119
sS'therefore,when,hydrochlorothiazide'
p27120
(F1
F0.00014334862385321102
I1
I0
I1
tp27121
sS'such,as,thorazine'
p27122
(F1
F0.00014334862385321102
I0
I1
I-1
tp27123
sS'times,daily,to'
p27124
(F1
F0.00014334862385321102
I0
I1
I-1
tp27125
sS'the,purpose,of'
p27126
(F1
F0.00014334862385321102
I0
I1
I-1
tp27127
sS'may,each,be'
p27128
(F1
F0.00014334862385321102
I1
I0
I1
tp27129
sS'for,increases,in'
p27130
(F1
F0.00014334862385321102
I1
I0
I1
tp27131
sS'due,to,transport-related'
p27132
(F1
F0.00014334862385321102
I1
I0
I1
tp27133
sS'body,by,the'
p27134
(F1
F0.00014334862385321102
I0
I1
I-1
tp27135
sS'not,only,block'
p27136
(F1
F0.00014334862385321102
I1
I0
I1
tp27137
sS'study,indicates,that'
p27138
(F1
F0.00014334862385321102
I0
I1
I-1
tp27139
sS'acetylsalicylic,acid,sali-cylates'
p27140
(F1
F0.00014334862385321102
I0
I1
I-1
tp27141
sS'of,doses,there'
p27142
(F1
F0.00014334862385321102
I0
I1
I-1
tp27143
sS'of,administered,orally'
p27144
(F1
F0.00014334862385321102
I0
I1
I-1
tp27145
sS'as,etc,is'
p27146
(F1
F0.00014334862385321102
I1
I0
I1
tp27147
sS'subnormal,release,and'
p27148
(F1
F0.00014334862385321102
I0
I1
I-1
tp27149
sS'systemic,corticosteroids,systemic'
p27150
(F1
F0.00014334862385321102
I0
I1
I-1
tp27151
sS'prescribers,should,also'
p27152
(F1
F0.00014334862385321102
I0
I1
I-1
tp27153
sS'depression,stupor,and'
p27154
(F1
F0.00014334862385321102
I1
I0
I1
tp27155
sS'mg,every,hours'
p27156
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp27157
sS'co-infected,with,tuberculosis'
p27158
(F1
F0.00014334862385321102
I0
I1
I-1
tp27159
sS'may,be,associated'
p27160
(F0
F0
I2
I2
I0
tp27161
sS'q12h,for,days'
p27162
(F1
F0.00014334862385321102
I1
I0
I1
tp27163
sS'ritonavir,combined,administration'
p27164
(F1
F0.00014334862385321102
I0
I1
I-1
tp27165
sS'concentration,and,auc'
p27166
(F1
F0.00014334862385321102
I1
I0
I1
tp27167
sS'cyp2c9,and,cyp3a4'
p27168
(F1
F0.00028669724770642203
I0
I2
I-2
tp27169
sS'auc,and,of'
p27170
(F1
F0.00014334862385321102
I1
I0
I1
tp27171
sS'induce,a,subgroup'
p27172
(F1
F0.00014334862385321102
I0
I1
I-1
tp27173
sS'advisable,to,administer'
p27174
(F1
F0.00014334862385321102
I1
I0
I1
tp27175
sS'therapeutic,value,of'
p27176
(F1
F0.00014334862385321102
I0
I1
I-1
tp27177
sS'the,systemic,administration'
p27178
(F1
F0.00014334862385321102
I1
I0
I1
tp27179
sS'cytochalasin,d,at'
p27180
(F1
F0.00014334862385321102
I1
I0
I1
tp27181
sS'against,the,positive'
p27182
(F1
F0.00014334862385321102
I0
I1
I-1
tp27183
sS'or,was,administered'
p27184
(F1
F0.00014334862385321102
I0
I1
I-1
tp27185
sS'clinically,relevant,effects'
p27186
(F1
F0.00014334862385321102
I0
I1
I-1
tp27187
sS'regularly,results,in'
p27188
(F1
F0.00014334862385321102
I0
I1
I-1
tp27189
sS'may,alter,hormone'
p27190
(F1
F0.00014334862385321102
I0
I1
I-1
tp27191
sS'in,levels,with'
p27192
(F1
F0.00014334862385321102
I1
I0
I1
tp27193
sS'concentrations,include,vaiproic'
p27194
(F1
F0.00014334862385321102
I1
I0
I1
tp27195
sS'blockers,may,also'
p27196
(F1
F0.00014334862385321102
I1
I0
I1
tp27197
sS'in,a,year'
p27198
(F1
F0.00014334862385321102
I0
I1
I-1
tp27199
sS'monitored,after,tracleer'
p27200
(F1
F0.00014334862385321102
I1
I0
I1
tp27201
sS'at,stable,as'
p27202
(F1
F0.00014334862385321102
I0
I1
I-1
tp27203
sS'increased,when,and'
p27204
(F1
F0.00014334862385321102
I1
I0
I1
tp27205
sS'cause,a,severe'
p27206
(F1
F0.00014334862385321102
I1
I0
I1
tp27207
sS'levonorgestrol,oral,product'
p27208
(F1
F0.00014334862385321102
I0
I1
I-1
tp27209
sS'mg,four,times'
p27210
(F1
F0.00014334862385321102
I0
I1
I-1
tp27211
sS'nifedipine,vardenafil,mg'
p27212
(F1
F0.00014334862385321102
I0
I1
I-1
tp27213
sS'of,binding,thiazide'
p27214
(F1
F0.00014334862385321102
I1
I0
I1
tp27215
sS'decreased,increased,dosages'
p27216
(F1
F0.00014334862385321102
I1
I0
I1
tp27217
sS'both,of,these'
p27218
(F1
F0.00014334862385321102
I1
I0
I1
tp27219
sS'part,to,mechanisms'
p27220
(F1
F0.00014334862385321102
I1
I0
I1
tp27221
sS'were,also,assessed'
p27222
(F1
F0.00014334862385321102
I0
I1
I-1
tp27223
sS'of,and,did'
p27224
(F1
F0.00043004587155963305
I0
I3
I-3
tp27225
sS'diabetic,chinese,hamsters'
p27226
(F1
F0.00014334862385321102
I0
I1
I-1
tp27227
sS'reduce,the,clearance'
p27228
(F1
F0.00014334862385321102
I1
I0
I1
tp27229
sS'result,in,decreases'
p27230
(F1
F0.00014334862385321102
I0
I1
I-1
tp27231
sS'alter,cardiac,conduction'
p27232
(F1
F0.00014334862385321102
I1
I0
I1
tp27233
sS'addition,fondaparinux,neither'
p27234
(F1
F0.00014334862385321102
I0
I1
I-1
tp27235
sS'prinivil,can,be'
p27236
(F1
F0.00014334862385321102
I1
I0
I1
tp27237
sS'result,in,decreased'
p27238
(F1
F0.00028669724770642203
I2
I0
I2
tp27239
sS'capsules,with,the'
p27240
(F1
F0.00014334862385321102
I0
I1
I-1
tp27241
sS'ibuprofen,produced,an'
p27242
(F1
F0.00014334862385321102
I1
I0
I1
tp27243
sS'it,is,believed'
p27244
(F1
F0.00014334862385321102
I1
I0
I1
tp27245
sS'showed,that,is'
p27246
(F1
F0.00014334862385321102
I0
I1
I-1
tp27247
sS'oxidation,responsible,for'
p27248
(F1
F0.00014334862385321102
I1
I0
I1
tp27249
sS'but,not,at'
p27250
(F1
F0.00014334862385321102
I0
I1
I-1
tp27251
sS'mg,daily,may'
p27252
(F1
F0.00014334862385321102
I1
I0
I1
tp27253
sS'resulted,in,erythro-fluorocitrate'
p27254
(F1
F0.00014334862385321102
I0
I1
I-1
tp27255
sS'cardiac,and,coronary'
p27256
(F1
F0.00014334862385321102
I0
I1
I-1
tp27257
sS'cardiac,arrhythmias,have'
p27258
(F1
F0.00014334862385321102
I1
I0
I1
tp27259
sS'and,triglycerides,sgot'
p27260
(F1
F0.00014334862385321102
I1
I0
I1
tp27261
sS'enzymes,the,interaction'
p27262
(F1
F0.00014334862385321102
I1
I0
I1
tp27263
sS'a,diabetic,patient'
p27264
(F1
F0.00014334862385321102
I1
I0
I1
tp27265
sS'by,in,males'
p27266
(F1
F0.00014334862385321102
I1
I0
I1
tp27267
sS'maintenance,dosing,lower'
p27268
(F1
F0.00014334862385321102
I1
I0
I1
tp27269
sS'was,observed,during'
p27270
(F1
F0.00014334862385321102
I0
I1
I-1
tp27271
sS'or,inhibitors,of'
p27272
(F0
F0
I2
I2
I0
tp27273
sS'blood,pressure,caution'
p27274
(F1
F0.00014334862385321102
I1
I0
I1
tp27275
sS'be,done,extremely'
p27276
(F1
F0.00014334862385321102
I1
I0
I1
tp27277
sS'maximum,concentration,cmax'
p27278
(F1
F0.00028669724770642203
I0
I2
I-2
tp27279
sS'agents,particularly,the'
p27280
(F1
F0.00014334862385321102
I1
I0
I1
tp27281
sS'fortified,with,elemental'
p27282
(F1
F0.00014334862385321102
I0
I1
I-1
tp27283
sS'and,have,demonstrated'
p27284
(F1
F0.00014334862385321102
I0
I1
I-1
tp27285
sS'of,angina,or'
p27286
(F1
F0.00014334862385321102
I1
I0
I1
tp27287
sS'and,to,determine'
p27288
(F1
F0.00014334862385321102
I0
I1
I-1
tp27289
sS'either,and,the'
p27290
(F0
F0
I1
I1
I0
tp27291
sS'once,daily,with'
p27292
(F1
F0.00014334862385321102
I0
I1
I-1
tp27293
sS'of,these,cyp3a4'
p27294
(F0
F0
I1
I1
I0
tp27295
sS'pivoxil,be,taken'
p27296
(F0
F0
I1
I1
I0
tp27297
sS'of,several,species'
p27298
(F1
F0.00014334862385321102
I0
I1
I-1
tp27299
sS'acid,oxolinic,acid'
p27300
(F1
F0.00014334862385321102
I1
I0
I1
tp27301
sS'and,no,dose'
p27302
(F1
F0.00014334862385321102
I0
I1
I-1
tp27303
sS'general,have,additive'
p27304
(F1
F0.00014334862385321102
I1
I0
I1
tp27305
sS'cyp2c9,cyp2d6,cyp2e1'
p27306
(F1
F0.00014334862385321102
I0
I1
I-1
tp27307
sS'and,were,indifferent'
p27308
(F1
F0.00028669724770642203
I2
I0
I2
tp27309
sS'advised,against,taking'
p27310
(F1
F0.00014334862385321102
I1
I0
I1
tp27311
sS'infusions,of,activase'
p27312
(F1
F0.00014334862385321102
I0
I1
I-1
tp27313
sS'although,has,a'
p27314
(F1
F0.00014334862385321102
I1
I0
I1
tp27315
sS'of,mg,capsules'
p27316
(F1
F0.00014334862385321102
I1
I0
I1
tp27317
sS'benedicts,solution,fehlings'
p27318
(F1
F0.00014334862385321102
I0
I1
I-1
tp27319
sS'other,injectable,produces'
p27320
(F1
F0.00014334862385321102
I1
I0
I1
tp27321
sS'ingredient,of,the'
p27322
(F1
F0.00014334862385321102
I0
I1
I-1
tp27323
sS'resulted,in,the'
p27324
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp27325
sS'alter,the,mean'
p27326
(F1
F0.00014334862385321102
I0
I1
I-1
tp27327
sS'and,decreased,with'
p27328
(F1
F0.00014334862385321102
I1
I0
I1
tp27329
sS'aeruginosa,particularly,serotype'
p27330
(F1
F0.00014334862385321102
I0
I1
I-1
tp27331
sS'failure,post-myocardial,infarction'
p27332
(F1
F0.00014334862385321102
I0
I1
I-1
tp27333
sS'medicinal,products,including'
p27334
(F1
F0.00014334862385321102
I1
I0
I1
tp27335
sS'although,administered,at'
p27336
(F1
F0.00014334862385321102
I0
I1
I-1
tp27337
sS'advised,in,the'
p27338
(F1
F0.00028669724770642203
I2
I0
I2
tp27339
sS'or,alter,the'
p27340
(F1
F0.00014334862385321102
I1
I0
I1
tp27341
sS'have,allergic,or'
p27342
(F1
F0.00014334862385321102
I0
I1
I-1
tp27343
sS'in,ra,clinical'
p27344
(F1
F0.00014334862385321102
I0
I1
I-1
tp27345
sS'binding,and,the'
p27346
(F1
F0.00014334862385321102
I0
I1
I-1
tp27347
sS'administration,of,vitamin'
p27348
(F1
F0.00014334862385321102
I1
I0
I1
tp27349
sS'at,and,hours'
p27350
(F1
F0.00014334862385321102
I1
I0
I1
tp27351
sS'serotonergic,effects,of'
p27352
(F1
F0.00014334862385321102
I1
I0
I1
tp27353
sS'dose,to,achieve'
p27354
(F1
F0.00014334862385321102
I1
I0
I1
tp27355
sS'pivoxil,resulted,in'
p27356
(F1
F0.00014334862385321102
I1
I0
I1
tp27357
sS'itraconazole,with,oral'
p27358
(F1
F0.00014334862385321102
I1
I0
I1
tp27359
sS'normal,renal,function'
p27360
(F1
F0.00014334862385321102
I0
I1
I-1
tp27361
sS'antiepileptic,effect,of'
p27362
(F1
F0.00014334862385321102
I1
I0
I1
tp27363
sS'in,a,significant'
p27364
(F0.5
F0.00028669724770642203
I3
I1
I2
tp27365
sS'the,authors,investigated'
p27366
(F1
F0.00014334862385321102
I0
I1
I-1
tp27367
sS'of,use,at'
p27368
(F1
F0.00014334862385321102
I0
I1
I-1
tp27369
sS'and,or,has'
p27370
(F1
F0.00043004587155963305
I3
I0
I3
tp27371
sS'recent,case,study'
p27372
(F1
F0.00014334862385321102
I1
I0
I1
tp27373
sS'of,tablets,containing'
p27374
(F1
F0.00014334862385321102
I0
I1
I-1
tp27375
sS'of,body,weight'
p27376
(F1
F0.00014334862385321102
I0
I1
I-1
tp27377
sS'clinically,significant,fluctuations'
p27378
(F1
F0.00014334862385321102
I1
I0
I1
tp27379
sS'treatment,with,derivatives'
p27380
(F1
F0.00014334862385321102
I0
I1
I-1
tp27381
sS'of,at,therapeutic'
p27382
(F1
F0.00014334862385321102
I0
I1
I-1
tp27383
sS'with,lowered,the'
p27384
(F1
F0.00014334862385321102
I1
I0
I1
tp27385
sS'erythromycin,and,ketoconazole'
p27386
(F1
F0.00014334862385321102
I0
I1
I-1
tp27387
sS'vitro,studies,with'
p27388
(F1
F0.00014334862385321102
I1
I0
I1
tp27389
sS'broad-spectrum,antibiotics-broad,spectrum'
p27390
(F1
F0.00014334862385321102
I0
I1
I-1
tp27391
sS'pegasys,should,be'
p27392
(F1
F0.00014334862385321102
I0
I1
I-1
tp27393
sS'treated,with,pcp'
p27394
(F1
F0.00014334862385321102
I0
I1
I-1
tp27395
sS'the,inhibitory,effects'
p27396
(F1
F0.00014334862385321102
I1
I0
I1
tp27397
sS'side,effects,and'
p27398
(F0
F0
I1
I1
I0
tp27399
sS'atypical,antipsychotic,was'
p27400
(F1
F0.00014334862385321102
I0
I1
I-1
tp27401
sS'or,pcp,were'
p27402
(F1
F0.00014334862385321102
I1
I0
I1
tp27403
sS'data,suggest,that'
p27404
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp27405
sS'used,because,the'
p27406
(F1
F0.00014334862385321102
I1
I0
I1
tp27407
sS'gliftor,difluoro-2,propanol'
p27408
(F1
F0.00014334862385321102
I0
I1
I-1
tp27409
sS'biochemical,toxicology,of'
p27410
(F1
F0.00014334862385321102
I0
I1
I-1
tp27411
sS'reduced,in,both'
p27412
(F1
F0.00014334862385321102
I0
I1
I-1
tp27413
sS'may,present,as'
p27414
(F1
F0.00014334862385321102
I1
I0
I1
tp27415
sS'of,exjade,with'
p27416
(F1
F0.00014334862385321102
I0
I1
I-1
tp27417
sS'the,plasma,level'
p27418
(F1
F0.00014334862385321102
I1
I0
I1
tp27419
sS'l,kg,h'
p27420
(F1
F0.00014334862385321102
I1
I0
I1
tp27421
sS'absence,of,a'
p27422
(F1
F0.00014334862385321102
I0
I1
I-1
tp27423
sS'healthy,male,volunteers'
p27424
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp27425
sS'reduce,the,therapeutic'
p27426
(F1
F0.00014334862385321102
I1
I0
I1
tp27427
sS'and,its,dosage'
p27428
(F1
F0.00014334862385321102
I1
I0
I1
tp27429
sS'as,or,should'
p27430
(F0
F0
I1
I1
I0
tp27431
sS'co-administered,with,brovana'
p27432
(F1
F0.00014334862385321102
I0
I1
I-1
tp27433
sS'combination,with,monoamine'
p27434
(F1
F0.00014334862385321102
I1
I0
I1
tp27435
sS'on,av,node'
p27436
(F1
F0.00014334862385321102
I1
I0
I1
tp27437
sS'mtc-mdp,as,the'
p27438
(F1
F0.00014334862385321102
I0
I1
I-1
tp27439
sS'and,pharmacodynamic,interactions'
p27440
(F1
F0.00014334862385321102
I0
I1
I-1
tp27441
sS'and,cyclopentyl-1,dipropylxanthine'
p27442
(F1
F0.00014334862385321102
I0
I1
I-1
tp27443
sS'of,toradol,on'
p27444
(F0
F0
I1
I1
I0
tp27445
sS'concentrations,of,andtolbutamide'
p27446
(F1
F0.00014334862385321102
I0
I1
I-1
tp27447
sS'of,other,inducers'
p27448
(F1
F0.00014334862385321102
I1
I0
I1
tp27449
sS'to,ng,ml'
p27450
(F0
F0
I1
I1
I0
tp27451
sS'and,and,a'
p27452
(F1
F0.00014334862385321102
I1
I0
I1
tp27453
sS'sodium,carboxymethylcellulose,nacmc'
p27454
(F1
F0.00014334862385321102
I0
I1
I-1
tp27455
sS'with,injectable,an'
p27456
(F1
F0.00014334862385321102
I1
I0
I1
tp27457
sS'of,invirase,or'
p27458
(F1
F0.00014334862385321102
I0
I1
I-1
tp27459
sS'single,mg,dose'
p27460
(F0.22222222222222221
F0.00057339449541284407
I11
I7
I4
tp27461
sS'of,birth,control'
p27462
(F1
F0.00014334862385321102
I1
I0
I1
tp27463
sS'evidence,of,interaction'
p27464
(F1
F0.00014334862385321102
I0
I1
I-1
tp27465
sS'are,to,lower'
p27466
(F1
F0.00014334862385321102
I0
I1
I-1
tp27467
sS'with,tablets,is'
p27468
(F1
F0.00014334862385321102
I1
I0
I1
tp27469
sS'drugs,that,cause'
p27470
(F1
F0.00014334862385321102
I1
I0
I1
tp27471
sS'most,common,distilled'
p27472
(F1
F0.00014334862385321102
I0
I1
I-1
tp27473
sS'in,vitro,anti-cryptosporidial'
p27474
(F1
F0.00014334862385321102
I0
I1
I-1
tp27475
sS'periodic,serum,level'
p27476
(F1
F0.00014334862385321102
I1
I0
I1
tp27477
sS'of,h-triglyceride,fractional'
p27478
(F1
F0.00014334862385321102
I1
I0
I1
tp27479
sS'differences,were,between'
p27480
(F1
F0.00014334862385321102
I0
I1
I-1
tp27481
sS'healthy,subjects,there'
p27482
(F1
F0.00014334862385321102
I0
I1
I-1
tp27483
sS'the,rat,stomach'
p27484
(F1
F0.00014334862385321102
I1
I0
I1
tp27485
sS'and,lodine,capsules'
p27486
(F1
F0.00014334862385321102
I1
I0
I1
tp27487
sS'be,useful,in'
p27488
(F1
F0.00014334862385321102
I1
I0
I1
tp27489
sS'nasal,spray,the'
p27490
(F1
F0.00014334862385321102
I1
I0
I1
tp27491
sS'may,be,administered'
p27492
(F1
F0.00014334862385321102
I0
I1
I-1
tp27493
sS'intrathecal,on,blocking'
p27494
(F1
F0.00014334862385321102
I0
I1
I-1
tp27495
sS'of,clostridium,three'
p27496
(F1
F0.00014334862385321102
I0
I1
I-1
tp27497
sS'reported,rarely,when'
p27498
(F1
F0.00014334862385321102
I1
I0
I1
tp27499
sS'safety,or,efficacy'
p27500
(F1
F0.00043004587155963305
I0
I3
I-3
tp27501
sS'tissue,damage,as'
p27502
(F1
F0.00014334862385321102
I1
I0
I1
tp27503
sS'the,clinical,effect'
p27504
(F1
F0.00014334862385321102
I0
I1
I-1
tp27505
sS'associated,with,qt-interval'
p27506
(F1
F0.00014334862385321102
I0
I1
I-1
tp27507
sS'that,the,action'
p27508
(F1
F0.00014334862385321102
I1
I0
I1
tp27509
sS'hypotensive,episodes,may'
p27510
(F1
F0.00014334862385321102
I1
I0
I1
tp27511
sS'as,they,can'
p27512
(F1
F0.00014334862385321102
I1
I0
I1
tp27513
sS'mcg,bid,for'
p27514
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27515
sS'toxicity,and,mechanisms'
p27516
(F1
F0.00014334862385321102
I0
I1
I-1
tp27517
sS'permeation,however,in'
p27518
(F1
F0.00014334862385321102
I0
I1
I-1
tp27519
sS'to,increase,when'
p27520
(F1
F0.00014334862385321102
I1
I0
I1
tp27521
sS'when,it,was'
p27522
(F0.5
F0.00028669724770642203
I3
I1
I2
tp27523
sS'enough,during,early'
p27524
(F1
F0.00014334862385321102
I1
I0
I1
tp27525
sS'develop,increased,serum'
p27526
(F1
F0.00014334862385321102
I1
I0
I1
tp27527
sS'caused,by,therapy'
p27528
(F1
F0.00014334862385321102
I0
I1
I-1
tp27529
sS'agents,and,oral'
p27530
(F1
F0.00014334862385321102
I1
I0
I1
tp27531
sS'and,hepatic,lipid'
p27532
(F1
F0.00014334862385321102
I1
I0
I1
tp27533
sS'as,or,from'
p27534
(F1
F0.00014334862385321102
I1
I0
I1
tp27535
sS'auc,more,than'
p27536
(F1
F0.00014334862385321102
I0
I1
I-1
tp27537
sS'constant,while,fractional'
p27538
(F1
F0.00014334862385321102
I0
I1
I-1
tp27539
sS'fold,when,at'
p27540
(F1
F0.00014334862385321102
I1
I0
I1
tp27541
sS'and,occurred,following'
p27542
(F1
F0.00014334862385321102
I1
I0
I1
tp27543
sS'existing,clinical,trials'
p27544
(F1
F0.00014334862385321102
I0
I1
I-1
tp27545
sS'either,the,tricyclic'
p27546
(F1
F0.00043004587155963305
I0
I3
I-3
tp27547
sS'the,emerging,roles'
p27548
(F1
F0.00014334862385321102
I0
I1
I-1
tp27549
sS'returned,to,baseline'
p27550
(F1
F0.00014334862385321102
I1
I0
I1
tp27551
sS'was,concluded,that'
p27552
(F0
F0
I1
I1
I0
tp27553
sS'both,are,direct'
p27554
(F1
F0.00014334862385321102
I1
I0
I1
tp27555
sS'the,primary,and'
p27556
(F1
F0.00014334862385321102
I1
I0
I1
tp27557
sS'on,platelet,function'
p27558
(F1
F0.00014334862385321102
I1
I0
I1
tp27559
sS'collected,through,hours'
p27560
(F1
F0.00014334862385321102
I0
I1
I-1
tp27561
sS'or,follow,dosing'
p27562
(F1
F0.00014334862385321102
I0
I1
I-1
tp27563
sS'alterations,associated,with'
p27564
(F1
F0.00014334862385321102
I0
I1
I-1
tp27565
sS'weeks,of,taking'
p27566
(F1
F0.00014334862385321102
I1
I0
I1
tp27567
sS'a,possible,interaction'
p27568
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp27569
sS'blocks,receptors,thus'
p27570
(F1
F0.00014334862385321102
I1
I0
I1
tp27571
sS'after,discontinuation,of'
p27572
(F1
F0.00014334862385321102
I0
I1
I-1
tp27573
sS'evidence,of,an'
p27574
(F1
F0.00014334862385321102
I0
I1
I-1
tp27575
sS'impairing,absorption,of'
p27576
(F1
F0.00014334862385321102
I1
I0
I1
tp27577
sS'combination,of,systemic'
p27578
(F1
F0.00014334862385321102
I1
I0
I1
tp27579
sS'when,infection,and'
p27580
(F1
F0.00014334862385321102
I1
I0
I1
tp27581
sS'any,serious,and'
p27582
(F1
F0.00014334862385321102
I0
I1
I-1
tp27583
sS'warfarin,the,effects'
p27584
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp27585
sS'urinary,uric,acid'
p27586
(F1
F0.00014334862385321102
I1
I0
I1
tp27587
sS'or,are,given'
p27588
(F1
F0.00014334862385321102
I0
I1
I-1
tp27589
sS'depression,such,as'
p27590
(F1
F0.00014334862385321102
I1
I0
I1
tp27591
sS'may,interact,altered'
p27592
(F1
F0.00014334862385321102
I0
I1
I-1
tp27593
sS'adverse,reactions,is'
p27594
(F1
F0.00014334862385321102
I1
I0
I1
tp27595
sS'to,was,increased'
p27596
(F1
F0.00028669724770642203
I2
I0
I2
tp27597
sS'vivo,interaction,study'
p27598
(F1
F0.00014334862385321102
I0
I1
I-1
tp27599
sS'misonidazole,protects,mouse'
p27600
(F1
F0.00014334862385321102
I1
I0
I1
tp27601
sS'systemic,etc,that'
p27602
(F1
F0.00014334862385321102
I1
I0
I1
tp27603
sS'the,rebound,hypertension'
p27604
(F1
F0.00014334862385321102
I1
I0
I1
tp27605
sS'two,combined,week'
p27606
(F1
F0.00014334862385321102
I0
I1
I-1
tp27607
sS'romazicon,exerts,a'
p27608
(F1
F0.00014334862385321102
I1
I0
I1
tp27609
sS'be,given,to'
p27610
(F1
F0.00043004587155963305
I3
I0
I3
tp27611
sS'were,concurrently,administered'
p27612
(F1
F0.00028669724770642203
I0
I2
I-2
tp27613
sS'vision,have,been'
p27614
(F1
F0.00028669724770642203
I2
I0
I2
tp27615
sS'and,use,may'
p27616
(F1
F0.00014334862385321102
I1
I0
I1
tp27617
sS'gentamicin,did,not'
p27618
(F1
F0.00014334862385321102
I0
I1
I-1
tp27619
sS'coli,and,one'
p27620
(F1
F0.00014334862385321102
I0
I1
I-1
tp27621
sS'increase,in,sprycel'
p27622
(F1
F0.00014334862385321102
I0
I1
I-1
tp27623
sS'clearance,and,add'
p27624
(F1
F0.00057339449541284407
I4
I0
I4
tp27625
sS'placebo,day,for'
p27626
(F1
F0.00014334862385321102
I0
I1
I-1
tp27627
sS'displacement,of,from'
p27628
(F1
F0.00014334862385321102
I1
I0
I1
tp27629
sS'damage,produced,a'
p27630
(F1
F0.00014334862385321102
I1
I0
I1
tp27631
sS'of,and,at'
p27632
(F1
F0.00028669724770642203
I0
I2
I-2
tp27633
sS'histidines,on,a'
p27634
(F1
F0.00014334862385321102
I0
I1
I-1
tp27635
sS'of,and,as'
p27636
(F1
F0.00014334862385321102
I1
I0
I1
tp27637
sS'with,anticoagulation,levels'
p27638
(F1
F0.00014334862385321102
I1
I0
I1
tp27639
sS'in,cardiac,output'
p27640
(F1
F0.00014334862385321102
I1
I0
I1
tp27641
sS'fade,hoof,twitch'
p27642
(F1
F0.00014334862385321102
I1
I0
I1
tp27643
sS'the,positive,inotropic'
p27644
(F1
F0.00014334862385321102
I1
I0
I1
tp27645
sS'of,and,an'
p27646
(F1
F0.00014334862385321102
I1
I0
I1
tp27647
sS'bleeding,with,xigris'
p27648
(F1
F0.00014334862385321102
I0
I1
I-1
tp27649
sS'the,patch-clamp,whole-cell'
p27650
(F1
F0.00014334862385321102
I0
I1
I-1
tp27651
sS'such,drugs,are'
p27652
(F1
F0.00014334862385321102
I0
I1
I-1
tp27653
sS'a,substitute,for'
p27654
(F1
F0.00057339449541284407
I0
I4
I-4
tp27655
sS'interactions,with,metabolized'
p27656
(F1
F0.00014334862385321102
I0
I1
I-1
tp27657
sS'conjugated,system,maybe'
p27658
(F1
F0.00014334862385321102
I0
I1
I-1
tp27659
sS'of,a,cyp3a4'
p27660
(F1
F0.00043004587155963305
I3
I0
I3
tp27661
sS'severe,toxicity,was'
p27662
(F1
F0.00014334862385321102
I1
I0
I1
tp27663
sS'while,not,systematically'
p27664
(F1
F0.00014334862385321102
I1
I0
I1
tp27665
sS'risk,of,relapse'
p27666
(F1
F0.00014334862385321102
I0
I1
I-1
tp27667
sS'and,aminoglycosides,drugs'
p27668
(F1
F0.00014334862385321102
I1
I0
I1
tp27669
sS'with,the,and'
p27670
(F1
F0.00014334862385321102
I0
I1
I-1
tp27671
sS'than,when,is'
p27672
(F1
F0.00014334862385321102
I1
I0
I1
tp27673
sS'in,ventricular,fibrillation'
p27674
(F1
F0.00014334862385321102
I0
I1
I-1
tp27675
sS'of,the,first-pass'
p27676
(F1
F0.00014334862385321102
I1
I0
I1
tp27677
sS'with,cyp2c19,the'
p27678
(F1
F0.00014334862385321102
I0
I1
I-1
tp27679
sS'of,enablex,with'
p27680
(F1
F0.00014334862385321102
I1
I0
I1
tp27681
sS'before,the,gradual'
p27682
(F1
F0.00028669724770642203
I2
I0
I2
tp27683
sS'n-desmethyldiazepam,there,is'
p27684
(F1
F0.00014334862385321102
I1
I0
I1
tp27685
sS'decreasing,the,clearance'
p27686
(F1
F0.00014334862385321102
I1
I0
I1
tp27687
sS'to,outweigh,the'
p27688
(F1
F0.00014334862385321102
I1
I0
I1
tp27689
sS'such,reduction,in'
p27690
(F1
F0.00014334862385321102
I1
I0
I1
tp27691
sS'of,hexalen,and'
p27692
(F1
F0.00028669724770642203
I2
I0
I2
tp27693
sS'substrate,of,cyp1a1'
p27694
(F1
F0.00014334862385321102
I0
I1
I-1
tp27695
sS'of,intrathecal,on'
p27696
(F1
F0.00014334862385321102
I0
I1
I-1
tp27697
sS'monurol,a,which'
p27698
(F1
F0.00014334862385321102
I1
I0
I1
tp27699
sS'dehydration,have,been'
p27700
(F1
F0.00014334862385321102
I1
I0
I1
tp27701
sS'retinyl,acetate,and'
p27702
(F1
F0.00014334862385321102
I1
I0
I1
tp27703
sS'to,mg,capsules'
p27704
(F1
F0.00014334862385321102
I1
I0
I1
tp27705
sS'aged,years,total'
p27706
(F1
F0.00014334862385321102
I0
I1
I-1
tp27707
sS'of,this,product'
p27708
(F1
F0.00014334862385321102
I0
I1
I-1
tp27709
sS'human,serum,proteins'
p27710
(F1
F0.00014334862385321102
I0
I1
I-1
tp27711
sS'irinotecan,concentrations,were'
p27712
(F1
F0.00014334862385321102
I0
I1
I-1
tp27713
sS'digoxin,in,a'
p27714
(F1
F0.00014334862385321102
I0
I1
I-1
tp27715
sS'psychotropic,medications,or'
p27716
(F1
F0.00014334862385321102
I1
I0
I1
tp27717
sS'the,benefit,of'
p27718
(F1
F0.00014334862385321102
I1
I0
I1
tp27719
sS'not,recommended,as'
p27720
(F1
F0.00014334862385321102
I0
I1
I-1
tp27721
sS'of,or,does'
p27722
(F1
F0.00014334862385321102
I0
I1
I-1
tp27723
sS'result,of,coadministration'
p27724
(F1
F0.00014334862385321102
I0
I1
I-1
tp27725
sS'have,had,an'
p27726
(F1
F0.00014334862385321102
I1
I0
I1
tp27727
sS'of,aliskiren,on'
p27728
(F1
F0.00014334862385321102
I0
I1
I-1
tp27729
sS'it,substituted,for'
p27730
(F1
F0.00014334862385321102
I0
I1
I-1
tp27731
sS'when,they,are'
p27732
(F1
F0.00043004587155963305
I3
I0
I3
tp27733
sS'protein,may,cause'
p27734
(F1
F0.00014334862385321102
I1
I0
I1
tp27735
sS'tablets,with,or'
p27736
(F1
F0.00014334862385321102
I1
I0
I1
tp27737
sS'performed,examining,the'
p27738
(F1
F0.00014334862385321102
I0
I1
I-1
tp27739
sS'significant,increases,in'
p27740
(F1
F0.00028669724770642203
I2
I0
I2
tp27741
sS'a,to,increase'
p27742
(F1
F0.00014334862385321102
I1
I0
I1
tp27743
sS'nitrates,nifedipine,may'
p27744
(F1
F0.00014334862385321102
I0
I1
I-1
tp27745
sS'practice,has,been'
p27746
(F1
F0.00014334862385321102
I1
I0
I1
tp27747
sS'have,been,greater'
p27748
(F1
F0.00028669724770642203
I2
I0
I2
tp27749
sS'based,on,in-vitro'
p27750
(F1
F0.00014334862385321102
I0
I1
I-1
tp27751
sS'with,the,potent'
p27752
(F1
F0.00014334862385321102
I1
I0
I1
tp27753
sS'weeks,was,associated'
p27754
(F1
F0.00014334862385321102
I1
I0
I1
tp27755
sS'products,that,contain'
p27756
(F1
F0.00014334862385321102
I1
I0
I1
tp27757
sS'studies,at,the'
p27758
(F1
F0.00014334862385321102
I0
I1
I-1
tp27759
sS'whether,this,potentiation'
p27760
(F1
F0.00014334862385321102
I1
I0
I1
tp27761
sS'maois,may,increase'
p27762
(F1
F0.00014334862385321102
I1
I0
I1
tp27763
sS'a,patient,has'
p27764
(F0.5
F0.00028669724770642203
I3
I1
I2
tp27765
sS'and,gastric,ph'
p27766
(F1
F0.00014334862385321102
I0
I1
I-1
tp27767
sS'placebo,and,intravenous'
p27768
(F1
F0.00028669724770642203
I0
I2
I-2
tp27769
sS'cardioplegic,solutions,and'
p27770
(F1
F0.00014334862385321102
I0
I1
I-1
tp27771
sS'into,three,doses'
p27772
(F1
F0.00014334862385321102
I1
I0
I1
tp27773
sS'potentially,resulting,in'
p27774
(F1
F0.00028669724770642203
I2
I0
I2
tp27775
sS'monitored,for,increases'
p27776
(F1
F0.00014334862385321102
I1
I0
I1
tp27777
sS'with,one-stage,coagulation'
p27778
(F1
F0.00014334862385321102
I0
I1
I-1
tp27779
sS'calcidiol,cholestyramine,cholestyramine'
p27780
(F1
F0.00043004587155963305
I3
I0
I3
tp27781
sS'and,sodium,plasma'
p27782
(F1
F0.00014334862385321102
I1
I0
I1
tp27783
sS'a,strong,likelihood'
p27784
(F1
F0.00014334862385321102
I1
I0
I1
tp27785
sS'suggested,to,mg'
p27786
(F1
F0.00014334862385321102
I0
I1
I-1
tp27787
sS'be,increased,by'
p27788
(F1
F0.00028669724770642203
I2
I0
I2
tp27789
sS'to,be,significantly'
p27790
(F1
F0.00014334862385321102
I0
I1
I-1
tp27791
sS'has,been,seen'
p27792
(F1
F0.00014334862385321102
I1
I0
I1
tp27793
sS'failure,of,to'
p27794
(F1
F0.00014334862385321102
I0
I1
I-1
tp27795
sS'interactions,posed,by'
p27796
(F1
F0.00014334862385321102
I0
I1
I-1
tp27797
sS'indicates,that,does'
p27798
(F1
F0.00028669724770642203
I0
I2
I-2
tp27799
sS'gastrointestinal,effects,of'
p27800
(F1
F0.00014334862385321102
I1
I0
I1
tp27801
sS'especially,neglect,of'
p27802
(F1
F0.00014334862385321102
I0
I1
I-1
tp27803
sS'that,or,and'
p27804
(F1
F0.00014334862385321102
I1
I0
I1
tp27805
sS'and,auc,increased'
p27806
(F1
F0.00014334862385321102
I1
I0
I1
tp27807
sS'with,small,doses'
p27808
(F1
F0.00014334862385321102
I1
I0
I1
tp27809
sS'these,increased,exposures'
p27810
(F1
F0.00014334862385321102
I1
I0
I1
tp27811
sS'hormonal,may,also'
p27812
(F1
F0.00014334862385321102
I1
I0
I1
tp27813
sS'respectively,have,been'
p27814
(F1
F0.00014334862385321102
I0
I1
I-1
tp27815
sS'clozapine,and,is'
p27816
(F1
F0.00014334862385321102
I1
I0
I1
tp27817
sS'was,taking,a'
p27818
(F1
F0.00014334862385321102
I0
I1
I-1
tp27819
sS'in,bovine,chromaffin'
p27820
(F1
F0.00028669724770642203
I0
I2
I-2
tp27821
sS'careful,observation,is'
p27822
(F1
F0.00014334862385321102
I1
I0
I1
tp27823
sS'elspar,or,during'
p27824
(F1
F0.00014334862385321102
I1
I0
I1
tp27825
sS'reduced,when,it'
p27826
(F1
F0.00014334862385321102
I1
I0
I1
tp27827
sS'system,inhibitors,of'
p27828
(F1
F0.00014334862385321102
I0
I1
I-1
tp27829
sS'seizure,risk,in'
p27830
(F1
F0.00014334862385321102
I1
I0
I1
tp27831
sS'administered,and,appropriate'
p27832
(F1
F0.00014334862385321102
I1
I0
I1
tp27833
sS'diarrhea,was,analyzed'
p27834
(F1
F0.00014334862385321102
I0
I1
I-1
tp27835
sS'for,commonly,used'
p27836
(F1
F0.00014334862385321102
I0
I1
I-1
tp27837
sS'specifically,cytochromes,p450'
p27838
(F1
F0.00014334862385321102
I0
I1
I-1
tp27839
sS'medications,are,used'
p27840
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp27841
sS'requirements,in,human'
p27842
(F1
F0.00014334862385321102
I1
I0
I1
tp27843
sS'coadministration,up,to'
p27844
(F1
F0.00014334862385321102
I1
I0
I1
tp27845
sS'monitoring,of,liver'
p27846
(F1
F0.00014334862385321102
I1
I0
I1
tp27847
sS'the,ec50,values'
p27848
(F1
F0.00014334862385321102
I0
I1
I-1
tp27849
sS'toward,normal,when'
p27850
(F1
F0.00014334862385321102
I0
I1
I-1
tp27851
sS'saquinavir,the,combination'
p27852
(F1
F0.00014334862385321102
I0
I1
I-1
tp27853
sS'patients,addition,of'
p27854
(F1
F0.00014334862385321102
I0
I1
I-1
tp27855
sS'rachitic,chicks,was'
p27856
(F1
F0.00014334862385321102
I1
I0
I1
tp27857
sS'additive,depressant,effect'
p27858
(F1
F0.00014334862385321102
I0
I1
I-1
tp27859
sS'vitro,data,showed'
p27860
(F1
F0.00014334862385321102
I0
I1
I-1
tp27861
sS'used,if,is'
p27862
(F1
F0.00043004587155963305
I3
I0
I3
tp27863
sS'administration,of,tablets'
p27864
(F0.5
F0.00028669724770642203
I3
I1
I2
tp27865
sS'failure,channel,blockers'
p27866
(F1
F0.00014334862385321102
I1
I0
I1
tp27867
sS'patients,taking,chronically'
p27868
(F0
F0
I1
I1
I0
tp27869
sS'at,either,dose'
p27870
(F1
F0.00014334862385321102
I0
I1
I-1
tp27871
sS'fold,and,css'
p27872
(F1
F0.00014334862385321102
I1
I0
I1
tp27873
sS'l-tyrosine,and,non-selective'
p27874
(F1
F0.00014334862385321102
I1
I0
I1
tp27875
sS'concentrations,auc,hrs'
p27876
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp27877
sS'elevated,liver,aminotransferases'
p27878
(F1
F0.00014334862385321102
I0
I1
I-1
tp27879
sS'subcutaneous,injection,q12h'
p27880
(F1
F0.00014334862385321102
I0
I1
I-1
tp27881
sS'all,associated,with'
p27882
(F1
F0.00014334862385321102
I1
I0
I1
tp27883
sS'observed,for,alterations'
p27884
(F1
F0.00014334862385321102
I1
I0
I1
tp27885
sS'chelation,complexes,with'
p27886
(F1
F0.00014334862385321102
I1
I0
I1
tp27887
sS'which,are,activated'
p27888
(F1
F0.00014334862385321102
I0
I1
I-1
tp27889
sS'have,produced,an'
p27890
(F1
F0.00043004587155963305
I3
I0
I3
tp27891
sS'mixed-function,mono-oxidases,in'
p27892
(F1
F0.00014334862385321102
I0
I1
I-1
tp27893
sS'effects,on,pharmacokinetics'
p27894
(F1
F0.00014334862385321102
I0
I1
I-1
tp27895
sS'allograft,recipients,during'
p27896
(F1
F0.00014334862385321102
I0
I1
I-1
tp27897
sS'kill,even,experienced'
p27898
(F1
F0.00014334862385321102
I1
I0
I1
tp27899
sS'with,a,pure'
p27900
(F1
F0.00014334862385321102
I1
I0
I1
tp27901
sS'that,is,rapidly'
p27902
(F1
F0.00014334862385321102
I0
I1
I-1
tp27903
sS'patients,receiving,preparations'
p27904
(F1
F0.00014334862385321102
I0
I1
I-1
tp27905
sS'mainly,by,cytochrome'
p27906
(F1
F0.00014334862385321102
I0
I1
I-1
tp27907
sS'of,this,isozyme'
p27908
(F1
F0.00014334862385321102
I0
I1
I-1
tp27909
sS'half-life,increased,to'
p27910
(F1
F0.00014334862385321102
I1
I0
I1
tp27911
sS'naproxen,sodium,and'
p27912
(F1
F0.00014334862385321102
I1
I0
I1
tp27913
sS'with,a,balanced'
p27914
(F1
F0.00014334862385321102
I0
I1
I-1
tp27915
sS'should,be,cautious'
p27916
(F1
F0.00028669724770642203
I2
I0
I2
tp27917
sS'i,cigarettes,and'
p27918
(F1
F0.00014334862385321102
I0
I1
I-1
tp27919
sS'kinds,of,and'
p27920
(F1
F0.00014334862385321102
I0
I1
I-1
tp27921
sS'closely,monitored,when'
p27922
(F1
F0.00014334862385321102
I1
I0
I1
tp27923
sS'dose,of,escherichia'
p27924
(F1
F0.00014334862385321102
I0
I1
I-1
tp27925
sS'the,secretion,of'
p27926
(F1
F0.00014334862385321102
I0
I1
I-1
tp27927
sS'inhibit,cyp3a4,may'
p27928
(F1
F0.00014334862385321102
I0
I1
I-1
tp27929
sS'on,the,central'
p27930
(F1
F0.00028669724770642203
I2
I0
I2
tp27931
sS'the,hyperuricemia,present'
p27932
(F1
F0.00014334862385321102
I1
I0
I1
tp27933
sS'associated,with,gastrointestinal'
p27934
(F1
F0.00014334862385321102
I1
I0
I1
tp27935
sS'greater,than,reduction'
p27936
(F1
F0.00014334862385321102
I1
I0
I1
tp27937
sS'kineret,and,therapy'
p27938
(F1
F0.00014334862385321102
I1
I0
I1
tp27939
sS'to,products,containing'
p27940
(F1
F0.00014334862385321102
I1
I0
I1
tp27941
sS'toradol,and,in'
p27942
(F1
F0.00014334862385321102
I0
I1
I-1
tp27943
sS'also,suggest,that'
p27944
(F1
F0.00014334862385321102
I1
I0
I1
tp27945
sS'for,placebo,were'
p27946
(F1
F0.00014334862385321102
I0
I1
I-1
tp27947
sS'with,only,bodyweight'
p27948
(F1
F0.00014334862385321102
I0
I1
I-1
tp27949
sS'mg,daily,for'
p27950
(F1
F0.00043004587155963305
I0
I3
I-3
tp27951
sS'potentially,toxic,such'
p27952
(F1
F0.00014334862385321102
I1
I0
I1
tp27953
sS'carried,out,studies'
p27954
(F1
F0.00014334862385321102
I0
I1
I-1
tp27955
sS'investigated,the,effects'
p27956
(F1
F0.00014334862385321102
I0
I1
I-1
tp27957
sS'should,have,a'
p27958
(F1
F0.00014334862385321102
I1
I0
I1
tp27959
sS'at,least,minutes'
p27960
(F1
F0.00028669724770642203
I2
I0
I2
tp27961
sS'other,agents,the'
p27962
(F1
F0.00014334862385321102
I1
I0
I1
tp27963
sS'glucose,and,can'
p27964
(F1
F0.00014334862385321102
I0
I1
I-1
tp27965
sS'increase,the,ototoxic'
p27966
(F1
F0.00028669724770642203
I2
I0
I2
tp27967
sS'where,iressa,and'
p27968
(F1
F0.00014334862385321102
I1
I0
I1
tp27969
sS'two,percent,of'
p27970
(F1
F0.00028669724770642203
I2
I0
I2
tp27971
sS'antagonists,and,that'
p27972
(F1
F0.00014334862385321102
I0
I1
I-1
tp27973
sS'reductions,of,mm'
p27974
(F1
F0.00014334862385321102
I1
I0
I1
tp27975
sS'be,given,simultaneously'
p27976
(F1
F0.00014334862385321102
I1
I0
I1
tp27977
sS'known,whether,this'
p27978
(F0
F0
I1
I1
I0
tp27979
sS'the,bad,general'
p27980
(F1
F0.00014334862385321102
I1
I0
I1
tp27981
sS'were,and,both'
p27982
(F1
F0.00014334862385321102
I0
I1
I-1
tp27983
sS'ketoconazole,coadministration,of'
p27984
(F1
F0.00028669724770642203
I2
I0
I2
tp27985
sS'acinar,cells,rr'
p27986
(F1
F0.00014334862385321102
I0
I1
I-1
tp27987
sS'coagulation,system,or'
p27988
(F1
F0.00014334862385321102
I0
I1
I-1
tp27989
sS'a4,may,increase'
p27990
(F1
F0.00014334862385321102
I0
I1
I-1
tp27991
sS'as,or,with'
p27992
(F1
F0.00014334862385321102
I1
I0
I1
tp27993
sS'therapy,with,similar'
p27994
(F1
F0.00014334862385321102
I0
I1
I-1
tp27995
sS'patients,receiving,high'
p27996
(F1
F0.00014334862385321102
I1
I0
I1
tp27997
sS'was,ng,ml'
p27998
(F1
F0.00014334862385321102
I1
I0
I1
tp27999
sS'to,but,are'
p28000
(F1
F0.00014334862385321102
I0
I1
I-1
tp28001
sS'one,gram,of'
p28002
(F1
F0.00014334862385321102
I1
I0
I1
tp28003
sS'serious,sometimes,fatal'
p28004
(F1
F0.00014334862385321102
I1
I0
I1
tp28005
sS'of,mao,inhibitors'
p28006
(F1
F0.00014334862385321102
I1
I0
I1
tp28007
sS'administered,after,inhalational'
p28008
(F1
F0.00014334862385321102
I0
I1
I-1
tp28009
sS'of,its,primary'
p28010
(F1
F0.00014334862385321102
I1
I0
I1
tp28011
sS'receiving,appeared,to'
p28012
(F1
F0.00014334862385321102
I1
I0
I1
tp28013
sS'effects,of,stress'
p28014
(F1
F0.00014334862385321102
I0
I1
I-1
tp28015
sS'if,these,agents'
p28016
(F1
F0.00014334862385321102
I1
I0
I1
tp28017
sS'also,referred,to'
p28018
(F1
F0.00014334862385321102
I0
I1
I-1
tp28019
sS'medications,such,as'
p28020
(F0
F0
I1
I1
I0
tp28021
sS'hypotension,with,the'
p28022
(F1
F0.00014334862385321102
I1
I0
I1
tp28023
sS'flolan,was,used'
p28024
(F1
F0.00014334862385321102
I1
I0
I1
tp28025
sS'when,mg,b'
p28026
(F1
F0.00014334862385321102
I1
I0
I1
tp28027
sS'replacement,therapy,should'
p28028
(F1
F0.00014334862385321102
I1
I0
I1
tp28029
sS'the,inhibits,the'
p28030
(F1
F0.00014334862385321102
I0
I1
I-1
tp28031
sS'is,likely,that'
p28032
(F1
F0.00014334862385321102
I1
I0
I1
tp28033
sS'may,displace,acidic'
p28034
(F1
F0.00014334862385321102
I1
I0
I1
tp28035
sS'half-life,by,and'
p28036
(F1
F0.00014334862385321102
I1
I0
I1
tp28037
sS'activity,should,if'
p28038
(F1
F0.00014334862385321102
I1
I0
I1
tp28039
sS'a,mg,m2'
p28040
(F1
F0.00014334862385321102
I1
I0
I1
tp28041
sS'concomitant,medications,such'
p28042
(F1
F0.00028669724770642203
I0
I2
I-2
tp28043
sS'abolished,as,a'
p28044
(F1
F0.00014334862385321102
I1
I0
I1
tp28045
sS'exacerbate,the,hypertensive'
p28046
(F1
F0.00014334862385321102
I1
I0
I1
tp28047
sS'of,more,severe'
p28048
(F1
F0.00014334862385321102
I0
I1
I-1
tp28049
sS'goal-directed,behavior,in'
p28050
(F1
F0.00014334862385321102
I0
I1
I-1
tp28051
sS'acid,may,also'
p28052
(F1
F0.00014334862385321102
I1
I0
I1
tp28053
sS'receiving,thiazide,agents'
p28054
(F1
F0.00014334862385321102
I0
I1
I-1
tp28055
sS'any,clinically,important'
p28056
(F1
F0.00057339449541284407
I0
I4
I-4
tp28057
sS'nephrosis,acromegaly,and'
p28058
(F1
F0.00014334862385321102
I0
I1
I-1
tp28059
sS'transient,elevations,in'
p28060
(F1
F0.00028669724770642203
I2
I0
I2
tp28061
sS'for,than,for'
p28062
(F1
F0.00014334862385321102
I1
I0
I1
tp28063
sS'should,receive,initial'
p28064
(F1
F0.00014334862385321102
I1
I0
I1
tp28065
sS'altered,by,amphotericin'
p28066
(F1
F0.00014334862385321102
I0
I1
I-1
tp28067
sS'for,the,increased'
p28068
(F1
F0.00028669724770642203
I2
I0
I2
tp28069
sS'cns,depressant,effects'
p28070
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp28071
sS'when,these,agents'
p28072
(F1
F0.00028669724770642203
I2
I0
I2
tp28073
sS'been,inconsistent,reports'
p28074
(F1
F0.00014334862385321102
I0
I1
I-1
tp28075
sS'retention,and,blurred'
p28076
(F1
F0.00014334862385321102
I1
I0
I1
tp28077
sS'of,amprenavir,and'
p28078
(F1
F0.00014334862385321102
I1
I0
I1
tp28079
sS'plasma,in,vitro'
p28080
(F1
F0.00014334862385321102
I0
I1
I-1
tp28081
sS'undesirable,involving,even'
p28082
(F1
F0.00028669724770642203
I0
I2
I-2
tp28083
sS'with,and,without'
p28084
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp28085
sS'probenecid,probenecid,a'
p28086
(F1
F0.00014334862385321102
I0
I1
I-1
tp28087
sS'substrate,response,is'
p28088
(F1
F0.00014334862385321102
I0
I1
I-1
tp28089
sS'recommended,that,cefditoren'
p28090
(F0
F0
I1
I1
I0
tp28091
sS'inhibition,of,cyp2a6'
p28092
(F1
F0.00014334862385321102
I1
I0
I1
tp28093
sS'adverse,neuropsychiatric,events'
p28094
(F1
F0.00014334862385321102
I1
I0
I1
tp28095
sS'pharmacokinetic,data,from'
p28096
(F1
F0.00014334862385321102
I1
I0
I1
tp28097
sS'vitro,was,altered'
p28098
(F1
F0.00014334862385321102
I0
I1
I-1
tp28099
sS'toxicity,from,normal'
p28100
(F1
F0.00014334862385321102
I0
I1
I-1
tp28101
sS'binds,bile,acids'
p28102
(F1
F0.00014334862385321102
I0
I1
I-1
tp28103
sS'cyp3a4,and,concomitant'
p28104
(F1
F0.00014334862385321102
I0
I1
I-1
tp28105
sS'high,dose,proleukin'
p28106
(F1
F0.00014334862385321102
I1
I0
I1
tp28107
sS'regarding,interactions,associated'
p28108
(F1
F0.00014334862385321102
I0
I1
I-1
tp28109
sS'carbonate,or,an'
p28110
(F1
F0.00014334862385321102
I1
I0
I1
tp28111
sS'are,thought,to'
p28112
(F1
F0.00014334862385321102
I0
I1
I-1
tp28113
sS'and,the,pharmacodynamics'
p28114
(F1
F0.00014334862385321102
I0
I1
I-1
tp28115
sS'oral,sulfate,may'
p28116
(F1
F0.00014334862385321102
I1
I0
I1
tp28117
sS'a,new,class'
p28118
(F1
F0.00014334862385321102
I0
I1
I-1
tp28119
sS'this,decrease,in'
p28120
(F0
F0
I1
I1
I0
tp28121
sS'allergic,or,hypersensitivity'
p28122
(F1
F0.00014334862385321102
I0
I1
I-1
tp28123
sS'than,for,other'
p28124
(F1
F0.00014334862385321102
I1
I0
I1
tp28125
sS'containing,may,decrease'
p28126
(F1
F0.00014334862385321102
I1
I0
I1
tp28127
sS'a,partially,impaired'
p28128
(F1
F0.00014334862385321102
I0
I1
I-1
tp28129
sS'a,rebound,in'
p28130
(F1
F0.00014334862385321102
I1
I0
I1
tp28131
sS'include,and,some'
p28132
(F1
F0.00014334862385321102
I0
I1
I-1
tp28133
sS'coadministration,with,mg'
p28134
(F1
F0.00014334862385321102
I1
I0
I1
tp28135
sS'analogues,didanosine,co-administration'
p28136
(F1
F0.00014334862385321102
I1
I0
I1
tp28137
sS'and,cardiac,transplant'
p28138
(F1
F0.00014334862385321102
I1
I0
I1
tp28139
sS'study,in,human'
p28140
(F1
F0.00014334862385321102
I1
I0
I1
tp28141
sS'myalgia,and,arthralgia'
p28142
(F1
F0.00014334862385321102
I1
I0
I1
tp28143
sS'the,rate,cmax'
p28144
(F1
F0.00014334862385321102
I1
I0
I1
tp28145
sS'evaluated,in,healthy'
p28146
(F1
F0.00043004587155963305
I0
I3
I-3
tp28147
sS'any,medication,including'
p28148
(F1
F0.00014334862385321102
I1
I0
I1
tp28149
sS'therapy,with,if'
p28150
(F1
F0.00014334862385321102
I1
I0
I1
tp28151
sS'support,the,choice'
p28152
(F1
F0.00014334862385321102
I0
I1
I-1
tp28153
sS'of,thereby,raising'
p28154
(F1
F0.00014334862385321102
I1
I0
I1
tp28155
sS'concomitantly,with,beta'
p28156
(F1
F0.00014334862385321102
I0
I1
I-1
tp28157
sS'on,phenytoin,therapy'
p28158
(F1
F0.00014334862385321102
I1
I0
I1
tp28159
sS'interaction,this,report'
p28160
(F1
F0.00014334862385321102
I1
I0
I1
tp28161
sS'with,four,resulted'
p28162
(F1
F0.00014334862385321102
I1
I0
I1
tp28163
sS'unexpected,adverse,reactions'
p28164
(F1
F0.00014334862385321102
I0
I1
I-1
tp28165
sS'in,levels,was'
p28166
(F1
F0.00014334862385321102
I1
I0
I1
tp28167
sS'to,decrease,prior'
p28168
(F1
F0.00014334862385321102
I0
I1
I-1
tp28169
sS'by,a,liquid'
p28170
(F1
F0.00014334862385321102
I0
I1
I-1
tp28171
sS'from,clinical,studies'
p28172
(F1
F0.00014334862385321102
I1
I0
I1
tp28173
sS'serum,protein,binding'
p28174
(F1
F0.00014334862385321102
I0
I1
I-1
tp28175
sS'concomitantly,with,for'
p28176
(F0
F0
I1
I1
I0
tp28177
sS'tablets,with,may'
p28178
(F1
F0.00014334862385321102
I1
I0
I1
tp28179
sS'and,second,contractile'
p28180
(F1
F0.00014334862385321102
I1
I0
I1
tp28181
sS'or,n,compared'
p28182
(F1
F0.00014334862385321102
I1
I0
I1
tp28183
sS'specific,for,the'
p28184
(F1
F0.00014334862385321102
I0
I1
I-1
tp28185
sS'patients,taking,or'
p28186
(F1
F0.00028669724770642203
I0
I2
I-2
tp28187
sS'include,azole,antifungals'
p28188
(F1
F0.00014334862385321102
I0
I1
I-1
tp28189
sS'nsaids,through,effects'
p28190
(F1
F0.00014334862385321102
I1
I0
I1
tp28191
sS'significantly,elevating,duodenal'
p28192
(F1
F0.00014334862385321102
I1
I0
I1
tp28193
sS'although,lexapro,did'
p28194
(F1
F0.00014334862385321102
I1
I0
I1
tp28195
sS'a,shortened,elimination'
p28196
(F1
F0.00014334862385321102
I1
I0
I1
tp28197
sS'butalbital,and,may'
p28198
(F1
F0.00014334862385321102
I1
I0
I1
tp28199
sS'plasma,maximum,concentration'
p28200
(F1
F0.00014334862385321102
I0
I1
I-1
tp28201
sS'or,may,intensify'
p28202
(F1
F0.00014334862385321102
I1
I0
I1
tp28203
sS'bioassay,procedures,for'
p28204
(F1
F0.00014334862385321102
I0
I1
I-1
tp28205
sS'and,by,inhibition'
p28206
(F1
F0.00014334862385321102
I1
I0
I1
tp28207
sS'daily,as,assessed'
p28208
(F1
F0.00014334862385321102
I0
I1
I-1
tp28209
sS'sodium,injection,should'
p28210
(F1
F0.00014334862385321102
I0
I1
I-1
tp28211
sS'valid,in,cardioplegic'
p28212
(F1
F0.00014334862385321102
I0
I1
I-1
tp28213
sS'of,particularly,with'
p28214
(F1
F0.00014334862385321102
I1
I0
I1
tp28215
sS'in,the,time'
p28216
(F1
F0.00014334862385321102
I1
I0
I1
tp28217
sS'it,significantly,decreased'
p28218
(F0
F0
I1
I1
I0
tp28219
sS'cholestyramine,resin,or'
p28220
(F1
F0.00014334862385321102
I0
I1
I-1
tp28221
sS'relative,to,that'
p28222
(F1
F0.00014334862385321102
I1
I0
I1
tp28223
sS'administration,of,wellbutrin'
p28224
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp28225
sS'and,maximal,plasma'
p28226
(F1
F0.00014334862385321102
I1
I0
I1
tp28227
sS'it,palliates,deficiencies'
p28228
(F1
F0.00014334862385321102
I0
I1
I-1
tp28229
sS'healthy,volunteers,show'
p28230
(F1
F0.00014334862385321102
I0
I1
I-1
tp28231
sS'concomitantly,receiving,oral'
p28232
(F1
F0.00014334862385321102
I1
I0
I1
tp28233
sS'and,are,metabolized'
p28234
(F1
F0.00014334862385321102
I0
I1
I-1
tp28235
sS'antiretroviral,regimens,consisted'
p28236
(F1
F0.00014334862385321102
I0
I1
I-1
tp28237
sS'significant,drug-drug,interaction'
p28238
(F1
F0.00014334862385321102
I0
I1
I-1
tp28239
sS'significant,drug-drug,interactions'
p28240
(F1
F0.00014334862385321102
I0
I1
I-1
tp28241
sS'coagulation,parameters,pt'
p28242
(F1
F0.00014334862385321102
I1
I0
I1
tp28243
sS'subjects,the,concurrent'
p28244
(F1
F0.00014334862385321102
I0
I1
I-1
tp28245
sS'treatment,of,induced'
p28246
(F1
F0.00014334862385321102
I0
I1
I-1
tp28247
sS'were,to,avoid'
p28248
(F1
F0.00014334862385321102
I0
I1
I-1
tp28249
sS'values,for,free'
p28250
(F1
F0.00014334862385321102
I0
I1
I-1
tp28251
sS'oral,regularly,results'
p28252
(F1
F0.00014334862385321102
I0
I1
I-1
tp28253
sS'active,hydroxy,acid'
p28254
(F1
F0.00014334862385321102
I1
I0
I1
tp28255
sS'certain,especially,and'
p28256
(F1
F0.00014334862385321102
I0
I1
I-1
tp28257
sS'volunteers,had,no'
p28258
(F1
F0.00014334862385321102
I1
I0
I1
tp28259
sS'bioavailability,of,is'
p28260
(F1
F0.00014334862385321102
I1
I0
I1
tp28261
sS'quetiapine,fumarate,seroquel'
p28262
(F1
F0.00014334862385321102
I0
I1
I-1
tp28263
sS'as,postmarketing,observations'
p28264
(F1
F0.00014334862385321102
I1
I0
I1
tp28265
sS'using,the,tablets'
p28266
(F1
F0.00014334862385321102
I1
I0
I1
tp28267
sS'of,a,selective'
p28268
(F1
F0.00014334862385321102
I1
I0
I1
tp28269
sS'the,bio-rad,laboratories'
p28270
(F1
F0.00014334862385321102
I0
I1
I-1
tp28271
sS'and,b12,because'
p28272
(F1
F0.00014334862385321102
I0
I1
I-1
tp28273
sS'tylenol,with,long-term'
p28274
(F1
F0.00014334862385321102
I1
I0
I1
tp28275
sS'propanol,to,difluoroacetone'
p28276
(F0
F0
I1
I1
I0
tp28277
sS'in,a,hour'
p28278
(F1
F0.0010034403669724771
I7
I0
I7
tp28279
sS'without,replacement,may'
p28280
(F1
F0.00014334862385321102
I0
I1
I-1
tp28281
sS'spectrum,may,sterilize'
p28282
(F1
F0.00014334862385321102
I0
I1
I-1
tp28283
sS'to,by,the'
p28284
(F1
F0.00028669724770642203
I0
I2
I-2
tp28285
sS'effects,of,mefloquine'
p28286
(F1
F0.00014334862385321102
I1
I0
I1
tp28287
sS'of,loratadine,and'
p28288
(F1
F0.00014334862385321102
I0
I1
I-1
tp28289
sS'both,first,and'
p28290
(F1
F0.00014334862385321102
I1
I0
I1
tp28291
sS'potassium-sparing,such,as'
p28292
(F1
F0.00014334862385321102
I0
I1
I-1
tp28293
sS'use,of,orally'
p28294
(F1
F0.00014334862385321102
I0
I1
I-1
tp28295
sS'from,to,micrograms'
p28296
(F1
F0.00014334862385321102
I0
I1
I-1
tp28297
sS'coumarin-type,anticoagulants,several'
p28298
(F1
F0.00014334862385321102
I0
I1
I-1
tp28299
sS'oral,contraceptives,valdecoxib'
p28300
(F1
F0.00014334862385321102
I0
I1
I-1
tp28301
sS'agents,a,pharmacokinetic'
p28302
(F1
F0.00014334862385321102
I0
I1
I-1
tp28303
sS'microm,preferentially,blocked'
p28304
(F1
F0.00014334862385321102
I1
I0
I1
tp28305
sS'inhibitor,pi,related'
p28306
(F1
F0.00014334862385321102
I0
I1
I-1
tp28307
sS'of,the,hypotension'
p28308
(F1
F0.00014334862385321102
I1
I0
I1
tp28309
sS'in,a,well-controlled'
p28310
(F1
F0.00028669724770642203
I0
I2
I-2
tp28311
sS'av,conduction,such'
p28312
(F1
F0.00014334862385321102
I1
I0
I1
tp28313
sS'pharmacokinetic,evaluation,of'
p28314
(F1
F0.00014334862385321102
I0
I1
I-1
tp28315
sS'two-lever,discrimination,and'
p28316
(F1
F0.00014334862385321102
I0
I1
I-1
tp28317
sS'hivid-associated,adverse,events'
p28318
(F1
F0.00014334862385321102
I1
I0
I1
tp28319
sS'of,in,a'
p28320
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp28321
sS'metabolism,and,the'
p28322
(F1
F0.00014334862385321102
I1
I0
I1
tp28323
sS'cmax,of,averaged'
p28324
(F1
F0.00014334862385321102
I1
I0
I1
tp28325
sS'the,rat,were'
p28326
(F1
F0.00014334862385321102
I0
I1
I-1
tp28327
sS'frequent,doses,of'
p28328
(F1
F0.00014334862385321102
I0
I1
I-1
tp28329
sS'of,single,mg'
p28330
(F1
F0.00014334862385321102
I0
I1
I-1
tp28331
sS'significantly,different,in'
p28332
(F1
F0.00014334862385321102
I0
I1
I-1
tp28333
sS'concentration,and,urinary'
p28334
(F1
F0.00014334862385321102
I1
I0
I1
tp28335
sS'taking,any,of'
p28336
(F0
F0
I1
I1
I0
tp28337
sS'certain,concomitant,medications'
p28338
(F1
F0.00028669724770642203
I0
I2
I-2
tp28339
sS'trileptal,the,auc'
p28340
(F1
F0.00014334862385321102
I1
I0
I1
tp28341
sS'lorazepam,injection,like'
p28342
(F1
F0.00014334862385321102
I1
I0
I1
tp28343
sS'meth,caused,a'
p28344
(F1
F0.00014334862385321102
I1
I0
I1
tp28345
sS'non-selective,beta-adrenergic,blocking'
p28346
(F1
F0.00014334862385321102
I1
I0
I1
tp28347
sS'reductions,in,or'
p28348
(F1
F0.00014334862385321102
I0
I1
I-1
tp28349
sS'was,co-administered,but'
p28350
(F1
F0.00014334862385321102
I0
I1
I-1
tp28351
sS'by,approximately,when'
p28352
(F1
F0.00043004587155963305
I3
I0
I3
tp28353
sS'cephalosporins,including,cefotaxime'
p28354
(F1
F0.00014334862385321102
I0
I1
I-1
tp28355
sS'postmarketing,observations,have'
p28356
(F1
F0.00014334862385321102
I1
I0
I1
tp28357
sS'difluoroacetone,to,erythro-fluorocitrate'
p28358
(F1
F0.00014334862385321102
I0
I1
I-1
tp28359
sS'norpace,does,not'
p28360
(F1
F0.00014334862385321102
I0
I1
I-1
tp28361
sS'to,be,fatal'
p28362
(F1
F0.00014334862385321102
I1
I0
I1
tp28363
sS'derived,from,the'
p28364
(F1
F0.00014334862385321102
I1
I0
I1
tp28365
sS'concurrently,with,anion-exchange'
p28366
(F1
F0.00014334862385321102
I1
I0
I1
tp28367
sS'six-healthy,male,volunteers'
p28368
(F1
F0.00014334862385321102
I0
I1
I-1
tp28369
sS'because,plasma,concentrations'
p28370
(F1
F0.00014334862385321102
I1
I0
I1
tp28371
sS'enantiomer,pharmacokinetics,were'
p28372
(F1
F0.00014334862385321102
I0
I1
I-1
tp28373
sS'receiving,revia,the'
p28374
(F1
F0.00014334862385321102
I1
I0
I1
tp28375
sS'to,examine,interactions'
p28376
(F1
F0.00014334862385321102
I0
I1
I-1
tp28377
sS'experienced,acute,atypical'
p28378
(F1
F0.00014334862385321102
I1
I0
I1
tp28379
sS'lower,serum,and'
p28380
(F1
F0.00028669724770642203
I2
I0
I2
tp28381
sS'cyp4a9,and,cyp4a11'
p28382
(F1
F0.00014334862385321102
I0
I1
I-1
tp28383
sS'inhibitors,and,decrease'
p28384
(F1
F0.00014334862385321102
I1
I0
I1
tp28385
sS'with,food,isrecommended'
p28386
(F1
F0.00014334862385321102
I1
I0
I1
tp28387
sS'to,trace,pathways'
p28388
(F1
F0.00014334862385321102
I0
I1
I-1
tp28389
sS'sodium,and,g'
p28390
(F1
F0.00014334862385321102
I1
I0
I1
tp28391
sS'measure,over,the'
p28392
(F1
F0.00014334862385321102
I0
I1
I-1
tp28393
sS'and,together,may'
p28394
(F1
F0.00014334862385321102
I1
I0
I1
tp28395
sS'q24h,for,days'
p28396
(F0
F0
I1
I1
I0
tp28397
sS'in,the,prescribing'
p28398
(F1
F0.00014334862385321102
I0
I1
I-1
tp28399
sS'dose,and,a'
p28400
(F1
F0.00014334862385321102
I1
I0
I1
tp28401
sS'sodium,the,bioavailability'
p28402
(F1
F0.00014334862385321102
I0
I1
I-1
tp28403
sS'a,monoamine,oxidase'
p28404
(F1
F0.00014334862385321102
I0
I1
I-1
tp28405
sS'physician,is,advised'
p28406
(F1
F0.00014334862385321102
I0
I1
I-1
tp28407
sS'efavirenz,has,demonstrated'
p28408
(F1
F0.00014334862385321102
I0
I1
I-1
tp28409
sS'active,metabolite,by'
p28410
(F1
F0.00014334862385321102
I1
I0
I1
tp28411
sS'that,may,depress'
p28412
(F1
F0.00014334862385321102
I1
I0
I1
tp28413
sS'in,corrected,qt'
p28414
(F1
F0.00014334862385321102
I0
I1
I-1
tp28415
sS'clinical,trial,data'
p28416
(F1
F0.00014334862385321102
I1
I0
I1
tp28417
sS'for,optimal,pulmonary'
p28418
(F1
F0.00014334862385321102
I0
I1
I-1
tp28419
sS'clearance,of,resulting'
p28420
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp28421
sS'dose,of,sodium'
p28422
(F1
F0.00014334862385321102
I1
I0
I1
tp28423
sS'that,elspar,can'
p28424
(F1
F0.00014334862385321102
I1
I0
I1
tp28425
sS'hydrocodone,increases,auc'
p28426
(F1
F0.00014334862385321102
I1
I0
I1
tp28427
sS'some,attenuation,in'
p28428
(F1
F0.00014334862385321102
I0
I1
I-1
tp28429
sS'diuretics,etodolac,has'
p28430
(F1
F0.00014334862385321102
I0
I1
I-1
tp28431
sS'monitor,concentrations,in'
p28432
(F1
F0.00014334862385321102
I1
I0
I1
tp28433
sS'not,been,seen'
p28434
(F1
F0.00014334862385321102
I0
I1
I-1
tp28435
sS'after,inhalational,muscle'
p28436
(F1
F0.00014334862385321102
I0
I1
I-1
tp28437
sS'because,there,are'
p28438
(F1
F0.00014334862385321102
I0
I1
I-1
tp28439
sS'enoxacin,does,not'
p28440
(F1
F0.00014334862385321102
I0
I1
I-1
tp28441
sS'modest,increases,in'
p28442
(F1
F0.00014334862385321102
I1
I0
I1
tp28443
sS'after,nasal,spray'
p28444
(F1
F0.00014334862385321102
I1
I0
I1
tp28445
sS'metabolized,by,a'
p28446
(F1
F0.00014334862385321102
I0
I1
I-1
tp28447
sS'evidence,suggests,that'
p28448
(F1
F0.00014334862385321102
I1
I0
I1
tp28449
sS'or,their,metabolites'
p28450
(F1
F0.00014334862385321102
I0
I1
I-1
tp28451
sS'a,single,oral'
p28452
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp28453
sS'reported,to,decrease'
p28454
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp28455
sS'in,human,immunodeficiency'
p28456
(F1
F0.00014334862385321102
I0
I1
I-1
tp28457
sS'does,not,exhibit'
p28458
(F1
F0.00014334862385321102
I1
I0
I1
tp28459
sS'has,been,too'
p28460
(F1
F0.00014334862385321102
I0
I1
I-1
tp28461
sS'use,of,prophylactic'
p28462
(F1
F0.00014334862385321102
I0
I1
I-1
tp28463
sS'only,minor,changes'
p28464
(F1
F0.00014334862385321102
I1
I0
I1
tp28465
sS'dosing,interval,for'
p28466
(F1
F0.00014334862385321102
I0
I1
I-1
tp28467
sS'secondary,to,vomiting'
p28468
(F1
F0.00014334862385321102
I1
I0
I1
tp28469
sS'observed,following,initiation'
p28470
(F1
F0.00014334862385321102
I1
I0
I1
tp28471
sS'of,however,serum'
p28472
(F1
F0.00014334862385321102
I1
I0
I1
tp28473
sS'hypothyroid,patients,and'
p28474
(F1
F0.00014334862385321102
I0
I1
I-1
tp28475
sS'multiple,dose,mg'
p28476
(F1
F0.00014334862385321102
I0
I1
I-1
tp28477
sS'mefenamic,acid,increased'
p28478
(F1
F0.00014334862385321102
I1
I0
I1
tp28479
sS'effect,of,the'
p28480
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp28481
sS'kg,or,to'
p28482
(F1
F0.00014334862385321102
I0
I1
I-1
tp28483
sS'with,and,requires'
p28484
(F1
F0.00014334862385321102
I1
I0
I1
tp28485
sS'anxiogenic,effects,of'
p28486
(F1
F0.00014334862385321102
I1
I0
I1
tp28487
sS'of,pipracil,may'
p28488
(F1
F0.00014334862385321102
I0
I1
I-1
tp28489
sS'receive,mg,of'
p28490
(F1
F0.00014334862385321102
I1
I0
I1
tp28491
sS'other,products,containing'
p28492
(F1
F0.00014334862385321102
I1
I0
I1
tp28493
sS'were,approximately,twice'
p28494
(F1
F0.00014334862385321102
I1
I0
I1
tp28495
sS'p-450,the,enzyme'
p28496
(F0
F0
I1
I1
I0
tp28497
sS'spectrum,of,actions'
p28498
(F1
F0.00014334862385321102
I0
I1
I-1
tp28499
sS'least,hours,after'
p28500
(F1
F0.00028669724770642203
I2
I0
I2
tp28501
sS'other,drugs,which'
p28502
(F1
F0.00014334862385321102
I1
I0
I1
tp28503
sS'the,immediate,release'
p28504
(F1
F0.00014334862385321102
I1
I0
I1
tp28505
sS'assigned,to,receive'
p28506
(F1
F0.00014334862385321102
I0
I1
I-1
tp28507
sS'and,hydroxide,reduce'
p28508
(F1
F0.00014334862385321102
I1
I0
I1
tp28509
sS'to,plenaxis,should'
p28510
(F1
F0.00014334862385321102
I0
I1
I-1
tp28511
sS'are,no,formal'
p28512
(F1
F0.00014334862385321102
I0
I1
I-1
tp28513
sS'are,likely,to'
p28514
(F1
F0.00043004587155963305
I3
I0
I3
tp28515
sS'as,and,dilantin'
p28516
(F1
F0.00014334862385321102
I1
I0
I1
tp28517
sS'or,was,seen'
p28518
(F1
F0.00014334862385321102
I0
I1
I-1
tp28519
sS'in,the,group'
p28520
(F1
F0.00014334862385321102
I0
I1
I-1
tp28521
sS'enhance,the,potential'
p28522
(F0
F0
I1
I1
I0
tp28523
sS'cypermethrin-induced,oxidative,stress'
p28524
(F1
F0.00014334862385321102
I1
I0
I1
tp28525
sS'is,similar,to'
p28526
(F1
F0.00014334862385321102
I1
I0
I1
tp28527
sS'to,monitor,tca'
p28528
(F1
F0.00057339449541284407
I0
I4
I-4
tp28529
sS'or,serial,use'
p28530
(F1
F0.00014334862385321102
I0
I1
I-1
tp28531
sS'shown,to,produce'
p28532
(F1
F0.00028669724770642203
I2
I0
I2
tp28533
sS'risk,of,developing'
p28534
(F1
F0.00014334862385321102
I1
I0
I1
tp28535
sS'than,and,does'
p28536
(F1
F0.00014334862385321102
I0
I1
I-1
tp28537
sS'of,vardenafil,mg'
p28538
(F1
F0.00028669724770642203
I2
I0
I2
tp28539
sS'and,the,electrocardiographic'
p28540
(F1
F0.00014334862385321102
I0
I1
I-1
tp28541
sS'co-administration,with,hydrochloride'
p28542
(F1
F0.00014334862385321102
I0
I1
I-1
tp28543
sS'interaction,when,administered'
p28544
(F1
F0.00014334862385321102
I0
I1
I-1
tp28545
sS'heart,failure,channel'
p28546
(F1
F0.00014334862385321102
I1
I0
I1
tp28547
sS'mg,three,mg'
p28548
(F1
F0.00014334862385321102
I1
I0
I1
tp28549
sS'inhibitors,and,angiotensin'
p28550
(F0
F0
I1
I1
I0
tp28551
sS'this,appears,to'
p28552
(F1
F0.00014334862385321102
I1
I0
I1
tp28553
sS'of,depletion,are'
p28554
(F1
F0.00014334862385321102
I0
I1
I-1
tp28555
sS'aed,on,mhd'
p28556
(F1
F0.00014334862385321102
I0
I1
I-1
tp28557
sS'potential,for,serious'
p28558
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp28559
sS'newly,diagnosed,subjects'
p28560
(F1
F0.00014334862385321102
I0
I1
I-1
tp28561
sS'to,mm,declining'
p28562
(F1
F0.00014334862385321102
I0
I1
I-1
tp28563
sS'a,consequent,possible'
p28564
(F1
F0.00014334862385321102
I1
I0
I1
tp28565
sS'also,significantly,decreased'
p28566
(F1
F0.00014334862385321102
I1
I0
I1
tp28567
sS'using,it,concomitantly'
p28568
(F1
F0.00014334862385321102
I1
I0
I1
tp28569
sS'g,and,was'
p28570
(F1
F0.00014334862385321102
I1
I0
I1
tp28571
sS'and,are,equipotent'
p28572
(F1
F0.00014334862385321102
I0
I1
I-1
tp28573
sS'of,nimbex,before'
p28574
(F1
F0.00014334862385321102
I0
I1
I-1
tp28575
sS'the,levels,shown'
p28576
(F1
F0.00014334862385321102
I0
I1
I-1
tp28577
sS'heart,failure,receiving'
p28578
(F1
F0.00014334862385321102
I1
I0
I1
tp28579
sS'use,in,patients'
p28580
(F1
F0.00028669724770642203
I2
I0
I2
tp28581
sS'd6,poor,metabolizers'
p28582
(F1
F0.00014334862385321102
I1
I0
I1
tp28583
sS'for,this,reason'
p28584
(F0
F0
I1
I1
I0
tp28585
sS'by,was,generally'
p28586
(F1
F0.00014334862385321102
I1
I0
I1
tp28587
sS'with,nephrotoxic,potential'
p28588
(F1
F0.00014334862385321102
I1
I0
I1
tp28589
sS'other,aeds,were'
p28590
(F1
F0.00014334862385321102
I0
I1
I-1
tp28591
sS'and,oral,resulting'
p28592
(F1
F0.00014334862385321102
I0
I1
I-1
tp28593
sS'decreased,even,when'
p28594
(F1
F0.00014334862385321102
I1
I0
I1
tp28595
sS'size,is,too'
p28596
(F1
F0.00014334862385321102
I0
I1
I-1
tp28597
sS'than,mg,qd'
p28598
(F1
F0.00014334862385321102
I0
I1
I-1
tp28599
sS'study,with,without'
p28600
(F1
F0.00014334862385321102
I0
I1
I-1
tp28601
sS'elapse,before,initiating'
p28602
(F1
F0.00014334862385321102
I1
I0
I1
tp28603
sS'at,micromol,l'
p28604
(F1
F0.00014334862385321102
I1
I0
I1
tp28605
sS'introduction,of,oral'
p28606
(F1
F0.00014334862385321102
I1
I0
I1
tp28607
sS'of,other,cyp3a4'
p28608
(F1
F0.00028669724770642203
I2
I0
I2
tp28609
sS'during,concomitant,protease'
p28610
(F1
F0.00014334862385321102
I1
I0
I1
tp28611
sS'this,route,and'
p28612
(F1
F0.00014334862385321102
I1
I0
I1
tp28613
sS'controlled,hypotensive,using'
p28614
(F1
F0.00014334862385321102
I1
I0
I1
tp28615
sS'may,affect,strategies'
p28616
(F1
F0.00014334862385321102
I0
I1
I-1
tp28617
sS'concentrations,above,ng'
p28618
(F1
F0.00014334862385321102
I1
I0
I1
tp28619
sS'nsaids,may,diminish'
p28620
(F1
F0.0010034403669724771
I7
I0
I7
tp28621
sS'drug,metabolism,increased'
p28622
(F1
F0.00014334862385321102
I1
I0
I1
tp28623
sS'unsatisfactory,lipid,response'
p28624
(F1
F0.00014334862385321102
I1
I0
I1
tp28625
sS'limb,digital,extensor'
p28626
(F1
F0.00014334862385321102
I0
I1
I-1
tp28627
sS'd,produced,a'
p28628
(F1
F0.00028669724770642203
I2
I0
I2
tp28629
sS'mg,or,placebo'
p28630
(F1
F0.00014334862385321102
I0
I1
I-1
tp28631
sS'other,therapy,should'
p28632
(F1
F0.00014334862385321102
I0
I1
I-1
tp28633
sS'not,display,the'
p28634
(F1
F0.00014334862385321102
I0
I1
I-1
tp28635
sS'esomeprazole,may,potentially'
p28636
(F1
F0.00014334862385321102
I0
I1
I-1
tp28637
sS'likely,viracept,should'
p28638
(F1
F0.00014334862385321102
I1
I0
I1
tp28639
sS'other,local,or'
p28640
(F1
F0.00014334862385321102
I1
I0
I1
tp28641
sS'in,the,hormone'
p28642
(F1
F0.00014334862385321102
I0
I1
I-1
tp28643
sS'nnrti-based,regimens,may'
p28644
(F1
F0.00014334862385321102
I0
I1
I-1
tp28645
sS'leukopenic,activity,of'
p28646
(F1
F0.00014334862385321102
I1
I0
I1
tp28647
sS'that,are,known'
p28648
(F1
F0.00028669724770642203
I2
I0
I2
tp28649
sS'was,followed,by'
p28650
(F1
F0.00014334862385321102
I1
I0
I1
tp28651
sS'that,your,health'
p28652
(F1
F0.00014334862385321102
I1
I0
I1
tp28653
sS'all,patients,as'
p28654
(F1
F0.00014334862385321102
I0
I1
I-1
tp28655
sS'studies,of,the'
p28656
(F1
F0.00014334862385321102
I1
I0
I1
tp28657
sS'may,not,appreciably'
p28658
(F1
F0.00014334862385321102
I0
I1
I-1
tp28659
sS'pertechnetate,tc99m,uptake'
p28660
(F1
F0.00014334862385321102
I0
I1
I-1
tp28661
sS'agents,are,to'
p28662
(F1
F0.00014334862385321102
I1
I0
I1
tp28663
sS'non-selective,monoamine,oxidase'
p28664
(F1
F0.00014334862385321102
I0
I1
I-1
tp28665
sS'with,folate,utilization'
p28666
(F1
F0.00014334862385321102
I1
I0
I1
tp28667
sS'the,dose,or'
p28668
(F1
F0.00014334862385321102
I0
I1
I-1
tp28669
sS'to,or,hours'
p28670
(F1
F0.00014334862385321102
I1
I0
I1
tp28671
sS'fluctuate,significantly,when'
p28672
(F1
F0.00014334862385321102
I1
I0
I1
tp28673
sS'nervous,system,when'
p28674
(F1
F0.00014334862385321102
I1
I0
I1
tp28675
sS'agents,may,alter'
p28676
(F1
F0.00014334862385321102
I0
I1
I-1
tp28677
sS'to,substantially,decrease'
p28678
(F1
F0.00014334862385321102
I0
I1
I-1
tp28679
sS'several,but,not'
p28680
(F1
F0.00014334862385321102
I0
I1
I-1
tp28681
sS'alphagan,p,the'
p28682
(F1
F0.00014334862385321102
I1
I0
I1
tp28683
sS'receiving,oral,an'
p28684
(F1
F0.00014334862385321102
I1
I0
I1
tp28685
sS'when,either,was'
p28686
(F1
F0.00028669724770642203
I2
I0
I2
tp28687
sS'intravenous,infusion,of'
p28688
(F1
F0.00028669724770642203
I0
I2
I-2
tp28689
sS'of,and,acamprosate'
p28690
(F1
F0.00014334862385321102
I0
I1
I-1
tp28691
sS'of,gastrointestinal,ulceration'
p28692
(F1
F0.00014334862385321102
I1
I0
I1
tp28693
sS'how,soon,after'
p28694
(F1
F0.00014334862385321102
I1
I0
I1
tp28695
sS'acid,binding,to'
p28696
(F1
F0.00028669724770642203
I2
I0
I2
tp28697
sS'nsaids,tnf,blocking'
p28698
(F1
F0.00014334862385321102
I0
I1
I-1
tp28699
sS'of,striatal,concentrations'
p28700
(F1
F0.00014334862385321102
I1
I0
I1
tp28701
sS'patients,taking,concurrent'
p28702
(F1
F0.00014334862385321102
I1
I0
I1
tp28703
sS'dosed,as,a'
p28704
(F1
F0.00014334862385321102
I0
I1
I-1
tp28705
sS'iii,and,iv'
p28706
(F1
F0.00028669724770642203
I0
I2
I-2
tp28707
sS'no,formal,studies'
p28708
(F1
F0.00014334862385321102
I0
I1
I-1
tp28709
sS'cause,renal,and'
p28710
(F1
F0.00014334862385321102
I0
I1
I-1
tp28711
sS'these,results,would'
p28712
(F1
F0.00014334862385321102
I1
I0
I1
tp28713
sS'range,of,is'
p28714
(F1
F0.00014334862385321102
I0
I1
I-1
tp28715
sS'aprepitant,on,the'
p28716
(F1
F0.00014334862385321102
I1
I0
I1
tp28717
sS's,a,cyp2c9'
p28718
(F1
F0.00014334862385321102
I1
I0
I1
tp28719
sS'chloride,in,a'
p28720
(F1
F0.00014334862385321102
I1
I0
I1
tp28721
sS'double,strength,mg'
p28722
(F1
F0.00014334862385321102
I0
I1
I-1
tp28723
sS'hypoglycemic,agents,in'
p28724
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp28725
sS'crossover,study,patients'
p28726
(F1
F0.00014334862385321102
I0
I1
I-1
tp28727
sS'in,interactions,toxicity'
p28728
(F1
F0.00014334862385321102
I1
I0
I1
tp28729
sS'hours,before,dosing'
p28730
(F1
F0.00014334862385321102
I1
I0
I1
tp28731
sS'hypertension,in,clinical'
p28732
(F1
F0.00014334862385321102
I1
I0
I1
tp28733
sS'and,citrate,elevations'
p28734
(F1
F0.00014334862385321102
I1
I0
I1
tp28735
sS'possible,clinical,significance'
p28736
(F1
F0.00014334862385321102
I1
I0
I1
tp28737
sS'doses,of,antizol'
p28738
(F1
F0.00014334862385321102
I1
I0
I1
tp28739
sS'the,cns-depressive,effects'
p28740
(F1
F0.00014334862385321102
I1
I0
I1
tp28741
sS'phenytoin,in,a'
p28742
(F1
F0.00014334862385321102
I0
I1
I-1
tp28743
sS'serious,falls,vs'
p28744
(F1
F0.00014334862385321102
I1
I0
I1
tp28745
sS'cyp,a4,inhibitors'
p28746
(F1
F0.00014334862385321102
I0
I1
I-1
tp28747
sS'so,plasma,concentrations'
p28748
(F1
F0.00014334862385321102
I1
I0
I1
tp28749
sS'of,fenofibric,acid'
p28750
(F1
F0.00014334862385321102
I0
I1
I-1
tp28751
sS'and,the,bad'
p28752
(F1
F0.00014334862385321102
I1
I0
I1
tp28753
sS'qt,interval,on'
p28754
(F1
F0.0010034403669724771
I7
I0
I7
tp28755
sS'when,and,non-steroidal'
p28756
(F1
F0.00014334862385321102
I1
I0
I1
tp28757
sS'to,confirm,that'
p28758
(F1
F0.00014334862385321102
I0
I1
I-1
tp28759
sS'and,individual,glucose'
p28760
(F1
F0.00014334862385321102
I1
I0
I1
tp28761
sS'other,related,compounds'
p28762
(F1
F0.00014334862385321102
I1
I0
I1
tp28763
sS'to,human,plasma'
p28764
(F1
F0.00028669724770642203
I0
I2
I-2
tp28765
sS'cyp,a4,substrate'
p28766
(F1
F0.00014334862385321102
I0
I1
I-1
tp28767
sS'relevant,elevation,of'
p28768
(F1
F0.00014334862385321102
I1
I0
I1
tp28769
sS'if,the,usual'
p28770
(F1
F0.00014334862385321102
I0
I1
I-1
tp28771
sS'although,there,is'
p28772
(F1
F0.00028669724770642203
I0
I2
I-2
tp28773
sS'other,psychoactive,or'
p28774
(F1
F0.00014334862385321102
I1
I0
I1
tp28775
sS'tarceva,dose,is'
p28776
(F1
F0.00014334862385321102
I1
I0
I1
tp28777
sS'in,clearance,and'
p28778
(F1
F0.00071674311926605509
I5
I0
I5
tp28779
sS'blood,glucose,and'
p28780
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp28781
sS'in,but,not'
p28782
(F1
F0.00014334862385321102
I1
I0
I1
tp28783
sS'combination,with,serotoninergic'
p28784
(F1
F0.00014334862385321102
I1
I0
I1
tp28785
sS'clinical,implications,of'
p28786
(F1
F0.00014334862385321102
I1
I0
I1
tp28787
sS'the,pharmacokinetics,and'
p28788
(F1
F0.00057339449541284407
I0
I4
I-4
tp28789
sS'being,converted,to'
p28790
(F1
F0.00014334862385321102
I1
I0
I1
tp28791
sS'of,supplemental,l-glutamine'
p28792
(F1
F0.00014334862385321102
I1
I0
I1
tp28793
sS'start,and,discontinuation'
p28794
(F1
F0.00014334862385321102
I1
I0
I1
tp28795
sS'in,vitamin,k'
p28796
(F1
F0.00014334862385321102
I1
I0
I1
tp28797
sS'as,and,oral'
p28798
(F1
F0.00014334862385321102
I0
I1
I-1
tp28799
sS'may,be,impaired'
p28800
(F1
F0.00014334862385321102
I0
I1
I-1
tp28801
sS'a,review,of'
p28802
(F1
F0.00014334862385321102
I1
I0
I1
tp28803
sS'controlled,studies,in'
p28804
(F1
F0.00014334862385321102
I1
I0
I1
tp28805
sS'and,imitrex,nasal'
p28806
(F1
F0.00014334862385321102
I0
I1
I-1
tp28807
sS'of,lymphatic,invasion'
p28808
(F1
F0.00014334862385321102
I1
I0
I1
tp28809
sS'n-methylthiotetrazole,or,methylthiadiazole'
p28810
(F1
F0.00014334862385321102
I0
I1
I-1
tp28811
sS'such,as,can'
p28812
(F1
F0.00014334862385321102
I1
I0
I1
tp28813
sS'sufficient,time,must'
p28814
(F1
F0.00014334862385321102
I1
I0
I1
tp28815
sS'is,coadministered,with'
p28816
(F1
F0.0010034403669724771
I7
I0
I7
tp28817
sS'rats,with,experimental'
p28818
(F1
F0.00014334862385321102
I1
I0
I1
tp28819
sS'taking,and,a'
p28820
(F1
F0.00014334862385321102
I1
I0
I1
tp28821
sS'microsomal,enzyme,inducer'
p28822
(F1
F0.00014334862385321102
I1
I0
I1
tp28823
sS'system,may,be'
p28824
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp28825
sS'analgesia,and,pupil'
p28826
(F1
F0.00014334862385321102
I0
I1
I-1
tp28827
sS'properties,and,a'
p28828
(F1
F0.00014334862385321102
I1
I0
I1
tp28829
sS'in,ambulatory,patients'
p28830
(F1
F0.00014334862385321102
I0
I1
I-1
tp28831
sS'analgesics,agonist,antagonist'
p28832
(F1
F0.00014334862385321102
I1
I0
I1
tp28833
sS'treatment,with,and'
p28834
(F1
F0.00043004587155963305
I3
I0
I3
tp28835
sS'lower,respectively,after'
p28836
(F1
F0.00014334862385321102
I0
I1
I-1
tp28837
sS'drugs,enhancing,heparin'
p28838
(F1
F0.00014334862385321102
I0
I1
I-1
tp28839
sS'such,as,choline'
p28840
(F1
F0.00014334862385321102
I1
I0
I1
tp28841
sS'to,beta-lactam,including'
p28842
(F1
F0.00014334862385321102
I1
I0
I1
tp28843
sS'anti-platelet,effect,is'
p28844
(F1
F0.00014334862385321102
I0
I1
I-1
tp28845
sS'their,tolerance,to'
p28846
(F1
F0.00014334862385321102
I1
I0
I1
tp28847
sS'been,prescribed,foradil'
p28848
(F1
F0.00014334862385321102
I0
I1
I-1
tp28849
sS'x,h,ml'
p28850
(F1
F0.00014334862385321102
I1
I0
I1
tp28851
sS'that,coadministration,with'
p28852
(F1
F0.00014334862385321102
I0
I1
I-1
tp28853
sS'moderately,reduced,approximately'
p28854
(F1
F0.00014334862385321102
I0
I1
I-1
tp28855
sS'enlargement,and,congestive'
p28856
(F1
F0.00014334862385321102
I1
I0
I1
tp28857
sS'appeared,to,prevent'
p28858
(F1
F0.00014334862385321102
I1
I0
I1
tp28859
sS'an,interaction,between'
p28860
(F1
F0.00028669724770642203
I2
I0
I2
tp28861
sS'and,administration,to'
p28862
(F1
F0.00014334862385321102
I0
I1
I-1
tp28863
sS'volume,and,sodium'
p28864
(F1
F0.00014334862385321102
I1
I0
I1
tp28865
sS'or,administration,for'
p28866
(F1
F0.00014334862385321102
I0
I1
I-1
tp28867
sS'reactions,atg,alg'
p28868
(F1
F0.00014334862385321102
I0
I1
I-1
tp28869
sS'action,of,certain'
p28870
(F1
F0.00014334862385321102
I1
I0
I1
tp28871
sS'day,administration,for'
p28872
(F1
F0.00014334862385321102
I0
I1
I-1
tp28873
sS'inhibitors,of,cyp3a'
p28874
(F1
F0.00014334862385321102
I0
I1
I-1
tp28875
sS'in,addition,there'
p28876
(F0
F0
I1
I1
I0
tp28877
sS'affect,idv,exposure'
p28878
(F1
F0.00014334862385321102
I0
I1
I-1
tp28879
sS'of,lanoxin,lanoxicaps'
p28880
(F1
F0.00014334862385321102
I1
I0
I1
tp28881
sS'respectively,on,the'
p28882
(F1
F0.00014334862385321102
I1
I0
I1
tp28883
sS'using,a,inhaler'
p28884
(F1
F0.00014334862385321102
I1
I0
I1
tp28885
sS'suppress,the,dopaminergic'
p28886
(F1
F0.00014334862385321102
I1
I0
I1
tp28887
sS'rigidity,myoclonus,autonomic'
p28888
(F1
F0.00014334862385321102
I1
I0
I1
tp28889
sS'serum,concentrations,of'
p28890
(F0.38461538461538464
F0.00071674311926605509
I9
I4
I5
tp28891
sS'to,a,mg'
p28892
(F1
F0.00014334862385321102
I1
I0
I1
tp28893
sS'and,its,active'
p28894
(F0.5
F0.00057339449541284407
I6
I2
I4
tp28895
sS'may,affect,the'
p28896
(F1
F0.00028669724770642203
I0
I2
I-2
tp28897
sS'exert,additive,ocular'
p28898
(F1
F0.00014334862385321102
I0
I1
I-1
tp28899
sS'serum,concentrations,or'
p28900
(F1
F0.00014334862385321102
I0
I1
I-1
tp28901
sS'male,subjects,no'
p28902
(F1
F0.00014334862385321102
I0
I1
I-1
tp28903
sS'mg,day,n'
p28904
(F1
F0.00014334862385321102
I0
I1
I-1
tp28905
sS'six,subjects,demonstrated'
p28906
(F1
F0.00014334862385321102
I1
I0
I1
tp28907
sS'therefore,the,concomitant'
p28908
(F1
F0.00014334862385321102
I1
I0
I1
tp28909
sS'who,received,mg'
p28910
(F1
F0.00014334862385321102
I1
I0
I1
tp28911
sS'peak,levels,and'
p28912
(F1
F0.00014334862385321102
I0
I1
I-1
tp28913
sS'and,crystalline,preparations'
p28914
(F1
F0.00014334862385321102
I0
I1
I-1
tp28915
sS'used,while,taking'
p28916
(F1
F0.00014334862385321102
I0
I1
I-1
tp28917
sS'have,shown,no'
p28918
(F1
F0.00028669724770642203
I0
I2
I-2
tp28919
sS'prostaglandins,play,an'
p28920
(F1
F0.00014334862385321102
I1
I0
I1
tp28921
sS'one,study,was'
p28922
(F1
F0.00014334862385321102
I0
I1
I-1
tp28923
sS'relaxants,and,muscle'
p28924
(F1
F0.00014334862385321102
I0
I1
I-1
tp28925
sS'had,a,modest'
p28926
(F1
F0.00028669724770642203
I2
I0
I2
tp28927
sS'following,coadministration,of'
p28928
(F0
F0
I1
I1
I0
tp28929
sS'parenterally,administered,in'
p28930
(F1
F0.00014334862385321102
I1
I0
I1
tp28931
sS'as,inotropes,and'
p28932
(F1
F0.00014334862385321102
I1
I0
I1
tp28933
sS'daily,maintenance,dose'
p28934
(F1
F0.00014334862385321102
I1
I0
I1
tp28935
sS'cholestyramine,and,absorption'
p28936
(F1
F0.00014334862385321102
I1
I0
I1
tp28937
sS'being,treated,with'
p28938
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp28939
sS'effects,in,prolonging'
p28940
(F1
F0.00014334862385321102
I1
I0
I1
tp28941
sS'shown,in,a'
p28942
(F1
F0.00014334862385321102
I0
I1
I-1
tp28943
sS'additive,when,was'
p28944
(F1
F0.00014334862385321102
I0
I1
I-1
tp28945
sS'profile,of,as'
p28946
(F1
F0.00028669724770642203
I0
I2
I-2
tp28947
sS'patients,with,neoplastic'
p28948
(F1
F0.00014334862385321102
I1
I0
I1
tp28949
sS'doctor,if,you'
p28950
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp28951
sS'at,these,doses'
p28952
(F1
F0.00014334862385321102
I1
I0
I1
tp28953
sS'ssris,have,been'
p28954
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp28955
sS'pharmacokinetic,studies,including'
p28956
(F1
F0.00014334862385321102
I0
I1
I-1
tp28957
sS'mean,additional,supine'
p28958
(F1
F0.00014334862385321102
I1
I0
I1
tp28959
sS'metabolism,of,combination'
p28960
(F1
F0.00014334862385321102
I1
I0
I1
tp28961
sS'may,potentially,interfere'
p28962
(F1
F0.00014334862385321102
I0
I1
I-1
tp28963
sS'hcl,blunts,the'
p28964
(F1
F0.00014334862385321102
I1
I0
I1
tp28965
sS'and,reuptake,thus'
p28966
(F1
F0.00028669724770642203
I2
I0
I2
tp28967
sS'between,administration,of'
p28968
(F1
F0.00014334862385321102
I1
I0
I1
tp28969
sS'of,should,also'
p28970
(F1
F0.00014334862385321102
I1
I0
I1
tp28971
sS'periods,of,up'
p28972
(F1
F0.00014334862385321102
I0
I1
I-1
tp28973
sS'about,compared,to'
p28974
(F1
F0.00014334862385321102
I1
I0
I1
tp28975
sS'by,the,coadministration'
p28976
(F1
F0.00028669724770642203
I0
I2
I-2
tp28977
sS'when,these,were'
p28978
(F1
F0.00014334862385321102
I1
I0
I1
tp28979
sS'control,mechanisms,of'
p28980
(F1
F0.00014334862385321102
I0
I1
I-1
tp28981
sS'administering,or,taking'
p28982
(F1
F0.00014334862385321102
I1
I0
I1
tp28983
sS'concomitant,agent,may'
p28984
(F1
F0.00014334862385321102
I1
I0
I1
tp28985
sS'pharmacokinetic,interaction,when'
p28986
(F1
F0.00057339449541284407
I0
I4
I-4
tp28987
sS'systematically,studied,certain'
p28988
(F1
F0.00014334862385321102
I1
I0
I1
tp28989
sS'and,the,ability'
p28990
(F1
F0.00014334862385321102
I0
I1
I-1
tp28991
sS'if,is,combined'
p28992
(F1
F0.00014334862385321102
I1
I0
I1
tp28993
sS'orders,of,magnitude'
p28994
(F1
F0.00014334862385321102
I0
I1
I-1
tp28995
sS'literature,reports,suggesting'
p28996
(F1
F0.00014334862385321102
I1
I0
I1
tp28997
sS'cholesterol,mg,dl'
p28998
(F1
F0.00014334862385321102
I0
I1
I-1
tp28999
sS'be,subject,to'
p29000
(F1
F0.00014334862385321102
I0
I1
I-1
tp29001
sS'pegasys,and,copegus'
p29002
(F1
F0.00014334862385321102
I0
I1
I-1
tp29003
sS'supporting,blood,pressure'
p29004
(F1
F0.00014334862385321102
I0
I1
I-1
tp29005
sS'urine,of,patients'
p29006
(F1
F0.00014334862385321102
I0
I1
I-1
tp29007
sS'were,found,between'
p29008
(F1
F0.00014334862385321102
I0
I1
I-1
tp29009
sS'review,of,the'
p29010
(F1
F0.00014334862385321102
I1
I0
I1
tp29011
sS'state,vioxx,mg'
p29012
(F1
F0.00014334862385321102
I0
I1
I-1
tp29013
sS'renal,tubular,secretion'
p29014
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp29015
sS'normal,volunteers,coadministration'
p29016
(F1
F0.00014334862385321102
I0
I1
I-1
tp29017
sS'of,hepatic,metabolism'
p29018
(F1
F0.00043004587155963305
I3
I0
I3
tp29019
sS'the,hypoglycemic,effect'
p29020
(F1
F0.00014334862385321102
I1
I0
I1
tp29021
sS'cns,depressants,with'
p29022
(F1
F0.00014334862385321102
I0
I1
I-1
tp29023
sS'functional,consequences,following'
p29024
(F1
F0.00028669724770642203
I0
I2
I-2
tp29025
sS'a,nonabsorbable,complex'
p29026
(F1
F0.00014334862385321102
I1
I0
I1
tp29027
sS'resecting,the,cecum'
p29028
(F1
F0.00014334862385321102
I0
I1
I-1
tp29029
sS'plasma,levels,or'
p29030
(F1
F0.00014334862385321102
I0
I1
I-1
tp29031
sS'demonstrated,no,significant'
p29032
(F1
F0.00014334862385321102
I0
I1
I-1
tp29033
sS'fentanyl,anesthesia,severe'
p29034
(F1
F0.00014334862385321102
I1
I0
I1
tp29035
sS'of,low,and'
p29036
(F1
F0.00014334862385321102
I0
I1
I-1
tp29037
sS'and,the,central'
p29038
(F1
F0.00014334862385321102
I1
I0
I1
tp29039
sS'plasma,levels,of'
p29040
(F0.64102564102564108
F0.0035837155963302754
I32
I7
I25
tp29041
sS'results,from,existing'
p29042
(F1
F0.00014334862385321102
I0
I1
I-1
tp29043
sS'antihistamines,contraindicated,due'
p29044
(F1
F0.00014334862385321102
I0
I1
I-1
tp29045
sS'cns,depressant,effect'
p29046
(F1
F0.00014334862385321102
I1
I0
I1
tp29047
sS'of,equetrotm,are'
p29048
(F1
F0.00028669724770642203
I2
I0
I2
tp29049
sS'oral,ccnu,by'
p29050
(F1
F0.00014334862385321102
I1
I0
I1
tp29051
sS'blocking,the,vasodilating'
p29052
(F1
F0.00014334862385321102
I1
I0
I1
tp29053
sS'enhancement,of,post-heparin'
p29054
(F1
F0.00014334862385321102
I1
I0
I1
tp29055
sS'and,should,have'
p29056
(F1
F0.00014334862385321102
I0
I1
I-1
tp29057
sS'dose,of,significant'
p29058
(F1
F0.00014334862385321102
I1
I0
I1
tp29059
sS'determined,by,a'
p29060
(F1
F0.00014334862385321102
I0
I1
I-1
tp29061
sS'and,the,channel'
p29062
(F1
F0.00014334862385321102
I0
I1
I-1
tp29063
sS'alter,the,concentrations'
p29064
(F1
F0.00014334862385321102
I1
I0
I1
tp29065
sS'agents,the,effect'
p29066
(F1
F0.00014334862385321102
I0
I1
I-1
tp29067
sS'and,t3,in'
p29068
(F1
F0.00014334862385321102
I1
I0
I1
tp29069
sS'hormone,therapy,oral'
p29070
(F1
F0.00014334862385321102
I0
I1
I-1
tp29071
sS'be,approximately,half'
p29072
(F1
F0.00014334862385321102
I0
I1
I-1
tp29073
sS'isis-2,currently,do'
p29074
(F1
F0.00014334862385321102
I0
I1
I-1
tp29075
sS'increase,cardiac,autonomic'
p29076
(F1
F0.00014334862385321102
I1
I0
I1
tp29077
sS'i,d,have'
p29078
(F1
F0.00014334862385321102
I0
I1
I-1
tp29079
sS'before,starting,and'
p29080
(F1
F0.00014334862385321102
I1
I0
I1
tp29081
sS'therapy,with,a'
p29082
(F1
F0.00057339449541284407
I4
I0
I4
tp29083
sS'levels,and,lethality'
p29084
(F1
F0.00014334862385321102
I0
I1
I-1
tp29085
sS'co-administration,of,tcas'
p29086
(F1
F0.00028669724770642203
I2
I0
I2
tp29087
sS'conclusion,cisapride,can'
p29088
(F1
F0.00014334862385321102
I0
I1
I-1
tp29089
sS'clinical,trials,similar'
p29090
(F1
F0.00014334862385321102
I0
I1
I-1
tp29091
sS'human,cells,whereas'
p29092
(F1
F0.00014334862385321102
I0
I1
I-1
tp29093
sS'interactions,with,and'
p29094
(F0
F0
I1
I1
I0
tp29095
sS'determine,if,the'
p29096
(F0.75
F0.0008600917431192661
I7
I1
I6
tp29097
sS'clinically,significant,interaction'
p29098
(F1
F0.00014334862385321102
I0
I1
I-1
tp29099
sS'and,in,some'
p29100
(F1
F0.00028669724770642203
I2
I0
I2
tp29101
sS'signs,and,symptoms'
p29102
(F1
F0.00043004587155963305
I3
I0
I3
tp29103
sS'nephrotoxic,potential,intravenous'
p29104
(F1
F0.00014334862385321102
I1
I0
I1
tp29105
sS'and,corticotropin,acth'
p29106
(F1
F0.00014334862385321102
I1
I0
I1
tp29107
sS'still,kill,even'
p29108
(F1
F0.00014334862385321102
I1
I0
I1
tp29109
sS'of,on,valproic'
p29110
(F1
F0.00014334862385321102
I1
I0
I1
tp29111
sS'as,this,could'
p29112
(F1
F0.00043004587155963305
I0
I3
I-3
tp29113
sS'compounds,that,are'
p29114
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp29115
sS'not,concurrently,use'
p29116
(F1
F0.00014334862385321102
I1
I0
I1
tp29117
sS'are,synergistic,such'
p29118
(F1
F0.00028669724770642203
I2
I0
I2
tp29119
sS'and,the,bioavailability'
p29120
(F1
F0.00014334862385321102
I0
I1
I-1
tp29121
sS'with,a,consequent'
p29122
(F1
F0.00014334862385321102
I1
I0
I1
tp29123
sS'lower,seizure,threshold'
p29124
(F1
F0.00014334862385321102
I1
I0
I1
tp29125
sS'dose-dependent,manner,the'
p29126
(F1
F0.00014334862385321102
I1
I0
I1
tp29127
sS'treated,with,coly-mycin'
p29128
(F1
F0.00014334862385321102
I1
I0
I1
tp29129
sS'concomitant,beta-1a,avonex'
p29130
(F1
F0.00014334862385321102
I0
I1
I-1
tp29131
sS'a,time-dependent,inhibitor'
p29132
(F1
F0.00014334862385321102
I0
I1
I-1
tp29133
sS'both,and,should'
p29134
(F1
F0.00014334862385321102
I1
I0
I1
tp29135
sS'short,s,interresponse'
p29136
(F1
F0.00014334862385321102
I0
I1
I-1
tp29137
sS'dose,levels,of'
p29138
(F1
F0.00014334862385321102
I0
I1
I-1
tp29139
sS'with,microalbuminuria,inspra'
p29140
(F1
F0.00014334862385321102
I1
I0
I1
tp29141
sS'interact,with,beta-adrenergic'
p29142
(F1
F0.00014334862385321102
I1
I0
I1
tp29143
sS'acetate,with,glycosides'
p29144
(F1
F0.00014334862385321102
I1
I0
I1
tp29145
sS'kerlone,with,the'
p29146
(F1
F0.00014334862385321102
I0
I1
I-1
tp29147
sS'caution,in,combining'
p29148
(F1
F0.00014334862385321102
I1
I0
I1
tp29149
sS'intravenous,and,brevibloc'
p29150
(F1
F0.00014334862385321102
I1
I0
I1
tp29151
sS'metabolism,of,one'
p29152
(F1
F0.00014334862385321102
I1
I0
I1
tp29153
sS'h2,antagonists,such'
p29154
(F1
F0.00014334862385321102
I0
I1
I-1
tp29155
sS'of,angiotensin,and'
p29156
(F1
F0.00014334862385321102
I0
I1
I-1
tp29157
sS'had,to,be'
p29158
(F1
F0.00014334862385321102
I0
I1
I-1
tp29159
sS'serotonin,reuptake,and'
p29160
(F1
F0.00014334862385321102
I1
I0
I1
tp29161
sS'with,life-threatening,ventricular'
p29162
(F1
F0.00014334862385321102
I0
I1
I-1
tp29163
sS'mg,b,i'
p29164
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp29165
sS'accuracy,in,patients'
p29166
(F1
F0.00014334862385321102
I1
I0
I1
tp29167
sS'transiently,elevated,by'
p29168
(F1
F0.00014334862385321102
I0
I1
I-1
tp29169
sS'interact,with,of'
p29170
(F1
F0.00028669724770642203
I2
I0
I2
tp29171
sS'another,interaction,study'
p29172
(F1
F0.00014334862385321102
I1
I0
I1
tp29173
sS'to,achieve,exposures'
p29174
(F1
F0.00028669724770642203
I2
I0
I2
tp29175
sS'metoprolol,administration,of'
p29176
(F1
F0.00014334862385321102
I1
I0
I1
tp29177
sS'or,symptoms,occur'
p29178
(F1
F0.00014334862385321102
I1
I0
I1
tp29179
sS'valproate,felbatol,causes'
p29180
(F1
F0.00014334862385321102
I1
I0
I1
tp29181
sS'interact,with,or'
p29182
(F0
F0
I3
I3
I0
tp29183
sS'sodium,succinate,and'
p29184
(F1
F0.00014334862385321102
I0
I1
I-1
tp29185
sS'cautious,initiation,of'
p29186
(F1
F0.00014334862385321102
I1
I0
I1
tp29187
sS'orally,with,channel'
p29188
(F1
F0.00014334862385321102
I1
I0
I1
tp29189
sS'however,co,administration'
p29190
(F1
F0.00014334862385321102
I1
I0
I1
tp29191
sS'of,a,including'
p29192
(F1
F0.00014334862385321102
I1
I0
I1
tp29193
sS'buffered,tablets,or'
p29194
(F1
F0.0011467889908256881
I8
I0
I8
tp29195
sS'with,doses,higher'
p29196
(F1
F0.00028669724770642203
I0
I2
I-2
tp29197
sS'of,antihypertensive,and'
p29198
(F1
F0.00014334862385321102
I1
I0
I1
tp29199
sS'of,less,than'
p29200
(F1
F0.00057339449541284407
I4
I0
I4
tp29201
sS'negative,and,depressive'
p29202
(F1
F0.00028669724770642203
I0
I2
I-2
tp29203
sS'dogs,unchanged,the'
p29204
(F1
F0.00014334862385321102
I0
I1
I-1
tp29205
sS'kg,dose,or'
p29206
(F1
F0.00014334862385321102
I1
I0
I1
tp29207
sS'response,to,or'
p29208
(F1
F0.00014334862385321102
I1
I0
I1
tp29209
sS'increase,the,excretion'
p29210
(F1
F0.00014334862385321102
I1
I0
I1
tp29211
sS'aminosalicylic,acid,anabolic'
p29212
(F1
F0.00014334862385321102
I1
I0
I1
tp29213
sS'inhibitors,may,potentiate'
p29214
(F1
F0.00014334862385321102
I1
I0
I1
tp29215
sS'oxytocic,may,result'
p29216
(F1
F0.00014334862385321102
I1
I0
I1
tp29217
sS'with,viracept,antiarrhythmics'
p29218
(F1
F0.00014334862385321102
I1
I0
I1
tp29219
sS'significantly,bound,to'
p29220
(F1
F0.00014334862385321102
I0
I1
I-1
tp29221
sS'coadministration,of,on'
p29222
(F1
F0.00014334862385321102
I0
I1
I-1
tp29223
sS'between,uroxatral,and'
p29224
(F1
F0.00014334862385321102
I0
I1
I-1
tp29225
sS'of,other,traditional'
p29226
(F1
F0.00014334862385321102
I0
I1
I-1
tp29227
sS'of,should,therefore'
p29228
(F1
F0.00014334862385321102
I1
I0
I1
tp29229
sS'therapies,i,tranexamic'
p29230
(F1
F0.00014334862385321102
I0
I1
I-1
tp29231
sS'contrast,preliminary,results'
p29232
(F1
F0.00014334862385321102
I0
I1
I-1
tp29233
sS'cimetidine,an,inhibitor'
p29234
(F1
F0.00014334862385321102
I1
I0
I1
tp29235
sS'be,reduced,while'
p29236
(F1
F0.00014334862385321102
I1
I0
I1
tp29237
sS'presence,of,enflurane'
p29238
(F1
F0.00014334862385321102
I0
I1
I-1
tp29239
sS'coadministration,of,or'
p29240
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp29241
sS'injury,as,manifested'
p29242
(F1
F0.00014334862385321102
I0
I1
I-1
tp29243
sS'effect,of,which'
p29244
(F1
F0.00014334862385321102
I0
I1
I-1
tp29245
sS'use,of,robinul'
p29246
(F1
F0.00014334862385321102
I1
I0
I1
tp29247
sS'nor,the,pharmacokinetics'
p29248
(F1
F0.00014334862385321102
I0
I1
I-1
tp29249
sS'including,hypertensive,crises'
p29250
(F1
F0.00014334862385321102
I1
I0
I1
tp29251
sS'concurrently,the,following'
p29252
(F1
F0.00028669724770642203
I2
I0
I2
tp29253
sS'studied,extensively,in'
p29254
(F1
F0.00014334862385321102
I0
I1
I-1
tp29255
sS'oral,doses,should'
p29256
(F1
F0.00014334862385321102
I1
I0
I1
tp29257
sS'vitro,from,to'
p29258
(F1
F0.00014334862385321102
I1
I0
I1
tp29259
sS'with,all,nsaids'
p29260
(F1
F0.00014334862385321102
I1
I0
I1
tp29261
sS'following,adverse,events'
p29262
(F1
F0.00014334862385321102
I1
I0
I1
tp29263
sS'treated,with,nevirapine-'
p29264
(F1
F0.00014334862385321102
I0
I1
I-1
tp29265
sS'and,in,unconjugated'
p29266
(F1
F0.00014334862385321102
I0
I1
I-1
tp29267
sS'possibility,nitric,oxide'
p29268
(F1
F0.00014334862385321102
I1
I0
I1
tp29269
sS'on,low-dose,combination'
p29270
(F1
F0.00014334862385321102
I0
I1
I-1
tp29271
sS'may,exacerbate,the'
p29272
(F1
F0.00043004587155963305
I3
I0
I3
tp29273
sS'on,tikosyn,had'
p29274
(F1
F0.00014334862385321102
I0
I1
I-1
tp29275
sS'used,to,aid'
p29276
(F1
F0.00014334862385321102
I0
I1
I-1
tp29277
sS'with,central,nervous'
p29278
(F0.5
F0.00028669724770642203
I3
I1
I2
tp29279
sS'sufficient,time,for'
p29280
(F1
F0.00014334862385321102
I0
I1
I-1
tp29281
sS'overactive,pain,medication'
p29282
(F1
F0.00014334862385321102
I0
I1
I-1
tp29283
sS'of,steady-state,l50'
p29284
(F1
F0.00014334862385321102
I0
I1
I-1
tp29285
sS'consequently,should,be'
p29286
(F1
F0.00014334862385321102
I1
I0
I1
tp29287
sS'co-treatment,with,the'
p29288
(F1
F0.00014334862385321102
I1
I0
I1
tp29289
sS'weeks,as,initial'
p29290
(F1
F0.00014334862385321102
I0
I1
I-1
tp29291
sS'recommended,that,they'
p29292
(F1
F0.00014334862385321102
I1
I0
I1
tp29293
sS'fluothane,as,arrhythmias'
p29294
(F1
F0.00014334862385321102
I1
I0
I1
tp29295
sS'of,the,induction'
p29296
(F1
F0.00014334862385321102
I1
I0
I1
tp29297
sS'with,and,lodine'
p29298
(F1
F0.00014334862385321102
I0
I1
I-1
tp29299
sS'are,ge,nerally'
p29300
(F1
F0.00014334862385321102
I0
I1
I-1
tp29301
sS'proleukin-induced,side,effects'
p29302
(F1
F0.00014334862385321102
I1
I0
I1
tp29303
sS'and,inhibition,of'
p29304
(F1
F0.00014334862385321102
I0
I1
I-1
tp29305
sS'antagonists,when,is'
p29306
(F1
F0.00014334862385321102
I1
I0
I1
tp29307
sS'regarding,the,effects'
p29308
(F1
F0.00014334862385321102
I0
I1
I-1
tp29309
sS'representing,a,potential'
p29310
(F1
F0.00014334862385321102
I1
I0
I1
tp29311
sS'may,substantially,interfere'
p29312
(F1
F0.00043004587155963305
I3
I0
I3
tp29313
sS'isoform,and,cyp1a2'
p29314
(F1
F0.00014334862385321102
I0
I1
I-1
tp29315
sS'in,patients,chronically'
p29316
(F1
F0.00014334862385321102
I1
I0
I1
tp29317
sS'may,be,effective'
p29318
(F1
F0.00014334862385321102
I1
I0
I1
tp29319
sS'administered,a,fixed'
p29320
(F1
F0.00014334862385321102
I0
I1
I-1
tp29321
sS'patients,undergoing,concurrent'
p29322
(F1
F0.00014334862385321102
I1
I0
I1
tp29323
sS'if,they,can'
p29324
(F1
F0.00014334862385321102
I0
I1
I-1
tp29325
sS'the,hepatoxicity,of'
p29326
(F1
F0.00014334862385321102
I1
I0
I1
tp29327
sS'absorption,of,v'
p29328
(F1
F0.00014334862385321102
I1
I0
I1
tp29329
sS'such,users,is'
p29330
(F1
F0.00014334862385321102
I0
I1
I-1
tp29331
sS'thus,may,increase'
p29332
(F1
F0.00028669724770642203
I2
I0
I2
tp29333
sS'histamine,h2,antagonists'
p29334
(F1
F0.00014334862385321102
I1
I0
I1
tp29335
sS'when,mefloquine,is'
p29336
(F1
F0.00014334862385321102
I1
I0
I1
tp29337
sS'absorption,of,g'
p29338
(F1
F0.00014334862385321102
I1
I0
I1
tp29339
sS'absorption,of,a'
p29340
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp29341
sS'may,have,resulted'
p29342
(F1
F0.00014334862385321102
I1
I0
I1
tp29343
sS'recommended,because,of'
p29344
(F1
F0.00043004587155963305
I3
I0
I3
tp29345
sS'may,occur,because'
p29346
(F1
F0.00014334862385321102
I1
I0
I1
tp29347
sS'mg,tid,was'
p29348
(F1
F0.00014334862385321102
I1
I0
I1
tp29349
sS'used,on,a'
p29350
(F1
F0.00014334862385321102
I0
I1
I-1
tp29351
sS'the,most,common'
p29352
(F1
F0.00028669724770642203
I0
I2
I-2
tp29353
sS'naftate,cephalothin,sodium'
p29354
(F1
F0.00014334862385321102
I0
I1
I-1
tp29355
sS'due,to,possible'
p29356
(F1
F0.00014334862385321102
I1
I0
I1
tp29357
sS'scale,of,displacement'
p29358
(F1
F0.00014334862385321102
I0
I1
I-1
tp29359
sS'av,conduction,when'
p29360
(F1
F0.00014334862385321102
I1
I0
I1
tp29361
sS'decrease,the,plasma'
p29362
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp29363
sS'or,dose,baseline'
p29364
(F1
F0.00014334862385321102
I0
I1
I-1
tp29365
sS'antagonized,the,inhibitory'
p29366
(F1
F0.00014334862385321102
I1
I0
I1
tp29367
sS'day,qd,cohort'
p29368
(F1
F0.00014334862385321102
I0
I1
I-1
tp29369
sS'acid,indicating,no'
p29370
(F1
F0.00014334862385321102
I0
I1
I-1
tp29371
sS'oral,inhaled,and'
p29372
(F1
F0.00014334862385321102
I0
I1
I-1
tp29373
sS'treatment,may,require'
p29374
(F1
F0.00014334862385321102
I1
I0
I1
tp29375
sS'mg,qd,did'
p29376
(F1
F0.00014334862385321102
I0
I1
I-1
tp29377
sS'was,bioequivalent,when'
p29378
(F1
F0.00014334862385321102
I0
I1
I-1
tp29379
sS'as,they,may'
p29380
(F0
F0
I1
I1
I0
tp29381
sS'general,antianxiety,and'
p29382
(F1
F0.00014334862385321102
I0
I1
I-1
tp29383
sS'clearance,of,and'
p29384
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp29385
sS'using,comparisons,to'
p29386
(F1
F0.00014334862385321102
I0
I1
I-1
tp29387
sS'however,the,systemic'
p29388
(F1
F0.00014334862385321102
I1
I0
I1
tp29389
sS'of,wellbutrin,following'
p29390
(F1
F0.00014334862385321102
I0
I1
I-1
tp29391
sS'shown,by,rats'
p29392
(F1
F0.00014334862385321102
I0
I1
I-1
tp29393
sS'l-arginine,supplements,taken'
p29394
(F1
F0.00014334862385321102
I1
I0
I1
tp29395
sS'because,of,the'
p29396
(F0.56521739130434778
F0.0018635321100917432
I18
I5
I13
tp29397
sS'therapy,for,initial'
p29398
(F1
F0.00014334862385321102
I0
I1
I-1
tp29399
sS'and,high,affinity'
p29400
(F1
F0.00014334862385321102
I0
I1
I-1
tp29401
sS'plus,experienced,severe'
p29402
(F1
F0.00014334862385321102
I1
I0
I1
tp29403
sS'clinical,data,on'
p29404
(F1
F0.00014334862385321102
I0
I1
I-1
tp29405
sS'sudden,increase,in'
p29406
(F1
F0.00014334862385321102
I1
I0
I1
tp29407
sS'be,administered,to'
p29408
(F0.5
F0.00028669724770642203
I3
I1
I2
tp29409
sS'on,pharmacokinetics,but'
p29410
(F1
F0.00014334862385321102
I1
I0
I1
tp29411
sS'a,agonist,can'
p29412
(F1
F0.00014334862385321102
I1
I0
I1
tp29413
sS'blockers,or,channel'
p29414
(F1
F0.00014334862385321102
I1
I0
I1
tp29415
sS'pharmacokinetic,studies,document'
p29416
(F1
F0.00014334862385321102
I0
I1
I-1
tp29417
sS'volunteers,or,given'
p29418
(F1
F0.00014334862385321102
I0
I1
I-1
tp29419
sS'of,epidural,local'
p29420
(F1
F0.00014334862385321102
I1
I0
I1
tp29421
sS'if,and,are'
p29422
(F1
F0.00028669724770642203
I2
I0
I2
tp29423
sS'mean,ratios,confidence'
p29424
(F1
F0.00014334862385321102
I0
I1
I-1
tp29425
sS'acarbose,has,no'
p29426
(F1
F0.00014334862385321102
I0
I1
I-1
tp29427
sS'leukemia,in,the'
p29428
(F1
F0.00014334862385321102
I1
I0
I1
tp29429
sS'analgesic,effect,of'
p29430
(F1
F0.00014334862385321102
I1
I0
I1
tp29431
sS'magnesium,magnesium-containing,preparations'
p29432
(F1
F0.00043004587155963305
I3
I0
I3
tp29433
sS'based,on,anecdotal'
p29434
(F1
F0.00014334862385321102
I1
I0
I1
tp29435
sS'staphylococcus,aureus,a'
p29436
(F1
F0.00014334862385321102
I1
I0
I1
tp29437
sS'anticoagulants,there,have'
p29438
(F1
F0.00028669724770642203
I2
I0
I2
tp29439
sS'and,clinically,important'
p29440
(F1
F0.00014334862385321102
I0
I1
I-1
tp29441
sS'enteric,coated,aspirin'
p29442
(F1
F0.00014334862385321102
I1
I0
I1
tp29443
sS'cancers,were,investigated'
p29444
(F1
F0.00014334862385321102
I0
I1
I-1
tp29445
sS'reduce,the,function'
p29446
(F1
F0.00014334862385321102
I0
I1
I-1
tp29447
sS'the,adverse,experience'
p29448
(F1
F0.00014334862385321102
I0
I1
I-1
tp29449
sS'therapy,of,ponstel'
p29450
(F1
F0.00014334862385321102
I1
I0
I1
tp29451
sS'weeks,should,elapse'
p29452
(F1
F0.00014334862385321102
I1
I0
I1
tp29453
sS'controlled,with,vardenafil'
p29454
(F1
F0.00014334862385321102
I1
I0
I1
tp29455
sS'muscle,relaxants,could'
p29456
(F1
F0.00014334862385321102
I1
I0
I1
tp29457
sS'applied,to,the'
p29458
(F1
F0.00014334862385321102
I1
I0
I1
tp29459
sS'disease,or,those'
p29460
(F1
F0.00014334862385321102
I1
I0
I1
tp29461
sS'of,hypoglycemic,medications'
p29462
(F1
F0.00014334862385321102
I1
I0
I1
tp29463
sS'when,doses,of'
p29464
(F1
F0.00014334862385321102
I1
I0
I1
tp29465
sS'are,treated,with'
p29466
(F1
F0.00014334862385321102
I1
I0
I1
tp29467
sS'of,and,its'
p29468
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp29469
sS'levels,or,activity'
p29470
(F1
F0.00014334862385321102
I1
I0
I1
tp29471
sS'study,with,showed'
p29472
(F1
F0.00014334862385321102
I0
I1
I-1
tp29473
sS'nph,human,novolog'
p29474
(F1
F0.00014334862385321102
I0
I1
I-1
tp29475
sS'discontinuation,of,and'
p29476
(F1
F0.00028669724770642203
I2
I0
I2
tp29477
sS'weekly,reduced,tysabri'
p29478
(F1
F0.00014334862385321102
I1
I0
I1
tp29479
sS'injection,use,resulted'
p29480
(F1
F0.00014334862385321102
I0
I1
I-1
tp29481
sS'eliminate,the,fluoride'
p29482
(F1
F0.00014334862385321102
I1
I0
I1
tp29483
sS'should,be,continuously'
p29484
(F1
F0.00014334862385321102
I1
I0
I1
tp29485
sS'administered,to,rats'
p29486
(F1
F0.00014334862385321102
I1
I0
I1
tp29487
sS'patients,using,cyp3a4'
p29488
(F1
F0.00014334862385321102
I1
I0
I1
tp29489
sS'intravenous,amphotericin,b'
p29490
(F1
F0.00014334862385321102
I1
I0
I1
tp29491
sS'of,initial,doses'
p29492
(F1
F0.00014334862385321102
I0
I1
I-1
tp29493
sS'those,prior,to'
p29494
(F1
F0.00014334862385321102
I0
I1
I-1
tp29495
sS'l-methionine,may,decrease'
p29496
(F1
F0.00014334862385321102
I1
I0
I1
tp29497
sS'of,agents,may'
p29498
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp29499
sS'or,t,max'
p29500
(F1
F0.00028669724770642203
I0
I2
I-2
tp29501
sS'warfarin-type,cyp2c9,and'
p29502
(F1
F0.00014334862385321102
I0
I1
I-1
tp29503
sS'digitalis,toxicity,may'
p29504
(F1
F0.00014334862385321102
I1
I0
I1
tp29505
sS'system,development,is'
p29506
(F1
F0.00014334862385321102
I0
I1
I-1
tp29507
sS'need,for,or'
p29508
(F1
F0.00014334862385321102
I0
I1
I-1
tp29509
sS'by,baseline,use'
p29510
(F1
F0.00014334862385321102
I0
I1
I-1
tp29511
sS'acamprosate,produced,a'
p29512
(F1
F0.00014334862385321102
I1
I0
I1
tp29513
sS'significantly,reduced,in'
p29514
(F1
F0.00014334862385321102
I0
I1
I-1
tp29515
sS'and,neither,were'
p29516
(F1
F0.00014334862385321102
I0
I1
I-1
tp29517
sS'closely,after,initiation'
p29518
(F1
F0.00014334862385321102
I1
I0
I1
tp29519
sS'possibly,by,competing'
p29520
(F1
F0.00014334862385321102
I1
I0
I1
tp29521
sS'with,no,clinically'
p29522
(F1
F0.00014334862385321102
I0
I1
I-1
tp29523
sS'was,far,more'
p29524
(F1
F0.00014334862385321102
I0
I1
I-1
tp29525
sS'effects,including,fever'
p29526
(F1
F0.00014334862385321102
I1
I0
I1
tp29527
sS'non-steroidal,agents,are'
p29528
(F1
F0.00014334862385321102
I1
I0
I1
tp29529
sS'and,cyp3a5,responsible'
p29530
(F1
F0.00014334862385321102
I0
I1
I-1
tp29531
sS'in,a,randomized'
p29532
(F1
F0.00028669724770642203
I0
I2
I-2
tp29533
sS'to,treat,an'
p29534
(F1
F0.00014334862385321102
I0
I1
I-1
tp29535
sS'defense,of,heparinized'
p29536
(F1
F0.00014334862385321102
I1
I0
I1
tp29537
sS'suggested,with,hormonal'
p29538
(F1
F0.00014334862385321102
I0
I1
I-1
tp29539
sS'of,with,viracept'
p29540
(F0.5
F0.00028669724770642203
I3
I1
I2
tp29541
sS'g,and,preparations'
p29542
(F1
F0.00014334862385321102
I1
I0
I1
tp29543
sS'monitoring,of,their'
p29544
(F1
F0.00014334862385321102
I1
I0
I1
tp29545
sS'because,may,enhance'
p29546
(F1
F0.00014334862385321102
I1
I0
I1
tp29547
sS'symptoms,suggestive,of'
p29548
(F1
F0.00014334862385321102
I1
I0
I1
tp29549
sS'bear,directly,on'
p29550
(F1
F0.00014334862385321102
I1
I0
I1
tp29551
sS'this,could,create'
p29552
(F1
F0.00043004587155963305
I0
I3
I-3
tp29553
sS'erpf,and,tm'
p29554
(F1
F0.00014334862385321102
I1
I0
I1
tp29555
sS'effective,duration,of'
p29556
(F1
F0.00014334862385321102
I1
I0
I1
tp29557
sS'the,blood-sugar,reducing'
p29558
(F1
F0.00014334862385321102
I1
I0
I1
tp29559
sS'that,are,not'
p29560
(F0
F0
I1
I1
I0
tp29561
sS'used,preanesthetic,or'
p29562
(F1
F0.00014334862385321102
I0
I1
I-1
tp29563
sS'prothrombin,times,or'
p29564
(F1
F0.00014334862385321102
I0
I1
I-1
tp29565
sS'to,the,vehicle'
p29566
(F1
F0.00014334862385321102
I1
I0
I1
tp29567
sS'in,the,mean'
p29568
(F1
F0.00043004587155963305
I3
I0
I3
tp29569
sS'and,somnolence,have'
p29570
(F1
F0.00014334862385321102
I1
I0
I1
tp29571
sS'information,for,the'
p29572
(F1
F0.00028669724770642203
I0
I2
I-2
tp29573
sS'suggest,that,when'
p29574
(F1
F0.00014334862385321102
I1
I0
I1
tp29575
sS'early-phase,schizophrenia,were'
p29576
(F1
F0.00014334862385321102
I0
I1
I-1
tp29577
sS'was,reduced,by'
p29578
(F0.5
F0.00028669724770642203
I3
I1
I2
tp29579
sS'in,accordance,with'
p29580
(F1
F0.00014334862385321102
I0
I1
I-1
tp29581
sS'that,increased,interaction'
p29582
(F1
F0.00014334862385321102
I0
I1
I-1
tp29583
sS'or,eliminated,the'
p29584
(F1
F0.00014334862385321102
I1
I0
I1
tp29585
sS'and,a,slight'
p29586
(F1
F0.00014334862385321102
I1
I0
I1
tp29587
sS'or,hepatic,enzyme'
p29588
(F1
F0.00014334862385321102
I1
I0
I1
tp29589
sS'derivatives,prothrombin,time'
p29590
(F1
F0.00014334862385321102
I1
I0
I1
tp29591
sS'extend,outside,the'
p29592
(F1
F0.00014334862385321102
I0
I1
I-1
tp29593
sS'or,those,taking'
p29594
(F1
F0.00014334862385321102
I1
I0
I1
tp29595
sS'results,in,prolongation'
p29596
(F1
F0.00014334862385321102
I1
I0
I1
tp29597
sS'was,compared,directly'
p29598
(F1
F0.00014334862385321102
I0
I1
I-1
tp29599
sS'clinical,interest,to'
p29600
(F1
F0.00014334862385321102
I0
I1
I-1
tp29601
sS'and,has,an'
p29602
(F1
F0.00014334862385321102
I1
I0
I1
tp29603
sS'the,overall,response'
p29604
(F1
F0.00014334862385321102
I1
I0
I1
tp29605
sS'its,activity,and'
p29606
(F1
F0.00014334862385321102
I0
I1
I-1
tp29607
sS'trial,using,escalating'
p29608
(F1
F0.00014334862385321102
I1
I0
I1
tp29609
sS'decreased,levels,of'
p29610
(F1
F0.00014334862385321102
I0
I1
I-1
tp29611
sS'chloride-induced,gastrointestinal,lesions'
p29612
(F1
F0.00014334862385321102
I1
I0
I1
tp29613
sS'demonstrated,superior,antipsychotic'
p29614
(F1
F0.00014334862385321102
I0
I1
I-1
tp29615
sS'factive,and,carbonate'
p29616
(F1
F0.00014334862385321102
I1
I0
I1
tp29617
sS'aspirin,ketoprofen,does'
p29618
(F1
F0.00014334862385321102
I0
I1
I-1
tp29619
sS'malignant,cells,this'
p29620
(F1
F0.00014334862385321102
I1
I0
I1
tp29621
sS'but,also,to'
p29622
(F1
F0.00014334862385321102
I1
I0
I1
tp29623
sS'was,combined,with'
p29624
(F0
F0
I1
I1
I0
tp29625
sS'therefore,it,would'
p29626
(F1
F0.00014334862385321102
I0
I1
I-1
tp29627
sS'and,a,reduction'
p29628
(F1
F0.00057339449541284407
I4
I0
I4
tp29629
sS'de,pointes,most'
p29630
(F1
F0.00014334862385321102
I1
I0
I1
tp29631
sS'ns,may,be'
p29632
(F1
F0.00014334862385321102
I1
I0
I1
tp29633
sS'concluded,that,may'
p29634
(F1
F0.00014334862385321102
I0
I1
I-1
tp29635
sS'metabolites,with,the'
p29636
(F1
F0.00014334862385321102
I0
I1
I-1
tp29637
sS'significantly,improve,the'
p29638
(F1
F0.00014334862385321102
I0
I1
I-1
tp29639
sS'the,natriuresis,and'
p29640
(F1
F0.00014334862385321102
I1
I0
I1
tp29641
sS'further,fe,abstract'
p29642
(F1
F0.00014334862385321102
I0
I1
I-1
tp29643
sS'auc,or,maximum'
p29644
(F1
F0.00014334862385321102
I0
I1
I-1
tp29645
sS'with,other,general'
p29646
(F1
F0.00014334862385321102
I1
I0
I1
tp29647
sS'could,enhance,the'
p29648
(F1
F0.00014334862385321102
I1
I0
I1
tp29649
sS'proleukin,may,increase'
p29650
(F1
F0.00014334862385321102
I1
I0
I1
tp29651
sS'salts,may,reduce'
p29652
(F1
F0.00014334862385321102
I1
I0
I1
tp29653
sS'should,be,observed'
p29654
(F0.53846153846153844
F0.0020068807339449542
I20
I6
I14
tp29655
sS'to,should,be'
p29656
(F1
F0.00028669724770642203
I2
I0
I2
tp29657
sS'or,changing,the'
p29658
(F1
F0.00014334862385321102
I1
I0
I1
tp29659
sS'patients,are,at'
p29660
(F1
F0.00028669724770642203
I2
I0
I2
tp29661
sS'inhibitors,with,sprycel'
p29662
(F1
F0.00014334862385321102
I1
I0
I1
tp29663
sS'cysteine,was,covalently'
p29664
(F1
F0.00014334862385321102
I0
I1
I-1
tp29665
sS'and,certainly,during'
p29666
(F1
F0.00014334862385321102
I1
I0
I1
tp29667
sS'as,those,used'
p29668
(F1
F0.00014334862385321102
I0
I1
I-1
tp29669
sS'cimetidine,ranitidine,in'
p29670
(F1
F0.00014334862385321102
I1
I0
I1
tp29671
sS'interaction,study,with'
p29672
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp29673
sS'replication,of,some'
p29674
(F1
F0.00014334862385321102
I1
I0
I1
tp29675
sS'were,reported,with'
p29676
(F1
F0.00014334862385321102
I0
I1
I-1
tp29677
sS'induction,or,inhibition'
p29678
(F1
F0.00014334862385321102
I0
I1
I-1
tp29679
sS'precedex,on,the'
p29680
(F1
F0.00014334862385321102
I1
I0
I1
tp29681
sS'based,upon,the'
p29682
(F1
F0.00014334862385321102
I1
I0
I1
tp29683
sS'important,interactions,to'
p29684
(F1
F0.00014334862385321102
I0
I1
I-1
tp29685
sS'derivatives,k,antagonists'
p29686
(F1
F0.00014334862385321102
I0
I1
I-1
tp29687
sS'gastric,acid,secretion'
p29688
(F0
F0
I1
I1
I0
tp29689
sS'the,cardiovascular,action'
p29690
(F1
F0.00014334862385321102
I1
I0
I1
tp29691
sS'using,more,specific'
p29692
(F1
F0.00014334862385321102
I0
I1
I-1
tp29693
sS'considerable,effect,in'
p29694
(F1
F0.00014334862385321102
I1
I0
I1
tp29695
sS'require,dosage,adjustment'
p29696
(F0
F0
I1
I1
I0
tp29697
sS'of,myopathy,during'
p29698
(F1
F0.00014334862385321102
I0
I1
I-1
tp29699
sS'although,a,day'
p29700
(F1
F0.00014334862385321102
I1
I0
I1
tp29701
sS'probably,responsible,for'
p29702
(F1
F0.00014334862385321102
I0
I1
I-1
tp29703
sS'oral,may,affect'
p29704
(F1
F0.00014334862385321102
I0
I1
I-1
tp29705
sS'induced,in,mcf-7'
p29706
(F1
F0.00014334862385321102
I0
I1
I-1
tp29707
sS'having,a,vitamin'
p29708
(F1
F0.00014334862385321102
I0
I1
I-1
tp29709
sS'fischer-344,strain,were'
p29710
(F1
F0.00014334862385321102
I0
I1
I-1
tp29711
sS'injected,and,its'
p29712
(F1
F0.00014334862385321102
I0
I1
I-1
tp29713
sS'alone,because,may'
p29714
(F1
F0.00014334862385321102
I1
I0
I1
tp29715
sS'adverse,effects,of'
p29716
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp29717
sS'therefore,it,is'
p29718
(F1
F0.00028669724770642203
I2
I0
I2
tp29719
sS'of,fell,by'
p29720
(F1
F0.00014334862385321102
I1
I0
I1
tp29721
sS'tachycardia,have,been'
p29722
(F1
F0.00014334862385321102
I1
I0
I1
tp29723
sS'was,potentiated,by'
p29724
(F1
F0.00014334862385321102
I0
I1
I-1
tp29725
sS'and,cyp,a'
p29726
(F1
F0.00014334862385321102
I0
I1
I-1
tp29727
sS'uncontrolled,domestic,studies'
p29728
(F1
F0.00014334862385321102
I0
I1
I-1
tp29729
sS'adverse,effects,or'
p29730
(F1
F0.00014334862385321102
I0
I1
I-1
tp29731
sS'unlikely,to,have'
p29732
(F1
F0.00057339449541284407
I0
I4
I-4
tp29733
sS'samples,for,measurement'
p29734
(F1
F0.00014334862385321102
I0
I1
I-1
tp29735
sS'a,that,inhibits'
p29736
(F1
F0.00014334862385321102
I0
I1
I-1
tp29737
sS'studies,showed,higher'
p29738
(F1
F0.00014334862385321102
I1
I0
I1
tp29739
sS'agents,may,represent'
p29740
(F1
F0.00014334862385321102
I0
I1
I-1
tp29741
sS'simultaneous,administration,of'
p29742
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp29743
sS'terminal,half-life,decreased'
p29744
(F1
F0.00014334862385321102
I1
I0
I1
tp29745
sS'are,increased,with'
p29746
(F1
F0.00014334862385321102
I1
I0
I1
tp29747
sS'effect,of,refludan'
p29748
(F1
F0.00014334862385321102
I0
I1
I-1
tp29749
sS'marketing,observations,have'
p29750
(F1
F0.00014334862385321102
I1
I0
I1
tp29751
sS'decreased,efficacy,of'
p29752
(F1
F0.00014334862385321102
I1
I0
I1
tp29753
sS'or,more,in'
p29754
(F1
F0.00014334862385321102
I1
I0
I1
tp29755
sS'oral,anticoagulants,in'
p29756
(F1
F0.00014334862385321102
I1
I0
I1
tp29757
sS'or,with,suspension'
p29758
(F1
F0.00014334862385321102
I0
I1
I-1
tp29759
sS'dose,adjustment,may'
p29760
(F1
F0.00014334862385321102
I1
I0
I1
tp29761
sS'including,anafranil,is'
p29762
(F1
F0.00014334862385321102
I0
I1
I-1
tp29763
sS'affected,by,co-administration'
p29764
(F1
F0.00014334862385321102
I0
I1
I-1
tp29765
sS'of,with,ace'
p29766
(F1
F0.00014334862385321102
I1
I0
I1
tp29767
sS'not,altered,when'
p29768
(F1
F0.00028669724770642203
I0
I2
I-2
tp29769
sS'two-fold,increase,in'
p29770
(F1
F0.00014334862385321102
I1
I0
I1
tp29771
sS'hormone,response,of'
p29772
(F1
F0.00014334862385321102
I1
I0
I1
tp29773
sS'with,and,against'
p29774
(F1
F0.00014334862385321102
I0
I1
I-1
tp29775
sS'with,an,angiotensin-converting'
p29776
(F1
F0.00014334862385321102
I1
I0
I1
tp29777
sS'on,may,show'
p29778
(F1
F0.00014334862385321102
I1
I0
I1
tp29779
sS'caused,by,bretylium'
p29780
(F1
F0.00014334862385321102
I1
I0
I1
tp29781
sS'alternative,non-cyp3a4,substrate'
p29782
(F1
F0.00014334862385321102
I0
I1
I-1
tp29783
sS'thioridazine,coadministration,of'
p29784
(F1
F0.00014334862385321102
I1
I0
I1
tp29785
sS'a,small,decrease'
p29786
(F1
F0.00028669724770642203
I2
I0
I2
tp29787
sS'when,is,either'
p29788
(F1
F0.00014334862385321102
I1
I0
I1
tp29789
sS'and,oral,concomitant'
p29790
(F1
F0.00014334862385321102
I1
I0
I1
tp29791
sS'reviewed,for,additional'
p29792
(F1
F0.00014334862385321102
I1
I0
I1
tp29793
sS'as,sole,protease'
p29794
(F1
F0.00014334862385321102
I0
I1
I-1
tp29795
sS'sodium,kg,for'
p29796
(F1
F0.00014334862385321102
I1
I0
I1
tp29797
sS'of,colonic,fluid'
p29798
(F1
F0.00014334862385321102
I0
I1
I-1
tp29799
sS'prinivil,has,been'
p29800
(F1
F0.00014334862385321102
I0
I1
I-1
tp29801
sS'a,pronounced,though'
p29802
(F1
F0.00014334862385321102
I1
I0
I1
tp29803
sS'toxicokinetic,studies,in'
p29804
(F1
F0.00014334862385321102
I0
I1
I-1
tp29805
sS'taken,concurrently,and'
p29806
(F1
F0.00014334862385321102
I0
I1
I-1
tp29807
sS'tubules,seminiferous,tubular'
p29808
(F1
F0.00014334862385321102
I0
I1
I-1
tp29809
sS'on,psychomotor,performance'
p29810
(F1
F0.00014334862385321102
I1
I0
I1
tp29811
sS'with,other,amphotericin'
p29812
(F1
F0.00014334862385321102
I1
I0
I1
tp29813
sS'of,treatment,in'
p29814
(F1
F0.00014334862385321102
I1
I0
I1
tp29815
sS'completely,evaluated,to'
p29816
(F1
F0.00014334862385321102
I0
I1
I-1
tp29817
sS'and,maintenance,doses'
p29818
(F1
F0.00014334862385321102
I1
I0
I1
tp29819
sS'and,the,metabolism'
p29820
(F1
F0.00014334862385321102
I0
I1
I-1
tp29821
sS'be,continued,if'
p29822
(F1
F0.00014334862385321102
I1
I0
I1
tp29823
sS'mg,daily,had'
p29824
(F1
F0.00014334862385321102
I0
I1
I-1
tp29825
sS'day,doses,of'
p29826
(F1
F0.00014334862385321102
I0
I1
I-1
tp29827
sS'phenytoin,etodolac,has'
p29828
(F1
F0.00014334862385321102
I0
I1
I-1
tp29829
sS'due,to,a'
p29830
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp29831
sS'over,hours,or'
p29832
(F1
F0.00014334862385321102
I0
I1
I-1
tp29833
sS'did,not,interfere'
p29834
(F1
F0.00057339449541284407
I0
I4
I-4
tp29835
sS'possibly,increasing,its'
p29836
(F1
F0.00014334862385321102
I1
I0
I1
tp29837
sS'of,acute,pretreatment'
p29838
(F1
F0.00014334862385321102
I0
I1
I-1
tp29839
sS'enhance,the,seizure'
p29840
(F1
F0.00014334862385321102
I1
I0
I1
tp29841
sS'generalized,urticaria,require'
p29842
(F1
F0.00014334862385321102
I0
I1
I-1
tp29843
sS'was,increased,by'
p29844
(F1
F0.00028669724770642203
I2
I0
I2
tp29845
sS'closely,in,time'
p29846
(F1
F0.00014334862385321102
I1
I0
I1
tp29847
sS'use,with,supplements'
p29848
(F1
F0.00014334862385321102
I0
I1
I-1
tp29849
sS'of,oral,or'
p29850
(F1
F0.00028669724770642203
I0
I2
I-2
tp29851
sS'is,however,possible'
p29852
(F1
F0.00014334862385321102
I1
I0
I1
tp29853
sS'inhibit,elimination,and'
p29854
(F1
F0.00014334862385321102
I1
I0
I1
tp29855
sS'the,resulting,increase'
p29856
(F1
F0.00014334862385321102
I0
I1
I-1
tp29857
sS'andusing,a,containing'
p29858
(F1
F0.00014334862385321102
I0
I1
I-1
tp29859
sS'mg,day,divided'
p29860
(F1
F0.00014334862385321102
I1
I0
I1
tp29861
sS'frequently,in,patients'
p29862
(F1
F0.00014334862385321102
I0
I1
I-1
tp29863
sS'rats,at,approximately'
p29864
(F1
F0.00014334862385321102
I1
I0
I1
tp29865
sS'administered,with,such'
p29866
(F1
F0.00014334862385321102
I1
I0
I1
tp29867
sS'ammonium,chloride,sodium'
p29868
(F1
F0.00028669724770642203
I2
I0
I2
tp29869
sS'one,or,both'
p29870
(F1
F0.00028669724770642203
I2
I0
I2
tp29871
sS'ability,to,inhibit'
p29872
(F1
F0.00014334862385321102
I1
I0
I1
tp29873
sS'the,extent,to'
p29874
(F1
F0.00071674311926605509
I5
I0
I5
tp29875
sS'vioxx,is,initiated'
p29876
(F1
F0.00014334862385321102
I1
I0
I1
tp29877
sS'and,some,nsaids'
p29878
(F1
F0.00014334862385321102
I1
I0
I1
tp29879
sS'the,higher,serum'
p29880
(F1
F0.00014334862385321102
I1
I0
I1
tp29881
sS'agents,including,and'
p29882
(F1
F0.00014334862385321102
I0
I1
I-1
tp29883
sS'agents,employed,since'
p29884
(F1
F0.00014334862385321102
I1
I0
I1
tp29885
sS'secretion,distribution,metabolism'
p29886
(F1
F0.00014334862385321102
I0
I1
I-1
tp29887
sS'dialyzed,were,and'
p29888
(F1
F0.00014334862385321102
I0
I1
I-1
tp29889
sS'using,or,concomitantly'
p29890
(F1
F0.00014334862385321102
I1
I0
I1
tp29891
sS'combination,with,sustiva'
p29892
(F1
F0.00014334862385321102
I0
I1
I-1
tp29893
sS'a,significant,difference'
p29894
(F1
F0.00014334862385321102
I0
I1
I-1
tp29895
sS'diabetics,and,undetectable'
p29896
(F1
F0.00014334862385321102
I0
I1
I-1
tp29897
sS'levels,but,changes'
p29898
(F1
F0.00014334862385321102
I0
I1
I-1
tp29899
sS'antiepileptic,periodic,serum'
p29900
(F1
F0.00014334862385321102
I1
I0
I1
tp29901
sS'interaction,between,zdv'
p29902
(F1
F0.00014334862385321102
I0
I1
I-1
tp29903
sS'azathioprine,allopurinol,inhibits'
p29904
(F1
F0.00014334862385321102
I1
I0
I1
tp29905
sS'and,the,mechanism'
p29906
(F1
F0.00014334862385321102
I1
I0
I1
tp29907
sS'attention,test,for'
p29908
(F1
F0.00014334862385321102
I1
I0
I1
tp29909
sS'possible,and,alternative'
p29910
(F1
F0.00014334862385321102
I1
I0
I1
tp29911
sS'estrogens,tend,to'
p29912
(F1
F0.00014334862385321102
I0
I1
I-1
tp29913
sS'resulted,in,increased'
p29914
(F1
F0.00028669724770642203
I2
I0
I2
tp29915
sS'the,enkephalinergic,neurons'
p29916
(F1
F0.00014334862385321102
I1
I0
I1
tp29917
sS'pathway,for,detoxification'
p29918
(F1
F0.00014334862385321102
I1
I0
I1
tp29919
sS'when,is,administered'
p29920
(F1
F0.0008600917431192661
I6
I0
I6
tp29921
sS'resulted,in,increases'
p29922
(F1
F0.00043004587155963305
I3
I0
I3
tp29923
sS'a,cyp3a4,substrate'
p29924
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp29925
sS'there,is,one'
p29926
(F0.5
F0.00028669724770642203
I3
I1
I2
tp29927
sS'and,following,multiple'
p29928
(F1
F0.00014334862385321102
I0
I1
I-1
tp29929
sS'duodenal,absorption,acting'
p29930
(F1
F0.00014334862385321102
I1
I0
I1
tp29931
sS'is,taken,with'
p29932
(F1
F0.00014334862385321102
I1
I0
I1
tp29933
sS'bleeding,time,of'
p29934
(F1
F0.00014334862385321102
I0
I1
I-1
tp29935
sS'pharmacokinetics,of,fenofibric'
p29936
(F1
F0.00014334862385321102
I0
I1
I-1
tp29937
sS'first,day,of'
p29938
(F1
F0.00014334862385321102
I0
I1
I-1
tp29939
sS'frequency,of,dosing'
p29940
(F1
F0.00014334862385321102
I0
I1
I-1
tp29941
sS'such,as,bradycardia'
p29942
(F1
F0.00014334862385321102
I1
I0
I1
tp29943
sS'during,the,trials'
p29944
(F1
F0.00028669724770642203
I0
I2
I-2
tp29945
sS'daily,was,coadministered'
p29946
(F1
F0.00014334862385321102
I0
I1
I-1
tp29947
sS'in,a,total'
p29948
(F1
F0.00014334862385321102
I0
I1
I-1
tp29949
sS'vertigo,syncope,presyncope'
p29950
(F1
F0.00014334862385321102
I1
I0
I1
tp29951
sS'at,and,min'
p29952
(F1
F0.00014334862385321102
I0
I1
I-1
tp29953
sS'temporarily,discontinued,or'
p29954
(F1
F0.00014334862385321102
I1
I0
I1
tp29955
sS'agents,and,might'
p29956
(F1
F0.00014334862385321102
I1
I0
I1
tp29957
sS'several,have,been'
p29958
(F1
F0.00014334862385321102
I1
I0
I1
tp29959
sS'that,results,in'
p29960
(F1
F0.00014334862385321102
I1
I0
I1
tp29961
sS'may,potentiate,amphotericin'
p29962
(F1
F0.00014334862385321102
I1
I0
I1
tp29963
sS'is,a,competitive'
p29964
(F1
F0.00014334862385321102
I1
I0
I1
tp29965
sS'hcl,and,sulfate'
p29966
(F1
F0.00014334862385321102
I1
I0
I1
tp29967
sS'by,reducing,the'
p29968
(F1
F0.00014334862385321102
I1
I0
I1
tp29969
sS'oral,certain,and'
p29970
(F1
F0.00014334862385321102
I1
I0
I1
tp29971
sS'dosed,with,vardenafil'
p29972
(F1
F0.00014334862385321102
I1
I0
I1
tp29973
sS'studied,the,concomitant'
p29974
(F1
F0.00014334862385321102
I1
I0
I1
tp29975
sS'characterization,or,by'
p29976
(F1
F0.00014334862385321102
I0
I1
I-1
tp29977
sS'therapy,eg,or'
p29978
(F1
F0.00014334862385321102
I1
I0
I1
tp29979
sS's,isomers,of'
p29980
(F1
F0.00014334862385321102
I0
I1
I-1
tp29981
sS'was,administered,to'
p29982
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp29983
sS'steroidal,agent,can'
p29984
(F1
F0.00014334862385321102
I1
I0
I1
tp29985
sS'before,a,long-acting'
p29986
(F1
F0.00014334862385321102
I0
I1
I-1
tp29987
sS'polyene,showed,differential'
p29988
(F1
F0.00014334862385321102
I0
I1
I-1
tp29989
sS'metabolites,oxo-desethylzaleplon,and'
p29990
(F1
F0.00014334862385321102
I0
I1
I-1
tp29991
sS'derivatives,and,may'
p29992
(F1
F0.00014334862385321102
I1
I0
I1
tp29993
sS'negative,inotropic,agents'
p29994
(F1
F0.00014334862385321102
I1
I0
I1
tp29995
sS'other,b-lactam,co-administration'
p29996
(F1
F0.00014334862385321102
I1
I0
I1
tp29997
sS'for,by,range'
p29998
(F1
F0.00014334862385321102
I1
I0
I1
tp29999
sS'infusions,of,nimbex'
p30000
(F1
F0.00014334862385321102
I1
I0
I1
tp30001
sS'is,increased,by'
p30002
(F1
F0.00014334862385321102
I1
I0
I1
tp30003
sS'between,zdv,and'
p30004
(F1
F0.00014334862385321102
I0
I1
I-1
tp30005
sS'add,a,high'
p30006
(F1
F0.0008600917431192661
I6
I0
I6
tp30007
sS'activated,prothrombin,complex'
p30008
(F1
F0.00014334862385321102
I0
I1
I-1
tp30009
sS'not,at,all'
p30010
(F1
F0.00014334862385321102
I1
I0
I1
tp30011
sS'cyp3a4,is,ordinarily'
p30012
(F1
F0.00014334862385321102
I0
I1
I-1
tp30013
sS'define,the,changes'
p30014
(F1
F0.00014334862385321102
I0
I1
I-1
tp30015
sS'in,concurrent,or'
p30016
(F1
F0.00014334862385321102
I0
I1
I-1
tp30017
sS'for,older,adults'
p30018
(F1
F0.00014334862385321102
I0
I1
I-1
tp30019
sS'gets,absorbed,into'
p30020
(F1
F0.00014334862385321102
I1
I0
I1
tp30021
sS'as,or,careful'
p30022
(F1
F0.00014334862385321102
I1
I0
I1
tp30023
sS'blood,pressure,or'
p30024
(F1
F0.00043004587155963305
I0
I3
I-3
tp30025
sS'such,as,implants'
p30026
(F1
F0.00014334862385321102
I0
I1
I-1
tp30027
sS'serial,plasma,and'
p30028
(F1
F0.00014334862385321102
I0
I1
I-1
tp30029
sS'the,need,for'
p30030
(F0
F0
I2
I2
I0
tp30031
sS'starlix,mg,three'
p30032
(F1
F0.00028669724770642203
I0
I2
I-2
tp30033
sS'combinations,of,these'
p30034
(F1
F0.00014334862385321102
I1
I0
I1
tp30035
sS'patients,with,elevated'
p30036
(F1
F0.00028669724770642203
I2
I0
I2
tp30037
sS'other,that,sensitize'
p30038
(F1
F0.00014334862385321102
I1
I0
I1
tp30039
sS'that,may,impair'
p30040
(F1
F0.00014334862385321102
I1
I0
I1
tp30041
sS'prothrombin,time,inr'
p30042
(F1
F0.00014334862385321102
I1
I0
I1
tp30043
sS'with,a,increase'
p30044
(F1
F0.00028669724770642203
I2
I0
I2
tp30045
sS'to,of,a'
p30046
(F1
F0.00014334862385321102
I0
I1
I-1
tp30047
sS'toxicity,may,have'
p30048
(F1
F0.00014334862385321102
I1
I0
I1
tp30049
sS'inhibited,by,ergosterol'
p30050
(F1
F0.00014334862385321102
I0
I1
I-1
tp30051
sS'by,stimulating,the'
p30052
(F1
F0.00014334862385321102
I0
I1
I-1
tp30053
sS'ml,h,did'
p30054
(F1
F0.00014334862385321102
I0
I1
I-1
tp30055
sS'with,each,dose'
p30056
(F1
F0.00014334862385321102
I1
I0
I1
tp30057
sS'dipropylxanthine,dpcpx,in'
p30058
(F1
F0.00014334862385321102
I0
I1
I-1
tp30059
sS'potentiation,of,the'
p30060
(F0
F0
I2
I2
I0
tp30061
sS'pump,inhibitors,long-term'
p30062
(F1
F0.00014334862385321102
I1
I0
I1
tp30063
sS'agents,actions,of'
p30064
(F1
F0.00014334862385321102
I0
I1
I-1
tp30065
sS'stimulus,response,in'
p30066
(F1
F0.00014334862385321102
I0
I1
I-1
tp30067
sS'clinical,studies,case'
p30068
(F1
F0.00014334862385321102
I0
I1
I-1
tp30069
sS'on,decreased,alertness'
p30070
(F1
F0.00028669724770642203
I2
I0
I2
tp30071
sS'investigated,in,patients'
p30072
(F1
F0.00014334862385321102
I0
I1
I-1
tp30073
sS'epa,supplements,and'
p30074
(F1
F0.00014334862385321102
I1
I0
I1
tp30075
sS'would,worsen,the'
p30076
(F1
F0.00014334862385321102
I1
I0
I1
tp30077
sS'chop,chemotherapy,regimen'
p30078
(F1
F0.00014334862385321102
I0
I1
I-1
tp30079
sS'reduced,the,urine'
p30080
(F1
F0.00014334862385321102
I1
I0
I1
tp30081
sS'mean,template,bleeding'
p30082
(F1
F0.00014334862385321102
I0
I1
I-1
tp30083
sS'u,of,to'
p30084
(F1
F0.00014334862385321102
I0
I1
I-1
tp30085
sS'serious,pneumonia,vs'
p30086
(F1
F0.00014334862385321102
I1
I0
I1
tp30087
sS'expected,that,a'
p30088
(F1
F0.00014334862385321102
I0
I1
I-1
tp30089
sS'with,a,agent'
p30090
(F1
F0.00014334862385321102
I1
I0
I1
tp30091
sS'with,general,antianxiety'
p30092
(F1
F0.00014334862385321102
I0
I1
I-1
tp30093
sS'impaired,renal,function'
p30094
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30095
sS'with,it,has'
p30096
(F1
F0.00014334862385321102
I0
I1
I-1
tp30097
sS'subsequently,increase,with'
p30098
(F1
F0.00014334862385321102
I0
I1
I-1
tp30099
sS'and,other,phe-nothiazines'
p30100
(F1
F0.00014334862385321102
I0
I1
I-1
tp30101
sS'second,generation,atypical'
p30102
(F1
F0.00014334862385321102
I0
I1
I-1
tp30103
sS'of,cyp2d6,because'
p30104
(F1
F0.00014334862385321102
I0
I1
I-1
tp30105
sS'were,observed,when'
p30106
(F1
F0.00043004587155963305
I0
I3
I-3
tp30107
sS'with,metal,cations'
p30108
(F1
F0.00014334862385321102
I1
I0
I1
tp30109
sS'studied,and,coadministration'
p30110
(F1
F0.00014334862385321102
I1
I0
I1
tp30111
sS'long,acting,nitrates'
p30112
(F1
F0.00014334862385321102
I0
I1
I-1
tp30113
sS'fluoroquinolones,macrolide,and'
p30114
(F1
F0.00014334862385321102
I0
I1
I-1
tp30115
sS'effect,of,administered'
p30116
(F1
F0.00014334862385321102
I0
I1
I-1
tp30117
sS'in,pharmacological,effect'
p30118
(F1
F0.00014334862385321102
I1
I0
I1
tp30119
sS'study,tambocor,and'
p30120
(F1
F0.00014334862385321102
I0
I1
I-1
tp30121
sS'similarity,of,the'
p30122
(F1
F0.00014334862385321102
I0
I1
I-1
tp30123
sS'the,parent,and'
p30124
(F1
F0.00014334862385321102
I1
I0
I1
tp30125
sS'for,example,complications'
p30126
(F1
F0.00014334862385321102
I0
I1
I-1
tp30127
sS'when,heart,function'
p30128
(F1
F0.00014334862385321102
I1
I0
I1
tp30129
sS'sixth,day,showed'
p30130
(F1
F0.00014334862385321102
I1
I0
I1
tp30131
sS'have,resulted,from'
p30132
(F1
F0.00014334862385321102
I1
I0
I1
tp30133
sS'the,bactericidal,action'
p30134
(F1
F0.00028669724770642203
I2
I0
I2
tp30135
sS'values,for,by'
p30136
(F1
F0.00014334862385321102
I1
I0
I1
tp30137
sS'or,micrograms,kg'
p30138
(F1
F0.00014334862385321102
I0
I1
I-1
tp30139
sS'racemic,were,not'
p30140
(F1
F0.00014334862385321102
I0
I1
I-1
tp30141
sS'shown,to,interfere'
p30142
(F1
F0.00071674311926605509
I5
I0
I5
tp30143
sS'day,in,the'
p30144
(F1
F0.00014334862385321102
I0
I1
I-1
tp30145
sS'which,contain,any'
p30146
(F1
F0.00014334862385321102
I1
I0
I1
tp30147
sS'inhibit,the,hepatic'
p30148
(F1
F0.00014334862385321102
I1
I0
I1
tp30149
sS'mellitus,and,may'
p30150
(F1
F0.00014334862385321102
I0
I1
I-1
tp30151
sS'enhanced,clearance,secondary'
p30152
(F1
F0.00014334862385321102
I1
I0
I1
tp30153
sS'to,which,ssri-tca'
p30154
(F1
F0.00057339449541284407
I4
I0
I4
tp30155
sS'of,but,no'
p30156
(F1
F0.00014334862385321102
I1
I0
I1
tp30157
sS'with,particularly,during'
p30158
(F1
F0.00014334862385321102
I1
I0
I1
tp30159
sS'patients,with,renal'
p30160
(F1
F0.00043004587155963305
I3
I0
I3
tp30161
sS'patients,receiving,acarbose'
p30162
(F1
F0.00014334862385321102
I0
I1
I-1
tp30163
sS'prednisolone,sodium,succinate'
p30164
(F1
F0.00014334862385321102
I0
I1
I-1
tp30165
sS'creatinine,in,patients'
p30166
(F1
F0.00028669724770642203
I2
I0
I2
tp30167
sS'must,be,administered'
p30168
(F0
F0
I1
I1
I0
tp30169
sS'maintenance,schedule,of'
p30170
(F1
F0.00014334862385321102
I1
I0
I1
tp30171
sS'undertaken,only,with'
p30172
(F1
F0.00014334862385321102
I1
I0
I1
tp30173
sS'clearance,and,renal'
p30174
(F1
F0.00014334862385321102
I1
I0
I1
tp30175
sS'liver,is,prevented'
p30176
(F1
F0.00014334862385321102
I1
I0
I1
tp30177
sS'group,interaction,study'
p30178
(F1
F0.00014334862385321102
I0
I1
I-1
tp30179
sS'by,but,decreased'
p30180
(F1
F0.00014334862385321102
I1
I0
I1
tp30181
sS'alteration,of,prothrombin'
p30182
(F1
F0.00014334862385321102
I1
I0
I1
tp30183
sS'of,p450,c9'
p30184
(F1
F0.00014334862385321102
I1
I0
I1
tp30185
sS'has,on,rare'
p30186
(F1
F0.00028669724770642203
I2
I0
I2
tp30187
sS'by,to,in'
p30188
(F1
F0.00014334862385321102
I1
I0
I1
tp30189
sS'inter-patient,variability,and'
p30190
(F1
F0.00014334862385321102
I0
I1
I-1
tp30191
sS'ketones,in,the'
p30192
(F1
F0.00028669724770642203
I0
I2
I-2
tp30193
sS'to,a,theoretical'
p30194
(F1
F0.00014334862385321102
I1
I0
I1
tp30195
sS'probenecid,given,concurrently'
p30196
(F1
F0.00014334862385321102
I1
I0
I1
tp30197
sS'of,plasma,levels'
p30198
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp30199
sS'malignant,hyperthermia,crisis'
p30200
(F1
F0.00014334862385321102
I1
I0
I1
tp30201
sS'daily,for,one'
p30202
(F0
F0
I1
I1
I0
tp30203
sS'estrogenic,component,in'
p30204
(F1
F0.00014334862385321102
I0
I1
I-1
tp30205
sS'a,strong,affinity'
p30206
(F1
F0.00014334862385321102
I0
I1
I-1
tp30207
sS'and,renal,vasodilator'
p30208
(F1
F0.00014334862385321102
I0
I1
I-1
tp30209
sS'switched,from,therapy'
p30210
(F1
F0.00014334862385321102
I0
I1
I-1
tp30211
sS'other,have,not'
p30212
(F1
F0.00028669724770642203
I0
I2
I-2
tp30213
sS'monitored,closely,for'
p30214
(F1
F0.00014334862385321102
I0
I1
I-1
tp30215
sS'adverse,events,was'
p30216
(F1
F0.00014334862385321102
I0
I1
I-1
tp30217
sS'the,thioxanthene,and'
p30218
(F1
F0.00014334862385321102
I1
I0
I1
tp30219
sS'different,times,after'
p30220
(F1
F0.00014334862385321102
I0
I1
I-1
tp30221
sS'zdv,and,which'
p30222
(F1
F0.00014334862385321102
I0
I1
I-1
tp30223
sS'condition,worse,and'
p30224
(F1
F0.00014334862385321102
I0
I1
I-1
tp30225
sS'in,poor,metabolizers'
p30226
(F1
F0.00014334862385321102
I0
I1
I-1
tp30227
sS'of,ethinyl,estradiol'
p30228
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp30229
sS'related,metabolic,disturbances'
p30230
(F1
F0.00014334862385321102
I0
I1
I-1
tp30231
sS'considerably,enhance,the'
p30232
(F1
F0.00014334862385321102
I0
I1
I-1
tp30233
sS'therapy,did,not'
p30234
(F1
F0.00028669724770642203
I0
I2
I-2
tp30235
sS'risk,of,elevated'
p30236
(F1
F0.00014334862385321102
I0
I1
I-1
tp30237
sS'substrate,with,oral'
p30238
(F1
F0.00014334862385321102
I1
I0
I1
tp30239
sS'on,half-life,the'
p30240
(F1
F0.00014334862385321102
I1
I0
I1
tp30241
sS'absorption,of,some'
p30242
(F1
F0.00014334862385321102
I1
I0
I1
tp30243
sS'both,and,retinyl'
p30244
(F1
F0.00014334862385321102
I1
I0
I1
tp30245
sS'administered,prior,to'
p30246
(F1
F0.00028669724770642203
I2
I0
I2
tp30247
sS'increase,exposure,to'
p30248
(F1
F0.00014334862385321102
I1
I0
I1
tp30249
sS'unlike,mc,does'
p30250
(F1
F0.00014334862385321102
I0
I1
I-1
tp30251
sS'wort,theo-dur,and'
p30252
(F1
F0.00014334862385321102
I1
I0
I1
tp30253
sS'the,volunteers,who'
p30254
(F1
F0.00014334862385321102
I1
I0
I1
tp30255
sS'it,was,concluded'
p30256
(F0
F0
I1
I1
I0
tp30257
sS'antimycobacterial,agents,benzodiazepines'
p30258
(F1
F0.00014334862385321102
I1
I0
I1
tp30259
sS'impairment,of,renal'
p30260
(F1
F0.00014334862385321102
I1
I0
I1
tp30261
sS'p1,and,n1'
p30262
(F1
F0.00014334862385321102
I1
I0
I1
tp30263
sS'of,theophylline-related,side-effects'
p30264
(F1
F0.00014334862385321102
I1
I0
I1
tp30265
sS'that,are,renally'
p30266
(F1
F0.00014334862385321102
I0
I1
I-1
tp30267
sS'taking,or,nsaids'
p30268
(F1
F0.00014334862385321102
I0
I1
I-1
tp30269
sS'oral,dose,followed'
p30270
(F1
F0.00014334862385321102
I1
I0
I1
tp30271
sS'was,administered,in'
p30272
(F1
F0.00043004587155963305
I0
I3
I-3
tp30273
sS'cns,depressants,such'
p30274
(F1
F0.00028669724770642203
I2
I0
I2
tp30275
sS'two,studies,were'
p30276
(F1
F0.00014334862385321102
I0
I1
I-1
tp30277
sS'increased,fold,by'
p30278
(F1
F0.00014334862385321102
I1
I0
I1
tp30279
sS'studied,in,patients'
p30280
(F0
F0
I1
I1
I0
tp30281
sS'generated,from,an'
p30282
(F1
F0.00014334862385321102
I0
I1
I-1
tp30283
sS'blocking,agents,by'
p30284
(F1
F0.00028669724770642203
I2
I0
I2
tp30285
sS'an,oral,overload'
p30286
(F1
F0.00014334862385321102
I0
I1
I-1
tp30287
sS'was,a,statistically'
p30288
(F1
F0.00014334862385321102
I1
I0
I1
tp30289
sS'completely,antagonized,the'
p30290
(F1
F0.00014334862385321102
I1
I0
I1
tp30291
sS'evaluating,the,administration'
p30292
(F1
F0.00014334862385321102
I1
I0
I1
tp30293
sS'arthritis,n,as'
p30294
(F1
F0.00014334862385321102
I0
I1
I-1
tp30295
sS'concentrations,or,above'
p30296
(F1
F0.00014334862385321102
I1
I0
I1
tp30297
sS'the,patients,who'
p30298
(F1
F0.00014334862385321102
I0
I1
I-1
tp30299
sS'administered,hours,before'
p30300
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30301
sS'patients,with,compromised'
p30302
(F1
F0.00028669724770642203
I2
I0
I2
tp30303
sS'studies,to,evaluate'
p30304
(F1
F0.00028669724770642203
I0
I2
I-2
tp30305
sS'with,agents,with'
p30306
(F1
F0.00028669724770642203
I2
I0
I2
tp30307
sS'dosing,of,the'
p30308
(F1
F0.00014334862385321102
I0
I1
I-1
tp30309
sS'requires,close,monitoring'
p30310
(F1
F0.00043004587155963305
I3
I0
I3
tp30311
sS'from,high-estradiol,rats'
p30312
(F1
F0.00014334862385321102
I1
I0
I1
tp30313
sS'closely,associated,with'
p30314
(F1
F0.00014334862385321102
I0
I1
I-1
tp30315
sS'led,to,a'
p30316
(F1
F0.00014334862385321102
I1
I0
I1
tp30317
sS'or,to,those'
p30318
(F1
F0.00014334862385321102
I1
I0
I1
tp30319
sS'both,its,activity'
p30320
(F1
F0.00014334862385321102
I0
I1
I-1
tp30321
sS'ccnu,either,alone'
p30322
(F1
F0.00014334862385321102
I0
I1
I-1
tp30323
sS'a,number,of'
p30324
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp30325
sS'range,observed,with'
p30326
(F1
F0.00014334862385321102
I0
I1
I-1
tp30327
sS'mean,renal,clearance'
p30328
(F1
F0.00014334862385321102
I1
I0
I1
tp30329
sS'the,problems,encountered'
p30330
(F1
F0.00014334862385321102
I0
I1
I-1
tp30331
sS'level,determinations,of'
p30332
(F1
F0.00014334862385321102
I1
I0
I1
tp30333
sS'weeks,oral,cordarone'
p30334
(F1
F0.00014334862385321102
I0
I1
I-1
tp30335
sS'subjects,r,b'
p30336
(F1
F0.00014334862385321102
I0
I1
I-1
tp30337
sS'of,and,iv'
p30338
(F1
F0.00014334862385321102
I1
I0
I1
tp30339
sS'not,indicate,a'
p30340
(F1
F0.00028669724770642203
I2
I0
I2
tp30341
sS'of,and,is'
p30342
(F1
F0.0010034403669724771
I7
I0
I7
tp30343
sS'hrs,of,loratadine'
p30344
(F1
F0.00014334862385321102
I0
I1
I-1
tp30345
sS'of,and,in'
p30346
(F0.69999999999999996
F0.0020068807339449542
I17
I3
I14
tp30347
sS'epinephrine,also,should'
p30348
(F1
F0.00014334862385321102
I1
I0
I1
tp30349
sS'to,those,of'
p30350
(F1
F0.00014334862385321102
I0
I1
I-1
tp30351
sS'copegus,should,not'
p30352
(F1
F0.00014334862385321102
I0
I1
I-1
tp30353
sS'in,vitro,showed'
p30354
(F1
F0.00014334862385321102
I0
I1
I-1
tp30355
sS'study,volunteers,mg'
p30356
(F1
F0.00014334862385321102
I0
I1
I-1
tp30357
sS'taking,with,or'
p30358
(F1
F0.00043004587155963305
I3
I0
I3
tp30359
sS'once,daily,was'
p30360
(F1
F0.00014334862385321102
I0
I1
I-1
tp30361
sS'ethacrynic,acid,have'
p30362
(F1
F0.00014334862385321102
I1
I0
I1
tp30363
sS'activity,of,krm-1648'
p30364
(F1
F0.00014334862385321102
I0
I1
I-1
tp30365
sS'coadministration,of,tambocor'
p30366
(F1
F0.00028669724770642203
I0
I2
I-2
tp30367
sS'hyperglycemia,and,hypoglycemia'
p30368
(F1
F0.00014334862385321102
I1
I0
I1
tp30369
sS'metabolite,beta-naltrexol,were'
p30370
(F1
F0.00014334862385321102
I0
I1
I-1
tp30371
sS'between,taxol,a'
p30372
(F1
F0.00014334862385321102
I0
I1
I-1
tp30373
sS'proportions,as,those'
p30374
(F1
F0.00014334862385321102
I0
I1
I-1
tp30375
sS'mg,of,kg'
p30376
(F0
F0
I1
I1
I0
tp30377
sS'a,reduction,in'
p30378
(F0.8571428571428571
F0.0017201834862385322
I13
I1
I12
tp30379
sS'dispersible,buffered,tablets'
p30380
(F1
F0.00014334862385321102
I1
I0
I1
tp30381
sS'mixed,with,or'
p30382
(F1
F0.00014334862385321102
I0
I1
I-1
tp30383
sS'days,because,severe'
p30384
(F1
F0.00014334862385321102
I1
I0
I1
tp30385
sS'led,to,significant'
p30386
(F1
F0.00014334862385321102
I0
I1
I-1
tp30387
sS'reduction,in,cardiac'
p30388
(F1
F0.00014334862385321102
I1
I0
I1
tp30389
sS'systematically,evaluated,but'
p30390
(F1
F0.00014334862385321102
I1
I0
I1
tp30391
sS'characterized,a,reliable'
p30392
(F1
F0.00014334862385321102
I1
I0
I1
tp30393
sS'a,possible,hypokalemic'
p30394
(F1
F0.00014334862385321102
I1
I0
I1
tp30395
sS'are,usually,administered'
p30396
(F1
F0.00014334862385321102
I1
I0
I1
tp30397
sS'from,treatment,dosage'
p30398
(F1
F0.00014334862385321102
I1
I0
I1
tp30399
sS'tetracyclines,since,both'
p30400
(F1
F0.00014334862385321102
I1
I0
I1
tp30401
sS'variables,for,were'
p30402
(F1
F0.00014334862385321102
I0
I1
I-1
tp30403
sS'revealed,concentration,dependent'
p30404
(F1
F0.00014334862385321102
I0
I1
I-1
tp30405
sS'increased,bun,serum'
p30406
(F1
F0.00014334862385321102
I1
I0
I1
tp30407
sS'folic,acid,from'
p30408
(F1
F0.00014334862385321102
I0
I1
I-1
tp30409
sS'salicylate,and,heparin'
p30410
(F1
F0.00014334862385321102
I1
I0
I1
tp30411
sS'with,significantly,decreased'
p30412
(F1
F0.00014334862385321102
I1
I0
I1
tp30413
sS'release,capsules,there'
p30414
(F1
F0.00014334862385321102
I1
I0
I1
tp30415
sS'because,their,vasospastic'
p30416
(F1
F0.00014334862385321102
I1
I0
I1
tp30417
sS'this,interaction,occurs'
p30418
(F1
F0.00014334862385321102
I0
I1
I-1
tp30419
sS'cyp1a2,cyp3a,a'
p30420
(F1
F0.00014334862385321102
I1
I0
I1
tp30421
sS'block,caution,is'
p30422
(F1
F0.00014334862385321102
I1
I0
I1
tp30423
sS'prolong,the,qtc'
p30424
(F1
F0.00014334862385321102
I1
I0
I1
tp30425
sS'while,the,effects'
p30426
(F1
F0.00014334862385321102
I1
I0
I1
tp30427
sS'a,regimen,of'
p30428
(F1
F0.00043004587155963305
I3
I0
I3
tp30429
sS'increased,the,steadystate'
p30430
(F1
F0.00014334862385321102
I1
I0
I1
tp30431
sS'patients,taking,acamprosate'
p30432
(F1
F0.00014334862385321102
I1
I0
I1
tp30433
sS'of,the,literature'
p30434
(F1
F0.00014334862385321102
I1
I0
I1
tp30435
sS'or,mg,of'
p30436
(F0
F0
I1
I1
I0
tp30437
sS'lovastatin,therapy,has'
p30438
(F1
F0.00014334862385321102
I0
I1
I-1
tp30439
sS'and,automaticity,as'
p30440
(F1
F0.00014334862385321102
I1
I0
I1
tp30441
sS'since,it,creates'
p30442
(F1
F0.00014334862385321102
I0
I1
I-1
tp30443
sS'iiia4,blocks,the'
p30444
(F1
F0.00014334862385321102
I1
I0
I1
tp30445
sS'and,and,their'
p30446
(F1
F0.00014334862385321102
I0
I1
I-1
tp30447
sS'like,due,to'
p30448
(F1
F0.00014334862385321102
I1
I0
I1
tp30449
sS'cyp,d6,and'
p30450
(F1
F0.00014334862385321102
I0
I1
I-1
tp30451
sS'thienobenzodiazepine,derivative,is'
p30452
(F1
F0.00014334862385321102
I0
I1
I-1
tp30453
sS'potential,to,increase'
p30454
(F1
F0.00014334862385321102
I1
I0
I1
tp30455
sS'by,compared,to'
p30456
(F1
F0.00014334862385321102
I1
I0
I1
tp30457
sS'absorbed,from,the'
p30458
(F1
F0.00014334862385321102
I0
I1
I-1
tp30459
sS'transfer,to,the'
p30460
(F1
F0.00014334862385321102
I0
I1
I-1
tp30461
sS'be,enhanced,by'
p30462
(F1
F0.00043004587155963305
I3
I0
I3
tp30463
sS'underlying,mechanism,for'
p30464
(F1
F0.00014334862385321102
I1
I0
I1
tp30465
sS'a,single-dose,pharmacokinetic'
p30466
(F1
F0.00014334862385321102
I0
I1
I-1
tp30467
sS'to,triple,therapy'
p30468
(F1
F0.00014334862385321102
I0
I1
I-1
tp30469
sS'competitively,inhibit,accumulation'
p30470
(F1
F0.00014334862385321102
I1
I0
I1
tp30471
sS'divergently,selected,for'
p30472
(F1
F0.00014334862385321102
I0
I1
I-1
tp30473
sS'and,enterococcus,faecium'
p30474
(F1
F0.00014334862385321102
I0
I1
I-1
tp30475
sS'an,intravenous,injection'
p30476
(F1
F0.00014334862385321102
I1
I0
I1
tp30477
sS'combined,with,either'
p30478
(F1
F0.00014334862385321102
I0
I1
I-1
tp30479
sS'increased,half-life,by'
p30480
(F1
F0.00014334862385321102
I1
I0
I1
tp30481
sS'of,drugs,possessing'
p30482
(F1
F0.00014334862385321102
I1
I0
I1
tp30483
sS'for,other,oral'
p30484
(F1
F0.00014334862385321102
I1
I0
I1
tp30485
sS'antidiuretic,activity,large'
p30486
(F1
F0.00014334862385321102
I0
I1
I-1
tp30487
sS'for,drug,interactions'
p30488
(F1
F0.00014334862385321102
I0
I1
I-1
tp30489
sS'to,affect,bleeding'
p30490
(F1
F0.00014334862385321102
I1
I0
I1
tp30491
sS'between,and,the'
p30492
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp30493
sS'the,auc,for'
p30494
(F1
F0.00014334862385321102
I1
I0
I1
tp30495
sS'observed,when,colestid'
p30496
(F1
F0.00014334862385321102
I1
I0
I1
tp30497
sS'with,than,those'
p30498
(F1
F0.00014334862385321102
I1
I0
I1
tp30499
sS'of,vitamin-d,mediated'
p30500
(F1
F0.00014334862385321102
I0
I1
I-1
tp30501
sS'reductase,resulting,in'
p30502
(F1
F0.00014334862385321102
I0
I1
I-1
tp30503
sS'hiv-related,systemic,non-hodgkin'
p30504
(F1
F0.00014334862385321102
I0
I1
I-1
tp30505
sS'was,a,increase'
p30506
(F1
F0.00014334862385321102
I1
I0
I1
tp30507
sS'pharmacokinetics,exposure-response,relationships'
p30508
(F1
F0.00014334862385321102
I0
I1
I-1
tp30509
sS'by,approx,because'
p30510
(F1
F0.00014334862385321102
I1
I0
I1
tp30511
sS'mainly,metabolized,by'
p30512
(F1
F0.00014334862385321102
I1
I0
I1
tp30513
sS'oxidative,stress,induction'
p30514
(F1
F0.00014334862385321102
I0
I1
I-1
tp30515
sS'the,duration,of'
p30516
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp30517
sS'between,keppra,and'
p30518
(F1
F0.00028669724770642203
I0
I2
I-2
tp30519
sS'tracleer,and,is'
p30520
(F1
F0.00014334862385321102
I1
I0
I1
tp30521
sS'residual,effects,of'
p30522
(F1
F0.00014334862385321102
I1
I0
I1
tp30523
sS'events,in,patients'
p30524
(F1
F0.00028669724770642203
I0
I2
I-2
tp30525
sS'aprepitant,was,administered'
p30526
(F0
F0
I2
I2
I0
tp30527
sS'initiated,apparent,oral'
p30528
(F1
F0.00014334862385321102
I1
I0
I1
tp30529
sS'interval,were,less'
p30530
(F1
F0.00014334862385321102
I1
I0
I1
tp30531
sS'that,reduce,the'
p30532
(F1
F0.00014334862385321102
I1
I0
I1
tp30533
sS'investigated,in,male'
p30534
(F1
F0.00014334862385321102
I0
I1
I-1
tp30535
sS'when,coadministered,in'
p30536
(F1
F0.00014334862385321102
I0
I1
I-1
tp30537
sS'has,not,demonstrated'
p30538
(F1
F0.00014334862385321102
I0
I1
I-1
tp30539
sS'by,measuring,locomotor'
p30540
(F1
F0.00014334862385321102
I0
I1
I-1
tp30541
sS'that,are,mainly'
p30542
(F0
F0
I1
I1
I0
tp30543
sS'vaprisol,the,clinician'
p30544
(F1
F0.00014334862385321102
I1
I0
I1
tp30545
sS'by,a,mean'
p30546
(F1
F0.00014334862385321102
I1
I0
I1
tp30547
sS'medical,supervision,after'
p30548
(F1
F0.00014334862385321102
I1
I0
I1
tp30549
sS'is,a,more'
p30550
(F1
F0.00014334862385321102
I0
I1
I-1
tp30551
sS'pi,related,metabolic'
p30552
(F1
F0.00014334862385321102
I0
I1
I-1
tp30553
sS'toradol,oral,and'
p30554
(F1
F0.00014334862385321102
I1
I0
I1
tp30555
sS'of,a,facilitates'
p30556
(F1
F0.00014334862385321102
I0
I1
I-1
tp30557
sS'of,deficiency,and'
p30558
(F1
F0.00014334862385321102
I0
I1
I-1
tp30559
sS'not,mc,decreases'
p30560
(F1
F0.00014334862385321102
I0
I1
I-1
tp30561
sS'increased,cns,depressant'
p30562
(F1
F0.00014334862385321102
I1
I0
I1
tp30563
sS'the,commercially,available'
p30564
(F1
F0.00014334862385321102
I0
I1
I-1
tp30565
sS'distribution,of,concentrations'
p30566
(F1
F0.00014334862385321102
I0
I1
I-1
tp30567
sS'have,not,been'
p30568
(F0.27272727272727271
F0.0008600917431192661
I8
I14
I-6
tp30569
sS'while,only,additive'
p30570
(F1
F0.00014334862385321102
I1
I0
I1
tp30571
sS'when,sodium,is'
p30572
(F1
F0.00014334862385321102
I1
I0
I1
tp30573
sS'a,patient,requires'
p30574
(F1
F0.00014334862385321102
I1
I0
I1
tp30575
sS'reduced,to,one-half'
p30576
(F1
F0.00043004587155963305
I3
I0
I3
tp30577
sS'the,coat-core,formulation'
p30578
(F1
F0.00014334862385321102
I1
I0
I1
tp30579
sS'with,the,auc'
p30580
(F1
F0.00014334862385321102
I1
I0
I1
tp30581
sS'greater,in,patients'
p30582
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp30583
sS'were,administered,a'
p30584
(F1
F0.00014334862385321102
I1
I0
I1
tp30585
sS'prevented,by,and'
p30586
(F1
F0.00014334862385321102
I1
I0
I1
tp30587
sS'marked,has,been'
p30588
(F1
F0.00028669724770642203
I0
I2
I-2
tp30589
sS'and,or,aluminum-containing'
p30590
(F1
F0.00014334862385321102
I1
I0
I1
tp30591
sS'cells,or,in'
p30592
(F1
F0.00014334862385321102
I1
I0
I1
tp30593
sS'subjects,taking,placebo'
p30594
(F1
F0.00014334862385321102
I0
I1
I-1
tp30595
sS'not,have,any'
p30596
(F1
F0.0008600917431192661
I0
I6
I-6
tp30597
sS'could,cause,heart'
p30598
(F1
F0.00014334862385321102
I1
I0
I1
tp30599
sS'of,to,treat'
p30600
(F1
F0.00014334862385321102
I1
I0
I1
tp30601
sS'concomitantly,with,potassium-depleting'
p30602
(F1
F0.00014334862385321102
I1
I0
I1
tp30603
sS'accutane,has,not'
p30604
(F1
F0.00014334862385321102
I0
I1
I-1
tp30605
sS'other,strong,cyp3a4'
p30606
(F1
F0.00014334862385321102
I1
I0
I1
tp30607
sS'occurs,when,eye'
p30608
(F1
F0.00014334862385321102
I0
I1
I-1
tp30609
sS'or,no,change'
p30610
(F1
F0.00014334862385321102
I0
I1
I-1
tp30611
sS'drugs,whose,absorption'
p30612
(F0
F0
I1
I1
I0
tp30613
sS'the,myocardium,to'
p30614
(F1
F0.00043004587155963305
I3
I0
I3
tp30615
sS'and,complications,compared'
p30616
(F1
F0.00014334862385321102
I1
I0
I1
tp30617
sS'use,of,l-phenylalanine'
p30618
(F1
F0.00014334862385321102
I1
I0
I1
tp30619
sS'in,a,single-dose'
p30620
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp30621
sS'been,reported,among'
p30622
(F1
F0.00028669724770642203
I2
I0
I2
tp30623
sS'selective,survival,in'
p30624
(F1
F0.00014334862385321102
I0
I1
I-1
tp30625
sS'characterized,by,severe'
p30626
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30627
sS'by,gleevec,gleevec'
p30628
(F1
F0.00014334862385321102
I1
I0
I1
tp30629
sS'serious,toxicity,may'
p30630
(F1
F0.00014334862385321102
I1
I0
I1
tp30631
sS'bone,marrow,megakaryocytes'
p30632
(F1
F0.00014334862385321102
I0
I1
I-1
tp30633
sS'they,can,potentially'
p30634
(F1
F0.00014334862385321102
I1
I0
I1
tp30635
sS'patients,receiving,proleukin'
p30636
(F1
F0.00014334862385321102
I1
I0
I1
tp30637
sS'to,the,induction'
p30638
(F1
F0.00014334862385321102
I1
I0
I1
tp30639
sS'week,study,has'
p30640
(F1
F0.00014334862385321102
I0
I1
I-1
tp30641
sS'neither,nor,should'
p30642
(F1
F0.00014334862385321102
I1
I0
I1
tp30643
sS'normal,volunteers,a'
p30644
(F1
F0.00014334862385321102
I1
I0
I1
tp30645
sS'the,luteinizing,hormone'
p30646
(F1
F0.00014334862385321102
I0
I1
I-1
tp30647
sS'when,these,are'
p30648
(F1
F0.00043004587155963305
I0
I3
I-3
tp30649
sS'used,concomitantly,within14'
p30650
(F1
F0.00014334862385321102
I1
I0
I1
tp30651
sS'normal,volunteers,n'
p30652
(F0
F0
I1
I1
I0
tp30653
sS'and,special,care'
p30654
(F1
F0.00014334862385321102
I1
I0
I1
tp30655
sS'potassium-sparing,or,supplements'
p30656
(F0
F0
I1
I1
I0
tp30657
sS'administered,with,a'
p30658
(F1
F0.00028669724770642203
I0
I2
I-2
tp30659
sS'the,minimum,inhibitory'
p30660
(F1
F0.00014334862385321102
I0
I1
I-1
tp30661
sS'an,interleukin-1,antagonist'
p30662
(F1
F0.00028669724770642203
I2
I0
I2
tp30663
sS'administered,with,g'
p30664
(F1
F0.00014334862385321102
I0
I1
I-1
tp30665
sS'for,periods,of'
p30666
(F1
F0.00014334862385321102
I0
I1
I-1
tp30667
sS'common,medications,used'
p30668
(F1
F0.00014334862385321102
I0
I1
I-1
tp30669
sS'loop,such,as'
p30670
(F1
F0.00014334862385321102
I1
I0
I1
tp30671
sS'ritonavir,mg,b'
p30672
(F1
F0.00014334862385321102
I1
I0
I1
tp30673
sS'fortovase,invirase,kaletra'
p30674
(F1
F0.00014334862385321102
I1
I0
I1
tp30675
sS'when,and,were'
p30676
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30677
sS'trials,in,patients'
p30678
(F0
F0
I1
I1
I0
tp30679
sS'rats,and,the'
p30680
(F1
F0.00028669724770642203
I0
I2
I-2
tp30681
sS'ventricular,tachycardia,induced'
p30682
(F1
F0.00014334862385321102
I1
I0
I1
tp30683
sS'difluoro-2,propanol,was'
p30684
(F1
F0.00014334862385321102
I0
I1
I-1
tp30685
sS'to,produce,persistently'
p30686
(F1
F0.00014334862385321102
I0
I1
I-1
tp30687
sS'therapy,were,treated'
p30688
(F1
F0.00014334862385321102
I0
I1
I-1
tp30689
sS'for,injection,in'
p30690
(F1
F0.00014334862385321102
I1
I0
I1
tp30691
sS'currently,receiving,therapy'
p30692
(F1
F0.00014334862385321102
I1
I0
I1
tp30693
sS'of,as,measured'
p30694
(F1
F0.00014334862385321102
I0
I1
I-1
tp30695
sS'brevibloc,steady-state,blood'
p30696
(F1
F0.00014334862385321102
I1
I0
I1
tp30697
sS'markedly,inhibits,the'
p30698
(F1
F0.00028669724770642203
I2
I0
I2
tp30699
sS'addition,of,causes'
p30700
(F1
F0.00014334862385321102
I1
I0
I1
tp30701
sS'mechanisms,of,pcp-induced'
p30702
(F1
F0.00014334862385321102
I0
I1
I-1
tp30703
sS'bradycardia,and,av'
p30704
(F1
F0.00014334862385321102
I1
I0
I1
tp30705
sS'and,incoordination,following'
p30706
(F1
F0.00014334862385321102
I1
I0
I1
tp30707
sS'should,be,treated'
p30708
(F0
F0
I1
I1
I0
tp30709
sS'the,incidence,or'
p30710
(F1
F0.00014334862385321102
I1
I0
I1
tp30711
sS'with,or,and'
p30712
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp30713
sS'who,were,drinking'
p30714
(F1
F0.00014334862385321102
I1
I0
I1
tp30715
sS'and,secondary,enzymes'
p30716
(F1
F0.00014334862385321102
I1
I0
I1
tp30717
sS'agents,the,possibility'
p30718
(F1
F0.00014334862385321102
I0
I1
I-1
tp30719
sS'with,or,any'
p30720
(F1
F0.00028669724770642203
I2
I0
I2
tp30721
sS'that,were,in'
p30722
(F1
F0.00014334862385321102
I1
I0
I1
tp30723
sS'are,on,therapy'
p30724
(F1
F0.00028669724770642203
I2
I0
I2
tp30725
sS'l,from,on'
p30726
(F1
F0.00014334862385321102
I1
I0
I1
tp30727
sS'the,tarceva,dose'
p30728
(F1
F0.00014334862385321102
I1
I0
I1
tp30729
sS'trials,patients,who'
p30730
(F1
F0.00014334862385321102
I0
I1
I-1
tp30731
sS'considered,when,coadministering'
p30732
(F1
F0.00014334862385321102
I1
I0
I1
tp30733
sS'light,dark,test'
p30734
(F1
F0.00014334862385321102
I0
I1
I-1
tp30735
sS'elevation,in,liver'
p30736
(F1
F0.00014334862385321102
I1
I0
I1
tp30737
sS'mg,when,given'
p30738
(F1
F0.00014334862385321102
I0
I1
I-1
tp30739
sS'release,from,the'
p30740
(F1
F0.00014334862385321102
I1
I0
I1
tp30741
sS'volunteers,hydrochloride,either'
p30742
(F1
F0.00014334862385321102
I1
I0
I1
tp30743
sS'studies,with,aprepitant'
p30744
(F1
F0.00014334862385321102
I1
I0
I1
tp30745
sS'was,applied,to'
p30746
(F1
F0.00014334862385321102
I1
I0
I1
tp30747
sS'not,benefit,from'
p30748
(F1
F0.00014334862385321102
I1
I0
I1
tp30749
sS'been,proposed,that'
p30750
(F1
F0.00014334862385321102
I1
I0
I1
tp30751
sS'been,safely,used'
p30752
(F1
F0.00043004587155963305
I0
I3
I-3
tp30753
sS'substances,that,may'
p30754
(F1
F0.00057339449541284407
I0
I4
I-4
tp30755
sS'interactions,between,taxol'
p30756
(F1
F0.00014334862385321102
I0
I1
I-1
tp30757
sS'a,min,interval'
p30758
(F1
F0.00014334862385321102
I1
I0
I1
tp30759
sS'are,reports,of'
p30760
(F1
F0.00014334862385321102
I1
I0
I1
tp30761
sS'randomized,double-blind,study'
p30762
(F1
F0.00014334862385321102
I0
I1
I-1
tp30763
sS'of,mg,mg'
p30764
(F1
F0.00014334862385321102
I0
I1
I-1
tp30765
sS'to,monitor,concentrations'
p30766
(F1
F0.00014334862385321102
I1
I0
I1
tp30767
sS'rarely,in,patients'
p30768
(F1
F0.00014334862385321102
I1
I0
I1
tp30769
sS'thiazide,may,contribute'
p30770
(F1
F0.00014334862385321102
I1
I0
I1
tp30771
sS'sympathetic,effects,of'
p30772
(F1
F0.00014334862385321102
I1
I0
I1
tp30773
sS'drugs,include,the'
p30774
(F1
F0.00014334862385321102
I0
I1
I-1
tp30775
sS'hour,observation,period'
p30776
(F1
F0.00014334862385321102
I0
I1
I-1
tp30777
sS'stabilized,on,should'
p30778
(F1
F0.00014334862385321102
I1
I0
I1
tp30779
sS'of,proleukin,in'
p30780
(F1
F0.00014334862385321102
I0
I1
I-1
tp30781
sS'was,analyzed,in'
p30782
(F1
F0.00014334862385321102
I0
I1
I-1
tp30783
sS'coadministered,with,aprepitant'
p30784
(F1
F0.00028669724770642203
I2
I0
I2
tp30785
sS'adverse,reactions,in'
p30786
(F1
F0.00014334862385321102
I0
I1
I-1
tp30787
sS'length,of,time'
p30788
(F1
F0.00014334862385321102
I1
I0
I1
tp30789
sS'of,the,potent'
p30790
(F1
F0.00014334862385321102
I1
I0
I1
tp30791
sS'pregnancy,and,estrogen-containing'
p30792
(F1
F0.00014334862385321102
I0
I1
I-1
tp30793
sS'agents,have,been'
p30794
(F1
F0.00028669724770642203
I2
I0
I2
tp30795
sS'lithium,lithium,toxicity'
p30796
(F1
F0.00028669724770642203
I2
I0
I2
tp30797
sS'enzyme,inhibitors,and'
p30798
(F1
F0.00028669724770642203
I2
I0
I2
tp30799
sS'needed,when,is'
p30800
(F1
F0.00014334862385321102
I1
I0
I1
tp30801
sS'limited,clinical,data'
p30802
(F0
F0
I1
I1
I0
tp30803
sS'capsules,with,ml'
p30804
(F1
F0.00014334862385321102
I1
I0
I1
tp30805
sS'closely,when,clozapine'
p30806
(F1
F0.00014334862385321102
I1
I0
I1
tp30807
sS'were,between,given'
p30808
(F1
F0.00014334862385321102
I0
I1
I-1
tp30809
sS'concomitant,in,rheumatoid'
p30810
(F1
F0.00014334862385321102
I0
I1
I-1
tp30811
sS'fatal,when,used'
p30812
(F1
F0.00014334862385321102
I1
I0
I1
tp30813
sS'multipledose,treatment,with'
p30814
(F1
F0.00014334862385321102
I0
I1
I-1
tp30815
sS'with,the,preservative'
p30816
(F1
F0.00014334862385321102
I1
I0
I1
tp30817
sS'the,wild-type,alleles'
p30818
(F1
F0.00014334862385321102
I0
I1
I-1
tp30819
sS'decreases,in,the'
p30820
(F1
F0.00014334862385321102
I1
I0
I1
tp30821
sS'has,been,coadministered'
p30822
(F1
F0.00028669724770642203
I0
I2
I-2
tp30823
sS'the,two,agents'
p30824
(F0
F0
I1
I1
I0
tp30825
sS'kill,curves,with'
p30826
(F1
F0.00014334862385321102
I1
I0
I1
tp30827
sS'enzyme,induction,and'
p30828
(F1
F0.00014334862385321102
I1
I0
I1
tp30829
sS'those,taking,mg'
p30830
(F1
F0.00014334862385321102
I0
I1
I-1
tp30831
sS'reduction,in,renal'
p30832
(F1
F0.00028669724770642203
I2
I0
I2
tp30833
sS'or,toxicologic,profile'
p30834
(F1
F0.00014334862385321102
I0
I1
I-1
tp30835
sS'regimen,of,oral'
p30836
(F1
F0.00014334862385321102
I1
I0
I1
tp30837
sS'although,no,specific'
p30838
(F1
F0.00014334862385321102
I1
I0
I1
tp30839
sS'to,significantly,alter'
p30840
(F1
F0.00014334862385321102
I1
I0
I1
tp30841
sS'in,a,schedule'
p30842
(F1
F0.00014334862385321102
I1
I0
I1
tp30843
sS'administration,of,morning'
p30844
(F1
F0.00014334862385321102
I0
I1
I-1
tp30845
sS'interaction,may,precipitate'
p30846
(F1
F0.00014334862385321102
I1
I0
I1
tp30847
sS'steady,state,therefore'
p30848
(F1
F0.00014334862385321102
I0
I1
I-1
tp30849
sS'danger,of,the'
p30850
(F1
F0.00014334862385321102
I1
I0
I1
tp30851
sS'to,mechanisms,involving'
p30852
(F1
F0.00014334862385321102
I1
I0
I1
tp30853
sS'of,a,slower'
p30854
(F1
F0.00014334862385321102
I1
I0
I1
tp30855
sS'physiological,supplementation,and'
p30856
(F1
F0.00014334862385321102
I0
I1
I-1
tp30857
sS'may,be,blunted'
p30858
(F1
F0.00028669724770642203
I2
I0
I2
tp30859
sS'higher,increases,in'
p30860
(F1
F0.00014334862385321102
I1
I0
I1
tp30861
sS'mean,steady-state,plasma'
p30862
(F1
F0.00014334862385321102
I1
I0
I1
tp30863
sS'or,weaken,the'
p30864
(F1
F0.00028669724770642203
I2
I0
I2
tp30865
sS'substitution,test,dsst'
p30866
(F1
F0.00014334862385321102
I1
I0
I1
tp30867
sS'drugs,to,affect'
p30868
(F1
F0.00028669724770642203
I0
I2
I-2
tp30869
sS'antipsychotic,agents,monoamine'
p30870
(F1
F0.00014334862385321102
I1
I0
I1
tp30871
sS'not,undergo,renal'
p30872
(F1
F0.00014334862385321102
I0
I1
I-1
tp30873
sS'olanzapine,coadministration,of'
p30874
(F1
F0.00014334862385321102
I1
I0
I1
tp30875
sS'for,preparations,before'
p30876
(F1
F0.00028669724770642203
I2
I0
I2
tp30877
sS'these,data,indicate'
p30878
(F1
F0.00014334862385321102
I0
I1
I-1
tp30879
sS'thus,may,make'
p30880
(F1
F0.00028669724770642203
I0
I2
I-2
tp30881
sS'eg,may,cause'
p30882
(F1
F0.00043004587155963305
I3
I0
I3
tp30883
sS'either,enbrel,ci'
p30884
(F1
F0.00014334862385321102
I1
I0
I1
tp30885
sS'and,produced,a'
p30886
(F1
F0.00014334862385321102
I1
I0
I1
tp30887
sS'hydrochloride,mg,twice'
p30888
(F1
F0.00014334862385321102
I0
I1
I-1
tp30889
sS'gene,expression,that'
p30890
(F1
F0.00014334862385321102
I0
I1
I-1
tp30891
sS'from,l,kg'
p30892
(F1
F0.00014334862385321102
I1
I0
I1
tp30893
sS'monitor,tcaplasma,levels'
p30894
(F1
F0.00014334862385321102
I0
I1
I-1
tp30895
sS'concentration,profile,or'
p30896
(F1
F0.00014334862385321102
I0
I1
I-1
tp30897
sS'of,interactions,have'
p30898
(F1
F0.00014334862385321102
I1
I0
I1
tp30899
sS'therapies,in,clinical'
p30900
(F1
F0.00014334862385321102
I0
I1
I-1
tp30901
sS'salt,restriction,or'
p30902
(F1
F0.00014334862385321102
I1
I0
I1
tp30903
sS'a,median,follow-up'
p30904
(F1
F0.00014334862385321102
I0
I1
I-1
tp30905
sS'ketoconazole,ketoconazole,has'
p30906
(F1
F0.00014334862385321102
I1
I0
I1
tp30907
sS'not,in,rats'
p30908
(F1
F0.00014334862385321102
I1
I0
I1
tp30909
sS'has,been,little'
p30910
(F1
F0.00014334862385321102
I0
I1
I-1
tp30911
sS'study,evaluated,the'
p30912
(F1
F0.00014334862385321102
I0
I1
I-1
tp30913
sS'and,safety,profiles'
p30914
(F1
F0.00014334862385321102
I0
I1
I-1
tp30915
sS'is,recommended,to'
p30916
(F0
F0
I1
I1
I0
tp30917
sS'basis,it,is'
p30918
(F1
F0.00014334862385321102
I0
I1
I-1
tp30919
sS'suspension,were,coadministered'
p30920
(F1
F0.00014334862385321102
I1
I0
I1
tp30921
sS'of,adverse,neuropsychiatric'
p30922
(F1
F0.00014334862385321102
I1
I0
I1
tp30923
sS'with,mg,qd'
p30924
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp30925
sS'since,the,nrtis'
p30926
(F1
F0.00014334862385321102
I0
I1
I-1
tp30927
sS'the,lack,of'
p30928
(F1
F0.00014334862385321102
I0
I1
I-1
tp30929
sS'taken,orally,imidazole'
p30930
(F1
F0.00014334862385321102
I1
I0
I1
tp30931
sS'animal,and,human'
p30932
(F1
F0.00014334862385321102
I0
I1
I-1
tp30933
sS'also,be,monitored'
p30934
(F1
F0.00014334862385321102
I1
I0
I1
tp30935
sS'the,cellular,and'
p30936
(F1
F0.00014334862385321102
I0
I1
I-1
tp30937
sS'beta-receptor,blockers,have'
p30938
(F1
F0.00014334862385321102
I0
I1
I-1
tp30939
sS'in,the,same'
p30940
(F1
F0.00028669724770642203
I0
I2
I-2
tp30941
sS'when,hydrochloride,was'
p30942
(F1
F0.00014334862385321102
I0
I1
I-1
tp30943
sS'reduced,and,titrated'
p30944
(F1
F0.00014334862385321102
I0
I1
I-1
tp30945
sS'used,at,doses'
p30946
(F1
F0.00014334862385321102
I1
I0
I1
tp30947
sS'in,altered,pharmacoktnetics'
p30948
(F1
F0.00014334862385321102
I0
I1
I-1
tp30949
sS'a2,and,a'
p30950
(F1
F0.00014334862385321102
I1
I0
I1
tp30951
sS'doses,of,as'
p30952
(F1
F0.00014334862385321102
I1
I0
I1
tp30953
sS'neuromuscular,block,following'
p30954
(F1
F0.00014334862385321102
I0
I1
I-1
tp30955
sS'when,are,given'
p30956
(F1
F0.00028669724770642203
I2
I0
I2
tp30957
sS'appreciably,metabolized,nor'
p30958
(F1
F0.00014334862385321102
I0
I1
I-1
tp30959
sS'and,greater,degrees'
p30960
(F1
F0.00014334862385321102
I1
I0
I1
tp30961
sS'that,the,metabolism'
p30962
(F1
F0.00028669724770642203
I2
I0
I2
tp30963
sS'of,arava,with'
p30964
(F1
F0.00014334862385321102
I1
I0
I1
tp30965
sS'on,the,results'
p30966
(F1
F0.00043004587155963305
I0
I3
I-3
tp30967
sS'randomized,trial,of'
p30968
(F1
F0.00014334862385321102
I1
I0
I1
tp30969
sS'doses,of,an'
p30970
(F1
F0.00014334862385321102
I1
I0
I1
tp30971
sS'as,antiparkinson,or'
p30972
(F1
F0.00014334862385321102
I1
I0
I1
tp30973
sS'toxicity,and,a'
p30974
(F1
F0.00014334862385321102
I0
I1
I-1
tp30975
sS'concomitantly,to,patients'
p30976
(F1
F0.00014334862385321102
I1
I0
I1
tp30977
sS'relaxing,effect,of'
p30978
(F1
F0.00014334862385321102
I1
I0
I1
tp30979
sS'age,the,mean'
p30980
(F1
F0.00014334862385321102
I0
I1
I-1
tp30981
sS'that,induce,cyp3a'
p30982
(F1
F0.00014334862385321102
I0
I1
I-1
tp30983
sS'the,mode,of'
p30984
(F1
F0.00014334862385321102
I0
I1
I-1
tp30985
sS'doses,of,cefditoren'
p30986
(F1
F0.00014334862385321102
I0
I1
I-1
tp30987
sS'tablets,may,reduce'
p30988
(F1
F0.00014334862385321102
I1
I0
I1
tp30989
sS'with,concomitant,augmentin'
p30990
(F1
F0.00014334862385321102
I0
I1
I-1
tp30991
sS'with,or,can'
p30992
(F1
F0.00014334862385321102
I1
I0
I1
tp30993
sS'the,dosing,of'
p30994
(F1
F0.00014334862385321102
I1
I0
I1
tp30995
sS'effects,of,increased'
p30996
(F1
F0.00014334862385321102
I1
I0
I1
tp30997
sS'that,nsaids,may'
p30998
(F1
F0.0010034403669724771
I7
I0
I7
tp30999
sS'systemic,concentrations,considerably'
p31000
(F1
F0.00014334862385321102
I1
I0
I1
tp31001
sS'hepatotoxic,potential,must'
p31002
(F1
F0.00014334862385321102
I1
I0
I1
tp31003
sS'of,mefloquine,and'
p31004
(F1
F0.00014334862385321102
I1
I0
I1
tp31005
sS'gradual,withdrawal,of'
p31006
(F1
F0.00014334862385321102
I0
I1
I-1
tp31007
sS'cortisol,does,not'
p31008
(F1
F0.00014334862385321102
I0
I1
I-1
tp31009
sS'was,administered,minute'
p31010
(F1
F0.00014334862385321102
I1
I0
I1
tp31011
sS'reveal,frequent,involvement'
p31012
(F1
F0.00014334862385321102
I1
I0
I1
tp31013
sS'of,doubled,the'
p31014
(F1
F0.00014334862385321102
I1
I0
I1
tp31015
sS'when,cyp3a4,inhibitors'
p31016
(F1
F0.00014334862385321102
I0
I1
I-1
tp31017
sS'the,peak,concentration'
p31018
(F1
F0.00014334862385321102
I0
I1
I-1
tp31019
sS'maoi,within,days'
p31020
(F1
F0.00014334862385321102
I1
I0
I1
tp31021
sS'of,absorption,of'
p31022
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31023
sS'loss,of,consciousness'
p31024
(F1
F0.00014334862385321102
I1
I0
I1
tp31025
sS'mg,day,a'
p31026
(F1
F0.00014334862385321102
I1
I0
I1
tp31027
sS'of,absorption,or'
p31028
(F1
F0.00014334862385321102
I0
I1
I-1
tp31029
sS'noted,that,discontinuation'
p31030
(F1
F0.00014334862385321102
I1
I0
I1
tp31031
sS'core,temperature,in'
p31032
(F1
F0.00014334862385321102
I0
I1
I-1
tp31033
sS'of,the,should'
p31034
(F0
F0
I2
I2
I0
tp31035
sS'standard,dose,and'
p31036
(F1
F0.00014334862385321102
I1
I0
I1
tp31037
sS'in,the,steady-state'
p31038
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp31039
sS'tolerated,but,there'
p31040
(F1
F0.00014334862385321102
I1
I0
I1
tp31041
sS'amantadine,limited,clinical'
p31042
(F1
F0.00014334862385321102
I1
I0
I1
tp31043
sS'with,another,drug'
p31044
(F1
F0.00014334862385321102
I0
I1
I-1
tp31045
sS'that,may,increase'
p31046
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp31047
sS'treatment,with,is'
p31048
(F1
F0.00014334862385321102
I0
I1
I-1
tp31049
sS'times,daily,for'
p31050
(F1
F0.00014334862385321102
I1
I0
I1
tp31051
sS'will,require,a'
p31052
(F1
F0.00014334862385321102
I1
I0
I1
tp31053
sS'and,tricyclic,antidepressants'
p31054
(F1
F0.00014334862385321102
I1
I0
I1
tp31055
sS'days,of,use'
p31056
(F1
F0.00014334862385321102
I0
I1
I-1
tp31057
sS'combination,with,was'
p31058
(F1
F0.00014334862385321102
I0
I1
I-1
tp31059
sS'mg,when,coadministered'
p31060
(F1
F0.00014334862385321102
I1
I0
I1
tp31061
sS'multiple,enzyme,systems'
p31062
(F1
F0.00014334862385321102
I0
I1
I-1
tp31063
sS'effects,of,epidural'
p31064
(F1
F0.00014334862385321102
I1
I0
I1
tp31065
sS'studies,with,or'
p31066
(F1
F0.00014334862385321102
I1
I0
I1
tp31067
sS'than,episodes,of'
p31068
(F1
F0.00014334862385321102
I0
I1
I-1
tp31069
sS'plasma,concentrations,were'
p31070
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp31071
sS'or,to,the'
p31072
(F1
F0.00028669724770642203
I0
I2
I-2
tp31073
sS'prostatectomy,radiation,therapy'
p31074
(F1
F0.00014334862385321102
I0
I1
I-1
tp31075
sS'may,temporarily,mask'
p31076
(F1
F0.00014334862385321102
I1
I0
I1
tp31077
sS'leukocytosis,elevated,serum'
p31078
(F1
F0.00014334862385321102
I1
I0
I1
tp31079
sS'intensity,uniformity,and'
p31080
(F1
F0.00014334862385321102
I0
I1
I-1
tp31081
sS'renal,function,since'
p31082
(F1
F0.00014334862385321102
I0
I1
I-1
tp31083
sS'should,not,exceed'
p31084
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp31085
sS'prothrombin,time,following'
p31086
(F1
F0.00028669724770642203
I0
I2
I-2
tp31087
sS'an,nad,dependent'
p31088
(F1
F0.00014334862385321102
I0
I1
I-1
tp31089
sS'be,effectively,and'
p31090
(F1
F0.00014334862385321102
I0
I1
I-1
tp31091
sS'us,a,comprehensive'
p31092
(F1
F0.00014334862385321102
I0
I1
I-1
tp31093
sS'but,may,produce'
p31094
(F1
F0.00014334862385321102
I1
I0
I1
tp31095
sS'and,bone,scintigraphy'
p31096
(F1
F0.00014334862385321102
I0
I1
I-1
tp31097
sS'systolic,blood,pressure'
p31098
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp31099
sS'hydrochloride,and,is'
p31100
(F1
F0.00014334862385321102
I0
I1
I-1
tp31101
sS'physiology,the,following'
p31102
(F1
F0.00014334862385321102
I0
I1
I-1
tp31103
sS'argatroban,and,concomitantly'
p31104
(F1
F0.00014334862385321102
I0
I1
I-1
tp31105
sS'association,with,increases'
p31106
(F1
F0.00014334862385321102
I1
I0
I1
tp31107
sS'controlled,and,uncontrolled'
p31108
(F1
F0.00014334862385321102
I0
I1
I-1
tp31109
sS'the,ibandronate,osteoporosis'
p31110
(F1
F0.00014334862385321102
I0
I1
I-1
tp31111
sS'show,significant,inhibition'
p31112
(F1
F0.00014334862385321102
I0
I1
I-1
tp31113
sS'mao-b,inhibitor,in'
p31114
(F1
F0.00014334862385321102
I0
I1
I-1
tp31115
sS'that,observed,with'
p31116
(F1
F0.00014334862385321102
I1
I0
I1
tp31117
sS'no,effect,was'
p31118
(F1
F0.00014334862385321102
I0
I1
I-1
tp31119
sS'certain,and,type'
p31120
(F1
F0.00014334862385321102
I1
I0
I1
tp31121
sS'approximately,half,of'
p31122
(F1
F0.00028669724770642203
I0
I2
I-2
tp31123
sS'day,and,on'
p31124
(F1
F0.00014334862385321102
I1
I0
I1
tp31125
sS'was,no,significant'
p31126
(F1
F0.00043004587155963305
I0
I3
I-3
tp31127
sS'have,clinically,significant'
p31128
(F1
F0.00028669724770642203
I0
I2
I-2
tp31129
sS'suggest,that,plasma'
p31130
(F1
F0.00014334862385321102
I1
I0
I1
tp31131
sS'inhibitors,and,various'
p31132
(F1
F0.00014334862385321102
I0
I1
I-1
tp31133
sS'the,anti-inflammatory,activity'
p31134
(F1
F0.00014334862385321102
I1
I0
I1
tp31135
sS'exposure,auc,to'
p31136
(F1
F0.00043004587155963305
I3
I0
I3
tp31137
sS'day,and,orally'
p31138
(F1
F0.00014334862385321102
I1
I0
I1
tp31139
sS'the,two,are'
p31140
(F1
F0.00028669724770642203
I2
I0
I2
tp31141
sS'anticholinesterase,agents,should'
p31142
(F1
F0.00014334862385321102
I1
I0
I1
tp31143
sS'with,a,decreased'
p31144
(F1
F0.00014334862385321102
I1
I0
I1
tp31145
sS'renal,function,and'
p31146
(F0
F0
I1
I1
I0
tp31147
sS'or,concurrent,use'
p31148
(F1
F0.00014334862385321102
I0
I1
I-1
tp31149
sS'baraclude,is,coadministered'
p31150
(F1
F0.00014334862385321102
I0
I1
I-1
tp31151
sS'of,and,mean'
p31152
(F1
F0.00014334862385321102
I1
I0
I1
tp31153
sS'blockade,by,was'
p31154
(F1
F0.00014334862385321102
I1
I0
I1
tp31155
sS'minutes,at,a'
p31156
(F1
F0.00014334862385321102
I0
I1
I-1
tp31157
sS'subjects,mean,steady-state'
p31158
(F1
F0.00014334862385321102
I1
I0
I1
tp31159
sS'and,the,levels'
p31160
(F1
F0.00014334862385321102
I0
I1
I-1
tp31161
sS'to,an,increased'
p31162
(F1
F0.00028669724770642203
I2
I0
I2
tp31163
sS'international,literature,between'
p31164
(F1
F0.00014334862385321102
I0
I1
I-1
tp31165
sS'of,factive,with'
p31166
(F1
F0.00014334862385321102
I1
I0
I1
tp31167
sS'therefore,and,should'
p31168
(F1
F0.00014334862385321102
I1
I0
I1
tp31169
sS'interactions,cephalosporins,including'
p31170
(F1
F0.00014334862385321102
I0
I1
I-1
tp31171
sS'sucralfate,and,containing'
p31172
(F1
F0.00014334862385321102
I1
I0
I1
tp31173
sS'should,either,be'
p31174
(F1
F0.00014334862385321102
I1
I0
I1
tp31175
sS'treatment-experienced,patients,have'
p31176
(F1
F0.00014334862385321102
I0
I1
I-1
tp31177
sS'with,aprepitant,reflects'
p31178
(F1
F0.00014334862385321102
I1
I0
I1
tp31179
sS'a,potent,inducer'
p31180
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp31181
sS'neoplastic,disease,except'
p31182
(F1
F0.00014334862385321102
I1
I0
I1
tp31183
sS'for,known,side'
p31184
(F1
F0.00014334862385321102
I1
I0
I1
tp31185
sS'effect,and,should'
p31186
(F1
F0.00014334862385321102
I1
I0
I1
tp31187
sS'no,significant,change'
p31188
(F1
F0.00028669724770642203
I0
I2
I-2
tp31189
sS'when,duloxetine,and'
p31190
(F1
F0.00014334862385321102
I0
I1
I-1
tp31191
sS'as,compared,to'
p31192
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp31193
sS'recipients,during,the'
p31194
(F1
F0.00014334862385321102
I0
I1
I-1
tp31195
sS'administration,of,concomitantly'
p31196
(F0
F0
I1
I1
I0
tp31197
sS'the,tricyclic,when'
p31198
(F1
F0.00014334862385321102
I1
I0
I1
tp31199
sS'day,with,coadministered'
p31200
(F1
F0.00014334862385321102
I1
I0
I1
tp31201
sS'if,combination,hormonal'
p31202
(F1
F0.00014334862385321102
I1
I0
I1
tp31203
sS'of,combined,administration'
p31204
(F1
F0.00014334862385321102
I0
I1
I-1
tp31205
sS'an,regimen,reduces'
p31206
(F1
F0.00014334862385321102
I0
I1
I-1
tp31207
sS'been,exploited,in'
p31208
(F1
F0.00014334862385321102
I0
I1
I-1
tp31209
sS'upon,discontinuation,of'
p31210
(F1
F0.00043004587155963305
I3
I0
I3
tp31211
sS'and,levo-dromoran,has'
p31212
(F1
F0.00014334862385321102
I1
I0
I1
tp31213
sS'the,active,epoxide'
p31214
(F1
F0.00014334862385321102
I0
I1
I-1
tp31215
sS'indomethacin,are,used'
p31216
(F1
F0.00014334862385321102
I0
I1
I-1
tp31217
sS'hypertension,were,examined'
p31218
(F1
F0.00014334862385321102
I0
I1
I-1
tp31219
sS'disorder,including,manic-depressive'
p31220
(F1
F0.00014334862385321102
I1
I0
I1
tp31221
sS'robinul,injection,and'
p31222
(F1
F0.00014334862385321102
I1
I0
I1
tp31223
sS'of,cholinesterase,inhibitors'
p31224
(F1
F0.00014334862385321102
I1
I0
I1
tp31225
sS'potential,for,protein'
p31226
(F1
F0.00014334862385321102
I0
I1
I-1
tp31227
sS'approved,prescription,dose'
p31228
(F1
F0.00014334862385321102
I1
I0
I1
tp31229
sS'system,depressants,other'
p31230
(F1
F0.00014334862385321102
I0
I1
I-1
tp31231
sS'interactions,between,trileptal'
p31232
(F1
F0.00014334862385321102
I0
I1
I-1
tp31233
sS'such,as,akineton'
p31234
(F1
F0.00014334862385321102
I1
I0
I1
tp31235
sS'reduction,in,cell'
p31236
(F1
F0.00014334862385321102
I1
I0
I1
tp31237
sS'in,mean,auc'
p31238
(F0.5
F0.00028669724770642203
I3
I1
I2
tp31239
sS'or,side,effects'
p31240
(F1
F0.00014334862385321102
I0
I1
I-1
tp31241
sS'data,suggest,similar'
p31242
(F1
F0.00014334862385321102
I0
I1
I-1
tp31243
sS'of,preliminary,studies'
p31244
(F1
F0.00014334862385321102
I1
I0
I1
tp31245
sS'cortex,that,was'
p31246
(F1
F0.00014334862385321102
I1
I0
I1
tp31247
sS'receiving,infusions,of'
p31248
(F1
F0.00014334862385321102
I0
I1
I-1
tp31249
sS'indicated,alternative,agents'
p31250
(F1
F0.00014334862385321102
I0
I1
I-1
tp31251
sS'alcohol,in,post-marketing'
p31252
(F1
F0.00014334862385321102
I1
I0
I1
tp31253
sS'min,and,copegus'
p31254
(F1
F0.00014334862385321102
I0
I1
I-1
tp31255
sS'depressive,effects,of'
p31256
(F1
F0.00014334862385321102
I1
I0
I1
tp31257
sS'in,the,use'
p31258
(F1
F0.00014334862385321102
I0
I1
I-1
tp31259
sS'the,number,of'
p31260
(F0
F0
I2
I2
I0
tp31261
sS'pulmonary,wedge,pressure'
p31262
(F1
F0.00014334862385321102
I1
I0
I1
tp31263
sS'steady-state,exposure,to'
p31264
(F1
F0.00014334862385321102
I0
I1
I-1
tp31265
sS'valproic,acid,with'
p31266
(F1
F0.00014334862385321102
I1
I0
I1
tp31267
sS'stomach,to,form'
p31268
(F1
F0.00014334862385321102
I1
I0
I1
tp31269
sS'active,dose,of'
p31270
(F1
F0.00014334862385321102
I0
I1
I-1
tp31271
sS'about,of,that'
p31272
(F1
F0.00014334862385321102
I0
I1
I-1
tp31273
sS'therapy,the,prothrombin'
p31274
(F1
F0.00014334862385321102
I1
I0
I1
tp31275
sS'inr,was,not'
p31276
(F1
F0.00014334862385321102
I0
I1
I-1
tp31277
sS'are,highly,protein'
p31278
(F1
F0.00043004587155963305
I3
I0
I3
tp31279
sS'niacin,nicotinic,acid'
p31280
(F1
F0.00028669724770642203
I0
I2
I-2
tp31281
sS'mercaptopurine,azathioprine,allopurinol'
p31282
(F1
F0.00014334862385321102
I1
I0
I1
tp31283
sS'non-matched,historicalcontrol,group'
p31284
(F1
F0.00014334862385321102
I1
I0
I1
tp31285
sS'of,gly-buride,and'
p31286
(F1
F0.00014334862385321102
I0
I1
I-1
tp31287
sS'reversal,of,the'
p31288
(F1
F0.00014334862385321102
I1
I0
I1
tp31289
sS'treated,with,have'
p31290
(F1
F0.00014334862385321102
I0
I1
I-1
tp31291
sS'has,occurred,in'
p31292
(F1
F0.00014334862385321102
I1
I0
I1
tp31293
sS'interactions,a,drugs'
p31294
(F1
F0.00014334862385321102
I0
I1
I-1
tp31295
sS'cyp2a6,cyp2c9,cyp2d6'
p31296
(F1
F0.00014334862385321102
I0
I1
I-1
tp31297
sS'elimination,of,antizol'
p31298
(F1
F0.00014334862385321102
I1
I0
I1
tp31299
sS'levels,of,anti-factor'
p31300
(F1
F0.00014334862385321102
I0
I1
I-1
tp31301
sS'concomitant,medications,besides'
p31302
(F1
F0.00014334862385321102
I0
I1
I-1
tp31303
sS'pharmacology-pharmacokinetics,drug-drug,interactions'
p31304
(F1
F0.00014334862385321102
I0
I1
I-1
tp31305
sS'not,be,reliable'
p31306
(F1
F0.00014334862385321102
I1
I0
I1
tp31307
sS'different,route,than'
p31308
(F1
F0.00014334862385321102
I0
I1
I-1
tp31309
sS'the,release,but'
p31310
(F1
F0.00014334862385321102
I0
I1
I-1
tp31311
sS'of,increased,by'
p31312
(F1
F0.00014334862385321102
I1
I0
I1
tp31313
sS'and,can,inhibit'
p31314
(F1
F0.00014334862385321102
I1
I0
I1
tp31315
sS'inhibitors,mg,bid'
p31316
(F1
F0.00014334862385321102
I1
I0
I1
tp31317
sS'strength,of,their'
p31318
(F1
F0.00014334862385321102
I1
I0
I1
tp31319
sS'of,serum,concentrations'
p31320
(F1
F0.00014334862385321102
I1
I0
I1
tp31321
sS'levels,of,if'
p31322
(F1
F0.00014334862385321102
I1
I0
I1
tp31323
sS'the,potential,to'
p31324
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp31325
sS'the,efficacy,of'
p31326
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp31327
sS'and,in,normal'
p31328
(F1
F0.00028669724770642203
I2
I0
I2
tp31329
sS'antimicrobial,combinations,of'
p31330
(F0
F0
I1
I1
I0
tp31331
sS'bone,marrow,suppression'
p31332
(F1
F0.00014334862385321102
I1
I0
I1
tp31333
sS'levels,of,in'
p31334
(F1
F0.00014334862385321102
I0
I1
I-1
tp31335
sS'was,observed,when'
p31336
(F0
F0
I3
I3
I0
tp31337
sS'without,alterations,of'
p31338
(F1
F0.00014334862385321102
I0
I1
I-1
tp31339
sS'this,was,expected'
p31340
(F1
F0.00014334862385321102
I0
I1
I-1
tp31341
sS'plasma,concentration-time,curve'
p31342
(F0
F0
I1
I1
I0
tp31343
sS'novolog,were,not'
p31344
(F1
F0.00014334862385321102
I0
I1
I-1
tp31345
sS'and,showed,no'
p31346
(F1
F0.00014334862385321102
I0
I1
I-1
tp31347
sS'produced,an,approximate'
p31348
(F1
F0.00014334862385321102
I1
I0
I1
tp31349
sS'such,combined,therapy'
p31350
(F1
F0.00014334862385321102
I1
I0
I1
tp31351
sS'are,used,concurrently'
p31352
(F0
F0
I2
I2
I0
tp31353
sS'nimbex,and,decrease'
p31354
(F1
F0.00014334862385321102
I1
I0
I1
tp31355
sS'an,increased,severity'
p31356
(F1
F0.00014334862385321102
I1
I0
I1
tp31357
sS'and,sometimes,prescribed'
p31358
(F1
F0.00014334862385321102
I1
I0
I1
tp31359
sS'first,and,second'
p31360
(F1
F0.00014334862385321102
I1
I0
I1
tp31361
sS'inhibitors,long-term,suppression'
p31362
(F1
F0.00014334862385321102
I1
I0
I1
tp31363
sS'be,needed,following'
p31364
(F1
F0.00014334862385321102
I1
I0
I1
tp31365
sS'subjects,receiving,either'
p31366
(F1
F0.00014334862385321102
I1
I0
I1
tp31367
sS'is,a,potent'
p31368
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp31369
sS'of,are,antagonized'
p31370
(F1
F0.00028669724770642203
I2
I0
I2
tp31371
sS'the,following,may'
p31372
(F1
F0.00028669724770642203
I2
I0
I2
tp31373
sS'phosphatases,in,the'
p31374
(F1
F0.00014334862385321102
I0
I1
I-1
tp31375
sS'an,association,between'
p31376
(F1
F0.00014334862385321102
I1
I0
I1
tp31377
sS'in,vitro,does'
p31378
(F1
F0.00014334862385321102
I0
I1
I-1
tp31379
sS'during,studies,involving'
p31380
(F1
F0.00014334862385321102
I1
I0
I1
tp31381
sS'profiles,in,young'
p31382
(F1
F0.00014334862385321102
I0
I1
I-1
tp31383
sS'contain,deet,n'
p31384
(F1
F0.00014334862385321102
I1
I0
I1
tp31385
sS'upon,administration,of'
p31386
(F1
F0.00014334862385321102
I1
I0
I1
tp31387
sS'patients,receiving,should'
p31388
(F1
F0.00014334862385321102
I1
I0
I1
tp31389
sS'less,active,isomer'
p31390
(F1
F0.00014334862385321102
I1
I0
I1
tp31391
sS'or,were,added'
p31392
(F1
F0.00014334862385321102
I0
I1
I-1
tp31393
sS'cause,adrenal,insufficiency'
p31394
(F1
F0.00014334862385321102
I1
I0
I1
tp31395
sS'when,concomitant,treatment'
p31396
(F1
F0.00014334862385321102
I1
I0
I1
tp31397
sS'the,cmax,of'
p31398
(F1
F0.00043004587155963305
I3
I0
I3
tp31399
sS'in,fdf,at'
p31400
(F1
F0.00043004587155963305
I3
I0
I3
tp31401
sS'and,av,block'
p31402
(F1
F0.00014334862385321102
I1
I0
I1
tp31403
sS'magnesium-,and,or'
p31404
(F1
F0.00014334862385321102
I1
I0
I1
tp31405
sS'and,amantadine,limited'
p31406
(F1
F0.00014334862385321102
I1
I0
I1
tp31407
sS'refractory,to,in'
p31408
(F1
F0.00014334862385321102
I1
I0
I1
tp31409
sS'hypersensitive,to,nonsteroidal'
p31410
(F1
F0.00014334862385321102
I1
I0
I1
tp31411
sS'administered,alone,suggesting'
p31412
(F1
F0.00014334862385321102
I1
I0
I1
tp31413
sS'sprycel,dose,reduction'
p31414
(F1
F0.00014334862385321102
I0
I1
I-1
tp31415
sS'dose,of,changed'
p31416
(F1
F0.00014334862385321102
I1
I0
I1
tp31417
sS'zalcitabine,inhibited,phosphorylation'
p31418
(F1
F0.00014334862385321102
I1
I0
I1
tp31419
sS'paba,containing,preparations'
p31420
(F1
F0.00014334862385321102
I1
I0
I1
tp31421
sS'enhanced,as,well'
p31422
(F1
F0.00014334862385321102
I1
I0
I1
tp31423
sS'was,designed,to'
p31424
(F1
F0.00014334862385321102
I0
I1
I-1
tp31425
sS'of,b,were'
p31426
(F1
F0.00014334862385321102
I0
I1
I-1
tp31427
sS'anticholinesterase,poisoning,although'
p31428
(F1
F0.00014334862385321102
I1
I0
I1
tp31429
sS'coadministered,with,nonselective'
p31430
(F1
F0.00014334862385321102
I1
I0
I1
tp31431
sS'angiotensin,converting,enzyme'
p31432
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp31433
sS'cytochrome,p450,cyp'
p31434
(F1
F0.00028669724770642203
I0
I2
I-2
tp31435
sS'the,combination,therapy'
p31436
(F1
F0.00014334862385321102
I1
I0
I1
tp31437
sS'by,either,mg'
p31438
(F1
F0.00014334862385321102
I0
I1
I-1
tp31439
sS'on,metabolism,in'
p31440
(F1
F0.00014334862385321102
I1
I0
I1
tp31441
sS'intravenous,mg,x'
p31442
(F1
F0.00014334862385321102
I0
I1
I-1
tp31443
sS'and,mental,status'
p31444
(F1
F0.00014334862385321102
I1
I0
I1
tp31445
sS'to,the,cautious'
p31446
(F1
F0.00014334862385321102
I1
I0
I1
tp31447
sS'on,the,antinonciceptive'
p31448
(F1
F0.00014334862385321102
I0
I1
I-1
tp31449
sS'be,an,interaction'
p31450
(F1
F0.00014334862385321102
I1
I0
I1
tp31451
sS'coumarin-type,the,addition'
p31452
(F1
F0.00014334862385321102
I1
I0
I1
tp31453
sS'or,low-dose,microg'
p31454
(F1
F0.00014334862385321102
I1
I0
I1
tp31455
sS'accentuate,the,electrolyte'
p31456
(F1
F0.00028669724770642203
I2
I0
I2
tp31457
sS'dexamethasone,and,retinyl'
p31458
(F1
F0.00014334862385321102
I1
I0
I1
tp31459
sS'up,to,weeks'
p31460
(F1
F0.00028669724770642203
I2
I0
I2
tp31461
sS'for,urinary,protein'
p31462
(F1
F0.00014334862385321102
I0
I1
I-1
tp31463
sS'more,with,activity--such'
p31464
(F1
F0.00014334862385321102
I1
I0
I1
tp31465
sS'binding,sites,during'
p31466
(F1
F0.00028669724770642203
I2
I0
I2
tp31467
sS'blockers,derivatives,and'
p31468
(F1
F0.00014334862385321102
I1
I0
I1
tp31469
sS'days,of,a'
p31470
(F1
F0.00014334862385321102
I1
I0
I1
tp31471
sS'were,transient,increases'
p31472
(F1
F0.00014334862385321102
I1
I0
I1
tp31473
sS'to,take,a'
p31474
(F1
F0.00014334862385321102
I1
I0
I1
tp31475
sS'concomitantly,with,oral'
p31476
(F0
F0
I1
I1
I0
tp31477
sS'number,of,patients'
p31478
(F1
F0.00043004587155963305
I0
I3
I-3
tp31479
sS'evidence,of,hypotension'
p31480
(F1
F0.00014334862385321102
I0
I1
I-1
tp31481
sS'produce,a,less'
p31482
(F1
F0.00014334862385321102
I1
I0
I1
tp31483
sS'the,recommended,twice'
p31484
(F1
F0.00014334862385321102
I0
I1
I-1
tp31485
sS'substitute,for,for'
p31486
(F1
F0.00043004587155963305
I0
I3
I-3
tp31487
sS'with,angiotensin-,converting'
p31488
(F1
F0.00014334862385321102
I0
I1
I-1
tp31489
sS'and,dose,should'
p31490
(F1
F0.00014334862385321102
I1
I0
I1
tp31491
sS'for,both,cyp2d6'
p31492
(F1
F0.00014334862385321102
I0
I1
I-1
tp31493
sS'the,stereoisomers,of'
p31494
(F1
F0.00014334862385321102
I0
I1
I-1
tp31495
sS'by,dose,modifying'
p31496
(F1
F0.00014334862385321102
I1
I0
I1
tp31497
sS'days,in,a'
p31498
(F1
F0.00014334862385321102
I0
I1
I-1
tp31499
sS'the,metabolic,effects'
p31500
(F1
F0.00028669724770642203
I2
I0
I2
tp31501
sS'over,pi-based,therapy'
p31502
(F1
F0.00014334862385321102
I0
I1
I-1
tp31503
sS'protease,inhibitors,protease'
p31504
(F1
F0.00014334862385321102
I0
I1
I-1
tp31505
sS'is,not,advisable'
p31506
(F1
F0.00014334862385321102
I1
I0
I1
tp31507
sS'high-dose,mg,kg'
p31508
(F1
F0.00014334862385321102
I1
I0
I1
tp31509
sS'levels,were,seen'
p31510
(F1
F0.00014334862385321102
I1
I0
I1
tp31511
sS'certain,weak,acids'
p31512
(F1
F0.00014334862385321102
I1
I0
I1
tp31513
sS'be,monitored,forevidence'
p31514
(F1
F0.00014334862385321102
I1
I0
I1
tp31515
sS'misonidazole,reduced,the'
p31516
(F1
F0.00014334862385321102
I1
I0
I1
tp31517
sS'conversion,could,be'
p31518
(F1
F0.00014334862385321102
I0
I1
I-1
tp31519
sS'with,should,generally'
p31520
(F1
F0.00014334862385321102
I1
I0
I1
tp31521
sS'from,prefrontal,cortical'
p31522
(F1
F0.00014334862385321102
I0
I1
I-1
tp31523
sS'a,double,blind'
p31524
(F1
F0.00014334862385321102
I0
I1
I-1
tp31525
sS'agents,such,as'
p31526
(F0
F0
I7
I7
I0
tp31527
sS'to,a,non-matched'
p31528
(F1
F0.00014334862385321102
I1
I0
I1
tp31529
sS'and,background,the'
p31530
(F1
F0.00014334862385321102
I0
I1
I-1
tp31531
sS'non-opioid,analgesics,was'
p31532
(F1
F0.00014334862385321102
I0
I1
I-1
tp31533
sS'hypotension,will,be'
p31534
(F1
F0.00014334862385321102
I1
I0
I1
tp31535
sS'associated,with,peripheral'
p31536
(F1
F0.00014334862385321102
I0
I1
I-1
tp31537
sS'of,the,specific'
p31538
(F1
F0.00014334862385321102
I0
I1
I-1
tp31539
sS'of,hydroxyzine,must'
p31540
(F1
F0.00014334862385321102
I1
I0
I1
tp31541
sS'effects,of,caution'
p31542
(F1
F0.00028669724770642203
I2
I0
I2
tp31543
sS'in,isolated,cases'
p31544
(F1
F0.00014334862385321102
I1
I0
I1
tp31545
sS'study,of,schizophrenic'
p31546
(F0
F0
I1
I1
I0
tp31547
sS'phenobarbital,it,appears'
p31548
(F1
F0.00014334862385321102
I1
I0
I1
tp31549
sS'receiving,catecholamine-depleting,such'
p31550
(F1
F0.00043004587155963305
I3
I0
I3
tp31551
sS'heparin,effect,digitalis'
p31552
(F1
F0.00014334862385321102
I1
I0
I1
tp31553
sS'inhibitor,of,aldehyde'
p31554
(F1
F0.00014334862385321102
I0
I1
I-1
tp31555
sS'inducer,mg,every'
p31556
(F1
F0.00014334862385321102
I1
I0
I1
tp31557
sS'also,higher,when'
p31558
(F1
F0.00014334862385321102
I1
I0
I1
tp31559
sS'methotrexate,ketoprofen,like'
p31560
(F1
F0.00014334862385321102
I1
I0
I1
tp31561
sS'a,dose-dependent,modification'
p31562
(F1
F0.00014334862385321102
I1
I0
I1
tp31563
sS'norpace,cr,lower'
p31564
(F1
F0.00014334862385321102
I1
I0
I1
tp31565
sS'in,regimens,where'
p31566
(F1
F0.00014334862385321102
I0
I1
I-1
tp31567
sS'juice,co-administration,of'
p31568
(F1
F0.00014334862385321102
I0
I1
I-1
tp31569
sS'when,is,concurrently'
p31570
(F1
F0.00014334862385321102
I0
I1
I-1
tp31571
sS'hour,period,in'
p31572
(F1
F0.00043004587155963305
I3
I0
I3
tp31573
sS'the,mg,orally'
p31574
(F1
F0.00014334862385321102
I1
I0
I1
tp31575
sS'the,antihypertensive,effect'
p31576
(F1
F0.0011467889908256881
I8
I0
I8
tp31577
sS'pharmacokinetic,studies,oral'
p31578
(F1
F0.00014334862385321102
I0
I1
I-1
tp31579
sS'in,external,subcutaneous'
p31580
(F1
F0.00014334862385321102
I0
I1
I-1
tp31581
sS'b,and,suggest'
p31582
(F1
F0.00014334862385321102
I1
I0
I1
tp31583
sS'in,lowering,the'
p31584
(F1
F0.00014334862385321102
I1
I0
I1
tp31585
sS'p450,a4,enzymes'
p31586
(F1
F0.00014334862385321102
I0
I1
I-1
tp31587
sS'accutane,use,has'
p31588
(F1
F0.00014334862385321102
I1
I0
I1
tp31589
sS'lead,to,decreased'
p31590
(F1
F0.00014334862385321102
I1
I0
I1
tp31591
sS'these,cases,was'
p31592
(F1
F0.00014334862385321102
I0
I1
I-1
tp31593
sS'agents,structurally,related'
p31594
(F1
F0.00014334862385321102
I1
I0
I1
tp31595
sS'of,tricor,and'
p31596
(F1
F0.00014334862385321102
I1
I0
I1
tp31597
sS'to,iii,and'
p31598
(F1
F0.00028669724770642203
I0
I2
I-2
tp31599
sS'in,glycemia,after'
p31600
(F1
F0.00014334862385321102
I0
I1
I-1
tp31601
sS'interaction,when,is'
p31602
(F1
F0.00014334862385321102
I0
I1
I-1
tp31603
sS'below,a,sub-'
p31604
(F1
F0.00014334862385321102
I0
I1
I-1
tp31605
sS'and,compared,to'
p31606
(F1
F0.00014334862385321102
I0
I1
I-1
tp31607
sS'about,higher,when'
p31608
(F1
F0.00014334862385321102
I1
I0
I1
tp31609
sS'both,or,its'
p31610
(F1
F0.00014334862385321102
I0
I1
I-1
tp31611
sS'enhanced,by,concurrent'
p31612
(F1
F0.00014334862385321102
I1
I0
I1
tp31613
sS'nonselective,inhibitor,of'
p31614
(F1
F0.00014334862385321102
I1
I0
I1
tp31615
sS'indocin,should,not'
p31616
(F1
F0.00014334862385321102
I1
I0
I1
tp31617
sS'and,active,metabolite'
p31618
(F1
F0.00028669724770642203
I2
I0
I2
tp31619
sS'cefditoren,pivoxil,had'
p31620
(F1
F0.00014334862385321102
I0
I1
I-1
tp31621
sS'derivative,while,left'
p31622
(F1
F0.00014334862385321102
I0
I1
I-1
tp31623
sS'on,mhd,concentration'
p31624
(F1
F0.00014334862385321102
I0
I1
I-1
tp31625
sS'thiazide,and,might'
p31626
(F1
F0.00014334862385321102
I1
I0
I1
tp31627
sS'combined,week,placebo'
p31628
(F1
F0.00014334862385321102
I0
I1
I-1
tp31629
sS'with,citrate,may'
p31630
(F1
F0.00014334862385321102
I1
I0
I1
tp31631
sS'animals,dosed,with'
p31632
(F1
F0.00014334862385321102
I0
I1
I-1
tp31633
sS'the,proposed,topical'
p31634
(F1
F0.00014334862385321102
I0
I1
I-1
tp31635
sS'of,and,mepron'
p31636
(F1
F0.00014334862385321102
I1
I0
I1
tp31637
sS'the,toxic,effects'
p31638
(F1
F0.00028669724770642203
I2
I0
I2
tp31639
sS'on,days,and'
p31640
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp31641
sS'warfarin,in,a'
p31642
(F1
F0.00028669724770642203
I0
I2
I-2
tp31643
sS'c,p,a'
p31644
(F1
F0.00014334862385321102
I1
I0
I1
tp31645
sS'beta-adrenergic,receptor,blockers'
p31646
(F1
F0.00014334862385321102
I0
I1
I-1
tp31647
sS'patients,with,depressed'
p31648
(F1
F0.00014334862385321102
I1
I0
I1
tp31649
sS'medications,motion,sickness'
p31650
(F1
F0.00014334862385321102
I0
I1
I-1
tp31651
sS'risk,for,potentially'
p31652
(F1
F0.00014334862385321102
I1
I0
I1
tp31653
sS'care,providers,are'
p31654
(F1
F0.00014334862385321102
I0
I1
I-1
tp31655
sS'was,no,effect'
p31656
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31657
sS'nsaids,like,aleve'
p31658
(F1
F0.00014334862385321102
I1
I0
I1
tp31659
sS'aspirin,should,be'
p31660
(F1
F0.00028669724770642203
I2
I0
I2
tp31661
sS'four,patients,in'
p31662
(F1
F0.00014334862385321102
I1
I0
I1
tp31663
sS'two-fold,of,and'
p31664
(F1
F0.00014334862385321102
I1
I0
I1
tp31665
sS'inhibition,of,elimination'
p31666
(F1
F0.00014334862385321102
I1
I0
I1
tp31667
sS'muscle,relaxants,most'
p31668
(F1
F0.00014334862385321102
I1
I0
I1
tp31669
sS'in,addition,to'
p31670
(F0.5
F0.00028669724770642203
I3
I1
I2
tp31671
sS'or,with,preparations'
p31672
(F1
F0.00014334862385321102
I1
I0
I1
tp31673
sS'on,coumarin-type,the'
p31674
(F1
F0.00014334862385321102
I1
I0
I1
tp31675
sS'at,least,months'
p31676
(F1
F0.00028669724770642203
I0
I2
I-2
tp31677
sS'were,studied,in'
p31678
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp31679
sS'patients,taking,with'
p31680
(F1
F0.00043004587155963305
I3
I0
I3
tp31681
sS'family,may,potentially'
p31682
(F1
F0.00014334862385321102
I0
I1
I-1
tp31683
sS'syndrome,cognitive,dysfunction'
p31684
(F1
F0.00014334862385321102
I1
I0
I1
tp31685
sS'studies,with,and'
p31686
(F1
F0.00057339449541284407
I0
I4
I-4
tp31687
sS'usage,of,and'
p31688
(F1
F0.00014334862385321102
I0
I1
I-1
tp31689
sS'antagonists,in,clinical'
p31690
(F1
F0.00014334862385321102
I0
I1
I-1
tp31691
sS'fractional,mucosal,cell'
p31692
(F1
F0.00014334862385321102
I0
I1
I-1
tp31693
sS'diuretics,the,reports'
p31694
(F1
F0.00014334862385321102
I1
I0
I1
tp31695
sS'effects,of,mixing'
p31696
(F1
F0.00014334862385321102
I0
I1
I-1
tp31697
sS'amounts,of,nondepolarizing'
p31698
(F1
F0.00014334862385321102
I0
I1
I-1
tp31699
sS'because,of,competitive'
p31700
(F1
F0.00014334862385321102
I1
I0
I1
tp31701
sS'peak,blood,concentration'
p31702
(F1
F0.00014334862385321102
I1
I0
I1
tp31703
sS'either,these,medications'
p31704
(F0
F0
I2
I2
I0
tp31705
sS'desloratadine,and,hydroxydesloratadine'
p31706
(F1
F0.00014334862385321102
I0
I1
I-1
tp31707
sS'or,moieties,are'
p31708
(F1
F0.00014334862385321102
I0
I1
I-1
tp31709
sS'live,typhoid,attenuation'
p31710
(F1
F0.00014334862385321102
I1
I0
I1
tp31711
sS'is,comparable,to'
p31712
(F1
F0.00014334862385321102
I0
I1
I-1
tp31713
sS'administration,of,strong'
p31714
(F1
F0.00014334862385321102
I0
I1
I-1
tp31715
sS'supplements,and,l-lysine'
p31716
(F1
F0.00014334862385321102
I1
I0
I1
tp31717
sS'and,hours,subsequent'
p31718
(F1
F0.00014334862385321102
I0
I1
I-1
tp31719
sS'selective,ca,channel'
p31720
(F1
F0.00014334862385321102
I0
I1
I-1
tp31721
sS'derive,from,its'
p31722
(F1
F0.00014334862385321102
I1
I0
I1
tp31723
sS'de,novo,kidney'
p31724
(F1
F0.00014334862385321102
I0
I1
I-1
tp31725
sS'in,rpmi1640,containing'
p31726
(F1
F0.00014334862385321102
I1
I0
I1
tp31727
sS'of,with,agents'
p31728
(F1
F0.00014334862385321102
I1
I0
I1
tp31729
sS'as,camptosar,than'
p31730
(F1
F0.00014334862385321102
I1
I0
I1
tp31731
sS'other,therapies,commonly'
p31732
(F1
F0.00014334862385321102
I0
I1
I-1
tp31733
sS'the,steady-state,auc'
p31734
(F1
F0.00043004587155963305
I3
I0
I3
tp31735
sS'as,alternatives,to'
p31736
(F1
F0.00014334862385321102
I1
I0
I1
tp31737
sS'the,a-v,node'
p31738
(F1
F0.00014334862385321102
I1
I0
I1
tp31739
sS'and,discontinuing,to'
p31740
(F1
F0.00028669724770642203
I2
I0
I2
tp31741
sS'reported,that,results'
p31742
(F1
F0.00014334862385321102
I1
I0
I1
tp31743
sS'daily,and,provide'
p31744
(F1
F0.00014334862385321102
I1
I0
I1
tp31745
sS'ellence,with,other'
p31746
(F1
F0.00014334862385321102
I1
I0
I1
tp31747
sS'effect,of,only'
p31748
(F1
F0.00028669724770642203
I2
I0
I2
tp31749
sS'in,a,multiple-dose'
p31750
(F1
F0.00014334862385321102
I1
I0
I1
tp31751
sS'maintained,on,gm'
p31752
(F1
F0.00014334862385321102
I1
I0
I1
tp31753
sS'of,serotonin,syndrome'
p31754
(F1
F0.00028669724770642203
I2
I0
I2
tp31755
sS'interfere,with,cyp2c19'
p31756
(F1
F0.00014334862385321102
I0
I1
I-1
tp31757
sS'of,aczone,gel'
p31758
(F1
F0.00014334862385321102
I0
I1
I-1
tp31759
sS'time,as,other'
p31760
(F1
F0.00014334862385321102
I1
I0
I1
tp31761
sS'current,evidence,suggests'
p31762
(F1
F0.00014334862385321102
I1
I0
I1
tp31763
sS'including,acetylsalicylic,acid'
p31764
(F1
F0.00014334862385321102
I0
I1
I-1
tp31765
sS'be,greater,than'
p31766
(F1
F0.00014334862385321102
I1
I0
I1
tp31767
sS'orally,because,of'
p31768
(F1
F0.00014334862385321102
I1
I0
I1
tp31769
sS'studies,did,not'
p31770
(F1
F0.00014334862385321102
I0
I1
I-1
tp31771
sS'doses,had,a'
p31772
(F1
F0.00014334862385321102
I1
I0
I1
tp31773
sS'patient,who,has'
p31774
(F1
F0.00028669724770642203
I2
I0
I2
tp31775
sS'study,demonstrated,that'
p31776
(F1
F0.00028669724770642203
I2
I0
I2
tp31777
sS'amevive,on,pregnancy'
p31778
(F1
F0.00014334862385321102
I0
I1
I-1
tp31779
sS'three,weeks,prior'
p31780
(F1
F0.00014334862385321102
I1
I0
I1
tp31781
sS'well-controlled,study,of'
p31782
(F1
F0.00014334862385321102
I0
I1
I-1
tp31783
sS'and,is,to'
p31784
(F1
F0.00014334862385321102
I1
I0
I1
tp31785
sS'production,of,tail-flick'
p31786
(F1
F0.00014334862385321102
I0
I1
I-1
tp31787
sS'transport,systems,lapatinib'
p31788
(F1
F0.00014334862385321102
I0
I1
I-1
tp31789
sS'mean,sodium,and'
p31790
(F1
F0.00014334862385321102
I1
I0
I1
tp31791
sS'interactions,may,pose'
p31792
(F1
F0.00057339449541284407
I4
I0
I4
tp31793
sS'in,such,users'
p31794
(F1
F0.00014334862385321102
I0
I1
I-1
tp31795
sS'evidence,indicating,that'
p31796
(F1
F0.00014334862385321102
I0
I1
I-1
tp31797
sS'dietary,deficiencies,affecting'
p31798
(F1
F0.00014334862385321102
I1
I0
I1
tp31799
sS'only,requires,oral'
p31800
(F1
F0.00014334862385321102
I0
I1
I-1
tp31801
sS'reduce,the,tubular'
p31802
(F1
F0.00014334862385321102
I1
I0
I1
tp31803
sS'the,best,approach'
p31804
(F1
F0.00014334862385321102
I0
I1
I-1
tp31805
sS'ml,may,interfere'
p31806
(F1
F0.00014334862385321102
I0
I1
I-1
tp31807
sS'undetectable,release,in'
p31808
(F1
F0.00014334862385321102
I0
I1
I-1
tp31809
sS'receiving,hmg-coa,reductase'
p31810
(F1
F0.00014334862385321102
I1
I0
I1
tp31811
sS'occasionally,induce,a'
p31812
(F1
F0.00014334862385321102
I0
I1
I-1
tp31813
sS'reactions,to,this'
p31814
(F1
F0.00014334862385321102
I0
I1
I-1
tp31815
sS'conjunction,with,a'
p31816
(F1
F0.00014334862385321102
I1
I0
I1
tp31817
sS'to,avoid,intoxication'
p31818
(F1
F0.00028669724770642203
I0
I2
I-2
tp31819
sS'treated,with,chop'
p31820
(F1
F0.00014334862385321102
I0
I1
I-1
tp31821
sS'studies,of,drug'
p31822
(F1
F0.00014334862385321102
I0
I1
I-1
tp31823
sS'interfere,with,blood'
p31824
(F1
F0.00014334862385321102
I1
I0
I1
tp31825
sS'with,creatinine,clearance'
p31826
(F1
F0.00014334862385321102
I0
I1
I-1
tp31827
sS'inhibitor,of,cyp3a4'
p31828
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp31829
sS'any,such,reduction'
p31830
(F1
F0.00014334862385321102
I1
I0
I1
tp31831
sS'emerging,roles,of'
p31832
(F1
F0.00014334862385321102
I0
I1
I-1
tp31833
sS'x,mg,tablets'
p31834
(F1
F0.00014334862385321102
I1
I0
I1
tp31835
sS'and,haldol,has'
p31836
(F1
F0.00014334862385321102
I0
I1
I-1
tp31837
sS'studies,and,nonclinical'
p31838
(F1
F0.00014334862385321102
I0
I1
I-1
tp31839
sS'a-v,node,higher'
p31840
(F1
F0.00014334862385321102
I1
I0
I1
tp31841
sS'of,the,period'
p31842
(F1
F0.00014334862385321102
I0
I1
I-1
tp31843
sS'significant,protection,against'
p31844
(F1
F0.00014334862385321102
I1
I0
I1
tp31845
sS'data,from,prospective'
p31846
(F1
F0.00014334862385321102
I0
I1
I-1
tp31847
sS'nicotinic,acid,may'
p31848
(F1
F0.00014334862385321102
I1
I0
I1
tp31849
sS'dependent,hypertension,including'
p31850
(F1
F0.00014334862385321102
I1
I0
I1
tp31851
sS'no,potentiation,of'
p31852
(F1
F0.00014334862385321102
I0
I1
I-1
tp31853
sS'is,administered,concurrently'
p31854
(F1
F0.00028669724770642203
I2
I0
I2
tp31855
sS'antibiotics,and,azole'
p31856
(F1
F0.00014334862385321102
I0
I1
I-1
tp31857
sS'is,added,to'
p31858
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp31859
sS'or,to,recommend'
p31860
(F1
F0.00014334862385321102
I0
I1
I-1
tp31861
sS'alone,mg,twice'
p31862
(F1
F0.00014334862385321102
I0
I1
I-1
tp31863
sS'metabolism,and,increase'
p31864
(F0
F0
I1
I1
I0
tp31865
sS'diflunisal,decreased,the'
p31866
(F1
F0.00028669724770642203
I2
I0
I2
tp31867
sS'days,as,a'
p31868
(F1
F0.00014334862385321102
I1
I0
I1
tp31869
sS'to,have,no'
p31870
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp31871
sS'concentrations,were,collected'
p31872
(F1
F0.00014334862385321102
I0
I1
I-1
tp31873
sS'the,last,two'
p31874
(F1
F0.00014334862385321102
I0
I1
I-1
tp31875
sS'degree,of,hypotension'
p31876
(F1
F0.00014334862385321102
I1
I0
I1
tp31877
sS'produced,in,the'
p31878
(F1
F0.00014334862385321102
I1
I0
I1
tp31879
sS'allowed,before,starting'
p31880
(F1
F0.00014334862385321102
I1
I0
I1
tp31881
sS'concurrently,without,any'
p31882
(F1
F0.00014334862385321102
I0
I1
I-1
tp31883
sS'been,performed,coadministration'
p31884
(F1
F0.00014334862385321102
I1
I0
I1
tp31885
sS'substantially,decrease,plasma'
p31886
(F1
F0.00014334862385321102
I0
I1
I-1
tp31887
sS'sporanox,nizoral,muscle'
p31888
(F1
F0.00014334862385321102
I0
I1
I-1
tp31889
sS'mg,single,oral'
p31890
(F1
F0.00028669724770642203
I0
I2
I-2
tp31891
sS'or,activated,in'
p31892
(F1
F0.00014334862385321102
I1
I0
I1
tp31893
sS'ordinarily,recommended,unless'
p31894
(F1
F0.00014334862385321102
I1
I0
I1
tp31895
sS'interaction,with,and'
p31896
(F0
F0
I1
I1
I0
tp31897
sS'femara,and,mg'
p31898
(F1
F0.00014334862385321102
I1
I0
I1
tp31899
sS'psychiatric,disorder,including'
p31900
(F1
F0.00014334862385321102
I1
I0
I1
tp31901
sS'and,except,for'
p31902
(F1
F0.00014334862385321102
I0
I1
I-1
tp31903
sS'interfere,with,measurement'
p31904
(F1
F0.00028669724770642203
I0
I2
I-2
tp31905
sS'v,to,m'
p31906
(F1
F0.00014334862385321102
I0
I1
I-1
tp31907
sS'observed,following,coadministration'
p31908
(F1
F0.00014334862385321102
I0
I1
I-1
tp31909
sS'calcium-rich,foods,or'
p31910
(F1
F0.00014334862385321102
I1
I0
I1
tp31911
sS'the,cecum,and'
p31912
(F1
F0.00014334862385321102
I0
I1
I-1
tp31913
sS'can,cause,a'
p31914
(F1
F0.00014334862385321102
I1
I0
I1
tp31915
sS'of,levo-dromoran,with'
p31916
(F1
F0.00014334862385321102
I1
I0
I1
tp31917
sS'and,medication,must'
p31918
(F1
F0.00014334862385321102
I1
I0
I1
tp31919
sS'can,cause,k'
p31920
(F1
F0.00014334862385321102
I0
I1
I-1
tp31921
sS'for,other,that'
p31922
(F1
F0.00014334862385321102
I0
I1
I-1
tp31923
sS'tablets,in,epileptic'
p31924
(F1
F0.00014334862385321102
I1
I0
I1
tp31925
sS'control,rats,at'
p31926
(F1
F0.00014334862385321102
I0
I1
I-1
tp31927
sS'inhibiting,parts,of'
p31928
(F1
F0.00014334862385321102
I1
I0
I1
tp31929
sS'trials,flolan,was'
p31930
(F1
F0.00014334862385321102
I1
I0
I1
tp31931
sS'of,bleeding,if'
p31932
(F1
F0.00014334862385321102
I1
I0
I1
tp31933
sS'increase,the,impairment'
p31934
(F1
F0.00014334862385321102
I0
I1
I-1
tp31935
sS'in,clinical,interaction'
p31936
(F1
F0.00014334862385321102
I0
I1
I-1
tp31937
sS'a,net,change'
p31938
(F1
F0.00043004587155963305
I3
I0
I3
tp31939
sS'a,that,can'
p31940
(F1
F0.00014334862385321102
I1
I0
I1
tp31941
sS'for,flolan,to'
p31942
(F1
F0.00014334862385321102
I1
I0
I1
tp31943
sS'receiving,either,or'
p31944
(F1
F0.00014334862385321102
I1
I0
I1
tp31945
sS'and,randomly,bred'
p31946
(F1
F0.00014334862385321102
I0
I1
I-1
tp31947
sS'investigated,the,possibility'
p31948
(F1
F0.00014334862385321102
I0
I1
I-1
tp31949
sS'prolixin,permitil,compazine'
p31950
(F1
F0.00014334862385321102
I0
I1
I-1
tp31951
sS'methotrexate,vioxx,and'
p31952
(F1
F0.00014334862385321102
I0
I1
I-1
tp31953
sS'agents,interfering,with'
p31954
(F1
F0.00028669724770642203
I2
I0
I2
tp31955
sS'delay,or,reduce'
p31956
(F1
F0.00014334862385321102
I1
I0
I1
tp31957
sS'were,coadministered,with'
p31958
(F1
F0.00014334862385321102
I0
I1
I-1
tp31959
sS'tablets,inhibit,the'
p31960
(F1
F0.00014334862385321102
I1
I0
I1
tp31961
sS'auc0-12,of,by'
p31962
(F1
F0.00014334862385321102
I1
I0
I1
tp31963
sS'a,catecholamine,depletor'
p31964
(F1
F0.00014334862385321102
I0
I1
I-1
tp31965
sS'under,a,multiple'
p31966
(F1
F0.00014334862385321102
I0
I1
I-1
tp31967
sS'by,when,co-administered'
p31968
(F1
F0.00014334862385321102
I1
I0
I1
tp31969
sS'acid,from,masking'
p31970
(F1
F0.00014334862385321102
I0
I1
I-1
tp31971
sS'nsaids,including,and'
p31972
(F1
F0.00014334862385321102
I1
I0
I1
tp31973
sS'by,combination,hormonal'
p31974
(F1
F0.00014334862385321102
I1
I0
I1
tp31975
sS'in,rat,liver'
p31976
(F1
F0.00014334862385321102
I0
I1
I-1
tp31977
sS'intervals,or,if'
p31978
(F1
F0.00014334862385321102
I1
I0
I1
tp31979
sS'supplemented,with,coenzyme'
p31980
(F1
F0.00014334862385321102
I0
I1
I-1
tp31981
sS'or,other,medications'
p31982
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp31983
sS'treated,with,alone'
p31984
(F1
F0.00014334862385321102
I1
I0
I1
tp31985
sS'hydrochloride,is,used'
p31986
(F1
F0.00014334862385321102
I1
I0
I1
tp31987
sS'given,with,two'
p31988
(F1
F0.00014334862385321102
I0
I1
I-1
tp31989
sS'and,therapeutic,superiority'
p31990
(F1
F0.00014334862385321102
I0
I1
I-1
tp31991
sS'confusion,and,dyspnea'
p31992
(F1
F0.00014334862385321102
I1
I0
I1
tp31993
sS'such,medicinal,products'
p31994
(F1
F0.00014334862385321102
I1
I0
I1
tp31995
sS'when,initiating,a'
p31996
(F1
F0.00014334862385321102
I1
I0
I1
tp31997
sS'antagonists,because,of'
p31998
(F1
F0.00014334862385321102
I1
I0
I1
tp31999
sS'highly,active,therapy'
p32000
(F1
F0.00014334862385321102
I0
I1
I-1
tp32001
sS'inhibitors,eg,grapefruit'
p32002
(F1
F0.00014334862385321102
I0
I1
I-1
tp32003
sS'there,are,rare'
p32004
(F1
F0.00014334862385321102
I1
I0
I1
tp32005
sS'that,was,responsible'
p32006
(F1
F0.00014334862385321102
I1
I0
I1
tp32007
sS'iga,glomerulonephritis,oculo-bulbar'
p32008
(F1
F0.00014334862385321102
I1
I0
I1
tp32009
sS'in,a,greater'
p32010
(F1
F0.00028669724770642203
I2
I0
I2
tp32011
sS'shortened,elimination,half-life'
p32012
(F1
F0.00014334862385321102
I1
I0
I1
tp32013
sS'of,ml,h'
p32014
(F1
F0.00014334862385321102
I0
I1
I-1
tp32015
sS'concentrations,of,may'
p32016
(F0
F0
I1
I1
I0
tp32017
sS'an,adequate,respiratory'
p32018
(F1
F0.00014334862385321102
I0
I1
I-1
tp32019
sS'cyp4a11,with,the'
p32020
(F1
F0.00014334862385321102
I0
I1
I-1
tp32021
sS'bradycardia,which,may'
p32022
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32023
sS'indocin,with,other'
p32024
(F1
F0.00014334862385321102
I1
I0
I1
tp32025
sS'non-steroidal,anti-inflammatory,may'
p32026
(F1
F0.00014334862385321102
I1
I0
I1
tp32027
sS'reaction,to,any'
p32028
(F1
F0.00014334862385321102
I1
I0
I1
tp32029
sS'day,monotherapy,did'
p32030
(F1
F0.00014334862385321102
I0
I1
I-1
tp32031
sS'significant,impact,on'
p32032
(F1
F0.00014334862385321102
I1
I0
I1
tp32033
sS'breast,cancer,cell'
p32034
(F1
F0.00014334862385321102
I0
I1
I-1
tp32035
sS'administered,antiepileptic,periodic'
p32036
(F1
F0.00014334862385321102
I1
I0
I1
tp32037
sS'to,affect,conversion'
p32038
(F1
F0.00014334862385321102
I0
I1
I-1
tp32039
sS'habituation,or,cns'
p32040
(F1
F0.00014334862385321102
I0
I1
I-1
tp32041
sS'agitation,while,other'
p32042
(F1
F0.00014334862385321102
I0
I1
I-1
tp32043
sS'to,ml,min'
p32044
(F1
F0.00014334862385321102
I1
I0
I1
tp32045
sS'decreasing,responding,whereas'
p32046
(F1
F0.00014334862385321102
I0
I1
I-1
tp32047
sS'enhance,the,cns'
p32048
(F1
F0.00014334862385321102
I1
I0
I1
tp32049
sS'mg,reduced,the'
p32050
(F1
F0.00014334862385321102
I1
I0
I1
tp32051
sS'loratadine,mg,in'
p32052
(F1
F0.00014334862385321102
I0
I1
I-1
tp32053
sS'nonfailing,myocardium,p'
p32054
(F1
F0.00014334862385321102
I1
I0
I1
tp32055
sS'indocin,and,are'
p32056
(F1
F0.00043004587155963305
I3
I0
I3
tp32057
sS'male,and,female'
p32058
(F0
F0
I1
I1
I0
tp32059
sS'study,did,not'
p32060
(F0
F0
I1
I1
I0
tp32061
sS'when,trileptal,was'
p32062
(F1
F0.00014334862385321102
I1
I0
I1
tp32063
sS'gleevec,gleevec,increases'
p32064
(F1
F0.00014334862385321102
I1
I0
I1
tp32065
sS'because,can,produce'
p32066
(F1
F0.00014334862385321102
I1
I0
I1
tp32067
sS'studies,tilade,has'
p32068
(F1
F0.00014334862385321102
I0
I1
I-1
tp32069
sS'of,antiaddictive,efficacy'
p32070
(F1
F0.00014334862385321102
I0
I1
I-1
tp32071
sS'sporadic,cases,of'
p32072
(F1
F0.00014334862385321102
I1
I0
I1
tp32073
sS'to,was,necessary'
p32074
(F1
F0.00014334862385321102
I1
I0
I1
tp32075
sS'effect,and,other'
p32076
(F1
F0.00014334862385321102
I0
I1
I-1
tp32077
sS'interactions,food,cns'
p32078
(F1
F0.00014334862385321102
I1
I0
I1
tp32079
sS'may,occur,up'
p32080
(F1
F0.00014334862385321102
I1
I0
I1
tp32081
sS'of,with,products'
p32082
(F1
F0.00014334862385321102
I1
I0
I1
tp32083
sS'a,control,period'
p32084
(F1
F0.00014334862385321102
I1
I0
I1
tp32085
sS'anxiogenic,effects,were'
p32086
(F1
F0.00014334862385321102
I1
I0
I1
tp32087
sS'in,increased,levels'
p32088
(F1
F0.00014334862385321102
I1
I0
I1
tp32089
sS'concentration,of,the'
p32090
(F1
F0.00043004587155963305
I3
I0
I3
tp32091
sS'system,and,cardiovascular'
p32092
(F1
F0.00014334862385321102
I1
I0
I1
tp32093
sS'of,the,diets'
p32094
(F1
F0.00014334862385321102
I0
I1
I-1
tp32095
sS'agents,or,with'
p32096
(F1
F0.00014334862385321102
I1
I0
I1
tp32097
sS'stress,in,rat'
p32098
(F1
F0.00014334862385321102
I1
I0
I1
tp32099
sS'amines,have,been'
p32100
(F1
F0.00014334862385321102
I1
I0
I1
tp32101
sS'to,be,concomitantly'
p32102
(F1
F0.00014334862385321102
I0
I1
I-1
tp32103
sS'risks,of,severe'
p32104
(F1
F0.00014334862385321102
I1
I0
I1
tp32105
sS'has,reduced,or'
p32106
(F1
F0.00014334862385321102
I1
I0
I1
tp32107
sS'dose,of,resulted'
p32108
(F1
F0.00014334862385321102
I1
I0
I1
tp32109
sS'high,in,vitamin'
p32110
(F1
F0.00014334862385321102
I1
I0
I1
tp32111
sS'of,the,relationship'
p32112
(F0
F0
I1
I1
I0
tp32113
sS'ventricular,hypokinesia,and'
p32114
(F1
F0.00014334862385321102
I1
I0
I1
tp32115
sS'significant,changes,to'
p32116
(F1
F0.00014334862385321102
I0
I1
I-1
tp32117
sS'healthy,white,female'
p32118
(F1
F0.00014334862385321102
I0
I1
I-1
tp32119
sS'less,than,and'
p32120
(F1
F0.00014334862385321102
I1
I0
I1
tp32121
sS'use,of,injection'
p32122
(F1
F0.00014334862385321102
I1
I0
I1
tp32123
sS'inhibitors,of,cyp2c9'
p32124
(F1
F0.00014334862385321102
I1
I0
I1
tp32125
sS'sequestrants,may,bind'
p32126
(F1
F0.00014334862385321102
I1
I0
I1
tp32127
sS'findings,to,humans'
p32128
(F1
F0.00014334862385321102
I1
I0
I1
tp32129
sS'coadministration,of,single'
p32130
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp32131
sS'patients,on,chronic'
p32132
(F1
F0.00057339449541284407
I4
I0
I4
tp32133
sS'in,steady-state,serum'
p32134
(F1
F0.00014334862385321102
I1
I0
I1
tp32135
sS'and,then,with'
p32136
(F1
F0.00014334862385321102
I0
I1
I-1
tp32137
sS'relaxants,amphotericin,b-induced'
p32138
(F1
F0.00014334862385321102
I1
I0
I1
tp32139
sS'other,coadministered,medicinal'
p32140
(F1
F0.00014334862385321102
I1
I0
I1
tp32141
sS'by,following,administration'
p32142
(F1
F0.00014334862385321102
I1
I0
I1
tp32143
sS'are,strong,central'
p32144
(F1
F0.00014334862385321102
I0
I1
I-1
tp32145
sS'inflammatory,agents,are'
p32146
(F1
F0.00014334862385321102
I1
I0
I1
tp32147
sS'of,phosphorylated,concentration'
p32148
(F1
F0.00014334862385321102
I0
I1
I-1
tp32149
sS'results,of,a'
p32150
(F1
F0.00028669724770642203
I2
I0
I2
tp32151
sS'on,alone,or'
p32152
(F1
F0.00014334862385321102
I0
I1
I-1
tp32153
sS'a,inhaler,take'
p32154
(F1
F0.00014334862385321102
I1
I0
I1
tp32155
sS'increase,of,level'
p32156
(F1
F0.00014334862385321102
I1
I0
I1
tp32157
sS'may,cause,bleeding'
p32158
(F1
F0.00014334862385321102
I0
I1
I-1
tp32159
sS'from,combined,use'
p32160
(F1
F0.00014334862385321102
I1
I0
I1
tp32161
sS'decreasing,the,concentration'
p32162
(F1
F0.00014334862385321102
I0
I1
I-1
tp32163
sS'the,substantial,interaction'
p32164
(F1
F0.00014334862385321102
I1
I0
I1
tp32165
sS'regimen,containing,mg'
p32166
(F1
F0.00014334862385321102
I0
I1
I-1
tp32167
sS'felbatol,on,other'
p32168
(F1
F0.00014334862385321102
I1
I0
I1
tp32169
sS'is,advised,when'
p32170
(F1
F0.00043004587155963305
I3
I0
I3
tp32171
sS'on,the,major'
p32172
(F1
F0.00014334862385321102
I0
I1
I-1
tp32173
sS'medium,consisting,of'
p32174
(F1
F0.00014334862385321102
I0
I1
I-1
tp32175
sS'approximate,reduction,of'
p32176
(F1
F0.00014334862385321102
I1
I0
I1
tp32177
sS'should,have,their'
p32178
(F0
F0
I1
I1
I0
tp32179
sS'is,recommended,that'
p32180
(F0.68421052631578949
F0.0018635321100917432
I16
I3
I13
tp32181
sS'secondary,to,this'
p32182
(F1
F0.00014334862385321102
I1
I0
I1
tp32183
sS'true,interaction,may'
p32184
(F1
F0.00014334862385321102
I1
I0
I1
tp32185
sS'little,or,no'
p32186
(F0
F0
I3
I3
I0
tp32187
sS'require,that,the'
p32188
(F1
F0.00014334862385321102
I1
I0
I1
tp32189
sS'by,after,to'
p32190
(F1
F0.00014334862385321102
I0
I1
I-1
tp32191
sS'allergic,reaction,and'
p32192
(F1
F0.00014334862385321102
I1
I0
I1
tp32193
sS'any,clinical,interaction'
p32194
(F1
F0.00014334862385321102
I0
I1
I-1
tp32195
sS'in,the,diabectics'
p32196
(F1
F0.00014334862385321102
I0
I1
I-1
tp32197
sS'of,actinic,keratoses'
p32198
(F1
F0.00014334862385321102
I1
I0
I1
tp32199
sS'also,produces,a'
p32200
(F1
F0.00014334862385321102
I1
I0
I1
tp32201
sS'human,trials,have'
p32202
(F1
F0.00014334862385321102
I1
I0
I1
tp32203
sS'taken,in,concurrent'
p32204
(F1
F0.00014334862385321102
I0
I1
I-1
tp32205
sS'approximately,minutes,faster'
p32206
(F1
F0.00014334862385321102
I1
I0
I1
tp32207
sS'review,was,made'
p32208
(F1
F0.00014334862385321102
I0
I1
I-1
tp32209
sS'observed,when,a'
p32210
(F1
F0.00014334862385321102
I0
I1
I-1
tp32211
sS'valproic,acid,depakene'
p32212
(F1
F0.00014334862385321102
I0
I1
I-1
tp32213
sS'reduces,the,plasma'
p32214
(F1
F0.00014334862385321102
I0
I1
I-1
tp32215
sS'other,antiretroviral,drugs'
p32216
(F1
F0.00014334862385321102
I1
I0
I1
tp32217
sS'lower,tablet,volume'
p32218
(F1
F0.00014334862385321102
I0
I1
I-1
tp32219
sS'death,potentially,associated'
p32220
(F1
F0.00014334862385321102
I1
I0
I1
tp32221
sS'enhanced,by,interaction'
p32222
(F1
F0.00014334862385321102
I1
I0
I1
tp32223
sS'study,involving,adult'
p32224
(F1
F0.00014334862385321102
I0
I1
I-1
tp32225
sS'secretory,effect,of'
p32226
(F1
F0.00014334862385321102
I1
I0
I1
tp32227
sS'some,patients,a'
p32228
(F1
F0.00014334862385321102
I0
I1
I-1
tp32229
sS'of,busulfex,were'
p32230
(F1
F0.00014334862385321102
I1
I0
I1
tp32231
sS'behaviors,most,closely'
p32232
(F1
F0.00014334862385321102
I0
I1
I-1
tp32233
sS'furosemide,when,was'
p32234
(F1
F0.00014334862385321102
I1
I0
I1
tp32235
sS'the,clinical,course'
p32236
(F1
F0.00014334862385321102
I0
I1
I-1
tp32237
sS'mg,day,increased'
p32238
(F1
F0.00014334862385321102
I1
I0
I1
tp32239
sS'receiving,or,similar'
p32240
(F1
F0.00014334862385321102
I1
I0
I1
tp32241
sS'in,relation,to'
p32242
(F1
F0.00014334862385321102
I0
I1
I-1
tp32243
sS'c,interval,msec'
p32244
(F1
F0.00014334862385321102
I1
I0
I1
tp32245
sS'products,with,and'
p32246
(F1
F0.00014334862385321102
I1
I0
I1
tp32247
sS'human,plasma,is'
p32248
(F1
F0.00014334862385321102
I0
I1
I-1
tp32249
sS'toxicity,when,deet'
p32250
(F1
F0.00014334862385321102
I0
I1
I-1
tp32251
sS'ultracentrifugation,indicated,that'
p32252
(F1
F0.00014334862385321102
I0
I1
I-1
tp32253
sS'following,the,administration'
p32254
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32255
sS'human,plasma,in'
p32256
(F1
F0.00014334862385321102
I0
I1
I-1
tp32257
sS'metabolism,with,increased'
p32258
(F1
F0.00014334862385321102
I1
I0
I1
tp32259
sS'decrease,mean,c'
p32260
(F1
F0.00014334862385321102
I0
I1
I-1
tp32261
sS'of,modest,degree'
p32262
(F1
F0.00014334862385321102
I0
I1
I-1
tp32263
sS'amiodarone,should,be'
p32264
(F1
F0.00014334862385321102
I0
I1
I-1
tp32265
sS'racemic,did,not'
p32266
(F1
F0.00014334862385321102
I0
I1
I-1
tp32267
sS'peroral,administration,of'
p32268
(F1
F0.00014334862385321102
I0
I1
I-1
tp32269
sS'with,mg,followed'
p32270
(F1
F0.00014334862385321102
I0
I1
I-1
tp32271
sS'the,enzyme-inducing,properties'
p32272
(F1
F0.00014334862385321102
I1
I0
I1
tp32273
sS'may,increase,slightly'
p32274
(F1
F0.00014334862385321102
I1
I0
I1
tp32275
sS'dysfunction,associated,with'
p32276
(F1
F0.00014334862385321102
I0
I1
I-1
tp32277
sS'block,following,initial'
p32278
(F1
F0.00014334862385321102
I0
I1
I-1
tp32279
sS'with,amprenavir,and'
p32280
(F1
F0.00014334862385321102
I1
I0
I1
tp32281
sS'maleate,mg,tid'
p32282
(F1
F0.00014334862385321102
I1
I0
I1
tp32283
sS'and,the,occurrence'
p32284
(F1
F0.00014334862385321102
I1
I0
I1
tp32285
sS'the,coagulation,times'
p32286
(F1
F0.00014334862385321102
I0
I1
I-1
tp32287
sS'disease,and,ulcerative'
p32288
(F1
F0.00014334862385321102
I1
I0
I1
tp32289
sS'or,the,auc'
p32290
(F1
F0.00014334862385321102
I1
I0
I1
tp32291
sS'differences,in,prothrombin'
p32292
(F1
F0.00014334862385321102
I0
I1
I-1
tp32293
sS'enhance,the,inhibition'
p32294
(F1
F0.00014334862385321102
I1
I0
I1
tp32295
sS'exposure,to,environmental'
p32296
(F1
F0.00014334862385321102
I1
I0
I1
tp32297
sS'and,cystic,fluid'
p32298
(F1
F0.00014334862385321102
I1
I0
I1
tp32299
sS'the,mean,daily'
p32300
(F1
F0.00014334862385321102
I0
I1
I-1
tp32301
sS'patients,coadministered,oral'
p32302
(F1
F0.00014334862385321102
I1
I0
I1
tp32303
sS'of,with,celebrex'
p32304
(F1
F0.00014334862385321102
I1
I0
I1
tp32305
sS'of,were,and'
p32306
(F1
F0.00014334862385321102
I1
I0
I1
tp32307
sS'receive,adl,mg'
p32308
(F1
F0.00014334862385321102
I0
I1
I-1
tp32309
sS'and,can,reduce'
p32310
(F1
F0.00014334862385321102
I1
I0
I1
tp32311
sS'repeat,doses,of'
p32312
(F1
F0.00014334862385321102
I0
I1
I-1
tp32313
sS'inhibitor,produced,a'
p32314
(F1
F0.00014334862385321102
I1
I0
I1
tp32315
sS'effects,on,steady-state'
p32316
(F1
F0.00014334862385321102
I0
I1
I-1
tp32317
sS'to,the,muscle'
p32318
(F1
F0.00014334862385321102
I1
I0
I1
tp32319
sS'is,expected,based'
p32320
(F1
F0.00014334862385321102
I0
I1
I-1
tp32321
sS'majority,of,patients'
p32322
(F1
F0.00014334862385321102
I0
I1
I-1
tp32323
sS'study,of,rheumatoid'
p32324
(F1
F0.00014334862385321102
I0
I1
I-1
tp32325
sS'constriction,were,unaffected'
p32326
(F1
F0.00014334862385321102
I0
I1
I-1
tp32327
sS'a,month,controlled'
p32328
(F1
F0.00014334862385321102
I0
I1
I-1
tp32329
sS'mg,bid,were'
p32330
(F1
F0.00014334862385321102
I0
I1
I-1
tp32331
sS'of,sodium,was'
p32332
(F1
F0.00014334862385321102
I0
I1
I-1
tp32333
sS'of,agents,simultaneous'
p32334
(F1
F0.00014334862385321102
I1
I0
I1
tp32335
sS'between,ssris,and'
p32336
(F1
F0.00014334862385321102
I0
I1
I-1
tp32337
sS'i,d,produced'
p32338
(F1
F0.00028669724770642203
I2
I0
I2
tp32339
sS'reported,to,reduce'
p32340
(F1
F0.0011467889908256881
I8
I0
I8
tp32341
sS'rate,of,absorption'
p32342
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32343
sS'system,notably,oral'
p32344
(F1
F0.00014334862385321102
I1
I0
I1
tp32345
sS'patients,with,angina'
p32346
(F1
F0.00014334862385321102
I1
I0
I1
tp32347
sS'of,before,intramuscular'
p32348
(F1
F0.00014334862385321102
I1
I0
I1
tp32349
sS'mg,kg,weight'
p32350
(F1
F0.00014334862385321102
I1
I0
I1
tp32351
sS'therapy,may,not'
p32352
(F1
F0.00014334862385321102
I0
I1
I-1
tp32353
sS'properties,of,is'
p32354
(F1
F0.00014334862385321102
I0
I1
I-1
tp32355
sS'with,patients,should'
p32356
(F1
F0.00014334862385321102
I1
I0
I1
tp32357
sS'levo-dromoran,reported,to'
p32358
(F1
F0.00014334862385321102
I0
I1
I-1
tp32359
sS'concomitantly,administered,with'
p32360
(F1
F0.00014334862385321102
I0
I1
I-1
tp32361
sS'in,pcp,discrimination'
p32362
(F1
F0.00014334862385321102
I0
I1
I-1
tp32363
sS'reported,when,and'
p32364
(F1
F0.00014334862385321102
I1
I0
I1
tp32365
sS'corticosteroids,may,increase'
p32366
(F1
F0.00014334862385321102
I1
I0
I1
tp32367
sS'a,reduced,antihypertensive'
p32368
(F1
F0.00014334862385321102
I0
I1
I-1
tp32369
sS'with,potassium-sparing,or'
p32370
(F1
F0.00014334862385321102
I1
I0
I1
tp32371
sS'patients,in,whom'
p32372
(F1
F0.00014334862385321102
I0
I1
I-1
tp32373
sS'and,thiazide,may'
p32374
(F1
F0.00014334862385321102
I1
I0
I1
tp32375
sS'persist,for,a'
p32376
(F1
F0.00014334862385321102
I0
I1
I-1
tp32377
sS'and,following,single'
p32378
(F1
F0.00014334862385321102
I0
I1
I-1
tp32379
sS'be,carefully,considered'
p32380
(F1
F0.00014334862385321102
I1
I0
I1
tp32381
sS'as,or,large'
p32382
(F1
F0.00014334862385321102
I0
I1
I-1
tp32383
sS'k,antagonists,and'
p32384
(F1
F0.00028669724770642203
I0
I2
I-2
tp32385
sS'aim,and,background'
p32386
(F1
F0.00014334862385321102
I0
I1
I-1
tp32387
sS'other,in,patients'
p32388
(F1
F0.00014334862385321102
I0
I1
I-1
tp32389
sS'mg,with,multiple'
p32390
(F1
F0.00014334862385321102
I1
I0
I1
tp32391
sS'than,nanm,in'
p32392
(F1
F0.00014334862385321102
I0
I1
I-1
tp32393
sS'pharmacokinetic,analyses,revealed'
p32394
(F1
F0.00014334862385321102
I0
I1
I-1
tp32395
sS'im,reduced,the'
p32396
(F1
F0.00014334862385321102
I1
I0
I1
tp32397
sS'potent,a4,inhibitors'
p32398
(F1
F0.00014334862385321102
I1
I0
I1
tp32399
sS'atg,alg,mycophenolate'
p32400
(F1
F0.00014334862385321102
I0
I1
I-1
tp32401
sS'the,maintenance,dose'
p32402
(F1
F0.00014334862385321102
I1
I0
I1
tp32403
sS'oral,azole,inhibits'
p32404
(F1
F0.00014334862385321102
I1
I0
I1
tp32405
sS'of,tricyclic,and'
p32406
(F1
F0.00014334862385321102
I1
I0
I1
tp32407
sS'interactions,given,the'
p32408
(F1
F0.00014334862385321102
I1
I0
I1
tp32409
sS'of,ci,of'
p32410
(F1
F0.00014334862385321102
I0
I1
I-1
tp32411
sS'be,antagonistic,to'
p32412
(F1
F0.00014334862385321102
I1
I0
I1
tp32413
sS'fibrillation,their,additive'
p32414
(F1
F0.00014334862385321102
I1
I0
I1
tp32415
sS'of,the,combination'
p32416
(F1
F0.00014334862385321102
I0
I1
I-1
tp32417
sS'patients,and,dosage'
p32418
(F1
F0.00014334862385321102
I1
I0
I1
tp32419
sS'increases,the,plasma'
p32420
(F1
F0.00014334862385321102
I1
I0
I1
tp32421
sS'definite,nondepolarizing,blocking'
p32422
(F1
F0.00014334862385321102
I0
I1
I-1
tp32423
sS'concurrently,administered,antiepileptic'
p32424
(F1
F0.00014334862385321102
I1
I0
I1
tp32425
sS'potential,for,renal'
p32426
(F1
F0.00014334862385321102
I1
I0
I1
tp32427
sS'daily,may,result'
p32428
(F1
F0.00014334862385321102
I1
I0
I1
tp32429
sS'a,nonsteroidal,anti'
p32430
(F1
F0.00014334862385321102
I1
I0
I1
tp32431
sS'to,cause,increases'
p32432
(F1
F0.00028669724770642203
I0
I2
I-2
tp32433
sS'cholestyramine,has,been'
p32434
(F1
F0.00043004587155963305
I3
I0
I3
tp32435
sS'ototoxicity,is,enhanced'
p32436
(F1
F0.00014334862385321102
I1
I0
I1
tp32437
sS'to,cause,increased'
p32438
(F1
F0.00014334862385321102
I0
I1
I-1
tp32439
sS'mg,if,is'
p32440
(F1
F0.00014334862385321102
I1
I0
I1
tp32441
sS'test,was,measured'
p32442
(F1
F0.00014334862385321102
I0
I1
I-1
tp32443
sS'cyp3a4,is,a'
p32444
(F1
F0.00028669724770642203
I0
I2
I-2
tp32445
sS'conditions,or,was'
p32446
(F1
F0.00014334862385321102
I0
I1
I-1
tp32447
sS'in,plasma,and'
p32448
(F1
F0.00014334862385321102
I1
I0
I1
tp32449
sS'systematic,changes,in'
p32450
(F1
F0.00014334862385321102
I0
I1
I-1
tp32451
sS'who,are,found'
p32452
(F1
F0.00014334862385321102
I1
I0
I1
tp32453
sS'two-second,increase,in'
p32454
(F1
F0.00014334862385321102
I1
I0
I1
tp32455
sS'increase,in,systemic'
p32456
(F1
F0.00014334862385321102
I1
I0
I1
tp32457
sS'episodes,of,concomitant'
p32458
(F1
F0.00014334862385321102
I0
I1
I-1
tp32459
sS'beginning,discontinuing,or'
p32460
(F1
F0.00014334862385321102
I1
I0
I1
tp32461
sS'induce,the,metabolism'
p32462
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32463
sS'used,concomitantly,careful'
p32464
(F1
F0.00014334862385321102
I0
I1
I-1
tp32465
sS'beta-adrenergic,blockers,presumably'
p32466
(F1
F0.00014334862385321102
I1
I0
I1
tp32467
sS'agonists,has,not'
p32468
(F1
F0.00014334862385321102
I0
I1
I-1
tp32469
sS'etc,in,vitro'
p32470
(F1
F0.00014334862385321102
I1
I0
I1
tp32471
sS'mimicked,by,the'
p32472
(F1
F0.00014334862385321102
I0
I1
I-1
tp32473
sS'patients,on,warfarin-type'
p32474
(F1
F0.00014334862385321102
I1
I0
I1
tp32475
sS'other,metabolized,via'
p32476
(F0
F0
I1
I1
I0
tp32477
sS'a,standing,systolic'
p32478
(F1
F0.00057339449541284407
I4
I0
I4
tp32479
sS'cellular,basis,of'
p32480
(F1
F0.00014334862385321102
I0
I1
I-1
tp32481
sS'vardenafil,mg,in'
p32482
(F1
F0.00028669724770642203
I2
I0
I2
tp32483
sS'determined,by,consulting'
p32484
(F1
F0.00014334862385321102
I0
I1
I-1
tp32485
sS'demonstrated,that,inhibits'
p32486
(F1
F0.00014334862385321102
I0
I1
I-1
tp32487
sS'muscle,relaxant,effect'
p32488
(F1
F0.00014334862385321102
I1
I0
I1
tp32489
sS'not,alter,the'
p32490
(F0.88888888888888884
F0.0022935779816513763
I1
I17
I-16
tp32491
sS'additive,cns,depression'
p32492
(F1
F0.00028669724770642203
I2
I0
I2
tp32493
sS'nanm,were,more'
p32494
(F1
F0.00014334862385321102
I1
I0
I1
tp32495
sS'tnf-blocking,agents,including'
p32496
(F1
F0.00014334862385321102
I1
I0
I1
tp32497
sS'to,crixivan,or'
p32498
(F1
F0.00028669724770642203
I0
I2
I-2
tp32499
sS'reports,of,enhanced'
p32500
(F1
F0.00014334862385321102
I1
I0
I1
tp32501
sS'with,non-steroidal,the'
p32502
(F1
F0.00014334862385321102
I1
I0
I1
tp32503
sS'of,has,not'
p32504
(F1
F0.00043004587155963305
I0
I3
I-3
tp32505
sS'patients,this,may'
p32506
(F1
F0.00014334862385321102
I0
I1
I-1
tp32507
sS'ketoconazole,cyp3a4,is'
p32508
(F1
F0.00014334862385321102
I0
I1
I-1
tp32509
sS'frequently,enough,during'
p32510
(F1
F0.00014334862385321102
I1
I0
I1
tp32511
sS'for,when,coadministered'
p32512
(F1
F0.00014334862385321102
I1
I0
I1
tp32513
sS'progestational,such,as'
p32514
(F1
F0.00014334862385321102
I0
I1
I-1
tp32515
sS'regularly,for,changes'
p32516
(F1
F0.00014334862385321102
I0
I1
I-1
tp32517
sS'highly,bound,to'
p32518
(F1
F0.00014334862385321102
I1
I0
I1
tp32519
sS'cerubidine,should,not'
p32520
(F1
F0.00014334862385321102
I1
I0
I1
tp32521
sS'deet,toxicity,when'
p32522
(F1
F0.00014334862385321102
I0
I1
I-1
tp32523
sS'trials,no,interactions'
p32524
(F1
F0.00014334862385321102
I0
I1
I-1
tp32525
sS'of,by,increasing'
p32526
(F1
F0.00014334862385321102
I1
I0
I1
tp32527
sS'conditions,to,healthy'
p32528
(F1
F0.00014334862385321102
I0
I1
I-1
tp32529
sS'diphenhydramine,hydrochloride,has'
p32530
(F1
F0.00014334862385321102
I1
I0
I1
tp32531
sS'concomitant,therapy,in'
p32532
(F1
F0.00014334862385321102
I0
I1
I-1
tp32533
sS'reports,describing,patients'
p32534
(F1
F0.00014334862385321102
I1
I0
I1
tp32535
sS'causing,renin,release'
p32536
(F1
F0.00028669724770642203
I2
I0
I2
tp32537
sS'severe,cardiovascular,disease'
p32538
(F1
F0.00014334862385321102
I1
I0
I1
tp32539
sS'maximum,recommended,daily'
p32540
(F1
F0.00014334862385321102
I1
I0
I1
tp32541
sS'although,a,causal'
p32542
(F1
F0.00014334862385321102
I1
I0
I1
tp32543
sS'all,the,selective'
p32544
(F1
F0.00071674311926605509
I0
I5
I-5
tp32545
sS'excretion,is,markedly'
p32546
(F1
F0.00014334862385321102
I1
I0
I1
tp32547
sS'with,those,in'
p32548
(F1
F0.00014334862385321102
I0
I1
I-1
tp32549
sS'potentiated,by,nonbarbiturate'
p32550
(F1
F0.00014334862385321102
I1
I0
I1
tp32551
sS'liver,microsomes,indicate'
p32552
(F1
F0.00014334862385321102
I0
I1
I-1
tp32553
sS'both,and,prothrombin'
p32554
(F1
F0.00014334862385321102
I1
I0
I1
tp32555
sS'days,of,discontinuing'
p32556
(F1
F0.00014334862385321102
I1
I0
I1
tp32557
sS'inhibitors,of,hepatic'
p32558
(F1
F0.00014334862385321102
I1
I0
I1
tp32559
sS'concentration,should,be'
p32560
(F0
F0
I1
I1
I0
tp32561
sS'preparations,since,there'
p32562
(F1
F0.00014334862385321102
I1
I0
I1
tp32563
sS'with,the,simultaneous'
p32564
(F1
F0.00014334862385321102
I1
I0
I1
tp32565
sS'and,dose,adjustment'
p32566
(F1
F0.00014334862385321102
I1
I0
I1
tp32567
sS'fold,higher,than'
p32568
(F1
F0.00014334862385321102
I1
I0
I1
tp32569
sS'on,rare,occasions'
p32570
(F1
F0.00028669724770642203
I2
I0
I2
tp32571
sS'some,increase,the'
p32572
(F1
F0.00014334862385321102
I1
I0
I1
tp32573
sS'amphotericin,b,or'
p32574
(F1
F0.00043004587155963305
I0
I3
I-3
tp32575
sS'possibility,of,additive'
p32576
(F1
F0.00014334862385321102
I1
I0
I1
tp32577
sS'mean,arterial,pressure'
p32578
(F1
F0.00014334862385321102
I1
I0
I1
tp32579
sS'h2-antagonists,and,proton'
p32580
(F1
F0.00014334862385321102
I0
I1
I-1
tp32581
sS'mg,by,hours'
p32582
(F1
F0.00014334862385321102
I1
I0
I1
tp32583
sS'mediating,stimulus-induced,neural'
p32584
(F1
F0.00014334862385321102
I0
I1
I-1
tp32585
sS'approximately,in,subjects'
p32586
(F1
F0.00014334862385321102
I1
I0
I1
tp32587
sS'to,two,patients'
p32588
(F1
F0.00028669724770642203
I2
I0
I2
tp32589
sS'concentrations,reach,to10'
p32590
(F1
F0.00014334862385321102
I1
I0
I1
tp32591
sS'of,compounds,that'
p32592
(F1
F0.00014334862385321102
I1
I0
I1
tp32593
sS'of,arava,to'
p32594
(F1
F0.00014334862385321102
I1
I0
I1
tp32595
sS'responsiveness,of,an'
p32596
(F1
F0.00014334862385321102
I1
I0
I1
tp32597
sS'inhibitors,oral,channel'
p32598
(F1
F0.00014334862385321102
I0
I1
I-1
tp32599
sS'first,study,concomitant'
p32600
(F1
F0.00014334862385321102
I1
I0
I1
tp32601
sS'concomitantly,with,other'
p32602
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp32603
sS'exceed,a,maximum'
p32604
(F1
F0.00043004587155963305
I3
I0
I3
tp32605
sS'antacid,products,absorption'
p32606
(F1
F0.00014334862385321102
I0
I1
I-1
tp32607
sS'inhibiting,their,metabolism'
p32608
(F1
F0.00014334862385321102
I1
I0
I1
tp32609
sS'closely,and,appropriate'
p32610
(F0
F0
I1
I1
I0
tp32611
sS'chemotherapy,agents,no'
p32612
(F1
F0.00014334862385321102
I0
I1
I-1
tp32613
sS'poisoning,although,they'
p32614
(F1
F0.00014334862385321102
I1
I0
I1
tp32615
sS'a,cause-and,effect'
p32616
(F1
F0.00028669724770642203
I2
I0
I2
tp32617
sS'established,on,an'
p32618
(F1
F0.00014334862385321102
I0
I1
I-1
tp32619
sS'sprycel,and,that'
p32620
(F1
F0.00014334862385321102
I1
I0
I1
tp32621
sS'diclofenac,and,other'
p32622
(F1
F0.00014334862385321102
I1
I0
I1
tp32623
sS'metabolism,by,cyp2d6'
p32624
(F1
F0.00014334862385321102
I0
I1
I-1
tp32625
sS'magnitude,and,duration'
p32626
(F1
F0.00028669724770642203
I2
I0
I2
tp32627
sS'cholestyramine,cholestyramine,binds'
p32628
(F1
F0.00014334862385321102
I1
I0
I1
tp32629
sS'interferes,with,renal'
p32630
(F1
F0.00014334862385321102
I1
I0
I1
tp32631
sS'of,sodium,carboxymethylcellulose'
p32632
(F1
F0.00014334862385321102
I0
I1
I-1
tp32633
sS'anecdotal,reports,there'
p32634
(F1
F0.00014334862385321102
I1
I0
I1
tp32635
sS'to,affect,other'
p32636
(F1
F0.00028669724770642203
I0
I2
I-2
tp32637
sS'effect,was,noted'
p32638
(F1
F0.00014334862385321102
I1
I0
I1
tp32639
sS'to,hours,should'
p32640
(F1
F0.00014334862385321102
I1
I0
I1
tp32641
sS'enzyme,preparations,containing'
p32642
(F1
F0.00014334862385321102
I1
I0
I1
tp32643
sS'cimetidine,in,the'
p32644
(F1
F0.00014334862385321102
I1
I0
I1
tp32645
sS'received,or,is'
p32646
(F1
F0.00014334862385321102
I1
I0
I1
tp32647
sS'added,to,triple-immunosuppression'
p32648
(F1
F0.00014334862385321102
I0
I1
I-1
tp32649
sS'have,been,conducted'
p32650
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp32651
sS'appeared,to,influence'
p32652
(F1
F0.00014334862385321102
I1
I0
I1
tp32653
sS'perioperative,period,has'
p32654
(F1
F0.00014334862385321102
I1
I0
I1
tp32655
sS'with,difluoro-2,propanol'
p32656
(F1
F0.00014334862385321102
I1
I0
I1
tp32657
sS'used,in,external'
p32658
(F1
F0.00014334862385321102
I0
I1
I-1
tp32659
sS'epileptic,patients,n'
p32660
(F1
F0.00014334862385321102
I0
I1
I-1
tp32661
sS'following,interactions,have'
p32662
(F1
F0.00014334862385321102
I1
I0
I1
tp32663
sS'during,the,same'
p32664
(F1
F0.00014334862385321102
I0
I1
I-1
tp32665
sS'abilify,aripiprazole,is'
p32666
(F1
F0.00014334862385321102
I0
I1
I-1
tp32667
sS'of,on,clonidines'
p32668
(F1
F0.00014334862385321102
I0
I1
I-1
tp32669
sS'probably,for,as'
p32670
(F1
F0.00014334862385321102
I0
I1
I-1
tp32671
sS'avoid,intoxication,plasma'
p32672
(F1
F0.00014334862385321102
I0
I1
I-1
tp32673
sS'and,pharmacokinetic,results'
p32674
(F1
F0.00014334862385321102
I1
I0
I1
tp32675
sS'data,have,been'
p32676
(F1
F0.00014334862385321102
I0
I1
I-1
tp32677
sS'patients,administered,prior'
p32678
(F1
F0.00014334862385321102
I1
I0
I1
tp32679
sS'in,a,group'
p32680
(F1
F0.00014334862385321102
I0
I1
I-1
tp32681
sS'evaluating,the,minimum'
p32682
(F1
F0.00014334862385321102
I0
I1
I-1
tp32683
sS'potentially,arise,from'
p32684
(F1
F0.00014334862385321102
I1
I0
I1
tp32685
sS'and,a,fluoroquinolone'
p32686
(F1
F0.00014334862385321102
I1
I0
I1
tp32687
sS'on,especially,those'
p32688
(F1
F0.00028669724770642203
I2
I0
I2
tp32689
sS'high,trileptal,doses'
p32690
(F1
F0.00014334862385321102
I1
I0
I1
tp32691
sS'report,which,suggests'
p32692
(F1
F0.00014334862385321102
I1
I0
I1
tp32693
sS'units,day,or'
p32694
(F1
F0.00014334862385321102
I0
I1
I-1
tp32695
sS'oral,hypoglycemics,initiating'
p32696
(F1
F0.00014334862385321102
I0
I1
I-1
tp32697
sS'the,effect,should'
p32698
(F1
F0.00014334862385321102
I1
I0
I1
tp32699
sS'orally,imidazole,compounds'
p32700
(F1
F0.00014334862385321102
I1
I0
I1
tp32701
sS'blockade,may,occur'
p32702
(F1
F0.00014334862385321102
I1
I0
I1
tp32703
sS'blocking,agents,these'
p32704
(F1
F0.00014334862385321102
I0
I1
I-1
tp32705
sS'only,with,careful'
p32706
(F1
F0.00014334862385321102
I0
I1
I-1
tp32707
sS'mineral,oil,interferes'
p32708
(F1
F0.00014334862385321102
I1
I0
I1
tp32709
sS'in,a,decreased'
p32710
(F1
F0.00028669724770642203
I2
I0
I2
tp32711
sS'acetate,similarly,inhibit'
p32712
(F1
F0.00014334862385321102
I1
I0
I1
tp32713
sS'incoordination,when,coadministered'
p32714
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32715
sS'of,are,altered'
p32716
(F1
F0.00014334862385321102
I1
I0
I1
tp32717
sS'psychotropic,have,not'
p32718
(F1
F0.00014334862385321102
I1
I0
I1
tp32719
sS'regarding,protease,inhibitor'
p32720
(F1
F0.00014334862385321102
I0
I1
I-1
tp32721
sS'mg,a,substrate'
p32722
(F1
F0.00014334862385321102
I1
I0
I1
tp32723
sS'of,required,to'
p32724
(F1
F0.00014334862385321102
I1
I0
I1
tp32725
sS'when,coreg,is'
p32726
(F1
F0.00014334862385321102
I1
I0
I1
tp32727
sS'insulin,or,oral'
p32728
(F0
F0
I1
I1
I0
tp32729
sS'periods,with,alone'
p32730
(F1
F0.00014334862385321102
I0
I1
I-1
tp32731
sS'of,sprycel,with'
p32732
(F1
F0.00014334862385321102
I1
I0
I1
tp32733
sS'be,reviewed,for'
p32734
(F1
F0.00014334862385321102
I1
I0
I1
tp32735
sS'demonstrate,that,and'
p32736
(F1
F0.00014334862385321102
I0
I1
I-1
tp32737
sS'serum,potassium,levels'
p32738
(F1
F0.00014334862385321102
I1
I0
I1
tp32739
sS'the,side,effects'
p32740
(F0
F0
I2
I2
I0
tp32741
sS'or,other,hivid-associated'
p32742
(F1
F0.00014334862385321102
I1
I0
I1
tp32743
sS'treatment,of,a'
p32744
(F1
F0.00014334862385321102
I0
I1
I-1
tp32745
sS'long-term,studies,on'
p32746
(F1
F0.00014334862385321102
I0
I1
I-1
tp32747
sS'ethopropazine,can,interact'
p32748
(F1
F0.00014334862385321102
I1
I0
I1
tp32749
sS'reduced,by,acidifying'
p32750
(F1
F0.00028669724770642203
I2
I0
I2
tp32751
sS'significantly,increased,vasoconstriction'
p32752
(F1
F0.00014334862385321102
I1
I0
I1
tp32753
sS'taking,therapy,are'
p32754
(F1
F0.00014334862385321102
I1
I0
I1
tp32755
sS'with,beta-receptor,blockers'
p32756
(F1
F0.00014334862385321102
I0
I1
I-1
tp32757
sS'comparison,to,groups'
p32758
(F1
F0.00014334862385321102
I1
I0
I1
tp32759
sS'one,report,l-glutamine'
p32760
(F1
F0.00014334862385321102
I1
I0
I1
tp32761
sS'been,conflicting,results'
p32762
(F1
F0.00014334862385321102
I1
I0
I1
tp32763
sS'patients,receiving,coumarin-type'
p32764
(F1
F0.00014334862385321102
I1
I0
I1
tp32765
sS'respectively,and,did'
p32766
(F1
F0.00014334862385321102
I1
I0
I1
tp32767
sS'should,be,halved'
p32768
(F1
F0.00014334862385321102
I1
I0
I1
tp32769
sS'a,cyp2c19,substrate'
p32770
(F1
F0.00014334862385321102
I1
I0
I1
tp32771
sS'possible,dose,of'
p32772
(F1
F0.00014334862385321102
I1
I0
I1
tp32773
sS'clearance,of,busulfex'
p32774
(F1
F0.00014334862385321102
I1
I0
I1
tp32775
sS'of,interactions,in'
p32776
(F1
F0.00014334862385321102
I0
I1
I-1
tp32777
sS'with,the,morning'
p32778
(F1
F0.00014334862385321102
I0
I1
I-1
tp32779
sS'crixivan,and,other'
p32780
(F1
F0.00014334862385321102
I0
I1
I-1
tp32781
sS'in,animals,treated'
p32782
(F1
F0.00014334862385321102
I1
I0
I1
tp32783
sS'interval,were,measured'
p32784
(F1
F0.00014334862385321102
I0
I1
I-1
tp32785
sS'because,may,increase'
p32786
(F1
F0.00014334862385321102
I1
I0
I1
tp32787
sS'assessed,by,evaluating'
p32788
(F1
F0.00014334862385321102
I0
I1
I-1
tp32789
sS'serum,levels,were'
p32790
(F1
F0.00014334862385321102
I1
I0
I1
tp32791
sS'to,days,after'
p32792
(F1
F0.00028669724770642203
I2
I0
I2
tp32793
sS'beta,blockers,although'
p32794
(F1
F0.00014334862385321102
I1
I0
I1
tp32795
sS'associated,with,prostatectomy'
p32796
(F1
F0.00014334862385321102
I0
I1
I-1
tp32797
sS'orally,administered,by'
p32798
(F1
F0.00014334862385321102
I0
I1
I-1
tp32799
sS'with,other,cardioactive'
p32800
(F1
F0.00014334862385321102
I1
I0
I1
tp32801
sS'plasma,clearance,of'
p32802
(F1
F0.00014334862385321102
I1
I0
I1
tp32803
sS'prolonged,or,delayed'
p32804
(F1
F0.00014334862385321102
I1
I0
I1
tp32805
sS'protects,mouse,tumour'
p32806
(F1
F0.00014334862385321102
I1
I0
I1
tp32807
sS'injection,q12h,for'
p32808
(F1
F0.00014334862385321102
I0
I1
I-1
tp32809
sS'group,of,healthy'
p32810
(F1
F0.00014334862385321102
I0
I1
I-1
tp32811
sS'plasma,clearance,or'
p32812
(F1
F0.00014334862385321102
I0
I1
I-1
tp32813
sS'indifferent,for,strains'
p32814
(F1
F0.00014334862385321102
I1
I0
I1
tp32815
sS'ingesting,the,steady-state'
p32816
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32817
sS'is,given,concomitantly'
p32818
(F0.5
F0.00028669724770642203
I3
I1
I2
tp32819
sS'of,changes,in'
p32820
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp32821
sS'by,conjugation,through'
p32822
(F1
F0.00014334862385321102
I0
I1
I-1
tp32823
sS'and,the,resulting'
p32824
(F1
F0.00014334862385321102
I1
I0
I1
tp32825
sS'healthy,male,and'
p32826
(F1
F0.00043004587155963305
I0
I3
I-3
tp32827
sS'by,aom,and'
p32828
(F1
F0.00014334862385321102
I0
I1
I-1
tp32829
sS'haloperidol,reduced,or'
p32830
(F1
F0.00014334862385321102
I1
I0
I1
tp32831
sS'crossover,clinical,pharmacology'
p32832
(F1
F0.00014334862385321102
I0
I1
I-1
tp32833
sS'and,quinolones,form'
p32834
(F1
F0.00014334862385321102
I0
I1
I-1
tp32835
sS'therapy,with,betagan'
p32836
(F1
F0.00014334862385321102
I1
I0
I1
tp32837
sS'patients,in,a'
p32838
(F1
F0.00028669724770642203
I2
I0
I2
tp32839
sS'ermbt,and,and'
p32840
(F1
F0.00014334862385321102
I0
I1
I-1
tp32841
sS'and,bezalip,retard'
p32842
(F1
F0.00014334862385321102
I1
I0
I1
tp32843
sS'given,the,enzyme-inducing'
p32844
(F1
F0.00014334862385321102
I1
I0
I1
tp32845
sS'of,active,vomiting'
p32846
(F1
F0.00014334862385321102
I1
I0
I1
tp32847
sS'induced,hypertension,were'
p32848
(F1
F0.00014334862385321102
I0
I1
I-1
tp32849
sS'the,electrocardiographic,qt'
p32850
(F1
F0.00014334862385321102
I0
I1
I-1
tp32851
sS'heroin-related,deaths,reveal'
p32852
(F1
F0.00014334862385321102
I1
I0
I1
tp32853
sS'in,subjects,who'
p32854
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32855
sS'effects,on,either'
p32856
(F1
F0.00028669724770642203
I0
I2
I-2
tp32857
sS'with,antihypertensive,agents'
p32858
(F1
F0.00014334862385321102
I1
I0
I1
tp32859
sS'supplementation,mg,kg'
p32860
(F1
F0.00014334862385321102
I0
I1
I-1
tp32861
sS'excretion,of,is'
p32862
(F1
F0.00071674311926605509
I5
I0
I5
tp32863
sS'curve,of,sulfoxide'
p32864
(F1
F0.00014334862385321102
I1
I0
I1
tp32865
sS'by,and,respectively'
p32866
(F1
F0.0010034403669724771
I7
I0
I7
tp32867
sS'amphetamines,may,decrease'
p32868
(F1
F0.00014334862385321102
I1
I0
I1
tp32869
sS'ms,contin,prelone'
p32870
(F1
F0.00014334862385321102
I1
I0
I1
tp32871
sS'a,patient,on'
p32872
(F1
F0.00028669724770642203
I2
I0
I2
tp32873
sS'which,can,lead'
p32874
(F1
F0.00014334862385321102
I1
I0
I1
tp32875
sS'not,induce,cyp1a2'
p32876
(F1
F0.00014334862385321102
I0
I1
I-1
tp32877
sS'administered,concomitantly,without'
p32878
(F1
F0.00014334862385321102
I0
I1
I-1
tp32879
sS'be,administered,until'
p32880
(F1
F0.00014334862385321102
I1
I0
I1
tp32881
sS'of,is,inhibited'
p32882
(F1
F0.00014334862385321102
I1
I0
I1
tp32883
sS'quantities,of,grapefruit'
p32884
(F1
F0.00014334862385321102
I0
I1
I-1
tp32885
sS'outweigh,the,risks'
p32886
(F1
F0.00028669724770642203
I2
I0
I2
tp32887
sS'sn38,the,active'
p32888
(F1
F0.00014334862385321102
I0
I1
I-1
tp32889
sS'as,systemic,levels'
p32890
(F1
F0.00014334862385321102
I0
I1
I-1
tp32891
sS'as,which,sensitize'
p32892
(F1
F0.00014334862385321102
I1
I0
I1
tp32893
sS'more,severe,structural'
p32894
(F1
F0.00014334862385321102
I0
I1
I-1
tp32895
sS'mg,kg,once'
p32896
(F1
F0.00028669724770642203
I0
I2
I-2
tp32897
sS'trials,similar,changes'
p32898
(F1
F0.00014334862385321102
I0
I1
I-1
tp32899
sS'effectiveness,against,multidrug-resistant'
p32900
(F1
F0.00014334862385321102
I0
I1
I-1
tp32901
sS'studies,including,normal'
p32902
(F1
F0.00014334862385321102
I0
I1
I-1
tp32903
sS'the,bioavailability,of'
p32904
(F0.33333333333333331
F0.00057339449541284407
I4
I8
I-4
tp32905
sS'been,no,reported'
p32906
(F1
F0.00014334862385321102
I0
I1
I-1
tp32907
sS'in,oa,patients'
p32908
(F1
F0.00014334862385321102
I0
I1
I-1
tp32909
sS'is,lengthened,and'
p32910
(F1
F0.00014334862385321102
I1
I0
I1
tp32911
sS'pharmacodynamic,profile,of'
p32912
(F1
F0.00014334862385321102
I0
I1
I-1
tp32913
sS'keppra,on,was'
p32914
(F1
F0.00014334862385321102
I0
I1
I-1
tp32915
sS'on,drug,metabolizing'
p32916
(F1
F0.00014334862385321102
I0
I1
I-1
tp32917
sS'study,administration,of'
p32918
(F1
F0.00014334862385321102
I1
I0
I1
tp32919
sS'to,to,mg'
p32920
(F1
F0.00028669724770642203
I0
I2
I-2
tp32921
sS'to,but,not'
p32922
(F1
F0.00014334862385321102
I1
I0
I1
tp32923
sS'g,m2,dose'
p32924
(F1
F0.00014334862385321102
I0
I1
I-1
tp32925
sS'levels,and,weight'
p32926
(F1
F0.00014334862385321102
I1
I0
I1
tp32927
sS'including,nonsteroidal,agents'
p32928
(F1
F0.00043004587155963305
I3
I0
I3
tp32929
sS'of,symptoms,termed'
p32930
(F1
F0.00014334862385321102
I1
I0
I1
tp32931
sS'with,that,may'
p32932
(F1
F0.00014334862385321102
I1
I0
I1
tp32933
sS'from,in,the'
p32934
(F1
F0.00028669724770642203
I0
I2
I-2
tp32935
sS'due,to,potential'
p32936
(F1
F0.00057339449541284407
I0
I4
I-4
tp32937
sS'buspirone,hydrochloride,not'
p32938
(F1
F0.00014334862385321102
I1
I0
I1
tp32939
sS'to,fivefold,increase'
p32940
(F1
F0.00014334862385321102
I0
I1
I-1
tp32941
sS'an,anionic-binding,has'
p32942
(F1
F0.00014334862385321102
I1
I0
I1
tp32943
sS'ed95,nimbex,at'
p32944
(F1
F0.00014334862385321102
I1
I0
I1
tp32945
sS'back-up,methods,of'
p32946
(F1
F0.00014334862385321102
I1
I0
I1
tp32947
sS'during,videx,therapy'
p32948
(F1
F0.00014334862385321102
I0
I1
I-1
tp32949
sS'arava,and,were'
p32950
(F1
F0.00014334862385321102
I1
I0
I1
tp32951
sS'or,substances,the'
p32952
(F1
F0.00014334862385321102
I1
I0
I1
tp32953
sS'controlled,clinical,trials'
p32954
(F1
F0.00028669724770642203
I0
I2
I-2
tp32955
sS'to,prevent,excessive'
p32956
(F1
F0.00014334862385321102
I1
I0
I1
tp32957
sS'humira,has,not'
p32958
(F1
F0.00014334862385321102
I0
I1
I-1
tp32959
sS'cells,whereas,the'
p32960
(F1
F0.00014334862385321102
I0
I1
I-1
tp32961
sS'enalapril,and,iv'
p32962
(F0
F0
I1
I1
I0
tp32963
sS'so,careful,monitoring'
p32964
(F1
F0.00014334862385321102
I1
I0
I1
tp32965
sS'predictable,sympathetic,effects'
p32966
(F1
F0.00014334862385321102
I1
I0
I1
tp32967
sS'potently,inhibits,the'
p32968
(F1
F0.00028669724770642203
I2
I0
I2
tp32969
sS'matulane,eldepryl,and'
p32970
(F1
F0.00014334862385321102
I0
I1
I-1
tp32971
sS'hepatic,microsomal,enzyme'
p32972
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp32973
sS'rings,from,high-estradiol'
p32974
(F1
F0.00014334862385321102
I1
I0
I1
tp32975
sS'be,at,least'
p32976
(F1
F0.00014334862385321102
I1
I0
I1
tp32977
sS'including,dry,mouth'
p32978
(F1
F0.00014334862385321102
I1
I0
I1
tp32979
sS'increased,the,c'
p32980
(F1
F0.00014334862385321102
I1
I0
I1
tp32981
sS'iodide,i131,a'
p32982
(F1
F0.00014334862385321102
I1
I0
I1
tp32983
sS'of,hydroxylamine,a'
p32984
(F1
F0.00014334862385321102
I0
I1
I-1
tp32985
sS'oral,upon,beginning'
p32986
(F1
F0.00014334862385321102
I1
I0
I1
tp32987
sS'heparins,effect,on'
p32988
(F1
F0.00014334862385321102
I0
I1
I-1
tp32989
sS'or,or,supplements'
p32990
(F1
F0.00014334862385321102
I0
I1
I-1
tp32991
sS'with,other,such'
p32992
(F0
F0
I1
I1
I0
tp32993
sS'all,with,the'
p32994
(F1
F0.00014334862385321102
I1
I0
I1
tp32995
sS'to,obstetric,blocks'
p32996
(F0
F0
I1
I1
I0
tp32997
sS'type,it,is'
p32998
(F1
F0.00014334862385321102
I1
I0
I1
tp32999
sS'in,healthy,individuals'
p33000
(F1
F0.00014334862385321102
I1
I0
I1
tp33001
sS'studies,demonstrated,no'
p33002
(F1
F0.00014334862385321102
I0
I1
I-1
tp33003
sS'of,after,a'
p33004
(F1
F0.00014334862385321102
I0
I1
I-1
tp33005
sS'serum,creatinine,in'
p33006
(F1
F0.00028669724770642203
I2
I0
I2
tp33007
sS'the,introduction,of'
p33008
(F1
F0.00014334862385321102
I1
I0
I1
tp33009
sS'with,may,increase'
p33010
(F1
F0.0008600917431192661
I6
I0
I6
tp33011
sS'a,cyp3a4,inducer'
p33012
(F1
F0.00014334862385321102
I0
I1
I-1
tp33013
sS'depressants,using,these'
p33014
(F1
F0.00014334862385321102
I1
I0
I1
tp33015
sS'and,could,have'
p33016
(F1
F0.00014334862385321102
I0
I1
I-1
tp33017
sS'from,ng,ml'
p33018
(F1
F0.00014334862385321102
I0
I1
I-1
tp33019
sS'were,receiving,beta'
p33020
(F1
F0.00014334862385321102
I0
I1
I-1
tp33021
sS'may,lead,to'
p33022
(F0.40000000000000002
F0.00057339449541284407
I3
I7
I-4
tp33023
sS'toradoliv,im,has'
p33024
(F1
F0.00014334862385321102
I0
I1
I-1
tp33025
sS'have,erroneously,low'
p33026
(F1
F0.00014334862385321102
I1
I0
I1
tp33027
sS'induction,thus,leading'
p33028
(F1
F0.00014334862385321102
I1
I0
I1
tp33029
sS'expected,lasma,concentrations'
p33030
(F1
F0.00014334862385321102
I0
I1
I-1
tp33031
sS'either,due,to'
p33032
(F1
F0.00014334862385321102
I0
I1
I-1
tp33033
sS'with,or,placebo'
p33034
(F1
F0.00014334862385321102
I0
I1
I-1
tp33035
sS'groups,of,patients'
p33036
(F1
F0.00014334862385321102
I0
I1
I-1
tp33037
sS'additive,effect,in'
p33038
(F1
F0.00014334862385321102
I1
I0
I1
tp33039
sS'initial,dosage,should'
p33040
(F1
F0.00014334862385321102
I1
I0
I1
tp33041
sS'since,does,not'
p33042
(F1
F0.00014334862385321102
I0
I1
I-1
tp33043
sS'of,its,lack'
p33044
(F1
F0.00043004587155963305
I0
I3
I-3
tp33045
sS'with,such,the'
p33046
(F1
F0.00014334862385321102
I0
I1
I-1
tp33047
sS'and,renal,function'
p33048
(F1
F0.00057339449541284407
I4
I0
I4
tp33049
sS'can,inhibit,adrenal'
p33050
(F1
F0.00014334862385321102
I1
I0
I1
tp33051
sS'with,metabolism,very'
p33052
(F1
F0.00014334862385321102
I0
I1
I-1
tp33053
sS'agents,pharmacokinetic,drug-drug'
p33054
(F1
F0.00014334862385321102
I0
I1
I-1
tp33055
sS'quinolones,including,nalidixic'
p33056
(F1
F0.00014334862385321102
I1
I0
I1
tp33057
sS'toxicity,at,lower'
p33058
(F1
F0.00014334862385321102
I1
I0
I1
tp33059
sS'the,peritoneal,cavity'
p33060
(F1
F0.00014334862385321102
I0
I1
I-1
tp33061
sS'and,also,increased'
p33062
(F1
F0.00014334862385321102
I1
I0
I1
tp33063
sS'an,angiotensin-converting,enzyme'
p33064
(F1
F0.00014334862385321102
I1
I0
I1
tp33065
sS'prolongation,and,an'
p33066
(F1
F0.00014334862385321102
I0
I1
I-1
tp33067
sS'spontaneous,reports,of'
p33068
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33069
sS'of,is,enhanced'
p33070
(F1
F0.00028669724770642203
I2
I0
I2
tp33071
sS'the,divided,attention'
p33072
(F1
F0.00014334862385321102
I1
I0
I1
tp33073
sS'is,important,that'
p33074
(F1
F0.00014334862385321102
I0
I1
I-1
tp33075
sS'of,by,possibly'
p33076
(F1
F0.00014334862385321102
I1
I0
I1
tp33077
sS'general,agents,and'
p33078
(F1
F0.00014334862385321102
I0
I1
I-1
tp33079
sS'consideration,in,patients'
p33080
(F1
F0.0010034403669724771
I7
I0
I7
tp33081
sS'inhibitors,result,in'
p33082
(F1
F0.00014334862385321102
I1
I0
I1
tp33083
sS'decrease,in,mean'
p33084
(F1
F0.00028669724770642203
I2
I0
I2
tp33085
sS'risk,of,gi'
p33086
(F1
F0.00014334862385321102
I1
I0
I1
tp33087
sS'reduced,as,much'
p33088
(F1
F0.00014334862385321102
I0
I1
I-1
tp33089
sS'potential,for,interactions'
p33090
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp33091
sS'occur,with,concomitant'
p33092
(F1
F0.00014334862385321102
I1
I0
I1
tp33093
sS'treated,with,either'
p33094
(F1
F0.00014334862385321102
I1
I0
I1
tp33095
sS'absorption,of,administered'
p33096
(F1
F0.00014334862385321102
I0
I1
I-1
tp33097
sS'exposure,presumably,by'
p33098
(F1
F0.00014334862385321102
I1
I0
I1
tp33099
sS'lithium,generally,should'
p33100
(F1
F0.00071674311926605509
I5
I0
I5
tp33101
sS'phosphorylation,in,tumor'
p33102
(F1
F0.00014334862385321102
I0
I1
I-1
tp33103
sS'up,to,days'
p33104
(F0
F0
I1
I1
I0
tp33105
sS'a,novel,purification'
p33106
(F1
F0.00014334862385321102
I0
I1
I-1
tp33107
sS'the,changes,in'
p33108
(F1
F0.00028669724770642203
I0
I2
I-2
tp33109
sS'design,that,have'
p33110
(F1
F0.00014334862385321102
I1
I0
I1
tp33111
sS'the,oral,self-administration'
p33112
(F1
F0.00014334862385321102
I0
I1
I-1
tp33113
sS'the,cautious,initiation'
p33114
(F1
F0.00014334862385321102
I1
I0
I1
tp33115
sS'can,exert,additive'
p33116
(F1
F0.00014334862385321102
I0
I1
I-1
tp33117
sS'and,other,pharmacokinetics'
p33118
(F1
F0.00014334862385321102
I1
I0
I1
tp33119
sS'the,clinical,use'
p33120
(F1
F0.00014334862385321102
I1
I0
I1
tp33121
sS'with,pulmonary,arterial'
p33122
(F1
F0.00014334862385321102
I0
I1
I-1
tp33123
sS'desyrel,and,buspirone'
p33124
(F1
F0.00014334862385321102
I1
I0
I1
tp33125
sS'each,study,there'
p33126
(F1
F0.00014334862385321102
I0
I1
I-1
tp33127
sS'hmgcoa,reductase,inhibitor'
p33128
(F1
F0.00014334862385321102
I0
I1
I-1
tp33129
sS'argatroban,is,to'
p33130
(F1
F0.00014334862385321102
I0
I1
I-1
tp33131
sS'stimulation,is,potentiated'
p33132
(F1
F0.00028669724770642203
I2
I0
I2
tp33133
sS'poor,metabolizers,with'
p33134
(F1
F0.00028669724770642203
I0
I2
I-2
tp33135
sS'are,unknown,slightly'
p33136
(F1
F0.00014334862385321102
I1
I0
I1
tp33137
sS'thyroid,physiology,the'
p33138
(F1
F0.00014334862385321102
I0
I1
I-1
tp33139
sS'mechanisms,involving,inhibition'
p33140
(F1
F0.00014334862385321102
I1
I0
I1
tp33141
sS'luteinizing,hormone,and'
p33142
(F1
F0.00014334862385321102
I0
I1
I-1
tp33143
sS'one,mg,capsule'
p33144
(F1
F0.00014334862385321102
I0
I1
I-1
tp33145
sS'as,methyltetrahydro-folate,and'
p33146
(F1
F0.00014334862385321102
I0
I1
I-1
tp33147
sS'state,conditions,to'
p33148
(F1
F0.00014334862385321102
I0
I1
I-1
tp33149
sS'alert,clinicians,to'
p33150
(F1
F0.00014334862385321102
I1
I0
I1
tp33151
sS'hcl,is,administered'
p33152
(F1
F0.00028669724770642203
I2
I0
I2
tp33153
sS'antidepressants,amphetamines,may'
p33154
(F1
F0.00028669724770642203
I2
I0
I2
tp33155
sS'with,mg,once'
p33156
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp33157
sS'clinically,relevant,consequences'
p33158
(F1
F0.00014334862385321102
I1
I0
I1
tp33159
sS'sympathetic,activity,ganglionic'
p33160
(F1
F0.00014334862385321102
I0
I1
I-1
tp33161
sS'and,torsades,de'
p33162
(F0
F0
I1
I1
I0
tp33163
sS'the,and,increased'
p33164
(F1
F0.00014334862385321102
I1
I0
I1
tp33165
sS'effects,of,but'
p33166
(F1
F0.00028669724770642203
I2
I0
I2
tp33167
sS'for,to,interact'
p33168
(F1
F0.00014334862385321102
I0
I1
I-1
tp33169
sS'in,vitro,data'
p33170
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp33171
sS'was,tested,by'
p33172
(F1
F0.00014334862385321102
I0
I1
I-1
tp33173
sS'individuals,plasma,concentrations'
p33174
(F1
F0.00014334862385321102
I1
I0
I1
tp33175
sS'pathway,suggesting,that'
p33176
(F1
F0.00014334862385321102
I0
I1
I-1
tp33177
sS'and,nonclinical,studies'
p33178
(F1
F0.00014334862385321102
I0
I1
I-1
tp33179
sS'receiving,both,agents'
p33180
(F1
F0.00014334862385321102
I0
I1
I-1
tp33181
sS'a,case,of'
p33182
(F0
F0
I1
I1
I0
tp33183
sS'and,symptoms,suggestive'
p33184
(F1
F0.00014334862385321102
I1
I0
I1
tp33185
sS'vitro,anti-cryptosporidial,activity'
p33186
(F1
F0.00014334862385321102
I0
I1
I-1
tp33187
sS'in,the,steady'
p33188
(F1
F0.00014334862385321102
I0
I1
I-1
tp33189
sS'nonsteroidal,probably,reduces'
p33190
(F1
F0.00014334862385321102
I1
I0
I1
tp33191
sS'the,patient,was'
p33192
(F1
F0.00043004587155963305
I0
I3
I-3
tp33193
sS'later,changed,to'
p33194
(F1
F0.00014334862385321102
I0
I1
I-1
tp33195
sS'least,two,weeks'
p33196
(F1
F0.00014334862385321102
I1
I0
I1
tp33197
sS'for,the,effect'
p33198
(F1
F0.00014334862385321102
I1
I0
I1
tp33199
sS'and,minutes,to'
p33200
(F1
F0.00014334862385321102
I0
I1
I-1
tp33201
sS'concurrently,with,since'
p33202
(F1
F0.00014334862385321102
I1
I0
I1
tp33203
sS'at,doses,above'
p33204
(F1
F0.00014334862385321102
I1
I0
I1
tp33205
sS'from,plasma,albumin'
p33206
(F1
F0.00014334862385321102
I1
I0
I1
tp33207
sS'could,theoretically,adversely'
p33208
(F1
F0.00014334862385321102
I1
I0
I1
tp33209
sS'fluoroquinolone,has,been'
p33210
(F1
F0.00014334862385321102
I1
I0
I1
tp33211
sS'with,heart,failure'
p33212
(F1
F0.00028669724770642203
I0
I2
I-2
tp33213
sS'on,certain,microsomal'
p33214
(F1
F0.00014334862385321102
I1
I0
I1
tp33215
sS'normal,subjects,with'
p33216
(F1
F0.00014334862385321102
I1
I0
I1
tp33217
sS'reports,regarding,the'
p33218
(F1
F0.00014334862385321102
I0
I1
I-1
tp33219
sS'pcp,in,either'
p33220
(F1
F0.00014334862385321102
I0
I1
I-1
tp33221
sS'a,agent,has'
p33222
(F1
F0.00014334862385321102
I1
I0
I1
tp33223
sS'even,so,plasma'
p33224
(F1
F0.00014334862385321102
I1
I0
I1
tp33225
sS'the,oral,combination'
p33226
(F1
F0.00014334862385321102
I1
I0
I1
tp33227
sS'warfarin,the,effect'
p33228
(F1
F0.00028669724770642203
I0
I2
I-2
tp33229
sS'high,intraperitoneal,doses'
p33230
(F1
F0.00014334862385321102
I1
I0
I1
tp33231
sS'intrinsic,effect,its'
p33232
(F1
F0.00014334862385321102
I1
I0
I1
tp33233
sS'under,steady-state,conditions'
p33234
(F1
F0.00028669724770642203
I0
I2
I-2
tp33235
sS'a,period,of'
p33236
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33237
sS'reported,that,may'
p33238
(F1
F0.00014334862385321102
I1
I0
I1
tp33239
sS'for,days,while'
p33240
(F1
F0.00014334862385321102
I1
I0
I1
tp33241
sS'testing,and,reaction'
p33242
(F1
F0.00014334862385321102
I1
I0
I1
tp33243
sS'vasospasm,and,its'
p33244
(F1
F0.00014334862385321102
I1
I0
I1
tp33245
sS'response,and,adverse'
p33246
(F1
F0.00014334862385321102
I0
I1
I-1
tp33247
sS'cyp2d6,sensipar,is'
p33248
(F1
F0.00014334862385321102
I0
I1
I-1
tp33249
sS'enzymes,bun,and'
p33250
(F1
F0.00014334862385321102
I1
I0
I1
tp33251
sS'and,that,is'
p33252
(F1
F0.00014334862385321102
I0
I1
I-1
tp33253
sS'possible,additive,effects'
p33254
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp33255
sS'overall,direct,treatment'
p33256
(F1
F0.00014334862385321102
I0
I1
I-1
tp33257
sS'adrenergic,antagonists,because'
p33258
(F1
F0.00014334862385321102
I1
I0
I1
tp33259
sS'major,membrane,sterol'
p33260
(F1
F0.00014334862385321102
I0
I1
I-1
tp33261
sS'however,possible,that'
p33262
(F1
F0.00014334862385321102
I1
I0
I1
tp33263
sS'interactions,is,summarized'
p33264
(F1
F0.00014334862385321102
I0
I1
I-1
tp33265
sS'be,exercised,during'
p33266
(F1
F0.00014334862385321102
I1
I0
I1
tp33267
sS'of,probenecid,probenecid'
p33268
(F1
F0.00014334862385321102
I0
I1
I-1
tp33269
sS'last,two,hours'
p33270
(F1
F0.00014334862385321102
I0
I1
I-1
tp33271
sS'are,not,receiving'
p33272
(F1
F0.00014334862385321102
I1
I0
I1
tp33273
sS'retard,and,then'
p33274
(F1
F0.00014334862385321102
I1
I0
I1
tp33275
sS'dose-related,increase,in'
p33276
(F1
F0.00014334862385321102
I1
I0
I1
tp33277
sS'were,increased,in'
p33278
(F1
F0.00014334862385321102
I0
I1
I-1
tp33279
sS'and,formulations,containing'
p33280
(F1
F0.00014334862385321102
I1
I0
I1
tp33281
sS'since,the,arrival'
p33282
(F1
F0.00014334862385321102
I0
I1
I-1
tp33283
sS'ketoconazole,increased,mean'
p33284
(F1
F0.00014334862385321102
I1
I0
I1
tp33285
sS'following,or,h'
p33286
(F1
F0.00014334862385321102
I1
I0
I1
tp33287
sS'toxicity,of,various'
p33288
(F1
F0.00014334862385321102
I0
I1
I-1
tp33289
sS'standard,cystic,fibrosis'
p33290
(F1
F0.00014334862385321102
I0
I1
I-1
tp33291
sS'co-administered,to,steady'
p33292
(F1
F0.00014334862385321102
I1
I0
I1
tp33293
sS'currently,available,and'
p33294
(F1
F0.00014334862385321102
I0
I1
I-1
tp33295
sS'when,bezalip,or'
p33296
(F1
F0.00028669724770642203
I2
I0
I2
tp33297
sS'in,the,duodenum'
p33298
(F1
F0.00014334862385321102
I0
I1
I-1
tp33299
sS'pattern,of,deficit'
p33300
(F1
F0.00014334862385321102
I0
I1
I-1
tp33301
sS'disorders,has,been'
p33302
(F1
F0.00014334862385321102
I1
I0
I1
tp33303
sS'therefore,a,starting'
p33304
(F1
F0.00014334862385321102
I0
I1
I-1
tp33305
sS'a,has,been'
p33306
(F1
F0.00014334862385321102
I1
I0
I1
tp33307
sS'inhalation,device,and'
p33308
(F1
F0.00014334862385321102
I0
I1
I-1
tp33309
sS'as,a,metabolite'
p33310
(F1
F0.00028669724770642203
I2
I0
I2
tp33311
sS'been,conducted,with'
p33312
(F0
F0
I1
I1
I0
tp33313
sS'in,the,preparation'
p33314
(F1
F0.00014334862385321102
I1
I0
I1
tp33315
sS'the,herbal,supplement'
p33316
(F1
F0.00014334862385321102
I0
I1
I-1
tp33317
sS'of,responses,with'
p33318
(F1
F0.00014334862385321102
I0
I1
I-1
tp33319
sS'the,patients,liver'
p33320
(F1
F0.00014334862385321102
I1
I0
I1
tp33321
sS'increased,if,and'
p33322
(F1
F0.00014334862385321102
I1
I0
I1
tp33323
sS'with,did,not'
p33324
(F1
F0.00014334862385321102
I0
I1
I-1
tp33325
sS'with,habituating,potential'
p33326
(F1
F0.00014334862385321102
I0
I1
I-1
tp33327
sS'response,to,toxoids'
p33328
(F1
F0.00014334862385321102
I1
I0
I1
tp33329
sS'the,ames,n-multistix'
p33330
(F1
F0.00014334862385321102
I0
I1
I-1
tp33331
sS'nor,retinyl,acetate'
p33332
(F1
F0.00014334862385321102
I1
I0
I1
tp33333
sS'can,be,effectively'
p33334
(F1
F0.00014334862385321102
I0
I1
I-1
tp33335
sS'pregnancy,and,fetal'
p33336
(F1
F0.00014334862385321102
I0
I1
I-1
tp33337
sS'elevated,serum,levels'
p33338
(F1
F0.0012901376146788992
I9
I0
I9
tp33339
sS'table,effects,on'
p33340
(F1
F0.00028669724770642203
I0
I2
I-2
tp33341
sS'either,or,kineret'
p33342
(F1
F0.00014334862385321102
I0
I1
I-1
tp33343
sS'weeks,should,be'
p33344
(F1
F0.00014334862385321102
I1
I0
I1
tp33345
sS'and,by,decreasing'
p33346
(F1
F0.00014334862385321102
I1
I0
I1
tp33347
sS'activity,persists,as'
p33348
(F1
F0.00014334862385321102
I1
I0
I1
tp33349
sS'tambocor,clinical,trials'
p33350
(F1
F0.00014334862385321102
I0
I1
I-1
tp33351
sS'the,oral,and'
p33352
(F1
F0.00028669724770642203
I2
I0
I2
tp33353
sS'immune,response,suggest'
p33354
(F1
F0.00014334862385321102
I0
I1
I-1
tp33355
sS'co-administration,of,did'
p33356
(F1
F0.00014334862385321102
I0
I1
I-1
tp33357
sS'the-curve,after,a'
p33358
(F1
F0.00014334862385321102
I1
I0
I1
tp33359
sS'agents,in,a'
p33360
(F1
F0.00014334862385321102
I0
I1
I-1
tp33361
sS'the,fraction,of'
p33362
(F1
F0.00014334862385321102
I0
I1
I-1
tp33363
sS'and,mesenteric,vasodilation'
p33364
(F0
F0
I1
I1
I0
tp33365
sS'reversible,upon,discontinuation'
p33366
(F1
F0.00014334862385321102
I1
I0
I1
tp33367
sS'to,fold,and'
p33368
(F1
F0.00028669724770642203
I2
I0
I2
tp33369
sS'of,this,oral'
p33370
(F1
F0.00014334862385321102
I0
I1
I-1
tp33371
sS'and,l-ccg,on'
p33372
(F1
F0.00014334862385321102
I0
I1
I-1
tp33373
sS'usp,has,not'
p33374
(F1
F0.00014334862385321102
I0
I1
I-1
tp33375
sS'via,the,activation'
p33376
(F1
F0.00014334862385321102
I0
I1
I-1
tp33377
sS'as,from,their'
p33378
(F1
F0.00014334862385321102
I1
I0
I1
tp33379
sS'synthesis,it,has'
p33380
(F1
F0.00014334862385321102
I1
I0
I1
tp33381
sS'ages,to,years'
p33382
(F1
F0.00014334862385321102
I1
I0
I1
tp33383
sS'cyp3a4,substrate,administered'
p33384
(F1
F0.00014334862385321102
I0
I1
I-1
tp33385
sS'that,inhibit,both'
p33386
(F1
F0.00014334862385321102
I1
I0
I1
tp33387
sS'of,caused,subnormal'
p33388
(F1
F0.00014334862385321102
I0
I1
I-1
tp33389
sS'patients,demonstrated,a'
p33390
(F1
F0.00014334862385321102
I1
I0
I1
tp33391
sS'of,release,in'
p33392
(F1
F0.00014334862385321102
I0
I1
I-1
tp33393
sS'regimen,plus,haart'
p33394
(F1
F0.00014334862385321102
I0
I1
I-1
tp33395
sS'at,the,same'
p33396
(F1
F0.00014334862385321102
I1
I0
I1
tp33397
sS'the,same,dose'
p33398
(F1
F0.00028669724770642203
I2
I0
I2
tp33399
sS'ca,subtypes,by'
p33400
(F1
F0.00014334862385321102
I0
I1
I-1
tp33401
sS'baraclude,with,that'
p33402
(F1
F0.00014334862385321102
I0
I1
I-1
tp33403
sS'reported,with,some'
p33404
(F1
F0.00014334862385321102
I0
I1
I-1
tp33405
sS'in,plasma,concentrations'
p33406
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp33407
sS'im,was,given'
p33408
(F1
F0.00014334862385321102
I0
I1
I-1
tp33409
sS'a,sensitive,cyp3a4'
p33410
(F1
F0.00014334862385321102
I1
I0
I1
tp33411
sS'effects,of,nonbenzodiazepine'
p33412
(F1
F0.00014334862385321102
I1
I0
I1
tp33413
sS'neither,case,were'
p33414
(F1
F0.00014334862385321102
I0
I1
I-1
tp33415
sS'acid,a-blockers,angiotensin-converting'
p33416
(F1
F0.00014334862385321102
I0
I1
I-1
tp33417
sS'in,an,increase'
p33418
(F0.73333333333333328
F0.0015768348623853212
I13
I2
I11
tp33419
sS'of,and,cause'
p33420
(F1
F0.00014334862385321102
I0
I1
I-1
tp33421
sS'with,occurs,dose'
p33422
(F1
F0.00014334862385321102
I1
I0
I1
tp33423
sS'tambocor,with,or'
p33424
(F1
F0.00014334862385321102
I0
I1
I-1
tp33425
sS'that,prolonged,administration'
p33426
(F1
F0.00014334862385321102
I0
I1
I-1
tp33427
sS'renal,impairment,the'
p33428
(F1
F0.00014334862385321102
I1
I0
I1
tp33429
sS'taking,or,other'
p33430
(F1
F0.00014334862385321102
I0
I1
I-1
tp33431
sS'reuptake,inhibitors,and'
p33432
(F1
F0.00028669724770642203
I0
I2
I-2
tp33433
sS'as,garlic,allium'
p33434
(F1
F0.00014334862385321102
I1
I0
I1
tp33435
sS'use,of,for'
p33436
(F1
F0.00014334862385321102
I0
I1
I-1
tp33437
sS'undergoing,concurrent,therapy'
p33438
(F1
F0.00014334862385321102
I1
I0
I1
tp33439
sS'at,to,days'
p33440
(F1
F0.00014334862385321102
I1
I0
I1
tp33441
sS'platelets,by,causing'
p33442
(F1
F0.00014334862385321102
I1
I0
I1
tp33443
sS'it,is,assumed'
p33444
(F1
F0.00014334862385321102
I0
I1
I-1
tp33445
sS'in,these,studies'
p33446
(F1
F0.00014334862385321102
I1
I0
I1
tp33447
sS'added,to,pooled'
p33448
(F1
F0.00014334862385321102
I0
I1
I-1
tp33449
sS'much,as,possible'
p33450
(F1
F0.00014334862385321102
I0
I1
I-1
tp33451
sS'for,preservation,of'
p33452
(F1
F0.00014334862385321102
I0
I1
I-1
tp33453
sS'be,monitored,for'
p33454
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33455
sS'of,vital,signs'
p33456
(F1
F0.00014334862385321102
I1
I0
I1
tp33457
sS'if,prinivil,is'
p33458
(F1
F0.00014334862385321102
I1
I0
I1
tp33459
sS'alone,and,subsequently'
p33460
(F1
F0.00014334862385321102
I1
I0
I1
tp33461
sS'hypersensitivity,reactions,all'
p33462
(F1
F0.00014334862385321102
I0
I1
I-1
tp33463
sS'taken,with,other'
p33464
(F1
F0.00014334862385321102
I1
I0
I1
tp33465
sS'with,most,other'
p33466
(F1
F0.00014334862385321102
I1
I0
I1
tp33467
sS'associated,with,fatal'
p33468
(F1
F0.00028669724770642203
I2
I0
I2
tp33469
sS'some,normal,volunteers'
p33470
(F1
F0.00014334862385321102
I1
I0
I1
tp33471
sS'three,times,a'
p33472
(F0
F0
I1
I1
I0
tp33473
sS'retinyl,acetate,x'
p33474
(F1
F0.00014334862385321102
I1
I0
I1
tp33475
sS'exjade,with,has'
p33476
(F1
F0.00014334862385321102
I0
I1
I-1
tp33477
sS'pose,a,hazard'
p33478
(F0
F0
I1
I1
I0
tp33479
sS'given,high,intraperitoneal'
p33480
(F1
F0.00014334862385321102
I1
I0
I1
tp33481
sS'either,potentiate,or'
p33482
(F1
F0.00028669724770642203
I2
I0
I2
tp33483
sS'weak,acids,such'
p33484
(F1
F0.00014334862385321102
I1
I0
I1
tp33485
sS'patient,has,been'
p33486
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33487
sS'interaction,studies,intravenous'
p33488
(F1
F0.00014334862385321102
I0
I1
I-1
tp33489
sS'd6,and,to'
p33490
(F1
F0.00014334862385321102
I0
I1
I-1
tp33491
sS'ii,or,its'
p33492
(F1
F0.00014334862385321102
I0
I1
I-1
tp33493
sS'contraindicated,due,to'
p33494
(F1
F0.00057339449541284407
I0
I4
I-4
tp33495
sS'maintained,on,the'
p33496
(F1
F0.00014334862385321102
I1
I0
I1
tp33497
sS'a4,has,no'
p33498
(F1
F0.00014334862385321102
I0
I1
I-1
tp33499
sS'or,prothrombin,times'
p33500
(F1
F0.00014334862385321102
I0
I1
I-1
tp33501
sS'an,ssri,is'
p33502
(F1
F0.00057339449541284407
I4
I0
I4
tp33503
sS'known,it,is'
p33504
(F0
F0
I1
I1
I0
tp33505
sS'of,difluoroacetone,a'
p33506
(F1
F0.00014334862385321102
I0
I1
I-1
tp33507
sS'of,hivid,and'
p33508
(F1
F0.00014334862385321102
I0
I1
I-1
tp33509
sS'with,maximum,levels'
p33510
(F1
F0.00014334862385321102
I0
I1
I-1
tp33511
sS'of,hydroxylamine,dha'
p33512
(F1
F0.00014334862385321102
I0
I1
I-1
tp33513
sS'carbamazepine,levels,should'
p33514
(F1
F0.00014334862385321102
I1
I0
I1
tp33515
sS'peak,concentrations,of'
p33516
(F1
F0.00014334862385321102
I0
I1
I-1
tp33517
sS'its,congeners,and'
p33518
(F1
F0.00014334862385321102
I0
I1
I-1
tp33519
sS'kg,s,c'
p33520
(F1
F0.00028669724770642203
I2
I0
I2
tp33521
sS'may,increase,blood'
p33522
(F1
F0.00014334862385321102
I1
I0
I1
tp33523
sS'known,to,induce'
p33524
(F1
F0.00057339449541284407
I0
I4
I-4
tp33525
sS'of,given,as'
p33526
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp33527
sS'co-administration,of,argatroban'
p33528
(F1
F0.00014334862385321102
I0
I1
I-1
tp33529
sS'metabolism,of,ethinyl'
p33530
(F1
F0.00028669724770642203
I2
I0
I2
tp33531
sS'a,rare,but'
p33532
(F1
F0.00014334862385321102
I1
I0
I1
tp33533
sS'a,single,daily'
p33534
(F1
F0.00014334862385321102
I0
I1
I-1
tp33535
sS'be,determined,with'
p33536
(F1
F0.00043004587155963305
I3
I0
I3
tp33537
sS'and,mean,renal'
p33538
(F1
F0.00014334862385321102
I1
I0
I1
tp33539
sS'efficacy,of,proleukin'
p33540
(F1
F0.00014334862385321102
I0
I1
I-1
tp33541
sS'limited,in,vivo'
p33542
(F1
F0.00014334862385321102
I1
I0
I1
tp33543
sS'rebound,hypertension,which'
p33544
(F1
F0.00014334862385321102
I1
I0
I1
tp33545
sS'may,protect,against'
p33546
(F1
F0.00014334862385321102
I1
I0
I1
tp33547
sS'compared,to,the'
p33548
(F0.5
F0.00028669724770642203
I3
I1
I2
tp33549
sS'of,fluvoxamine,tablets'
p33550
(F1
F0.00014334862385321102
I1
I0
I1
tp33551
sS'auc,but,no'
p33552
(F1
F0.00014334862385321102
I1
I0
I1
tp33553
sS'concomitantly,may,develop'
p33554
(F1
F0.00014334862385321102
I1
I0
I1
tp33555
sS'exposure,of,mg'
p33556
(F1
F0.00014334862385321102
I1
I0
I1
tp33557
sS'an,eight-fold,increase'
p33558
(F1
F0.00028669724770642203
I2
I0
I2
tp33559
sS'on,histamine-,or'
p33560
(F1
F0.00014334862385321102
I1
I0
I1
tp33561
sS'intraperitoneal,injections,of'
p33562
(F1
F0.00014334862385321102
I0
I1
I-1
tp33563
sS'oral,estrogens,may'
p33564
(F1
F0.00014334862385321102
I1
I0
I1
tp33565
sS'least,in,part'
p33566
(F1
F0.00014334862385321102
I1
I0
I1
tp33567
sS'subjects,with,mg'
p33568
(F1
F0.00014334862385321102
I0
I1
I-1
tp33569
sS'n,under,steady'
p33570
(F1
F0.00014334862385321102
I0
I1
I-1
tp33571
sS'shown,to,increase'
p33572
(F1
F0.0010034403669724771
I7
I0
I7
tp33573
sS'agents,by,non-steroidal'
p33574
(F1
F0.00014334862385321102
I1
I0
I1
tp33575
sS'low,and,high'
p33576
(F1
F0.00014334862385321102
I0
I1
I-1
tp33577
sS'at,least,halved'
p33578
(F1
F0.00014334862385321102
I1
I0
I1
tp33579
sS'should,be,maintained'
p33580
(F1
F0.00014334862385321102
I1
I0
I1
tp33581
sS'of,vitamin,d'
p33582
(F0
F0
I2
I2
I0
tp33583
sS'of,vitamin,a'
p33584
(F1
F0.00014334862385321102
I1
I0
I1
tp33585
sS'desirable,to,monitor'
p33586
(F1
F0.00071674311926605509
I0
I5
I-5
tp33587
sS'and,concerns,regarding'
p33588
(F1
F0.00014334862385321102
I0
I1
I-1
tp33589
sS'of,sulfoxide,by'
p33590
(F1
F0.00014334862385321102
I1
I0
I1
tp33591
sS'may,displace,less'
p33592
(F1
F0.00014334862385321102
I1
I0
I1
tp33593
sS'when,lotensin,was'
p33594
(F1
F0.00014334862385321102
I0
I1
I-1
tp33595
sS'and,sustiva,mg'
p33596
(F1
F0.00014334862385321102
I0
I1
I-1
tp33597
sS'of,blood,concentrations'
p33598
(F1
F0.00014334862385321102
I0
I1
I-1
tp33599
sS'other,beta2,agonists'
p33600
(F1
F0.00014334862385321102
I1
I0
I1
tp33601
sS'of,the,physiological'
p33602
(F1
F0.00014334862385321102
I0
I1
I-1
tp33603
sS'myocardium,to,the'
p33604
(F1
F0.00028669724770642203
I2
I0
I2
tp33605
sS'toxicity,in,these'
p33606
(F1
F0.00014334862385321102
I1
I0
I1
tp33607
sS'thalidomide,co-administration,with'
p33608
(F1
F0.00014334862385321102
I0
I1
I-1
tp33609
sS'use,of,intravenously'
p33610
(F1
F0.00014334862385321102
I0
I1
I-1
tp33611
sS'were,not,affected'
p33612
(F1
F0.0021502293577981653
I0
I15
I-15
tp33613
sS'and,but,may'
p33614
(F1
F0.00014334862385321102
I1
I0
I1
tp33615
sS'pharmacologic,studies,indicate'
p33616
(F1
F0.00014334862385321102
I1
I0
I1
tp33617
sS'while,you,are'
p33618
(F1
F0.00014334862385321102
I1
I0
I1
tp33619
sS'an,isoform,also'
p33620
(F1
F0.00014334862385321102
I1
I0
I1
tp33621
sS'but,are,not'
p33622
(F1
F0.00014334862385321102
I0
I1
I-1
tp33623
sS'is,administered,with'
p33624
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp33625
sS'mononuclear,cells,or'
p33626
(F1
F0.00014334862385321102
I1
I0
I1
tp33627
sS'due,to,nonlethal'
p33628
(F1
F0.00014334862385321102
I0
I1
I-1
tp33629
sS'increases,the,risk'
p33630
(F1
F0.00057339449541284407
I4
I0
I4
tp33631
sS'systemic,are,known'
p33632
(F1
F0.00014334862385321102
I0
I1
I-1
tp33633
sS'presence,of,these'
p33634
(F1
F0.00014334862385321102
I1
I0
I1
tp33635
sS'in,some,patients'
p33636
(F0.81818181818181823
F0.0025802752293577983
I20
I2
I18
tp33637
sS'interval,were,observed'
p33638
(F1
F0.00014334862385321102
I0
I1
I-1
tp33639
sS'based,on,some'
p33640
(F1
F0.00014334862385321102
I0
I1
I-1
tp33641
sS'trials,patients,were'
p33642
(F1
F0.00014334862385321102
I0
I1
I-1
tp33643
sS'not,recommended,because'
p33644
(F1
F0.00043004587155963305
I3
I0
I3
tp33645
sS'blockers,and,organic'
p33646
(F1
F0.00028669724770642203
I2
I0
I2
tp33647
sS'or,reverse,the'
p33648
(F1
F0.00028669724770642203
I2
I0
I2
tp33649
sS'used,in,diabetic'
p33650
(F1
F0.00014334862385321102
I0
I1
I-1
tp33651
sS'glucose,concentrations,with'
p33652
(F1
F0.00014334862385321102
I1
I0
I1
tp33653
sS'lower,when,the'
p33654
(F1
F0.00014334862385321102
I1
I0
I1
tp33655
sS'inhibitor,the,auc'
p33656
(F1
F0.00014334862385321102
I1
I0
I1
tp33657
sS'rifampin,significantly,decreased'
p33658
(F1
F0.00014334862385321102
I1
I0
I1
tp33659
sS'fortified,with,iron'
p33660
(F1
F0.00014334862385321102
I1
I0
I1
tp33661
sS'combination,of,hivid'
p33662
(F1
F0.00014334862385321102
I0
I1
I-1
tp33663
sS'increased,approximately,fold'
p33664
(F1
F0.00014334862385321102
I1
I0
I1
tp33665
sS'of,dissolution,of'
p33666
(F1
F0.00014334862385321102
I0
I1
I-1
tp33667
sS'changed,the,serum'
p33668
(F1
F0.00014334862385321102
I1
I0
I1
tp33669
sS'inflammatory,reactions,develop'
p33670
(F1
F0.00014334862385321102
I1
I0
I1
tp33671
sS'blood,thinners,coumadin'
p33672
(F1
F0.00014334862385321102
I0
I1
I-1
tp33673
sS'a,stable,dosage'
p33674
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33675
sS'statistically,significant,decrease'
p33676
(F1
F0.00014334862385321102
I1
I0
I1
tp33677
sS'no,clinical,data'
p33678
(F1
F0.00014334862385321102
I0
I1
I-1
tp33679
sS'administered,with,and'
p33680
(F0
F0
I2
I2
I0
tp33681
sS'neuropsychiatric,events,or'
p33682
(F1
F0.00014334862385321102
I1
I0
I1
tp33683
sS'report,of,one'
p33684
(F1
F0.00014334862385321102
I1
I0
I1
tp33685
sS'administered,with,any'
p33686
(F1
F0.00014334862385321102
I0
I1
I-1
tp33687
sS'be,used,together'
p33688
(F1
F0.00028669724770642203
I2
I0
I2
tp33689
sS'sn38,levels,in'
p33690
(F1
F0.00014334862385321102
I0
I1
I-1
tp33691
sS'treatment,of,crohn'
p33692
(F1
F0.00014334862385321102
I0
I1
I-1
tp33693
sS'to,difluoroacetone,mg'
p33694
(F1
F0.00014334862385321102
I0
I1
I-1
tp33695
sS'cefamandole,naftate,cephalothin'
p33696
(F1
F0.00014334862385321102
I0
I1
I-1
tp33697
sS'of,and,agents'
p33698
(F1
F0.00014334862385321102
I1
I0
I1
tp33699
sS'orudis,kt,oruvail'
p33700
(F1
F0.00014334862385321102
I0
I1
I-1
tp33701
sS'toxicity,when,given'
p33702
(F1
F0.00014334862385321102
I1
I0
I1
tp33703
sS'tested,up,to'
p33704
(F1
F0.00014334862385321102
I0
I1
I-1
tp33705
sS'did,not,detect'
p33706
(F1
F0.00014334862385321102
I0
I1
I-1
tp33707
sS'high,as,in'
p33708
(F1
F0.00014334862385321102
I0
I1
I-1
tp33709
sS'reports,of,positive'
p33710
(F1
F0.00014334862385321102
I0
I1
I-1
tp33711
sS'use,of,hmg-coa'
p33712
(F1
F0.00014334862385321102
I1
I0
I1
tp33713
sS'and,cmax,increased'
p33714
(F1
F0.00014334862385321102
I1
I0
I1
tp33715
sS'medicines,thiazide,use'
p33716
(F1
F0.00014334862385321102
I1
I0
I1
tp33717
sS'to,wshow,that'
p33718
(F1
F0.00014334862385321102
I0
I1
I-1
tp33719
sS'a,day,washout'
p33720
(F1
F0.00014334862385321102
I0
I1
I-1
tp33721
sS'type,diabetes,used'
p33722
(F1
F0.00014334862385321102
I1
I0
I1
tp33723
sS'these,have,not'
p33724
(F1
F0.00014334862385321102
I1
I0
I1
tp33725
sS'population,pharmacokinetic,studies'
p33726
(F1
F0.00014334862385321102
I1
I0
I1
tp33727
sS'reduced,in,hypothyroid'
p33728
(F1
F0.00014334862385321102
I0
I1
I-1
tp33729
sS'cholesterol,the,major'
p33730
(F1
F0.00014334862385321102
I0
I1
I-1
tp33731
sS'on,measures,of'
p33732
(F1
F0.00014334862385321102
I0
I1
I-1
tp33733
sS'decrease,the,ed50'
p33734
(F1
F0.00014334862385321102
I1
I0
I1
tp33735
sS'of,all,prescription'
p33736
(F1
F0.00014334862385321102
I0
I1
I-1
tp33737
sS'co-administered,with,anticoagulation'
p33738
(F1
F0.00014334862385321102
I1
I0
I1
tp33739
sS'administered,mg,reduced'
p33740
(F1
F0.00014334862385321102
I1
I0
I1
tp33741
sS'technique,in,combination'
p33742
(F1
F0.00014334862385321102
I0
I1
I-1
tp33743
sS'ribavirin,see,contraindications'
p33744
(F1
F0.00014334862385321102
I0
I1
I-1
tp33745
sS'taking,concomitantly,with'
p33746
(F1
F0.00028669724770642203
I2
I0
I2
tp33747
sS'temporarily,reduced,creatinine'
p33748
(F1
F0.00014334862385321102
I1
I0
I1
tp33749
sS'mg2,converted,difluoroacetone'
p33750
(F1
F0.00014334862385321102
I0
I1
I-1
tp33751
sS'with,in,clinical'
p33752
(F1
F0.00014334862385321102
I0
I1
I-1
tp33753
sS'weekly,doses,of'
p33754
(F1
F0.00014334862385321102
I0
I1
I-1
tp33755
sS'mg,of,decreased'
p33756
(F1
F0.00014334862385321102
I1
I0
I1
tp33757
sS'leading,to,a'
p33758
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33759
sS'change,significantly,while'
p33760
(F1
F0.00014334862385321102
I0
I1
I-1
tp33761
sS'of,these,studies'
p33762
(F1
F0.00028669724770642203
I0
I2
I-2
tp33763
sS'to,copaxone,did'
p33764
(F1
F0.00014334862385321102
I0
I1
I-1
tp33765
sS'this,parenteral,may'
p33766
(F1
F0.00014334862385321102
I1
I0
I1
tp33767
sS'interaction,between,b12'
p33768
(F1
F0.00014334862385321102
I1
I0
I1
tp33769
sS'hoof,twitch,was'
p33770
(F0
F0
I1
I1
I0
tp33771
sS'inhibited,the,dmpge2'
p33772
(F1
F0.00014334862385321102
I1
I0
I1
tp33773
sS'k,epoxide,reductase'
p33774
(F1
F0.00014334862385321102
I0
I1
I-1
tp33775
sS'been,noted,to'
p33776
(F1
F0.00014334862385321102
I1
I0
I1
tp33777
sS'relevant,consequences,for'
p33778
(F1
F0.00014334862385321102
I1
I0
I1
tp33779
sS'slight,decrease,about'
p33780
(F1
F0.00014334862385321102
I1
I0
I1
tp33781
sS'cox-2,inhibitor,at'
p33782
(F1
F0.00014334862385321102
I0
I1
I-1
tp33783
sS'prolonged,or,increased'
p33784
(F1
F0.00014334862385321102
I0
I1
I-1
tp33785
sS'information,on,the'
p33786
(F1
F0.00014334862385321102
I0
I1
I-1
tp33787
sS'dose,may,need'
p33788
(F1
F0.00014334862385321102
I0
I1
I-1
tp33789
sS'that,inhibit,or'
p33790
(F1
F0.00014334862385321102
I0
I1
I-1
tp33791
sS'may,contribute,to'
p33792
(F1
F0.00014334862385321102
I1
I0
I1
tp33793
sS'of,in,proportion'
p33794
(F1
F0.00014334862385321102
I0
I1
I-1
tp33795
sS'been,demonstrated,between'
p33796
(F0
F0
I1
I1
I0
tp33797
sS'coumarin,type,revealed'
p33798
(F1
F0.00014334862385321102
I0
I1
I-1
tp33799
sS'shown,to,induce'
p33800
(F1
F0.00014334862385321102
I1
I0
I1
tp33801
sS'of,a,non-'
p33802
(F1
F0.00014334862385321102
I1
I0
I1
tp33803
sS'indicated,that,significantly'
p33804
(F1
F0.00014334862385321102
I1
I0
I1
tp33805
sS'antidiabetic,requirements,i'
p33806
(F1
F0.00014334862385321102
I0
I1
I-1
tp33807
sS'tca,is,co-administered'
p33808
(F1
F0.00014334862385321102
I1
I0
I1
tp33809
sS'such,as,but'
p33810
(F1
F0.00014334862385321102
I1
I0
I1
tp33811
sS'enzyme,activity,may'
p33812
(F1
F0.00014334862385321102
I1
I0
I1
tp33813
sS'plasma,concentrations,reach'
p33814
(F1
F0.00014334862385321102
I1
I0
I1
tp33815
sS'from,one,to'
p33816
(F1
F0.00014334862385321102
I0
I1
I-1
tp33817
sS'fi,responding,produced'
p33818
(F1
F0.00014334862385321102
I1
I0
I1
tp33819
sS'hypotensite,effects,due'
p33820
(F1
F0.00014334862385321102
I1
I0
I1
tp33821
sS'and,susceptibility,to'
p33822
(F1
F0.00028669724770642203
I0
I2
I-2
tp33823
sS'nicotinic,acid,channel'
p33824
(F1
F0.00028669724770642203
I0
I2
I-2
tp33825
sS'in,vitro,antiviral'
p33826
(F1
F0.00014334862385321102
I1
I0
I1
tp33827
sS'shown,to,depress'
p33828
(F1
F0.00028669724770642203
I2
I0
I2
tp33829
sS'in,about,of'
p33830
(F1
F0.00014334862385321102
I0
I1
I-1
tp33831
sS'myopathy,which,is'
p33832
(F1
F0.00014334862385321102
I0
I1
I-1
tp33833
sS'or,cimetidine,concomitant'
p33834
(F1
F0.00014334862385321102
I1
I0
I1
tp33835
sS'ortho-novum,produced,average'
p33836
(F1
F0.00014334862385321102
I1
I0
I1
tp33837
sS'to,be,discontinued'
p33838
(F1
F0.00014334862385321102
I1
I0
I1
tp33839
sS'or,too,frequent'
p33840
(F1
F0.00014334862385321102
I0
I1
I-1
tp33841
sS'effect,of,exogenous'
p33842
(F1
F0.00014334862385321102
I0
I1
I-1
tp33843
sS'with,the,initiation'
p33844
(F1
F0.00014334862385321102
I0
I1
I-1
tp33845
sS'data,suggest,a'
p33846
(F1
F0.00014334862385321102
I1
I0
I1
tp33847
sS'daily,dosage,of'
p33848
(F1
F0.00014334862385321102
I0
I1
I-1
tp33849
sS'reduction,in,dosage'
p33850
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33851
sS'may,cause,hypertension'
p33852
(F1
F0.00014334862385321102
I1
I0
I1
tp33853
sS'reduced,although,the'
p33854
(F1
F0.00014334862385321102
I1
I0
I1
tp33855
sS'of,was,not'
p33856
(F1
F0.00071674311926605509
I0
I5
I-5
tp33857
sS'used,in,surgery'
p33858
(F1
F0.00014334862385321102
I0
I1
I-1
tp33859
sS'dose,proleukin,and'
p33860
(F1
F0.00014334862385321102
I1
I0
I1
tp33861
sS'cyp1a2,inhibitors,as'
p33862
(F1
F0.00014334862385321102
I0
I1
I-1
tp33863
sS'hyperuricemia,present,in'
p33864
(F1
F0.00014334862385321102
I1
I0
I1
tp33865
sS'possible,interaction,between'
p33866
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp33867
sS'of,serotonin,in'
p33868
(F1
F0.00014334862385321102
I0
I1
I-1
tp33869
sS'inhibitory,effects,of'
p33870
(F0
F0
I1
I1
I0
tp33871
sS'day,of,from'
p33872
(F1
F0.00014334862385321102
I0
I1
I-1
tp33873
sS'for,minutes,at'
p33874
(F1
F0.00014334862385321102
I0
I1
I-1
tp33875
sS'study,male,rats'
p33876
(F1
F0.00014334862385321102
I0
I1
I-1
tp33877
sS'structural,similarity,to'
p33878
(F1
F0.00014334862385321102
I1
I0
I1
tp33879
sS'hydroxylation,catalyzed,by'
p33880
(F1
F0.00014334862385321102
I0
I1
I-1
tp33881
sS'intensify,the,effect'
p33882
(F1
F0.00014334862385321102
I1
I0
I1
tp33883
sS'tracrium,should,not'
p33884
(F1
F0.00014334862385321102
I1
I0
I1
tp33885
sS'there,may,be'
p33886
(F1
F0.00028669724770642203
I2
I0
I2
tp33887
sS'maoi,as,well'
p33888
(F1
F0.00028669724770642203
I2
I0
I2
tp33889
sS'systemic,it,is'
p33890
(F1
F0.00014334862385321102
I1
I0
I1
tp33891
sS'sensipar,is,a'
p33892
(F1
F0.00014334862385321102
I0
I1
I-1
tp33893
sS'indicated,and,then'
p33894
(F1
F0.00014334862385321102
I1
I0
I1
tp33895
sS'not,recommended,since'
p33896
(F1
F0.00014334862385321102
I1
I0
I1
tp33897
sS'have,demonstrated,the'
p33898
(F1
F0.00014334862385321102
I0
I1
I-1
tp33899
sS'culture,the,effect'
p33900
(F1
F0.00014334862385321102
I1
I0
I1
tp33901
sS'all,been,used'
p33902
(F1
F0.00014334862385321102
I0
I1
I-1
tp33903
sS'chains,of,n-methylthiotetrazole'
p33904
(F1
F0.00014334862385321102
I0
I1
I-1
tp33905
sS'methods,of,contraception'
p33906
(F0
F0
I1
I1
I0
tp33907
sS'interaction,will,lead'
p33908
(F1
F0.00014334862385321102
I1
I0
I1
tp33909
sS'that,clorazepate,dipotassium'
p33910
(F1
F0.00014334862385321102
I1
I0
I1
tp33911
sS'zyvox,and,concomitant'
p33912
(F1
F0.00014334862385321102
I1
I0
I1
tp33913
sS'of,a,krm-1648'
p33914
(F1
F0.00014334862385321102
I0
I1
I-1
tp33915
sS'studies,with,have'
p33916
(F1
F0.00014334862385321102
I1
I0
I1
tp33917
sS'and,hours,prior'
p33918
(F1
F0.00014334862385321102
I0
I1
I-1
tp33919
sS'for,increased,both'
p33920
(F1
F0.00014334862385321102
I0
I1
I-1
tp33921
sS'was,administered,concurrently'
p33922
(F1
F0.00014334862385321102
I0
I1
I-1
tp33923
sS'little,if,any'
p33924
(F1
F0.00014334862385321102
I0
I1
I-1
tp33925
sS'the,orally,disintegrating'
p33926
(F1
F0.00014334862385321102
I1
I0
I1
tp33927
sS'time,in,all'
p33928
(F1
F0.00014334862385321102
I1
I0
I1
tp33929
sS'n,did,not'
p33930
(F1
F0.00014334862385321102
I0
I1
I-1
tp33931
sS'doses,of,or'
p33932
(F1
F0.00043004587155963305
I0
I3
I-3
tp33933
sS'stopped,during,treatment'
p33934
(F1
F0.00014334862385321102
I1
I0
I1
tp33935
sS'mean,of,minutes'
p33936
(F1
F0.00014334862385321102
I0
I1
I-1
tp33937
sS'busulfex,were,studied'
p33938
(F1
F0.00014334862385321102
I1
I0
I1
tp33939
sS'substrate,for,uptake-1'
p33940
(F1
F0.00014334862385321102
I0
I1
I-1
tp33941
sS'in,liver,alt'
p33942
(F1
F0.00014334862385321102
I1
I0
I1
tp33943
sS'and,mg,decreased'
p33944
(F1
F0.00014334862385321102
I1
I0
I1
tp33945
sS'of,bepridil,and'
p33946
(F1
F0.00014334862385321102
I0
I1
I-1
tp33947
sS'and,a,lesser'
p33948
(F1
F0.00014334862385321102
I1
I0
I1
tp33949
sS'trazodone,hydrochloride,desyrel'
p33950
(F1
F0.00014334862385321102
I1
I0
I1
tp33951
sS'of,or,other'
p33952
(F0
F0
I2
I2
I0
tp33953
sS'unchanged,the,secretion'
p33954
(F1
F0.00014334862385321102
I0
I1
I-1
tp33955
sS'agents,in,this'
p33956
(F1
F0.00014334862385321102
I1
I0
I1
tp33957
sS'of,cyp3a4,alter'
p33958
(F1
F0.00014334862385321102
I0
I1
I-1
tp33959
sS'the,following,precautions'
p33960
(F1
F0.00014334862385321102
I1
I0
I1
tp33961
sS'satisfactory,hypotensive,effect'
p33962
(F1
F0.00014334862385321102
I1
I0
I1
tp33963
sS'cyp1a2,and,cyp2d6'
p33964
(F1
F0.00014334862385321102
I0
I1
I-1
tp33965
sS'tc,suspension,reduces'
p33966
(F1
F0.00014334862385321102
I1
I0
I1
tp33967
sS'eliminated,the,increases'
p33968
(F1
F0.00014334862385321102
I1
I0
I1
tp33969
sS'agent,on,the'
p33970
(F1
F0.00014334862385321102
I0
I1
I-1
tp33971
sS'rats,giving,superimposed'
p33972
(F1
F0.00014334862385321102
I0
I1
I-1
tp33973
sS'with,the,effect'
p33974
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp33975
sS'weight,was,shown'
p33976
(F1
F0.00014334862385321102
I1
I0
I1
tp33977
sS'information,for,regarding'
p33978
(F1
F0.00014334862385321102
I0
I1
I-1
tp33979
sS'of,anaphylactic,reaction'
p33980
(F1
F0.00014334862385321102
I1
I0
I1
tp33981
sS'psychoactive,medications,patients'
p33982
(F1
F0.00014334862385321102
I1
I0
I1
tp33983
sS'or,without,tdp'
p33984
(F1
F0.00014334862385321102
I0
I1
I-1
tp33985
sS'effect,of,as'
p33986
(F1
F0.00014334862385321102
I0
I1
I-1
tp33987
sS'pathway,in,the'
p33988
(F1
F0.00014334862385321102
I0
I1
I-1
tp33989
sS'they,are,begun'
p33990
(F1
F0.00014334862385321102
I1
I0
I1
tp33991
sS'prolonged,prothrombin,time'
p33992
(F1
F0.00014334862385321102
I1
I0
I1
tp33993
sS'mao,inhibitors,should'
p33994
(F1
F0.00028669724770642203
I2
I0
I2
tp33995
sS'help,to,trace'
p33996
(F1
F0.00014334862385321102
I0
I1
I-1
tp33997
sS'ethanol,clinical,evidence'
p33998
(F1
F0.00014334862385321102
I1
I0
I1
tp33999
sS'co-administration,leading,to'
p34000
(F1
F0.00014334862385321102
I1
I0
I1
tp34001
sS'or,orally,administered'
p34002
(F1
F0.00014334862385321102
I0
I1
I-1
tp34003
sS'completely,depressed,the'
p34004
(F1
F0.00014334862385321102
I1
I0
I1
tp34005
sS'caffeine,theobromine,grepafloxacin'
p34006
(F1
F0.00014334862385321102
I1
I0
I1
tp34007
sS'angina,or,other'
p34008
(F1
F0.00014334862385321102
I1
I0
I1
tp34009
sS'reflex,tachycardia,produced'
p34010
(F1
F0.00014334862385321102
I1
I0
I1
tp34011
sS'parenteral,enzyme,supplements'
p34012
(F1
F0.00014334862385321102
I0
I1
I-1
tp34013
sS'enhancing,heparin,effect'
p34014
(F1
F0.00014334862385321102
I0
I1
I-1
tp34015
sS'enteric,coating,of'
p34016
(F1
F0.00014334862385321102
I1
I0
I1
tp34017
sS'including,were,concurrently'
p34018
(F1
F0.00014334862385321102
I0
I1
I-1
tp34019
sS'of,enhancing,the'
p34020
(F1
F0.00014334862385321102
I1
I0
I1
tp34021
sS'antihypertensive,effect,and'
p34022
(F1
F0.00014334862385321102
I1
I0
I1
tp34023
sS'it,is,concluded'
p34024
(F0
F0
I2
I2
I0
tp34025
sS'to,adjust,the'
p34026
(F1
F0.00014334862385321102
I1
I0
I1
tp34027
sS'd,is,a'
p34028
(F1
F0.00014334862385321102
I0
I1
I-1
tp34029
sS'clearance,of,metabolized'
p34030
(F1
F0.00014334862385321102
I0
I1
I-1
tp34031
sS'ii,receptor,antagonists'
p34032
(F0
F0
I1
I1
I0
tp34033
sS'felbatol,as,compared'
p34034
(F1
F0.00028669724770642203
I2
I0
I2
tp34035
sS'and,the,appearance'
p34036
(F1
F0.00014334862385321102
I0
I1
I-1
tp34037
sS'with,oral,or'
p34038
(F0
F0
I1
I1
I0
tp34039
sS'proteins,is,only'
p34040
(F1
F0.00014334862385321102
I1
I0
I1
tp34041
sS'therapy,may,require'
p34042
(F1
F0.00043004587155963305
I3
I0
I3
tp34043
sS'inositol,trisphosphate,insp'
p34044
(F1
F0.00014334862385321102
I0
I1
I-1
tp34045
sS'sodium,and,urinary'
p34046
(F1
F0.00014334862385321102
I1
I0
I1
tp34047
sS'expected,changes,in'
p34048
(F1
F0.00014334862385321102
I0
I1
I-1
tp34049
sS'period,of,days'
p34050
(F1
F0.00014334862385321102
I0
I1
I-1
tp34051
sS'reported,following,doses'
p34052
(F1
F0.00014334862385321102
I1
I0
I1
tp34053
sS'rhabdomyolysis,secondary,to'
p34054
(F1
F0.00014334862385321102
I1
I0
I1
tp34055
sS'healthy,male,subjects'
p34056
(F0
F0
I1
I1
I0
tp34057
sS'group,of,patients'
p34058
(F1
F0.00014334862385321102
I0
I1
I-1
tp34059
sS'required,when,hydrochloride'
p34060
(F1
F0.00014334862385321102
I1
I0
I1
tp34061
sS'either,or,concurrently'
p34062
(F1
F0.00014334862385321102
I1
I0
I1
tp34063
sS'may,prevent,the'
p34064
(F1
F0.00028669724770642203
I2
I0
I2
tp34065
sS'patients,not,receiving'
p34066
(F1
F0.00028669724770642203
I2
I0
I2
tp34067
sS'inhibitors,or,inducers'
p34068
(F1
F0.00014334862385321102
I0
I1
I-1
tp34069
sS'inhibitors,was,delayed'
p34070
(F1
F0.00014334862385321102
I1
I0
I1
tp34071
sS'would,not,result'
p34072
(F1
F0.00014334862385321102
I0
I1
I-1
tp34073
sS'patients,receiving,long-'
p34074
(F1
F0.00014334862385321102
I1
I0
I1
tp34075
sS'or,has,been'
p34076
(F1
F0.00028669724770642203
I2
I0
I2
tp34077
sS'appropriate,dosage,adjustments'
p34078
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp34079
sS'is,via,the'
p34080
(F1
F0.00014334862385321102
I0
I1
I-1
tp34081
sS'example,sparing,pharmacological'
p34082
(F1
F0.00014334862385321102
I0
I1
I-1
tp34083
sS'loperamide,and,and'
p34084
(F0
F0
I1
I1
I0
tp34085
sS'we,have,carried'
p34086
(F1
F0.00014334862385321102
I0
I1
I-1
tp34087
sS'therapy,with,the'
p34088
(F1
F0.00028669724770642203
I0
I2
I-2
tp34089
sS'blood,concentration,cmax'
p34090
(F1
F0.00014334862385321102
I1
I0
I1
tp34091
sS'hydrochloride,a,channel'
p34092
(F1
F0.00014334862385321102
I0
I1
I-1
tp34093
sS'aminosalicylic,acid,higher'
p34094
(F1
F0.00014334862385321102
I1
I0
I1
tp34095
sS'a,dose-dependent,manner'
p34096
(F1
F0.00028669724770642203
I2
I0
I2
tp34097
sS'concentrations,it,is'
p34098
(F1
F0.00014334862385321102
I0
I1
I-1
tp34099
sS'percentage,of,endotoxin-induced'
p34100
(F1
F0.00014334862385321102
I1
I0
I1
tp34101
sS'and,other,including'
p34102
(F1
F0.00014334862385321102
I1
I0
I1
tp34103
sS'had,an,unsatisfactory'
p34104
(F1
F0.00014334862385321102
I1
I0
I1
tp34105
sS'agents,with,decreased'
p34106
(F1
F0.00014334862385321102
I0
I1
I-1
tp34107
sS'patients,receiving,inspra'
p34108
(F1
F0.00014334862385321102
I0
I1
I-1
tp34109
sS'which,enbrel,was'
p34110
(F1
F0.00014334862385321102
I1
I0
I1
tp34111
sS'agents,and,without'
p34112
(F1
F0.00028669724770642203
I0
I2
I-2
tp34113
sS'coagulation,parameters,should'
p34114
(F1
F0.00014334862385321102
I0
I1
I-1
tp34115
sS'is,therefore,advisable'
p34116
(F1
F0.00014334862385321102
I1
I0
I1
tp34117
sS'capacity,to,inhibit'
p34118
(F1
F0.00014334862385321102
I1
I0
I1
tp34119
sS'be,free,of'
p34120
(F1
F0.00014334862385321102
I0
I1
I-1
tp34121
sS'one,week,plasma'
p34122
(F1
F0.00014334862385321102
I1
I0
I1
tp34123
sS'alt,and,ast'
p34124
(F1
F0.00014334862385321102
I1
I0
I1
tp34125
sS'male,volunteers,did'
p34126
(F1
F0.00014334862385321102
I0
I1
I-1
tp34127
sS'of,with,of'
p34128
(F1
F0.00014334862385321102
I1
I0
I1
tp34129
sS'a,disulfiram-like,reaction'
p34130
(F1
F0.00014334862385321102
I0
I1
I-1
tp34131
sS'or,salt,substitutes'
p34132
(F1
F0.00014334862385321102
I0
I1
I-1
tp34133
sS'addition,studies,in'
p34134
(F1
F0.00014334862385321102
I0
I1
I-1
tp34135
sS'does,not,interfere'
p34136
(F1
F0.00028669724770642203
I0
I2
I-2
tp34137
sS'model,peptide,and'
p34138
(F1
F0.00014334862385321102
I0
I1
I-1
tp34139
sS'and,kappa-selective,was'
p34140
(F1
F0.00014334862385321102
I0
I1
I-1
tp34141
sS'drug,interaction,studies'
p34142
(F1
F0.00028669724770642203
I0
I2
I-2
tp34143
sS'of,with,or'
p34144
(F1
F0.00057339449541284407
I4
I0
I4
tp34145
sS'aware,when,is'
p34146
(F1
F0.00014334862385321102
I1
I0
I1
tp34147
sS'trough,cmin,plasma'
p34148
(F1
F0.00028669724770642203
I0
I2
I-2
tp34149
sS'the,large,placebo-controlled'
p34150
(F1
F0.00014334862385321102
I0
I1
I-1
tp34151
sS'far,more,potent'
p34152
(F1
F0.00014334862385321102
I0
I1
I-1
tp34153
sS'depressants,but,regular'
p34154
(F1
F0.00014334862385321102
I0
I1
I-1
tp34155
sS'known,metabolic,profiles'
p34156
(F1
F0.00014334862385321102
I0
I1
I-1
tp34157
sS'influence,of,angiotensin'
p34158
(F1
F0.00014334862385321102
I0
I1
I-1
tp34159
sS'with,the,growth'
p34160
(F1
F0.00014334862385321102
I0
I1
I-1
tp34161
sS'mycophenolate,mofetil,respectively'
p34162
(F1
F0.00014334862385321102
I1
I0
I1
tp34163
sS'mg,were,administered'
p34164
(F1
F0.00014334862385321102
I0
I1
I-1
tp34165
sS'of,its,structural'
p34166
(F1
F0.00014334862385321102
I1
I0
I1
tp34167
sS'and,butyrophenone,classes'
p34168
(F1
F0.00014334862385321102
I1
I0
I1
tp34169
sS'cells,u937,and'
p34170
(F1
F0.00014334862385321102
I1
I0
I1
tp34171
sS'pharmacokinetics,effectiveness,against'
p34172
(F1
F0.00014334862385321102
I0
I1
I-1
tp34173
sS'may,change,the'
p34174
(F0
F0
I1
I1
I0
tp34175
sS'studies,in,which'
p34176
(F1
F0.00014334862385321102
I0
I1
I-1
tp34177
sS'lapatinib,on,drug'
p34178
(F1
F0.00014334862385321102
I0
I1
I-1
tp34179
sS'indicate,no,discernible'
p34180
(F1
F0.00014334862385321102
I0
I1
I-1
tp34181
sS'g,kg,body'
p34182
(F1
F0.00014334862385321102
I0
I1
I-1
tp34183
sS'observed,in,comparative'
p34184
(F1
F0.00014334862385321102
I0
I1
I-1
tp34185
sS'during,multiple-dose,suggesting'
p34186
(F1
F0.00014334862385321102
I0
I1
I-1
tp34187
sS'to,depress,plasma'
p34188
(F1
F0.00028669724770642203
I2
I0
I2
tp34189
sS'the,frequency,of'
p34190
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp34191
sS'such,as,clinistix'
p34192
(F1
F0.00014334862385321102
I0
I1
I-1
tp34193
sS'in,the,intestine'
p34194
(F1
F0.00014334862385321102
I1
I0
I1
tp34195
sS'course,of,at'
p34196
(F1
F0.00057339449541284407
I4
I0
I4
tp34197
sS'aminoglycoside,are,also'
p34198
(F1
F0.00014334862385321102
I1
I0
I1
tp34199
sS'protease,inhibitors,are'
p34200
(F1
F0.00014334862385321102
I0
I1
I-1
tp34201
sS'treatment,with,incisive'
p34202
(F1
F0.00014334862385321102
I0
I1
I-1
tp34203
sS'are,often,administered'
p34204
(F1
F0.00014334862385321102
I0
I1
I-1
tp34205
sS'renal,function,have'
p34206
(F1
F0.00014334862385321102
I0
I1
I-1
tp34207
sS'the,maximal,effects'
p34208
(F1
F0.00014334862385321102
I0
I1
I-1
tp34209
sS'single,weekly,doses'
p34210
(F1
F0.00014334862385321102
I0
I1
I-1
tp34211
sS'pharmacokinetic,studies,of'
p34212
(F1
F0.00014334862385321102
I0
I1
I-1
tp34213
sS'with,reduces,both'
p34214
(F1
F0.00014334862385321102
I1
I0
I1
tp34215
sS'been,noted,in'
p34216
(F1
F0.00014334862385321102
I1
I0
I1
tp34217
sS'used,with,arimidex'
p34218
(F1
F0.00014334862385321102
I1
I0
I1
tp34219
sS'found,in,interaction'
p34220
(F1
F0.00028669724770642203
I0
I2
I-2
tp34221
sS'rapid,equilibration,of'
p34222
(F1
F0.00014334862385321102
I0
I1
I-1
tp34223
sS'system,depressants,the'
p34224
(F1
F0.00014334862385321102
I1
I0
I1
tp34225
sS'may,increase,oral'
p34226
(F1
F0.00028669724770642203
I2
I0
I2
tp34227
sS'addition,to,this'
p34228
(F1
F0.00014334862385321102
I1
I0
I1
tp34229
sS'antagonists,histamine,h2-receptor'
p34230
(F1
F0.00014334862385321102
I0
I1
I-1
tp34231
sS'exposures,of,r-warfarin'
p34232
(F1
F0.00014334862385321102
I1
I0
I1
tp34233
sS'of,cefditoren,pivoxil'
p34234
(F0
F0
I1
I1
I0
tp34235
sS'the,blood-glucose,lowering'
p34236
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp34237
sS'range,while,in'
p34238
(F1
F0.00014334862385321102
I0
I1
I-1
tp34239
sS'as,retention,in'
p34240
(F1
F0.00014334862385321102
I0
I1
I-1
tp34241
sS'significant,metabolism,by'
p34242
(F1
F0.00014334862385321102
I1
I0
I1
tp34243
sS'of,it,has'
p34244
(F1
F0.00014334862385321102
I0
I1
I-1
tp34245
sS'with,gram,absorption'
p34246
(F1
F0.00014334862385321102
I1
I0
I1
tp34247
sS'use,of,duragesic'
p34248
(F1
F0.00014334862385321102
I1
I0
I1
tp34249
sS'clotting,time,have'
p34250
(F1
F0.00014334862385321102
I0
I1
I-1
tp34251
sS'potentiated,when,these'
p34252
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp34253
sS'amphetamines,inhibit,the'
p34254
(F1
F0.00028669724770642203
I2
I0
I2
tp34255
sS'ip,the,effect'
p34256
(F1
F0.00014334862385321102
I1
I0
I1
tp34257
sS'or,potassium-containing,salt'
p34258
(F0
F0
I1
I1
I0
tp34259
sS'inhibitors,reports,suggest'
p34260
(F1
F0.00043004587155963305
I3
I0
I3
tp34261
sS'rate,of,aerosol'
p34262
(F1
F0.00014334862385321102
I0
I1
I-1
tp34263
sS'in,human,liver'
p34264
(F0
F0
I1
I1
I0
tp34265
sS'result,in,the'
p34266
(F0
F0
I1
I1
I0
tp34267
sS'coadministration,leads,to'
p34268
(F1
F0.00028669724770642203
I2
I0
I2
tp34269
sS'wear,off,before'
p34270
(F1
F0.00014334862385321102
I0
I1
I-1
tp34271
sS'of,cholinesterase,activity'
p34272
(F1
F0.00014334862385321102
I1
I0
I1
tp34273
sS'including,ether,and'
p34274
(F1
F0.00014334862385321102
I1
I0
I1
tp34275
sS'primarily,metabolized,to'
p34276
(F1
F0.00014334862385321102
I0
I1
I-1
tp34277
sS'enhancing,effects,of'
p34278
(F1
F0.00014334862385321102
I0
I1
I-1
tp34279
sS'methotrexate,valdecoxib,mg'
p34280
(F1
F0.00014334862385321102
I0
I1
I-1
tp34281
sS'after,administration,was'
p34282
(F1
F0.00014334862385321102
I1
I0
I1
tp34283
sS'immediate-early,genes,iegs'
p34284
(F1
F0.00014334862385321102
I0
I1
I-1
tp34285
sS'of,hypoglycemic,agents'
p34286
(F1
F0.00014334862385321102
I1
I0
I1
tp34287
sS'of,toxicity,in'
p34288
(F1
F0.00014334862385321102
I1
I0
I1
tp34289
sS'administration,of,drugs'
p34290
(F1
F0.00014334862385321102
I1
I0
I1
tp34291
sS'period,followed,by'
p34292
(F1
F0.00014334862385321102
I0
I1
I-1
tp34293
sS'observed,after,concomitant'
p34294
(F1
F0.00014334862385321102
I0
I1
I-1
tp34295
sS'patients,without,significantly'
p34296
(F1
F0.00014334862385321102
I0
I1
I-1
tp34297
sS'liver,enzymes,is'
p34298
(F1
F0.00014334862385321102
I1
I0
I1
tp34299
sS'hypokalemia,which,may'
p34300
(F1
F0.00014334862385321102
I1
I0
I1
tp34301
sS'hypotensive,including,ganglionic'
p34302
(F1
F0.00014334862385321102
I1
I0
I1
tp34303
sS'co-administered,antiepilepsy,aeds'
p34304
(F1
F0.00014334862385321102
I0
I1
I-1
tp34305
sS'of,an,effect'
p34306
(F1
F0.00014334862385321102
I0
I1
I-1
tp34307
sS'bromide,is,minimally'
p34308
(F1
F0.00014334862385321102
I1
I0
I1
tp34309
sS'development,of,myalgia'
p34310
(F1
F0.00014334862385321102
I1
I0
I1
tp34311
sS'in,additive,central'
p34312
(F1
F0.00014334862385321102
I1
I0
I1
tp34313
sS'emerge,if,is'
p34314
(F1
F0.00014334862385321102
I1
I0
I1
tp34315
sS'by,endothelial,dysfunction'
p34316
(F1
F0.00014334862385321102
I0
I1
I-1
tp34317
sS'lack,of,interaction'
p34318
(F1
F0.00043004587155963305
I0
I3
I-3
tp34319
sS'of,this,interaction'
p34320
(F1
F0.00028669724770642203
I0
I2
I-2
tp34321
sS'mediated,transport,of'
p34322
(F1
F0.00014334862385321102
I0
I1
I-1
tp34323
sS'blockers,and,proton'
p34324
(F1
F0.00014334862385321102
I0
I1
I-1
tp34325
sS'used,concomitantly,the'
p34326
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp34327
sS'patients,receiving,either'
p34328
(F0
F0
I1
I1
I0
tp34329
sS'initiating,adjusting,or'
p34330
(F1
F0.00014334862385321102
I1
I0
I1
tp34331
sS'the,tmax,by'
p34332
(F1
F0.00014334862385321102
I1
I0
I1
tp34333
sS'effect,in,lowering'
p34334
(F1
F0.00014334862385321102
I1
I0
I1
tp34335
sS'shown,that,like'
p34336
(F1
F0.00014334862385321102
I1
I0
I1
tp34337
sS'that,or,acth'
p34338
(F1
F0.00014334862385321102
I0
I1
I-1
tp34339
sS'spray,during,the'
p34340
(F1
F0.00014334862385321102
I0
I1
I-1
tp34341
sS'of,chronic,dosing'
p34342
(F1
F0.00014334862385321102
I0
I1
I-1
tp34343
sS'one,contra-indication,overt'
p34344
(F1
F0.00014334862385321102
I0
I1
I-1
tp34345
sS'the,possible,complications'
p34346
(F1
F0.00014334862385321102
I1
I0
I1
tp34347
sS'as,in,rheumatic'
p34348
(F1
F0.00014334862385321102
I1
I0
I1
tp34349
sS'of,an,increase'
p34350
(F1
F0.00014334862385321102
I1
I0
I1
tp34351
sS'basis,of,clinical'
p34352
(F1
F0.00028669724770642203
I2
I0
I2
tp34353
sS'drugs,drugs,such'
p34354
(F1
F0.00014334862385321102
I0
I1
I-1
tp34355
sS'inducers,or,inhibitors'
p34356
(F1
F0.00014334862385321102
I0
I1
I-1
tp34357
sS'or,its,derivatives'
p34358
(F1
F0.00057339449541284407
I4
I0
I4
tp34359
sS'taking,aminosalicylic,acid'
p34360
(F1
F0.00014334862385321102
I1
I0
I1
tp34361
sS'the,risks,to'
p34362
(F1
F0.00014334862385321102
I1
I0
I1
tp34363
sS'interaction,between,wellbutrin'
p34364
(F1
F0.00014334862385321102
I1
I0
I1
tp34365
sS'in,vitro,interferes'
p34366
(F1
F0.00014334862385321102
I1
I0
I1
tp34367
sS'in,most,subjects'
p34368
(F1
F0.00014334862385321102
I1
I0
I1
tp34369
sS'and,with,transdermal'
p34370
(F1
F0.00014334862385321102
I1
I0
I1
tp34371
sS'cyclosporine,doses,trough'
p34372
(F1
F0.00014334862385321102
I0
I1
I-1
tp34373
sS'uptake,blocking,agents'
p34374
(F1
F0.00014334862385321102
I0
I1
I-1
tp34375
sS'observed,which,was'
p34376
(F1
F0.00028669724770642203
I2
I0
I2
tp34377
sS'cyp3a4,inhibitor,which'
p34378
(F1
F0.00014334862385321102
I1
I0
I1
tp34379
sS'the,literature,revealed'
p34380
(F1
F0.00014334862385321102
I1
I0
I1
tp34381
sS'effects,on,prolonging'
p34382
(F1
F0.00014334862385321102
I1
I0
I1
tp34383
sS'elimination,half-life,was'
p34384
(F1
F0.00014334862385321102
I0
I1
I-1
tp34385
sS'with,elemental,primarily'
p34386
(F1
F0.00014334862385321102
I0
I1
I-1
tp34387
sS'experiencing,increases,in'
p34388
(F1
F0.00014334862385321102
I1
I0
I1
tp34389
sS'adl,and,differed'
p34390
(F1
F0.00014334862385321102
I0
I1
I-1
tp34391
sS'and,concomitant,beta-1a'
p34392
(F1
F0.00014334862385321102
I0
I1
I-1
tp34393
sS'lithium,valdecoxib,mg'
p34394
(F1
F0.00014334862385321102
I1
I0
I1
tp34395
sS'cause,elimination,of'
p34396
(F1
F0.00028669724770642203
I2
I0
I2
tp34397
sS'observations,on,hepatotoxicity'
p34398
(F1
F0.00014334862385321102
I1
I0
I1
tp34399
sS'ketamine,is,clinically'
p34400
(F1
F0.00014334862385321102
I0
I1
I-1
tp34401
sS'prothrombin,time,or'
p34402
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp34403
sS'used,when,and'
p34404
(F1
F0.00014334862385321102
I1
I0
I1
tp34405
sS'concurrent,use,with'
p34406
(F0
F0
I5
I5
I0
tp34407
sS'to,erythro-fluorocitrate,in'
p34408
(F1
F0.00014334862385321102
I1
I0
I1
tp34409
sS'baseline,phenytoin,serum'
p34410
(F1
F0.00014334862385321102
I1
I0
I1
tp34411
sS'possible,extrarenal,mechanisms'
p34412
(F1
F0.00014334862385321102
I0
I1
I-1
tp34413
sS'was,similar,among'
p34414
(F1
F0.00014334862385321102
I0
I1
I-1
tp34415
sS'effects,of,organic'
p34416
(F1
F0.00014334862385321102
I1
I0
I1
tp34417
sS'of,non-depolarising,muscle'
p34418
(F1
F0.00014334862385321102
I1
I0
I1
tp34419
sS'treatment,of,chronic'
p34420
(F1
F0.00014334862385321102
I0
I1
I-1
tp34421
sS'day,or,mg'
p34422
(F1
F0.00014334862385321102
I0
I1
I-1
tp34423
sS'increased,metabolism,of'
p34424
(F1
F0.00014334862385321102
I1
I0
I1
tp34425
sS'alcohol,or,potentiation'
p34426
(F1
F0.00028669724770642203
I0
I2
I-2
tp34427
sS'life,of,and'
p34428
(F1
F0.00014334862385321102
I1
I0
I1
tp34429
sS'and,behavioral,changes'
p34430
(F1
F0.00014334862385321102
I0
I1
I-1
tp34431
sS'k,aquamephyton,synkayvite'
p34432
(F1
F0.00014334862385321102
I0
I1
I-1
tp34433
sS'through,increased,metabolism'
p34434
(F1
F0.00014334862385321102
I1
I0
I1
tp34435
sS'and,commentaries,and'
p34436
(F1
F0.00014334862385321102
I0
I1
I-1
tp34437
sS'for,the,calcium-entry'
p34438
(F1
F0.00014334862385321102
I0
I1
I-1
tp34439
sS'titrated,according,to'
p34440
(F1
F0.00014334862385321102
I1
I0
I1
tp34441
sS'supplements,and,foods'
p34442
(F1
F0.00014334862385321102
I1
I0
I1
tp34443
sS'disorders,treated,with'
p34444
(F1
F0.00014334862385321102
I1
I0
I1
tp34445
sS'in,rodent,studies'
p34446
(F1
F0.00014334862385321102
I0
I1
I-1
tp34447
sS'of,mesenteric,arteries'
p34448
(F1
F0.00014334862385321102
I0
I1
I-1
tp34449
sS'risk,of,using'
p34450
(F1
F0.00014334862385321102
I1
I0
I1
tp34451
sS'idv,exposure,despite'
p34452
(F1
F0.00014334862385321102
I0
I1
I-1
tp34453
sS'not,induce,metabolic'
p34454
(F1
F0.00014334862385321102
I0
I1
I-1
tp34455
sS'their,increased,renal'
p34456
(F1
F0.00014334862385321102
I0
I1
I-1
tp34457
sS'sonata,mg,potentiated'
p34458
(F1
F0.00014334862385321102
I1
I0
I1
tp34459
sS'reached,after,administration'
p34460
(F1
F0.00014334862385321102
I1
I0
I1
tp34461
sS'may,produce,malabsorption'
p34462
(F1
F0.00014334862385321102
I1
I0
I1
tp34463
sS'curve,and,maximal'
p34464
(F1
F0.00014334862385321102
I1
I0
I1
tp34465
sS'been,administered,safely'
p34466
(F1
F0.00014334862385321102
I0
I1
I-1
tp34467
sS'of,antizol,by'
p34468
(F1
F0.00014334862385321102
I1
I0
I1
tp34469
sS'four,days,in'
p34470
(F1
F0.00014334862385321102
I0
I1
I-1
tp34471
sS'difference,p,in'
p34472
(F1
F0.00014334862385321102
I0
I1
I-1
tp34473
sS'reduced,in,order'
p34474
(F1
F0.00014334862385321102
I0
I1
I-1
tp34475
sS'tension,hoof,twitch'
p34476
(F1
F0.00014334862385321102
I0
I1
I-1
tp34477
sS'many,other,and'
p34478
(F1
F0.00071674311926605509
I0
I5
I-5
tp34479
sS'pharmacodynamics,of,acetylsalicylic'
p34480
(F1
F0.00014334862385321102
I0
I1
I-1
tp34481
sS'associated,dental,complications'
p34482
(F1
F0.00014334862385321102
I1
I0
I1
tp34483
sS'when,healthy,subjects'
p34484
(F1
F0.00014334862385321102
I0
I1
I-1
tp34485
sS'within,hours,before'
p34486
(F1
F0.00028669724770642203
I2
I0
I2
tp34487
sS'corticotropin,acth,may'
p34488
(F1
F0.00014334862385321102
I1
I0
I1
tp34489
sS'early,components,p1'
p34490
(F1
F0.00014334862385321102
I1
I0
I1
tp34491
sS'and,dilantin,phenobarbital'
p34492
(F1
F0.00014334862385321102
I1
I0
I1
tp34493
sS'peripheral,vasospasm,and'
p34494
(F1
F0.00014334862385321102
I0
I1
I-1
tp34495
sS'acid,calcium,channel-blocking'
p34496
(F1
F0.00014334862385321102
I0
I1
I-1
tp34497
sS'potassium,levels,the'
p34498
(F1
F0.00014334862385321102
I1
I0
I1
tp34499
sS'the,b-blocking,agent'
p34500
(F1
F0.00014334862385321102
I1
I0
I1
tp34501
sS'reduced,by,hepatic'
p34502
(F1
F0.00014334862385321102
I1
I0
I1
tp34503
sS'for,days,received'
p34504
(F1
F0.00014334862385321102
I0
I1
I-1
tp34505
sS'with,drugs,administered'
p34506
(F1
F0.00014334862385321102
I0
I1
I-1
tp34507
sS'of,the,dosage'
p34508
(F1
F0.00028669724770642203
I2
I0
I2
tp34509
sS'iii,decreased,antithrombin'
p34510
(F1
F0.00014334862385321102
I0
I1
I-1
tp34511
sS'days,and,titrated'
p34512
(F1
F0.00014334862385321102
I0
I1
I-1
tp34513
sS'and,or,resulted'
p34514
(F1
F0.00014334862385321102
I1
I0
I1
tp34515
sS'produced,approximately,the'
p34516
(F1
F0.00014334862385321102
I0
I1
I-1
tp34517
sS'the,digit,symbol'
p34518
(F1
F0.00014334862385321102
I1
I0
I1
tp34519
sS'decrease,in,auc'
p34520
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp34521
sS'possible,that,the'
p34522
(F1
F0.00028669724770642203
I2
I0
I2
tp34523
sS'data,vardenafil,should'
p34524
(F1
F0.00014334862385321102
I1
I0
I1
tp34525
sS'exerts,a,slight'
p34526
(F1
F0.00014334862385321102
I1
I0
I1
tp34527
sS'are,due,not'
p34528
(F1
F0.00014334862385321102
I1
I0
I1
tp34529
sS'contains,a,carbonic'
p34530
(F1
F0.00014334862385321102
I0
I1
I-1
tp34531
sS'the,calcium-entry,blocking'
p34532
(F1
F0.00014334862385321102
I0
I1
I-1
tp34533
sS'either,medicine,that'
p34534
(F1
F0.00014334862385321102
I1
I0
I1
tp34535
sS'apparent,oral,clearance'
p34536
(F1
F0.00043004587155963305
I3
I0
I3
tp34537
sS'treatment,with,synthetic'
p34538
(F1
F0.00014334862385321102
I0
I1
I-1
tp34539
sS'coadministration,with,increased'
p34540
(F1
F0.00014334862385321102
I1
I0
I1
tp34541
sS'clonazepam,literature,reports'
p34542
(F1
F0.00014334862385321102
I0
I1
I-1
tp34543
sS'falls,vs,and'
p34544
(F1
F0.00014334862385321102
I1
I0
I1
tp34545
sS'that,ingestion,may'
p34546
(F1
F0.00014334862385321102
I1
I0
I1
tp34547
sS'ra,were,treated'
p34548
(F1
F0.00028669724770642203
I2
I0
I2
tp34549
sS'the,channel,blocker'
p34550
(F1
F0.00014334862385321102
I0
I1
I-1
tp34551
sS'and,intestinal,beta-glucuronidase'
p34552
(F1
F0.00014334862385321102
I0
I1
I-1
tp34553
sS'has,been,effectively'
p34554
(F1
F0.00014334862385321102
I0
I1
I-1
tp34555
sS'four-day,regimen,of'
p34556
(F1
F0.00014334862385321102
I1
I0
I1
tp34557
sS'on,bar-press,behavior'
p34558
(F1
F0.00014334862385321102
I0
I1
I-1
tp34559
sS'interaction,with,other'
p34560
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp34561
sS'in,laboratory,assessments'
p34562
(F1
F0.00014334862385321102
I0
I1
I-1
tp34563
sS'clearance,and,significantly'
p34564
(F1
F0.00028669724770642203
I2
I0
I2
tp34565
sS'affect,renal,nonrenal'
p34566
(F1
F0.00014334862385321102
I0
I1
I-1
tp34567
sS'activity,of,low-dose'
p34568
(F1
F0.00014334862385321102
I0
I1
I-1
tp34569
sS'verapamil,also,significantly'
p34570
(F1
F0.00014334862385321102
I1
I0
I1
tp34571
sS'beta-adrenergic,blocking,add'
p34572
(F1
F0.00014334862385321102
I1
I0
I1
tp34573
sS'mean,terminal,half-life'
p34574
(F1
F0.00028669724770642203
I2
I0
I2
tp34575
sS'with,may,also'
p34576
(F1
F0.00014334862385321102
I1
I0
I1
tp34577
sS'their,similar,mechanism'
p34578
(F1
F0.00014334862385321102
I1
I0
I1
tp34579
sS'that,the,use'
p34580
(F1
F0.00014334862385321102
I0
I1
I-1
tp34581
sS'auc,of,ethinyl'
p34582
(F1
F0.00014334862385321102
I1
I0
I1
tp34583
sS'ethanol,an,additive'
p34584
(F1
F0.00014334862385321102
I1
I0
I1
tp34585
sS'pegasys,in,combination'
p34586
(F1
F0.00014334862385321102
I0
I1
I-1
tp34587
sS'in,absorption,results'
p34588
(F1
F0.00014334862385321102
I0
I1
I-1
tp34589
sS'dose,bioavailability,studies'
p34590
(F1
F0.00014334862385321102
I0
I1
I-1
tp34591
sS'to,eliminate,the'
p34592
(F1
F0.00014334862385321102
I1
I0
I1
tp34593
sS'concurrently,treated,with'
p34594
(F1
F0.00014334862385321102
I1
I0
I1
tp34595
sS'psychotomimetic,effects,in'
p34596
(F1
F0.00014334862385321102
I0
I1
I-1
tp34597
sS'experiments,on,dogs'
p34598
(F1
F0.00014334862385321102
I0
I1
I-1
tp34599
sS'does,not,undergo'
p34600
(F1
F0.00014334862385321102
I0
I1
I-1
tp34601
sS'of,the,cyp3a4'
p34602
(F1
F0.00028669724770642203
I2
I0
I2
tp34603
sS'single,mg,doses'
p34604
(F1
F0.00014334862385321102
I1
I0
I1
tp34605
sS'requirement,of,our'
p34606
(F1
F0.00014334862385321102
I1
I0
I1
tp34607
sS'january,and,august'
p34608
(F1
F0.00014334862385321102
I0
I1
I-1
tp34609
sS'medications,besides,mtx'
p34610
(F1
F0.00014334862385321102
I0
I1
I-1
tp34611
sS'that,apoptosis,can'
p34612
(F1
F0.00014334862385321102
I0
I1
I-1
tp34613
sS'tolbutamide,aprepitant,when'
p34614
(F1
F0.00014334862385321102
I1
I0
I1
tp34615
sS'by,resulting,in'
p34616
(F0
F0
I1
I1
I0
tp34617
sS'hivid,should,be'
p34618
(F1
F0.00014334862385321102
I0
I1
I-1
tp34619
sS'lithium,carbonate,mg'
p34620
(F1
F0.00014334862385321102
I0
I1
I-1
tp34621
sS'cyp3a4,eg,channel'
p34622
(F1
F0.00014334862385321102
I1
I0
I1
tp34623
sS'patients,taking,labetalol'
p34624
(F1
F0.00014334862385321102
I1
I0
I1
tp34625
sS'other,nonsteroidal,given'
p34626
(F1
F0.00014334862385321102
I0
I1
I-1
tp34627
sS'theophylline,vioxx,and'
p34628
(F1
F0.00014334862385321102
I1
I0
I1
tp34629
sS'prolongation,of,the'
p34630
(F0.875
F0.0020068807339449542
I15
I1
I14
tp34631
sS'urinary,retention,blurred'
p34632
(F1
F0.00014334862385321102
I1
I0
I1
tp34633
sS'disodium,interferes,with'
p34634
(F1
F0.00014334862385321102
I1
I0
I1
tp34635
sS'kt,oruvail,voltaren'
p34636
(F1
F0.00014334862385321102
I0
I1
I-1
tp34637
sS'adverse,reactions,to'
p34638
(F1
F0.00014334862385321102
I1
I0
I1
tp34639
sS'metabolized,by,hepatic'
p34640
(F1
F0.00014334862385321102
I1
I0
I1
tp34641
sS'did,not,produce'
p34642
(F1
F0.00014334862385321102
I0
I1
I-1
tp34643
sS'contrast,media,a'
p34644
(F1
F0.00014334862385321102
I1
I0
I1
tp34645
sS'since,invirase,is'
p34646
(F1
F0.00014334862385321102
I1
I0
I1
tp34647
sS'studied,and,have'
p34648
(F1
F0.00014334862385321102
I0
I1
I-1
tp34649
sS'l,induced,concentration-dependent'
p34650
(F1
F0.00014334862385321102
I0
I1
I-1
tp34651
sS'sodium,blood,levels'
p34652
(F1
F0.00014334862385321102
I1
I0
I1
tp34653
sS'signs,and,mental'
p34654
(F1
F0.00014334862385321102
I1
I0
I1
tp34655
sS'of,ascorbic,acid'
p34656
(F1
F0.00014334862385321102
I1
I0
I1
tp34657
sS'consideration,should,be'
p34658
(F1
F0.00043004587155963305
I3
I0
I3
tp34659
sS'vasodilation,is,not'
p34660
(F1
F0.00014334862385321102
I0
I1
I-1
tp34661
sS'kg,bwt,were'
p34662
(F1
F0.00014334862385321102
I0
I1
I-1
tp34663
sS'agents,gastrointestinal,alkalinizing'
p34664
(F1
F0.00014334862385321102
I1
I0
I1
tp34665
sS'made,of,mg'
p34666
(F1
F0.00014334862385321102
I0
I1
I-1
tp34667
sS'intensify,the,drying'
p34668
(F1
F0.00014334862385321102
I1
I0
I1
tp34669
sS'increasing,the,salt'
p34670
(F1
F0.00057339449541284407
I4
I0
I4
tp34671
sS'and,cell,permeability'
p34672
(F1
F0.00014334862385321102
I0
I1
I-1
tp34673
sS'important,potentiation,of'
p34674
(F1
F0.00014334862385321102
I0
I1
I-1
tp34675
sS'been,administered,concurrently'
p34676
(F1
F0.00014334862385321102
I0
I1
I-1
tp34677
sS'by,or,more'
p34678
(F1
F0.00014334862385321102
I1
I0
I1
tp34679
sS'with,concurrent,administration'
p34680
(F1
F0.00014334862385321102
I0
I1
I-1
tp34681
sS'p450,enzymes,i'
p34682
(F1
F0.00014334862385321102
I0
I1
I-1
tp34683
sS'significant,interactions,are'
p34684
(F1
F0.00014334862385321102
I0
I1
I-1
tp34685
sS'with,bleeding,or'
p34686
(F1
F0.00014334862385321102
I0
I1
I-1
tp34687
sS'intervals,or,in'
p34688
(F1
F0.00014334862385321102
I0
I1
I-1
tp34689
sS'levodopa,and,amantadine'
p34690
(F1
F0.00014334862385321102
I1
I0
I1
tp34691
sS'resulting,in,toxicity'
p34692
(F1
F0.00014334862385321102
I1
I0
I1
tp34693
sS'these,data,suggest'
p34694
(F1
F0.00014334862385321102
I0
I1
I-1
tp34695
sS'should,elapse,before'
p34696
(F1
F0.00014334862385321102
I1
I0
I1
tp34697
sS'metabolized,by,cyp1a2'
p34698
(F1
F0.00014334862385321102
I0
I1
I-1
tp34699
sS'or,intravenous,or'
p34700
(F1
F0.00014334862385321102
I1
I0
I1
tp34701
sS'dose,of,did'
p34702
(F1
F0.00014334862385321102
I0
I1
I-1
tp34703
sS'this,might,be'
p34704
(F1
F0.00014334862385321102
I1
I0
I1
tp34705
sS'administered,simultaneously,because'
p34706
(F1
F0.00014334862385321102
I1
I0
I1
tp34707
sS'a,such,as'
p34708
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp34709
sS'nonlinear,kinetic,characteristics'
p34710
(F1
F0.00014334862385321102
I0
I1
I-1
tp34711
sS'oral,injectable,transdermal'
p34712
(F1
F0.00028669724770642203
I2
I0
I2
tp34713
sS'products,concurrent,administration'
p34714
(F1
F0.00014334862385321102
I1
I0
I1
tp34715
sS'as,evidenced,by'
p34716
(F1
F0.00014334862385321102
I1
I0
I1
tp34717
sS'that,the,combination'
p34718
(F1
F0.00043004587155963305
I3
I0
I3
tp34719
sS'gland,who,are'
p34720
(F1
F0.00014334862385321102
I1
I0
I1
tp34721
sS'than,and,a'
p34722
(F1
F0.00014334862385321102
I1
I0
I1
tp34723
sS'patients,receiving,nonselective'
p34724
(F1
F0.00014334862385321102
I1
I0
I1
tp34725
sS'measured,from,the'
p34726
(F1
F0.00014334862385321102
I0
I1
I-1
tp34727
sS'blood,levels,was'
p34728
(F1
F0.00014334862385321102
I1
I0
I1
tp34729
sS'potentiates,the,effect'
p34730
(F1
F0.00014334862385321102
I1
I0
I1
tp34731
sS'into,the,systemic'
p34732
(F1
F0.00014334862385321102
I1
I0
I1
tp34733
sS'of,serious,reaction'
p34734
(F1
F0.00014334862385321102
I1
I0
I1
tp34735
sS'agents,including,humira'
p34736
(F1
F0.00014334862385321102
I1
I0
I1
tp34737
sS'controlled,studies,to'
p34738
(F1
F0.00014334862385321102
I0
I1
I-1
tp34739
sS'since,the,therapeutic'
p34740
(F1
F0.00014334862385321102
I0
I1
I-1
tp34741
sS'the,second,response'
p34742
(F1
F0.00014334862385321102
I0
I1
I-1
tp34743
sS'it,is,of'
p34744
(F1
F0.00014334862385321102
I0
I1
I-1
tp34745
sS'mg,causing,no'
p34746
(F1
F0.00014334862385321102
I0
I1
I-1
tp34747
sS'of,equetrotm,due'
p34748
(F1
F0.00014334862385321102
I1
I0
I1
tp34749
sS'combination,with,patients'
p34750
(F1
F0.00014334862385321102
I1
I0
I1
tp34751
sS'thiazide,may,increase'
p34752
(F1
F0.00014334862385321102
I1
I0
I1
tp34753
sS'the,authors,examined'
p34754
(F1
F0.00014334862385321102
I0
I1
I-1
tp34755
sS'recovery,in,a'
p34756
(F1
F0.00014334862385321102
I0
I1
I-1
tp34757
sS'of,an,additive'
p34758
(F1
F0.00028669724770642203
I2
I0
I2
tp34759
sS'artery,disease,aged'
p34760
(F1
F0.00014334862385321102
I0
I1
I-1
tp34761
sS'in,patients,with'
p34762
(F0.31428571428571428
F0.0015768348623853212
I12
I23
I-11
tp34763
sS'healthy,subjects,administered'
p34764
(F1
F0.00014334862385321102
I1
I0
I1
tp34765
sS'who,had,depleting'
p34766
(F1
F0.00014334862385321102
I0
I1
I-1
tp34767
sS'therapy,could,prolong'
p34768
(F1
F0.00014334862385321102
I1
I0
I1
tp34769
sS'approximately,of,the'
p34770
(F1
F0.00014334862385321102
I0
I1
I-1
tp34771
sS'prepared,in,water'
p34772
(F1
F0.00014334862385321102
I0
I1
I-1
tp34773
sS'increases,excretion,and'
p34774
(F1
F0.00014334862385321102
I1
I0
I1
tp34775
sS'loratadine,mg,once'
p34776
(F1
F0.00014334862385321102
I0
I1
I-1
tp34777
sS'effects,in,each'
p34778
(F1
F0.00014334862385321102
I0
I1
I-1
tp34779
sS'brevibloc,and,does'
p34780
(F1
F0.00014334862385321102
I0
I1
I-1
tp34781
sS'some,studies,and'
p34782
(F1
F0.00014334862385321102
I1
I0
I1
tp34783
sS'administered,with,maxipime'
p34784
(F1
F0.00014334862385321102
I1
I0
I1
tp34785
sS'state,serum,levels'
p34786
(F1
F0.00014334862385321102
I0
I1
I-1
tp34787
sS'cyp3a,may,increase'
p34788
(F1
F0.00014334862385321102
I0
I1
I-1
tp34789
sS'sensitive,to,ph'
p34790
(F1
F0.00014334862385321102
I0
I1
I-1
tp34791
sS'qd,resulted,in'
p34792
(F1
F0.00043004587155963305
I3
I0
I3
tp34793
sS'and,concentrations,and'
p34794
(F1
F0.00014334862385321102
I0
I1
I-1
tp34795
sS'use,of,hormone'
p34796
(F1
F0.00014334862385321102
I0
I1
I-1
tp34797
sS'administration,of,mg'
p34798
(F0.57894736842105265
F0.0015768348623853212
I15
I4
I11
tp34799
sS'of,warfarin-type,cyp2c9'
p34800
(F1
F0.00014334862385321102
I0
I1
I-1
tp34801
sS'observed,in,the'
p34802
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp34803
sS'to,either,was'
p34804
(F1
F0.00014334862385321102
I0
I1
I-1
tp34805
sS'deleted,from,a'
p34806
(F1
F0.00014334862385321102
I1
I0
I1
tp34807
sS'pose,clinical,problems'
p34808
(F1
F0.00071674311926605509
I5
I0
I5
tp34809
sS'a,renal,tubular'
p34810
(F1
F0.00014334862385321102
I0
I1
I-1
tp34811
sS'unaltered,by,concomitant'
p34812
(F1
F0.00014334862385321102
I0
I1
I-1
tp34813
sS'an,in,vitro'
p34814
(F1
F0.00028669724770642203
I2
I0
I2
tp34815
sS'known,to,inhibit'
p34816
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp34817
sS'microsomal,enzyme,system'
p34818
(F1
F0.00014334862385321102
I1
I0
I1
tp34819
sS'metabolites,dfur,fu'
p34820
(F1
F0.00014334862385321102
I0
I1
I-1
tp34821
sS'prepared,by,resecting'
p34822
(F1
F0.00014334862385321102
I0
I1
I-1
tp34823
sS'p450,a4,cyp'
p34824
(F1
F0.00014334862385321102
I1
I0
I1
tp34825
sS'the,secretory,effect'
p34826
(F1
F0.00014334862385321102
I1
I0
I1
tp34827
sS'with,but,this'
p34828
(F1
F0.00014334862385321102
I1
I0
I1
tp34829
sS'of,depressive,and'
p34830
(F1
F0.00014334862385321102
I0
I1
I-1
tp34831
sS'i131,a,rebound'
p34832
(F1
F0.00014334862385321102
I1
I0
I1
tp34833
sS'mesylate,has,been'
p34834
(F1
F0.00014334862385321102
I0
I1
I-1
tp34835
sS'tricyclic,antidepressant,or'
p34836
(F1
F0.00028669724770642203
I0
I2
I-2
tp34837
sS'megakaryocytes,with,extracellular'
p34838
(F1
F0.00014334862385321102
I1
I0
I1
tp34839
sS'risk,of,neurotoxic'
p34840
(F1
F0.00014334862385321102
I1
I0
I1
tp34841
sS'rpmi1640,containing,microgram'
p34842
(F1
F0.00014334862385321102
I0
I1
I-1
tp34843
sS'of,clonazepam,literature'
p34844
(F1
F0.00014334862385321102
I0
I1
I-1
tp34845
sS'and,a,mechanism'
p34846
(F1
F0.00014334862385321102
I1
I0
I1
tp34847
sS'doses,of,vitamin'
p34848
(F1
F0.00014334862385321102
I0
I1
I-1
tp34849
sS'dosage,may,be'
p34850
(F1
F0.00014334862385321102
I0
I1
I-1
tp34851
sS'decreased,the,antinociceptive'
p34852
(F1
F0.00028669724770642203
I2
I0
I2
tp34853
sS'and,human,studies'
p34854
(F1
F0.00014334862385321102
I0
I1
I-1
tp34855
sS'b,and,was'
p34856
(F1
F0.00014334862385321102
I1
I0
I1
tp34857
sS'surgical,procedures,during'
p34858
(F1
F0.00014334862385321102
I1
I0
I1
tp34859
sS'pharmacokinetic,interaction,occurred'
p34860
(F1
F0.00014334862385321102
I0
I1
I-1
tp34861
sS'fixed-ratio,fi,fr'
p34862
(F1
F0.00014334862385321102
I0
I1
I-1
tp34863
sS'interactions,the,central'
p34864
(F1
F0.00014334862385321102
I1
I0
I1
tp34865
sS'biological,and,behavioral'
p34866
(F1
F0.00014334862385321102
I1
I0
I1
tp34867
sS'among,bosentan-,and'
p34868
(F1
F0.00014334862385321102
I0
I1
I-1
tp34869
sS'the,steadystate,trough'
p34870
(F1
F0.00014334862385321102
I0
I1
I-1
tp34871
sS'demonstrated,by,the'
p34872
(F1
F0.00014334862385321102
I0
I1
I-1
tp34873
sS'the,oral,absorption'
p34874
(F1
F0.00043004587155963305
I3
I0
I3
tp34875
sS'an,deficiency,can'
p34876
(F1
F0.00014334862385321102
I1
I0
I1
tp34877
sS'physician,should,be'
p34878
(F0
F0
I2
I2
I0
tp34879
sS'be,acutely,worsened'
p34880
(F1
F0.00014334862385321102
I1
I0
I1
tp34881
sS'mortality,rate,in'
p34882
(F1
F0.00014334862385321102
I0
I1
I-1
tp34883
sS'the,gradual,withdrawal'
p34884
(F1
F0.00014334862385321102
I0
I1
I-1
tp34885
sS'renal,vasodilator,effects'
p34886
(F1
F0.00014334862385321102
I0
I1
I-1
tp34887
sS'following,co-administration,of'
p34888
(F1
F0.00014334862385321102
I0
I1
I-1
tp34889
sS'agents,ethinyl,estradiol'
p34890
(F1
F0.00014334862385321102
I0
I1
I-1
tp34891
sS'elemental,reduced,extent'
p34892
(F1
F0.00014334862385321102
I1
I0
I1
tp34893
sS'signs,of,hypoglycemia'
p34894
(F1
F0.00028669724770642203
I0
I2
I-2
tp34895
sS'class,which,includes'
p34896
(F1
F0.00014334862385321102
I0
I1
I-1
tp34897
sS'those,seen,prior'
p34898
(F1
F0.00014334862385321102
I1
I0
I1
tp34899
sS'of,high,doses'
p34900
(F0
F0
I1
I1
I0
tp34901
sS'monitored,especially,if'
p34902
(F1
F0.00014334862385321102
I0
I1
I-1
tp34903
sS'of,enterococcus,faecalis'
p34904
(F1
F0.00014334862385321102
I0
I1
I-1
tp34905
sS'animals,were,not'
p34906
(F1
F0.00014334862385321102
I0
I1
I-1
tp34907
sS'and,return,toward'
p34908
(F1
F0.00014334862385321102
I0
I1
I-1
tp34909
sS'proposed,topical,dose'
p34910
(F1
F0.00014334862385321102
I0
I1
I-1
tp34911
sS'isoflurane,potentiates,the'
p34912
(F1
F0.00014334862385321102
I1
I0
I1
tp34913
sS'zyvox,may,experience'
p34914
(F1
F0.00014334862385321102
I1
I0
I1
tp34915
sS'hormones,appear,to'
p34916
(F1
F0.00014334862385321102
I0
I1
I-1
tp34917
sS'of,systemically,administered'
p34918
(F1
F0.00014334862385321102
I0
I1
I-1
tp34919
sS'disease,may,experience'
p34920
(F1
F0.00014334862385321102
I1
I0
I1
tp34921
sS'bismuth,subsalicylate,given'
p34922
(F1
F0.00014334862385321102
I1
I0
I1
tp34923
sS'supplements,may,give'
p34924
(F1
F0.00014334862385321102
I1
I0
I1
tp34925
sS'the,body,via'
p34926
(F1
F0.00014334862385321102
I1
I0
I1
tp34927
sS'the,study,dosed'
p34928
(F1
F0.00014334862385321102
I0
I1
I-1
tp34929
sS'of,these,potentially'
p34930
(F1
F0.00014334862385321102
I1
I0
I1
tp34931
sS'of,the,ermbt'
p34932
(F1
F0.00014334862385321102
I0
I1
I-1
tp34933
sS'clinician,should,be'
p34934
(F1
F0.00014334862385321102
I1
I0
I1
tp34935
sS'administration,with,racemic'
p34936
(F1
F0.00014334862385321102
I1
I0
I1
tp34937
sS'observed,when,multiple'
p34938
(F1
F0.00014334862385321102
I1
I0
I1
tp34939
sS'during,the,hour'
p34940
(F1
F0.00014334862385321102
I0
I1
I-1
tp34941
sS'inactivate,by,bacterial'
p34942
(F1
F0.00014334862385321102
I1
I0
I1
tp34943
sS'of,indocin,and'
p34944
(F1
F0.00028669724770642203
I2
I0
I2
tp34945
sS'effect,on,felbatol'
p34946
(F1
F0.00014334862385321102
I0
I1
I-1
tp34947
sS'concomitantly,taking,or'
p34948
(F1
F0.00014334862385321102
I0
I1
I-1
tp34949
sS'aldehyde,oxidase,and'
p34950
(F1
F0.00014334862385321102
I1
I0
I1
tp34951
sS'was,due,to'
p34952
(F1
F0.00014334862385321102
I0
I1
I-1
tp34953
sS'beta,blockers,should'
p34954
(F1
F0.00014334862385321102
I1
I0
I1
tp34955
sS'each,task,it'
p34956
(F1
F0.00014334862385321102
I0
I1
I-1
tp34957
sS'infusion,in,horses'
p34958
(F1
F0.00014334862385321102
I0
I1
I-1
tp34959
sS'revia,and,other'
p34960
(F1
F0.00014334862385321102
I0
I1
I-1
tp34961
sS'was,analyzed,for'
p34962
(F1
F0.00014334862385321102
I0
I1
I-1
tp34963
sS'of,and,subsalicylate'
p34964
(F1
F0.00014334862385321102
I1
I0
I1
tp34965
sS'vitro,does,not'
p34966
(F1
F0.00014334862385321102
I0
I1
I-1
tp34967
sS'a2-selective,agonist,but'
p34968
(F1
F0.00014334862385321102
I1
I0
I1
tp34969
sS'is,highly,bound'
p34970
(F1
F0.00014334862385321102
I1
I0
I1
tp34971
sS'weeks,in,healthy'
p34972
(F1
F0.00014334862385321102
I1
I0
I1
tp34973
sS'excretion,ibuprofen,ibuprofen'
p34974
(F1
F0.00014334862385321102
I0
I1
I-1
tp34975
sS'warfarin,administration,of'
p34976
(F1
F0.00014334862385321102
I0
I1
I-1
tp34977
sS'binding,of,hcl'
p34978
(F1
F0.00014334862385321102
I0
I1
I-1
tp34979
sS'alone,auc,increased'
p34980
(F1
F0.00014334862385321102
I1
I0
I1
tp34981
sS'to,avoid,the'
p34982
(F0
F0
I1
I1
I0
tp34983
sS'restriction,or,dialysis'
p34984
(F1
F0.00014334862385321102
I1
I0
I1
tp34985
sS'with,does,not'
p34986
(F1
F0.00014334862385321102
I0
I1
I-1
tp34987
sS'listed,below,drugs'
p34988
(F1
F0.00014334862385321102
I1
I0
I1
tp34989
sS'the,manufacturer,or'
p34990
(F1
F0.00014334862385321102
I0
I1
I-1
tp34991
sS'compounds,and,beta-adrenergic'
p34992
(F1
F0.00014334862385321102
I1
I0
I1
tp34993
sS'of,both,s-warfarin'
p34994
(F1
F0.00014334862385321102
I1
I0
I1
tp34995
sS'maintained,on,monotherapy'
p34996
(F1
F0.00014334862385321102
I0
I1
I-1
tp34997
sS'drug,eg,and'
p34998
(F1
F0.00014334862385321102
I1
I0
I1
tp34999
sS'or,other,as'
p35000
(F1
F0.00014334862385321102
I1
I0
I1
tp35001
sS'by,and,hour'
p35002
(F1
F0.00014334862385321102
I1
I0
I1
tp35003
sS'should,be,watched'
p35004
(F1
F0.00014334862385321102
I1
I0
I1
tp35005
sS'adverse,events,associated'
p35006
(F1
F0.00014334862385321102
I1
I0
I1
tp35007
sS'decreased,when,administered'
p35008
(F1
F0.00028669724770642203
I2
I0
I2
tp35009
sS'limit,adverse,experiences'
p35010
(F1
F0.00014334862385321102
I1
I0
I1
tp35011
sS'maximum,of,mg'
p35012
(F1
F0.00043004587155963305
I3
I0
I3
tp35013
sS'an,attempt,to'
p35014
(F1
F0.00014334862385321102
I1
I0
I1
tp35015
sS'is,reasonable,to'
p35016
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35017
sS'who,are,treated'
p35018
(F1
F0.00014334862385321102
I1
I0
I1
tp35019
sS'to,an,enhancement'
p35020
(F1
F0.00014334862385321102
I1
I0
I1
tp35021
sS'since,and,potassium-sparing'
p35022
(F1
F0.00014334862385321102
I1
I0
I1
tp35023
sS'to,potentiate,the'
p35024
(F1
F0.00014334862385321102
I0
I1
I-1
tp35025
sS'haemodynamic,effects,of'
p35026
(F1
F0.00014334862385321102
I0
I1
I-1
tp35027
sS'lymphoma,on,combination'
p35028
(F1
F0.00014334862385321102
I0
I1
I-1
tp35029
sS'be,mimicked,by'
p35030
(F1
F0.00014334862385321102
I0
I1
I-1
tp35031
sS'a,hmg-coa,reductase'
p35032
(F1
F0.00014334862385321102
I1
I0
I1
tp35033
sS'tcas,such,as'
p35034
(F1
F0.00014334862385321102
I1
I0
I1
tp35035
sS'the,myasthenic,patient'
p35036
(F1
F0.00014334862385321102
I1
I0
I1
tp35037
sS'in,urinary,and'
p35038
(F1
F0.00014334862385321102
I1
I0
I1
tp35039
sS'ia,such,as'
p35040
(F1
F0.00014334862385321102
I1
I0
I1
tp35041
sS'nsaid,users,the'
p35042
(F1
F0.00014334862385321102
I0
I1
I-1
tp35043
sS'fi,fr,schedule'
p35044
(F1
F0.00014334862385321102
I0
I1
I-1
tp35045
sS'molecular,basis,for'
p35046
(F0
F0
I1
I1
I0
tp35047
sS'dexamethasone,at,m'
p35048
(F1
F0.00014334862385321102
I1
I0
I1
tp35049
sS'cyp2d6,is,unlikely'
p35050
(F1
F0.00014334862385321102
I0
I1
I-1
tp35051
sS'or,life-threatening,reactions'
p35052
(F1
F0.00014334862385321102
I0
I1
I-1
tp35053
sS'noted,to,develop'
p35054
(F1
F0.00014334862385321102
I1
I0
I1
tp35055
sS'cyp3a4,inducer,the'
p35056
(F1
F0.00014334862385321102
I1
I0
I1
tp35057
sS'first,hour,after'
p35058
(F1
F0.00014334862385321102
I1
I0
I1
tp35059
sS'to,high,temperature'
p35060
(F1
F0.00014334862385321102
I1
I0
I1
tp35061
sS'bound,to,serum'
p35062
(F1
F0.00014334862385321102
I1
I0
I1
tp35063
sS'since,an,increase'
p35064
(F1
F0.00014334862385321102
I1
I0
I1
tp35065
sS'ingestion,of,an'
p35066
(F1
F0.00014334862385321102
I1
I0
I1
tp35067
sS'href,bupropz_od,htm'
p35068
(F1
F0.00014334862385321102
I1
I0
I1
tp35069
sS'or,abolished,as'
p35070
(F1
F0.00014334862385321102
I1
I0
I1
tp35071
sS'metabolite,and,the'
p35072
(F1
F0.00014334862385321102
I0
I1
I-1
tp35073
sS'to,or,oral'
p35074
(F1
F0.00014334862385321102
I1
I0
I1
tp35075
sS'reduces,the,clearance'
p35076
(F1
F0.00028669724770642203
I2
I0
I2
tp35077
sS'inhibitor,resulted,in'
p35078
(F1
F0.00014334862385321102
I0
I1
I-1
tp35079
sS'fixed-interval,fixed-ratio,fi'
p35080
(F1
F0.00014334862385321102
I0
I1
I-1
tp35081
sS'attenuation,of,immunization'
p35082
(F1
F0.00014334862385321102
I1
I0
I1
tp35083
sS'that,identify,chromatin'
p35084
(F1
F0.00014334862385321102
I1
I0
I1
tp35085
sS'at,mg,qid'
p35086
(F1
F0.00014334862385321102
I1
I0
I1
tp35087
sS'with,other,cyp3a4'
p35088
(F1
F0.00014334862385321102
I1
I0
I1
tp35089
sS'given,with,nonsteroidal'
p35090
(F1
F0.00014334862385321102
I1
I0
I1
tp35091
sS'clinical,isolates,of'
p35092
(F1
F0.00014334862385321102
I0
I1
I-1
tp35093
sS'body,increase,in'
p35094
(F1
F0.00014334862385321102
I0
I1
I-1
tp35095
sS'nonsteroidal,given,with'
p35096
(F1
F0.00014334862385321102
I0
I1
I-1
tp35097
sS'inhibitors,mao,inhibitors'
p35098
(F1
F0.00014334862385321102
I0
I1
I-1
tp35099
sS'with,neurontin,mg'
p35100
(F1
F0.00014334862385321102
I1
I0
I1
tp35101
sS'and,monoamine,oxidase'
p35102
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp35103
sS'although,the,results'
p35104
(F1
F0.00014334862385321102
I1
I0
I1
tp35105
sS'cardiac,channel,blockers'
p35106
(F1
F0.00014334862385321102
I0
I1
I-1
tp35107
sS'the,antiedematous,action'
p35108
(F1
F0.00014334862385321102
I1
I0
I1
tp35109
sS'and,other,may'
p35110
(F1
F0.00043004587155963305
I3
I0
I3
tp35111
sS'angiotensin,ii,receptor'
p35112
(F0
F0
I1
I1
I0
tp35113
sS'decrease,to,increase'
p35114
(F1
F0.00028669724770642203
I2
I0
I2
tp35115
sS'anticholinesterase,effect,of'
p35116
(F1
F0.00014334862385321102
I1
I0
I1
tp35117
sS'recommended,that,be'
p35118
(F0
F0
I1
I1
I0
tp35119
sS'been,administered,without'
p35120
(F1
F0.00014334862385321102
I0
I1
I-1
tp35121
sS'than,usual,and'
p35122
(F1
F0.00014334862385321102
I1
I0
I1
tp35123
sS'effects,on,renal'
p35124
(F1
F0.00014334862385321102
I1
I0
I1
tp35125
sS'beta-blockers,and,other'
p35126
(F1
F0.00014334862385321102
I1
I0
I1
tp35127
sS'taking,another,class'
p35128
(F1
F0.00014334862385321102
I1
I0
I1
tp35129
sS'other,potent,a4'
p35130
(F1
F0.00014334862385321102
I1
I0
I1
tp35131
sS'notably,nondepolarizing,muscle'
p35132
(F1
F0.00014334862385321102
I1
I0
I1
tp35133
sS'interaction,of,foscavir'
p35134
(F1
F0.00014334862385321102
I1
I0
I1
tp35135
sS'of,postoperative,pain'
p35136
(F1
F0.00014334862385321102
I0
I1
I-1
tp35137
sS'agents,negative,inotropic'
p35138
(F1
F0.00014334862385321102
I1
I0
I1
tp35139
sS'absolute,number,of'
p35140
(F1
F0.00014334862385321102
I0
I1
I-1
tp35141
sS'antacids,aluminum-,or'
p35142
(F1
F0.00014334862385321102
I1
I0
I1
tp35143
sS'with,nonsteroidal,anti-inflammatory'
p35144
(F1
F0.00014334862385321102
I1
I0
I1
tp35145
sS'cancer,cell,growth'
p35146
(F1
F0.00014334862385321102
I0
I1
I-1
tp35147
sS'does,not,change'
p35148
(F1
F0.00014334862385321102
I0
I1
I-1
tp35149
sS'patients,taking,since'
p35150
(F1
F0.00014334862385321102
I1
I0
I1
tp35151
sS'cause,changes,in'
p35152
(F1
F0.00028669724770642203
I2
I0
I2
tp35153
sS'optimal,dosing,interval'
p35154
(F1
F0.00014334862385321102
I0
I1
I-1
tp35155
sS'clinically,important,interactions'
p35156
(F1
F0.00028669724770642203
I0
I2
I-2
tp35157
sS'is,administered,immediately'
p35158
(F1
F0.00014334862385321102
I1
I0
I1
tp35159
sS'nsaids,a,interaction'
p35160
(F1
F0.00014334862385321102
I0
I1
I-1
tp35161
sS'derived,from,a'
p35162
(F1
F0.00014334862385321102
I1
I0
I1
tp35163
sS'dactinomycin,may,interfere'
p35164
(F1
F0.00014334862385321102
I0
I1
I-1
tp35165
sS'taking,that,inhibit'
p35166
(F1
F0.00014334862385321102
I0
I1
I-1
tp35167
sS'other,that,block'
p35168
(F1
F0.00014334862385321102
I0
I1
I-1
tp35169
sS'blockers,including,were'
p35170
(F1
F0.00014334862385321102
I0
I1
I-1
tp35171
sS'probenecid,probenecid,increases'
p35172
(F1
F0.00014334862385321102
I1
I0
I1
tp35173
sS'kineret,and,developed'
p35174
(F1
F0.00014334862385321102
I1
I0
I1
tp35175
sS'combination,with,against'
p35176
(F1
F0.00014334862385321102
I0
I1
I-1
tp35177
sS'inhibition,significantly,reduced'
p35178
(F1
F0.00014334862385321102
I1
I0
I1
tp35179
sS'should,consider,discontinuation'
p35180
(F1
F0.00014334862385321102
I1
I0
I1
tp35181
sS'likely,to,be'
p35182
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp35183
sS'a,four-day,regimen'
p35184
(F1
F0.00014334862385321102
I1
I0
I1
tp35185
sS'therefore,such,use'
p35186
(F1
F0.00014334862385321102
I1
I0
I1
tp35187
sS'or,monitoring,of'
p35188
(F1
F0.00014334862385321102
I0
I1
I-1
tp35189
sS'more,efficiently,inhibited'
p35190
(F1
F0.00014334862385321102
I0
I1
I-1
tp35191
sS'with,similar,responses'
p35192
(F1
F0.00014334862385321102
I0
I1
I-1
tp35193
sS'q12h,for,four'
p35194
(F1
F0.00014334862385321102
I0
I1
I-1
tp35195
sS'in,plasma,exposures'
p35196
(F1
F0.00014334862385321102
I1
I0
I1
tp35197
sS'as,indicated,by'
p35198
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35199
sS'agents,are,used'
p35200
(F1
F0.00071674311926605509
I5
I0
I5
tp35201
sS'conducted,it,is'
p35202
(F1
F0.00014334862385321102
I1
I0
I1
tp35203
sS'not,due,to'
p35204
(F0
F0
I1
I1
I0
tp35205
sS'and,a,new'
p35206
(F1
F0.00014334862385321102
I0
I1
I-1
tp35207
sS'between,treatments,with'
p35208
(F1
F0.00014334862385321102
I0
I1
I-1
tp35209
sS'concentrations,of,micrograms'
p35210
(F1
F0.00014334862385321102
I0
I1
I-1
tp35211
sS'carefully,monitored,for'
p35212
(F1
F0.00014334862385321102
I1
I0
I1
tp35213
sS'the,mucocutaneous,and'
p35214
(F1
F0.00014334862385321102
I0
I1
I-1
tp35215
sS'upon,the,reaction'
p35216
(F1
F0.00014334862385321102
I1
I0
I1
tp35217
sS'that,and,its'
p35218
(F1
F0.00014334862385321102
I0
I1
I-1
tp35219
sS'reactions,including,hypertensive'
p35220
(F1
F0.00014334862385321102
I1
I0
I1
tp35221
sS'evaluating,the,effect'
p35222
(F1
F0.00014334862385321102
I1
I0
I1
tp35223
sS'by,since,and'
p35224
(F1
F0.00014334862385321102
I1
I0
I1
tp35225
sS'in,a,clinical'
p35226
(F0
F0
I3
I3
I0
tp35227
sS'been,reported,predominantly'
p35228
(F1
F0.00014334862385321102
I1
I0
I1
tp35229
sS'mg,administered,daily'
p35230
(F1
F0.00014334862385321102
I0
I1
I-1
tp35231
sS'side,effects,kemstro'
p35232
(F1
F0.00014334862385321102
I0
I1
I-1
tp35233
sS'usually,depresses,activity'
p35234
(F1
F0.00014334862385321102
I1
I0
I1
tp35235
sS'and,g,resulted'
p35236
(F1
F0.00014334862385321102
I1
I0
I1
tp35237
sS'enbrel,was,unaltered'
p35238
(F1
F0.00014334862385321102
I0
I1
I-1
tp35239
sS'ketoconazole,phenytoin,phenobarbitol'
p35240
(F1
F0.00014334862385321102
I0
I1
I-1
tp35241
sS'prior,to,administration'
p35242
(F1
F0.00014334862385321102
I0
I1
I-1
tp35243
sS'been,found,in'
p35244
(F1
F0.00028669724770642203
I0
I2
I-2
tp35245
sS'with,other,antiepileptic'
p35246
(F1
F0.00014334862385321102
I1
I0
I1
tp35247
sS'be,given,only'
p35248
(F1
F0.00014334862385321102
I0
I1
I-1
tp35249
sS'anti,platelet,agents'
p35250
(F1
F0.00014334862385321102
I0
I1
I-1
tp35251
sS'last,intravenous,dose'
p35252
(F1
F0.00014334862385321102
I1
I0
I1
tp35253
sS'soluble,to,the'
p35254
(F1
F0.00014334862385321102
I0
I1
I-1
tp35255
sS'discontinued,or,decreased'
p35256
(F1
F0.00014334862385321102
I1
I0
I1
tp35257
sS'not,potentiate,the'
p35258
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp35259
sS'adverse,events,when'
p35260
(F1
F0.00028669724770642203
I0
I2
I-2
tp35261
sS'were,not,co-administered'
p35262
(F1
F0.00014334862385321102
I0
I1
I-1
tp35263
sS'pharmacokinetics,in,patients'
p35264
(F1
F0.00014334862385321102
I0
I1
I-1
tp35265
sS'should,be,exercised'
p35266
(F0.47826086956521741
F0.0015768348623853212
I17
I6
I11
tp35267
sS'perfused,pancreases,of'
p35268
(F1
F0.00014334862385321102
I0
I1
I-1
tp35269
sS'caution,to,patients'
p35270
(F1
F0.0008600917431192661
I6
I0
I6
tp35271
sS'hydroxytolbutamide,and,by'
p35272
(F1
F0.00014334862385321102
I0
I1
I-1
tp35273
sS'of,breakthrough,symptoms'
p35274
(F1
F0.00014334862385321102
I0
I1
I-1
tp35275
sS'aliskiren,on,other'
p35276
(F1
F0.00014334862385321102
I0
I1
I-1
tp35277
sS'protein,the,administration'
p35278
(F1
F0.00014334862385321102
I1
I0
I1
tp35279
sS'experimental,soft-gelatin,capsule'
p35280
(F1
F0.00014334862385321102
I1
I0
I1
tp35281
sS'to,a,regimen'
p35282
(F1
F0.00014334862385321102
I1
I0
I1
tp35283
sS'ig,for,days'
p35284
(F1
F0.00014334862385321102
I1
I0
I1
tp35285
sS'response,to,agents'
p35286
(F1
F0.00014334862385321102
I1
I0
I1
tp35287
sS'that,are,potent'
p35288
(F1
F0.00043004587155963305
I3
I0
I3
tp35289
sS'trials,with,these'
p35290
(F1
F0.00014334862385321102
I1
I0
I1
tp35291
sS'to,be,receiving'
p35292
(F1
F0.00014334862385321102
I1
I0
I1
tp35293
sS'facultative,and,anaerobic'
p35294
(F1
F0.00014334862385321102
I0
I1
I-1
tp35295
sS'effect,of,aeds'
p35296
(F1
F0.00014334862385321102
I1
I0
I1
tp35297
sS'and,coexisting,in'
p35298
(F1
F0.00014334862385321102
I0
I1
I-1
tp35299
sS'were,added,to'
p35300
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp35301
sS'and,cmax,of'
p35302
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp35303
sS'increase,blood,levels'
p35304
(F1
F0.00014334862385321102
I1
I0
I1
tp35305
sS'depression,or,may'
p35306
(F1
F0.00014334862385321102
I1
I0
I1
tp35307
sS'the,cns-depressant,action'
p35308
(F1
F0.00014334862385321102
I1
I0
I1
tp35309
sS'hours,after,injection'
p35310
(F1
F0.00014334862385321102
I1
I0
I1
tp35311
sS'impairment,the,use'
p35312
(F1
F0.00014334862385321102
I1
I0
I1
tp35313
sS'a,antidepressant,eg'
p35314
(F1
F0.00014334862385321102
I1
I0
I1
tp35315
sS'heart,failure,nyha'
p35316
(F1
F0.00014334862385321102
I0
I1
I-1
tp35317
sS'use,of,certain'
p35318
(F1
F0.00014334862385321102
I0
I1
I-1
tp35319
sS'advisable,to,continue'
p35320
(F1
F0.00014334862385321102
I1
I0
I1
tp35321
sS'given,the,long'
p35322
(F1
F0.00014334862385321102
I1
I0
I1
tp35323
sS'alone,had,no'
p35324
(F1
F0.00028669724770642203
I2
I0
I2
tp35325
sS'to,minutes,p'
p35326
(F1
F0.00014334862385321102
I1
I0
I1
tp35327
sS'indocin,mg,t'
p35328
(F1
F0.00014334862385321102
I1
I0
I1
tp35329
sS'with,tikosyn,as'
p35330
(F1
F0.00014334862385321102
I1
I0
I1
tp35331
sS'included,brovana,doses'
p35332
(F1
F0.00014334862385321102
I0
I1
I-1
tp35333
sS'shown,a,significant'
p35334
(F1
F0.00028669724770642203
I2
I0
I2
tp35335
sS'or,uncomplicated,urinary'
p35336
(F1
F0.00014334862385321102
I0
I1
I-1
tp35337
sS'the,study,had'
p35338
(F1
F0.00014334862385321102
I0
I1
I-1
tp35339
sS'when,sustiva,is'
p35340
(F0
F0
I1
I1
I0
tp35341
sS'taking,labetalol,hcl'
p35342
(F1
F0.00014334862385321102
I1
I0
I1
tp35343
sS'should,be,adjusted'
p35344
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35345
sS'post-myocardial,infarction,in'
p35346
(F1
F0.00014334862385321102
I0
I1
I-1
tp35347
sS'ra,clinical,studies'
p35348
(F1
F0.00014334862385321102
I0
I1
I-1
tp35349
sS'and,other,inducers'
p35350
(F0
F0
I1
I1
I0
tp35351
sS'actions,and,will'
p35352
(F1
F0.00014334862385321102
I0
I1
I-1
tp35353
sS'other,than,suggest'
p35354
(F1
F0.00028669724770642203
I2
I0
I2
tp35355
sS'a,lower,affinity'
p35356
(F1
F0.00014334862385321102
I1
I0
I1
tp35357
sS'prostaglandins,and,increase'
p35358
(F1
F0.00014334862385321102
I0
I1
I-1
tp35359
sS'is,advised,to'
p35360
(F1
F0.00014334862385321102
I0
I1
I-1
tp35361
sS'weekly,or,glatiramer'
p35362
(F1
F0.00014334862385321102
I0
I1
I-1
tp35363
sS'alertness,and,impaired'
p35364
(F1
F0.00028669724770642203
I2
I0
I2
tp35365
sS'by,while,those'
p35366
(F1
F0.00014334862385321102
I1
I0
I1
tp35367
sS'with,other,drugs'
p35368
(F1
F0.00028669724770642203
I0
I2
I-2
tp35369
sS'since,the,toxic'
p35370
(F1
F0.00028669724770642203
I2
I0
I2
tp35371
sS'with,concomitant,agents'
p35372
(F1
F0.00014334862385321102
I0
I1
I-1
tp35373
sS'mg,single,dose'
p35374
(F1
F0.00028669724770642203
I2
I0
I2
tp35375
sS't,max,increased'
p35376
(F1
F0.00014334862385321102
I1
I0
I1
tp35377
sS'heart,rate,and'
p35378
(F1
F0.00014334862385321102
I1
I0
I1
tp35379
sS'concentrations,were,found'
p35380
(F1
F0.00014334862385321102
I0
I1
I-1
tp35381
sS'as,muscle,pain'
p35382
(F1
F0.00014334862385321102
I0
I1
I-1
tp35383
sS'profound,sedation,or'
p35384
(F1
F0.00014334862385321102
I1
I0
I1
tp35385
sS'the,time,of'
p35386
(F0
F0
I1
I1
I0
tp35387
sS'general,population,of'
p35388
(F1
F0.00014334862385321102
I0
I1
I-1
tp35389
sS'hg,compared,to'
p35390
(F1
F0.00014334862385321102
I1
I0
I1
tp35391
sS'agents,known,to'
p35392
(F1
F0.00014334862385321102
I1
I0
I1
tp35393
sS'interaction,with,its'
p35394
(F1
F0.00014334862385321102
I1
I0
I1
tp35395
sS'with,an,intravenous'
p35396
(F1
F0.00028669724770642203
I2
I0
I2
tp35397
sS'clinical,studies,adjuvant'
p35398
(F1
F0.00014334862385321102
I1
I0
I1
tp35399
sS'of,on,high'
p35400
(F1
F0.00014334862385321102
I0
I1
I-1
tp35401
sS'however,concomitant,administration'
p35402
(F1
F0.00014334862385321102
I1
I0
I1
tp35403
sS'level,of,was'
p35404
(F1
F0.00014334862385321102
I1
I0
I1
tp35405
sS'step,in,metabolism'
p35406
(F1
F0.00014334862385321102
I0
I1
I-1
tp35407
sS'a4,increased,the'
p35408
(F1
F0.00014334862385321102
I1
I0
I1
tp35409
sS'a,vitamin,b12'
p35410
(F1
F0.00014334862385321102
I1
I0
I1
tp35411
sS'co-administration,of,tikosyn'
p35412
(F1
F0.00014334862385321102
I1
I0
I1
tp35413
sS'of,other,on'
p35414
(F1
F0.00028669724770642203
I0
I2
I-2
tp35415
sS'griseofulvin,may,induce'
p35416
(F1
F0.00014334862385321102
I1
I0
I1
tp35417
sS'ventricular,fibrulation,and'
p35418
(F1
F0.00014334862385321102
I1
I0
I1
tp35419
sS'for,five,days'
p35420
(F1
F0.00014334862385321102
I0
I1
I-1
tp35421
sS'increase,awareness,of'
p35422
(F1
F0.00014334862385321102
I1
I0
I1
tp35423
sS'compared,with,administered'
p35424
(F1
F0.00014334862385321102
I1
I0
I1
tp35425
sS'nicotine,may,provoke'
p35426
(F1
F0.00014334862385321102
I1
I0
I1
tp35427
sS'should,be,introduced'
p35428
(F1
F0.00014334862385321102
I1
I0
I1
tp35429
sS'and,electrolyte,disturbances'
p35430
(F1
F0.00014334862385321102
I1
I0
I1
tp35431
sS'for,metabolism,were'
p35432
(F1
F0.00014334862385321102
I0
I1
I-1
tp35433
sS'days,and,for'
p35434
(F1
F0.00014334862385321102
I0
I1
I-1
tp35435
sS'these,techniques,confirmation'
p35436
(F1
F0.00014334862385321102
I0
I1
I-1
tp35437
sS'hormonal,increasing,plasma'
p35438
(F1
F0.00014334862385321102
I1
I0
I1
tp35439
sS'absolute,in,a'
p35440
(F1
F0.00014334862385321102
I0
I1
I-1
tp35441
sS'or,camp-stimulated,acid'
p35442
(F1
F0.00014334862385321102
I1
I0
I1
tp35443
sS'in,eight,healthy'
p35444
(F1
F0.00014334862385321102
I1
I0
I1
tp35445
sS'with,on,the'
p35446
(F1
F0.00014334862385321102
I1
I0
I1
tp35447
sS'concentrations,of,or'
p35448
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp35449
sS'other,highly,plasma'
p35450
(F1
F0.00014334862385321102
I1
I0
I1
tp35451
sS'their,serum,half-life'
p35452
(F1
F0.00014334862385321102
I0
I1
I-1
tp35453
sS'the,above,effects'
p35454
(F1
F0.00014334862385321102
I1
I0
I1
tp35455
sS'evidence,that,and'
p35456
(F1
F0.00014334862385321102
I0
I1
I-1
tp35457
sS'that,has,been'
p35458
(F1
F0.00014334862385321102
I1
I0
I1
tp35459
sS'theophylline,grepafloxacin,is'
p35460
(F1
F0.00014334862385321102
I1
I0
I1
tp35461
sS'caused,by,high'
p35462
(F1
F0.00014334862385321102
I1
I0
I1
tp35463
sS'and,calcium-rich,foods'
p35464
(F1
F0.00014334862385321102
I1
I0
I1
tp35465
sS'or,in,two'
p35466
(F1
F0.00014334862385321102
I1
I0
I1
tp35467
sS'or,videx,chewable'
p35468
(F1
F0.00043004587155963305
I3
I0
I3
tp35469
sS'reduced,or,the'
p35470
(F1
F0.00014334862385321102
I1
I0
I1
tp35471
sS'verapamil,the,risk'
p35472
(F1
F0.00014334862385321102
I1
I0
I1
tp35473
sS'relaxants,birth,control'
p35474
(F1
F0.00014334862385321102
I0
I1
I-1
tp35475
sS'cytochrome,cyp,c9'
p35476
(F1
F0.00014334862385321102
I0
I1
I-1
tp35477
sS'both,increases,and'
p35478
(F1
F0.00014334862385321102
I1
I0
I1
tp35479
sS'and,oral,and'
p35480
(F1
F0.00014334862385321102
I0
I1
I-1
tp35481
sS'the,time,for'
p35482
(F1
F0.00014334862385321102
I0
I1
I-1
tp35483
sS'blood,is,drawn'
p35484
(F1
F0.00014334862385321102
I1
I0
I1
tp35485
sS'affect,responding,for'
p35486
(F1
F0.00014334862385321102
I0
I1
I-1
tp35487
sS'in,anti-inflammatory,activity'
p35488
(F1
F0.00014334862385321102
I1
I0
I1
tp35489
sS'injection,and,should'
p35490
(F1
F0.00014334862385321102
I1
I0
I1
tp35491
sS'of,leading,to'
p35492
(F1
F0.00071674311926605509
I5
I0
I5
tp35493
sS'cumulative,incidence,of'
p35494
(F1
F0.00014334862385321102
I0
I1
I-1
tp35495
sS'at,increased,risk'
p35496
(F0
F0
I2
I2
I0
tp35497
sS'likely,to,occur'
p35498
(F1
F0.00014334862385321102
I0
I1
I-1
tp35499
sS'were,there,any'
p35500
(F1
F0.00014334862385321102
I0
I1
I-1
tp35501
sS'to,accelerate,the'
p35502
(F1
F0.00014334862385321102
I0
I1
I-1
tp35503
sS'administration,of,nonsteroial'
p35504
(F1
F0.00014334862385321102
I1
I0
I1
tp35505
sS'than,when,or'
p35506
(F1
F0.00014334862385321102
I0
I1
I-1
tp35507
sS'be,prolonged,in'
p35508
(F1
F0.00014334862385321102
I1
I0
I1
tp35509
sS'drugs,alcohol,when'
p35510
(F1
F0.00014334862385321102
I0
I1
I-1
tp35511
sS'is,accelerated,when'
p35512
(F1
F0.00014334862385321102
I1
I0
I1
tp35513
sS'tricyclic,metabolism,may'
p35514
(F1
F0.00014334862385321102
I1
I0
I1
tp35515
sS'lead,to,an'
p35516
(F1
F0.00043004587155963305
I3
I0
I3
tp35517
sS'concomitant,medications,that'
p35518
(F0
F0
I1
I1
I0
tp35519
sS'clinical,pharmacology,drug-'
p35520
(F1
F0.00014334862385321102
I0
I1
I-1
tp35521
sS'maintenance,dose,should'
p35522
(F1
F0.00014334862385321102
I1
I0
I1
tp35523
sS'in,any,statistically'
p35524
(F1
F0.00014334862385321102
I0
I1
I-1
tp35525
sS'similar,effects,and'
p35526
(F1
F0.00014334862385321102
I0
I1
I-1
tp35527
sS'and,have,a'
p35528
(F1
F0.00028669724770642203
I0
I2
I-2
tp35529
sS'labetalol,hcl,blunts'
p35530
(F1
F0.00014334862385321102
I1
I0
I1
tp35531
sS'in,the,blood'
p35532
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp35533
sS'should,precede,dosing'
p35534
(F1
F0.00014334862385321102
I0
I1
I-1
tp35535
sS'taking,vioxx,concomitantly'
p35536
(F1
F0.00014334862385321102
I1
I0
I1
tp35537
sS'tbars,levels,in'
p35538
(F1
F0.00014334862385321102
I1
I0
I1
tp35539
sS'gain,and,increased'
p35540
(F1
F0.00014334862385321102
I0
I1
I-1
tp35541
sS'a,with,c'
p35542
(F1
F0.00014334862385321102
I0
I1
I-1
tp35543
sS'or,other,cns'
p35544
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp35545
sS'of,oral,agents'
p35546
(F1
F0.00014334862385321102
I0
I1
I-1
tp35547
sS'as,mg,twice'
p35548
(F1
F0.00014334862385321102
I1
I0
I1
tp35549
sS'increased,effects,of'
p35550
(F1
F0.00014334862385321102
I0
I1
I-1
tp35551
sS'proleukin,and,thus'
p35552
(F1
F0.00014334862385321102
I1
I0
I1
tp35553
sS'p,although,consistent'
p35554
(F1
F0.00014334862385321102
I0
I1
I-1
tp35555
sS'etc,that,lower'
p35556
(F1
F0.00014334862385321102
I1
I0
I1
tp35557
sS'fe,instead,of'
p35558
(F1
F0.00014334862385321102
I1
I0
I1
tp35559
sS'or,prolong,adverse'
p35560
(F1
F0.00014334862385321102
I1
I0
I1
tp35561
sS'given,as,sequential'
p35562
(F1
F0.00014334862385321102
I1
I0
I1
tp35563
sS'without,significantly,lowering'
p35564
(F1
F0.00014334862385321102
I0
I1
I-1
tp35565
sS'tuberculosis,showed,a'
p35566
(F1
F0.00014334862385321102
I1
I0
I1
tp35567
sS'fold,increases,in'
p35568
(F0
F0
I1
I1
I0
tp35569
sS'is,very,low'
p35570
(F1
F0.00014334862385321102
I0
I1
I-1
tp35571
sS'trials,the,concomitant'
p35572
(F1
F0.00014334862385321102
I0
I1
I-1
tp35573
sS'treatment,study,and'
p35574
(F1
F0.00014334862385321102
I0
I1
I-1
tp35575
sS'extensive,metabolizers,of'
p35576
(F1
F0.00014334862385321102
I1
I0
I1
tp35577
sS'was,seen,on'
p35578
(F1
F0.00014334862385321102
I0
I1
I-1
tp35579
sS'however,l-name,and'
p35580
(F1
F0.00014334862385321102
I0
I1
I-1
tp35581
sS'between,and,pharmacokinetics'
p35582
(F1
F0.00014334862385321102
I0
I1
I-1
tp35583
sS'nsaids,on,gi'
p35584
(F1
F0.00028669724770642203
I2
I0
I2
tp35585
sS'altered,to,a'
p35586
(F1
F0.00014334862385321102
I0
I1
I-1
tp35587
sS'oxo-desethylzaleplon,glucuronide,account'
p35588
(F1
F0.00014334862385321102
I0
I1
I-1
tp35589
sS'administered,in,patients'
p35590
(F1
F0.00014334862385321102
I1
I0
I1
tp35591
sS'and,can,produce'
p35592
(F1
F0.00014334862385321102
I1
I0
I1
tp35593
sS'on,diuretic,therapy'
p35594
(F1
F0.00043004587155963305
I3
I0
I3
tp35595
sS'and,other,non-steroidal'
p35596
(F1
F0.00028669724770642203
I2
I0
I2
tp35597
sS'of,withdrawal,syndrome'
p35598
(F1
F0.00014334862385321102
I1
I0
I1
tp35599
sS'such,as,belladonna'
p35600
(F1
F0.00014334862385321102
I1
I0
I1
tp35601
sS'marrow,megakaryocytes,with'
p35602
(F1
F0.00014334862385321102
I0
I1
I-1
tp35603
sS'received,concomitant,at'
p35604
(F1
F0.00028669724770642203
I0
I2
I-2
tp35605
sS'from,bovine,lung'
p35606
(F1
F0.00014334862385321102
I0
I1
I-1
tp35607
sS'have,enhanced,the'
p35608
(F1
F0.00014334862385321102
I1
I0
I1
tp35609
sS'cmax,of,were'
p35610
(F1
F0.00014334862385321102
I1
I0
I1
tp35611
sS'a,mean,of'
p35612
(F0
F0
I1
I1
I0
tp35613
sS'increase,in,bleeding'
p35614
(F1
F0.00014334862385321102
I0
I1
I-1
tp35615
sS'fade,recovery,took'
p35616
(F1
F0.00014334862385321102
I1
I0
I1
tp35617
sS'isoform,mediate,the'
p35618
(F1
F0.00014334862385321102
I0
I1
I-1
tp35619
sS'are,begun,in'
p35620
(F1
F0.00014334862385321102
I1
I0
I1
tp35621
sS'of,and,sodium'
p35622
(F1
F0.00014334862385321102
I0
I1
I-1
tp35623
sS'therapeutic,monitoring,can'
p35624
(F1
F0.00014334862385321102
I1
I0
I1
tp35625
sS'potentiate,the,therapeutic'
p35626
(F1
F0.00014334862385321102
I1
I0
I1
tp35627
sS'narrow,therapeutic,indices'
p35628
(F1
F0.00014334862385321102
I1
I0
I1
tp35629
sS'metabolism,of,antagonists'
p35630
(F1
F0.00014334862385321102
I0
I1
I-1
tp35631
sS'several,hours,for'
p35632
(F1
F0.00014334862385321102
I1
I0
I1
tp35633
sS'or,stopping,since'
p35634
(F1
F0.00014334862385321102
I1
I0
I1
tp35635
sS'the,majority,of'
p35636
(F1
F0.00014334862385321102
I0
I1
I-1
tp35637
sS'of,various,doses'
p35638
(F1
F0.00014334862385321102
I0
I1
I-1
tp35639
sS'patients,the,incidence'
p35640
(F1
F0.00014334862385321102
I0
I1
I-1
tp35641
sS'reported,for,other'
p35642
(F1
F0.00014334862385321102
I0
I1
I-1
tp35643
sS'incidence,of,peritoneal'
p35644
(F1
F0.00014334862385321102
I0
I1
I-1
tp35645
sS'enhance,the,mitogenic'
p35646
(F1
F0.00014334862385321102
I1
I0
I1
tp35647
sS'including,cyp1a2,cyp2c9'
p35648
(F1
F0.00014334862385321102
I0
I1
I-1
tp35649
sS'some,patients,have'
p35650
(F1
F0.00014334862385321102
I1
I0
I1
tp35651
sS'interaction,of,exjade'
p35652
(F1
F0.00014334862385321102
I0
I1
I-1
tp35653
sS'than,of,the'
p35654
(F1
F0.00014334862385321102
I0
I1
I-1
tp35655
sS'digitalis,or,may'
p35656
(F1
F0.00014334862385321102
I1
I0
I1
tp35657
sS'order,to,produce'
p35658
(F1
F0.00014334862385321102
I1
I0
I1
tp35659
sS'l-histidine,was,observed'
p35660
(F1
F0.00014334862385321102
I1
I0
I1
tp35661
sS'dihydroxycholecalciferol,d3,oh'
p35662
(F1
F0.00014334862385321102
I0
I1
I-1
tp35663
sS'has,the,potential'
p35664
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp35665
sS'in,using,concomitant'
p35666
(F1
F0.00014334862385321102
I0
I1
I-1
tp35667
sS'its,derivatives,and'
p35668
(F1
F0.00028669724770642203
I2
I0
I2
tp35669
sS'agents,or,other'
p35670
(F1
F0.00014334862385321102
I1
I0
I1
tp35671
sS'day,a,dose'
p35672
(F1
F0.00014334862385321102
I1
I0
I1
tp35673
sS'oral,and,resulted'
p35674
(F1
F0.00014334862385321102
I1
I0
I1
tp35675
sS'in,healthy,volunteers'
p35676
(F0.10000000000000001
F0.00028669724770642203
I9
I11
I-2
tp35677
sS'of,or,a'
p35678
(F1
F0.00014334862385321102
I0
I1
I-1
tp35679
sS'inhibitors,has,been'
p35680
(F1
F0.00014334862385321102
I1
I0
I1
tp35681
sS'including,for,example'
p35682
(F1
F0.00014334862385321102
I1
I0
I1
tp35683
sS'of,hepatic,cytochrome'
p35684
(F0
F0
I1
I1
I0
tp35685
sS'of,b,can'
p35686
(F1
F0.00014334862385321102
I0
I1
I-1
tp35687
sS'neither,metabolized,by'
p35688
(F1
F0.00014334862385321102
I0
I1
I-1
tp35689
sS'underlies,the,antipsychotic'
p35690
(F1
F0.00014334862385321102
I0
I1
I-1
tp35691
sS'daily,to,patients'
p35692
(F1
F0.00014334862385321102
I0
I1
I-1
tp35693
sS'known,to,prolong'
p35694
(F1
F0.00028669724770642203
I2
I0
I2
tp35695
sS'of,treatment,did'
p35696
(F1
F0.00014334862385321102
I0
I1
I-1
tp35697
sS'agents,and,hypoglycemia'
p35698
(F1
F0.00014334862385321102
I0
I1
I-1
tp35699
sS'therefore,should,not'
p35700
(F1
F0.00014334862385321102
I1
I0
I1
tp35701
sS'after,and,increases'
p35702
(F1
F0.00014334862385321102
I1
I0
I1
tp35703
sS'however,the,effects'
p35704
(F1
F0.00014334862385321102
I0
I1
I-1
tp35705
sS'synthesis,of,the'
p35706
(F1
F0.00014334862385321102
I0
I1
I-1
tp35707
sS'concentration,were,not'
p35708
(F1
F0.00014334862385321102
I0
I1
I-1
tp35709
sS'in,gene,expression'
p35710
(F1
F0.00014334862385321102
I0
I1
I-1
tp35711
sS'by,the,presence'
p35712
(F1
F0.00014334862385321102
I0
I1
I-1
tp35713
sS'all,animal,species'
p35714
(F1
F0.00014334862385321102
I0
I1
I-1
tp35715
sS'although,no,interaction'
p35716
(F1
F0.00014334862385321102
I1
I0
I1
tp35717
sS'procedure,is,recommended'
p35718
(F1
F0.00014334862385321102
I0
I1
I-1
tp35719
sS'mean,daily,trough'
p35720
(F1
F0.00014334862385321102
I0
I1
I-1
tp35721
sS'of,significant,respiratory'
p35722
(F1
F0.00014334862385321102
I1
I0
I1
tp35723
sS'studies,involving,renal'
p35724
(F1
F0.00014334862385321102
I1
I0
I1
tp35725
sS'milk,milk,products'
p35726
(F1
F0.00014334862385321102
I1
I0
I1
tp35727
sS'and,differed,from'
p35728
(F1
F0.00014334862385321102
I0
I1
I-1
tp35729
sS'receiving,nonselective,monoamine'
p35730
(F1
F0.00014334862385321102
I1
I0
I1
tp35731
sS'patients,taking,should'
p35732
(F1
F0.00014334862385321102
I1
I0
I1
tp35733
sS'received,days,of'
p35734
(F0
F0
I1
I1
I0
tp35735
sS'this,interaction,should'
p35736
(F1
F0.0010034403669724771
I7
I0
I7
tp35737
sS'safe,problem,associated'
p35738
(F1
F0.00014334862385321102
I1
I0
I1
tp35739
sS'pra,as,well'
p35740
(F1
F0.00014334862385321102
I0
I1
I-1
tp35741
sS'cause,myopathy,which'
p35742
(F1
F0.00014334862385321102
I0
I1
I-1
tp35743
sS'exercised,because,there'
p35744
(F1
F0.00014334862385321102
I1
I0
I1
tp35745
sS'interactions,are,not'
p35746
(F1
F0.00014334862385321102
I0
I1
I-1
tp35747
sS'curves,derived,from'
p35748
(F1
F0.00014334862385321102
I1
I0
I1
tp35749
sS'inhibit,the,hypotensive'
p35750
(F1
F0.00028669724770642203
I2
I0
I2
tp35751
sS'demonstrated,any,effect'
p35752
(F1
F0.00014334862385321102
I0
I1
I-1
tp35753
sS'injection,produced,some'
p35754
(F1
F0.00014334862385321102
I0
I1
I-1
tp35755
sS'observed,when,this'
p35756
(F1
F0.00014334862385321102
I1
I0
I1
tp35757
sS'following,a,meal'
p35758
(F1
F0.00014334862385321102
I1
I0
I1
tp35759
sS'cyp2c19,the,major'
p35760
(F1
F0.00014334862385321102
I0
I1
I-1
tp35761
sS'steroidal,and,progestogen'
p35762
(F1
F0.00014334862385321102
I0
I1
I-1
tp35763
sS'aeds,phenytoin,tiagabine'
p35764
(F1
F0.00014334862385321102
I0
I1
I-1
tp35765
sS'of,rejection,episodes'
p35766
(F1
F0.00014334862385321102
I0
I1
I-1
tp35767
sS'gemfibrozil,other,niacin'
p35768
(F1
F0.00014334862385321102
I0
I1
I-1
tp35769
sS'cisapride,can,be'
p35770
(F1
F0.00014334862385321102
I0
I1
I-1
tp35771
sS'given,the,abundance'
p35772
(F1
F0.00014334862385321102
I0
I1
I-1
tp35773
sS'increase,of,apparent'
p35774
(F1
F0.00014334862385321102
I1
I0
I1
tp35775
sS'mg,on,day'
p35776
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp35777
sS'to,normal,healthy'
p35778
(F1
F0.00028669724770642203
I0
I2
I-2
tp35779
sS'in,an,eight-fold'
p35780
(F1
F0.00014334862385321102
I1
I0
I1
tp35781
sS'have,indicated,that'
p35782
(F1
F0.00014334862385321102
I0
I1
I-1
tp35783
sS'however,neither,nor'
p35784
(F1
F0.00014334862385321102
I0
I1
I-1
tp35785
sS'danger,of,blocking'
p35786
(F1
F0.00014334862385321102
I1
I0
I1
tp35787
sS'that,this,alteration'
p35788
(F1
F0.00014334862385321102
I0
I1
I-1
tp35789
sS'the,mixing,of'
p35790
(F1
F0.00014334862385321102
I1
I0
I1
tp35791
sS'be,compromised,in'
p35792
(F1
F0.00014334862385321102
I1
I0
I1
tp35793
sS'but,the,effect'
p35794
(F1
F0.00014334862385321102
I1
I0
I1
tp35795
sS'the,acute,locomotor'
p35796
(F1
F0.00014334862385321102
I1
I0
I1
tp35797
sS'that,potentiate,the'
p35798
(F1
F0.00014334862385321102
I0
I1
I-1
tp35799
sS'increased,serum,concentrations'
p35800
(F1
F0.00014334862385321102
I1
I0
I1
tp35801
sS'the,depth,of'
p35802
(F1
F0.00014334862385321102
I1
I0
I1
tp35803
sS'adverse,events,should'
p35804
(F1
F0.00014334862385321102
I0
I1
I-1
tp35805
sS'randomized,multiple-dose,crossover'
p35806
(F1
F0.00014334862385321102
I0
I1
I-1
tp35807
sS'concurrent,use,may'
p35808
(F1
F0.00028669724770642203
I0
I2
I-2
tp35809
sS'glucose,concentrations,were'
p35810
(F1
F0.00014334862385321102
I1
I0
I1
tp35811
sS'bleeding,in,etodolac-treated'
p35812
(F1
F0.00014334862385321102
I1
I0
I1
tp35813
sS'levels,generally,by'
p35814
(F1
F0.00014334862385321102
I0
I1
I-1
tp35815
sS'but,these,would'
p35816
(F1
F0.00014334862385321102
I1
I0
I1
tp35817
sS'unaffected,by,baseline'
p35818
(F1
F0.00014334862385321102
I0
I1
I-1
tp35819
sS'the,results,suggest'
p35820
(F1
F0.00014334862385321102
I1
I0
I1
tp35821
sS'rats,hydrochloride,was'
p35822
(F1
F0.00014334862385321102
I1
I0
I1
tp35823
sS'narcotic,such,as'
p35824
(F1
F0.00014334862385321102
I1
I0
I1
tp35825
sS'clearance,and,increases'
p35826
(F1
F0.00014334862385321102
I1
I0
I1
tp35827
sS'insure,that,no'
p35828
(F1
F0.00014334862385321102
I1
I0
I1
tp35829
sS'or,systolic,blood'
p35830
(F1
F0.00014334862385321102
I0
I1
I-1
tp35831
sS'evidence,of,marked'
p35832
(F1
F0.00014334862385321102
I1
I0
I1
tp35833
sS'with,some,agents'
p35834
(F1
F0.00014334862385321102
I0
I1
I-1
tp35835
sS'expected,to,affect'
p35836
(F1
F0.00014334862385321102
I0
I1
I-1
tp35837
sS'in,pigeons,but'
p35838
(F1
F0.00014334862385321102
I1
I0
I1
tp35839
sS'efficacy,of,used'
p35840
(F1
F0.00014334862385321102
I0
I1
I-1
tp35841
sS'not,to,exceed'
p35842
(F1
F0.00043004587155963305
I3
I0
I3
tp35843
sS'of,after,being'
p35844
(F1
F0.00014334862385321102
I0
I1
I-1
tp35845
sS'or,minus,in'
p35846
(F1
F0.00014334862385321102
I1
I0
I1
tp35847
sS'doses,of,pcp'
p35848
(F1
F0.00014334862385321102
I1
I0
I1
tp35849
sS'furthermore,it,has'
p35850
(F1
F0.00014334862385321102
I1
I0
I1
tp35851
sS'cefotaxime,sodium,are'
p35852
(F1
F0.00014334862385321102
I0
I1
I-1
tp35853
sS'a,euthyroid,state'
p35854
(F1
F0.00014334862385321102
I0
I1
I-1
tp35855
sS'doses,trough,concentrations'
p35856
(F1
F0.00014334862385321102
I0
I1
I-1
tp35857
sS'that,concomitan,administration'
p35858
(F1
F0.00014334862385321102
I1
I0
I1
tp35859
sS'effects,of,low'
p35860
(F1
F0.00014334862385321102
I0
I1
I-1
tp35861
sS'disrupts,the,behavioral'
p35862
(F1
F0.00014334862385321102
I0
I1
I-1
tp35863
sS'of,contraception,during'
p35864
(F1
F0.00014334862385321102
I1
I0
I1
tp35865
sS'more,pronounced,when'
p35866
(F1
F0.00014334862385321102
I1
I0
I1
tp35867
sS'studies,these,results'
p35868
(F1
F0.00014334862385321102
I0
I1
I-1
tp35869
sS'with,ethacrynic,acid'
p35870
(F1
F0.00014334862385321102
I1
I0
I1
tp35871
sS'to,and,was'
p35872
(F1
F0.00014334862385321102
I0
I1
I-1
tp35873
sS'and,auc,of'
p35874
(F1
F0.0011467889908256881
I8
I0
I8
tp35875
sS'substrate,single,dose'
p35876
(F1
F0.00028669724770642203
I0
I2
I-2
tp35877
sS'botulinum,prior,to'
p35878
(F1
F0.00014334862385321102
I1
I0
I1
tp35879
sS'any,patient,in'
p35880
(F1
F0.00014334862385321102
I0
I1
I-1
tp35881
sS'body,weight,every'
p35882
(F1
F0.00014334862385321102
I0
I1
I-1
tp35883
sS'diabetic,patient,s'
p35884
(F1
F0.00014334862385321102
I1
I0
I1
tp35885
sS'pah,cannot,be'
p35886
(F1
F0.00014334862385321102
I1
I0
I1
tp35887
sS'that,users,of'
p35888
(F1
F0.00028669724770642203
I2
I0
I2
tp35889
sS'between,and,or'
p35890
(F1
F0.00014334862385321102
I0
I1
I-1
tp35891
sS'as,possible,when'
p35892
(F1
F0.00014334862385321102
I0
I1
I-1
tp35893
sS'a,two-fold,increase'
p35894
(F1
F0.00014334862385321102
I1
I0
I1
tp35895
sS'max,or,t'
p35896
(F1
F0.00014334862385321102
I0
I1
I-1
tp35897
sS'and,therefore,the'
p35898
(F1
F0.00028669724770642203
I2
I0
I2
tp35899
sS'potential,for,abilify'
p35900
(F1
F0.00014334862385321102
I0
I1
I-1
tp35901
sS'administration,of,large'
p35902
(F1
F0.00014334862385321102
I0
I1
I-1
tp35903
sS'effects,are,likely'
p35904
(F1
F0.00014334862385321102
I1
I0
I1
tp35905
sS'felodipine,may,increase'
p35906
(F1
F0.00014334862385321102
I0
I1
I-1
tp35907
sS'co-administration,of,hmg-coa'
p35908
(F1
F0.00014334862385321102
I1
I0
I1
tp35909
sS'in,addition,the'
p35910
(F1
F0.00014334862385321102
I1
I0
I1
tp35911
sS'of,and,significantly'
p35912
(F1
F0.00014334862385321102
I1
I0
I1
tp35913
sS'and,followed,by'
p35914
(F1
F0.00014334862385321102
I0
I1
I-1
tp35915
sS'pharmacokinetic,interactions,were'
p35916
(F1
F0.00028669724770642203
I0
I2
I-2
tp35917
sS'in,opioid-dependent,patients'
p35918
(F1
F0.00014334862385321102
I0
I1
I-1
tp35919
sS'of,oral,regularly'
p35920
(F1
F0.00014334862385321102
I0
I1
I-1
tp35921
sS'activity,in,the'
p35922
(F1
F0.00014334862385321102
I1
I0
I1
tp35923
sS'amiodarone,amiodarone,therapy'
p35924
(F1
F0.00014334862385321102
I0
I1
I-1
tp35925
sS'the,increased,possibility'
p35926
(F1
F0.00028669724770642203
I2
I0
I2
tp35927
sS'long,lasting,depletions'
p35928
(F1
F0.00014334862385321102
I1
I0
I1
tp35929
sS'person,and,plasma'
p35930
(F1
F0.00014334862385321102
I0
I1
I-1
tp35931
sS'potential,to,reduce'
p35932
(F1
F0.00014334862385321102
I0
I1
I-1
tp35933
sS'and,by,means'
p35934
(F1
F0.00014334862385321102
I0
I1
I-1
tp35935
sS'phenytoin,and,are'
p35936
(F1
F0.00014334862385321102
I0
I1
I-1
tp35937
sS'hypoglycemics,bepridil,has'
p35938
(F1
F0.00014334862385321102
I0
I1
I-1
tp35939
sS'not,generally,recommended'
p35940
(F1
F0.00028669724770642203
I2
I0
I2
tp35941
sS'hypotension,cimetidine,an'
p35942
(F1
F0.00014334862385321102
I1
I0
I1
tp35943
sS'prothrombin,time,when'
p35944
(F0
F0
I1
I1
I0
tp35945
sS'concomitantly,with,increases'
p35946
(F1
F0.00028669724770642203
I0
I2
I-2
tp35947
sS'with,diethyl,pyrocarbonate'
p35948
(F1
F0.00014334862385321102
I0
I1
I-1
tp35949
sS'interact,significantly,with'
p35950
(F1
F0.00014334862385321102
I0
I1
I-1
tp35951
sS'absorption,when,it'
p35952
(F1
F0.00014334862385321102
I1
I0
I1
tp35953
sS'recorded,at,and'
p35954
(F1
F0.00014334862385321102
I0
I1
I-1
tp35955
sS'vehicle-controlled,studies,of'
p35956
(F1
F0.00014334862385321102
I0
I1
I-1
tp35957
sS'in,the,lower'
p35958
(F1
F0.00014334862385321102
I1
I0
I1
tp35959
sS'in,hydatid,cyst'
p35960
(F1
F0.00014334862385321102
I1
I0
I1
tp35961
sS'in,average,steady-'
p35962
(F1
F0.00014334862385321102
I1
I0
I1
tp35963
sS'inhibitors,of,the'
p35964
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp35965
sS'with,since,interactions'
p35966
(F1
F0.00014334862385321102
I1
I0
I1
tp35967
sS'blocking,agent,orally'
p35968
(F1
F0.00014334862385321102
I1
I0
I1
tp35969
sS'with,a,therapeutic'
p35970
(F1
F0.00014334862385321102
I1
I0
I1
tp35971
sS'kg,with,an'
p35972
(F1
F0.00014334862385321102
I1
I0
I1
tp35973
sS'cyclosporin,reports,indicate'
p35974
(F1
F0.00014334862385321102
I1
I0
I1
tp35975
sS'discussion,clarithromycin,is'
p35976
(F1
F0.00014334862385321102
I1
I0
I1
tp35977
sS'the,biological,and'
p35978
(F1
F0.00014334862385321102
I1
I0
I1
tp35979
sS'with,in,patients'
p35980
(F1
F0.00028669724770642203
I2
I0
I2
tp35981
sS'antacid,when,and'
p35982
(F1
F0.00014334862385321102
I1
I0
I1
tp35983
sS'greater,extent,than'
p35984
(F1
F0.00028669724770642203
I0
I2
I-2
tp35985
sS'small,to,allow'
p35986
(F1
F0.00014334862385321102
I0
I1
I-1
tp35987
sS'potentially,hepatotoxic,medications'
p35988
(F1
F0.00014334862385321102
I1
I0
I1
tp35989
sS'decreased,on,average'
p35990
(F1
F0.00014334862385321102
I1
I0
I1
tp35991
sS'elevated,by,minimally'
p35992
(F1
F0.00014334862385321102
I0
I1
I-1
tp35993
sS'avoided,and,alternative'
p35994
(F1
F0.00014334862385321102
I1
I0
I1
tp35995
sS'the,cyp1a2,substrate'
p35996
(F1
F0.00014334862385321102
I0
I1
I-1
tp35997
sS'not,inhibit,the'
p35998
(F1
F0.00028669724770642203
I0
I2
I-2
tp35999
sS'suppression,of,organs'
p36000
(F1
F0.00014334862385321102
I0
I1
I-1
tp36001
sS'inhibition,of,cyp'
p36002
(F1
F0.00014334862385321102
I0
I1
I-1
tp36003
sS'since,paranoid,symptoms'
p36004
(F1
F0.00014334862385321102
I1
I0
I1
tp36005
sS'inhibit,the,intracellular'
p36006
(F1
F0.00014334862385321102
I1
I0
I1
tp36007
sS'but,not,by'
p36008
(F1
F0.00028669724770642203
I2
I0
I2
tp36009
sS'was,recently,instituted'
p36010
(F1
F0.00057339449541284407
I4
I0
I4
tp36011
sS'the,are,to'
p36012
(F1
F0.00014334862385321102
I0
I1
I-1
tp36013
sS'has,an,effect'
p36014
(F1
F0.00014334862385321102
I1
I0
I1
tp36015
sS'pretreatment,with,or'
p36016
(F1
F0.00014334862385321102
I1
I0
I1
tp36017
sS'an,in,vivo'
p36018
(F1
F0.00014334862385321102
I0
I1
I-1
tp36019
sS'if,at,all'
p36020
(F0
F0
I1
I1
I0
tp36021
sS'profile,or,renal'
p36022
(F1
F0.00014334862385321102
I0
I1
I-1
tp36023
sS'microg,kg,body'
p36024
(F1
F0.00014334862385321102
I0
I1
I-1
tp36025
sS'following,simultaneous,administration'
p36026
(F1
F0.00014334862385321102
I1
I0
I1
tp36027
sS'possibly,have,some'
p36028
(F1
F0.00014334862385321102
I0
I1
I-1
tp36029
sS'their,combined,use'
p36030
(F1
F0.00014334862385321102
I1
I0
I1
tp36031
sS'submitted,to,daily'
p36032
(F1
F0.00014334862385321102
I0
I1
I-1
tp36033
sS'fluoxetine,and,increased'
p36034
(F1
F0.00014334862385321102
I0
I1
I-1
tp36035
sS'administering,gleevec,with'
p36036
(F1
F0.00028669724770642203
I2
I0
I2
tp36037
sS'can,be,rationalized'
p36038
(F1
F0.00014334862385321102
I0
I1
I-1
tp36039
sS'in,vitro,study'
p36040
(F1
F0.00014334862385321102
I1
I0
I1
tp36041
sS'a,patients,should'
p36042
(F1
F0.00014334862385321102
I1
I0
I1
tp36043
sS'sole,indication,of'
p36044
(F1
F0.00014334862385321102
I0
I1
I-1
tp36045
sS'bind,and,decrease'
p36046
(F1
F0.00014334862385321102
I1
I0
I1
tp36047
sS'increase,the,mean'
p36048
(F1
F0.00028669724770642203
I2
I0
I2
tp36049
sS'noted,below,a'
p36050
(F1
F0.00014334862385321102
I0
I1
I-1
tp36051
sS'though,has,been'
p36052
(F1
F0.00028669724770642203
I0
I2
I-2
tp36053
sS'parent,and,active'
p36054
(F1
F0.00014334862385321102
I1
I0
I1
tp36055
sS'mydriasis,tachycardia,dryness'
p36056
(F1
F0.00014334862385321102
I1
I0
I1
tp36057
sS'the,tail-flick,inhibition'
p36058
(F0.5
F0.00028669724770642203
I3
I1
I2
tp36059
sS'and,hydroxides,does'
p36060
(F1
F0.00014334862385321102
I0
I1
I-1
tp36061
sS'decreased,the,hyperuricemic'
p36062
(F1
F0.00028669724770642203
I2
I0
I2
tp36063
sS'inhibitors,or,may'
p36064
(F1
F0.00043004587155963305
I3
I0
I3
tp36065
sS'adrenocortical,steroids,chloral'
p36066
(F1
F0.00014334862385321102
I1
I0
I1
tp36067
sS'isolated,cases,a'
p36068
(F1
F0.00014334862385321102
I1
I0
I1
tp36069
sS'a,novel,peripherally'
p36070
(F1
F0.00014334862385321102
I1
I0
I1
tp36071
sS'vitro,can,result'
p36072
(F1
F0.00014334862385321102
I1
I0
I1
tp36073
sS'copegus,pegasys,treatment'
p36074
(F1
F0.00014334862385321102
I0
I1
I-1
tp36075
sS'with,co-administered,with'
p36076
(F1
F0.00014334862385321102
I1
I0
I1
tp36077
sS'co-administration,of,cyp3a4'
p36078
(F1
F0.00014334862385321102
I0
I1
I-1
tp36079
sS'similar,effects,of'
p36080
(F1
F0.00014334862385321102
I0
I1
I-1
tp36081
sS'of,methylpyrazole,mg'
p36082
(F0
F0
I1
I1
I0
tp36083
sS'followed,by,irreversible'
p36084
(F1
F0.00014334862385321102
I1
I0
I1
tp36085
sS'scales,and,in'
p36086
(F1
F0.00014334862385321102
I0
I1
I-1
tp36087
sS'performance,of,gross'
p36088
(F1
F0.00014334862385321102
I0
I1
I-1
tp36089
sS'in,proprietary,cold'
p36090
(F1
F0.00014334862385321102
I1
I0
I1
tp36091
sS'of,ergocalcitriol,by'
p36092
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp36093
sS'alteration,in,steady-state'
p36094
(F1
F0.00014334862385321102
I1
I0
I1
tp36095
sS'agents,with,increased'
p36096
(F1
F0.00014334862385321102
I1
I0
I1
tp36097
sS'including,nalidixic,acid'
p36098
(F1
F0.00014334862385321102
I1
I0
I1
tp36099
sS'coadministration,with,available'
p36100
(F1
F0.00014334862385321102
I1
I0
I1
tp36101
sS'in,temperature,began'
p36102
(F1
F0.00014334862385321102
I0
I1
I-1
tp36103
sS'vs,myocardial,infarction'
p36104
(F1
F0.00014334862385321102
I1
I0
I1
tp36105
sS'these,data,emphasize'
p36106
(F1
F0.00014334862385321102
I0
I1
I-1
tp36107
sS'for,equetrotm,may'
p36108
(F0
F0
I1
I1
I0
tp36109
sS'therefore,when,central'
p36110
(F1
F0.00014334862385321102
I1
I0
I1
tp36111
sS'was,delayed,and'
p36112
(F1
F0.00014334862385321102
I1
I0
I1
tp36113
sS'vioxx,should,be'
p36114
(F1
F0.00014334862385321102
I0
I1
I-1
tp36115
sS'pharmacokinetic,interactions,with'
p36116
(F1
F0.00043004587155963305
I0
I3
I-3
tp36117
sS'in,separate,studies'
p36118
(F1
F0.00028669724770642203
I0
I2
I-2
tp36119
sS'and,antithrombin,iii'
p36120
(F1
F0.00014334862385321102
I0
I1
I-1
tp36121
sS'same,proportions,as'
p36122
(F1
F0.00014334862385321102
I0
I1
I-1
tp36123
sS'development,is,not'
p36124
(F1
F0.00014334862385321102
I0
I1
I-1
tp36125
sS'with,other,will'
p36126
(F1
F0.00014334862385321102
I0
I1
I-1
tp36127
sS'alter,a,diabetic'
p36128
(F1
F0.00014334862385321102
I1
I0
I1
tp36129
sS'following,concomitant,use'
p36130
(F1
F0.00014334862385321102
I0
I1
I-1
tp36131
sS'not,significantly,increase'
p36132
(F1
F0.00014334862385321102
I0
I1
I-1
tp36133
sS'use,of,enablex'
p36134
(F1
F0.00014334862385321102
I1
I0
I1
tp36135
sS'blood,pressure,medications'
p36136
(F1
F0.00014334862385321102
I0
I1
I-1
tp36137
sS'agents,were,reported'
p36138
(F1
F0.00014334862385321102
I0
I1
I-1
tp36139
sS'and,sodium,bicarbonate'
p36140
(F1
F0.00014334862385321102
I1
I0
I1
tp36141
sS'approximately,to,representing'
p36142
(F1
F0.00014334862385321102
I1
I0
I1
tp36143
sS'appear,to,overlap'
p36144
(F1
F0.00014334862385321102
I0
I1
I-1
tp36145
sS'as,and,see'
p36146
(F1
F0.00014334862385321102
I1
I0
I1
tp36147
sS'relevant,changes,in'
p36148
(F1
F0.0008600917431192661
I0
I6
I-6
tp36149
sS'maintained,at,of'
p36150
(F1
F0.00014334862385321102
I0
I1
I-1
tp36151
sS'be,withdrawn,several'
p36152
(F1
F0.00014334862385321102
I1
I0
I1
tp36153
sS'as,manifested,by'
p36154
(F1
F0.00014334862385321102
I0
I1
I-1
tp36155
sS'interactions,between,treatments'
p36156
(F1
F0.00014334862385321102
I0
I1
I-1
tp36157
sS'hydroxides,and,did'
p36158
(F1
F0.00014334862385321102
I0
I1
I-1
tp36159
sS'to,maintain,trough'
p36160
(F1
F0.00014334862385321102
I1
I0
I1
tp36161
sS'in,the,levels'
p36162
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp36163
sS'mac,minimum,alveolar'
p36164
(F1
F0.00028669724770642203
I2
I0
I2
tp36165
sS'following,antibiotics,rifampin'
p36166
(F1
F0.00014334862385321102
I0
I1
I-1
tp36167
sS'sclerosis,patients,taking'
p36168
(F1
F0.00014334862385321102
I0
I1
I-1
tp36169
sS'be,fatal,when'
p36170
(F1
F0.00014334862385321102
I1
I0
I1
tp36171
sS'these,with,lodosyn'
p36172
(F1
F0.00014334862385321102
I0
I1
I-1
tp36173
sS'such,as,sulfamethoxazole-trimethoprim'
p36174
(F1
F0.00014334862385321102
I0
I1
I-1
tp36175
sS'of,fludrocortisone,acetate'
p36176
(F1
F0.00014334862385321102
I1
I0
I1
tp36177
sS'or,compounds,which'
p36178
(F1
F0.00014334862385321102
I0
I1
I-1
tp36179
sS'sodium,following,oral'
p36180
(F1
F0.00014334862385321102
I0
I1
I-1
tp36181
sS'levetiracetam,had,no'
p36182
(F1
F0.00014334862385321102
I0
I1
I-1
tp36183
sS'lithium,reversible,increases'
p36184
(F1
F0.00014334862385321102
I1
I0
I1
tp36185
sS'in,part,a'
p36186
(F1
F0.00014334862385321102
I0
I1
I-1
tp36187
sS'for,a,substantial'
p36188
(F1
F0.00014334862385321102
I0
I1
I-1
tp36189
sS'patients,understand,how'
p36190
(F1
F0.00014334862385321102
I0
I1
I-1
tp36191
sS'an,acute,increase'
p36192
(F1
F0.00014334862385321102
I0
I1
I-1
tp36193
sS'healthy,subjects,the'
p36194
(F1
F0.00014334862385321102
I0
I1
I-1
tp36195
sS'on,acth,induced'
p36196
(F1
F0.00014334862385321102
I0
I1
I-1
tp36197
sS'ml,resulted,in'
p36198
(F1
F0.00014334862385321102
I0
I1
I-1
tp36199
sS'pupil,constriction,were'
p36200
(F1
F0.00014334862385321102
I0
I1
I-1
tp36201
sS'when,patients,take'
p36202
(F1
F0.00014334862385321102
I1
I0
I1
tp36203
sS'levels,were,also'
p36204
(F1
F0.00014334862385321102
I1
I0
I1
tp36205
sS'patients,receiving,with'
p36206
(F1
F0.00014334862385321102
I1
I0
I1
tp36207
sS'another,report,nine'
p36208
(F1
F0.00014334862385321102
I1
I0
I1
tp36209
sS'revia,and,is'
p36210
(F1
F0.00014334862385321102
I1
I0
I1
tp36211
sS'done,to,see'
p36212
(F1
F0.00014334862385321102
I1
I0
I1
tp36213
sS'time-curve,increased,from'
p36214
(F1
F0.00014334862385321102
I1
I0
I1
tp36215
sS'rheumatoid,arthritis,concomitant'
p36216
(F1
F0.00014334862385321102
I0
I1
I-1
tp36217
sS'steady-state,trough,concentrations'
p36218
(F1
F0.00043004587155963305
I3
I0
I3
tp36219
sS'and,fluvoxamine,tablets'
p36220
(F1
F0.00014334862385321102
I1
I0
I1
tp36221
sS'of,the,parent'
p36222
(F1
F0.00014334862385321102
I1
I0
I1
tp36223
sS'to,that,observed'
p36224
(F1
F0.00014334862385321102
I1
I0
I1
tp36225
sS'reduction,in,blood'
p36226
(F1
F0.00014334862385321102
I1
I0
I1
tp36227
sS'intubating,dose,of'
p36228
(F1
F0.00014334862385321102
I1
I0
I1
tp36229
sS'of,such,preparations'
p36230
(F1
F0.00014334862385321102
I1
I0
I1
tp36231
sS'during,clinical,trials'
p36232
(F1
F0.00014334862385321102
I0
I1
I-1
tp36233
sS'are,unknown,neither'
p36234
(F1
F0.00014334862385321102
I1
I0
I1
tp36235
sS'ca,i,increase'
p36236
(F1
F0.00014334862385321102
I1
I0
I1
tp36237
sS'cohort,then,received'
p36238
(F1
F0.00014334862385321102
I0
I1
I-1
tp36239
sS'routine,administration,of'
p36240
(F1
F0.00014334862385321102
I1
I0
I1
tp36241
sS'between,and,following'
p36242
(F1
F0.00028669724770642203
I0
I2
I-2
tp36243
sS'as,marplan,nardil'
p36244
(F1
F0.00014334862385321102
I0
I1
I-1
tp36245
sS'when,these,medications'
p36246
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp36247
sS'inhibition,of,cytochrome'
p36248
(F1
F0.00014334862385321102
I0
I1
I-1
tp36249
sS'may,regulate,the'
p36250
(F1
F0.00014334862385321102
I1
I0
I1
tp36251
sS'of,decreased,by'
p36252
(F1
F0.00014334862385321102
I1
I0
I1
tp36253
sS'concentrations,cyp3a4,inhibitors'
p36254
(F1
F0.00014334862385321102
I0
I1
I-1
tp36255
sS'for,at,least'
p36256
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp36257
sS'the,dose,levels'
p36258
(F1
F0.00014334862385321102
I0
I1
I-1
tp36259
sS'pharmacologically,with,orally'
p36260
(F1
F0.00014334862385321102
I1
I0
I1
tp36261
sS'of,pcp,in'
p36262
(F1
F0.00043004587155963305
I0
I3
I-3
tp36263
sS'prevent,the,urinary'
p36264
(F1
F0.00014334862385321102
I1
I0
I1
tp36265
sS'the,two,medicines'
p36266
(F1
F0.00014334862385321102
I1
I0
I1
tp36267
sS'the,trials,of'
p36268
(F1
F0.00014334862385321102
I0
I1
I-1
tp36269
sS'with,a,nonfunctioning'
p36270
(F1
F0.00014334862385321102
I1
I0
I1
tp36271
sS'if,a,tca'
p36272
(F1
F0.00014334862385321102
I1
I0
I1
tp36273
sS'or,alternatively,the'
p36274
(F1
F0.00014334862385321102
I0
I1
I-1
tp36275
sS'concurrently,concentrations,should'
p36276
(F1
F0.00014334862385321102
I1
I0
I1
tp36277
sS'retention,blurred,vision'
p36278
(F1
F0.00014334862385321102
I1
I0
I1
tp36279
sS'male,rats,hydrochloride'
p36280
(F1
F0.00014334862385321102
I1
I0
I1
tp36281
sS'with,tikosyn,or'
p36282
(F1
F0.00014334862385321102
I0
I1
I-1
tp36283
sS'at,three,different'
p36284
(F1
F0.00014334862385321102
I0
I1
I-1
tp36285
sS'patients,receiving,injection'
p36286
(F1
F0.00014334862385321102
I0
I1
I-1
tp36287
sS'and,adrenoreceptors,on'
p36288
(F1
F0.00014334862385321102
I0
I1
I-1
tp36289
sS'prothrombin,time,reported'
p36290
(F1
F0.00014334862385321102
I1
I0
I1
tp36291
sS'activity,of,four'
p36292
(F1
F0.00014334862385321102
I0
I1
I-1
tp36293
sS'doses,or,infusions'
p36294
(F1
F0.00014334862385321102
I0
I1
I-1
tp36295
sS'a,type,ii'
p36296
(F1
F0.00014334862385321102
I1
I0
I1
tp36297
sS'may,potentiate,a'
p36298
(F1
F0.00014334862385321102
I1
I0
I1
tp36299
sS'on,the,advice'
p36300
(F1
F0.00014334862385321102
I1
I0
I1
tp36301
sS'of,including,tricor'
p36302
(F1
F0.00014334862385321102
I1
I0
I1
tp36303
sS'amantadine,and,maois'
p36304
(F1
F0.00014334862385321102
I1
I0
I1
tp36305
sS'trace,pathways,which'
p36306
(F1
F0.00014334862385321102
I0
I1
I-1
tp36307
sS'of,prothrombin,time'
p36308
(F0.5
F0.00028669724770642203
I3
I1
I2
tp36309
sS'decreased,plasma,levels'
p36310
(F0
F0
I1
I1
I0
tp36311
sS'taking,on,a'
p36312
(F1
F0.00014334862385321102
I0
I1
I-1
tp36313
sS'time,for,heparins'
p36314
(F1
F0.00014334862385321102
I0
I1
I-1
tp36315
sS'dosed,with,difluoroacetone'
p36316
(F1
F0.00014334862385321102
I0
I1
I-1
tp36317
sS'reported,when,was'
p36318
(F1
F0.00014334862385321102
I1
I0
I1
tp36319
sS'reported,to,have'
p36320
(F1
F0.00028669724770642203
I2
I0
I2
tp36321
sS'diphenoxylate,hcl,and'
p36322
(F1
F0.00014334862385321102
I1
I0
I1
tp36323
sS'accelerate,the,metabolism'
p36324
(F1
F0.00014334862385321102
I0
I1
I-1
tp36325
sS'serious,and,or'
p36326
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp36327
sS'when,used,with'
p36328
(F1
F0.00014334862385321102
I0
I1
I-1
tp36329
sS'interactions,with,fentanyl'
p36330
(F1
F0.00014334862385321102
I0
I1
I-1
tp36331
sS'in,the,area'
p36332
(F1
F0.00057339449541284407
I4
I0
I4
tp36333
sS'mediated,signalling,or'
p36334
(F1
F0.00014334862385321102
I0
I1
I-1
tp36335
sS'followed,by,in'
p36336
(F1
F0.00014334862385321102
I0
I1
I-1
tp36337
sS'the,volume,of'
p36338
(F1
F0.00014334862385321102
I0
I1
I-1
tp36339
sS'concurrently,plasma,levels'
p36340
(F1
F0.00014334862385321102
I1
I0
I1
tp36341
sS'and,synthetic,on'
p36342
(F1
F0.00014334862385321102
I0
I1
I-1
tp36343
sS'rash,while,receiving'
p36344
(F1
F0.00014334862385321102
I1
I0
I1
tp36345
sS'not,demonstrate,any'
p36346
(F1
F0.00028669724770642203
I0
I2
I-2
tp36347
sS'day,will,require'
p36348
(F1
F0.00014334862385321102
I1
I0
I1
tp36349
sS'of,contraception,inwomen'
p36350
(F1
F0.00014334862385321102
I1
I0
I1
tp36351
sS'the,and,this'
p36352
(F1
F0.00014334862385321102
I0
I1
I-1
tp36353
sS'cardiac,arrythmias,ventricular'
p36354
(F1
F0.00014334862385321102
I1
I0
I1
tp36355
sS'the,amount,absorbed'
p36356
(F1
F0.00014334862385321102
I0
I1
I-1
tp36357
sS'microalbuminuria,inspra,mg'
p36358
(F1
F0.00014334862385321102
I1
I0
I1
tp36359
sS'other,that,are'
p36360
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp36361
sS'reactions,in,vitro'
p36362
(F1
F0.00014334862385321102
I0
I1
I-1
tp36363
sS'to,the,presence'
p36364
(F1
F0.00014334862385321102
I0
I1
I-1
tp36365
sS'not,reported,in'
p36366
(F1
F0.00014334862385321102
I1
I0
I1
tp36367
sS'and,one,mg'
p36368
(F1
F0.00014334862385321102
I1
I0
I1
tp36369
sS'to,an,insufficient'
p36370
(F1
F0.00014334862385321102
I0
I1
I-1
tp36371
sS'events,and,therapeutic'
p36372
(F1
F0.00014334862385321102
I0
I1
I-1
tp36373
sS'agents,that,cause'
p36374
(F1
F0.00028669724770642203
I2
I0
I2
tp36375
sS'sodium,it,is'
p36376
(F1
F0.00014334862385321102
I1
I0
I1
tp36377
sS'cause,synergistic,elevation'
p36378
(F1
F0.00014334862385321102
I1
I0
I1
tp36379
sS'in,overall,improvements'
p36380
(F1
F0.00014334862385321102
I0
I1
I-1
tp36381
sS'for,example,may'
p36382
(F1
F0.00014334862385321102
I0
I1
I-1
tp36383
sS'may,be,affected'
p36384
(F0
F0
I2
I2
I0
tp36385
sS'receiving,the,initial'
p36386
(F1
F0.00014334862385321102
I1
I0
I1
tp36387
sS'that,and,markedly'
p36388
(F1
F0.00028669724770642203
I2
I0
I2
tp36389
sS'on,the,day'
p36390
(F1
F0.00014334862385321102
I1
I0
I1
tp36391
sS'death,have,occurred'
p36392
(F1
F0.00014334862385321102
I1
I0
I1
tp36393
sS'rare,occasions,resulted'
p36394
(F1
F0.00028669724770642203
I2
I0
I2
tp36395
sS'alternate,sequence,ie'
p36396
(F1
F0.00014334862385321102
I1
I0
I1
tp36397
sS'using,the,terms'
p36398
(F1
F0.00014334862385321102
I0
I1
I-1
tp36399
sS'lodine,can,reduce'
p36400
(F1
F0.00014334862385321102
I1
I0
I1
tp36401
sS'or,recovery,following'
p36402
(F1
F0.00014334862385321102
I1
I0
I1
tp36403
sS'primary,effect,of'
p36404
(F1
F0.00014334862385321102
I1
I0
I1
tp36405
sS'a,mg,neurontin'
p36406
(F1
F0.00014334862385321102
I1
I0
I1
tp36407
sS'preparations,glyceryl,trinitrate'
p36408
(F1
F0.00014334862385321102
I0
I1
I-1
tp36409
sS'protease,inhibitor,pi'
p36410
(F1
F0.00014334862385321102
I0
I1
I-1
tp36411
sS'alfenta,can,significantly'
p36412
(F1
F0.00014334862385321102
I1
I0
I1
tp36413
sS'other,manufacturers,have'
p36414
(F1
F0.00014334862385321102
I0
I1
I-1
tp36415
sS'anticoagulants,increased,prothrombin'
p36416
(F1
F0.00014334862385321102
I1
I0
I1
tp36417
sS'trough,concentrations,were'
p36418
(F1
F0.00014334862385321102
I1
I0
I1
tp36419
sS'the,increase,of'
p36420
(F0
F0
I1
I1
I0
tp36421
sS'administration,trough,concentrations'
p36422
(F1
F0.00014334862385321102
I0
I1
I-1
tp36423
sS'unlikely,that,would'
p36424
(F1
F0.00014334862385321102
I0
I1
I-1
tp36425
sS'found,with,at'
p36426
(F1
F0.00014334862385321102
I0
I1
I-1
tp36427
sS'treatment,did,not'
p36428
(F1
F0.00028669724770642203
I0
I2
I-2
tp36429
sS'the,pharmacologic,effect'
p36430
(F1
F0.00014334862385321102
I1
I0
I1
tp36431
sS'when,any,of'
p36432
(F1
F0.00014334862385321102
I0
I1
I-1
tp36433
sS'changes,to,the'
p36434
(F1
F0.00014334862385321102
I0
I1
I-1
tp36435
sS'when,given,concomitantly'
p36436
(F1
F0.00028669724770642203
I0
I2
I-2
tp36437
sS'use,with,ribavirin'
p36438
(F1
F0.00028669724770642203
I0
I2
I-2
tp36439
sS'the,therapeutic,range'
p36440
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp36441
sS'these,subjects,increased'
p36442
(F1
F0.00014334862385321102
I1
I0
I1
tp36443
sS'absorption,results,in'
p36444
(F1
F0.00014334862385321102
I0
I1
I-1
tp36445
sS'depress,plasma,prothrombin'
p36446
(F1
F0.00028669724770642203
I2
I0
I2
tp36447
sS'in,an,additive'
p36448
(F1
F0.00014334862385321102
I1
I0
I1
tp36449
sS'obstetric,blocks,and'
p36450
(F0
F0
I1
I1
I0
tp36451
sS'extended,release,tablets'
p36452
(F1
F0.00028669724770642203
I2
I0
I2
tp36453
sS'neurontin,mg,appears'
p36454
(F1
F0.00014334862385321102
I1
I0
I1
tp36455
sS'indicate,that,there'
p36456
(F1
F0.00014334862385321102
I1
I0
I1
tp36457
sS'with,and,monoamine'
p36458
(F0
F0
I2
I2
I0
tp36459
sS'a,narrower,spectrum'
p36460
(F1
F0.00014334862385321102
I0
I1
I-1
tp36461
sS'of,administered,alone'
p36462
(F1
F0.00014334862385321102
I0
I1
I-1
tp36463
sS'interaction,between,toradoliv'
p36464
(F1
F0.00014334862385321102
I0
I1
I-1
tp36465
sS'attenuated,the,hypotensive'
p36466
(F1
F0.00014334862385321102
I1
I0
I1
tp36467
sS'of,and,partly'
p36468
(F1
F0.00014334862385321102
I1
I0
I1
tp36469
sS'alterations,of,the'
p36470
(F1
F0.00014334862385321102
I1
I0
I1
tp36471
sS'of,the,toxic'
p36472
(F1
F0.00014334862385321102
I0
I1
I-1
tp36473
sS'and,that,affect'
p36474
(F0
F0
I1
I1
I0
tp36475
sS'interaction,has,been'
p36476
(F1
F0.00014334862385321102
I0
I1
I-1
tp36477
sS'slightly,enhance,the'
p36478
(F1
F0.00014334862385321102
I1
I0
I1
tp36479
sS'and,para-aminobenzoic,acid'
p36480
(F1
F0.00014334862385321102
I1
I0
I1
tp36481
sS'of,organs,actively'
p36482
(F1
F0.00014334862385321102
I0
I1
I-1
tp36483
sS'day,decreases,blood'
p36484
(F1
F0.00014334862385321102
I1
I0
I1
tp36485
sS'experience,an,increased'
p36486
(F1
F0.00014334862385321102
I0
I1
I-1
tp36487
sS'be,kept,in'
p36488
(F0
F0
I1
I1
I0
tp36489
sS'conjugated,and,and'
p36490
(F1
F0.00014334862385321102
I0
I1
I-1
tp36491
sS'such,interaction,should'
p36492
(F1
F0.00014334862385321102
I0
I1
I-1
tp36493
sS'clinically,relevant,changes'
p36494
(F1
F0.0008600917431192661
I0
I6
I-6
tp36495
sS'mefenamic,acid,by'
p36496
(F1
F0.00014334862385321102
I1
I0
I1
tp36497
sS'demonstrated,in,a'
p36498
(F1
F0.00014334862385321102
I1
I0
I1
tp36499
sS'with,ganglionic,or'
p36500
(F1
F0.00014334862385321102
I0
I1
I-1
tp36501
sS'rat,kidney,homogenates'
p36502
(F1
F0.00014334862385321102
I0
I1
I-1
tp36503
sS'affect,the,pharmacokinetic'
p36504
(F0
F0
I1
I1
I0
tp36505
sS'patients,with,early-phase'
p36506
(F1
F0.00014334862385321102
I0
I1
I-1
tp36507
sS'inhibitors,aminosalicylic,acid'
p36508
(F1
F0.00014334862385321102
I1
I0
I1
tp36509
sS'is,withdrawn,from'
p36510
(F1
F0.00014334862385321102
I1
I0
I1
tp36511
sS'which,may,predispose'
p36512
(F1
F0.00014334862385321102
I1
I0
I1
tp36513
sS'enhance,the,serotonergic'
p36514
(F1
F0.00014334862385321102
I1
I0
I1
tp36515
sS'been,no,controlled'
p36516
(F1
F0.00014334862385321102
I0
I1
I-1
tp36517
sS'with,mild,to'
p36518
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp36519
sS'antidepressant,agent,or'
p36520
(F1
F0.00014334862385321102
I0
I1
I-1
tp36521
sS'drugs,and,other'
p36522
(F1
F0.00014334862385321102
I1
I0
I1
tp36523
sS'no,effect,on'
p36524
(F0.61538461538461542
F0.0045871559633027525
I10
I42
I-32
tp36525
sS'drugs,that,reportedly'
p36526
(F1
F0.00028669724770642203
I2
I0
I2
tp36527
sS'and,caution,should'
p36528
(F1
F0.00028669724770642203
I0
I2
I-2
tp36529
sS'kidney,function,and'
p36530
(F1
F0.00014334862385321102
I0
I1
I-1
tp36531
sS'spectrophotometrically,determined,urinary'
p36532
(F1
F0.00014334862385321102
I0
I1
I-1
tp36533
sS'no,effect,of'
p36534
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp36535
sS'a,dose,adjustment'
p36536
(F1
F0.00028669724770642203
I2
I0
I2
tp36537
sS'from,the,in'
p36538
(F1
F0.00028669724770642203
I0
I2
I-2
tp36539
sS'carbonate,the,stimulatory'
p36540
(F1
F0.00014334862385321102
I1
I0
I1
tp36541
sS'with,human,immunodeficiency'
p36542
(F1
F0.00014334862385321102
I0
I1
I-1
tp36543
sS'in,blood,sugar'
p36544
(F1
F0.00014334862385321102
I1
I0
I1
tp36545
sS'been,observed,following'
p36546
(F1
F0.00014334862385321102
I1
I0
I1
tp36547
sS'and,safely,used'
p36548
(F1
F0.00014334862385321102
I0
I1
I-1
tp36549
sS'of,hivid,with'
p36550
(F1
F0.00014334862385321102
I1
I0
I1
tp36551
sS'synthesis,or,in'
p36552
(F1
F0.00014334862385321102
I0
I1
I-1
tp36553
sS'of,bioavailability,of'
p36554
(F1
F0.00014334862385321102
I0
I1
I-1
tp36555
sS'corticosteroid,binding,globulin'
p36556
(F1
F0.00014334862385321102
I0
I1
I-1
tp36557
sS'reported,in,organ'
p36558
(F1
F0.00014334862385321102
I1
I0
I1
tp36559
sS'has,been,used'
p36560
(F1
F0.0010034403669724771
I0
I7
I-7
tp36561
sS'griseofulvin,griseofulvin,may'
p36562
(F1
F0.00014334862385321102
I1
I0
I1
tp36563
sS'such,as,prolonged'
p36564
(F1
F0.00014334862385321102
I0
I1
I-1
tp36565
sS'patients,with,congestive'
p36566
(F0
F0
I1
I1
I0
tp36567
sS'diamond,trials,the'
p36568
(F1
F0.00014334862385321102
I0
I1
I-1
tp36569
sS'doses,of,tmp'
p36570
(F1
F0.00014334862385321102
I0
I1
I-1
tp36571
sS'be,safely,co-administered'
p36572
(F1
F0.00014334862385321102
I0
I1
I-1
tp36573
sS'incisive,by,therapeutic'
p36574
(F1
F0.00014334862385321102
I0
I1
I-1
tp36575
sS'co,administered,and'
p36576
(F1
F0.00014334862385321102
I1
I0
I1
tp36577
sS'occasionally,experience,an'
p36578
(F1
F0.00057339449541284407
I4
I0
I4
tp36579
sS'effect,of,cholinesterase'
p36580
(F1
F0.00014334862385321102
I1
I0
I1
tp36581
sS'increase,in,qtc'
p36582
(F1
F0.00014334862385321102
I1
I0
I1
tp36583
sS'during,or,less'
p36584
(F1
F0.00014334862385321102
I1
I0
I1
tp36585
sS'increase,in,steady-state'
p36586
(F1
F0.00014334862385321102
I1
I0
I1
tp36587
sS'half-life,or,serum'
p36588
(F1
F0.00014334862385321102
I1
I0
I1
tp36589
sS'of,any,of'
p36590
(F1
F0.00043004587155963305
I0
I3
I-3
tp36591
sS'reports,and,commentaries'
p36592
(F1
F0.00014334862385321102
I0
I1
I-1
tp36593
sS'is,frequently,co-administered'
p36594
(F1
F0.00014334862385321102
I0
I1
I-1
tp36595
sS'the,serum,concentration'
p36596
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp36597
sS'potentiate,the,effects'
p36598
(F1
F0.00057339449541284407
I4
I0
I4
tp36599
sS'with,strong,inhibitors'
p36600
(F1
F0.00014334862385321102
I1
I0
I1
tp36601
sS'on,the,action'
p36602
(F1
F0.00014334862385321102
I1
I0
I1
tp36603
sS'of,distribution,or'
p36604
(F1
F0.00014334862385321102
I0
I1
I-1
tp36605
sS'each,be,associated'
p36606
(F1
F0.00014334862385321102
I1
I0
I1
tp36607
sS'males,in,separate'
p36608
(F1
F0.00014334862385321102
I0
I1
I-1
tp36609
sS'm2,plus,to'
p36610
(F1
F0.00014334862385321102
I0
I1
I-1
tp36611
sS'as,and,should'
p36612
(F1
F0.00014334862385321102
I1
I0
I1
tp36613
sS'responses,being,observed'
p36614
(F1
F0.00014334862385321102
I0
I1
I-1
tp36615
sS'oral,who,are'
p36616
(F1
F0.00014334862385321102
I1
I0
I1
tp36617
sS'rofecoxib,mg,once'
p36618
(F1
F0.00014334862385321102
I0
I1
I-1
tp36619
sS'healthy,male,n'
p36620
(F1
F0.00014334862385321102
I0
I1
I-1
tp36621
sS'agents,receiving,velcade'
p36622
(F1
F0.00014334862385321102
I1
I0
I1
tp36623
sS'when,clozapine,is'
p36624
(F1
F0.00014334862385321102
I1
I0
I1
tp36625
sS'and,respectively,by'
p36626
(F1
F0.00014334862385321102
I1
I0
I1
tp36627
sS'or,maintenance,bolus'
p36628
(F1
F0.00014334862385321102
I0
I1
I-1
tp36629
sS'decreased,approximately,fold'
p36630
(F1
F0.00014334862385321102
I1
I0
I1
tp36631
sS'action,is,enhanced'
p36632
(F1
F0.00014334862385321102
I0
I1
I-1
tp36633
sS'kg,min,over'
p36634
(F1
F0.00014334862385321102
I0
I1
I-1
tp36635
sS'caution,using,small'
p36636
(F1
F0.00014334862385321102
I1
I0
I1
tp36637
sS'plasma,concentrations,substances'
p36638
(F1
F0.00014334862385321102
I0
I1
I-1
tp36639
sS'and,viracept,resulted'
p36640
(F1
F0.00028669724770642203
I2
I0
I2
tp36641
sS'adverse,events,by'
p36642
(F1
F0.00014334862385321102
I1
I0
I1
tp36643
sS'augment,the,neuromuscular'
p36644
(F1
F0.00014334862385321102
I1
I0
I1
tp36645
sS'constellation,of,symptoms'
p36646
(F1
F0.00014334862385321102
I1
I0
I1
tp36647
sS'xigris,caution,should'
p36648
(F1
F0.00014334862385321102
I0
I1
I-1
tp36649
sS'of,other,known'
p36650
(F1
F0.00028669724770642203
I2
I0
I2
tp36651
sS'with,taxol,should'
p36652
(F1
F0.00014334862385321102
I0
I1
I-1
tp36653
sS'been,evaluated,and'
p36654
(F0
F0
I1
I1
I0
tp36655
sS'period,of,concurrent'
p36656
(F1
F0.00014334862385321102
I1
I0
I1
tp36657
sS'transplant,patients,receiving'
p36658
(F1
F0.00014334862385321102
I1
I0
I1
tp36659
sS'with,maois,or'
p36660
(F1
F0.00014334862385321102
I1
I0
I1
tp36661
sS'and,confusion,extrapyramidal'
p36662
(F1
F0.00014334862385321102
I1
I0
I1
tp36663
sS'steady-state,pharmacokinetic,variables'
p36664
(F1
F0.00014334862385321102
I0
I1
I-1
tp36665
sS'coadministration,of,beta-adrenergic'
p36666
(F1
F0.00014334862385321102
I0
I1
I-1
tp36667
sS'intervals,during,administration'
p36668
(F1
F0.00014334862385321102
I0
I1
I-1
tp36669
sS'acetaminophen,diminished,the'
p36670
(F1
F0.00014334862385321102
I1
I0
I1
tp36671
sS'sumatriptan,sumatriptan,has'
p36672
(F1
F0.00014334862385321102
I1
I0
I1
tp36673
sS'lower,rate,of'
p36674
(F1
F0.00014334862385321102
I1
I0
I1
tp36675
sS'concentrations,in,serum'
p36676
(F1
F0.00014334862385321102
I0
I1
I-1
tp36677
sS'or,potassium-depleting,and'
p36678
(F1
F0.00014334862385321102
I0
I1
I-1
tp36679
sS'a,possible,drug'
p36680
(F1
F0.00043004587155963305
I3
I0
I3
tp36681
sS'normal,metabolizers,resemble'
p36682
(F1
F0.00014334862385321102
I0
I1
I-1
tp36683
sS'used,when,nsaids'
p36684
(F1
F0.00014334862385321102
I1
I0
I1
tp36685
sS'concomitantly,with,or'
p36686
(F1
F0.00071674311926605509
I5
I0
I5
tp36687
sS'subcutaneous,injections,in'
p36688
(F1
F0.00014334862385321102
I0
I1
I-1
tp36689
sS'is,not,appreciably'
p36690
(F1
F0.00014334862385321102
I0
I1
I-1
tp36691
sS'levels,are,decreased'
p36692
(F1
F0.00014334862385321102
I0
I1
I-1
tp36693
sS'from,a,number'
p36694
(F1
F0.00014334862385321102
I0
I1
I-1
tp36695
sS'is,advised,and'
p36696
(F1
F0.00014334862385321102
I1
I0
I1
tp36697
sS'vitamin,k,oral'
p36698
(F1
F0.00014334862385321102
I1
I0
I1
tp36699
sS'generally,by,effects'
p36700
(F1
F0.00014334862385321102
I0
I1
I-1
tp36701
sS'transient,increases,in'
p36702
(F0
F0
I1
I1
I0
tp36703
sS'and,signs,of'
p36704
(F1
F0.00014334862385321102
I1
I0
I1
tp36705
sS'or,metabolite,i'
p36706
(F1
F0.00014334862385321102
I0
I1
I-1
tp36707
sS'p450,d6,many'
p36708
(F1
F0.00071674311926605509
I0
I5
I-5
tp36709
sS'recommended,to,be'
p36710
(F1
F0.00014334862385321102
I1
I0
I1
tp36711
sS'metabolic,profiles,clinically'
p36712
(F1
F0.00014334862385321102
I0
I1
I-1
tp36713
sS'reduced,by,one-third'
p36714
(F1
F0.00028669724770642203
I0
I2
I-2
tp36715
sS'data,which,suggest'
p36716
(F1
F0.00014334862385321102
I1
I0
I1
tp36717
sS'electrolyte,loss,associated'
p36718
(F1
F0.00028669724770642203
I2
I0
I2
tp36719
sS'for,coadministration,with'
p36720
(F1
F0.00028669724770642203
I0
I2
I-2
tp36721
sS'and,when,administered'
p36722
(F1
F0.00014334862385321102
I1
I0
I1
tp36723
sS'hydrate,and,interact'
p36724
(F1
F0.00014334862385321102
I1
I0
I1
tp36725
sS'mouth,urinary,retention'
p36726
(F1
F0.00028669724770642203
I2
I0
I2
tp36727
sS'to,groups,treated'
p36728
(F1
F0.00014334862385321102
I1
I0
I1
tp36729
sS'in,the,vehicle-controlled'
p36730
(F1
F0.00014334862385321102
I0
I1
I-1
tp36731
sS'stabilized,on,a'
p36732
(F1
F0.00014334862385321102
I1
I0
I1
tp36733
sS'definitively,demonstrated,that'
p36734
(F1
F0.00014334862385321102
I1
I0
I1
tp36735
sS'taking,revia,may'
p36736
(F1
F0.00014334862385321102
I1
I0
I1
tp36737
sS'vomiting,and,or'
p36738
(F1
F0.00014334862385321102
I1
I0
I1
tp36739
sS'elimination,of,leading'
p36740
(F1
F0.00014334862385321102
I1
I0
I1
tp36741
sS'activity,is,in'
p36742
(F1
F0.00014334862385321102
I0
I1
I-1
tp36743
sS'of,azole,agents'
p36744
(F1
F0.00014334862385321102
I1
I0
I1
tp36745
sS'treatment,with,hivid'
p36746
(F0
F0
I1
I1
I0
tp36747
sS'which,may,induce'
p36748
(F1
F0.00014334862385321102
I0
I1
I-1
tp36749
sS'trials,were,maintained'
p36750
(F1
F0.00014334862385321102
I0
I1
I-1
tp36751
sS'oral,dose,should'
p36752
(F1
F0.00014334862385321102
I1
I0
I1
tp36753
sS'enhanced,by,general'
p36754
(F1
F0.00014334862385321102
I0
I1
I-1
tp36755
sS'cyclooxygenase-2,cox-2,inhibitor'
p36756
(F1
F0.00014334862385321102
I0
I1
I-1
tp36757
sS'of,aldehyde,oxidase'
p36758
(F1
F0.00014334862385321102
I0
I1
I-1
tp36759
sS'dietary-obese,rats,are'
p36760
(F1
F0.00014334862385321102
I0
I1
I-1
tp36761
sS'inhibitors,nnrtis,nevirapine'
p36762
(F1
F0.00014334862385321102
I1
I0
I1
tp36763
sS'mhd,did,occur'
p36764
(F1
F0.00014334862385321102
I0
I1
I-1
tp36765
sS'significance,of,these'
p36766
(F1
F0.00014334862385321102
I1
I0
I1
tp36767
sS'of,pcp,or'
p36768
(F1
F0.00014334862385321102
I1
I0
I1
tp36769
sS'oral,and,supplemental'
p36770
(F1
F0.00014334862385321102
I1
I0
I1
tp36771
sS'increase,the,photosensitivity'
p36772
(F1
F0.00014334862385321102
I1
I0
I1
tp36773
sS'or,with,formulations'
p36774
(F1
F0.00014334862385321102
I1
I0
I1
tp36775
sS'benzthiazide,may,interact'
p36776
(F1
F0.00014334862385321102
I1
I0
I1
tp36777
sS'are,not,inhibitors'
p36778
(F1
F0.00014334862385321102
I0
I1
I-1
tp36779
sS'this,period,of'
p36780
(F1
F0.00014334862385321102
I0
I1
I-1
tp36781
sS'long-sedation,time,lst'
p36782
(F1
F0.00014334862385321102
I0
I1
I-1
tp36783
sS'may,enhance,nutrient'
p36784
(F1
F0.00014334862385321102
I1
I0
I1
tp36785
sS'potentiates,other,cholinesterase'
p36786
(F1
F0.00014334862385321102
I1
I0
I1
tp36787
sS'system,depressants,eg'
p36788
(F1
F0.00014334862385321102
I1
I0
I1
tp36789
sS'as,sequential,infusions'
p36790
(F1
F0.00014334862385321102
I1
I0
I1
tp36791
sS'and,systemic,eg'
p36792
(F1
F0.00014334862385321102
I0
I1
I-1
tp36793
sS'preconstricted,with,micromol'
p36794
(F1
F0.00014334862385321102
I0
I1
I-1
tp36795
sS'by,an,average'
p36796
(F1
F0.00043004587155963305
I3
I0
I3
tp36797
sS'when,starlix,mg'
p36798
(F1
F0.00028669724770642203
I0
I2
I-2
tp36799
sS'ssri,is,clinically'
p36800
(F1
F0.00057339449541284407
I4
I0
I4
tp36801
sS'and,iv,compared'
p36802
(F1
F0.00014334862385321102
I0
I1
I-1
tp36803
sS'predominantly,metabolized,by'
p36804
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp36805
sS'been,coadministered,with'
p36806
(F1
F0.00043004587155963305
I0
I3
I-3
tp36807
sS'no,pharmacodynamic,interaction'
p36808
(F1
F0.00028669724770642203
I0
I2
I-2
tp36809
sS'should,refer,to'
p36810
(F1
F0.00014334862385321102
I0
I1
I-1
tp36811
sS'for,weeks,in'
p36812
(F1
F0.00014334862385321102
I1
I0
I1
tp36813
sS'of,with,with'
p36814
(F1
F0.00014334862385321102
I1
I0
I1
tp36815
sS'clinical,studies,the'
p36816
(F1
F0.00014334862385321102
I0
I1
I-1
tp36817
sS'be,discontinued,for'
p36818
(F1
F0.00014334862385321102
I1
I0
I1
tp36819
sS'reduce,the,number'
p36820
(F1
F0.00014334862385321102
I1
I0
I1
tp36821
sS'to,provide,information'
p36822
(F1
F0.00014334862385321102
I0
I1
I-1
tp36823
sS'amitriptyline,concurrent,administration'
p36824
(F1
F0.00014334862385321102
I1
I0
I1
tp36825
sS'lst,short,sedation'
p36826
(F1
F0.00014334862385321102
I0
I1
I-1
tp36827
sS'hours,and,as'
p36828
(F1
F0.00014334862385321102
I1
I0
I1
tp36829
sS'toradoliv,im,was'
p36830
(F1
F0.00014334862385321102
I0
I1
I-1
tp36831
sS'extracellular,rr,microm'
p36832
(F1
F0.00014334862385321102
I1
I0
I1
tp36833
sS'to,achieve,the'
p36834
(F0
F0
I1
I1
I0
tp36835
sS'tablets,an,can'
p36836
(F1
F0.00014334862385321102
I1
I0
I1
tp36837
sS'carbamazepine,coadministration,of'
p36838
(F1
F0.00014334862385321102
I1
I0
I1
tp36839
sS'these,are,taken'
p36840
(F1
F0.00014334862385321102
I1
I0
I1
tp36841
sS'because,is,metabolized'
p36842
(F1
F0.00057339449541284407
I0
I4
I-4
tp36843
sS'some,are,analgesic'
p36844
(F1
F0.00014334862385321102
I0
I1
I-1
tp36845
sS'both,control,and'
p36846
(F1
F0.00014334862385321102
I0
I1
I-1
tp36847
sS'whom,therapy,with'
p36848
(F1
F0.00014334862385321102
I1
I0
I1
tp36849
sS'that,is,metabolized'
p36850
(F1
F0.00014334862385321102
I0
I1
I-1
tp36851
sS'in,an,opposite'
p36852
(F1
F0.00014334862385321102
I1
I0
I1
tp36853
sS'followed,by,the'
p36854
(F1
F0.00014334862385321102
I0
I1
I-1
tp36855
sS'that,are,extensively'
p36856
(F1
F0.00014334862385321102
I1
I0
I1
tp36857
sS'on,hormone,synthesis'
p36858
(F1
F0.00014334862385321102
I0
I1
I-1
tp36859
sS'and,are,predominantly'
p36860
(F1
F0.00014334862385321102
I0
I1
I-1
tp36861
sS'of,the,patient'
p36862
(F1
F0.0008600917431192661
I6
I0
I6
tp36863
sS'and,produce,false'
p36864
(F1
F0.00028669724770642203
I0
I2
I-2
tp36865
sS'produces,depression,of'
p36866
(F1
F0.00014334862385321102
I1
I0
I1
tp36867
sS'be,expected,and'
p36868
(F1
F0.00014334862385321102
I1
I0
I1
tp36869
sS'for,renal,toxicity'
p36870
(F1
F0.00014334862385321102
I1
I0
I1
tp36871
sS'the,auc0-120hr,by'
p36872
(F1
F0.00014334862385321102
I1
I0
I1
tp36873
sS'hypoglycemic,action,of'
p36874
(F1
F0.00057339449541284407
I4
I0
I4
tp36875
sS'amiodarone,caused,a'
p36876
(F1
F0.00014334862385321102
I0
I1
I-1
tp36877
sS'in,a,c'
p36878
(F1
F0.00014334862385321102
I1
I0
I1
tp36879
sS'available,assay,methods'
p36880
(F1
F0.00014334862385321102
I0
I1
I-1
tp36881
sS'and,anti-depressants,could'
p36882
(F1
F0.00014334862385321102
I1
I0
I1
tp36883
sS'celebrex,mg,bid'
p36884
(F1
F0.00014334862385321102
I1
I0
I1
tp36885
sS'day,on,day'
p36886
(F1
F0.00014334862385321102
I1
I0
I1
tp36887
sS'subject,given,one'
p36888
(F1
F0.00014334862385321102
I1
I0
I1
tp36889
sS'oral,clearance,and'
p36890
(F1
F0.00014334862385321102
I1
I0
I1
tp36891
sS'in,patients,below'
p36892
(F1
F0.00014334862385321102
I0
I1
I-1
tp36893
sS'recommended,unless,the'
p36894
(F1
F0.00014334862385321102
I1
I0
I1
tp36895
sS'by,approximately,by'
p36896
(F1
F0.00014334862385321102
I1
I0
I1
tp36897
sS'necrolysis,has,been'
p36898
(F1
F0.00014334862385321102
I0
I1
I-1
tp36899
sS'release,in,either'
p36900
(F1
F0.00014334862385321102
I0
I1
I-1
tp36901
sS'using,small,initial'
p36902
(F1
F0.00014334862385321102
I1
I0
I1
tp36903
sS'to,compete,for'
p36904
(F1
F0.00014334862385321102
I0
I1
I-1
tp36905
sS'is,recommended,not'
p36906
(F1
F0.00043004587155963305
I3
I0
I3
tp36907
sS'in,effectiveness,of'
p36908
(F1
F0.00014334862385321102
I1
I0
I1
tp36909
sS'of,and,metabolite'
p36910
(F1
F0.00014334862385321102
I1
I0
I1
tp36911
sS'a,light,meal'
p36912
(F0
F0
I1
I1
I0
tp36913
sS'in,a,further'
p36914
(F1
F0.00028669724770642203
I2
I0
I2
tp36915
sS'introduction,of,beta'
p36916
(F1
F0.00014334862385321102
I1
I0
I1
tp36917
sS'hypotension,or,exacerbation'
p36918
(F1
F0.00014334862385321102
I1
I0
I1
tp36919
sS'pharmacokinetic,interactions,occurred'
p36920
(F1
F0.00028669724770642203
I0
I2
I-2
tp36921
sS'diphen-hydramine,and,h2'
p36922
(F1
F0.00014334862385321102
I0
I1
I-1
tp36923
sS'kaletra,norvir,viracept'
p36924
(F1
F0.00014334862385321102
I1
I0
I1
tp36925
sS'thus,the,selective'
p36926
(F1
F0.00014334862385321102
I0
I1
I-1
tp36927
sS'corticosteroids,and,corticotropin'
p36928
(F1
F0.00014334862385321102
I1
I0
I1
tp36929
sS'which,increases,gastrointestinal'
p36930
(F1
F0.00014334862385321102
I1
I0
I1
tp36931
sS'lithium,coadministration,of'
p36932
(F1
F0.00014334862385321102
I0
I1
I-1
tp36933
sS'the,dmpge2,mg'
p36934
(F1
F0.00014334862385321102
I1
I0
I1
tp36935
sS'cyp1a2,in,vitro'
p36936
(F1
F0.00014334862385321102
I0
I1
I-1
tp36937
sS'patients,receiving,hctz'
p36938
(F1
F0.00014334862385321102
I1
I0
I1
tp36939
sS'substrate,for,both'
p36940
(F1
F0.00014334862385321102
I0
I1
I-1
tp36941
sS'by,gram-negative,organisms'
p36942
(F1
F0.00014334862385321102
I0
I1
I-1
tp36943
sS'inhibits,platelet,function'
p36944
(F1
F0.00014334862385321102
I1
I0
I1
tp36945
sS'weight,for,days'
p36946
(F1
F0.00014334862385321102
I0
I1
I-1
tp36947
sS'via,dehydrogenase,inhibition'
p36948
(F1
F0.00014334862385321102
I1
I0
I1
tp36949
sS'study,in,diabetics'
p36950
(F1
F0.00014334862385321102
I1
I0
I1
tp36951
sS'know,if,you'
p36952
(F1
F0.00014334862385321102
I1
I0
I1
tp36953
sS'a4,inhibitors,such'
p36954
(F0
F0
I1
I1
I0
tp36955
sS'antagonists,the,effect'
p36956
(F1
F0.00014334862385321102
I0
I1
I-1
tp36957
sS'of,foods,highly'
p36958
(F1
F0.00014334862385321102
I0
I1
I-1
tp36959
sS'diminished,urinary,excretion'
p36960
(F1
F0.00014334862385321102
I1
I0
I1
tp36961
sS'have,any,effect'
p36962
(F1
F0.00028669724770642203
I0
I2
I-2
tp36963
sS'also,been,shown'
p36964
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp36965
sS'a,clinical,study'
p36966
(F0
F0
I2
I2
I0
tp36967
sS'before,meals,was'
p36968
(F1
F0.00028669724770642203
I0
I2
I-2
tp36969
sS'enzyme,inducers,and'
p36970
(F1
F0.00028669724770642203
I2
I0
I2
tp36971
sS'should,be,delayed'
p36972
(F1
F0.00014334862385321102
I1
I0
I1
tp36973
sS'powder,for,oral'
p36974
(F1
F0.0010034403669724771
I7
I0
I7
tp36975
sS'nabilone,has,been'
p36976
(F1
F0.00014334862385321102
I1
I0
I1
tp36977
sS'antagonists,may,be'
p36978
(F1
F0.00014334862385321102
I1
I0
I1
tp36979
sS'test,dsst,symbol'
p36980
(F1
F0.00014334862385321102
I1
I0
I1
tp36981
sS'mcg,ml,nor'
p36982
(F1
F0.00014334862385321102
I0
I1
I-1
tp36983
sS'the,release,of'
p36984
(F1
F0.00014334862385321102
I0
I1
I-1
tp36985
sS'dysrhythmias,of,other'
p36986
(F1
F0.00014334862385321102
I1
I0
I1
tp36987
sS'activity,transient,cardiac'
p36988
(F1
F0.00014334862385321102
I1
I0
I1
tp36989
sS'to,decreased,synthesis'
p36990
(F1
F0.00028669724770642203
I2
I0
I2
tp36991
sS'the,harmonic,mean'
p36992
(F1
F0.00014334862385321102
I0
I1
I-1
tp36993
sS'that,may,selectively'
p36994
(F1
F0.00014334862385321102
I1
I0
I1
tp36995
sS'concomitantly,with,lodosyn'
p36996
(F1
F0.00014334862385321102
I0
I1
I-1
tp36997
sS'a,novel,chemical'
p36998
(F1
F0.00014334862385321102
I1
I0
I1
tp36999
sS'the,and,cns'
p37000
(F0
F0
I2
I2
I0
tp37001
sS'phenytoin,felbatol,causes'
p37002
(F1
F0.00014334862385321102
I1
I0
I1
tp37003
sS'requirements,i,may'
p37004
(F1
F0.00014334862385321102
I0
I1
I-1
tp37005
sS'antagonists,cimetidine,inhibits'
p37006
(F1
F0.00014334862385321102
I1
I0
I1
tp37007
sS'of,other,neuromuscular'
p37008
(F1
F0.00028669724770642203
I2
I0
I2
tp37009
sS'and,channel,blockers'
p37010
(F1
F0.00028669724770642203
I2
I0
I2
tp37011
sS'humans,have,demonstrated'
p37012
(F1
F0.00014334862385321102
I0
I1
I-1
tp37013
sS'be,used,concomitantly'
p37014
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp37015
sS'to,monitor,tcaplasma'
p37016
(F1
F0.00014334862385321102
I0
I1
I-1
tp37017
sS'studies,in,healthy'
p37018
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp37019
sS'isoforms,cyp3a4,cyp2d6'
p37020
(F1
F0.00014334862385321102
I0
I1
I-1
tp37021
sS'effects,of,antihypertensive'
p37022
(F1
F0.00014334862385321102
I1
I0
I1
tp37023
sS'carbonate,mg,bid'
p37024
(F1
F0.00014334862385321102
I0
I1
I-1
tp37025
sS'with,elevations,of'
p37026
(F1
F0.00014334862385321102
I1
I0
I1
tp37027
sS'antidepressant,class,including'
p37028
(F1
F0.00014334862385321102
I0
I1
I-1
tp37029
sS'cardiovascular,collapse,in'
p37030
(F1
F0.00014334862385321102
I0
I1
I-1
tp37031
sS'study,comparing,the'
p37032
(F1
F0.00014334862385321102
I0
I1
I-1
tp37033
sS'use,of,adenocard'
p37034
(F1
F0.00014334862385321102
I1
I0
I1
tp37035
sS'and,completely,depressed'
p37036
(F1
F0.00014334862385321102
I1
I0
I1
tp37037
sS'of,cromolyn,sodium'
p37038
(F1
F0.00014334862385321102
I1
I0
I1
tp37039
sS'elemental,as,feso4'
p37040
(F1
F0.00014334862385321102
I1
I0
I1
tp37041
sS'inhibitor,of,cyp'
p37042
(F1
F0.00014334862385321102
I0
I1
I-1
tp37043
sS'this,is,given'
p37044
(F1
F0.00014334862385321102
I0
I1
I-1
tp37045
sS'reduce,the,gastrointestinal'
p37046
(F1
F0.00014334862385321102
I1
I0
I1
tp37047
sS'ng,ml,resulted'
p37048
(F1
F0.00014334862385321102
I0
I1
I-1
tp37049
sS'three,mg,capsules'
p37050
(F1
F0.00014334862385321102
I1
I0
I1
tp37051
sS'although,it,significantly'
p37052
(F1
F0.00014334862385321102
I1
I0
I1
tp37053
sS'a,further,deterioration'
p37054
(F1
F0.00028669724770642203
I2
I0
I2
tp37055
sS'in,monkeys,nanm'
p37056
(F1
F0.00014334862385321102
I0
I1
I-1
tp37057
sS'to,its,antidiuretic'
p37058
(F1
F0.00014334862385321102
I0
I1
I-1
tp37059
sS'of,following,ultracentrifugation'
p37060
(F1
F0.00014334862385321102
I0
I1
I-1
tp37061
sS'relationship,between,these'
p37062
(F1
F0.00014334862385321102
I0
I1
I-1
tp37063
sS'capsules,or,ml'
p37064
(F1
F0.00014334862385321102
I1
I0
I1
tp37065
sS'clinical,studies,one'
p37066
(F1
F0.00014334862385321102
I1
I0
I1
tp37067
sS'its,activity,was'
p37068
(F1
F0.00014334862385321102
I0
I1
I-1
tp37069
sS'antihypertensive,medications,or'
p37070
(F1
F0.00028669724770642203
I2
I0
I2
tp37071
sS'take,first,and'
p37072
(F1
F0.00014334862385321102
I1
I0
I1
tp37073
sS'escherichia,coli,in'
p37074
(F1
F0.00014334862385321102
I0
I1
I-1
tp37075
sS'but,does,not'
p37076
(F1
F0.00014334862385321102
I1
I0
I1
tp37077
sS'involvement,of,reactive'
p37078
(F1
F0.00014334862385321102
I0
I1
I-1
tp37079
sS'decrease,of,phosphorylated'
p37080
(F1
F0.00014334862385321102
I0
I1
I-1
tp37081
sS'other,members,of'
p37082
(F1
F0.00028669724770642203
I2
I0
I2
tp37083
sS'block,is,shortened'
p37084
(F1
F0.00014334862385321102
I1
I0
I1
tp37085
sS'serum,proteins,indicate'
p37086
(F1
F0.00014334862385321102
I0
I1
I-1
tp37087
sS'and,thus,may'
p37088
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp37089
sS'cause,a,sharp'
p37090
(F1
F0.00014334862385321102
I1
I0
I1
tp37091
sS'novolog,should,be'
p37092
(F1
F0.00014334862385321102
I0
I1
I-1
tp37093
sS'a,similar,effect'
p37094
(F1
F0.00014334862385321102
I0
I1
I-1
tp37095
sS'agent,or,incompletely'
p37096
(F1
F0.00014334862385321102
I0
I1
I-1
tp37097
sS'serum,enzymes,bun'
p37098
(F1
F0.00014334862385321102
I1
I0
I1
tp37099
sS'increased,appetite,and'
p37100
(F1
F0.00014334862385321102
I0
I1
I-1
tp37101
sS'auc,of,increased'
p37102
(F1
F0.00028669724770642203
I2
I0
I2
tp37103
sS'apparent,volume,of'
p37104
(F1
F0.00014334862385321102
I0
I1
I-1
tp37105
sS'significant,interactions,were'
p37106
(F1
F0.00014334862385321102
I0
I1
I-1
tp37107
sS'who,require,anticoagulation'
p37108
(F1
F0.00014334862385321102
I0
I1
I-1
tp37109
sS'butyrophenone,classes,of'
p37110
(F1
F0.00014334862385321102
I1
I0
I1
tp37111
sS'the,recommended,maximum'
p37112
(F1
F0.00028669724770642203
I2
I0
I2
tp37113
sS'had,depleting,added'
p37114
(F1
F0.00014334862385321102
I0
I1
I-1
tp37115
sS'dose,even,when'
p37116
(F1
F0.00014334862385321102
I0
I1
I-1
tp37117
sS'and,or,stereotypic'
p37118
(F1
F0.00014334862385321102
I0
I1
I-1
tp37119
sS'effect,of,microdosed'
p37120
(F1
F0.00028669724770642203
I2
I0
I2
tp37121
sS'these,results,suggest'
p37122
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp37123
sS'dispersible,tablet,formulation'
p37124
(F1
F0.00014334862385321102
I1
I0
I1
tp37125
sS'increases,in,fi'
p37126
(F0
F0
I1
I1
I0
tp37127
sS'risk,of,neutropenia'
p37128
(F1
F0.00028669724770642203
I2
I0
I2
tp37129
sS'if,patients,are'
p37130
(F1
F0.00014334862385321102
I1
I0
I1
tp37131
sS'regular,users,develop'
p37132
(F1
F0.00014334862385321102
I0
I1
I-1
tp37133
sS'focus,on,investigation'
p37134
(F1
F0.00014334862385321102
I0
I1
I-1
tp37135
sS'in,human,cells'
p37136
(F1
F0.00014334862385321102
I0
I1
I-1
tp37137
sS'metabolite,i,with'
p37138
(F1
F0.00014334862385321102
I0
I1
I-1
tp37139
sS'days,intraperitoneally,ip'
p37140
(F1
F0.00014334862385321102
I1
I0
I1
tp37141
sS'agents,in,one'
p37142
(F1
F0.00014334862385321102
I0
I1
I-1
tp37143
sS'agents,calcium,channel'
p37144
(F1
F0.00014334862385321102
I0
I1
I-1
tp37145
sS'discernible,changes,in'
p37146
(F1
F0.00014334862385321102
I0
I1
I-1
tp37147
sS'effect,of,brevibloc'
p37148
(F1
F0.00014334862385321102
I0
I1
I-1
tp37149
sS'drugs,in,some'
p37150
(F1
F0.00028669724770642203
I2
I0
I2
tp37151
sS'and,cerebyx,dosage'
p37152
(F1
F0.00014334862385321102
I1
I0
I1
tp37153
sS'active,in,inhibiting'
p37154
(F1
F0.00014334862385321102
I1
I0
I1
tp37155
sS'administered,with,see'
p37156
(F1
F0.00014334862385321102
I1
I0
I1
tp37157
sS'metabolism,via,p450'
p37158
(F1
F0.00014334862385321102
I1
I0
I1
tp37159
sS'by,when,extended'
p37160
(F1
F0.00014334862385321102
I0
I1
I-1
tp37161
sS'some,forms,of'
p37162
(F1
F0.00014334862385321102
I0
I1
I-1
tp37163
sS'did,occur,at'
p37164
(F1
F0.00014334862385321102
I0
I1
I-1
tp37165
sS'the,excretion,of'
p37166
(F1
F0.00028669724770642203
I2
I0
I2
tp37167
sS'for,characterization,or'
p37168
(F1
F0.00014334862385321102
I0
I1
I-1
tp37169
sS'therapy,and,had'
p37170
(F1
F0.00014334862385321102
I1
I0
I1
tp37171
sS'injection,in,combination'
p37172
(F1
F0.00014334862385321102
I1
I0
I1
tp37173
sS'inhibits,cyp3a4,and'
p37174
(F0
F0
I1
I1
I0
tp37175
sS'bid,for,days'
p37176
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp37177
sS'suggest,that,may'
p37178
(F1
F0.00028669724770642203
I2
I0
I2
tp37179
sS'of,anti-platelet,effect'
p37180
(F1
F0.00014334862385321102
I0
I1
I-1
tp37181
sS'produce,severe,weakness'
p37182
(F1
F0.00014334862385321102
I1
I0
I1
tp37183
sS'reduces,both,the'
p37184
(F1
F0.00014334862385321102
I1
I0
I1
tp37185
sS'should,not,require'
p37186
(F1
F0.00014334862385321102
I0
I1
I-1
tp37187
sS'initiation,of,treatment'
p37188
(F1
F0.0010034403669724771
I7
I0
I7
tp37189
sS'anxiogenic,effects,by'
p37190
(F1
F0.00014334862385321102
I1
I0
I1
tp37191
sS'uricosuric,agents,which'
p37192
(F1
F0.00014334862385321102
I1
I0
I1
tp37193
sS'generation,atypical,antipsychotic'
p37194
(F1
F0.00014334862385321102
I0
I1
I-1
tp37195
sS'qd,or,mg'
p37196
(F1
F0.00014334862385321102
I0
I1
I-1
tp37197
sS'abnormal,renal,uptake'
p37198
(F1
F0.00014334862385321102
I1
I0
I1
tp37199
sS'twitch,from,to'
p37200
(F1
F0.00014334862385321102
I1
I0
I1
tp37201
sS'on,the,compatibility'
p37202
(F1
F0.00014334862385321102
I0
I1
I-1
tp37203
sS'a,patient,maintained'
p37204
(F1
F0.00014334862385321102
I1
I0
I1
tp37205
sS'as,sulfamethoxazole-trimethoprim,bactrim'
p37206
(F1
F0.00014334862385321102
I0
I1
I-1
tp37207
sS'cmax,values,were'
p37208
(F1
F0.00014334862385321102
I0
I1
I-1
tp37209
sS'day,is,easy'
p37210
(F1
F0.00014334862385321102
I0
I1
I-1
tp37211
sS'ie,from,ml'
p37212
(F1
F0.00014334862385321102
I0
I1
I-1
tp37213
sS'this,isozyme,and'
p37214
(F0
F0
I1
I1
I0
tp37215
sS'similar,personality,characteristics'
p37216
(F1
F0.00014334862385321102
I0
I1
I-1
tp37217
sS'following,adrenocorticoids,cortisone-like'
p37218
(F1
F0.00014334862385321102
I1
I0
I1
tp37219
sS'ethyl,mao,inhibitors'
p37220
(F1
F0.00014334862385321102
I1
I0
I1
tp37221
sS'and,an,ssri'
p37222
(F1
F0.00057339449541284407
I4
I0
I4
tp37223
sS'prolonged,by,therapy'
p37224
(F1
F0.00014334862385321102
I1
I0
I1
tp37225
sS'initiating,a,multi-day'
p37226
(F1
F0.00014334862385321102
I1
I0
I1
tp37227
sS'for,alterations,of'
p37228
(F1
F0.00014334862385321102
I1
I0
I1
tp37229
sS'of,interference,by'
p37230
(F1
F0.00014334862385321102
I0
I1
I-1
tp37231
sS'acid,secretion,stimulated'
p37232
(F1
F0.00014334862385321102
I0
I1
I-1
tp37233
sS'sensitivity,and,enhance'
p37234
(F1
F0.00014334862385321102
I1
I0
I1
tp37235
sS'digoxin,rofecoxib,mg'
p37236
(F1
F0.00014334862385321102
I0
I1
I-1
tp37237
sS'a,single-dose,crossover'
p37238
(F1
F0.00014334862385321102
I1
I0
I1
tp37239
sS'carbamazepine,causes,an'
p37240
(F1
F0.00014334862385321102
I1
I0
I1
tp37241
sS'effect,is,small'
p37242
(F1
F0.00014334862385321102
I0
I1
I-1
tp37243
sS'eprosartan,doses,of'
p37244
(F1
F0.00014334862385321102
I0
I1
I-1
tp37245
sS'coadministration,of,which'
p37246
(F1
F0.00014334862385321102
I1
I0
I1
tp37247
sS'vitamin,b12,which'
p37248
(F1
F0.00014334862385321102
I1
I0
I1
tp37249
sS'of,oral,ccnu'
p37250
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37251
sS'be,potentiated,resulting'
p37252
(F1
F0.00014334862385321102
I1
I0
I1
tp37253
sS'combination,therapy,dose'
p37254
(F1
F0.00014334862385321102
I1
I0
I1
tp37255
sS'replacement,may,alter'
p37256
(F1
F0.00014334862385321102
I0
I1
I-1
tp37257
sS'and,low,affinity'
p37258
(F1
F0.00014334862385321102
I0
I1
I-1
tp37259
sS'concentrates,has,not'
p37260
(F1
F0.00014334862385321102
I0
I1
I-1
tp37261
sS'completely,absorbed,from'
p37262
(F1
F0.00014334862385321102
I0
I1
I-1
tp37263
sS'for,days,with'
p37264
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp37265
sS'with,nsaids,has'
p37266
(F1
F0.00014334862385321102
I1
I0
I1
tp37267
sS'to,dose-related,decrease'
p37268
(F1
F0.00014334862385321102
I1
I0
I1
tp37269
sS'variable,half-life,of'
p37270
(F1
F0.00014334862385321102
I0
I1
I-1
tp37271
sS'clinically,important,effects'
p37272
(F1
F0.00028669724770642203
I0
I2
I-2
tp37273
sS'of,were,almost'
p37274
(F1
F0.00014334862385321102
I1
I0
I1
tp37275
sS'if,novolog,is'
p37276
(F1
F0.00014334862385321102
I0
I1
I-1
tp37277
sS'side,effects,particularly'
p37278
(F1
F0.00014334862385321102
I1
I0
I1
tp37279
sS'test,should,be'
p37280
(F1
F0.00043004587155963305
I3
I0
I3
tp37281
sS'in,the,dose'
p37282
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37283
sS'fluconazole,and,ketoconazole'
p37284
(F1
F0.00014334862385321102
I0
I1
I-1
tp37285
sS'kidney,allograft,recipients'
p37286
(F1
F0.00014334862385321102
I0
I1
I-1
tp37287
sS'enzymes,and,thus'
p37288
(F1
F0.00014334862385321102
I1
I0
I1
tp37289
sS'prevent,the,from'
p37290
(F1
F0.00014334862385321102
I1
I0
I1
tp37291
sS'monkeys,the,effects'
p37292
(F1
F0.00014334862385321102
I1
I0
I1
tp37293
sS'hours,of,subjects'
p37294
(F1
F0.00014334862385321102
I1
I0
I1
tp37295
sS'ataxia,a,typical'
p37296
(F1
F0.00014334862385321102
I0
I1
I-1
tp37297
sS'antacids,and,sucralfate'
p37298
(F1
F0.00014334862385321102
I1
I0
I1
tp37299
sS'the,activity,of'
p37300
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp37301
sS'the,induction,of'
p37302
(F1
F0.00028669724770642203
I2
I0
I2
tp37303
sS'indocin,reduces,basal'
p37304
(F1
F0.00014334862385321102
I0
I1
I-1
tp37305
sS'of,the,pronounced'
p37306
(F1
F0.00014334862385321102
I1
I0
I1
tp37307
sS'of,toxicity,associated'
p37308
(F1
F0.00014334862385321102
I1
I0
I1
tp37309
sS'cyp2c9,such,as'
p37310
(F1
F0.00014334862385321102
I1
I0
I1
tp37311
sS'metabolism,produced,an'
p37312
(F1
F0.00014334862385321102
I1
I0
I1
tp37313
sS'metabolism,decreased,the'
p37314
(F1
F0.00014334862385321102
I1
I0
I1
tp37315
sS'not,affect,renal'
p37316
(F1
F0.00014334862385321102
I0
I1
I-1
tp37317
sS'certain,endocrine,and'
p37318
(F1
F0.00028669724770642203
I0
I2
I-2
tp37319
sS'simulect,is,added'
p37320
(F1
F0.00014334862385321102
I0
I1
I-1
tp37321
sS'and,returned,to'
p37322
(F1
F0.00014334862385321102
I0
I1
I-1
tp37323
sS'pointes-type,ventricular,tachycardia'
p37324
(F1
F0.00014334862385321102
I0
I1
I-1
tp37325
sS'metabolizers,of,such'
p37326
(F1
F0.00028669724770642203
I0
I2
I-2
tp37327
sS'another,study,in'
p37328
(F1
F0.00014334862385321102
I1
I0
I1
tp37329
sS'mesylate,did,not'
p37330
(F1
F0.00014334862385321102
I0
I1
I-1
tp37331
sS'of,and,results'
p37332
(F1
F0.00014334862385321102
I1
I0
I1
tp37333
sS'agents,calcium-channel,blocking'
p37334
(F1
F0.00014334862385321102
I0
I1
I-1
tp37335
sS'phenothiazines,and,may'
p37336
(F1
F0.00028669724770642203
I2
I0
I2
tp37337
sS'concomitantly,indicate,that'
p37338
(F1
F0.00014334862385321102
I1
I0
I1
tp37339
sS'to,the,action'
p37340
(F1
F0.00014334862385321102
I1
I0
I1
tp37341
sS'three-fold,compared,to'
p37342
(F1
F0.00014334862385321102
I0
I1
I-1
tp37343
sS'of,major,clinical'
p37344
(F1
F0.00014334862385321102
I1
I0
I1
tp37345
sS'daily,with,mg'
p37346
(F1
F0.00014334862385321102
I0
I1
I-1
tp37347
sS'pyrocarbonate,could,be'
p37348
(F1
F0.00014334862385321102
I0
I1
I-1
tp37349
sS'hydrochloride,was,found'
p37350
(F1
F0.00014334862385321102
I1
I0
I1
tp37351
sS'showed,that,the'
p37352
(F1
F0.00014334862385321102
I0
I1
I-1
tp37353
sS'treated,for,up'
p37354
(F1
F0.00028669724770642203
I2
I0
I2
tp37355
sS'other,metal,cations'
p37356
(F1
F0.00014334862385321102
I1
I0
I1
tp37357
sS'maximum,concentration,and'
p37358
(F1
F0.00014334862385321102
I0
I1
I-1
tp37359
sS'and,fbs,followed'
p37360
(F1
F0.00014334862385321102
I1
I0
I1
tp37361
sS'hepatic,microsomal,monooxygenase'
p37362
(F1
F0.00014334862385321102
I0
I1
I-1
tp37363
sS'study,in,seven'
p37364
(F1
F0.00014334862385321102
I0
I1
I-1
tp37365
sS'induce,metabolism,causing'
p37366
(F1
F0.00014334862385321102
I1
I0
I1
tp37367
sS'the,proliferation,of'
p37368
(F1
F0.00028669724770642203
I2
I0
I2
tp37369
sS'therapy,including,and'
p37370
(F1
F0.00014334862385321102
I0
I1
I-1
tp37371
sS'receiving,preparations,or'
p37372
(F1
F0.00014334862385321102
I0
I1
I-1
tp37373
sS'in,isolated,single'
p37374
(F1
F0.00014334862385321102
I0
I1
I-1
tp37375
sS'who,have,pre-existing'
p37376
(F1
F0.00014334862385321102
I1
I0
I1
tp37377
sS'accumulation,of,as'
p37378
(F1
F0.00028669724770642203
I0
I2
I-2
tp37379
sS'used,for,relief'
p37380
(F1
F0.00014334862385321102
I0
I1
I-1
tp37381
sS'until,the,end'
p37382
(F1
F0.00014334862385321102
I0
I1
I-1
tp37383
sS'with,suspension,yielded'
p37384
(F1
F0.00014334862385321102
I0
I1
I-1
tp37385
sS'to,be,of'
p37386
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37387
sS'a,nonlethal,dose'
p37388
(F0
F0
I1
I1
I0
tp37389
sS'the,oral,route'
p37390
(F1
F0.00014334862385321102
I0
I1
I-1
tp37391
sS'some,reports,of'
p37392
(F1
F0.00014334862385321102
I0
I1
I-1
tp37393
sS'concentrations,has,not'
p37394
(F1
F0.00014334862385321102
I0
I1
I-1
tp37395
sS'warfarin,atorvastatin,had'
p37396
(F1
F0.00014334862385321102
I0
I1
I-1
tp37397
sS'effects,of,upon'
p37398
(F1
F0.00014334862385321102
I0
I1
I-1
tp37399
sS'use,of,bepridil'
p37400
(F1
F0.00028669724770642203
I0
I2
I-2
tp37401
sS'stomach,drugs,such'
p37402
(F1
F0.00014334862385321102
I1
I0
I1
tp37403
sS'of,argatroban,with'
p37404
(F0
F0
I1
I1
I0
tp37405
sS'gastric,fistulas,were'
p37406
(F1
F0.00014334862385321102
I0
I1
I-1
tp37407
sS'the,heat,stimulus'
p37408
(F1
F0.00014334862385321102
I0
I1
I-1
tp37409
sS'a,consequence,when'
p37410
(F1
F0.00014334862385321102
I1
I0
I1
tp37411
sS'the,prothrombin,time'
p37412
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp37413
sS'with,in,adults'
p37414
(F1
F0.00014334862385321102
I0
I1
I-1
tp37415
sS'nasal,spray,during'
p37416
(F1
F0.00014334862385321102
I0
I1
I-1
tp37417
sS'toxicologic,profile,of'
p37418
(F1
F0.00014334862385321102
I0
I1
I-1
tp37419
sS'if,these,are'
p37420
(F1
F0.00043004587155963305
I0
I3
I-3
tp37421
sS'and,behavioral,effects'
p37422
(F1
F0.00014334862385321102
I0
I1
I-1
tp37423
sS'and,or,were'
p37424
(F1
F0.00014334862385321102
I0
I1
I-1
tp37425
sS'investigated,using,higher'
p37426
(F1
F0.00014334862385321102
I1
I0
I1
tp37427
sS'exercised,if,peganone'
p37428
(F1
F0.00014334862385321102
I1
I0
I1
tp37429
sS'methoxycoronaridine,mc,and'
p37430
(F1
F0.00014334862385321102
I0
I1
I-1
tp37431
sS'system,depressant,cns'
p37432
(F1
F0.00014334862385321102
I0
I1
I-1
tp37433
sS'antifibrinolytic,therapies,i'
p37434
(F1
F0.00014334862385321102
I0
I1
I-1
tp37435
sS'subjects,receiving,daily'
p37436
(F1
F0.00014334862385321102
I0
I1
I-1
tp37437
sS'a4,enzymes,lapatinib'
p37438
(F1
F0.00014334862385321102
I0
I1
I-1
tp37439
sS'of,m1,peak'
p37440
(F1
F0.00014334862385321102
I1
I0
I1
tp37441
sS'of,striatal,but'
p37442
(F1
F0.00014334862385321102
I1
I0
I1
tp37443
sS'diet,resulted,in'
p37444
(F1
F0.00014334862385321102
I1
I0
I1
tp37445
sS'no,significant,pharmacokinetic'
p37446
(F1
F0.00043004587155963305
I0
I3
I-3
tp37447
sS'was,observed,in'
p37448
(F1
F0.00014334862385321102
I0
I1
I-1
tp37449
sS'clearance,when,administered'
p37450
(F1
F0.00014334862385321102
I1
I0
I1
tp37451
sS'transport,of,may'
p37452
(F1
F0.00014334862385321102
I1
I0
I1
tp37453
sS'an,increased,peak'
p37454
(F1
F0.00014334862385321102
I1
I0
I1
tp37455
sS'effect,the,enteric'
p37456
(F1
F0.00014334862385321102
I1
I0
I1
tp37457
sS'that,the,addition'
p37458
(F1
F0.00014334862385321102
I1
I0
I1
tp37459
sS'and,decreased,efficacy'
p37460
(F1
F0.00014334862385321102
I0
I1
I-1
tp37461
sS'degree,in,the'
p37462
(F1
F0.00014334862385321102
I0
I1
I-1
tp37463
sS'numerous,interactions,are'
p37464
(F1
F0.00014334862385321102
I0
I1
I-1
tp37465
sS'addition,interfere,with'
p37466
(F1
F0.00014334862385321102
I1
I0
I1
tp37467
sS'neither,reversed,by'
p37468
(F1
F0.00014334862385321102
I1
I0
I1
tp37469
sS'tissue,culture,and'
p37470
(F1
F0.00014334862385321102
I1
I0
I1
tp37471
sS'of,r,or'
p37472
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp37473
sS'only,where,definitely'
p37474
(F1
F0.00014334862385321102
I1
I0
I1
tp37475
sS'agents,was,not'
p37476
(F1
F0.00014334862385321102
I0
I1
I-1
tp37477
sS'etodolac,has,no'
p37478
(F1
F0.00043004587155963305
I0
I3
I-3
tp37479
sS'of,which,may'
p37480
(F1
F0.00014334862385321102
I1
I0
I1
tp37481
sS'eg,would,be'
p37482
(F1
F0.00014334862385321102
I1
I0
I1
tp37483
sS'an,inducer,of'
p37484
(F0
F0
I1
I1
I0
tp37485
sS'the,morning,dose'
p37486
(F1
F0.00014334862385321102
I0
I1
I-1
tp37487
sS'discontinuation,of,the'
p37488
(F1
F0.00014334862385321102
I0
I1
I-1
tp37489
sS'dosage,adjustments,made'
p37490
(F1
F0.00028669724770642203
I0
I2
I-2
tp37491
sS'to,maintain,concentrations'
p37492
(F1
F0.00014334862385321102
I0
I1
I-1
tp37493
sS'than,pediatrics,mean'
p37494
(F1
F0.00014334862385321102
I1
I0
I1
tp37495
sS'isoenzyme,daily,doses'
p37496
(F1
F0.00014334862385321102
I1
I0
I1
tp37497
sS'cases,of,conduction'
p37498
(F1
F0.00014334862385321102
I1
I0
I1
tp37499
sS'depressive,and,negative'
p37500
(F1
F0.00014334862385321102
I0
I1
I-1
tp37501
sS'using,escalating,doses'
p37502
(F1
F0.00014334862385321102
I1
I0
I1
tp37503
sS'recommended,during,treatment'
p37504
(F1
F0.00014334862385321102
I1
I0
I1
tp37505
sS'regardless,of,the'
p37506
(F1
F0.00028669724770642203
I0
I2
I-2
tp37507
sS'exposure,auc,higher'
p37508
(F1
F0.00014334862385321102
I1
I0
I1
tp37509
sS'inhibition,of,metabolism'
p37510
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp37511
sS'prior,to,hours'
p37512
(F1
F0.00014334862385321102
I1
I0
I1
tp37513
sS'potentially,result,in'
p37514
(F1
F0.00014334862385321102
I1
I0
I1
tp37515
sS'haldol,may,be'
p37516
(F1
F0.00014334862385321102
I1
I0
I1
tp37517
sS'of,the,extremities'
p37518
(F1
F0.00014334862385321102
I0
I1
I-1
tp37519
sS'months,had,no'
p37520
(F1
F0.00014334862385321102
I0
I1
I-1
tp37521
sS'can,increase,the'
p37522
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp37523
sS'limited,clinical,experience'
p37524
(F1
F0.00014334862385321102
I1
I0
I1
tp37525
sS'while,attenuating,s'
p37526
(F1
F0.00014334862385321102
I1
I0
I1
tp37527
sS'exposure,of,the'
p37528
(F0
F0
I1
I1
I0
tp37529
sS'on,metabolism,by'
p37530
(F1
F0.00014334862385321102
I0
I1
I-1
tp37531
sS'although,it,has'
p37532
(F1
F0.00028669724770642203
I2
I0
I2
tp37533
sS'equipotent,inducers,of'
p37534
(F1
F0.00014334862385321102
I0
I1
I-1
tp37535
sS'interactions,between,copaxone'
p37536
(F1
F0.00014334862385321102
I0
I1
I-1
tp37537
sS'among,subjects,who'
p37538
(F1
F0.00014334862385321102
I0
I1
I-1
tp37539
sS'appear,to,affect'
p37540
(F1
F0.00014334862385321102
I0
I1
I-1
tp37541
sS'in,substantial,inactivation'
p37542
(F1
F0.00014334862385321102
I1
I0
I1
tp37543
sS'cas,but,can'
p37544
(F1
F0.00014334862385321102
I1
I0
I1
tp37545
sS'or,prolonged,therapy'
p37546
(F1
F0.00014334862385321102
I0
I1
I-1
tp37547
sS'not,been,well'
p37548
(F1
F0.00014334862385321102
I0
I1
I-1
tp37549
sS'of,micrograms,completely'
p37550
(F1
F0.00014334862385321102
I1
I0
I1
tp37551
sS'and,cmax,the'
p37552
(F1
F0.00014334862385321102
I0
I1
I-1
tp37553
sS'curve,after,a'
p37554
(F1
F0.00014334862385321102
I1
I0
I1
tp37555
sS'antiarrhythmic,agents,class'
p37556
(F1
F0.00014334862385321102
I0
I1
I-1
tp37557
sS'following,days,of'
p37558
(F1
F0.00014334862385321102
I0
I1
I-1
tp37559
sS'which,may,result'
p37560
(F0
F0
I1
I1
I0
tp37561
sS'may,reduce,seizure'
p37562
(F1
F0.00014334862385321102
I1
I0
I1
tp37563
sS'evaluate,the,impact'
p37564
(F1
F0.00014334862385321102
I0
I1
I-1
tp37565
sS'is,indicated,reduction'
p37566
(F1
F0.00014334862385321102
I1
I0
I1
tp37567
sS'these,aeds,do'
p37568
(F1
F0.00014334862385321102
I0
I1
I-1
tp37569
sS'performed,on,day'
p37570
(F1
F0.00014334862385321102
I0
I1
I-1
tp37571
sS'rapid,and,significant'
p37572
(F1
F0.00014334862385321102
I1
I0
I1
tp37573
sS'a,day,course'
p37574
(F1
F0.00014334862385321102
I0
I1
I-1
tp37575
sS'been,adequately,evaluated'
p37576
(F1
F0.00014334862385321102
I0
I1
I-1
tp37577
sS'revia,may,not'
p37578
(F1
F0.00014334862385321102
I1
I0
I1
tp37579
sS'shown,that,acarbose'
p37580
(F1
F0.00014334862385321102
I0
I1
I-1
tp37581
sS'oral,an,inhibitor'
p37582
(F1
F0.00014334862385321102
I0
I1
I-1
tp37583
sS'microsomes,inhibition,of'
p37584
(F1
F0.00014334862385321102
I1
I0
I1
tp37585
sS'not,needed,when'
p37586
(F1
F0.00014334862385321102
I1
I0
I1
tp37587
sS'to,increases,in'
p37588
(F1
F0.00014334862385321102
I0
I1
I-1
tp37589
sS'low-dose,mg,once'
p37590
(F1
F0.00014334862385321102
I0
I1
I-1
tp37591
sS'cmax,of,and'
p37592
(F1
F0.00014334862385321102
I1
I0
I1
tp37593
sS'additive,hypotensite,effects'
p37594
(F1
F0.00014334862385321102
I1
I0
I1
tp37595
sS'after,initiating,therapy'
p37596
(F1
F0.00014334862385321102
I1
I0
I1
tp37597
sS'bid,mg,qd'
p37598
(F1
F0.00014334862385321102
I1
I0
I1
tp37599
sS'rate,or,corrected'
p37600
(F1
F0.00014334862385321102
I0
I1
I-1
tp37601
sS'serum,time,profiles'
p37602
(F1
F0.00014334862385321102
I0
I1
I-1
tp37603
sS'blockers,have,been'
p37604
(F1
F0.00014334862385321102
I0
I1
I-1
tp37605
sS'plasma,enzymes,or'
p37606
(F1
F0.00014334862385321102
I0
I1
I-1
tp37607
sS'is,metabolized,in'
p37608
(F1
F0.00014334862385321102
I0
I1
I-1
tp37609
sS'motrin,advil,nuprin'
p37610
(F1
F0.00014334862385321102
I0
I1
I-1
tp37611
sS'nonsteroidal,agents,folic'
p37612
(F1
F0.00028669724770642203
I0
I2
I-2
tp37613
sS'of,their,usual'
p37614
(F1
F0.00014334862385321102
I1
I0
I1
tp37615
sS'of,mg,q24h'
p37616
(F1
F0.00014334862385321102
I0
I1
I-1
tp37617
sS'mg,on,the'
p37618
(F1
F0.00028669724770642203
I0
I2
I-2
tp37619
sS'in,volume,of'
p37620
(F1
F0.00014334862385321102
I1
I0
I1
tp37621
sS'sequential,infusions,myelosuppression'
p37622
(F1
F0.00014334862385321102
I1
I0
I1
tp37623
sS'with,colorectal,cancer'
p37624
(F1
F0.00014334862385321102
I0
I1
I-1
tp37625
sS'cyp2d6,are,responsible'
p37626
(F1
F0.00014334862385321102
I0
I1
I-1
tp37627
sS'felbatol,gris-peg,nizoral'
p37628
(F1
F0.00014334862385321102
I1
I0
I1
tp37629
sS'of,or,metabolite'
p37630
(F1
F0.00014334862385321102
I0
I1
I-1
tp37631
sS'with,these,or'
p37632
(F1
F0.00014334862385321102
I1
I0
I1
tp37633
sS'felbatol,the,coadministration'
p37634
(F1
F0.00014334862385321102
I0
I1
I-1
tp37635
sS'reduces,the,level'
p37636
(F1
F0.00014334862385321102
I1
I0
I1
tp37637
sS'of,an,interaction'
p37638
(F1
F0.00014334862385321102
I1
I0
I1
tp37639
sS'following,may,interact'
p37640
(F1
F0.00028669724770642203
I2
I0
I2
tp37641
sS'is,a,novel'
p37642
(F1
F0.00014334862385321102
I1
I0
I1
tp37643
sS'adequate,monitoring,of'
p37644
(F1
F0.00014334862385321102
I1
I0
I1
tp37645
sS'taken,hour,before'
p37646
(F1
F0.00014334862385321102
I0
I1
I-1
tp37647
sS'on,cas,but'
p37648
(F1
F0.00014334862385321102
I1
I0
I1
tp37649
sS'inhibitors,studies,in'
p37650
(F1
F0.00014334862385321102
I1
I0
I1
tp37651
sS'received,ace,inhibitors'
p37652
(F1
F0.00014334862385321102
I0
I1
I-1
tp37653
sS'inhibition,of,renal'
p37654
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp37655
sS'other,calcium-containing,medicines'
p37656
(F1
F0.00014334862385321102
I0
I1
I-1
tp37657
sS'interaction,should,be'
p37658
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp37659
sS'total,bioavailability,of'
p37660
(F1
F0.00014334862385321102
I0
I1
I-1
tp37661
sS'and,for,several'
p37662
(F1
F0.00014334862385321102
I1
I0
I1
tp37663
sS'systemic,levels,may'
p37664
(F1
F0.00014334862385321102
I0
I1
I-1
tp37665
sS'multiple,dosing,beta-1a'
p37666
(F1
F0.00014334862385321102
I1
I0
I1
tp37667
sS'to,cause,weakness'
p37668
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp37669
sS'a,nitrosamine,which'
p37670
(F1
F0.00014334862385321102
I1
I0
I1
tp37671
sS'maalox,tc,had'
p37672
(F1
F0.00014334862385321102
I0
I1
I-1
tp37673
sS'bodyweight,gain,occurred'
p37674
(F1
F0.00014334862385321102
I0
I1
I-1
tp37675
sS'increase,and,may'
p37676
(F1
F0.00014334862385321102
I0
I1
I-1
tp37677
sS'be,given,concurrently'
p37678
(F1
F0.00014334862385321102
I1
I0
I1
tp37679
sS'between,epa,supplements'
p37680
(F1
F0.00014334862385321102
I1
I0
I1
tp37681
sS'concentrations,of,endotoxin-treated'
p37682
(F0
F0
I1
I1
I0
tp37683
sS'neuron,blocking,agents'
p37684
(F1
F0.00014334862385321102
I0
I1
I-1
tp37685
sS'therapy,with,amprenavir'
p37686
(F1
F0.00014334862385321102
I1
I0
I1
tp37687
sS'levels,and,adjust'
p37688
(F1
F0.00014334862385321102
I1
I0
I1
tp37689
sS'because,the,effects'
p37690
(F1
F0.00014334862385321102
I1
I0
I1
tp37691
sS'acid,decrease,in'
p37692
(F1
F0.00014334862385321102
I1
I0
I1
tp37693
sS'following,doses,of'
p37694
(F1
F0.00014334862385321102
I1
I0
I1
tp37695
sS'of,ci,when'
p37696
(F1
F0.00014334862385321102
I1
I0
I1
tp37697
sS'this,study,adverse'
p37698
(F1
F0.00014334862385321102
I1
I0
I1
tp37699
sS'the,antidepressant,was'
p37700
(F1
F0.00014334862385321102
I0
I1
I-1
tp37701
sS'of,future,studies'
p37702
(F1
F0.00014334862385321102
I0
I1
I-1
tp37703
sS'thus,an,enhancement'
p37704
(F1
F0.00014334862385321102
I1
I0
I1
tp37705
sS'a4,by,oxc'
p37706
(F1
F0.00014334862385321102
I0
I1
I-1
tp37707
sS'with,the,elimination'
p37708
(F1
F0.00014334862385321102
I1
I0
I1
tp37709
sS'may,require,additional'
p37710
(F1
F0.00014334862385321102
I1
I0
I1
tp37711
sS'should,be,given'
p37712
(F0.69230769230769229
F0.0012901376146788992
I11
I2
I9
tp37713
sS'because,changes,in'
p37714
(F1
F0.00014334862385321102
I1
I0
I1
tp37715
sS'using,romazicon,in'
p37716
(F1
F0.00014334862385321102
I1
I0
I1
tp37717
sS'by,increased,catabloism'
p37718
(F1
F0.00014334862385321102
I0
I1
I-1
tp37719
sS'or,tmax,at'
p37720
(F1
F0.00014334862385321102
I0
I1
I-1
tp37721
sS'reduced,in,myocardium'
p37722
(F1
F0.00014334862385321102
I0
I1
I-1
tp37723
sS'adjustment,of,strattera'
p37724
(F1
F0.00014334862385321102
I1
I0
I1
tp37725
sS'of,oral,during'
p37726
(F1
F0.00014334862385321102
I1
I0
I1
tp37727
sS'step,of,the'
p37728
(F1
F0.00014334862385321102
I1
I0
I1
tp37729
sS'subsequently,administered,radiographic'
p37730
(F1
F0.00014334862385321102
I1
I0
I1
tp37731
sS'of,taxol,and'
p37732
(F1
F0.00014334862385321102
I0
I1
I-1
tp37733
sS'of,was,lower'
p37734
(F1
F0.00028669724770642203
I2
I0
I2
tp37735
sS'other,macrolide,and'
p37736
(F1
F0.00014334862385321102
I1
I0
I1
tp37737
sS'auc,of,absorption'
p37738
(F1
F0.00014334862385321102
I1
I0
I1
tp37739
sS'complete,prescribing,information'
p37740
(F1
F0.00014334862385321102
I0
I1
I-1
tp37741
sS'result,in,a'
p37742
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp37743
sS'of,with,oral'
p37744
(F1
F0.00028669724770642203
I2
I0
I2
tp37745
sS'serum,reverse,triiodothyronine'
p37746
(F1
F0.00014334862385321102
I0
I1
I-1
tp37747
sS'possible,benefits,of'
p37748
(F1
F0.00014334862385321102
I1
I0
I1
tp37749
sS'atromid-s,neoral,sandimmune'
p37750
(F1
F0.00014334862385321102
I1
I0
I1
tp37751
sS'anticholinergic,may,antagonize'
p37752
(F1
F0.00014334862385321102
I1
I0
I1
tp37753
sS'steady-state,cmin,decreased'
p37754
(F1
F0.00014334862385321102
I1
I0
I1
tp37755
sS'by,the,stimulant'
p37756
(F1
F0.00014334862385321102
I0
I1
I-1
tp37757
sS'given,with,sustiva'
p37758
(F1
F0.00014334862385321102
I1
I0
I1
tp37759
sS'study,involving,healthy'
p37760
(F1
F0.00014334862385321102
I1
I0
I1
tp37761
sS'cimetidine,mg,b'
p37762
(F1
F0.00014334862385321102
I0
I1
I-1
tp37763
sS'cause,additive,cns'
p37764
(F1
F0.00014334862385321102
I1
I0
I1
tp37765
sS'different,type,of'
p37766
(F1
F0.00014334862385321102
I1
I0
I1
tp37767
sS'changing,vioxx,therapy'
p37768
(F1
F0.00014334862385321102
I1
I0
I1
tp37769
sS'fortovase,as,the'
p37770
(F1
F0.00014334862385321102
I0
I1
I-1
tp37771
sS'proteins,or,alter'
p37772
(F1
F0.00014334862385321102
I1
I0
I1
tp37773
sS'regarding,asthma,therapy'
p37774
(F1
F0.00014334862385321102
I0
I1
I-1
tp37775
sS'of,tcas,with'
p37776
(F1
F0.00043004587155963305
I3
I0
I3
tp37777
sS'as,mg,day'
p37778
(F1
F0.00014334862385321102
I1
I0
I1
tp37779
sS'hypotension,or,marked'
p37780
(F1
F0.00014334862385321102
I0
I1
I-1
tp37781
sS'solution,fehlings,solution'
p37782
(F1
F0.00014334862385321102
I0
I1
I-1
tp37783
sS'to,iodinated,contrast'
p37784
(F1
F0.00014334862385321102
I1
I0
I1
tp37785
sS'acid,and,abciximab'
p37786
(F1
F0.00014334862385321102
I1
I0
I1
tp37787
sS'on,oral,who'
p37788
(F1
F0.00014334862385321102
I1
I0
I1
tp37789
sS'like,aleve,or'
p37790
(F1
F0.00014334862385321102
I1
I0
I1
tp37791
sS'gastric,ph,on'
p37792
(F1
F0.00014334862385321102
I0
I1
I-1
tp37793
sS'coadministered,with,each'
p37794
(F1
F0.00014334862385321102
I1
I0
I1
tp37795
sS'acid,and,vitamin'
p37796
(F1
F0.00014334862385321102
I0
I1
I-1
tp37797
sS'enhance,toxicity,and'
p37798
(F1
F0.00014334862385321102
I0
I1
I-1
tp37799
sS'volunteers,have,shown'
p37800
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp37801
sS'clinical,studies,with'
p37802
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp37803
sS'in,patients,being'
p37804
(F1
F0.00057339449541284407
I4
I0
I4
tp37805
sS'bradycardia,and,decreased'
p37806
(F1
F0.00014334862385321102
I0
I1
I-1
tp37807
sS'and,serial,measurement'
p37808
(F1
F0.00014334862385321102
I1
I0
I1
tp37809
sS'should,generally,not'
p37810
(F1
F0.00014334862385321102
I1
I0
I1
tp37811
sS'volunteers,there,was'
p37812
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp37813
sS'and,risks,of'
p37814
(F1
F0.00014334862385321102
I1
I0
I1
tp37815
sS'results,for,the'
p37816
(F1
F0.00014334862385321102
I1
I0
I1
tp37817
sS'treatment,of,anaphylactic'
p37818
(F1
F0.00014334862385321102
I1
I0
I1
tp37819
sS'of,norpace,and'
p37820
(F1
F0.00014334862385321102
I1
I0
I1
tp37821
sS'possibly,concomitant,administration'
p37822
(F1
F0.00014334862385321102
I1
I0
I1
tp37823
sS'mg,five,times'
p37824
(F1
F0.00014334862385321102
I0
I1
I-1
tp37825
sS'for,estimation,of'
p37826
(F1
F0.00014334862385321102
I0
I1
I-1
tp37827
sS'of,cmax,and'
p37828
(F1
F0.00014334862385321102
I0
I1
I-1
tp37829
sS'healthy,female,subjects'
p37830
(F1
F0.00028669724770642203
I0
I2
I-2
tp37831
sS'alkaline,earth,and'
p37832
(F1
F0.00014334862385321102
I0
I1
I-1
tp37833
sS'maoi,there,have'
p37834
(F1
F0.00014334862385321102
I1
I0
I1
tp37835
sS'effect,agents,derivatives'
p37836
(F1
F0.00014334862385321102
I0
I1
I-1
tp37837
sS'man,include,and'
p37838
(F1
F0.00014334862385321102
I0
I1
I-1
tp37839
sS'by,one-third,to'
p37840
(F1
F0.00014334862385321102
I0
I1
I-1
tp37841
sS'of,on,stimulated'
p37842
(F1
F0.00014334862385321102
I0
I1
I-1
tp37843
sS'when,was,used'
p37844
(F1
F0.00014334862385321102
I1
I0
I1
tp37845
sS'weight,approximately,ml'
p37846
(F1
F0.00014334862385321102
I0
I1
I-1
tp37847
sS'ze,patients,no'
p37848
(F1
F0.00014334862385321102
I0
I1
I-1
tp37849
sS'determine,whether,the'
p37850
(F1
F0.00014334862385321102
I1
I0
I1
tp37851
sS'clearance,measurements,of'
p37852
(F1
F0.00014334862385321102
I1
I0
I1
tp37853
sS'some,organisms,contained'
p37854
(F1
F0.00014334862385321102
I1
I0
I1
tp37855
sS'are,used,on'
p37856
(F1
F0.00014334862385321102
I0
I1
I-1
tp37857
sS'toxicity,in,some'
p37858
(F1
F0.00014334862385321102
I1
I0
I1
tp37859
sS'you,may,need'
p37860
(F1
F0.00028669724770642203
I2
I0
I2
tp37861
sS'neuromuscular,transmission,curare-like'
p37862
(F1
F0.00028669724770642203
I2
I0
I2
tp37863
sS'other,may,potentiate'
p37864
(F1
F0.00014334862385321102
I1
I0
I1
tp37865
sS'cyp3a4,or,epoxide'
p37866
(F1
F0.00014334862385321102
I0
I1
I-1
tp37867
sS'mg,when,co-administered'
p37868
(F1
F0.00014334862385321102
I0
I1
I-1
tp37869
sS'the,pharmacodynamic,effect'
p37870
(F1
F0.00014334862385321102
I0
I1
I-1
tp37871
sS'following,elspar,therapy'
p37872
(F1
F0.00014334862385321102
I1
I0
I1
tp37873
sS'on,concomitant,use'
p37874
(F1
F0.00014334862385321102
I0
I1
I-1
tp37875
sS'show,clinically,relevant'
p37876
(F1
F0.00014334862385321102
I0
I1
I-1
tp37877
sS'pump,inhibitors,eg'
p37878
(F1
F0.00014334862385321102
I1
I0
I1
tp37879
sS'not,totally,known'
p37880
(F1
F0.00014334862385321102
I1
I0
I1
tp37881
sS'with,other,the'
p37882
(F0
F0
I1
I1
I0
tp37883
sS'basis,of,antistress'
p37884
(F1
F0.00014334862385321102
I0
I1
I-1
tp37885
sS'mg,kg,was'
p37886
(F1
F0.00014334862385321102
I0
I1
I-1
tp37887
sS'cyclopropane,or,halogenated'
p37888
(F1
F0.00014334862385321102
I1
I0
I1
tp37889
sS'initiation,of,felbatol'
p37890
(F1
F0.00014334862385321102
I0
I1
I-1
tp37891
sS'abilify,to,affect'
p37892
(F1
F0.00014334862385321102
I0
I1
I-1
tp37893
sS'mumol,liter,potentiated'
p37894
(F1
F0.00014334862385321102
I1
I0
I1
tp37895
sS'resulting,from,smoking'
p37896
(F1
F0.00014334862385321102
I0
I1
I-1
tp37897
sS'dosing,with,would'
p37898
(F1
F0.00014334862385321102
I0
I1
I-1
tp37899
sS'is,the,rate-limiting'
p37900
(F1
F0.00014334862385321102
I0
I1
I-1
tp37901
sS'and,containing,maalox'
p37902
(F1
F0.00014334862385321102
I1
I0
I1
tp37903
sS'other,agents,interfering'
p37904
(F1
F0.00028669724770642203
I2
I0
I2
tp37905
sS'or,and,within'
p37906
(F1
F0.00014334862385321102
I1
I0
I1
tp37907
sS'or,discontinued,in'
p37908
(F1
F0.00014334862385321102
I1
I0
I1
tp37909
sS'to,cups,of'
p37910
(F1
F0.00014334862385321102
I0
I1
I-1
tp37911
sS'gleevec,oral-dose,clearance'
p37912
(F1
F0.00014334862385321102
I1
I0
I1
tp37913
sS'renal,function,should'
p37914
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp37915
sS'as,antineoplastic,agents'
p37916
(F1
F0.00014334862385321102
I1
I0
I1
tp37917
sS'of,increased,prothrombin'
p37918
(F1
F0.00014334862385321102
I1
I0
I1
tp37919
sS'patients,on,especially'
p37920
(F1
F0.00028669724770642203
I2
I0
I2
tp37921
sS'received,alone,mg'
p37922
(F1
F0.00014334862385321102
I0
I1
I-1
tp37923
sS'free,fraction,of'
p37924
(F1
F0.00028669724770642203
I0
I2
I-2
tp37925
sS'durations,of,neuromuscular'
p37926
(F1
F0.00014334862385321102
I1
I0
I1
tp37927
sS'decreasing,the,gastrointestinal'
p37928
(F1
F0.00014334862385321102
I1
I0
I1
tp37929
sS'cmin,concentration,was'
p37930
(F0
F0
I1
I1
I0
tp37931
sS'associated,adverse,event'
p37932
(F1
F0.00014334862385321102
I0
I1
I-1
tp37933
sS'other,hivid-associated,adverse'
p37934
(F1
F0.00014334862385321102
I1
I0
I1
tp37935
sS'competition,for,binding'
p37936
(F1
F0.00014334862385321102
I1
I0
I1
tp37937
sS'duragesic,is,not'
p37938
(F1
F0.00014334862385321102
I1
I0
I1
tp37939
sS'erbitux,was,administered'
p37940
(F1
F0.00014334862385321102
I0
I1
I-1
tp37941
sS'to,monitor,the'
p37942
(F1
F0.00014334862385321102
I0
I1
I-1
tp37943
sS'with,other,cns'
p37944
(F1
F0.00043004587155963305
I3
I0
I3
tp37945
sS'and,limited,sampling'
p37946
(F1
F0.00014334862385321102
I0
I1
I-1
tp37947
sS'decrease,blood,glucose'
p37948
(F1
F0.00028669724770642203
I2
I0
I2
tp37949
sS'administration,of,had'
p37950
(F1
F0.00014334862385321102
I0
I1
I-1
tp37951
sS'and,probably,for'
p37952
(F1
F0.00014334862385321102
I0
I1
I-1
tp37953
sS'administration,of,has'
p37954
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp37955
sS'and,serotonin2-receptors,underlies'
p37956
(F1
F0.00014334862385321102
I0
I1
I-1
tp37957
sS'imipramine,and,did'
p37958
(F1
F0.00014334862385321102
I0
I1
I-1
tp37959
sS'perchlorate,in,several'
p37960
(F1
F0.00014334862385321102
I0
I1
I-1
tp37961
sS'concomitantly,of,whom'
p37962
(F1
F0.00014334862385321102
I0
I1
I-1
tp37963
sS'clotting,time,was'
p37964
(F1
F0.00014334862385321102
I0
I1
I-1
tp37965
sS'was,noted,when'
p37966
(F1
F0.00014334862385321102
I0
I1
I-1
tp37967
sS'a,nd,female'
p37968
(F1
F0.00014334862385321102
I0
I1
I-1
tp37969
sS'dehydrogenase,inhibition,significantly'
p37970
(F1
F0.00014334862385321102
I1
I0
I1
tp37971
sS'serum,half-life,leading'
p37972
(F1
F0.00014334862385321102
I0
I1
I-1
tp37973
sS'physicians,are,provided'
p37974
(F1
F0.00014334862385321102
I1
I0
I1
tp37975
sS'anticoagulant,inhibition,was'
p37976
(F1
F0.00014334862385321102
I0
I1
I-1
tp37977
sS'to,mg,tricor'
p37978
(F1
F0.00028669724770642203
I2
I0
I2
tp37979
sS'use,of,or'
p37980
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp37981
sS'when,maleate,mg'
p37982
(F1
F0.00028669724770642203
I2
I0
I2
tp37983
sS'or,s-,enantiomers'
p37984
(F1
F0.00014334862385321102
I0
I1
I-1
tp37985
sS'reduced,higher,doses'
p37986
(F1
F0.00043004587155963305
I0
I3
I-3
tp37987
sS'i,d,had'
p37988
(F1
F0.00014334862385321102
I0
I1
I-1
tp37989
sS'of,gl,with'
p37990
(F0
F0
I1
I1
I0
tp37991
sS'a,neutralizing,agent'
p37992
(F1
F0.00014334862385321102
I1
I0
I1
tp37993
sS'dmpge2,induced,diarrhea'
p37994
(F1
F0.00014334862385321102
I0
I1
I-1
tp37995
sS'products,containing,and'
p37996
(F1
F0.00028669724770642203
I2
I0
I2
tp37997
sS'the,major,membrane'
p37998
(F1
F0.00014334862385321102
I0
I1
I-1
tp37999
sS'interferes,minimally,or'
p38000
(F1
F0.00014334862385321102
I1
I0
I1
tp38001
sS'peripheral,because,the'
p38002
(F1
F0.00014334862385321102
I1
I0
I1
tp38003
sS'in,the,tail-flick'
p38004
(F1
F0.00028669724770642203
I2
I0
I2
tp38005
sS'ace,inhibitors,monoamine'
p38006
(F1
F0.00014334862385321102
I0
I1
I-1
tp38007
sS'use,may,increase'
p38008
(F0
F0
I1
I1
I0
tp38009
sS'bleeding,associated,with'
p38010
(F1
F0.00014334862385321102
I1
I0
I1
tp38011
sS'agents,should,not'
p38012
(F1
F0.00014334862385321102
I1
I0
I1
tp38013
sS'with,metabolized,by'
p38014
(F1
F0.00014334862385321102
I0
I1
I-1
tp38015
sS'stable,dosage,of'
p38016
(F1
F0.00014334862385321102
I0
I1
I-1
tp38017
sS'in,urinary,excretion'
p38018
(F1
F0.00014334862385321102
I1
I0
I1
tp38019
sS'stable,dosage,on'
p38020
(F1
F0.00028669724770642203
I2
I0
I2
tp38021
sS'a,metabolite,i'
p38022
(F1
F0.00014334862385321102
I0
I1
I-1
tp38023
sS'acute,delirium,associated'
p38024
(F1
F0.00014334862385321102
I1
I0
I1
tp38025
sS'and,a,fold'
p38026
(F1
F0.0008600917431192661
I6
I0
I6
tp38027
sS'in,urinary,uric'
p38028
(F1
F0.00014334862385321102
I1
I0
I1
tp38029
sS'probenecid,probenecid,interferes'
p38030
(F1
F0.00014334862385321102
I1
I0
I1
tp38031
sS'on,investigation,of'
p38032
(F1
F0.00014334862385321102
I0
I1
I-1
tp38033
sS'use,of,transdermal'
p38034
(F1
F0.00014334862385321102
I1
I0
I1
tp38035
sS'trileptal,and,other'
p38036
(F1
F0.00014334862385321102
I0
I1
I-1
tp38037
sS'on,absorption,when'
p38038
(F1
F0.00014334862385321102
I1
I0
I1
tp38039
sS'ingestion,may,increase'
p38040
(F1
F0.00014334862385321102
I1
I0
I1
tp38041
sS'to,interact,with'
p38042
(F0
F0
I3
I3
I0
tp38043
sS'based,on,total'
p38044
(F1
F0.00014334862385321102
I1
I0
I1
tp38045
sS'this,formal,interaction'
p38046
(F1
F0.00014334862385321102
I0
I1
I-1
tp38047
sS'the,reduced,interaction'
p38048
(F1
F0.00014334862385321102
I0
I1
I-1
tp38049
sS'decrease,blood,levels'
p38050
(F1
F0.00014334862385321102
I1
I0
I1
tp38051
sS'of,permits,at'
p38052
(F1
F0.00014334862385321102
I1
I0
I1
tp38053
sS'phase,ii,clinical'
p38054
(F1
F0.00014334862385321102
I1
I0
I1
tp38055
sS'a,known,inhibitor'
p38056
(F1
F0.00043004587155963305
I3
I0
I3
tp38057
sS'gleevec,increased,gleevec'
p38058
(F1
F0.00014334862385321102
I1
I0
I1
tp38059
sS'during,co-administration,systemic'
p38060
(F1
F0.00014334862385321102
I0
I1
I-1
tp38061
sS'tolazamide,a,case'
p38062
(F1
F0.00014334862385321102
I1
I0
I1
tp38063
sS'were,not,different'
p38064
(F1
F0.00014334862385321102
I0
I1
I-1
tp38065
sS'sterilize,the,bowel'
p38066
(F1
F0.00014334862385321102
I0
I1
I-1
tp38067
sS'reduced,infusion,rates'
p38068
(F1
F0.00014334862385321102
I1
I0
I1
tp38069
sS'and,the,duration'
p38070
(F0
F0
I1
I1
I0
tp38071
sS'or,an,equivalent'
p38072
(F1
F0.00014334862385321102
I0
I1
I-1
tp38073
sS'alfenta,induction,the'
p38074
(F1
F0.00014334862385321102
I1
I0
I1
tp38075
sS'expected,when,is'
p38076
(F1
F0.00014334862385321102
I1
I0
I1
tp38077
sS'and,cause,increased'
p38078
(F1
F0.00014334862385321102
I1
I0
I1
tp38079
sS'agents,including,yields'
p38080
(F1
F0.00014334862385321102
I1
I0
I1
tp38081
sS'a,tendency,to'
p38082
(F1
F0.00014334862385321102
I1
I0
I1
tp38083
sS'at,clinically,relevant'
p38084
(F1
F0.00014334862385321102
I0
I1
I-1
tp38085
sS'changes,in,blood'
p38086
(F1
F0.00014334862385321102
I1
I0
I1
tp38087
sS'alter,the,plasma'
p38088
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp38089
sS'escalating,doses,of'
p38090
(F1
F0.00014334862385321102
I1
I0
I1
tp38091
sS'estradiol,and,norethindrone'
p38092
(F1
F0.00014334862385321102
I1
I0
I1
tp38093
sS'will,be,increased'
p38094
(F1
F0.00014334862385321102
I1
I0
I1
tp38095
sS'tindal,thorazine,prolixin'
p38096
(F1
F0.00014334862385321102
I0
I1
I-1
tp38097
sS'aucs,of,the'
p38098
(F1
F0.00014334862385321102
I0
I1
I-1
tp38099
sS'poor,metabolizers,have'
p38100
(F1
F0.00071674311926605509
I0
I5
I-5
tp38101
sS'diminished,the,binding'
p38102
(F1
F0.00014334862385321102
I1
I0
I1
tp38103
sS'complex,concentrates,should'
p38104
(F1
F0.00014334862385321102
I0
I1
I-1
tp38105
sS'certain,by,up'
p38106
(F1
F0.00014334862385321102
I1
I0
I1
tp38107
sS'objectives,to,examine'
p38108
(F1
F0.00014334862385321102
I0
I1
I-1
tp38109
sS'were,treated,with'
p38110
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp38111
sS'talk,to,your'
p38112
(F1
F0.00014334862385321102
I0
I1
I-1
tp38113
sS'oral,the,prothrombin'
p38114
(F1
F0.00014334862385321102
I1
I0
I1
tp38115
sS'of,most,other'
p38116
(F1
F0.00014334862385321102
I1
I0
I1
tp38117
sS'require,a,reduction'
p38118
(F1
F0.00014334862385321102
I1
I0
I1
tp38119
sS'reduction,in,urinary'
p38120
(F1
F0.00014334862385321102
I1
I0
I1
tp38121
sS'arc,mrna,level'
p38122
(F1
F0.00014334862385321102
I1
I0
I1
tp38123
sS'therapy,with,vioxx'
p38124
(F1
F0.00014334862385321102
I1
I0
I1
tp38125
sS'or,channel,antagonists'
p38126
(F1
F0.00014334862385321102
I0
I1
I-1
tp38127
sS'increased,deet,toxicity'
p38128
(F1
F0.00014334862385321102
I0
I1
I-1
tp38129
sS'elevated,by,and'
p38130
(F1
F0.00014334862385321102
I0
I1
I-1
tp38131
sS'camptosar,and,it'
p38132
(F1
F0.00014334862385321102
I1
I0
I1
tp38133
sS'to,be,displaced'
p38134
(F1
F0.00014334862385321102
I1
I0
I1
tp38135
sS'metabolizers,of,interactions'
p38136
(F1
F0.00014334862385321102
I1
I0
I1
tp38137
sS'aquamephyton,synkayvite,use'
p38138
(F1
F0.00014334862385321102
I0
I1
I-1
tp38139
sS'to,double,the'
p38140
(F1
F0.00014334862385321102
I1
I0
I1
tp38141
sS'was,given,after'
p38142
(F0
F0
I1
I1
I0
tp38143
sS'anticoagulants,interaction,studies'
p38144
(F1
F0.00028669724770642203
I0
I2
I-2
tp38145
sS'metabolism,inhibitors,of'
p38146
(F1
F0.00014334862385321102
I1
I0
I1
tp38147
sS'pharmacokinetic,interaction,study'
p38148
(F1
F0.00014334862385321102
I0
I1
I-1
tp38149
sS'fold,elevations,on'
p38150
(F1
F0.00014334862385321102
I1
I0
I1
tp38151
sS'by,which,could'
p38152
(F1
F0.00014334862385321102
I0
I1
I-1
tp38153
sS'given,concurrently,it'
p38154
(F1
F0.00014334862385321102
I0
I1
I-1
tp38155
sS'noted,that,or'
p38156
(F1
F0.00014334862385321102
I0
I1
I-1
tp38157
sS'concomitant,oral,administration'
p38158
(F1
F0.00014334862385321102
I1
I0
I1
tp38159
sS'schizophrenia,in,the'
p38160
(F1
F0.00014334862385321102
I0
I1
I-1
tp38161
sS'possible,resistance,to'
p38162
(F1
F0.00028669724770642203
I0
I2
I-2
tp38163
sS'orthostatic,changes,in'
p38164
(F1
F0.00014334862385321102
I1
I0
I1
tp38165
sS'an,and,containing'
p38166
(F1
F0.00014334862385321102
I1
I0
I1
tp38167
sS'when,toradol,was'
p38168
(F1
F0.00014334862385321102
I1
I0
I1
tp38169
sS'dose,mg,tid'
p38170
(F1
F0.00014334862385321102
I0
I1
I-1
tp38171
sS'were,additive,when'
p38172
(F1
F0.00014334862385321102
I0
I1
I-1
tp38173
sS'of,concomitant,on'
p38174
(F1
F0.00014334862385321102
I0
I1
I-1
tp38175
sS'could,cause,or'
p38176
(F1
F0.00014334862385321102
I1
I0
I1
tp38177
sS'indicates,that,requirements'
p38178
(F1
F0.00014334862385321102
I1
I0
I1
tp38179
sS'non-cyp3a4,substrate,agent'
p38180
(F1
F0.00014334862385321102
I0
I1
I-1
tp38181
sS'other,suitable,coagulation'
p38182
(F1
F0.00028669724770642203
I2
I0
I2
tp38183
sS'b-lactam,co-administration,of'
p38184
(F1
F0.00014334862385321102
I1
I0
I1
tp38185
sS'trisilicate,when,administered'
p38186
(F1
F0.00014334862385321102
I1
I0
I1
tp38187
sS'the,steady,state'
p38188
(F0
F0
I1
I1
I0
tp38189
sS'studies,fully,evaluating'
p38190
(F1
F0.00014334862385321102
I0
I1
I-1
tp38191
sS'from,to,fold'
p38192
(F1
F0.00014334862385321102
I1
I0
I1
tp38193
sS'marrow,suppression,by'
p38194
(F1
F0.00014334862385321102
I1
I0
I1
tp38195
sS'levels,of,racemic'
p38196
(F1
F0.00014334862385321102
I0
I1
I-1
tp38197
sS'protein,binding,of'
p38198
(F0.40000000000000002
F0.00057339449541284407
I3
I7
I-4
tp38199
sS'low,compared,to'
p38200
(F1
F0.00014334862385321102
I0
I1
I-1
tp38201
sS'in,vitro,perfused'
p38202
(F1
F0.00014334862385321102
I0
I1
I-1
tp38203
sS'effects,of,or'
p38204
(F1
F0.00057339449541284407
I4
I0
I4
tp38205
sS'and,arthralgia,adverse'
p38206
(F1
F0.00014334862385321102
I1
I0
I1
tp38207
sS'effects,of,on'
p38208
(F0.59999999999999998
F0.0008600917431192661
I2
I8
I-6
tp38209
sS'the,dose,in'
p38210
(F1
F0.00028669724770642203
I0
I2
I-2
tp38211
sS'platelet,function,may'
p38212
(F1
F0.00014334862385321102
I0
I1
I-1
tp38213
sS'metabolism,which,is'
p38214
(F1
F0.00014334862385321102
I1
I0
I1
tp38215
sS'agents,other,systemic'
p38216
(F1
F0.00014334862385321102
I1
I0
I1
tp38217
sS'nevirapinemay,lower,the'
p38218
(F1
F0.00014334862385321102
I1
I0
I1
tp38219
sS'decreases,effectiveness,by'
p38220
(F1
F0.00014334862385321102
I1
I0
I1
tp38221
sS'of,and,can'
p38222
(F1
F0.00071674311926605509
I5
I0
I5
tp38223
sS'for,the,inhibitory'
p38224
(F1
F0.00014334862385321102
I1
I0
I1
tp38225
sS'other,cyp3a4,inhibitors'
p38226
(F1
F0.00028669724770642203
I2
I0
I2
tp38227
sS'cns,depression,when'
p38228
(F1
F0.00014334862385321102
I1
I0
I1
tp38229
sS'sites,for,in'
p38230
(F1
F0.00014334862385321102
I0
I1
I-1
tp38231
sS'ethacrynic,acid,as'
p38232
(F1
F0.00014334862385321102
I1
I0
I1
tp38233
sS'liver,but,its'
p38234
(F1
F0.00014334862385321102
I0
I1
I-1
tp38235
sS'observed,between,and'
p38236
(F0
F0
I1
I1
I0
tp38237
sS'in,ovarian,cancer'
p38238
(F1
F0.00014334862385321102
I1
I0
I1
tp38239
sS'agents,when,an'
p38240
(F0
F0
I1
I1
I0
tp38241
sS'exists,for,a'
p38242
(F1
F0.00014334862385321102
I1
I0
I1
tp38243
sS'pivoxil,administered,following'
p38244
(F1
F0.00014334862385321102
I1
I0
I1
tp38245
sS'dicumarol,it,has'
p38246
(F1
F0.00014334862385321102
I1
I0
I1
tp38247
sS'been,cases,reported'
p38248
(F1
F0.00014334862385321102
I1
I0
I1
tp38249
sS'will,have,erroneously'
p38250
(F1
F0.00014334862385321102
I1
I0
I1
tp38251
sS'which,only,requires'
p38252
(F1
F0.00014334862385321102
I0
I1
I-1
tp38253
sS'of,low-dose,mg'
p38254
(F1
F0.00014334862385321102
I0
I1
I-1
tp38255
sS'rashes,in,patients'
p38256
(F1
F0.00014334862385321102
I1
I0
I1
tp38257
sS'no,significant,interactions'
p38258
(F1
F0.00057339449541284407
I0
I4
I-4
tp38259
sS'cholecystokinin--of,h-spiroperidol,binding'
p38260
(F1
F0.00014334862385321102
I0
I1
I-1
tp38261
sS'result,in,sub-therapeutic'
p38262
(F1
F0.00014334862385321102
I1
I0
I1
tp38263
sS'amiodarone,is,known'
p38264
(F1
F0.00014334862385321102
I1
I0
I1
tp38265
sS'medicines,may,increase'
p38266
(F1
F0.00057339449541284407
I0
I4
I-4
tp38267
sS'is,a,strong'
p38268
(F0
F0
I1
I1
I0
tp38269
sS'the,relationship,between'
p38270
(F1
F0.00014334862385321102
I0
I1
I-1
tp38271
sS'normalizing,the,intake'
p38272
(F1
F0.00014334862385321102
I0
I1
I-1
tp38273
sS'a,to,avoid'
p38274
(F1
F0.00014334862385321102
I1
I0
I1
tp38275
sS'decrease,the,required'
p38276
(F1
F0.00014334862385321102
I1
I0
I1
tp38277
sS'ketoconazole,potential,interaction'
p38278
(F1
F0.00014334862385321102
I1
I0
I1
tp38279
sS'a,day,did'
p38280
(F1
F0.00014334862385321102
I0
I1
I-1
tp38281
sS'with,any,of'
p38282
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp38283
sS'were,followed,for'
p38284
(F1
F0.00014334862385321102
I0
I1
I-1
tp38285
sS'of,tcas,when'
p38286
(F1
F0.00057339449541284407
I0
I4
I-4
tp38287
sS'the,translocating,action'
p38288
(F1
F0.00014334862385321102
I0
I1
I-1
tp38289
sS'but,not,nanm'
p38290
(F1
F0.00028669724770642203
I2
I0
I2
tp38291
sS'not,receiving,these'
p38292
(F1
F0.00028669724770642203
I2
I0
I2
tp38293
sS'all,are,indeed'
p38294
(F1
F0.00014334862385321102
I0
I1
I-1
tp38295
sS'treatment,and,gi'
p38296
(F1
F0.00014334862385321102
I0
I1
I-1
tp38297
sS'and,sodium,colistemethate'
p38298
(F1
F0.00014334862385321102
I1
I0
I1
tp38299
sS'decreases,in,creatinine'
p38300
(F1
F0.00014334862385321102
I1
I0
I1
tp38301
sS'conclude,that,the'
p38302
(F1
F0.00014334862385321102
I1
I0
I1
tp38303
sS'with,micromol,l'
p38304
(F1
F0.00014334862385321102
I0
I1
I-1
tp38305
sS'which,can,result'
p38306
(F1
F0.00057339449541284407
I4
I0
I4
tp38307
sS'by,in,healthy'
p38308
(F1
F0.00014334862385321102
I1
I0
I1
tp38309
sS'marked,bradycardia,which'
p38310
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp38311
sS'and,treatment,ataxia'
p38312
(F1
F0.00014334862385321102
I0
I1
I-1
tp38313
sS'be,administered,at'
p38314
(F1
F0.00057339449541284407
I4
I0
I4
tp38315
sS'but,may,potentiate'
p38316
(F1
F0.00014334862385321102
I1
I0
I1
tp38317
sS'of,or,dihydroxyflavone'
p38318
(F1
F0.00014334862385321102
I0
I1
I-1
tp38319
sS'with,fluoxetine,a'
p38320
(F1
F0.00014334862385321102
I0
I1
I-1
tp38321
sS'may,subsequently,increase'
p38322
(F1
F0.00014334862385321102
I0
I1
I-1
tp38323
sS'not,significantly,different'
p38324
(F1
F0.00028669724770642203
I0
I2
I-2
tp38325
sS'and,which,are'
p38326
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp38327
sS'platelet,function,such'
p38328
(F1
F0.00014334862385321102
I1
I0
I1
tp38329
sS'chronic,hepatitis,c'
p38330
(F1
F0.00014334862385321102
I0
I1
I-1
tp38331
sS'given,injections,of'
p38332
(F1
F0.00014334862385321102
I0
I1
I-1
tp38333
sS'of,toxicity,when'
p38334
(F1
F0.00014334862385321102
I1
I0
I1
tp38335
sS'and,chloride,excretion'
p38336
(F1
F0.00014334862385321102
I1
I0
I1
tp38337
sS'inotropic,and,or'
p38338
(F1
F0.00014334862385321102
I0
I1
I-1
tp38339
sS'of,all,muscle'
p38340
(F1
F0.00014334862385321102
I1
I0
I1
tp38341
sS'cmax,the,geometric'
p38342
(F1
F0.00014334862385321102
I0
I1
I-1
tp38343
sS'parameters,affected,by'
p38344
(F1
F0.00014334862385321102
I0
I1
I-1
tp38345
sS'particularly,in,subjects'
p38346
(F1
F0.00014334862385321102
I1
I0
I1
tp38347
sS'the,cmax,auc'
p38348
(F1
F0.00014334862385321102
I1
I0
I1
tp38349
sS'studies,is,metabolized'
p38350
(F1
F0.00014334862385321102
I0
I1
I-1
tp38351
sS'combination,has,been'
p38352
(F1
F0.00014334862385321102
I1
I0
I1
tp38353
sS'decrease,in,absorption'
p38354
(F1
F0.00014334862385321102
I0
I1
I-1
tp38355
sS'exception,of,cyp2c19'
p38356
(F1
F0.00014334862385321102
I0
I1
I-1
tp38357
sS'month,controlled,trial'
p38358
(F1
F0.00014334862385321102
I0
I1
I-1
tp38359
sS'and,is,derived'
p38360
(F1
F0.00014334862385321102
I1
I0
I1
tp38361
sS'of,progestin-only,oral'
p38362
(F1
F0.00014334862385321102
I0
I1
I-1
tp38363
sS'significant,adverse,interactions'
p38364
(F1
F0.00014334862385321102
I0
I1
I-1
tp38365
sS'hour,after,or'
p38366
(F1
F0.00014334862385321102
I1
I0
I1
tp38367
sS'fluvoxamine,tablets,and'
p38368
(F1
F0.00014334862385321102
I1
I0
I1
tp38369
sS'patient,s,response'
p38370
(F1
F0.00014334862385321102
I1
I0
I1
tp38371
sS'd,had,no'
p38372
(F1
F0.00014334862385321102
I0
I1
I-1
tp38373
sS'simulect,was,reduced'
p38374
(F1
F0.00014334862385321102
I1
I0
I1
tp38375
sS'by,alt,and'
p38376
(F1
F0.00014334862385321102
I0
I1
I-1
tp38377
sS'in,humans,remain'
p38378
(F1
F0.00014334862385321102
I0
I1
I-1
tp38379
sS'cytochalasin,d,inhibited'
p38380
(F1
F0.00014334862385321102
I1
I0
I1
tp38381
sS'pharmacokinetic,studies,showed'
p38382
(F1
F0.00014334862385321102
I1
I0
I1
tp38383
sS'emit-d,a,u'
p38384
(F1
F0.00014334862385321102
I0
I1
I-1
tp38385
sS'of,a,test'
p38386
(F1
F0.00014334862385321102
I0
I1
I-1
tp38387
sS'closely,for,any'
p38388
(F1
F0.00014334862385321102
I0
I1
I-1
tp38389
sS'containing,multivalent,cations'
p38390
(F1
F0.00014334862385321102
I1
I0
I1
tp38391
sS'patients,who,developed'
p38392
(F1
F0.00014334862385321102
I1
I0
I1
tp38393
sS'possible,interactions,of'
p38394
(F1
F0.00014334862385321102
I1
I0
I1
tp38395
sS'clozapine,plasma,levels'
p38396
(F1
F0.00014334862385321102
I1
I0
I1
tp38397
sS'intravenous,in,ontario'
p38398
(F1
F0.00014334862385321102
I0
I1
I-1
tp38399
sS'could,decrease,first'
p38400
(F1
F0.00014334862385321102
I0
I1
I-1
tp38401
sS'and,on,the'
p38402
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp38403
sS'and,by,a'
p38404
(F1
F0.00014334862385321102
I1
I0
I1
tp38405
sS'enzyme,inducers,inhibitors'
p38406
(F1
F0.00014334862385321102
I1
I0
I1
tp38407
sS'and,min,for'
p38408
(F1
F0.00014334862385321102
I1
I0
I1
tp38409
sS'tnf,antagonist,with'
p38410
(F1
F0.00014334862385321102
I1
I0
I1
tp38411
sS'time,kill,curves'
p38412
(F1
F0.00014334862385321102
I1
I0
I1
tp38413
sS'each,other,is'
p38414
(F1
F0.00014334862385321102
I1
I0
I1
tp38415
sS'd,h,e'
p38416
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp38417
sS'of,oxidative,stress'
p38418
(F1
F0.00014334862385321102
I0
I1
I-1
tp38419
sS'of,injection,and'
p38420
(F1
F0.00014334862385321102
I1
I0
I1
tp38421
sS'in,no,effect'
p38422
(F1
F0.00014334862385321102
I0
I1
I-1
tp38423
sS'been,conducted,concomitant'
p38424
(F1
F0.00014334862385321102
I1
I0
I1
tp38425
sS'of,when,coadministered'
p38426
(F1
F0.00014334862385321102
I0
I1
I-1
tp38427
sS'and,potentiate,sulfate'
p38428
(F1
F0.00014334862385321102
I0
I1
I-1
tp38429
sS'related,anabolic,hormones'
p38430
(F0
F0
I1
I1
I0
tp38431
sS'tca,concentrations,may'
p38432
(F1
F0.00014334862385321102
I1
I0
I1
tp38433
sS'cognitive,function,seen'
p38434
(F1
F0.00014334862385321102
I0
I1
I-1
tp38435
sS'ventricular,tachycardia,was'
p38436
(F1
F0.00014334862385321102
I1
I0
I1
tp38437
sS'months,received,mg'
p38438
(F1
F0.00014334862385321102
I0
I1
I-1
tp38439
sS'of,activated,prothrombin'
p38440
(F1
F0.00014334862385321102
I0
I1
I-1
tp38441
sS'absence,of,or'
p38442
(F1
F0.00014334862385321102
I0
I1
I-1
tp38443
sS'treatment,of,positive'
p38444
(F1
F0.00014334862385321102
I0
I1
I-1
tp38445
sS'inhibits,proliferation,stimulated'
p38446
(F1
F0.00014334862385321102
I1
I0
I1
tp38447
sS'serum,antidepressant,levels'
p38448
(F1
F0.00014334862385321102
I1
I0
I1
tp38449
sS'healthy,volunteers,administration'
p38450
(F1
F0.00014334862385321102
I0
I1
I-1
tp38451
sS'patients,taking,prothrombin'
p38452
(F1
F0.00014334862385321102
I1
I0
I1
tp38453
sS'toxicity,may,be'
p38454
(F1
F0.00028669724770642203
I2
I0
I2
tp38455
sS'a,theoretical,risk'
p38456
(F1
F0.00014334862385321102
I1
I0
I1
tp38457
sS'first,double-blind,comparative'
p38458
(F1
F0.00014334862385321102
I0
I1
I-1
tp38459
sS'activity,of,lamprene'
p38460
(F1
F0.00014334862385321102
I1
I0
I1
tp38461
sS'increase,or,inhibit'
p38462
(F1
F0.00014334862385321102
I1
I0
I1
tp38463
sS'administered,separately,by'
p38464
(F1
F0.00014334862385321102
I1
I0
I1
tp38465
sS'consider,additive,sedative'
p38466
(F1
F0.00014334862385321102
I1
I0
I1
tp38467
sS'spermine,and,to'
p38468
(F1
F0.00014334862385321102
I0
I1
I-1
tp38469
sS'which,suggest,that'
p38470
(F1
F0.00014334862385321102
I1
I0
I1
tp38471
sS'albuterol,strattera,should'
p38472
(F1
F0.00014334862385321102
I1
I0
I1
tp38473
sS'the,r-value,of'
p38474
(F1
F0.00028669724770642203
I0
I2
I-2
tp38475
sS'hydrophilic,molecule,naflu'
p38476
(F1
F0.00014334862385321102
I0
I1
I-1
tp38477
sS'paranoid,symptoms,have'
p38478
(F1
F0.00014334862385321102
I1
I0
I1
tp38479
sS'where,gastric,ph'
p38480
(F1
F0.00028669724770642203
I2
I0
I2
tp38481
sS'breakthrough,bleeding,shortly'
p38482
(F1
F0.00014334862385321102
I0
I1
I-1
tp38483
sS'by,approximately,fold'
p38484
(F1
F0.00014334862385321102
I1
I0
I1
tp38485
sS'cavity,or,on'
p38486
(F1
F0.00014334862385321102
I0
I1
I-1
tp38487
sS'blood,and,or'
p38488
(F1
F0.00014334862385321102
I1
I0
I1
tp38489
sS'levels,in,cerebral'
p38490
(F1
F0.00014334862385321102
I1
I0
I1
tp38491
sS'acute,toxicity,of'
p38492
(F1
F0.00014334862385321102
I1
I0
I1
tp38493
sS'be,seen,after'
p38494
(F1
F0.00014334862385321102
I1
I0
I1
tp38495
sS'serious,constellation,of'
p38496
(F1
F0.00014334862385321102
I1
I0
I1
tp38497
sS'potentiated,by,the'
p38498
(F1
F0.00014334862385321102
I1
I0
I1
tp38499
sS'and,or,other'
p38500
(F1
F0.00071674311926605509
I5
I0
I5
tp38501
sS'or,may,result'
p38502
(F1
F0.00014334862385321102
I1
I0
I1
tp38503
sS'dosing,by,hours'
p38504
(F1
F0.00014334862385321102
I0
I1
I-1
tp38505
sS'studies,the,consequences'
p38506
(F1
F0.00014334862385321102
I0
I1
I-1
tp38507
sS'of,male,subjects'
p38508
(F1
F0.00014334862385321102
I1
I0
I1
tp38509
sS'of,was,studied'
p38510
(F1
F0.00028669724770642203
I0
I2
I-2
tp38511
sS'the,other,agent'
p38512
(F1
F0.00014334862385321102
I0
I1
I-1
tp38513
sS'of,cmi,has'
p38514
(F1
F0.00028669724770642203
I2
I0
I2
tp38515
sS'in,many,of'
p38516
(F1
F0.00014334862385321102
I0
I1
I-1
tp38517
sS'elevation,in,gastric'
p38518
(F1
F0.00014334862385321102
I1
I0
I1
tp38519
sS'mg,kg,ml'
p38520
(F1
F0.00014334862385321102
I0
I1
I-1
tp38521
sS'media,experienced,acute'
p38522
(F1
F0.00014334862385321102
I1
I0
I1
tp38523
sS'clinical,trials,have'
p38524
(F1
F0.00028669724770642203
I0
I2
I-2
tp38525
sS'be,considered,during'
p38526
(F1
F0.00014334862385321102
I1
I0
I1
tp38527
sS'results,of,studies'
p38528
(F0
F0
I1
I1
I0
tp38529
sS'patients,demonstrated,no'
p38530
(F1
F0.00014334862385321102
I0
I1
I-1
tp38531
sS'mg,kg,mg'
p38532
(F1
F0.00028669724770642203
I0
I2
I-2
tp38533
sS'active,sulfide,metabolite'
p38534
(F1
F0.00014334862385321102
I1
I0
I1
tp38535
sS'addition,of,in'
p38536
(F1
F0.00014334862385321102
I0
I1
I-1
tp38537
sS'as,and,in'
p38538
(F1
F0.00014334862385321102
I0
I1
I-1
tp38539
sS'receiving,prinivil,an'
p38540
(F1
F0.00014334862385321102
I1
I0
I1
tp38541
sS'the,mean,minimum'
p38542
(F1
F0.00014334862385321102
I0
I1
I-1
tp38543
sS'effect,on,platelet'
p38544
(F1
F0.00028669724770642203
I2
I0
I2
tp38545
sS'palliates,deficiencies,by'
p38546
(F1
F0.00014334862385321102
I0
I1
I-1
tp38547
sS'therapy,discontinuation,of'
p38548
(F1
F0.00014334862385321102
I1
I0
I1
tp38549
sS'other,inhibitors,of'
p38550
(F1
F0.00014334862385321102
I1
I0
I1
tp38551
sS'that,exposure,of'
p38552
(F1
F0.00014334862385321102
I1
I0
I1
tp38553
sS'in,how,it'
p38554
(F1
F0.00014334862385321102
I0
I1
I-1
tp38555
sS'the,desired,lactulose-induced'
p38556
(F1
F0.00014334862385321102
I1
I0
I1
tp38557
sS'before,or,after'
p38558
(F1
F0.00014334862385321102
I1
I0
I1
tp38559
sS'reduced,the,plasma'
p38560
(F1
F0.00014334862385321102
I1
I0
I1
tp38561
sS'hours,after,receiving'
p38562
(F1
F0.00014334862385321102
I1
I0
I1
tp38563
sS'products,containing,ferrous'
p38564
(F1
F0.00014334862385321102
I1
I0
I1
tp38565
sS'or,hours,before'
p38566
(F1
F0.00014334862385321102
I1
I0
I1
tp38567
sS'within14,days,following'
p38568
(F1
F0.00014334862385321102
I1
I0
I1
tp38569
sS'undertaken,with,caution'
p38570
(F1
F0.00028669724770642203
I2
I0
I2
tp38571
sS'day,n,compared'
p38572
(F1
F0.00014334862385321102
I1
I0
I1
tp38573
sS'and,may,be'
p38574
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp38575
sS'considered,and,the'
p38576
(F1
F0.00014334862385321102
I1
I0
I1
tp38577
sS'agonists,within,hours'
p38578
(F1
F0.00028669724770642203
I2
I0
I2
tp38579
sS'potential,for,such'
p38580
(F1
F0.00014334862385321102
I0
I1
I-1
tp38581
sS'of,on,natriuresis'
p38582
(F1
F0.00014334862385321102
I1
I0
I1
tp38583
sS'concentrations,of,when'
p38584
(F1
F0.00014334862385321102
I0
I1
I-1
tp38585
sS'as,a,substitute'
p38586
(F1
F0.00014334862385321102
I0
I1
I-1
tp38587
sS'quickens,the,onset'
p38588
(F1
F0.00014334862385321102
I1
I0
I1
tp38589
sS'ethanol,sonata,mg'
p38590
(F1
F0.00014334862385321102
I1
I0
I1
tp38591
sS'choice,of,as'
p38592
(F1
F0.00014334862385321102
I0
I1
I-1
tp38593
sS'cmax,of,ranging'
p38594
(F1
F0.00014334862385321102
I1
I0
I1
tp38595
sS'extensive,cyp2d6,metabolizers'
p38596
(F1
F0.00014334862385321102
I0
I1
I-1
tp38597
sS'induce,cyp,a4'
p38598
(F1
F0.00014334862385321102
I1
I0
I1
tp38599
sS'effect,of,sodium'
p38600
(F0
F0
I1
I1
I0
tp38601
sS'b,and,intravenous'
p38602
(F1
F0.00014334862385321102
I1
I0
I1
tp38603
sS'with,epilepsy,ingesting'
p38604
(F1
F0.00043004587155963305
I0
I3
I-3
tp38605
sS'single,doses,or'
p38606
(F1
F0.00014334862385321102
I0
I1
I-1
tp38607
sS'paroxetine,produced,only'
p38608
(F1
F0.00014334862385321102
I1
I0
I1
tp38609
sS'consumption,of,during'
p38610
(F1
F0.00014334862385321102
I1
I0
I1
tp38611
sS'not,show,clinically'
p38612
(F1
F0.00014334862385321102
I0
I1
I-1
tp38613
sS'reduced,the,bioavailability'
p38614
(F1
F0.00014334862385321102
I1
I0
I1
tp38615
sS'single,doses,of'
p38616
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp38617
sS'systemic,exposure,auc'
p38618
(F1
F0.00028669724770642203
I2
I0
I2
tp38619
sS'studies,document,no'
p38620
(F1
F0.00014334862385321102
I0
I1
I-1
tp38621
sS'enzyme,system,leading'
p38622
(F1
F0.00028669724770642203
I0
I2
I-2
tp38623
sS'diffusible,treatment,during'
p38624
(F1
F0.00014334862385321102
I0
I1
I-1
tp38625
sS'from,an,solution'
p38626
(F1
F0.00014334862385321102
I0
I1
I-1
tp38627
sS'to,inter-patient,variation'
p38628
(F1
F0.00014334862385321102
I1
I0
I1
tp38629
sS'with,hemodynamic,compromise'
p38630
(F1
F0.00014334862385321102
I1
I0
I1
tp38631
sS'for,ketones,in'
p38632
(F1
F0.00028669724770642203
I0
I2
I-2
tp38633
sS'and,hepatic,tissues'
p38634
(F1
F0.00014334862385321102
I1
I0
I1
tp38635
sS'the,formation,of'
p38636
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp38637
sS'effect,of,either'
p38638
(F1
F0.00014334862385321102
I1
I0
I1
tp38639
sS'of,dosage,are'
p38640
(F0
F0
I1
I1
I0
tp38641
sS'known,to,have'
p38642
(F1
F0.00014334862385321102
I1
I0
I1
tp38643
sS'state,plasma,concentrations'
p38644
(F0
F0
I1
I1
I0
tp38645
sS'in,an,emergency'
p38646
(F1
F0.00014334862385321102
I1
I0
I1
tp38647
sS'apparently,by,increased'
p38648
(F1
F0.00014334862385321102
I0
I1
I-1
tp38649
sS'therefore,a,slower'
p38650
(F1
F0.00014334862385321102
I1
I0
I1
tp38651
sS'fluoxetine,does,not'
p38652
(F1
F0.00014334862385321102
I0
I1
I-1
tp38653
sS'co-administered,dose,level'
p38654
(F1
F0.00014334862385321102
I0
I1
I-1
tp38655
sS'where,serious,ventricular'
p38656
(F1
F0.00014334862385321102
I0
I1
I-1
tp38657
sS'causing,an,approximately'
p38658
(F1
F0.00014334862385321102
I1
I0
I1
tp38659
sS'to,affect,its'
p38660
(F1
F0.00014334862385321102
I0
I1
I-1
tp38661
sS'sodium,absorption,the'
p38662
(F1
F0.00014334862385321102
I1
I0
I1
tp38663
sS'was,given,with'
p38664
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp38665
sS'tricyclic,thereby,delaying'
p38666
(F1
F0.00014334862385321102
I1
I0
I1
tp38667
sS'tacrolimus,co-administration,of'
p38668
(F1
F0.00014334862385321102
I0
I1
I-1
tp38669
sS'krm-1648,either,singly'
p38670
(F1
F0.00014334862385321102
I0
I1
I-1
tp38671
sS'and,efficacy,has'
p38672
(F1
F0.00014334862385321102
I0
I1
I-1
tp38673
sS'for,the,maintenance'
p38674
(F1
F0.00014334862385321102
I0
I1
I-1
tp38675
sS'two,regimens,was'
p38676
(F1
F0.00014334862385321102
I0
I1
I-1
tp38677
sS'from,twitch,to'
p38678
(F1
F0.00014334862385321102
I1
I0
I1
tp38679
sS'insufficiency,hyperbilirubinemia,confusion'
p38680
(F1
F0.00014334862385321102
I1
I0
I1
tp38681
sS'subjects,receiving,no'
p38682
(F1
F0.00014334862385321102
I0
I1
I-1
tp38683
sS'substrate,by,on'
p38684
(F1
F0.00014334862385321102
I1
I0
I1
tp38685
sS'add,some,further'
p38686
(F1
F0.00014334862385321102
I1
I0
I1
tp38687
sS'cough,and,cold'
p38688
(F0
F0
I1
I1
I0
tp38689
sS'a,substantial,number'
p38690
(F1
F0.00014334862385321102
I1
I0
I1
tp38691
sS'from,to,ng'
p38692
(F1
F0.00014334862385321102
I1
I0
I1
tp38693
sS'required,to,prevent'
p38694
(F1
F0.00014334862385321102
I1
I0
I1
tp38695
sS'p450,c9,decreased'
p38696
(F1
F0.00014334862385321102
I1
I0
I1
tp38697
sS'carbidopa,given,with'
p38698
(F1
F0.00014334862385321102
I0
I1
I-1
tp38699
sS'intravenous,agents,and'
p38700
(F1
F0.00014334862385321102
I0
I1
I-1
tp38701
sS'to,infusions,of'
p38702
(F1
F0.00014334862385321102
I1
I0
I1
tp38703
sS'copper,sulfate,tests'
p38704
(F1
F0.00014334862385321102
I0
I1
I-1
tp38705
sS'c,and,cmin'
p38706
(F1
F0.00043004587155963305
I3
I0
I3
tp38707
sS'been,definitively,demonstrated'
p38708
(F1
F0.00014334862385321102
I1
I0
I1
tp38709
sS'were,unaffected,given'
p38710
(F1
F0.00014334862385321102
I1
I0
I1
tp38711
sS'and,dosage,should'
p38712
(F1
F0.00014334862385321102
I1
I0
I1
tp38713
sS'cautious,when,administering'
p38714
(F1
F0.00028669724770642203
I2
I0
I2
tp38715
sS'or,with,cancidas'
p38716
(F1
F0.00014334862385321102
I1
I0
I1
tp38717
sS'between,use,of'
p38718
(F1
F0.00014334862385321102
I1
I0
I1
tp38719
sS'treatment,in,a'
p38720
(F1
F0.00014334862385321102
I0
I1
I-1
tp38721
sS'more,than,two'
p38722
(F1
F0.00014334862385321102
I1
I0
I1
tp38723
sS'steady-state,peak,serum'
p38724
(F1
F0.00014334862385321102
I1
I0
I1
tp38725
sS'increases,of,modest'
p38726
(F1
F0.00014334862385321102
I0
I1
I-1
tp38727
sS'of,other,such'
p38728
(F1
F0.00014334862385321102
I1
I0
I1
tp38729
sS'd,agonists,within'
p38730
(F1
F0.00014334862385321102
I1
I0
I1
tp38731
sS'relevant,effects,on'
p38732
(F1
F0.00014334862385321102
I0
I1
I-1
tp38733
sS'days,following,days'
p38734
(F1
F0.00014334862385321102
I0
I1
I-1
tp38735
sS'doses,there,were'
p38736
(F1
F0.00014334862385321102
I0
I1
I-1
tp38737
sS'precedex,a,reduction'
p38738
(F1
F0.00014334862385321102
I1
I0
I1
tp38739
sS'and,were,coadministered'
p38740
(F1
F0.00028669724770642203
I2
I0
I2
tp38741
sS'study,of,coadministration'
p38742
(F1
F0.00014334862385321102
I1
I0
I1
tp38743
sS'although,this,effect'
p38744
(F1
F0.00014334862385321102
I1
I0
I1
tp38745
sS'of,potent,inducer'
p38746
(F1
F0.00014334862385321102
I1
I0
I1
tp38747
sS'of,subutex,or'
p38748
(F1
F0.00014334862385321102
I0
I1
I-1
tp38749
sS'approximate,doubling,in'
p38750
(F1
F0.00014334862385321102
I1
I0
I1
tp38751
sS'shbg,leading,to'
p38752
(F1
F0.00028669724770642203
I0
I2
I-2
tp38753
sS'alter,the,serum'
p38754
(F1
F0.00014334862385321102
I0
I1
I-1
tp38755
sS'general,or,other'
p38756
(F1
F0.00028669724770642203
I2
I0
I2
tp38757
sS'antihypertensive,necessitating,a'
p38758
(F1
F0.00014334862385321102
I1
I0
I1
tp38759
sS'appropriate,dose,for'
p38760
(F1
F0.00014334862385321102
I0
I1
I-1
tp38761
sS'the,determination,of'
p38762
(F1
F0.00014334862385321102
I0
I1
I-1
tp38763
sS'potential,for,additive'
p38764
(F1
F0.00028669724770642203
I2
I0
I2
tp38765
sS'monitored,at,the'
p38766
(F1
F0.00014334862385321102
I1
I0
I1
tp38767
sS'sular,tablets,in'
p38768
(F1
F0.00014334862385321102
I1
I0
I1
tp38769
sS'therapy,a,decrease'
p38770
(F1
F0.00014334862385321102
I1
I0
I1
tp38771
sS'toxicity,since,it'
p38772
(F1
F0.00014334862385321102
I0
I1
I-1
tp38773
sS'lead,to,hypotension'
p38774
(F1
F0.00014334862385321102
I1
I0
I1
tp38775
sS'in,the,present'
p38776
(F1
F0.00028669724770642203
I0
I2
I-2
tp38777
sS'to,elevated,serum'
p38778
(F1
F0.00043004587155963305
I3
I0
I3
tp38779
sS'supersensitive,to,compared'
p38780
(F1
F0.00014334862385321102
I1
I0
I1
tp38781
sS'with,and,interfere'
p38782
(F1
F0.00014334862385321102
I1
I0
I1
tp38783
sS'inhibited,by,several'
p38784
(F1
F0.00014334862385321102
I1
I0
I1
tp38785
sS'and,or,impairing'
p38786
(F1
F0.00014334862385321102
I1
I0
I1
tp38787
sS'blood,concentration,c12hr'
p38788
(F1
F0.00014334862385321102
I1
I0
I1
tp38789
sS'of,oral,platelet'
p38790
(F1
F0.00014334862385321102
I0
I1
I-1
tp38791
sS'affected,the,proliferation'
p38792
(F1
F0.00014334862385321102
I1
I0
I1
tp38793
sS'dipivoxil,or,tenofovir'
p38794
(F1
F0.00014334862385321102
I0
I1
I-1
tp38795
sS'imipramine,hydrochloride,may'
p38796
(F1
F0.00014334862385321102
I1
I0
I1
tp38797
sS'reduced,to,prevent'
p38798
(F1
F0.00014334862385321102
I1
I0
I1
tp38799
sS'of,renal,tubular'
p38800
(F1
F0.00014334862385321102
I1
I0
I1
tp38801
sS'significant,effect,of'
p38802
(F1
F0.00043004587155963305
I0
I3
I-3
tp38803
sS'other,pharmacokinetics,parameters'
p38804
(F1
F0.00014334862385321102
I1
I0
I1
tp38805
sS'which,are,vasoconstrictive'
p38806
(F1
F0.00014334862385321102
I1
I0
I1
tp38807
sS'did,not,extend'
p38808
(F1
F0.00014334862385321102
I0
I1
I-1
tp38809
sS'm2,given,as'
p38810
(F1
F0.00014334862385321102
I1
I0
I1
tp38811
sS'degrees,of,heart'
p38812
(F1
F0.00014334862385321102
I1
I0
I1
tp38813
sS'hivid,with,is'
p38814
(F1
F0.00014334862385321102
I1
I0
I1
tp38815
sS'elevations,in,serum'
p38816
(F1
F0.00028669724770642203
I2
I0
I2
tp38817
sS'mg,dose,had'
p38818
(F1
F0.00014334862385321102
I0
I1
I-1
tp38819
sS'agents,concurrent,use'
p38820
(F0
F0
I1
I1
I0
tp38821
sS'system,when,administered'
p38822
(F1
F0.00014334862385321102
I1
I0
I1
tp38823
sS'of,absorption,after'
p38824
(F1
F0.00014334862385321102
I0
I1
I-1
tp38825
sS'in,which,healthy'
p38826
(F0
F0
I1
I1
I0
tp38827
sS'with,early-phase,schizophrenia'
p38828
(F1
F0.00014334862385321102
I0
I1
I-1
tp38829
sS'ht3,antagonists,in'
p38830
(F1
F0.00014334862385321102
I0
I1
I-1
tp38831
sS'that,included,brovana'
p38832
(F1
F0.00014334862385321102
I0
I1
I-1
tp38833
sS'of,pra,induced'
p38834
(F1
F0.00014334862385321102
I0
I1
I-1
tp38835
sS'in,several,clinical'
p38836
(F1
F0.00014334862385321102
I0
I1
I-1
tp38837
sS'was,not,altered'
p38838
(F1
F0.00028669724770642203
I0
I2
I-2
tp38839
sS'substances,that,are'
p38840
(F0
F0
I1
I1
I0
tp38841
sS'antacids,on,felbatol'
p38842
(F1
F0.00014334862385321102
I0
I1
I-1
tp38843
sS'may,cause,hypermagnesemia'
p38844
(F1
F0.00043004587155963305
I3
I0
I3
tp38845
sS'depressants,causing,increased'
p38846
(F1
F0.00014334862385321102
I1
I0
I1
tp38847
sS'peripheral,vasoconstriction,caused'
p38848
(F1
F0.00014334862385321102
I1
I0
I1
tp38849
sS'to,both,increase'
p38850
(F1
F0.00014334862385321102
I1
I0
I1
tp38851
sS'cyp3a4,substrate,and'
p38852
(F0
F0
I2
I2
I0
tp38853
sS'the,following,are'
p38854
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp38855
sS'preparations,sunscreens,and'
p38856
(F1
F0.00014334862385321102
I1
I0
I1
tp38857
sS'potent,cyp3a,inducers'
p38858
(F1
F0.00014334862385321102
I1
I0
I1
tp38859
sS'which,is,further'
p38860
(F1
F0.00014334862385321102
I0
I1
I-1
tp38861
sS'volume,depletion,may'
p38862
(F1
F0.00014334862385321102
I1
I0
I1
tp38863
sS'volunteers,show,that'
p38864
(F1
F0.00014334862385321102
I0
I1
I-1
tp38865
sS'effect,on,metabolism'
p38866
(F1
F0.00028669724770642203
I0
I2
I-2
tp38867
sS'does,not,influence'
p38868
(F1
F0.00043004587155963305
I0
I3
I-3
tp38869
sS'increase,in,area'
p38870
(F1
F0.00014334862385321102
I1
I0
I1
tp38871
sS'avoid,administration,of'
p38872
(F1
F0.00014334862385321102
I0
I1
I-1
tp38873
sS'necessary,to,continue'
p38874
(F1
F0.00014334862385321102
I1
I0
I1
tp38875
sS'used,as,alternatives'
p38876
(F1
F0.00014334862385321102
I1
I0
I1
tp38877
sS'blood,pressure,usually'
p38878
(F1
F0.00014334862385321102
I1
I0
I1
tp38879
sS'amounts,may,counteract'
p38880
(F1
F0.00014334862385321102
I1
I0
I1
tp38881
sS'effects,of,gabitril'
p38882
(F1
F0.00014334862385321102
I0
I1
I-1
tp38883
sS'hypothyroidism,may,interfere'
p38884
(F1
F0.00014334862385321102
I0
I1
I-1
tp38885
sS'blockers,and,should'
p38886
(F1
F0.00014334862385321102
I1
I0
I1
tp38887
sS'recommended,when,administered'
p38888
(F1
F0.00014334862385321102
I1
I0
I1
tp38889
sS'time,to,onset'
p38890
(F1
F0.00014334862385321102
I1
I0
I1
tp38891
sS'influence,of,and'
p38892
(F1
F0.00028669724770642203
I0
I2
I-2
tp38893
sS'to,decrease,overall'
p38894
(F1
F0.00014334862385321102
I0
I1
I-1
tp38895
sS'of,the,coumarin'
p38896
(F1
F0.00014334862385321102
I0
I1
I-1
tp38897
sS'well,as,normal'
p38898
(F1
F0.00014334862385321102
I0
I1
I-1
tp38899
sS'no,information,is'
p38900
(F1
F0.00028669724770642203
I0
I2
I-2
tp38901
sS'were,determined,after'
p38902
(F1
F0.00014334862385321102
I0
I1
I-1
tp38903
sS'expected,to,have'
p38904
(F0
F0
I1
I1
I0
tp38905
sS'must,be,directed'
p38906
(F1
F0.00014334862385321102
I1
I0
I1
tp38907
sS'this,indicates,that'
p38908
(F1
F0.00028669724770642203
I0
I2
I-2
tp38909
sS'and,cautioned,that'
p38910
(F1
F0.00014334862385321102
I0
I1
I-1
tp38911
sS'are,receiving,high'
p38912
(F1
F0.00014334862385321102
I1
I0
I1
tp38913
sS'study,with,administration'
p38914
(F1
F0.00014334862385321102
I0
I1
I-1
tp38915
sS'mg,of,acetate'
p38916
(F1
F0.00014334862385321102
I0
I1
I-1
tp38917
sS'of,during,the'
p38918
(F1
F0.00014334862385321102
I0
I1
I-1
tp38919
sS'shown,that,nsaids'
p38920
(F1
F0.00057339449541284407
I4
I0
I4
tp38921
sS'in,elimination,half-life'
p38922
(F1
F0.00014334862385321102
I1
I0
I1
tp38923
sS'pneumocystis,carinii,pneumonia'
p38924
(F1
F0.00014334862385321102
I1
I0
I1
tp38925
sS'of,level,however'
p38926
(F1
F0.00014334862385321102
I1
I0
I1
tp38927
sS'had,a,similar'
p38928
(F1
F0.00014334862385321102
I0
I1
I-1
tp38929
sS'been,seen,as'
p38930
(F1
F0.00014334862385321102
I1
I0
I1
tp38931
sS'camptosar,than,when'
p38932
(F1
F0.00014334862385321102
I1
I0
I1
tp38933
sS'and,hivid,has'
p38934
(F1
F0.00014334862385321102
I1
I0
I1
tp38935
sS'what,to,do'
p38936
(F1
F0.00014334862385321102
I0
I1
I-1
tp38937
sS'proteins,the,following'
p38938
(F1
F0.00014334862385321102
I1
I0
I1
tp38939
sS'with,physicians,should'
p38940
(F1
F0.00014334862385321102
I0
I1
I-1
tp38941
sS'to,achieve,mac'
p38942
(F1
F0.00014334862385321102
I1
I0
I1
tp38943
sS'vasoconstrictor,but,the'
p38944
(F1
F0.00014334862385321102
I0
I1
I-1
tp38945
sS'uptake,and,or'
p38946
(F1
F0.00014334862385321102
I1
I0
I1
tp38947
sS'and,multiple,dose'
p38948
(F0
F0
I1
I1
I0
tp38949
sS'lotensin,was,administered'
p38950
(F1
F0.00014334862385321102
I0
I1
I-1
tp38951
sS'other,that,may'
p38952
(F1
F0.00028669724770642203
I0
I2
I-2
tp38953
sS'molecule,thereby,decreasing'
p38954
(F1
F0.00014334862385321102
I1
I0
I1
tp38955
sS'monitoring,of,blood'
p38956
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp38957
sS'concurrent,and,sodium'
p38958
(F1
F0.00014334862385321102
I1
I0
I1
tp38959
sS'grepafloxacin,is,a'
p38960
(F1
F0.00014334862385321102
I1
I0
I1
tp38961
sS'changing,therapy,with'
p38962
(F1
F0.00014334862385321102
I1
I0
I1
tp38963
sS'or,parenteral,enzyme'
p38964
(F1
F0.00014334862385321102
I0
I1
I-1
tp38965
sS'with,itraconazole,has'
p38966
(F1
F0.00014334862385321102
I1
I0
I1
tp38967
sS'concentrations,in,patients'
p38968
(F0
F0
I1
I1
I0
tp38969
sS'be,potentiated,by'
p38970
(F1
F0.0014334862385321102
I10
I0
I10
tp38971
sS'of,p450,d6'
p38972
(F1
F0.00014334862385321102
I0
I1
I-1
tp38973
sS'mg,of,had'
p38974
(F0
F0
I1
I1
I0
tp38975
sS'qtc,interval,were'
p38976
(F1
F0.00014334862385321102
I0
I1
I-1
tp38977
sS'resin,or,at'
p38978
(F1
F0.00014334862385321102
I0
I1
I-1
tp38979
sS'synergism,was,observed'
p38980
(F1
F0.00014334862385321102
I1
I0
I1
tp38981
sS'the,range,of'
p38982
(F1
F0.00057339449541284407
I0
I4
I-4
tp38983
sS'with,because,of'
p38984
(F1
F0.00014334862385321102
I1
I0
I1
tp38985
sS'been,used,in'
p38986
(F1
F0.00014334862385321102
I0
I1
I-1
tp38987
sS'eg,may,result'
p38988
(F1
F0.00014334862385321102
I1
I0
I1
tp38989
sS'a,dose,increase'
p38990
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp38991
sS'a,nonsteroidal,nsaid'
p38992
(F1
F0.00014334862385321102
I0
I1
I-1
tp38993
sS'or,in,metabolite'
p38994
(F1
F0.00014334862385321102
I0
I1
I-1
tp38995
sS'levels,shown,by'
p38996
(F1
F0.00014334862385321102
I0
I1
I-1
tp38997
sS'toxicity,of,edetate'
p38998
(F1
F0.00014334862385321102
I1
I0
I1
tp38999
sS'will,be,required'
p39000
(F1
F0.00014334862385321102
I0
I1
I-1
tp39001
sS'of,grapefruit,juice'
p39002
(F1
F0.00028669724770642203
I0
I2
I-2
tp39003
sS'volunteers,there,were'
p39004
(F1
F0.00014334862385321102
I0
I1
I-1
tp39005
sS'paclitaxel,in,one'
p39006
(F1
F0.00014334862385321102
I1
I0
I1
tp39007
sS'these,agents,have'
p39008
(F1
F0.00014334862385321102
I1
I0
I1
tp39009
sS'that,inhibit,these'
p39010
(F1
F0.00014334862385321102
I0
I1
I-1
tp39011
sS'organ,transplant,patients'
p39012
(F1
F0.00014334862385321102
I1
I0
I1
tp39013
sS'following,single,dose'
p39014
(F1
F0.00014334862385321102
I0
I1
I-1
tp39015
sS'only,block,the'
p39016
(F1
F0.00014334862385321102
I1
I0
I1
tp39017
sS'when,administering,celebrex'
p39018
(F1
F0.00014334862385321102
I1
I0
I1
tp39019
sS'to,patients,who'
p39020
(F1
F0.00043004587155963305
I3
I0
I3
tp39021
sS'study,was,conducted'
p39022
(F1
F0.00014334862385321102
I0
I1
I-1
tp39023
sS'drug,interaction,during'
p39024
(F1
F0.00014334862385321102
I0
I1
I-1
tp39025
sS'volume,fewer,interactions'
p39026
(F1
F0.00014334862385321102
I0
I1
I-1
tp39027
sS'immediately,beginning,depletion'
p39028
(F1
F0.00014334862385321102
I1
I0
I1
tp39029
sS'may,be,more'
p39030
(F0
F0
I1
I1
I0
tp39031
sS'of,hydrochloride,x'
p39032
(F1
F0.00014334862385321102
I1
I0
I1
tp39033
sS'patients,taking,lexapro'
p39034
(F1
F0.00014334862385321102
I1
I0
I1
tp39035
sS'neuromuscular,block,induced'
p39036
(F1
F0.00028669724770642203
I2
I0
I2
tp39037
sS'at,least,one'
p39038
(F1
F0.00014334862385321102
I1
I0
I1
tp39039
sS'also,conducted,with'
p39040
(F1
F0.00014334862385321102
I0
I1
I-1
tp39041
sS'atomoxetine,is,primarily'
p39042
(F1
F0.00014334862385321102
I0
I1
I-1
tp39043
sS'at,the,time'
p39044
(F1
F0.00014334862385321102
I0
I1
I-1
tp39045
sS'theophylline,ethinyl,estradiol'
p39046
(F1
F0.00014334862385321102
I1
I0
I1
tp39047
sS'levels,comparable,to'
p39048
(F1
F0.00014334862385321102
I0
I1
I-1
tp39049
sS'a,mg,controlled-release'
p39050
(F1
F0.00014334862385321102
I1
I0
I1
tp39051
sS'by,a,single'
p39052
(F1
F0.00043004587155963305
I3
I0
I3
tp39053
sS'enterocolitis,diarrhea,and'
p39054
(F1
F0.00014334862385321102
I1
I0
I1
tp39055
sS'on,therapy,may'
p39056
(F1
F0.00043004587155963305
I3
I0
I3
tp39057
sS'from,the,combination'
p39058
(F1
F0.00014334862385321102
I1
I0
I1
tp39059
sS'known,photosensitizing,agents'
p39060
(F1
F0.00014334862385321102
I1
I0
I1
tp39061
sS'with,a,single'
p39062
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp39063
sS'qid,n,the'
p39064
(F1
F0.00014334862385321102
I1
I0
I1
tp39065
sS'concluded,that,chloral'
p39066
(F1
F0.00014334862385321102
I0
I1
I-1
tp39067
sS'an,oral,has'
p39068
(F1
F0.00014334862385321102
I1
I0
I1
tp39069
sS'study,without,co-administered'
p39070
(F1
F0.00014334862385321102
I0
I1
I-1
tp39071
sS'blood,sugar,concentrations'
p39072
(F1
F0.00014334862385321102
I1
I0
I1
tp39073
sS'supplements,containing,vitamin'
p39074
(F1
F0.00014334862385321102
I1
I0
I1
tp39075
sS'is,significantly,bound'
p39076
(F1
F0.00014334862385321102
I0
I1
I-1
tp39077
sS'initiation,of,combined'
p39078
(F1
F0.00014334862385321102
I1
I0
I1
tp39079
sS'in,nonfailing,myocardium'
p39080
(F1
F0.00014334862385321102
I1
I0
I1
tp39081
sS'of,metabolized,by'
p39082
(F1
F0.00028669724770642203
I0
I2
I-2
tp39083
sS'therapy,in,patients'
p39084
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp39085
sS'decrease,the,effects'
p39086
(F1
F0.00043004587155963305
I3
I0
I3
tp39087
sS'inhaled,with,no'
p39088
(F1
F0.00014334862385321102
I0
I1
I-1
tp39089
sS'may,increase,toxicity'
p39090
(F0
F0
I1
I1
I0
tp39091
sS'caused,no,systematic'
p39092
(F1
F0.00014334862385321102
I0
I1
I-1
tp39093
sS'rate,cmax,and'
p39094
(F1
F0.00014334862385321102
I1
I0
I1
tp39095
sS'known,that,cyp1a2'
p39096
(F1
F0.00014334862385321102
I1
I0
I1
tp39097
sS'at,therapeutic,concentrations'
p39098
(F0
F0
I1
I1
I0
tp39099
sS'channel,blockers,and'
p39100
(F1
F0.00043004587155963305
I3
I0
I3
tp39101
sS'activity,large,doses'
p39102
(F1
F0.00014334862385321102
I0
I1
I-1
tp39103
sS'is,a,consequence'
p39104
(F1
F0.00014334862385321102
I1
I0
I1
tp39105
sS'sympatholytic,medicinal,products'
p39106
(F1
F0.00028669724770642203
I0
I2
I-2
tp39107
sS'to,factrel,may'
p39108
(F1
F0.00014334862385321102
I1
I0
I1
tp39109
sS'and,other,cns'
p39110
(F1
F0.00028669724770642203
I2
I0
I2
tp39111
sS'levels,with,the'
p39112
(F0
F0
I1
I1
I0
tp39113
sS'trials,database,three'
p39114
(F1
F0.00014334862385321102
I0
I1
I-1
tp39115
sS'patients,on,stable'
p39116
(F1
F0.00014334862385321102
I0
I1
I-1
tp39117
sS'and,in,females'
p39118
(F1
F0.00014334862385321102
I1
I0
I1
tp39119
sS'tab,ria,kit'
p39120
(F1
F0.00014334862385321102
I0
I1
I-1
tp39121
sS'used,in,conjunction'
p39122
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp39123
sS'to,healthy,men'
p39124
(F1
F0.00014334862385321102
I0
I1
I-1
tp39125
sS'and,increased,the'
p39126
(F1
F0.00028669724770642203
I2
I0
I2
tp39127
sS'case,report,which'
p39128
(F1
F0.00014334862385321102
I1
I0
I1
tp39129
sS'from,single,doses'
p39130
(F1
F0.00014334862385321102
I0
I1
I-1
tp39131
sS'the,tricyclic,antidepressant'
p39132
(F1
F0.00043004587155963305
I0
I3
I-3
tp39133
sS'cerebyx,were,concurrently'
p39134
(F1
F0.00014334862385321102
I0
I1
I-1
tp39135
sS'a,lower,pulmonary'
p39136
(F1
F0.00014334862385321102
I1
I0
I1
tp39137
sS'ventricular,arrhythmias,who'
p39138
(F1
F0.00014334862385321102
I0
I1
I-1
tp39139
sS'valproic,acid,and'
p39140
(F0
F0
I1
I1
I0
tp39141
sS'monitored,to,ensure'
p39142
(F1
F0.00014334862385321102
I1
I0
I1
tp39143
sS'with,that,reduce'
p39144
(F1
F0.00014334862385321102
I0
I1
I-1
tp39145
sS'serum,levels,carbamazepine'
p39146
(F1
F0.00014334862385321102
I1
I0
I1
tp39147
sS'or,not,at'
p39148
(F1
F0.00014334862385321102
I1
I0
I1
tp39149
sS'the,test,period'
p39150
(F1
F0.00014334862385321102
I1
I0
I1
tp39151
sS'these,data,appeared'
p39152
(F1
F0.00014334862385321102
I0
I1
I-1
tp39153
sS'twelve,healthy,male'
p39154
(F1
F0.00014334862385321102
I0
I1
I-1
tp39155
sS'based,on,these'
p39156
(F0
F0
I1
I1
I0
tp39157
sS'lead,to,resulting'
p39158
(F1
F0.00014334862385321102
I1
I0
I1
tp39159
sS'psychomotor,performance,for'
p39160
(F1
F0.00028669724770642203
I2
I0
I2
tp39161
sS'or,not,an'
p39162
(F1
F0.00014334862385321102
I0
I1
I-1
tp39163
sS'respiratory,depression,hypotension'
p39164
(F1
F0.00014334862385321102
I1
I0
I1
tp39165
sS'trials,of,postoperative'
p39166
(F1
F0.00014334862385321102
I0
I1
I-1
tp39167
sS'increases,enterohepatic,elimination'
p39168
(F1
F0.00014334862385321102
I0
I1
I-1
tp39169
sS'a,day,pretreatment'
p39170
(F1
F0.00014334862385321102
I0
I1
I-1
tp39171
sS'of,and,significant'
p39172
(F1
F0.00014334862385321102
I1
I0
I1
tp39173
sS'observed,between,both'
p39174
(F1
F0.00014334862385321102
I0
I1
I-1
tp39175
sS'exhibit,an,additive'
p39176
(F1
F0.00028669724770642203
I2
I0
I2
tp39177
sS'when,celebrex,is'
p39178
(F1
F0.00014334862385321102
I1
I0
I1
tp39179
sS'action,of,hypoglycemic'
p39180
(F1
F0.00014334862385321102
I1
I0
I1
tp39181
sS'hepatic,metabolism,rifampin'
p39182
(F1
F0.00014334862385321102
I1
I0
I1
tp39183
sS'between,clozapine,and'
p39184
(F1
F0.00014334862385321102
I1
I0
I1
tp39185
sS'renally,eliminated,or'
p39186
(F1
F0.00014334862385321102
I0
I1
I-1
tp39187
sS'from,co-administration,of'
p39188
(F1
F0.00014334862385321102
I1
I0
I1
tp39189
sS'of,u,of'
p39190
(F1
F0.00014334862385321102
I0
I1
I-1
tp39191
sS'diuretic,therapy,patients'
p39192
(F1
F0.00043004587155963305
I3
I0
I3
tp39193
sS'doses,of,trileptal'
p39194
(F1
F0.00014334862385321102
I1
I0
I1
tp39195
sS'estradiol,and,or'
p39196
(F1
F0.00014334862385321102
I1
I0
I1
tp39197
sS'of,and,no'
p39198
(F1
F0.00014334862385321102
I0
I1
I-1
tp39199
sS'not,be,taken'
p39200
(F1
F0.0011467889908256881
I8
I0
I8
tp39201
sS'tightly,bound,like'
p39202
(F1
F0.00014334862385321102
I0
I1
I-1
tp39203
sS'the,anticholinesterase,effect'
p39204
(F1
F0.00014334862385321102
I1
I0
I1
tp39205
sS'and,or,hypokalemia'
p39206
(F1
F0.00014334862385321102
I1
I0
I1
tp39207
sS'this,therapy,may'
p39208
(F1
F0.00014334862385321102
I0
I1
I-1
tp39209
sS'or,other,coadministered'
p39210
(F1
F0.00014334862385321102
I0
I1
I-1
tp39211
sS'axert,within,hours'
p39212
(F1
F0.00014334862385321102
I1
I0
I1
tp39213
sS'group,resulted,in'
p39214
(F1
F0.00014334862385321102
I1
I0
I1
tp39215
sS'same,procedures,were'
p39216
(F1
F0.00014334862385321102
I0
I1
I-1
tp39217
sS'crystalline,preparations,novolog'
p39218
(F1
F0.00014334862385321102
I0
I1
I-1
tp39219
sS'various,pesticides,this'
p39220
(F1
F0.00014334862385321102
I0
I1
I-1
tp39221
sS'levels,was,seen'
p39222
(F1
F0.00014334862385321102
I1
I0
I1
tp39223
sS'or,no,increase'
p39224
(F1
F0.00028669724770642203
I2
I0
I2
tp39225
sS'values,of,both'
p39226
(F1
F0.00014334862385321102
I1
I0
I1
tp39227
sS'insp,mediated,responses'
p39228
(F1
F0.00014334862385321102
I0
I1
I-1
tp39229
sS'homozygous,for,the'
p39230
(F1
F0.00014334862385321102
I0
I1
I-1
tp39231
sS'recommended,dose,in'
p39232
(F1
F0.00014334862385321102
I1
I0
I1
tp39233
sS'if,replacing,by'
p39234
(F1
F0.00014334862385321102
I1
I0
I1
tp39235
sS'oral,and,as'
p39236
(F1
F0.00014334862385321102
I0
I1
I-1
tp39237
sS'patients,receiving,or'
p39238
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp39239
sS'the,peak,levels'
p39240
(F1
F0.00014334862385321102
I0
I1
I-1
tp39241
sS'with,the,activity'
p39242
(F1
F0.00014334862385321102
I0
I1
I-1
tp39243
sS'or,with,containing'
p39244
(F1
F0.00028669724770642203
I2
I0
I2
tp39245
sS'received,one,or'
p39246
(F1
F0.00014334862385321102
I0
I1
I-1
tp39247
sS'appeared,to,alter'
p39248
(F1
F0.00014334862385321102
I1
I0
I1
tp39249
sS'indanedione,including,or'
p39250
(F1
F0.00014334862385321102
I0
I1
I-1
tp39251
sS'result,in,serious'
p39252
(F1
F0.00014334862385321102
I0
I1
I-1
tp39253
sS'studies,were,not'
p39254
(F1
F0.00028669724770642203
I0
I2
I-2
tp39255
sS'depakene,use,of'
p39256
(F1
F0.00014334862385321102
I0
I1
I-1
tp39257
sS'be,used,to'
p39258
(F0.5
F0.00028669724770642203
I3
I1
I2
tp39259
sS'normally,to,but'
p39260
(F1
F0.00014334862385321102
I0
I1
I-1
tp39261
sS'pretreatment,did,not'
p39262
(F1
F0.00014334862385321102
I0
I1
I-1
tp39263
sS'dose,should,be'
p39264
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp39265
sS'reducing,the,plasma'
p39266
(F1
F0.00014334862385321102
I1
I0
I1
tp39267
sS'with,the,ace'
p39268
(F1
F0.00028669724770642203
I2
I0
I2
tp39269
sS'with,who,are'
p39270
(F1
F0.00014334862385321102
I0
I1
I-1
tp39271
sS'potent,of,glucocorticoid-induced'
p39272
(F1
F0.00014334862385321102
I0
I1
I-1
tp39273
sS'the,pressor,response'
p39274
(F1
F0.00014334862385321102
I1
I0
I1
tp39275
sS'patients,taking,cyp3a4'
p39276
(F1
F0.00014334862385321102
I0
I1
I-1
tp39277
sS'can,avoid,iatrogenic'
p39278
(F1
F0.00014334862385321102
I1
I0
I1
tp39279
sS'myocardium,in,functional'
p39280
(F1
F0.00014334862385321102
I0
I1
I-1
tp39281
sS'dose,to,approximately'
p39282
(F1
F0.00014334862385321102
I1
I0
I1
tp39283
sS'human,serum,at'
p39284
(F1
F0.00014334862385321102
I0
I1
I-1
tp39285
sS'type,c,antiarrhythrnics'
p39286
(F1
F0.00014334862385321102
I0
I1
I-1
tp39287
sS'most,instances,synergism'
p39288
(F1
F0.00014334862385321102
I1
I0
I1
tp39289
sS'supplements,should,be'
p39290
(F1
F0.00014334862385321102
I0
I1
I-1
tp39291
sS'concentration,of,mg'
p39292
(F1
F0.00014334862385321102
I1
I0
I1
tp39293
sS'reductase,inhibitors,that'
p39294
(F1
F0.00028669724770642203
I2
I0
I2
tp39295
sS'especially,and,have'
p39296
(F1
F0.00014334862385321102
I0
I1
I-1
tp39297
sS'excessive,widening,of'
p39298
(F1
F0.00014334862385321102
I1
I0
I1
tp39299
sS'subjects,had,treatment-emergent'
p39300
(F1
F0.00014334862385321102
I0
I1
I-1
tp39301
sS'which,ssri-tcainteractions,may'
p39302
(F1
F0.00014334862385321102
I1
I0
I1
tp39303
sS'and,a,supersensitivity'
p39304
(F1
F0.00014334862385321102
I1
I0
I1
tp39305
sS'the,cns,effects'
p39306
(F1
F0.00014334862385321102
I1
I0
I1
tp39307
sS'tubular,secretion,has'
p39308
(F1
F0.00014334862385321102
I1
I0
I1
tp39309
sS'clearance,in,patients'
p39310
(F1
F0.00014334862385321102
I1
I0
I1
tp39311
sS'clearance,based,upon'
p39312
(F1
F0.00014334862385321102
I1
I0
I1
tp39313
sS'that,have,one'
p39314
(F1
F0.00014334862385321102
I0
I1
I-1
tp39315
sS'or,kcl,mmol'
p39316
(F1
F0.00014334862385321102
I0
I1
I-1
tp39317
sS'ontario,the,mortality'
p39318
(F1
F0.00014334862385321102
I0
I1
I-1
tp39319
sS'an,insufficient,intake'
p39320
(F1
F0.00014334862385321102
I0
I1
I-1
tp39321
sS'responsive,to,a'
p39322
(F1
F0.00014334862385321102
I0
I1
I-1
tp39323
sS'pegasys,alone,or'
p39324
(F1
F0.00028669724770642203
I0
I2
I-2
tp39325
sS'of,the,above'
p39326
(F1
F0.00014334862385321102
I1
I0
I1
tp39327
sS'to,other,general'
p39328
(F1
F0.00014334862385321102
I1
I0
I1
tp39329
sS'a,theoretical,basis'
p39330
(F1
F0.00028669724770642203
I2
I0
I2
tp39331
sS'tested,by,determination'
p39332
(F1
F0.00014334862385321102
I0
I1
I-1
tp39333
sS'disruptive,effects,of'
p39334
(F1
F0.00014334862385321102
I1
I0
I1
tp39335
sS'dose,co-administered,with'
p39336
(F1
F0.00028669724770642203
I2
I0
I2
tp39337
sS'of,administered,as'
p39338
(F1
F0.00028669724770642203
I0
I2
I-2
tp39339
sS'for,in,subcortical'
p39340
(F1
F0.00014334862385321102
I0
I1
I-1
tp39341
sS'produce,excessive,reduction'
p39342
(F1
F0.00014334862385321102
I1
I0
I1
tp39343
sS'medicine,may,cause'
p39344
(F1
F0.00014334862385321102
I1
I0
I1
tp39345
sS'valdecoxib,did,not'
p39346
(F1
F0.00014334862385321102
I0
I1
I-1
tp39347
sS'of,these,subjects'
p39348
(F1
F0.00014334862385321102
I1
I0
I1
tp39349
sS'eg,grapefruit,juice'
p39350
(F1
F0.00014334862385321102
I0
I1
I-1
tp39351
sS'recommended,that,not'
p39352
(F1
F0.00014334862385321102
I1
I0
I1
tp39353
sS'is,not,recommended'
p39354
(F0.625
F0.0014334862385321102
I13
I3
I10
tp39355
sS'kg,ml,sc'
p39356
(F1
F0.00014334862385321102
I0
I1
I-1
tp39357
sS'study,of,healthy'
p39358
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp39359
sS'as,hours,after'
p39360
(F1
F0.00014334862385321102
I1
I0
I1
tp39361
sS'to,aid,sleep'
p39362
(F1
F0.00014334862385321102
I0
I1
I-1
tp39363
sS'those,in,patients'
p39364
(F1
F0.00014334862385321102
I0
I1
I-1
tp39365
sS'anti-inflammatory,drugs,has'
p39366
(F1
F0.00014334862385321102
I1
I0
I1
tp39367
sS'for,changes,in'
p39368
(F1
F0.00014334862385321102
I0
I1
I-1
tp39369
sS'deaths,is,far'
p39370
(F1
F0.00014334862385321102
I0
I1
I-1
tp39371
sS'half-life,may,be'
p39372
(F1
F0.00014334862385321102
I1
I0
I1
tp39373
sS'in,bleeding,time'
p39374
(F1
F0.00014334862385321102
I0
I1
I-1
tp39375
sS'g,ml,the'
p39376
(F1
F0.00014334862385321102
I1
I0
I1
tp39377
sS'n-diethyl,m-toluamide,a'
p39378
(F1
F0.00014334862385321102
I1
I0
I1
tp39379
sS'reported,to,enhance'
p39380
(F1
F0.00043004587155963305
I3
I0
I3
tp39381
sS'following,protease,inhibitors'
p39382
(F1
F0.00014334862385321102
I0
I1
I-1
tp39383
sS'mg,total,daily'
p39384
(F1
F0.00014334862385321102
I0
I1
I-1
tp39385
sS'and,sinus,medicines'
p39386
(F1
F0.00014334862385321102
I1
I0
I1
tp39387
sS'serum,level,is'
p39388
(F1
F0.00014334862385321102
I0
I1
I-1
tp39389
sS'drugs,decreasing,heparin'
p39390
(F1
F0.00014334862385321102
I1
I0
I1
tp39391
sS'coingestion,of,with'
p39392
(F1
F0.00014334862385321102
I1
I0
I1
tp39393
sS'phosphorylation,in,a'
p39394
(F1
F0.00014334862385321102
I1
I0
I1
tp39395
sS'quinidine,coadministration,of'
p39396
(F1
F0.00014334862385321102
I1
I0
I1
tp39397
sS'and,cyp3a4,substrate'
p39398
(F1
F0.00014334862385321102
I0
I1
I-1
tp39399
sS'others,may,inhibit'
p39400
(F1
F0.00028669724770642203
I0
I2
I-2
tp39401
sS'tablets,should,be'
p39402
(F1
F0.00014334862385321102
I0
I1
I-1
tp39403
sS'when,coumarin,anticoagulants'
p39404
(F1
F0.00014334862385321102
I1
I0
I1
tp39405
sS'to,discriminate,between'
p39406
(F1
F0.00014334862385321102
I0
I1
I-1
tp39407
sS'used,general,and'
p39408
(F1
F0.00014334862385321102
I0
I1
I-1
tp39409
sS'for,clinical,use'
p39410
(F1
F0.00014334862385321102
I0
I1
I-1
tp39411
sS'ketamine,marked,hypertension'
p39412
(F1
F0.00014334862385321102
I1
I0
I1
tp39413
sS'were,no,signs'
p39414
(F1
F0.00014334862385321102
I1
I0
I1
tp39415
sS'candesartan,cilexetil,given'
p39416
(F1
F0.00014334862385321102
I0
I1
I-1
tp39417
sS'when,vardenafil,dosing'
p39418
(F1
F0.00014334862385321102
I1
I0
I1
tp39419
sS'x,m,enhance'
p39420
(F1
F0.00014334862385321102
I1
I0
I1
tp39421
sS'that,levels,be'
p39422
(F1
F0.00043004587155963305
I3
I0
I3
tp39423
sS'interaction,between,mao'
p39424
(F1
F0.00014334862385321102
I1
I0
I1
tp39425
sS'volunteers,exjade,had'
p39426
(F1
F0.00014334862385321102
I0
I1
I-1
tp39427
sS'alone,and,ng'
p39428
(F1
F0.00014334862385321102
I1
I0
I1
tp39429
sS'well,as,a'
p39430
(F1
F0.00028669724770642203
I2
I0
I2
tp39431
sS'concomitant,administration,may'
p39432
(F1
F0.00014334862385321102
I1
I0
I1
tp39433
sS'be,premedicated,with'
p39434
(F1
F0.00014334862385321102
I0
I1
I-1
tp39435
sS'by,and,appears'
p39436
(F1
F0.00014334862385321102
I0
I1
I-1
tp39437
sS'of,one,patient'
p39438
(F1
F0.00014334862385321102
I1
I0
I1
tp39439
sS'cefditoren,with,a'
p39440
(F1
F0.00014334862385321102
I1
I0
I1
tp39441
sS'of,each,to'
p39442
(F1
F0.00014334862385321102
I1
I0
I1
tp39443
sS'coadministered,with,sustiva'
p39444
(F1
F0.00014334862385321102
I0
I1
I-1
tp39445
sS'bound,to,protein'
p39446
(F1
F0.00014334862385321102
I1
I0
I1
tp39447
sS'initiating,tcatreatment,in'
p39448
(F1
F0.00014334862385321102
I1
I0
I1
tp39449
sS'the,combination,is'
p39450
(F1
F0.00014334862385321102
I1
I0
I1
tp39451
sS'phosphorylated,concentration,is'
p39452
(F1
F0.00014334862385321102
I0
I1
I-1
tp39453
sS'interaction,studies,demonstrate'
p39454
(F1
F0.00014334862385321102
I0
I1
I-1
tp39455
sS'to,baseline,values'
p39456
(F1
F0.00014334862385321102
I1
I0
I1
tp39457
sS'and,or,frequency'
p39458
(F1
F0.00014334862385321102
I1
I0
I1
tp39459
sS'respectively,were,added'
p39460
(F1
F0.00014334862385321102
I1
I0
I1
tp39461
sS'of,sulfoxide,were'
p39462
(F1
F0.00014334862385321102
I1
I0
I1
tp39463
sS'decreased,when,are'
p39464
(F1
F0.00014334862385321102
I1
I0
I1
tp39465
sS'of,involvement,labeling'
p39466
(F1
F0.00014334862385321102
I0
I1
I-1
tp39467
sS'these,changes,were'
p39468
(F1
F0.00014334862385321102
I0
I1
I-1
tp39469
sS'the,concentration,of'
p39470
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp39471
sS'cardiovasculars,cardiac,glycosides'
p39472
(F1
F0.00014334862385321102
I0
I1
I-1
tp39473
sS'did,not,display'
p39474
(F1
F0.00014334862385321102
I0
I1
I-1
tp39475
sS'to,treat,pneumocystis'
p39476
(F0
F0
I1
I1
I0
tp39477
sS'dose,will,need'
p39478
(F1
F0.00014334862385321102
I1
I0
I1
tp39479
sS'leading,to,increases'
p39480
(F1
F0.00014334862385321102
I0
I1
I-1
tp39481
sS'subjects,with,normal'
p39482
(F1
F0.00014334862385321102
I0
I1
I-1
tp39483
sS'pharmacokinetics,of,were'
p39484
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp39485
sS'therefore,the,efficacy'
p39486
(F1
F0.00014334862385321102
I1
I0
I1
tp39487
sS'acids,may,interfere'
p39488
(F1
F0.00014334862385321102
I0
I1
I-1
tp39489
sS'the,present,study'
p39490
(F1
F0.00028669724770642203
I0
I2
I-2
tp39491
sS'is,extensively,metabolized'
p39492
(F0
F0
I1
I1
I0
tp39493
sS'inhibition,of,prostaglandin'
p39494
(F1
F0.00014334862385321102
I1
I0
I1
tp39495
sS'glucose,alone,and'
p39496
(F1
F0.00014334862385321102
I0
I1
I-1
tp39497
sS'infections,was,observed'
p39498
(F1
F0.00028669724770642203
I2
I0
I2
tp39499
sS'of,which,can'
p39500
(F1
F0.00057339449541284407
I4
I0
I4
tp39501
sS'less,than,two-fold'
p39502
(F1
F0.00014334862385321102
I1
I0
I1
tp39503
sS'last,subcutaneous,dose'
p39504
(F1
F0.00014334862385321102
I1
I0
I1
tp39505
sS'changes,in,glucose'
p39506
(F1
F0.00014334862385321102
I1
I0
I1
tp39507
sS'that,indocin,does'
p39508
(F1
F0.00014334862385321102
I0
I1
I-1
tp39509
sS'injectable,implantable,insertable'
p39510
(F1
F0.00014334862385321102
I0
I1
I-1
tp39511
sS'when,mg,every'
p39512
(F1
F0.00014334862385321102
I1
I0
I1
tp39513
sS'of,from,plasma'
p39514
(F1
F0.00014334862385321102
I1
I0
I1
tp39515
sS'an,agent,that'
p39516
(F1
F0.00014334862385321102
I0
I1
I-1
tp39517
sS'warfarin,quinolones,have'
p39518
(F1
F0.00014334862385321102
I1
I0
I1
tp39519
sS'minimized,by,either'
p39520
(F1
F0.00071674311926605509
I5
I0
I5
tp39521
sS'if,is,co-administered'
p39522
(F1
F0.00028669724770642203
I2
I0
I2
tp39523
sS'judgment,of,the'
p39524
(F1
F0.00014334862385321102
I1
I0
I1
tp39525
sS'produce,additive,cns'
p39526
(F1
F0.00014334862385321102
I1
I0
I1
tp39527
sS'tablet,volume,fewer'
p39528
(F1
F0.00014334862385321102
I0
I1
I-1
tp39529
sS'on,the,clinical'
p39530
(F1
F0.00014334862385321102
I0
I1
I-1
tp39531
sS'the,frontal,cortex'
p39532
(F1
F0.00014334862385321102
I0
I1
I-1
tp39533
sS'concomitantly,the,patient'
p39534
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp39535
sS'non-ionized,species,of'
p39536
(F1
F0.00014334862385321102
I1
I0
I1
tp39537
sS'to,about,one-third'
p39538
(F1
F0.00014334862385321102
I1
I0
I1
tp39539
sS'in,a,similar'
p39540
(F1
F0.00014334862385321102
I1
I0
I1
tp39541
sS'coumarin,anticoagulants,in'
p39542
(F1
F0.00014334862385321102
I0
I1
I-1
tp39543
sS'in,seven,experiments'
p39544
(F1
F0.00014334862385321102
I0
I1
I-1
tp39545
sS'known,cytochrome,cyp'
p39546
(F1
F0.00014334862385321102
I0
I1
I-1
tp39547
sS'excess,may,decrease'
p39548
(F1
F0.00014334862385321102
I1
I0
I1
tp39549
sS'high,doses,of'
p39550
(F0.45454545454545453
F0.00071674311926605509
I8
I3
I5
tp39551
sS'system,depressants,such'
p39552
(F1
F0.00014334862385321102
I1
I0
I1
tp39553
sS'but,a,lower'
p39554
(F1
F0.00014334862385321102
I0
I1
I-1
tp39555
sS'effects,of,romazicon'
p39556
(F1
F0.00014334862385321102
I0
I1
I-1
tp39557
sS'of,cancidas,mg'
p39558
(F1
F0.00014334862385321102
I1
I0
I1
tp39559
sS'for,loss,of'
p39560
(F0
F0
I1
I1
I0
tp39561
sS'that,is,known'
p39562
(F1
F0.00014334862385321102
I0
I1
I-1
tp39563
sS'eg,other,general'
p39564
(F1
F0.00014334862385321102
I1
I0
I1
tp39565
sS'relevant,effect,was'
p39566
(F1
F0.00014334862385321102
I1
I0
I1
tp39567
sS'may,emerge,with'
p39568
(F1
F0.00014334862385321102
I1
I0
I1
tp39569
sS'clinical,significance,of'
p39570
(F1
F0.00028669724770642203
I2
I0
I2
tp39571
sS'are,also,blocked'
p39572
(F1
F0.00014334862385321102
I1
I0
I1
tp39573
sS'accordingly,careful,patient'
p39574
(F1
F0.00014334862385321102
I1
I0
I1
tp39575
sS'with,increases,serum'
p39576
(F1
F0.00014334862385321102
I0
I1
I-1
tp39577
sS't24,cells,but'
p39578
(F1
F0.00014334862385321102
I1
I0
I1
tp39579
sS'contraception,inwomen,taking'
p39580
(F1
F0.00014334862385321102
I1
I0
I1
tp39581
sS'but,in,a'
p39582
(F1
F0.00014334862385321102
I0
I1
I-1
tp39583
sS'human,subjects,ingesting'
p39584
(F1
F0.00014334862385321102
I1
I0
I1
tp39585
sS'with,close,monitoring'
p39586
(F1
F0.00014334862385321102
I1
I0
I1
tp39587
sS'cyclosporine,l-arginine,may'
p39588
(F1
F0.00014334862385321102
I1
I0
I1
tp39589
sS'excretion,compared,with'
p39590
(F1
F0.00014334862385321102
I1
I0
I1
tp39591
sS'monoamine,oxidase,inhibiting'
p39592
(F1
F0.00014334862385321102
I1
I0
I1
tp39593
sS'interval,prolongation,ischemic'
p39594
(F1
F0.00014334862385321102
I1
I0
I1
tp39595
sS'serum,concentration,that'
p39596
(F1
F0.00014334862385321102
I0
I1
I-1
tp39597
sS'was,administered,together'
p39598
(F1
F0.00014334862385321102
I0
I1
I-1
tp39599
sS'study,in,patients'
p39600
(F1
F0.00028669724770642203
I0
I2
I-2
tp39601
sS'there,has,been'
p39602
(F0
F0
I2
I2
I0
tp39603
sS'interactions,between,argatroban'
p39604
(F1
F0.00014334862385321102
I0
I1
I-1
tp39605
sS'plasma,levels,increased'
p39606
(F1
F0.00028669724770642203
I2
I0
I2
tp39607
sS'with,were,not'
p39608
(F1
F0.00014334862385321102
I1
I0
I1
tp39609
sS'and,axert,within'
p39610
(F1
F0.00014334862385321102
I1
I0
I1
tp39611
sS'have,a,statistically'
p39612
(F1
F0.00014334862385321102
I0
I1
I-1
tp39613
sS'its,nephrotoxicity,may'
p39614
(F1
F0.00014334862385321102
I1
I0
I1
tp39615
sS'activity,can,occur'
p39616
(F1
F0.00014334862385321102
I1
I0
I1
tp39617
sS'given,hour,prior'
p39618
(F1
F0.00014334862385321102
I1
I0
I1
tp39619
sS'intestinal,cancers,it'
p39620
(F1
F0.00014334862385321102
I0
I1
I-1
tp39621
sS'possibly,other,macrolide'
p39622
(F1
F0.00014334862385321102
I1
I0
I1
tp39623
sS'in,the,united'
p39624
(F0
F0
I1
I1
I0
tp39625
sS'have,demonstrated,moderate'
p39626
(F1
F0.00014334862385321102
I1
I0
I1
tp39627
sS'short-acting,because,the'
p39628
(F1
F0.00014334862385321102
I1
I0
I1
tp39629
sS'with,neoplastic,disease'
p39630
(F1
F0.00014334862385321102
I1
I0
I1
tp39631
sS'no,relevant,effect'
p39632
(F1
F0.00014334862385321102
I0
I1
I-1
tp39633
sS'severe,in,the'
p39634
(F1
F0.00014334862385321102
I0
I1
I-1
tp39635
sS'has,been,implicated'
p39636
(F0
F0
I1
I1
I0
tp39637
sS'on,the,subjective'
p39638
(F1
F0.00028669724770642203
I0
I2
I-2
tp39639
sS'antiedematous,action,of'
p39640
(F1
F0.00014334862385321102
I1
I0
I1
tp39641
sS'location,histologic,type'
p39642
(F1
F0.00014334862385321102
I0
I1
I-1
tp39643
sS'reverse,the,pressor'
p39644
(F1
F0.00028669724770642203
I2
I0
I2
tp39645
sS'and,some,gram-positive'
p39646
(F1
F0.00014334862385321102
I0
I1
I-1
tp39647
sS'axert,and,an'
p39648
(F1
F0.00014334862385321102
I1
I0
I1
tp39649
sS'to,increased,total'
p39650
(F1
F0.00028669724770642203
I0
I2
I-2
tp39651
sS'with,chop,chemotherapy'
p39652
(F1
F0.00014334862385321102
I0
I1
I-1
tp39653
sS'concentrations,and,significant'
p39654
(F1
F0.00014334862385321102
I1
I0
I1
tp39655
sS'under,the,curve'
p39656
(F1
F0.00043004587155963305
I3
I0
I3
tp39657
sS'bioavailability,of,by'
p39658
(F1
F0.00014334862385321102
I1
I0
I1
tp39659
sS'adjustments,made,when'
p39660
(F1
F0.00028669724770642203
I0
I2
I-2
tp39661
sS'levels,is,likely'
p39662
(F1
F0.00014334862385321102
I1
I0
I1
tp39663
sS'susceptibility,to,hypoglycemia'
p39664
(F1
F0.00028669724770642203
I0
I2
I-2
tp39665
sS'cbg,sex,hormone-binding'
p39666
(F1
F0.00014334862385321102
I0
I1
I-1
tp39667
sS'no,effects,on'
p39668
(F1
F0.00028669724770642203
I0
I2
I-2
tp39669
sS'the,and,a'
p39670
(F1
F0.00028669724770642203
I0
I2
I-2
tp39671
sS'h2antagonists,reduced,plasma'
p39672
(F1
F0.00014334862385321102
I1
I0
I1
tp39673
sS'retinyl,acetate,stimulated'
p39674
(F1
F0.00014334862385321102
I1
I0
I1
tp39675
sS'examined,the,effect'
p39676
(F1
F0.00028669724770642203
I0
I2
I-2
tp39677
sS'mean,c,max'
p39678
(F0
F0
I1
I1
I0
tp39679
sS'and,antiparkinsonian,agents'
p39680
(F1
F0.00014334862385321102
I1
I0
I1
tp39681
sS'hypoglycemia,has,been'
p39682
(F1
F0.00043004587155963305
I3
I0
I3
tp39683
sS'in,any,intentional'
p39684
(F1
F0.00014334862385321102
I1
I0
I1
tp39685
sS'cyp,drug-metabolizing,enzymes'
p39686
(F1
F0.00014334862385321102
I0
I1
I-1
tp39687
sS'ensure,that,a'
p39688
(F1
F0.00014334862385321102
I1
I0
I1
tp39689
sS'patients,beginning,therapy'
p39690
(F1
F0.00014334862385321102
I1
I0
I1
tp39691
sS'the,hour,observation'
p39692
(F1
F0.00014334862385321102
I0
I1
I-1
tp39693
sS'chronic,dosing,effects'
p39694
(F1
F0.00014334862385321102
I0
I1
I-1
tp39695
sS'that,would,affect'
p39696
(F1
F0.00014334862385321102
I0
I1
I-1
tp39697
sS'patients,in,parentheses'
p39698
(F1
F0.00014334862385321102
I0
I1
I-1
tp39699
sS'blocking,agents,anesthetics'
p39700
(F1
F0.00014334862385321102
I1
I0
I1
tp39701
sS'instead,of,mg'
p39702
(F1
F0.00014334862385321102
I1
I0
I1
tp39703
sS'maalox,maalox,reduced'
p39704
(F1
F0.00014334862385321102
I1
I0
I1
tp39705
sS'the,free,fraction'
p39706
(F1
F0.00028669724770642203
I0
I2
I-2
tp39707
sS'severe,dry,mouth'
p39708
(F1
F0.00028669724770642203
I2
I0
I2
tp39709
sS'or,daily,alternating'
p39710
(F1
F0.00014334862385321102
I0
I1
I-1
tp39711
sS'increases,in,the'
p39712
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp39713
sS'closely,monitored,during'
p39714
(F1
F0.00014334862385321102
I1
I0
I1
tp39715
sS'of,cyp1a2,concomitant'
p39716
(F1
F0.00014334862385321102
I1
I0
I1
tp39717
sS'mechanism,may,be'
p39718
(F1
F0.00014334862385321102
I1
I0
I1
tp39719
sS'or,nsaids,was'
p39720
(F1
F0.00014334862385321102
I0
I1
I-1
tp39721
sS'theophylline,combined,administration'
p39722
(F1
F0.00014334862385321102
I0
I1
I-1
tp39723
sS'hepatoxicity,of,in'
p39724
(F1
F0.00014334862385321102
I1
I0
I1
tp39725
sS'eliminated,by,conjugation'
p39726
(F1
F0.00014334862385321102
I0
I1
I-1
tp39727
sS'with,mg,every'
p39728
(F1
F0.00028669724770642203
I0
I2
I-2
tp39729
sS'fexofenadine,had,no'
p39730
(F1
F0.00014334862385321102
I0
I1
I-1
tp39731
sS'oral,hypoglycemics,bepridil'
p39732
(F1
F0.00014334862385321102
I0
I1
I-1
tp39733
sS'stupor,and,or'
p39734
(F1
F0.00014334862385321102
I1
I0
I1
tp39735
sS'nitrofurantoin,interferes,with'
p39736
(F1
F0.00014334862385321102
I1
I0
I1
tp39737
sS'phenytoin,in,post-marketing'
p39738
(F1
F0.00014334862385321102
I1
I0
I1
tp39739
sS'bone,scintigraphy,employing'
p39740
(F1
F0.00014334862385321102
I0
I1
I-1
tp39741
sS'parenteral,forms,of'
p39742
(F1
F0.00014334862385321102
I0
I1
I-1
tp39743
sS'can,inhibit,renal'
p39744
(F1
F0.00014334862385321102
I1
I0
I1
tp39745
sS'tc,suspension,were'
p39746
(F1
F0.00014334862385321102
I1
I0
I1
tp39747
sS'glycosides,could,exaggerate'
p39748
(F1
F0.00014334862385321102
I1
I0
I1
tp39749
sS'after,the,effects'
p39750
(F1
F0.00014334862385321102
I0
I1
I-1
tp39751
sS'by,cgs,nor'
p39752
(F1
F0.00014334862385321102
I1
I0
I1
tp39753
sS'its,action,on'
p39754
(F1
F0.00014334862385321102
I1
I0
I1
tp39755
sS'combination,of,intravenous'
p39756
(F1
F0.00014334862385321102
I1
I0
I1
tp39757
sS'in,each,study'
p39758
(F1
F0.00028669724770642203
I0
I2
I-2
tp39759
sS'of,by,patients'
p39760
(F1
F0.00014334862385321102
I1
I0
I1
tp39761
sS'other,than,myopathy'
p39762
(F1
F0.00014334862385321102
I0
I1
I-1
tp39763
sS'alter,hormone,or'
p39764
(F1
F0.00014334862385321102
I0
I1
I-1
tp39765
sS'toxicity,of,patients'
p39766
(F1
F0.00014334862385321102
I0
I1
I-1
tp39767
sS'is,mixed,with'
p39768
(F1
F0.00014334862385321102
I0
I1
I-1
tp39769
sS'studies,were,conducted'
p39770
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp39771
sS'imipramine,coadministration,of'
p39772
(F1
F0.00014334862385321102
I1
I0
I1
tp39773
sS'as,arrhythmias,may'
p39774
(F1
F0.00014334862385321102
I1
I0
I1
tp39775
sS'exercised,when,coumarin'
p39776
(F1
F0.00014334862385321102
I1
I0
I1
tp39777
sS'assays,based,on'
p39778
(F1
F0.00014334862385321102
I0
I1
I-1
tp39779
sS'm,v,nacmc'
p39780
(F1
F0.00014334862385321102
I0
I1
I-1
tp39781
sS'steady,state,in'
p39782
(F1
F0.00014334862385321102
I0
I1
I-1
tp39783
sS'intrathecal,injection,of'
p39784
(F1
F0.00014334862385321102
I1
I0
I1
tp39785
sS'adenocarcinomas,which,was'
p39786
(F1
F0.00014334862385321102
I1
I0
I1
tp39787
sS'that,these,effects'
p39788
(F1
F0.00028669724770642203
I2
I0
I2
tp39789
sS'vitamin,d3,calcitriol'
p39790
(F1
F0.00043004587155963305
I3
I0
I3
tp39791
sS'initiates,or,discontinues'
p39792
(F1
F0.00014334862385321102
I1
I0
I1
tp39793
sS'or,bezalip,retard'
p39794
(F1
F0.00043004587155963305
I3
I0
I3
tp39795
sS'disease,medications,were'
p39796
(F1
F0.00014334862385321102
I0
I1
I-1
tp39797
sS'changes,in,function'
p39798
(F1
F0.00014334862385321102
I0
I1
I-1
tp39799
sS'other,having,vasodilator'
p39800
(F1
F0.00014334862385321102
I1
I0
I1
tp39801
sS'as,random,observations'
p39802
(F1
F0.00014334862385321102
I1
I0
I1
tp39803
sS'among,or,nsaid'
p39804
(F1
F0.00014334862385321102
I0
I1
I-1
tp39805
sS'absorption,of,sodium'
p39806
(F1
F0.00014334862385321102
I1
I0
I1
tp39807
sS'the,interactions,between'
p39808
(F1
F0.00014334862385321102
I0
I1
I-1
tp39809
sS'in,monkeys,the'
p39810
(F1
F0.00014334862385321102
I1
I0
I1
tp39811
sS'failed,to,alter'
p39812
(F1
F0.00014334862385321102
I0
I1
I-1
tp39813
sS'were,no,reports'
p39814
(F1
F0.00014334862385321102
I0
I1
I-1
tp39815
sS'was,to,investigate'
p39816
(F1
F0.00014334862385321102
I0
I1
I-1
tp39817
sS'macrolide,and,may'
p39818
(F1
F0.00014334862385321102
I1
I0
I1
tp39819
sS'aminosalicylic,acid,may'
p39820
(F1
F0.00028669724770642203
I2
I0
I2
tp39821
sS'adults,to,be'
p39822
(F1
F0.00014334862385321102
I0
I1
I-1
tp39823
sS'ratios,of,the'
p39824
(F1
F0.00014334862385321102
I0
I1
I-1
tp39825
sS'continue,to,increase'
p39826
(F1
F0.00014334862385321102
I1
I0
I1
tp39827
sS'to,the,complete'
p39828
(F1
F0.00014334862385321102
I0
I1
I-1
tp39829
sS'antihypertensive,effect,although'
p39830
(F1
F0.00014334862385321102
I0
I1
I-1
tp39831
sS'antagonists,and,could'
p39832
(F1
F0.00014334862385321102
I0
I1
I-1
tp39833
sS'wshow,that,significantly'
p39834
(F1
F0.00014334862385321102
I0
I1
I-1
tp39835
sS'higher,doses,of'
p39836
(F0
F0
I4
I4
I0
tp39837
sS'with,moieties,significantly'
p39838
(F1
F0.00014334862385321102
I0
I1
I-1
tp39839
sS'reported,cases,from'
p39840
(F1
F0.00014334862385321102
I0
I1
I-1
tp39841
sS'homocysteine,in,the'
p39842
(F1
F0.00014334862385321102
I0
I1
I-1
tp39843
sS'fifteen,to,minutes'
p39844
(F1
F0.00014334862385321102
I0
I1
I-1
tp39845
sS'mg,of,daily'
p39846
(F1
F0.00014334862385321102
I1
I0
I1
tp39847
sS'trial,a,reduction'
p39848
(F1
F0.00014334862385321102
I0
I1
I-1
tp39849
sS'that,the,prophylactic'
p39850
(F1
F0.00014334862385321102
I1
I0
I1
tp39851
sS'this,neurotoxic,effect'
p39852
(F1
F0.00014334862385321102
I1
I0
I1
tp39853
sS'microsomal,enzymes,and'
p39854
(F1
F0.00014334862385321102
I1
I0
I1
tp39855
sS'ace,inhibitors,calcium-channel'
p39856
(F1
F0.00014334862385321102
I0
I1
I-1
tp39857
sS'transport,of,or'
p39858
(F1
F0.00014334862385321102
I0
I1
I-1
tp39859
sS'therapy,with,other'
p39860
(F1
F0.00028669724770642203
I0
I2
I-2
tp39861
sS'oral,including,or'
p39862
(F1
F0.00014334862385321102
I1
I0
I1
tp39863
sS'and,may,produce'
p39864
(F1
F0.00043004587155963305
I3
I0
I3
tp39865
sS'studies,with,sustiva'
p39866
(F1
F0.00014334862385321102
I0
I1
I-1
tp39867
sS'be,avoided,and'
p39868
(F1
F0.00014334862385321102
I1
I0
I1
tp39869
sS'agents,nitrogen,mustard'
p39870
(F1
F0.00014334862385321102
I0
I1
I-1
tp39871
sS'cns,depressants,using'
p39872
(F1
F0.00014334862385321102
I1
I0
I1
tp39873
sS'rheumatic,disease,may'
p39874
(F1
F0.00014334862385321102
I1
I0
I1
tp39875
sS'adjustment,of,hypoglycemic'
p39876
(F1
F0.00014334862385321102
I1
I0
I1
tp39877
sS'increased,and,prolonged'
p39878
(F1
F0.00014334862385321102
I1
I0
I1
tp39879
sS'additive,effects,on'
p39880
(F1
F0.00071674311926605509
I5
I0
I5
tp39881
sS'k,may,reduce'
p39882
(F1
F0.00043004587155963305
I3
I0
I3
tp39883
sS'nonsteroidal,that,inhibit'
p39884
(F1
F0.00014334862385321102
I1
I0
I1
tp39885
sS'days,in,combination'
p39886
(F1
F0.00014334862385321102
I0
I1
I-1
tp39887
sS'since,bacteriostatic,may'
p39888
(F1
F0.00014334862385321102
I1
I0
I1
tp39889
sS'toxic,effects,of'
p39890
(F1
F0.00014334862385321102
I1
I0
I1
tp39891
sS'recommended,that,levels'
p39892
(F1
F0.00043004587155963305
I3
I0
I3
tp39893
sS'agents,although,ipratropium'
p39894
(F1
F0.00014334862385321102
I1
I0
I1
tp39895
sS'administration,of,diffusible'
p39896
(F1
F0.00014334862385321102
I0
I1
I-1
tp39897
sS'their,dose,of'
p39898
(F1
F0.00014334862385321102
I0
I1
I-1
tp39899
sS'to,be,approved'
p39900
(F1
F0.00014334862385321102
I0
I1
I-1
tp39901
sS'step,in,the'
p39902
(F1
F0.00014334862385321102
I0
I1
I-1
tp39903
sS'in,healthy,males'
p39904
(F1
F0.00014334862385321102
I0
I1
I-1
tp39905
sS'cyp2a6,hydroxylation,of'
p39906
(F1
F0.00014334862385321102
I1
I0
I1
tp39907
sS'a,patient,population'
p39908
(F1
F0.00014334862385321102
I0
I1
I-1
tp39909
sS'effect,on,insp'
p39910
(F1
F0.00014334862385321102
I0
I1
I-1
tp39911
sS'taking,these,with'
p39912
(F1
F0.00014334862385321102
I0
I1
I-1
tp39913
sS'of,mean,serum'
p39914
(F1
F0.00014334862385321102
I1
I0
I1
tp39915
sS'vs,serious,falls'
p39916
(F1
F0.00014334862385321102
I1
I0
I1
tp39917
sS'their,dose,or'
p39918
(F1
F0.00014334862385321102
I1
I0
I1
tp39919
sS'valdecoxib,steady,state'
p39920
(F1
F0.00014334862385321102
I0
I1
I-1
tp39921
sS'of,the,total'
p39922
(F0
F0
I1
I1
I0
tp39923
sS'such,as,because'
p39924
(F1
F0.00057339449541284407
I4
I0
I4
tp39925
sS'to,similar,effects'
p39926
(F1
F0.00014334862385321102
I0
I1
I-1
tp39927
sS'an,blood,coagulation'
p39928
(F1
F0.00014334862385321102
I1
I0
I1
tp39929
sS'kg,injected,with'
p39930
(F1
F0.00014334862385321102
I1
I0
I1
tp39931
sS'if,or,estrogen-containing'
p39932
(F1
F0.00014334862385321102
I1
I0
I1
tp39933
sS'in,a,defined'
p39934
(F1
F0.00014334862385321102
I0
I1
I-1
tp39935
sS'response,and,possible'
p39936
(F1
F0.00028669724770642203
I0
I2
I-2
tp39937
sS'basis,of,therapeutic'
p39938
(F1
F0.00014334862385321102
I0
I1
I-1
tp39939
sS'are,listed,below'
p39940
(F1
F0.00014334862385321102
I1
I0
I1
tp39941
sS'and,beta,adrenergic'
p39942
(F1
F0.00043004587155963305
I3
I0
I3
tp39943
sS'side,effects,caused'
p39944
(F1
F0.00014334862385321102
I1
I0
I1
tp39945
sS'for,and,respectively'
p39946
(F1
F0.00028669724770642203
I0
I2
I-2
tp39947
sS'conditions,concentrations,were'
p39948
(F1
F0.00014334862385321102
I0
I1
I-1
tp39949
sS'gabapentin,is,not'
p39950
(F1
F0.00014334862385321102
I0
I1
I-1
tp39951
sS'avoid,the,possible'
p39952
(F1
F0.00014334862385321102
I1
I0
I1
tp39953
sS'distribution,of,phosphatases'
p39954
(F1
F0.00014334862385321102
I0
I1
I-1
tp39955
sS'stimulated,by,but'
p39956
(F1
F0.00014334862385321102
I0
I1
I-1
tp39957
sS'instituted,may,occasionally'
p39958
(F1
F0.00043004587155963305
I3
I0
I3
tp39959
sS'kg,mc,mg'
p39960
(F1
F0.00014334862385321102
I0
I1
I-1
tp39961
sS'three,times,daily'
p39962
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp39963
sS'baseline,for,h'
p39964
(F1
F0.00014334862385321102
I0
I1
I-1
tp39965
sS'with,that,have'
p39966
(F1
F0.00014334862385321102
I1
I0
I1
tp39967
sS'our,patient,appeared'
p39968
(F1
F0.00014334862385321102
I1
I0
I1
tp39969
sS'fat,digestion,and'
p39970
(F1
F0.00014334862385321102
I0
I1
I-1
tp39971
sS'of,lexapro,and'
p39972
(F1
F0.00014334862385321102
I0
I1
I-1
tp39973
sS'suggests,that,renal'
p39974
(F1
F0.00014334862385321102
I1
I0
I1
tp39975
sS'reduce,the,natriuretic'
p39976
(F1
F0.0018635321100917432
I13
I0
I13
tp39977
sS'at,recommended,dosages'
p39978
(F1
F0.00014334862385321102
I1
I0
I1
tp39979
sS'induce,toxicity,since'
p39980
(F1
F0.00014334862385321102
I0
I1
I-1
tp39981
sS'atrioventricular,conduction,disturbances'
p39982
(F1
F0.00014334862385321102
I1
I0
I1
tp39983
sS'anticipated,if,stadol'
p39984
(F1
F0.00014334862385321102
I1
I0
I1
tp39985
sS'however,other,published'
p39986
(F1
F0.00014334862385321102
I1
I0
I1
tp39987
sS'of,and,initiation'
p39988
(F1
F0.00014334862385321102
I1
I0
I1
tp39989
sS'clinically,important,pharmacokinetic'
p39990
(F1
F0.00057339449541284407
I0
I4
I-4
tp39991
sS'shorter,durations,of'
p39992
(F1
F0.00014334862385321102
I1
I0
I1
tp39993
sS'the,synthesis,of'
p39994
(F1
F0.00028669724770642203
I0
I2
I-2
tp39995
sS'doses,of,required'
p39996
(F1
F0.00014334862385321102
I1
I0
I1
tp39997
sS'sodium,and,in'
p39998
(F1
F0.00014334862385321102
I0
I1
I-1
tp39999
sS'caution,is,therefore'
p40000
(F1
F0.00028669724770642203
I2
I0
I2
tp40001
sS'to,evaluate,the'
p40002
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp40003
sS'and,urinary,excretion'
p40004
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40005
sS'mg,clo-4,simultaneously'
p40006
(F1
F0.00014334862385321102
I0
I1
I-1
tp40007
sS'which,d,h'
p40008
(F1
F0.00014334862385321102
I1
I0
I1
tp40009
sS'relaxants,eg,and'
p40010
(F1
F0.00014334862385321102
I1
I0
I1
tp40011
sS'the,brief,psychiatric'
p40012
(F1
F0.00014334862385321102
I1
I0
I1
tp40013
sS'with,as,hypercalcemia'
p40014
(F1
F0.00043004587155963305
I3
I0
I3
tp40015
sS'co-administration,of,mg'
p40016
(F0.5
F0.00028669724770642203
I3
I1
I2
tp40017
sS'reaction,at,concentrations'
p40018
(F1
F0.00014334862385321102
I0
I1
I-1
tp40019
sS'it,is,expected'
p40020
(F1
F0.00014334862385321102
I1
I0
I1
tp40021
sS'the,mean,auc'
p40022
(F1
F0.00014334862385321102
I0
I1
I-1
tp40023
sS'tablets,or,pediatric'
p40024
(F1
F0.00028669724770642203
I2
I0
I2
tp40025
sS'dose,of,subutex'
p40026
(F1
F0.00014334862385321102
I0
I1
I-1
tp40027
sS'or,are,expected'
p40028
(F1
F0.00043004587155963305
I3
I0
I3
tp40029
sS'within,the,first'
p40030
(F1
F0.00028669724770642203
I2
I0
I2
tp40031
sS'upon,beginning,or'
p40032
(F1
F0.00014334862385321102
I1
I0
I1
tp40033
sS'are,extensively,metabolized'
p40034
(F1
F0.00014334862385321102
I1
I0
I1
tp40035
sS'of,its,action'
p40036
(F1
F0.00014334862385321102
I1
I0
I1
tp40037
sS'inhibitor,of,p450'
p40038
(F0
F0
I1
I1
I0
tp40039
sS'celebrex,did,not'
p40040
(F1
F0.00014334862385321102
I0
I1
I-1
tp40041
sS'response,to,and'
p40042
(F1
F0.00014334862385321102
I0
I1
I-1
tp40043
sS'metabolic,responses,to'
p40044
(F1
F0.00014334862385321102
I0
I1
I-1
tp40045
sS'normal,dose,when'
p40046
(F1
F0.00014334862385321102
I1
I0
I1
tp40047
sS'and,both,thiazide-like'
p40048
(F1
F0.00014334862385321102
I0
I1
I-1
tp40049
sS'of,taking,mao'
p40050
(F1
F0.00014334862385321102
I1
I0
I1
tp40051
sS'without,other,enzyme-'
p40052
(F1
F0.00028669724770642203
I2
I0
I2
tp40053
sS'active,s-isomer,and'
p40054
(F1
F0.00014334862385321102
I0
I1
I-1
tp40055
sS'an,a2-selective,agonist'
p40056
(F1
F0.00014334862385321102
I1
I0
I1
tp40057
sS'ml,twice,daily'
p40058
(F1
F0.00014334862385321102
I1
I0
I1
tp40059
sS'coadministered,the,beta'
p40060
(F1
F0.00014334862385321102
I1
I0
I1
tp40061
sS'also,be,taken'
p40062
(F1
F0.00014334862385321102
I0
I1
I-1
tp40063
sS'indicating,that,impairment'
p40064
(F1
F0.00014334862385321102
I0
I1
I-1
tp40065
sS'and,that,induce'
p40066
(F1
F0.00014334862385321102
I0
I1
I-1
tp40067
sS'eia,test,in'
p40068
(F1
F0.00014334862385321102
I0
I1
I-1
tp40069
sS'sensitivity,to,the'
p40070
(F1
F0.00014334862385321102
I1
I0
I1
tp40071
sS's,c,completely'
p40072
(F1
F0.00014334862385321102
I1
I0
I1
tp40073
sS'produced,transient,increases'
p40074
(F1
F0.00014334862385321102
I0
I1
I-1
tp40075
sS'sodium,can,attenuate'
p40076
(F1
F0.00014334862385321102
I1
I0
I1
tp40077
sS'fluoxetine,and,its'
p40078
(F1
F0.00014334862385321102
I0
I1
I-1
tp40079
sS'diabetic,patients,demonstrated'
p40080
(F1
F0.00014334862385321102
I0
I1
I-1
tp40081
sS'reduce,the,antihypertensive'
p40082
(F1
F0.00043004587155963305
I3
I0
I3
tp40083
sS'not,require,dosage'
p40084
(F1
F0.00014334862385321102
I0
I1
I-1
tp40085
sS'agents,in,pharmacokinetic'
p40086
(F1
F0.00014334862385321102
I0
I1
I-1
tp40087
sS'blocking,agents,calcium'
p40088
(F1
F0.00014334862385321102
I0
I1
I-1
tp40089
sS'concentrations,of,should'
p40090
(F1
F0.00043004587155963305
I3
I0
I3
tp40091
sS'ingesting,the,steadystate'
p40092
(F1
F0.00014334862385321102
I0
I1
I-1
tp40093
sS'to,the,disruptive'
p40094
(F1
F0.00014334862385321102
I1
I0
I1
tp40095
sS'have,been,demonstrated'
p40096
(F1
F0.00014334862385321102
I0
I1
I-1
tp40097
sS'n,resulted,in'
p40098
(F1
F0.00014334862385321102
I1
I0
I1
tp40099
sS'the,therapeutic,action'
p40100
(F1
F0.00014334862385321102
I1
I0
I1
tp40101
sS'anticoagulants,combination,hormonal'
p40102
(F1
F0.00014334862385321102
I1
I0
I1
tp40103
sS'the,may,occur'
p40104
(F1
F0.00014334862385321102
I1
I0
I1
tp40105
sS'depressants,or,should'
p40106
(F1
F0.00014334862385321102
I1
I0
I1
tp40107
sS'of,g,hour'
p40108
(F1
F0.00014334862385321102
I1
I0
I1
tp40109
sS'be,reduced,when'
p40110
(F1
F0.00014334862385321102
I1
I0
I1
tp40111
sS'avastin,when,compared'
p40112
(F1
F0.00014334862385321102
I0
I1
I-1
tp40113
sS'are,not,sufficient'
p40114
(F1
F0.00014334862385321102
I0
I1
I-1
tp40115
sS'the,steady-state,plasma'
p40116
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp40117
sS'agents,leading,to'
p40118
(F1
F0.00043004587155963305
I3
I0
I3
tp40119
sS'drugs,significant,decreases'
p40120
(F1
F0.00014334862385321102
I1
I0
I1
tp40121
sS'substances,the,following'
p40122
(F1
F0.00014334862385321102
I1
I0
I1
tp40123
sS'toxicity,possibly,due'
p40124
(F1
F0.00028669724770642203
I2
I0
I2
tp40125
sS'known,hence,is'
p40126
(F1
F0.00014334862385321102
I1
I0
I1
tp40127
sS'in,a,higher'
p40128
(F1
F0.00014334862385321102
I1
I0
I1
tp40129
sS'therapy,free,may'
p40130
(F1
F0.00014334862385321102
I1
I0
I1
tp40131
sS'mic,of,flucoxacillin'
p40132
(F1
F0.00014334862385321102
I0
I1
I-1
tp40133
sS'to,a,interaction'
p40134
(F1
F0.00014334862385321102
I1
I0
I1
tp40135
sS'alteration,caused,by'
p40136
(F1
F0.00014334862385321102
I0
I1
I-1
tp40137
sS'the,aim,of'
p40138
(F1
F0.00028669724770642203
I0
I2
I-2
tp40139
sS'with,an,active'
p40140
(F1
F0.00014334862385321102
I0
I1
I-1
tp40141
sS'coadministered,with,dopa'
p40142
(F1
F0.00014334862385321102
I0
I1
I-1
tp40143
sS'effects,of,during'
p40144
(F1
F0.00014334862385321102
I0
I1
I-1
tp40145
sS'of,m,ptx'
p40146
(F1
F0.00014334862385321102
I1
I0
I1
tp40147
sS'weeks,after,initiating'
p40148
(F1
F0.00014334862385321102
I1
I0
I1
tp40149
sS'by,the,they'
p40150
(F1
F0.00014334862385321102
I1
I0
I1
tp40151
sS'could,be,the'
p40152
(F1
F0.00014334862385321102
I0
I1
I-1
tp40153
sS'treatment,with,inhibitors'
p40154
(F1
F0.00014334862385321102
I1
I0
I1
tp40155
sS'given,as,tablets'
p40156
(F1
F0.00014334862385321102
I0
I1
I-1
tp40157
sS'as,myelosuppression,and'
p40158
(F1
F0.00014334862385321102
I1
I0
I1
tp40159
sS'diabetes,there,were'
p40160
(F1
F0.00014334862385321102
I0
I1
I-1
tp40161
sS'concomitantly,should,have'
p40162
(F1
F0.00014334862385321102
I1
I0
I1
tp40163
sS'with,there,was'
p40164
(F1
F0.00014334862385321102
I1
I0
I1
tp40165
sS'was,to,determine'
p40166
(F1
F0.00014334862385321102
I0
I1
I-1
tp40167
sS'detoxification,of,is'
p40168
(F1
F0.00014334862385321102
I1
I0
I1
tp40169
sS'with,prinivil,at'
p40170
(F1
F0.00014334862385321102
I1
I0
I1
tp40171
sS'of,st,john'
p40172
(F1
F0.00014334862385321102
I0
I1
I-1
tp40173
sS'have,long,half-lives'
p40174
(F1
F0.00014334862385321102
I0
I1
I-1
tp40175
sS'to,bleeding,associated'
p40176
(F1
F0.00014334862385321102
I1
I0
I1
tp40177
sS'lodine,can,give'
p40178
(F1
F0.00014334862385321102
I0
I1
I-1
tp40179
sS'events,was,similar'
p40180
(F1
F0.00014334862385321102
I0
I1
I-1
tp40181
sS'day,there,were'
p40182
(F1
F0.00014334862385321102
I0
I1
I-1
tp40183
sS'creatinine,and,serum'
p40184
(F1
F0.00014334862385321102
I1
I0
I1
tp40185
sS'care,in,patients'
p40186
(F1
F0.00043004587155963305
I3
I0
I3
tp40187
sS'levels,possibly,by'
p40188
(F1
F0.00014334862385321102
I1
I0
I1
tp40189
sS'products,associated,with'
p40190
(F1
F0.00014334862385321102
I0
I1
I-1
tp40191
sS'reported,in,patients'
p40192
(F0.90476190476190477
F0.0027236238532110093
I20
I1
I19
tp40193
sS'and,are,sequestered'
p40194
(F1
F0.00014334862385321102
I0
I1
I-1
tp40195
sS'bile,acid,sequestrants'
p40196
(F1
F0.00014334862385321102
I1
I0
I1
tp40197
sS'levels,in,all'
p40198
(F1
F0.00014334862385321102
I1
I0
I1
tp40199
sS'of,other,that'
p40200
(F1
F0.00014334862385321102
I1
I0
I1
tp40201
sS'study,in,normal'
p40202
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp40203
sS'argatroban,and,mg'
p40204
(F0
F0
I1
I1
I0
tp40205
sS'a,interaction,between'
p40206
(F1
F0.00014334862385321102
I1
I0
I1
tp40207
sS'that,can,reduce'
p40208
(F1
F0.00014334862385321102
I1
I0
I1
tp40209
sS'in,a,to'
p40210
(F1
F0.00014334862385321102
I1
I0
I1
tp40211
sS'vasodilator,properties,on'
p40212
(F1
F0.00014334862385321102
I0
I1
I-1
tp40213
sS'in,liver,enzymes'
p40214
(F1
F0.00014334862385321102
I1
I0
I1
tp40215
sS'twice,daily,mg'
p40216
(F1
F0.00014334862385321102
I0
I1
I-1
tp40217
sS'oral,or,have'
p40218
(F1
F0.00014334862385321102
I0
I1
I-1
tp40219
sS'should,be,titrated'
p40220
(F1
F0.00014334862385321102
I1
I0
I1
tp40221
sS'authors,investigated,the'
p40222
(F1
F0.00014334862385321102
I0
I1
I-1
tp40223
sS'who,were,randomly'
p40224
(F1
F0.00014334862385321102
I0
I1
I-1
tp40225
sS'these,medicines,may'
p40226
(F1
F0.00057339449541284407
I0
I4
I-4
tp40227
sS'decreased,slightly,from'
p40228
(F1
F0.00014334862385321102
I1
I0
I1
tp40229
sS'however,the,peak'
p40230
(F1
F0.00014334862385321102
I1
I0
I1
tp40231
sS'erythrocyte,acetylcholinesterase,ache'
p40232
(F1
F0.00014334862385321102
I1
I0
I1
tp40233
sS'theo-dur,key,pharmaceuticals'
p40234
(F1
F0.00014334862385321102
I1
I0
I1
tp40235
sS'with,nalfon,may'
p40236
(F1
F0.00014334862385321102
I1
I0
I1
tp40237
sS'in,the,adverse'
p40238
(F1
F0.00014334862385321102
I0
I1
I-1
tp40239
sS'either,or,its'
p40240
(F1
F0.00014334862385321102
I0
I1
I-1
tp40241
sS'with,plus,catecholamine'
p40242
(F1
F0.00014334862385321102
I1
I0
I1
tp40243
sS'easy,and,can'
p40244
(F1
F0.00014334862385321102
I0
I1
I-1
tp40245
sS'and,effects,of'
p40246
(F1
F0.00071674311926605509
I5
I0
I5
tp40247
sS'is,necessary,to'
p40248
(F1
F0.00014334862385321102
I1
I0
I1
tp40249
sS'and,effects,on'
p40250
(F1
F0.00014334862385321102
I0
I1
I-1
tp40251
sS'nuromax,before,to'
p40252
(F1
F0.00014334862385321102
I0
I1
I-1
tp40253
sS'demonstrate,that,with'
p40254
(F1
F0.00014334862385321102
I0
I1
I-1
tp40255
sS'orally,as,mg'
p40256
(F1
F0.00028669724770642203
I2
I0
I2
tp40257
sS'using,such,as'
p40258
(F1
F0.00014334862385321102
I1
I0
I1
tp40259
sS'inducers,are,taken'
p40260
(F1
F0.00014334862385321102
I1
I0
I1
tp40261
sS'added,or,deleted'
p40262
(F1
F0.00028669724770642203
I2
I0
I2
tp40263
sS'vs,and,tmax'
p40264
(F1
F0.00014334862385321102
I0
I1
I-1
tp40265
sS'from,severe,enterocolitis'
p40266
(F1
F0.00014334862385321102
I1
I0
I1
tp40267
sS'effect,of,angiotensin'
p40268
(F1
F0.00028669724770642203
I2
I0
I2
tp40269
sS'been,reported,concomitant'
p40270
(F1
F0.00014334862385321102
I1
I0
I1
tp40271
sS'mefloquine,on,travelers'
p40272
(F1
F0.00014334862385321102
I1
I0
I1
tp40273
sS'decrease,in,phosphorylation'
p40274
(F1
F0.00014334862385321102
I1
I0
I1
tp40275
sS'prescription,of,to'
p40276
(F1
F0.00014334862385321102
I1
I0
I1
tp40277
sS'synergistic,effect,with'
p40278
(F1
F0.00014334862385321102
I1
I0
I1
tp40279
sS'and,to,groups'
p40280
(F1
F0.00014334862385321102
I0
I1
I-1
tp40281
sS'although,inhibition,of'
p40282
(F1
F0.00014334862385321102
I0
I1
I-1
tp40283
sS'anti-inflammatory,agents,in'
p40284
(F1
F0.00028669724770642203
I2
I0
I2
tp40285
sS'on,exjade,pharmacokinetics'
p40286
(F1
F0.00014334862385321102
I0
I1
I-1
tp40287
sS'levels,and,clearance'
p40288
(F1
F0.00014334862385321102
I0
I1
I-1
tp40289
sS'microg,ml,when'
p40290
(F1
F0.00014334862385321102
I0
I1
I-1
tp40291
sS'however,serum,levels'
p40292
(F1
F0.00014334862385321102
I1
I0
I1
tp40293
sS'was,administered,with'
p40294
(F0
F0
I2
I2
I0
tp40295
sS'mg,of,vardenafil'
p40296
(F1
F0.00043004587155963305
I3
I0
I3
tp40297
sS'with,multivalent,cation-containing'
p40298
(F1
F0.00014334862385321102
I1
I0
I1
tp40299
sS'in,an,interaction'
p40300
(F1
F0.00014334862385321102
I0
I1
I-1
tp40301
sS'first,response,was'
p40302
(F1
F0.00014334862385321102
I0
I1
I-1
tp40303
sS'this,study,the'
p40304
(F1
F0.00014334862385321102
I0
I1
I-1
tp40305
sS'exists,between,the'
p40306
(F1
F0.00014334862385321102
I0
I1
I-1
tp40307
sS'containing,mg,of'
p40308
(F0
F0
I1
I1
I0
tp40309
sS'administering,with,since'
p40310
(F1
F0.00014334862385321102
I1
I0
I1
tp40311
sS'another,study,showed'
p40312
(F1
F0.00014334862385321102
I0
I1
I-1
tp40313
sS'cyp,a4,or'
p40314
(F1
F0.00014334862385321102
I1
I0
I1
tp40315
sS'increase,excretion,of'
p40316
(F1
F0.00014334862385321102
I0
I1
I-1
tp40317
sS'radiographic,iodinated,contrast'
p40318
(F1
F0.00014334862385321102
I1
I0
I1
tp40319
sS'during,photic,stimulation'
p40320
(F1
F0.00014334862385321102
I0
I1
I-1
tp40321
sS'to,avoid,this'
p40322
(F1
F0.00014334862385321102
I1
I0
I1
tp40323
sS'careful,observations,on'
p40324
(F1
F0.00014334862385321102
I1
I0
I1
tp40325
sS'furosemide,administered,concurrently'
p40326
(F1
F0.00014334862385321102
I0
I1
I-1
tp40327
sS'test,interaction,because'
p40328
(F1
F0.00014334862385321102
I0
I1
I-1
tp40329
sS'with,tambocor,are'
p40330
(F1
F0.00014334862385321102
I1
I0
I1
tp40331
sS'of,and,k'
p40332
(F1
F0.00028669724770642203
I2
I0
I2
tp40333
sS'of,and,g'
p40334
(F1
F0.00014334862385321102
I1
I0
I1
tp40335
sS'is,required,to'
p40336
(F1
F0.00014334862385321102
I1
I0
I1
tp40337
sS'of,and,a'
p40338
(F1
F0.0008600917431192661
I6
I0
I6
tp40339
sS'in,clotting,time'
p40340
(F1
F0.00028669724770642203
I0
I2
I-2
tp40341
sS'bind,other,drugs'
p40342
(F1
F0.00014334862385321102
I0
I1
I-1
tp40343
sS'are,examples,of'
p40344
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp40345
sS'during,treatment,with'
p40346
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp40347
sS'logarithmic,fashion,from'
p40348
(F1
F0.00014334862385321102
I0
I1
I-1
tp40349
sS'not,studied,with'
p40350
(F1
F0.00014334862385321102
I1
I0
I1
tp40351
sS'of,and,during'
p40352
(F1
F0.00014334862385321102
I0
I1
I-1
tp40353
sS'the,intake,of'
p40354
(F1
F0.00014334862385321102
I1
I0
I1
tp40355
sS'incidence,of,endoscopic'
p40356
(F1
F0.00014334862385321102
I0
I1
I-1
tp40357
sS'formed,via,cyp3a4'
p40358
(F1
F0.00014334862385321102
I0
I1
I-1
tp40359
sS'that,acarbose,has'
p40360
(F1
F0.00014334862385321102
I0
I1
I-1
tp40361
sS'and,therapy,a'
p40362
(F1
F0.00028669724770642203
I2
I0
I2
tp40363
sS'the,management,of'
p40364
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp40365
sS'has,a,less'
p40366
(F1
F0.00014334862385321102
I1
I0
I1
tp40367
sS'other,narcotic,general'
p40368
(F1
F0.00014334862385321102
I1
I0
I1
tp40369
sS'maximal,hypotension,was'
p40370
(F1
F0.00014334862385321102
I0
I1
I-1
tp40371
sS'persists,as,long'
p40372
(F1
F0.00014334862385321102
I1
I0
I1
tp40373
sS'or,known,to'
p40374
(F1
F0.00014334862385321102
I1
I0
I1
tp40375
sS'key,pharmaceuticals,inc'
p40376
(F1
F0.00014334862385321102
I1
I0
I1
tp40377
sS'had,little,or'
p40378
(F1
F0.00014334862385321102
I0
I1
I-1
tp40379
sS'in,addition,we'
p40380
(F1
F0.00014334862385321102
I0
I1
I-1
tp40381
sS'and,did,not'
p40382
(F0.81818181818181823
F0.0012901376146788992
I1
I10
I-9
tp40383
sS'the,mediation,of'
p40384
(F1
F0.00014334862385321102
I0
I1
I-1
tp40385
sS'administered,with,vaprisol'
p40386
(F1
F0.00014334862385321102
I1
I0
I1
tp40387
sS'doses,of,may'
p40388
(F1
F0.0010034403669724771
I7
I0
I7
tp40389
sS'pharmacokinetics,except,that'
p40390
(F1
F0.00014334862385321102
I1
I0
I1
tp40391
sS'carbamazepine,equetrotm,increases'
p40392
(F1
F0.00014334862385321102
I1
I0
I1
tp40393
sS'to,one-half,and'
p40394
(F1
F0.00014334862385321102
I0
I1
I-1
tp40395
sS'clarithromycin,is,a'
p40396
(F1
F0.00014334862385321102
I1
I0
I1
tp40397
sS'to,a,greater'
p40398
(F0
F0
I1
I1
I0
tp40399
sS'same,dose,of'
p40400
(F1
F0.00028669724770642203
I2
I0
I2
tp40401
sS'clinically,relevant,concentrations'
p40402
(F1
F0.00014334862385321102
I0
I1
I-1
tp40403
sS'or,increasing,salt'
p40404
(F1
F0.00014334862385321102
I1
I0
I1
tp40405
sS'no,capacity,to'
p40406
(F1
F0.00014334862385321102
I0
I1
I-1
tp40407
sS'p450iiia4,isozyme,and'
p40408
(F1
F0.00014334862385321102
I1
I0
I1
tp40409
sS'evaluated,using,comparisons'
p40410
(F1
F0.00014334862385321102
I0
I1
I-1
tp40411
sS'atacand,so,careful'
p40412
(F1
F0.00014334862385321102
I1
I0
I1
tp40413
sS'secretion,via,organic'
p40414
(F1
F0.00014334862385321102
I1
I0
I1
tp40415
sS'rings,with,intact'
p40416
(F1
F0.00014334862385321102
I1
I0
I1
tp40417
sS'vitro,and,or'
p40418
(F1
F0.00028669724770642203
I2
I0
I2
tp40419
sS'of,and,plasma'
p40420
(F1
F0.00014334862385321102
I1
I0
I1
tp40421
sS'to,induce,both'
p40422
(F1
F0.00014334862385321102
I0
I1
I-1
tp40423
sS'days,was,decreased'
p40424
(F1
F0.00014334862385321102
I1
I0
I1
tp40425
sS'volunteers,taking,mg'
p40426
(F1
F0.00014334862385321102
I1
I0
I1
tp40427
sS'a,with,any'
p40428
(F1
F0.00014334862385321102
I1
I0
I1
tp40429
sS'aspirin,concomitant,administration'
p40430
(F1
F0.00043004587155963305
I3
I0
I3
tp40431
sS'activation,of,vitamin-d'
p40432
(F1
F0.00014334862385321102
I0
I1
I-1
tp40433
sS's,disease,medications'
p40434
(F1
F0.00014334862385321102
I0
I1
I-1
tp40435
sS'panretin,gel,should'
p40436
(F1
F0.00014334862385321102
I1
I0
I1
tp40437
sS'antithyroid,b-adrenergic,blocking'
p40438
(F1
F0.00014334862385321102
I0
I1
I-1
tp40439
sS'drugs,that,should'
p40440
(F0
F0
I1
I1
I0
tp40441
sS'separated,by,hours'
p40442
(F1
F0.00014334862385321102
I1
I0
I1
tp40443
sS'receiving,concomitant,antihypertensive'
p40444
(F1
F0.00014334862385321102
I1
I0
I1
tp40445
sS'the,are,a'
p40446
(F1
F0.00028669724770642203
I0
I2
I-2
tp40447
sS'plasma,levels,be'
p40448
(F1
F0.00014334862385321102
I1
I0
I1
tp40449
sS'plasma,levels,by'
p40450
(F1
F0.00028669724770642203
I2
I0
I2
tp40451
sS'monitoring,for,known'
p40452
(F1
F0.00014334862385321102
I1
I0
I1
tp40453
sS'enzyme,inducers,indicate'
p40454
(F1
F0.00014334862385321102
I1
I0
I1
tp40455
sS'laboratory,assessments,of'
p40456
(F1
F0.00014334862385321102
I0
I1
I-1
tp40457
sS'renal,uptake,to'
p40458
(F1
F0.00014334862385321102
I1
I0
I1
tp40459
sS'be,mixed,with'
p40460
(F1
F0.00043004587155963305
I0
I3
I-3
tp40461
sS'with,and,placebo'
p40462
(F1
F0.00014334862385321102
I0
I1
I-1
tp40463
sS'attenuating,s,influence'
p40464
(F1
F0.00014334862385321102
I1
I0
I1
tp40465
sS'risks,of,cns'
p40466
(F1
F0.00014334862385321102
I1
I0
I1
tp40467
sS'oral,solution,may'
p40468
(F1
F0.00057339449541284407
I4
I0
I4
tp40469
sS'antibiotics,chloramphenicol,or'
p40470
(F1
F0.00014334862385321102
I1
I0
I1
tp40471
sS'and,current,responses'
p40472
(F1
F0.00014334862385321102
I1
I0
I1
tp40473
sS'their,dosage,when'
p40474
(F1
F0.00014334862385321102
I1
I0
I1
tp40475
sS'treatment,which,causes'
p40476
(F1
F0.00014334862385321102
I1
I0
I1
tp40477
sS'to,concurrent,administration'
p40478
(F1
F0.00014334862385321102
I1
I0
I1
tp40479
sS'oral-dose,clearance,by'
p40480
(F1
F0.00014334862385321102
I1
I0
I1
tp40481
sS'to,mac,or'
p40482
(F1
F0.00014334862385321102
I0
I1
I-1
tp40483
sS'submitted,to,a'
p40484
(F1
F0.00014334862385321102
I0
I1
I-1
tp40485
sS'enhanced,the,likelihood'
p40486
(F1
F0.00014334862385321102
I1
I0
I1
tp40487
sS'rate,compared,with'
p40488
(F1
F0.00014334862385321102
I1
I0
I1
tp40489
sS'beta-naltrexol,were,unaffected'
p40490
(F1
F0.00014334862385321102
I0
I1
I-1
tp40491
sS'the,relevance,of'
p40492
(F1
F0.00014334862385321102
I1
I0
I1
tp40493
sS'with,these,medicines'
p40494
(F1
F0.00043004587155963305
I0
I3
I-3
tp40495
sS'patients,with,coronary'
p40496
(F1
F0.00014334862385321102
I0
I1
I-1
tp40497
sS'bactrim,septra,gantrisin'
p40498
(F1
F0.00014334862385321102
I0
I1
I-1
tp40499
sS'these,agents,including'
p40500
(F1
F0.00014334862385321102
I0
I1
I-1
tp40501
sS'lean,animals,where'
p40502
(F1
F0.00014334862385321102
I0
I1
I-1
tp40503
sS'intestinal,permeation,of'
p40504
(F1
F0.00028669724770642203
I0
I2
I-2
tp40505
sS'on,clonidines,analgesic'
p40506
(F1
F0.00014334862385321102
I0
I1
I-1
tp40507
sS'of,lapatinib,on'
p40508
(F1
F0.00014334862385321102
I0
I1
I-1
tp40509
sS'human,liver,are'
p40510
(F1
F0.00014334862385321102
I0
I1
I-1
tp40511
sS'clinical,pharmacology,study'
p40512
(F0
F0
I1
I1
I0
tp40513
sS'cyp,c9,substrates'
p40514
(F1
F0.00014334862385321102
I0
I1
I-1
tp40515
sS'oxidase,inhibitors,should'
p40516
(F1
F0.00014334862385321102
I1
I0
I1
tp40517
sS'make,normal,metabolizers'
p40518
(F1
F0.00014334862385321102
I0
I1
I-1
tp40519
sS'prescribed,to,control'
p40520
(F1
F0.00014334862385321102
I1
I0
I1
tp40521
sS'preparations,minipills,that'
p40522
(F1
F0.00014334862385321102
I1
I0
I1
tp40523
sS'of,argatroban,and'
p40524
(F0
F0
I1
I1
I0
tp40525
sS'by,a,corresponding'
p40526
(F1
F0.00014334862385321102
I1
I0
I1
tp40527
sS'coadministered,with,the'
p40528
(F1
F0.00014334862385321102
I1
I0
I1
tp40529
sS'exhibits,non-linear,pharmacokinetics'
p40530
(F1
F0.00014334862385321102
I1
I0
I1
tp40531
sS'evidence,of,incompatibility'
p40532
(F1
F0.00028669724770642203
I0
I2
I-2
tp40533
sS'of,precedex,with'
p40534
(F1
F0.00014334862385321102
I1
I0
I1
tp40535
sS'the,replication,of'
p40536
(F1
F0.00014334862385321102
I1
I0
I1
tp40537
sS'possible,with,some'
p40538
(F1
F0.00014334862385321102
I0
I1
I-1
tp40539
sS'potentiated,apparently,by'
p40540
(F1
F0.00014334862385321102
I0
I1
I-1
tp40541
sS'be,exercised,when'
p40542
(F0.42857142857142855
F0.0008600917431192661
I10
I4
I6
tp40543
sS'have,additive,effects'
p40544
(F1
F0.00028669724770642203
I2
I0
I2
tp40545
sS'period,particularly,at'
p40546
(F1
F0.00014334862385321102
I1
I0
I1
tp40547
sS'form,of,at'
p40548
(F1
F0.00014334862385321102
I0
I1
I-1
tp40549
sS'were,prohibited,in'
p40550
(F1
F0.00014334862385321102
I0
I1
I-1
tp40551
sS'not,affected,during'
p40552
(F1
F0.00028669724770642203
I0
I2
I-2
tp40553
sS'acid,concentrations,prior'
p40554
(F1
F0.00014334862385321102
I0
I1
I-1
tp40555
sS'for,any,conclusions'
p40556
(F1
F0.00014334862385321102
I0
I1
I-1
tp40557
sS'this,medicine,certain'
p40558
(F1
F0.00014334862385321102
I0
I1
I-1
tp40559
sS'and,the,concomitant'
p40560
(F0
F0
I1
I1
I0
tp40561
sS'a,may,increase'
p40562
(F1
F0.00014334862385321102
I1
I0
I1
tp40563
sS'dosing,with,because'
p40564
(F1
F0.00014334862385321102
I1
I0
I1
tp40565
sS'dopa,decarboxylase,inhibitor'
p40566
(F1
F0.00014334862385321102
I0
I1
I-1
tp40567
sS'every,hours,are'
p40568
(F1
F0.00014334862385321102
I1
I0
I1
tp40569
sS'hormonal,differ,in'
p40570
(F1
F0.00014334862385321102
I0
I1
I-1
tp40571
sS'and,single,dose'
p40572
(F1
F0.00014334862385321102
I0
I1
I-1
tp40573
sS'tnf-blocking,agent,has'
p40574
(F1
F0.00014334862385321102
I1
I0
I1
tp40575
sS'the,following,cisplatin'
p40576
(F1
F0.00014334862385321102
I1
I0
I1
tp40577
sS'isoenzymes,caution,should'
p40578
(F1
F0.00014334862385321102
I1
I0
I1
tp40579
sS'mao,inhibitor,may'
p40580
(F1
F0.00014334862385321102
I1
I0
I1
tp40581
sS'of,when,used'
p40582
(F1
F0.00014334862385321102
I1
I0
I1
tp40583
sS'colorectal,cancer,were'
p40584
(F1
F0.00014334862385321102
I0
I1
I-1
tp40585
sS'albendazole,mg,kg'
p40586
(F1
F0.00014334862385321102
I1
I0
I1
tp40587
sS'may,alter,a'
p40588
(F1
F0.00014334862385321102
I1
I0
I1
tp40589
sS'for,vitamin,d'
p40590
(F1
F0.00043004587155963305
I3
I0
I3
tp40591
sS'other,chemotherapy,agents'
p40592
(F1
F0.00014334862385321102
I0
I1
I-1
tp40593
sS'than,in,patients'
p40594
(F1
F0.00014334862385321102
I1
I0
I1
tp40595
sS'a,useful,pharmacological'
p40596
(F1
F0.00014334862385321102
I0
I1
I-1
tp40597
sS'such,as,narcotics'
p40598
(F1
F0.00014334862385321102
I1
I0
I1
tp40599
sS'including,indocin,has'
p40600
(F1
F0.00014334862385321102
I1
I0
I1
tp40601
sS'approved,for,clinical'
p40602
(F1
F0.00014334862385321102
I0
I1
I-1
tp40603
sS'inhibitors,or,with'
p40604
(F1
F0.00014334862385321102
I1
I0
I1
tp40605
sS'cytochrome,p-450,inducers'
p40606
(F1
F0.00014334862385321102
I1
I0
I1
tp40607
sS'only,of,the'
p40608
(F1
F0.00014334862385321102
I0
I1
I-1
tp40609
sS'absorption,and,result'
p40610
(F1
F0.00014334862385321102
I1
I0
I1
tp40611
sS'of,starlix,and'
p40612
(F1
F0.00028669724770642203
I2
I0
I2
tp40613
sS'behavioral,changes,northern'
p40614
(F1
F0.00014334862385321102
I0
I1
I-1
tp40615
sS'and,invalidate,folic'
p40616
(F1
F0.00014334862385321102
I0
I1
I-1
tp40617
sS'and,decreased,measured'
p40618
(F1
F0.00014334862385321102
I1
I0
I1
tp40619
sS'antiarrhythmics,other,such'
p40620
(F1
F0.00014334862385321102
I0
I1
I-1
tp40621
sS'h,without,to'
p40622
(F1
F0.00014334862385321102
I1
I0
I1
tp40623
sS'itraconazole,plasma,concentrations'
p40624
(F1
F0.00014334862385321102
I1
I0
I1
tp40625
sS'that,serum,levels'
p40626
(F1
F0.00028669724770642203
I2
I0
I2
tp40627
sS'and,copegus,are'
p40628
(F1
F0.00014334862385321102
I0
I1
I-1
tp40629
sS'a,greater,extent'
p40630
(F1
F0.00014334862385321102
I0
I1
I-1
tp40631
sS'relaxation,of,mesenteric'
p40632
(F1
F0.00014334862385321102
I0
I1
I-1
tp40633
sS'pharmacokinetics,of,affected'
p40634
(F1
F0.00014334862385321102
I0
I1
I-1
tp40635
sS'the,ototoxic,potential'
p40636
(F1
F0.00028669724770642203
I2
I0
I2
tp40637
sS'ketoconazole,in,healthy'
p40638
(F1
F0.00014334862385321102
I1
I0
I1
tp40639
sS'significantly,greater,than'
p40640
(F1
F0.00014334862385321102
I0
I1
I-1
tp40641
sS'blood,glucose,was'
p40642
(F1
F0.00014334862385321102
I0
I1
I-1
tp40643
sS'minutes,to,min'
p40644
(F1
F0.00014334862385321102
I0
I1
I-1
tp40645
sS'mefloquine,and,other'
p40646
(F1
F0.00014334862385321102
I1
I0
I1
tp40647
sS'trileptal,doses,in'
p40648
(F1
F0.00014334862385321102
I1
I0
I1
tp40649
sS'additive,negative,inotropic'
p40650
(F1
F0.00014334862385321102
I1
I0
I1
tp40651
sS'unknown,slightly,shorter'
p40652
(F1
F0.00014334862385321102
I1
I0
I1
tp40653
sS'of,renal,failure'
p40654
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40655
sS'levels,of,previously'
p40656
(F1
F0.00014334862385321102
I0
I1
I-1
tp40657
sS'p,a,such'
p40658
(F1
F0.00014334862385321102
I1
I0
I1
tp40659
sS'that,modulates,in'
p40660
(F1
F0.00014334862385321102
I1
I0
I1
tp40661
sS'cancer,were,given'
p40662
(F1
F0.00014334862385321102
I0
I1
I-1
tp40663
sS'care,when,myocardial'
p40664
(F1
F0.00014334862385321102
I1
I0
I1
tp40665
sS'alter,the,effects'
p40666
(F1
F0.00043004587155963305
I0
I3
I-3
tp40667
sS'of,mice,treated'
p40668
(F1
F0.00014334862385321102
I0
I1
I-1
tp40669
sS'combined,with,against'
p40670
(F1
F0.00014334862385321102
I1
I0
I1
tp40671
sS'reported,during,therapy'
p40672
(F1
F0.00014334862385321102
I1
I0
I1
tp40673
sS'there,is,evidence'
p40674
(F1
F0.00014334862385321102
I0
I1
I-1
tp40675
sS'inducer,of,metabolism'
p40676
(F1
F0.00014334862385321102
I1
I0
I1
tp40677
sS'twice,daily,dose'
p40678
(F1
F0.00014334862385321102
I0
I1
I-1
tp40679
sS'of,the,supraventricular'
p40680
(F1
F0.00014334862385321102
I1
I0
I1
tp40681
sS'treated,with,monoamine'
p40682
(F1
F0.00028669724770642203
I2
I0
I2
tp40683
sS'co-administration,with,antifungal'
p40684
(F1
F0.00014334862385321102
I0
I1
I-1
tp40685
sS'inhibitor,has,been'
p40686
(F1
F0.00014334862385321102
I1
I0
I1
tp40687
sS'antagonists,drugs,that'
p40688
(F1
F0.00014334862385321102
I1
I0
I1
tp40689
sS'and,dosage,of'
p40690
(F1
F0.00043004587155963305
I0
I3
I-3
tp40691
sS'a,pulmonary,extract'
p40692
(F1
F0.00014334862385321102
I0
I1
I-1
tp40693
sS'and,antineoplastic,agents'
p40694
(F1
F0.00014334862385321102
I1
I0
I1
tp40695
sS'a,pharmacodynamic,interaction'
p40696
(F1
F0.00014334862385321102
I1
I0
I1
tp40697
sS'drugs,the,addition'
p40698
(F1
F0.00014334862385321102
I1
I0
I1
tp40699
sS'of,hypotensive,effects'
p40700
(F1
F0.00071674311926605509
I5
I0
I5
tp40701
sS'potential,differences,in'
p40702
(F1
F0.00014334862385321102
I0
I1
I-1
tp40703
sS'be,administered,concurrently'
p40704
(F1
F0.00057339449541284407
I4
I0
I4
tp40705
sS'increase,the,serum'
p40706
(F1
F0.00043004587155963305
I3
I0
I3
tp40707
sS'maximal,effects,of'
p40708
(F1
F0.00014334862385321102
I0
I1
I-1
tp40709
sS'of,exposure,to'
p40710
(F0
F0
I1
I1
I0
tp40711
sS'patients,with,heparin-induced'
p40712
(F1
F0.00014334862385321102
I0
I1
I-1
tp40713
sS'occurring,interactions,are'
p40714
(F1
F0.00014334862385321102
I1
I0
I1
tp40715
sS'zdv,as,shown'
p40716
(F1
F0.00014334862385321102
I1
I0
I1
tp40717
sS'a,single,study'
p40718
(F1
F0.00014334862385321102
I1
I0
I1
tp40719
sS'serotonin,releaser,and'
p40720
(F1
F0.00014334862385321102
I1
I0
I1
tp40721
sS'that,the,analgesic'
p40722
(F1
F0.00014334862385321102
I1
I0
I1
tp40723
sS'to,have,an'
p40724
(F0
F0
I1
I1
I0
tp40725
sS'hepatic,tissues,induced'
p40726
(F1
F0.00014334862385321102
I1
I0
I1
tp40727
sS'take,a,vitamin'
p40728
(F1
F0.00014334862385321102
I1
I0
I1
tp40729
sS'grapefruit,juice,co-administration'
p40730
(F1
F0.00014334862385321102
I0
I1
I-1
tp40731
sS'hydrochloride,ferrous,sulfate'
p40732
(F1
F0.00014334862385321102
I1
I0
I1
tp40733
sS'lamivudine,and,may'
p40734
(F1
F0.00014334862385321102
I1
I0
I1
tp40735
sS'effects,of,beta'
p40736
(F1
F0.00014334862385321102
I1
I0
I1
tp40737
sS'i,trial,using'
p40738
(F1
F0.00014334862385321102
I1
I0
I1
tp40739
sS'levels,of,agents'
p40740
(F1
F0.00014334862385321102
I1
I0
I1
tp40741
sS'normal,subjects,concurrent'
p40742
(F1
F0.00014334862385321102
I1
I0
I1
tp40743
sS'irreversible,brain,damage'
p40744
(F1
F0.00014334862385321102
I1
I0
I1
tp40745
sS'an,additive,cns'
p40746
(F1
F0.00014334862385321102
I1
I0
I1
tp40747
sS'such,as,nuromax'
p40748
(F1
F0.00014334862385321102
I1
I0
I1
tp40749
sS'result,in,fatal'
p40750
(F1
F0.00014334862385321102
I1
I0
I1
tp40751
sS'on,hormone,therapy'
p40752
(F1
F0.00014334862385321102
I0
I1
I-1
tp40753
sS'given,concurrently,patients'
p40754
(F1
F0.00014334862385321102
I1
I0
I1
tp40755
sS'auc,after,a'
p40756
(F1
F0.00014334862385321102
I1
I0
I1
tp40757
sS'tagamet,prozac,sporanox'
p40758
(F1
F0.00014334862385321102
I0
I1
I-1
tp40759
sS'inhibit,phosphatase,activities'
p40760
(F1
F0.00014334862385321102
I1
I0
I1
tp40761
sS'pancreatic,supplements,use'
p40762
(F1
F0.00014334862385321102
I1
I0
I1
tp40763
sS'depressants,such,as'
p40764
(F1
F0.00028669724770642203
I2
I0
I2
tp40765
sS'heart,medicine,may'
p40766
(F1
F0.00014334862385321102
I1
I0
I1
tp40767
sS'increase,toxicity,and'
p40768
(F1
F0.00014334862385321102
I0
I1
I-1
tp40769
sS'given,to,rats'
p40770
(F1
F0.00014334862385321102
I0
I1
I-1
tp40771
sS'given,to,healthy'
p40772
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40773
sS'be,seen,on'
p40774
(F1
F0.00014334862385321102
I1
I0
I1
tp40775
sS'brovana,at,steady-state'
p40776
(F1
F0.00014334862385321102
I0
I1
I-1
tp40777
sS'observed,when,norpace'
p40778
(F1
F0.00014334862385321102
I0
I1
I-1
tp40779
sS'were,neither,reversed'
p40780
(F1
F0.00014334862385321102
I1
I0
I1
tp40781
sS'co-administered,but,not'
p40782
(F1
F0.00014334862385321102
I0
I1
I-1
tp40783
sS'concentration,especially,in'
p40784
(F1
F0.00014334862385321102
I1
I0
I1
tp40785
sS'conclusions,single-dose,coadministration'
p40786
(F1
F0.00014334862385321102
I1
I0
I1
tp40787
sS'tosylate,these,are'
p40788
(F1
F0.00014334862385321102
I0
I1
I-1
tp40789
sS'epileptic,patients,lowered'
p40790
(F1
F0.00014334862385321102
I1
I0
I1
tp40791
sS'marked,bradycardia,or'
p40792
(F1
F0.00014334862385321102
I1
I0
I1
tp40793
sS'of,as,determined'
p40794
(F1
F0.00014334862385321102
I0
I1
I-1
tp40795
sS'and,may,interfere'
p40796
(F1
F0.00014334862385321102
I1
I0
I1
tp40797
sS'recommended,that,patients'
p40798
(F1
F0.00014334862385321102
I0
I1
I-1
tp40799
sS'of,mg,co-administered'
p40800
(F1
F0.00014334862385321102
I1
I0
I1
tp40801
sS'when,cancidas,and'
p40802
(F1
F0.00014334862385321102
I1
I0
I1
tp40803
sS'in,gastrointestinal,transit'
p40804
(F1
F0.00014334862385321102
I1
I0
I1
tp40805
sS'simulect,with,no'
p40806
(F1
F0.00014334862385321102
I0
I1
I-1
tp40807
sS'absence,of,did'
p40808
(F1
F0.00014334862385321102
I0
I1
I-1
tp40809
sS'bid,day,and'
p40810
(F0
F0
I1
I1
I0
tp40811
sS'isosorbide,dinitrate,chloride'
p40812
(F1
F0.00014334862385321102
I0
I1
I-1
tp40813
sS'patients,whose,hypertension'
p40814
(F1
F0.00014334862385321102
I1
I0
I1
tp40815
sS'kidney,homogenates,supplemented'
p40816
(F1
F0.00014334862385321102
I0
I1
I-1
tp40817
sS'not,alter,tromethamine'
p40818
(F1
F0.00014334862385321102
I0
I1
I-1
tp40819
sS'the,ccnu,is'
p40820
(F1
F0.00014334862385321102
I0
I1
I-1
tp40821
sS'cimetidine,increased,the'
p40822
(F1
F0.00014334862385321102
I1
I0
I1
tp40823
sS'dose,of,reduced'
p40824
(F1
F0.00014334862385321102
I0
I1
I-1
tp40825
sS'secretion,may,result'
p40826
(F1
F0.00014334862385321102
I1
I0
I1
tp40827
sS'may,exhibit,an'
p40828
(F1
F0.00028669724770642203
I2
I0
I2
tp40829
sS'ergotamine-containing,or,ergot-type'
p40830
(F1
F0.00043004587155963305
I3
I0
I3
tp40831
sS'of,ergotamine-containing,or'
p40832
(F1
F0.00043004587155963305
I3
I0
I3
tp40833
sS'with,and,and'
p40834
(F1
F0.00014334862385321102
I0
I1
I-1
tp40835
sS'measured,by,high-performance'
p40836
(F1
F0.00014334862385321102
I0
I1
I-1
tp40837
sS'and,blood,pressure'
p40838
(F1
F0.00028669724770642203
I2
I0
I2
tp40839
sS'in,males,and'
p40840
(F1
F0.00014334862385321102
I1
I0
I1
tp40841
sS'on,glycosides,may'
p40842
(F1
F0.00014334862385321102
I0
I1
I-1
tp40843
sS'pharmacokinetic,interaction,between'
p40844
(F0.55555555555555558
F0.00071674311926605509
I2
I7
I-5
tp40845
sS'indocin,can,reduce'
p40846
(F1
F0.00028669724770642203
I2
I0
I2
tp40847
sS'difluoro-2,propanol,to'
p40848
(F0
F0
I1
I1
I0
tp40849
sS'of,inhibition,and'
p40850
(F1
F0.00071674311926605509
I5
I0
I5
tp40851
sS'are,negatively,coupled'
p40852
(F1
F0.00014334862385321102
I0
I1
I-1
tp40853
sS'in,approximately,fold'
p40854
(F1
F0.00028669724770642203
I0
I2
I-2
tp40855
sS'therapy,administration,of'
p40856
(F1
F0.00014334862385321102
I0
I1
I-1
tp40857
sS'potassium-containing,salt,substitutes'
p40858
(F0
F0
I1
I1
I0
tp40859
sS'epidemiological,studies,of'
p40860
(F1
F0.00014334862385321102
I1
I0
I1
tp40861
sS'effects,with,beta-adrenergic'
p40862
(F1
F0.00014334862385321102
I1
I0
I1
tp40863
sS'of,aprepitant,may'
p40864
(F1
F0.00014334862385321102
I1
I0
I1
tp40865
sS'with,significantly,fewer'
p40866
(F1
F0.00014334862385321102
I0
I1
I-1
tp40867
sS'prothrombin,test,results'
p40868
(F1
F0.00014334862385321102
I0
I1
I-1
tp40869
sS'or,inhibition,of'
p40870
(F1
F0.00014334862385321102
I0
I1
I-1
tp40871
sS'affect,plasma,concentrations'
p40872
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp40873
sS'concentrations,and,urinary'
p40874
(F1
F0.00014334862385321102
I1
I0
I1
tp40875
sS'glycemia,after,overload'
p40876
(F1
F0.00014334862385321102
I0
I1
I-1
tp40877
sS'and,possible,toxicity'
p40878
(F1
F0.00014334862385321102
I0
I1
I-1
tp40879
sS'in,addition,studies'
p40880
(F1
F0.00014334862385321102
I0
I1
I-1
tp40881
sS'antibiotics,and,agents'
p40882
(F1
F0.00014334862385321102
I1
I0
I1
tp40883
sS'inhibitors,and,has'
p40884
(F1
F0.00028669724770642203
I2
I0
I2
tp40885
sS'maalox,decreased,auc'
p40886
(F1
F0.00014334862385321102
I1
I0
I1
tp40887
sS'levels,to,below'
p40888
(F1
F0.00014334862385321102
I1
I0
I1
tp40889
sS'may,even,decrease'
p40890
(F1
F0.00014334862385321102
I0
I1
I-1
tp40891
sS'particularly,serotype,o11'
p40892
(F1
F0.00014334862385321102
I0
I1
I-1
tp40893
sS'termed,serotonin,syndrome'
p40894
(F1
F0.00014334862385321102
I1
I0
I1
tp40895
sS'aprepitant,mg,on'
p40896
(F1
F0.00014334862385321102
I1
I0
I1
tp40897
sS'toxicity,should,be'
p40898
(F1
F0.00028669724770642203
I2
I0
I2
tp40899
sS'increased,possibility,of'
p40900
(F1
F0.00028669724770642203
I2
I0
I2
tp40901
sS'of,are,reported'
p40902
(F1
F0.00014334862385321102
I1
I0
I1
tp40903
sS'dose,reduction,for'
p40904
(F1
F0.00014334862385321102
I0
I1
I-1
tp40905
sS'cyp3a4,cimetidine,cimetidine'
p40906
(F1
F0.00014334862385321102
I1
I0
I1
tp40907
sS'oral,or,did'
p40908
(F1
F0.00014334862385321102
I0
I1
I-1
tp40909
sS'd3,calcitriol,and'
p40910
(F1
F0.00043004587155963305
I3
I0
I3
tp40911
sS'study,and,nonsteroidal'
p40912
(F1
F0.00028669724770642203
I0
I2
I-2
tp40913
sS'been,reported,for'
p40914
(F1
F0.00014334862385321102
I0
I1
I-1
tp40915
sS'day,n,for'
p40916
(F1
F0.00014334862385321102
I0
I1
I-1
tp40917
sS'coadministration,of,tcas'
p40918
(F1
F0.00014334862385321102
I1
I0
I1
tp40919
sS'cimetidine,can,inhibit'
p40920
(F1
F0.00014334862385321102
I1
I0
I1
tp40921
sS'using,tricor,with'
p40922
(F1
F0.00014334862385321102
I1
I0
I1
tp40923
sS'co-administered,which,may'
p40924
(F1
F0.00014334862385321102
I1
I0
I1
tp40925
sS'rats,have,shown'
p40926
(F1
F0.00014334862385321102
I1
I0
I1
tp40927
sS'intramuscular,injection,of'
p40928
(F1
F0.00014334862385321102
I1
I0
I1
tp40929
sS'levels,have,been'
p40930
(F1
F0.00043004587155963305
I3
I0
I3
tp40931
sS'different,routes,a'
p40932
(F1
F0.00014334862385321102
I1
I0
I1
tp40933
sS'ketoprofen,does,not'
p40934
(F1
F0.00014334862385321102
I0
I1
I-1
tp40935
sS'an,adolescent,with'
p40936
(F1
F0.00014334862385321102
I1
I0
I1
tp40937
sS'and,an,deficiency'
p40938
(F1
F0.00014334862385321102
I1
I0
I1
tp40939
sS'patients,taking,celebrex'
p40940
(F0
F0
I1
I1
I0
tp40941
sS'in,diabetics,with'
p40942
(F1
F0.00014334862385321102
I1
I0
I1
tp40943
sS'in,three,pharmacokinetic'
p40944
(F1
F0.00014334862385321102
I0
I1
I-1
tp40945
sS'ergot,alkaloids,should'
p40946
(F1
F0.00014334862385321102
I1
I0
I1
tp40947
sS'isozyme,and,which'
p40948
(F1
F0.00014334862385321102
I1
I0
I1
tp40949
sS'or,mg,twice'
p40950
(F1
F0.00014334862385321102
I0
I1
I-1
tp40951
sS'of,were,increased'
p40952
(F1
F0.00014334862385321102
I0
I1
I-1
tp40953
sS'in,nucleoside-experienced,patients'
p40954
(F1
F0.00014334862385321102
I0
I1
I-1
tp40955
sS'oral,contraceptives,multiple'
p40956
(F1
F0.00028669724770642203
I0
I2
I-2
tp40957
sS'of,neuropathy,or'
p40958
(F1
F0.00014334862385321102
I0
I1
I-1
tp40959
sS'oral,adl,mg'
p40960
(F1
F0.00014334862385321102
I0
I1
I-1
tp40961
sS'anafranil,with,that'
p40962
(F1
F0.00014334862385321102
I0
I1
I-1
tp40963
sS'an,and,a'
p40964
(F1
F0.00014334862385321102
I1
I0
I1
tp40965
sS'be,avoided,in'
p40966
(F0.5
F0.00028669724770642203
I3
I1
I2
tp40967
sS'on,balance,testing'
p40968
(F1
F0.00014334862385321102
I1
I0
I1
tp40969
sS'occur,when,duragesic'
p40970
(F1
F0.00014334862385321102
I0
I1
I-1
tp40971
sS'the,alkaloid,class'
p40972
(F1
F0.00014334862385321102
I1
I0
I1
tp40973
sS'cause,a,rise'
p40974
(F1
F0.00014334862385321102
I1
I0
I1
tp40975
sS'potential,interaction,of'
p40976
(F1
F0.00028669724770642203
I2
I0
I2
tp40977
sS'adverse,reactions,thought'
p40978
(F1
F0.00014334862385321102
I0
I1
I-1
tp40979
sS'of,total,formation'
p40980
(F1
F0.00014334862385321102
I1
I0
I1
tp40981
sS'vitro,sodium,is'
p40982
(F1
F0.00014334862385321102
I0
I1
I-1
tp40983
sS'vitamin,e,mg'
p40984
(F1
F0.00014334862385321102
I1
I0
I1
tp40985
sS'or,verapamil,the'
p40986
(F1
F0.00014334862385321102
I1
I0
I1
tp40987
sS'or,fr,responding'
p40988
(F1
F0.00014334862385321102
I1
I0
I1
tp40989
sS'toxi-lab,a,thin-layer'
p40990
(F1
F0.00014334862385321102
I0
I1
I-1
tp40991
sS'development,of,dependence'
p40992
(F1
F0.00014334862385321102
I0
I1
I-1
tp40993
sS'with,the,contraceptive'
p40994
(F1
F0.00014334862385321102
I1
I0
I1
tp40995
sS'with,racemic,citalopram'
p40996
(F1
F0.00014334862385321102
I1
I0
I1
tp40997
sS'to,micrograms,caused'
p40998
(F1
F0.00014334862385321102
I1
I0
I1
tp40999
sS'time,ratio,or'
p41000
(F1
F0.00014334862385321102
I0
I1
I-1
tp41001
sS'treated,with,non-steroidal'
p41002
(F1
F0.00014334862385321102
I1
I0
I1
tp41003
sS'appropriate,adjustment,of'
p41004
(F0
F0
I1
I1
I0
tp41005
sS'disease,except,leukemia'
p41006
(F1
F0.00014334862385321102
I1
I0
I1
tp41007
sS'and,sgpt,alt'
p41008
(F1
F0.00014334862385321102
I1
I0
I1
tp41009
sS'to,continue,treatment'
p41010
(F1
F0.00014334862385321102
I1
I0
I1
tp41011
sS'pharmacokinetic,variables,of'
p41012
(F1
F0.00014334862385321102
I0
I1
I-1
tp41013
sS'should,be,considered'
p41014
(F0
F0
I10
I10
I0
tp41015
sS'in,this,category'
p41016
(F1
F0.00014334862385321102
I1
I0
I1
tp41017
sS'to,continue,to'
p41018
(F1
F0.00014334862385321102
I1
I0
I1
tp41019
sS'identified,potentially,significant'
p41020
(F1
F0.00014334862385321102
I1
I0
I1
tp41021
sS'receiving,gm,daily'
p41022
(F1
F0.00014334862385321102
I1
I0
I1
tp41023
sS'mg,bid,resulted'
p41024
(F1
F0.00014334862385321102
I1
I0
I1
tp41025
sS'days,with,co-administration'
p41026
(F1
F0.00014334862385321102
I1
I0
I1
tp41027
sS'for,and,were'
p41028
(F1
F0.00014334862385321102
I0
I1
I-1
tp41029
sS'to,the,administration'
p41030
(F0.5
F0.00028669724770642203
I3
I1
I2
tp41031
sS'with,tablets,usp'
p41032
(F1
F0.00014334862385321102
I1
I0
I1
tp41033
sS'to,a,randomized'
p41034
(F1
F0.00014334862385321102
I0
I1
I-1
tp41035
sS'daily,dose,is'
p41036
(F1
F0.00014334862385321102
I1
I0
I1
tp41037
sS'phenytoin,no,significant'
p41038
(F1
F0.00014334862385321102
I0
I1
I-1
tp41039
sS'the,excreted,levels'
p41040
(F1
F0.00014334862385321102
I0
I1
I-1
tp41041
sS'significantly,eliminated,by'
p41042
(F1
F0.00014334862385321102
I1
I0
I1
tp41043
sS'seen,in,cyp'
p41044
(F1
F0.00014334862385321102
I1
I0
I1
tp41045
sS'to,patients,receiving'
p41046
(F0.5
F0.0011467889908256881
I12
I4
I8
tp41047
sS'also,bleeding,and'
p41048
(F1
F0.00014334862385321102
I1
I0
I1
tp41049
sS'of,mg,qhs'
p41050
(F1
F0.00014334862385321102
I0
I1
I-1
tp41051
sS'containing,side,chains'
p41052
(F1
F0.00014334862385321102
I0
I1
I-1
tp41053
sS'of,isocarboxazid,and'
p41054
(F1
F0.00014334862385321102
I1
I0
I1
tp41055
sS'other,nsaids,may'
p41056
(F0
F0
I1
I1
I0
tp41057
sS'daily,dose,in'
p41058
(F1
F0.00014334862385321102
I0
I1
I-1
tp41059
sS'decrease,extracellular,levels'
p41060
(F1
F0.00014334862385321102
I0
I1
I-1
tp41061
sS'make,your,condition'
p41062
(F1
F0.00014334862385321102
I0
I1
I-1
tp41063
sS'dose,of,mg'
p41064
(F0.034482758620689655
F0.00014334862385321102
I14
I15
I-1
tp41065
sS'hepatic,cytochrome,p-450'
p41066
(F0
F0
I1
I1
I0
tp41067
sS'concomitant,treatment,with'
p41068
(F0.66666666666666663
F0.0011467889908256881
I10
I2
I8
tp41069
sS'to,withhold,during'
p41070
(F1
F0.00014334862385321102
I1
I0
I1
tp41071
sS'compounds,taken,concomitantly'
p41072
(F1
F0.00014334862385321102
I1
I0
I1
tp41073
sS'or,mg,per'
p41074
(F1
F0.00014334862385321102
I0
I1
I-1
tp41075
sS'cells,this,effect'
p41076
(F1
F0.00014334862385321102
I1
I0
I1
tp41077
sS'effectiveness,when,used'
p41078
(F1
F0.00014334862385321102
I0
I1
I-1
tp41079
sS'attenuates,loss,caused'
p41080
(F1
F0.00014334862385321102
I1
I0
I1
tp41081
sS'metabolized,by,cytochrome'
p41082
(F0.33333333333333331
F0.00043004587155963305
I3
I6
I-3
tp41083
sS'plasma,has,not'
p41084
(F1
F0.00014334862385321102
I1
I0
I1
tp41085
sS'of,previously,stable'
p41086
(F1
F0.00014334862385321102
I1
I0
I1
tp41087
sS'doses,in,vivo'
p41088
(F1
F0.00014334862385321102
I1
I0
I1
tp41089
sS'doses,of,either'
p41090
(F1
F0.00028669724770642203
I2
I0
I2
tp41091
sS'co-administration,with,other'
p41092
(F1
F0.00014334862385321102
I0
I1
I-1
tp41093
sS'emerge,with,the'
p41094
(F1
F0.00014334862385321102
I1
I0
I1
tp41095
sS'a,less,pronounced'
p41096
(F1
F0.00014334862385321102
I1
I0
I1
tp41097
sS'intravenous,or,other'
p41098
(F1
F0.00014334862385321102
I1
I0
I1
tp41099
sS'whether,or,or'
p41100
(F1
F0.00014334862385321102
I0
I1
I-1
tp41101
sS'may,reduce,pulse'
p41102
(F1
F0.00014334862385321102
I1
I0
I1
tp41103
sS'single,dose,bioavailability'
p41104
(F1
F0.00014334862385321102
I0
I1
I-1
tp41105
sS'cell,and,was'
p41106
(F1
F0.00014334862385321102
I0
I1
I-1
tp41107
sS'increase,the,dose'
p41108
(F0
F0
I1
I1
I0
tp41109
sS'of,sodium,is'
p41110
(F1
F0.00014334862385321102
I1
I0
I1
tp41111
sS'lithium,nonsteroidal,agents'
p41112
(F1
F0.00014334862385321102
I1
I0
I1
tp41113
sS'parameters,of,either'
p41114
(F1
F0.00014334862385321102
I0
I1
I-1
tp41115
sS'trilisate,disalcid,others'
p41116
(F1
F0.00014334862385321102
I1
I0
I1
tp41117
sS'd1,antagonist,sch-23390'
p41118
(F1
F0.00014334862385321102
I1
I0
I1
tp41119
sS'administered,within,hours'
p41120
(F1
F0.00014334862385321102
I1
I0
I1
tp41121
sS'which,has,not'
p41122
(F1
F0.00014334862385321102
I1
I0
I1
tp41123
sS'advised,to,obtain'
p41124
(F1
F0.00014334862385321102
I1
I0
I1
tp41125
sS'provoke,vasoconstriction,in'
p41126
(F1
F0.00014334862385321102
I1
I0
I1
tp41127
sS'plasma,protein,is'
p41128
(F1
F0.00014334862385321102
I0
I1
I-1
tp41129
sS'other,tnf-blocking,agents'
p41130
(F1
F0.00014334862385321102
I1
I0
I1
tp41131
sS'relevant,interactions,with'
p41132
(F1
F0.00014334862385321102
I0
I1
I-1
tp41133
sS'erectile,dysfunction,associated'
p41134
(F1
F0.00014334862385321102
I0
I1
I-1
tp41135
sS'lowering,effect,agents'
p41136
(F1
F0.00014334862385321102
I0
I1
I-1
tp41137
sS'brevibloc,concentrations,were'
p41138
(F1
F0.00014334862385321102
I1
I0
I1
tp41139
sS'injection,clonidine,may'
p41140
(F1
F0.00014334862385321102
I1
I0
I1
tp41141
sS'exceed,micrograms,g'
p41142
(F1
F0.00014334862385321102
I0
I1
I-1
tp41143
sS'no,clinically,meaningful'
p41144
(F1
F0.00028669724770642203
I0
I2
I-2
tp41145
sS'been,administered,with'
p41146
(F1
F0.00014334862385321102
I0
I1
I-1
tp41147
sS'clinical,trials,in'
p41148
(F1
F0.00014334862385321102
I1
I0
I1
tp41149
sS'of,acetate,in'
p41150
(F1
F0.00014334862385321102
I1
I0
I1
tp41151
sS'until,a,patient'
p41152
(F1
F0.00014334862385321102
I1
I0
I1
tp41153
sS'for,up,to'
p41154
(F1
F0.00043004587155963305
I3
I0
I3
tp41155
sS'yet,statistically,significant'
p41156
(F1
F0.00014334862385321102
I0
I1
I-1
tp41157
sS'rapidly,hydrolyzed,intravenous'
p41158
(F1
F0.00014334862385321102
I0
I1
I-1
tp41159
sS'describes,two,cases'
p41160
(F1
F0.00014334862385321102
I1
I0
I1
tp41161
sS'and,h2,antagonists'
p41162
(F1
F0.00014334862385321102
I0
I1
I-1
tp41163
sS'approximately,increase,in'
p41164
(F1
F0.00014334862385321102
I1
I0
I1
tp41165
sS'an,adverse,interaction'
p41166
(F1
F0.00014334862385321102
I0
I1
I-1
tp41167
sS'blockade,produced,by'
p41168
(F1
F0.00028669724770642203
I2
I0
I2
tp41169
sS'with,channel,blockers'
p41170
(F1
F0.00014334862385321102
I1
I0
I1
tp41171
sS'a,very,weak'
p41172
(F1
F0.00014334862385321102
I1
I0
I1
tp41173
sS'tablets,reduces,the'
p41174
(F1
F0.00014334862385321102
I1
I0
I1
tp41175
sS'symptoms,p,although'
p41176
(F1
F0.00014334862385321102
I0
I1
I-1
tp41177
sS'when,romazicon,was'
p41178
(F1
F0.00014334862385321102
I0
I1
I-1
tp41179
sS'should,be,followed'
p41180
(F1
F0.00014334862385321102
I0
I1
I-1
tp41181
sS'the,kidneys,coadministration'
p41182
(F1
F0.00014334862385321102
I0
I1
I-1
tp41183
sS'but,the,overall'
p41184
(F1
F0.00014334862385321102
I1
I0
I1
tp41185
sS'of,developing,an'
p41186
(F1
F0.00014334862385321102
I1
I0
I1
tp41187
sS'an,average,and'
p41188
(F1
F0.00014334862385321102
I1
I0
I1
tp41189
sS'suggest,the,need'
p41190
(F1
F0.00014334862385321102
I0
I1
I-1
tp41191
sS'and,other,thyroid'
p41192
(F1
F0.00014334862385321102
I0
I1
I-1
tp41193
sS'agents,which,increase'
p41194
(F1
F0.00014334862385321102
I1
I0
I1
tp41195
sS'with,incisive,by'
p41196
(F1
F0.00014334862385321102
I0
I1
I-1
tp41197
sS'from,the,combined'
p41198
(F1
F0.00014334862385321102
I1
I0
I1
tp41199
sS'ace,inhibitors,or'
p41200
(F1
F0.00014334862385321102
I0
I1
I-1
tp41201
sS'reported,following,concomitant'
p41202
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp41203
sS'administered,with,ethyl'
p41204
(F1
F0.00014334862385321102
I1
I0
I1
tp41205
sS'prolonged,by,concurrent'
p41206
(F1
F0.00014334862385321102
I1
I0
I1
tp41207
sS'patients,who,are'
p41208
(F1
F0.0018635321100917432
I13
I0
I13
tp41209
sS'oral,combination,of'
p41210
(F1
F0.00014334862385321102
I1
I0
I1
tp41211
sS'pupil,size,mydriasis'
p41212
(F1
F0.00014334862385321102
I1
I0
I1
tp41213
sS'were,observed,there'
p41214
(F1
F0.00014334862385321102
I0
I1
I-1
tp41215
sS'increase,the,danger'
p41216
(F1
F0.00014334862385321102
I1
I0
I1
tp41217
sS'improved,the,transport'
p41218
(F1
F0.00014334862385321102
I0
I1
I-1
tp41219
sS'to,rats,hours'
p41220
(F1
F0.00014334862385321102
I0
I1
I-1
tp41221
sS'sodium,and,other'
p41222
(F1
F0.00014334862385321102
I1
I0
I1
tp41223
sS'x,use,with'
p41224
(F1
F0.00014334862385321102
I0
I1
I-1
tp41225
sS'longitudinal,assessment,of'
p41226
(F1
F0.00014334862385321102
I0
I1
I-1
tp41227
sS'therapeutic,doses,of'
p41228
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp41229
sS'and,progestogen,administration'
p41230
(F1
F0.00014334862385321102
I0
I1
I-1
tp41231
sS'and,were,administered'
p41232
(F1
F0.00028669724770642203
I0
I2
I-2
tp41233
sS'revealed,that,mtx'
p41234
(F1
F0.00014334862385321102
I0
I1
I-1
tp41235
sS'exposure,by,approximately'
p41236
(F1
F0.00014334862385321102
I1
I0
I1
tp41237
sS'potential,for,duloxetine'
p41238
(F1
F0.00014334862385321102
I0
I1
I-1
tp41239
sS'cations,or,videx'
p41240
(F1
F0.00014334862385321102
I1
I0
I1
tp41241
sS't,i,d'
p41242
(F1
F0.00043004587155963305
I3
I0
I3
tp41243
sS'by,the,auc0-120hr'
p41244
(F1
F0.00014334862385321102
I1
I0
I1
tp41245
sS'with,hepatic,enzyme'
p41246
(F1
F0.00014334862385321102
I1
I0
I1
tp41247
sS'nonsteroidal,agents,some'
p41248
(F1
F0.00014334862385321102
I1
I0
I1
tp41249
sS'micrograms,ml,may'
p41250
(F1
F0.00014334862385321102
I0
I1
I-1
tp41251
sS'decreased,by,a'
p41252
(F1
F0.00014334862385321102
I1
I0
I1
tp41253
sS'nervous,system,cns'
p41254
(F0
F0
I1
I1
I0
tp41255
sS'initiated,as,a'
p41256
(F1
F0.00014334862385321102
I1
I0
I1
tp41257
sS'and,comparison,of'
p41258
(F1
F0.00014334862385321102
I0
I1
I-1
tp41259
sS'and,under,acidic'
p41260
(F1
F0.00014334862385321102
I1
I0
I1
tp41261
sS'at,different,levels'
p41262
(F1
F0.00014334862385321102
I0
I1
I-1
tp41263
sS'no,binding,displacement'
p41264
(F1
F0.00014334862385321102
I0
I1
I-1
tp41265
sS'altered,by,cyp3a4'
p41266
(F1
F0.00014334862385321102
I0
I1
I-1
tp41267
sS'moderate,to,severe'
p41268
(F1
F0.00014334862385321102
I1
I0
I1
tp41269
sS'with,fluvoxamine,tablets'
p41270
(F1
F0.00014334862385321102
I1
I0
I1
tp41271
sS'release,was,measured'
p41272
(F1
F0.00014334862385321102
I0
I1
I-1
tp41273
sS'exposures,of,and'
p41274
(F1
F0.00014334862385321102
I1
I0
I1
tp41275
sS'agents,monoamine,oxidase'
p41276
(F1
F0.00014334862385321102
I1
I0
I1
tp41277
sS'decreases,in,plasma'
p41278
(F1
F0.00014334862385321102
I1
I0
I1
tp41279
sS'to,c,p'
p41280
(F1
F0.00014334862385321102
I0
I1
I-1
tp41281
sS'infant,has,not'
p41282
(F1
F0.00014334862385321102
I0
I1
I-1
tp41283
sS'with,a,short-acting'
p41284
(F1
F0.00014334862385321102
I0
I1
I-1
tp41285
sS'that,if,casodex'
p41286
(F1
F0.00014334862385321102
I1
I0
I1
tp41287
sS'after,a,day'
p41288
(F1
F0.00014334862385321102
I0
I1
I-1
tp41289
sS'other,high,concentrations'
p41290
(F1
F0.00014334862385321102
I0
I1
I-1
tp41291
sS'mustard,etc,should'
p41292
(F1
F0.00014334862385321102
I0
I1
I-1
tp41293
sS'cyp,c9,and'
p41294
(F1
F0.00014334862385321102
I0
I1
I-1
tp41295
sS'analogues,vitamin,d2'
p41296
(F1
F0.00043004587155963305
I3
I0
I3
tp41297
sS'prinivil,was,used'
p41298
(F1
F0.00014334862385321102
I0
I1
I-1
tp41299
sS'in,plasma,exposure'
p41300
(F1
F0.00014334862385321102
I1
I0
I1
tp41301
sS'have,been,administered'
p41302
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp41303
sS'containing,or,as'
p41304
(F1
F0.00014334862385321102
I1
I0
I1
tp41305
sS'a,role,of'
p41306
(F1
F0.00014334862385321102
I0
I1
I-1
tp41307
sS'of,an,aluminum'
p41308
(F1
F0.00014334862385321102
I0
I1
I-1
tp41309
sS'effective,as,intravenous'
p41310
(F1
F0.00014334862385321102
I0
I1
I-1
tp41311
sS'hcl,and,a'
p41312
(F1
F0.00014334862385321102
I0
I1
I-1
tp41313
sS'this,interaction,include'
p41314
(F1
F0.00028669724770642203
I0
I2
I-2
tp41315
sS'isoenzyme,and,are'
p41316
(F1
F0.00014334862385321102
I0
I1
I-1
tp41317
sS'for,an,interaction'
p41318
(F1
F0.00014334862385321102
I0
I1
I-1
tp41319
sS'blood,platelets,by'
p41320
(F1
F0.00014334862385321102
I1
I0
I1
tp41321
sS'carefully,about,and'
p41322
(F1
F0.00014334862385321102
I0
I1
I-1
tp41323
sS'from,dietary-obese,rats'
p41324
(F1
F0.00028669724770642203
I0
I2
I-2
tp41325
sS'patients,receiving,purinethol'
p41326
(F1
F0.00014334862385321102
I1
I0
I1
tp41327
sS'adverse,experiences,in'
p41328
(F0
F0
I1
I1
I0
tp41329
sS'these,medicines,central'
p41330
(F1
F0.00014334862385321102
I1
I0
I1
tp41331
sS'displacement,of,in'
p41332
(F1
F0.00014334862385321102
I0
I1
I-1
tp41333
sS'chronic,or,therapy'
p41334
(F1
F0.00014334862385321102
I1
I0
I1
tp41335
sS'use,of,potassium-sparing'
p41336
(F1
F0.00014334862385321102
I0
I1
I-1
tp41337
sS'antifungals,in,vitro'
p41338
(F1
F0.00014334862385321102
I1
I0
I1
tp41339
sS'observed,when,and'
p41340
(F1
F0.00014334862385321102
I0
I1
I-1
tp41341
sS'and,n-acetyl,by'
p41342
(F1
F0.00014334862385321102
I0
I1
I-1
tp41343
sS'hypotensive,effects,can'
p41344
(F1
F0.00014334862385321102
I1
I0
I1
tp41345
sS'or,bleeding,have'
p41346
(F1
F0.00014334862385321102
I1
I0
I1
tp41347
sS'above,effects,concerning'
p41348
(F1
F0.00014334862385321102
I1
I0
I1
tp41349
sS'was,withdrawn,and'
p41350
(F1
F0.00014334862385321102
I0
I1
I-1
tp41351
sS'plus,to,those'
p41352
(F1
F0.00014334862385321102
I0
I1
I-1
tp41353
sS'vioxx,and,mg'
p41354
(F0
F0
I1
I1
I0
tp41355
sS'has,been,co-administered'
p41356
(F1
F0.00014334862385321102
I0
I1
I-1
tp41357
sS'occasionally,intensify,the'
p41358
(F1
F0.00014334862385321102
I1
I0
I1
tp41359
sS'and,hours,after'
p41360
(F1
F0.00014334862385321102
I1
I0
I1
tp41361
sS'risk,of,severe'
p41362
(F1
F0.00014334862385321102
I1
I0
I1
tp41363
sS'within,minutes,of'
p41364
(F1
F0.00014334862385321102
I1
I0
I1
tp41365
sS'oral,clearance,of'
p41366
(F1
F0.00014334862385321102
I1
I0
I1
tp41367
sS'certain,cyp450,enzymes'
p41368
(F1
F0.00014334862385321102
I0
I1
I-1
tp41369
sS'has,not,been'
p41370
(F0.090909090909090912
F0.00043004587155963305
I15
I18
I-3
tp41371
sS'vitamin,c,has'
p41372
(F1
F0.00014334862385321102
I0
I1
I-1
tp41373
sS'vasoconstrictor,can,combine'
p41374
(F1
F0.00014334862385321102
I1
I0
I1
tp41375
sS'formulation,of,was'
p41376
(F1
F0.00014334862385321102
I0
I1
I-1
tp41377
sS'incidence,or,severity'
p41378
(F1
F0.00014334862385321102
I1
I0
I1
tp41379
sS'inhibitor,nnrti,based'
p41380
(F1
F0.00014334862385321102
I0
I1
I-1
tp41381
sS'antifungal,agents,should'
p41382
(F1
F0.00014334862385321102
I1
I0
I1
tp41383
sS'reduced,clearance,based'
p41384
(F1
F0.00014334862385321102
I1
I0
I1
tp41385
sS'arrhythmias,may,mask'
p41386
(F1
F0.00014334862385321102
I0
I1
I-1
tp41387
sS'however,appear,to'
p41388
(F1
F0.00014334862385321102
I0
I1
I-1
tp41389
sS'by,the,initial'
p41390
(F1
F0.00014334862385321102
I1
I0
I1
tp41391
sS'days,n,or'
p41392
(F1
F0.00014334862385321102
I0
I1
I-1
tp41393
sS'effectiveness,of,pegasys'
p41394
(F1
F0.00014334862385321102
I0
I1
I-1
tp41395
sS'oral,cordarone,administration'
p41396
(F1
F0.00014334862385321102
I0
I1
I-1
tp41397
sS'combined,with,other'
p41398
(F1
F0.00028669724770642203
I2
I0
I2
tp41399
sS'discontinuation,of,or'
p41400
(F1
F0.00014334862385321102
I1
I0
I1
tp41401
sS'that,does,not'
p41402
(F1
F0.0011467889908256881
I0
I8
I-8
tp41403
sS's-warfarin,with,the'
p41404
(F1
F0.00014334862385321102
I0
I1
I-1
tp41405
sS'with,combined,use'
p41406
(F1
F0.00014334862385321102
I1
I0
I1
tp41407
sS'potentially,fatal,prolongation'
p41408
(F1
F0.00014334862385321102
I1
I0
I1
tp41409
sS'when,given,in'
p41410
(F1
F0.00028669724770642203
I0
I2
I-2
tp41411
sS'hours,does,not'
p41412
(F1
F0.00028669724770642203
I2
I0
I2
tp41413
sS'depresses,tubular,secretion'
p41414
(F1
F0.00014334862385321102
I1
I0
I1
tp41415
sS'hypoglycemia,have,been'
p41416
(F1
F0.00014334862385321102
I1
I0
I1
tp41417
sS'of,with,other'
p41418
(F0.16666666666666666
F0.00028669724770642203
I7
I5
I2
tp41419
sS'authors,compared,retrospectively'
p41420
(F1
F0.00014334862385321102
I0
I1
I-1
tp41421
sS'increased,its,effectiveness'
p41422
(F1
F0.00014334862385321102
I0
I1
I-1
tp41423
sS'drugs,which,require'
p41424
(F1
F0.00014334862385321102
I1
I0
I1
tp41425
sS'levels,could,lessen'
p41426
(F1
F0.00014334862385321102
I0
I1
I-1
tp41427
sS'potential,must,not'
p41428
(F1
F0.00014334862385321102
I1
I0
I1
tp41429
sS'via,conjugation,with'
p41430
(F1
F0.00014334862385321102
I1
I0
I1
tp41431
sS'the,octapeptide,cholecystokinin--of'
p41432
(F1
F0.00014334862385321102
I0
I1
I-1
tp41433
sS'provide,information,for'
p41434
(F1
F0.00014334862385321102
I0
I1
I-1
tp41435
sS'increases,substantially,the'
p41436
(F1
F0.00014334862385321102
I1
I0
I1
tp41437
sS'when,channel,blockers'
p41438
(F1
F0.00028669724770642203
I2
I0
I2
tp41439
sS'of,aeds,in'
p41440
(F1
F0.00014334862385321102
I1
I0
I1
tp41441
sS'clearance,and,concentration'
p41442
(F1
F0.00014334862385321102
I0
I1
I-1
tp41443
sS'induces,or,does'
p41444
(F1
F0.00014334862385321102
I0
I1
I-1
tp41445
sS'cannot,be,made'
p41446
(F1
F0.00014334862385321102
I1
I0
I1
tp41447
sS'hydroxide,reduce,the'
p41448
(F1
F0.00014334862385321102
I1
I0
I1
tp41449
sS'the,variability,component'
p41450
(F1
F0.00014334862385321102
I1
I0
I1
tp41451
sS'of,mg,twice-daily'
p41452
(F1
F0.00014334862385321102
I1
I0
I1
tp41453
sS'potentiation,of,rashes'
p41454
(F1
F0.00014334862385321102
I1
I0
I1
tp41455
sS'acetate,and,possibly'
p41456
(F1
F0.00014334862385321102
I1
I0
I1
tp41457
sS'monitoring,of,prothrombin'
p41458
(F1
F0.00043004587155963305
I3
I0
I3
tp41459
sS'acetaminophen,pharmacokinetic,or'
p41460
(F1
F0.00014334862385321102
I0
I1
I-1
tp41461
sS'since,chronic,dosing'
p41462
(F1
F0.00014334862385321102
I0
I1
I-1
tp41463
sS'fluctuations,in,steady-state'
p41464
(F1
F0.00014334862385321102
I1
I0
I1
tp41465
sS'aim,of,this'
p41466
(F1
F0.00028669724770642203
I0
I2
I-2
tp41467
sS'cancer,indicated,that'
p41468
(F1
F0.00014334862385321102
I1
I0
I1
tp41469
sS'although,it,is'
p41470
(F1
F0.00014334862385321102
I1
I0
I1
tp41471
sS'urine,using,a'
p41472
(F1
F0.00014334862385321102
I0
I1
I-1
tp41473
sS'minor,metabolic,pathway'
p41474
(F1
F0.00014334862385321102
I0
I1
I-1
tp41475
sS'n,with,n'
p41476
(F1
F0.00014334862385321102
I0
I1
I-1
tp41477
sS'possible,pharmacokinetic,interactions'
p41478
(F1
F0.00014334862385321102
I1
I0
I1
tp41479
sS'suggested,that,in'
p41480
(F1
F0.00014334862385321102
I1
I0
I1
tp41481
sS'isomers,of,were'
p41482
(F1
F0.00014334862385321102
I0
I1
I-1
tp41483
sS'channel,blockers,should'
p41484
(F1
F0.00014334862385321102
I1
I0
I1
tp41485
sS'muscle,in,the'
p41486
(F1
F0.00014334862385321102
I1
I0
I1
tp41487
sS'secretion,by,the'
p41488
(F1
F0.00014334862385321102
I0
I1
I-1
tp41489
sS'of,the,week'
p41490
(F1
F0.00014334862385321102
I0
I1
I-1
tp41491
sS'myocardial,depressants,or'
p41492
(F1
F0.00014334862385321102
I1
I0
I1
tp41493
sS'for,migraine,therapy'
p41494
(F1
F0.00014334862385321102
I1
I0
I1
tp41495
sS'regard,to,concomitant'
p41496
(F1
F0.00028669724770642203
I0
I2
I-2
tp41497
sS'and,cortex,that'
p41498
(F1
F0.00014334862385321102
I1
I0
I1
tp41499
sS'of,serious,infections'
p41500
(F1
F0.00071674311926605509
I5
I0
I5
tp41501
sS'nephrotoxic,medications,agents'
p41502
(F1
F0.00014334862385321102
I0
I1
I-1
tp41503
sS'suggests,the,potential'
p41504
(F1
F0.00014334862385321102
I1
I0
I1
tp41505
sS'and,hypoglycemic,agents'
p41506
(F1
F0.00014334862385321102
I1
I0
I1
tp41507
sS'recommended,levetiracetam,had'
p41508
(F1
F0.00014334862385321102
I0
I1
I-1
tp41509
sS'exposure,from,the'
p41510
(F1
F0.00014334862385321102
I0
I1
I-1
tp41511
sS'of,products,with'
p41512
(F1
F0.00014334862385321102
I1
I0
I1
tp41513
sS'for,additional,that'
p41514
(F1
F0.00014334862385321102
I1
I0
I1
tp41515
sS'sheep,interactions,of'
p41516
(F1
F0.00014334862385321102
I0
I1
I-1
tp41517
sS'and,range,from'
p41518
(F1
F0.00014334862385321102
I1
I0
I1
tp41519
sS'pharmacokinetic,profiles,of'
p41520
(F1
F0.00014334862385321102
I0
I1
I-1
tp41521
sS'intracellular,exposure,to'
p41522
(F1
F0.00014334862385321102
I1
I0
I1
tp41523
sS'volunteers,resulted,in'
p41524
(F0.5
F0.00028669724770642203
I3
I1
I2
tp41525
sS'caverject,the,potential'
p41526
(F1
F0.00014334862385321102
I0
I1
I-1
tp41527
sS'medications,or,or'
p41528
(F0
F0
I2
I2
I0
tp41529
sS'patient,has,recovered'
p41530
(F1
F0.00014334862385321102
I1
I0
I1
tp41531
sS'mc,has,much'
p41532
(F1
F0.00014334862385321102
I0
I1
I-1
tp41533
sS'cimetidine,cimetidine,can'
p41534
(F1
F0.00014334862385321102
I1
I0
I1
tp41535
sS'class,of,with'
p41536
(F1
F0.00014334862385321102
I0
I1
I-1
tp41537
sS'daily,increases,in'
p41538
(F1
F0.00014334862385321102
I1
I0
I1
tp41539
sS'agents,affecting,sympathetic'
p41540
(F1
F0.00028669724770642203
I0
I2
I-2
tp41541
sS'of,diarrhea,but'
p41542
(F1
F0.00014334862385321102
I1
I0
I1
tp41543
sS'blockers,antagonists,and'
p41544
(F1
F0.00014334862385321102
I0
I1
I-1
tp41545
sS'in,most,common'
p41546
(F1
F0.00014334862385321102
I0
I1
I-1
tp41547
sS'auc,approximately,fold'
p41548
(F1
F0.00014334862385321102
I1
I0
I1
tp41549
sS'novolog,but,that'
p41550
(F1
F0.00014334862385321102
I0
I1
I-1
tp41551
sS'administration,with,other'
p41552
(F1
F0.00014334862385321102
I0
I1
I-1
tp41553
sS'within,the,normal'
p41554
(F1
F0.00014334862385321102
I1
I0
I1
tp41555
sS'dosage,of,adjusted'
p41556
(F1
F0.00043004587155963305
I0
I3
I-3
tp41557
sS'either,be,temporarily'
p41558
(F1
F0.00014334862385321102
I1
I0
I1
tp41559
sS'the,most,potent'
p41560
(F1
F0.00014334862385321102
I0
I1
I-1
tp41561
sS'by,concomitant,medications'
p41562
(F1
F0.00014334862385321102
I1
I0
I1
tp41563
sS'of,microdosed,progestin-containing'
p41564
(F1
F0.00014334862385321102
I1
I0
I1
tp41565
sS'rats,responding,in'
p41566
(F1
F0.00014334862385321102
I1
I0
I1
tp41567
sS'developed,neutropenia,anc'
p41568
(F1
F0.00028669724770642203
I2
I0
I2
tp41569
sS'below,the,age'
p41570
(F1
F0.00014334862385321102
I0
I1
I-1
tp41571
sS'with,congestive,heart'
p41572
(F0
F0
I1
I1
I0
tp41573
sS'and,or,embryocidal'
p41574
(F1
F0.00014334862385321102
I0
I1
I-1
tp41575
sS'agents,may,enhance'
p41576
(F1
F0.00014334862385321102
I1
I0
I1
tp41577
sS'likewise,pharmacokinetics,were'
p41578
(F1
F0.00014334862385321102
I0
I1
I-1
tp41579
sS'that,these,are'
p41580
(F1
F0.00014334862385321102
I0
I1
I-1
tp41581
sS'demonstrated,a,lack'
p41582
(F1
F0.00014334862385321102
I0
I1
I-1
tp41583
sS'by,subsequent,treatment'
p41584
(F1
F0.00014334862385321102
I1
I0
I1
tp41585
sS'the,toxicity,of'
p41586
(F0
F0
I2
I2
I0
tp41587
sS'depressants,eg,other'
p41588
(F1
F0.00014334862385321102
I1
I0
I1
tp41589
sS'must,be,avoided'
p41590
(F1
F0.00014334862385321102
I1
I0
I1
tp41591
sS'dihydroergotamine,contraindicated,due'
p41592
(F1
F0.00014334862385321102
I0
I1
I-1
tp41593
sS'comparing,the,intravenous'
p41594
(F1
F0.00014334862385321102
I0
I1
I-1
tp41595
sS'reduced,to,one'
p41596
(F1
F0.00014334862385321102
I1
I0
I1
tp41597
sS'which,also,lowers'
p41598
(F1
F0.00014334862385321102
I0
I1
I-1
tp41599
sS'of,the,formation'
p41600
(F1
F0.00014334862385321102
I0
I1
I-1
tp41601
sS'through,the,a-v'
p41602
(F1
F0.00014334862385321102
I1
I0
I1
tp41603
sS'symptoms,of,serotonin'
p41604
(F1
F0.00014334862385321102
I1
I0
I1
tp41605
sS'studies,with,propecia'
p41606
(F1
F0.00014334862385321102
I0
I1
I-1
tp41607
sS'through,hours,following'
p41608
(F1
F0.00014334862385321102
I0
I1
I-1
tp41609
sS'both,species,nanm'
p41610
(F1
F0.00014334862385321102
I1
I0
I1
tp41611
sS'vardenafil,with,has'
p41612
(F1
F0.00014334862385321102
I0
I1
I-1
tp41613
sS'the,following,eight'
p41614
(F1
F0.00014334862385321102
I0
I1
I-1
tp41615
sS'with,acute,delirium'
p41616
(F1
F0.00014334862385321102
I1
I0
I1
tp41617
sS'an,oral,produced'
p41618
(F1
F0.00014334862385321102
I1
I0
I1
tp41619
sS'within,days,of'
p41620
(F1
F0.00014334862385321102
I1
I0
I1
tp41621
sS'the,hepatic,metabolism'
p41622
(F1
F0.00043004587155963305
I3
I0
I3
tp41623
sS'temperature,in,female'
p41624
(F1
F0.00014334862385321102
I0
I1
I-1
tp41625
sS'reports,of,changes'
p41626
(F1
F0.00014334862385321102
I0
I1
I-1
tp41627
sS'tnf,blocking,agent'
p41628
(F1
F0.00014334862385321102
I1
I0
I1
tp41629
sS'hydrochlorothiazide,given,concomitantly'
p41630
(F1
F0.00014334862385321102
I1
I0
I1
tp41631
sS'gastric,secretion,chronic'
p41632
(F1
F0.00014334862385321102
I0
I1
I-1
tp41633
sS'with,increased,exposure'
p41634
(F1
F0.00014334862385321102
I1
I0
I1
tp41635
sS'adrenergic-blocking,agents,calcium-blocking'
p41636
(F1
F0.00014334862385321102
I0
I1
I-1
tp41637
sS'increased,rate,of'
p41638
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41639
sS'important,role,in'
p41640
(F1
F0.00028669724770642203
I2
I0
I2
tp41641
sS'beta-adrenergic,blocking,agent'
p41642
(F1
F0.00014334862385321102
I1
I0
I1
tp41643
sS'and,have,not'
p41644
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp41645
sS'volunteers,no,significant'
p41646
(F1
F0.00014334862385321102
I0
I1
I-1
tp41647
sS'angiotensin,ii,antagonists'
p41648
(F0
F0
I1
I1
I0
tp41649
sS'udp-glucuronyl,transferase,it'
p41650
(F1
F0.00014334862385321102
I0
I1
I-1
tp41651
sS'of,neuropathy,during'
p41652
(F1
F0.00014334862385321102
I0
I1
I-1
tp41653
sS'for,adult-onset,diabetics'
p41654
(F1
F0.00014334862385321102
I1
I0
I1
tp41655
sS'alphagan,p,in'
p41656
(F1
F0.00014334862385321102
I1
I0
I1
tp41657
sS'in,the,striatum'
p41658
(F1
F0.00014334862385321102
I1
I0
I1
tp41659
sS'every,hours,is'
p41660
(F1
F0.00014334862385321102
I1
I0
I1
tp41661
sS'mhd,concentration,mean'
p41662
(F1
F0.00014334862385321102
I0
I1
I-1
tp41663
sS'deviation,to,ml'
p41664
(F1
F0.00014334862385321102
I1
I0
I1
tp41665
sS'within,days,because'
p41666
(F1
F0.00014334862385321102
I1
I0
I1
tp41667
sS'the,nucleus,accumbens'
p41668
(F1
F0.00014334862385321102
I0
I1
I-1
tp41669
sS'decreased,by,the'
p41670
(F1
F0.00014334862385321102
I1
I0
I1
tp41671
sS'renal,clearances,by'
p41672
(F1
F0.00014334862385321102
I1
I0
I1
tp41673
sS'should,be,performed'
p41674
(F1
F0.00014334862385321102
I1
I0
I1
tp41675
sS'of,nondepolarizing,relaxants'
p41676
(F1
F0.00014334862385321102
I0
I1
I-1
tp41677
sS'dosage,adjustments,of'
p41678
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41679
sS'for,the,determination'
p41680
(F1
F0.00014334862385321102
I0
I1
I-1
tp41681
sS'coenzyme,a,hmg-coa'
p41682
(F1
F0.00014334862385321102
I1
I0
I1
tp41683
sS'clearance,from,l'
p41684
(F1
F0.00014334862385321102
I1
I0
I1
tp41685
sS'enalapril,iv,has'
p41686
(F1
F0.00014334862385321102
I0
I1
I-1
tp41687
sS'nonsteroidal,anti,inflammatory'
p41688
(F1
F0.00014334862385321102
I1
I0
I1
tp41689
sS'is,approximately,minutes'
p41690
(F1
F0.00014334862385321102
I1
I0
I1
tp41691
sS'subjects,no,significant'
p41692
(F1
F0.00014334862385321102
I0
I1
I-1
tp41693
sS'increased,by,compared'
p41694
(F1
F0.00014334862385321102
I1
I0
I1
tp41695
sS'other,medicines,or'
p41696
(F1
F0.00014334862385321102
I1
I0
I1
tp41697
sS'hours,experienced,a'
p41698
(F1
F0.00014334862385321102
I1
I0
I1
tp41699
sS'the,antidepressant,or'
p41700
(F1
F0.00014334862385321102
I0
I1
I-1
tp41701
sS'indocin,and,should'
p41702
(F1
F0.00014334862385321102
I1
I0
I1
tp41703
sS'the,half-life,of'
p41704
(F1
F0.00043004587155963305
I3
I0
I3
tp41705
sS'tissues,induced,by'
p41706
(F1
F0.00014334862385321102
I1
I0
I1
tp41707
sS'negatively,coupled,to'
p41708
(F1
F0.00014334862385321102
I0
I1
I-1
tp41709
sS'in,sn38,levels'
p41710
(F1
F0.00014334862385321102
I0
I1
I-1
tp41711
sS'receiving,concomitantly,with'
p41712
(F1
F0.00043004587155963305
I3
I0
I3
tp41713
sS'samples,may,interfere'
p41714
(F1
F0.00014334862385321102
I0
I1
I-1
tp41715
sS'addition,we,have'
p41716
(F1
F0.00014334862385321102
I0
I1
I-1
tp41717
sS'intrathecal,on,the'
p41718
(F1
F0.00014334862385321102
I0
I1
I-1
tp41719
sS'reports,have,shown'
p41720
(F1
F0.00043004587155963305
I3
I0
I3
tp41721
sS'and,hypoglycemia,have'
p41722
(F1
F0.00014334862385321102
I1
I0
I1
tp41723
sS'include,optimal,pharmacokinetics'
p41724
(F1
F0.00014334862385321102
I0
I1
I-1
tp41725
sS'in,one,controlled'
p41726
(F1
F0.00014334862385321102
I1
I0
I1
tp41727
sS'containing,or,may'
p41728
(F1
F0.00014334862385321102
I1
I0
I1
tp41729
sS'possible,decrease,in'
p41730
(F1
F0.00014334862385321102
I1
I0
I1
tp41731
sS'as,is,a'
p41732
(F1
F0.00014334862385321102
I0
I1
I-1
tp41733
sS'l-glutamine,and,human'
p41734
(F1
F0.00014334862385321102
I1
I0
I1
tp41735
sS'each,found,to'
p41736
(F1
F0.00014334862385321102
I0
I1
I-1
tp41737
sS'is,contraindicated,in'
p41738
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41739
sS'been,observed,between'
p41740
(F1
F0.00028669724770642203
I0
I2
I-2
tp41741
sS'day,pretreatment,period'
p41742
(F1
F0.00014334862385321102
I0
I1
I-1
tp41743
sS'ketoconazole,when,a'
p41744
(F0
F0
I1
I1
I0
tp41745
sS'effect,of,toradol'
p41746
(F0
F0
I1
I1
I0
tp41747
sS'when,initiating,extraneal'
p41748
(F1
F0.00014334862385321102
I1
I0
I1
tp41749
sS'the,have,been'
p41750
(F1
F0.00043004587155963305
I3
I0
I3
tp41751
sS'daily,has,been'
p41752
(F1
F0.00014334862385321102
I0
I1
I-1
tp41753
sS'no,clinically,relevant'
p41754
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp41755
sS'reason,the,dose'
p41756
(F0
F0
I1
I1
I0
tp41757
sS'used,with,care'
p41758
(F1
F0.00014334862385321102
I1
I0
I1
tp41759
sS'the,pharmacokinetics,exposure'
p41760
(F1
F0.00014334862385321102
I0
I1
I-1
tp41761
sS'for,drugs,such'
p41762
(F1
F0.00014334862385321102
I1
I0
I1
tp41763
sS'also,be,applied'
p41764
(F1
F0.00014334862385321102
I0
I1
I-1
tp41765
sS'other,than,have'
p41766
(F1
F0.00014334862385321102
I0
I1
I-1
tp41767
sS'the,literature,suggest'
p41768
(F1
F0.00014334862385321102
I1
I0
I1
tp41769
sS'nor,does,it'
p41770
(F1
F0.00028669724770642203
I0
I2
I-2
tp41771
sS'appear,to,cause'
p41772
(F1
F0.00014334862385321102
I0
I1
I-1
tp41773
sS'administration,of,kerlone'
p41774
(F1
F0.00014334862385321102
I0
I1
I-1
tp41775
sS'with,crohns,disease'
p41776
(F1
F0.00014334862385321102
I1
I0
I1
tp41777
sS'with,those,achieved'
p41778
(F1
F0.00014334862385321102
I1
I0
I1
tp41779
sS'cell,number,induced'
p41780
(F1
F0.00014334862385321102
I1
I0
I1
tp41781
sS'porpranolol,may,exacerbate'
p41782
(F1
F0.00014334862385321102
I1
I0
I1
tp41783
sS'with,an,appropriate'
p41784
(F1
F0.00014334862385321102
I1
I0
I1
tp41785
sS'the,treatment,regimen'
p41786
(F1
F0.00014334862385321102
I1
I0
I1
tp41787
sS'single,intravenous,infusion'
p41788
(F1
F0.00014334862385321102
I0
I1
I-1
tp41789
sS'the,first,few'
p41790
(F1
F0.00043004587155963305
I3
I0
I3
tp41791
sS'and,its,effect'
p41792
(F1
F0.00014334862385321102
I1
I0
I1
tp41793
sS'well-controlled,patients,receiving'
p41794
(F1
F0.00014334862385321102
I1
I0
I1
tp41795
sS'a,concomitantly,any'
p41796
(F1
F0.00014334862385321102
I1
I0
I1
tp41797
sS'heart,disease,in'
p41798
(F1
F0.00014334862385321102
I0
I1
I-1
tp41799
sS'fe,per,kg'
p41800
(F1
F0.00014334862385321102
I1
I0
I1
tp41801
sS'patients,with,schizophrenia'
p41802
(F1
F0.00043004587155963305
I0
I3
I-3
tp41803
sS'and,degenerative,changes'
p41804
(F1
F0.00014334862385321102
I0
I1
I-1
tp41805
sS'in,older,men'
p41806
(F1
F0.00014334862385321102
I0
I1
I-1
tp41807
sS'of,on,endotoxin-induced'
p41808
(F1
F0.00014334862385321102
I0
I1
I-1
tp41809
sS'administered,orally,has'
p41810
(F1
F0.00014334862385321102
I0
I1
I-1
tp41811
sS'seminiferous,tubular,atrophy'
p41812
(F1
F0.00014334862385321102
I0
I1
I-1
tp41813
sS'pentamidine,treatment,with'
p41814
(F1
F0.00014334862385321102
I0
I1
I-1
tp41815
sS'pancreatic,acinar,cells'
p41816
(F1
F0.00014334862385321102
I0
I1
I-1
tp41817
sS'volunteers,either,simultaneously'
p41818
(F1
F0.00014334862385321102
I1
I0
I1
tp41819
sS'these,in,normal'
p41820
(F1
F0.00014334862385321102
I0
I1
I-1
tp41821
sS'ventricular,arrhythmias,during'
p41822
(F1
F0.00014334862385321102
I1
I0
I1
tp41823
sS'there,is,little'
p41824
(F1
F0.00028669724770642203
I0
I2
I-2
tp41825
sS'antitumor,activity,of'
p41826
(F1
F0.00014334862385321102
I0
I1
I-1
tp41827
sS'the,palytoxin-induced,contraction'
p41828
(F1
F0.00014334862385321102
I0
I1
I-1
tp41829
sS'and,oral,hypoglycemic'
p41830
(F1
F0.00071674311926605509
I5
I0
I5
tp41831
sS'half-life,of,thereby'
p41832
(F1
F0.00014334862385321102
I1
I0
I1
tp41833
sS'these,results,do'
p41834
(F1
F0.00014334862385321102
I1
I0
I1
tp41835
sS'may,potentially,interact'
p41836
(F1
F0.00014334862385321102
I0
I1
I-1
tp41837
sS'the,and,and'
p41838
(F1
F0.00014334862385321102
I1
I0
I1
tp41839
sS'e2,dmpge2,induced'
p41840
(F1
F0.00014334862385321102
I0
I1
I-1
tp41841
sS'effects,with,can'
p41842
(F1
F0.00014334862385321102
I1
I0
I1
tp41843
sS'of,glycemia,induced'
p41844
(F1
F0.00014334862385321102
I0
I1
I-1
tp41845
sS'alter,gastrointestinal,motility'
p41846
(F1
F0.00014334862385321102
I1
I0
I1
tp41847
sS'this,isozyme,including'
p41848
(F0
F0
I1
I1
I0
tp41849
sS'interactions,were,observed'
p41850
(F1
F0.00028669724770642203
I0
I2
I-2
tp41851
sS'been,safely,tolerated'
p41852
(F1
F0.00014334862385321102
I0
I1
I-1
tp41853
sS'are,taking,or'
p41854
(F1
F0.00014334862385321102
I1
I0
I1
tp41855
sS'of,tail-flick,inhibition'
p41856
(F1
F0.00014334862385321102
I0
I1
I-1
tp41857
sS'smaller,alfenta,doses'
p41858
(F1
F0.00014334862385321102
I0
I1
I-1
tp41859
sS'vivo,interaction,studies'
p41860
(F1
F0.00057339449541284407
I0
I4
I-4
tp41861
sS'to,pentobarbital-induced,sedation'
p41862
(F1
F0.00014334862385321102
I0
I1
I-1
tp41863
sS'theoretical,potential,for'
p41864
(F1
F0.00014334862385321102
I1
I0
I1
tp41865
sS'ototoxic,potential,of'
p41866
(F1
F0.00028669724770642203
I2
I0
I2
tp41867
sS'medications,muscle,relaxants'
p41868
(F1
F0.00014334862385321102
I0
I1
I-1
tp41869
sS'enzyme,supplements,oral'
p41870
(F1
F0.00014334862385321102
I0
I1
I-1
tp41871
sS'incompletely,responsive,to'
p41872
(F1
F0.00014334862385321102
I0
I1
I-1
tp41873
sS'similar,properties,such'
p41874
(F1
F0.00014334862385321102
I1
I0
I1
tp41875
sS'decreased,the,plasma'
p41876
(F1
F0.00057339449541284407
I4
I0
I4
tp41877
sS'particular,caution,should'
p41878
(F0
F0
I1
I1
I0
tp41879
sS'considered,for,patients'
p41880
(F1
F0.00014334862385321102
I1
I0
I1
tp41881
sS'exaggeration,of,the'
p41882
(F1
F0.00014334862385321102
I1
I0
I1
tp41883
sS'on,the,pharmacodynamics'
p41884
(F1
F0.00057339449541284407
I0
I4
I-4
tp41885
sS'substrates,dasatinib,is'
p41886
(F1
F0.00014334862385321102
I0
I1
I-1
tp41887
sS'of,decreased,with'
p41888
(F1
F0.00028669724770642203
I2
I0
I2
tp41889
sS'currently,do,not'
p41890
(F1
F0.00014334862385321102
I0
I1
I-1
tp41891
sS'to,have,negative'
p41892
(F1
F0.00014334862385321102
I0
I1
I-1
tp41893
sS'the,week,period'
p41894
(F1
F0.00014334862385321102
I1
I0
I1
tp41895
sS'diazepam,diazepam,valium'
p41896
(F1
F0.00014334862385321102
I0
I1
I-1
tp41897
sS'macrolide,have,been'
p41898
(F1
F0.00014334862385321102
I1
I0
I1
tp41899
sS'mean,half-life,and'
p41900
(F1
F0.00014334862385321102
I1
I0
I1
tp41901
sS'dose,when,concomitant'
p41902
(F1
F0.00014334862385321102
I1
I0
I1
tp41903
sS'and,n-oxide,were'
p41904
(F1
F0.00014334862385321102
I0
I1
I-1
tp41905
sS'oral,was,associated'
p41906
(F1
F0.00014334862385321102
I1
I0
I1
tp41907
sS'and,compared,with'
p41908
(F1
F0.00014334862385321102
I0
I1
I-1
tp41909
sS'tract,to,healthy'
p41910
(F1
F0.00014334862385321102
I1
I0
I1
tp41911
sS'muscle,relaxants,sleeping'
p41912
(F1
F0.00014334862385321102
I0
I1
I-1
tp41913
sS'this,interaction,which'
p41914
(F1
F0.00014334862385321102
I1
I0
I1
tp41915
sS'reduced,by,an'
p41916
(F1
F0.00014334862385321102
I1
I0
I1
tp41917
sS'the,plasma,clearance'
p41918
(F1
F0.00014334862385321102
I1
I0
I1
tp41919
sS'reduced,by,at'
p41920
(F1
F0.00014334862385321102
I1
I0
I1
tp41921
sS'nsaids,and,did'
p41922
(F1
F0.00014334862385321102
I0
I1
I-1
tp41923
sS'on,the,neuromuscular'
p41924
(F1
F0.00014334862385321102
I0
I1
I-1
tp41925
sS'k,can,antagonize'
p41926
(F1
F0.00014334862385321102
I1
I0
I1
tp41927
sS'of,fibric,acid'
p41928
(F1
F0.00014334862385321102
I0
I1
I-1
tp41929
sS'nsaids,should,be'
p41930
(F1
F0.00028669724770642203
I2
I0
I2
tp41931
sS'monitoring,of,serum'
p41932
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41933
sS'can,completely,block'
p41934
(F1
F0.00014334862385321102
I1
I0
I1
tp41935
sS'decrease,in,hypothyroid'
p41936
(F1
F0.00014334862385321102
I0
I1
I-1
tp41937
sS'suggest,similar,effects'
p41938
(F1
F0.00014334862385321102
I0
I1
I-1
tp41939
sS'ephedrine,ephedrine,may'
p41940
(F1
F0.00014334862385321102
I1
I0
I1
tp41941
sS'mg,produced,a'
p41942
(F1
F0.00014334862385321102
I1
I0
I1
tp41943
sS'crixivan,and,are'
p41944
(F1
F0.00014334862385321102
I0
I1
I-1
tp41945
sS'implicated,in,the'
p41946
(F0
F0
I1
I1
I0
tp41947
sS'decrease,between,and'
p41948
(F1
F0.00014334862385321102
I0
I1
I-1
tp41949
sS'the,therapeutic,value'
p41950
(F1
F0.00014334862385321102
I0
I1
I-1
tp41951
sS'used,with,general'
p41952
(F1
F0.00014334862385321102
I0
I1
I-1
tp41953
sS'in,the,body'
p41954
(F1
F0.00014334862385321102
I0
I1
I-1
tp41955
sS'of,autoimmune,and'
p41956
(F1
F0.00014334862385321102
I1
I0
I1
tp41957
sS'and,release,was'
p41958
(F1
F0.00014334862385321102
I0
I1
I-1
tp41959
sS'of,the,ionized'
p41960
(F1
F0.00028669724770642203
I2
I0
I2
tp41961
sS'micro-dosed,progesterone,preparations'
p41962
(F1
F0.00014334862385321102
I1
I0
I1
tp41963
sS'volunteers,received,alone'
p41964
(F1
F0.00014334862385321102
I0
I1
I-1
tp41965
sS'inhibitors,beta,blockers'
p41966
(F1
F0.00014334862385321102
I0
I1
I-1
tp41967
sS'with,other,centrally'
p41968
(F1
F0.00028669724770642203
I2
I0
I2
tp41969
sS'folic,acid,in'
p41970
(F1
F0.00014334862385321102
I1
I0
I1
tp41971
sS'been,postmarketing,reports'
p41972
(F1
F0.00014334862385321102
I1
I0
I1
tp41973
sS'and,agents,is'
p41974
(F1
F0.00014334862385321102
I1
I0
I1
tp41975
sS'therapy,indicate,no'
p41976
(F1
F0.00014334862385321102
I0
I1
I-1
tp41977
sS'a,patient,who'
p41978
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp41979
sS'potent,inhalational,such'
p41980
(F1
F0.00014334862385321102
I1
I0
I1
tp41981
sS'interactions,were,seen'
p41982
(F1
F0.00014334862385321102
I0
I1
I-1
tp41983
sS'been,one,report'
p41984
(F1
F0.00014334862385321102
I1
I0
I1
tp41985
sS'month,toxicology,study'
p41986
(F1
F0.00014334862385321102
I0
I1
I-1
tp41987
sS'fluoride,or,citrate'
p41988
(F1
F0.00014334862385321102
I0
I1
I-1
tp41989
sS'concomitantly,with,ethacrynic'
p41990
(F1
F0.00014334862385321102
I1
I0
I1
tp41991
sS'was,admini,stered'
p41992
(F1
F0.00014334862385321102
I1
I0
I1
tp41993
sS'common,distilled,and'
p41994
(F1
F0.00014334862385321102
I0
I1
I-1
tp41995
sS'if,administered,prior'
p41996
(F1
F0.00014334862385321102
I1
I0
I1
tp41997
sS'cyp2d6,cyp2c9,cyp2c19'
p41998
(F1
F0.00014334862385321102
I0
I1
I-1
tp41999
sS'in,steady-state,peak'
p42000
(F1
F0.00014334862385321102
I1
I0
I1
tp42001
sS'meal,and,mg'
p42002
(F1
F0.00014334862385321102
I1
I0
I1
tp42003
sS'hours,concurrently,with'
p42004
(F1
F0.00014334862385321102
I0
I1
I-1
tp42005
sS'a,reversible,enhancement'
p42006
(F1
F0.00014334862385321102
I1
I0
I1
tp42007
sS'taking,placebo,with'
p42008
(F1
F0.00014334862385321102
I0
I1
I-1
tp42009
sS'nonsteroidal,antiinflammatory,agents'
p42010
(F1
F0.00028669724770642203
I2
I0
I2
tp42011
sS'the,smallest,effective'
p42012
(F1
F0.00014334862385321102
I0
I1
I-1
tp42013
sS'to,existing,therapy'
p42014
(F1
F0.00014334862385321102
I0
I1
I-1
tp42015
sS'study,in,eight'
p42016
(F1
F0.00014334862385321102
I1
I0
I1
tp42017
sS'or,azoles,were'
p42018
(F1
F0.00014334862385321102
I0
I1
I-1
tp42019
sS'of,cyp2d6,increased'
p42020
(F1
F0.00014334862385321102
I1
I0
I1
tp42021
sS'clinical,trials,currently'
p42022
(F1
F0.00014334862385321102
I0
I1
I-1
tp42023
sS'affect,bleeding,parameters'
p42024
(F1
F0.00014334862385321102
I1
I0
I1
tp42025
sS'according,to,the'
p42026
(F1
F0.00014334862385321102
I1
I0
I1
tp42027
sS'the,interaction,studies'
p42028
(F1
F0.00014334862385321102
I0
I1
I-1
tp42029
sS'urinary,and,chloride'
p42030
(F1
F0.00014334862385321102
I1
I0
I1
tp42031
sS'ipratropium,bromide,is'
p42032
(F1
F0.00014334862385321102
I1
I0
I1
tp42033
sS'r-value,of,naflu'
p42034
(F1
F0.00028669724770642203
I0
I2
I-2
tp42035
sS'of,tablets,and'
p42036
(F1
F0.00014334862385321102
I1
I0
I1
tp42037
sS'days,following,initiation'
p42038
(F1
F0.00014334862385321102
I1
I0
I1
tp42039
sS'anabolic,hormones,complex'
p42040
(F1
F0.00014334862385321102
I0
I1
I-1
tp42041
sS'adrenergic,stimulant,type'
p42042
(F1
F0.00014334862385321102
I0
I1
I-1
tp42043
sS'partially,impaired,renal'
p42044
(F1
F0.00014334862385321102
I0
I1
I-1
tp42045
sS'of,when,both'
p42046
(F1
F0.00014334862385321102
I1
I0
I1
tp42047
sS'such,patients,may'
p42048
(F1
F0.00043004587155963305
I3
I0
I3
tp42049
sS'the,clearance,by'
p42050
(F1
F0.00014334862385321102
I0
I1
I-1
tp42051
sS'among,the,risk'
p42052
(F1
F0.00014334862385321102
I1
I0
I1
tp42053
sS'on,the,chemical'
p42054
(F1
F0.00014334862385321102
I1
I0
I1
tp42055
sS'noted,when,hydrochloride'
p42056
(F1
F0.00014334862385321102
I0
I1
I-1
tp42057
sS'interaction,studies,of'
p42058
(F1
F0.00043004587155963305
I0
I3
I-3
tp42059
sS'interfere,with,folate'
p42060
(F1
F0.00014334862385321102
I1
I0
I1
tp42061
sS'inhibitors,the,use'
p42062
(F1
F0.00014334862385321102
I1
I0
I1
tp42063
sS'need,for,dose'
p42064
(F1
F0.00028669724770642203
I0
I2
I-2
tp42065
sS'cyp1a2,results,in'
p42066
(F1
F0.00014334862385321102
I1
I0
I1
tp42067
sS'trials,of,the'
p42068
(F1
F0.00014334862385321102
I1
I0
I1
tp42069
sS'the,dimethylprostaglandin,e2'
p42070
(F1
F0.00014334862385321102
I0
I1
I-1
tp42071
sS'was,to,evaluate'
p42072
(F1
F0.00014334862385321102
I0
I1
I-1
tp42073
sS'or,other,complications'
p42074
(F1
F0.00028669724770642203
I2
I0
I2
tp42075
sS'serum,concentration,has'
p42076
(F1
F0.00014334862385321102
I1
I0
I1
tp42077
sS'the,two,hormonal'
p42078
(F1
F0.00014334862385321102
I1
I0
I1
tp42079
sS'kg,was,significantly'
p42080
(F1
F0.00014334862385321102
I1
I0
I1
tp42081
sS'with,the,oral'
p42082
(F1
F0.00014334862385321102
I0
I1
I-1
tp42083
sS'glycosides,in,patients'
p42084
(F1
F0.00014334862385321102
I0
I1
I-1
tp42085
sS'this,kind,with'
p42086
(F1
F0.00014334862385321102
I1
I0
I1
tp42087
sS'organs,actively,concentrating'
p42088
(F1
F0.00014334862385321102
I0
I1
I-1
tp42089
sS'measures,have,been'
p42090
(F1
F0.00014334862385321102
I0
I1
I-1
tp42091
sS'beta-blockers,in,controlled'
p42092
(F1
F0.00014334862385321102
I0
I1
I-1
tp42093
sS'unlikely,to,be'
p42094
(F1
F0.00014334862385321102
I0
I1
I-1
tp42095
sS'other,medications,that'
p42096
(F1
F0.00014334862385321102
I1
I0
I1
tp42097
sS'meaningful,increases,in'
p42098
(F1
F0.00014334862385321102
I0
I1
I-1
tp42099
sS'sumatriptan,has,been'
p42100
(F1
F0.00014334862385321102
I1
I0
I1
tp42101
sS'excretion,of,many'
p42102
(F1
F0.00014334862385321102
I1
I0
I1
tp42103
sS'interfere,with,normal'
p42104
(F1
F0.00014334862385321102
I0
I1
I-1
tp42105
sS'with,of,a'
p42106
(F1
F0.00014334862385321102
I0
I1
I-1
tp42107
sS'therapy,with,flolan'
p42108
(F1
F0.00028669724770642203
I2
I0
I2
tp42109
sS'with,dual,therapy'
p42110
(F1
F0.00014334862385321102
I0
I1
I-1
tp42111
sS'that,a,dose'
p42112
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp42113
sS'decreased,in,the'
p42114
(F1
F0.00014334862385321102
I1
I0
I1
tp42115
sS'extensively,metabolized,by'
p42116
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp42117
sS'effect,on,protein'
p42118
(F1
F0.00014334862385321102
I0
I1
I-1
tp42119
sS'seen,in,difluoro-2'
p42120
(F1
F0.00014334862385321102
I1
I0
I1
tp42121
sS'coadministration,of,resulted'
p42122
(F1
F0.00014334862385321102
I1
I0
I1
tp42123
sS'microsomal,enzymes,were'
p42124
(F1
F0.00014334862385321102
I0
I1
I-1
tp42125
sS'so,that,peak'
p42126
(F1
F0.00014334862385321102
I0
I1
I-1
tp42127
sS'and,incoordination,when'
p42128
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp42129
sS'who,have,used'
p42130
(F1
F0.00014334862385321102
I0
I1
I-1
tp42131
sS'in,their,prothrombin'
p42132
(F1
F0.00014334862385321102
I1
I0
I1
tp42133
sS'of,and,prolongation'
p42134
(F1
F0.00014334862385321102
I1
I0
I1
tp42135
sS'acquainted,with,the'
p42136
(F1
F0.00014334862385321102
I0
I1
I-1
tp42137
sS'bentiromide,may,interact'
p42138
(F1
F0.00014334862385321102
I1
I0
I1
tp42139
sS'whose,absorption,is'
p42140
(F1
F0.00014334862385321102
I0
I1
I-1
tp42141
sS'at,least,hours'
p42142
(F1
F0.0015768348623853212
I11
I0
I11
tp42143
sS'accordingly,and,should'
p42144
(F1
F0.00014334862385321102
I1
I0
I1
tp42145
sS'yields,a,net'
p42146
(F1
F0.00014334862385321102
I1
I0
I1
tp42147
sS'and,was,followed'
p42148
(F1
F0.00014334862385321102
I1
I0
I1
tp42149
sS'in,the,pharmacokinetic'
p42150
(F1
F0.00014334862385321102
I0
I1
I-1
tp42151
sS'effects,on,potassium'
p42152
(F1
F0.00014334862385321102
I1
I0
I1
tp42153
sS'obtained,for,any'
p42154
(F1
F0.00014334862385321102
I0
I1
I-1
tp42155
sS'molt-4,cells,revealed'
p42156
(F1
F0.00014334862385321102
I1
I0
I1
tp42157
sS'strong,inhibitor,of'
p42158
(F1
F0.00014334862385321102
I1
I0
I1
tp42159
sS'instances,of,interactions'
p42160
(F1
F0.00014334862385321102
I1
I0
I1
tp42161
sS'trial,there,have'
p42162
(F1
F0.00014334862385321102
I0
I1
I-1
tp42163
sS'oral,and,oral'
p42164
(F1
F0.00043004587155963305
I3
I0
I3
tp42165
sS'and,to,lower'
p42166
(F1
F0.00014334862385321102
I0
I1
I-1
tp42167
sS'basis,that,these'
p42168
(F1
F0.00028669724770642203
I2
I0
I2
tp42169
sS'antagonists,and,may'
p42170
(F1
F0.00014334862385321102
I1
I0
I1
tp42171
sS'by,evaluating,the'
p42172
(F1
F0.00014334862385321102
I0
I1
I-1
tp42173
sS'symptoms,i,severe'
p42174
(F1
F0.00014334862385321102
I1
I0
I1
tp42175
sS'a,first,rapid'
p42176
(F1
F0.00014334862385321102
I0
I1
I-1
tp42177
sS'levels,of,exposure'
p42178
(F1
F0.00014334862385321102
I0
I1
I-1
tp42179
sS'with,hepatotoxicity,concomitant'
p42180
(F1
F0.00014334862385321102
I1
I0
I1
tp42181
sS'for,day,in'
p42182
(F1
F0.00014334862385321102
I0
I1
I-1
tp42183
sS'doxil,may,interact'
p42184
(F1
F0.00014334862385321102
I0
I1
I-1
tp42185
sS'and,their,bioavailability'
p42186
(F1
F0.00014334862385321102
I1
I0
I1
tp42187
sS'the,pharmacologic,effects'
p42188
(F1
F0.00014334862385321102
I1
I0
I1
tp42189
sS'have,also,shown'
p42190
(F1
F0.00014334862385321102
I1
I0
I1
tp42191
sS'to,therapy,could'
p42192
(F1
F0.00014334862385321102
I1
I0
I1
tp42193
sS'because,severe,and'
p42194
(F1
F0.00014334862385321102
I1
I0
I1
tp42195
sS'be,cyp,a'
p42196
(F1
F0.00028669724770642203
I2
I0
I2
tp42197
sS'vasospastic,reactions,have'
p42198
(F1
F0.00014334862385321102
I1
I0
I1
tp42199
sS'but,is,probably'
p42200
(F1
F0.00014334862385321102
I1
I0
I1
tp42201
sS'systems,lapatinib,inhibits'
p42202
(F1
F0.00014334862385321102
I0
I1
I-1
tp42203
sS'in,no,significant'
p42204
(F1
F0.00014334862385321102
I0
I1
I-1
tp42205
sS'auc,for,and'
p42206
(F0
F0
I1
I1
I0
tp42207
sS'with,tylenol,chloromycetin'
p42208
(F1
F0.00014334862385321102
I1
I0
I1
tp42209
sS'of,or,during'
p42210
(F1
F0.00014334862385321102
I0
I1
I-1
tp42211
sS'presence,of,ml'
p42212
(F1
F0.00014334862385321102
I0
I1
I-1
tp42213
sS'of,minutes,to'
p42214
(F1
F0.00014334862385321102
I0
I1
I-1
tp42215
sS'interactions,vardenafil,had'
p42216
(F1
F0.00014334862385321102
I0
I1
I-1
tp42217
sS'nalfon,and,a'
p42218
(F1
F0.00014334862385321102
I1
I0
I1
tp42219
sS'have,been,case'
p42220
(F1
F0.00014334862385321102
I0
I1
I-1
tp42221
sS'more,conservatively,adjusted'
p42222
(F1
F0.00014334862385321102
I1
I0
I1
tp42223
sS'with,drugs,that'
p42224
(F1
F0.00014334862385321102
I0
I1
I-1
tp42225
sS'the,extremities,and'
p42226
(F1
F0.00014334862385321102
I0
I1
I-1
tp42227
sS'teratogenic,and,or'
p42228
(F1
F0.00014334862385321102
I0
I1
I-1
tp42229
sS'especially,those,with'
p42230
(F1
F0.00014334862385321102
I1
I0
I1
tp42231
sS'urinary,excretion,is'
p42232
(F1
F0.00014334862385321102
I1
I0
I1
tp42233
sS'toxic,action,of'
p42234
(F1
F0.00014334862385321102
I0
I1
I-1
tp42235
sS'who,were,to'
p42236
(F1
F0.00014334862385321102
I0
I1
I-1
tp42237
sS'induce,cytochrome,p450'
p42238
(F0
F0
I1
I1
I0
tp42239
sS'haloperidol,haloperidol,blocks'
p42240
(F1
F0.00028669724770642203
I2
I0
I2
tp42241
sS'because,or,activase'
p42242
(F1
F0.00014334862385321102
I0
I1
I-1
tp42243
sS'pressure,of,less'
p42244
(F1
F0.00028669724770642203
I2
I0
I2
tp42245
sS'the,mean,half-life'
p42246
(F1
F0.00014334862385321102
I1
I0
I1
tp42247
sS'for,or,oral'
p42248
(F1
F0.00028669724770642203
I0
I2
I-2
tp42249
sS'on,the,involvement'
p42250
(F1
F0.00014334862385321102
I1
I0
I1
tp42251
sS'in,rats,did'
p42252
(F1
F0.00014334862385321102
I0
I1
I-1
tp42253
sS'after,injection,of'
p42254
(F1
F0.00014334862385321102
I1
I0
I1
tp42255
sS'mg,qd,and'
p42256
(F1
F0.00028669724770642203
I2
I0
I2
tp42257
sS'which,metabolizes,may'
p42258
(F1
F0.00014334862385321102
I0
I1
I-1
tp42259
sS'were,conducted,with'
p42260
(F1
F0.00014334862385321102
I0
I1
I-1
tp42261
sS'of,sodium,iodide'
p42262
(F1
F0.00014334862385321102
I1
I0
I1
tp42263
sS'hypercalcemia,too,much'
p42264
(F1
F0.00014334862385321102
I1
I0
I1
tp42265
sS'mg,m2,without'
p42266
(F1
F0.00014334862385321102
I0
I1
I-1
tp42267
sS'patients,with,impaired'
p42268
(F0.5
F0.00028669724770642203
I3
I1
I2
tp42269
sS'oral,with,may'
p42270
(F1
F0.00014334862385321102
I1
I0
I1
tp42271
sS'on,dopamine2-,and'
p42272
(F1
F0.00014334862385321102
I0
I1
I-1
tp42273
sS'app,polymer,p'
p42274
(F1
F0.00014334862385321102
I0
I1
I-1
tp42275
sS'because,moderate,cyp3a4'
p42276
(F1
F0.00014334862385321102
I1
I0
I1
tp42277
sS'clinical,problems,will'
p42278
(F1
F0.00071674311926605509
I5
I0
I5
tp42279
sS'decrease,thyroidal,uptake'
p42280
(F1
F0.00014334862385321102
I1
I0
I1
tp42281
sS'separate,studies,hydrochloride'
p42282
(F1
F0.00014334862385321102
I0
I1
I-1
tp42283
sS'phenytoin,amphetamines,may'
p42284
(F1
F0.00028669724770642203
I2
I0
I2
tp42285
sS'be,minimized,or'
p42286
(F1
F0.00014334862385321102
I1
I0
I1
tp42287
sS'corticosteroids,concomitant,administration'
p42288
(F1
F0.00014334862385321102
I1
I0
I1
tp42289
sS'to,the,formation'
p42290
(F1
F0.00014334862385321102
I1
I0
I1
tp42291
sS'following,concomitant,administration'
p42292
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp42293
sS'and,distribution,of'
p42294
(F1
F0.00014334862385321102
I0
I1
I-1
tp42295
sS'pr,interval,were'
p42296
(F1
F0.00014334862385321102
I1
I0
I1
tp42297
sS'relaxants,has,not'
p42298
(F1
F0.00014334862385321102
I0
I1
I-1
tp42299
sS'interaction,during,pregnancy'
p42300
(F1
F0.00014334862385321102
I0
I1
I-1
tp42301
sS'on,these,components'
p42302
(F1
F0.00014334862385321102
I0
I1
I-1
tp42303
sS'given,intravenously,over'
p42304
(F1
F0.00014334862385321102
I0
I1
I-1
tp42305
sS'drug,is,used'
p42306
(F1
F0.00014334862385321102
I1
I0
I1
tp42307
sS'the,stomach,drugs'
p42308
(F1
F0.00014334862385321102
I1
I0
I1
tp42309
sS'decreased,by,concomitant'
p42310
(F1
F0.00014334862385321102
I1
I0
I1
tp42311
sS'as,acetylsalicylic,acid'
p42312
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp42313
sS'was,used,to'
p42314
(F1
F0.00014334862385321102
I0
I1
I-1
tp42315
sS'in,urinary,homocysteine'
p42316
(F1
F0.00014334862385321102
I0
I1
I-1
tp42317
sS'prostatic,epithelium,in'
p42318
(F1
F0.00014334862385321102
I1
I0
I1
tp42319
sS'treatment,of,psychotic'
p42320
(F1
F0.00014334862385321102
I0
I1
I-1
tp42321
sS'and,reduced,the'
p42322
(F1
F0.00014334862385321102
I1
I0
I1
tp42323
sS'of,have,not'
p42324
(F1
F0.00014334862385321102
I0
I1
I-1
tp42325
sS'ldl-c,reduction,were'
p42326
(F1
F0.00014334862385321102
I0
I1
I-1
tp42327
sS'inhibition,of,erythrocyte'
p42328
(F1
F0.00014334862385321102
I1
I0
I1
tp42329
sS'when,and,crixivan'
p42330
(F1
F0.00014334862385321102
I1
I0
I1
tp42331
sS'p450,system,though'
p42332
(F1
F0.00014334862385321102
I1
I0
I1
tp42333
sS'collected,by,a'
p42334
(F1
F0.00014334862385321102
I0
I1
I-1
tp42335
sS'of,disrupts,the'
p42336
(F1
F0.00014334862385321102
I0
I1
I-1
tp42337
sS'use,of,indocin'
p42338
(F1
F0.00028669724770642203
I2
I0
I2
tp42339
sS'estimated,number,of'
p42340
(F1
F0.00014334862385321102
I0
I1
I-1
tp42341
sS'inhibit,the,antitumor'
p42342
(F1
F0.00014334862385321102
I0
I1
I-1
tp42343
sS'date,levosimendan,does'
p42344
(F1
F0.00014334862385321102
I0
I1
I-1
tp42345
sS'those,obtained,after'
p42346
(F1
F0.00014334862385321102
I1
I0
I1
tp42347
sS'fraction,of,and'
p42348
(F1
F0.00014334862385321102
I0
I1
I-1
tp42349
sS'tegretol,trileptal,topamax'
p42350
(F1
F0.00014334862385321102
I1
I0
I1
tp42351
sS'effect,of,aprepitant'
p42352
(F1
F0.00014334862385321102
I1
I0
I1
tp42353
sS'clearance,of,caused'
p42354
(F1
F0.00014334862385321102
I1
I0
I1
tp42355
sS'artery,vasospasm,and'
p42356
(F1
F0.00014334862385321102
I1
I0
I1
tp42357
sS'b,or,corticosteroids'
p42358
(F1
F0.00014334862385321102
I0
I1
I-1
tp42359
sS'of,fe,over'
p42360
(F1
F0.00014334862385321102
I0
I1
I-1
tp42361
sS'used,when,cyp3a4'
p42362
(F1
F0.00014334862385321102
I0
I1
I-1
tp42363
sS'in,serum,concentration'
p42364
(F0
F0
I1
I1
I0
tp42365
sS'interact,with,addictive'
p42366
(F1
F0.00014334862385321102
I0
I1
I-1
tp42367
sS'and,l-lysine,may'
p42368
(F1
F0.00014334862385321102
I1
I0
I1
tp42369
sS'with,either,or'
p42370
(F0
F0
I1
I1
I0
tp42371
sS'effective,there,have'
p42372
(F1
F0.00014334862385321102
I0
I1
I-1
tp42373
sS'probably,is,adsorption'
p42374
(F1
F0.00014334862385321102
I1
I0
I1
tp42375
sS'mg,qd,was'
p42376
(F1
F0.00014334862385321102
I0
I1
I-1
tp42377
sS'alone,or,in'
p42378
(F1
F0.0012901376146788992
I0
I9
I-9
tp42379
sS'moderate,cyp1a2,inhibitors'
p42380
(F1
F0.00014334862385321102
I1
I0
I1
tp42381
sS'given,or,times'
p42382
(F1
F0.00014334862385321102
I0
I1
I-1
tp42383
sS'sular,with,or'
p42384
(F1
F0.00014334862385321102
I1
I0
I1
tp42385
sS'inc,demonstrated,less'
p42386
(F1
F0.00014334862385321102
I1
I0
I1
tp42387
sS'rats,at,but'
p42388
(F1
F0.00014334862385321102
I0
I1
I-1
tp42389
sS'gut,motility,may'
p42390
(F1
F0.00014334862385321102
I1
I0
I1
tp42391
sS'and,increased,its'
p42392
(F1
F0.00014334862385321102
I0
I1
I-1
tp42393
sS'decrease,anti-inflammatory,action'
p42394
(F1
F0.00014334862385321102
I1
I0
I1
tp42395
sS'other,pressor,agents'
p42396
(F1
F0.00014334862385321102
I0
I1
I-1
tp42397
sS'of,flucoxacillin,and'
p42398
(F1
F0.00014334862385321102
I0
I1
I-1
tp42399
sS'of,theophylline-related,side'
p42400
(F1
F0.00028669724770642203
I2
I0
I2
tp42401
sS'stopping,fluvoxamine,tablets'
p42402
(F1
F0.00014334862385321102
I1
I0
I1
tp42403
sS'three-,to,fivefold'
p42404
(F1
F0.00014334862385321102
I0
I1
I-1
tp42405
sS'and,bone,and'
p42406
(F1
F0.00014334862385321102
I1
I0
I1
tp42407
sS'and,may,require'
p42408
(F0
F0
I1
I1
I0
tp42409
sS'option,in,the'
p42410
(F1
F0.00014334862385321102
I0
I1
I-1
tp42411
sS'therapeutic,dose,of'
p42412
(F1
F0.00014334862385321102
I1
I0
I1
tp42413
sS'a,significant,reduction'
p42414
(F1
F0.00014334862385321102
I1
I0
I1
tp42415
sS'results,of,assays'
p42416
(F1
F0.00014334862385321102
I0
I1
I-1
tp42417
sS'patients,taking,tricyclic'
p42418
(F1
F0.00014334862385321102
I1
I0
I1
tp42419
sS'females,and,auc'
p42420
(F1
F0.00014334862385321102
I1
I0
I1
tp42421
sS'to,although,there'
p42422
(F1
F0.00014334862385321102
I1
I0
I1
tp42423
sS'also,due,to'
p42424
(F1
F0.00014334862385321102
I1
I0
I1
tp42425
sS'serum,prostate-specific,antigen'
p42426
(F1
F0.00014334862385321102
I0
I1
I-1
tp42427
sS'than,that,observed'
p42428
(F1
F0.00028669724770642203
I2
I0
I2
tp42429
sS'regimens,may,have'
p42430
(F1
F0.00014334862385321102
I0
I1
I-1
tp42431
sS'cytochrome,p450,enzyme-inducer'
p42432
(F1
F0.00014334862385321102
I1
I0
I1
tp42433
sS'times,daily,before'
p42434
(F1
F0.00028669724770642203
I0
I2
I-2
tp42435
sS'such,as,cns'
p42436
(F1
F0.00014334862385321102
I0
I1
I-1
tp42437
sS'other,and,have'
p42438
(F1
F0.00014334862385321102
I0
I1
I-1
tp42439
sS'is,a,agonist'
p42440
(F1
F0.00014334862385321102
I1
I0
I1
tp42441
sS'considered,for,the'
p42442
(F1
F0.00014334862385321102
I0
I1
I-1
tp42443
sS'known,to,cause'
p42444
(F1
F0.00014334862385321102
I0
I1
I-1
tp42445
sS'exception,of,there'
p42446
(F1
F0.00014334862385321102
I0
I1
I-1
tp42447
sS'blocking,the,tail-flick'
p42448
(F1
F0.00014334862385321102
I0
I1
I-1
tp42449
sS'once,weekly,or'
p42450
(F1
F0.00014334862385321102
I0
I1
I-1
tp42451
sS'and,behavioral,inhibition'
p42452
(F1
F0.00014334862385321102
I0
I1
I-1
tp42453
sS'the,same,day'
p42454
(F1
F0.00014334862385321102
I1
I0
I1
tp42455
sS'and,is,generally'
p42456
(F1
F0.00014334862385321102
I1
I0
I1
tp42457
sS'qid,did,not'
p42458
(F1
F0.00014334862385321102
I0
I1
I-1
tp42459
sS'with,simultaneous,dosing'
p42460
(F1
F0.00028669724770642203
I2
I0
I2
tp42461
sS'in,patients,is'
p42462
(F1
F0.00014334862385321102
I1
I0
I1
tp42463
sS'level,is,recommended'
p42464
(F1
F0.00014334862385321102
I0
I1
I-1
tp42465
sS'be,used,in'
p42466
(F0.81818181818181823
F0.0012901376146788992
I10
I1
I9
tp42467
sS'in,patients,in'
p42468
(F1
F0.00014334862385321102
I0
I1
I-1
tp42469
sS'folate,utilization,including'
p42470
(F1
F0.00014334862385321102
I1
I0
I1
tp42471
sS'active,phosphorylated,which'
p42472
(F1
F0.00014334862385321102
I1
I0
I1
tp42473
sS'acid,aminocaproic,acid'
p42474
(F1
F0.00014334862385321102
I0
I1
I-1
tp42475
sS'or,the,initial'
p42476
(F1
F0.00014334862385321102
I1
I0
I1
tp42477
sS'of,neural,pathways'
p42478
(F1
F0.00014334862385321102
I0
I1
I-1
tp42479
sS'training,dose,in'
p42480
(F1
F0.00014334862385321102
I0
I1
I-1
tp42481
sS'since,is,frequently'
p42482
(F1
F0.00014334862385321102
I0
I1
I-1
tp42483
sS'levels,total,auc'
p42484
(F1
F0.00014334862385321102
I1
I0
I1
tp42485
sS'both,and,coreg'
p42486
(F1
F0.00014334862385321102
I1
I0
I1
tp42487
sS'include,increased,sedation'
p42488
(F1
F0.00014334862385321102
I1
I0
I1
tp42489
sS'effects,of,ruthenium'
p42490
(F1
F0.00014334862385321102
I0
I1
I-1
tp42491
sS'to,fold,elevation'
p42492
(F1
F0.00014334862385321102
I1
I0
I1
tp42493
sS'of,increased,dramatically'
p42494
(F1
F0.00014334862385321102
I0
I1
I-1
tp42495
sS'intracranial,pressure,their'
p42496
(F1
F0.00014334862385321102
I1
I0
I1
tp42497
sS'by,a,nonlethal'
p42498
(F1
F0.00014334862385321102
I0
I1
I-1
tp42499
sS'levels,considerably,lower'
p42500
(F1
F0.00028669724770642203
I2
I0
I2
tp42501
sS'given,single,mg'
p42502
(F1
F0.00014334862385321102
I1
I0
I1
tp42503
sS'test,results,and'
p42504
(F1
F0.00014334862385321102
I1
I0
I1
tp42505
sS'other,given,concurrently'
p42506
(F1
F0.00014334862385321102
I1
I0
I1
tp42507
sS'p450,d6,and'
p42508
(F1
F0.00014334862385321102
I0
I1
I-1
tp42509
sS'structures,whereas,h-spiroperidol'
p42510
(F1
F0.00014334862385321102
I0
I1
I-1
tp42511
sS'other,vasoconstrictor,can'
p42512
(F1
F0.00014334862385321102
I1
I0
I1
tp42513
sS'hydrochloride,mg,every'
p42514
(F1
F0.00014334862385321102
I0
I1
I-1
tp42515
sS'concentrations,in,otherwise'
p42516
(F1
F0.00014334862385321102
I1
I0
I1
tp42517
sS'l-arginine,supplements,theoretically'
p42518
(F1
F0.00014334862385321102
I1
I0
I1
tp42519
sS'inr,or,due'
p42520
(F1
F0.00014334862385321102
I0
I1
I-1
tp42521
sS'or,increased,prothrombin'
p42522
(F1
F0.00014334862385321102
I1
I0
I1
tp42523
sS'erythro-fluorocitrate,synthesis,or'
p42524
(F1
F0.00014334862385321102
I0
I1
I-1
tp42525
sS'approximately,and,respectively'
p42526
(F1
F0.00028669724770642203
I2
I0
I2
tp42527
sS'basic,as,well'
p42528
(F1
F0.00014334862385321102
I1
I0
I1
tp42529
sS'been,observed,with'
p42530
(F1
F0.00028669724770642203
I0
I2
I-2
tp42531
sS'doses,has,been'
p42532
(F1
F0.00014334862385321102
I1
I0
I1
tp42533
sS'or,corrected,qt'
p42534
(F1
F0.00014334862385321102
I0
I1
I-1
tp42535
sS'depressant,effect,of'
p42536
(F1
F0.00014334862385321102
I1
I0
I1
tp42537
sS'of,hours,after'
p42538
(F1
F0.00014334862385321102
I1
I0
I1
tp42539
sS'caused,a,dose-related'
p42540
(F1
F0.00028669724770642203
I2
I0
I2
tp42541
sS'interfere,with,bioassay'
p42542
(F1
F0.00014334862385321102
I0
I1
I-1
tp42543
sS'mg,vardenafil,dose'
p42544
(F1
F0.00043004587155963305
I3
I0
I3
tp42545
sS'study,data,to'
p42546
(F1
F0.00014334862385321102
I1
I0
I1
tp42547
sS'of,metabolism,via'
p42548
(F1
F0.00014334862385321102
I1
I0
I1
tp42549
sS'on,hepatic,cytochrome'
p42550
(F1
F0.00014334862385321102
I0
I1
I-1
tp42551
sS'is,of,clinical'
p42552
(F1
F0.00028669724770642203
I0
I2
I-2
tp42553
sS'in,all,animal'
p42554
(F1
F0.00014334862385321102
I0
I1
I-1
tp42555
sS'with,that,potentiate'
p42556
(F1
F0.00014334862385321102
I0
I1
I-1
tp42557
sS'four-session,placebo-controlled,within-subject'
p42558
(F1
F0.00014334862385321102
I0
I1
I-1
tp42559
sS'of,robinul,injection'
p42560
(F1
F0.00028669724770642203
I2
I0
I2
tp42561
sS'm1,the,active'
p42562
(F1
F0.00014334862385321102
I1
I0
I1
tp42563
sS'responsiveness,to,the'
p42564
(F1
F0.00028669724770642203
I0
I2
I-2
tp42565
sS'and,mg,each'
p42566
(F0
F0
I1
I1
I0
tp42567
sS'major,psychotic,disorders'
p42568
(F1
F0.00014334862385321102
I1
I0
I1
tp42569
sS'unchanged,alkaloids,and'
p42570
(F1
F0.00014334862385321102
I1
I0
I1
tp42571
sS'means,of,the'
p42572
(F1
F0.00014334862385321102
I0
I1
I-1
tp42573
sS'kg,day,is'
p42574
(F1
F0.00014334862385321102
I0
I1
I-1
tp42575
sS'of,and,lodine'
p42576
(F1
F0.00014334862385321102
I1
I0
I1
tp42577
sS'hepatic,enzymes,such'
p42578
(F1
F0.00014334862385321102
I1
I0
I1
tp42579
sS'adverse,events,in'
p42580
(F1
F0.00028669724770642203
I0
I2
I-2
tp42581
sS'supervision,and,careful'
p42582
(F0
F0
I2
I2
I0
tp42583
sS'formulation,comparable,to'
p42584
(F1
F0.00028669724770642203
I2
I0
I2
tp42585
sS'kg,day,in'
p42586
(F1
F0.00014334862385321102
I1
I0
I1
tp42587
sS'in,a,study'
p42588
(F0.18518518518518517
F0.00071674311926605509
I16
I11
I5
tp42589
sS'in,adults,on'
p42590
(F1
F0.00014334862385321102
I1
I0
I1
tp42591
sS'should,not,beadministered'
p42592
(F1
F0.00028669724770642203
I2
I0
I2
tp42593
sS'that,are,actively'
p42594
(F1
F0.00014334862385321102
I1
I0
I1
tp42595
sS'case-control,and,cohort'
p42596
(F1
F0.00014334862385321102
I1
I0
I1
tp42597
sS'least,one,hour'
p42598
(F1
F0.00014334862385321102
I1
I0
I1
tp42599
sS'interactions,with,commonly'
p42600
(F1
F0.00014334862385321102
I0
I1
I-1
tp42601
sS'carefully,observed,for'
p42602
(F0
F0
I1
I1
I0
tp42603
sS'were,administered,one'
p42604
(F1
F0.00014334862385321102
I0
I1
I-1
tp42605
sS'prescription,and,nonprescription'
p42606
(F1
F0.00014334862385321102
I0
I1
I-1
tp42607
sS'an,oral,antagonist'
p42608
(F1
F0.00014334862385321102
I1
I0
I1
tp42609
sS'warranted,in,patients'
p42610
(F1
F0.00014334862385321102
I1
I0
I1
tp42611
sS'vision,and,other'
p42612
(F1
F0.00014334862385321102
I1
I0
I1
tp42613
sS'given,in,a'
p42614
(F1
F0.00014334862385321102
I1
I0
I1
tp42615
sS'to,midcycle,day'
p42616
(F1
F0.00014334862385321102
I0
I1
I-1
tp42617
sS'is,completely,cleared'
p42618
(F1
F0.00014334862385321102
I0
I1
I-1
tp42619
sS'of,was,associated'
p42620
(F1
F0.00014334862385321102
I0
I1
I-1
tp42621
sS'on,a,mg'
p42622
(F1
F0.00014334862385321102
I1
I0
I1
tp42623
sS'administered,with,food'
p42624
(F1
F0.00014334862385321102
I1
I0
I1
tp42625
sS'may,produce,severe'
p42626
(F1
F0.00071674311926605509
I5
I0
I5
tp42627
sS'of,desmopressin,is'
p42628
(F1
F0.00014334862385321102
I0
I1
I-1
tp42629
sS'resistance,to,the'
p42630
(F1
F0.00014334862385321102
I1
I0
I1
tp42631
sS'enhanced,by,the'
p42632
(F1
F0.00028669724770642203
I2
I0
I2
tp42633
sS'on,the,repeat'
p42634
(F1
F0.00014334862385321102
I0
I1
I-1
tp42635
sS'effect,on,cas'
p42636
(F1
F0.00014334862385321102
I1
I0
I1
tp42637
sS'antagonists,phenyltheophylline,and'
p42638
(F1
F0.00014334862385321102
I0
I1
I-1
tp42639
sS'eg,may,increase'
p42640
(F1
F0.00014334862385321102
I1
I0
I1
tp42641
sS'formulations,containing,buffer'
p42642
(F1
F0.00014334862385321102
I1
I0
I1
tp42643
sS'not,detect,an'
p42644
(F1
F0.00014334862385321102
I0
I1
I-1
tp42645
sS'given,to,patients'
p42646
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp42647
sS'concomitant,and,chemotherapy'
p42648
(F1
F0.00014334862385321102
I0
I1
I-1
tp42649
sS'of,competitive,displacement'
p42650
(F1
F0.00014334862385321102
I0
I1
I-1
tp42651
sS'increase,the,absorption'
p42652
(F1
F0.00014334862385321102
I1
I0
I1
tp42653
sS'stimulate,egf-,or'
p42654
(F1
F0.00014334862385321102
I1
I0
I1
tp42655
sS'proteins,in,vitro'
p42656
(F1
F0.00014334862385321102
I0
I1
I-1
tp42657
sS'hyperreflexia,and,incoordination'
p42658
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp42659
sS'to,cause,a'
p42660
(F0
F0
I1
I1
I0
tp42661
sS'nsaids,was,similar'
p42662
(F1
F0.00014334862385321102
I0
I1
I-1
tp42663
sS'average,by,and'
p42664
(F1
F0.00014334862385321102
I1
I0
I1
tp42665
sS'patients,with,human'
p42666
(F1
F0.00014334862385321102
I0
I1
I-1
tp42667
sS'if,combination,therapy'
p42668
(F1
F0.00014334862385321102
I0
I1
I-1
tp42669
sS'in,several,dose'
p42670
(F1
F0.00014334862385321102
I0
I1
I-1
tp42671
sS'patients,already,stabilized'
p42672
(F1
F0.00014334862385321102
I1
I0
I1
tp42673
sS'lower,affinity,for'
p42674
(F1
F0.00014334862385321102
I1
I0
I1
tp42675
sS'a,sulfa-based,such'
p42676
(F1
F0.00014334862385321102
I0
I1
I-1
tp42677
sS'administration,of,hydroxide'
p42678
(F1
F0.00014334862385321102
I0
I1
I-1
tp42679
sS'to,oral,the'
p42680
(F1
F0.00014334862385321102
I0
I1
I-1
tp42681
sS'days,after,administration'
p42682
(F1
F0.00014334862385321102
I1
I0
I1
tp42683
sS'similar,to,and'
p42684
(F1
F0.00014334862385321102
I0
I1
I-1
tp42685
sS'a,times,increase'
p42686
(F1
F0.00014334862385321102
I1
I0
I1
tp42687
sS'per,day,ig'
p42688
(F1
F0.00014334862385321102
I1
I0
I1
tp42689
sS'significantly,improved,permeation'
p42690
(F1
F0.00014334862385321102
I0
I1
I-1
tp42691
sS'increased,the,incidence'
p42692
(F1
F0.00014334862385321102
I1
I0
I1
tp42693
sS'in,order,to'
p42694
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp42695
sS'then,mg,kg'
p42696
(F1
F0.00014334862385321102
I0
I1
I-1
tp42697
sS'urinary,bilirubin,urobilin'
p42698
(F1
F0.00014334862385321102
I0
I1
I-1
tp42699
sS'vivo,the,primary'
p42700
(F1
F0.00014334862385321102
I1
I0
I1
tp42701
sS'a,narrow,therapeutic'
p42702
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp42703
sS'of,class,ia'
p42704
(F1
F0.00014334862385321102
I1
I0
I1
tp42705
sS'enhance,the,cns-depressive'
p42706
(F1
F0.00014334862385321102
I1
I0
I1
tp42707
sS'acute,myocardial,infarction'
p42708
(F1
F0.00014334862385321102
I0
I1
I-1
tp42709
sS'of,a,mg'
p42710
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp42711
sS'a,maintenance,schedule'
p42712
(F1
F0.00014334862385321102
I1
I0
I1
tp42713
sS'whereas,the,mean'
p42714
(F1
F0.00014334862385321102
I1
I0
I1
tp42715
sS'studies,are,summarized'
p42716
(F1
F0.00014334862385321102
I0
I1
I-1
tp42717
sS'the,initiate,therapy'
p42718
(F1
F0.00014334862385321102
I1
I0
I1
tp42719
sS'if,additional,adrenergic'
p42720
(F1
F0.00014334862385321102
I1
I0
I1
tp42721
sS'agents,gastrointestinal,acidifying'
p42722
(F1
F0.00014334862385321102
I1
I0
I1
tp42723
sS'effect,of,concomitant'
p42724
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp42725
sS'mixing,of,an'
p42726
(F1
F0.00014334862385321102
I1
I0
I1
tp42727
sS'cardiovascular,system,may'
p42728
(F1
F0.00028669724770642203
I2
I0
I2
tp42729
sS'as,have,the'
p42730
(F1
F0.00014334862385321102
I1
I0
I1
tp42731
sS'of,plasma,half-life'
p42732
(F0
F0
I1
I1
I0
tp42733
sS'be,reduced,in'
p42734
(F1
F0.00028669724770642203
I0
I2
I-2
tp42735
sS'patients,with,high'
p42736
(F1
F0.00028669724770642203
I0
I2
I-2
tp42737
sS'beta-blockers,not,only'
p42738
(F1
F0.00014334862385321102
I1
I0
I1
tp42739
sS'system,mainly,responsible'
p42740
(F1
F0.00014334862385321102
I1
I0
I1
tp42741
sS'blunts,the,reflex'
p42742
(F1
F0.00014334862385321102
I1
I0
I1
tp42743
sS'coadministration,of,itraconazole'
p42744
(F1
F0.00028669724770642203
I2
I0
I2
tp42745
sS'plasma,concentration,for'
p42746
(F1
F0.00014334862385321102
I0
I1
I-1
tp42747
sS'the,potential,of'
p42748
(F1
F0.00043004587155963305
I3
I0
I3
tp42749
sS'blocker,of,renal'
p42750
(F1
F0.00014334862385321102
I0
I1
I-1
tp42751
sS'alprazolam,when,maleate'
p42752
(F1
F0.00014334862385321102
I1
I0
I1
tp42753
sS'x,kg,in'
p42754
(F1
F0.00014334862385321102
I0
I1
I-1
tp42755
sS'to,see,whether'
p42756
(F1
F0.00014334862385321102
I1
I0
I1
tp42757
sS'macrolide,immunosuppressant,metabolized'
p42758
(F1
F0.00014334862385321102
I0
I1
I-1
tp42759
sS'antacids,may,interfere'
p42760
(F1
F0.00014334862385321102
I1
I0
I1
tp42761
sS'blockers,may,result'
p42762
(F1
F0.00014334862385321102
I0
I1
I-1
tp42763
sS'vasospasm,and,ischemia'
p42764
(F1
F0.00014334862385321102
I0
I1
I-1
tp42765
sS'in,cortisol,does'
p42766
(F1
F0.00014334862385321102
I0
I1
I-1
tp42767
sS'using,labetalol,hcl'
p42768
(F1
F0.00014334862385321102
I1
I0
I1
tp42769
sS'studies,show,that'
p42770
(F1
F0.00014334862385321102
I0
I1
I-1
tp42771
sS'th,day,provided'
p42772
(F1
F0.00014334862385321102
I1
I0
I1
tp42773
sS'for,cyp3a4,and'
p42774
(F1
F0.00014334862385321102
I0
I1
I-1
tp42775
sS'active,metabolite,of'
p42776
(F1
F0.00028669724770642203
I0
I2
I-2
tp42777
sS'interactions,a,false-positive'
p42778
(F1
F0.00028669724770642203
I0
I2
I-2
tp42779
sS'sodium,valproic,acid'
p42780
(F1
F0.00014334862385321102
I1
I0
I1
tp42781
sS'have,resulted,when'
p42782
(F1
F0.00014334862385321102
I1
I0
I1
tp42783
sS'human,plasma,indicate'
p42784
(F1
F0.00014334862385321102
I0
I1
I-1
tp42785
sS'concurrent,administration,with'
p42786
(F1
F0.00014334862385321102
I1
I0
I1
tp42787
sS'mg,dl,submitted'
p42788
(F1
F0.00014334862385321102
I0
I1
I-1
tp42789
sS'when,k,antagonists'
p42790
(F1
F0.00014334862385321102
I1
I0
I1
tp42791
sS'or,related,psychoses'
p42792
(F1
F0.00014334862385321102
I0
I1
I-1
tp42793
sS'unaffected,given,the'
p42794
(F1
F0.00014334862385321102
I1
I0
I1
tp42795
sS'therapy,includes,such'
p42796
(F1
F0.00014334862385321102
I0
I1
I-1
tp42797
sS'eproxindine,ethanol,flupenthixol'
p42798
(F1
F0.00014334862385321102
I1
I0
I1
tp42799
sS'and,emit-d,a'
p42800
(F1
F0.00014334862385321102
I0
I1
I-1
tp42801
sS'was,used,in'
p42802
(F1
F0.00028669724770642203
I2
I0
I2
tp42803
sS'hour,after,receiving'
p42804
(F1
F0.00014334862385321102
I1
I0
I1
tp42805
sS'studies,with,human'
p42806
(F1
F0.00028669724770642203
I0
I2
I-2
tp42807
sS'glucuronide,account,for'
p42808
(F1
F0.00014334862385321102
I0
I1
I-1
tp42809
sS'two,weeks,prior'
p42810
(F1
F0.00014334862385321102
I1
I0
I1
tp42811
sS'leading,to,inter-patient'
p42812
(F1
F0.00014334862385321102
I1
I0
I1
tp42813
sS'elimination,half-life,and'
p42814
(F1
F0.00014334862385321102
I1
I0
I1
tp42815
sS'were,subsequently,administered'
p42816
(F1
F0.00014334862385321102
I1
I0
I1
tp42817
sS'serial,measurement,of'
p42818
(F1
F0.00014334862385321102
I1
I0
I1
tp42819
sS'oral,product,in'
p42820
(F1
F0.00014334862385321102
I0
I1
I-1
tp42821
sS'required,during,omnicef'
p42822
(F1
F0.00028669724770642203
I2
I0
I2
tp42823
sS'of,other,with'
p42824
(F1
F0.00014334862385321102
I1
I0
I1
tp42825
sS'volunteers,who,had'
p42826
(F1
F0.00014334862385321102
I0
I1
I-1
tp42827
sS'in,addition,fondaparinux'
p42828
(F1
F0.00014334862385321102
I0
I1
I-1
tp42829
sS'and,a,known'
p42830
(F1
F0.00014334862385321102
I1
I0
I1
tp42831
sS'zinecard,does,not'
p42832
(F1
F0.00014334862385321102
I0
I1
I-1
tp42833
sS'vitro,binding,of'
p42834
(F1
F0.00014334862385321102
I1
I0
I1
tp42835
sS'g,kg,mg'
p42836
(F1
F0.00014334862385321102
I0
I1
I-1
tp42837
sS'mao,inhibitors,studies'
p42838
(F1
F0.00014334862385321102
I1
I0
I1
tp42839
sS'avoided,unless,clinically'
p42840
(F1
F0.00014334862385321102
I1
I0
I1
tp42841
sS'diabetes,mellitus,and'
p42842
(F1
F0.00014334862385321102
I0
I1
I-1
tp42843
sS'for,excretion,in'
p42844
(F1
F0.00014334862385321102
I1
I0
I1
tp42845
sS'b,the,effects'
p42846
(F1
F0.00014334862385321102
I0
I1
I-1
tp42847
sS'of,hypotension,will'
p42848
(F1
F0.00014334862385321102
I1
I0
I1
tp42849
sS'develop,toxicity,characteristics'
p42850
(F1
F0.00014334862385321102
I1
I0
I1
tp42851
sS'types,of,channels'
p42852
(F1
F0.00014334862385321102
I0
I1
I-1
tp42853
sS'were,experienced,more'
p42854
(F1
F0.00014334862385321102
I1
I0
I1
tp42855
sS'analogue,d-ala2,metenkephalinamide'
p42856
(F1
F0.00014334862385321102
I0
I1
I-1
tp42857
sS'because,a,similar'
p42858
(F1
F0.00014334862385321102
I1
I0
I1
tp42859
sS'clearance,and,a'
p42860
(F1
F0.00014334862385321102
I1
I0
I1
tp42861
sS'average,of,fold'
p42862
(F1
F0.00014334862385321102
I1
I0
I1
tp42863
sS'started,in,patients'
p42864
(F1
F0.00014334862385321102
I1
I0
I1
tp42865
sS'antacids,kaolin-pectin,certain'
p42866
(F1
F0.00014334862385321102
I1
I0
I1
tp42867
sS'tablets,as,well'
p42868
(F1
F0.00014334862385321102
I1
I0
I1
tp42869
sS'among,patients,with'
p42870
(F1
F0.00014334862385321102
I1
I0
I1
tp42871
sS'day,microg,kg'
p42872
(F1
F0.00014334862385321102
I0
I1
I-1
tp42873
sS'with,amevive,before'
p42874
(F1
F0.00014334862385321102
I0
I1
I-1
tp42875
sS'mg,increased,the'
p42876
(F1
F0.00028669724770642203
I2
I0
I2
tp42877
sS'rr,had,no'
p42878
(F1
F0.00014334862385321102
I0
I1
I-1
tp42879
sS'hours,after,or'
p42880
(F1
F0.00014334862385321102
I1
I0
I1
tp42881
sS'was,no,pharmacodynamic'
p42882
(F1
F0.00028669724770642203
I0
I2
I-2
tp42883
sS'examine,interactions,have'
p42884
(F1
F0.00014334862385321102
I0
I1
I-1
tp42885
sS'serious,and,life-threatening'
p42886
(F1
F0.00014334862385321102
I0
I1
I-1
tp42887
sS'or,primidone,no'
p42888
(F1
F0.00014334862385321102
I0
I1
I-1
tp42889
sS'to,function,as'
p42890
(F1
F0.00014334862385321102
I0
I1
I-1
tp42891
sS'of,was,lowered'
p42892
(F1
F0.00014334862385321102
I1
I0
I1
tp42893
sS'renal,excretion,is'
p42894
(F1
F0.00014334862385321102
I1
I0
I1
tp42895
sS'oxidase,inhibitors,or'
p42896
(F1
F0.00071674311926605509
I5
I0
I5
tp42897
sS'the,csf,primarily'
p42898
(F1
F0.00014334862385321102
I0
I1
I-1
tp42899
sS'nc,denotes,a'
p42900
(F1
F0.00014334862385321102
I1
I0
I1
tp42901
sS'increase,of,approximately'
p42902
(F0
F0
I1
I1
I0
tp42903
sS'human,immediately,before'
p42904
(F1
F0.00014334862385321102
I0
I1
I-1
tp42905
sS'the,elderly,and'
p42906
(F1
F0.00014334862385321102
I0
I1
I-1
tp42907
sS'vasculature,without,disturbing'
p42908
(F1
F0.00014334862385321102
I0
I1
I-1
tp42909
sS'toxoids,should,be'
p42910
(F1
F0.00014334862385321102
I1
I0
I1
tp42911
sS'by,added,cholesterol'
p42912
(F1
F0.00014334862385321102
I0
I1
I-1
tp42913
sS'effects,of,brovana'
p42914
(F1
F0.00014334862385321102
I1
I0
I1
tp42915
sS'relevant,concentrations,in'
p42916
(F1
F0.00014334862385321102
I0
I1
I-1
tp42917
sS'disturbances,were,not'
p42918
(F1
F0.00014334862385321102
I1
I0
I1
tp42919
sS'treatment,of,negative'
p42920
(F1
F0.00028669724770642203
I0
I2
I-2
tp42921
sS'emergency,situation,when'
p42922
(F1
F0.00014334862385321102
I1
I0
I1
tp42923
sS'anti-hiv,protease,inhibitors'
p42924
(F1
F0.00014334862385321102
I0
I1
I-1
tp42925
sS'be,expected,that'
p42926
(F0
F0
I1
I1
I0
tp42927
sS'in,patients,to'
p42928
(F1
F0.00014334862385321102
I1
I0
I1
tp42929
sS'studies,ie,timi-ii'
p42930
(F1
F0.00014334862385321102
I0
I1
I-1
tp42931
sS'is,available,about'
p42932
(F1
F0.00028669724770642203
I0
I2
I-2
tp42933
sS'or,hypokalemia,that'
p42934
(F1
F0.00014334862385321102
I1
I0
I1
tp42935
sS'decrease,the,amount'
p42936
(F1
F0.00014334862385321102
I1
I0
I1
tp42937
sS'omeprazole,should,be'
p42938
(F1
F0.00014334862385321102
I0
I1
I-1
tp42939
sS'intravenously,administered,mg'
p42940
(F1
F0.00014334862385321102
I1
I0
I1
tp42941
sS'of,methylpyrazole,seen'
p42942
(F1
F0.00014334862385321102
I1
I0
I1
tp42943
sS'amprenavir,plus,was'
p42944
(F0
F0
I1
I1
I0
tp42945
sS'triazole,have,not'
p42946
(F1
F0.00014334862385321102
I0
I1
I-1
tp42947
sS'including,humira,may'
p42948
(F1
F0.00014334862385321102
I1
I0
I1
tp42949
sS'volunteers,of,subjects'
p42950
(F1
F0.00014334862385321102
I1
I0
I1
tp42951
sS'cmax,leading,to'
p42952
(F1
F0.00014334862385321102
I1
I0
I1
tp42953
sS'mice,from,the'
p42954
(F1
F0.00014334862385321102
I0
I1
I-1
tp42955
sS'prodrug,form,of'
p42956
(F1
F0.00014334862385321102
I0
I1
I-1
tp42957
sS'particularly,during,the'
p42958
(F1
F0.00014334862385321102
I1
I0
I1
tp42959
sS'erythromycin,in,healthy'
p42960
(F1
F0.00014334862385321102
I1
I0
I1
tp42961
sS'when,myocardial,depressants'
p42962
(F1
F0.00014334862385321102
I1
I0
I1
tp42963
sS'phenyl-butazone,sodium,and'
p42964
(F1
F0.00014334862385321102
I0
I1
I-1
tp42965
sS'using,it,is'
p42966
(F1
F0.00014334862385321102
I1
I0
I1
tp42967
sS'depressants,are,administered'
p42968
(F1
F0.00014334862385321102
I1
I0
I1
tp42969
sS'have,a,narrow'
p42970
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp42971
sS'or,cyp3a4,in'
p42972
(F1
F0.00014334862385321102
I0
I1
I-1
tp42973
sS'patients,the,steroidal'
p42974
(F1
F0.00014334862385321102
I1
I0
I1
tp42975
sS'daily,produced,a'
p42976
(F1
F0.00014334862385321102
I1
I0
I1
tp42977
sS'of,for,up'
p42978
(F1
F0.00014334862385321102
I0
I1
I-1
tp42979
sS'simply,normalizing,the'
p42980
(F1
F0.00014334862385321102
I0
I1
I-1
tp42981
sS'effect,with,in'
p42982
(F1
F0.00014334862385321102
I1
I0
I1
tp42983
sS'lowest,recommended,dose'
p42984
(F1
F0.00014334862385321102
I1
I0
I1
tp42985
sS'pharmacokinetic,substudy,in'
p42986
(F1
F0.00014334862385321102
I1
I0
I1
tp42987
sS'mg,kg,with'
p42988
(F1
F0.00014334862385321102
I1
I0
I1
tp42989
sS'digitalized,hypothyroid,patient'
p42990
(F1
F0.00014334862385321102
I1
I0
I1
tp42991
sS'a,broad,spectrum'
p42992
(F1
F0.00014334862385321102
I0
I1
I-1
tp42993
sS'effect,of,these'
p42994
(F1
F0.00028669724770642203
I0
I2
I-2
tp42995
sS'were,used,to'
p42996
(F1
F0.00014334862385321102
I0
I1
I-1
tp42997
sS'was,obtained,for'
p42998
(F1
F0.00014334862385321102
I0
I1
I-1
tp42999
sS'on,an,oral'
p43000
(F1
F0.00014334862385321102
I0
I1
I-1
tp43001
sS'or,less,frequent'
p43002
(F1
F0.00014334862385321102
I1
I0
I1
tp43003
sS'inactivate,the,activity'
p43004
(F1
F0.00014334862385321102
I1
I0
I1
tp43005
sS'nor,should,be'
p43006
(F1
F0.00014334862385321102
I1
I0
I1
tp43007
sS'of,these,leading'
p43008
(F1
F0.00014334862385321102
I1
I0
I1
tp43009
sS'concern,regarding,asthma'
p43010
(F1
F0.00014334862385321102
I0
I1
I-1
tp43011
sS'of,contraception,should'
p43012
(F1
F0.00014334862385321102
I1
I0
I1
tp43013
sS'acid,have,been'
p43014
(F1
F0.00014334862385321102
I1
I0
I1
tp43015
sS'hypotensive,using,labetalol'
p43016
(F1
F0.00014334862385321102
I1
I0
I1
tp43017
sS'been,evaluated,these'
p43018
(F1
F0.00014334862385321102
I0
I1
I-1
tp43019
sS'subject,before,and'
p43020
(F1
F0.00014334862385321102
I0
I1
I-1
tp43021
sS'to,and,st'
p43022
(F1
F0.00014334862385321102
I0
I1
I-1
tp43023
sS'doubled,in,the'
p43024
(F1
F0.00014334862385321102
I0
I1
I-1
tp43025
sS'was,increased,when'
p43026
(F1
F0.00014334862385321102
I1
I0
I1
tp43027
sS'with,some,other'
p43028
(F1
F0.00028669724770642203
I2
I0
I2
tp43029
sS'percentage,increase,in'
p43030
(F1
F0.00057339449541284407
I4
I0
I4
tp43031
sS'large,quantities,of'
p43032
(F1
F0.00014334862385321102
I0
I1
I-1
tp43033
sS'protein-bound,with,narrow'
p43034
(F1
F0.00014334862385321102
I1
I0
I1
tp43035
sS'agents,channel,blockers'
p43036
(F1
F0.00014334862385321102
I1
I0
I1
tp43037
sS'interactions,have,not'
p43038
(F1
F0.00071674311926605509
I0
I5
I-5
tp43039
sS'either,procedure,even'
p43040
(F1
F0.00014334862385321102
I0
I1
I-1
tp43041
sS'and,hours,were'
p43042
(F1
F0.00014334862385321102
I1
I0
I1
tp43043
sS'affinity,for,than'
p43044
(F1
F0.00014334862385321102
I1
I0
I1
tp43045
sS'blocker,was,studied'
p43046
(F1
F0.00014334862385321102
I0
I1
I-1
tp43047
sS'foods,highly,fortified'
p43048
(F1
F0.00014334862385321102
I0
I1
I-1
tp43049
sS'and,adjustment,of'
p43050
(F1
F0.00071674311926605509
I5
I0
I5
tp43051
sS'period,of,min'
p43052
(F1
F0.00014334862385321102
I1
I0
I1
tp43053
sS'their,bioavailability,was'
p43054
(F1
F0.00014334862385321102
I1
I0
I1
tp43055
sS'inter-patient,variation,in'
p43056
(F1
F0.00014334862385321102
I1
I0
I1
tp43057
sS'either,discontinuing,the'
p43058
(F1
F0.00071674311926605509
I5
I0
I5
tp43059
sS'diltiazem,plasma,levels'
p43060
(F1
F0.00014334862385321102
I0
I1
I-1
tp43061
sS'cns,depressants,causing'
p43062
(F1
F0.00028669724770642203
I2
I0
I2
tp43063
sS'and,tnf,antagonists'
p43064
(F1
F0.00014334862385321102
I1
I0
I1
tp43065
sS'neither,were,pharmacokinetic'
p43066
(F1
F0.00014334862385321102
I0
I1
I-1
tp43067
sS'or,nsaid,users'
p43068
(F1
F0.00014334862385321102
I0
I1
I-1
tp43069
sS'drawn,if,a'
p43070
(F1
F0.00014334862385321102
I1
I0
I1
tp43071
sS'range,of,patients'
p43072
(F1
F0.00014334862385321102
I1
I0
I1
tp43073
sS'with,beta-adrenergic,blocking'
p43074
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp43075
sS'and,intravenous,placebo'
p43076
(F1
F0.00014334862385321102
I0
I1
I-1
tp43077
sS'contraceptives,valdecoxib,mg'
p43078
(F1
F0.00014334862385321102
I0
I1
I-1
tp43079
sS'or,pcp,in'
p43080
(F1
F0.00014334862385321102
I1
I0
I1
tp43081
sS'extraneal,on,absorption'
p43082
(F1
F0.00014334862385321102
I0
I1
I-1
tp43083
sS'that,the,time'
p43084
(F1
F0.00014334862385321102
I0
I1
I-1
tp43085
sS'acid-catalyzed,ethanolysis,of'
p43086
(F1
F0.00014334862385321102
I1
I0
I1
tp43087
sS'increase,the,frequency'
p43088
(F1
F0.00028669724770642203
I2
I0
I2
tp43089
sS'gain,and,weight'
p43090
(F1
F0.00014334862385321102
I1
I0
I1
tp43091
sS'colestipol,plasma,concentrations'
p43092
(F1
F0.00014334862385321102
I1
I0
I1
tp43093
sS'with,systemically-administered,oral'
p43094
(F1
F0.00014334862385321102
I1
I0
I1
tp43095
sS'pancreases,of,normal'
p43096
(F1
F0.00014334862385321102
I0
I1
I-1
tp43097
sS'carbamazepine,tiagabine,had'
p43098
(F1
F0.00014334862385321102
I0
I1
I-1
tp43099
sS'important,effect,on'
p43100
(F1
F0.0008600917431192661
I0
I6
I-6
tp43101
sS'the,digi-,tab'
p43102
(F1
F0.00014334862385321102
I0
I1
I-1
tp43103
sS'is,necessary,but'
p43104
(F1
F0.00014334862385321102
I0
I1
I-1
tp43105
sS'hypertension,in,patients'
p43106
(F1
F0.00014334862385321102
I1
I0
I1
tp43107
sS'dissolution,of,aerosol'
p43108
(F1
F0.00014334862385321102
I0
I1
I-1
tp43109
sS'thiazide,can,be'
p43110
(F1
F0.00014334862385321102
I1
I0
I1
tp43111
sS'data,lower,doses'
p43112
(F1
F0.00014334862385321102
I1
I0
I1
tp43113
sS'hmg-coa,reductase,may'
p43114
(F1
F0.00014334862385321102
I0
I1
I-1
tp43115
sS'reduce,its,serum'
p43116
(F1
F0.00014334862385321102
I0
I1
I-1
tp43117
sS'hours,competes,for'
p43118
(F1
F0.00014334862385321102
I1
I0
I1
tp43119
sS'studies,with,ace'
p43120
(F1
F0.00014334862385321102
I1
I0
I1
tp43121
sS'of,needed,to'
p43122
(F1
F0.00014334862385321102
I1
I0
I1
tp43123
sS'co-administration,of,angiomax'
p43124
(F0
F0
I1
I1
I0
tp43125
sS'of,the,bile-acidsequestering'
p43126
(F1
F0.00014334862385321102
I0
I1
I-1
tp43127
sS'triazolo-benzodiazepines,dihydropyridine,channel'
p43128
(F1
F0.00014334862385321102
I1
I0
I1
tp43129
sS'when,the,two'
p43130
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp43131
sS'of,age,the'
p43132
(F1
F0.00014334862385321102
I0
I1
I-1
tp43133
sS'auc,of,there'
p43134
(F1
F0.00014334862385321102
I1
I0
I1
tp43135
sS'and,mycophenolate,mofetil'
p43136
(F1
F0.00014334862385321102
I1
I0
I1
tp43137
sS'least,hours,should'
p43138
(F1
F0.00014334862385321102
I1
I0
I1
tp43139
sS'of,the,effects'
p43140
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp43141
sS'known,to,be'
p43142
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp43143
sS'measure,plasma,concentrations'
p43144
(F1
F0.00014334862385321102
I0
I1
I-1
tp43145
sS'with,one,gram'
p43146
(F1
F0.00014334862385321102
I1
I0
I1
tp43147
sS'that,act,on'
p43148
(F1
F0.00014334862385321102
I1
I0
I1
tp43149
sS'cause,severe,orthostatic'
p43150
(F1
F0.00014334862385321102
I1
I0
I1
tp43151
sS'cohort,or,mg'
p43152
(F1
F0.00014334862385321102
I0
I1
I-1
tp43153
sS'increase,of,the'
p43154
(F1
F0.00014334862385321102
I1
I0
I1
tp43155
sS'sodium,approximately,hours'
p43156
(F1
F0.00014334862385321102
I1
I0
I1
tp43157
sS'in,one,report'
p43158
(F1
F0.00014334862385321102
I1
I0
I1
tp43159
sS'agonists,concomitant,use'
p43160
(F1
F0.00014334862385321102
I1
I0
I1
tp43161
sS'taking,an,eg'
p43162
(F1
F0.00014334862385321102
I1
I0
I1
tp43163
sS'renal,and,mesenteric'
p43164
(F0
F0
I1
I1
I0
tp43165
sS'reports,of,oral'
p43166
(F1
F0.00014334862385321102
I0
I1
I-1
tp43167
sS'after,prolonged,administration'
p43168
(F1
F0.00014334862385321102
I0
I1
I-1
tp43169
sS'following,specific,interactions'
p43170
(F1
F0.00014334862385321102
I0
I1
I-1
tp43171
sS'fibric,acid,derivatives'
p43172
(F1
F0.00028669724770642203
I0
I2
I-2
tp43173
sS'kg,of,co'
p43174
(F1
F0.00014334862385321102
I0
I1
I-1
tp43175
sS'events,when,was'
p43176
(F1
F0.00014334862385321102
I0
I1
I-1
tp43177
sS'interact,with,medication'
p43178
(F1
F0.00014334862385321102
I0
I1
I-1
tp43179
sS'in,niddm,subjects'
p43180
(F1
F0.00014334862385321102
I0
I1
I-1
tp43181
sS'meperidine,amphetamines,potentiate'
p43182
(F1
F0.00028669724770642203
I2
I0
I2
tp43183
sS'oral,self-administration,of'
p43184
(F1
F0.00014334862385321102
I0
I1
I-1
tp43185
sS'the,proton,pump'
p43186
(F1
F0.00014334862385321102
I1
I0
I1
tp43187
sS'were,cardiac,and'
p43188
(F1
F0.00014334862385321102
I0
I1
I-1
tp43189
sS'can,diminish,or'
p43190
(F1
F0.00014334862385321102
I1
I0
I1
tp43191
sS'serum,levels,with'
p43192
(F0
F0
I1
I1
I0
tp43193
sS'creatinine,clearance,in'
p43194
(F1
F0.00014334862385321102
I1
I0
I1
tp43195
sS'needed,the,dose'
p43196
(F1
F0.00014334862385321102
I1
I0
I1
tp43197
sS'constant,volume,of'
p43198
(F1
F0.00014334862385321102
I0
I1
I-1
tp43199
sS'as,hours,and'
p43200
(F1
F0.00014334862385321102
I1
I0
I1
tp43201
sS'pharmacological,tool,with'
p43202
(F1
F0.00014334862385321102
I0
I1
I-1
tp43203
sS'glyburide,is,a'
p43204
(F1
F0.00014334862385321102
I0
I1
I-1
tp43205
sS'of,by,sodium'
p43206
(F1
F0.00014334862385321102
I0
I1
I-1
tp43207
sS'patients,who,received'
p43208
(F1
F0.00014334862385321102
I0
I1
I-1
tp43209
sS'in,the,urine'
p43210
(F1
F0.00071674311926605509
I0
I5
I-5
tp43211
sS'plasma,levels,whenever'
p43212
(F1
F0.00057339449541284407
I0
I4
I-4
tp43213
sS'with,has,not'
p43214
(F1
F0.00043004587155963305
I0
I3
I-3
tp43215
sS'peak,plasma,levels'
p43216
(F1
F0.00071674311926605509
I5
I0
I5
tp43217
sS'only,observed,in'
p43218
(F1
F0.00014334862385321102
I1
I0
I1
tp43219
sS'this,oral,did'
p43220
(F1
F0.00014334862385321102
I0
I1
I-1
tp43221
sS'mg,resulted,in'
p43222
(F1
F0.00028669724770642203
I2
I0
I2
tp43223
sS'converted,to,the'
p43224
(F1
F0.00014334862385321102
I1
I0
I1
tp43225
sS'severe,and,unpredictable'
p43226
(F1
F0.00014334862385321102
I1
I0
I1
tp43227
sS'levels,increased,approximately'
p43228
(F1
F0.00014334862385321102
I1
I0
I1
tp43229
sS'on,the,mechanism'
p43230
(F1
F0.00014334862385321102
I0
I1
I-1
tp43231
sS'time,concomitant,supplementation'
p43232
(F1
F0.00014334862385321102
I0
I1
I-1
tp43233
sS'warfarin-type,certain,and'
p43234
(F1
F0.00014334862385321102
I1
I0
I1
tp43235
sS'may,be,an'
p43236
(F1
F0.00028669724770642203
I2
I0
I2
tp43237
sS'side,effects,of'
p43238
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp43239
sS'vardenafil,mg,produced'
p43240
(F1
F0.00014334862385321102
I1
I0
I1
tp43241
sS'mg,once,a'
p43242
(F1
F0.00014334862385321102
I0
I1
I-1
tp43243
sS'and,certain,nonsteroidal'
p43244
(F1
F0.00014334862385321102
I1
I0
I1
tp43245
sS'dosage,of,needed'
p43246
(F1
F0.00014334862385321102
I1
I0
I1
tp43247
sS'recommended,maximum,cumulative'
p43248
(F1
F0.00014334862385321102
I1
I0
I1
tp43249
sS'hcl,with,most'
p43250
(F1
F0.00014334862385321102
I1
I0
I1
tp43251
sS'may,be,at'
p43252
(F1
F0.00028669724770642203
I0
I2
I-2
tp43253
sS'compared,to,subjects'
p43254
(F1
F0.00014334862385321102
I1
I0
I1
tp43255
sS'was,added,in'
p43256
(F1
F0.00014334862385321102
I0
I1
I-1
tp43257
sS'short-term,pharmacokinetic,studies'
p43258
(F1
F0.00014334862385321102
I1
I0
I1
tp43259
sS'monthly,comparison,study'
p43260
(F1
F0.00014334862385321102
I0
I1
I-1
tp43261
sS'with,since,an'
p43262
(F1
F0.00014334862385321102
I1
I0
I1
tp43263
sS'day,washout,period'
p43264
(F1
F0.00014334862385321102
I0
I1
I-1
tp43265
sS'body,weight,and'
p43266
(F1
F0.00014334862385321102
I0
I1
I-1
tp43267
sS'the,results,raise'
p43268
(F1
F0.00014334862385321102
I1
I0
I1
tp43269
sS'results,would,seem'
p43270
(F1
F0.00014334862385321102
I1
I0
I1
tp43271
sS'ethanolysis,of,in'
p43272
(F1
F0.00014334862385321102
I1
I0
I1
tp43273
sS'cilexetil,given,with'
p43274
(F1
F0.00014334862385321102
I0
I1
I-1
tp43275
sS'scale,were,increased'
p43276
(F1
F0.00014334862385321102
I1
I0
I1
tp43277
sS'other,cns-active,should'
p43278
(F1
F0.00014334862385321102
I1
I0
I1
tp43279
sS'in,humans,and'
p43280
(F1
F0.00014334862385321102
I1
I0
I1
tp43281
sS'involving,concomitant,administration'
p43282
(F1
F0.00014334862385321102
I0
I1
I-1
tp43283
sS'may,have,life-threatening'
p43284
(F1
F0.00014334862385321102
I1
I0
I1
tp43285
sS'itraconazole,and,oral'
p43286
(F1
F0.00014334862385321102
I1
I0
I1
tp43287
sS'biliary,excretion,glucuronidation'
p43288
(F1
F0.00014334862385321102
I0
I1
I-1
tp43289
sS'administration,decreased,bioavailability'
p43290
(F1
F0.00014334862385321102
I1
I0
I1
tp43291
sS'concentrations,were,equivocally'
p43292
(F1
F0.00014334862385321102
I1
I0
I1
tp43293
sS'increase,in,clearance'
p43294
(F1
F0.00028669724770642203
I2
I0
I2
tp43295
sS'for,therapy,and'
p43296
(F1
F0.00014334862385321102
I0
I1
I-1
tp43297
sS'with,depen,cuprimine'
p43298
(F1
F0.00014334862385321102
I1
I0
I1
tp43299
sS'the,in,nursing'
p43300
(F1
F0.00014334862385321102
I0
I1
I-1
tp43301
sS'dysfunction,or,cardiac'
p43302
(F1
F0.00014334862385321102
I0
I1
I-1
tp43303
sS'who,were,already'
p43304
(F1
F0.00014334862385321102
I0
I1
I-1
tp43305
sS'were,unaffected,following'
p43306
(F1
F0.00014334862385321102
I0
I1
I-1
tp43307
sS'release,in,the'
p43308
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp43309
sS'antiretroviral,drugs,significant'
p43310
(F1
F0.00014334862385321102
I1
I0
I1
tp43311
sS'drugs,which,induce'
p43312
(F1
F0.00028669724770642203
I2
I0
I2
tp43313
sS'administered,or,if'
p43314
(F1
F0.00014334862385321102
I0
I1
I-1
tp43315
sS'indocin,is,administered'
p43316
(F1
F0.00014334862385321102
I1
I0
I1
tp43317
sS'during,the,longterm'
p43318
(F1
F0.00014334862385321102
I0
I1
I-1
tp43319
sS'of,brevibloc,and'
p43320
(F0
F0
I1
I1
I0
tp43321
sS'with,have,a'
p43322
(F1
F0.00014334862385321102
I0
I1
I-1
tp43323
sS'used,if,patients'
p43324
(F1
F0.00014334862385321102
I1
I0
I1
tp43325
sS'hepatitis,has,been'
p43326
(F1
F0.00014334862385321102
I1
I0
I1
tp43327
sS'mg,and,mg'
p43328
(F0.090909090909090912
F0.00028669724770642203
I12
I10
I2
tp43329
sS'that,are,metabolized'
p43330
(F0.27272727272727271
F0.00043004587155963305
I4
I7
I-3
tp43331
sS'even,when,tested'
p43332
(F1
F0.00014334862385321102
I0
I1
I-1
tp43333
sS'instituted,as,well'
p43334
(F1
F0.00014334862385321102
I1
I0
I1
tp43335
sS'may,be,negatively'
p43336
(F1
F0.00014334862385321102
I0
I1
I-1
tp43337
sS'mcg,twice,daily'
p43338
(F1
F0.00014334862385321102
I0
I1
I-1
tp43339
sS'of,racemic,celexa'
p43340
(F1
F0.00014334862385321102
I1
I0
I1
tp43341
sS'pharmacoeconomic,analyses,indicate'
p43342
(F1
F0.00014334862385321102
I0
I1
I-1
tp43343
sS'although,theoretically,coadministration'
p43344
(F1
F0.00014334862385321102
I1
I0
I1
tp43345
sS'during,can,be'
p43346
(F1
F0.00014334862385321102
I1
I0
I1
tp43347
sS'because,increases,the'
p43348
(F1
F0.00014334862385321102
I1
I0
I1
tp43349
sS'for,the,appropriate'
p43350
(F1
F0.00014334862385321102
I0
I1
I-1
tp43351
sS'were,completely,inhibited'
p43352
(F1
F0.00014334862385321102
I1
I0
I1
tp43353
sS'ways,to,avoid'
p43354
(F1
F0.00014334862385321102
I0
I1
I-1
tp43355
sS'inhibitory,towards,the'
p43356
(F1
F0.00014334862385321102
I0
I1
I-1
tp43357
sS'interaction,studies,did'
p43358
(F1
F0.00014334862385321102
I0
I1
I-1
tp43359
sS'the,diets,no'
p43360
(F1
F0.00014334862385321102
I0
I1
I-1
tp43361
sS'reduced,by,the'
p43362
(F1
F0.00014334862385321102
I1
I0
I1
tp43363
sS'higher,than,that'
p43364
(F1
F0.00043004587155963305
I3
I0
I3
tp43365
sS'and,instruct,the'
p43366
(F1
F0.00014334862385321102
I0
I1
I-1
tp43367
sS'the,or,type'
p43368
(F1
F0.00014334862385321102
I1
I0
I1
tp43369
sS'a,more,efficient'
p43370
(F1
F0.00014334862385321102
I0
I1
I-1
tp43371
sS'comparable,to,those'
p43372
(F1
F0.00028669724770642203
I0
I2
I-2
tp43373
sS'beta-1a,avonex,mcg'
p43374
(F0
F0
I1
I1
I0
tp43375
sS'effective,in,significantly'
p43376
(F1
F0.00014334862385321102
I1
I0
I1
tp43377
sS'reduce,the,effects'
p43378
(F1
F0.00014334862385321102
I1
I0
I1
tp43379
sS'these,in,combination'
p43380
(F1
F0.00043004587155963305
I0
I3
I-3
tp43381
sS'minimum,inhibitory,concentration'
p43382
(F1
F0.00014334862385321102
I0
I1
I-1
tp43383
sS'day,regimen,of'
p43384
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp43385
sS'n,pretreatment,with'
p43386
(F1
F0.00014334862385321102
I1
I0
I1
tp43387
sS'to,have,decreased'
p43388
(F1
F0.00028669724770642203
I2
I0
I2
tp43389
sS'agents,enalapril,and'
p43390
(F1
F0.00014334862385321102
I0
I1
I-1
tp43391
sS'but,its,inhibitory'
p43392
(F1
F0.00014334862385321102
I0
I1
I-1
tp43393
sS'reduce,the,bioavailability'
p43394
(F1
F0.00014334862385321102
I1
I0
I1
tp43395
sS'of,pointer,dogs'
p43396
(F1
F0.00014334862385321102
I0
I1
I-1
tp43397
sS'both,the,and'
p43398
(F1
F0.00014334862385321102
I1
I0
I1
tp43399
sS'tricyclic,when,used'
p43400
(F1
F0.00014334862385321102
I1
I0
I1
tp43401
sS'dose,to,mg'
p43402
(F1
F0.00057339449541284407
I4
I0
I4
tp43403
sS'the,may,be'
p43404
(F1
F0.00028669724770642203
I2
I0
I2
tp43405
sS'the,anti-glaucoma,action'
p43406
(F1
F0.00014334862385321102
I1
I0
I1
tp43407
sS'relationship,have,not'
p43408
(F1
F0.00014334862385321102
I1
I0
I1
tp43409
sS'of,other,aeds'
p43410
(F1
F0.00014334862385321102
I0
I1
I-1
tp43411
sS'animals,edetate,disodium'
p43412
(F1
F0.00014334862385321102
I1
I0
I1
tp43413
sS'ethinyl,estradiol,by'
p43414
(F1
F0.00043004587155963305
I3
I0
I3
tp43415
sS'by,mg,day'
p43416
(F1
F0.00014334862385321102
I1
I0
I1
tp43417
sS'the,uptake,inhibitor'
p43418
(F1
F0.00014334862385321102
I0
I1
I-1
tp43419
sS'be,precipitated,by'
p43420
(F1
F0.00014334862385321102
I0
I1
I-1
tp43421
sS'time,for,hour'
p43422
(F1
F0.00014334862385321102
I1
I0
I1
tp43423
sS'with,bextra,in'
p43424
(F1
F0.00028669724770642203
I2
I0
I2
tp43425
sS'a,day,before'
p43426
(F1
F0.00014334862385321102
I0
I1
I-1
tp43427
sS'the,carbachol-stimulated,intracellular'
p43428
(F1
F0.00014334862385321102
I1
I0
I1
tp43429
sS'when,taking,placebo'
p43430
(F1
F0.00014334862385321102
I0
I1
I-1
tp43431
sS'sulfate,sulfate,and'
p43432
(F1
F0.00014334862385321102
I1
I0
I1
tp43433
sS'intravenously,or,orally'
p43434
(F1
F0.00014334862385321102
I0
I1
I-1
tp43435
sS'of,are,due'
p43436
(F1
F0.00014334862385321102
I1
I0
I1
tp43437
sS'in,man,we'
p43438
(F1
F0.00014334862385321102
I0
I1
I-1
tp43439
sS'toxicity,and,pharmacokinetics'
p43440
(F1
F0.00014334862385321102
I0
I1
I-1
tp43441
sS'with,mixed,agonist'
p43442
(F1
F0.00014334862385321102
I1
I0
I1
tp43443
sS'uptake,to,be'
p43444
(F1
F0.00014334862385321102
I1
I0
I1
tp43445
sS'carbamazepine,carbamazepine,causes'
p43446
(F1
F0.00014334862385321102
I1
I0
I1
tp43447
sS'and,enhance,the'
p43448
(F1
F0.00014334862385321102
I1
I0
I1
tp43449
sS'alpha-blockers,when,vardenafil'
p43450
(F1
F0.00014334862385321102
I1
I0
I1
tp43451
sS'interaction,trials,have'
p43452
(F1
F0.00014334862385321102
I0
I1
I-1
tp43453
sS'of,protease,inhibitors'
p43454
(F1
F0.00014334862385321102
I0
I1
I-1
tp43455
sS'the,most,commonly'
p43456
(F1
F0.00014334862385321102
I1
I0
I1
tp43457
sS'to,antiepileptic,aeds'
p43458
(F1
F0.00014334862385321102
I1
I0
I1
tp43459
sS'of,may,occur'
p43460
(F1
F0.00014334862385321102
I1
I0
I1
tp43461
sS'to,inhibit,phosphatase'
p43462
(F1
F0.00014334862385321102
I1
I0
I1
tp43463
sS'dose,reduced,by'
p43464
(F1
F0.00014334862385321102
I1
I0
I1
tp43465
sS'iron,salts,may'
p43466
(F1
F0.00014334862385321102
I1
I0
I1
tp43467
sS'common,component,of'
p43468
(F1
F0.00014334862385321102
I1
I0
I1
tp43469
sS'in,using,it'
p43470
(F1
F0.00014334862385321102
I1
I0
I1
tp43471
sS'adrenergic,blockers,adrenergic'
p43472
(F1
F0.00028669724770642203
I2
I0
I2
tp43473
sS'co-administration,of,decreased'
p43474
(F1
F0.00043004587155963305
I3
I0
I3
tp43475
sS'it,adversely,affected'
p43476
(F1
F0.00014334862385321102
I1
I0
I1
tp43477
sS'may,delay,intestinal'
p43478
(F1
F0.0008600917431192661
I6
I0
I6
tp43479
sS'coadministration,of,using'
p43480
(F1
F0.00014334862385321102
I1
I0
I1
tp43481
sS'substitute,for,oral'
p43482
(F1
F0.00014334862385321102
I0
I1
I-1
tp43483
sS'that,zebeta,be'
p43484
(F1
F0.00014334862385321102
I1
I0
I1
tp43485
sS'the,derivative,implications'
p43486
(F1
F0.00014334862385321102
I0
I1
I-1
tp43487
sS'receiving,azole,agents'
p43488
(F1
F0.00014334862385321102
I1
I0
I1
tp43489
sS'initiated,or,withdrawn'
p43490
(F1
F0.00014334862385321102
I0
I1
I-1
tp43491
sS'a,randomized,trial'
p43492
(F1
F0.00014334862385321102
I1
I0
I1
tp43493
sS'once,daily,for'
p43494
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp43495
sS'resulted,in,previous'
p43496
(F1
F0.00014334862385321102
I1
I0
I1
tp43497
sS'injection,of,mg'
p43498
(F1
F0.00014334862385321102
I1
I0
I1
tp43499
sS'uptake,of,radiolabeled'
p43500
(F1
F0.00014334862385321102
I0
I1
I-1
tp43501
sS'to,occur,if'
p43502
(F1
F0.00014334862385321102
I0
I1
I-1
tp43503
sS'whether,to,discontinue'
p43504
(F1
F0.00014334862385321102
I0
I1
I-1
tp43505
sS'doses,of,short-acting'
p43506
(F1
F0.00014334862385321102
I0
I1
I-1
tp43507
sS'amevive,before,one'
p43508
(F1
F0.00014334862385321102
I0
I1
I-1
tp43509
sS'normal,volunteers,it'
p43510
(F1
F0.00014334862385321102
I1
I0
I1
tp43511
sS'blockers,cardiac,h2'
p43512
(F1
F0.00014334862385321102
I0
I1
I-1
tp43513
sS'the,serum,levels'
p43514
(F1
F0.00043004587155963305
I3
I0
I3
tp43515
sS'over,patients,in'
p43516
(F1
F0.00014334862385321102
I1
I0
I1
tp43517
sS'displacing,the,from'
p43518
(F1
F0.00014334862385321102
I1
I0
I1
tp43519
sS'initial,dose,of'
p43520
(F1
F0.00014334862385321102
I0
I1
I-1
tp43521
sS'digoxin,in,patients'
p43522
(F1
F0.00014334862385321102
I0
I1
I-1
tp43523
sS'effect,of,acetate'
p43524
(F1
F0.00014334862385321102
I1
I0
I1
tp43525
sS'for,the,appearance'
p43526
(F1
F0.00014334862385321102
I1
I0
I1
tp43527
sS'welchol,with,or'
p43528
(F1
F0.00014334862385321102
I0
I1
I-1
tp43529
sS'mao,inhibitors,serious'
p43530
(F1
F0.00014334862385321102
I0
I1
I-1
tp43531
sS'adenocard,has,been'
p43532
(F1
F0.00014334862385321102
I0
I1
I-1
tp43533
sS'or,who,increase'
p43534
(F1
F0.00014334862385321102
I1
I0
I1
tp43535
sS'to,produce,adverse'
p43536
(F1
F0.00014334862385321102
I0
I1
I-1
tp43537
sS'consisting,of,usp'
p43538
(F1
F0.00014334862385321102
I1
I0
I1
tp43539
sS'evaluate,the,possibility'
p43540
(F1
F0.00014334862385321102
I1
I0
I1
tp43541
sS'of,maalox,tc'
p43542
(F1
F0.00014334862385321102
I0
I1
I-1
tp43543
sS'although,this,interaction'
p43544
(F1
F0.00014334862385321102
I1
I0
I1
tp43545
sS'transfer,to,oral'
p43546
(F1
F0.00014334862385321102
I0
I1
I-1
tp43547
sS'was,about,times'
p43548
(F1
F0.00014334862385321102
I0
I1
I-1
tp43549
sS'reports,of,serotonin'
p43550
(F1
F0.00014334862385321102
I1
I0
I1
tp43551
sS'in-vitro,studies,is'
p43552
(F1
F0.00014334862385321102
I0
I1
I-1
tp43553
sS'and,through,pharmacokinetic'
p43554
(F1
F0.00014334862385321102
I0
I1
I-1
tp43555
sS'acid,with,at'
p43556
(F1
F0.00014334862385321102
I1
I0
I1
tp43557
sS'level,dosage,adjustment'
p43558
(F1
F0.00014334862385321102
I1
I0
I1
tp43559
sS'and,increase,in'
p43560
(F1
F0.00014334862385321102
I1
I0
I1
tp43561
sS'in,the,antidepressant'
p43562
(F1
F0.00014334862385321102
I0
I1
I-1
tp43563
sS'example,inhibitors,include'
p43564
(F1
F0.00014334862385321102
I0
I1
I-1
tp43565
sS'extended,release,formulation'
p43566
(F1
F0.00014334862385321102
I0
I1
I-1
tp43567
sS'other,schizophrenic,patients'
p43568
(F1
F0.00014334862385321102
I1
I0
I1
tp43569
sS'by,approximately,peak'
p43570
(F1
F0.00014334862385321102
I1
I0
I1
tp43571
sS'containing,medicines,such'
p43572
(F1
F0.00014334862385321102
I1
I0
I1
tp43573
sS'or,orthostatic,changes'
p43574
(F1
F0.00014334862385321102
I1
I0
I1
tp43575
sS'its,metabolism,and'
p43576
(F1
F0.00014334862385321102
I0
I1
I-1
tp43577
sS'iv,injection,of'
p43578
(F1
F0.00014334862385321102
I1
I0
I1
tp43579
sS'at,high,to'
p43580
(F1
F0.00014334862385321102
I1
I0
I1
tp43581
sS'responsible,for,metabolism'
p43582
(F1
F0.00014334862385321102
I0
I1
I-1
tp43583
sS'by,either,alpha-'
p43584
(F1
F0.00014334862385321102
I0
I1
I-1
tp43585
sS'furosemide,may,add'
p43586
(F1
F0.00014334862385321102
I1
I0
I1
tp43587
sS'isozymes,in,the'
p43588
(F1
F0.00014334862385321102
I0
I1
I-1
tp43589
sS'arthritis,thyroiditis,bullous'
p43590
(F1
F0.00014334862385321102
I1
I0
I1
tp43591
sS'in,two,controlled'
p43592
(F1
F0.00014334862385321102
I0
I1
I-1
tp43593
sS'elspar,therapy,when'
p43594
(F1
F0.00014334862385321102
I1
I0
I1
tp43595
sS'significantly,interact,with'
p43596
(F1
F0.00014334862385321102
I0
I1
I-1
tp43597
sS'affect,steady-state,pharmacokinetic'
p43598
(F1
F0.00014334862385321102
I0
I1
I-1
tp43599
sS'induction,of,p-450iie1'
p43600
(F1
F0.00014334862385321102
I1
I0
I1
tp43601
sS'by,increased,half-life'
p43602
(F1
F0.00014334862385321102
I1
I0
I1
tp43603
sS'against,the,elevation'
p43604
(F1
F0.00014334862385321102
I1
I0
I1
tp43605
sS'period,has,been'
p43606
(F1
F0.00014334862385321102
I1
I0
I1
tp43607
sS'of,with,a'
p43608
(F0
F0
I2
I2
I0
tp43609
sS'of,cholino-,and'
p43610
(F1
F0.00014334862385321102
I0
I1
I-1
tp43611
sS'agents,including,such'
p43612
(F1
F0.00014334862385321102
I1
I0
I1
tp43613
sS'and,aluminum-containing,preparations'
p43614
(F1
F0.00014334862385321102
I0
I1
I-1
tp43615
sS'parameters,including,the'
p43616
(F1
F0.00014334862385321102
I0
I1
I-1
tp43617
sS'serotoninergic,agents,there'
p43618
(F1
F0.00014334862385321102
I1
I0
I1
tp43619
sS'require,additional,titration'
p43620
(F1
F0.00014334862385321102
I1
I0
I1
tp43621
sS'and,levonorgestrel-treated,rats'
p43622
(F1
F0.00014334862385321102
I0
I1
I-1
tp43623
sS'of,clozapine,potentially'
p43624
(F1
F0.00014334862385321102
I1
I0
I1
tp43625
sS'of,an,with'
p43626
(F1
F0.00014334862385321102
I1
I0
I1
tp43627
sS'combined,therapy,if'
p43628
(F1
F0.00014334862385321102
I1
I0
I1
tp43629
sS'toxicity,was,reported'
p43630
(F1
F0.00014334862385321102
I1
I0
I1
tp43631
sS'affect,the,pharmacokinetics'
p43632
(F1
F0.0024369266055045873
I0
I17
I-17
tp43633
sS'microsomal,monooxygenase,activities'
p43634
(F1
F0.00014334862385321102
I0
I1
I-1
tp43635
sS'phenobarbital,decreases,effectiveness'
p43636
(F1
F0.00014334862385321102
I1
I0
I1
tp43637
sS'to,three,cancer'
p43638
(F1
F0.00014334862385321102
I1
I0
I1
tp43639
sS'cardiac,output,and'
p43640
(F1
F0.00028669724770642203
I2
I0
I2
tp43641
sS'morphine-induced,increases,in'
p43642
(F1
F0.00014334862385321102
I1
I0
I1
tp43643
sS'consequent,possible,decrease'
p43644
(F1
F0.00014334862385321102
I1
I0
I1
tp43645
sS'morphine,analgesia,and'
p43646
(F1
F0.00014334862385321102
I0
I1
I-1
tp43647
sS'reduction,of,crixivan'
p43648
(F1
F0.00028669724770642203
I2
I0
I2
tp43649
sS'or,stereotypic,effects'
p43650
(F1
F0.00014334862385321102
I0
I1
I-1
tp43651
sS'than,parkinsons,disease'
p43652
(F1
F0.00014334862385321102
I0
I1
I-1
tp43653
sS'interactions,resulting,in'
p43654
(F1
F0.00014334862385321102
I0
I1
I-1
tp43655
sS'affected,by,concomitant'
p43656
(F1
F0.00014334862385321102
I0
I1
I-1
tp43657
sS'blocking,agents,experience'
p43658
(F1
F0.00014334862385321102
I1
I0
I1
tp43659
sS'metabolized,via,a'
p43660
(F1
F0.00014334862385321102
I0
I1
I-1
tp43661
sS'shown,to,cause'
p43662
(F1
F0.00028669724770642203
I0
I2
I-2
tp43663
sS'for,an,unusually'
p43664
(F1
F0.00014334862385321102
I1
I0
I1
tp43665
sS'there,is,thus'
p43666
(F1
F0.00014334862385321102
I1
I0
I1
tp43667
sS'efficacy,of,h1'
p43668
(F1
F0.00014334862385321102
I1
I0
I1
tp43669
sS'white,male,rats'
p43670
(F1
F0.00014334862385321102
I0
I1
I-1
tp43671
sS'and,channel,antagonists'
p43672
(F1
F0.00014334862385321102
I0
I1
I-1
tp43673
sS'slightly,shorter,durations'
p43674
(F1
F0.00014334862385321102
I1
I0
I1
tp43675
sS'with,the,lipid-lowering'
p43676
(F1
F0.00014334862385321102
I0
I1
I-1
tp43677
sS'mg,kg,removes'
p43678
(F1
F0.00014334862385321102
I1
I0
I1
tp43679
sS'may,affect,renal'
p43680
(F1
F0.00014334862385321102
I0
I1
I-1
tp43681
sS'the,safety,and'
p43682
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp43683
sS'marine,coelenterates,of'
p43684
(F1
F0.00014334862385321102
I0
I1
I-1
tp43685
sS'and,has,also'
p43686
(F1
F0.00014334862385321102
I0
I1
I-1
tp43687
sS'are,substrates,and'
p43688
(F1
F0.00014334862385321102
I0
I1
I-1
tp43689
sS'oral,inhibits,the'
p43690
(F1
F0.00028669724770642203
I2
I0
I2
tp43691
sS'powder,or,products'
p43692
(F1
F0.00014334862385321102
I1
I0
I1
tp43693
sS'selective,mao,inhibitor'
p43694
(F1
F0.00014334862385321102
I1
I0
I1
tp43695
sS'level,in,the'
p43696
(F1
F0.00014334862385321102
I1
I0
I1
tp43697
sS'patients,when,and'
p43698
(F1
F0.00014334862385321102
I1
I0
I1
tp43699
sS'in,vitro,binding'
p43700
(F0
F0
I1
I1
I0
tp43701
sS'activity,of,endogenous'
p43702
(F1
F0.00014334862385321102
I1
I0
I1
tp43703
sS'be,avoided,as'
p43704
(F1
F0.00043004587155963305
I0
I3
I-3
tp43705
sS'when,simulect,is'
p43706
(F1
F0.00014334862385321102
I0
I1
I-1
tp43707
sS'of,to,subjects'
p43708
(F1
F0.00014334862385321102
I1
I0
I1
tp43709
sS'or,imuran,the'
p43710
(F1
F0.00014334862385321102
I1
I0
I1
tp43711
sS'interact,altered,hypo-prothrombinemic'
p43712
(F1
F0.00014334862385321102
I0
I1
I-1
tp43713
sS'observed,it,is'
p43714
(F1
F0.00014334862385321102
I1
I0
I1
tp43715
sS'administered,concurrently,without'
p43716
(F1
F0.00014334862385321102
I0
I1
I-1
tp43717
sS'of,different,descending'
p43718
(F1
F0.00014334862385321102
I0
I1
I-1
tp43719
sS'contraceptive,based,on'
p43720
(F1
F0.00014334862385321102
I0
I1
I-1
tp43721
sS'those,required,to'
p43722
(F1
F0.00014334862385321102
I1
I0
I1
tp43723
sS'days,followed,by'
p43724
(F1
F0.00028669724770642203
I0
I2
I-2
tp43725
sS'clearance,in,a'
p43726
(F1
F0.00014334862385321102
I1
I0
I1
tp43727
sS'which,was,partially'
p43728
(F1
F0.00014334862385321102
I1
I0
I1
tp43729
sS'receiving,acarbose,in'
p43730
(F1
F0.00014334862385321102
I0
I1
I-1
tp43731
sS'type,c,eg'
p43732
(F1
F0.00014334862385321102
I1
I0
I1
tp43733
sS'induce,cyp3a4,activity'
p43734
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp43735
sS'agents,did,not'
p43736
(F1
F0.00043004587155963305
I0
I3
I-3
tp43737
sS'short-acting,has,been'
p43738
(F1
F0.00014334862385321102
I0
I1
I-1
tp43739
sS'and,can,increase'
p43740
(F1
F0.00014334862385321102
I1
I0
I1
tp43741
sS'administration,attenuates,certain'
p43742
(F1
F0.00014334862385321102
I1
I0
I1
tp43743
sS'with,the,supplied'
p43744
(F1
F0.00014334862385321102
I0
I1
I-1
tp43745
sS'this,combination,outweigh'
p43746
(F1
F0.00014334862385321102
I1
I0
I1
tp43747
sS'cimetidine,reduces,the'
p43748
(F1
F0.00014334862385321102
I1
I0
I1
tp43749
sS'time,response,in'
p43750
(F1
F0.00028669724770642203
I2
I0
I2
tp43751
sS'indicated,that,pulmozyme'
p43752
(F1
F0.00014334862385321102
I0
I1
I-1
tp43753
sS'ethinyl,estradiol,may'
p43754
(F1
F0.00028669724770642203
I2
I0
I2
tp43755
sS'single,dose,administration'
p43756
(F0
F0
I1
I1
I0
tp43757
sS'severe,persistent,hypertension'
p43758
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp43759
sS'aminoglycosides,the,mixing'
p43760
(F1
F0.00014334862385321102
I1
I0
I1
tp43761
sS'mg,dl,dose'
p43762
(F1
F0.00014334862385321102
I1
I0
I1
tp43763
sS'progesterone,preparations,micro-dosed'
p43764
(F1
F0.00014334862385321102
I1
I0
I1
tp43765
sS'interactions,as,with'
p43766
(F1
F0.00028669724770642203
I0
I2
I-2
tp43767
sS'pre-treatment,with,the'
p43768
(F1
F0.00014334862385321102
I1
I0
I1
tp43769
sS'were,only,observed'
p43770
(F1
F0.00014334862385321102
I0
I1
I-1
tp43771
sS'fewer,infusion,reactions'
p43772
(F1
F0.00014334862385321102
I0
I1
I-1
tp43773
sS'mepron,suspension,results'
p43774
(F1
F0.00014334862385321102
I1
I0
I1
tp43775
sS'patients,to,be'
p43776
(F1
F0.00014334862385321102
I1
I0
I1
tp43777
sS'observed,when,viracept'
p43778
(F1
F0.00014334862385321102
I0
I1
I-1
tp43779
sS'of,psychiatric,disorder'
p43780
(F1
F0.00014334862385321102
I1
I0
I1
tp43781
sS'kidney,and,the'
p43782
(F1
F0.00014334862385321102
I0
I1
I-1
tp43783
sS'and,and,mg'
p43784
(F0
F0
I2
I2
I0
tp43785
sS'result,of,a'
p43786
(F1
F0.00014334862385321102
I1
I0
I1
tp43787
sS'inhibitors,ssris,seriraline'
p43788
(F1
F0.00014334862385321102
I0
I1
I-1
tp43789
sS'weaken,the,blood-glucose'
p43790
(F1
F0.00028669724770642203
I2
I0
I2
tp43791
sS'thyroid,preparations,may'
p43792
(F1
F0.00014334862385321102
I1
I0
I1
tp43793
sS'sedation,hallucinations,and'
p43794
(F1
F0.00014334862385321102
I1
I0
I1
tp43795
sS'of,within,the'
p43796
(F1
F0.00014334862385321102
I0
I1
I-1
tp43797
sS'are,found,to'
p43798
(F1
F0.00014334862385321102
I1
I0
I1
tp43799
sS'studied,two,appear'
p43800
(F1
F0.00014334862385321102
I1
I0
I1
tp43801
sS'limited,data,in'
p43802
(F1
F0.00014334862385321102
I1
I0
I1
tp43803
sS'decreases,the,elimination'
p43804
(F1
F0.00014334862385321102
I1
I0
I1
tp43805
sS'enoxacin,may,raise'
p43806
(F1
F0.00014334862385321102
I1
I0
I1
tp43807
sS'no,influence,on'
p43808
(F1
F0.00028669724770642203
I0
I2
I-2
tp43809
sS'approach,to,treatment'
p43810
(F1
F0.00014334862385321102
I0
I1
I-1
tp43811
sS'patients,on,treatment'
p43812
(F1
F0.00014334862385321102
I1
I0
I1
tp43813
sS'reduction,at,the'
p43814
(F1
F0.00014334862385321102
I0
I1
I-1
tp43815
sS'geocillin,carbenicillin,indanyl'
p43816
(F1
F0.00014334862385321102
I1
I0
I1
tp43817
sS'alter,the,clearance'
p43818
(F1
F0.00014334862385321102
I0
I1
I-1
tp43819
sS'anabolin,anavar,anadrol'
p43820
(F1
F0.00014334862385321102
I0
I1
I-1
tp43821
sS'with,or,clinically'
p43822
(F1
F0.00014334862385321102
I0
I1
I-1
tp43823
sS'for,days,after'
p43824
(F1
F0.00014334862385321102
I0
I1
I-1
tp43825
sS'magnesium-,and,aluminum-containing'
p43826
(F1
F0.00014334862385321102
I1
I0
I1
tp43827
sS'that,concentrations,be'
p43828
(F1
F0.00014334862385321102
I1
I0
I1
tp43829
sS'twitch,was,maintained'
p43830
(F1
F0.00014334862385321102
I0
I1
I-1
tp43831
sS'certain,thereby,increasing'
p43832
(F1
F0.00014334862385321102
I1
I0
I1
tp43833
sS'of,coma,and'
p43834
(F1
F0.00014334862385321102
I1
I0
I1
tp43835
sS'of,to,decrease'
p43836
(F1
F0.00014334862385321102
I1
I0
I1
tp43837
sS'by,when,coadministered'
p43838
(F1
F0.00014334862385321102
I1
I0
I1
tp43839
sS'vioxx,with,the'
p43840
(F1
F0.00014334862385321102
I1
I0
I1
tp43841
sS'potent,inhibitors,of'
p43842
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp43843
sS'and,micromol,l'
p43844
(F1
F0.00014334862385321102
I0
I1
I-1
tp43845
sS'treatment,resulted,in'
p43846
(F1
F0.00014334862385321102
I1
I0
I1
tp43847
sS'arrest,with,full'
p43848
(F1
F0.00014334862385321102
I0
I1
I-1
tp43849
sS'decreased,symptoms,of'
p43850
(F1
F0.00014334862385321102
I1
I0
I1
tp43851
sS'injury,should,be'
p43852
(F1
F0.00014334862385321102
I0
I1
I-1
tp43853
sS'taking,since,nevirapinemay'
p43854
(F1
F0.00014334862385321102
I1
I0
I1
tp43855
sS'of,displacement,of'
p43856
(F1
F0.00014334862385321102
I0
I1
I-1
tp43857
sS'switching,from,one'
p43858
(F1
F0.00057339449541284407
I4
I0
I4
tp43859
sS'mean,neutrophil,counts'
p43860
(F1
F0.00014334862385321102
I1
I0
I1
tp43861
sS'similar,length,of'
p43862
(F1
F0.00014334862385321102
I1
I0
I1
tp43863
sS'containing,for,at'
p43864
(F1
F0.00014334862385321102
I1
I0
I1
tp43865
sS'until,blood,pressure'
p43866
(F1
F0.00014334862385321102
I1
I0
I1
tp43867
sS'ketoconazole,sensipar,is'
p43868
(F1
F0.00014334862385321102
I0
I1
I-1
tp43869
sS'that,rr,is'
p43870
(F1
F0.00014334862385321102
I0
I1
I-1
tp43871
sS'the,ecg,changes'
p43872
(F1
F0.00014334862385321102
I1
I0
I1
tp43873
sS'products,such,as'
p43874
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp43875
sS'two,instances,and'
p43876
(F1
F0.00014334862385321102
I1
I0
I1
tp43877
sS'prospective,long-term,studies'
p43878
(F1
F0.00014334862385321102
I0
I1
I-1
tp43879
sS'among,the,volunteers'
p43880
(F1
F0.00014334862385321102
I1
I0
I1
tp43881
sS'receiving,and,concomitantly'
p43882
(F1
F0.00014334862385321102
I1
I0
I1
tp43883
sS'rifampin,has,been'
p43884
(F1
F0.00014334862385321102
I1
I0
I1
tp43885
sS'employed,because,of'
p43886
(F1
F0.00014334862385321102
I1
I0
I1
tp43887
sS'that,in,combination'
p43888
(F1
F0.00014334862385321102
I0
I1
I-1
tp43889
sS'action,independent,of'
p43890
(F1
F0.00014334862385321102
I0
I1
I-1
tp43891
sS'required,if,such'
p43892
(F1
F0.00014334862385321102
I0
I1
I-1
tp43893
sS'of,the,estimated'
p43894
(F1
F0.00014334862385321102
I0
I1
I-1
tp43895
sS'patients,on,long-term'
p43896
(F1
F0.00014334862385321102
I1
I0
I1
tp43897
sS'to,treated,patients'
p43898
(F1
F0.00014334862385321102
I0
I1
I-1
tp43899
sS'lower,plasma,concentration'
p43900
(F1
F0.00014334862385321102
I0
I1
I-1
tp43901
sS'activity,such,as'
p43902
(F1
F0.00028669724770642203
I2
I0
I2
tp43903
sS'reduced,accordingly,in'
p43904
(F1
F0.00014334862385321102
I1
I0
I1
tp43905
sS'inhibitors,and,both'
p43906
(F1
F0.00014334862385321102
I0
I1
I-1
tp43907
sS'to,years,who'
p43908
(F1
F0.00014334862385321102
I1
I0
I1
tp43909
sS'their,usual,dose'
p43910
(F1
F0.00014334862385321102
I1
I0
I1
tp43911
sS'metabolite,are,inhibitors'
p43912
(F1
F0.00014334862385321102
I0
I1
I-1
tp43913
sS'to,increase,with'
p43914
(F1
F0.00014334862385321102
I1
I0
I1
tp43915
sS'who,had,received'
p43916
(F0
F0
I1
I1
I0
tp43917
sS'likely,to,interfere'
p43918
(F1
F0.00014334862385321102
I1
I0
I1
tp43919
sS'mc,and,are'
p43920
(F1
F0.00014334862385321102
I0
I1
I-1
tp43921
sS'extended,release,mg'
p43922
(F1
F0.00014334862385321102
I0
I1
I-1
tp43923
sS'regulation,of,voltage-dependent'
p43924
(F1
F0.00014334862385321102
I0
I1
I-1
tp43925
sS'cyp2c9,cyp2c19,or'
p43926
(F1
F0.00014334862385321102
I0
I1
I-1
tp43927
sS'from,combined,therapy'
p43928
(F1
F0.00014334862385321102
I1
I0
I1
tp43929
sS'analyzed,in,cecectomized'
p43930
(F1
F0.00014334862385321102
I0
I1
I-1
tp43931
sS'that,plasma,levels'
p43932
(F1
F0.00028669724770642203
I2
I0
I2
tp43933
sS'ruthenium,red,rr'
p43934
(F1
F0.00014334862385321102
I0
I1
I-1
tp43935
sS'narrower,spectrum,of'
p43936
(F1
F0.00014334862385321102
I0
I1
I-1
tp43937
sS'you,are,also'
p43938
(F1
F0.00014334862385321102
I1
I0
I1
tp43939
sS'of,busulfex,at'
p43940
(F1
F0.00014334862385321102
I1
I0
I1
tp43941
sS'by,this,isoenzyme'
p43942
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp43943
sS'absence,of,renal'
p43944
(F1
F0.00014334862385321102
I1
I0
I1
tp43945
sS'metabolism,and,and'
p43946
(F1
F0.00014334862385321102
I0
I1
I-1
tp43947
sS'designed,to,investigate'
p43948
(F1
F0.00014334862385321102
I0
I1
I-1
tp43949
sS'increase,the,depth'
p43950
(F1
F0.00014334862385321102
I1
I0
I1
tp43951
sS'local,and,para-aminobenzoic'
p43952
(F1
F0.00014334862385321102
I1
I0
I1
tp43953
sS'occasionally,been,used'
p43954
(F1
F0.00014334862385321102
I0
I1
I-1
tp43955
sS'a,facilitates,acquisition'
p43956
(F1
F0.00014334862385321102
I0
I1
I-1
tp43957
sS'p450,a4,inhibitors'
p43958
(F1
F0.00014334862385321102
I0
I1
I-1
tp43959
sS'c,max,decreased'
p43960
(F1
F0.00014334862385321102
I1
I0
I1
tp43961
sS'study,both,agents'
p43962
(F1
F0.00014334862385321102
I0
I1
I-1
tp43963
sS'of,rats,results'
p43964
(F1
F0.00014334862385321102
I1
I0
I1
tp43965
sS'may,lower,meclofenamate'
p43966
(F1
F0.00014334862385321102
I1
I0
I1
tp43967
sS'agonists,only,if'
p43968
(F1
F0.00014334862385321102
I1
I0
I1
tp43969
sS'clinical,studies,coadministration'
p43970
(F1
F0.00014334862385321102
I0
I1
I-1
tp43971
sS'or,a,cardioselective'
p43972
(F1
F0.00014334862385321102
I0
I1
I-1
tp43973
sS'oral,is,significantly'
p43974
(F1
F0.00014334862385321102
I1
I0
I1
tp43975
sS'the,dosage,of'
p43976
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp43977
sS'coumarin-derivative,should,be'
p43978
(F1
F0.00014334862385321102
I0
I1
I-1
tp43979
sS'and,its,vasculature'
p43980
(F1
F0.00014334862385321102
I0
I1
I-1
tp43981
sS'blood-sugar,reducing,effect'
p43982
(F1
F0.00014334862385321102
I1
I0
I1
tp43983
sS'and,therapeutic,concentration'
p43984
(F1
F0.00014334862385321102
I1
I0
I1
tp43985
sS'nor,appears,to'
p43986
(F1
F0.00014334862385321102
I0
I1
I-1
tp43987
sS'because,does,not'
p43988
(F1
F0.00014334862385321102
I0
I1
I-1
tp43989
sS'as,diphen-hydramine,and'
p43990
(F1
F0.00014334862385321102
I0
I1
I-1
tp43991
sS'tricor,at,least'
p43992
(F1
F0.00014334862385321102
I1
I0
I1
tp43993
sS'of,the,major'
p43994
(F0
F0
I1
I1
I0
tp43995
sS'interactions,are,possible'
p43996
(F1
F0.00014334862385321102
I0
I1
I-1
tp43997
sS'with,hepatotoxic,potential'
p43998
(F1
F0.00014334862385321102
I1
I0
I1
tp43999
sS'slower,onset,can'
p44000
(F1
F0.00014334862385321102
I1
I0
I1
tp44001
sS'and,tachycardia,have'
p44002
(F1
F0.00014334862385321102
I1
I0
I1
tp44003
sS'felbatol,phenytoin,phenytoin'
p44004
(F1
F0.00014334862385321102
I1
I0
I1
tp44005
sS'uptake-1,carrier,density'
p44006
(F1
F0.00014334862385321102
I0
I1
I-1
tp44007
sS'levels,of,when'
p44008
(F1
F0.00028669724770642203
I2
I0
I2
tp44009
sS'healthy,volunteers,taking'
p44010
(F1
F0.00014334862385321102
I1
I0
I1
tp44011
sS'elevated,levels,it'
p44012
(F1
F0.00014334862385321102
I1
I0
I1
tp44013
sS'in,a,decrease'
p44014
(F1
F0.0012901376146788992
I9
I0
I9
tp44015
sS'by,patients,taking'
p44016
(F1
F0.00014334862385321102
I1
I0
I1
tp44017
sS'indicate,that,the'
p44018
(F1
F0.00028669724770642203
I2
I0
I2
tp44019
sS'simultaneously,with,vardenafil'
p44020
(F1
F0.00014334862385321102
I1
I0
I1
tp44021
sS'and,sigma-2,receptors'
p44022
(F1
F0.00014334862385321102
I0
I1
I-1
tp44023
sS'because,the,ccnu'
p44024
(F1
F0.00014334862385321102
I0
I1
I-1
tp44025
sS'patients,receiving,thiazide'
p44026
(F1
F0.00014334862385321102
I0
I1
I-1
tp44027
sS'activity,of,ganoderma'
p44028
(F1
F0.00014334862385321102
I0
I1
I-1
tp44029
sS'and,tablets,may'
p44030
(F1
F0.00028669724770642203
I2
I0
I2
tp44031
sS'including,those,of'
p44032
(F1
F0.00014334862385321102
I1
I0
I1
tp44033
sS'cyp3a4,substrates,dasatinib'
p44034
(F1
F0.00014334862385321102
I0
I1
I-1
tp44035
sS'and,patients,should'
p44036
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp44037
sS'a,homodimeric,disintegrin'
p44038
(F1
F0.00014334862385321102
I0
I1
I-1
tp44039
sS'an,omega-agatoxin,iva-sensitive'
p44040
(F1
F0.00014334862385321102
I0
I1
I-1
tp44041
sS'thyroxine,increases,the'
p44042
(F1
F0.00014334862385321102
I1
I0
I1
tp44043
sS'non-steroidal,antiinflammatory,including'
p44044
(F1
F0.00014334862385321102
I1
I0
I1
tp44045
sS'plasma,protein,binding'
p44046
(F1
F0.00043004587155963305
I0
I3
I-3
tp44047
sS'rodent,studies,these'
p44048
(F1
F0.00014334862385321102
I0
I1
I-1
tp44049
sS'contraceptives,multiple,dose'
p44050
(F1
F0.00014334862385321102
I0
I1
I-1
tp44051
sS'ocular,and,renal'
p44052
(F1
F0.00014334862385321102
I0
I1
I-1
tp44053
sS'exposure,to,either'
p44054
(F1
F0.00014334862385321102
I0
I1
I-1
tp44055
sS'as,with,other'
p44056
(F0.5714285714285714
F0.0011467889908256881
I11
I3
I8
tp44057
sS'other,agents,of'
p44058
(F1
F0.00014334862385321102
I0
I1
I-1
tp44059
sS'for,duloxetine,to'
p44060
(F1
F0.00014334862385321102
I0
I1
I-1
tp44061
sS'of,bromocriptine,mesylate'
p44062
(F1
F0.00014334862385321102
I1
I0
I1
tp44063
sS'damage,as,indicated'
p44064
(F1
F0.00014334862385321102
I1
I0
I1
tp44065
sS'other,agents,or'
p44066
(F1
F0.00014334862385321102
I0
I1
I-1
tp44067
sS'patients,treated,with'
p44068
(F0.36842105263157893
F0.0010034403669724771
I13
I6
I7
tp44069
sS'of,cmc-cys,exhibiting'
p44070
(F1
F0.00014334862385321102
I0
I1
I-1
tp44071
sS'insufficient,experience,to'
p44072
(F1
F0.00014334862385321102
I1
I0
I1
tp44073
sS'users,develop,physiological'
p44074
(F1
F0.00014334862385321102
I0
I1
I-1
tp44075
sS'our,data,suggest'
p44076
(F1
F0.00014334862385321102
I1
I0
I1
tp44077
sS'has,a,narrower'
p44078
(F1
F0.00014334862385321102
I0
I1
I-1
tp44079
sS'however,the,pharmacodynamics'
p44080
(F1
F0.00014334862385321102
I0
I1
I-1
tp44081
sS'drug,interaction,with'
p44082
(F0
F0
I2
I2
I0
tp44083
sS'of,concomitant,administration'
p44084
(F0
F0
I5
I5
I0
tp44085
sS'while,taking,or'
p44086
(F1
F0.00014334862385321102
I1
I0
I1
tp44087
sS'acebutolol,and,low'
p44088
(F1
F0.00014334862385321102
I0
I1
I-1
tp44089
sS'with,mg,bid'
p44090
(F1
F0.00057339449541284407
I4
I0
I4
tp44091
sS'and,depletion,related'
p44092
(F1
F0.00014334862385321102
I0
I1
I-1
tp44093
sS'and,and,these'
p44094
(F1
F0.00014334862385321102
I0
I1
I-1
tp44095
sS'of,antistress,effects'
p44096
(F1
F0.00014334862385321102
I0
I1
I-1
tp44097
sS'apart,on,an'
p44098
(F1
F0.00014334862385321102
I1
I0
I1
tp44099
sS'with,most,psychoactive'
p44100
(F1
F0.00014334862385321102
I1
I0
I1
tp44101
sS'of,cmax,cmin'
p44102
(F1
F0.00014334862385321102
I0
I1
I-1
tp44103
sS'of,heart,block'
p44104
(F1
F0.00014334862385321102
I1
I0
I1
tp44105
sS'among,co-administered,antiepilepsy'
p44106
(F1
F0.00014334862385321102
I0
I1
I-1
tp44107
sS'sampling,the,extent'
p44108
(F1
F0.00014334862385321102
I0
I1
I-1
tp44109
sS'is,required,for'
p44110
(F1
F0.00014334862385321102
I0
I1
I-1
tp44111
sS'concentrations,from,mg'
p44112
(F1
F0.00014334862385321102
I1
I0
I1
tp44113
sS'in,large,amounts'
p44114
(F1
F0.00014334862385321102
I1
I0
I1
tp44115
sS'to,produce,significant'
p44116
(F1
F0.00014334862385321102
I1
I0
I1
tp44117
sS'significantly,potentiates,the'
p44118
(F1
F0.00014334862385321102
I1
I0
I1
tp44119
sS'and,drug,transport'
p44120
(F1
F0.00014334862385321102
I0
I1
I-1
tp44121
sS'from,a,study'
p44122
(F0
F0
I1
I1
I0
tp44123
sS'should,be,noted'
p44124
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp44125
sS'and,may,necessitate'
p44126
(F1
F0.00014334862385321102
I1
I0
I1
tp44127
sS'by,increasing,gastric'
p44128
(F1
F0.00014334862385321102
I1
I0
I1
tp44129
sS'toradol,therapy,have'
p44130
(F1
F0.00014334862385321102
I1
I0
I1
tp44131
sS'digestion,and,absorption'
p44132
(F1
F0.00014334862385321102
I0
I1
I-1
tp44133
sS'may,potentiate,any'
p44134
(F1
F0.00014334862385321102
I1
I0
I1
tp44135
sS'concentrations,were,observed'
p44136
(F1
F0.00014334862385321102
I1
I0
I1
tp44137
sS'agents,concomitant,administration'
p44138
(F1
F0.00014334862385321102
I1
I0
I1
tp44139
sS'oral,and,you'
p44140
(F1
F0.00014334862385321102
I1
I0
I1
tp44141
sS'derivatives,in,patients'
p44142
(F1
F0.00014334862385321102
I1
I0
I1
tp44143
sS'summarized,in,the'
p44144
(F1
F0.00028669724770642203
I0
I2
I-2
tp44145
sS'could,create,possible'
p44146
(F1
F0.00043004587155963305
I0
I3
I-3
tp44147
sS'for,and,placebo'
p44148
(F1
F0.00014334862385321102
I0
I1
I-1
tp44149
sS'drug-drug,interactions,in'
p44150
(F1
F0.00014334862385321102
I0
I1
I-1
tp44151
sS'control,atrial,fibrillation'
p44152
(F1
F0.00014334862385321102
I1
I0
I1
tp44153
sS'supplements,or,potassium-containing'
p44154
(F0
F0
I1
I1
I0
tp44155
sS'when,given,as'
p44156
(F1
F0.00043004587155963305
I3
I0
I3
tp44157
sS'inhibitors,and,which'
p44158
(F1
F0.00014334862385321102
I0
I1
I-1
tp44159
sS'to,wide,interindividual'
p44160
(F1
F0.00014334862385321102
I1
I0
I1
tp44161
sS'function,such,as'
p44162
(F1
F0.00014334862385321102
I1
I0
I1
tp44163
sS'the,interaction,effects'
p44164
(F1
F0.00014334862385321102
I0
I1
I-1
tp44165
sS'its,derivatives,in'
p44166
(F1
F0.00014334862385321102
I1
I0
I1
tp44167
sS'occur,when,levsin'
p44168
(F1
F0.00014334862385321102
I1
I0
I1
tp44169
sS'with,phenyl-butazone,sodium'
p44170
(F1
F0.00014334862385321102
I0
I1
I-1
tp44171
sS'although,there,are'
p44172
(F1
F0.00014334862385321102
I1
I0
I1
tp44173
sS'misonidazole,has,a'
p44174
(F1
F0.00014334862385321102
I1
I0
I1
tp44175
sS'for,days,has'
p44176
(F1
F0.00043004587155963305
I3
I0
I3
tp44177
sS'more,were,concomitantly'
p44178
(F1
F0.00014334862385321102
I0
I1
I-1
tp44179
sS'reports,of,theophylline-related'
p44180
(F1
F0.00043004587155963305
I3
I0
I3
tp44181
sS'for,days,had'
p44182
(F1
F0.00057339449541284407
I0
I4
I-4
tp44183
sS'your,condition,worse'
p44184
(F1
F0.00014334862385321102
I0
I1
I-1
tp44185
sS'tmp,and,smx'
p44186
(F1
F0.00014334862385321102
I0
I1
I-1
tp44187
sS'response,is,due'
p44188
(F1
F0.00014334862385321102
I0
I1
I-1
tp44189
sS'no,interaction,between'
p44190
(F1
F0.00014334862385321102
I1
I0
I1
tp44191
sS'concentrations,of,by'
p44192
(F0
F0
I1
I1
I0
tp44193
sS'other,drug,interaction'
p44194
(F1
F0.00014334862385321102
I0
I1
I-1
tp44195
sS'increased,levels,of'
p44196
(F1
F0.00014334862385321102
I0
I1
I-1
tp44197
sS'inhibitor,increased,the'
p44198
(F1
F0.00014334862385321102
I1
I0
I1
tp44199
sS'absorption,of,was'
p44200
(F1
F0.00014334862385321102
I0
I1
I-1
tp44201
sS'by,inhibiting,parts'
p44202
(F1
F0.00014334862385321102
I1
I0
I1
tp44203
sS'take,other,drugs'
p44204
(F1
F0.00014334862385321102
I0
I1
I-1
tp44205
sS'for,that,may'
p44206
(F1
F0.00014334862385321102
I0
I1
I-1
tp44207
sS'and,other,multivalent'
p44208
(F1
F0.00028669724770642203
I2
I0
I2
tp44209
sS'and,induce,metabolism'
p44210
(F1
F0.00014334862385321102
I1
I0
I1
tp44211
sS'of,from,nerves'
p44212
(F1
F0.00014334862385321102
I0
I1
I-1
tp44213
sS'lead,to,a'
p44214
(F0
F0
I1
I1
I0
tp44215
sS'expression,that,may'
p44216
(F1
F0.00014334862385321102
I0
I1
I-1
tp44217
sS'by,adl,and'
p44218
(F1
F0.00014334862385321102
I0
I1
I-1
tp44219
sS'may,help,to'
p44220
(F1
F0.00014334862385321102
I0
I1
I-1
tp44221
sS'on,malignant,cells'
p44222
(F1
F0.00014334862385321102
I1
I0
I1
tp44223
sS'cmin,were,decreased'
p44224
(F1
F0.00028669724770642203
I2
I0
I2
tp44225
sS'beta,to,copaxone'
p44226
(F1
F0.00014334862385321102
I0
I1
I-1
tp44227
sS'enoxaparin,dosed,as'
p44228
(F1
F0.00014334862385321102
I0
I1
I-1
tp44229
sS'and,and,thus'
p44230
(F1
F0.00014334862385321102
I1
I0
I1
tp44231
sS'then,begins,a'
p44232
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp44233
sS'potential,to,enhance'
p44234
(F1
F0.00014334862385321102
I1
I0
I1
tp44235
sS'paroxetine,mg,qd'
p44236
(F1
F0.00014334862385321102
I1
I0
I1
tp44237
sS'be,anticipated,with'
p44238
(F1
F0.00028669724770642203
I2
I0
I2
tp44239
sS'effects,of,acute'
p44240
(F1
F0.00014334862385321102
I0
I1
I-1
tp44241
sS'the,cyclooxygenase-2,cox-2'
p44242
(F1
F0.00014334862385321102
I0
I1
I-1
tp44243
sS'patient,maintained,on'
p44244
(F1
F0.00028669724770642203
I2
I0
I2
tp44245
sS'therapy,nicotinic,acid'
p44246
(F1
F0.00014334862385321102
I1
I0
I1
tp44247
sS'of,symptom,control'
p44248
(F1
F0.00014334862385321102
I1
I0
I1
tp44249
sS'circulation,the,discontinuance'
p44250
(F1
F0.00014334862385321102
I1
I0
I1
tp44251
sS'treatment,dyspnea,requiring'
p44252
(F1
F0.00014334862385321102
I0
I1
I-1
tp44253
sS'of,vitamin,k'
p44254
(F1
F0.00014334862385321102
I1
I0
I1
tp44255
sS'or,oral,hypoglycemics'
p44256
(F0
F0
I1
I1
I0
tp44257
sS'totally,known,enzyme'
p44258
(F1
F0.00014334862385321102
I1
I0
I1
tp44259
sS'anitagonism,without,affecting'
p44260
(F1
F0.00014334862385321102
I1
I0
I1
tp44261
sS'respectively,compared,to'
p44262
(F1
F0.00014334862385321102
I1
I0
I1
tp44263
sS'or,agents,such'
p44264
(F1
F0.00014334862385321102
I1
I0
I1
tp44265
sS'resulted,in,approximately'
p44266
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp44267
sS'blood,pressure,of'
p44268
(F1
F0.00028669724770642203
I2
I0
I2
tp44269
sS'separating,the,doses'
p44270
(F1
F0.00014334862385321102
I1
I0
I1
tp44271
sS'rarely,associated,with'
p44272
(F1
F0.00028669724770642203
I2
I0
I2
tp44273
sS'test,interactions,a'
p44274
(F1
F0.00028669724770642203
I0
I2
I-2
tp44275
sS'show,a,change'
p44276
(F1
F0.00014334862385321102
I0
I1
I-1
tp44277
sS'and,to,improve'
p44278
(F1
F0.00014334862385321102
I0
I1
I-1
tp44279
sS'these,polyene,showed'
p44280
(F1
F0.00014334862385321102
I0
I1
I-1
tp44281
sS'initial,and,maintenance'
p44282
(F1
F0.00014334862385321102
I1
I0
I1
tp44283
sS'increased,about,and'
p44284
(F1
F0.00014334862385321102
I1
I0
I1
tp44285
sS'been,conducted,it'
p44286
(F1
F0.00014334862385321102
I1
I0
I1
tp44287
sS'once,daily,resulted'
p44288
(F1
F0.00014334862385321102
I1
I0
I1
tp44289
sS'used,with,extreme'
p44290
(F1
F0.00014334862385321102
I1
I0
I1
tp44291
sS'need,for,an'
p44292
(F1
F0.00014334862385321102
I1
I0
I1
tp44293
sS'when,amines,have'
p44294
(F1
F0.00014334862385321102
I1
I0
I1
tp44295
sS'presence,of,impaired'
p44296
(F1
F0.00028669724770642203
I2
I0
I2
tp44297
sS'with,normal,fat'
p44298
(F1
F0.00014334862385321102
I0
I1
I-1
tp44299
sS'hydrochloride,with,either'
p44300
(F1
F0.00014334862385321102
I1
I0
I1
tp44301
sS'of,is,mg'
p44302
(F1
F0.00014334862385321102
I0
I1
I-1
tp44303
sS'given,as,mg'
p44304
(F0.5
F0.00028669724770642203
I3
I1
I2
tp44305
sS'has,also,been'
p44306
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp44307
sS'for,four,doses'
p44308
(F1
F0.00014334862385321102
I0
I1
I-1
tp44309
sS'drugs,administered,after'
p44310
(F1
F0.00014334862385321102
I0
I1
I-1
tp44311
sS'medications,in,the'
p44312
(F1
F0.00014334862385321102
I0
I1
I-1
tp44313
sS'other,concurrent,administration'
p44314
(F1
F0.00014334862385321102
I1
I0
I1
tp44315
sS'suggesting,a,modest'
p44316
(F1
F0.00014334862385321102
I1
I0
I1
tp44317
sS'affected,by,alterations'
p44318
(F1
F0.00014334862385321102
I0
I1
I-1
tp44319
sS'if,diminished,renal'
p44320
(F1
F0.00014334862385321102
I1
I0
I1
tp44321
sS'pharmacology,studies,in'
p44322
(F1
F0.00028669724770642203
I0
I2
I-2
tp44323
sS'oral,for,a'
p44324
(F1
F0.00014334862385321102
I1
I0
I1
tp44325
sS'increased,and,the'
p44326
(F1
F0.00014334862385321102
I0
I1
I-1
tp44327
sS'to,ensure,clinically'
p44328
(F1
F0.00014334862385321102
I1
I0
I1
tp44329
sS'certain,antipsychotic,medications'
p44330
(F1
F0.00014334862385321102
I0
I1
I-1
tp44331
sS'chirocaine,that,are'
p44332
(F1
F0.00014334862385321102
I0
I1
I-1
tp44333
sS'with,blood,glucose'
p44334
(F1
F0.00014334862385321102
I1
I0
I1
tp44335
sS'at,mg,qd'
p44336
(F1
F0.00014334862385321102
I1
I0
I1
tp44337
sS'juices,etc,lower'
p44338
(F1
F0.00014334862385321102
I1
I0
I1
tp44339
sS'onset,were,prohibited'
p44340
(F1
F0.00014334862385321102
I0
I1
I-1
tp44341
sS'however,retinyl,acetate'
p44342
(F1
F0.00014334862385321102
I1
I0
I1
tp44343
sS'dextromethorphan,is,a'
p44344
(F1
F0.00014334862385321102
I0
I1
I-1
tp44345
sS'cmax,and,about'
p44346
(F1
F0.00014334862385321102
I0
I1
I-1
tp44347
sS'pooled,human,serum'
p44348
(F1
F0.00014334862385321102
I0
I1
I-1
tp44349
sS'conversely,may,interfere'
p44350
(F1
F0.00014334862385321102
I1
I0
I1
tp44351
sS'using,acetate,with'
p44352
(F1
F0.00014334862385321102
I1
I0
I1
tp44353
sS'drug,interactions,have'
p44354
(F1
F0.00014334862385321102
I1
I0
I1
tp44355
sS'of,antidepressant,when'
p44356
(F1
F0.00014334862385321102
I1
I0
I1
tp44357
sS'of,clinical,interest'
p44358
(F1
F0.00014334862385321102
I0
I1
I-1
tp44359
sS'of,healthy,males'
p44360
(F1
F0.00014334862385321102
I0
I1
I-1
tp44361
sS'of,blood,pressure'
p44362
(F1
F0.00071674311926605509
I5
I0
I5
tp44363
sS'diuretics,studies,in'
p44364
(F1
F0.00014334862385321102
I1
I0
I1
tp44365
sS'agents,some,increase'
p44366
(F1
F0.00014334862385321102
I1
I0
I1
tp44367
sS'of,bextra,mg'
p44368
(F1
F0.00014334862385321102
I0
I1
I-1
tp44369
sS'antipsychotic,agent,which'
p44370
(F1
F0.00014334862385321102
I0
I1
I-1
tp44371
sS'member,have,been'
p44372
(F1
F0.00014334862385321102
I1
I0
I1
tp44373
sS'elevate,serum,levels'
p44374
(F1
F0.00014334862385321102
I1
I0
I1
tp44375
sS'significantly,lower,with'
p44376
(F1
F0.00014334862385321102
I0
I1
I-1
tp44377
sS'and,to,mg'
p44378
(F1
F0.00014334862385321102
I0
I1
I-1
tp44379
sS'a,causal,mechanism'
p44380
(F1
F0.00014334862385321102
I1
I0
I1
tp44381
sS'were,homozygous,for'
p44382
(F1
F0.00014334862385321102
I0
I1
I-1
tp44383
sS'potassium,supplements,and'
p44384
(F1
F0.00028669724770642203
I2
I0
I2
tp44385
sS'of,toradol,with'
p44386
(F1
F0.00014334862385321102
I0
I1
I-1
tp44387
sS'certainly,during,periods'
p44388
(F1
F0.00014334862385321102
I1
I0
I1
tp44389
sS'cyp2e1,or,cyp3a4'
p44390
(F1
F0.00014334862385321102
I0
I1
I-1
tp44391
sS'elimination,of,its'
p44392
(F1
F0.00014334862385321102
I1
I0
I1
tp44393
sS'myocardium,may,induce'
p44394
(F1
F0.00014334862385321102
I1
I0
I1
tp44395
sS'of,clearance,such'
p44396
(F1
F0.00014334862385321102
I1
I0
I1
tp44397
sS'poorly,tolerated,and'
p44398
(F1
F0.00014334862385321102
I1
I0
I1
tp44399
sS'comedication,particularly,diabetics'
p44400
(F1
F0.00014334862385321102
I1
I0
I1
tp44401
sS'additional,titration,of'
p44402
(F1
F0.00014334862385321102
I1
I0
I1
tp44403
sS'inhibitors,and,agents'
p44404
(F1
F0.00014334862385321102
I0
I1
I-1
tp44405
sS'mg,daily,and'
p44406
(F0
F0
I1
I1
I0
tp44407
sS'b,was,more'
p44408
(F1
F0.00014334862385321102
I0
I1
I-1
tp44409
sS'kg,or,tmax'
p44410
(F1
F0.00014334862385321102
I0
I1
I-1
tp44411
sS'other,products,oral'
p44412
(F1
F0.00028669724770642203
I0
I2
I-2
tp44413
sS'coadministration,of,other'
p44414
(F1
F0.00014334862385321102
I1
I0
I1
tp44415
sS'are,reported,to'
p44416
(F1
F0.00028669724770642203
I2
I0
I2
tp44417
sS'may,be,enhanced'
p44418
(F1
F0.00057339449541284407
I4
I0
I4
tp44419
sS'flushing,mydriasis,tachycardia'
p44420
(F1
F0.00014334862385321102
I1
I0
I1
tp44421
sS'other,compounds,that'
p44422
(F1
F0.00014334862385321102
I0
I1
I-1
tp44423
sS'decreased,the,r-value'
p44424
(F1
F0.00014334862385321102
I0
I1
I-1
tp44425
sS'daily,should,be'
p44426
(F1
F0.00014334862385321102
I0
I1
I-1
tp44427
sS'with,other,antiretroviral'
p44428
(F0
F0
I1
I1
I0
tp44429
sS'reported,to,result'
p44430
(F1
F0.00071674311926605509
I5
I0
I5
tp44431
sS'the,diet,or'
p44432
(F1
F0.00014334862385321102
I0
I1
I-1
tp44433
sS'starlix,is,a'
p44434
(F1
F0.00014334862385321102
I1
I0
I1
tp44435
sS'at,an,increased'
p44436
(F1
F0.00028669724770642203
I2
I0
I2
tp44437
sS'the,disposition,of'
p44438
(F1
F0.00028669724770642203
I0
I2
I-2
tp44439
sS'potential,of,increased'
p44440
(F1
F0.00028669724770642203
I2
I0
I2
tp44441
sS'were,maintained,on'
p44442
(F1
F0.00014334862385321102
I0
I1
I-1
tp44443
sS'well,as,retention'
p44444
(F1
F0.00014334862385321102
I0
I1
I-1
tp44445
sS'or,renal,elimination'
p44446
(F1
F0.00028669724770642203
I0
I2
I-2
tp44447
sS'doubling,the,dose'
p44448
(F1
F0.00014334862385321102
I0
I1
I-1
tp44449
sS'elevations,of,pra'
p44450
(F1
F0.00014334862385321102
I0
I1
I-1
tp44451
sS'cervical,laceration,especially'
p44452
(F1
F0.00014334862385321102
I1
I0
I1
tp44453
sS'the,principal,given'
p44454
(F1
F0.00014334862385321102
I0
I1
I-1
tp44455
sS'the,gi,tract'
p44456
(F1
F0.00014334862385321102
I1
I0
I1
tp44457
sS'beta,blockers,in'
p44458
(F1
F0.00014334862385321102
I0
I1
I-1
tp44459
sS'the,remainder,no'
p44460
(F1
F0.00014334862385321102
I0
I1
I-1
tp44461
sS'data,indicate,that'
p44462
(F0.75
F0.0008600917431192661
I7
I1
I6
tp44463
sS'interfering,with,the'
p44464
(F1
F0.00014334862385321102
I1
I0
I1
tp44465
sS'of,based,on'
p44466
(F1
F0.00014334862385321102
I1
I0
I1
tp44467
sS'auc,of,mg'
p44468
(F1
F0.00014334862385321102
I1
I0
I1
tp44469
sS'a,considerable,effect'
p44470
(F1
F0.00014334862385321102
I1
I0
I1
tp44471
sS'a,consequence,of'
p44472
(F1
F0.00028669724770642203
I2
I0
I2
tp44473
sS'standing,systolic,blood'
p44474
(F1
F0.00071674311926605509
I5
I0
I5
tp44475
sS'within,minutes,after'
p44476
(F1
F0.00014334862385321102
I0
I1
I-1
tp44477
sS'long,half-life,of'
p44478
(F1
F0.00014334862385321102
I1
I0
I1
tp44479
sS'diagnosed,schizophrenia,schizoaffective'
p44480
(F1
F0.00014334862385321102
I1
I0
I1
tp44481
sS'as,with,most'
p44482
(F1
F0.00014334862385321102
I1
I0
I1
tp44483
sS'given,with,beta'
p44484
(F1
F0.00014334862385321102
I1
I0
I1
tp44485
sS'thus,should,not'
p44486
(F1
F0.00014334862385321102
I1
I0
I1
tp44487
sS't1,of,were'
p44488
(F1
F0.00014334862385321102
I1
I0
I1
tp44489
sS'traditional,agents,for'
p44490
(F1
F0.00014334862385321102
I0
I1
I-1
tp44491
sS'agents,the,antihypertensive'
p44492
(F1
F0.00014334862385321102
I1
I0
I1
tp44493
sS'orally,given,and'
p44494
(F1
F0.00014334862385321102
I0
I1
I-1
tp44495
sS'of,in,human'
p44496
(F0
F0
I1
I1
I0
tp44497
sS'reaction,during,treatment'
p44498
(F1
F0.00014334862385321102
I0
I1
I-1
tp44499
sS'flolan,was,initiated'
p44500
(F1
F0.00014334862385321102
I1
I0
I1
tp44501
sS'in,contrast,preliminary'
p44502
(F1
F0.00014334862385321102
I0
I1
I-1
tp44503
sS'short-acting,aerosol,of'
p44504
(F1
F0.00014334862385321102
I0
I1
I-1
tp44505
sS'interaction,whole,blood'
p44506
(F1
F0.00014334862385321102
I1
I0
I1
tp44507
sS'with,antithrombin,iii'
p44508
(F1
F0.00014334862385321102
I1
I0
I1
tp44509
sS'l,did,not'
p44510
(F1
F0.00014334862385321102
I0
I1
I-1
tp44511
sS'possibly,due,to'
p44512
(F1
F0.00043004587155963305
I3
I0
I3
tp44513
sS'it,is,given'
p44514
(F1
F0.00057339449541284407
I4
I0
I4
tp44515
sS'other,strong,inhibitors'
p44516
(F1
F0.00014334862385321102
I0
I1
I-1
tp44517
sS'the,year,risk'
p44518
(F1
F0.00014334862385321102
I0
I1
I-1
tp44519
sS'in,cardioplegic,solutions'
p44520
(F1
F0.00014334862385321102
I0
I1
I-1
tp44521
sS'to,results,from'
p44522
(F1
F0.00014334862385321102
I1
I0
I1
tp44523
sS'available,and,except'
p44524
(F1
F0.00014334862385321102
I0
I1
I-1
tp44525
sS'and,muscle,relaxant'
p44526
(F1
F0.00014334862385321102
I0
I1
I-1
tp44527
sS'associated,with,physicians'
p44528
(F1
F0.00014334862385321102
I0
I1
I-1
tp44529
sS'clearance,of,should'
p44530
(F1
F0.00014334862385321102
I1
I0
I1
tp44531
sS'ectopic,pacemaker,activity'
p44532
(F1
F0.00014334862385321102
I1
I0
I1
tp44533
sS'selegiline,l-phenylalanine,and'
p44534
(F1
F0.00014334862385321102
I1
I0
I1
tp44535
sS'a,methotrexate,there'
p44536
(F1
F0.00014334862385321102
I1
I0
I1
tp44537
sS'or,concurrently,with'
p44538
(F1
F0.00014334862385321102
I1
I0
I1
tp44539
sS'oral,route,in'
p44540
(F1
F0.00014334862385321102
I0
I1
I-1
tp44541
sS'exhibited,strong,synergistic'
p44542
(F1
F0.00014334862385321102
I1
I0
I1
tp44543
sS'mesylate,was,administered'
p44544
(F1
F0.00014334862385321102
I1
I0
I1
tp44545
sS'thus,smaller,doses'
p44546
(F1
F0.00014334862385321102
I1
I0
I1
tp44547
sS'were,conducted,between'
p44548
(F1
F0.00014334862385321102
I1
I0
I1
tp44549
sS'mg,and,sustiva'
p44550
(F1
F0.00014334862385321102
I0
I1
I-1
tp44551
sS'oral,as,well'
p44552
(F1
F0.00014334862385321102
I0
I1
I-1
tp44553
sS'although,not,studied'
p44554
(F0
F0
I1
I1
I0
tp44555
sS'replaced,by,the'
p44556
(F1
F0.00014334862385321102
I0
I1
I-1
tp44557
sS'including,remicade,used'
p44558
(F1
F0.00014334862385321102
I1
I0
I1
tp44559
sS'non-,steroidal,antiinflammatory'
p44560
(F1
F0.00014334862385321102
I1
I0
I1
tp44561
sS'mg,of,fe'
p44562
(F1
F0.00014334862385321102
I1
I0
I1
tp44563
sS'uterine,hypertonus,possibly'
p44564
(F1
F0.00014334862385321102
I1
I0
I1
tp44565
sS'therefore,serum,levels'
p44566
(F1
F0.00028669724770642203
I0
I2
I-2
tp44567
sS'of,felbatol,given'
p44568
(F1
F0.00028669724770642203
I2
I0
I2
tp44569
sS'sali-cylates,nsaids,including'
p44570
(F1
F0.00014334862385321102
I0
I1
I-1
tp44571
sS'function,may,also'
p44572
(F1
F0.00014334862385321102
I0
I1
I-1
tp44573
sS'may,make,normal'
p44574
(F1
F0.00028669724770642203
I0
I2
I-2
tp44575
sS'v,decreased,the'
p44576
(F1
F0.00014334862385321102
I0
I1
I-1
tp44577
sS'of,was,bioequivalent'
p44578
(F1
F0.00014334862385321102
I0
I1
I-1
tp44579
sS'for,signs,and'
p44580
(F1
F0.00014334862385321102
I1
I0
I1
tp44581
sS'or,with,mg'
p44582
(F1
F0.00014334862385321102
I0
I1
I-1
tp44583
sS'days,and,mmol'
p44584
(F1
F0.00014334862385321102
I0
I1
I-1
tp44585
sS'of,acute,phase'
p44586
(F1
F0.00014334862385321102
I0
I1
I-1
tp44587
sS'of,and,hydroxydesloratadine'
p44588
(F1
F0.00014334862385321102
I0
I1
I-1
tp44589
sS'or,the,fda'
p44590
(F1
F0.00014334862385321102
I0
I1
I-1
tp44591
sS'in,exposure,with'
p44592
(F1
F0.00014334862385321102
I1
I0
I1
tp44593
sS'to,protein,may'
p44594
(F1
F0.00014334862385321102
I1
I0
I1
tp44595
sS'and,catabolic,enzymes'
p44596
(F1
F0.00043004587155963305
I3
I0
I3
tp44597
sS'the,duration,but'
p44598
(F1
F0.00014334862385321102
I1
I0
I1
tp44599
sS'seriraline,and,inhibit'
p44600
(F1
F0.00014334862385321102
I0
I1
I-1
tp44601
sS'lower,pulmonary,wedge'
p44602
(F1
F0.00014334862385321102
I1
I0
I1
tp44603
sS'kg,for,up'
p44604
(F1
F0.00014334862385321102
I1
I0
I1
tp44605
sS'coagulation,assays,based'
p44606
(F1
F0.00014334862385321102
I0
I1
I-1
tp44607
sS'without,tdp,in'
p44608
(F1
F0.00014334862385321102
I0
I1
I-1
tp44609
sS'day,of,resulted'
p44610
(F1
F0.00014334862385321102
I1
I0
I1
tp44611
sS'duloxetine,clinical,trials'
p44612
(F1
F0.00014334862385321102
I0
I1
I-1
tp44613
sS'that,meth,caused'
p44614
(F1
F0.00014334862385321102
I1
I0
I1
tp44615
sS'mean,apparent,oral'
p44616
(F1
F0.00014334862385321102
I1
I0
I1
tp44617
sS'depressant,and,cautioned'
p44618
(F1
F0.00014334862385321102
I0
I1
I-1
tp44619
sS'the,sole,indication'
p44620
(F1
F0.00014334862385321102
I0
I1
I-1
tp44621
sS'protein,is,not'
p44622
(F1
F0.00014334862385321102
I0
I1
I-1
tp44623
sS'co,administration,of'
p44624
(F1
F0.00014334862385321102
I1
I0
I1
tp44625
sS'on,the,location'
p44626
(F1
F0.00014334862385321102
I0
I1
I-1
tp44627
sS'are,conflicting,results'
p44628
(F1
F0.00014334862385321102
I1
I0
I1
tp44629
sS'because,the,sum'
p44630
(F1
F0.00014334862385321102
I0
I1
I-1
tp44631
sS'for,management,of'
p44632
(F1
F0.00014334862385321102
I1
I0
I1
tp44633
sS'superior,to,to'
p44634
(F1
F0.00028669724770642203
I0
I2
I-2
tp44635
sS'interactions,observed,in'
p44636
(F1
F0.00014334862385321102
I1
I0
I1
tp44637
sS'enroll,patients,currently'
p44638
(F1
F0.00014334862385321102
I0
I1
I-1
tp44639
sS'hiv-infected,individuals,with'
p44640
(F1
F0.00014334862385321102
I0
I1
I-1
tp44641
sS'pregnancy,cromolyn,sodium'
p44642
(F1
F0.00014334862385321102
I0
I1
I-1
tp44643
sS'in,tissue,culture'
p44644
(F1
F0.00014334862385321102
I1
I0
I1
tp44645
sS'was,also,conducted'
p44646
(F1
F0.00014334862385321102
I0
I1
I-1
tp44647
sS'thiazide,and,inhibitors'
p44648
(F1
F0.00014334862385321102
I1
I0
I1
tp44649
sS'united,states,and'
p44650
(F1
F0.00014334862385321102
I0
I1
I-1
tp44651
sS'h,ml,and'
p44652
(F1
F0.00028669724770642203
I2
I0
I2
tp44653
sS'phenytoin,increases,the'
p44654
(F1
F0.00014334862385321102
I1
I0
I1
tp44655
sS'did,indeed,have'
p44656
(F1
F0.00014334862385321102
I1
I0
I1
tp44657
sS'or,increasing,the'
p44658
(F1
F0.00057339449541284407
I4
I0
I4
tp44659
sS'been,established,in'
p44660
(F1
F0.00014334862385321102
I0
I1
I-1
tp44661
sS'aspirin,celebrex,can'
p44662
(F1
F0.00014334862385321102
I1
I0
I1
tp44663
sS'metabolites,were,measured'
p44664
(F1
F0.00014334862385321102
I0
I1
I-1
tp44665
sS'the,pharmacodynamics,of'
p44666
(F1
F0.00071674311926605509
I0
I5
I-5
tp44667
sS'inhibitors,and,one'
p44668
(F1
F0.00014334862385321102
I0
I1
I-1
tp44669
sS'serious,side,effects'
p44670
(F1
F0.00014334862385321102
I0
I1
I-1
tp44671
sS'large,placebo-controlled,osteoporosis'
p44672
(F1
F0.00014334862385321102
I0
I1
I-1
tp44673
sS'or,withdrawn,from'
p44674
(F1
F0.00014334862385321102
I1
I0
I1
tp44675
sS'known,health,care'
p44676
(F1
F0.00014334862385321102
I0
I1
I-1
tp44677
sS'the,pharmacodynamics,or'
p44678
(F1
F0.00014334862385321102
I0
I1
I-1
tp44679
sS'of,supplements,and'
p44680
(F1
F0.00014334862385321102
I1
I0
I1
tp44681
sS'and,cold,preparations'
p44682
(F0
F0
I1
I1
I0
tp44683
sS'of,the,genetically'
p44684
(F1
F0.00014334862385321102
I0
I1
I-1
tp44685
sS'to,mg,every'
p44686
(F1
F0.00057339449541284407
I4
I0
I4
tp44687
sS'is,increased,when'
p44688
(F1
F0.00014334862385321102
I1
I0
I1
tp44689
sS'measured,as,inr'
p44690
(F1
F0.00014334862385321102
I1
I0
I1
tp44691
sS'even,when,administered'
p44692
(F1
F0.00014334862385321102
I1
I0
I1
tp44693
sS'epoxide,hydrolase,carbamazepine'
p44694
(F1
F0.00014334862385321102
I0
I1
I-1
tp44695
sS'the,atac,trial'
p44696
(F1
F0.00014334862385321102
I1
I0
I1
tp44697
sS'quinidine,at,mg'
p44698
(F1
F0.00014334862385321102
I1
I0
I1
tp44699
sS'concentration,of,increased'
p44700
(F1
F0.00014334862385321102
I0
I1
I-1
tp44701
sS'uptake,of,sodium'
p44702
(F1
F0.00014334862385321102
I1
I0
I1
tp44703
sS'pharmacology,clinical,studies'
p44704
(F1
F0.00014334862385321102
I1
I0
I1
tp44705
sS'auc,by,in'
p44706
(F1
F0.00014334862385321102
I1
I0
I1
tp44707
sS'that,might,increase'
p44708
(F1
F0.00014334862385321102
I1
I0
I1
tp44709
sS'voltaren,cataflam,lodine'
p44710
(F1
F0.00014334862385321102
I0
I1
I-1
tp44711
sS'treatment,and,prevention'
p44712
(F1
F0.00014334862385321102
I0
I1
I-1
tp44713
sS'the,plasma,levels'
p44714
(F0.5
F0.0011467889908256881
I12
I4
I8
tp44715
sS'been,conducted,to'
p44716
(F1
F0.00028669724770642203
I0
I2
I-2
tp44717
sS'august,were,identified'
p44718
(F1
F0.00014334862385321102
I0
I1
I-1
tp44719
sS'were,almost,fold'
p44720
(F1
F0.00014334862385321102
I1
I0
I1
tp44721
sS'steady-state,levels,of'
p44722
(F1
F0.00014334862385321102
I0
I1
I-1
tp44723
sS'sinus,rhythm,following'
p44724
(F1
F0.00014334862385321102
I1
I0
I1
tp44725
sS'and,therapy,indicate'
p44726
(F1
F0.00014334862385321102
I0
I1
I-1
tp44727
sS'clinical,pharmacology,coadministration'
p44728
(F1
F0.00014334862385321102
I1
I0
I1
tp44729
sS'inhibition,and,suggest'
p44730
(F1
F0.00014334862385321102
I0
I1
I-1
tp44731
sS'encephalopathic,syndrome,characterized'
p44732
(F1
F0.00014334862385321102
I1
I0
I1
tp44733
sS'smallest,effective,dose'
p44734
(F1
F0.00014334862385321102
I0
I1
I-1
tp44735
sS'any,reduction,in'
p44736
(F1
F0.00014334862385321102
I1
I0
I1
tp44737
sS'objective,of,this'
p44738
(F1
F0.00014334862385321102
I0
I1
I-1
tp44739
sS'as,monotherapy,given'
p44740
(F1
F0.00014334862385321102
I0
I1
I-1
tp44741
sS'if,therapy,is'
p44742
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp44743
sS'nonclinical,studies,show'
p44744
(F1
F0.00014334862385321102
I0
I1
I-1
tp44745
sS'aspirin,concomitant,may'
p44746
(F1
F0.00014334862385321102
I1
I0
I1
tp44747
sS'a,synergistic,relationship'
p44748
(F1
F0.00014334862385321102
I1
I0
I1
tp44749
sS'd,but,may'
p44750
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp44751
sS'regimens,for,therapy'
p44752
(F1
F0.00014334862385321102
I0
I1
I-1
tp44753
sS'for,subjects,had'
p44754
(F1
F0.00014334862385321102
I0
I1
I-1
tp44755
sS'should,be,stopped'
p44756
(F1
F0.00014334862385321102
I1
I0
I1
tp44757
sS'may,decrease,the'
p44758
(F0.80000000000000004
F0.0022935779816513763
I18
I2
I16
tp44759
sS'significant,decrease,by'
p44760
(F1
F0.00014334862385321102
I0
I1
I-1
tp44761
sS'their,o-desacetyl,metabolites'
p44762
(F1
F0.00014334862385321102
I0
I1
I-1
tp44763
sS'of,recovery,from'
p44764
(F1
F0.00014334862385321102
I0
I1
I-1
tp44765
sS'sympathetic,activity,the'
p44766
(F1
F0.00014334862385321102
I0
I1
I-1
tp44767
sS'as,nsaids,and'
p44768
(F1
F0.00014334862385321102
I0
I1
I-1
tp44769
sS'be,advised,to'
p44770
(F1
F0.00014334862385321102
I1
I0
I1
tp44771
sS'and,on,day'
p44772
(F1
F0.00014334862385321102
I1
I0
I1
tp44773
sS'with,decreased,levels'
p44774
(F1
F0.00014334862385321102
I0
I1
I-1
tp44775
sS'metoclopramide,when,coadministered'
p44776
(F1
F0.00014334862385321102
I1
I0
I1
tp44777
sS'metabolism,of,to'
p44778
(F1
F0.00028669724770642203
I0
I2
I-2
tp44779
sS'of,had,plasma'
p44780
(F1
F0.00014334862385321102
I1
I0
I1
tp44781
sS'requiring,increased,dosage'
p44782
(F1
F0.00014334862385321102
I1
I0
I1
tp44783
sS'by,to,several'
p44784
(F1
F0.00014334862385321102
I0
I1
I-1
tp44785
sS'withdrawn,from,given'
p44786
(F1
F0.00014334862385321102
I1
I0
I1
tp44787
sS'decrease,effectiveness,by'
p44788
(F1
F0.00014334862385321102
I0
I1
I-1
tp44789
sS'of,gross,motor'
p44790
(F1
F0.00014334862385321102
I0
I1
I-1
tp44791
sS'be,a,non-enzyme'
p44792
(F1
F0.00014334862385321102
I0
I1
I-1
tp44793
sS'proscar,mg,when'
p44794
(F1
F0.00014334862385321102
I0
I1
I-1
tp44795
sS'two,agents,were'
p44796
(F1
F0.00014334862385321102
I0
I1
I-1
tp44797
sS'cyp3a4,inducer,decreased'
p44798
(F1
F0.00014334862385321102
I1
I0
I1
tp44799
sS'no,formal,pharmacokinetic'
p44800
(F1
F0.00014334862385321102
I0
I1
I-1
tp44801
sS'day9,of,a'
p44802
(F1
F0.00014334862385321102
I1
I0
I1
tp44803
sS'impaired,in,the'
p44804
(F1
F0.00014334862385321102
I1
I0
I1
tp44805
sS'medications,or,n'
p44806
(F1
F0.00014334862385321102
I1
I0
I1
tp44807
sS'converted,difluoroacetone,to'
p44808
(F1
F0.00014334862385321102
I0
I1
I-1
tp44809
sS'relationship,has,not'
p44810
(F1
F0.00014334862385321102
I1
I0
I1
tp44811
sS'they,may,diminish'
p44812
(F1
F0.00014334862385321102
I1
I0
I1
tp44813
sS'agents,zyvox,or'
p44814
(F1
F0.00014334862385321102
I1
I0
I1
tp44815
sS'reported,from,the'
p44816
(F1
F0.00014334862385321102
I1
I0
I1
tp44817
sS'comparing,the,approved'
p44818
(F1
F0.00014334862385321102
I0
I1
I-1
tp44819
sS'their,dosage,should'
p44820
(F1
F0.00014334862385321102
I1
I0
I1
tp44821
sS'of,nimbex,in'
p44822
(F1
F0.00014334862385321102
I1
I0
I1
tp44823
sS'earlier,than,might'
p44824
(F1
F0.00014334862385321102
I1
I0
I1
tp44825
sS'theoretically,interfere,with'
p44826
(F1
F0.00014334862385321102
I0
I1
I-1
tp44827
sS'lasma,concentrations,of'
p44828
(F1
F0.00014334862385321102
I0
I1
I-1
tp44829
sS'oral,solution,should'
p44830
(F1
F0.00028669724770642203
I2
I0
I2
tp44831
sS'with,any,other'
p44832
(F1
F0.00014334862385321102
I0
I1
I-1
tp44833
sS'failure,nyha,class'
p44834
(F1
F0.00014334862385321102
I0
I1
I-1
tp44835
sS'similar,to,that'
p44836
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp44837
sS'were,on,average'
p44838
(F1
F0.00014334862385321102
I0
I1
I-1
tp44839
sS'in,renal,clearance'
p44840
(F1
F0.00028669724770642203
I2
I0
I2
tp44841
sS'receiving,mg,fe'
p44842
(F1
F0.00014334862385321102
I1
I0
I1
tp44843
sS'other,drugs,aliskiren'
p44844
(F1
F0.00014334862385321102
I0
I1
I-1
tp44845
sS'that,have,a'
p44846
(F1
F0.00014334862385321102
I1
I0
I1
tp44847
sS'oral,contraceptive,based'
p44848
(F1
F0.00014334862385321102
I0
I1
I-1
tp44849
sS'it,is,administered'
p44850
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp44851
sS'provide,close,medical'
p44852
(F1
F0.00014334862385321102
I1
I0
I1
tp44853
sS'cancer,in,postmenopausal'
p44854
(F1
F0.00014334862385321102
I1
I0
I1
tp44855
sS'two,mg,kg'
p44856
(F1
F0.00014334862385321102
I1
I0
I1
tp44857
sS'studied,alternative,or'
p44858
(F1
F0.00014334862385321102
I1
I0
I1
tp44859
sS'dose,have,not'
p44860
(F1
F0.00014334862385321102
I0
I1
I-1
tp44861
sS'very,weak,effect'
p44862
(F1
F0.00014334862385321102
I1
I0
I1
tp44863
sS'in,cecectomized,rats'
p44864
(F1
F0.00028669724770642203
I0
I2
I-2
tp44865
sS'neuropathy,has,occurred'
p44866
(F1
F0.00014334862385321102
I0
I1
I-1
tp44867
sS'tikosyn,with,resulted'
p44868
(F1
F0.00014334862385321102
I1
I0
I1
tp44869
sS'and,effectiveness,of'
p44870
(F1
F0.00028669724770642203
I0
I2
I-2
tp44871
sS'are,not,altered'
p44872
(F1
F0.00028669724770642203
I0
I2
I-2
tp44873
sS'brevibloc,and,in'
p44874
(F1
F0.00014334862385321102
I1
I0
I1
tp44875
sS'when,either,is'
p44876
(F0
F0
I1
I1
I0
tp44877
sS'alone,and,minutes'
p44878
(F1
F0.00014334862385321102
I0
I1
I-1
tp44879
sS'salt,intake,approximately'
p44880
(F1
F0.00014334862385321102
I1
I0
I1
tp44881
sS'not,clear,whether'
p44882
(F1
F0.00014334862385321102
I0
I1
I-1
tp44883
sS'ml,h,in'
p44884
(F1
F0.00014334862385321102
I0
I1
I-1
tp44885
sS'a,greater,ischemic'
p44886
(F1
F0.00014334862385321102
I1
I0
I1
tp44887
sS'in,plasma,concentration'
p44888
(F1
F0.00014334862385321102
I0
I1
I-1
tp44889
sS'subjects,demonstrated,that'
p44890
(F1
F0.00014334862385321102
I1
I0
I1
tp44891
sS'pharmacokinetic,study,maximum'
p44892
(F1
F0.00014334862385321102
I1
I0
I1
tp44893
sS'decrease,the,levels'
p44894
(F1
F0.00014334862385321102
I1
I0
I1
tp44895
sS'chemotherapy,or,a'
p44896
(F1
F0.00014334862385321102
I0
I1
I-1
tp44897
sS'dose,of,gleevec'
p44898
(F1
F0.00014334862385321102
I1
I0
I1
tp44899
sS'did,not,meaningfully'
p44900
(F1
F0.00014334862385321102
I0
I1
I-1
tp44901
sS'or,st,john'
p44902
(F1
F0.00014334862385321102
I1
I0
I1
tp44903
sS'return,toward,normal'
p44904
(F1
F0.00014334862385321102
I0
I1
I-1
tp44905
sS'have,been,reviewed'
p44906
(F1
F0.00014334862385321102
I1
I0
I1
tp44907
sS'therefore,not,be'
p44908
(F1
F0.00043004587155963305
I3
I0
I3
tp44909
sS'such,as,cough'
p44910
(F1
F0.00014334862385321102
I1
I0
I1
tp44911
sS'no,changes,in'
p44912
(F1
F0.00014334862385321102
I0
I1
I-1
tp44913
sS'of,in,dependence'
p44914
(F1
F0.00014334862385321102
I0
I1
I-1
tp44915
sS'vivo,studies,nitrates'
p44916
(F1
F0.00014334862385321102
I1
I0
I1
tp44917
sS'syndrome,characterized,by'
p44918
(F1
F0.00014334862385321102
I1
I0
I1
tp44919
sS'or,pharmacist,of'
p44920
(F1
F0.00014334862385321102
I0
I1
I-1
tp44921
sS'and,other,nondepolarizing'
p44922
(F1
F0.00014334862385321102
I0
I1
I-1
tp44923
sS'of,pgf2alpha,upon'
p44924
(F1
F0.00014334862385321102
I1
I0
I1
tp44925
sS'to,inhibition,of'
p44926
(F1
F0.00028669724770642203
I2
I0
I2
tp44927
sS'of,assays,using'
p44928
(F1
F0.00014334862385321102
I0
I1
I-1
tp44929
sS'from,marine,coelenterates'
p44930
(F1
F0.00014334862385321102
I0
I1
I-1
tp44931
sS'not,to,potentiate'
p44932
(F1
F0.00014334862385321102
I0
I1
I-1
tp44933
sS'using,human,liver'
p44934
(F1
F0.00014334862385321102
I0
I1
I-1
tp44935
sS'ns,and,imitrex'
p44936
(F1
F0.00014334862385321102
I0
I1
I-1
tp44937
sS'for,information,on'
p44938
(F1
F0.00014334862385321102
I0
I1
I-1
tp44939
sS'insufficient,plasma,and'
p44940
(F1
F0.00014334862385321102
I1
I0
I1
tp44941
sS'only,clinically,relevant'
p44942
(F1
F0.00014334862385321102
I1
I0
I1
tp44943
sS'of,kg,was'
p44944
(F1
F0.00014334862385321102
I1
I0
I1
tp44945
sS'increasing,blood,levels'
p44946
(F1
F0.00014334862385321102
I1
I0
I1
tp44947
sS'reduced,serum,levels'
p44948
(F1
F0.00014334862385321102
I1
I0
I1
tp44949
sS'studies,demonstrated,that'
p44950
(F1
F0.00014334862385321102
I0
I1
I-1
tp44951
sS'demonstrated,between,and'
p44952
(F1
F0.00014334862385321102
I1
I0
I1
tp44953
sS'when,duragesic,is'
p44954
(F1
F0.00014334862385321102
I0
I1
I-1
tp44955
sS'rats,results,in'
p44956
(F1
F0.00014334862385321102
I1
I0
I1
tp44957
sS'on,day,there'
p44958
(F0
F0
I1
I1
I0
tp44959
sS'digital,extensor,tension'
p44960
(F1
F0.00014334862385321102
I0
I1
I-1
tp44961
sS'potentially,important,drug'
p44962
(F1
F0.00014334862385321102
I1
I0
I1
tp44963
sS'for,the,control'
p44964
(F1
F0.00014334862385321102
I0
I1
I-1
tp44965
sS'but,changes,in'
p44966
(F1
F0.00014334862385321102
I0
I1
I-1
tp44967
sS'categories,result,in'
p44968
(F1
F0.00014334862385321102
I1
I0
I1
tp44969
sS'receiving,oral,may'
p44970
(F1
F0.00014334862385321102
I0
I1
I-1
tp44971
sS'of,mg,was'
p44972
(F0
F0
I2
I2
I0
tp44973
sS'wellbutrin,and,agents'
p44974
(F1
F0.00014334862385321102
I1
I0
I1
tp44975
sS'bromocriptine,mesylate,with'
p44976
(F1
F0.00014334862385321102
I1
I0
I1
tp44977
sS'be,borne,in'
p44978
(F0
F0
I1
I1
I0
tp44979
sS'indicate,that,oral'
p44980
(F1
F0.00057339449541284407
I4
I0
I4
tp44981
sS'mg,twice-daily,with'
p44982
(F1
F0.00014334862385321102
I1
I0
I1
tp44983
sS'use,of,prostaglandin'
p44984
(F1
F0.00014334862385321102
I1
I0
I1
tp44985
sS'adjusted,when,these'
p44986
(F1
F0.00014334862385321102
I0
I1
I-1
tp44987
sS'in,mice,selectively'
p44988
(F1
F0.00014334862385321102
I0
I1
I-1
tp44989
sS'estradiol,following,administration'
p44990
(F1
F0.00014334862385321102
I0
I1
I-1
tp44991
sS'it,appears,that'
p44992
(F1
F0.00014334862385321102
I1
I0
I1
tp44993
sS'in,auc,vs'
p44994
(F1
F0.00014334862385321102
I0
I1
I-1
tp44995
sS'and,may,enhance'
p44996
(F0.5
F0.00028669724770642203
I3
I1
I2
tp44997
sS'products,you,may'
p44998
(F1
F0.00014334862385321102
I0
I1
I-1
tp44999
sS'with,erectile,dysfunction'
p45000
(F1
F0.00014334862385321102
I0
I1
I-1
tp45001
sS'agents,along,with'
p45002
(F1
F0.00014334862385321102
I1
I0
I1
tp45003
sS'be,reduced,thus'
p45004
(F1
F0.00014334862385321102
I1
I0
I1
tp45005
sS'pharmacokinetics,of,see'
p45006
(F1
F0.00014334862385321102
I0
I1
I-1
tp45007
sS'did,not,show'
p45008
(F1
F0.00057339449541284407
I0
I4
I-4
tp45009
sS'plasma,mean,cmax'
p45010
(F1
F0.00014334862385321102
I1
I0
I1
tp45011
sS'xr,was,given'
p45012
(F1
F0.00014334862385321102
I0
I1
I-1
tp45013
sS'study,in,six'
p45014
(F1
F0.00028669724770642203
I2
I0
I2
tp45015
sS'binding,studies,with'
p45016
(F1
F0.00014334862385321102
I0
I1
I-1
tp45017
sS'of,mg,with'
p45018
(F1
F0.00043004587155963305
I3
I0
I3
tp45019
sS'indinavir,may,be'
p45020
(F1
F0.00014334862385321102
I1
I0
I1
tp45021
sS'effects,by,cgs21680'
p45022
(F1
F0.00014334862385321102
I1
I0
I1
tp45023
sS'compromised,renal,function'
p45024
(F1
F0.00028669724770642203
I2
I0
I2
tp45025
sS'eg,may,decrease'
p45026
(F1
F0.00014334862385321102
I1
I0
I1
tp45027
sS'avoid,intoxication,appropriate'
p45028
(F1
F0.00014334862385321102
I0
I1
I-1
tp45029
sS'potent,inhibition,inhibition'
p45030
(F1
F0.00014334862385321102
I0
I1
I-1
tp45031
sS'to,interfere,with'
p45032
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp45033
sS'a,different,route'
p45034
(F1
F0.00014334862385321102
I0
I1
I-1
tp45035
sS'cyclopentolate,may,interfere'
p45036
(F1
F0.00014334862385321102
I1
I0
I1
tp45037
sS'of,when,has'
p45038
(F1
F0.00014334862385321102
I1
I0
I1
tp45039
sS'broad,spectrum,of'
p45040
(F1
F0.00014334862385321102
I0
I1
I-1
tp45041
sS'agents,protease,inhibitors'
p45042
(F1
F0.00014334862385321102
I1
I0
I1
tp45043
sS'because,reduces,the'
p45044
(F1
F0.00014334862385321102
I1
I0
I1
tp45045
sS'mean,steady-state,trough'
p45046
(F1
F0.00014334862385321102
I0
I1
I-1
tp45047
sS'of,blood,glucose'
p45048
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp45049
sS'some,blockers,may'
p45050
(F1
F0.00014334862385321102
I1
I0
I1
tp45051
sS'to,avoid,impeding'
p45052
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp45053
sS'and,significant,increases'
p45054
(F1
F0.00014334862385321102
I1
I0
I1
tp45055
sS'and,can,cause'
p45056
(F1
F0.00014334862385321102
I1
I0
I1
tp45057
sS'toxic,and,traumatic'
p45058
(F1
F0.00014334862385321102
I1
I0
I1
tp45059
sS'as,a,regimen'
p45060
(F1
F0.00028669724770642203
I2
I0
I2
tp45061
sS'levels,whenever,an'
p45062
(F1
F0.00014334862385321102
I0
I1
I-1
tp45063
sS'oral,in,patients'
p45064
(F1
F0.00014334862385321102
I0
I1
I-1
tp45065
sS'to,be,lower'
p45066
(F1
F0.00014334862385321102
I0
I1
I-1
tp45067
sS'renal,clearance,of'
p45068
(F0.5
F0.00028669724770642203
I3
I1
I2
tp45069
sS'chance,of,developing'
p45070
(F1
F0.00014334862385321102
I1
I0
I1
tp45071
sS'administration,of,uricosuric'
p45072
(F1
F0.00014334862385321102
I1
I0
I1
tp45073
sS'patients,on,such'
p45074
(F1
F0.00014334862385321102
I1
I0
I1
tp45075
sS'and,given,before'
p45076
(F1
F0.00014334862385321102
I0
I1
I-1
tp45077
sS'crescentic,iga,glomerulonephritis'
p45078
(F1
F0.00014334862385321102
I1
I0
I1
tp45079
sS'such,medication,and'
p45080
(F1
F0.00014334862385321102
I0
I1
I-1
tp45081
sS'volunteers,in,the'
p45082
(F1
F0.00014334862385321102
I0
I1
I-1
tp45083
sS'agents,these,agents'
p45084
(F1
F0.00014334862385321102
I1
I0
I1
tp45085
sS'effect,on,plasma'
p45086
(F1
F0.0008600917431192661
I0
I6
I-6
tp45087
sS'steady-state,l50,mg'
p45088
(F1
F0.00014334862385321102
I0
I1
I-1
tp45089
sS'toxicologic,and,toxicokinetic'
p45090
(F1
F0.00014334862385321102
I0
I1
I-1
tp45091
sS'in,an,animal'
p45092
(F1
F0.00014334862385321102
I1
I0
I1
tp45093
sS'studies,was,administered'
p45094
(F1
F0.00014334862385321102
I0
I1
I-1
tp45095
sS'the,absorption,or'
p45096
(F1
F0.00014334862385321102
I0
I1
I-1
tp45097
sS'reduce,its,renal'
p45098
(F1
F0.00043004587155963305
I3
I0
I3
tp45099
sS'manifestation,of,corneal'
p45100
(F1
F0.00014334862385321102
I1
I0
I1
tp45101
sS'peripheral,anitagonism,without'
p45102
(F1
F0.00014334862385321102
I1
I0
I1
tp45103
sS'co-administered,with,racemic'
p45104
(F1
F0.00014334862385321102
I1
I0
I1
tp45105
sS'release,captopril,s'
p45106
(F1
F0.00014334862385321102
I1
I0
I1
tp45107
sS'the,absorption,of'
p45108
(F0.83333333333333337
F0.0028669724770642203
I22
I2
I20
tp45109
sS'protein,binding,in'
p45110
(F1
F0.00014334862385321102
I1
I0
I1
tp45111
sS'pcp,produces,psychotomimetic'
p45112
(F1
F0.00014334862385321102
I0
I1
I-1
tp45113
sS'formed,with,concurrent'
p45114
(F1
F0.00014334862385321102
I1
I0
I1
tp45115
sS'to,produce,a'
p45116
(F0.5
F0.00028669724770642203
I3
I1
I2
tp45117
sS'like,may,enhance'
p45118
(F1
F0.00014334862385321102
I1
I0
I1
tp45119
sS'fexofenadine,has,been'
p45120
(F1
F0.00014334862385321102
I0
I1
I-1
tp45121
sS'non-significantly,reduced,relative'
p45122
(F1
F0.00014334862385321102
I0
I1
I-1
tp45123
sS'in,humans,was'
p45124
(F1
F0.00014334862385321102
I0
I1
I-1
tp45125
sS'blood,pressure,reductions'
p45126
(F1
F0.00014334862385321102
I1
I0
I1
tp45127
sS'were,no,differential'
p45128
(F1
F0.00014334862385321102
I0
I1
I-1
tp45129
sS'can,be,induced'
p45130
(F1
F0.00014334862385321102
I0
I1
I-1
tp45131
sS'as,those,found'
p45132
(F1
F0.00014334862385321102
I0
I1
I-1
tp45133
sS'of,orthostatic,hypotension'
p45134
(F1
F0.00014334862385321102
I0
I1
I-1
tp45135
sS'of,was,investigated'
p45136
(F1
F0.00014334862385321102
I0
I1
I-1
tp45137
sS'weight,every,other'
p45138
(F1
F0.00014334862385321102
I0
I1
I-1
tp45139
sS'sulfamethoxazole-trimethoprim,bactrim,septra'
p45140
(F1
F0.00014334862385321102
I0
I1
I-1
tp45141
sS'the,has,been'
p45142
(F1
F0.00014334862385321102
I0
I1
I-1
tp45143
sS'adolescent,with,altered'
p45144
(F1
F0.00014334862385321102
I1
I0
I1
tp45145
sS'therapy,urinary,excretion'
p45146
(F1
F0.00028669724770642203
I2
I0
I2
tp45147
sS'intermediate,doses,of'
p45148
(F0
F0
I1
I1
I0
tp45149
sS'also,increased,rate'
p45150
(F1
F0.00014334862385321102
I0
I1
I-1
tp45151
sS'contraindications,significant,teratogenic'
p45152
(F1
F0.00014334862385321102
I0
I1
I-1
tp45153
sS'of,the,hypoglycemic'
p45154
(F1
F0.00014334862385321102
I1
I0
I1
tp45155
sS'under,the,plasma'
p45156
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp45157
sS'are,enhanced,by'
p45158
(F1
F0.00014334862385321102
I1
I0
I1
tp45159
sS'intensify,the,antimuscarinic'
p45160
(F1
F0.00014334862385321102
I1
I0
I1
tp45161
sS'in,decreases,in'
p45162
(F1
F0.00014334862385321102
I0
I1
I-1
tp45163
sS'used,in,addition'
p45164
(F1
F0.00014334862385321102
I1
I0
I1
tp45165
sS'strong,synergistic,activity'
p45166
(F1
F0.00014334862385321102
I1
I0
I1
tp45167
sS'unconjugated,nacmc,m'
p45168
(F1
F0.00014334862385321102
I0
I1
I-1
tp45169
sS'also,occur,with'
p45170
(F1
F0.00014334862385321102
I0
I1
I-1
tp45171
sS'followed,for,estimation'
p45172
(F1
F0.00014334862385321102
I0
I1
I-1
tp45173
sS'have,their,dose'
p45174
(F1
F0.00014334862385321102
I0
I1
I-1
tp45175
sS'rats,epidural,injection'
p45176
(F1
F0.00014334862385321102
I1
I0
I1
tp45177
sS'function,and,one'
p45178
(F1
F0.00014334862385321102
I0
I1
I-1
tp45179
sS'need,for,therapy'
p45180
(F1
F0.00014334862385321102
I1
I0
I1
tp45181
sS'the,rate-decreasing,effects'
p45182
(F1
F0.00014334862385321102
I1
I0
I1
tp45183
sS'therapy,allow,sufficient'
p45184
(F1
F0.00014334862385321102
I0
I1
I-1
tp45185
sS'treatment,with,can'
p45186
(F1
F0.00014334862385321102
I1
I0
I1
tp45187
sS'oral,and,to'
p45188
(F1
F0.00014334862385321102
I1
I0
I1
tp45189
sS'many,selective,serotonin'
p45190
(F1
F0.00028669724770642203
I0
I2
I-2
tp45191
sS'been,shown,not'
p45192
(F1
F0.00014334862385321102
I0
I1
I-1
tp45193
sS'of,decreased,slightly'
p45194
(F1
F0.00014334862385321102
I1
I0
I1
tp45195
sS'day,of,therapy'
p45196
(F1
F0.00014334862385321102
I1
I0
I1
tp45197
sS'system,though,this'
p45198
(F1
F0.00014334862385321102
I1
I0
I1
tp45199
sS'considered,if,systemic'
p45200
(F1
F0.00014334862385321102
I0
I1
I-1
tp45201
sS'warfarin-vitamin,k,can'
p45202
(F1
F0.00014334862385321102
I1
I0
I1
tp45203
sS'may,augment,the'
p45204
(F1
F0.00043004587155963305
I3
I0
I3
tp45205
sS'actions,desirable,or'
p45206
(F1
F0.00028669724770642203
I0
I2
I-2
tp45207
sS'patients,receiving,itraconazole'
p45208
(F1
F0.00014334862385321102
I1
I0
I1
tp45209
sS'be,used,as'
p45210
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45211
sS'of,serious,ventricular'
p45212
(F1
F0.00014334862385321102
I1
I0
I1
tp45213
sS'and,av,conduction'
p45214
(F1
F0.00014334862385321102
I0
I1
I-1
tp45215
sS'of,immunoreactive,after'
p45216
(F1
F0.00014334862385321102
I0
I1
I-1
tp45217
sS'of,developing,peripheral'
p45218
(F1
F0.00014334862385321102
I1
I0
I1
tp45219
sS'effects,of,aliskiren'
p45220
(F1
F0.00014334862385321102
I0
I1
I-1
tp45221
sS'the,clinical,studies'
p45222
(F1
F0.00014334862385321102
I0
I1
I-1
tp45223
sS'hiv-infected,patients,the'
p45224
(F1
F0.00014334862385321102
I1
I0
I1
tp45225
sS'effects,of,are'
p45226
(F1
F0.00057339449541284407
I4
I0
I4
tp45227
sS'approximately,times,the'
p45228
(F1
F0.00028669724770642203
I2
I0
I2
tp45229
sS'from,both,lean'
p45230
(F1
F0.00028669724770642203
I0
I2
I-2
tp45231
sS'high-estradiol,treated,rats'
p45232
(F1
F0.00014334862385321102
I1
I0
I1
tp45233
sS'open,three-period,randomized'
p45234
(F1
F0.00014334862385321102
I0
I1
I-1
tp45235
sS'prospective,clinical,trials'
p45236
(F1
F0.00014334862385321102
I0
I1
I-1
tp45237
sS'target,added,drug'
p45238
(F1
F0.00014334862385321102
I0
I1
I-1
tp45239
sS'of,on,fi'
p45240
(F1
F0.00014334862385321102
I1
I0
I1
tp45241
sS'clinical,practice,has'
p45242
(F1
F0.00014334862385321102
I1
I0
I1
tp45243
sS'initiated,to,see'
p45244
(F1
F0.00014334862385321102
I1
I0
I1
tp45245
sS'celebrex,should,be'
p45246
(F1
F0.00014334862385321102
I1
I0
I1
tp45247
sS'subjects,nor,does'
p45248
(F1
F0.00014334862385321102
I0
I1
I-1
tp45249
sS'may,render,these'
p45250
(F1
F0.00014334862385321102
I1
I0
I1
tp45251
sS'from,ml,h'
p45252
(F0
F0
I1
I1
I0
tp45253
sS'the,package,insert'
p45254
(F1
F0.00028669724770642203
I2
I0
I2
tp45255
sS'induce,cyp3a4,rifampicin'
p45256
(F1
F0.00014334862385321102
I1
I0
I1
tp45257
sS'be,warned,of'
p45258
(F1
F0.00014334862385321102
I1
I0
I1
tp45259
sS'sodium,fluorescein,naflu'
p45260
(F1
F0.00014334862385321102
I0
I1
I-1
tp45261
sS'a,multicenter,randomized'
p45262
(F1
F0.00014334862385321102
I0
I1
I-1
tp45263
sS'acamprosate,concomitantly,with'
p45264
(F0
F0
I1
I1
I0
tp45265
sS'and,oral,administration'
p45266
(F1
F0.00014334862385321102
I0
I1
I-1
tp45267
sS'have,secondary,actions'
p45268
(F1
F0.00014334862385321102
I1
I0
I1
tp45269
sS'for,in,combination'
p45270
(F1
F0.00014334862385321102
I0
I1
I-1
tp45271
sS'before,or,to'
p45272
(F1
F0.00014334862385321102
I0
I1
I-1
tp45273
sS'coadministered,with,a'
p45274
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45275
sS'in,pharmacokinetics,auc'
p45276
(F1
F0.00014334862385321102
I0
I1
I-1
tp45277
sS'to,difluoroacetone,by'
p45278
(F1
F0.00014334862385321102
I0
I1
I-1
tp45279
sS'were,administered,mg'
p45280
(F1
F0.00014334862385321102
I0
I1
I-1
tp45281
sS'activity,eg,and'
p45282
(F1
F0.00014334862385321102
I1
I0
I1
tp45283
sS'short-acting,inhaled,such'
p45284
(F1
F0.00014334862385321102
I0
I1
I-1
tp45285
sS'muscle,relaxants,has'
p45286
(F1
F0.00014334862385321102
I0
I1
I-1
tp45287
sS'saquinavir,steady-state,cmax'
p45288
(F1
F0.00014334862385321102
I1
I0
I1
tp45289
sS'catecholamine-depleting,drugs,such'
p45290
(F1
F0.00014334862385321102
I1
I0
I1
tp45291
sS'with,mg,sular'
p45292
(F1
F0.00014334862385321102
I1
I0
I1
tp45293
sS'in,each,subject'
p45294
(F1
F0.00014334862385321102
I0
I1
I-1
tp45295
sS'added,to,therapy'
p45296
(F1
F0.00028669724770642203
I2
I0
I2
tp45297
sS'of,medline,premedline'
p45298
(F1
F0.00014334862385321102
I0
I1
I-1
tp45299
sS'pressure,may,occur'
p45300
(F1
F0.00014334862385321102
I1
I0
I1
tp45301
sS'combination,study,of'
p45302
(F1
F0.00014334862385321102
I1
I0
I1
tp45303
sS'sample,size,is'
p45304
(F1
F0.00014334862385321102
I0
I1
I-1
tp45305
sS'concentration,as,compared'
p45306
(F1
F0.00014334862385321102
I0
I1
I-1
tp45307
sS'similar,effect,in'
p45308
(F1
F0.00014334862385321102
I0
I1
I-1
tp45309
sS'after,the,start'
p45310
(F1
F0.00014334862385321102
I1
I0
I1
tp45311
sS'of,sodium,fluorescein'
p45312
(F1
F0.00014334862385321102
I0
I1
I-1
tp45313
sS'disposition,of,and'
p45314
(F1
F0.00014334862385321102
I0
I1
I-1
tp45315
sS'ten,patients,who'
p45316
(F1
F0.00014334862385321102
I0
I1
I-1
tp45317
sS'clozapine,and,or'
p45318
(F1
F0.00014334862385321102
I1
I0
I1
tp45319
sS'of,concomitant,treatment'
p45320
(F1
F0.00014334862385321102
I0
I1
I-1
tp45321
sS'of,an,analog'
p45322
(F1
F0.00014334862385321102
I0
I1
I-1
tp45323
sS'mg,bid,for'
p45324
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp45325
sS'of,overdosage,cns'
p45326
(F1
F0.00028669724770642203
I2
I0
I2
tp45327
sS'any,procedure,in'
p45328
(F1
F0.00014334862385321102
I0
I1
I-1
tp45329
sS'diamond,patient,populations'
p45330
(F1
F0.00014334862385321102
I1
I0
I1
tp45331
sS'on,the,enhancement'
p45332
(F1
F0.00014334862385321102
I0
I1
I-1
tp45333
sS'necessary,during,and'
p45334
(F1
F0.00014334862385321102
I1
I0
I1
tp45335
sS'rats,responses,to'
p45336
(F1
F0.00014334862385321102
I0
I1
I-1
tp45337
sS'had,returned,to'
p45338
(F1
F0.00014334862385321102
I1
I0
I1
tp45339
sS'by,bacterial,metabolism'
p45340
(F1
F0.00014334862385321102
I1
I0
I1
tp45341
sS'initial,therapy,with'
p45342
(F1
F0.00014334862385321102
I0
I1
I-1
tp45343
sS'patients,with,tuberculosis'
p45344
(F1
F0.00014334862385321102
I1
I0
I1
tp45345
sS'and,these,imidazole'
p45346
(F1
F0.00014334862385321102
I0
I1
I-1
tp45347
sS'with,the,rate'
p45348
(F1
F0.00014334862385321102
I0
I1
I-1
tp45349
sS'binding,proteins,may'
p45350
(F1
F0.00028669724770642203
I0
I2
I-2
tp45351
sS'although,the,difference'
p45352
(F1
F0.00014334862385321102
I0
I1
I-1
tp45353
sS'anticoagulant,therapy,should'
p45354
(F1
F0.00014334862385321102
I1
I0
I1
tp45355
sS'paralytic,ileus,may'
p45356
(F1
F0.00014334862385321102
I1
I0
I1
tp45357
sS'of,may,decrease'
p45358
(F1
F0.00043004587155963305
I3
I0
I3
tp45359
sS'produce,any,additional'
p45360
(F1
F0.00014334862385321102
I1
I0
I1
tp45361
sS'effect,of,other'
p45362
(F1
F0.00028669724770642203
I0
I2
I-2
tp45363
sS'depression,producing,medications'
p45364
(F1
F0.00014334862385321102
I0
I1
I-1
tp45365
sS'on,either,the'
p45366
(F1
F0.00057339449541284407
I0
I4
I-4
tp45367
sS'in,men,years'
p45368
(F1
F0.00014334862385321102
I0
I1
I-1
tp45369
sS'neuropathy,or,other'
p45370
(F1
F0.00014334862385321102
I1
I0
I1
tp45371
sS'second,response,is'
p45372
(F1
F0.00014334862385321102
I0
I1
I-1
tp45373
sS'which,healthy,volunteers'
p45374
(F1
F0.00014334862385321102
I1
I0
I1
tp45375
sS'with,vioxx,may'
p45376
(F1
F0.00014334862385321102
I1
I0
I1
tp45377
sS'with,and,when'
p45378
(F1
F0.00014334862385321102
I1
I0
I1
tp45379
sS'increased,metabolism,and'
p45380
(F1
F0.00014334862385321102
I1
I0
I1
tp45381
sS'strains,of,staphylococcus'
p45382
(F1
F0.00014334862385321102
I1
I0
I1
tp45383
sS'bepridil,has,been'
p45384
(F1
F0.00014334862385321102
I0
I1
I-1
tp45385
sS'metabolized,nor,does'
p45386
(F1
F0.00014334862385321102
I0
I1
I-1
tp45387
sS'in,a,patient'
p45388
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp45389
sS'increase,in,glycemia'
p45390
(F1
F0.00014334862385321102
I0
I1
I-1
tp45391
sS'administration,of,mefloquine'
p45392
(F1
F0.00014334862385321102
I1
I0
I1
tp45393
sS'their,metabolism,in'
p45394
(F1
F0.00014334862385321102
I1
I0
I1
tp45395
sS'assay,and,emit-d'
p45396
(F1
F0.00014334862385321102
I0
I1
I-1
tp45397
sS'when,known,to'
p45398
(F1
F0.00014334862385321102
I0
I1
I-1
tp45399
sS'addition,is,not'
p45400
(F1
F0.00014334862385321102
I0
I1
I-1
tp45401
sS'will,interfere,with'
p45402
(F1
F0.00014334862385321102
I1
I0
I1
tp45403
sS'chemical,reaction,between'
p45404
(F1
F0.00014334862385321102
I1
I0
I1
tp45405
sS'secretion,blocking,agent'
p45406
(F1
F0.00014334862385321102
I0
I1
I-1
tp45407
sS'test,for,using'
p45408
(F1
F0.00014334862385321102
I0
I1
I-1
tp45409
sS'for,mg,qd'
p45410
(F1
F0.00014334862385321102
I1
I0
I1
tp45411
sS'when,lodine,is'
p45412
(F1
F0.00014334862385321102
I1
I0
I1
tp45413
sS'use,of,trileptal'
p45414
(F1
F0.00014334862385321102
I1
I0
I1
tp45415
sS'potentiating,effect,on'
p45416
(F1
F0.00014334862385321102
I1
I0
I1
tp45417
sS'predispose,the,patient'
p45418
(F1
F0.00014334862385321102
I1
I0
I1
tp45419
sS'drugs,fibric,acid'
p45420
(F1
F0.00014334862385321102
I0
I1
I-1
tp45421
sS'after,oral,mg'
p45422
(F1
F0.00014334862385321102
I0
I1
I-1
tp45423
sS'involving,inhibition,of'
p45424
(F1
F0.00014334862385321102
I1
I0
I1
tp45425
sS'have,a,strong'
p45426
(F1
F0.00014334862385321102
I0
I1
I-1
tp45427
sS'be,avoided,beta-blockers'
p45428
(F1
F0.00014334862385321102
I1
I0
I1
tp45429
sS'were,observed,following'
p45430
(F0
F0
I1
I1
I0
tp45431
sS'minimum,concentration,increased'
p45432
(F1
F0.00014334862385321102
I0
I1
I-1
tp45433
sS'and,mg,of'
p45434
(F1
F0.00057339449541284407
I4
I0
I4
tp45435
sS'impaired,psychomotor,performance'
p45436
(F1
F0.00028669724770642203
I2
I0
I2
tp45437
sS'elc,should,be'
p45438
(F1
F0.00014334862385321102
I1
I0
I1
tp45439
sS'and,mg,or'
p45440
(F1
F0.00014334862385321102
I0
I1
I-1
tp45441
sS'propranolol,may,decrease'
p45442
(F1
F0.00014334862385321102
I1
I0
I1
tp45443
sS'this,table,is'
p45444
(F1
F0.00014334862385321102
I0
I1
I-1
tp45445
sS'agents,there,were'
p45446
(F1
F0.00014334862385321102
I1
I0
I1
tp45447
sS'window,is,different'
p45448
(F1
F0.00014334862385321102
I1
I0
I1
tp45449
sS'basis,of,the'
p45450
(F0
F0
I1
I1
I0
tp45451
sS'patient,with,such'
p45452
(F1
F0.00014334862385321102
I0
I1
I-1
tp45453
sS'and,may,ameliorate'
p45454
(F1
F0.00014334862385321102
I1
I0
I1
tp45455
sS'in,vitro,metabolism'
p45456
(F1
F0.00014334862385321102
I0
I1
I-1
tp45457
sS'day,for,days'
p45458
(F0.33333333333333331
F0.00057339449541284407
I4
I8
I-4
tp45459
sS'most,are,contraindicated'
p45460
(F1
F0.00014334862385321102
I1
I0
I1
tp45461
sS'flurbiprofen,pretreatment,attenuated'
p45462
(F1
F0.00014334862385321102
I1
I0
I1
tp45463
sS'not,influence,the'
p45464
(F1
F0.0012901376146788992
I0
I9
I-9
tp45465
sS'and,respectively,on'
p45466
(F1
F0.00014334862385321102
I1
I0
I1
tp45467
sS'changes,in,prothrombin'
p45468
(F1
F0.00057339449541284407
I0
I4
I-4
tp45469
sS'possible,effectiveness,of'
p45470
(F1
F0.00014334862385321102
I1
I0
I1
tp45471
sS'assess,the,effect'
p45472
(F1
F0.00014334862385321102
I0
I1
I-1
tp45473
sS'of,morning,and'
p45474
(F1
F0.00014334862385321102
I0
I1
I-1
tp45475
sS'with,that,inhibit'
p45476
(F1
F0.00028669724770642203
I0
I2
I-2
tp45477
sS'elimination,route,of'
p45478
(F1
F0.00014334862385321102
I1
I0
I1
tp45479
sS'and,absorption,of'
p45480
(F1
F0.00014334862385321102
I1
I0
I1
tp45481
sS'medications,for,the'
p45482
(F1
F0.00014334862385321102
I0
I1
I-1
tp45483
sS'daily,and,mcg'
p45484
(F1
F0.00014334862385321102
I0
I1
I-1
tp45485
sS'similar,in,patients'
p45486
(F1
F0.00028669724770642203
I0
I2
I-2
tp45487
sS'or,preanesthetic,and'
p45488
(F1
F0.00014334862385321102
I0
I1
I-1
tp45489
sS'variability,component,of'
p45490
(F1
F0.00014334862385321102
I1
I0
I1
tp45491
sS'body,weight,for'
p45492
(F1
F0.00014334862385321102
I0
I1
I-1
tp45493
sS'be,necessary,to'
p45494
(F1
F0.00014334862385321102
I1
I0
I1
tp45495
sS'starting,and,frequently'
p45496
(F1
F0.00014334862385321102
I1
I0
I1
tp45497
sS'should,be,interrupted'
p45498
(F1
F0.00014334862385321102
I0
I1
I-1
tp45499
sS'did,not,seem'
p45500
(F1
F0.00014334862385321102
I0
I1
I-1
tp45501
sS'pharmacokinetic,parameters,without'
p45502
(F1
F0.00014334862385321102
I0
I1
I-1
tp45503
sS'gentamicin,methionine,may'
p45504
(F1
F0.00014334862385321102
I1
I0
I1
tp45505
sS'dosage,or,monitoring'
p45506
(F1
F0.00014334862385321102
I0
I1
I-1
tp45507
sS'dexamethasone,aprepitant,when'
p45508
(F1
F0.00014334862385321102
I1
I0
I1
tp45509
sS'uroxatral,should,not'
p45510
(F1
F0.00014334862385321102
I1
I0
I1
tp45511
sS'initial,dose,should'
p45512
(F1
F0.00014334862385321102
I0
I1
I-1
tp45513
sS'drug,interactions,benzodiazepines'
p45514
(F1
F0.00014334862385321102
I1
I0
I1
tp45515
sS'abnormalities,and,hearing'
p45516
(F1
F0.00014334862385321102
I1
I0
I1
tp45517
sS'may,reduce,serum'
p45518
(F1
F0.00014334862385321102
I1
I0
I1
tp45519
sS'and,provide,close'
p45520
(F1
F0.00014334862385321102
I1
I0
I1
tp45521
sS'was,no,clinically'
p45522
(F1
F0.00014334862385321102
I0
I1
I-1
tp45523
sS'concomitantly,with,plendil'
p45524
(F1
F0.00014334862385321102
I0
I1
I-1
tp45525
sS'systemic,exposure,auc0-12'
p45526
(F1
F0.00014334862385321102
I0
I1
I-1
tp45527
sS'adjustment,of,uricosuric'
p45528
(F1
F0.00014334862385321102
I1
I0
I1
tp45529
sS'patients,concurrently,treated'
p45530
(F1
F0.00014334862385321102
I1
I0
I1
tp45531
sS'and,celexa,in'
p45532
(F1
F0.00014334862385321102
I1
I0
I1
tp45533
sS'fashion,from,to'
p45534
(F1
F0.00014334862385321102
I0
I1
I-1
tp45535
sS'ecg,and,blood'
p45536
(F1
F0.00014334862385321102
I1
I0
I1
tp45537
sS'with,an,adjustment'
p45538
(F1
F0.00014334862385321102
I0
I1
I-1
tp45539
sS'include,certain,and'
p45540
(F1
F0.00028669724770642203
I2
I0
I2
tp45541
sS'therapeutic,monitoring,the'
p45542
(F1
F0.00014334862385321102
I0
I1
I-1
tp45543
sS'plasma,half-life,may'
p45544
(F1
F0.00014334862385321102
I1
I0
I1
tp45545
sS'in,treatment-experienced,patients'
p45546
(F1
F0.00014334862385321102
I0
I1
I-1
tp45547
sS'therefore,the,potential'
p45548
(F0
F0
I1
I1
I0
tp45549
sS'of,naflu,to'
p45550
(F1
F0.00014334862385321102
I0
I1
I-1
tp45551
sS'or,carbidopa-levodopa,combination'
p45552
(F1
F0.00014334862385321102
I0
I1
I-1
tp45553
sS'hypertension,where,the'
p45554
(F1
F0.00014334862385321102
I0
I1
I-1
tp45555
sS'have,used,combined'
p45556
(F1
F0.00014334862385321102
I0
I1
I-1
tp45557
sS'blocker,given,in'
p45558
(F1
F0.00014334862385321102
I1
I0
I1
tp45559
sS'the,effectiveness,of'
p45560
(F0.5
F0.00028669724770642203
I3
I1
I2
tp45561
sS'screening,urine,for'
p45562
(F1
F0.00014334862385321102
I0
I1
I-1
tp45563
sS'extreme,caution,should'
p45564
(F1
F0.00014334862385321102
I1
I0
I1
tp45565
sS'with,mg,daily'
p45566
(F0
F0
I1
I1
I0
tp45567
sS'controlled,clinical,study'
p45568
(F1
F0.00014334862385321102
I1
I0
I1
tp45569
sS'arterial,hypertension,did'
p45570
(F1
F0.00014334862385321102
I0
I1
I-1
tp45571
sS'does,not,predispose'
p45572
(F1
F0.00014334862385321102
I0
I1
I-1
tp45573
sS'and,others,plasma'
p45574
(F1
F0.00014334862385321102
I0
I1
I-1
tp45575
sS'similar,to,hydrochloride'
p45576
(F1
F0.00014334862385321102
I0
I1
I-1
tp45577
sS'p450,c9,by'
p45578
(F1
F0.00014334862385321102
I1
I0
I1
tp45579
sS'days,has,been'
p45580
(F0.5
F0.00028669724770642203
I3
I1
I2
tp45581
sS'was,effective,in'
p45582
(F1
F0.00014334862385321102
I1
I0
I1
tp45583
sS'maximum,block,following'
p45584
(F1
F0.00014334862385321102
I1
I0
I1
tp45585
sS'reduced,tolerance,in'
p45586
(F1
F0.00014334862385321102
I1
I0
I1
tp45587
sS'therapy,the,initial'
p45588
(F1
F0.00014334862385321102
I0
I1
I-1
tp45589
sS'rates,in,the'
p45590
(F1
F0.00014334862385321102
I0
I1
I-1
tp45591
sS'be,evaluated,after'
p45592
(F1
F0.00014334862385321102
I1
I0
I1
tp45593
sS'of,hctz,alone'
p45594
(F1
F0.00014334862385321102
I0
I1
I-1
tp45595
sS'a,mg,kg'
p45596
(F1
F0.00014334862385321102
I0
I1
I-1
tp45597
sS'with,measurement,of'
p45598
(F1
F0.00028669724770642203
I0
I2
I-2
tp45599
sS'reduced,thus,necessitating'
p45600
(F1
F0.00014334862385321102
I1
I0
I1
tp45601
sS'as,and,sometimes'
p45602
(F1
F0.00014334862385321102
I1
I0
I1
tp45603
sS'following,administration,of'
p45604
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp45605
sS'concentrations,may,need'
p45606
(F1
F0.00014334862385321102
I1
I0
I1
tp45607
sS'gastric,emptying,may'
p45608
(F1
F0.00014334862385321102
I1
I0
I1
tp45609
sS'ortho-novum,increased,the'
p45610
(F1
F0.00014334862385321102
I1
I0
I1
tp45611
sS'patients,and,result'
p45612
(F1
F0.00014334862385321102
I1
I0
I1
tp45613
sS'of,tambocor,with'
p45614
(F1
F0.00014334862385321102
I0
I1
I-1
tp45615
sS'after,coadministration,of'
p45616
(F1
F0.00014334862385321102
I0
I1
I-1
tp45617
sS'medications,were,grouped'
p45618
(F1
F0.00014334862385321102
I0
I1
I-1
tp45619
sS'avoided,because,accutane'
p45620
(F1
F0.00014334862385321102
I1
I0
I1
tp45621
sS'of,the,aucs'
p45622
(F1
F0.00014334862385321102
I0
I1
I-1
tp45623
sS'warfarin,co-,administration'
p45624
(F1
F0.00014334862385321102
I0
I1
I-1
tp45625
sS'carefully,for,signs'
p45626
(F1
F0.00057339449541284407
I4
I0
I4
tp45627
sS'excessive,effects,including'
p45628
(F1
F0.00014334862385321102
I1
I0
I1
tp45629
sS'failure,have,been'
p45630
(F1
F0.00014334862385321102
I1
I0
I1
tp45631
sS'effects,of,stimulation'
p45632
(F1
F0.00014334862385321102
I0
I1
I-1
tp45633
sS'profound,when,taxol'
p45634
(F1
F0.00014334862385321102
I1
I0
I1
tp45635
sS'equetrotm,increases,the'
p45636
(F1
F0.00014334862385321102
I1
I0
I1
tp45637
sS'like,monoamine,oxidase'
p45638
(F1
F0.00014334862385321102
I1
I0
I1
tp45639
sS'revlimid,is,neither'
p45640
(F1
F0.00014334862385321102
I0
I1
I-1
tp45641
sS'that,strongly,induce'
p45642
(F1
F0.00014334862385321102
I1
I0
I1
tp45643
sS'induce,cyp1a2,activity'
p45644
(F1
F0.00014334862385321102
I0
I1
I-1
tp45645
sS'have,been,noted'
p45646
(F1
F0.00028669724770642203
I2
I0
I2
tp45647
sS'requires,oral,physiological'
p45648
(F1
F0.00014334862385321102
I0
I1
I-1
tp45649
sS'a,potentially,fatal'
p45650
(F1
F0.00014334862385321102
I1
I0
I1
tp45651
sS'therapy,oral,containing'
p45652
(F1
F0.00014334862385321102
I0
I1
I-1
tp45653
sS'effects,vioxx,is'
p45654
(F1
F0.00014334862385321102
I0
I1
I-1
tp45655
sS'not,recommended,levetiracetam'
p45656
(F1
F0.00014334862385321102
I0
I1
I-1
tp45657
sS'interaction,between,oral'
p45658
(F1
F0.00043004587155963305
I3
I0
I3
tp45659
sS'receiving,velcade,treatment'
p45660
(F1
F0.00014334862385321102
I1
I0
I1
tp45661
sS'captopril-digoxin,interaction,could'
p45662
(F1
F0.00014334862385321102
I0
I1
I-1
tp45663
sS'increasing,the,non-renal'
p45664
(F1
F0.00014334862385321102
I1
I0
I1
tp45665
sS'are,case,reports'
p45666
(F1
F0.00014334862385321102
I1
I0
I1
tp45667
sS'as,nonsteroidal,agents'
p45668
(F1
F0.00014334862385321102
I0
I1
I-1
tp45669
sS'is,no,significant'
p45670
(F1
F0.00028669724770642203
I0
I2
I-2
tp45671
sS'as,the,potential'
p45672
(F1
F0.00014334862385321102
I1
I0
I1
tp45673
sS'formation,of,hydroxylamine'
p45674
(F1
F0.00014334862385321102
I0
I1
I-1
tp45675
sS'channel,blockers,sustained-release'
p45676
(F1
F0.00014334862385321102
I0
I1
I-1
tp45677
sS'large,doses,may'
p45678
(F1
F0.00014334862385321102
I0
I1
I-1
tp45679
sS'to,a,different'
p45680
(F1
F0.00014334862385321102
I1
I0
I1
tp45681
sS'and,increasing,steady-state'
p45682
(F1
F0.00014334862385321102
I1
I0
I1
tp45683
sS'to,in,the'
p45684
(F1
F0.00028669724770642203
I2
I0
I2
tp45685
sS'effect,of,panretin'
p45686
(F1
F0.00014334862385321102
I0
I1
I-1
tp45687
sS'maleate,or,mao-inhibitors'
p45688
(F1
F0.00014334862385321102
I1
I0
I1
tp45689
sS'days,with,mg'
p45690
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp45691
sS'a,starting,daily'
p45692
(F1
F0.00014334862385321102
I0
I1
I-1
tp45693
sS'erythromycin,co-administration,of'
p45694
(F1
F0.00014334862385321102
I0
I1
I-1
tp45695
sS'remains,constant,while'
p45696
(F1
F0.00014334862385321102
I0
I1
I-1
tp45697
sS'of,studies,in'
p45698
(F0
F0
I1
I1
I0
tp45699
sS'between,and,racemic'
p45700
(F1
F0.00014334862385321102
I0
I1
I-1
tp45701
sS'or,without,replacement'
p45702
(F1
F0.00014334862385321102
I0
I1
I-1
tp45703
sS'reduced,from,approximately'
p45704
(F1
F0.00014334862385321102
I1
I0
I1
tp45705
sS'blocker,and,a'
p45706
(F1
F0.00014334862385321102
I1
I0
I1
tp45707
sS'isoenzyme,and,thus'
p45708
(F1
F0.00014334862385321102
I0
I1
I-1
tp45709
sS'mesenteric,vasodilation,is'
p45710
(F1
F0.00014334862385321102
I0
I1
I-1
tp45711
sS'mellitus,certain,neurologic'
p45712
(F1
F0.00014334862385321102
I0
I1
I-1
tp45713
sS'mao,inhibitors,in'
p45714
(F1
F0.00014334862385321102
I1
I0
I1
tp45715
sS'that,discontinuation,of'
p45716
(F1
F0.00014334862385321102
I1
I0
I1
tp45717
sS'in,addition,neuromuscular'
p45718
(F1
F0.00014334862385321102
I0
I1
I-1
tp45719
sS'assessed,in,clinical'
p45720
(F1
F0.00014334862385321102
I0
I1
I-1
tp45721
sS'a,simultaneous,fold'
p45722
(F1
F0.00014334862385321102
I1
I0
I1
tp45723
sS'in,case,of'
p45724
(F1
F0.00014334862385321102
I1
I0
I1
tp45725
sS'loads,treated,with'
p45726
(F1
F0.00014334862385321102
I0
I1
I-1
tp45727
sS'appeared,to,produce'
p45728
(F1
F0.00014334862385321102
I1
I0
I1
tp45729
sS'trial,should,not'
p45730
(F1
F0.00014334862385321102
I1
I0
I1
tp45731
sS'incidence,of,upper'
p45732
(F1
F0.00043004587155963305
I0
I3
I-3
tp45733
sS'taken,concomitantly,by'
p45734
(F1
F0.00014334862385321102
I1
I0
I1
tp45735
sS'glucocorticoid-induced,mouse,mammary'
p45736
(F1
F0.00014334862385321102
I0
I1
I-1
tp45737
sS'treat,a,wide'
p45738
(F1
F0.00014334862385321102
I0
I1
I-1
tp45739
sS'potential,of,nephrotoxicity'
p45740
(F1
F0.00014334862385321102
I1
I0
I1
tp45741
sS'initial,or,maintenance'
p45742
(F1
F0.00014334862385321102
I0
I1
I-1
tp45743
sS'with,impaired,renal'
p45744
(F1
F0.00014334862385321102
I1
I0
I1
tp45745
sS'blocking,agents,channel'
p45746
(F1
F0.00014334862385321102
I1
I0
I1
tp45747
sS'effects,on,arterial'
p45748
(F1
F0.00014334862385321102
I1
I0
I1
tp45749
sS'hcl,ascorbic,acid'
p45750
(F1
F0.00014334862385321102
I1
I0
I1
tp45751
sS'that,in,most'
p45752
(F1
F0.00014334862385321102
I1
I0
I1
tp45753
sS'analysis,of,total'
p45754
(F1
F0.00014334862385321102
I0
I1
I-1
tp45755
sS'development,including,immune'
p45756
(F1
F0.00014334862385321102
I0
I1
I-1
tp45757
sS'and,low,hepatic'
p45758
(F1
F0.00014334862385321102
I0
I1
I-1
tp45759
sS'warfarin,multiple,oral'
p45760
(F1
F0.00014334862385321102
I0
I1
I-1
tp45761
sS'blockers,may,increase'
p45762
(F1
F0.00014334862385321102
I1
I0
I1
tp45763
sS'and,hydroxydesloratadine,pharmacokinetics'
p45764
(F1
F0.00014334862385321102
I0
I1
I-1
tp45765
sS'viracept,and,that'
p45766
(F1
F0.00028669724770642203
I0
I2
I-2
tp45767
sS'interaction,fosinopril,may'
p45768
(F1
F0.00014334862385321102
I0
I1
I-1
tp45769
sS'known,inhibitor,of'
p45770
(F1
F0.00043004587155963305
I3
I0
I3
tp45771
sS'capsule,formulation,with'
p45772
(F1
F0.00028669724770642203
I2
I0
I2
tp45773
sS'and,nondepolarizing,muscle'
p45774
(F1
F0.00014334862385321102
I0
I1
I-1
tp45775
sS'gastrointestinal,transit,time'
p45776
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp45777
sS'with,xanthine,derivatives'
p45778
(F1
F0.00014334862385321102
I1
I0
I1
tp45779
sS'and,protease,inhibitors'
p45780
(F1
F0.00014334862385321102
I0
I1
I-1
tp45781
sS'and,cyp2d6,are'
p45782
(F1
F0.00014334862385321102
I0
I1
I-1
tp45783
sS'of,itraconazole,with'
p45784
(F1
F0.00028669724770642203
I2
I0
I2
tp45785
sS'co-administration,of,copegus'
p45786
(F1
F0.00014334862385321102
I1
I0
I1
tp45787
sS'the,intestinal,absorption'
p45788
(F1
F0.00014334862385321102
I0
I1
I-1
tp45789
sS'and,ethacrynic,acid'
p45790
(F1
F0.00014334862385321102
I1
I0
I1
tp45791
sS'develop,in,patients'
p45792
(F1
F0.00014334862385321102
I1
I0
I1
tp45793
sS'caused,by,a'
p45794
(F1
F0.00014334862385321102
I1
I0
I1
tp45795
sS'index,such,as'
p45796
(F1
F0.00014334862385321102
I1
I0
I1
tp45797
sS'compared,with,patients'
p45798
(F1
F0.00014334862385321102
I1
I0
I1
tp45799
sS'both,dietary,concentrations'
p45800
(F1
F0.00014334862385321102
I0
I1
I-1
tp45801
sS'necessary,when,tagamet'
p45802
(F1
F0.00014334862385321102
I1
I0
I1
tp45803
sS'digoxin,the,concomitant'
p45804
(F1
F0.00014334862385321102
I0
I1
I-1
tp45805
sS'coadministration,whereas,the'
p45806
(F1
F0.00014334862385321102
I1
I0
I1
tp45807
sS'the,to,bind'
p45808
(F1
F0.00014334862385321102
I0
I1
I-1
tp45809
sS'other,and,may'
p45810
(F1
F0.00014334862385321102
I1
I0
I1
tp45811
sS'administered,alone,and'
p45812
(F0
F0
I1
I1
I0
tp45813
sS'patients,receiving,for'
p45814
(F1
F0.00014334862385321102
I0
I1
I-1
tp45815
sS'up,to,and'
p45816
(F1
F0.00043004587155963305
I3
I0
I3
tp45817
sS'that,cyp1a2,is'
p45818
(F1
F0.00014334862385321102
I1
I0
I1
tp45819
sS'with,type,diabetes'
p45820
(F1
F0.00028669724770642203
I0
I2
I-2
tp45821
sS'hydantoin,antiepileptic,and'
p45822
(F1
F0.00014334862385321102
I1
I0
I1
tp45823
sS'exacerbated,by,administration'
p45824
(F1
F0.00014334862385321102
I1
I0
I1
tp45825
sS'the,antimicrobial,combinations'
p45826
(F1
F0.00014334862385321102
I1
I0
I1
tp45827
sS'seizures,in,susceptible'
p45828
(F1
F0.00028669724770642203
I2
I0
I2
tp45829
sS'injection,should,not'
p45830
(F1
F0.00014334862385321102
I0
I1
I-1
tp45831
sS'by,coadministration,with'
p45832
(F1
F0.00014334862385321102
I0
I1
I-1
tp45833
sS'and,phase,days'
p45834
(F1
F0.00014334862385321102
I0
I1
I-1
tp45835
sS'haloperidol,blocks,and'
p45836
(F1
F0.00014334862385321102
I1
I0
I1
tp45837
sS'with,flolan,which'
p45838
(F1
F0.00014334862385321102
I1
I0
I1
tp45839
sS'the,mean,qt'
p45840
(F1
F0.00014334862385321102
I1
I0
I1
tp45841
sS'modify,the,mitogenic'
p45842
(F1
F0.00014334862385321102
I1
I0
I1
tp45843
sS'fractional,clearance,rate'
p45844
(F1
F0.00014334862385321102
I1
I0
I1
tp45845
sS'of,nimbex,are'
p45846
(F1
F0.00014334862385321102
I1
I0
I1
tp45847
sS'of,gastrointestinal,toxicity'
p45848
(F1
F0.00028669724770642203
I2
I0
I2
tp45849
sS'concentrations,tested,to'
p45850
(F1
F0.00014334862385321102
I0
I1
I-1
tp45851
sS'aeds,in,pediatric'
p45852
(F1
F0.00014334862385321102
I1
I0
I1
tp45853
sS'elevation,of,tbars'
p45854
(F1
F0.00014334862385321102
I1
I0
I1
tp45855
sS'age,of,years'
p45856
(F1
F0.00014334862385321102
I0
I1
I-1
tp45857
sS'supervision,after,the'
p45858
(F1
F0.00014334862385321102
I1
I0
I1
tp45859
sS'three,strains,of'
p45860
(F1
F0.00014334862385321102
I0
I1
I-1
tp45861
sS'the,dose,adjustment'
p45862
(F1
F0.00014334862385321102
I1
I0
I1
tp45863
sS'response,to,campath'
p45864
(F1
F0.00014334862385321102
I0
I1
I-1
tp45865
sS'vitro,displacement,studies'
p45866
(F1
F0.00014334862385321102
I0
I1
I-1
tp45867
sS'stress,induction,by'
p45868
(F1
F0.00014334862385321102
I0
I1
I-1
tp45869
sS'of,levels,and'
p45870
(F1
F0.00014334862385321102
I0
I1
I-1
tp45871
sS'and,results,in'
p45872
(F1
F0.00014334862385321102
I1
I0
I1
tp45873
sS'the,ph,of'
p45874
(F1
F0.00014334862385321102
I1
I0
I1
tp45875
sS'subjects,single-dose,administration'
p45876
(F1
F0.00014334862385321102
I0
I1
I-1
tp45877
sS'patients,with,are'
p45878
(F1
F0.00014334862385321102
I0
I1
I-1
tp45879
sS'valproic,acid,were'
p45880
(F1
F0.00014334862385321102
I0
I1
I-1
tp45881
sS'absorption,of,fat'
p45882
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp45883
sS'channel,subtypes,using'
p45884
(F1
F0.00014334862385321102
I0
I1
I-1
tp45885
sS'was,established,that'
p45886
(F1
F0.00014334862385321102
I0
I1
I-1
tp45887
sS'metabolism,by,is'
p45888
(F1
F0.00014334862385321102
I0
I1
I-1
tp45889
sS'of,vasopressor,and'
p45890
(F1
F0.00014334862385321102
I0
I1
I-1
tp45891
sS'studied,in,rat'
p45892
(F1
F0.00014334862385321102
I0
I1
I-1
tp45893
sS'p-450,isoenzymes,caution'
p45894
(F1
F0.00014334862385321102
I1
I0
I1
tp45895
sS'local,close,supervision'
p45896
(F1
F0.00014334862385321102
I0
I1
I-1
tp45897
sS'augmented,the,depressant'
p45898
(F1
F0.00014334862385321102
I1
I0
I1
tp45899
sS'seen,in,clinical'
p45900
(F1
F0.00014334862385321102
I0
I1
I-1
tp45901
sS'least,hours,prior'
p45902
(F1
F0.00028669724770642203
I2
I0
I2
tp45903
sS'concentrations,after,initiation'
p45904
(F1
F0.00014334862385321102
I1
I0
I1
tp45905
sS'revealed,a,significant'
p45906
(F1
F0.00014334862385321102
I0
I1
I-1
tp45907
sS'some,patients,and'
p45908
(F1
F0.00014334862385321102
I1
I0
I1
tp45909
sS'inducers,such,as'
p45910
(F1
F0.00043004587155963305
I3
I0
I3
tp45911
sS'increased,by,chronic'
p45912
(F1
F0.00014334862385321102
I1
I0
I1
tp45913
sS'two,mg,tablets'
p45914
(F1
F0.00014334862385321102
I0
I1
I-1
tp45915
sS'shown,to,be'
p45916
(F1
F0.00014334862385321102
I1
I0
I1
tp45917
sS'prolonged,prothrombin,times'
p45918
(F1
F0.00014334862385321102
I1
I0
I1
tp45919
sS'for,glucose,in'
p45920
(F1
F0.00028669724770642203
I0
I2
I-2
tp45921
sS'of,starlix,mg'
p45922
(F1
F0.00014334862385321102
I0
I1
I-1
tp45923
sS'hypokalemia,may,enhance'
p45924
(F1
F0.00014334862385321102
I1
I0
I1
tp45925
sS'tmax,at,daily'
p45926
(F1
F0.00014334862385321102
I0
I1
I-1
tp45927
sS'dose,administration,mg'
p45928
(F1
F0.00014334862385321102
I0
I1
I-1
tp45929
sS'when,given,supplemental'
p45930
(F1
F0.00014334862385321102
I1
I0
I1
tp45931
sS'with,treatment,in'
p45932
(F1
F0.00014334862385321102
I0
I1
I-1
tp45933
sS'plasma,auc,of'
p45934
(F1
F0.00014334862385321102
I1
I0
I1
tp45935
sS'following,initial,or'
p45936
(F1
F0.00014334862385321102
I0
I1
I-1
tp45937
sS'an,analysis,of'
p45938
(F1
F0.00014334862385321102
I1
I0
I1
tp45939
sS'for,one,week'
p45940
(F1
F0.00014334862385321102
I1
I0
I1
tp45941
sS'occurs,dose,should'
p45942
(F1
F0.00014334862385321102
I1
I0
I1
tp45943
sS'suppression,of,release'
p45944
(F1
F0.00014334862385321102
I0
I1
I-1
tp45945
sS'those,with,severe'
p45946
(F1
F0.00014334862385321102
I1
I0
I1
tp45947
sS'the,cyp2c9,catalyzed'
p45948
(F1
F0.00014334862385321102
I1
I0
I1
tp45949
sS'potassium-sparing,on,kinetics'
p45950
(F1
F0.00014334862385321102
I1
I0
I1
tp45951
sS'physiological,oral,supplementation'
p45952
(F1
F0.00028669724770642203
I0
I2
I-2
tp45953
sS'and,without,an'
p45954
(F1
F0.00014334862385321102
I1
I0
I1
tp45955
sS'since,bile,acid'
p45956
(F1
F0.00014334862385321102
I1
I0
I1
tp45957
sS'the,reaction,of'
p45958
(F1
F0.00014334862385321102
I1
I0
I1
tp45959
sS'gain,occurred,significantly'
p45960
(F1
F0.00014334862385321102
I0
I1
I-1
tp45961
sS'to,cause,tumors'
p45962
(F1
F0.00014334862385321102
I1
I0
I1
tp45963
sS'hormone,may,enhance'
p45964
(F1
F0.00014334862385321102
I1
I0
I1
tp45965
sS'several,dose,fractions'
p45966
(F1
F0.00014334862385321102
I0
I1
I-1
tp45967
sS'because,have,been'
p45968
(F1
F0.00014334862385321102
I1
I0
I1
tp45969
sS'with,dynacirc,an'
p45970
(F1
F0.00014334862385321102
I0
I1
I-1
tp45971
sS'serial,pharmacokinetic,dosing'
p45972
(F1
F0.00014334862385321102
I0
I1
I-1
tp45973
sS'during,coadministration,with'
p45974
(F1
F0.00028669724770642203
I2
I0
I2
tp45975
sS'however,appropriate,monitoring'
p45976
(F1
F0.00014334862385321102
I1
I0
I1
tp45977
sS'best,tool,for'
p45978
(F1
F0.00014334862385321102
I0
I1
I-1
tp45979
sS'other,including,ether'
p45980
(F1
F0.00014334862385321102
I1
I0
I1
tp45981
sS'secretion,of,and'
p45982
(F1
F0.00043004587155963305
I3
I0
I3
tp45983
sS'days,after,initiating'
p45984
(F1
F0.00014334862385321102
I1
I0
I1
tp45985
sS'p450,isoforms,cyp1a2'
p45986
(F1
F0.00014334862385321102
I0
I1
I-1
tp45987
sS'a,hmgcoa,reductase'
p45988
(F1
F0.00014334862385321102
I0
I1
I-1
tp45989
sS'and,hydrochloride,a'
p45990
(F1
F0.00014334862385321102
I0
I1
I-1
tp45991
sS'tissue,culture,the'
p45992
(F1
F0.00014334862385321102
I1
I0
I1
tp45993
sS'on,the,incidence'
p45994
(F1
F0.00014334862385321102
I0
I1
I-1
tp45995
sS'auc,of,cyp3a4'
p45996
(F1
F0.00014334862385321102
I1
I0
I1
tp45997
sS'life,in,patients'
p45998
(F1
F0.00014334862385321102
I0
I1
I-1
tp45999
sS'prothrombin,measures,have'
p46000
(F1
F0.00014334862385321102
I0
I1
I-1
tp46001
sS'available,data,are'
p46002
(F1
F0.00014334862385321102
I0
I1
I-1
tp46003
sS'time,course,of'
p46004
(F1
F0.00014334862385321102
I0
I1
I-1
tp46005
sS'combinations,were,determined'
p46006
(F1
F0.00014334862385321102
I0
I1
I-1
tp46007
sS'developed,regarding,interactions'
p46008
(F1
F0.00014334862385321102
I0
I1
I-1
tp46009
sS'several,studies,indicate'
p46010
(F1
F0.00014334862385321102
I0
I1
I-1
tp46011
sS'be,the,underlying'
p46012
(F1
F0.00014334862385321102
I1
I0
I1
tp46013
sS'other,antiepileptic,drugs'
p46014
(F0.5
F0.00028669724770642203
I3
I1
I2
tp46015
sS'shown,a,increase'
p46016
(F1
F0.00014334862385321102
I1
I0
I1
tp46017
sS'those,patients,reveiving'
p46018
(F1
F0.00014334862385321102
I1
I0
I1
tp46019
sS'd6,they,may'
p46020
(F1
F0.00071674311926605509
I0
I5
I-5
tp46021
sS'in,subjects,treated'
p46022
(F1
F0.00014334862385321102
I0
I1
I-1
tp46023
sS'qd,cohort,or'
p46024
(F1
F0.00014334862385321102
I0
I1
I-1
tp46025
sS'progressing,to,delirium'
p46026
(F1
F0.00014334862385321102
I1
I0
I1
tp46027
sS'indeed,agents,and'
p46028
(F1
F0.00014334862385321102
I0
I1
I-1
tp46029
sS'oral,antifungal,agents'
p46030
(F1
F0.00014334862385321102
I1
I0
I1
tp46031
sS'clo-4,simultaneously,or'
p46032
(F1
F0.00014334862385321102
I0
I1
I-1
tp46033
sS'rifampicin,in,a'
p46034
(F1
F0.00014334862385321102
I1
I0
I1
tp46035
sS'when,both,are'
p46036
(F1
F0.00014334862385321102
I1
I0
I1
tp46037
sS'was,not,associated'
p46038
(F1
F0.00014334862385321102
I0
I1
I-1
tp46039
sS'to,emerge,if'
p46040
(F1
F0.00014334862385321102
I1
I0
I1
tp46041
sS'in,a,increase'
p46042
(F1
F0.0011467889908256881
I8
I0
I8
tp46043
sS'is,no,pharmacokinetic'
p46044
(F1
F0.00028669724770642203
I0
I2
I-2
tp46045
sS'control,rbc,were'
p46046
(F1
F0.00014334862385321102
I0
I1
I-1
tp46047
sS'inhalation,aerosol,with'
p46048
(F1
F0.00014334862385321102
I1
I0
I1
tp46049
sS'preparations,micro-dosed,preparations'
p46050
(F1
F0.00014334862385321102
I1
I0
I1
tp46051
sS'of,with,containing'
p46052
(F1
F0.00014334862385321102
I1
I0
I1
tp46053
sS'with,medication,iodine-containing'
p46054
(F1
F0.00014334862385321102
I0
I1
I-1
tp46055
sS'core,temperature,was'
p46056
(F1
F0.00014334862385321102
I1
I0
I1
tp46057
sS'any,interaction,between'
p46058
(F1
F0.00014334862385321102
I0
I1
I-1
tp46059
sS'mg,increased,exposure'
p46060
(F1
F0.00014334862385321102
I1
I0
I1
tp46061
sS'with,sprycel,is'
p46062
(F1
F0.00014334862385321102
I1
I0
I1
tp46063
sS'clearance,by,and'
p46064
(F1
F0.00028669724770642203
I2
I0
I2
tp46065
sS'anti-depressants,could,exaggerate'
p46066
(F1
F0.00014334862385321102
I1
I0
I1
tp46067
sS'microsomal,enzyme,oxidation'
p46068
(F1
F0.00014334862385321102
I0
I1
I-1
tp46069
sS'hiv,classified,as'
p46070
(F1
F0.00014334862385321102
I1
I0
I1
tp46071
sS'with,dilaudid,may'
p46072
(F1
F0.00014334862385321102
I1
I0
I1
tp46073
sS'which,was,also'
p46074
(F1
F0.00014334862385321102
I0
I1
I-1
tp46075
sS'are,receiving,ace'
p46076
(F1
F0.00014334862385321102
I1
I0
I1
tp46077
sS'ergomar,and,other'
p46078
(F1
F0.00014334862385321102
I1
I0
I1
tp46079
sS'administered,with,other'
p46080
(F1
F0.00014334862385321102
I1
I0
I1
tp46081
sS'of,and,serotonergic'
p46082
(F1
F0.00014334862385321102
I0
I1
I-1
tp46083
sS'treatment,in,patients'
p46084
(F1
F0.00028669724770642203
I0
I2
I-2
tp46085
sS'with,has,also'
p46086
(F1
F0.00014334862385321102
I0
I1
I-1
tp46087
sS'administered,or,discontinued'
p46088
(F1
F0.00014334862385321102
I1
I0
I1
tp46089
sS'clomipramine,hcl,phenytoin'
p46090
(F1
F0.00014334862385321102
I1
I0
I1
tp46091
sS'clonazepam,does,not'
p46092
(F1
F0.00014334862385321102
I0
I1
I-1
tp46093
sS'approximately,decrease,range'
p46094
(F1
F0.00014334862385321102
I1
I0
I1
tp46095
sS'negative,inotropic,properties'
p46096
(F1
F0.00014334862385321102
I1
I0
I1
tp46097
sS'patient,receiving,hydrochloride'
p46098
(F1
F0.00014334862385321102
I1
I0
I1
tp46099
sS'effects,of,metabotropic'
p46100
(F1
F0.00014334862385321102
I0
I1
I-1
tp46101
sS'adjustments,of,concomitant'
p46102
(F1
F0.00014334862385321102
I0
I1
I-1
tp46103
sS'diphenhydramine,is,reported'
p46104
(F1
F0.00014334862385321102
I0
I1
I-1
tp46105
sS'significant,differences,were'
p46106
(F1
F0.00043004587155963305
I0
I3
I-3
tp46107
sS'if,necessary,for'
p46108
(F1
F0.00014334862385321102
I0
I1
I-1
tp46109
sS'concentrations,of,iressa'
p46110
(F1
F0.00014334862385321102
I1
I0
I1
tp46111
sS'and,may,reduce'
p46112
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp46113
sS'via,cytochrome,p450'
p46114
(F1
F0.00028669724770642203
I0
I2
I-2
tp46115
sS'these,reasons,it'
p46116
(F1
F0.00014334862385321102
I1
I0
I1
tp46117
sS'day,of,approximately'
p46118
(F1
F0.00014334862385321102
I1
I0
I1
tp46119
sS'and,possible,adjustment'
p46120
(F1
F0.00014334862385321102
I0
I1
I-1
tp46121
sS'was,used,with'
p46122
(F1
F0.00014334862385321102
I1
I0
I1
tp46123
sS'baseline,use,of'
p46124
(F1
F0.00014334862385321102
I0
I1
I-1
tp46125
sS'after,the,coadministration'
p46126
(F1
F0.00014334862385321102
I1
I0
I1
tp46127
sS'clinical,status,is'
p46128
(F1
F0.00014334862385321102
I1
I0
I1
tp46129
sS'healthy,subjects,who'
p46130
(F1
F0.00028669724770642203
I0
I2
I-2
tp46131
sS'is,initiated,in'
p46132
(F1
F0.00071674311926605509
I5
I0
I5
tp46133
sS'to,which,enbrel'
p46134
(F1
F0.00014334862385321102
I1
I0
I1
tp46135
sS'may,experience,enhanced'
p46136
(F1
F0.00014334862385321102
I1
I0
I1
tp46137
sS'welchol,decreased,the'
p46138
(F1
F0.00014334862385321102
I1
I0
I1
tp46139
sS'coadministered,with,monoamine'
p46140
(F1
F0.00014334862385321102
I1
I0
I1
tp46141
sS'in,which,patients'
p46142
(F1
F0.00028669724770642203
I2
I0
I2
tp46143
sS'concurrently,with,reduced'
p46144
(F1
F0.00014334862385321102
I1
I0
I1
tp46145
sS'multiple,fixed-interval,fixed-ratio'
p46146
(F1
F0.00014334862385321102
I0
I1
I-1
tp46147
sS'is,potentiated,by'
p46148
(F1
F0.00014334862385321102
I1
I0
I1
tp46149
sS'steady,state,following'
p46150
(F1
F0.00014334862385321102
I0
I1
I-1
tp46151
sS'after,than,with'
p46152
(F1
F0.00014334862385321102
I1
I0
I1
tp46153
sS'blocking,action,is'
p46154
(F1
F0.00014334862385321102
I0
I1
I-1
tp46155
sS'of,prostaglandin,synthesis'
p46156
(F1
F0.00014334862385321102
I1
I0
I1
tp46157
sS'the,superiority,of'
p46158
(F1
F0.00014334862385321102
I0
I1
I-1
tp46159
sS'inhibitor,in,two'
p46160
(F1
F0.00014334862385321102
I0
I1
I-1
tp46161
sS'typical,side,effect'
p46162
(F1
F0.00014334862385321102
I0
I1
I-1
tp46163
sS'a,small,increase'
p46164
(F1
F0.00014334862385321102
I0
I1
I-1
tp46165
sS'of,accutane,to'
p46166
(F1
F0.00014334862385321102
I1
I0
I1
tp46167
sS'of,zebeta,on'
p46168
(F1
F0.00014334862385321102
I0
I1
I-1
tp46169
sS'reductase,inhibitor,is'
p46170
(F1
F0.00014334862385321102
I1
I0
I1
tp46171
sS'increases,in,plasma'
p46172
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp46173
sS'or,induce,cytochrome'
p46174
(F1
F0.00014334862385321102
I0
I1
I-1
tp46175
sS'h2,antagonists,cimetidine'
p46176
(F1
F0.00014334862385321102
I1
I0
I1
tp46177
sS'pharmacokinetic,disposition,of'
p46178
(F1
F0.00014334862385321102
I0
I1
I-1
tp46179
sS'of,macrolide,and'
p46180
(F1
F0.00014334862385321102
I1
I0
I1
tp46181
sS'increased,exposures,to'
p46182
(F1
F0.00014334862385321102
I1
I0
I1
tp46183
sS'an,containing,gram'
p46184
(F1
F0.00014334862385321102
I1
I0
I1
tp46185
sS'sites,during,the'
p46186
(F1
F0.00028669724770642203
I2
I0
I2
tp46187
sS'mg,separated,by'
p46188
(F1
F0.00014334862385321102
I1
I0
I1
tp46189
sS'in,arc,mrna'
p46190
(F1
F0.00014334862385321102
I1
I0
I1
tp46191
sS'responses,to,ptx'
p46192
(F1
F0.00014334862385321102
I1
I0
I1
tp46193
sS'inspra,is,administered'
p46194
(F1
F0.00014334862385321102
I1
I0
I1
tp46195
sS'be,ineffective,if'
p46196
(F1
F0.00014334862385321102
I1
I0
I1
tp46197
sS'hormonal,contraceptives,including'
p46198
(F1
F0.00014334862385321102
I1
I0
I1
tp46199
sS'prior,ingestion,of'
p46200
(F1
F0.00014334862385321102
I1
I0
I1
tp46201
sS'total,were,and'
p46202
(F1
F0.00014334862385321102
I0
I1
I-1
tp46203
sS'increased,catabloism,of'
p46204
(F1
F0.00014334862385321102
I0
I1
I-1
tp46205
sS'agents,having,similar'
p46206
(F1
F0.00014334862385321102
I1
I0
I1
tp46207
sS'with,the,tricyclic'
p46208
(F1
F0.00014334862385321102
I1
I0
I1
tp46209
sS'cells,respond,normally'
p46210
(F1
F0.00014334862385321102
I0
I1
I-1
tp46211
sS'antineoplastic,agents,or'
p46212
(F1
F0.00014334862385321102
I1
I0
I1
tp46213
sS'to,diminish,oral'
p46214
(F1
F0.00028669724770642203
I2
I0
I2
tp46215
sS'antagonists,particularly,of'
p46216
(F1
F0.00014334862385321102
I1
I0
I1
tp46217
sS'pharmacokinetics,of,intravenous'
p46218
(F1
F0.00014334862385321102
I1
I0
I1
tp46219
sS'ordinarily,a,minor'
p46220
(F1
F0.00014334862385321102
I0
I1
I-1
tp46221
sS'during,adjunctive,therapy'
p46222
(F1
F0.00014334862385321102
I1
I0
I1
tp46223
sS'stadol,ns,may'
p46224
(F1
F0.00014334862385321102
I1
I0
I1
tp46225
sS'increase,in,auc0-12'
p46226
(F1
F0.00014334862385321102
I1
I0
I1
tp46227
sS'most,patients,treated'
p46228
(F1
F0.00014334862385321102
I0
I1
I-1
tp46229
sS'agents,no,interactions'
p46230
(F1
F0.00014334862385321102
I0
I1
I-1
tp46231
sS'naltrexone,trexan,with'
p46232
(F1
F0.00014334862385321102
I0
I1
I-1
tp46233
sS'a,substrate,of'
p46234
(F1
F0.00028669724770642203
I0
I2
I-2
tp46235
sS'may,use,especially'
p46236
(F1
F0.00014334862385321102
I0
I1
I-1
tp46237
sS'during,toradol,therapy'
p46238
(F1
F0.00014334862385321102
I1
I0
I1
tp46239
sS'nimodipine,and,losartan'
p46240
(F1
F0.00014334862385321102
I0
I1
I-1
tp46241
sS'for,this,interaction'
p46242
(F1
F0.00028669724770642203
I2
I0
I2
tp46243
sS'others,prelone,pediapred'
p46244
(F1
F0.00014334862385321102
I0
I1
I-1
tp46245
sS'to,mg,day'
p46246
(F0.55555555555555558
F0.00071674311926605509
I2
I7
I-5
tp46247
sS'those,seen,when'
p46248
(F1
F0.00014334862385321102
I1
I0
I1
tp46249
sS'reduce,its,absorption'
p46250
(F1
F0.00014334862385321102
I1
I0
I1
tp46251
sS'sodium,a,period'
p46252
(F1
F0.00014334862385321102
I1
I0
I1
tp46253
sS'with,oral,live'
p46254
(F1
F0.00014334862385321102
I1
I0
I1
tp46255
sS'i,and,with'
p46256
(F1
F0.00014334862385321102
I0
I1
I-1
tp46257
sS'with,caution,using'
p46258
(F1
F0.00014334862385321102
I1
I0
I1
tp46259
sS'zdv,has,been'
p46260
(F1
F0.00014334862385321102
I0
I1
I-1
tp46261
sS'effect,on,in'
p46262
(F1
F0.00014334862385321102
I0
I1
I-1
tp46263
sS'affinity,binding,sites'
p46264
(F1
F0.00028669724770642203
I0
I2
I-2
tp46265
sS'bezalip,and,bezalip'
p46266
(F1
F0.00014334862385321102
I1
I0
I1
tp46267
sS'was,altered,by'
p46268
(F1
F0.00014334862385321102
I0
I1
I-1
tp46269
sS'in,reducing,the'
p46270
(F1
F0.00014334862385321102
I1
I0
I1
tp46271
sS'patients,receiving,these'
p46272
(F1
F0.00028669724770642203
I0
I2
I-2
tp46273
sS'physicians,should,refer'
p46274
(F1
F0.00014334862385321102
I0
I1
I-1
tp46275
sS'accelerated,markedly,with'
p46276
(F1
F0.00014334862385321102
I1
I0
I1
tp46277
sS'controlled,parallel,group'
p46278
(F1
F0.00014334862385321102
I0
I1
I-1
tp46279
sS'with,increased,concentrations'
p46280
(F1
F0.00014334862385321102
I0
I1
I-1
tp46281
sS'related,to,amide-type'
p46282
(F1
F0.00014334862385321102
I1
I0
I1
tp46283
sS'in,metabolism,is'
p46284
(F1
F0.00014334862385321102
I0
I1
I-1
tp46285
sS'with,preparations,since'
p46286
(F1
F0.00014334862385321102
I1
I0
I1
tp46287
sS'with,antagonists,and'
p46288
(F1
F0.00014334862385321102
I1
I0
I1
tp46289
sS'it,may,increase'
p46290
(F0
F0
I1
I1
I0
tp46291
sS'with,proscar,mg'
p46292
(F1
F0.00014334862385321102
I0
I1
I-1
tp46293
sS'viracept,was,coadministered'
p46294
(F1
F0.00014334862385321102
I0
I1
I-1
tp46295
sS'family,cyp3a4,and'
p46296
(F1
F0.00014334862385321102
I0
I1
I-1
tp46297
sS'consisting,of,basal'
p46298
(F1
F0.00014334862385321102
I0
I1
I-1
tp46299
sS'the,rate,but'
p46300
(F1
F0.00014334862385321102
I0
I1
I-1
tp46301
sS'effect,of,dmpge2'
p46302
(F1
F0.00014334862385321102
I0
I1
I-1
tp46303
sS'at,a,low'
p46304
(F1
F0.00014334862385321102
I0
I1
I-1
tp46305
sS'inhibitors,because,the'
p46306
(F1
F0.00014334862385321102
I1
I0
I1
tp46307
sS'receiving,other,general'
p46308
(F1
F0.00014334862385321102
I1
I0
I1
tp46309
sS'advised,especially,at'
p46310
(F1
F0.00014334862385321102
I0
I1
I-1
tp46311
sS'p450,system,such'
p46312
(F1
F0.00014334862385321102
I0
I1
I-1
tp46313
sS'purpose,of,this'
p46314
(F1
F0.00014334862385321102
I0
I1
I-1
tp46315
sS'affect,platelet,function'
p46316
(F0
F0
I1
I1
I0
tp46317
sS'to,a,lesser'
p46318
(F1
F0.00028669724770642203
I0
I2
I-2
tp46319
sS'although,increased,plasma'
p46320
(F1
F0.00028669724770642203
I0
I2
I-2
tp46321
sS'increases,ethinyl,estradiol'
p46322
(F1
F0.00014334862385321102
I0
I1
I-1
tp46323
sS'be,exercised,because'
p46324
(F1
F0.00014334862385321102
I1
I0
I1
tp46325
sS'synkayvite,use,of'
p46326
(F1
F0.00014334862385321102
I0
I1
I-1
tp46327
sS'which,a,sulfonamide'
p46328
(F1
F0.00014334862385321102
I1
I0
I1
tp46329
sS'the,several-fold,higher'
p46330
(F1
F0.00014334862385321102
I0
I1
I-1
tp46331
sS'were,observed,with'
p46332
(F1
F0.00014334862385321102
I1
I0
I1
tp46333
sS'and,monitoring,of'
p46334
(F1
F0.00014334862385321102
I1
I0
I1
tp46335
sS'important,that,patients'
p46336
(F1
F0.00014334862385321102
I0
I1
I-1
tp46337
sS'the,intracellular,exposure'
p46338
(F1
F0.00014334862385321102
I1
I0
I1
tp46339
sS'decreased,binding,in'
p46340
(F1
F0.00014334862385321102
I1
I0
I1
tp46341
sS'repeating,the,study'
p46342
(F1
F0.00014334862385321102
I0
I1
I-1
tp46343
sS'have,been,conflicting'
p46344
(F1
F0.00014334862385321102
I1
I0
I1
tp46345
sS'in,the,ninds'
p46346
(F1
F0.00014334862385321102
I0
I1
I-1
tp46347
sS'desirable,or,undesirable'
p46348
(F1
F0.00028669724770642203
I0
I2
I-2
tp46349
sS'form,chelation,complexes'
p46350
(F1
F0.00014334862385321102
I1
I0
I1
tp46351
sS'differently,than,and'
p46352
(F1
F0.00014334862385321102
I0
I1
I-1
tp46353
sS'may,indicate,that'
p46354
(F1
F0.00014334862385321102
I1
I0
I1
tp46355
sS'considered,clinically,significant'
p46356
(F1
F0.00014334862385321102
I0
I1
I-1
tp46357
sS'and,the,potent'
p46358
(F1
F0.00014334862385321102
I1
I0
I1
tp46359
sS'diminished,binding,of'
p46360
(F1
F0.00014334862385321102
I1
I0
I1
tp46361
sS'be,expected,than'
p46362
(F1
F0.00014334862385321102
I1
I0
I1
tp46363
sS'somatrem,somatropin,excessive'
p46364
(F1
F0.00014334862385321102
I0
I1
I-1
tp46365
sS'lactulose-induced,drop,in'
p46366
(F1
F0.00014334862385321102
I1
I0
I1
tp46367
sS'coadministration,with,to'
p46368
(F1
F0.00014334862385321102
I1
I0
I1
tp46369
sS'to,competitively,inhibit'
p46370
(F1
F0.00014334862385321102
I1
I0
I1
tp46371
sS'the,enteric,coating'
p46372
(F1
F0.00014334862385321102
I1
I0
I1
tp46373
sS'of,anti-factor,xa'
p46374
(F1
F0.00014334862385321102
I0
I1
I-1
tp46375
sS'in,qt,prolongation'
p46376
(F1
F0.00014334862385321102
I1
I0
I1
tp46377
sS'suggested,may,be'
p46378
(F1
F0.00014334862385321102
I0
I1
I-1
tp46379
sS'patients,have,been'
p46380
(F1
F0.00014334862385321102
I1
I0
I1
tp46381
sS'such,as,certain'
p46382
(F1
F0.00014334862385321102
I1
I0
I1
tp46383
sS'study,of,in'
p46384
(F1
F0.00014334862385321102
I0
I1
I-1
tp46385
sS'be,modified,by'
p46386
(F1
F0.00014334862385321102
I1
I0
I1
tp46387
sS'cyp3a4,and,cyp2c8'
p46388
(F1
F0.00028669724770642203
I0
I2
I-2
tp46389
sS'relaxants,nondepolarizing,used'
p46390
(F1
F0.00014334862385321102
I0
I1
I-1
tp46391
sS'alone,suggesting,that'
p46392
(F1
F0.00014334862385321102
I1
I0
I1
tp46393
sS'been,rare,reports'
p46394
(F1
F0.00057339449541284407
I4
I0
I4
tp46395
sS'with,with,respectto'
p46396
(F1
F0.00014334862385321102
I0
I1
I-1
tp46397
sS'with,the,iop'
p46398
(F1
F0.00014334862385321102
I1
I0
I1
tp46399
sS'effect,on,the'
p46400
(F0.7192982456140351
F0.0058772935779816517
I8
I49
I-41
tp46401
sS'toxicity,and,cause'
p46402
(F1
F0.00014334862385321102
I0
I1
I-1
tp46403
sS'against,cryptosporidium,parvum'
p46404
(F1
F0.00014334862385321102
I0
I1
I-1
tp46405
sS'based,on,reports'
p46406
(F1
F0.00014334862385321102
I1
I0
I1
tp46407
sS'respectively,suggesting,an'
p46408
(F1
F0.00014334862385321102
I1
I0
I1
tp46409
sS'an,additive,effect'
p46410
(F1
F0.0010034403669724771
I7
I0
I7
tp46411
sS'with,cardiac,channel'
p46412
(F1
F0.00014334862385321102
I0
I1
I-1
tp46413
sS'after,cessation,of'
p46414
(F1
F0.00014334862385321102
I0
I1
I-1
tp46415
sS'during,both,periods'
p46416
(F1
F0.00014334862385321102
I0
I1
I-1
tp46417
sS'clinical,interaction,study'
p46418
(F1
F0.00014334862385321102
I0
I1
I-1
tp46419
sS'increased,plasma,levels'
p46420
(F1
F0.00028669724770642203
I2
I0
I2
tp46421
sS'or,skeletal-muscle,relaxants'
p46422
(F1
F0.00014334862385321102
I0
I1
I-1
tp46423
sS'in,turn,discussing'
p46424
(F1
F0.00014334862385321102
I0
I1
I-1
tp46425
sS'been,frequently,administered'
p46426
(F1
F0.00014334862385321102
I0
I1
I-1
tp46427
sS'and,stimulatory,effects'
p46428
(F1
F0.00014334862385321102
I1
I0
I1
tp46429
sS'mefloquine,may,reduce'
p46430
(F1
F0.00014334862385321102
I1
I0
I1
tp46431
sS'patients,taking,both'
p46432
(F1
F0.00028669724770642203
I2
I0
I2
tp46433
sS'divalproex,sodium,valproic'
p46434
(F1
F0.00014334862385321102
I1
I0
I1
tp46435
sS'the,serum,concentrations'
p46436
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp46437
sS'the,intestine,thus'
p46438
(F1
F0.00014334862385321102
I1
I0
I1
tp46439
sS'oral,resulting,in'
p46440
(F1
F0.00014334862385321102
I0
I1
I-1
tp46441
sS'or,toxoids,should'
p46442
(F1
F0.00014334862385321102
I1
I0
I1
tp46443
sS'alone,they,modify'
p46444
(F1
F0.00014334862385321102
I1
I0
I1
tp46445
sS'coadministration,with,compounds'
p46446
(F1
F0.00014334862385321102
I1
I0
I1
tp46447
sS'association,though,less'
p46448
(F1
F0.00028669724770642203
I0
I2
I-2
tp46449
sS'not,modify,the'
p46450
(F1
F0.00014334862385321102
I0
I1
I-1
tp46451
sS'of,the,exposure'
p46452
(F1
F0.00014334862385321102
I0
I1
I-1
tp46453
sS'taken,during,therapy'
p46454
(F1
F0.00043004587155963305
I3
I0
I3
tp46455
sS'by,intraventricular,injection'
p46456
(F1
F0.00014334862385321102
I1
I0
I1
tp46457
sS'gleevec,will,increase'
p46458
(F1
F0.00014334862385321102
I1
I0
I1
tp46459
sS'not,statistically,significant'
p46460
(F1
F0.00014334862385321102
I1
I0
I1
tp46461
sS'or,administered,with'
p46462
(F1
F0.00014334862385321102
I1
I0
I1
tp46463
sS'in,which,erbitux'
p46464
(F1
F0.00014334862385321102
I0
I1
I-1
tp46465
sS'a,increase,in'
p46466
(F1
F0.0030103211009174314
I21
I0
I21
tp46467
sS'symptoms,support,the'
p46468
(F1
F0.00014334862385321102
I0
I1
I-1
tp46469
sS'the,blood,concentration'
p46470
(F1
F0.00014334862385321102
I0
I1
I-1
tp46471
sS'with,the,concomitant'
p46472
(F1
F0.0008600917431192661
I6
I0
I6
tp46473
sS'may,increase,when'
p46474
(F1
F0.00028669724770642203
I2
I0
I2
tp46475
sS'inhibitory,concentration,greater'
p46476
(F1
F0.00014334862385321102
I0
I1
I-1
tp46477
sS'acid,may,potentiate'
p46478
(F1
F0.00014334862385321102
I1
I0
I1
tp46479
sS'fluoride,and,citrate'
p46480
(F1
F0.00014334862385321102
I1
I0
I1
tp46481
sS'calcium,channel,blockers'
p46482
(F1
F0.00028669724770642203
I2
I0
I2
tp46483
sS'symptoms,and,was'
p46484
(F1
F0.00014334862385321102
I0
I1
I-1
tp46485
sS'oral,and,are'
p46486
(F1
F0.00014334862385321102
I1
I0
I1
tp46487
sS'be,rationalized,at'
p46488
(F1
F0.00014334862385321102
I0
I1
I-1
tp46489
sS'be,monitored,closely'
p46490
(F0.5
F0.00057339449541284407
I6
I2
I4
tp46491
sS'by,possibly,by'
p46492
(F1
F0.00014334862385321102
I1
I0
I1
tp46493
sS'patient,being,withdrawn'
p46494
(F1
F0.00014334862385321102
I1
I0
I1
tp46495
sS'patients,receiving,hcl'
p46496
(F1
F0.00028669724770642203
I2
I0
I2
tp46497
sS'at,hours,postdose'
p46498
(F1
F0.00014334862385321102
I1
I0
I1
tp46499
sS'the,inhibitory,activity'
p46500
(F1
F0.00014334862385321102
I1
I0
I1
tp46501
sS'other,general,or'
p46502
(F1
F0.00028669724770642203
I2
I0
I2
tp46503
sS'in,erythro-fluorocitrate,synthesis'
p46504
(F1
F0.00014334862385321102
I0
I1
I-1
tp46505
sS'metabolism,of,other'
p46506
(F0
F0
I1
I1
I0
tp46507
sS'the,label,should'
p46508
(F1
F0.00014334862385321102
I1
I0
I1
tp46509
sS'acetate,and,mcg'
p46510
(F1
F0.00014334862385321102
I0
I1
I-1
tp46511
sS'levels,of,equetrotm'
p46512
(F1
F0.00028669724770642203
I2
I0
I2
tp46513
sS'for,strains,and'
p46514
(F1
F0.00014334862385321102
I1
I0
I1
tp46515
sS'pharmacokinetics,and,cardiovascular'
p46516
(F1
F0.00014334862385321102
I0
I1
I-1
tp46517
sS'and,other,when'
p46518
(F1
F0.00014334862385321102
I1
I0
I1
tp46519
sS'rr,microm,also'
p46520
(F1
F0.00014334862385321102
I1
I0
I1
tp46521
sS'reduced,clearance,prolongation'
p46522
(F1
F0.00014334862385321102
I0
I1
I-1
tp46523
sS'ototoxic,potential,especially'
p46524
(F1
F0.00014334862385321102
I1
I0
I1
tp46525
sS'carbamazepine,epoxide,steady-state'
p46526
(F1
F0.00014334862385321102
I0
I1
I-1
tp46527
sS'alpha,interferons,such'
p46528
(F1
F0.00014334862385321102
I0
I1
I-1
tp46529
sS'produce,a,false'
p46530
(F1
F0.00014334862385321102
I0
I1
I-1
tp46531
sS'patients,taking,other'
p46532
(F0
F0
I1
I1
I0
tp46533
sS'improved,permeation,was'
p46534
(F1
F0.00014334862385321102
I0
I1
I-1
tp46535
sS'receiving,ace,inhibitors'
p46536
(F1
F0.00043004587155963305
I3
I0
I3
tp46537
sS'not,affect,the'
p46538
(F0.9375
F0.0043004587155963305
I1
I31
I-30
tp46539
sS'that,renal,function'
p46540
(F1
F0.00014334862385321102
I1
I0
I1
tp46541
sS'interval,must,not'
p46542
(F1
F0.00014334862385321102
I1
I0
I1
tp46543
sS'sodium,and,possibly'
p46544
(F1
F0.00028669724770642203
I0
I2
I-2
tp46545
sS'agents,that,have'
p46546
(F1
F0.00014334862385321102
I1
I0
I1
tp46547
sS'these,medicines,during'
p46548
(F1
F0.00014334862385321102
I1
I0
I1
tp46549
sS'may,be,deeper'
p46550
(F1
F0.00014334862385321102
I1
I0
I1
tp46551
sS'with,the,preparation'
p46552
(F1
F0.00014334862385321102
I1
I0
I1
tp46553
sS'of,bombesin-enhanced,peritoneal'
p46554
(F1
F0.00014334862385321102
I1
I0
I1
tp46555
sS'anafranil,is,administered'
p46556
(F1
F0.00014334862385321102
I1
I0
I1
tp46557
sS'occur,if,and'
p46558
(F1
F0.00014334862385321102
I1
I0
I1
tp46559
sS'for,eight,of'
p46560
(F1
F0.00014334862385321102
I1
I0
I1
tp46561
sS'with,torsades,de'
p46562
(F1
F0.00014334862385321102
I0
I1
I-1
tp46563
sS'th,generation,of'
p46564
(F1
F0.00014334862385321102
I0
I1
I-1
tp46565
sS'agents,are,reduced'
p46566
(F1
F0.00014334862385321102
I1
I0
I1
tp46567
sS'in,cmax,leading'
p46568
(F1
F0.00014334862385321102
I1
I0
I1
tp46569
sS'and,electrophysiologic,interactions'
p46570
(F1
F0.00014334862385321102
I0
I1
I-1
tp46571
sS'neurons,and,the'
p46572
(F1
F0.00014334862385321102
I1
I0
I1
tp46573
sS'the,optimal,dose'
p46574
(F1
F0.00028669724770642203
I0
I2
I-2
tp46575
sS'uricosuric,agents,aspirin'
p46576
(F1
F0.00014334862385321102
I1
I0
I1
tp46577
sS'm1,peak,levels'
p46578
(F1
F0.00014334862385321102
I1
I0
I1
tp46579
sS'with,mg,increased'
p46580
(F1
F0.00014334862385321102
I1
I0
I1
tp46581
sS'interactions,of,and'
p46582
(F1
F0.00014334862385321102
I1
I0
I1
tp46583
sS'following,ultracentrifugation,indicated'
p46584
(F1
F0.00014334862385321102
I0
I1
I-1
tp46585
sS'reversible,enhancement,of'
p46586
(F1
F0.00014334862385321102
I1
I0
I1
tp46587
sS'with,acute,toxicity'
p46588
(F1
F0.00028669724770642203
I2
I0
I2
tp46589
sS'hypoglycemia,oral,antidiabetes'
p46590
(F1
F0.00014334862385321102
I0
I1
I-1
tp46591
sS'studies,failed,to'
p46592
(F1
F0.00014334862385321102
I0
I1
I-1
tp46593
sS'promethazine,coadministration,of'
p46594
(F1
F0.00014334862385321102
I1
I0
I1
tp46595
sS'alkalinizing,agents,some'
p46596
(F1
F0.00014334862385321102
I1
I0
I1
tp46597
sS'prolong,and,intensify'
p46598
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp46599
sS'descarboethoxyloratadine,after,days'
p46600
(F1
F0.00014334862385321102
I0
I1
I-1
tp46601
sS'clinical,experience,with'
p46602
(F1
F0.00014334862385321102
I0
I1
I-1
tp46603
sS'action,of,starlix'
p46604
(F1
F0.00028669724770642203
I2
I0
I2
tp46605
sS'and,without,coadministration'
p46606
(F1
F0.00014334862385321102
I0
I1
I-1
tp46607
sS'direct,coombs,reactions'
p46608
(F1
F0.00014334862385321102
I0
I1
I-1
tp46609
sS'naproxen,the,concomitant'
p46610
(F1
F0.00014334862385321102
I1
I0
I1
tp46611
sS'hence,is,not'
p46612
(F1
F0.00014334862385321102
I1
I0
I1
tp46613
sS'significant,pharmacokinetic,interaction'
p46614
(F1
F0.00028669724770642203
I0
I2
I-2
tp46615
sS'healthy,volunteers,did'
p46616
(F1
F0.00014334862385321102
I0
I1
I-1
tp46617
sS'with,an,inhibitor'
p46618
(F1
F0.00028669724770642203
I2
I0
I2
tp46619
sS'experiences,in,the'
p46620
(F1
F0.00014334862385321102
I0
I1
I-1
tp46621
sS'or,potentiation,of'
p46622
(F1
F0.00028669724770642203
I0
I2
I-2
tp46623
sS'agents,that,inhibit'
p46624
(F1
F0.00014334862385321102
I0
I1
I-1
tp46625
sS'both,lean,and'
p46626
(F1
F0.00028669724770642203
I0
I2
I-2
tp46627
sS'the,reduction,of'
p46628
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp46629
sS'patients,n,maintained'
p46630
(F1
F0.00014334862385321102
I0
I1
I-1
tp46631
sS'is,different,than'
p46632
(F1
F0.00014334862385321102
I1
I0
I1
tp46633
sS'antagonized,by,either'
p46634
(F1
F0.00014334862385321102
I0
I1
I-1
tp46635
sS'but,quickens,the'
p46636
(F1
F0.00014334862385321102
I1
I0
I1
tp46637
sS'function,tests,may'
p46638
(F1
F0.00028669724770642203
I0
I2
I-2
tp46639
sS'of,equetrotm,may'
p46640
(F1
F0.00014334862385321102
I0
I1
I-1
tp46641
sS'that,precipitation,occurs'
p46642
(F1
F0.00014334862385321102
I0
I1
I-1
tp46643
sS'subjects,n,compared'
p46644
(F1
F0.00014334862385321102
I1
I0
I1
tp46645
sS'inhibition,inhibition,at'
p46646
(F1
F0.00014334862385321102
I0
I1
I-1
tp46647
sS'given,with,to'
p46648
(F1
F0.00014334862385321102
I0
I1
I-1
tp46649
sS'excretion,of,oxypurines'
p46650
(F1
F0.00014334862385321102
I1
I0
I1
tp46651
sS'displacement,studies,with'
p46652
(F1
F0.00014334862385321102
I0
I1
I-1
tp46653
sS'inhibitors,has,had'
p46654
(F1
F0.00014334862385321102
I1
I0
I1
tp46655
sS'palythoa,tuberculosa,caused'
p46656
(F1
F0.00014334862385321102
I0
I1
I-1
tp46657
sS'were,unaffected,by'
p46658
(F1
F0.00028669724770642203
I0
I2
I-2
tp46659
sS'to,improve,the'
p46660
(F1
F0.00014334862385321102
I0
I1
I-1
tp46661
sS'for,decreased,dosing'
p46662
(F1
F0.00014334862385321102
I0
I1
I-1
tp46663
sS'and,such,medicinal'
p46664
(F1
F0.00014334862385321102
I1
I0
I1
tp46665
sS'p450,a,cyp3a'
p46666
(F1
F0.00014334862385321102
I0
I1
I-1
tp46667
sS'increase,in,auc'
p46668
(F1
F0.0014334862385321102
I10
I0
I10
tp46669
sS'the,nad,dependent'
p46670
(F1
F0.00014334862385321102
I1
I0
I1
tp46671
sS'neurontin,and,to'
p46672
(F1
F0.00014334862385321102
I0
I1
I-1
tp46673
sS'i,d,dosage'
p46674
(F1
F0.00014334862385321102
I1
I0
I1
tp46675
sS'of,fe,per'
p46676
(F1
F0.00014334862385321102
I1
I0
I1
tp46677
sS'cyp3a4,inhibitor,the'
p46678
(F1
F0.00014334862385321102
I1
I0
I1
tp46679
sS'mg,per,ml'
p46680
(F1
F0.00014334862385321102
I0
I1
I-1
tp46681
sS'cyp3a4,inhibitors,such'
p46682
(F1
F0.00057339449541284407
I4
I0
I4
tp46683
sS'the,elimination,half'
p46684
(F1
F0.00014334862385321102
I1
I0
I1
tp46685
sS'incidence,of,both'
p46686
(F1
F0.00014334862385321102
I1
I0
I1
tp46687
sS'alone,were,compared'
p46688
(F1
F0.00014334862385321102
I0
I1
I-1
tp46689
sS'nsaids,in,in'
p46690
(F1
F0.00014334862385321102
I0
I1
I-1
tp46691
sS'hydroxyzine,must,be'
p46692
(F1
F0.00014334862385321102
I1
I0
I1
tp46693
sS'to,a,decreased'
p46694
(F1
F0.00014334862385321102
I1
I0
I1
tp46695
sS'increase,the,incidence'
p46696
(F1
F0.00014334862385321102
I1
I0
I1
tp46697
sS'of,other,oral'
p46698
(F1
F0.00014334862385321102
I1
I0
I1
tp46699
sS'with,zyvox,and'
p46700
(F1
F0.00014334862385321102
I1
I0
I1
tp46701
sS'use,with,may'
p46702
(F0
F0
I4
I4
I0
tp46703
sS'in,decreased,clearance'
p46704
(F1
F0.00014334862385321102
I1
I0
I1
tp46705
sS'vitro,showed,no'
p46706
(F1
F0.00014334862385321102
I0
I1
I-1
tp46707
sS'ethyol,in,patients'
p46708
(F1
F0.00014334862385321102
I1
I0
I1
tp46709
sS'most,other,psychotropic'
p46710
(F1
F0.00014334862385321102
I1
I0
I1
tp46711
sS'within,the,therapeutic'
p46712
(F1
F0.00014334862385321102
I0
I1
I-1
tp46713
sS'that,could,enhance'
p46714
(F1
F0.00014334862385321102
I1
I0
I1
tp46715
sS'elemental,oz,has'
p46716
(F1
F0.00014334862385321102
I0
I1
I-1
tp46717
sS'auranofin,should,not'
p46718
(F1
F0.00014334862385321102
I1
I0
I1
tp46719
sS'oxypurines,hypoxanthine,and'
p46720
(F1
F0.00014334862385321102
I1
I0
I1
tp46721
sS'or,supplemented,with'
p46722
(F1
F0.00014334862385321102
I1
I0
I1
tp46723
sS'system,depression,or'
p46724
(F1
F0.00014334862385321102
I1
I0
I1
tp46725
sS'slows,the,renal'
p46726
(F1
F0.00014334862385321102
I0
I1
I-1
tp46727
sS'inhibit,cyp3a4,ketoconazole'
p46728
(F1
F0.00014334862385321102
I0
I1
I-1
tp46729
sS'increase,the,bleeding'
p46730
(F1
F0.00014334862385321102
I1
I0
I1
tp46731
sS'acid,metabolite,and'
p46732
(F1
F0.00014334862385321102
I0
I1
I-1
tp46733
sS'of,is,still'
p46734
(F1
F0.00014334862385321102
I0
I1
I-1
tp46735
sS'by,concomitant,useof'
p46736
(F1
F0.00014334862385321102
I1
I0
I1
tp46737
sS'mg,appears,to'
p46738
(F1
F0.00014334862385321102
I1
I0
I1
tp46739
sS'followed,by,cardiac'
p46740
(F1
F0.00014334862385321102
I1
I0
I1
tp46741
sS'lowering,of,the'
p46742
(F1
F0.00014334862385321102
I1
I0
I1
tp46743
sS'that,at,therapeutic'
p46744
(F1
F0.00014334862385321102
I1
I0
I1
tp46745
sS'caution,is,indicated'
p46746
(F1
F0.00057339449541284407
I4
I0
I4
tp46747
sS'interferences,dicumarol,and'
p46748
(F1
F0.00014334862385321102
I0
I1
I-1
tp46749
sS'clearance,of,was'
p46750
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp46751
sS'of,and,haldol'
p46752
(F1
F0.00014334862385321102
I0
I1
I-1
tp46753
sS'enhanced,secretion,of'
p46754
(F1
F0.00014334862385321102
I0
I1
I-1
tp46755
sS'plasma,indicate,that'
p46756
(F1
F0.00014334862385321102
I0
I1
I-1
tp46757
sS'and,mcg,once'
p46758
(F1
F0.00014334862385321102
I0
I1
I-1
tp46759
sS'taking,and,renal'
p46760
(F1
F0.00028669724770642203
I2
I0
I2
tp46761
sS'therefore,hormonal,including'
p46762
(F1
F0.00014334862385321102
I1
I0
I1
tp46763
sS'action,on,sodium'
p46764
(F1
F0.00014334862385321102
I1
I0
I1
tp46765
sS'coadminstered,with,viracept'
p46766
(F1
F0.00014334862385321102
I1
I0
I1
tp46767
sS'by,in,the'
p46768
(F1
F0.00014334862385321102
I1
I0
I1
tp46769
sS'mouth,bodyweight,gain'
p46770
(F1
F0.00014334862385321102
I0
I1
I-1
tp46771
sS'for,which,is'
p46772
(F1
F0.00014334862385321102
I0
I1
I-1
tp46773
sS'mg,with,neurontin'
p46774
(F1
F0.00014334862385321102
I1
I0
I1
tp46775
sS'reported,in,the'
p46776
(F1
F0.00014334862385321102
I1
I0
I1
tp46777
sS'concurrent,with,busulfex'
p46778
(F1
F0.00014334862385321102
I1
I0
I1
tp46779
sS'cyclophosphamide,treatment,which'
p46780
(F1
F0.00014334862385321102
I1
I0
I1
tp46781
sS'up,to,units'
p46782
(F1
F0.00014334862385321102
I0
I1
I-1
tp46783
sS'therapy,to,avoid'
p46784
(F1
F0.00014334862385321102
I1
I0
I1
tp46785
sS'with,the,addition'
p46786
(F1
F0.00014334862385321102
I0
I1
I-1
tp46787
sS'to,be,reduced'
p46788
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp46789
sS'compared,to,dosing'
p46790
(F1
F0.00028669724770642203
I2
I0
I2
tp46791
sS'glycosides,patients,on'
p46792
(F1
F0.00014334862385321102
I0
I1
I-1
tp46793
sS'elicited,enhancement,of'
p46794
(F1
F0.00014334862385321102
I1
I0
I1
tp46795
sS'number,of,autoimmune'
p46796
(F1
F0.00014334862385321102
I1
I0
I1
tp46797
sS'to,in,healthy'
p46798
(F1
F0.00014334862385321102
I1
I0
I1
tp46799
sS'restricted,antagonist,that'
p46800
(F1
F0.00014334862385321102
I1
I0
I1
tp46801
sS'which,cause,a'
p46802
(F1
F0.00014334862385321102
I1
I0
I1
tp46803
sS'of,the,absorption'
p46804
(F1
F0.00014334862385321102
I0
I1
I-1
tp46805
sS'fluctuations,of,vital'
p46806
(F1
F0.00014334862385321102
I1
I0
I1
tp46807
sS'blood,levels,were'
p46808
(F0
F0
I1
I1
I0
tp46809
sS'when,other,antiplatelet'
p46810
(F1
F0.00014334862385321102
I1
I0
I1
tp46811
sS'the,systemic,circulation'
p46812
(F1
F0.00014334862385321102
I1
I0
I1
tp46813
sS'study,was,performed'
p46814
(F1
F0.00014334862385321102
I0
I1
I-1
tp46815
sS'mg,q,i'
p46816
(F1
F0.00014334862385321102
I1
I0
I1
tp46817
sS'subjects,increased,the'
p46818
(F1
F0.00014334862385321102
I1
I0
I1
tp46819
sS'drug,laboratorytest,interactions'
p46820
(F1
F0.00014334862385321102
I0
I1
I-1
tp46821
sS'and,serotonergic,agents'
p46822
(F0
F0
I1
I1
I0
tp46823
sS'mg,q,d'
p46824
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp46825
sS'the,manifestation,of'
p46826
(F1
F0.00014334862385321102
I1
I0
I1
tp46827
sS'subjects,with,steady'
p46828
(F1
F0.00014334862385321102
I1
I0
I1
tp46829
sS'for,urinary,bilirubin'
p46830
(F1
F0.00014334862385321102
I0
I1
I-1
tp46831
sS'function,there,is'
p46832
(F1
F0.00014334862385321102
I1
I0
I1
tp46833
sS'hiv-infected,individuals,were'
p46834
(F1
F0.00014334862385321102
I0
I1
I-1
tp46835
sS'symptoms,termed,serotonin'
p46836
(F1
F0.00014334862385321102
I1
I0
I1
tp46837
sS'endotoxin-treated,rats,increased'
p46838
(F1
F0.00014334862385321102
I1
I0
I1
tp46839
sS'excretion,in,chronic'
p46840
(F1
F0.00014334862385321102
I1
I0
I1
tp46841
sS'substantially,decrease,the'
p46842
(F1
F0.00014334862385321102
I1
I0
I1
tp46843
sS'its,effects,concomitant'
p46844
(F1
F0.00014334862385321102
I0
I1
I-1
tp46845
sS'predispose,to,premature'
p46846
(F1
F0.00014334862385321102
I0
I1
I-1
tp46847
sS'was,measured,in'
p46848
(F1
F0.00014334862385321102
I0
I1
I-1
tp46849
sS'stimulation,and,inhibition'
p46850
(F1
F0.00014334862385321102
I0
I1
I-1
tp46851
sS'inducer,should,be'
p46852
(F1
F0.00028669724770642203
I2
I0
I2
tp46853
sS'of,subjects,who'
p46854
(F1
F0.00014334862385321102
I1
I0
I1
tp46855
sS'seven,days,increases'
p46856
(F1
F0.00014334862385321102
I0
I1
I-1
tp46857
sS'and,potassium-depleting,agents'
p46858
(F1
F0.00014334862385321102
I1
I0
I1
tp46859
sS'obtained,with,alone'
p46860
(F1
F0.00014334862385321102
I1
I0
I1
tp46861
sS'or,the,concomitant'
p46862
(F1
F0.00014334862385321102
I1
I0
I1
tp46863
sS'resulted,in,markedly'
p46864
(F1
F0.00014334862385321102
I1
I0
I1
tp46865
sS'blockers,concurrently,did'
p46866
(F1
F0.00014334862385321102
I0
I1
I-1
tp46867
sS'is,also,reported'
p46868
(F1
F0.00014334862385321102
I1
I0
I1
tp46869
sS'volunteers,in,a'
p46870
(F1
F0.00014334862385321102
I0
I1
I-1
tp46871
sS'several,interaction,studies'
p46872
(F1
F0.00014334862385321102
I0
I1
I-1
tp46873
sS'the,appearance,of'
p46874
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp46875
sS'the,sedative,effects'
p46876
(F1
F0.00014334862385321102
I1
I0
I1
tp46877
sS'in,controlled,studies'
p46878
(F1
F0.00014334862385321102
I1
I0
I1
tp46879
sS'study,had,no'
p46880
(F1
F0.00014334862385321102
I0
I1
I-1
tp46881
sS'were,noted,at'
p46882
(F1
F0.00014334862385321102
I0
I1
I-1
tp46883
sS'clinical,data,in'
p46884
(F1
F0.00028669724770642203
I0
I2
I-2
tp46885
sS'selective,regulation,of'
p46886
(F1
F0.00014334862385321102
I0
I1
I-1
tp46887
sS'is,used,alone'
p46888
(F1
F0.00014334862385321102
I1
I0
I1
tp46889
sS'acid,erythromycin,azole'
p46890
(F1
F0.00014334862385321102
I0
I1
I-1
tp46891
sS'of,oral,including'
p46892
(F1
F0.00014334862385321102
I1
I0
I1
tp46893
sS'hydrochlorothiazide,a,study'
p46894
(F1
F0.00014334862385321102
I0
I1
I-1
tp46895
sS'are,a,rapidly'
p46896
(F1
F0.00014334862385321102
I0
I1
I-1
tp46897
sS'inhalation,mefenamic,acid'
p46898
(F1
F0.00014334862385321102
I1
I0
I1
tp46899
sS'an,mao,inhibitor'
p46900
(F1
F0.00028669724770642203
I2
I0
I2
tp46901
sS'concentration,and,other'
p46902
(F1
F0.00014334862385321102
I1
I0
I1
tp46903
sS'certain,microsomal,enzyme'
p46904
(F1
F0.00014334862385321102
I1
I0
I1
tp46905
sS'at,mg,daily'
p46906
(F1
F0.00014334862385321102
I1
I0
I1
tp46907
sS'theophylline,as,with'
p46908
(F1
F0.00014334862385321102
I1
I0
I1
tp46909
sS'in,a,times'
p46910
(F1
F0.00014334862385321102
I1
I0
I1
tp46911
sS'combination,of,therapeutic'
p46912
(F1
F0.00014334862385321102
I0
I1
I-1
tp46913
sS'however,another,hmg-coa'
p46914
(F1
F0.00014334862385321102
I1
I0
I1
tp46915
sS'of,the,pressor'
p46916
(F1
F0.00014334862385321102
I1
I0
I1
tp46917
sS'be,a,weak'
p46918
(F1
F0.00014334862385321102
I0
I1
I-1
tp46919
sS'significant,reduction,in'
p46920
(F1
F0.00014334862385321102
I1
I0
I1
tp46921
sS'intestinal,absorption,of'
p46922
(F0.5
F0.00028669724770642203
I3
I1
I2
tp46923
sS'adjustment,of,by'
p46924
(F1
F0.00014334862385321102
I0
I1
I-1
tp46925
sS'of,resulted,in'
p46926
(F1
F0.00057339449541284407
I4
I0
I4
tp46927
sS'examining,the,addition'
p46928
(F1
F0.00014334862385321102
I0
I1
I-1
tp46929
sS'cholinergic,reactions,of'
p46930
(F1
F0.00014334862385321102
I0
I1
I-1
tp46931
sS'three,duloxetine-treated,patients'
p46932
(F1
F0.00014334862385321102
I0
I1
I-1
tp46933
sS'ventricular,failure,and'
p46934
(F1
F0.00014334862385321102
I0
I1
I-1
tp46935
sS'the,initial,presentation'
p46936
(F1
F0.00014334862385321102
I1
I0
I1
tp46937
sS'citrate,elevations,seen'
p46938
(F1
F0.00014334862385321102
I1
I0
I1
tp46939
sS'blocking,cardiac,contractility'
p46940
(F1
F0.00014334862385321102
I1
I0
I1
tp46941
sS'whether,other,progestational'
p46942
(F1
F0.00014334862385321102
I0
I1
I-1
tp46943
sS'class,ia,such'
p46944
(F1
F0.00014334862385321102
I1
I0
I1
tp46945
sS'they,may,provoke'
p46946
(F1
F0.00014334862385321102
I0
I1
I-1
tp46947
sS'is,rapid,equilibration'
p46948
(F1
F0.00014334862385321102
I0
I1
I-1
tp46949
sS'or,bleeding,events'
p46950
(F1
F0.00014334862385321102
I1
I0
I1
tp46951
sS'between,oh,d3'
p46952
(F1
F0.00014334862385321102
I0
I1
I-1
tp46953
sS'cns-depressant,effects,when'
p46954
(F1
F0.00014334862385321102
I1
I0
I1
tp46955
sS'immunoreactive,after,concurrent'
p46956
(F1
F0.00014334862385321102
I0
I1
I-1
tp46957
sS'maintain,trough,concentrations'
p46958
(F1
F0.00014334862385321102
I1
I0
I1
tp46959
sS'additional,effect,beyond'
p46960
(F1
F0.00014334862385321102
I1
I0
I1
tp46961
sS'cause,a,significant'
p46962
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp46963
sS'thirty,male,rats'
p46964
(F1
F0.00014334862385321102
I0
I1
I-1
tp46965
sS'from,ml,min'
p46966
(F1
F0.00014334862385321102
I1
I0
I1
tp46967
sS'such,as,may'
p46968
(F1
F0.00028669724770642203
I2
I0
I2
tp46969
sS'into,the,effect'
p46970
(F1
F0.00014334862385321102
I0
I1
I-1
tp46971
sS'the,antinonciceptive,effect'
p46972
(F1
F0.00014334862385321102
I0
I1
I-1
tp46973
sS'are,known,to'
p46974
(F0.69230769230769229
F0.0012901376146788992
I2
I11
I-9
tp46975
sS'that,has,the'
p46976
(F1
F0.00014334862385321102
I0
I1
I-1
tp46977
sS'modest,effect,on'
p46978
(F1
F0.00028669724770642203
I2
I0
I2
tp46979
sS'that,there,may'
p46980
(F1
F0.00014334862385321102
I1
I0
I1
tp46981
sS'meals,for,day'
p46982
(F1
F0.00014334862385321102
I0
I1
I-1
tp46983
sS'renal,dysfunction,by'
p46984
(F1
F0.00014334862385321102
I1
I0
I1
tp46985
sS'patients,with,haca'
p46986
(F1
F0.00014334862385321102
I0
I1
I-1
tp46987
sS'ferrous,sulfate,multivitamin'
p46988
(F1
F0.00014334862385321102
I1
I0
I1
tp46989
sS'mg,kg,injected'
p46990
(F1
F0.00014334862385321102
I1
I0
I1
tp46991
sS'higher,as,was'
p46992
(F1
F0.00014334862385321102
I1
I0
I1
tp46993
sS'agent,administered,at'
p46994
(F1
F0.00014334862385321102
I0
I1
I-1
tp46995
sS'stable,therapy,were'
p46996
(F1
F0.00014334862385321102
I0
I1
I-1
tp46997
sS'pharmacokinetics,of,interactions'
p46998
(F1
F0.00014334862385321102
I0
I1
I-1
tp46999
sS'study,of,neurontin'
p47000
(F1
F0.00014334862385321102
I0
I1
I-1
tp47001
sS'nonabsorbable,complex,between'
p47002
(F1
F0.00014334862385321102
I1
I0
I1
tp47003
sS'additional,efficacy,over'
p47004
(F1
F0.00014334862385321102
I1
I0
I1
tp47005
sS'n,or,with'
p47006
(F1
F0.00014334862385321102
I0
I1
I-1
tp47007
sS'other,metabolized,by'
p47008
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp47009
sS'showed,that,was'
p47010
(F1
F0.00014334862385321102
I1
I0
I1
tp47011
sS'agents,may,bind'
p47012
(F1
F0.00014334862385321102
I1
I0
I1
tp47013
sS'patients,lowered,the'
p47014
(F1
F0.00014334862385321102
I1
I0
I1
tp47015
sS'was,administered,at'
p47016
(F1
F0.00014334862385321102
I1
I0
I1
tp47017
sS'through,the,increase'
p47018
(F1
F0.00014334862385321102
I0
I1
I-1
tp47019
sS'the,displacing,effect'
p47020
(F1
F0.00014334862385321102
I0
I1
I-1
tp47021
sS'pharmacology,studies,at'
p47022
(F1
F0.00014334862385321102
I0
I1
I-1
tp47023
sS'hypotension,and,loss'
p47024
(F1
F0.00014334862385321102
I1
I0
I1
tp47025
sS'were,considerably,lower'
p47026
(F1
F0.00014334862385321102
I1
I0
I1
tp47027
sS'injected,with,was'
p47028
(F1
F0.00014334862385321102
I1
I0
I1
tp47029
sS'hypoglycemic,medications,may'
p47030
(F1
F0.00014334862385321102
I1
I0
I1
tp47031
sS'inhibitory,activity,which'
p47032
(F1
F0.00014334862385321102
I1
I0
I1
tp47033
sS'may,make,your'
p47034
(F1
F0.00014334862385321102
I0
I1
I-1
tp47035
sS'or,intravenous,antagonists'
p47036
(F1
F0.00014334862385321102
I1
I0
I1
tp47037
sS'auc,of,decreased'
p47038
(F1
F0.00014334862385321102
I1
I0
I1
tp47039
sS'cyp,at,clinically'
p47040
(F1
F0.00014334862385321102
I0
I1
I-1
tp47041
sS'dogs,anesthetized,with'
p47042
(F1
F0.00014334862385321102
I1
I0
I1
tp47043
sS'with,compromised,renal'
p47044
(F1
F0.00028669724770642203
I2
I0
I2
tp47045
sS'maoi,could,theoretically'
p47046
(F1
F0.00014334862385321102
I1
I0
I1
tp47047
sS'nyha,class,ii'
p47048
(F1
F0.00014334862385321102
I0
I1
I-1
tp47049
sS'pumps,for,novolog'
p47050
(F1
F0.00014334862385321102
I0
I1
I-1
tp47051
sS'time,profiles,in'
p47052
(F1
F0.00014334862385321102
I0
I1
I-1
tp47053
sS'effects,with,prinivil'
p47054
(F1
F0.00014334862385321102
I1
I0
I1
tp47055
sS'vioxx,with,mg'
p47056
(F1
F0.00014334862385321102
I1
I0
I1
tp47057
sS'levels,at,some'
p47058
(F1
F0.00014334862385321102
I1
I0
I1
tp47059
sS'been,reported,rarely'
p47060
(F0.5
F0.00028669724770642203
I3
I1
I2
tp47061
sS'effectiveness,by,increasing'
p47062
(F1
F0.00014334862385321102
I0
I1
I-1
tp47063
sS'discussing,the,main'
p47064
(F1
F0.00014334862385321102
I0
I1
I-1
tp47065
sS'like,other,injectable'
p47066
(F1
F0.00014334862385321102
I1
I0
I1
tp47067
sS'nicotinic,acid,sympathomimet-ics'
p47068
(F1
F0.00014334862385321102
I0
I1
I-1
tp47069
sS'warfarin,digoxin,salicylate'
p47070
(F1
F0.00014334862385321102
I1
I0
I1
tp47071
sS'may,develop,toxicity'
p47072
(F1
F0.00014334862385321102
I1
I0
I1
tp47073
sS'was,found,between'
p47074
(F1
F0.00014334862385321102
I0
I1
I-1
tp47075
sS'medications,included,mtx'
p47076
(F1
F0.00014334862385321102
I0
I1
I-1
tp47077
sS'not,known,hence'
p47078
(F1
F0.00014334862385321102
I1
I0
I1
tp47079
sS'established,that,there'
p47080
(F1
F0.00014334862385321102
I1
I0
I1
tp47081
sS'of,copegus,and'
p47082
(F1
F0.00014334862385321102
I1
I0
I1
tp47083
sS'of,camptosar,such'
p47084
(F1
F0.00014334862385321102
I1
I0
I1
tp47085
sS'a,multi-day,course'
p47086
(F1
F0.00014334862385321102
I1
I0
I1
tp47087
sS'inhibitor,class,see'
p47088
(F1
F0.00014334862385321102
I1
I0
I1
tp47089
sS'healthy,volunteers,significantly'
p47090
(F1
F0.00014334862385321102
I1
I0
I1
tp47091
sS'for,maintenance,of'
p47092
(F1
F0.00014334862385321102
I0
I1
I-1
tp47093
sS'daily,of,brovana'
p47094
(F1
F0.00014334862385321102
I0
I1
I-1
tp47095
sS'a,positive,level'
p47096
(F1
F0.00014334862385321102
I1
I0
I1
tp47097
sS'aprepitant,with,these'
p47098
(F1
F0.00014334862385321102
I1
I0
I1
tp47099
sS'nsaid,such,as'
p47100
(F1
F0.00014334862385321102
I0
I1
I-1
tp47101
sS'to,rachitic,chicks'
p47102
(F1
F0.00014334862385321102
I1
I0
I1
tp47103
sS'interactions,dactinomycin,may'
p47104
(F1
F0.00014334862385321102
I0
I1
I-1
tp47105
sS'well,acquainted,with'
p47106
(F1
F0.00014334862385321102
I0
I1
I-1
tp47107
sS'with,and,or'
p47108
(F1
F0.00014334862385321102
I0
I1
I-1
tp47109
sS'inhibitors,duragesic,is'
p47110
(F1
F0.00014334862385321102
I1
I0
I1
tp47111
sS'a,cyp,a4'
p47112
(F1
F0.00028669724770642203
I0
I2
I-2
tp47113
sS'recommended,that,buspirone'
p47114
(F1
F0.00014334862385321102
I1
I0
I1
tp47115
sS'that,nsaids,can'
p47116
(F1
F0.00057339449541284407
I4
I0
I4
tp47117
sS'to,increase,the'
p47118
(F0.78947368421052633
F0.0021502293577981653
I17
I2
I15
tp47119
sS'problem,associated,with'
p47120
(F1
F0.00014334862385321102
I1
I0
I1
tp47121
sS'of,natrecor,with'
p47122
(F1
F0.00014334862385321102
I0
I1
I-1
tp47123
sS'of,immobilised,cmc-cys7'
p47124
(F1
F0.00014334862385321102
I0
I1
I-1
tp47125
sS'iressa,and,have'
p47126
(F1
F0.00014334862385321102
I1
I0
I1
tp47127
sS'neoral,sandimmune,hiv'
p47128
(F1
F0.00014334862385321102
I1
I0
I1
tp47129
sS'reports,of,prolonged'
p47130
(F1
F0.00014334862385321102
I1
I0
I1
tp47131
sS'while,under,treatment'
p47132
(F1
F0.00014334862385321102
I1
I0
I1
tp47133
sS'studies,have,not'
p47134
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp47135
sS'is,narrow,serum'
p47136
(F1
F0.00014334862385321102
I0
I1
I-1
tp47137
sS'syndrome,in,patients'
p47138
(F1
F0.00014334862385321102
I1
I0
I1
tp47139
sS'related,may,decrease'
p47140
(F1
F0.00014334862385321102
I1
I0
I1
tp47141
sS'receiving,and,concurrently'
p47142
(F1
F0.00014334862385321102
I1
I0
I1
tp47143
sS'it,is,reasonable'
p47144
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp47145
sS'oxidation,system,decreased'
p47146
(F1
F0.00014334862385321102
I0
I1
I-1
tp47147
sS'nodal,conduction,channel'
p47148
(F1
F0.00014334862385321102
I1
I0
I1
tp47149
sS'delay,in,the'
p47150
(F1
F0.00028669724770642203
I2
I0
I2
tp47151
sS'produce,severe,prolonged'
p47152
(F1
F0.00014334862385321102
I1
I0
I1
tp47153
sS'ml,with,alone'
p47154
(F1
F0.00014334862385321102
I1
I0
I1
tp47155
sS'and,its,toxicity'
p47156
(F1
F0.00014334862385321102
I1
I0
I1
tp47157
sS'facilitates,acquisition,of'
p47158
(F1
F0.00014334862385321102
I0
I1
I-1
tp47159
sS'glucuronidation,is,unlikely'
p47160
(F1
F0.00014334862385321102
I0
I1
I-1
tp47161
sS'and,dosage,adjustment'
p47162
(F1
F0.00028669724770642203
I0
I2
I-2
tp47163
sS'produce,aucs,m'
p47164
(F1
F0.00014334862385321102
I1
I0
I1
tp47165
sS'and,to,increase'
p47166
(F0
F0
I1
I1
I0
tp47167
sS'amitriptyline,in,combination'
p47168
(F1
F0.00014334862385321102
I1
I0
I1
tp47169
sS'those,of,other'
p47170
(F1
F0.00014334862385321102
I0
I1
I-1
tp47171
sS'by,six,typical'
p47172
(F1
F0.00014334862385321102
I0
I1
I-1
tp47173
sS'a,minor,increase'
p47174
(F1
F0.00014334862385321102
I1
I0
I1
tp47175
sS'supraventricular,tachycardia,in'
p47176
(F1
F0.00014334862385321102
I1
I0
I1
tp47177
sS'and,excretion,in'
p47178
(F1
F0.00014334862385321102
I1
I0
I1
tp47179
sS'including,fever,renal'
p47180
(F1
F0.00014334862385321102
I1
I0
I1
tp47181
sS'i,d,with'
p47182
(F1
F0.00014334862385321102
I1
I0
I1
tp47183
sS'every,hours,for'
p47184
(F1
F0.00028669724770642203
I0
I2
I-2
tp47185
sS'or,clinitest,tablets'
p47186
(F1
F0.00014334862385321102
I0
I1
I-1
tp47187
sS'also,increase,the'
p47188
(F1
F0.00028669724770642203
I0
I2
I-2
tp47189
sS'may,increase,sensitivity'
p47190
(F1
F0.00028669724770642203
I2
I0
I2
tp47191
sS'by,determination,of'
p47192
(F1
F0.00028669724770642203
I0
I2
I-2
tp47193
sS'because,both,of'
p47194
(F1
F0.00014334862385321102
I1
I0
I1
tp47195
sS'kg,in,a'
p47196
(F1
F0.00014334862385321102
I0
I1
I-1
tp47197
sS'by,compared,with'
p47198
(F1
F0.00014334862385321102
I1
I0
I1
tp47199
sS'based,on,auc'
p47200
(F1
F0.00014334862385321102
I0
I1
I-1
tp47201
sS'methotrexate,an,increased'
p47202
(F1
F0.00014334862385321102
I1
I0
I1
tp47203
sS'was,no,apparent'
p47204
(F1
F0.00014334862385321102
I0
I1
I-1
tp47205
sS'activity,of,the'
p47206
(F1
F0.00014334862385321102
I0
I1
I-1
tp47207
sS'acid,and,heavy'
p47208
(F1
F0.00014334862385321102
I1
I0
I1
tp47209
sS'we,have,shown'
p47210
(F1
F0.00014334862385321102
I0
I1
I-1
tp47211
sS'values,were,not'
p47212
(F1
F0.00028669724770642203
I0
I2
I-2
tp47213
sS'resulting,in,unexpectedly'
p47214
(F1
F0.00014334862385321102
I1
I0
I1
tp47215
sS'the,urinary,antiseptic'
p47216
(F1
F0.00014334862385321102
I1
I0
I1
tp47217
sS'before,conducting,an'
p47218
(F1
F0.00014334862385321102
I1
I0
I1
tp47219
sS'of,elevated,liver'
p47220
(F1
F0.00014334862385321102
I0
I1
I-1
tp47221
sS'administered,one,hour'
p47222
(F1
F0.00014334862385321102
I1
I0
I1
tp47223
sS'both,in,diabetic'
p47224
(F1
F0.00014334862385321102
I0
I1
I-1
tp47225
sS'performed,when,initiating'
p47226
(F1
F0.00014334862385321102
I1
I0
I1
tp47227
sS'those,with,intravascular'
p47228
(F1
F0.00014334862385321102
I1
I0
I1
tp47229
sS'with,the,action'
p47230
(F1
F0.00014334862385321102
I1
I0
I1
tp47231
sS'or,elimination,or'
p47232
(F1
F0.00014334862385321102
I0
I1
I-1
tp47233
sS'metabolized,via,the'
p47234
(F1
F0.00014334862385321102
I0
I1
I-1
tp47235
sS'or,more,of'
p47236
(F1
F0.00014334862385321102
I0
I1
I-1
tp47237
sS'mg,produced,additive'
p47238
(F1
F0.00028669724770642203
I2
I0
I2
tp47239
sS'hcl,is,antagonized'
p47240
(F1
F0.00014334862385321102
I1
I0
I1
tp47241
sS'that,oral,potently'
p47242
(F1
F0.00028669724770642203
I2
I0
I2
tp47243
sS'blocking,agents,chloral'
p47244
(F1
F0.00014334862385321102
I0
I1
I-1
tp47245
sS'which,erbitux,was'
p47246
(F1
F0.00014334862385321102
I0
I1
I-1
tp47247
sS'cations,multivitamins,quinolones'
p47248
(F1
F0.00014334862385321102
I0
I1
I-1
tp47249
sS'and,following,infusions'
p47250
(F1
F0.00014334862385321102
I0
I1
I-1
tp47251
sS'change,the,pharmacokinetics'
p47252
(F1
F0.00014334862385321102
I0
I1
I-1
tp47253
sS'complications,careful,monitoring'
p47254
(F1
F0.00014334862385321102
I0
I1
I-1
tp47255
sS'and,and,hydroxides'
p47256
(F1
F0.00014334862385321102
I0
I1
I-1
tp47257
sS'effects,in,human'
p47258
(F1
F0.00014334862385321102
I0
I1
I-1
tp47259
sS'grapefruit,juice,with'
p47260
(F1
F0.00028669724770642203
I0
I2
I-2
tp47261
sS'after,initiation,of'
p47262
(F0.75
F0.0008600917431192661
I7
I1
I6
tp47263
sS'directed,to,cross'
p47264
(F1
F0.00014334862385321102
I1
I0
I1
tp47265
sS'pharmacokinetic,studies,have'
p47266
(F0
F0
I2
I2
I0
tp47267
sS'with,rr,microm'
p47268
(F1
F0.00014334862385321102
I1
I0
I1
tp47269
sS'oral,co-administration,of'
p47270
(F1
F0.00014334862385321102
I1
I0
I1
tp47271
sS'anti-infectives,without,evidence'
p47272
(F1
F0.00014334862385321102
I0
I1
I-1
tp47273
sS'beta-lactamtype,or,may'
p47274
(F1
F0.00014334862385321102
I1
I0
I1
tp47275
sS'of,novolog,were'
p47276
(F1
F0.00014334862385321102
I0
I1
I-1
tp47277
sS'renal,impairment,reportedly'
p47278
(F1
F0.00014334862385321102
I1
I0
I1
tp47279
sS'dose,increase,of'
p47280
(F1
F0.00043004587155963305
I3
I0
I3
tp47281
sS'from,human,in'
p47282
(F1
F0.00014334862385321102
I0
I1
I-1
tp47283
sS'concentration,time-curve,increased'
p47284
(F1
F0.00014334862385321102
I1
I0
I1
tp47285
sS'of,in,peripheral'
p47286
(F1
F0.00014334862385321102
I0
I1
I-1
tp47287
sS'the,positive,and'
p47288
(F1
F0.00014334862385321102
I0
I1
I-1
tp47289
sS'after,the,last'
p47290
(F1
F0.00014334862385321102
I1
I0
I1
tp47291
sS'with,other,therapy'
p47292
(F1
F0.00014334862385321102
I0
I1
I-1
tp47293
sS'been,observed,after'
p47294
(F1
F0.00014334862385321102
I0
I1
I-1
tp47295
sS'events,reported,significantly'
p47296
(F1
F0.00014334862385321102
I0
I1
I-1
tp47297
sS'such,as,and'
p47298
(F0.33333333333333331
F0.0017201834862385322
I24
I12
I12
tp47299
sS'therefore,viracept,should'
p47300
(F1
F0.00014334862385321102
I1
I0
I1
tp47301
sS'which,may,enhance'
p47302
(F1
F0.00057339449541284407
I4
I0
I4
tp47303
sS'regression,analyses,of'
p47304
(F1
F0.00014334862385321102
I1
I0
I1
tp47305
sS'thus,necessitating,an'
p47306
(F1
F0.00014334862385321102
I1
I0
I1
tp47307
sS'concomitantly,with,hepatic'
p47308
(F1
F0.00014334862385321102
I1
I0
I1
tp47309
sS'gland,who,is'
p47310
(F1
F0.00014334862385321102
I1
I0
I1
tp47311
sS'is,combined,with'
p47312
(F1
F0.00028669724770642203
I2
I0
I2
tp47313
sS'blocking,agents,and'
p47314
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp47315
sS'prolonged,hot,weather'
p47316
(F1
F0.00014334862385321102
I1
I0
I1
tp47317
sS'coadministration,with,coadministration'
p47318
(F1
F0.00014334862385321102
I1
I0
I1
tp47319
sS'bullous,pemphigoid,and'
p47320
(F1
F0.00014334862385321102
I1
I0
I1
tp47321
sS'and,to,eliminate'
p47322
(F1
F0.00014334862385321102
I1
I0
I1
tp47323
sS'potential,interactions,for'
p47324
(F1
F0.00014334862385321102
I1
I0
I1
tp47325
sS'glycosides,therapeutic,effects'
p47326
(F1
F0.00014334862385321102
I0
I1
I-1
tp47327
sS'may,be,resistant'
p47328
(F1
F0.00014334862385321102
I1
I0
I1
tp47329
sS'with,nonselective,inhibitor'
p47330
(F1
F0.00014334862385321102
I1
I0
I1
tp47331
sS'with,activity--such,as'
p47332
(F1
F0.00014334862385321102
I1
I0
I1
tp47333
sS'of,dcg-iv,and'
p47334
(F1
F0.00014334862385321102
I0
I1
I-1
tp47335
sS'ethinyl,estradiol,were'
p47336
(F1
F0.00014334862385321102
I0
I1
I-1
tp47337
sS'in,the,light'
p47338
(F1
F0.00014334862385321102
I1
I0
I1
tp47339
sS'vascular,dilation,associated'
p47340
(F1
F0.00014334862385321102
I1
I0
I1
tp47341
sS'with,regard,to'
p47342
(F1
F0.00043004587155963305
I0
I3
I-3
tp47343
sS'attention,must,be'
p47344
(F1
F0.00014334862385321102
I1
I0
I1
tp47345
sS'antipyrine,because,does'
p47346
(F1
F0.00014334862385321102
I0
I1
I-1
tp47347
sS'on,its,rate'
p47348
(F1
F0.00014334862385321102
I0
I1
I-1
tp47349
sS'as,it,had'
p47350
(F1
F0.00014334862385321102
I0
I1
I-1
tp47351
sS'with,cmi,because'
p47352
(F1
F0.00014334862385321102
I1
I0
I1
tp47353
sS'for,and,on'
p47354
(F1
F0.00014334862385321102
I0
I1
I-1
tp47355
sS'haart,with,a'
p47356
(F1
F0.00014334862385321102
I0
I1
I-1
tp47357
sS'and,effect,relationship'
p47358
(F1
F0.00014334862385321102
I1
I0
I1
tp47359
sS'reduces,the,rate'
p47360
(F1
F0.00014334862385321102
I1
I0
I1
tp47361
sS'time,by,after'
p47362
(F1
F0.00014334862385321102
I0
I1
I-1
tp47363
sS'that,a,small'
p47364
(F1
F0.00014334862385321102
I1
I0
I1
tp47365
sS'enzymes,was,seen'
p47366
(F1
F0.00014334862385321102
I1
I0
I1
tp47367
sS'reduction,of,to'
p47368
(F1
F0.00028669724770642203
I2
I0
I2
tp47369
sS'and,systemic,and'
p47370
(F0
F0
I1
I1
I0
tp47371
sS'may,occur,earlier'
p47372
(F1
F0.00014334862385321102
I1
I0
I1
tp47373
sS'subjects,receiving,mg'
p47374
(F1
F0.00014334862385321102
I1
I0
I1
tp47375
sS'if,the,two'
p47376
(F1
F0.00028669724770642203
I2
I0
I2
tp47377
sS'any,change,in'
p47378
(F1
F0.00014334862385321102
I0
I1
I-1
tp47379
sS'given,the,primary'
p47380
(F1
F0.00028669724770642203
I2
I0
I2
tp47381
sS'range,mg,if'
p47382
(F1
F0.00014334862385321102
I1
I0
I1
tp47383
sS'were,observed,by'
p47384
(F1
F0.00014334862385321102
I0
I1
I-1
tp47385
sS'extreme,caution,in'
p47386
(F1
F0.00028669724770642203
I2
I0
I2
tp47387
sS'of,including,with'
p47388
(F1
F0.00014334862385321102
I1
I0
I1
tp47389
sS'no,pharmacokinetic,interactions'
p47390
(F1
F0.00028669724770642203
I0
I2
I-2
tp47391
sS'result,from,the'
p47392
(F1
F0.00014334862385321102
I1
I0
I1
tp47393
sS'the,vehicle-controlled,studies'
p47394
(F1
F0.00014334862385321102
I0
I1
I-1
tp47395
sS'could,lead,to'
p47396
(F1
F0.00014334862385321102
I1
I0
I1
tp47397
sS'since,a,decline'
p47398
(F1
F0.00014334862385321102
I0
I1
I-1
tp47399
sS'pharmacokinetic,parameters,for'
p47400
(F1
F0.00014334862385321102
I0
I1
I-1
tp47401
sS'of,peritoneal,metastasis'
p47402
(F1
F0.00014334862385321102
I0
I1
I-1
tp47403
sS'inhibits,the,cyp2c9'
p47404
(F1
F0.00014334862385321102
I1
I0
I1
tp47405
sS'each,subject,before'
p47406
(F1
F0.00014334862385321102
I0
I1
I-1
tp47407
sS'cyp,a4,but'
p47408
(F1
F0.00014334862385321102
I0
I1
I-1
tp47409
sS'had,treatment-emergent,positive'
p47410
(F1
F0.00014334862385321102
I0
I1
I-1
tp47411
sS'observed,when,gl'
p47412
(F1
F0.00014334862385321102
I1
I0
I1
tp47413
sS'and,the,effect'
p47414
(F0
F0
I1
I1
I0
tp47415
sS'probenecid,pretreatment,with'
p47416
(F1
F0.00014334862385321102
I1
I0
I1
tp47417
sS'coadministered,with,mg'
p47418
(F1
F0.00043004587155963305
I0
I3
I-3
tp47419
sS'vardenafil,mg,and'
p47420
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp47421
sS'or,pharmacokinetics,during'
p47422
(F1
F0.00014334862385321102
I0
I1
I-1
tp47423
sS'therapeutic,index,such'
p47424
(F1
F0.00014334862385321102
I1
I0
I1
tp47425
sS'frequently,co-administered,with'
p47426
(F1
F0.00014334862385321102
I0
I1
I-1
tp47427
sS'and,is,unknown'
p47428
(F1
F0.00014334862385321102
I1
I0
I1
tp47429
sS'various,containing,regimens'
p47430
(F1
F0.00014334862385321102
I1
I0
I1
tp47431
sS'be,superior,to'
p47432
(F1
F0.00014334862385321102
I0
I1
I-1
tp47433
sS'gram-negative,organisms,but'
p47434
(F1
F0.00014334862385321102
I0
I1
I-1
tp47435
sS'kg,mg,kg'
p47436
(F1
F0.00043004587155963305
I0
I3
I-3
tp47437
sS'in,the,loss'
p47438
(F1
F0.00014334862385321102
I1
I0
I1
tp47439
sS'and,prevention,studies'
p47440
(F1
F0.00014334862385321102
I0
I1
I-1
tp47441
sS'ethoxzolamide,may,increase'
p47442
(F1
F0.00014334862385321102
I1
I0
I1
tp47443
sS'caution,is,necessary'
p47444
(F1
F0.00014334862385321102
I1
I0
I1
tp47445
sS'oral,may,potentiate'
p47446
(F1
F0.00014334862385321102
I1
I0
I1
tp47447
sS'rauwolfia,alkaloid,while'
p47448
(F1
F0.00014334862385321102
I1
I0
I1
tp47449
sS'd,respectively,of'
p47450
(F1
F0.00014334862385321102
I1
I0
I1
tp47451
sS'too,much,in'
p47452
(F0
F0
I1
I1
I0
tp47453
sS'efficacy,of,concomitant'
p47454
(F1
F0.00014334862385321102
I1
I0
I1
tp47455
sS'not,show,potential'
p47456
(F1
F0.00014334862385321102
I0
I1
I-1
tp47457
sS'there,is,no'
p47458
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp47459
sS'cholinesterase,inhibitors,dipyridamole'
p47460
(F1
F0.00014334862385321102
I1
I0
I1
tp47461
sS'twice,daily,increased'
p47462
(F1
F0.00014334862385321102
I1
I0
I1
tp47463
sS'inhibition,of,response'
p47464
(F1
F0.00014334862385321102
I1
I0
I1
tp47465
sS'that,may,reduce'
p47466
(F0
F0
I2
I2
I0
tp47467
sS'a,mean,fold'
p47468
(F1
F0.00014334862385321102
I1
I0
I1
tp47469
sS'for,the,coadministration'
p47470
(F1
F0.00014334862385321102
I0
I1
I-1
tp47471
sS'for,additive,effects'
p47472
(F1
F0.00028669724770642203
I2
I0
I2
tp47473
sS'amide-type,local,since'
p47474
(F1
F0.00014334862385321102
I1
I0
I1
tp47475
sS'normal,volunteers,did'
p47476
(F1
F0.00014334862385321102
I0
I1
I-1
tp47477
sS'the,apparent,volume'
p47478
(F1
F0.00014334862385321102
I0
I1
I-1
tp47479
sS'dried,and,collected'
p47480
(F1
F0.00014334862385321102
I0
I1
I-1
tp47481
sS'acute,toxicity,characterized'
p47482
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp47483
sS'drugs,nsaids,the'
p47484
(F1
F0.00014334862385321102
I1
I0
I1
tp47485
sS'to,a,far'
p47486
(F1
F0.00014334862385321102
I0
I1
I-1
tp47487
sS'and,with,at'
p47488
(F1
F0.00014334862385321102
I0
I1
I-1
tp47489
sS'mao,inhibitor,and'
p47490
(F1
F0.00014334862385321102
I1
I0
I1
tp47491
sS'hours,of,treatment'
p47492
(F1
F0.00014334862385321102
I1
I0
I1
tp47493
sS'that,you,are'
p47494
(F1
F0.00014334862385321102
I1
I0
I1
tp47495
sS'from,several,studies'
p47496
(F1
F0.00014334862385321102
I0
I1
I-1
tp47497
sS'but,not,these'
p47498
(F1
F0.00014334862385321102
I0
I1
I-1
tp47499
sS'clearance,prolongation,of'
p47500
(F1
F0.00014334862385321102
I0
I1
I-1
tp47501
sS'as,directed,and'
p47502
(F1
F0.00014334862385321102
I0
I1
I-1
tp47503
sS'increase,in,unbound'
p47504
(F1
F0.00014334862385321102
I1
I0
I1
tp47505
sS'a,randomized,multiple-dose'
p47506
(F1
F0.00014334862385321102
I0
I1
I-1
tp47507
sS'rarely,reported,to'
p47508
(F1
F0.00014334862385321102
I1
I0
I1
tp47509
sS'steroids,enhance,the'
p47510
(F1
F0.00014334862385321102
I1
I0
I1
tp47511
sS'both,in,the'
p47512
(F1
F0.00014334862385321102
I0
I1
I-1
tp47513
sS'mg,decreased,the'
p47514
(F1
F0.00014334862385321102
I1
I0
I1
tp47515
sS'difluoroacetone,by,an'
p47516
(F1
F0.00014334862385321102
I0
I1
I-1
tp47517
sS'auc0-24hr,in,patients'
p47518
(F0
F0
I1
I1
I0
tp47519
sS'they,reduce,its'
p47520
(F1
F0.00043004587155963305
I3
I0
I3
tp47521
sS'the,training,dose'
p47522
(F1
F0.00014334862385321102
I0
I1
I-1
tp47523
sS'in,serum,hormone'
p47524
(F1
F0.00014334862385321102
I0
I1
I-1
tp47525
sS'reaction,and,produce'
p47526
(F1
F0.00028669724770642203
I0
I2
I-2
tp47527
sS'reported,to,interfere'
p47528
(F1
F0.00014334862385321102
I0
I1
I-1
tp47529
sS'and,substrates,drugs'
p47530
(F1
F0.00014334862385321102
I1
I0
I1
tp47531
sS'with,these,does'
p47532
(F1
F0.00014334862385321102
I0
I1
I-1
tp47533
sS'and,extended,a'
p47534
(F1
F0.00014334862385321102
I1
I0
I1
tp47535
sS'concentrations,and,an'
p47536
(F1
F0.00014334862385321102
I1
I0
I1
tp47537
sS'and,may,even'
p47538
(F1
F0.00014334862385321102
I0
I1
I-1
tp47539
sS'effect,on,bioavailability'
p47540
(F1
F0.00014334862385321102
I0
I1
I-1
tp47541
sS'vascularity,of,intestinal'
p47542
(F1
F0.00014334862385321102
I0
I1
I-1
tp47543
sS'administered,to,individuals'
p47544
(F1
F0.00014334862385321102
I0
I1
I-1
tp47545
sS'recommendations,were,to'
p47546
(F1
F0.00014334862385321102
I0
I1
I-1
tp47547
sS'therapy,including,more'
p47548
(F1
F0.00014334862385321102
I0
I1
I-1
tp47549
sS'with,intact,endothelium'
p47550
(F1
F0.00014334862385321102
I1
I0
I1
tp47551
sS'inhibition,at,microm'
p47552
(F1
F0.00014334862385321102
I0
I1
I-1
tp47553
sS'a,significant,interaction'
p47554
(F1
F0.00014334862385321102
I1
I0
I1
tp47555
sS'currently,available,hmgcoa'
p47556
(F1
F0.00014334862385321102
I0
I1
I-1
tp47557
sS'administration,impairs,metabolism'
p47558
(F1
F0.00014334862385321102
I0
I1
I-1
tp47559
sS'patients,or,the'
p47560
(F1
F0.00014334862385321102
I0
I1
I-1
tp47561
sS'to,characterize,the'
p47562
(F1
F0.00014334862385321102
I0
I1
I-1
tp47563
sS'warfarin,co-administration,of'
p47564
(F1
F0.00014334862385321102
I1
I0
I1
tp47565
sS'during,early,therapy'
p47566
(F1
F0.00014334862385321102
I1
I0
I1
tp47567
sS'concentration,curve,of'
p47568
(F1
F0.00014334862385321102
I1
I0
I1
tp47569
sS'potent,inhibitor,of'
p47570
(F0.23076923076923078
F0.00043004587155963305
I8
I5
I3
tp47571
sS'acid,level,dosage'
p47572
(F1
F0.00014334862385321102
I1
I0
I1
tp47573
sS'through,udp-glucuronyl,transferase'
p47574
(F1
F0.00014334862385321102
I0
I1
I-1
tp47575
sS'differences,in,adverse'
p47576
(F1
F0.00028669724770642203
I0
I2
I-2
tp47577
sS'an,additive,hypotensive'
p47578
(F1
F0.00014334862385321102
I1
I0
I1
tp47579
sS'the,locomotor,and'
p47580
(F1
F0.00014334862385321102
I0
I1
I-1
tp47581
sS'may,be,modified'
p47582
(F1
F0.00014334862385321102
I1
I0
I1
tp47583
sS'of,on,absorption'
p47584
(F1
F0.00014334862385321102
I0
I1
I-1
tp47585
sS'it,alter,the'
p47586
(F1
F0.00014334862385321102
I0
I1
I-1
tp47587
sS'given,to,adult'
p47588
(F1
F0.00014334862385321102
I0
I1
I-1
tp47589
sS'be,carefully,observed'
p47590
(F0
F0
I1
I1
I0
tp47591
sS'to,steady,state'
p47592
(F1
F0.00014334862385321102
I1
I0
I1
tp47593
sS'patients,and,normal'
p47594
(F1
F0.00014334862385321102
I1
I0
I1
tp47595
sS'which,to,examine'
p47596
(F1
F0.00014334862385321102
I0
I1
I-1
tp47597
sS'be,warranted,when'
p47598
(F1
F0.00014334862385321102
I0
I1
I-1
tp47599
sS'and,will,have'
p47600
(F1
F0.00014334862385321102
I0
I1
I-1
tp47601
sS'usually,administered,hours'
p47602
(F1
F0.00014334862385321102
I1
I0
I1
tp47603
sS'alternatives,to,should'
p47604
(F1
F0.00028669724770642203
I2
I0
I2
tp47605
sS'mg,day,with'
p47606
(F1
F0.00014334862385321102
I1
I0
I1
tp47607
sS'from,therapy,with'
p47608
(F1
F0.00014334862385321102
I0
I1
I-1
tp47609
sS'states,to,emerge'
p47610
(F1
F0.00014334862385321102
I1
I0
I1
tp47611
sS'volunteers,has,shown'
p47612
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp47613
sS'myasthenia,gravis,inflammatory'
p47614
(F1
F0.00014334862385321102
I1
I0
I1
tp47615
sS'phenytoin,population,pharmacokinetic'
p47616
(F1
F0.00014334862385321102
I1
I0
I1
tp47617
sS'while,taking,fortovase'
p47618
(F1
F0.00014334862385321102
I0
I1
I-1
tp47619
sS'for,therapy,should'
p47620
(F1
F0.00014334862385321102
I1
I0
I1
tp47621
sS'oral,should,be'
p47622
(F1
F0.00014334862385321102
I0
I1
I-1
tp47623
sS'inhibiting,eg,may'
p47624
(F1
F0.00014334862385321102
I1
I0
I1
tp47625
sS'and,sodium,it'
p47626
(F1
F0.00014334862385321102
I1
I0
I1
tp47627
sS'when,colestid,tablets'
p47628
(F1
F0.00014334862385321102
I1
I0
I1
tp47629
sS'not,a,true'
p47630
(F1
F0.00014334862385321102
I1
I0
I1
tp47631
sS'made,on,the'
p47632
(F1
F0.00014334862385321102
I0
I1
I-1
tp47633
sS'chloromycetin,local,and'
p47634
(F1
F0.00014334862385321102
I1
I0
I1
tp47635
sS'cold,preparations,nsaids'
p47636
(F1
F0.00014334862385321102
I0
I1
I-1
tp47637
sS'both,the,r'
p47638
(F1
F0.00014334862385321102
I0
I1
I-1
tp47639
sS'equally,antagonized,in'
p47640
(F1
F0.00014334862385321102
I1
I0
I1
tp47641
sS'rate,constant,volume'
p47642
(F1
F0.00014334862385321102
I0
I1
I-1
tp47643
sS'in,post-marketing,experience'
p47644
(F1
F0.00057339449541284407
I4
I0
I4
tp47645
sS'of,toradol,and'
p47646
(F1
F0.00014334862385321102
I1
I0
I1
tp47647
sS'omeprazole,the,rate'
p47648
(F1
F0.00014334862385321102
I0
I1
I-1
tp47649
sS'and,mc,enhance'
p47650
(F1
F0.00014334862385321102
I0
I1
I-1
tp47651
sS'and,significantly,reduces'
p47652
(F1
F0.00014334862385321102
I1
I0
I1
tp47653
sS'consequently,the,combination'
p47654
(F1
F0.00014334862385321102
I1
I0
I1
tp47655
sS'dosed,subjects,with'
p47656
(F1
F0.00014334862385321102
I0
I1
I-1
tp47657
sS'trecator,has,been'
p47658
(F1
F0.00014334862385321102
I1
I0
I1
tp47659
sS'significant,effects,on'
p47660
(F1
F0.00043004587155963305
I0
I3
I-3
tp47661
sS'to,the,general'
p47662
(F1
F0.00014334862385321102
I0
I1
I-1
tp47663
sS'by,hours,experienced'
p47664
(F1
F0.00014334862385321102
I1
I0
I1
tp47665
sS'volunteers,a,one-week'
p47666
(F1
F0.00014334862385321102
I1
I0
I1
tp47667
sS'and,is,unlikely'
p47668
(F1
F0.00014334862385321102
I0
I1
I-1
tp47669
sS'pharmacodynamics,prothrombin,time'
p47670
(F1
F0.00014334862385321102
I0
I1
I-1
tp47671
sS'blocking,hepatic,metabolism'
p47672
(F1
F0.00014334862385321102
I1
I0
I1
tp47673
sS'ip,or,vitamin'
p47674
(F1
F0.00014334862385321102
I1
I0
I1
tp47675
sS'n,as,well'
p47676
(F1
F0.00014334862385321102
I0
I1
I-1
tp47677
sS'be,adjusted,accordingly'
p47678
(F1
F0.00014334862385321102
I1
I0
I1
tp47679
sS'product,with,in'
p47680
(F1
F0.00014334862385321102
I0
I1
I-1
tp47681
sS'solubility,of,is'
p47682
(F1
F0.00014334862385321102
I0
I1
I-1
tp47683
sS'concomitantly,with,known'
p47684
(F1
F0.00014334862385321102
I1
I0
I1
tp47685
sS'urine,volume,in'
p47686
(F1
F0.00014334862385321102
I1
I0
I1
tp47687
sS'one,mg,kg'
p47688
(F1
F0.00014334862385321102
I1
I0
I1
tp47689
sS'h2,antagonists,hmg-coa'
p47690
(F1
F0.00014334862385321102
I0
I1
I-1
tp47691
sS'interaction,between,intravenous'
p47692
(F1
F0.00014334862385321102
I0
I1
I-1
tp47693
sS'cyclosporine,modest,increases'
p47694
(F1
F0.00014334862385321102
I1
I0
I1
tp47695
sS'effect,measured,by'
p47696
(F1
F0.00014334862385321102
I0
I1
I-1
tp47697
sS'had,achieved,steady-state'
p47698
(F1
F0.00014334862385321102
I0
I1
I-1
tp47699
sS'administration,of,vasopressor'
p47700
(F0
F0
I1
I1
I0
tp47701
sS'diabectics,than,in'
p47702
(F1
F0.00014334862385321102
I0
I1
I-1
tp47703
sS'adjustment,of,doses'
p47704
(F1
F0.00014334862385321102
I0
I1
I-1
tp47705
sS'following,medications,tylenol'
p47706
(F1
F0.00014334862385321102
I1
I0
I1
tp47707
sS'produced,by,the'
p47708
(F1
F0.00028669724770642203
I0
I2
I-2
tp47709
sS'administered,minute,after'
p47710
(F1
F0.00014334862385321102
I1
I0
I1
tp47711
sS'including,sodium,and'
p47712
(F1
F0.00014334862385321102
I1
I0
I1
tp47713
sS'those,used,to'
p47714
(F1
F0.00014334862385321102
I0
I1
I-1
tp47715
sS'in,females,and'
p47716
(F1
F0.00014334862385321102
I1
I0
I1
tp47717
sS'myocardium,to,effects'
p47718
(F1
F0.00014334862385321102
I1
I0
I1
tp47719
sS'of,vioxx,should'
p47720
(F1
F0.00014334862385321102
I0
I1
I-1
tp47721
sS'reports,of,significant'
p47722
(F1
F0.00014334862385321102
I1
I0
I1
tp47723
sS'the,plasma,exposure'
p47724
(F0
F0
I1
I1
I0
tp47725
sS'to,fluctuate,significantly'
p47726
(F1
F0.00014334862385321102
I1
I0
I1
tp47727
sS'potential,for,reduction'
p47728
(F1
F0.00014334862385321102
I1
I0
I1
tp47729
sS'sodium,was,evaluated'
p47730
(F1
F0.00014334862385321102
I0
I1
I-1
tp47731
sS'parameters,for,or'
p47732
(F1
F0.00014334862385321102
I0
I1
I-1
tp47733
sS'the,potential,benefits'
p47734
(F1
F0.00028669724770642203
I2
I0
I2
tp47735
sS'a,risk,of'
p47736
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp47737
sS'of,osteoarthritis,when'
p47738
(F1
F0.00014334862385321102
I0
I1
I-1
tp47739
sS'or,or,should'
p47740
(F1
F0.00014334862385321102
I1
I0
I1
tp47741
sS'channel,blockers,did'
p47742
(F1
F0.00014334862385321102
I0
I1
I-1
tp47743
sS'studies,in,steady-state'
p47744
(F1
F0.00014334862385321102
I1
I0
I1
tp47745
sS'and,fluoride,accumulation'
p47746
(F1
F0.00014334862385321102
I0
I1
I-1
tp47747
sS'study,has,suggested'
p47748
(F1
F0.00014334862385321102
I0
I1
I-1
tp47749
sS'the,auc,after'
p47750
(F1
F0.00014334862385321102
I1
I0
I1
tp47751
sS'warrant,alteration,of'
p47752
(F1
F0.00014334862385321102
I0
I1
I-1
tp47753
sS'of,is,necessary'
p47754
(F1
F0.00014334862385321102
I0
I1
I-1
tp47755
sS'pharmacokinetic,changes,to'
p47756
(F1
F0.00014334862385321102
I1
I0
I1
tp47757
sS'of,levels,it'
p47758
(F1
F0.00014334862385321102
I1
I0
I1
tp47759
sS'infusion,requirements,of'
p47760
(F1
F0.00014334862385321102
I1
I0
I1
tp47761
sS'hemodynamic,compromise,have'
p47762
(F1
F0.00014334862385321102
I1
I0
I1
tp47763
sS'depletion,related,to'
p47764
(F1
F0.00014334862385321102
I0
I1
I-1
tp47765
sS'potentiation,of,otthostatic'
p47766
(F1
F0.00014334862385321102
I0
I1
I-1
tp47767
sS'and,increases,the'
p47768
(F1
F0.00028669724770642203
I2
I0
I2
tp47769
sS'to,mg,also'
p47770
(F1
F0.00014334862385321102
I0
I1
I-1
tp47771
sS'other,ace,inhibitors'
p47772
(F1
F0.00014334862385321102
I1
I0
I1
tp47773
sS'nalidixic,acid,may'
p47774
(F1
F0.00014334862385321102
I1
I0
I1
tp47775
sS'antacids,nonclinical,data'
p47776
(F1
F0.00014334862385321102
I0
I1
I-1
tp47777
sS'in,a,slower'
p47778
(F1
F0.00014334862385321102
I1
I0
I1
tp47779
sS'of,cyp3a4,the'
p47780
(F1
F0.00014334862385321102
I1
I0
I1
tp47781
sS'of,and,these'
p47782
(F1
F0.00014334862385321102
I0
I1
I-1
tp47783
sS'for,regarding,interactions'
p47784
(F1
F0.00014334862385321102
I0
I1
I-1
tp47785
sS'concurrently,with,mg'
p47786
(F1
F0.00014334862385321102
I0
I1
I-1
tp47787
sS'sigma-2,receptors,sodium'
p47788
(F1
F0.00014334862385321102
I0
I1
I-1
tp47789
sS'of,a,novel'
p47790
(F1
F0.00014334862385321102
I0
I1
I-1
tp47791
sS'trough,concentrations,similar'
p47792
(F1
F0.00014334862385321102
I1
I0
I1
tp47793
sS'cortisone-like,medicine,blood'
p47794
(F1
F0.00014334862385321102
I1
I0
I1
tp47795
sS'food,isrecommended,in'
p47796
(F1
F0.00014334862385321102
I1
I0
I1
tp47797
sS'of,the,clearance'
p47798
(F1
F0.00014334862385321102
I1
I0
I1
tp47799
sS'myocarditis,ventricular,hypokinesia'
p47800
(F1
F0.00014334862385321102
I1
I0
I1
tp47801
sS'not,be,combined'
p47802
(F1
F0.00014334862385321102
I1
I0
I1
tp47803
sS'healthy,subjects,stabilized'
p47804
(F1
F0.00014334862385321102
I1
I0
I1
tp47805
sS'and,can,decrease'
p47806
(F1
F0.00014334862385321102
I1
I0
I1
tp47807
sS'reduced,by,to'
p47808
(F0
F0
I1
I1
I0
tp47809
sS'of,tablets,with'
p47810
(F1
F0.00028669724770642203
I2
I0
I2
tp47811
sS'active,metabolites,were'
p47812
(F1
F0.00014334862385321102
I0
I1
I-1
tp47813
sS'protein,bound,drugs'
p47814
(F1
F0.00014334862385321102
I0
I1
I-1
tp47815
sS'removes,the,antiedematous'
p47816
(F1
F0.00014334862385321102
I1
I0
I1
tp47817
sS'were,more,than'
p47818
(F1
F0.00014334862385321102
I1
I0
I1
tp47819
sS'volunteers,receiving,decreased'
p47820
(F1
F0.00014334862385321102
I1
I0
I1
tp47821
sS'the,ermbt,and'
p47822
(F1
F0.00014334862385321102
I0
I1
I-1
tp47823
sS'reliable,when,tracleer'
p47824
(F1
F0.00014334862385321102
I1
I0
I1
tp47825
sS'temperature,was,decreased'
p47826
(F1
F0.00014334862385321102
I1
I0
I1
tp47827
sS'are,used,physiological'
p47828
(F1
F0.00014334862385321102
I0
I1
I-1
tp47829
sS'an,interactive,effect'
p47830
(F1
F0.00028669724770642203
I0
I2
I-2
tp47831
sS'water-miscible,or,parenteral'
p47832
(F1
F0.00014334862385321102
I0
I1
I-1
tp47833
sS'used,in,relation'
p47834
(F1
F0.00014334862385321102
I0
I1
I-1
tp47835
sS'response,to,indirect-acting'
p47836
(F1
F0.00014334862385321102
I1
I0
I1
tp47837
sS'are,actively,secreted'
p47838
(F1
F0.00014334862385321102
I1
I0
I1
tp47839
sS'be,observed,when'
p47840
(F1
F0.00028669724770642203
I2
I0
I2
tp47841
sS'arrhythmias,and,sudden'
p47842
(F1
F0.00014334862385321102
I1
I0
I1
tp47843
sS'and,exert,additive'
p47844
(F1
F0.00014334862385321102
I0
I1
I-1
tp47845
sS'risk,of,hypoglycemia'
p47846
(F1
F0.00014334862385321102
I1
I0
I1
tp47847
sS'of,cyp2c9,and'
p47848
(F1
F0.00014334862385321102
I0
I1
I-1
tp47849
sS'effects,caused,by'
p47850
(F1
F0.00014334862385321102
I1
I0
I1
tp47851
sS'abundance,and,wide'
p47852
(F1
F0.00014334862385321102
I0
I1
I-1
tp47853
sS'then,received,plus'
p47854
(F1
F0.00014334862385321102
I0
I1
I-1
tp47855
sS'number,of,regular'
p47856
(F1
F0.00014334862385321102
I0
I1
I-1
tp47857
sS'assays,using,red'
p47858
(F1
F0.00014334862385321102
I0
I1
I-1
tp47859
sS'prolonged,recovery,time'
p47860
(F1
F0.00014334862385321102
I1
I0
I1
tp47861
sS'additive,vasodilator,properties'
p47862
(F1
F0.00014334862385321102
I0
I1
I-1
tp47863
sS'baraclude,with,other'
p47864
(F1
F0.00014334862385321102
I0
I1
I-1
tp47865
sS'patients,receiving,concurrently'
p47866
(F1
F0.00014334862385321102
I1
I0
I1
tp47867
sS'without,bleeding,in'
p47868
(F1
F0.00014334862385321102
I1
I0
I1
tp47869
sS'hours,following,symptom'
p47870
(F1
F0.00014334862385321102
I0
I1
I-1
tp47871
sS'may,decrease,serum'
p47872
(F1
F0.00028669724770642203
I2
I0
I2
tp47873
sS'difluoroacetone,did,not'
p47874
(F1
F0.00014334862385321102
I0
I1
I-1
tp47875
sS'was,longer,in'
p47876
(F1
F0.00014334862385321102
I1
I0
I1
tp47877
sS'the,following,blood'
p47878
(F1
F0.00014334862385321102
I0
I1
I-1
tp47879
sS'symptoms,resolved,when'
p47880
(F1
F0.00014334862385321102
I0
I1
I-1
tp47881
sS'other,studies,strongly'
p47882
(F1
F0.00014334862385321102
I0
I1
I-1
tp47883
sS'under,lying,the'
p47884
(F1
F0.00014334862385321102
I1
I0
I1
tp47885
sS'as,prolonged,or'
p47886
(F1
F0.00014334862385321102
I0
I1
I-1
tp47887
sS'transplant,recipients,a'
p47888
(F1
F0.00014334862385321102
I1
I0
I1
tp47889
sS'and,is,therefore'
p47890
(F1
F0.00014334862385321102
I1
I0
I1
tp47891
sS'studies,showed,increased'
p47892
(F1
F0.00014334862385321102
I0
I1
I-1
tp47893
sS'injection,of,insufficient'
p47894
(F1
F0.00014334862385321102
I1
I0
I1
tp47895
sS'accordingly,in,patients'
p47896
(F1
F0.00028669724770642203
I2
I0
I2
tp47897
sS'to,the,dosing'
p47898
(F1
F0.00014334862385321102
I1
I0
I1
tp47899
sS'are,suggested,when'
p47900
(F1
F0.00014334862385321102
I1
I0
I1
tp47901
sS'well,tolerated,in'
p47902
(F1
F0.00014334862385321102
I0
I1
I-1
tp47903
sS'max,is,about'
p47904
(F1
F0.00014334862385321102
I1
I0
I1
tp47905
sS'patients,with,heart'
p47906
(F1
F0.00028669724770642203
I0
I2
I-2
tp47907
sS'with,or,h2antagonists'
p47908
(F1
F0.00014334862385321102
I1
I0
I1
tp47909
sS'interaction,with,the'
p47910
(F1
F0.00028669724770642203
I0
I2
I-2
tp47911
sS'cyp2c19,substrate,resulted'
p47912
(F1
F0.00014334862385321102
I1
I0
I1
tp47913
sS'these,patients,are'
p47914
(F1
F0.00028669724770642203
I2
I0
I2
tp47915
sS'to,warrant,dosage'
p47916
(F1
F0.00014334862385321102
I1
I0
I1
tp47917
sS'normal,variability,and'
p47918
(F1
F0.00014334862385321102
I1
I0
I1
tp47919
sS'with,crohn,s'
p47920
(F1
F0.00014334862385321102
I0
I1
I-1
tp47921
sS'c,inhibited,the'
p47922
(F1
F0.00014334862385321102
I1
I0
I1
tp47923
sS'adequate,methods,of'
p47924
(F1
F0.00014334862385321102
I0
I1
I-1
tp47925
sS'to,increase,serum'
p47926
(F1
F0.00028669724770642203
I0
I2
I-2
tp47927
sS'furthermore,and,other'
p47928
(F1
F0.00014334862385321102
I1
I0
I1
tp47929
sS'flupenthixol,increases,the'
p47930
(F1
F0.00014334862385321102
I1
I0
I1
tp47931
sS'monitored,for,possible'
p47932
(F1
F0.00014334862385321102
I1
I0
I1
tp47933
sS'of,migraine,has'
p47934
(F1
F0.00014334862385321102
I0
I1
I-1
tp47935
sS'phenytoin,phenobarbital,the'
p47936
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp47937
sS'healthy,subjects,with'
p47938
(F1
F0.00028669724770642203
I0
I2
I-2
tp47939
sS'a,to,fold'
p47940
(F1
F0.00014334862385321102
I1
I0
I1
tp47941
sS'arava,to,subjects'
p47942
(F1
F0.00014334862385321102
I1
I0
I1
tp47943
sS'differences,in,balance'
p47944
(F1
F0.00014334862385321102
I0
I1
I-1
tp47945
sS'doses,of,to'
p47946
(F0
F0
I2
I2
I0
tp47947
sS'antagonists,which,cause'
p47948
(F1
F0.00014334862385321102
I1
I0
I1
tp47949
sS'dose,reduction,should'
p47950
(F1
F0.00014334862385321102
I0
I1
I-1
tp47951
sS'although,the,specific'
p47952
(F1
F0.00014334862385321102
I0
I1
I-1
tp47953
sS'consequently,concomitant,administration'
p47954
(F1
F0.00014334862385321102
I1
I0
I1
tp47955
sS'needing,to,treatpatients'
p47956
(F1
F0.00014334862385321102
I0
I1
I-1
tp47957
sS'of,cyp3a4,and'
p47958
(F1
F0.00028669724770642203
I0
I2
I-2
tp47959
sS'of,thiazide,to'
p47960
(F1
F0.00028669724770642203
I2
I0
I2
tp47961
sS'reduced,from,ml'
p47962
(F1
F0.00014334862385321102
I1
I0
I1
tp47963
sS'with,experienced,tremor'
p47964
(F1
F0.00014334862385321102
I1
I0
I1
tp47965
sS'cisapride,was,well'
p47966
(F1
F0.00014334862385321102
I0
I1
I-1
tp47967
sS'to,possible,decrease'
p47968
(F1
F0.00028669724770642203
I2
I0
I2
tp47969
sS'may,be,superior'
p47970
(F1
F0.00014334862385321102
I0
I1
I-1
tp47971
sS'in,escalating,doses'
p47972
(F1
F0.00014334862385321102
I0
I1
I-1
tp47973
sS'v,concentrations,greater'
p47974
(F1
F0.00014334862385321102
I0
I1
I-1
tp47975
sS'anti-platelet,activity,of'
p47976
(F1
F0.00014334862385321102
I0
I1
I-1
tp47977
sS'to,a,level'
p47978
(F1
F0.00014334862385321102
I0
I1
I-1
tp47979
sS'metabolite,after,intravenous'
p47980
(F1
F0.00014334862385321102
I0
I1
I-1
tp47981
sS'for,serious,reactions'
p47982
(F1
F0.00014334862385321102
I0
I1
I-1
tp47983
sS'mac,or,had'
p47984
(F1
F0.00014334862385321102
I0
I1
I-1
tp47985
sS'sites,may,be'
p47986
(F1
F0.00014334862385321102
I0
I1
I-1
tp47987
sS'on,the,pharmacokinetics'
p47988
(F0.93333333333333335
F0.0040137614678899085
I1
I29
I-28
tp47989
sS'in,monkeys,and'
p47990
(F1
F0.00014334862385321102
I0
I1
I-1
tp47991
sS'vitro,study,in'
p47992
(F1
F0.00014334862385321102
I1
I0
I1
tp47993
sS'dogs,have,demonstrated'
p47994
(F1
F0.00014334862385321102
I0
I1
I-1
tp47995
sS'healthy,volunteers,who'
p47996
(F1
F0.00014334862385321102
I0
I1
I-1
tp47997
sS'difluoro-2,propanol,derive'
p47998
(F1
F0.00014334862385321102
I1
I0
I1
tp47999
sS'maintenance,dose,and'
p48000
(F1
F0.00014334862385321102
I1
I0
I1
tp48001
sS'low,therapeutic,margin'
p48002
(F1
F0.00014334862385321102
I0
I1
I-1
tp48003
sS'healthy,women,of'
p48004
(F1
F0.00014334862385321102
I0
I1
I-1
tp48005
sS'patients,have,not'
p48006
(F1
F0.00014334862385321102
I0
I1
I-1
tp48007
sS'sensitive,to,c'
p48008
(F1
F0.00014334862385321102
I0
I1
I-1
tp48009
sS'by,during,this'
p48010
(F1
F0.00014334862385321102
I0
I1
I-1
tp48011
sS'without,evidence,of'
p48012
(F1
F0.0011467889908256881
I0
I8
I-8
tp48013
sS'reaction,although,it'
p48014
(F1
F0.00014334862385321102
I1
I0
I1
tp48015
sS'blockers,l-type,omega-conotoxin'
p48016
(F1
F0.00014334862385321102
I0
I1
I-1
tp48017
sS'the,frequency,and'
p48018
(F1
F0.00028669724770642203
I2
I0
I2
tp48019
sS'but,not,with'
p48020
(F1
F0.00043004587155963305
I0
I3
I-3
tp48021
sS'p450,d6,they'
p48022
(F1
F0.00071674311926605509
I0
I5
I-5
tp48023
sS'have,received,muscle'
p48024
(F1
F0.00014334862385321102
I1
I0
I1
tp48025
sS'respectively,and,for'
p48026
(F1
F0.00014334862385321102
I1
I0
I1
tp48027
sS'peripheral,neuropathy,include'
p48028
(F1
F0.00014334862385321102
I0
I1
I-1
tp48029
sS'clearance,such,as'
p48030
(F1
F0.00014334862385321102
I1
I0
I1
tp48031
sS'mental,status,changes'
p48032
(F1
F0.00014334862385321102
I1
I0
I1
tp48033
sS'pre-existing,cardiac,abnormalities'
p48034
(F1
F0.00014334862385321102
I1
I0
I1
tp48035
sS'm,failed,to'
p48036
(F1
F0.00014334862385321102
I1
I0
I1
tp48037
sS'in,which,the'
p48038
(F0
F0
I1
I1
I0
tp48039
sS'due,to,its'
p48040
(F1
F0.00014334862385321102
I1
I0
I1
tp48041
sS'undergoing,treatment,with'
p48042
(F1
F0.00043004587155963305
I3
I0
I3
tp48043
sS'hundred,mg,of'
p48044
(F1
F0.00014334862385321102
I0
I1
I-1
tp48045
sS'blood,coagulation,system'
p48046
(F1
F0.00014334862385321102
I0
I1
I-1
tp48047
sS'the,stadol,ns'
p48048
(F1
F0.00014334862385321102
I1
I0
I1
tp48049
sS'with,the,digi-'
p48050
(F1
F0.00014334862385321102
I0
I1
I-1
tp48051
sS'with,cefizox,nephrotoxicity'
p48052
(F1
F0.00014334862385321102
I1
I0
I1
tp48053
sS'receiving,or,oral'
p48054
(F1
F0.00014334862385321102
I0
I1
I-1
tp48055
sS'ischemic,heart,disease'
p48056
(F1
F0.00028669724770642203
I2
I0
I2
tp48057
sS'voltage-dependent,ca,channel'
p48058
(F1
F0.00014334862385321102
I0
I1
I-1
tp48059
sS'pharmacodynamic,interactions,when'
p48060
(F1
F0.00014334862385321102
I1
I0
I1
tp48061
sS'average,of,and'
p48062
(F1
F0.00028669724770642203
I2
I0
I2
tp48063
sS'that,of,urate'
p48064
(F1
F0.00014334862385321102
I1
I0
I1
tp48065
sS'no,greater,than'
p48066
(F1
F0.00014334862385321102
I1
I0
I1
tp48067
sS'increased,the,systemic'
p48068
(F1
F0.00014334862385321102
I1
I0
I1
tp48069
sS'an,increased,rate'
p48070
(F1
F0.00028669724770642203
I2
I0
I2
tp48071
sS'terfenadine,and,are'
p48072
(F1
F0.00014334862385321102
I1
I0
I1
tp48073
sS'and,receptors,thus'
p48074
(F1
F0.00014334862385321102
I1
I0
I1
tp48075
sS'those,produced,by'
p48076
(F1
F0.00014334862385321102
I1
I0
I1
tp48077
sS'nutrition,herb,interactions'
p48078
(F1
F0.00014334862385321102
I1
I0
I1
tp48079
sS'mixed,signalled-unsignalled,differential-reinforcement'
p48080
(F1
F0.00014334862385321102
I0
I1
I-1
tp48081
sS'interactions,between,keppra'
p48082
(F1
F0.00028669724770642203
I0
I2
I-2
tp48083
sS'medicine,certain,such'
p48084
(F1
F0.00014334862385321102
I0
I1
I-1
tp48085
sS'days,and,the'
p48086
(F1
F0.00028669724770642203
I0
I2
I-2
tp48087
sS'novel,purification,protocol'
p48088
(F1
F0.00014334862385321102
I0
I1
I-1
tp48089
sS'this,enzyme,prolongs'
p48090
(F1
F0.00014334862385321102
I0
I1
I-1
tp48091
sS'nalfon,to,therapy'
p48092
(F1
F0.00014334862385321102
I1
I0
I1
tp48093
sS'this,isoenzyme,and'
p48094
(F1
F0.00028669724770642203
I0
I2
I-2
tp48095
sS'and,serum,levels'
p48096
(F1
F0.00014334862385321102
I1
I0
I1
tp48097
sS'pharmacokinetics,or,pharmacodynamics'
p48098
(F1
F0.00028669724770642203
I0
I2
I-2
tp48099
sS'the,treatment,with'
p48100
(F1
F0.00014334862385321102
I1
I0
I1
tp48101
sS'immediate,release,capsules'
p48102
(F1
F0.00028669724770642203
I2
I0
I2
tp48103
sS'an,immune,response'
p48104
(F1
F0.00014334862385321102
I0
I1
I-1
tp48105
sS'a,rapid,and'
p48106
(F1
F0.00028669724770642203
I2
I0
I2
tp48107
sS'nmda,and,sigma-2'
p48108
(F1
F0.00014334862385321102
I0
I1
I-1
tp48109
sS'b,has,been'
p48110
(F1
F0.00014334862385321102
I1
I0
I1
tp48111
sS'reaction,for,ketones'
p48112
(F1
F0.00028669724770642203
I0
I2
I-2
tp48113
sS'cognitive,dysfunction,hyperpyrexia'
p48114
(F1
F0.00014334862385321102
I1
I0
I1
tp48115
sS'molecular,mechanisms,of'
p48116
(F1
F0.00014334862385321102
I0
I1
I-1
tp48117
sS'is,not,metabolized'
p48118
(F1
F0.00028669724770642203
I0
I2
I-2
tp48119
sS'increased,exposure,following'
p48120
(F1
F0.00014334862385321102
I1
I0
I1
tp48121
sS'may,even,be'
p48122
(F1
F0.00014334862385321102
I1
I0
I1
tp48123
sS'with,coadministration,were'
p48124
(F1
F0.00014334862385321102
I1
I0
I1
tp48125
sS'still,advisable,to'
p48126
(F1
F0.00014334862385321102
I1
I0
I1
tp48127
sS'reported,to,both'
p48128
(F1
F0.00014334862385321102
I1
I0
I1
tp48129
sS'l,and,by'
p48130
(F1
F0.00014334862385321102
I1
I0
I1
tp48131
sS'and,h2,blockers'
p48132
(F1
F0.00014334862385321102
I1
I0
I1
tp48133
sS'patients,who,were'
p48134
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp48135
sS'concentration,of,and'
p48136
(F1
F0.00028669724770642203
I2
I0
I2
tp48137
sS'toradol,and,or'
p48138
(F1
F0.00014334862385321102
I1
I0
I1
tp48139
sS'monitored,closely,after'
p48140
(F1
F0.00014334862385321102
I1
I0
I1
tp48141
sS'faecium,to,the'
p48142
(F1
F0.00014334862385321102
I0
I1
I-1
tp48143
sS'several-fold,higher,daily'
p48144
(F1
F0.00014334862385321102
I0
I1
I-1
tp48145
sS'discrimination,and,behavioral'
p48146
(F1
F0.00014334862385321102
I0
I1
I-1
tp48147
sS'in,epileptic,patients'
p48148
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48149
sS'of,chloride-induced,gastrointestinal'
p48150
(F1
F0.00014334862385321102
I1
I0
I1
tp48151
sS'with,for,two'
p48152
(F1
F0.00014334862385321102
I1
I0
I1
tp48153
sS'fold,increase,in'
p48154
(F0.5
F0.0008600917431192661
I9
I3
I6
tp48155
sS'beginning,therapy,should'
p48156
(F1
F0.00014334862385321102
I1
I0
I1
tp48157
sS'of,did,not'
p48158
(F1
F0.0010034403669724771
I0
I7
I-7
tp48159
sS'meal,as,evidenced'
p48160
(F1
F0.00014334862385321102
I1
I0
I1
tp48161
sS'produces,psychotomimetic,effects'
p48162
(F1
F0.00014334862385321102
I0
I1
I-1
tp48163
sS'nalfon,and,is'
p48164
(F1
F0.00014334862385321102
I1
I0
I1
tp48165
sS'ht1b,d,agonists'
p48166
(F1
F0.00014334862385321102
I1
I0
I1
tp48167
sS'indicates,that,this'
p48168
(F1
F0.00014334862385321102
I0
I1
I-1
tp48169
sS'receiving,or,halogenated'
p48170
(F1
F0.00014334862385321102
I1
I0
I1
tp48171
sS'similar,changes,in'
p48172
(F1
F0.00014334862385321102
I0
I1
I-1
tp48173
sS'binding,with,high'
p48174
(F1
F0.00014334862385321102
I0
I1
I-1
tp48175
sS'at,mg,per'
p48176
(F1
F0.00014334862385321102
I1
I0
I1
tp48177
sS'even,be,more'
p48178
(F1
F0.00014334862385321102
I1
I0
I1
tp48179
sS'with,high,affinity'
p48180
(F1
F0.00014334862385321102
I0
I1
I-1
tp48181
sS'cardiac,dysrhythmias,some'
p48182
(F1
F0.00014334862385321102
I1
I0
I1
tp48183
sS'chick,by,means'
p48184
(F1
F0.00014334862385321102
I0
I1
I-1
tp48185
sS'between,brevibloc,and'
p48186
(F1
F0.00014334862385321102
I0
I1
I-1
tp48187
sS'with,containing,or'
p48188
(F1
F0.00014334862385321102
I1
I0
I1
tp48189
sS'micrograms,kg,of'
p48190
(F1
F0.00014334862385321102
I0
I1
I-1
tp48191
sS'mg,day,orally'
p48192
(F1
F0.00014334862385321102
I1
I0
I1
tp48193
sS'eg,or,than'
p48194
(F1
F0.00014334862385321102
I1
I0
I1
tp48195
sS'because,of,an'
p48196
(F1
F0.00014334862385321102
I1
I0
I1
tp48197
sS'that,induce,hepatic'
p48198
(F1
F0.00014334862385321102
I1
I0
I1
tp48199
sS'commercially,available,assay'
p48200
(F1
F0.00014334862385321102
I0
I1
I-1
tp48201
sS'plasma,levels,were'
p48202
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp48203
sS'conjugated,with,further'
p48204
(F1
F0.00014334862385321102
I0
I1
I-1
tp48205
sS'mglur,agonists,dcg-iv'
p48206
(F1
F0.00014334862385321102
I0
I1
I-1
tp48207
sS'in,patients,suffering'
p48208
(F1
F0.00014334862385321102
I1
I0
I1
tp48209
sS'to,might,decrease'
p48210
(F1
F0.00014334862385321102
I1
I0
I1
tp48211
sS'either,concomitant,therapy'
p48212
(F1
F0.00014334862385321102
I0
I1
I-1
tp48213
sS'after,at,the'
p48214
(F1
F0.00014334862385321102
I0
I1
I-1
tp48215
sS'in,the,fed'
p48216
(F1
F0.00014334862385321102
I1
I0
I1
tp48217
sS'or,more,were'
p48218
(F1
F0.00014334862385321102
I0
I1
I-1
tp48219
sS'verapamil,concomitant,use'
p48220
(F1
F0.00014334862385321102
I0
I1
I-1
tp48221
sS'in,insufficient,plasma'
p48222
(F1
F0.00014334862385321102
I1
I0
I1
tp48223
sS'the,experiment,rats'
p48224
(F1
F0.00014334862385321102
I0
I1
I-1
tp48225
sS'protease,inhibitor,due'
p48226
(F1
F0.00014334862385321102
I0
I1
I-1
tp48227
sS'there,is,the'
p48228
(F0
F0
I1
I1
I0
tp48229
sS'p450,a4,grapefruit'
p48230
(F1
F0.00014334862385321102
I1
I0
I1
tp48231
sS'returned,to,normal'
p48232
(F1
F0.00014334862385321102
I0
I1
I-1
tp48233
sS'and,less,suppression'
p48234
(F1
F0.00014334862385321102
I0
I1
I-1
tp48235
sS'was,to,examine'
p48236
(F1
F0.00014334862385321102
I0
I1
I-1
tp48237
sS'enablex,is,used'
p48238
(F1
F0.00014334862385321102
I1
I0
I1
tp48239
sS'monitoring,of,clinical'
p48240
(F1
F0.00014334862385321102
I1
I0
I1
tp48241
sS'caution,in,using'
p48242
(F0
F0
I1
I1
I0
tp48243
sS'metabolic,pathway,for'
p48244
(F1
F0.00028669724770642203
I0
I2
I-2
tp48245
sS'or,cyp2d6,eg'
p48246
(F1
F0.00014334862385321102
I1
I0
I1
tp48247
sS'supplements,uncontrolled,intake'
p48248
(F1
F0.00043004587155963305
I0
I3
I-3
tp48249
sS'mg,bid,was'
p48250
(F1
F0.00014334862385321102
I1
I0
I1
tp48251
sS'maois,which,may'
p48252
(F1
F0.00014334862385321102
I0
I1
I-1
tp48253
sS'multiple,oral,doses'
p48254
(F0
F0
I1
I1
I0
tp48255
sS'concentrations,and,auc'
p48256
(F1
F0.00014334862385321102
I0
I1
I-1
tp48257
sS'potential,for,clinically'
p48258
(F1
F0.00014334862385321102
I0
I1
I-1
tp48259
sS'mediated,by,cimetidines'
p48260
(F1
F0.00014334862385321102
I1
I0
I1
tp48261
sS'known,whether,the'
p48262
(F1
F0.00014334862385321102
I1
I0
I1
tp48263
sS'of,than,when'
p48264
(F1
F0.00014334862385321102
I1
I0
I1
tp48265
sS'studies,where,patients'
p48266
(F1
F0.00014334862385321102
I0
I1
I-1
tp48267
sS'metabolism,is,hydroxylation'
p48268
(F1
F0.00014334862385321102
I0
I1
I-1
tp48269
sS'may,elevate,serum'
p48270
(F1
F0.00014334862385321102
I1
I0
I1
tp48271
sS'subjects,no,evidence'
p48272
(F1
F0.00014334862385321102
I0
I1
I-1
tp48273
sS'of,such,as'
p48274
(F0
F0
I2
I2
I0
tp48275
sS'for,any,patient'
p48276
(F1
F0.00014334862385321102
I0
I1
I-1
tp48277
sS'therapy,may,exhibit'
p48278
(F1
F0.00014334862385321102
I1
I0
I1
tp48279
sS'of,and,some'
p48280
(F1
F0.00014334862385321102
I1
I0
I1
tp48281
sS'has,a,tendency'
p48282
(F1
F0.00014334862385321102
I1
I0
I1
tp48283
sS'serum,concentrations,and'
p48284
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48285
sS'and,brain,was'
p48286
(F1
F0.00014334862385321102
I1
I0
I1
tp48287
sS'epidermal,necrolysis,has'
p48288
(F1
F0.00014334862385321102
I0
I1
I-1
tp48289
sS'dimenhydrinate,may,decrease'
p48290
(F1
F0.00014334862385321102
I1
I0
I1
tp48291
sS'reports,indicate,that'
p48292
(F1
F0.00028669724770642203
I2
I0
I2
tp48293
sS'vasodilator,activity,should'
p48294
(F1
F0.00014334862385321102
I1
I0
I1
tp48295
sS'argatroban,with,thrombolytic'
p48296
(F1
F0.00014334862385321102
I0
I1
I-1
tp48297
sS'worsened,by,especially'
p48298
(F1
F0.00014334862385321102
I1
I0
I1
tp48299
sS'dosage,when,is'
p48300
(F1
F0.00014334862385321102
I1
I0
I1
tp48301
sS'aggregation,but,did'
p48302
(F1
F0.00014334862385321102
I1
I0
I1
tp48303
sS'cyp3a4,rifampin,cyp3a4'
p48304
(F1
F0.00014334862385321102
I0
I1
I-1
tp48305
sS'aggregation,and,serum'
p48306
(F1
F0.00014334862385321102
I0
I1
I-1
tp48307
sS'first,study,both'
p48308
(F1
F0.00014334862385321102
I0
I1
I-1
tp48309
sS'increased,frequency,of'
p48310
(F1
F0.00014334862385321102
I0
I1
I-1
tp48311
sS'transfusions,acute,pulmonary'
p48312
(F1
F0.00014334862385321102
I1
I0
I1
tp48313
sS'does,not,cause'
p48314
(F1
F0.00014334862385321102
I0
I1
I-1
tp48315
sS'increases,should,be'
p48316
(F1
F0.00014334862385321102
I1
I0
I1
tp48317
sS'diagnostic,or,therapeutic'
p48318
(F1
F0.00014334862385321102
I0
I1
I-1
tp48319
sS'and,other,hydroxymethylglutaryl'
p48320
(F1
F0.00014334862385321102
I1
I0
I1
tp48321
sS'expected,with,higher'
p48322
(F1
F0.00014334862385321102
I1
I0
I1
tp48323
sS'survival,in,and'
p48324
(F1
F0.00014334862385321102
I0
I1
I-1
tp48325
sS'the,serum,creatinine'
p48326
(F1
F0.00014334862385321102
I1
I0
I1
tp48327
sS'be,exceeded,when'
p48328
(F1
F0.00014334862385321102
I1
I0
I1
tp48329
sS'antibiotics,macrolide,have'
p48330
(F1
F0.00014334862385321102
I1
I0
I1
tp48331
sS'auc,values,of'
p48332
(F1
F0.00014334862385321102
I1
I0
I1
tp48333
sS'that,chloral,hydrate'
p48334
(F1
F0.00014334862385321102
I0
I1
I-1
tp48335
sS'affect,the,aptt'
p48336
(F1
F0.00014334862385321102
I0
I1
I-1
tp48337
sS'matrix,may,increase'
p48338
(F1
F0.00014334862385321102
I1
I0
I1
tp48339
sS'erythromycin,clarithromycin,telithromycin'
p48340
(F1
F0.00014334862385321102
I0
I1
I-1
tp48341
sS'caffeine,administered,concurrently'
p48342
(F1
F0.00014334862385321102
I1
I0
I1
tp48343
sS'the,steadystate,cmin'
p48344
(F1
F0.00014334862385321102
I1
I0
I1
tp48345
sS'the,qrs,complex'
p48346
(F1
F0.00014334862385321102
I1
I0
I1
tp48347
sS'an,endogenous,marker'
p48348
(F1
F0.00014334862385321102
I1
I0
I1
tp48349
sS'antizol,and,that'
p48350
(F1
F0.00014334862385321102
I1
I0
I1
tp48351
sS'been,administered,concomitantly'
p48352
(F1
F0.00014334862385321102
I0
I1
I-1
tp48353
sS'approximately,threefold,from'
p48354
(F1
F0.00014334862385321102
I1
I0
I1
tp48355
sS'coadministration,with,of'
p48356
(F1
F0.00014334862385321102
I0
I1
I-1
tp48357
sS'of,either,agent'
p48358
(F1
F0.00014334862385321102
I0
I1
I-1
tp48359
sS'micrograms,ml,when'
p48360
(F1
F0.00014334862385321102
I1
I0
I1
tp48361
sS'significant,difference,p'
p48362
(F1
F0.00014334862385321102
I0
I1
I-1
tp48363
sS'weak,inhibitor,of'
p48364
(F1
F0.00014334862385321102
I0
I1
I-1
tp48365
sS'as,diminished,effects'
p48366
(F1
F0.00014334862385321102
I1
I0
I1
tp48367
sS'interaction,for,the'
p48368
(F1
F0.00014334862385321102
I1
I0
I1
tp48369
sS'benign,prostatic,hyperplasia'
p48370
(F1
F0.00014334862385321102
I0
I1
I-1
tp48371
sS'may,experience,increased'
p48372
(F1
F0.00014334862385321102
I0
I1
I-1
tp48373
sS'dose,of,stadol'
p48374
(F1
F0.00014334862385321102
I1
I0
I1
tp48375
sS'schedule,of,indocin'
p48376
(F1
F0.00014334862385321102
I1
I0
I1
tp48377
sS'antagonize,the,effect'
p48378
(F1
F0.00014334862385321102
I1
I0
I1
tp48379
sS'usual,and,the'
p48380
(F1
F0.00014334862385321102
I1
I0
I1
tp48381
sS'may,also,occur'
p48382
(F1
F0.00014334862385321102
I0
I1
I-1
tp48383
sS'alprazolam,caution,is'
p48384
(F1
F0.00014334862385321102
I1
I0
I1
tp48385
sS'higher,when,mg'
p48386
(F1
F0.00014334862385321102
I1
I0
I1
tp48387
sS'healthy,subjects,were'
p48388
(F1
F0.00014334862385321102
I0
I1
I-1
tp48389
sS'product,erythro-fluorocitrate,from'
p48390
(F1
F0.00014334862385321102
I0
I1
I-1
tp48391
sS'mg,qhs,after'
p48392
(F1
F0.00014334862385321102
I0
I1
I-1
tp48393
sS'to,assess,the'
p48394
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp48395
sS'when,or,were'
p48396
(F1
F0.00014334862385321102
I0
I1
I-1
tp48397
sS'with,systemic,antiretroviral'
p48398
(F1
F0.00014334862385321102
I0
I1
I-1
tp48399
sS'experience,in,over'
p48400
(F1
F0.00014334862385321102
I1
I0
I1
tp48401
sS'available,about,the'
p48402
(F1
F0.00028669724770642203
I0
I2
I-2
tp48403
sS'a,clinical,interaction'
p48404
(F1
F0.00014334862385321102
I0
I1
I-1
tp48405
sS'medications,concurrent,use'
p48406
(F1
F0.00014334862385321102
I0
I1
I-1
tp48407
sS'or,triazolam,no'
p48408
(F1
F0.00014334862385321102
I0
I1
I-1
tp48409
sS'in,a-chloralose,anesthetized'
p48410
(F1
F0.00014334862385321102
I0
I1
I-1
tp48411
sS'from,the,proposed'
p48412
(F1
F0.00014334862385321102
I0
I1
I-1
tp48413
sS'potential,interaction,involving'
p48414
(F1
F0.00014334862385321102
I1
I0
I1
tp48415
sS'patients,taking,mg'
p48416
(F1
F0.00014334862385321102
I0
I1
I-1
tp48417
sS'normal,subjects,nor'
p48418
(F1
F0.00014334862385321102
I0
I1
I-1
tp48419
sS'pletal,is,coadministered'
p48420
(F1
F0.00014334862385321102
I1
I0
I1
tp48421
sS'acromegaly,and,after'
p48422
(F1
F0.00014334862385321102
I0
I1
I-1
tp48423
sS'dose,is,adjusted'
p48424
(F1
F0.00014334862385321102
I1
I0
I1
tp48425
sS'and,moderate,cyp1a2'
p48426
(F1
F0.00014334862385321102
I1
I0
I1
tp48427
sS'female,volunteers,suggests'
p48428
(F1
F0.00014334862385321102
I1
I0
I1
tp48429
sS'occur,with,labetalol'
p48430
(F1
F0.00014334862385321102
I1
I0
I1
tp48431
sS'exposure,despite,persistent'
p48432
(F1
F0.00014334862385321102
I0
I1
I-1
tp48433
sS'it,is,still'
p48434
(F1
F0.00014334862385321102
I1
I0
I1
tp48435
sS'differences,in,dosing'
p48436
(F1
F0.00014334862385321102
I0
I1
I-1
tp48437
sS'of,some,patients'
p48438
(F1
F0.00014334862385321102
I0
I1
I-1
tp48439
sS'toxic,such,as'
p48440
(F1
F0.00014334862385321102
I1
I0
I1
tp48441
sS'hyperpolarized,by,mu-'
p48442
(F1
F0.00014334862385321102
I0
I1
I-1
tp48443
sS'high,inter-patient,variability'
p48444
(F1
F0.00014334862385321102
I0
I1
I-1
tp48445
sS'the,iv,dose'
p48446
(F1
F0.00014334862385321102
I1
I0
I1
tp48447
sS'while,levels,of'
p48448
(F1
F0.00014334862385321102
I1
I0
I1
tp48449
sS'by,severe,peripheral'
p48450
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48451
sS'than,when,was'
p48452
(F1
F0.00028669724770642203
I2
I0
I2
tp48453
sS'itraconazole,ketoconazole,erythromycin'
p48454
(F1
F0.00014334862385321102
I0
I1
I-1
tp48455
sS'minutes,of,exposure'
p48456
(F1
F0.00014334862385321102
I0
I1
I-1
tp48457
sS'known,to,raise'
p48458
(F1
F0.00014334862385321102
I1
I0
I1
tp48459
sS'toradol,with,muscle'
p48460
(F1
F0.00014334862385321102
I0
I1
I-1
tp48461
sS'control,hypertension,in'
p48462
(F1
F0.00014334862385321102
I1
I0
I1
tp48463
sS'increased,approximately,twofold'
p48464
(F1
F0.00014334862385321102
I1
I0
I1
tp48465
sS'volunteers,when,administered'
p48466
(F1
F0.00014334862385321102
I0
I1
I-1
tp48467
sS'receiving,high,doses'
p48468
(F1
F0.00028669724770642203
I2
I0
I2
tp48469
sS'and,hydroxydesloratadine,were'
p48470
(F1
F0.00014334862385321102
I0
I1
I-1
tp48471
sS'ketoconazole,fexofenadine,has'
p48472
(F1
F0.00014334862385321102
I0
I1
I-1
tp48473
sS'study,showed,that'
p48474
(F1
F0.00014334862385321102
I0
I1
I-1
tp48475
sS'manner,when,was'
p48476
(F1
F0.00014334862385321102
I1
I0
I1
tp48477
sS'history,of,severe'
p48478
(F1
F0.00014334862385321102
I1
I0
I1
tp48479
sS'the,clinical,dose'
p48480
(F1
F0.00014334862385321102
I0
I1
I-1
tp48481
sS'in,general,and'
p48482
(F1
F0.00014334862385321102
I0
I1
I-1
tp48483
sS'hypersensitivity,reactions,have'
p48484
(F1
F0.00014334862385321102
I1
I0
I1
tp48485
sS'patients,on,concomitant'
p48486
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp48487
sS'bred,for,differential'
p48488
(F1
F0.00014334862385321102
I0
I1
I-1
tp48489
sS'use,of,alone'
p48490
(F1
F0.00014334862385321102
I0
I1
I-1
tp48491
sS'state,levels,of'
p48492
(F1
F0.00014334862385321102
I0
I1
I-1
tp48493
sS'in,serum,levels'
p48494
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48495
sS'in,a,separate'
p48496
(F1
F0.00014334862385321102
I0
I1
I-1
tp48497
sS'use,as,part'
p48498
(F1
F0.00014334862385321102
I0
I1
I-1
tp48499
sS'and,or,the'
p48500
(F1
F0.00057339449541284407
I4
I0
I4
tp48501
sS'by,use,of'
p48502
(F1
F0.00014334862385321102
I0
I1
I-1
tp48503
sS'reuptake,inhibitor,should'
p48504
(F1
F0.00014334862385321102
I1
I0
I1
tp48505
sS'gl,was,combined'
p48506
(F1
F0.00014334862385321102
I1
I0
I1
tp48507
sS'as,a,consequence'
p48508
(F1
F0.00028669724770642203
I2
I0
I2
tp48509
sS'studies,with,in'
p48510
(F1
F0.00014334862385321102
I0
I1
I-1
tp48511
sS'and,and,no'
p48512
(F1
F0.00014334862385321102
I0
I1
I-1
tp48513
sS'added,in,and'
p48514
(F1
F0.00014334862385321102
I0
I1
I-1
tp48515
sS'with,sustiva,in'
p48516
(F1
F0.00014334862385321102
I0
I1
I-1
tp48517
sS'therapy,are,at'
p48518
(F1
F0.00014334862385321102
I1
I0
I1
tp48519
sS'of,these,cases'
p48520
(F1
F0.00014334862385321102
I0
I1
I-1
tp48521
sS'ethacrynic,acid,because'
p48522
(F1
F0.00014334862385321102
I1
I0
I1
tp48523
sS'certain,tcas,such'
p48524
(F1
F0.00014334862385321102
I1
I0
I1
tp48525
sS'supplements,can,increase'
p48526
(F1
F0.00028669724770642203
I0
I2
I-2
tp48527
sS'post,and,returned'
p48528
(F1
F0.00014334862385321102
I0
I1
I-1
tp48529
sS'administration,of,hepatic'
p48530
(F1
F0.00028669724770642203
I2
I0
I2
tp48531
sS'of,patients,treated'
p48532
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp48533
sS'mg,qd,is'
p48534
(F1
F0.00014334862385321102
I1
I0
I1
tp48535
sS'and,consequently,alter'
p48536
(F1
F0.00014334862385321102
I0
I1
I-1
tp48537
sS'could,be,affected'
p48538
(F1
F0.00014334862385321102
I0
I1
I-1
tp48539
sS'other,currently,available'
p48540
(F1
F0.00014334862385321102
I0
I1
I-1
tp48541
sS'adrenergic,agonists,on'
p48542
(F1
F0.00014334862385321102
I1
I0
I1
tp48543
sS'of,an,mao'
p48544
(F1
F0.00014334862385321102
I1
I0
I1
tp48545
sS'experience,indicates,that'
p48546
(F1
F0.00028669724770642203
I2
I0
I2
tp48547
sS'blockers,proton,pump'
p48548
(F1
F0.00014334862385321102
I1
I0
I1
tp48549
sS'responding,under,a'
p48550
(F1
F0.00014334862385321102
I0
I1
I-1
tp48551
sS'bolus-ifl,with,or'
p48552
(F1
F0.00014334862385321102
I0
I1
I-1
tp48553
sS'in,lower,plasma'
p48554
(F1
F0.00043004587155963305
I3
I0
I3
tp48555
sS'concurrent,or,serial'
p48556
(F1
F0.00014334862385321102
I0
I1
I-1
tp48557
sS'of,results,in'
p48558
(F1
F0.00014334862385321102
I1
I0
I1
tp48559
sS'mg,qd,in'
p48560
(F1
F0.00014334862385321102
I0
I1
I-1
tp48561
sS'n,and,n'
p48562
(F1
F0.00014334862385321102
I1
I0
I1
tp48563
sS'changes,in,the'
p48564
(F0.23076923076923078
F0.00043004587155963305
I5
I8
I-3
tp48565
sS'the,doses,of'
p48566
(F1
F0.00043004587155963305
I3
I0
I3
tp48567
sS'placebo-controlled,osteoporosis,treatment'
p48568
(F1
F0.00014334862385321102
I0
I1
I-1
tp48569
sS'combination,may,cause'
p48570
(F1
F0.00028669724770642203
I2
I0
I2
tp48571
sS'neuronal,damage,produced'
p48572
(F1
F0.00014334862385321102
I1
I0
I1
tp48573
sS'or,mg,orally'
p48574
(F1
F0.00028669724770642203
I0
I2
I-2
tp48575
sS'half-life,of,because'
p48576
(F1
F0.00014334862385321102
I1
I0
I1
tp48577
sS'limited,number,of'
p48578
(F1
F0.00014334862385321102
I0
I1
I-1
tp48579
sS'in,animals,demonstrate'
p48580
(F1
F0.00014334862385321102
I1
I0
I1
tp48581
sS'another,serotonin,reuptake'
p48582
(F1
F0.00014334862385321102
I1
I0
I1
tp48583
sS'cryptosporidium,parvum,in'
p48584
(F1
F0.00014334862385321102
I0
I1
I-1
tp48585
sS's,nor,were'
p48586
(F1
F0.00014334862385321102
I0
I1
I-1
tp48587
sS'the,within,a'
p48588
(F1
F0.00014334862385321102
I1
I0
I1
tp48589
sS'substrate,the,auc'
p48590
(F1
F0.00014334862385321102
I1
I0
I1
tp48591
sS'anti-coagulant,effect,of'
p48592
(F1
F0.00014334862385321102
I0
I1
I-1
tp48593
sS'effects,of,felbatol'
p48594
(F0
F0
I1
I1
I0
tp48595
sS'drug,transport,systems'
p48596
(F1
F0.00014334862385321102
I0
I1
I-1
tp48597
sS'in,decreased,antihypertensive'
p48598
(F1
F0.00014334862385321102
I1
I0
I1
tp48599
sS'aged,or,over'
p48600
(F1
F0.00014334862385321102
I0
I1
I-1
tp48601
sS'do,not,bear'
p48602
(F1
F0.00014334862385321102
I1
I0
I1
tp48603
sS'non-selective,mao,inhibitors'
p48604
(F1
F0.00028669724770642203
I2
I0
I2
tp48605
sS'patients,with,moderate'
p48606
(F1
F0.00014334862385321102
I1
I0
I1
tp48607
sS'of,ergotamine-containing,when'
p48608
(F1
F0.00014334862385321102
I1
I0
I1
tp48609
sS'q,i,d'
p48610
(F1
F0.00014334862385321102
I1
I0
I1
tp48611
sS'b,can,be'
p48612
(F1
F0.00014334862385321102
I0
I1
I-1
tp48613
sS'zidovudine,there,is'
p48614
(F1
F0.00014334862385321102
I0
I1
I-1
tp48615
sS'these,agents,include'
p48616
(F1
F0.00014334862385321102
I0
I1
I-1
tp48617
sS'days,and,to'
p48618
(F1
F0.00014334862385321102
I0
I1
I-1
tp48619
sS'at,the,cellular'
p48620
(F1
F0.00014334862385321102
I0
I1
I-1
tp48621
sS'early,therapy,to'
p48622
(F1
F0.00014334862385321102
I1
I0
I1
tp48623
sS'inhibitor,at,mg'
p48624
(F1
F0.00014334862385321102
I1
I0
I1
tp48625
sS'nephrotoxic,myelotoxic,chemotherapy'
p48626
(F1
F0.00014334862385321102
I1
I0
I1
tp48627
sS'association,between,use'
p48628
(F1
F0.00014334862385321102
I1
I0
I1
tp48629
sS'sinus,node,function'
p48630
(F1
F0.00014334862385321102
I1
I0
I1
tp48631
sS's-isomer,and,changes'
p48632
(F1
F0.00014334862385321102
I0
I1
I-1
tp48633
sS'l,were,similar'
p48634
(F1
F0.00014334862385321102
I0
I1
I-1
tp48635
sS'not,affect,pharmacokinetics'
p48636
(F1
F0.00014334862385321102
I1
I0
I1
tp48637
sS'phenytoin,phenytoin,causes'
p48638
(F1
F0.00014334862385321102
I1
I0
I1
tp48639
sS'and,prevent,the'
p48640
(F1
F0.00014334862385321102
I0
I1
I-1
tp48641
sS'concentration-time,curve,and'
p48642
(F1
F0.00014334862385321102
I1
I0
I1
tp48643
sS'interval,because,the'
p48644
(F1
F0.00014334862385321102
I1
I0
I1
tp48645
sS'or,other,caution'
p48646
(F1
F0.00028669724770642203
I2
I0
I2
tp48647
sS'study,of,the'
p48648
(F1
F0.00028669724770642203
I0
I2
I-2
tp48649
sS'pi,over,weeks'
p48650
(F1
F0.00014334862385321102
I0
I1
I-1
tp48651
sS'increase,the,plasma'
p48652
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp48653
sS'tilade,has,been'
p48654
(F1
F0.00014334862385321102
I0
I1
I-1
tp48655
sS'when,and,maalox'
p48656
(F1
F0.00014334862385321102
I1
I0
I1
tp48657
sS'anaesthetised,with,fluothane'
p48658
(F1
F0.00014334862385321102
I1
I0
I1
tp48659
sS'given,with,other'
p48660
(F0
F0
I1
I1
I0
tp48661
sS'cyp,enzymes,are'
p48662
(F1
F0.00014334862385321102
I1
I0
I1
tp48663
sS'effects,affecting,the'
p48664
(F1
F0.00057339449541284407
I4
I0
I4
tp48665
sS'or,mg,rat'
p48666
(F1
F0.00014334862385321102
I0
I1
I-1
tp48667
sS'cmi,has,been'
p48668
(F1
F0.00028669724770642203
I2
I0
I2
tp48669
sS'of,treatment,and'
p48670
(F1
F0.00014334862385321102
I0
I1
I-1
tp48671
sS'patients,liver,which'
p48672
(F1
F0.00014334862385321102
I1
I0
I1
tp48673
sS'derivative,is,a'
p48674
(F1
F0.00014334862385321102
I0
I1
I-1
tp48675
sS'half-lives,to,days'
p48676
(F1
F0.00014334862385321102
I0
I1
I-1
tp48677
sS'and,produced,an'
p48678
(F1
F0.00014334862385321102
I0
I1
I-1
tp48679
sS'together,the,signs'
p48680
(F1
F0.00014334862385321102
I1
I0
I1
tp48681
sS'for,days,to'
p48682
(F1
F0.00028669724770642203
I0
I2
I-2
tp48683
sS'products,sharing,that'
p48684
(F1
F0.00014334862385321102
I1
I0
I1
tp48685
sS'prothrombin,time,be'
p48686
(F1
F0.00028669724770642203
I2
I0
I2
tp48687
sS'receiving,therapy,who'
p48688
(F1
F0.00014334862385321102
I1
I0
I1
tp48689
sS'and,abciximab,may'
p48690
(F1
F0.00014334862385321102
I1
I0
I1
tp48691
sS'liver,microsomes,inhibition'
p48692
(F1
F0.00014334862385321102
I1
I0
I1
tp48693
sS'about,when,and'
p48694
(F1
F0.00014334862385321102
I1
I0
I1
tp48695
sS'of,videx,to'
p48696
(F1
F0.00014334862385321102
I1
I0
I1
tp48697
sS'precipitation,procedure,is'
p48698
(F1
F0.00014334862385321102
I0
I1
I-1
tp48699
sS'prothrombin,time,by'
p48700
(F1
F0.00014334862385321102
I0
I1
I-1
tp48701
sS'is,a,serotonin'
p48702
(F1
F0.00014334862385321102
I1
I0
I1
tp48703
sS'in,cerebral,and'
p48704
(F1
F0.00014334862385321102
I1
I0
I1
tp48705
sS'class,is,increased'
p48706
(F1
F0.00014334862385321102
I0
I1
I-1
tp48707
sS'use,of,mefloquine'
p48708
(F1
F0.00014334862385321102
I1
I0
I1
tp48709
sS'effects,of,that'
p48710
(F1
F0.00014334862385321102
I1
I0
I1
tp48711
sS'significant,changes,in'
p48712
(F1
F0.00057339449541284407
I0
I4
I-4
tp48713
sS'effective,while,you'
p48714
(F1
F0.00014334862385321102
I1
I0
I1
tp48715
sS'such,as,impulsivity'
p48716
(F1
F0.00014334862385321102
I0
I1
I-1
tp48717
sS'that,mg,kg'
p48718
(F1
F0.00014334862385321102
I1
I0
I1
tp48719
sS'exert,additive,vasodilator'
p48720
(F1
F0.00014334862385321102
I0
I1
I-1
tp48721
sS'elimination,and,increases'
p48722
(F1
F0.00014334862385321102
I0
I1
I-1
tp48723
sS'therefore,use,of'
p48724
(F1
F0.00014334862385321102
I1
I0
I1
tp48725
sS'about,fold,when'
p48726
(F1
F0.00014334862385321102
I1
I0
I1
tp48727
sS'the,solubility,of'
p48728
(F1
F0.00014334862385321102
I0
I1
I-1
tp48729
sS'sensitive,cyp3a4,substrate'
p48730
(F1
F0.00014334862385321102
I1
I0
I1
tp48731
sS'as,triple,combination'
p48732
(F1
F0.00014334862385321102
I0
I1
I-1
tp48733
sS'prolong,the,serum'
p48734
(F1
F0.00014334862385321102
I1
I0
I1
tp48735
sS'nsaids,and,anti-infectives'
p48736
(F1
F0.00014334862385321102
I0
I1
I-1
tp48737
sS'physiological,doses,of'
p48738
(F1
F0.00014334862385321102
I0
I1
I-1
tp48739
sS'levels,and,area-under'
p48740
(F1
F0.00014334862385321102
I1
I0
I1
tp48741
sS'other,hepatic,enzyme'
p48742
(F1
F0.00014334862385321102
I1
I0
I1
tp48743
sS'racemic,mg,day'
p48744
(F1
F0.00043004587155963305
I0
I3
I-3
tp48745
sS'kg,once,every'
p48746
(F1
F0.00028669724770642203
I0
I2
I-2
tp48747
sS'probable,benefits,outweigh'
p48748
(F1
F0.00014334862385321102
I1
I0
I1
tp48749
sS'may,occasionally,experience'
p48750
(F1
F0.00071674311926605509
I5
I0
I5
tp48751
sS'and,behavioral,responsiveness'
p48752
(F1
F0.00014334862385321102
I1
I0
I1
tp48753
sS'the,marrow,toxicity'
p48754
(F1
F0.00014334862385321102
I0
I1
I-1
tp48755
sS'a,hazard,to'
p48756
(F0
F0
I1
I1
I0
tp48757
sS'interaction,between,a'
p48758
(F1
F0.00014334862385321102
I0
I1
I-1
tp48759
sS'these,categories,result'
p48760
(F1
F0.00014334862385321102
I1
I0
I1
tp48761
sS'metabolized,to,by'
p48762
(F1
F0.00043004587155963305
I0
I3
I-3
tp48763
sS'had,no,substantive'
p48764
(F1
F0.00014334862385321102
I0
I1
I-1
tp48765
sS'when,and,viracept'
p48766
(F1
F0.00014334862385321102
I0
I1
I-1
tp48767
sS'in,blood,levels'
p48768
(F1
F0.00014334862385321102
I1
I0
I1
tp48769
sS'an,and,oral'
p48770
(F1
F0.00014334862385321102
I1
I0
I1
tp48771
sS'to,date,levosimendan'
p48772
(F1
F0.00014334862385321102
I0
I1
I-1
tp48773
sS'of,mg,has'
p48774
(F1
F0.00014334862385321102
I0
I1
I-1
tp48775
sS'such,as,marplan'
p48776
(F1
F0.00028669724770642203
I0
I2
I-2
tp48777
sS'on,should,receive'
p48778
(F1
F0.00014334862385321102
I1
I0
I1
tp48779
sS'as,choline,trilisate'
p48780
(F1
F0.00014334862385321102
I1
I0
I1
tp48781
sS'mg,controlled-release,capsule'
p48782
(F1
F0.00014334862385321102
I1
I0
I1
tp48783
sS'mg,bid,on'
p48784
(F1
F0.00028669724770642203
I0
I2
I-2
tp48785
sS'concentrating,as,effective'
p48786
(F1
F0.00014334862385321102
I0
I1
I-1
tp48787
sS'concentration,that,may'
p48788
(F1
F0.00014334862385321102
I0
I1
I-1
tp48789
sS'an,important,role'
p48790
(F1
F0.00028669724770642203
I2
I0
I2
tp48791
sS'benign,intracranial,hypertension'
p48792
(F1
F0.00014334862385321102
I1
I0
I1
tp48793
sS'dosage,and,permit'
p48794
(F1
F0.00014334862385321102
I0
I1
I-1
tp48795
sS'for,a,interaction'
p48796
(F1
F0.00014334862385321102
I1
I0
I1
tp48797
sS'both,synthetic,and'
p48798
(F1
F0.00043004587155963305
I3
I0
I3
tp48799
sS'clearance,has,not'
p48800
(F1
F0.00014334862385321102
I0
I1
I-1
tp48801
sS'the,duloxetine,clinical'
p48802
(F1
F0.00014334862385321102
I0
I1
I-1
tp48803
sS'in,altering,activity'
p48804
(F1
F0.00014334862385321102
I0
I1
I-1
tp48805
sS'case,reports,of'
p48806
(F0
F0
I1
I1
I0
tp48807
sS'of,these,larger'
p48808
(F1
F0.00014334862385321102
I1
I0
I1
tp48809
sS'of,thereby,decreasing'
p48810
(F1
F0.00014334862385321102
I1
I0
I1
tp48811
sS'as,liver,enzyme'
p48812
(F1
F0.00014334862385321102
I1
I0
I1
tp48813
sS'motion,sickness,medications'
p48814
(F1
F0.00014334862385321102
I0
I1
I-1
tp48815
sS'once,daily,the'
p48816
(F1
F0.00014334862385321102
I1
I0
I1
tp48817
sS'other,potent,parental'
p48818
(F1
F0.00014334862385321102
I1
I0
I1
tp48819
sS'it,has,not'
p48820
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp48821
sS'of,and,viracept'
p48822
(F1
F0.00028669724770642203
I2
I0
I2
tp48823
sS'with,mg,kg'
p48824
(F0
F0
I2
I2
I0
tp48825
sS'five,commonly,used'
p48826
(F1
F0.00014334862385321102
I0
I1
I-1
tp48827
sS'phenothiazines,taking,and'
p48828
(F1
F0.00014334862385321102
I1
I0
I1
tp48829
sS'pharmacokinetic,parameters,of'
p48830
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp48831
sS'based,regimens,for'
p48832
(F1
F0.00014334862385321102
I0
I1
I-1
tp48833
sS'with,or,subsequent'
p48834
(F1
F0.00014334862385321102
I1
I0
I1
tp48835
sS'n,compared,to'
p48836
(F1
F0.00014334862385321102
I1
I0
I1
tp48837
sS'renal,clearance,with'
p48838
(F1
F0.00014334862385321102
I1
I0
I1
tp48839
sS'azole,agents,and'
p48840
(F1
F0.00014334862385321102
I1
I0
I1
tp48841
sS'rifabutin,another,is'
p48842
(F1
F0.00014334862385321102
I0
I1
I-1
tp48843
sS'the,enhancement,of'
p48844
(F0
F0
I1
I1
I0
tp48845
sS'male,subjects,ages'
p48846
(F1
F0.00014334862385321102
I1
I0
I1
tp48847
sS'occurrence,of,severe'
p48848
(F1
F0.00014334862385321102
I0
I1
I-1
tp48849
sS'day,and,aprepitant'
p48850
(F1
F0.00014334862385321102
I1
I0
I1
tp48851
sS'other,nsaid,while'
p48852
(F1
F0.00014334862385321102
I1
I0
I1
tp48853
sS'likely,by,inhibition'
p48854
(F1
F0.00014334862385321102
I1
I0
I1
tp48855
sS'daily,under,steady-state'
p48856
(F1
F0.00014334862385321102
I0
I1
I-1
tp48857
sS'remedies,and,vasoconstrictive'
p48858
(F1
F0.00014334862385321102
I1
I0
I1
tp48859
sS'administered,at,a'
p48860
(F0
F0
I1
I1
I0
tp48861
sS'or,fatal,adverse'
p48862
(F1
F0.00014334862385321102
I0
I1
I-1
tp48863
sS'maintaining,a,given'
p48864
(F1
F0.00014334862385321102
I0
I1
I-1
tp48865
sS'delayed,for,several'
p48866
(F1
F0.00014334862385321102
I1
I0
I1
tp48867
sS'serious,symptoms,i'
p48868
(F1
F0.00014334862385321102
I1
I0
I1
tp48869
sS'interactions,when,and'
p48870
(F0
F0
I1
I1
I0
tp48871
sS'dose,and,plasma'
p48872
(F1
F0.00014334862385321102
I1
I0
I1
tp48873
sS'number,of,reports'
p48874
(F1
F0.00014334862385321102
I1
I0
I1
tp48875
sS'vivo,studies,to'
p48876
(F1
F0.00014334862385321102
I0
I1
I-1
tp48877
sS'in,the,clearance'
p48878
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp48879
sS'increase,resulting,in'
p48880
(F1
F0.00014334862385321102
I1
I0
I1
tp48881
sS'eight,hiv-infected,individuals'
p48882
(F1
F0.00014334862385321102
I0
I1
I-1
tp48883
sS'since,bacteriostatic,such'
p48884
(F1
F0.00014334862385321102
I1
I0
I1
tp48885
sS'of,exposure,were'
p48886
(F1
F0.00014334862385321102
I0
I1
I-1
tp48887
sS'pharmacokinetics,if,the'
p48888
(F1
F0.00014334862385321102
I0
I1
I-1
tp48889
sS'antidiabetic,agents,disturbances'
p48890
(F1
F0.00014334862385321102
I1
I0
I1
tp48891
sS'increase,plasma,concentrations'
p48892
(F0
F0
I2
I2
I0
tp48893
sS'high,concentrations,it'
p48894
(F1
F0.00014334862385321102
I0
I1
I-1
tp48895
sS'with,oral,the'
p48896
(F1
F0.00014334862385321102
I1
I0
I1
tp48897
sS'volunteers,receiving,the'
p48898
(F1
F0.00014334862385321102
I1
I0
I1
tp48899
sS'nsaids,and,may'
p48900
(F1
F0.00014334862385321102
I1
I0
I1
tp48901
sS'inhibitors,and,concomitantly'
p48902
(F1
F0.00014334862385321102
I1
I0
I1
tp48903
sS'clidinium,may,decrease'
p48904
(F1
F0.00014334862385321102
I1
I0
I1
tp48905
sS'significant,interaction,between'
p48906
(F0
F0
I1
I1
I0
tp48907
sS'taken,as,directed'
p48908
(F1
F0.00014334862385321102
I0
I1
I-1
tp48909
sS'who,have,received'
p48910
(F1
F0.00028669724770642203
I2
I0
I2
tp48911
sS'another,drug,known'
p48912
(F1
F0.00014334862385321102
I0
I1
I-1
tp48913
sS'patients,receiving,low'
p48914
(F1
F0.00014334862385321102
I0
I1
I-1
tp48915
sS'and,and,increase'
p48916
(F1
F0.00028669724770642203
I2
I0
I2
tp48917
sS'of,certain,compounds'
p48918
(F1
F0.00014334862385321102
I1
I0
I1
tp48919
sS'mg,enteric,coated'
p48920
(F1
F0.00014334862385321102
I0
I1
I-1
tp48921
sS'minutes,before,any'
p48922
(F1
F0.00014334862385321102
I1
I0
I1
tp48923
sS'such,as,nonsteroidal'
p48924
(F1
F0.00014334862385321102
I1
I0
I1
tp48925
sS'to,its,nephrotoxicity'
p48926
(F1
F0.00014334862385321102
I1
I0
I1
tp48927
sS'not,established,a'
p48928
(F1
F0.00014334862385321102
I1
I0
I1
tp48929
sS'trileptal,greater,than'
p48930
(F1
F0.00014334862385321102
I1
I0
I1
tp48931
sS'use,of,parenterally'
p48932
(F1
F0.00014334862385321102
I1
I0
I1
tp48933
sS'not,different,and'
p48934
(F1
F0.00014334862385321102
I0
I1
I-1
tp48935
sS'changes,to,be'
p48936
(F1
F0.00014334862385321102
I1
I0
I1
tp48937
sS'phenobarbital,primidone,population'
p48938
(F1
F0.00014334862385321102
I1
I0
I1
tp48939
sS'amplifies,the,therapeutic'
p48940
(F1
F0.00014334862385321102
I1
I0
I1
tp48941
sS'proportion,to,the'
p48942
(F1
F0.00014334862385321102
I0
I1
I-1
tp48943
sS'administered,iron-fortified,infant'
p48944
(F1
F0.00014334862385321102
I0
I1
I-1
tp48945
sS'a,study,with'
p48946
(F1
F0.00014334862385321102
I0
I1
I-1
tp48947
sS'or,by,a'
p48948
(F1
F0.00014334862385321102
I0
I1
I-1
tp48949
sS'a,marked,effect'
p48950
(F1
F0.00014334862385321102
I1
I0
I1
tp48951
sS'that,the,administration'
p48952
(F1
F0.00014334862385321102
I1
I0
I1
tp48953
sS'however,reports,suggest'
p48954
(F1
F0.00014334862385321102
I1
I0
I1
tp48955
sS'began,within,minutes'
p48956
(F1
F0.00014334862385321102
I0
I1
I-1
tp48957
sS'mg,neurontin,and'
p48958
(F1
F0.00014334862385321102
I0
I1
I-1
tp48959
sS'wort,may,increase'
p48960
(F1
F0.00014334862385321102
I0
I1
I-1
tp48961
sS'of,which,also'
p48962
(F1
F0.00014334862385321102
I0
I1
I-1
tp48963
sS'approximate,increase,in'
p48964
(F1
F0.00057339449541284407
I4
I0
I4
tp48965
sS'the,sensitivity,of'
p48966
(F1
F0.00014334862385321102
I0
I1
I-1
tp48967
sS'protective,effect,of'
p48968
(F1
F0.00014334862385321102
I1
I0
I1
tp48969
sS'cyp,a4,by'
p48970
(F1
F0.00014334862385321102
I0
I1
I-1
tp48971
sS'videx,to,two'
p48972
(F1
F0.00014334862385321102
I1
I0
I1
tp48973
sS'increase,metabolism,and'
p48974
(F1
F0.00014334862385321102
I0
I1
I-1
tp48975
sS'not,in,and'
p48976
(F1
F0.00014334862385321102
I1
I0
I1
tp48977
sS'sodium,is,given'
p48978
(F1
F0.00028669724770642203
I2
I0
I2
tp48979
sS'acetazolamide,and,sodium'
p48980
(F1
F0.00014334862385321102
I1
I0
I1
tp48981
sS'agents,may,have'
p48982
(F1
F0.00014334862385321102
I1
I0
I1
tp48983
sS'in,whom,therapy'
p48984
(F1
F0.00071674311926605509
I5
I0
I5
tp48985
sS'before,any,oral'
p48986
(F1
F0.00014334862385321102
I1
I0
I1
tp48987
sS'were,grouped,as'
p48988
(F1
F0.00014334862385321102
I0
I1
I-1
tp48989
sS'drugs,the,administration'
p48990
(F1
F0.00014334862385321102
I1
I0
I1
tp48991
sS'of,renal,clearance'
p48992
(F1
F0.00028669724770642203
I0
I2
I-2
tp48993
sS'the,plasma,concentration-time'
p48994
(F0
F0
I1
I1
I0
tp48995
sS'be,avoided,except'
p48996
(F1
F0.00014334862385321102
I1
I0
I1
tp48997
sS'tolerated,in,patients'
p48998
(F1
F0.00028669724770642203
I0
I2
I-2
tp48999
sS'in,fi,or'
p49000
(F1
F0.00014334862385321102
I1
I0
I1
tp49001
sS'are,obtained,should'
p49002
(F1
F0.00014334862385321102
I1
I0
I1
tp49003
sS'by,displacing,the'
p49004
(F1
F0.00014334862385321102
I1
I0
I1
tp49005
sS'concentrations,of,active'
p49006
(F1
F0.00014334862385321102
I1
I0
I1
tp49007
sS'from,nerves,and'
p49008
(F1
F0.00014334862385321102
I0
I1
I-1
tp49009
sS'inhibited,by,concomitant'
p49010
(F1
F0.00014334862385321102
I1
I0
I1
tp49011
sS'days,to,healthy'
p49012
(F1
F0.00014334862385321102
I0
I1
I-1
tp49013
sS'sparine,phenergan,mellaril'
p49014
(F1
F0.00014334862385321102
I0
I1
I-1
tp49015
sS'other,than,with'
p49016
(F1
F0.00014334862385321102
I0
I1
I-1
tp49017
sS'containing,microgram,ml'
p49018
(F1
F0.00014334862385321102
I0
I1
I-1
tp49019
sS'affect,either,the'
p49020
(F1
F0.00014334862385321102
I0
I1
I-1
tp49021
sS'low-dose,combination,oral'
p49022
(F1
F0.00014334862385321102
I0
I1
I-1
tp49023
sS'and,has,been'
p49024
(F0.63636363636363635
F0.0010034403669724771
I9
I2
I7
tp49025
sS'transit,time,by'
p49026
(F1
F0.00014334862385321102
I1
I0
I1
tp49027
sS'the,interactions,observed'
p49028
(F1
F0.00014334862385321102
I1
I0
I1
tp49029
sS'clearance,of,r-warfarin'
p49030
(F1
F0.00014334862385321102
I1
I0
I1
tp49031
sS'used,during,muscle'
p49032
(F1
F0.00014334862385321102
I0
I1
I-1
tp49033
sS'greater,than,one-tenth'
p49034
(F1
F0.00014334862385321102
I1
I0
I1
tp49035
sS'including,tricor,there'
p49036
(F1
F0.00014334862385321102
I1
I0
I1
tp49037
sS'acetate,because,of'
p49038
(F1
F0.00014334862385321102
I1
I0
I1
tp49039
sS'to,its,inhibitory'
p49040
(F1
F0.00014334862385321102
I1
I0
I1
tp49041
sS'mice,treated,with'
p49042
(F1
F0.00014334862385321102
I0
I1
I-1
tp49043
sS'potentiates,the,reduction'
p49044
(F1
F0.00014334862385321102
I1
I0
I1
tp49045
sS'in,a,rapid'
p49046
(F1
F0.00014334862385321102
I1
I0
I1
tp49047
sS'inhibitors,and,the'
p49048
(F1
F0.00014334862385321102
I1
I0
I1
tp49049
sS'precipitation,of,oxypurines'
p49050
(F1
F0.00014334862385321102
I0
I1
I-1
tp49051
sS'cyp3a4,inducer,a'
p49052
(F1
F0.00014334862385321102
I0
I1
I-1
tp49053
sS'as,can,also'
p49054
(F1
F0.00014334862385321102
I1
I0
I1
tp49055
sS'was,the,ld50'
p49056
(F1
F0.00014334862385321102
I1
I0
I1
tp49057
sS'blocking,agents,such'
p49058
(F0
F0
I1
I1
I0
tp49059
sS'also,being,given'
p49060
(F1
F0.00014334862385321102
I1
I0
I1
tp49061
sS'no,information,regarding'
p49062
(F1
F0.00014334862385321102
I0
I1
I-1
tp49063
sS'not,necessitate,an'
p49064
(F1
F0.00014334862385321102
I0
I1
I-1
tp49065
sS'of,a,cyp2d6'
p49066
(F1
F0.00014334862385321102
I1
I0
I1
tp49067
sS'and,other,substances'
p49068
(F1
F0.00014334862385321102
I1
I0
I1
tp49069
sS'in,water,from'
p49070
(F1
F0.00014334862385321102
I0
I1
I-1
tp49071
sS'levsin,is,administered'
p49072
(F1
F0.00014334862385321102
I1
I0
I1
tp49073
sS'time,be,monitored'
p49074
(F1
F0.00014334862385321102
I1
I0
I1
tp49075
sS'and,are,all'
p49076
(F1
F0.00028669724770642203
I2
I0
I2
tp49077
sS'sixty,minutes,following'
p49078
(F1
F0.00014334862385321102
I1
I0
I1
tp49079
sS'kg,was,investigated'
p49080
(F1
F0.00014334862385321102
I0
I1
I-1
tp49081
sS'serum,by,a'
p49082
(F1
F0.00014334862385321102
I1
I0
I1
tp49083
sS'photic,stimulation,study'
p49084
(F1
F0.00014334862385321102
I0
I1
I-1
tp49085
sS'a,thin-layer,chromatographic'
p49086
(F1
F0.00014334862385321102
I0
I1
I-1
tp49087
sS'altered,distribution,in'
p49088
(F1
F0.00014334862385321102
I1
I0
I1
tp49089
sS'at,as,v'
p49090
(F1
F0.00014334862385321102
I0
I1
I-1
tp49091
sS'to,approximately,to'
p49092
(F1
F0.00014334862385321102
I1
I0
I1
tp49093
sS'to,plasma,protein'
p49094
(F1
F0.00014334862385321102
I0
I1
I-1
tp49095
sS'account,bezalip,and'
p49096
(F1
F0.00014334862385321102
I1
I0
I1
tp49097
sS'within,two,to'
p49098
(F1
F0.00014334862385321102
I1
I0
I1
tp49099
sS'into,account,bezalip'
p49100
(F1
F0.00014334862385321102
I1
I0
I1
tp49101
sS'cyp3a,compounds,that'
p49102
(F1
F0.00014334862385321102
I1
I0
I1
tp49103
sS'can,also,be'
p49104
(F1
F0.00014334862385321102
I1
I0
I1
tp49105
sS'cisplatin,hcl,phenytoin'
p49106
(F1
F0.00014334862385321102
I1
I0
I1
tp49107
sS'in,the,contents'
p49108
(F1
F0.00014334862385321102
I0
I1
I-1
tp49109
sS'prolong,the,clinically'
p49110
(F1
F0.00014334862385321102
I1
I0
I1
tp49111
sS'and,short-acting,has'
p49112
(F1
F0.00014334862385321102
I0
I1
I-1
tp49113
sS'sodium,is,not'
p49114
(F1
F0.00014334862385321102
I0
I1
I-1
tp49115
sS'buffer,should,be'
p49116
(F1
F0.00014334862385321102
I1
I0
I1
tp49117
sS'serum,concentration,during'
p49118
(F1
F0.00014334862385321102
I1
I0
I1
tp49119
sS'administration,of,with'
p49120
(F0.59999999999999998
F0.0025802752293577983
I24
I6
I18
tp49121
sS'over,to,determine'
p49122
(F1
F0.00014334862385321102
I0
I1
I-1
tp49123
sS'ergotamine,or,acute'
p49124
(F1
F0.00014334862385321102
I0
I1
I-1
tp49125
sS'multiple,dose,administration'
p49126
(F1
F0.00014334862385321102
I0
I1
I-1
tp49127
sS'this,represents,an'
p49128
(F1
F0.00014334862385321102
I0
I1
I-1
tp49129
sS'agents,derivatives,hormones'
p49130
(F1
F0.00028669724770642203
I0
I2
I-2
tp49131
sS'with,were,performed'
p49132
(F1
F0.00014334862385321102
I0
I1
I-1
tp49133
sS'increase,due,to'
p49134
(F1
F0.00014334862385321102
I1
I0
I1
tp49135
sS'additive,coadministration,of'
p49136
(F1
F0.00014334862385321102
I1
I0
I1
tp49137
sS'that,when,a'
p49138
(F1
F0.00014334862385321102
I1
I0
I1
tp49139
sS'most,like,due'
p49140
(F1
F0.00014334862385321102
I1
I0
I1
tp49141
sS'may,effect,the'
p49142
(F1
F0.00014334862385321102
I1
I0
I1
tp49143
sS'previously,stable,plasma'
p49144
(F1
F0.00028669724770642203
I2
I0
I2
tp49145
sS'therefore,advisable,to'
p49146
(F1
F0.00014334862385321102
I1
I0
I1
tp49147
sS'because,prostaglandins,play'
p49148
(F1
F0.00014334862385321102
I1
I0
I1
tp49149
sS'up,to,doses'
p49150
(F1
F0.00014334862385321102
I0
I1
I-1
tp49151
sS'present,in,plasma'
p49152
(F1
F0.00014334862385321102
I0
I1
I-1
tp49153
sS'meq,or,duloxetine'
p49154
(F1
F0.00014334862385321102
I0
I1
I-1
tp49155
sS'use,however,pharmacokinetic'
p49156
(F1
F0.00014334862385321102
I0
I1
I-1
tp49157
sS'than,myopathy,and'
p49158
(F1
F0.00014334862385321102
I0
I1
I-1
tp49159
sS'serum,and,with'
p49160
(F1
F0.00014334862385321102
I0
I1
I-1
tp49161
sS'by,the,ability'
p49162
(F1
F0.00014334862385321102
I1
I0
I1
tp49163
sS'of,uricosuric,agents'
p49164
(F1
F0.00014334862385321102
I1
I0
I1
tp49165
sS'patients,mixed,agonist'
p49166
(F1
F0.00014334862385321102
I0
I1
I-1
tp49167
sS'exaggerate,the,prolongation'
p49168
(F1
F0.00014334862385321102
I1
I0
I1
tp49169
sS'be,watched,very'
p49170
(F1
F0.00014334862385321102
I1
I0
I1
tp49171
sS'substrates,of,cyp3a4'
p49172
(F1
F0.00014334862385321102
I0
I1
I-1
tp49173
sS'when,alfenta,is'
p49174
(F1
F0.00014334862385321102
I1
I0
I1
tp49175
sS'patients,receiving,oral'
p49176
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp49177
sS'specific,studies,have'
p49178
(F0
F0
I1
I1
I0
tp49179
sS'of,interaction,with'
p49180
(F1
F0.00014334862385321102
I0
I1
I-1
tp49181
sS'once,every,hours'
p49182
(F1
F0.00028669724770642203
I0
I2
I-2
tp49183
sS'in,either,diabetics'
p49184
(F1
F0.00014334862385321102
I0
I1
I-1
tp49185
sS'the,coadministration,with'
p49186
(F1
F0.00014334862385321102
I1
I0
I1
tp49187
sS'were,already,receiving'
p49188
(F1
F0.00014334862385321102
I0
I1
I-1
tp49189
sS'with,tikosyn,and'
p49190
(F1
F0.00014334862385321102
I0
I1
I-1
tp49191
sS'on,day,of'
p49192
(F1
F0.00014334862385321102
I1
I0
I1
tp49193
sS'risk,for,death'
p49194
(F1
F0.00014334862385321102
I0
I1
I-1
tp49195
sS'the,muscle,to'
p49196
(F1
F0.00014334862385321102
I1
I0
I1
tp49197
sS'on,day,on'
p49198
(F0
F0
I1
I1
I0
tp49199
sS'and,the,two'
p49200
(F1
F0.00014334862385321102
I0
I1
I-1
tp49201
sS'of,relapse,rehospitalisation'
p49202
(F1
F0.00014334862385321102
I0
I1
I-1
tp49203
sS'is,only,slightly'
p49204
(F1
F0.00014334862385321102
I1
I0
I1
tp49205
sS'such,as,inderal'
p49206
(F1
F0.00014334862385321102
I0
I1
I-1
tp49207
sS'long-acting,is,completely'
p49208
(F1
F0.00014334862385321102
I0
I1
I-1
tp49209
sS'considering,that,the'
p49210
(F1
F0.00014334862385321102
I0
I1
I-1
tp49211
sS'tricyclic,flupenthixol,increases'
p49212
(F1
F0.00014334862385321102
I1
I0
I1
tp49213
sS'locomotion,and,behavioral'
p49214
(F1
F0.00014334862385321102
I0
I1
I-1
tp49215
sS'be,used,because'
p49216
(F1
F0.00014334862385321102
I1
I0
I1
tp49217
sS'trials,were,administered'
p49218
(F1
F0.00014334862385321102
I0
I1
I-1
tp49219
sS'of,absorption,mean'
p49220
(F1
F0.00014334862385321102
I1
I0
I1
tp49221
sS'bilirubin,urobilin,due'
p49222
(F1
F0.00014334862385321102
I0
I1
I-1
tp49223
sS'of,novolog,but'
p49224
(F1
F0.00014334862385321102
I0
I1
I-1
tp49225
sS'but,coadministration,of'
p49226
(F1
F0.00014334862385321102
I0
I1
I-1
tp49227
sS'and,decrease,absorption'
p49228
(F1
F0.00014334862385321102
I1
I0
I1
tp49229
sS'is,not,generally'
p49230
(F1
F0.00028669724770642203
I2
I0
I2
tp49231
sS'observed,with,dual'
p49232
(F1
F0.00014334862385321102
I0
I1
I-1
tp49233
sS'inotropic,such,as'
p49234
(F1
F0.00014334862385321102
I1
I0
I1
tp49235
sS'administration,reaching,a'
p49236
(F1
F0.00014334862385321102
I0
I1
I-1
tp49237
sS'principal,given,number'
p49238
(F1
F0.00014334862385321102
I0
I1
I-1
tp49239
sS'n,hypotension,vs'
p49240
(F1
F0.00014334862385321102
I1
I0
I1
tp49241
sS'the,neuromuscular,blockade'
p49242
(F1
F0.00028669724770642203
I2
I0
I2
tp49243
sS'was,also,chronically'
p49244
(F1
F0.00014334862385321102
I0
I1
I-1
tp49245
sS'of,targretin,capsules'
p49246
(F1
F0.00014334862385321102
I1
I0
I1
tp49247
sS'hormonal,components,ee'
p49248
(F1
F0.00014334862385321102
I1
I0
I1
tp49249
sS'resulting,in,excessive'
p49250
(F1
F0.00014334862385321102
I1
I0
I1
tp49251
sS'reactions,from,the'
p49252
(F1
F0.00014334862385321102
I0
I1
I-1
tp49253
sS'increased,mean,maximum'
p49254
(F1
F0.00014334862385321102
I1
I0
I1
tp49255
sS'dihydropyridine,channel,blockers'
p49256
(F1
F0.00014334862385321102
I1
I0
I1
tp49257
sS'this,reason,the'
p49258
(F0
F0
I1
I1
I0
tp49259
sS'with,orencia,has'
p49260
(F1
F0.00014334862385321102
I1
I0
I1
tp49261
sS'with,addictive,medications'
p49262
(F1
F0.00014334862385321102
I0
I1
I-1
tp49263
sS'minus,in,ovarian'
p49264
(F1
F0.00014334862385321102
I1
I0
I1
tp49265
sS'of,and,treatment'
p49266
(F1
F0.00014334862385321102
I0
I1
I-1
tp49267
sS'exercised,when,is'
p49268
(F1
F0.00014334862385321102
I1
I0
I1
tp49269
sS'and,had,an'
p49270
(F1
F0.00014334862385321102
I0
I1
I-1
tp49271
sS'anticholinergics,antagonize,the'
p49272
(F1
F0.00014334862385321102
I0
I1
I-1
tp49273
sS'aminoglutethimide,diminishes,the'
p49274
(F1
F0.00014334862385321102
I1
I0
I1
tp49275
sS'serum,clearance,and'
p49276
(F1
F0.00014334862385321102
I1
I0
I1
tp49277
sS'consuming,while,on'
p49278
(F1
F0.00014334862385321102
I1
I0
I1
tp49279
sS'by,hepatic,oxidation'
p49280
(F1
F0.00014334862385321102
I1
I0
I1
tp49281
sS'apoptosis,in,breast'
p49282
(F1
F0.00014334862385321102
I0
I1
I-1
tp49283
sS'by,a,day'
p49284
(F1
F0.00014334862385321102
I0
I1
I-1
tp49285
sS'for,documented,hypokalemia'
p49286
(F1
F0.00014334862385321102
I0
I1
I-1
tp49287
sS'lowest,possible,dose'
p49288
(F1
F0.00014334862385321102
I1
I0
I1
tp49289
sS'shifts,in,treatment'
p49290
(F1
F0.00014334862385321102
I0
I1
I-1
tp49291
sS'effects,seen,during'
p49292
(F1
F0.00014334862385321102
I1
I0
I1
tp49293
sS'action,which,may'
p49294
(F1
F0.00014334862385321102
I0
I1
I-1
tp49295
sS'appeared,to,be'
p49296
(F0
F0
I1
I1
I0
tp49297
sS'whereas,b,was'
p49298
(F1
F0.00014334862385321102
I0
I1
I-1
tp49299
sS'demonstrated,similar,efficacy'
p49300
(F1
F0.00014334862385321102
I0
I1
I-1
tp49301
sS'c,max,of'
p49302
(F1
F0.00014334862385321102
I1
I0
I1
tp49303
sS'and,many,that'
p49304
(F1
F0.00071674311926605509
I0
I5
I-5
tp49305
sS'interval,of,at'
p49306
(F1
F0.00014334862385321102
I1
I0
I1
tp49307
sS'agent,has,been'
p49308
(F1
F0.00028669724770642203
I2
I0
I2
tp49309
sS'c,max,or'
p49310
(F1
F0.00028669724770642203
I0
I2
I-2
tp49311
sS'taking,low-dose,mg'
p49312
(F1
F0.00014334862385321102
I0
I1
I-1
tp49313
sS'reported,that,can'
p49314
(F1
F0.00014334862385321102
I1
I0
I1
tp49315
sS'since,the,absorption'
p49316
(F1
F0.00014334862385321102
I1
I0
I1
tp49317
sS'these,doses,is'
p49318
(F1
F0.00014334862385321102
I1
I0
I1
tp49319
sS'therefore,advised,when'
p49320
(F1
F0.00014334862385321102
I1
I0
I1
tp49321
sS'commonly,occurring,interactions'
p49322
(F1
F0.00014334862385321102
I1
I0
I1
tp49323
sS'this,class,of'
p49324
(F1
F0.00014334862385321102
I0
I1
I-1
tp49325
sS'rats,with,mg'
p49326
(F1
F0.00014334862385321102
I1
I0
I1
tp49327
sS'normal,healthy,volunteers'
p49328
(F1
F0.00028669724770642203
I0
I2
I-2
tp49329
sS'as,effective,as'
p49330
(F1
F0.00014334862385321102
I0
I1
I-1
tp49331
sS'and,hydroxy-1,on'
p49332
(F1
F0.00014334862385321102
I1
I0
I1
tp49333
sS'through,effects,on'
p49334
(F1
F0.00014334862385321102
I1
I0
I1
tp49335
sS'the,literature,provides'
p49336
(F1
F0.00014334862385321102
I0
I1
I-1
tp49337
sS'increased,by,and'
p49338
(F1
F0.00043004587155963305
I3
I0
I3
tp49339
sS'there,were,no'
p49340
(F0.83333333333333337
F0.0014334862385321102
I1
I11
I-10
tp49341
sS'disturbances,of,blood'
p49342
(F1
F0.00014334862385321102
I1
I0
I1
tp49343
sS'studied,as,triple'
p49344
(F1
F0.00014334862385321102
I0
I1
I-1
tp49345
sS'of,the,small'
p49346
(F1
F0.00014334862385321102
I1
I0
I1
tp49347
sS'secretion,p-aminosalicylic,acid'
p49348
(F1
F0.00014334862385321102
I0
I1
I-1
tp49349
sS'where,definitely,indicated'
p49350
(F1
F0.00014334862385321102
I1
I0
I1
tp49351
sS'by,increasing,the'
p49352
(F0
F0
I1
I1
I0
tp49353
sS'and,may,explain'
p49354
(F1
F0.00014334862385321102
I0
I1
I-1
tp49355
sS'the,growth,of'
p49356
(F1
F0.00028669724770642203
I0
I2
I-2
tp49357
sS'its,antidiuretic,activity'
p49358
(F1
F0.00014334862385321102
I0
I1
I-1
tp49359
sS'for,a,second'
p49360
(F1
F0.00014334862385321102
I0
I1
I-1
tp49361
sS'many,that,are'
p49362
(F1
F0.00071674311926605509
I0
I5
I-5
tp49363
sS'the,mean,concentrations'
p49364
(F1
F0.00014334862385321102
I0
I1
I-1
tp49365
sS'were,found,to'
p49366
(F1
F0.00014334862385321102
I0
I1
I-1
tp49367
sS'l-phenylalanine,may,potentiate'
p49368
(F1
F0.00014334862385321102
I1
I0
I1
tp49369
sS'disease,aged,years'
p49370
(F1
F0.00014334862385321102
I0
I1
I-1
tp49371
sS'recovered,from,succinylcholine-induced'
p49372
(F1
F0.00014334862385321102
I1
I0
I1
tp49373
sS'synthesis,and,may'
p49374
(F1
F0.00014334862385321102
I1
I0
I1
tp49375
sS'of,angiomax,with'
p49376
(F1
F0.00014334862385321102
I1
I0
I1
tp49377
sS'be,the,only'
p49378
(F1
F0.00014334862385321102
I1
I0
I1
tp49379
sS'over,the,course'
p49380
(F1
F0.00014334862385321102
I0
I1
I-1
tp49381
sS'tests,interactions,because'
p49382
(F1
F0.00014334862385321102
I0
I1
I-1
tp49383
sS'taking,other,psychoactive'
p49384
(F1
F0.00014334862385321102
I1
I0
I1
tp49385
sS'observed,with,regimens'
p49386
(F1
F0.00014334862385321102
I0
I1
I-1
tp49387
sS'receiving,combination,regimens'
p49388
(F1
F0.00014334862385321102
I1
I0
I1
tp49389
sS'ethinyl,estradiol,should'
p49390
(F1
F0.00014334862385321102
I1
I0
I1
tp49391
sS'of,itraconazole,and'
p49392
(F1
F0.00028669724770642203
I2
I0
I2
tp49393
sS'of,by,and'
p49394
(F1
F0.00014334862385321102
I1
I0
I1
tp49395
sS'of,that,necessitated'
p49396
(F1
F0.00014334862385321102
I1
I0
I1
tp49397
sS'on,the,steady-state'
p49398
(F1
F0.0008600917431192661
I0
I6
I-6
tp49399
sS'overdose,especially,cyclic'
p49400
(F1
F0.00014334862385321102
I1
I0
I1
tp49401
sS'i,coadministration,of'
p49402
(F1
F0.00014334862385321102
I1
I0
I1
tp49403
sS'apoptotic,index,or'
p49404
(F1
F0.00014334862385321102
I0
I1
I-1
tp49405
sS'one,class,to'
p49406
(F1
F0.00057339449541284407
I4
I0
I4
tp49407
sS'drugs,that,induce'
p49408
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp49409
sS'response,to,in'
p49410
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp49411
sS'effect,on,a'
p49412
(F1
F0.00014334862385321102
I0
I1
I-1
tp49413
sS'they,should,be'
p49414
(F1
F0.00028669724770642203
I2
I0
I2
tp49415
sS'is,expected,to'
p49416
(F1
F0.00014334862385321102
I1
I0
I1
tp49417
sS'of,breast,cancer'
p49418
(F0
F0
I1
I1
I0
tp49419
sS'the,first,day'
p49420
(F1
F0.00014334862385321102
I0
I1
I-1
tp49421
sS'digoxin,sonata,mg'
p49422
(F1
F0.00014334862385321102
I0
I1
I-1
tp49423
sS'coadministration,of,mg'
p49424
(F0.20000000000000001
F0.00043004587155963305
I9
I6
I3
tp49425
sS'system,at,a'
p49426
(F1
F0.00014334862385321102
I1
I0
I1
tp49427
sS'elevations,with,evidence'
p49428
(F1
F0.00014334862385321102
I0
I1
I-1
tp49429
sS'use,of,other'
p49430
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp49431
sS'sulfate,sodium,polystyrene'
p49432
(F1
F0.00014334862385321102
I1
I0
I1
tp49433
sS'low-dose,plus,were'
p49434
(F1
F0.00014334862385321102
I0
I1
I-1
tp49435
sS'week,intraperitoneal,injections'
p49436
(F1
F0.00014334862385321102
I0
I1
I-1
tp49437
sS'including,may,enhance'
p49438
(F1
F0.00028669724770642203
I2
I0
I2
tp49439
sS'administration,of,exjade'
p49440
(F1
F0.00028669724770642203
I0
I2
I-2
tp49441
sS'of,sodium,perchlorate'
p49442
(F1
F0.00014334862385321102
I0
I1
I-1
tp49443
sS'potentiate,the,action'
p49444
(F1
F0.00028669724770642203
I2
I0
I2
tp49445
sS'l-arginine,may,counteract'
p49446
(F1
F0.00014334862385321102
I1
I0
I1
tp49447
sS'metabolic,clearance,that'
p49448
(F1
F0.00014334862385321102
I1
I0
I1
tp49449
sS'increase,in,adverse'
p49450
(F1
F0.00028669724770642203
I0
I2
I-2
tp49451
sS'or,reduce,the'
p49452
(F1
F0.00014334862385321102
I1
I0
I1
tp49453
sS'day,relative,to'
p49454
(F1
F0.00014334862385321102
I1
I0
I1
tp49455
sS'sinus,bradycardia,has'
p49456
(F1
F0.00014334862385321102
I0
I1
I-1
tp49457
sS'regularly,during,simultaneous'
p49458
(F1
F0.00014334862385321102
I0
I1
I-1
tp49459
sS'however,in,a'
p49460
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp49461
sS'initiate,therapy,with'
p49462
(F1
F0.00014334862385321102
I1
I0
I1
tp49463
sS'hydrocarbon,general,such'
p49464
(F1
F0.00014334862385321102
I1
I0
I1
tp49465
sS'a4,substrate,and'
p49466
(F1
F0.00014334862385321102
I0
I1
I-1
tp49467
sS'orasone,others,medrol'
p49468
(F1
F0.00014334862385321102
I0
I1
I-1
tp49469
sS'the,in,situ'
p49470
(F1
F0.00014334862385321102
I0
I1
I-1
tp49471
sS'in,an,approximately'
p49472
(F1
F0.00014334862385321102
I1
I0
I1
tp49473
sS'as,most,excretion'
p49474
(F1
F0.00014334862385321102
I0
I1
I-1
tp49475
sS'be,taken,when'
p49476
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp49477
sS'oral,dose,for'
p49478
(F1
F0.00014334862385321102
I0
I1
I-1
tp49479
sS'decreasing,gut,motility'
p49480
(F1
F0.00014334862385321102
I1
I0
I1
tp49481
sS'interference,with,propranolols'
p49482
(F1
F0.00014334862385321102
I1
I0
I1
tp49483
sS'concomitant,use,with'
p49484
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp49485
sS'the,salt,intake'
p49486
(F1
F0.00057339449541284407
I4
I0
I4
tp49487
sS'of,possible,clinical'
p49488
(F1
F0.00014334862385321102
I1
I0
I1
tp49489
sS'potentially,toxic,to'
p49490
(F1
F0.00014334862385321102
I0
I1
I-1
tp49491
sS'with,and,antagonists'
p49492
(F1
F0.00014334862385321102
I1
I0
I1
tp49493
sS'cream,and,other'
p49494
(F1
F0.00014334862385321102
I0
I1
I-1
tp49495
sS'and,bretylium,tosylate'
p49496
(F1
F0.00014334862385321102
I0
I1
I-1
tp49497
sS'and,concurrent,use'
p49498
(F1
F0.00028669724770642203
I2
I0
I2
tp49499
sS'blood,pressure,may'
p49500
(F1
F0.00014334862385321102
I1
I0
I1
tp49501
sS'the,regimen,of'
p49502
(F0
F0
I1
I1
I0
tp49503
sS'regimens,who,were'
p49504
(F1
F0.00014334862385321102
I1
I0
I1
tp49505
sS'may,be,required'
p49506
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp49507
sS'to,blunt,the'
p49508
(F1
F0.00028669724770642203
I2
I0
I2
tp49509
sS'by,several,medicinal'
p49510
(F1
F0.00014334862385321102
I1
I0
I1
tp49511
sS'of,aggression,and'
p49512
(F1
F0.00014334862385321102
I0
I1
I-1
tp49513
sS'administration,of,alone'
p49514
(F0
F0
I1
I1
I0
tp49515
sS'sensitize,resistant,strains'
p49516
(F1
F0.00014334862385321102
I0
I1
I-1
tp49517
sS'including,medications,such'
p49518
(F1
F0.00014334862385321102
I1
I0
I1
tp49519
sS'before,resulted,in'
p49520
(F1
F0.00014334862385321102
I1
I0
I1
tp49521
sS'with,potent,cyp3a4'
p49522
(F1
F0.00014334862385321102
I1
I0
I1
tp49523
sS'iv,im,reduced'
p49524
(F1
F0.00014334862385321102
I1
I0
I1
tp49525
sS'hyperlipidemia,or,elevated'
p49526
(F1
F0.00014334862385321102
I1
I0
I1
tp49527
sS'mg,daily,resulted'
p49528
(F1
F0.00014334862385321102
I1
I0
I1
tp49529
sS'and,cardiac,glycosides'
p49530
(F0
F0
I1
I1
I0
tp49531
sS'and,renal,excretion'
p49532
(F1
F0.00014334862385321102
I0
I1
I-1
tp49533
sS'other,psychotropic,medications'
p49534
(F1
F0.00028669724770642203
I2
I0
I2
tp49535
sS'of,antipsychotic,agents'
p49536
(F1
F0.00014334862385321102
I1
I0
I1
tp49537
sS'or,duloxetine,with'
p49538
(F1
F0.00014334862385321102
I0
I1
I-1
tp49539
sS'known,if,the'
p49540
(F1
F0.00014334862385321102
I1
I0
I1
tp49541
sS'with,concentrations,at'
p49542
(F1
F0.00014334862385321102
I0
I1
I-1
tp49543
sS'ephesus,patients,receiving'
p49544
(F1
F0.00014334862385321102
I0
I1
I-1
tp49545
sS'recommended,because,is'
p49546
(F1
F0.00028669724770642203
I2
I0
I2
tp49547
sS'lowers,serum,concentrations'
p49548
(F1
F0.00014334862385321102
I0
I1
I-1
tp49549
sS'of,oral,on'
p49550
(F1
F0.00028669724770642203
I0
I2
I-2
tp49551
sS'not,these,in'
p49552
(F1
F0.00014334862385321102
I0
I1
I-1
tp49553
sS'to,the,need'
p49554
(F1
F0.00014334862385321102
I0
I1
I-1
tp49555
sS'of,and,occurred'
p49556
(F1
F0.00014334862385321102
I1
I0
I1
tp49557
sS'with,highly,protein'
p49558
(F1
F0.00014334862385321102
I0
I1
I-1
tp49559
sS'that,nonabsorbable,given'
p49560
(F1
F0.00014334862385321102
I1
I0
I1
tp49561
sS'cyp2c9,substrate,and'
p49562
(F1
F0.00014334862385321102
I1
I0
I1
tp49563
sS'receiving,bolus-ifl,alone'
p49564
(F1
F0.00014334862385321102
I0
I1
I-1
tp49565
sS'human,in,patients'
p49566
(F1
F0.00014334862385321102
I1
I0
I1
tp49567
sS'recipients,suggest,that'
p49568
(F1
F0.00014334862385321102
I0
I1
I-1
tp49569
sS'cns,depression,may'
p49570
(F1
F0.00014334862385321102
I1
I0
I1
tp49571
sS'titrated,with,caution'
p49572
(F1
F0.00014334862385321102
I1
I0
I1
tp49573
sS'large,reduction,in'
p49574
(F1
F0.00014334862385321102
I1
I0
I1
tp49575
sS'in,vivo,data'
p49576
(F1
F0.00043004587155963305
I3
I0
I3
tp49577
sS'in,free,fraction'
p49578
(F1
F0.00014334862385321102
I1
I0
I1
tp49579
sS'norfluoxe-tine,have,long'
p49580
(F1
F0.00014334862385321102
I0
I1
I-1
tp49581
sS'wax,matrix,may'
p49582
(F1
F0.00014334862385321102
I1
I0
I1
tp49583
sS'effects,of,by'
p49584
(F1
F0.00014334862385321102
I1
I0
I1
tp49585
sS'modify,acth,induced'
p49586
(F1
F0.00014334862385321102
I0
I1
I-1
tp49587
sS'hydroxymethylglutaryl,coenzyme,a'
p49588
(F1
F0.00014334862385321102
I1
I0
I1
tp49589
sS'patients,receiving,combination'
p49590
(F1
F0.00014334862385321102
I1
I0
I1
tp49591
sS'to,sensitize,the'
p49592
(F1
F0.00014334862385321102
I1
I0
I1
tp49593
sS'mg,orally,min'
p49594
(F1
F0.00014334862385321102
I0
I1
I-1
tp49595
sS'in,an,analysis'
p49596
(F1
F0.00014334862385321102
I1
I0
I1
tp49597
sS'taking,other,that'
p49598
(F1
F0.00014334862385321102
I1
I0
I1
tp49599
sS'to,changes,in'
p49600
(F1
F0.00014334862385321102
I0
I1
I-1
tp49601
sS'in,a,multiple'
p49602
(F1
F0.00014334862385321102
I1
I0
I1
tp49603
sS'years,who,were'
p49604
(F1
F0.00014334862385321102
I1
I0
I1
tp49605
sS'therapy,with,another'
p49606
(F1
F0.00014334862385321102
I1
I0
I1
tp49607
sS'the,plasma,pharmacokinetics'
p49608
(F1
F0.00014334862385321102
I0
I1
I-1
tp49609
sS'cause,qt,prolongation'
p49610
(F1
F0.00014334862385321102
I0
I1
I-1
tp49611
sS'and,coreg,slow'
p49612
(F1
F0.00014334862385321102
I1
I0
I1
tp49613
sS'cns,depressants,including'
p49614
(F1
F0.00057339449541284407
I4
I0
I4
tp49615
sS'salicylic,acid,indicating'
p49616
(F1
F0.00014334862385321102
I0
I1
I-1
tp49617
sS'by,and,mean'
p49618
(F1
F0.00014334862385321102
I1
I0
I1
tp49619
sS'salicylic,acid,in'
p49620
(F1
F0.00014334862385321102
I0
I1
I-1
tp49621
sS'male,rats,treated'
p49622
(F1
F0.00014334862385321102
I0
I1
I-1
tp49623
sS'in,supporting,blood'
p49624
(F1
F0.00014334862385321102
I0
I1
I-1
tp49625
sS'oral,contraceptives,coadministration'
p49626
(F1
F0.00014334862385321102
I1
I0
I1
tp49627
sS'death,due,to'
p49628
(F1
F0.00014334862385321102
I1
I0
I1
tp49629
sS'possibility,of,a'
p49630
(F0
F0
I1
I1
I0
tp49631
sS'with,oh,d3'
p49632
(F1
F0.00014334862385321102
I1
I0
I1
tp49633
sS'as,thiazide,and'
p49634
(F1
F0.00014334862385321102
I1
I0
I1
tp49635
sS'prothrombin,time,with'
p49636
(F1
F0.00014334862385321102
I1
I0
I1
tp49637
sS'b-blocking,properties,may'
p49638
(F1
F0.00028669724770642203
I2
I0
I2
tp49639
sS'is,suggested,that'
p49640
(F1
F0.00057339449541284407
I4
I0
I4
tp49641
sS'supplementation,and,depletion'
p49642
(F1
F0.00014334862385321102
I0
I1
I-1
tp49643
sS'mg,as,mg'
p49644
(F1
F0.00014334862385321102
I0
I1
I-1
tp49645
sS'in,high,doses'
p49646
(F1
F0.00014334862385321102
I1
I0
I1
tp49647
sS'the,cyp2c9,isoenzyme'
p49648
(F1
F0.00014334862385321102
I1
I0
I1
tp49649
sS'received,a,single'
p49650
(F1
F0.00014334862385321102
I0
I1
I-1
tp49651
sS'times,as,well'
p49652
(F1
F0.00014334862385321102
I0
I1
I-1
tp49653
sS'anti-inflammatory,have,been'
p49654
(F1
F0.00014334862385321102
I1
I0
I1
tp49655
sS'conservatively,adjusted,in'
p49656
(F1
F0.00014334862385321102
I1
I0
I1
tp49657
sS'drugs,are,withdrawn'
p49658
(F1
F0.00014334862385321102
I0
I1
I-1
tp49659
sS'impact,of,chemotherapy'
p49660
(F1
F0.00014334862385321102
I0
I1
I-1
tp49661
sS'phenobarbital,estimates,of'
p49662
(F1
F0.00014334862385321102
I0
I1
I-1
tp49663
sS'agents,and,increases'
p49664
(F1
F0.00014334862385321102
I1
I0
I1
tp49665
sS'levels,with,resultant'
p49666
(F1
F0.00014334862385321102
I0
I1
I-1
tp49667
sS'alcohol,has,a'
p49668
(F1
F0.00014334862385321102
I1
I0
I1
tp49669
sS'patients,with,crohn'
p49670
(F1
F0.00014334862385321102
I0
I1
I-1
tp49671
sS'dosage,must,be'
p49672
(F1
F0.00043004587155963305
I3
I0
I3
tp49673
sS'and,secondary,deficiencies'
p49674
(F1
F0.00014334862385321102
I0
I1
I-1
tp49675
sS'may,still,kill'
p49676
(F1
F0.00014334862385321102
I1
I0
I1
tp49677
sS'solution,can,form'
p49678
(F1
F0.00014334862385321102
I1
I0
I1
tp49679
sS'of,increased,effects'
p49680
(F1
F0.00028669724770642203
I2
I0
I2
tp49681
sS'the,occurrence,of'
p49682
(F0
F0
I1
I1
I0
tp49683
sS'chromaffin,cell,could'
p49684
(F1
F0.00014334862385321102
I0
I1
I-1
tp49685
sS'or,over,to'
p49686
(F1
F0.00014334862385321102
I0
I1
I-1
tp49687
sS'studies,of,with'
p49688
(F1
F0.00043004587155963305
I0
I3
I-3
tp49689
sS'total,formation,in'
p49690
(F1
F0.00014334862385321102
I1
I0
I1
tp49691
sS'dosage,on,one'
p49692
(F1
F0.00014334862385321102
I1
I0
I1
tp49693
sS'and,auc,hrs'
p49694
(F1
F0.00014334862385321102
I0
I1
I-1
tp49695
sS'during,concomitant,use'
p49696
(F1
F0.00014334862385321102
I1
I0
I1
tp49697
sS'morning,and,lunch'
p49698
(F1
F0.00014334862385321102
I0
I1
I-1
tp49699
sS'for,include,increased'
p49700
(F1
F0.00014334862385321102
I1
I0
I1
tp49701
sS'in,hypothyroid,patients'
p49702
(F1
F0.00028669724770642203
I0
I2
I-2
tp49703
sS'exercised,if,an'
p49704
(F1
F0.00014334862385321102
I1
I0
I1
tp49705
sS'used,cautiously,with'
p49706
(F1
F0.00028669724770642203
I2
I0
I2
tp49707
sS'simultaneously,or,mg'
p49708
(F1
F0.00014334862385321102
I0
I1
I-1
tp49709
sS'could,potentially,arise'
p49710
(F1
F0.00014334862385321102
I1
I0
I1
tp49711
sS'patients,with,left'
p49712
(F1
F0.00014334862385321102
I0
I1
I-1
tp49713
sS'shown,to,interact'
p49714
(F1
F0.00028669724770642203
I2
I0
I2
tp49715
sS'trisphosphate,insp,induced'
p49716
(F1
F0.00014334862385321102
I0
I1
I-1
tp49717
sS'blot,analysis,of'
p49718
(F1
F0.00014334862385321102
I0
I1
I-1
tp49719
sS'and,intravenous,administration'
p49720
(F1
F0.00014334862385321102
I0
I1
I-1
tp49721
sS'and,an,increase'
p49722
(F1
F0.0008600917431192661
I6
I0
I6
tp49723
sS'class,resulting,in'
p49724
(F1
F0.00014334862385321102
I1
I0
I1
tp49725
sS'covalently,linked,to'
p49726
(F1
F0.00014334862385321102
I0
I1
I-1
tp49727
sS'the,possibility,that'
p49728
(F1
F0.00057339449541284407
I4
I0
I4
tp49729
sS'such,as,motrin'
p49730
(F1
F0.00014334862385321102
I0
I1
I-1
tp49731
sS'study,rats,given'
p49732
(F1
F0.00014334862385321102
I1
I0
I1
tp49733
sS'of,at,mg'
p49734
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp49735
sS'and,efficacy,is'
p49736
(F1
F0.00028669724770642203
I2
I0
I2
tp49737
sS'pregnancy,registry,by'
p49738
(F1
F0.00014334862385321102
I0
I1
I-1
tp49739
sS'with,concurrent,enbrel'
p49740
(F1
F0.00014334862385321102
I1
I0
I1
tp49741
sS'overdose,with,a'
p49742
(F1
F0.00014334862385321102
I1
I0
I1
tp49743
sS'dha,was,more'
p49744
(F1
F0.00014334862385321102
I0
I1
I-1
tp49745
sS'in,an,regimen'
p49746
(F1
F0.00014334862385321102
I0
I1
I-1
tp49747
sS'some,of,which'
p49748
(F1
F0.00014334862385321102
I1
I0
I1
tp49749
sS'not,beadministered,concomitantly'
p49750
(F1
F0.00028669724770642203
I2
I0
I2
tp49751
sS'day,and,fold'
p49752
(F1
F0.00014334862385321102
I1
I0
I1
tp49753
sS'min,over,hours'
p49754
(F1
F0.00014334862385321102
I0
I1
I-1
tp49755
sS'psychotic,disorders,treated'
p49756
(F1
F0.00014334862385321102
I1
I0
I1
tp49757
sS't,max,were'
p49758
(F1
F0.00014334862385321102
I0
I1
I-1
tp49759
sS'antiplatelet,agents,or'
p49760
(F1
F0.00014334862385321102
I1
I0
I1
tp49761
sS'arrhythmias,qt,prolongation'
p49762
(F1
F0.00014334862385321102
I0
I1
I-1
tp49763
sS'derivatives,and,has'
p49764
(F1
F0.00014334862385321102
I1
I0
I1
tp49765
sS'epoxide,concentrations,were'
p49766
(F1
F0.00014334862385321102
I0
I1
I-1
tp49767
sS'the,polyene,many'
p49768
(F1
F0.00014334862385321102
I0
I1
I-1
tp49769
sS'volunteers,mg,times'
p49770
(F1
F0.00014334862385321102
I0
I1
I-1
tp49771
sS'serum,i,binding'
p49772
(F1
F0.00014334862385321102
I0
I1
I-1
tp49773
sS'increased,exposure,and'
p49774
(F1
F0.00014334862385321102
I1
I0
I1
tp49775
sS'drugs,that,reduce'
p49776
(F1
F0.00014334862385321102
I1
I0
I1
tp49777
sS'to,the,initial'
p49778
(F1
F0.00014334862385321102
I0
I1
I-1
tp49779
sS'when,you,are'
p49780
(F1
F0.00014334862385321102
I1
I0
I1
tp49781
sS'concomitantly,with,reduce'
p49782
(F1
F0.00014334862385321102
I1
I0
I1
tp49783
sS'or,to,hours'
p49784
(F1
F0.00014334862385321102
I0
I1
I-1
tp49785
sS'significant,difference,exists'
p49786
(F1
F0.00014334862385321102
I0
I1
I-1
tp49787
sS'was,necessary,for'
p49788
(F1
F0.00014334862385321102
I1
I0
I1
tp49789
sS'like,other,may'
p49790
(F1
F0.00014334862385321102
I1
I0
I1
tp49791
sS'naproxen,had,no'
p49792
(F1
F0.00014334862385321102
I0
I1
I-1
tp49793
sS'theophylline,theophylline,clearance'
p49794
(F1
F0.00014334862385321102
I0
I1
I-1
tp49795
sS'not,substantially,increased'
p49796
(F1
F0.00014334862385321102
I1
I0
I1
tp49797
sS'or,at,as'
p49798
(F1
F0.00014334862385321102
I0
I1
I-1
tp49799
sS'clonidine,hydrochloride,may'
p49800
(F1
F0.00014334862385321102
I1
I0
I1
tp49801
sS'remainder,no,adjustment'
p49802
(F1
F0.00014334862385321102
I0
I1
I-1
tp49803
sS'equetrotm,are,the'
p49804
(F1
F0.00028669724770642203
I2
I0
I2
tp49805
sS'nevertheless,the,prothrombin'
p49806
(F1
F0.00014334862385321102
I1
I0
I1
tp49807
sS'that,clearance,is'
p49808
(F1
F0.00043004587155963305
I3
I0
I3
tp49809
sS'the,behavioral,effects'
p49810
(F1
F0.00028669724770642203
I0
I2
I-2
tp49811
sS'may,require,lower'
p49812
(F1
F0.0010034403669724771
I0
I7
I-7
tp49813
sS'studies,with,fortovase'
p49814
(F1
F0.00014334862385321102
I0
I1
I-1
tp49815
sS'histidine,residues,on'
p49816
(F1
F0.00014334862385321102
I0
I1
I-1
tp49817
sS'combination,with,any'
p49818
(F1
F0.00014334862385321102
I0
I1
I-1
tp49819
sS'controlled,crossover,clinical'
p49820
(F1
F0.00014334862385321102
I0
I1
I-1
tp49821
sS'using,immunoanalytical,methods'
p49822
(F1
F0.00014334862385321102
I0
I1
I-1
tp49823
sS'as,hypercalcemia,in'
p49824
(F1
F0.00043004587155963305
I3
I0
I3
tp49825
sS'the,following,have'
p49826
(F1
F0.00014334862385321102
I0
I1
I-1
tp49827
sS'either,or,is'
p49828
(F1
F0.00014334862385321102
I1
I0
I1
tp49829
sS'may,add,to'
p49830
(F1
F0.00028669724770642203
I2
I0
I2
tp49831
sS'p450,a4,isozyme'
p49832
(F1
F0.00014334862385321102
I0
I1
I-1
tp49833
sS'lansoprazole,has,also'
p49834
(F1
F0.00014334862385321102
I0
I1
I-1
tp49835
sS'may,precipitate,seizures'
p49836
(F1
F0.00014334862385321102
I1
I0
I1
tp49837
sS'bound,like,and'
p49838
(F1
F0.00014334862385321102
I0
I1
I-1
tp49839
sS'occur,when,are'
p49840
(F1
F0.00014334862385321102
I1
I0
I1
tp49841
sS'may,be,needed'
p49842
(F1
F0.00014334862385321102
I1
I0
I1
tp49843
sS'myopathy,during,treatment'
p49844
(F1
F0.00014334862385321102
I0
I1
I-1
tp49845
sS'further,the,duration'
p49846
(F1
F0.00014334862385321102
I1
I0
I1
tp49847
sS'vioxx,and,are'
p49848
(F1
F0.00028669724770642203
I2
I0
I2
tp49849
sS'preventing,erythro-fluorocitrate,synthesis'
p49850
(F1
F0.00014334862385321102
I0
I1
I-1
tp49851
sS'and,oxo-desethylzaleplon,glucuronide'
p49852
(F1
F0.00014334862385321102
I0
I1
I-1
tp49853
sS'buforin,ii,may'
p49854
(F1
F0.00014334862385321102
I1
I0
I1
tp49855
sS'subjects,with,epilepsy'
p49856
(F1
F0.00057339449541284407
I0
I4
I-4
tp49857
sS'effects,of,triazo'
p49858
(F1
F0.00014334862385321102
I0
I1
I-1
tp49859
sS'in,by,decreasing'
p49860
(F1
F0.00014334862385321102
I1
I0
I1
tp49861
sS'not,with,enzyme'
p49862
(F1
F0.00014334862385321102
I0
I1
I-1
tp49863
sS'of,an,oral'
p49864
(F1
F0.00014334862385321102
I0
I1
I-1
tp49865
sS'with,any,one'
p49866
(F1
F0.00014334862385321102
I0
I1
I-1
tp49867
sS'placebo,as,indicated'
p49868
(F1
F0.00014334862385321102
I0
I1
I-1
tp49869
sS'in,three,well-controlled'
p49870
(F1
F0.00014334862385321102
I0
I1
I-1
tp49871
sS'and,ulcerative,colitis'
p49872
(F1
F0.00014334862385321102
I1
I0
I1
tp49873
sS'ml,and,minimal'
p49874
(F1
F0.00014334862385321102
I0
I1
I-1
tp49875
sS'patients,with,a'
p49876
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp49877
sS'concentrations,greater,than'
p49878
(F1
F0.00014334862385321102
I0
I1
I-1
tp49879
sS'optimal,pharmacokinetics,effectiveness'
p49880
(F1
F0.00014334862385321102
I0
I1
I-1
tp49881
sS'others,are,also'
p49882
(F1
F0.00014334862385321102
I1
I0
I1
tp49883
sS'serum,concentration,curve'
p49884
(F1
F0.00014334862385321102
I1
I0
I1
tp49885
sS'potassium-depleting,are,a'
p49886
(F1
F0.00014334862385321102
I1
I0
I1
tp49887
sS'shown,that,the'
p49888
(F1
F0.00057339449541284407
I4
I0
I4
tp49889
sS'may,represent,the'
p49890
(F1
F0.00014334862385321102
I0
I1
I-1
tp49891
sS'the,reddish,color'
p49892
(F1
F0.00014334862385321102
I1
I0
I1
tp49893
sS'digoxin,in,subjects'
p49894
(F1
F0.00014334862385321102
I0
I1
I-1
tp49895
sS'indinavir,coadministration,of'
p49896
(F1
F0.00014334862385321102
I1
I0
I1
tp49897
sS'discontinue,pegasys,and'
p49898
(F1
F0.00014334862385321102
I0
I1
I-1
tp49899
sS'coadministered,with,monurol'
p49900
(F1
F0.00014334862385321102
I1
I0
I1
tp49901
sS'nonclinical,data,demonstrate'
p49902
(F1
F0.00014334862385321102
I0
I1
I-1
tp49903
sS'progestin-only,oral,poc'
p49904
(F1
F0.00014334862385321102
I0
I1
I-1
tp49905
sS'more,effective,than'
p49906
(F1
F0.00014334862385321102
I0
I1
I-1
tp49907
sS'longer,intervals,between'
p49908
(F1
F0.00014334862385321102
I1
I0
I1
tp49909
sS'require,increases,in'
p49910
(F1
F0.00014334862385321102
I1
I0
I1
tp49911
sS'have,been,reports'
p49912
(F0.42857142857142855
F0.0008600917431192661
I10
I4
I6
tp49913
sS'calcium,supplements,uncontrolled'
p49914
(F1
F0.00043004587155963305
I0
I3
I-3
tp49915
sS'coronary,artery,disease'
p49916
(F1
F0.00014334862385321102
I0
I1
I-1
tp49917
sS'the,user,such'
p49918
(F1
F0.00014334862385321102
I0
I1
I-1
tp49919
sS'aliskiren,based,on'
p49920
(F1
F0.00014334862385321102
I0
I1
I-1
tp49921
sS'to,hydrochloride,including'
p49922
(F1
F0.00014334862385321102
I0
I1
I-1
tp49923
sS'an,emergency,situation'
p49924
(F1
F0.00014334862385321102
I1
I0
I1
tp49925
sS'unmodified,nacmc,m'
p49926
(F1
F0.00014334862385321102
I0
I1
I-1
tp49927
sS'in,the,stomach'
p49928
(F1
F0.00028669724770642203
I2
I0
I2
tp49929
sS'prior,to,initiating'
p49930
(F1
F0.00014334862385321102
I1
I0
I1
tp49931
sS'rare,reports,of'
p49932
(F1
F0.00057339449541284407
I4
I0
I4
tp49933
sS'pathway,for,the'
p49934
(F1
F0.00014334862385321102
I0
I1
I-1
tp49935
sS'after,receiving,the'
p49936
(F1
F0.00014334862385321102
I1
I0
I1
tp49937
sS'therefore,patients,without'
p49938
(F1
F0.00014334862385321102
I1
I0
I1
tp49939
sS'release,of,from'
p49940
(F1
F0.00014334862385321102
I0
I1
I-1
tp49941
sS'psoriatic,arthritis,clinical'
p49942
(F1
F0.00014334862385321102
I0
I1
I-1
tp49943
sS'tikosyn,and,therapy'
p49944
(F1
F0.00014334862385321102
I1
I0
I1
tp49945
sS'the,macrolide,class'
p49946
(F1
F0.00014334862385321102
I1
I0
I1
tp49947
sS'already,stabilized,on'
p49948
(F1
F0.00014334862385321102
I1
I0
I1
tp49949
sS'equivalent,to,mg'
p49950
(F1
F0.00028669724770642203
I2
I0
I2
tp49951
sS'by,the,effects'
p49952
(F1
F0.00014334862385321102
I0
I1
I-1
tp49953
sS'trexan,with,long-term'
p49954
(F1
F0.00014334862385321102
I0
I1
I-1
tp49955
sS'used,concomitantly,patients'
p49956
(F1
F0.00014334862385321102
I1
I0
I1
tp49957
sS'inhibitors,as,systemic'
p49958
(F1
F0.00014334862385321102
I0
I1
I-1
tp49959
sS'either,or,bind'
p49960
(F1
F0.00014334862385321102
I1
I0
I1
tp49961
sS'osteoporosis,treatment,and'
p49962
(F1
F0.00014334862385321102
I0
I1
I-1
tp49963
sS'include,vaiproic,acid'
p49964
(F1
F0.00014334862385321102
I1
I0
I1
tp49965
sS'can,prolong,the'
p49966
(F1
F0.00014334862385321102
I1
I0
I1
tp49967
sS'and,other,potent'
p49968
(F1
F0.00014334862385321102
I1
I0
I1
tp49969
sS'against,gram-negative,and'
p49970
(F1
F0.00014334862385321102
I0
I1
I-1
tp49971
sS'subutex,and,suboxone'
p49972
(F1
F0.00014334862385321102
I1
I0
I1
tp49973
sS'neuromuscular,blockade,will'
p49974
(F1
F0.00014334862385321102
I0
I1
I-1
tp49975
sS'morphine,pharmacokinetic,parameter'
p49976
(F1
F0.00014334862385321102
I0
I1
I-1
tp49977
sS'another,tnf,blocking'
p49978
(F1
F0.00014334862385321102
I1
I0
I1
tp49979
sS'including,derivatives,indandione'
p49980
(F1
F0.00014334862385321102
I1
I0
I1
tp49981
sS'the,or,mg'
p49982
(F1
F0.00014334862385321102
I0
I1
I-1
tp49983
sS'less,than,pediatrics'
p49984
(F1
F0.00014334862385321102
I1
I0
I1
tp49985
sS'as,an,antipsychotic'
p49986
(F1
F0.00014334862385321102
I1
I0
I1
tp49987
sS'to,administration,on'
p49988
(F1
F0.00014334862385321102
I0
I1
I-1
tp49989
sS'pump,inhibitors,was'
p49990
(F1
F0.00014334862385321102
I1
I0
I1
tp49991
sS'dose,of,had'
p49992
(F1
F0.00028669724770642203
I0
I2
I-2
tp49993
sS'and,classes,or'
p49994
(F1
F0.00014334862385321102
I1
I0
I1
tp49995
sS'other,drugs,that'
p49996
(F0
F0
I1
I1
I0
tp49997
sS'with,antiplatelet,agents'
p49998
(F1
F0.00014334862385321102
I1
I0
I1
tp49999
sS'both,angiotensins,inhibited'
p50000
(F1
F0.00014334862385321102
I0
I1
I-1
tp50001
sS'and,decreased,respectively'
p50002
(F1
F0.00014334862385321102
I1
I0
I1
tp50003
sS'polystyrene,sulfonate,soybean'
p50004
(F1
F0.00014334862385321102
I1
I0
I1
tp50005
sS'inhibitors,such,as'
p50006
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp50007
sS'demonstrated,effectiveness,in'
p50008
(F1
F0.00014334862385321102
I0
I1
I-1
tp50009
sS'initiation,of,argatroban'
p50010
(F1
F0.00014334862385321102
I0
I1
I-1
tp50011
sS'on,the,protein'
p50012
(F1
F0.00028669724770642203
I0
I2
I-2
tp50013
sS'aptt,to,decrease'
p50014
(F1
F0.00014334862385321102
I0
I1
I-1
tp50015
sS'that,concomitant,use'
p50016
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp50017
sS'shown,that,can'
p50018
(F1
F0.00028669724770642203
I2
I0
I2
tp50019
sS'mm,declining,to'
p50020
(F1
F0.00014334862385321102
I0
I1
I-1
tp50021
sS'of,the,effect'
p50022
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp50023
sS'particularly,important,that'
p50024
(F1
F0.00014334862385321102
I0
I1
I-1
tp50025
sS'the,groups,fed'
p50026
(F1
F0.00014334862385321102
I0
I1
I-1
tp50027
sS'recommended,and,adjustment'
p50028
(F1
F0.00028669724770642203
I2
I0
I2
tp50029
sS'certain,tricyclic,thereby'
p50030
(F1
F0.00014334862385321102
I1
I0
I1
tp50031
sS'of,oral,in'
p50032
(F1
F0.00014334862385321102
I0
I1
I-1
tp50033
sS'one-half,and,prothrombin'
p50034
(F1
F0.00014334862385321102
I0
I1
I-1
tp50035
sS'however,there,has'
p50036
(F1
F0.00014334862385321102
I1
I0
I1
tp50037
sS'administration,of,oral'
p50038
(F0
F0
I1
I1
I0
tp50039
sS'therapeutic,window,such'
p50040
(F1
F0.00014334862385321102
I1
I0
I1
tp50041
sS'that,inhibits,the'
p50042
(F1
F0.00014334862385321102
I1
I0
I1
tp50043
sS'excreted,by,the'
p50044
(F1
F0.00014334862385321102
I0
I1
I-1
tp50045
sS'of,meclofenamate,sodium'
p50046
(F1
F0.00014334862385321102
I0
I1
I-1
tp50047
sS'studies,when,was'
p50048
(F1
F0.00014334862385321102
I0
I1
I-1
tp50049
sS'sufficient,to,predict'
p50050
(F1
F0.00014334862385321102
I0
I1
I-1
tp50051
sS'test,interaction,fosinopril'
p50052
(F1
F0.00014334862385321102
I0
I1
I-1
tp50053
sS'serious,symptoms,severe'
p50054
(F1
F0.00014334862385321102
I1
I0
I1
tp50055
sS'course,of,patients'
p50056
(F1
F0.00014334862385321102
I0
I1
I-1
tp50057
sS'discontinue,after,concurrent'
p50058
(F1
F0.00014334862385321102
I1
I0
I1
tp50059
sS'used,in,therapeutic'
p50060
(F1
F0.00014334862385321102
I1
I0
I1
tp50061
sS'was,given,to'
p50062
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp50063
sS'species,ros,has'
p50064
(F1
F0.00014334862385321102
I0
I1
I-1
tp50065
sS'in,more,than'
p50066
(F1
F0.00014334862385321102
I0
I1
I-1
tp50067
sS'and,cerebyx,were'
p50068
(F1
F0.00014334862385321102
I0
I1
I-1
tp50069
sS'muscle,relaxants,amphotericin'
p50070
(F1
F0.00014334862385321102
I1
I0
I1
tp50071
sS'for,and,its'
p50072
(F1
F0.00014334862385321102
I0
I1
I-1
tp50073
sS'all,strains,of'
p50074
(F1
F0.00014334862385321102
I0
I1
I-1
tp50075
sS'disintegrin,and,monomeric'
p50076
(F1
F0.00014334862385321102
I0
I1
I-1
tp50077
sS'reddish,color,is'
p50078
(F1
F0.00014334862385321102
I1
I0
I1
tp50079
sS'vessels,was,studied'
p50080
(F1
F0.00014334862385321102
I0
I1
I-1
tp50081
sS'p450,pathway,suggesting'
p50082
(F1
F0.00014334862385321102
I0
I1
I-1
tp50083
sS'niacin,antihypertensive,therapy'
p50084
(F1
F0.00014334862385321102
I1
I0
I1
tp50085
sS'dopamine,d2,antagonists'
p50086
(F1
F0.00014334862385321102
I1
I0
I1
tp50087
sS'extended,sodium,capsules'
p50088
(F1
F0.00014334862385321102
I0
I1
I-1
tp50089
sS'tambocor,and,concurrently'
p50090
(F1
F0.00014334862385321102
I1
I0
I1
tp50091
sS'of,nalfon,may'
p50092
(F1
F0.00014334862385321102
I1
I0
I1
tp50093
sS'by,minimally,elevated'
p50094
(F1
F0.00014334862385321102
I0
I1
I-1
tp50095
sS's,d,and'
p50096
(F1
F0.00014334862385321102
I1
I0
I1
tp50097
sS'occur,when,cime-tidine'
p50098
(F1
F0.00014334862385321102
I1
I0
I1
tp50099
sS'novolog,is,mixed'
p50100
(F1
F0.00014334862385321102
I0
I1
I-1
tp50101
sS'interaction,as,a'
p50102
(F1
F0.00014334862385321102
I0
I1
I-1
tp50103
sS'antagonism,exists,between'
p50104
(F1
F0.00043004587155963305
I3
I0
I3
tp50105
sS'nsaids,affect,platelet'
p50106
(F1
F0.00014334862385321102
I1
I0
I1
tp50107
sS'during,use,of'
p50108
(F1
F0.00014334862385321102
I0
I1
I-1
tp50109
sS'studied,in,rheumatoid'
p50110
(F1
F0.00014334862385321102
I0
I1
I-1
tp50111
sS'atypical,antipsychotic,with'
p50112
(F1
F0.00014334862385321102
I0
I1
I-1
tp50113
sS'is,impaired,by'
p50114
(F1
F0.00043004587155963305
I3
I0
I3
tp50115
sS'doses,of,hcl'
p50116
(F1
F0.00028669724770642203
I2
I0
I2
tp50117
sS'that,inhibit,cyp3a'
p50118
(F1
F0.00014334862385321102
I0
I1
I-1
tp50119
sS'and,heparin,the'
p50120
(F1
F0.00014334862385321102
I1
I0
I1
tp50121
sS'its,capacity,to'
p50122
(F1
F0.00014334862385321102
I1
I0
I1
tp50123
sS'metabolism,studies,and'
p50124
(F1
F0.00014334862385321102
I0
I1
I-1
tp50125
sS'adrenergic,from,working'
p50126
(F1
F0.00014334862385321102
I0
I1
I-1
tp50127
sS'of,and,hypoglycemic'
p50128
(F1
F0.00014334862385321102
I1
I0
I1
tp50129
sS'folic,acid,should'
p50130
(F1
F0.00014334862385321102
I0
I1
I-1
tp50131
sS'observed,when,or'
p50132
(F1
F0.00014334862385321102
I0
I1
I-1
tp50133
sS'mechanisms,of,status'
p50134
(F1
F0.00014334862385321102
I0
I1
I-1
tp50135
sS'x,ed95,nimbex'
p50136
(F1
F0.00014334862385321102
I1
I0
I1
tp50137
sS'iron,concomitant,administration'
p50138
(F1
F0.00014334862385321102
I1
I0
I1
tp50139
sS'in,dose,and'
p50140
(F1
F0.00014334862385321102
I1
I0
I1
tp50141
sS'renal,clearance,measurements'
p50142
(F1
F0.00014334862385321102
I1
I0
I1
tp50143
sS'with,vardenafil,mg'
p50144
(F1
F0.0010034403669724771
I7
I0
I7
tp50145
sS'compounds,are,inhibitors'
p50146
(F1
F0.00014334862385321102
I1
I0
I1
tp50147
sS'and,nicotine-induced,release'
p50148
(F1
F0.00014334862385321102
I1
I0
I1
tp50149
sS'with,reduced,serum'
p50150
(F1
F0.00014334862385321102
I1
I0
I1
tp50151
sS'to,avoid,while'
p50152
(F1
F0.00014334862385321102
I1
I0
I1
tp50153
sS'may,have,allergic'
p50154
(F1
F0.00014334862385321102
I0
I1
I-1
tp50155
sS'the,interaction,of'
p50156
(F1
F0.00071674311926605509
I0
I5
I-5
tp50157
sS'known,if,hormonal'
p50158
(F1
F0.00014334862385321102
I0
I1
I-1
tp50159
sS'action,by,competing'
p50160
(F1
F0.00014334862385321102
I1
I0
I1
tp50161
sS'effect,its,abrupt'
p50162
(F1
F0.00014334862385321102
I1
I0
I1
tp50163
sS'you,may,use'
p50164
(F1
F0.00014334862385321102
I0
I1
I-1
tp50165
sS'to,initiating,combination'
p50166
(F1
F0.00014334862385321102
I1
I0
I1
tp50167
sS'aed,concentration,mean'
p50168
(F1
F0.00014334862385321102
I0
I1
I-1
tp50169
sS'prolongation,of,its'
p50170
(F1
F0.00014334862385321102
I1
I0
I1
tp50171
sS'concentrations,of,and'
p50172
(F0
F0
I7
I7
I0
tp50173
sS'dose,in,a'
p50174
(F1
F0.00028669724770642203
I2
I0
I2
tp50175
sS'determined,by,using'
p50176
(F1
F0.00014334862385321102
I0
I1
I-1
tp50177
sS'several,clinically,important'
p50178
(F1
F0.00014334862385321102
I0
I1
I-1
tp50179
sS'anhydrase,inhibitors,rare'
p50180
(F1
F0.00014334862385321102
I1
I0
I1
tp50181
sS'when,was,given'
p50182
(F0
F0
I1
I1
I0
tp50183
sS'a,reduced,clearance'
p50184
(F1
F0.00014334862385321102
I1
I0
I1
tp50185
sS'interactions,may,occur'
p50186
(F0.5
F0.00028669724770642203
I3
I1
I2
tp50187
sS'inhibits,the,metabolism'
p50188
(F1
F0.0008600917431192661
I6
I0
I6
tp50189
sS'days,after,a'
p50190
(F1
F0.00014334862385321102
I0
I1
I-1
tp50191
sS'digoxin,digoxin,concentrations'
p50192
(F1
F0.00014334862385321102
I1
I0
I1
tp50193
sS'receiving,beta-adrenergic,blocking'
p50194
(F1
F0.00028669724770642203
I2
I0
I2
tp50195
sS'depletion,may,occasionally'
p50196
(F1
F0.00014334862385321102
I1
I0
I1
tp50197
sS'when,a,is'
p50198
(F1
F0.00043004587155963305
I3
I0
I3
tp50199
sS'the,ssris,and'
p50200
(F1
F0.00057339449541284407
I4
I0
I4
tp50201
sS'in,either,pharmacokinetics'
p50202
(F1
F0.00014334862385321102
I0
I1
I-1
tp50203
sS'of,selective,serotonin'
p50204
(F1
F0.00014334862385321102
I1
I0
I1
tp50205
sS'unlikely,to,cause'
p50206
(F1
F0.00014334862385321102
I0
I1
I-1
tp50207
sS'neither,nor,retinyl'
p50208
(F1
F0.00014334862385321102
I1
I0
I1
tp50209
sS'catecholamine-depleting,such,as'
p50210
(F1
F0.00043004587155963305
I3
I0
I3
tp50211
sS'about,in,healthy'
p50212
(F1
F0.00014334862385321102
I1
I0
I1
tp50213
sS'not,studied,but'
p50214
(F1
F0.00014334862385321102
I0
I1
I-1
tp50215
sS'similarly,patients,receiving'
p50216
(F1
F0.00014334862385321102
I0
I1
I-1
tp50217
sS'either,added,or'
p50218
(F1
F0.00028669724770642203
I2
I0
I2
tp50219
sS'lowering,the,rate'
p50220
(F1
F0.00014334862385321102
I1
I0
I1
tp50221
sS'certain,neurologic,disorders'
p50222
(F1
F0.00014334862385321102
I0
I1
I-1
tp50223
sS'which,inhibits,the'
p50224
(F1
F0.00014334862385321102
I1
I0
I1
tp50225
sS'the,need,to'
p50226
(F1
F0.00014334862385321102
I0
I1
I-1
tp50227
sS'in,dosing,and'
p50228
(F1
F0.00014334862385321102
I0
I1
I-1
tp50229
sS'related,to,cytochrome'
p50230
(F1
F0.00014334862385321102
I1
I0
I1
tp50231
sS'oral,or,intravenous'
p50232
(F1
F0.00028669724770642203
I2
I0
I2
tp50233
sS'vasodilation,induced,with'
p50234
(F1
F0.00014334862385321102
I1
I0
I1
tp50235
sS'clinical,study,did'
p50236
(F1
F0.00014334862385321102
I1
I0
I1
tp50237
sS'the,test,results'
p50238
(F1
F0.00014334862385321102
I1
I0
I1
tp50239
sS'no,studies,have'
p50240
(F1
F0.00014334862385321102
I1
I0
I1
tp50241
sS'does,not,markedly'
p50242
(F1
F0.00014334862385321102
I0
I1
I-1
tp50243
sS'of,the,displacing'
p50244
(F1
F0.00014334862385321102
I0
I1
I-1
tp50245
sS'on,antinociceptive,effect'
p50246
(F1
F0.00014334862385321102
I0
I1
I-1
tp50247
sS'crohn,s,disease'
p50248
(F1
F0.00043004587155963305
I0
I3
I-3
tp50249
sS'the,general,conditions'
p50250
(F1
F0.00014334862385321102
I0
I1
I-1
tp50251
sS'only,be,performed'
p50252
(F1
F0.00028669724770642203
I2
I0
I2
tp50253
sS'day,and,mg'
p50254
(F0
F0
I4
I4
I0
tp50255
sS'time,to,peak'
p50256
(F1
F0.00014334862385321102
I0
I1
I-1
tp50257
sS'time,after,or'
p50258
(F1
F0.00014334862385321102
I1
I0
I1
tp50259
sS'potassium,prinivil,attenuates'
p50260
(F1
F0.00014334862385321102
I1
I0
I1
tp50261
sS'doses,will,be'
p50262
(F1
F0.00014334862385321102
I0
I1
I-1
tp50263
sS'plasma,concentrations,to'
p50264
(F1
F0.00028669724770642203
I2
I0
I2
tp50265
sS'follow-up,of,months'
p50266
(F1
F0.00014334862385321102
I0
I1
I-1
tp50267
sS'after,administration,may'
p50268
(F1
F0.00014334862385321102
I1
I0
I1
tp50269
sS'of,sodium,given'
p50270
(F1
F0.00014334862385321102
I0
I1
I-1
tp50271
sS'showed,a,fold'
p50272
(F1
F0.00014334862385321102
I1
I0
I1
tp50273
sS'mao,inhibitors,maoi'
p50274
(F1
F0.00028669724770642203
I2
I0
I2
tp50275
sS'the,biochemical,toxicology'
p50276
(F1
F0.00014334862385321102
I0
I1
I-1
tp50277
sS'lipitor,atromid-s,neoral'
p50278
(F1
F0.00014334862385321102
I1
I0
I1
tp50279
sS'studies,strongly,support'
p50280
(F1
F0.00014334862385321102
I0
I1
I-1
tp50281
sS'effects,of,sublingual'
p50282
(F1
F0.00014334862385321102
I1
I0
I1
tp50283
sS'eg,and,should'
p50284
(F1
F0.00014334862385321102
I1
I0
I1
tp50285
sS'in,some,cases'
p50286
(F1
F0.00014334862385321102
I0
I1
I-1
tp50287
sS'of,immunization,cannot'
p50288
(F1
F0.00014334862385321102
I1
I0
I1
tp50289
sS'older,men,who'
p50290
(F1
F0.00014334862385321102
I0
I1
I-1
tp50291
sS'difference,between,the'
p50292
(F1
F0.00014334862385321102
I0
I1
I-1
tp50293
sS'and,azole,antifungals'
p50294
(F1
F0.00014334862385321102
I0
I1
I-1
tp50295
sS'in,the,week'
p50296
(F1
F0.00014334862385321102
I1
I0
I1
tp50297
sS'taking,prothrombin,time'
p50298
(F1
F0.00014334862385321102
I1
I0
I1
tp50299
sS'aminoglycosides,drugs,such'
p50300
(F1
F0.00014334862385321102
I1
I0
I1
tp50301
sS'exemestane,is,extensively'
p50302
(F1
F0.00014334862385321102
I0
I1
I-1
tp50303
sS'and,antacids,and'
p50304
(F1
F0.00014334862385321102
I1
I0
I1
tp50305
sS'observed,with,concomitant'
p50306
(F1
F0.00014334862385321102
I1
I0
I1
tp50307
sS'on,and,especially'
p50308
(F1
F0.00043004587155963305
I3
I0
I3
tp50309
sS'myocardial,infarction,or'
p50310
(F1
F0.00014334862385321102
I0
I1
I-1
tp50311
sS'studies,of,candesartan'
p50312
(F1
F0.00014334862385321102
I0
I1
I-1
tp50313
sS'a,similar,to'
p50314
(F1
F0.00014334862385321102
I1
I0
I1
tp50315
sS'relaxants,nondepolarizing,possible'
p50316
(F1
F0.00028669724770642203
I0
I2
I-2
tp50317
sS'data,in,human'
p50318
(F1
F0.00014334862385321102
I0
I1
I-1
tp50319
sS'novolog,and,crystalline'
p50320
(F1
F0.00014334862385321102
I0
I1
I-1
tp50321
sS'heart,block,were'
p50322
(F1
F0.00014334862385321102
I0
I1
I-1
tp50323
sS'over,indinavir-based,regimens'
p50324
(F1
F0.00014334862385321102
I0
I1
I-1
tp50325
sS'and,cholestytamine,and'
p50326
(F1
F0.00014334862385321102
I1
I0
I1
tp50327
sS'preparations,may,increase'
p50328
(F1
F0.00014334862385321102
I1
I0
I1
tp50329
sS'blood,pressure,by'
p50330
(F1
F0.00014334862385321102
I1
I0
I1
tp50331
sS'thus,should,be'
p50332
(F1
F0.00014334862385321102
I1
I0
I1
tp50333
sS'the,plasma-level,of'
p50334
(F1
F0.00014334862385321102
I1
I0
I1
tp50335
sS'the,desired,effect'
p50336
(F0.75
F0.0008600917431192661
I7
I1
I6
tp50337
sS'should,only,be'
p50338
(F1
F0.00028669724770642203
I2
I0
I2
tp50339
sS'in,addition,most'
p50340
(F1
F0.00014334862385321102
I1
I0
I1
tp50341
sS'of,its,normal'
p50342
(F1
F0.00014334862385321102
I1
I0
I1
tp50343
sS'additive,effect,on'
p50344
(F1
F0.00014334862385321102
I1
I0
I1
tp50345
sS'norpace,or,norpace'
p50346
(F1
F0.00014334862385321102
I1
I0
I1
tp50347
sS'heparin,no,human'
p50348
(F1
F0.00014334862385321102
I0
I1
I-1
tp50349
sS'that,inhibits,c9'
p50350
(F1
F0.00014334862385321102
I0
I1
I-1
tp50351
sS'including,and,type'
p50352
(F1
F0.00014334862385321102
I1
I0
I1
tp50353
sS'mg,daily,should'
p50354
(F1
F0.00014334862385321102
I0
I1
I-1
tp50355
sS'the,added,beta-adrenergic'
p50356
(F1
F0.00014334862385321102
I1
I0
I1
tp50357
sS'of,sonata,reflecting'
p50358
(F1
F0.00014334862385321102
I0
I1
I-1
tp50359
sS'ewes,given,mg'
p50360
(F1
F0.00014334862385321102
I1
I0
I1
tp50361
sS'or,with,had'
p50362
(F1
F0.00014334862385321102
I0
I1
I-1
tp50363
sS'affect,its,metabolism'
p50364
(F1
F0.00014334862385321102
I0
I1
I-1
tp50365
sS'potent,than,nanm'
p50366
(F1
F0.00014334862385321102
I0
I1
I-1
tp50367
sS'in,which,a'
p50368
(F1
F0.00014334862385321102
I1
I0
I1
tp50369
sS'it,is,important'
p50370
(F1
F0.00028669724770642203
I0
I2
I-2
tp50371
sS'caution,is,advised'
p50372
(F1
F0.0008600917431192661
I6
I0
I6
tp50373
sS'abased,on,reports'
p50374
(F1
F0.00014334862385321102
I1
I0
I1
tp50375
sS'reported,rarely,to'
p50376
(F0
F0
I1
I1
I0
tp50377
sS'on,chronic,therapy'
p50378
(F0
F0
I1
I1
I0
tp50379
sS'episodes,permit,reductions'
p50380
(F1
F0.00014334862385321102
I0
I1
I-1
tp50381
sS'during,the,first'
p50382
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp50383
sS'involving,levo-dromoran,reported'
p50384
(F1
F0.00014334862385321102
I0
I1
I-1
tp50385
sS'although,concomitant,use'
p50386
(F1
F0.00014334862385321102
I1
I0
I1
tp50387
sS'the,is,given'
p50388
(F1
F0.00014334862385321102
I1
I0
I1
tp50389
sS'antacids,and,antacids'
p50390
(F1
F0.00014334862385321102
I1
I0
I1
tp50391
sS'myocardium,versus,nonfailing'
p50392
(F1
F0.00014334862385321102
I0
I1
I-1
tp50393
sS'closely,if,a'
p50394
(F1
F0.00014334862385321102
I1
I0
I1
tp50395
sS'conditions,similar,to'
p50396
(F1
F0.00014334862385321102
I1
I0
I1
tp50397
sS'live-attenuated,should,not'
p50398
(F1
F0.00014334862385321102
I1
I0
I1
tp50399
sS'use,of,oral'
p50400
(F0
F0
I1
I1
I0
tp50401
sS'because,of,this'
p50402
(F1
F0.00014334862385321102
I0
I1
I-1
tp50403
sS'with,the,clinical'
p50404
(F1
F0.00028669724770642203
I0
I2
I-2
tp50405
sS'of,cyp450,enzyme'
p50406
(F1
F0.00014334862385321102
I0
I1
I-1
tp50407
sS'compounds,tested,in'
p50408
(F1
F0.00014334862385321102
I0
I1
I-1
tp50409
sS'effect,on,histamine-'
p50410
(F1
F0.00014334862385321102
I1
I0
I1
tp50411
sS'with,n,or'
p50412
(F1
F0.00028669724770642203
I0
I2
I-2
tp50413
sS'in,two,clinical'
p50414
(F1
F0.00014334862385321102
I1
I0
I1
tp50415
sS'neurontin,capsule,n'
p50416
(F1
F0.00014334862385321102
I1
I0
I1
tp50417
sS'oral,concomitant,administration'
p50418
(F1
F0.00014334862385321102
I1
I0
I1
tp50419
sS'antagonized,in,a'
p50420
(F1
F0.00014334862385321102
I1
I0
I1
tp50421
sS'has,had,less'
p50422
(F1
F0.00014334862385321102
I1
I0
I1
tp50423
sS'enhanced,by,bezalip'
p50424
(F1
F0.00014334862385321102
I1
I0
I1
tp50425
sS'inhibitors,in,combination'
p50426
(F1
F0.00014334862385321102
I1
I0
I1
tp50427
sS'a,channel,blocker'
p50428
(F1
F0.00014334862385321102
I0
I1
I-1
tp50429
sS'individuals,with,a'
p50430
(F1
F0.00014334862385321102
I0
I1
I-1
tp50431
sS'and,oral,an'
p50432
(F1
F0.00014334862385321102
I0
I1
I-1
tp50433
sS'other,that,interfere'
p50434
(F1
F0.00014334862385321102
I0
I1
I-1
tp50435
sS'interfere,with,spectrophotometrically'
p50436
(F1
F0.00014334862385321102
I0
I1
I-1
tp50437
sS'depletors,should,therefore'
p50438
(F1
F0.00014334862385321102
I1
I0
I1
tp50439
sS'bph,psa,levels'
p50440
(F1
F0.00014334862385321102
I0
I1
I-1
tp50441
sS'auc,increased,by'
p50442
(F1
F0.00043004587155963305
I3
I0
I3
tp50443
sS'dopaminergic,renal,and'
p50444
(F1
F0.00014334862385321102
I1
I0
I1
tp50445
sS'in,male,rats'
p50446
(F1
F0.00014334862385321102
I0
I1
I-1
tp50447
sS'responses,in,a'
p50448
(F1
F0.00014334862385321102
I1
I0
I1
tp50449
sS'and,can,be'
p50450
(F0
F0
I2
I2
I0
tp50451
sS'molecule,naflu,and'
p50452
(F1
F0.00014334862385321102
I0
I1
I-1
tp50453
sS'of,p450,a2'
p50454
(F1
F0.00014334862385321102
I1
I0
I1
tp50455
sS'ovcon-35,resulted,in'
p50456
(F1
F0.00014334862385321102
I1
I0
I1
tp50457
sS'was,investigated,in'
p50458
(F1
F0.00043004587155963305
I0
I3
I-3
tp50459
sS'acidity,in,the'
p50460
(F1
F0.00014334862385321102
I1
I0
I1
tp50461
sS'of,the,risk'
p50462
(F1
F0.00028669724770642203
I2
I0
I2
tp50463
sS'from,to,microg'
p50464
(F1
F0.00014334862385321102
I0
I1
I-1
tp50465
sS'interactions,with,other'
p50466
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp50467
sS'fluoride,accumulation,characteristic'
p50468
(F1
F0.00014334862385321102
I0
I1
I-1
tp50469
sS'side,reactions,of'
p50470
(F1
F0.00014334862385321102
I1
I0
I1
tp50471
sS'caused,by,mtc-methylene'
p50472
(F1
F0.00014334862385321102
I1
I0
I1
tp50473
sS'patients,on,hormone'
p50474
(F1
F0.00014334862385321102
I0
I1
I-1
tp50475
sS'upon,concomitant,administration'
p50476
(F1
F0.00014334862385321102
I1
I0
I1
tp50477
sS'patients,in,the'
p50478
(F0
F0
I1
I1
I0
tp50479
sS'other,in,vivo'
p50480
(F1
F0.00014334862385321102
I0
I1
I-1
tp50481
sS'and,even,in'
p50482
(F1
F0.00014334862385321102
I1
I0
I1
tp50483
sS'action,of,hydroxyzine'
p50484
(F1
F0.00014334862385321102
I1
I0
I1
tp50485
sS'for,interactions,with'
p50486
(F0
F0
I1
I1
I0
tp50487
sS'in,the,auc'
p50488
(F0.090909090909090912
F0.00014334862385321102
I6
I5
I1
tp50489
sS'levels,and,auc'
p50490
(F0
F0
I1
I1
I0
tp50491
sS'potassium-depleting,and,related'
p50492
(F1
F0.00014334862385321102
I0
I1
I-1
tp50493
sS'degrees,of,recovery'
p50494
(F1
F0.00014334862385321102
I0
I1
I-1
tp50495
sS'with,but,there'
p50496
(F1
F0.00014334862385321102
I0
I1
I-1
tp50497
sS'for,either,or'
p50498
(F1
F0.00014334862385321102
I0
I1
I-1
tp50499
sS'of,sodium,including'
p50500
(F1
F0.00028669724770642203
I2
I0
I2
tp50501
sS'lesser,extent,of'
p50502
(F1
F0.00014334862385321102
I1
I0
I1
tp50503
sS'not,altered,its'
p50504
(F1
F0.00014334862385321102
I0
I1
I-1
tp50505
sS'indocin,has,been'
p50506
(F1
F0.00014334862385321102
I1
I0
I1
tp50507
sS'absorption,the,following'
p50508
(F1
F0.00014334862385321102
I1
I0
I1
tp50509
sS'seizures,have,been'
p50510
(F1
F0.00043004587155963305
I3
I0
I3
tp50511
sS'pharmacokinetics,over,the'
p50512
(F1
F0.00014334862385321102
I1
I0
I1
tp50513
sS'result,in,an'
p50514
(F1
F0.0017201834862385322
I12
I0
I12
tp50515
sS'in,these,patients'
p50516
(F1
F0.00028669724770642203
I2
I0
I2
tp50517
sS'and,other,bronchodilators'
p50518
(F1
F0.00014334862385321102
I1
I0
I1
tp50519
sS'less,pronounced,effect'
p50520
(F1
F0.00014334862385321102
I1
I0
I1
tp50521
sS'blocks,and,ergot-type'
p50522
(F0
F0
I1
I1
I0
tp50523
sS'treatment,with,bezalip'
p50524
(F1
F0.00014334862385321102
I1
I0
I1
tp50525
sS'are,no,data'
p50526
(F1
F0.00014334862385321102
I0
I1
I-1
tp50527
sS'exogenous,on,the'
p50528
(F1
F0.00014334862385321102
I0
I1
I-1
tp50529
sS'of,wellbutrin,on'
p50530
(F1
F0.00014334862385321102
I0
I1
I-1
tp50531
sS'achieve,the,dose'
p50532
(F1
F0.00014334862385321102
I1
I0
I1
tp50533
sS'that,mc,has'
p50534
(F1
F0.00014334862385321102
I0
I1
I-1
tp50535
sS'medications,and,vasodilators'
p50536
(F1
F0.00014334862385321102
I1
I0
I1
tp50537
sS'about,when,was'
p50538
(F1
F0.00014334862385321102
I1
I0
I1
tp50539
sS'metabolism,and,has'
p50540
(F1
F0.00014334862385321102
I1
I0
I1
tp50541
sS'cardiovascular,system,can'
p50542
(F1
F0.00014334862385321102
I1
I0
I1
tp50543
sS'auc,of,a'
p50544
(F1
F0.00057339449541284407
I4
I0
I4
tp50545
sS'injectable,transdermal,and'
p50546
(F1
F0.00028669724770642203
I2
I0
I2
tp50547
sS'rats,were,given'
p50548
(F1
F0.00014334862385321102
I0
I1
I-1
tp50549
sS'these,patients,may'
p50550
(F1
F0.00014334862385321102
I0
I1
I-1
tp50551
sS'hypokinesia,and,severe'
p50552
(F1
F0.00014334862385321102
I1
I0
I1
tp50553
sS'auc,of,p'
p50554
(F1
F0.00014334862385321102
I1
I0
I1
tp50555
sS'reported,with,concomitant'
p50556
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp50557
sS'auc,of,r'
p50558
(F1
F0.00014334862385321102
I1
I0
I1
tp50559
sS'may,mask,the'
p50560
(F1
F0.00014334862385321102
I0
I1
I-1
tp50561
sS'inhibit,cyp3a4,to'
p50562
(F1
F0.00014334862385321102
I0
I1
I-1
tp50563
sS'nonrenal,and,total'
p50564
(F1
F0.00014334862385321102
I0
I1
I-1
tp50565
sS'and,prolong,the'
p50566
(F1
F0.00028669724770642203
I2
I0
I2
tp50567
sS'relaxants,intravenous,agents'
p50568
(F1
F0.00014334862385321102
I0
I1
I-1
tp50569
sS'intentional,or,unintentional'
p50570
(F1
F0.00014334862385321102
I1
I0
I1
tp50571
sS'toxic,that,is'
p50572
(F1
F0.00014334862385321102
I0
I1
I-1
tp50573
sS'resulted,in,decreases'
p50574
(F1
F0.00014334862385321102
I1
I0
I1
tp50575
sS'of,placental,vessels'
p50576
(F1
F0.00014334862385321102
I1
I0
I1
tp50577
sS'when,and,brevibloc'
p50578
(F1
F0.00014334862385321102
I1
I0
I1
tp50579
sS'resulted,in,decreased'
p50580
(F0
F0
I1
I1
I0
tp50581
sS'observed,in,mean'
p50582
(F1
F0.00014334862385321102
I0
I1
I-1
tp50583
sS'supplement,while,taking'
p50584
(F1
F0.00014334862385321102
I1
I0
I1
tp50585
sS'of,and,o-desacetylrifabutin'
p50586
(F1
F0.00014334862385321102
I1
I0
I1
tp50587
sS'in,a,reduction'
p50588
(F1
F0.00057339449541284407
I4
I0
I4
tp50589
sS'such,as,triazolopyridazines'
p50590
(F1
F0.00014334862385321102
I1
I0
I1
tp50591
sS'which,may,also'
p50592
(F1
F0.00014334862385321102
I0
I1
I-1
tp50593
sS'extreme,caution,to'
p50594
(F1
F0.00014334862385321102
I1
I0
I1
tp50595
sS'concomitantly,administered,in'
p50596
(F1
F0.00014334862385321102
I1
I0
I1
tp50597
sS'certain,intravenously,administered'
p50598
(F1
F0.00014334862385321102
I1
I0
I1
tp50599
sS'with,various,containing'
p50600
(F1
F0.00014334862385321102
I1
I0
I1
tp50601
sS'volunteers,with,multiple'
p50602
(F1
F0.00014334862385321102
I1
I0
I1
tp50603
sS'to,those,in'
p50604
(F1
F0.00014334862385321102
I0
I1
I-1
tp50605
sS'patients,combined,use'
p50606
(F1
F0.00014334862385321102
I1
I0
I1
tp50607
sS'water,from,a'
p50608
(F1
F0.00014334862385321102
I0
I1
I-1
tp50609
sS'the,level,of'
p50610
(F0
F0
I3
I3
I0
tp50611
sS'observations,have,shown'
p50612
(F1
F0.0008600917431192661
I6
I0
I6
tp50613
sS'requiring,angioedema,or'
p50614
(F1
F0.00014334862385321102
I0
I1
I-1
tp50615
sS'behavioral,effects,of'
p50616
(F1
F0.00043004587155963305
I0
I3
I-3
tp50617
sS'effects,of,ganglionic'
p50618
(F1
F0.00014334862385321102
I1
I0
I1
tp50619
sS'antagonists,are,administered'
p50620
(F1
F0.00014334862385321102
I1
I0
I1
tp50621
sS'concomitant,high-dose,and'
p50622
(F1
F0.00014334862385321102
I1
I0
I1
tp50623
sS'c9,c19,d6'
p50624
(F1
F0.00014334862385321102
I0
I1
I-1
tp50625
sS'hyperbilirubinemia,confusion,and'
p50626
(F1
F0.00014334862385321102
I1
I0
I1
tp50627
sS'blood,concentrations,should'
p50628
(F1
F0.00014334862385321102
I1
I0
I1
tp50629
sS'likely,to,outweigh'
p50630
(F1
F0.00014334862385321102
I1
I0
I1
tp50631
sS'of,the,molecule'
p50632
(F1
F0.00043004587155963305
I3
I0
I3
tp50633
sS'substances,are,known'
p50634
(F1
F0.00014334862385321102
I0
I1
I-1
tp50635
sS'patients,on,oral'
p50636
(F1
F0.00014334862385321102
I1
I0
I1
tp50637
sS'respectively,after,administration'
p50638
(F1
F0.00014334862385321102
I0
I1
I-1
tp50639
sS'dmpge2,mg,kg'
p50640
(F1
F0.00014334862385321102
I1
I0
I1
tp50641
sS'denotes,a,mean'
p50642
(F1
F0.00014334862385321102
I1
I0
I1
tp50643
sS'potential,intravenous,and'
p50644
(F1
F0.00014334862385321102
I1
I0
I1
tp50645
sS'safely,co-administered,with'
p50646
(F1
F0.00014334862385321102
I0
I1
I-1
tp50647
sS'and,or,severity'
p50648
(F1
F0.00014334862385321102
I1
I0
I1
tp50649
sS'a,reduction,of'
p50650
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp50651
sS'these,actions,were'
p50652
(F1
F0.00014334862385321102
I1
I0
I1
tp50653
sS'acarbose,due,to'
p50654
(F1
F0.00014334862385321102
I1
I0
I1
tp50655
sS'concurrently,use,products'
p50656
(F1
F0.00014334862385321102
I1
I0
I1
tp50657
sS'all,patients,treated'
p50658
(F0
F0
I1
I1
I0
tp50659
sS'to,expect,that'
p50660
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp50661
sS'crixivan,and,is'
p50662
(F1
F0.00014334862385321102
I1
I0
I1
tp50663
sS'the,vascular,dilation'
p50664
(F1
F0.00014334862385321102
I1
I0
I1
tp50665
sS'reports,of,an'
p50666
(F1
F0.00014334862385321102
I1
I0
I1
tp50667
sS'relationship,and,a'
p50668
(F1
F0.00014334862385321102
I1
I0
I1
tp50669
sS'rapid,and,transient'
p50670
(F1
F0.00014334862385321102
I1
I0
I1
tp50671
sS'including,oral,injectable'
p50672
(F1
F0.00028669724770642203
I2
I0
I2
tp50673
sS'as,well,concurent'
p50674
(F1
F0.00014334862385321102
I1
I0
I1
tp50675
sS'with,such,as'
p50676
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp50677
sS'maoi,maoi,could'
p50678
(F1
F0.00014334862385321102
I1
I0
I1
tp50679
sS'd3,the,active'
p50680
(F1
F0.00014334862385321102
I0
I1
I-1
tp50681
sS'study,the,ureidopenicillins'
p50682
(F1
F0.00014334862385321102
I1
I0
I1
tp50683
sS'with,proleukin,may'
p50684
(F1
F0.00028669724770642203
I2
I0
I2
tp50685
sS'angina,pectoris,additional'
p50686
(F1
F0.00014334862385321102
I1
I0
I1
tp50687
sS'the,impairment,of'
p50688
(F1
F0.00014334862385321102
I0
I1
I-1
tp50689
sS'and,penthrane,has'
p50690
(F1
F0.00014334862385321102
I1
I0
I1
tp50691
sS'nevertheless,plasma,levels'
p50692
(F1
F0.00014334862385321102
I0
I1
I-1
tp50693
sS'hydrobromide,may,result'
p50694
(F1
F0.00014334862385321102
I1
I0
I1
tp50695
sS'were,treated,for'
p50696
(F1
F0.00028669724770642203
I2
I0
I2
tp50697
sS'concentrations,when,coadministered'
p50698
(F1
F0.00014334862385321102
I0
I1
I-1
tp50699
sS'the,diamond,trials'
p50700
(F1
F0.00028669724770642203
I0
I2
I-2
tp50701
sS'than,and,to'
p50702
(F1
F0.00014334862385321102
I0
I1
I-1
tp50703
sS'of,total,rna'
p50704
(F1
F0.00014334862385321102
I0
I1
I-1
tp50705
sS'of,glucose,and'
p50706
(F1
F0.00014334862385321102
I0
I1
I-1
tp50707
sS'products,h2-antagonists,and'
p50708
(F1
F0.00014334862385321102
I0
I1
I-1
tp50709
sS'is,started,in'
p50710
(F1
F0.00014334862385321102
I1
I0
I1
tp50711
sS'over,the,first'
p50712
(F1
F0.00014334862385321102
I0
I1
I-1
tp50713
sS'to,discontinue,nursing'
p50714
(F1
F0.00014334862385321102
I0
I1
I-1
tp50715
sS'and,that,of'
p50716
(F1
F0.00014334862385321102
I0
I1
I-1
tp50717
sS'remicade,used,in'
p50718
(F1
F0.00014334862385321102
I1
I0
I1
tp50719
sS'morphine,a,literature'
p50720
(F1
F0.00014334862385321102
I1
I0
I1
tp50721
sS'its,metabolism,to'
p50722
(F1
F0.00014334862385321102
I1
I0
I1
tp50723
sS'following,concomitant,medications'
p50724
(F1
F0.00014334862385321102
I0
I1
I-1
tp50725
sS'ketoconazole,ketoconazole,may'
p50726
(F1
F0.00043004587155963305
I3
I0
I3
tp50727
sS'neuromuscular,blocking,agents'
p50728
(F1
F0.00028669724770642203
I2
I0
I2
tp50729
sS'cardiovascular,action,of'
p50730
(F1
F0.00014334862385321102
I1
I0
I1
tp50731
sS'tablets,the,initial'
p50732
(F1
F0.00014334862385321102
I1
I0
I1
tp50733
sS'dose,of,arimidex'
p50734
(F1
F0.00014334862385321102
I0
I1
I-1
tp50735
sS'were,unchanged,following'
p50736
(F1
F0.00028669724770642203
I0
I2
I-2
tp50737
sS'with,that,strongly'
p50738
(F1
F0.00014334862385321102
I1
I0
I1
tp50739
sS'potential,for,increased'
p50740
(F1
F0.00028669724770642203
I2
I0
I2
tp50741
sS'vision,and,in'
p50742
(F1
F0.00014334862385321102
I1
I0
I1
tp50743
sS'by,irreversible,brain'
p50744
(F1
F0.00014334862385321102
I1
I0
I1
tp50745
sS'creatinine,levels,by'
p50746
(F1
F0.00028669724770642203
I0
I2
I-2
tp50747
sS'day,days,plus'
p50748
(F1
F0.00014334862385321102
I0
I1
I-1
tp50749
sS'inhibit,both,synthetic'
p50750
(F1
F0.00043004587155963305
I3
I0
I3
tp50751
sS'net,effect,of'
p50752
(F1
F0.00014334862385321102
I0
I1
I-1
tp50753
sS'threshold,concurrent,administration'
p50754
(F1
F0.00014334862385321102
I1
I0
I1
tp50755
sS'mc,block,morphine-induced'
p50756
(F1
F0.00014334862385321102
I1
I0
I1
tp50757
sS'unrecognized,interaction,between'
p50758
(F1
F0.00014334862385321102
I1
I0
I1
tp50759
sS'groups,fed,further'
p50760
(F1
F0.00014334862385321102
I0
I1
I-1
tp50761
sS'alter,the,adverse'
p50762
(F1
F0.00014334862385321102
I0
I1
I-1
tp50763
sS'given,number,of'
p50764
(F1
F0.00014334862385321102
I0
I1
I-1
tp50765
sS'among,the,patients'
p50766
(F1
F0.00014334862385321102
I0
I1
I-1
tp50767
sS'hours,before,conducting'
p50768
(F1
F0.00014334862385321102
I1
I0
I1
tp50769
sS'lowering,effect,and'
p50770
(F1
F0.00028669724770642203
I0
I2
I-2
tp50771
sS'adjustment,is,not'
p50772
(F0
F0
I1
I1
I0
tp50773
sS'when,trisenox,is'
p50774
(F1
F0.00014334862385321102
I1
I0
I1
tp50775
sS'exposure,to,when'
p50776
(F1
F0.00014334862385321102
I1
I0
I1
tp50777
sS'and,were,given'
p50778
(F1
F0.00014334862385321102
I0
I1
I-1
tp50779
sS'brovana,doses,of'
p50780
(F1
F0.00014334862385321102
I0
I1
I-1
tp50781
sS'gastrointestinal,bleeding,have'
p50782
(F1
F0.00014334862385321102
I1
I0
I1
tp50783
sS'contain,an,may'
p50784
(F1
F0.00014334862385321102
I1
I0
I1
tp50785
sS'and,may,cause'
p50786
(F1
F0.00071674311926605509
I5
I0
I5
tp50787
sS'hypotension,requiring,treatment'
p50788
(F1
F0.00014334862385321102
I0
I1
I-1
tp50789
sS'ketoconazole,tablets,inhibit'
p50790
(F1
F0.00014334862385321102
I1
I0
I1
tp50791
sS'cautiously,with,other'
p50792
(F1
F0.00014334862385321102
I1
I0
I1
tp50793
sS'six-day,course,of'
p50794
(F1
F0.00014334862385321102
I1
I0
I1
tp50795
sS'vitro,studies,m1'
p50796
(F1
F0.00028669724770642203
I0
I2
I-2
tp50797
sS'and,usually,a'
p50798
(F1
F0.00014334862385321102
I1
I0
I1
tp50799
sS'epidural,local,including'
p50800
(F1
F0.00014334862385321102
I1
I0
I1
tp50801
sS'increase,respiratory,and'
p50802
(F1
F0.00014334862385321102
I1
I0
I1
tp50803
sS'and,may,compete'
p50804
(F1
F0.00014334862385321102
I1
I0
I1
tp50805
sS'and,other,agents'
p50806
(F0
F0
I1
I1
I0
tp50807
sS'mg,intravenous,dose'
p50808
(F1
F0.00014334862385321102
I0
I1
I-1
tp50809
sS'amprenavir,and,have'
p50810
(F1
F0.00014334862385321102
I1
I0
I1
tp50811
sS'both,in,vivo'
p50812
(F1
F0.00014334862385321102
I0
I1
I-1
tp50813
sS'subjects,clearance,and'
p50814
(F1
F0.00014334862385321102
I0
I1
I-1
tp50815
sS'other,drugs,alcohol'
p50816
(F1
F0.00014334862385321102
I0
I1
I-1
tp50817
sS'it,is,possible'
p50818
(F1
F0.00043004587155963305
I3
I0
I3
tp50819
sS'of,tmp,smx'
p50820
(F1
F0.00014334862385321102
I0
I1
I-1
tp50821
sS'can,directly,interfere'
p50822
(F1
F0.00014334862385321102
I1
I0
I1
tp50823
sS'evaluated,in,men'
p50824
(F1
F0.00014334862385321102
I0
I1
I-1
tp50825
sS'documentation,of,such'
p50826
(F1
F0.00014334862385321102
I0
I1
I-1
tp50827
sS'brevibloc,should,be'
p50828
(F1
F0.00014334862385321102
I1
I0
I1
tp50829
sS'inhibited,phosphorylation,at'
p50830
(F1
F0.00014334862385321102
I1
I0
I1
tp50831
sS'coadministration,of,and'
p50832
(F0.6470588235294118
F0.0015768348623853212
I14
I3
I11
tp50833
sS'significantly,superior,to'
p50834
(F1
F0.00014334862385321102
I0
I1
I-1
tp50835
sS'therefore,signs,of'
p50836
(F1
F0.00014334862385321102
I0
I1
I-1
tp50837
sS'monkeys,and,sustained'
p50838
(F1
F0.00014334862385321102
I0
I1
I-1
tp50839
sS'reductase,inhibitors,simvastatin'
p50840
(F1
F0.00014334862385321102
I0
I1
I-1
tp50841
sS'coadministration,of,any'
p50842
(F1
F0.00043004587155963305
I0
I3
I-3
tp50843
sS'the,start,and'
p50844
(F1
F0.00014334862385321102
I1
I0
I1
tp50845
sS'from,the,th'
p50846
(F1
F0.00014334862385321102
I0
I1
I-1
tp50847
sS'week,placebo,controlled'
p50848
(F1
F0.00014334862385321102
I0
I1
I-1
tp50849
sS'those,with,a'
p50850
(F1
F0.00014334862385321102
I1
I0
I1
tp50851
sS'that,dose,adjustment'
p50852
(F1
F0.00014334862385321102
I1
I0
I1
tp50853
sS'new,class,of'
p50854
(F1
F0.00014334862385321102
I0
I1
I-1
tp50855
sS'neurochemical,and,functional'
p50856
(F1
F0.00028669724770642203
I0
I2
I-2
tp50857
sS'clindamycin,has,been'
p50858
(F1
F0.00014334862385321102
I1
I0
I1
tp50859
sS'begins,a,course'
p50860
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp50861
sS'induced,hypotension,because'
p50862
(F1
F0.00014334862385321102
I0
I1
I-1
tp50863
sS'various,chemotherapy,agents'
p50864
(F1
F0.00014334862385321102
I0
I1
I-1
tp50865
sS'autonomic,instability,with'
p50866
(F1
F0.00014334862385321102
I1
I0
I1
tp50867
sS'nervous,system,depressants'
p50868
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp50869
sS'receiving,concomitant,hydrochloride'
p50870
(F1
F0.00014334862385321102
I0
I1
I-1
tp50871
sS'taking,or,who'
p50872
(F1
F0.00014334862385321102
I1
I0
I1
tp50873
sS'nine,otherwise,healthy'
p50874
(F1
F0.00014334862385321102
I0
I1
I-1
tp50875
sS'very,high,doses'
p50876
(F0
F0
I1
I1
I0
tp50877
sS'as,international,normalized'
p50878
(F1
F0.00014334862385321102
I1
I0
I1
tp50879
sS'to,be,increased'
p50880
(F1
F0.00071674311926605509
I5
I0
I5
tp50881
sS'hypertensive,crises,have'
p50882
(F1
F0.00014334862385321102
I1
I0
I1
tp50883
sS'steady-state,trough,serum'
p50884
(F1
F0.00014334862385321102
I0
I1
I-1
tp50885
sS'by,the,same'
p50886
(F1
F0.00014334862385321102
I0
I1
I-1
tp50887
sS'on,the,renal'
p50888
(F1
F0.00014334862385321102
I1
I0
I1
tp50889
sS'that,are,predominantly'
p50890
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp50891
sS'blood,sugar,in'
p50892
(F1
F0.00014334862385321102
I1
I0
I1
tp50893
sS'with,sulfamethoxazole,concomitant'
p50894
(F1
F0.00014334862385321102
I0
I1
I-1
tp50895
sS'inhibitor,of,cytochrome'
p50896
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp50897
sS'case,of,an'
p50898
(F1
F0.00014334862385321102
I1
I0
I1
tp50899
sS'urine,red-orange,which'
p50900
(F1
F0.00014334862385321102
I0
I1
I-1
tp50901
sS'such,as,beta-adrenergic'
p50902
(F1
F0.00014334862385321102
I0
I1
I-1
tp50903
sS'may,require,dosage'
p50904
(F1
F0.00014334862385321102
I1
I0
I1
tp50905
sS'and,chloride,in'
p50906
(F1
F0.00014334862385321102
I1
I0
I1
tp50907
sS'probenecid,is,known'
p50908
(F1
F0.00014334862385321102
I1
I0
I1
tp50909
sS'attenuate,morphine-induced,locomotion'
p50910
(F1
F0.00014334862385321102
I0
I1
I-1
tp50911
sS'itraconazole,and,or'
p50912
(F1
F0.00014334862385321102
I1
I0
I1
tp50913
sS'kg,day,groups'
p50914
(F1
F0.00014334862385321102
I1
I0
I1
tp50915
sS'of,increased,approximately'
p50916
(F1
F0.00028669724770642203
I2
I0
I2
tp50917
sS'doses,vioxx,mg'
p50918
(F1
F0.00014334862385321102
I1
I0
I1
tp50919
sS'doses,have,been'
p50920
(F1
F0.00014334862385321102
I0
I1
I-1
tp50921
sS'intravenous,mg,kg'
p50922
(F1
F0.00014334862385321102
I0
I1
I-1
tp50923
sS'substances,demonstrated,to'
p50924
(F1
F0.00014334862385321102
I1
I0
I1
tp50925
sS'by,nuromax,is'
p50926
(F1
F0.00014334862385321102
I1
I0
I1
tp50927
sS'two-fold,increases,of'
p50928
(F1
F0.00014334862385321102
I1
I0
I1
tp50929
sS'and,may,have'
p50930
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp50931
sS'preferentially,blocked,the'
p50932
(F1
F0.00014334862385321102
I1
I0
I1
tp50933
sS'is,unaffected,by'
p50934
(F1
F0.00028669724770642203
I0
I2
I-2
tp50935
sS'dcg-iv,were,very'
p50936
(F1
F0.00014334862385321102
I1
I0
I1
tp50937
sS'however,prudent,medical'
p50938
(F1
F0.00014334862385321102
I1
I0
I1
tp50939
sS'was,given,intravenously'
p50940
(F1
F0.00014334862385321102
I0
I1
I-1
tp50941
sS'with,mg,tablets'
p50942
(F1
F0.00014334862385321102
I0
I1
I-1
tp50943
sS'pharmacokinetics,were,not'
p50944
(F1
F0.00014334862385321102
I0
I1
I-1
tp50945
sS'a,placebo-controlled,trial'
p50946
(F1
F0.00014334862385321102
I1
I0
I1
tp50947
sS'antianxiety,agents,the'
p50948
(F1
F0.00014334862385321102
I1
I0
I1
tp50949
sS'found,or,are'
p50950
(F1
F0.00043004587155963305
I3
I0
I3
tp50951
sS'clinically,significant,and'
p50952
(F1
F0.00014334862385321102
I0
I1
I-1
tp50953
sS'by,the,oral'
p50954
(F1
F0.00014334862385321102
I0
I1
I-1
tp50955
sS'pediatric,use,the'
p50956
(F1
F0.00014334862385321102
I0
I1
I-1
tp50957
sS'brain,damage,has'
p50958
(F1
F0.00014334862385321102
I1
I0
I1
tp50959
sS'a,the,initial'
p50960
(F1
F0.00014334862385321102
I0
I1
I-1
tp50961
sS'increase,following,administration'
p50962
(F1
F0.00014334862385321102
I1
I0
I1
tp50963
sS'and,immediately,beginning'
p50964
(F1
F0.00014334862385321102
I1
I0
I1
tp50965
sS'volunteers,a,small'
p50966
(F1
F0.00014334862385321102
I1
I0
I1
tp50967
sS'given,as,a'
p50968
(F0
F0
I2
I2
I0
tp50969
sS'analysis,of,the'
p50970
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp50971
sS'on,the,same'
p50972
(F1
F0.00014334862385321102
I1
I0
I1
tp50973
sS'injection,like,other'
p50974
(F1
F0.00014334862385321102
I1
I0
I1
tp50975
sS'of,was,given'
p50976
(F1
F0.00014334862385321102
I0
I1
I-1
tp50977
sS'microm,also,inhibited'
p50978
(F1
F0.00014334862385321102
I1
I0
I1
tp50979
sS'by,one-third,when'
p50980
(F1
F0.00014334862385321102
I0
I1
I-1
tp50981
sS'ketoconazole,mg,daily'
p50982
(F1
F0.00014334862385321102
I0
I1
I-1
tp50983
sS'media,a,review'
p50984
(F1
F0.00014334862385321102
I1
I0
I1
tp50985
sS'is,a,pharmacokinetic'
p50986
(F1
F0.00028669724770642203
I0
I2
I-2
tp50987
sS'be,minimized,by'
p50988
(F1
F0.00071674311926605509
I5
I0
I5
tp50989
sS'the,intake,and'
p50990
(F1
F0.00014334862385321102
I0
I1
I-1
tp50991
sS'gastrointestinal,absorption,of'
p50992
(F1
F0.00071674311926605509
I5
I0
I5
tp50993
sS'taking,amyl,nitrite'
p50994
(F1
F0.00014334862385321102
I1
I0
I1
tp50995
sS'oxidation,of,and'
p50996
(F1
F0.00014334862385321102
I1
I0
I1
tp50997
sS'after,a,mg'
p50998
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp50999
sS'every,hours,q24h'
p51000
(F1
F0.00014334862385321102
I1
I0
I1
tp51001
sS'hormonal,may,increase'
p51002
(F1
F0.00071674311926605509
I5
I0
I5
tp51003
sS'plasma,prothrombin,activity'
p51004
(F1
F0.00028669724770642203
I2
I0
I2
tp51005
sS'be,maintained,between'
p51006
(F1
F0.00014334862385321102
I1
I0
I1
tp51007
sS'displace,acidic,such'
p51008
(F1
F0.00014334862385321102
I1
I0
I1
tp51009
sS'manifested,as,muscle'
p51010
(F1
F0.00014334862385321102
I0
I1
I-1
tp51011
sS'been,administered,in'
p51012
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp51013
sS'approximately,the,same'
p51014
(F1
F0.00014334862385321102
I0
I1
I-1
tp51015
sS'assessed,in,the'
p51016
(F1
F0.00014334862385321102
I0
I1
I-1
tp51017
sS'days,produced,no'
p51018
(F1
F0.00014334862385321102
I0
I1
I-1
tp51019
sS'it,should,be'
p51020
(F0.5
F0.00028669724770642203
I3
I1
I2
tp51021
sS'exercised,when,the'
p51022
(F1
F0.00014334862385321102
I0
I1
I-1
tp51023
sS'mc,probably,has'
p51024
(F1
F0.00014334862385321102
I0
I1
I-1
tp51025
sS'with,male,rats'
p51026
(F1
F0.00014334862385321102
I1
I0
I1
tp51027
sS'to,patients,taking'
p51028
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp51029
sS'that,interferes,with'
p51030
(F1
F0.00014334862385321102
I1
I0
I1
tp51031
sS'levels,of,homocysteine'
p51032
(F1
F0.00014334862385321102
I0
I1
I-1
tp51033
sS'actions,of,some'
p51034
(F1
F0.00014334862385321102
I0
I1
I-1
tp51035
sS'a,multiple,dose'
p51036
(F1
F0.00014334862385321102
I1
I0
I1
tp51037
sS'stimulus-induced,neural,plasticity'
p51038
(F1
F0.00014334862385321102
I0
I1
I-1
tp51039
sS'of,aprepitant,with'
p51040
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp51041
sS'years,total,cholesterol'
p51042
(F1
F0.00014334862385321102
I0
I1
I-1
tp51043
sS'pharmacokinetic,data,suggest'
p51044
(F1
F0.00014334862385321102
I1
I0
I1
tp51045
sS'to,overlap,to'
p51046
(F1
F0.00014334862385321102
I0
I1
I-1
tp51047
sS'in,kidney,recipients'
p51048
(F1
F0.00014334862385321102
I0
I1
I-1
tp51049
sS'patients,by,inhibiting'
p51050
(F1
F0.00014334862385321102
I1
I0
I1
tp51051
sS'titration,to,the'
p51052
(F1
F0.00014334862385321102
I1
I0
I1
tp51053
sS'volunteers,coadministration,of'
p51054
(F1
F0.00014334862385321102
I0
I1
I-1
tp51055
sS'clinistix,and,glucose'
p51056
(F1
F0.00014334862385321102
I0
I1
I-1
tp51057
sS'increased,levels,in'
p51058
(F1
F0.00043004587155963305
I3
I0
I3
tp51059
sS'between,vitamin,d'
p51060
(F1
F0.00043004587155963305
I3
I0
I3
tp51061
sS'absorption,mean,c'
p51062
(F1
F0.00014334862385321102
I1
I0
I1
tp51063
sS'reexacerbation,of,pulmonary'
p51064
(F1
F0.00014334862385321102
I1
I0
I1
tp51065
sS'inducer,with,mg'
p51066
(F1
F0.00014334862385321102
I1
I0
I1
tp51067
sS'be,administered,together'
p51068
(F1
F0.00014334862385321102
I1
I0
I1
tp51069
sS'may,be,useful'
p51070
(F1
F0.00014334862385321102
I1
I0
I1
tp51071
sS'isocarboxazid,should,be'
p51072
(F1
F0.00014334862385321102
I1
I0
I1
tp51073
sS'evaluate,the,antianginal'
p51074
(F1
F0.00014334862385321102
I0
I1
I-1
tp51075
sS'the,second,day'
p51076
(F1
F0.00014334862385321102
I1
I0
I1
tp51077
sS'increase,their,dose'
p51078
(F1
F0.00028669724770642203
I2
I0
I2
tp51079
sS'reported,to,block'
p51080
(F1
F0.00014334862385321102
I1
I0
I1
tp51081
sS'which,may,require'
p51082
(F1
F0.00014334862385321102
I1
I0
I1
tp51083
sS'trileptal,on,aed'
p51084
(F1
F0.00014334862385321102
I0
I1
I-1
tp51085
sS'and,maois,may'
p51086
(F1
F0.00028669724770642203
I2
I0
I2
tp51087
sS'which,is,not'
p51088
(F1
F0.00014334862385321102
I0
I1
I-1
tp51089
sS'but,serious,constellation'
p51090
(F1
F0.00014334862385321102
I1
I0
I1
tp51091
sS'stimulating,effect,in'
p51092
(F1
F0.00014334862385321102
I1
I0
I1
tp51093
sS'clinical,study,the'
p51094
(F1
F0.00014334862385321102
I1
I0
I1
tp51095
sS'to,the,monomeric'
p51096
(F1
F0.00014334862385321102
I0
I1
I-1
tp51097
sS'myasthenic,patient,only'
p51098
(F1
F0.00014334862385321102
I1
I0
I1
tp51099
sS'these,oral,and'
p51100
(F1
F0.00014334862385321102
I1
I0
I1
tp51101
sS'similar,to,those'
p51102
(F1
F0.00057339449541284407
I4
I0
I4
tp51103
sS'when,using,doses'
p51104
(F1
F0.00014334862385321102
I1
I0
I1
tp51105
sS'and,were,not'
p51106
(F1
F0.00028669724770642203
I0
I2
I-2
tp51107
sS'pesticides,this,study'
p51108
(F1
F0.00014334862385321102
I0
I1
I-1
tp51109
sS'when,xigris,is'
p51110
(F1
F0.00014334862385321102
I0
I1
I-1
tp51111
sS'or,salt,or'
p51112
(F1
F0.00014334862385321102
I0
I1
I-1
tp51113
sS'studies,with,were'
p51114
(F1
F0.00014334862385321102
I0
I1
I-1
tp51115
sS'whether,this,represents'
p51116
(F1
F0.00014334862385321102
I0
I1
I-1
tp51117
sS'morphine,prolonged,gastrointestinal'
p51118
(F1
F0.00014334862385321102
I1
I0
I1
tp51119
sS'duration,but,quickens'
p51120
(F1
F0.00014334862385321102
I1
I0
I1
tp51121
sS'metabolism,increased,altretamines'
p51122
(F1
F0.00014334862385321102
I1
I0
I1
tp51123
sS'to,be,related'
p51124
(F1
F0.00014334862385321102
I0
I1
I-1
tp51125
sS'but,that,the'
p51126
(F1
F0.00014334862385321102
I0
I1
I-1
tp51127
sS'antiarrhythmics,antihistamines,antimigraine'
p51128
(F1
F0.00014334862385321102
I1
I0
I1
tp51129
sS'therefore,when,using'
p51130
(F1
F0.00014334862385321102
I1
I0
I1
tp51131
sS'tail-flick,response,induced'
p51132
(F1
F0.00014334862385321102
I1
I0
I1
tp51133
sS'potential,interactions,between'
p51134
(F1
F0.00057339449541284407
I0
I4
I-4
tp51135
sS'subsequent,treatment,with'
p51136
(F1
F0.00014334862385321102
I1
I0
I1
tp51137
sS'agents,with,less'
p51138
(F1
F0.00014334862385321102
I0
I1
I-1
tp51139
sS'dry,mouth,bodyweight'
p51140
(F1
F0.00014334862385321102
I0
I1
I-1
tp51141
sS'a,decreased,efficacy'
p51142
(F1
F0.00014334862385321102
I1
I0
I1
tp51143
sS'be,discontinued,slowly'
p51144
(F1
F0.00014334862385321102
I1
I0
I1
tp51145
sS'cmax,a,c'
p51146
(F1
F0.00043004587155963305
I3
I0
I3
tp51147
sS'and,bound,by'
p51148
(F1
F0.00014334862385321102
I1
I0
I1
tp51149
sS'in,comparison,to'
p51150
(F1
F0.00014334862385321102
I1
I0
I1
tp51151
sS'l-glutamine,and,may'
p51152
(F1
F0.00014334862385321102
I1
I0
I1
tp51153
sS'use,of,angiotensin'
p51154
(F1
F0.00014334862385321102
I1
I0
I1
tp51155
sS'desmopressin,tablets,should'
p51156
(F1
F0.00014334862385321102
I0
I1
I-1
tp51157
sS'is,greater,in'
p51158
(F1
F0.00043004587155963305
I3
I0
I3
tp51159
sS'for,that,protects'
p51160
(F1
F0.00014334862385321102
I1
I0
I1
tp51161
sS'enhanced,by,monoamine'
p51162
(F1
F0.00014334862385321102
I1
I0
I1
tp51163
sS'affected,when,administered'
p51164
(F1
F0.00014334862385321102
I0
I1
I-1
tp51165
sS'decrease,clozapine,plasma'
p51166
(F1
F0.00014334862385321102
I1
I0
I1
tp51167
sS'mptp,induced,long'
p51168
(F1
F0.00014334862385321102
I1
I0
I1
tp51169
sS'stimulant,type,may'
p51170
(F1
F0.00014334862385321102
I0
I1
I-1
tp51171
sS'to,reduce,hepatic'
p51172
(F1
F0.00014334862385321102
I1
I0
I1
tp51173
sS'or,inr,days'
p51174
(F1
F0.00014334862385321102
I1
I0
I1
tp51175
sS'cyp1a2,is,inhibited'
p51176
(F1
F0.00014334862385321102
I1
I0
I1
tp51177
sS'and,other,have'
p51178
(F1
F0.00028669724770642203
I0
I2
I-2
tp51179
sS'by,approximately,of'
p51180
(F1
F0.00014334862385321102
I1
I0
I1
tp51181
sS'and,a,rapidly'
p51182
(F1
F0.00014334862385321102
I0
I1
I-1
tp51183
sS'useful,in,combination'
p51184
(F1
F0.00014334862385321102
I1
I0
I1
tp51185
sS'for,adverse,reactions'
p51186
(F0
F0
I1
I1
I0
tp51187
sS'and,in,a'
p51188
(F1
F0.00014334862385321102
I0
I1
I-1
tp51189
sS'toxicity,in,those'
p51190
(F1
F0.00014334862385321102
I1
I0
I1
tp51191
sS'absorption,mean,auc'
p51192
(F1
F0.00014334862385321102
I1
I0
I1
tp51193
sS'to,co-administration,of'
p51194
(F1
F0.00014334862385321102
I0
I1
I-1
tp51195
sS'oral,clearance,values'
p51196
(F1
F0.00014334862385321102
I1
I0
I1
tp51197
sS'of,rhabdomyolysis,resulting'
p51198
(F1
F0.00014334862385321102
I0
I1
I-1
tp51199
sS'cardiac,contractility,conductivity'
p51200
(F1
F0.00014334862385321102
I1
I0
I1
tp51201
sS'the,lowest,effective'
p51202
(F1
F0.00028669724770642203
I2
I0
I2
tp51203
sS'have,similar,effects'
p51204
(F1
F0.00014334862385321102
I0
I1
I-1
tp51205
sS'can,significantly,inhibit'
p51206
(F1
F0.00014334862385321102
I1
I0
I1
tp51207
sS'nalfon,may,be'
p51208
(F1
F0.00014334862385321102
I1
I0
I1
tp51209
sS'have,benign,prostatic'
p51210
(F1
F0.00014334862385321102
I0
I1
I-1
tp51211
sS'furosemide,toradol,iv'
p51212
(F1
F0.00014334862385321102
I1
I0
I1
tp51213
sS'can,reduce,the'
p51214
(F1
F0.0020068807339449542
I14
I0
I14
tp51215
sS'related,psychoses,to'
p51216
(F1
F0.00028669724770642203
I0
I2
I-2
tp51217
sS'the,th,day'
p51218
(F1
F0.00028669724770642203
I2
I0
I2
tp51219
sS'a,high,risk'
p51220
(F1
F0.0008600917431192661
I6
I0
I6
tp51221
sS'not,significantly,improve'
p51222
(F1
F0.00014334862385321102
I0
I1
I-1
tp51223
sS'twice,daily,mcg'
p51224
(F1
F0.00014334862385321102
I0
I1
I-1
tp51225
sS'hour,before,or'
p51226
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp51227
sS'psychotropic,that,interfere'
p51228
(F1
F0.00014334862385321102
I1
I0
I1
tp51229
sS'conducted,the,most'
p51230
(F1
F0.00014334862385321102
I0
I1
I-1
tp51231
sS'auc,exhibited,similar'
p51232
(F1
F0.00014334862385321102
I0
I1
I-1
tp51233
sS'if,signs,and'
p51234
(F1
F0.00014334862385321102
I1
I0
I1
tp51235
sS'receiving,to,mg'
p51236
(F1
F0.00014334862385321102
I1
I0
I1
tp51237
sS'significantly,more,effective'
p51238
(F1
F0.00014334862385321102
I0
I1
I-1
tp51239
sS'has,been,administered'
p51240
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp51241
sS'or,proton,pump'
p51242
(F1
F0.00043004587155963305
I3
I0
I3
tp51243
sS'level,of,acidity'
p51244
(F1
F0.00014334862385321102
I1
I0
I1
tp51245
sS'enzyme,inducer,may'
p51246
(F1
F0.00014334862385321102
I1
I0
I1
tp51247
sS'healthy,subjects,no'
p51248
(F1
F0.00014334862385321102
I0
I1
I-1
tp51249
sS'for,to,hours'
p51250
(F1
F0.00028669724770642203
I2
I0
I2
tp51251
sS'acth,treatment,of'
p51252
(F1
F0.00014334862385321102
I0
I1
I-1
tp51253
sS'use,with,thiazide'
p51254
(F1
F0.00014334862385321102
I1
I0
I1
tp51255
sS'showed,an,increase'
p51256
(F1
F0.00014334862385321102
I1
I0
I1
tp51257
sS'be,taken,within'
p51258
(F1
F0.00043004587155963305
I3
I0
I3
tp51259
sS'share,a,common'
p51260
(F1
F0.00014334862385321102
I0
I1
I-1
tp51261
sS'have,no,clinically'
p51262
(F1
F0.00014334862385321102
I0
I1
I-1
tp51263
sS'with,prinivil,can'
p51264
(F1
F0.00014334862385321102
I1
I0
I1
tp51265
sS'instability,with,possible'
p51266
(F1
F0.00014334862385321102
I1
I0
I1
tp51267
sS'immune,system,development'
p51268
(F1
F0.00014334862385321102
I0
I1
I-1
tp51269
sS'minimally,or,not'
p51270
(F1
F0.00014334862385321102
I1
I0
I1
tp51271
sS'the,action,of'
p51272
(F1
F0.0024369266055045873
I17
I0
I17
tp51273
sS'certain,that,are'
p51274
(F1
F0.00028669724770642203
I0
I2
I-2
tp51275
sS'of,the,history'
p51276
(F1
F0.00014334862385321102
I0
I1
I-1
tp51277
sS'blood,pressure,lowering'
p51278
(F1
F0.00014334862385321102
I1
I0
I1
tp51279
sS'activity,of,desmopressin'
p51280
(F1
F0.00014334862385321102
I0
I1
I-1
tp51281
sS'by,the,level'
p51282
(F1
F0.00014334862385321102
I1
I0
I1
tp51283
sS'increased,fold,during'
p51284
(F1
F0.00014334862385321102
I1
I0
I1
tp51285
sS'warfarin,no,significant'
p51286
(F1
F0.00014334862385321102
I0
I1
I-1
tp51287
sS'tam,significantly,potentiates'
p51288
(F1
F0.00014334862385321102
I1
I0
I1
tp51289
sS'conditions,or,with'
p51290
(F1
F0.00014334862385321102
I0
I1
I-1
tp51291
sS'some,further,antihypertensive'
p51292
(F1
F0.00014334862385321102
I1
I0
I1
tp51293
sS'reduce,lithiums,renal'
p51294
(F1
F0.00014334862385321102
I1
I0
I1
tp51295
sS'suggest,that,exposure'
p51296
(F1
F0.00028669724770642203
I2
I0
I2
tp51297
sS'acid,and,nor'
p51298
(F1
F0.00014334862385321102
I0
I1
I-1
tp51299
sS'of,with,occurs'
p51300
(F1
F0.00014334862385321102
I1
I0
I1
tp51301
sS'to,modify,acth'
p51302
(F1
F0.00014334862385321102
I0
I1
I-1
tp51303
sS'clearance,at,steady-state'
p51304
(F1
F0.00014334862385321102
I0
I1
I-1
tp51305
sS'secondary,actions,certain'
p51306
(F1
F0.00014334862385321102
I1
I0
I1
tp51307
sS'given,lodine,or'
p51308
(F1
F0.00014334862385321102
I0
I1
I-1
tp51309
sS'administered,with,antihypertensive'
p51310
(F1
F0.00014334862385321102
I1
I0
I1
tp51311
sS'novel,chemical,reaction'
p51312
(F1
F0.00014334862385321102
I1
I0
I1
tp51313
sS'narrow,therapeutic,index'
p51314
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp51315
sS'that,oral,markedly'
p51316
(F1
F0.00014334862385321102
I1
I0
I1
tp51317
sS'low,dose,did'
p51318
(F1
F0.00014334862385321102
I0
I1
I-1
tp51319
sS'one,patient,taking'
p51320
(F1
F0.00014334862385321102
I1
I0
I1
tp51321
sS'delaying,elimination,and'
p51322
(F1
F0.00028669724770642203
I2
I0
I2
tp51323
sS'following,or,moieties'
p51324
(F1
F0.00014334862385321102
I0
I1
I-1
tp51325
sS'major,bleeding,events'
p51326
(F1
F0.00014334862385321102
I1
I0
I1
tp51327
sS'cyp3a4,inducer,such'
p51328
(F1
F0.00014334862385321102
I0
I1
I-1
tp51329
sS'studies,no,dosage'
p51330
(F1
F0.00014334862385321102
I0
I1
I-1
tp51331
sS'medications,and,other'
p51332
(F1
F0.00014334862385321102
I1
I0
I1
tp51333
sS'with,may,change'
p51334
(F1
F0.00014334862385321102
I1
I0
I1
tp51335
sS'doses,should,be'
p51336
(F0
F0
I1
I1
I0
tp51337
sS'cyp-450,inhibitor,resulted'
p51338
(F1
F0.00014334862385321102
I0
I1
I-1
tp51339
sS'indicate,a,safe'
p51340
(F1
F0.00014334862385321102
I1
I0
I1
tp51341
sS'in,a,single'
p51342
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp51343
sS'for,bleeding,is'
p51344
(F1
F0.00014334862385321102
I0
I1
I-1
tp51345
sS'toradoliv,im,and'
p51346
(F1
F0.00014334862385321102
I0
I1
I-1
tp51347
sS'auc,of,were'
p51348
(F1
F0.00028669724770642203
I2
I0
I2
tp51349
sS'of,pegasys,in'
p51350
(F1
F0.00014334862385321102
I0
I1
I-1
tp51351
sS'gastrointestinal,alkalinizing,agents'
p51352
(F1
F0.00014334862385321102
I1
I0
I1
tp51353
sS'be,ingested,simultaneously'
p51354
(F1
F0.00014334862385321102
I1
I0
I1
tp51355
sS'alternative,or,back-up'
p51356
(F1
F0.00014334862385321102
I1
I0
I1
tp51357
sS'different,types,of'
p51358
(F1
F0.00014334862385321102
I0
I1
I-1
tp51359
sS'in,the,frontal'
p51360
(F1
F0.00014334862385321102
I0
I1
I-1
tp51361
sS'in,serum,half-life'
p51362
(F1
F0.00014334862385321102
I1
I0
I1
tp51363
sS'the,qtc,interval'
p51364
(F1
F0.00028669724770642203
I2
I0
I2
tp51365
sS'with,potent,inducers'
p51366
(F1
F0.00014334862385321102
I0
I1
I-1
tp51367
sS'minipills,that,do'
p51368
(F1
F0.00014334862385321102
I1
I0
I1
tp51369
sS'double-blind,placebo-controlled,study'
p51370
(F1
F0.00014334862385321102
I0
I1
I-1
tp51371
sS'methamphetamine,like,mptp'
p51372
(F1
F0.00014334862385321102
I1
I0
I1
tp51373
sS'may,render,oral'
p51374
(F1
F0.00028669724770642203
I2
I0
I2
tp51375
sS'involving,the,latter'
p51376
(F1
F0.00014334862385321102
I1
I0
I1
tp51377
sS'comparable,cognitive,enhancing'
p51378
(F1
F0.00014334862385321102
I0
I1
I-1
tp51379
sS'h2-receptor,antagonists,co-administration'
p51380
(F1
F0.00014334862385321102
I1
I0
I1
tp51381
sS'with,pcp,dcg-iv'
p51382
(F1
F0.00014334862385321102
I0
I1
I-1
tp51383
sS'additional,that,are'
p51384
(F1
F0.00014334862385321102
I0
I1
I-1
tp51385
sS'levels,during,toradol'
p51386
(F1
F0.00014334862385321102
I1
I0
I1
tp51387
sS'the,following,or'
p51388
(F1
F0.00014334862385321102
I0
I1
I-1
tp51389
sS'and,cohort,design'
p51390
(F1
F0.00014334862385321102
I1
I0
I1
tp51391
sS'representations,of,neural'
p51392
(F1
F0.00014334862385321102
I0
I1
I-1
tp51393
sS'pharmacokinetics,were,unaltered'
p51394
(F1
F0.00014334862385321102
I0
I1
I-1
tp51395
sS'oral,and,its'
p51396
(F1
F0.00014334862385321102
I1
I0
I1
tp51397
sS'and,when,and'
p51398
(F1
F0.00014334862385321102
I1
I0
I1
tp51399
sS'did,not,inhibit'
p51400
(F1
F0.00014334862385321102
I0
I1
I-1
tp51401
sS'steady-state,trough,plasma'
p51402
(F1
F0.00028669724770642203
I0
I2
I-2
tp51403
sS'abolished,both,its'
p51404
(F1
F0.00014334862385321102
I0
I1
I-1
tp51405
sS'and,may,sensitize'
p51406
(F1
F0.00014334862385321102
I1
I0
I1
tp51407
sS'active,metabolite,concentration'
p51408
(F1
F0.00014334862385321102
I1
I0
I1
tp51409
sS'of,the,r'
p51410
(F1
F0.00014334862385321102
I1
I0
I1
tp51411
sS'include,the,following'
p51412
(F1
F0.00043004587155963305
I0
I3
I-3
tp51413
sS'in,the,placebo-controlled'
p51414
(F1
F0.00014334862385321102
I0
I1
I-1
tp51415
sS'translocating,action,of'
p51416
(F1
F0.00014334862385321102
I0
I1
I-1
tp51417
sS'of,l-tyrosine,and'
p51418
(F1
F0.00014334862385321102
I1
I0
I1
tp51419
sS'inhibitory,effects,in'
p51420
(F1
F0.00014334862385321102
I0
I1
I-1
tp51421
sS'no,deleterious,interactions'
p51422
(F1
F0.00014334862385321102
I0
I1
I-1
tp51423
sS'erythromycin,on,felbatol'
p51424
(F1
F0.00014334862385321102
I0
I1
I-1
tp51425
sS'doses,may,inhibit'
p51426
(F1
F0.00014334862385321102
I0
I1
I-1
tp51427
sS'accompanied,by,similar'
p51428
(F1
F0.00014334862385321102
I0
I1
I-1
tp51429
sS'therapy,plasma,levels'
p51430
(F1
F0.00014334862385321102
I1
I0
I1
tp51431
sS'equivocally,higher,when'
p51432
(F1
F0.00014334862385321102
I1
I0
I1
tp51433
sS'and,had,returned'
p51434
(F1
F0.00014334862385321102
I1
I0
I1
tp51435
sS'liquid,did,not'
p51436
(F1
F0.00014334862385321102
I0
I1
I-1
tp51437
sS'accumulation,characteristic,of'
p51438
(F1
F0.00014334862385321102
I0
I1
I-1
tp51439
sS'cyp3a4,activity,eg'
p51440
(F1
F0.00028669724770642203
I2
I0
I2
tp51441
sS'bextra,mg,bid'
p51442
(F1
F0.00014334862385321102
I0
I1
I-1
tp51443
sS'of,in,rats'
p51444
(F1
F0.00014334862385321102
I1
I0
I1
tp51445
sS'bretylium,tosylate,these'
p51446
(F1
F0.00014334862385321102
I0
I1
I-1
tp51447
sS'literature,reports,suggest'
p51448
(F0
F0
I1
I1
I0
tp51449
sS'presumably,acts,as'
p51450
(F1
F0.00014334862385321102
I1
I0
I1
tp51451
sS'macrolide,class,resulting'
p51452
(F1
F0.00014334862385321102
I1
I0
I1
tp51453
sS'were,coadministered,plasma'
p51454
(F1
F0.00014334862385321102
I1
I0
I1
tp51455
sS'volunteers,the,administration'
p51456
(F1
F0.00014334862385321102
I1
I0
I1
tp51457
sS'the,small,effect'
p51458
(F1
F0.00014334862385321102
I1
I0
I1
tp51459
sS'united,kingdom,with'
p51460
(F1
F0.00014334862385321102
I1
I0
I1
tp51461
sS'sodium,channels,and'
p51462
(F1
F0.00014334862385321102
I0
I1
I-1
tp51463
sS'that,affect,the'
p51464
(F0
F0
I1
I1
I0
tp51465
sS'a,serotonin,releaser'
p51466
(F1
F0.00014334862385321102
I1
I0
I1
tp51467
sS'parallel,group,interaction'
p51468
(F1
F0.00014334862385321102
I0
I1
I-1
tp51469
sS'in,vitro,therefore'
p51470
(F1
F0.00014334862385321102
I0
I1
I-1
tp51471
sS'to,a,digitalized'
p51472
(F1
F0.00014334862385321102
I1
I0
I1
tp51473
sS'nonsteroidal,nsaid,such'
p51474
(F1
F0.00014334862385321102
I0
I1
I-1
tp51475
sS'acetazolamide,may,prevent'
p51476
(F1
F0.00014334862385321102
I1
I0
I1
tp51477
sS'increase,serum,levels'
p51478
(F1
F0.00014334862385321102
I0
I1
I-1
tp51479
sS'of,were,considerably'
p51480
(F1
F0.00014334862385321102
I1
I0
I1
tp51481
sS'plasma,level,of'
p51482
(F1
F0.00028669724770642203
I2
I0
I2
tp51483
sS'studies,demonstrate,that'
p51484
(F1
F0.00014334862385321102
I0
I1
I-1
tp51485
sS'pharmacodynamic,effects,of'
p51486
(F1
F0.00014334862385321102
I0
I1
I-1
tp51487
sS'potential,for,altering'
p51488
(F1
F0.00014334862385321102
I0
I1
I-1
tp51489
sS'the,ht3,antagonist'
p51490
(F1
F0.00014334862385321102
I1
I0
I1
tp51491
sS'inhibitors,of,cyp2c19'
p51492
(F1
F0.00014334862385321102
I1
I0
I1
tp51493
sS'monitored,and,their'
p51494
(F1
F0.00014334862385321102
I1
I0
I1
tp51495
sS'with,the,mg'
p51496
(F1
F0.00014334862385321102
I1
I0
I1
tp51497
sS'by,single,high'
p51498
(F1
F0.00014334862385321102
I1
I0
I1
tp51499
sS'interaction,was,observed'
p51500
(F1
F0.00014334862385321102
I0
I1
I-1
tp51501
sS'as,a,gas'
p51502
(F1
F0.00014334862385321102
I0
I1
I-1
tp51503
sS'and,hydroxide,does'
p51504
(F1
F0.00014334862385321102
I0
I1
I-1
tp51505
sS'reports,of,profound'
p51506
(F1
F0.00014334862385321102
I1
I0
I1
tp51507
sS'cyp3a4,did,not'
p51508
(F1
F0.00014334862385321102
I0
I1
I-1
tp51509
sS'combination,with,oral'
p51510
(F1
F0.00014334862385321102
I0
I1
I-1
tp51511
sS'of,in,each'
p51512
(F1
F0.00014334862385321102
I0
I1
I-1
tp51513
sS'all,muscle,relaxants'
p51514
(F1
F0.00014334862385321102
I1
I0
I1
tp51515
sS'of,uricosuric,medication'
p51516
(F1
F0.00014334862385321102
I1
I0
I1
tp51517
sS'antidotal,properties,of'
p51518
(F1
F0.00014334862385321102
I1
I0
I1
tp51519
sS'single,subject,given'
p51520
(F1
F0.00014334862385321102
I1
I0
I1
tp51521
sS'involving,renal,and'
p51522
(F1
F0.00014334862385321102
I1
I0
I1
tp51523
sS'of,excretion,of'
p51524
(F1
F0.00014334862385321102
I1
I0
I1
tp51525
sS'effect,of,hydrochloride'
p51526
(F1
F0.00014334862385321102
I1
I0
I1
tp51527
sS'this,could,lead'
p51528
(F1
F0.00014334862385321102
I1
I0
I1
tp51529
sS'impaired,by,containing'
p51530
(F1
F0.00014334862385321102
I1
I0
I1
tp51531
sS'produced,some,attenuation'
p51532
(F1
F0.00014334862385321102
I0
I1
I-1
tp51533
sS'with,absorption,resulting'
p51534
(F1
F0.00028669724770642203
I2
I0
I2
tp51535
sS'antihistamines,antimigraine,derivatives'
p51536
(F1
F0.00014334862385321102
I1
I0
I1
tp51537
sS'vitamin,d,have'
p51538
(F1
F0.00043004587155963305
I0
I3
I-3
tp51539
sS'natrecor,with,iv'
p51540
(F1
F0.00014334862385321102
I0
I1
I-1
tp51541
sS'of,intestinal,cancers'
p51542
(F1
F0.00028669724770642203
I0
I2
I-2
tp51543
sS'of,on,hepatic'
p51544
(F1
F0.00014334862385321102
I0
I1
I-1
tp51545
sS'taking,concurrent,and'
p51546
(F1
F0.00014334862385321102
I1
I0
I1
tp51547
sS'whom,either,long-acting'
p51548
(F1
F0.00014334862385321102
I0
I1
I-1
tp51549
sS'this,information,to'
p51550
(F1
F0.00014334862385321102
I1
I0
I1
tp51551
sS'this,isoenzyme,family'
p51552
(F1
F0.00014334862385321102
I0
I1
I-1
tp51553
sS'concentration-dependent,relaxation,of'
p51554
(F1
F0.00014334862385321102
I0
I1
I-1
tp51555
sS'muscle,relaxants,that'
p51556
(F1
F0.00014334862385321102
I0
I1
I-1
tp51557
sS'flexeril,may,enhance'
p51558
(F1
F0.00014334862385321102
I1
I0
I1
tp51559
sS'drug-drug,interactions,the'
p51560
(F1
F0.00014334862385321102
I0
I1
I-1
tp51561
sS'cyp3a4,substrate,given'
p51562
(F1
F0.00014334862385321102
I0
I1
I-1
tp51563
sS'dipotassium,prolongs,the'
p51564
(F1
F0.00014334862385321102
I1
I0
I1
tp51565
sS'acid,and,others'
p51566
(F1
F0.00014334862385321102
I1
I0
I1
tp51567
sS'medicines,diabetic,nsaids'
p51568
(F1
F0.00014334862385321102
I1
I0
I1
tp51569
sS'cohort,received,plus'
p51570
(F1
F0.00014334862385321102
I0
I1
I-1
tp51571
sS'interaction,of,with'
p51572
(F0
F0
I1
I1
I0
tp51573
sS'have,their,plasma'
p51574
(F0
F0
I1
I1
I0
tp51575
sS'a,cytostatic,agent'
p51576
(F1
F0.00014334862385321102
I1
I0
I1
tp51577
sS'as,the,and'
p51578
(F1
F0.00028669724770642203
I2
I0
I2
tp51579
sS'receiving,or,in'
p51580
(F1
F0.00014334862385321102
I1
I0
I1
tp51581
sS'with,oral,in'
p51582
(F1
F0.00014334862385321102
I0
I1
I-1
tp51583
sS'a,potent,cyp3a4'
p51584
(F0
F0
I2
I2
I0
tp51585
sS'vecuronium,when,used'
p51586
(F1
F0.00014334862385321102
I1
I0
I1
tp51587
sS'increase,sensitivity,and'
p51588
(F1
F0.00014334862385321102
I1
I0
I1
tp51589
sS'no,effect,one'
p51590
(F1
F0.00014334862385321102
I1
I0
I1
tp51591
sS'midcycle,day,of'
p51592
(F1
F0.00014334862385321102
I0
I1
I-1
tp51593
sS'valproic,acid,has'
p51594
(F1
F0.00014334862385321102
I1
I0
I1
tp51595
sS'following,synthetic,steroidal'
p51596
(F1
F0.00014334862385321102
I0
I1
I-1
tp51597
sS'and,other,than'
p51598
(F1
F0.00014334862385321102
I0
I1
I-1
tp51599
sS'or,initiating,therapy'
p51600
(F1
F0.00014334862385321102
I1
I0
I1
tp51601
sS'of,extraneal,on'
p51602
(F1
F0.00014334862385321102
I0
I1
I-1
tp51603
sS'of,were,unaffected'
p51604
(F1
F0.00014334862385321102
I0
I1
I-1
tp51605
sS'propranolol,attenuated,the'
p51606
(F1
F0.00014334862385321102
I1
I0
I1
tp51607
sS'of,inhibition,of'
p51608
(F0
F0
I1
I1
I0
tp51609
sS'responding,whereas,in'
p51610
(F1
F0.00014334862385321102
I0
I1
I-1
tp51611
sS'antagonize,the,anorectic'
p51612
(F1
F0.00014334862385321102
I1
I0
I1
tp51613
sS'function,as,well'
p51614
(F1
F0.00028669724770642203
I2
I0
I2
tp51615
sS'and,other,that'
p51616
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp51617
sS'some,other,concurrent'
p51618
(F1
F0.00014334862385321102
I1
I0
I1
tp51619
sS'during,this,period'
p51620
(F1
F0.00014334862385321102
I0
I1
I-1
tp51621
sS'levels,of,increased'
p51622
(F1
F0.00043004587155963305
I3
I0
I3
tp51623
sS'therapy,diabetes,mellitus'
p51624
(F1
F0.00014334862385321102
I0
I1
I-1
tp51625
sS'elemental,primarily,iron-fortified'
p51626
(F1
F0.00014334862385321102
I0
I1
I-1
tp51627
sS'sole,protease,inhibitor'
p51628
(F1
F0.00028669724770642203
I0
I2
I-2
tp51629
sS'indicate,that,may'
p51630
(F1
F0.00014334862385321102
I1
I0
I1
tp51631
sS'concomitantly,given,did'
p51632
(F1
F0.00014334862385321102
I0
I1
I-1
tp51633
sS'day,of,concomitant'
p51634
(F1
F0.00014334862385321102
I0
I1
I-1
tp51635
sS'that,significantly,inhibited'
p51636
(F1
F0.00014334862385321102
I1
I0
I1
tp51637
sS'will,not,affect'
p51638
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp51639
sS'when,enablex,is'
p51640
(F1
F0.00014334862385321102
I1
I0
I1
tp51641
sS'on,concomitant,administration'
p51642
(F1
F0.00028669724770642203
I0
I2
I-2
tp51643
sS'imipramine,mg,kg'
p51644
(F1
F0.00014334862385321102
I0
I1
I-1
tp51645
sS'and,possibly,concomitant'
p51646
(F1
F0.00014334862385321102
I1
I0
I1
tp51647
sS'however,mg,of'
p51648
(F1
F0.00014334862385321102
I1
I0
I1
tp51649
sS'daily,before,meals'
p51650
(F1
F0.00028669724770642203
I0
I2
I-2
tp51651
sS'during,muscle,relaxants'
p51652
(F1
F0.00014334862385321102
I0
I1
I-1
tp51653
sS'proportion,of,the'
p51654
(F1
F0.00014334862385321102
I1
I0
I1
tp51655
sS'the,mechanism,for'
p51656
(F1
F0.00014334862385321102
I1
I0
I1
tp51657
sS'the,adrenergic,from'
p51658
(F1
F0.00014334862385321102
I0
I1
I-1
tp51659
sS'intraventricular,and,was'
p51660
(F1
F0.00014334862385321102
I0
I1
I-1
tp51661
sS'of,ketoconazole,and'
p51662
(F1
F0.00014334862385321102
I1
I0
I1
tp51663
sS'binding,globulin,shbg'
p51664
(F1
F0.00014334862385321102
I0
I1
I-1
tp51665
sS'of,the,prothrombin'
p51666
(F1
F0.00028669724770642203
I2
I0
I2
tp51667
sS'spermatozoa,from,the'
p51668
(F1
F0.00014334862385321102
I0
I1
I-1
tp51669
sS'for,clinically,significant'
p51670
(F1
F0.00014334862385321102
I0
I1
I-1
tp51671
sS'dextromethorphan,dextromethorphan,is'
p51672
(F1
F0.00014334862385321102
I0
I1
I-1
tp51673
sS'resulting,in,increases'
p51674
(F1
F0.00014334862385321102
I1
I0
I1
tp51675
sS'and,live-attenuated,should'
p51676
(F1
F0.00014334862385321102
I1
I0
I1
tp51677
sS'stimulation,study,of'
p51678
(F1
F0.00014334862385321102
I0
I1
I-1
tp51679
sS'may,wish,to'
p51680
(F1
F0.00014334862385321102
I1
I0
I1
tp51681
sS'r,and,s'
p51682
(F1
F0.00014334862385321102
I0
I1
I-1
tp51683
sS'resulting,in,increased'
p51684
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp51685
sS'events,or,qtc'
p51686
(F1
F0.00014334862385321102
I0
I1
I-1
tp51687
sS'dose,in,healthy'
p51688
(F1
F0.00014334862385321102
I0
I1
I-1
tp51689
sS'that,haldol,may'
p51690
(F1
F0.00014334862385321102
I1
I0
I1
tp51691
sS'following,subcutaneous,injections'
p51692
(F1
F0.00014334862385321102
I0
I1
I-1
tp51693
sS'gastrointestinal,tract,hydoxide'
p51694
(F1
F0.00014334862385321102
I1
I0
I1
tp51695
sS'doses,of,intravenous'
p51696
(F1
F0.00014334862385321102
I0
I1
I-1
tp51697
sS'of,other,antituberculous'
p51698
(F1
F0.00014334862385321102
I1
I0
I1
tp51699
sS'unless,the,probable'
p51700
(F1
F0.00014334862385321102
I1
I0
I1
tp51701
sS'and,and,type'
p51702
(F1
F0.00014334862385321102
I1
I0
I1
tp51703
sS'urinary,tract,infections'
p51704
(F1
F0.00014334862385321102
I0
I1
I-1
tp51705
sS'initial,release,of'
p51706
(F1
F0.00014334862385321102
I1
I0
I1
tp51707
sS'experience,profile,seen'
p51708
(F1
F0.00014334862385321102
I0
I1
I-1
tp51709
sS'tablets,usp,or'
p51710
(F1
F0.00014334862385321102
I1
I0
I1
tp51711
sS'of,with,is'
p51712
(F1
F0.00014334862385321102
I1
I0
I1
tp51713
sS'micrograms,ml,with'
p51714
(F1
F0.00014334862385321102
I0
I1
I-1
tp51715
sS'no,clinically,significant'
p51716
(F1
F0.0024369266055045873
I0
I17
I-17
tp51717
sS'the,dose,during'
p51718
(F1
F0.00014334862385321102
I0
I1
I-1
tp51719
sS'untreated,hypothyroidism,may'
p51720
(F1
F0.00014334862385321102
I0
I1
I-1
tp51721
sS'with,other,diagnostic'
p51722
(F1
F0.00014334862385321102
I0
I1
I-1
tp51723
sS'the,high-dose,mg'
p51724
(F1
F0.00014334862385321102
I1
I0
I1
tp51725
sS'may,depress,the'
p51726
(F1
F0.00014334862385321102
I1
I0
I1
tp51727
sS'were,and,micrograms'
p51728
(F1
F0.00014334862385321102
I0
I1
I-1
tp51729
sS'mc,decrease,extracellular'
p51730
(F1
F0.00014334862385321102
I0
I1
I-1
tp51731
sS'a,causal,relationship'
p51732
(F1
F0.00014334862385321102
I0
I1
I-1
tp51733
sS'concomitant,and,should'
p51734
(F1
F0.00014334862385321102
I1
I0
I1
tp51735
sS'contraception,should,be'
p51736
(F1
F0.00014334862385321102
I1
I0
I1
tp51737
sS'amiodarone,or,verapamil'
p51738
(F1
F0.00014334862385321102
I1
I0
I1
tp51739
sS'frequent,maintenance,dosing'
p51740
(F1
F0.00014334862385321102
I1
I0
I1
tp51741
sS'whose,efficacy,is'
p51742
(F1
F0.00014334862385321102
I1
I0
I1
tp51743
sS'or,pharmacodynamic,interaction'
p51744
(F1
F0.00028669724770642203
I0
I2
I-2
tp51745
sS'in,the,prothrombin'
p51746
(F1
F0.00014334862385321102
I1
I0
I1
tp51747
sS'permit,larger,doses'
p51748
(F1
F0.00014334862385321102
I0
I1
I-1
tp51749
sS'to,but,the'
p51750
(F1
F0.00014334862385321102
I1
I0
I1
tp51751
sS'medicines,or,substances'
p51752
(F1
F0.00014334862385321102
I1
I0
I1
tp51753
sS'psychoses,to,mg'
p51754
(F1
F0.00014334862385321102
I0
I1
I-1
tp51755
sS'no,interaction,trials'
p51756
(F1
F0.00014334862385321102
I0
I1
I-1
tp51757
sS'the,possibility,should'
p51758
(F1
F0.00014334862385321102
I0
I1
I-1
tp51759
sS'of,tubular,secretion'
p51760
(F1
F0.00014334862385321102
I1
I0
I1
tp51761
sS'of,prolonged,prothrombin'
p51762
(F1
F0.00028669724770642203
I2
I0
I2
tp51763
sS'cmax,of,by'
p51764
(F1
F0.00014334862385321102
I1
I0
I1
tp51765
sS'arabinoside,a,cytostatic'
p51766
(F1
F0.00014334862385321102
I1
I0
I1
tp51767
sS'of,concentrations,tested'
p51768
(F1
F0.00014334862385321102
I0
I1
I-1
tp51769
sS'stopping,before,starting'
p51770
(F1
F0.00014334862385321102
I1
I0
I1
tp51771
sS'blocking,agents,when'
p51772
(F1
F0.00028669724770642203
I2
I0
I2
tp51773
sS'laboratories,platelia,aspergillus'
p51774
(F1
F0.00014334862385321102
I0
I1
I-1
tp51775
sS'estrogen-containing,compounds,meclofenamic'
p51776
(F1
F0.00014334862385321102
I1
I0
I1
tp51777
sS'heart,failure,were'
p51778
(F1
F0.00014334862385321102
I0
I1
I-1
tp51779
sS'aluminum-containing,had,no'
p51780
(F1
F0.00014334862385321102
I0
I1
I-1
tp51781
sS'spontaneous,motility,of'
p51782
(F1
F0.00014334862385321102
I1
I0
I1
tp51783
sS'by,confidence,interval'
p51784
(F1
F0.00014334862385321102
I0
I1
I-1
tp51785
sS'experienced,severe,toxicity'
p51786
(F1
F0.00014334862385321102
I1
I0
I1
tp51787
sS'reports,there,may'
p51788
(F1
F0.00014334862385321102
I1
I0
I1
tp51789
sS'therefore,you,may'
p51790
(F1
F0.00014334862385321102
I1
I0
I1
tp51791
sS'of,gleevec,increased'
p51792
(F1
F0.00014334862385321102
I1
I0
I1
tp51793
sS'patients,may,be'
p51794
(F1
F0.00014334862385321102
I0
I1
I-1
tp51795
sS'compared,with,only'
p51796
(F1
F0.00014334862385321102
I0
I1
I-1
tp51797
sS'aprepitant,when,given'
p51798
(F1
F0.00057339449541284407
I4
I0
I4
tp51799
sS'of,toxicity,may'
p51800
(F1
F0.00014334862385321102
I1
I0
I1
tp51801
sS'efficacy,against,the'
p51802
(F1
F0.00014334862385321102
I0
I1
I-1
tp51803
sS'using,cardiac,and'
p51804
(F1
F0.00014334862385321102
I0
I1
I-1
tp51805
sS'absorbed,into,the'
p51806
(F1
F0.00014334862385321102
I1
I0
I1
tp51807
sS'overload,of,ml'
p51808
(F1
F0.00014334862385321102
I0
I1
I-1
tp51809
sS'of,had,a'
p51810
(F1
F0.00014334862385321102
I0
I1
I-1
tp51811
sS'whether,the,desired'
p51812
(F1
F0.00014334862385321102
I1
I0
I1
tp51813
sS'when,anafranil,is'
p51814
(F1
F0.00014334862385321102
I1
I0
I1
tp51815
sS'was,about,when'
p51816
(F1
F0.00014334862385321102
I1
I0
I1
tp51817
sS'was,used,concomitantly'
p51818
(F1
F0.00028669724770642203
I0
I2
I-2
tp51819
sS'and,vitamin,b12'
p51820
(F1
F0.00014334862385321102
I0
I1
I-1
tp51821
sS'metabolism,of,difluoroacetone'
p51822
(F1
F0.00014334862385321102
I0
I1
I-1
tp51823
sS'harmonic,mean,elimination'
p51824
(F1
F0.00014334862385321102
I0
I1
I-1
tp51825
sS'the,failing,heart'
p51826
(F1
F0.00014334862385321102
I0
I1
I-1
tp51827
sS'coagulation,test,should'
p51828
(F1
F0.00028669724770642203
I2
I0
I2
tp51829
sS'levels,is,recommended'
p51830
(F1
F0.00014334862385321102
I1
I0
I1
tp51831
sS'to,prevent,symptoms'
p51832
(F1
F0.00014334862385321102
I1
I0
I1
tp51833
sS'rats,simultaneous,ingestion'
p51834
(F1
F0.00014334862385321102
I1
I0
I1
tp51835
sS'or,the,level'
p51836
(F1
F0.00014334862385321102
I0
I1
I-1
tp51837
sS'affected,during,concomitant'
p51838
(F1
F0.00014334862385321102
I0
I1
I-1
tp51839
sS'treatment,of,addiction'
p51840
(F1
F0.00014334862385321102
I0
I1
I-1
tp51841
sS'symptoms,leukocytosis,elevated'
p51842
(F1
F0.00014334862385321102
I1
I0
I1
tp51843
sS'crixivan,may,not'
p51844
(F1
F0.00014334862385321102
I1
I0
I1
tp51845
sS'was,coadministered,although'
p51846
(F1
F0.00014334862385321102
I0
I1
I-1
tp51847
sS'pseudotumor,cerebri,benign'
p51848
(F1
F0.00014334862385321102
I1
I0
I1
tp51849
sS'the,anti-coagulant,effect'
p51850
(F1
F0.00014334862385321102
I0
I1
I-1
tp51851
sS'that,interfere,with'
p51852
(F0
F0
I2
I2
I0
tp51853
sS'b12,supplement,while'
p51854
(F1
F0.00014334862385321102
I1
I0
I1
tp51855
sS'did,not,significantly'
p51856
(F0.7142857142857143
F0.0014334862385321102
I2
I12
I-10
tp51857
sS'with,other,broad-spectrum'
p51858
(F1
F0.00014334862385321102
I1
I0
I1
tp51859
sS'in,contrast,in'
p51860
(F1
F0.00014334862385321102
I0
I1
I-1
tp51861
sS'to,the,release'
p51862
(F1
F0.00014334862385321102
I0
I1
I-1
tp51863
sS'elimination,of,most'
p51864
(F1
F0.00014334862385321102
I1
I0
I1
tp51865
sS'solution,may,substantially'
p51866
(F1
F0.00028669724770642203
I2
I0
I2
tp51867
sS'inhibitory,activity,towards'
p51868
(F1
F0.00014334862385321102
I1
I0
I1
tp51869
sS'tikosyn,or,the'
p51870
(F1
F0.00014334862385321102
I0
I1
I-1
tp51871
sS'measuring,serum,total'
p51872
(F1
F0.00014334862385321102
I0
I1
I-1
tp51873
sS'concomitant,medications,in'
p51874
(F1
F0.00014334862385321102
I0
I1
I-1
tp51875
sS'exposure,auc,of'
p51876
(F1
F0.00028669724770642203
I2
I0
I2
tp51877
sS'serum,levels,in'
p51878
(F1
F0.00014334862385321102
I1
I0
I1
tp51879
sS'with,those,produced'
p51880
(F1
F0.00014334862385321102
I1
I0
I1
tp51881
sS'to,the,aucs'
p51882
(F1
F0.00014334862385321102
I0
I1
I-1
tp51883
sS'were,given,fu'
p51884
(F1
F0.00014334862385321102
I0
I1
I-1
tp51885
sS'establish,a,cause-and'
p51886
(F1
F0.00014334862385321102
I1
I0
I1
tp51887
sS'to,or,concurrent'
p51888
(F1
F0.00014334862385321102
I1
I0
I1
tp51889
sS'increase,in,the'
p51890
(F0.61538461538461542
F0.0022935779816513763
I21
I5
I16
tp51891
sS'especially,of,amphotericin'
p51892
(F1
F0.00014334862385321102
I0
I1
I-1
tp51893
sS'the,authors,compared'
p51894
(F1
F0.00014334862385321102
I0
I1
I-1
tp51895
sS'day,course,of'
p51896
(F1
F0.00014334862385321102
I0
I1
I-1
tp51897
sS'and,a,delay'
p51898
(F1
F0.00014334862385321102
I1
I0
I1
tp51899
sS'and,upon,concomitant'
p51900
(F1
F0.00014334862385321102
I1
I0
I1
tp51901
sS'of,the,endotoxin-treated'
p51902
(F1
F0.00014334862385321102
I1
I0
I1
tp51903
sS'sonata,mg,did'
p51904
(F1
F0.00014334862385321102
I0
I1
I-1
tp51905
sS'receiving,and,serious'
p51906
(F1
F0.00014334862385321102
I1
I0
I1
tp51907
sS'not,been,conducted'
p51908
(F0
F0
I1
I1
I0
tp51909
sS'determined,by,checkerboard'
p51910
(F1
F0.00014334862385321102
I0
I1
I-1
tp51911
sS'with,an,in'
p51912
(F1
F0.00014334862385321102
I1
I0
I1
tp51913
sS'should,be,checked'
p51914
(F1
F0.00014334862385321102
I1
I0
I1
tp51915
sS'use,of,toradol'
p51916
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp51917
sS'taking,most,and'
p51918
(F1
F0.00014334862385321102
I0
I1
I-1
tp51919
sS'monoamine,oxidase,inhibitor'
p51920
(F1
F0.00014334862385321102
I0
I1
I-1
tp51921
sS'avoided,as,this'
p51922
(F1
F0.00043004587155963305
I0
I3
I-3
tp51923
sS'in,auc,a'
p51924
(F1
F0.00014334862385321102
I1
I0
I1
tp51925
sS'and,discontinuing,hydrochloride'
p51926
(F1
F0.00014334862385321102
I1
I0
I1
tp51927
sS'stadol,ns,is'
p51928
(F1
F0.00014334862385321102
I1
I0
I1
tp51929
sS'with,the,first'
p51930
(F1
F0.00014334862385321102
I0
I1
I-1
tp51931
sS'underlie,its,long-lasting'
p51932
(F1
F0.00014334862385321102
I0
I1
I-1
tp51933
sS'discontinued,slowly,over'
p51934
(F1
F0.00014334862385321102
I1
I0
I1
tp51935
sS'affect,the,peak'
p51936
(F1
F0.00014334862385321102
I0
I1
I-1
tp51937
sS'following,interactions,must'
p51938
(F1
F0.00014334862385321102
I1
I0
I1
tp51939
sS'increase,the,likelihood'
p51940
(F1
F0.00028669724770642203
I2
I0
I2
tp51941
sS'be,additive,with'
p51942
(F1
F0.00057339449541284407
I4
I0
I4
tp51943
sS'be,used,clinically'
p51944
(F1
F0.00014334862385321102
I0
I1
I-1
tp51945
sS'increased,the,auc'
p51946
(F1
F0.0014334862385321102
I10
I0
I10
tp51947
sS'should,receive,mg'
p51948
(F1
F0.00014334862385321102
I1
I0
I1
tp51949
sS'nursing,infant,has'
p51950
(F1
F0.00014334862385321102
I0
I1
I-1
tp51951
sS'apart,so,that'
p51952
(F1
F0.00014334862385321102
I0
I1
I-1
tp51953
sS'with,antacids,administration'
p51954
(F1
F0.00014334862385321102
I1
I0
I1
tp51955
sS'hours,two,times'
p51956
(F1
F0.00014334862385321102
I0
I1
I-1
tp51957
sS'concomitant,medication,but'
p51958
(F1
F0.00014334862385321102
I0
I1
I-1
tp51959
sS'but,brevibloc,steady-state'
p51960
(F1
F0.00014334862385321102
I1
I0
I1
tp51961
sS'single,oral,dose'
p51962
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp51963
sS'such,agents,should'
p51964
(F1
F0.00014334862385321102
I0
I1
I-1
tp51965
sS'by,fold,which'
p51966
(F1
F0.00014334862385321102
I1
I0
I1
tp51967
sS'hiv-infected,subjects,to'
p51968
(F1
F0.00014334862385321102
I0
I1
I-1
tp51969
sS'in,vitro,and'
p51970
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp51971
sS'of,the,pharmacodynamic'
p51972
(F1
F0.00014334862385321102
I0
I1
I-1
tp51973
sS'and,compromise,their'
p51974
(F1
F0.00014334862385321102
I1
I0
I1
tp51975
sS'r-warfarin,a,cyp3a4'
p51976
(F1
F0.00014334862385321102
I1
I0
I1
tp51977
sS'displaces,from,protein'
p51978
(F1
F0.00014334862385321102
I1
I0
I1
tp51979
sS'patients,with,active'
p51980
(F1
F0.00028669724770642203
I2
I0
I2
tp51981
sS'nervous,system,depression'
p51982
(F1
F0.00014334862385321102
I1
I0
I1
tp51983
sS'therapy,and,concerns'
p51984
(F1
F0.00014334862385321102
I0
I1
I-1
tp51985
sS'which,competes,for'
p51986
(F1
F0.00014334862385321102
I1
I0
I1
tp51987
sS'toxicity,of,and'
p51988
(F1
F0.00014334862385321102
I0
I1
I-1
tp51989
sS'suffering,from,chronic'
p51990
(F1
F0.00014334862385321102
I1
I0
I1
tp51991
sS'especially,the,and'
p51992
(F1
F0.00014334862385321102
I1
I0
I1
tp51993
sS'benzodiazepine,class,of'
p51994
(F1
F0.00014334862385321102
I1
I0
I1
tp51995
sS'the,anti-platelet,activity'
p51996
(F1
F0.00014334862385321102
I0
I1
I-1
tp51997
sS'neutrophil,counts,in'
p51998
(F1
F0.00014334862385321102
I1
I0
I1
tp51999
sS'which,sensitize,the'
p52000
(F1
F0.00014334862385321102
I1
I0
I1
tp52001
sS'include,adrenocortical,steroids'
p52002
(F1
F0.00014334862385321102
I1
I0
I1
tp52003
sS'may,alter,plasma'
p52004
(F1
F0.00014334862385321102
I1
I0
I1
tp52005
sS'on,average,higher'
p52006
(F1
F0.00014334862385321102
I0
I1
I-1
tp52007
sS'mg,iv,was'
p52008
(F1
F0.00014334862385321102
I0
I1
I-1
tp52009
sS'nitrite,after,drinking'
p52010
(F1
F0.00014334862385321102
I1
I0
I1
tp52011
sS'bioavailability,of,and'
p52012
(F0
F0
I1
I1
I0
tp52013
sS'a,nasal,vasoconstrictor'
p52014
(F1
F0.00014334862385321102
I0
I1
I-1
tp52015
sS'zofran,and,kytril'
p52016
(F1
F0.00014334862385321102
I0
I1
I-1
tp52017
sS'decreases,in,levels'
p52018
(F1
F0.00014334862385321102
I1
I0
I1
tp52019
sS'in,a,placebo-controlled'
p52020
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp52021
sS'by,of,bombesin-enhanced'
p52022
(F1
F0.00014334862385321102
I1
I0
I1
tp52023
sS'directly,interfere,with'
p52024
(F1
F0.00014334862385321102
I1
I0
I1
tp52025
sS'for,recovery,from'
p52026
(F1
F0.00014334862385321102
I0
I1
I-1
tp52027
sS'was,included,as'
p52028
(F1
F0.00014334862385321102
I0
I1
I-1
tp52029
sS'greater,patients,when'
p52030
(F1
F0.00014334862385321102
I1
I0
I1
tp52031
sS'and,cmc-cys,conjugates'
p52032
(F1
F0.00014334862385321102
I0
I1
I-1
tp52033
sS'reactions,thought,to'
p52034
(F1
F0.00014334862385321102
I0
I1
I-1
tp52035
sS'against,bacillus,subtilis'
p52036
(F1
F0.00014334862385321102
I1
I0
I1
tp52037
sS'currently,taking,amevive'
p52038
(F1
F0.00014334862385321102
I0
I1
I-1
tp52039
sS'of,vasopressor,for'
p52040
(F1
F0.00014334862385321102
I1
I0
I1
tp52041
sS'patients,receiving,vioxx'
p52042
(F1
F0.00014334862385321102
I1
I0
I1
tp52043
sS'coumarin-derivative,concomitantly,with'
p52044
(F1
F0.00014334862385321102
I1
I0
I1
tp52045
sS'kg,of,fe'
p52046
(F1
F0.00014334862385321102
I0
I1
I-1
tp52047
sS'alter,the,biological'
p52048
(F1
F0.00014334862385321102
I1
I0
I1
tp52049
sS'as,immediate-early,genes'
p52050
(F1
F0.00014334862385321102
I0
I1
I-1
tp52051
sS'have,a,mild'
p52052
(F1
F0.00014334862385321102
I0
I1
I-1
tp52053
sS'administration,of,certain'
p52054
(F1
F0.00014334862385321102
I1
I0
I1
tp52055
sS'also,likely,to'
p52056
(F1
F0.00014334862385321102
I1
I0
I1
tp52057
sS'thus,may,prevent'
p52058
(F1
F0.00014334862385321102
I0
I1
I-1
tp52059
sS'to,plasma,proteins'
p52060
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp52061
sS'that,the,hepatoxicity'
p52062
(F1
F0.00014334862385321102
I1
I0
I1
tp52063
sS'metabolic,clearance,of'
p52064
(F1
F0.00071674311926605509
I5
I0
I5
tp52065
sS'to,slow,the'
p52066
(F1
F0.00014334862385321102
I1
I0
I1
tp52067
sS'arteries,from,lean'
p52068
(F1
F0.00014334862385321102
I0
I1
I-1
tp52069
sS'editorials,concerning,published'
p52070
(F1
F0.00014334862385321102
I0
I1
I-1
tp52071
sS'possible,interaction,has'
p52072
(F1
F0.00014334862385321102
I0
I1
I-1
tp52073
sS'of,the,qtc'
p52074
(F1
F0.00014334862385321102
I1
I0
I1
tp52075
sS'mg,for,at'
p52076
(F1
F0.00014334862385321102
I0
I1
I-1
tp52077
sS'cyp3a4,inhibitors,and'
p52078
(F0
F0
I1
I1
I0
tp52079
sS'obtained,when,it'
p52080
(F1
F0.00028669724770642203
I2
I0
I2
tp52081
sS'this,study,indicates'
p52082
(F1
F0.00014334862385321102
I0
I1
I-1
tp52083
sS'with,potassium-depleting,agents'
p52084
(F1
F0.00014334862385321102
I1
I0
I1
tp52085
sS'to,mg,per'
p52086
(F1
F0.00014334862385321102
I0
I1
I-1
tp52087
sS'on,the,apparent'
p52088
(F1
F0.00014334862385321102
I0
I1
I-1
tp52089
sS'were,concomitantly,administered'
p52090
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp52091
sS'by,effects,on'
p52092
(F1
F0.00014334862385321102
I0
I1
I-1
tp52093
sS'patients,suffering,from'
p52094
(F1
F0.00014334862385321102
I1
I0
I1
tp52095
sS'and,fentanyl,in'
p52096
(F1
F0.00014334862385321102
I1
I0
I1
tp52097
sS'channel,an,omega-agatoxin'
p52098
(F1
F0.00014334862385321102
I0
I1
I-1
tp52099
sS'celebrex,may,result'
p52100
(F1
F0.00014334862385321102
I1
I0
I1
tp52101
sS'levels,may,be'
p52102
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp52103
sS'higher,incidence,of'
p52104
(F1
F0.00014334862385321102
I1
I0
I1
tp52105
sS'of,refludan,on'
p52106
(F1
F0.00014334862385321102
I0
I1
I-1
tp52107
sS'and,therefore,signs'
p52108
(F1
F0.00014334862385321102
I0
I1
I-1
tp52109
sS'task,it,substituted'
p52110
(F1
F0.00014334862385321102
I0
I1
I-1
tp52111
sS'period,of,observation'
p52112
(F1
F0.00014334862385321102
I0
I1
I-1
tp52113
sS'such,as,p-glycoprotein'
p52114
(F1
F0.00014334862385321102
I1
I0
I1
tp52115
sS'the,mean,clearances'
p52116
(F1
F0.00014334862385321102
I1
I0
I1
tp52117
sS'clinical,trials,patients'
p52118
(F1
F0.00014334862385321102
I0
I1
I-1
tp52119
sS'action,of,nondepolarizing'
p52120
(F1
F0.00043004587155963305
I3
I0
I3
tp52121
sS'provides,considerable,evidence'
p52122
(F1
F0.00014334862385321102
I0
I1
I-1
tp52123
sS'with,would,not'
p52124
(F1
F0.00014334862385321102
I0
I1
I-1
tp52125
sS'benzylpenicillin,and,have'
p52126
(F1
F0.00014334862385321102
I0
I1
I-1
tp52127
sS'with,interferon,beta'
p52128
(F1
F0.00014334862385321102
I0
I1
I-1
tp52129
sS'been,received,among'
p52130
(F1
F0.00014334862385321102
I0
I1
I-1
tp52131
sS'result,in,higher'
p52132
(F0
F0
I1
I1
I0
tp52133
sS'secretion,of,a'
p52134
(F1
F0.00014334862385321102
I0
I1
I-1
tp52135
sS'in,those,patients'
p52136
(F1
F0.00028669724770642203
I2
I0
I2
tp52137
sS'even,more,conservatively'
p52138
(F1
F0.00014334862385321102
I1
I0
I1
tp52139
sS'therefore,has,the'
p52140
(F0
F0
I1
I1
I0
tp52141
sS'fenfluramine,may,increase'
p52142
(F1
F0.00014334862385321102
I1
I0
I1
tp52143
sS'in,ewes,given'
p52144
(F1
F0.00014334862385321102
I1
I0
I1
tp52145
sS'pharmacokinetic,study,evaluating'
p52146
(F1
F0.00014334862385321102
I1
I0
I1
tp52147
sS'dose,pharmacokinetic,interaction'
p52148
(F1
F0.00014334862385321102
I0
I1
I-1
tp52149
sS'they,reduce,lithiums'
p52150
(F1
F0.00014334862385321102
I1
I0
I1
tp52151
sS'disturbances,have,led'
p52152
(F1
F0.00014334862385321102
I0
I1
I-1
tp52153
sS'deterioration,in,renal'
p52154
(F1
F0.00014334862385321102
I0
I1
I-1
tp52155
sS'diclofenac,administration,of'
p52156
(F1
F0.00014334862385321102
I0
I1
I-1
tp52157
sS'should,also,be'
p52158
(F0
F0
I2
I2
I0
tp52159
sS'by,h2,blockers'
p52160
(F1
F0.00014334862385321102
I1
I0
I1
tp52161
sS'effect,on,that'
p52162
(F1
F0.00014334862385321102
I0
I1
I-1
tp52163
sS'spray,the,auc'
p52164
(F1
F0.00014334862385321102
I1
I0
I1
tp52165
sS'a,week,endoscopy'
p52166
(F1
F0.00014334862385321102
I0
I1
I-1
tp52167
sS'in,cmax,when'
p52168
(F1
F0.00043004587155963305
I3
I0
I3
tp52169
sS'alter,the,metabolism'
p52170
(F1
F0.00043004587155963305
I3
I0
I3
tp52171
sS'dose,adjustments,considered'
p52172
(F1
F0.00014334862385321102
I1
I0
I1
tp52173
sS'exploited,in,the'
p52174
(F1
F0.00014334862385321102
I0
I1
I-1
tp52175
sS'min,or,t'
p52176
(F1
F0.00014334862385321102
I0
I1
I-1
tp52177
sS'to,increase,plasma'
p52178
(F1
F0.00057339449541284407
I4
I0
I4
tp52179
sS'component,of,insect'
p52180
(F1
F0.00014334862385321102
I1
I0
I1
tp52181
sS'on,average,by'
p52182
(F1
F0.00014334862385321102
I1
I0
I1
tp52183
sS'antidepressants,in,vitro'
p52184
(F1
F0.00014334862385321102
I1
I0
I1
tp52185
sS'altered,in,patients'
p52186
(F1
F0.00014334862385321102
I0
I1
I-1
tp52187
sS'downward,adjustment,of'
p52188
(F1
F0.00028669724770642203
I2
I0
I2
tp52189
sS'may,show,elevations'
p52190
(F1
F0.00014334862385321102
I1
I0
I1
tp52191
sS'patients,taking,when'
p52192
(F0
F0
I1
I1
I0
tp52193
sS'the,co-administered,dose'
p52194
(F1
F0.00014334862385321102
I0
I1
I-1
tp52195
sS'of,serum,levels'
p52196
(F0
F0
I1
I1
I0
tp52197
sS'administration,of,sonata'
p52198
(F1
F0.00014334862385321102
I1
I0
I1
tp52199
sS'of,hydroxide,and'
p52200
(F1
F0.00014334862385321102
I0
I1
I-1
tp52201
sS'inhibitors,of,these'
p52202
(F1
F0.00014334862385321102
I0
I1
I-1
tp52203
sS'clearances,of,were'
p52204
(F1
F0.00014334862385321102
I1
I0
I1
tp52205
sS'administered,with,the'
p52206
(F1
F0.00014334862385321102
I1
I0
I1
tp52207
sS'that,block,angiotensin'
p52208
(F1
F0.00014334862385321102
I0
I1
I-1
tp52209
sS'pretreatment,with,reduces'
p52210
(F1
F0.00014334862385321102
I1
I0
I1
tp52211
sS'substrate,by,fold'
p52212
(F1
F0.00043004587155963305
I3
I0
I3
tp52213
sS'clinical,patterns,of'
p52214
(F1
F0.00014334862385321102
I0
I1
I-1
tp52215
sS'administered,to,mice'
p52216
(F1
F0.00014334862385321102
I0
I1
I-1
tp52217
sS'administration,twice,a'
p52218
(F1
F0.00014334862385321102
I0
I1
I-1
tp52219
sS'failure,severe,hypotension'
p52220
(F1
F0.00014334862385321102
I1
I0
I1
tp52221
sS'hypotensive,effects,with'
p52222
(F1
F0.00057339449541284407
I4
I0
I4
tp52223
sS'of,antifibrinolytic,therapies'
p52224
(F1
F0.00014334862385321102
I0
I1
I-1
tp52225
sS'limited,inhibitory,activity'
p52226
(F1
F0.00014334862385321102
I1
I0
I1
tp52227
sS'affected,by,or'
p52228
(F1
F0.00014334862385321102
I0
I1
I-1
tp52229
sS'not,recommended,when'
p52230
(F1
F0.00014334862385321102
I1
I0
I1
tp52231
sS'as,amphotericin,b'
p52232
(F1
F0.00014334862385321102
I1
I0
I1
tp52233
sS'to,peak,and'
p52234
(F1
F0.00014334862385321102
I0
I1
I-1
tp52235
sS'zebeta,on,prothrombin'
p52236
(F1
F0.00014334862385321102
I0
I1
I-1
tp52237
sS'co-administration,of,natrecor'
p52238
(F1
F0.00014334862385321102
I0
I1
I-1
tp52239
sS'amphetamines,may,delay'
p52240
(F1
F0.0008600917431192661
I6
I0
I6
tp52241
sS'sodium,unreliable,prothrombin'
p52242
(F1
F0.00014334862385321102
I1
I0
I1
tp52243
sS'indicate,that,has'
p52244
(F1
F0.00014334862385321102
I0
I1
I-1
tp52245
sS'or,in,patients'
p52246
(F1
F0.00014334862385321102
I0
I1
I-1
tp52247
sS'increased,and,decreased'
p52248
(F1
F0.00014334862385321102
I1
I0
I1
tp52249
sS'for,two,weeks'
p52250
(F1
F0.00014334862385321102
I1
I0
I1
tp52251
sS'treatment,with,sprycel'
p52252
(F1
F0.00014334862385321102
I0
I1
I-1
tp52253
sS'been,filtrated,to'
p52254
(F1
F0.00014334862385321102
I1
I0
I1
tp52255
sS'oxidase,and,cyp3a4'
p52256
(F1
F0.00014334862385321102
I1
I0
I1
tp52257
sS'expected,to,occur'
p52258
(F1
F0.00014334862385321102
I0
I1
I-1
tp52259
sS'agents,coadministration,of'
p52260
(F1
F0.00028669724770642203
I0
I2
I-2
tp52261
sS'be,monitored,in'
p52262
(F1
F0.00014334862385321102
I1
I0
I1
tp52263
sS'hydrochloride,may,enhance'
p52264
(F1
F0.00014334862385321102
I1
I0
I1
tp52265
sS'anticonvulsants,in,a'
p52266
(F1
F0.00014334862385321102
I1
I0
I1
tp52267
sS'or,will,not'
p52268
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp52269
sS'mg,and,multiple'
p52270
(F1
F0.00028669724770642203
I0
I2
I-2
tp52271
sS'left,ventricular,dysfunction'
p52272
(F1
F0.00014334862385321102
I0
I1
I-1
tp52273
sS'drugs,that,have'
p52274
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp52275
sS'aed,induces,or'
p52276
(F1
F0.00014334862385321102
I0
I1
I-1
tp52277
sS'and,inhibit,platelet'
p52278
(F1
F0.00014334862385321102
I0
I1
I-1
tp52279
sS'nitrogen,mustard,etc'
p52280
(F1
F0.00014334862385321102
I0
I1
I-1
tp52281
sS'c,interval,prolongation'
p52282
(F1
F0.00014334862385321102
I1
I0
I1
tp52283
sS'intramuscular,doses,of'
p52284
(F1
F0.00014334862385321102
I0
I1
I-1
tp52285
sS'concentration,and,prolong'
p52286
(F1
F0.00014334862385321102
I1
I0
I1
tp52287
sS'aspirin,concurrent,administration'
p52288
(F1
F0.00028669724770642203
I2
I0
I2
tp52289
sS'but,physicians,should'
p52290
(F1
F0.00028669724770642203
I2
I0
I2
tp52291
sS'the,growth,response'
p52292
(F1
F0.00014334862385321102
I0
I1
I-1
tp52293
sS'caused,a,first'
p52294
(F1
F0.00014334862385321102
I0
I1
I-1
tp52295
sS'group,specifically,cytochromes'
p52296
(F1
F0.00014334862385321102
I0
I1
I-1
tp52297
sS'of,dry,mouth'
p52298
(F1
F0.00014334862385321102
I1
I0
I1
tp52299
sS'no,dose,adjustment'
p52300
(F1
F0.00071674311926605509
I0
I5
I-5
tp52301
sS'potentiated,by,which'
p52302
(F1
F0.00014334862385321102
I1
I0
I1
tp52303
sS'potentiate,the,hypotensive'
p52304
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp52305
sS'may,have,decreased'
p52306
(F1
F0.00014334862385321102
I0
I1
I-1
tp52307
sS'from,one,class'
p52308
(F1
F0.00057339449541284407
I4
I0
I4
tp52309
sS'hypothesis,there,is'
p52310
(F1
F0.00014334862385321102
I0
I1
I-1
tp52311
sS'combination,with,is'
p52312
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp52313
sS'and,nonsteroidal,anti-inflammatory'
p52314
(F1
F0.00014334862385321102
I0
I1
I-1
tp52315
sS'and,longer,intervals'
p52316
(F1
F0.00014334862385321102
I1
I0
I1
tp52317
sS'despite,the,several-fold'
p52318
(F1
F0.00014334862385321102
I0
I1
I-1
tp52319
sS'rat,were,evaluated'
p52320
(F1
F0.00014334862385321102
I0
I1
I-1
tp52321
sS'other,has,not'
p52322
(F1
F0.00014334862385321102
I1
I0
I1
tp52323
sS'with,it,is'
p52324
(F1
F0.00014334862385321102
I0
I1
I-1
tp52325
sS'dose,of,itraconazole'
p52326
(F1
F0.00014334862385321102
I0
I1
I-1
tp52327
sS'of,the,active'
p52328
(F0
F0
I1
I1
I0
tp52329
sS'verapamil,produced,a'
p52330
(F1
F0.00014334862385321102
I0
I1
I-1
tp52331
sS'and,caused,excessive'
p52332
(F1
F0.00014334862385321102
I0
I1
I-1
tp52333
sS'the,interaction,between'
p52334
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp52335
sS'activity,effects,may'
p52336
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp52337
sS'inhibitors,in,patients'
p52338
(F1
F0.00028669724770642203
I2
I0
I2
tp52339
sS'given,exclusively,by'
p52340
(F1
F0.00014334862385321102
I0
I1
I-1
tp52341
sS'inhibitors,of,cyp1a2'
p52342
(F1
F0.00014334862385321102
I1
I0
I1
tp52343
sS'would,seem,to'
p52344
(F1
F0.00014334862385321102
I1
I0
I1
tp52345
sS'and,intravenously,administered'
p52346
(F1
F0.00014334862385321102
I1
I0
I1
tp52347
sS'leukocyte,transfusions,acute'
p52348
(F1
F0.00014334862385321102
I1
I0
I1
tp52349
sS'syndrome,associated,with'
p52350
(F1
F0.00014334862385321102
I1
I0
I1
tp52351
sS'oxidase,in,vitro'
p52352
(F1
F0.00014334862385321102
I1
I0
I1
tp52353
sS'increases,the,effect'
p52354
(F1
F0.00028669724770642203
I2
I0
I2
tp52355
sS'does,not,appear'
p52356
(F1
F0.00057339449541284407
I0
I4
I-4
tp52357
sS'receiving,injection,who'
p52358
(F1
F0.00014334862385321102
I0
I1
I-1
tp52359
sS'and,half-life,increased'
p52360
(F1
F0.00028669724770642203
I2
I0
I2
tp52361
sS'kg,for,days'
p52362
(F1
F0.00014334862385321102
I1
I0
I1
tp52363
sS'including,normal,healthy'
p52364
(F1
F0.00014334862385321102
I0
I1
I-1
tp52365
sS'isoenzyme,including,other'
p52366
(F1
F0.00014334862385321102
I1
I0
I1
tp52367
sS'with,chirocaine,that'
p52368
(F1
F0.00014334862385321102
I0
I1
I-1
tp52369
sS'agents,or,glycosides'
p52370
(F1
F0.00014334862385321102
I0
I1
I-1
tp52371
sS'adjustment,for,mg'
p52372
(F1
F0.00014334862385321102
I1
I0
I1
tp52373
sS'qd,by,about'
p52374
(F1
F0.00014334862385321102
I1
I0
I1
tp52375
sS'like,mptp,produced'
p52376
(F1
F0.00014334862385321102
I1
I0
I1
tp52377
sS'brevibloc,but,the'
p52378
(F1
F0.00014334862385321102
I1
I0
I1
tp52379
sS'increase,in,prothrombin'
p52380
(F1
F0.00014334862385321102
I1
I0
I1
tp52381
sS'responding,produced,by'
p52382
(F1
F0.00014334862385321102
I1
I0
I1
tp52383
sS'to,m,markedly'
p52384
(F1
F0.00014334862385321102
I1
I0
I1
tp52385
sS'and,non-selective,beta-adrenergic'
p52386
(F1
F0.00014334862385321102
I1
I0
I1
tp52387
sS'the,enzymes,responsible'
p52388
(F1
F0.00014334862385321102
I0
I1
I-1
tp52389
sS'increase,the,pharmacologic'
p52390
(F1
F0.00028669724770642203
I2
I0
I2
tp52391
sS'negative,symptoms,and'
p52392
(F1
F0.00014334862385321102
I0
I1
I-1
tp52393
sS'study,the,influence'
p52394
(F1
F0.00014334862385321102
I0
I1
I-1
tp52395
sS'of,cyp3a4,activity'
p52396
(F0.5
F0.00028669724770642203
I3
I1
I2
tp52397
sS'hours,of,each'
p52398
(F1
F0.00043004587155963305
I3
I0
I3
tp52399
sS'in,exposure,to'
p52400
(F1
F0.00014334862385321102
I1
I0
I1
tp52401
sS'laboratory,tests,interactions'
p52402
(F1
F0.00014334862385321102
I0
I1
I-1
tp52403
sS'carbachol-stimulated,intracellular,ca'
p52404
(F1
F0.00014334862385321102
I1
I0
I1
tp52405
sS'coombs,reactions,in'
p52406
(F1
F0.00014334862385321102
I0
I1
I-1
tp52407
sS'index,and,most'
p52408
(F1
F0.00014334862385321102
I0
I1
I-1
tp52409
sS'the,lower,rate'
p52410
(F1
F0.00014334862385321102
I1
I0
I1
tp52411
sS'co-administered,with,care'
p52412
(F1
F0.00014334862385321102
I1
I0
I1
tp52413
sS'fici,was,determined'
p52414
(F1
F0.00014334862385321102
I0
I1
I-1
tp52415
sS'cimetidine,concomitant,use'
p52416
(F1
F0.00014334862385321102
I0
I1
I-1
tp52417
sS'a,frequent,cause'
p52418
(F1
F0.00014334862385321102
I1
I0
I1
tp52419
sS'co-administration,with,high'
p52420
(F1
F0.00014334862385321102
I1
I0
I1
tp52421
sS'singly,or,in'
p52422
(F1
F0.00014334862385321102
I0
I1
I-1
tp52423
sS'with,against,bacillus'
p52424
(F1
F0.00014334862385321102
I1
I0
I1
tp52425
sS'or,substantially,interfere'
p52426
(F1
F0.00014334862385321102
I1
I0
I1
tp52427
sS'two,patients,with'
p52428
(F1
F0.00028669724770642203
I2
I0
I2
tp52429
sS'mononitrate,may,be'
p52430
(F1
F0.00014334862385321102
I1
I0
I1
tp52431
sS'sub-therapeutic,concentrations,of'
p52432
(F1
F0.00014334862385321102
I1
I0
I1
tp52433
sS'clinical,use,of'
p52434
(F1
F0.00014334862385321102
I1
I0
I1
tp52435
sS'and,streptozotocin-induced,diabetic'
p52436
(F1
F0.00014334862385321102
I0
I1
I-1
tp52437
sS'substances,that,inhibit'
p52438
(F1
F0.00014334862385321102
I0
I1
I-1
tp52439
sS'suggesting,a,metabolite'
p52440
(F1
F0.00014334862385321102
I0
I1
I-1
tp52441
sS'have,occurred,with'
p52442
(F1
F0.00014334862385321102
I1
I0
I1
tp52443
sS'administered,together,with'
p52444
(F0
F0
I1
I1
I0
tp52445
sS'whether,these,are'
p52446
(F1
F0.00014334862385321102
I1
I0
I1
tp52447
sS'on,the,intestinal'
p52448
(F1
F0.00014334862385321102
I0
I1
I-1
tp52449
sS'also,assessed,by'
p52450
(F1
F0.00014334862385321102
I0
I1
I-1
tp52451
sS'of,increased,the'
p52452
(F1
F0.00014334862385321102
I1
I0
I1
tp52453
sS'toxic,reactions,to'
p52454
(F1
F0.00014334862385321102
I0
I1
I-1
tp52455
sS'of,brovana,may'
p52456
(F1
F0.00014334862385321102
I1
I0
I1
tp52457
sS't,max,although'
p52458
(F1
F0.00014334862385321102
I0
I1
I-1
tp52459
sS'and,thereby,delaying'
p52460
(F1
F0.00014334862385321102
I1
I0
I1
tp52461
sS'potential,for,an'
p52462
(F0
F0
I1
I1
I0
tp52463
sS'with,may,inhibit'
p52464
(F1
F0.00014334862385321102
I1
I0
I1
tp52465
sS'day,of,cancidas'
p52466
(F1
F0.00014334862385321102
I1
I0
I1
tp52467
sS'hydroxides,be,used'
p52468
(F1
F0.00014334862385321102
I1
I0
I1
tp52469
sS'bile,and,cystic'
p52470
(F1
F0.00014334862385321102
I1
I0
I1
tp52471
sS'stable,as,v'
p52472
(F1
F0.00014334862385321102
I0
I1
I-1
tp52473
sS'enbrel,was,added'
p52474
(F1
F0.00014334862385321102
I1
I0
I1
tp52475
sS'lethargy,and,somnolence'
p52476
(F1
F0.00014334862385321102
I1
I0
I1
tp52477
sS'proliferation,of,prostate'
p52478
(F1
F0.00014334862385321102
I1
I0
I1
tp52479
sS'been,a,number'
p52480
(F1
F0.00014334862385321102
I1
I0
I1
tp52481
sS'for,days,produced'
p52482
(F0
F0
I1
I1
I0
tp52483
sS'benefits,and,risks'
p52484
(F1
F0.00014334862385321102
I1
I0
I1
tp52485
sS'syndrome,in,phase'
p52486
(F1
F0.00014334862385321102
I0
I1
I-1
tp52487
sS'hours,was,given'
p52488
(F1
F0.00014334862385321102
I1
I0
I1
tp52489
sS'the,time,to'
p52490
(F0
F0
I1
I1
I0
tp52491
sS'dissolution,of,in'
p52492
(F1
F0.00014334862385321102
I0
I1
I-1
tp52493
sS'mg,to,mg'
p52494
(F1
F0.00014334862385321102
I1
I0
I1
tp52495
sS'as,convulsions,and'
p52496
(F1
F0.00014334862385321102
I1
I0
I1
tp52497
sS'well,as,postmarketing'
p52498
(F1
F0.00014334862385321102
I1
I0
I1
tp52499
sS'with,first-episode,or'
p52500
(F1
F0.00014334862385321102
I0
I1
I-1
tp52501
sS'dosing,reduced,as'
p52502
(F1
F0.00014334862385321102
I0
I1
I-1
tp52503
sS'was,lower,when'
p52504
(F1
F0.00014334862385321102
I1
I0
I1
tp52505
sS'with,renal,impairment'
p52506
(F1
F0.00028669724770642203
I2
I0
I2
tp52507
sS'more,specific,methods'
p52508
(F1
F0.00014334862385321102
I0
I1
I-1
tp52509
sS'decreased,clearance,by'
p52510
(F1
F0.00043004587155963305
I3
I0
I3
tp52511
sS'concentrations,just,prior'
p52512
(F1
F0.00014334862385321102
I0
I1
I-1
tp52513
sS'of,up,to'
p52514
(F1
F0.00028669724770642203
I0
I2
I-2
tp52515
sS'pharmacokinetics,of,clonazepam'
p52516
(F1
F0.00014334862385321102
I0
I1
I-1
tp52517
sS'cimetidine,atorvastatin,plasma'
p52518
(F1
F0.00014334862385321102
I0
I1
I-1
tp52519
sS'disulfiram-ethanol,reaction,in'
p52520
(F1
F0.00014334862385321102
I0
I1
I-1
tp52521
sS'dl,submitted,to'
p52522
(F1
F0.00014334862385321102
I0
I1
I-1
tp52523
sS'the,interactions,noted'
p52524
(F1
F0.00014334862385321102
I0
I1
I-1
tp52525
sS'when,hcl,is'
p52526
(F1
F0.00014334862385321102
I1
I0
I1
tp52527
sS'major,metabolites,dfur'
p52528
(F1
F0.00014334862385321102
I0
I1
I-1
tp52529
sS'been,performed,examining'
p52530
(F1
F0.00014334862385321102
I0
I1
I-1
tp52531
sS'trough,concentrations,of'
p52532
(F0
F0
I3
I3
I0
tp52533
sS'camptosar,would,worsen'
p52534
(F1
F0.00014334862385321102
I1
I0
I1
tp52535
sS'induced,by,meth'
p52536
(F1
F0.00014334862385321102
I0
I1
I-1
tp52537
sS'a,antimicrobial,is'
p52538
(F1
F0.00028669724770642203
I2
I0
I2
tp52539
sS'dose,of,such'
p52540
(F1
F0.00014334862385321102
I0
I1
I-1
tp52541
sS'interactions,with,carbamazepine'
p52542
(F1
F0.00014334862385321102
I1
I0
I1
tp52543
sS'other,have,demonstrated'
p52544
(F1
F0.00014334862385321102
I1
I0
I1
tp52545
sS'dose,administered,once'
p52546
(F1
F0.00014334862385321102
I0
I1
I-1
tp52547
sS'physicians,are,advised'
p52548
(F1
F0.00014334862385321102
I1
I0
I1
tp52549
sS'clinically,important,interaction'
p52550
(F1
F0.00014334862385321102
I0
I1
I-1
tp52551
sS'diabetic,rats,were'
p52552
(F1
F0.00014334862385321102
I0
I1
I-1
tp52553
sS'glycoprotein,iib,iiia'
p52554
(F1
F0.00014334862385321102
I1
I0
I1
tp52555
sS'shown,that,concurrent'
p52556
(F1
F0.00014334862385321102
I1
I0
I1
tp52557
sS'the,spinal,endorphinergic'
p52558
(F1
F0.00014334862385321102
I0
I1
I-1
tp52559
sS'and,urine,sampling'
p52560
(F1
F0.00014334862385321102
I0
I1
I-1
tp52561
sS'avoided,in,the'
p52562
(F1
F0.00014334862385321102
I0
I1
I-1
tp52563
sS'the,gaba-ergic,system'
p52564
(F1
F0.00014334862385321102
I1
I0
I1
tp52565
sS'the,pharmacokinetic,parameters'
p52566
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp52567
sS'hydrogen,breath,test'
p52568
(F1
F0.00014334862385321102
I0
I1
I-1
tp52569
sS'approximately,in,cyp2d6'
p52570
(F1
F0.00014334862385321102
I1
I0
I1
tp52571
sS'well,tolerated,when'
p52572
(F1
F0.00014334862385321102
I0
I1
I-1
tp52573
sS'excretion,of,meclofenamate'
p52574
(F1
F0.00014334862385321102
I0
I1
I-1
tp52575
sS'or,hours,after'
p52576
(F1
F0.00071674311926605509
I5
I0
I5
tp52577
sS'resulting,respiratory,depression'
p52578
(F1
F0.00014334862385321102
I1
I0
I1
tp52579
sS'dysfunction,and,b'
p52580
(F1
F0.00014334862385321102
I0
I1
I-1
tp52581
sS'doses,of,concomitantly'
p52582
(F1
F0.00014334862385321102
I1
I0
I1
tp52583
sS'effect,will,be'
p52584
(F1
F0.00014334862385321102
I1
I0
I1
tp52585
sS'with,lodosyn,carbidopa'
p52586
(F1
F0.00014334862385321102
I0
I1
I-1
tp52587
sS'higher-than,expected,steady-state'
p52588
(F1
F0.00014334862385321102
I1
I0
I1
tp52589
sS'strattera,should,be'
p52590
(F1
F0.00014334862385321102
I1
I0
I1
tp52591
sS'strong,likelihood,of'
p52592
(F1
F0.00014334862385321102
I1
I0
I1
tp52593
sS'of,cases,of'
p52594
(F1
F0.00014334862385321102
I1
I0
I1
tp52595
sS'surgery,or,skeletal-muscle'
p52596
(F1
F0.00014334862385321102
I0
I1
I-1
tp52597
sS'administration,of,resulting'
p52598
(F1
F0.00028669724770642203
I2
I0
I2
tp52599
sS'both,the,magnitude'
p52600
(F1
F0.00014334862385321102
I1
I0
I1
tp52601
sS'certain,and,thereby'
p52602
(F1
F0.00014334862385321102
I1
I0
I1
tp52603
sS'of,equivalent,to'
p52604
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp52605
sS'taking,chronically,had'
p52606
(F0
F0
I1
I1
I0
tp52607
sS'complications,compared,to'
p52608
(F1
F0.00028669724770642203
I2
I0
I2
tp52609
sS'red,cells,from'
p52610
(F1
F0.00014334862385321102
I0
I1
I-1
tp52611
sS'immunosuppressant,metabolized,by'
p52612
(F1
F0.00014334862385321102
I0
I1
I-1
tp52613
sS'nonsteroidal,were,taken'
p52614
(F1
F0.00028669724770642203
I0
I2
I-2
tp52615
sS'inhibitors,serious,side'
p52616
(F1
F0.00014334862385321102
I0
I1
I-1
tp52617
sS'that,may,reach'
p52618
(F1
F0.00014334862385321102
I0
I1
I-1
tp52619
sS'hypothyroid,patients,with'
p52620
(F1
F0.00014334862385321102
I0
I1
I-1
tp52621
sS'platelet,agents,are'
p52622
(F1
F0.00014334862385321102
I0
I1
I-1
tp52623
sS'vardenafil,mg,did'
p52624
(F1
F0.00014334862385321102
I0
I1
I-1
tp52625
sS'mephenytoin,mesantoin,use'
p52626
(F1
F0.00014334862385321102
I0
I1
I-1
tp52627
sS'exposure,was,decreased'
p52628
(F1
F0.00014334862385321102
I1
I0
I1
tp52629
sS'in,patients,given'
p52630
(F1
F0.00014334862385321102
I1
I0
I1
tp52631
sS'nonsedating,and,when'
p52632
(F1
F0.00014334862385321102
I1
I0
I1
tp52633
sS'significantly,increase,and'
p52634
(F1
F0.00014334862385321102
I0
I1
I-1
tp52635
sS'statistically,significant,difference'
p52636
(F1
F0.00014334862385321102
I0
I1
I-1
tp52637
sS'reports,that,may'
p52638
(F1
F0.00014334862385321102
I1
I0
I1
tp52639
sS'the,following,acetazolamide'
p52640
(F1
F0.00014334862385321102
I1
I0
I1
tp52641
sS'or,can,inhibit'
p52642
(F1
F0.00014334862385321102
I1
I0
I1
tp52643
sS'aprepitant,and,on'
p52644
(F0
F0
I1
I1
I0
tp52645
sS'taking,ace,inhibitors'
p52646
(F1
F0.00014334862385321102
I0
I1
I-1
tp52647
sS'taken,on,the'
p52648
(F1
F0.00014334862385321102
I1
I0
I1
tp52649
sS'doses,of,followed'
p52650
(F1
F0.00014334862385321102
I1
I0
I1
tp52651
sS'orthostatic,hypotension,cimetidine'
p52652
(F1
F0.00014334862385321102
I1
I0
I1
tp52653
sS'of,possible,additive'
p52654
(F1
F0.00043004587155963305
I3
I0
I3
tp52655
sS'frontal,cortex,and'
p52656
(F1
F0.00014334862385321102
I0
I1
I-1
tp52657
sS'pharmacologically,predictable,sympathetic'
p52658
(F1
F0.00014334862385321102
I1
I0
I1
tp52659
sS'absorption,of,if'
p52660
(F1
F0.00014334862385321102
I1
I0
I1
tp52661
sS'are,cyp,inducers'
p52662
(F1
F0.00014334862385321102
I1
I0
I1
tp52663
sS'variable,effects,an'
p52664
(F1
F0.00014334862385321102
I1
I0
I1
tp52665
sS'absorption,of,is'
p52666
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp52667
sS'anaphylactic,reaction,although'
p52668
(F1
F0.00014334862385321102
I1
I0
I1
tp52669
sS'citrate,theoretically,l-arginine'
p52670
(F1
F0.00014334862385321102
I1
I0
I1
tp52671
sS'related,member,of'
p52672
(F1
F0.00014334862385321102
I1
I0
I1
tp52673
sS'include,a,variety'
p52674
(F1
F0.00014334862385321102
I0
I1
I-1
tp52675
sS'is,concurrently,administered'
p52676
(F1
F0.00014334862385321102
I0
I1
I-1
tp52677
sS'iodine-containing,products,h2-antagonists'
p52678
(F1
F0.00014334862385321102
I0
I1
I-1
tp52679
sS'of,mcg,twice'
p52680
(F1
F0.00014334862385321102
I0
I1
I-1
tp52681
sS'agent,orally,because'
p52682
(F1
F0.00014334862385321102
I1
I0
I1
tp52683
sS'in,vitro,was'
p52684
(F1
F0.00014334862385321102
I0
I1
I-1
tp52685
sS'of,orally,administered'
p52686
(F1
F0.00014334862385321102
I0
I1
I-1
tp52687
sS'values,for,which'
p52688
(F1
F0.00014334862385321102
I0
I1
I-1
tp52689
sS'ssris,and,agents'
p52690
(F1
F0.00014334862385321102
I1
I0
I1
tp52691
sS'is,administered,shortly'
p52692
(F0
F0
I1
I1
I0
tp52693
sS'in,the,cmax'
p52694
(F1
F0.00014334862385321102
I0
I1
I-1
tp52695
sS'cases,where,serious'
p52696
(F1
F0.00014334862385321102
I0
I1
I-1
tp52697
sS'initiated,after,cessation'
p52698
(F1
F0.00014334862385321102
I0
I1
I-1
tp52699
sS'affect,strategies,during'
p52700
(F1
F0.00014334862385321102
I0
I1
I-1
tp52701
sS'inhibiting,the,central'
p52702
(F1
F0.00057339449541284407
I4
I0
I4
tp52703
sS'precipitous,reduction,of'
p52704
(F1
F0.00014334862385321102
I1
I0
I1
tp52705
sS'mean,scores,on'
p52706
(F1
F0.00014334862385321102
I1
I0
I1
tp52707
sS'least,months,had'
p52708
(F1
F0.00014334862385321102
I0
I1
I-1
tp52709
sS'with,or,has'
p52710
(F1
F0.00014334862385321102
I1
I0
I1
tp52711
sS'for,vitamin,b3'
p52712
(F1
F0.00014334862385321102
I1
I0
I1
tp52713
sS'to,control,supraventricular'
p52714
(F1
F0.00014334862385321102
I1
I0
I1
tp52715
sS'other,or,maois'
p52716
(F1
F0.00014334862385321102
I0
I1
I-1
tp52717
sS'the,monoamine,oxidase'
p52718
(F1
F0.00014334862385321102
I0
I1
I-1
tp52719
sS'with,or,had'
p52720
(F1
F0.00014334862385321102
I1
I0
I1
tp52721
sS'nonfunctioning,gland,who'
p52722
(F1
F0.00014334862385321102
I1
I0
I1
tp52723
sS'users,of,intravenous'
p52724
(F1
F0.00014334862385321102
I0
I1
I-1
tp52725
sS'appropriate,package,insert'
p52726
(F1
F0.00014334862385321102
I0
I1
I-1
tp52727
sS'studies,should,focus'
p52728
(F1
F0.00014334862385321102
I0
I1
I-1
tp52729
sS'reduction,when,coadminstered'
p52730
(F1
F0.00014334862385321102
I1
I0
I1
tp52731
sS'no,significant,alteration'
p52732
(F1
F0.00014334862385321102
I1
I0
I1
tp52733
sS'steady-state,cmin,to'
p52734
(F1
F0.00014334862385321102
I1
I0
I1
tp52735
sS'may,increase,plasma'
p52736
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp52737
sS'study,in,humans'
p52738
(F1
F0.00014334862385321102
I0
I1
I-1
tp52739
sS'el,eg,for'
p52740
(F1
F0.00014334862385321102
I1
I0
I1
tp52741
sS'these,who,are'
p52742
(F1
F0.00014334862385321102
I0
I1
I-1
tp52743
sS'cytochrome,p450,d6'
p52744
(F1
F0.0010034403669724771
I0
I7
I-7
tp52745
sS'adjusted,upward,the'
p52746
(F1
F0.00014334862385321102
I1
I0
I1
tp52747
sS'stomach,of,people'
p52748
(F1
F0.00014334862385321102
I1
I0
I1
tp52749
sS'demonstrated,renal,precipitation'
p52750
(F1
F0.00014334862385321102
I0
I1
I-1
tp52751
sS'in,a,interaction'
p52752
(F1
F0.00014334862385321102
I0
I1
I-1
tp52753
sS'fosinopril,sodium,can'
p52754
(F1
F0.00014334862385321102
I1
I0
I1
tp52755
sS'result,i,n'
p52756
(F1
F0.00014334862385321102
I1
I0
I1
tp52757
sS'decreases,in,auc'
p52758
(F1
F0.00014334862385321102
I0
I1
I-1
tp52759
sS'vitro,studies,suggest'
p52760
(F1
F0.00014334862385321102
I1
I0
I1
tp52761
sS'initial,doses,or'
p52762
(F1
F0.00014334862385321102
I0
I1
I-1
tp52763
sS'endothelium-intact,aortic,rings'
p52764
(F1
F0.00014334862385321102
I1
I0
I1
tp52765
sS'with,serotonin,syndrome'
p52766
(F1
F0.00014334862385321102
I0
I1
I-1
tp52767
sS'but,significantly,decreased'
p52768
(F1
F0.00028669724770642203
I2
I0
I2
tp52769
sS'and,alternative,hypoglycemic'
p52770
(F1
F0.00014334862385321102
I1
I0
I1
tp52771
sS'others,plasma,levels'
p52772
(F1
F0.00014334862385321102
I0
I1
I-1
tp52773
sS'of,with,increased'
p52774
(F1
F0.00028669724770642203
I2
I0
I2
tp52775
sS'if,argatroban,is'
p52776
(F1
F0.00014334862385321102
I0
I1
I-1
tp52777
sS'of,with,increases'
p52778
(F1
F0.00014334862385321102
I0
I1
I-1
tp52779
sS'days,increased,plasma'
p52780
(F1
F0.00028669724770642203
I2
I0
I2
tp52781
sS'videx,was,administered'
p52782
(F1
F0.00014334862385321102
I1
I0
I1
tp52783
sS'in,rats,epidural'
p52784
(F1
F0.00014334862385321102
I1
I0
I1
tp52785
sS'to,the,changes'
p52786
(F1
F0.00014334862385321102
I0
I1
I-1
tp52787
sS'by,weakness,lethargy'
p52788
(F1
F0.00014334862385321102
I1
I0
I1
tp52789
sS'unlikely,that,co-administration'
p52790
(F1
F0.00014334862385321102
I0
I1
I-1
tp52791
sS'cognitive,and,motor'
p52792
(F1
F0.00014334862385321102
I1
I0
I1
tp52793
sS'ii,clinical,trial'
p52794
(F1
F0.00014334862385321102
I1
I0
I1
tp52795
sS'amphetamines,enhance,the'
p52796
(F1
F0.00028669724770642203
I2
I0
I2
tp52797
sS'were,investigated,in'
p52798
(F1
F0.00014334862385321102
I0
I1
I-1
tp52799
sS'revealed,that,significantly'
p52800
(F1
F0.00014334862385321102
I1
I0
I1
tp52801
sS'were,administered,during'
p52802
(F1
F0.00014334862385321102
I0
I1
I-1
tp52803
sS'nicotinic,acid,erythromycin'
p52804
(F1
F0.00014334862385321102
I0
I1
I-1
tp52805
sS'and,in,patients'
p52806
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp52807
sS'the,case,of'
p52808
(F1
F0.00014334862385321102
I1
I0
I1
tp52809
sS'separate,group,of'
p52810
(F1
F0.00014334862385321102
I1
I0
I1
tp52811
sS'clearance,of,compared'
p52812
(F1
F0.00014334862385321102
I1
I0
I1
tp52813
sS'conversion,of,to'
p52814
(F1
F0.00014334862385321102
I0
I1
I-1
tp52815
sS'concomitant,antihypertensive,medications'
p52816
(F1
F0.00014334862385321102
I1
I0
I1
tp52817
sS'used,in,patients'
p52818
(F1
F0.00057339449541284407
I4
I0
I4
tp52819
sS'class,of,may'
p52820
(F1
F0.00028669724770642203
I2
I0
I2
tp52821
sS'a2,an,isoform'
p52822
(F1
F0.00014334862385321102
I1
I0
I1
tp52823
sS'severe,weakness,in'
p52824
(F1
F0.00014334862385321102
I1
I0
I1
tp52825
sS'median,gastric,ph'
p52826
(F1
F0.00014334862385321102
I1
I0
I1
tp52827
sS'mg,x,kg'
p52828
(F1
F0.00014334862385321102
I0
I1
I-1
tp52829
sS'of,baseline,for'
p52830
(F1
F0.00014334862385321102
I0
I1
I-1
tp52831
sS'multivalent,cation-containing,products'
p52832
(F1
F0.00014334862385321102
I1
I0
I1
tp52833
sS'shortly,after,nasal'
p52834
(F1
F0.00014334862385321102
I1
I0
I1
tp52835
sS'been,characterized,to'
p52836
(F1
F0.00014334862385321102
I0
I1
I-1
tp52837
sS'significant,decrease,in'
p52838
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp52839
sS'half-life,of,potential'
p52840
(F1
F0.00014334862385321102
I0
I1
I-1
tp52841
sS'are,taking,any'
p52842
(F0
F0
I1
I1
I0
tp52843
sS'at,ph,was'
p52844
(F1
F0.00014334862385321102
I0
I1
I-1
tp52845
sS'increased,vasoconstriction,after'
p52846
(F1
F0.00014334862385321102
I1
I0
I1
tp52847
sS'enzymes,is,recommended'
p52848
(F1
F0.00014334862385321102
I1
I0
I1
tp52849
sS'with,those,of'
p52850
(F1
F0.00014334862385321102
I0
I1
I-1
tp52851
sS'studies,and,the'
p52852
(F1
F0.00014334862385321102
I0
I1
I-1
tp52853
sS'been,effectively,administered'
p52854
(F1
F0.00014334862385321102
I0
I1
I-1
tp52855
sS'amphotericin,b,patients'
p52856
(F1
F0.00014334862385321102
I1
I0
I1
tp52857
sS'the,blood,glucose'
p52858
(F1
F0.00014334862385321102
I1
I0
I1
tp52859
sS'dmpge2,given,intraluminally'
p52860
(F1
F0.00014334862385321102
I0
I1
I-1
tp52861
sS'a,course,of'
p52862
(F0.5
F0.00028669724770642203
I3
I1
I2
tp52863
sS'accelerated,when,they'
p52864
(F1
F0.00014334862385321102
I1
I0
I1
tp52865
sS'magnesium-containing,meq,or'
p52866
(F1
F0.00014334862385321102
I0
I1
I-1
tp52867
sS'the,cytochrome,p450iiia4'
p52868
(F1
F0.00014334862385321102
I1
I0
I1
tp52869
sS'frequently,with,in'
p52870
(F1
F0.00014334862385321102
I0
I1
I-1
tp52871
sS'of,another,tnf'
p52872
(F1
F0.00014334862385321102
I1
I0
I1
tp52873
sS'avoid,the,use'
p52874
(F1
F0.00014334862385321102
I1
I0
I1
tp52875
sS'after,being,dosed'
p52876
(F1
F0.00014334862385321102
I0
I1
I-1
tp52877
sS'prolonged,from,minutes'
p52878
(F1
F0.00014334862385321102
I1
I0
I1
tp52879
sS'supplementation,which,is'
p52880
(F1
F0.00014334862385321102
I0
I1
I-1
tp52881
sS'efficacy,in,the'
p52882
(F1
F0.00014334862385321102
I0
I1
I-1
tp52883
sS'and,mixed,signalled-unsignalled'
p52884
(F1
F0.00014334862385321102
I0
I1
I-1
tp52885
sS'day,showed,that'
p52886
(F1
F0.00014334862385321102
I0
I1
I-1
tp52887
sS'interfere,with,absorption'
p52888
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp52889
sS'or,as,well'
p52890
(F1
F0.00014334862385321102
I1
I0
I1
tp52891
sS'inhibits,the,effects'
p52892
(F1
F0.00014334862385321102
I1
I0
I1
tp52893
sS'of,prostaglandin,synthase'
p52894
(F1
F0.00014334862385321102
I1
I0
I1
tp52895
sS'from,to,was'
p52896
(F1
F0.00014334862385321102
I1
I0
I1
tp52897
sS'a,lack,of'
p52898
(F1
F0.00014334862385321102
I0
I1
I-1
tp52899
sS'and,normal,subjects'
p52900
(F1
F0.00014334862385321102
I1
I0
I1
tp52901
sS'additive,effect,when'
p52902
(F1
F0.00071674311926605509
I5
I0
I5
tp52903
sS'the,reduction,in'
p52904
(F0
F0
I1
I1
I0
tp52905
sS'enantiomers,or,the'
p52906
(F1
F0.00014334862385321102
I0
I1
I-1
tp52907
sS'vitro,antiviral,activity'
p52908
(F1
F0.00014334862385321102
I1
I0
I1
tp52909
sS'levels,of,several'
p52910
(F1
F0.00014334862385321102
I1
I0
I1
tp52911
sS'sh,da,sh'
p52912
(F1
F0.00014334862385321102
I0
I1
I-1
tp52913
sS'h1,and,h2'
p52914
(F1
F0.00014334862385321102
I1
I0
I1
tp52915
sS'discontinues,therapy,with'
p52916
(F1
F0.00014334862385321102
I1
I0
I1
tp52917
sS'more,specific,sulfosalicylic'
p52918
(F1
F0.00014334862385321102
I0
I1
I-1
tp52919
sS'have,synergistic,activity'
p52920
(F1
F0.00014334862385321102
I1
I0
I1
tp52921
sS'to,be,initiated'
p52922
(F1
F0.00014334862385321102
I0
I1
I-1
tp52923
sS'cyp,c19,substrate'
p52924
(F1
F0.00014334862385321102
I0
I1
I-1
tp52925
sS'affected,by,multiple-dose'
p52926
(F1
F0.00014334862385321102
I0
I1
I-1
tp52927
sS'result,from,combined'
p52928
(F1
F0.00014334862385321102
I1
I0
I1
tp52929
sS'with,caution,should'
p52930
(F1
F0.00014334862385321102
I1
I0
I1
tp52931
sS'humans,show,that'
p52932
(F1
F0.00014334862385321102
I1
I0
I1
tp52933
sS'enhanced,possibility,of'
p52934
(F1
F0.00014334862385321102
I0
I1
I-1
tp52935
sS'as,assessed,by'
p52936
(F1
F0.00043004587155963305
I0
I3
I-3
tp52937
sS'fold,lower,than'
p52938
(F1
F0.00014334862385321102
I1
I0
I1
tp52939
sS'and,in,dogs'
p52940
(F1
F0.00028669724770642203
I2
I0
I2
tp52941
sS'dry,mouth,urinary'
p52942
(F1
F0.00028669724770642203
I2
I0
I2
tp52943
sS'days,received,mg'
p52944
(F1
F0.00014334862385321102
I0
I1
I-1
tp52945
sS'double,the,bioavailability'
p52946
(F1
F0.00014334862385321102
I1
I0
I1
tp52947
sS'absorbed,when,taking'
p52948
(F1
F0.00014334862385321102
I0
I1
I-1
tp52949
sS'concomitant,use,may'
p52950
(F1
F0.00014334862385321102
I1
I0
I1
tp52951
sS'as,loop,or'
p52952
(F1
F0.00014334862385321102
I1
I0
I1
tp52953
sS'dosing,was,separated'
p52954
(F1
F0.00014334862385321102
I1
I0
I1
tp52955
sS'of,the,urinary'
p52956
(F1
F0.00014334862385321102
I0
I1
I-1
tp52957
sS'no,positive,reaction'
p52958
(F1
F0.00014334862385321102
I0
I1
I-1
tp52959
sS'at,five,commonly'
p52960
(F1
F0.00014334862385321102
I0
I1
I-1
tp52961
sS'ml,sc,or'
p52962
(F1
F0.00014334862385321102
I0
I1
I-1
tp52963
sS'arterial,pressure,of'
p52964
(F1
F0.00014334862385321102
I1
I0
I1
tp52965
sS'mg,produced,mean'
p52966
(F1
F0.00014334862385321102
I1
I0
I1
tp52967
sS'as,selective,serotonin'
p52968
(F1
F0.00014334862385321102
I1
I0
I1
tp52969
sS'in,free,radical-mediated'
p52970
(F1
F0.00014334862385321102
I1
I0
I1
tp52971
sS'clinically,meaningful,interactions'
p52972
(F1
F0.00014334862385321102
I0
I1
I-1
tp52973
sS'in,inhibition,of'
p52974
(F1
F0.00014334862385321102
I1
I0
I1
tp52975
sS'life-threatening,interactions,with'
p52976
(F1
F0.00014334862385321102
I1
I0
I1
tp52977
sS'lead,to,electrolyte'
p52978
(F1
F0.00014334862385321102
I1
I0
I1
tp52979
sS'for,the,treatment'
p52980
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp52981
sS'invasion,of,adenocarcinomas'
p52982
(F1
F0.00014334862385321102
I1
I0
I1
tp52983
sS'depression,hypotension,and'
p52984
(F1
F0.00014334862385321102
I1
I0
I1
tp52985
sS'cardioactive,compounds,that'
p52986
(F1
F0.00014334862385321102
I1
I0
I1
tp52987
sS'clinical,trials,however'
p52988
(F1
F0.00014334862385321102
I0
I1
I-1
tp52989
sS'or,a,dose'
p52990
(F1
F0.00014334862385321102
I0
I1
I-1
tp52991
sS'reduce,both,the'
p52992
(F1
F0.00014334862385321102
I1
I0
I1
tp52993
sS'bioavailability,of,novolog'
p52994
(F1
F0.00014334862385321102
I0
I1
I-1
tp52995
sS'homodimeric,disintegrin,and'
p52996
(F1
F0.00014334862385321102
I0
I1
I-1
tp52997
sS'm,g,h'
p52998
(F1
F0.00014334862385321102
I1
I0
I1
tp52999
sS'hcl,is,given'
p53000
(F1
F0.00014334862385321102
I0
I1
I-1
tp53001
sS'concurrently,increases,anion'
p53002
(F1
F0.00014334862385321102
I1
I0
I1
tp53003
sS'pressor,agents,only'
p53004
(F1
F0.00014334862385321102
I0
I1
I-1
tp53005
sS'considered,when,taking'
p53006
(F1
F0.00014334862385321102
I1
I0
I1
tp53007
sS'pharmacokinetic,drug-drug,interaction'
p53008
(F1
F0.00014334862385321102
I0
I1
I-1
tp53009
sS'with,absorption,and'
p53010
(F1
F0.00014334862385321102
I1
I0
I1
tp53011
sS'alkaloids,should,be'
p53012
(F1
F0.00014334862385321102
I1
I0
I1
tp53013
sS'of,a,beta'
p53014
(F1
F0.00014334862385321102
I1
I0
I1
tp53015
sS'of,mcg,ml'
p53016
(F1
F0.00014334862385321102
I0
I1
I-1
tp53017
sS'cocaine,sometimes,proves'
p53018
(F1
F0.00014334862385321102
I1
I0
I1
tp53019
sS'morphological,markers,that'
p53020
(F1
F0.00014334862385321102
I1
I0
I1
tp53021
sS'transient,cardiac,arrhythmias'
p53022
(F1
F0.00014334862385321102
I1
I0
I1
tp53023
sS'impacted,by,concomitant'
p53024
(F1
F0.00014334862385321102
I0
I1
I-1
tp53025
sS'with,or,with'
p53026
(F1
F0.00014334862385321102
I1
I0
I1
tp53027
sS'or,supplements,can'
p53028
(F1
F0.00028669724770642203
I0
I2
I-2
tp53029
sS'increases,about,two'
p53030
(F1
F0.00014334862385321102
I1
I0
I1
tp53031
sS'suggest,that,acute'
p53032
(F1
F0.00014334862385321102
I0
I1
I-1
tp53033
sS'plus,was,poorly'
p53034
(F1
F0.00014334862385321102
I1
I0
I1
tp53035
sS'time,should,be'
p53036
(F1
F0.00043004587155963305
I3
I0
I3
tp53037
sS'the,v,v'
p53038
(F1
F0.00014334862385321102
I0
I1
I-1
tp53039
sS'large,well,controlled'
p53040
(F1
F0.00014334862385321102
I0
I1
I-1
tp53041
sS'have,one,or'
p53042
(F1
F0.00014334862385321102
I0
I1
I-1
tp53043
sS'because,nephrotoxicity,may'
p53044
(F1
F0.00014334862385321102
I1
I0
I1
tp53045
sS'hoof,twitch,from'
p53046
(F1
F0.00014334862385321102
I1
I0
I1
tp53047
sS'b,injection,and'
p53048
(F1
F0.00014334862385321102
I1
I0
I1
tp53049
sS'mean,distribution,of'
p53050
(F1
F0.00014334862385321102
I0
I1
I-1
tp53051
sS's,effect,will'
p53052
(F1
F0.00014334862385321102
I1
I0
I1
tp53053
sS'decreased,synthesis,of'
p53054
(F1
F0.00028669724770642203
I2
I0
I2
tp53055
sS'other,no,clinically'
p53056
(F1
F0.00014334862385321102
I0
I1
I-1
tp53057
sS'or,diarrhea,induced'
p53058
(F1
F0.00014334862385321102
I1
I0
I1
tp53059
sS'mg,kg,hours'
p53060
(F1
F0.00014334862385321102
I1
I0
I1
tp53061
sS'injection,who,were'
p53062
(F1
F0.00014334862385321102
I0
I1
I-1
tp53063
sS'observed,with,preparations'
p53064
(F1
F0.00014334862385321102
I1
I0
I1
tp53065
sS'that,and,significantly'
p53066
(F1
F0.00014334862385321102
I1
I0
I1
tp53067
sS'aprepitant,was,given'
p53068
(F1
F0.00014334862385321102
I0
I1
I-1
tp53069
sS'steady,state,serum'
p53070
(F1
F0.00014334862385321102
I0
I1
I-1
tp53071
sS'who,were,subsequently'
p53072
(F0
F0
I1
I1
I0
tp53073
sS'signs,of,renal'
p53074
(F0
F0
I1
I1
I0
tp53075
sS'benefits,of,combined'
p53076
(F1
F0.00014334862385321102
I1
I0
I1
tp53077
sS'non-steroidal,anti-inflammatory,drugs'
p53078
(F1
F0.00028669724770642203
I2
I0
I2
tp53079
sS'tricyclic,have,been'
p53080
(F1
F0.00028669724770642203
I2
I0
I2
tp53081
sS'of,each,other'
p53082
(F1
F0.00071674311926605509
I5
I0
I5
tp53083
sS'a,major,contributing'
p53084
(F1
F0.00014334862385321102
I1
I0
I1
tp53085
sS'studies,do,not'
p53086
(F1
F0.00014334862385321102
I1
I0
I1
tp53087
sS'of,was,prepared'
p53088
(F1
F0.00014334862385321102
I0
I1
I-1
tp53089
sS'receiving,known,enzyme'
p53090
(F1
F0.00014334862385321102
I1
I0
I1
tp53091
sS'doses,of,but'
p53092
(F1
F0.00014334862385321102
I0
I1
I-1
tp53093
sS'or,a,diminished'
p53094
(F1
F0.00014334862385321102
I1
I0
I1
tp53095
sS'usp,to,subjects'
p53096
(F1
F0.00014334862385321102
I1
I0
I1
tp53097
sS'tendency,to,cause'
p53098
(F1
F0.00014334862385321102
I1
I0
I1
tp53099
sS'be,observed,with'
p53100
(F1
F0.00014334862385321102
I1
I0
I1
tp53101
sS'concurrent,and,avastin'
p53102
(F1
F0.00014334862385321102
I0
I1
I-1
tp53103
sS'aleve,or,ibuprofen'
p53104
(F1
F0.00014334862385321102
I1
I0
I1
tp53105
sS'showed,increased,deet'
p53106
(F1
F0.00014334862385321102
I0
I1
I-1
tp53107
sS'this,reduction,is'
p53108
(F1
F0.00014334862385321102
I1
I0
I1
tp53109
sS'to,for,the'
p53110
(F1
F0.00014334862385321102
I1
I0
I1
tp53111
sS'and,the,muscle'
p53112
(F1
F0.00014334862385321102
I1
I0
I1
tp53113
sS'since,the,effect'
p53114
(F1
F0.00014334862385321102
I0
I1
I-1
tp53115
sS'diets,containing,either'
p53116
(F1
F0.00014334862385321102
I0
I1
I-1
tp53117
sS'phase,i,trial'
p53118
(F0
F0
I1
I1
I0
tp53119
sS'or,within,hours'
p53120
(F1
F0.00028669724770642203
I2
I0
I2
tp53121
sS'the,tablets,as'
p53122
(F1
F0.00014334862385321102
I1
I0
I1
tp53123
sS'than,expected,lasma'
p53124
(F1
F0.00014334862385321102
I0
I1
I-1
tp53125
sS'k,oral,unreliable'
p53126
(F1
F0.00014334862385321102
I1
I0
I1
tp53127
sS'were,not,attenuated'
p53128
(F1
F0.00014334862385321102
I0
I1
I-1
tp53129
sS'drugs,on,felbatol'
p53130
(F1
F0.00014334862385321102
I1
I0
I1
tp53131
sS'of,these,could'
p53132
(F1
F0.00014334862385321102
I1
I0
I1
tp53133
sS'recovery,following,an'
p53134
(F1
F0.00014334862385321102
I1
I0
I1
tp53135
sS'basis,of,this'
p53136
(F1
F0.00014334862385321102
I0
I1
I-1
tp53137
sS'ph,was,used'
p53138
(F1
F0.00014334862385321102
I0
I1
I-1
tp53139
sS'to,a,reduction'
p53140
(F1
F0.00014334862385321102
I1
I0
I1
tp53141
sS'drug-drug,interactions,given'
p53142
(F1
F0.00014334862385321102
I1
I0
I1
tp53143
sS'time,must,elapse'
p53144
(F1
F0.00014334862385321102
I1
I0
I1
tp53145
sS'been,well,studied'
p53146
(F1
F0.00014334862385321102
I0
I1
I-1
tp53147
sS'trial,data,where'
p53148
(F1
F0.00014334862385321102
I1
I0
I1
tp53149
sS'concentration,of,one'
p53150
(F1
F0.00014334862385321102
I0
I1
I-1
tp53151
sS'kerlone,and,have'
p53152
(F1
F0.00014334862385321102
I0
I1
I-1
tp53153
sS'there,is,rapid'
p53154
(F1
F0.00014334862385321102
I0
I1
I-1
tp53155
sS's,that,are'
p53156
(F1
F0.00014334862385321102
I1
I0
I1
tp53157
sS'circulating,metabolite,hydroxy-estazolam'
p53158
(F1
F0.00014334862385321102
I0
I1
I-1
tp53159
sS'particles,of,in'
p53160
(F1
F0.00014334862385321102
I0
I1
I-1
tp53161
sS'cells,in,response'
p53162
(F1
F0.00014334862385321102
I0
I1
I-1
tp53163
sS'only,additive,effects'
p53164
(F1
F0.00014334862385321102
I1
I0
I1
tp53165
sS'change,the,dose'
p53166
(F1
F0.00014334862385321102
I0
I1
I-1
tp53167
sS'and,l-ccg,upon'
p53168
(F1
F0.00014334862385321102
I0
I1
I-1
tp53169
sS'studies,of,mevacor'
p53170
(F1
F0.00014334862385321102
I0
I1
I-1
tp53171
sS'of,by,is'
p53172
(F1
F0.00014334862385321102
I1
I0
I1
tp53173
sS'inhibited,phosphorylation,in'
p53174
(F1
F0.00014334862385321102
I1
I0
I1
tp53175
sS'anti-inflammatory,agents,and'
p53176
(F1
F0.00014334862385321102
I1
I0
I1
tp53177
sS'auc,of,by'
p53178
(F1
F0.00071674311926605509
I5
I0
I5
tp53179
sS'of,felbatol,therapy'
p53180
(F1
F0.00014334862385321102
I0
I1
I-1
tp53181
sS'binding,of,was'
p53182
(F0
F0
I1
I1
I0
tp53183
sS'in,over,patients'
p53184
(F1
F0.00014334862385321102
I1
I0
I1
tp53185
sS'adjustments,considered,for'
p53186
(F1
F0.00014334862385321102
I1
I0
I1
tp53187
sS'on,the,fertility'
p53188
(F1
F0.00014334862385321102
I0
I1
I-1
tp53189
sS'bioavailability,of,relative'
p53190
(F1
F0.00014334862385321102
I0
I1
I-1
tp53191
sS'some,patients,receiving'
p53192
(F1
F0.00014334862385321102
I1
I0
I1
tp53193
sS'or,acth,treatment'
p53194
(F1
F0.00014334862385321102
I0
I1
I-1
tp53195
sS'ci,when,was'
p53196
(F1
F0.00014334862385321102
I1
I0
I1
tp53197
sS'cytochrome,p450iid6,such'
p53198
(F1
F0.00014334862385321102
I1
I0
I1
tp53199
sS'and,related,may'
p53200
(F1
F0.00028669724770642203
I2
I0
I2
tp53201
sS'occasions,resulted,in'
p53202
(F1
F0.00028669724770642203
I2
I0
I2
tp53203
sS'receiving,a,potent'
p53204
(F1
F0.00014334862385321102
I0
I1
I-1
tp53205
sS'that,are,cyp3a4'
p53206
(F1
F0.00014334862385321102
I1
I0
I1
tp53207
sS'and,oral,a'
p53208
(F1
F0.00014334862385321102
I1
I0
I1
tp53209
sS'following,precautions,should'
p53210
(F1
F0.00014334862385321102
I1
I0
I1
tp53211
sS'therapeutic,range,in'
p53212
(F1
F0.00014334862385321102
I1
I0
I1
tp53213
sS'psychiatric,rating,scale'
p53214
(F1
F0.00014334862385321102
I1
I0
I1
tp53215
sS'treatment,of,hypotension'
p53216
(F0
F0
I1
I1
I0
tp53217
sS'at,least,days'
p53218
(F1
F0.00014334862385321102
I1
I0
I1
tp53219
sS'activation,in,vitro'
p53220
(F1
F0.00014334862385321102
I0
I1
I-1
tp53221
sS'in,serum,auc'
p53222
(F1
F0.00014334862385321102
I1
I0
I1
tp53223
sS'can,be,administered'
p53224
(F1
F0.00043004587155963305
I0
I3
I-3
tp53225
sS'administered,with,extreme'
p53226
(F1
F0.00028669724770642203
I2
I0
I2
tp53227
sS'peripheral,blood,mononuclear'
p53228
(F1
F0.00028669724770642203
I2
I0
I2
tp53229
sS'and,oral,in'
p53230
(F1
F0.00014334862385321102
I0
I1
I-1
tp53231
sS'changes,in,pharmacokinetics'
p53232
(F1
F0.00028669724770642203
I0
I2
I-2
tp53233
sS'ability,of,the'
p53234
(F1
F0.00014334862385321102
I0
I1
I-1
tp53235
sS'phenytoin,if,is'
p53236
(F1
F0.00014334862385321102
I1
I0
I1
tp53237
sS'all,subjects,received'
p53238
(F1
F0.00028669724770642203
I0
I2
I-2
tp53239
sS'tricyclic,tcas,when'
p53240
(F1
F0.00014334862385321102
I0
I1
I-1
tp53241
sS'animal,studies,indicate'
p53242
(F1
F0.00028669724770642203
I2
I0
I2
tp53243
sS'that,are,negatively'
p53244
(F1
F0.00014334862385321102
I0
I1
I-1
tp53245
sS'to,be,produced'
p53246
(F1
F0.00014334862385321102
I0
I1
I-1
tp53247
sS'are,indicated,alternative'
p53248
(F1
F0.00014334862385321102
I0
I1
I-1
tp53249
sS'or,tumor,vascularity'
p53250
(F1
F0.00014334862385321102
I0
I1
I-1
tp53251
sS'and,subsalicylate,should'
p53252
(F1
F0.00014334862385321102
I1
I0
I1
tp53253
sS'increased,the,exposure'
p53254
(F1
F0.00028669724770642203
I2
I0
I2
tp53255
sS'avoid,concurrent,administration'
p53256
(F1
F0.00014334862385321102
I1
I0
I1
tp53257
sS'single,or,repeated'
p53258
(F1
F0.00014334862385321102
I0
I1
I-1
tp53259
sS'intravenous,misuse,of'
p53260
(F1
F0.00014334862385321102
I1
I0
I1
tp53261
sS'was,investigated,as'
p53262
(F1
F0.00014334862385321102
I0
I1
I-1
tp53263
sS'by,overdose,with'
p53264
(F1
F0.00014334862385321102
I1
I0
I1
tp53265
sS'but,no,change'
p53266
(F1
F0.00014334862385321102
I1
I0
I1
tp53267
sS'renal,prostaglandins,may'
p53268
(F1
F0.00014334862385321102
I1
I0
I1
tp53269
sS'low-dose,has,been'
p53270
(F1
F0.00014334862385321102
I1
I0
I1
tp53271
sS'evoked,hind,limb'
p53272
(F1
F0.00014334862385321102
I0
I1
I-1
tp53273
sS'the,diuretic,natriuretic'
p53274
(F1
F0.00014334862385321102
I1
I0
I1
tp53275
sS'amphotericin,b,injection'
p53276
(F1
F0.00014334862385321102
I1
I0
I1
tp53277
sS'increase,in,sn38'
p53278
(F1
F0.00014334862385321102
I0
I1
I-1
tp53279
sS'of,intravenous,sodium'
p53280
(F0
F0
I1
I1
I0
tp53281
sS'that,the,solubility'
p53282
(F1
F0.00014334862385321102
I0
I1
I-1
tp53283
sS'was,higher,than'
p53284
(F1
F0.00028669724770642203
I2
I0
I2
tp53285
sS'hypoglycemia,secondary,to'
p53286
(F1
F0.00014334862385321102
I1
I0
I1
tp53287
sS'as,much,as'
p53288
(F0
F0
I1
I1
I0
tp53289
sS'have,occurred,in'
p53290
(F1
F0.00057339449541284407
I4
I0
I4
tp53291
sS'haca,titers,may'
p53292
(F1
F0.00014334862385321102
I0
I1
I-1
tp53293
sS'renal,precipitation,of'
p53294
(F1
F0.00014334862385321102
I0
I1
I-1
tp53295
sS'of,zdv,as'
p53296
(F1
F0.00014334862385321102
I1
I0
I1
tp53297
sS'least,hour,before'
p53298
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp53299
sS'simvastatin,cyp3a4,substrate'
p53300
(F1
F0.00014334862385321102
I0
I1
I-1
tp53301
sS'release,capsules,since'
p53302
(F1
F0.00014334862385321102
I1
I0
I1
tp53303
sS'negative,inotropic,effects'
p53304
(F1
F0.00014334862385321102
I1
I0
I1
tp53305
sS'effects,kemstro,the'
p53306
(F1
F0.00014334862385321102
I0
I1
I-1
tp53307
sS'appearance,of,unsteady'
p53308
(F1
F0.00014334862385321102
I1
I0
I1
tp53309
sS'microm,which,was'
p53310
(F1
F0.00014334862385321102
I0
I1
I-1
tp53311
sS'index,of,the'
p53312
(F1
F0.00028669724770642203
I0
I2
I-2
tp53313
sS'have,cholesterol,levels'
p53314
(F1
F0.00014334862385321102
I1
I0
I1
tp53315
sS'episode,of,migraine'
p53316
(F1
F0.00014334862385321102
I0
I1
I-1
tp53317
sS'on,absorption,has'
p53318
(F1
F0.00014334862385321102
I0
I1
I-1
tp53319
sS'decreasing,heparin,effect'
p53320
(F1
F0.00014334862385321102
I1
I0
I1
tp53321
sS'as,or,iv'
p53322
(F1
F0.00014334862385321102
I0
I1
I-1
tp53323
sS'there,are,case'
p53324
(F1
F0.00014334862385321102
I1
I0
I1
tp53325
sS'the,fertility,of'
p53326
(F1
F0.00014334862385321102
I0
I1
I-1
tp53327
sS'studies,nitrates,the'
p53328
(F1
F0.00014334862385321102
I1
I0
I1
tp53329
sS'hypotensive,effect,has'
p53330
(F1
F0.00014334862385321102
I1
I0
I1
tp53331
sS'therapy,the,introduction'
p53332
(F1
F0.00014334862385321102
I1
I0
I1
tp53333
sS'fr,responding,produced'
p53334
(F1
F0.00014334862385321102
I1
I0
I1
tp53335
sS'substrates,for,the'
p53336
(F1
F0.00014334862385321102
I0
I1
I-1
tp53337
sS'by,an,elevation'
p53338
(F1
F0.00014334862385321102
I0
I1
I-1
tp53339
sS'patients,on,may'
p53340
(F1
F0.00028669724770642203
I2
I0
I2
tp53341
sS'steady-state,pharmacokinetics,after'
p53342
(F1
F0.00014334862385321102
I0
I1
I-1
tp53343
sS'either,single,or'
p53344
(F1
F0.00014334862385321102
I0
I1
I-1
tp53345
sS'on,felbatol,the'
p53346
(F1
F0.00028669724770642203
I0
I2
I-2
tp53347
sS'self-administration,of,and'
p53348
(F1
F0.00014334862385321102
I0
I1
I-1
tp53349
sS'striatal,concentrations,and'
p53350
(F1
F0.00014334862385321102
I1
I0
I1
tp53351
sS'be,interrupted,when'
p53352
(F1
F0.00014334862385321102
I0
I1
I-1
tp53353
sS'cation-containing,products,concurrent'
p53354
(F1
F0.00014334862385321102
I1
I0
I1
tp53355
sS'in,switching,from'
p53356
(F1
F0.00057339449541284407
I4
I0
I4
tp53357
sS'warfarin,a,single'
p53358
(F1
F0.00014334862385321102
I0
I1
I-1
tp53359
sS'as,nonsteroidal,anti-inflammatory'
p53360
(F1
F0.00014334862385321102
I1
I0
I1
tp53361
sS'analyses,indicate,that'
p53362
(F0.5
F0.00028669724770642203
I3
I1
I2
tp53363
sS'indinavir,and,formulations'
p53364
(F1
F0.00014334862385321102
I1
I0
I1
tp53365
sS'the,other,that'
p53366
(F1
F0.00014334862385321102
I0
I1
I-1
tp53367
sS'concomitant,administration,on'
p53368
(F1
F0.00014334862385321102
I0
I1
I-1
tp53369
sS'a,substantially,greater'
p53370
(F1
F0.00014334862385321102
I0
I1
I-1
tp53371
sS'concomitant,administration,of'
p53372
(F0.4925373134328358
F0.0094610091743119271
I100
I34
I66
tp53373
sS'while,those,of'
p53374
(F0
F0
I1
I1
I0
tp53375
sS'antihypertensive,medications,and'
p53376
(F1
F0.00014334862385321102
I1
I0
I1
tp53377
sS'of,hydroxylated,in'
p53378
(F1
F0.00014334862385321102
I1
I0
I1
tp53379
sS'by,hepatic,enzyme'
p53380
(F1
F0.00014334862385321102
I1
I0
I1
tp53381
sS'clinical,trials,database'
p53382
(F1
F0.00014334862385321102
I0
I1
I-1
tp53383
sS'cyp1a2,cyp2a6,cyp2b6'
p53384
(F1
F0.00014334862385321102
I0
I1
I-1
tp53385
sS'deet,n,n-diethyl'
p53386
(F1
F0.00014334862385321102
I1
I0
I1
tp53387
sS'inconsistent,reports,regarding'
p53388
(F1
F0.00014334862385321102
I0
I1
I-1
tp53389
sS'sodium,colistemethate,salts'
p53390
(F1
F0.00014334862385321102
I1
I0
I1
tp53391
sS'inducer,the,auc'
p53392
(F1
F0.00014334862385321102
I1
I0
I1
tp53393
sS'be,approved,for'
p53394
(F1
F0.00014334862385321102
I0
I1
I-1
tp53395
sS'bleeding,and,should'
p53396
(F1
F0.00014334862385321102
I1
I0
I1
tp53397
sS'kingdom,with,foscavir'
p53398
(F1
F0.00014334862385321102
I1
I0
I1
tp53399
sS'platelet,activation,in'
p53400
(F1
F0.00014334862385321102
I0
I1
I-1
tp53401
sS'general,local,like'
p53402
(F1
F0.00014334862385321102
I0
I1
I-1
tp53403
sS'sexual,activity,is'
p53404
(F1
F0.00014334862385321102
I0
I1
I-1
tp53405
sS'co-administered,with,mg'
p53406
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp53407
sS'reports,of,serious'
p53408
(F1
F0.00028669724770642203
I2
I0
I2
tp53409
sS'divalent,and,trivalent'
p53410
(F1
F0.00028669724770642203
I2
I0
I2
tp53411
sS'immediate,release,but'
p53412
(F1
F0.00014334862385321102
I1
I0
I1
tp53413
sS'at,high,trileptal'
p53414
(F1
F0.00014334862385321102
I1
I0
I1
tp53415
sS'additional,supine,systolic'
p53416
(F1
F0.00014334862385321102
I1
I0
I1
tp53417
sS'to,any,medication'
p53418
(F1
F0.00014334862385321102
I1
I0
I1
tp53419
sS'of,was,evaluated'
p53420
(F1
F0.00028669724770642203
I0
I2
I-2
tp53421
sS'of,patients,experiencing'
p53422
(F1
F0.00014334862385321102
I1
I0
I1
tp53423
sS'drugs,ethanol,an'
p53424
(F1
F0.00014334862385321102
I1
I0
I1
tp53425
sS'given,mg,of'
p53426
(F1
F0.00014334862385321102
I1
I0
I1
tp53427
sS'significant,in,patients'
p53428
(F1
F0.00014334862385321102
I1
I0
I1
tp53429
sS'patients,receiving,nalfon'
p53430
(F1
F0.00014334862385321102
I1
I0
I1
tp53431
sS'decrease,the,efficacy'
p53432
(F1
F0.00014334862385321102
I1
I0
I1
tp53433
sS'affinity,for,anions'
p53434
(F1
F0.00014334862385321102
I0
I1
I-1
tp53435
sS'activity,which,was'
p53436
(F1
F0.00014334862385321102
I1
I0
I1
tp53437
sS'loss,of,symptom'
p53438
(F1
F0.00014334862385321102
I1
I0
I1
tp53439
sS'clinical,studies,involving'
p53440
(F1
F0.00028669724770642203
I2
I0
I2
tp53441
sS'growth,of,pseudomonas'
p53442
(F1
F0.00014334862385321102
I0
I1
I-1
tp53443
sS'after,or,after'
p53444
(F1
F0.00014334862385321102
I1
I0
I1
tp53445
sS'transferase,it,is'
p53446
(F1
F0.00014334862385321102
I0
I1
I-1
tp53447
sS'is,structurally,distinct'
p53448
(F1
F0.00014334862385321102
I0
I1
I-1
tp53449
sS'fractional,inhibitory,concentration'
p53450
(F1
F0.00014334862385321102
I0
I1
I-1
tp53451
sS'alkalinizing,agents,sodium'
p53452
(F1
F0.00014334862385321102
I1
I0
I1
tp53453
sS'taking,mg,day'
p53454
(F1
F0.00014334862385321102
I1
I0
I1
tp53455
sS'since,nevirapinemay,lower'
p53456
(F1
F0.00014334862385321102
I1
I0
I1
tp53457
sS'may,interfere,with'
p53458
(F0.30434782608695654
F0.0010034403669724771
I15
I8
I7
tp53459
sS'a,main,meal'
p53460
(F1
F0.00014334862385321102
I0
I1
I-1
tp53461
sS'potential,benefits,outweigh'
p53462
(F1
F0.00028669724770642203
I2
I0
I2
tp53463
sS'pharmacodynamic,interaction,use'
p53464
(F1
F0.00014334862385321102
I1
I0
I1
tp53465
sS'withdrawal,methadone,maintained'
p53466
(F1
F0.00014334862385321102
I1
I0
I1
tp53467
sS'n,combination,study'
p53468
(F1
F0.00014334862385321102
I1
I0
I1
tp53469
sS'of,tricyclic,tcas'
p53470
(F1
F0.00014334862385321102
I0
I1
I-1
tp53471
sS'chlorpromazine,chlorpromazine,blocks'
p53472
(F1
F0.00028669724770642203
I2
I0
I2
tp53473
sS'an,oral,for'
p53474
(F1
F0.00028669724770642203
I2
I0
I2
tp53475
sS'in,approximately,decrease'
p53476
(F1
F0.00014334862385321102
I1
I0
I1
tp53477
sS'and,antidotal,properties'
p53478
(F1
F0.00014334862385321102
I1
I0
I1
tp53479
sS'bromocriptine,mesylate,in'
p53480
(F1
F0.00014334862385321102
I1
I0
I1
tp53481
sS'and,possibly,nicotinic'
p53482
(F1
F0.00014334862385321102
I0
I1
I-1
tp53483
sS'indicated,reduction,of'
p53484
(F1
F0.00014334862385321102
I1
I0
I1
tp53485
sS'kg,removes,the'
p53486
(F1
F0.00014334862385321102
I1
I0
I1
tp53487
sS'maximum,concentration,increased'
p53488
(F1
F0.00014334862385321102
I1
I0
I1
tp53489
sS'alfenta,clearance,and'
p53490
(F1
F0.00014334862385321102
I1
I0
I1
tp53491
sS'or,other,beta2'
p53492
(F1
F0.00014334862385321102
I1
I0
I1
tp53493
sS'changes,in,serum'
p53494
(F1
F0.00014334862385321102
I0
I1
I-1
tp53495
sS'when,an,and'
p53496
(F1
F0.00014334862385321102
I1
I0
I1
tp53497
sS'four,kinds,of'
p53498
(F1
F0.00014334862385321102
I0
I1
I-1
tp53499
sS'absorption,but,had'
p53500
(F1
F0.00014334862385321102
I0
I1
I-1
tp53501
sS'oral,in,combination'
p53502
(F1
F0.00014334862385321102
I0
I1
I-1
tp53503
sS'day,was,coadministered'
p53504
(F1
F0.00014334862385321102
I1
I0
I1
tp53505
sS'northern,blot,analysis'
p53506
(F1
F0.00014334862385321102
I0
I1
I-1
tp53507
sS'aminoglutethimide,may,diminish'
p53508
(F1
F0.00014334862385321102
I1
I0
I1
tp53509
sS'receiving,these,concomitant'
p53510
(F1
F0.00014334862385321102
I1
I0
I1
tp53511
sS'pipracil,may,result'
p53512
(F1
F0.00014334862385321102
I0
I1
I-1
tp53513
sS'by,interaction,with'
p53514
(F1
F0.00014334862385321102
I1
I0
I1
tp53515
sS'subjects,received,mg'
p53516
(F1
F0.00028669724770642203
I0
I2
I-2
tp53517
sS'cytadren,accelerates,the'
p53518
(F1
F0.00014334862385321102
I1
I0
I1
tp53519
sS'because,bleeding,has'
p53520
(F1
F0.00014334862385321102
I1
I0
I1
tp53521
sS'separated,by,at'
p53522
(F1
F0.00014334862385321102
I1
I0
I1
tp53523
sS'cytochrome,p450iid6,may'
p53524
(F1
F0.00014334862385321102
I0
I1
I-1
tp53525
sS'with,other,antipsychotic'
p53526
(F1
F0.00014334862385321102
I1
I0
I1
tp53527
sS'study,received,either'
p53528
(F1
F0.00014334862385321102
I0
I1
I-1
tp53529
sS'compounds,meclofenamic,acid'
p53530
(F1
F0.00014334862385321102
I1
I0
I1
tp53531
sS'the,physiological,behavioral'
p53532
(F1
F0.00014334862385321102
I0
I1
I-1
tp53533
sS'use,of,anticholinesterase'
p53534
(F1
F0.00014334862385321102
I1
I0
I1
tp53535
sS'praziquantel,in,the'
p53536
(F1
F0.00014334862385321102
I1
I0
I1
tp53537
sS'the,following,nicotinic'
p53538
(F1
F0.00014334862385321102
I0
I1
I-1
tp53539
sS'immediate,discontinuation,of'
p53540
(F1
F0.00014334862385321102
I0
I1
I-1
tp53541
sS'these,may,be'
p53542
(F1
F0.00014334862385321102
I1
I0
I1
tp53543
sS'the,blockade,of'
p53544
(F1
F0.00014334862385321102
I0
I1
I-1
tp53545
sS'doses,than,usually'
p53546
(F1
F0.0010034403669724771
I0
I7
I-7
tp53547
sS'did,not,modify'
p53548
(F1
F0.00014334862385321102
I0
I1
I-1
tp53549
sS'valium,is,a'
p53550
(F1
F0.00014334862385321102
I0
I1
I-1
tp53551
sS'trial,that,included'
p53552
(F1
F0.00014334862385321102
I0
I1
I-1
tp53553
sS'of,the,during'
p53554
(F1
F0.00014334862385321102
I1
I0
I1
tp53555
sS'is,believed,that'
p53556
(F1
F0.00014334862385321102
I1
I0
I1
tp53557
sS'mrna,level,in'
p53558
(F1
F0.00014334862385321102
I1
I0
I1
tp53559
sS'amyl,nitrite,after'
p53560
(F1
F0.00014334862385321102
I1
I0
I1
tp53561
sS'of,tbars,levels'
p53562
(F1
F0.00014334862385321102
I1
I0
I1
tp53563
sS'twitch,was,for'
p53564
(F1
F0.00014334862385321102
I1
I0
I1
tp53565
sS'predominantly,in,the'
p53566
(F1
F0.00014334862385321102
I1
I0
I1
tp53567
sS'angiotensin,on,pentagastrin-'
p53568
(F1
F0.00014334862385321102
I0
I1
I-1
tp53569
sS'administration,of,ponstel'
p53570
(F1
F0.00014334862385321102
I1
I0
I1
tp53571
sS'invirase,or,fortovase'
p53572
(F1
F0.00014334862385321102
I0
I1
I-1
tp53573
sS'and,pharmacodynamics,ecg'
p53574
(F1
F0.00014334862385321102
I0
I1
I-1
tp53575
sS'neuropathy,include,nucleoside'
p53576
(F1
F0.00014334862385321102
I0
I1
I-1
tp53577
sS'one,controlled,clinical'
p53578
(F1
F0.00014334862385321102
I1
I0
I1
tp53579
sS'or,marked,changes'
p53580
(F1
F0.00014334862385321102
I1
I0
I1
tp53581
sS'oral,during,administration'
p53582
(F1
F0.00014334862385321102
I1
I0
I1
tp53583
sS'significant,deterioration,in'
p53584
(F1
F0.00014334862385321102
I0
I1
I-1
tp53585
sS'when,extended,sodium'
p53586
(F1
F0.00014334862385321102
I0
I1
I-1
tp53587
sS'administration,with,may'
p53588
(F1
F0.00028669724770642203
I2
I0
I2
tp53589
sS'elevating,duodenal,absorption'
p53590
(F1
F0.00014334862385321102
I1
I0
I1
tp53591
sS'oral,antidiabetes,products'
p53592
(F1
F0.00014334862385321102
I0
I1
I-1
tp53593
sS'of,positive,and'
p53594
(F1
F0.00014334862385321102
I0
I1
I-1
tp53595
sS'mg,vardenafil,in'
p53596
(F1
F0.00014334862385321102
I0
I1
I-1
tp53597
sS'b-blocking,agent,should'
p53598
(F1
F0.00014334862385321102
I1
I0
I1
tp53599
sS'or,its,components'
p53600
(F1
F0.00014334862385321102
I0
I1
I-1
tp53601
sS'and,increase,its'
p53602
(F1
F0.00014334862385321102
I1
I0
I1
tp53603
sS'used,concomitantly,and'
p53604
(F1
F0.00014334862385321102
I1
I0
I1
tp53605
sS'been,established,but'
p53606
(F0
F0
I1
I1
I0
tp53607
sS'single,study,rats'
p53608
(F1
F0.00014334862385321102
I1
I0
I1
tp53609
sS'glyburide,an,increased'
p53610
(F1
F0.00014334862385321102
I0
I1
I-1
tp53611
sS'addition,or,deletion'
p53612
(F1
F0.00014334862385321102
I0
I1
I-1
tp53613
sS'a,twofold,increase'
p53614
(F1
F0.00014334862385321102
I1
I0
I1
tp53615
sS'protein,when,was'
p53616
(F1
F0.00014334862385321102
I0
I1
I-1
tp53617
sS'was,a,small'
p53618
(F0
F0
I1
I1
I0
tp53619
sS'altered,tsh,secretion'
p53620
(F1
F0.00014334862385321102
I0
I1
I-1
tp53621
sS'pegasys,once,weekly'
p53622
(F1
F0.00014334862385321102
I1
I0
I1
tp53623
sS'antihypertensive,effect,in'
p53624
(F1
F0.00014334862385321102
I1
I0
I1
tp53625
sS'prior,administration,of'
p53626
(F0
F0
I2
I2
I0
tp53627
sS'may,cause,hypotension'
p53628
(F1
F0.00014334862385321102
I0
I1
I-1
tp53629
sS'clotting,factors,when'
p53630
(F1
F0.00014334862385321102
I0
I1
I-1
tp53631
sS'daily,oral,dose'
p53632
(F1
F0.00014334862385321102
I0
I1
I-1
tp53633
sS'of,with,elspar'
p53634
(F1
F0.00014334862385321102
I1
I0
I1
tp53635
sS'v,did,not'
p53636
(F1
F0.00014334862385321102
I0
I1
I-1
tp53637
sS'pronestyl,sulfa,medicines'
p53638
(F1
F0.00014334862385321102
I1
I0
I1
tp53639
sS'use,of,romazicon'
p53640
(F1
F0.00014334862385321102
I0
I1
I-1
tp53641
sS'formulation,of,fluorescence'
p53642
(F1
F0.00014334862385321102
I0
I1
I-1
tp53643
sS'there,any,changes'
p53644
(F1
F0.00014334862385321102
I0
I1
I-1
tp53645
sS'warranted,when,is'
p53646
(F0
F0
I1
I1
I0
tp53647
sS'animals,treated,with'
p53648
(F1
F0.00014334862385321102
I1
I0
I1
tp53649
sS'known,property,of'
p53650
(F1
F0.00014334862385321102
I1
I0
I1
tp53651
sS'more,pronounced,if'
p53652
(F1
F0.00014334862385321102
I1
I0
I1
tp53653
sS'half-life,leading,to'
p53654
(F1
F0.00014334862385321102
I0
I1
I-1
tp53655
sS'receive,low-molecular,weight'
p53656
(F1
F0.00014334862385321102
I0
I1
I-1
tp53657
sS'bleeding,and,or'
p53658
(F1
F0.00014334862385321102
I1
I0
I1
tp53659
sS'of,or,were'
p53660
(F1
F0.00014334862385321102
I0
I1
I-1
tp53661
sS'observed,during,the'
p53662
(F1
F0.00014334862385321102
I0
I1
I-1
tp53663
sS'other,asthma,or'
p53664
(F1
F0.00014334862385321102
I0
I1
I-1
tp53665
sS'rifampicin,racemic,exposure'
p53666
(F1
F0.00014334862385321102
I1
I0
I1
tp53667
sS'a,dihydropyridine,derivative'
p53668
(F1
F0.00014334862385321102
I0
I1
I-1
tp53669
sS'possible,pharmacodynamic,interactions'
p53670
(F1
F0.00014334862385321102
I1
I0
I1
tp53671
sS'a,small,yet'
p53672
(F1
F0.00014334862385321102
I0
I1
I-1
tp53673
sS'of,revia,and'
p53674
(F1
F0.00014334862385321102
I1
I0
I1
tp53675
sS'completely,inhibited,by'
p53676
(F1
F0.00014334862385321102
I1
I0
I1
tp53677
sS'and,therefore,has'
p53678
(F1
F0.00014334862385321102
I0
I1
I-1
tp53679
sS'the,intracellular,phosphorylation'
p53680
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp53681
sS'observed,during,studies'
p53682
(F1
F0.00014334862385321102
I1
I0
I1
tp53683
sS'an,approximate,doubling'
p53684
(F1
F0.00028669724770642203
I2
I0
I2
tp53685
sS'as,they,might'
p53686
(F1
F0.00014334862385321102
I1
I0
I1
tp53687
sS'felbamate,treatment,resulted'
p53688
(F1
F0.00014334862385321102
I1
I0
I1
tp53689
sS'the,plasma,protein'
p53690
(F1
F0.00028669724770642203
I0
I2
I-2
tp53691
sS'that,the,diabetic'
p53692
(F1
F0.00014334862385321102
I0
I1
I-1
tp53693
sS'its,normal,dose'
p53694
(F1
F0.00014334862385321102
I1
I0
I1
tp53695
sS'these,increases,should'
p53696
(F1
F0.00014334862385321102
I1
I0
I1
tp53697
sS'metabolized,should,have'
p53698
(F1
F0.00014334862385321102
I1
I0
I1
tp53699
sS'coadministered,although,the'
p53700
(F1
F0.00014334862385321102
I0
I1
I-1
tp53701
sS'major,clinical,importance'
p53702
(F1
F0.00014334862385321102
I1
I0
I1
tp53703
sS'the,steady-state,pharmacokinetics'
p53704
(F1
F0.00057339449541284407
I0
I4
I-4
tp53705
sS'were,very,strong'
p53706
(F1
F0.00014334862385321102
I1
I0
I1
tp53707
sS'monthly,was,similar'
p53708
(F1
F0.00014334862385321102
I0
I1
I-1
tp53709
sS'may,present,a'
p53710
(F1
F0.00014334862385321102
I1
I0
I1
tp53711
sS'oral,administration,even'
p53712
(F1
F0.00014334862385321102
I0
I1
I-1
tp53713
sS'and,anticoagulants,increased'
p53714
(F1
F0.00014334862385321102
I1
I0
I1
tp53715
sS'avonex,indicates,that'
p53716
(F1
F0.00014334862385321102
I0
I1
I-1
tp53717
sS'recommended,that,concentrations'
p53718
(F1
F0.00014334862385321102
I1
I0
I1
tp53719
sS'indinavir,concentrations,may'
p53720
(F1
F0.00014334862385321102
I1
I0
I1
tp53721
sS'have,a,significant'
p53722
(F1
F0.00028669724770642203
I0
I2
I-2
tp53723
sS'substrate,of,cyp3a4'
p53724
(F1
F0.00014334862385321102
I0
I1
I-1
tp53725
sS'especially,at,arterial'
p53726
(F1
F0.00014334862385321102
I0
I1
I-1
tp53727
sS'may,be,decreased'
p53728
(F1
F0.00043004587155963305
I3
I0
I3
tp53729
sS'be,made,by'
p53730
(F1
F0.00014334862385321102
I0
I1
I-1
tp53731
sS'an,hmg-coa,reductase'
p53732
(F1
F0.00014334862385321102
I1
I0
I1
tp53733
sS'concentrations,and,a'
p53734
(F1
F0.00028669724770642203
I2
I0
I2
tp53735
sS'mcf-7,cells,either'
p53736
(F1
F0.00014334862385321102
I0
I1
I-1
tp53737
sS'mechanism,and,a'
p53738
(F1
F0.00014334862385321102
I1
I0
I1
tp53739
sS'given,fu,bolus-ifl'
p53740
(F1
F0.00014334862385321102
I0
I1
I-1
tp53741
sS'before,a,nonlethal'
p53742
(F1
F0.00014334862385321102
I1
I0
I1
tp53743
sS'enhance,the,effects'
p53744
(F1
F0.0017201834862385322
I12
I0
I12
tp53745
sS'study,involving,six-healthy'
p53746
(F1
F0.00014334862385321102
I0
I1
I-1
tp53747
sS'thyroid,products,oral'
p53748
(F1
F0.00014334862385321102
I0
I1
I-1
tp53749
sS'with,and,has'
p53750
(F1
F0.00014334862385321102
I0
I1
I-1
tp53751
sS'may,be,produced'
p53752
(F0
F0
I1
I1
I0
tp53753
sS'when,parenteral,are'
p53754
(F1
F0.00014334862385321102
I0
I1
I-1
tp53755
sS'are,representations,of'
p53756
(F1
F0.00014334862385321102
I0
I1
I-1
tp53757
sS'of,ponstel,with'
p53758
(F1
F0.00014334862385321102
I1
I0
I1
tp53759
sS'inhalation,aerosol,has'
p53760
(F1
F0.00014334862385321102
I0
I1
I-1
tp53761
sS'than,and,would'
p53762
(F1
F0.00014334862385321102
I0
I1
I-1
tp53763
sS'aerosol,and,these'
p53764
(F1
F0.00014334862385321102
I0
I1
I-1
tp53765
sS'with,major,psychotic'
p53766
(F1
F0.00014334862385321102
I1
I0
I1
tp53767
sS'the,dopaminergic,renal'
p53768
(F1
F0.00014334862385321102
I1
I0
I1
tp53769
sS'providers,are,encouraged'
p53770
(F1
F0.00014334862385321102
I0
I1
I-1
tp53771
sS'serum,levels,of'
p53772
(F1
F0.0015768348623853212
I11
I0
I11
tp53773
sS'a,or,induce'
p53774
(F1
F0.00014334862385321102
I0
I1
I-1
tp53775
sS'serum,levels,or'
p53776
(F1
F0.00014334862385321102
I1
I0
I1
tp53777
sS'with,appropriate,adjustment'
p53778
(F1
F0.00014334862385321102
I0
I1
I-1
tp53779
sS'the,decreased,urinary'
p53780
(F1
F0.00014334862385321102
I0
I1
I-1
tp53781
sS'at,of,baseline'
p53782
(F1
F0.00014334862385321102
I0
I1
I-1
tp53783
sS'is,given,with'
p53784
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp53785
sS'even,when,an'
p53786
(F1
F0.00014334862385321102
I1
I0
I1
tp53787
sS'as,and,may'
p53788
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp53789
sS'initial,step,in'
p53790
(F1
F0.00014334862385321102
I0
I1
I-1
tp53791
sS'on,the,basis'
p53792
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp53793
sS'for,uptake-1,were'
p53794
(F1
F0.00014334862385321102
I0
I1
I-1
tp53795
sS'acetaminophen,oral,phenytoin'
p53796
(F1
F0.00014334862385321102
I1
I0
I1
tp53797
sS'isolated,single,pancreatic'
p53798
(F1
F0.00014334862385321102
I0
I1
I-1
tp53799
sS'therapies,including,oral'
p53800
(F1
F0.00014334862385321102
I0
I1
I-1
tp53801
sS'eliminated,by,the'
p53802
(F1
F0.00014334862385321102
I0
I1
I-1
tp53803
sS'of,grams,three'
p53804
(F1
F0.00014334862385321102
I1
I0
I1
tp53805
sS'metabolic,enzymes,is'
p53806
(F1
F0.00014334862385321102
I0
I1
I-1
tp53807
sS'opioids,are,strong'
p53808
(F1
F0.00014334862385321102
I0
I1
I-1
tp53809
sS'in,a,double'
p53810
(F1
F0.00014334862385321102
I0
I1
I-1
tp53811
sS'estradiol,and,some'
p53812
(F1
F0.00014334862385321102
I1
I0
I1
tp53813
sS'propanolol,the,pharmacokinetics'
p53814
(F1
F0.00014334862385321102
I0
I1
I-1
tp53815
sS'should,also,refer'
p53816
(F1
F0.00014334862385321102
I0
I1
I-1
tp53817
sS'marked,effect,on'
p53818
(F1
F0.00014334862385321102
I1
I0
I1
tp53819
sS'the,elimination,rate'
p53820
(F1
F0.00014334862385321102
I0
I1
I-1
tp53821
sS'tegretol,tagamet,prozac'
p53822
(F1
F0.00014334862385321102
I0
I1
I-1
tp53823
sS'years,have,not'
p53824
(F1
F0.00014334862385321102
I0
I1
I-1
tp53825
sS'by,concomitant,administration'
p53826
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp53827
sS'not,been,completely'
p53828
(F1
F0.00014334862385321102
I0
I1
I-1
tp53829
sS'and,therapy,were'
p53830
(F1
F0.00014334862385321102
I0
I1
I-1
tp53831
sS'other,nsaids,have'
p53832
(F1
F0.00014334862385321102
I1
I0
I1
tp53833
sS'on,application,mode'
p53834
(F1
F0.00014334862385321102
I0
I1
I-1
tp53835
sS'two,hours,of'
p53836
(F1
F0.00014334862385321102
I0
I1
I-1
tp53837
sS'synthesis,and,did'
p53838
(F1
F0.00014334862385321102
I0
I1
I-1
tp53839
sS'prinivil,with,potassium-sparing'
p53840
(F1
F0.00014334862385321102
I1
I0
I1
tp53841
sS'on,the,biotransformation'
p53842
(F1
F0.00014334862385321102
I1
I0
I1
tp53843
sS'need,to,use'
p53844
(F1
F0.00014334862385321102
I1
I0
I1
tp53845
sS'as,possible,to'
p53846
(F1
F0.00014334862385321102
I0
I1
I-1
tp53847
sS'to,a,patients'
p53848
(F1
F0.00014334862385321102
I1
I0
I1
tp53849
sS'etofibrate,elicited,enhancement'
p53850
(F1
F0.00014334862385321102
I1
I0
I1
tp53851
sS'catabloism,of,k-dependent'
p53852
(F1
F0.00014334862385321102
I0
I1
I-1
tp53853
sS'fenofibric,acid,were'
p53854
(F1
F0.00014334862385321102
I0
I1
I-1
tp53855
sS'initiation,of,the'
p53856
(F1
F0.00014334862385321102
I1
I0
I1
tp53857
sS'did,not,include'
p53858
(F1
F0.00014334862385321102
I0
I1
I-1
tp53859
sS'the,pharmacokinetits,of'
p53860
(F1
F0.00014334862385321102
I0
I1
I-1
tp53861
sS'depletions,of,striatal'
p53862
(F1
F0.00028669724770642203
I2
I0
I2
tp53863
sS'of,the,cyclooxygenase-2'
p53864
(F1
F0.00014334862385321102
I0
I1
I-1
tp53865
sS'or,the,pharmacodynamics'
p53866
(F1
F0.00028669724770642203
I0
I2
I-2
tp53867
sS'increase,for,equetrotm'
p53868
(F1
F0.00014334862385321102
I1
I0
I1
tp53869
sS'reductase,inhibitors,have'
p53870
(F1
F0.00014334862385321102
I1
I0
I1
tp53871
sS'although,c,max'
p53872
(F1
F0.00014334862385321102
I0
I1
I-1
tp53873
sS'with,other,highly'
p53874
(F0
F0
I1
I1
I0
tp53875
sS'decreases,in,tbg'
p53876
(F1
F0.00014334862385321102
I0
I1
I-1
tp53877
sS'within,weeks,of'
p53878
(F1
F0.00014334862385321102
I1
I0
I1
tp53879
sS'efficacy,toxicity,and'
p53880
(F1
F0.00014334862385321102
I0
I1
I-1
tp53881
sS'patients,a,disulfiram-like'
p53882
(F1
F0.00014334862385321102
I0
I1
I-1
tp53883
sS'a,corresponding,increase'
p53884
(F1
F0.00028669724770642203
I2
I0
I2
tp53885
sS'of,the,are'
p53886
(F1
F0.00014334862385321102
I0
I1
I-1
tp53887
sS'reduced,by,concomitant'
p53888
(F1
F0.00014334862385321102
I1
I0
I1
tp53889
sS'that,inhibit,pgp'
p53890
(F1
F0.00014334862385321102
I0
I1
I-1
tp53891
sS'the,coadministration,of'
p53892
(F0.33333333333333331
F0.0008600917431192661
I6
I12
I-6
tp53893
sS'fungal,resistance,to'
p53894
(F1
F0.00014334862385321102
I1
I0
I1
tp53895
sS'c19,d6,e1'
p53896
(F1
F0.00014334862385321102
I0
I1
I-1
tp53897
sS'd,analogues,should'
p53898
(F1
F0.00043004587155963305
I0
I3
I-3
tp53899
sS'background,the,pharmacokinetic'
p53900
(F1
F0.00014334862385321102
I0
I1
I-1
tp53901
sS'is,the,primary'
p53902
(F1
F0.00014334862385321102
I1
I0
I1
tp53903
sS'not,recommended,for'
p53904
(F0.5
F0.00028669724770642203
I3
I1
I2
tp53905
sS'well,as,formulations'
p53906
(F1
F0.00014334862385321102
I1
I0
I1
tp53907
sS'patients,with,rheumatoid'
p53908
(F1
F0.00014334862385321102
I0
I1
I-1
tp53909
sS'area-under,the-curve,after'
p53910
(F1
F0.00014334862385321102
I1
I0
I1
tp53911
sS'given,the,time'
p53912
(F1
F0.00014334862385321102
I0
I1
I-1
tp53913
sS'ii,may,be'
p53914
(F1
F0.00014334862385321102
I1
I0
I1
tp53915
sS'oral,contraceptives,a'
p53916
(F1
F0.00014334862385321102
I0
I1
I-1
tp53917
sS'and,organic,were'
p53918
(F1
F0.00028669724770642203
I2
I0
I2
tp53919
sS'of,tablets,in'
p53920
(F1
F0.00014334862385321102
I1
I0
I1
tp53921
sS'g,h,ml'
p53922
(F1
F0.00014334862385321102
I1
I0
I1
tp53923
sS'tests,such,as'
p53924
(F1
F0.00014334862385321102
I0
I1
I-1
tp53925
sS'metabolism,were,homozygous'
p53926
(F1
F0.00014334862385321102
I0
I1
I-1
tp53927
sS'with,or,glycoprotein'
p53928
(F1
F0.00014334862385321102
I1
I0
I1
tp53929
sS'therapy,with,prinivil'
p53930
(F1
F0.00014334862385321102
I1
I0
I1
tp53931
sS'such,as,antiparkinson'
p53932
(F1
F0.00014334862385321102
I1
I0
I1
tp53933
sS'antagonists,congestive,heart'
p53934
(F1
F0.00014334862385321102
I0
I1
I-1
tp53935
sS'of,pseudotumor,cerebri'
p53936
(F1
F0.00014334862385321102
I1
I0
I1
tp53937
sS'were,performed,both'
p53938
(F1
F0.00014334862385321102
I0
I1
I-1
tp53939
sS'mhd,and,with'
p53940
(F1
F0.00014334862385321102
I0
I1
I-1
tp53941
sS'the,exception,of'
p53942
(F1
F0.00028669724770642203
I0
I2
I-2
tp53943
sS'not,in,functional'
p53944
(F1
F0.00014334862385321102
I1
I0
I1
tp53945
sS'reported,upon,discontinuation'
p53946
(F1
F0.00014334862385321102
I1
I0
I1
tp53947
sS'benzodiazepines,were,administered'
p53948
(F1
F0.00014334862385321102
I0
I1
I-1
tp53949
sS'and,dpcpx-induced,anxiogenic'
p53950
(F1
F0.00014334862385321102
I1
I0
I1
tp53951
sS'added,to,or'
p53952
(F1
F0.00014334862385321102
I1
I0
I1
tp53953
sS'absorption,decreases,gastrointestinal'
p53954
(F1
F0.00014334862385321102
I1
I0
I1
tp53955
sS'drugs,can,lead'
p53956
(F1
F0.00014334862385321102
I1
I0
I1
tp53957
sS'was,no,clinical'
p53958
(F1
F0.00014334862385321102
I0
I1
I-1
tp53959
sS'minipill,preparations,are'
p53960
(F1
F0.00014334862385321102
I1
I0
I1
tp53961
sS'table,changes,in'
p53962
(F1
F0.00014334862385321102
I0
I1
I-1
tp53963
sS'hydroxy,acid,metabolite'
p53964
(F1
F0.00014334862385321102
I1
I0
I1
tp53965
sS'because,prostaglandina,play'
p53966
(F1
F0.00014334862385321102
I1
I0
I1
tp53967
sS'studies,in,peripheral'
p53968
(F1
F0.00014334862385321102
I1
I0
I1
tp53969
sS'vivo,and,clinically'
p53970
(F1
F0.00014334862385321102
I0
I1
I-1
tp53971
sS'margin,such,as'
p53972
(F1
F0.00014334862385321102
I0
I1
I-1
tp53973
sS'hours,for,and'
p53974
(F1
F0.00014334862385321102
I0
I1
I-1
tp53975
sS'they,may,lead'
p53976
(F1
F0.00014334862385321102
I0
I1
I-1
tp53977
sS'hours,for,any'
p53978
(F1
F0.00014334862385321102
I1
I0
I1
tp53979
sS'concentrations,which,could'
p53980
(F1
F0.00014334862385321102
I1
I0
I1
tp53981
sS'omega-conotoxin,gvia,omega-agatoxin'
p53982
(F1
F0.00014334862385321102
I0
I1
I-1
tp53983
sS'to,campath,may'
p53984
(F1
F0.00014334862385321102
I0
I1
I-1
tp53985
sS'patient,for,possible'
p53986
(F1
F0.00014334862385321102
I0
I1
I-1
tp53987
sS'warning,potential,for'
p53988
(F1
F0.00014334862385321102
I0
I1
I-1
tp53989
sS'with,other,and'
p53990
(F1
F0.00014334862385321102
I1
I0
I1
tp53991
sS'tetracycline,a,bacteriostatic'
p53992
(F1
F0.00028669724770642203
I2
I0
I2
tp53993
sS'with,long-,and'
p53994
(F1
F0.00014334862385321102
I0
I1
I-1
tp53995
sS'or,inactivated,due'
p53996
(F1
F0.00014334862385321102
I1
I0
I1
tp53997
sS'glucose,in,the'
p53998
(F1
F0.00028669724770642203
I0
I2
I-2
tp53999
sS'cytochrome,p-450,isoenzymes'
p54000
(F1
F0.00014334862385321102
I1
I0
I1
tp54001
sS'of,tolerance,min'
p54002
(F1
F0.00014334862385321102
I0
I1
I-1
tp54003
sS'withdrawn,from,patients'
p54004
(F1
F0.00014334862385321102
I0
I1
I-1
tp54005
sS'produce,cns-depressant,effects'
p54006
(F1
F0.00014334862385321102
I1
I0
I1
tp54007
sS'normalized,ratio,when'
p54008
(F1
F0.00014334862385321102
I1
I0
I1
tp54009
sS'acid,the,mean'
p54010
(F1
F0.00014334862385321102
I0
I1
I-1
tp54011
sS'the,trials,due'
p54012
(F1
F0.00014334862385321102
I0
I1
I-1
tp54013
sS'receiving,therapy,administration'
p54014
(F1
F0.00014334862385321102
I0
I1
I-1
tp54015
sS'the,interaction,study'
p54016
(F1
F0.00014334862385321102
I1
I0
I1
tp54017
sS'the,nervous,system'
p54018
(F1
F0.00014334862385321102
I1
I0
I1
tp54019
sS'to,a,release'
p54020
(F1
F0.00014334862385321102
I0
I1
I-1
tp54021
sS'of,healthy,subjects'
p54022
(F1
F0.00014334862385321102
I0
I1
I-1
tp54023
sS'n,ingestion,of'
p54024
(F1
F0.00014334862385321102
I1
I0
I1
tp54025
sS'theophylline,the,pharmacokinetics'
p54026
(F1
F0.00014334862385321102
I0
I1
I-1
tp54027
sS'ph,may,be'
p54028
(F1
F0.00014334862385321102
I0
I1
I-1
tp54029
sS'markedly,decreased,even'
p54030
(F1
F0.00014334862385321102
I1
I0
I1
tp54031
sS'treatment,with,axert'
p54032
(F1
F0.00028669724770642203
I2
I0
I2
tp54033
sS'and,a,together'
p54034
(F1
F0.00014334862385321102
I1
I0
I1
tp54035
sS'and,coagulation,factor'
p54036
(F1
F0.00014334862385321102
I0
I1
I-1
tp54037
sS'delayed,elimination,and'
p54038
(F1
F0.00014334862385321102
I0
I1
I-1
tp54039
sS'the,translocation,when'
p54040
(F1
F0.00014334862385321102
I0
I1
I-1
tp54041
sS'min,compared,to'
p54042
(F1
F0.00014334862385321102
I0
I1
I-1
tp54043
sS'at,mg,day'
p54044
(F1
F0.00043004587155963305
I3
I0
I3
tp54045
sS'low,to,measure'
p54046
(F1
F0.00014334862385321102
I0
I1
I-1
tp54047
sS'have,been,found'
p54048
(F0
F0
I3
I3
I0
tp54049
sS'h,e,mesylate'
p54050
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp54051
sS'concentrations,and,therapeutic'
p54052
(F1
F0.00014334862385321102
I1
I0
I1
tp54053
sS'clinically,relevant,effect'
p54054
(F1
F0.00014334862385321102
I1
I0
I1
tp54055
sS'treatment,with,xanthine'
p54056
(F1
F0.00014334862385321102
I1
I0
I1
tp54057
sS'concentrations,of,but'
p54058
(F1
F0.00014334862385321102
I1
I0
I1
tp54059
sS'dose,of,pcp'
p54060
(F1
F0.00014334862385321102
I0
I1
I-1
tp54061
sS'to,take,and'
p54062
(F1
F0.00014334862385321102
I1
I0
I1
tp54063
sS'reduced,if,a'
p54064
(F1
F0.00014334862385321102
I1
I0
I1
tp54065
sS'mg,as,a'
p54066
(F1
F0.00014334862385321102
I0
I1
I-1
tp54067
sS'which,may,interfere'
p54068
(F1
F0.00014334862385321102
I0
I1
I-1
tp54069
sS'cytotoxic,agents,enhanced'
p54070
(F1
F0.00014334862385321102
I1
I0
I1
tp54071
sS'in,both,species'
p54072
(F1
F0.00014334862385321102
I1
I0
I1
tp54073
sS'and,a,high'
p54074
(F1
F0.00014334862385321102
I1
I0
I1
tp54075
sS'suggest,that,in'
p54076
(F0
F0
I1
I1
I0
tp54077
sS'are,potent,inducers'
p54078
(F1
F0.00014334862385321102
I1
I0
I1
tp54079
sS'trough,plasma,and'
p54080
(F1
F0.00014334862385321102
I0
I1
I-1
tp54081
sS'racemic,titrated,to'
p54082
(F1
F0.00014334862385321102
I0
I1
I-1
tp54083
sS'concern,about,the'
p54084
(F1
F0.00014334862385321102
I1
I0
I1
tp54085
sS'especially,in,cases'
p54086
(F1
F0.00014334862385321102
I1
I0
I1
tp54087
sS'behavioral,responses,to'
p54088
(F1
F0.00014334862385321102
I0
I1
I-1
tp54089
sS'of,given,later'
p54090
(F1
F0.00014334862385321102
I1
I0
I1
tp54091
sS'resulting,from,concomitant'
p54092
(F0
F0
I1
I1
I0
tp54093
sS'does,not,displace'
p54094
(F1
F0.00014334862385321102
I0
I1
I-1
tp54095
sS'estradiol,by,and'
p54096
(F1
F0.00014334862385321102
I1
I0
I1
tp54097
sS'relaxants,may,temporarily'
p54098
(F1
F0.00014334862385321102
I1
I0
I1
tp54099
sS'should,be,initiated'
p54100
(F1
F0.00028669724770642203
I2
I0
I2
tp54101
sS'antihypertensive,effect,to'
p54102
(F1
F0.00014334862385321102
I1
I0
I1
tp54103
sS'greater,than,mug'
p54104
(F1
F0.00014334862385321102
I0
I1
I-1
tp54105
sS'was,and,micrograms'
p54106
(F1
F0.00014334862385321102
I0
I1
I-1
tp54107
sS'reported,to,competitively'
p54108
(F1
F0.00014334862385321102
I1
I0
I1
tp54109
sS'to,increased,risk'
p54110
(F1
F0.00014334862385321102
I1
I0
I1
tp54111
sS'delirium,associated,with'
p54112
(F1
F0.00014334862385321102
I1
I0
I1
tp54113
sS'following,multiple,doses'
p54114
(F1
F0.00014334862385321102
I0
I1
I-1
tp54115
sS'and,metabolite,concentrations'
p54116
(F1
F0.00014334862385321102
I1
I0
I1
tp54117
sS'increased,in,patients'
p54118
(F1
F0.00014334862385321102
I1
I0
I1
tp54119
sS'with,targretin,capsules'
p54120
(F1
F0.00014334862385321102
I1
I0
I1
tp54121
sS'particularly,those,patients'
p54122
(F1
F0.00014334862385321102
I0
I1
I-1
tp54123
sS'added,to,a'
p54124
(F1
F0.00014334862385321102
I1
I0
I1
tp54125
sS'mao,inhibitors,or'
p54126
(F1
F0.00014334862385321102
I1
I0
I1
tp54127
sS'was,correlated,with'
p54128
(F1
F0.00014334862385321102
I0
I1
I-1
tp54129
sS'increased,to,approximately'
p54130
(F1
F0.00014334862385321102
I1
I0
I1
tp54131
sS'was,necessary,to'
p54132
(F1
F0.00014334862385321102
I1
I0
I1
tp54133
sS'between,discontinuation,of'
p54134
(F1
F0.00028669724770642203
I2
I0
I2
tp54135
sS'with,or,sodium'
p54136
(F1
F0.00014334862385321102
I1
I0
I1
tp54137
sS'resulting,in,low'
p54138
(F1
F0.00014334862385321102
I1
I0
I1
tp54139
sS'the,sixth,day'
p54140
(F1
F0.00014334862385321102
I1
I0
I1
tp54141
sS'and,extent,of'
p54142
(F1
F0.00028669724770642203
I0
I2
I-2
tp54143
sS'safely,used,in'
p54144
(F1
F0.00028669724770642203
I0
I2
I-2
tp54145
sS'therefore,the,use'
p54146
(F1
F0.00014334862385321102
I0
I1
I-1
tp54147
sS'therapy,alone,can'
p54148
(F1
F0.00014334862385321102
I0
I1
I-1
tp54149
sS'multiple,dose,study'
p54150
(F1
F0.00014334862385321102
I1
I0
I1
tp54151
sS'antibiotics,videx,should'
p54152
(F1
F0.00014334862385321102
I1
I0
I1
tp54153
sS'also,used,it'
p54154
(F1
F0.00014334862385321102
I1
I0
I1
tp54155
sS'after,tracleer,is'
p54156
(F1
F0.00014334862385321102
I1
I0
I1
tp54157
sS'study,of,interaction'
p54158
(F1
F0.00014334862385321102
I0
I1
I-1
tp54159
sS'therapy,were,increased'
p54160
(F1
F0.00014334862385321102
I0
I1
I-1
tp54161
sS'for,were,determined'
p54162
(F1
F0.00014334862385321102
I0
I1
I-1
tp54163
sS'lapatinib,inhibits,cyp3a4'
p54164
(F1
F0.00014334862385321102
I0
I1
I-1
tp54165
sS'to,their,similar'
p54166
(F1
F0.00014334862385321102
I1
I0
I1
tp54167
sS'emptying,may,also'
p54168
(F1
F0.00014334862385321102
I1
I0
I1
tp54169
sS'that,this,decrease'
p54170
(F1
F0.00014334862385321102
I0
I1
I-1
tp54171
sS'monitored,for,a'
p54172
(F1
F0.00014334862385321102
I1
I0
I1
tp54173
sS'interactions,may,be'
p54174
(F1
F0.00014334862385321102
I1
I0
I1
tp54175
sS'a,controlled,clinical'
p54176
(F1
F0.00014334862385321102
I0
I1
I-1
tp54177
sS'administration,of,both'
p54178
(F1
F0.00014334862385321102
I0
I1
I-1
tp54179
sS'antipsychotic,eg,an'
p54180
(F1
F0.00014334862385321102
I1
I0
I1
tp54181
sS'ethacrynic,acid,and'
p54182
(F1
F0.00014334862385321102
I0
I1
I-1
tp54183
sS'infections,an,increased'
p54184
(F1
F0.00014334862385321102
I1
I0
I1
tp54185
sS'for,on,dopamine2-'
p54186
(F1
F0.00014334862385321102
I0
I1
I-1
tp54187
sS'cyp3a4,may,decrease'
p54188
(F1
F0.00014334862385321102
I0
I1
I-1
tp54189
sS'as,post,marketing'
p54190
(F1
F0.00014334862385321102
I1
I0
I1
tp54191
sS'controlled,on,receiving'
p54192
(F1
F0.00014334862385321102
I1
I0
I1
tp54193
sS'in,other,schizophrenic'
p54194
(F1
F0.00014334862385321102
I1
I0
I1
tp54195
sS'therapy,with,all'
p54196
(F1
F0.00014334862385321102
I1
I0
I1
tp54197
sS'by,checkerboard,assay'
p54198
(F1
F0.00014334862385321102
I0
I1
I-1
tp54199
sS'been,observed,when'
p54200
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp54201
sS'bioequivalent,when,proquin'
p54202
(F1
F0.00014334862385321102
I0
I1
I-1
tp54203
sS'ventricular,arrhythmias,qt'
p54204
(F1
F0.00014334862385321102
I0
I1
I-1
tp54205
sS'oral,solution,one'
p54206
(F1
F0.00014334862385321102
I1
I0
I1
tp54207
sS'of,because,they'
p54208
(F1
F0.00014334862385321102
I1
I0
I1
tp54209
sS'may,become,subtherapeutic'
p54210
(F1
F0.00014334862385321102
I1
I0
I1
tp54211
sS'in,and,epoxide'
p54212
(F1
F0.00014334862385321102
I0
I1
I-1
tp54213
sS'mg,qd,cohort'
p54214
(F1
F0.00014334862385321102
I0
I1
I-1
tp54215
sS'discrimination,and,it'
p54216
(F1
F0.00014334862385321102
I0
I1
I-1
tp54217
sS'new,agents,are'
p54218
(F1
F0.00014334862385321102
I0
I1
I-1
tp54219
sS'or,of,patients'
p54220
(F1
F0.00014334862385321102
I0
I1
I-1
tp54221
sS'was,noted,even'
p54222
(F1
F0.00014334862385321102
I1
I0
I1
tp54223
sS'renin,release,captopril'
p54224
(F1
F0.00014334862385321102
I1
I0
I1
tp54225
sS'to,a,mean'
p54226
(F1
F0.00014334862385321102
I0
I1
I-1
tp54227
sS'coagulation,have,been'
p54228
(F1
F0.00014334862385321102
I1
I0
I1
tp54229
sS'oxidase,inhibitor,maoi'
p54230
(F1
F0.00014334862385321102
I0
I1
I-1
tp54231
sS'whether,or,not'
p54232
(F1
F0.00014334862385321102
I0
I1
I-1
tp54233
sS'including,anti-arrhythmic,agents'
p54234
(F1
F0.00014334862385321102
I0
I1
I-1
tp54235
sS'to,possible,pharmacodynamic'
p54236
(F1
F0.00014334862385321102
I1
I0
I1
tp54237
sS'an,altered,distribution'
p54238
(F1
F0.00014334862385321102
I1
I0
I1
tp54239
sS'but,not,when'
p54240
(F1
F0.00014334862385321102
I1
I0
I1
tp54241
sS'potentiated,by,through'
p54242
(F1
F0.00014334862385321102
I0
I1
I-1
tp54243
sS'it,interfere,with'
p54244
(F1
F0.00014334862385321102
I0
I1
I-1
tp54245
sS'involving,healthy,subjects'
p54246
(F1
F0.00014334862385321102
I1
I0
I1
tp54247
sS'per,day,for'
p54248
(F1
F0.00014334862385321102
I0
I1
I-1
tp54249
sS'were,dry,mouth'
p54250
(F1
F0.00014334862385321102
I0
I1
I-1
tp54251
sS'loop,diuretics,furosemide'
p54252
(F1
F0.00014334862385321102
I0
I1
I-1
tp54253
sS'concomitantly,with,beta-adrenergic'
p54254
(F1
F0.00014334862385321102
I0
I1
I-1
tp54255
sS'in,two,combined'
p54256
(F1
F0.00014334862385321102
I0
I1
I-1
tp54257
sS'reduction,were,not'
p54258
(F1
F0.00014334862385321102
I0
I1
I-1
tp54259
sS'single,dose,pharmacokinetics'
p54260
(F1
F0.00014334862385321102
I0
I1
I-1
tp54261
sS'the,pathway,that'
p54262
(F1
F0.00014334862385321102
I0
I1
I-1
tp54263
sS'be,monitored,to'
p54264
(F1
F0.00014334862385321102
I1
I0
I1
tp54265
sS'pharmacokinetic,variables,for'
p54266
(F1
F0.00014334862385321102
I0
I1
I-1
tp54267
sS'potential,that,the'
p54268
(F1
F0.00014334862385321102
I0
I1
I-1
tp54269
sS'against,the,concurrent'
p54270
(F1
F0.00014334862385321102
I1
I0
I1
tp54271
sS'metabolite,n-desmethyldiazepam,there'
p54272
(F1
F0.00014334862385321102
I1
I0
I1
tp54273
sS'effect,of,foods'
p54274
(F1
F0.00014334862385321102
I0
I1
I-1
tp54275
sS'of,a,agonist'
p54276
(F1
F0.00014334862385321102
I1
I0
I1
tp54277
sS'of,gabitril,on'
p54278
(F1
F0.00014334862385321102
I0
I1
I-1
tp54279
sS'preliminary,studies,in'
p54280
(F1
F0.00014334862385321102
I1
I0
I1
tp54281
sS'of,but,not'
p54282
(F1
F0.00014334862385321102
I0
I1
I-1
tp54283
sS'anticoagulation,should,receive'
p54284
(F1
F0.00014334862385321102
I0
I1
I-1
tp54285
sS'a,delayed,elimination'
p54286
(F1
F0.00014334862385321102
I0
I1
I-1
tp54287
sS'when,is,used'
p54288
(F1
F0.00057339449541284407
I4
I0
I4
tp54289
sS'concerning,published,in'
p54290
(F1
F0.00014334862385321102
I0
I1
I-1
tp54291
sS'patients,on,thiazide'
p54292
(F1
F0.00028669724770642203
I2
I0
I2
tp54293
sS'recommended,dose,may'
p54294
(F1
F0.00014334862385321102
I1
I0
I1
tp54295
sS'were,seen,on'
p54296
(F1
F0.00014334862385321102
I0
I1
I-1
tp54297
sS'of,subjects,experienced'
p54298
(F1
F0.00028669724770642203
I2
I0
I2
tp54299
sS'is,increased,and'
p54300
(F1
F0.00043004587155963305
I3
I0
I3
tp54301
sS'at,or,recovery'
p54302
(F1
F0.00014334862385321102
I1
I0
I1
tp54303
sS'both,t4,and'
p54304
(F1
F0.00014334862385321102
I1
I0
I1
tp54305
sS'reduction,of,plasma'
p54306
(F1
F0.00028669724770642203
I2
I0
I2
tp54307
sS'voltage-dependent,ca,subtypes'
p54308
(F1
F0.00014334862385321102
I0
I1
I-1
tp54309
sS'secretion,and,reduces'
p54310
(F1
F0.00014334862385321102
I1
I0
I1
tp54311
sS'exercised,nonetheless,since'
p54312
(F1
F0.00014334862385321102
I1
I0
I1
tp54313
sS'oxidase,inhibitors,hypertensive'
p54314
(F1
F0.00014334862385321102
I1
I0
I1
tp54315
sS'receiving,and,no'
p54316
(F1
F0.00014334862385321102
I0
I1
I-1
tp54317
sS'synthase,inhibiting,eg'
p54318
(F1
F0.00014334862385321102
I1
I0
I1
tp54319
sS'when,videx,was'
p54320
(F1
F0.00014334862385321102
I1
I0
I1
tp54321
sS'of,other,cardioactive'
p54322
(F1
F0.00014334862385321102
I0
I1
I-1
tp54323
sS'with,other,known'
p54324
(F1
F0.00014334862385321102
I1
I0
I1
tp54325
sS'suggested,when,is'
p54326
(F1
F0.00014334862385321102
I1
I0
I1
tp54327
sS'for,days,and'
p54328
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp54329
sS'beta,blockers,calcium-channel'
p54330
(F1
F0.00014334862385321102
I0
I1
I-1
tp54331
sS'k,the,net'
p54332
(F1
F0.00014334862385321102
I1
I0
I1
tp54333
sS'mg,respectively,resulted'
p54334
(F1
F0.00014334862385321102
I1
I0
I1
tp54335
sS'to,be,markedly'
p54336
(F1
F0.00014334862385321102
I1
I0
I1
tp54337
sS'the,concurrent,administration'
p54338
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp54339
sS'cholestyramine-concomitant,intake,of'
p54340
(F1
F0.00014334862385321102
I1
I0
I1
tp54341
sS'conduction,eg,or'
p54342
(F1
F0.00014334862385321102
I1
I0
I1
tp54343
sS'special,consideration,should'
p54344
(F1
F0.00014334862385321102
I1
I0
I1
tp54345
sS'antitumour,activity,acute'
p54346
(F1
F0.00014334862385321102
I0
I1
I-1
tp54347
sS'activase,may,cause'
p54348
(F1
F0.00014334862385321102
I0
I1
I-1
tp54349
sS'failed,to,identify'
p54350
(F1
F0.00014334862385321102
I0
I1
I-1
tp54351
sS'potassium-sparing,each,may'
p54352
(F1
F0.00014334862385321102
I0
I1
I-1
tp54353
sS'to,decrease,the'
p54354
(F0.75
F0.0008600917431192661
I7
I1
I6
tp54355
sS'oral,diabetes,medicine'
p54356
(F1
F0.00014334862385321102
I1
I0
I1
tp54357
sS'also,should,be'
p54358
(F1
F0.00014334862385321102
I1
I0
I1
tp54359
sS'most,common,adverse'
p54360
(F1
F0.00014334862385321102
I0
I1
I-1
tp54361
sS'clearance,rate,compared'
p54362
(F1
F0.00014334862385321102
I1
I0
I1
tp54363
sS'is,higher,in'
p54364
(F1
F0.00014334862385321102
I1
I0
I1
tp54365
sS'narcotic,may,potentiate'
p54366
(F1
F0.00014334862385321102
I1
I0
I1
tp54367
sS'a,marked,and'
p54368
(F1
F0.00014334862385321102
I1
I0
I1
tp54369
sS'risk,of,prolonged'
p54370
(F1
F0.00014334862385321102
I1
I0
I1
tp54371
sS'of,potential,for'
p54372
(F1
F0.00014334862385321102
I0
I1
I-1
tp54373
sS'statistically,significant,effect'
p54374
(F1
F0.00028669724770642203
I0
I2
I-2
tp54375
sS'administration,of,tracleer'
p54376
(F1
F0.00014334862385321102
I1
I0
I1
tp54377
sS'on,plasma,levels'
p54378
(F1
F0.00028669724770642203
I0
I2
I-2
tp54379
sS'cases,reported,in'
p54380
(F1
F0.00014334862385321102
I1
I0
I1
tp54381
sS'of,and,thiazide'
p54382
(F1
F0.00014334862385321102
I1
I0
I1
tp54383
sS'body,it,is'
p54384
(F1
F0.00014334862385321102
I0
I1
I-1
tp54385
sS'of,a,that'
p54386
(F1
F0.00043004587155963305
I0
I3
I-3
tp54387
sS'study,objective,to'
p54388
(F1
F0.00014334862385321102
I0
I1
I-1
tp54389
sS'all,nsaids,including'
p54390
(F1
F0.00014334862385321102
I1
I0
I1
tp54391
sS'used,when,abilify'
p54392
(F1
F0.00014334862385321102
I1
I0
I1
tp54393
sS'doxazosin,mesylate,has'
p54394
(F1
F0.00014334862385321102
I0
I1
I-1
tp54395
sS'phosphorylation,inhibition,of'
p54396
(F1
F0.00014334862385321102
I1
I0
I1
tp54397
sS'seen,as,early'
p54398
(F1
F0.00014334862385321102
I1
I0
I1
tp54399
sS'total,body,clearance'
p54400
(F1
F0.00043004587155963305
I3
I0
I3
tp54401
sS'to,reduce,plasma'
p54402
(F1
F0.00028669724770642203
I2
I0
I2
tp54403
sS'type,ii,diabetic'
p54404
(F1
F0.00014334862385321102
I1
I0
I1
tp54405
sS'cns-impairing,effects,of'
p54406
(F1
F0.00014334862385321102
I1
I0
I1
tp54407
sS'an,active,dose'
p54408
(F1
F0.00014334862385321102
I0
I1
I-1
tp54409
sS'treated,concomitantly,with'
p54410
(F1
F0.00014334862385321102
I1
I0
I1
tp54411
sS'kg,doses,increased'
p54412
(F1
F0.00014334862385321102
I1
I0
I1
tp54413
sS'practice,dictates,careful'
p54414
(F1
F0.00014334862385321102
I1
I0
I1
tp54415
sS'of,treatment,with'
p54416
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp54417
sS'in,the,range'
p54418
(F1
F0.00028669724770642203
I0
I2
I-2
tp54419
sS'complex,concentrates,or'
p54420
(F1
F0.00014334862385321102
I0
I1
I-1
tp54421
sS'at,mg,twice'
p54422
(F1
F0.00028669724770642203
I2
I0
I2
tp54423
sS'acarbose,in,combination'
p54424
(F1
F0.00014334862385321102
I0
I1
I-1
tp54425
sS'primary,and,secondary'
p54426
(F0
F0
I1
I1
I0
tp54427
sS'of,fluorescence,labelled'
p54428
(F1
F0.00014334862385321102
I0
I1
I-1
tp54429
sS'other,cardioactive,compounds'
p54430
(F1
F0.00014334862385321102
I1
I0
I1
tp54431
sS'optimal,dose,of'
p54432
(F1
F0.00028669724770642203
I0
I2
I-2
tp54433
sS'drug,interactions,general'
p54434
(F1
F0.00014334862385321102
I0
I1
I-1
tp54435
sS'interleukin-1,antagonist,has'
p54436
(F1
F0.00014334862385321102
I1
I0
I1
tp54437
sS'may,decrease,anti-inflammatory'
p54438
(F1
F0.00014334862385321102
I1
I0
I1
tp54439
sS'dose-related,decrease,in'
p54440
(F1
F0.00014334862385321102
I1
I0
I1
tp54441
sS'no,pharmacokinetic,drug-drug'
p54442
(F1
F0.00014334862385321102
I0
I1
I-1
tp54443
sS'although,not,a'
p54444
(F1
F0.00014334862385321102
I1
I0
I1
tp54445
sS'of,with,an'
p54446
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp54447
sS'metabolite,i,suggesting'
p54448
(F1
F0.00014334862385321102
I0
I1
I-1
tp54449
sS'antihistamines,may,have'
p54450
(F1
F0.00014334862385321102
I1
I0
I1
tp54451
sS'with,a,that'
p54452
(F1
F0.00014334862385321102
I0
I1
I-1
tp54453
sS'control,blood,glucose'
p54454
(F1
F0.00014334862385321102
I0
I1
I-1
tp54455
sS'prednisone,rofecoxib,did'
p54456
(F1
F0.00014334862385321102
I0
I1
I-1
tp54457
sS'agents,there,have'
p54458
(F1
F0.00014334862385321102
I1
I0
I1
tp54459
sS'in,any,condition'
p54460
(F1
F0.00014334862385321102
I1
I0
I1
tp54461
sS'and,cyp3a4,patients'
p54462
(F1
F0.00014334862385321102
I0
I1
I-1
tp54463
sS'elevated,levels,and'
p54464
(F1
F0.00014334862385321102
I1
I0
I1
tp54465
sS'administration,of,hexalen'
p54466
(F1
F0.00014334862385321102
I1
I0
I1
tp54467
sS'other,drugs,based'
p54468
(F1
F0.00014334862385321102
I0
I1
I-1
tp54469
sS'if,supplements,are'
p54470
(F1
F0.00014334862385321102
I1
I0
I1
tp54471
sS'including,certain,and'
p54472
(F1
F0.00014334862385321102
I1
I0
I1
tp54473
sS'upon,chylomicron,metabolism'
p54474
(F1
F0.00014334862385321102
I0
I1
I-1
tp54475
sS'agents,and,other'
p54476
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp54477
sS'have,elevated,plasma'
p54478
(F1
F0.00014334862385321102
I1
I0
I1
tp54479
sS'acid,may,decrease'
p54480
(F1
F0.00014334862385321102
I1
I0
I1
tp54481
sS'in,the,myasthenic'
p54482
(F1
F0.00014334862385321102
I1
I0
I1
tp54483
sS'with,absorption,of'
p54484
(F1
F0.00014334862385321102
I0
I1
I-1
tp54485
sS'half,the,standard'
p54486
(F1
F0.00014334862385321102
I1
I0
I1
tp54487
sS'increased,by,up'
p54488
(F1
F0.00014334862385321102
I1
I0
I1
tp54489
sS'followed,by,either'
p54490
(F1
F0.00014334862385321102
I0
I1
I-1
tp54491
sS'traumatic,edemas,that'
p54492
(F1
F0.00014334862385321102
I1
I0
I1
tp54493
sS'concomitant,protease,inhibitor'
p54494
(F1
F0.00014334862385321102
I1
I0
I1
tp54495
sS'be,employed,when'
p54496
(F1
F0.00014334862385321102
I0
I1
I-1
tp54497
sS'was,observed,to'
p54498
(F1
F0.00028669724770642203
I2
I0
I2
tp54499
sS'the,activation,of'
p54500
(F0
F0
I1
I1
I0
tp54501
sS'the,agents,employed'
p54502
(F1
F0.00014334862385321102
I1
I0
I1
tp54503
sS'number,induced,by'
p54504
(F1
F0.00014334862385321102
I1
I0
I1
tp54505
sS'binding,globulin,cbg'
p54506
(F1
F0.00028669724770642203
I0
I2
I-2
tp54507
sS'if,a,is'
p54508
(F1
F0.00028669724770642203
I2
I0
I2
tp54509
sS'insulin,a,clinical'
p54510
(F1
F0.00014334862385321102
I0
I1
I-1
tp54511
sS'agents,co-administration,of'
p54512
(F1
F0.00014334862385321102
I0
I1
I-1
tp54513
sS'heart,failure,are'
p54514
(F1
F0.00014334862385321102
I0
I1
I-1
tp54515
sS'appropriate,in,patients'
p54516
(F1
F0.00014334862385321102
I0
I1
I-1
tp54517
sS'hormone,may,accelerate'
p54518
(F1
F0.00014334862385321102
I0
I1
I-1
tp54519
sS'interact,with,antagonists'
p54520
(F1
F0.00014334862385321102
I1
I0
I1
tp54521
sS'of,during,treatment'
p54522
(F1
F0.00014334862385321102
I1
I0
I1
tp54523
sS'is,assumed,that'
p54524
(F1
F0.00014334862385321102
I0
I1
I-1
tp54525
sS'digoxin,plasma,levels'
p54526
(F1
F0.00014334862385321102
I0
I1
I-1
tp54527
sS'clinical,trials,of'
p54528
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp54529
sS'or,may,substantially'
p54530
(F1
F0.00014334862385321102
I1
I0
I1
tp54531
sS'other,known,to'
p54532
(F1
F0.00028669724770642203
I2
I0
I2
tp54533
sS'chinese,hamsters,in'
p54534
(F1
F0.00014334862385321102
I0
I1
I-1
tp54535
sS'medications,were,identified'
p54536
(F1
F0.00014334862385321102
I1
I0
I1
tp54537
sS'an,important,determinant'
p54538
(F1
F0.00028669724770642203
I2
I0
I2
tp54539
sS'itraconazole,therapy,and'
p54540
(F1
F0.00014334862385321102
I1
I0
I1
tp54541
sS'of,a,similar'
p54542
(F0
F0
I1
I1
I0
tp54543
sS'and,mhd,induce'
p54544
(F1
F0.00014334862385321102
I0
I1
I-1
tp54545
sS'the,possible,potentiation'
p54546
(F1
F0.00014334862385321102
I0
I1
I-1
tp54547
sS'but,it,is'
p54548
(F0
F0
I1
I1
I0
tp54549
sS'heparin,the,in'
p54550
(F1
F0.00014334862385321102
I1
I0
I1
tp54551
sS'vs,serious,pneumonia'
p54552
(F1
F0.00014334862385321102
I1
I0
I1
tp54553
sS'work,involved,the'
p54554
(F1
F0.00014334862385321102
I0
I1
I-1
tp54555
sS'influence,in,vitro'
p54556
(F1
F0.00014334862385321102
I0
I1
I-1
tp54557
sS'and,norethindrone,coadministration'
p54558
(F1
F0.00014334862385321102
I1
I0
I1
tp54559
sS'subjects,aged,years'
p54560
(F1
F0.00014334862385321102
I1
I0
I1
tp54561
sS'studies,beta-receptor,blockers'
p54562
(F1
F0.00014334862385321102
I0
I1
I-1
tp54563
sS'a,second,generation'
p54564
(F1
F0.00014334862385321102
I0
I1
I-1
tp54565
sS'days,increased,the'
p54566
(F1
F0.00014334862385321102
I1
I0
I1
tp54567
sS'when,was,applied'
p54568
(F1
F0.00014334862385321102
I1
I0
I1
tp54569
sS'or,may,partially'
p54570
(F1
F0.00014334862385321102
I1
I0
I1
tp54571
sS'other,significant,inhibitors'
p54572
(F1
F0.00014334862385321102
I0
I1
I-1
tp54573
sS'user,such,as'
p54574
(F1
F0.00014334862385321102
I0
I1
I-1
tp54575
sS'both,together,have'
p54576
(F1
F0.00028669724770642203
I2
I0
I2
tp54577
sS'with,its,congeners'
p54578
(F1
F0.00014334862385321102
I0
I1
I-1
tp54579
sS'resins,an,interval'
p54580
(F1
F0.00014334862385321102
I1
I0
I1
tp54581
sS'coadministration,of,crixivan'
p54582
(F0
F0
I1
I1
I0
tp54583
sS'in,comparison,with'
p54584
(F0
F0
I1
I1
I0
tp54585
sS'the,dose,at'
p54586
(F1
F0.00014334862385321102
I0
I1
I-1
tp54587
sS'oral,or,other'
p54588
(F1
F0.00014334862385321102
I0
I1
I-1
tp54589
sS'to,ph,may'
p54590
(F1
F0.00014334862385321102
I0
I1
I-1
tp54591
sS'because,is,a'
p54592
(F1
F0.00014334862385321102
I1
I0
I1
tp54593
sS'adefovir,dipivoxil,or'
p54594
(F1
F0.00014334862385321102
I0
I1
I-1
tp54595
sS'increased,potential,of'
p54596
(F1
F0.00014334862385321102
I1
I0
I1
tp54597
sS'a,short-acting,inhaled'
p54598
(F1
F0.00014334862385321102
I0
I1
I-1
tp54599
sS'with,reports,of'
p54600
(F1
F0.00014334862385321102
I0
I1
I-1
tp54601
sS'confusion,extrapyramidal,symptoms'
p54602
(F1
F0.00014334862385321102
I1
I0
I1
tp54603
sS'after,starting,st'
p54604
(F1
F0.00014334862385321102
I0
I1
I-1
tp54605
sS'route,than,and'
p54606
(F1
F0.00014334862385321102
I0
I1
I-1
tp54607
sS'including,oral,inhaled'
p54608
(F1
F0.00014334862385321102
I0
I1
I-1
tp54609
sS'h,antagonists,when'
p54610
(F1
F0.00014334862385321102
I1
I0
I1
tp54611
sS'considering,the,use'
p54612
(F1
F0.00014334862385321102
I1
I0
I1
tp54613
sS'that,requirements,for'
p54614
(F1
F0.00014334862385321102
I1
I0
I1
tp54615
sS'the,is,administered'
p54616
(F1
F0.00014334862385321102
I0
I1
I-1
tp54617
sS'ethanol,nutrition,herb'
p54618
(F1
F0.00014334862385321102
I1
I0
I1
tp54619
sS'for,hour,after'
p54620
(F1
F0.00014334862385321102
I1
I0
I1
tp54621
sS'diuretic,agents,may'
p54622
(F1
F0.00014334862385321102
I1
I0
I1
tp54623
sS'day5,of,a'
p54624
(F1
F0.00014334862385321102
I1
I0
I1
tp54625
sS'spinal,naloxone-sensitive,endorphinergic'
p54626
(F1
F0.00014334862385321102
I0
I1
I-1
tp54627
sS'containing,vitamin,a'
p54628
(F1
F0.00014334862385321102
I1
I0
I1
tp54629
sS'systems,inhibition,of'
p54630
(F1
F0.00014334862385321102
I0
I1
I-1
tp54631
sS'the,requirement,of'
p54632
(F1
F0.00014334862385321102
I1
I0
I1
tp54633
sS'and,glucose,enzymatic'
p54634
(F1
F0.00014334862385321102
I0
I1
I-1
tp54635
sS'eg,or,beta-adrenergic'
p54636
(F1
F0.00014334862385321102
I1
I0
I1
tp54637
sS'tca,is,going'
p54638
(F1
F0.00057339449541284407
I0
I4
I-4
tp54639
sS'be,a,result'
p54640
(F1
F0.00014334862385321102
I0
I1
I-1
tp54641
sS'non-infection,unwanted,effects'
p54642
(F1
F0.00014334862385321102
I0
I1
I-1
tp54643
sS'both,alone,at'
p54644
(F1
F0.00014334862385321102
I0
I1
I-1
tp54645
sS'normal,volunteers,receiving'
p54646
(F1
F0.00028669724770642203
I2
I0
I2
tp54647
sS'as,narcotics,non-narcotic'
p54648
(F1
F0.00014334862385321102
I1
I0
I1
tp54649
sS'level,however,is'
p54650
(F1
F0.00014334862385321102
I1
I0
I1
tp54651
sS'day,to,patients'
p54652
(F1
F0.00014334862385321102
I0
I1
I-1
tp54653
sS'sustiva,and,these'
p54654
(F1
F0.00014334862385321102
I0
I1
I-1
tp54655
sS'as,three,weeks'
p54656
(F1
F0.00014334862385321102
I1
I0
I1
tp54657
sS'these,aeds,during'
p54658
(F1
F0.00014334862385321102
I0
I1
I-1
tp54659
sS'their,combined,effects'
p54660
(F1
F0.00014334862385321102
I1
I0
I1
tp54661
sS'of,elemental,as'
p54662
(F1
F0.00014334862385321102
I1
I0
I1
tp54663
sS'tablets,and,is'
p54664
(F1
F0.00014334862385321102
I1
I0
I1
tp54665
sS'adrenergic,agents,some'
p54666
(F1
F0.00014334862385321102
I1
I0
I1
tp54667
sS'patients,receiving,monoamine'
p54668
(F1
F0.00057339449541284407
I4
I0
I4
tp54669
sS'consider,starting,other'
p54670
(F1
F0.00014334862385321102
I0
I1
I-1
tp54671
sS'between,january,and'
p54672
(F1
F0.00014334862385321102
I0
I1
I-1
tp54673
sS'and,diarrhea,would'
p54674
(F1
F0.00014334862385321102
I1
I0
I1
tp54675
sS'the,pharmacokinetic,or'
p54676
(F1
F0.00014334862385321102
I0
I1
I-1
tp54677
sS'have,been,prescribed'
p54678
(F1
F0.00014334862385321102
I0
I1
I-1
tp54679
sS'by,and,creatinine'
p54680
(F1
F0.00014334862385321102
I1
I0
I1
tp54681
sS'presence,of,high'
p54682
(F1
F0.00014334862385321102
I1
I0
I1
tp54683
sS'kg,or,mg'
p54684
(F1
F0.00014334862385321102
I0
I1
I-1
tp54685
sS'was,added,were'
p54686
(F1
F0.00014334862385321102
I1
I0
I1
tp54687
sS'inr,were,observed'
p54688
(F1
F0.00014334862385321102
I0
I1
I-1
tp54689
sS'serum,levels,should'
p54690
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp54691
sS'additionally,and,did'
p54692
(F1
F0.00014334862385321102
I0
I1
I-1
tp54693
sS'crossover,study,examining'
p54694
(F1
F0.00014334862385321102
I1
I0
I1
tp54695
sS'failure,were,not'
p54696
(F1
F0.00014334862385321102
I0
I1
I-1
tp54697
sS'doses,of,vardenafil'
p54698
(F1
F0.00014334862385321102
I0
I1
I-1
tp54699
sS'of,oral,users'
p54700
(F1
F0.00014334862385321102
I0
I1
I-1
tp54701
sS'associated,with,ventricular'
p54702
(F1
F0.00014334862385321102
I1
I0
I1
tp54703
sS'single,oral,doses'
p54704
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp54705
sS'and,are,used'
p54706
(F1
F0.00043004587155963305
I3
I0
I3
tp54707
sS'by,in,bovine'
p54708
(F1
F0.00014334862385321102
I0
I1
I-1
tp54709
sS'first,and,then'
p54710
(F1
F0.00014334862385321102
I1
I0
I1
tp54711
sS'may,counteract,the'
p54712
(F1
F0.00071674311926605509
I5
I0
I5
tp54713
sS'an,excessive,reduction'
p54714
(F1
F0.00057339449541284407
I4
I0
I4
tp54715
sS'ca,channel,subtypes'
p54716
(F1
F0.00014334862385321102
I0
I1
I-1
tp54717
sS'solution,was,given'
p54718
(F1
F0.00014334862385321102
I0
I1
I-1
tp54719
sS'flurbiprofen,did,not'
p54720
(F1
F0.00014334862385321102
I1
I0
I1
tp54721
sS'has,no,clinically'
p54722
(F1
F0.00014334862385321102
I0
I1
I-1
tp54723
sS'renal,impairment,particularly'
p54724
(F1
F0.00014334862385321102
I0
I1
I-1
tp54725
sS'ibogaine,but,not'
p54726
(F1
F0.00014334862385321102
I0
I1
I-1
tp54727
sS'selegiline,combination,hormonal'
p54728
(F1
F0.00014334862385321102
I1
I0
I1
tp54729
sS'to,determine,whether'
p54730
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp54731
sS'of,each,would'
p54732
(F1
F0.00014334862385321102
I0
I1
I-1
tp54733
sS'q,d,for'
p54734
(F1
F0.00014334862385321102
I1
I0
I1
tp54735
sS'in,lowered,plasma'
p54736
(F1
F0.00014334862385321102
I0
I1
I-1
tp54737
sS'to,develop,a'
p54738
(F1
F0.00014334862385321102
I1
I0
I1
tp54739
sS'respect,of,competitive'
p54740
(F1
F0.00014334862385321102
I0
I1
I-1
tp54741
sS'depressants,including,but'
p54742
(F1
F0.00014334862385321102
I1
I0
I1
tp54743
sS'than,in,control'
p54744
(F1
F0.00014334862385321102
I0
I1
I-1
tp54745
sS'increase,the,action'
p54746
(F1
F0.00014334862385321102
I1
I0
I1
tp54747
sS'pharmacokinetics,of,that'
p54748
(F1
F0.00014334862385321102
I1
I0
I1
tp54749
sS'plasma,m1,the'
p54750
(F1
F0.00014334862385321102
I1
I0
I1
tp54751
sS'cns,depressants,should'
p54752
(F1
F0.00014334862385321102
I1
I0
I1
tp54753
sS'bicarbonate,etc,increase'
p54754
(F1
F0.00014334862385321102
I1
I0
I1
tp54755
sS'agents,may,increase'
p54756
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp54757
sS'prolonged,sodation,of'
p54758
(F1
F0.00014334862385321102
I1
I0
I1
tp54759
sS'action,of,adrenergic'
p54760
(F1
F0.00014334862385321102
I1
I0
I1
tp54761
sS'oh,d3,the'
p54762
(F1
F0.00014334862385321102
I0
I1
I-1
tp54763
sS'methadone,levels,may'
p54764
(F1
F0.00014334862385321102
I1
I0
I1
tp54765
sS'beneficial,effects,on'
p54766
(F1
F0.00014334862385321102
I1
I0
I1
tp54767
sS'weekly,dosage,schedule'
p54768
(F1
F0.00014334862385321102
I1
I0
I1
tp54769
sS'women,who,have'
p54770
(F1
F0.00014334862385321102
I0
I1
I-1
tp54771
sS'beneficial,effects,of'
p54772
(F1
F0.00014334862385321102
I1
I0
I1
tp54773
sS'needed,following,coadministration'
p54774
(F1
F0.00014334862385321102
I1
I0
I1
tp54775
sS'up,to,when'
p54776
(F1
F0.00014334862385321102
I1
I0
I1
tp54777
sS'pain,without,evidence'
p54778
(F1
F0.00014334862385321102
I0
I1
I-1
tp54779
sS'to,fade,recovery'
p54780
(F1
F0.00014334862385321102
I1
I0
I1
tp54781
sS'an,average,increase'
p54782
(F1
F0.00014334862385321102
I1
I0
I1
tp54783
sS'of,racemic,titrated'
p54784
(F1
F0.00014334862385321102
I0
I1
I-1
tp54785
sS'substitutes,containing,may'
p54786
(F1
F0.00014334862385321102
I0
I1
I-1
tp54787
sS'with,gastrointestinal,irritation'
p54788
(F1
F0.00014334862385321102
I1
I0
I1
tp54789
sS'such,as,the'
p54790
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp54791
sS'sensitize,the,myocardium'
p54792
(F1
F0.00057339449541284407
I4
I0
I4
tp54793
sS'other,agent,should'
p54794
(F1
F0.00014334862385321102
I0
I1
I-1
tp54795
sS'studies,with,male'
p54796
(F1
F0.00014334862385321102
I1
I0
I1
tp54797
sS'for,when,screening'
p54798
(F1
F0.00014334862385321102
I0
I1
I-1
tp54799
sS'report,describes,a'
p54800
(F1
F0.00014334862385321102
I1
I0
I1
tp54801
sS'plasma,concentrations,include'
p54802
(F1
F0.00043004587155963305
I3
I0
I3
tp54803
sS'iodine-containing,preparations,and'
p54804
(F1
F0.00014334862385321102
I0
I1
I-1
tp54805
sS'interactions,to,date'
p54806
(F1
F0.00014334862385321102
I0
I1
I-1
tp54807
sS'relationship,between,folic'
p54808
(F1
F0.00014334862385321102
I0
I1
I-1
tp54809
sS'of,both,ethynyl'
p54810
(F1
F0.00014334862385321102
I0
I1
I-1
tp54811
sS'possibility,of,toxicity'
p54812
(F1
F0.00014334862385321102
I1
I0
I1
tp54813
sS'conversely,decreases,in'
p54814
(F1
F0.00014334862385321102
I1
I0
I1
tp54815
sS'preanesthetic,or,used'
p54816
(F1
F0.00014334862385321102
I0
I1
I-1
tp54817
sS'use,of,fludara'
p54818
(F1
F0.00014334862385321102
I1
I0
I1
tp54819
sS'potentiated,the,risk'
p54820
(F1
F0.00014334862385321102
I1
I0
I1
tp54821
sS'steroids,chloral,hydrate'
p54822
(F1
F0.00028669724770642203
I2
I0
I2
tp54823
sS'of,channels,in'
p54824
(F1
F0.00014334862385321102
I0
I1
I-1
tp54825
sS'to,unique,biopharmaceutical'
p54826
(F1
F0.00014334862385321102
I0
I1
I-1
tp54827
sS'with,diabetes,mellitus'
p54828
(F1
F0.00014334862385321102
I0
I1
I-1
tp54829
sS'of,strattera,may'
p54830
(F1
F0.00014334862385321102
I1
I0
I1
tp54831
sS'physostigmine,pretreatment,augmented'
p54832
(F1
F0.00014334862385321102
I1
I0
I1
tp54833
sS'withdrawn,from,the'
p54834
(F1
F0.00014334862385321102
I1
I0
I1
tp54835
sS'tysabri,associated,adverse'
p54836
(F1
F0.00014334862385321102
I0
I1
I-1
tp54837
sS'mouse,tumour,and'
p54838
(F1
F0.00014334862385321102
I1
I0
I1
tp54839
sS'disturbances,have,been'
p54840
(F1
F0.00014334862385321102
I1
I0
I1
tp54841
sS'included,as,proof'
p54842
(F1
F0.00014334862385321102
I0
I1
I-1
tp54843
sS'as,nimbex,include'
p54844
(F1
F0.00014334862385321102
I1
I0
I1
tp54845
sS'with,mg,and'
p54846
(F0
F0
I1
I1
I0
tp54847
sS'of,two,or'
p54848
(F1
F0.00014334862385321102
I1
I0
I1
tp54849
sS'containing,or,videx'
p54850
(F1
F0.00014334862385321102
I1
I0
I1
tp54851
sS'mg,for,weeks'
p54852
(F1
F0.00014334862385321102
I1
I0
I1
tp54853
sS'implantable,insertable,hormonal'
p54854
(F1
F0.00014334862385321102
I0
I1
I-1
tp54855
sS'bioavailability,was,reduced'
p54856
(F1
F0.00014334862385321102
I1
I0
I1
tp54857
sS'an,approximate,increase'
p54858
(F1
F0.00057339449541284407
I4
I0
I4
tp54859
sS'of,are,decreased'
p54860
(F1
F0.00028669724770642203
I2
I0
I2
tp54861
sS'with,renal,tubular'
p54862
(F1
F0.00014334862385321102
I1
I0
I1
tp54863
sS'compared,to,these'
p54864
(F1
F0.00028669724770642203
I2
I0
I2
tp54865
sS'microsomes,indicate,that'
p54866
(F1
F0.00014334862385321102
I0
I1
I-1
tp54867
sS'possible,potentiation,of'
p54868
(F1
F0.00014334862385321102
I0
I1
I-1
tp54869
sS'agents,experience,in'
p54870
(F1
F0.00014334862385321102
I1
I0
I1
tp54871
sS'more,frequently,in'
p54872
(F1
F0.00014334862385321102
I0
I1
I-1
tp54873
sS'of,the,weekly'
p54874
(F1
F0.00014334862385321102
I1
I0
I1
tp54875
sS'be,additive,use'
p54876
(F1
F0.00028669724770642203
I2
I0
I2
tp54877
sS'available,for,the'
p54878
(F1
F0.00014334862385321102
I0
I1
I-1
tp54879
sS'day,resulted,in'
p54880
(F1
F0.00014334862385321102
I1
I0
I1
tp54881
sS'safety,of,using'
p54882
(F1
F0.00014334862385321102
I0
I1
I-1
tp54883
sS'misused,by,self-injection'
p54884
(F1
F0.00014334862385321102
I0
I1
I-1
tp54885
sS'v,and,that'
p54886
(F1
F0.00014334862385321102
I0
I1
I-1
tp54887
sS'red,rr,on'
p54888
(F1
F0.00014334862385321102
I0
I1
I-1
tp54889
sS'derivatives,or,may'
p54890
(F1
F0.00014334862385321102
I1
I0
I1
tp54891
sS'including,an,omega-conotoxin'
p54892
(F1
F0.00014334862385321102
I0
I1
I-1
tp54893
sS'should,be,taken'
p54894
(F0.5
F0.0008600917431192661
I9
I3
I6
tp54895
sS'hearing,have,been'
p54896
(F1
F0.00014334862385321102
I1
I0
I1
tp54897
sS'following,use,of'
p54898
(F1
F0.00014334862385321102
I1
I0
I1
tp54899
sS'use,of,does'
p54900
(F1
F0.00014334862385321102
I0
I1
I-1
tp54901
sS'including,produce,additive'
p54902
(F1
F0.00014334862385321102
I1
I0
I1
tp54903
sS'reduce,the,absorption'
p54904
(F1
F0.00057339449541284407
I4
I0
I4
tp54905
sS'production,of,but'
p54906
(F1
F0.00014334862385321102
I0
I1
I-1
tp54907
sS'of,interaction,of'
p54908
(F1
F0.00014334862385321102
I0
I1
I-1
tp54909
sS'alone,and,min'
p54910
(F1
F0.00028669724770642203
I2
I0
I2
tp54911
sS'n6-cyclopentyladenosine,cpa,an'
p54912
(F1
F0.00014334862385321102
I1
I0
I1
tp54913
sS'i,corticosteroid,binding'
p54914
(F1
F0.00014334862385321102
I0
I1
I-1
tp54915
sS'mu,systems,for'
p54916
(F1
F0.00014334862385321102
I0
I1
I-1
tp54917
sS'pretreatment,with,the'
p54918
(F1
F0.00014334862385321102
I1
I0
I1
tp54919
sS'monitoring,for,bleeding'
p54920
(F1
F0.00014334862385321102
I0
I1
I-1
tp54921
sS'were,randomly,assigned'
p54922
(F1
F0.00028669724770642203
I0
I2
I-2
tp54923
sS'one,dose,of'
p54924
(F1
F0.00014334862385321102
I1
I0
I1
tp54925
sS'these,or,other'
p54926
(F1
F0.00014334862385321102
I1
I0
I1
tp54927
sS'in,inhibiting,yeast'
p54928
(F1
F0.00014334862385321102
I0
I1
I-1
tp54929
sS'with,copegus,pegasys'
p54930
(F1
F0.00014334862385321102
I0
I1
I-1
tp54931
sS'with,that,associated'
p54932
(F1
F0.00014334862385321102
I0
I1
I-1
tp54933
sS'and,markedly,inhibit'
p54934
(F1
F0.00028669724770642203
I2
I0
I2
tp54935
sS'regimen,consisting,of'
p54936
(F1
F0.00014334862385321102
I1
I0
I1
tp54937
sS'if,an,hmg-coa'
p54938
(F1
F0.00014334862385321102
I1
I0
I1
tp54939
sS'with,g,kg'
p54940
(F1
F0.00014334862385321102
I0
I1
I-1
tp54941
sS'other,nsaids,is'
p54942
(F1
F0.00028669724770642203
I2
I0
I2
tp54943
sS'should,be,drawn'
p54944
(F1
F0.00014334862385321102
I0
I1
I-1
tp54945
sS'with,and,indicated'
p54946
(F1
F0.00014334862385321102
I0
I1
I-1
tp54947
sS'a,macrolide,immunosuppressant'
p54948
(F1
F0.00014334862385321102
I0
I1
I-1
tp54949
sS'an,inadequate,method'
p54950
(F1
F0.00014334862385321102
I1
I0
I1
tp54951
sS'including,both,sensory'
p54952
(F1
F0.00014334862385321102
I1
I0
I1
tp54953
sS'other,agents,prinivil'
p54954
(F1
F0.00014334862385321102
I0
I1
I-1
tp54955
sS'including,and,either'
p54956
(F1
F0.00014334862385321102
I0
I1
I-1
tp54957
sS'in,most,instances'
p54958
(F1
F0.00014334862385321102
I1
I0
I1
tp54959
sS'that,no,significant'
p54960
(F1
F0.00014334862385321102
I1
I0
I1
tp54961
sS'clinically,meaningful,increases'
p54962
(F1
F0.00014334862385321102
I0
I1
I-1
tp54963
sS'and,intravenous,has'
p54964
(F1
F0.00014334862385321102
I1
I0
I1
tp54965
sS'concomitant,therapy,although'
p54966
(F1
F0.00028669724770642203
I0
I2
I-2
tp54967
sS'prothrombin,time,should'
p54968
(F1
F0.00043004587155963305
I3
I0
I3
tp54969
sS'weeks,has,been'
p54970
(F1
F0.00014334862385321102
I1
I0
I1
tp54971
sS'of,which,involved'
p54972
(F1
F0.00014334862385321102
I1
I0
I1
tp54973
sS'auc,of,although'
p54974
(F1
F0.00014334862385321102
I1
I0
I1
tp54975
sS'irritation,caution,should'
p54976
(F1
F0.00014334862385321102
I1
I0
I1
tp54977
sS'efficacy,of,in'
p54978
(F1
F0.00043004587155963305
I0
I3
I-3
tp54979
sS'by,co-administration,of'
p54980
(F1
F0.00014334862385321102
I0
I1
I-1
tp54981
sS'upper,gastrointestinal,bleeding'
p54982
(F1
F0.00014334862385321102
I1
I0
I1
tp54983
sS'therapy,had,no'
p54984
(F1
F0.00014334862385321102
I0
I1
I-1
tp54985
sS'haart,on,the'
p54986
(F1
F0.00014334862385321102
I0
I1
I-1
tp54987
sS'anagrelide,demonstrates,some'
p54988
(F1
F0.00014334862385321102
I1
I0
I1
tp54989
sS'suspension,contains,a'
p54990
(F1
F0.00014334862385321102
I0
I1
I-1
tp54991
sS'observations,i,these'
p54992
(F1
F0.00014334862385321102
I0
I1
I-1
tp54993
sS'upper,gastrointestinal,adverse'
p54994
(F1
F0.00028669724770642203
I0
I2
I-2
tp54995
sS'any,signs,or'
p54996
(F1
F0.00014334862385321102
I1
I0
I1
tp54997
sS'of,with,vitamin'
p54998
(F0
F0
I3
I3
I0
tp54999
sS'interaction,of,gabitril'
p55000
(F1
F0.00028669724770642203
I0
I2
I-2
tp55001
sS'study,n,ingestion'
p55002
(F1
F0.00014334862385321102
I1
I0
I1
tp55003
sS'observed,when,therapy'
p55004
(F1
F0.00014334862385321102
I1
I0
I1
tp55005
sS'deoxy,to,is'
p55006
(F1
F0.00014334862385321102
I0
I1
I-1
tp55007
sS'increase,plasma,concentration'
p55008
(F1
F0.00028669724770642203
I2
I0
I2
tp55009
sS'accordingly,when,is'
p55010
(F1
F0.00014334862385321102
I1
I0
I1
tp55011
sS'is,not,ordinarily'
p55012
(F1
F0.00014334862385321102
I1
I0
I1
tp55013
sS'decrease,vascular,response'
p55014
(F1
F0.00014334862385321102
I1
I0
I1
tp55015
sS'migraine,has,not'
p55016
(F1
F0.00014334862385321102
I0
I1
I-1
tp55017
sS'may,vary,in'
p55018
(F1
F0.00071674311926605509
I0
I5
I-5
tp55019
sS'thus,inhibiting,the'
p55020
(F1
F0.00057339449541284407
I4
I0
I4
tp55021
sS'orudis,doses,greater'
p55022
(F1
F0.00014334862385321102
I0
I1
I-1
tp55023
sS'properties,and,is'
p55024
(F1
F0.00014334862385321102
I1
I0
I1
tp55025
sS'hypotensive,effect,of'
p55026
(F1
F0.0008600917431192661
I6
I0
I6
tp55027
sS'therefore,if,replacement'
p55028
(F1
F0.00014334862385321102
I0
I1
I-1
tp55029
sS'anafranil,to,patients'
p55030
(F1
F0.00014334862385321102
I1
I0
I1
tp55031
sS'when,vioxx,is'
p55032
(F1
F0.00014334862385321102
I0
I1
I-1
tp55033
sS'orencia,mtx,nsaids'
p55034
(F1
F0.00014334862385321102
I0
I1
I-1
tp55035
sS'also,interact,with'
p55036
(F1
F0.00014334862385321102
I0
I1
I-1
tp55037
sS'although,clinical,evidence'
p55038
(F1
F0.00014334862385321102
I0
I1
I-1
tp55039
sS'reaction,may,be'
p55040
(F1
F0.00014334862385321102
I0
I1
I-1
tp55041
sS'reactions,compared,to'
p55042
(F1
F0.00014334862385321102
I0
I1
I-1
tp55043
sS'antihypertensives,amiodarone,should'
p55044
(F1
F0.00014334862385321102
I0
I1
I-1
tp55045
sS'qd,or,hctz'
p55046
(F1
F0.00014334862385321102
I0
I1
I-1
tp55047
sS'binding,thiazide,and'
p55048
(F1
F0.00014334862385321102
I1
I0
I1
tp55049
sS'blocking,effect,and'
p55050
(F1
F0.00014334862385321102
I1
I0
I1
tp55051
sS'cause,hypercalcemia,too'
p55052
(F1
F0.00014334862385321102
I1
I0
I1
tp55053
sS'enhancement,of,the'
p55054
(F1
F0.00014334862385321102
I1
I0
I1
tp55055
sS'to,this,regimen'
p55056
(F1
F0.00014334862385321102
I1
I0
I1
tp55057
sS'increase,certain,actions'
p55058
(F1
F0.00014334862385321102
I0
I1
I-1
tp55059
sS'dose,of,x'
p55060
(F1
F0.00014334862385321102
I1
I0
I1
tp55061
sS'daily,increased,the'
p55062
(F1
F0.00014334862385321102
I1
I0
I1
tp55063
sS'patients,the,prothrombin'
p55064
(F1
F0.00014334862385321102
I1
I0
I1
tp55065
sS'monitored,particularly,during'
p55066
(F1
F0.00014334862385321102
I1
I0
I1
tp55067
sS'be,noted,when'
p55068
(F1
F0.00014334862385321102
I0
I1
I-1
tp55069
sS'of,augmentin,xr'
p55070
(F1
F0.00014334862385321102
I0
I1
I-1
tp55071
sS'study,toradoliv,im'
p55072
(F1
F0.00014334862385321102
I0
I1
I-1
tp55073
sS'dose,in,pcp'
p55074
(F1
F0.00014334862385321102
I0
I1
I-1
tp55075
sS'several,advantages,over'
p55076
(F1
F0.00014334862385321102
I0
I1
I-1
tp55077
sS'hypertension,did,not'
p55078
(F1
F0.00014334862385321102
I0
I1
I-1
tp55079
sS'addition,of,results'
p55080
(F1
F0.00014334862385321102
I1
I0
I1
tp55081
sS'impaired,but,not'
p55082
(F1
F0.00014334862385321102
I0
I1
I-1
tp55083
sS'among,patients,receiving'
p55084
(F1
F0.00014334862385321102
I1
I0
I1
tp55085
sS'used,physiological,oral'
p55086
(F1
F0.00014334862385321102
I0
I1
I-1
tp55087
sS'in,a,comparison'
p55088
(F1
F0.00014334862385321102
I1
I0
I1
tp55089
sS'of,an,and'
p55090
(F1
F0.00014334862385321102
I1
I0
I1
tp55091
sS'two,potentially,hepatotoxic'
p55092
(F1
F0.00014334862385321102
I1
I0
I1
tp55093
sS'and,area,under'
p55094
(F0
F0
I1
I1
I0
tp55095
sS'and,a,should'
p55096
(F1
F0.00014334862385321102
I1
I0
I1
tp55097
sS'small,initial,doses'
p55098
(F1
F0.00014334862385321102
I1
I0
I1
tp55099
sS'or,might,have'
p55100
(F1
F0.00014334862385321102
I0
I1
I-1
tp55101
sS'clinical,trials,was'
p55102
(F1
F0.00014334862385321102
I0
I1
I-1
tp55103
sS'interactions,when,was'
p55104
(F1
F0.00014334862385321102
I0
I1
I-1
tp55105
sS'be,mediated,by'
p55106
(F0
F0
I2
I2
I0
tp55107
sS'contractility,when,systemic'
p55108
(F1
F0.00014334862385321102
I1
I0
I1
tp55109
sS'days,before,the'
p55110
(F1
F0.00043004587155963305
I3
I0
I3
tp55111
sS'and,containing,or'
p55112
(F1
F0.00014334862385321102
I1
I0
I1
tp55113
sS'before,the,evening'
p55114
(F0
F0
I1
I1
I0
tp55115
sS'cross-reactivity,of,with'
p55116
(F1
F0.00014334862385321102
I1
I0
I1
tp55117
sS'acting,nitrates,nifedipine'
p55118
(F1
F0.00014334862385321102
I0
I1
I-1
tp55119
sS'of,be,adjusted'
p55120
(F1
F0.00014334862385321102
I1
I0
I1
tp55121
sS'aprepitant,reflects,an'
p55122
(F1
F0.00014334862385321102
I1
I0
I1
tp55123
sS'or,the,dosage'
p55124
(F1
F0.00014334862385321102
I1
I0
I1
tp55125
sS'and,thus,if'
p55126
(F1
F0.00028669724770642203
I2
I0
I2
tp55127
sS'procedure,even,when'
p55128
(F1
F0.00014334862385321102
I0
I1
I-1
tp55129
sS'administration,of,lodine'
p55130
(F1
F0.00014334862385321102
I1
I0
I1
tp55131
sS'metabolism,of,wellbutrin'
p55132
(F1
F0.00014334862385321102
I0
I1
I-1
tp55133
sS'have,occurred,when'
p55134
(F1
F0.00014334862385321102
I0
I1
I-1
tp55135
sS'and,therefore,should'
p55136
(F1
F0.00014334862385321102
I0
I1
I-1
tp55137
sS'effects,of,medicinal'
p55138
(F1
F0.00014334862385321102
I1
I0
I1
tp55139
sS'characteristics,for,and'
p55140
(F1
F0.00014334862385321102
I0
I1
I-1
tp55141
sS'pth,and,serum'
p55142
(F1
F0.00014334862385321102
I1
I0
I1
tp55143
sS'in,comparative,data'
p55144
(F1
F0.00014334862385321102
I0
I1
I-1
tp55145
sS'administration,of,or'
p55146
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp55147
sS'adult,volunteers,toradoloral'
p55148
(F1
F0.00014334862385321102
I0
I1
I-1
tp55149
sS'substrates,for,p450'
p55150
(F1
F0.00071674311926605509
I0
I5
I-5
tp55151
sS'reported,that,these'
p55152
(F1
F0.00014334862385321102
I0
I1
I-1
tp55153
sS'oxide,to,achieve'
p55154
(F1
F0.00014334862385321102
I1
I0
I1
tp55155
sS'hypertonus,possibly,causing'
p55156
(F1
F0.00014334862385321102
I1
I0
I1
tp55157
sS'administration,of,on'
p55158
(F1
F0.00014334862385321102
I0
I1
I-1
tp55159
sS'was,comparable,in'
p55160
(F1
F0.00014334862385321102
I0
I1
I-1
tp55161
sS's,wort,may'
p55162
(F0
F0
I1
I1
I0
tp55163
sS'have,previously,received'
p55164
(F1
F0.00014334862385321102
I1
I0
I1
tp55165
sS'potassium-sparing,diuretics,lotensin'
p55166
(F1
F0.00014334862385321102
I1
I0
I1
tp55167
sS'probably,reduces,the'
p55168
(F1
F0.00014334862385321102
I1
I0
I1
tp55169
sS'minimized,or,avoided'
p55170
(F1
F0.00014334862385321102
I1
I0
I1
tp55171
sS'and,depressive,symptoms'
p55172
(F1
F0.00028669724770642203
I0
I2
I-2
tp55173
sS'identify,any,clinically'
p55174
(F1
F0.00014334862385321102
I0
I1
I-1
tp55175
sS'produces,a,complete'
p55176
(F1
F0.00014334862385321102
I1
I0
I1
tp55177
sS'patient,with,acute'
p55178
(F1
F0.00014334862385321102
I1
I0
I1
tp55179
sS'consider,discontinuation,of'
p55180
(F1
F0.00014334862385321102
I1
I0
I1
tp55181
sS'nevertheless,the,possibility'
p55182
(F1
F0.00014334862385321102
I1
I0
I1
tp55183
sS'oral,response,ie'
p55184
(F1
F0.00057339449541284407
I4
I0
I4
tp55185
sS'the,they,should'
p55186
(F1
F0.00014334862385321102
I1
I0
I1
tp55187
sS'with,a,corresponding'
p55188
(F1
F0.00014334862385321102
I1
I0
I1
tp55189
sS'smoking,cessation,with'
p55190
(F1
F0.00014334862385321102
I0
I1
I-1
tp55191
sS'showed,no,clinically'
p55192
(F1
F0.00014334862385321102
I0
I1
I-1
tp55193
sS'of,to,human'
p55194
(F1
F0.00014334862385321102
I1
I0
I1
tp55195
sS'numbers,of,subjects'
p55196
(F1
F0.00014334862385321102
I0
I1
I-1
tp55197
sS'effect,in,the'
p55198
(F1
F0.00028669724770642203
I0
I2
I-2
tp55199
sS'of,the,short-acting'
p55200
(F1
F0.00014334862385321102
I0
I1
I-1
tp55201
sS'the,or,increasing'
p55202
(F1
F0.00071674311926605509
I5
I0
I5
tp55203
sS'substrate,resulted,in'
p55204
(F1
F0.00014334862385321102
I1
I0
I1
tp55205
sS'if,tykerb,is'
p55206
(F1
F0.00014334862385321102
I0
I1
I-1
tp55207
sS'cyp2e1,cyp4a9,and'
p55208
(F1
F0.00014334862385321102
I0
I1
I-1
tp55209
sS'enzyme,system,at'
p55210
(F1
F0.00014334862385321102
I1
I0
I1
tp55211
sS'daily,as,a'
p55212
(F1
F0.00014334862385321102
I1
I0
I1
tp55213
sS'closely,observed,for'
p55214
(F0
F0
I1
I1
I0
tp55215
sS'studies,of,pegasys'
p55216
(F1
F0.00014334862385321102
I0
I1
I-1
tp55217
sS'by,at,least'
p55218
(F1
F0.00014334862385321102
I1
I0
I1
tp55219
sS'of,serious,gi'
p55220
(F1
F0.00028669724770642203
I2
I0
I2
tp55221
sS'was,more,profound'
p55222
(F1
F0.00014334862385321102
I1
I0
I1
tp55223
sS'patients,on,should'
p55224
(F1
F0.00028669724770642203
I2
I0
I2
tp55225
sS'doses,from,to'
p55226
(F1
F0.00014334862385321102
I0
I1
I-1
tp55227
sS'epileptic,patients,on'
p55228
(F1
F0.00014334862385321102
I1
I0
I1
tp55229
sS'those,seen,in'
p55230
(F1
F0.00014334862385321102
I1
I0
I1
tp55231
sS'viracept,should,not'
p55232
(F1
F0.00014334862385321102
I1
I0
I1
tp55233
sS'ace,inhibitors,beta'
p55234
(F1
F0.00014334862385321102
I0
I1
I-1
tp55235
sS'cause,increases,in'
p55236
(F1
F0.00014334862385321102
I0
I1
I-1
tp55237
sS'subjects,to,determine'
p55238
(F1
F0.00014334862385321102
I0
I1
I-1
tp55239
sS'and,persistent,inhibition'
p55240
(F1
F0.00014334862385321102
I1
I0
I1
tp55241
sS'hind,limb,digital'
p55242
(F1
F0.00014334862385321102
I0
I1
I-1
tp55243
sS'of,videx,hours'
p55244
(F1
F0.00014334862385321102
I1
I0
I1
tp55245
sS'as,and,similar'
p55246
(F1
F0.00014334862385321102
I0
I1
I-1
tp55247
sS'w,in,a'
p55248
(F1
F0.00014334862385321102
I1
I0
I1
tp55249
sS'cyp3a4,ketoconazole,cyp3a4'
p55250
(F1
F0.00014334862385321102
I0
I1
I-1
tp55251
sS'epoxide,hydrolase,inhibitors'
p55252
(F1
F0.00014334862385321102
I0
I1
I-1
tp55253
sS'binding,is,reduced'
p55254
(F1
F0.00014334862385321102
I1
I0
I1
tp55255
sS'recently,instituted,as'
p55256
(F1
F0.00014334862385321102
I1
I0
I1
tp55257
sS'enhancing,absorption,decreases'
p55258
(F1
F0.00014334862385321102
I1
I0
I1
tp55259
sS'after,treatment,with'
p55260
(F1
F0.00014334862385321102
I0
I1
I-1
tp55261
sS'patients,n,and'
p55262
(F1
F0.00014334862385321102
I1
I0
I1
tp55263
sS'congeners,and,coexisting'
p55264
(F1
F0.00014334862385321102
I0
I1
I-1
tp55265
sS'in,the,chick'
p55266
(F1
F0.00014334862385321102
I0
I1
I-1
tp55267
sS'containing,or,with'
p55268
(F1
F0.00028669724770642203
I2
I0
I2
tp55269
sS'vivo,drug-drug,interaction'
p55270
(F1
F0.00014334862385321102
I1
I0
I1
tp55271
sS'clinical,and,paraclinical'
p55272
(F1
F0.00014334862385321102
I0
I1
I-1
tp55273
sS'decreased,alertness,and'
p55274
(F1
F0.00028669724770642203
I2
I0
I2
tp55275
sS'in,sheep,interactions'
p55276
(F1
F0.00014334862385321102
I0
I1
I-1
tp55277
sS'mesylate,in,combination'
p55278
(F1
F0.00014334862385321102
I1
I0
I1
tp55279
sS'half,of,the'
p55280
(F1
F0.00028669724770642203
I0
I2
I-2
tp55281
sS'clearance,of,felbatol'
p55282
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp55283
sS'recording,technique,in'
p55284
(F1
F0.00014334862385321102
I0
I1
I-1
tp55285
sS'response,by,displacing'
p55286
(F1
F0.00014334862385321102
I1
I0
I1
tp55287
sS'were,seen,when'
p55288
(F0
F0
I1
I1
I0
tp55289
sS'valid,prothrombin,time'
p55290
(F1
F0.00014334862385321102
I1
I0
I1
tp55291
sS'studies,in,rabbit'
p55292
(F1
F0.00014334862385321102
I1
I0
I1
tp55293
sS'on,the,blood'
p55294
(F1
F0.00014334862385321102
I0
I1
I-1
tp55295
sS'the,patient,with'
p55296
(F1
F0.00014334862385321102
I0
I1
I-1
tp55297
sS'blood,glucose,concentrations'
p55298
(F1
F0.00028669724770642203
I2
I0
I2
tp55299
sS'in,vitro,inhibitor'
p55300
(F1
F0.00014334862385321102
I0
I1
I-1
tp55301
sS'concurrently,increases,the'
p55302
(F1
F0.00014334862385321102
I1
I0
I1
tp55303
sS'time,from,to'
p55304
(F1
F0.00014334862385321102
I1
I0
I1
tp55305
sS'cyp3a4,inhibitor,at'
p55306
(F1
F0.00014334862385321102
I1
I0
I1
tp55307
sS'time,determinations,vitamin'
p55308
(F1
F0.00014334862385321102
I1
I0
I1
tp55309
sS'that,variable,effects'
p55310
(F1
F0.00014334862385321102
I1
I0
I1
tp55311
sS'unchanged,after,coadministration'
p55312
(F1
F0.00014334862385321102
I0
I1
I-1
tp55313
sS'treatment,with,amevive'
p55314
(F1
F0.00014334862385321102
I0
I1
I-1
tp55315
sS'or,acute,ergot'
p55316
(F1
F0.00014334862385321102
I0
I1
I-1
tp55317
sS'in,a,reduced'
p55318
(F1
F0.00014334862385321102
I1
I0
I1
tp55319
sS'methods,hydrocortisone,mg'
p55320
(F1
F0.00014334862385321102
I0
I1
I-1
tp55321
sS'propoxyphene,in,cases'
p55322
(F1
F0.00028669724770642203
I2
I0
I2
tp55323
sS'microsomal,enzyme,systems'
p55324
(F0
F0
I1
I1
I0
tp55325
sS'effects,would,be'
p55326
(F1
F0.00014334862385321102
I0
I1
I-1
tp55327
sS'complications,considerably,enhance'
p55328
(F1
F0.00014334862385321102
I0
I1
I-1
tp55329
sS'dosage,range,mg'
p55330
(F1
F0.00014334862385321102
I1
I0
I1
tp55331
sS'and,without,and'
p55332
(F1
F0.00014334862385321102
I0
I1
I-1
tp55333
sS'concentrations,substances,that'
p55334
(F1
F0.00014334862385321102
I0
I1
I-1
tp55335
sS'the,pesticide,gliftor'
p55336
(F1
F0.00014334862385321102
I0
I1
I-1
tp55337
sS'its,structural,similarity'
p55338
(F1
F0.00014334862385321102
I1
I0
I1
tp55339
sS'enhances,the,effect'
p55340
(F1
F0.00014334862385321102
I1
I0
I1
tp55341
sS'of,to,approximately'
p55342
(F1
F0.00014334862385321102
I1
I0
I1
tp55343
sS'administration,for,days'
p55344
(F1
F0.00028669724770642203
I0
I2
I-2
tp55345
sS'c,max,by'
p55346
(F0
F0
I1
I1
I0
tp55347
sS'elimination,of,because'
p55348
(F1
F0.00014334862385321102
I0
I1
I-1
tp55349
sS'support,the,effectiveness'
p55350
(F1
F0.00014334862385321102
I0
I1
I-1
tp55351
sS'parameters,should,be'
p55352
(F1
F0.00014334862385321102
I0
I1
I-1
tp55353
sS'sodium,an,inducer'
p55354
(F1
F0.00014334862385321102
I0
I1
I-1
tp55355
sS'no,apparent,effect'
p55356
(F1
F0.00014334862385321102
I0
I1
I-1
tp55357
sS'concomitant,administration,should'
p55358
(F1
F0.00014334862385321102
I1
I0
I1
tp55359
sS'and,in,controlled'
p55360
(F1
F0.00014334862385321102
I0
I1
I-1
tp55361
sS'in,systemic,concentrations'
p55362
(F1
F0.00014334862385321102
I1
I0
I1
tp55363
sS'with,avastin,when'
p55364
(F1
F0.00014334862385321102
I0
I1
I-1
tp55365
sS'to,the,level'
p55366
(F1
F0.00014334862385321102
I0
I1
I-1
tp55367
sS'with,multiple,doses'
p55368
(F0.5
F0.00028669724770642203
I3
I1
I2
tp55369
sS'continued,need,for'
p55370
(F1
F0.00014334862385321102
I0
I1
I-1
tp55371
sS'most,psychoactive,medications'
p55372
(F1
F0.00014334862385321102
I1
I0
I1
tp55373
sS'm,v,significantly'
p55374
(F1
F0.00014334862385321102
I0
I1
I-1
tp55375
sS'caused,a,three-'
p55376
(F1
F0.00014334862385321102
I0
I1
I-1
tp55377
sS'from,the,administration'
p55378
(F1
F0.00014334862385321102
I1
I0
I1
tp55379
sS'ecg,changes,and'
p55380
(F1
F0.00014334862385321102
I1
I0
I1
tp55381
sS'be,induced,in'
p55382
(F1
F0.00014334862385321102
I0
I1
I-1
tp55383
sS'be,greater,in'
p55384
(F0
F0
I1
I1
I0
tp55385
sS'absorption,of,as'
p55386
(F0
F0
I1
I1
I0
tp55387
sS'adverse,reactions,atg'
p55388
(F1
F0.00014334862385321102
I0
I1
I-1
tp55389
sS'event,profile,between'
p55390
(F1
F0.00014334862385321102
I0
I1
I-1
tp55391
sS'or,iv,ace'
p55392
(F1
F0.00014334862385321102
I0
I1
I-1
tp55393
sS'their,concomitant,medications'
p55394
(F1
F0.00014334862385321102
I0
I1
I-1
tp55395
sS'mesylate,injection,usp'
p55396
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp55397
sS'to,normal,volunteers'
p55398
(F1
F0.00028669724770642203
I2
I0
I2
tp55399
sS'gastric,ph,h2-receptor'
p55400
(F1
F0.00014334862385321102
I1
I0
I1
tp55401
sS'evaluating,the,interaction'
p55402
(F1
F0.00014334862385321102
I0
I1
I-1
tp55403
sS'a,one-week,course'
p55404
(F1
F0.00014334862385321102
I1
I0
I1
tp55405
sS'patients,receiving,blocking'
p55406
(F1
F0.00014334862385321102
I0
I1
I-1
tp55407
sS'imidazole,and,the'
p55408
(F1
F0.00014334862385321102
I1
I0
I1
tp55409
sS'be,monitored,with'
p55410
(F1
F0.00028669724770642203
I0
I2
I-2
tp55411
sS'a,decreased,plasma'
p55412
(F1
F0.00014334862385321102
I1
I0
I1
tp55413
sS'mg,co-administered,with'
p55414
(F1
F0.00014334862385321102
I1
I0
I1
tp55415
sS'slow-release,mg,or'
p55416
(F1
F0.00014334862385321102
I0
I1
I-1
tp55417
sS'at,approximately,times'
p55418
(F1
F0.00014334862385321102
I1
I0
I1
tp55419
sS'immediately,following,a'
p55420
(F1
F0.00014334862385321102
I1
I0
I1
tp55421
sS'or,maois,which'
p55422
(F1
F0.00014334862385321102
I0
I1
I-1
tp55423
sS'in,peak,serum'
p55424
(F1
F0.00014334862385321102
I1
I0
I1
tp55425
sS'danger,inherent,in'
p55426
(F1
F0.00014334862385321102
I1
I0
I1
tp55427
sS'nonetheless,since,interactions'
p55428
(F1
F0.00014334862385321102
I1
I0
I1
tp55429
sS'with,the,hepatic'
p55430
(F1
F0.00014334862385321102
I1
I0
I1
tp55431
sS'of,proteus,rettgeri'
p55432
(F1
F0.00014334862385321102
I0
I1
I-1
tp55433
sS'rats,of,the'
p55434
(F1
F0.00014334862385321102
I0
I1
I-1
tp55435
sS'to,that,of'
p55436
(F0
F0
I1
I1
I0
tp55437
sS'interfere,with,laboratory'
p55438
(F1
F0.00014334862385321102
I0
I1
I-1
tp55439
sS'when,an,adequate'
p55440
(F1
F0.00014334862385321102
I0
I1
I-1
tp55441
sS'avoid,them,and'
p55442
(F1
F0.00014334862385321102
I0
I1
I-1
tp55443
sS'the,pk,properties'
p55444
(F1
F0.00014334862385321102
I0
I1
I-1
tp55445
sS'time,or,other'
p55446
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp55447
sS'of,a,large'
p55448
(F1
F0.00014334862385321102
I1
I0
I1
tp55449
sS'for,these,reasons'
p55450
(F1
F0.00014334862385321102
I1
I0
I1
tp55451
sS'in,auc,values'
p55452
(F1
F0.00014334862385321102
I1
I0
I1
tp55453
sS'weeks,may,produce'
p55454
(F1
F0.00014334862385321102
I1
I0
I1
tp55455
sS'and,these,with'
p55456
(F1
F0.00014334862385321102
I0
I1
I-1
tp55457
sS'interaction,study,co-administration'
p55458
(F0
F0
I1
I1
I0
tp55459
sS'combined,therapy,with'
p55460
(F1
F0.00043004587155963305
I3
I0
I3
tp55461
sS'and,mg,did'
p55462
(F1
F0.00043004587155963305
I0
I3
I-3
tp55463
sS'a,regular,basis'
p55464
(F1
F0.00014334862385321102
I0
I1
I-1
tp55465
sS'of,metabolism,by'
p55466
(F1
F0.00014334862385321102
I0
I1
I-1
tp55467
sS'bile-acidsequestering,agent,on'
p55468
(F1
F0.00014334862385321102
I0
I1
I-1
tp55469
sS'ascorbic,acid,fruit'
p55470
(F1
F0.00014334862385321102
I1
I0
I1
tp55471
sS'the,impact,of'
p55472
(F1
F0.00014334862385321102
I0
I1
I-1
tp55473
sS'occurred,following,simultaneous'
p55474
(F1
F0.00014334862385321102
I1
I0
I1
tp55475
sS'false,positive,readings'
p55476
(F1
F0.00014334862385321102
I0
I1
I-1
tp55477
sS'may,antagonize,the'
p55478
(F1
F0.0014334862385321102
I10
I0
I10
tp55479
sS'dose,until,blood'
p55480
(F1
F0.00014334862385321102
I1
I0
I1
tp55481
sS'were,to,fold'
p55482
(F1
F0.00014334862385321102
I1
I0
I1
tp55483
sS'in,interaction,studies'
p55484
(F1
F0.00028669724770642203
I0
I2
I-2
tp55485
sS'maximum,approved,prescription'
p55486
(F1
F0.00014334862385321102
I1
I0
I1
tp55487
sS'was,taken,hours'
p55488
(F1
F0.00014334862385321102
I0
I1
I-1
tp55489
sS'indices,as,competition'
p55490
(F1
F0.00014334862385321102
I1
I0
I1
tp55491
sS'of,and,must'
p55492
(F1
F0.00014334862385321102
I0
I1
I-1
tp55493
sS'needed,to,cause'
p55494
(F1
F0.00014334862385321102
I1
I0
I1
tp55495
sS'cyp,a4,and'
p55496
(F1
F0.00028669724770642203
I0
I2
I-2
tp55497
sS'have,demonstrated,that'
p55498
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp55499
sS'administration,of,indigestion'
p55500
(F1
F0.00014334862385321102
I1
I0
I1
tp55501
sS'associated,with,hepatotoxicity'
p55502
(F1
F0.00014334862385321102
I1
I0
I1
tp55503
sS'from,to,which'
p55504
(F1
F0.00014334862385321102
I1
I0
I1
tp55505
sS'if,the,desired'
p55506
(F0.75
F0.0008600917431192661
I7
I1
I6
tp55507
sS'for,oral,suspension'
p55508
(F1
F0.00014334862385321102
I0
I1
I-1
tp55509
sS'patients,with,hiv-related'
p55510
(F1
F0.00014334862385321102
I0
I1
I-1
tp55511
sS'but,there,was'
p55512
(F1
F0.00014334862385321102
I1
I0
I1
tp55513
sS'a,small,effect'
p55514
(F1
F0.00014334862385321102
I0
I1
I-1
tp55515
sS'phosphorylation,of,in'
p55516
(F1
F0.00014334862385321102
I0
I1
I-1
tp55517
sS'examined,the,interactions'
p55518
(F1
F0.00014334862385321102
I0
I1
I-1
tp55519
sS'occur,with,that'
p55520
(F1
F0.00014334862385321102
I0
I1
I-1
tp55521
sS'of,preparations,in'
p55522
(F1
F0.00014334862385321102
I1
I0
I1
tp55523
sS'levels,and,efficacy'
p55524
(F1
F0.00014334862385321102
I1
I0
I1
tp55525
sS'response,ie,increased'
p55526
(F1
F0.00028669724770642203
I2
I0
I2
tp55527
sS'displace,such,as'
p55528
(F1
F0.00014334862385321102
I1
I0
I1
tp55529
sS'hypertension,and,tachycardia'
p55530
(F1
F0.00014334862385321102
I1
I0
I1
tp55531
sS'clearance,ml,min'
p55532
(F1
F0.00014334862385321102
I0
I1
I-1
tp55533
sS'state,conditions,or'
p55534
(F1
F0.00014334862385321102
I0
I1
I-1
tp55535
sS'nimotop,was,observed'
p55536
(F1
F0.00014334862385321102
I1
I0
I1
tp55537
sS'that,tikosyn,does'
p55538
(F1
F0.00028669724770642203
I0
I2
I-2
tp55539
sS'system,can,be'
p55540
(F1
F0.00014334862385321102
I1
I0
I1
tp55541
sS'pyrocarbonate,abolished,both'
p55542
(F1
F0.00014334862385321102
I0
I1
I-1
tp55543
sS'the,lowest,recommended'
p55544
(F1
F0.00014334862385321102
I1
I0
I1
tp55545
sS'postoperatively,patients,were'
p55546
(F1
F0.00014334862385321102
I0
I1
I-1
tp55547
sS'adequately,evaluated,in'
p55548
(F1
F0.00014334862385321102
I0
I1
I-1
tp55549
sS'recommended,that,ecg'
p55550
(F1
F0.00014334862385321102
I1
I0
I1
tp55551
sS'of,with,tablets'
p55552
(F1
F0.00028669724770642203
I2
I0
I2
tp55553
sS'nsaids,monoamine,oxidase'
p55554
(F1
F0.00014334862385321102
I1
I0
I1
tp55555
sS'each,dose,of'
p55556
(F1
F0.00014334862385321102
I1
I0
I1
tp55557
sS'effect,with,inomax'
p55558
(F1
F0.00014334862385321102
I1
I0
I1
tp55559
sS'drugs,phenytoin,felbatol'
p55560
(F1
F0.00014334862385321102
I1
I0
I1
tp55561
sS'effectively,administered,in'
p55562
(F1
F0.00014334862385321102
I0
I1
I-1
tp55563
sS'which,inhibit,neuronal'
p55564
(F1
F0.00014334862385321102
I0
I1
I-1
tp55565
sS'with,orencia,mtx'
p55566
(F1
F0.00014334862385321102
I0
I1
I-1
tp55567
sS'been,found,or'
p55568
(F1
F0.00043004587155963305
I3
I0
I3
tp55569
sS'vitro,mixing,of'
p55570
(F1
F0.00014334862385321102
I1
I0
I1
tp55571
sS'b-induced,hypokalemia,may'
p55572
(F1
F0.00028669724770642203
I2
I0
I2
tp55573
sS'with,hereditary,antithrombin'
p55574
(F1
F0.00014334862385321102
I1
I0
I1
tp55575
sS'administration,of,some'
p55576
(F1
F0.00014334862385321102
I1
I0
I1
tp55577
sS'no,significant,effects'
p55578
(F1
F0.00043004587155963305
I0
I3
I-3
tp55579
sS'in,mice,on'
p55580
(F1
F0.00014334862385321102
I0
I1
I-1
tp55581
sS'on,pentagastrin-,and'
p55582
(F1
F0.00014334862385321102
I0
I1
I-1
tp55583
sS'steady,state,auc'
p55584
(F1
F0.00014334862385321102
I1
I0
I1
tp55585
sS'injection,of,and'
p55586
(F0
F0
I1
I1
I0
tp55587
sS'at,receptors,such'
p55588
(F1
F0.00014334862385321102
I1
I0
I1
tp55589
sS'increased,toxicity,cns'
p55590
(F1
F0.00014334862385321102
I0
I1
I-1
tp55591
sS'occurrence,of,upper'
p55592
(F1
F0.00014334862385321102
I1
I0
I1
tp55593
sS'medicine,such,as'
p55594
(F1
F0.00014334862385321102
I0
I1
I-1
tp55595
sS'to,mg,or'
p55596
(F1
F0.00014334862385321102
I1
I0
I1
tp55597
sS'reduced,plasma,concentrations'
p55598
(F0.5
F0.00028669724770642203
I3
I1
I2
tp55599
sS'treatment,following,the'
p55600
(F1
F0.00014334862385321102
I1
I0
I1
tp55601
sS'no,interaction,with'
p55602
(F1
F0.00028669724770642203
I0
I2
I-2
tp55603
sS'without,any,evidence'
p55604
(F1
F0.00028669724770642203
I0
I2
I-2
tp55605
sS'to,mg,of'
p55606
(F1
F0.00014334862385321102
I1
I0
I1
tp55607
sS'of,mg,per'
p55608
(F1
F0.00014334862385321102
I1
I0
I1
tp55609
sS'and,mg,when'
p55610
(F1
F0.00014334862385321102
I0
I1
I-1
tp55611
sS'may,be,compromised'
p55612
(F1
F0.00014334862385321102
I1
I0
I1
tp55613
sS'confidence,interval,and'
p55614
(F1
F0.00014334862385321102
I0
I1
I-1
tp55615
sS'and,a,cyp2c19'
p55616
(F1
F0.00014334862385321102
I1
I0
I1
tp55617
sS'micromol,l,and'
p55618
(F1
F0.00014334862385321102
I1
I0
I1
tp55619
sS'ponstel,with,the'
p55620
(F1
F0.00014334862385321102
I1
I0
I1
tp55621
sS'of,the,tnf'
p55622
(F1
F0.00014334862385321102
I1
I0
I1
tp55623
sS'addictive,medications,especially'
p55624
(F1
F0.00014334862385321102
I0
I1
I-1
tp55625
sS'the,reflex,tachycardia'
p55626
(F1
F0.00014334862385321102
I1
I0
I1
tp55627
sS'blocking,agents,should'
p55628
(F0
F0
I1
I1
I0
tp55629
sS'ribavirin,is,genotoxic'
p55630
(F1
F0.00014334862385321102
I0
I1
I-1
tp55631
sS'containing,or,to'
p55632
(F1
F0.00043004587155963305
I3
I0
I3
tp55633
sS'light,meal,h'
p55634
(F1
F0.00014334862385321102
I1
I0
I1
tp55635
sS'intake,of,mineral'
p55636
(F1
F0.00014334862385321102
I1
I0
I1
tp55637
sS'agents,these,medicines'
p55638
(F1
F0.00014334862385321102
I0
I1
I-1
tp55639
sS'injection,of,given'
p55640
(F1
F0.00014334862385321102
I1
I0
I1
tp55641
sS'day,in,six'
p55642
(F1
F0.00014334862385321102
I1
I0
I1
tp55643
sS'and,these,have'
p55644
(F1
F0.00014334862385321102
I0
I1
I-1
tp55645
sS'data,suggesting,a'
p55646
(F1
F0.00014334862385321102
I1
I0
I1
tp55647
sS'the,two,at'
p55648
(F1
F0.00014334862385321102
I0
I1
I-1
tp55649
sS'activity,in,arteries'
p55650
(F1
F0.00014334862385321102
I0
I1
I-1
tp55651
sS'production,of,hypotension'
p55652
(F1
F0.00028669724770642203
I2
I0
I2
tp55653
sS'can,potentiate,the'
p55654
(F1
F0.00014334862385321102
I1
I0
I1
tp55655
sS'of,rashes,with'
p55656
(F1
F0.00014334862385321102
I0
I1
I-1
tp55657
sS'the,administration,of'
p55658
(F0.5
F0.0025802752293577983
I27
I9
I18
tp55659
sS'kidney,which,was'
p55660
(F1
F0.00014334862385321102
I0
I1
I-1
tp55661
sS'from,marketing,experiences'
p55662
(F1
F0.00014334862385321102
I1
I0
I1
tp55663
sS'low,hepatic,clearance'
p55664
(F1
F0.00014334862385321102
I0
I1
I-1
tp55665
sS'including,or,its'
p55666
(F1
F0.00014334862385321102
I1
I0
I1
tp55667
sS'soluble,such,as'
p55668
(F1
F0.00014334862385321102
I0
I1
I-1
tp55669
sS'employed,since,the'
p55670
(F1
F0.00014334862385321102
I1
I0
I1
tp55671
sS'kg,day,group'
p55672
(F1
F0.00014334862385321102
I1
I0
I1
tp55673
sS'fluconazole,an,inhibitor'
p55674
(F1
F0.00014334862385321102
I1
I0
I1
tp55675
sS'spent,in,the'
p55676
(F1
F0.00014334862385321102
I1
I0
I1
tp55677
sS'interaction,study,demonstrated'
p55678
(F1
F0.00014334862385321102
I1
I0
I1
tp55679
sS'no,significant,differences'
p55680
(F1
F0.00043004587155963305
I0
I3
I-3
tp55681
sS'starting,the,or'
p55682
(F1
F0.00014334862385321102
I0
I1
I-1
tp55683
sS'employed,cautiously,as'
p55684
(F1
F0.00014334862385321102
I0
I1
I-1
tp55685
sS'enzymes,may,change'
p55686
(F1
F0.00014334862385321102
I0
I1
I-1
tp55687
sS'with,reduced,the'
p55688
(F1
F0.00014334862385321102
I1
I0
I1
tp55689
sS'mao,inhibitors,including'
p55690
(F0
F0
I1
I1
I0
tp55691
sS'ace,inhibitors,may'
p55692
(F0
F0
I1
I1
I0
tp55693
sS'as,has,been'
p55694
(F0
F0
I1
I1
I0
tp55695
sS'levels,to,continue'
p55696
(F1
F0.00014334862385321102
I1
I0
I1
tp55697
sS'by,peripheral,vasospasm'
p55698
(F1
F0.00014334862385321102
I0
I1
I-1
tp55699
sS'cancer,were,reported'
p55700
(F1
F0.00014334862385321102
I1
I0
I1
tp55701
sS'and,aetiopathogenic--,for'
p55702
(F1
F0.00014334862385321102
I0
I1
I-1
tp55703
sS'conversely,the,have'
p55704
(F1
F0.00014334862385321102
I1
I0
I1
tp55705
sS'receiving,there,have'
p55706
(F1
F0.00014334862385321102
I1
I0
I1
tp55707
sS'pharmacokinetic,study,of'
p55708
(F1
F0.00014334862385321102
I0
I1
I-1
tp55709
sS'in,tambocor,clinical'
p55710
(F1
F0.00014334862385321102
I0
I1
I-1
tp55711
sS'induce,cyp3a4,rifampin'
p55712
(F1
F0.00014334862385321102
I0
I1
I-1
tp55713
sS'tml,or,mg'
p55714
(F1
F0.00014334862385321102
I0
I1
I-1
tp55715
sS'adrenergic,blockers,are'
p55716
(F1
F0.00028669724770642203
I2
I0
I2
tp55717
sS'aspirin,as,with'
p55718
(F1
F0.00014334862385321102
I1
I0
I1
tp55719
sS'non-specific,cyp-450,inhibitor'
p55720
(F1
F0.00014334862385321102
I0
I1
I-1
tp55721
sS'clinically,significant,pharmacokinetic'
p55722
(F1
F0.00014334862385321102
I0
I1
I-1
tp55723
sS'of,peptide,in'
p55724
(F1
F0.00014334862385321102
I0
I1
I-1
tp55725
sS'the,effect,measured'
p55726
(F1
F0.00014334862385321102
I0
I1
I-1
tp55727
sS'exhibited,similar,temporal'
p55728
(F1
F0.00014334862385321102
I0
I1
I-1
tp55729
sS'insulin-dependent,diabetic,patients'
p55730
(F1
F0.00014334862385321102
I0
I1
I-1
tp55731
sS'can,in,addition'
p55732
(F1
F0.00014334862385321102
I1
I0
I1
tp55733
sS'effects,of,in'
p55734
(F0.25
F0.00028669724770642203
I5
I3
I2
tp55735
sS'phenothiazines,tindal,thorazine'
p55736
(F1
F0.00014334862385321102
I0
I1
I-1
tp55737
sS'altretamines,half-life,and'
p55738
(F1
F0.00014334862385321102
I1
I0
I1
tp55739
sS'and,exposure,auc'
p55740
(F1
F0.00014334862385321102
I1
I0
I1
tp55741
sS'subjects,dosed,simultaneously'
p55742
(F1
F0.00014334862385321102
I1
I0
I1
tp55743
sS'serotonin,syndrome,cognitive'
p55744
(F1
F0.00014334862385321102
I1
I0
I1
tp55745
sS'estazolam,interaction,with'
p55746
(F1
F0.00028669724770642203
I0
I2
I-2
tp55747
sS'effects,of,it'
p55748
(F1
F0.00014334862385321102
I0
I1
I-1
tp55749
sS'lead,tml,or'
p55750
(F1
F0.00014334862385321102
I0
I1
I-1
tp55751
sS'when,prinivil,was'
p55752
(F1
F0.00014334862385321102
I0
I1
I-1
tp55753
sS'embryos,in,comparison'
p55754
(F1
F0.00014334862385321102
I1
I0
I1
tp55755
sS'adult,diabetics,who'
p55756
(F1
F0.00014334862385321102
I0
I1
I-1
tp55757
sS'and,chop,chemotherapy'
p55758
(F1
F0.00014334862385321102
I0
I1
I-1
tp55759
sS'of,other,is'
p55760
(F1
F0.00014334862385321102
I0
I1
I-1
tp55761
sS'ranitidine,in,normal'
p55762
(F1
F0.00014334862385321102
I1
I0
I1
tp55763
sS'is,too,small'
p55764
(F1
F0.00014334862385321102
I0
I1
I-1
tp55765
sS'the,levulan,kerastick'
p55766
(F1
F0.00014334862385321102
I1
I0
I1
tp55767
sS'of,or,oral'
p55768
(F1
F0.00014334862385321102
I1
I0
I1
tp55769
sS't,a,with'
p55770
(F1
F0.00014334862385321102
I1
I0
I1
tp55771
sS'of,other,in'
p55772
(F1
F0.00014334862385321102
I0
I1
I-1
tp55773
sS'halogenated,hydrocarbon,increase'
p55774
(F1
F0.00014334862385321102
I1
I0
I1
tp55775
sS'substrate,administered,in'
p55776
(F1
F0.00014334862385321102
I0
I1
I-1
tp55777
sS'caused,by,two'
p55778
(F1
F0.00014334862385321102
I0
I1
I-1
tp55779
sS'and,significant,increase'
p55780
(F1
F0.00014334862385321102
I1
I0
I1
tp55781
sS'electrolyte,disturbances,were'
p55782
(F1
F0.00014334862385321102
I1
I0
I1
tp55783
sS'determined,with,care'
p55784
(F1
F0.00043004587155963305
I3
I0
I3
tp55785
sS'increases,of,with'
p55786
(F1
F0.00014334862385321102
I0
I1
I-1
tp55787
sS'fold,prolongation,in'
p55788
(F1
F0.00028669724770642203
I0
I2
I-2
tp55789
sS'your,doctor,if'
p55790
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp55791
sS'and,another,tnf-blocking'
p55792
(F1
F0.00014334862385321102
I1
I0
I1
tp55793
sS'the,following,macrolide'
p55794
(F1
F0.00014334862385321102
I1
I0
I1
tp55795
sS'been,conducted,the'
p55796
(F1
F0.00014334862385321102
I0
I1
I-1
tp55797
sS'clearance,of,by'
p55798
(F1
F0.00028669724770642203
I2
I0
I2
tp55799
sS'tcaplasma,levels,whenever'
p55800
(F1
F0.00014334862385321102
I0
I1
I-1
tp55801
sS'olanzapine,is,associated'
p55802
(F1
F0.00014334862385321102
I0
I1
I-1
tp55803
sS'concentrations,of,in'
p55804
(F0
F0
I1
I1
I0
tp55805
sS'cause,an,increased'
p55806
(F1
F0.00014334862385321102
I1
I0
I1
tp55807
sS'tenormin,sectral,lopressor'
p55808
(F1
F0.00014334862385321102
I0
I1
I-1
tp55809
sS'as,risk,of'
p55810
(F1
F0.00014334862385321102
I0
I1
I-1
tp55811
sS'risk,that,an'
p55812
(F1
F0.00014334862385321102
I1
I0
I1
tp55813
sS'h-spiroperidol,binding,with'
p55814
(F1
F0.00014334862385321102
I0
I1
I-1
tp55815
sS'indicate,that,could'
p55816
(F1
F0.00014334862385321102
I1
I0
I1
tp55817
sS'reduction,was,greater'
p55818
(F1
F0.00014334862385321102
I1
I0
I1
tp55819
sS'patterns,during,the'
p55820
(F1
F0.00014334862385321102
I0
I1
I-1
tp55821
sS'reported,with,oral'
p55822
(F0
F0
I1
I1
I0
tp55823
sS'neuromuscular,transmission,should'
p55824
(F1
F0.00014334862385321102
I0
I1
I-1
tp55825
sS'not,all,are'
p55826
(F1
F0.00014334862385321102
I0
I1
I-1
tp55827
sS'erroneously,low,erpf'
p55828
(F1
F0.00014334862385321102
I1
I0
I1
tp55829
sS'in,addition,several'
p55830
(F1
F0.00014334862385321102
I1
I0
I1
tp55831
sS'derivatives,indandione,derivatives'
p55832
(F1
F0.00014334862385321102
I1
I0
I1
tp55833
sS'metabolized,by,this'
p55834
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp55835
sS'for,four,days'
p55836
(F1
F0.00014334862385321102
I0
I1
I-1
tp55837
sS'exceed,mg,when'
p55838
(F1
F0.00014334862385321102
I1
I0
I1
tp55839
sS'of,one,ng'
p55840
(F1
F0.00014334862385321102
I0
I1
I-1
tp55841
sS'with,ribavirin,ribavirin'
p55842
(F1
F0.00014334862385321102
I0
I1
I-1
tp55843
sS'auc,and,decrease'
p55844
(F1
F0.00014334862385321102
I1
I0
I1
tp55845
sS'after,days,of'
p55846
(F1
F0.00043004587155963305
I0
I3
I-3
tp55847
sS'ventricular,dysfunction,or'
p55848
(F1
F0.00014334862385321102
I0
I1
I-1
tp55849
sS'discontinuing,hydrochloride,therapy'
p55850
(F1
F0.00014334862385321102
I1
I0
I1
tp55851
sS'intravenous,self-administration,of'
p55852
(F0
F0
I1
I1
I0
tp55853
sS'agents,given,concomitantly'
p55854
(F1
F0.00014334862385321102
I0
I1
I-1
tp55855
sS'as,cough,and'
p55856
(F1
F0.00014334862385321102
I1
I0
I1
tp55857
sS'administering,disulfiram,to'
p55858
(F1
F0.00014334862385321102
I1
I0
I1
tp55859
sS'that,increase,or'
p55860
(F1
F0.00014334862385321102
I1
I0
I1
tp55861
sS'loss,of,virologic'
p55862
(F1
F0.00028669724770642203
I0
I2
I-2
tp55863
sS'and,uncontrolled,domestic'
p55864
(F1
F0.00014334862385321102
I0
I1
I-1
tp55865
sS'weighed,against,an'
p55866
(F1
F0.00014334862385321102
I1
I0
I1
tp55867
sS'but,increased,effects'
p55868
(F1
F0.00014334862385321102
I0
I1
I-1
tp55869
sS'events,associated,with'
p55870
(F1
F0.00014334862385321102
I1
I0
I1
tp55871
sS'daily,inhalation,dose'
p55872
(F1
F0.00014334862385321102
I1
I0
I1
tp55873
sS'the,mouth,and'
p55874
(F1
F0.00014334862385321102
I1
I0
I1
tp55875
sS'previous,studies,have'
p55876
(F1
F0.00014334862385321102
I1
I0
I1
tp55877
sS'were,reported,in'
p55878
(F1
F0.00014334862385321102
I0
I1
I-1
tp55879
sS'excretion,of,resulting'
p55880
(F1
F0.00014334862385321102
I1
I0
I1
tp55881
sS'treated,with,agonists'
p55882
(F1
F0.00014334862385321102
I1
I0
I1
tp55883
sS'to,the,possibility'
p55884
(F1
F0.00028669724770642203
I2
I0
I2
tp55885
sS'calcium-channel,blocking,agents'
p55886
(F1
F0.00014334862385321102
I0
I1
I-1
tp55887
sS'blockers,did,not'
p55888
(F1
F0.00014334862385321102
I0
I1
I-1
tp55889
sS'as,or,other'
p55890
(F1
F0.00014334862385321102
I1
I0
I1
tp55891
sS'to,when,gleevec'
p55892
(F1
F0.00014334862385321102
I1
I0
I1
tp55893
sS'both,increase,and'
p55894
(F1
F0.00014334862385321102
I1
I0
I1
tp55895
sS'and,other,highly'
p55896
(F1
F0.00014334862385321102
I0
I1
I-1
tp55897
sS'close,supervision,and'
p55898
(F0
F0
I2
I2
I0
tp55899
sS'such,as,or'
p55900
(F0.25
F0.0008600917431192661
I15
I9
I6
tp55901
sS'dose,adjustment,required'
p55902
(F1
F0.00014334862385321102
I1
I0
I1
tp55903
sS'carefully,monitored,especially'
p55904
(F1
F0.00014334862385321102
I0
I1
I-1
tp55905
sS'as,initial,therapy'
p55906
(F1
F0.00014334862385321102
I0
I1
I-1
tp55907
sS'significantly,p,decreased'
p55908
(F1
F0.00014334862385321102
I1
I0
I1
tp55909
sS'long,as,plasma'
p55910
(F1
F0.00014334862385321102
I1
I0
I1
tp55911
sS'a,follow-up,study'
p55912
(F1
F0.00014334862385321102
I0
I1
I-1
tp55913
sS'hour,prior,to'
p55914
(F1
F0.00014334862385321102
I1
I0
I1
tp55915
sS'not,all,inclusive'
p55916
(F1
F0.00014334862385321102
I0
I1
I-1
tp55917
sS'pharmacodynamic,interactions,between'
p55918
(F1
F0.00014334862385321102
I0
I1
I-1
tp55919
sS'during,pregnancy,cromolyn'
p55920
(F1
F0.00014334862385321102
I0
I1
I-1
tp55921
sS'with,some,like'
p55922
(F1
F0.00014334862385321102
I1
I0
I1
tp55923
sS'echistatin,alone,had'
p55924
(F1
F0.00014334862385321102
I1
I0
I1
tp55925
sS'and,cmax,differences'
p55926
(F1
F0.00014334862385321102
I0
I1
I-1
tp55927
sS'increases,in,urine'
p55928
(F1
F0.00014334862385321102
I1
I0
I1
tp55929
sS'the,half-life,by'
p55930
(F1
F0.00014334862385321102
I1
I0
I1
tp55931
sS'with,an,oral'
p55932
(F1
F0.00028669724770642203
I2
I0
I2
tp55933
sS'of,and,penthrane'
p55934
(F1
F0.00014334862385321102
I1
I0
I1
tp55935
sS'eg,may,elevate'
p55936
(F1
F0.00014334862385321102
I1
I0
I1
tp55937
sS'produced,a,increase'
p55938
(F1
F0.00028669724770642203
I2
I0
I2
tp55939
sS'no,pharmacokinetic,interaction'
p55940
(F1
F0.00043004587155963305
I0
I3
I-3
tp55941
sS'in,rats,simultaneous'
p55942
(F1
F0.00014334862385321102
I1
I0
I1
tp55943
sS'of,histidine,residues'
p55944
(F1
F0.00014334862385321102
I0
I1
I-1
tp55945
sS'significant,interactions,with'
p55946
(F1
F0.00028669724770642203
I0
I2
I-2
tp55947
sS'of,after,their'
p55948
(F1
F0.00014334862385321102
I0
I1
I-1
tp55949
sS'ace,inhibitor,to'
p55950
(F1
F0.00014334862385321102
I1
I0
I1
tp55951
sS'also,ineffective,in'
p55952
(F1
F0.00014334862385321102
I0
I1
I-1
tp55953
sS'cmin,concentrations,were'
p55954
(F1
F0.00014334862385321102
I0
I1
I-1
tp55955
sS'when,taking,mg'
p55956
(F1
F0.00014334862385321102
I1
I0
I1
tp55957
sS'ph,was,significantly'
p55958
(F1
F0.00014334862385321102
I1
I0
I1
tp55959
sS'on,the,intracellular'
p55960
(F0
F0
I1
I1
I0
tp55961
sS'some,oxytocic,may'
p55962
(F1
F0.00014334862385321102
I1
I0
I1
tp55963
sS'the,non-depolarizing,muscle'
p55964
(F1
F0.00014334862385321102
I1
I0
I1
tp55965
sS'been,performed,based'
p55966
(F1
F0.00014334862385321102
I1
I0
I1
tp55967
sS'to,or,on'
p55968
(F1
F0.00014334862385321102
I1
I0
I1
tp55969
sS'the,experiments,reported'
p55970
(F1
F0.00014334862385321102
I0
I1
I-1
tp55971
sS'plasma,concentrations,when'
p55972
(F0
F0
I1
I1
I0
tp55973
sS'effect,in,most'
p55974
(F1
F0.00014334862385321102
I1
I0
I1
tp55975
sS'and,subsequently,treated'
p55976
(F1
F0.00014334862385321102
I1
I0
I1
tp55977
sS'effects,were,seen'
p55978
(F1
F0.00014334862385321102
I0
I1
I-1
tp55979
sS'adult,data,lower'
p55980
(F1
F0.00014334862385321102
I1
I0
I1
tp55981
sS'administered,with,hexalen'
p55982
(F1
F0.00014334862385321102
I1
I0
I1
tp55983
sS'administration,may,be'
p55984
(F1
F0.00014334862385321102
I1
I0
I1
tp55985
sS'inhibitor,the,risk'
p55986
(F1
F0.00014334862385321102
I1
I0
I1
tp55987
sS'the,should,be'
p55988
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp55989
sS'serotonin,in,the'
p55990
(F1
F0.00014334862385321102
I0
I1
I-1
tp55991
sS'mg,qd,or'
p55992
(F1
F0.00028669724770642203
I0
I2
I-2
tp55993
sS'ss,of,o-desacetylrifabutin'
p55994
(F1
F0.00014334862385321102
I1
I0
I1
tp55995
sS'affect,the,test'
p55996
(F1
F0.00014334862385321102
I1
I0
I1
tp55997
sS'with,coadministered,orally'
p55998
(F1
F0.00014334862385321102
I1
I0
I1
tp55999
sS'and,mg,were'
p56000
(F1
F0.00014334862385321102
I0
I1
I-1
tp56001
sS'be,expected,with'
p56002
(F1
F0.00014334862385321102
I0
I1
I-1
tp56003
sS'with,sustiva,is'
p56004
(F1
F0.00014334862385321102
I0
I1
I-1
tp56005
sS'half-life,and,toxicity'
p56006
(F1
F0.00014334862385321102
I1
I0
I1
tp56007
sS'reported,here,we'
p56008
(F1
F0.00014334862385321102
I0
I1
I-1
tp56009
sS'of,cerubidine,in'
p56010
(F1
F0.00014334862385321102
I1
I0
I1
tp56011
sS'a,href,frova_od'
p56012
(F1
F0.00014334862385321102
I1
I0
I1
tp56013
sS'on,metabolism,or'
p56014
(F1
F0.00014334862385321102
I0
I1
I-1
tp56015
sS'least,partially,related'
p56016
(F1
F0.00014334862385321102
I1
I0
I1
tp56017
sS'metabolizers,and,extensive'
p56018
(F1
F0.00014334862385321102
I0
I1
I-1
tp56019
sS'in,a,mean'
p56020
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp56021
sS'this,protein,in'
p56022
(F1
F0.00014334862385321102
I1
I0
I1
tp56023
sS'and,were,agonists'
p56024
(F1
F0.00014334862385321102
I1
I0
I1
tp56025
sS'these,patients,when'
p56026
(F1
F0.00014334862385321102
I1
I0
I1
tp56027
sS'or,has,resulted'
p56028
(F1
F0.00028669724770642203
I2
I0
I2
tp56029
sS'volunteers,were,administered'
p56030
(F1
F0.00014334862385321102
I0
I1
I-1
tp56031
sS'administration,of,proton'
p56032
(F1
F0.00014334862385321102
I0
I1
I-1
tp56033
sS'levels,and,compromise'
p56034
(F1
F0.00014334862385321102
I1
I0
I1
tp56035
sS'in,arteries,from'
p56036
(F1
F0.00014334862385321102
I0
I1
I-1
tp56037
sS'discontinuance,of,could'
p56038
(F1
F0.00014334862385321102
I1
I0
I1
tp56039
sS'therapy,is,needed'
p56040
(F1
F0.00014334862385321102
I1
I0
I1
tp56041
sS'l50,mg,bid'
p56042
(F1
F0.00014334862385321102
I0
I1
I-1
tp56043
sS'require,downward,adjustment'
p56044
(F1
F0.00028669724770642203
I2
I0
I2
tp56045
sS'ii,alone,and'
p56046
(F1
F0.00028669724770642203
I0
I2
I-2
tp56047
sS'of,upper,gastrointestinal'
p56048
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp56049
sS'rifampin,is,a'
p56050
(F1
F0.00014334862385321102
I0
I1
I-1
tp56051
sS'urinary,levels,could'
p56052
(F1
F0.00014334862385321102
I0
I1
I-1
tp56053
sS'tablets,are,either'
p56054
(F1
F0.00014334862385321102
I1
I0
I1
tp56055
sS'patients,steady-state,auc'
p56056
(F1
F0.00014334862385321102
I1
I0
I1
tp56057
sS'available,in,the'
p56058
(F1
F0.00014334862385321102
I0
I1
I-1
tp56059
sS'estrogens,may,decrease'
p56060
(F1
F0.00014334862385321102
I1
I0
I1
tp56061
sS'of,by,an'
p56062
(F1
F0.00014334862385321102
I1
I0
I1
tp56063
sS'and,mepron,suspension'
p56064
(F1
F0.00014334862385321102
I1
I0
I1
tp56065
sS'percent,of,patients'
p56066
(F1
F0.00028669724770642203
I2
I0
I2
tp56067
sS'administration,of,another'
p56068
(F1
F0.00028669724770642203
I2
I0
I2
tp56069
sS'e1,and,cyp'
p56070
(F1
F0.00014334862385321102
I0
I1
I-1
tp56071
sS'the,concomitant,administration'
p56072
(F0.36842105263157893
F0.0020068807339449542
I26
I12
I14
tp56073
sS'b,patients,should'
p56074
(F1
F0.00014334862385321102
I1
I0
I1
tp56075
sS'ci,kg,or'
p56076
(F1
F0.00014334862385321102
I0
I1
I-1
tp56077
sS'ml,h,or'
p56078
(F1
F0.00014334862385321102
I0
I1
I-1
tp56079
sS'the,jaff,reaction'
p56080
(F1
F0.00014334862385321102
I0
I1
I-1
tp56081
sS'patients,take,other'
p56082
(F1
F0.00014334862385321102
I0
I1
I-1
tp56083
sS'studies,showed,that'
p56084
(F1
F0.00014334862385321102
I1
I0
I1
tp56085
sS'are,administered,separately'
p56086
(F1
F0.00014334862385321102
I1
I0
I1
tp56087
sS'half-life,multiple-dose,pharmacokinetic'
p56088
(F1
F0.00014334862385321102
I0
I1
I-1
tp56089
sS'be,resistant,to'
p56090
(F1
F0.00014334862385321102
I1
I0
I1
tp56091
sS'or,than,in'
p56092
(F1
F0.00014334862385321102
I1
I0
I1
tp56093
sS'fold,and,prolonged'
p56094
(F1
F0.00014334862385321102
I1
I0
I1
tp56095
sS'of,therapeutic,doses'
p56096
(F1
F0.00014334862385321102
I0
I1
I-1
tp56097
sS'transporter,as,demonstrated'
p56098
(F1
F0.00014334862385321102
I0
I1
I-1
tp56099
sS'retard,may,enhance'
p56100
(F1
F0.00014334862385321102
I1
I0
I1
tp56101
sS'antithrombin,iii,decreased'
p56102
(F1
F0.00014334862385321102
I0
I1
I-1
tp56103
sS'of,g,per'
p56104
(F1
F0.00014334862385321102
I0
I1
I-1
tp56105
sS'ace,inhibitors,concomitant'
p56106
(F1
F0.00014334862385321102
I0
I1
I-1
tp56107
sS'rats,are,mediated'
p56108
(F1
F0.00014334862385321102
I0
I1
I-1
tp56109
sS'vitro,upon,combination'
p56110
(F1
F0.00014334862385321102
I1
I0
I1
tp56111
sS'serum,slightly,about'
p56112
(F1
F0.00014334862385321102
I1
I0
I1
tp56113
sS'have,increased,the'
p56114
(F1
F0.00014334862385321102
I1
I0
I1
tp56115
sS'coadministered,prescribers,should'
p56116
(F1
F0.00014334862385321102
I0
I1
I-1
tp56117
sS'increase,the,clearance'
p56118
(F0.75
F0.0008600917431192661
I7
I1
I6
tp56119
sS'steady-state,auc,and'
p56120
(F1
F0.00014334862385321102
I1
I0
I1
tp56121
sS'and,may,also'
p56122
(F1
F0.00014334862385321102
I0
I1
I-1
tp56123
sS'camptosar,such,as'
p56124
(F1
F0.00014334862385321102
I1
I0
I1
tp56125
sS'of,the,dose'
p56126
(F0.75
F0.0008600917431192661
I7
I1
I6
tp56127
sS'dose,of,other'
p56128
(F1
F0.00014334862385321102
I1
I0
I1
tp56129
sS'depression,may,occur'
p56130
(F1
F0.00014334862385321102
I1
I0
I1
tp56131
sS'or,given,with'
p56132
(F1
F0.00014334862385321102
I0
I1
I-1
tp56133
sS'and,epoxide,concentrations'
p56134
(F1
F0.00014334862385321102
I0
I1
I-1
tp56135
sS'suggest,that,there'
p56136
(F1
F0.00014334862385321102
I0
I1
I-1
tp56137
sS'the,nursing,infant'
p56138
(F1
F0.00014334862385321102
I0
I1
I-1
tp56139
sS'less,marked,has'
p56140
(F1
F0.00028669724770642203
I0
I2
I-2
tp56141
sS'hemodynamic,and,electrophysiologic'
p56142
(F1
F0.00014334862385321102
I0
I1
I-1
tp56143
sS'test,results,during'
p56144
(F1
F0.00014334862385321102
I0
I1
I-1
tp56145
sS'treated,patients,no'
p56146
(F1
F0.00014334862385321102
I0
I1
I-1
tp56147
sS'the,combination,oral'
p56148
(F1
F0.00014334862385321102
I0
I1
I-1
tp56149
sS'generally,not,recommended'
p56150
(F1
F0.00014334862385321102
I1
I0
I1
tp56151
sS'andtolbutamide,did,not'
p56152
(F1
F0.00014334862385321102
I0
I1
I-1
tp56153
sS'identified,that,would'
p56154
(F1
F0.00014334862385321102
I0
I1
I-1
tp56155
sS'cyp3a4,inducer,with'
p56156
(F1
F0.00014334862385321102
I1
I0
I1
tp56157
sS'agonist,it,is'
p56158
(F1
F0.00014334862385321102
I1
I0
I1
tp56159
sS'however,its,effects'
p56160
(F1
F0.00014334862385321102
I0
I1
I-1
tp56161
sS'of,the,that'
p56162
(F1
F0.00014334862385321102
I1
I0
I1
tp56163
sS'quinolones,may,enhance'
p56164
(F1
F0.00014334862385321102
I1
I0
I1
tp56165
sS'levels,or,increase'
p56166
(F1
F0.00014334862385321102
I1
I0
I1
tp56167
sS'increasing,serum,potassium'
p56168
(F1
F0.00028669724770642203
I2
I0
I2
tp56169
sS'binding,of,in'
p56170
(F1
F0.00028669724770642203
I0
I2
I-2
tp56171
sS'action,of,after'
p56172
(F1
F0.00014334862385321102
I0
I1
I-1
tp56173
sS'electrocardiographic,qt,c'
p56174
(F1
F0.00014334862385321102
I0
I1
I-1
tp56175
sS'time,in,healthy'
p56176
(F1
F0.00014334862385321102
I1
I0
I1
tp56177
sS'is,shortened,in'
p56178
(F1
F0.00014334862385321102
I1
I0
I1
tp56179
sS'into,consideration,when'
p56180
(F1
F0.00014334862385321102
I1
I0
I1
tp56181
sS'brovana,treated,subjects'
p56182
(F1
F0.00028669724770642203
I0
I2
I-2
tp56183
sS'use,and,has'
p56184
(F1
F0.00014334862385321102
I0
I1
I-1
tp56185
sS'hcl,phenytoin,and'
p56186
(F1
F0.00028669724770642203
I2
I0
I2
tp56187
sS'permit,reductions,in'
p56188
(F1
F0.00014334862385321102
I0
I1
I-1
tp56189
sS'but,did,slightly'
p56190
(F1
F0.00014334862385321102
I1
I0
I1
tp56191
sS'mg,kg,body'
p56192
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp56193
sS'additive,effect,with'
p56194
(F1
F0.00014334862385321102
I1
I0
I1
tp56195
sS'the,ht3,zofran'
p56196
(F1
F0.00014334862385321102
I0
I1
I-1
tp56197
sS'resulted,in,no'
p56198
(F1
F0.00057339449541284407
I0
I4
I-4
tp56199
sS'effect,of,orally'
p56200
(F1
F0.00014334862385321102
I0
I1
I-1
tp56201
sS'products,ace,inhibitors'
p56202
(F1
F0.00028669724770642203
I0
I2
I-2
tp56203
sS'compared,to,triple'
p56204
(F1
F0.00014334862385321102
I0
I1
I-1
tp56205
sS'results,raise,the'
p56206
(F1
F0.00014334862385321102
I1
I0
I1
tp56207
sS'concomitantly,renal,function'
p56208
(F1
F0.00014334862385321102
I1
I0
I1
tp56209
sS'equilibration,of,between'
p56210
(F1
F0.00014334862385321102
I0
I1
I-1
tp56211
sS'clinically,significant,degree'
p56212
(F1
F0.00014334862385321102
I0
I1
I-1
tp56213
sS'of,on,diastolic'
p56214
(F1
F0.00014334862385321102
I0
I1
I-1
tp56215
sS'to,be,monitored'
p56216
(F1
F0.00028669724770642203
I2
I0
I2
tp56217
sS'associated,with,may'
p56218
(F1
F0.00014334862385321102
I1
I0
I1
tp56219
sS'not,demonstrated,renal'
p56220
(F1
F0.00014334862385321102
I0
I1
I-1
tp56221
sS'by,was,unaffected'
p56222
(F1
F0.00014334862385321102
I1
I0
I1
tp56223
sS'cytokines,have,been'
p56224
(F1
F0.00014334862385321102
I0
I1
I-1
tp56225
sS'pigeons,did,not'
p56226
(F1
F0.00014334862385321102
I0
I1
I-1
tp56227
sS'been,isolated,reports'
p56228
(F1
F0.00043004587155963305
I3
I0
I3
tp56229
sS'treatment,costs,despite'
p56230
(F1
F0.00014334862385321102
I0
I1
I-1
tp56231
sS'in,dosage,may'
p56232
(F1
F0.00014334862385321102
I0
I1
I-1
tp56233
sS'use,of,vasoconstricting'
p56234
(F1
F0.00014334862385321102
I1
I0
I1
tp56235
sS'prevent,excessive,prolongation'
p56236
(F1
F0.00014334862385321102
I1
I0
I1
tp56237
sS'although,the,interaction'
p56238
(F1
F0.00014334862385321102
I1
I0
I1
tp56239
sS'of,following,a'
p56240
(F1
F0.00014334862385321102
I0
I1
I-1
tp56241
sS'ranitidine,also,has'
p56242
(F1
F0.00014334862385321102
I0
I1
I-1
tp56243
sS'is,antagonized,by'
p56244
(F1
F0.00014334862385321102
I1
I0
I1
tp56245
sS'of,to,be'
p56246
(F1
F0.00014334862385321102
I0
I1
I-1
tp56247
sS'amphotericin,b,has'
p56248
(F1
F0.00014334862385321102
I1
I0
I1
tp56249
sS'of,to,desbutyl'
p56250
(F1
F0.00014334862385321102
I0
I1
I-1
tp56251
sS'and,agents,for'
p56252
(F1
F0.00014334862385321102
I1
I0
I1
tp56253
sS'study,involving,concomitant'
p56254
(F1
F0.00014334862385321102
I0
I1
I-1
tp56255
sS'information,regarding,the'
p56256
(F1
F0.00014334862385321102
I0
I1
I-1
tp56257
sS'iva-sensitive,p-type,channel'
p56258
(F1
F0.00014334862385321102
I0
I1
I-1
tp56259
sS'hepatic,metabolism,produced'
p56260
(F1
F0.00014334862385321102
I1
I0
I1
tp56261
sS'the,range,observed'
p56262
(F1
F0.00014334862385321102
I0
I1
I-1
tp56263
sS'administered,over,the'
p56264
(F1
F0.00014334862385321102
I0
I1
I-1
tp56265
sS'between,and,mg'
p56266
(F1
F0.00014334862385321102
I0
I1
I-1
tp56267
sS'cyp3a4,the,major'
p56268
(F1
F0.00014334862385321102
I1
I0
I1
tp56269
sS'a,mg,daily'
p56270
(F1
F0.00014334862385321102
I1
I0
I1
tp56271
sS'prolong,further,the'
p56272
(F1
F0.00014334862385321102
I1
I0
I1
tp56273
sS'type,diabetes,there'
p56274
(F1
F0.00014334862385321102
I0
I1
I-1
tp56275
sS'viracept,astramorph,kadian'
p56276
(F1
F0.00014334862385321102
I1
I0
I1
tp56277
sS'elicit,their,pharmacological'
p56278
(F1
F0.00014334862385321102
I0
I1
I-1
tp56279
sS'caused,by,gram-negative'
p56280
(F1
F0.00014334862385321102
I0
I1
I-1
tp56281
sS'related,presumably,through'
p56282
(F1
F0.00014334862385321102
I1
I0
I1
tp56283
sS'in,functional,class'
p56284
(F0
F0
I1
I1
I0
tp56285
sS'are,being,treated'
p56286
(F1
F0.00028669724770642203
I2
I0
I2
tp56287
sS'of,substances,that'
p56288
(F1
F0.00057339449541284407
I0
I4
I-4
tp56289
sS'ht3,antagonists,based'
p56290
(F1
F0.00014334862385321102
I1
I0
I1
tp56291
sS'medications,can,interfere'
p56292
(F1
F0.00014334862385321102
I1
I0
I1
tp56293
sS'the,long,and'
p56294
(F1
F0.00014334862385321102
I0
I1
I-1
tp56295
sS'to,onset,of'
p56296
(F1
F0.00014334862385321102
I1
I0
I1
tp56297
sS'administration,regimens,lower'
p56298
(F1
F0.00014334862385321102
I0
I1
I-1
tp56299
sS'of,carbamazepine,equetrotm'
p56300
(F1
F0.00014334862385321102
I1
I0
I1
tp56301
sS'stadol,ns,absorbed'
p56302
(F1
F0.00014334862385321102
I0
I1
I-1
tp56303
sS'same,time,as'
p56304
(F1
F0.00014334862385321102
I1
I0
I1
tp56305
sS'subjects,receiving,the'
p56306
(F1
F0.00014334862385321102
I1
I0
I1
tp56307
sS'or,supplements,should'
p56308
(F1
F0.00014334862385321102
I0
I1
I-1
tp56309
sS'is,also,expected'
p56310
(F1
F0.00028669724770642203
I2
I0
I2
tp56311
sS'day,there,was'
p56312
(F1
F0.00014334862385321102
I1
I0
I1
tp56313
sS'respectively,after,days'
p56314
(F1
F0.00014334862385321102
I1
I0
I1
tp56315
sS'eg,rt-pa,or'
p56316
(F1
F0.00014334862385321102
I0
I1
I-1
tp56317
sS'or,any,known'
p56318
(F1
F0.00028669724770642203
I2
I0
I2
tp56319
sS'difference,between,coadministered'
p56320
(F1
F0.00014334862385321102
I0
I1
I-1
tp56321
sS'by,activation,of'
p56322
(F1
F0.00014334862385321102
I0
I1
I-1
tp56323
sS'by,fold,compared'
p56324
(F1
F0.00014334862385321102
I1
I0
I1
tp56325
sS'of,negative,and'
p56326
(F1
F0.00028669724770642203
I0
I2
I-2
tp56327
sS'the,hypoprothrombinemic,effect'
p56328
(F1
F0.00014334862385321102
I0
I1
I-1
tp56329
sS'vivo,data,show'
p56330
(F1
F0.00014334862385321102
I1
I0
I1
tp56331
sS'above,ng,ml'
p56332
(F1
F0.00014334862385321102
I1
I0
I1
tp56333
sS'drug,interactions,a'
p56334
(F1
F0.00014334862385321102
I0
I1
I-1
tp56335
sS'or,co-administration,enhances'
p56336
(F1
F0.00014334862385321102
I1
I0
I1
tp56337
sS'given,and,hours'
p56338
(F1
F0.00014334862385321102
I0
I1
I-1
tp56339
sS'insulins,ability,to'
p56340
(F1
F0.00014334862385321102
I0
I1
I-1
tp56341
sS'anti-inflammatory,drugs,nsaids'
p56342
(F0
F0
I1
I1
I0
tp56343
sS'and,is,comparable'
p56344
(F1
F0.00014334862385321102
I0
I1
I-1
tp56345
sS'or,as,these'
p56346
(F1
F0.00014334862385321102
I1
I0
I1
tp56347
sS'be,performed,when'
p56348
(F1
F0.00014334862385321102
I1
I0
I1
tp56349
sS'recommended,when,administering'
p56350
(F1
F0.00028669724770642203
I2
I0
I2
tp56351
sS'study,healthy,female'
p56352
(F1
F0.00028669724770642203
I0
I2
I-2
tp56353
sS'patients,receiving,to'
p56354
(F1
F0.00014334862385321102
I1
I0
I1
tp56355
sS'like,does,not'
p56356
(F1
F0.00014334862385321102
I0
I1
I-1
tp56357
sS'be,blunted,by'
p56358
(F1
F0.00028669724770642203
I2
I0
I2
tp56359
sS'tricyclic,and,in'
p56360
(F1
F0.00014334862385321102
I1
I0
I1
tp56361
sS'steady-state,were,not'
p56362
(F1
F0.00014334862385321102
I0
I1
I-1
tp56363
sS'generally,should,not'
p56364
(F1
F0.00071674311926605509
I5
I0
I5
tp56365
sS'amphetamines,can,cause'
p56366
(F1
F0.00014334862385321102
I1
I0
I1
tp56367
sS'occur,at,high'
p56368
(F1
F0.00014334862385321102
I0
I1
I-1
tp56369
sS'with,camptosar,would'
p56370
(F1
F0.00014334862385321102
I1
I0
I1
tp56371
sS'these,agents,with'
p56372
(F1
F0.00028669724770642203
I2
I0
I2
tp56373
sS'same,enzyme,and'
p56374
(F1
F0.00014334862385321102
I0
I1
I-1
tp56375
sS'was,not,considered'
p56376
(F1
F0.00014334862385321102
I0
I1
I-1
tp56377
sS'beta-blocking,agents,a'
p56378
(F1
F0.00014334862385321102
I0
I1
I-1
tp56379
sS'concurrent,with,oral'
p56380
(F1
F0.00014334862385321102
I1
I0
I1
tp56381
sS'interactions,exists,not'
p56382
(F1
F0.00014334862385321102
I0
I1
I-1
tp56383
sS'day,in,eight'
p56384
(F1
F0.00014334862385321102
I1
I0
I1
tp56385
sS'action,of,tracrium'
p56386
(F1
F0.00014334862385321102
I1
I0
I1
tp56387
sS'may,raise,serum'
p56388
(F1
F0.00014334862385321102
I1
I0
I1
tp56389
sS'necessary,the,dosage'
p56390
(F1
F0.00014334862385321102
I1
I0
I1
tp56391
sS'as,have,not'
p56392
(F1
F0.00014334862385321102
I0
I1
I-1
tp56393
sS'the,oral,contraceptive'
p56394
(F1
F0.00014334862385321102
I0
I1
I-1
tp56395
sS'here,demonstrate,that'
p56396
(F1
F0.00014334862385321102
I0
I1
I-1
tp56397
sS'it,is,however'
p56398
(F1
F0.00014334862385321102
I1
I0
I1
tp56399
sS'carbamazepine,steady-state,trough'
p56400
(F1
F0.00014334862385321102
I0
I1
I-1
tp56401
sS'been,fully,characterized'
p56402
(F1
F0.00014334862385321102
I1
I0
I1
tp56403
sS'fluoxetine,ocs,macrolide'
p56404
(F1
F0.00014334862385321102
I0
I1
I-1
tp56405
sS'the,in,vitro'
p56406
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp56407
sS'msec,was,with'
p56408
(F1
F0.00014334862385321102
I1
I0
I1
tp56409
sS'on,gm,day'
p56410
(F1
F0.00014334862385321102
I1
I0
I1
tp56411
sS'objective,was,to'
p56412
(F1
F0.00028669724770642203
I0
I2
I-2
tp56413
sS'the,insp,mediated'
p56414
(F1
F0.00014334862385321102
I0
I1
I-1
tp56415
sS'coadministration,with,tambocor'
p56416
(F1
F0.00014334862385321102
I1
I0
I1
tp56417
sS'heart,disease,congestive'
p56418
(F1
F0.00014334862385321102
I1
I0
I1
tp56419
sS'while,in,the'
p56420
(F1
F0.00014334862385321102
I0
I1
I-1
tp56421
sS'on,possible,interactions'
p56422
(F1
F0.00014334862385321102
I1
I0
I1
tp56423
sS'may,also,have'
p56424
(F0
F0
I1
I1
I0
tp56425
sS'both,with,and'
p56426
(F1
F0.00014334862385321102
I0
I1
I-1
tp56427
sS'also,refer,to'
p56428
(F1
F0.00014334862385321102
I0
I1
I-1
tp56429
sS'suppression,by,of'
p56430
(F1
F0.00014334862385321102
I1
I0
I1
tp56431
sS'the,slow,phasic'
p56432
(F1
F0.00014334862385321102
I0
I1
I-1
tp56433
sS'human,studies,have'
p56434
(F1
F0.00014334862385321102
I0
I1
I-1
tp56435
sS'potential,prolonged,concurrent'
p56436
(F1
F0.00014334862385321102
I0
I1
I-1
tp56437
sS'agents,for,the'
p56438
(F1
F0.00014334862385321102
I0
I1
I-1
tp56439
sS'clearance,values,in'
p56440
(F1
F0.00014334862385321102
I0
I1
I-1
tp56441
sS'higher,serum,exposure'
p56442
(F1
F0.00014334862385321102
I1
I0
I1
tp56443
sS'receiving,a,cyp3a4'
p56444
(F1
F0.00014334862385321102
I1
I0
I1
tp56445
sS'rifampin,rifampin,increases'
p56446
(F1
F0.00014334862385321102
I1
I0
I1
tp56447
sS'dose,reduction,when'
p56448
(F1
F0.00014334862385321102
I1
I0
I1
tp56449
sS'like,or,and'
p56450
(F1
F0.00043004587155963305
I3
I0
I3
tp56451
sS'for,drug-induced,renal'
p56452
(F1
F0.00014334862385321102
I0
I1
I-1
tp56453
sS'patients,receiving,therapy'
p56454
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp56455
sS'cyp3a4,and,cyp3a5'
p56456
(F1
F0.00014334862385321102
I0
I1
I-1
tp56457
sS'monitored,frequently,if'
p56458
(F1
F0.00043004587155963305
I3
I0
I3
tp56459
sS'increased,both,in'
p56460
(F1
F0.00014334862385321102
I0
I1
I-1
tp56461
sS'epidural,may,prolong'
p56462
(F1
F0.00014334862385321102
I1
I0
I1
tp56463
sS'of,cyp2d6,was'
p56464
(F1
F0.00014334862385321102
I0
I1
I-1
tp56465
sS'estrogens,including,oral'
p56466
(F1
F0.00014334862385321102
I1
I0
I1
tp56467
sS'concentrations,decreases,the'
p56468
(F1
F0.00014334862385321102
I1
I0
I1
tp56469
sS'lysing,human,red'
p56470
(F1
F0.00014334862385321102
I0
I1
I-1
tp56471
sS'elevation,in,fluoride'
p56472
(F1
F0.00014334862385321102
I0
I1
I-1
tp56473
sS'manifested,by,alt'
p56474
(F1
F0.00014334862385321102
I0
I1
I-1
tp56475
sS'function,or,in'
p56476
(F1
F0.00014334862385321102
I0
I1
I-1
tp56477
sS'not,antagonize,the'
p56478
(F1
F0.00014334862385321102
I1
I0
I1
tp56479
sS'treat,strongyloidiasis,during'
p56480
(F1
F0.00014334862385321102
I1
I0
I1
tp56481
sS'c9,respectively,have'
p56482
(F1
F0.00014334862385321102
I0
I1
I-1
tp56483
sS'a,patient,receiving'
p56484
(F1
F0.00057339449541284407
I4
I0
I4
tp56485
sS'inn,when,coadministered'
p56486
(F1
F0.00014334862385321102
I0
I1
I-1
tp56487
sS'a,medicine,such'
p56488
(F1
F0.00014334862385321102
I0
I1
I-1
tp56489
sS'plasma,and,brain'
p56490
(F1
F0.00014334862385321102
I1
I0
I1
tp56491
sS'inducer,of,cytochrome'
p56492
(F1
F0.00014334862385321102
I1
I0
I1
tp56493
sS'do,not,influence'
p56494
(F1
F0.00014334862385321102
I0
I1
I-1
tp56495
sS'cholestyramine,cholestyramine,has'
p56496
(F1
F0.00043004587155963305
I3
I0
I3
tp56497
sS'action,of,oleate'
p56498
(F1
F0.00014334862385321102
I0
I1
I-1
tp56499
sS'two-way,interaction,between'
p56500
(F1
F0.00014334862385321102
I1
I0
I1
tp56501
sS'are,limited,in'
p56502
(F1
F0.00014334862385321102
I1
I0
I1
tp56503
sS'inhibitors,also,referred'
p56504
(F1
F0.00014334862385321102
I0
I1
I-1
tp56505
sS'd6,may,require'
p56506
(F1
F0.0008600917431192661
I0
I6
I-6
tp56507
sS'racemic,exposure,was'
p56508
(F1
F0.00014334862385321102
I1
I0
I1
tp56509
sS'well-controlled,studies,caused'
p56510
(F1
F0.00014334862385321102
I0
I1
I-1
tp56511
sS'subjects,treated,with'
p56512
(F1
F0.00028669724770642203
I0
I2
I-2
tp56513
sS'administered,with,oral'
p56514
(F1
F0.00028669724770642203
I2
I0
I2
tp56515
sS'induction,and,displacement'
p56516
(F1
F0.00014334862385321102
I1
I0
I1
tp56517
sS'is,going,to'
p56518
(F1
F0.00071674311926605509
I0
I5
I-5
tp56519
sS'vioxx,and,have'
p56520
(F1
F0.00014334862385321102
I0
I1
I-1
tp56521
sS'for,days,decreased'
p56522
(F1
F0.00014334862385321102
I1
I0
I1
tp56523
sS'the,dissolution,rate'
p56524
(F1
F0.00014334862385321102
I0
I1
I-1
tp56525
sS'blockers,in,the'
p56526
(F1
F0.00014334862385321102
I0
I1
I-1
tp56527
sS'like,other,nsaids'
p56528
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp56529
sS'increased,intracranial,pressure'
p56530
(F1
F0.00014334862385321102
I1
I0
I1
tp56531
sS'mg,qid,did'
p56532
(F1
F0.00014334862385321102
I0
I1
I-1
tp56533
sS'increases,the,metabolism'
p56534
(F1
F0.00014334862385321102
I1
I0
I1
tp56535
sS'coadministration,of,bextra'
p56536
(F1
F0.00014334862385321102
I0
I1
I-1
tp56537
sS'the,single,dose'
p56538
(F1
F0.00014334862385321102
I0
I1
I-1
tp56539
sS'receiving,daily,doses'
p56540
(F1
F0.00014334862385321102
I0
I1
I-1
tp56541
sS'of,the,side'
p56542
(F1
F0.00028669724770642203
I0
I2
I-2
tp56543
sS'suggests,that,may'
p56544
(F1
F0.00014334862385321102
I1
I0
I1
tp56545
sS'alone,versus,mg'
p56546
(F1
F0.00014334862385321102
I0
I1
I-1
tp56547
sS'of,the,divided'
p56548
(F1
F0.00014334862385321102
I1
I0
I1
tp56549
sS'a,mg,b'
p56550
(F1
F0.00014334862385321102
I1
I0
I1
tp56551
sS'to,have,occurred'
p56552
(F1
F0.00014334862385321102
I1
I0
I1
tp56553
sS'conducted,with,alphagan'
p56554
(F1
F0.00014334862385321102
I1
I0
I1
tp56555
sS'and,leading,to'
p56556
(F0
F0
I1
I1
I0
tp56557
sS'decreased,the,auc'
p56558
(F1
F0.00071674311926605509
I5
I0
I5
tp56559
sS'or,in,combination'
p56560
(F0.81818181818181823
F0.0012901376146788992
I1
I10
I-9
tp56561
sS'days,of,treatment'
p56562
(F1
F0.00014334862385321102
I0
I1
I-1
tp56563
sS'clinical,trials,concomitant'
p56564
(F1
F0.00014334862385321102
I0
I1
I-1
tp56565
sS'dose,of,inspra'
p56566
(F1
F0.00014334862385321102
I1
I0
I1
tp56567
sS'in,mac,was'
p56568
(F1
F0.00014334862385321102
I0
I1
I-1
tp56569
sS'patients,receiving,maintenance'
p56570
(F1
F0.00014334862385321102
I0
I1
I-1
tp56571
sS'sparing,pharmacological,doses'
p56572
(F1
F0.00014334862385321102
I0
I1
I-1
tp56573
sS'ventricular,fibrillation,when'
p56574
(F1
F0.00014334862385321102
I1
I0
I1
tp56575
sS'of,stadol,ns'
p56576
(F0
F0
I2
I2
I0
tp56577
sS'azole,antifungals,grapefruit'
p56578
(F1
F0.00014334862385321102
I1
I0
I1
tp56579
sS'in,a,small'
p56580
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp56581
sS'of,certain,with'
p56582
(F1
F0.00014334862385321102
I0
I1
I-1
tp56583
sS'with,acamprosate,concomitantly'
p56584
(F1
F0.00014334862385321102
I0
I1
I-1
tp56585
sS'that,itraconazole,enhances'
p56586
(F1
F0.00014334862385321102
I1
I0
I1
tp56587
sS'of,precedex,on'
p56588
(F1
F0.00014334862385321102
I1
I0
I1
tp56589
sS'the,clinical,basis'
p56590
(F1
F0.00014334862385321102
I0
I1
I-1
tp56591
sS'authors,examined,the'
p56592
(F1
F0.00014334862385321102
I0
I1
I-1
tp56593
sS'nephrotoxic,such,as'
p56594
(F1
F0.00014334862385321102
I1
I0
I1
tp56595
sS'elimination,of,these'
p56596
(F1
F0.00014334862385321102
I1
I0
I1
tp56597
sS'controlled,trial,that'
p56598
(F1
F0.00014334862385321102
I0
I1
I-1
tp56599
sS'and,a,single'
p56600
(F1
F0.00014334862385321102
I1
I0
I1
tp56601
sS'either,or,compounds'
p56602
(F1
F0.00014334862385321102
I0
I1
I-1
tp56603
sS'of,other,narcotic'
p56604
(F1
F0.00014334862385321102
I1
I0
I1
tp56605
sS'of,trileptal,on'
p56606
(F1
F0.00014334862385321102
I0
I1
I-1
tp56607
sS'increased,by,concomitant'
p56608
(F1
F0.00014334862385321102
I1
I0
I1
tp56609
sS'may,require,close'
p56610
(F1
F0.00014334862385321102
I1
I0
I1
tp56611
sS'doses,mg,qd'
p56612
(F1
F0.00014334862385321102
I1
I0
I1
tp56613
sS'to,temporarily,suspending'
p56614
(F1
F0.00014334862385321102
I1
I0
I1
tp56615
sS'tolerance,in,patients'
p56616
(F1
F0.00014334862385321102
I1
I0
I1
tp56617
sS'cancidas,is,co-administered'
p56618
(F1
F0.00014334862385321102
I1
I0
I1
tp56619
sS'and,increased,blood'
p56620
(F1
F0.00014334862385321102
I0
I1
I-1
tp56621
sS'of,may,interfere'
p56622
(F0
F0
I1
I1
I0
tp56623
sS'of,supplemental,folic'
p56624
(F1
F0.00014334862385321102
I0
I1
I-1
tp56625
sS'complicated,or,uncomplicated'
p56626
(F1
F0.00014334862385321102
I0
I1
I-1
tp56627
sS'administered,could,theoretically'
p56628
(F1
F0.00014334862385321102
I0
I1
I-1
tp56629
sS'compared,with,in'
p56630
(F1
F0.00028669724770642203
I0
I2
I-2
tp56631
sS'sirolimus,mammalian,target'
p56632
(F1
F0.00014334862385321102
I0
I1
I-1
tp56633
sS'glutamate,mglur,agonists'
p56634
(F1
F0.00014334862385321102
I0
I1
I-1
tp56635
sS'concentrations,has,also'
p56636
(F1
F0.00014334862385321102
I0
I1
I-1
tp56637
sS'rats,are,not'
p56638
(F1
F0.00014334862385321102
I0
I1
I-1
tp56639
sS'addition,does,not'
p56640
(F1
F0.00014334862385321102
I0
I1
I-1
tp56641
sS'in,in,vivo'
p56642
(F1
F0.00014334862385321102
I0
I1
I-1
tp56643
sS'alterations,caused,by'
p56644
(F1
F0.00014334862385321102
I1
I0
I1
tp56645
sS'examining,mg,and'
p56646
(F1
F0.00014334862385321102
I1
I0
I1
tp56647
sS'pseudomonas,aeruginosa,serotype'
p56648
(F1
F0.00014334862385321102
I0
I1
I-1
tp56649
sS'particularly,of,the'
p56650
(F1
F0.00014334862385321102
I1
I0
I1
tp56651
sS'drugs,aripiprazole,is'
p56652
(F1
F0.00014334862385321102
I0
I1
I-1
tp56653
sS'agents,benzodiazepines,gi'
p56654
(F1
F0.00014334862385321102
I1
I0
I1
tp56655
sS'use,foradil,fumarate'
p56656
(F1
F0.00014334862385321102
I0
I1
I-1
tp56657
sS'co-administration,of,another'
p56658
(F1
F0.00014334862385321102
I0
I1
I-1
tp56659
sS'with,co-administration,of'
p56660
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp56661
sS'observed,with,beta-receptor'
p56662
(F1
F0.00014334862385321102
I0
I1
I-1
tp56663
sS'retinyl,acetate,at'
p56664
(F1
F0.00014334862385321102
I1
I0
I1
tp56665
sS'but,decreased,the'
p56666
(F1
F0.00014334862385321102
I1
I0
I1
tp56667
sS'were,in,the'
p56668
(F0
F0
I1
I1
I0
tp56669
sS'agonist,antagonist,may'
p56670
(F1
F0.00014334862385321102
I0
I1
I-1
tp56671
sS'hypotension,caused,by'
p56672
(F1
F0.00014334862385321102
I1
I0
I1
tp56673
sS'clonidine,concomitant,administration'
p56674
(F1
F0.00014334862385321102
I1
I0
I1
tp56675
sS'function,who,are'
p56676
(F1
F0.00028669724770642203
I2
I0
I2
tp56677
sS'single,mg,subcutaneous'
p56678
(F1
F0.00014334862385321102
I0
I1
I-1
tp56679
sS'qd,was,co-administered'
p56680
(F1
F0.00014334862385321102
I0
I1
I-1
tp56681
sS'was,about,a'
p56682
(F1
F0.00014334862385321102
I1
I0
I1
tp56683
sS'depleting,added,to'
p56684
(F1
F0.00014334862385321102
I0
I1
I-1
tp56685
sS'mild,but,definite'
p56686
(F1
F0.00014334862385321102
I0
I1
I-1
tp56687
sS'concurrently,with,other'
p56688
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp56689
sS'to,compared,to'
p56690
(F1
F0.00014334862385321102
I1
I0
I1
tp56691
sS'anion,exchange,it'
p56692
(F1
F0.00014334862385321102
I0
I1
I-1
tp56693
sS'with,derivatives,k'
p56694
(F1
F0.00014334862385321102
I0
I1
I-1
tp56695
sS'natriuresis,is,not'
p56696
(F1
F0.00014334862385321102
I1
I0
I1
tp56697
sS'both,agents,did'
p56698
(F1
F0.00014334862385321102
I0
I1
I-1
tp56699
sS'and,may,antagonize'
p56700
(F1
F0.00014334862385321102
I1
I0
I1
tp56701
sS'indicate,a,significant'
p56702
(F1
F0.00014334862385321102
I1
I0
I1
tp56703
sS'immediate,and,extended'
p56704
(F1
F0.00014334862385321102
I1
I0
I1
tp56705
sS'cardiac,autonomic,irritability'
p56706
(F1
F0.00014334862385321102
I1
I0
I1
tp56707
sS'direct,cardiac,stimulants'
p56708
(F1
F0.00014334862385321102
I1
I0
I1
tp56709
sS'lethargy,fever,tremulousness'
p56710
(F1
F0.00014334862385321102
I1
I0
I1
tp56711
sS'the,discontinuance,of'
p56712
(F1
F0.00014334862385321102
I1
I0
I1
tp56713
sS'combination,hormonal,causing'
p56714
(F1
F0.00014334862385321102
I1
I0
I1
tp56715
sS'following,macrolide,antibiotics'
p56716
(F1
F0.00014334862385321102
I1
I0
I1
tp56717
sS'were,given,weekly'
p56718
(F1
F0.00014334862385321102
I0
I1
I-1
tp56719
sS'pharmacokinetics,of,and'
p56720
(F1
F0.0011467889908256881
I0
I8
I-8
tp56721
sS'drug,interaction,for'
p56722
(F1
F0.00014334862385321102
I1
I0
I1
tp56723
sS'system,or,the'
p56724
(F1
F0.00014334862385321102
I0
I1
I-1
tp56725
sS'is,a,weak'
p56726
(F1
F0.00014334862385321102
I1
I0
I1
tp56727
sS'aetiopathogenic--,for,example'
p56728
(F1
F0.00014334862385321102
I0
I1
I-1
tp56729
sS'fold,by,coadministration'
p56730
(F1
F0.00014334862385321102
I1
I0
I1
tp56731
sS'levels,and,there'
p56732
(F1
F0.00014334862385321102
I1
I0
I1
tp56733
sS'weight,loss,compared'
p56734
(F1
F0.00014334862385321102
I1
I0
I1
tp56735
sS'treatment,regimen,includes'
p56736
(F1
F0.00014334862385321102
I1
I0
I1
tp56737
sS'with,amphotericin,b'
p56738
(F1
F0.00028669724770642203
I2
I0
I2
tp56739
sS'exercised,when,taking'
p56740
(F1
F0.00014334862385321102
I0
I1
I-1
tp56741
sS'level,to,alert'
p56742
(F1
F0.00014334862385321102
I1
I0
I1
tp56743
sS'orally,disintegrating,tablet'
p56744
(F1
F0.00014334862385321102
I1
I0
I1
tp56745
sS'known,microsomal,enzyme'
p56746
(F1
F0.00014334862385321102
I1
I0
I1
tp56747
sS'significant,inhibition,of'
p56748
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp56749
sS'conclusion,that,it'
p56750
(F1
F0.00014334862385321102
I1
I0
I1
tp56751
sS'inomax,has,been'
p56752
(F1
F0.00014334862385321102
I0
I1
I-1
tp56753
sS'and,mac,minimum'
p56754
(F1
F0.00014334862385321102
I1
I0
I1
tp56755
sS'when,pletal,is'
p56756
(F1
F0.00014334862385321102
I1
I0
I1
tp56757
sS'theophylline,in,three'
p56758
(F1
F0.00014334862385321102
I0
I1
I-1
tp56759
sS'increases,the,prothrombin'
p56760
(F1
F0.00014334862385321102
I0
I1
I-1
tp56761
sS'a,a,cyp3a4'
p56762
(F1
F0.00014334862385321102
I1
I0
I1
tp56763
sS'and,mu,systems'
p56764
(F1
F0.00014334862385321102
I0
I1
I-1
tp56765
sS'established,that,interferes'
p56766
(F1
F0.00014334862385321102
I1
I0
I1
tp56767
sS'from,a,stock'
p56768
(F1
F0.00014334862385321102
I0
I1
I-1
tp56769
sS'h,s,concomitantly'
p56770
(F1
F0.00014334862385321102
I1
I0
I1
tp56771
sS'and,reached,after'
p56772
(F1
F0.00014334862385321102
I1
I0
I1
tp56773
sS'cmax,vs,and'
p56774
(F1
F0.00014334862385321102
I0
I1
I-1
tp56775
sS'and,foods,fortified'
p56776
(F1
F0.00014334862385321102
I1
I0
I1
tp56777
sS'an,inhibition,of'
p56778
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp56779
sS'the,clinical,trials'
p56780
(F1
F0.00014334862385321102
I1
I0
I1
tp56781
sS'cmax,was,observed'
p56782
(F1
F0.00014334862385321102
I0
I1
I-1
tp56783
sS'were,each,found'
p56784
(F1
F0.00014334862385321102
I0
I1
I-1
tp56785
sS'of,the,have'
p56786
(F1
F0.00014334862385321102
I1
I0
I1
tp56787
sS'of,transdermal,with'
p56788
(F1
F0.00014334862385321102
I1
I0
I1
tp56789
sS'in,the,excretion'
p56790
(F1
F0.00014334862385321102
I1
I0
I1
tp56791
sS'celebrex,can,be'
p56792
(F1
F0.00014334862385321102
I1
I0
I1
tp56793
sS'foods,fortified,with'
p56794
(F1
F0.00014334862385321102
I1
I0
I1
tp56795
sS'duration,of,its'
p56796
(F1
F0.00014334862385321102
I1
I0
I1
tp56797
sS'with,axert,and'
p56798
(F1
F0.00014334862385321102
I1
I0
I1
tp56799
sS'when,nsaids,and'
p56800
(F1
F0.00028669724770642203
I2
I0
I2
tp56801
sS'hydrochloride,in,combination'
p56802
(F1
F0.00014334862385321102
I1
I0
I1
tp56803
sS'should,be,continued'
p56804
(F1
F0.00014334862385321102
I1
I0
I1
tp56805
sS'elevated,creatinine,despite'
p56806
(F1
F0.00014334862385321102
I0
I1
I-1
tp56807
sS'increases,in,heart'
p56808
(F1
F0.00028669724770642203
I2
I0
I2
tp56809
sS'ieg,response,induced'
p56810
(F1
F0.00014334862385321102
I0
I1
I-1
tp56811
sS'intracellular,phosphorylation,of'
p56812
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp56813
sS'and,incoordination,have'
p56814
(F1
F0.00014334862385321102
I1
I0
I1
tp56815
sS'yeast,and,for'
p56816
(F1
F0.00014334862385321102
I0
I1
I-1
tp56817
sS'methotrexate,there,has'
p56818
(F1
F0.00014334862385321102
I1
I0
I1
tp56819
sS'stimulants,and,their'
p56820
(F1
F0.00014334862385321102
I1
I0
I1
tp56821
sS'or,hepatotoxic,effects'
p56822
(F1
F0.00014334862385321102
I1
I0
I1
tp56823
sS'to,be,terminated'
p56824
(F1
F0.00014334862385321102
I1
I0
I1
tp56825
sS'blockers,presumably,because'
p56826
(F1
F0.00014334862385321102
I1
I0
I1
tp56827
sS'channel,blocking,agents'
p56828
(F1
F0.00028669724770642203
I0
I2
I-2
tp56829
sS'controlled,studies,failed'
p56830
(F1
F0.00014334862385321102
I0
I1
I-1
tp56831
sS'synergistic,activity,if'
p56832
(F1
F0.00014334862385321102
I1
I0
I1
tp56833
sS'and,micrograms,ml'
p56834
(F1
F0.00028669724770642203
I0
I2
I-2
tp56835
sS'elevation,of,plasma'
p56836
(F1
F0.00071674311926605509
I5
I0
I5
tp56837
sS'may,inhibit,both'
p56838
(F1
F0.00043004587155963305
I3
I0
I3
tp56839
sS'effects,can,be'
p56840
(F1
F0.00014334862385321102
I1
I0
I1
tp56841
sS'patients,receiving,in'
p56842
(F1
F0.00014334862385321102
I1
I0
I1
tp56843
sS'patients,anaesthetised,with'
p56844
(F1
F0.00014334862385321102
I1
I0
I1
tp56845
sS'not,metabolized,by'
p56846
(F1
F0.00028669724770642203
I0
I2
I-2
tp56847
sS'of,heroin-related,deaths'
p56848
(F1
F0.00014334862385321102
I1
I0
I1
tp56849
sS'or,ototoxicity,and'
p56850
(F1
F0.00014334862385321102
I0
I1
I-1
tp56851
sS'the,initial,dosage'
p56852
(F1
F0.00014334862385321102
I1
I0
I1
tp56853
sS'moreover,additional,interaction'
p56854
(F1
F0.00014334862385321102
I0
I1
I-1
tp56855
sS'variables,of,compared'
p56856
(F1
F0.00014334862385321102
I0
I1
I-1
tp56857
sS'symbol,copying,test'
p56858
(F1
F0.00014334862385321102
I1
I0
I1
tp56859
sS'statistically,significant,increase'
p56860
(F1
F0.00043004587155963305
I3
I0
I3
tp56861
sS'to,ace,inhibitors'
p56862
(F1
F0.00014334862385321102
I1
I0
I1
tp56863
sS'the,first,study'
p56864
(F0
F0
I1
I1
I0
tp56865
sS'no,interactions,with'
p56866
(F1
F0.00014334862385321102
I0
I1
I-1
tp56867
sS'cyp2c9,substrate,trough'
p56868
(F1
F0.00014334862385321102
I1
I0
I1
tp56869
sS'electrocardiographic,parameters,including'
p56870
(F1
F0.00014334862385321102
I0
I1
I-1
tp56871
sS'hiv-nhl,the,authors'
p56872
(F1
F0.00014334862385321102
I0
I1
I-1
tp56873
sS'in,the,rat'
p56874
(F1
F0.00014334862385321102
I1
I0
I1
tp56875
sS'co-administered,with,tikosyn'
p56876
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp56877
sS'rat,stomach,to'
p56878
(F1
F0.00014334862385321102
I1
I0
I1
tp56879
sS'was,increased,about'
p56880
(F1
F0.00014334862385321102
I1
I0
I1
tp56881
sS'agents,and,some'
p56882
(F1
F0.00014334862385321102
I0
I1
I-1
tp56883
sS'stimulation,by,cerulein--an'
p56884
(F1
F0.00014334862385321102
I0
I1
I-1
tp56885
sS'although,the,interactions'
p56886
(F1
F0.00014334862385321102
I1
I0
I1
tp56887
sS'the,potential,nephrotoxicity'
p56888
(F1
F0.00014334862385321102
I0
I1
I-1
tp56889
sS'we,conclude,that'
p56890
(F1
F0.00028669724770642203
I2
I0
I2
tp56891
sS'additive,sedative,effects'
p56892
(F1
F0.00014334862385321102
I1
I0
I1
tp56893
sS'shown,to,exhibit'
p56894
(F1
F0.00014334862385321102
I0
I1
I-1
tp56895
sS'anti-inflammatory,agent,can'
p56896
(F1
F0.00028669724770642203
I2
I0
I2
tp56897
sS'tracleer,is,initiated'
p56898
(F1
F0.00014334862385321102
I1
I0
I1
tp56899
sS'anticoagulants,flurbiprofen,like'
p56900
(F1
F0.00014334862385321102
I1
I0
I1
tp56901
sS'result,in,increased'
p56902
(F0.25
F0.00028669724770642203
I5
I3
I2
tp56903
sS'antagonized,by,beta-adrenergic'
p56904
(F1
F0.00014334862385321102
I1
I0
I1
tp56905
sS'median,follow-up,of'
p56906
(F1
F0.00014334862385321102
I0
I1
I-1
tp56907
sS'in,tumor,cells'
p56908
(F1
F0.00014334862385321102
I0
I1
I-1
tp56909
sS'of,that,from'
p56910
(F1
F0.00014334862385321102
I0
I1
I-1
tp56911
sS'in,treatment-naive,patients'
p56912
(F1
F0.00014334862385321102
I0
I1
I-1
tp56913
sS'antihypertensive,and,the'
p56914
(F1
F0.00014334862385321102
I1
I0
I1
tp56915
sS'was,significantly,higher'
p56916
(F1
F0.00028669724770642203
I2
I0
I2
tp56917
sS'clinitest,tablets,but'
p56918
(F1
F0.00014334862385321102
I0
I1
I-1
tp56919
sS'results,from,human'
p56920
(F1
F0.00014334862385321102
I0
I1
I-1
tp56921
sS'of,two,potentially'
p56922
(F1
F0.00014334862385321102
I1
I0
I1
tp56923
sS'of,using,bromocriptine'
p56924
(F1
F0.00014334862385321102
I1
I0
I1
tp56925
sS'stomach,acidity,does'
p56926
(F1
F0.00014334862385321102
I0
I1
I-1
tp56927
sS'leading,to,elevated'
p56928
(F1
F0.00028669724770642203
I2
I0
I2
tp56929
sS'significantly,decreases,clearance'
p56930
(F1
F0.00014334862385321102
I1
I0
I1
tp56931
sS'modest,increases,about'
p56932
(F1
F0.00014334862385321102
I1
I0
I1
tp56933
sS'amiodarone,is,metabolized'
p56934
(F1
F0.00014334862385321102
I0
I1
I-1
tp56935
sS'when,the,patient'
p56936
(F1
F0.00014334862385321102
I0
I1
I-1
tp56937
sS'but,regular,users'
p56938
(F1
F0.00014334862385321102
I0
I1
I-1
tp56939
sS'brevibloc,were,concomitantly'
p56940
(F1
F0.00028669724770642203
I2
I0
I2
tp56941
sS'myocardial,injury,including'
p56942
(F1
F0.00014334862385321102
I1
I0
I1
tp56943
sS'to,cause,the'
p56944
(F1
F0.00014334862385321102
I1
I0
I1
tp56945
sS'be,prescribed,with'
p56946
(F1
F0.00014334862385321102
I1
I0
I1
tp56947
sS'kg,hours,apart'
p56948
(F1
F0.00014334862385321102
I1
I0
I1
tp56949
sS'counts,in,comparison'
p56950
(F1
F0.00014334862385321102
I1
I0
I1
tp56951
sS'change,of,less'
p56952
(F1
F0.00014334862385321102
I1
I0
I1
tp56953
sS'with,demonstrated,no'
p56954
(F1
F0.00014334862385321102
I0
I1
I-1
tp56955
sS'that,the,toxicity'
p56956
(F1
F0.00014334862385321102
I1
I0
I1
tp56957
sS'are,tricky,using'
p56958
(F1
F0.00014334862385321102
I0
I1
I-1
tp56959
sS'cns,stimulation,is'
p56960
(F1
F0.00028669724770642203
I2
I0
I2
tp56961
sS'been,established,that'
p56962
(F1
F0.00028669724770642203
I2
I0
I2
tp56963
sS'efficient,substrate,for'
p56964
(F1
F0.00014334862385321102
I0
I1
I-1
tp56965
sS'oral,physiological,supplementation'
p56966
(F1
F0.00014334862385321102
I0
I1
I-1
tp56967
sS'of,p-glycoprotein,loop'
p56968
(F1
F0.00014334862385321102
I0
I1
I-1
tp56969
sS'of,averaged,s'
p56970
(F1
F0.00014334862385321102
I1
I0
I1
tp56971
sS'the,higher,end'
p56972
(F1
F0.00014334862385321102
I0
I1
I-1
tp56973
sS'are,reduced,when'
p56974
(F1
F0.00014334862385321102
I1
I0
I1
tp56975
sS'other,agents,dynamic'
p56976
(F1
F0.00014334862385321102
I0
I1
I-1
tp56977
sS'its,breakdown,products'
p56978
(F1
F0.00014334862385321102
I1
I0
I1
tp56979
sS'copaxone,and,other'
p56980
(F1
F0.00014334862385321102
I0
I1
I-1
tp56981
sS'reflected,in,urinary'
p56982
(F1
F0.00014334862385321102
I1
I0
I1
tp56983
sS'rats,prepared,by'
p56984
(F1
F0.00014334862385321102
I0
I1
I-1
tp56985
sS'ml,and,micrograms'
p56986
(F1
F0.00014334862385321102
I0
I1
I-1
tp56987
sS'in,diabetic,patients'
p56988
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp56989
sS'effect,of,each'
p56990
(F1
F0.00014334862385321102
I1
I0
I1
tp56991
sS'be,impaired,when'
p56992
(F1
F0.00014334862385321102
I0
I1
I-1
tp56993
sS'from,the,high-dose'
p56994
(F1
F0.00014334862385321102
I1
I0
I1
tp56995
sS'route,of,including'
p56996
(F1
F0.00014334862385321102
I1
I0
I1
tp56997
sS'bid,the,cmax'
p56998
(F1
F0.00014334862385321102
I1
I0
I1
tp56999
sS'effect,of,various'
p57000
(F0
F0
I1
I1
I0
tp57001
sS'for,most,of'
p57002
(F1
F0.00014334862385321102
I0
I1
I-1
tp57003
sS'treated,with,systemically-administered'
p57004
(F1
F0.00014334862385321102
I1
I0
I1
tp57005
sS'cytochrome,p450,cyp450'
p57006
(F1
F0.00014334862385321102
I0
I1
I-1
tp57007
sS'other,have,been'
p57008
(F1
F0.00014334862385321102
I1
I0
I1
tp57009
sS'agonist,antagonist,eg'
p57010
(F1
F0.00014334862385321102
I1
I0
I1
tp57011
sS'due,to,release'
p57012
(F1
F0.00014334862385321102
I1
I0
I1
tp57013
sS'mc,has,a'
p57014
(F1
F0.00014334862385321102
I0
I1
I-1
tp57015
sS'not,increase,the'
p57016
(F1
F0.00043004587155963305
I0
I3
I-3
tp57017
sS'subcutaneous,injections,of'
p57018
(F1
F0.00014334862385321102
I0
I1
I-1
tp57019
sS'that,sensitize,the'
p57020
(F1
F0.00014334862385321102
I1
I0
I1
tp57021
sS'and,o-desacetylrifabutin,and'
p57022
(F1
F0.00014334862385321102
I1
I0
I1
tp57023
sS'form,chelates,with'
p57024
(F1
F0.00028669724770642203
I0
I2
I-2
tp57025
sS'clinical,trials,were'
p57026
(F1
F0.00028669724770642203
I0
I2
I-2
tp57027
sS'the,photosensitivity,reaction'
p57028
(F1
F0.00014334862385321102
I1
I0
I1
tp57029
sS'increase,sensitivity,to'
p57030
(F1
F0.00014334862385321102
I1
I0
I1
tp57031
sS'oral,containing,mcg'
p57032
(F1
F0.00014334862385321102
I1
I0
I1
tp57033
sS'objective,to,evaluate'
p57034
(F1
F0.00014334862385321102
I0
I1
I-1
tp57035
sS'and,a,do'
p57036
(F1
F0.00014334862385321102
I1
I0
I1
tp57037
sS'mode,of,toxic'
p57038
(F1
F0.00014334862385321102
I0
I1
I-1
tp57039
sS'out,to,study'
p57040
(F1
F0.00014334862385321102
I0
I1
I-1
tp57041
sS'tcas,decrease,the'
p57042
(F1
F0.00014334862385321102
I1
I0
I1
tp57043
sS'by,containing,or'
p57044
(F1
F0.00014334862385321102
I1
I0
I1
tp57045
sS'approximately,given,to'
p57046
(F1
F0.00014334862385321102
I1
I0
I1
tp57047
sS'inhibitors,protease,inhibitors'
p57048
(F1
F0.00014334862385321102
I0
I1
I-1
tp57049
sS'reverse,transcriptase,inhibitor'
p57050
(F1
F0.00014334862385321102
I0
I1
I-1
tp57051
sS'after,or,hours'
p57052
(F1
F0.00014334862385321102
I1
I0
I1
tp57053
sS'until,the,relevance'
p57054
(F1
F0.00014334862385321102
I1
I0
I1
tp57055
sS'combined,with,these'
p57056
(F1
F0.00014334862385321102
I1
I0
I1
tp57057
sS'the,blood,levels'
p57058
(F1
F0.00014334862385321102
I1
I0
I1
tp57059
sS'dose,level,p'
p57060
(F1
F0.00014334862385321102
I0
I1
I-1
tp57061
sS'may,require,dose'
p57062
(F1
F0.00014334862385321102
I0
I1
I-1
tp57063
sS'cytokines,cytokines,have'
p57064
(F1
F0.00014334862385321102
I0
I1
I-1
tp57065
sS'was,more,pronounced'
p57066
(F1
F0.00014334862385321102
I0
I1
I-1
tp57067
sS'enzyme,based,tests'
p57068
(F1
F0.00014334862385321102
I0
I1
I-1
tp57069
sS'the,transport,ratio'
p57070
(F1
F0.00014334862385321102
I0
I1
I-1
tp57071
sS'relationships,between,and'
p57072
(F1
F0.00014334862385321102
I0
I1
I-1
tp57073
sS'necessary,when,eulexin'
p57074
(F1
F0.00014334862385321102
I1
I0
I1
tp57075
sS'cimetidine,is,reported'
p57076
(F1
F0.00014334862385321102
I1
I0
I1
tp57077
sS'events,in,subjects'
p57078
(F1
F0.00014334862385321102
I0
I1
I-1
tp57079
sS'receiving,blocking,agents'
p57080
(F1
F0.00014334862385321102
I0
I1
I-1
tp57081
sS'in,the,concomitant'
p57082
(F1
F0.00014334862385321102
I1
I0
I1
tp57083
sS'some,patients,the'
p57084
(F1
F0.0010034403669724771
I7
I0
I7
tp57085
sS'and,may,alter'
p57086
(F1
F0.00014334862385321102
I1
I0
I1
tp57087
sS'vitamin,k,aquamephyton'
p57088
(F1
F0.00014334862385321102
I0
I1
I-1
tp57089
sS'on,administration,of'
p57090
(F1
F0.00014334862385321102
I1
I0
I1
tp57091
sS'of,antithrombotics,aspirin'
p57092
(F1
F0.00014334862385321102
I0
I1
I-1
tp57093
sS'the,light,zone'
p57094
(F1
F0.00014334862385321102
I1
I0
I1
tp57095
sS'should,be,evaluated'
p57096
(F1
F0.00014334862385321102
I1
I0
I1
tp57097
sS'fractional,transfer,to'
p57098
(F1
F0.00014334862385321102
I0
I1
I-1
tp57099
sS'trials,was,used'
p57100
(F1
F0.00014334862385321102
I0
I1
I-1
tp57101
sS'mg,day,followed'
p57102
(F1
F0.00014334862385321102
I1
I0
I1
tp57103
sS'as,an,index'
p57104
(F1
F0.00014334862385321102
I0
I1
I-1
tp57105
sS'changes,in,desloratadine'
p57106
(F1
F0.00014334862385321102
I0
I1
I-1
tp57107
sS'therefore,consideration,should'
p57108
(F1
F0.00014334862385321102
I1
I0
I1
tp57109
sS'hormone,replacement,therapy'
p57110
(F1
F0.00014334862385321102
I0
I1
I-1
tp57111
sS'increase,in,cmax'
p57112
(F1
F0.0014334862385321102
I10
I0
I10
tp57113
sS'anticholinesterase,agents,and'
p57114
(F1
F0.00014334862385321102
I1
I0
I1
tp57115
sS'single,dose,in'
p57116
(F1
F0.00014334862385321102
I0
I1
I-1
tp57117
sS'affect,the,bioavailability'
p57118
(F1
F0.00014334862385321102
I0
I1
I-1
tp57119
sS'and,a4,isozymes'
p57120
(F1
F0.00014334862385321102
I0
I1
I-1
tp57121
sS'sex,hormone,response'
p57122
(F1
F0.00014334862385321102
I1
I0
I1
tp57123
sS'drugs,metabolized,by'
p57124
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp57125
sS'however,it,has'
p57126
(F1
F0.00014334862385321102
I1
I0
I1
tp57127
sS'if,necessary,should'
p57128
(F1
F0.00014334862385321102
I0
I1
I-1
tp57129
sS'anti-arrhythmic,agents,such'
p57130
(F1
F0.00014334862385321102
I0
I1
I-1
tp57131
sS'in,prolongation,of'
p57132
(F1
F0.00071674311926605509
I5
I0
I5
tp57133
sS'addition,several,aed'
p57134
(F1
F0.00014334862385321102
I1
I0
I1
tp57135
sS'vitro,on,the'
p57136
(F1
F0.00014334862385321102
I0
I1
I-1
tp57137
sS'have,no,influence'
p57138
(F1
F0.00014334862385321102
I0
I1
I-1
tp57139
sS'supplemental,folic,acid'
p57140
(F1
F0.00014334862385321102
I0
I1
I-1
tp57141
sS'tail-flick,inhibition,and'
p57142
(F1
F0.00014334862385321102
I0
I1
I-1
tp57143
sS'was,responsible,for'
p57144
(F1
F0.00014334862385321102
I1
I0
I1
tp57145
sS'higher,daily,acquisition'
p57146
(F1
F0.00014334862385321102
I0
I1
I-1
tp57147
sS'by,cyp2d6,isoenzyme'
p57148
(F1
F0.00014334862385321102
I1
I0
I1
tp57149
sS'mg,once,monthly'
p57150
(F1
F0.00014334862385321102
I0
I1
I-1
tp57151
sS'the,cyp3a4,pathway'
p57152
(F1
F0.00014334862385321102
I1
I0
I1
tp57153
sS'kg,of,body'
p57154
(F1
F0.00014334862385321102
I0
I1
I-1
tp57155
sS'in,vitro,appears'
p57156
(F1
F0.00014334862385321102
I1
I0
I1
tp57157
sS'pharmacological,doses,of'
p57158
(F1
F0.00014334862385321102
I0
I1
I-1
tp57159
sS'nondepolarizing,neuromuscular,blocking'
p57160
(F1
F0.00028669724770642203
I2
I0
I2
tp57161
sS'may,be,less'
p57162
(F1
F0.00014334862385321102
I1
I0
I1
tp57163
sS'effect,of,zebeta'
p57164
(F1
F0.00014334862385321102
I0
I1
I-1
tp57165
sS'cyp3a4,activity,would'
p57166
(F1
F0.00014334862385321102
I0
I1
I-1
tp57167
sS'of,the,antidepressant'
p57168
(F1
F0.00014334862385321102
I0
I1
I-1
tp57169
sS'local,agents,when'
p57170
(F1
F0.00014334862385321102
I0
I1
I-1
tp57171
sS'in,all,patients'
p57172
(F0
F0
I1
I1
I0
tp57173
sS'glucose,and,exert'
p57174
(F1
F0.00014334862385321102
I0
I1
I-1
tp57175
sS'was,expected,because'
p57176
(F1
F0.00014334862385321102
I0
I1
I-1
tp57177
sS'medications,is,not'
p57178
(F1
F0.00014334862385321102
I1
I0
I1
tp57179
sS'or,may,interfere'
p57180
(F1
F0.00014334862385321102
I1
I0
I1
tp57181
sS'of,platelet,aggregation'
p57182
(F1
F0.00014334862385321102
I0
I1
I-1
tp57183
sS'are,taking,other'
p57184
(F1
F0.00014334862385321102
I1
I0
I1
tp57185
sS'with,oral,resulted'
p57186
(F1
F0.00014334862385321102
I1
I0
I1
tp57187
sS'active,metabolite,exposure'
p57188
(F1
F0.00014334862385321102
I1
I0
I1
tp57189
sS'to,control,inflammation'
p57190
(F1
F0.00014334862385321102
I1
I0
I1
tp57191
sS'times,when,was'
p57192
(F1
F0.00014334862385321102
I1
I0
I1
tp57193
sS'agents,of,the'
p57194
(F1
F0.00014334862385321102
I1
I0
I1
tp57195
sS'in,plasmaconcentrations,may'
p57196
(F1
F0.00028669724770642203
I2
I0
I2
tp57197
sS'hepatic,clearance,or'
p57198
(F1
F0.00014334862385321102
I0
I1
I-1
tp57199
sS'lead,to,significant'
p57200
(F0
F0
I1
I1
I0
tp57201
sS'for,days,systemic'
p57202
(F1
F0.00028669724770642203
I2
I0
I2
tp57203
sS'daily,brovana,dose'
p57204
(F1
F0.00014334862385321102
I0
I1
I-1
tp57205
sS'very,little,change'
p57206
(F1
F0.00014334862385321102
I1
I0
I1
tp57207
sS'that,an,interaction'
p57208
(F1
F0.00014334862385321102
I1
I0
I1
tp57209
sS'low-dose,microg,kg'
p57210
(F1
F0.00014334862385321102
I1
I0
I1
tp57211
sS'tachypnea,lethargy,and'
p57212
(F1
F0.00014334862385321102
I1
I0
I1
tp57213
sS'gram,of,hydroxide'
p57214
(F1
F0.00014334862385321102
I1
I0
I1
tp57215
sS'approximate,decrease,in'
p57216
(F1
F0.00057339449541284407
I4
I0
I4
tp57217
sS'd,the,coadministration'
p57218
(F1
F0.00043004587155963305
I0
I3
I-3
tp57219
sS'of,that,increase'
p57220
(F1
F0.00014334862385321102
I1
I0
I1
tp57221
sS'beta-blockers,concomitant,use'
p57222
(F1
F0.00014334862385321102
I1
I0
I1
tp57223
sS'sirolimus-diltiazem,interaction,whole'
p57224
(F1
F0.00014334862385321102
I1
I0
I1
tp57225
sS'g,of,per'
p57226
(F1
F0.00014334862385321102
I1
I0
I1
tp57227
sS'and,traumatic,edemas'
p57228
(F1
F0.00014334862385321102
I1
I0
I1
tp57229
sS'observation,period,in'
p57230
(F1
F0.00014334862385321102
I0
I1
I-1
tp57231
sS'agents,glutamic,acid'
p57232
(F1
F0.00014334862385321102
I1
I0
I1
tp57233
sS'administration,of,innovar'
p57234
(F1
F0.00014334862385321102
I1
I0
I1
tp57235
sS'or,use,of'
p57236
(F1
F0.00014334862385321102
I1
I0
I1
tp57237
sS'by,nonbarbiturate,antianxiety'
p57238
(F1
F0.00014334862385321102
I1
I0
I1
tp57239
sS'for,adverse,events'
p57240
(F1
F0.00014334862385321102
I0
I1
I-1
tp57241
sS'itraconazole,decreases,clearance'
p57242
(F1
F0.00014334862385321102
I1
I0
I1
tp57243
sS'lithium,inhibition,of'
p57244
(F1
F0.00014334862385321102
I0
I1
I-1
tp57245
sS'interaction,between,the'
p57246
(F0
F0
I1
I1
I0
tp57247
sS'of,these,drugs'
p57248
(F1
F0.00014334862385321102
I0
I1
I-1
tp57249
sS'play,a,critical'
p57250
(F1
F0.00014334862385321102
I0
I1
I-1
tp57251
sS'no,evidence,of'
p57252
(F1
F0.0010034403669724771
I0
I7
I-7
tp57253
sS'effect,of,is'
p57254
(F1
F0.00028669724770642203
I2
I0
I2
tp57255
sS'being,withdrawn,from'
p57256
(F1
F0.00014334862385321102
I1
I0
I1
tp57257
sS'factor,viii,ix'
p57258
(F1
F0.00014334862385321102
I0
I1
I-1
tp57259
sS'using,morphological,markers'
p57260
(F1
F0.00014334862385321102
I1
I0
I1
tp57261
sS'by,bezalip,or'
p57262
(F1
F0.00014334862385321102
I1
I0
I1
tp57263
sS'towards,cyp1a2,which'
p57264
(F1
F0.00014334862385321102
I1
I0
I1
tp57265
sS'metabolic,enzymes,and'
p57266
(F1
F0.00014334862385321102
I0
I1
I-1
tp57267
sS'suggested,to,monitor'
p57268
(F1
F0.00014334862385321102
I1
I0
I1
tp57269
sS'or,with,particularly'
p57270
(F1
F0.00014334862385321102
I1
I0
I1
tp57271
sS'has,a,considerable'
p57272
(F1
F0.00014334862385321102
I1
I0
I1
tp57273
sS'in,serum,concentrations'
p57274
(F0
F0
I1
I1
I0
tp57275
sS'digitalis,enhanced,possibility'
p57276
(F1
F0.00014334862385321102
I0
I1
I-1
tp57277
sS'or,tubular,secretion'
p57278
(F1
F0.00014334862385321102
I0
I1
I-1
tp57279
sS'effect,on,prothrombin'
p57280
(F1
F0.00028669724770642203
I0
I2
I-2
tp57281
sS'may,exacerbate,rebound'
p57282
(F1
F0.00014334862385321102
I1
I0
I1
tp57283
sS'in,animals,indicate'
p57284
(F1
F0.00014334862385321102
I1
I0
I1
tp57285
sS'healthy,volunteers,under'
p57286
(F1
F0.00014334862385321102
I0
I1
I-1
tp57287
sS'administration,of,ethyol'
p57288
(F1
F0.00014334862385321102
I1
I0
I1
tp57289
sS'and,pth,and'
p57290
(F1
F0.00014334862385321102
I1
I0
I1
tp57291
sS'comparable,in,effects'
p57292
(F1
F0.00014334862385321102
I0
I1
I-1
tp57293
sS'a,strong,inhibitor'
p57294
(F1
F0.00014334862385321102
I1
I0
I1
tp57295
sS'at,least,partially'
p57296
(F1
F0.00014334862385321102
I1
I0
I1
tp57297
sS'crises,have,resulted'
p57298
(F1
F0.00014334862385321102
I1
I0
I1
tp57299
sS'replacement,therapy,free'
p57300
(F1
F0.00014334862385321102
I1
I0
I1
tp57301
sS'by,lowering,the'
p57302
(F1
F0.00014334862385321102
I1
I0
I1
tp57303
sS'and,local,agents'
p57304
(F1
F0.00028669724770642203
I0
I2
I-2
tp57305
sS'patients,receiving,treatment'
p57306
(F1
F0.00014334862385321102
I0
I1
I-1
tp57307
sS'either,oral,or'
p57308
(F1
F0.00014334862385321102
I1
I0
I1
tp57309
sS'therefore,when,and'
p57310
(F1
F0.00028669724770642203
I2
I0
I2
tp57311
sS'information,to,increase'
p57312
(F1
F0.00014334862385321102
I1
I0
I1
tp57313
sS'levulan,kerastick,for'
p57314
(F1
F0.00014334862385321102
I1
I0
I1
tp57315
sS'in,normal,volunteers'
p57316
(F0.22222222222222221
F0.00057339449541284407
I11
I7
I4
tp57317
sS'for,and,urine'
p57318
(F1
F0.00014334862385321102
I0
I1
I-1
tp57319
sS'study,the,pancreatic'
p57320
(F1
F0.00014334862385321102
I0
I1
I-1
tp57321
sS'indicate,that,levels'
p57322
(F1
F0.00014334862385321102
I1
I0
I1
tp57323
sS'population,chronically,receiving'
p57324
(F1
F0.00014334862385321102
I0
I1
I-1
tp57325
sS'with,equetrotm,it'
p57326
(F1
F0.00014334862385321102
I1
I0
I1
tp57327
sS'that,may,decrease'
p57328
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp57329
sS'in,type,diabetes'
p57330
(F1
F0.00014334862385321102
I1
I0
I1
tp57331
sS'acetate,affected,the'
p57332
(F1
F0.00014334862385321102
I1
I0
I1
tp57333
sS'shown,that,rr'
p57334
(F1
F0.00014334862385321102
I0
I1
I-1
tp57335
sS'given,very,high'
p57336
(F1
F0.00014334862385321102
I1
I0
I1
tp57337
sS'concentrations,in,bile'
p57338
(F1
F0.00014334862385321102
I1
I0
I1
tp57339
sS'another,tnf-blocking,agent'
p57340
(F1
F0.00014334862385321102
I1
I0
I1
tp57341
sS'crixivan,fortovase,invirase'
p57342
(F1
F0.00014334862385321102
I1
I0
I1
tp57343
sS'the,most,significant'
p57344
(F1
F0.00014334862385321102
I0
I1
I-1
tp57345
sS'and,or,parenteral'
p57346
(F1
F0.00014334862385321102
I0
I1
I-1
tp57347
sS'although,trough,plasma'
p57348
(F1
F0.00014334862385321102
I1
I0
I1
tp57349
sS'and,severe,rhabdomyolysis'
p57350
(F1
F0.00014334862385321102
I1
I0
I1
tp57351
sS'to,m,g'
p57352
(F1
F0.00014334862385321102
I1
I0
I1
tp57353
sS'though,this,has'
p57354
(F1
F0.00014334862385321102
I1
I0
I1
tp57355
sS'either,levels,or'
p57356
(F1
F0.00014334862385321102
I0
I1
I-1
tp57357
sS'with,elevations,in'
p57358
(F1
F0.00028669724770642203
I2
I0
I2
tp57359
sS'to,m,v'
p57360
(F1
F0.00014334862385321102
I0
I1
I-1
tp57361
sS'coadministration,with,invirase'
p57362
(F1
F0.00014334862385321102
I0
I1
I-1
tp57363
sS'digoxin,salicylate,and'
p57364
(F1
F0.00014334862385321102
I1
I0
I1
tp57365
sS'experience,a,reversible'
p57366
(F1
F0.00014334862385321102
I1
I0
I1
tp57367
sS'could,be,prolonged'
p57368
(F1
F0.00014334862385321102
I1
I0
I1
tp57369
sS'gel,in,combination'
p57370
(F1
F0.00014334862385321102
I0
I1
I-1
tp57371
sS'was,performed,in'
p57372
(F1
F0.00014334862385321102
I0
I1
I-1
tp57373
sS'cytochrome,p450,a'
p57374
(F1
F0.00043004587155963305
I0
I3
I-3
tp57375
sS'any,efficacy,benefit'
p57376
(F1
F0.00014334862385321102
I0
I1
I-1
tp57377
sS'metabolite,of,does'
p57378
(F1
F0.00014334862385321102
I0
I1
I-1
tp57379
sS'reduced,cmax,up'
p57380
(F1
F0.00014334862385321102
I1
I0
I1
tp57381
sS'effects,of,pcp'
p57382
(F1
F0.00014334862385321102
I0
I1
I-1
tp57383
sS'h,antagonists,the'
p57384
(F1
F0.00014334862385321102
I0
I1
I-1
tp57385
sS'methotrexate,mexate,use'
p57386
(F1
F0.00014334862385321102
I1
I0
I1
tp57387
sS'in,patients,either'
p57388
(F1
F0.00014334862385321102
I0
I1
I-1
tp57389
sS'action,of,on'
p57390
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp57391
sS'dicumarol,and,may'
p57392
(F1
F0.00014334862385321102
I0
I1
I-1
tp57393
sS'concentrations,of,concomitant'
p57394
(F1
F0.00014334862385321102
I1
I0
I1
tp57395
sS'in,the,serum'
p57396
(F1
F0.00043004587155963305
I3
I0
I3
tp57397
sS'schizophrenia,or,related'
p57398
(F1
F0.00014334862385321102
I0
I1
I-1
tp57399
sS'of,plasma,concentrations'
p57400
(F1
F0.00014334862385321102
I1
I0
I1
tp57401
sS'of,metabolism,and'
p57402
(F1
F0.00028669724770642203
I2
I0
I2
tp57403
sS'or,patients,using'
p57404
(F1
F0.00014334862385321102
I1
I0
I1
tp57405
sS'hydrochloride,with,in'
p57406
(F1
F0.00014334862385321102
I1
I0
I1
tp57407
sS'pathway,showed,a'
p57408
(F1
F0.00014334862385321102
I1
I0
I1
tp57409
sS'strains,and,six'
p57410
(F1
F0.00014334862385321102
I0
I1
I-1
tp57411
sS'decreased,when,given'
p57412
(F1
F0.00014334862385321102
I1
I0
I1
tp57413
sS'in,using,preparations'
p57414
(F1
F0.00014334862385321102
I0
I1
I-1
tp57415
sS'on,the,serum'
p57416
(F1
F0.00028669724770642203
I0
I2
I-2
tp57417
sS'marked,changes,in'
p57418
(F1
F0.00014334862385321102
I1
I0
I1
tp57419
sS'in,normal,healthy'
p57420
(F1
F0.00014334862385321102
I0
I1
I-1
tp57421
sS'patients,taking,revia'
p57422
(F1
F0.00014334862385321102
I1
I0
I1
tp57423
sS'the,appropriate,dose'
p57424
(F1
F0.00014334862385321102
I0
I1
I-1
tp57425
sS'nicotinic,receptors,mc'
p57426
(F1
F0.00014334862385321102
I0
I1
I-1
tp57427
sS'sustiva,is,given'
p57428
(F1
F0.00014334862385321102
I0
I1
I-1
tp57429
sS'p450,a4,may'
p57430
(F1
F0.00014334862385321102
I1
I0
I1
tp57431
sS'with,a,strong'
p57432
(F1
F0.00014334862385321102
I1
I0
I1
tp57433
sS'taking,low-dose,plus'
p57434
(F1
F0.00014334862385321102
I0
I1
I-1
tp57435
sS'unchanged,following,a'
p57436
(F1
F0.00014334862385321102
I0
I1
I-1
tp57437
sS'iv,have,been'
p57438
(F1
F0.00014334862385321102
I0
I1
I-1
tp57439
sS'onset,of,maximum'
p57440
(F1
F0.00014334862385321102
I1
I0
I1
tp57441
sS'at,a,plasma'
p57442
(F1
F0.00014334862385321102
I0
I1
I-1
tp57443
sS'should,therefore,be'
p57444
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp57445
sS'instances,and,antagonism'
p57446
(F1
F0.00014334862385321102
I1
I0
I1
tp57447
sS'alone,at,therapeutic'
p57448
(F1
F0.00014334862385321102
I0
I1
I-1
tp57449
sS'indomethacin,concomitant,use'
p57450
(F1
F0.00014334862385321102
I1
I0
I1
tp57451
sS'capsules,every,hours'
p57452
(F1
F0.00014334862385321102
I1
I0
I1
tp57453
sS'a,which,increases'
p57454
(F1
F0.00014334862385321102
I1
I0
I1
tp57455
sS'of,and,monitoring'
p57456
(F1
F0.00014334862385321102
I1
I0
I1
tp57457
sS'urine,of,both'
p57458
(F1
F0.00014334862385321102
I0
I1
I-1
tp57459
sS'of,free,had'
p57460
(F1
F0.00014334862385321102
I0
I1
I-1
tp57461
sS'of,at,steady'
p57462
(F1
F0.00014334862385321102
I0
I1
I-1
tp57463
sS'these,effects,is'
p57464
(F1
F0.00014334862385321102
I1
I0
I1
tp57465
sS'combination,therapy,is'
p57466
(F1
F0.00014334862385321102
I0
I1
I-1
tp57467
sS'observed,there,were'
p57468
(F1
F0.00014334862385321102
I0
I1
I-1
tp57469
sS'breakfast,cereals,on'
p57470
(F1
F0.00014334862385321102
I0
I1
I-1
tp57471
sS'significant,degree,when'
p57472
(F1
F0.00014334862385321102
I0
I1
I-1
tp57473
sS'by,through,the'
p57474
(F1
F0.00014334862385321102
I0
I1
I-1
tp57475
sS'received,tended,to'
p57476
(F1
F0.00014334862385321102
I0
I1
I-1
tp57477
sS'hypotension,developed,in'
p57478
(F1
F0.00014334862385321102
I1
I0
I1
tp57479
sS'or,their,guardians'
p57480
(F1
F0.00014334862385321102
I0
I1
I-1
tp57481
sS'concomitant,crohn,s'
p57482
(F1
F0.00014334862385321102
I0
I1
I-1
tp57483
sS'contrast,mm,and'
p57484
(F1
F0.00014334862385321102
I0
I1
I-1
tp57485
sS'by,inhibiting,their'
p57486
(F1
F0.00014334862385321102
I1
I0
I1
tp57487
sS'either,increase,or'
p57488
(F1
F0.00014334862385321102
I1
I0
I1
tp57489
sS'concomitantly,with,antagonists'
p57490
(F1
F0.00014334862385321102
I1
I0
I1
tp57491
sS'interaction,to,patients'
p57492
(F1
F0.00014334862385321102
I0
I1
I-1
tp57493
sS'among,the,polyene'
p57494
(F1
F0.00014334862385321102
I0
I1
I-1
tp57495
sS'blocked,the,secretory'
p57496
(F1
F0.00014334862385321102
I1
I0
I1
tp57497
sS'preparation,this,parenteral'
p57498
(F1
F0.00014334862385321102
I1
I0
I1
tp57499
sS'simultaneous,ingestion,of'
p57500
(F1
F0.00014334862385321102
I1
I0
I1
tp57501
sS'receiving,the,cyp3a4'
p57502
(F1
F0.00014334862385321102
I1
I0
I1
tp57503
sS'receiving,concurrently,with'
p57504
(F1
F0.00014334862385321102
I1
I0
I1
tp57505
sS'prinivil,given,concomitantly'
p57506
(F1
F0.00014334862385321102
I0
I1
I-1
tp57507
sS'may,affect,gastrointestinal'
p57508
(F1
F0.00014334862385321102
I1
I0
I1
tp57509
sS'it,is,known'
p57510
(F1
F0.00028669724770642203
I2
I0
I2
tp57511
sS'the,liver,to'
p57512
(F1
F0.00014334862385321102
I0
I1
I-1
tp57513
sS'the,plasma,and'
p57514
(F1
F0.00014334862385321102
I1
I0
I1
tp57515
sS'is,structurally,similar'
p57516
(F1
F0.00014334862385321102
I0
I1
I-1
tp57517
sS'limited,experience,with'
p57518
(F1
F0.00014334862385321102
I0
I1
I-1
tp57519
sS'parameters,the,degree'
p57520
(F1
F0.00014334862385321102
I0
I1
I-1
tp57521
sS'initial,presentation,of'
p57522
(F1
F0.00014334862385321102
I1
I0
I1
tp57523
sS'mefenamic,acid,monoamine'
p57524
(F1
F0.00014334862385321102
I1
I0
I1
tp57525
sS'and,was,potentiated'
p57526
(F1
F0.00014334862385321102
I0
I1
I-1
tp57527
sS'can,form,chelation'
p57528
(F1
F0.00014334862385321102
I1
I0
I1
tp57529
sS'and,without,evidence'
p57530
(F1
F0.00028669724770642203
I0
I2
I-2
tp57531
sS'have,effects,on'
p57532
(F1
F0.00014334862385321102
I0
I1
I-1
tp57533
sS'than,usually,prescribed'
p57534
(F1
F0.0010034403669724771
I0
I7
I-7
tp57535
sS'dose,of,administered'
p57536
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp57537
sS'induced,by,a'
p57538
(F1
F0.00014334862385321102
I0
I1
I-1
tp57539
sS'it,is,unknown'
p57540
(F1
F0.00014334862385321102
I0
I1
I-1
tp57541
sS'given,concomitantly,physicians'
p57542
(F1
F0.00014334862385321102
I1
I0
I1
tp57543
sS'of,either,one'
p57544
(F1
F0.00014334862385321102
I1
I0
I1
tp57545
sS'the,known,cyp3a4'
p57546
(F1
F0.00014334862385321102
I1
I0
I1
tp57547
sS'particularly,in,the'
p57548
(F1
F0.00014334862385321102
I1
I0
I1
tp57549
sS'interaction,with,drugs'
p57550
(F1
F0.00014334862385321102
I0
I1
I-1
tp57551
sS'no,measurable,effect'
p57552
(F1
F0.00014334862385321102
I0
I1
I-1
tp57553
sS'difluoroacetone,mg,kg'
p57554
(F1
F0.00028669724770642203
I0
I2
I-2
tp57555
sS'cyp3a4,eg,or'
p57556
(F1
F0.00014334862385321102
I1
I0
I1
tp57557
sS'use,of,ergotamine-containing'
p57558
(F1
F0.00043004587155963305
I3
I0
I3
tp57559
sS'suspension,results,in'
p57560
(F1
F0.00014334862385321102
I1
I0
I1
tp57561
sS'studied,certain,may'
p57562
(F1
F0.00014334862385321102
I1
I0
I1
tp57563
sS'muscle,relaxants,may'
p57564
(F1
F0.00014334862385321102
I1
I0
I1
tp57565
sS'because,oral,may'
p57566
(F1
F0.00014334862385321102
I1
I0
I1
tp57567
sS'reflects,an,approximate'
p57568
(F1
F0.00014334862385321102
I1
I0
I1
tp57569
sS'placebo,was,and'
p57570
(F1
F0.00014334862385321102
I0
I1
I-1
tp57571
sS'or,mg,every'
p57572
(F1
F0.00014334862385321102
I0
I1
I-1
tp57573
sS'administered,until,a'
p57574
(F1
F0.00014334862385321102
I1
I0
I1
tp57575
sS'by,hour,and'
p57576
(F1
F0.00014334862385321102
I1
I0
I1
tp57577
sS'the,maximum,plasma'
p57578
(F1
F0.00043004587155963305
I3
I0
I3
tp57579
sS'with,care,when'
p57580
(F1
F0.00014334862385321102
I1
I0
I1
tp57581
sS'not,been,performed'
p57582
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp57583
sS'since,may,prolong'
p57584
(F1
F0.00014334862385321102
I1
I0
I1
tp57585
sS'psa,levels,are'
p57586
(F1
F0.00014334862385321102
I0
I1
I-1
tp57587
sS'of,hcl,no'
p57588
(F1
F0.00014334862385321102
I1
I0
I1
tp57589
sS'and,agents,other'
p57590
(F1
F0.00014334862385321102
I1
I0
I1
tp57591
sS'in,excessive,effects'
p57592
(F1
F0.00014334862385321102
I1
I0
I1
tp57593
sS'following,dosing,of'
p57594
(F1
F0.00014334862385321102
I0
I1
I-1
tp57595
sS'given,simultaneously,with'
p57596
(F1
F0.00014334862385321102
I1
I0
I1
tp57597
sS'mg,both,a'
p57598
(F1
F0.00014334862385321102
I0
I1
I-1
tp57599
sS'bid,on,the'
p57600
(F1
F0.00028669724770642203
I0
I2
I-2
tp57601
sS'the,mortality,rate'
p57602
(F1
F0.00014334862385321102
I0
I1
I-1
tp57603
sS'metabolizers,after,multiple-dose'
p57604
(F1
F0.00014334862385321102
I0
I1
I-1
tp57605
sS'irritability,and,may'
p57606
(F1
F0.00014334862385321102
I1
I0
I1
tp57607
sS'treatment,with,wellbutrin'
p57608
(F1
F0.00014334862385321102
I1
I0
I1
tp57609
sS'concomitant,use,should'
p57610
(F1
F0.00014334862385321102
I0
I1
I-1
tp57611
sS'in,some,normal'
p57612
(F1
F0.00014334862385321102
I1
I0
I1
tp57613
sS'that,are,on'
p57614
(F1
F0.00014334862385321102
I1
I0
I1
tp57615
sS'to,the,pharmacokinetics'
p57616
(F1
F0.00014334862385321102
I0
I1
I-1
tp57617
sS'supplemental,l-glutamine,for'
p57618
(F1
F0.00014334862385321102
I1
I0
I1
tp57619
sS'manufacturers,have,not'
p57620
(F1
F0.00014334862385321102
I0
I1
I-1
tp57621
sS'of,on,was'
p57622
(F1
F0.00014334862385321102
I0
I1
I-1
tp57623
sS'p450,a2,an'
p57624
(F1
F0.00014334862385321102
I1
I0
I1
tp57625
sS'injectable,produces,depression'
p57626
(F1
F0.00014334862385321102
I1
I0
I1
tp57627
sS'nevirapine,and,should'
p57628
(F1
F0.00028669724770642203
I2
I0
I2
tp57629
sS'agents,iodine-containing,compounds'
p57630
(F1
F0.00014334862385321102
I0
I1
I-1
tp57631
sS'active,metabolite,at'
p57632
(F1
F0.00014334862385321102
I1
I0
I1
tp57633
sS'after,the,initial'
p57634
(F1
F0.00014334862385321102
I1
I0
I1
tp57635
sS'thought,to,play'
p57636
(F1
F0.00014334862385321102
I0
I1
I-1
tp57637
sS'prescribed,with,caution'
p57638
(F1
F0.00014334862385321102
I1
I0
I1
tp57639
sS'a,delay,in'
p57640
(F1
F0.00014334862385321102
I1
I0
I1
tp57641
sS'chinese,hamster,s'
p57642
(F1
F0.00014334862385321102
I0
I1
I-1
tp57643
sS'milk,products,and'
p57644
(F1
F0.00014334862385321102
I1
I0
I1
tp57645
sS'reducing,the,number'
p57646
(F1
F0.00014334862385321102
I1
I0
I1
tp57647
sS'with,increased,serum'
p57648
(F1
F0.00028669724770642203
I2
I0
I2
tp57649
sS'associated,with,hepatic'
p57650
(F1
F0.00014334862385321102
I0
I1
I-1
tp57651
sS'the,nerve,transmission'
p57652
(F1
F0.00014334862385321102
I0
I1
I-1
tp57653
sS'cannot,be,further'
p57654
(F1
F0.00014334862385321102
I0
I1
I-1
tp57655
sS'volunteers,it,was'
p57656
(F1
F0.00014334862385321102
I1
I0
I1
tp57657
sS'interaction,probably,is'
p57658
(F1
F0.00014334862385321102
I1
I0
I1
tp57659
sS'kappa-selective,was,significantly'
p57660
(F1
F0.00014334862385321102
I0
I1
I-1
tp57661
sS'change,the,pharmacokinetic'
p57662
(F1
F0.00014334862385321102
I0
I1
I-1
tp57663
sS'that,necessitated,changes'
p57664
(F1
F0.00014334862385321102
I1
I0
I1
tp57665
sS'observation,is,required'
p57666
(F1
F0.00014334862385321102
I1
I0
I1
tp57667
sS'day,of,cromolyn'
p57668
(F1
F0.00014334862385321102
I1
I0
I1
tp57669
sS'serum,half-life,of'
p57670
(F1
F0.00014334862385321102
I1
I0
I1
tp57671
sS'man,include,aminosalicylic'
p57672
(F1
F0.00014334862385321102
I1
I0
I1
tp57673
sS'hydrochloride,therapy,to'
p57674
(F1
F0.00014334862385321102
I1
I0
I1
tp57675
sS'rate,of,dissolution'
p57676
(F1
F0.00014334862385321102
I0
I1
I-1
tp57677
sS'tubular,organic,cation'
p57678
(F0
F0
I1
I1
I0
tp57679
sS'intake,of,supplemental'
p57680
(F1
F0.00014334862385321102
I0
I1
I-1
tp57681
sS'the,exposure,auc'
p57682
(F1
F0.00014334862385321102
I1
I0
I1
tp57683
sS'a,one,week'
p57684
(F1
F0.00014334862385321102
I1
I0
I1
tp57685
sS'the,auc,ss'
p57686
(F1
F0.00028669724770642203
I2
I0
I2
tp57687
sS'not,been,shown'
p57688
(F0
F0
I1
I1
I0
tp57689
sS'levo-dromoran,has,been'
p57690
(F1
F0.00014334862385321102
I1
I0
I1
tp57691
sS'by,the,reduction'
p57692
(F1
F0.00043004587155963305
I0
I3
I-3
tp57693
sS'and,therapy,eg'
p57694
(F1
F0.00014334862385321102
I0
I1
I-1
tp57695
sS'kg,days,mg'
p57696
(F1
F0.00014334862385321102
I0
I1
I-1
tp57697
sS'medium,rpmi1640,containing'
p57698
(F1
F0.00014334862385321102
I0
I1
I-1
tp57699
sS'patients,with,diabetes'
p57700
(F1
F0.00014334862385321102
I0
I1
I-1
tp57701
sS'one-week,course,of'
p57702
(F1
F0.00014334862385321102
I1
I0
I1
tp57703
sS'ratio,or,enantiomer'
p57704
(F1
F0.00014334862385321102
I0
I1
I-1
tp57705
sS'a,clinical,trial'
p57706
(F0
F0
I1
I1
I0
tp57707
sS'was,given,alone'
p57708
(F1
F0.00014334862385321102
I0
I1
I-1
tp57709
sS'using,for,example'
p57710
(F1
F0.00014334862385321102
I0
I1
I-1
tp57711
sS'coadministered,with,kerlone'
p57712
(F1
F0.00014334862385321102
I0
I1
I-1
tp57713
sS'comparative,analysis,of'
p57714
(F1
F0.00014334862385321102
I0
I1
I-1
tp57715
sS'as,mhd,the'
p57716
(F1
F0.00014334862385321102
I0
I1
I-1
tp57717
sS'conduction,such,as'
p57718
(F1
F0.00014334862385321102
I1
I0
I1
tp57719
sS'and,was,significantly'
p57720
(F0
F0
I1
I1
I0
tp57721
sS'greater,risk,of'
p57722
(F1
F0.00014334862385321102
I0
I1
I-1
tp57723
sS'antiarrhythmics,amiodarone,contraindicated'
p57724
(F1
F0.00014334862385321102
I0
I1
I-1
tp57725
sS'consider,the,possibility'
p57726
(F1
F0.00014334862385321102
I1
I0
I1
tp57727
sS'the,fluoride,and'
p57728
(F1
F0.00014334862385321102
I1
I0
I1
tp57729
sS'a,bacteriostatic,may'
p57730
(F1
F0.00028669724770642203
I2
I0
I2
tp57731
sS'of,an,nsaid'
p57732
(F1
F0.00014334862385321102
I1
I0
I1
tp57733
sS'principal,pathway,for'
p57734
(F1
F0.00014334862385321102
I1
I0
I1
tp57735
sS'clearance,of,decreased'
p57736
(F1
F0.00014334862385321102
I1
I0
I1
tp57737
sS'inhibitor,to,mg'
p57738
(F1
F0.00014334862385321102
I1
I0
I1
tp57739
sS'with,aprepitant,to'
p57740
(F1
F0.00028669724770642203
I2
I0
I2
tp57741
sS'received,mg,day'
p57742
(F1
F0.00014334862385321102
I0
I1
I-1
tp57743
sS'in,healthy,male'
p57744
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp57745
sS'enzyme,inhibitors,aminosalicylic'
p57746
(F1
F0.00014334862385321102
I1
I0
I1
tp57747
sS'be,monitored,carefully'
p57748
(F1
F0.00028669724770642203
I2
I0
I2
tp57749
sS'effect,for,i'
p57750
(F1
F0.00014334862385321102
I1
I0
I1
tp57751
sS'cimetidine,increases,hcl'
p57752
(F1
F0.00014334862385321102
I1
I0
I1
tp57753
sS'in,renal,transplant'
p57754
(F1
F0.00014334862385321102
I1
I0
I1
tp57755
sS'use,of,bromocriptine'
p57756
(F1
F0.00014334862385321102
I1
I0
I1
tp57757
sS'block,may,be'
p57758
(F1
F0.00028669724770642203
I2
I0
I2
tp57759
sS'were,nonsteroidal,agents'
p57760
(F1
F0.00014334862385321102
I0
I1
I-1
tp57761
sS'together,may,decrease'
p57762
(F1
F0.00014334862385321102
I1
I0
I1
tp57763
sS'control,and,levonorgestrel-treated'
p57764
(F1
F0.00014334862385321102
I0
I1
I-1
tp57765
sS'alt,in,a'
p57766
(F1
F0.00014334862385321102
I1
I0
I1
tp57767
sS'or,inhibit,the'
p57768
(F1
F0.00014334862385321102
I1
I0
I1
tp57769
sS'or,the,strength'
p57770
(F1
F0.00014334862385321102
I1
I0
I1
tp57771
sS'fold,and,auc'
p57772
(F1
F0.00014334862385321102
I1
I0
I1
tp57773
sS'to,displace,from'
p57774
(F1
F0.00014334862385321102
I1
I0
I1
tp57775
sS'than,changes,seen'
p57776
(F1
F0.00014334862385321102
I0
I1
I-1
tp57777
sS'humans,may,result'
p57778
(F1
F0.00014334862385321102
I1
I0
I1
tp57779
sS'of,severe,adverse'
p57780
(F1
F0.00014334862385321102
I0
I1
I-1
tp57781
sS'quinolones,have,been'
p57782
(F1
F0.00028669724770642203
I2
I0
I2
tp57783
sS'of,agents,such'
p57784
(F1
F0.00014334862385321102
I0
I1
I-1
tp57785
sS'made,by,using'
p57786
(F1
F0.00014334862385321102
I0
I1
I-1
tp57787
sS'and,one,with'
p57788
(F1
F0.00014334862385321102
I0
I1
I-1
tp57789
sS'excretion,as,well'
p57790
(F1
F0.00014334862385321102
I0
I1
I-1
tp57791
sS'synthetic,hydroalcoholic,solutions'
p57792
(F1
F0.00014334862385321102
I0
I1
I-1
tp57793
sS'higher,end,of'
p57794
(F1
F0.00014334862385321102
I0
I1
I-1
tp57795
sS'vehicle,or,low-dose'
p57796
(F1
F0.00014334862385321102
I1
I0
I1
tp57797
sS'methylxanthines,and,diuretics'
p57798
(F1
F0.00014334862385321102
I1
I0
I1
tp57799
sS'phenytoin,steady,state'
p57800
(F1
F0.00014334862385321102
I1
I0
I1
tp57801
sS'without,altering,prothrombin'
p57802
(F1
F0.00014334862385321102
I1
I0
I1
tp57803
sS'of,prostaglandin,f2alpha'
p57804
(F0
F0
I1
I1
I0
tp57805
sS'that,contain,deet'
p57806
(F1
F0.00014334862385321102
I1
I0
I1
tp57807
sS'increase,the,concentration'
p57808
(F1
F0.00057339449541284407
I4
I0
I4
tp57809
sS'tablets,containing,mg'
p57810
(F1
F0.00014334862385321102
I0
I1
I-1
tp57811
sS'the,year,monthly'
p57812
(F1
F0.00014334862385321102
I0
I1
I-1
tp57813
sS'in,decreased,effectiveness'
p57814
(F1
F0.00014334862385321102
I1
I0
I1
tp57815
sS'therefore,when,sodium'
p57816
(F1
F0.00014334862385321102
I1
I0
I1
tp57817
sS'hypotension,was,more'
p57818
(F1
F0.00014334862385321102
I0
I1
I-1
tp57819
sS'with,for,less'
p57820
(F1
F0.00014334862385321102
I0
I1
I-1
tp57821
sS'was,prolonged,from'
p57822
(F1
F0.00014334862385321102
I1
I0
I1
tp57823
sS'other,non-steroidal,anti-inflammatory'
p57824
(F1
F0.00014334862385321102
I1
I0
I1
tp57825
sS'high,to,toxic'
p57826
(F1
F0.00014334862385321102
I1
I0
I1
tp57827
sS'doxorubicin,doxorubicin,caused'
p57828
(F1
F0.00014334862385321102
I1
I0
I1
tp57829
sS'chemotherapy,plus,haart'
p57830
(F1
F0.00014334862385321102
I0
I1
I-1
tp57831
sS'nefazodone,cyclosporine,large'
p57832
(F1
F0.00014334862385321102
I0
I1
I-1
tp57833
sS'subjects,administered,a'
p57834
(F1
F0.00014334862385321102
I1
I0
I1
tp57835
sS'concomitant,administration,trough'
p57836
(F1
F0.00014334862385321102
I0
I1
I-1
tp57837
sS'kidney,recipients,suggest'
p57838
(F1
F0.00014334862385321102
I0
I1
I-1
tp57839
sS'alternatively,the,effect'
p57840
(F1
F0.00014334862385321102
I0
I1
I-1
tp57841
sS'diuretics,concomitant,treatment'
p57842
(F1
F0.00014334862385321102
I1
I0
I1
tp57843
sS'between,these,events'
p57844
(F1
F0.00014334862385321102
I0
I1
I-1
tp57845
sS'antagonists,and,oral'
p57846
(F1
F0.00014334862385321102
I0
I1
I-1
tp57847
sS'or,excess,may'
p57848
(F1
F0.00014334862385321102
I1
I0
I1
tp57849
sS'substrate,for,p-glycoprotein'
p57850
(F1
F0.00014334862385321102
I0
I1
I-1
tp57851
sS'of,certain,concomitant'
p57852
(F1
F0.00014334862385321102
I0
I1
I-1
tp57853
sS'may,increase,respiratory'
p57854
(F1
F0.00014334862385321102
I1
I0
I1
tp57855
sS'alterations,in,the'
p57856
(F1
F0.00043004587155963305
I0
I3
I-3
tp57857
sS'including,with,a'
p57858
(F1
F0.00014334862385321102
I1
I0
I1
tp57859
sS'three,equal,groups'
p57860
(F1
F0.00014334862385321102
I0
I1
I-1
tp57861
sS'antagonists,should,be'
p57862
(F1
F0.00014334862385321102
I1
I0
I1
tp57863
sS'vasodilator,effects,on'
p57864
(F1
F0.00014334862385321102
I0
I1
I-1
tp57865
sS'impairment,of,mental'
p57866
(F1
F0.00014334862385321102
I0
I1
I-1
tp57867
sS'results,in,approximately'
p57868
(F1
F0.00014334862385321102
I1
I0
I1
tp57869
sS'hours,should,elapse'
p57870
(F1
F0.00014334862385321102
I1
I0
I1
tp57871
sS'viracept,may,not'
p57872
(F1
F0.00014334862385321102
I0
I1
I-1
tp57873
sS'demonstrated,in,all'
p57874
(F1
F0.00014334862385321102
I0
I1
I-1
tp57875
sS'because,some,have'
p57876
(F1
F0.00028669724770642203
I2
I0
I2
tp57877
sS'were,about,higher'
p57878
(F1
F0.00014334862385321102
I1
I0
I1
tp57879
sS'of,animals,dosed'
p57880
(F1
F0.00014334862385321102
I0
I1
I-1
tp57881
sS'days,and,cohort'
p57882
(F1
F0.00014334862385321102
I0
I1
I-1
tp57883
sS'when,treated,with'
p57884
(F1
F0.00014334862385321102
I0
I1
I-1
tp57885
sS'in,any,unexpected'
p57886
(F1
F0.00014334862385321102
I0
I1
I-1
tp57887
sS'of,the,elimination'
p57888
(F0
F0
I1
I1
I0
tp57889
sS'or,weakness,associated'
p57890
(F1
F0.00014334862385321102
I0
I1
I-1
tp57891
sS'by,mg,once'
p57892
(F1
F0.00014334862385321102
I0
I1
I-1
tp57893
sS'lower,in,epileptic'
p57894
(F1
F0.00014334862385321102
I1
I0
I1
tp57895
sS'these,trace,elements'
p57896
(F1
F0.00014334862385321102
I0
I1
I-1
tp57897
sS'observed,by,measuring'
p57898
(F1
F0.00014334862385321102
I0
I1
I-1
tp57899
sS'furosemide,in,normal'
p57900
(F1
F0.00014334862385321102
I0
I1
I-1
tp57901
sS'reviewed,in,an'
p57902
(F1
F0.00014334862385321102
I1
I0
I1
tp57903
sS'received,both,and'
p57904
(F1
F0.00014334862385321102
I0
I1
I-1
tp57905
sS'dose,of,videx'
p57906
(F1
F0.00014334862385321102
I1
I0
I1
tp57907
sS'shown,to,provoke'
p57908
(F1
F0.00014334862385321102
I0
I1
I-1
tp57909
sS'qt,c,interval'
p57910
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp57911
sS'interactions,the,cns-depressant'
p57912
(F1
F0.00014334862385321102
I1
I0
I1
tp57913
sS'to,which,resulted'
p57914
(F1
F0.00014334862385321102
I1
I0
I1
tp57915
sS'it,would,be'
p57916
(F0
F0
I1
I1
I0
tp57917
sS'anesthesia,severe,hypotension'
p57918
(F1
F0.00014334862385321102
I1
I0
I1
tp57919
sS'the,following,interactions'
p57920
(F1
F0.00028669724770642203
I2
I0
I2
tp57921
sS'because,is,eliminated'
p57922
(F0
F0
I1
I1
I0
tp57923
sS'respectively,of,the'
p57924
(F1
F0.00014334862385321102
I0
I1
I-1
tp57925
sS'to,be,reversed'
p57926
(F1
F0.00014334862385321102
I1
I0
I1
tp57927
sS'affected,response,duration'
p57928
(F1
F0.00014334862385321102
I1
I0
I1
tp57929
sS'therefore,advised,in'
p57930
(F1
F0.00014334862385321102
I1
I0
I1
tp57931
sS'conducted,for,colazal'
p57932
(F1
F0.00014334862385321102
I0
I1
I-1
tp57933
sS'of,with,these'
p57934
(F1
F0.00043004587155963305
I0
I3
I-3
tp57935
sS'bleeding,reduced,dosage'
p57936
(F1
F0.00014334862385321102
I1
I0
I1
tp57937
sS'each,other,when'
p57938
(F1
F0.00014334862385321102
I1
I0
I1
tp57939
sS'administration,of,decreased'
p57940
(F1
F0.00028669724770642203
I2
I0
I2
tp57941
sS'is,initiated,adjusted'
p57942
(F1
F0.00014334862385321102
I1
I0
I1
tp57943
sS'the,auc,but'
p57944
(F1
F0.00014334862385321102
I1
I0
I1
tp57945
sS'urine,which,may'
p57946
(F1
F0.00014334862385321102
I0
I1
I-1
tp57947
sS'change,the,amount'
p57948
(F1
F0.00014334862385321102
I1
I0
I1
tp57949
sS'since,the,coadministration'
p57950
(F1
F0.00014334862385321102
I0
I1
I-1
tp57951
sS'of,intravenous,and'
p57952
(F1
F0.00014334862385321102
I1
I0
I1
tp57953
sS'increase,toxicity,in'
p57954
(F1
F0.00014334862385321102
I1
I0
I1
tp57955
sS'studies,on,two'
p57956
(F1
F0.00014334862385321102
I0
I1
I-1
tp57957
sS'a-chloralose,anesthetized,swine'
p57958
(F1
F0.00014334862385321102
I0
I1
I-1
tp57959
sS'involved,either,the'
p57960
(F1
F0.00014334862385321102
I0
I1
I-1
tp57961
sS'when,amitriptyline,hcl'
p57962
(F0
F0
I1
I1
I0
tp57963
sS'channel,blockers,l-type'
p57964
(F1
F0.00014334862385321102
I0
I1
I-1
tp57965
sS'auc,and,cmax'
p57966
(F0.14285714285714285
F0.00028669724770642203
I6
I8
I-2
tp57967
sS'seizure,threshold,concurrent'
p57968
(F1
F0.00014334862385321102
I1
I0
I1
tp57969
sS'include,but,are'
p57970
(F1
F0.00014334862385321102
I0
I1
I-1
tp57971
sS'daily,a,potent'
p57972
(F1
F0.00014334862385321102
I1
I0
I1
tp57973
sS'norethindrone,coadministration,of'
p57974
(F1
F0.00014334862385321102
I1
I0
I1
tp57975
sS'that,included,a'
p57976
(F1
F0.00014334862385321102
I0
I1
I-1
tp57977
sS'when,is,added'
p57978
(F1
F0.00071674311926605509
I5
I0
I5
tp57979
sS'fluoxetine,indanavir,ketoconazole'
p57980
(F1
F0.00014334862385321102
I0
I1
I-1
tp57981
sS'size,mydriasis,resulting'
p57982
(F1
F0.00014334862385321102
I1
I0
I1
tp57983
sS'observed,following,concurrent'
p57984
(F1
F0.00014334862385321102
I1
I0
I1
tp57985
sS'interaction,was,noted'
p57986
(F1
F0.00014334862385321102
I0
I1
I-1
tp57987
sS'serious,cardiac,dysrhythmias'
p57988
(F1
F0.00014334862385321102
I1
I0
I1
tp57989
sS'expected,to,cause'
p57990
(F1
F0.00014334862385321102
I0
I1
I-1
tp57991
sS'blood,pressure,response'
p57992
(F1
F0.00014334862385321102
I0
I1
I-1
tp57993
sS'binding,of,acetylsalicylic'
p57994
(F1
F0.00014334862385321102
I0
I1
I-1
tp57995
sS'recommended,that,allegra'
p57996
(F1
F0.00014334862385321102
I0
I1
I-1
tp57997
sS'in,markedly,increased'
p57998
(F1
F0.00014334862385321102
I1
I0
I1
tp57999
sS'not,observed,in'
p58000
(F1
F0.00014334862385321102
I1
I0
I1
tp58001
sS'bioavailability,or,due'
p58002
(F1
F0.00014334862385321102
I0
I1
I-1
tp58003
sS'gonadotropin,levels,may'
p58004
(F1
F0.00014334862385321102
I0
I1
I-1
tp58005
sS'reduced,by,about'
p58006
(F1
F0.00014334862385321102
I1
I0
I1
tp58007
sS'has,shown,a'
p58008
(F1
F0.00071674311926605509
I5
I0
I5
tp58009
sS'including,produce,cns-depressant'
p58010
(F1
F0.00014334862385321102
I1
I0
I1
tp58011
sS'as,demonstrated,by'
p58012
(F1
F0.00014334862385321102
I0
I1
I-1
tp58013
sS'of,decreased,the'
p58014
(F1
F0.0010034403669724771
I7
I0
I7
tp58015
sS'documented,hypokalemia,and'
p58016
(F1
F0.00014334862385321102
I0
I1
I-1
tp58017
sS'effect,on,blood'
p58018
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp58019
sS'report,nine,patients'
p58020
(F1
F0.00014334862385321102
I1
I0
I1
tp58021
sS'form,a,sudden'
p58022
(F1
F0.00014334862385321102
I1
I0
I1
tp58023
sS'was,preceded,by'
p58024
(F1
F0.00014334862385321102
I0
I1
I-1
tp58025
sS'result,in,lower'
p58026
(F1
F0.00014334862385321102
I1
I0
I1
tp58027
sS'of,serious,or'
p58028
(F1
F0.00014334862385321102
I0
I1
I-1
tp58029
sS'of,cyp2d6,i'
p58030
(F1
F0.00014334862385321102
I1
I0
I1
tp58031
sS'of,these,resulting'
p58032
(F1
F0.00014334862385321102
I1
I0
I1
tp58033
sS'and,a,prolongation'
p58034
(F1
F0.00014334862385321102
I1
I0
I1
tp58035
sS'cns,effect,caution'
p58036
(F1
F0.00014334862385321102
I1
I0
I1
tp58037
sS'this,may,occur'
p58038
(F1
F0.00014334862385321102
I1
I0
I1
tp58039
sS'exposures,to,may'
p58040
(F1
F0.00014334862385321102
I1
I0
I1
tp58041
sS'receiving,other,antianxiety'
p58042
(F1
F0.00014334862385321102
I1
I0
I1
tp58043
sS'not,appear,to'
p58044
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp58045
sS'of,nalfon,the'
p58046
(F1
F0.00014334862385321102
I1
I0
I1
tp58047
sS'mg,each,administered'
p58048
(F1
F0.00014334862385321102
I1
I0
I1
tp58049
sS'interactions,in,vitro'
p58050
(F1
F0.00014334862385321102
I0
I1
I-1
tp58051
sS'drug,interactions,oral'
p58052
(F1
F0.00014334862385321102
I0
I1
I-1
tp58053
sS'danazol,the,risk'
p58054
(F1
F0.00014334862385321102
I1
I0
I1
tp58055
sS'of,in,vitro'
p58056
(F1
F0.00014334862385321102
I1
I0
I1
tp58057
sS'enhances,the,manifestation'
p58058
(F1
F0.00014334862385321102
I1
I0
I1
tp58059
sS'to,see,if'
p58060
(F1
F0.00014334862385321102
I1
I0
I1
tp58061
sS'patients,on,and'
p58062
(F1
F0.00043004587155963305
I3
I0
I3
tp58063
sS'acutely,worsened,by'
p58064
(F1
F0.00014334862385321102
I1
I0
I1
tp58065
sS'report,of,severe'
p58066
(F1
F0.00014334862385321102
I1
I0
I1
tp58067
sS'to,increase,their'
p58068
(F1
F0.00014334862385321102
I1
I0
I1
tp58069
sS'or,other,oral'
p58070
(F1
F0.00014334862385321102
I1
I0
I1
tp58071
sS'produce,clinically,significant'
p58072
(F1
F0.00028669724770642203
I2
I0
I2
tp58073
sS'treated,with,ibandronate'
p58074
(F1
F0.00014334862385321102
I0
I1
I-1
tp58075
sS'aluminum-containing,antacid,products'
p58076
(F1
F0.00014334862385321102
I0
I1
I-1
tp58077
sS'acidifying,agents,glutamic'
p58078
(F1
F0.00014334862385321102
I1
I0
I1
tp58079
sS'respectively,a,strong'
p58080
(F1
F0.00014334862385321102
I1
I0
I1
tp58081
sS'other,aeds,and'
p58082
(F1
F0.00028669724770642203
I0
I2
I-2
tp58083
sS'mao,inhibitors,duragesic'
p58084
(F1
F0.00014334862385321102
I1
I0
I1
tp58085
sS'the,long,half-life'
p58086
(F1
F0.00014334862385321102
I1
I0
I1
tp58087
sS'increased,by,the'
p58088
(F1
F0.00028669724770642203
I2
I0
I2
tp58089
sS'users,the,incidence'
p58090
(F1
F0.00014334862385321102
I0
I1
I-1
tp58091
sS'myelosuppression,was,more'
p58092
(F1
F0.00014334862385321102
I1
I0
I1
tp58093
sS'treated,with,other'
p58094
(F1
F0.00014334862385321102
I0
I1
I-1
tp58095
sS'and,are,administered'
p58096
(F1
F0.00057339449541284407
I4
I0
I4
tp58097
sS'pharmacokinetics,of,gemzar'
p58098
(F1
F0.00014334862385321102
I0
I1
I-1
tp58099
sS'indocin,and,potassium-sparing'
p58100
(F0
F0
I1
I1
I0
tp58101
sS'thereafter,and,the'
p58102
(F1
F0.00014334862385321102
I1
I0
I1
tp58103
sS'following,use,with'
p58104
(F1
F0.00014334862385321102
I1
I0
I1
tp58105
sS'on,combination,therapy'
p58106
(F1
F0.00014334862385321102
I0
I1
I-1
tp58107
sS'fold,and,the'
p58108
(F1
F0.00057339449541284407
I4
I0
I4
tp58109
sS'change,to,a'
p58110
(F1
F0.00014334862385321102
I1
I0
I1
tp58111
sS'by,decreased,clearance'
p58112
(F1
F0.00043004587155963305
I3
I0
I3
tp58113
sS'other,when,is'
p58114
(F1
F0.00014334862385321102
I1
I0
I1
tp58115
sS'with,heparin-induced,thrombocytopenia'
p58116
(F1
F0.00014334862385321102
I0
I1
I-1
tp58117
sS'conjunction,with,central'
p58118
(F1
F0.00014334862385321102
I1
I0
I1
tp58119
sS'to,one,third'
p58120
(F1
F0.00014334862385321102
I1
I0
I1
tp58121
sS'other,may,increase'
p58122
(F1
F0.00028669724770642203
I2
I0
I2
tp58123
sS'receiving,careful,monitoring'
p58124
(F1
F0.00014334862385321102
I1
I0
I1
tp58125
sS'vitamin-d,mediated,signalling'
p58126
(F1
F0.00014334862385321102
I0
I1
I-1
tp58127
sS'were,above,or'
p58128
(F1
F0.00014334862385321102
I1
I0
I1
tp58129
sS'a,molecular,basis'
p58130
(F1
F0.00014334862385321102
I1
I0
I1
tp58131
sS'and,iv,is'
p58132
(F1
F0.00014334862385321102
I1
I0
I1
tp58133
sS'such,as,acetylsalicylic'
p58134
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp58135
sS'renin,activity,pra'
p58136
(F1
F0.00014334862385321102
I0
I1
I-1
tp58137
sS'including,immune,system'
p58138
(F1
F0.00014334862385321102
I0
I1
I-1
tp58139
sS'receiving,intravenous,amphotericin'
p58140
(F1
F0.00014334862385321102
I1
I0
I1
tp58141
sS'antipsychotic,action,of'
p58142
(F1
F0.00014334862385321102
I0
I1
I-1
tp58143
sS'be,introduced,at'
p58144
(F1
F0.00014334862385321102
I1
I0
I1
tp58145
sS'per,day,are'
p58146
(F1
F0.00014334862385321102
I0
I1
I-1
tp58147
sS'supersensitive,to,when'
p58148
(F1
F0.00014334862385321102
I1
I0
I1
tp58149
sS'on,the,plasma'
p58150
(F0
F0
I2
I2
I0
tp58151
sS'were,significantly,altered'
p58152
(F1
F0.00014334862385321102
I1
I0
I1
tp58153
sS'mao,inhibitors,has'
p58154
(F1
F0.00014334862385321102
I1
I0
I1
tp58155
sS'causal,relationship,has'
p58156
(F1
F0.00014334862385321102
I1
I0
I1
tp58157
sS'when,the,is'
p58158
(F1
F0.00014334862385321102
I1
I0
I1
tp58159
sS'use,short-acting,because'
p58160
(F1
F0.00014334862385321102
I1
I0
I1
tp58161
sS'control,pills,sleeping'
p58162
(F1
F0.00014334862385321102
I0
I1
I-1
tp58163
sS'awareness,of,the'
p58164
(F1
F0.00014334862385321102
I1
I0
I1
tp58165
sS'fluconazole,concomitant,administration'
p58166
(F1
F0.00014334862385321102
I1
I0
I1
tp58167
sS'p450,enzymes,carbamazepine'
p58168
(F1
F0.00014334862385321102
I0
I1
I-1
tp58169
sS'treatment,during,the'
p58170
(F1
F0.00014334862385321102
I0
I1
I-1
tp58171
sS'a,large,reduction'
p58172
(F1
F0.00014334862385321102
I1
I0
I1
tp58173
sS'by,a,decrease'
p58174
(F1
F0.00028669724770642203
I2
I0
I2
tp58175
sS'involvement,of,other'
p58176
(F1
F0.00014334862385321102
I1
I0
I1
tp58177
sS'are,used,in'
p58178
(F1
F0.00014334862385321102
I1
I0
I1
tp58179
sS'increasing,the,effectiveness'
p58180
(F1
F0.00014334862385321102
I1
I0
I1
tp58181
sS'is,the,potential'
p58182
(F0
F0
I1
I1
I0
tp58183
sS'approximately,when,coadministered'
p58184
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp58185
sS'over,the,dosage'
p58186
(F1
F0.00014334862385321102
I1
I0
I1
tp58187
sS'once,a,day'
p58188
(F1
F0.00014334862385321102
I0
I1
I-1
tp58189
sS'the,oral,dose'
p58190
(F1
F0.00014334862385321102
I1
I0
I1
tp58191
sS'of,whether,these'
p58192
(F1
F0.00014334862385321102
I1
I0
I1
tp58193
sS'other,diagnostic,or'
p58194
(F1
F0.00014334862385321102
I0
I1
I-1
tp58195
sS'acid,and,related'
p58196
(F1
F0.00014334862385321102
I0
I1
I-1
tp58197
sS'the,acute,toxicity'
p58198
(F1
F0.00014334862385321102
I1
I0
I1
tp58199
sS'other,amphotericin,b'
p58200
(F1
F0.00014334862385321102
I1
I0
I1
tp58201
sS'sirolimus,works,differently'
p58202
(F1
F0.00014334862385321102
I0
I1
I-1
tp58203
sS'observed,increase,in'
p58204
(F1
F0.00014334862385321102
I1
I0
I1
tp58205
sS'neostgmine,can,enhance'
p58206
(F1
F0.00014334862385321102
I0
I1
I-1
tp58207
sS'and,amphotericin,b'
p58208
(F1
F0.00014334862385321102
I1
I0
I1
tp58209
sS'result,in,fold'
p58210
(F1
F0.00014334862385321102
I1
I0
I1
tp58211
sS'retrospectively,a,group'
p58212
(F1
F0.00014334862385321102
I0
I1
I-1
tp58213
sS'efficacy,and,safety'
p58214
(F1
F0.00014334862385321102
I0
I1
I-1
tp58215
sS'administration,of,non-steroidal'
p58216
(F1
F0.00014334862385321102
I1
I0
I1
tp58217
sS'substitutes,may,lead'
p58218
(F0
F0
I1
I1
I0
tp58219
sS'substrates,drugs,which'
p58220
(F1
F0.00014334862385321102
I1
I0
I1
tp58221
sS'without,a,functioning'
p58222
(F1
F0.00014334862385321102
I1
I0
I1
tp58223
sS'cell,growth,both'
p58224
(F1
F0.00014334862385321102
I0
I1
I-1
tp58225
sS'and,may,result'
p58226
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp58227
sS'to,daily,treatment'
p58228
(F1
F0.00014334862385321102
I0
I1
I-1
tp58229
sS'in,cmax,and'
p58230
(F1
F0.0010034403669724771
I7
I0
I7
tp58231
sS'interaction,occurs,with'
p58232
(F1
F0.00014334862385321102
I0
I1
I-1
tp58233
sS'of,and,effects'
p58234
(F1
F0.00014334862385321102
I0
I1
I-1
tp58235
sS'of,seizures,have'
p58236
(F1
F0.00014334862385321102
I1
I0
I1
tp58237
sS'on,the,degree'
p58238
(F1
F0.00071674311926605509
I5
I0
I5
tp58239
sS'of,buforin,ii'
p58240
(F1
F0.00028669724770642203
I0
I2
I-2
tp58241
sS'adverse,interaction,to'
p58242
(F1
F0.00014334862385321102
I0
I1
I-1
tp58243
sS'relaxants,could,be'
p58244
(F1
F0.00014334862385321102
I1
I0
I1
tp58245
sS'capsules,there,have'
p58246
(F1
F0.00014334862385321102
I1
I0
I1
tp58247
sS'used,concomitantly,renal'
p58248
(F1
F0.00014334862385321102
I1
I0
I1
tp58249
sS'dynacirc,an,increased'
p58250
(F1
F0.00014334862385321102
I0
I1
I-1
tp58251
sS'fluids,might,be'
p58252
(F1
F0.00014334862385321102
I0
I1
I-1
tp58253
sS'extent,of,absorption'
p58254
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp58255
sS'daily,resulted,in'
p58256
(F1
F0.00043004587155963305
I3
I0
I3
tp58257
sS'potent,cytochrome,p450'
p58258
(F1
F0.00014334862385321102
I1
I0
I1
tp58259
sS'on,the,concomitant'
p58260
(F1
F0.00014334862385321102
I1
I0
I1
tp58261
sS'and,ast,when'
p58262
(F1
F0.00014334862385321102
I1
I0
I1
tp58263
sS'although,specific,interaction'
p58264
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp58265
sS'in,a,month'
p58266
(F1
F0.00028669724770642203
I0
I2
I-2
tp58267
sS'with,bioavailability,parameters'
p58268
(F1
F0.00014334862385321102
I0
I1
I-1
tp58269
sS'as,plasma,asparagine'
p58270
(F1
F0.00014334862385321102
I1
I0
I1
tp58271
sS'of,mm,or'
p58272
(F1
F0.00014334862385321102
I0
I1
I-1
tp58273
sS'over,three,hours'
p58274
(F1
F0.00014334862385321102
I0
I1
I-1
tp58275
sS'coadministration,of,lexapro'
p58276
(F1
F0.00014334862385321102
I0
I1
I-1
tp58277
sS'that,received,mg'
p58278
(F1
F0.00014334862385321102
I0
I1
I-1
tp58279
sS'subjects,received,in'
p58280
(F1
F0.00014334862385321102
I0
I1
I-1
tp58281
sS'least,halved,and'
p58282
(F1
F0.00014334862385321102
I1
I0
I1
tp58283
sS'the,antipsychotic,action'
p58284
(F1
F0.00014334862385321102
I0
I1
I-1
tp58285
sS'pharmacokinetics,of,sonata'
p58286
(F1
F0.00014334862385321102
I0
I1
I-1
tp58287
sS'acarbose,was,bioequivalent'
p58288
(F1
F0.00014334862385321102
I0
I1
I-1
tp58289
sS'antihistamines,amphetamines,may'
p58290
(F1
F0.00028669724770642203
I2
I0
I2
tp58291
sS'received,mg,of'
p58292
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp58293
sS'be,due,to'
p58294
(F1
F0.00014334862385321102
I1
I0
I1
tp58295
sS'is,an,interactive'
p58296
(F1
F0.00028669724770642203
I0
I2
I-2
tp58297
sS'with,indicate,that'
p58298
(F1
F0.00014334862385321102
I1
I0
I1
tp58299
sS'added,of,the'
p58300
(F1
F0.00014334862385321102
I1
I0
I1
tp58301
sS'of,was,generally'
p58302
(F1
F0.00014334862385321102
I0
I1
I-1
tp58303
sS'contents,of,the'
p58304
(F1
F0.00014334862385321102
I0
I1
I-1
tp58305
sS'flucytosine,while,a'
p58306
(F1
F0.00014334862385321102
I1
I0
I1
tp58307
sS'levonorgestrel-treated,rats,and'
p58308
(F1
F0.00014334862385321102
I0
I1
I-1
tp58309
sS'compared,to,its'
p58310
(F1
F0.00014334862385321102
I0
I1
I-1
tp58311
sS'and,which,has'
p58312
(F1
F0.00014334862385321102
I0
I1
I-1
tp58313
sS'kg,via,dehydrogenase'
p58314
(F1
F0.00014334862385321102
I1
I0
I1
tp58315
sS'telithromycin,hiv,protease'
p58316
(F1
F0.00014334862385321102
I0
I1
I-1
tp58317
sS'days,does,not'
p58318
(F1
F0.00014334862385321102
I0
I1
I-1
tp58319
sS'and,mg,day'
p58320
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp58321
sS'inherent,in,any'
p58322
(F1
F0.00014334862385321102
I1
I0
I1
tp58323
sS'max,increased,by'
p58324
(F0
F0
I1
I1
I0
tp58325
sS'and,with,plus'
p58326
(F1
F0.00014334862385321102
I0
I1
I-1
tp58327
sS'enoxacin,is,a'
p58328
(F1
F0.00028669724770642203
I2
I0
I2
tp58329
sS'decreased,levels,in'
p58330
(F1
F0.00014334862385321102
I0
I1
I-1
tp58331
sS'transferred,to,the'
p58332
(F1
F0.00014334862385321102
I0
I1
I-1
tp58333
sS'determined,on,day'
p58334
(F1
F0.00014334862385321102
I1
I0
I1
tp58335
sS'anticoagulants,in,a'
p58336
(F1
F0.00014334862385321102
I0
I1
I-1
tp58337
sS'provoke,toxicity,because'
p58338
(F1
F0.00014334862385321102
I0
I1
I-1
tp58339
sS'exercised,during,the'
p58340
(F1
F0.00014334862385321102
I1
I0
I1
tp58341
sS'and,total,body'
p58342
(F1
F0.00014334862385321102
I0
I1
I-1
tp58343
sS'of,mg,increased'
p58344
(F1
F0.00014334862385321102
I1
I0
I1
tp58345
sS'activase,in,the'
p58346
(F1
F0.00014334862385321102
I0
I1
I-1
tp58347
sS'of,and,should'
p58348
(F1
F0.00028669724770642203
I2
I0
I2
tp58349
sS'effects,on,av'
p58350
(F1
F0.00014334862385321102
I1
I0
I1
tp58351
sS'inactivated,due,to'
p58352
(F1
F0.00014334862385321102
I1
I0
I1
tp58353
sS'use,of,in'
p58354
(F1
F0.00014334862385321102
I1
I0
I1
tp58355
sS'metabolism,are,unlikely'
p58356
(F1
F0.00014334862385321102
I0
I1
I-1
tp58357
sS'an,animal,model'
p58358
(F1
F0.00014334862385321102
I1
I0
I1
tp58359
sS'withdrawn,at,least'
p58360
(F1
F0.00028669724770642203
I2
I0
I2
tp58361
sS'or,monoamine,oxidase'
p58362
(F1
F0.00014334862385321102
I1
I0
I1
tp58363
sS'modify,the,rate'
p58364
(F1
F0.00014334862385321102
I0
I1
I-1
tp58365
sS'auc,ss,of'
p58366
(F1
F0.00028669724770642203
I2
I0
I2
tp58367
sS'agents,and,has'
p58368
(F1
F0.00014334862385321102
I1
I0
I1
tp58369
sS'physician,or,are'
p58370
(F1
F0.00014334862385321102
I1
I0
I1
tp58371
sS'grapefruit,juice,given'
p58372
(F1
F0.00014334862385321102
I0
I1
I-1
tp58373
sS'and,primarily,metabolized'
p58374
(F1
F0.00014334862385321102
I0
I1
I-1
tp58375
sS'the,possible,additive'
p58376
(F1
F0.00014334862385321102
I1
I0
I1
tp58377
sS'use,of,is'
p58378
(F1
F0.00014334862385321102
I1
I0
I1
tp58379
sS'patients,although,combining'
p58380
(F1
F0.00014334862385321102
I0
I1
I-1
tp58381
sS'if,labetalol,hcl'
p58382
(F1
F0.00014334862385321102
I1
I0
I1
tp58383
sS'to,cause,coronary'
p58384
(F1
F0.00014334862385321102
I1
I0
I1
tp58385
sS'symptoms,of,hyperlipidemia'
p58386
(F1
F0.00014334862385321102
I1
I0
I1
tp58387
sS'gastrointestinal,toxicity,with'
p58388
(F1
F0.00028669724770642203
I2
I0
I2
tp58389
sS'as,toxic,epidermal'
p58390
(F1
F0.00014334862385321102
I0
I1
I-1
tp58391
sS'increased,dose,mg'
p58392
(F1
F0.00014334862385321102
I1
I0
I1
tp58393
sS'eight,healthy,volunteers'
p58394
(F1
F0.00014334862385321102
I1
I0
I1
tp58395
sS'furosemide,should,not'
p58396
(F1
F0.00014334862385321102
I1
I0
I1
tp58397
sS'fever,tremulousness,and'
p58398
(F1
F0.00014334862385321102
I1
I0
I1
tp58399
sS'micromol,l,or'
p58400
(F1
F0.00014334862385321102
I0
I1
I-1
tp58401
sS'cells,rr,had'
p58402
(F1
F0.00014334862385321102
I0
I1
I-1
tp58403
sS'about,and,greater'
p58404
(F1
F0.00014334862385321102
I1
I0
I1
tp58405
sS'infections,and,increased'
p58406
(F1
F0.00014334862385321102
I1
I0
I1
tp58407
sS'aucs,of,unbound'
p58408
(F1
F0.00014334862385321102
I0
I1
I-1
tp58409
sS'barbiturates,may,decrease'
p58410
(F1
F0.00014334862385321102
I1
I0
I1
tp58411
sS'levels,of,metabolized'
p58412
(F1
F0.00014334862385321102
I0
I1
I-1
tp58413
sS'diagnosis,of,deficiency'
p58414
(F1
F0.00014334862385321102
I0
I1
I-1
tp58415
sS'auc,a,fold'
p58416
(F1
F0.00014334862385321102
I1
I0
I1
tp58417
sS'clinical,bleeding,has'
p58418
(F1
F0.00028669724770642203
I2
I0
I2
tp58419
sS'stadol,ns,was'
p58420
(F1
F0.00028669724770642203
I2
I0
I2
tp58421
sS'or,use,may'
p58422
(F1
F0.00014334862385321102
I0
I1
I-1
tp58423
sS'the,concomitant,intake'
p58424
(F1
F0.00014334862385321102
I0
I1
I-1
tp58425
sS'other,nonsteroidal,can'
p58426
(F1
F0.00014334862385321102
I1
I0
I1
tp58427
sS'is,given,to'
p58428
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp58429
sS'dose,adjustments,of'
p58430
(F1
F0.00014334862385321102
I0
I1
I-1
tp58431
sS'intrathecal,micrograms,had'
p58432
(F1
F0.00014334862385321102
I1
I0
I1
tp58433
sS'since,photic,evoked'
p58434
(F1
F0.00014334862385321102
I0
I1
I-1
tp58435
sS'substrates,and,inhibitors'
p58436
(F1
F0.00014334862385321102
I0
I1
I-1
tp58437
sS'and,rises,in'
p58438
(F1
F0.00014334862385321102
I1
I0
I1
tp58439
sS'bleeding,parameters,in'
p58440
(F1
F0.00014334862385321102
I1
I0
I1
tp58441
sS'protein,and,therefore'
p58442
(F1
F0.00014334862385321102
I0
I1
I-1
tp58443
sS'increase,in,arc'
p58444
(F1
F0.00014334862385321102
I1
I0
I1
tp58445
sS'starting,other,therapy'
p58446
(F1
F0.00014334862385321102
I0
I1
I-1
tp58447
sS'a,cyp2d6,substrate'
p58448
(F1
F0.00014334862385321102
I1
I0
I1
tp58449
sS'subjects,ingesting,these'
p58450
(F1
F0.00014334862385321102
I1
I0
I1
tp58451
sS'clinical,studies,performed'
p58452
(F1
F0.00014334862385321102
I0
I1
I-1
tp58453
sS'between,toradoliv,im'
p58454
(F1
F0.00014334862385321102
I0
I1
I-1
tp58455
sS'tolerance,allowing,gradually'
p58456
(F1
F0.00014334862385321102
I0
I1
I-1
tp58457
sS'heart,rate,at'
p58458
(F1
F0.00014334862385321102
I0
I1
I-1
tp58459
sS'or,the,pediatric'
p58460
(F1
F0.0008600917431192661
I6
I0
I6
tp58461
sS'reports,of,adverse'
p58462
(F1
F0.00014334862385321102
I1
I0
I1
tp58463
sS'with,sustained-release,channel'
p58464
(F1
F0.00014334862385321102
I0
I1
I-1
tp58465
sS'received,concomitant,and'
p58466
(F1
F0.00014334862385321102
I0
I1
I-1
tp58467
sS'didanosine-placebo,tablets,a'
p58468
(F1
F0.00014334862385321102
I1
I0
I1
tp58469
sS'suitable,anticoagulation,test'
p58470
(F1
F0.00014334862385321102
I1
I0
I1
tp58471
sS'often,used,in'
p58472
(F1
F0.00014334862385321102
I0
I1
I-1
tp58473
sS'studies,on,the'
p58474
(F1
F0.00014334862385321102
I0
I1
I-1
tp58475
sS'and,thus,lower'
p58476
(F1
F0.00014334862385321102
I1
I0
I1
tp58477
sS'coadministered,with,cyp2d6'
p58478
(F1
F0.00014334862385321102
I1
I0
I1
tp58479
sS'that,can,deplete'
p58480
(F1
F0.00014334862385321102
I1
I0
I1
tp58481
sS'and,extensive,cyp2d6'
p58482
(F1
F0.00014334862385321102
I0
I1
I-1
tp58483
sS'was,evaluated,in'
p58484
(F1
F0.0008600917431192661
I0
I6
I-6
tp58485
sS'as,because,of'
p58486
(F1
F0.00043004587155963305
I3
I0
I3
tp58487
sS'respectto,safety,and'
p58488
(F1
F0.00014334862385321102
I0
I1
I-1
tp58489
sS'be,given,concomitantly'
p58490
(F1
F0.00014334862385321102
I0
I1
I-1
tp58491
sS'many,people,use'
p58492
(F1
F0.00014334862385321102
I0
I1
I-1
tp58493
sS'such,as,convulsions'
p58494
(F1
F0.00014334862385321102
I1
I0
I1
tp58495
sS'on,blood,levels'
p58496
(F0
F0
I1
I1
I0
tp58497
sS'on,adult,data'
p58498
(F1
F0.00014334862385321102
I1
I0
I1
tp58499
sS'were,significantly,greater'
p58500
(F1
F0.00014334862385321102
I0
I1
I-1
tp58501
sS'depressants,including,concomitantly'
p58502
(F1
F0.00028669724770642203
I2
I0
I2
tp58503
sS'glucuronidation,and,intestinal'
p58504
(F1
F0.00014334862385321102
I0
I1
I-1
tp58505
sS'activity,of,buforin'
p58506
(F1
F0.00028669724770642203
I0
I2
I-2
tp58507
sS'deferred,until,therapy'
p58508
(F1
F0.00014334862385321102
I1
I0
I1
tp58509
sS'a,fluoroquinolone,has'
p58510
(F1
F0.00014334862385321102
I1
I0
I1
tp58511
sS'days,with,a'
p58512
(F1
F0.00014334862385321102
I1
I0
I1
tp58513
sS'to,study,the'
p58514
(F1
F0.00057339449541284407
I0
I4
I-4
tp58515
sS'medication,including,solganal'
p58516
(F1
F0.00014334862385321102
I1
I0
I1
tp58517
sS'epidural,include,hypotension'
p58518
(F1
F0.00014334862385321102
I1
I0
I1
tp58519
sS'addition,of,to'
p58520
(F0
F0
I2
I2
I0
tp58521
sS'dietary,concentrations,showing'
p58522
(F1
F0.00014334862385321102
I0
I1
I-1
tp58523
sS'inhibit,cyp3a4,activity'
p58524
(F1
F0.00014334862385321102
I0
I1
I-1
tp58525
sS'revia,the,amount'
p58526
(F1
F0.00014334862385321102
I1
I0
I1
tp58527
sS'red,blood,cells'
p58528
(F1
F0.00014334862385321102
I0
I1
I-1
tp58529
sS'interact,with,concurrently'
p58530
(F1
F0.00014334862385321102
I1
I0
I1
tp58531
sS'significant,changes,occurred'
p58532
(F1
F0.00014334862385321102
I0
I1
I-1
tp58533
sS'taken,closely,in'
p58534
(F1
F0.00014334862385321102
I1
I0
I1
tp58535
sS'potent,non-nucleoside,reverse'
p58536
(F1
F0.00014334862385321102
I0
I1
I-1
tp58537
sS'blocker,should,be'
p58538
(F1
F0.00014334862385321102
I1
I0
I1
tp58539
sS'secreted,via,this'
p58540
(F1
F0.00014334862385321102
I1
I0
I1
tp58541
sS'data,where,iressa'
p58542
(F1
F0.00014334862385321102
I1
I0
I1
tp58543
sS'apoptosis,can,be'
p58544
(F1
F0.00014334862385321102
I0
I1
I-1
tp58545
sS'requiring,an,increase'
p58546
(F1
F0.00014334862385321102
I1
I0
I1
tp58547
sS'patients,taking,that'
p58548
(F1
F0.00014334862385321102
I0
I1
I-1
tp58549
sS'for,the,p-glycoprotein'
p58550
(F1
F0.00014334862385321102
I0
I1
I-1
tp58551
sS'and,or,a'
p58552
(F1
F0.00014334862385321102
I1
I0
I1
tp58553
sS'are,increased,by'
p58554
(F1
F0.00028669724770642203
I2
I0
I2
tp58555
sS'potential,for,to'
p58556
(F1
F0.00014334862385321102
I0
I1
I-1
tp58557
sS'of,distribution,of'
p58558
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp58559
sS'copegus,and,is'
p58560
(F1
F0.00014334862385321102
I1
I0
I1
tp58561
sS'administered,once,daily'
p58562
(F0
F0
I2
I2
I0
tp58563
sS'inhibit,these,isoenzymes'
p58564
(F1
F0.00014334862385321102
I0
I1
I-1
tp58565
sS'blockade,by,of'
p58566
(F1
F0.00014334862385321102
I1
I0
I1
tp58567
sS'failure,in,two'
p58568
(F1
F0.00014334862385321102
I1
I0
I1
tp58569
sS'mean,increase,in'
p58570
(F1
F0.00028669724770642203
I2
I0
I2
tp58571
sS'analyses,of,patient'
p58572
(F1
F0.00014334862385321102
I1
I0
I1
tp58573
sS'levels,with,co-administration'
p58574
(F1
F0.00014334862385321102
I1
I0
I1
tp58575
sS'concomitantly,in,the'
p58576
(F1
F0.00014334862385321102
I1
I0
I1
tp58577
sS'incidence,of,lymphatic'
p58578
(F1
F0.00014334862385321102
I1
I0
I1
tp58579
sS'the,bactericidal,effect'
p58580
(F1
F0.00014334862385321102
I1
I0
I1
tp58581
sS'with,epilepsy,also'
p58582
(F1
F0.00014334862385321102
I0
I1
I-1
tp58583
sS'treatment,should,be'
p58584
(F1
F0.00043004587155963305
I3
I0
I3
tp58585
sS'pressure,their,combined'
p58586
(F1
F0.00014334862385321102
I1
I0
I1
tp58587
sS'extent,to,which'
p58588
(F1
F0.00071674311926605509
I5
I0
I5
tp58589
sS'renal,and,cardiac'
p58590
(F1
F0.00028669724770642203
I2
I0
I2
tp58591
sS'procedure,it,was'
p58592
(F1
F0.00014334862385321102
I0
I1
I-1
tp58593
sS'partially,related,to'
p58594
(F1
F0.00014334862385321102
I1
I0
I1
tp58595
sS'if,coreg,is'
p58596
(F1
F0.00014334862385321102
I1
I0
I1
tp58597
sS'diabetic,patients,the'
p58598
(F1
F0.00028669724770642203
I2
I0
I2
tp58599
sS'supplementation,with,water-miscible'
p58600
(F1
F0.00014334862385321102
I0
I1
I-1
tp58601
sS'substrate,and,a'
p58602
(F1
F0.00028669724770642203
I0
I2
I-2
tp58603
sS'increased,about,compared'
p58604
(F1
F0.00014334862385321102
I1
I0
I1
tp58605
sS'except,leukemia,in'
p58606
(F1
F0.00014334862385321102
I1
I0
I1
tp58607
sS'confidence,interval,decrease'
p58608
(F1
F0.00014334862385321102
I0
I1
I-1
tp58609
sS'effectiveness,of,proleukin'
p58610
(F1
F0.00014334862385321102
I1
I0
I1
tp58611
sS'reduced,protein,binding'
p58612
(F1
F0.00014334862385321102
I1
I0
I1
tp58613
sS'cmax,a,increase'
p58614
(F1
F0.00014334862385321102
I1
I0
I1
tp58615
sS'certain,narcotic,such'
p58616
(F1
F0.00014334862385321102
I1
I0
I1
tp58617
sS'methotrexate,lodine,like'
p58618
(F1
F0.00014334862385321102
I1
I0
I1
tp58619
sS'concentrations,are,increased'
p58620
(F1
F0.00014334862385321102
I1
I0
I1
tp58621
sS'concurrent,enbrel,and'
p58622
(F1
F0.00014334862385321102
I1
I0
I1
tp58623
sS'concomitantly,with,significantly'
p58624
(F1
F0.00014334862385321102
I1
I0
I1
tp58625
sS'value,of,serum'
p58626
(F1
F0.00014334862385321102
I0
I1
I-1
tp58627
sS'rupture,or,cervical'
p58628
(F1
F0.00014334862385321102
I1
I0
I1
tp58629
sS'suggest,that,nsaids'
p58630
(F1
F0.0010034403669724771
I7
I0
I7
tp58631
sS'prolonging,av,conduction'
p58632
(F1
F0.00014334862385321102
I1
I0
I1
tp58633
sS'or,may,not'
p58634
(F1
F0.00014334862385321102
I1
I0
I1
tp58635
sS'enterococcus,faecalis,and'
p58636
(F1
F0.00014334862385321102
I0
I1
I-1
tp58637
sS'agents,that,are'
p58638
(F1
F0.00043004587155963305
I3
I0
I3
tp58639
sS'tnfa-blocking,agents,including'
p58640
(F1
F0.00014334862385321102
I1
I0
I1
tp58641
sS'grapefruit,juice,and'
p58642
(F1
F0.00014334862385321102
I1
I0
I1
tp58643
sS'four,diets,containing'
p58644
(F1
F0.00014334862385321102
I0
I1
I-1
tp58645
sS'and,or,mg'
p58646
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp58647
sS'clearance,and,or'
p58648
(F1
F0.00014334862385321102
I1
I0
I1
tp58649
sS'identified,through,searches'
p58650
(F1
F0.00014334862385321102
I0
I1
I-1
tp58651
sS'with,platelet-aggregation,reactions'
p58652
(F1
F0.00014334862385321102
I1
I0
I1
tp58653
sS'diastolic,blood,pressure'
p58654
(F1
F0.00014334862385321102
I1
I0
I1
tp58655
sS'cholecystokinin,octapeptide,was'
p58656
(F1
F0.00014334862385321102
I0
I1
I-1
tp58657
sS'alcohol,increases,bioavailability'
p58658
(F1
F0.00014334862385321102
I0
I1
I-1
tp58659
sS'cyclosporine,and,concentrations'
p58660
(F1
F0.00014334862385321102
I1
I0
I1
tp58661
sS'hydrochloride,does,not'
p58662
(F1
F0.00014334862385321102
I0
I1
I-1
tp58663
sS'withdrawal,of,or'
p58664
(F1
F0.00014334862385321102
I0
I1
I-1
tp58665
sS'unaltered,in,the'
p58666
(F1
F0.00014334862385321102
I0
I1
I-1
tp58667
sS'conducted,on,days'
p58668
(F1
F0.00014334862385321102
I0
I1
I-1
tp58669
sS'and,which,competes'
p58670
(F1
F0.00014334862385321102
I1
I0
I1
tp58671
sS'concomitant,on,the'
p58672
(F1
F0.00014334862385321102
I0
I1
I-1
tp58673
sS'inhibitors,nalidixic,acid'
p58674
(F1
F0.00014334862385321102
I1
I0
I1
tp58675
sS'mice,selectively,bred'
p58676
(F1
F0.00014334862385321102
I0
I1
I-1
tp58677
sS'as,and,which'
p58678
(F1
F0.00014334862385321102
I0
I1
I-1
tp58679
sS'studies,used,anti-peptic'
p58680
(F1
F0.00014334862385321102
I0
I1
I-1
tp58681
sS'may,raise,the'
p58682
(F1
F0.00014334862385321102
I1
I0
I1
tp58683
sS'in,the,literature'
p58684
(F1
F0.00014334862385321102
I1
I0
I1
tp58685
sS'in,overdose,especially'
p58686
(F1
F0.00014334862385321102
I1
I0
I1
tp58687
sS'for,the,first-pass'
p58688
(F0
F0
I1
I1
I0
tp58689
sS'bacterial,metabolism,in'
p58690
(F1
F0.00014334862385321102
I1
I0
I1
tp58691
sS'the,pesticide,the'
p58692
(F1
F0.00014334862385321102
I0
I1
I-1
tp58693
sS'pharmacokinetic,studies,indicate'
p58694
(F1
F0.00014334862385321102
I0
I1
I-1
tp58695
sS'be,concomitantly,administered'
p58696
(F1
F0.00014334862385321102
I0
I1
I-1
tp58697
sS'the,usual,amounts'
p58698
(F1
F0.00014334862385321102
I0
I1
I-1
tp58699
sS'aeds,whether,or'
p58700
(F1
F0.00014334862385321102
I0
I1
I-1
tp58701
sS'that,has,benefits'
p58702
(F1
F0.00014334862385321102
I0
I1
I-1
tp58703
sS'potentiation,of,warfarin-type'
p58704
(F1
F0.00014334862385321102
I0
I1
I-1
tp58705
sS'antagonistic,to,beta-lactam'
p58706
(F1
F0.00014334862385321102
I1
I0
I1
tp58707
sS'studies,of,iopidine'
p58708
(F1
F0.00014334862385321102
I1
I0
I1
tp58709
sS'to,be,a'
p58710
(F1
F0.00028669724770642203
I0
I2
I-2
tp58711
sS'expected,steady-state,serum'
p58712
(F1
F0.00014334862385321102
I1
I0
I1
tp58713
sS'hydrochloride,is,to'
p58714
(F1
F0.00014334862385321102
I1
I0
I1
tp58715
sS'gleevec,with,cyp3a4'
p58716
(F1
F0.00014334862385321102
I1
I0
I1
tp58717
sS'since,the,concomitant'
p58718
(F0
F0
I1
I1
I0
tp58719
sS'produce,persistently,elevated'
p58720
(F1
F0.00014334862385321102
I0
I1
I-1
tp58721
sS'rats,was,investigated'
p58722
(F1
F0.00014334862385321102
I0
I1
I-1
tp58723
sS'necessary,for,eight'
p58724
(F1
F0.00014334862385321102
I1
I0
I1
tp58725
sS'circulating,fluids,might'
p58726
(F1
F0.00014334862385321102
I0
I1
I-1
tp58727
sS'on,renal,and'
p58728
(F1
F0.00014334862385321102
I0
I1
I-1
tp58729
sS'of,this,paper'
p58730
(F1
F0.00014334862385321102
I0
I1
I-1
tp58731
sS'severe,dietary,salt'
p58732
(F1
F0.00014334862385321102
I1
I0
I1
tp58733
sS'structurally,distinct,from'
p58734
(F1
F0.00014334862385321102
I0
I1
I-1
tp58735
sS'laboratory,test,alterations'
p58736
(F1
F0.00014334862385321102
I0
I1
I-1
tp58737
sS'plasma,kinetics,of'
p58738
(F1
F0.00014334862385321102
I0
I1
I-1
tp58739
sS'the,serum,uric'
p58740
(F1
F0.00014334862385321102
I1
I0
I1
tp58741
sS'shown,that,and'
p58742
(F1
F0.00014334862385321102
I0
I1
I-1
tp58743
sS'inhibitors,and,others'
p58744
(F1
F0.00028669724770642203
I0
I2
I-2
tp58745
sS'propantheline,and,by'
p58746
(F1
F0.00014334862385321102
I1
I0
I1
tp58747
sS'conjugation,with,glutathione'
p58748
(F1
F0.00014334862385321102
I1
I0
I1
tp58749
sS'effect,of,skeletal'
p58750
(F1
F0.00014334862385321102
I1
I0
I1
tp58751
sS'the,enzyme,system'
p58752
(F0
F0
I1
I1
I0
tp58753
sS'mao,inhibitors,such'
p58754
(F1
F0.00014334862385321102
I0
I1
I-1
tp58755
sS'and,sodium,excretion'
p58756
(F1
F0.00014334862385321102
I1
I0
I1
tp58757
sS'combined,actions,desirable'
p58758
(F1
F0.00028669724770642203
I0
I2
I-2
tp58759
sS'additive,central,nervous'
p58760
(F1
F0.00014334862385321102
I1
I0
I1
tp58761
sS'in,dogs,anesthetized'
p58762
(F1
F0.00014334862385321102
I1
I0
I1
tp58763
sS'enzymes,such,as'
p58764
(F1
F0.00014334862385321102
I1
I0
I1
tp58765
sS'dose-dependently,inhibits,the'
p58766
(F1
F0.00014334862385321102
I1
I0
I1
tp58767
sS'maoi,such,as'
p58768
(F1
F0.00014334862385321102
I0
I1
I-1
tp58769
sS'added,to,human'
p58770
(F1
F0.00014334862385321102
I0
I1
I-1
tp58771
sS'potassium-sparing,with,nsaids'
p58772
(F1
F0.00014334862385321102
I1
I0
I1
tp58773
sS'inhibitors,and,with'
p58774
(F1
F0.00014334862385321102
I1
I0
I1
tp58775
sS'on,the,metabolism'
p58776
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp58777
sS'exacerbated,by,other'
p58778
(F1
F0.00014334862385321102
I1
I0
I1
tp58779
sS'when,considering,the'
p58780
(F1
F0.00014334862385321102
I1
I0
I1
tp58781
sS'the,co-administration,of'
p58782
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp58783
sS'bile,acids,may'
p58784
(F1
F0.00014334862385321102
I0
I1
I-1
tp58785
sS'metabolite,concentrations,when'
p58786
(F1
F0.00014334862385321102
I1
I0
I1
tp58787
sS'recovery,from,twitch'
p58788
(F1
F0.00014334862385321102
I1
I0
I1
tp58789
sS'closely,for,evidence'
p58790
(F1
F0.00014334862385321102
I1
I0
I1
tp58791
sS'effects,of,dcg-iv'
p58792
(F0
F0
I1
I1
I0
tp58793
sS'not,been,adequately'
p58794
(F1
F0.00014334862385321102
I0
I1
I-1
tp58795
sS'was,not,studied'
p58796
(F1
F0.00014334862385321102
I0
I1
I-1
tp58797
sS'at,least,a'
p58798
(F1
F0.00014334862385321102
I1
I0
I1
tp58799
sS'study,week,of'
p58800
(F1
F0.00014334862385321102
I0
I1
I-1
tp58801
sS'a,drugs,enhancing'
p58802
(F1
F0.00014334862385321102
I0
I1
I-1
tp58803
sS'gi,bleeding,a'
p58804
(F1
F0.00014334862385321102
I0
I1
I-1
tp58805
sS'known,cyp3a4,inducer'
p58806
(F1
F0.00028669724770642203
I2
I0
I2
tp58807
sS'or,epoxide,hydrolase'
p58808
(F1
F0.00028669724770642203
I0
I2
I-2
tp58809
sS'adl,mg,or'
p58810
(F1
F0.00014334862385321102
I0
I1
I-1
tp58811
sS'to,when,mg'
p58812
(F1
F0.00014334862385321102
I1
I0
I1
tp58813
sS'prostaglandin,synthesis,have'
p58814
(F1
F0.00014334862385321102
I1
I0
I1
tp58815
sS'concentrations,auc,by'
p58816
(F1
F0.00014334862385321102
I1
I0
I1
tp58817
sS'nizoral,tablets,with'
p58818
(F1
F0.00014334862385321102
I1
I0
I1
tp58819
sS'load,constitutes,the'
p58820
(F1
F0.00014334862385321102
I0
I1
I-1
tp58821
sS'coronary,oral,cough'
p58822
(F1
F0.00014334862385321102
I0
I1
I-1
tp58823
sS'used,with,caution'
p58824
(F0.69230769230769229
F0.0012901376146788992
I11
I2
I9
tp58825
sS'resulted,from,a'
p58826
(F1
F0.00014334862385321102
I1
I0
I1
tp58827
sS'offered,by,this'
p58828
(F1
F0.00014334862385321102
I0
I1
I-1
tp58829
sS'its,two,metabolites'
p58830
(F1
F0.00014334862385321102
I0
I1
I-1
tp58831
sS'dosage,adjustment,as'
p58832
(F1
F0.00014334862385321102
I0
I1
I-1
tp58833
sS'under,acidic,conditions'
p58834
(F1
F0.00014334862385321102
I1
I0
I1
tp58835
sS'and,the,risk'
p58836
(F1
F0.00014334862385321102
I0
I1
I-1
tp58837
sS'no,significant,difference'
p58838
(F1
F0.00043004587155963305
I0
I3
I-3
tp58839
sS'the,requirements,in'
p58840
(F1
F0.00014334862385321102
I1
I0
I1
tp58841
sS'prothrombin,time,response'
p58842
(F1
F0.00014334862385321102
I0
I1
I-1
tp58843
sS'on,bone,loss'
p58844
(F1
F0.00028669724770642203
I0
I2
I-2
tp58845
sS'receiving,brovana,has'
p58846
(F1
F0.00014334862385321102
I0
I1
I-1
tp58847
sS'non-diabetic,and,streptozotocin-induced'
p58848
(F1
F0.00014334862385321102
I0
I1
I-1
tp58849
sS'which,effectiveness,is'
p58850
(F1
F0.00014334862385321102
I0
I1
I-1
tp58851
sS'due,not,only'
p58852
(F1
F0.00014334862385321102
I1
I0
I1
tp58853
sS'administration,of,are'
p58854
(F1
F0.00014334862385321102
I1
I0
I1
tp58855
sS'with,inhibitors,of'
p58856
(F1
F0.00043004587155963305
I3
I0
I3
tp58857
sS'enhance,the,effect'
p58858
(F0.5
F0.00028669724770642203
I3
I1
I2
tp58859
sS'prothrombin,time,beyond'
p58860
(F1
F0.00014334862385321102
I1
I0
I1
tp58861
sS'may,be,used'
p58862
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp58863
sS'of,therapeutic,response'
p58864
(F1
F0.00014334862385321102
I0
I1
I-1
tp58865
sS'to,patients,not'
p58866
(F1
F0.00028669724770642203
I2
I0
I2
tp58867
sS'and,renal,clearances'
p58868
(F1
F0.00014334862385321102
I1
I0
I1
tp58869
sS'expected,and,uroxatral'
p58870
(F1
F0.00014334862385321102
I1
I0
I1
tp58871
sS'bound,monoamine,oxidase'
p58872
(F1
F0.00043004587155963305
I3
I0
I3
tp58873
sS'conduction,disturbances,including'
p58874
(F1
F0.00014334862385321102
I0
I1
I-1
tp58875
sS'reviewed,after,the'
p58876
(F1
F0.00014334862385321102
I0
I1
I-1
tp58877
sS'with,increases,in'
p58878
(F1
F0.00014334862385321102
I1
I0
I1
tp58879
sS'of,metabolism,mediated'
p58880
(F1
F0.00014334862385321102
I0
I1
I-1
tp58881
sS'elimination,of,sodium'
p58882
(F1
F0.00028669724770642203
I2
I0
I2
tp58883
sS'allopurinol,the,principal'
p58884
(F1
F0.00014334862385321102
I1
I0
I1
tp58885
sS'i,d,or'
p58886
(F0
F0
I1
I1
I0
tp58887
sS'of,mineral,oil'
p58888
(F1
F0.00014334862385321102
I1
I0
I1
tp58889
sS'regarding,interactions,when'
p58890
(F1
F0.00014334862385321102
I0
I1
I-1
tp58891
sS'particularly,have,been'
p58892
(F1
F0.00014334862385321102
I1
I0
I1
tp58893
sS'this,isoenzyme,macrolide'
p58894
(F1
F0.00014334862385321102
I1
I0
I1
tp58895
sS'for,aerobic,facultative'
p58896
(F1
F0.00014334862385321102
I0
I1
I-1
tp58897
sS'use,the,safety'
p58898
(F1
F0.00014334862385321102
I0
I1
I-1
tp58899
sS'a,long-acting,is'
p58900
(F1
F0.00014334862385321102
I0
I1
I-1
tp58901
sS'nsaids,concomitantly,with'
p58902
(F1
F0.00043004587155963305
I3
I0
I3
tp58903
sS'diabetic,patient,maintained'
p58904
(F1
F0.00014334862385321102
I1
I0
I1
tp58905
sS'data,in,a'
p58906
(F1
F0.00014334862385321102
I0
I1
I-1
tp58907
sS'a4,may,cause'
p58908
(F1
F0.00014334862385321102
I1
I0
I1
tp58909
sS'this,alteration,in'
p58910
(F1
F0.00014334862385321102
I0
I1
I-1
tp58911
sS'to,sensitize,resistant'
p58912
(F1
F0.00014334862385321102
I0
I1
I-1
tp58913
sS'anticoagulation,levels,should'
p58914
(F1
F0.00014334862385321102
I1
I0
I1
tp58915
sS'small,study,of'
p58916
(F1
F0.00014334862385321102
I0
I1
I-1
tp58917
sS'of,iopidine,ophthalmic'
p58918
(F1
F0.00014334862385321102
I1
I0
I1
tp58919
sS'another,hmg-coa,reductase'
p58920
(F1
F0.00014334862385321102
I1
I0
I1
tp58921
sS'of,the,low'
p58922
(F1
F0.00014334862385321102
I0
I1
I-1
tp58923
sS'may,affect,bioavailabillty'
p58924
(F1
F0.00014334862385321102
I0
I1
I-1
tp58925
sS'contraceptives,including,oral'
p58926
(F1
F0.00014334862385321102
I1
I0
I1
tp58927
sS'anesthetics,sedatives,hypnotics'
p58928
(F1
F0.00014334862385321102
I1
I0
I1
tp58929
sS'of,this,class'
p58930
(F1
F0.00014334862385321102
I0
I1
I-1
tp58931
sS'or,potentiating,effects'
p58932
(F1
F0.00014334862385321102
I1
I0
I1
tp58933
sS'separate,studies,of'
p58934
(F1
F0.00014334862385321102
I0
I1
I-1
tp58935
sS'bioavailability,of,valproic'
p58936
(F1
F0.00014334862385321102
I0
I1
I-1
tp58937
sS'ulceration,and,may'
p58938
(F1
F0.00014334862385321102
I1
I0
I1
tp58939
sS'probenecid,the,oral'
p58940
(F1
F0.00014334862385321102
I1
I0
I1
tp58941
sS'experience,bleeding,events'
p58942
(F1
F0.00014334862385321102
I1
I0
I1
tp58943
sS'cyp3a4,inhibitor,produced'
p58944
(F1
F0.00014334862385321102
I1
I0
I1
tp58945
sS'adult-onset,diabetics,dosage'
p58946
(F1
F0.00014334862385321102
I1
I0
I1
tp58947
sS'of,renal,impairment'
p58948
(F1
F0.00014334862385321102
I0
I1
I-1
tp58949
sS'effects,of,either'
p58950
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp58951
sS'and,have,been'
p58952
(F0.45454545454545453
F0.00071674311926605509
I3
I8
I-5
tp58953
sS'of,some,organisms'
p58954
(F1
F0.00014334862385321102
I1
I0
I1
tp58955
sS'cmax,by,approximately'
p58956
(F1
F0.00014334862385321102
I1
I0
I1
tp58957
sS'expected,to,compromise'
p58958
(F1
F0.00014334862385321102
I1
I0
I1
tp58959
sS'plasma,concentration,altered'
p58960
(F0
F0
I1
I1
I0
tp58961
sS'with,betagan,and'
p58962
(F1
F0.00014334862385321102
I1
I0
I1
tp58963
sS'supplements,and,potassium-sparing'
p58964
(F1
F0.00028669724770642203
I2
I0
I2
tp58965
sS'measured,during,both'
p58966
(F1
F0.00014334862385321102
I0
I1
I-1
tp58967
sS'mg,followed,by'
p58968
(F1
F0.00014334862385321102
I0
I1
I-1
tp58969
sS'agents,patients,taking'
p58970
(F1
F0.00014334862385321102
I1
I0
I1
tp58971
sS'short-acting,adrenergic,stimulant'
p58972
(F1
F0.00014334862385321102
I0
I1
I-1
tp58973
sS'of,particular,importance'
p58974
(F1
F0.00014334862385321102
I1
I0
I1
tp58975
sS'withdrawn,from,treatment'
p58976
(F1
F0.00014334862385321102
I1
I0
I1
tp58977
sS'patients,the,effects'
p58978
(F1
F0.00014334862385321102
I0
I1
I-1
tp58979
sS'and,toxicity,have'
p58980
(F1
F0.00014334862385321102
I1
I0
I1
tp58981
sS'or,prophylactic,doses'
p58982
(F1
F0.00014334862385321102
I0
I1
I-1
tp58983
sS'of,min,after'
p58984
(F1
F0.00014334862385321102
I1
I0
I1
tp58985
sS'and,within,hours'
p58986
(F1
F0.00014334862385321102
I1
I0
I1
tp58987
sS'oxidase,inhibiting,may'
p58988
(F1
F0.00014334862385321102
I1
I0
I1
tp58989
sS'and,sodium,the'
p58990
(F1
F0.00014334862385321102
I0
I1
I-1
tp58991
sS'in,psychopathology,rating'
p58992
(F1
F0.00014334862385321102
I0
I1
I-1
tp58993
sS'tests,the,combination'
p58994
(F1
F0.00014334862385321102
I1
I0
I1
tp58995
sS'because,the,potential'
p58996
(F1
F0.00014334862385321102
I1
I0
I1
tp58997
sS'response,to,pressor'
p58998
(F1
F0.00014334862385321102
I1
I0
I1
tp58999
sS'taking,and,together'
p59000
(F1
F0.00014334862385321102
I1
I0
I1
tp59001
sS'arava,with,a'
p59002
(F1
F0.00014334862385321102
I1
I0
I1
tp59003
sS'drawn,regarding,the'
p59004
(F1
F0.00014334862385321102
I0
I1
I-1
tp59005
sS'tricyclic,antidepressants,use'
p59006
(F1
F0.00014334862385321102
I1
I0
I1
tp59007
sS'animal,studies,suggest'
p59008
(F1
F0.00014334862385321102
I1
I0
I1
tp59009
sS'cmax,and,extent'
p59010
(F1
F0.00014334862385321102
I1
I0
I1
tp59011
sS'the,aptt,to'
p59012
(F1
F0.00014334862385321102
I0
I1
I-1
tp59013
sS'the,use,of'
p59014
(F0.037037037037037035
F0.00014334862385321102
I14
I13
I1
tp59015
sS'blockade,of,the'
p59016
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp59017
sS'enzymes,carbamazepine,is'
p59018
(F1
F0.00014334862385321102
I0
I1
I-1
tp59019
sS'or,salicylic,acid'
p59020
(F1
F0.00028669724770642203
I0
I2
I-2
tp59021
sS'dosing,with,camptosar'
p59022
(F1
F0.00014334862385321102
I1
I0
I1
tp59023
sS'triple,therapy,with'
p59024
(F1
F0.00014334862385321102
I0
I1
I-1
tp59025
sS'reports,of,qtc'
p59026
(F1
F0.00014334862385321102
I0
I1
I-1
tp59027
sS'hc1,concomitant,use'
p59028
(F1
F0.00014334862385321102
I1
I0
I1
tp59029
sS'by,cyp1a2,in'
p59030
(F1
F0.00014334862385321102
I0
I1
I-1
tp59031
sS'mg,with,coadministered'
p59032
(F1
F0.00014334862385321102
I1
I0
I1
tp59033
sS'presence,of,both'
p59034
(F1
F0.00014334862385321102
I1
I0
I1
tp59035
sS'precedex,for,minutes'
p59036
(F1
F0.00014334862385321102
I0
I1
I-1
tp59037
sS'pcp,discrimination,and'
p59038
(F1
F0.00014334862385321102
I0
I1
I-1
tp59039
sS'does,not,result'
p59040
(F1
F0.00028669724770642203
I0
I2
I-2
tp59041
sS'with,human,volunteers'
p59042
(F1
F0.00014334862385321102
I0
I1
I-1
tp59043
sS'patients,on,no'
p59044
(F1
F0.00014334862385321102
I1
I0
I1
tp59045
sS'in,both,groups'
p59046
(F1
F0.00014334862385321102
I0
I1
I-1
tp59047
sS'qtc,interval,must'
p59048
(F1
F0.00014334862385321102
I1
I0
I1
tp59049
sS'post,marketing,observations'
p59050
(F1
F0.00014334862385321102
I1
I0
I1
tp59051
sS'oral,dose,have'
p59052
(F1
F0.00014334862385321102
I0
I1
I-1
tp59053
sS'the,signs,of'
p59054
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp59055
sS'has,occurred,more'
p59056
(F1
F0.00014334862385321102
I0
I1
I-1
tp59057
sS'products,may,interfere'
p59058
(F1
F0.00014334862385321102
I1
I0
I1
tp59059
sS'leading,to,increased'
p59060
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp59061
sS'pentagastrin-,and,histamine-induced'
p59062
(F1
F0.00014334862385321102
I0
I1
I-1
tp59063
sS'gram-negative,and,some'
p59064
(F1
F0.00014334862385321102
I0
I1
I-1
tp59065
sS'the,initial,dose'
p59066
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp59067
sS'is,usually,well'
p59068
(F0
F0
I1
I1
I0
tp59069
sS'determinations,of,these'
p59070
(F1
F0.00014334862385321102
I1
I0
I1
tp59071
sS'well,as,g'
p59072
(F1
F0.00014334862385321102
I1
I0
I1
tp59073
sS'since,may,antagonize'
p59074
(F1
F0.00014334862385321102
I1
I0
I1
tp59075
sS'and,mc,block'
p59076
(F1
F0.00014334862385321102
I1
I0
I1
tp59077
sS'oral,produced,minor'
p59078
(F1
F0.00014334862385321102
I1
I0
I1
tp59079
sS'complex,fashion,and'
p59080
(F1
F0.00014334862385321102
I0
I1
I-1
tp59081
sS'and,possibly,other'
p59082
(F1
F0.00057339449541284407
I4
I0
I4
tp59083
sS'the,liver,microsomes'
p59084
(F1
F0.00014334862385321102
I0
I1
I-1
tp59085
sS'of,psychotic,patients'
p59086
(F1
F0.00014334862385321102
I0
I1
I-1
tp59087
sS'the,lower,end'
p59088
(F1
F0.00014334862385321102
I1
I0
I1
tp59089
sS'and,lodine,should'
p59090
(F1
F0.00014334862385321102
I0
I1
I-1
tp59091
sS'or,mycophenolate,mofetil'
p59092
(F1
F0.00014334862385321102
I0
I1
I-1
tp59093
sS'psychomotor,performance,was'
p59094
(F1
F0.00014334862385321102
I1
I0
I1
tp59095
sS'and,reducing,absorption'
p59096
(F1
F0.00014334862385321102
I1
I0
I1
tp59097
sS'resulting,in,death'
p59098
(F1
F0.00014334862385321102
I1
I0
I1
tp59099
sS'can,result,in'
p59100
(F0.81818181818181823
F0.0012901376146788992
I10
I1
I9
tp59101
sS'v,nacmc,conjugated'
p59102
(F1
F0.00014334862385321102
I0
I1
I-1
tp59103
sS'interactions,with,isosorbide'
p59104
(F1
F0.00014334862385321102
I0
I1
I-1
tp59105
sS'when,mg,day'
p59106
(F1
F0.00014334862385321102
I1
I0
I1
tp59107
sS'hormones,and,estrogen-containing'
p59108
(F1
F0.00014334862385321102
I1
I0
I1
tp59109
sS'acid,nonsteroidal,anti-inflammatory'
p59110
(F1
F0.00014334862385321102
I1
I0
I1
tp59111
sS'groups,of,rats'
p59112
(F1
F0.00014334862385321102
I0
I1
I-1
tp59113
sS'associated,with,elevated'
p59114
(F0
F0
I1
I1
I0
tp59115
sS'test,interactions,cephalosporins'
p59116
(F1
F0.00014334862385321102
I0
I1
I-1
tp59117
sS'however,since,there'
p59118
(F1
F0.00014334862385321102
I0
I1
I-1
tp59119
sS'tromethamine,control,vs'
p59120
(F1
F0.00014334862385321102
I1
I0
I1
tp59121
sS'or,elevated,serum'
p59122
(F1
F0.00014334862385321102
I1
I0
I1
tp59123
sS'such,interactions,have'
p59124
(F1
F0.00014334862385321102
I0
I1
I-1
tp59125
sS'supraventricular,arrhythmias,may'
p59126
(F1
F0.00014334862385321102
I0
I1
I-1
tp59127
sS'insulin,sulfonylureas,requirements'
p59128
(F1
F0.00014334862385321102
I0
I1
I-1
tp59129
sS'that,the,acute'
p59130
(F1
F0.00014334862385321102
I1
I0
I1
tp59131
sS'weakness,lethargy,fever'
p59132
(F1
F0.00014334862385321102
I1
I0
I1
tp59133
sS'effect,of,an'
p59134
(F1
F0.00028669724770642203
I0
I2
I-2
tp59135
sS'addition,patients,taking'
p59136
(F1
F0.00014334862385321102
I0
I1
I-1
tp59137
sS'an,oral,and'
p59138
(F1
F0.00014334862385321102
I1
I0
I1
tp59139
sS'a,with,diethyl'
p59140
(F1
F0.00014334862385321102
I0
I1
I-1
tp59141
sS'the,hypotensive,effect'
p59142
(F1
F0.0010034403669724771
I7
I0
I7
tp59143
sS'p-glycoprotein,in,vivo'
p59144
(F1
F0.00014334862385321102
I1
I0
I1
tp59145
sS'azlocillin,should,not'
p59146
(F1
F0.00014334862385321102
I1
I0
I1
tp59147
sS'anastrozole,did,not'
p59148
(F1
F0.00014334862385321102
I0
I1
I-1
tp59149
sS'that,are,cyp'
p59150
(F1
F0.00014334862385321102
I1
I0
I1
tp59151
sS'hepatotoxic,effects,with'
p59152
(F1
F0.00014334862385321102
I1
I0
I1
tp59153
sS'the,age,of'
p59154
(F1
F0.00014334862385321102
I0
I1
I-1
tp59155
sS'no,interaction,studies'
p59156
(F1
F0.00014334862385321102
I0
I1
I-1
tp59157
sS'guanethidine,or,similarly'
p59158
(F1
F0.00014334862385321102
I0
I1
I-1
tp59159
sS'evaluated,after,concomitant'
p59160
(F1
F0.00014334862385321102
I1
I0
I1
tp59161
sS'therefore,agents,affecting'
p59162
(F1
F0.00014334862385321102
I0
I1
I-1
tp59163
sS'serious,clinical,bleeding'
p59164
(F1
F0.00014334862385321102
I1
I0
I1
tp59165
sS'and,in,the'
p59166
(F0.076923076923076927
F0.00014334862385321102
I6
I7
I-1
tp59167
sS'per,kg,diet'
p59168
(F1
F0.00014334862385321102
I1
I0
I1
tp59169
sS'the,low,dietary'
p59170
(F1
F0.00014334862385321102
I0
I1
I-1
tp59171
sS'on,sgpt,alt'
p59172
(F1
F0.00014334862385321102
I1
I0
I1
tp59173
sS'function,or,av'
p59174
(F1
F0.00014334862385321102
I1
I0
I1
tp59175
sS'in,human,trials'
p59176
(F1
F0.00014334862385321102
I1
I0
I1
tp59177
sS'system,depressants,are'
p59178
(F1
F0.00014334862385321102
I1
I0
I1
tp59179
sS'found,in,most'
p59180
(F1
F0.00014334862385321102
I0
I1
I-1
tp59181
sS'of,trileptal,the'
p59182
(F1
F0.00014334862385321102
I1
I0
I1
tp59183
sS'prior,to,concurrent'
p59184
(F1
F0.00014334862385321102
I1
I0
I1
tp59185
sS'were,observed,in'
p59186
(F1
F0.00071674311926605509
I0
I5
I-5
tp59187
sS'given,alone,or'
p59188
(F1
F0.00014334862385321102
I0
I1
I-1
tp59189
sS'sublingual,mg,taken'
p59190
(F1
F0.00014334862385321102
I1
I0
I1
tp59191
sS'foods,or,may'
p59192
(F1
F0.00014334862385321102
I1
I0
I1
tp59193
sS'or,supplements,or'
p59194
(F0
F0
I1
I1
I0
tp59195
sS'including,but,not'
p59196
(F1
F0.00014334862385321102
I1
I0
I1
tp59197
sS'schizophrenic,patients,who'
p59198
(F1
F0.00014334862385321102
I0
I1
I-1
tp59199
sS'while,the,patient'
p59200
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp59201
sS'from,to,m'
p59202
(F1
F0.00014334862385321102
I1
I0
I1
tp59203
sS'considered,when,these'
p59204
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp59205
sS'with,d,h'
p59206
(F1
F0.00014334862385321102
I1
I0
I1
tp59207
sS'cause,an,increase'
p59208
(F1
F0.00028669724770642203
I2
I0
I2
tp59209
sS'time,of,onset'
p59210
(F1
F0.00014334862385321102
I1
I0
I1
tp59211
sS'multivalent,cations,such'
p59212
(F1
F0.00014334862385321102
I1
I0
I1
tp59213
sS'hormonal,may,decrease'
p59214
(F1
F0.00014334862385321102
I1
I0
I1
tp59215
sS'range,of,the'
p59216
(F1
F0.00014334862385321102
I1
I0
I1
tp59217
sS'treatment,with,antithrombin'
p59218
(F1
F0.00028669724770642203
I2
I0
I2
tp59219
sS'used,concurrently,resulting'
p59220
(F1
F0.00014334862385321102
I1
I0
I1
tp59221
sS'of,or,hepatic'
p59222
(F1
F0.00014334862385321102
I1
I0
I1
tp59223
sS'and,have,similar'
p59224
(F1
F0.00014334862385321102
I0
I1
I-1
tp59225
sS'severe,enterocolitis,diarrhea'
p59226
(F1
F0.00014334862385321102
I1
I0
I1
tp59227
sS'nondepolarizing,relaxants,are'
p59228
(F1
F0.00014334862385321102
I0
I1
I-1
tp59229
sS'these,include,and'
p59230
(F1
F0.00014334862385321102
I0
I1
I-1
tp59231
sS'enzyme,systems,inhibition'
p59232
(F1
F0.00014334862385321102
I0
I1
I-1
tp59233
sS'during,the,course'
p59234
(F0
F0
I1
I1
I0
tp59235
sS'modulates,in,an'
p59236
(F1
F0.00014334862385321102
I1
I0
I1
tp59237
sS'contraceptive,effect,of'
p59238
(F1
F0.00014334862385321102
I1
I0
I1
tp59239
sS'of,and,hydroxides'
p59240
(F1
F0.00014334862385321102
I0
I1
I-1
tp59241
sS'necessary,when,coadministered'
p59242
(F1
F0.00014334862385321102
I1
I0
I1
tp59243
sS'a,significant,effect'
p59244
(F1
F0.00043004587155963305
I0
I3
I-3
tp59245
sS'inhibitors,and,leading'
p59246
(F1
F0.00014334862385321102
I0
I1
I-1
tp59247
sS'mechanism,of,action'
p59248
(F0
F0
I1
I1
I0
tp59249
sS'may,occur,when'
p59250
(F0.75
F0.0008600917431192661
I7
I1
I6
tp59251
sS'here,we,show'
p59252
(F1
F0.00014334862385321102
I0
I1
I-1
tp59253
sS'anticoagulants,ten,patients'
p59254
(F1
F0.00014334862385321102
I0
I1
I-1
tp59255
sS'heavy,intake,for'
p59256
(F1
F0.00014334862385321102
I1
I0
I1
tp59257
sS'patients,no,effect'
p59258
(F1
F0.00014334862385321102
I0
I1
I-1
tp59259
sS'not,altered,by'
p59260
(F1
F0.00057339449541284407
I0
I4
I-4
tp59261
sS'a,risk,that'
p59262
(F1
F0.00014334862385321102
I1
I0
I1
tp59263
sS'should,be,accompanied'
p59264
(F1
F0.00014334862385321102
I0
I1
I-1
tp59265
sS'bid,in,conjunction'
p59266
(F1
F0.00014334862385321102
I1
I0
I1
tp59267
sS'properties,of,the'
p59268
(F1
F0.00014334862385321102
I1
I0
I1
tp59269
sS'with,tikosyn,mcg'
p59270
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp59271
sS'week,course,of'
p59272
(F1
F0.00043004587155963305
I3
I0
I3
tp59273
sS'concomitant,intake,of'
p59274
(F1
F0.00014334862385321102
I0
I1
I-1
tp59275
sS'see,clinical,pharmacology'
p59276
(F0.5
F0.00028669724770642203
I3
I1
I2
tp59277
sS'more,than,times'
p59278
(F1
F0.00014334862385321102
I1
I0
I1
tp59279
sS'so,that,intoxication'
p59280
(F1
F0.00014334862385321102
I1
I0
I1
tp59281
sS'cessation,of,therapy'
p59282
(F1
F0.00014334862385321102
I0
I1
I-1
tp59283
sS'significant,effect,in'
p59284
(F1
F0.00014334862385321102
I0
I1
I-1
tp59285
sS'nelfinavir,steady-state,cmax'
p59286
(F1
F0.00014334862385321102
I1
I0
I1
tp59287
sS'because,accutane,use'
p59288
(F1
F0.00014334862385321102
I1
I0
I1
tp59289
sS'or,other,metabolized'
p59290
(F1
F0.00014334862385321102
I1
I0
I1
tp59291
sS'biogen,pregnancy,registry'
p59292
(F1
F0.00014334862385321102
I0
I1
I-1
tp59293
sS'include,certain,especially'
p59294
(F1
F0.00014334862385321102
I1
I0
I1
tp59295
sS'less,frequent,maintenance'
p59296
(F1
F0.00014334862385321102
I1
I0
I1
tp59297
sS'of,cytochrome,p450'
p59298
(F0
F0
I3
I3
I0
tp59299
sS'of,hepatic,enzyme'
p59300
(F1
F0.00028669724770642203
I2
I0
I2
tp59301
sS'of,the,stereoisomers'
p59302
(F1
F0.00014334862385321102
I0
I1
I-1
tp59303
sS'the,disruptive,effects'
p59304
(F1
F0.00014334862385321102
I1
I0
I1
tp59305
sS'plasma,concentrations,peak'
p59306
(F1
F0.00014334862385321102
I1
I0
I1
tp59307
sS'coadministered,with,were'
p59308
(F1
F0.00014334862385321102
I1
I0
I1
tp59309
sS'mean,value,of'
p59310
(F1
F0.00014334862385321102
I0
I1
I-1
tp59311
sS'of,and,alone'
p59312
(F1
F0.00014334862385321102
I0
I1
I-1
tp59313
sS'carefully,monitored,because'
p59314
(F1
F0.00014334862385321102
I1
I0
I1
tp59315
sS'the,stimulant,action'
p59316
(F1
F0.00014334862385321102
I0
I1
I-1
tp59317
sS'a,day,regimen'
p59318
(F1
F0.00043004587155963305
I3
I0
I3
tp59319
sS'of,various,pesticides'
p59320
(F1
F0.00014334862385321102
I0
I1
I-1
tp59321
sS'due,to,fulminant'
p59322
(F1
F0.00014334862385321102
I1
I0
I1
tp59323
sS'atorvastatin,plasma,concentrations'
p59324
(F1
F0.00014334862385321102
I0
I1
I-1
tp59325
sS'least,four,times'
p59326
(F1
F0.00014334862385321102
I0
I1
I-1
tp59327
sS'model,possibly,increasing'
p59328
(F1
F0.00014334862385321102
I1
I0
I1
tp59329
sS'of,adverse,reactions'
p59330
(F1
F0.00014334862385321102
I0
I1
I-1
tp59331
sS'was,prepared,in'
p59332
(F1
F0.00014334862385321102
I0
I1
I-1
tp59333
sS'is,not,significantly'
p59334
(F1
F0.00014334862385321102
I0
I1
I-1
tp59335
sS'of,concomitant,use'
p59336
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp59337
sS'be,maximal,to'
p59338
(F1
F0.00014334862385321102
I1
I0
I1
tp59339
sS'to,fulminant,pancreatitis'
p59340
(F1
F0.00014334862385321102
I1
I0
I1
tp59341
sS'by,the,slow'
p59342
(F1
F0.00014334862385321102
I0
I1
I-1
tp59343
sS'dose,adjustment,of'
p59344
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp59345
sS'active,epoxide,which'
p59346
(F1
F0.00014334862385321102
I0
I1
I-1
tp59347
sS'or,prolongation,of'
p59348
(F0
F0
I1
I1
I0
tp59349
sS'common,adverse,reaction'
p59350
(F1
F0.00014334862385321102
I0
I1
I-1
tp59351
sS'not,significantly,altered'
p59352
(F1
F0.00028669724770642203
I0
I2
I-2
tp59353
sS'brevibloc,should,not'
p59354
(F1
F0.00014334862385321102
I1
I0
I1
tp59355
sS'of,and,when'
p59356
(F1
F0.00014334862385321102
I1
I0
I1
tp59357
sS'or,systemic,medications'
p59358
(F1
F0.00014334862385321102
I1
I0
I1
tp59359
sS'experience,fewer,infusion'
p59360
(F1
F0.00014334862385321102
I0
I1
I-1
tp59361
sS'with,practically,only'
p59362
(F1
F0.00014334862385321102
I0
I1
I-1
tp59363
sS'inhibitor,of,iiia4'
p59364
(F1
F0.00014334862385321102
I1
I0
I1
tp59365
sS'and,local,which'
p59366
(F1
F0.00014334862385321102
I1
I0
I1
tp59367
sS'such,as,selective'
p59368
(F1
F0.00014334862385321102
I1
I0
I1
tp59369
sS'significant,interactions,when'
p59370
(F1
F0.00014334862385321102
I0
I1
I-1
tp59371
sS'they,modify,the'
p59372
(F1
F0.00014334862385321102
I1
I0
I1
tp59373
sS'iron-fortified,infant,formula'
p59374
(F1
F0.00014334862385321102
I0
I1
I-1
tp59375
sS'the,following,eye'
p59376
(F1
F0.00014334862385321102
I1
I0
I1
tp59377
sS'may,decrease,blood'
p59378
(F1
F0.00028669724770642203
I2
I0
I2
tp59379
sS'to,increase,resulting'
p59380
(F1
F0.00014334862385321102
I1
I0
I1
tp59381
sS'although,acid-base,and'
p59382
(F1
F0.00014334862385321102
I1
I0
I1
tp59383
sS'response,to,the'
p59384
(F1
F0.00014334862385321102
I0
I1
I-1
tp59385
sS'in,the,context'
p59386
(F1
F0.00014334862385321102
I0
I1
I-1
tp59387
sS'even,when,co-administered'
p59388
(F1
F0.00014334862385321102
I0
I1
I-1
tp59389
sS'took,min,for'
p59390
(F1
F0.00028669724770642203
I2
I0
I2
tp59391
sS'the,following,adverse'
p59392
(F1
F0.00014334862385321102
I1
I0
I1
tp59393
sS'clinical,trial,a'
p59394
(F1
F0.00014334862385321102
I0
I1
I-1
tp59395
sS'no,prolongation,in'
p59396
(F1
F0.00014334862385321102
I0
I1
I-1
tp59397
sS'as,clinistix,and'
p59398
(F1
F0.00014334862385321102
I0
I1
I-1
tp59399
sS'compromise,have,been'
p59400
(F1
F0.00014334862385321102
I1
I0
I1
tp59401
sS'this,inhibitory,action'
p59402
(F1
F0.00014334862385321102
I0
I1
I-1
tp59403
sS'cases,of,overdosage'
p59404
(F1
F0.00028669724770642203
I2
I0
I2
tp59405
sS'otherwise,healthy,subjects'
p59406
(F1
F0.00043004587155963305
I0
I3
I-3
tp59407
sS'with,grapefruit,juice'
p59408
(F1
F0.00014334862385321102
I0
I1
I-1
tp59409
sS'a,digitalized,hypothyroid'
p59410
(F1
F0.00014334862385321102
I1
I0
I1
tp59411
sS'oral,in,healthy'
p59412
(F1
F0.00028669724770642203
I0
I2
I-2
tp59413
sS'skin,rash,has'
p59414
(F1
F0.00014334862385321102
I1
I0
I1
tp59415
sS'in,pigeons,nanm'
p59416
(F1
F0.00014334862385321102
I0
I1
I-1
tp59417
sS'used,to,study'
p59418
(F1
F0.00014334862385321102
I0
I1
I-1
tp59419
sS'with,with,no'
p59420
(F1
F0.00014334862385321102
I0
I1
I-1
tp59421
sS'mg,ethinyl,estradiol'
p59422
(F1
F0.00028669724770642203
I0
I2
I-2
tp59423
sS'may,decrease,in'
p59424
(F1
F0.00014334862385321102
I0
I1
I-1
tp59425
sS'atromid-s,may,displace'
p59426
(F1
F0.00014334862385321102
I1
I0
I1
tp59427
sS'and,the,cyp1a2'
p59428
(F1
F0.00014334862385321102
I0
I1
I-1
tp59429
sS'h-spiroperidol,and,high'
p59430
(F1
F0.00014334862385321102
I0
I1
I-1
tp59431
sS'or,glatiramer,acetate'
p59432
(F1
F0.00014334862385321102
I0
I1
I-1
tp59433
sS'preliminary,studies,indicate'
p59434
(F1
F0.00014334862385321102
I1
I0
I1
tp59435
sS'reaction,between,a'
p59436
(F1
F0.00014334862385321102
I1
I0
I1
tp59437
sS'coffee,was,administered'
p59438
(F1
F0.00014334862385321102
I0
I1
I-1
tp59439
sS'model,using,the'
p59440
(F1
F0.00014334862385321102
I0
I1
I-1
tp59441
sS'vardenafil,in,a'
p59442
(F1
F0.00014334862385321102
I1
I0
I1
tp59443
sS'decreased,by,about'
p59444
(F1
F0.00014334862385321102
I1
I0
I1
tp59445
sS'diabetes,were,administered'
p59446
(F1
F0.00014334862385321102
I0
I1
I-1
tp59447
sS'n-desmethylclozapine,and,n-oxide'
p59448
(F1
F0.00014334862385321102
I0
I1
I-1
tp59449
sS'wellbutrin,on,the'
p59450
(F1
F0.00014334862385321102
I0
I1
I-1
tp59451
sS'greater,than,two-fold'
p59452
(F1
F0.00014334862385321102
I1
I0
I1
tp59453
sS'the,antimuscarinic,effects'
p59454
(F1
F0.00014334862385321102
I1
I0
I1
tp59455
sS'acid,doses,of'
p59456
(F1
F0.00014334862385321102
I1
I0
I1
tp59457
sS'as,or,ergot'
p59458
(F1
F0.00014334862385321102
I1
I0
I1
tp59459
sS'interindividual,variability,in'
p59460
(F1
F0.00014334862385321102
I1
I0
I1
tp59461
sS'with,double,strength'
p59462
(F1
F0.00014334862385321102
I0
I1
I-1
tp59463
sS'however,requirement,i'
p59464
(F1
F0.00014334862385321102
I1
I0
I1
tp59465
sS'adjustment,is,needed'
p59466
(F1
F0.00014334862385321102
I0
I1
I-1
tp59467
sS'prolonged,because,of'
p59468
(F1
F0.00014334862385321102
I0
I1
I-1
tp59469
sS'and,about,a'
p59470
(F1
F0.00014334862385321102
I1
I0
I1
tp59471
sS'administered,orally,with'
p59472
(F1
F0.00014334862385321102
I1
I0
I1
tp59473
sS'interaction,between,brevibloc'
p59474
(F1
F0.00014334862385321102
I0
I1
I-1
tp59475
sS'nsaid,and,particularly'
p59476
(F1
F0.00014334862385321102
I0
I1
I-1
tp59477
sS'should,be,determined'
p59478
(F0
F0
I1
I1
I0
tp59479
sS'depressants,other,than'
p59480
(F1
F0.00014334862385321102
I0
I1
I-1
tp59481
sS'structural,heart,disease'
p59482
(F1
F0.00014334862385321102
I0
I1
I-1
tp59483
sS'indicating,no,potential'
p59484
(F1
F0.00014334862385321102
I0
I1
I-1
tp59485
sS'distribution,or,total'
p59486
(F1
F0.00014334862385321102
I0
I1
I-1
tp59487
sS'plasma,concentrations,mg'
p59488
(F1
F0.00014334862385321102
I0
I1
I-1
tp59489
sS'weight,gain,and'
p59490
(F1
F0.00014334862385321102
I1
I0
I1
tp59491
sS'should,be,kept'
p59492
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp59493
sS'the,reversal,of'
p59494
(F1
F0.00014334862385321102
I1
I0
I1
tp59495
sS'divided,attention,test'
p59496
(F1
F0.00014334862385321102
I1
I0
I1
tp59497
sS'transient,dose-dependent,increase'
p59498
(F1
F0.00014334862385321102
I1
I0
I1
tp59499
sS'who,were,on'
p59500
(F1
F0.00014334862385321102
I1
I0
I1
tp59501
sS'and,others,are'
p59502
(F1
F0.00014334862385321102
I1
I0
I1
tp59503
sS'that,patients,understand'
p59504
(F1
F0.00014334862385321102
I0
I1
I-1
tp59505
sS'inhibitor,of,breast'
p59506
(F1
F0.00014334862385321102
I0
I1
I-1
tp59507
sS'advisable,to,check'
p59508
(F1
F0.00014334862385321102
I1
I0
I1
tp59509
sS'with,in,a'
p59510
(F1
F0.00014334862385321102
I0
I1
I-1
tp59511
sS'levels,and,increase'
p59512
(F1
F0.00014334862385321102
I1
I0
I1
tp59513
sS'threshold,should,be'
p59514
(F1
F0.00014334862385321102
I1
I0
I1
tp59515
sS'of,in,renally'
p59516
(F1
F0.00014334862385321102
I0
I1
I-1
tp59517
sS'men,with,mild'
p59518
(F1
F0.00014334862385321102
I0
I1
I-1
tp59519
sS'we,observed,that'
p59520
(F1
F0.00014334862385321102
I1
I0
I1
tp59521
sS'angiotensins,inhibited,gastric'
p59522
(F1
F0.00014334862385321102
I0
I1
I-1
tp59523
sS'the,antihypertensive,effects'
p59524
(F1
F0.00028669724770642203
I2
I0
I2
tp59525
sS'augmentin,xr,patients'
p59526
(F1
F0.00014334862385321102
I0
I1
I-1
tp59527
sS'its,toxicity,may'
p59528
(F1
F0.00014334862385321102
I1
I0
I1
tp59529
sS'reduced,creatinine,clearance'
p59530
(F1
F0.00014334862385321102
I1
I0
I1
tp59531
sS'of,administered,concomitantly'
p59532
(F1
F0.00014334862385321102
I0
I1
I-1
tp59533
sS'l-phenylalanine,and,non-selective'
p59534
(F1
F0.00014334862385321102
I1
I0
I1
tp59535
sS'the,therapeutic,effect'
p59536
(F0
F0
I1
I1
I0
tp59537
sS'mc,mg,kg'
p59538
(F1
F0.00014334862385321102
I0
I1
I-1
tp59539
sS'during,and,for'
p59540
(F1
F0.00014334862385321102
I1
I0
I1
tp59541
sS'oral,agents,and'
p59542
(F1
F0.00057339449541284407
I0
I4
I-4
tp59543
sS'coated,plus,vioxx'
p59544
(F1
F0.00014334862385321102
I0
I1
I-1
tp59545
sS'significant,hypotension,developed'
p59546
(F1
F0.00014334862385321102
I1
I0
I1
tp59547
sS'monitored,when,itraconazole'
p59548
(F1
F0.00028669724770642203
I2
I0
I2
tp59549
sS'that,allegra,should'
p59550
(F1
F0.00014334862385321102
I0
I1
I-1
tp59551
sS'cause,weakness,hyperreflexia'
p59552
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp59553
sS'the,major,cytochrome'
p59554
(F1
F0.00014334862385321102
I0
I1
I-1
tp59555
sS'between,the,mean'
p59556
(F1
F0.00014334862385321102
I0
I1
I-1
tp59557
sS'allopurinol,inhibits,the'
p59558
(F1
F0.00014334862385321102
I1
I0
I1
tp59559
sS'possible,interaction,of'
p59560
(F1
F0.00014334862385321102
I1
I0
I1
tp59561
sS'experiences,of,changes'
p59562
(F1
F0.00014334862385321102
I1
I0
I1
tp59563
sS'to,increase,blood'
p59564
(F1
F0.00014334862385321102
I1
I0
I1
tp59565
sS'loss,of,spermatozoa'
p59566
(F1
F0.00014334862385321102
I0
I1
I-1
tp59567
sS'phenytoin,and,thus'
p59568
(F1
F0.00028669724770642203
I2
I0
I2
tp59569
sS'of,a,a'
p59570
(F1
F0.00014334862385321102
I1
I0
I1
tp59571
sS'than,those,seen'
p59572
(F1
F0.00014334862385321102
I1
I0
I1
tp59573
sS'possible,adjustment,of'
p59574
(F1
F0.00014334862385321102
I0
I1
I-1
tp59575
sS'depresses,activity,and'
p59576
(F1
F0.00014334862385321102
I1
I0
I1
tp59577
sS'steady-state,auc,of'
p59578
(F1
F0.00028669724770642203
I2
I0
I2
tp59579
sS'solution,dried,and'
p59580
(F1
F0.00014334862385321102
I0
I1
I-1
tp59581
sS'coumadin,other,tegretol'
p59582
(F1
F0.00014334862385321102
I0
I1
I-1
tp59583
sS'present,study,evoked'
p59584
(F1
F0.00014334862385321102
I0
I1
I-1
tp59585
sS'systemically,administered,enter'
p59586
(F1
F0.00014334862385321102
I0
I1
I-1
tp59587
sS'although,there,have'
p59588
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp59589
sS'absorption,of,fat-soluble'
p59590
(F1
F0.00014334862385321102
I1
I0
I1
tp59591
sS'dose,and,total'
p59592
(F1
F0.00014334862385321102
I1
I0
I1
tp59593
sS'ingested,or,from'
p59594
(F1
F0.00014334862385321102
I0
I1
I-1
tp59595
sS'method,this,study'
p59596
(F1
F0.00014334862385321102
I0
I1
I-1
tp59597
sS'with,ace,inhibitors'
p59598
(F1
F0.00028669724770642203
I2
I0
I2
tp59599
sS'plenaxis,should,be'
p59600
(F1
F0.00014334862385321102
I0
I1
I-1
tp59601
sS'careful,monitoring,for'
p59602
(F0
F0
I1
I1
I0
tp59603
sS'per,day,in'
p59604
(F1
F0.00014334862385321102
I1
I0
I1
tp59605
sS'antagonist,that,may'
p59606
(F1
F0.00014334862385321102
I1
I0
I1
tp59607
sS'antacids,in,a'
p59608
(F1
F0.00028669724770642203
I2
I0
I2
tp59609
sS'of,nimbex,were'
p59610
(F1
F0.00014334862385321102
I1
I0
I1
tp59611
sS'of,with,that'
p59612
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp59613
sS'clearance,of,from'
p59614
(F1
F0.00014334862385321102
I1
I0
I1
tp59615
sS'with,a,closely'
p59616
(F1
F0.00014334862385321102
I1
I0
I1
tp59617
sS'when,hydrochloride,has'
p59618
(F1
F0.00014334862385321102
I1
I0
I1
tp59619
sS'vitro,studies,it'
p59620
(F1
F0.00014334862385321102
I0
I1
I-1
tp59621
sS'clearance,does,not'
p59622
(F1
F0.00014334862385321102
I0
I1
I-1
tp59623
sS'for,sustiva,and'
p59624
(F1
F0.00014334862385321102
I0
I1
I-1
tp59625
sS'when,the,stadol'
p59626
(F1
F0.00014334862385321102
I1
I0
I1
tp59627
sS'by,and,that'
p59628
(F1
F0.00014334862385321102
I0
I1
I-1
tp59629
sS'is,required,concentrations'
p59630
(F1
F0.00014334862385321102
I1
I0
I1
tp59631
sS'was,maintained,at'
p59632
(F1
F0.00014334862385321102
I0
I1
I-1
tp59633
sS'vitro,studies,in'
p59634
(F1
F0.00028669724770642203
I2
I0
I2
tp59635
sS'levels,of,are'
p59636
(F1
F0.00014334862385321102
I1
I0
I1
tp59637
sS'suggesting,that,may'
p59638
(F1
F0.00014334862385321102
I1
I0
I1
tp59639
sS'patients,by,use'
p59640
(F1
F0.00014334862385321102
I0
I1
I-1
tp59641
sS'with,an,an'
p59642
(F1
F0.00014334862385321102
I0
I1
I-1
tp59643
sS'it,concomitantly,with'
p59644
(F1
F0.00014334862385321102
I1
I0
I1
tp59645
sS'estradiol,and,an'
p59646
(F1
F0.00014334862385321102
I1
I0
I1
tp59647
sS'of,hyperlipidemia,or'
p59648
(F1
F0.00014334862385321102
I1
I0
I1
tp59649
sS'metabolism,of,these'
p59650
(F1
F0.00014334862385321102
I1
I0
I1
tp59651
sS'a4,macrolide,such'
p59652
(F1
F0.00014334862385321102
I1
I0
I1
tp59653
sS'from,regression,analyses'
p59654
(F1
F0.00014334862385321102
I1
I0
I1
tp59655
sS'agents,may,decrease'
p59656
(F1
F0.00028669724770642203
I2
I0
I2
tp59657
sS'of,some,of'
p59658
(F1
F0.00014334862385321102
I0
I1
I-1
tp59659
sS'release,of,caused'
p59660
(F1
F0.00014334862385321102
I1
I0
I1
tp59661
sS'of,single,oral'
p59662
(F1
F0.00014334862385321102
I1
I0
I1
tp59663
sS'of,with,its'
p59664
(F1
F0.00014334862385321102
I0
I1
I-1
tp59665
sS'inhibitors,acetylsalicylic,acid'
p59666
(F1
F0.00014334862385321102
I0
I1
I-1
tp59667
sS'with,a,has'
p59668
(F1
F0.00014334862385321102
I1
I0
I1
tp59669
sS'asparagine,levels,are'
p59670
(F1
F0.00014334862385321102
I1
I0
I1
tp59671
sS'may,cause,increases'
p59672
(F1
F0.00014334862385321102
I0
I1
I-1
tp59673
sS'pressure,effect,of'
p59674
(F1
F0.00014334862385321102
I1
I0
I1
tp59675
sS'fold,in,hydatid'
p59676
(F1
F0.00014334862385321102
I1
I0
I1
tp59677
sS'could,exaggerate,the'
p59678
(F1
F0.00028669724770642203
I2
I0
I2
tp59679
sS'incidence,of,sedation'
p59680
(F1
F0.00014334862385321102
I1
I0
I1
tp59681
sS'reuptake,and,the'
p59682
(F1
F0.00014334862385321102
I1
I0
I1
tp59683
sS'in,metabolism,inhibitors'
p59684
(F1
F0.00014334862385321102
I1
I0
I1
tp59685
sS'by,any,of'
p59686
(F1
F0.00014334862385321102
I1
I0
I1
tp59687
sS'cyp3a4,as,it'
p59688
(F1
F0.00014334862385321102
I0
I1
I-1
tp59689
sS'natriuretic,and,effects'
p59690
(F1
F0.00057339449541284407
I4
I0
I4
tp59691
sS'hypoglycemic,effect,of'
p59692
(F1
F0.00014334862385321102
I1
I0
I1
tp59693
sS'of,in,well-controlled'
p59694
(F1
F0.00014334862385321102
I1
I0
I1
tp59695
sS'mg,tablets,results'
p59696
(F1
F0.00014334862385321102
I1
I0
I1
tp59697
sS'to,toxic,concentrations'
p59698
(F1
F0.00014334862385321102
I1
I0
I1
tp59699
sS'while,left,ventricular'
p59700
(F1
F0.00014334862385321102
I0
I1
I-1
tp59701
sS'of,coadministration,with'
p59702
(F1
F0.00014334862385321102
I1
I0
I1
tp59703
sS'in,uptake,may'
p59704
(F1
F0.00014334862385321102
I1
I0
I1
tp59705
sS'study,caused,a'
p59706
(F1
F0.00014334862385321102
I1
I0
I1
tp59707
sS'exceeded,when,used'
p59708
(F1
F0.00014334862385321102
I1
I0
I1
tp59709
sS'by,chronic,administration'
p59710
(F1
F0.00014334862385321102
I1
I0
I1
tp59711
sS'cyp1a2,cyp2a6,cyp2c9'
p59712
(F1
F0.00043004587155963305
I0
I3
I-3
tp59713
sS'prelone,pediapred,others'
p59714
(F1
F0.00014334862385321102
I0
I1
I-1
tp59715
sS'common,transport,pathway'
p59716
(F1
F0.00014334862385321102
I0
I1
I-1
tp59717
sS'pharmacokinetics,and,protein'
p59718
(F1
F0.00014334862385321102
I0
I1
I-1
tp59719
sS'an,approximate,decrease'
p59720
(F1
F0.00057339449541284407
I4
I0
I4
tp59721
sS'hydroxydesloratadine,pharmacokinetics,in'
p59722
(F1
F0.00014334862385321102
I0
I1
I-1
tp59723
sS'to,affect,duloxetine'
p59724
(F1
F0.00014334862385321102
I0
I1
I-1
tp59725
sS'with,copper,sulfate'
p59726
(F1
F0.00014334862385321102
I0
I1
I-1
tp59727
sS'with,pivoxil,resulted'
p59728
(F1
F0.00014334862385321102
I1
I0
I1
tp59729
sS'exposure,of,under'
p59730
(F1
F0.00014334862385321102
I1
I0
I1
tp59731
sS'may,persist,for'
p59732
(F1
F0.00014334862385321102
I0
I1
I-1
tp59733
sS'alter,glucose,metabolism'
p59734
(F1
F0.00014334862385321102
I0
I1
I-1
tp59735
sS'diuretics,furosemide,administered'
p59736
(F1
F0.00014334862385321102
I0
I1
I-1
tp59737
sS'was,separated,from'
p59738
(F1
F0.00014334862385321102
I1
I0
I1
tp59739
sS'and,various,chemotherapy'
p59740
(F1
F0.00014334862385321102
I0
I1
I-1
tp59741
sS'treatment,with,tablets'
p59742
(F1
F0.00014334862385321102
I1
I0
I1
tp59743
sS'potentiate,the,hypoglycemic'
p59744
(F1
F0.00014334862385321102
I1
I0
I1
tp59745
sS'of,short-acting,such'
p59746
(F1
F0.00014334862385321102
I0
I1
I-1
tp59747
sS'auc,of,and'
p59748
(F1
F0.00043004587155963305
I3
I0
I3
tp59749
sS'activity,may,increase'
p59750
(F1
F0.00014334862385321102
I0
I1
I-1
tp59751
sS'properties,if,coreg'
p59752
(F1
F0.00014334862385321102
I1
I0
I1
tp59753
sS'hyperprolactinaemia,as,seen'
p59754
(F1
F0.00014334862385321102
I0
I1
I-1
tp59755
sS'of,antizol,and'
p59756
(F1
F0.00014334862385321102
I1
I0
I1
tp59757
sS'and,therapeutic,effects'
p59758
(F1
F0.00014334862385321102
I1
I0
I1
tp59759
sS'of,homocysteine,in'
p59760
(F1
F0.00014334862385321102
I0
I1
I-1
tp59761
sS'and,are,associated'
p59762
(F1
F0.00014334862385321102
I0
I1
I-1
tp59763
sS'shown,to,influence'
p59764
(F1
F0.00014334862385321102
I1
I0
I1
tp59765
sS'dose,in,adults'
p59766
(F1
F0.00014334862385321102
I1
I0
I1
tp59767
sS'with,hormonal,may'
p59768
(F1
F0.00014334862385321102
I1
I0
I1
tp59769
sS'and,also,in'
p59770
(F1
F0.00057339449541284407
I4
I0
I4
tp59771
sS'the,history,prior'
p59772
(F1
F0.00014334862385321102
I0
I1
I-1
tp59773
sS'the,extent,of'
p59774
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp59775
sS'a,loss,of'
p59776
(F1
F0.00014334862385321102
I0
I1
I-1
tp59777
sS'pharmacodynamics,of,coadministration'
p59778
(F1
F0.00014334862385321102
I0
I1
I-1
tp59779
sS'that,may,result'
p59780
(F1
F0.00028669724770642203
I2
I0
I2
tp59781
sS'metabolism,of,by'
p59782
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp59783
sS'administered,hydrochloride,alone'
p59784
(F1
F0.00014334862385321102
I0
I1
I-1
tp59785
sS'excretion,of,urate'
p59786
(F1
F0.00014334862385321102
I1
I0
I1
tp59787
sS'as,implants,and'
p59788
(F1
F0.00014334862385321102
I0
I1
I-1
tp59789
sS'drinking,during,treatment'
p59790
(F1
F0.00014334862385321102
I1
I0
I1
tp59791
sS'and,ethanol,cause'
p59792
(F1
F0.00014334862385321102
I1
I0
I1
tp59793
sS'if,necessary,the'
p59794
(F1
F0.00014334862385321102
I1
I0
I1
tp59795
sS'injection,and,potassium-depleting'
p59796
(F1
F0.00014334862385321102
I1
I0
I1
tp59797
sS'random,observations,have'
p59798
(F1
F0.00014334862385321102
I1
I0
I1
tp59799
sS'were,increased,by'
p59800
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp59801
sS'has,a,direct'
p59802
(F1
F0.00014334862385321102
I0
I1
I-1
tp59803
sS'for,days,did'
p59804
(F1
F0.0010034403669724771
I0
I7
I-7
tp59805
sS'body,weight,was'
p59806
(F0
F0
I1
I1
I0
tp59807
sS'frequent,cause,of'
p59808
(F1
F0.00014334862385321102
I1
I0
I1
tp59809
sS'exercised,in,the'
p59810
(F0
F0
I1
I1
I0
tp59811
sS'however,plasma,concentrations'
p59812
(F1
F0.00014334862385321102
I0
I1
I-1
tp59813
sS'reported,that,when'
p59814
(F1
F0.00014334862385321102
I1
I0
I1
tp59815
sS'obtain,serum,levels'
p59816
(F1
F0.00014334862385321102
I1
I0
I1
tp59817
sS'for,days,followed'
p59818
(F1
F0.00028669724770642203
I0
I2
I-2
tp59819
sS'week,controlled,study'
p59820
(F1
F0.00014334862385321102
I0
I1
I-1
tp59821
sS'have,been,co-administered'
p59822
(F1
F0.00014334862385321102
I1
I0
I1
tp59823
sS'striatum,and,cortex'
p59824
(F1
F0.00014334862385321102
I1
I0
I1
tp59825
sS'nonsteroidal,anti-inflammatory,agents'
p59826
(F0.5
F0.00028669724770642203
I3
I1
I2
tp59827
sS'atropine,either,alone'
p59828
(F1
F0.00014334862385321102
I0
I1
I-1
tp59829
sS'exacerbation,or,the'
p59830
(F1
F0.00014334862385321102
I1
I0
I1
tp59831
sS'be,closely,monitored'
p59832
(F1
F0.0012901376146788992
I9
I0
I9
tp59833
sS'clozapine,potentially,resulting'
p59834
(F1
F0.00014334862385321102
I1
I0
I1
tp59835
sS'dose-dependent,increase,in'
p59836
(F1
F0.00014334862385321102
I1
I0
I1
tp59837
sS'and,c19,the'
p59838
(F1
F0.00014334862385321102
I0
I1
I-1
tp59839
sS'by,is,not'
p59840
(F1
F0.00014334862385321102
I1
I0
I1
tp59841
sS'in,lysing,human'
p59842
(F1
F0.00014334862385321102
I0
I1
I-1
tp59843
sS'however,severe,reactions'
p59844
(F1
F0.00014334862385321102
I0
I1
I-1
tp59845
sS'e-strain,subjects,to'
p59846
(F1
F0.00014334862385321102
I0
I1
I-1
tp59847
sS'factive,had,no'
p59848
(F1
F0.00028669724770642203
I0
I2
I-2
tp59849
sS'alternative,therapy,should'
p59850
(F1
F0.00014334862385321102
I1
I0
I1
tp59851
sS'to,decrease,established'
p59852
(F1
F0.00014334862385321102
I1
I0
I1
tp59853
sS'patients,treated,concomitantly'
p59854
(F1
F0.00014334862385321102
I1
I0
I1
tp59855
sS'interactions,with,topical'
p59856
(F1
F0.00014334862385321102
I1
I0
I1
tp59857
sS'stimulant,effects,of'
p59858
(F1
F0.00028669724770642203
I2
I0
I2
tp59859
sS'the,mean,distribution'
p59860
(F1
F0.00014334862385321102
I0
I1
I-1
tp59861
sS'of,acute,myocardial'
p59862
(F1
F0.00014334862385321102
I0
I1
I-1
tp59863
sS'hour,lag,phase'
p59864
(F1
F0.00014334862385321102
I0
I1
I-1
tp59865
sS'days,of,co-administration'
p59866
(F1
F0.00028669724770642203
I0
I2
I-2
tp59867
sS'with,and,the'
p59868
(F1
F0.00028669724770642203
I0
I2
I-2
tp59869
sS'pharmacokinetic,results,from'
p59870
(F1
F0.00014334862385321102
I1
I0
I1
tp59871
sS'did,not,experience'
p59872
(F1
F0.00014334862385321102
I0
I1
I-1
tp59873
sS'with,b-blocking,properties'
p59874
(F1
F0.00071674311926605509
I5
I0
I5
tp59875
sS'subjects,on,stable'
p59876
(F1
F0.00014334862385321102
I0
I1
I-1
tp59877
sS'color,is,due'
p59878
(F1
F0.00014334862385321102
I1
I0
I1
tp59879
sS'videx,chewable,dispersible'
p59880
(F1
F0.00014334862385321102
I1
I0
I1
tp59881
sS'established,but,should'
p59882
(F1
F0.00014334862385321102
I0
I1
I-1
tp59883
sS'interaction,of,ketoconazole'
p59884
(F1
F0.00014334862385321102
I1
I0
I1
tp59885
sS'including,most,ssris'
p59886
(F1
F0.00014334862385321102
I0
I1
I-1
tp59887
sS'hypotension,vs,myocardial'
p59888
(F1
F0.00014334862385321102
I1
I0
I1
tp59889
sS'unaffected,by,the'
p59890
(F1
F0.00014334862385321102
I0
I1
I-1
tp59891
sS'of,brevibloc,on'
p59892
(F1
F0.00014334862385321102
I0
I1
I-1
tp59893
sS'resulted,when,amines'
p59894
(F1
F0.00014334862385321102
I1
I0
I1
tp59895
sS'each,volunteer,received'
p59896
(F1
F0.00014334862385321102
I0
I1
I-1
tp59897
sS'reported,due,to'
p59898
(F1
F0.00014334862385321102
I1
I0
I1
tp59899
sS'of,beta,blockers'
p59900
(F1
F0.00028669724770642203
I2
I0
I2
tp59901
sS'with,lowered,blood'
p59902
(F1
F0.00014334862385321102
I1
I0
I1
tp59903
sS'excretion,was,enhanced'
p59904
(F1
F0.00014334862385321102
I0
I1
I-1
tp59905
sS'viracept,antiarrhythmics,antihistamines'
p59906
(F1
F0.00014334862385321102
I1
I0
I1
tp59907
sS'effect,on,bone'
p59908
(F1
F0.00028669724770642203
I0
I2
I-2
tp59909
sS'aluminum,hydroxide-,and'
p59910
(F1
F0.00014334862385321102
I0
I1
I-1
tp59911
sS'for,chelation,and'
p59912
(F1
F0.00014334862385321102
I0
I1
I-1
tp59913
sS'caution,is,recommended'
p59914
(F1
F0.00057339449541284407
I4
I0
I4
tp59915
sS'advised,in,using'
p59916
(F1
F0.00014334862385321102
I1
I0
I1
tp59917
sS'less,than,additive'
p59918
(F1
F0.00014334862385321102
I1
I0
I1
tp59919
sS'increased,central,nervous'
p59920
(F1
F0.00014334862385321102
I1
I0
I1
tp59921
sS'induced,responses,were'
p59922
(F1
F0.00014334862385321102
I0
I1
I-1
tp59923
sS'of,in,by'
p59924
(F1
F0.00014334862385321102
I1
I0
I1
tp59925
sS'of,were,significantly'
p59926
(F1
F0.00014334862385321102
I1
I0
I1
tp59927
sS'of,by,blocking'
p59928
(F1
F0.00014334862385321102
I1
I0
I1
tp59929
sS'isozyme,including,and'
p59930
(F1
F0.00014334862385321102
I1
I0
I1
tp59931
sS'glycemia,induced,by'
p59932
(F1
F0.00014334862385321102
I0
I1
I-1
tp59933
sS'l,and,mg'
p59934
(F1
F0.00014334862385321102
I0
I1
I-1
tp59935
sS'conductivity,and,automaticity'
p59936
(F1
F0.00014334862385321102
I1
I0
I1
tp59937
sS'thinners,decongestant,allergy'
p59938
(F1
F0.00014334862385321102
I1
I0
I1
tp59939
sS'for,plasma,and'
p59940
(F1
F0.00014334862385321102
I0
I1
I-1
tp59941
sS'therefore,when,indocin'
p59942
(F0
F0
I1
I1
I0
tp59943
sS'of,interactions,resulting'
p59944
(F1
F0.00014334862385321102
I0
I1
I-1
tp59945
sS'trials,the,safety'
p59946
(F1
F0.00014334862385321102
I0
I1
I-1
tp59947
sS'transit-enhancing,effect,of'
p59948
(F1
F0.00014334862385321102
I0
I1
I-1
tp59949
sS'dietary-obese,rats,giving'
p59950
(F1
F0.00014334862385321102
I0
I1
I-1
tp59951
sS'of,with,doses'
p59952
(F1
F0.00028669724770642203
I0
I2
I-2
tp59953
sS'and,its,major'
p59954
(F1
F0.00028669724770642203
I0
I2
I-2
tp59955
sS'to,and,m'
p59956
(F1
F0.00014334862385321102
I0
I1
I-1
tp59957
sS'and,agents,of'
p59958
(F1
F0.00014334862385321102
I1
I0
I1
tp59959
sS'of,were,approximately'
p59960
(F1
F0.00014334862385321102
I1
I0
I1
tp59961
sS'or,including,combined'
p59962
(F1
F0.00014334862385321102
I0
I1
I-1
tp59963
sS'inhibition,of,arachidonate-'
p59964
(F1
F0.00014334862385321102
I0
I1
I-1
tp59965
sS'pharmacokinetics,of,mg'
p59966
(F1
F0.00071674311926605509
I0
I5
I-5
tp59967
sS'lack,of,anti-platelet'
p59968
(F1
F0.00014334862385321102
I0
I1
I-1
tp59969
sS'and,lethality,in'
p59970
(F1
F0.00014334862385321102
I0
I1
I-1
tp59971
sS'in,a,prospective'
p59972
(F1
F0.00014334862385321102
I0
I1
I-1
tp59973
sS'hypoglycemic,agents,leading'
p59974
(F1
F0.00043004587155963305
I3
I0
I3
tp59975
sS'of,d,h'
p59976
(F0
F0
I1
I1
I0
tp59977
sS'index,or,tumor'
p59978
(F1
F0.00014334862385321102
I0
I1
I-1
tp59979
sS'of,inspra,mg'
p59980
(F1
F0.00014334862385321102
I1
I0
I1
tp59981
sS'to,micrograms,ml'
p59982
(F0
F0
I1
I1
I0
tp59983
sS'where,patients,were'
p59984
(F1
F0.00014334862385321102
I0
I1
I-1
tp59985
sS'is,concluded,that'
p59986
(F0
F0
I2
I2
I0
tp59987
sS'amiodarone,therapy,alone'
p59988
(F1
F0.00014334862385321102
I0
I1
I-1
tp59989
sS'need,for,the'
p59990
(F1
F0.00014334862385321102
I0
I1
I-1
tp59991
sS'studies,in,animals'
p59992
(F1
F0.00028669724770642203
I2
I0
I2
tp59993
sS'seen,in,animals'
p59994
(F1
F0.00014334862385321102
I1
I0
I1
tp59995
sS'high,doses,mg'
p59996
(F1
F0.00014334862385321102
I1
I0
I1
tp59997
sS'non-,steroidal,anti-'
p59998
(F1
F0.00014334862385321102
I1
I0
I1
tp59999
sS'from,the,toxicity'
p60000
(F1
F0.00014334862385321102
I1
I0
I1
tp60001
sS'is,a,potential'
p60002
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp60003
sS'lumen,at,as'
p60004
(F1
F0.00014334862385321102
I0
I1
I-1
tp60005
sS'in,hiv-infected,individuals'
p60006
(F1
F0.00014334862385321102
I0
I1
I-1
tp60007
sS'by,decreasing,gut'
p60008
(F1
F0.00014334862385321102
I1
I0
I1
tp60009
sS'nephrotoxicity,and,ototoxicity'
p60010
(F0
F0
I1
I1
I0
tp60011
sS'drugs,l-phenylalanine,may'
p60012
(F1
F0.00014334862385321102
I1
I0
I1
tp60013
sS'at,mg,b'
p60014
(F1
F0.00014334862385321102
I1
I0
I1
tp60015
sS'than,to,mg'
p60016
(F1
F0.00014334862385321102
I0
I1
I-1
tp60017
sS'with,brovana,at'
p60018
(F1
F0.00014334862385321102
I0
I1
I-1
tp60019
sS'medications,like,or'
p60020
(F1
F0.00043004587155963305
I3
I0
I3
tp60021
sS'or,its,plasma'
p60022
(F1
F0.00014334862385321102
I0
I1
I-1
tp60023
sS'local,including,both'
p60024
(F1
F0.00014334862385321102
I1
I0
I1
tp60025
sS'is,only,a'
p60026
(F1
F0.00014334862385321102
I0
I1
I-1
tp60027
sS'probenecid,probenecid,slows'
p60028
(F1
F0.00014334862385321102
I0
I1
I-1
tp60029
sS'such,as,not'
p60030
(F1
F0.00014334862385321102
I1
I0
I1
tp60031
sS'other,reported,interactions'
p60032
(F1
F0.00014334862385321102
I0
I1
I-1
tp60033
sS'be,more,severe'
p60034
(F1
F0.00014334862385321102
I0
I1
I-1
tp60035
sS'or,and,to'
p60036
(F1
F0.00014334862385321102
I0
I1
I-1
tp60037
sS'antacids,administration,of'
p60038
(F0
F0
I1
I1
I0
tp60039
sS'and,plasma,expanders'
p60040
(F1
F0.00014334862385321102
I0
I1
I-1
tp60041
sS'cmc-cys7,from,m'
p60042
(F1
F0.00014334862385321102
I0
I1
I-1
tp60043
sS'suspension,yielded,similar'
p60044
(F1
F0.00014334862385321102
I0
I1
I-1
tp60045
sS'course,of,therapy'
p60046
(F1
F0.00014334862385321102
I1
I0
I1
tp60047
sS'hydroxylamine,a,metabolite'
p60048
(F1
F0.00014334862385321102
I0
I1
I-1
tp60049
sS'jaff,reaction,and'
p60050
(F1
F0.00014334862385321102
I0
I1
I-1
tp60051
sS'of,intravenously,administered'
p60052
(F1
F0.00014334862385321102
I1
I0
I1
tp60053
sS'rate,or,extent'
p60054
(F1
F0.00043004587155963305
I0
I3
I-3
tp60055
sS'inhibitors,maoi,there'
p60056
(F1
F0.00014334862385321102
I1
I0
I1
tp60057
sS'taxol,and,aggressive'
p60058
(F1
F0.00014334862385321102
I0
I1
I-1
tp60059
sS'concentrations,and,reduce'
p60060
(F1
F0.00014334862385321102
I0
I1
I-1
tp60061
sS'of,methotrexate-related,toxicity'
p60062
(F1
F0.00028669724770642203
I2
I0
I2
tp60063
sS'with,a,cyp3a4'
p60064
(F1
F0.00014334862385321102
I0
I1
I-1
tp60065
sS'have,a,substantially'
p60066
(F1
F0.00014334862385321102
I0
I1
I-1
tp60067
sS'cyp3a4,inducer,mg'
p60068
(F1
F0.00014334862385321102
I1
I0
I1
tp60069
sS'in,phosphorylation,inhibition'
p60070
(F1
F0.00014334862385321102
I1
I0
I1
tp60071
sS'octapeptide,cholecystokinin--of,h-spiroperidol'
p60072
(F1
F0.00014334862385321102
I0
I1
I-1
tp60073
sS'a,during,the'
p60074
(F1
F0.00014334862385321102
I0
I1
I-1
tp60075
sS'simvastatin,and,other'
p60076
(F1
F0.00014334862385321102
I1
I0
I1
tp60077
sS'half-life,of,increased'
p60078
(F1
F0.00014334862385321102
I1
I0
I1
tp60079
sS'mg,day,to'
p60080
(F1
F0.00014334862385321102
I0
I1
I-1
tp60081
sS'synthesis,have,been'
p60082
(F1
F0.00014334862385321102
I1
I0
I1
tp60083
sS'is,totally,atoxic'
p60084
(F1
F0.00014334862385321102
I0
I1
I-1
tp60085
sS'dietary,concentration,as'
p60086
(F1
F0.00014334862385321102
I0
I1
I-1
tp60087
sS'requires,maintaining,a'
p60088
(F1
F0.00014334862385321102
I0
I1
I-1
tp60089
sS'oxidase,inhibitory,effects'
p60090
(F1
F0.00014334862385321102
I0
I1
I-1
tp60091
sS'recovery,took,min'
p60092
(F1
F0.00014334862385321102
I1
I0
I1
tp60093
sS'duration,of,block'
p60094
(F1
F0.00014334862385321102
I1
I0
I1
tp60095
sS'been,completed,with'
p60096
(F1
F0.00014334862385321102
I0
I1
I-1
tp60097
sS'closely,for,adverse'
p60098
(F1
F0.00014334862385321102
I0
I1
I-1
tp60099
sS'doses,of,nanm'
p60100
(F1
F0.00014334862385321102
I0
I1
I-1
tp60101
sS'and,potent,inhibitors'
p60102
(F1
F0.00014334862385321102
I0
I1
I-1
tp60103
sS'when,administering,to'
p60104
(F1
F0.00028669724770642203
I2
I0
I2
tp60105
sS'of,and,or'
p60106
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp60107
sS'alkaline,urine,red-orange'
p60108
(F1
F0.00014334862385321102
I0
I1
I-1
tp60109
sS'was,abolished,by'
p60110
(F1
F0.00014334862385321102
I1
I0
I1
tp60111
sS'effect,of,certain'
p60112
(F1
F0.00014334862385321102
I1
I0
I1
tp60113
sS'a,dose,reduction'
p60114
(F0.5
F0.00028669724770642203
I3
I1
I2
tp60115
sS'a,highly,potent'
p60116
(F1
F0.00014334862385321102
I1
I0
I1
tp60117
sS'subjects,when,doses'
p60118
(F1
F0.00014334862385321102
I1
I0
I1
tp60119
sS'of,urate,are'
p60120
(F1
F0.00014334862385321102
I1
I0
I1
tp60121
sS'reduced,tysabri,clearance'
p60122
(F1
F0.00014334862385321102
I1
I0
I1
tp60123
sS'by,cyp2d6,cyp2c9'
p60124
(F1
F0.00014334862385321102
I0
I1
I-1
tp60125
sS'racemic,nor,binding'
p60126
(F1
F0.00014334862385321102
I0
I1
I-1
tp60127
sS'in,concentrations,above'
p60128
(F1
F0.00014334862385321102
I1
I0
I1
tp60129
sS'plasma,samples,may'
p60130
(F1
F0.00014334862385321102
I0
I1
I-1
tp60131
sS'be,considered,for'
p60132
(F1
F0.00014334862385321102
I0
I1
I-1
tp60133
sS'in,cases,of'
p60134
(F1
F0.00057339449541284407
I4
I0
I4
tp60135
sS'performed,doses,of'
p60136
(F1
F0.00014334862385321102
I0
I1
I-1
tp60137
sS'morphine,combination,hormonal'
p60138
(F1
F0.00014334862385321102
I1
I0
I1
tp60139
sS'most,ssris,many'
p60140
(F1
F0.00014334862385321102
I0
I1
I-1
tp60141
sS'anabolic,steroids,chloral'
p60142
(F1
F0.00014334862385321102
I1
I0
I1
tp60143
sS'not,by,n6-cyclopentyladenosine'
p60144
(F1
F0.00014334862385321102
I1
I0
I1
tp60145
sS'study,maximum,plasma'
p60146
(F1
F0.00014334862385321102
I1
I0
I1
tp60147
sS'dynacirc,and,does'
p60148
(F1
F0.00014334862385321102
I0
I1
I-1
tp60149
sS'improves,quality,of'
p60150
(F1
F0.00014334862385321102
I0
I1
I-1
tp60151
sS'of,nonbenzodiazepine,agonists'
p60152
(F1
F0.00014334862385321102
I1
I0
I1
tp60153
sS'suggested,the,mediation'
p60154
(F1
F0.00014334862385321102
I0
I1
I-1
tp60155
sS'serotonin,syndrome,has'
p60156
(F1
F0.00014334862385321102
I1
I0
I1
tp60157
sS'evaluated,to,determine'
p60158
(F1
F0.00014334862385321102
I0
I1
I-1
tp60159
sS'administered,at,least'
p60160
(F1
F0.00057339449541284407
I4
I0
I4
tp60161
sS'effect,on,pharmacokinetics'
p60162
(F0
F0
I1
I1
I0
tp60163
sS'these,six,volunteers'
p60164
(F1
F0.00014334862385321102
I0
I1
I-1
tp60165
sS'depressant,cns,including'
p60166
(F1
F0.00014334862385321102
I0
I1
I-1
tp60167
sS'indocin,is,given'
p60168
(F1
F0.00014334862385321102
I1
I0
I1
tp60169
sS'was,only,observed'
p60170
(F1
F0.00014334862385321102
I1
I0
I1
tp60171
sS'absorption,of,the'
p60172
(F1
F0.00014334862385321102
I1
I0
I1
tp60173
sS'or,resulted,in'
p60174
(F1
F0.00014334862385321102
I1
I0
I1
tp60175
sS'cytochrome,p-450,the'
p60176
(F0
F0
I1
I1
I0
tp60177
sS'or,or,its'
p60178
(F1
F0.00014334862385321102
I0
I1
I-1
tp60179
sS'receiving,itraconazole,and'
p60180
(F1
F0.00028669724770642203
I2
I0
I2
tp60181
sS'indicated,that,there'
p60182
(F1
F0.00028669724770642203
I0
I2
I-2
tp60183
sS'in,pigeons,and'
p60184
(F1
F0.00014334862385321102
I0
I1
I-1
tp60185
sS'agents,demonstrated,similar'
p60186
(F1
F0.00014334862385321102
I0
I1
I-1
tp60187
sS'control,blood,sugar'
p60188
(F1
F0.00014334862385321102
I1
I0
I1
tp60189
sS'as,platelet,inhibitors'
p60190
(F1
F0.00014334862385321102
I0
I1
I-1
tp60191
sS'of,individual,simulect'
p60192
(F1
F0.00014334862385321102
I0
I1
I-1
tp60193
sS'clearance,with,a'
p60194
(F1
F0.00014334862385321102
I1
I0
I1
tp60195
sS'such,as,those'
p60196
(F1
F0.00014334862385321102
I0
I1
I-1
tp60197
sS'monitoring,the,problems'
p60198
(F1
F0.00014334862385321102
I0
I1
I-1
tp60199
sS'erythro-fluorocitrate,synthesis,in'
p60200
(F1
F0.00014334862385321102
I0
I1
I-1
tp60201
sS'on,the,gi'
p60202
(F1
F0.00014334862385321102
I1
I0
I1
tp60203
sS'of,is,recommended'
p60204
(F1
F0.00043004587155963305
I3
I0
I3
tp60205
sS'case,of,a'
p60206
(F1
F0.00014334862385321102
I1
I0
I1
tp60207
sS'or,thiazide,can'
p60208
(F1
F0.00014334862385321102
I1
I0
I1
tp60209
sS'diminish,the,antihypertensive'
p60210
(F1
F0.00043004587155963305
I3
I0
I3
tp60211
sS'effectiveness,and,increased'
p60212
(F1
F0.00014334862385321102
I1
I0
I1
tp60213
sS'm2,and,or'
p60214
(F1
F0.00014334862385321102
I1
I0
I1
tp60215
sS'agents,may,either'
p60216
(F1
F0.00014334862385321102
I1
I0
I1
tp60217
sS'exercised,when,pletal'
p60218
(F1
F0.00014334862385321102
I1
I0
I1
tp60219
sS'injection,usp,has'
p60220
(F1
F0.00014334862385321102
I0
I1
I-1
tp60221
sS'primarily,metabolized,by'
p60222
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp60223
sS'in,vitro,interaction'
p60224
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp60225
sS'cmin,auc,ci'
p60226
(F1
F0.00014334862385321102
I0
I1
I-1
tp60227
sS'powders,showed,that'
p60228
(F1
F0.00014334862385321102
I1
I0
I1
tp60229
sS'taken,in,combination'
p60230
(F1
F0.00014334862385321102
I1
I0
I1
tp60231
sS'ganglionic,blocking,agents'
p60232
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp60233
sS'primarily,as,methyltetrahydro-folate'
p60234
(F1
F0.00014334862385321102
I0
I1
I-1
tp60235
sS'volunteers,developed,rash'
p60236
(F1
F0.00014334862385321102
I1
I0
I1
tp60237
sS'trileptal,was,given'
p60238
(F1
F0.00014334862385321102
I1
I0
I1
tp60239
sS'thought,to,be'
p60240
(F1
F0.00014334862385321102
I0
I1
I-1
tp60241
sS'antagonist,were,a'
p60242
(F1
F0.00014334862385321102
I0
I1
I-1
tp60243
sS'derivatives,and,possibly'
p60244
(F1
F0.00014334862385321102
I1
I0
I1
tp60245
sS'patient,population,chronically'
p60246
(F1
F0.00014334862385321102
I0
I1
I-1
tp60247
sS'daily,dose,was'
p60248
(F1
F0.00014334862385321102
I0
I1
I-1
tp60249
sS'its,cellular,uptake'
p60250
(F1
F0.00014334862385321102
I1
I0
I1
tp60251
sS'clinical,laboratory,tests'
p60252
(F1
F0.00028669724770642203
I0
I2
I-2
tp60253
sS'procedure,in,which'
p60254
(F1
F0.00014334862385321102
I0
I1
I-1
tp60255
sS'that,of,n-desmethyldiazepam'
p60256
(F1
F0.00014334862385321102
I0
I1
I-1
tp60257
sS'used,for,management'
p60258
(F1
F0.00014334862385321102
I1
I0
I1
tp60259
sS'toxicity,of,b'
p60260
(F1
F0.00014334862385321102
I0
I1
I-1
tp60261
sS'the,day,of'
p60262
(F1
F0.00014334862385321102
I1
I0
I1
tp60263
sS'coadministered,steady-state,plasma'
p60264
(F1
F0.00014334862385321102
I1
I0
I1
tp60265
sS'decreased,urinary,levels'
p60266
(F1
F0.00014334862385321102
I0
I1
I-1
tp60267
sS'administration,of,macrolide'
p60268
(F1
F0.00014334862385321102
I1
I0
I1
tp60269
sS'and,xanthine,and'
p60270
(F1
F0.00014334862385321102
I1
I0
I1
tp60271
sS'or,cervical,laceration'
p60272
(F1
F0.00014334862385321102
I1
I0
I1
tp60273
sS'an,analog,of'
p60274
(F1
F0.00014334862385321102
I0
I1
I-1
tp60275
sS'microg,kg,day'
p60276
(F0
F0
I1
I1
I0
tp60277
sS'be,reliable,when'
p60278
(F1
F0.00014334862385321102
I1
I0
I1
tp60279
sS'of,with,targretin'
p60280
(F1
F0.00014334862385321102
I1
I0
I1
tp60281
sS'administration,of,at'
p60282
(F0
F0
I1
I1
I0
tp60283
sS'level,while,the'
p60284
(F0
F0
I1
I1
I0
tp60285
sS'affect,the,cyp2b6'
p60286
(F1
F0.00014334862385321102
I1
I0
I1
tp60287
sS'patients,with,major'
p60288
(F1
F0.00014334862385321102
I1
I0
I1
tp60289
sS'your,health,care'
p60290
(F1
F0.00014334862385321102
I1
I0
I1
tp60291
sS'or,increase,the'
p60292
(F1
F0.00014334862385321102
I1
I0
I1
tp60293
sS'cause,too,much'
p60294
(F1
F0.00014334862385321102
I0
I1
I-1
tp60295
sS'to,the,has'
p60296
(F0
F0
I1
I1
I0
tp60297
sS'therapy,was,recently'
p60298
(F1
F0.00057339449541284407
I4
I0
I4
tp60299
sS'were,coadministered,steady-state'
p60300
(F1
F0.00014334862385321102
I1
I0
I1
tp60301
sS'inhibited,by,added'
p60302
(F1
F0.00014334862385321102
I0
I1
I-1
tp60303
sS'medicines,since,the'
p60304
(F1
F0.00014334862385321102
I1
I0
I1
tp60305
sS'oral,hypoglycemic,agents'
p60306
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp60307
sS'normal,fat,digestion'
p60308
(F1
F0.00014334862385321102
I0
I1
I-1
tp60309
sS'muscle,pain,or'
p60310
(F1
F0.00014334862385321102
I0
I1
I-1
tp60311
sS'and,other,potentially'
p60312
(F1
F0.00014334862385321102
I1
I0
I1
tp60313
sS'resulted,in,a'
p60314
(F1
F0.0044438073394495415
I31
I0
I31
tp60315
sS'replacement,therapy,a'
p60316
(F1
F0.00014334862385321102
I0
I1
I-1
tp60317
sS'patients,over,a'
p60318
(F1
F0.00014334862385321102
I1
I0
I1
tp60319
sS'platelet,function,eg'
p60320
(F1
F0.00014334862385321102
I1
I0
I1
tp60321
sS'second,study,administration'
p60322
(F1
F0.00014334862385321102
I1
I0
I1
tp60323
sS'tmax,vs,for'
p60324
(F1
F0.00014334862385321102
I0
I1
I-1
tp60325
sS'management,of,malignant'
p60326
(F1
F0.00014334862385321102
I1
I0
I1
tp60327
sS'm,m,m'
p60328
(F1
F0.00014334862385321102
I1
I0
I1
tp60329
sS'm,m,i'
p60330
(F1
F0.00014334862385321102
I1
I0
I1
tp60331
sS'groups,and,were'
p60332
(F1
F0.00014334862385321102
I0
I1
I-1
tp60333
sS'of,the,day'
p60334
(F0
F0
I2
I2
I0
tp60335
sS'depletion,are,tricky'
p60336
(F1
F0.00014334862385321102
I0
I1
I-1
tp60337
sS'used,if,indocin'
p60338
(F1
F0.00014334862385321102
I1
I0
I1
tp60339
sS'injection,of,would'
p60340
(F1
F0.00014334862385321102
I0
I1
I-1
tp60341
sS'from,the,beginning'
p60342
(F1
F0.00014334862385321102
I0
I1
I-1
tp60343
sS'on,either,s'
p60344
(F1
F0.00014334862385321102
I0
I1
I-1
tp60345
sS'thyroid,administration,to'
p60346
(F1
F0.00014334862385321102
I1
I0
I1
tp60347
sS'gabitril,is,considered'
p60348
(F1
F0.00014334862385321102
I0
I1
I-1
tp60349
sS'two,type,strains'
p60350
(F1
F0.00014334862385321102
I0
I1
I-1
tp60351
sS'mouth,and,nose'
p60352
(F1
F0.00014334862385321102
I1
I0
I1
tp60353
sS'absence,of,adequate'
p60354
(F1
F0.00014334862385321102
I1
I0
I1
tp60355
sS'therapeutic,actions,and'
p60356
(F1
F0.00014334862385321102
I1
I0
I1
tp60357
sS'this,has,not'
p60358
(F1
F0.00028669724770642203
I2
I0
I2
tp60359
sS'the,neuromuscular,blocking'
p60360
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp60361
sS'further,no,effects'
p60362
(F1
F0.00014334862385321102
I0
I1
I-1
tp60363
sS'then,with,caution'
p60364
(F1
F0.00014334862385321102
I0
I1
I-1
tp60365
sS'on,potassium,kinetics'
p60366
(F1
F0.00014334862385321102
I1
I0
I1
tp60367
sS'phe-nothiazines,products,oral'
p60368
(F1
F0.00014334862385321102
I0
I1
I-1
tp60369
sS'occur,with,copper'
p60370
(F1
F0.00014334862385321102
I0
I1
I-1
tp60371
sS'between,h-spiroperidol,and'
p60372
(F1
F0.00028669724770642203
I0
I2
I-2
tp60373
sS'sex,hormone,binding'
p60374
(F1
F0.00014334862385321102
I0
I1
I-1
tp60375
sS'cardiac,contractility,when'
p60376
(F1
F0.00014334862385321102
I1
I0
I1
tp60377
sS'css,max,is'
p60378
(F1
F0.00014334862385321102
I1
I0
I1
tp60379
sS'ketoconazole,erythromycin,clarithromycin'
p60380
(F1
F0.00014334862385321102
I0
I1
I-1
tp60381
sS'the,physician,should'
p60382
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp60383
sS'relaxants,most,notably'
p60384
(F1
F0.00014334862385321102
I1
I0
I1
tp60385
sS'is,some,potential'
p60386
(F1
F0.00014334862385321102
I1
I0
I1
tp60387
sS'dihydropyridine,derivative,while'
p60388
(F1
F0.00014334862385321102
I0
I1
I-1
tp60389
sS'after,the,long-term'
p60390
(F1
F0.00014334862385321102
I0
I1
I-1
tp60391
sS'decreased,mean,cmax'
p60392
(F1
F0.00014334862385321102
I1
I0
I1
tp60393
sS'reductions,in,elimination'
p60394
(F1
F0.00014334862385321102
I1
I0
I1
tp60395
sS'interactions,and,central'
p60396
(F1
F0.00014334862385321102
I0
I1
I-1
tp60397
sS'with,or,without'
p60398
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp60399
sS'arimidex,as,they'
p60400
(F1
F0.00014334862385321102
I1
I0
I1
tp60401
sS'or,glycosides,concurrent'
p60402
(F1
F0.00014334862385321102
I0
I1
I-1
tp60403
sS'intestinal,absorption,resulting'
p60404
(F1
F0.00014334862385321102
I1
I0
I1
tp60405
sS'precautions,should,be'
p60406
(F1
F0.00014334862385321102
I1
I0
I1
tp60407
sS'by,confidence,limit'
p60408
(F1
F0.00014334862385321102
I0
I1
I-1
tp60409
sS'day,and,a'
p60410
(F1
F0.00014334862385321102
I1
I0
I1
tp60411
sS'than,that,of'
p60412
(F0
F0
I1
I1
I0
tp60413
sS'compounds,enhanced,tendency'
p60414
(F1
F0.00014334862385321102
I0
I1
I-1
tp60415
sS'dose-dependent,manner,when'
p60416
(F1
F0.00014334862385321102
I1
I0
I1
tp60417
sS'compazine,sparine,phenergan'
p60418
(F1
F0.00014334862385321102
I0
I1
I-1
tp60419
sS'hydroxy-iso,by,range'
p60420
(F1
F0.00014334862385321102
I1
I0
I1
tp60421
sS'clinical,use,and'
p60422
(F1
F0.00014334862385321102
I0
I1
I-1
tp60423
sS'reaching,a,maximal'
p60424
(F1
F0.00014334862385321102
I0
I1
I-1
tp60425
sS'multiple-dose,study,was'
p60426
(F1
F0.00014334862385321102
I0
I1
I-1
tp60427
sS'been,investigated,using'
p60428
(F1
F0.00014334862385321102
I1
I0
I1
tp60429
sS'alkaloids,and,would'
p60430
(F1
F0.00014334862385321102
I1
I0
I1
tp60431
sS'etopophos,with,that'
p60432
(F1
F0.00014334862385321102
I1
I0
I1
tp60433
sS'is,normal,but'
p60434
(F1
F0.00014334862385321102
I1
I0
I1
tp60435
sS'absorption,or,its'
p60436
(F1
F0.00014334862385321102
I0
I1
I-1
tp60437
sS'co-administration,of,or'
p60438
(F1
F0.00014334862385321102
I0
I1
I-1
tp60439
sS'clinical,study,in'
p60440
(F1
F0.00028669724770642203
I0
I2
I-2
tp60441
sS'aggravated,by,the'
p60442
(F1
F0.00014334862385321102
I1
I0
I1
tp60443
sS'proposed,that,resulted'
p60444
(F1
F0.00014334862385321102
I1
I0
I1
tp60445
sS'action,or,dosing'
p60446
(F1
F0.00014334862385321102
I0
I1
I-1
tp60447
sS'including,and,commonly'
p60448
(F1
F0.00014334862385321102
I0
I1
I-1
tp60449
sS'not,necessitate,reduction'
p60450
(F1
F0.00014334862385321102
I0
I1
I-1
tp60451
sS'eprosartan,up,to'
p60452
(F1
F0.00014334862385321102
I0
I1
I-1
tp60453
sS'diabetes,used,to'
p60454
(F1
F0.00014334862385321102
I1
I0
I1
tp60455
sS'acetaminophen,tylenol,with'
p60456
(F1
F0.00014334862385321102
I1
I0
I1
tp60457
sS'affect,the,in'
p60458
(F1
F0.00014334862385321102
I0
I1
I-1
tp60459
sS'when,hydrochloride,is'
p60460
(F1
F0.00014334862385321102
I1
I0
I1
tp60461
sS'plasma,asparagine,levels'
p60462
(F1
F0.00028669724770642203
I2
I0
I2
tp60463
sS'when,gl,was'
p60464
(F1
F0.00014334862385321102
I1
I0
I1
tp60465
sS'thyroidal,uptake,of'
p60466
(F1
F0.00014334862385321102
I1
I0
I1
tp60467
sS'is,a,major'
p60468
(F1
F0.00014334862385321102
I0
I1
I-1
tp60469
sS'a,mg,single'
p60470
(F1
F0.00028669724770642203
I2
I0
I2
tp60471
sS'on,pupil,size'
p60472
(F1
F0.00014334862385321102
I1
I0
I1
tp60473
sS'pulmonary,arterial,hypertension'
p60474
(F1
F0.00014334862385321102
I0
I1
I-1
tp60475
sS'of,the,danger'
p60476
(F1
F0.00028669724770642203
I2
I0
I2
tp60477
sS'types,of,indications'
p60478
(F1
F0.00014334862385321102
I0
I1
I-1
tp60479
sS'dose,or,the'
p60480
(F1
F0.00014334862385321102
I0
I1
I-1
tp60481
sS'others,that,interfere'
p60482
(F1
F0.00014334862385321102
I1
I0
I1
tp60483
sS'erythromycin,has,been'
p60484
(F1
F0.00043004587155963305
I3
I0
I3
tp60485
sS'chloral,hydrate,and'
p60486
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp60487
sS'were,on,established'
p60488
(F1
F0.00014334862385321102
I1
I0
I1
tp60489
sS'as,or,are'
p60490
(F1
F0.00014334862385321102
I1
I0
I1
tp60491
sS'fibrillation,when,combined'
p60492
(F1
F0.00014334862385321102
I1
I0
I1
tp60493
sS'injury,including,myocardial'
p60494
(F1
F0.00014334862385321102
I1
I0
I1
tp60495
sS'commonly,results,in'
p60496
(F1
F0.00014334862385321102
I1
I0
I1
tp60497
sS'primarily,iron-fortified,breakfast'
p60498
(F1
F0.00014334862385321102
I0
I1
I-1
tp60499
sS'would,warrant,alteration'
p60500
(F1
F0.00014334862385321102
I0
I1
I-1
tp60501
sS'quinolones,including,may'
p60502
(F1
F0.00028669724770642203
I2
I0
I2
tp60503
sS'concurrently,with,because'
p60504
(F1
F0.00014334862385321102
I1
I0
I1
tp60505
sS'in,one,survey'
p60506
(F1
F0.00014334862385321102
I1
I0
I1
tp60507
sS'aptt,assay,xigris'
p60508
(F1
F0.00014334862385321102
I0
I1
I-1
tp60509
sS'a,krm-1648,either'
p60510
(F1
F0.00014334862385321102
I0
I1
I-1
tp60511
sS'healthy,volunteers,receiving'
p60512
(F1
F0.00014334862385321102
I1
I0
I1
tp60513
sS'utilization,including,medications'
p60514
(F1
F0.00014334862385321102
I1
I0
I1
tp60515
sS'phenytoin,isoniazid,may'
p60516
(F1
F0.00014334862385321102
I1
I0
I1
tp60517
sS'and,mhd,however'
p60518
(F1
F0.00014334862385321102
I0
I1
I-1
tp60519
sS'and,buspirone,hcl'
p60520
(F1
F0.00014334862385321102
I1
I0
I1
tp60521
sS'cardiotoxicity,associated,with'
p60522
(F1
F0.00014334862385321102
I0
I1
I-1
tp60523
sS'elevated,cerebral,and'
p60524
(F1
F0.00014334862385321102
I1
I0
I1
tp60525
sS'mao,inhibitor,plus'
p60526
(F1
F0.00014334862385321102
I1
I0
I1
tp60527
sS'evaluated,and,concomitant'
p60528
(F1
F0.00014334862385321102
I1
I0
I1
tp60529
sS'drug-drug,pharmacokinetic,or'
p60530
(F1
F0.00014334862385321102
I0
I1
I-1
tp60531
sS'prophylaxis,may,have'
p60532
(F1
F0.00014334862385321102
I1
I0
I1
tp60533
sS'auc,to,was'
p60534
(F1
F0.00043004587155963305
I3
I0
I3
tp60535
sS'of,were,on'
p60536
(F1
F0.00014334862385321102
I0
I1
I-1
tp60537
sS'this,effect,is'
p60538
(F1
F0.00014334862385321102
I0
I1
I-1
tp60539
sS'antineoplastic,agents,nitrogen'
p60540
(F1
F0.00014334862385321102
I0
I1
I-1
tp60541
sS'occasionally,experience,a'
p60542
(F1
F0.00014334862385321102
I1
I0
I1
tp60543
sS'by,coadministration,of'
p60544
(F0
F0
I2
I2
I0
tp60545
sS'experience,bleeding,has'
p60546
(F1
F0.00014334862385321102
I1
I0
I1
tp60547
sS'of,succinylcholine-induced,neuromuscular'
p60548
(F1
F0.00014334862385321102
I0
I1
I-1
tp60549
sS'endoscopy,study,conducted'
p60550
(F1
F0.00014334862385321102
I0
I1
I-1
tp60551
sS'and,videx,didanosine'
p60552
(F1
F0.00014334862385321102
I1
I0
I1
tp60553
sS'mg,tid,study'
p60554
(F1
F0.00014334862385321102
I0
I1
I-1
tp60555
sS'be,carefully,monitored'
p60556
(F0.5
F0.00057339449541284407
I6
I2
I4
tp60557
sS'an,equivalent,amount'
p60558
(F1
F0.00014334862385321102
I0
I1
I-1
tp60559
sS'derivative,implications,for'
p60560
(F1
F0.00014334862385321102
I0
I1
I-1
tp60561
sS'auc,c,max'
p60562
(F1
F0.00028669724770642203
I0
I2
I-2
tp60563
sS'whether,the,concurrent'
p60564
(F1
F0.00014334862385321102
I1
I0
I1
tp60565
sS'oral,mg,dose'
p60566
(F1
F0.00014334862385321102
I0
I1
I-1
tp60567
sS'daily,doses,of'
p60568
(F0
F0
I2
I2
I0
tp60569
sS'plus,vioxx,mg'
p60570
(F1
F0.00014334862385321102
I0
I1
I-1
tp60571
sS'concurrent,usage,of'
p60572
(F1
F0.00014334862385321102
I0
I1
I-1
tp60573
sS'effects,of,for'
p60574
(F1
F0.00014334862385321102
I1
I0
I1
tp60575
sS'fluorouracil,is,increased'
p60576
(F1
F0.00014334862385321102
I1
I0
I1
tp60577
sS'taking,tysabri,and'
p60578
(F1
F0.00014334862385321102
I0
I1
I-1
tp60579
sS'p450iid6,cyp2d6,many'
p60580
(F1
F0.00014334862385321102
I0
I1
I-1
tp60581
sS'with,food,is'
p60582
(F1
F0.00014334862385321102
I1
I0
I1
tp60583
sS'other,there,appears'
p60584
(F1
F0.00014334862385321102
I0
I1
I-1
tp60585
sS'if,possible,anticholinesterase'
p60586
(F1
F0.00014334862385321102
I1
I0
I1
tp60587
sS'recipients,over,the'
p60588
(F1
F0.00014334862385321102
I0
I1
I-1
tp60589
sS'in,neither,case'
p60590
(F1
F0.00014334862385321102
I0
I1
I-1
tp60591
sS'be,given,with'
p60592
(F1
F0.00057339449541284407
I4
I0
I4
tp60593
sS'potassium-depleting,agents,amphotericin'
p60594
(F1
F0.00014334862385321102
I1
I0
I1
tp60595
sS'intravascular,volume,depletion'
p60596
(F1
F0.00014334862385321102
I1
I0
I1
tp60597
sS'of,beta-adrenoceptor,blocking'
p60598
(F1
F0.00028669724770642203
I2
I0
I2
tp60599
sS'between,or,its'
p60600
(F1
F0.00014334862385321102
I1
I0
I1
tp60601
sS'exposure,following,a'
p60602
(F1
F0.00014334862385321102
I1
I0
I1
tp60603
sS'mg,twice,daily'
p60604
(F0.33333333333333331
F0.0008600917431192661
I6
I12
I-6
tp60605
sS'performed,based,on'
p60606
(F1
F0.00014334862385321102
I1
I0
I1
tp60607
sS'mean,area,under'
p60608
(F1
F0.00014334862385321102
I1
I0
I1
tp60609
sS'affinities,than,for'
p60610
(F1
F0.00014334862385321102
I0
I1
I-1
tp60611
sS'relevant,interaction,of'
p60612
(F1
F0.00014334862385321102
I1
I0
I1
tp60613
sS'have,been,observed'
p60614
(F0
F0
I3
I3
I0
tp60615
sS'prozac,sporanox,nizoral'
p60616
(F1
F0.00014334862385321102
I0
I1
I-1
tp60617
sS'elapse,between,administration'
p60618
(F1
F0.00014334862385321102
I1
I0
I1
tp60619
sS'however,the,absolute'
p60620
(F1
F0.00014334862385321102
I0
I1
I-1
tp60621
sS'in,the,apparent'
p60622
(F1
F0.00014334862385321102
I1
I0
I1
tp60623
sS'fluvoxamine,tablets,not'
p60624
(F1
F0.00014334862385321102
I1
I0
I1
tp60625
sS'been,concern,about'
p60626
(F1
F0.00014334862385321102
I1
I0
I1
tp60627
sS'to,enhancing,absorption'
p60628
(F1
F0.00014334862385321102
I1
I0
I1
tp60629
sS'anticholinesterases,neostgmine,can'
p60630
(F1
F0.00014334862385321102
I0
I1
I-1
tp60631
sS'anesthetized,with,innovar'
p60632
(F1
F0.00014334862385321102
I1
I0
I1
tp60633
sS'in,the,judgment'
p60634
(F1
F0.00014334862385321102
I1
I0
I1
tp60635
sS'the,rate,and'
p60636
(F0
F0
I2
I2
I0
tp60637
sS'or,were,administered'
p60638
(F1
F0.00014334862385321102
I0
I1
I-1
tp60639
sS'binding,of,of'
p60640
(F1
F0.00014334862385321102
I0
I1
I-1
tp60641
sS'felbatol,causes,an'
p60642
(F1
F0.00028669724770642203
I2
I0
I2
tp60643
sS'literature,between,january'
p60644
(F1
F0.00014334862385321102
I0
I1
I-1
tp60645
sS'required,to,treat'
p60646
(F1
F0.00014334862385321102
I1
I0
I1
tp60647
sS'following,agents,clomipramine'
p60648
(F1
F0.00014334862385321102
I1
I0
I1
tp60649
sS'when,administering,concurrently'
p60650
(F1
F0.00014334862385321102
I1
I0
I1
tp60651
sS'eulexin,capsules,are'
p60652
(F1
F0.00014334862385321102
I1
I0
I1
tp60653
sS'vitamin,a,and'
p60654
(F1
F0.00014334862385321102
I1
I0
I1
tp60655
sS'd,analogues,vitamin'
p60656
(F1
F0.00043004587155963305
I3
I0
I3
tp60657
sS'hepatic,cyp,drug-metabolizing'
p60658
(F1
F0.00014334862385321102
I0
I1
I-1
tp60659
sS'urinary,alkalinizers,decrease'
p60660
(F1
F0.00014334862385321102
I0
I1
I-1
tp60661
sS'achieve,exposures,of'
p60662
(F1
F0.00028669724770642203
I2
I0
I2
tp60663
sS'diethyl,pyrocarbonate,at'
p60664
(F1
F0.00014334862385321102
I0
I1
I-1
tp60665
sS'six,of,these'
p60666
(F1
F0.00014334862385321102
I1
I0
I1
tp60667
sS'of,oral,upon'
p60668
(F1
F0.00014334862385321102
I1
I0
I1
tp60669
sS'of,pah,cannot'
p60670
(F1
F0.00014334862385321102
I1
I0
I1
tp60671
sS'groups,sh,da'
p60672
(F1
F0.00014334862385321102
I0
I1
I-1
tp60673
sS'be,monitored,when'
p60674
(F1
F0.0011467889908256881
I8
I0
I8
tp60675
sS'not,affect,any'
p60676
(F1
F0.00014334862385321102
I0
I1
I-1
tp60677
sS'may,have,enhanced'
p60678
(F1
F0.00014334862385321102
I1
I0
I1
tp60679
sS'cyp,a4,to'
p60680
(F1
F0.00014334862385321102
I0
I1
I-1
tp60681
sS'the,study,regardless'
p60682
(F1
F0.00014334862385321102
I0
I1
I-1
tp60683
sS'proliferation,in,the'
p60684
(F1
F0.00014334862385321102
I1
I0
I1
tp60685
sS'have,received,maoi'
p60686
(F1
F0.00014334862385321102
I1
I0
I1
tp60687
sS'antidepressant,single,dose'
p60688
(F1
F0.00014334862385321102
I1
I0
I1
tp60689
sS'transdermal,may,also'
p60690
(F1
F0.00014334862385321102
I1
I0
I1
tp60691
sS'may,potentiate,blood-pressure'
p60692
(F1
F0.00014334862385321102
I1
I0
I1
tp60693
sS'renal,function,are'
p60694
(F1
F0.00014334862385321102
I0
I1
I-1
tp60695
sS'vitro,aspirin-mediated,inhibition'
p60696
(F1
F0.00014334862385321102
I0
I1
I-1
tp60697
sS'increased,responsiveness,to'
p60698
(F1
F0.00028669724770642203
I0
I2
I-2
tp60699
sS'study,was,also'
p60700
(F1
F0.00014334862385321102
I0
I1
I-1
tp60701
sS'experience,with,nonsteroidal'
p60702
(F1
F0.00014334862385321102
I1
I0
I1
tp60703
sS'antimycobacterial,agents,contraindicated'
p60704
(F1
F0.00014334862385321102
I0
I1
I-1
tp60705
sS'days,of,coadministration'
p60706
(F1
F0.00014334862385321102
I0
I1
I-1
tp60707
sS'orally,administered,could'
p60708
(F1
F0.00014334862385321102
I0
I1
I-1
tp60709
sS'system,or,should'
p60710
(F1
F0.00014334862385321102
I1
I0
I1
tp60711
sS'and,this,should'
p60712
(F1
F0.00014334862385321102
I0
I1
I-1
tp60713
sS'increased,from,to'
p60714
(F0
F0
I1
I1
I0
tp60715
sS'as,these,agents'
p60716
(F1
F0.00028669724770642203
I2
I0
I2
tp60717
sS'corticosteroids,methylxanthines,and'
p60718
(F1
F0.00014334862385321102
I1
I0
I1
tp60719
sS'metabolizers,resemble,poor'
p60720
(F1
F0.00014334862385321102
I0
I1
I-1
tp60721
sS'it,was,combined'
p60722
(F1
F0.00014334862385321102
I0
I1
I-1
tp60723
sS'level,of,phosphatase'
p60724
(F1
F0.00014334862385321102
I0
I1
I-1
tp60725
sS'approximately,peak,blood'
p60726
(F1
F0.00014334862385321102
I1
I0
I1
tp60727
sS'of,these,and'
p60728
(F1
F0.00014334862385321102
I0
I1
I-1
tp60729
sS'aggregation,inhibitors,such'
p60730
(F1
F0.00014334862385321102
I1
I0
I1
tp60731
sS'atrovent,inhalation,aerosol'
p60732
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp60733
sS'from,spontaneous,reports'
p60734
(F1
F0.00014334862385321102
I0
I1
I-1
tp60735
sS'as,was,the'
p60736
(F1
F0.00014334862385321102
I1
I0
I1
tp60737
sS'sildenafil,dose,should'
p60738
(F1
F0.00014334862385321102
I1
I0
I1
tp60739
sS'bosentan,has,no'
p60740
(F1
F0.00014334862385321102
I0
I1
I-1
tp60741
sS'vitro,and,its'
p60742
(F1
F0.00014334862385321102
I0
I1
I-1
tp60743
sS'which,resulted,in'
p60744
(F1
F0.00014334862385321102
I1
I0
I1
tp60745
sS'the,following,other'
p60746
(F1
F0.00014334862385321102
I0
I1
I-1
tp60747
sS'may,increase,their'
p60748
(F1
F0.00014334862385321102
I0
I1
I-1
tp60749
sS'patients,receiving,catecholamine-depleting'
p60750
(F1
F0.00043004587155963305
I3
I0
I3
tp60751
sS'on,this,inhibitory'
p60752
(F1
F0.00014334862385321102
I0
I1
I-1
tp60753
sS'nimbex,is,approximately'
p60754
(F1
F0.00014334862385321102
I1
I0
I1
tp60755
sS'antibiotics,no,human'
p60756
(F1
F0.00014334862385321102
I0
I1
I-1
tp60757
sS'index,including,certain'
p60758
(F1
F0.00014334862385321102
I1
I0
I1
tp60759
sS'nitrates,the,blood'
p60760
(F1
F0.00014334862385321102
I1
I0
I1
tp60761
sS'doses,of,mcg'
p60762
(F1
F0.00014334862385321102
I0
I1
I-1
tp60763
sS'of,increases,the'
p60764
(F1
F0.00014334862385321102
I1
I0
I1
tp60765
sS'concomitantly,administered,iron-fortified'
p60766
(F1
F0.00014334862385321102
I0
I1
I-1
tp60767
sS'prevents,gastrointestinal,effects'
p60768
(F1
F0.00014334862385321102
I1
I0
I1
tp60769
sS'initiating,and,discontinuing'
p60770
(F1
F0.00014334862385321102
I1
I0
I1
tp60771
sS'rate-decreasing,effects,of'
p60772
(F1
F0.00014334862385321102
I1
I0
I1
tp60773
sS'not,report,any'
p60774
(F1
F0.00014334862385321102
I0
I1
I-1
tp60775
sS'from,approximately,to'
p60776
(F1
F0.00014334862385321102
I1
I0
I1
tp60777
sS'tubular,secretion,blocking'
p60778
(F1
F0.00014334862385321102
I0
I1
I-1
tp60779
sS'clinically,effective,duration'
p60780
(F1
F0.00014334862385321102
I1
I0
I1
tp60781
sS'and,on,bar-press'
p60782
(F1
F0.00014334862385321102
I0
I1
I-1
tp60783
sS'three,types,of'
p60784
(F1
F0.00014334862385321102
I0
I1
I-1
tp60785
sS'isolated,from,marine'
p60786
(F1
F0.00014334862385321102
I0
I1
I-1
tp60787
sS'sometimes,prescribed,to'
p60788
(F1
F0.00014334862385321102
I1
I0
I1
tp60789
sS'steady,state,levels'
p60790
(F1
F0.00014334862385321102
I0
I1
I-1
tp60791
sS'markedly,inhibit,cyp450s'
p60792
(F1
F0.00014334862385321102
I0
I1
I-1
tp60793
sS'the,simultaneous,use'
p60794
(F0
F0
I1
I1
I0
tp60795
sS'pure,powders,showed'
p60796
(F1
F0.00014334862385321102
I1
I0
I1
tp60797
sS'adults,at,high'
p60798
(F1
F0.00014334862385321102
I1
I0
I1
tp60799
sS'with,showed,no'
p60800
(F1
F0.00014334862385321102
I0
I1
I-1
tp60801
sS'curare-like,compounds,should'
p60802
(F1
F0.00028669724770642203
I2
I0
I2
tp60803
sS'ca,channel,blockers'
p60804
(F1
F0.00014334862385321102
I0
I1
I-1
tp60805
sS'be,gradual,in'
p60806
(F1
F0.00014334862385321102
I1
I0
I1
tp60807
sS'certain,such,as'
p60808
(F1
F0.00014334862385321102
I1
I0
I1
tp60809
sS'concurrent,therapy,with'
p60810
(F1
F0.00057339449541284407
I4
I0
I4
tp60811
sS'cancidas,has,no'
p60812
(F1
F0.00014334862385321102
I0
I1
I-1
tp60813
sS'but,not,under'
p60814
(F1
F0.00014334862385321102
I0
I1
I-1
tp60815
sS'additional,research,is'
p60816
(F1
F0.00014334862385321102
I0
I1
I-1
tp60817
sS'the,antagonist,were'
p60818
(F1
F0.00014334862385321102
I0
I1
I-1
tp60819
sS'rocaltrol,may,be'
p60820
(F1
F0.00043004587155963305
I0
I3
I-3
tp60821
sS'controlled,study,of'
p60822
(F1
F0.00014334862385321102
I0
I1
I-1
tp60823
sS'intravenous,placebo,oral'
p60824
(F1
F0.00014334862385321102
I0
I1
I-1
tp60825
sS'in,small,groups'
p60826
(F1
F0.00014334862385321102
I0
I1
I-1
tp60827
sS'formulations,of,which'
p60828
(F1
F0.00014334862385321102
I1
I0
I1
tp60829
sS'with,known,microsomal'
p60830
(F1
F0.00014334862385321102
I1
I0
I1
tp60831
sS'trials,have,used'
p60832
(F1
F0.00014334862385321102
I0
I1
I-1
tp60833
sS'of,the,same'
p60834
(F1
F0.00028669724770642203
I0
I2
I-2
tp60835
sS'hepatic,toxicity,in'
p60836
(F1
F0.00014334862385321102
I1
I0
I1
tp60837
sS'which,may,intensify'
p60838
(F1
F0.00014334862385321102
I0
I1
I-1
tp60839
sS'for,serious,and'
p60840
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp60841
sS'a,significant,elevation'
p60842
(F1
F0.00014334862385321102
I1
I0
I1
tp60843
sS'duloxetine,with,had'
p60844
(F1
F0.00014334862385321102
I0
I1
I-1
tp60845
sS'when,are,used'
p60846
(F1
F0.00014334862385321102
I0
I1
I-1
tp60847
sS'absorption,of,vitamin'
p60848
(F1
F0.00014334862385321102
I1
I0
I1
tp60849
sS'inhibitors,and,should'
p60850
(F1
F0.00014334862385321102
I0
I1
I-1
tp60851
sS'pharmacokinetic,study,healthy'
p60852
(F1
F0.00028669724770642203
I0
I2
I-2
tp60853
sS'found,in,vivo'
p60854
(F1
F0.00014334862385321102
I1
I0
I1
tp60855
sS'usually,results,in'
p60856
(F1
F0.00014334862385321102
I1
I0
I1
tp60857
sS'rr,is,a'
p60858
(F1
F0.00014334862385321102
I0
I1
I-1
tp60859
sS'we,show,that'
p60860
(F1
F0.00014334862385321102
I0
I1
I-1
tp60861
sS'in,an,increased'
p60862
(F1
F0.00057339449541284407
I4
I0
I4
tp60863
sS'stered,orally,prior'
p60864
(F1
F0.00014334862385321102
I1
I0
I1
tp60865
sS'by,patients,receiving'
p60866
(F1
F0.00014334862385321102
I0
I1
I-1
tp60867
sS'of,nalfon,and'
p60868
(F1
F0.00014334862385321102
I1
I0
I1
tp60869
sS'is,needed,the'
p60870
(F0
F0
I1
I1
I0
tp60871
sS'urinary,protein,when'
p60872
(F1
F0.00014334862385321102
I0
I1
I-1
tp60873
sS'not,morphine-induced,tail-flick'
p60874
(F1
F0.00014334862385321102
I0
I1
I-1
tp60875
sS'depression,cns,depressants'
p60876
(F1
F0.00014334862385321102
I0
I1
I-1
tp60877
sS'can,give,rise'
p60878
(F1
F0.00014334862385321102
I1
I0
I1
tp60879
sS'concurrently,with,agents'
p60880
(F1
F0.00014334862385321102
I0
I1
I-1
tp60881
sS'can,be,reduced'
p60882
(F1
F0.00014334862385321102
I1
I0
I1
tp60883
sS'of,the,enkephalinergic'
p60884
(F1
F0.00014334862385321102
I1
I0
I1
tp60885
sS'ketoconazole,combined,administration'
p60886
(F1
F0.00014334862385321102
I1
I0
I1
tp60887
sS'given,to,a'
p60888
(F1
F0.00014334862385321102
I1
I0
I1
tp60889
sS'approximately,was,necessary'
p60890
(F1
F0.00014334862385321102
I1
I0
I1
tp60891
sS'completely,cleared,from'
p60892
(F1
F0.00014334862385321102
I0
I1
I-1
tp60893
sS'example,complications,of'
p60894
(F1
F0.00014334862385321102
I0
I1
I-1
tp60895
sS'since,zarontin,may'
p60896
(F1
F0.00014334862385321102
I1
I0
I1
tp60897
sS'auc,and,cmin'
p60898
(F1
F0.00014334862385321102
I1
I0
I1
tp60899
sS'and,others,may'
p60900
(F1
F0.00028669724770642203
I0
I2
I-2
tp60901
sS'decreases,heart,rate'
p60902
(F1
F0.00014334862385321102
I0
I1
I-1
tp60903
sS'amphotericin,b-induced,hypokalemia'
p60904
(F1
F0.00028669724770642203
I2
I0
I2
tp60905
sS'second,hour,then'
p60906
(F1
F0.00014334862385321102
I0
I1
I-1
tp60907
sS'n,in,each'
p60908
(F1
F0.00028669724770642203
I0
I2
I-2
tp60909
sS'of,these,two'
p60910
(F1
F0.00014334862385321102
I1
I0
I1
tp60911
sS'sodium,binding,to'
p60912
(F1
F0.00014334862385321102
I1
I0
I1
tp60913
sS'blood,cells,whereas'
p60914
(F1
F0.00014334862385321102
I0
I1
I-1
tp60915
sS'influence,on,components'
p60916
(F1
F0.00014334862385321102
I1
I0
I1
tp60917
sS'safely,without,additional'
p60918
(F1
F0.00014334862385321102
I0
I1
I-1
tp60919
sS'have,been,safely'
p60920
(F1
F0.00028669724770642203
I0
I2
I-2
tp60921
sS'to,decrease,conduction'
p60922
(F1
F0.00014334862385321102
I1
I0
I1
tp60923
sS'and,oral,solution'
p60924
(F1
F0.00014334862385321102
I1
I0
I1
tp60925
sS'when,midamor,and'
p60926
(F1
F0.00014334862385321102
I1
I0
I1
tp60927
sS'careful,consideration,should'
p60928
(F1
F0.00014334862385321102
I1
I0
I1
tp60929
sS'implications,of,interactions'
p60930
(F1
F0.00014334862385321102
I1
I0
I1
tp60931
sS'in,clinical,pharmacokinetic'
p60932
(F1
F0.00014334862385321102
I0
I1
I-1
tp60933
sS'the,same,episode'
p60934
(F1
F0.00014334862385321102
I0
I1
I-1
tp60935
sS'inhibitors,macrolide,antibiotics'
p60936
(F1
F0.00014334862385321102
I0
I1
I-1
tp60937
sS'although,beta-adrenergic,blockers'
p60938
(F1
F0.00014334862385321102
I1
I0
I1
tp60939
sS'brevibloc,and,showed'
p60940
(F1
F0.00014334862385321102
I0
I1
I-1
tp60941
sS'taking,when,is'
p60942
(F1
F0.00014334862385321102
I1
I0
I1
tp60943
sS'retinyl,acetate,similarly'
p60944
(F1
F0.00014334862385321102
I1
I0
I1
tp60945
sS'lithium,increased,serum'
p60946
(F1
F0.00043004587155963305
I3
I0
I3
tp60947
sS'xr,should,be'
p60948
(F1
F0.00014334862385321102
I0
I1
I-1
tp60949
sS'reactions,to,products'
p60950
(F1
F0.00014334862385321102
I1
I0
I1
tp60951
sS'inhibit,metabolism,via'
p60952
(F1
F0.00014334862385321102
I0
I1
I-1
tp60953
sS'in,qtc,values'
p60954
(F1
F0.00014334862385321102
I1
I0
I1
tp60955
sS'or,substrates,of'
p60956
(F1
F0.00014334862385321102
I1
I0
I1
tp60957
sS'the,muscle,in'
p60958
(F1
F0.00014334862385321102
I1
I0
I1
tp60959
sS'of,mg,five'
p60960
(F1
F0.00014334862385321102
I0
I1
I-1
tp60961
sS'no,formal,clinical'
p60962
(F1
F0.00028669724770642203
I0
I2
I-2
tp60963
sS'has,shown,no'
p60964
(F1
F0.00014334862385321102
I0
I1
I-1
tp60965
sS'were,not,quantitatively'
p60966
(F1
F0.00014334862385321102
I0
I1
I-1
tp60967
sS'by,the,jaff'
p60968
(F1
F0.00014334862385321102
I0
I1
I-1
tp60969
sS'receiving,camptosar,and'
p60970
(F1
F0.00014334862385321102
I1
I0
I1
tp60971
sS'the,metabolism,and'
p60972
(F1
F0.00014334862385321102
I0
I1
I-1
tp60973
sS'iib,iiia,inhibitors'
p60974
(F1
F0.00014334862385321102
I1
I0
I1
tp60975
sS'because,xigris,may'
p60976
(F1
F0.00014334862385321102
I0
I1
I-1
tp60977
sS'oral,ccnu,either'
p60978
(F1
F0.00014334862385321102
I0
I1
I-1
tp60979
sS'the,area,under'
p60980
(F1
F0.0008600917431192661
I6
I0
I6
tp60981
sS'ibuprofen,and,high'
p60982
(F1
F0.00014334862385321102
I1
I0
I1
tp60983
sS'other,nsaid,and'
p60984
(F1
F0.00014334862385321102
I0
I1
I-1
tp60985
sS'mg,day,monotherapy'
p60986
(F1
F0.00014334862385321102
I0
I1
I-1
tp60987
sS'inhibit,neuronal,reuptake'
p60988
(F1
F0.00014334862385321102
I0
I1
I-1
tp60989
sS'cimetidine,cimetidine,inhibits'
p60990
(F1
F0.00014334862385321102
I1
I0
I1
tp60991
sS'psychostimulant,effects,of'
p60992
(F1
F0.00014334862385321102
I0
I1
I-1
tp60993
sS'occur,following,concomitant'
p60994
(F1
F0.00014334862385321102
I0
I1
I-1
tp60995
sS'may,induce,fungal'
p60996
(F1
F0.00014334862385321102
I1
I0
I1
tp60997
sS'hours,or,follow'
p60998
(F1
F0.00014334862385321102
I0
I1
I-1
tp60999
sS'central,nervous,system'
p61000
(F0.36842105263157893
F0.0010034403669724771
I13
I6
I7
tp61001
sS'of,subjects,n'
p61002
(F1
F0.00014334862385321102
I1
I0
I1
tp61003
sS'wort,may,significantly'
p61004
(F1
F0.00014334862385321102
I1
I0
I1
tp61005
sS'volunteers,co-administration,of'
p61006
(F1
F0.00014334862385321102
I0
I1
I-1
tp61007
sS'm,min,in'
p61008
(F1
F0.00014334862385321102
I1
I0
I1
tp61009
sS'history,of,neuropathy'
p61010
(F1
F0.00014334862385321102
I0
I1
I-1
tp61011
sS'medications,that,affect'
p61012
(F1
F0.00014334862385321102
I1
I0
I1
tp61013
sS's,influence,on'
p61014
(F1
F0.00014334862385321102
I1
I0
I1
tp61015
sS'relationship,physicians,should'
p61016
(F1
F0.00014334862385321102
I1
I0
I1
tp61017
sS'metabolism,causing,an'
p61018
(F1
F0.00014334862385321102
I1
I0
I1
tp61019
sS'as,are,used'
p61020
(F1
F0.00014334862385321102
I1
I0
I1
tp61021
sS'probenecid,is,a'
p61022
(F1
F0.00014334862385321102
I0
I1
I-1
tp61023
sS'blockers,or,h1-blocking'
p61024
(F1
F0.00014334862385321102
I1
I0
I1
tp61025
sS'c,diethyl,pyrocarbonate'
p61026
(F1
F0.00014334862385321102
I0
I1
I-1
tp61027
sS'is,not,needed'
p61028
(F1
F0.00014334862385321102
I1
I0
I1
tp61029
sS'csf,primarily,as'
p61030
(F1
F0.00014334862385321102
I0
I1
I-1
tp61031
sS'loss,compared,with'
p61032
(F1
F0.00014334862385321102
I1
I0
I1
tp61033
sS'in,t24,cells'
p61034
(F1
F0.00014334862385321102
I1
I0
I1
tp61035
sS'of,other,and'
p61036
(F1
F0.00014334862385321102
I0
I1
I-1
tp61037
sS'angiotensln,converting,enzyme'
p61038
(F1
F0.00014334862385321102
I1
I0
I1
tp61039
sS'relation,to,other'
p61040
(F1
F0.00014334862385321102
I0
I1
I-1
tp61041
sS'itraconazole,was,coadministered'
p61042
(F1
F0.00014334862385321102
I1
I0
I1
tp61043
sS'male,volunteers,in'
p61044
(F1
F0.00014334862385321102
I0
I1
I-1
tp61045
sS'which,is,manifested'
p61046
(F1
F0.00014334862385321102
I0
I1
I-1
tp61047
sS'on,the,use'
p61048
(F1
F0.00014334862385321102
I1
I0
I1
tp61049
sS'dose,of,micrograms'
p61050
(F1
F0.00014334862385321102
I1
I0
I1
tp61051
sS'kg,person,and'
p61052
(F1
F0.00014334862385321102
I0
I1
I-1
tp61053
sS'dosing,of,vardenafil'
p61054
(F1
F0.00028669724770642203
I2
I0
I2
tp61055
sS'chewable,dispersible,tablet'
p61056
(F1
F0.00014334862385321102
I1
I0
I1
tp61057
sS'to,investigate,the'
p61058
(F1
F0.00043004587155963305
I0
I3
I-3
tp61059
sS'dose,did,not'
p61060
(F1
F0.00014334862385321102
I0
I1
I-1
tp61061
sS'with,copegus,did'
p61062
(F1
F0.00014334862385321102
I0
I1
I-1
tp61063
sS'containing,containing,or'
p61064
(F1
F0.00014334862385321102
I1
I0
I1
tp61065
sS'flolan,in,clinical'
p61066
(F1
F0.00014334862385321102
I0
I1
I-1
tp61067
sS'of,acidity,in'
p61068
(F1
F0.00014334862385321102
I1
I0
I1
tp61069
sS'including,hyperthermia,rigidity'
p61070
(F1
F0.00014334862385321102
I1
I0
I1
tp61071
sS'lower,and,the'
p61072
(F1
F0.00014334862385321102
I1
I0
I1
tp61073
sS'medications,or,other'
p61074
(F1
F0.00028669724770642203
I2
I0
I2
tp61075
sS'than,additive,effects'
p61076
(F1
F0.00014334862385321102
I1
I0
I1
tp61077
sS'with,ototoxic,potential'
p61078
(F1
F0.00014334862385321102
I1
I0
I1
tp61079
sS'indirect-acting,agents,or'
p61080
(F1
F0.00014334862385321102
I1
I0
I1
tp61081
sS'cyp3a4,inhibitor,because'
p61082
(F1
F0.00014334862385321102
I0
I1
I-1
tp61083
sS'however,the,antagonism'
p61084
(F1
F0.00014334862385321102
I1
I0
I1
tp61085
sS'required,may,be'
p61086
(F1
F0.00014334862385321102
I1
I0
I1
tp61087
sS'of,the,treatment'
p61088
(F1
F0.00014334862385321102
I1
I0
I1
tp61089
sS'either,mg,once'
p61090
(F1
F0.00014334862385321102
I0
I1
I-1
tp61091
sS'conduction,when,using'
p61092
(F1
F0.00014334862385321102
I1
I0
I1
tp61093
sS'coadministration,of,had'
p61094
(F1
F0.00014334862385321102
I0
I1
I-1
tp61095
sS'cannot,be,used'
p61096
(F1
F0.00014334862385321102
I0
I1
I-1
tp61097
sS'strains,and,synergistic'
p61098
(F1
F0.00014334862385321102
I1
I0
I1
tp61099
sS'and,is,contraindicated'
p61100
(F1
F0.00014334862385321102
I1
I0
I1
tp61101
sS'especially,or,preanesthetic'
p61102
(F1
F0.00014334862385321102
I0
I1
I-1
tp61103
sS'relaxants,are,given'
p61104
(F1
F0.00014334862385321102
I0
I1
I-1
tp61105
sS'allergy,cold,and'
p61106
(F1
F0.00014334862385321102
I1
I0
I1
tp61107
sS'cyclosporine,combination,hormonal'
p61108
(F1
F0.00014334862385321102
I1
I0
I1
tp61109
sS'and,a,sprycel'
p61110
(F1
F0.00014334862385321102
I0
I1
I-1
tp61111
sS'tiagabine,causes,a'
p61112
(F1
F0.00014334862385321102
I1
I0
I1
tp61113
sS'is,unlikely,that'
p61114
(F1
F0.00028669724770642203
I0
I2
I-2
tp61115
sS'patients,with,hypertension'
p61116
(F1
F0.00014334862385321102
I1
I0
I1
tp61117
sS'fever,severe,obstipation'
p61118
(F1
F0.00014334862385321102
I1
I0
I1
tp61119
sS'then,wait,about'
p61120
(F1
F0.00014334862385321102
I1
I0
I1
tp61121
sS'difluoroacetone,a,known'
p61122
(F1
F0.00014334862385321102
I0
I1
I-1
tp61123
sS'evidence,was,obtained'
p61124
(F1
F0.00014334862385321102
I0
I1
I-1
tp61125
sS'is,not,totally'
p61126
(F1
F0.00014334862385321102
I1
I0
I1
tp61127
sS'and,its,synergism'
p61128
(F1
F0.00014334862385321102
I1
I0
I1
tp61129
sS'of,acute,angina'
p61130
(F1
F0.00014334862385321102
I0
I1
I-1
tp61131
sS'with,beta-blockers,concomitant'
p61132
(F1
F0.00014334862385321102
I1
I0
I1
tp61133
sS'episodes,may,occur'
p61134
(F1
F0.00014334862385321102
I1
I0
I1
tp61135
sS'first-line,option,in'
p61136
(F1
F0.00014334862385321102
I0
I1
I-1
tp61137
sS'sprycel,with,should'
p61138
(F1
F0.00014334862385321102
I1
I0
I1
tp61139
sS'has,shown,that'
p61140
(F0.5
F0.00028669724770642203
I3
I1
I2
tp61141
sS'known,enzyme,inducer'
p61142
(F1
F0.00014334862385321102
I1
I0
I1
tp61143
sS'and,non-steroidal,anti-inflammatory'
p61144
(F1
F0.00043004587155963305
I3
I0
I3
tp61145
sS'prothrombin,times,with'
p61146
(F1
F0.00014334862385321102
I1
I0
I1
tp61147
sS'neurologic,disorders,and'
p61148
(F1
F0.00014334862385321102
I0
I1
I-1
tp61149
sS'vasoconstriction,after,a'
p61150
(F1
F0.00014334862385321102
I1
I0
I1
tp61151
sS'of,b6,physiological'
p61152
(F1
F0.00014334862385321102
I0
I1
I-1
tp61153
sS'using,red,cells'
p61154
(F1
F0.00014334862385321102
I0
I1
I-1
tp61155
sS'blood,levels,may'
p61156
(F1
F0.00014334862385321102
I1
I0
I1
tp61157
sS'use,lowest,possible'
p61158
(F1
F0.00014334862385321102
I1
I0
I1
tp61159
sS'suitable,coagulation,test'
p61160
(F1
F0.00028669724770642203
I2
I0
I2
tp61161
sS'the,clinical,differences'
p61162
(F1
F0.00014334862385321102
I0
I1
I-1
tp61163
sS'agents,or,are'
p61164
(F1
F0.00014334862385321102
I1
I0
I1
tp61165
sS'an,week,trial'
p61166
(F1
F0.00014334862385321102
I0
I1
I-1
tp61167
sS'this,antagonistic,effect'
p61168
(F1
F0.00014334862385321102
I1
I0
I1
tp61169
sS'change,in,meclofenamate'
p61170
(F1
F0.00014334862385321102
I0
I1
I-1
tp61171
sS'inhibit,the,cyp450'
p61172
(F1
F0.00014334862385321102
I0
I1
I-1
tp61173
sS'prolongation,and,torsades'
p61174
(F1
F0.00014334862385321102
I0
I1
I-1
tp61175
sS'of,potential,to'
p61176
(F1
F0.00014334862385321102
I1
I0
I1
tp61177
sS'drugs,that,interfere'
p61178
(F1
F0.00014334862385321102
I0
I1
I-1
tp61179
sS'values,for,n'
p61180
(F1
F0.00014334862385321102
I1
I0
I1
tp61181
sS'were,noted,to'
p61182
(F1
F0.00014334862385321102
I1
I0
I1
tp61183
sS'doxylamine,may,enhance'
p61184
(F1
F0.00014334862385321102
I1
I0
I1
tp61185
sS'induce,a,positive'
p61186
(F1
F0.00014334862385321102
I0
I1
I-1
tp61187
sS'd6,cyp2d6,sensipar'
p61188
(F1
F0.00014334862385321102
I0
I1
I-1
tp61189
sS'bosentan,is,also'
p61190
(F1
F0.00028669724770642203
I2
I0
I2
tp61191
sS'have,previously,been'
p61192
(F1
F0.00014334862385321102
I0
I1
I-1
tp61193
sS'of,the,may'
p61194
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp61195
sS'cyp450,enzyme,group'
p61196
(F1
F0.00014334862385321102
I0
I1
I-1
tp61197
sS'therapeutic,margin,such'
p61198
(F1
F0.00014334862385321102
I0
I1
I-1
tp61199
sS'of,the,mao'
p61200
(F1
F0.00014334862385321102
I1
I0
I1
tp61201
sS'prior,to,difluoroacetone'
p61202
(F1
F0.00014334862385321102
I0
I1
I-1
tp61203
sS't4,and,t3'
p61204
(F1
F0.00014334862385321102
I1
I0
I1
tp61205
sS'because,both,are'
p61206
(F1
F0.00014334862385321102
I1
I0
I1
tp61207
sS'than,reduction,in'
p61208
(F1
F0.00014334862385321102
I1
I0
I1
tp61209
sS'qt,prolongation,cardiac'
p61210
(F1
F0.00014334862385321102
I1
I0
I1
tp61211
sS'parenteral,may,cause'
p61212
(F1
F0.00014334862385321102
I1
I0
I1
tp61213
sS'p450,cyp450,enzyme'
p61214
(F1
F0.00014334862385321102
I0
I1
I-1
tp61215
sS'a,strong,cyp3a4'
p61216
(F1
F0.00028669724770642203
I2
I0
I2
tp61217
sS'from,healthy,subjects'
p61218
(F1
F0.00014334862385321102
I0
I1
I-1
tp61219
sS'variability,and,individual'
p61220
(F1
F0.00014334862385321102
I1
I0
I1
tp61221
sS'resulting,in,a'
p61222
(F0.63636363636363635
F0.0010034403669724771
I9
I2
I7
tp61223
sS'studied,of,the'
p61224
(F1
F0.00014334862385321102
I0
I1
I-1
tp61225
sS'bodyweight,gain,and'
p61226
(F1
F0.00014334862385321102
I0
I1
I-1
tp61227
sS'when,initiating,or'
p61228
(F1
F0.00014334862385321102
I1
I0
I1
tp61229
sS'tmp,smx,such'
p61230
(F1
F0.00014334862385321102
I0
I1
I-1
tp61231
sS'active,monohydroxy,metabolite'
p61232
(F1
F0.00014334862385321102
I0
I1
I-1
tp61233
sS'and,an,are'
p61234
(F1
F0.00014334862385321102
I1
I0
I1
tp61235
sS'kadian,ms,contin'
p61236
(F1
F0.00014334862385321102
I1
I0
I1
tp61237
sS'in,a,subset'
p61238
(F1
F0.00014334862385321102
I0
I1
I-1
tp61239
sS'thereby,delaying,elimination'
p61240
(F1
F0.00028669724770642203
I2
I0
I2
tp61241
sS'cation-containing,products,such'
p61242
(F1
F0.00014334862385321102
I1
I0
I1
tp61243
sS'of,brovana,treated'
p61244
(F1
F0.00014334862385321102
I0
I1
I-1
tp61245
sS'administration,of,non-potassium'
p61246
(F1
F0.00014334862385321102
I1
I0
I1
tp61247
sS'sustiva,and,nrtis'
p61248
(F1
F0.00014334862385321102
I0
I1
I-1
tp61249
sS'compounds,should,only'
p61250
(F1
F0.00028669724770642203
I2
I0
I2
tp61251
sS'therapy,a,baseline'
p61252
(F1
F0.00014334862385321102
I1
I0
I1
tp61253
sS'for,the,concomitant'
p61254
(F1
F0.00014334862385321102
I1
I0
I1
tp61255
sS'no,data,are'
p61256
(F1
F0.00014334862385321102
I0
I1
I-1
tp61257
sS'well,controlled,on'
p61258
(F1
F0.00014334862385321102
I1
I0
I1
tp61259
sS'without,coadministration,of'
p61260
(F1
F0.00014334862385321102
I0
I1
I-1
tp61261
sS'exjade,and,aluminum-containing'
p61262
(F1
F0.00014334862385321102
I0
I1
I-1
tp61263
sS'those,in,whom'
p61264
(F1
F0.00057339449541284407
I4
I0
I4
tp61265
sS'may,decrease,hepatic'
p61266
(F1
F0.00014334862385321102
I1
I0
I1
tp61267
sS'decreased,clearance,of'
p61268
(F1
F0.00014334862385321102
I1
I0
I1
tp61269
sS'demonstrated,no,evidence'
p61270
(F1
F0.00028669724770642203
I0
I2
I-2
tp61271
sS'due,to,inhibition'
p61272
(F1
F0.00028669724770642203
I2
I0
I2
tp61273
sS'or,no,capacity'
p61274
(F1
F0.00014334862385321102
I0
I1
I-1
tp61275
sS'the,body,by'
p61276
(F1
F0.00014334862385321102
I0
I1
I-1
tp61277
sS'exposure,to,but'
p61278
(F1
F0.00014334862385321102
I1
I0
I1
tp61279
sS'of,by,the'
p61280
(F1
F0.00014334862385321102
I1
I0
I1
tp61281
sS'administration,of,including'
p61282
(F1
F0.00014334862385321102
I1
I0
I1
tp61283
sS'demonstrate,any,alterations'
p61284
(F1
F0.00014334862385321102
I0
I1
I-1
tp61285
sS'concentrations,increased,by'
p61286
(F1
F0.00014334862385321102
I1
I0
I1
tp61287
sS'taking,mao,inhibitors'
p61288
(F1
F0.00014334862385321102
I1
I0
I1
tp61289
sS'chlorthalidone,and,related'
p61290
(F1
F0.00028669724770642203
I2
I0
I2
tp61291
sS'of,and,coadministration'
p61292
(F1
F0.00028669724770642203
I2
I0
I2
tp61293
sS'of,adverse,events'
p61294
(F1
F0.00028669724770642203
I0
I2
I-2
tp61295
sS'b,and,may'
p61296
(F1
F0.00014334862385321102
I1
I0
I1
tp61297
sS'are,expected,with'
p61298
(F1
F0.00014334862385321102
I1
I0
I1
tp61299
sS'by,this,procedure'
p61300
(F1
F0.00014334862385321102
I0
I1
I-1
tp61301
sS'cmax,cmin,auc'
p61302
(F1
F0.00014334862385321102
I0
I1
I-1
tp61303
sS'subjects,ages,to'
p61304
(F1
F0.00014334862385321102
I1
I0
I1
tp61305
sS'a,strong,selective'
p61306
(F1
F0.00014334862385321102
I1
I0
I1
tp61307
sS'medicine,you,take'
p61308
(F1
F0.00014334862385321102
I1
I0
I1
tp61309
sS'no,clinical,studies'
p61310
(F1
F0.00014334862385321102
I1
I0
I1
tp61311
sS'experienced,tremor,as'
p61312
(F1
F0.00014334862385321102
I1
I0
I1
tp61313
sS'symptoms,but,not'
p61314
(F1
F0.00014334862385321102
I0
I1
I-1
tp61315
sS'following,acetazolamide,azole'
p61316
(F1
F0.00014334862385321102
I1
I0
I1
tp61317
sS'with,the,nerve'
p61318
(F1
F0.00014334862385321102
I0
I1
I-1
tp61319
sS'following,mptp,administration'
p61320
(F1
F0.00014334862385321102
I0
I1
I-1
tp61321
sS'when,at,an'
p61322
(F1
F0.00014334862385321102
I1
I0
I1
tp61323
sS'dynamic,and,release'
p61324
(F1
F0.00014334862385321102
I0
I1
I-1
tp61325
sS'abolish,the,effect'
p61326
(F1
F0.00014334862385321102
I1
I0
I1
tp61327
sS'the,survanta,and'
p61328
(F1
F0.00014334862385321102
I0
I1
I-1
tp61329
sS'advised,when,beginning'
p61330
(F1
F0.00014334862385321102
I1
I0
I1
tp61331
sS'eliminated,or,are'
p61332
(F1
F0.00014334862385321102
I0
I1
I-1
tp61333
sS'and,other,psychotropic'
p61334
(F1
F0.00014334862385321102
I1
I0
I1
tp61335
sS'cyp3a,inducers,such'
p61336
(F1
F0.00014334862385321102
I1
I0
I1
tp61337
sS'have,been,extensively'
p61338
(F1
F0.00014334862385321102
I0
I1
I-1
tp61339
sS'antibiotics,rifampin,is'
p61340
(F1
F0.00014334862385321102
I0
I1
I-1
tp61341
sS'not,exceed,micrograms'
p61342
(F1
F0.00014334862385321102
I0
I1
I-1
tp61343
sS'and,diamond,patient'
p61344
(F1
F0.00014334862385321102
I1
I0
I1
tp61345
sS'strong,inhibitors,of'
p61346
(F0
F0
I1
I1
I0
tp61347
sS'treatments,with,an'
p61348
(F1
F0.00014334862385321102
I0
I1
I-1
tp61349
sS'the,measurable,limit'
p61350
(F1
F0.00014334862385321102
I1
I0
I1
tp61351
sS'strategies,during,conversion'
p61352
(F1
F0.00014334862385321102
I0
I1
I-1
tp61353
sS'nevertheless,clinical,studies'
p61354
(F1
F0.00014334862385321102
I1
I0
I1
tp61355
sS'concomitantly,serum,levels'
p61356
(F1
F0.00014334862385321102
I1
I0
I1
tp61357
sS'when,this,is'
p61358
(F1
F0.00014334862385321102
I0
I1
I-1
tp61359
sS'tablets,administered,once'
p61360
(F1
F0.00014334862385321102
I0
I1
I-1
tp61361
sS'recommended,to,avoid'
p61362
(F1
F0.00014334862385321102
I1
I0
I1
tp61363
sS'transcriptase,inhibitors,nnrtis'
p61364
(F1
F0.00014334862385321102
I1
I0
I1
tp61365
sS'direct,treatment,costs'
p61366
(F1
F0.00014334862385321102
I0
I1
I-1
tp61367
sS'the,antiprothrombinemic,effect'
p61368
(F1
F0.00014334862385321102
I0
I1
I-1
tp61369
sS'whereas,the,effects'
p61370
(F1
F0.00014334862385321102
I0
I1
I-1
tp61371
sS'desired,and,or'
p61372
(F1
F0.00014334862385321102
I1
I0
I1
tp61373
sS'not,nanm,antagonized'
p61374
(F1
F0.00014334862385321102
I1
I0
I1
tp61375
sS'against,positive,and'
p61376
(F1
F0.00014334862385321102
I0
I1
I-1
tp61377
sS'of,interfere,with'
p61378
(F1
F0.00014334862385321102
I1
I0
I1
tp61379
sS'may,be,a'
p61380
(F1
F0.00028669724770642203
I0
I2
I-2
tp61381
sS'antiparkinsonian,drug,eg'
p61382
(F1
F0.00014334862385321102
I1
I0
I1
tp61383
sS'daily,dose,of'
p61384
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp61385
sS'c,eg,and'
p61386
(F1
F0.00014334862385321102
I1
I0
I1
tp61387
sS'and,irrational,behavior'
p61388
(F1
F0.00014334862385321102
I1
I0
I1
tp61389
sS'about,mm,hg'
p61390
(F1
F0.00014334862385321102
I1
I0
I1
tp61391
sS'cmc-cys,exhibiting,m'
p61392
(F1
F0.00014334862385321102
I0
I1
I-1
tp61393
sS'cmax,auc,and'
p61394
(F1
F0.00014334862385321102
I1
I0
I1
tp61395
sS'no,influence,in'
p61396
(F1
F0.00014334862385321102
I0
I1
I-1
tp61397
sS'than,times,higher'
p61398
(F1
F0.00014334862385321102
I1
I0
I1
tp61399
sS'and,frova,within'
p61400
(F1
F0.00014334862385321102
I1
I0
I1
tp61401
sS'pharmacokinetic,interactions,between'
p61402
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp61403
sS'oral,and,inhaled'
p61404
(F1
F0.00014334862385321102
I0
I1
I-1
tp61405
sS'of,sodium,kg'
p61406
(F1
F0.00014334862385321102
I1
I0
I1
tp61407
sS'pharmacokinetics,of,other'
p61408
(F1
F0.00014334862385321102
I0
I1
I-1
tp61409
sS'between,xanthine,and'
p61410
(F1
F0.00014334862385321102
I1
I0
I1
tp61411
sS'use,of,psychotropic'
p61412
(F1
F0.00014334862385321102
I1
I0
I1
tp61413
sS'consider,doubling,the'
p61414
(F1
F0.00014334862385321102
I0
I1
I-1
tp61415
sS'vitro,interaction,of'
p61416
(F1
F0.00014334862385321102
I1
I0
I1
tp61417
sS'when,taken,at'
p61418
(F1
F0.00014334862385321102
I1
I0
I1
tp61419
sS'levels,and,possible'
p61420
(F1
F0.00014334862385321102
I0
I1
I-1
tp61421
sS'a,single,agent'
p61422
(F1
F0.00014334862385321102
I0
I1
I-1
tp61423
sS'with,the,specific'
p61424
(F1
F0.00014334862385321102
I1
I0
I1
tp61425
sS'ether,and,sodium'
p61426
(F1
F0.00014334862385321102
I1
I0
I1
tp61427
sS'with,ovcon-35,resulted'
p61428
(F1
F0.00014334862385321102
I1
I0
I1
tp61429
sS'of,it,is'
p61430
(F0.5
F0.00028669724770642203
I3
I1
I2
tp61431
sS'p-glycoprotein,mediated,transport'
p61432
(F1
F0.00014334862385321102
I0
I1
I-1
tp61433
sS'imidazole,compounds,like'
p61434
(F1
F0.00014334862385321102
I1
I0
I1
tp61435
sS'neuromuscular,blockade,produced'
p61436
(F1
F0.00014334862385321102
I1
I0
I1
tp61437
sS'causal,relationship,between'
p61438
(F1
F0.00014334862385321102
I0
I1
I-1
tp61439
sS'decrease,the,effect'
p61440
(F1
F0.00028669724770642203
I2
I0
I2
tp61441
sS'the,hypertensive,response'
p61442
(F1
F0.00014334862385321102
I1
I0
I1
tp61443
sS'vitro,and,decrease'
p61444
(F1
F0.00014334862385321102
I0
I1
I-1
tp61445
sS'distinctive,effects,in'
p61446
(F1
F0.00014334862385321102
I0
I1
I-1
tp61447
sS'to,avoid,concurrent'
p61448
(F1
F0.00014334862385321102
I1
I0
I1
tp61449
sS'by,intraventricular,and'
p61450
(F1
F0.00028669724770642203
I0
I2
I-2
tp61451
sS'package,insert,labeling'
p61452
(F1
F0.00014334862385321102
I0
I1
I-1
tp61453
sS'test,for,hours'
p61454
(F1
F0.00014334862385321102
I1
I0
I1
tp61455
sS'that,given,with'
p61456
(F1
F0.00014334862385321102
I1
I0
I1
tp61457
sS'enzymes,or,the'
p61458
(F1
F0.00014334862385321102
I0
I1
I-1
tp61459
sS'not,meaningfully,alter'
p61460
(F1
F0.00014334862385321102
I0
I1
I-1
tp61461
sS'or,led,to'
p61462
(F1
F0.00014334862385321102
I1
I0
I1
tp61463
sS'time,caused,by'
p61464
(F1
F0.00014334862385321102
I0
I1
I-1
tp61465
sS'alter,the,renal'
p61466
(F0
F0
I1
I1
I0
tp61467
sS'use,of,ace'
p61468
(F1
F0.00014334862385321102
I0
I1
I-1
tp61469
sS'as,inr,was'
p61470
(F1
F0.00014334862385321102
I1
I0
I1
tp61471
sS'coadministration,of,grapefruit'
p61472
(F1
F0.00014334862385321102
I0
I1
I-1
tp61473
sS'bound,such,as'
p61474
(F1
F0.00014334862385321102
I0
I1
I-1
tp61475
sS'other,oral,with'
p61476
(F1
F0.00014334862385321102
I1
I0
I1
tp61477
sS'mg,of,elemental'
p61478
(F1
F0.00014334862385321102
I1
I0
I1
tp61479
sS'tikosyn,does,not'
p61480
(F1
F0.00028669724770642203
I0
I2
I-2
tp61481
sS'are,incompatible,with'
p61482
(F1
F0.00014334862385321102
I0
I1
I-1
tp61483
sS'r,or,s-'
p61484
(F1
F0.00014334862385321102
I0
I1
I-1
tp61485
sS'two,were,administered'
p61486
(F1
F0.00014334862385321102
I1
I0
I1
tp61487
sS'administered,minutes,after'
p61488
(F1
F0.00014334862385321102
I1
I0
I1
tp61489
sS'of,side,effects'
p61490
(F0.25
F0.00028669724770642203
I5
I3
I2
tp61491
sS'mechanism,under,lying'
p61492
(F1
F0.00014334862385321102
I1
I0
I1
tp61493
sS'cerubidine,in,a'
p61494
(F1
F0.00014334862385321102
I1
I0
I1
tp61495
sS'is,limited,therefore'
p61496
(F1
F0.00014334862385321102
I1
I0
I1
tp61497
sS'ganciclovir,administration,of'
p61498
(F1
F0.00014334862385321102
I1
I0
I1
tp61499
sS'of,and,acetylsalicylic'
p61500
(F1
F0.00014334862385321102
I1
I0
I1
tp61501
sS'reported,with,therapeutic'
p61502
(F1
F0.00014334862385321102
I1
I0
I1
tp61503
sS'from,women,who'
p61504
(F1
F0.00014334862385321102
I0
I1
I-1
tp61505
sS'with,other,central'
p61506
(F1
F0.00028669724770642203
I2
I0
I2
tp61507
sS'pharmacokinetics,of,r-warfarin'
p61508
(F1
F0.00014334862385321102
I0
I1
I-1
tp61509
sS'ht1,agonists,have'
p61510
(F1
F0.00014334862385321102
I1
I0
I1
tp61511
sS'may,prolong,the'
p61512
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp61513
sS'an,additive,or'
p61514
(F1
F0.00043004587155963305
I3
I0
I3
tp61515
sS'to,be,unlikely'
p61516
(F1
F0.00014334862385321102
I0
I1
I-1
tp61517
sS'may,decrease,thyroidal'
p61518
(F1
F0.00014334862385321102
I1
I0
I1
tp61519
sS'as,increasing,overall'
p61520
(F1
F0.00014334862385321102
I0
I1
I-1
tp61521
sS'volunteers,the,concomitant'
p61522
(F0
F0
I1
I1
I0
tp61523
sS'tended,to,experience'
p61524
(F1
F0.00014334862385321102
I0
I1
I-1
tp61525
sS'time,or,clotting'
p61526
(F1
F0.00014334862385321102
I0
I1
I-1
tp61527
sS'creatinine,and,because'
p61528
(F1
F0.00014334862385321102
I1
I0
I1
tp61529
sS'significant,difference,was'
p61530
(F1
F0.00014334862385321102
I0
I1
I-1
tp61531
sS'c,a,increase'
p61532
(F1
F0.00014334862385321102
I1
I0
I1
tp61533
sS'vasoactive,resulting,in'
p61534
(F1
F0.00014334862385321102
I1
I0
I1
tp61535
sS'lower,relative,absorption'
p61536
(F1
F0.00014334862385321102
I0
I1
I-1
tp61537
sS'by,the,lack'
p61538
(F1
F0.00014334862385321102
I0
I1
I-1
tp61539
sS'suppression,of,the'
p61540
(F1
F0.00014334862385321102
I1
I0
I1
tp61541
sS'is,no,information'
p61542
(F1
F0.00014334862385321102
I0
I1
I-1
tp61543
sS'therapy,or,daily'
p61544
(F1
F0.00014334862385321102
I0
I1
I-1
tp61545
sS'role,of,cyp2d6'
p61546
(F1
F0.00014334862385321102
I0
I1
I-1
tp61547
sS'and,cardiac,dysrhythmias'
p61548
(F1
F0.00014334862385321102
I1
I0
I1
tp61549
sS'little,published,information'
p61550
(F1
F0.00014334862385321102
I0
I1
I-1
tp61551
sS'nph,human,immediately'
p61552
(F1
F0.00014334862385321102
I0
I1
I-1
tp61553
sS'n,and,volunteers'
p61554
(F1
F0.00014334862385321102
I1
I0
I1
tp61555
sS'discontinuing,or,changing'
p61556
(F1
F0.00014334862385321102
I1
I0
I1
tp61557
sS'nicotinic,acid,calcium'
p61558
(F1
F0.00014334862385321102
I0
I1
I-1
tp61559
sS'have,been,exploited'
p61560
(F1
F0.00014334862385321102
I0
I1
I-1
tp61561
sS'pyrocarbonate,at,ph'
p61562
(F1
F0.00014334862385321102
I0
I1
I-1
tp61563
sS'single,pancreatic,acinar'
p61564
(F1
F0.00014334862385321102
I0
I1
I-1
tp61565
sS'sedatives,hypnotics,contraindicated'
p61566
(F1
F0.00014334862385321102
I0
I1
I-1
tp61567
sS'interact,with,that'
p61568
(F1
F0.00014334862385321102
I0
I1
I-1
tp61569
sS'marked,and,persistent'
p61570
(F1
F0.00014334862385321102
I1
I0
I1
tp61571
sS'and,against,cryptosporidium'
p61572
(F1
F0.00014334862385321102
I0
I1
I-1
tp61573
sS'on,cyp,a4'
p61574
(F1
F0.00014334862385321102
I0
I1
I-1
tp61575
sS'antitumour,activity,of'
p61576
(F1
F0.00014334862385321102
I1
I0
I1
tp61577
sS'whenever,an,agent'
p61578
(F1
F0.00014334862385321102
I0
I1
I-1
tp61579
sS'concentrations,and,pharmacologic'
p61580
(F1
F0.00014334862385321102
I0
I1
I-1
tp61581
sS'of,nonsmoking,healthy'
p61582
(F1
F0.00014334862385321102
I0
I1
I-1
tp61583
sS'in,excretion,of'
p61584
(F1
F0.00014334862385321102
I1
I0
I1
tp61585
sS'affect,gastrointestinal,absorption'
p61586
(F1
F0.00014334862385321102
I1
I0
I1
tp61587
sS'wait,about,minutes'
p61588
(F1
F0.00014334862385321102
I1
I0
I1
tp61589
sS'and,creatinine,an'
p61590
(F1
F0.00014334862385321102
I1
I0
I1
tp61591
sS'of,certain,intravenously'
p61592
(F1
F0.00014334862385321102
I1
I0
I1
tp61593
sS'multicenter,randomized,double-blind'
p61594
(F1
F0.00014334862385321102
I0
I1
I-1
tp61595
sS'sensitivity,of,rat'
p61596
(F1
F0.00014334862385321102
I0
I1
I-1
tp61597
sS'channel,blocker,on'
p61598
(F1
F0.00014334862385321102
I0
I1
I-1
tp61599
sS'increase,in,serum'
p61600
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp61601
sS'balance,were,only'
p61602
(F1
F0.00014334862385321102
I0
I1
I-1
tp61603
sS'relaxants,and,may'
p61604
(F1
F0.00028669724770642203
I2
I0
I2
tp61605
sS'significantly,reduced,and'
p61606
(F1
F0.00014334862385321102
I1
I0
I1
tp61607
sS'a,release,of'
p61608
(F1
F0.00014334862385321102
I0
I1
I-1
tp61609
sS'the,following,specific'
p61610
(F1
F0.00014334862385321102
I0
I1
I-1
tp61611
sS'levels,the,adverse'
p61612
(F1
F0.00014334862385321102
I0
I1
I-1
tp61613
sS'sedative,effects,and'
p61614
(F1
F0.00014334862385321102
I1
I0
I1
tp61615
sS'of,therapy,allow'
p61616
(F1
F0.00014334862385321102
I0
I1
I-1
tp61617
sS'taking,should,be'
p61618
(F1
F0.00014334862385321102
I1
I0
I1
tp61619
sS'relaxants,and,mac'
p61620
(F1
F0.00014334862385321102
I1
I0
I1
tp61621
sS'coadministration,of,relative'
p61622
(F1
F0.00014334862385321102
I1
I0
I1
tp61623
sS'laboratory,tests,the'
p61624
(F1
F0.00014334862385321102
I1
I0
I1
tp61625
sS'the,possibility,nitric'
p61626
(F1
F0.00014334862385321102
I1
I0
I1
tp61627
sS'naloxone-sensitive,endorphinergic,system'
p61628
(F1
F0.00014334862385321102
I0
I1
I-1
tp61629
sS'hepatic,metabolism,of'
p61630
(F1
F0.0008600917431192661
I6
I0
I6
tp61631
sS'derivatives,antimycobacterial,agents'
p61632
(F1
F0.00014334862385321102
I1
I0
I1
tp61633
sS'potential,danger,of'
p61634
(F1
F0.00014334862385321102
I1
I0
I1
tp61635
sS'containing,or,or'
p61636
(F1
F0.00028669724770642203
I2
I0
I2
tp61637
sS'is,still,advisable'
p61638
(F1
F0.00014334862385321102
I1
I0
I1
tp61639
sS'significant,teratogenic,and'
p61640
(F1
F0.00014334862385321102
I0
I1
I-1
tp61641
sS'three,different,concentrations'
p61642
(F1
F0.00014334862385321102
I0
I1
I-1
tp61643
sS'and,fenofibric,acid'
p61644
(F1
F0.00014334862385321102
I0
I1
I-1
tp61645
sS'may,also,potentiate'
p61646
(F1
F0.00014334862385321102
I1
I0
I1
tp61647
sS'that,the,pharmacokinetics'
p61648
(F1
F0.00043004587155963305
I0
I3
I-3
tp61649
sS'and,of,the'
p61650
(F1
F0.00014334862385321102
I1
I0
I1
tp61651
sS'pointer,dogs,have'
p61652
(F1
F0.00014334862385321102
I0
I1
I-1
tp61653
sS'absorption,as,well'
p61654
(F1
F0.00014334862385321102
I0
I1
I-1
tp61655
sS'hepatotoxicity,are,suggested'
p61656
(F1
F0.00014334862385321102
I1
I0
I1
tp61657
sS'severity,of,chloride-induced'
p61658
(F1
F0.00014334862385321102
I1
I0
I1
tp61659
sS'as,decreasing,its'
p61660
(F1
F0.00014334862385321102
I1
I0
I1
tp61661
sS'effect,of,norfloxacin'
p61662
(F1
F0.00014334862385321102
I1
I0
I1
tp61663
sS'receiving,the,plasma'
p61664
(F1
F0.00014334862385321102
I1
I0
I1
tp61665
sS'are,potentiated,by'
p61666
(F1
F0.00014334862385321102
I1
I0
I1
tp61667
sS'or,due,to'
p61668
(F1
F0.00028669724770642203
I0
I2
I-2
tp61669
sS'increased,sedation,if'
p61670
(F1
F0.00014334862385321102
I1
I0
I1
tp61671
sS'dose,of,with'
p61672
(F1
F0.00028669724770642203
I2
I0
I2
tp61673
sS'an,eg,valproic'
p61674
(F1
F0.00014334862385321102
I1
I0
I1
tp61675
sS'as,slowly,dissolving'
p61676
(F1
F0.00014334862385321102
I1
I0
I1
tp61677
sS'actions,of,the'
p61678
(F1
F0.00014334862385321102
I1
I0
I1
tp61679
sS'through,inhibition,of'
p61680
(F1
F0.00014334862385321102
I1
I0
I1
tp61681
sS'max,and,auc'
p61682
(F1
F0.00014334862385321102
I0
I1
I-1
tp61683
sS'of,action,it'
p61684
(F1
F0.00014334862385321102
I1
I0
I1
tp61685
sS'tubular,secretion,and'
p61686
(F1
F0.00014334862385321102
I1
I0
I1
tp61687
sS'extent,enhanced,the'
p61688
(F1
F0.00014334862385321102
I0
I1
I-1
tp61689
sS'or,stopped,to'
p61690
(F1
F0.00014334862385321102
I1
I0
I1
tp61691
sS'total,clearance,of'
p61692
(F1
F0.00014334862385321102
I1
I0
I1
tp61693
sS'as,anorexia,tachypnea'
p61694
(F1
F0.00014334862385321102
I1
I0
I1
tp61695
sS'led,to,an'
p61696
(F1
F0.00014334862385321102
I1
I0
I1
tp61697
sS'a,and,under'
p61698
(F1
F0.00014334862385321102
I1
I0
I1
tp61699
sS'by,pretreatment,with'
p61700
(F1
F0.00028669724770642203
I2
I0
I2
tp61701
sS'since,may,reduce'
p61702
(F1
F0.00028669724770642203
I2
I0
I2
tp61703
sS'after,administration,but'
p61704
(F1
F0.00014334862385321102
I0
I1
I-1
tp61705
sS'and,some,pronestyl'
p61706
(F1
F0.00014334862385321102
I1
I0
I1
tp61707
sS'is,recommended,during'
p61708
(F1
F0.00057339449541284407
I4
I0
I4
tp61709
sS'auc,after,administration'
p61710
(F1
F0.00014334862385321102
I1
I0
I1
tp61711
sS'a,member,have'
p61712
(F1
F0.00014334862385321102
I1
I0
I1
tp61713
sS'sulfate,tests,benedicts'
p61714
(F1
F0.00014334862385321102
I0
I1
I-1
tp61715
sS'which,can,follow'
p61716
(F1
F0.00014334862385321102
I1
I0
I1
tp61717
sS'both,ethynyl,and'
p61718
(F1
F0.00014334862385321102
I0
I1
I-1
tp61719
sS'clearance,of,zebeta'
p61720
(F1
F0.00014334862385321102
I1
I0
I1
tp61721
sS'cyp3a4,patients,who'
p61722
(F1
F0.00014334862385321102
I0
I1
I-1
tp61723
sS'acetaminophen,and,valproic'
p61724
(F1
F0.00014334862385321102
I0
I1
I-1
tp61725
sS'subjects,there,were'
p61726
(F1
F0.00014334862385321102
I0
I1
I-1
tp61727
sS'of,zebeta,may'
p61728
(F1
F0.00014334862385321102
I1
I0
I1
tp61729
sS'effected,by,endothelial'
p61730
(F1
F0.00014334862385321102
I0
I1
I-1
tp61731
sS'interactions,with,systemic'
p61732
(F1
F0.00014334862385321102
I0
I1
I-1
tp61733
sS'initial,or,prolonged'
p61734
(F1
F0.00014334862385321102
I0
I1
I-1
tp61735
sS'discontinuation,of,in'
p61736
(F1
F0.00014334862385321102
I1
I0
I1
tp61737
sS'inflammatory,disorders,has'
p61738
(F1
F0.00014334862385321102
I1
I0
I1
tp61739
sS'the,chance,of'
p61740
(F0
F0
I5
I5
I0
tp61741
sS'occur,when,the'
p61742
(F1
F0.00014334862385321102
I1
I0
I1
tp61743
sS'additional,reductions,in'
p61744
(F1
F0.00014334862385321102
I1
I0
I1
tp61745
sS'in,patients,taking'
p61746
(F0.51515151515151514
F0.0024369266055045873
I25
I8
I17
tp61747
sS'contrast,in,isolated'
p61748
(F1
F0.00014334862385321102
I0
I1
I-1
tp61749
sS'methotrexate-related,toxicity,when'
p61750
(F1
F0.00014334862385321102
I1
I0
I1
tp61751
sS'subsequent,to,initiation'
p61752
(F1
F0.00014334862385321102
I0
I1
I-1
tp61753
sS'both,sensory,and'
p61754
(F1
F0.00014334862385321102
I1
I0
I1
tp61755
sS'of,although,overall'
p61756
(F1
F0.00014334862385321102
I1
I0
I1
tp61757
sS'to,insure,that'
p61758
(F1
F0.00014334862385321102
I1
I0
I1
tp61759
sS'pharmacodynamic,interactions,with'
p61760
(F1
F0.00014334862385321102
I1
I0
I1
tp61761
sS'inhibitors,maoi,maoi'
p61762
(F1
F0.00014334862385321102
I1
I0
I1
tp61763
sS'clearance,or,toxicologic'
p61764
(F1
F0.00014334862385321102
I0
I1
I-1
tp61765
sS'p450-based,metabolic,interactions'
p61766
(F1
F0.00014334862385321102
I0
I1
I-1
tp61767
sS'receiving,hydrochloride,is'
p61768
(F1
F0.00014334862385321102
I1
I0
I1
tp61769
sS'case,that,you'
p61770
(F1
F0.00014334862385321102
I1
I0
I1
tp61771
sS'concomitantly,with,has'
p61772
(F1
F0.00043004587155963305
I3
I0
I3
tp61773
sS'by,consulting,the'
p61774
(F1
F0.00014334862385321102
I0
I1
I-1
tp61775
sS'have,been,occasional'
p61776
(F1
F0.00014334862385321102
I1
I0
I1
tp61777
sS'and,agents,and'
p61778
(F1
F0.00014334862385321102
I0
I1
I-1
tp61779
sS'of,escherichia,coli'
p61780
(F1
F0.00028669724770642203
I0
I2
I-2
tp61781
sS'to,treatpatients,co-infected'
p61782
(F1
F0.00014334862385321102
I0
I1
I-1
tp61783
sS'impactor,for,characterization'
p61784
(F1
F0.00014334862385321102
I0
I1
I-1
tp61785
sS'hormone,and,levels'
p61786
(F1
F0.00014334862385321102
I0
I1
I-1
tp61787
sS'possible,increased,responsiveness'
p61788
(F1
F0.00028669724770642203
I0
I2
I-2
tp61789
sS'of,felbatol,to'
p61790
(F1
F0.00014334862385321102
I1
I0
I1
tp61791
sS'inr,days,after'
p61792
(F1
F0.00014334862385321102
I1
I0
I1
tp61793
sS'oral,agents,receiving'
p61794
(F1
F0.00014334862385321102
I1
I0
I1
tp61795
sS'of,metabotropic,glutamate'
p61796
(F1
F0.00014334862385321102
I0
I1
I-1
tp61797
sS'and,kytril,have'
p61798
(F1
F0.00014334862385321102
I0
I1
I-1
tp61799
sS'however,since,nsaids'
p61800
(F1
F0.00014334862385321102
I1
I0
I1
tp61801
sS'metabolized,by,cyp'
p61802
(F1
F0.00057339449541284407
I0
I4
I-4
tp61803
sS'and,or,inhibitors'
p61804
(F0
F0
I1
I1
I0
tp61805
sS'antidepressant,or,the'
p61806
(F1
F0.00014334862385321102
I0
I1
I-1
tp61807
sS'prothrombin,response,by'
p61808
(F1
F0.00014334862385321102
I1
I0
I1
tp61809
sS'or,altering,their'
p61810
(F1
F0.00014334862385321102
I0
I1
I-1
tp61811
sS'regimens,and,superiority'
p61812
(F1
F0.00014334862385321102
I0
I1
I-1
tp61813
sS'tam,which,also'
p61814
(F1
F0.00014334862385321102
I0
I1
I-1
tp61815
sS'that,mixing,novolog'
p61816
(F1
F0.00014334862385321102
I0
I1
I-1
tp61817
sS'incompatibility,of,these'
p61818
(F1
F0.00014334862385321102
I0
I1
I-1
tp61819
sS'of,patients,in'
p61820
(F1
F0.00043004587155963305
I0
I3
I-3
tp61821
sS'isoenzyme,including,many'
p61822
(F1
F0.00014334862385321102
I0
I1
I-1
tp61823
sS'of,the,use'
p61824
(F1
F0.00028669724770642203
I0
I2
I-2
tp61825
sS'scores,on,the'
p61826
(F1
F0.00014334862385321102
I1
I0
I1
tp61827
sS'uptake,may,occur'
p61828
(F1
F0.00014334862385321102
I1
I0
I1
tp61829
sS'range,of,doses'
p61830
(F1
F0.00014334862385321102
I0
I1
I-1
tp61831
sS'the,patients,treated'
p61832
(F1
F0.00014334862385321102
I0
I1
I-1
tp61833
sS'effects,of,may'
p61834
(F0.75
F0.0008600917431192661
I7
I1
I6
tp61835
sS'function,seen,with'
p61836
(F1
F0.00014334862385321102
I0
I1
I-1
tp61837
sS'to,hours,or'
p61838
(F1
F0.00014334862385321102
I1
I0
I1
tp61839
sS'occur,in,patients'
p61840
(F1
F0.00028669724770642203
I2
I0
I2
tp61841
sS'in,previously,stable'
p61842
(F1
F0.00014334862385321102
I1
I0
I1
tp61843
sS'by,cyp2c9,and'
p61844
(F1
F0.00014334862385321102
I0
I1
I-1
tp61845
sS'is,impaired,in'
p61846
(F1
F0.00014334862385321102
I1
I0
I1
tp61847
sS'r-warfarin,and,s-warfarin'
p61848
(F1
F0.00014334862385321102
I1
I0
I1
tp61849
sS'individuals,were,treated'
p61850
(F1
F0.00014334862385321102
I0
I1
I-1
tp61851
sS'in,addition,that'
p61852
(F1
F0.00014334862385321102
I1
I0
I1
tp61853
sS'of,patients,is'
p61854
(F1
F0.00014334862385321102
I0
I1
I-1
tp61855
sS'in,study,patients'
p61856
(F1
F0.00014334862385321102
I0
I1
I-1
tp61857
sS'this,interaction,probably'
p61858
(F1
F0.00014334862385321102
I1
I0
I1
tp61859
sS'subjects,who,were'
p61860
(F1
F0.00028669724770642203
I0
I2
I-2
tp61861
sS'be,prolonged,by'
p61862
(F1
F0.00028669724770642203
I2
I0
I2
tp61863
sS'produced,by,high'
p61864
(F1
F0.00014334862385321102
I1
I0
I1
tp61865
sS'of,and,resulted'
p61866
(F0.75
F0.0008600917431192661
I7
I1
I6
tp61867
sS'bone,and,joint'
p61868
(F1
F0.00014334862385321102
I1
I0
I1
tp61869
sS'may,be,taken'
p61870
(F0
F0
I1
I1
I0
tp61871
sS'changing,from,intravenous'
p61872
(F1
F0.00014334862385321102
I0
I1
I-1
tp61873
sS'warfarin,when,healthy'
p61874
(F1
F0.00014334862385321102
I0
I1
I-1
tp61875
sS'a,single,subject'
p61876
(F1
F0.00014334862385321102
I1
I0
I1
tp61877
sS'other,potent,cyp3a4'
p61878
(F1
F0.00014334862385321102
I1
I0
I1
tp61879
sS'avoided,also,see'
p61880
(F1
F0.00014334862385321102
I1
I0
I1
tp61881
sS'decreased,auc,by'
p61882
(F1
F0.00014334862385321102
I1
I0
I1
tp61883
sS'with,and,concurrently'
p61884
(F1
F0.00014334862385321102
I1
I0
I1
tp61885
sS'conducted,in,oa'
p61886
(F1
F0.00014334862385321102
I0
I1
I-1
tp61887
sS'exceed,a,single'
p61888
(F1
F0.00043004587155963305
I3
I0
I3
tp61889
sS'and,other,inhibitors'
p61890
(F1
F0.00014334862385321102
I1
I0
I1
tp61891
sS'administration,of,particularly'
p61892
(F1
F0.00014334862385321102
I1
I0
I1
tp61893
sS'that,a,potent'
p61894
(F1
F0.00014334862385321102
I1
I0
I1
tp61895
sS'adults,were,conducted'
p61896
(F1
F0.00014334862385321102
I0
I1
I-1
tp61897
sS'dosage,adjustment,of'
p61898
(F0.5
F0.00057339449541284407
I6
I2
I4
tp61899
sS'used,concomitantly,indicate'
p61900
(F1
F0.00014334862385321102
I1
I0
I1
tp61901
sS'vitro,studies,demonstrated'
p61902
(F1
F0.00028669724770642203
I0
I2
I-2
tp61903
sS'with,modest,increases'
p61904
(F1
F0.00014334862385321102
I1
I0
I1
tp61905
sS'co-administered,with,multiple'
p61906
(F1
F0.00014334862385321102
I1
I0
I1
tp61907
sS'lying,the,interference'
p61908
(F1
F0.00014334862385321102
I1
I0
I1
tp61909
sS'tc,had,no'
p61910
(F1
F0.00014334862385321102
I0
I1
I-1
tp61911
sS'with,may,have'
p61912
(F1
F0.00014334862385321102
I0
I1
I-1
tp61913
sS'kinetics,and,renal'
p61914
(F1
F0.00028669724770642203
I2
I0
I2
tp61915
sS'slight,decreases,in'
p61916
(F1
F0.00014334862385321102
I1
I0
I1
tp61917
sS'effect,of,in'
p61918
(F0
F0
I1
I1
I0
tp61919
sS'zebeta,resulting,in'
p61920
(F1
F0.00014334862385321102
I1
I0
I1
tp61921
sS'maois,selegiline,hydrochloride'
p61922
(F1
F0.00014334862385321102
I1
I0
I1
tp61923
sS'prostate,epithelium,by'
p61924
(F1
F0.00014334862385321102
I1
I0
I1
tp61925
sS'increase,when,patients'
p61926
(F1
F0.00014334862385321102
I1
I0
I1
tp61927
sS'taking,celebrex,did'
p61928
(F1
F0.00014334862385321102
I0
I1
I-1
tp61929
sS'interfere,with,platelet-aggregation'
p61930
(F1
F0.00014334862385321102
I1
I0
I1
tp61931
sS'labetalol,hcl,has'
p61932
(F1
F0.00014334862385321102
I0
I1
I-1
tp61933
sS'because,is,coadministered'
p61934
(F1
F0.00014334862385321102
I0
I1
I-1
tp61935
sS'test,for,urinary'
p61936
(F1
F0.00014334862385321102
I0
I1
I-1
tp61937
sS'the,normal,variability'
p61938
(F1
F0.00014334862385321102
I1
I0
I1
tp61939
sS'reactions,related,to'
p61940
(F1
F0.00014334862385321102
I0
I1
I-1
tp61941
sS'necessary,when,nimbex'
p61942
(F1
F0.00014334862385321102
I0
I1
I-1
tp61943
sS'co-administration,concomitant,use'
p61944
(F1
F0.00014334862385321102
I1
I0
I1
tp61945
sS'mg,experienced,a'
p61946
(F1
F0.00014334862385321102
I1
I0
I1
tp61947
sS'ocs,macrolide,antibiotics'
p61948
(F1
F0.00014334862385321102
I0
I1
I-1
tp61949
sS'only,in,the'
p61950
(F1
F0.00028669724770642203
I2
I0
I2
tp61951
sS'is,no,experience'
p61952
(F1
F0.00014334862385321102
I0
I1
I-1
tp61953
sS'auc,higher,in'
p61954
(F1
F0.00014334862385321102
I1
I0
I1
tp61955
sS'used,in,any'
p61956
(F1
F0.00014334862385321102
I1
I0
I1
tp61957
sS'of,the,disulfiram-ethanol'
p61958
(F1
F0.00028669724770642203
I0
I2
I-2
tp61959
sS'and,inn,when'
p61960
(F1
F0.00014334862385321102
I0
I1
I-1
tp61961
sS'fixed,g,m2'
p61962
(F1
F0.00014334862385321102
I0
I1
I-1
tp61963
sS'topical,glaucoma,or'
p61964
(F1
F0.00014334862385321102
I1
I0
I1
tp61965
sS'products,and,may'
p61966
(F1
F0.00014334862385321102
I1
I0
I1
tp61967
sS'action,of,of'
p61968
(F1
F0.00014334862385321102
I1
I0
I1
tp61969
sS'primary,cns,effect'
p61970
(F1
F0.00014334862385321102
I1
I0
I1
tp61971
sS'aluminum-,or,magnesium-containing'
p61972
(F1
F0.00014334862385321102
I1
I0
I1
tp61973
sS'can,enhance,toxicity'
p61974
(F1
F0.00014334862385321102
I0
I1
I-1
tp61975
sS'about,fold,prolongation'
p61976
(F1
F0.00014334862385321102
I0
I1
I-1
tp61977
sS'virus-positive,patients,by'
p61978
(F1
F0.00014334862385321102
I0
I1
I-1
tp61979
sS'hctz,mg,qd'
p61980
(F1
F0.00014334862385321102
I0
I1
I-1
tp61981
sS'intravenous,injection,of'
p61982
(F1
F0.00028669724770642203
I2
I0
I2
tp61983
sS'clearance,of,fell'
p61984
(F1
F0.00014334862385321102
I1
I0
I1
tp61985
sS'effects,of,these'
p61986
(F0
F0
I2
I2
I0
tp61987
sS'hormonal,and,the'
p61988
(F1
F0.00014334862385321102
I0
I1
I-1
tp61989
sS'insufficient,intake,which'
p61990
(F1
F0.00014334862385321102
I0
I1
I-1
tp61991
sS'in,mean,area'
p61992
(F1
F0.00014334862385321102
I1
I0
I1
tp61993
sS'other,b-lactam,renal'
p61994
(F1
F0.00014334862385321102
I1
I0
I1
tp61995
sS'elapse,between,discontinuation'
p61996
(F1
F0.00028669724770642203
I2
I0
I2
tp61997
sS'or,ml,twice'
p61998
(F1
F0.00014334862385321102
I1
I0
I1
tp61999
sS'day,of,were'
p62000
(F1
F0.00014334862385321102
I1
I0
I1
tp62001
sS'been,identified,that'
p62002
(F1
F0.00014334862385321102
I0
I1
I-1
tp62003
sS'when,and,other'
p62004
(F1
F0.00014334862385321102
I1
I0
I1
tp62005
sS'supersensitivity,to,the'
p62006
(F1
F0.00014334862385321102
I1
I0
I1
tp62007
sS'other,antineoplastic,agents'
p62008
(F1
F0.00014334862385321102
I1
I0
I1
tp62009
sS'several-,fold,increases'
p62010
(F1
F0.00014334862385321102
I0
I1
I-1
tp62011
sS'administration,of,doubled'
p62012
(F1
F0.00014334862385321102
I1
I0
I1
tp62013
sS'between,doses,may'
p62014
(F1
F0.00014334862385321102
I1
I0
I1
tp62015
sS'with,the,antidepressant'
p62016
(F0
F0
I1
I1
I0
tp62017
sS'by,increased,exposure'
p62018
(F1
F0.00014334862385321102
I1
I0
I1
tp62019
sS'day,racemic,for'
p62020
(F1
F0.00014334862385321102
I0
I1
I-1
tp62021
sS'the,occurrence,has'
p62022
(F1
F0.00014334862385321102
I1
I0
I1
tp62023
sS'with,alfenta,can'
p62024
(F1
F0.00014334862385321102
I1
I0
I1
tp62025
sS'repeated,exposure,in'
p62026
(F1
F0.00014334862385321102
I0
I1
I-1
tp62027
sS'mice,on,the'
p62028
(F1
F0.00014334862385321102
I0
I1
I-1
tp62029
sS'co-administration,of,resulted'
p62030
(F1
F0.00014334862385321102
I1
I0
I1
tp62031
sS'serum,concentrations,increase'
p62032
(F1
F0.00014334862385321102
I1
I0
I1
tp62033
sS'was,shown,on'
p62034
(F1
F0.00014334862385321102
I0
I1
I-1
tp62035
sS'clinically,significant,changes'
p62036
(F1
F0.00043004587155963305
I0
I3
I-3
tp62037
sS'therapeutic,efficacy,of'
p62038
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp62039
sS'glycosides,may,be'
p62040
(F1
F0.00014334862385321102
I0
I1
I-1
tp62041
sS'no,apparent,pharmacokinetic'
p62042
(F1
F0.00057339449541284407
I0
I4
I-4
tp62043
sS'exercised,when,indocin'
p62044
(F1
F0.00014334862385321102
I1
I0
I1
tp62045
sS'statins,co-administration,of'
p62046
(F1
F0.00014334862385321102
I1
I0
I1
tp62047
sS'another,botulinum,prior'
p62048
(F1
F0.00014334862385321102
I1
I0
I1
tp62049
sS'examples,include,the'
p62050
(F1
F0.00014334862385321102
I0
I1
I-1
tp62051
sS'shown,that,antagonized'
p62052
(F1
F0.00014334862385321102
I1
I0
I1
tp62053
sS'on,the,extent'
p62054
(F1
F0.00057339449541284407
I0
I4
I-4
tp62055
sS'history,of,injection'
p62056
(F1
F0.00014334862385321102
I0
I1
I-1
tp62057
sS'substrate,and,its'
p62058
(F1
F0.00014334862385321102
I1
I0
I1
tp62059
sS'occurred,when,lotensin'
p62060
(F1
F0.00014334862385321102
I0
I1
I-1
tp62061
sS'methods,such,as'
p62062
(F1
F0.00014334862385321102
I0
I1
I-1
tp62063
sS'indicates,that,clorazepate'
p62064
(F1
F0.00014334862385321102
I1
I0
I1
tp62065
sS'coadministered,with,viracept'
p62066
(F1
F0.00014334862385321102
I1
I0
I1
tp62067
sS'diabetics,with,microalbuminuria'
p62068
(F1
F0.00014334862385321102
I1
I0
I1
tp62069
sS'the,presence,or'
p62070
(F1
F0.00014334862385321102
I0
I1
I-1
tp62071
sS'unless,the,potential'
p62072
(F1
F0.00014334862385321102
I1
I0
I1
tp62073
sS'a,separate,study'
p62074
(F1
F0.00014334862385321102
I0
I1
I-1
tp62075
sS'acetate,l-histidine,was'
p62076
(F1
F0.00014334862385321102
I1
I0
I1
tp62077
sS'the,presence,of'
p62078
(F0.066666666666666666
F0.00028669724770642203
I14
I16
I-2
tp62079
sS'a4,enzyme,activity'
p62080
(F1
F0.00014334862385321102
I1
I0
I1
tp62081
sS'and,uroxatral,should'
p62082
(F1
F0.00014334862385321102
I1
I0
I1
tp62083
sS'following,oral,and'
p62084
(F1
F0.00014334862385321102
I0
I1
I-1
tp62085
sS'considered,when,rebif'
p62086
(F1
F0.00014334862385321102
I0
I1
I-1
tp62087
sS'renal,elimination,of'
p62088
(F1
F0.00028669724770642203
I0
I2
I-2
tp62089
sS'urine,may,occur'
p62090
(F1
F0.00043004587155963305
I0
I3
I-3
tp62091
sS'factors,when,administered'
p62092
(F1
F0.00014334862385321102
I0
I1
I-1
tp62093
sS'available,hmgcoa,reductase'
p62094
(F1
F0.00014334862385321102
I0
I1
I-1
tp62095
sS'coumarin-type,the,physician'
p62096
(F1
F0.00014334862385321102
I1
I0
I1
tp62097
sS'studies,with,normal'
p62098
(F1
F0.00014334862385321102
I0
I1
I-1
tp62099
sS'or,stimulus,response'
p62100
(F1
F0.00014334862385321102
I0
I1
I-1
tp62101
sS'a,defined,medium'
p62102
(F1
F0.00014334862385321102
I0
I1
I-1
tp62103
sS'of,adrenergic,agonists'
p62104
(F1
F0.00014334862385321102
I1
I0
I1
tp62105
sS'm,i,mg'
p62106
(F1
F0.00014334862385321102
I1
I0
I1
tp62107
sS'as,with,some'
p62108
(F1
F0.00028669724770642203
I2
I0
I2
tp62109
sS'a,tnf,antagonist'
p62110
(F1
F0.00014334862385321102
I1
I0
I1
tp62111
sS'in,a,min'
p62112
(F1
F0.00014334862385321102
I1
I0
I1
tp62113
sS'increases,the,auc'
p62114
(F1
F0.00014334862385321102
I1
I0
I1
tp62115
sS'administered,safely,with'
p62116
(F1
F0.00014334862385321102
I0
I1
I-1
tp62117
sS'cause,renal,impairment'
p62118
(F1
F0.00014334862385321102
I1
I0
I1
tp62119
sS'on,the,activity'
p62120
(F1
F0.00014334862385321102
I0
I1
I-1
tp62121
sS'distribution,of,decreased'
p62122
(F1
F0.00014334862385321102
I1
I0
I1
tp62123
sS'cimetidine,and,may'
p62124
(F1
F0.00014334862385321102
I1
I0
I1
tp62125
sS'flavoridin,alone,was'
p62126
(F1
F0.00014334862385321102
I1
I0
I1
tp62127
sS'enzyme,induction,potential'
p62128
(F1
F0.00014334862385321102
I0
I1
I-1
tp62129
sS'as,noted,below'
p62130
(F1
F0.00014334862385321102
I0
I1
I-1
tp62131
sS'exposure,or,renal'
p62132
(F1
F0.00014334862385321102
I0
I1
I-1
tp62133
sS'of,conduction,disturbance'
p62134
(F1
F0.00014334862385321102
I1
I0
I1
tp62135
sS'these,imidazole,and'
p62136
(F1
F0.00014334862385321102
I0
I1
I-1
tp62137
sS'increase,with,the'
p62138
(F1
F0.00014334862385321102
I0
I1
I-1
tp62139
sS'medicines,during,the'
p62140
(F1
F0.00014334862385321102
I1
I0
I1
tp62141
sS'theophylline-induced,anxiogenic,effects'
p62142
(F1
F0.00014334862385321102
I1
I0
I1
tp62143
sS'patients,receiving,the'
p62144
(F0
F0
I1
I1
I0
tp62145
sS'other,and,antiparkinsonian'
p62146
(F1
F0.00014334862385321102
I1
I0
I1
tp62147
sS'plasma,and,epoxide'
p62148
(F1
F0.00014334862385321102
I0
I1
I-1
tp62149
sS'brain,was,longer'
p62150
(F1
F0.00014334862385321102
I1
I0
I1
tp62151
sS'same,episode,of'
p62152
(F1
F0.00014334862385321102
I0
I1
I-1
tp62153
sS'cyp1a2,inhibitors,including'
p62154
(F1
F0.00014334862385321102
I1
I0
I1
tp62155
sS'with,other,b-lactam'
p62156
(F1
F0.00043004587155963305
I3
I0
I3
tp62157
sS'eg,valproic,acid'
p62158
(F1
F0.00014334862385321102
I1
I0
I1
tp62159
sS'on,known,metabolic'
p62160
(F1
F0.00014334862385321102
I0
I1
I-1
tp62161
sS'the,weekly,dosage'
p62162
(F1
F0.00014334862385321102
I1
I0
I1
tp62163
sS'clinical,pharmacology,studies'
p62164
(F1
F0.00043004587155963305
I0
I3
I-3
tp62165
sS'rapidly,growing,class'
p62166
(F1
F0.00014334862385321102
I0
I1
I-1
tp62167
sS'weight,and,subcutaneous'
p62168
(F1
F0.00014334862385321102
I0
I1
I-1
tp62169
sS'antiacid,didanosine,fluconazole'
p62170
(F1
F0.00014334862385321102
I0
I1
I-1
tp62171
sS'histologic,type,depth'
p62172
(F1
F0.00014334862385321102
I0
I1
I-1
tp62173
sS'action,of,and'
p62174
(F1
F0.00043004587155963305
I3
I0
I3
tp62175
sS'when,an,oral'
p62176
(F1
F0.00028669724770642203
I2
I0
I2
tp62177
sS'nitrates,the,concomitant'
p62178
(F1
F0.00014334862385321102
I0
I1
I-1
tp62179
sS'than,for,exjade'
p62180
(F1
F0.00014334862385321102
I1
I0
I1
tp62181
sS'period,in,patients'
p62182
(F1
F0.00043004587155963305
I3
I0
I3
tp62183
sS'studies,in,humans'
p62184
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp62185
sS'therapy,is,prolonged'
p62186
(F1
F0.00014334862385321102
I0
I1
I-1
tp62187
sS'caution,in,those'
p62188
(F1
F0.00014334862385321102
I1
I0
I1
tp62189
sS'binding,of,by'
p62190
(F1
F0.00028669724770642203
I2
I0
I2
tp62191
sS'an,elevation,of'
p62192
(F1
F0.00057339449541284407
I4
I0
I4
tp62193
sS'antinociceptive,effect,of'
p62194
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp62195
sS'to,years,old'
p62196
(F1
F0.00014334862385321102
I0
I1
I-1
tp62197
sS'four,doses,did'
p62198
(F1
F0.00014334862385321102
I0
I1
I-1
tp62199
sS'and,ng,ml'
p62200
(F1
F0.00014334862385321102
I1
I0
I1
tp62201
sS'but,not,all'
p62202
(F1
F0.00014334862385321102
I0
I1
I-1
tp62203
sS'when,the,orally'
p62204
(F1
F0.00014334862385321102
I1
I0
I1
tp62205
sS'medicine,blood,thinners'
p62206
(F1
F0.00014334862385321102
I1
I0
I1
tp62207
sS'or,the,mean'
p62208
(F1
F0.00028669724770642203
I0
I2
I-2
tp62209
sS'function,should,be'
p62210
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp62211
sS'critical,role,in'
p62212
(F1
F0.00014334862385321102
I0
I1
I-1
tp62213
sS'dose,that,maximally'
p62214
(F1
F0.00014334862385321102
I0
I1
I-1
tp62215
sS'by,inhibition,of'
p62216
(F0.5
F0.00028669724770642203
I3
I1
I2
tp62217
sS'from,the,atac'
p62218
(F1
F0.00014334862385321102
I1
I0
I1
tp62219
sS'any,great,extent'
p62220
(F1
F0.00014334862385321102
I0
I1
I-1
tp62221
sS'adjuvant,treatment,of'
p62222
(F1
F0.00014334862385321102
I1
I0
I1
tp62223
sS'with,such,medications'
p62224
(F1
F0.00014334862385321102
I1
I0
I1
tp62225
sS'of,a,potent'
p62226
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp62227
sS'behavioral,changes,induced'
p62228
(F1
F0.00014334862385321102
I0
I1
I-1
tp62229
sS'of,welchol,with'
p62230
(F1
F0.00014334862385321102
I0
I1
I-1
tp62231
sS'normal,healthy,subjects'
p62232
(F1
F0.00014334862385321102
I0
I1
I-1
tp62233
sS'or,symptoms,of'
p62234
(F1
F0.00014334862385321102
I1
I0
I1
tp62235
sS'patient,currently,receiving'
p62236
(F1
F0.00028669724770642203
I2
I0
I2
tp62237
sS'wort,based,on'
p62238
(F1
F0.00014334862385321102
I0
I1
I-1
tp62239
sS'nursing,or,discontinue'
p62240
(F1
F0.00014334862385321102
I0
I1
I-1
tp62241
sS'activity,and,increase'
p62242
(F1
F0.00014334862385321102
I1
I0
I1
tp62243
sS'hepatotoxic,medications,is'
p62244
(F1
F0.00014334862385321102
I1
I0
I1
tp62245
sS'and,following,treatment'
p62246
(F1
F0.00014334862385321102
I0
I1
I-1
tp62247
sS'formulations,containing,divalent'
p62248
(F1
F0.00028669724770642203
I2
I0
I2
tp62249
sS'receiving,or,concurrently'
p62250
(F1
F0.00014334862385321102
I1
I0
I1
tp62251
sS'concentration,mic,of'
p62252
(F1
F0.00014334862385321102
I0
I1
I-1
tp62253
sS'dose,of,when'
p62254
(F1
F0.00028669724770642203
I0
I2
I-2
tp62255
sS'eg,and,is'
p62256
(F1
F0.00014334862385321102
I1
I0
I1
tp62257
sS'diabetic,patients,and'
p62258
(F1
F0.00014334862385321102
I1
I0
I1
tp62259
sS'equetrotm,may,reduce'
p62260
(F1
F0.00014334862385321102
I0
I1
I-1
tp62261
sS'concurrently,with,phenurone'
p62262
(F1
F0.00014334862385321102
I1
I0
I1
tp62263
sS'trough,plasma,levels'
p62264
(F1
F0.00028669724770642203
I2
I0
I2
tp62265
sS'of,approximately,msec'
p62266
(F1
F0.00014334862385321102
I1
I0
I1
tp62267
sS'that,a,single'
p62268
(F1
F0.00014334862385321102
I0
I1
I-1
tp62269
sS'pcp-induced,behavioral,changes'
p62270
(F1
F0.00014334862385321102
I0
I1
I-1
tp62271
sS'fever,renal,insufficiency'
p62272
(F1
F0.00014334862385321102
I1
I0
I1
tp62273
sS'significant,sustained,elevation'
p62274
(F1
F0.00014334862385321102
I1
I0
I1
tp62275
sS'like,mc,probably'
p62276
(F1
F0.00014334862385321102
I0
I1
I-1
tp62277
sS'on,high,threshold'
p62278
(F1
F0.00014334862385321102
I0
I1
I-1
tp62279
sS'relapses,for,periods'
p62280
(F1
F0.00014334862385321102
I0
I1
I-1
tp62281
sS'sustiva,mg,all'
p62282
(F1
F0.00014334862385321102
I0
I1
I-1
tp62283
sS'observed,for,increased'
p62284
(F1
F0.00014334862385321102
I0
I1
I-1
tp62285
sS'of,the,tysabri'
p62286
(F1
F0.00014334862385321102
I0
I1
I-1
tp62287
sS'ambulatory,patients,the'
p62288
(F1
F0.00014334862385321102
I0
I1
I-1
tp62289
sS'patients,in,three'
p62290
(F1
F0.00014334862385321102
I0
I1
I-1
tp62291
sS'increases,the,bioavailability'
p62292
(F1
F0.00014334862385321102
I0
I1
I-1
tp62293
sS'studies,in,mice'
p62294
(F1
F0.00014334862385321102
I0
I1
I-1
tp62295
sS'no,experience,with'
p62296
(F1
F0.00014334862385321102
I0
I1
I-1
tp62297
sS'the,beneficial,effects'
p62298
(F1
F0.00028669724770642203
I2
I0
I2
tp62299
sS'dose,should,not'
p62300
(F1
F0.00057339449541284407
I4
I0
I4
tp62301
sS'interval,decrease,mean'
p62302
(F1
F0.00014334862385321102
I0
I1
I-1
tp62303
sS'on,severe,dietary'
p62304
(F1
F0.00014334862385321102
I1
I0
I1
tp62305
sS'phosphorylated,which,may'
p62306
(F1
F0.00014334862385321102
I1
I0
I1
tp62307
sS'to,measure,over'
p62308
(F1
F0.00014334862385321102
I0
I1
I-1
tp62309
sS'acid,nsaids,and'
p62310
(F1
F0.00014334862385321102
I0
I1
I-1
tp62311
sS'fibrulation,and,torsades'
p62312
(F1
F0.00014334862385321102
I1
I0
I1
tp62313
sS'glucose,was,determined'
p62314
(F1
F0.00014334862385321102
I0
I1
I-1
tp62315
sS'interaction,has,not'
p62316
(F0
F0
I1
I1
I0
tp62317
sS'its,active,metabolites'
p62318
(F1
F0.00014334862385321102
I0
I1
I-1
tp62319
sS'agents,anesthetics,general'
p62320
(F1
F0.00014334862385321102
I1
I0
I1
tp62321
sS'duloxetine,with,other'
p62322
(F1
F0.00014334862385321102
I1
I0
I1
tp62323
sS'acidifying,agents,used'
p62324
(F1
F0.00028669724770642203
I2
I0
I2
tp62325
sS'different,and,neither'
p62326
(F1
F0.00014334862385321102
I0
I1
I-1
tp62327
sS'possible,when,administered'
p62328
(F1
F0.00014334862385321102
I0
I1
I-1
tp62329
sS'degree,of,enhancement'
p62330
(F1
F0.00014334862385321102
I0
I1
I-1
tp62331
sS'single-dose,coadministration,leads'
p62332
(F1
F0.00014334862385321102
I1
I0
I1
tp62333
sS'a,cause,and'
p62334
(F1
F0.00014334862385321102
I1
I0
I1
tp62335
sS'vioxx,is,not'
p62336
(F1
F0.00014334862385321102
I0
I1
I-1
tp62337
sS'of,cyp3a4,mg'
p62338
(F1
F0.00014334862385321102
I1
I0
I1
tp62339
sS'pressor,activity,of'
p62340
(F1
F0.00014334862385321102
I0
I1
I-1
tp62341
sS'monitored,carefully,and'
p62342
(F1
F0.00014334862385321102
I1
I0
I1
tp62343
sS'beta-adrenoceptor,blocking,agents'
p62344
(F1
F0.00028669724770642203
I2
I0
I2
tp62345
sS'in,the,pharmacokinetics'
p62346
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp62347
sS'additive,cns,depressant'
p62348
(F1
F0.00057339449541284407
I4
I0
I4
tp62349
sS'used,if,therapy'
p62350
(F1
F0.00014334862385321102
I1
I0
I1
tp62351
sS'conditions,to,normal'
p62352
(F1
F0.00014334862385321102
I0
I1
I-1
tp62353
sS'cause,respiratory,depression'
p62354
(F1
F0.00014334862385321102
I1
I0
I1
tp62355
sS'decrease,elimination,and'
p62356
(F1
F0.00014334862385321102
I1
I0
I1
tp62357
sS'not,have,clinically'
p62358
(F1
F0.00057339449541284407
I0
I4
I-4
tp62359
sS'pharmacist,of,all'
p62360
(F1
F0.00014334862385321102
I0
I1
I-1
tp62361
sS'five,days,of'
p62362
(F1
F0.00014334862385321102
I0
I1
I-1
tp62363
sS'in,inr,or'
p62364
(F1
F0.00014334862385321102
I0
I1
I-1
tp62365
sS'warfarin,meclofenamate,sodium'
p62366
(F1
F0.00014334862385321102
I1
I0
I1
tp62367
sS'arteries,from,both'
p62368
(F1
F0.00014334862385321102
I0
I1
I-1
tp62369
sS'neuronal,reuptake,of'
p62370
(F1
F0.00014334862385321102
I0
I1
I-1
tp62371
sS'from,smoking,cessation'
p62372
(F1
F0.00014334862385321102
I0
I1
I-1
tp62373
sS'increased,concentrations,has'
p62374
(F1
F0.00014334862385321102
I0
I1
I-1
tp62375
sS'type,c,and'
p62376
(F1
F0.00014334862385321102
I1
I0
I1
tp62377
sS'of,l-phenylalanine,and'
p62378
(F1
F0.00014334862385321102
I1
I0
I1
tp62379
sS'analogues,should,be'
p62380
(F1
F0.00043004587155963305
I0
I3
I-3
tp62381
sS'measured,at,steady'
p62382
(F1
F0.00014334862385321102
I0
I1
I-1
tp62383
sS'but,not,mc'
p62384
(F1
F0.00014334862385321102
I0
I1
I-1
tp62385
sS'histamine-,or,camp-stimulated'
p62386
(F1
F0.00014334862385321102
I1
I0
I1
tp62387
sS'including,sulfate,sulfate'
p62388
(F0
F0
I1
I1
I0
tp62389
sS'patients,receiving,tricyclic'
p62390
(F1
F0.00014334862385321102
I1
I0
I1
tp62391
sS'its,vasculature,without'
p62392
(F1
F0.00014334862385321102
I0
I1
I-1
tp62393
sS'following,cyclosporine,a'
p62394
(F1
F0.00014334862385321102
I0
I1
I-1
tp62395
sS'd3,oh,d3'
p62396
(F1
F0.00014334862385321102
I0
I1
I-1
tp62397
sS'dose,increase,for'
p62398
(F1
F0.00014334862385321102
I1
I0
I1
tp62399
sS'function,and,in'
p62400
(F1
F0.00014334862385321102
I1
I0
I1
tp62401
sS'receiving,multiple,doses'
p62402
(F1
F0.00014334862385321102
I1
I0
I1
tp62403
sS'of,myalgia,and'
p62404
(F1
F0.00014334862385321102
I1
I0
I1
tp62405
sS'and,mhd,did'
p62406
(F1
F0.00014334862385321102
I0
I1
I-1
tp62407
sS'on,inositol,trisphosphate'
p62408
(F1
F0.00014334862385321102
I0
I1
I-1
tp62409
sS'expected,based,on'
p62410
(F1
F0.00014334862385321102
I0
I1
I-1
tp62411
sS'actions,of,intrathecal'
p62412
(F1
F0.00014334862385321102
I0
I1
I-1
tp62413
sS'with,with,and'
p62414
(F1
F0.00014334862385321102
I1
I0
I1
tp62415
sS'seizure,control,by'
p62416
(F1
F0.00014334862385321102
I1
I0
I1
tp62417
sS'combination,of,arimidex'
p62418
(F1
F0.00014334862385321102
I0
I1
I-1
tp62419
sS'adjustment,of,sensipar'
p62420
(F1
F0.00014334862385321102
I1
I0
I1
tp62421
sS'as,intravenous,mg'
p62422
(F1
F0.00014334862385321102
I0
I1
I-1
tp62423
sS'exacerbate,rebound,hypertension'
p62424
(F1
F0.00014334862385321102
I1
I0
I1
tp62425
sS'monitor,tca,plasma'
p62426
(F1
F0.00057339449541284407
I0
I4
I-4
tp62427
sS'observed,that,mptp'
p62428
(F1
F0.00014334862385321102
I1
I0
I1
tp62429
sS'terms,viagra,and'
p62430
(F1
F0.00014334862385321102
I0
I1
I-1
tp62431
sS'do,not,contain'
p62432
(F1
F0.00014334862385321102
I1
I0
I1
tp62433
sS'vs,and,bone'
p62434
(F1
F0.00014334862385321102
I1
I0
I1
tp62435
sS'were,increased,over'
p62436
(F1
F0.00014334862385321102
I1
I0
I1
tp62437
sS'or,and,possibly'
p62438
(F1
F0.00028669724770642203
I2
I0
I2
tp62439
sS'of,pregnancy,from'
p62440
(F1
F0.00014334862385321102
I0
I1
I-1
tp62441
sS'inhibits,the,biotransformation'
p62442
(F1
F0.00014334862385321102
I1
I0
I1
tp62443
sS'therefore,concomitant,use'
p62444
(F1
F0.00014334862385321102
I1
I0
I1
tp62445
sS'antagonized,by,such'
p62446
(F1
F0.00014334862385321102
I1
I0
I1
tp62447
sS'because,of,potential'
p62448
(F1
F0.00014334862385321102
I1
I0
I1
tp62449
sS'that,and,had'
p62450
(F1
F0.00014334862385321102
I0
I1
I-1
tp62451
sS'or,the,therapeutic'
p62452
(F1
F0.00014334862385321102
I0
I1
I-1
tp62453
sS'consequences,following,methyl-4'
p62454
(F1
F0.00014334862385321102
I0
I1
I-1
tp62455
sS'dosage,adjustments,patients'
p62456
(F1
F0.00014334862385321102
I1
I0
I1
tp62457
sS'net,decrease,in'
p62458
(F1
F0.00014334862385321102
I1
I0
I1
tp62459
sS'of,hepatitis,has'
p62460
(F1
F0.00014334862385321102
I1
I0
I1
tp62461
sS'any,unexpected,adverse'
p62462
(F1
F0.00014334862385321102
I0
I1
I-1
tp62463
sS'however,when,any'
p62464
(F1
F0.00014334862385321102
I1
I0
I1
tp62465
sS'directed,and,proquin'
p62466
(F1
F0.00014334862385321102
I0
I1
I-1
tp62467
sS'the,bactercidal,effect'
p62468
(F1
F0.00014334862385321102
I1
I0
I1
tp62469
sS'combination,of,conjugated'
p62470
(F1
F0.00014334862385321102
I0
I1
I-1
tp62471
sS'an,approximate,reduction'
p62472
(F1
F0.00014334862385321102
I1
I0
I1
tp62473
sS'use,of,supplements'
p62474
(F1
F0.00014334862385321102
I1
I0
I1
tp62475
sS'on,day,when'
p62476
(F1
F0.00043004587155963305
I3
I0
I3
tp62477
sS'the,first,double-blind'
p62478
(F1
F0.00014334862385321102
I0
I1
I-1
tp62479
sS'may,occur,with'
p62480
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp62481
sS'or,more,pharmacologic'
p62482
(F1
F0.00014334862385321102
I0
I1
I-1
tp62483
sS'periods,of,time'
p62484
(F1
F0.00014334862385321102
I0
I1
I-1
tp62485
sS'sensipar,sensipar,is'
p62486
(F1
F0.00014334862385321102
I0
I1
I-1
tp62487
sS'preparations,or,beta-adrenergic'
p62488
(F1
F0.00014334862385321102
I0
I1
I-1
tp62489
sS'hypokalemia,that,may'
p62490
(F1
F0.00014334862385321102
I1
I0
I1
tp62491
sS'nervous,system,depressant'
p62492
(F1
F0.00014334862385321102
I0
I1
I-1
tp62493
sS'did,not,influence'
p62494
(F1
F0.0008600917431192661
I0
I6
I-6
tp62495
sS'mg,has,been'
p62496
(F1
F0.00014334862385321102
I0
I1
I-1
tp62497
sS'there,is,insufficient'
p62498
(F1
F0.00014334862385321102
I1
I0
I1
tp62499
sS'diminished,response,to'
p62500
(F1
F0.00014334862385321102
I1
I0
I1
tp62501
sS'that,maximally,suppresses'
p62502
(F1
F0.00014334862385321102
I0
I1
I-1
tp62503
sS'response,to,plenaxis'
p62504
(F1
F0.00014334862385321102
I0
I1
I-1
tp62505
sS'have,been,established'
p62506
(F1
F0.00014334862385321102
I0
I1
I-1
tp62507
sS'by,tromethamine,control'
p62508
(F1
F0.00014334862385321102
I1
I0
I1
tp62509
sS'occur,up,to'
p62510
(F1
F0.00014334862385321102
I1
I0
I1
tp62511
sS'elevations,of,concentrations'
p62512
(F1
F0.00014334862385321102
I1
I0
I1
tp62513
sS'both,minimal,inhibitory'
p62514
(F1
F0.00014334862385321102
I0
I1
I-1
tp62515
sS'steroid,hormones,such'
p62516
(F1
F0.00014334862385321102
I1
I0
I1
tp62517
sS'of,hydroxide,with'
p62518
(F1
F0.00014334862385321102
I1
I0
I1
tp62519
sS'or,of,the'
p62520
(F1
F0.00014334862385321102
I0
I1
I-1
tp62521
sS'by,cytochrome,p-450'
p62522
(F1
F0.00014334862385321102
I1
I0
I1
tp62523
sS'hours,subsequent,to'
p62524
(F1
F0.00014334862385321102
I0
I1
I-1
tp62525
sS'on,established,therapy'
p62526
(F1
F0.00014334862385321102
I1
I0
I1
tp62527
sS'prolonged,administration,twice'
p62528
(F1
F0.00014334862385321102
I0
I1
I-1
tp62529
sS'was,coadministered,on'
p62530
(F1
F0.00014334862385321102
I1
I0
I1
tp62531
sS'alt,and,total'
p62532
(F1
F0.00014334862385321102
I0
I1
I-1
tp62533
sS'bioavailabillty,and,may'
p62534
(F1
F0.00014334862385321102
I0
I1
I-1
tp62535
sS'and,coadministration,of'
p62536
(F1
F0.00028669724770642203
I2
I0
I2
tp62537
sS'frequently,if,prinivil'
p62538
(F1
F0.00014334862385321102
I1
I0
I1
tp62539
sS'control,inflammation,associated'
p62540
(F1
F0.00014334862385321102
I1
I0
I1
tp62541
sS'necessary,to,maintain'
p62542
(F1
F0.00014334862385321102
I1
I0
I1
tp62543
sS'be,made,of'
p62544
(F1
F0.00014334862385321102
I1
I0
I1
tp62545
sS'be,made,on'
p62546
(F1
F0.00014334862385321102
I0
I1
I-1
tp62547
sS'as,cyp3a4,inhibitors'
p62548
(F1
F0.00014334862385321102
I1
I0
I1
tp62549
sS'a,single,intravenous'
p62550
(F1
F0.00014334862385321102
I0
I1
I-1
tp62551
sS'antiepilepsy,aeds,whether'
p62552
(F1
F0.00014334862385321102
I0
I1
I-1
tp62553
sS'result,in,substantial'
p62554
(F1
F0.00014334862385321102
I1
I0
I1
tp62555
sS'when,is,initiated'
p62556
(F1
F0.00028669724770642203
I2
I0
I2
tp62557
sS'after,drinking,may'
p62558
(F1
F0.00014334862385321102
I1
I0
I1
tp62559
sS'may,induce,the'
p62560
(F1
F0.00028669724770642203
I2
I0
I2
tp62561
sS'volunteers,the,auc'
p62562
(F1
F0.00014334862385321102
I1
I0
I1
tp62563
sS'change,in,plasma'
p62564
(F1
F0.00014334862385321102
I1
I0
I1
tp62565
sS'in,the,elderly'
p62566
(F0
F0
I1
I1
I0
tp62567
sS'lower,than,the'
p62568
(F1
F0.00028669724770642203
I0
I2
I-2
tp62569
sS'greater,proportion,of'
p62570
(F1
F0.00014334862385321102
I1
I0
I1
tp62571
sS'is,advised,digoxin'
p62572
(F1
F0.00014334862385321102
I0
I1
I-1
tp62573
sS'secretion,stimulated,by'
p62574
(F1
F0.00014334862385321102
I0
I1
I-1
tp62575
sS'ratio,or,inr'
p62576
(F1
F0.00014334862385321102
I1
I0
I1
tp62577
sS'of,in,survanta'
p62578
(F1
F0.00014334862385321102
I0
I1
I-1
tp62579
sS'as,those,on'
p62580
(F1
F0.00014334862385321102
I1
I0
I1
tp62581
sS'these,pharmacokinetic,effects'
p62582
(F1
F0.00014334862385321102
I1
I0
I1
tp62583
sS'usually,well,tolerated'
p62584
(F0
F0
I1
I1
I0
tp62585
sS'ventricular,arrhythmias,in'
p62586
(F1
F0.00014334862385321102
I0
I1
I-1
tp62587
sS'tricyclic,antidepressants,foradil'
p62588
(F1
F0.00014334862385321102
I1
I0
I1
tp62589
sS'by,oxc,and'
p62590
(F1
F0.00028669724770642203
I0
I2
I-2
tp62591
sS'be,taken,as'
p62592
(F1
F0.00014334862385321102
I0
I1
I-1
tp62593
sS'who,may,need'
p62594
(F1
F0.00014334862385321102
I1
I0
I1
tp62595
sS'of,may,render'
p62596
(F1
F0.00014334862385321102
I1
I0
I1
tp62597
sS'have,been,treated'
p62598
(F1
F0.00014334862385321102
I1
I0
I1
tp62599
sS'days,a,decrease'
p62600
(F1
F0.00014334862385321102
I1
I0
I1
tp62601
sS'while,mc,and'
p62602
(F1
F0.00014334862385321102
I0
I1
I-1
tp62603
sS'time,spent,in'
p62604
(F1
F0.00014334862385321102
I1
I0
I1
tp62605
sS'while,other,studies'
p62606
(F1
F0.00014334862385321102
I0
I1
I-1
tp62607
sS'of,at,steady-state'
p62608
(F0
F0
I1
I1
I0
tp62609
sS'through,increased,the'
p62610
(F1
F0.00014334862385321102
I1
I0
I1
tp62611
sS'slowly,over,several'
p62612
(F1
F0.00014334862385321102
I1
I0
I1
tp62613
sS'for,the,metabolism'
p62614
(F1
F0.00014334862385321102
I0
I1
I-1
tp62615
sS'tract,hydoxide,hydrochloride'
p62616
(F1
F0.00014334862385321102
I1
I0
I1
tp62617
sS'micrograms,ml,for'
p62618
(F1
F0.00014334862385321102
I0
I1
I-1
tp62619
sS'cyp3a4,inducers,eg'
p62620
(F1
F0.00014334862385321102
I0
I1
I-1
tp62621
sS'of,other,potassium-sparing'
p62622
(F1
F0.00014334862385321102
I1
I0
I1
tp62623
sS'systematically,in,clinical'
p62624
(F1
F0.00014334862385321102
I0
I1
I-1
tp62625
sS'on,the,r-value'
p62626
(F1
F0.00014334862385321102
I0
I1
I-1
tp62627
sS'of,neurontin,in'
p62628
(F1
F0.00014334862385321102
I0
I1
I-1
tp62629
sS'been,administered,to'
p62630
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp62631
sS'mg,sular,tablets'
p62632
(F1
F0.00014334862385321102
I1
I0
I1
tp62633
sS's,disease,including'
p62634
(F1
F0.00014334862385321102
I0
I1
I-1
tp62635
sS'table,is,not'
p62636
(F1
F0.00014334862385321102
I0
I1
I-1
tp62637
sS'discontinuation,ordinarily,should'
p62638
(F1
F0.00014334862385321102
I0
I1
I-1
tp62639
sS'have,a,positive'
p62640
(F1
F0.00014334862385321102
I0
I1
I-1
tp62641
sS'to,define,the'
p62642
(F1
F0.00014334862385321102
I0
I1
I-1
tp62643
sS'theophylline,twelve,healthy'
p62644
(F1
F0.00014334862385321102
I0
I1
I-1
tp62645
sS'too,low,to'
p62646
(F1
F0.00014334862385321102
I0
I1
I-1
tp62647
sS'would,be,expected'
p62648
(F0.14285714285714285
F0.00028669724770642203
I8
I6
I2
tp62649
sS'cyp2d6,i,selective'
p62650
(F1
F0.00014334862385321102
I1
I0
I1
tp62651
sS'therapy,compliance,especially'
p62652
(F1
F0.00014334862385321102
I0
I1
I-1
tp62653
sS'of,nanm,but'
p62654
(F1
F0.00014334862385321102
I1
I0
I1
tp62655
sS'zebeta,should,not'
p62656
(F1
F0.00014334862385321102
I1
I0
I1
tp62657
sS'orlistat-orlistat,may,decrease'
p62658
(F1
F0.00014334862385321102
I1
I0
I1
tp62659
sS'a,patient,initiates'
p62660
(F1
F0.00014334862385321102
I1
I0
I1
tp62661
sS'might,also,contribute'
p62662
(F1
F0.00014334862385321102
I1
I0
I1
tp62663
sS'cmax,respectively,of'
p62664
(F1
F0.00014334862385321102
I0
I1
I-1
tp62665
sS'a,small,study'
p62666
(F1
F0.00014334862385321102
I0
I1
I-1
tp62667
sS'treatment,costs,of'
p62668
(F1
F0.00014334862385321102
I0
I1
I-1
tp62669
sS'who,are,concurrently'
p62670
(F1
F0.00028669724770642203
I2
I0
I2
tp62671
sS'to,be,well'
p62672
(F0
F0
I1
I1
I0
tp62673
sS'from,masking,symptoms'
p62674
(F1
F0.00014334862385321102
I0
I1
I-1
tp62675
sS'enzyme,inducers,iodinated'
p62676
(F1
F0.00014334862385321102
I0
I1
I-1
tp62677
sS'of,elemental,reduced'
p62678
(F1
F0.00014334862385321102
I1
I0
I1
tp62679
sS'was,added,to'
p62680
(F0.5
F0.00028669724770642203
I3
I1
I2
tp62681
sS'use,of,monoamine'
p62682
(F1
F0.00014334862385321102
I1
I0
I1
tp62683
sS'hctz,hydrodiuril,diuril'
p62684
(F1
F0.00014334862385321102
I0
I1
I-1
tp62685
sS'because,they,may'
p62686
(F0
F0
I1
I1
I0
tp62687
sS'celebrex,with,since'
p62688
(F1
F0.00014334862385321102
I1
I0
I1
tp62689
sS'h-spiroperidol,binding,after'
p62690
(F1
F0.00014334862385321102
I0
I1
I-1
tp62691
sS'the,uptake,inhibitors'
p62692
(F1
F0.00014334862385321102
I1
I0
I1
tp62693
sS'the,fractional,inhibitory'
p62694
(F1
F0.00014334862385321102
I0
I1
I-1
tp62695
sS'quinolones,including,decrease'
p62696
(F1
F0.00014334862385321102
I1
I0
I1
tp62697
sS'highly,potent,cyp3a4'
p62698
(F1
F0.00014334862385321102
I1
I0
I1
tp62699
sS'the,resulting,respiratory'
p62700
(F1
F0.00014334862385321102
I1
I0
I1
tp62701
sS'therapeutic,effect,for'
p62702
(F1
F0.00014334862385321102
I0
I1
I-1
tp62703
sS'such,that,users'
p62704
(F1
F0.00028669724770642203
I2
I0
I2
tp62705
sS'and,associated,dental'
p62706
(F1
F0.00014334862385321102
I1
I0
I1
tp62707
sS'and,extends,its'
p62708
(F1
F0.00014334862385321102
I1
I0
I1
tp62709
sS'potential,for,interaction'
p62710
(F1
F0.00028669724770642203
I2
I0
I2
tp62711
sS'caused,subnormal,release'
p62712
(F1
F0.00014334862385321102
I0
I1
I-1
tp62713
sS'glucose,lowering,effect'
p62714
(F1
F0.00014334862385321102
I1
I0
I1
tp62715
sS'azole,antifungals,protease'
p62716
(F1
F0.00014334862385321102
I0
I1
I-1
tp62717
sS'hydrochloride,could,pose'
p62718
(F1
F0.00014334862385321102
I0
I1
I-1
tp62719
sS'this,study,we'
p62720
(F1
F0.00014334862385321102
I0
I1
I-1
tp62721
sS'lower,doses,of'
p62722
(F0
F0
I1
I1
I0
tp62723
sS'coadministered,with,inhibitors'
p62724
(F1
F0.00014334862385321102
I1
I0
I1
tp62725
sS'not,be,expected'
p62726
(F1
F0.00028669724770642203
I0
I2
I-2
tp62727
sS'reduction,in,the'
p62728
(F1
F0.00043004587155963305
I3
I0
I3
tp62729
sS'are,rare,reports'
p62730
(F1
F0.00014334862385321102
I1
I0
I1
tp62731
sS'both,and,under'
p62732
(F1
F0.00014334862385321102
I0
I1
I-1
tp62733
sS'to,prevent,folic'
p62734
(F1
F0.00014334862385321102
I0
I1
I-1
tp62735
sS'anti-inflammatory,action,by'
p62736
(F1
F0.00014334862385321102
I1
I0
I1
tp62737
sS'concomitant,augmentin,xr'
p62738
(F1
F0.00014334862385321102
I0
I1
I-1
tp62739
sS'cr,lower,plasma'
p62740
(F1
F0.00014334862385321102
I1
I0
I1
tp62741
sS'not,been,done'
p62742
(F0
F0
I1
I1
I0
tp62743
sS'biopharmaceutical,properties,relative'
p62744
(F1
F0.00014334862385321102
I0
I1
I-1
tp62745
sS'however,in,the'
p62746
(F0
F0
I1
I1
I0
tp62747
sS'daily,alternating,therapy'
p62748
(F1
F0.00014334862385321102
I0
I1
I-1
tp62749
sS'associated,with,increased'
p62750
(F0
F0
I2
I2
I0
tp62751
sS'with,food,one'
p62752
(F1
F0.00014334862385321102
I1
I0
I1
tp62753
sS'auc,values,for'
p62754
(F1
F0.00028669724770642203
I2
I0
I2
tp62755
sS'platelet,effects,vioxx'
p62756
(F1
F0.00014334862385321102
I0
I1
I-1
tp62757
sS'one,report,suggesting'
p62758
(F1
F0.00014334862385321102
I1
I0
I1
tp62759
sS'was,noted,with'
p62760
(F1
F0.00014334862385321102
I0
I1
I-1
tp62761
sS'with,other,in'
p62762
(F1
F0.00014334862385321102
I0
I1
I-1
tp62763
sS'volunteers,a,six-day'
p62764
(F1
F0.00014334862385321102
I1
I0
I1
tp62765
sS'on,gi,bleeding'
p62766
(F1
F0.00028669724770642203
I2
I0
I2
tp62767
sS'induction,the,concomitant'
p62768
(F1
F0.00014334862385321102
I1
I0
I1
tp62769
sS'small,yet,statistically'
p62770
(F1
F0.00014334862385321102
I0
I1
I-1
tp62771
sS'normalized,ratio,or'
p62772
(F1
F0.00014334862385321102
I1
I0
I1
tp62773
sS'therefore,to,maximize'
p62774
(F1
F0.00014334862385321102
I0
I1
I-1
tp62775
sS'eg,an,antiparkinsonian'
p62776
(F1
F0.00014334862385321102
I1
I0
I1
tp62777
sS'to,reported,to'
p62778
(F1
F0.00014334862385321102
I1
I0
I1
tp62779
sS'radiation,therapy,diabetes'
p62780
(F1
F0.00014334862385321102
I0
I1
I-1
tp62781
sS'the,danger,of'
p62782
(F1
F0.00028669724770642203
I2
I0
I2
tp62783
sS'inhibitor,mg,increased'
p62784
(F1
F0.00014334862385321102
I1
I0
I1
tp62785
sS'increase,its,serum'
p62786
(F1
F0.00014334862385321102
I1
I0
I1
tp62787
sS'rhabdomyolysis,have,occasionally'
p62788
(F1
F0.00014334862385321102
I0
I1
I-1
tp62789
sS'in,studies,in'
p62790
(F1
F0.00014334862385321102
I0
I1
I-1
tp62791
sS'inr,should,be'
p62792
(F1
F0.00014334862385321102
I1
I0
I1
tp62793
sS'years,of,age'
p62794
(F1
F0.00014334862385321102
I0
I1
I-1
tp62795
sS'response,of,male'
p62796
(F1
F0.00014334862385321102
I1
I0
I1
tp62797
sS'patients,taking,beta'
p62798
(F1
F0.00014334862385321102
I1
I0
I1
tp62799
sS'of,udp-glucuronyl,transferase'
p62800
(F1
F0.00014334862385321102
I0
I1
I-1
tp62801
sS'and,concomitantly,of'
p62802
(F1
F0.00014334862385321102
I0
I1
I-1
tp62803
sS'observed,but,were'
p62804
(F1
F0.00014334862385321102
I0
I1
I-1
tp62805
sS'of,were,unchanged'
p62806
(F1
F0.00014334862385321102
I0
I1
I-1
tp62807
sS'peripherally,restricted,antagonist'
p62808
(F1
F0.00014334862385321102
I1
I0
I1
tp62809
sS'the,decrease,in'
p62810
(F1
F0.00014334862385321102
I0
I1
I-1
tp62811
sS'and,mumol,liter'
p62812
(F1
F0.00014334862385321102
I1
I0
I1
tp62813
sS'curve,at,steady'
p62814
(F1
F0.00014334862385321102
I1
I0
I1
tp62815
sS'nitrous,oxide,to'
p62816
(F1
F0.00014334862385321102
I1
I0
I1
tp62817
sS'receiving,no,significant'
p62818
(F1
F0.00014334862385321102
I0
I1
I-1
tp62819
sS'plasma,concentrations,should'
p62820
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp62821
sS'with,available,data'
p62822
(F1
F0.00014334862385321102
I1
I0
I1
tp62823
sS'with,either,mg'
p62824
(F1
F0.00014334862385321102
I0
I1
I-1
tp62825
sS'is,no,documentation'
p62826
(F1
F0.00014334862385321102
I0
I1
I-1
tp62827
sS'well,as,increasing'
p62828
(F1
F0.00014334862385321102
I0
I1
I-1
tp62829
sS'of,and,to'
p62830
(F0
F0
I3
I3
I0
tp62831
sS'of,simulect,was'
p62832
(F1
F0.00014334862385321102
I1
I0
I1
tp62833
sS'inhibitor,of,microsomal'
p62834
(F1
F0.00014334862385321102
I1
I0
I1
tp62835
sS'affect,this,activity'
p62836
(F1
F0.00014334862385321102
I0
I1
I-1
tp62837
sS'values,of,the'
p62838
(F1
F0.00014334862385321102
I0
I1
I-1
tp62839
sS'reports,of,prolongation'
p62840
(F1
F0.00014334862385321102
I1
I0
I1
tp62841
sS'f2alpha,and,synthetic'
p62842
(F1
F0.00014334862385321102
I0
I1
I-1
tp62843
sS'interactions,the,urine'
p62844
(F1
F0.00014334862385321102
I0
I1
I-1
tp62845
sS'to,extend,the'
p62846
(F1
F0.00014334862385321102
I1
I0
I1
tp62847
sS'acid,higher,doses'
p62848
(F1
F0.00014334862385321102
I1
I0
I1
tp62849
sS'its,active,metabolite'
p62850
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp62851
sS'interaction,may,be'
p62852
(F1
F0.00014334862385321102
I0
I1
I-1
tp62853
sS'some,of,the'
p62854
(F1
F0.00043004587155963305
I0
I3
I-3
tp62855
sS'level,has,been'
p62856
(F1
F0.00014334862385321102
I1
I0
I1
tp62857
sS'be,closely,watched'
p62858
(F1
F0.00014334862385321102
I0
I1
I-1
tp62859
sS'hypokalemia,and,then'
p62860
(F1
F0.00014334862385321102
I0
I1
I-1
tp62861
sS'of,glucocorticoid-induced,mouse'
p62862
(F1
F0.00014334862385321102
I0
I1
I-1
tp62863
sS'premature,ventricular,arrhythmias'
p62864
(F1
F0.00014334862385321102
I0
I1
I-1
tp62865
sS'hemostasis,and,has'
p62866
(F1
F0.00014334862385321102
I1
I0
I1
tp62867
sS'binding,of,salicylic'
p62868
(F1
F0.00014334862385321102
I1
I0
I1
tp62869
sS'given,singly,and'
p62870
(F1
F0.00014334862385321102
I0
I1
I-1
tp62871
sS'be,increased,and'
p62872
(F1
F0.00028669724770642203
I2
I0
I2
tp62873
sS'taking,mg,daily'
p62874
(F1
F0.00014334862385321102
I0
I1
I-1
tp62875
sS'neutralizing,agent,for'
p62876
(F1
F0.00014334862385321102
I1
I0
I1
tp62877
sS'oral,and,plasma'
p62878
(F1
F0.00014334862385321102
I1
I0
I1
tp62879
sS'oral,products,ace'
p62880
(F1
F0.00014334862385321102
I0
I1
I-1
tp62881
sS'auc,by,approximately'
p62882
(F1
F0.00014334862385321102
I1
I0
I1
tp62883
sS'mouth,constipation,blurred'
p62884
(F1
F0.00014334862385321102
I1
I0
I1
tp62885
sS'volunteers,receiving,low'
p62886
(F1
F0.00014334862385321102
I1
I0
I1
tp62887
sS'results,of,these'
p62888
(F1
F0.00014334862385321102
I0
I1
I-1
tp62889
sS'without,and,with'
p62890
(F1
F0.00014334862385321102
I0
I1
I-1
tp62891
sS'by,fold,on'
p62892
(F1
F0.00043004587155963305
I3
I0
I3
tp62893
sS'the,extent,and'
p62894
(F1
F0.00014334862385321102
I0
I1
I-1
tp62895
sS'reduction,should,be'
p62896
(F1
F0.00014334862385321102
I0
I1
I-1
tp62897
sS'well,after,clinical'
p62898
(F1
F0.00014334862385321102
I0
I1
I-1
tp62899
sS'rbc,were,used'
p62900
(F1
F0.00014334862385321102
I0
I1
I-1
tp62901
sS'about,the,interaction'
p62902
(F0
F0
I1
I1
I0
tp62903
sS'taking,vitamin,supplements'
p62904
(F1
F0.00014334862385321102
I1
I0
I1
tp62905
sS'who,is,receiving'
p62906
(F1
F0.00014334862385321102
I1
I0
I1
tp62907
sS'rejection,episodes,permit'
p62908
(F1
F0.00014334862385321102
I0
I1
I-1
tp62909
sS'a,closely,related'
p62910
(F1
F0.00014334862385321102
I1
I0
I1
tp62911
sS'altering,their,need'
p62912
(F1
F0.00014334862385321102
I0
I1
I-1
tp62913
sS'the,stimulatory,effects'
p62914
(F1
F0.00014334862385321102
I1
I0
I1
tp62915
sS'risk,of,central'
p62916
(F1
F0.00014334862385321102
I1
I0
I1
tp62917
sS'not,contain,an'
p62918
(F1
F0.00014334862385321102
I1
I0
I1
tp62919
sS'elimination,of,a'
p62920
(F1
F0.00014334862385321102
I0
I1
I-1
tp62921
sS'somatropin,excessive,concurrent'
p62922
(F1
F0.00014334862385321102
I0
I1
I-1
tp62923
sS'the,principal,pathway'
p62924
(F1
F0.00014334862385321102
I1
I0
I1
tp62925
sS'in,several,well-controlled'
p62926
(F1
F0.00014334862385321102
I0
I1
I-1
tp62927
sS'tarceva,with,and'
p62928
(F1
F0.00014334862385321102
I1
I0
I1
tp62929
sS'simultaneously,because,both'
p62930
(F1
F0.00014334862385321102
I1
I0
I1
tp62931
sS'absorption,and,thus'
p62932
(F1
F0.00014334862385321102
I0
I1
I-1
tp62933
sS'increase,the,formation'
p62934
(F1
F0.00014334862385321102
I0
I1
I-1
tp62935
sS'to,increase,cmax'
p62936
(F1
F0.00014334862385321102
I1
I0
I1
tp62937
sS'products,containing,or'
p62938
(F1
F0.00028669724770642203
I2
I0
I2
tp62939
sS'amphetamines,potentiate,the'
p62940
(F1
F0.00028669724770642203
I2
I0
I2
tp62941
sS'additional,effect,is'
p62942
(F1
F0.00014334862385321102
I1
I0
I1
tp62943
sS'with,carbamazepine,concomitant'
p62944
(F1
F0.00014334862385321102
I1
I0
I1
tp62945
sS'the,protective,effect'
p62946
(F1
F0.00014334862385321102
I1
I0
I1
tp62947
sS'are,used,concomitantly'
p62948
(F0.5
F0.0008600917431192661
I9
I3
I6
tp62949
sS'affect,behaviors,most'
p62950
(F1
F0.00014334862385321102
I0
I1
I-1
tp62951
sS'established,that,both'
p62952
(F1
F0.00014334862385321102
I0
I1
I-1
tp62953
sS'protein,binding,sites'
p62954
(F1
F0.00014334862385321102
I1
I0
I1
tp62955
sS'urinary,excretion,as'
p62956
(F1
F0.00014334862385321102
I0
I1
I-1
tp62957
sS'because,anafranil,is'
p62958
(F1
F0.00014334862385321102
I1
I0
I1
tp62959
sS'of,followed,by'
p62960
(F1
F0.00014334862385321102
I1
I0
I1
tp62961
sS'could,theoretically,affect'
p62962
(F1
F0.00014334862385321102
I1
I0
I1
tp62963
sS'cmax,of,a'
p62964
(F1
F0.00014334862385321102
I0
I1
I-1
tp62965
sS'cardiac,glycosides,inducers'
p62966
(F1
F0.00014334862385321102
I0
I1
I-1
tp62967
sS'other,with,potent'
p62968
(F1
F0.00014334862385321102
I1
I0
I1
tp62969
sS'of,subjects,dosed'
p62970
(F1
F0.00028669724770642203
I2
I0
I2
tp62971
sS'potent,cyp3a4,inhibitors'
p62972
(F1
F0.00028669724770642203
I2
I0
I2
tp62973
sS'some,including,have'
p62974
(F1
F0.00028669724770642203
I2
I0
I2
tp62975
sS'grams,three,times'
p62976
(F1
F0.00014334862385321102
I1
I0
I1
tp62977
sS'a4,or,st'
p62978
(F1
F0.00014334862385321102
I1
I0
I1
tp62979
sS'administration,of,indocin'
p62980
(F1
F0.00014334862385321102
I1
I0
I1
tp62981
sS'may,inhibit,k'
p62982
(F1
F0.00014334862385321102
I0
I1
I-1
tp62983
sS'decreased,with,coadministration'
p62984
(F1
F0.00028669724770642203
I2
I0
I2
tp62985
sS'rate,and,extent'
p62986
(F0
F0
I2
I2
I0
tp62987
sS'in,fat,and'
p62988
(F1
F0.00014334862385321102
I0
I1
I-1
tp62989
sS'was,similar,to'
p62990
(F1
F0.00057339449541284407
I0
I4
I-4
tp62991
sS'potentiate,blood-pressure,and'
p62992
(F1
F0.00014334862385321102
I1
I0
I1
tp62993
sS'cancidas,did,not'
p62994
(F1
F0.00014334862385321102
I0
I1
I-1
tp62995
sS'rheumatoid,arthritis,n'
p62996
(F1
F0.00014334862385321102
I0
I1
I-1
tp62997
sS'of,the,metabolism'
p62998
(F1
F0.00014334862385321102
I1
I0
I1
tp62999
sS'with,compounds,that'
p63000
(F1
F0.00014334862385321102
I1
I0
I1
tp63001
sS'decrease,hepatic,toxicity'
p63002
(F1
F0.00014334862385321102
I1
I0
I1
tp63003
sS'blood,sampling,for'
p63004
(F1
F0.00014334862385321102
I0
I1
I-1
tp63005
sS'conjugation,at,nacmc'
p63006
(F1
F0.00014334862385321102
I0
I1
I-1
tp63007
sS'because,there,is'
p63008
(F1
F0.00028669724770642203
I2
I0
I2
tp63009
sS'bioavailabillty,when,they'
p63010
(F1
F0.00014334862385321102
I1
I0
I1
tp63011
sS'on,some,reports'
p63012
(F1
F0.00014334862385321102
I0
I1
I-1
tp63013
sS'urinary,homocysteine,following'
p63014
(F1
F0.00014334862385321102
I0
I1
I-1
tp63015
sS'this,article,looks'
p63016
(F1
F0.00014334862385321102
I0
I1
I-1
tp63017
sS'cimetidine,albendazole,sulfoxide'
p63018
(F1
F0.00014334862385321102
I1
I0
I1
tp63019
sS'interaction,study,of'
p63020
(F1
F0.00043004587155963305
I0
I3
I-3
tp63021
sS'celebrex,is,introduced'
p63022
(F1
F0.00014334862385321102
I1
I0
I1
tp63023
sS'no,human,interaction'
p63024
(F1
F0.00028669724770642203
I0
I2
I-2
tp63025
sS'recommended,not,to'
p63026
(F1
F0.00043004587155963305
I3
I0
I3
tp63027
sS'received,under,steady'
p63028
(F1
F0.00014334862385321102
I0
I1
I-1
tp63029
sS'who,had,achieved'
p63030
(F1
F0.00014334862385321102
I0
I1
I-1
tp63031
sS'paraclinical,pattern,of'
p63032
(F1
F0.00014334862385321102
I0
I1
I-1
tp63033
sS'mitogenic,effect,of'
p63034
(F1
F0.00014334862385321102
I1
I0
I1
tp63035
sS'some,patients,taking'
p63036
(F1
F0.00014334862385321102
I1
I0
I1
tp63037
sS'fasted,and,the'
p63038
(F1
F0.00014334862385321102
I0
I1
I-1
tp63039
sS'discontinued,it,is'
p63040
(F1
F0.00014334862385321102
I1
I0
I1
tp63041
sS'the,relative,bioavailability'
p63042
(F1
F0.00014334862385321102
I0
I1
I-1
tp63043
sS'after,stopping,before'
p63044
(F1
F0.00014334862385321102
I1
I0
I1
tp63045
sS'ht1,agonists,has'
p63046
(F1
F0.00014334862385321102
I0
I1
I-1
tp63047
sS'generally,recommended,because'
p63048
(F1
F0.00028669724770642203
I2
I0
I2
tp63049
sS'patients,receiving,azopt'
p63050
(F1
F0.00014334862385321102
I0
I1
I-1
tp63051
sS'penicillin-type,are,administered'
p63052
(F1
F0.00014334862385321102
I1
I0
I1
tp63053
sS'pcp,dcg-iv,and'
p63054
(F1
F0.00014334862385321102
I0
I1
I-1
tp63055
sS'a,rapidly,hydrolyzed'
p63056
(F1
F0.00014334862385321102
I0
I1
I-1
tp63057
sS'of,oxypurines,in'
p63058
(F1
F0.00014334862385321102
I0
I1
I-1
tp63059
sS'at,min,after'
p63060
(F1
F0.00014334862385321102
I0
I1
I-1
tp63061
sS'to,experience,fewer'
p63062
(F1
F0.00014334862385321102
I0
I1
I-1
tp63063
sS'the,daily,dose'
p63064
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp63065
sS'frequency,and,severity'
p63066
(F1
F0.00014334862385321102
I1
I0
I1
tp63067
sS'and,mg,experienced'
p63068
(F1
F0.00014334862385321102
I1
I0
I1
tp63069
sS'tablet,was,given'
p63070
(F1
F0.00014334862385321102
I1
I0
I1
tp63071
sS'and,a,subsequent'
p63072
(F1
F0.00014334862385321102
I1
I0
I1
tp63073
sS'mtx,nsaids,tnf'
p63074
(F1
F0.00014334862385321102
I0
I1
I-1
tp63075
sS'inhibitory,concentration,index'
p63076
(F1
F0.00014334862385321102
I0
I1
I-1
tp63077
sS'deficiencies,constitute,the'
p63078
(F1
F0.00014334862385321102
I0
I1
I-1
tp63079
sS'system,such,as'
p63080
(F1
F0.00014334862385321102
I0
I1
I-1
tp63081
sS'produced,significant,decreases'
p63082
(F1
F0.00014334862385321102
I1
I0
I1
tp63083
sS'the,patient,to'
p63084
(F1
F0.00014334862385321102
I1
I0
I1
tp63085
sS'inhibitors,should,be'
p63086
(F1
F0.0008600917431192661
I6
I0
I6
tp63087
sS'experienced,users,particularly'
p63088
(F1
F0.00014334862385321102
I1
I0
I1
tp63089
sS'clearance,leading,to'
p63090
(F1
F0.00028669724770642203
I0
I2
I-2
tp63091
sS'low,molecular,weight'
p63092
(F1
F0.00014334862385321102
I0
I1
I-1
tp63093
sS'tambocor,and,were'
p63094
(F1
F0.00014334862385321102
I0
I1
I-1
tp63095
sS'the,hypoglycemic,action'
p63096
(F1
F0.00057339449541284407
I4
I0
I4
tp63097
sS'was,no,evidence'
p63098
(F1
F0.00028669724770642203
I0
I2
I-2
tp63099
sS'and,following,the'
p63100
(F1
F0.00014334862385321102
I0
I1
I-1
tp63101
sS'dosing,with,failed'
p63102
(F1
F0.00014334862385321102
I0
I1
I-1
tp63103
sS'and,beta,cells'
p63104
(F1
F0.00014334862385321102
I0
I1
I-1
tp63105
sS'felbatol,causes,a'
p63106
(F1
F0.00014334862385321102
I1
I0
I1
tp63107
sS'inducers,that,have'
p63108
(F1
F0.00014334862385321102
I1
I0
I1
tp63109
sS'in,zollinger-ellison,ze'
p63110
(F1
F0.00014334862385321102
I0
I1
I-1
tp63111
sS'dosing,of,mg'
p63112
(F1
F0.00014334862385321102
I0
I1
I-1
tp63113
sS'tiagabine,has,shown'
p63114
(F1
F0.00014334862385321102
I0
I1
I-1
tp63115
sS'mac,was,correlated'
p63116
(F1
F0.00014334862385321102
I0
I1
I-1
tp63117
sS'felt,that,in'
p63118
(F1
F0.00014334862385321102
I1
I0
I1
tp63119
sS'mineral,oil-concomitant,intake'
p63120
(F1
F0.00014334862385321102
I1
I0
I1
tp63121
sS'distilled,and,fermented'
p63122
(F1
F0.00014334862385321102
I0
I1
I-1
tp63123
sS'human,interaction,studies'
p63124
(F1
F0.00028669724770642203
I0
I2
I-2
tp63125
sS'crisis,until,the'
p63126
(F1
F0.00014334862385321102
I1
I0
I1
tp63127
sS'dosage,of,and'
p63128
(F1
F0.00014334862385321102
I0
I1
I-1
tp63129
sS'guide,to,further'
p63130
(F1
F0.00014334862385321102
I1
I0
I1
tp63131
sS'of,and,moderate'
p63132
(F1
F0.00014334862385321102
I1
I0
I1
tp63133
sS'evaluated,in,preclinical'
p63134
(F1
F0.00014334862385321102
I0
I1
I-1
tp63135
sS'and,the,total'
p63136
(F1
F0.00014334862385321102
I0
I1
I-1
tp63137
sS'a4,would,be'
p63138
(F1
F0.00014334862385321102
I1
I0
I1
tp63139
sS'in,in,vitro'
p63140
(F1
F0.00028669724770642203
I0
I2
I-2
tp63141
sS'vet,or,the'
p63142
(F1
F0.00014334862385321102
I1
I0
I1
tp63143
sS'three,pharmacokinetic,studies'
p63144
(F1
F0.00014334862385321102
I0
I1
I-1
tp63145
sS'other,hand,the'
p63146
(F1
F0.00014334862385321102
I0
I1
I-1
tp63147
sS'at,doses,of'
p63148
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp63149
sS'during,treatment,and'
p63150
(F1
F0.00014334862385321102
I1
I0
I1
tp63151
sS'cumulative,doses,of'
p63152
(F1
F0.00014334862385321102
I1
I0
I1
tp63153
sS'ml,when,was'
p63154
(F1
F0.00014334862385321102
I0
I1
I-1
tp63155
sS'corn,oil,ml'
p63156
(F1
F0.00014334862385321102
I0
I1
I-1
tp63157
sS'lodine,or,any'
p63158
(F1
F0.00014334862385321102
I0
I1
I-1
tp63159
sS'contraceptives,an,interaction'
p63160
(F1
F0.00014334862385321102
I1
I0
I1
tp63161
sS'every,hours,should'
p63162
(F1
F0.00014334862385321102
I1
I0
I1
tp63163
sS'effects,prolonged,sodation'
p63164
(F1
F0.00014334862385321102
I1
I0
I1
tp63165
sS'qt,interval,certain'
p63166
(F1
F0.00028669724770642203
I2
I0
I2
tp63167
sS'combining,with,other'
p63168
(F1
F0.00014334862385321102
I1
I0
I1
tp63169
sS'activity,may,enhance'
p63170
(F1
F0.00014334862385321102
I1
I0
I1
tp63171
sS'theoretically,may,potentiate'
p63172
(F1
F0.00014334862385321102
I1
I0
I1
tp63173
sS'because,of,reports'
p63174
(F1
F0.00014334862385321102
I1
I0
I1
tp63175
sS'systemic,medications,were'
p63176
(F1
F0.00014334862385321102
I1
I0
I1
tp63177
sS'of,agents,in'
p63178
(F1
F0.00014334862385321102
I0
I1
I-1
tp63179
sS'other,and,type'
p63180
(F1
F0.00014334862385321102
I1
I0
I1
tp63181
sS'alerted,to,the'
p63182
(F1
F0.00014334862385321102
I0
I1
I-1
tp63183
sS'human,pharmacokinetic,data'
p63184
(F1
F0.00014334862385321102
I1
I0
I1
tp63185
sS'of,nuromax,and'
p63186
(F1
F0.00014334862385321102
I0
I1
I-1
tp63187
sS'characterized,to,define'
p63188
(F1
F0.00014334862385321102
I0
I1
I-1
tp63189
sS'result,in,clinically-'
p63190
(F1
F0.00014334862385321102
I0
I1
I-1
tp63191
sS'each,may,be'
p63192
(F1
F0.00014334862385321102
I0
I1
I-1
tp63193
sS'impact,on,the'
p63194
(F1
F0.00014334862385321102
I1
I0
I1
tp63195
sS'the,early,components'
p63196
(F1
F0.00014334862385321102
I1
I0
I1
tp63197
sS'mg,starlix,three'
p63198
(F1
F0.00014334862385321102
I0
I1
I-1
tp63199
sS'pyrantel,antiminth,taking'
p63200
(F1
F0.00014334862385321102
I1
I0
I1
tp63201
sS'both,free,and'
p63202
(F1
F0.00014334862385321102
I1
I0
I1
tp63203
sS'greater,when,and'
p63204
(F1
F0.00014334862385321102
I1
I0
I1
tp63205
sS'were,co-administered,has'
p63206
(F1
F0.00014334862385321102
I1
I0
I1
tp63207
sS'to,in,of'
p63208
(F1
F0.00014334862385321102
I1
I0
I1
tp63209
sS'therapy,with,an'
p63210
(F1
F0.00014334862385321102
I1
I0
I1
tp63211
sS'produced,minor,changes'
p63212
(F1
F0.00014334862385321102
I1
I0
I1
tp63213
sS'since,and,may'
p63214
(F1
F0.00014334862385321102
I1
I0
I1
tp63215
sS'level,that,was'
p63216
(F1
F0.00014334862385321102
I0
I1
I-1
tp63217
sS'enhanced,when,alfenta'
p63218
(F1
F0.00014334862385321102
I1
I0
I1
tp63219
sS'blood,pressure,effect'
p63220
(F1
F0.00014334862385321102
I1
I0
I1
tp63221
sS'serum,concentrations,should'
p63222
(F1
F0.00043004587155963305
I3
I0
I3
tp63223
sS'characterize,the,steady-state'
p63224
(F1
F0.00014334862385321102
I0
I1
I-1
tp63225
sS'properties,such,as'
p63226
(F1
F0.00014334862385321102
I1
I0
I1
tp63227
sS'ranging,from,to'
p63228
(F1
F0.00028669724770642203
I2
I0
I2
tp63229
sS'blunted,by,and'
p63230
(F1
F0.00014334862385321102
I1
I0
I1
tp63231
sS'enablex,with,other'
p63232
(F1
F0.00014334862385321102
I1
I0
I1
tp63233
sS'administration,of,suggesting'
p63234
(F1
F0.00014334862385321102
I0
I1
I-1
tp63235
sS'diabetic,nsaids,like'
p63236
(F1
F0.00014334862385321102
I1
I0
I1
tp63237
sS'activity,and,may'
p63238
(F1
F0.00014334862385321102
I1
I0
I1
tp63239
sS'suggest,that,the'
p63240
(F1
F0.00057339449541284407
I4
I0
I4
tp63241
sS'did,not,result'
p63242
(F0.75
F0.0008600917431192661
I1
I7
I-6
tp63243
sS'when,patients,being'
p63244
(F1
F0.00014334862385321102
I0
I1
I-1
tp63245
sS'major,metabolic,pathway'
p63246
(F1
F0.00014334862385321102
I0
I1
I-1
tp63247
sS'polymer,p,app'
p63248
(F1
F0.00014334862385321102
I0
I1
I-1
tp63249
sS'experience,enhanced,side'
p63250
(F1
F0.00014334862385321102
I1
I0
I1
tp63251
sS'inducer,of,microsomal'
p63252
(F1
F0.00014334862385321102
I0
I1
I-1
tp63253
sS'glyburide,the,concomitant'
p63254
(F1
F0.00014334862385321102
I1
I0
I1
tp63255
sS'or,type,it'
p63256
(F1
F0.00014334862385321102
I1
I0
I1
tp63257
sS'johns,wort,theo-dur'
p63258
(F1
F0.00014334862385321102
I1
I0
I1
tp63259
sS'molecule,thereby,increasing'
p63260
(F1
F0.00028669724770642203
I2
I0
I2
tp63261
sS'of,may,potentiate'
p63262
(F1
F0.00014334862385321102
I1
I0
I1
tp63263
sS'supplement,st,johns'
p63264
(F1
F0.00014334862385321102
I0
I1
I-1
tp63265
sS'usedas,the,sole'
p63266
(F1
F0.00014334862385321102
I1
I0
I1
tp63267
sS'at,different,times'
p63268
(F1
F0.00014334862385321102
I0
I1
I-1
tp63269
sS'the,degree,of'
p63270
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp63271
sS'cause,striking,and'
p63272
(F1
F0.00028669724770642203
I2
I0
I2
tp63273
sS'on,day,relative'
p63274
(F1
F0.00014334862385321102
I1
I0
I1
tp63275
sS'mixed,with,nph'
p63276
(F1
F0.00014334862385321102
I0
I1
I-1
tp63277
sS'moieties,are,known'
p63278
(F1
F0.00014334862385321102
I0
I1
I-1
tp63279
sS'isoform,also,involved'
p63280
(F1
F0.00014334862385321102
I1
I0
I1
tp63281
sS'dosage,of,should'
p63282
(F0
F0
I1
I1
I0
tp63283
sS'patients,who,discontinue'
p63284
(F1
F0.00014334862385321102
I1
I0
I1
tp63285
sS'mg,daily,the'
p63286
(F1
F0.00014334862385321102
I1
I0
I1
tp63287
sS'further,deterioration,of'
p63288
(F1
F0.00028669724770642203
I2
I0
I2
tp63289
sS'approximately,twice,those'
p63290
(F1
F0.00014334862385321102
I1
I0
I1
tp63291
sS'by,about,in'
p63292
(F1
F0.00028669724770642203
I2
I0
I2
tp63293
sS'be,treated,with'
p63294
(F0
F0
I1
I1
I0
tp63295
sS'empiric,adjustment,of'
p63296
(F1
F0.00014334862385321102
I0
I1
I-1
tp63297
sS'hydroxide-containing,maalox,on'
p63298
(F1
F0.00014334862385321102
I0
I1
I-1
tp63299
sS'when,administering,gleevec'
p63300
(F1
F0.00028669724770642203
I2
I0
I2
tp63301
sS'hydroxyphenyl,piperidine,prevents'
p63302
(F1
F0.00014334862385321102
I1
I0
I1
tp63303
sS'occur,with,the'
p63304
(F0
F0
I1
I1
I0
tp63305
sS'as,ace,inhibitors'
p63306
(F1
F0.00014334862385321102
I0
I1
I-1
tp63307
sS'to,desbutyl,levobupivacaine'
p63308
(F1
F0.00014334862385321102
I0
I1
I-1
tp63309
sS'significance,is,not'
p63310
(F0
F0
I1
I1
I0
tp63311
sS'levels,and,valproic'
p63312
(F1
F0.00014334862385321102
I1
I0
I1
tp63313
sS'while,taking,acarbose'
p63314
(F1
F0.00014334862385321102
I0
I1
I-1
tp63315
sS'uroxatral,and,other'
p63316
(F1
F0.00014334862385321102
I0
I1
I-1
tp63317
sS'not,experience,an'
p63318
(F1
F0.00014334862385321102
I0
I1
I-1
tp63319
sS'multivitamins,or,other'
p63320
(F1
F0.00014334862385321102
I1
I0
I1
tp63321
sS'be,administered,within'
p63322
(F1
F0.00014334862385321102
I1
I0
I1
tp63323
sS'shown,to,alter'
p63324
(F1
F0.00014334862385321102
I0
I1
I-1
tp63325
sS'of,some,has'
p63326
(F1
F0.00014334862385321102
I1
I0
I1
tp63327
sS'given,consideration,in'
p63328
(F1
F0.0010034403669724771
I7
I0
I7
tp63329
sS'meals,for,four'
p63330
(F1
F0.00014334862385321102
I0
I1
I-1
tp63331
sS'that,in,alcoholics'
p63332
(F1
F0.00014334862385321102
I0
I1
I-1
tp63333
sS'minutes,following,administration'
p63334
(F1
F0.00014334862385321102
I1
I0
I1
tp63335
sS'to,were,not'
p63336
(F1
F0.00014334862385321102
I0
I1
I-1
tp63337
sS'a,comparison,of'
p63338
(F1
F0.00014334862385321102
I1
I0
I1
tp63339
sS'the,continued,need'
p63340
(F1
F0.00014334862385321102
I0
I1
I-1
tp63341
sS'and,impaired,psychomotor'
p63342
(F1
F0.00028669724770642203
I2
I0
I2
tp63343
sS'be,well,acquainted'
p63344
(F1
F0.00014334862385321102
I0
I1
I-1
tp63345
sS'studied,following,subcutaneous'
p63346
(F1
F0.00014334862385321102
I0
I1
I-1
tp63347
sS'and,cardiovascular,safety'
p63348
(F1
F0.00014334862385321102
I0
I1
I-1
tp63349
sS'may,have,additive'
p63350
(F1
F0.00043004587155963305
I3
I0
I3
tp63351
sS'for,example,since'
p63352
(F1
F0.00014334862385321102
I1
I0
I1
tp63353
sS'when,itraconazole,was'
p63354
(F1
F0.00014334862385321102
I1
I0
I1
tp63355
sS'drugs,which,themselves'
p63356
(F1
F0.00014334862385321102
I1
I0
I1
tp63357
sS'or,may,increase'
p63358
(F1
F0.00014334862385321102
I0
I1
I-1
tp63359
sS'observed,when,was'
p63360
(F1
F0.00014334862385321102
I1
I0
I1
tp63361
sS'are,equipotent,inducers'
p63362
(F1
F0.00014334862385321102
I0
I1
I-1
tp63363
sS'which,may,accentuate'
p63364
(F1
F0.00014334862385321102
I0
I1
I-1
tp63365
sS'of,mg,day'
p63366
(F0.14285714285714285
F0.00028669724770642203
I8
I6
I2
tp63367
sS'a,metabolite,of'
p63368
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp63369
sS'maximize,the,effects'
p63370
(F1
F0.00014334862385321102
I0
I1
I-1
tp63371
sS'with,in,five'
p63372
(F1
F0.00014334862385321102
I1
I0
I1
tp63373
sS'be,unaffected,by'
p63374
(F1
F0.00014334862385321102
I0
I1
I-1
tp63375
sS'treatment,with,equetrotm'
p63376
(F1
F0.00014334862385321102
I1
I0
I1
tp63377
sS'that,iressa,may'
p63378
(F1
F0.00014334862385321102
I1
I0
I1
tp63379
sS'anions,other,than'
p63380
(F1
F0.00014334862385321102
I0
I1
I-1
tp63381
sS'renal,excretion,of'
p63382
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp63383
sS'for,long,periods'
p63384
(F1
F0.00014334862385321102
I0
I1
I-1
tp63385
sS'hypotension,was,found'
p63386
(F1
F0.00014334862385321102
I0
I1
I-1
tp63387
sS'a,stimulator,of'
p63388
(F1
F0.00014334862385321102
I1
I0
I1
tp63389
sS'neuromuscular,block,may'
p63390
(F1
F0.00014334862385321102
I1
I0
I1
tp63391
sS'carinii,pneumonia,treatment'
p63392
(F1
F0.00014334862385321102
I1
I0
I1
tp63393
sS'phase,in,either'
p63394
(F1
F0.00014334862385321102
I0
I1
I-1
tp63395
sS'together,with,rr'
p63396
(F1
F0.00014334862385321102
I1
I0
I1
tp63397
sS'on,felbatol,phenytoin'
p63398
(F1
F0.00014334862385321102
I1
I0
I1
tp63399
sS'prostate-specific,antigen,psa'
p63400
(F1
F0.00014334862385321102
I0
I1
I-1
tp63401
sS'onset,and,may'
p63402
(F1
F0.00014334862385321102
I1
I0
I1
tp63403
sS'or,did,not'
p63404
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp63405
sS'pharmacokinetic,or,pharmacodynamic'
p63406
(F1
F0.00071674311926605509
I0
I5
I-5
tp63407
sS'and,alpha-adrenergic,stimulants'
p63408
(F1
F0.00014334862385321102
I1
I0
I1
tp63409
sS'adjustment,as,appropriate'
p63410
(F1
F0.00014334862385321102
I0
I1
I-1
tp63411
sS'other,highly,bound'
p63412
(F1
F0.00014334862385321102
I0
I1
I-1
tp63413
sS'that,the,coadministration'
p63414
(F1
F0.00014334862385321102
I0
I1
I-1
tp63415
sS'other,which,may'
p63416
(F1
F0.00028669724770642203
I2
I0
I2
tp63417
sS'in,area,under'
p63418
(F1
F0.00014334862385321102
I1
I0
I1
tp63419
sS'produce,vertigo,syncope'
p63420
(F1
F0.00028669724770642203
I2
I0
I2
tp63421
sS'either,alone,the'
p63422
(F1
F0.00014334862385321102
I1
I0
I1
tp63423
sS'fluconazole,and,the'
p63424
(F1
F0.00014334862385321102
I0
I1
I-1
tp63425
sS'blocking,properties,that'
p63426
(F1
F0.00028669724770642203
I2
I0
I2
tp63427
sS'with,to,extend'
p63428
(F1
F0.00014334862385321102
I1
I0
I1
tp63429
sS'cardiovascular,effects,may'
p63430
(F1
F0.00014334862385321102
I1
I0
I1
tp63431
sS'who,inactivate,by'
p63432
(F1
F0.00014334862385321102
I1
I0
I1
tp63433
sS'risk,of,adverse'
p63434
(F1
F0.00028669724770642203
I0
I2
I-2
tp63435
sS'ibandronate,should,be'
p63436
(F1
F0.00014334862385321102
I1
I0
I1
tp63437
sS'or,aluminum-containing,products'
p63438
(F1
F0.00014334862385321102
I1
I0
I1
tp63439
sS'dosage,of,oral'
p63440
(F1
F0.00014334862385321102
I1
I0
I1
tp63441
sS'that,may,interfere'
p63442
(F1
F0.00028669724770642203
I2
I0
I2
tp63443
sS'aerobic,facultative,and'
p63444
(F1
F0.00014334862385321102
I0
I1
I-1
tp63445
sS'occur,with,tests'
p63446
(F1
F0.00028669724770642203
I0
I2
I-2
tp63447
sS'that,in,control'
p63448
(F1
F0.00014334862385321102
I0
I1
I-1
tp63449
sS'some,resulting,in'
p63450
(F1
F0.00043004587155963305
I3
I0
I3
tp63451
sS'hydoxide,hydrochloride,ferrous'
p63452
(F1
F0.00014334862385321102
I1
I0
I1
tp63453
sS'test,agent,for'
p63454
(F1
F0.00014334862385321102
I0
I1
I-1
tp63455
sS'contribute,to,a'
p63456
(F1
F0.00014334862385321102
I1
I0
I1
tp63457
sS'heart,function,is'
p63458
(F1
F0.00014334862385321102
I1
I0
I1
tp63459
sS'hydroxide,containing,to'
p63460
(F1
F0.00014334862385321102
I1
I0
I1
tp63461
sS'the,has,reduced'
p63462
(F1
F0.00014334862385321102
I1
I0
I1
tp63463
sS'reported,in,a'
p63464
(F1
F0.00043004587155963305
I3
I0
I3
tp63465
sS'with,racemic,mg'
p63466
(F1
F0.00014334862385321102
I1
I0
I1
tp63467
sS'the,steroidal,agent'
p63468
(F1
F0.00014334862385321102
I1
I0
I1
tp63469
sS'require,dose,adjustment'
p63470
(F1
F0.00014334862385321102
I0
I1
I-1
tp63471
sS'concurent,therapy,with'
p63472
(F1
F0.00014334862385321102
I1
I0
I1
tp63473
sS'bio-rad,laboratories,platelia'
p63474
(F1
F0.00014334862385321102
I0
I1
I-1
tp63475
sS'prothrombin,times,were'
p63476
(F1
F0.00014334862385321102
I0
I1
I-1
tp63477
sS'liver,and,in'
p63478
(F1
F0.00014334862385321102
I1
I0
I1
tp63479
sS'metabolite,at,least'
p63480
(F1
F0.00014334862385321102
I1
I0
I1
tp63481
sS'by,cimetidines,known'
p63482
(F1
F0.00014334862385321102
I1
I0
I1
tp63483
sS'antagonist,and,another'
p63484
(F1
F0.00014334862385321102
I1
I0
I1
tp63485
sS'with,occasional,doses'
p63486
(F1
F0.00014334862385321102
I0
I1
I-1
tp63487
sS'gallate,showed,the'
p63488
(F1
F0.00014334862385321102
I0
I1
I-1
tp63489
sS'of,sular,tended'
p63490
(F1
F0.00014334862385321102
I1
I0
I1
tp63491
sS'inhibition,of,this'
p63492
(F1
F0.00014334862385321102
I0
I1
I-1
tp63493
sS'antiaddictive,efficacy,toxicity'
p63494
(F1
F0.00014334862385321102
I0
I1
I-1
tp63495
sS'could,prolong,the'
p63496
(F1
F0.00014334862385321102
I1
I0
I1
tp63497
sS'containing,divalent,and'
p63498
(F1
F0.00028669724770642203
I2
I0
I2
tp63499
sS'iv,attenuate,loss'
p63500
(F1
F0.00014334862385321102
I1
I0
I1
tp63501
sS'protease,inhibitors,macrolide'
p63502
(F1
F0.00014334862385321102
I0
I1
I-1
tp63503
sS'significantly,reduced,when'
p63504
(F1
F0.00014334862385321102
I0
I1
I-1
tp63505
sS'no,significant,drug-drug'
p63506
(F1
F0.00043004587155963305
I0
I3
I-3
tp63507
sS'other,substances,demonstrated'
p63508
(F1
F0.00014334862385321102
I1
I0
I1
tp63509
sS'as,or,use'
p63510
(F1
F0.00014334862385321102
I1
I0
I1
tp63511
sS'serious,infections,and'
p63512
(F1
F0.00028669724770642203
I2
I0
I2
tp63513
sS'were,treated,concurrently'
p63514
(F1
F0.00014334862385321102
I0
I1
I-1
tp63515
sS'because,there,have'
p63516
(F1
F0.00014334862385321102
I1
I0
I1
tp63517
sS'the,brovana,treated'
p63518
(F1
F0.00014334862385321102
I0
I1
I-1
tp63519
sS'superiority,compared,with'
p63520
(F1
F0.00014334862385321102
I0
I1
I-1
tp63521
sS'coadministration,with,that'
p63522
(F1
F0.00014334862385321102
I1
I0
I1
tp63523
sS'treat,pneumocystis,carinii'
p63524
(F1
F0.00014334862385321102
I1
I0
I1
tp63525
sS'in,association,with'
p63526
(F0.5
F0.00028669724770642203
I3
I1
I2
tp63527
sS'that,have,secondary'
p63528
(F1
F0.00014334862385321102
I1
I0
I1
tp63529
sS'had,no,clinically'
p63530
(F1
F0.00071674311926605509
I0
I5
I-5
tp63531
sS'system,maybe,useful'
p63532
(F1
F0.00014334862385321102
I0
I1
I-1
tp63533
sS'indicated,by,elevated'
p63534
(F1
F0.00014334862385321102
I1
I0
I1
tp63535
sS'are,using,the'
p63536
(F1
F0.00014334862385321102
I1
I0
I1
tp63537
sS'torsades,de,pointes-type'
p63538
(F1
F0.00014334862385321102
I0
I1
I-1
tp63539
sS'levels,and,followed'
p63540
(F1
F0.00014334862385321102
I0
I1
I-1
tp63541
sS'administration,with,signs'
p63542
(F1
F0.00014334862385321102
I1
I0
I1
tp63543
sS'in,a,mouse'
p63544
(F1
F0.00014334862385321102
I0
I1
I-1
tp63545
sS'of,with,atacand'
p63546
(F1
F0.00014334862385321102
I1
I0
I1
tp63547
sS'chronically,receiving,resulted'
p63548
(F1
F0.00014334862385321102
I0
I1
I-1
tp63549
sS'renal,prostaglandins,and'
p63550
(F1
F0.00014334862385321102
I0
I1
I-1
tp63551
sS'of,may,lower'
p63552
(F1
F0.00014334862385321102
I1
I0
I1
tp63553
sS'naflu,compared,to'
p63554
(F1
F0.00014334862385321102
I0
I1
I-1
tp63555
sS'para-aminosalicylic,acid,and'
p63556
(F1
F0.00014334862385321102
I1
I0
I1
tp63557
sS'are,excreted,in'
p63558
(F1
F0.00014334862385321102
I0
I1
I-1
tp63559
sS'prinivil,an,additional'
p63560
(F1
F0.00014334862385321102
I1
I0
I1
tp63561
sS'may,delay,or'
p63562
(F1
F0.00014334862385321102
I1
I0
I1
tp63563
sS'containing,cremophor,el'
p63564
(F1
F0.00014334862385321102
I1
I0
I1
tp63565
sS'usp,is,a'
p63566
(F1
F0.00014334862385321102
I1
I0
I1
tp63567
sS'be,the,smallest'
p63568
(F1
F0.00014334862385321102
I0
I1
I-1
tp63569
sS'early,as,three'
p63570
(F1
F0.00014334862385321102
I1
I0
I1
tp63571
sS'and,their,combined'
p63572
(F1
F0.00014334862385321102
I1
I0
I1
tp63573
sS'swine,has,resulted'
p63574
(F1
F0.00014334862385321102
I0
I1
I-1
tp63575
sS'use,in,ambulatory'
p63576
(F1
F0.00014334862385321102
I0
I1
I-1
tp63577
sS'at,all,with'
p63578
(F1
F0.00014334862385321102
I1
I0
I1
tp63579
sS'however,due,to'
p63580
(F1
F0.00014334862385321102
I1
I0
I1
tp63581
sS'epidural,injection,clonidine'
p63582
(F1
F0.00014334862385321102
I1
I0
I1
tp63583
sS'other,day,and'
p63584
(F1
F0.00014334862385321102
I0
I1
I-1
tp63585
sS'blocking,agents,with'
p63586
(F1
F0.00014334862385321102
I1
I0
I1
tp63587
sS'usual,daily,maintenance'
p63588
(F1
F0.00014334862385321102
I1
I0
I1
tp63589
sS'assigned,in,a'
p63590
(F1
F0.00014334862385321102
I0
I1
I-1
tp63591
sS'of,cyp3a4,did'
p63592
(F1
F0.00014334862385321102
I0
I1
I-1
tp63593
sS'that,a,satisfactory'
p63594
(F1
F0.00014334862385321102
I1
I0
I1
tp63595
sS'on,travelers,receiving'
p63596
(F1
F0.00014334862385321102
I1
I0
I1
tp63597
sS'the,antithrombotic,agent'
p63598
(F1
F0.00014334862385321102
I1
I0
I1
tp63599
sS'antidiabetic,oral,agents'
p63600
(F1
F0.00057339449541284407
I0
I4
I-4
tp63601
sS'phosphorylation,of,zdv'
p63602
(F1
F0.00014334862385321102
I1
I0
I1
tp63603
sS's,nephrotoxicity,and'
p63604
(F1
F0.00014334862385321102
I0
I1
I-1
tp63605
sS'metabolizers,of,the'
p63606
(F1
F0.00014334862385321102
I1
I0
I1
tp63607
sS'during,omnicef,therapy'
p63608
(F1
F0.00028669724770642203
I2
I0
I2
tp63609
sS'antidepressant,when,therapy'
p63610
(F1
F0.00014334862385321102
I1
I0
I1
tp63611
sS'other,interactions,vardenafil'
p63612
(F1
F0.00014334862385321102
I0
I1
I-1
tp63613
sS'chloral,hydrate,may'
p63614
(F1
F0.00014334862385321102
I1
I0
I1
tp63615
sS'of,angiotensin,converting'
p63616
(F1
F0.00043004587155963305
I3
I0
I3
tp63617
sS'glycosides,heart,medicine'
p63618
(F1
F0.00014334862385321102
I1
I0
I1
tp63619
sS'tests,performed,in'
p63620
(F1
F0.00014334862385321102
I0
I1
I-1
tp63621
sS'enzyme-inducing,properties,of'
p63622
(F1
F0.00014334862385321102
I1
I0
I1
tp63623
sS'oral,and,fluvoxamine'
p63624
(F1
F0.00014334862385321102
I1
I0
I1
tp63625
sS'agents,folic,acid'
p63626
(F1
F0.00014334862385321102
I0
I1
I-1
tp63627
sS'ie,increased,prothrombin'
p63628
(F1
F0.00028669724770642203
I2
I0
I2
tp63629
sS'that,should,not'
p63630
(F0.5
F0.00028669724770642203
I3
I1
I2
tp63631
sS'when,initiating,adjusting'
p63632
(F1
F0.00057339449541284407
I4
I0
I4
tp63633
sS'permitil,compazine,phenergan'
p63634
(F1
F0.00014334862385321102
I0
I1
I-1
tp63635
sS'were,no,alterations'
p63636
(F1
F0.00014334862385321102
I0
I1
I-1
tp63637
sS'no,study,data'
p63638
(F1
F0.00014334862385321102
I1
I0
I1
tp63639
sS'the,central,stimulant'
p63640
(F1
F0.00057339449541284407
I4
I0
I4
tp63641
sS'interactions,attributed,to'
p63642
(F1
F0.00014334862385321102
I1
I0
I1
tp63643
sS'or,from,breast'
p63644
(F1
F0.00014334862385321102
I0
I1
I-1
tp63645
sS'time,is,recommended'
p63646
(F1
F0.00028669724770642203
I2
I0
I2
tp63647
sS'been,used,concurrently'
p63648
(F1
F0.00014334862385321102
I0
I1
I-1
tp63649
sS'johns,wort,based'
p63650
(F1
F0.00014334862385321102
I0
I1
I-1
tp63651
sS'when,plasma,concentrations'
p63652
(F1
F0.00014334862385321102
I1
I0
I1
tp63653
sS'the,patients,on'
p63654
(F1
F0.00014334862385321102
I0
I1
I-1
tp63655
sS'acamprosate,does,not'
p63656
(F1
F0.00014334862385321102
I0
I1
I-1
tp63657
sS'may,significantly,decrease'
p63658
(F1
F0.00014334862385321102
I1
I0
I1
tp63659
sS'than,expected,antidepressant'
p63660
(F1
F0.00014334862385321102
I1
I0
I1
tp63661
sS'administered,with,or'
p63662
(F1
F0.00014334862385321102
I1
I0
I1
tp63663
sS'of,mg,b'
p63664
(F1
F0.00028669724770642203
I2
I0
I2
tp63665
sS'of,mg,a'
p63666
(F1
F0.00014334862385321102
I1
I0
I1
tp63667
sS'exposure,when,coadministered'
p63668
(F1
F0.00014334862385321102
I1
I0
I1
tp63669
sS'effects,on,decreased'
p63670
(F1
F0.00028669724770642203
I2
I0
I2
tp63671
sS'of,mg,l'
p63672
(F1
F0.00014334862385321102
I0
I1
I-1
tp63673
sS'proteins,indicate,that'
p63674
(F1
F0.00014334862385321102
I0
I1
I-1
tp63675
sS'because,false,positive'
p63676
(F1
F0.00014334862385321102
I0
I1
I-1
tp63677
sS'variability,and,limited'
p63678
(F1
F0.00014334862385321102
I0
I1
I-1
tp63679
sS'n-oxide,were,elevated'
p63680
(F1
F0.00014334862385321102
I0
I1
I-1
tp63681
sS'potentiation,by,mao'
p63682
(F1
F0.00014334862385321102
I1
I0
I1
tp63683
sS'prothrombin,time,pt'
p63684
(F1
F0.00014334862385321102
I1
I0
I1
tp63685
sS'acarbose,may,affect'
p63686
(F1
F0.00014334862385321102
I0
I1
I-1
tp63687
sS'with,each,of'
p63688
(F1
F0.00014334862385321102
I0
I1
I-1
tp63689
sS'the,strength,of'
p63690
(F1
F0.00014334862385321102
I1
I0
I1
tp63691
sS'for,increased,sedation'
p63692
(F1
F0.00014334862385321102
I1
I0
I1
tp63693
sS'a,mg,capsule'
p63694
(F1
F0.00014334862385321102
I1
I0
I1
tp63695
sS'changes,seen,with'
p63696
(F1
F0.00014334862385321102
I0
I1
I-1
tp63697
sS'accumulation,of,both'
p63698
(F1
F0.00014334862385321102
I1
I0
I1
tp63699
sS'contained,in,proprietary'
p63700
(F1
F0.00014334862385321102
I1
I0
I1
tp63701
sS'the,levels,or'
p63702
(F1
F0.00014334862385321102
I1
I0
I1
tp63703
sS'with,mefloquine,although'
p63704
(F1
F0.00014334862385321102
I1
I0
I1
tp63705
sS'to,have,a'
p63706
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp63707
sS'is,initiated,a'
p63708
(F1
F0.00014334862385321102
I0
I1
I-1
tp63709
sS'particles,of,were'
p63710
(F1
F0.00014334862385321102
I0
I1
I-1
tp63711
sS'taken,when,enablex'
p63712
(F1
F0.00014334862385321102
I1
I0
I1
tp63713
sS'found,minutes,post'
p63714
(F1
F0.00014334862385321102
I0
I1
I-1
tp63715
sS'at,m,or'
p63716
(F1
F0.00014334862385321102
I1
I0
I1
tp63717
sS'most,common,medications'
p63718
(F1
F0.00014334862385321102
I0
I1
I-1
tp63719
sS'the,levels,of'
p63720
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp63721
sS'sucralfate,should,not'
p63722
(F1
F0.00014334862385321102
I1
I0
I1
tp63723
sS'with,less,enzyme'
p63724
(F1
F0.00014334862385321102
I0
I1
I-1
tp63725
sS'are,developed,regarding'
p63726
(F1
F0.00014334862385321102
I0
I1
I-1
tp63727
sS'in,or,concentrations'
p63728
(F1
F0.00014334862385321102
I0
I1
I-1
tp63729
sS'with,very,high'
p63730
(F1
F0.00014334862385321102
I0
I1
I-1
tp63731
sS'enzyme,group,specifically'
p63732
(F1
F0.00014334862385321102
I0
I1
I-1
tp63733
sS'advised,against,the'
p63734
(F0
F0
I1
I1
I0
tp63735
sS'and,potassium-sparing,each'
p63736
(F1
F0.00014334862385321102
I0
I1
I-1
tp63737
sS'chemotherapy,cardiotoxic,or'
p63738
(F1
F0.00014334862385321102
I1
I0
I1
tp63739
sS'taken,into,consideration'
p63740
(F1
F0.00014334862385321102
I1
I0
I1
tp63741
sS'additive,effects,such'
p63742
(F1
F0.00014334862385321102
I1
I0
I1
tp63743
sS'most,closely,associated'
p63744
(F1
F0.00014334862385321102
I0
I1
I-1
tp63745
sS'containing,or,other'
p63746
(F1
F0.00014334862385321102
I1
I0
I1
tp63747
sS'of,a,increase'
p63748
(F1
F0.00014334862385321102
I1
I0
I1
tp63749
sS'was,administered,minutes'
p63750
(F1
F0.00014334862385321102
I1
I0
I1
tp63751
sS'recommended,as,they'
p63752
(F1
F0.00014334862385321102
I0
I1
I-1
tp63753
sS'the,urinary,recovery'
p63754
(F1
F0.00014334862385321102
I0
I1
I-1
tp63755
sS'with,full,recovery'
p63756
(F1
F0.00014334862385321102
I0
I1
I-1
tp63757
sS'to,approximately,fold'
p63758
(F1
F0.00014334862385321102
I1
I0
I1
tp63759
sS'and,class,iii'
p63760
(F1
F0.00014334862385321102
I1
I0
I1
tp63761
sS'anxiety,depressive,symptoms'
p63762
(F1
F0.00014334862385321102
I0
I1
I-1
tp63763
sS'to,use,short-acting'
p63764
(F1
F0.00014334862385321102
I1
I0
I1
tp63765
sS'on,indicates,that'
p63766
(F1
F0.00014334862385321102
I1
I0
I1
tp63767
sS'controlled,clinical,trial'
p63768
(F1
F0.00014334862385321102
I0
I1
I-1
tp63769
sS'results,of,the'
p63770
(F1
F0.00014334862385321102
I0
I1
I-1
tp63771
sS'concentrations,may,be'
p63772
(F1
F0.00014334862385321102
I1
I0
I1
tp63773
sS'of,hcl,should'
p63774
(F1
F0.00014334862385321102
I1
I0
I1
tp63775
sS'ethanol,or,triazolam'
p63776
(F1
F0.00014334862385321102
I0
I1
I-1
tp63777
sS'of,increased,gastric'
p63778
(F1
F0.00014334862385321102
I0
I1
I-1
tp63779
sS'contraceptives,estrogens,tend'
p63780
(F1
F0.00014334862385321102
I0
I1
I-1
tp63781
sS'or,should,not'
p63782
(F1
F0.00014334862385321102
I1
I0
I1
tp63783
sS'both,and,can'
p63784
(F1
F0.00014334862385321102
I1
I0
I1
tp63785
sS'avoid,the,occurrence'
p63786
(F1
F0.00014334862385321102
I0
I1
I-1
tp63787
sS'interaction,of,intramuscularly'
p63788
(F1
F0.00014334862385321102
I0
I1
I-1
tp63789
sS'agent,which,has'
p63790
(F1
F0.00014334862385321102
I0
I1
I-1
tp63791
sS'aprepitant,with,each'
p63792
(F1
F0.00014334862385321102
I1
I0
I1
tp63793
sS'similarly,to,or'
p63794
(F1
F0.00014334862385321102
I1
I0
I1
tp63795
sS'of,the,volume'
p63796
(F1
F0.00014334862385321102
I0
I1
I-1
tp63797
sS'with,lotensin,can'
p63798
(F1
F0.00014334862385321102
I1
I0
I1
tp63799
sS'failing,heart,can'
p63800
(F1
F0.00014334862385321102
I0
I1
I-1
tp63801
sS'nsaids,the,concomitant'
p63802
(F1
F0.00014334862385321102
I1
I0
I1
tp63803
sS'are,all,metabolized'
p63804
(F1
F0.00014334862385321102
I1
I0
I1
tp63805
sS'of,time,concomitant'
p63806
(F1
F0.00014334862385321102
I0
I1
I-1
tp63807
sS'demonstrated,to,interfere'
p63808
(F1
F0.00014334862385321102
I1
I0
I1
tp63809
sS'infusion,to,maintain'
p63810
(F1
F0.00014334862385321102
I0
I1
I-1
tp63811
sS'affect,the,course'
p63812
(F1
F0.00014334862385321102
I0
I1
I-1
tp63813
sS'increase,by,about'
p63814
(F1
F0.00014334862385321102
I1
I0
I1
tp63815
sS'only,a,increase'
p63816
(F1
F0.00014334862385321102
I1
I0
I1
tp63817
sS'or,parenteral,forms'
p63818
(F1
F0.00014334862385321102
I0
I1
I-1
tp63819
sS'in,increases,in'
p63820
(F1
F0.00057339449541284407
I4
I0
I4
tp63821
sS'for,either,the'
p63822
(F1
F0.0008600917431192661
I0
I6
I-6
tp63823
sS'when,intravenous,and'
p63824
(F1
F0.00014334862385321102
I1
I0
I1
tp63825
sS'in,their,dosage'
p63826
(F1
F0.00014334862385321102
I1
I0
I1
tp63827
sS'after,starting,the'
p63828
(F1
F0.00014334862385321102
I0
I1
I-1
tp63829
sS'to,the,prescribing'
p63830
(F1
F0.00014334862385321102
I0
I1
I-1
tp63831
sS'with,alphagan,p'
p63832
(F1
F0.00028669724770642203
I2
I0
I2
tp63833
sS'administered,agents,but'
p63834
(F1
F0.00014334862385321102
I1
I0
I1
tp63835
sS'of,is,approximately'
p63836
(F1
F0.00014334862385321102
I1
I0
I1
tp63837
sS'for,days,in'
p63838
(F1
F0.00014334862385321102
I1
I0
I1
tp63839
sS'toxic,levels,of'
p63840
(F1
F0.00014334862385321102
I1
I0
I1
tp63841
sS'theoretically,l-arginine,supplements'
p63842
(F1
F0.00014334862385321102
I1
I0
I1
tp63843
sS'mean,cmax,a'
p63844
(F1
F0.00014334862385321102
I1
I0
I1
tp63845
sS'and,some,are'
p63846
(F1
F0.00014334862385321102
I0
I1
I-1
tp63847
sS'period,when,used'
p63848
(F1
F0.00057339449541284407
I4
I0
I4
tp63849
sS'ethyl,increases,the'
p63850
(F1
F0.00014334862385321102
I1
I0
I1
tp63851
sS'of,mg,bid'
p63852
(F0.40000000000000002
F0.00057339449541284407
I7
I3
I4
tp63853
sS'and,its,n-demethylated'
p63854
(F1
F0.00014334862385321102
I0
I1
I-1
tp63855
sS'augment,the,hypotension'
p63856
(F1
F0.00014334862385321102
I1
I0
I1
tp63857
sS'of,mg,sodium'
p63858
(F1
F0.00014334862385321102
I1
I0
I1
tp63859
sS'be,drawn,regarding'
p63860
(F1
F0.00014334862385321102
I0
I1
I-1
tp63861
sS'tca,may,need'
p63862
(F1
F0.00014334862385321102
I1
I0
I1
tp63863
sS'monoamine,oxidase,mao'
p63864
(F0.20000000000000001
F0.00028669724770642203
I4
I6
I-2
tp63865
sS'of,the,non-ionized'
p63866
(F1
F0.00014334862385321102
I1
I0
I1
tp63867
sS'confirmation,should,be'
p63868
(F1
F0.00014334862385321102
I0
I1
I-1
tp63869
sS'levels,the,potential'
p63870
(F1
F0.00014334862385321102
I1
I0
I1
tp63871
sS'double-blind,study,of'
p63872
(F1
F0.00014334862385321102
I0
I1
I-1
tp63873
sS'or,pharmacodynamic,drug-drug'
p63874
(F1
F0.00014334862385321102
I0
I1
I-1
tp63875
sS'neurons,hyperpolarized,by'
p63876
(F1
F0.00014334862385321102
I0
I1
I-1
tp63877
sS'videx,therapy,see'
p63878
(F1
F0.00014334862385321102
I0
I1
I-1
tp63879
sS'potent,iiia4,inhibitor'
p63880
(F1
F0.00014334862385321102
I1
I0
I1
tp63881
sS'the,central,nervous'
p63882
(F1
F0.00028669724770642203
I2
I0
I2
tp63883
sS'since,the,excretion'
p63884
(F1
F0.00014334862385321102
I1
I0
I1
tp63885
sS'didanosine,it,is'
p63886
(F1
F0.00014334862385321102
I0
I1
I-1
tp63887
sS'and,inhaled,with'
p63888
(F1
F0.00014334862385321102
I0
I1
I-1
tp63889
sS'administration,of,pipracil'
p63890
(F1
F0.00014334862385321102
I0
I1
I-1
tp63891
sS'levels,be,monitored'
p63892
(F1
F0.0008600917431192661
I6
I0
I6
tp63893
sS'and,have,no'
p63894
(F1
F0.00014334862385321102
I0
I1
I-1
tp63895
sS'of,n-desmethyldiazepam,to'
p63896
(F1
F0.00014334862385321102
I0
I1
I-1
tp63897
sS'higher,than,mg'
p63898
(F1
F0.00028669724770642203
I0
I2
I-2
tp63899
sS'in,a,kg'
p63900
(F1
F0.00014334862385321102
I0
I1
I-1
tp63901
sS'been,performed,with'
p63902
(F1
F0.00014334862385321102
I0
I1
I-1
tp63903
sS'with,flolan,was'
p63904
(F1
F0.00014334862385321102
I1
I0
I1
tp63905
sS'drug,interactions,the'
p63906
(F1
F0.00014334862385321102
I1
I0
I1
tp63907
sS'acute,pulmonary,toxicity'
p63908
(F1
F0.00014334862385321102
I1
I0
I1
tp63909
sS'for,and,and'
p63910
(F1
F0.00028669724770642203
I0
I2
I-2
tp63911
sS'conjunction,with,one'
p63912
(F1
F0.00014334862385321102
I0
I1
I-1
tp63913
sS'is,initiated,or'
p63914
(F0
F0
I1
I1
I0
tp63915
sS'colestipol-concomitant,intake,of'
p63916
(F1
F0.00014334862385321102
I1
I0
I1
tp63917
sS'are,incompletely,responsive'
p63918
(F1
F0.00014334862385321102
I0
I1
I-1
tp63919
sS'checkerboard,assay,for'
p63920
(F1
F0.00014334862385321102
I0
I1
I-1
tp63921
sS'received,maoi,within'
p63922
(F1
F0.00014334862385321102
I1
I0
I1
tp63923
sS'gastrointestinal,ulceration,and'
p63924
(F1
F0.00014334862385321102
I1
I0
I1
tp63925
sS'potential,for,flolan'
p63926
(F1
F0.00014334862385321102
I1
I0
I1
tp63927
sS'need,to,increase'
p63928
(F1
F0.00014334862385321102
I1
I0
I1
tp63929
sS'is,a,member'
p63930
(F1
F0.00014334862385321102
I1
I0
I1
tp63931
sS'with,the,patch-clamp'
p63932
(F1
F0.00014334862385321102
I0
I1
I-1
tp63933
sS'and,or,bleeding'
p63934
(F1
F0.00028669724770642203
I2
I0
I2
tp63935
sS'the,residual,effects'
p63936
(F1
F0.00014334862385321102
I1
I0
I1
tp63937
sS'as,seen,with'
p63938
(F1
F0.00014334862385321102
I0
I1
I-1
tp63939
sS'effects,with,or'
p63940
(F1
F0.00014334862385321102
I1
I0
I1
tp63941
sS'no,significant,changes'
p63942
(F1
F0.00028669724770642203
I0
I2
I-2
tp63943
sS'active,ra,were'
p63944
(F1
F0.00028669724770642203
I2
I0
I2
tp63945
sS'decreased,blood,levels'
p63946
(F1
F0.00014334862385321102
I1
I0
I1
tp63947
sS'gl,with,four'
p63948
(F0
F0
I1
I1
I0
tp63949
sS'clearance,of,when'
p63950
(F1
F0.00014334862385321102
I1
I0
I1
tp63951
sS'use,of,should'
p63952
(F1
F0.00014334862385321102
I1
I0
I1
tp63953
sS'p,in,auc'
p63954
(F1
F0.00014334862385321102
I0
I1
I-1
tp63955
sS'of,either,due'
p63956
(F1
F0.00014334862385321102
I0
I1
I-1
tp63957
sS'with,a,dopa'
p63958
(F1
F0.00014334862385321102
I0
I1
I-1
tp63959
sS'again,neutralized,the'
p63960
(F1
F0.00014334862385321102
I0
I1
I-1
tp63961
sS'concentrations,of,interfere'
p63962
(F1
F0.00014334862385321102
I1
I0
I1
tp63963
sS'inhibits,c9,c19'
p63964
(F1
F0.00014334862385321102
I0
I1
I-1
tp63965
sS'population,of,the'
p63966
(F1
F0.00014334862385321102
I0
I1
I-1
tp63967
sS'in,those,with'
p63968
(F1
F0.00028669724770642203
I2
I0
I2
tp63969
sS'interaction,of,aprepitant'
p63970
(F1
F0.00014334862385321102
I0
I1
I-1
tp63971
sS'titrated,to,mg'
p63972
(F1
F0.00028669724770642203
I0
I2
I-2
tp63973
sS'drugs,demonstrated,to'
p63974
(F1
F0.00014334862385321102
I1
I0
I1
tp63975
sS'treatment,with,accutane'
p63976
(F1
F0.00014334862385321102
I1
I0
I1
tp63977
sS'alert,to,the'
p63978
(F1
F0.00028669724770642203
I2
I0
I2
tp63979
sS'nervous,system,or'
p63980
(F1
F0.00014334862385321102
I1
I0
I1
tp63981
sS'presence,of,m'
p63982
(F0
F0
I1
I1
I0
tp63983
sS'nephrotoxicity,has,been'
p63984
(F1
F0.0008600917431192661
I6
I0
I6
tp63985
sS'pharmacodynamic,effect,of'
p63986
(F1
F0.00014334862385321102
I0
I1
I-1
tp63987
sS'treated,with,mg'
p63988
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp63989
sS'both,species,during'
p63990
(F1
F0.00014334862385321102
I1
I0
I1
tp63991
sS'warfarin,when,maleate'
p63992
(F1
F0.00014334862385321102
I1
I0
I1
tp63993
sS'amphotericin,b-,induced'
p63994
(F1
F0.00014334862385321102
I1
I0
I1
tp63995
sS'diminished,when,it'
p63996
(F1
F0.00014334862385321102
I1
I0
I1
tp63997
sS'cause,hypotension,bradycardia'
p63998
(F1
F0.00014334862385321102
I0
I1
I-1
tp63999
sS'following,observations,i'
p64000
(F1
F0.00014334862385321102
I0
I1
I-1
tp64001
sS'either,the,dose'
p64002
(F1
F0.00014334862385321102
I0
I1
I-1
tp64003
sS'day,racemic,combined'
p64004
(F0
F0
I1
I1
I0
tp64005
sS'in,these,subjects'
p64006
(F1
F0.00028669724770642203
I0
I2
I-2
tp64007
sS'variability,in,the'
p64008
(F1
F0.00028669724770642203
I2
I0
I2
tp64009
sS'of,theo-dur,key'
p64010
(F1
F0.00014334862385321102
I1
I0
I1
tp64011
sS'not,markedly,inhibit'
p64012
(F1
F0.00014334862385321102
I0
I1
I-1
tp64013
sS'patients,may,experience'
p64014
(F1
F0.00014334862385321102
I1
I0
I1
tp64015
sS'dose,followed,by'
p64016
(F1
F0.00014334862385321102
I1
I0
I1
tp64017
sS'this,activity,enough'
p64018
(F1
F0.00014334862385321102
I0
I1
I-1
tp64019
sS'agents,dynamic,and'
p64020
(F1
F0.00014334862385321102
I0
I1
I-1
tp64021
sS'with,emtriva,has'
p64022
(F1
F0.00014334862385321102
I0
I1
I-1
tp64023
sS'and,international,normalized'
p64024
(F1
F0.00014334862385321102
I1
I0
I1
tp64025
sS'enhancement,of,toxicity'
p64026
(F1
F0.00014334862385321102
I1
I0
I1
tp64027
sS'mean,confidence,interval'
p64028
(F1
F0.00014334862385321102
I1
I0
I1
tp64029
sS'events,when,baraclude'
p64030
(F1
F0.00014334862385321102
I0
I1
I-1
tp64031
sS'subjective,and,behavioral'
p64032
(F1
F0.00028669724770642203
I0
I2
I-2
tp64033
sS'rats,suggest,that'
p64034
(F1
F0.00014334862385321102
I1
I0
I1
tp64035
sS'the,specific,interaction'
p64036
(F1
F0.00014334862385321102
I0
I1
I-1
tp64037
sS'a,therapeutic,supplement'
p64038
(F1
F0.00014334862385321102
I1
I0
I1
tp64039
sS'inhibition,and,the'
p64040
(F1
F0.00071674311926605509
I5
I0
I5
tp64041
sS'platelet,aggregation,and'
p64042
(F1
F0.00014334862385321102
I0
I1
I-1
tp64043
sS'action,of,effect'
p64044
(F1
F0.00014334862385321102
I0
I1
I-1
tp64045
sS'in,vivo,drug-drug'
p64046
(F1
F0.00014334862385321102
I1
I0
I1
tp64047
sS'the,major,are'
p64048
(F1
F0.00014334862385321102
I1
I0
I1
tp64049
sS'any,alterations,in'
p64050
(F1
F0.00014334862385321102
I0
I1
I-1
tp64051
sS'on,the,effect'
p64052
(F1
F0.00043004587155963305
I0
I3
I-3
tp64053
sS'anti-cryptosporidial,activity,of'
p64054
(F1
F0.00014334862385321102
I0
I1
I-1
tp64055
sS'for,alone,and'
p64056
(F0.5
F0.00028669724770642203
I3
I1
I2
tp64057
sS'ml,nor,is'
p64058
(F1
F0.00014334862385321102
I0
I1
I-1
tp64059
sS'to,lower,respectively'
p64060
(F1
F0.00014334862385321102
I0
I1
I-1
tp64061
sS'whether,would,cause'
p64062
(F1
F0.00014334862385321102
I0
I1
I-1
tp64063
sS'there,was,not'
p64064
(F1
F0.00014334862385321102
I0
I1
I-1
tp64065
sS'potential,components,are'
p64066
(F1
F0.00014334862385321102
I0
I1
I-1
tp64067
sS'with,a,to'
p64068
(F1
F0.00014334862385321102
I1
I0
I1
tp64069
sS'prophylactic,low,dose'
p64070
(F1
F0.00028669724770642203
I0
I2
I-2
tp64071
sS'chemotherapy,or,surgery'
p64072
(F1
F0.00014334862385321102
I0
I1
I-1
tp64073
sS'in,two,instances'
p64074
(F1
F0.00014334862385321102
I1
I0
I1
tp64075
sS'phenergan,mellaril,stelazine'
p64076
(F1
F0.00014334862385321102
I0
I1
I-1
tp64077
sS'control,and,half-life'
p64078
(F1
F0.00014334862385321102
I1
I0
I1
tp64079
sS'the,metabolite,of'
p64080
(F1
F0.00014334862385321102
I0
I1
I-1
tp64081
sS'time,in,patients'
p64082
(F0
F0
I2
I2
I0
tp64083
sS'inflammatory,with,a'
p64084
(F1
F0.00014334862385321102
I1
I0
I1
tp64085
sS'as,but,not'
p64086
(F1
F0.00014334862385321102
I1
I0
I1
tp64087
sS'exercised,when,combining'
p64088
(F1
F0.00014334862385321102
I0
I1
I-1
tp64089
sS'are,co,administered'
p64090
(F1
F0.00014334862385321102
I1
I0
I1
tp64091
sS'of,equetrotm,and'
p64092
(F1
F0.00014334862385321102
I0
I1
I-1
tp64093
sS'man,significantly,include'
p64094
(F1
F0.00028669724770642203
I2
I0
I2
tp64095
sS'although,the,clearance'
p64096
(F1
F0.00014334862385321102
I1
I0
I1
tp64097
sS'may,pose,clinical'
p64098
(F1
F0.00071674311926605509
I5
I0
I5
tp64099
sS'dosage,adjustment,may'
p64100
(F1
F0.00028669724770642203
I0
I2
I-2
tp64101
sS'administered,on,an'
p64102
(F1
F0.00014334862385321102
I0
I1
I-1
tp64103
sS'ocupress,should,be'
p64104
(F1
F0.00014334862385321102
I1
I0
I1
tp64105
sS'been,shown,in'
p64106
(F1
F0.00014334862385321102
I1
I0
I1
tp64107
sS'antihypertensives,bumetanide,may'
p64108
(F1
F0.00014334862385321102
I1
I0
I1
tp64109
sS'mg,of,cancidas'
p64110
(F1
F0.00014334862385321102
I1
I0
I1
tp64111
sS'of,most,likely'
p64112
(F1
F0.00014334862385321102
I1
I0
I1
tp64113
sS'potential,pharmacokinetic,interactions'
p64114
(F1
F0.00014334862385321102
I0
I1
I-1
tp64115
sS'need,to,take'
p64116
(F1
F0.00028669724770642203
I2
I0
I2
tp64117
sS'tumor,vascularity,of'
p64118
(F1
F0.00014334862385321102
I0
I1
I-1
tp64119
sS'with,dopa,decarboxylase'
p64120
(F1
F0.00014334862385321102
I0
I1
I-1
tp64121
sS'that,an,acute'
p64122
(F1
F0.00014334862385321102
I0
I1
I-1
tp64123
sS'myocardium,p,but'
p64124
(F1
F0.00014334862385321102
I1
I0
I1
tp64125
sS'mucocutaneous,and,cytoprotective'
p64126
(F1
F0.00014334862385321102
I0
I1
I-1
tp64127
sS'addition,of,given'
p64128
(F1
F0.00014334862385321102
I0
I1
I-1
tp64129
sS'of,anticholinesterase,poisoning'
p64130
(F1
F0.00014334862385321102
I1
I0
I1
tp64131
sS'requirement,i,mac'
p64132
(F1
F0.00014334862385321102
I1
I0
I1
tp64133
sS'faster,with,prior'
p64134
(F1
F0.00014334862385321102
I1
I0
I1
tp64135
sS'days,and,and'
p64136
(F1
F0.00014334862385321102
I0
I1
I-1
tp64137
sS'male,rats,and'
p64138
(F1
F0.00014334862385321102
I0
I1
I-1
tp64139
sS'and,vitamin,k'
p64140
(F1
F0.00028669724770642203
I2
I0
I2
tp64141
sS'conducting,an,arbutamine-mediated'
p64142
(F1
F0.00014334862385321102
I1
I0
I1
tp64143
sS'data,are,available'
p64144
(F1
F0.00014334862385321102
I0
I1
I-1
tp64145
sS'the,steady-state,serum'
p64146
(F1
F0.00014334862385321102
I1
I0
I1
tp64147
sS'resulted,in,greater'
p64148
(F1
F0.00014334862385321102
I1
I0
I1
tp64149
sS'cognitive,enhancing,effects'
p64150
(F1
F0.00014334862385321102
I0
I1
I-1
tp64151
sS'patient,only,where'
p64152
(F1
F0.00014334862385321102
I1
I0
I1
tp64153
sS'administration,of,during'
p64154
(F1
F0.00014334862385321102
I1
I0
I1
tp64155
sS'injection,and,oral'
p64156
(F1
F0.00014334862385321102
I1
I0
I1
tp64157
sS'use,of,cerubidine'
p64158
(F1
F0.00014334862385321102
I1
I0
I1
tp64159
sS'cmax,and,fold'
p64160
(F1
F0.00014334862385321102
I0
I1
I-1
tp64161
sS'the,pharmacology,of'
p64162
(F1
F0.00014334862385321102
I1
I0
I1
tp64163
sS'resulted,in,ventricular'
p64164
(F1
F0.00014334862385321102
I0
I1
I-1
tp64165
sS'replacement,therapy,may'
p64166
(F0
F0
I1
I1
I0
tp64167
sS'other,psychotropic,agents'
p64168
(F1
F0.00028669724770642203
I2
I0
I2
tp64169
sS'the,main,non-infection'
p64170
(F1
F0.00014334862385321102
I0
I1
I-1
tp64171
sS'of,gemzar,and'
p64172
(F1
F0.00014334862385321102
I0
I1
I-1
tp64173
sS'd,and,a'
p64174
(F1
F0.00014334862385321102
I1
I0
I1
tp64175
sS'lesser,extent,enhanced'
p64176
(F1
F0.00014334862385321102
I0
I1
I-1
tp64177
sS'to,is,catalyzed'
p64178
(F1
F0.00014334862385321102
I0
I1
I-1
tp64179
sS'of,both,resorptions'
p64180
(F1
F0.00014334862385321102
I1
I0
I1
tp64181
sS'to,patients,with'
p64182
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp64183
sS'post-marketing,experience,of'
p64184
(F1
F0.00014334862385321102
I1
I0
I1
tp64185
sS'concurrently,with,kineret'
p64186
(F1
F0.00014334862385321102
I1
I0
I1
tp64187
sS'affect,hepatic,metabolism'
p64188
(F1
F0.00014334862385321102
I1
I0
I1
tp64189
sS'reported,to,prolong'
p64190
(F1
F0.00014334862385321102
I1
I0
I1
tp64191
sS'is,not,expected'
p64192
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp64193
sS'reactions,of,if'
p64194
(F1
F0.00014334862385321102
I1
I0
I1
tp64195
sS'and,auc,a'
p64196
(F1
F0.00014334862385321102
I1
I0
I1
tp64197
sS'not,change,significantly'
p64198
(F1
F0.00014334862385321102
I0
I1
I-1
tp64199
sS'aluminum-containing,administered,concomitantly'
p64200
(F1
F0.00014334862385321102
I1
I0
I1
tp64201
sS'expected,to,substantially'
p64202
(F1
F0.00014334862385321102
I0
I1
I-1
tp64203
sS'to,decreased,serum'
p64204
(F1
F0.00014334862385321102
I1
I0
I1
tp64205
sS'serotonin2-receptors,underlies,the'
p64206
(F1
F0.00014334862385321102
I0
I1
I-1
tp64207
sS'demonstrated,that,administration'
p64208
(F1
F0.00014334862385321102
I0
I1
I-1
tp64209
sS'frequent,involvement,of'
p64210
(F1
F0.00014334862385321102
I1
I0
I1
tp64211
sS'postmarketing,experience,when'
p64212
(F1
F0.00014334862385321102
I1
I0
I1
tp64213
sS'of,tubular,organic'
p64214
(F0
F0
I1
I1
I0
tp64215
sS'postmarketing,reports,describing'
p64216
(F1
F0.00014334862385321102
I1
I0
I1
tp64217
sS'and,it,has'
p64218
(F1
F0.00028669724770642203
I2
I0
I2
tp64219
sS'or,more,with'
p64220
(F1
F0.00014334862385321102
I1
I0
I1
tp64221
sS'the,hypotensive,effects'
p64222
(F0.5
F0.00028669724770642203
I3
I1
I2
tp64223
sS'function,since,a'
p64224
(F1
F0.00014334862385321102
I0
I1
I-1
tp64225
sS'are,highly,effective'
p64226
(F1
F0.00014334862385321102
I0
I1
I-1
tp64227
sS'used,with,in'
p64228
(F1
F0.00014334862385321102
I1
I0
I1
tp64229
sS'i,d,co-administered'
p64230
(F1
F0.00028669724770642203
I2
I0
I2
tp64231
sS'in,dosage,should'
p64232
(F1
F0.00014334862385321102
I1
I0
I1
tp64233
sS'patients,were,on'
p64234
(F1
F0.00014334862385321102
I0
I1
I-1
tp64235
sS'hrs,of,and'
p64236
(F1
F0.00028669724770642203
I0
I2
I-2
tp64237
sS'on,the,cmax'
p64238
(F1
F0.00014334862385321102
I1
I0
I1
tp64239
sS'different,levels,of'
p64240
(F1
F0.00014334862385321102
I0
I1
I-1
tp64241
sS'auc,values,are'
p64242
(F1
F0.00014334862385321102
I0
I1
I-1
tp64243
sS'to,report,a'
p64244
(F1
F0.00014334862385321102
I0
I1
I-1
tp64245
sS'and,the,hydroxytamoxifen'
p64246
(F1
F0.00014334862385321102
I0
I1
I-1
tp64247
sS'substrates,and,or'
p64248
(F1
F0.00014334862385321102
I0
I1
I-1
tp64249
sS'monitored,especially,when'
p64250
(F1
F0.00014334862385321102
I1
I0
I1
tp64251
sS'there,are,reports'
p64252
(F1
F0.00014334862385321102
I1
I0
I1
tp64253
sS'phospholine,iodide,potentiates'
p64254
(F1
F0.00014334862385321102
I1
I0
I1
tp64255
sS'arrhythmias,who,are'
p64256
(F1
F0.00014334862385321102
I0
I1
I-1
tp64257
sS'mg,daily,did'
p64258
(F1
F0.00014334862385321102
I0
I1
I-1
tp64259
sS'and,and,on'
p64260
(F1
F0.00014334862385321102
I0
I1
I-1
tp64261
sS'the,general,concern'
p64262
(F1
F0.00014334862385321102
I0
I1
I-1
tp64263
sS'are,taken,concurrently'
p64264
(F1
F0.00014334862385321102
I1
I0
I1
tp64265
sS'others,orudis,orudis'
p64266
(F1
F0.00014334862385321102
I0
I1
I-1
tp64267
sS'cimetidine,in,subjects'
p64268
(F1
F0.00014334862385321102
I1
I0
I1
tp64269
sS'hepatitis,c,treated'
p64270
(F1
F0.00014334862385321102
I0
I1
I-1
tp64271
sS'treatment,with,or'
p64272
(F0
F0
I1
I1
I0
tp64273
sS'effect,of,steady-state'
p64274
(F1
F0.00014334862385321102
I0
I1
I-1
tp64275
sS'antiparkinson,or,may'
p64276
(F1
F0.00014334862385321102
I1
I0
I1
tp64277
sS'additionally,anti-malarial,such'
p64278
(F1
F0.00014334862385321102
I1
I0
I1
tp64279
sS'addition,most,are'
p64280
(F1
F0.00014334862385321102
I1
I0
I1
tp64281
sS'indicate,cyp3a4,isoform'
p64282
(F1
F0.00014334862385321102
I0
I1
I-1
tp64283
sS'the,intestinal,permeation'
p64284
(F1
F0.00028669724770642203
I0
I2
I-2
tp64285
sS'of,would,permit'
p64286
(F1
F0.00014334862385321102
I0
I1
I-1
tp64287
sS'urine,creatinine,levels'
p64288
(F1
F0.00028669724770642203
I0
I2
I-2
tp64289
sS'in,six,patients'
p64290
(F1
F0.00014334862385321102
I0
I1
I-1
tp64291
sS'anticoagulants,while,studies'
p64292
(F1
F0.00014334862385321102
I1
I0
I1
tp64293
sS'contraindicated,since,the'
p64294
(F1
F0.00014334862385321102
I0
I1
I-1
tp64295
sS'healthy,volunteers,resulting'
p64296
(F1
F0.00014334862385321102
I0
I1
I-1
tp64297
sS'with,either,single'
p64298
(F1
F0.00014334862385321102
I0
I1
I-1
tp64299
sS'resulted,in,lower'
p64300
(F1
F0.00014334862385321102
I1
I0
I1
tp64301
sS'were,co-administered,to'
p64302
(F1
F0.00014334862385321102
I1
I0
I1
tp64303
sS'glutamic,acid,hcl'
p64304
(F1
F0.00014334862385321102
I1
I0
I1
tp64305
sS'is,prolonged,because'
p64306
(F1
F0.00014334862385321102
I0
I1
I-1
tp64307
sS'intestine,thus,impairing'
p64308
(F1
F0.00014334862385321102
I1
I0
I1
tp64309
sS'day-old,chick,embryos'
p64310
(F1
F0.00014334862385321102
I1
I0
I1
tp64311
sS'on,the,clearance'
p64312
(F1
F0.00014334862385321102
I0
I1
I-1
tp64313
sS'in,the,magnitude'
p64314
(F1
F0.00014334862385321102
I0
I1
I-1
tp64315
sS'add,to,or'
p64316
(F1
F0.00028669724770642203
I2
I0
I2
tp64317
sS'high-dose,with,sodium'
p64318
(F1
F0.00014334862385321102
I1
I0
I1
tp64319
sS'agents,but,the'
p64320
(F1
F0.00014334862385321102
I1
I0
I1
tp64321
sS'in,binding,decrease'
p64322
(F1
F0.00014334862385321102
I1
I0
I1
tp64323
sS'to,be,metabolized'
p64324
(F0
F0
I1
I1
I0
tp64325
sS'above,of,should'
p64326
(F1
F0.00014334862385321102
I1
I0
I1
tp64327
sS'on,concomitant,treatment'
p64328
(F1
F0.00014334862385321102
I1
I0
I1
tp64329
sS'mg,with,viracept'
p64330
(F1
F0.00014334862385321102
I1
I0
I1
tp64331
sS'behavioral,response,of'
p64332
(F1
F0.00014334862385321102
I0
I1
I-1
tp64333
sS'the,and,other'
p64334
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp64335
sS'and,a,catecholamine'
p64336
(F1
F0.00014334862385321102
I0
I1
I-1
tp64337
sS'to,the,other'
p64338
(F1
F0.00014334862385321102
I0
I1
I-1
tp64339
sS'or,which,inhibit'
p64340
(F1
F0.00014334862385321102
I1
I0
I1
tp64341
sS'concentration,ca,i'
p64342
(F1
F0.00014334862385321102
I1
I0
I1
tp64343
sS'light,meal,hour'
p64344
(F1
F0.00014334862385321102
I0
I1
I-1
tp64345
sS'relapse,rehospitalisation,was'
p64346
(F1
F0.00014334862385321102
I0
I1
I-1
tp64347
sS'valproate,a,recent'
p64348
(F1
F0.00014334862385321102
I1
I0
I1
tp64349
sS'clearance,or,no'
p64350
(F1
F0.00014334862385321102
I0
I1
I-1
tp64351
sS'tablets,the,hypoglycemic'
p64352
(F1
F0.00014334862385321102
I1
I0
I1
tp64353
sS'conclusions,macrolide,inhibit'
p64354
(F1
F0.00014334862385321102
I1
I0
I1
tp64355
sS'compounds,that,could'
p64356
(F1
F0.00014334862385321102
I1
I0
I1
tp64357
sS'or,no,first-pass'
p64358
(F1
F0.00014334862385321102
I0
I1
I-1
tp64359
sS'hydrolase,inhibitors,it'
p64360
(F1
F0.00014334862385321102
I0
I1
I-1
tp64361
sS'txb2,generation,in'
p64362
(F1
F0.00014334862385321102
I0
I1
I-1
tp64363
sS'toxicology,study,male'
p64364
(F1
F0.00014334862385321102
I0
I1
I-1
tp64365
sS'that,of,crude'
p64366
(F1
F0.00014334862385321102
I0
I1
I-1
tp64367
sS'increased,and,more'
p64368
(F1
F0.00014334862385321102
I1
I0
I1
tp64369
sS'acid,depakene,use'
p64370
(F1
F0.00014334862385321102
I0
I1
I-1
tp64371
sS'antizol,by,approximately'
p64372
(F1
F0.00014334862385321102
I1
I0
I1
tp64373
sS'interaction,study,evaluated'
p64374
(F1
F0.00014334862385321102
I0
I1
I-1
tp64375
sS'blocker,on,the'
p64376
(F1
F0.00014334862385321102
I0
I1
I-1
tp64377
sS'or,decreased,by'
p64378
(F1
F0.00014334862385321102
I1
I0
I1
tp64379
sS'weeks,with,concurrent'
p64380
(F1
F0.00028669724770642203
I2
I0
I2
tp64381
sS'analog,of,cholecystokinin'
p64382
(F1
F0.00014334862385321102
I0
I1
I-1
tp64383
sS'in,the,frequency'
p64384
(F1
F0.00028669724770642203
I2
I0
I2
tp64385
sS'first,hours,following'
p64386
(F1
F0.00014334862385321102
I0
I1
I-1
tp64387
sS'metabolized,by,cyp2d6'
p64388
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp64389
sS'clearance,and,rises'
p64390
(F1
F0.00014334862385321102
I1
I0
I1
tp64391
sS'therefore,co-administration,of'
p64392
(F1
F0.00057339449541284407
I4
I0
I4
tp64393
sS'the,therapeutic,effects'
p64394
(F1
F0.00014334862385321102
I1
I0
I1
tp64395
sS'lower,doses,than'
p64396
(F1
F0.0010034403669724771
I0
I7
I-7
tp64397
sS'hypotension,and,or'
p64398
(F1
F0.00043004587155963305
I3
I0
I3
tp64399
sS'the,biologic,half-life'
p64400
(F1
F0.00014334862385321102
I1
I0
I1
tp64401
sS'to,one-half,of'
p64402
(F1
F0.00028669724770642203
I2
I0
I2
tp64403
sS'may,bind,other'
p64404
(F0
F0
I1
I1
I0
tp64405
sS'due,to,wide'
p64406
(F1
F0.00014334862385321102
I1
I0
I1
tp64407
sS'proliferation,of,prostatic'
p64408
(F1
F0.00014334862385321102
I1
I0
I1
tp64409
sS'blood-pressure,and,heart-rate'
p64410
(F1
F0.00014334862385321102
I1
I0
I1
tp64411
sS'days,n,under'
p64412
(F1
F0.00014334862385321102
I0
I1
I-1
tp64413
sS'moreover,as,noted'
p64414
(F1
F0.00014334862385321102
I1
I0
I1
tp64415
sS'diabetes,mellitus,certain'
p64416
(F1
F0.00014334862385321102
I0
I1
I-1
tp64417
sS'known,to,accelerate'
p64418
(F1
F0.00014334862385321102
I0
I1
I-1
tp64419
sS'enzymes,including,cyp1a2'
p64420
(F1
F0.00014334862385321102
I0
I1
I-1
tp64421
sS'thus,requiring,an'
p64422
(F1
F0.00014334862385321102
I1
I0
I1
tp64423
sS'cyclophosphamide,used,concurrently'
p64424
(F1
F0.00014334862385321102
I1
I0
I1
tp64425
sS'trials,with,simulect'
p64426
(F1
F0.00014334862385321102
I0
I1
I-1
tp64427
sS'including,and,requires'
p64428
(F1
F0.00014334862385321102
I1
I0
I1
tp64429
sS'and,no,clinically'
p64430
(F1
F0.00014334862385321102
I0
I1
I-1
tp64431
sS'with,the,therapeutic'
p64432
(F1
F0.00014334862385321102
I1
I0
I1
tp64433
sS'mg,qd,has'
p64434
(F1
F0.00014334862385321102
I0
I1
I-1
tp64435
sS'used,clinically,because'
p64436
(F1
F0.00014334862385321102
I0
I1
I-1
tp64437
sS'cytochrome,p450,a4'
p64438
(F0.076923076923076927
F0.00014334862385321102
I7
I6
I1
tp64439
sS'separately,by,different'
p64440
(F1
F0.00014334862385321102
I1
I0
I1
tp64441
sS'evidence,of,increased'
p64442
(F1
F0.00014334862385321102
I0
I1
I-1
tp64443
sS'metabolism,of,which'
p64444
(F1
F0.00057339449541284407
I4
I0
I4
tp64445
sS'safety,of,at'
p64446
(F1
F0.00014334862385321102
I0
I1
I-1
tp64447
sS'to,adult,diabetics'
p64448
(F1
F0.00014334862385321102
I0
I1
I-1
tp64449
sS'of,acarbose,and'
p64450
(F1
F0.00014334862385321102
I1
I0
I1
tp64451
sS'if,the,patient'
p64452
(F1
F0.00014334862385321102
I1
I0
I1
tp64453
sS'was,given,at'
p64454
(F1
F0.00014334862385321102
I1
I0
I1
tp64455
sS'was,given,as'
p64456
(F1
F0.00014334862385321102
I0
I1
I-1
tp64457
sS'structurally,similar,to'
p64458
(F1
F0.00014334862385321102
I0
I1
I-1
tp64459
sS'as,p-glycoprotein,in'
p64460
(F1
F0.00014334862385321102
I1
I0
I1
tp64461
sS'transferring,the,phosphohydrolase'
p64462
(F1
F0.00014334862385321102
I0
I1
I-1
tp64463
sS'administration,of,factive'
p64464
(F1
F0.00028669724770642203
I2
I0
I2
tp64465
sS'patients,no,dose'
p64466
(F1
F0.00014334862385321102
I0
I1
I-1
tp64467
sS'interaction,with,tikosyn'
p64468
(F1
F0.00014334862385321102
I0
I1
I-1
tp64469
sS'excessive,fall,in'
p64470
(F1
F0.00014334862385321102
I1
I0
I1
tp64471
sS'inhibitors,of,hmg-coa'
p64472
(F1
F0.00014334862385321102
I0
I1
I-1
tp64473
sS'max,although,c'
p64474
(F1
F0.00014334862385321102
I0
I1
I-1
tp64475
sS'clinically,necessary,because'
p64476
(F1
F0.00014334862385321102
I1
I0
I1
tp64477
sS'prior,to,this'
p64478
(F1
F0.00014334862385321102
I1
I0
I1
tp64479
sS'test,interactions,certain'
p64480
(F1
F0.00014334862385321102
I0
I1
I-1
tp64481
sS'clonidine,may,potentiate'
p64482
(F1
F0.00014334862385321102
I1
I0
I1
tp64483
sS'drugs,aeds,on'
p64484
(F1
F0.00014334862385321102
I1
I0
I1
tp64485
sS'potassium-sparing,and,others'
p64486
(F1
F0.00028669724770642203
I0
I2
I-2
tp64487
sS'higher,when,was'
p64488
(F1
F0.00014334862385321102
I1
I0
I1
tp64489
sS'a,cardioselective,could'
p64490
(F1
F0.00014334862385321102
I0
I1
I-1
tp64491
sS'receiving,a,beta-adrenergic'
p64492
(F1
F0.00014334862385321102
I1
I0
I1
tp64493
sS'of,in,sheep'
p64494
(F1
F0.00014334862385321102
I0
I1
I-1
tp64495
sS'no,additional,benefit'
p64496
(F1
F0.00028669724770642203
I2
I0
I2
tp64497
sS'for,alterations,in'
p64498
(F1
F0.00014334862385321102
I1
I0
I1
tp64499
sS'adverse,events,were'
p64500
(F1
F0.00014334862385321102
I1
I0
I1
tp64501
sS'induced,long,lasting'
p64502
(F1
F0.00014334862385321102
I1
I0
I1
tp64503
sS'also,used,the'
p64504
(F1
F0.00014334862385321102
I1
I0
I1
tp64505
sS'assess,the,potential'
p64506
(F1
F0.00014334862385321102
I0
I1
I-1
tp64507
sS'with,medications,that'
p64508
(F1
F0.00014334862385321102
I1
I0
I1
tp64509
sS'fruit,juices,etc'
p64510
(F1
F0.00014334862385321102
I1
I0
I1
tp64511
sS'sodium,is,augmented'
p64512
(F1
F0.00014334862385321102
I1
I0
I1
tp64513
sS'degree,of,inhibition'
p64514
(F1
F0.0008600917431192661
I6
I0
I6
tp64515
sS'decrease,by,concomitant'
p64516
(F1
F0.00014334862385321102
I1
I0
I1
tp64517
sS'administered,one,mg'
p64518
(F1
F0.00014334862385321102
I0
I1
I-1
tp64519
sS'reported,examples,of'
p64520
(F1
F0.00028669724770642203
I0
I2
I-2
tp64521
sS'that,small,quantities'
p64522
(F1
F0.00014334862385321102
I0
I1
I-1
tp64523
sS'photosensitivity,reaction,of'
p64524
(F1
F0.00014334862385321102
I1
I0
I1
tp64525
sS'if,possible,be'
p64526
(F1
F0.00014334862385321102
I1
I0
I1
tp64527
sS'fraction,fdf,at'
p64528
(F1
F0.00014334862385321102
I1
I0
I1
tp64529
sS'in,the,international'
p64530
(F1
F0.00014334862385321102
I0
I1
I-1
tp64531
sS'after,repeated,co-administration'
p64532
(F1
F0.00014334862385321102
I1
I0
I1
tp64533
sS'in,humans,show'
p64534
(F1
F0.00014334862385321102
I1
I0
I1
tp64535
sS'increased,the,plasma'
p64536
(F1
F0.00043004587155963305
I3
I0
I3
tp64537
sS'lengthened,and,the'
p64538
(F1
F0.00014334862385321102
I1
I0
I1
tp64539
sS'mg,day,racemic'
p64540
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp64541
sS'which,was,higher'
p64542
(F1
F0.00028669724770642203
I2
I0
I2
tp64543
sS'aspergillus,eia,test'
p64544
(F1
F0.00014334862385321102
I0
I1
I-1
tp64545
sS'and,potassium-sparing,on'
p64546
(F1
F0.00014334862385321102
I1
I0
I1
tp64547
sS'and,high-estradiol,treated'
p64548
(F1
F0.00014334862385321102
I1
I0
I1
tp64549
sS'time,sst,and'
p64550
(F1
F0.00014334862385321102
I0
I1
I-1
tp64551
sS'oral,an,and'
p64552
(F1
F0.00014334862385321102
I1
I0
I1
tp64553
sS'may,reach,toxic'
p64554
(F1
F0.00014334862385321102
I0
I1
I-1
tp64555
sS'a,greater,than'
p64556
(F1
F0.00014334862385321102
I1
I0
I1
tp64557
sS'via,the,human'
p64558
(F1
F0.00014334862385321102
I0
I1
I-1
tp64559
sS'medications,patients,should'
p64560
(F1
F0.00014334862385321102
I1
I0
I1
tp64561
sS'are,predominantly,metabolized'
p64562
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp64563
sS'antagonist,with,orencia'
p64564
(F1
F0.00014334862385321102
I1
I0
I1
tp64565
sS'buspirone,hcl,and'
p64566
(F1
F0.00014334862385321102
I1
I0
I1
tp64567
sS'been,implicated,in'
p64568
(F0
F0
I1
I1
I0
tp64569
sS'however,from,marketing'
p64570
(F1
F0.00014334862385321102
I1
I0
I1
tp64571
sS'and,retinyl,acetate'
p64572
(F1
F0.00028669724770642203
I2
I0
I2
tp64573
sS'laboratory,test,interferences'
p64574
(F1
F0.00014334862385321102
I0
I1
I-1
tp64575
sS'c,min,or'
p64576
(F1
F0.00014334862385321102
I0
I1
I-1
tp64577
sS'produced,an,increase'
p64578
(F1
F0.00014334862385321102
I1
I0
I1
tp64579
sS'because,binds,bile'
p64580
(F1
F0.00014334862385321102
I0
I1
I-1
tp64581
sS'results,and,pancreatic'
p64582
(F1
F0.00014334862385321102
I1
I0
I1
tp64583
sS'experiences,and,achieve'
p64584
(F1
F0.00014334862385321102
I1
I0
I1
tp64585
sS'cyp3a4,inducers,such'
p64586
(F0
F0
I1
I1
I0
tp64587
sS'users,is,at'
p64588
(F1
F0.00014334862385321102
I0
I1
I-1
tp64589
sS'interaction,use,of'
p64590
(F1
F0.00014334862385321102
I1
I0
I1
tp64591
sS'antiepileptic,drugs,aeds'
p64592
(F1
F0.00014334862385321102
I0
I1
I-1
tp64593
sS'the,general,population'
p64594
(F1
F0.00014334862385321102
I0
I1
I-1
tp64595
sS'elevations,of,cholesterol'
p64596
(F1
F0.00014334862385321102
I1
I0
I1
tp64597
sS'of,hydrochloride,and'
p64598
(F1
F0.00028669724770642203
I0
I2
I-2
tp64599
sS'reported,in,which'
p64600
(F1
F0.00014334862385321102
I1
I0
I1
tp64601
sS'dose,of,each'
p64602
(F1
F0.00014334862385321102
I1
I0
I1
tp64603
sS'other,cyp3a4,inducers'
p64604
(F1
F0.00014334862385321102
I0
I1
I-1
tp64605
sS'continuously,observed,for'
p64606
(F1
F0.00014334862385321102
I1
I0
I1
tp64607
sS'that,and,do'
p64608
(F1
F0.00014334862385321102
I0
I1
I-1
tp64609
sS'combination,with,should'
p64610
(F1
F0.00014334862385321102
I0
I1
I-1
tp64611
sS'laboratory,tests,response'
p64612
(F1
F0.00014334862385321102
I0
I1
I-1
tp64613
sS'all,inclusive,viracept'
p64614
(F1
F0.00014334862385321102
I0
I1
I-1
tp64615
sS'reductase,inhibitor,has'
p64616
(F1
F0.00014334862385321102
I1
I0
I1
tp64617
sS'accordance,with,standard'
p64618
(F1
F0.00014334862385321102
I0
I1
I-1
tp64619
sS'some,substances,are'
p64620
(F1
F0.00014334862385321102
I0
I1
I-1
tp64621
sS'reported,to,fluctuate'
p64622
(F1
F0.00014334862385321102
I1
I0
I1
tp64623
sS'with,mhd,and'
p64624
(F1
F0.00014334862385321102
I0
I1
I-1
tp64625
sS'distribution,of,the'
p64626
(F0
F0
I1
I1
I0
tp64627
sS'isocarboxazid,may,persist'
p64628
(F1
F0.00014334862385321102
I0
I1
I-1
tp64629
sS'the,elderly,in'
p64630
(F1
F0.00014334862385321102
I1
I0
I1
tp64631
sS'decrease,the,metabolic'
p64632
(F1
F0.00014334862385321102
I1
I0
I1
tp64633
sS'increases,in,liver'
p64634
(F1
F0.00014334862385321102
I1
I0
I1
tp64635
sS'profiles,comparable,to'
p64636
(F1
F0.00014334862385321102
I0
I1
I-1
tp64637
sS'change,in,prothrombin'
p64638
(F1
F0.00014334862385321102
I0
I1
I-1
tp64639
sS'administered,following,a'
p64640
(F1
F0.00014334862385321102
I1
I0
I1
tp64641
sS'great,an,interval'
p64642
(F1
F0.00014334862385321102
I0
I1
I-1
tp64643
sS'is,used,concurrently'
p64644
(F1
F0.00014334862385321102
I1
I0
I1
tp64645
sS'we,examined,the'
p64646
(F1
F0.00028669724770642203
I0
I2
I-2
tp64647
sS'effect,although,the'
p64648
(F1
F0.00014334862385321102
I0
I1
I-1
tp64649
sS'potentially,interfere,with'
p64650
(F1
F0.00014334862385321102
I0
I1
I-1
tp64651
sS'adjustment,is,recommended'
p64652
(F1
F0.00014334862385321102
I0
I1
I-1
tp64653
sS'warfarin,quinolones,including'
p64654
(F1
F0.00014334862385321102
I1
I0
I1
tp64655
sS'dipyridamole,may,counteract'
p64656
(F1
F0.00014334862385321102
I1
I0
I1
tp64657
sS'mg,day,proved'
p64658
(F1
F0.00014334862385321102
I0
I1
I-1
tp64659
sS'and,half-life,multiple-dose'
p64660
(F1
F0.00014334862385321102
I0
I1
I-1
tp64661
sS'of,is,narrow'
p64662
(F1
F0.00014334862385321102
I0
I1
I-1
tp64663
sS'gi,motility,agents'
p64664
(F1
F0.00014334862385321102
I0
I1
I-1
tp64665
sS'h2,blockers,and'
p64666
(F1
F0.00014334862385321102
I0
I1
I-1
tp64667
sS'in,the,first'
p64668
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp64669
sS'stimulants,including,those'
p64670
(F1
F0.00014334862385321102
I1
I0
I1
tp64671
sS'used,to,sensitize'
p64672
(F1
F0.00014334862385321102
I0
I1
I-1
tp64673
sS'should,be,alert'
p64674
(F0
F0
I2
I2
I0
tp64675
sS'administering,etopophos,with'
p64676
(F1
F0.00014334862385321102
I1
I0
I1
tp64677
sS'than,when,these'
p64678
(F1
F0.00014334862385321102
I1
I0
I1
tp64679
sS'concomitantly,used,in'
p64680
(F1
F0.00014334862385321102
I0
I1
I-1
tp64681
sS'inhibitors,and,mumol'
p64682
(F1
F0.00014334862385321102
I1
I0
I1
tp64683
sS'effect,beyond,that'
p64684
(F1
F0.00014334862385321102
I1
I0
I1
tp64685
sS'plasma,exposure,when'
p64686
(F1
F0.00014334862385321102
I1
I0
I1
tp64687
sS'days,mg,times'
p64688
(F1
F0.00014334862385321102
I0
I1
I-1
tp64689
sS'or,organophosphate,and'
p64690
(F1
F0.00014334862385321102
I1
I0
I1
tp64691
sS'mucosal,accumulation,of'
p64692
(F1
F0.00014334862385321102
I0
I1
I-1
tp64693
sS'concurrently,resulting,in'
p64694
(F1
F0.00014334862385321102
I1
I0
I1
tp64695
sS'hours,apart,so'
p64696
(F1
F0.00014334862385321102
I0
I1
I-1
tp64697
sS'decrease,in,cmax'
p64698
(F1
F0.00043004587155963305
I3
I0
I3
tp64699
sS'demonstrated,that,mixing'
p64700
(F1
F0.00014334862385321102
I0
I1
I-1
tp64701
sS'was,more,potent'
p64702
(F1
F0.00014334862385321102
I0
I1
I-1
tp64703
sS'potentiate,the,vasoconstrictive'
p64704
(F1
F0.00014334862385321102
I1
I0
I1
tp64705
sS'with,was,evaluated'
p64706
(F1
F0.00028669724770642203
I0
I2
I-2
tp64707
sS'propranolol,increases,hydralazines'
p64708
(F1
F0.00014334862385321102
I1
I0
I1
tp64709
sS'and,and,hours'
p64710
(F1
F0.00014334862385321102
I0
I1
I-1
tp64711
sS'that,of,most'
p64712
(F1
F0.00014334862385321102
I1
I0
I1
tp64713
sS'the,pr,interval'
p64714
(F1
F0.00014334862385321102
I1
I0
I1
tp64715
sS'synergistic,relationship,with'
p64716
(F1
F0.00014334862385321102
I1
I0
I1
tp64717
sS'an,increase,in'
p64718
(F0.80000000000000004
F0.0045871559633027525
I36
I4
I32
tp64719
sS'exaggerated,hypertensive,responses'
p64720
(F1
F0.00014334862385321102
I1
I0
I1
tp64721
sS'drug,interactions,under'
p64722
(F1
F0.00014334862385321102
I0
I1
I-1
tp64723
sS'b-blocking,properties,and'
p64724
(F1
F0.00028669724770642203
I2
I0
I2
tp64725
sS'mc,and,have'
p64726
(F1
F0.00014334862385321102
I0
I1
I-1
tp64727
sS'the,labeling,index'
p64728
(F1
F0.00014334862385321102
I0
I1
I-1
tp64729
sS'with,allopurinol,the'
p64730
(F1
F0.00014334862385321102
I1
I0
I1
tp64731
sS'drugs,on,the'
p64732
(F1
F0.00014334862385321102
I0
I1
I-1
tp64733
sS'in,such,patients'
p64734
(F1
F0.00043004587155963305
I3
I0
I3
tp64735
sS'been,found,with'
p64736
(F1
F0.00014334862385321102
I0
I1
I-1
tp64737
sS'dilaudid,may,exhibit'
p64738
(F1
F0.00014334862385321102
I1
I0
I1
tp64739
sS'poor,metabolizers,suggesting'
p64740
(F1
F0.00014334862385321102
I1
I0
I1
tp64741
sS'used,together,the'
p64742
(F1
F0.00014334862385321102
I1
I0
I1
tp64743
sS'of,a,study'
p64744
(F1
F0.00014334862385321102
I1
I0
I1
tp64745
sS'together,with,bezalip'
p64746
(F1
F0.00014334862385321102
I1
I0
I1
tp64747
sS'may,induce,bleeding'
p64748
(F1
F0.00014334862385321102
I1
I0
I1
tp64749
sS'the,bioavailabillty,when'
p64750
(F1
F0.00014334862385321102
I1
I0
I1
tp64751
sS'urine,levels,considerably'
p64752
(F1
F0.00014334862385321102
I1
I0
I1
tp64753
sS'release,and,less'
p64754
(F1
F0.00014334862385321102
I0
I1
I-1
tp64755
sS'risk,of,decreased'
p64756
(F1
F0.00014334862385321102
I0
I1
I-1
tp64757
sS'significantly,increased,plasma'
p64758
(F1
F0.00014334862385321102
I1
I0
I1
tp64759
sS'some,instances,a'
p64760
(F1
F0.00014334862385321102
I1
I0
I1
tp64761
sS'itraconazole,co-administration,of'
p64762
(F1
F0.00014334862385321102
I0
I1
I-1
tp64763
sS'fertility,of,male'
p64764
(F1
F0.00014334862385321102
I0
I1
I-1
tp64765
sS'co-administration,of,reduced'
p64766
(F1
F0.00014334862385321102
I1
I0
I1
tp64767
sS's,regimen,particularly'
p64768
(F1
F0.00014334862385321102
I1
I0
I1
tp64769
sS'and,liver,function'
p64770
(F1
F0.00028669724770642203
I0
I2
I-2
tp64771
sS'duloxetine-treated,patients,had'
p64772
(F1
F0.00014334862385321102
I0
I1
I-1
tp64773
sS'or,other,coumarin-like'
p64774
(F1
F0.00014334862385321102
I1
I0
I1
tp64775
sS'to,chemically,modify'
p64776
(F1
F0.00014334862385321102
I0
I1
I-1
tp64777
sS'as,appropriate,in'
p64778
(F1
F0.00014334862385321102
I0
I1
I-1
tp64779
sS'hcl,may,have'
p64780
(F1
F0.00014334862385321102
I1
I0
I1
tp64781
sS'with,aluminum-,and'
p64782
(F1
F0.00014334862385321102
I0
I1
I-1
tp64783
sS'with,human,serum'
p64784
(F1
F0.00014334862385321102
I0
I1
I-1
tp64785
sS'another,drug,is'
p64786
(F1
F0.00014334862385321102
I0
I1
I-1
tp64787
sS'many,of,these'
p64788
(F1
F0.00014334862385321102
I0
I1
I-1
tp64789
sS'inhibitors,have,resulted'
p64790
(F1
F0.00014334862385321102
I1
I0
I1
tp64791
sS'mac,was,depressed'
p64792
(F1
F0.00014334862385321102
I1
I0
I1
tp64793
sS'videx,didanosine,chewable'
p64794
(F1
F0.00028669724770642203
I2
I0
I2
tp64795
sS'to,significantly,interact'
p64796
(F1
F0.00014334862385321102
I0
I1
I-1
tp64797
sS'min,mean,standard'
p64798
(F1
F0.00014334862385321102
I1
I0
I1
tp64799
sS'n,compared,with'
p64800
(F1
F0.00028669724770642203
I2
I0
I2
tp64801
sS'blood,glucose,including'
p64802
(F1
F0.00014334862385321102
I1
I0
I1
tp64803
sS'betaseron,on,metabolism'
p64804
(F1
F0.00014334862385321102
I1
I0
I1
tp64805
sS'of,mg,of'
p64806
(F0.33333333333333331
F0.00057339449541284407
I8
I4
I4
tp64807
sS'mg,kg,decreases'
p64808
(F1
F0.00014334862385321102
I0
I1
I-1
tp64809
sS'affect,pharmacokinetics,except'
p64810
(F1
F0.00014334862385321102
I1
I0
I1
tp64811
sS'to,the,manufacturer'
p64812
(F1
F0.00014334862385321102
I0
I1
I-1
tp64813
sS'of,mg,on'
p64814
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp64815
sS'bactercidal,effect,of'
p64816
(F1
F0.00014334862385321102
I1
I0
I1
tp64817
sS'breakdown,products,and'
p64818
(F1
F0.00014334862385321102
I1
I0
I1
tp64819
sS'of,mg,or'
p64820
(F0
F0
I1
I1
I0
tp64821
sS'mg,kg,decreased'
p64822
(F1
F0.00014334862385321102
I1
I0
I1
tp64823
sS'unlikely,to,interact'
p64824
(F1
F0.00014334862385321102
I0
I1
I-1
tp64825
sS'certain,anticancer,and'
p64826
(F1
F0.00014334862385321102
I1
I0
I1
tp64827
sS'amphotericin,b,and'
p64828
(F1
F0.00071674311926605509
I5
I0
I5
tp64829
sS'the,interaction,observed'
p64830
(F1
F0.00014334862385321102
I1
I0
I1
tp64831
sS'studied,but,these'
p64832
(F1
F0.00014334862385321102
I1
I0
I1
tp64833
sS'necessary,because,of'
p64834
(F1
F0.00014334862385321102
I1
I0
I1
tp64835
sS'actions,and,side-effects'
p64836
(F1
F0.00014334862385321102
I1
I0
I1
tp64837
sS'values,of,approximately'
p64838
(F1
F0.00014334862385321102
I1
I0
I1
tp64839
sS'of,and,asa'
p64840
(F1
F0.00014334862385321102
I0
I1
I-1
tp64841
sS'mg,capsule,within'
p64842
(F1
F0.00014334862385321102
I1
I0
I1
tp64843
sS'the,following,concomitant'
p64844
(F1
F0.00014334862385321102
I0
I1
I-1
tp64845
sS'observed,for,the'
p64846
(F0
F0
I1
I1
I0
tp64847
sS'rats,hours,prior'
p64848
(F1
F0.00014334862385321102
I0
I1
I-1
tp64849
sS'serum,concentration,and'
p64850
(F1
F0.00028669724770642203
I2
I0
I2
tp64851
sS'cautiously,as,toxic'
p64852
(F1
F0.00014334862385321102
I0
I1
I-1
tp64853
sS'affected,by,the'
p64854
(F0
F0
I3
I3
I0
tp64855
sS'induced,locomotion,and'
p64856
(F1
F0.00014334862385321102
I0
I1
I-1
tp64857
sS'blocking,agents,did'
p64858
(F1
F0.00028669724770642203
I0
I2
I-2
tp64859
sS'positive,test,results'
p64860
(F1
F0.00014334862385321102
I0
I1
I-1
tp64861
sS'co-administration,of,may'
p64862
(F1
F0.00028669724770642203
I2
I0
I2
tp64863
sS'atorvastatin,increases,the'
p64864
(F1
F0.00014334862385321102
I1
I0
I1
tp64865
sS'assumed,that,increased'
p64866
(F1
F0.00014334862385321102
I0
I1
I-1
tp64867
sS'increases,anion,plasma'
p64868
(F1
F0.00014334862385321102
I1
I0
I1
tp64869
sS'several,clinical,trials'
p64870
(F1
F0.00014334862385321102
I0
I1
I-1
tp64871
sS'possible,to,avoid'
p64872
(F1
F0.00014334862385321102
I0
I1
I-1
tp64873
sS'on,the,pharmacokinetic'
p64874
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp64875
sS'prostin,e2,may'
p64876
(F1
F0.00014334862385321102
I1
I0
I1
tp64877
sS'contraction,followed,by'
p64878
(F1
F0.00014334862385321102
I0
I1
I-1
tp64879
sS'six,healthy,volunteers'
p64880
(F1
F0.00014334862385321102
I1
I0
I1
tp64881
sS'effect,with,cns'
p64882
(F1
F0.00028669724770642203
I2
I0
I2
tp64883
sS'therapeutic,indices,as'
p64884
(F1
F0.00014334862385321102
I1
I0
I1
tp64885
sS'in,heart,rate'
p64886
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp64887
sS'characteristics,in,the'
p64888
(F1
F0.00014334862385321102
I0
I1
I-1
tp64889
sS'by,without,altering'
p64890
(F1
F0.00014334862385321102
I1
I0
I1
tp64891
sS'shown,that,concomitant'
p64892
(F0
F0
I1
I1
I0
tp64893
sS'of,dehydration,secondary'
p64894
(F1
F0.00014334862385321102
I1
I0
I1
tp64895
sS'when,given,once'
p64896
(F1
F0.00014334862385321102
I1
I0
I1
tp64897
sS'preliminary,clinical,data'
p64898
(F1
F0.00014334862385321102
I1
I0
I1
tp64899
sS'a,potent,inhibitor'
p64900
(F0.23076923076923078
F0.00043004587155963305
I8
I5
I3
tp64901
sS'reported,that,prolongs'
p64902
(F1
F0.00014334862385321102
I1
I0
I1
tp64903
sS'amiodarone,taken,concomitantly'
p64904
(F1
F0.00043004587155963305
I0
I3
I-3
tp64905
sS'and,was,performed'
p64906
(F1
F0.00014334862385321102
I0
I1
I-1
tp64907
sS'and,mg,daily'
p64908
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp64909
sS'on,other,antiepileptic'
p64910
(F1
F0.00014334862385321102
I1
I0
I1
tp64911
sS'to,prinivil,given'
p64912
(F1
F0.00014334862385321102
I0
I1
I-1
tp64913
sS'monitoring,of,levels'
p64914
(F1
F0.00014334862385321102
I0
I1
I-1
tp64915
sS'bleeding,events,compared'
p64916
(F1
F0.00014334862385321102
I1
I0
I1
tp64917
sS'the,subjective,and'
p64918
(F1
F0.00028669724770642203
I0
I2
I-2
tp64919
sS'because,is,not'
p64920
(F1
F0.00014334862385321102
I0
I1
I-1
tp64921
sS'be,given,hour'
p64922
(F1
F0.00014334862385321102
I1
I0
I1
tp64923
sS'unchanged,accounts,for'
p64924
(F1
F0.00014334862385321102
I0
I1
I-1
tp64925
sS'hrs,of,decreased'
p64926
(F1
F0.00014334862385321102
I1
I0
I1
tp64927
sS'auc,by,and'
p64928
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp64929
sS'known,whether,or'
p64930
(F1
F0.00014334862385321102
I0
I1
I-1
tp64931
sS'enzymes,is,an'
p64932
(F1
F0.00014334862385321102
I0
I1
I-1
tp64933
sS'receiving,oral,the'
p64934
(F1
F0.00014334862385321102
I0
I1
I-1
tp64935
sS'but,had,no'
p64936
(F1
F0.00014334862385321102
I1
I0
I1
tp64937
sS'tuberculosis,andusing,a'
p64938
(F1
F0.00014334862385321102
I0
I1
I-1
tp64939
sS'cholestyramine,binds,both'
p64940
(F1
F0.00014334862385321102
I1
I0
I1
tp64941
sS'p450-mediated,metabolism,of'
p64942
(F1
F0.00014334862385321102
I0
I1
I-1
tp64943
sS'including,ethacrynic,acid'
p64944
(F1
F0.00014334862385321102
I1
I0
I1
tp64945
sS'carbamazepine,in,healthy'
p64946
(F1
F0.00014334862385321102
I1
I0
I1
tp64947
sS'can,displace,such'
p64948
(F1
F0.00014334862385321102
I1
I0
I1
tp64949
sS'approximately,fold,and'
p64950
(F1
F0.00043004587155963305
I3
I0
I3
tp64951
sS'close,monitoring,for'
p64952
(F0
F0
I1
I1
I0
tp64953
sS'by,cyp2c9,such'
p64954
(F1
F0.00014334862385321102
I1
I0
I1
tp64955
sS'in,an,attempt'
p64956
(F1
F0.00014334862385321102
I1
I0
I1
tp64957
sS'with,high,doses'
p64958
(F1
F0.00014334862385321102
I1
I0
I1
tp64959
sS'function,in,the'
p64960
(F1
F0.00014334862385321102
I0
I1
I-1
tp64961
sS'is,a,useful'
p64962
(F1
F0.00014334862385321102
I0
I1
I-1
tp64963
sS'mg,kg,doses'
p64964
(F1
F0.00014334862385321102
I1
I0
I1
tp64965
sS'classified,as,protease'
p64966
(F1
F0.00014334862385321102
I1
I0
I1
tp64967
sS'monitored,during,and'
p64968
(F1
F0.00014334862385321102
I1
I0
I1
tp64969
sS'in,and,of'
p64970
(F1
F0.00014334862385321102
I0
I1
I-1
tp64971
sS'oa,patients,there'
p64972
(F1
F0.00014334862385321102
I0
I1
I-1
tp64973
sS'experience,an,excessive'
p64974
(F1
F0.00057339449541284407
I4
I0
I4
tp64975
sS'of,to,healthy'
p64976
(F1
F0.00028669724770642203
I0
I2
I-2
tp64977
sS'is,receiving,a'
p64978
(F1
F0.00014334862385321102
I1
I0
I1
tp64979
sS'zebeta,may,produce'
p64980
(F1
F0.00014334862385321102
I1
I0
I1
tp64981
sS'in,increased,plasma'
p64982
(F0
F0
I4
I4
I0
tp64983
sS'administered,during,days'
p64984
(F1
F0.00014334862385321102
I0
I1
I-1
tp64985
sS'although,these,results'
p64986
(F1
F0.00014334862385321102
I1
I0
I1
tp64987
sS'in,and,or'
p64988
(F1
F0.00014334862385321102
I1
I0
I1
tp64989
sS'injection,and,chloride'
p64990
(F1
F0.00014334862385321102
I1
I0
I1
tp64991
sS'dose,increase,in'
p64992
(F1
F0.00014334862385321102
I0
I1
I-1
tp64993
sS'other,systemic,etc'
p64994
(F1
F0.00014334862385321102
I1
I0
I1
tp64995
sS'studies,evaluating,the'
p64996
(F1
F0.00014334862385321102
I0
I1
I-1
tp64997
sS'mc,does,not'
p64998
(F1
F0.00014334862385321102
I0
I1
I-1
tp64999
sS'of,the,concentration'
p65000
(F1
F0.00014334862385321102
I0
I1
I-1
tp65001
sS'one,report,that'
p65002
(F1
F0.00014334862385321102
I1
I0
I1
tp65003
sS'rats,was,more'
p65004
(F1
F0.00014334862385321102
I0
I1
I-1
tp65005
sS'n,had,no'
p65006
(F1
F0.00014334862385321102
I0
I1
I-1
tp65007
sS'is,required,when'
p65008
(F1
F0.00014334862385321102
I1
I0
I1
tp65009
sS'to,or,the'
p65010
(F1
F0.00014334862385321102
I1
I0
I1
tp65011
sS'for,several,hours'
p65012
(F1
F0.00014334862385321102
I1
I0
I1
tp65013
sS'sodium,iodide,i131'
p65014
(F1
F0.00014334862385321102
I1
I0
I1
tp65015
sS'serum,uric,acid'
p65016
(F1
F0.00014334862385321102
I1
I0
I1
tp65017
sS'to,increase,steadystate'
p65018
(F1
F0.00014334862385321102
I1
I0
I1
tp65019
sS'the,first,response'
p65020
(F1
F0.00014334862385321102
I0
I1
I-1
tp65021
sS'interfere,with,neuromuscular'
p65022
(F1
F0.00014334862385321102
I0
I1
I-1
tp65023
sS'receptor,antagonists,cimetidine'
p65024
(F1
F0.00014334862385321102
I1
I0
I1
tp65025
sS'of,nephrotoxicity,and'
p65026
(F1
F0.00014334862385321102
I1
I0
I1
tp65027
sS'considered,during,the'
p65028
(F1
F0.00014334862385321102
I1
I0
I1
tp65029
sS'days,to,of'
p65030
(F1
F0.00014334862385321102
I0
I1
I-1
tp65031
sS'increasing,its,cellular'
p65032
(F1
F0.00014334862385321102
I1
I0
I1
tp65033
sS'with,other,ht1'
p65034
(F1
F0.00014334862385321102
I0
I1
I-1
tp65035
sS'or,angiotensin,ii'
p65036
(F1
F0.00014334862385321102
I0
I1
I-1
tp65037
sS'reduced,the,rate'
p65038
(F1
F0.00014334862385321102
I1
I0
I1
tp65039
sS'of,and,proleukin'
p65040
(F1
F0.00014334862385321102
I1
I0
I1
tp65041
sS'in,five,normal'
p65042
(F1
F0.00014334862385321102
I1
I0
I1
tp65043
sS'the,concomitant,use'
p65044
(F0.58823529411764708
F0.0028669724770642203
I27
I7
I20
tp65045
sS'properties,may,enhance'
p65046
(F1
F0.00014334862385321102
I1
I0
I1
tp65047
sS'with,ml,maalox'
p65048
(F1
F0.00014334862385321102
I1
I0
I1
tp65049
sS'erythromycin,and,and'
p65050
(F1
F0.00014334862385321102
I1
I0
I1
tp65051
sS'increased,dosages,may'
p65052
(F1
F0.00014334862385321102
I1
I0
I1
tp65053
sS'subjects,given,and'
p65054
(F1
F0.00014334862385321102
I1
I0
I1
tp65055
sS'drugs,that,lower'
p65056
(F1
F0.00014334862385321102
I1
I0
I1
tp65057
sS'form,a,nitrosamine'
p65058
(F1
F0.00014334862385321102
I1
I0
I1
tp65059
sS'this,conjugated,system'
p65060
(F1
F0.00014334862385321102
I0
I1
I-1
tp65061
sS'normal,subjects,single-dose'
p65062
(F1
F0.00014334862385321102
I0
I1
I-1
tp65063
sS'trough,concentrations,and'
p65064
(F1
F0.00014334862385321102
I0
I1
I-1
tp65065
sS'administered,by,any'
p65066
(F1
F0.00014334862385321102
I1
I0
I1
tp65067
sS'patients,receiving,without'
p65068
(F1
F0.00014334862385321102
I0
I1
I-1
tp65069
sS'uptake,inhibitor,hydrogen-3'
p65070
(F1
F0.00014334862385321102
I0
I1
I-1
tp65071
sS'intravenous,has,been'
p65072
(F1
F0.00014334862385321102
I0
I1
I-1
tp65073
sS'cancer,cells,that'
p65074
(F1
F0.00014334862385321102
I1
I0
I1
tp65075
sS'are,also,using'
p65076
(F1
F0.00014334862385321102
I1
I0
I1
tp65077
sS'viral,loads,treated'
p65078
(F1
F0.00014334862385321102
I0
I1
I-1
tp65079
sS'of,amphotericin,b'
p65080
(F0
F0
I2
I2
I0
tp65081
sS'and,min,following'
p65082
(F1
F0.00014334862385321102
I0
I1
I-1
tp65083
sS'h,by,infusion'
p65084
(F1
F0.00014334862385321102
I0
I1
I-1
tp65085
sS'of,clonazepam,on'
p65086
(F1
F0.00014334862385321102
I0
I1
I-1
tp65087
sS'determine,whether,injection'
p65088
(F1
F0.00014334862385321102
I0
I1
I-1
tp65089
sS'these,have,negative'
p65090
(F1
F0.00014334862385321102
I1
I0
I1
tp65091
sS'er,extended,release'
p65092
(F1
F0.00014334862385321102
I0
I1
I-1
tp65093
sS'that,the,concomitant'
p65094
(F1
F0.0008600917431192661
I6
I0
I6
tp65095
sS'thus,if,a'
p65096
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp65097
sS'shortly,after,initiation'
p65098
(F1
F0.00014334862385321102
I0
I1
I-1
tp65099
sS'potential,exists,for'
p65100
(F1
F0.00014334862385321102
I1
I0
I1
tp65101
sS'for,example,sparing'
p65102
(F1
F0.00014334862385321102
I0
I1
I-1
tp65103
sS'alone,has,little'
p65104
(F1
F0.00014334862385321102
I1
I0
I1
tp65105
sS'infants,a,decision'
p65106
(F1
F0.00014334862385321102
I0
I1
I-1
tp65107
sS'of,cyp3a4,eg'
p65108
(F1
F0.00028669724770642203
I2
I0
I2
tp65109
sS'with,any,that'
p65110
(F1
F0.00014334862385321102
I0
I1
I-1
tp65111
sS'in,the,second'
p65112
(F0
F0
I1
I1
I0
tp65113
sS'correlated,with,brain'
p65114
(F1
F0.00014334862385321102
I0
I1
I-1
tp65115
sS'of,oral,is'
p65116
(F1
F0.00014334862385321102
I1
I0
I1
tp65117
sS'these,enzymes,may'
p65118
(F1
F0.00014334862385321102
I0
I1
I-1
tp65119
sS'have,demonstrated,a'
p65120
(F1
F0.00014334862385321102
I1
I0
I1
tp65121
sS'adrenocorticoids,cortisone-like,medicine'
p65122
(F1
F0.00014334862385321102
I1
I0
I1
tp65123
sS'if,sprycel,must'
p65124
(F1
F0.00014334862385321102
I0
I1
I-1
tp65125
sS'and,oral,markedly'
p65126
(F1
F0.00014334862385321102
I1
I0
I1
tp65127
sS'cmax,and,a'
p65128
(F1
F0.00043004587155963305
I3
I0
I3
tp65129
sS'drugs,with,a'
p65130
(F1
F0.00028669724770642203
I0
I2
I-2
tp65131
sS'potentiating,effect,with'
p65132
(F1
F0.00028669724770642203
I2
I0
I2
tp65133
sS'ergotamine,concurrent,use'
p65134
(F1
F0.00014334862385321102
I1
I0
I1
tp65135
sS'to,be,unaffected'
p65136
(F1
F0.00014334862385321102
I0
I1
I-1
tp65137
sS'drugs,such,as'
p65138
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp65139
sS'also,chronically,receiving'
p65140
(F1
F0.00014334862385321102
I0
I1
I-1
tp65141
sS'potential,for,arava'
p65142
(F1
F0.00014334862385321102
I1
I0
I1
tp65143
sS'bile,acid,binding'
p65144
(F1
F0.00043004587155963305
I3
I0
I3
tp65145
sS'fehlings,solution,or'
p65146
(F1
F0.00014334862385321102
I0
I1
I-1
tp65147
sS'who,discontinue,after'
p65148
(F1
F0.00014334862385321102
I1
I0
I1
tp65149
sS'theoretically,coadministration,of'
p65150
(F1
F0.00014334862385321102
I1
I0
I1
tp65151
sS'same,study,it'
p65152
(F1
F0.00014334862385321102
I0
I1
I-1
tp65153
sS'that,may,cause'
p65154
(F1
F0.00014334862385321102
I0
I1
I-1
tp65155
sS'effect,of,has'
p65156
(F1
F0.00014334862385321102
I1
I0
I1
tp65157
sS'concentrations,of,tricyclic'
p65158
(F1
F0.00014334862385321102
I0
I1
I-1
tp65159
sS'decrease,prior,to'
p65160
(F1
F0.00014334862385321102
I0
I1
I-1
tp65161
sS'as,used,for'
p65162
(F1
F0.00014334862385321102
I1
I0
I1
tp65163
sS'infections,caused,by'
p65164
(F1
F0.00014334862385321102
I0
I1
I-1
tp65165
sS'is,primarily,eliminated'
p65166
(F1
F0.00014334862385321102
I0
I1
I-1
tp65167
sS'that,be,administered'
p65168
(F1
F0.00014334862385321102
I0
I1
I-1
tp65169
sS'cyp3a4,eg,could'
p65170
(F1
F0.00014334862385321102
I1
I0
I1
tp65171
sS'p-450,isozymes,responsible'
p65172
(F1
F0.00028669724770642203
I2
I0
I2
tp65173
sS'sucralfate,metal,cations'
p65174
(F1
F0.00014334862385321102
I0
I1
I-1
tp65175
sS'data,on,possible'
p65176
(F1
F0.00014334862385321102
I1
I0
I1
tp65177
sS'studies,with,acetylsalicylic'
p65178
(F1
F0.00014334862385321102
I0
I1
I-1
tp65179
sS'normal,when,a'
p65180
(F1
F0.00014334862385321102
I0
I1
I-1
tp65181
sS'significant,fluctuations,in'
p65182
(F1
F0.00014334862385321102
I1
I0
I1
tp65183
sS'actively,secreted,via'
p65184
(F1
F0.00014334862385321102
I1
I0
I1
tp65185
sS'c,treated,with'
p65186
(F1
F0.00014334862385321102
I0
I1
I-1
tp65187
sS'a,with,metabolism'
p65188
(F1
F0.00014334862385321102
I0
I1
I-1
tp65189
sS'auc,and,for'
p65190
(F1
F0.00014334862385321102
I1
I0
I1
tp65191
sS'a,agonist,it'
p65192
(F1
F0.00014334862385321102
I1
I0
I1
tp65193
sS'rate,in,such'
p65194
(F1
F0.00014334862385321102
I0
I1
I-1
tp65195
sS'during,concomitant,treatment'
p65196
(F1
F0.00014334862385321102
I1
I0
I1
tp65197
sS'noncardioselective,porpranolol,may'
p65198
(F1
F0.00014334862385321102
I1
I0
I1
tp65199
sS'with,agents,that'
p65200
(F1
F0.00014334862385321102
I0
I1
I-1
tp65201
sS'mg,when,used'
p65202
(F1
F0.00014334862385321102
I0
I1
I-1
tp65203
sS'hypercalcemia,in,such'
p65204
(F1
F0.00043004587155963305
I3
I0
I3
tp65205
sS'concurrently,with,may'
p65206
(F1
F0.00014334862385321102
I1
I0
I1
tp65207
sS'basal,medium,rpmi1640'
p65208
(F1
F0.00014334862385321102
I0
I1
I-1
tp65209
sS'are,used,together'
p65210
(F1
F0.00014334862385321102
I1
I0
I1
tp65211
sS'akineton,are,administered'
p65212
(F1
F0.00014334862385321102
I1
I0
I1
tp65213
sS'not,require,empiric'
p65214
(F1
F0.00014334862385321102
I0
I1
I-1
tp65215
sS'absorbed,while,taking'
p65216
(F1
F0.00014334862385321102
I0
I1
I-1
tp65217
sS'ovarian,cancer,indicated'
p65218
(F1
F0.00014334862385321102
I1
I0
I1
tp65219
sS'two,reverse,transcriptase'
p65220
(F1
F0.00014334862385321102
I0
I1
I-1
tp65221
sS'made,when,these'
p65222
(F1
F0.00028669724770642203
I0
I2
I-2
tp65223
sS'overlap,to,any'
p65224
(F1
F0.00014334862385321102
I0
I1
I-1
tp65225
sS'particularly,diabetics,or'
p65226
(F1
F0.00014334862385321102
I1
I0
I1
tp65227
sS'of,hormone,may'
p65228
(F1
F0.00014334862385321102
I0
I1
I-1
tp65229
sS'on,oral,agents'
p65230
(F1
F0.00014334862385321102
I1
I0
I1
tp65231
sS'bovine,chromaffin,cell'
p65232
(F1
F0.00028669724770642203
I0
I2
I-2
tp65233
sS'of,a,cyp'
p65234
(F0
F0
I1
I1
I0
tp65235
sS'metformin,when,starlix'
p65236
(F1
F0.00014334862385321102
I0
I1
I-1
tp65237
sS'krm-1648,either,alone'
p65238
(F1
F0.00014334862385321102
I0
I1
I-1
tp65239
sS'a,diminished,prothrombin'
p65240
(F1
F0.00014334862385321102
I1
I0
I1
tp65241
sS'seen,on,plasma'
p65242
(F1
F0.00014334862385321102
I0
I1
I-1
tp65243
sS'in,approximately,a'
p65244
(F1
F0.00014334862385321102
I1
I0
I1
tp65245
sS'heart,rate,when'
p65246
(F1
F0.00014334862385321102
I1
I0
I1
tp65247
sS'of,the,iatrogenic'
p65248
(F1
F0.00014334862385321102
I0
I1
I-1
tp65249
sS'failure,receiving,or'
p65250
(F1
F0.00014334862385321102
I1
I0
I1
tp65251
sS'in,the,patients'
p65252
(F0
F0
I1
I1
I0
tp65253
sS'course,of,the'
p65254
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp65255
sS'are,decreased,when'
p65256
(F1
F0.00028669724770642203
I2
I0
I2
tp65257
sS'agents,aspirin,may'
p65258
(F1
F0.00014334862385321102
I1
I0
I1
tp65259
sS'for,tubular,secretion'
p65260
(F1
F0.00014334862385321102
I1
I0
I1
tp65261
sS'between,the,survanta'
p65262
(F1
F0.00014334862385321102
I0
I1
I-1
tp65263
sS'and,hmg-coa,reductase'
p65264
(F1
F0.00014334862385321102
I1
I0
I1
tp65265
sS'fluvoxamine,tablets,the'
p65266
(F1
F0.00014334862385321102
I1
I0
I1
tp65267
sS'function,were,not'
p65268
(F1
F0.00014334862385321102
I0
I1
I-1
tp65269
sS'in,the,coadministration'
p65270
(F1
F0.00028669724770642203
I2
I0
I2
tp65271
sS'a,mcg,once'
p65272
(F1
F0.00014334862385321102
I0
I1
I-1
tp65273
sS'serum,level,has'
p65274
(F1
F0.00014334862385321102
I1
I0
I1
tp65275
sS'doses,of,sodium'
p65276
(F1
F0.00014334862385321102
I0
I1
I-1
tp65277
sS'exposure,in,mice'
p65278
(F1
F0.00014334862385321102
I0
I1
I-1
tp65279
sS'inhibitor,of,the'
p65280
(F1
F0.00071674311926605509
I5
I0
I5
tp65281
sS'steady-state,conditions,to'
p65282
(F1
F0.00014334862385321102
I0
I1
I-1
tp65283
sS'increases,in,prothrombin'
p65284
(F1
F0.00028669724770642203
I2
I0
I2
tp65285
sS'oral,doses,of'
p65286
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp65287
sS'free,fraction,fdf'
p65288
(F1
F0.00014334862385321102
I1
I0
I1
tp65289
sS'responses,both,ca'
p65290
(F1
F0.00014334862385321102
I1
I0
I1
tp65291
sS'therapy,is,to'
p65292
(F1
F0.00014334862385321102
I1
I0
I1
tp65293
sS'of,non-nucleoside,reverse'
p65294
(F1
F0.00014334862385321102
I0
I1
I-1
tp65295
sS'been,more,than'
p65296
(F1
F0.00014334862385321102
I0
I1
I-1
tp65297
sS'over,the,last'
p65298
(F1
F0.00014334862385321102
I0
I1
I-1
tp65299
sS'in,single,and'
p65300
(F1
F0.00014334862385321102
I1
I0
I1
tp65301
sS'to,assess,if'
p65302
(F1
F0.00028669724770642203
I0
I2
I-2
tp65303
sS'could,have,a'
p65304
(F1
F0.00014334862385321102
I0
I1
I-1
tp65305
sS'counteract,the,anticoagulation'
p65306
(F1
F0.00014334862385321102
I1
I0
I1
tp65307
sS'ferrous,sulfate,sodium'
p65308
(F1
F0.00014334862385321102
I1
I0
I1
tp65309
sS'with,dsm-iv,diagnosed'
p65310
(F1
F0.00014334862385321102
I1
I0
I1
tp65311
sS'and,does,not'
p65312
(F1
F0.00043004587155963305
I0
I3
I-3
tp65313
sS'or,was,added'
p65314
(F1
F0.00014334862385321102
I0
I1
I-1
tp65315
sS'was,taken,in'
p65316
(F1
F0.00014334862385321102
I0
I1
I-1
tp65317
sS'co-administration,of,two'
p65318
(F1
F0.00014334862385321102
I0
I1
I-1
tp65319
sS'reduced,the,oral'
p65320
(F1
F0.00014334862385321102
I1
I0
I1
tp65321
sS'atropinization,flushing,mydriasis'
p65322
(F1
F0.00014334862385321102
I1
I0
I1
tp65323
sS'fecal,and,urinary'
p65324
(F1
F0.00014334862385321102
I0
I1
I-1
tp65325
sS'elderly,patients,receiving'
p65326
(F1
F0.00014334862385321102
I1
I0
I1
tp65327
sS'cases,a,pronounced'
p65328
(F1
F0.00014334862385321102
I1
I0
I1
tp65329
sS'when,either,or'
p65330
(F1
F0.00014334862385321102
I1
I0
I1
tp65331
sS'on,the,bioavailability'
p65332
(F1
F0.00028669724770642203
I0
I2
I-2
tp65333
sS'shown,that,lodine'
p65334
(F1
F0.00014334862385321102
I1
I0
I1
tp65335
sS'altered,by,coadministration'
p65336
(F1
F0.00014334862385321102
I0
I1
I-1
tp65337
sS'blood,pressure,in'
p65338
(F1
F0.00014334862385321102
I0
I1
I-1
tp65339
sS'and,achieve,the'
p65340
(F1
F0.00014334862385321102
I1
I0
I1
tp65341
sS'more,frequently,and'
p65342
(F1
F0.00014334862385321102
I0
I1
I-1
tp65343
sS'the,antitumor,activity'
p65344
(F1
F0.00014334862385321102
I0
I1
I-1
tp65345
sS'of,either,or'
p65346
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp65347
sS'two,different,types'
p65348
(F1
F0.00014334862385321102
I0
I1
I-1
tp65349
sS'avoided,unless,the'
p65350
(F1
F0.00014334862385321102
I1
I0
I1
tp65351
sS'should,be,restricted'
p65352
(F1
F0.00014334862385321102
I0
I1
I-1
tp65353
sS'first,step,of'
p65354
(F1
F0.00014334862385321102
I0
I1
I-1
tp65355
sS'a,week,course'
p65356
(F1
F0.00028669724770642203
I2
I0
I2
tp65357
sS'and,nose,may'
p65358
(F1
F0.00014334862385321102
I1
I0
I1
tp65359
sS'and,commonly,used'
p65360
(F1
F0.00014334862385321102
I0
I1
I-1
tp65361
sS'not,considered,clinically'
p65362
(F1
F0.00014334862385321102
I0
I1
I-1
tp65363
sS'similar,effects,would'
p65364
(F1
F0.00014334862385321102
I0
I1
I-1
tp65365
sS'pediatric,powder,or'
p65366
(F1
F0.00014334862385321102
I1
I0
I1
tp65367
sS'mild,decrease,in'
p65368
(F1
F0.00014334862385321102
I1
I0
I1
tp65369
sS'adverse,effects,could'
p65370
(F1
F0.00014334862385321102
I1
I0
I1
tp65371
sS'levels,and,prolongation'
p65372
(F1
F0.00057339449541284407
I4
I0
I4
tp65373
sS'may,substantially,decrease'
p65374
(F1
F0.00014334862385321102
I1
I0
I1
tp65375
sS'av,node,conduction'
p65376
(F1
F0.00014334862385321102
I1
I0
I1
tp65377
sS'with,caution,because'
p65378
(F1
F0.00043004587155963305
I3
I0
I3
tp65379
sS'effect,of,oral'
p65380
(F1
F0.00014334862385321102
I0
I1
I-1
tp65381
sS'or,renal,tubular'
p65382
(F1
F0.00014334862385321102
I1
I0
I1
tp65383
sS'hour,after,starting'
p65384
(F1
F0.00014334862385321102
I0
I1
I-1
tp65385
sS'when,this,combination'
p65386
(F1
F0.00014334862385321102
I1
I0
I1
tp65387
sS'be,augmented,by'
p65388
(F1
F0.00014334862385321102
I1
I0
I1
tp65389
sS'interact,with,blood'
p65390
(F1
F0.00014334862385321102
I1
I0
I1
tp65391
sS'if,hydrochloride,is'
p65392
(F1
F0.00014334862385321102
I1
I0
I1
tp65393
sS'with,that,are'
p65394
(F0.5
F0.00028669724770642203
I3
I1
I2
tp65395
sS'not,been,established'
p65396
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp65397
sS'genotypes,of,cyp2c9'
p65398
(F1
F0.00014334862385321102
I0
I1
I-1
tp65399
sS'withdrawn,in,conjunction'
p65400
(F1
F0.00014334862385321102
I0
I1
I-1
tp65401
sS'copying,test,and'
p65402
(F1
F0.00014334862385321102
I1
I0
I1
tp65403
sS'in,a,few'
p65404
(F1
F0.00028669724770642203
I2
I0
I2
tp65405
sS'hypoglycemics,diclofenac,does'
p65406
(F1
F0.00014334862385321102
I0
I1
I-1
tp65407
sS'muscle,relaxants,intravenous'
p65408
(F1
F0.00014334862385321102
I0
I1
I-1
tp65409
sS'thus,when,and'
p65410
(F1
F0.00014334862385321102
I1
I0
I1
tp65411
sS'citalopram,since,is'
p65412
(F1
F0.00014334862385321102
I1
I0
I1
tp65413
sS'migraine,therapy,such'
p65414
(F1
F0.00014334862385321102
I1
I0
I1
tp65415
sS'and,with,a'
p65416
(F1
F0.00014334862385321102
I1
I0
I1
tp65417
sS'experience,increased,concentrations'
p65418
(F1
F0.00014334862385321102
I0
I1
I-1
tp65419
sS'formal,clinical,studies'
p65420
(F1
F0.00028669724770642203
I0
I2
I-2
tp65421
sS'not,suggest,the'
p65422
(F1
F0.00014334862385321102
I0
I1
I-1
tp65423
sS'ec50,values,for'
p65424
(F1
F0.00014334862385321102
I0
I1
I-1
tp65425
sS'synergistic,activity,while'
p65426
(F1
F0.00014334862385321102
I1
I0
I1
tp65427
sS'estradiol,were,similar'
p65428
(F1
F0.00014334862385321102
I0
I1
I-1
tp65429
sS'of,drug,interactions'
p65430
(F1
F0.00014334862385321102
I0
I1
I-1
tp65431
sS'a,false-positive,reaction'
p65432
(F1
F0.00071674311926605509
I0
I5
I-5
tp65433
sS'or,other,metal'
p65434
(F1
F0.00014334862385321102
I1
I0
I1
tp65435
sS'and,careful,adjustment'
p65436
(F0
F0
I2
I2
I0
tp65437
sS'in,addition,patients'
p65438
(F1
F0.00014334862385321102
I0
I1
I-1
tp65439
sS'by,a,type'
p65440
(F1
F0.00014334862385321102
I0
I1
I-1
tp65441
sS'patients,in,ra'
p65442
(F1
F0.00014334862385321102
I0
I1
I-1
tp65443
sS'isoniazid,is,known'
p65444
(F1
F0.00014334862385321102
I1
I0
I1
tp65445
sS'inhibitors,concomitant,use'
p65446
(F1
F0.00014334862385321102
I0
I1
I-1
tp65447
sS'orally,inhaled,and'
p65448
(F0
F0
I1
I1
I0
tp65449
sS'effects,of,competitive'
p65450
(F1
F0.00014334862385321102
I0
I1
I-1
tp65451
sS'suggest,that,concomitant'
p65452
(F0
F0
I1
I1
I0
tp65453
sS'be,necessary,if'
p65454
(F1
F0.00043004587155963305
I0
I3
I-3
tp65455
sS'its,inhibitory,effect'
p65456
(F1
F0.00014334862385321102
I1
I0
I1
tp65457
sS'and,increased,risk'
p65458
(F1
F0.00014334862385321102
I1
I0
I1
tp65459
sS'ionized,species,of'
p65460
(F1
F0.00028669724770642203
I2
I0
I2
tp65461
sS'has,led,to'
p65462
(F1
F0.00043004587155963305
I3
I0
I3
tp65463
sS'animal,source,or'
p65464
(F1
F0.00014334862385321102
I0
I1
I-1
tp65465
sS'examine,the,effects'
p65466
(F1
F0.00014334862385321102
I0
I1
I-1
tp65467
sS'recovery,from,single'
p65468
(F1
F0.00014334862385321102
I0
I1
I-1
tp65469
sS'sites,or,a'
p65470
(F1
F0.00014334862385321102
I1
I0
I1
tp65471
sS'who,have,had'
p65472
(F1
F0.00014334862385321102
I1
I0
I1
tp65473
sS'or,ergot-type,medications'
p65474
(F1
F0.00043004587155963305
I3
I0
I3
tp65475
sS'who,consume,and'
p65476
(F1
F0.00014334862385321102
I1
I0
I1
tp65477
sS'serum,i,corticosteroid'
p65478
(F1
F0.00014334862385321102
I0
I1
I-1
tp65479
sS'concentrations,when,compared'
p65480
(F1
F0.00014334862385321102
I0
I1
I-1
tp65481
sS'with,peripheral,because'
p65482
(F1
F0.00014334862385321102
I1
I0
I1
tp65483
sS'with,lodosyn,and'
p65484
(F1
F0.00014334862385321102
I0
I1
I-1
tp65485
sS'receptors,thus,inhibiting'
p65486
(F1
F0.00028669724770642203
I2
I0
I2
tp65487
sS'a4,isoenzyme,system'
p65488
(F1
F0.00014334862385321102
I0
I1
I-1
tp65489
sS'chromatographic,assay,and'
p65490
(F1
F0.00014334862385321102
I0
I1
I-1
tp65491
sS'more,commonly,reported'
p65492
(F1
F0.00014334862385321102
I1
I0
I1
tp65493
sS'auc,were,not'
p65494
(F1
F0.00014334862385321102
I0
I1
I-1
tp65495
sS'given,should,be'
p65496
(F1
F0.00028669724770642203
I2
I0
I2
tp65497
sS'risk,of,having'
p65498
(F1
F0.00014334862385321102
I0
I1
I-1
tp65499
sS'cyp3a4,mg,daily'
p65500
(F1
F0.00014334862385321102
I1
I0
I1
tp65501
sS'natriuretic,and,antihypertensive'
p65502
(F1
F0.00043004587155963305
I3
I0
I3
tp65503
sS'pharmacological,effect,when'
p65504
(F1
F0.00014334862385321102
I1
I0
I1
tp65505
sS'long-,and,short-acting'
p65506
(F1
F0.00014334862385321102
I0
I1
I-1
tp65507
sS'one,strain,of'
p65508
(F1
F0.00014334862385321102
I0
I1
I-1
tp65509
sS'hydrochloride,was,administered'
p65510
(F1
F0.00014334862385321102
I0
I1
I-1
tp65511
sS'antifungals,grapefruit,juice'
p65512
(F1
F0.00014334862385321102
I1
I0
I1
tp65513
sS'per,day,to'
p65514
(F1
F0.00014334862385321102
I0
I1
I-1
tp65515
sS'compared,to,a'
p65516
(F0
F0
I1
I1
I0
tp65517
sS'the,binding,of'
p65518
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp65519
sS'limited,to,and'
p65520
(F1
F0.00014334862385321102
I0
I1
I-1
tp65521
sS'and,the,and'
p65522
(F1
F0.00014334862385321102
I1
I0
I1
tp65523
sS'inhibitors,atomoxetine,is'
p65524
(F1
F0.00014334862385321102
I0
I1
I-1
tp65525
sS'as,well,and'
p65526
(F1
F0.00014334862385321102
I0
I1
I-1
tp65527
sS'includes,anafranil,with'
p65528
(F1
F0.00014334862385321102
I0
I1
I-1
tp65529
sS'synthetase,inhibitors,also'
p65530
(F1
F0.00014334862385321102
I0
I1
I-1
tp65531
sS'its,metabolites,n-desmethylclozapine'
p65532
(F1
F0.00014334862385321102
I0
I1
I-1
tp65533
sS'hcl,has,been'
p65534
(F1
F0.00014334862385321102
I1
I0
I1
tp65535
sS'aprepitant,increased,the'
p65536
(F1
F0.00028669724770642203
I2
I0
I2
tp65537
sS'administering,hcl,to'
p65538
(F1
F0.00014334862385321102
I1
I0
I1
tp65539
sS'to,have,similar'
p65540
(F1
F0.00014334862385321102
I0
I1
I-1
tp65541
sS'was,to,study'
p65542
(F1
F0.00014334862385321102
I0
I1
I-1
tp65543
sS'rebif,is,used'
p65544
(F1
F0.00014334862385321102
I0
I1
I-1
tp65545
sS'the,acute,myocardial'
p65546
(F1
F0.00014334862385321102
I0
I1
I-1
tp65547
sS'and,a,increase'
p65548
(F1
F0.0012901376146788992
I9
I0
I9
tp65549
sS'kg,on,balance'
p65550
(F1
F0.00014334862385321102
I1
I0
I1
tp65551
sS'in,metabolite,or'
p65552
(F1
F0.00014334862385321102
I0
I1
I-1
tp65553
sS'deplete,and,monoamine'
p65554
(F1
F0.00014334862385321102
I1
I0
I1
tp65555
sS'tool,with,which'
p65556
(F1
F0.00014334862385321102
I0
I1
I-1
tp65557
sS'elevated,plasma,levels'
p65558
(F1
F0.0008600917431192661
I6
I0
I6
tp65559
sS'heparinized,patients,may'
p65560
(F1
F0.00014334862385321102
I1
I0
I1
tp65561
sS'inderal,tenormin,sectral'
p65562
(F1
F0.00014334862385321102
I0
I1
I-1
tp65563
sS'diethyl,pyrocarbonate,abolished'
p65564
(F1
F0.00014334862385321102
I0
I1
I-1
tp65565
sS'studies,m1,was'
p65566
(F1
F0.00028669724770642203
I0
I2
I-2
tp65567
sS'if,casodex,is'
p65568
(F1
F0.00014334862385321102
I1
I0
I1
tp65569
sS'hypoglycemics,agents,with'
p65570
(F1
F0.00014334862385321102
I1
I0
I1
tp65571
sS'on,may,be'
p65572
(F1
F0.00014334862385321102
I1
I0
I1
tp65573
sS'performed,with,sustiva'
p65574
(F1
F0.00014334862385321102
I0
I1
I-1
tp65575
sS'other,nondepolarizing,neuromuscular'
p65576
(F0
F0
I1
I1
I0
tp65577
sS'in,decreases,of'
p65578
(F1
F0.00014334862385321102
I1
I0
I1
tp65579
sS'and,enhance,activity'
p65580
(F1
F0.00014334862385321102
I1
I0
I1
tp65581
sS'and,the,numerous'
p65582
(F1
F0.00014334862385321102
I0
I1
I-1
tp65583
sS'gabitril,with,highly'
p65584
(F1
F0.00014334862385321102
I0
I1
I-1
tp65585
sS'concurrently,with,enbrel'
p65586
(F1
F0.00014334862385321102
I1
I0
I1
tp65587
sS'tc99m,uptake,of'
p65588
(F1
F0.00014334862385321102
I0
I1
I-1
tp65589
sS'mefloquine,although,theoretically'
p65590
(F1
F0.00014334862385321102
I1
I0
I1
tp65591
sS'when,was,co-administered'
p65592
(F0
F0
I1
I1
I0
tp65593
sS'monitoring,can,avoid'
p65594
(F1
F0.00014334862385321102
I1
I0
I1
tp65595
sS'inhibitors,in,studies'
p65596
(F1
F0.00014334862385321102
I1
I0
I1
tp65597
sS'of,absorption,but'
p65598
(F1
F0.00014334862385321102
I0
I1
I-1
tp65599
sS'seen,when,two'
p65600
(F1
F0.00014334862385321102
I0
I1
I-1
tp65601
sS'changes,in,plasma'
p65602
(F1
F0.00014334862385321102
I1
I0
I1
tp65603
sS'concomitantly,by,patients'
p65604
(F1
F0.00014334862385321102
I1
I0
I1
tp65605
sS'auc,ci,kg'
p65606
(F1
F0.00014334862385321102
I0
I1
I-1
tp65607
sS'pharmacokinetics,and,gastric'
p65608
(F1
F0.00014334862385321102
I0
I1
I-1
tp65609
sS'was,seen,in'
p65610
(F1
F0.00014334862385321102
I1
I0
I1
tp65611
sS'administration,of,targretin'
p65612
(F1
F0.00014334862385321102
I1
I0
I1
tp65613
sS'monitoring,and,dose'
p65614
(F1
F0.00014334862385321102
I1
I0
I1
tp65615
sS'clearance,of,some'
p65616
(F1
F0.00014334862385321102
I1
I0
I1
tp65617
sS'disalcid,others,choline'
p65618
(F1
F0.00014334862385321102
I1
I0
I1
tp65619
sS'drops,containing,are'
p65620
(F1
F0.00014334862385321102
I0
I1
I-1
tp65621
sS'of,zebeta,resulting'
p65622
(F1
F0.00014334862385321102
I1
I0
I1
tp65623
sS'opioid-induced,gastrointestinal,effects'
p65624
(F1
F0.00014334862385321102
I1
I0
I1
tp65625
sS'interact,with,some'
p65626
(F1
F0.00014334862385321102
I1
I0
I1
tp65627
sS'a,non-steroidal,anti-inflammatory'
p65628
(F1
F0.00028669724770642203
I2
I0
I2
tp65629
sS'used,concomitantly,serum'
p65630
(F1
F0.00014334862385321102
I1
I0
I1
tp65631
sS'novolog,should,not'
p65632
(F1
F0.00028669724770642203
I0
I2
I-2
tp65633
sS'therapy,patients,on'
p65634
(F1
F0.00043004587155963305
I3
I0
I3
tp65635
sS'more,than,doubled'
p65636
(F1
F0.00014334862385321102
I0
I1
I-1
tp65637
sS'both,its,therapeutic'
p65638
(F1
F0.00014334862385321102
I0
I1
I-1
tp65639
sS'some,potential,for'
p65640
(F1
F0.00014334862385321102
I1
I0
I1
tp65641
sS'prevent,the,conversion'
p65642
(F1
F0.00014334862385321102
I1
I0
I1
tp65643
sS'receiving,either,concomitant'
p65644
(F1
F0.00014334862385321102
I0
I1
I-1
tp65645
sS'apparent,total,body'
p65646
(F1
F0.00014334862385321102
I1
I0
I1
tp65647
sS'of,daily,increases'
p65648
(F1
F0.00014334862385321102
I1
I0
I1
tp65649
sS'has,much,lower'
p65650
(F1
F0.00014334862385321102
I0
I1
I-1
tp65651
sS'administered,with,that'
p65652
(F1
F0.00014334862385321102
I0
I1
I-1
tp65653
sS'of,alone,versus'
p65654
(F1
F0.00014334862385321102
I0
I1
I-1
tp65655
sS'of,in,patients'
p65656
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp65657
sS'as,the,physician'
p65658
(F1
F0.00014334862385321102
I0
I1
I-1
tp65659
sS'made,whether,to'
p65660
(F1
F0.00014334862385321102
I0
I1
I-1
tp65661
sS'receiving,mg,bid'
p65662
(F1
F0.00014334862385321102
I1
I0
I1
tp65663
sS'binding,of,to'
p65664
(F1
F0.00028669724770642203
I2
I0
I2
tp65665
sS'by,using,more'
p65666
(F1
F0.00014334862385321102
I0
I1
I-1
tp65667
sS'reductase,inhibitors,inhibitors'
p65668
(F1
F0.00014334862385321102
I0
I1
I-1
tp65669
sS'given,with,but'
p65670
(F1
F0.00014334862385321102
I1
I0
I1
tp65671
sS'd6,e1,and'
p65672
(F1
F0.00014334862385321102
I0
I1
I-1
tp65673
sS'and,in,vitro'
p65674
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp65675
sS'cimetidine,has,been'
p65676
(F1
F0.00043004587155963305
I3
I0
I3
tp65677
sS'include,aminosalicylic,acid'
p65678
(F1
F0.00014334862385321102
I1
I0
I1
tp65679
sS'the,selective,toxicity'
p65680
(F1
F0.00014334862385321102
I0
I1
I-1
tp65681
sS'vitro,interferes,minimally'
p65682
(F1
F0.00014334862385321102
I1
I0
I1
tp65683
sS'and,slight,decreases'
p65684
(F1
F0.00014334862385321102
I1
I0
I1
tp65685
sS'markers,that,identify'
p65686
(F1
F0.00014334862385321102
I1
I0
I1
tp65687
sS'dose-dependent,inhibition,of'
p65688
(F1
F0.00014334862385321102
I1
I0
I1
tp65689
sS'such,as,hctz'
p65690
(F1
F0.00014334862385321102
I0
I1
I-1
tp65691
sS'international,pharmaceutical,abstracts'
p65692
(F1
F0.00014334862385321102
I0
I1
I-1
tp65693
sS'between,oral,and'
p65694
(F1
F0.00043004587155963305
I3
I0
I3
tp65695
sS'protease,inhibitors,in'
p65696
(F0
F0
I1
I1
I0
tp65697
sS'cordarone,administration,impairs'
p65698
(F1
F0.00014334862385321102
I0
I1
I-1
tp65699
sS'either,one,or'
p65700
(F1
F0.00014334862385321102
I1
I0
I1
tp65701
sS'did,not,indicate'
p65702
(F1
F0.00014334862385321102
I1
I0
I1
tp65703
sS'been,well,tolerated'
p65704
(F1
F0.00014334862385321102
I0
I1
I-1
tp65705
sS'taking,this,medicine'
p65706
(F1
F0.00014334862385321102
I0
I1
I-1
tp65707
sS'investigated,the,effect'
p65708
(F1
F0.00014334862385321102
I0
I1
I-1
tp65709
sS'concomitantly,only,with'
p65710
(F1
F0.00028669724770642203
I0
I2
I-2
tp65711
sS'with,the,following'
p65712
(F0.14285714285714285
F0.00014334862385321102
I3
I4
I-1
tp65713
sS'in,two,other'
p65714
(F1
F0.00014334862385321102
I1
I0
I1
tp65715
sS'increasing,steady-state,concentrations'
p65716
(F1
F0.00014334862385321102
I1
I0
I1
tp65717
sS'of,pipracil,produces'
p65718
(F1
F0.00014334862385321102
I1
I0
I1
tp65719
sS'day,against,positive'
p65720
(F1
F0.00014334862385321102
I0
I1
I-1
tp65721
sS'radical-mediated,tissue,damage'
p65722
(F1
F0.00014334862385321102
I1
I0
I1
tp65723
sS'and,increased,amounts'
p65724
(F1
F0.00014334862385321102
I0
I1
I-1
tp65725
sS'quinolones,have,also'
p65726
(F1
F0.00014334862385321102
I1
I0
I1
tp65727
sS'and,liver,is'
p65728
(F1
F0.00014334862385321102
I1
I0
I1
tp65729
sS'also,in,vitro'
p65730
(F1
F0.00014334862385321102
I0
I1
I-1
tp65731
sS'reduce,seizure,control'
p65732
(F1
F0.00014334862385321102
I1
I0
I1
tp65733
sS'concentrations,of,probably'
p65734
(F1
F0.00014334862385321102
I1
I0
I1
tp65735
sS'monitoring,of,patients'
p65736
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp65737
sS'to,the,trans-diol'
p65738
(F1
F0.00014334862385321102
I0
I1
I-1
tp65739
sS'other,antiepileptic,the'
p65740
(F1
F0.00014334862385321102
I0
I1
I-1
tp65741
sS'the,intravenous,prodrug'
p65742
(F1
F0.00014334862385321102
I0
I1
I-1
tp65743
sS'consideration,when,selecting'
p65744
(F1
F0.00014334862385321102
I1
I0
I1
tp65745
sS'the,release,whereas'
p65746
(F1
F0.00014334862385321102
I0
I1
I-1
tp65747
sS'medications,that,are'
p65748
(F0
F0
I1
I1
I0
tp65749
sS'characterized,by,weakness'
p65750
(F1
F0.00014334862385321102
I1
I0
I1
tp65751
sS'to,require,replacement'
p65752
(F1
F0.00014334862385321102
I1
I0
I1
tp65753
sS'max,decreased,by'
p65754
(F1
F0.00014334862385321102
I1
I0
I1
tp65755
sS'formal,interaction,study'
p65756
(F1
F0.00014334862385321102
I0
I1
I-1
tp65757
sS'relief,of,breakthrough'
p65758
(F1
F0.00014334862385321102
I0
I1
I-1
tp65759
sS'avoided,except,in'
p65760
(F1
F0.00014334862385321102
I1
I0
I1
tp65761
sS'the,beta-adrenergic,blocker'
p65762
(F1
F0.00014334862385321102
I1
I0
I1
tp65763
sS'antihypertensives,amphetamines,may'
p65764
(F1
F0.00028669724770642203
I2
I0
I2
tp65765
sS'hours,of,the'
p65766
(F1
F0.00028669724770642203
I2
I0
I2
tp65767
sS'of,micrograms,ml'
p65768
(F1
F0.00014334862385321102
I0
I1
I-1
tp65769
sS'increases,the,clearance'
p65770
(F1
F0.00014334862385321102
I1
I0
I1
tp65771
sS'interfere,with,intestinal'
p65772
(F1
F0.00014334862385321102
I1
I0
I1
tp65773
sS'been,demonstrated,that'
p65774
(F1
F0.00014334862385321102
I1
I0
I1
tp65775
sS'effects,may,be'
p65776
(F0.20000000000000001
F0.00028669724770642203
I6
I4
I2
tp65777
sS'although,the,magnitude'
p65778
(F1
F0.00014334862385321102
I1
I0
I1
tp65779
sS'cyp2d6,because,cyp2d6'
p65780
(F1
F0.00014334862385321102
I0
I1
I-1
tp65781
sS'were,extensive,metabolizers'
p65782
(F1
F0.00014334862385321102
I1
I0
I1
tp65783
sS'to,the,therapy'
p65784
(F1
F0.00014334862385321102
I1
I0
I1
tp65785
sS'the,us,a'
p65786
(F1
F0.00014334862385321102
I0
I1
I-1
tp65787
sS'treatment,of,some'
p65788
(F1
F0.00028669724770642203
I0
I2
I-2
tp65789
sS'gm,daily,for'
p65790
(F1
F0.00014334862385321102
I1
I0
I1
tp65791
sS'receiving,hcl,alternatives'
p65792
(F1
F0.00014334862385321102
I1
I0
I1
tp65793
sS'order,to,avoid'
p65794
(F0
F0
I2
I2
I0
tp65795
sS'arrhythmias,or,toxicity'
p65796
(F1
F0.00014334862385321102
I0
I1
I-1
tp65797
sS'results,during,the'
p65798
(F1
F0.00014334862385321102
I0
I1
I-1
tp65799
sS'and,about,fold'
p65800
(F1
F0.00014334862385321102
I0
I1
I-1
tp65801
sS'for,which,effectiveness'
p65802
(F1
F0.00014334862385321102
I0
I1
I-1
tp65803
sS'inhalation,aerosol,and'
p65804
(F1
F0.00014334862385321102
I0
I1
I-1
tp65805
sS'steady,state,while'
p65806
(F1
F0.00014334862385321102
I1
I0
I1
tp65807
sS'incombination,with,with'
p65808
(F1
F0.00014334862385321102
I0
I1
I-1
tp65809
sS'other,that,have'
p65810
(F1
F0.00014334862385321102
I1
I0
I1
tp65811
sS'risks,of,using'
p65812
(F1
F0.00014334862385321102
I1
I0
I1
tp65813
sS'supplements,oral,or'
p65814
(F1
F0.00014334862385321102
I0
I1
I-1
tp65815
sS'about,a,increase'
p65816
(F1
F0.00028669724770642203
I2
I0
I2
tp65817
sS'contractility,conductivity,and'
p65818
(F1
F0.00014334862385321102
I1
I0
I1
tp65819
sS'nonsteroidal,anti-inflammatory,nsaids'
p65820
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp65821
sS'interactions,no,clinically'
p65822
(F1
F0.00014334862385321102
I0
I1
I-1
tp65823
sS'and,a,cyp3a4'
p65824
(F1
F0.00014334862385321102
I0
I1
I-1
tp65825
sS'antiepileptic,and,the'
p65826
(F1
F0.00014334862385321102
I1
I0
I1
tp65827
sS'because,the,combination'
p65828
(F1
F0.00028669724770642203
I2
I0
I2
tp65829
sS'of,and,similarly'
p65830
(F1
F0.00014334862385321102
I1
I0
I1
tp65831
sS'and,mg,iv'
p65832
(F1
F0.00014334862385321102
I0
I1
I-1
tp65833
sS'use,of,increases'
p65834
(F1
F0.00014334862385321102
I1
I0
I1
tp65835
sS'mg,qid,n'
p65836
(F1
F0.00014334862385321102
I1
I0
I1
tp65837
sS'basis,for,this'
p65838
(F1
F0.00014334862385321102
I1
I0
I1
tp65839
sS'differently,from,the'
p65840
(F1
F0.00014334862385321102
I0
I1
I-1
tp65841
sS'other,hydroxymethylglutaryl,coenzyme'
p65842
(F1
F0.00014334862385321102
I1
I0
I1
tp65843
sS'as,the,sole'
p65844
(F1
F0.00014334862385321102
I0
I1
I-1
tp65845
sS'presence,of,using'
p65846
(F1
F0.00014334862385321102
I0
I1
I-1
tp65847
sS'that,the,cardiovascular'
p65848
(F1
F0.00014334862385321102
I1
I0
I1
tp65849
sS'days,systemic,exposure'
p65850
(F1
F0.00028669724770642203
I2
I0
I2
tp65851
sS'mask,the,residual'
p65852
(F1
F0.00014334862385321102
I1
I0
I1
tp65853
sS'infarction,vs,serious'
p65854
(F1
F0.00014334862385321102
I1
I0
I1
tp65855
sS'fold,increase,of'
p65856
(F1
F0.00014334862385321102
I1
I0
I1
tp65857
sS'effects,of,concomitant'
p65858
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp65859
sS'bezalip,retard,may'
p65860
(F1
F0.00014334862385321102
I1
I0
I1
tp65861
sS'if,higher,dosages'
p65862
(F1
F0.00014334862385321102
I0
I1
I-1
tp65863
sS'differ,in,their'
p65864
(F1
F0.00014334862385321102
I0
I1
I-1
tp65865
sS'in,adults,at'
p65866
(F1
F0.00014334862385321102
I1
I0
I1
tp65867
sS'with,normal,subjects'
p65868
(F1
F0.00014334862385321102
I0
I1
I-1
tp65869
sS'welchol,was,found'
p65870
(F1
F0.00014334862385321102
I0
I1
I-1
tp65871
sS'a,wide,variety'
p65872
(F1
F0.00014334862385321102
I0
I1
I-1
tp65873
sS'p-type,channel,and'
p65874
(F1
F0.00014334862385321102
I0
I1
I-1
tp65875
sS'tests,response,to'
p65876
(F1
F0.00014334862385321102
I0
I1
I-1
tp65877
sS'agents,some,and'
p65878
(F1
F0.00014334862385321102
I1
I0
I1
tp65879
sS'study,co-administration,of'
p65880
(F0
F0
I1
I1
I0
tp65881
sS'activity,towards,cyp1a2'
p65882
(F1
F0.00014334862385321102
I1
I0
I1
tp65883
sS'the,mechanisms,underlying'
p65884
(F1
F0.00014334862385321102
I0
I1
I-1
tp65885
sS'increased,effects,when'
p65886
(F1
F0.00028669724770642203
I2
I0
I2
tp65887
sS'effective,than,to'
p65888
(F1
F0.00014334862385321102
I0
I1
I-1
tp65889
sS'studies,of,concomitant'
p65890
(F1
F0.00014334862385321102
I0
I1
I-1
tp65891
sS'in,fluoride,levels'
p65892
(F1
F0.00014334862385321102
I0
I1
I-1
tp65893
sS'may,diminish,the'
p65894
(F1
F0.0011467889908256881
I8
I0
I8
tp65895
sS'foscarnet,and,aminoglycosides'
p65896
(F1
F0.00014334862385321102
I1
I0
I1
tp65897
sS'after,the,same'
p65898
(F1
F0.00014334862385321102
I1
I0
I1
tp65899
sS'have,additive,or'
p65900
(F1
F0.00014334862385321102
I1
I0
I1
tp65901
sS'polyene,many,like'
p65902
(F1
F0.00014334862385321102
I0
I1
I-1
tp65903
sS'isomer,of,racemic'
p65904
(F1
F0.00014334862385321102
I1
I0
I1
tp65905
sS'and,estrogen-containing,compounds'
p65906
(F1
F0.00014334862385321102
I1
I0
I1
tp65907
sS'serotonin,reuptake,inhibitors'
p65908
(F0.14285714285714285
F0.00028669724770642203
I6
I8
I-2
tp65909
sS'to,occasionally,intensify'
p65910
(F1
F0.00014334862385321102
I1
I0
I1
tp65911
sS'inhibitors,or,because'
p65912
(F1
F0.00014334862385321102
I1
I0
I1
tp65913
sS'severe,hyperkalemia,in'
p65914
(F1
F0.00014334862385321102
I1
I0
I1
tp65915
sS'calcium-channel,blockers,cardiac'
p65916
(F1
F0.00014334862385321102
I0
I1
I-1
tp65917
sS'nervous,e-strain,subjects'
p65918
(F1
F0.00014334862385321102
I0
I1
I-1
tp65919
sS'is,about,to'
p65920
(F1
F0.00014334862385321102
I1
I0
I1
tp65921
sS'at,about,x'
p65922
(F1
F0.00014334862385321102
I1
I0
I1
tp65923
sS'depressants,the,concomitant'
p65924
(F1
F0.00014334862385321102
I1
I0
I1
tp65925
sS'enhance,in,tissue'
p65926
(F1
F0.00014334862385321102
I1
I0
I1
tp65927
sS'condition,in,which'
p65928
(F1
F0.00014334862385321102
I1
I0
I1
tp65929
sS'loratadine,and,descarboethoxyloratadine'
p65930
(F1
F0.00014334862385321102
I0
I1
I-1
tp65931
sS'days,results,in'
p65932
(F1
F0.00014334862385321102
I1
I0
I1
tp65933
sS'duloxetine,and,were'
p65934
(F1
F0.00014334862385321102
I0
I1
I-1
tp65935
sS'concentrations,are,observed'
p65936
(F1
F0.00014334862385321102
I0
I1
I-1
tp65937
sS'coadministration,of,once'
p65938
(F1
F0.00014334862385321102
I1
I0
I1
tp65939
sS'an,effect,of'
p65940
(F1
F0.00043004587155963305
I0
I3
I-3
tp65941
sS'be,monitored,frequently'
p65942
(F1
F0.00043004587155963305
I3
I0
I3
tp65943
sS'regular,users,of'
p65944
(F1
F0.00014334862385321102
I0
I1
I-1
tp65945
sS'in,simultaneous,treatment'
p65946
(F1
F0.00014334862385321102
I1
I0
I1
tp65947
sS'an,effect,on'
p65948
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp65949
sS'at,concentrations,as'
p65950
(F1
F0.00014334862385321102
I0
I1
I-1
tp65951
sS'oral,with,must'
p65952
(F1
F0.00014334862385321102
I1
I0
I1
tp65953
sS'that,reduce,renal'
p65954
(F1
F0.00014334862385321102
I0
I1
I-1
tp65955
sS'prolonged,long,acting'
p65956
(F1
F0.00014334862385321102
I1
I0
I1
tp65957
sS'inhaled,such,as'
p65958
(F1
F0.00014334862385321102
I0
I1
I-1
tp65959
sS'with,busulfex,may'
p65960
(F1
F0.00014334862385321102
I1
I0
I1
tp65961
sS'medications,used,concomitantly'
p65962
(F1
F0.00014334862385321102
I0
I1
I-1
tp65963
sS'in,long,surgical'
p65964
(F1
F0.00014334862385321102
I1
I0
I1
tp65965
sS'if,and,or'
p65966
(F1
F0.00014334862385321102
I1
I0
I1
tp65967
sS'expected,to,prolong'
p65968
(F1
F0.00014334862385321102
I1
I0
I1
tp65969
sS'as,are,employed'
p65970
(F1
F0.00014334862385321102
I1
I0
I1
tp65971
sS'modify,exposed,histidine'
p65972
(F1
F0.00014334862385321102
I0
I1
I-1
tp65973
sS'of,innovar,on'
p65974
(F1
F0.00014334862385321102
I0
I1
I-1
tp65975
sS'platelet-aggregation,reactions,the'
p65976
(F1
F0.00014334862385321102
I1
I0
I1
tp65977
sS'diabetic,patients,without'
p65978
(F1
F0.00014334862385321102
I0
I1
I-1
tp65979
sS'the,tca,may'
p65980
(F1
F0.00014334862385321102
I1
I0
I1
tp65981
sS'its,protein,binding'
p65982
(F1
F0.00014334862385321102
I1
I0
I1
tp65983
sS'investigated,in,the'
p65984
(F1
F0.00014334862385321102
I0
I1
I-1
tp65985
sS'of,the,combined'
p65986
(F1
F0.00014334862385321102
I0
I1
I-1
tp65987
sS'caution,if,at'
p65988
(F1
F0.00014334862385321102
I1
I0
I1
tp65989
sS'of,innovar,or'
p65990
(F1
F0.00014334862385321102
I1
I0
I1
tp65991
sS'mg,day,and'
p65992
(F1
F0.00028669724770642203
I2
I0
I2
tp65993
sS'coadministration,of,viracept'
p65994
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp65995
sS'of,other,cns'
p65996
(F0
F0
I1
I1
I0
tp65997
sS'aom,mg,kg'
p65998
(F1
F0.00014334862385321102
I0
I1
I-1
tp65999
sS'cimetidine,cimetidine,has'
p66000
(F1
F0.00028669724770642203
I2
I0
I2
tp66001
sS'are,direct,cardiac'
p66002
(F1
F0.00014334862385321102
I1
I0
I1
tp66003
sS'tendency,produced,by'
p66004
(F1
F0.00014334862385321102
I1
I0
I1
tp66005
sS'or,increased,sedation'
p66006
(F1
F0.00014334862385321102
I0
I1
I-1
tp66007
sS'indicated,in,the'
p66008
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp66009
sS'a,lesser,extent'
p66010
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp66011
sS'of,any,from'
p66012
(F1
F0.00014334862385321102
I0
I1
I-1
tp66013
sS'concentrations,of,azole'
p66014
(F1
F0.00014334862385321102
I1
I0
I1
tp66015
sS'autonomic,irritability,and'
p66016
(F1
F0.00014334862385321102
I1
I0
I1
tp66017
sS'with,intravenous,administration'
p66018
(F1
F0.00014334862385321102
I0
I1
I-1
tp66019
sS'many,angiotensin-converting,enzyme'
p66020
(F1
F0.00014334862385321102
I1
I0
I1
tp66021
sS'dose,of,diamox'
p66022
(F1
F0.00014334862385321102
I1
I0
I1
tp66023
sS'unexpected,adverse,effects'
p66024
(F1
F0.00014334862385321102
I0
I1
I-1
tp66025
sS'was,in,respect'
p66026
(F1
F0.00014334862385321102
I0
I1
I-1
tp66027
sS'day,group,were'
p66028
(F1
F0.00014334862385321102
I1
I0
I1
tp66029
sS'reduced,antihypertensive,effect'
p66030
(F1
F0.00014334862385321102
I0
I1
I-1
tp66031
sS'intravenous,iv,injection'
p66032
(F1
F0.00014334862385321102
I1
I0
I1
tp66033
sS'chelation,and,these'
p66034
(F1
F0.00014334862385321102
I0
I1
I-1
tp66035
sS'day,are,used'
p66036
(F1
F0.00014334862385321102
I0
I1
I-1
tp66037
sS'to,inhibit,p450'
p66038
(F1
F0.00014334862385321102
I1
I0
I1
tp66039
sS'sulfoxide,were,about'
p66040
(F1
F0.00014334862385321102
I1
I0
I1
tp66041
sS'capsules,and,resulted'
p66042
(F1
F0.00014334862385321102
I1
I0
I1
tp66043
sS'analogues,which,promote'
p66044
(F1
F0.00043004587155963305
I3
I0
I3
tp66045
sS'eight-fold,increase,of'
p66046
(F1
F0.00014334862385321102
I1
I0
I1
tp66047
sS'of,blocking,hepatic'
p66048
(F1
F0.00014334862385321102
I1
I0
I1
tp66049
sS'increased,mean,plasma'
p66050
(F1
F0.00028669724770642203
I2
I0
I2
tp66051
sS'concentration,of,synthetic'
p66052
(F1
F0.00028669724770642203
I2
I0
I2
tp66053
sS'any,clinical,signs'
p66054
(F1
F0.00014334862385321102
I1
I0
I1
tp66055
sS'reduced,interaction,between'
p66056
(F1
F0.00014334862385321102
I0
I1
I-1
tp66057
sS'disease,including,or'
p66058
(F1
F0.00014334862385321102
I0
I1
I-1
tp66059
sS'of,insufficient,to'
p66060
(F1
F0.00014334862385321102
I1
I0
I1
tp66061
sS'concomitantly,with,produces'
p66062
(F1
F0.00014334862385321102
I1
I0
I1
tp66063
sS'on,replacement,therapy'
p66064
(F1
F0.00014334862385321102
I1
I0
I1
tp66065
sS'beta-adrenergic,blockers,or'
p66066
(F1
F0.00014334862385321102
I1
I0
I1
tp66067
sS'beta-adrenergic,blocking,action'
p66068
(F1
F0.00014334862385321102
I1
I0
I1
tp66069
sS'thus,concomitant,administration'
p66070
(F1
F0.00014334862385321102
I1
I0
I1
tp66071
sS'and,aluminum-containing,administered'
p66072
(F1
F0.00014334862385321102
I1
I0
I1
tp66073
sS'with,another,known'
p66074
(F1
F0.00057339449541284407
I0
I4
I-4
tp66075
sS'modified,by,the'
p66076
(F1
F0.00014334862385321102
I1
I0
I1
tp66077
sS'taking,fortovase,as'
p66078
(F1
F0.00014334862385321102
I0
I1
I-1
tp66079
sS'patient,with,a'
p66080
(F1
F0.00014334862385321102
I1
I0
I1
tp66081
sS'this,effect,may'
p66082
(F0
F0
I1
I1
I0
tp66083
sS'a,atp,oxaloacetate'
p66084
(F1
F0.00014334862385321102
I0
I1
I-1
tp66085
sS'cyp3a4,substrate,by'
p66086
(F1
F0.00057339449541284407
I4
I0
I4
tp66087
sS'nicotine-induced,release,in'
p66088
(F1
F0.00014334862385321102
I1
I0
I1
tp66089
sS'approximately,one-third,to'
p66090
(F1
F0.00014334862385321102
I1
I0
I1
tp66091
sS'methotrexate,ibuprofen,as'
p66092
(F1
F0.00014334862385321102
I1
I0
I1
tp66093
sS'research,is,needed'
p66094
(F1
F0.00014334862385321102
I0
I1
I-1
tp66095
sS'is,changed,by'
p66096
(F1
F0.00014334862385321102
I1
I0
I1
tp66097
sS'patients,including,the'
p66098
(F1
F0.00014334862385321102
I0
I1
I-1
tp66099
sS'the,mitogenic,activity'
p66100
(F1
F0.00014334862385321102
I1
I0
I1
tp66101
sS'clinicians,should,be'
p66102
(F1
F0.00014334862385321102
I1
I0
I1
tp66103
sS'or,decreases,the'
p66104
(F1
F0.00014334862385321102
I1
I0
I1
tp66105
sS'm,v,decreased'
p66106
(F1
F0.00014334862385321102
I0
I1
I-1
tp66107
sS'potentiate,or,weaken'
p66108
(F1
F0.00028669724770642203
I2
I0
I2
tp66109
sS'required,or,may'
p66110
(F1
F0.00014334862385321102
I1
I0
I1
tp66111
sS'short-term,controlled,studies'
p66112
(F1
F0.00014334862385321102
I0
I1
I-1
tp66113
sS'with,the,mao-b'
p66114
(F1
F0.00014334862385321102
I0
I1
I-1
tp66115
sS'anticoagulant,activity,should'
p66116
(F1
F0.00014334862385321102
I1
I0
I1
tp66117
sS'under,the,influence'
p66118
(F1
F0.00028669724770642203
I0
I2
I-2
tp66119
sS'angina,patients,receiving'
p66120
(F1
F0.00014334862385321102
I0
I1
I-1
tp66121
sS'suggest,that,oral'
p66122
(F1
F0.00014334862385321102
I1
I0
I1
tp66123
sS'in,vivo,resulting'
p66124
(F1
F0.00014334862385321102
I1
I0
I1
tp66125
sS'that,induce,cyp'
p66126
(F1
F0.00014334862385321102
I1
I0
I1
tp66127
sS'valproate,the,addition'
p66128
(F1
F0.00014334862385321102
I1
I0
I1
tp66129
sS'hydrochloride,either,had'
p66130
(F1
F0.00014334862385321102
I1
I0
I1
tp66131
sS'a,complete,and'
p66132
(F1
F0.00014334862385321102
I1
I0
I1
tp66133
sS'v,solution,of'
p66134
(F1
F0.00014334862385321102
I0
I1
I-1
tp66135
sS'is,therefore,necessary'
p66136
(F1
F0.00014334862385321102
I0
I1
I-1
tp66137
sS'for,arava,levels'
p66138
(F1
F0.00014334862385321102
I1
I0
I1
tp66139
sS'great,extent,with'
p66140
(F1
F0.00014334862385321102
I0
I1
I-1
tp66141
sS'with,cyp3a4,substrates'
p66142
(F1
F0.00014334862385321102
I1
I0
I1
tp66143
sS'and,dyspnea,concomitant'
p66144
(F1
F0.00014334862385321102
I1
I0
I1
tp66145
sS'of,habituation,or'
p66146
(F1
F0.00014334862385321102
I0
I1
I-1
tp66147
sS'of,or,decreases'
p66148
(F1
F0.00014334862385321102
I1
I0
I1
tp66149
sS'tylenol,chloromycetin,local'
p66150
(F1
F0.00014334862385321102
I1
I0
I1
tp66151
sS'pharmacokinetics,were,observed'
p66152
(F1
F0.00014334862385321102
I0
I1
I-1
tp66153
sS'receiving,the,administration'
p66154
(F1
F0.00014334862385321102
I1
I0
I1
tp66155
sS'affect,the,clearance'
p66156
(F1
F0.00014334862385321102
I0
I1
I-1
tp66157
sS'clinical,pharmacology,drug'
p66158
(F1
F0.00014334862385321102
I1
I0
I1
tp66159
sS'nacmc,and,cmc-cys'
p66160
(F1
F0.00014334862385321102
I0
I1
I-1
tp66161
sS'of,influence,through'
p66162
(F1
F0.00014334862385321102
I0
I1
I-1
tp66163
sS'of,the,cytochrome'
p66164
(F0
F0
I3
I3
I0
tp66165
sS'were,administered,to'
p66166
(F1
F0.00014334862385321102
I0
I1
I-1
tp66167
sS'whom,therapy,was'
p66168
(F1
F0.00057339449541284407
I4
I0
I4
tp66169
sS'trial,in,normal'
p66170
(F1
F0.00014334862385321102
I1
I0
I1
tp66171
sS'the,currently,available'
p66172
(F1
F0.00014334862385321102
I0
I1
I-1
tp66173
sS'these,in,vivo'
p66174
(F1
F0.00014334862385321102
I0
I1
I-1
tp66175
sS'and,d,h'
p66176
(F0
F0
I1
I1
I0
tp66177
sS'however,careful,attention'
p66178
(F1
F0.00014334862385321102
I1
I0
I1
tp66179
sS'of,cholesterol,and'
p66180
(F1
F0.00014334862385321102
I1
I0
I1
tp66181
sS'regimens,has,been'
p66182
(F1
F0.00014334862385321102
I0
I1
I-1
tp66183
sS'and,other,medications'
p66184
(F1
F0.00014334862385321102
I1
I0
I1
tp66185
sS'disodium,in,animals'
p66186
(F1
F0.00014334862385321102
I1
I0
I1
tp66187
sS'to,the,active'
p66188
(F1
F0.00028669724770642203
I0
I2
I-2
tp66189
sS'with,either,secobarbitone'
p66190
(F1
F0.00014334862385321102
I1
I0
I1
tp66191
sS'cause,tumors,and'
p66192
(F1
F0.00014334862385321102
I1
I0
I1
tp66193
sS'valproic,acid,the'
p66194
(F1
F0.00014334862385321102
I0
I1
I-1
tp66195
sS'when,coadminstered,with'
p66196
(F1
F0.00014334862385321102
I1
I0
I1
tp66197
sS'with,of,animal'
p66198
(F1
F0.00014334862385321102
I0
I1
I-1
tp66199
sS'there,are,types'
p66200
(F1
F0.00014334862385321102
I0
I1
I-1
tp66201
sS'does,not,alter'
p66202
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp66203
sS'depressants,may,still'
p66204
(F1
F0.00014334862385321102
I1
I0
I1
tp66205
sS'with,parasite,reduction'
p66206
(F1
F0.00014334862385321102
I0
I1
I-1
tp66207
sS'agents,clomipramine,hcl'
p66208
(F1
F0.00014334862385321102
I1
I0
I1
tp66209
sS'watched,very,closely'
p66210
(F1
F0.00014334862385321102
I1
I0
I1
tp66211
sS'as,stadol,ns'
p66212
(F1
F0.00028669724770642203
I0
I2
I-2
tp66213
sS'normal,subjects,no'
p66214
(F1
F0.00014334862385321102
I1
I0
I1
tp66215
sS'those,for,which'
p66216
(F1
F0.00014334862385321102
I0
I1
I-1
tp66217
sS'amiodarone,may,suppress'
p66218
(F1
F0.00014334862385321102
I0
I1
I-1
tp66219
sS'psychotropic,agents,such'
p66220
(F1
F0.00014334862385321102
I1
I0
I1
tp66221
sS'modification,of,the'
p66222
(F1
F0.00014334862385321102
I1
I0
I1
tp66223
sS'employed,when,xigris'
p66224
(F1
F0.00014334862385321102
I0
I1
I-1
tp66225
sS'approximately,by,the'
p66226
(F1
F0.00014334862385321102
I1
I0
I1
tp66227
sS'n-acetyltransferase,may,have'
p66228
(F1
F0.00014334862385321102
I1
I0
I1
tp66229
sS'to,in,rat'
p66230
(F1
F0.00014334862385321102
I0
I1
I-1
tp66231
sS'with,caution,since'
p66232
(F1
F0.00014334862385321102
I0
I1
I-1
tp66233
sS'studied,systematically,in'
p66234
(F1
F0.00014334862385321102
I0
I1
I-1
tp66235
sS'involved,in,the'
p66236
(F1
F0.00014334862385321102
I0
I1
I-1
tp66237
sS'parietal,cells,in'
p66238
(F1
F0.00014334862385321102
I0
I1
I-1
tp66239
sS'ml,min,and'
p66240
(F1
F0.00014334862385321102
I0
I1
I-1
tp66241
sS'total,concentrations,increased'
p66242
(F1
F0.00014334862385321102
I1
I0
I1
tp66243
sS'borne,in,mind'
p66244
(F0
F0
I1
I1
I0
tp66245
sS'clearance,by,fold'
p66246
(F1
F0.00014334862385321102
I1
I0
I1
tp66247
sS'treatment,with,eg'
p66248
(F1
F0.00014334862385321102
I0
I1
I-1
tp66249
sS'indicate,that,binds'
p66250
(F1
F0.00014334862385321102
I0
I1
I-1
tp66251
sS'both,and,have'
p66252
(F1
F0.00014334862385321102
I0
I1
I-1
tp66253
sS'oral,mg,twice'
p66254
(F1
F0.00014334862385321102
I1
I0
I1
tp66255
sS'beta2,agonists,because'
p66256
(F1
F0.00014334862385321102
I1
I0
I1
tp66257
sS'cyp3a,channel,blockers'
p66258
(F1
F0.00014334862385321102
I0
I1
I-1
tp66259
sS'to,occasionally,induce'
p66260
(F1
F0.00014334862385321102
I0
I1
I-1
tp66261
sS'of,when,co-administered'
p66262
(F1
F0.00014334862385321102
I0
I1
I-1
tp66263
sS'in,the,large'
p66264
(F1
F0.00014334862385321102
I0
I1
I-1
tp66265
sS'mg,qd,of'
p66266
(F1
F0.00014334862385321102
I0
I1
I-1
tp66267
sS'the,pediatric,powder'
p66268
(F1
F0.0008600917431192661
I6
I0
I6
tp66269
sS'although,betagan,used'
p66270
(F1
F0.00014334862385321102
I1
I0
I1
tp66271
sS'and,fold,prolongation'
p66272
(F1
F0.00014334862385321102
I0
I1
I-1
tp66273
sS'interactions,when,co-administered'
p66274
(F1
F0.00014334862385321102
I1
I0
I1
tp66275
sS'antitumor,effectiveness,of'
p66276
(F1
F0.00014334862385321102
I1
I0
I1
tp66277
sS'cardiovascular,disease,in'
p66278
(F1
F0.00014334862385321102
I0
I1
I-1
tp66279
sS'co-administration,mean,trough'
p66280
(F1
F0.00014334862385321102
I0
I1
I-1
tp66281
sS'p-450,for,days'
p66282
(F1
F0.00014334862385321102
I1
I0
I1
tp66283
sS'results,in,increased'
p66284
(F1
F0.00014334862385321102
I1
I0
I1
tp66285
sS'usp,should,not'
p66286
(F1
F0.00028669724770642203
I2
I0
I2
tp66287
sS'intravenous,adenocard,has'
p66288
(F1
F0.00014334862385321102
I0
I1
I-1
tp66289
sS'blockade,will,be'
p66290
(F1
F0.00014334862385321102
I0
I1
I-1
tp66291
sS'coma,and,death'
p66292
(F1
F0.00014334862385321102
I1
I0
I1
tp66293
sS'of,absolute,in'
p66294
(F1
F0.00014334862385321102
I0
I1
I-1
tp66295
sS'o,every,hours'
p66296
(F1
F0.00014334862385321102
I1
I0
I1
tp66297
sS'of,local,solutions'
p66298
(F1
F0.00043004587155963305
I3
I0
I3
tp66299
sS'washout,period,followed'
p66300
(F1
F0.00014334862385321102
I0
I1
I-1
tp66301
sS'however,it,is'
p66302
(F1
F0.00014334862385321102
I0
I1
I-1
tp66303
sS'were,administered,orally'
p66304
(F1
F0.00014334862385321102
I0
I1
I-1
tp66305
sS'like,other,nonsteroidal'
p66306
(F1
F0.00028669724770642203
I2
I0
I2
tp66307
sS'resistance,to,crixivan'
p66308
(F1
F0.00028669724770642203
I0
I2
I-2
tp66309
sS'supine,systolic,diastolic'
p66310
(F1
F0.00014334862385321102
I1
I0
I1
tp66311
sS'cyp2d6,metabolizers,after'
p66312
(F1
F0.00014334862385321102
I0
I1
I-1
tp66313
sS'bacteriostatic,such,as'
p66314
(F1
F0.00014334862385321102
I1
I0
I1
tp66315
sS'induced,by,in'
p66316
(F1
F0.00014334862385321102
I1
I0
I1
tp66317
sS'use,of,products'
p66318
(F1
F0.00014334862385321102
I1
I0
I1
tp66319
sS'incoordination,have,been'
p66320
(F1
F0.00014334862385321102
I1
I0
I1
tp66321
sS'antagonize,the,decreases'
p66322
(F1
F0.00014334862385321102
I1
I0
I1
tp66323
sS'systemic,non-hodgkin,lymphoma'
p66324
(F1
F0.00014334862385321102
I0
I1
I-1
tp66325
sS'of,toxic,reactions'
p66326
(F1
F0.00014334862385321102
I0
I1
I-1
tp66327
sS'in,contrast,to'
p66328
(F1
F0.00014334862385321102
I0
I1
I-1
tp66329
sS'a,potential,interaction'
p66330
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp66331
sS'decrease,plasma,concentrations'
p66332
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp66333
sS'mouse,model,using'
p66334
(F1
F0.00014334862385321102
I0
I1
I-1
tp66335
sS'intestinal,adsorbents,and'
p66336
(F1
F0.00014334862385321102
I1
I0
I1
tp66337
sS'greater,than,changes'
p66338
(F1
F0.00014334862385321102
I0
I1
I-1
tp66339
sS'with,concurrently,administered'
p66340
(F1
F0.00014334862385321102
I1
I0
I1
tp66341
sS'such,as,etc'
p66342
(F1
F0.00014334862385321102
I1
I0
I1
tp66343
sS'of,were,administered'
p66344
(F1
F0.00014334862385321102
I1
I0
I1
tp66345
sS'decrease,in,temperature'
p66346
(F1
F0.00014334862385321102
I0
I1
I-1
tp66347
sS'of,and,signs'
p66348
(F1
F0.00014334862385321102
I0
I1
I-1
tp66349
sS'sodium,iodide,i'
p66350
(F1
F0.00014334862385321102
I0
I1
I-1
tp66351
sS'any,of,the'
p66352
(F0.076923076923076927
F0.00014334862385321102
I7
I6
I1
tp66353
sS'cmax,differences,were'
p66354
(F1
F0.00014334862385321102
I0
I1
I-1
tp66355
sS'relevant,pharmacokinetic,interactions'
p66356
(F1
F0.00014334862385321102
I0
I1
I-1
tp66357
sS'antagonists,and,brovana'
p66358
(F1
F0.00014334862385321102
I1
I0
I1
tp66359
sS'and,nor,the'
p66360
(F1
F0.00014334862385321102
I0
I1
I-1
tp66361
sS'marplan,nardil,matulane'
p66362
(F1
F0.00014334862385321102
I0
I1
I-1
tp66363
sS'unless,in,the'
p66364
(F1
F0.00014334862385321102
I1
I0
I1
tp66365
sS'concurrently,being,treated'
p66366
(F1
F0.00028669724770642203
I2
I0
I2
tp66367
sS'been,reported,with'
p66368
(F0.59999999999999998
F0.0017201834862385322
I16
I4
I12
tp66369
sS'corresponding,values,for'
p66370
(F1
F0.00028669724770642203
I0
I2
I-2
tp66371
sS'lastly,local,use'
p66372
(F1
F0.00014334862385321102
I0
I1
I-1
tp66373
sS'since,there,have'
p66374
(F1
F0.00043004587155963305
I3
I0
I3
tp66375
sS'meaningfully,alter,the'
p66376
(F1
F0.00014334862385321102
I0
I1
I-1
tp66377
sS'of,should,not'
p66378
(F1
F0.00014334862385321102
I1
I0
I1
tp66379
sS'prothrombin,times,when'
p66380
(F1
F0.00014334862385321102
I1
I0
I1
tp66381
sS'mg,bid,in'
p66382
(F1
F0.00014334862385321102
I1
I0
I1
tp66383
sS'an,oral,containing'
p66384
(F0
F0
I1
I1
I0
tp66385
sS'weight,to,erythro-fluorocitrate'
p66386
(F1
F0.00014334862385321102
I1
I0
I1
tp66387
sS'to,increase,and'
p66388
(F1
F0.00014334862385321102
I1
I0
I1
tp66389
sS'min,before,the'
p66390
(F1
F0.00014334862385321102
I0
I1
I-1
tp66391
sS'gel,on,the'
p66392
(F1
F0.00014334862385321102
I0
I1
I-1
tp66393
sS'we,propose,these'
p66394
(F1
F0.00014334862385321102
I1
I0
I1
tp66395
sS'inhibitors,psychotropic,medications'
p66396
(F1
F0.00014334862385321102
I1
I0
I1
tp66397
sS'cardiac,stimulants,and'
p66398
(F1
F0.00014334862385321102
I1
I0
I1
tp66399
sS'not,mix,toradol'
p66400
(F1
F0.00014334862385321102
I0
I1
I-1
tp66401
sS'and,cns,depressant'
p66402
(F0
F0
I2
I2
I0
tp66403
sS'dose,of,felbatol'
p66404
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp66405
sS'and,or,effect'
p66406
(F1
F0.00014334862385321102
I1
I0
I1
tp66407
sS'diet,for,weeks'
p66408
(F1
F0.00014334862385321102
I1
I0
I1
tp66409
sS'therapy,with,camptosar'
p66410
(F1
F0.00014334862385321102
I1
I0
I1
tp66411
sS'then,careful,adjustment'
p66412
(F1
F0.00014334862385321102
I1
I0
I1
tp66413
sS'syndrome,has,been'
p66414
(F1
F0.00014334862385321102
I1
I0
I1
tp66415
sS'to,subjects,already'
p66416
(F1
F0.00014334862385321102
I1
I0
I1
tp66417
sS'serum,levels,and'
p66418
(F1
F0.0012901376146788992
I9
I0
I9
tp66419
sS'showed,that,concomitant'
p66420
(F1
F0.00014334862385321102
I0
I1
I-1
tp66421
sS'should,also,not'
p66422
(F1
F0.00014334862385321102
I1
I0
I1
tp66423
sS'consequently,it,is'
p66424
(F1
F0.00028669724770642203
I2
I0
I2
tp66425
sS'homocysteine,excretion,rate'
p66426
(F1
F0.00014334862385321102
I0
I1
I-1
tp66427
sS'clearance,of,fludrocortisone'
p66428
(F1
F0.00014334862385321102
I1
I0
I1
tp66429
sS'prolongation,and,have'
p66430
(F1
F0.00014334862385321102
I0
I1
I-1
tp66431
sS'result,in,vertigo'
p66432
(F1
F0.00014334862385321102
I0
I1
I-1
tp66433
sS'unchanged,following,coadministration'
p66434
(F1
F0.00014334862385321102
I0
I1
I-1
tp66435
sS'fumarate,seroquel,is'
p66436
(F1
F0.00014334862385321102
I0
I1
I-1
tp66437
sS'an,are,used'
p66438
(F1
F0.00014334862385321102
I1
I0
I1
tp66439
sS'anti-asthma,medications,including'
p66440
(F1
F0.00014334862385321102
I0
I1
I-1
tp66441
sS'these,disturbances,have'
p66442
(F1
F0.00014334862385321102
I1
I0
I1
tp66443
sS'is,an,increased'
p66444
(F1
F0.00014334862385321102
I0
I1
I-1
tp66445
sS's-warfarin,and,respectively'
p66446
(F1
F0.00014334862385321102
I1
I0
I1
tp66447
sS'experience,there,have'
p66448
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp66449
sS'interval,msec,was'
p66450
(F1
F0.00014334862385321102
I1
I0
I1
tp66451
sS'organic,were,used'
p66452
(F1
F0.00028669724770642203
I2
I0
I2
tp66453
sS'of,functional,antagonism'
p66454
(F1
F0.00043004587155963305
I3
I0
I3
tp66455
sS'activity,ganglionic,blocking'
p66456
(F1
F0.00014334862385321102
I0
I1
I-1
tp66457
sS'tolerated,and,of'
p66458
(F1
F0.00014334862385321102
I1
I0
I1
tp66459
sS'theophylline,clearance,may'
p66460
(F1
F0.00014334862385321102
I0
I1
I-1
tp66461
sS'liver,aminotransferases,was'
p66462
(F1
F0.00014334862385321102
I0
I1
I-1
tp66463
sS'with,other,has'
p66464
(F1
F0.00014334862385321102
I1
I0
I1
tp66465
sS'on,concomitant,therapy'
p66466
(F1
F0.00028669724770642203
I2
I0
I2
tp66467
sS'including,more,convenient'
p66468
(F1
F0.00014334862385321102
I0
I1
I-1
tp66469
sS'either,s,bioavailability'
p66470
(F1
F0.00014334862385321102
I0
I1
I-1
tp66471
sS'elevated,levels,have'
p66472
(F1
F0.00014334862385321102
I1
I0
I1
tp66473
sS'experience,a,precipitous'
p66474
(F1
F0.00014334862385321102
I1
I0
I1
tp66475
sS'it,is,structurally'
p66476
(F1
F0.00014334862385321102
I0
I1
I-1
tp66477
sS'affect,protein,tyrosine'
p66478
(F1
F0.00014334862385321102
I0
I1
I-1
tp66479
sS'pills,is,reduced'
p66480
(F1
F0.00014334862385321102
I1
I0
I1
tp66481
sS'eg,and,other'
p66482
(F1
F0.00028669724770642203
I2
I0
I2
tp66483
sS'of,vardenafil,in'
p66484
(F1
F0.00028669724770642203
I2
I0
I2
tp66485
sS'patients,given,both'
p66486
(F1
F0.00014334862385321102
I1
I0
I1
tp66487
sS'long-term,administration,of'
p66488
(F1
F0.00014334862385321102
I0
I1
I-1
tp66489
sS'antagonists,such,as'
p66490
(F1
F0.00043004587155963305
I3
I0
I3
tp66491
sS'but,may,reduce'
p66492
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp66493
sS'in,evaluating,the'
p66494
(F1
F0.00014334862385321102
I0
I1
I-1
tp66495
sS'had,a,small'
p66496
(F1
F0.00028669724770642203
I0
I2
I-2
tp66497
sS'of,enhancement,of'
p66498
(F1
F0.00014334862385321102
I0
I1
I-1
tp66499
sS'to,mg,b'
p66500
(F1
F0.00028669724770642203
I0
I2
I-2
tp66501
sS'used,together,with'
p66502
(F1
F0.00014334862385321102
I1
I0
I1
tp66503
sS'concentrations,of,both'
p66504
(F1
F0.00014334862385321102
I1
I0
I1
tp66505
sS'mean,percentage,increase'
p66506
(F1
F0.00014334862385321102
I1
I0
I1
tp66507
sS'requires,tikosyn,and'
p66508
(F1
F0.00014334862385321102
I1
I0
I1
tp66509
sS'fatal,reactions,including'
p66510
(F1
F0.00014334862385321102
I1
I0
I1
tp66511
sS'of,the,cyp2d6'
p66512
(F0
F0
I1
I1
I0
tp66513
sS'successfully,concurrently,with'
p66514
(F1
F0.00028669724770642203
I0
I2
I-2
tp66515
sS'additive,interaction,with'
p66516
(F1
F0.00014334862385321102
I1
I0
I1
tp66517
sS'on,the,pr'
p66518
(F1
F0.00014334862385321102
I1
I0
I1
tp66519
sS'antagonists,increased,mean'
p66520
(F1
F0.00014334862385321102
I1
I0
I1
tp66521
sS'in,maximal,plasma'
p66522
(F1
F0.00014334862385321102
I1
I0
I1
tp66523
sS'as,inhibitors,for'
p66524
(F1
F0.00014334862385321102
I0
I1
I-1
tp66525
sS'did,slightly,enhance'
p66526
(F1
F0.00014334862385321102
I1
I0
I1
tp66527
sS'interactions,between,uroxatral'
p66528
(F1
F0.00014334862385321102
I0
I1
I-1
tp66529
sS'concentrate,should,not'
p66530
(F1
F0.00014334862385321102
I1
I0
I1
tp66531
sS'symptom,onset,were'
p66532
(F1
F0.00014334862385321102
I0
I1
I-1
tp66533
sS'coadministration,of,femara'
p66534
(F0
F0
I1
I1
I0
tp66535
sS'patients,receiving,hmg-coa'
p66536
(F1
F0.00014334862385321102
I1
I0
I1
tp66537
sS'hours,before,resulted'
p66538
(F1
F0.00014334862385321102
I1
I0
I1
tp66539
sS'which,patients,with'
p66540
(F1
F0.00028669724770642203
I2
I0
I2
tp66541
sS'herbal,supplement,st'
p66542
(F1
F0.00014334862385321102
I0
I1
I-1
tp66543
sS'intoxication,appropriate,adjustment'
p66544
(F1
F0.00014334862385321102
I0
I1
I-1
tp66545
sS'and,the,time'
p66546
(F1
F0.00014334862385321102
I0
I1
I-1
tp66547
sS'route,and,should'
p66548
(F1
F0.00014334862385321102
I1
I0
I1
tp66549
sS'these,effects,may'
p66550
(F1
F0.00028669724770642203
I2
I0
I2
tp66551
sS'thrombocytopenia,the,co-administration'
p66552
(F1
F0.00014334862385321102
I0
I1
I-1
tp66553
sS'for,days,as'
p66554
(F1
F0.00014334862385321102
I1
I0
I1
tp66555
sS'ketoconazole,has,been'
p66556
(F1
F0.00014334862385321102
I1
I0
I1
tp66557
sS'cisapride,should,not'
p66558
(F1
F0.00014334862385321102
I1
I0
I1
tp66559
sS'agonists,at,receptors'
p66560
(F1
F0.00014334862385321102
I1
I0
I1
tp66561
sS'edema,has,been'
p66562
(F1
F0.00014334862385321102
I1
I0
I1
tp66563
sS'primary,elimination,route'
p66564
(F1
F0.00014334862385321102
I1
I0
I1
tp66565
sS'tricyclic,antidepressant,agent'
p66566
(F1
F0.00014334862385321102
I0
I1
I-1
tp66567
sS'the,concomitant,or'
p66568
(F1
F0.00014334862385321102
I1
I0
I1
tp66569
sS'which,affect,hepatic'
p66570
(F1
F0.00014334862385321102
I0
I1
I-1
tp66571
sS'of,by,competitive'
p66572
(F1
F0.00014334862385321102
I1
I0
I1
tp66573
sS'a,kg,person'
p66574
(F1
F0.00014334862385321102
I0
I1
I-1
tp66575
sS'therapy,may,cause'
p66576
(F1
F0.00014334862385321102
I0
I1
I-1
tp66577
sS'situ,ligated,duodenal'
p66578
(F1
F0.00014334862385321102
I0
I1
I-1
tp66579
sS'but,these,changes'
p66580
(F1
F0.00014334862385321102
I0
I1
I-1
tp66581
sS'antagonist,has,been'
p66582
(F1
F0.00014334862385321102
I1
I0
I1
tp66583
sS'this,effect,was'
p66584
(F1
F0.00014334862385321102
I1
I0
I1
tp66585
sS'significantly,improved,the'
p66586
(F1
F0.00014334862385321102
I0
I1
I-1
tp66587
sS'not,attenuated,by'
p66588
(F1
F0.00014334862385321102
I0
I1
I-1
tp66589
sS'including,indocin,is'
p66590
(F1
F0.00014334862385321102
I1
I0
I1
tp66591
sS'high-dose,and,carbonic'
p66592
(F1
F0.00014334862385321102
I1
I0
I1
tp66593
sS'volunteers,under,fasting'
p66594
(F1
F0.00014334862385321102
I0
I1
I-1
tp66595
sS'of,bleeding,particularly'
p66596
(F1
F0.00014334862385321102
I1
I0
I1
tp66597
sS'between,and,intravenously'
p66598
(F1
F0.00014334862385321102
I1
I0
I1
tp66599
sS'of,nor,does'
p66600
(F1
F0.00014334862385321102
I0
I1
I-1
tp66601
sS'rarely,with,concomitant'
p66602
(F1
F0.00014334862385321102
I1
I0
I1
tp66603
sS'sulindac,the,concomitant'
p66604
(F1
F0.00014334862385321102
I1
I0
I1
tp66605
sS'to,control,hypertension'
p66606
(F1
F0.00014334862385321102
I1
I0
I1
tp66607
sS'orencia,has,been'
p66608
(F1
F0.00014334862385321102
I1
I0
I1
tp66609
sS'receive,tablets,at'
p66610
(F1
F0.00014334862385321102
I0
I1
I-1
tp66611
sS'agents,affecting,cytochrome'
p66612
(F1
F0.00014334862385321102
I0
I1
I-1
tp66613
sS'taken,at,and'
p66614
(F1
F0.00014334862385321102
I1
I0
I1
tp66615
sS'sometimes,proves,to'
p66616
(F1
F0.00014334862385321102
I1
I0
I1
tp66617
sS'other,nonsteroidal,probably'
p66618
(F1
F0.00014334862385321102
I1
I0
I1
tp66619
sS'mg,given,once'
p66620
(F1
F0.00014334862385321102
I1
I0
I1
tp66621
sS'digoxin,coadministration,of'
p66622
(F1
F0.00014334862385321102
I1
I0
I1
tp66623
sS'naproxen,and,other'
p66624
(F1
F0.00014334862385321102
I1
I0
I1
tp66625
sS'sonata,mg,and'
p66626
(F0.5
F0.00028669724770642203
I3
I1
I2
tp66627
sS'in,cyp,d6'
p66628
(F1
F0.00014334862385321102
I1
I0
I1
tp66629
sS'the,protein,binding'
p66630
(F0
F0
I2
I2
I0
tp66631
sS'range,of,mg'
p66632
(F0
F0
I1
I1
I0
tp66633
sS'of,other,related'
p66634
(F1
F0.00014334862385321102
I1
I0
I1
tp66635
sS'micro-dosed,preparations,minipills'
p66636
(F1
F0.00014334862385321102
I1
I0
I1
tp66637
sS'antacids,containing,hydroxide'
p66638
(F1
F0.00014334862385321102
I1
I0
I1
tp66639
sS'hepatic,cytochrome,p-'
p66640
(F1
F0.00014334862385321102
I0
I1
I-1
tp66641
sS'the,pressor,effects'
p66642
(F1
F0.00028669724770642203
I2
I0
I2
tp66643
sS'dose,in,accordance'
p66644
(F1
F0.00014334862385321102
I0
I1
I-1
tp66645
sS'estimation,of,tolerance'
p66646
(F1
F0.00014334862385321102
I0
I1
I-1
tp66647
sS'class,including,for'
p66648
(F1
F0.00014334862385321102
I1
I0
I1
tp66649
sS'microsomal,drug,metabolism'
p66650
(F1
F0.00014334862385321102
I1
I0
I1
tp66651
sS'dictates,careful,monitoring'
p66652
(F1
F0.00014334862385321102
I1
I0
I1
tp66653
sS'provided,significant,protection'
p66654
(F1
F0.00014334862385321102
I1
I0
I1
tp66655
sS'oral,birth,control'
p66656
(F1
F0.00014334862385321102
I0
I1
I-1
tp66657
sS'maintained,patients,beginning'
p66658
(F1
F0.00014334862385321102
I1
I0
I1
tp66659
sS'enzyme,inducers,are'
p66660
(F1
F0.00014334862385321102
I1
I0
I1
tp66661
sS'may,also,adversely'
p66662
(F1
F0.00014334862385321102
I1
I0
I1
tp66663
sS'anti-,inflammatory,agents'
p66664
(F1
F0.00014334862385321102
I1
I0
I1
tp66665
sS'oral,anticoagulants,thyroid'
p66666
(F1
F0.00014334862385321102
I0
I1
I-1
tp66667
sS'a,pharmacological,analysis'
p66668
(F1
F0.00014334862385321102
I0
I1
I-1
tp66669
sS'of,synthetic,possibly'
p66670
(F1
F0.00014334862385321102
I1
I0
I1
tp66671
sS'compromise,the,beneficial'
p66672
(F1
F0.00014334862385321102
I1
I0
I1
tp66673
sS'gram,absorption,of'
p66674
(F1
F0.00014334862385321102
I1
I0
I1
tp66675
sS'dietary-obese,rats,responses'
p66676
(F1
F0.00014334862385321102
I0
I1
I-1
tp66677
sS'nervous,system,may'
p66678
(F1
F0.00014334862385321102
I0
I1
I-1
tp66679
sS'day,increased,the'
p66680
(F1
F0.00014334862385321102
I1
I0
I1
tp66681
sS'clinically,warranted,appropriate'
p66682
(F1
F0.00057339449541284407
I4
I0
I4
tp66683
sS'interfere,with,the'
p66684
(F0.35294117647058826
F0.0017201834862385322
I23
I11
I12
tp66685
sS'was,decreased,an'
p66686
(F1
F0.00028669724770642203
I2
I0
I2
tp66687
sS'of,with,hydroxide'
p66688
(F1
F0.00014334862385321102
I1
I0
I1
tp66689
sS'that,m,was'
p66690
(F1
F0.00014334862385321102
I0
I1
I-1
tp66691
sS'risk,of,rashes'
p66692
(F1
F0.00014334862385321102
I0
I1
I-1
tp66693
sS'laboratory,testing,should'
p66694
(F1
F0.00014334862385321102
I1
I0
I1
tp66695
sS'k,antagonists,drugs'
p66696
(F1
F0.00014334862385321102
I1
I0
I1
tp66697
sS'affect,the,conversion'
p66698
(F1
F0.00014334862385321102
I0
I1
I-1
tp66699
sS'not,known,whether'
p66700
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp66701
sS'be,reduced,by'
p66702
(F0.25
F0.00028669724770642203
I5
I3
I2
tp66703
sS'inhalation,dose,in'
p66704
(F1
F0.00014334862385321102
I1
I0
I1
tp66705
sS'be,negatively,impacted'
p66706
(F1
F0.00014334862385321102
I0
I1
I-1
tp66707
sS'in,three,separate'
p66708
(F1
F0.00014334862385321102
I0
I1
I-1
tp66709
sS'to,a,maintenance'
p66710
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp66711
sS'given,concomitantly,in'
p66712
(F1
F0.00014334862385321102
I1
I0
I1
tp66713
sS'enhanced,if,combination'
p66714
(F1
F0.00014334862385321102
I1
I0
I1
tp66715
sS'difluoroacetone,in,the'
p66716
(F1
F0.00014334862385321102
I1
I0
I1
tp66717
sS'metabolized,and,renal'
p66718
(F1
F0.00014334862385321102
I0
I1
I-1
tp66719
sS'other,concomitant,therapy'
p66720
(F1
F0.00043004587155963305
I0
I3
I-3
tp66721
sS'levels,may,increase'
p66722
(F0
F0
I1
I1
I0
tp66723
sS'concomitant,supplementation,with'
p66724
(F1
F0.00014334862385321102
I0
I1
I-1
tp66725
sS'striking,and,sustained'
p66726
(F1
F0.00028669724770642203
I2
I0
I2
tp66727
sS'rat,brain,and'
p66728
(F1
F0.00014334862385321102
I1
I0
I1
tp66729
sS'on,the,sensitivity'
p66730
(F1
F0.00014334862385321102
I0
I1
I-1
tp66731
sS'are,mainly,metabolized'
p66732
(F1
F0.00014334862385321102
I1
I0
I1
tp66733
sS'reported,concomitant,use'
p66734
(F1
F0.00014334862385321102
I1
I0
I1
tp66735
sS'prefrontal,cortical,tissues'
p66736
(F1
F0.00014334862385321102
I0
I1
I-1
tp66737
sS'administration,should,also'
p66738
(F1
F0.00014334862385321102
I1
I0
I1
tp66739
sS'treated,with,acamprosate'
p66740
(F1
F0.00014334862385321102
I0
I1
I-1
tp66741
sS'bwt,were,given'
p66742
(F1
F0.00014334862385321102
I0
I1
I-1
tp66743
sS'there,was,about'
p66744
(F1
F0.00014334862385321102
I1
I0
I1
tp66745
sS'psychoses,to,a'
p66746
(F1
F0.00014334862385321102
I0
I1
I-1
tp66747
sS'induced,by,intraventricular'
p66748
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp66749
sS'less,than,two-second'
p66750
(F1
F0.00014334862385321102
I1
I0
I1
tp66751
sS'concentrations,caution,is'
p66752
(F1
F0.00014334862385321102
I1
I0
I1
tp66753
sS'such,as,salicylic'
p66754
(F1
F0.00014334862385321102
I0
I1
I-1
tp66755
sS'volunteers,administration,of'
p66756
(F1
F0.00014334862385321102
I0
I1
I-1
tp66757
sS'drug,laboratory,tests'
p66758
(F1
F0.00014334862385321102
I0
I1
I-1
tp66759
sS'of,basal,medium'
p66760
(F1
F0.00014334862385321102
I0
I1
I-1
tp66761
sS'of,some,and'
p66762
(F1
F0.00014334862385321102
I1
I0
I1
tp66763
sS'plasma,concentrations,auc'
p66764
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp66765
sS'vitamin,d,by'
p66766
(F1
F0.00043004587155963305
I3
I0
I3
tp66767
sS'following,beta-adrenergic,blocking'
p66768
(F1
F0.00014334862385321102
I0
I1
I-1
tp66769
sS'similar,association,though'
p66770
(F1
F0.00028669724770642203
I0
I2
I-2
tp66771
sS'inhibitors,including,sulfate'
p66772
(F0
F0
I1
I1
I0
tp66773
sS'by,monoamine,oxidase'
p66774
(F0.5
F0.00028669724770642203
I3
I1
I2
tp66775
sS'in,a,large'
p66776
(F1
F0.00014334862385321102
I0
I1
I-1
tp66777
sS'no,clinically,or'
p66778
(F1
F0.00014334862385321102
I0
I1
I-1
tp66779
sS'ingestion,of,and'
p66780
(F1
F0.00014334862385321102
I1
I0
I1
tp66781
sS'dexfenfluramine,should,not'
p66782
(F1
F0.00014334862385321102
I1
I0
I1
tp66783
sS'a,p-glycoprotein,substrate'
p66784
(F1
F0.00014334862385321102
I1
I0
I1
tp66785
sS'reduce,or,reverse'
p66786
(F1
F0.00028669724770642203
I2
I0
I2
tp66787
sS'intraventricular,and,elicit'
p66788
(F1
F0.00014334862385321102
I0
I1
I-1
tp66789
sS'chloral,hydrate,diet'
p66790
(F1
F0.00014334862385321102
I1
I0
I1
tp66791
sS'with,the,conversion'
p66792
(F1
F0.00014334862385321102
I0
I1
I-1
tp66793
sS'induce,bleeding,and'
p66794
(F1
F0.00014334862385321102
I1
I0
I1
tp66795
sS'alpha-adrenergic,stimulants,including'
p66796
(F1
F0.00014334862385321102
I1
I0
I1
tp66797
sS'first,post-transplant,year'
p66798
(F1
F0.00014334862385321102
I0
I1
I-1
tp66799
sS'of,norfloxacin,in'
p66800
(F1
F0.00014334862385321102
I1
I0
I1
tp66801
sS'gastrointestinal,lesions,as'
p66802
(F1
F0.00014334862385321102
I1
I0
I1
tp66803
sS'oral,formulations,of'
p66804
(F1
F0.00014334862385321102
I1
I0
I1
tp66805
sS'taking,both,agents'
p66806
(F1
F0.00014334862385321102
I1
I0
I1
tp66807
sS'increased,approximately,threefold'
p66808
(F1
F0.00014334862385321102
I1
I0
I1
tp66809
sS'active,metabolite,norfluoxe-tine'
p66810
(F1
F0.00014334862385321102
I0
I1
I-1
tp66811
sS'effects,of,ergomar'
p66812
(F1
F0.00028669724770642203
I2
I0
I2
tp66813
sS'were,observed,after'
p66814
(F1
F0.00014334862385321102
I0
I1
I-1
tp66815
sS'chloride,excretion,compared'
p66816
(F1
F0.00014334862385321102
I1
I0
I1
tp66817
sS'to,temporarily,raise'
p66818
(F1
F0.00014334862385321102
I1
I0
I1
tp66819
sS'auc,increased,approximately'
p66820
(F1
F0.00014334862385321102
I1
I0
I1
tp66821
sS'sodium,may,enhance'
p66822
(F1
F0.00014334862385321102
I1
I0
I1
tp66823
sS'are,a,major'
p66824
(F1
F0.00014334862385321102
I1
I0
I1
tp66825
sS'appear,to,be'
p66826
(F0
F0
I2
I2
I0
tp66827
sS'or,cns,depression'
p66828
(F1
F0.00014334862385321102
I0
I1
I-1
tp66829
sS'in,breast,cancer'
p66830
(F1
F0.00014334862385321102
I0
I1
I-1
tp66831
sS'oxytocic,may,cause'
p66832
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp66833
sS'treated,subjects,received'
p66834
(F1
F0.00028669724770642203
I0
I2
I-2
tp66835
sS'proleukin,including,crescentic'
p66836
(F1
F0.00014334862385321102
I1
I0
I1
tp66837
sS'exercised,when,lexapro'
p66838
(F1
F0.00014334862385321102
I1
I0
I1
tp66839
sS'not,a,short-acting'
p66840
(F1
F0.00014334862385321102
I1
I0
I1
tp66841
sS'affect,subjective,responses'
p66842
(F1
F0.00014334862385321102
I0
I1
I-1
tp66843
sS'anions,antithyroid,b-adrenergic'
p66844
(F1
F0.00014334862385321102
I0
I1
I-1
tp66845
sS'of,microg,kg'
p66846
(F1
F0.00014334862385321102
I0
I1
I-1
tp66847
sS'minute,after,a'
p66848
(F1
F0.00014334862385321102
I1
I0
I1
tp66849
sS'cytochrome,p450-mediated,metabolism'
p66850
(F1
F0.00014334862385321102
I0
I1
I-1
tp66851
sS'discontinuation,of,produced'
p66852
(F1
F0.00014334862385321102
I1
I0
I1
tp66853
sS'and,the,selective'
p66854
(F1
F0.00014334862385321102
I1
I0
I1
tp66855
sS'endogenous,steroid,hormones'
p66856
(F1
F0.00014334862385321102
I1
I0
I1
tp66857
sS'metabolizers,suggesting,that'
p66858
(F1
F0.00014334862385321102
I1
I0
I1
tp66859
sS'possibility,that,a'
p66860
(F1
F0.00014334862385321102
I1
I0
I1
tp66861
sS'neuroleptic,drugs,l-phenylalanine'
p66862
(F1
F0.00014334862385321102
I1
I0
I1
tp66863
sS'to,the,dose'
p66864
(F1
F0.00014334862385321102
I0
I1
I-1
tp66865
sS'caused,an,eight-fold'
p66866
(F1
F0.00014334862385321102
I1
I0
I1
tp66867
sS'the,serum,protein'
p66868
(F1
F0.00014334862385321102
I0
I1
I-1
tp66869
sS'should,not,be'
p66870
(F0.74193548387096775
F0.0065940366972477068
I54
I8
I46
tp66871
sS'containing,regimens,who'
p66872
(F1
F0.00014334862385321102
I1
I0
I1
tp66873
sS'single,agent,or'
p66874
(F1
F0.00014334862385321102
I0
I1
I-1
tp66875
sS'balance,testing,and'
p66876
(F1
F0.00014334862385321102
I1
I0
I1
tp66877
sS'increased,when,either'
p66878
(F1
F0.00014334862385321102
I1
I0
I1
tp66879
sS'antineoplastic,agents,having'
p66880
(F1
F0.00014334862385321102
I1
I0
I1
tp66881
sS'as,with,high'
p66882
(F1
F0.00014334862385321102
I0
I1
I-1
tp66883
sS'unreliable,prothrombin,time'
p66884
(F1
F0.00028669724770642203
I2
I0
I2
tp66885
sS'oral,antagonist,was'
p66886
(F1
F0.00014334862385321102
I1
I0
I1
tp66887
sS'combinations,of,and'
p66888
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp66889
sS'expected,to,reduce'
p66890
(F1
F0.00028669724770642203
I2
I0
I2
tp66891
sS'l,while,corresponding'
p66892
(F1
F0.00014334862385321102
I0
I1
I-1
tp66893
sS'of,and,has'
p66894
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp66895
sS'secretion,by,h2'
p66896
(F1
F0.00014334862385321102
I1
I0
I1
tp66897
sS'concentration,of,following'
p66898
(F1
F0.00014334862385321102
I0
I1
I-1
tp66899
sS'combined,effects,may'
p66900
(F1
F0.00014334862385321102
I1
I0
I1
tp66901
sS'of,and,had'
p66902
(F1
F0.00043004587155963305
I0
I3
I-3
tp66903
sS'and,an,decrease'
p66904
(F1
F0.00014334862385321102
I1
I0
I1
tp66905
sS'package,insert,for'
p66906
(F1
F0.00028669724770642203
I2
I0
I2
tp66907
sS'or,other,should'
p66908
(F1
F0.00014334862385321102
I1
I0
I1
tp66909
sS'result,in,prolongation'
p66910
(F1
F0.00043004587155963305
I3
I0
I3
tp66911
sS'a4,isozyme,which'
p66912
(F1
F0.00014334862385321102
I0
I1
I-1
tp66913
sS'alkaloid,class,of'
p66914
(F1
F0.00014334862385321102
I1
I0
I1
tp66915
sS'binding,displacement,between'
p66916
(F1
F0.00014334862385321102
I0
I1
I-1
tp66917
sS'by,intermediate,doses'
p66918
(F1
F0.00014334862385321102
I1
I0
I1
tp66919
sS'enzyme,induction,thus'
p66920
(F1
F0.00014334862385321102
I1
I0
I1
tp66921
sS'with,mg,day'
p66922
(F0
F0
I1
I1
I0
tp66923
sS'of,both,together'
p66924
(F1
F0.00028669724770642203
I2
I0
I2
tp66925
sS'taking,cyp3a4,inducers'
p66926
(F1
F0.00014334862385321102
I0
I1
I-1
tp66927
sS'a,single,case'
p66928
(F1
F0.00014334862385321102
I1
I0
I1
tp66929
sS'and,aprepitant,when'
p66930
(F1
F0.00014334862385321102
I1
I0
I1
tp66931
sS'glomerular,filtration,or'
p66932
(F1
F0.00014334862385321102
I0
I1
I-1
tp66933
sS'an,nsaid,has'
p66934
(F1
F0.00014334862385321102
I0
I1
I-1
tp66935
sS'qt,interval,clinical'
p66936
(F1
F0.00014334862385321102
I0
I1
I-1
tp66937
sS'standard,therapy,includes'
p66938
(F1
F0.00014334862385321102
I0
I1
I-1
tp66939
sS'premedicated,with,such'
p66940
(F1
F0.00014334862385321102
I0
I1
I-1
tp66941
sS'administration,systemic,clearance'
p66942
(F1
F0.00014334862385321102
I1
I0
I1
tp66943
sS'diminished,renal,function'
p66944
(F1
F0.00014334862385321102
I1
I0
I1
tp66945
sS'the,type,caution'
p66946
(F1
F0.00014334862385321102
I1
I0
I1
tp66947
sS'response,to,pentobarbital-induced'
p66948
(F1
F0.00014334862385321102
I0
I1
I-1
tp66949
sS'twice,daily,for'
p66950
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp66951
sS'patients,taking,nsaids'
p66952
(F1
F0.00057339449541284407
I4
I0
I4
tp66953
sS'is,insufficient,experience'
p66954
(F1
F0.00014334862385321102
I1
I0
I1
tp66955
sS'concurrently,with,norpace'
p66956
(F1
F0.00014334862385321102
I1
I0
I1
tp66957
sS'a,theoretical,potential'
p66958
(F1
F0.00014334862385321102
I1
I0
I1
tp66959
sS'ml,min,p'
p66960
(F1
F0.00014334862385321102
I1
I0
I1
tp66961
sS'subjects,experienced,a'
p66962
(F1
F0.00028669724770642203
I2
I0
I2
tp66963
sS'cations,likely,will'
p66964
(F1
F0.00014334862385321102
I1
I0
I1
tp66965
sS'or,may,impair'
p66966
(F1
F0.00014334862385321102
I1
I0
I1
tp66967
sS'mg,fe,instead'
p66968
(F1
F0.00014334862385321102
I1
I0
I1
tp66969
sS'safely,used,concomitantly'
p66970
(F1
F0.00028669724770642203
I0
I2
I-2
tp66971
sS'of,distribution,and'
p66972
(F1
F0.00014334862385321102
I0
I1
I-1
tp66973
sS'any,additional,including'
p66974
(F1
F0.00014334862385321102
I1
I0
I1
tp66975
sS'diuretic,agents,reduce'
p66976
(F1
F0.00028669724770642203
I2
I0
I2
tp66977
sS'using,preparations,containing'
p66978
(F1
F0.00014334862385321102
I0
I1
I-1
tp66979
sS'with,accutane,and'
p66980
(F1
F0.00014334862385321102
I1
I0
I1
tp66981
sS'v,significantly,improved'
p66982
(F1
F0.00014334862385321102
I0
I1
I-1
tp66983
sS'interact,with,wthionamide'
p66984
(F1
F0.00014334862385321102
I0
I1
I-1
tp66985
sS'dose,of,cefditoren'
p66986
(F1
F0.00014334862385321102
I1
I0
I1
tp66987
sS'g,hour,before'
p66988
(F1
F0.00014334862385321102
I1
I0
I1
tp66989
sS'ranitidine,mg,twice'
p66990
(F1
F0.00014334862385321102
I0
I1
I-1
tp66991
sS'dose,of,increased'
p66992
(F1
F0.00014334862385321102
I1
I0
I1
tp66993
sS'and,cyp,c19'
p66994
(F1
F0.00014334862385321102
I0
I1
I-1
tp66995
sS'that,levels,may'
p66996
(F1
F0.00014334862385321102
I1
I0
I1
tp66997
sS'to,human,serum'
p66998
(F1
F0.00014334862385321102
I1
I0
I1
tp66999
sS'decrease,the,absorption'
p67000
(F1
F0.00043004587155963305
I3
I0
I3
tp67001
sS'screening,in,the'
p67002
(F1
F0.00014334862385321102
I0
I1
I-1
tp67003
sS'but,not,limited'
p67004
(F1
F0.00028669724770642203
I2
I0
I2
tp67005
sS'as,antiemetic,prophylaxis'
p67006
(F1
F0.00014334862385321102
I1
I0
I1
tp67007
sS'effect,of,extraneal'
p67008
(F1
F0.00014334862385321102
I0
I1
I-1
tp67009
sS'very,potent,inhibitors'
p67010
(F1
F0.00014334862385321102
I1
I0
I1
tp67011
sS'juice,with,may'
p67012
(F1
F0.00014334862385321102
I0
I1
I-1
tp67013
sS'inhibit,cyp,a4'
p67014
(F1
F0.00014334862385321102
I1
I0
I1
tp67015
sS'hydroxide,with,mg'
p67016
(F1
F0.00014334862385321102
I1
I0
I1
tp67017
sS'a,d,e'
p67018
(F1
F0.00014334862385321102
I0
I1
I-1
tp67019
sS'to,prevent,the'
p67020
(F1
F0.00028669724770642203
I2
I0
I2
tp67021
sS'that,dopamine-induced,ventricular'
p67022
(F1
F0.00014334862385321102
I1
I0
I1
tp67023
sS'by,cytochrome,p450'
p67024
(F0.25
F0.00028669724770642203
I3
I5
I-2
tp67025
sS'any,conclusions,to'
p67026
(F1
F0.00014334862385321102
I0
I1
I-1
tp67027
sS'antiinflammatory,including,indocin'
p67028
(F1
F0.00014334862385321102
I1
I0
I1
tp67029
sS'daily,for,the'
p67030
(F1
F0.00014334862385321102
I0
I1
I-1
tp67031
sS'that,is,a'
p67032
(F1
F0.00014334862385321102
I1
I0
I1
tp67033
sS'for,dose,adjustment'
p67034
(F1
F0.00028669724770642203
I0
I2
I-2
tp67035
sS'patients,that,are'
p67036
(F1
F0.00014334862385321102
I1
I0
I1
tp67037
sS'up,to,leading'
p67038
(F1
F0.00014334862385321102
I1
I0
I1
tp67039
sS'minimal,effects,on'
p67040
(F1
F0.00014334862385321102
I0
I1
I-1
tp67041
sS'following,agents,may'
p67042
(F0
F0
I2
I2
I0
tp67043
sS'blockers,of,the'
p67044
(F1
F0.00014334862385321102
I1
I0
I1
tp67045
sS'and,concentrations,should'
p67046
(F1
F0.00014334862385321102
I1
I0
I1
tp67047
sS'antifungals,the,effect'
p67048
(F1
F0.00014334862385321102
I0
I1
I-1
tp67049
sS'mg,m2,plus'
p67050
(F1
F0.00014334862385321102
I0
I1
I-1
tp67051
sS'lithiums,renal,clearance'
p67052
(F1
F0.00014334862385321102
I1
I0
I1
tp67053
sS'complete,and,immediately'
p67054
(F1
F0.00014334862385321102
I1
I0
I1
tp67055
sS'significant,difference,in'
p67056
(F1
F0.00014334862385321102
I0
I1
I-1
tp67057
sS'receiving,could,result'
p67058
(F1
F0.00014334862385321102
I0
I1
I-1
tp67059
sS'the,patients,should'
p67060
(F1
F0.00014334862385321102
I1
I0
I1
tp67061
sS'class,i,such'
p67062
(F1
F0.00014334862385321102
I0
I1
I-1
tp67063
sS'either,erythro-fluorocitrate,synthesis'
p67064
(F1
F0.00014334862385321102
I0
I1
I-1
tp67065
sS'in,otherwise,healthy'
p67066
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp67067
sS'on,components,p2'
p67068
(F1
F0.00014334862385321102
I1
I0
I1
tp67069
sS'eg,channel,blockers'
p67070
(F1
F0.00014334862385321102
I1
I0
I1
tp67071
sS'dose,of,didanosine-placebo'
p67072
(F1
F0.00014334862385321102
I1
I0
I1
tp67073
sS'heart,failure,severe'
p67074
(F1
F0.00014334862385321102
I1
I0
I1
tp67075
sS'atypical,antipsychotic,agent'
p67076
(F1
F0.00014334862385321102
I0
I1
I-1
tp67077
sS'sufficient,to,warrant'
p67078
(F1
F0.00014334862385321102
I1
I0
I1
tp67079
sS'quantitative,approach,to'
p67080
(F1
F0.00014334862385321102
I0
I1
I-1
tp67081
sS'or,marked,bradycardia'
p67082
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp67083
sS'a,single,enzyme'
p67084
(F1
F0.00014334862385321102
I0
I1
I-1
tp67085
sS'in,whom,cyp3a4'
p67086
(F1
F0.00014334862385321102
I0
I1
I-1
tp67087
sS'and,discontinuation,ordinarily'
p67088
(F1
F0.00014334862385321102
I0
I1
I-1
tp67089
sS'reduce,the,diuretic'
p67090
(F1
F0.00014334862385321102
I1
I0
I1
tp67091
sS'as,and,and'
p67092
(F1
F0.00043004587155963305
I3
I0
I3
tp67093
sS'recommended,that,in'
p67094
(F1
F0.00014334862385321102
I1
I0
I1
tp67095
sS'drugs,sporadic,cases'
p67096
(F1
F0.00014334862385321102
I1
I0
I1
tp67097
sS'recommended,that,if'
p67098
(F1
F0.00014334862385321102
I1
I0
I1
tp67099
sS'not,sufficient,to'
p67100
(F0
F0
I1
I1
I0
tp67101
sS'times,long-sedation,time'
p67102
(F1
F0.00014334862385321102
I0
I1
I-1
tp67103
sS'a,should,be'
p67104
(F1
F0.00014334862385321102
I1
I0
I1
tp67105
sS'from,to,minutes'
p67106
(F1
F0.00014334862385321102
I1
I0
I1
tp67107
sS'many,and,are'
p67108
(F1
F0.00014334862385321102
I0
I1
I-1
tp67109
sS'are,started,thus'
p67110
(F1
F0.00014334862385321102
I1
I0
I1
tp67111
sS'shown,a,decrease'
p67112
(F1
F0.00014334862385321102
I1
I0
I1
tp67113
sS'or,placebo,was'
p67114
(F1
F0.00014334862385321102
I0
I1
I-1
tp67115
sS'medicinal,products,could'
p67116
(F1
F0.00014334862385321102
I1
I0
I1
tp67117
sS'or,potentiated,the'
p67118
(F1
F0.00014334862385321102
I1
I0
I1
tp67119
sS'reports,that,the'
p67120
(F1
F0.00014334862385321102
I1
I0
I1
tp67121
sS'adl,a,trans-3'
p67122
(F1
F0.00014334862385321102
I1
I0
I1
tp67123
sS'pk,properties,of'
p67124
(F1
F0.00014334862385321102
I0
I1
I-1
tp67125
sS'free,radical-mediated,tissue'
p67126
(F1
F0.00014334862385321102
I1
I0
I1
tp67127
sS'p-glycoprotein,transporter,as'
p67128
(F1
F0.00014334862385321102
I0
I1
I-1
tp67129
sS'and,levels,were'
p67130
(F1
F0.00014334862385321102
I1
I0
I1
tp67131
sS'simultaneous,fold,increase'
p67132
(F1
F0.00014334862385321102
I1
I0
I1
tp67133
sS'showed,comparable,cognitive'
p67134
(F1
F0.00014334862385321102
I0
I1
I-1
tp67135
sS'efficacy,on,measures'
p67136
(F1
F0.00014334862385321102
I0
I1
I-1
tp67137
sS'and,monitored,regularly'
p67138
(F1
F0.00014334862385321102
I0
I1
I-1
tp67139
sS'nimbex,were,comparable'
p67140
(F1
F0.00014334862385321102
I1
I0
I1
tp67141
sS'levels,did,not'
p67142
(F1
F0.00014334862385321102
I0
I1
I-1
tp67143
sS'be,less,effective'
p67144
(F1
F0.00014334862385321102
I1
I0
I1
tp67145
sS'large,amounts,may'
p67146
(F1
F0.00014334862385321102
I1
I0
I1
tp67147
sS'felbatol,on,low-dose'
p67148
(F1
F0.00014334862385321102
I0
I1
I-1
tp67149
sS'prolongation,with,or'
p67150
(F1
F0.00014334862385321102
I0
I1
I-1
tp67151
sS'the,oral,has'
p67152
(F1
F0.00014334862385321102
I0
I1
I-1
tp67153
sS'fortovase,may,not'
p67154
(F1
F0.00014334862385321102
I0
I1
I-1
tp67155
sS'p450,a4,would'
p67156
(F1
F0.00014334862385321102
I1
I0
I1
tp67157
sS'injections,of,saline'
p67158
(F1
F0.00014334862385321102
I0
I1
I-1
tp67159
sS'with,peripheral,neuropathy'
p67160
(F1
F0.00014334862385321102
I0
I1
I-1
tp67161
sS'in,cell,number'
p67162
(F1
F0.00014334862385321102
I1
I0
I1
tp67163
sS'of,for,patients'
p67164
(F1
F0.00014334862385321102
I1
I0
I1
tp67165
sS'relationship,of,accutane'
p67166
(F1
F0.00014334862385321102
I1
I0
I1
tp67167
sS'of,incompatibility,of'
p67168
(F1
F0.00028669724770642203
I0
I2
I-2
tp67169
sS'from,given,the'
p67170
(F1
F0.00014334862385321102
I1
I0
I1
tp67171
sS'benefits,against,symptoms'
p67172
(F1
F0.00014334862385321102
I0
I1
I-1
tp67173
sS'on,the,other'
p67174
(F0
F0
I1
I1
I0
tp67175
sS'control,supraventricular,tachycardia'
p67176
(F1
F0.00014334862385321102
I1
I0
I1
tp67177
sS'administration,of,inapsine'
p67178
(F1
F0.00014334862385321102
I1
I0
I1
tp67179
sS'medications,have,been'
p67180
(F1
F0.00028669724770642203
I0
I2
I-2
tp67181
sS'beyond,that,obtained'
p67182
(F1
F0.00014334862385321102
I1
I0
I1
tp67183
sS'doses,of,tambocor'
p67184
(F1
F0.00014334862385321102
I1
I0
I1
tp67185
sS'to,a,prolongation'
p67186
(F1
F0.00014334862385321102
I1
I0
I1
tp67187
sS'prescribed,for,either'
p67188
(F1
F0.0010034403669724771
I0
I7
I-7
tp67189
sS'selecting,an,oral'
p67190
(F1
F0.00028669724770642203
I2
I0
I2
tp67191
sS'activity,of,these'
p67192
(F1
F0.00014334862385321102
I0
I1
I-1
tp67193
sS'no,significant,additional'
p67194
(F1
F0.00014334862385321102
I1
I0
I1
tp67195
sS'agents,the,safety'
p67196
(F1
F0.00014334862385321102
I0
I1
I-1
tp67197
sS'have,been,coadministered'
p67198
(F1
F0.00014334862385321102
I0
I1
I-1
tp67199
sS'small,effect,on'
p67200
(F0
F0
I1
I1
I0
tp67201
sS'use,of,vardenafil'
p67202
(F1
F0.00014334862385321102
I1
I0
I1
tp67203
sS'rifampin,cyp3a4,is'
p67204
(F1
F0.00014334862385321102
I0
I1
I-1
tp67205
sS'increase,serum,thyroxine-binding'
p67206
(F1
F0.00014334862385321102
I0
I1
I-1
tp67207
sS'inhibitors,concurrent,use'
p67208
(F0
F0
I2
I2
I0
tp67209
sS'cyclosporine-induced,toxicity,possibly'
p67210
(F1
F0.00028669724770642203
I2
I0
I2
tp67211
sS'corticotropin,may,accentuate'
p67212
(F1
F0.00028669724770642203
I2
I0
I2
tp67213
sS'such,as,which'
p67214
(F1
F0.00014334862385321102
I1
I0
I1
tp67215
sS'turn,discussing,the'
p67216
(F1
F0.00014334862385321102
I0
I1
I-1
tp67217
sS'v,remains,constant'
p67218
(F1
F0.00014334862385321102
I0
I1
I-1
tp67219
sS'resulting,in,qt'
p67220
(F1
F0.00014334862385321102
I1
I0
I1
tp67221
sS'therapies,should,not'
p67222
(F1
F0.00014334862385321102
I1
I0
I1
tp67223
sS'evaluated,and,patients'
p67224
(F1
F0.00014334862385321102
I0
I1
I-1
tp67225
sS'anticipated,with,cmi'
p67226
(F1
F0.00028669724770642203
I2
I0
I2
tp67227
sS'mao,inhibitors,concurrent'
p67228
(F0
F0
I2
I2
I0
tp67229
sS'forms,may,not'
p67230
(F1
F0.00014334862385321102
I1
I0
I1
tp67231
sS'absorbed,is,unaffected'
p67232
(F1
F0.00014334862385321102
I0
I1
I-1
tp67233
sS'were,assessed,in'
p67234
(F1
F0.00043004587155963305
I0
I3
I-3
tp67235
sS'kg,x,ed95'
p67236
(F1
F0.00014334862385321102
I1
I0
I1
tp67237
sS'ssris,many,and'
p67238
(F1
F0.00014334862385321102
I0
I1
I-1
tp67239
sS'likely,that,the'
p67240
(F1
F0.00014334862385321102
I1
I0
I1
tp67241
sS'lodosyn,carbidopa,given'
p67242
(F1
F0.00014334862385321102
I0
I1
I-1
tp67243
sS'morphine-induced,and,nicotine-induced'
p67244
(F1
F0.00014334862385321102
I1
I0
I1
tp67245
sS'levels,whenever,a'
p67246
(F1
F0.00057339449541284407
I0
I4
I-4
tp67247
sS'subjects,increased,plasma'
p67248
(F1
F0.00014334862385321102
I1
I0
I1
tp67249
sS'in,balance,were'
p67250
(F1
F0.00014334862385321102
I0
I1
I-1
tp67251
sS'concomitant,intravenous,misuse'
p67252
(F1
F0.00014334862385321102
I1
I0
I1
tp67253
sS'few,patients,treated'
p67254
(F1
F0.00014334862385321102
I1
I0
I1
tp67255
sS'not,after,administration'
p67256
(F1
F0.00014334862385321102
I1
I0
I1
tp67257
sS'self-administration,of,while'
p67258
(F1
F0.00014334862385321102
I1
I0
I1
tp67259
sS'levels,suggesting,that'
p67260
(F1
F0.00014334862385321102
I1
I0
I1
tp67261
sS'combination,with,has'
p67262
(F1
F0.00014334862385321102
I0
I1
I-1
tp67263
sS'accumulated,in,the'
p67264
(F1
F0.00014334862385321102
I1
I0
I1
tp67265
sS'blockers,in,one'
p67266
(F1
F0.00014334862385321102
I0
I1
I-1
tp67267
sS'on,arterial,thrombus'
p67268
(F1
F0.00014334862385321102
I1
I0
I1
tp67269
sS'in,reversible,acute'
p67270
(F1
F0.00014334862385321102
I1
I0
I1
tp67271
sS'and,iv,myocardium'
p67272
(F1
F0.00014334862385321102
I0
I1
I-1
tp67273
sS'of,absorbed,while'
p67274
(F1
F0.00014334862385321102
I0
I1
I-1
tp67275
sS'exceeded,in,a'
p67276
(F1
F0.00014334862385321102
I1
I0
I1
tp67277
sS'increase,catabolism,of'
p67278
(F1
F0.00014334862385321102
I0
I1
I-1
tp67279
sS'enhance,the,renal'
p67280
(F1
F0.00014334862385321102
I1
I0
I1
tp67281
sS'antidiabetics,oral,diabetes'
p67282
(F1
F0.00014334862385321102
I1
I0
I1
tp67283
sS'the,fischer-344,strain'
p67284
(F1
F0.00014334862385321102
I0
I1
I-1
tp67285
sS's-,enantiomers,or'
p67286
(F1
F0.00014334862385321102
I0
I1
I-1
tp67287
sS'when,and,mycophenolate'
p67288
(F1
F0.00014334862385321102
I1
I0
I1
tp67289
sS'which,may,increase'
p67290
(F1
F0.00014334862385321102
I0
I1
I-1
tp67291
sS'effects,concomitant,use'
p67292
(F1
F0.00014334862385321102
I0
I1
I-1
tp67293
sS'of,increased,and'
p67294
(F1
F0.00028669724770642203
I2
I0
I2
tp67295
sS'physiologic,activity,thus'
p67296
(F1
F0.00014334862385321102
I1
I0
I1
tp67297
sS'containing,mcg,of'
p67298
(F1
F0.00014334862385321102
I1
I0
I1
tp67299
sS'unaffected,by,indicating'
p67300
(F1
F0.00014334862385321102
I0
I1
I-1
tp67301
sS'with,or,prolongation'
p67302
(F1
F0.00014334862385321102
I0
I1
I-1
tp67303
sS'levels,and,slight'
p67304
(F1
F0.00014334862385321102
I1
I0
I1
tp67305
sS'healthy,individuals,plasma'
p67306
(F1
F0.00014334862385321102
I1
I0
I1
tp67307
sS'that,may,inhibit'
p67308
(F1
F0.00014334862385321102
I1
I0
I1
tp67309
sS'amprenavir,significantly,decreases'
p67310
(F1
F0.00014334862385321102
I1
I0
I1
tp67311
sS'for,days,intraperitoneally'
p67312
(F1
F0.00014334862385321102
I1
I0
I1
tp67313
sS'while,studies,have'
p67314
(F1
F0.00014334862385321102
I1
I0
I1
tp67315
sS'in,mean,trough'
p67316
(F1
F0.00014334862385321102
I1
I0
I1
tp67317
sS'one,reported,case'
p67318
(F1
F0.00014334862385321102
I1
I0
I1
tp67319
sS'have,been,attributed'
p67320
(F1
F0.00014334862385321102
I1
I0
I1
tp67321
sS'for,cyp2d6,resulted'
p67322
(F1
F0.00014334862385321102
I1
I0
I1
tp67323
sS'fluothane,may,augment'
p67324
(F1
F0.00014334862385321102
I1
I0
I1
tp67325
sS'fraction,of,stadol'
p67326
(F1
F0.00014334862385321102
I0
I1
I-1
tp67327
sS'as,certain,antagonists'
p67328
(F1
F0.00014334862385321102
I1
I0
I1
tp67329
sS'digitalis,immediate,release'
p67330
(F1
F0.00014334862385321102
I1
I0
I1
tp67331
sS'of,g,kg'
p67332
(F1
F0.00014334862385321102
I1
I0
I1
tp67333
sS'toxicity,including,convulsions'
p67334
(F1
F0.00014334862385321102
I1
I0
I1
tp67335
sS'pharmacological,therapy,which'
p67336
(F1
F0.00014334862385321102
I0
I1
I-1
tp67337
sS'of,impaired,renal'
p67338
(F1
F0.00014334862385321102
I1
I0
I1
tp67339
sS'from,in,vitro'
p67340
(F1
F0.00028669724770642203
I2
I0
I2
tp67341
sS'that,adl,prevents'
p67342
(F1
F0.00014334862385321102
I1
I0
I1
tp67343
sS'interferes,with,the'
p67344
(F1
F0.0008600917431192661
I6
I0
I6
tp67345
sS'mg,and,intravenous'
p67346
(F1
F0.00014334862385321102
I0
I1
I-1
tp67347
sS'and,appropriate,dose'
p67348
(F1
F0.00014334862385321102
I1
I0
I1
tp67349
sS'muscle,relaxants,eg'
p67350
(F1
F0.00014334862385321102
I1
I0
I1
tp67351
sS'dinitrate,chloride,folic'
p67352
(F1
F0.00014334862385321102
I0
I1
I-1
tp67353
sS'that,the,ethanolysis'
p67354
(F1
F0.00014334862385321102
I1
I0
I1
tp67355
sS'in,two-lever,discrimination'
p67356
(F1
F0.00014334862385321102
I0
I1
I-1
tp67357
sS'the,beta,blocker'
p67358
(F1
F0.00014334862385321102
I1
I0
I1
tp67359
sS'administered,agents,should'
p67360
(F1
F0.00014334862385321102
I0
I1
I-1
tp67361
sS'of,the,tca'
p67362
(F1
F0.00014334862385321102
I1
I0
I1
tp67363
sS'with,the,modulation'
p67364
(F1
F0.00014334862385321102
I1
I0
I1
tp67365
sS'macrolide,and,hiv'
p67366
(F1
F0.00014334862385321102
I0
I1
I-1
tp67367
sS'the,findings,of'
p67368
(F1
F0.00014334862385321102
I0
I1
I-1
tp67369
sS'patient,receiving,prinivil'
p67370
(F1
F0.00014334862385321102
I1
I0
I1
tp67371
sS'were,considered,to'
p67372
(F1
F0.00014334862385321102
I1
I0
I1
tp67373
sS'produced,a,significant'
p67374
(F1
F0.00014334862385321102
I1
I0
I1
tp67375
sS'and,estrogen-containing,oral'
p67376
(F1
F0.00014334862385321102
I0
I1
I-1
tp67377
sS'regimen,of,patients'
p67378
(F1
F0.00028669724770642203
I0
I2
I-2
tp67379
sS'digitalis,thyroid,preparations'
p67380
(F1
F0.00014334862385321102
I1
I0
I1
tp67381
sS'whom,died,compared'
p67382
(F1
F0.00014334862385321102
I0
I1
I-1
tp67383
sS'estradiol,may,inhibit'
p67384
(F1
F0.00028669724770642203
I2
I0
I2
tp67385
sS'effect,for,which'
p67386
(F1
F0.00014334862385321102
I0
I1
I-1
tp67387
sS'decreased,the,incidence'
p67388
(F0
F0
I1
I1
I0
tp67389
sS'animal,model,possibly'
p67390
(F1
F0.00014334862385321102
I1
I0
I1
tp67391
sS'the,following,beta-adrenergic'
p67392
(F1
F0.00014334862385321102
I0
I1
I-1
tp67393
sS'sodium,excretion,seen'
p67394
(F1
F0.00014334862385321102
I1
I0
I1
tp67395
sS'to,mice,min'
p67396
(F1
F0.00014334862385321102
I0
I1
I-1
tp67397
sS'received,among,patients'
p67398
(F1
F0.00014334862385321102
I0
I1
I-1
tp67399
sS'potentiate,the,tardive'
p67400
(F1
F0.00014334862385321102
I1
I0
I1
tp67401
sS'the,ld50,of'
p67402
(F1
F0.00014334862385321102
I1
I0
I1
tp67403
sS'of,salicylic,acid'
p67404
(F1
F0.00014334862385321102
I1
I0
I1
tp67405
sS'inhibit,or,induce'
p67406
(F1
F0.00014334862385321102
I0
I1
I-1
tp67407
sS'with,fluothane,as'
p67408
(F1
F0.00014334862385321102
I1
I0
I1
tp67409
sS'epoxide,metabolite,in'
p67410
(F1
F0.00014334862385321102
I0
I1
I-1
tp67411
sS'cimetidine,cimetidine,does'
p67412
(F1
F0.00014334862385321102
I0
I1
I-1
tp67413
sS'of,when,any'
p67414
(F1
F0.00014334862385321102
I0
I1
I-1
tp67415
sS'cyp3a4,may,have'
p67416
(F1
F0.00014334862385321102
I0
I1
I-1
tp67417
sS'properties,of,equetrotm'
p67418
(F1
F0.00014334862385321102
I0
I1
I-1
tp67419
sS'adverse,reactions,related'
p67420
(F1
F0.00014334862385321102
I0
I1
I-1
tp67421
sS'metabolism,mediated,by'
p67422
(F1
F0.00014334862385321102
I0
I1
I-1
tp67423
sS'especially,those,in'
p67424
(F1
F0.00057339449541284407
I4
I0
I4
tp67425
sS'of,severe,myopathy'
p67426
(F1
F0.00014334862385321102
I1
I0
I1
tp67427
sS'commonly,used,general'
p67428
(F1
F0.00014334862385321102
I0
I1
I-1
tp67429
sS'in,excessive,widening'
p67430
(F1
F0.00014334862385321102
I1
I0
I1
tp67431
sS'the,arrival,of'
p67432
(F1
F0.00014334862385321102
I0
I1
I-1
tp67433
sS'relaxants,in,postmarketing'
p67434
(F1
F0.00014334862385321102
I0
I1
I-1
tp67435
sS'mao-inhibitors,with,hepatotoxic'
p67436
(F1
F0.00014334862385321102
I1
I0
I1
tp67437
sS'dose,range,of'
p67438
(F1
F0.00028669724770642203
I2
I0
I2
tp67439
sS'when,itraconazole,and'
p67440
(F1
F0.00028669724770642203
I2
I0
I2
tp67441
sS'enzyme,abnormalities,and'
p67442
(F1
F0.00014334862385321102
I1
I0
I1
tp67443
sS'emtriva,has,been'
p67444
(F1
F0.00014334862385321102
I0
I1
I-1
tp67445
sS'inhibitors,of,cytochrome'
p67446
(F0
F0
I1
I1
I0
tp67447
sS'a,inhibitors,of'
p67448
(F1
F0.00014334862385321102
I1
I0
I1
tp67449
sS'tissues,from,the'
p67450
(F1
F0.00014334862385321102
I1
I0
I1
tp67451
sS'did,not,have'
p67452
(F1
F0.0014334862385321102
I0
I10
I-10
tp67453
sS'doses,of,and'
p67454
(F0.5
F0.00057339449541284407
I6
I2
I4
tp67455
sS'other,strong,selective'
p67456
(F1
F0.00014334862385321102
I1
I0
I1
tp67457
sS'anti-factor,xa,and'
p67458
(F1
F0.00014334862385321102
I0
I1
I-1
tp67459
sS'drugs,clonazepam,does'
p67460
(F1
F0.00014334862385321102
I0
I1
I-1
tp67461
sS'cyp3a4,metabolized,triazolo-benzodiazepines'
p67462
(F1
F0.00014334862385321102
I1
I0
I1
tp67463
sS'kidneys,coadministration,of'
p67464
(F1
F0.00014334862385321102
I0
I1
I-1
tp67465
sS'and,live,or'
p67466
(F1
F0.00014334862385321102
I1
I0
I1
tp67467
sS'maois,or,within'
p67468
(F1
F0.00014334862385321102
I1
I0
I1
tp67469
sS'tested,in,combination'
p67470
(F1
F0.00014334862385321102
I0
I1
I-1
tp67471
sS'drugs,in,small'
p67472
(F1
F0.00014334862385321102
I0
I1
I-1
tp67473
sS'historicalcontrol,group,resulted'
p67474
(F1
F0.00014334862385321102
I1
I0
I1
tp67475
sS'respectively,resulted,in'
p67476
(F1
F0.00014334862385321102
I1
I0
I1
tp67477
sS'of,sedation,hallucinations'
p67478
(F1
F0.00014334862385321102
I1
I0
I1
tp67479
sS'of,pharmacokinetics,in'
p67480
(F1
F0.00014334862385321102
I0
I1
I-1
tp67481
sS'pharmacodynamics,blood,glucose'
p67482
(F1
F0.00014334862385321102
I0
I1
I-1
tp67483
sS'anti,inflammatory,with'
p67484
(F1
F0.00014334862385321102
I1
I0
I1
tp67485
sS'not,result,in'
p67486
(F0.81818181818181823
F0.0012901376146788992
I1
I10
I-9
tp67487
sS'a,study,involving'
p67488
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp67489
sS'clinical,trials,and'
p67490
(F1
F0.00014334862385321102
I0
I1
I-1
tp67491
sS'hormone,binding,globulin'
p67492
(F1
F0.00014334862385321102
I0
I1
I-1
tp67493
sS'levels,and,cardiovascular'
p67494
(F1
F0.00014334862385321102
I1
I0
I1
tp67495
sS'racemic,mg,and'
p67496
(F1
F0.00014334862385321102
I1
I0
I1
tp67497
sS'be,administered,with'
p67498
(F0.73333333333333328
F0.0015768348623853212
I13
I2
I11
tp67499
sS'safety,profiles,comparable'
p67500
(F1
F0.00014334862385321102
I0
I1
I-1
tp67501
sS'be,considered,in'
p67502
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp67503
sS'other,products,associated'
p67504
(F1
F0.00014334862385321102
I0
I1
I-1
tp67505
sS'experience,with,the'
p67506
(F1
F0.00028669724770642203
I0
I2
I-2
tp67507
sS'be,considered,if'
p67508
(F0
F0
I1
I1
I0
tp67509
sS'of,lodine,and'
p67510
(F1
F0.00014334862385321102
I1
I0
I1
tp67511
sS'with,resulting,in'
p67512
(F1
F0.00014334862385321102
I1
I0
I1
tp67513
sS'international,normalized,ratio'
p67514
(F1
F0.00043004587155963305
I3
I0
I3
tp67515
sS'on,weeks,and'
p67516
(F1
F0.00014334862385321102
I0
I1
I-1
tp67517
sS'may,react,with'
p67518
(F1
F0.00014334862385321102
I1
I0
I1
tp67519
sS'and,efficacy,of'
p67520
(F0
F0
I2
I2
I0
tp67521
sS'were,also,not'
p67522
(F1
F0.00028669724770642203
I0
I2
I-2
tp67523
sS'of,the,ht3'
p67524
(F1
F0.00014334862385321102
I1
I0
I1
tp67525
sS'digoxin,nimodipine,and'
p67526
(F1
F0.00014334862385321102
I0
I1
I-1
tp67527
sS'antagonize,the,bactercidal'
p67528
(F1
F0.00014334862385321102
I1
I0
I1
tp67529
sS'or,tenofovir,disoproxil'
p67530
(F1
F0.00014334862385321102
I0
I1
I-1
tp67531
sS'marked,hypertension,and'
p67532
(F1
F0.00014334862385321102
I1
I0
I1
tp67533
sS'by,possibly,increasing'
p67534
(F1
F0.00014334862385321102
I1
I0
I1
tp67535
sS'with,the,alternate'
p67536
(F1
F0.00014334862385321102
I1
I0
I1
tp67537
sS'in,increase,in'
p67538
(F1
F0.00014334862385321102
I1
I0
I1
tp67539
sS'vitamin,k,antagonists'
p67540
(F1
F0.00028669724770642203
I2
I0
I2
tp67541
sS'between,and,beta'
p67542
(F1
F0.00014334862385321102
I0
I1
I-1
tp67543
sS'diuretic,hydrochlorothiazide,given'
p67544
(F1
F0.00014334862385321102
I1
I0
I1
tp67545
sS'for,the,ability'
p67546
(F1
F0.00014334862385321102
I0
I1
I-1
tp67547
sS'of,lamprene,have'
p67548
(F1
F0.00014334862385321102
I1
I0
I1
tp67549
sS'administered,in,conjunction'
p67550
(F1
F0.00014334862385321102
I0
I1
I-1
tp67551
sS'the,best,tool'
p67552
(F1
F0.00014334862385321102
I0
I1
I-1
tp67553
sS'i,d,for'
p67554
(F1
F0.00014334862385321102
I1
I0
I1
tp67555
sS'of,compounds,are'
p67556
(F1
F0.00014334862385321102
I1
I0
I1
tp67557
sS'in,addition,under'
p67558
(F1
F0.00028669724770642203
I0
I2
I-2
tp67559
sS'm1,was,shown'
p67560
(F1
F0.00028669724770642203
I0
I2
I-2
tp67561
sS'c,has,not'
p67562
(F1
F0.00014334862385321102
I0
I1
I-1
tp67563
sS'coadministered,with,therapeutic'
p67564
(F1
F0.00014334862385321102
I0
I1
I-1
tp67565
sS'when,co-administered,with'
p67566
(F0.25
F0.00028669724770642203
I5
I3
I2
tp67567
sS'been,seen,with'
p67568
(F1
F0.00028669724770642203
I2
I0
I2
tp67569
sS'effectiveness,of,in'
p67570
(F1
F0.00014334862385321102
I0
I1
I-1
tp67571
sS'that,the,dosage'
p67572
(F1
F0.00014334862385321102
I1
I0
I1
tp67573
sS'sodium,does,not'
p67574
(F1
F0.00014334862385321102
I0
I1
I-1
tp67575
sS'salicylates-salicylates,in,large'
p67576
(F1
F0.00014334862385321102
I0
I1
I-1
tp67577
sS'of,onset,of'
p67578
(F1
F0.00014334862385321102
I1
I0
I1
tp67579
sS'effect,on,absorption'
p67580
(F1
F0.00014334862385321102
I1
I0
I1
tp67581
sS'exchange,it,may'
p67582
(F1
F0.00014334862385321102
I0
I1
I-1
tp67583
sS'use,of,and'
p67584
(F1
F0.0018635321100917432
I13
I0
I13
tp67585
sS'hydrolase,carbamazepine,is'
p67586
(F1
F0.00014334862385321102
I0
I1
I-1
tp67587
sS'alkaloid,while,you'
p67588
(F1
F0.00014334862385321102
I1
I0
I1
tp67589
sS'pharmacokinetics,of,was'
p67590
(F1
F0.00043004587155963305
I0
I3
I-3
tp67591
sS'reductase,inhibitor,class'
p67592
(F1
F0.00014334862385321102
I1
I0
I1
tp67593
sS'lower,doses,because'
p67594
(F1
F0.00014334862385321102
I1
I0
I1
tp67595
sS'and,cardiovascular,effects'
p67596
(F1
F0.00014334862385321102
I1
I0
I1
tp67597
sS'were,within,the'
p67598
(F1
F0.00014334862385321102
I1
I0
I1
tp67599
sS'after,receiving,appeared'
p67600
(F1
F0.00014334862385321102
I1
I0
I1
tp67601
sS'reduces,the,tubular'
p67602
(F1
F0.00014334862385321102
I1
I0
I1
tp67603
sS'haloperidol,blocks,receptors'
p67604
(F1
F0.00014334862385321102
I1
I0
I1
tp67605
sS'of,patients,taking'
p67606
(F1
F0.00014334862385321102
I1
I0
I1
tp67607
sS'function,is,not'
p67608
(F1
F0.00014334862385321102
I0
I1
I-1
tp67609
sS'influence,the,plasma'
p67610
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp67611
sS'overall,response,is'
p67612
(F1
F0.00014334862385321102
I1
I0
I1
tp67613
sS'clearance,of,thereby'
p67614
(F1
F0.00014334862385321102
I1
I0
I1
tp67615
sS'for,any,evidence'
p67616
(F1
F0.00014334862385321102
I0
I1
I-1
tp67617
sS'such,a,similar'
p67618
(F1
F0.00014334862385321102
I0
I1
I-1
tp67619
sS'serious,ventricular,arrhythmias'
p67620
(F0
F0
I1
I1
I0
tp67621
sS'rifabutin,did,not'
p67622
(F1
F0.00014334862385321102
I0
I1
I-1
tp67623
sS'to,induction,of'
p67624
(F0
F0
I1
I1
I0
tp67625
sS'depression,may,be'
p67626
(F1
F0.00014334862385321102
I1
I0
I1
tp67627
sS'that,inhibit,prostaglandin'
p67628
(F1
F0.00014334862385321102
I1
I0
I1
tp67629
sS'augmentin,xr,may'
p67630
(F1
F0.00014334862385321102
I1
I0
I1
tp67631
sS'increased,the,maximum'
p67632
(F1
F0.00028669724770642203
I2
I0
I2
tp67633
sS'solutions,and,for'
p67634
(F1
F0.00014334862385321102
I0
I1
I-1
tp67635
sS'other,and,because'
p67636
(F1
F0.00014334862385321102
I0
I1
I-1
tp67637
sS'sodium,may,prolong'
p67638
(F1
F0.00014334862385321102
I0
I1
I-1
tp67639
sS'toradol,to,patients'
p67640
(F1
F0.00014334862385321102
I1
I0
I1
tp67641
sS'dose,of,hours'
p67642
(F1
F0.00014334862385321102
I1
I0
I1
tp67643
sS'suspension,reduces,the'
p67644
(F1
F0.00014334862385321102
I1
I0
I1
tp67645
sS'a,cyp,c9'
p67646
(F1
F0.00014334862385321102
I0
I1
I-1
tp67647
sS'propranolols,hypotensive,effect'
p67648
(F1
F0.00014334862385321102
I1
I0
I1
tp67649
sS'significant,interactions,following'
p67650
(F1
F0.00014334862385321102
I0
I1
I-1
tp67651
sS'trilafon,compazine,sparine'
p67652
(F1
F0.00014334862385321102
I0
I1
I-1
tp67653
sS'containing,hydroxide,and'
p67654
(F1
F0.00014334862385321102
I1
I0
I1
tp67655
sS'not,in,dietary-obese'
p67656
(F1
F0.00014334862385321102
I0
I1
I-1
tp67657
sS'effect,digitalis,or'
p67658
(F1
F0.00014334862385321102
I1
I0
I1
tp67659
sS'syndrome,can,occur'
p67660
(F1
F0.00014334862385321102
I1
I0
I1
tp67661
sS'effect,of,clonazepam'
p67662
(F1
F0.00014334862385321102
I0
I1
I-1
tp67663
sS'agents,aspirin,is'
p67664
(F1
F0.00014334862385321102
I1
I0
I1
tp67665
sS'incidence,of,rashes'
p67666
(F1
F0.00014334862385321102
I1
I0
I1
tp67667
sS'mg,week,for'
p67668
(F1
F0.00014334862385321102
I1
I0
I1
tp67669
sS'methenamine,therapy,urinary'
p67670
(F1
F0.00028669724770642203
I2
I0
I2
tp67671
sS'multiple-dose,suggesting,no'
p67672
(F1
F0.00014334862385321102
I0
I1
I-1
tp67673
sS'and,cohort,received'
p67674
(F1
F0.00014334862385321102
I0
I1
I-1
tp67675
sS'of,interaction,between'
p67676
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp67677
sS'enhances,cocaine-induced,increases'
p67678
(F1
F0.00014334862385321102
I1
I0
I1
tp67679
sS'of,once,daily'
p67680
(F1
F0.00028669724770642203
I2
I0
I2
tp67681
sS'bacteriostatic,may,interfere'
p67682
(F1
F0.00014334862385321102
I1
I0
I1
tp67683
sS'effects,and,had'
p67684
(F1
F0.00014334862385321102
I0
I1
I-1
tp67685
sS'reductase,inhibitors,in'
p67686
(F1
F0.00014334862385321102
I1
I0
I1
tp67687
sS'exposure,or,the'
p67688
(F1
F0.00014334862385321102
I0
I1
I-1
tp67689
sS'hypotension,av,conduction'
p67690
(F1
F0.00014334862385321102
I1
I0
I1
tp67691
sS'that,significantly,affected'
p67692
(F1
F0.00014334862385321102
I0
I1
I-1
tp67693
sS'of,sodium,capsules'
p67694
(F1
F0.00014334862385321102
I1
I0
I1
tp67695
sS'administration,of,cerebyx'
p67696
(F1
F0.00014334862385321102
I0
I1
I-1
tp67697
sS'reactions,all,patients'
p67698
(F1
F0.00014334862385321102
I0
I1
I-1
tp67699
sS'the,clinically,effective'
p67700
(F1
F0.00014334862385321102
I1
I0
I1
tp67701
sS'bid,were,not'
p67702
(F1
F0.00014334862385321102
I0
I1
I-1
tp67703
sS'when,these,drugs'
p67704
(F1
F0.00014334862385321102
I0
I1
I-1
tp67705
sS'and,because,renal'
p67706
(F1
F0.00014334862385321102
I1
I0
I1
tp67707
sS'angiotensin-,converting,enzyme'
p67708
(F1
F0.00014334862385321102
I0
I1
I-1
tp67709
sS'to,evaluate,possible'
p67710
(F1
F0.00014334862385321102
I0
I1
I-1
tp67711
sS'half-life,was,and'
p67712
(F1
F0.00014334862385321102
I0
I1
I-1
tp67713
sS'combination,hormonal,are'
p67714
(F1
F0.00014334862385321102
I1
I0
I1
tp67715
sS'class,may,cause'
p67716
(F1
F0.00014334862385321102
I1
I0
I1
tp67717
sS'reduced,by,approx'
p67718
(F1
F0.00014334862385321102
I1
I0
I1
tp67719
sS'of,caution,should'
p67720
(F1
F0.00028669724770642203
I2
I0
I2
tp67721
sS'to,electrolyte,abnormalities'
p67722
(F1
F0.00014334862385321102
I1
I0
I1
tp67723
sS'cimetidine,in,a'
p67724
(F1
F0.00014334862385321102
I1
I0
I1
tp67725
sS'hcl,to,patients'
p67726
(F1
F0.00014334862385321102
I1
I0
I1
tp67727
sS'acellular,live,and'
p67728
(F1
F0.00014334862385321102
I1
I0
I1
tp67729
sS'is,a,risk'
p67730
(F1
F0.00014334862385321102
I1
I0
I1
tp67731
sS'cyp,d6,poor'
p67732
(F1
F0.00014334862385321102
I1
I0
I1
tp67733
sS'decreases,in,serum'
p67734
(F0
F0
I1
I1
I0
tp67735
sS'commonly,used,preanesthetic'
p67736
(F1
F0.00014334862385321102
I0
I1
I-1
tp67737
sS'contraceptives,keppra,mg'
p67738
(F1
F0.00014334862385321102
I0
I1
I-1
tp67739
sS'the,percentage,of'
p67740
(F0
F0
I1
I1
I0
tp67741
sS'when,two,single'
p67742
(F1
F0.00014334862385321102
I0
I1
I-1
tp67743
sS'clozapine,caution,is'
p67744
(F1
F0.00014334862385321102
I1
I0
I1
tp67745
sS'reactive,species,ros'
p67746
(F1
F0.00014334862385321102
I0
I1
I-1
tp67747
sS'on,the,production'
p67748
(F1
F0.00014334862385321102
I0
I1
I-1
tp67749
sS'plasma,concentrations,increased'
p67750
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp67751
sS'concentrations,and,appropriate'
p67752
(F1
F0.00014334862385321102
I0
I1
I-1
tp67753
sS'estradiol,levels,of'
p67754
(F1
F0.00014334862385321102
I1
I0
I1
tp67755
sS'as,high,as'
p67756
(F1
F0.00028669724770642203
I0
I2
I-2
tp67757
sS'morphine-induced,tail-flick,inhibition'
p67758
(F1
F0.00014334862385321102
I0
I1
I-1
tp67759
sS'or,concurrently,should'
p67760
(F1
F0.00014334862385321102
I1
I0
I1
tp67761
sS'deficiency,and,the'
p67762
(F1
F0.00014334862385321102
I0
I1
I-1
tp67763
sS'additive,effects,in'
p67764
(F1
F0.00014334862385321102
I1
I0
I1
tp67765
sS'for,example,when'
p67766
(F1
F0.00014334862385321102
I1
I0
I1
tp67767
sS'in,pharmacokinetic,studies'
p67768
(F1
F0.00014334862385321102
I0
I1
I-1
tp67769
sS'values,are,to'
p67770
(F1
F0.00014334862385321102
I0
I1
I-1
tp67771
sS'the,behavioral,response'
p67772
(F1
F0.00014334862385321102
I0
I1
I-1
tp67773
sS'therapy,with,should'
p67774
(F1
F0.00014334862385321102
I1
I0
I1
tp67775
sS'either,inhibit,sodium'
p67776
(F1
F0.00014334862385321102
I1
I0
I1
tp67777
sS'confusional,states,to'
p67778
(F1
F0.00014334862385321102
I1
I0
I1
tp67779
sS'should,be,advised'
p67780
(F0.5
F0.00028669724770642203
I3
I1
I2
tp67781
sS'the,major,enzyme'
p67782
(F1
F0.00014334862385321102
I1
I0
I1
tp67783
sS'mg,per,day'
p67784
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp67785
sS'kg,or,vehicle'
p67786
(F1
F0.00014334862385321102
I0
I1
I-1
tp67787
sS'subjective,responses,to'
p67788
(F1
F0.00014334862385321102
I0
I1
I-1
tp67789
sS'iodide,potentiates,other'
p67790
(F1
F0.00014334862385321102
I1
I0
I1
tp67791
sS'patients,to,whom'
p67792
(F1
F0.00014334862385321102
I1
I0
I1
tp67793
sS'any,route,they'
p67794
(F1
F0.00014334862385321102
I1
I0
I1
tp67795
sS'to,l,kg'
p67796
(F1
F0.00014334862385321102
I1
I0
I1
tp67797
sS'a,potent,iiia4'
p67798
(F1
F0.00014334862385321102
I1
I0
I1
tp67799
sS'and,or,increased'
p67800
(F1
F0.00014334862385321102
I1
I0
I1
tp67801
sS'confirmed,these,effects'
p67802
(F1
F0.00014334862385321102
I0
I1
I-1
tp67803
sS'effects,of,a'
p67804
(F1
F0.00014334862385321102
I1
I0
I1
tp67805
sS'or,is,used'
p67806
(F1
F0.00014334862385321102
I1
I0
I1
tp67807
sS'effects,of,b'
p67808
(F1
F0.00014334862385321102
I0
I1
I-1
tp67809
sS'g,kg,min'
p67810
(F1
F0.00014334862385321102
I0
I1
I-1
tp67811
sS'loss,between,systemic'
p67812
(F1
F0.00014334862385321102
I0
I1
I-1
tp67813
sS'food,one,hour'
p67814
(F1
F0.00014334862385321102
I1
I0
I1
tp67815
sS'response,and,the'
p67816
(F1
F0.00014334862385321102
I0
I1
I-1
tp67817
sS'status,and,mixed--pharmacological'
p67818
(F1
F0.00014334862385321102
I0
I1
I-1
tp67819
sS'increased,inr,international'
p67820
(F1
F0.00014334862385321102
I1
I0
I1
tp67821
sS'with,cefamandole,naftate'
p67822
(F1
F0.00014334862385321102
I0
I1
I-1
tp67823
sS'the,plasma,concentrations'
p67824
(F0.80000000000000004
F0.0011467889908256881
I9
I1
I8
tp67825
sS'probenecid,or,cimetidine'
p67826
(F1
F0.00014334862385321102
I1
I0
I1
tp67827
sS'plasma,was,analyzed'
p67828
(F1
F0.00014334862385321102
I0
I1
I-1
tp67829
sS'a,single,dose'
p67830
(F0
F0
I14
I14
I0
tp67831
sS'binding,may,also'
p67832
(F1
F0.00014334862385321102
I1
I0
I1
tp67833
sS'exposure-response,relationships,and'
p67834
(F1
F0.00014334862385321102
I0
I1
I-1
tp67835
sS'hydrate,and,may'
p67836
(F1
F0.00014334862385321102
I0
I1
I-1
tp67837
sS'use,with,allopurinol'
p67838
(F1
F0.00014334862385321102
I1
I0
I1
tp67839
sS'of,and,were'
p67840
(F0
F0
I4
I4
I0
tp67841
sS'check,coagulation,time'
p67842
(F1
F0.00014334862385321102
I1
I0
I1
tp67843
sS'day,during,adjunctive'
p67844
(F1
F0.00014334862385321102
I1
I0
I1
tp67845
sS'inhibitory,action,of'
p67846
(F1
F0.00014334862385321102
I0
I1
I-1
tp67847
sS'antagonize,the,bactericidal'
p67848
(F1
F0.00014334862385321102
I1
I0
I1
tp67849
sS'starlix,mg,before'
p67850
(F1
F0.00014334862385321102
I0
I1
I-1
tp67851
sS'oxidation,elc,should'
p67852
(F1
F0.00014334862385321102
I1
I0
I1
tp67853
sS'or,mao-inhibitors,with'
p67854
(F1
F0.00014334862385321102
I1
I0
I1
tp67855
sS'pharmacokinetics,of,r'
p67856
(F1
F0.00043004587155963305
I0
I3
I-3
tp67857
sS'of,endotoxin-treated,rats'
p67858
(F0
F0
I1
I1
I0
tp67859
sS'anticoagulants,oral,in'
p67860
(F1
F0.00014334862385321102
I0
I1
I-1
tp67861
sS'pharmacokinetics,of,a'
p67862
(F1
F0.0011467889908256881
I0
I8
I-8
tp67863
sS'versus,mg,of'
p67864
(F1
F0.00014334862385321102
I0
I1
I-1
tp67865
sS'pharmacokinetics,of,d'
p67866
(F1
F0.00014334862385321102
I0
I1
I-1
tp67867
sS'concomitant,and,ace'
p67868
(F1
F0.00014334862385321102
I1
I0
I1
tp67869
sS'with,tambocor,unless'
p67870
(F1
F0.00014334862385321102
I1
I0
I1
tp67871
sS'observed,carefully,for'
p67872
(F1
F0.00057339449541284407
I4
I0
I4
tp67873
sS'anticonvulsants,phenytoin,steady'
p67874
(F1
F0.00014334862385321102
I1
I0
I1
tp67875
sS'prothrombin,response,in'
p67876
(F1
F0.00028669724770642203
I2
I0
I2
tp67877
sS'study,of,patients'
p67878
(F1
F0.00043004587155963305
I0
I3
I-3
tp67879
sS'an,antipsychotic,eg'
p67880
(F1
F0.00014334862385321102
I1
I0
I1
tp67881
sS'may,also,decrease'
p67882
(F1
F0.00043004587155963305
I3
I0
I3
tp67883
sS'in,patients,not'
p67884
(F1
F0.00014334862385321102
I1
I0
I1
tp67885
sS'fibrosis,therapies,including'
p67886
(F1
F0.00014334862385321102
I0
I1
I-1
tp67887
sS'platelet,aggregation,inhibitors'
p67888
(F1
F0.00014334862385321102
I1
I0
I1
tp67889
sS'binding,experiments,using'
p67890
(F1
F0.00014334862385321102
I0
I1
I-1
tp67891
sS'must,elapse,before'
p67892
(F1
F0.00014334862385321102
I1
I0
I1
tp67893
sS'neuromuscular,blockade,by'
p67894
(F1
F0.00014334862385321102
I1
I0
I1
tp67895
sS'crixivan,or,to'
p67896
(F1
F0.00028669724770642203
I0
I2
I-2
tp67897
sS'interact,with,any'
p67898
(F1
F0.00014334862385321102
I1
I0
I1
tp67899
sS'addition,of,inspra'
p67900
(F1
F0.00014334862385321102
I1
I0
I1
tp67901
sS'fu,bolus-ifl,with'
p67902
(F1
F0.00014334862385321102
I0
I1
I-1
tp67903
sS'cardiac,effects,of'
p67904
(F1
F0.00014334862385321102
I1
I0
I1
tp67905
sS'decrease,the,metabolism'
p67906
(F0
F0
I1
I1
I0
tp67907
sS'dose,should,elapse'
p67908
(F1
F0.00014334862385321102
I1
I0
I1
tp67909
sS'block,contortrostatin-induced,phosphorylation'
p67910
(F1
F0.00014334862385321102
I1
I0
I1
tp67911
sS'of,patients,to'
p67912
(F1
F0.00014334862385321102
I1
I0
I1
tp67913
sS'release,of,in'
p67914
(F1
F0.00014334862385321102
I0
I1
I-1
tp67915
sS'with,copegus,in'
p67916
(F1
F0.00014334862385321102
I0
I1
I-1
tp67917
sS'other,ht1,agonists'
p67918
(F0
F0
I1
I1
I0
tp67919
sS'agent,can,reduce'
p67920
(F1
F0.00071674311926605509
I5
I0
I5
tp67921
sS'not,been,studied'
p67922
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp67923
sS'management,of,schizophrenia'
p67924
(F1
F0.00014334862385321102
I0
I1
I-1
tp67925
sS'of,cancidas,should'
p67926
(F1
F0.00014334862385321102
I1
I0
I1
tp67927
sS'from,the,results'
p67928
(F1
F0.00014334862385321102
I1
I0
I1
tp67929
sS'increase,the,chance'
p67930
(F0
F0
I5
I5
I0
tp67931
sS'effects,have,been'
p67932
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp67933
sS'oral,may,be'
p67934
(F1
F0.00014334862385321102
I1
I0
I1
tp67935
sS'day,to,midcycle'
p67936
(F1
F0.00014334862385321102
I0
I1
I-1
tp67937
sS'coadministered,with,or'
p67938
(F1
F0.00043004587155963305
I3
I0
I3
tp67939
sS'and,epidural,include'
p67940
(F1
F0.00014334862385321102
I1
I0
I1
tp67941
sS'tolerance,to,the'
p67942
(F1
F0.00028669724770642203
I2
I0
I2
tp67943
sS'exposures,of,similar'
p67944
(F1
F0.00028669724770642203
I2
I0
I2
tp67945
sS'the,maximum,approved'
p67946
(F1
F0.00014334862385321102
I1
I0
I1
tp67947
sS'in,experiments,on'
p67948
(F1
F0.00014334862385321102
I0
I1
I-1
tp67949
sS'by,and,prothrombin'
p67950
(F1
F0.00014334862385321102
I1
I0
I1
tp67951
sS'mean,maximum,plasma'
p67952
(F1
F0.00014334862385321102
I1
I0
I1
tp67953
sS'of,days,in'
p67954
(F1
F0.00014334862385321102
I0
I1
I-1
tp67955
sS'cyp,a,inhibitors'
p67956
(F1
F0.00028669724770642203
I2
I0
I2
tp67957
sS'seen,on,mtc-mdp'
p67958
(F1
F0.00014334862385321102
I1
I0
I1
tp67959
sS'observed,when,is'
p67960
(F1
F0.00014334862385321102
I1
I0
I1
tp67961
sS'and,urine,was'
p67962
(F1
F0.00014334862385321102
I0
I1
I-1
tp67963
sS'and,volume,of'
p67964
(F1
F0.00014334862385321102
I1
I0
I1
tp67965
sS'for,peroral,administration'
p67966
(F1
F0.00014334862385321102
I0
I1
I-1
tp67967
sS'coadministered,with,on'
p67968
(F0
F0
I1
I1
I0
tp67969
sS'blockers,and,nonsteroidal'
p67970
(F1
F0.00014334862385321102
I0
I1
I-1
tp67971
sS'once,daily,of'
p67972
(F1
F0.00014334862385321102
I0
I1
I-1
tp67973
sS'and,and,class'
p67974
(F1
F0.00014334862385321102
I1
I0
I1
tp67975
sS'and,reduction,in'
p67976
(F1
F0.00014334862385321102
I1
I0
I1
tp67977
sS'combined,treatment,should'
p67978
(F1
F0.00014334862385321102
I1
I0
I1
tp67979
sS'of,fluorouracil,is'
p67980
(F1
F0.00014334862385321102
I1
I0
I1
tp67981
sS'rat,days,showed'
p67982
(F1
F0.00014334862385321102
I0
I1
I-1
tp67983
sS'and,its,metabolites'
p67984
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp67985
sS'with,a,group'
p67986
(F1
F0.00014334862385321102
I0
I1
I-1
tp67987
sS'vehicle-,progesterone-,and'
p67988
(F1
F0.00014334862385321102
I1
I0
I1
tp67989
sS'agents,eg,and'
p67990
(F1
F0.00014334862385321102
I1
I0
I1
tp67991
sS'ng,x,h'
p67992
(F1
F0.00014334862385321102
I1
I0
I1
tp67993
sS'sufficient,numbers,of'
p67994
(F1
F0.00014334862385321102
I0
I1
I-1
tp67995
sS'in,addition,steady'
p67996
(F1
F0.00014334862385321102
I0
I1
I-1
tp67997
sS'bovine,lung,survanta'
p67998
(F1
F0.00014334862385321102
I0
I1
I-1
tp67999
sS'these,effects,were'
p68000
(F1
F0.00014334862385321102
I0
I1
I-1
tp68001
sS'amount,of,placebo'
p68002
(F1
F0.00014334862385321102
I0
I1
I-1
tp68003
sS'coadministration,in,hiv-infected'
p68004
(F1
F0.00014334862385321102
I0
I1
I-1
tp68005
sS'etc,but,physicians'
p68006
(F1
F0.00014334862385321102
I1
I0
I1
tp68007
sS'day,as,camptosar'
p68008
(F1
F0.00014334862385321102
I1
I0
I1
tp68009
sS'use,of,agents'
p68010
(F1
F0.00014334862385321102
I0
I1
I-1
tp68011
sS'erythro-fluorocitrate,synthesis,and'
p68012
(F1
F0.00014334862385321102
I0
I1
I-1
tp68013
sS'fluvoxamine,tablets,at'
p68014
(F1
F0.00014334862385321102
I1
I0
I1
tp68015
sS'antiinflammatory,agent,can'
p68016
(F1
F0.00014334862385321102
I1
I0
I1
tp68017
sS'and,downward,dose'
p68018
(F1
F0.00014334862385321102
I1
I0
I1
tp68019
sS'although,a,dose'
p68020
(F1
F0.00014334862385321102
I1
I0
I1
tp68021
sS'coadministered,intravenously,as'
p68022
(F1
F0.00014334862385321102
I1
I0
I1
tp68023
sS'one,report,of'
p68024
(F0
F0
I1
I1
I0
tp68025
sS'concentration,is,of'
p68026
(F1
F0.00014334862385321102
I0
I1
I-1
tp68027
sS'further,metabolized,to'
p68028
(F1
F0.00014334862385321102
I0
I1
I-1
tp68029
sS'when,tested,up'
p68030
(F1
F0.00014334862385321102
I0
I1
I-1
tp68031
sS'been,systematically,evaluated'
p68032
(F1
F0.00014334862385321102
I1
I0
I1
tp68033
sS'divided,into,three'
p68034
(F0
F0
I1
I1
I0
tp68035
sS'day,when,a'
p68036
(F1
F0.00028669724770642203
I2
I0
I2
tp68037
sS'intake,which,only'
p68038
(F1
F0.00014334862385321102
I0
I1
I-1
tp68039
sS'known,side,effects'
p68040
(F1
F0.00014334862385321102
I1
I0
I1
tp68041
sS'the,usual,dose'
p68042
(F1
F0.00028669724770642203
I2
I0
I2
tp68043
sS'study,has,shown'
p68044
(F1
F0.00028669724770642203
I2
I0
I2
tp68045
sS'occur,because,competitively'
p68046
(F1
F0.00014334862385321102
I1
I0
I1
tp68047
sS'atorvastatin,had,no'
p68048
(F1
F0.00014334862385321102
I0
I1
I-1
tp68049
sS'and,particularly,those'
p68050
(F1
F0.00014334862385321102
I0
I1
I-1
tp68051
sS'the,steady-state,concentrations'
p68052
(F1
F0.00014334862385321102
I0
I1
I-1
tp68053
sS'postmarketing,reports,of'
p68054
(F1
F0.00014334862385321102
I1
I0
I1
tp68055
sS'still,valid,in'
p68056
(F1
F0.00014334862385321102
I0
I1
I-1
tp68057
sS'by,competitive,interaction'
p68058
(F1
F0.00014334862385321102
I1
I0
I1
tp68059
sS'sonata,reflecting,the'
p68060
(F1
F0.00014334862385321102
I0
I1
I-1
tp68061
sS'drug,known,to'
p68062
(F1
F0.00014334862385321102
I0
I1
I-1
tp68063
sS'might,decrease,the'
p68064
(F1
F0.00014334862385321102
I1
I0
I1
tp68065
sS'with,other,coadministered'
p68066
(F1
F0.00014334862385321102
I1
I0
I1
tp68067
sS'or,or,other'
p68068
(F0
F0
I2
I2
I0
tp68069
sS'mononuclear,cells,u937'
p68070
(F1
F0.00014334862385321102
I1
I0
I1
tp68071
sS'aspirin,and,have'
p68072
(F1
F0.00014334862385321102
I0
I1
I-1
tp68073
sS'on,one,of'
p68074
(F1
F0.00014334862385321102
I1
I0
I1
tp68075
sS'liver,microsomes,the'
p68076
(F1
F0.00014334862385321102
I0
I1
I-1
tp68077
sS'every,hours,or'
p68078
(F1
F0.00028669724770642203
I0
I2
I-2
tp68079
sS'clearance,resulting,in'
p68080
(F1
F0.00014334862385321102
I0
I1
I-1
tp68081
sS'rhabdomyolysis,appear,to'
p68082
(F1
F0.00014334862385321102
I1
I0
I1
tp68083
sS'dosage,reduced,accordingly'
p68084
(F1
F0.00014334862385321102
I1
I0
I1
tp68085
sS'of,twice,daily'
p68086
(F1
F0.00014334862385321102
I0
I1
I-1
tp68087
sS'well,concurrent,therapy'
p68088
(F1
F0.00014334862385321102
I1
I0
I1
tp68089
sS'induce,hypercalcemia,by'
p68090
(F1
F0.00043004587155963305
I0
I3
I-3
tp68091
sS'subcortical,structures,whereas'
p68092
(F1
F0.00014334862385321102
I0
I1
I-1
tp68093
sS'n-type,or,omega-agatoxin'
p68094
(F1
F0.00014334862385321102
I0
I1
I-1
tp68095
sS'action,of,nimbex'
p68096
(F1
F0.00014334862385321102
I1
I0
I1
tp68097
sS'alcohol,when,duloxetine'
p68098
(F1
F0.00014334862385321102
I0
I1
I-1
tp68099
sS'eg,are,indicated'
p68100
(F1
F0.00014334862385321102
I0
I1
I-1
tp68101
sS'relevant,effect,on'
p68102
(F1
F0.00014334862385321102
I0
I1
I-1
tp68103
sS'action,of,initial'
p68104
(F0
F0
I1
I1
I0
tp68105
sS'antacids,concomitant,administration'
p68106
(F0
F0
I2
I2
I0
tp68107
sS'applying,panretin,gel'
p68108
(F1
F0.00014334862385321102
I1
I0
I1
tp68109
sS'in,renal,function'
p68110
(F1
F0.00014334862385321102
I0
I1
I-1
tp68111
sS'also,contribute,to'
p68112
(F1
F0.00014334862385321102
I1
I0
I1
tp68113
sS'of,either,was'
p68114
(F1
F0.00014334862385321102
I0
I1
I-1
tp68115
sS'levels,induced,by'
p68116
(F1
F0.00014334862385321102
I0
I1
I-1
tp68117
sS'in,a,two-fold'
p68118
(F1
F0.00014334862385321102
I1
I0
I1
tp68119
sS'with,maxipime,because'
p68120
(F1
F0.00014334862385321102
I1
I0
I1
tp68121
sS'function,as,has'
p68122
(F1
F0.00014334862385321102
I0
I1
I-1
tp68123
sS'and,more,prolonged'
p68124
(F1
F0.00014334862385321102
I1
I0
I1
tp68125
sS'to,patients,n'
p68126
(F1
F0.00014334862385321102
I0
I1
I-1
tp68127
sS'bextra,in,patients'
p68128
(F1
F0.00014334862385321102
I1
I0
I1
tp68129
sS'interact,with,increasing'
p68130
(F1
F0.00014334862385321102
I1
I0
I1
tp68131
sS'plasma,concentration,should'
p68132
(F1
F0.00014334862385321102
I1
I0
I1
tp68133
sS'similar,interaction,is'
p68134
(F1
F0.00014334862385321102
I1
I0
I1
tp68135
sS'of,cholinergic,reactions'
p68136
(F1
F0.00014334862385321102
I0
I1
I-1
tp68137
sS'modest,degree,in'
p68138
(F1
F0.00014334862385321102
I0
I1
I-1
tp68139
sS'patients,with,dsm-iv'
p68140
(F1
F0.00014334862385321102
I1
I0
I1
tp68141
sS'olanzapine,treatment,improves'
p68142
(F1
F0.00014334862385321102
I0
I1
I-1
tp68143
sS'to,patients,already'
p68144
(F1
F0.00014334862385321102
I0
I1
I-1
tp68145
sS'concentrations,of,were'
p68146
(F0
F0
I1
I1
I0
tp68147
sS'herbs,such,as'
p68148
(F1
F0.00014334862385321102
I1
I0
I1
tp68149
sS'hiv-nhl,who,were'
p68150
(F1
F0.00014334862385321102
I0
I1
I-1
tp68151
sS'butenafine,hcl,cream'
p68152
(F1
F0.00014334862385321102
I0
I1
I-1
tp68153
sS'between,b12,and'
p68154
(F1
F0.00014334862385321102
I1
I0
I1
tp68155
sS'administered,with,iron-fortified'
p68156
(F1
F0.00014334862385321102
I0
I1
I-1
tp68157
sS'concentrations,of,the'
p68158
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp68159
sS'and,there,is'
p68160
(F1
F0.00014334862385321102
I1
I0
I1
tp68161
sS'oral,or,has'
p68162
(F1
F0.00014334862385321102
I1
I0
I1
tp68163
sS'blocks,and,reuptake'
p68164
(F1
F0.00028669724770642203
I2
I0
I2
tp68165
sS'alkalinizers,decrease,effectiveness'
p68166
(F1
F0.00014334862385321102
I0
I1
I-1
tp68167
sS'performance,for,to'
p68168
(F1
F0.00028669724770642203
I2
I0
I2
tp68169
sS'of,cyp1a1,cyp1a2'
p68170
(F1
F0.00014334862385321102
I0
I1
I-1
tp68171
sS'there,appears,to'
p68172
(F1
F0.00014334862385321102
I0
I1
I-1
tp68173
sS'was,co-administered,with'
p68174
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp68175
sS'is,a,time-dependent'
p68176
(F1
F0.00014334862385321102
I0
I1
I-1
tp68177
sS'day,was,superior'
p68178
(F1
F0.00014334862385321102
I0
I1
I-1
tp68179
sS'been,reported,resulting'
p68180
(F1
F0.00014334862385321102
I1
I0
I1
tp68181
sS'and,decrease,by'
p68182
(F1
F0.00014334862385321102
I1
I0
I1
tp68183
sS'and,acamprosate,does'
p68184
(F1
F0.00014334862385321102
I0
I1
I-1
tp68185
sS'pain,or,weakness'
p68186
(F1
F0.00014334862385321102
I0
I1
I-1
tp68187
sS'of,response,to'
p68188
(F1
F0.00014334862385321102
I1
I0
I1
tp68189
sS'receiving,antihypertensive,medications'
p68190
(F1
F0.00014334862385321102
I1
I0
I1
tp68191
sS'to,exhibit,minimal'
p68192
(F1
F0.00014334862385321102
I0
I1
I-1
tp68193
sS'oral,the,hypoprothrombinemic'
p68194
(F1
F0.00014334862385321102
I0
I1
I-1
tp68195
sS'or,changed,in'
p68196
(F1
F0.00014334862385321102
I1
I0
I1
tp68197
sS'or,activase,may'
p68198
(F1
F0.00014334862385321102
I0
I1
I-1
tp68199
sS'h-2,antagonists,in'
p68200
(F1
F0.00014334862385321102
I0
I1
I-1
tp68201
sS'uric,acid,level'
p68202
(F1
F0.00014334862385321102
I1
I0
I1
tp68203
sS'rr,on,inositol'
p68204
(F1
F0.00014334862385321102
I0
I1
I-1
tp68205
sS'likely,to,cause'
p68206
(F1
F0.00014334862385321102
I0
I1
I-1
tp68207
sS'the,depressant,effect'
p68208
(F1
F0.00014334862385321102
I1
I0
I1
tp68209
sS'oral,may,render'
p68210
(F1
F0.00014334862385321102
I1
I0
I1
tp68211
sS'lower,auc,for'
p68212
(F1
F0.00014334862385321102
I0
I1
I-1
tp68213
sS'with,hivid,should'
p68214
(F0
F0
I1
I1
I0
tp68215
sS'may,cause,hypercalcemia'
p68216
(F1
F0.00014334862385321102
I1
I0
I1
tp68217
sS'however,patients,with'
p68218
(F1
F0.00014334862385321102
I1
I0
I1
tp68219
sS'in,rare,instances'
p68220
(F1
F0.00014334862385321102
I1
I0
I1
tp68221
sS'ergot,toxicity,characterized'
p68222
(F1
F0.00014334862385321102
I0
I1
I-1
tp68223
sS'tablets,not,be'
p68224
(F1
F0.00014334862385321102
I1
I0
I1
tp68225
sS'in,patients,exposed'
p68226
(F1
F0.00014334862385321102
I1
I0
I1
tp68227
sS'anticoagulants,oral,co-administration'
p68228
(F1
F0.00014334862385321102
I1
I0
I1
tp68229
sS'multiple,sclerosis,patients'
p68230
(F1
F0.00014334862385321102
I0
I1
I-1
tp68231
sS'was,carried,out'
p68232
(F1
F0.00014334862385321102
I0
I1
I-1
tp68233
sS'competitive,inhibitor,of'
p68234
(F1
F0.00014334862385321102
I1
I0
I1
tp68235
sS'see,whether,the'
p68236
(F1
F0.00014334862385321102
I1
I0
I1
tp68237
sS'no,significant,effect'
p68238
(F0.88235294117647056
F0.0021502293577981653
I1
I16
I-15
tp68239
sS'or,copd,medications'
p68240
(F1
F0.00014334862385321102
I0
I1
I-1
tp68241
sS'post-transplant,year,pharmacokinetics'
p68242
(F1
F0.00014334862385321102
I0
I1
I-1
tp68243
sS'care,should,be'
p68244
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp68245
sS'nucleoside,analogues,didanosine'
p68246
(F1
F0.00014334862385321102
I1
I0
I1
tp68247
sS'class,including,anafranil'
p68248
(F1
F0.00014334862385321102
I0
I1
I-1
tp68249
sS'already,accumulated,in'
p68250
(F1
F0.00014334862385321102
I1
I0
I1
tp68251
sS'risks,of,major'
p68252
(F1
F0.00014334862385321102
I1
I0
I1
tp68253
sS'or,may,diminish'
p68254
(F1
F0.00014334862385321102
I1
I0
I1
tp68255
sS'administered,intravenously,to'
p68256
(F1
F0.00014334862385321102
I1
I0
I1
tp68257
sS'function,tests,occur'
p68258
(F1
F0.00014334862385321102
I1
I0
I1
tp68259
sS'be,avoided,because'
p68260
(F1
F0.00028669724770642203
I2
I0
I2
tp68261
sS'notably,systemic,exposure'
p68262
(F1
F0.00014334862385321102
I0
I1
I-1
tp68263
sS'chop-like,regimen,i'
p68264
(F1
F0.00014334862385321102
I0
I1
I-1
tp68265
sS'of,may,therefore'
p68266
(F1
F0.00014334862385321102
I1
I0
I1
tp68267
sS'and,respectively,a'
p68268
(F1
F0.00014334862385321102
I1
I0
I1
tp68269
sS'in,the,prolongation'
p68270
(F1
F0.00014334862385321102
I1
I0
I1
tp68271
sS'with,sustiva,and'
p68272
(F1
F0.00028669724770642203
I0
I2
I-2
tp68273
sS'dose,increase,to'
p68274
(F1
F0.00014334862385321102
I0
I1
I-1
tp68275
sS'should,be,borne'
p68276
(F0
F0
I1
I1
I0
tp68277
sS'other,concomitant,therapies'
p68278
(F1
F0.00014334862385321102
I0
I1
I-1
tp68279
sS'indicate,that,inhibits'
p68280
(F1
F0.00014334862385321102
I1
I0
I1
tp68281
sS'possibility,should,be'
p68282
(F1
F0.00014334862385321102
I0
I1
I-1
tp68283
sS'receiving,resulted,in'
p68284
(F1
F0.00014334862385321102
I0
I1
I-1
tp68285
sS'decreased,the,renal'
p68286
(F1
F0.00028669724770642203
I2
I0
I2
tp68287
sS'serum,levels,be'
p68288
(F1
F0.00028669724770642203
I2
I0
I2
tp68289
sS'may,impair,the'
p68290
(F0
F0
I1
I1
I0
tp68291
sS'prothrombin,time,ratio'
p68292
(F1
F0.00014334862385321102
I0
I1
I-1
tp68293
sS'serotonin,syndrome,in'
p68294
(F1
F0.00014334862385321102
I0
I1
I-1
tp68295
sS'acid,temporarily,reduced'
p68296
(F1
F0.00014334862385321102
I1
I0
I1
tp68297
sS'cytochrome,p450,pathway'
p68298
(F1
F0.00014334862385321102
I0
I1
I-1
tp68299
sS'liver,alt,and'
p68300
(F1
F0.00014334862385321102
I1
I0
I1
tp68301
sS'elimination,and,and'
p68302
(F1
F0.00014334862385321102
I1
I0
I1
tp68303
sS'as,one,possible'
p68304
(F1
F0.00014334862385321102
I0
I1
I-1
tp68305
sS'promote,absorption,and'
p68306
(F1
F0.00043004587155963305
I3
I0
I3
tp68307
sS'since,are,potentiated'
p68308
(F1
F0.00014334862385321102
I1
I0
I1
tp68309
sS'substance,to,form'
p68310
(F1
F0.00014334862385321102
I1
I0
I1
tp68311
sS'and,lead,to'
p68312
(F1
F0.00014334862385321102
I1
I0
I1
tp68313
sS'potentiation,of,bradycardia'
p68314
(F1
F0.00014334862385321102
I0
I1
I-1
tp68315
sS'excretion,of,as'
p68316
(F1
F0.00014334862385321102
I1
I0
I1
tp68317
sS'disease,has,not'
p68318
(F1
F0.00014334862385321102
I1
I0
I1
tp68319
sS'infection,in,but'
p68320
(F1
F0.00014334862385321102
I1
I0
I1
tp68321
sS'of,another,botulinum'
p68322
(F1
F0.00014334862385321102
I1
I0
I1
tp68323
sS'and,non-,steroidal'
p68324
(F1
F0.00014334862385321102
I1
I0
I1
tp68325
sS'agents,which,are'
p68326
(F1
F0.00014334862385321102
I1
I0
I1
tp68327
sS'impairment,of,efficacy'
p68328
(F1
F0.00014334862385321102
I0
I1
I-1
tp68329
sS'ge,nerally,classified'
p68330
(F1
F0.00014334862385321102
I0
I1
I-1
tp68331
sS'to,identify,any'
p68332
(F1
F0.00014334862385321102
I0
I1
I-1
tp68333
sS'tardive,dyskinesia,side'
p68334
(F1
F0.00014334862385321102
I1
I0
I1
tp68335
sS'as,the,primary'
p68336
(F1
F0.00014334862385321102
I1
I0
I1
tp68337
sS'terfenadine,astemizole,and'
p68338
(F1
F0.00014334862385321102
I0
I1
I-1
tp68339
sS'concentrations,increased,from'
p68340
(F1
F0.00014334862385321102
I0
I1
I-1
tp68341
sS'or,other,nonsteroidal'
p68342
(F1
F0.00014334862385321102
I1
I0
I1
tp68343
sS'in,levels,comparable'
p68344
(F1
F0.00014334862385321102
I0
I1
I-1
tp68345
sS'iiia,inhibitors,was'
p68346
(F1
F0.00014334862385321102
I1
I0
I1
tp68347
sS'with,precedex,a'
p68348
(F1
F0.00014334862385321102
I1
I0
I1
tp68349
sS'of,and,mg'
p68350
(F0
F0
I1
I1
I0
tp68351
sS'acid,diminished,binding'
p68352
(F1
F0.00014334862385321102
I1
I0
I1
tp68353
sS'a,less,than'
p68354
(F1
F0.00014334862385321102
I1
I0
I1
tp68355
sS'concentrations,cyp3a4,inducers'
p68356
(F1
F0.00014334862385321102
I0
I1
I-1
tp68357
sS'dopamine2-,and,serotonin2-receptors'
p68358
(F1
F0.00014334862385321102
I0
I1
I-1
tp68359
sS'becausedecreases,in,plasmaconcentrations'
p68360
(F1
F0.00028669724770642203
I2
I0
I2
tp68361
sS'however,the,concomitant'
p68362
(F1
F0.00014334862385321102
I1
I0
I1
tp68363
sS'therefore,patients,on'
p68364
(F1
F0.00014334862385321102
I1
I0
I1
tp68365
sS'half,of,that'
p68366
(F1
F0.00014334862385321102
I0
I1
I-1
tp68367
sS'of,and,n-acetyl'
p68368
(F1
F0.00014334862385321102
I0
I1
I-1
tp68369
sS'until,further,data'
p68370
(F1
F0.00014334862385321102
I0
I1
I-1
tp68371
sS'iodinated,contrast,media'
p68372
(F1
F0.00014334862385321102
I1
I0
I1
tp68373
sS'these,patients,whose'
p68374
(F1
F0.00014334862385321102
I1
I0
I1
tp68375
sS'patients,receiving,bolus-ifl'
p68376
(F1
F0.00028669724770642203
I0
I2
I-2
tp68377
sS'increase,in,blood'
p68378
(F1
F0.00014334862385321102
I1
I0
I1
tp68379
sS'data,in,angina'
p68380
(F1
F0.00014334862385321102
I0
I1
I-1
tp68381
sS'administered,enter,the'
p68382
(F1
F0.00014334862385321102
I0
I1
I-1
tp68383
sS'several,short-term,controlled'
p68384
(F1
F0.00014334862385321102
I0
I1
I-1
tp68385
sS'is,approximately,to'
p68386
(F1
F0.00014334862385321102
I1
I0
I1
tp68387
sS'activities,similar,to'
p68388
(F1
F0.00014334862385321102
I0
I1
I-1
tp68389
sS'another,study,with'
p68390
(F1
F0.00014334862385321102
I0
I1
I-1
tp68391
sS'levels,of,vardenafil'
p68392
(F1
F0.00014334862385321102
I0
I1
I-1
tp68393
sS'association,with,concomitant'
p68394
(F1
F0.00014334862385321102
I1
I0
I1
tp68395
sS'tumors,and,it'
p68396
(F1
F0.00014334862385321102
I1
I0
I1
tp68397
sS'on,the,availability'
p68398
(F1
F0.00014334862385321102
I1
I0
I1
tp68399
sS'were,more,likely'
p68400
(F1
F0.00014334862385321102
I0
I1
I-1
tp68401
sS'diuretic,natriuretic,and'
p68402
(F1
F0.00014334862385321102
I1
I0
I1
tp68403
sS'when,and,nonsteroidal'
p68404
(F1
F0.00014334862385321102
I1
I0
I1
tp68405
sS'levels,of,but'
p68406
(F1
F0.00014334862385321102
I1
I0
I1
tp68407
sS'results,in,inhibition'
p68408
(F1
F0.00014334862385321102
I1
I0
I1
tp68409
sS'antifungal,agents,such'
p68410
(F1
F0.00014334862385321102
I0
I1
I-1
tp68411
sS'relationship,of,functional'
p68412
(F1
F0.00043004587155963305
I3
I0
I3
tp68413
sS'patients,with,stable'
p68414
(F1
F0.00014334862385321102
I0
I1
I-1
tp68415
sS'healthy,men,n'
p68416
(F1
F0.00014334862385321102
I0
I1
I-1
tp68417
sS'and,the,frequency'
p68418
(F1
F0.00014334862385321102
I0
I1
I-1
tp68419
sS'begun,in,patients'
p68420
(F1
F0.00014334862385321102
I1
I0
I1
tp68421
sS'synthetic,by,possibly'
p68422
(F1
F0.00014334862385321102
I1
I0
I1
tp68423
sS'used,as,sole'
p68424
(F1
F0.00014334862385321102
I0
I1
I-1
tp68425
sS'was,seen,with'
p68426
(F1
F0.00014334862385321102
I1
I0
I1
tp68427
sS'of,arachidonate-,or'
p68428
(F1
F0.00014334862385321102
I0
I1
I-1
tp68429
sS'uricosuric,medication,may'
p68430
(F1
F0.00014334862385321102
I1
I0
I1
tp68431
sS'cardiac,glycosides,could'
p68432
(F1
F0.00014334862385321102
I1
I0
I1
tp68433
sS'human,serum,by'
p68434
(F1
F0.00014334862385321102
I1
I0
I1
tp68435
sS'their,metabolites,may'
p68436
(F1
F0.00014334862385321102
I0
I1
I-1
tp68437
sS'resulted,in,about'
p68438
(F1
F0.00014334862385321102
I1
I0
I1
tp68439
sS'by,mtc-methylene,diphosphonate'
p68440
(F1
F0.00014334862385321102
I1
I0
I1
tp68441
sS'or,mg,kg'
p68442
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp68443
sS'be,effective,due'
p68444
(F0
F0
I1
I1
I0
tp68445
sS'depressive,symptoms,p'
p68446
(F1
F0.00014334862385321102
I0
I1
I-1
tp68447
sS'injections,of,or'
p68448
(F1
F0.00014334862385321102
I0
I1
I-1
tp68449
sS'state,while,levels'
p68450
(F1
F0.00014334862385321102
I1
I0
I1
tp68451
sS'to,administering,disulfiram'
p68452
(F1
F0.00014334862385321102
I1
I0
I1
tp68453
sS'aeds,during,placebo-controlled'
p68454
(F1
F0.00014334862385321102
I0
I1
I-1
tp68455
sS'although,not,observed'
p68456
(F1
F0.00014334862385321102
I1
I0
I1
tp68457
sS'is,started,or'
p68458
(F1
F0.00014334862385321102
I1
I0
I1
tp68459
sS'of,cyp3a4,substrates'
p68460
(F1
F0.00014334862385321102
I0
I1
I-1
tp68461
sS'a,study,conducted'
p68462
(F1
F0.00014334862385321102
I1
I0
I1
tp68463
sS'causes,a,slight'
p68464
(F1
F0.00014334862385321102
I1
I0
I1
tp68465
sS'treatment,with,suboxone'
p68466
(F1
F0.00014334862385321102
I1
I0
I1
tp68467
sS'is,receiving,replacement'
p68468
(F1
F0.00014334862385321102
I1
I0
I1
tp68469
sS'nimbex,at,or'
p68470
(F1
F0.00014334862385321102
I1
I0
I1
tp68471
sS'average,higher,in'
p68472
(F1
F0.00014334862385321102
I0
I1
I-1
tp68473
sS'day,was,significantly'
p68474
(F1
F0.00014334862385321102
I0
I1
I-1
tp68475
sS'heart,disease,has'
p68476
(F1
F0.00014334862385321102
I1
I0
I1
tp68477
sS'yielded,similar,serum'
p68478
(F1
F0.00014334862385321102
I0
I1
I-1
tp68479
sS'suggest,that,also'
p68480
(F1
F0.00014334862385321102
I1
I0
I1
tp68481
sS'iegs,are,thought'
p68482
(F1
F0.00014334862385321102
I0
I1
I-1
tp68483
sS'and,with,some'
p68484
(F1
F0.00014334862385321102
I1
I0
I1
tp68485
sS'may,have,their'
p68486
(F0
F0
I1
I1
I0
tp68487
sS'mg,of,mefenamic'
p68488
(F1
F0.00014334862385321102
I1
I0
I1
tp68489
sS'probenecid,concomitant,administration'
p68490
(F1
F0.00014334862385321102
I1
I0
I1
tp68491
sS'who,are,taking'
p68492
(F1
F0.00014334862385321102
I1
I0
I1
tp68493
sS'trials,have,indicated'
p68494
(F1
F0.00014334862385321102
I0
I1
I-1
tp68495
sS'just,prior,to'
p68496
(F1
F0.00014334862385321102
I0
I1
I-1
tp68497
sS'thorazine,prolixin,serentil'
p68498
(F1
F0.00014334862385321102
I0
I1
I-1
tp68499
sS'for,incombination,with'
p68500
(F1
F0.00014334862385321102
I0
I1
I-1
tp68501
sS'develop,delirium,high'
p68502
(F1
F0.00014334862385321102
I1
I0
I1
tp68503
sS'monitored,with,appropriate'
p68504
(F1
F0.00014334862385321102
I0
I1
I-1
tp68505
sS'with,bezalip,or'
p68506
(F1
F0.00028669724770642203
I2
I0
I2
tp68507
sS'oral,contraceptives,keppra'
p68508
(F1
F0.00014334862385321102
I0
I1
I-1
tp68509
sS'lipid-lowering,activity,of'
p68510
(F1
F0.00014334862385321102
I0
I1
I-1
tp68511
sS'by,hepatic,enzyme-inducing'
p68512
(F1
F0.00014334862385321102
I1
I0
I1
tp68513
sS'min,after,m-tco'
p68514
(F1
F0.00014334862385321102
I1
I0
I1
tp68515
sS'to,rats,and'
p68516
(F1
F0.00014334862385321102
I0
I1
I-1
tp68517
sS'most,of,the'
p68518
(F0
F0
I1
I1
I0
tp68519
sS'may,potentiate,renal'
p68520
(F1
F0.00014334862385321102
I1
I0
I1
tp68521
sS'about,times,more'
p68522
(F1
F0.00014334862385321102
I0
I1
I-1
tp68523
sS'converted,to,sinus'
p68524
(F1
F0.00014334862385321102
I1
I0
I1
tp68525
sS'also,result,i'
p68526
(F1
F0.00014334862385321102
I1
I0
I1
tp68527
sS'blood,or,urine'
p68528
(F1
F0.00014334862385321102
I0
I1
I-1
tp68529
sS'of,because,these'
p68530
(F1
F0.00014334862385321102
I1
I0
I1
tp68531
sS'significant,effects,have'
p68532
(F1
F0.00014334862385321102
I1
I0
I1
tp68533
sS'photic,evoked,potential'
p68534
(F1
F0.00014334862385321102
I0
I1
I-1
tp68535
sS'too,little,experience'
p68536
(F1
F0.00014334862385321102
I0
I1
I-1
tp68537
sS'humans,that,resemble'
p68538
(F1
F0.00014334862385321102
I0
I1
I-1
tp68539
sS'altering,cyp1a2-mediated,metabolism'
p68540
(F1
F0.00014334862385321102
I0
I1
I-1
tp68541
sS'components,p1,and'
p68542
(F1
F0.00014334862385321102
I1
I0
I1
tp68543
sS'hydrate,and,were'
p68544
(F1
F0.00014334862385321102
I0
I1
I-1
tp68545
sS'cytostatic,agent,has'
p68546
(F1
F0.00014334862385321102
I1
I0
I1
tp68547
sS'between,mao,inhibitors'
p68548
(F1
F0.00014334862385321102
I1
I0
I1
tp68549
sS'also,be,expected'
p68550
(F1
F0.00014334862385321102
I1
I0
I1
tp68551
sS'agents,class,i'
p68552
(F1
F0.00014334862385321102
I0
I1
I-1
tp68553
sS'hypersensitivity,reactions,to'
p68554
(F1
F0.00014334862385321102
I1
I0
I1
tp68555
sS'juice,resulted,in'
p68556
(F1
F0.00014334862385321102
I0
I1
I-1
tp68557
sS'appears,to,affect'
p68558
(F1
F0.00014334862385321102
I0
I1
I-1
tp68559
sS'develop,a,mild'
p68560
(F1
F0.00014334862385321102
I1
I0
I1
tp68561
sS'of,rats,followed'
p68562
(F1
F0.00014334862385321102
I0
I1
I-1
tp68563
sS'physician,may,wish'
p68564
(F1
F0.00014334862385321102
I1
I0
I1
tp68565
sS'also,increased,fold'
p68566
(F1
F0.00014334862385321102
I1
I0
I1
tp68567
sS'inhibit,platelet,activation'
p68568
(F1
F0.00014334862385321102
I0
I1
I-1
tp68569
sS'therapy,which,may'
p68570
(F1
F0.00014334862385321102
I0
I1
I-1
tp68571
sS'to,several,days'
p68572
(F1
F0.00014334862385321102
I0
I1
I-1
tp68573
sS'breast,milk,on'
p68574
(F1
F0.00014334862385321102
I0
I1
I-1
tp68575
sS'acute,phase,schizophrenia'
p68576
(F1
F0.00014334862385321102
I0
I1
I-1
tp68577
sS'of,vistide,and'
p68578
(F1
F0.00014334862385321102
I1
I0
I1
tp68579
sS'increased,prothrombin,time'
p68580
(F1
F0.00043004587155963305
I3
I0
I3
tp68581
sS'potentiate,the,undesirable'
p68582
(F1
F0.00014334862385321102
I1
I0
I1
tp68583
sS'of,aom,mg'
p68584
(F1
F0.00014334862385321102
I0
I1
I-1
tp68585
sS'reuptake,inhibitor,in'
p68586
(F1
F0.00014334862385321102
I1
I0
I1
tp68587
sS'resolved,when,was'
p68588
(F1
F0.00014334862385321102
I0
I1
I-1
tp68589
sS'inhibitors,within,two'
p68590
(F1
F0.00014334862385321102
I1
I0
I1
tp68591
sS'alone,and,in'
p68592
(F1
F0.0008600917431192661
I0
I6
I-6
tp68593
sS'advised,when,administering'
p68594
(F1
F0.00014334862385321102
I1
I0
I1
tp68595
sS'suggest,that,intraventricular'
p68596
(F1
F0.00014334862385321102
I0
I1
I-1
tp68597
sS'known,whether,other'
p68598
(F1
F0.00014334862385321102
I0
I1
I-1
tp68599
sS'lower,meclofenamate,sodium'
p68600
(F1
F0.00014334862385321102
I1
I0
I1
tp68601
sS'pump,inhibitors,should'
p68602
(F1
F0.00014334862385321102
I1
I0
I1
tp68603
sS'need,to,change'
p68604
(F0
F0
I1
I1
I0
tp68605
sS'has,been,investigated'
p68606
(F1
F0.00014334862385321102
I0
I1
I-1
tp68607
sS'may,blunt,the'
p68608
(F1
F0.00014334862385321102
I0
I1
I-1
tp68609
sS'as,and,have'
p68610
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp68611
sS'increase,in,mean'
p68612
(F1
F0.0008600917431192661
I6
I0
I6
tp68613
sS'who,require,additional'
p68614
(F1
F0.00014334862385321102
I0
I1
I-1
tp68615
sS'or,mg,h'
p68616
(F1
F0.00014334862385321102
I1
I0
I1
tp68617
sS'hormonal,may,inhibit'
p68618
(F1
F0.00014334862385321102
I1
I0
I1
tp68619
sS'carrier,density,in'
p68620
(F1
F0.00014334862385321102
I0
I1
I-1
tp68621
sS'to,a,marketed'
p68622
(F1
F0.00014334862385321102
I1
I0
I1
tp68623
sS'from,a,previously'
p68624
(F1
F0.00014334862385321102
I1
I0
I1
tp68625
sS'pharmacodynamics,of,glucose'
p68626
(F1
F0.00014334862385321102
I0
I1
I-1
tp68627
sS'nabilone,should,be'
p68628
(F1
F0.00014334862385321102
I1
I0
I1
tp68629
sS'rate,of,serious'
p68630
(F1
F0.00028669724770642203
I2
I0
I2
tp68631
sS'clinically,relevant,interaction'
p68632
(F1
F0.00014334862385321102
I1
I0
I1
tp68633
sS'on,reports,of'
p68634
(F1
F0.00028669724770642203
I2
I0
I2
tp68635
sS'and,or,its'
p68636
(F1
F0.00014334862385321102
I1
I0
I1
tp68637
sS'following,varying,degrees'
p68638
(F1
F0.00014334862385321102
I0
I1
I-1
tp68639
sS'produced,distinctive,effects'
p68640
(F1
F0.00014334862385321102
I0
I1
I-1
tp68641
sS'of,mixing,novolog'
p68642
(F1
F0.00014334862385321102
I0
I1
I-1
tp68643
sS'cells,whereas,b'
p68644
(F1
F0.00014334862385321102
I0
I1
I-1
tp68645
sS'to,exceed,a'
p68646
(F1
F0.00043004587155963305
I3
I0
I3
tp68647
sS'serum,potassium,prinivil'
p68648
(F1
F0.00014334862385321102
I1
I0
I1
tp68649
sS'improve,the,general'
p68650
(F1
F0.00014334862385321102
I0
I1
I-1
tp68651
sS'when,indocin,is'
p68652
(F1
F0.00014334862385321102
I1
I0
I1
tp68653
sS'more,convenient,administration'
p68654
(F1
F0.00014334862385321102
I0
I1
I-1
tp68655
sS'occurred,more,frequently'
p68656
(F1
F0.00014334862385321102
I0
I1
I-1
tp68657
sS'a,false,positive'
p68658
(F1
F0.00014334862385321102
I0
I1
I-1
tp68659
sS'injectables,are,adequate'
p68660
(F1
F0.00014334862385321102
I0
I1
I-1
tp68661
sS'of,nizoral,tablets'
p68662
(F1
F0.00014334862385321102
I1
I0
I1
tp68663
sS'with,a,mean'
p68664
(F1
F0.00014334862385321102
I1
I0
I1
tp68665
sS'least,days,should'
p68666
(F1
F0.00014334862385321102
I1
I0
I1
tp68667
sS'there,have,been'
p68668
(F0.42105263157894735
F0.0022935779816513763
I27
I11
I16
tp68669
sS'mg,of,betaseron'
p68670
(F1
F0.00014334862385321102
I1
I0
I1
tp68671
sS'interval,whole,blood'
p68672
(F1
F0.00014334862385321102
I1
I0
I1
tp68673
sS'fatal,prolongation,of'
p68674
(F1
F0.00014334862385321102
I1
I0
I1
tp68675
sS'mg,of,q12h'
p68676
(F1
F0.00014334862385321102
I1
I0
I1
tp68677
sS'have,a,marked'
p68678
(F1
F0.00014334862385321102
I1
I0
I1
tp68679
sS'interactions,flupenthixol,may'
p68680
(F1
F0.00014334862385321102
I1
I0
I1
tp68681
sS'of,serum,level'
p68682
(F1
F0.00014334862385321102
I0
I1
I-1
tp68683
sS'of,both,species'
p68684
(F1
F0.00014334862385321102
I1
I0
I1
tp68685
sS'in,six,healthy'
p68686
(F1
F0.00014334862385321102
I1
I0
I1
tp68687
sS'profile,prothrombin,time'
p68688
(F1
F0.00014334862385321102
I0
I1
I-1
tp68689
sS'and,the,may'
p68690
(F1
F0.00014334862385321102
I1
I0
I1
tp68691
sS'the,potential,exists'
p68692
(F1
F0.00014334862385321102
I1
I0
I1
tp68693
sS'temporarily,raise,serum'
p68694
(F1
F0.00014334862385321102
I1
I0
I1
tp68695
sS'of,the,homocysteine'
p68696
(F1
F0.00014334862385321102
I0
I1
I-1
tp68697
sS'of,toxic,levels'
p68698
(F1
F0.00014334862385321102
I1
I0
I1
tp68699
sS'oculo-bulbar,myasthenia,gravis'
p68700
(F1
F0.00014334862385321102
I1
I0
I1
tp68701
sS'meq,l,were'
p68702
(F1
F0.00014334862385321102
I0
I1
I-1
tp68703
sS'cyp450,enzymes,including'
p68704
(F1
F0.00014334862385321102
I0
I1
I-1
tp68705
sS'with,that,induce'
p68706
(F1
F0.00014334862385321102
I0
I1
I-1
tp68707
sS'of,rocaltrol,may'
p68708
(F1
F0.00043004587155963305
I0
I3
I-3
tp68709
sS'clearance,and,may'
p68710
(F1
F0.00014334862385321102
I1
I0
I1
tp68711
sS'permits,at,least'
p68712
(F1
F0.00014334862385321102
I1
I0
I1
tp68713
sS'concomitant,oral,medication'
p68714
(F1
F0.00014334862385321102
I1
I0
I1
tp68715
sS'cholestyramine,resin,may'
p68716
(F1
F0.00014334862385321102
I0
I1
I-1
tp68717
sS'as,acute,toxicity'
p68718
(F1
F0.00014334862385321102
I0
I1
I-1
tp68719
sS'coadministration,of,maalox'
p68720
(F1
F0.00014334862385321102
I0
I1
I-1
tp68721
sS'thus,concomitant,therapy'
p68722
(F1
F0.00014334862385321102
I0
I1
I-1
tp68723
sS'systemic,exposure,of'
p68724
(F1
F0.00014334862385321102
I1
I0
I1
tp68725
sS'however,there,are'
p68726
(F1
F0.00014334862385321102
I1
I0
I1
tp68727
sS'elderly,in,association'
p68728
(F1
F0.00014334862385321102
I1
I0
I1
tp68729
sS'reported,following,the'
p68730
(F1
F0.00014334862385321102
I0
I1
I-1
tp68731
sS'account,for,only'
p68732
(F1
F0.00014334862385321102
I0
I1
I-1
tp68733
sS'many,like,cannot'
p68734
(F1
F0.00014334862385321102
I0
I1
I-1
tp68735
sS'vitro,appears,to'
p68736
(F1
F0.00014334862385321102
I1
I0
I1
tp68737
sS'that,have,demonstrated'
p68738
(F1
F0.00014334862385321102
I1
I0
I1
tp68739
sS'different,descending,pain'
p68740
(F1
F0.00014334862385321102
I0
I1
I-1
tp68741
sS'studies,have,been'
p68742
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp68743
sS'if,treatment,with'
p68744
(F1
F0.00014334862385321102
I1
I0
I1
tp68745
sS'intravenous,pentamidine,treatment'
p68746
(F1
F0.00014334862385321102
I0
I1
I-1
tp68747
sS'no,systematic,changes'
p68748
(F1
F0.00014334862385321102
I0
I1
I-1
tp68749
sS'acid-base,and,electrolyte'
p68750
(F1
F0.00014334862385321102
I1
I0
I1
tp68751
sS'is,an,used'
p68752
(F1
F0.00014334862385321102
I0
I1
I-1
tp68753
sS'times,the,daily'
p68754
(F1
F0.00014334862385321102
I0
I1
I-1
tp68755
sS'or,its,effects'
p68756
(F1
F0.00014334862385321102
I0
I1
I-1
tp68757
sS'extract,from,bovine'
p68758
(F1
F0.00014334862385321102
I0
I1
I-1
tp68759
sS'cholesterol,levels,monitored'
p68760
(F1
F0.00014334862385321102
I1
I0
I1
tp68761
sS'two,weeks,plasma'
p68762
(F1
F0.00014334862385321102
I1
I0
I1
tp68763
sS'carbonate,the,anorectic'
p68764
(F1
F0.00014334862385321102
I1
I0
I1
tp68765
sS'presumably,because,both'
p68766
(F1
F0.00014334862385321102
I1
I0
I1
tp68767
sS'ph,on,the'
p68768
(F1
F0.00014334862385321102
I0
I1
I-1
tp68769
sS'reported,with,caution'
p68770
(F1
F0.00014334862385321102
I1
I0
I1
tp68771
sS'with,these,on'
p68772
(F1
F0.00014334862385321102
I0
I1
I-1
tp68773
sS'cyp2c9,substrate,by'
p68774
(F1
F0.00014334862385321102
I1
I0
I1
tp68775
sS'with,other,psychotropic'
p68776
(F1
F0.00043004587155963305
I3
I0
I3
tp68777
sS'been,occasional,literature'
p68778
(F1
F0.00014334862385321102
I1
I0
I1
tp68779
sS'sodium,or,other'
p68780
(F1
F0.00014334862385321102
I1
I0
I1
tp68781
sS'designed,to,examine'
p68782
(F1
F0.00014334862385321102
I0
I1
I-1
tp68783
sS'in,prothrombin,test'
p68784
(F1
F0.00028669724770642203
I0
I2
I-2
tp68785
sS'including,many,selective'
p68786
(F1
F0.00028669724770642203
I0
I2
I-2
tp68787
sS'in,nephrosis,acromegaly'
p68788
(F1
F0.00014334862385321102
I0
I1
I-1
tp68789
sS'mix,toradol,and'
p68790
(F1
F0.00014334862385321102
I0
I1
I-1
tp68791
sS'of,post-heparin,lipolytic'
p68792
(F1
F0.00014334862385321102
I1
I0
I1
tp68793
sS'administration,of,thiazide'
p68794
(F1
F0.00028669724770642203
I2
I0
I2
tp68795
sS'although,studies,designed'
p68796
(F1
F0.00014334862385321102
I0
I1
I-1
tp68797
sS'or,abolish,the'
p68798
(F1
F0.00014334862385321102
I1
I0
I1
tp68799
sS'hyperpyrexia,has,been'
p68800
(F1
F0.00014334862385321102
I1
I0
I1
tp68801
sS'plendil,the,pharmacokinetics'
p68802
(F1
F0.00014334862385321102
I0
I1
I-1
tp68803
sS'concurrently,it,is'
p68804
(F1
F0.00014334862385321102
I0
I1
I-1
tp68805
sS'phenothiazine-related,compounds,and'
p68806
(F1
F0.00014334862385321102
I1
I0
I1
tp68807
sS'therapy,with,antiplatelet'
p68808
(F1
F0.00014334862385321102
I1
I0
I1
tp68809
sS'against,the,simultaneous'
p68810
(F1
F0.00014334862385321102
I0
I1
I-1
tp68811
sS'containing,mg,ethinyl'
p68812
(F1
F0.00028669724770642203
I0
I2
I-2
tp68813
sS'any,evidence,of'
p68814
(F1
F0.00028669724770642203
I0
I2
I-2
tp68815
sS'when,the,drug'
p68816
(F1
F0.00014334862385321102
I1
I0
I1
tp68817
sS'mg,day,in'
p68818
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp68819
sS'this,study,demonstrated'
p68820
(F1
F0.00014334862385321102
I1
I0
I1
tp68821
sS'report,of,cardiopulmonary'
p68822
(F1
F0.00014334862385321102
I0
I1
I-1
tp68823
sS'mg,orally,disintegrating'
p68824
(F1
F0.00014334862385321102
I1
I0
I1
tp68825
sS'a,result,of'
p68826
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp68827
sS'false,low,measurement'
p68828
(F1
F0.00014334862385321102
I0
I1
I-1
tp68829
sS'node,function,or'
p68830
(F1
F0.00014334862385321102
I1
I0
I1
tp68831
sS'inhibitors,or,other'
p68832
(F1
F0.00014334862385321102
I0
I1
I-1
tp68833
sS'be,carried,out'
p68834
(F1
F0.00014334862385321102
I0
I1
I-1
tp68835
sS'is,used,in'
p68836
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp68837
sS'of,p-450iie1,in'
p68838
(F1
F0.00014334862385321102
I1
I0
I1
tp68839
sS'inhibition,are,expected'
p68840
(F1
F0.00014334862385321102
I1
I0
I1
tp68841
sS'it,was,co-administered'
p68842
(F1
F0.00014334862385321102
I1
I0
I1
tp68843
sS'on,the,retention'
p68844
(F1
F0.00014334862385321102
I1
I0
I1
tp68845
sS'altered,by,gleevec'
p68846
(F1
F0.00014334862385321102
I1
I0
I1
tp68847
sS'anticoagulants,including,derivatives'
p68848
(F1
F0.00014334862385321102
I1
I0
I1
tp68849
sS'pharmacodynamics,arecoline,eproxindine'
p68850
(F1
F0.00014334862385321102
I1
I0
I1
tp68851
sS'triazolam,no,significant'
p68852
(F1
F0.00014334862385321102
I0
I1
I-1
tp68853
sS'receiving,either,tagamet'
p68854
(F1
F0.00014334862385321102
I1
I0
I1
tp68855
sS'presyncope,or,orthostatic'
p68856
(F1
F0.00014334862385321102
I1
I0
I1
tp68857
sS'be,expected,since'
p68858
(F1
F0.00014334862385321102
I0
I1
I-1
tp68859
sS'aeds,phenytoin,keppra'
p68860
(F1
F0.00014334862385321102
I0
I1
I-1
tp68861
sS'intersubject,variability,in'
p68862
(F1
F0.00014334862385321102
I1
I0
I1
tp68863
sS'medications,containing,multivalent'
p68864
(F1
F0.00014334862385321102
I1
I0
I1
tp68865
sS'lithium,should,generally'
p68866
(F1
F0.00014334862385321102
I1
I0
I1
tp68867
sS'interact,with,the'
p68868
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp68869
sS'with,monurol,a'
p68870
(F1
F0.00014334862385321102
I1
I0
I1
tp68871
sS'produced,a,clinically'
p68872
(F1
F0.00014334862385321102
I1
I0
I1
tp68873
sS'with,are,illustrated'
p68874
(F1
F0.00014334862385321102
I0
I1
I-1
tp68875
sS'who,are,on'
p68876
(F1
F0.00043004587155963305
I3
I0
I3
tp68877
sS'avoid,iatrogenic,alterations'
p68878
(F1
F0.00014334862385321102
I1
I0
I1
tp68879
sS'this,paper,was'
p68880
(F1
F0.00014334862385321102
I0
I1
I-1
tp68881
sS'with,both,invirase'
p68882
(F1
F0.00014334862385321102
I0
I1
I-1
tp68883
sS'used,in,a'
p68884
(F1
F0.00014334862385321102
I0
I1
I-1
tp68885
sS'nonselective,monoamine,oxidase'
p68886
(F1
F0.00014334862385321102
I1
I0
I1
tp68887
sS'no,depressant,effect'
p68888
(F1
F0.00014334862385321102
I0
I1
I-1
tp68889
sS'concentrations,increased,the'
p68890
(F1
F0.00014334862385321102
I1
I0
I1
tp68891
sS'days,had,no'
p68892
(F1
F0.00057339449541284407
I0
I4
I-4
tp68893
sS'bid,as,compared'
p68894
(F1
F0.00014334862385321102
I1
I0
I1
tp68895
sS'sedation,if,is'
p68896
(F1
F0.00014334862385321102
I1
I0
I1
tp68897
sS'auc,values,in'
p68898
(F1
F0.00014334862385321102
I1
I0
I1
tp68899
sS'significant,change,in'
p68900
(F1
F0.00028669724770642203
I0
I2
I-2
tp68901
sS'cyp3a4,activity,may'
p68902
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp68903
sS'other,bronchodilators,has'
p68904
(F1
F0.00014334862385321102
I1
I0
I1
tp68905
sS'concentration,monitoring,is'
p68906
(F1
F0.00014334862385321102
I1
I0
I1
tp68907
sS'of,life-,threatening'
p68908
(F1
F0.00014334862385321102
I1
I0
I1
tp68909
sS'lamivudine,in,vitro'
p68910
(F1
F0.00014334862385321102
I1
I0
I1
tp68911
sS'study,a,nd'
p68912
(F1
F0.00014334862385321102
I0
I1
I-1
tp68913
sS'avoided,in,patients'
p68914
(F1
F0.00028669724770642203
I2
I0
I2
tp68915
sS'flexeril,may,have'
p68916
(F1
F0.00014334862385321102
I1
I0
I1
tp68917
sS'ed50,of,nuromax'
p68918
(F1
F0.00014334862385321102
I1
I0
I1
tp68919
sS'once,daily,has'
p68920
(F1
F0.00014334862385321102
I0
I1
I-1
tp68921
sS'at,all,when'
p68922
(F1
F0.00014334862385321102
I1
I0
I1
tp68923
sS'with,the,release'
p68924
(F1
F0.00014334862385321102
I0
I1
I-1
tp68925
sS'once,daily,had'
p68926
(F1
F0.00014334862385321102
I0
I1
I-1
tp68927
sS'day,was,studied'
p68928
(F1
F0.00014334862385321102
I0
I1
I-1
tp68929
sS'use,of,medications'
p68930
(F1
F0.00014334862385321102
I0
I1
I-1
tp68931
sS'disintegrins,and,for'
p68932
(F1
F0.00014334862385321102
I0
I1
I-1
tp68933
sS'affect,sinus,node'
p68934
(F1
F0.00014334862385321102
I1
I0
I1
tp68935
sS'significant,differences,in'
p68936
(F1
F0.00028669724770642203
I0
I2
I-2
tp68937
sS'platelet,aggregation,in'
p68938
(F1
F0.00014334862385321102
I0
I1
I-1
tp68939
sS'ethacrynic,acid,hepatotoxic'
p68940
(F1
F0.00014334862385321102
I1
I0
I1
tp68941
sS'plasma,albumin,binding'
p68942
(F1
F0.00014334862385321102
I1
I0
I1
tp68943
sS'non-potassium,sparing,such'
p68944
(F1
F0.00014334862385321102
I1
I0
I1
tp68945
sS'beta-adrenergic,antagonists,and'
p68946
(F1
F0.00028669724770642203
I2
I0
I2
tp68947
sS'inhibition,of,both'
p68948
(F1
F0.00014334862385321102
I0
I1
I-1
tp68949
sS'to,maintain,twitch'
p68950
(F1
F0.00014334862385321102
I0
I1
I-1
tp68951
sS'by,approximately,in'
p68952
(F0
F0
I1
I1
I0
tp68953
sS'pressure,than,when'
p68954
(F1
F0.00014334862385321102
I1
I0
I1
tp68955
sS'studied,increased,exposures'
p68956
(F1
F0.00014334862385321102
I1
I0
I1
tp68957
sS'is,unlikely,for'
p68958
(F1
F0.00014334862385321102
I0
I1
I-1
tp68959
sS'cholestyramine,and,cholestytamine'
p68960
(F1
F0.00014334862385321102
I1
I0
I1
tp68961
sS'inhibitors,in,vitro'
p68962
(F1
F0.00014334862385321102
I1
I0
I1
tp68963
sS'the,p-glycoprotein,transporter'
p68964
(F1
F0.00014334862385321102
I0
I1
I-1
tp68965
sS'the,total,bioavailability'
p68966
(F1
F0.00014334862385321102
I0
I1
I-1
tp68967
sS'effect,of,stadol'
p68968
(F1
F0.00014334862385321102
I1
I0
I1
tp68969
sS'special,care,should'
p68970
(F1
F0.00014334862385321102
I1
I0
I1
tp68971
sS'of,rats,with'
p68972
(F1
F0.00014334862385321102
I1
I0
I1
tp68973
sS'suggest,that,co-administration'
p68974
(F1
F0.00014334862385321102
I1
I0
I1
tp68975
sS'about,in,the'
p68976
(F1
F0.00014334862385321102
I1
I0
I1
tp68977
sS'may,explain,in'
p68978
(F1
F0.00014334862385321102
I0
I1
I-1
tp68979
sS'doses,of,mg'
p68980
(F0.14285714285714285
F0.00028669724770642203
I6
I8
I-2
tp68981
sS'videx,hours,prior'
p68982
(F1
F0.00014334862385321102
I1
I0
I1
tp68983
sS'reduced,while,the'
p68984
(F1
F0.00014334862385321102
I1
I0
I1
tp68985
sS'calcium,channel,antagonists'
p68986
(F1
F0.00014334862385321102
I0
I1
I-1
tp68987
sS'and,these,aeds'
p68988
(F1
F0.00014334862385321102
I0
I1
I-1
tp68989
sS'or,statistically,significant'
p68990
(F1
F0.00014334862385321102
I0
I1
I-1
tp68991
sS'combination,with,double'
p68992
(F1
F0.00014334862385321102
I0
I1
I-1
tp68993
sS'concentrations,of,either'
p68994
(F1
F0.00014334862385321102
I0
I1
I-1
tp68995
sS'reaction,of,actinic'
p68996
(F1
F0.00014334862385321102
I1
I0
I1
tp68997
sS'interaction,study,tambocor'
p68998
(F1
F0.00014334862385321102
I0
I1
I-1
tp68999
sS'conflicting,results,regarding'
p69000
(F1
F0.00014334862385321102
I1
I0
I1
tp69001
sS'data,from,clinical'
p69002
(F1
F0.00014334862385321102
I1
I0
I1
tp69003
sS'sodium,approximately,times'
p69004
(F1
F0.00014334862385321102
I1
I0
I1
tp69005
sS'concurrently,with,such'
p69006
(F1
F0.00014334862385321102
I0
I1
I-1
tp69007
sS'or,mg,day'
p69008
(F1
F0.00014334862385321102
I0
I1
I-1
tp69009
sS'ewes,with,an'
p69010
(F1
F0.00014334862385321102
I1
I0
I1
tp69011
sS'transmission,at,the'
p69012
(F1
F0.00014334862385321102
I0
I1
I-1
tp69013
sS'alfenta,doses,will'
p69014
(F1
F0.00014334862385321102
I0
I1
I-1
tp69015
sS'healthy,subjects,to'
p69016
(F1
F0.00014334862385321102
I0
I1
I-1
tp69017
sS'peak,serum,levels'
p69018
(F1
F0.00014334862385321102
I1
I0
I1
tp69019
sS'will,need,to'
p69020
(F1
F0.00014334862385321102
I1
I0
I1
tp69021
sS'the,ureidopenicillins,including'
p69022
(F1
F0.00014334862385321102
I1
I0
I1
tp69023
sS'synergistic,elevation,of'
p69024
(F1
F0.00014334862385321102
I1
I0
I1
tp69025
sS'mg,with,the'
p69026
(F1
F0.00014334862385321102
I0
I1
I-1
tp69027
sS'doses,of,m1'
p69028
(F1
F0.00014334862385321102
I1
I0
I1
tp69029
sS'by,approximately,and'
p69030
(F1
F0.00028669724770642203
I2
I0
I2
tp69031
sS'pharmacodynamics,or,pharmacokinetics'
p69032
(F1
F0.00014334862385321102
I0
I1
I-1
tp69033
sS'blockers,sustained-release,with'
p69034
(F1
F0.00014334862385321102
I0
I1
I-1
tp69035
sS'comparison,of,tolerance'
p69036
(F1
F0.00014334862385321102
I1
I0
I1
tp69037
sS'observed,that,meth'
p69038
(F1
F0.00014334862385321102
I1
I0
I1
tp69039
sS'of,concentrations,or'
p69040
(F1
F0.00014334862385321102
I0
I1
I-1
tp69041
sS'time,response,to'
p69042
(F1
F0.00014334862385321102
I0
I1
I-1
tp69043
sS'min,before,a'
p69044
(F1
F0.00014334862385321102
I1
I0
I1
tp69045
sS'cimetidine,co-administration,with'
p69046
(F1
F0.00014334862385321102
I1
I0
I1
tp69047
sS'of,elimination,of'
p69048
(F1
F0.00028669724770642203
I2
I0
I2
tp69049
sS'with,either,oral'
p69050
(F1
F0.00014334862385321102
I1
I0
I1
tp69051
sS'unknown,neither,nor'
p69052
(F1
F0.00014334862385321102
I1
I0
I1
tp69053
sS'angiotensin-converting,enzyme,inhibitors'
p69054
(F1
F0.00014334862385321102
I1
I0
I1
tp69055
sS'the,groups,receiving'
p69056
(F1
F0.00014334862385321102
I1
I0
I1
tp69057
sS'severe,rhabdomyolysis,appear'
p69058
(F1
F0.00014334862385321102
I1
I0
I1
tp69059
sS'these,are,often'
p69060
(F1
F0.00014334862385321102
I0
I1
I-1
tp69061
sS'therapeutic,superiority,compared'
p69062
(F1
F0.00014334862385321102
I0
I1
I-1
tp69063
sS'ml,at,baseline'
p69064
(F1
F0.00014334862385321102
I0
I1
I-1
tp69065
sS'for,only,of'
p69066
(F1
F0.00014334862385321102
I0
I1
I-1
tp69067
sS'treatment,with,mg'
p69068
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp69069
sS'are,receiving,a'
p69070
(F1
F0.00014334862385321102
I1
I0
I1
tp69071
sS'and,respectively,compared'
p69072
(F1
F0.00014334862385321102
I1
I0
I1
tp69073
sS'as,pure,powders'
p69074
(F1
F0.00014334862385321102
I1
I0
I1
tp69075
sS'reaction,for,glucose'
p69076
(F1
F0.00028669724770642203
I0
I2
I-2
tp69077
sS'cause,severe,persistent'
p69078
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp69079
sS'could,theoretically,interfere'
p69080
(F1
F0.00014334862385321102
I0
I1
I-1
tp69081
sS'or,when,proquin'
p69082
(F1
F0.00014334862385321102
I0
I1
I-1
tp69083
sS'imuran,the,concomitant'
p69084
(F1
F0.00014334862385321102
I1
I0
I1
tp69085
sS'caution,because,of'
p69086
(F1
F0.00014334862385321102
I1
I0
I1
tp69087
sS'the,median,of'
p69088
(F1
F0.00014334862385321102
I1
I0
I1
tp69089
sS'additional,significantly,inhibited'
p69090
(F1
F0.00014334862385321102
I1
I0
I1
tp69091
sS'p-,by,which'
p69092
(F1
F0.00014334862385321102
I0
I1
I-1
tp69093
sS'concentrations,of,are'
p69094
(F0.5
F0.00028669724770642203
I3
I1
I2
tp69095
sS'toxicity,occur,when'
p69096
(F1
F0.00014334862385321102
I1
I0
I1
tp69097
sS'found,to,have'
p69098
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp69099
sS'of,clinically,significant'
p69100
(F1
F0.00071674311926605509
I0
I5
I-5
tp69101
sS'thus,in,order'
p69102
(F1
F0.00014334862385321102
I1
I0
I1
tp69103
sS'effects,were,observed'
p69104
(F1
F0.00014334862385321102
I1
I0
I1
tp69105
sS'sedation,when,is'
p69106
(F1
F0.00014334862385321102
I1
I0
I1
tp69107
sS'is,taken,concurrently'
p69108
(F0
F0
I1
I1
I0
tp69109
sS'depend,on,the'
p69110
(F1
F0.00071674311926605509
I5
I0
I5
tp69111
sS'similar,events,have'
p69112
(F1
F0.00014334862385321102
I0
I1
I-1
tp69113
sS'not,been,observed'
p69114
(F1
F0.00028669724770642203
I0
I2
I-2
tp69115
sS'example,when,k'
p69116
(F1
F0.00014334862385321102
I1
I0
I1
tp69117
sS'of,megakaryocytes,with'
p69118
(F1
F0.00014334862385321102
I1
I0
I1
tp69119
sS'one-half,the,usual'
p69120
(F1
F0.00014334862385321102
I1
I0
I1
tp69121
sS'plus,or,minus'
p69122
(F1
F0.00014334862385321102
I1
I0
I1
tp69123
sS'levamisole,hydrochloride,has'
p69124
(F1
F0.00014334862385321102
I1
I0
I1
tp69125
sS'by,mao,inhibitors'
p69126
(F1
F0.00014334862385321102
I1
I0
I1
tp69127
sS'the,case,that'
p69128
(F1
F0.00014334862385321102
I1
I0
I1
tp69129
sS'ratio,inr,elevations'
p69130
(F1
F0.00014334862385321102
I1
I0
I1
tp69131
sS'by,a,net'
p69132
(F1
F0.00043004587155963305
I3
I0
I3
tp69133
sS'to,this,mechanism'
p69134
(F1
F0.00014334862385321102
I1
I0
I1
tp69135
sS'of,orally,inhaled'
p69136
(F0
F0
I1
I1
I0
tp69137
sS'on,placental,vessels'
p69138
(F1
F0.00014334862385321102
I0
I1
I-1
tp69139
sS'days,through,increased'
p69140
(F1
F0.00014334862385321102
I1
I0
I1
tp69141
sS'should,be,alerted'
p69142
(F1
F0.00014334862385321102
I0
I1
I-1
tp69143
sS'may,be,clinically'
p69144
(F0
F0
I1
I1
I0
tp69145
sS'by,cerulein--an,analog'
p69146
(F1
F0.00014334862385321102
I0
I1
I-1
tp69147
sS'oral,contraceptives,the'
p69148
(F1
F0.00014334862385321102
I0
I1
I-1
tp69149
sS'or,altered,tsh'
p69150
(F1
F0.00014334862385321102
I0
I1
I-1
tp69151
sS'with,for,the'
p69152
(F1
F0.00028669724770642203
I2
I0
I2
tp69153
sS'containing,and,other'
p69154
(F1
F0.00028669724770642203
I2
I0
I2
tp69155
sS'with,commonly,used'
p69156
(F1
F0.00014334862385321102
I0
I1
I-1
tp69157
sS'indication,of,physiological'
p69158
(F1
F0.00014334862385321102
I0
I1
I-1
tp69159
sS'a,the,maximal'
p69160
(F1
F0.00014334862385321102
I0
I1
I-1
tp69161
sS'alkaloids,amphetamines,inhibit'
p69162
(F1
F0.00028669724770642203
I2
I0
I2
tp69163
sS'manufacturer,or,the'
p69164
(F1
F0.00014334862385321102
I0
I1
I-1
tp69165
sS'severe,hypotension,or'
p69166
(F1
F0.00014334862385321102
I1
I0
I1
tp69167
sS'acid,etc,increase'
p69168
(F1
F0.00028669724770642203
I2
I0
I2
tp69169
sS'cholinesterase,activity,potentiates'
p69170
(F1
F0.00014334862385321102
I1
I0
I1
tp69171
sS'could,be,reversed'
p69172
(F1
F0.00014334862385321102
I0
I1
I-1
tp69173
sS'discontinuation,of,taxol'
p69174
(F1
F0.00014334862385321102
I0
I1
I-1
tp69175
sS's,concomitantly,with'
p69176
(F1
F0.00014334862385321102
I1
I0
I1
tp69177
sS'be,observed,carefully'
p69178
(F1
F0.00057339449541284407
I4
I0
I4
tp69179
sS'changes,that,include'
p69180
(F1
F0.00014334862385321102
I1
I0
I1
tp69181
sS'with,mg,tid'
p69182
(F1
F0.00014334862385321102
I1
I0
I1
tp69183
sS'oral,on,the'
p69184
(F1
F0.00014334862385321102
I0
I1
I-1
tp69185
sS'because,the,clearance'
p69186
(F1
F0.00014334862385321102
I1
I0
I1
tp69187
sS'of,were,generated'
p69188
(F1
F0.00014334862385321102
I0
I1
I-1
tp69189
sS'enzyme,system,ketoconazole'
p69190
(F1
F0.00014334862385321102
I1
I0
I1
tp69191
sS'caffeine,enoxacin,is'
p69192
(F1
F0.00014334862385321102
I1
I0
I1
tp69193
sS'receiving,these,in'
p69194
(F1
F0.00014334862385321102
I0
I1
I-1
tp69195
sS'cyst,patients,treated'
p69196
(F1
F0.00014334862385321102
I1
I0
I1
tp69197
sS'in,elevated,serum'
p69198
(F1
F0.00043004587155963305
I3
I0
I3
tp69199
sS'the,following,cyclosporine'
p69200
(F1
F0.00014334862385321102
I0
I1
I-1
tp69201
sS'with,respectto,safety'
p69202
(F1
F0.00014334862385321102
I0
I1
I-1
tp69203
sS'coli,in,male'
p69204
(F1
F0.00014334862385321102
I0
I1
I-1
tp69205
sS'attributed,to,the'
p69206
(F1
F0.00014334862385321102
I1
I0
I1
tp69207
sS'excretion,in,the'
p69208
(F1
F0.00014334862385321102
I1
I0
I1
tp69209
sS'cmax,by,fold'
p69210
(F1
F0.00014334862385321102
I1
I0
I1
tp69211
sS'alpha-,or,beta-adrenergic'
p69212
(F1
F0.00014334862385321102
I0
I1
I-1
tp69213
sS'nacmc,at,m'
p69214
(F1
F0.00014334862385321102
I0
I1
I-1
tp69215
sS'and,a,molecular'
p69216
(F1
F0.00014334862385321102
I1
I0
I1
tp69217
sS'therapy,with,to'
p69218
(F1
F0.00014334862385321102
I1
I0
I1
tp69219
sS'inhibitors,dasatinib,is'
p69220
(F1
F0.00014334862385321102
I0
I1
I-1
tp69221
sS'concomitant,hydrochloride,and'
p69222
(F1
F0.00014334862385321102
I0
I1
I-1
tp69223
sS'dose,study,n'
p69224
(F1
F0.00014334862385321102
I1
I0
I1
tp69225
sS'd,by,patients'
p69226
(F1
F0.00043004587155963305
I3
I0
I3
tp69227
sS'recommended,during,coadministration'
p69228
(F1
F0.00028669724770642203
I2
I0
I2
tp69229
sS'agonists,on,the'
p69230
(F1
F0.00014334862385321102
I1
I0
I1
tp69231
sS'approximately,in,uptake-1'
p69232
(F1
F0.00014334862385321102
I0
I1
I-1
tp69233
sS'can,give,a'
p69234
(F1
F0.00014334862385321102
I0
I1
I-1
tp69235
sS'ssri-tca,interactions,may'
p69236
(F1
F0.00057339449541284407
I4
I0
I4
tp69237
sS'was,to,characterize'
p69238
(F1
F0.00014334862385321102
I0
I1
I-1
tp69239
sS'including,midamor,may'
p69240
(F1
F0.00014334862385321102
I1
I0
I1
tp69241
sS'for,p450,d6'
p69242
(F1
F0.00071674311926605509
I0
I5
I-5
tp69243
sS'therapy,to,insure'
p69244
(F1
F0.00014334862385321102
I1
I0
I1
tp69245
sS'cytochrome,isozymes,are'
p69246
(F1
F0.00014334862385321102
I0
I1
I-1
tp69247
sS'a,gas,chromatographic-mass'
p69248
(F1
F0.00014334862385321102
I0
I1
I-1
tp69249
sS'digoxin,keppra,mg'
p69250
(F1
F0.00014334862385321102
I0
I1
I-1
tp69251
sS'months,the,combination'
p69252
(F1
F0.00014334862385321102
I0
I1
I-1
tp69253
sS'however,as,with'
p69254
(F1
F0.00014334862385321102
I1
I0
I1
tp69255
sS'cross,toxicity,and'
p69256
(F1
F0.00014334862385321102
I1
I0
I1
tp69257
sS'simulect,clearance,values'
p69258
(F1
F0.00014334862385321102
I0
I1
I-1
tp69259
sS'of,proton,pump'
p69260
(F1
F0.00014334862385321102
I0
I1
I-1
tp69261
sS'a,significant,decrease'
p69262
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp69263
sS'renal,tubular,excretion'
p69264
(F1
F0.00014334862385321102
I1
I0
I1
tp69265
sS'four,resulted,in'
p69266
(F1
F0.00014334862385321102
I1
I0
I1
tp69267
sS'be,associated,with'
p69268
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp69269
sS'micromol,l,induced'
p69270
(F1
F0.00014334862385321102
I0
I1
I-1
tp69271
sS'isoenzymes,may,decrease'
p69272
(F1
F0.00014334862385321102
I0
I1
I-1
tp69273
sS'of,m,v'
p69274
(F1
F0.00014334862385321102
I0
I1
I-1
tp69275
sS'to,date,has'
p69276
(F1
F0.00014334862385321102
I0
I1
I-1
tp69277
sS'total,bilirubin,elevations'
p69278
(F1
F0.00014334862385321102
I0
I1
I-1
tp69279
sS'of,m,g'
p69280
(F1
F0.00014334862385321102
I1
I0
I1
tp69281
sS'bid,with,resulted'
p69282
(F1
F0.00014334862385321102
I1
I0
I1
tp69283
sS'on,clearance,has'
p69284
(F1
F0.00014334862385321102
I0
I1
I-1
tp69285
sS'of,onto,the'
p69286
(F1
F0.00014334862385321102
I1
I0
I1
tp69287
sS'failure,etc,or'
p69288
(F1
F0.00014334862385321102
I1
I0
I1
tp69289
sS'decrease,the,cyp3a4-mediated'
p69290
(F1
F0.00014334862385321102
I1
I0
I1
tp69291
sS'for,h,by'
p69292
(F1
F0.00014334862385321102
I0
I1
I-1
tp69293
sS'cyp2d6,was,co-administered'
p69294
(F1
F0.00014334862385321102
I0
I1
I-1
tp69295
sS'inhibition,of,tubular'
p69296
(F1
F0.00014334862385321102
I1
I0
I1
tp69297
sS'an,index,of'
p69298
(F1
F0.00014334862385321102
I0
I1
I-1
tp69299
sS'displace,less,firmly'
p69300
(F1
F0.00014334862385321102
I1
I0
I1
tp69301
sS'was,performed,on'
p69302
(F1
F0.00014334862385321102
I0
I1
I-1
tp69303
sS'consider,hmg-coa,reductase'
p69304
(F1
F0.00014334862385321102
I1
I0
I1
tp69305
sS'clinical,trials,suggest'
p69306
(F1
F0.00014334862385321102
I0
I1
I-1
tp69307
sS'of,to,a'
p69308
(F1
F0.00014334862385321102
I1
I0
I1
tp69309
sS'humans,and,rats'
p69310
(F1
F0.00014334862385321102
I1
I0
I1
tp69311
sS'female,volunteers,established'
p69312
(F1
F0.00014334862385321102
I0
I1
I-1
tp69313
sS'affect,the,extent'
p69314
(F1
F0.00014334862385321102
I0
I1
I-1
tp69315
sS'sometimes,fatal,reactions'
p69316
(F1
F0.00014334862385321102
I1
I0
I1
tp69317
sS'tachycardia,in,the'
p69318
(F1
F0.00014334862385321102
I1
I0
I1
tp69319
sS'aluminum-,and,magnesium-containing'
p69320
(F1
F0.00014334862385321102
I0
I1
I-1
tp69321
sS'in,either,erythro-fluorocitrate'
p69322
(F1
F0.00014334862385321102
I0
I1
I-1
tp69323
sS'extends,its,plasma'
p69324
(F1
F0.00014334862385321102
I1
I0
I1
tp69325
sS'and,or,diarrhea'
p69326
(F1
F0.00014334862385321102
I1
I0
I1
tp69327
sS'mg,bid,as'
p69328
(F1
F0.00014334862385321102
I1
I0
I1
tp69329
sS'improve,the,permeation'
p69330
(F1
F0.00014334862385321102
I0
I1
I-1
tp69331
sS'i,binding,globulin'
p69332
(F1
F0.00014334862385321102
I0
I1
I-1
tp69333
sS'well,tolerated,but'
p69334
(F0
F0
I1
I1
I0
tp69335
sS'anti-inflammatory,concomitantly,with'
p69336
(F1
F0.00014334862385321102
I1
I0
I1
tp69337
sS'each,study,a'
p69338
(F1
F0.00014334862385321102
I0
I1
I-1
tp69339
sS'after,a,single'
p69340
(F0
F0
I1
I1
I0
tp69341
sS'for,and,ethinyl'
p69342
(F1
F0.00014334862385321102
I1
I0
I1
tp69343
sS'status,changes,that'
p69344
(F1
F0.00014334862385321102
I1
I0
I1
tp69345
sS'administration,of,racemic'
p69346
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp69347
sS'digoxin,when,multiple'
p69348
(F1
F0.00014334862385321102
I1
I0
I1
tp69349
sS'these,patients,the'
p69350
(F1
F0.00014334862385321102
I0
I1
I-1
tp69351
sS'of,medicinal,products'
p69352
(F1
F0.00014334862385321102
I1
I0
I1
tp69353
sS'as,the,vascular'
p69354
(F1
F0.00014334862385321102
I1
I0
I1
tp69355
sS'can,be,acutely'
p69356
(F1
F0.00014334862385321102
I1
I0
I1
tp69357
sS'deet,was,included'
p69358
(F1
F0.00014334862385321102
I0
I1
I-1
tp69359
sS'keratoses,treated,with'
p69360
(F1
F0.00014334862385321102
I1
I0
I1
tp69361
sS'the,oral,hormonal'
p69362
(F1
F0.00014334862385321102
I1
I0
I1
tp69363
sS'of,enterococcus,three'
p69364
(F1
F0.00014334862385321102
I0
I1
I-1
tp69365
sS'to,increased,plasma'
p69366
(F1
F0.00043004587155963305
I3
I0
I3
tp69367
sS'were,submitted,to'
p69368
(F1
F0.00014334862385321102
I0
I1
I-1
tp69369
sS'short-acting,and,that'
p69370
(F1
F0.00014334862385321102
I1
I0
I1
tp69371
sS'produced,average,decreases'
p69372
(F1
F0.00014334862385321102
I1
I0
I1
tp69373
sS'maintenance,doses,of'
p69374
(F0
F0
I1
I1
I0
tp69375
sS'however,reduced,cmax'
p69376
(F1
F0.00014334862385321102
I1
I0
I1
tp69377
sS'iv,such,as'
p69378
(F1
F0.00014334862385321102
I0
I1
I-1
tp69379
sS'different,than,for'
p69380
(F1
F0.00014334862385321102
I1
I0
I1
tp69381
sS'maintenance,doses,or'
p69382
(F1
F0.00014334862385321102
I1
I0
I1
tp69383
sS'dose,of,arava'
p69384
(F1
F0.00014334862385321102
I1
I0
I1
tp69385
sS'other,including,when'
p69386
(F1
F0.00014334862385321102
I1
I0
I1
tp69387
sS'isozyme,including,many'
p69388
(F1
F0.00014334862385321102
I0
I1
I-1
tp69389
sS'aliskiren,does,not'
p69390
(F1
F0.00014334862385321102
I0
I1
I-1
tp69391
sS'obtained,should,not'
p69392
(F1
F0.00014334862385321102
I1
I0
I1
tp69393
sS'enhance,cns,depression'
p69394
(F1
F0.00014334862385321102
I1
I0
I1
tp69395
sS'regular,monitoring,of'
p69396
(F1
F0.00014334862385321102
I0
I1
I-1
tp69397
sS'levels,or,prothrombin'
p69398
(F1
F0.00014334862385321102
I0
I1
I-1
tp69399
sS'given,concurrently,increases'
p69400
(F1
F0.00014334862385321102
I1
I0
I1
tp69401
sS'the,other,agents'
p69402
(F1
F0.00014334862385321102
I0
I1
I-1
tp69403
sS'with,mg,m2'
p69404
(F1
F0.00014334862385321102
I0
I1
I-1
tp69405
sS'aprepitant,is,unlikely'
p69406
(F1
F0.00014334862385321102
I0
I1
I-1
tp69407
sS'mg,was,taken'
p69408
(F1
F0.00014334862385321102
I0
I1
I-1
tp69409
sS'you,take,by'
p69410
(F1
F0.00014334862385321102
I1
I0
I1
tp69411
sS'these,studies,indicate'
p69412
(F1
F0.00014334862385321102
I1
I0
I1
tp69413
sS'through,an,effect'
p69414
(F1
F0.00014334862385321102
I1
I0
I1
tp69415
sS'achieve,mac,minimum'
p69416
(F1
F0.00014334862385321102
I1
I0
I1
tp69417
sS'than,mug,ml'
p69418
(F1
F0.00014334862385321102
I0
I1
I-1
tp69419
sS'type,strains,and'
p69420
(F1
F0.00014334862385321102
I0
I1
I-1
tp69421
sS'taking,lexapro,is'
p69422
(F1
F0.00014334862385321102
I1
I0
I1
tp69423
sS'high,concentrations,of'
p69424
(F1
F0.00028669724770642203
I0
I2
I-2
tp69425
sS'alcohol,g,kg'
p69426
(F1
F0.00014334862385321102
I0
I1
I-1
tp69427
sS'high,concentrations,or'
p69428
(F1
F0.00014334862385321102
I1
I0
I1
tp69429
sS'hepatotoxicity,of,by'
p69430
(F1
F0.00014334862385321102
I1
I0
I1
tp69431
sS'sulfate,may,enhance'
p69432
(F1
F0.00014334862385321102
I1
I0
I1
tp69433
sS'fentanyl,in,patients'
p69434
(F1
F0.00014334862385321102
I1
I0
I1
tp69435
sS'use,of,beta-adrenergic'
p69436
(F1
F0.00028669724770642203
I2
I0
I2
tp69437
sS'should,be,administered'
p69438
(F1
F0.0020068807339449542
I14
I0
I14
tp69439
sS'of,but,significantly'
p69440
(F1
F0.00014334862385321102
I1
I0
I1
tp69441
sS'in,a,four-session'
p69442
(F1
F0.00014334862385321102
I0
I1
I-1
tp69443
sS'with,oral,may'
p69444
(F1
F0.00014334862385321102
I1
I0
I1
tp69445
sS'elimination,but,also'
p69446
(F1
F0.00014334862385321102
I1
I0
I1
tp69447
sS'cns,agents,concurrent'
p69448
(F1
F0.00014334862385321102
I1
I0
I1
tp69449
sS'hypoglycemic,agents,eg'
p69450
(F1
F0.00014334862385321102
I1
I0
I1
tp69451
sS'eg,and,may'
p69452
(F1
F0.00014334862385321102
I1
I0
I1
tp69453
sS'lipid,response,to'
p69454
(F1
F0.00014334862385321102
I1
I0
I1
tp69455
sS'compounds,that,induce'
p69456
(F1
F0.00014334862385321102
I1
I0
I1
tp69457
sS'via,its,metabolism'
p69458
(F1
F0.00014334862385321102
I1
I0
I1
tp69459
sS'with,l-tryptophan,may'
p69460
(F1
F0.00014334862385321102
I0
I1
I-1
tp69461
sS'renal,impairment,clcr'
p69462
(F1
F0.00014334862385321102
I1
I0
I1
tp69463
sS'the,actions,of'
p69464
(F1
F0.00014334862385321102
I1
I0
I1
tp69465
sS'the,blood,which'
p69466
(F1
F0.00014334862385321102
I1
I0
I1
tp69467
sS'ketoconazole,tablets,may'
p69468
(F1
F0.00014334862385321102
I1
I0
I1
tp69469
sS'maalox,tc,suspension'
p69470
(F1
F0.00028669724770642203
I2
I0
I2
tp69471
sS'have,been,postmarketing'
p69472
(F1
F0.00014334862385321102
I1
I0
I1
tp69473
sS'absorption,is,sensitive'
p69474
(F1
F0.00014334862385321102
I0
I1
I-1
tp69475
sS'pressure,in,patients'
p69476
(F1
F0.00014334862385321102
I0
I1
I-1
tp69477
sS'of,in,alcoholic'
p69478
(F1
F0.00014334862385321102
I1
I0
I1
tp69479
sS'or,pharmacodynamic,interactions'
p69480
(F1
F0.00014334862385321102
I0
I1
I-1
tp69481
sS'presence,of,carbamazepine'
p69482
(F0
F0
I1
I1
I0
tp69483
sS'parental,such,as'
p69484
(F1
F0.00014334862385321102
I1
I0
I1
tp69485
sS'were,not,performed'
p69486
(F1
F0.00028669724770642203
I0
I2
I-2
tp69487
sS'interfere,with,subsequent'
p69488
(F1
F0.00014334862385321102
I0
I1
I-1
tp69489
sS'warfarin,quinolones,may'
p69490
(F1
F0.00014334862385321102
I1
I0
I1
tp69491
sS'concomitantly,there,is'
p69492
(F1
F0.00014334862385321102
I1
I0
I1
tp69493
sS'than,when,either'
p69494
(F1
F0.00043004587155963305
I3
I0
I3
tp69495
sS'substrate,and,cyp'
p69496
(F1
F0.00014334862385321102
I0
I1
I-1
tp69497
sS'magnesium-containing,preparations,eg'
p69498
(F1
F0.00043004587155963305
I3
I0
I3
tp69499
sS'or,either,stereoisomer'
p69500
(F1
F0.00014334862385321102
I1
I0
I1
tp69501
sS'their,coagulation,parameters'
p69502
(F1
F0.00014334862385321102
I1
I0
I1
tp69503
sS'itraconazole,enhances,the'
p69504
(F1
F0.00014334862385321102
I1
I0
I1
tp69505
sS'by,n6-cyclopentyladenosine,cpa'
p69506
(F1
F0.00014334862385321102
I1
I0
I1
tp69507
sS'significantly,with,multiple'
p69508
(F1
F0.00014334862385321102
I0
I1
I-1
tp69509
sS'the,genetically,nervous'
p69510
(F1
F0.00014334862385321102
I0
I1
I-1
tp69511
sS'on,anecdotal,reports'
p69512
(F1
F0.00014334862385321102
I1
I0
I1
tp69513
sS'not,cause,induction'
p69514
(F1
F0.00014334862385321102
I0
I1
I-1
tp69515
sS'times,the,recommended'
p69516
(F0
F0
I1
I1
I0
tp69517
sS'days,after,the'
p69518
(F0.5
F0.00028669724770642203
I3
I1
I2
tp69519
sS'disease,who,received'
p69520
(F1
F0.00014334862385321102
I0
I1
I-1
tp69521
sS'alternatives,to,such'
p69522
(F1
F0.00028669724770642203
I0
I2
I-2
tp69523
sS'intravenous,administration,of'
p69524
(F1
F0.00028669724770642203
I0
I2
I-2
tp69525
sS'either,the,pharmacokinetics'
p69526
(F1
F0.00028669724770642203
I0
I2
I-2
tp69527
sS'not,nanm,or'
p69528
(F1
F0.00014334862385321102
I1
I0
I1
tp69529
sS'vitro,glucuronidation,of'
p69530
(F1
F0.00014334862385321102
I0
I1
I-1
tp69531
sS'cmax,by,in'
p69532
(F1
F0.00014334862385321102
I1
I0
I1
tp69533
sS'john,s,wort'
p69534
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp69535
sS'of,voltage-dependent,ca'
p69536
(F1
F0.00014334862385321102
I0
I1
I-1
tp69537
sS'and,pharmacokinetics,of'
p69538
(F1
F0.00014334862385321102
I0
I1
I-1
tp69539
sS'and,mg,administered'
p69540
(F1
F0.00014334862385321102
I1
I0
I1
tp69541
sS'taking,or,oral'
p69542
(F1
F0.00014334862385321102
I0
I1
I-1
tp69543
sS'r-warfarin,the,less'
p69544
(F1
F0.00014334862385321102
I1
I0
I1
tp69545
sS'may,potentiate,vecuronium-induced'
p69546
(F1
F0.00014334862385321102
I1
I0
I1
tp69547
sS'effectiveness,of,supplemental'
p69548
(F1
F0.00014334862385321102
I1
I0
I1
tp69549
sS'clinical,evidence,has'
p69550
(F1
F0.00014334862385321102
I1
I0
I1
tp69551
sS'low-dose,with,vioxx'
p69552
(F1
F0.00014334862385321102
I1
I0
I1
tp69553
sS'concentrations,include,acute'
p69554
(F1
F0.00014334862385321102
I1
I0
I1
tp69555
sS'and,increased,appetite'
p69556
(F1
F0.00014334862385321102
I0
I1
I-1
tp69557
sS'to,the,cross-reactivity'
p69558
(F1
F0.00014334862385321102
I1
I0
I1
tp69559
sS'such,the,dose'
p69560
(F1
F0.00014334862385321102
I0
I1
I-1
tp69561
sS'tubular,transport,of'
p69562
(F1
F0.00014334862385321102
I1
I0
I1
tp69563
sS'acute,pretreatment,on'
p69564
(F1
F0.00014334862385321102
I0
I1
I-1
tp69565
sS'mg,bid,otc'
p69566
(F1
F0.00014334862385321102
I1
I0
I1
tp69567
sS'deficiencies,affecting,blood'
p69568
(F1
F0.00014334862385321102
I1
I0
I1
tp69569
sS'tolerant,patients,or'
p69570
(F1
F0.00014334862385321102
I0
I1
I-1
tp69571
sS'of,both,and'
p69572
(F1
F0.00057339449541284407
I4
I0
I4
tp69573
sS'these,isoenzymes,may'
p69574
(F1
F0.00014334862385321102
I0
I1
I-1
tp69575
sS'or,serum,levels'
p69576
(F1
F0.00014334862385321102
I1
I0
I1
tp69577
sS'reduce,the,antitumor'
p69578
(F1
F0.00014334862385321102
I1
I0
I1
tp69579
sS'its,epoxide,metabolite'
p69580
(F1
F0.00014334862385321102
I0
I1
I-1
tp69581
sS'concentration,greater,than'
p69582
(F1
F0.00014334862385321102
I0
I1
I-1
tp69583
sS'undergoing,ptca,pci'
p69584
(F1
F0.00014334862385321102
I1
I0
I1
tp69585
sS'insert,labeling,of'
p69586
(F1
F0.00014334862385321102
I0
I1
I-1
tp69587
sS'belladonna,alkaloids,and'
p69588
(F1
F0.00014334862385321102
I1
I0
I1
tp69589
sS'products,could,theoretically'
p69590
(F1
F0.00014334862385321102
I1
I0
I1
tp69591
sS'somnolence,have,been'
p69592
(F1
F0.00014334862385321102
I1
I0
I1
tp69593
sS'report,the,case'
p69594
(F1
F0.00014334862385321102
I1
I0
I1
tp69595
sS'pharmacokinetics,of,busulfex'
p69596
(F1
F0.00014334862385321102
I1
I0
I1
tp69597
sS'in,studies,with'
p69598
(F0
F0
I1
I1
I0
tp69599
sS'adjust,the,dosage'
p69600
(F1
F0.00014334862385321102
I1
I0
I1
tp69601
sS'channel,blockers,requires'
p69602
(F1
F0.00014334862385321102
I1
I0
I1
tp69603
sS'for,yeast,and'
p69604
(F1
F0.00014334862385321102
I0
I1
I-1
tp69605
sS'effects,of,the'
p69606
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp69607
sS'acetate,x,m'
p69608
(F1
F0.00014334862385321102
I1
I0
I1
tp69609
sS'on,pharmacokinetics,and'
p69610
(F1
F0.00014334862385321102
I0
I1
I-1
tp69611
sS'mcg,im,once'
p69612
(F0
F0
I1
I1
I0
tp69613
sS'conduction,disturbance,rarely'
p69614
(F1
F0.00014334862385321102
I1
I0
I1
tp69615
sS'study,in,hypertensive'
p69616
(F1
F0.00014334862385321102
I0
I1
I-1
tp69617
sS'coagulation,times,were'
p69618
(F1
F0.00014334862385321102
I0
I1
I-1
tp69619
sS'and,if,necessary'
p69620
(F0
F0
I1
I1
I0
tp69621
sS'is,hydroxylation,catalyzed'
p69622
(F1
F0.00014334862385321102
I0
I1
I-1
tp69623
sS'addicts,were,completely'
p69624
(F1
F0.00014334862385321102
I1
I0
I1
tp69625
sS'levels,may,rise'
p69626
(F1
F0.00014334862385321102
I0
I1
I-1
tp69627
sS'mammary,tumor,virus'
p69628
(F1
F0.00014334862385321102
I0
I1
I-1
tp69629
sS'of,unchanged,alkaloids'
p69630
(F1
F0.00014334862385321102
I1
I0
I1
tp69631
sS'influence,of,the'
p69632
(F1
F0.00014334862385321102
I0
I1
I-1
tp69633
sS'of,argatroban,g'
p69634
(F1
F0.00014334862385321102
I0
I1
I-1
tp69635
sS'oral,has,led'
p69636
(F1
F0.00014334862385321102
I1
I0
I1
tp69637
sS'for,the,selective'
p69638
(F1
F0.00014334862385321102
I0
I1
I-1
tp69639
sS'however,patients,receiving'
p69640
(F1
F0.00014334862385321102
I0
I1
I-1
tp69641
sS'cause,hypermagnesemia,and'
p69642
(F1
F0.00043004587155963305
I3
I0
I3
tp69643
sS'such,as,channel-blockers'
p69644
(F1
F0.00014334862385321102
I0
I1
I-1
tp69645
sS'exercised,when,are'
p69646
(F1
F0.00014334862385321102
I1
I0
I1
tp69647
sS'and,may,possibly'
p69648
(F1
F0.00014334862385321102
I0
I1
I-1
tp69649
sS'required,it,is'
p69650
(F1
F0.00014334862385321102
I1
I0
I1
tp69651
sS'amprenavir,significantly,increased'
p69652
(F1
F0.00014334862385321102
I1
I0
I1
tp69653
sS'mg,of,twice'
p69654
(F1
F0.00014334862385321102
I0
I1
I-1
tp69655
sS'death,have,been'
p69656
(F1
F0.00014334862385321102
I0
I1
I-1
tp69657
sS'recommended,dosages,or'
p69658
(F1
F0.00014334862385321102
I1
I0
I1
tp69659
sS'diagnostic,serum,tests'
p69660
(F1
F0.00014334862385321102
I0
I1
I-1
tp69661
sS'antagonize,the,in'
p69662
(F1
F0.00014334862385321102
I1
I0
I1
tp69663
sS'no,evidence,was'
p69664
(F1
F0.00014334862385321102
I0
I1
I-1
tp69665
sS'have,caused,to'
p69666
(F1
F0.00014334862385321102
I1
I0
I1
tp69667
sS'metoclopramide,bioavailability,is'
p69668
(F1
F0.00014334862385321102
I1
I0
I1
tp69669
sS'treatment,of,patients'
p69670
(F1
F0.00014334862385321102
I1
I0
I1
tp69671
sS'evaluated,but,should'
p69672
(F1
F0.00028669724770642203
I2
I0
I2
tp69673
sS'since,higher,doses'
p69674
(F1
F0.00014334862385321102
I1
I0
I1
tp69675
sS'b,i,d'
p69676
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp69677
sS'profile,of,mg'
p69678
(F1
F0.00014334862385321102
I0
I1
I-1
tp69679
sS'cholestographic,agents,iodine-containing'
p69680
(F1
F0.00014334862385321102
I0
I1
I-1
tp69681
sS'may,be,prolonged'
p69682
(F1
F0.00028669724770642203
I2
I0
I2
tp69683
sS'interactions,albuterol,strattera'
p69684
(F1
F0.00014334862385321102
I1
I0
I1
tp69685
sS'patients,receiving,concomitantly'
p69686
(F1
F0.00043004587155963305
I3
I0
I3
tp69687
sS'of,both,agents'
p69688
(F1
F0.00014334862385321102
I0
I1
I-1
tp69689
sS'other,that,inhibit'
p69690
(F1
F0.00014334862385321102
I0
I1
I-1
tp69691
sS'during,conversion,from'
p69692
(F1
F0.00014334862385321102
I0
I1
I-1
tp69693
sS'mg,dl,triglycerides'
p69694
(F1
F0.00014334862385321102
I0
I1
I-1
tp69695
sS'inhibitors,of,c'
p69696
(F1
F0.00014334862385321102
I1
I0
I1
tp69697
sS'some,have,been'
p69698
(F1
F0.00028669724770642203
I2
I0
I2
tp69699
sS'duloxetine,did,not'
p69700
(F1
F0.00014334862385321102
I0
I1
I-1
tp69701
sS'been,established,current'
p69702
(F1
F0.00014334862385321102
I1
I0
I1
tp69703
sS'or,enantiomer,pharmacokinetics'
p69704
(F1
F0.00014334862385321102
I0
I1
I-1
tp69705
sS'appear,to,increase'
p69706
(F0
F0
I1
I1
I0
tp69707
sS'vitro,studies,indicate'
p69708
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp69709
sS'pharmacokinetics,exposure,or'
p69710
(F1
F0.00014334862385321102
I0
I1
I-1
tp69711
sS'cyp3a4,therefore,potential'
p69712
(F1
F0.00014334862385321102
I0
I1
I-1
tp69713
sS'male,volunteers,were'
p69714
(F1
F0.00014334862385321102
I0
I1
I-1
tp69715
sS'closely,when,initiating'
p69716
(F1
F0.00014334862385321102
I1
I0
I1
tp69717
sS'potentiate,the,cns-depressive'
p69718
(F1
F0.00014334862385321102
I1
I0
I1
tp69719
sS'toradol,on,clearance'
p69720
(F1
F0.00014334862385321102
I0
I1
I-1
tp69721
sS'in,the,ibandronate'
p69722
(F1
F0.00014334862385321102
I0
I1
I-1
tp69723
sS'and,mg,for'
p69724
(F1
F0.00014334862385321102
I0
I1
I-1
tp69725
sS'elevated,serum,enzymes'
p69726
(F1
F0.00014334862385321102
I1
I0
I1
tp69727
sS'intoxication,plasma,levels'
p69728
(F1
F0.00014334862385321102
I0
I1
I-1
tp69729
sS'are,taken,as'
p69730
(F1
F0.00014334862385321102
I1
I0
I1
tp69731
sS'was,reduced,from'
p69732
(F1
F0.00028669724770642203
I2
I0
I2
tp69733
sS'may,cause,abnormal'
p69734
(F1
F0.00014334862385321102
I1
I0
I1
tp69735
sS'proteins,may,be'
p69736
(F1
F0.00028669724770642203
I0
I2
I-2
tp69737
sS's,alpha,and'
p69738
(F1
F0.00014334862385321102
I0
I1
I-1
tp69739
sS'anticoagulants,caution,should'
p69740
(F1
F0.00014334862385321102
I1
I0
I1
tp69741
sS'patients,on,therapy'
p69742
(F1
F0.00028669724770642203
I2
I0
I2
tp69743
sS'in,amiodarone-treated,patients'
p69744
(F1
F0.00014334862385321102
I0
I1
I-1
tp69745
sS'lower,end,of'
p69746
(F1
F0.00014334862385321102
I1
I0
I1
tp69747
sS'its,effect,could'
p69748
(F1
F0.00014334862385321102
I1
I0
I1
tp69749
sS'terfenadine,in,a'
p69750
(F1
F0.00014334862385321102
I0
I1
I-1
tp69751
sS'dose,once,daily'
p69752
(F1
F0.00014334862385321102
I0
I1
I-1
tp69753
sS'positive,and,anxiety'
p69754
(F1
F0.00014334862385321102
I0
I1
I-1
tp69755
sS'methotrexate,humira,has'
p69756
(F1
F0.00014334862385321102
I0
I1
I-1
tp69757
sS'resulted,in,more'
p69758
(F1
F0.00014334862385321102
I0
I1
I-1
tp69759
sS'of,apparent,total'
p69760
(F1
F0.00014334862385321102
I1
I0
I1
tp69761
sS'in,addition,interfere'
p69762
(F1
F0.00014334862385321102
I1
I0
I1
tp69763
sS'would,coincide,duloxetine'
p69764
(F1
F0.00014334862385321102
I0
I1
I-1
tp69765
sS'acth,intensified,electrolyte'
p69766
(F1
F0.00028669724770642203
I0
I2
I-2
tp69767
sS'bile,caution,should'
p69768
(F1
F0.00014334862385321102
I0
I1
I-1
tp69769
sS'monkeys,responding,under'
p69770
(F1
F0.00014334862385321102
I0
I1
I-1
tp69771
sS'committed,step,of'
p69772
(F1
F0.00014334862385321102
I1
I0
I1
tp69773
sS'and,fold,on'
p69774
(F1
F0.00014334862385321102
I1
I0
I1
tp69775
sS'depressasnts,such,as'
p69776
(F1
F0.00014334862385321102
I1
I0
I1
tp69777
sS'elimination,of,by'
p69778
(F1
F0.00028669724770642203
I2
I0
I2
tp69779
sS'of,causes,an'
p69780
(F1
F0.00014334862385321102
I1
I0
I1
tp69781
sS'to,was,not'
p69782
(F1
F0.00014334862385321102
I1
I0
I1
tp69783
sS'aspirin,nonsteroidal,antiinflammatory'
p69784
(F1
F0.00014334862385321102
I0
I1
I-1
tp69785
sS'has,been,found'
p69786
(F1
F0.00028669724770642203
I2
I0
I2
tp69787
sS'that,cefditoren,pivoxil'
p69788
(F0
F0
I1
I1
I0
tp69789
sS'clinically,important,effect'
p69790
(F1
F0.0008600917431192661
I0
I6
I-6
tp69791
sS'that,induce,cyp3a4'
p69792
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp69793
sS'to,sinus,rhythm'
p69794
(F1
F0.00014334862385321102
I1
I0
I1
tp69795
sS'compared,to,those'
p69796
(F1
F0.00014334862385321102
I0
I1
I-1
tp69797
sS'should,receive,low-molecular'
p69798
(F1
F0.00014334862385321102
I0
I1
I-1
tp69799
sS'the,concentrations,of'
p69800
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp69801
sS'when,agents,such'
p69802
(F1
F0.00014334862385321102
I1
I0
I1
tp69803
sS'hydrochloride,may,potentiate'
p69804
(F1
F0.00014334862385321102
I1
I0
I1
tp69805
sS'its,inhibitory,effects'
p69806
(F1
F0.00014334862385321102
I0
I1
I-1
tp69807
sS'blood,concentration,should'
p69808
(F1
F0.00014334862385321102
I0
I1
I-1
tp69809
sS'should,be,approximately'
p69810
(F1
F0.00014334862385321102
I0
I1
I-1
tp69811
sS'but,statistically,significant'
p69812
(F1
F0.00014334862385321102
I1
I0
I1
tp69813
sS'concentrations,were,also'
p69814
(F1
F0.00014334862385321102
I0
I1
I-1
tp69815
sS'of,american,coffee'
p69816
(F1
F0.00014334862385321102
I0
I1
I-1
tp69817
sS'with,pegasys,in'
p69818
(F1
F0.00014334862385321102
I0
I1
I-1
tp69819
sS'by,meth,has'
p69820
(F1
F0.00014334862385321102
I0
I1
I-1
tp69821
sS'aprepitant,with,in'
p69822
(F1
F0.00014334862385321102
I0
I1
I-1
tp69823
sS'that,a,the'
p69824
(F1
F0.00014334862385321102
I0
I1
I-1
tp69825
sS'a,similar,proportion'
p69826
(F1
F0.00014334862385321102
I1
I0
I1
tp69827
sS'or,potentiate,the'
p69828
(F1
F0.00028669724770642203
I2
I0
I2
tp69829
sS'opioid,analgesics,agonist'
p69830
(F1
F0.00014334862385321102
I1
I0
I1
tp69831
sS'qd,increased,the'
p69832
(F1
F0.00014334862385321102
I1
I0
I1
tp69833
sS'with,the,patient'
p69834
(F0
F0
I1
I1
I0
tp69835
sS'of,mg,four'
p69836
(F1
F0.00014334862385321102
I0
I1
I-1
tp69837
sS'and,extended,release'
p69838
(F1
F0.00014334862385321102
I1
I0
I1
tp69839
sS'with,a,non-specific'
p69840
(F1
F0.00014334862385321102
I0
I1
I-1
tp69841
sS'be,enhanced,if'
p69842
(F1
F0.00014334862385321102
I1
I0
I1
tp69843
sS'is,generally,not'
p69844
(F1
F0.00014334862385321102
I1
I0
I1
tp69845
sS'produced,significantly,increased'
p69846
(F1
F0.00014334862385321102
I1
I0
I1
tp69847
sS'coadministration,of,atrovent'
p69848
(F1
F0.00014334862385321102
I1
I0
I1
tp69849
sS'with,cancidas,may'
p69850
(F1
F0.00014334862385321102
I1
I0
I1
tp69851
sS'blockers,although,not'
p69852
(F1
F0.00014334862385321102
I1
I0
I1
tp69853
sS'effects,of,antimicrobial'
p69854
(F1
F0.00014334862385321102
I0
I1
I-1
tp69855
sS'to,be,given'
p69856
(F1
F0.00014334862385321102
I1
I0
I1
tp69857
sS'by,antihypertensive,agents'
p69858
(F1
F0.00028669724770642203
I2
I0
I2
tp69859
sS'aspirin,acetaminophen,pharmacokinetic'
p69860
(F1
F0.00014334862385321102
I0
I1
I-1
tp69861
sS'effects,when,coadministered'
p69862
(F1
F0.00028669724770642203
I2
I0
I2
tp69863
sS'the,depression,of'
p69864
(F1
F0.00028669724770642203
I2
I0
I2
tp69865
sS'class,see,warnings'
p69866
(F1
F0.00014334862385321102
I1
I0
I1
tp69867
sS'unaffected,by,concurrent'
p69868
(F1
F0.00014334862385321102
I0
I1
I-1
tp69869
sS'noted,in,patients'
p69870
(F1
F0.00014334862385321102
I1
I0
I1
tp69871
sS'evaluated,in,an'
p69872
(F1
F0.00014334862385321102
I0
I1
I-1
tp69873
sS'may,enhance,cns'
p69874
(F1
F0.00014334862385321102
I1
I0
I1
tp69875
sS'patients,using,cardiac'
p69876
(F1
F0.00014334862385321102
I0
I1
I-1
tp69877
sS'and,other,strong'
p69878
(F1
F0.00014334862385321102
I1
I0
I1
tp69879
sS'aspirin-mediated,inhibition,of'
p69880
(F1
F0.00014334862385321102
I0
I1
I-1
tp69881
sS'stadol,ns,and'
p69882
(F1
F0.00014334862385321102
I0
I1
I-1
tp69883
sS'cells,revealed,that'
p69884
(F1
F0.00014334862385321102
I1
I0
I1
tp69885
sS'not,have,a'
p69886
(F1
F0.00028669724770642203
I0
I2
I-2
tp69887
sS'with,altered,renal'
p69888
(F1
F0.00014334862385321102
I0
I1
I-1
tp69889
sS'depression,of,the'
p69890
(F1
F0.00014334862385321102
I1
I0
I1
tp69891
sS'is,easy,and'
p69892
(F1
F0.00014334862385321102
I0
I1
I-1
tp69893
sS'schizophrenia,were,significantly'
p69894
(F1
F0.00014334862385321102
I0
I1
I-1
tp69895
sS'vardenafil,experienced,a'
p69896
(F1
F0.00014334862385321102
I1
I0
I1
tp69897
sS'however,co-administration,of'
p69898
(F1
F0.00014334862385321102
I0
I1
I-1
tp69899
sS'or,channel,blockers'
p69900
(F1
F0.00014334862385321102
I1
I0
I1
tp69901
sS'concentration,of,fluorouracil'
p69902
(F1
F0.00014334862385321102
I1
I0
I1
tp69903
sS'is,advised,in'
p69904
(F1
F0.00043004587155963305
I3
I0
I3
tp69905
sS'allopurinol,the,auc'
p69906
(F1
F0.00014334862385321102
I1
I0
I1
tp69907
sS'high,doses,has'
p69908
(F1
F0.00014334862385321102
I1
I0
I1
tp69909
sS'mg,day,lexapro'
p69910
(F1
F0.00014334862385321102
I1
I0
I1
tp69911
sS'neuromuscular,blocking,action'
p69912
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp69913
sS'chronic,treatment,following'
p69914
(F1
F0.00014334862385321102
I1
I0
I1
tp69915
sS'of,co,and'
p69916
(F1
F0.00014334862385321102
I0
I1
I-1
tp69917
sS'plasma,levels,during'
p69918
(F1
F0.00014334862385321102
I1
I0
I1
tp69919
sS'lapatinib,undergoes,extensive'
p69920
(F1
F0.00014334862385321102
I0
I1
I-1
tp69921
sS'of,nuromax,before'
p69922
(F1
F0.00014334862385321102
I0
I1
I-1
tp69923
sS'although,romazicon,exerts'
p69924
(F1
F0.00014334862385321102
I1
I0
I1
tp69925
sS'regimen,particularly,in'
p69926
(F1
F0.00014334862385321102
I1
I0
I1
tp69927
sS'whose,hypertension,was'
p69928
(F1
F0.00014334862385321102
I1
I0
I1
tp69929
sS'capsule,with,an'
p69930
(F1
F0.00014334862385321102
I1
I0
I1
tp69931
sS'reports,of,a'
p69932
(F1
F0.00014334862385321102
I0
I1
I-1
tp69933
sS'genetically,nervous,e-strain'
p69934
(F1
F0.00014334862385321102
I0
I1
I-1
tp69935
sS'rr,microm,inhibited'
p69936
(F1
F0.00014334862385321102
I1
I0
I1
tp69937
sS'in,and,may'
p69938
(F1
F0.00014334862385321102
I0
I1
I-1
tp69939
sS'is,not,clear'
p69940
(F1
F0.00014334862385321102
I0
I1
I-1
tp69941
sS'of,duloxetine,and'
p69942
(F1
F0.00014334862385321102
I1
I0
I1
tp69943
sS'changes,in,or'
p69944
(F1
F0.00014334862385321102
I0
I1
I-1
tp69945
sS'hypnotics,opioids,co-administration'
p69946
(F1
F0.00014334862385321102
I1
I0
I1
tp69947
sS'immunodeficiency,virus-positive,patients'
p69948
(F1
F0.00014334862385321102
I0
I1
I-1
tp69949
sS'kg,and,oral'
p69950
(F1
F0.00014334862385321102
I0
I1
I-1
tp69951
sS'interaction,with,central'
p69952
(F1
F0.00014334862385321102
I0
I1
I-1
tp69953
sS'therefore,close,monitoring'
p69954
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp69955
sS'use,in,conjunction'
p69956
(F1
F0.00014334862385321102
I1
I0
I1
tp69957
sS'sinus,arrest,and'
p69958
(F1
F0.00014334862385321102
I0
I1
I-1
tp69959
sS'bioavailability,of,n'
p69960
(F1
F0.00014334862385321102
I1
I0
I1
tp69961
sS'of,phosphatase,activity'
p69962
(F1
F0.00014334862385321102
I0
I1
I-1
tp69963
sS'not,be,usedas'
p69964
(F1
F0.00014334862385321102
I1
I0
I1
tp69965
sS'tablet,if,a'
p69966
(F1
F0.00014334862385321102
I1
I0
I1
tp69967
sS'study,suggested,to'
p69968
(F1
F0.00014334862385321102
I0
I1
I-1
tp69969
sS'are,cyp3a4,inhibitors'
p69970
(F1
F0.00014334862385321102
I1
I0
I1
tp69971
sS'occurred,significantly,more'
p69972
(F1
F0.00014334862385321102
I0
I1
I-1
tp69973
sS'can,inhibit,elimination'
p69974
(F1
F0.00014334862385321102
I1
I0
I1
tp69975
sS'hydroxide,and,with'
p69976
(F1
F0.00014334862385321102
I1
I0
I1
tp69977
sS'not,only,with'
p69978
(F1
F0.00014334862385321102
I0
I1
I-1
tp69979
sS'a,known,enzyme'
p69980
(F1
F0.00014334862385321102
I1
I0
I1
tp69981
sS'in,induction,of'
p69982
(F1
F0.00014334862385321102
I1
I0
I1
tp69983
sS'automaticity,as,well'
p69984
(F1
F0.00014334862385321102
I1
I0
I1
tp69985
sS'acidifying,agents,ammonium'
p69986
(F1
F0.00014334862385321102
I1
I0
I1
tp69987
sS'nacmc,with,moieties'
p69988
(F1
F0.00014334862385321102
I0
I1
I-1
tp69989
sS'nitric,oxide,donor'
p69990
(F1
F0.00014334862385321102
I1
I0
I1
tp69991
sS'agents,some,individuals'
p69992
(F1
F0.00014334862385321102
I1
I0
I1
tp69993
sS'and,displacement,of'
p69994
(F1
F0.00014334862385321102
I1
I0
I1
tp69995
sS'and,cyp1a2,inhibitors'
p69996
(F1
F0.00014334862385321102
I0
I1
I-1
tp69997
sS'prescribed,foradil,should'
p69998
(F1
F0.00014334862385321102
I0
I1
I-1
tp69999
sS'the,antihypertensive,action'
p70000
(F1
F0.00014334862385321102
I1
I0
I1
tp70001
sS'safety,profile,of'
p70002
(F1
F0.00028669724770642203
I0
I2
I-2
tp70003
sS'blockade,was,studied'
p70004
(F1
F0.00014334862385321102
I0
I1
I-1
tp70005
sS'href,frova_od,htm'
p70006
(F1
F0.00014334862385321102
I1
I0
I1
tp70007
sS'amounts,may,be'
p70008
(F1
F0.00014334862385321102
I0
I1
I-1
tp70009
sS'with,narrow,therapeutic'
p70010
(F1
F0.00014334862385321102
I1
I0
I1
tp70011
sS'available,data,suggest'
p70012
(F1
F0.00014334862385321102
I0
I1
I-1
tp70013
sS'given,with,such'
p70014
(F1
F0.00014334862385321102
I1
I0
I1
tp70015
sS'occasional,doses,of'
p70016
(F1
F0.00014334862385321102
I0
I1
I-1
tp70017
sS'in,each,task'
p70018
(F1
F0.00014334862385321102
I0
I1
I-1
tp70019
sS'not,have,effects'
p70020
(F1
F0.00014334862385321102
I0
I1
I-1
tp70021
sS'by,indicating,no'
p70022
(F1
F0.00014334862385321102
I0
I1
I-1
tp70023
sS'cyp3a4,have,not'
p70024
(F1
F0.00014334862385321102
I0
I1
I-1
tp70025
sS'male,volunteers,no'
p70026
(F1
F0.00014334862385321102
I0
I1
I-1
tp70027
sS'usual,concentrations,following'
p70028
(F1
F0.00014334862385321102
I0
I1
I-1
tp70029
sS'may,increase,cyp'
p70030
(F1
F0.00014334862385321102
I1
I0
I1
tp70031
sS'density,in,functional'
p70032
(F1
F0.00014334862385321102
I0
I1
I-1
tp70033
sS'by,therapeutic,monitoring'
p70034
(F1
F0.00014334862385321102
I0
I1
I-1
tp70035
sS'be,accompanied,by'
p70036
(F1
F0.00014334862385321102
I0
I1
I-1
tp70037
sS'of,to,volunteers'
p70038
(F1
F0.00014334862385321102
I0
I1
I-1
tp70039
sS'arteries,preconstricted,with'
p70040
(F1
F0.00014334862385321102
I0
I1
I-1
tp70041
sS'which,the,use'
p70042
(F1
F0.00014334862385321102
I0
I1
I-1
tp70043
sS'hepatic,injury,should'
p70044
(F1
F0.00014334862385321102
I0
I1
I-1
tp70045
sS'or,from,their'
p70046
(F1
F0.00014334862385321102
I1
I0
I1
tp70047
sS'reaction,profile,of'
p70048
(F1
F0.00014334862385321102
I0
I1
I-1
tp70049
sS'properties,relative,to'
p70050
(F1
F0.00014334862385321102
I0
I1
I-1
tp70051
sS'do,not,mix'
p70052
(F1
F0.00014334862385321102
I0
I1
I-1
tp70053
sS'pgp,increased,concentrations'
p70054
(F1
F0.00014334862385321102
I0
I1
I-1
tp70055
sS'ssris,and,inhibit'
p70056
(F1
F0.00057339449541284407
I0
I4
I-4
tp70057
sS'with,possible,rapid'
p70058
(F1
F0.00014334862385321102
I1
I0
I1
tp70059
sS'antihistamines,benzodiazepines,gi'
p70060
(F1
F0.00014334862385321102
I0
I1
I-1
tp70061
sS'was,not,due'
p70062
(F1
F0.00014334862385321102
I0
I1
I-1
tp70063
sS'may,also,interfere'
p70064
(F1
F0.00014334862385321102
I1
I0
I1
tp70065
sS'epilepsy,ingesting,the'
p70066
(F1
F0.00043004587155963305
I0
I3
I-3
tp70067
sS'doses,of,given'
p70068
(F1
F0.00014334862385321102
I1
I0
I1
tp70069
sS'bicarbonate,used,concurrently'
p70070
(F1
F0.00014334862385321102
I1
I0
I1
tp70071
sS'by,at,the'
p70072
(F1
F0.00014334862385321102
I1
I0
I1
tp70073
sS'duration,suggesting,that'
p70074
(F1
F0.00014334862385321102
I1
I0
I1
tp70075
sS'interconversion,between,and'
p70076
(F1
F0.00014334862385321102
I0
I1
I-1
tp70077
sS'between,both,dietary'
p70078
(F1
F0.00014334862385321102
I0
I1
I-1
tp70079
sS'human,pharmacokinetics,data'
p70080
(F1
F0.00028669724770642203
I2
I0
I2
tp70081
sS'postdose,a,similar'
p70082
(F1
F0.00014334862385321102
I1
I0
I1
tp70083
sS'but,definite,nondepolarizing'
p70084
(F1
F0.00014334862385321102
I0
I1
I-1
tp70085
sS'experienced,a,standing'
p70086
(F1
F0.00057339449541284407
I4
I0
I4
tp70087
sS'concentrations,of,sn38'
p70088
(F1
F0.00014334862385321102
I0
I1
I-1
tp70089
sS'plasma,pharmacokinetics,or'
p70090
(F1
F0.00014334862385321102
I0
I1
I-1
tp70091
sS'nerve,transmission,at'
p70092
(F1
F0.00014334862385321102
I0
I1
I-1
tp70093
sS'certain,may,induce'
p70094
(F1
F0.00014334862385321102
I1
I0
I1
tp70095
sS'drug-drug,interaction,was'
p70096
(F1
F0.00014334862385321102
I0
I1
I-1
tp70097
sS'shown,no,effect'
p70098
(F1
F0.00014334862385321102
I0
I1
I-1
tp70099
sS'of,this,reduction'
p70100
(F1
F0.00014334862385321102
I1
I0
I1
tp70101
sS'by,resecting,the'
p70102
(F1
F0.00014334862385321102
I0
I1
I-1
tp70103
sS'metabolism,of,etc'
p70104
(F1
F0.00014334862385321102
I1
I0
I1
tp70105
sS'is,given,or'
p70106
(F1
F0.00014334862385321102
I0
I1
I-1
tp70107
sS'weather,prolonged,long'
p70108
(F1
F0.00014334862385321102
I1
I0
I1
tp70109
sS'antagonism,has,been'
p70110
(F1
F0.00014334862385321102
I1
I0
I1
tp70111
sS'receptors,such,as'
p70112
(F1
F0.00014334862385321102
I1
I0
I1
tp70113
sS'in,effects,on'
p70114
(F1
F0.00014334862385321102
I0
I1
I-1
tp70115
sS'to,subjects,the'
p70116
(F1
F0.00014334862385321102
I1
I0
I1
tp70117
sS'are,altered,by'
p70118
(F1
F0.00014334862385321102
I1
I0
I1
tp70119
sS'in,effects,of'
p70120
(F1
F0.00014334862385321102
I1
I0
I1
tp70121
sS'severe,hypersensitivity,reactions'
p70122
(F0
F0
I1
I1
I0
tp70123
sS'cerivastatin,plasma,concentrations'
p70124
(F1
F0.00043004587155963305
I0
I3
I-3
tp70125
sS'clearance,by,increased'
p70126
(F1
F0.00014334862385321102
I1
I0
I1
tp70127
sS'mm,or,mg'
p70128
(F1
F0.00014334862385321102
I0
I1
I-1
tp70129
sS'treatment,with,agents'
p70130
(F1
F0.00014334862385321102
I1
I0
I1
tp70131
sS'of,to,regimens'
p70132
(F1
F0.00014334862385321102
I0
I1
I-1
tp70133
sS'water,pill,such'
p70134
(F1
F0.00014334862385321102
I0
I1
I-1
tp70135
sS'concomitantly,with,the'
p70136
(F0
F0
I2
I2
I0
tp70137
sS'blocking,agents,has'
p70138
(F1
F0.00014334862385321102
I1
I0
I1
tp70139
sS'xigris,is,used'
p70140
(F1
F0.00014334862385321102
I0
I1
I-1
tp70141
sS'starting,a,non-selective'
p70142
(F1
F0.00014334862385321102
I1
I0
I1
tp70143
sS'toxicology,studies,of'
p70144
(F1
F0.00014334862385321102
I1
I0
I1
tp70145
sS'than,fold,increases'
p70146
(F1
F0.00014334862385321102
I1
I0
I1
tp70147
sS'supplements,or,salt'
p70148
(F1
F0.00014334862385321102
I0
I1
I-1
tp70149
sS'anticoagulants,several,short-term'
p70150
(F1
F0.00014334862385321102
I0
I1
I-1
tp70151
sS'to,intravenous,and'
p70152
(F1
F0.00014334862385321102
I1
I0
I1
tp70153
sS'significance,on,the'
p70154
(F1
F0.00014334862385321102
I1
I0
I1
tp70155
sS'systemic,eg,flu-like'
p70156
(F1
F0.00014334862385321102
I0
I1
I-1
tp70157
sS'clearance,by,up'
p70158
(F1
F0.00014334862385321102
I1
I0
I1
tp70159
sS'of,selective,peripheral'
p70160
(F1
F0.00014334862385321102
I1
I0
I1
tp70161
sS'of,h2,blockers'
p70162
(F1
F0.00028669724770642203
I2
I0
I2
tp70163
sS'cefotan,and,an'
p70164
(F1
F0.00014334862385321102
I1
I0
I1
tp70165
sS'affect,the,plasma'
p70166
(F1
F0.00014334862385321102
I0
I1
I-1
tp70167
sS'and,international,pharmaceutical'
p70168
(F1
F0.00014334862385321102
I0
I1
I-1
tp70169
sS'and,vitamin,c'
p70170
(F1
F0.00014334862385321102
I0
I1
I-1
tp70171
sS'augmented,by,that'
p70172
(F1
F0.00014334862385321102
I1
I0
I1
tp70173
sS'should,be,even'
p70174
(F1
F0.00014334862385321102
I1
I0
I1
tp70175
sS'conjunction,with,demonstrated'
p70176
(F1
F0.00014334862385321102
I0
I1
I-1
tp70177
sS'with,a,decrease'
p70178
(F1
F0.00057339449541284407
I4
I0
I4
tp70179
sS'therefore,should,be'
p70180
(F0.5
F0.00028669724770642203
I3
I1
I2
tp70181
sS'due,to,their'
p70182
(F0
F0
I1
I1
I0
tp70183
sS'bleeding,time,caused'
p70184
(F1
F0.00014334862385321102
I0
I1
I-1
tp70185
sS'tablets,injection,and'
p70186
(F1
F0.00014334862385321102
I1
I0
I1
tp70187
sS'and,anti-infectives,without'
p70188
(F1
F0.00014334862385321102
I0
I1
I-1
tp70189
sS'the,effects,of'
p70190
(F0.064935064935064929
F0.00071674311926605509
I36
I41
I-5
tp70191
sS'multiple,dosing,caution'
p70192
(F1
F0.00014334862385321102
I1
I0
I1
tp70193
sS'the,effects,on'
p70194
(F1
F0.00014334862385321102
I0
I1
I-1
tp70195
sS'category,and,then'
p70196
(F1
F0.00014334862385321102
I1
I0
I1
tp70197
sS'the,systemic,exposure'
p70198
(F1
F0.00028669724770642203
I2
I0
I2
tp70199
sS'ability,of,to'
p70200
(F1
F0.00014334862385321102
I1
I0
I1
tp70201
sS'and,increasing,blood'
p70202
(F1
F0.00014334862385321102
I1
I0
I1
tp70203
sS'with,other,that'
p70204
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp70205
sS'given,concomitantly,the'
p70206
(F1
F0.00014334862385321102
I1
I0
I1
tp70207
sS'with,other,than'
p70208
(F1
F0.00014334862385321102
I0
I1
I-1
tp70209
sS'cause,clinically,important'
p70210
(F1
F0.00014334862385321102
I0
I1
I-1
tp70211
sS'of,cyp1a2,results'
p70212
(F1
F0.00014334862385321102
I1
I0
I1
tp70213
sS'day,days,after'
p70214
(F1
F0.00014334862385321102
I1
I0
I1
tp70215
sS'to,and,may'
p70216
(F0
F0
I1
I1
I0
tp70217
sS'parameters,in,patients'
p70218
(F1
F0.00014334862385321102
I1
I0
I1
tp70219
sS'compared,to,similar'
p70220
(F1
F0.00014334862385321102
I0
I1
I-1
tp70221
sS'of,mg,oral'
p70222
(F1
F0.00014334862385321102
I1
I0
I1
tp70223
sS'nonsteroidal,agents,and'
p70224
(F1
F0.00014334862385321102
I1
I0
I1
tp70225
sS'these,resulting,in'
p70226
(F1
F0.00014334862385321102
I1
I0
I1
tp70227
sS'a,newly,introduced'
p70228
(F1
F0.00014334862385321102
I0
I1
I-1
tp70229
sS'oxidative,stress,in'
p70230
(F1
F0.00014334862385321102
I1
I0
I1
tp70231
sS'once,daily,did'
p70232
(F1
F0.00014334862385321102
I0
I1
I-1
tp70233
sS'taken,when,using'
p70234
(F1
F0.00014334862385321102
I0
I1
I-1
tp70235
sS'with,wshow,no'
p70236
(F1
F0.00014334862385321102
I0
I1
I-1
tp70237
sS'two,appear,to'
p70238
(F1
F0.00014334862385321102
I1
I0
I1
tp70239
sS'to,the,inhibition'
p70240
(F1
F0.00028669724770642203
I2
I0
I2
tp70241
sS'decreased,the,binding'
p70242
(F1
F0.00014334862385321102
I1
I0
I1
tp70243
sS'with,agents,or'
p70244
(F0
F0
I1
I1
I0
tp70245
sS'several,studies,ie'
p70246
(F1
F0.00014334862385321102
I0
I1
I-1
tp70247
sS'three,separate,controlled'
p70248
(F1
F0.00014334862385321102
I0
I1
I-1
tp70249
sS'report,a,case'
p70250
(F1
F0.00014334862385321102
I0
I1
I-1
tp70251
sS'metenkephalinamide,or,on'
p70252
(F1
F0.00014334862385321102
I0
I1
I-1
tp70253
sS'the,alternate,sequence'
p70254
(F1
F0.00014334862385321102
I1
I0
I1
tp70255
sS'alone,can,cause'
p70256
(F1
F0.00014334862385321102
I0
I1
I-1
tp70257
sS'dose,for,incombination'
p70258
(F1
F0.00014334862385321102
I0
I1
I-1
tp70259
sS'steady-state,cmax,a'
p70260
(F1
F0.00043004587155963305
I3
I0
I3
tp70261
sS'during,the,test'
p70262
(F1
F0.00014334862385321102
I1
I0
I1
tp70263
sS'mediation,of,influence'
p70264
(F1
F0.00014334862385321102
I0
I1
I-1
tp70265
sS'is,administered,or'
p70266
(F1
F0.00014334862385321102
I1
I0
I1
tp70267
sS'safely,tolerated,in'
p70268
(F1
F0.00014334862385321102
I0
I1
I-1
tp70269
sS'other,cns-depressant,should'
p70270
(F1
F0.00014334862385321102
I1
I0
I1
tp70271
sS'oral,platelet,inhibitors'
p70272
(F1
F0.00014334862385321102
I0
I1
I-1
tp70273
sS'requires,more,or'
p70274
(F1
F0.00014334862385321102
I0
I1
I-1
tp70275
sS'few,spontaneous,reports'
p70276
(F1
F0.00014334862385321102
I1
I0
I1
tp70277
sS'of,could,pose'
p70278
(F1
F0.00014334862385321102
I1
I0
I1
tp70279
sS'half-life,and,the'
p70280
(F1
F0.00014334862385321102
I1
I0
I1
tp70281
sS'in,normal,subjects'
p70282
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp70283
sS's,interresponse,times'
p70284
(F1
F0.00014334862385321102
I0
I1
I-1
tp70285
sS'absorption,of,and'
p70286
(F1
F0.00014334862385321102
I1
I0
I1
tp70287
sS'avonex,and,study'
p70288
(F1
F0.00014334862385321102
I0
I1
I-1
tp70289
sS'ketamine,when,administered'
p70290
(F1
F0.00014334862385321102
I1
I0
I1
tp70291
sS'of,patient,pharmacokinetic'
p70292
(F1
F0.00014334862385321102
I1
I0
I1
tp70293
sS'leads,to,higher'
p70294
(F1
F0.00014334862385321102
I1
I0
I1
tp70295
sS'given,prior,to'
p70296
(F0
F0
I1
I1
I0
tp70297
sS'of,was,increased'
p70298
(F1
F0.00028669724770642203
I2
I0
I2
tp70299
sS'with,such,medication'
p70300
(F1
F0.00014334862385321102
I0
I1
I-1
tp70301
sS'because,of,its'
p70302
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp70303
sS'liver,enzymes,was'
p70304
(F1
F0.00014334862385321102
I1
I0
I1
tp70305
sS'maintained,on,without'
p70306
(F1
F0.00014334862385321102
I0
I1
I-1
tp70307
sS'or,deleted,from'
p70308
(F1
F0.00028669724770642203
I2
I0
I2
tp70309
sS'the,cmax,and'
p70310
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp70311
sS'and,which,inhibit'
p70312
(F1
F0.00014334862385321102
I1
I0
I1
tp70313
sS'especially,important,in'
p70314
(F1
F0.00014334862385321102
I0
I1
I-1
tp70315
sS'is,a,cyp'
p70316
(F1
F0.00043004587155963305
I0
I3
I-3
tp70317
sS'of,the,unbound'
p70318
(F1
F0.00014334862385321102
I1
I0
I1
tp70319
sS'significant,additional,efficacy'
p70320
(F1
F0.00014334862385321102
I1
I0
I1
tp70321
sS'protease,inhibitor,therapy'
p70322
(F1
F0.00014334862385321102
I1
I0
I1
tp70323
sS'by,or,salicylic'
p70324
(F1
F0.00014334862385321102
I0
I1
I-1
tp70325
sS'of,g,and'
p70326
(F1
F0.00014334862385321102
I1
I0
I1
tp70327
sS'in,vivo,and'
p70328
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp70329
sS'which,are,substrates'
p70330
(F1
F0.00014334862385321102
I0
I1
I-1
tp70331
sS'may,be,diminished'
p70332
(F1
F0.00014334862385321102
I1
I0
I1
tp70333
sS'other,antianxiety,agents'
p70334
(F1
F0.00014334862385321102
I1
I0
I1
tp70335
sS'of,with,strong'
p70336
(F1
F0.00014334862385321102
I1
I0
I1
tp70337
sS'etc,increase,the'
p70338
(F1
F0.00028669724770642203
I2
I0
I2
tp70339
sS'have,been,cases'
p70340
(F1
F0.00014334862385321102
I1
I0
I1
tp70341
sS'when,atromid-s,is'
p70342
(F1
F0.00014334862385321102
I1
I0
I1
tp70343
sS'were,given,injections'
p70344
(F1
F0.00014334862385321102
I0
I1
I-1
tp70345
sS'subsequent,to,increase'
p70346
(F1
F0.00014334862385321102
I1
I0
I1
tp70347
sS'or,insulin-induced,proliferation'
p70348
(F1
F0.00014334862385321102
I1
I0
I1
tp70349
sS'are,expected,to'
p70350
(F0.5
F0.00028669724770642203
I3
I1
I2
tp70351
sS'i,trial,in'
p70352
(F1
F0.00014334862385321102
I0
I1
I-1
tp70353
sS'cases,of,seizures'
p70354
(F1
F0.00014334862385321102
I1
I0
I1
tp70355
sS'effects,with,proleukin'
p70356
(F1
F0.00014334862385321102
I1
I0
I1
tp70357
sS'ketoconazole,itraconazole,macrolides'
p70358
(F1
F0.00014334862385321102
I0
I1
I-1
tp70359
sS'treatment,dosage,adjustment'
p70360
(F1
F0.00014334862385321102
I1
I0
I1
tp70361
sS'or,deletion,of'
p70362
(F1
F0.00014334862385321102
I0
I1
I-1
tp70363
sS'interaction,was,not'
p70364
(F1
F0.00014334862385321102
I0
I1
I-1
tp70365
sS'continue,the,initiate'
p70366
(F1
F0.00014334862385321102
I1
I0
I1
tp70367
sS'affecting,cytochrome,p450'
p70368
(F1
F0.00014334862385321102
I0
I1
I-1
tp70369
sS'seen,when,romazicon'
p70370
(F1
F0.00014334862385321102
I0
I1
I-1
tp70371
sS'of,the,patients'
p70372
(F1
F0.00043004587155963305
I0
I3
I-3
tp70373
sS'colestid,tablets,are'
p70374
(F1
F0.00014334862385321102
I1
I0
I1
tp70375
sS'd,and,s'
p70376
(F1
F0.00014334862385321102
I1
I0
I1
tp70377
sS'since,inhibits,platelet'
p70378
(F1
F0.00014334862385321102
I1
I0
I1
tp70379
sS'were,a,dihydropyridine'
p70380
(F1
F0.00014334862385321102
I0
I1
I-1
tp70381
sS'of,nondepolarizing,neuromuscular'
p70382
(F1
F0.00014334862385321102
I1
I0
I1
tp70383
sS'metabolite,concentration,and'
p70384
(F1
F0.00014334862385321102
I1
I0
I1
tp70385
sS'methotrexate,piperacillin,sodium'
p70386
(F1
F0.00014334862385321102
I1
I0
I1
tp70387
sS'coadministration,of,gly-buride'
p70388
(F1
F0.00014334862385321102
I0
I1
I-1
tp70389
sS'ecg,of,given'
p70390
(F1
F0.00014334862385321102
I0
I1
I-1
tp70391
sS'kg,day,and'
p70392
(F1
F0.00014334862385321102
I0
I1
I-1
tp70393
sS'patients,enrolled,in'
p70394
(F1
F0.00014334862385321102
I0
I1
I-1
tp70395
sS'with,high,viral'
p70396
(F1
F0.00014334862385321102
I0
I1
I-1
tp70397
sS'via,a,different'
p70398
(F1
F0.00014334862385321102
I0
I1
I-1
tp70399
sS'bleeding,are,synergistic'
p70400
(F1
F0.00028669724770642203
I2
I0
I2
tp70401
sS'patients,currently,receiving'
p70402
(F1
F0.00014334862385321102
I1
I0
I1
tp70403
sS'k,antagonists,are'
p70404
(F1
F0.00014334862385321102
I1
I0
I1
tp70405
sS'although,have,been'
p70406
(F1
F0.00014334862385321102
I1
I0
I1
tp70407
sS'that,may,make'
p70408
(F1
F0.00014334862385321102
I0
I1
I-1
tp70409
sS'pseudomonas,aeruginosa,particularly'
p70410
(F1
F0.00014334862385321102
I0
I1
I-1
tp70411
sS'hypnotics,contraindicated,due'
p70412
(F1
F0.00014334862385321102
I0
I1
I-1
tp70413
sS'levels,meq,l'
p70414
(F1
F0.00014334862385321102
I0
I1
I-1
tp70415
sS'unwanted,effects,ways'
p70416
(F1
F0.00014334862385321102
I0
I1
I-1
tp70417
sS'hcl,in,association'
p70418
(F1
F0.00014334862385321102
I1
I0
I1
tp70419
sS'the,effects,may'
p70420
(F1
F0.00014334862385321102
I1
I0
I1
tp70421
sS'male,volunteers,treatment'
p70422
(F1
F0.00014334862385321102
I1
I0
I1
tp70423
sS'of,and,bretylium'
p70424
(F1
F0.00014334862385321102
I0
I1
I-1
tp70425
sS'observed,that,is'
p70426
(F1
F0.00014334862385321102
I0
I1
I-1
tp70427
sS'degrees,of,inhibition'
p70428
(F1
F0.00014334862385321102
I1
I0
I1
tp70429
sS'p450,a4,had'
p70430
(F1
F0.00014334862385321102
I0
I1
I-1
tp70431
sS'standard,deviation,to'
p70432
(F1
F0.00014334862385321102
I1
I0
I1
tp70433
sS'and,losartan,bosentan'
p70434
(F1
F0.00014334862385321102
I0
I1
I-1
tp70435
sS'was,administered,hours'
p70436
(F1
F0.00057339449541284407
I4
I0
I4
tp70437
sS'study,evoked,potentials'
p70438
(F1
F0.00014334862385321102
I0
I1
I-1
tp70439
sS'ratio,when,arava'
p70440
(F1
F0.00014334862385321102
I1
I0
I1
tp70441
sS'reduction,in,mac'
p70442
(F1
F0.00014334862385321102
I0
I1
I-1
tp70443
sS'as,ophthalmic,and'
p70444
(F0
F0
I1
I1
I0
tp70445
sS'daily,and,one'
p70446
(F1
F0.00014334862385321102
I1
I0
I1
tp70447
sS'may,reduce,plasma'
p70448
(F1
F0.00028669724770642203
I2
I0
I2
tp70449
sS'weeks,after,stopping'
p70450
(F1
F0.00028669724770642203
I2
I0
I2
tp70451
sS'analgesia,must,be'
p70452
(F1
F0.00014334862385321102
I1
I0
I1
tp70453
sS'were,potentiated,by'
p70454
(F1
F0.00014334862385321102
I1
I0
I1
tp70455
sS'to,the,combined'
p70456
(F1
F0.00014334862385321102
I1
I0
I1
tp70457
sS'with,other,tnf-blocking'
p70458
(F1
F0.00014334862385321102
I1
I0
I1
tp70459
sS'with,inducers,of'
p70460
(F1
F0.00014334862385321102
I1
I0
I1
tp70461
sS'because,cyp2d6,is'
p70462
(F1
F0.00014334862385321102
I0
I1
I-1
tp70463
sS'medications,have,included'
p70464
(F1
F0.00014334862385321102
I0
I1
I-1
tp70465
sS'including,have,also'
p70466
(F1
F0.00014334862385321102
I1
I0
I1
tp70467
sS'the,intestinal,mucosa'
p70468
(F1
F0.00014334862385321102
I1
I0
I1
tp70469
sS'to,produce,antabuse-like'
p70470
(F1
F0.00014334862385321102
I1
I0
I1
tp70471
sS'following,eye,product'
p70472
(F1
F0.00014334862385321102
I1
I0
I1
tp70473
sS'in,some,studies'
p70474
(F1
F0.00014334862385321102
I1
I0
I1
tp70475
sS'and,would,be'
p70476
(F0
F0
I2
I2
I0
tp70477
sS'prescription,dose,co-administered'
p70478
(F1
F0.00028669724770642203
I2
I0
I2
tp70479
sS'of,with,causes'
p70480
(F1
F0.00014334862385321102
I1
I0
I1
tp70481
sS'possibility,that,may'
p70482
(F1
F0.00014334862385321102
I1
I0
I1
tp70483
sS'hormone-binding,globulin,shbg'
p70484
(F1
F0.00014334862385321102
I0
I1
I-1
tp70485
sS'due,to,an'
p70486
(F1
F0.00028669724770642203
I0
I2
I-2
tp70487
sS'where,is,given'
p70488
(F1
F0.00014334862385321102
I0
I1
I-1
tp70489
sS'interactions,cimetidine,concomitant'
p70490
(F1
F0.00014334862385321102
I0
I1
I-1
tp70491
sS'constitute,the,sole'
p70492
(F1
F0.00014334862385321102
I0
I1
I-1
tp70493
sS'the,united,kingdom'
p70494
(F1
F0.00014334862385321102
I1
I0
I1
tp70495
sS'with,other,products'
p70496
(F1
F0.00014334862385321102
I0
I1
I-1
tp70497
sS'to,min,compared'
p70498
(F1
F0.00014334862385321102
I0
I1
I-1
tp70499
sS'output,and,usually'
p70500
(F1
F0.00014334862385321102
I1
I0
I1
tp70501
sS'given,with,the'
p70502
(F1
F0.00014334862385321102
I0
I1
I-1
tp70503
sS'similar,agents,since'
p70504
(F1
F0.00014334862385321102
I1
I0
I1
tp70505
sS'dipyridamole,has,been'
p70506
(F1
F0.00014334862385321102
I1
I0
I1
tp70507
sS'in,addition,does'
p70508
(F1
F0.00014334862385321102
I0
I1
I-1
tp70509
sS'aortic,rings,with'
p70510
(F1
F0.00014334862385321102
I1
I0
I1
tp70511
sS'be,provided,for'
p70512
(F1
F0.00014334862385321102
I0
I1
I-1
tp70513
sS'with,glutathione,use'
p70514
(F1
F0.00014334862385321102
I1
I0
I1
tp70515
sS'before,taking,tell'
p70516
(F1
F0.00014334862385321102
I1
I0
I1
tp70517
sS'one,ng,ml'
p70518
(F1
F0.00014334862385321102
I0
I1
I-1
tp70519
sS'via,p450,c9'
p70520
(F1
F0.00014334862385321102
I1
I0
I1
tp70521
sS'of,ruthenium,red'
p70522
(F1
F0.00014334862385321102
I0
I1
I-1
tp70523
sS'encountered,during,the'
p70524
(F1
F0.00014334862385321102
I0
I1
I-1
tp70525
sS'significant,respiratory,depression'
p70526
(F1
F0.00014334862385321102
I1
I0
I1
tp70527
sS'for,days,however'
p70528
(F1
F0.00014334862385321102
I1
I0
I1
tp70529
sS'concentrations,and,decreased'
p70530
(F1
F0.00014334862385321102
I0
I1
I-1
tp70531
sS'or,tsh,levels'
p70532
(F1
F0.00014334862385321102
I0
I1
I-1
tp70533
sS'change,in,their'
p70534
(F1
F0.00014334862385321102
I1
I0
I1
tp70535
sS'i,and,have'
p70536
(F1
F0.00014334862385321102
I0
I1
I-1
tp70537
sS'of,but,may'
p70538
(F0
F0
I1
I1
I0
tp70539
sS'on,concurrent,usage'
p70540
(F1
F0.00014334862385321102
I0
I1
I-1
tp70541
sS'that,the,incidence'
p70542
(F1
F0.00014334862385321102
I1
I0
I1
tp70543
sS'omega-conotoxin,gvia,n-type'
p70544
(F1
F0.00014334862385321102
I0
I1
I-1
tp70545
sS'that,may,potentiate'
p70546
(F1
F0.00014334862385321102
I1
I0
I1
tp70547
sS'may,decrease,vascular'
p70548
(F1
F0.00014334862385321102
I1
I0
I1
tp70549
sS'developed,in,a'
p70550
(F1
F0.00014334862385321102
I1
I0
I1
tp70551
sS'and,must,be'
p70552
(F1
F0.00014334862385321102
I0
I1
I-1
tp70553
sS'taken,within,hours'
p70554
(F1
F0.00043004587155963305
I3
I0
I3
tp70555
sS'the,or,may'
p70556
(F1
F0.00014334862385321102
I1
I0
I1
tp70557
sS'or,with,salts'
p70558
(F1
F0.00014334862385321102
I0
I1
I-1
tp70559
sS'inclusive,viracept,may'
p70560
(F1
F0.00014334862385321102
I0
I1
I-1
tp70561
sS'by,similar,personality'
p70562
(F1
F0.00014334862385321102
I0
I1
I-1
tp70563
sS'hydroxy-3,methylglutaryl,coenzyme'
p70564
(F1
F0.00014334862385321102
I0
I1
I-1
tp70565
sS'data,on,the'
p70566
(F1
F0.00028669724770642203
I0
I2
I-2
tp70567
sS'depress,the,nervous'
p70568
(F1
F0.00014334862385321102
I1
I0
I1
tp70569
sS'that,may,underlie'
p70570
(F1
F0.00014334862385321102
I0
I1
I-1
tp70571
sS'brovana,has,not'
p70572
(F1
F0.00014334862385321102
I0
I1
I-1
tp70573
sS'enhance,the,magnitude'
p70574
(F1
F0.00014334862385321102
I1
I0
I1
tp70575
sS'haldol,has,not'
p70576
(F1
F0.00014334862385321102
I0
I1
I-1
tp70577
sS'indandione,derivatives,and'
p70578
(F1
F0.00014334862385321102
I1
I0
I1
tp70579
sS'with,increases,the'
p70580
(F1
F0.00043004587155963305
I0
I3
I-3
tp70581
sS'with,increased,levels'
p70582
(F1
F0.00028669724770642203
I2
I0
I2
tp70583
sS'of,synthetic,by'
p70584
(F1
F0.00014334862385321102
I1
I0
I1
tp70585
sS'may,experience,a'
p70586
(F1
F0.00014334862385321102
I1
I0
I1
tp70587
sS'or,fortovase,and'
p70588
(F1
F0.00014334862385321102
I0
I1
I-1
tp70589
sS'inducers,of,clearance'
p70590
(F1
F0.00028669724770642203
I2
I0
I2
tp70591
sS'separate,study,concomitant'
p70592
(F1
F0.00014334862385321102
I0
I1
I-1
tp70593
sS'and,or,marked'
p70594
(F1
F0.00028669724770642203
I2
I0
I2
tp70595
sS'dose-dependent,modification,of'
p70596
(F1
F0.00014334862385321102
I1
I0
I1
tp70597
sS'tablets,or,the'
p70598
(F1
F0.0008600917431192661
I6
I0
I6
tp70599
sS'contraindicated,and,alternative'
p70600
(F1
F0.00014334862385321102
I1
I0
I1
tp70601
sS'fluvoxamine,tablets,should'
p70602
(F1
F0.00014334862385321102
I1
I0
I1
tp70603
sS'inhibitor,mg,q'
p70604
(F1
F0.00014334862385321102
I1
I0
I1
tp70605
sS'each,other,should'
p70606
(F1
F0.00028669724770642203
I2
I0
I2
tp70607
sS'cyp1a2,isoform,mediate'
p70608
(F1
F0.00014334862385321102
I0
I1
I-1
tp70609
sS'been,taking,on'
p70610
(F1
F0.00014334862385321102
I0
I1
I-1
tp70611
sS'reported,to,increase'
p70612
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp70613
sS'subjects,to,a'
p70614
(F1
F0.00014334862385321102
I0
I1
I-1
tp70615
sS'with,a,broad'
p70616
(F1
F0.00014334862385321102
I0
I1
I-1
tp70617
sS'tricyclic,in,combination'
p70618
(F1
F0.00014334862385321102
I1
I0
I1
tp70619
sS'have,no,effect'
p70620
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp70621
sS'general,exaggeration,of'
p70622
(F1
F0.00014334862385321102
I1
I0
I1
tp70623
sS'have,been,tested'
p70624
(F1
F0.00014334862385321102
I0
I1
I-1
tp70625
sS'been,tested,in'
p70626
(F1
F0.00014334862385321102
I0
I1
I-1
tp70627
sS'are,withdrawn,from'
p70628
(F1
F0.00014334862385321102
I0
I1
I-1
tp70629
sS'time,when,was'
p70630
(F1
F0.00014334862385321102
I1
I0
I1
tp70631
sS'was,significantly,reduced'
p70632
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp70633
sS'sedatives,hypnotics,opioids'
p70634
(F1
F0.00014334862385321102
I1
I0
I1
tp70635
sS'and,decreased,the'
p70636
(F1
F0.00043004587155963305
I3
I0
I3
tp70637
sS'recommended,it,should'
p70638
(F1
F0.00014334862385321102
I1
I0
I1
tp70639
sS'a,net,decrease'
p70640
(F1
F0.00014334862385321102
I1
I0
I1
tp70641
sS'one-third,to,one-fourth'
p70642
(F1
F0.00014334862385321102
I1
I0
I1
tp70643
sS'been,studied,in'
p70644
(F1
F0.00071674311926605509
I0
I5
I-5
tp70645
sS'to,receive,adl'
p70646
(F1
F0.00014334862385321102
I0
I1
I-1
tp70647
sS'time,of,minutes'
p70648
(F1
F0.00014334862385321102
I0
I1
I-1
tp70649
sS'may,worsen,side'
p70650
(F1
F0.00014334862385321102
I1
I0
I1
tp70651
sS'determine,the,presence'
p70652
(F1
F0.00014334862385321102
I0
I1
I-1
tp70653
sS'long-acting,such,as'
p70654
(F1
F0.00014334862385321102
I0
I1
I-1
tp70655
sS'discontinuing,the,or'
p70656
(F1
F0.00071674311926605509
I5
I0
I5
tp70657
sS'compounds,like,may'
p70658
(F1
F0.00014334862385321102
I1
I0
I1
tp70659
sS'cytochrome,p-,by'
p70660
(F1
F0.00014334862385321102
I0
I1
I-1
tp70661
sS'patient,in,whom'
p70662
(F1
F0.00014334862385321102
I0
I1
I-1
tp70663
sS'the,hypotension,caused'
p70664
(F1
F0.00014334862385321102
I1
I0
I1
tp70665
sS'and,which,have'
p70666
(F1
F0.00028669724770642203
I2
I0
I2
tp70667
sS'the,hour,lag'
p70668
(F1
F0.00014334862385321102
I0
I1
I-1
tp70669
sS'prolongs,and,potentiates'
p70670
(F1
F0.00014334862385321102
I0
I1
I-1
tp70671
sS'evaluate,possible,interactions'
p70672
(F1
F0.00014334862385321102
I0
I1
I-1
tp70673
sS'administration,of,because'
p70674
(F1
F0.00028669724770642203
I2
I0
I2
tp70675
sS'nimbex,and,therefore'
p70676
(F1
F0.00014334862385321102
I0
I1
I-1
tp70677
sS'that,may,either'
p70678
(F1
F0.00014334862385321102
I1
I0
I1
tp70679
sS'blood,concentrations,and'
p70680
(F1
F0.00014334862385321102
I0
I1
I-1
tp70681
sS'may,possibly,have'
p70682
(F1
F0.00014334862385321102
I0
I1
I-1
tp70683
sS'course,of,septic'
p70684
(F1
F0.00014334862385321102
I0
I1
I-1
tp70685
sS'but,dose-dependently,inhibits'
p70686
(F1
F0.00014334862385321102
I1
I0
I1
tp70687
sS'clearance,of,approximately'
p70688
(F1
F0.00014334862385321102
I1
I0
I1
tp70689
sS'tablets,may,alter'
p70690
(F1
F0.00014334862385321102
I1
I0
I1
tp70691
sS'have,led,to'
p70692
(F1
F0.00014334862385321102
I0
I1
I-1
tp70693
sS'concomitantly,with,injectable'
p70694
(F1
F0.00014334862385321102
I1
I0
I1
tp70695
sS'require,replacement,therapy'
p70696
(F1
F0.00014334862385321102
I1
I0
I1
tp70697
sS'a,smaller,week'
p70698
(F1
F0.00014334862385321102
I0
I1
I-1
tp70699
sS'proquin,xr,was'
p70700
(F1
F0.00014334862385321102
I0
I1
I-1
tp70701
sS'patients,received,concomitant'
p70702
(F1
F0.00014334862385321102
I0
I1
I-1
tp70703
sS'meclofenamate,sodium,plasma'
p70704
(F1
F0.00014334862385321102
I1
I0
I1
tp70705
sS'three,weeks,after'
p70706
(F1
F0.00014334862385321102
I1
I0
I1
tp70707
sS'cecectomized,rats,prepared'
p70708
(F1
F0.00014334862385321102
I0
I1
I-1
tp70709
sS'agent,for,that'
p70710
(F1
F0.00014334862385321102
I1
I0
I1
tp70711
sS'pregnancy,from,women'
p70712
(F1
F0.00014334862385321102
I0
I1
I-1
tp70713
sS'including,or,their'
p70714
(F1
F0.00014334862385321102
I0
I1
I-1
tp70715
sS'patients,with,first-episode'
p70716
(F1
F0.00014334862385321102
I0
I1
I-1
tp70717
sS'maois,may,enhance'
p70718
(F1
F0.00014334862385321102
I1
I0
I1
tp70719
sS'adrenergic,neuron,blocking'
p70720
(F1
F0.00014334862385321102
I0
I1
I-1
tp70721
sS'such,an,effect'
p70722
(F1
F0.00028669724770642203
I2
I0
I2
tp70723
sS'healthy,volunteers,increased'
p70724
(F1
F0.00014334862385321102
I0
I1
I-1
tp70725
sS'significantly,affect,steady-state'
p70726
(F1
F0.00014334862385321102
I0
I1
I-1
tp70727
sS'with,an,nsaid'
p70728
(F1
F0.00014334862385321102
I0
I1
I-1
tp70729
sS'antagonized,evidently,the'
p70730
(F1
F0.00014334862385321102
I1
I0
I1
tp70731
sS'the,interaction,is'
p70732
(F1
F0.00014334862385321102
I1
I0
I1
tp70733
sS'labelling,of,histidine'
p70734
(F1
F0.00014334862385321102
I0
I1
I-1
tp70735
sS'doses,of,had'
p70736
(F1
F0.00014334862385321102
I0
I1
I-1
tp70737
sS'to,do,if'
p70738
(F1
F0.00014334862385321102
I0
I1
I-1
tp70739
sS'response,to,various'
p70740
(F1
F0.00014334862385321102
I0
I1
I-1
tp70741
sS'dose,of,enablex'
p70742
(F1
F0.00014334862385321102
I1
I0
I1
tp70743
sS'gastrointestinal,irritation,caution'
p70744
(F1
F0.00014334862385321102
I1
I0
I1
tp70745
sS'patients,receiving,known'
p70746
(F1
F0.00014334862385321102
I1
I0
I1
tp70747
sS'and,prothrombin,times'
p70748
(F0
F0
I1
I1
I0
tp70749
sS'have,not,altered'
p70750
(F1
F0.00014334862385321102
I0
I1
I-1
tp70751
sS'monitor,the,plasma'
p70752
(F1
F0.00014334862385321102
I0
I1
I-1
tp70753
sS'inhibitors,including,quinolone'
p70754
(F1
F0.00014334862385321102
I1
I0
I1
tp70755
sS'alternate-day,administration,of'
p70756
(F1
F0.00014334862385321102
I1
I0
I1
tp70757
sS'estradiol,mg,mcg'
p70758
(F1
F0.00014334862385321102
I0
I1
I-1
tp70759
sS'the,kidney,and'
p70760
(F1
F0.00014334862385321102
I0
I1
I-1
tp70761
sS'exclusively,by,the'
p70762
(F1
F0.00014334862385321102
I0
I1
I-1
tp70763
sS'observed,closely,for'
p70764
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp70765
sS'lowering,the,plasma'
p70766
(F1
F0.00014334862385321102
I1
I0
I1
tp70767
sS'use,of,such'
p70768
(F1
F0.00028669724770642203
I2
I0
I2
tp70769
sS'be,restricted,and'
p70770
(F1
F0.00014334862385321102
I0
I1
I-1
tp70771
sS'was,observed,that'
p70772
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp70773
sS'metabolism,to,might'
p70774
(F1
F0.00014334862385321102
I1
I0
I1
tp70775
sS'mg,or,more'
p70776
(F1
F0.00014334862385321102
I0
I1
I-1
tp70777
sS'therefore,this,conjugated'
p70778
(F1
F0.00014334862385321102
I0
I1
I-1
tp70779
sS'absorption,of,diamox'
p70780
(F1
F0.00014334862385321102
I1
I0
I1
tp70781
sS'impaired,by,include'
p70782
(F1
F0.00014334862385321102
I1
I0
I1
tp70783
sS'one,day,and'
p70784
(F1
F0.00014334862385321102
I0
I1
I-1
tp70785
sS'were,observed,between'
p70786
(F1
F0.00014334862385321102
I0
I1
I-1
tp70787
sS'including,or,non-opioid'
p70788
(F1
F0.00014334862385321102
I0
I1
I-1
tp70789
sS'tambocor,to,healthy'
p70790
(F1
F0.00014334862385321102
I1
I0
I1
tp70791
sS'sustiva,in,treatment-naive'
p70792
(F1
F0.00014334862385321102
I0
I1
I-1
tp70793
sS'results,demonstrate,that'
p70794
(F1
F0.00014334862385321102
I0
I1
I-1
tp70795
sS'and,very,little'
p70796
(F1
F0.00014334862385321102
I1
I0
I1
tp70797
sS'mg,h,s'
p70798
(F1
F0.00014334862385321102
I1
I0
I1
tp70799
sS'in,a,potentiation'
p70800
(F1
F0.00014334862385321102
I1
I0
I1
tp70801
sS'hiv,protease,inhibitors'
p70802
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp70803
sS'were,also,higher'
p70804
(F1
F0.00014334862385321102
I1
I0
I1
tp70805
sS'coadministration,of,a'
p70806
(F0
F0
I4
I4
I0
tp70807
sS'and,then,begins'
p70808
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp70809
sS'of,and,was'
p70810
(F1
F0.00014334862385321102
I0
I1
I-1
tp70811
sS'anticoagulants,are,given'
p70812
(F1
F0.00014334862385321102
I1
I0
I1
tp70813
sS'total,circulating,and'
p70814
(F1
F0.00028669724770642203
I0
I2
I-2
tp70815
sS'of,an,interleukin-1'
p70816
(F1
F0.00014334862385321102
I1
I0
I1
tp70817
sS'pancreatic,supplements,may'
p70818
(F1
F0.00014334862385321102
I1
I0
I1
tp70819
sS'actinic,keratoses,treated'
p70820
(F1
F0.00014334862385321102
I1
I0
I1
tp70821
sS'treatment,of,relapses'
p70822
(F1
F0.00014334862385321102
I0
I1
I-1
tp70823
sS'males,and,in'
p70824
(F1
F0.00014334862385321102
I1
I0
I1
tp70825
sS'of,inapsine,the'
p70826
(F1
F0.00014334862385321102
I1
I0
I1
tp70827
sS'of,s,and'
p70828
(F1
F0.00014334862385321102
I1
I0
I1
tp70829
sS'ketoconazole,may,inhibit'
p70830
(F1
F0.00043004587155963305
I3
I0
I3
tp70831
sS'p450,system,inhibitors'
p70832
(F1
F0.00014334862385321102
I0
I1
I-1
tp70833
sS'interactions,with,mixed'
p70834
(F1
F0.00014334862385321102
I1
I0
I1
tp70835
sS'been,established,if'
p70836
(F1
F0.00014334862385321102
I0
I1
I-1
tp70837
sS'bid,resulted,in'
p70838
(F1
F0.00014334862385321102
I1
I0
I1
tp70839
sS'characteristic,of,animals'
p70840
(F1
F0.00014334862385321102
I0
I1
I-1
tp70841
sS'range,of,concentrations'
p70842
(F1
F0.00014334862385321102
I0
I1
I-1
tp70843
sS'day,and,or'
p70844
(F1
F0.00014334862385321102
I0
I1
I-1
tp70845
sS'subjects,receiving,gm'
p70846
(F1
F0.00014334862385321102
I1
I0
I1
tp70847
sS'concentration,of,as'
p70848
(F1
F0.00014334862385321102
I0
I1
I-1
tp70849
sS'peritoneal,metastasis,of'
p70850
(F0
F0
I1
I1
I0
tp70851
sS'in,the,nucleus'
p70852
(F1
F0.00014334862385321102
I0
I1
I-1
tp70853
sS'and,brevibloc,were'
p70854
(F1
F0.00028669724770642203
I2
I0
I2
tp70855
sS'probably,secondary,to'
p70856
(F1
F0.00014334862385321102
I1
I0
I1
tp70857
sS'reaction,time,for'
p70858
(F1
F0.00014334862385321102
I1
I0
I1
tp70859
sS'of,that,undergo'
p70860
(F1
F0.00014334862385321102
I1
I0
I1
tp70861
sS'regimens,including,and'
p70862
(F1
F0.00014334862385321102
I0
I1
I-1
tp70863
sS'of,including,ethacrynic'
p70864
(F1
F0.00014334862385321102
I1
I0
I1
tp70865
sS'one,man,the'
p70866
(F1
F0.00014334862385321102
I1
I0
I1
tp70867
sS'hour,after,administration'
p70868
(F1
F0.00014334862385321102
I1
I0
I1
tp70869
sS'certain,other,and'
p70870
(F1
F0.00014334862385321102
I0
I1
I-1
tp70871
sS'value,of,b'
p70872
(F1
F0.00014334862385321102
I0
I1
I-1
tp70873
sS'of,neutropenia,and'
p70874
(F1
F0.00028669724770642203
I2
I0
I2
tp70875
sS'precipitate,seizures,in'
p70876
(F1
F0.00014334862385321102
I1
I0
I1
tp70877
sS'and,interact,pharmacologically'
p70878
(F1
F0.00014334862385321102
I1
I0
I1
tp70879
sS'and,the,cyp3a4'
p70880
(F1
F0.00014334862385321102
I0
I1
I-1
tp70881
sS'each,to,mg'
p70882
(F1
F0.00014334862385321102
I1
I0
I1
tp70883
sS'fed,state,mg'
p70884
(F1
F0.00014334862385321102
I1
I0
I1
tp70885
sS'one-tenth,of,the'
p70886
(F1
F0.00014334862385321102
I1
I0
I1
tp70887
sS'cyp3a5,responsible,for'
p70888
(F1
F0.00014334862385321102
I0
I1
I-1
tp70889
sS'of,in,an'
p70890
(F1
F0.00014334862385321102
I1
I0
I1
tp70891
sS'oral,solution,can'
p70892
(F1
F0.00014334862385321102
I1
I0
I1
tp70893
sS'alg,mycophenolate,mofetil'
p70894
(F1
F0.00014334862385321102
I0
I1
I-1
tp70895
sS'a,significantly,improved'
p70896
(F1
F0.00014334862385321102
I0
I1
I-1
tp70897
sS'such,as,risk'
p70898
(F1
F0.00014334862385321102
I0
I1
I-1
tp70899
sS'containing,higher,and'
p70900
(F1
F0.00014334862385321102
I0
I1
I-1
tp70901
sS'channel,blocker,was'
p70902
(F1
F0.00014334862385321102
I0
I1
I-1
tp70903
sS'valproic,acid,diminished'
p70904
(F1
F0.00014334862385321102
I1
I0
I1
tp70905
sS'the,undesirable,effects'
p70906
(F1
F0.00014334862385321102
I1
I0
I1
tp70907
sS'used,with,peripheral'
p70908
(F1
F0.00014334862385321102
I1
I0
I1
tp70909
sS'cimetidine,concomitant,administration'
p70910
(F1
F0.00014334862385321102
I1
I0
I1
tp70911
sS'leading,to,unique'
p70912
(F1
F0.00014334862385321102
I0
I1
I-1
tp70913
sS'uric,acid,excretion'
p70914
(F1
F0.00014334862385321102
I1
I0
I1
tp70915
sS'occurred,when,was'
p70916
(F1
F0.00014334862385321102
I0
I1
I-1
tp70917
sS'plasma,concentrations,caution'
p70918
(F1
F0.00014334862385321102
I1
I0
I1
tp70919
sS'pretreatment,attenuated,the'
p70920
(F1
F0.00014334862385321102
I1
I0
I1
tp70921
sS'without,indicated,that'
p70922
(F1
F0.00014334862385321102
I0
I1
I-1
tp70923
sS'with,hypercholesterolemia,concomitant'
p70924
(F1
F0.00014334862385321102
I0
I1
I-1
tp70925
sS'for,heparins,effect'
p70926
(F1
F0.00014334862385321102
I0
I1
I-1
tp70927
sS'may,either,potentiate'
p70928
(F1
F0.00028669724770642203
I2
I0
I2
tp70929
sS'hydrate,diet,high'
p70930
(F1
F0.00014334862385321102
I1
I0
I1
tp70931
sS'receiving,oral,and'
p70932
(F1
F0.00014334862385321102
I1
I0
I1
tp70933
sS'of,alcohol-related,deaths'
p70934
(F1
F0.00014334862385321102
I0
I1
I-1
tp70935
sS'block,induced,by'
p70936
(F1
F0.00014334862385321102
I1
I0
I1
tp70937
sS'action,it,is'
p70938
(F1
F0.00014334862385321102
I1
I0
I1
tp70939
sS'patients,receiving,concurrent'
p70940
(F0
F0
I1
I1
I0
tp70941
sS'of,other,hiv'
p70942
(F1
F0.00014334862385321102
I0
I1
I-1
tp70943
sS'of,andtolbutamide,did'
p70944
(F1
F0.00014334862385321102
I0
I1
I-1
tp70945
sS'administered,in,normal'
p70946
(F1
F0.00014334862385321102
I1
I0
I1
tp70947
sS'other,that,produce'
p70948
(F1
F0.00043004587155963305
I3
I0
I3
tp70949
sS'addition,that,are'
p70950
(F1
F0.00014334862385321102
I1
I0
I1
tp70951
sS'not,be,treated'
p70952
(F1
F0.00014334862385321102
I1
I0
I1
tp70953
sS'other,hiv,protease'
p70954
(F1
F0.00014334862385321102
I0
I1
I-1
tp70955
sS'at,high,concentrations'
p70956
(F1
F0.00014334862385321102
I0
I1
I-1
tp70957
sS'or,elevated,liver'
p70958
(F1
F0.00014334862385321102
I1
I0
I1
tp70959
sS'increase,absorption,in'
p70960
(F1
F0.00014334862385321102
I1
I0
I1
tp70961
sS'the,ninds,t-pa'
p70962
(F1
F0.00014334862385321102
I0
I1
I-1
tp70963
sS'protection,against,the'
p70964
(F1
F0.00014334862385321102
I1
I0
I1
tp70965
sS'concurrently,with,tambocor'
p70966
(F1
F0.00014334862385321102
I1
I0
I1
tp70967
sS'acid,combination,hormonal'
p70968
(F1
F0.00028669724770642203
I2
I0
I2
tp70969
sS'co-administration,of,vioxx'
p70970
(F1
F0.00014334862385321102
I1
I0
I1
tp70971
sS'administered,alone,at'
p70972
(F1
F0.00014334862385321102
I1
I0
I1
tp70973
sS'heart,block,may'
p70974
(F1
F0.00014334862385321102
I1
I0
I1
tp70975
sS'anabolic,particularly,c-17'
p70976
(F1
F0.00014334862385321102
I0
I1
I-1
tp70977
sS'because,may,potentiate'
p70978
(F1
F0.00014334862385321102
I1
I0
I1
tp70979
sS'taking,acarbose,was'
p70980
(F1
F0.00014334862385321102
I0
I1
I-1
tp70981
sS'with,should,be'
p70982
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp70983
sS'and,that,inhibit'
p70984
(F0
F0
I1
I1
I0
tp70985
sS'week,period,particularly'
p70986
(F1
F0.00014334862385321102
I1
I0
I1
tp70987
sS'with,the,blood'
p70988
(F1
F0.00014334862385321102
I0
I1
I-1
tp70989
sS'in,nine,otherwise'
p70990
(F1
F0.00014334862385321102
I0
I1
I-1
tp70991
sS'in,clearance,of'
p70992
(F1
F0.00014334862385321102
I1
I0
I1
tp70993
sS'in,additive,effect'
p70994
(F1
F0.00014334862385321102
I1
I0
I1
tp70995
sS'highly,plasma,protein-bound'
p70996
(F1
F0.00014334862385321102
I1
I0
I1
tp70997
sS'less,specific,regulation'
p70998
(F1
F0.00014334862385321102
I0
I1
I-1
tp70999
sS'physiological,changes,resulting'
p71000
(F1
F0.00014334862385321102
I0
I1
I-1
tp71001
sS'inhibitors,of,tubular'
p71002
(F0
F0
I1
I1
I0
tp71003
sS'terfenadine,administration,of'
p71004
(F1
F0.00014334862385321102
I0
I1
I-1
tp71005
sS'electrocardiographic,parameters,clinical'
p71006
(F1
F0.00014334862385321102
I0
I1
I-1
tp71007
sS'nsaids,may,decrease'
p71008
(F1
F0.00014334862385321102
I1
I0
I1
tp71009
sS'd3,and,the'
p71010
(F1
F0.00014334862385321102
I0
I1
I-1
tp71011
sS'cns,depression,tricyclic'
p71012
(F1
F0.00014334862385321102
I1
I0
I1
tp71013
sS'of,the,case-control'
p71014
(F1
F0.00014334862385321102
I1
I0
I1
tp71015
sS'use,with,is'
p71016
(F1
F0.00014334862385321102
I0
I1
I-1
tp71017
sS'when,levsin,is'
p71018
(F1
F0.00014334862385321102
I1
I0
I1
tp71019
sS'compared,to,when'
p71020
(F1
F0.00028669724770642203
I2
I0
I2
tp71021
sS'occur,when,flolan'
p71022
(F1
F0.00014334862385321102
I1
I0
I1
tp71023
sS'while,corresponding,values'
p71024
(F1
F0.00014334862385321102
I0
I1
I-1
tp71025
sS'the,mechanism,of'
p71026
(F0
F0
I1
I1
I0
tp71027
sS'agents,primarily,h2'
p71028
(F1
F0.00014334862385321102
I0
I1
I-1
tp71029
sS'maleate,mg,qd'
p71030
(F1
F0.00014334862385321102
I1
I0
I1
tp71031
sS'decreases,of,more'
p71032
(F1
F0.00014334862385321102
I1
I0
I1
tp71033
sS'anti-inflammatory,drugs,in'
p71034
(F1
F0.00028669724770642203
I2
I0
I2
tp71035
sS'pharmacokinetics,of,following'
p71036
(F1
F0.00014334862385321102
I0
I1
I-1
tp71037
sS'with,agonists,only'
p71038
(F1
F0.00014334862385321102
I1
I0
I1
tp71039
sS'hours,should,be'
p71040
(F1
F0.00028669724770642203
I2
I0
I2
tp71041
sS'nephrotoxicity,of,coly-mycin'
p71042
(F1
F0.00014334862385321102
I1
I0
I1
tp71043
sS'because,is,primarily'
p71044
(F1
F0.00014334862385321102
I0
I1
I-1
tp71045
sS'plasma,concentrations,by'
p71046
(F1
F0.00014334862385321102
I1
I0
I1
tp71047
sS'more,of,the'
p71048
(F1
F0.00014334862385321102
I0
I1
I-1
tp71049
sS'show,that,the'
p71050
(F0
F0
I1
I1
I0
tp71051
sS'p450,cyp,a4'
p71052
(F1
F0.00014334862385321102
I0
I1
I-1
tp71053
sS'growing,class,of'
p71054
(F1
F0.00014334862385321102
I0
I1
I-1
tp71055
sS'as,or,organophosphate'
p71056
(F1
F0.00014334862385321102
I1
I0
I1
tp71057
sS'acid,as,the'
p71058
(F1
F0.00014334862385321102
I1
I0
I1
tp71059
sS'induced,by,nuromax'
p71060
(F1
F0.00014334862385321102
I1
I0
I1
tp71061
sS'see,if,clearance'
p71062
(F1
F0.00014334862385321102
I1
I0
I1
tp71063
sS'agents,simultaneous,use'
p71064
(F1
F0.00014334862385321102
I1
I0
I1
tp71065
sS'interact,with,mao'
p71066
(F1
F0.00014334862385321102
I1
I0
I1
tp71067
sS'result,in,severe'
p71068
(F1
F0.00014334862385321102
I1
I0
I1
tp71069
sS'benzodiazepines,benzodiazepines,metabolized'
p71070
(F1
F0.00014334862385321102
I1
I0
I1
tp71071
sS'of,myopathy,rhabdomyolysis'
p71072
(F1
F0.00028669724770642203
I2
I0
I2
tp71073
sS'loop,or,thiazide'
p71074
(F1
F0.00014334862385321102
I1
I0
I1
tp71075
sS'was,studied,in'
p71076
(F1
F0.00071674311926605509
I0
I5
I-5
tp71077
sS'activity,eg,would'
p71078
(F1
F0.00014334862385321102
I1
I0
I1
tp71079
sS'therefore,smaller,alfenta'
p71080
(F1
F0.00014334862385321102
I0
I1
I-1
tp71081
sS'p450,cyp,at'
p71082
(F1
F0.00014334862385321102
I0
I1
I-1
tp71083
sS'of,indocin,resulted'
p71084
(F1
F0.00014334862385321102
I1
I0
I1
tp71085
sS'clinical,studies,sodium'
p71086
(F1
F0.00014334862385321102
I0
I1
I-1
tp71087
sS'lotensin,can,be'
p71088
(F1
F0.00014334862385321102
I1
I0
I1
tp71089
sS'extent,auc,of'
p71090
(F1
F0.00014334862385321102
I1
I0
I1
tp71091
sS'theophylline,serum,levels'
p71092
(F1
F0.00014334862385321102
I1
I0
I1
tp71093
sS'toxic,levels,with'
p71094
(F1
F0.00014334862385321102
I0
I1
I-1
tp71095
sS'as,may,result'
p71096
(F1
F0.00014334862385321102
I1
I0
I1
tp71097
sS'be,potentiated,when'
p71098
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp71099
sS'with,in,or'
p71100
(F1
F0.00014334862385321102
I0
I1
I-1
tp71101
sS'co-administration,with,should'
p71102
(F1
F0.00014334862385321102
I0
I1
I-1
tp71103
sS'was,found,that'
p71104
(F1
F0.00014334862385321102
I1
I0
I1
tp71105
sS'few,weeks,after'
p71106
(F1
F0.00014334862385321102
I1
I0
I1
tp71107
sS'however,ldl-c,reduction'
p71108
(F1
F0.00014334862385321102
I1
I0
I1
tp71109
sS'and,in,vivo'
p71110
(F1
F0.00014334862385321102
I1
I0
I1
tp71111
sS'behavioral,responsiveness,of'
p71112
(F1
F0.00014334862385321102
I1
I0
I1
tp71113
sS'and,respectively,which'
p71114
(F1
F0.00014334862385321102
I0
I1
I-1
tp71115
sS'with,other,agents'
p71116
(F0.5
F0.00028669724770642203
I3
I1
I2
tp71117
sS'contain,any,amine'
p71118
(F1
F0.00014334862385321102
I1
I0
I1
tp71119
sS'diazepam,at,doses'
p71120
(F1
F0.00014334862385321102
I1
I0
I1
tp71121
sS'apart,was,administered'
p71122
(F1
F0.00014334862385321102
I1
I0
I1
tp71123
sS'sum,of,desethylzaleplon'
p71124
(F1
F0.00014334862385321102
I0
I1
I-1
tp71125
sS'and,urine,immunoreactive'
p71126
(F1
F0.00014334862385321102
I0
I1
I-1
tp71127
sS'which,concomitant,use'
p71128
(F1
F0.00014334862385321102
I1
I0
I1
tp71129
sS'st,john,s'
p71130
(F0
F0
I1
I1
I0
tp71131
sS'substantial,increases,in'
p71132
(F1
F0.00014334862385321102
I1
I0
I1
tp71133
sS'mg,kg,via'
p71134
(F1
F0.00014334862385321102
I1
I0
I1
tp71135
sS'cyp2d6,many,including'
p71136
(F1
F0.00014334862385321102
I0
I1
I-1
tp71137
sS'response,induced,by'
p71138
(F0
F0
I1
I1
I0
tp71139
sS'were,similar,regardless'
p71140
(F1
F0.00014334862385321102
I0
I1
I-1
tp71141
sS'in,addition,results'
p71142
(F1
F0.00014334862385321102
I1
I0
I1
tp71143
sS'an,open,three-period'
p71144
(F1
F0.00014334862385321102
I0
I1
I-1
tp71145
sS'tambocor,are,unknown'
p71146
(F1
F0.00014334862385321102
I1
I0
I1
tp71147
sS'antagonize,the,skeletal'
p71148
(F1
F0.00014334862385321102
I1
I0
I1
tp71149
sS'kg,subcutaneous,injection'
p71150
(F1
F0.00014334862385321102
I0
I1
I-1
tp71151
sS'indicate,that,mesylate'
p71152
(F1
F0.00014334862385321102
I0
I1
I-1
tp71153
sS'received,increases,the'
p71154
(F1
F0.00014334862385321102
I1
I0
I1
tp71155
sS'treated,with,may'
p71156
(F1
F0.00028669724770642203
I2
I0
I2
tp71157
sS'combination,with,than'
p71158
(F1
F0.00014334862385321102
I1
I0
I1
tp71159
sS'study,in,insulin-dependent'
p71160
(F1
F0.00014334862385321102
I0
I1
I-1
tp71161
sS'approximately,fold,increase'
p71162
(F1
F0.00028669724770642203
I0
I2
I-2
tp71163
sS'rare,but,serious'
p71164
(F1
F0.00014334862385321102
I1
I0
I1
tp71165
sS'treated,with,mao'
p71166
(F1
F0.00014334862385321102
I1
I0
I1
tp71167
sS'in,elevated,plasma'
p71168
(F1
F0.00071674311926605509
I5
I0
I5
tp71169
sS'between,and,are'
p71170
(F1
F0.00014334862385321102
I1
I0
I1
tp71171
sS'which,may,produce'
p71172
(F1
F0.00028669724770642203
I2
I0
I2
tp71173
sS'inotropic,properties,and'
p71174
(F1
F0.00014334862385321102
I1
I0
I1
tp71175
sS'p-aminosalicylic,acid,and'
p71176
(F1
F0.00014334862385321102
I0
I1
I-1
tp71177
sS'the,advice,of'
p71178
(F1
F0.00014334862385321102
I1
I0
I1
tp71179
sS'and,decreased,have'
p71180
(F1
F0.00014334862385321102
I1
I0
I1
tp71181
sS'amphotericin,b,non-steroidal'
p71182
(F1
F0.00014334862385321102
I0
I1
I-1
tp71183
sS'vioxx,may,result'
p71184
(F1
F0.00014334862385321102
I1
I0
I1
tp71185
sS'and,to,a'
p71186
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp71187
sS'increased,by,hour'
p71188
(F1
F0.00014334862385321102
I1
I0
I1
tp71189
sS'trough,cmin,concentration'
p71190
(F0
F0
I1
I1
I0
tp71191
sS'if,hormonal,differ'
p71192
(F1
F0.00014334862385321102
I0
I1
I-1
tp71193
sS'zone,and,dpcpx-induced'
p71194
(F1
F0.00014334862385321102
I1
I0
I1
tp71195
sS'vasoconstriction,caused,by'
p71196
(F1
F0.00014334862385321102
I1
I0
I1
tp71197
sS'the,following,observations'
p71198
(F1
F0.00014334862385321102
I0
I1
I-1
tp71199
sS'ss,of,by'
p71200
(F1
F0.00028669724770642203
I2
I0
I2
tp71201
sS'respond,normally,to'
p71202
(F1
F0.00014334862385321102
I0
I1
I-1
tp71203
sS'is,drawn,if'
p71204
(F1
F0.00014334862385321102
I1
I0
I1
tp71205
sS'been,seen,in'
p71206
(F1
F0.00014334862385321102
I0
I1
I-1
tp71207
sS'inhibitors,serotonin,reuptake'
p71208
(F1
F0.00014334862385321102
I1
I0
I1
tp71209
sS'nsaids,including,ketorolac'
p71210
(F1
F0.00014334862385321102
I0
I1
I-1
tp71211
sS'for,toxicity,and'
p71212
(F0
F0
I1
I1
I0
tp71213
sS'net,change,of'
p71214
(F1
F0.00043004587155963305
I3
I0
I3
tp71215
sS'cmax,when,co-administered'
p71216
(F1
F0.00028669724770642203
I2
I0
I2
tp71217
sS'mixed,overdosage,since'
p71218
(F1
F0.00014334862385321102
I1
I0
I1
tp71219
sS'to,use,foradil'
p71220
(F1
F0.00014334862385321102
I0
I1
I-1
tp71221
sS'edetate,disodium,interferes'
p71222
(F1
F0.00014334862385321102
I1
I0
I1
tp71223
sS'prothrombin,complex,concentrates'
p71224
(F1
F0.00014334862385321102
I0
I1
I-1
tp71225
sS'of,a,number'
p71226
(F1
F0.00014334862385321102
I1
I0
I1
tp71227
sS'additionally,higher,than'
p71228
(F1
F0.00014334862385321102
I1
I0
I1
tp71229
sS'increased,blood,levels'
p71230
(F0
F0
I1
I1
I0
tp71231
sS'hydrogen,maleate,or'
p71232
(F1
F0.00014334862385321102
I1
I0
I1
tp71233
sS'including,and,or'
p71234
(F1
F0.00014334862385321102
I1
I0
I1
tp71235
sS'min,for,alone'
p71236
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp71237
sS'mg,of,or'
p71238
(F1
F0.00014334862385321102
I0
I1
I-1
tp71239
sS'the,dose,should'
p71240
(F1
F0.00043004587155963305
I3
I0
I3
tp71241
sS'introduced,at,the'
p71242
(F1
F0.00014334862385321102
I1
I0
I1
tp71243
sS'at,the,start'
p71244
(F1
F0.00014334862385321102
I1
I0
I1
tp71245
sS'ns,is,administered'
p71246
(F1
F0.00014334862385321102
I1
I0
I1
tp71247
sS'other,nephrotoxic,medications'
p71248
(F1
F0.00014334862385321102
I0
I1
I-1
tp71249
sS'to,any,great'
p71250
(F1
F0.00014334862385321102
I0
I1
I-1
tp71251
sS'concomitant,medications,included'
p71252
(F1
F0.00014334862385321102
I0
I1
I-1
tp71253
sS'duration,of,neuromuscular'
p71254
(F0
F0
I1
I1
I0
tp71255
sS'and,ischemia,of'
p71256
(F1
F0.00014334862385321102
I0
I1
I-1
tp71257
sS'of,the,alkaloid'
p71258
(F1
F0.00014334862385321102
I1
I0
I1
tp71259
sS'on,other,antiepilepsy'
p71260
(F1
F0.00014334862385321102
I0
I1
I-1
tp71261
sS'and,of,pseudomonas'
p71262
(F1
F0.00014334862385321102
I0
I1
I-1
tp71263
sS'and,has,not'
p71264
(F0
F0
I3
I3
I0
tp71265
sS'by,general,local'
p71266
(F1
F0.00014334862385321102
I0
I1
I-1
tp71267
sS'that,mtx,nsaids'
p71268
(F1
F0.00014334862385321102
I0
I1
I-1
tp71269
sS'bleeding,higher,than'
p71270
(F1
F0.00028669724770642203
I2
I0
I2
tp71271
sS'nose,may,occur'
p71272
(F1
F0.00014334862385321102
I1
I0
I1
tp71273
sS'by,a,variety'
p71274
(F1
F0.00014334862385321102
I0
I1
I-1
tp71275
sS'evaluated,in,vitro'
p71276
(F1
F0.00014334862385321102
I0
I1
I-1
tp71277
sS'metabolism,rifampin,reduced'
p71278
(F1
F0.00014334862385321102
I1
I0
I1
tp71279
sS'arimidex,with,other'
p71280
(F1
F0.00014334862385321102
I0
I1
I-1
tp71281
sS'in,an,in'
p71282
(F1
F0.00014334862385321102
I1
I0
I1
tp71283
sS'of,these,enzymes'
p71284
(F1
F0.00014334862385321102
I0
I1
I-1
tp71285
sS'any,oral,medications'
p71286
(F1
F0.00014334862385321102
I1
I0
I1
tp71287
sS'who,are,not'
p71288
(F1
F0.00014334862385321102
I1
I0
I1
tp71289
sS'after,the,initiation'
p71290
(F1
F0.00014334862385321102
I1
I0
I1
tp71291
sS'was,covalently,linked'
p71292
(F1
F0.00014334862385321102
I0
I1
I-1
tp71293
sS'co-administer,and,is'
p71294
(F1
F0.00014334862385321102
I1
I0
I1
tp71295
sS'of,mg,and'
p71296
(F0.5
F0.00057339449541284407
I2
I6
I-4
tp71297
sS'patients,receiving,brovana'
p71298
(F1
F0.00014334862385321102
I0
I1
I-1
tp71299
sS'used,to,control'
p71300
(F1
F0.00028669724770642203
I2
I0
I2
tp71301
sS'time,measured,as'
p71302
(F1
F0.00028669724770642203
I2
I0
I2
tp71303
sS'positive,readings,were'
p71304
(F1
F0.00014334862385321102
I0
I1
I-1
tp71305
sS'tolbutamide,in,diabetic'
p71306
(F1
F0.00014334862385321102
I0
I1
I-1
tp71307
sS'erection-supporting,medication,patients'
p71308
(F1
F0.00014334862385321102
I0
I1
I-1
tp71309
sS'mean,elimination,half-life'
p71310
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp71311
sS'local,which,contain'
p71312
(F1
F0.00014334862385321102
I1
I0
I1
tp71313
sS'inhibition,of,a'
p71314
(F1
F0.00014334862385321102
I0
I1
I-1
tp71315
sS'causes,increase,by'
p71316
(F1
F0.00014334862385321102
I1
I0
I1
tp71317
sS'from,the,mg'
p71318
(F1
F0.00014334862385321102
I0
I1
I-1
tp71319
sS'following,are,examples'
p71320
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp71321
sS'differential-reinforcement,of-low,rates'
p71322
(F1
F0.00014334862385321102
I0
I1
I-1
tp71323
sS'aripiprazole,is,unlikely'
p71324
(F1
F0.00014334862385321102
I0
I1
I-1
tp71325
sS'basis,to,mg'
p71326
(F1
F0.00014334862385321102
I1
I0
I1
tp71327
sS'increase,of,glycemia'
p71328
(F1
F0.00014334862385321102
I0
I1
I-1
tp71329
sS'or,are,metabolized'
p71330
(F1
F0.00014334862385321102
I1
I0
I1
tp71331
sS'antiinflammatory,agents,aspirin'
p71332
(F1
F0.00014334862385321102
I1
I0
I1
tp71333
sS'inducer,of,hepatic'
p71334
(F1
F0.00014334862385321102
I1
I0
I1
tp71335
sS'and,thus,decrease'
p71336
(F1
F0.00014334862385321102
I1
I0
I1
tp71337
sS'and,female,volunteers'
p71338
(F0
F0
I1
I1
I0
tp71339
sS'with,to,patients'
p71340
(F1
F0.00014334862385321102
I0
I1
I-1
tp71341
sS'ergot,derivatives,dihydroergotamine'
p71342
(F1
F0.00014334862385321102
I0
I1
I-1
tp71343
sS'dose,of,gram'
p71344
(F1
F0.00014334862385321102
I1
I0
I1
tp71345
sS'in,hemostasis,and'
p71346
(F1
F0.00028669724770642203
I2
I0
I2
tp71347
sS'blood,levels,and'
p71348
(F1
F0.00043004587155963305
I3
I0
I3
tp71349
sS'or,divalent,or'
p71350
(F1
F0.00014334862385321102
I0
I1
I-1
tp71351
sS'hemostatic,defense,of'
p71352
(F1
F0.00014334862385321102
I1
I0
I1
tp71353
sS'four,times,as'
p71354
(F1
F0.00014334862385321102
I0
I1
I-1
tp71355
sS'an,appropriate,adjustment'
p71356
(F1
F0.00014334862385321102
I1
I0
I1
tp71357
sS'with,serotoninergic,agents'
p71358
(F1
F0.00014334862385321102
I1
I0
I1
tp71359
sS'is,one,report'
p71360
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp71361
sS'when,was,coadministered'
p71362
(F0
F0
I2
I2
I0
tp71363
sS'of,toxicity,occur'
p71364
(F1
F0.00014334862385321102
I1
I0
I1
tp71365
sS'for,the,other'
p71366
(F1
F0.00014334862385321102
I0
I1
I-1
tp71367
sS'occurred,when,and'
p71368
(F1
F0.00014334862385321102
I0
I1
I-1
tp71369
sS'that,alter,renal'
p71370
(F1
F0.00014334862385321102
I0
I1
I-1
tp71371
sS'of,infections,caused'
p71372
(F1
F0.00014334862385321102
I0
I1
I-1
tp71373
sS'a,thienobenzodiazepine,derivative'
p71374
(F1
F0.00014334862385321102
I0
I1
I-1
tp71375
sS'necessary,to,adjust'
p71376
(F1
F0.00014334862385321102
I1
I0
I1
tp71377
sS'fbs,followed,by'
p71378
(F1
F0.00014334862385321102
I1
I0
I1
tp71379
sS'and,concomitant,administration'
p71380
(F1
F0.00014334862385321102
I0
I1
I-1
tp71381
sS'mg,before,meals'
p71382
(F1
F0.00014334862385321102
I0
I1
I-1
tp71383
sS'other,psychotropic,have'
p71384
(F1
F0.00014334862385321102
I1
I0
I1
tp71385
sS'is,reduced,although'
p71386
(F1
F0.00014334862385321102
I1
I0
I1
tp71387
sS'a,significant,increase'
p71388
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp71389
sS'lead,to,increases'
p71390
(F1
F0.00014334862385321102
I0
I1
I-1
tp71391
sS'the,benzodiazepine,class'
p71392
(F1
F0.00014334862385321102
I1
I0
I1
tp71393
sS'and,implantable,contraceptives'
p71394
(F1
F0.00014334862385321102
I1
I0
I1
tp71395
sS'viracept,and,primarily'
p71396
(F1
F0.00014334862385321102
I0
I1
I-1
tp71397
sS'calcium-blocking,agents,and'
p71398
(F1
F0.00014334862385321102
I0
I1
I-1
tp71399
sS'antihypertensive,effect,of'
p71400
(F1
F0.0008600917431192661
I6
I0
I6
tp71401
sS'with,a,light'
p71402
(F0
F0
I1
I1
I0
tp71403
sS'combination,see,drug'
p71404
(F1
F0.00014334862385321102
I0
I1
I-1
tp71405
sS'on,auc,and'
p71406
(F1
F0.00014334862385321102
I0
I1
I-1
tp71407
sS'drugs,possessing,nephrotoxic'
p71408
(F1
F0.00014334862385321102
I1
I0
I1
tp71409
sS'activity,may,decrease'
p71410
(F1
F0.00014334862385321102
I0
I1
I-1
tp71411
sS'patients,taking,tysabri'
p71412
(F1
F0.00014334862385321102
I0
I1
I-1
tp71413
sS'to,be,maximal'
p71414
(F1
F0.00014334862385321102
I1
I0
I1
tp71415
sS'its,ability,to'
p71416
(F1
F0.00014334862385321102
I1
I0
I1
tp71417
sS'deltasone,orasone,others'
p71418
(F1
F0.00014334862385321102
I0
I1
I-1
tp71419
sS'reports,of,interaction'
p71420
(F1
F0.00014334862385321102
I0
I1
I-1
tp71421
sS'of,neuromuscular,blockade'
p71422
(F1
F0.00014334862385321102
I1
I0
I1
tp71423
sS'of,hmg-coa,reductase'
p71424
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp71425
sS'other,known,photosensitizing'
p71426
(F1
F0.00014334862385321102
I1
I0
I1
tp71427
sS'decreased,effectiveness,and'
p71428
(F1
F0.00014334862385321102
I1
I0
I1
tp71429
sS'bleeding,complications,careful'
p71430
(F1
F0.00014334862385321102
I0
I1
I-1
tp71431
sS'vioxx,mg,daily'
p71432
(F1
F0.00014334862385321102
I0
I1
I-1
tp71433
sS'reaction,of,placental'
p71434
(F1
F0.00014334862385321102
I1
I0
I1
tp71435
sS'document,no,clinically'
p71436
(F1
F0.00014334862385321102
I0
I1
I-1
tp71437
sS'of,competitive,suppression'
p71438
(F1
F0.00014334862385321102
I0
I1
I-1
tp71439
sS'glycosides,inducers,of'
p71440
(F1
F0.00014334862385321102
I0
I1
I-1
tp71441
sS'chronic,therapy,the'
p71442
(F1
F0.00014334862385321102
I1
I0
I1
tp71443
sS'not,when,the'
p71444
(F1
F0.00014334862385321102
I1
I0
I1
tp71445
sS'increase,respectively,and'
p71446
(F1
F0.00014334862385321102
I1
I0
I1
tp71447
sS'monitored,if,a'
p71448
(F1
F0.00028669724770642203
I2
I0
I2
tp71449
sS'may,be,elevated'
p71450
(F1
F0.00028669724770642203
I0
I2
I-2
tp71451
sS'an,average,of'
p71452
(F1
F0.00071674311926605509
I5
I0
I5
tp71453
sS'auc,and,about'
p71454
(F1
F0.00014334862385321102
I1
I0
I1
tp71455
sS'result,in,any'
p71456
(F1
F0.00071674311926605509
I0
I5
I-5
tp71457
sS'clearance,of,enhancing'
p71458
(F1
F0.00014334862385321102
I1
I0
I1
tp71459
sS'reported,to,inactivate'
p71460
(F1
F0.00014334862385321102
I1
I0
I1
tp71461
sS'present,work,involved'
p71462
(F1
F0.00014334862385321102
I0
I1
I-1
tp71463
sS'may,produce,additive'
p71464
(F1
F0.00014334862385321102
I0
I1
I-1
tp71465
sS'blockers,such,as'
p71466
(F0
F0
I1
I1
I0
tp71467
sS'potential,interactions,may'
p71468
(F1
F0.00014334862385321102
I0
I1
I-1
tp71469
sS'of,dynacirc,and'
p71470
(F1
F0.00028669724770642203
I0
I2
I-2
tp71471
sS'interact,with,cefamandole'
p71472
(F1
F0.00014334862385321102
I0
I1
I-1
tp71473
sS'of,the,luteinizing'
p71474
(F1
F0.00014334862385321102
I0
I1
I-1
tp71475
sS'of,progestin-only,pills'
p71476
(F1
F0.00014334862385321102
I1
I0
I1
tp71477
sS'additional,therapy,the'
p71478
(F1
F0.00014334862385321102
I0
I1
I-1
tp71479
sS'by,interfering,with'
p71480
(F1
F0.00014334862385321102
I1
I0
I1
tp71481
sS'lymphatic,invasion,of'
p71482
(F1
F0.00014334862385321102
I1
I0
I1
tp71483
sS'large,doses,of'
p71484
(F1
F0.00028669724770642203
I0
I2
I-2
tp71485
sS'in,increased,blood'
p71486
(F1
F0.00014334862385321102
I1
I0
I1
tp71487
sS'a,direct,causal'
p71488
(F1
F0.00014334862385321102
I1
I0
I1
tp71489
sS'and,parnate,using'
p71490
(F1
F0.00014334862385321102
I0
I1
I-1
tp71491
sS'levels,of,tmp'
p71492
(F1
F0.00014334862385321102
I0
I1
I-1
tp71493
sS'be,employed,cautiously'
p71494
(F1
F0.00014334862385321102
I0
I1
I-1
tp71495
sS'times,were,increased'
p71496
(F1
F0.00014334862385321102
I0
I1
I-1
tp71497
sS'bioavailability,was,about'
p71498
(F1
F0.00014334862385321102
I1
I0
I1
tp71499
sS'was,about,equipotent'
p71500
(F1
F0.00014334862385321102
I0
I1
I-1
tp71501
sS'immunosuppressives,cyclosporine,cyp3a4'
p71502
(F1
F0.00014334862385321102
I0
I1
I-1
tp71503
sS'other,highly,protein'
p71504
(F1
F0.00014334862385321102
I0
I1
I-1
tp71505
sS'data,on,concomitant'
p71506
(F1
F0.00014334862385321102
I0
I1
I-1
tp71507
sS'adversely,affected,response'
p71508
(F1
F0.00014334862385321102
I1
I0
I1
tp71509
sS'citrate,may,potentiate'
p71510
(F1
F0.00014334862385321102
I1
I0
I1
tp71511
sS'rate,increase,following'
p71512
(F1
F0.00014334862385321102
I1
I0
I1
tp71513
sS'may,either,inhibit'
p71514
(F1
F0.00014334862385321102
I1
I0
I1
tp71515
sS'was,no,interaction'
p71516
(F1
F0.00014334862385321102
I0
I1
I-1
tp71517
sS'significant,decreases,in'
p71518
(F1
F0.00028669724770642203
I2
I0
I2
tp71519
sS'when,vardenafil,or'
p71520
(F1
F0.00014334862385321102
I1
I0
I1
tp71521
sS'effects,with,those'
p71522
(F1
F0.00014334862385321102
I1
I0
I1
tp71523
sS'hour,and,a'
p71524
(F1
F0.00014334862385321102
I1
I0
I1
tp71525
sS'to,the,blood'
p71526
(F1
F0.00014334862385321102
I1
I0
I1
tp71527
sS'interactions,when,is'
p71528
(F1
F0.00014334862385321102
I1
I0
I1
tp71529
sS'of,novolog,and'
p71530
(F1
F0.00014334862385321102
I0
I1
I-1
tp71531
sS'with,prostatectomy,radiation'
p71532
(F1
F0.00014334862385321102
I0
I1
I-1
tp71533
sS'required,and,pth'
p71534
(F1
F0.00014334862385321102
I1
I0
I1
tp71535
sS'parvum,growth,in'
p71536
(F1
F0.00014334862385321102
I1
I0
I1
tp71537
sS'not,significantly,inhibit'
p71538
(F1
F0.00014334862385321102
I1
I0
I1
tp71539
sS'these,medications,or'
p71540
(F0
F0
I2
I2
I0
tp71541
sS'antagonist,opioid,analgesics'
p71542
(F1
F0.00014334862385321102
I1
I0
I1
tp71543
sS'synergism,with,camp'
p71544
(F1
F0.00014334862385321102
I1
I0
I1
tp71545
sS'an,agent,administered'
p71546
(F1
F0.00014334862385321102
I0
I1
I-1
tp71547
sS'concurrently,with,oral'
p71548
(F1
F0.00014334862385321102
I1
I0
I1
tp71549
sS'was,a,slight'
p71550
(F1
F0.00014334862385321102
I1
I0
I1
tp71551
sS'decrease,the,k'
p71552
(F1
F0.00014334862385321102
I0
I1
I-1
tp71553
sS'of,parenterally,administered'
p71554
(F1
F0.00014334862385321102
I1
I0
I1
tp71555
sS'inhibitor,should,not'
p71556
(F1
F0.00014334862385321102
I1
I0
I1
tp71557
sS'similarly,had,no'
p71558
(F1
F0.00014334862385321102
I0
I1
I-1
tp71559
sS'varying,degrees,of'
p71560
(F1
F0.00014334862385321102
I0
I1
I-1
tp71561
sS'accumulation,in,rabbit'
p71562
(F1
F0.00014334862385321102
I1
I0
I1
tp71563
sS'anticancer,and,may'
p71564
(F1
F0.00014334862385321102
I1
I0
I1
tp71565
sS'by,cyp3a4,as'
p71566
(F1
F0.00014334862385321102
I0
I1
I-1
tp71567
sS'and,that,transferred'
p71568
(F1
F0.00014334862385321102
I0
I1
I-1
tp71569
sS'to,days,following'
p71570
(F1
F0.00014334862385321102
I1
I0
I1
tp71571
sS'reported,to,diminish'
p71572
(F1
F0.00028669724770642203
I2
I0
I2
tp71573
sS'in,the,reduced'
p71574
(F1
F0.00028669724770642203
I0
I2
I-2
tp71575
sS'either,protective,or'
p71576
(F1
F0.00014334862385321102
I0
I1
I-1
tp71577
sS'a,maintenance,level'
p71578
(F0
F0
I1
I1
I0
tp71579
sS'the,model,peptide'
p71580
(F1
F0.00014334862385321102
I0
I1
I-1
tp71581
sS'multidrug-resistant,organisms,and'
p71582
(F1
F0.00014334862385321102
I0
I1
I-1
tp71583
sS'presence,of,more'
p71584
(F1
F0.00014334862385321102
I0
I1
I-1
tp71585
sS'such,as,valium'
p71586
(F1
F0.00014334862385321102
I1
I0
I1
tp71587
sS'responsible,for,the'
p71588
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp71589
sS'a,double-blind,fashion'
p71590
(F1
F0.00014334862385321102
I0
I1
I-1
tp71591
sS'concomitantly,with,gram'
p71592
(F1
F0.00014334862385321102
I1
I0
I1
tp71593
sS'post-marketing,reports,of'
p71594
(F1
F0.00014334862385321102
I0
I1
I-1
tp71595
sS'decreased,in,rats'
p71596
(F1
F0.00014334862385321102
I1
I0
I1
tp71597
sS'initiated,in,a'
p71598
(F1
F0.00043004587155963305
I3
I0
I3
tp71599
sS'a,high,dose'
p71600
(F1
F0.00014334862385321102
I1
I0
I1
tp71601
sS'of,with,should'
p71602
(F1
F0.00028669724770642203
I2
I0
I2
tp71603
sS'combination,with,sulfamethoxazole'
p71604
(F1
F0.00014334862385321102
I0
I1
I-1
tp71605
sS'simultaneously,or,hours'
p71606
(F1
F0.00014334862385321102
I1
I0
I1
tp71607
sS'examine,the,insp'
p71608
(F1
F0.00014334862385321102
I0
I1
I-1
tp71609
sS'ability,to,control'
p71610
(F1
F0.00014334862385321102
I0
I1
I-1
tp71611
sS'carcinogenesis,by,or'
p71612
(F1
F0.00014334862385321102
I0
I1
I-1
tp71613
sS'and,between,given'
p71614
(F1
F0.00014334862385321102
I0
I1
I-1
tp71615
sS'following,oral,administration'
p71616
(F1
F0.00014334862385321102
I0
I1
I-1
tp71617
sS'cumulative,urinary,excretion'
p71618
(F1
F0.00014334862385321102
I0
I1
I-1
tp71619
sS'co-administration,of,and'
p71620
(F0.1111111111111111
F0.00014334862385321102
I5
I4
I1
tp71621
sS'effect,when,initiating'
p71622
(F1
F0.00014334862385321102
I1
I0
I1
tp71623
sS'or,large,doses'
p71624
(F1
F0.00014334862385321102
I0
I1
I-1
tp71625
sS'be,monitored,at'
p71626
(F1
F0.00014334862385321102
I1
I0
I1
tp71627
sS'led,to,increased'
p71628
(F1
F0.00028669724770642203
I2
I0
I2
tp71629
sS'anticholinergic,agents,although'
p71630
(F1
F0.00014334862385321102
I1
I0
I1
tp71631
sS'an,aed,induces'
p71632
(F1
F0.00014334862385321102
I0
I1
I-1
tp71633
sS'particularly,in,patients'
p71634
(F1
F0.00014334862385321102
I1
I0
I1
tp71635
sS'wide,variety,of'
p71636
(F1
F0.00014334862385321102
I0
I1
I-1
tp71637
sS'besides,mtx,were'
p71638
(F1
F0.00014334862385321102
I0
I1
I-1
tp71639
sS'agents,is,usually'
p71640
(F1
F0.00014334862385321102
I1
I0
I1
tp71641
sS'comparison,of,pharmacokinetics'
p71642
(F1
F0.00014334862385321102
I0
I1
I-1
tp71643
sS'at,nacmc,with'
p71644
(F1
F0.00014334862385321102
I0
I1
I-1
tp71645
sS'insufficient,to,produce'
p71646
(F1
F0.00014334862385321102
I1
I0
I1
tp71647
sS'more,than,episodes'
p71648
(F1
F0.00014334862385321102
I0
I1
I-1
tp71649
sS'to,increase,awareness'
p71650
(F1
F0.00014334862385321102
I1
I0
I1
tp71651
sS'wellbutrin,following,concomitant'
p71652
(F1
F0.00014334862385321102
I0
I1
I-1
tp71653
sS'is,used,at'
p71654
(F1
F0.00014334862385321102
I1
I0
I1
tp71655
sS'is,not,a'
p71656
(F0.7142857142857143
F0.00071674311926605509
I1
I6
I-5
tp71657
sS'central,effects,of'
p71658
(F1
F0.00014334862385321102
I1
I0
I1
tp71659
sS'received,plus,for'
p71660
(F1
F0.00014334862385321102
I0
I1
I-1
tp71661
sS'of,hydrochloride,with'
p71662
(F1
F0.00028669724770642203
I2
I0
I2
tp71663
sS'suggest,that,an'
p71664
(F1
F0.00014334862385321102
I0
I1
I-1
tp71665
sS'latter,agents,when'
p71666
(F1
F0.00014334862385321102
I1
I0
I1
tp71667
sS'studies,performed,with'
p71668
(F1
F0.00014334862385321102
I0
I1
I-1
tp71669
sS'metabolite,hydroxy-estazolam,and'
p71670
(F1
F0.00014334862385321102
I0
I1
I-1
tp71671
sS'at,a,dose'
p71672
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp71673
sS'patient,receiving,revia'
p71674
(F1
F0.00014334862385321102
I1
I0
I1
tp71675
sS'colchicine,is,inhibited'
p71676
(F1
F0.00014334862385321102
I1
I0
I1
tp71677
sS'lowest,effective,dose'
p71678
(F1
F0.00014334862385321102
I1
I0
I1
tp71679
sS'potentials,were,recorded'
p71680
(F1
F0.00014334862385321102
I0
I1
I-1
tp71681
sS'had,no,significant'
p71682
(F0.81818181818181823
F0.0012901376146788992
I1
I10
I-9
tp71683
sS'followed,by,determination'
p71684
(F1
F0.00014334862385321102
I0
I1
I-1
tp71685
sS'not,be,predictive'
p71686
(F1
F0.00014334862385321102
I0
I1
I-1
tp71687
sS'may,be,expected'
p71688
(F1
F0.00028669724770642203
I2
I0
I2
tp71689
sS'increase,the,metabolism'
p71690
(F1
F0.00014334862385321102
I1
I0
I1
tp71691
sS'of,and,enhance'
p71692
(F1
F0.00014334862385321102
I1
I0
I1
tp71693
sS'or,some,leading'
p71694
(F1
F0.00014334862385321102
I1
I0
I1
tp71695
sS'may,be,capable'
p71696
(F1
F0.00014334862385321102
I1
I0
I1
tp71697
sS'duration,of,pharmacologic'
p71698
(F1
F0.00014334862385321102
I1
I0
I1
tp71699
sS'on,the,requirement'
p71700
(F1
F0.00014334862385321102
I1
I0
I1
tp71701
sS'the,pharmacokinetics,pharmacodynamics'
p71702
(F1
F0.00014334862385321102
I0
I1
I-1
tp71703
sS'the,plasma,kinetics'
p71704
(F1
F0.00014334862385321102
I0
I1
I-1
tp71705
sS'concentration,during,concomitant'
p71706
(F1
F0.00014334862385321102
I1
I0
I1
tp71707
sS'in,humans,may'
p71708
(F1
F0.00014334862385321102
I1
I0
I1
tp71709
sS'acute,dosing,with'
p71710
(F1
F0.00028669724770642203
I0
I2
I-2
tp71711
sS'increased,decreased,and'
p71712
(F1
F0.00014334862385321102
I1
I0
I1
tp71713
sS'urine,was,analyzed'
p71714
(F1
F0.00014334862385321102
I0
I1
I-1
tp71715
sS'to,be,the'
p71716
(F1
F0.00028669724770642203
I2
I0
I2
tp71717
sS'monotherapy,did,not'
p71718
(F1
F0.00014334862385321102
I0
I1
I-1
tp71719
sS'not,displace,tightly'
p71720
(F1
F0.00014334862385321102
I0
I1
I-1
tp71721
sS'of,various,antihypertensive'
p71722
(F1
F0.00014334862385321102
I1
I0
I1
tp71723
sS'cyp3a,the,metabolism'
p71724
(F1
F0.00014334862385321102
I0
I1
I-1
tp71725
sS'has,recently,received'
p71726
(F1
F0.00014334862385321102
I1
I0
I1
tp71727
sS'of,sn38,the'
p71728
(F1
F0.00014334862385321102
I0
I1
I-1
tp71729
sS'demonstrated,a,decrease'
p71730
(F1
F0.00014334862385321102
I1
I0
I1
tp71731
sS'anabolic,anabolin,anavar'
p71732
(F1
F0.00014334862385321102
I0
I1
I-1
tp71733
sS'and,nrtis,other'
p71734
(F1
F0.00014334862385321102
I0
I1
I-1
tp71735
sS'withdrawn,several,days'
p71736
(F1
F0.00014334862385321102
I1
I0
I1
tp71737
sS'absorption,of,both'
p71738
(F1
F0.00014334862385321102
I1
I0
I1
tp71739
sS'ml,with,coadministration'
p71740
(F1
F0.00014334862385321102
I1
I0
I1
tp71741
sS'showed,no,positive'
p71742
(F1
F0.00014334862385321102
I0
I1
I-1
tp71743
sS'high,temperature,and'
p71744
(F1
F0.00014334862385321102
I1
I0
I1
tp71745
sS'the,anticoagulation,effects'
p71746
(F1
F0.00014334862385321102
I1
I0
I1
tp71747
sS'the,cyp3a4,inducer'
p71748
(F1
F0.00028669724770642203
I2
I0
I2
tp71749
sS'resulted,in,slight'
p71750
(F1
F0.00014334862385321102
I1
I0
I1
tp71751
sS'the,safety,profile'
p71752
(F1
F0.00043004587155963305
I0
I3
I-3
tp71753
sS'the,possibility,of'
p71754
(F0.59999999999999998
F0.0012901376146788992
I12
I3
I9
tp71755
sS'with,acetylsalicylic,acid'
p71756
(F1
F0.00014334862385321102
I0
I1
I-1
tp71757
sS'with,cerubidine,may'
p71758
(F1
F0.00014334862385321102
I1
I0
I1
tp71759
sS'is,given,concurrently'
p71760
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp71761
sS'such,as,loop'
p71762
(F1
F0.00014334862385321102
I1
I0
I1
tp71763
sS'and,the,auc'
p71764
(F1
F0.00014334862385321102
I1
I0
I1
tp71765
sS'xanthine,and,other'
p71766
(F1
F0.00014334862385321102
I1
I0
I1
tp71767
sS'a,mean,change'
p71768
(F1
F0.00014334862385321102
I1
I0
I1
tp71769
sS'other,and,the'
p71770
(F1
F0.00071674311926605509
I0
I5
I-5
tp71771
sS'sedation,time,sst'
p71772
(F1
F0.00014334862385321102
I0
I1
I-1
tp71773
sS'reactions,to,iodinated'
p71774
(F1
F0.00014334862385321102
I1
I0
I1
tp71775
sS'gastric,ph,was'
p71776
(F1
F0.00014334862385321102
I1
I0
I1
tp71777
sS'to,difluoroacetone,in'
p71778
(F1
F0.00014334862385321102
I1
I0
I1
tp71779
sS'be,administered,simultaneously'
p71780
(F1
F0.00014334862385321102
I1
I0
I1
tp71781
sS'd2,antagonists,and'
p71782
(F1
F0.00014334862385321102
I1
I0
I1
tp71783
sS'doses,of,er'
p71784
(F1
F0.00014334862385321102
I0
I1
I-1
tp71785
sS'g,sometimes,mcg'
p71786
(F1
F0.00014334862385321102
I0
I1
I-1
tp71787
sS'since,exhibits,non-linear'
p71788
(F1
F0.00014334862385321102
I1
I0
I1
tp71789
sS'was,similar,in'
p71790
(F1
F0.00014334862385321102
I0
I1
I-1
tp71791
sS'cyp3a4,and,the'
p71792
(F1
F0.00014334862385321102
I0
I1
I-1
tp71793
sS'and,cyp3a4,cimetidine'
p71794
(F1
F0.00014334862385321102
I1
I0
I1
tp71795
sS'and,ii,the'
p71796
(F1
F0.00014334862385321102
I0
I1
I-1
tp71797
sS'also,there,were'
p71798
(F1
F0.00014334862385321102
I0
I1
I-1
tp71799
sS'the,mao-b,inhibitor'
p71800
(F1
F0.00014334862385321102
I0
I1
I-1
tp71801
sS'clinical,pharmacokinetic,studies'
p71802
(F1
F0.00014334862385321102
I0
I1
I-1
tp71803
sS'with,maleate,its'
p71804
(F1
F0.00014334862385321102
I1
I0
I1
tp71805
sS'was,coadministered,with'
p71806
(F0
F0
I4
I4
I0
tp71807
sS'of,trileptal,greater'
p71808
(F1
F0.00014334862385321102
I1
I0
I1
tp71809
sS'it,is,potentially'
p71810
(F1
F0.00014334862385321102
I0
I1
I-1
tp71811
sS'simultaneous,use,of'
p71812
(F0
F0
I2
I2
I0
tp71813
sS'pneumonia,treatment,with'
p71814
(F1
F0.00014334862385321102
I1
I0
I1
tp71815
sS'levels,in,the'
p71816
(F0.5
F0.00028669724770642203
I3
I1
I2
tp71817
sS'linear,logarithmic,fashion'
p71818
(F1
F0.00014334862385321102
I0
I1
I-1
tp71819
sS'warranted,appropriate,observation'
p71820
(F1
F0.00057339449541284407
I4
I0
I4
tp71821
sS'and,or,ototoxicity'
p71822
(F1
F0.00014334862385321102
I0
I1
I-1
tp71823
sS'pretreatment,of,rats'
p71824
(F1
F0.00014334862385321102
I1
I0
I1
tp71825
sS'initiating,or,changing'
p71826
(F1
F0.00028669724770642203
I2
I0
I2
tp71827
sS'hormonal,are,highly'
p71828
(F1
F0.00014334862385321102
I0
I1
I-1
tp71829
sS'of,to,about'
p71830
(F1
F0.00014334862385321102
I1
I0
I1
tp71831
sS'of,both,cyp2c9'
p71832
(F1
F0.00014334862385321102
I0
I1
I-1
tp71833
sS'extract,alone,and'
p71834
(F1
F0.00014334862385321102
I0
I1
I-1
tp71835
sS'catalyzed,by,cytochrome'
p71836
(F1
F0.00014334862385321102
I0
I1
I-1
tp71837
sS'this,potentiation,of'
p71838
(F1
F0.00014334862385321102
I1
I0
I1
tp71839
sS'dose,had,little'
p71840
(F1
F0.00014334862385321102
I0
I1
I-1
tp71841
sS'affinities,for,kappa'
p71842
(F1
F0.00014334862385321102
I0
I1
I-1
tp71843
sS'thus,careful,monitoring'
p71844
(F1
F0.00014334862385321102
I1
I0
I1
tp71845
sS'may,enhance,s'
p71846
(F1
F0.00014334862385321102
I0
I1
I-1
tp71847
sS'on,the,contrary'
p71848
(F1
F0.00014334862385321102
I1
I0
I1
tp71849
sS'who,were,treated'
p71850
(F0
F0
I1
I1
I0
tp71851
sS'p-450,a,family'
p71852
(F1
F0.00014334862385321102
I1
I0
I1
tp71853
sS'no,documentation,of'
p71854
(F1
F0.00014334862385321102
I0
I1
I-1
tp71855
sS'results,indicate,that'
p71856
(F1
F0.00043004587155963305
I0
I3
I-3
tp71857
sS'the,patient,in'
p71858
(F1
F0.00014334862385321102
I0
I1
I-1
tp71859
sS'the,patient,is'
p71860
(F1
F0.00043004587155963305
I3
I0
I3
tp71861
sS'system,with,other'
p71862
(F1
F0.00014334862385321102
I1
I0
I1
tp71863
sS'acid,and,sodium'
p71864
(F1
F0.00014334862385321102
I1
I0
I1
tp71865
sS'tenofovir,disoproxil,fumarate'
p71866
(F1
F0.00014334862385321102
I0
I1
I-1
tp71867
sS'in,rats,at'
p71868
(F1
F0.00014334862385321102
I1
I0
I1
tp71869
sS'duloxetine,and,should'
p71870
(F1
F0.00014334862385321102
I1
I0
I1
tp71871
sS'as,thorazine,prolixin'
p71872
(F1
F0.00014334862385321102
I0
I1
I-1
tp71873
sS'elimination,half-life,of'
p71874
(F1
F0.00028669724770642203
I2
I0
I2
tp71875
sS'catecholamine,depletors,should'
p71876
(F1
F0.00014334862385321102
I1
I0
I1
tp71877
sS'or,h,receptor'
p71878
(F1
F0.00014334862385321102
I1
I0
I1
tp71879
sS'and,other,aeds'
p71880
(F1
F0.00028669724770642203
I0
I2
I-2
tp71881
sS'of,cyp3a,and'
p71882
(F0
F0
I1
I1
I0
tp71883
sS'no,increase,in'
p71884
(F1
F0.00014334862385321102
I0
I1
I-1
tp71885
sS'and,increase,the'
p71886
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp71887
sS'and,for,injection'
p71888
(F1
F0.00014334862385321102
I1
I0
I1
tp71889
sS'serum,level,should'
p71890
(F1
F0.00014334862385321102
I1
I0
I1
tp71891
sS'of,upon,chylomicron'
p71892
(F1
F0.00014334862385321102
I0
I1
I-1
tp71893
sS'was,seen,when'
p71894
(F1
F0.00014334862385321102
I0
I1
I-1
tp71895
sS'will,result,in'
p71896
(F1
F0.00014334862385321102
I0
I1
I-1
tp71897
sS'or,above,of'
p71898
(F1
F0.00014334862385321102
I1
I0
I1
tp71899
sS'in,uptake-1,carrier'
p71900
(F1
F0.00014334862385321102
I0
I1
I-1
tp71901
sS'indocin,relafen,daypro'
p71902
(F1
F0.00014334862385321102
I0
I1
I-1
tp71903
sS'by,range,from'
p71904
(F1
F0.00014334862385321102
I1
I0
I1
tp71905
sS'effect,on,its'
p71906
(F1
F0.00014334862385321102
I0
I1
I-1
tp71907
sS'both,and,mc'
p71908
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp71909
sS'action,of,non-depolarising'
p71910
(F1
F0.00014334862385321102
I1
I0
I1
tp71911
sS'addition,certain,that'
p71912
(F1
F0.00028669724770642203
I0
I2
I-2
tp71913
sS'significantly,include,adrenocortical'
p71914
(F1
F0.00014334862385321102
I1
I0
I1
tp71915
sS'is,likely,to'
p71916
(F1
F0.00071674311926605509
I5
I0
I5
tp71917
sS'mean,auc,or'
p71918
(F1
F0.00014334862385321102
I0
I1
I-1
tp71919
sS'on,absorption,and'
p71920
(F1
F0.00014334862385321102
I0
I1
I-1
tp71921
sS'peak,levels,were'
p71922
(F1
F0.00014334862385321102
I1
I0
I1
tp71923
sS'these,data,vardenafil'
p71924
(F1
F0.00014334862385321102
I1
I0
I1
tp71925
sS'salt,substitutes,may'
p71926
(F0
F0
I1
I1
I0
tp71927
sS'mean,auc,of'
p71928
(F1
F0.00014334862385321102
I1
I0
I1
tp71929
sS'distinct,from,the'
p71930
(F1
F0.00014334862385321102
I0
I1
I-1
tp71931
sS'influence,of,trileptal'
p71932
(F1
F0.00014334862385321102
I0
I1
I-1
tp71933
sS'p450,a2,and'
p71934
(F1
F0.00014334862385321102
I1
I0
I1
tp71935
sS'anti-inflammatory,drugs,the'
p71936
(F1
F0.00014334862385321102
I1
I0
I1
tp71937
sS'conversion,of,deoxy'
p71938
(F1
F0.00014334862385321102
I0
I1
I-1
tp71939
sS'these,leading,to'
p71940
(F1
F0.00014334862385321102
I1
I0
I1
tp71941
sS'clearance,a,prolongation'
p71942
(F1
F0.00014334862385321102
I1
I0
I1
tp71943
sS'combination,with,beta-adrenergic'
p71944
(F1
F0.00014334862385321102
I1
I0
I1
tp71945
sS'steady-state,cmin,concentrations'
p71946
(F1
F0.00014334862385321102
I0
I1
I-1
tp71947
sS'and,a,dose'
p71948
(F1
F0.00028669724770642203
I2
I0
I2
tp71949
sS'chop,chemotherapy,or'
p71950
(F1
F0.00014334862385321102
I0
I1
I-1
tp71951
sS'alone,and,administered'
p71952
(F1
F0.00014334862385321102
I0
I1
I-1
tp71953
sS'd,dosage,must'
p71954
(F1
F0.00043004587155963305
I3
I0
I3
tp71955
sS'increased,by,following'
p71956
(F1
F0.00014334862385321102
I1
I0
I1
tp71957
sS'and,paraclinical,pattern'
p71958
(F1
F0.00014334862385321102
I0
I1
I-1
tp71959
sS'has,previously,received'
p71960
(F1
F0.00014334862385321102
I1
I0
I1
tp71961
sS'of,qtc,prolongation'
p71962
(F1
F0.00014334862385321102
I0
I1
I-1
tp71963
sS'the,major,circulating'
p71964
(F1
F0.00014334862385321102
I0
I1
I-1
tp71965
sS'of,protein,binding'
p71966
(F1
F0.00014334862385321102
I0
I1
I-1
tp71967
sS'decrease,in,s'
p71968
(F1
F0.00014334862385321102
I1
I0
I1
tp71969
sS'against,multidrug-resistant,organisms'
p71970
(F1
F0.00014334862385321102
I0
I1
I-1
tp71971
sS'a,subsequent,to'
p71972
(F1
F0.00014334862385321102
I1
I0
I1
tp71973
sS'probenecid,as,with'
p71974
(F1
F0.00057339449541284407
I4
I0
I4
tp71975
sS'taking,tell,your'
p71976
(F1
F0.00014334862385321102
I1
I0
I1
tp71977
sS'and,hc1,concomitant'
p71978
(F1
F0.00014334862385321102
I1
I0
I1
tp71979
sS'the,decreases,in'
p71980
(F1
F0.00014334862385321102
I1
I0
I1
tp71981
sS'that,impairment,of'
p71982
(F1
F0.00014334862385321102
I0
I1
I-1
tp71983
sS'concomitant,agents,such'
p71984
(F1
F0.00014334862385321102
I0
I1
I-1
tp71985
sS'acetaminophen,a,report'
p71986
(F1
F0.00014334862385321102
I1
I0
I1
tp71987
sS'depressant,effect,when'
p71988
(F0
F0
I1
I1
I0
tp71989
sS'concomitant,medications,were'
p71990
(F1
F0.00014334862385321102
I0
I1
I-1
tp71991
sS'inhibitors,and,decreased'
p71992
(F1
F0.00014334862385321102
I1
I0
I1
tp71993
sS'in,the,oral'
p71994
(F1
F0.00014334862385321102
I1
I0
I1
tp71995
sS'on,and,transport'
p71996
(F1
F0.00014334862385321102
I0
I1
I-1
tp71997
sS'of,either,these'
p71998
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp71999
sS'have,a,dose'
p72000
(F1
F0.00014334862385321102
I1
I0
I1
tp72001
sS'days,should,elapse'
p72002
(F1
F0.00014334862385321102
I1
I0
I1
tp72003
sS'capsules,are,administered'
p72004
(F1
F0.00014334862385321102
I1
I0
I1
tp72005
sS'metabolism,of,toxic'
p72006
(F1
F0.00014334862385321102
I1
I0
I1
tp72007
sS'found,to,require'
p72008
(F1
F0.00014334862385321102
I1
I0
I1
tp72009
sS'glucose,including,hyperglycemia'
p72010
(F1
F0.00014334862385321102
I1
I0
I1
tp72011
sS'nonsmoking,healthy,white'
p72012
(F1
F0.00014334862385321102
I0
I1
I-1
tp72013
sS'or,norpace,cr'
p72014
(F1
F0.00014334862385321102
I1
I0
I1
tp72015
sS'solutions,containing,higher'
p72016
(F1
F0.00014334862385321102
I0
I1
I-1
tp72017
sS'days,and,decreased'
p72018
(F1
F0.00028669724770642203
I2
I0
I2
tp72019
sS'clinical,studies,had'
p72020
(F1
F0.00014334862385321102
I0
I1
I-1
tp72021
sS'concurrently,should,be'
p72022
(F1
F0.00014334862385321102
I1
I0
I1
tp72023
sS'renal,function,the'
p72024
(F1
F0.00014334862385321102
I1
I0
I1
tp72025
sS'of,but,there'
p72026
(F1
F0.00014334862385321102
I1
I0
I1
tp72027
sS'it,is,suggested'
p72028
(F1
F0.00071674311926605509
I5
I0
I5
tp72029
sS'benazepril,like,other'
p72030
(F1
F0.00014334862385321102
I1
I0
I1
tp72031
sS'm,v,in'
p72032
(F1
F0.00014334862385321102
I0
I1
I-1
tp72033
sS'may,decrease,arterial'
p72034
(F1
F0.00043004587155963305
I3
I0
I3
tp72035
sS'increase,two-fold,or'
p72036
(F1
F0.00014334862385321102
I1
I0
I1
tp72037
sS'capsules,mg,tid'
p72038
(F1
F0.00014334862385321102
I0
I1
I-1
tp72039
sS'from,the,soluble'
p72040
(F1
F0.00014334862385321102
I0
I1
I-1
tp72041
sS'in,a,controlled'
p72042
(F0
F0
I1
I1
I0
tp72043
sS'basis,appears,to'
p72044
(F1
F0.00014334862385321102
I1
I0
I1
tp72045
sS'rhabdomyolysis,is,increased'
p72046
(F1
F0.00028669724770642203
I2
I0
I2
tp72047
sS'examine,the,interaction'
p72048
(F1
F0.00014334862385321102
I0
I1
I-1
tp72049
sS'defect,in,the'
p72050
(F1
F0.00014334862385321102
I0
I1
I-1
tp72051
sS'prinivil,at,a'
p72052
(F1
F0.00014334862385321102
I1
I0
I1
tp72053
sS'elspar,can,diminish'
p72054
(F1
F0.00014334862385321102
I1
I0
I1
tp72055
sS'low,affinity,binding'
p72056
(F1
F0.00014334862385321102
I0
I1
I-1
tp72057
sS'agents,was,evaluated'
p72058
(F1
F0.00014334862385321102
I0
I1
I-1
tp72059
sS'to,potential,for'
p72060
(F1
F0.00057339449541284407
I0
I4
I-4
tp72061
sS'cytochrome,cyp,p450'
p72062
(F1
F0.00014334862385321102
I0
I1
I-1
tp72063
sS'drugs,that,alter'
p72064
(F0
F0
I1
I1
I0
tp72065
sS'important,that,physicians'
p72066
(F1
F0.00014334862385321102
I0
I1
I-1
tp72067
sS'racemic,citalopram,citalopram'
p72068
(F1
F0.00014334862385321102
I1
I0
I1
tp72069
sS'concentrations,of,tcas'
p72070
(F1
F0.00057339449541284407
I0
I4
I-4
tp72071
sS'atrial,fibrillation,their'
p72072
(F1
F0.00014334862385321102
I1
I0
I1
tp72073
sS'unaffected,by,brevibloc'
p72074
(F1
F0.00014334862385321102
I1
I0
I1
tp72075
sS'problems,encountered,during'
p72076
(F1
F0.00014334862385321102
I0
I1
I-1
tp72077
sS'by,on,day'
p72078
(F1
F0.00028669724770642203
I2
I0
I2
tp72079
sS'day,in,overall'
p72080
(F1
F0.00014334862385321102
I0
I1
I-1
tp72081
sS'with,the,renal'
p72082
(F1
F0.00014334862385321102
I1
I0
I1
tp72083
sS'and,nonprescription,products'
p72084
(F1
F0.00014334862385321102
I0
I1
I-1
tp72085
sS'levels,by,the'
p72086
(F1
F0.00014334862385321102
I0
I1
I-1
tp72087
sS'no,difference,in'
p72088
(F1
F0.00028669724770642203
I0
I2
I-2
tp72089
sS'result,of,inhibition'
p72090
(F1
F0.00014334862385321102
I0
I1
I-1
tp72091
sS'of,over,indinavir-based'
p72092
(F1
F0.00014334862385321102
I0
I1
I-1
tp72093
sS'the,mean,estimates'
p72094
(F1
F0.00014334862385321102
I0
I1
I-1
tp72095
sS'therefore,patients,under'
p72096
(F1
F0.00014334862385321102
I1
I0
I1
tp72097
sS'of,unbound,to'
p72098
(F1
F0.00014334862385321102
I0
I1
I-1
tp72099
sS'results,of,an'
p72100
(F1
F0.00014334862385321102
I0
I1
I-1
tp72101
sS'increases,in,previously'
p72102
(F1
F0.00014334862385321102
I1
I0
I1
tp72103
sS'daily,taken,with'
p72104
(F1
F0.00014334862385321102
I1
I0
I1
tp72105
sS'does,not,compensate'
p72106
(F1
F0.00028669724770642203
I2
I0
I2
tp72107
sS'bleeding,shortly,after'
p72108
(F1
F0.00014334862385321102
I0
I1
I-1
tp72109
sS'the,urine,of'
p72110
(F1
F0.00028669724770642203
I0
I2
I-2
tp72111
sS'this,time,window'
p72112
(F1
F0.00014334862385321102
I1
I0
I1
tp72113
sS'elevated,plasma,concentrations'
p72114
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp72115
sS'omega-conotoxin,gvia-sensitive,n-type'
p72116
(F1
F0.00014334862385321102
I0
I1
I-1
tp72117
sS'parentheses,were,cardiac'
p72118
(F1
F0.00014334862385321102
I0
I1
I-1
tp72119
sS'vitro,studies,and'
p72120
(F1
F0.00014334862385321102
I1
I0
I1
tp72121
sS'carbamazepine,isoniazid,is'
p72122
(F1
F0.00014334862385321102
I1
I0
I1
tp72123
sS'treatment,with,sodium'
p72124
(F1
F0.00014334862385321102
I1
I0
I1
tp72125
sS'to,marked,interference'
p72126
(F1
F0.00014334862385321102
I1
I0
I1
tp72127
sS'cyp3a4,substrate,in'
p72128
(F1
F0.00028669724770642203
I0
I2
I-2
tp72129
sS'absorption,of,in'
p72130
(F1
F0.00014334862385321102
I1
I0
I1
tp72131
sS'be,at,increased'
p72132
(F1
F0.00028669724770642203
I0
I2
I-2
tp72133
sS'antagonist,was,added'
p72134
(F1
F0.00014334862385321102
I1
I0
I1
tp72135
sS'were,collected,through'
p72136
(F1
F0.00014334862385321102
I0
I1
I-1
tp72137
sS'nondepolarizing,muscle,relaxants'
p72138
(F0
F0
I1
I1
I0
tp72139
sS'the,r,and'
p72140
(F1
F0.00014334862385321102
I0
I1
I-1
tp72141
sS'interest,to,study'
p72142
(F1
F0.00014334862385321102
I0
I1
I-1
tp72143
sS'vehicle,corn,oil'
p72144
(F1
F0.00014334862385321102
I0
I1
I-1
tp72145
sS'cecectomized,rats,was'
p72146
(F1
F0.00014334862385321102
I0
I1
I-1
tp72147
sS'increased,the,frequency'
p72148
(F1
F0.00014334862385321102
I1
I0
I1
tp72149
sS'other,should,be'
p72150
(F1
F0.00043004587155963305
I3
I0
I3
tp72151
sS'had,no,measurable'
p72152
(F1
F0.00014334862385321102
I0
I1
I-1
tp72153
sS'prolonged,administration,of'
p72154
(F1
F0.00014334862385321102
I0
I1
I-1
tp72155
sS'a,greater,amount'
p72156
(F1
F0.00014334862385321102
I1
I0
I1
tp72157
sS'inhibitor,at,steady'
p72158
(F1
F0.00014334862385321102
I0
I1
I-1
tp72159
sS'excretion,of,unchanged'
p72160
(F1
F0.00014334862385321102
I0
I1
I-1
tp72161
sS'in,the,kidney'
p72162
(F1
F0.00014334862385321102
I0
I1
I-1
tp72163
sS'against,an,increased'
p72164
(F1
F0.00014334862385321102
I1
I0
I1
tp72165
sS'of,its,active'
p72166
(F1
F0.00014334862385321102
I1
I0
I1
tp72167
sS'causing,a,gritty'
p72168
(F1
F0.00014334862385321102
I1
I0
I1
tp72169
sS'hormonal,may,render'
p72170
(F1
F0.00014334862385321102
I1
I0
I1
tp72171
sS'agents,since,these'
p72172
(F1
F0.00014334862385321102
I1
I0
I1
tp72173
sS'fumarate,capsules,with'
p72174
(F1
F0.00014334862385321102
I0
I1
I-1
tp72175
sS'either,the,safety'
p72176
(F1
F0.00043004587155963305
I0
I3
I-3
tp72177
sS'be,lower,than'
p72178
(F1
F0.00014334862385321102
I0
I1
I-1
tp72179
sS'egf,ng,ml'
p72180
(F1
F0.00014334862385321102
I0
I1
I-1
tp72181
sS'be,well,controlled'
p72182
(F1
F0.00014334862385321102
I1
I0
I1
tp72183
sS'mg,of,hydrochloride'
p72184
(F1
F0.00014334862385321102
I1
I0
I1
tp72185
sS'to,possibly,increase'
p72186
(F1
F0.00014334862385321102
I1
I0
I1
tp72187
sS'and,require,that'
p72188
(F1
F0.00014334862385321102
I1
I0
I1
tp72189
sS'flu-like,effects,may'
p72190
(F1
F0.00014334862385321102
I0
I1
I-1
tp72191
sS'of,patients,were'
p72192
(F1
F0.00014334862385321102
I0
I1
I-1
tp72193
sS'be,required,to'
p72194
(F1
F0.00014334862385321102
I1
I0
I1
tp72195
sS'physiological,oral,load'
p72196
(F1
F0.00014334862385321102
I0
I1
I-1
tp72197
sS'mg,day,for'
p72198
(F0.1111111111111111
F0.00014334862385321102
I4
I5
I-1
tp72199
sS'as,v,and'
p72200
(F1
F0.00014334862385321102
I0
I1
I-1
tp72201
sS'clinical,evidence,to'
p72202
(F1
F0.00014334862385321102
I0
I1
I-1
tp72203
sS'enhanced,side,effects'
p72204
(F1
F0.00014334862385321102
I1
I0
I1
tp72205
sS'the,enhanced,secretion'
p72206
(F1
F0.00014334862385321102
I0
I1
I-1
tp72207
sS'mean,serum,slightly'
p72208
(F1
F0.00014334862385321102
I1
I0
I1
tp72209
sS'minimal,inhibitory,concentrations'
p72210
(F1
F0.00014334862385321102
I0
I1
I-1
tp72211
sS'given,plasma,concentration'
p72212
(F1
F0.00014334862385321102
I0
I1
I-1
tp72213
sS'mainly,via,the'
p72214
(F1
F0.00014334862385321102
I0
I1
I-1
tp72215
sS'discontinuation,of,either'
p72216
(F1
F0.00014334862385321102
I1
I0
I1
tp72217
sS'auc,infinity,auc'
p72218
(F1
F0.00014334862385321102
I0
I1
I-1
tp72219
sS'has,been,safely'
p72220
(F1
F0.00043004587155963305
I0
I3
I-3
tp72221
sS'profile,seen,with'
p72222
(F1
F0.00014334862385321102
I0
I1
I-1
tp72223
sS'confidence,limit,decrease'
p72224
(F1
F0.00014334862385321102
I0
I1
I-1
tp72225
sS'phenytoin,therapy,a'
p72226
(F1
F0.00014334862385321102
I1
I0
I1
tp72227
sS'and,a,simultaneous'
p72228
(F1
F0.00014334862385321102
I1
I0
I1
tp72229
sS'pharmacology,study,coadministration'
p72230
(F1
F0.00014334862385321102
I1
I0
I1
tp72231
sS'cromolyn,sodium,and'
p72232
(F1
F0.00014334862385321102
I0
I1
I-1
tp72233
sS'indicate,that,iressa'
p72234
(F1
F0.00014334862385321102
I1
I0
I1
tp72235
sS'allium,sativum,and'
p72236
(F1
F0.00014334862385321102
I1
I0
I1
tp72237
sS'to,produce,additive'
p72238
(F1
F0.00014334862385321102
I1
I0
I1
tp72239
sS'sodium,citrate,potentiate'
p72240
(F1
F0.00014334862385321102
I1
I0
I1
tp72241
sS'therapy,the,patients'
p72242
(F1
F0.00014334862385321102
I1
I0
I1
tp72243
sS'in,some,instances'
p72244
(F1
F0.00028669724770642203
I2
I0
I2
tp72245
sS'of,heparinized,patients'
p72246
(F1
F0.00014334862385321102
I1
I0
I1
tp72247
sS'a,patient,with'
p72248
(F1
F0.00028669724770642203
I2
I0
I2
tp72249
sS'daily,treatment,with'
p72250
(F1
F0.00014334862385321102
I0
I1
I-1
tp72251
sS'contortrostatin-induced,phosphorylation,of'
p72252
(F1
F0.00014334862385321102
I1
I0
I1
tp72253
sS'as,well,concurrent'
p72254
(F1
F0.00014334862385321102
I1
I0
I1
tp72255
sS'approximately,when,taking'
p72256
(F1
F0.00014334862385321102
I1
I0
I1
tp72257
sS'duration,of,the'
p72258
(F1
F0.00014334862385321102
I0
I1
I-1
tp72259
sS'of,erythrocyte,acetylcholinesterase'
p72260
(F1
F0.00014334862385321102
I1
I0
I1
tp72261
sS'to,rats,in'
p72262
(F1
F0.00014334862385321102
I0
I1
I-1
tp72263
sS'is,an,important'
p72264
(F1
F0.00028669724770642203
I2
I0
I2
tp72265
sS'in,mediating,stimulus-induced'
p72266
(F1
F0.00014334862385321102
I0
I1
I-1
tp72267
sS'data,demonstrate,that'
p72268
(F1
F0.00014334862385321102
I0
I1
I-1
tp72269
sS'administration,of,the'
p72270
(F0
F0
I2
I2
I0
tp72271
sS'agents,with,and'
p72272
(F1
F0.00014334862385321102
I1
I0
I1
tp72273
sS'of,and,increase'
p72274
(F0
F0
I1
I1
I0
tp72275
sS'isoenzyme,system,fentanyl'
p72276
(F1
F0.00014334862385321102
I0
I1
I-1
tp72277
sS'mixing,of,with'
p72278
(F1
F0.00014334862385321102
I1
I0
I1
tp72279
sS'auc,hrs,of'
p72280
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp72281
sS'probably,has,an'
p72282
(F1
F0.00014334862385321102
I0
I1
I-1
tp72283
sS'from,concomitant,use'
p72284
(F1
F0.00014334862385321102
I0
I1
I-1
tp72285
sS'and,like,mc'
p72286
(F1
F0.00014334862385321102
I0
I1
I-1
tp72287
sS'of,between,the'
p72288
(F1
F0.00014334862385321102
I0
I1
I-1
tp72289
sS'drugs,aliskiren,does'
p72290
(F1
F0.00014334862385321102
I0
I1
I-1
tp72291
sS'diagnosed,subjects,with'
p72292
(F1
F0.00014334862385321102
I0
I1
I-1
tp72293
sS'enablex,should,not'
p72294
(F1
F0.00014334862385321102
I1
I0
I1
tp72295
sS'in,prothrombin,measures'
p72296
(F1
F0.00014334862385321102
I0
I1
I-1
tp72297
sS'of,on,and'
p72298
(F1
F0.00014334862385321102
I0
I1
I-1
tp72299
sS'advil,nuprin,others'
p72300
(F1
F0.00014334862385321102
I0
I1
I-1
tp72301
sS'and,nonsteroidal,were'
p72302
(F1
F0.00028669724770642203
I0
I2
I-2
tp72303
sS'the,phosphohydrolase,from'
p72304
(F1
F0.00014334862385321102
I0
I1
I-1
tp72305
sS'gi,tract,to'
p72306
(F1
F0.00014334862385321102
I1
I0
I1
tp72307
sS'spontaneous,motility,in'
p72308
(F1
F0.00014334862385321102
I1
I0
I1
tp72309
sS'doses,of,ergotamine-containing'
p72310
(F1
F0.00014334862385321102
I1
I0
I1
tp72311
sS'phosphohydrolase,from,the'
p72312
(F1
F0.00014334862385321102
I0
I1
I-1
tp72313
sS'seizure,threshold,should'
p72314
(F1
F0.00014334862385321102
I1
I0
I1
tp72315
sS'of,in,plasma'
p72316
(F1
F0.00014334862385321102
I1
I0
I1
tp72317
sS'mg,daily,of'
p72318
(F1
F0.00014334862385321102
I1
I0
I1
tp72319
sS'im,once,weekly'
p72320
(F0
F0
I1
I1
I0
tp72321
sS'lipolytic,activity,and'
p72322
(F1
F0.00014334862385321102
I1
I0
I1
tp72323
sS'the,th,generation'
p72324
(F1
F0.00014334862385321102
I0
I1
I-1
tp72325
sS'study,was,to'
p72326
(F1
F0.00043004587155963305
I0
I3
I-3
tp72327
sS'methadone,maintained,patients'
p72328
(F1
F0.00014334862385321102
I1
I0
I1
tp72329
sS'is,markedly,decreased'
p72330
(F1
F0.00014334862385321102
I1
I0
I1
tp72331
sS'concomitantly,with,citrate'
p72332
(F1
F0.00014334862385321102
I1
I0
I1
tp72333
sS'randomized,crossover,study'
p72334
(F1
F0.00014334862385321102
I0
I1
I-1
tp72335
sS'another,class,antimicrobial'
p72336
(F1
F0.00014334862385321102
I1
I0
I1
tp72337
sS'reduced,by,approximately'
p72338
(F1
F0.00057339449541284407
I4
I0
I4
tp72339
sS'with,orencia,and'
p72340
(F1
F0.00014334862385321102
I1
I0
I1
tp72341
sS'anticholinesterases,concomitant,use'
p72342
(F1
F0.00014334862385321102
I1
I0
I1
tp72343
sS'using,an,experimental'
p72344
(F1
F0.00014334862385321102
I1
I0
I1
tp72345
sS'a,complication,of'
p72346
(F1
F0.00014334862385321102
I0
I1
I-1
tp72347
sS'give,a,false-positive'
p72348
(F1
F0.00014334862385321102
I0
I1
I-1
tp72349
sS'day,on,days'
p72350
(F0
F0
I2
I2
I0
tp72351
sS'the,absorption,site'
p72352
(F1
F0.00014334862385321102
I0
I1
I-1
tp72353
sS'been,used,concomitantly'
p72354
(F0.42857142857142855
F0.00043004587155963305
I2
I5
I-3
tp72355
sS'mg,kg,days'
p72356
(F1
F0.00014334862385321102
I0
I1
I-1
tp72357
sS'drugs,in,healthy'
p72358
(F1
F0.00014334862385321102
I0
I1
I-1
tp72359
sS'an,solution,dried'
p72360
(F1
F0.00014334862385321102
I0
I1
I-1
tp72361
sS'inhibitors,may,increase'
p72362
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp72363
sS'for,use,in'
p72364
(F1
F0.00014334862385321102
I1
I0
I1
tp72365
sS'of,botox,and'
p72366
(F1
F0.00014334862385321102
I1
I0
I1
tp72367
sS'in,vitro,studies'
p72368
(F0.20000000000000001
F0.00071674311926605509
I10
I15
I-5
tp72369
sS'potentially,serious,cardiovascular'
p72370
(F1
F0.00014334862385321102
I1
I0
I1
tp72371
sS'of,candesartan,cilexetil'
p72372
(F1
F0.00014334862385321102
I0
I1
I-1
tp72373
sS'patients,the,administration'
p72374
(F1
F0.00071674311926605509
I5
I0
I5
tp72375
sS'are,potent,inhibitors'
p72376
(F1
F0.00014334862385321102
I1
I0
I1
tp72377
sS'rats,did,not'
p72378
(F1
F0.00028669724770642203
I0
I2
I-2
tp72379
sS'course,of,treatment'
p72380
(F0
F0
I1
I1
I0
tp72381
sS'that,acute,dosing'
p72382
(F1
F0.00014334862385321102
I0
I1
I-1
tp72383
sS'dosage,should,be'
p72384
(F0.5
F0.00028669724770642203
I3
I1
I2
tp72385
sS'day,and,decreased'
p72386
(F1
F0.00014334862385321102
I1
I0
I1
tp72387
sS'if,concomitant,treatment'
p72388
(F1
F0.00057339449541284407
I4
I0
I4
tp72389
sS'determination,of,the'
p72390
(F1
F0.00028669724770642203
I0
I2
I-2
tp72391
sS'inhibitors,administered,alone'
p72392
(F1
F0.00014334862385321102
I1
I0
I1
tp72393
sS'safely,with,such'
p72394
(F1
F0.00014334862385321102
I0
I1
I-1
tp72395
sS'preparations,produced,by'
p72396
(F1
F0.00014334862385321102
I0
I1
I-1
tp72397
sS'are,also,being'
p72398
(F1
F0.00014334862385321102
I1
I0
I1
tp72399
sS'on,the,disposition'
p72400
(F1
F0.00014334862385321102
I0
I1
I-1
tp72401
sS'added,were,noted'
p72402
(F1
F0.00014334862385321102
I1
I0
I1
tp72403
sS'were,conducted,on'
p72404
(F1
F0.00014334862385321102
I0
I1
I-1
tp72405
sS'of,ponstel,and'
p72406
(F1
F0.00014334862385321102
I1
I0
I1
tp72407
sS'and,or,carbidopa-levodopa'
p72408
(F1
F0.00014334862385321102
I0
I1
I-1
tp72409
sS'agonist,antagonist,opioid'
p72410
(F1
F0.00014334862385321102
I1
I0
I1
tp72411
sS'to,result,in'
p72412
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp72413
sS'with,antifungal,agents'
p72414
(F1
F0.00014334862385321102
I0
I1
I-1
tp72415
sS'unless,clinically,necessary'
p72416
(F1
F0.00014334862385321102
I1
I0
I1
tp72417
sS'cure,and,the'
p72418
(F1
F0.00014334862385321102
I1
I0
I1
tp72419
sS'may,be,safely'
p72420
(F1
F0.00028669724770642203
I0
I2
I-2
tp72421
sS'is,eliminated,from'
p72422
(F1
F0.00014334862385321102
I1
I0
I1
tp72423
sS'are,given,the'
p72424
(F1
F0.00014334862385321102
I0
I1
I-1
tp72425
sS'symptoms,of,aggression'
p72426
(F1
F0.00014334862385321102
I0
I1
I-1
tp72427
sS'of,hepatic,cyp'
p72428
(F1
F0.00014334862385321102
I0
I1
I-1
tp72429
sS'the,day,regimen'
p72430
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp72431
sS'and,higher,doses'
p72432
(F1
F0.00014334862385321102
I1
I0
I1
tp72433
sS'binding,and,increased'
p72434
(F1
F0.00014334862385321102
I1
I0
I1
tp72435
sS'following,the,use'
p72436
(F1
F0.00014334862385321102
I1
I0
I1
tp72437
sS'tablet,was,administered'
p72438
(F1
F0.00014334862385321102
I1
I0
I1
tp72439
sS'prevent,symptoms,of'
p72440
(F1
F0.00014334862385321102
I1
I0
I1
tp72441
sS'mean,fold,increase'
p72442
(F1
F0.00014334862385321102
I1
I0
I1
tp72443
sS'norfloxacin,in,the'
p72444
(F1
F0.00014334862385321102
I1
I0
I1
tp72445
sS'agranulocytosis,as,seen'
p72446
(F1
F0.00014334862385321102
I0
I1
I-1
tp72447
sS'subjects,received,concomitant'
p72448
(F1
F0.00028669724770642203
I0
I2
I-2
tp72449
sS'personality,characteristics,in'
p72450
(F1
F0.00014334862385321102
I0
I1
I-1
tp72451
sS'containing,either,or'
p72452
(F1
F0.00014334862385321102
I0
I1
I-1
tp72453
sS'glucose,levels,or'
p72454
(F0
F0
I1
I1
I0
tp72455
sS'to,release,from'
p72456
(F1
F0.00014334862385321102
I1
I0
I1
tp72457
sS'or,the,simultaneous'
p72458
(F1
F0.00014334862385321102
I0
I1
I-1
tp72459
sS'penthrane,has,been'
p72460
(F1
F0.00014334862385321102
I1
I0
I1
tp72461
sS'furosemide,clinical,studies'
p72462
(F1
F0.00071674311926605509
I5
I0
I5
tp72463
sS'produced,a,fold'
p72464
(F1
F0.00028669724770642203
I2
I0
I2
tp72465
sS'mcg,per,day'
p72466
(F1
F0.00014334862385321102
I0
I1
I-1
tp72467
sS'albumin,binding,sites'
p72468
(F1
F0.00014334862385321102
I1
I0
I1
tp72469
sS'with,severe,short'
p72470
(F1
F0.00014334862385321102
I1
I0
I1
tp72471
sS'toxicity,in,a'
p72472
(F1
F0.00014334862385321102
I1
I0
I1
tp72473
sS'depressive,symptoms,but'
p72474
(F1
F0.00014334862385321102
I0
I1
I-1
tp72475
sS'cell,permeability,of'
p72476
(F1
F0.00014334862385321102
I0
I1
I-1
tp72477
sS'the,gastrointestinal,tract'
p72478
(F1
F0.00028669724770642203
I2
I0
I2
tp72479
sS'study,conducted,in'
p72480
(F0
F0
I1
I1
I0
tp72481
sS'found,between,the'
p72482
(F1
F0.00014334862385321102
I0
I1
I-1
tp72483
sS'outweigh,the,increased'
p72484
(F1
F0.00014334862385321102
I1
I0
I1
tp72485
sS'blood,glucose,levels'
p72486
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp72487
sS'some,molecular,mechanisms'
p72488
(F1
F0.00014334862385321102
I0
I1
I-1
tp72489
sS'determinant,of,bioavailability'
p72490
(F1
F0.00028669724770642203
I2
I0
I2
tp72491
sS'elimination,and,increasing'
p72492
(F1
F0.00028669724770642203
I2
I0
I2
tp72493
sS'with,enzyme,based'
p72494
(F1
F0.00014334862385321102
I0
I1
I-1
tp72495
sS'h,did,not'
p72496
(F1
F0.00014334862385321102
I0
I1
I-1
tp72497
sS'no,formal,interaction'
p72498
(F1
F0.00028669724770642203
I0
I2
I-2
tp72499
sS'in,serum,clearance'
p72500
(F1
F0.00014334862385321102
I1
I0
I1
tp72501
sS'there,is,limited'
p72502
(F1
F0.00014334862385321102
I0
I1
I-1
tp72503
sS'sustained,increases,in'
p72504
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp72505
sS'also,been,observed'
p72506
(F1
F0.00014334862385321102
I0
I1
I-1
tp72507
sS'discontinued,at,least'
p72508
(F1
F0.00014334862385321102
I1
I0
I1
tp72509
sS'amount,of,required'
p72510
(F1
F0.00014334862385321102
I1
I0
I1
tp72511
sS'occurs,with,ganglionic'
p72512
(F1
F0.00014334862385321102
I0
I1
I-1
tp72513
sS'cyp3a4,inhibitors,result'
p72514
(F1
F0.00014334862385321102
I1
I0
I1
tp72515
sS'received,angiomax,in'
p72516
(F1
F0.00014334862385321102
I0
I1
I-1
tp72517
sS'patients,on,a'
p72518
(F1
F0.00014334862385321102
I1
I0
I1
tp72519
sS'cimetidine,does,not'
p72520
(F1
F0.00014334862385321102
I0
I1
I-1
tp72521
sS'patients,with,altered'
p72522
(F1
F0.00014334862385321102
I0
I1
I-1
tp72523
sS'of,difluoroacetone,mg'
p72524
(F1
F0.00014334862385321102
I0
I1
I-1
tp72525
sS'regimen,i,and'
p72526
(F1
F0.00014334862385321102
I0
I1
I-1
tp72527
sS'of,ewes,with'
p72528
(F1
F0.00014334862385321102
I1
I0
I1
tp72529
sS'for,a,nondrug'
p72530
(F1
F0.00014334862385321102
I0
I1
I-1
tp72531
sS'occur,physicians,should'
p72532
(F1
F0.00014334862385321102
I1
I0
I1
tp72533
sS'naproxen,coadministration,n'
p72534
(F1
F0.00014334862385321102
I1
I0
I1
tp72535
sS'not,inhibitory,towards'
p72536
(F1
F0.00014334862385321102
I0
I1
I-1
tp72537
sS'which,induce,cytochrome'
p72538
(F1
F0.00014334862385321102
I1
I0
I1
tp72539
sS'is,one,reported'
p72540
(F1
F0.00014334862385321102
I1
I0
I1
tp72541
sS'that,may,react'
p72542
(F1
F0.00014334862385321102
I1
I0
I1
tp72543
sS'induction,of,cytochrome'
p72544
(F1
F0.00014334862385321102
I0
I1
I-1
tp72545
sS'reported,itraconazole,co-administration'
p72546
(F1
F0.00014334862385321102
I0
I1
I-1
tp72547
sS'with,was,found'
p72548
(F1
F0.00014334862385321102
I1
I0
I1
tp72549
sS'thus,patients,receiving'
p72550
(F1
F0.00014334862385321102
I1
I0
I1
tp72551
sS'blockers,may,exacerbate'
p72552
(F1
F0.00028669724770642203
I2
I0
I2
tp72553
sS'oral,nicotinic,acid'
p72554
(F1
F0.00057339449541284407
I0
I4
I-4
tp72555
sS'serial,use,of'
p72556
(F1
F0.00014334862385321102
I0
I1
I-1
tp72557
sS'albendazole,sulfoxide,concentrations'
p72558
(F1
F0.00014334862385321102
I1
I0
I1
tp72559
sS'of,a,strong'
p72560
(F1
F0.00043004587155963305
I3
I0
I3
tp72561
sS'increased,total,circulating'
p72562
(F1
F0.00028669724770642203
I0
I2
I-2
tp72563
sS'appear,to,have'
p72564
(F1
F0.00014334862385321102
I0
I1
I-1
tp72565
sS'in,adverse,reactions'
p72566
(F1
F0.00014334862385321102
I0
I1
I-1
tp72567
sS'of,or,similar'
p72568
(F1
F0.00014334862385321102
I1
I0
I1
tp72569
sS'the,reduced,absorption'
p72570
(F1
F0.00014334862385321102
I0
I1
I-1
tp72571
sS'labeling,index,of'
p72572
(F1
F0.00014334862385321102
I0
I1
I-1
tp72573
sS'when,therapeutic,concentrations'
p72574
(F1
F0.00014334862385321102
I0
I1
I-1
tp72575
sS'enzymes,primarily,cyp3a4'
p72576
(F1
F0.00014334862385321102
I0
I1
I-1
tp72577
sS'some,of,agents'
p72578
(F1
F0.00014334862385321102
I0
I1
I-1
tp72579
sS'titrated,to,achieve'
p72580
(F1
F0.00014334862385321102
I0
I1
I-1
tp72581
sS'maximal,plasma,concentrations'
p72582
(F1
F0.00028669724770642203
I2
I0
I2
tp72583
sS'extrapyramidal,symptoms,leukocytosis'
p72584
(F1
F0.00014334862385321102
I1
I0
I1
tp72585
sS'reports,describe,modest'
p72586
(F1
F0.00014334862385321102
I1
I0
I1
tp72587
sS'prolong,adverse,effects'
p72588
(F1
F0.00014334862385321102
I1
I0
I1
tp72589
sS'inhibit,alfenta,clearance'
p72590
(F1
F0.00014334862385321102
I1
I0
I1
tp72591
sS'as,are,likely'
p72592
(F1
F0.00014334862385321102
I1
I0
I1
tp72593
sS'in,the,release'
p72594
(F1
F0.00014334862385321102
I0
I1
I-1
tp72595
sS'healthy,volunteers,of'
p72596
(F1
F0.00014334862385321102
I1
I0
I1
tp72597
sS'that,can,be'
p72598
(F1
F0.00014334862385321102
I1
I0
I1
tp72599
sS'patients,exposed,to'
p72600
(F1
F0.00014334862385321102
I1
I0
I1
tp72601
sS'clearance,or,with'
p72602
(F1
F0.00014334862385321102
I1
I0
I1
tp72603
sS'no,differences,in'
p72604
(F1
F0.00014334862385321102
I0
I1
I-1
tp72605
sS'use,of,revia'
p72606
(F1
F0.00014334862385321102
I1
I0
I1
tp72607
sS'max,of,was'
p72608
(F1
F0.00014334862385321102
I1
I0
I1
tp72609
sS'healthy,volunteers,or'
p72610
(F1
F0.00014334862385321102
I0
I1
I-1
tp72611
sS'half-life,of,decreased'
p72612
(F1
F0.00014334862385321102
I1
I0
I1
tp72613
sS'may,cause,severe'
p72614
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp72615
sS'pharmacokinetics,have,not'
p72616
(F1
F0.00014334862385321102
I0
I1
I-1
tp72617
sS'patients,who,switched'
p72618
(F1
F0.00014334862385321102
I0
I1
I-1
tp72619
sS'on,aliskiren,based'
p72620
(F1
F0.00014334862385321102
I0
I1
I-1
tp72621
sS'changes,in,clotting'
p72622
(F1
F0.00014334862385321102
I0
I1
I-1
tp72623
sS'because,may,interfere'
p72624
(F1
F0.00014334862385321102
I1
I0
I1
tp72625
sS'cause,a,false'
p72626
(F1
F0.00014334862385321102
I0
I1
I-1
tp72627
sS'of,clearance,or'
p72628
(F1
F0.00014334862385321102
I1
I0
I1
tp72629
sS'ergot,alkaloids,is'
p72630
(F1
F0.00014334862385321102
I1
I0
I1
tp72631
sS'response,was,not'
p72632
(F1
F0.00014334862385321102
I0
I1
I-1
tp72633
sS'with,invirase,and'
p72634
(F1
F0.00014334862385321102
I0
I1
I-1
tp72635
sS'in,levels,to'
p72636
(F1
F0.00014334862385321102
I1
I0
I1
tp72637
sS'in,a,fold'
p72638
(F1
F0.00057339449541284407
I4
I0
I4
tp72639
sS'ratios,confidence,interval'
p72640
(F1
F0.00014334862385321102
I0
I1
I-1
tp72641
sS'on,the,nursing'
p72642
(F1
F0.00014334862385321102
I0
I1
I-1
tp72643
sS'of,corneal,lesions'
p72644
(F1
F0.00014334862385321102
I1
I0
I1
tp72645
sS'coadministered,with,tikosyn'
p72646
(F1
F0.00014334862385321102
I1
I0
I1
tp72647
sS'be,unlikely,that'
p72648
(F1
F0.00014334862385321102
I0
I1
I-1
tp72649
sS'of,the,long'
p72650
(F1
F0.00014334862385321102
I0
I1
I-1
tp72651
sS'its,metabolites,oxo-desethylzaleplon'
p72652
(F1
F0.00014334862385321102
I0
I1
I-1
tp72653
sS'increases,extracellular,levels'
p72654
(F1
F0.00014334862385321102
I0
I1
I-1
tp72655
sS'urate,are,also'
p72656
(F1
F0.00014334862385321102
I1
I0
I1
tp72657
sS'day,groups,pd2'
p72658
(F1
F0.00014334862385321102
I1
I0
I1
tp72659
sS'olanzapine,a,thienobenzodiazepine'
p72660
(F1
F0.00014334862385321102
I0
I1
I-1
tp72661
sS'been,demonstrated,to'
p72662
(F1
F0.00014334862385321102
I1
I0
I1
tp72663
sS'altering,activity,in'
p72664
(F1
F0.00014334862385321102
I0
I1
I-1
tp72665
sS'p,o,induced'
p72666
(F1
F0.00014334862385321102
I1
I0
I1
tp72667
sS'observed,in,nephrosis'
p72668
(F1
F0.00014334862385321102
I0
I1
I-1
tp72669
sS'variety,of,infections'
p72670
(F1
F0.00014334862385321102
I0
I1
I-1
tp72671
sS'clinical,evidence,in'
p72672
(F1
F0.00014334862385321102
I0
I1
I-1
tp72673
sS'cure,and,to'
p72674
(F1
F0.00014334862385321102
I0
I1
I-1
tp72675
sS'be,required,with'
p72676
(F1
F0.00014334862385321102
I0
I1
I-1
tp72677
sS'risk,of,toxic'
p72678
(F1
F0.00014334862385321102
I0
I1
I-1
tp72679
sS'not,produce,any'
p72680
(F1
F0.00014334862385321102
I0
I1
I-1
tp72681
sS'did,not,alter'
p72682
(F1
F0.0022935779816513763
I0
I16
I-16
tp72683
sS'aerosol,of,the'
p72684
(F1
F0.00014334862385321102
I0
I1
I-1
tp72685
sS'and,therefore,such'
p72686
(F1
F0.00014334862385321102
I1
I0
I1
tp72687
sS'of,microsomal,drug'
p72688
(F1
F0.00014334862385321102
I1
I0
I1
tp72689
sS'some,individuals,receiving'
p72690
(F1
F0.00014334862385321102
I1
I0
I1
tp72691
sS'blood,glucose,when'
p72692
(F1
F0.00014334862385321102
I0
I1
I-1
tp72693
sS'as,the,interaction'
p72694
(F1
F0.00014334862385321102
I0
I1
I-1
tp72695
sS'which,were,considered'
p72696
(F1
F0.00014334862385321102
I1
I0
I1
tp72697
sS'chronically,had,no'
p72698
(F0
F0
I1
I1
I0
tp72699
sS'not,change,fasting'
p72700
(F1
F0.00014334862385321102
I0
I1
I-1
tp72701
sS'directly,on,the'
p72702
(F1
F0.00014334862385321102
I1
I0
I1
tp72703
sS'and,terminal,half-life'
p72704
(F1
F0.00014334862385321102
I1
I0
I1
tp72705
sS'organisms,and,oral'
p72706
(F1
F0.00014334862385321102
I0
I1
I-1
tp72707
sS'an,unsatisfactory,lipid'
p72708
(F1
F0.00014334862385321102
I1
I0
I1
tp72709
sS'adl,prevents,morphine-induced'
p72710
(F1
F0.00014334862385321102
I1
I0
I1
tp72711
sS'placebo,coadministered,with'
p72712
(F1
F0.00014334862385321102
I0
I1
I-1
tp72713
sS'produced,mean,additional'
p72714
(F1
F0.00014334862385321102
I1
I0
I1
tp72715
sS'and,concomitantly,may'
p72716
(F1
F0.00028669724770642203
I2
I0
I2
tp72717
sS'from,concomitant,therapy'
p72718
(F1
F0.00014334862385321102
I1
I0
I1
tp72719
sS'although,overall,exposure'
p72720
(F1
F0.00014334862385321102
I1
I0
I1
tp72721
sS'day,proved,to'
p72722
(F1
F0.00014334862385321102
I0
I1
I-1
tp72723
sS'clinical,trials,no'
p72724
(F1
F0.00014334862385321102
I0
I1
I-1
tp72725
sS'hypertensive,response,seen'
p72726
(F1
F0.00014334862385321102
I1
I0
I1
tp72727
sS'the,seminiferous,tubules'
p72728
(F1
F0.00014334862385321102
I0
I1
I-1
tp72729
sS'lodine,should,not'
p72730
(F1
F0.00014334862385321102
I0
I1
I-1
tp72731
sS'medication,must,be'
p72732
(F1
F0.00014334862385321102
I1
I0
I1
tp72733
sS'prior,to,dosing'
p72734
(F1
F0.00028669724770642203
I2
I0
I2
tp72735
sS'the,usual,daily'
p72736
(F1
F0.00014334862385321102
I1
I0
I1
tp72737
sS'coexisting,in,the'
p72738
(F1
F0.00014334862385321102
I0
I1
I-1
tp72739
sS'for,binding,sites'
p72740
(F1
F0.00014334862385321102
I1
I0
I1
tp72741
sS'assessment,of,in'
p72742
(F1
F0.00014334862385321102
I0
I1
I-1
tp72743
sS'usp,or,initiating'
p72744
(F1
F0.00014334862385321102
I1
I0
I1
tp72745
sS'were,equivocally,higher'
p72746
(F1
F0.00014334862385321102
I1
I0
I1
tp72747
sS'not,primarily,metabolized'
p72748
(F1
F0.00014334862385321102
I1
I0
I1
tp72749
sS'medications,agents,such'
p72750
(F1
F0.00014334862385321102
I0
I1
I-1
tp72751
sS'genes,iegs,are'
p72752
(F1
F0.00014334862385321102
I0
I1
I-1
tp72753
sS'of,there,are'
p72754
(F1
F0.00014334862385321102
I0
I1
I-1
tp72755
sS'of,q12h,for'
p72756
(F1
F0.00014334862385321102
I1
I0
I1
tp72757
sS'of,loop,potassium-'
p72758
(F1
F0.00014334862385321102
I1
I0
I1
tp72759
sS'source,or,preparations'
p72760
(F1
F0.00014334862385321102
I0
I1
I-1
tp72761
sS'the,corrected,qt'
p72762
(F1
F0.00014334862385321102
I0
I1
I-1
tp72763
sS'responding,for,a'
p72764
(F1
F0.00014334862385321102
I0
I1
I-1
tp72765
sS'be,reduced,if'
p72766
(F1
F0.00014334862385321102
I1
I0
I1
tp72767
sS'as,and,inhibit'
p72768
(F1
F0.00014334862385321102
I0
I1
I-1
tp72769
sS'of,were,also'
p72770
(F1
F0.00014334862385321102
I0
I1
I-1
tp72771
sS'are,applying,panretin'
p72772
(F1
F0.00014334862385321102
I1
I0
I1
tp72773
sS'oral,dose,of'
p72774
(F0
F0
I2
I2
I0
tp72775
sS'hormonal,ortho-novum,produced'
p72776
(F1
F0.00014334862385321102
I1
I0
I1
tp72777
sS'assessments,of,pt'
p72778
(F1
F0.00014334862385321102
I0
I1
I-1
tp72779
sS'produced,by,any'
p72780
(F1
F0.00014334862385321102
I1
I0
I1
tp72781
sS'metformin,in,a'
p72782
(F1
F0.00014334862385321102
I0
I1
I-1
tp72783
sS'resulting,in,an'
p72784
(F1
F0.00043004587155963305
I3
I0
I3
tp72785
sS'are,reduced,by'
p72786
(F1
F0.00014334862385321102
I1
I0
I1
tp72787
sS'cmax,when,a'
p72788
(F1
F0.00014334862385321102
I1
I0
I1
tp72789
sS'be,closely,observed'
p72790
(F0
F0
I1
I1
I0
tp72791
sS'later,also,produces'
p72792
(F1
F0.00014334862385321102
I1
I0
I1
tp72793
sS'of,non-steroidal,concomitantly'
p72794
(F1
F0.00014334862385321102
I1
I0
I1
tp72795
sS'can,be,safely'
p72796
(F1
F0.00014334862385321102
I0
I1
I-1
tp72797
sS'prostaglandin,synthetase,inhibitors'
p72798
(F1
F0.00014334862385321102
I0
I1
I-1
tp72799
sS'or,other,potent'
p72800
(F1
F0.00014334862385321102
I1
I0
I1
tp72801
sS'in,lipid,levels'
p72802
(F1
F0.00014334862385321102
I1
I0
I1
tp72803
sS'transplant,patients,suffering'
p72804
(F1
F0.00014334862385321102
I1
I0
I1
tp72805
sS'a,mg,vardenafil'
p72806
(F1
F0.00014334862385321102
I1
I0
I1
tp72807
sS'steady-state,pharmacokinetics,of'
p72808
(F1
F0.00057339449541284407
I0
I4
I-4
tp72809
sS'added,to,their'
p72810
(F1
F0.00014334862385321102
I0
I1
I-1
tp72811
sS'that,alter,gastrointestinal'
p72812
(F1
F0.00014334862385321102
I1
I0
I1
tp72813
sS'the,potential,danger'
p72814
(F1
F0.00014334862385321102
I1
I0
I1
tp72815
sS'tolerated,but,available'
p72816
(F1
F0.00014334862385321102
I0
I1
I-1
tp72817
sS'or,without,other'
p72818
(F1
F0.00043004587155963305
I3
I0
I3
tp72819
sS'a,blockade,by'
p72820
(F1
F0.00014334862385321102
I1
I0
I1
tp72821
sS'dependence,on,application'
p72822
(F1
F0.00014334862385321102
I0
I1
I-1
tp72823
sS'of,sustained-release,calan'
p72824
(F1
F0.00014334862385321102
I1
I0
I1
tp72825
sS'magnesium-aluminum,hydroxide,cerivastatin'
p72826
(F1
F0.00014334862385321102
I0
I1
I-1
tp72827
sS'of,the,experiment'
p72828
(F1
F0.00014334862385321102
I0
I1
I-1
tp72829
sS'and,ergot-type,oxytocic'
p72830
(F0
F0
I1
I1
I0
tp72831
sS'activity,of,by'
p72832
(F1
F0.00014334862385321102
I1
I0
I1
tp72833
sS'taking,the,effect'
p72834
(F1
F0.00014334862385321102
I1
I0
I1
tp72835
sS'to,form,or'
p72836
(F1
F0.00014334862385321102
I1
I0
I1
tp72837
sS'on,the,anti-platelet'
p72838
(F1
F0.00014334862385321102
I0
I1
I-1
tp72839
sS'shown,to,elevate'
p72840
(F1
F0.00014334862385321102
I1
I0
I1
tp72841
sS'suggesting,that,coadministration'
p72842
(F1
F0.00014334862385321102
I0
I1
I-1
tp72843
sS'than,suggest,a'
p72844
(F1
F0.00028669724770642203
I2
I0
I2
tp72845
sS'abilify,is,taken'
p72846
(F1
F0.00014334862385321102
I1
I0
I1
tp72847
sS'complex,anions,antithyroid'
p72848
(F1
F0.00014334862385321102
I0
I1
I-1
tp72849
sS'with,formulations,containing'
p72850
(F1
F0.00014334862385321102
I1
I0
I1
tp72851
sS'ml,when,mg'
p72852
(F1
F0.00014334862385321102
I1
I0
I1
tp72853
sS'for,a,change'
p72854
(F1
F0.00014334862385321102
I1
I0
I1
tp72855
sS'caused,by,increased'
p72856
(F1
F0.00014334862385321102
I1
I0
I1
tp72857
sS'medical,practice,dictates'
p72858
(F1
F0.00014334862385321102
I1
I0
I1
tp72859
sS'combination,with,or'
p72860
(F1
F0.00028669724770642203
I0
I2
I-2
tp72861
sS'erythromycin,use,in'
p72862
(F1
F0.00014334862385321102
I1
I0
I1
tp72863
sS'significantly,reduced,the'
p72864
(F1
F0.00028669724770642203
I2
I0
I2
tp72865
sS'the,exposure,of'
p72866
(F0
F0
I1
I1
I0
tp72867
sS'concluded,that,although'
p72868
(F1
F0.00014334862385321102
I1
I0
I1
tp72869
sS'patients,may,induce'
p72870
(F1
F0.00014334862385321102
I1
I0
I1
tp72871
sS'that,lower,seizure'
p72872
(F1
F0.00014334862385321102
I1
I0
I1
tp72873
sS'time,was,observed'
p72874
(F1
F0.00014334862385321102
I0
I1
I-1
tp72875
sS'main,non-infection,unwanted'
p72876
(F1
F0.00014334862385321102
I0
I1
I-1
tp72877
sS'reduced,by,and'
p72878
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp72879
sS'inhibition,of,hepatic'
p72880
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp72881
sS'on,these,data'
p72882
(F1
F0.00014334862385321102
I1
I0
I1
tp72883
sS'be,stopped,during'
p72884
(F1
F0.00014334862385321102
I1
I0
I1
tp72885
sS'muscle,to,m'
p72886
(F1
F0.00014334862385321102
I1
I0
I1
tp72887
sS'mildly,reduced,approximately'
p72888
(F1
F0.00014334862385321102
I1
I0
I1
tp72889
sS'were,subsequently,found'
p72890
(F1
F0.00014334862385321102
I0
I1
I-1
tp72891
sS'slow,phasic,contraction'
p72892
(F1
F0.00014334862385321102
I0
I1
I-1
tp72893
sS'decreased,active,metabolite'
p72894
(F1
F0.00014334862385321102
I1
I0
I1
tp72895
sS'of,ml,of'
p72896
(F1
F0.00014334862385321102
I0
I1
I-1
tp72897
sS'with,its,protein'
p72898
(F1
F0.00014334862385321102
I1
I0
I1
tp72899
sS'single,daily,oral'
p72900
(F1
F0.00014334862385321102
I0
I1
I-1
tp72901
sS'with,hours,before'
p72902
(F1
F0.00014334862385321102
I1
I0
I1
tp72903
sS'of,a,physician'
p72904
(F1
F0.00014334862385321102
I1
I0
I1
tp72905
sS'involving,even,though'
p72906
(F1
F0.00028669724770642203
I0
I2
I-2
tp72907
sS'mmol,l,from'
p72908
(F1
F0.00014334862385321102
I0
I1
I-1
tp72909
sS'oral,and,vitamin'
p72910
(F1
F0.00014334862385321102
I1
I0
I1
tp72911
sS'combination,of,or'
p72912
(F1
F0.00014334862385321102
I0
I1
I-1
tp72913
sS'values,for,and'
p72914
(F0
F0
I1
I1
I0
tp72915
sS'volunteers,suggests,that'
p72916
(F1
F0.00014334862385321102
I1
I0
I1
tp72917
sS'inducer,such,as'
p72918
(F1
F0.00014334862385321102
I0
I1
I-1
tp72919
sS'of,this,combination'
p72920
(F1
F0.00014334862385321102
I1
I0
I1
tp72921
sS'evening,meal,would'
p72922
(F1
F0.00014334862385321102
I0
I1
I-1
tp72923
sS'have,no,significant'
p72924
(F1
F0.00028669724770642203
I0
I2
I-2
tp72925
sS'mg,of,vioxx'
p72926
(F1
F0.00014334862385321102
I0
I1
I-1
tp72927
sS'can,be,carried'
p72928
(F1
F0.00014334862385321102
I0
I1
I-1
tp72929
sS'administration,of,in'
p72930
(F0
F0
I1
I1
I0
tp72931
sS'results,together,with'
p72932
(F1
F0.00014334862385321102
I0
I1
I-1
tp72933
sS'administration,of,it'
p72934
(F1
F0.00014334862385321102
I0
I1
I-1
tp72935
sS'ii,the,effects'
p72936
(F1
F0.00014334862385321102
I0
I1
I-1
tp72937
sS'among,patients,concurrently'
p72938
(F1
F0.00014334862385321102
I1
I0
I1
tp72939
sS'subjects,aged,or'
p72940
(F1
F0.00014334862385321102
I0
I1
I-1
tp72941
sS'patient,is,recommended'
p72942
(F1
F0.00028669724770642203
I2
I0
I2
tp72943
sS'influence,the,percentage'
p72944
(F1
F0.00014334862385321102
I1
I0
I1
tp72945
sS'with,since,these'
p72946
(F1
F0.00014334862385321102
I1
I0
I1
tp72947
sS'occur,in,the'
p72948
(F1
F0.00014334862385321102
I1
I0
I1
tp72949
sS'monitored,when,initiating'
p72950
(F1
F0.00043004587155963305
I3
I0
I3
tp72951
sS'of,regular,users'
p72952
(F1
F0.00014334862385321102
I0
I1
I-1
tp72953
sS'may,be,potentiated'
p72954
(F0.5
F0.0011467889908256881
I12
I4
I8
tp72955
sS'given,with,agents'
p72956
(F1
F0.00014334862385321102
I0
I1
I-1
tp72957
sS'l-histidine,via,its'
p72958
(F1
F0.00014334862385321102
I1
I0
I1
tp72959
sS'mucosal,cell,accumulation'
p72960
(F1
F0.00014334862385321102
I0
I1
I-1
tp72961
sS'the,mean,value'
p72962
(F1
F0.00014334862385321102
I0
I1
I-1
tp72963
sS'or,lead,to'
p72964
(F1
F0.00014334862385321102
I1
I0
I1
tp72965
sS'in,auc,and'
p72966
(F0.59999999999999998
F0.0008600917431192661
I8
I2
I6
tp72967
sS'that,may,induce'
p72968
(F1
F0.00014334862385321102
I1
I0
I1
tp72969
sS'hydrochloride,is,an'
p72970
(F1
F0.00014334862385321102
I0
I1
I-1
tp72971
sS'of,containing,or'
p72972
(F1
F0.00014334862385321102
I1
I0
I1
tp72973
sS'for,increased,lipid'
p72974
(F1
F0.00014334862385321102
I0
I1
I-1
tp72975
sS'geometric,mean,confidence'
p72976
(F1
F0.00014334862385321102
I1
I0
I1
tp72977
sS'received,the,recommended'
p72978
(F1
F0.00014334862385321102
I1
I0
I1
tp72979
sS'and,may,subsequently'
p72980
(F1
F0.00014334862385321102
I0
I1
I-1
tp72981
sS'hydroxide,does,not'
p72982
(F1
F0.00014334862385321102
I0
I1
I-1
tp72983
sS'those,patients,on'
p72984
(F1
F0.00014334862385321102
I1
I0
I1
tp72985
sS'of,duloxetine,with'
p72986
(F0
F0
I1
I1
I0
tp72987
sS'increased,plasma,concentration'
p72988
(F1
F0.00014334862385321102
I1
I0
I1
tp72989
sS'treated,with,pegasys'
p72990
(F1
F0.00014334862385321102
I0
I1
I-1
tp72991
sS'this,study,was'
p72992
(F1
F0.00071674311926605509
I0
I5
I-5
tp72993
sS'average,and,when'
p72994
(F1
F0.00014334862385321102
I1
I0
I1
tp72995
sS'to,induce,cyp1a2'
p72996
(F1
F0.00014334862385321102
I0
I1
I-1
tp72997
sS'cholinesterase,inhibitors,thereby'
p72998
(F1
F0.00014334862385321102
I1
I0
I1
tp72999
sS'herb,interactions,food'
p73000
(F1
F0.00014334862385321102
I1
I0
I1
tp73001
sS'tumor,cells,by'
p73002
(F1
F0.00014334862385321102
I0
I1
I-1
tp73003
sS'modest,elevations,less'
p73004
(F1
F0.00014334862385321102
I1
I0
I1
tp73005
sS'rarely,reported,due'
p73006
(F1
F0.00014334862385321102
I1
I0
I1
tp73007
sS'increased,intestinal,permeability'
p73008
(F1
F0.00014334862385321102
I1
I0
I1
tp73009
sS'stimulatory,effects,of'
p73010
(F1
F0.00028669724770642203
I2
I0
I2
tp73011
sS'these,results,confirm'
p73012
(F1
F0.00014334862385321102
I0
I1
I-1
tp73013
sS'upon,pcp,induced'
p73014
(F1
F0.00014334862385321102
I0
I1
I-1
tp73015
sS'as,motrin,advil'
p73016
(F1
F0.00014334862385321102
I0
I1
I-1
tp73017
sS'including,have,been'
p73018
(F1
F0.00014334862385321102
I1
I0
I1
tp73019
sS'antimicrobial,activity,of'
p73020
(F1
F0.00014334862385321102
I0
I1
I-1
tp73021
sS'of,crohn,s'
p73022
(F1
F0.00014334862385321102
I0
I1
I-1
tp73023
sS'this,allows,to'
p73024
(F1
F0.00014334862385321102
I1
I0
I1
tp73025
sS'shown,in,rats'
p73026
(F1
F0.00014334862385321102
I1
I0
I1
tp73027
sS'the,toxic,product'
p73028
(F1
F0.00014334862385321102
I0
I1
I-1
tp73029
sS'interact,with,amphotericin'
p73030
(F1
F0.00014334862385321102
I1
I0
I1
tp73031
sS'or,other,agents'
p73032
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp73033
sS'iv,myocardium,versus'
p73034
(F1
F0.00014334862385321102
I0
I1
I-1
tp73035
sS'also,potentiate,the'
p73036
(F1
F0.00014334862385321102
I1
I0
I1
tp73037
sS'of,the,therapeutic'
p73038
(F1
F0.00014334862385321102
I1
I0
I1
tp73039
sS'mean,values,of'
p73040
(F1
F0.00014334862385321102
I0
I1
I-1
tp73041
sS'increased,when,coadministered'
p73042
(F1
F0.00028669724770642203
I2
I0
I2
tp73043
sS'shortened,in,patients'
p73044
(F1
F0.00014334862385321102
I1
I0
I1
tp73045
sS'p450iid6,may,require'
p73046
(F1
F0.00014334862385321102
I0
I1
I-1
tp73047
sS'with,topical,glaucoma'
p73048
(F1
F0.00014334862385321102
I1
I0
I1
tp73049
sS'appears,to,have'
p73050
(F1
F0.00014334862385321102
I1
I0
I1
tp73051
sS'p450,a4,isoenzyme'
p73052
(F1
F0.00014334862385321102
I0
I1
I-1
tp73053
sS'in,situ,ligated'
p73054
(F1
F0.00014334862385321102
I0
I1
I-1
tp73055
sS'between,study,without'
p73056
(F1
F0.00014334862385321102
I0
I1
I-1
tp73057
sS'and,thus,the'
p73058
(F1
F0.00014334862385321102
I1
I0
I1
tp73059
sS'exercised,if,and'
p73060
(F1
F0.00014334862385321102
I1
I0
I1
tp73061
sS'until,therapy,is'
p73062
(F1
F0.00014334862385321102
I1
I0
I1
tp73063
sS'excretion,of,both'
p73064
(F1
F0.00014334862385321102
I1
I0
I1
tp73065
sS'in,separate,randomized'
p73066
(F1
F0.00014334862385321102
I0
I1
I-1
tp73067
sS'mg,q24h,for'
p73068
(F1
F0.00014334862385321102
I0
I1
I-1
tp73069
sS'interaction,or,should'
p73070
(F1
F0.00014334862385321102
I1
I0
I1
tp73071
sS'by,cyp3a4,substrates'
p73072
(F1
F0.00014334862385321102
I0
I1
I-1
tp73073
sS'didrex,should,not'
p73074
(F1
F0.00014334862385321102
I1
I0
I1
tp73075
sS'metabolite,may,be'
p73076
(F1
F0.00014334862385321102
I1
I0
I1
tp73077
sS'of,nanm,nanm'
p73078
(F1
F0.00014334862385321102
I0
I1
I-1
tp73079
sS'prothrombin,time,monitored'
p73080
(F1
F0.00014334862385321102
I1
I0
I1
tp73081
sS'be,determined,before'
p73082
(F1
F0.00014334862385321102
I1
I0
I1
tp73083
sS'some,cases,where'
p73084
(F1
F0.00014334862385321102
I0
I1
I-1
tp73085
sS'and,other,antiepileptic'
p73086
(F1
F0.00014334862385321102
I0
I1
I-1
tp73087
sS'on,plasma,has'
p73088
(F1
F0.00014334862385321102
I1
I0
I1
tp73089
sS'of,the,hepatic'
p73090
(F1
F0.00014334862385321102
I0
I1
I-1
tp73091
sS'to,hypertensive,patients'
p73092
(F1
F0.00014334862385321102
I0
I1
I-1
tp73093
sS'and,increased,plasma'
p73094
(F1
F0.00014334862385321102
I1
I0
I1
tp73095
sS'be,taken,into'
p73096
(F1
F0.00028669724770642203
I2
I0
I2
tp73097
sS'binding,sites,for'
p73098
(F1
F0.00028669724770642203
I0
I2
I-2
tp73099
sS'demonstrated,that,co-administration'
p73100
(F1
F0.00014334862385321102
I1
I0
I1
tp73101
sS'levels,has,been'
p73102
(F1
F0.00014334862385321102
I1
I0
I1
tp73103
sS'gi,bleeding,are'
p73104
(F1
F0.00028669724770642203
I2
I0
I2
tp73105
sS'administration,of,did'
p73106
(F1
F0.00014334862385321102
I0
I1
I-1
tp73107
sS'inspra,and,nsaids'
p73108
(F1
F0.00014334862385321102
I1
I0
I1
tp73109
sS'be,avoided,by'
p73110
(F1
F0.00014334862385321102
I1
I0
I1
tp73111
sS'increased,and,because'
p73112
(F1
F0.00014334862385321102
I1
I0
I1
tp73113
sS'responses,to,were'
p73114
(F1
F0.00014334862385321102
I0
I1
I-1
tp73115
sS'higher,than,recommended'
p73116
(F1
F0.00014334862385321102
I1
I0
I1
tp73117
sS'patch-clamp,whole-cell,recording'
p73118
(F1
F0.00014334862385321102
I0
I1
I-1
tp73119
sS'conducted,between,and'
p73120
(F1
F0.00014334862385321102
I1
I0
I1
tp73121
sS'have,shown,casodex'
p73122
(F1
F0.00014334862385321102
I1
I0
I1
tp73123
sS'blocking,agents,coadministration'
p73124
(F1
F0.00028669724770642203
I0
I2
I-2
tp73125
sS'studies,designed,to'
p73126
(F1
F0.00014334862385321102
I0
I1
I-1
tp73127
sS'affect,hepatic,microsomal'
p73128
(F1
F0.00014334862385321102
I0
I1
I-1
tp73129
sS'digitalis,glycosides,therapeutic'
p73130
(F1
F0.00014334862385321102
I0
I1
I-1
tp73131
sS'diastolic,or,systolic'
p73132
(F1
F0.00014334862385321102
I0
I1
I-1
tp73133
sS'anticholinergics,concurrent,administration'
p73134
(F1
F0.00014334862385321102
I1
I0
I1
tp73135
sS'to,provoke,convulsions'
p73136
(F1
F0.00014334862385321102
I0
I1
I-1
tp73137
sS'monitoring,for,toxicity'
p73138
(F0
F0
I1
I1
I0
tp73139
sS'iv,was,given'
p73140
(F1
F0.00014334862385321102
I0
I1
I-1
tp73141
sS'of,mevacor,in'
p73142
(F1
F0.00014334862385321102
I0
I1
I-1
tp73143
sS'to,the,resolution'
p73144
(F1
F0.00014334862385321102
I1
I0
I1
tp73145
sS'including,were,reported'
p73146
(F1
F0.00014334862385321102
I1
I0
I1
tp73147
sS'experience,of,coma'
p73148
(F1
F0.00014334862385321102
I1
I0
I1
tp73149
sS'bid,a,potent'
p73150
(F1
F0.00028669724770642203
I2
I0
I2
tp73151
sS'another,study,toradoliv'
p73152
(F1
F0.00014334862385321102
I0
I1
I-1
tp73153
sS'b,were,more'
p73154
(F1
F0.00014334862385321102
I0
I1
I-1
tp73155
sS'the,main,hemostatic'
p73156
(F1
F0.00014334862385321102
I1
I0
I1
tp73157
sS'reach,to10,m'
p73158
(F1
F0.00014334862385321102
I1
I0
I1
tp73159
sS'already,receiving,prothrombin'
p73160
(F1
F0.00014334862385321102
I1
I0
I1
tp73161
sS'cystic,fibrosis,therapies'
p73162
(F1
F0.00014334862385321102
I0
I1
I-1
tp73163
sS'wild-type,alleles,cyp2c9'
p73164
(F1
F0.00014334862385321102
I0
I1
I-1
tp73165
sS'prinivil,is,administered'
p73166
(F1
F0.00014334862385321102
I1
I0
I1
tp73167
sS'commentaries,and,editorials'
p73168
(F1
F0.00014334862385321102
I0
I1
I-1
tp73169
sS'the,specific,d1'
p73170
(F1
F0.00014334862385321102
I1
I0
I1
tp73171
sS'long,periods,of'
p73172
(F1
F0.00014334862385321102
I0
I1
I-1
tp73173
sS'dose,of,to'
p73174
(F0
F0
I1
I1
I0
tp73175
sS'pump,inhibitors,in'
p73176
(F1
F0.00014334862385321102
I1
I0
I1
tp73177
sS'conjunction,with,standard'
p73178
(F1
F0.00014334862385321102
I0
I1
I-1
tp73179
sS'decreased,the,rate'
p73180
(F1
F0.00014334862385321102
I1
I0
I1
tp73181
sS'of,deficit,i'
p73182
(F1
F0.00014334862385321102
I0
I1
I-1
tp73183
sS'possible,atrioventricular,conduction'
p73184
(F1
F0.00014334862385321102
I1
I0
I1
tp73185
sS'maintain,twitch,for'
p73186
(F1
F0.00014334862385321102
I0
I1
I-1
tp73187
sS'suggesting,that,is'
p73188
(F1
F0.00014334862385321102
I0
I1
I-1
tp73189
sS'of,liquid,did'
p73190
(F1
F0.00014334862385321102
I0
I1
I-1
tp73191
sS'however,coadministration,of'
p73192
(F1
F0.00014334862385321102
I0
I1
I-1
tp73193
sS'and,as,much'
p73194
(F1
F0.00014334862385321102
I1
I0
I1
tp73195
sS'resulting,in,adverse'
p73196
(F1
F0.00014334862385321102
I0
I1
I-1
tp73197
sS'or,less,specific'
p73198
(F1
F0.00014334862385321102
I0
I1
I-1
tp73199
sS'totally,atoxic,since'
p73200
(F1
F0.00014334862385321102
I0
I1
I-1
tp73201
sS'in,a,dose'
p73202
(F1
F0.00028669724770642203
I2
I0
I2
tp73203
sS'risk,of,myopathy'
p73204
(F0
F0
I2
I2
I0
tp73205
sS'these,medicines,with'
p73206
(F0
F0
I1
I1
I0
tp73207
sS'toxic,effect,in'
p73208
(F1
F0.00014334862385321102
I1
I0
I1
tp73209
sS'approximately,msec,compared'
p73210
(F1
F0.00014334862385321102
I1
I0
I1
tp73211
sS'ml,and,maximum'
p73212
(F1
F0.00014334862385321102
I1
I0
I1
tp73213
sS'as,poor,metabolizers'
p73214
(F1
F0.00028669724770642203
I0
I2
I-2
tp73215
sS'with,other,cns-active'
p73216
(F1
F0.00014334862385321102
I1
I0
I1
tp73217
sS'lexapro,did,not'
p73218
(F1
F0.00014334862385321102
I1
I0
I1
tp73219
sS'of,and,single'
p73220
(F1
F0.00014334862385321102
I0
I1
I-1
tp73221
sS'marrow,toxicity,of'
p73222
(F1
F0.00014334862385321102
I0
I1
I-1
tp73223
sS'acetylsalicylic,acid,a-blockers'
p73224
(F1
F0.00014334862385321102
I0
I1
I-1
tp73225
sS'be,required,when'
p73226
(F1
F0.00014334862385321102
I0
I1
I-1
tp73227
sS'antimuscarinic,effects,and'
p73228
(F1
F0.00014334862385321102
I1
I0
I1
tp73229
sS'resulting,in,vitamin'
p73230
(F1
F0.00014334862385321102
I0
I1
I-1
tp73231
sS'be,inhibited,by'
p73232
(F1
F0.00028669724770642203
I2
I0
I2
tp73233
sS'on,a,with'
p73234
(F1
F0.00014334862385321102
I0
I1
I-1
tp73235
sS'concentration,due,to'
p73236
(F1
F0.00014334862385321102
I1
I0
I1
tp73237
sS'contraceptive,agents,ethinyl'
p73238
(F1
F0.00014334862385321102
I0
I1
I-1
tp73239
sS'protein-bound,such,as'
p73240
(F1
F0.00014334862385321102
I0
I1
I-1
tp73241
sS'thus,agents,likely'
p73242
(F1
F0.00014334862385321102
I0
I1
I-1
tp73243
sS'test,and,the'
p73244
(F1
F0.00014334862385321102
I1
I0
I1
tp73245
sS'interactions,with,beta-blockers'
p73246
(F1
F0.00014334862385321102
I1
I0
I1
tp73247
sS'metabolized,by,cyp2c9'
p73248
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp73249
sS'cause,k,deficiency'
p73250
(F1
F0.00014334862385321102
I0
I1
I-1
tp73251
sS'increases,gastrointestinal,motility'
p73252
(F1
F0.00014334862385321102
I1
I0
I1
tp73253
sS'administration,of,anafranil'
p73254
(F1
F0.00014334862385321102
I1
I0
I1
tp73255
sS'including,other,and'
p73256
(F1
F0.00014334862385321102
I1
I0
I1
tp73257
sS'bound,to,human'
p73258
(F1
F0.00014334862385321102
I0
I1
I-1
tp73259
sS'sodium,acid,etc'
p73260
(F1
F0.00028669724770642203
I2
I0
I2
tp73261
sS'have,confirmed,these'
p73262
(F1
F0.00014334862385321102
I0
I1
I-1
tp73263
sS'effects,particularly,have'
p73264
(F1
F0.00014334862385321102
I1
I0
I1
tp73265
sS'to,mg,led'
p73266
(F1
F0.00014334862385321102
I1
I0
I1
tp73267
sS'agents,nsaids,concomitant'
p73268
(F1
F0.00014334862385321102
I1
I0
I1
tp73269
sS'blockers,adrenergic,blockers'
p73270
(F1
F0.00028669724770642203
I2
I0
I2
tp73271
sS'if,taken,hour'
p73272
(F1
F0.00014334862385321102
I0
I1
I-1
tp73273
sS'increases,the,rate'
p73274
(F1
F0.00014334862385321102
I1
I0
I1
tp73275
sS'are,concurrently,being'
p73276
(F1
F0.00028669724770642203
I2
I0
I2
tp73277
sS'when,gleevec,is'
p73278
(F1
F0.00014334862385321102
I1
I0
I1
tp73279
sS'and,weight,loss'
p73280
(F1
F0.00014334862385321102
I1
I0
I1
tp73281
sS'system,ketoconazole,tablets'
p73282
(F1
F0.00014334862385321102
I1
I0
I1
tp73283
sS'suppress,certain,cyp450'
p73284
(F1
F0.00014334862385321102
I0
I1
I-1
tp73285
sS'grepafloxacin,like,other'
p73286
(F1
F0.00014334862385321102
I1
I0
I1
tp73287
sS'quality,of,life'
p73288
(F1
F0.00014334862385321102
I0
I1
I-1
tp73289
sS'that,antagonized,evidently'
p73290
(F1
F0.00014334862385321102
I1
I0
I1
tp73291
sS'maalox,coadministration,of'
p73292
(F1
F0.00014334862385321102
I0
I1
I-1
tp73293
sS'gabitril,carbamazepine,population'
p73294
(F1
F0.00014334862385321102
I1
I0
I1
tp73295
sS'the,iatrogenic,alteration'
p73296
(F1
F0.00014334862385321102
I0
I1
I-1
tp73297
sS'signs,of,atropinization'
p73298
(F1
F0.00014334862385321102
I1
I0
I1
tp73299
sS'the,nrtis,are'
p73300
(F1
F0.00014334862385321102
I0
I1
I-1
tp73301
sS'ampicillin,amoxicillin,an'
p73302
(F1
F0.00014334862385321102
I1
I0
I1
tp73303
sS'healthy,subjects,clearance'
p73304
(F1
F0.00014334862385321102
I0
I1
I-1
tp73305
sS'and,may,decrease'
p73306
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp73307
sS'nondepolarizing,blocking,action'
p73308
(F1
F0.00014334862385321102
I0
I1
I-1
tp73309
sS'not,performed,doses'
p73310
(F1
F0.00014334862385321102
I0
I1
I-1
tp73311
sS'as,topical,injectable'
p73312
(F1
F0.00014334862385321102
I0
I1
I-1
tp73313
sS'this,interaction,or'
p73314
(F1
F0.00014334862385321102
I1
I0
I1
tp73315
sS'can,combine,to'
p73316
(F1
F0.00014334862385321102
I1
I0
I1
tp73317
sS'aid,sleep,drowsiness-causing'
p73318
(F1
F0.00014334862385321102
I0
I1
I-1
tp73319
sS'other,eg,have'
p73320
(F1
F0.00014334862385321102
I0
I1
I-1
tp73321
sS'effectiveness,of,these'
p73322
(F1
F0.00014334862385321102
I1
I0
I1
tp73323
sS'on,or,other'
p73324
(F1
F0.00014334862385321102
I1
I0
I1
tp73325
sS'iodine,or,excess'
p73326
(F1
F0.00014334862385321102
I1
I0
I1
tp73327
sS'explain,the,increase'
p73328
(F1
F0.00014334862385321102
I1
I0
I1
tp73329
sS'a,fixed,g'
p73330
(F1
F0.00014334862385321102
I0
I1
I-1
tp73331
sS'fold,in,healthy'
p73332
(F1
F0.00014334862385321102
I1
I0
I1
tp73333
sS'use,of,l-glutamine'
p73334
(F1
F0.00028669724770642203
I2
I0
I2
tp73335
sS'of,the,protective'
p73336
(F1
F0.00014334862385321102
I1
I0
I1
tp73337
sS'effect,of,compounds'
p73338
(F1
F0.00014334862385321102
I1
I0
I1
tp73339
sS'be,temporarily,discontinued'
p73340
(F1
F0.00014334862385321102
I1
I0
I1
tp73341
sS'occurred,in,patients'
p73342
(F1
F0.00043004587155963305
I3
I0
I3
tp73343
sS'respectively,and,in'
p73344
(F1
F0.00014334862385321102
I1
I0
I1
tp73345
sS'half-life,of,by'
p73346
(F1
F0.00014334862385321102
I1
I0
I1
tp73347
sS'to,mg,qd'
p73348
(F0
F0
I1
I1
I0
tp73349
sS'inducers,drugs,that'
p73350
(F1
F0.00014334862385321102
I0
I1
I-1
tp73351
sS'been,studied,as'
p73352
(F1
F0.00014334862385321102
I0
I1
I-1
tp73353
sS'inhibit,the,in'
p73354
(F1
F0.00014334862385321102
I1
I0
I1
tp73355
sS'transport-related,effects,such'
p73356
(F1
F0.00014334862385321102
I1
I0
I1
tp73357
sS'schizophrenic,patients,treated'
p73358
(F1
F0.00014334862385321102
I1
I0
I1
tp73359
sS'lodine,capsules,and'
p73360
(F1
F0.00014334862385321102
I1
I0
I1
tp73361
sS'cyp2d6,substrate,the'
p73362
(F1
F0.00014334862385321102
I1
I0
I1
tp73363
sS'for,any,excessive'
p73364
(F1
F0.00014334862385321102
I1
I0
I1
tp73365
sS'that,gets,absorbed'
p73366
(F1
F0.00014334862385321102
I1
I0
I1
tp73367
sS'demonstrated,no,effect'
p73368
(F1
F0.00014334862385321102
I0
I1
I-1
tp73369
sS'elevations,in,the'
p73370
(F1
F0.00028669724770642203
I2
I0
I2
tp73371
sS'at,but,not'
p73372
(F1
F0.00014334862385321102
I0
I1
I-1
tp73373
sS'drug-drug,interaction,study'
p73374
(F0
F0
I1
I1
I0
tp73375
sS'may,activate,the'
p73376
(F1
F0.00014334862385321102
I0
I1
I-1
tp73377
sS'concentration,of,preparations'
p73378
(F1
F0.00014334862385321102
I1
I0
I1
tp73379
sS'recovery,time,may'
p73380
(F1
F0.00014334862385321102
I1
I0
I1
tp73381
sS'as,formulations,containing'
p73382
(F1
F0.00014334862385321102
I1
I0
I1
tp73383
sS'cyp,p450,isoforms'
p73384
(F1
F0.00014334862385321102
I0
I1
I-1
tp73385
sS'together,may,increase'
p73386
(F1
F0.00014334862385321102
I1
I0
I1
tp73387
sS'on,the,second'
p73388
(F1
F0.00014334862385321102
I1
I0
I1
tp73389
sS'patients,on,has'
p73390
(F1
F0.00014334862385321102
I1
I0
I1
tp73391
sS'or,its,synthetic'
p73392
(F1
F0.00014334862385321102
I0
I1
I-1
tp73393
sS'of,interactions,with'
p73394
(F1
F0.00014334862385321102
I0
I1
I-1
tp73395
sS'showed,higher,concentrations'
p73396
(F1
F0.00014334862385321102
I1
I0
I1
tp73397
sS'approximately,a,fold'
p73398
(F1
F0.00014334862385321102
I1
I0
I1
tp73399
sS'concentrations,in,vitro'
p73400
(F1
F0.00014334862385321102
I0
I1
I-1
tp73401
sS'when,given,with'
p73402
(F1
F0.00071674311926605509
I5
I0
I5
tp73403
sS'considered,prior,to'
p73404
(F1
F0.00014334862385321102
I1
I0
I1
tp73405
sS'mg,in,men'
p73406
(F1
F0.00014334862385321102
I0
I1
I-1
tp73407
sS'significant,interactions,would'
p73408
(F1
F0.00014334862385321102
I0
I1
I-1
tp73409
sS'preparations,and,the'
p73410
(F1
F0.00014334862385321102
I0
I1
I-1
tp73411
sS'steady,state,vioxx'
p73412
(F1
F0.00014334862385321102
I0
I1
I-1
tp73413
sS'pharmacokinetics,of,enbrel'
p73414
(F1
F0.00014334862385321102
I0
I1
I-1
tp73415
sS'been,studied,and'
p73416
(F1
F0.00014334862385321102
I1
I0
I1
tp73417
sS'damage,has,occurred'
p73418
(F1
F0.00014334862385321102
I1
I0
I1
tp73419
sS'induces,the,cytochrome'
p73420
(F1
F0.00014334862385321102
I0
I1
I-1
tp73421
sS'is,evidence,that'
p73422
(F1
F0.00014334862385321102
I0
I1
I-1
tp73423
sS'blood,mononuclear,cells'
p73424
(F1
F0.00028669724770642203
I2
I0
I2
tp73425
sS'acetylsalicylic,acid,temporarily'
p73426
(F1
F0.00014334862385321102
I1
I0
I1
tp73427
sS'an,agent,with'
p73428
(F1
F0.00014334862385321102
I1
I0
I1
tp73429
sS'considered,when,changing'
p73430
(F1
F0.00014334862385321102
I0
I1
I-1
tp73431
sS'or,when,new'
p73432
(F1
F0.00014334862385321102
I0
I1
I-1
tp73433
sS'cytochrome,p-450,a'
p73434
(F1
F0.00014334862385321102
I1
I0
I1
tp73435
sS'hydroxylation,of,by'
p73436
(F1
F0.00014334862385321102
I1
I0
I1
tp73437
sS'of,having,a'
p73438
(F1
F0.00014334862385321102
I0
I1
I-1
tp73439
sS'of,these,in'
p73440
(F1
F0.00028669724770642203
I0
I2
I-2
tp73441
sS'effects,were,neither'
p73442
(F1
F0.00014334862385321102
I1
I0
I1
tp73443
sS'of,these,is'
p73444
(F0
F0
I1
I1
I0
tp73445
sS'vitamin,d,analogues'
p73446
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp73447
sS'each,administered,alone'
p73448
(F1
F0.00014334862385321102
I1
I0
I1
tp73449
sS'of,atropinization,flushing'
p73450
(F1
F0.00014334862385321102
I1
I0
I1
tp73451
sS'mg,l,while'
p73452
(F1
F0.00014334862385321102
I0
I1
I-1
tp73453
sS'day,until,the'
p73454
(F1
F0.00014334862385321102
I0
I1
I-1
tp73455
sS'of,betaseron,on'
p73456
(F1
F0.00014334862385321102
I1
I0
I1
tp73457
sS'xigris,may,affect'
p73458
(F1
F0.00014334862385321102
I0
I1
I-1
tp73459
sS'and,appears,to'
p73460
(F1
F0.00014334862385321102
I0
I1
I-1
tp73461
sS'resulted,in,elevated'
p73462
(F1
F0.00028669724770642203
I2
I0
I2
tp73463
sS'idv,does,not'
p73464
(F1
F0.00014334862385321102
I0
I1
I-1
tp73465
sS'adl,mg,and'
p73466
(F1
F0.00014334862385321102
I0
I1
I-1
tp73467
sS'guardians,carefully,about'
p73468
(F1
F0.00014334862385321102
I0
I1
I-1
tp73469
sS'proleukin,in,combination'
p73470
(F1
F0.00014334862385321102
I0
I1
I-1
tp73471
sS'therefore,extreme,caution'
p73472
(F1
F0.00014334862385321102
I1
I0
I1
tp73473
sS'and,area-under,the-curve'
p73474
(F1
F0.00014334862385321102
I1
I0
I1
tp73475
sS'or,av,nodal'
p73476
(F1
F0.00014334862385321102
I1
I0
I1
tp73477
sS'than,the,number'
p73478
(F1
F0.00014334862385321102
I0
I1
I-1
tp73479
sS'day,divided,into'
p73480
(F1
F0.00014334862385321102
I1
I0
I1
tp73481
sS'to,alert,clinicians'
p73482
(F1
F0.00014334862385321102
I1
I0
I1
tp73483
sS'labeling,of,progestin-only'
p73484
(F1
F0.00014334862385321102
I0
I1
I-1
tp73485
sS'antagonists,based,on'
p73486
(F1
F0.00014334862385321102
I1
I0
I1
tp73487
sS'been,studied,the'
p73488
(F1
F0.00014334862385321102
I1
I0
I1
tp73489
sS'oxidized,metabolites,with'
p73490
(F1
F0.00014334862385321102
I0
I1
I-1
tp73491
sS'complications,blurred,vision'
p73492
(F1
F0.00014334862385321102
I1
I0
I1
tp73493
sS'alone,and,following'
p73494
(F1
F0.00014334862385321102
I0
I1
I-1
tp73495
sS'deficit,i,acute'
p73496
(F1
F0.00014334862385321102
I0
I1
I-1
tp73497
sS'norpace,and,resulted'
p73498
(F1
F0.00014334862385321102
I1
I0
I1
tp73499
sS'exposure,to,and'
p73500
(F1
F0.00014334862385321102
I1
I0
I1
tp73501
sS'data,from,these'
p73502
(F1
F0.00014334862385321102
I1
I0
I1
tp73503
sS'survey,of,patients'
p73504
(F1
F0.00014334862385321102
I1
I0
I1
tp73505
sS'selected,for,response'
p73506
(F1
F0.00014334862385321102
I0
I1
I-1
tp73507
sS'to,their,concomitant'
p73508
(F1
F0.00014334862385321102
I0
I1
I-1
tp73509
sS'of,may,reduce'
p73510
(F1
F0.00057339449541284407
I4
I0
I4
tp73511
sS'regimen,did,not'
p73512
(F1
F0.00014334862385321102
I1
I0
I1
tp73513
sS'potentiate,the,cns'
p73514
(F0
F0
I2
I2
I0
tp73515
sS'of,chemotherapy,plus'
p73516
(F1
F0.00014334862385321102
I0
I1
I-1
tp73517
sS'were,compared,with'
p73518
(F1
F0.00014334862385321102
I0
I1
I-1
tp73519
sS'caution,and,patients'
p73520
(F1
F0.00014334862385321102
I1
I0
I1
tp73521
sS'volunteers,resulting,in'
p73522
(F1
F0.00014334862385321102
I0
I1
I-1
tp73523
sS'used,cautiously,if'
p73524
(F1
F0.00014334862385321102
I0
I1
I-1
tp73525
sS'using,these,techniques'
p73526
(F1
F0.00014334862385321102
I0
I1
I-1
tp73527
sS'range,from,decrease'
p73528
(F1
F0.00028669724770642203
I2
I0
I2
tp73529
sS'during,dosing,with'
p73530
(F1
F0.00014334862385321102
I1
I0
I1
tp73531
sS'curariform,muscle,relaxants'
p73532
(F1
F0.00014334862385321102
I1
I0
I1
tp73533
sS'used,cautiously,in'
p73534
(F1
F0.0008600917431192661
I6
I0
I6
tp73535
sS'of,the,clinical'
p73536
(F1
F0.00014334862385321102
I0
I1
I-1
tp73537
sS'in,bioavailability,was'
p73538
(F1
F0.00014334862385321102
I1
I0
I1
tp73539
sS'lithium,diclofenac,decreases'
p73540
(F1
F0.00014334862385321102
I1
I0
I1
tp73541
sS'have,decreased,symptoms'
p73542
(F1
F0.00014334862385321102
I1
I0
I1
tp73543
sS'effects,were,not'
p73544
(F1
F0.00014334862385321102
I0
I1
I-1
tp73545
sS'inhibitor,does,not'
p73546
(F1
F0.00014334862385321102
I0
I1
I-1
tp73547
sS'metabolized,similarly,to'
p73548
(F1
F0.00014334862385321102
I1
I0
I1
tp73549
sS'glatiramer,acetate,were'
p73550
(F1
F0.00014334862385321102
I0
I1
I-1
tp73551
sS'made,with,any'
p73552
(F1
F0.00014334862385321102
I1
I0
I1
tp73553
sS'taking,a,or'
p73554
(F1
F0.00014334862385321102
I1
I0
I1
tp73555
sS'and,sodium,citrate'
p73556
(F1
F0.00014334862385321102
I1
I0
I1
tp73557
sS'men,years,of'
p73558
(F1
F0.00014334862385321102
I0
I1
I-1
tp73559
sS'concentration,of,in'
p73560
(F1
F0.00028669724770642203
I2
I0
I2
tp73561
sS'or,efficacy,of'
p73562
(F1
F0.00043004587155963305
I0
I3
I-3
tp73563
sS'in,a,false-positive'
p73564
(F1
F0.00014334862385321102
I0
I1
I-1
tp73565
sS'a,non-matched,historicalcontrol'
p73566
(F1
F0.00014334862385321102
I1
I0
I1
tp73567
sS'increases,both,free'
p73568
(F1
F0.00014334862385321102
I1
I0
I1
tp73569
sS'six,clinical,isolates'
p73570
(F1
F0.00014334862385321102
I0
I1
I-1
tp73571
sS'agents,now,available'
p73572
(F1
F0.00014334862385321102
I0
I1
I-1
tp73573
sS'chloramphenicol,or,may'
p73574
(F1
F0.00014334862385321102
I1
I0
I1
tp73575
sS'clearance,and,an'
p73576
(F1
F0.00028669724770642203
I2
I0
I2
tp73577
sS'take,lodine,can'
p73578
(F1
F0.00014334862385321102
I0
I1
I-1
tp73579
sS'on,performance,of'
p73580
(F1
F0.00014334862385321102
I0
I1
I-1
tp73581
sS'in,the,liver'
p73582
(F0
F0
I1
I1
I0
tp73583
sS'and,its,pharmacologically'
p73584
(F1
F0.00014334862385321102
I0
I1
I-1
tp73585
sS'effects,of,clozapine'
p73586
(F1
F0.00014334862385321102
I1
I0
I1
tp73587
sS'of,patients,interaction'
p73588
(F1
F0.00014334862385321102
I0
I1
I-1
tp73589
sS'piperacillin,sodium,may'
p73590
(F1
F0.00014334862385321102
I1
I0
I1
tp73591
sS'make,normal,metab-olizers'
p73592
(F1
F0.00014334862385321102
I0
I1
I-1
tp73593
sS'experienced,a,decrease'
p73594
(F1
F0.00014334862385321102
I1
I0
I1
tp73595
sS'of,the,capsule'
p73596
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp73597
sS'of,potassium-sparing,supplements'
p73598
(F1
F0.00014334862385321102
I0
I1
I-1
tp73599
sS'taking,certain,such'
p73600
(F1
F0.00014334862385321102
I0
I1
I-1
tp73601
sS'and,six,clinical'
p73602
(F1
F0.00014334862385321102
I0
I1
I-1
tp73603
sS'these,should,be'
p73604
(F1
F0.00014334862385321102
I1
I0
I1
tp73605
sS'necessitating,a,reduction'
p73606
(F1
F0.00014334862385321102
I1
I0
I1
tp73607
sS'effect,and,susceptibility'
p73608
(F1
F0.00028669724770642203
I0
I2
I-2
tp73609
sS'sgpt,alt,in'
p73610
(F1
F0.00028669724770642203
I2
I0
I2
tp73611
sS'this,increase,is'
p73612
(F1
F0.00014334862385321102
I1
I0
I1
tp73613
sS'this,category,and'
p73614
(F1
F0.00014334862385321102
I1
I0
I1
tp73615
sS'other,drugs,drugs'
p73616
(F1
F0.00028669724770642203
I0
I2
I-2
tp73617
sS'particularly,at,to'
p73618
(F1
F0.00014334862385321102
I1
I0
I1
tp73619
sS'along,with,either'
p73620
(F1
F0.00014334862385321102
I1
I0
I1
tp73621
sS'a,slower,onset'
p73622
(F1
F0.00014334862385321102
I1
I0
I1
tp73623
sS'inhibitors,has,not'
p73624
(F1
F0.00014334862385321102
I0
I1
I-1
tp73625
sS'gastrointestinal,motility,lowers'
p73626
(F1
F0.00014334862385321102
I1
I0
I1
tp73627
sS'adverse,events,and'
p73628
(F1
F0.00014334862385321102
I0
I1
I-1
tp73629
sS'interaction,study,in'
p73630
(F1
F0.00028669724770642203
I0
I2
I-2
tp73631
sS'domestic,studies,suggest'
p73632
(F1
F0.00014334862385321102
I0
I1
I-1
tp73633
sS'nephrotoxicity,with,decreases'
p73634
(F1
F0.00014334862385321102
I1
I0
I1
tp73635
sS'is,reported,to'
p73636
(F0
F0
I1
I1
I0
tp73637
sS'affected,during,multiple-dose'
p73638
(F1
F0.00014334862385321102
I0
I1
I-1
tp73639
sS'codeine,in,combination'
p73640
(F1
F0.00014334862385321102
I1
I0
I1
tp73641
sS'of,other,ht1b'
p73642
(F1
F0.00014334862385321102
I1
I0
I1
tp73643
sS'patients,already,receiving'
p73644
(F1
F0.00014334862385321102
I1
I0
I1
tp73645
sS'have,been,rarely'
p73646
(F1
F0.00028669724770642203
I2
I0
I2
tp73647
sS'however,administration,of'
p73648
(F1
F0.00014334862385321102
I0
I1
I-1
tp73649
sS'intraluminally,was,only'
p73650
(F1
F0.00014334862385321102
I0
I1
I-1
tp73651
sS'blockers,isolated,cases'
p73652
(F1
F0.00014334862385321102
I1
I0
I1
tp73653
sS'may,compete,for'
p73654
(F1
F0.00014334862385321102
I1
I0
I1
tp73655
sS'catecholamine,depletor,should'
p73656
(F1
F0.00014334862385321102
I0
I1
I-1
tp73657
sS'number,of,sites'
p73658
(F1
F0.00014334862385321102
I0
I1
I-1
tp73659
sS'any,hypokalemic,effect'
p73660
(F1
F0.00014334862385321102
I1
I0
I1
tp73661
sS'similar,proportion,of'
p73662
(F1
F0.00014334862385321102
I1
I0
I1
tp73663
sS'cmax,of,was'
p73664
(F1
F0.00043004587155963305
I3
I0
I3
tp73665
sS'of,by,on'
p73666
(F1
F0.00014334862385321102
I1
I0
I1
tp73667
sS'calcium,antagonists,after'
p73668
(F1
F0.00014334862385321102
I1
I0
I1
tp73669
sS'of,toxicity,have'
p73670
(F1
F0.00043004587155963305
I3
I0
I3
tp73671
sS'of,cyp2a6,hydroxylation'
p73672
(F1
F0.00014334862385321102
I1
I0
I1
tp73673
sS'inhibiting,may,result'
p73674
(F1
F0.00014334862385321102
I1
I0
I1
tp73675
sS'that,protects,against'
p73676
(F1
F0.00014334862385321102
I1
I0
I1
tp73677
sS'p450iid6,such,as'
p73678
(F1
F0.00014334862385321102
I1
I0
I1
tp73679
sS'of,by,or'
p73680
(F1
F0.00014334862385321102
I1
I0
I1
tp73681
sS'expected,between,viracept'
p73682
(F1
F0.00014334862385321102
I0
I1
I-1
tp73683
sS'therapy,with,small'
p73684
(F1
F0.00014334862385321102
I1
I0
I1
tp73685
sS'treatment,of,acute'
p73686
(F1
F0.00014334862385321102
I0
I1
I-1
tp73687
sS'less,effective,while'
p73688
(F1
F0.00014334862385321102
I1
I0
I1
tp73689
sS'including,and,these'
p73690
(F1
F0.00014334862385321102
I0
I1
I-1
tp73691
sS'potential,terfenadine,astemizole'
p73692
(F1
F0.00014334862385321102
I0
I1
I-1
tp73693
sS'a,mao,inhibitor'
p73694
(F1
F0.00014334862385321102
I1
I0
I1
tp73695
sS'the,vasoconstrictive,action'
p73696
(F1
F0.00014334862385321102
I1
I0
I1
tp73697
sS'and,the,same'
p73698
(F1
F0.00014334862385321102
I0
I1
I-1
tp73699
sS'preliminary,data,which'
p73700
(F1
F0.00014334862385321102
I1
I0
I1
tp73701
sS'except,that,a'
p73702
(F1
F0.00014334862385321102
I1
I0
I1
tp73703
sS'or,in,whom'
p73704
(F1
F0.00014334862385321102
I1
I0
I1
tp73705
sS'ht3,zofran,and'
p73706
(F1
F0.00014334862385321102
I0
I1
I-1
tp73707
sS'a,slight,delay'
p73708
(F1
F0.00014334862385321102
I1
I0
I1
tp73709
sS'intravenous,and,non-steroidal'
p73710
(F1
F0.00014334862385321102
I1
I0
I1
tp73711
sS'exogenous,also,appeared'
p73712
(F1
F0.00014334862385321102
I1
I0
I1
tp73713
sS'and,agents,used'
p73714
(F1
F0.00014334862385321102
I0
I1
I-1
tp73715
sS'parkinsons,disease,patients'
p73716
(F1
F0.00014334862385321102
I0
I1
I-1
tp73717
sS'phase,days,mg'
p73718
(F1
F0.00014334862385321102
I0
I1
I-1
tp73719
sS'of,at,concentrations'
p73720
(F1
F0.00014334862385321102
I0
I1
I-1
tp73721
sS'who,were,stabilized'
p73722
(F1
F0.00028669724770642203
I0
I2
I-2
tp73723
sS'did,not,report'
p73724
(F1
F0.00014334862385321102
I0
I1
I-1
tp73725
sS'and,clinical,response'
p73726
(F1
F0.00014334862385321102
I0
I1
I-1
tp73727
sS'and,the,antithrombotic'
p73728
(F1
F0.00014334862385321102
I1
I0
I1
tp73729
sS'increased,concentrations,of'
p73730
(F1
F0.00014334862385321102
I0
I1
I-1
tp73731
sS'with,coadministration,whereas'
p73732
(F1
F0.00014334862385321102
I1
I0
I1
tp73733
sS'therapeutic,range,of'
p73734
(F1
F0.00014334862385321102
I0
I1
I-1
tp73735
sS'for,other,drugs'
p73736
(F1
F0.00028669724770642203
I0
I2
I-2
tp73737
sS'immunosuppressive,drugs,fibric'
p73738
(F1
F0.00014334862385321102
I0
I1
I-1
tp73739
sS'was,increased,fold'
p73740
(F1
F0.00014334862385321102
I1
I0
I1
tp73741
sS'the,oral,or'
p73742
(F1
F0.00043004587155963305
I3
I0
I3
tp73743
sS'possible,interactions,between'
p73744
(F0
F0
I1
I1
I0
tp73745
sS'aeds,do,not'
p73746
(F1
F0.00014334862385321102
I0
I1
I-1
tp73747
sS'of,the,tail-flick'
p73748
(F0
F0
I1
I1
I0
tp73749
sS'safety,and,effectiveness'
p73750
(F1
F0.00028669724770642203
I0
I2
I-2
tp73751
sS'and,the,area'
p73752
(F1
F0.00014334862385321102
I1
I0
I1
tp73753
sS'cyp2c8,drugs,substances'
p73754
(F1
F0.00014334862385321102
I0
I1
I-1
tp73755
sS'since,in,high'
p73756
(F1
F0.00014334862385321102
I1
I0
I1
tp73757
sS'survanta,on,the'
p73758
(F1
F0.00014334862385321102
I0
I1
I-1
tp73759
sS'prothrom-bin,time,response'
p73760
(F1
F0.00028669724770642203
I2
I0
I2
tp73761
sS'concomitant,administration,with'
p73762
(F0.5
F0.00028669724770642203
I3
I1
I2
tp73763
sS'mcg,of,ethinyl'
p73764
(F0
F0
I1
I1
I0
tp73765
sS'receiving,the,and'
p73766
(F1
F0.00014334862385321102
I0
I1
I-1
tp73767
sS'fold,which,significantly'
p73768
(F1
F0.00014334862385321102
I1
I0
I1
tp73769
sS'interference,by,chloral'
p73770
(F1
F0.00014334862385321102
I0
I1
I-1
tp73771
sS'uncontrolled,intake,of'
p73772
(F1
F0.00043004587155963305
I0
I3
I-3
tp73773
sS'gi,ulceration,and'
p73774
(F1
F0.00014334862385321102
I1
I0
I1
tp73775
sS'used,the,risk'
p73776
(F1
F0.00014334862385321102
I1
I0
I1
tp73777
sS'vertigo,syncope,or'
p73778
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp73779
sS'or,ergot,alkaloids'
p73780
(F1
F0.00014334862385321102
I1
I0
I1
tp73781
sS'effect,on,activity'
p73782
(F1
F0.00014334862385321102
I1
I0
I1
tp73783
sS'oral,and,can'
p73784
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp73785
sS'live,or,inactivated'
p73786
(F1
F0.00014334862385321102
I1
I0
I1
tp73787
sS'slightly,reduced,by'
p73788
(F1
F0.00014334862385321102
I1
I0
I1
tp73789
sS'dyspnea,requiring,angioedema'
p73790
(F1
F0.00014334862385321102
I0
I1
I-1
tp73791
sS'on,renal,prostaglandins'
p73792
(F1
F0.00014334862385321102
I1
I0
I1
tp73793
sS'of,lower,doses'
p73794
(F1
F0.00014334862385321102
I0
I1
I-1
tp73795
sS'be,deferred,until'
p73796
(F1
F0.00014334862385321102
I1
I0
I1
tp73797
sS'and,renal,clearance'
p73798
(F1
F0.00014334862385321102
I1
I0
I1
tp73799
sS'important,interaction,with'
p73800
(F1
F0.00014334862385321102
I0
I1
I-1
tp73801
sS'coincide,duloxetine,did'
p73802
(F1
F0.00014334862385321102
I0
I1
I-1
tp73803
sS'animal,studies,with'
p73804
(F1
F0.00014334862385321102
I1
I0
I1
tp73805
sS'target,of,inhibitor'
p73806
(F1
F0.00014334862385321102
I0
I1
I-1
tp73807
sS'the,complete,prescribing'
p73808
(F1
F0.00014334862385321102
I0
I1
I-1
tp73809
sS'cyclic,may,emerge'
p73810
(F1
F0.00014334862385321102
I1
I0
I1
tp73811
sS'the,time,scale'
p73812
(F1
F0.00014334862385321102
I0
I1
I-1
tp73813
sS'pharmacodynamic,interactions,have'
p73814
(F1
F0.00014334862385321102
I0
I1
I-1
tp73815
sS'qd,for,five'
p73816
(F1
F0.00014334862385321102
I0
I1
I-1
tp73817
sS'with,gastric,fistulas'
p73818
(F1
F0.00014334862385321102
I0
I1
I-1
tp73819
sS'additive,with,d'
p73820
(F1
F0.00014334862385321102
I1
I0
I1
tp73821
sS'p-type,in,bovine'
p73822
(F1
F0.00014334862385321102
I0
I1
I-1
tp73823
sS'following,initiation,of'
p73824
(F1
F0.00028669724770642203
I2
I0
I2
tp73825
sS'administration,on,day'
p73826
(F1
F0.00014334862385321102
I0
I1
I-1
tp73827
sS'few,days,after'
p73828
(F1
F0.00028669724770642203
I2
I0
I2
tp73829
sS'i,severe,dry'
p73830
(F1
F0.00014334862385321102
I1
I0
I1
tp73831
sS'wish,to,withhold'
p73832
(F1
F0.00014334862385321102
I1
I0
I1
tp73833
sS'laboratory,tests,vital'
p73834
(F1
F0.00028669724770642203
I0
I2
I-2
tp73835
sS'without,additional,caution'
p73836
(F1
F0.00014334862385321102
I0
I1
I-1
tp73837
sS'cecum,and,its'
p73838
(F1
F0.00014334862385321102
I0
I1
I-1
tp73839
sS'inhalation,are,reduced'
p73840
(F1
F0.00014334862385321102
I1
I0
I1
tp73841
sS'of,when,it'
p73842
(F1
F0.00014334862385321102
I1
I0
I1
tp73843
sS'of,when,is'
p73844
(F1
F0.00014334862385321102
I1
I0
I1
tp73845
sS'evaluation,of,the'
p73846
(F1
F0.00014334862385321102
I0
I1
I-1
tp73847
sS'contraction,of,guinea-pig'
p73848
(F1
F0.00014334862385321102
I0
I1
I-1
tp73849
sS'or,medications,with'
p73850
(F1
F0.00014334862385321102
I1
I0
I1
tp73851
sS'are,no,significant'
p73852
(F1
F0.00014334862385321102
I0
I1
I-1
tp73853
sS'alone,was,found'
p73854
(F1
F0.00014334862385321102
I1
I0
I1
tp73855
sS'interference,with,the'
p73856
(F1
F0.00028669724770642203
I2
I0
I2
tp73857
sS'bleeding,or,with'
p73858
(F1
F0.00014334862385321102
I0
I1
I-1
tp73859
sS'effects,of,combined'
p73860
(F1
F0.00014334862385321102
I0
I1
I-1
tp73861
sS'study,concomitant,administration'
p73862
(F0
F0
I1
I1
I0
tp73863
sS'does,not,necessitate'
p73864
(F1
F0.00028669724770642203
I0
I2
I-2
tp73865
sS'and,in,absorption'
p73866
(F1
F0.00014334862385321102
I1
I0
I1
tp73867
sS'reduction,of,excretion'
p73868
(F1
F0.00043004587155963305
I0
I3
I-3
tp73869
sS'as,post-marketing,observations'
p73870
(F1
F0.00043004587155963305
I3
I0
I3
tp73871
sS'severe,hypotension,and'
p73872
(F1
F0.00014334862385321102
I1
I0
I1
tp73873
sS'and,proquin,xr'
p73874
(F1
F0.00014334862385321102
I0
I1
I-1
tp73875
sS'male,animals,were'
p73876
(F1
F0.00014334862385321102
I0
I1
I-1
tp73877
sS'efficacy,of,the'
p73878
(F1
F0.00014334862385321102
I1
I0
I1
tp73879
sS'other,nsaids,concomitant'
p73880
(F1
F0.00028669724770642203
I2
I0
I2
tp73881
sS'or,are,known'
p73882
(F1
F0.00014334862385321102
I0
I1
I-1
tp73883
sS'can,be,potentiated'
p73884
(F1
F0.00014334862385321102
I1
I0
I1
tp73885
sS'cyp3a4,there,is'
p73886
(F1
F0.00014334862385321102
I0
I1
I-1
tp73887
sS'although,neither,nor'
p73888
(F1
F0.00014334862385321102
I1
I0
I1
tp73889
sS'lodine,as,measured'
p73890
(F1
F0.00014334862385321102
I0
I1
I-1
tp73891
sS'of,itraconazole,therapy'
p73892
(F1
F0.00014334862385321102
I1
I0
I1
tp73893
sS'did,not,systematically'
p73894
(F1
F0.00014334862385321102
I0
I1
I-1
tp73895
sS'used,in,combination'
p73896
(F0.5
F0.0008600917431192661
I9
I3
I6
tp73897
sS'or,may,produce'
p73898
(F1
F0.00043004587155963305
I3
I0
I3
tp73899
sS'or,trivalent,cations'
p73900
(F1
F0.00014334862385321102
I0
I1
I-1
tp73901
sS'keppra,mg,daily'
p73902
(F1
F0.00014334862385321102
I0
I1
I-1
tp73903
sS'subcutaneous,infusion,pumps'
p73904
(F1
F0.00014334862385321102
I0
I1
I-1
tp73905
sS'such,use,is'
p73906
(F1
F0.00014334862385321102
I1
I0
I1
tp73907
sS'be,withdrawn,at'
p73908
(F1
F0.00028669724770642203
I2
I0
I2
tp73909
sS'threshold,voltage-dependent,ca'
p73910
(F1
F0.00014334862385321102
I0
I1
I-1
tp73911
sS'a,separate,group'
p73912
(F1
F0.00014334862385321102
I1
I0
I1
tp73913
sS'tacrolimus,felodipine,may'
p73914
(F1
F0.00014334862385321102
I0
I1
I-1
tp73915
sS'induce,hepatic,enzymes'
p73916
(F1
F0.00014334862385321102
I1
I0
I1
tp73917
sS'concentrations,and,toxicity'
p73918
(F1
F0.00014334862385321102
I1
I0
I1
tp73919
sS'reduce,proleukin-induced,side'
p73920
(F1
F0.00014334862385321102
I1
I0
I1
tp73921
sS'used,with,oral'
p73922
(F1
F0.00014334862385321102
I1
I0
I1
tp73923
sS'neuromuscular,blockade,of'
p73924
(F1
F0.00014334862385321102
I1
I0
I1
tp73925
sS'and,decrease,the'
p73926
(F0.5
F0.00028669724770642203
I3
I1
I2
tp73927
sS'm2,dose,of'
p73928
(F1
F0.00014334862385321102
I0
I1
I-1
tp73929
sS'inhibits,the,gastrointestinal'
p73930
(F1
F0.00014334862385321102
I1
I0
I1
tp73931
sS'and,to,discriminate'
p73932
(F1
F0.00014334862385321102
I0
I1
I-1
tp73933
sS'and,hearing,impairment'
p73934
(F1
F0.00014334862385321102
I1
I0
I1
tp73935
sS'with,multiple,dosing'
p73936
(F1
F0.00014334862385321102
I1
I0
I1
tp73937
sS'of,in,parkinsons'
p73938
(F1
F0.00014334862385321102
I1
I0
I1
tp73939
sS'ames,n-multistix,sg'
p73940
(F1
F0.00014334862385321102
I0
I1
I-1
tp73941
sS'with,other,cns-depressant'
p73942
(F1
F0.00014334862385321102
I1
I0
I1
tp73943
sS'might,be,required'
p73944
(F1
F0.00014334862385321102
I0
I1
I-1
tp73945
sS'known,to,interact'
p73946
(F0
F0
I1
I1
I0
tp73947
sS'lead,to,reduced'
p73948
(F1
F0.00014334862385321102
I0
I1
I-1
tp73949
sS'interactions,following,administration'
p73950
(F1
F0.00014334862385321102
I0
I1
I-1
tp73951
sS'observed,for,loss'
p73952
(F1
F0.00014334862385321102
I0
I1
I-1
tp73953
sS'affect,abilify,aripiprazole'
p73954
(F1
F0.00014334862385321102
I0
I1
I-1
tp73955
sS'that,the,neuromuscular'
p73956
(F1
F0.00014334862385321102
I1
I0
I1
tp73957
sS'a,toxic,effect'
p73958
(F1
F0.00014334862385321102
I1
I0
I1
tp73959
sS'rapidly,and,essentially'
p73960
(F1
F0.00014334862385321102
I0
I1
I-1
tp73961
sS'and,r-warfarin,a'
p73962
(F1
F0.00014334862385321102
I1
I0
I1
tp73963
sS'with,other,medications'
p73964
(F1
F0.00014334862385321102
I1
I0
I1
tp73965
sS'of,enablex,should'
p73966
(F1
F0.00014334862385321102
I1
I0
I1
tp73967
sS'cold,and,sinus'
p73968
(F1
F0.00014334862385321102
I1
I0
I1
tp73969
sS'increased,peak,plasma'
p73970
(F1
F0.00014334862385321102
I1
I0
I1
tp73971
sS'to,representing,a'
p73972
(F1
F0.00014334862385321102
I1
I0
I1
tp73973
sS'oral,cough,and'
p73974
(F1
F0.00014334862385321102
I0
I1
I-1
tp73975
sS'are,types,of'
p73976
(F1
F0.00014334862385321102
I0
I1
I-1
tp73977
sS'tubular,secretion,may'
p73978
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp73979
sS'the,patients,receiving'
p73980
(F1
F0.00014334862385321102
I0
I1
I-1
tp73981
sS'with,an,hydroxide'
p73982
(F1
F0.00014334862385321102
I1
I0
I1
tp73983
sS'systems,has,been'
p73984
(F1
F0.00014334862385321102
I1
I0
I1
tp73985
sS'or,may,interact'
p73986
(F1
F0.00028669724770642203
I2
I0
I2
tp73987
sS'channel,blockers,of'
p73988
(F1
F0.00014334862385321102
I1
I0
I1
tp73989
sS'carefully,and,the'
p73990
(F1
F0.00014334862385321102
I1
I0
I1
tp73991
sS'using,bromocriptine,mesylate'
p73992
(F1
F0.00014334862385321102
I1
I0
I1
tp73993
sS'of,these,oral'
p73994
(F1
F0.00014334862385321102
I1
I0
I1
tp73995
sS'qd,days,with'
p73996
(F0
F0
I1
I1
I0
tp73997
sS'reported,resulting,in'
p73998
(F1
F0.00014334862385321102
I1
I0
I1
tp73999
sS'closely,watched,during'
p74000
(F1
F0.00014334862385321102
I0
I1
I-1
tp74001
sS'p450,a4,such'
p74002
(F1
F0.00014334862385321102
I1
I0
I1
tp74003
sS'sampling,were,conducted'
p74004
(F1
F0.00014334862385321102
I0
I1
I-1
tp74005
sS'several,hours,apart'
p74006
(F1
F0.00014334862385321102
I0
I1
I-1
tp74007
sS'increased,the,steady-state'
p74008
(F1
F0.00014334862385321102
I1
I0
I1
tp74009
sS'and,iv,have'
p74010
(F1
F0.00014334862385321102
I0
I1
I-1
tp74011
sS'hcl,should,receive'
p74012
(F1
F0.00014334862385321102
I1
I0
I1
tp74013
sS'inhibitors,inhibitors,of'
p74014
(F1
F0.00014334862385321102
I0
I1
I-1
tp74015
sS'increased,approximately,in'
p74016
(F1
F0.00014334862385321102
I1
I0
I1
tp74017
sS'acid,antagonists,such'
p74018
(F1
F0.00014334862385321102
I1
I0
I1
tp74019
sS'effects,on,positive'
p74020
(F1
F0.00014334862385321102
I0
I1
I-1
tp74021
sS'profound,hypotensive,episodes'
p74022
(F1
F0.00014334862385321102
I1
I0
I1
tp74023
sS'and,maximum,concentration'
p74024
(F0
F0
I1
I1
I0
tp74025
sS'of,higher,doses'
p74026
(F1
F0.00014334862385321102
I0
I1
I-1
tp74027
sS'following,table,effects'
p74028
(F1
F0.00014334862385321102
I0
I1
I-1
tp74029
sS'calcitriol,and,calcidiol'
p74030
(F1
F0.00043004587155963305
I3
I0
I3
tp74031
sS'acid,because,of'
p74032
(F1
F0.00014334862385321102
I1
I0
I1
tp74033
sS'block,were,more'
p74034
(F1
F0.00014334862385321102
I0
I1
I-1
tp74035
sS'demonstrates,that,concurrent'
p74036
(F1
F0.00014334862385321102
I1
I0
I1
tp74037
sS'that,the,involvement'
p74038
(F1
F0.00014334862385321102
I0
I1
I-1
tp74039
sS'live,and,live-attenuated'
p74040
(F1
F0.00014334862385321102
I1
I0
I1
tp74041
sS'renal,failure,and'
p74042
(F1
F0.00014334862385321102
I1
I0
I1
tp74043
sS'and,their,dose'
p74044
(F1
F0.00014334862385321102
I1
I0
I1
tp74045
sS'pulmonary,extract,from'
p74046
(F1
F0.00014334862385321102
I0
I1
I-1
tp74047
sS'blockade,was,prolonged'
p74048
(F1
F0.00014334862385321102
I1
I0
I1
tp74049
sS'after,administration,reaching'
p74050
(F1
F0.00014334862385321102
I0
I1
I-1
tp74051
sS'however,no,clinically'
p74052
(F1
F0.00014334862385321102
I0
I1
I-1
tp74053
sS'phosphorylation,at,high'
p74054
(F1
F0.00014334862385321102
I1
I0
I1
tp74055
sS'a,liquid,impinger'
p74056
(F1
F0.00014334862385321102
I0
I1
I-1
tp74057
sS'protease,inhibitor,in'
p74058
(F1
F0.00014334862385321102
I0
I1
I-1
tp74059
sS'v,concentrations,up'
p74060
(F1
F0.00014334862385321102
I0
I1
I-1
tp74061
sS'parasite,reduction,at'
p74062
(F1
F0.00014334862385321102
I0
I1
I-1
tp74063
sS'may,induce,toxicity'
p74064
(F1
F0.00014334862385321102
I0
I1
I-1
tp74065
sS'more,profound,when'
p74066
(F1
F0.00014334862385321102
I1
I0
I1
tp74067
sS'levels,indicating,that'
p74068
(F1
F0.00014334862385321102
I0
I1
I-1
tp74069
sS'in,one,man'
p74070
(F1
F0.00014334862385321102
I1
I0
I1
tp74071
sS'cautiously,coadministered,with'
p74072
(F1
F0.00014334862385321102
I1
I0
I1
tp74073
sS'vitro,activity,of'
p74074
(F1
F0.00014334862385321102
I0
I1
I-1
tp74075
sS'the,total,were'
p74076
(F1
F0.00014334862385321102
I0
I1
I-1
tp74077
sS'and,others,that'
p74078
(F1
F0.00014334862385321102
I1
I0
I1
tp74079
sS'coadministration,of,potent'
p74080
(F1
F0.00014334862385321102
I1
I0
I1
tp74081
sS'a,are,available'
p74082
(F1
F0.00014334862385321102
I0
I1
I-1
tp74083
sS'magnesium,aluminum-containing,antacid'
p74084
(F1
F0.00014334862385321102
I0
I1
I-1
tp74085
sS'were,coadministered,than'
p74086
(F1
F0.00014334862385321102
I1
I0
I1
tp74087
sS'striatal,but,these'
p74088
(F1
F0.00014334862385321102
I1
I0
I1
tp74089
sS'and,these,are'
p74090
(F1
F0.00014334862385321102
I0
I1
I-1
tp74091
sS'however,patients,who'
p74092
(F1
F0.00014334862385321102
I0
I1
I-1
tp74093
sS'in,healthy,women'
p74094
(F1
F0.00014334862385321102
I0
I1
I-1
tp74095
sS'tablets,should,have'
p74096
(F1
F0.00014334862385321102
I1
I0
I1
tp74097
sS'both,s-warfarin,a'
p74098
(F1
F0.00014334862385321102
I1
I0
I1
tp74099
sS'of,effect,of'
p74100
(F1
F0.00014334862385321102
I0
I1
I-1
tp74101
sS'an,additive,interaction'
p74102
(F1
F0.00014334862385321102
I1
I0
I1
tp74103
sS'which,healthy,subjects'
p74104
(F1
F0.00014334862385321102
I0
I1
I-1
tp74105
sS'interaction,observed,between'
p74106
(F1
F0.00014334862385321102
I1
I0
I1
tp74107
sS'of,cardiac,function'
p74108
(F1
F0.00014334862385321102
I1
I0
I1
tp74109
sS'consequence,of,blocking'
p74110
(F1
F0.00014334862385321102
I1
I0
I1
tp74111
sS'who,take,lodine'
p74112
(F1
F0.00014334862385321102
I0
I1
I-1
tp74113
sS'experiments,reported,here'
p74114
(F1
F0.00014334862385321102
I0
I1
I-1
tp74115
sS'although,may,increase'
p74116
(F1
F0.00014334862385321102
I1
I0
I1
tp74117
sS'in,normal,and'
p74118
(F1
F0.00014334862385321102
I0
I1
I-1
tp74119
sS'of,this,protein'
p74120
(F1
F0.00014334862385321102
I1
I0
I1
tp74121
sS'enkephalinergic,neurons,and'
p74122
(F1
F0.00014334862385321102
I1
I0
I1
tp74123
sS'influence,the,pharmacokinetics'
p74124
(F1
F0.00043004587155963305
I0
I3
I-3
tp74125
sS'acid,in,large'
p74126
(F1
F0.00014334862385321102
I1
I0
I1
tp74127
sS'avoided,because,of'
p74128
(F1
F0.00014334862385321102
I1
I0
I1
tp74129
sS'and,during,concomitant'
p74130
(F1
F0.00028669724770642203
I0
I2
I-2
tp74131
sS'or,induces,the'
p74132
(F1
F0.00014334862385321102
I0
I1
I-1
tp74133
sS'complication,of,treatment'
p74134
(F1
F0.00014334862385321102
I0
I1
I-1
tp74135
sS'study,it,was'
p74136
(F1
F0.00014334862385321102
I0
I1
I-1
tp74137
sS'partly,antagonized,the'
p74138
(F1
F0.00014334862385321102
I1
I0
I1
tp74139
sS'be,carefully,titrated'
p74140
(F1
F0.00014334862385321102
I1
I0
I1
tp74141
sS'two,times,the'
p74142
(F1
F0.00014334862385321102
I0
I1
I-1
tp74143
sS'system,regardless,of'
p74144
(F1
F0.00014334862385321102
I1
I0
I1
tp74145
sS'other,niacin,nicotinic'
p74146
(F1
F0.00014334862385321102
I0
I1
I-1
tp74147
sS'and,pharmacological,therapy'
p74148
(F1
F0.00014334862385321102
I0
I1
I-1
tp74149
sS'converting,difluoro-2,propanol'
p74150
(F1
F0.00014334862385321102
I1
I0
I1
tp74151
sS'to,increase,catabolism'
p74152
(F1
F0.00014334862385321102
I0
I1
I-1
tp74153
sS'by,causing,bone'
p74154
(F1
F0.00014334862385321102
I1
I0
I1
tp74155
sS'evidence,to,date'
p74156
(F1
F0.00014334862385321102
I0
I1
I-1
tp74157
sS'vistide,and,agents'
p74158
(F1
F0.00014334862385321102
I1
I0
I1
tp74159
sS'with,agents,known'
p74160
(F1
F0.00014334862385321102
I1
I0
I1
tp74161
sS'rats,given,high'
p74162
(F1
F0.00014334862385321102
I1
I0
I1
tp74163
sS'other,hormonal,are'
p74164
(F1
F0.00014334862385321102
I0
I1
I-1
tp74165
sS'humans,can,lead'
p74166
(F1
F0.00014334862385321102
I1
I0
I1
tp74167
sS'case,of,toxicity'
p74168
(F1
F0.00014334862385321102
I1
I0
I1
tp74169
sS'results,from,an'
p74170
(F1
F0.00028669724770642203
I0
I2
I-2
tp74171
sS'h,receptor,antagonists'
p74172
(F1
F0.00014334862385321102
I1
I0
I1
tp74173
sS'supplements,may,result'
p74174
(F1
F0.00014334862385321102
I0
I1
I-1
tp74175
sS'ketoconazole,did,not'
p74176
(F1
F0.00014334862385321102
I0
I1
I-1
tp74177
sS'inhibitors,and,substrates'
p74178
(F1
F0.00014334862385321102
I1
I0
I1
tp74179
sS'kg,w,in'
p74180
(F1
F0.00014334862385321102
I1
I0
I1
tp74181
sS'suggest,that,affect'
p74182
(F1
F0.00014334862385321102
I0
I1
I-1
tp74183
sS'subjects,concurrent,administration'
p74184
(F1
F0.00014334862385321102
I1
I0
I1
tp74185
sS'increase,the,risks'
p74186
(F1
F0.00014334862385321102
I1
I0
I1
tp74187
sS'cell,lines,u937'
p74188
(F1
F0.00014334862385321102
I1
I0
I1
tp74189
sS'other,agents,with'
p74190
(F1
F0.00014334862385321102
I1
I0
I1
tp74191
sS'compatible,with,the'
p74192
(F1
F0.00014334862385321102
I0
I1
I-1
tp74193
sS'which,inhibit,cyp'
p74194
(F1
F0.00014334862385321102
I1
I0
I1
tp74195
sS'the,homocysteine,excretion'
p74196
(F1
F0.00014334862385321102
I0
I1
I-1
tp74197
sS'interactions,with,antacids'
p74198
(F1
F0.00014334862385321102
I1
I0
I1
tp74199
sS'membrane,sterol,in'
p74200
(F1
F0.00014334862385321102
I0
I1
I-1
tp74201
sS'imidazole,and,triazole'
p74202
(F1
F0.00014334862385321102
I0
I1
I-1
tp74203
sS'of,cyp-2c19,by'
p74204
(F1
F0.00014334862385321102
I0
I1
I-1
tp74205
sS'coadministration,of,decreases'
p74206
(F1
F0.00014334862385321102
I1
I0
I1
tp74207
sS'vioxx,therapy,in'
p74208
(F1
F0.00014334862385321102
I1
I0
I1
tp74209
sS'dose,pharmacokinetics,of'
p74210
(F1
F0.00028669724770642203
I0
I2
I-2
tp74211
sS'therefore,proton,pump'
p74212
(F1
F0.00014334862385321102
I1
I0
I1
tp74213
sS'effective,in,the'
p74214
(F1
F0.00014334862385321102
I1
I0
I1
tp74215
sS'beta,adrenergic-blocking,agents'
p74216
(F1
F0.00014334862385321102
I0
I1
I-1
tp74217
sS'induce,microsomal,enzymes'
p74218
(F1
F0.00014334862385321102
I1
I0
I1
tp74219
sS'of,be,reduced'
p74220
(F1
F0.00014334862385321102
I1
I0
I1
tp74221
sS'coadministration,of,decreased'
p74222
(F1
F0.00014334862385321102
I1
I0
I1
tp74223
sS'a,valid,prothrombin'
p74224
(F1
F0.00014334862385321102
I1
I0
I1
tp74225
sS'the,capsule,formulation'
p74226
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp74227
sS'mg,kg,mc'
p74228
(F1
F0.00014334862385321102
I0
I1
I-1
tp74229
sS'usually,a,lower'
p74230
(F1
F0.00014334862385321102
I1
I0
I1
tp74231
sS'to,as,nsaids'
p74232
(F1
F0.00014334862385321102
I0
I1
I-1
tp74233
sS'pathway,that,is'
p74234
(F1
F0.00014334862385321102
I0
I1
I-1
tp74235
sS'mg,m2,and'
p74236
(F1
F0.00014334862385321102
I1
I0
I1
tp74237
sS'soon,after,administration'
p74238
(F1
F0.00014334862385321102
I1
I0
I1
tp74239
sS'they,respond,differently'
p74240
(F1
F0.00014334862385321102
I0
I1
I-1
tp74241
sS'glucose,metabolism,in'
p74242
(F1
F0.00014334862385321102
I0
I1
I-1
tp74243
sS'are,not,effected'
p74244
(F1
F0.00014334862385321102
I0
I1
I-1
tp74245
sS'nizoral,tablets,and'
p74246
(F1
F0.00014334862385321102
I1
I0
I1
tp74247
sS'co-administration,of,with'
p74248
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp74249
sS'induced,by,administration'
p74250
(F1
F0.00014334862385321102
I0
I1
I-1
tp74251
sS'apparent,pharmacokinetic,interaction'
p74252
(F1
F0.00057339449541284407
I0
I4
I-4
tp74253
sS'and,appropriate,dosage'
p74254
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp74255
sS'daily,followed,by'
p74256
(F1
F0.00014334862385321102
I1
I0
I1
tp74257
sS'of,measured,at'
p74258
(F1
F0.00014334862385321102
I0
I1
I-1
tp74259
sS'its,effects,on'
p74260
(F1
F0.00014334862385321102
I0
I1
I-1
tp74261
sS'rhythm,following,administration'
p74262
(F1
F0.00014334862385321102
I1
I0
I1
tp74263
sS'in,the,concentration'
p74264
(F1
F0.00028669724770642203
I2
I0
I2
tp74265
sS'the,clearance,or'
p74266
(F1
F0.00014334862385321102
I0
I1
I-1
tp74267
sS'with,can,be'
p74268
(F1
F0.00014334862385321102
I1
I0
I1
tp74269
sS'when,cime-tidine,therapy'
p74270
(F1
F0.00014334862385321102
I1
I0
I1
tp74271
sS'tested,more,frequently'
p74272
(F1
F0.00014334862385321102
I0
I1
I-1
tp74273
sS'effects,on,blood'
p74274
(F1
F0.00014334862385321102
I0
I1
I-1
tp74275
sS'the,clearance,of'
p74276
(F0.58620689655172409
F0.0024369266055045873
I23
I6
I17
tp74277
sS'and,and,possibly'
p74278
(F1
F0.00014334862385321102
I1
I0
I1
tp74279
sS'that,may,affect'
p74280
(F1
F0.00028669724770642203
I0
I2
I-2
tp74281
sS'h,to,ml'
p74282
(F0
F0
I1
I1
I0
tp74283
sS'increased,risks,of'
p74284
(F1
F0.00014334862385321102
I1
I0
I1
tp74285
sS'however,it,adversely'
p74286
(F1
F0.00014334862385321102
I1
I0
I1
tp74287
sS'serum,levels,is'
p74288
(F1
F0.00014334862385321102
I1
I0
I1
tp74289
sS'the,choice,of'
p74290
(F1
F0.00014334862385321102
I0
I1
I-1
tp74291
sS'function,or,compete'
p74292
(F1
F0.00014334862385321102
I0
I1
I-1
tp74293
sS'adverse,event,profile'
p74294
(F1
F0.00014334862385321102
I0
I1
I-1
tp74295
sS'be,an,inhibitor'
p74296
(F1
F0.00071674311926605509
I0
I5
I-5
tp74297
sS'be,noted,that'
p74298
(F1
F0.00028669724770642203
I2
I0
I2
tp74299
sS'because,the,degree'
p74300
(F1
F0.00014334862385321102
I1
I0
I1
tp74301
sS'and,sodium,an'
p74302
(F1
F0.00014334862385321102
I0
I1
I-1
tp74303
sS'foscavir,should,be'
p74304
(F1
F0.00014334862385321102
I1
I0
I1
tp74305
sS'potentiates,the,muscle'
p74306
(F1
F0.00014334862385321102
I1
I0
I1
tp74307
sS'this,may,indicate'
p74308
(F1
F0.00014334862385321102
I1
I0
I1
tp74309
sS'were,not,significantly'
p74310
(F1
F0.0008600917431192661
I0
I6
I-6
tp74311
sS'orthostatic,hypotension,has'
p74312
(F1
F0.00028669724770642203
I2
I0
I2
tp74313
sS'in,the,diabetics'
p74314
(F1
F0.00014334862385321102
I0
I1
I-1
tp74315
sS'or,nitrous,oxide'
p74316
(F1
F0.00014334862385321102
I0
I1
I-1
tp74317
sS'busulfex,at,the'
p74318
(F1
F0.00014334862385321102
I1
I0
I1
tp74319
sS'were,tested,for'
p74320
(F1
F0.00014334862385321102
I0
I1
I-1
tp74321
sS'normal,but,should'
p74322
(F1
F0.00014334862385321102
I1
I0
I1
tp74323
sS'inhibit,cyp3a4,eg'
p74324
(F1
F0.00014334862385321102
I1
I0
I1
tp74325
sS'optimal,pulmonary,function'
p74326
(F1
F0.00014334862385321102
I0
I1
I-1
tp74327
sS'pharmacokinetic,dosing,of'
p74328
(F1
F0.00014334862385321102
I0
I1
I-1
tp74329
sS'strong,and,completely'
p74330
(F1
F0.00014334862385321102
I1
I0
I1
tp74331
sS'that,accompany,high'
p74332
(F1
F0.00014334862385321102
I1
I0
I1
tp74333
sS'concomitantly,within14,days'
p74334
(F1
F0.00014334862385321102
I1
I0
I1
tp74335
sS'significantly,decreased,when'
p74336
(F1
F0.00014334862385321102
I1
I0
I1
tp74337
sS'fdf,at,micromol'
p74338
(F1
F0.00014334862385321102
I1
I0
I1
tp74339
sS'considered,in,patients'
p74340
(F1
F0.00028669724770642203
I0
I2
I-2
tp74341
sS'of,and,ortho-novum'
p74342
(F1
F0.00014334862385321102
I1
I0
I1
tp74343
sS'acid,and,b12'
p74344
(F1
F0.00014334862385321102
I0
I1
I-1
tp74345
sS'r,b,the'
p74346
(F1
F0.00014334862385321102
I0
I1
I-1
tp74347
sS'less,enzyme,induction'
p74348
(F1
F0.00014334862385321102
I0
I1
I-1
tp74349
sS'effect,on,certain'
p74350
(F1
F0.00014334862385321102
I1
I0
I1
tp74351
sS'ketoconazole,ketoconazole,and'
p74352
(F1
F0.00014334862385321102
I0
I1
I-1
tp74353
sS'metal,cations,or'
p74354
(F1
F0.00014334862385321102
I1
I0
I1
tp74355
sS'high,affinity,binding'
p74356
(F1
F0.00028669724770642203
I0
I2
I-2
tp74357
sS'and,mg,qd'
p74358
(F0
F0
I1
I1
I0
tp74359
sS'hyperthermia,crisis,until'
p74360
(F1
F0.00014334862385321102
I1
I0
I1
tp74361
sS'major,circulating,metabolite'
p74362
(F1
F0.00014334862385321102
I0
I1
I-1
tp74363
sS'may,alter,the'
p74364
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp74365
sS'bone,marrow,depression'
p74366
(F1
F0.00014334862385321102
I1
I0
I1
tp74367
sS'use,of,activated'
p74368
(F1
F0.00014334862385321102
I0
I1
I-1
tp74369
sS'the,following,agents'
p74370
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp74371
sS'the,liver,and'
p74372
(F1
F0.00057339449541284407
I4
I0
I4
tp74373
sS'of,increased,interaction'
p74374
(F1
F0.00014334862385321102
I0
I1
I-1
tp74375
sS'induced,concentration-dependent,relaxation'
p74376
(F1
F0.00014334862385321102
I0
I1
I-1
tp74377
sS'inhibition,of,total'
p74378
(F1
F0.00014334862385321102
I1
I0
I1
tp74379
sS'kg,decreases,the'
p74380
(F1
F0.00014334862385321102
I0
I1
I-1
tp74381
sS'blocking,agents,the'
p74382
(F0
F0
I1
I1
I0
tp74383
sS'normal,volunteers,concomitant'
p74384
(F1
F0.00043004587155963305
I3
I0
I3
tp74385
sS'potent,in,inhibiting'
p74386
(F1
F0.00014334862385321102
I0
I1
I-1
tp74387
sS'controlled-release,capsule,was'
p74388
(F1
F0.00014334862385321102
I1
I0
I1
tp74389
sS'red-orange,which,may'
p74390
(F1
F0.00014334862385321102
I0
I1
I-1
tp74391
sS'therapeutic,index,and'
p74392
(F1
F0.00014334862385321102
I0
I1
I-1
tp74393
sS'receiving,zyvox,may'
p74394
(F1
F0.00014334862385321102
I1
I0
I1
tp74395
sS'pcp,in,two-lever'
p74396
(F1
F0.00014334862385321102
I0
I1
I-1
tp74397
sS'levels,increased,by'
p74398
(F1
F0.00014334862385321102
I1
I0
I1
tp74399
sS'in,mice,after'
p74400
(F1
F0.00014334862385321102
I0
I1
I-1
tp74401
sS'not,been,reported'
p74402
(F1
F0.00028669724770642203
I2
I0
I2
tp74403
sS'and,addicts,were'
p74404
(F1
F0.00014334862385321102
I1
I0
I1
tp74405
sS'slow-channel,blockers,such'
p74406
(F1
F0.00014334862385321102
I0
I1
I-1
tp74407
sS'and,at,concentrations'
p74408
(F1
F0.00014334862385321102
I0
I1
I-1
tp74409
sS'coadministration,of,sular'
p74410
(F1
F0.00014334862385321102
I1
I0
I1
tp74411
sS'but,available,data'
p74412
(F1
F0.00014334862385321102
I0
I1
I-1
tp74413
sS'of,in,lean'
p74414
(F1
F0.00014334862385321102
I0
I1
I-1
tp74415
sS'antidepressant,levels,and'
p74416
(F1
F0.00014334862385321102
I1
I0
I1
tp74417
sS'carbamazepine,is,known'
p74418
(F1
F0.00014334862385321102
I0
I1
I-1
tp74419
sS'much,lower,affinities'
p74420
(F1
F0.00014334862385321102
I0
I1
I-1
tp74421
sS'patients,with,normal'
p74422
(F1
F0.00014334862385321102
I1
I0
I1
tp74423
sS'inhibitor,is,administered'
p74424
(F1
F0.00014334862385321102
I1
I0
I1
tp74425
sS'administration,of,hydrochloride'
p74426
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp74427
sS'epithelium,proliferates,in'
p74428
(F1
F0.00014334862385321102
I0
I1
I-1
tp74429
sS'neutralized,the,increase'
p74430
(F1
F0.00028669724770642203
I0
I2
I-2
tp74431
sS'may,be,reduced'
p74432
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp74433
sS'vivo,by,inhibition'
p74434
(F1
F0.00014334862385321102
I0
I1
I-1
tp74435
sS'desired,lactulose-induced,drop'
p74436
(F1
F0.00014334862385321102
I1
I0
I1
tp74437
sS'these,is,likely'
p74438
(F1
F0.00014334862385321102
I1
I0
I1
tp74439
sS'as,or,a'
p74440
(F1
F0.00014334862385321102
I0
I1
I-1
tp74441
sS'it,is,felt'
p74442
(F1
F0.00014334862385321102
I1
I0
I1
tp74443
sS'has,been,studied'
p74444
(F1
F0.00071674311926605509
I0
I5
I-5
tp74445
sS'self-injection,of,crushed'
p74446
(F1
F0.00014334862385321102
I0
I1
I-1
tp74447
sS'inhibit,p450,d6'
p74448
(F1
F0.00071674311926605509
I0
I5
I-5
tp74449
sS'reduce,the,effect'
p74450
(F1
F0.00028669724770642203
I2
I0
I2
tp74451
sS'chromaffin,cell,including'
p74452
(F1
F0.00014334862385321102
I0
I1
I-1
tp74453
sS'day,followed,by'
p74454
(F1
F0.00014334862385321102
I1
I0
I1
tp74455
sS'calcium-containing,medicines,including'
p74456
(F1
F0.00014334862385321102
I0
I1
I-1
tp74457
sS'lethargy,and,coma'
p74458
(F1
F0.00014334862385321102
I1
I0
I1
tp74459
sS'of,oral,and'
p74460
(F1
F0.00043004587155963305
I3
I0
I3
tp74461
sS'nizoral,sporanox,lipitor'
p74462
(F1
F0.00014334862385321102
I1
I0
I1
tp74463
sS'concomitantly,with,should'
p74464
(F1
F0.00014334862385321102
I1
I0
I1
tp74465
sS'and,should,therefore'
p74466
(F1
F0.00043004587155963305
I3
I0
I3
tp74467
sS'users,experiencing,breakthrough'
p74468
(F1
F0.00014334862385321102
I0
I1
I-1
tp74469
sS'pressure,reductions,of'
p74470
(F1
F0.00014334862385321102
I1
I0
I1
tp74471
sS'with,the,commonly'
p74472
(F1
F0.00014334862385321102
I0
I1
I-1
tp74473
sS'this,isoenzyme,including'
p74474
(F0
F0
I1
I1
I0
tp74475
sS'therapies,standard,monitoring'
p74476
(F1
F0.00014334862385321102
I0
I1
I-1
tp74477
sS'escherichia,coli,and'
p74478
(F1
F0.00014334862385321102
I0
I1
I-1
tp74479
sS'c,max,and'
p74480
(F1
F0.00014334862385321102
I0
I1
I-1
tp74481
sS'blockers,although,the'
p74482
(F1
F0.00014334862385321102
I1
I0
I1
tp74483
sS'pesticide,the,metabolism'
p74484
(F1
F0.00014334862385321102
I0
I1
I-1
tp74485
sS'wort,in,patients'
p74486
(F1
F0.00014334862385321102
I0
I1
I-1
tp74487
sS'impairment,clcr,and'
p74488
(F1
F0.00014334862385321102
I1
I0
I1
tp74489
sS'low-dose,hcl,and'
p74490
(F1
F0.00014334862385321102
I1
I0
I1
tp74491
sS'to,be,administered'
p74492
(F0.33333333333333331
F0.00028669724770642203
I4
I2
I2
tp74493
sS'of,suggested,the'
p74494
(F1
F0.00014334862385321102
I0
I1
I-1
tp74495
sS'metabolism,or,on'
p74496
(F1
F0.00014334862385321102
I0
I1
I-1
tp74497
sS'of,patients,who'
p74498
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp74499
sS'addition,steady,state'
p74500
(F1
F0.00014334862385321102
I0
I1
I-1
tp74501
sS'carefully,monitored,see'
p74502
(F1
F0.00014334862385321102
I0
I1
I-1
tp74503
sS'but,the,rate'
p74504
(F1
F0.00014334862385321102
I0
I1
I-1
tp74505
sS'when,was,administered'
p74506
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp74507
sS'gabitril,on,other'
p74508
(F1
F0.00014334862385321102
I0
I1
I-1
tp74509
sS'factors,studied,two'
p74510
(F1
F0.00014334862385321102
I1
I0
I1
tp74511
sS'metabolized,in,part'
p74512
(F1
F0.00014334862385321102
I0
I1
I-1
tp74513
sS'and,this,neurotoxic'
p74514
(F1
F0.00014334862385321102
I1
I0
I1
tp74515
sS'on,blocking,the'
p74516
(F1
F0.00014334862385321102
I0
I1
I-1
tp74517
sS'of,mental,and'
p74518
(F1
F0.00014334862385321102
I0
I1
I-1
tp74519
sS'a,lower,plasma'
p74520
(F1
F0.00014334862385321102
I0
I1
I-1
tp74521
sS'treatment,folic,acid'
p74522
(F1
F0.00014334862385321102
I1
I0
I1
tp74523
sS'usually,within,the'
p74524
(F1
F0.00014334862385321102
I1
I0
I1
tp74525
sS'sedative,effects,of'
p74526
(F1
F0.00014334862385321102
I1
I0
I1
tp74527
sS'its,abrupt,suppression'
p74528
(F1
F0.00014334862385321102
I1
I0
I1
tp74529
sS'is,an,anion'
p74530
(F1
F0.00014334862385321102
I0
I1
I-1
tp74531
sS'delayed,adverse,reactions'
p74532
(F1
F0.00014334862385321102
I1
I0
I1
tp74533
sS'potential,for,other'
p74534
(F1
F0.00028669724770642203
I0
I2
I-2
tp74535
sS'involvement,labeling,index'
p74536
(F1
F0.00014334862385321102
I0
I1
I-1
tp74537
sS'peripheral,neuropathy,or'
p74538
(F1
F0.00014334862385321102
I1
I0
I1
tp74539
sS'use,of,usually'
p74540
(F1
F0.00014334862385321102
I1
I0
I1
tp74541
sS'on,day5,of'
p74542
(F1
F0.00014334862385321102
I1
I0
I1
tp74543
sS'to,about,absorption'
p74544
(F1
F0.00014334862385321102
I0
I1
I-1
tp74545
sS'e,mg,kg'
p74546
(F1
F0.00014334862385321102
I1
I0
I1
tp74547
sS'on,the,pharmacokinetits'
p74548
(F1
F0.00014334862385321102
I0
I1
I-1
tp74549
sS'closely,monitored,and'
p74550
(F1
F0.00028669724770642203
I2
I0
I2
tp74551
sS'vascular,response,to'
p74552
(F1
F0.00014334862385321102
I1
I0
I1
tp74553
sS'by,ex,vivo'
p74554
(F1
F0.00014334862385321102
I0
I1
I-1
tp74555
sS'ketoconazole,at,mg'
p74556
(F1
F0.00014334862385321102
I1
I0
I1
tp74557
sS'ketoconazole,concomitant,use'
p74558
(F1
F0.00014334862385321102
I0
I1
I-1
tp74559
sS'as,have,been'
p74560
(F1
F0.00014334862385321102
I1
I0
I1
tp74561
sS'for,several,days'
p74562
(F1
F0.00043004587155963305
I3
I0
I3
tp74563
sS'chlorthalidone,may,add'
p74564
(F1
F0.00014334862385321102
I1
I0
I1
tp74565
sS'an,alternative,non-cyp3a4'
p74566
(F1
F0.00014334862385321102
I0
I1
I-1
tp74567
sS'and,were,in'
p74568
(F1
F0.00014334862385321102
I0
I1
I-1
tp74569
sS'to,reduce,proleukin-induced'
p74570
(F1
F0.00014334862385321102
I1
I0
I1
tp74571
sS'patients,receiving,will'
p74572
(F1
F0.00014334862385321102
I1
I0
I1
tp74573
sS'greater,than,when'
p74574
(F1
F0.00014334862385321102
I1
I0
I1
tp74575
sS'together,with,depen'
p74576
(F1
F0.00014334862385321102
I1
I0
I1
tp74577
sS'its,dose,should'
p74578
(F1
F0.00014334862385321102
I1
I0
I1
tp74579
sS'to,may,be'
p74580
(F1
F0.00014334862385321102
I1
I0
I1
tp74581
sS'days,and,a'
p74582
(F1
F0.00014334862385321102
I1
I0
I1
tp74583
sS'intestinal,beta-glucuronidase,are'
p74584
(F1
F0.00014334862385321102
I0
I1
I-1
tp74585
sS'following,immunosuppressives,cyclosporine'
p74586
(F1
F0.00014334862385321102
I0
I1
I-1
tp74587
sS'among,these,patients'
p74588
(F1
F0.00014334862385321102
I0
I1
I-1
tp74589
sS'refer,to,the'
p74590
(F0
F0
I2
I2
I0
tp74591
sS'administration,of,d-penicillamine'
p74592
(F1
F0.00014334862385321102
I0
I1
I-1
tp74593
sS'the,antimicrobial,effect'
p74594
(F1
F0.00014334862385321102
I0
I1
I-1
tp74595
sS'a,gritty,substance'
p74596
(F1
F0.00014334862385321102
I1
I0
I1
tp74597
sS'and,unpredictable,potentiation'
p74598
(F1
F0.00014334862385321102
I1
I0
I1
tp74599
sS'appetite,and,compared'
p74600
(F1
F0.00014334862385321102
I0
I1
I-1
tp74601
sS'secretion,of,based'
p74602
(F1
F0.00014334862385321102
I1
I0
I1
tp74603
sS'and,the,therapeutic'
p74604
(F1
F0.00014334862385321102
I0
I1
I-1
tp74605
sS'with,dosage,adjustment'
p74606
(F1
F0.00014334862385321102
I0
I1
I-1
tp74607
sS'oral,and,other'
p74608
(F1
F0.00014334862385321102
I1
I0
I1
tp74609
sS'potential,for,pharmacokinetic'
p74610
(F1
F0.00014334862385321102
I0
I1
I-1
tp74611
sS'dosing,recommendations,for'
p74612
(F1
F0.00014334862385321102
I0
I1
I-1
tp74613
sS'in,rats,in'
p74614
(F1
F0.00014334862385321102
I1
I0
I1
tp74615
sS'as,a,mg'
p74616
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp74617
sS'efficiently,inhibited,by'
p74618
(F1
F0.00014334862385321102
I0
I1
I-1
tp74619
sS'properly,and,and'
p74620
(F1
F0.00014334862385321102
I0
I1
I-1
tp74621
sS'diazepam,the,co-administration'
p74622
(F1
F0.00014334862385321102
I1
I0
I1
tp74623
sS'transit,time,hydrogen'
p74624
(F1
F0.00014334862385321102
I0
I1
I-1
tp74625
sS'two,studies,in'
p74626
(F1
F0.00014334862385321102
I1
I0
I1
tp74627
sS'concentrations,were,to'
p74628
(F1
F0.00014334862385321102
I1
I0
I1
tp74629
sS'of,the,increased'
p74630
(F0
F0
I1
I1
I0
tp74631
sS'altered,renal,function'
p74632
(F1
F0.00014334862385321102
I0
I1
I-1
tp74633
sS'pharmacodynamics,of,or'
p74634
(F1
F0.00014334862385321102
I0
I1
I-1
tp74635
sS'be,considered,and'
p74636
(F1
F0.00043004587155963305
I0
I3
I-3
tp74637
sS'pharmacology,drug,interactions'
p74638
(F1
F0.00014334862385321102
I1
I0
I1
tp74639
sS'and,were,variable'
p74640
(F1
F0.00014334862385321102
I0
I1
I-1
tp74641
sS'in,the,pharmacodynamic'
p74642
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp74643
sS'and,motor,effects'
p74644
(F1
F0.00014334862385321102
I1
I0
I1
tp74645
sS'enhances,the,degree'
p74646
(F1
F0.00014334862385321102
I1
I0
I1
tp74647
sS'of,mg,causing'
p74648
(F1
F0.00014334862385321102
I0
I1
I-1
tp74649
sS'with,cgs,an'
p74650
(F1
F0.00014334862385321102
I1
I0
I1
tp74651
sS'dexbrompheniramine,can,interact'
p74652
(F1
F0.00028669724770642203
I2
I0
I2
tp74653
sS'onset,can,be'
p74654
(F1
F0.00014334862385321102
I1
I0
I1
tp74655
sS'physicians,needing,to'
p74656
(F1
F0.00014334862385321102
I0
I1
I-1
tp74657
sS'who,switched,from'
p74658
(F1
F0.00014334862385321102
I0
I1
I-1
tp74659
sS'plasmaconcentration,of,other'
p74660
(F1
F0.00014334862385321102
I1
I0
I1
tp74661
sS'plasma,concentration,and'
p74662
(F1
F0.00043004587155963305
I3
I0
I3
tp74663
sS'in,significantly,elevating'
p74664
(F1
F0.00014334862385321102
I1
I0
I1
tp74665
sS'one,hour,apart'
p74666
(F1
F0.00014334862385321102
I1
I0
I1
tp74667
sS'extent,with,that'
p74668
(F1
F0.00014334862385321102
I0
I1
I-1
tp74669
sS'bun,and,fbs'
p74670
(F1
F0.00014334862385321102
I1
I0
I1
tp74671
sS'level,of,exposure'
p74672
(F1
F0.00014334862385321102
I1
I0
I1
tp74673
sS'slight,delay,in'
p74674
(F1
F0.00014334862385321102
I1
I0
I1
tp74675
sS'products,absorption,of'
p74676
(F1
F0.00014334862385321102
I0
I1
I-1
tp74677
sS'antiepileptic,drugs,on'
p74678
(F1
F0.00014334862385321102
I1
I0
I1
tp74679
sS'may,reduce,endogenous'
p74680
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp74681
sS'antigen,psa,decreased'
p74682
(F1
F0.00014334862385321102
I0
I1
I-1
tp74683
sS'injection,lorazepam,injection'
p74684
(F1
F0.00014334862385321102
I1
I0
I1
tp74685
sS'reduce,hepatic,metabolism'
p74686
(F1
F0.00014334862385321102
I1
I0
I1
tp74687
sS'acitretin,interferes,with'
p74688
(F1
F0.00014334862385321102
I1
I0
I1
tp74689
sS'which,could,cause'
p74690
(F1
F0.00014334862385321102
I0
I1
I-1
tp74691
sS'femara,with,these'
p74692
(F1
F0.00014334862385321102
I0
I1
I-1
tp74693
sS'therapy,with,and'
p74694
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp74695
sS'nacmc,conjugated,with'
p74696
(F1
F0.00014334862385321102
I0
I1
I-1
tp74697
sS'sulfate,prednisolone,sodium'
p74698
(F1
F0.00014334862385321102
I0
I1
I-1
tp74699
sS'increased,during,concomitant'
p74700
(F1
F0.00014334862385321102
I1
I0
I1
tp74701
sS'lofexidine,may,enhance'
p74702
(F1
F0.00028669724770642203
I2
I0
I2
tp74703
sS'the,contraceptive,effect'
p74704
(F1
F0.00014334862385321102
I1
I0
I1
tp74705
sS'vardenafil,or,mg'
p74706
(F1
F0.00014334862385321102
I1
I0
I1
tp74707
sS'arginine,in,the'
p74708
(F1
F0.00028669724770642203
I0
I2
I-2
tp74709
sS'inducer,of,udp-glucuronyl'
p74710
(F1
F0.00014334862385321102
I0
I1
I-1
tp74711
sS'and,may,occur'
p74712
(F1
F0.00014334862385321102
I1
I0
I1
tp74713
sS'comparison,study,and'
p74714
(F1
F0.00014334862385321102
I0
I1
I-1
tp74715
sS'concurrently,subjects,should'
p74716
(F1
F0.00057339449541284407
I4
I0
I4
tp74717
sS'doses,of,desmopressin'
p74718
(F1
F0.00014334862385321102
I0
I1
I-1
tp74719
sS'the,concurrent,use'
p74720
(F0.33333333333333331
F0.00043004587155963305
I6
I3
I3
tp74721
sS'of,to,micrograms'
p74722
(F1
F0.00028669724770642203
I2
I0
I2
tp74723
sS'pretreatment,augmented,the'
p74724
(F1
F0.00014334862385321102
I1
I0
I1
tp74725
sS'in,general,most'
p74726
(F1
F0.00014334862385321102
I0
I1
I-1
tp74727
sS'oruvail,voltaren,cataflam'
p74728
(F1
F0.00014334862385321102
I0
I1
I-1
tp74729
sS'though,such,interactions'
p74730
(F1
F0.00014334862385321102
I0
I1
I-1
tp74731
sS'for,therapeutic,efficacy'
p74732
(F1
F0.00014334862385321102
I0
I1
I-1
tp74733
sS'in,vitro,has'
p74734
(F1
F0.00014334862385321102
I1
I0
I1
tp74735
sS'cause,significant,sustained'
p74736
(F1
F0.00014334862385321102
I1
I0
I1
tp74737
sS'ranging,from,in'
p74738
(F1
F0.00028669724770642203
I0
I2
I-2
tp74739
sS'acetate,were,inconclusive'
p74740
(F1
F0.00014334862385321102
I0
I1
I-1
tp74741
sS'therefore,concurrent,use'
p74742
(F1
F0.00028669724770642203
I2
I0
I2
tp74743
sS'vivo,and,in'
p74744
(F1
F0.00014334862385321102
I0
I1
I-1
tp74745
sS'increased,blood,at'
p74746
(F1
F0.00014334862385321102
I0
I1
I-1
tp74747
sS'treated,with,plus'
p74748
(F1
F0.00014334862385321102
I1
I0
I1
tp74749
sS'monitored,in,the'
p74750
(F1
F0.00014334862385321102
I1
I0
I1
tp74751
sS'a,or,any'
p74752
(F1
F0.00014334862385321102
I1
I0
I1
tp74753
sS'there,are,no'
p74754
(F0.59999999999999998
F0.00043004587155963305
I1
I4
I-3
tp74755
sS'cholino-,and,adrenoreceptors'
p74756
(F1
F0.00014334862385321102
I0
I1
I-1
tp74757
sS'who,begin,taking'
p74758
(F1
F0.00014334862385321102
I1
I0
I1
tp74759
sS'can,suppress,the'
p74760
(F1
F0.00014334862385321102
I1
I0
I1
tp74761
sS'altered,decrease,in'
p74762
(F1
F0.00014334862385321102
I1
I0
I1
tp74763
sS'a,pharmacokinetic,interaction'
p74764
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp74765
sS'daily,dose,once'
p74766
(F1
F0.00014334862385321102
I0
I1
I-1
tp74767
sS'animal,studies,also'
p74768
(F1
F0.00014334862385321102
I1
I0
I1
tp74769
sS'capsule,n,mean'
p74770
(F1
F0.00014334862385321102
I1
I0
I1
tp74771
sS'and,nsaids,are'
p74772
(F1
F0.00014334862385321102
I1
I0
I1
tp74773
sS'and,respectively,suggesting'
p74774
(F1
F0.00014334862385321102
I1
I0
I1
tp74775
sS'substrates,in,vitro'
p74776
(F1
F0.00014334862385321102
I0
I1
I-1
tp74777
sS'acid,monoamine,oxidase'
p74778
(F1
F0.00014334862385321102
I1
I0
I1
tp74779
sS'doses,of,rocaltrol'
p74780
(F1
F0.00043004587155963305
I0
I3
I-3
tp74781
sS'curariform,effect,of'
p74782
(F1
F0.00014334862385321102
I1
I0
I1
tp74783
sS'study,adverse,effects'
p74784
(F1
F0.00014334862385321102
I1
I0
I1
tp74785
sS'single,dose,of'
p74786
(F0.037037037037037035
F0.00014334862385321102
I14
I13
I1
tp74787
sS'a,rauwolfia,alkaloid'
p74788
(F1
F0.00014334862385321102
I1
I0
I1
tp74789
sS'a,true,interaction'
p74790
(F1
F0.00014334862385321102
I1
I0
I1
tp74791
sS'i,selective,serotonin'
p74792
(F1
F0.00014334862385321102
I1
I0
I1
tp74793
sS'single,dose,or'
p74794
(F1
F0.00014334862385321102
I0
I1
I-1
tp74795
sS'buspirone,hcl,may'
p74796
(F1
F0.00014334862385321102
I1
I0
I1
tp74797
sS'interact,with,known'
p74798
(F1
F0.00014334862385321102
I0
I1
I-1
tp74799
sS'be,required,and'
p74800
(F0
F0
I1
I1
I0
tp74801
sS'with,any,antineoplastic'
p74802
(F1
F0.00014334862385321102
I0
I1
I-1
tp74803
sS'mind,when,orudis'
p74804
(F1
F0.00014334862385321102
I0
I1
I-1
tp74805
sS'the,clinical,significance'
p74806
(F0.5
F0.00028669724770642203
I3
I1
I2
tp74807
sS'result,in,coma'
p74808
(F1
F0.00014334862385321102
I1
I0
I1
tp74809
sS'these,in,vitro'
p74810
(F1
F0.00014334862385321102
I1
I0
I1
tp74811
sS'activity,of,this'
p74812
(F1
F0.00028669724770642203
I0
I2
I-2
tp74813
sS'cevimeline,should,be'
p74814
(F1
F0.00014334862385321102
I1
I0
I1
tp74815
sS'average,of,ci'
p74816
(F1
F0.00014334862385321102
I1
I0
I1
tp74817
sS'effectiveness,of,a'
p74818
(F1
F0.00014334862385321102
I1
I0
I1
tp74819
sS'of,may,increase'
p74820
(F1
F0.00028669724770642203
I2
I0
I2
tp74821
sS'to,to,cups'
p74822
(F1
F0.00014334862385321102
I0
I1
I-1
tp74823
sS'system,depressants,including'
p74824
(F1
F0.00028669724770642203
I2
I0
I2
tp74825
sS'which,could,decrease'
p74826
(F1
F0.00014334862385321102
I0
I1
I-1
tp74827
sS'other,coumarin-like,should'
p74828
(F1
F0.00014334862385321102
I1
I0
I1
tp74829
sS'by,any,route'
p74830
(F1
F0.00014334862385321102
I1
I0
I1
tp74831
sS'little,has,been'
p74832
(F1
F0.00014334862385321102
I0
I1
I-1
tp74833
sS'and,injectables,are'
p74834
(F1
F0.00014334862385321102
I0
I1
I-1
tp74835
sS'in,toxicity,in'
p74836
(F1
F0.00014334862385321102
I1
I0
I1
tp74837
sS'activity,of,within'
p74838
(F1
F0.00014334862385321102
I0
I1
I-1
tp74839
sS'receiving,and,which'
p74840
(F1
F0.00014334862385321102
I1
I0
I1
tp74841
sS'patients,using,should'
p74842
(F1
F0.00014334862385321102
I1
I0
I1
tp74843
sS'baseline,to,ng'
p74844
(F1
F0.00014334862385321102
I0
I1
I-1
tp74845
sS'administered,mg,orally'
p74846
(F1
F0.00014334862385321102
I0
I1
I-1
tp74847
sS'was,greater,when'
p74848
(F1
F0.00014334862385321102
I1
I0
I1
tp74849
sS'patients,on,tikosyn'
p74850
(F1
F0.00014334862385321102
I0
I1
I-1
tp74851
sS'demonstrated,moderate,to'
p74852
(F1
F0.00014334862385321102
I1
I0
I1
tp74853
sS'to,both,minimal'
p74854
(F1
F0.00014334862385321102
I0
I1
I-1
tp74855
sS'to,inactivate,the'
p74856
(F1
F0.00014334862385321102
I1
I0
I1
tp74857
sS'a,safe,problem'
p74858
(F1
F0.00014334862385321102
I1
I0
I1
tp74859
sS'before,or,hours'
p74860
(F1
F0.00057339449541284407
I4
I0
I4
tp74861
sS'necessary,eg,may'
p74862
(F1
F0.00014334862385321102
I1
I0
I1
tp74863
sS'bilirubin,elevations,with'
p74864
(F1
F0.00014334862385321102
I0
I1
I-1
tp74865
sS'weight,were,administered'
p74866
(F1
F0.00014334862385321102
I0
I1
I-1
tp74867
sS'drugs,cimetidine,co-administration'
p74868
(F1
F0.00014334862385321102
I0
I1
I-1
tp74869
sS'of,the,adverse'
p74870
(F1
F0.00014334862385321102
I0
I1
I-1
tp74871
sS'liter,potentiated,the'
p74872
(F1
F0.00014334862385321102
I1
I0
I1
tp74873
sS'a,six-day,course'
p74874
(F1
F0.00014334862385321102
I1
I0
I1
tp74875
sS'exposed,histidines,on'
p74876
(F1
F0.00014334862385321102
I0
I1
I-1
tp74877
sS'increases,ranging,from'
p74878
(F1
F0.00028669724770642203
I0
I2
I-2
tp74879
sS'prior,to,administering'
p74880
(F1
F0.00014334862385321102
I1
I0
I1
tp74881
sS'cyp450s,cyp1a2,cyp2a6'
p74882
(F1
F0.00014334862385321102
I0
I1
I-1
tp74883
sS'a,penicillin-type,are'
p74884
(F1
F0.00014334862385321102
I1
I0
I1
tp74885
sS'increases,in,mean'
p74886
(F1
F0.00014334862385321102
I1
I0
I1
tp74887
sS'various,such,as'
p74888
(F1
F0.00014334862385321102
I1
I0
I1
tp74889
sS'generally,converted,to'
p74890
(F1
F0.00014334862385321102
I1
I0
I1
tp74891
sS'of,intestinal,carcinogenesis'
p74892
(F1
F0.00014334862385321102
I0
I1
I-1
tp74893
sS'use,of,brevibloc'
p74894
(F1
F0.00014334862385321102
I1
I0
I1
tp74895
sS'these,have,been'
p74896
(F1
F0.00014334862385321102
I0
I1
I-1
tp74897
sS'nondepolarizing,possible,increased'
p74898
(F1
F0.00028669724770642203
I0
I2
I-2
tp74899
sS'higher,exposure,presumably'
p74900
(F1
F0.00014334862385321102
I1
I0
I1
tp74901
sS'or,mg,with'
p74902
(F1
F0.00014334862385321102
I1
I0
I1
tp74903
sS'endotoxin-induced,deaths,in'
p74904
(F1
F0.00014334862385321102
I1
I0
I1
tp74905
sS'its,metabolites,with'
p74906
(F1
F0.00014334862385321102
I1
I0
I1
tp74907
sS'activity,should,be'
p74908
(F1
F0.00014334862385321102
I1
I0
I1
tp74909
sS'on,sensipar,sensipar'
p74910
(F1
F0.00014334862385321102
I0
I1
I-1
tp74911
sS'alfenta,is,administered'
p74912
(F1
F0.00014334862385321102
I1
I0
I1
tp74913
sS'with,angiotensln,converting'
p74914
(F1
F0.00014334862385321102
I1
I0
I1
tp74915
sS'change,fasting,or'
p74916
(F1
F0.00014334862385321102
I0
I1
I-1
tp74917
sS'use,of,antithrombotics'
p74918
(F1
F0.00014334862385321102
I0
I1
I-1
tp74919
sS'to,check,coagulation'
p74920
(F1
F0.00014334862385321102
I1
I0
I1
tp74921
sS'increased,to,fold'
p74922
(F1
F0.00014334862385321102
I1
I0
I1
tp74923
sS'when,administering,etopophos'
p74924
(F1
F0.00014334862385321102
I1
I0
I1
tp74925
sS'contin,prelone,st'
p74926
(F1
F0.00014334862385321102
I1
I0
I1
tp74927
sS'produced,by,other'
p74928
(F1
F0.00014334862385321102
I0
I1
I-1
tp74929
sS'bleeding,particularly,in'
p74930
(F1
F0.00014334862385321102
I1
I0
I1
tp74931
sS'n,of,sodium'
p74932
(F1
F0.00014334862385321102
I1
I0
I1
tp74933
sS'preparations,before,use'
p74934
(F1
F0.00028669724770642203
I2
I0
I2
tp74935
sS'of,d,is'
p74936
(F1
F0.00014334862385321102
I0
I1
I-1
tp74937
sS'agents,likely,to'
p74938
(F1
F0.00014334862385321102
I0
I1
I-1
tp74939
sS'of,is,similar'
p74940
(F1
F0.00014334862385321102
I1
I0
I1
tp74941
sS'twice,those,observed'
p74942
(F1
F0.00014334862385321102
I1
I0
I1
tp74943
sS'edecrin,may,increase'
p74944
(F1
F0.00014334862385321102
I1
I0
I1
tp74945
sS'produce,nephrotoxicity,with'
p74946
(F1
F0.00014334862385321102
I1
I0
I1
tp74947
sS'in,a,follow-up'
p74948
(F1
F0.00014334862385321102
I0
I1
I-1
tp74949
sS'most,potent,inhibition'
p74950
(F1
F0.00014334862385321102
I0
I1
I-1
tp74951
sS'efficacy,compared,with'
p74952
(F1
F0.00014334862385321102
I0
I1
I-1
tp74953
sS'the,first,year'
p74954
(F1
F0.00014334862385321102
I0
I1
I-1
tp74955
sS'from,its,binding'
p74956
(F1
F0.00043004587155963305
I3
I0
I3
tp74957
sS'blood,at,different'
p74958
(F1
F0.00014334862385321102
I0
I1
I-1
tp74959
sS'analog,of,the'
p74960
(F1
F0.00014334862385321102
I0
I1
I-1
tp74961
sS'ten-subject,study,coadministration'
p74962
(F1
F0.00014334862385321102
I1
I0
I1
tp74963
sS'shown,to,reduce'
p74964
(F1
F0.00028669724770642203
I2
I0
I2
tp74965
sS'relative,risk,for'
p74966
(F1
F0.00014334862385321102
I0
I1
I-1
tp74967
sS'be,expected,when'
p74968
(F1
F0.00014334862385321102
I1
I0
I1
tp74969
sS'and,plasma,levels'
p74970
(F0
F0
I1
I1
I0
tp74971
sS'or,compete,for'
p74972
(F1
F0.00014334862385321102
I0
I1
I-1
tp74973
sS'with,may,enhance'
p74974
(F1
F0.00014334862385321102
I1
I0
I1
tp74975
sS'studies,involving,metabolized'
p74976
(F1
F0.00014334862385321102
I1
I0
I1
tp74977
sS'before,dosing,with'
p74978
(F1
F0.00014334862385321102
I1
I0
I1
tp74979
sS'anticholinergic,agents,may'
p74980
(F1
F0.00014334862385321102
I1
I0
I1
tp74981
sS'importance,sufficient,time'
p74982
(F1
F0.00014334862385321102
I1
I0
I1
tp74983
sS'cardiac,conduction,eg'
p74984
(F1
F0.00014334862385321102
I1
I0
I1
tp74985
sS'interaction,with,concomitantly'
p74986
(F1
F0.00014334862385321102
I1
I0
I1
tp74987
sS'course,of,mg'
p74988
(F0
F0
I1
I1
I0
tp74989
sS'increase,the,risk'
p74990
(F0.36363636363636365
F0.0011467889908256881
I15
I7
I8
tp74991
sS'weakness,hyperreflexia,and'
p74992
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp74993
sS'serum,concentration,of'
p74994
(F0
F0
I1
I1
I0
tp74995
sS'mc,decreases,heart'
p74996
(F1
F0.00014334862385321102
I0
I1
I-1
tp74997
sS'with,pegasys,once'
p74998
(F1
F0.00014334862385321102
I1
I0
I1
tp74999
sS'increase,plasma,levels'
p75000
(F1
F0.00043004587155963305
I3
I0
I3
tp75001
sS'rifampin,reduced,plasma'
p75002
(F1
F0.00014334862385321102
I1
I0
I1
tp75003
sS'triazolopyridazines,and,others'
p75004
(F1
F0.00014334862385321102
I1
I0
I1
tp75005
sS'nephrolithiasis,is,higher'
p75006
(F1
F0.00014334862385321102
I1
I0
I1
tp75007
sS'suggesting,that,at'
p75008
(F1
F0.00014334862385321102
I1
I0
I1
tp75009
sS'requiring,treatment,dyspnea'
p75010
(F1
F0.00014334862385321102
I0
I1
I-1
tp75011
sS'initiation,of,itraconazole'
p75012
(F1
F0.00014334862385321102
I1
I0
I1
tp75013
sS'of,decreased,approximately'
p75014
(F1
F0.00028669724770642203
I2
I0
I2
tp75015
sS'and,increases,in'
p75016
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp75017
sS'concentrations,and,peak'
p75018
(F1
F0.00014334862385321102
I1
I0
I1
tp75019
sS'blood,pressure,without'
p75020
(F1
F0.00014334862385321102
I1
I0
I1
tp75021
sS'benzodiazepines,combination,hormonal'
p75022
(F1
F0.00014334862385321102
I1
I0
I1
tp75023
sS'been,greater,than'
p75024
(F1
F0.00028669724770642203
I2
I0
I2
tp75025
sS'for,an,additive'
p75026
(F1
F0.00014334862385321102
I1
I0
I1
tp75027
sS'were,administered,concomitantly'
p75028
(F1
F0.00028669724770642203
I0
I2
I-2
tp75029
sS'epilepsy,also,receiving'
p75030
(F1
F0.00014334862385321102
I0
I1
I-1
tp75031
sS'therapy,for,maintenance'
p75032
(F1
F0.00014334862385321102
I0
I1
I-1
tp75033
sS'expected,that,the'
p75034
(F1
F0.00014334862385321102
I1
I0
I1
tp75035
sS'antibiotics,pregnancy,has'
p75036
(F1
F0.00014334862385321102
I0
I1
I-1
tp75037
sS'iv,ace,inhibitors'
p75038
(F1
F0.00014334862385321102
I0
I1
I-1
tp75039
sS'or,kineret,when'
p75040
(F1
F0.00014334862385321102
I0
I1
I-1
tp75041
sS'are,excreted,by'
p75042
(F1
F0.00014334862385321102
I0
I1
I-1
tp75043
sS'also,verified,by'
p75044
(F1
F0.00014334862385321102
I0
I1
I-1
tp75045
sS'antipsychotic,was,tested'
p75046
(F1
F0.00014334862385321102
I0
I1
I-1
tp75047
sS'involving,nizoral,tablets'
p75048
(F1
F0.00014334862385321102
I1
I0
I1
tp75049
sS'of,the,hypotensive'
p75050
(F1
F0.00014334862385321102
I1
I0
I1
tp75051
sS'supplements,theoretically,may'
p75052
(F1
F0.00014334862385321102
I1
I0
I1
tp75053
sS'to,the,major'
p75054
(F1
F0.00014334862385321102
I0
I1
I-1
tp75055
sS'mexate,use,of'
p75056
(F1
F0.00014334862385321102
I1
I0
I1
tp75057
sS'levels,of,antidepressant'
p75058
(F1
F0.00014334862385321102
I1
I0
I1
tp75059
sS'included,beta-adrenergic,receptor'
p75060
(F1
F0.00014334862385321102
I0
I1
I-1
tp75061
sS'abnormalities,and,increase'
p75062
(F1
F0.00014334862385321102
I1
I0
I1
tp75063
sS'treatment,with,a'
p75064
(F0
F0
I1
I1
I0
tp75065
sS'of,r-warfarin,the'
p75066
(F1
F0.00014334862385321102
I1
I0
I1
tp75067
sS'mg,qd,by'
p75068
(F1
F0.00014334862385321102
I1
I0
I1
tp75069
sS'implications,for,decreased'
p75070
(F1
F0.00014334862385321102
I0
I1
I-1
tp75071
sS'separate,controlled,parallel'
p75072
(F1
F0.00014334862385321102
I0
I1
I-1
tp75073
sS'in,part,to'
p75074
(F1
F0.00014334862385321102
I1
I0
I1
tp75075
sS'there,is,some'
p75076
(F1
F0.00014334862385321102
I1
I0
I1
tp75077
sS'non-steroidal,anti-inflammatory,but'
p75078
(F1
F0.00014334862385321102
I0
I1
I-1
tp75079
sS'suggest,that,are'
p75080
(F1
F0.00014334862385321102
I0
I1
I-1
tp75081
sS'significantly,while,those'
p75082
(F1
F0.00014334862385321102
I0
I1
I-1
tp75083
sS'blocks,the,metabolism'
p75084
(F1
F0.00014334862385321102
I1
I0
I1
tp75085
sS'shown,to,prevent'
p75086
(F1
F0.00014334862385321102
I1
I0
I1
tp75087
sS'days,the,dose'
p75088
(F1
F0.00014334862385321102
I0
I1
I-1
tp75089
sS'the,addition,of'
p75090
(F0.2857142857142857
F0.00057339449541284407
I9
I5
I4
tp75091
sS'and,are,inhibitors'
p75092
(F1
F0.00014334862385321102
I0
I1
I-1
tp75093
sS'of,increased,when'
p75094
(F1
F0.00014334862385321102
I1
I0
I1
tp75095
sS'also,receiving,mg'
p75096
(F1
F0.00014334862385321102
I0
I1
I-1
tp75097
sS'and,potentiates,the'
p75098
(F1
F0.00014334862385321102
I0
I1
I-1
tp75099
sS'tachycardia,produced,by'
p75100
(F1
F0.00014334862385321102
I1
I0
I1
tp75101
sS'aerolizertm,inhalation,device'
p75102
(F1
F0.00014334862385321102
I0
I1
I-1
tp75103
sS'intake,prior,to'
p75104
(F1
F0.00057339449541284407
I4
I0
I4
tp75105
sS'not,affect,either'
p75106
(F1
F0.00014334862385321102
I0
I1
I-1
tp75107
sS'of,or,an'
p75108
(F1
F0.00028669724770642203
I0
I2
I-2
tp75109
sS'separated,from,mg'
p75110
(F1
F0.00014334862385321102
I1
I0
I1
tp75111
sS'general,these,are'
p75112
(F1
F0.00014334862385321102
I0
I1
I-1
tp75113
sS'mean,plasma,concentrations'
p75114
(F1
F0.00028669724770642203
I2
I0
I2
tp75115
sS'addiction,while,they'
p75116
(F1
F0.00014334862385321102
I0
I1
I-1
tp75117
sS'of,therapy,with'
p75118
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp75119
sS'of,human,breast'
p75120
(F1
F0.00014334862385321102
I1
I0
I1
tp75121
sS'primary,cns,effects'
p75122
(F1
F0.00028669724770642203
I2
I0
I2
tp75123
sS'streptozotocin-induced,diabetic,rats'
p75124
(F1
F0.00014334862385321102
I0
I1
I-1
tp75125
sS'incompatible,with,and'
p75126
(F1
F0.00014334862385321102
I0
I1
I-1
tp75127
sS'of,increased,plasma'
p75128
(F1
F0.00043004587155963305
I3
I0
I3
tp75129
sS'the,adverse,effects'
p75130
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp75131
sS'of,was,higher'
p75132
(F1
F0.00014334862385321102
I1
I0
I1
tp75133
sS'were,inconclusive,with'
p75134
(F1
F0.00014334862385321102
I0
I1
I-1
tp75135
sS'however,in,clinical'
p75136
(F1
F0.00014334862385321102
I0
I1
I-1
tp75137
sS'or,may,reduce'
p75138
(F1
F0.00014334862385321102
I1
I0
I1
tp75139
sS'mg,capsules,with'
p75140
(F1
F0.00014334862385321102
I1
I0
I1
tp75141
sS'significantly,inhibit,proliferation'
p75142
(F1
F0.00014334862385321102
I1
I0
I1
tp75143
sS'treated,with,taxol'
p75144
(F1
F0.00014334862385321102
I0
I1
I-1
tp75145
sS'it,is,necessary'
p75146
(F1
F0.00014334862385321102
I1
I0
I1
tp75147
sS'inducers,and,adjustment'
p75148
(F1
F0.00014334862385321102
I1
I0
I1
tp75149
sS'sustiva,mg,once'
p75150
(F1
F0.00014334862385321102
I1
I0
I1
tp75151
sS'substrate,for,cyp3a4'
p75152
(F1
F0.00028669724770642203
I0
I2
I-2
tp75153
sS'weekly,subcutaneous,injections'
p75154
(F1
F0.00014334862385321102
I0
I1
I-1
tp75155
sS'the,tysabri,associated'
p75156
(F1
F0.00014334862385321102
I0
I1
I-1
tp75157
sS'the,acute,phase'
p75158
(F1
F0.00014334862385321102
I0
I1
I-1
tp75159
sS'methionine,may,protect'
p75160
(F1
F0.00014334862385321102
I1
I0
I1
tp75161
sS'it,is,especially'
p75162
(F1
F0.00014334862385321102
I1
I0
I1
tp75163
sS'resistance,arteries,from'
p75164
(F1
F0.00014334862385321102
I0
I1
I-1
tp75165
sS'when,coadministering,these'
p75166
(F1
F0.00014334862385321102
I1
I0
I1
tp75167
sS'either,agent,or'
p75168
(F1
F0.00014334862385321102
I0
I1
I-1
tp75169
sS'mhd,however,is'
p75170
(F1
F0.00014334862385321102
I0
I1
I-1
tp75171
sS'profile,of,either'
p75172
(F0
F0
I1
I1
I0
tp75173
sS'g,per,day'
p75174
(F1
F0.00014334862385321102
I0
I1
I-1
tp75175
sS'in,either,procedure'
p75176
(F1
F0.00014334862385321102
I0
I1
I-1
tp75177
sS'by,self-injection,of'
p75178
(F1
F0.00014334862385321102
I0
I1
I-1
tp75179
sS'studies,coadministration,of'
p75180
(F1
F0.00014334862385321102
I0
I1
I-1
tp75181
sS'considerable,evidence,indicating'
p75182
(F1
F0.00014334862385321102
I0
I1
I-1
tp75183
sS'children,who,have'
p75184
(F1
F0.00014334862385321102
I0
I1
I-1
tp75185
sS'basis,for,the'
p75186
(F1
F0.00014334862385321102
I0
I1
I-1
tp75187
sS'aeds,on,gabitril'
p75188
(F1
F0.00014334862385321102
I1
I0
I1
tp75189
sS'from,the,lumen'
p75190
(F1
F0.00014334862385321102
I0
I1
I-1
tp75191
sS'gain,when,was'
p75192
(F1
F0.00014334862385321102
I1
I0
I1
tp75193
sS'octapeptide,was,replaced'
p75194
(F1
F0.00014334862385321102
I0
I1
I-1
tp75195
sS'term,therapy,after'
p75196
(F1
F0.00014334862385321102
I1
I0
I1
tp75197
sS'combination,with,other'
p75198
(F0.66666666666666663
F0.00057339449541284407
I5
I1
I4
tp75199
sS'elevations,seen,in'
p75200
(F1
F0.00014334862385321102
I1
I0
I1
tp75201
sS'cephalosporins-cephalosporins,containing,side'
p75202
(F1
F0.00014334862385321102
I0
I1
I-1
tp75203
sS'with,krm-1648,exhibited'
p75204
(F1
F0.00014334862385321102
I1
I0
I1
tp75205
sS'role,in,mediating'
p75206
(F1
F0.00014334862385321102
I0
I1
I-1
tp75207
sS'both,cyp2c9,and'
p75208
(F1
F0.00014334862385321102
I0
I1
I-1
tp75209
sS'injectable,an,increased'
p75210
(F1
F0.00014334862385321102
I1
I0
I1
tp75211
sS'of,toxicity,should'
p75212
(F1
F0.00014334862385321102
I1
I0
I1
tp75213
sS'of,were,reduced'
p75214
(F1
F0.00057339449541284407
I4
I0
I4
tp75215
sS'glyburide,etodolac,has'
p75216
(F1
F0.00014334862385321102
I0
I1
I-1
tp75217
sS'kinetic,characteristics,for'
p75218
(F1
F0.00014334862385321102
I0
I1
I-1
tp75219
sS'on,receiving,concurrent'
p75220
(F1
F0.00014334862385321102
I1
I0
I1
tp75221
sS'alter,renal,excretion'
p75222
(F1
F0.00014334862385321102
I0
I1
I-1
tp75223
sS'is,given,should'
p75224
(F1
F0.00014334862385321102
I1
I0
I1
tp75225
sS'fully,evaluating,the'
p75226
(F1
F0.00014334862385321102
I0
I1
I-1
tp75227
sS'in,lowering,of'
p75228
(F1
F0.00014334862385321102
I1
I0
I1
tp75229
sS'normal,male,and'
p75230
(F1
F0.00014334862385321102
I1
I0
I1
tp75231
sS'toxicity,cns,depression'
p75232
(F1
F0.00014334862385321102
I0
I1
I-1
tp75233
sS'v,has,been'
p75234
(F1
F0.00014334862385321102
I0
I1
I-1
tp75235
sS'below,drugs,that'
p75236
(F1
F0.00014334862385321102
I1
I0
I1
tp75237
sS'channel,blockers,may'
p75238
(F0
F0
I1
I1
I0
tp75239
sS'with,produced,approximately'
p75240
(F1
F0.00014334862385321102
I0
I1
I-1
tp75241
sS'routes,a,reduction'
p75242
(F1
F0.00014334862385321102
I1
I0
I1
tp75243
sS'also,has,no'
p75244
(F0
F0
I1
I1
I0
tp75245
sS'with,oral,carbonic'
p75246
(F1
F0.00028669724770642203
I2
I0
I2
tp75247
sS'other,than,the'
p75248
(F1
F0.00014334862385321102
I0
I1
I-1
tp75249
sS'nsaids,can,inhibit'
p75250
(F1
F0.00014334862385321102
I1
I0
I1
tp75251
sS'substituted,for,the'
p75252
(F1
F0.00014334862385321102
I0
I1
I-1
tp75253
sS'not,bear,directly'
p75254
(F1
F0.00014334862385321102
I1
I0
I1
tp75255
sS'serum,valproic,acid'
p75256
(F1
F0.00014334862385321102
I0
I1
I-1
tp75257
sS'breast,cancer,cells'
p75258
(F0
F0
I1
I1
I0
tp75259
sS'seen,during,treatment'
p75260
(F1
F0.00014334862385321102
I1
I0
I1
tp75261
sS'probenecid,interferes,with'
p75262
(F1
F0.00014334862385321102
I1
I0
I1
tp75263
sS'while,plasma,exposure'
p75264
(F1
F0.00014334862385321102
I1
I0
I1
tp75265
sS'subjects,no,effect'
p75266
(F1
F0.00014334862385321102
I1
I0
I1
tp75267
sS'days,however,reduced'
p75268
(F1
F0.00014334862385321102
I1
I0
I1
tp75269
sS'cyp1a2,concomitant,use'
p75270
(F1
F0.00014334862385321102
I1
I0
I1
tp75271
sS'this,may,interact'
p75272
(F1
F0.00028669724770642203
I0
I2
I-2
tp75273
sS'three,lines,divergently'
p75274
(F1
F0.00014334862385321102
I0
I1
I-1
tp75275
sS'of,racemic,mg'
p75276
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp75277
sS'levels,were,increased'
p75278
(F1
F0.00043004587155963305
I3
I0
I3
tp75279
sS'estradiol,should,be'
p75280
(F1
F0.00014334862385321102
I1
I0
I1
tp75281
sS'experience,with,concomitant'
p75282
(F1
F0.00028669724770642203
I0
I2
I-2
tp75283
sS'the,effect,may'
p75284
(F0
F0
I1
I1
I0
tp75285
sS'function,accompanied,by'
p75286
(F1
F0.00014334862385321102
I1
I0
I1
tp75287
sS'in,about,a'
p75288
(F1
F0.00014334862385321102
I1
I0
I1
tp75289
sS'experiments,demonstrated,a'
p75290
(F1
F0.00014334862385321102
I0
I1
I-1
tp75291
sS'tachycardia,was,significantly'
p75292
(F1
F0.00014334862385321102
I1
I0
I1
tp75293
sS'and,vasodilators,the'
p75294
(F1
F0.00014334862385321102
I1
I0
I1
tp75295
sS'inhibitors,maois,selegiline'
p75296
(F1
F0.00014334862385321102
I1
I0
I1
tp75297
sS'here,we,examined'
p75298
(F1
F0.00014334862385321102
I0
I1
I-1
tp75299
sS'has,a,synergistic'
p75300
(F1
F0.00014334862385321102
I1
I0
I1
tp75301
sS'to,affect,renal'
p75302
(F1
F0.00028669724770642203
I0
I2
I-2
tp75303
sS'if,leprosy-associated,inflammatory'
p75304
(F1
F0.00014334862385321102
I1
I0
I1
tp75305
sS'or,the,presence'
p75306
(F1
F0.00014334862385321102
I0
I1
I-1
tp75307
sS'from,the,other'
p75308
(F1
F0.00014334862385321102
I0
I1
I-1
tp75309
sS'using,the,tail-flick'
p75310
(F1
F0.00014334862385321102
I0
I1
I-1
tp75311
sS'the,potential,that'
p75312
(F1
F0.00014334862385321102
I0
I1
I-1
tp75313
sS'because,of,a'
p75314
(F1
F0.00014334862385321102
I0
I1
I-1
tp75315
sS'the,desired,and'
p75316
(F1
F0.00014334862385321102
I1
I0
I1
tp75317
sS'rate,when,taken'
p75318
(F1
F0.00014334862385321102
I1
I0
I1
tp75319
sS'to,adverse,events'
p75320
(F1
F0.00014334862385321102
I0
I1
I-1
tp75321
sS'of,a,solution'
p75322
(F1
F0.00014334862385321102
I0
I1
I-1
tp75323
sS'of,the,vitamin'
p75324
(F1
F0.00043004587155963305
I0
I3
I-3
tp75325
sS'with,further,enhanced'
p75326
(F1
F0.00014334862385321102
I0
I1
I-1
tp75327
sS'cyp3a4,should,be'
p75328
(F1
F0.00014334862385321102
I1
I0
I1
tp75329
sS'chick,embryos,in'
p75330
(F1
F0.00014334862385321102
I1
I0
I1
tp75331
sS'i,without,alterations'
p75332
(F1
F0.00014334862385321102
I0
I1
I-1
tp75333
sS'administration,of,methylpyrazole'
p75334
(F0
F0
I1
I1
I0
tp75335
sS'to,influence,the'
p75336
(F1
F0.00028669724770642203
I2
I0
I2
tp75337
sS'that,fluvoxamine,tablets'
p75338
(F1
F0.00014334862385321102
I1
I0
I1
tp75339
sS'interpretation,glucose,and'
p75340
(F1
F0.00014334862385321102
I0
I1
I-1
tp75341
sS'intravenously,as,mg'
p75342
(F1
F0.00014334862385321102
I1
I0
I1
tp75343
sS'with,administration,of'
p75344
(F1
F0.00014334862385321102
I0
I1
I-1
tp75345
sS'myopathy,rhabdomyolysis,and'
p75346
(F1
F0.00014334862385321102
I1
I0
I1
tp75347
sS'co-administered,with,another'
p75348
(F1
F0.00057339449541284407
I0
I4
I-4
tp75349
sS'tachycardia,induced,by'
p75350
(F1
F0.00014334862385321102
I1
I0
I1
tp75351
sS'have,similar,affinities'
p75352
(F1
F0.00014334862385321102
I0
I1
I-1
tp75353
sS'doses,of,the'
p75354
(F1
F0.00014334862385321102
I0
I1
I-1
tp75355
sS'also,lowers,serum'
p75356
(F1
F0.00014334862385321102
I0
I1
I-1
tp75357
sS'cause,induction,or'
p75358
(F1
F0.00014334862385321102
I0
I1
I-1
tp75359
sS'in,addition,higher-than'
p75360
(F1
F0.00014334862385321102
I1
I0
I1
tp75361
sS'elevated,with,by'
p75362
(F1
F0.00014334862385321102
I0
I1
I-1
tp75363
sS'glucose,when,was'
p75364
(F1
F0.00014334862385321102
I0
I1
I-1
tp75365
sS'to,mg,daily'
p75366
(F1
F0.00014334862385321102
I0
I1
I-1
tp75367
sS'of,baraclude,with'
p75368
(F1
F0.00028669724770642203
I0
I2
I-2
tp75369
sS'are,hypersensitive,to'
p75370
(F1
F0.00014334862385321102
I1
I0
I1
tp75371
sS'nimbex,include,certain'
p75372
(F1
F0.00014334862385321102
I1
I0
I1
tp75373
sS'inhibited,by,and'
p75374
(F1
F0.00014334862385321102
I1
I0
I1
tp75375
sS'fed,further,fe'
p75376
(F1
F0.00014334862385321102
I0
I1
I-1
tp75377
sS'in,the,diet'
p75378
(F0
F0
I1
I1
I0
tp75379
sS'of,the,hmg-coa'
p75380
(F0
F0
I1
I1
I0
tp75381
sS'following,eight,target'
p75382
(F1
F0.00014334862385321102
I0
I1
I-1
tp75383
sS'be,reviewed,and'
p75384
(F1
F0.00014334862385321102
I1
I0
I1
tp75385
sS'trials,and,were'
p75386
(F1
F0.00014334862385321102
I0
I1
I-1
tp75387
sS'activity,with,lowered'
p75388
(F1
F0.00014334862385321102
I1
I0
I1
tp75389
sS'with,or,may'
p75390
(F1
F0.00014334862385321102
I1
I0
I1
tp75391
sS'only,with,concomitant'
p75392
(F1
F0.00014334862385321102
I0
I1
I-1
tp75393
sS'starlix,three,times'
p75394
(F1
F0.00014334862385321102
I0
I1
I-1
tp75395
sS'possibility,of,an'
p75396
(F1
F0.00028669724770642203
I2
I0
I2
tp75397
sS'shock,can,in'
p75398
(F1
F0.00014334862385321102
I1
I0
I1
tp75399
sS'withdrawn,and,recurred'
p75400
(F1
F0.00014334862385321102
I0
I1
I-1
tp75401
sS'of,an,containing'
p75402
(F1
F0.00014334862385321102
I1
I0
I1
tp75403
sS'be,adjusted,when'
p75404
(F1
F0.00014334862385321102
I0
I1
I-1
tp75405
sS'precipitation,occurs,when'
p75406
(F1
F0.00014334862385321102
I0
I1
I-1
tp75407
sS'that,and,fenofibric'
p75408
(F1
F0.00014334862385321102
I0
I1
I-1
tp75409
sS'neuromuscular,weakness,may'
p75410
(F1
F0.00014334862385321102
I1
I0
I1
tp75411
sS'corticosteroids,systemic,are'
p75412
(F1
F0.00014334862385321102
I0
I1
I-1
tp75413
sS'cyp1a2,inducers,and'
p75414
(F1
F0.00014334862385321102
I0
I1
I-1
tp75415
sS'microdosed,minipill,preparations'
p75416
(F1
F0.00014334862385321102
I1
I0
I1
tp75417
sS'levels,occurred,at'
p75418
(F1
F0.00014334862385321102
I1
I0
I1
tp75419
sS'and,others,or'
p75420
(F1
F0.00028669724770642203
I0
I2
I-2
tp75421
sS'and,because,of'
p75422
(F1
F0.00028669724770642203
I2
I0
I2
tp75423
sS'with,little,or'
p75424
(F1
F0.00028669724770642203
I2
I0
I2
tp75425
sS'require,a,dose'
p75426
(F1
F0.00014334862385321102
I1
I0
I1
tp75427
sS'volunteer,received,a'
p75428
(F1
F0.00014334862385321102
I0
I1
I-1
tp75429
sS'for,a,fold'
p75430
(F1
F0.00014334862385321102
I0
I1
I-1
tp75431
sS'at,least,four'
p75432
(F1
F0.00014334862385321102
I0
I1
I-1
tp75433
sS'levels,of,however'
p75434
(F1
F0.00014334862385321102
I1
I0
I1
tp75435
sS'oxc,and,mhd'
p75436
(F1
F0.00028669724770642203
I0
I2
I-2
tp75437
sS'absorption,after,administration'
p75438
(F1
F0.00014334862385321102
I0
I1
I-1
tp75439
sS'cause,direct,coombs'
p75440
(F1
F0.00014334862385321102
I0
I1
I-1
tp75441
sS'hour,then,mg'
p75442
(F1
F0.00014334862385321102
I0
I1
I-1
tp75443
sS'indeed,have,a'
p75444
(F1
F0.00014334862385321102
I1
I0
I1
tp75445
sS'and,resulted,in'
p75446
(F0.84615384615384615
F0.0015768348623853212
I12
I1
I11
tp75447
sS'to,severe,hypoglycemia'
p75448
(F1
F0.00043004587155963305
I3
I0
I3
tp75449
sS'including,such,as'
p75450
(F1
F0.00028669724770642203
I2
I0
I2
tp75451
sS'sequential,high,dose'
p75452
(F1
F0.00014334862385321102
I1
I0
I1
tp75453
sS'dose,of,their'
p75454
(F1
F0.00014334862385321102
I1
I0
I1
tp75455
sS'was,administered,concomitantly'
p75456
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp75457
sS'clearance,in,psychiatric'
p75458
(F1
F0.00014334862385321102
I1
I0
I1
tp75459
sS'and,loss,of'
p75460
(F1
F0.00014334862385321102
I1
I0
I1
tp75461
sS'essentially,completely,absorbed'
p75462
(F1
F0.00014334862385321102
I0
I1
I-1
tp75463
sS'steady,state,plasma'
p75464
(F0.5
F0.00028669724770642203
I3
I1
I2
tp75465
sS'long-term,therapy,eg'
p75466
(F1
F0.00014334862385321102
I1
I0
I1
tp75467
sS'single,mg,vardenafil'
p75468
(F1
F0.00028669724770642203
I2
I0
I2
tp75469
sS'inducers,of,cyp3a'
p75470
(F1
F0.00014334862385321102
I1
I0
I1
tp75471
sS'the,pharmacokinetic,profile'
p75472
(F1
F0.00028669724770642203
I2
I0
I2
tp75473
sS'side,chains,of'
p75474
(F1
F0.00014334862385321102
I0
I1
I-1
tp75475
sS'lag,phase,in'
p75476
(F1
F0.00014334862385321102
I0
I1
I-1
tp75477
sS'animal,experience,indicates'
p75478
(F1
F0.00014334862385321102
I1
I0
I1
tp75479
sS'as,deltasone,orasone'
p75480
(F1
F0.00014334862385321102
I0
I1
I-1
tp75481
sS'may,have,several'
p75482
(F1
F0.00014334862385321102
I0
I1
I-1
tp75483
sS'phenytoin,tiagabine,had'
p75484
(F1
F0.00014334862385321102
I0
I1
I-1
tp75485
sS'of,by,inhibiting'
p75486
(F1
F0.00014334862385321102
I1
I0
I1
tp75487
sS'the,onset,and'
p75488
(F1
F0.00014334862385321102
I1
I0
I1
tp75489
sS'midamor,may,each'
p75490
(F1
F0.00014334862385321102
I1
I0
I1
tp75491
sS'been,associated,in'
p75492
(F1
F0.00028669724770642203
I2
I0
I2
tp75493
sS'and,inr,were'
p75494
(F1
F0.00014334862385321102
I0
I1
I-1
tp75495
sS'high-dose,a,resulting'
p75496
(F1
F0.00014334862385321102
I1
I0
I1
tp75497
sS'at,daily,doses'
p75498
(F1
F0.00014334862385321102
I0
I1
I-1
tp75499
sS'placebo,oral,placebo'
p75500
(F1
F0.00014334862385321102
I0
I1
I-1
tp75501
sS'other,nsaids,can'
p75502
(F1
F0.00028669724770642203
I2
I0
I2
tp75503
sS'of,unbound,was'
p75504
(F1
F0.00014334862385321102
I0
I1
I-1
tp75505
sS'decrease,the,tubular'
p75506
(F1
F0.00028669724770642203
I2
I0
I2
tp75507
sS'of,low,molecular'
p75508
(F1
F0.00014334862385321102
I0
I1
I-1
tp75509
sS'recommended,that,fluvoxamine'
p75510
(F1
F0.00014334862385321102
I1
I0
I1
tp75511
sS'of,and,nsaids'
p75512
(F1
F0.00028669724770642203
I2
I0
I2
tp75513
sS'who,developed,increased'
p75514
(F1
F0.00014334862385321102
I1
I0
I1
tp75515
sS'decreases,gastrointestinal,secretion'
p75516
(F1
F0.00014334862385321102
I1
I0
I1
tp75517
sS'the,diabetic,chinese'
p75518
(F1
F0.00014334862385321102
I0
I1
I-1
tp75519
sS'is,especially,important'
p75520
(F1
F0.00014334862385321102
I1
I0
I1
tp75521
sS'cromolyn,sodium,approximately'
p75522
(F1
F0.00014334862385321102
I1
I0
I1
tp75523
sS'of,administered,h'
p75524
(F1
F0.00014334862385321102
I0
I1
I-1
tp75525
sS'when,the,treatment'
p75526
(F1
F0.00014334862385321102
I1
I0
I1
tp75527
sS'several,days,after'
p75528
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp75529
sS'are,antagonized,by'
p75530
(F1
F0.00028669724770642203
I2
I0
I2
tp75531
sS'was,only,half'
p75532
(F1
F0.00014334862385321102
I0
I1
I-1
tp75533
sS'into,three,equal'
p75534
(F1
F0.00014334862385321102
I0
I1
I-1
tp75535
sS'is,not,known'
p75536
(F0
F0
I6
I6
I0
tp75537
sS'groups,treated,with'
p75538
(F1
F0.00014334862385321102
I1
I0
I1
tp75539
sS'by,cyp3a4,and'
p75540
(F1
F0.00028669724770642203
I0
I2
I-2
tp75541
sS'possible,be,discontinued'
p75542
(F1
F0.00014334862385321102
I1
I0
I1
tp75543
sS'niddm,subjects,decreases'
p75544
(F1
F0.00014334862385321102
I0
I1
I-1
tp75545
sS'study,we,investigated'
p75546
(F1
F0.00014334862385321102
I0
I1
I-1
tp75547
sS'blockers,nonsteroidal,antiinflammatories'
p75548
(F1
F0.00014334862385321102
I0
I1
I-1
tp75549
sS'in,serum,creatinine'
p75550
(F1
F0.00043004587155963305
I3
I0
I3
tp75551
sS'ml,egf,ng'
p75552
(F1
F0.00014334862385321102
I0
I1
I-1
tp75553
sS'recommended,to,determine'
p75554
(F1
F0.00014334862385321102
I0
I1
I-1
tp75555
sS'to,be,combined'
p75556
(F1
F0.00014334862385321102
I1
I0
I1
tp75557
sS'method,of,contraception'
p75558
(F1
F0.00028669724770642203
I2
I0
I2
tp75559
sS'and,molecular,level'
p75560
(F1
F0.00014334862385321102
I0
I1
I-1
tp75561
sS'affect,other,drugs'
p75562
(F1
F0.00028669724770642203
I0
I2
I-2
tp75563
sS'the,group,that'
p75564
(F1
F0.00014334862385321102
I0
I1
I-1
tp75565
sS'crossover,study,of'
p75566
(F1
F0.00014334862385321102
I0
I1
I-1
tp75567
sS'ssris,and,d'
p75568
(F1
F0.00014334862385321102
I0
I1
I-1
tp75569
sS'days,or,mg'
p75570
(F1
F0.00014334862385321102
I0
I1
I-1
tp75571
sS'hypotension,has,been'
p75572
(F1
F0.00043004587155963305
I3
I0
I3
tp75573
sS'however,it,was'
p75574
(F1
F0.00014334862385321102
I0
I1
I-1
tp75575
sS'when,deet,was'
p75576
(F1
F0.00014334862385321102
I0
I1
I-1
tp75577
sS'single,case,report'
p75578
(F1
F0.00014334862385321102
I1
I0
I1
tp75579
sS'and,have,in'
p75580
(F1
F0.00014334862385321102
I1
I0
I1
tp75581
sS'represent,the,best'
p75582
(F1
F0.00014334862385321102
I0
I1
I-1
tp75583
sS'of,potent,non-nucleoside'
p75584
(F1
F0.00014334862385321102
I0
I1
I-1
tp75585
sS'prothrombin,time,determinations'
p75586
(F1
F0.00028669724770642203
I2
I0
I2
tp75587
sS'minimal,inhibitory,concentration'
p75588
(F1
F0.00014334862385321102
I0
I1
I-1
tp75589
sS'effects,including,dry'
p75590
(F1
F0.00014334862385321102
I1
I0
I1
tp75591
sS'first-pass,metabolism,are'
p75592
(F1
F0.00014334862385321102
I0
I1
I-1
tp75593
sS'a,typical,side'
p75594
(F1
F0.00014334862385321102
I0
I1
I-1
tp75595
sS'between,a,and'
p75596
(F1
F0.00014334862385321102
I1
I0
I1
tp75597
sS'considered,if,the'
p75598
(F1
F0.00014334862385321102
I1
I0
I1
tp75599
sS'significant,pharmacokinetic,or'
p75600
(F1
F0.00014334862385321102
I0
I1
I-1
tp75601
sS'to,be,greater'
p75602
(F1
F0.00014334862385321102
I1
I0
I1
tp75603
sS'antipyrine,antipyrine,pharmacokinetics'
p75604
(F1
F0.00014334862385321102
I0
I1
I-1
tp75605
sS'the,mitogenic,effect'
p75606
(F1
F0.00014334862385321102
I1
I0
I1
tp75607
sS'was,no,change'
p75608
(F1
F0.00014334862385321102
I1
I0
I1
tp75609
sS'or,and,axert'
p75610
(F1
F0.00014334862385321102
I1
I0
I1
tp75611
sS'undergo,enterohepatic,circulation'
p75612
(F1
F0.00014334862385321102
I1
I0
I1
tp75613
sS'ns,was,administered'
p75614
(F1
F0.00028669724770642203
I2
I0
I2
tp75615
sS'and,inhibit,p450'
p75616
(F1
F0.00071674311926605509
I0
I5
I-5
tp75617
sS'for,other,and'
p75618
(F1
F0.00014334862385321102
I0
I1
I-1
tp75619
sS'events,or,reduced'
p75620
(F1
F0.00014334862385321102
I1
I0
I1
tp75621
sS'when,meclofenamate,sodium'
p75622
(F1
F0.00014334862385321102
I1
I0
I1
tp75623
sS'thiazide,may,prevent'
p75624
(F1
F0.00014334862385321102
I1
I0
I1
tp75625
sS'approximately,to,fold'
p75626
(F1
F0.00014334862385321102
I1
I0
I1
tp75627
sS'concentrations,showing,a'
p75628
(F1
F0.00014334862385321102
I0
I1
I-1
tp75629
sS'the,last,subcutaneous'
p75630
(F1
F0.00014334862385321102
I1
I0
I1
tp75631
sS'and,is,likely'
p75632
(F1
F0.00028669724770642203
I2
I0
I2
tp75633
sS'o,induced,diarrhea'
p75634
(F1
F0.00014334862385321102
I1
I0
I1
tp75635
sS'interaction,after,treatment'
p75636
(F1
F0.00014334862385321102
I0
I1
I-1
tp75637
sS'levels,were,not'
p75638
(F1
F0.00028669724770642203
I0
I2
I-2
tp75639
sS'combination,with,indicate'
p75640
(F1
F0.00014334862385321102
I1
I0
I1
tp75641
sS'to,avoid,them'
p75642
(F1
F0.00014334862385321102
I0
I1
I-1
tp75643
sS'of,and,concurrent'
p75644
(F1
F0.00028669724770642203
I2
I0
I2
tp75645
sS'by,an,nad'
p75646
(F1
F0.00014334862385321102
I0
I1
I-1
tp75647
sS'metabolism,of,s'
p75648
(F1
F0.00014334862385321102
I1
I0
I1
tp75649
sS'effectiveness,in,men'
p75650
(F1
F0.00014334862385321102
I0
I1
I-1
tp75651
sS'patients,below,the'
p75652
(F1
F0.00014334862385321102
I0
I1
I-1
tp75653
sS'after,introduction,of'
p75654
(F1
F0.00014334862385321102
I1
I0
I1
tp75655
sS'because,severe,hypoglycemia'
p75656
(F1
F0.00014334862385321102
I1
I0
I1
tp75657
sS'other,and,for'
p75658
(F1
F0.00014334862385321102
I0
I1
I-1
tp75659
sS'dexamethasone,steady-state,trough'
p75660
(F1
F0.00014334862385321102
I1
I0
I1
tp75661
sS'administration,of,as'
p75662
(F1
F0.00014334862385321102
I1
I0
I1
tp75663
sS'administration,of,an'
p75664
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp75665
sS'between,coadministered,with'
p75666
(F1
F0.00014334862385321102
I0
I1
I-1
tp75667
sS'potentiate,amphotericin,b-'
p75668
(F1
F0.00014334862385321102
I1
I0
I1
tp75669
sS'other,broad-spectrum,augmentin'
p75670
(F1
F0.00014334862385321102
I1
I0
I1
tp75671
sS'of,clinically,important'
p75672
(F1
F0.00014334862385321102
I0
I1
I-1
tp75673
sS'a4,inhibitors,elevated'
p75674
(F1
F0.00014334862385321102
I0
I1
I-1
tp75675
sS'sustiva,and,in'
p75676
(F1
F0.00014334862385321102
I0
I1
I-1
tp75677
sS'with,qt-interval,prolongation'
p75678
(F1
F0.00014334862385321102
I0
I1
I-1
tp75679
sS'hormonal,contraceptives,it'
p75680
(F1
F0.00014334862385321102
I0
I1
I-1
tp75681
sS'mg,mg,bid'
p75682
(F1
F0.00014334862385321102
I0
I1
I-1
tp75683
sS'of,some,forms'
p75684
(F1
F0.00014334862385321102
I0
I1
I-1
tp75685
sS'severe,orthostatic,hypotension'
p75686
(F1
F0.00014334862385321102
I1
I0
I1
tp75687
sS'resistant,to,both'
p75688
(F1
F0.00014334862385321102
I0
I1
I-1
tp75689
sS'of,with,alfenta'
p75690
(F1
F0.00014334862385321102
I1
I0
I1
tp75691
sS'inhibitors,for,most'
p75692
(F1
F0.00014334862385321102
I0
I1
I-1
tp75693
sS'plasma,concentrations,c'
p75694
(F1
F0.00014334862385321102
I0
I1
I-1
tp75695
sS'fluorescence,labelled,and'
p75696
(F1
F0.00014334862385321102
I0
I1
I-1
tp75697
sS'colonic,transit-enhancing,effect'
p75698
(F1
F0.00014334862385321102
I0
I1
I-1
tp75699
sS'l-glutamine,at,a'
p75700
(F1
F0.00028669724770642203
I2
I0
I2
tp75701
sS'of,subjects,aged'
p75702
(F1
F0.00014334862385321102
I0
I1
I-1
tp75703
sS'demonstrated,between,argatroban'
p75704
(F1
F0.00014334862385321102
I0
I1
I-1
tp75705
sS'exposure,of,rats'
p75706
(F1
F0.00014334862385321102
I1
I0
I1
tp75707
sS'a,chop-like,regimen'
p75708
(F1
F0.00014334862385321102
I0
I1
I-1
tp75709
sS'metal,cations,multivitamins'
p75710
(F1
F0.00014334862385321102
I0
I1
I-1
tp75711
sS'elimination,and,cause'
p75712
(F1
F0.00014334862385321102
I1
I0
I1
tp75713
sS'qd,mg,tid'
p75714
(F1
F0.00014334862385321102
I1
I0
I1
tp75715
sS'with,one,of'
p75716
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp75717
sS'the,prolongation,of'
p75718
(F1
F0.00028669724770642203
I2
I0
I2
tp75719
sS'are,no,study'
p75720
(F1
F0.00014334862385321102
I1
I0
I1
tp75721
sS'sodium,capsules,mg'
p75722
(F0
F0
I1
I1
I0
tp75723
sS'symptoms,have,been'
p75724
(F1
F0.00014334862385321102
I1
I0
I1
tp75725
sS'labeling,index,apoptotic'
p75726
(F1
F0.00014334862385321102
I0
I1
I-1
tp75727
sS'although,specific,studies'
p75728
(F1
F0.00014334862385321102
I1
I0
I1
tp75729
sS'dual,effect,of'
p75730
(F1
F0.00014334862385321102
I0
I1
I-1
tp75731
sS'concentrations,during,concomitant'
p75732
(F1
F0.00014334862385321102
I1
I0
I1
tp75733
sS'and,at,steady-state'
p75734
(F1
F0.00014334862385321102
I0
I1
I-1
tp75735
sS'antidepressants,foradil,should'
p75736
(F1
F0.00014334862385321102
I1
I0
I1
tp75737
sS'aeruginosa,serotype,o11'
p75738
(F1
F0.00014334862385321102
I0
I1
I-1
tp75739
sS'antacids,enteric,coated'
p75740
(F1
F0.00014334862385321102
I1
I0
I1
tp75741
sS'ischemia,of,the'
p75742
(F1
F0.00014334862385321102
I0
I1
I-1
tp75743
sS'administration,of,tambocor'
p75744
(F1
F0.00014334862385321102
I1
I0
I1
tp75745
sS'as,valium,and'
p75746
(F1
F0.00014334862385321102
I1
I0
I1
tp75747
sS'shown,consistent,effects'
p75748
(F1
F0.00014334862385321102
I0
I1
I-1
tp75749
sS'potentiated,by,a'
p75750
(F1
F0.00014334862385321102
I1
I0
I1
tp75751
sS'against,two,type'
p75752
(F1
F0.00014334862385321102
I0
I1
I-1
tp75753
sS'effect,of,all'
p75754
(F1
F0.00014334862385321102
I1
I0
I1
tp75755
sS'agents,decrease,blood'
p75756
(F1
F0.00014334862385321102
I1
I0
I1
tp75757
sS'is,metabolized,mainly'
p75758
(F1
F0.00028669724770642203
I0
I2
I-2
tp75759
sS'minutes,post,and'
p75760
(F1
F0.00014334862385321102
I0
I1
I-1
tp75761
sS'of,status,and'
p75762
(F1
F0.00014334862385321102
I0
I1
I-1
tp75763
sS'of,the,co-administered'
p75764
(F1
F0.00014334862385321102
I0
I1
I-1
tp75765
sS'amiodarone,contraindicated,due'
p75766
(F1
F0.00014334862385321102
I0
I1
I-1
tp75767
sS'excessive,release,in'
p75768
(F1
F0.00014334862385321102
I0
I1
I-1
tp75769
sS'with,the,cyp3a4'
p75770
(F1
F0.00014334862385321102
I1
I0
I1
tp75771
sS'in,normovolemic,healthy'
p75772
(F1
F0.00014334862385321102
I1
I0
I1
tp75773
sS'mg,qd,resulted'
p75774
(F1
F0.00043004587155963305
I3
I0
I3
tp75775
sS'reduced,risk,of'
p75776
(F1
F0.00014334862385321102
I0
I1
I-1
tp75777
sS'for,novolog,should'
p75778
(F1
F0.00014334862385321102
I0
I1
I-1
tp75779
sS'secretion,may,increase'
p75780
(F1
F0.00014334862385321102
I0
I1
I-1
tp75781
sS'digoxin,some,blockers'
p75782
(F1
F0.00014334862385321102
I1
I0
I1
tp75783
sS'possibility,that,might'
p75784
(F1
F0.00014334862385321102
I1
I0
I1
tp75785
sS'or,the,side'
p75786
(F1
F0.00043004587155963305
I3
I0
I3
tp75787
sS'repeated,co-administration,of'
p75788
(F1
F0.00014334862385321102
I1
I0
I1
tp75789
sS'studies,of,patients'
p75790
(F0
F0
I1
I1
I0
tp75791
sS'two,cases,in'
p75792
(F1
F0.00014334862385321102
I1
I0
I1
tp75793
sS'of,spontaneous,motility'
p75794
(F1
F0.00028669724770642203
I2
I0
I2
tp75795
sS'of,l-glutamine,and'
p75796
(F1
F0.00028669724770642203
I2
I0
I2
tp75797
sS'twelve,strains,of'
p75798
(F1
F0.00014334862385321102
I1
I0
I1
tp75799
sS'to,produce,clinically'
p75800
(F1
F0.00014334862385321102
I1
I0
I1
tp75801
sS'compared,to,ace'
p75802
(F1
F0.00014334862385321102
I1
I0
I1
tp75803
sS'antagonists,hmg-coa,reductase'
p75804
(F1
F0.00014334862385321102
I0
I1
I-1
tp75805
sS'systemic,circulation,there'
p75806
(F1
F0.00014334862385321102
I1
I0
I1
tp75807
sS'kg,on,the'
p75808
(F1
F0.00014334862385321102
I1
I0
I1
tp75809
sS'withdrawal,and,dose'
p75810
(F1
F0.00014334862385321102
I1
I0
I1
tp75811
sS'interrupted,when,the'
p75812
(F1
F0.00014334862385321102
I0
I1
I-1
tp75813
sS'pretreatment,of,healthy'
p75814
(F1
F0.00014334862385321102
I1
I0
I1
tp75815
sS'approximately,hours,after'
p75816
(F1
F0.00014334862385321102
I1
I0
I1
tp75817
sS'combined,with,krm-1648'
p75818
(F1
F0.00014334862385321102
I1
I0
I1
tp75819
sS'contraceptives,a,group'
p75820
(F1
F0.00014334862385321102
I0
I1
I-1
tp75821
sS'and,s,isomers'
p75822
(F1
F0.00014334862385321102
I0
I1
I-1
tp75823
sS'cyp3a4,inhibitor,or'
p75824
(F1
F0.00014334862385321102
I0
I1
I-1
tp75825
sS'vitro,therefore,this'
p75826
(F1
F0.00014334862385321102
I0
I1
I-1
tp75827
sS'absorption,of,resulting'
p75828
(F1
F0.00043004587155963305
I3
I0
I3
tp75829
sS'the,pharmacokinetic,variables'
p75830
(F1
F0.00014334862385321102
I0
I1
I-1
tp75831
sS'm2,basis,to'
p75832
(F1
F0.00014334862385321102
I1
I0
I1
tp75833
sS'of,tyrosine,phosphorylation'
p75834
(F1
F0.00014334862385321102
I0
I1
I-1
tp75835
sS'of,used,in'
p75836
(F1
F0.00014334862385321102
I0
I1
I-1
tp75837
sS'forevidence,of,withdrawal'
p75838
(F1
F0.00014334862385321102
I1
I0
I1
tp75839
sS'caused,by,the'
p75840
(F1
F0.00014334862385321102
I1
I0
I1
tp75841
sS'arava,levels,to'
p75842
(F1
F0.00014334862385321102
I1
I0
I1
tp75843
sS'found,to,inhibit'
p75844
(F1
F0.00014334862385321102
I1
I0
I1
tp75845
sS'adrenocortical,dependent,hypertension'
p75846
(F1
F0.00014334862385321102
I1
I0
I1
tp75847
sS'kg,and,mg'
p75848
(F0
F0
I2
I2
I0
tp75849
sS'given,supplemental,l-glutamine'
p75850
(F1
F0.00014334862385321102
I1
I0
I1
tp75851
sS'gly-buride,and,did'
p75852
(F1
F0.00014334862385321102
I0
I1
I-1
tp75853
sS'aed,s,that'
p75854
(F1
F0.00014334862385321102
I1
I0
I1
tp75855
sS'to,enhance,the'
p75856
(F1
F0.00057339449541284407
I4
I0
I4
tp75857
sS'immunoanalytical,methods,to'
p75858
(F1
F0.00014334862385321102
I0
I1
I-1
tp75859
sS'oral,aprepitant,when'
p75860
(F1
F0.00014334862385321102
I1
I0
I1
tp75861
sS'of,viracept,and'
p75862
(F1
F0.00043004587155963305
I0
I3
I-3
tp75863
sS'a,maximum,of'
p75864
(F1
F0.00043004587155963305
I3
I0
I3
tp75865
sS'any,antineoplastic,agents'
p75866
(F1
F0.00014334862385321102
I0
I1
I-1
tp75867
sS'recipients,a,reduction'
p75868
(F1
F0.00014334862385321102
I1
I0
I1
tp75869
sS'addition,of,felbatol'
p75870
(F1
F0.00014334862385321102
I1
I0
I1
tp75871
sS'may,be,seen'
p75872
(F1
F0.00014334862385321102
I1
I0
I1
tp75873
sS'including,complete,heart'
p75874
(F1
F0.00014334862385321102
I0
I1
I-1
tp75875
sS'general,cognitive,function'
p75876
(F1
F0.00014334862385321102
I0
I1
I-1
tp75877
sS'not,suggest,any'
p75878
(F1
F0.00014334862385321102
I0
I1
I-1
tp75879
sS'prior,to,or'
p75880
(F1
F0.00028669724770642203
I2
I0
I2
tp75881
sS'reduced,or,eliminated'
p75882
(F1
F0.00014334862385321102
I1
I0
I1
tp75883
sS'with,causes,an'
p75884
(F1
F0.00014334862385321102
I1
I0
I1
tp75885
sS'of,ellence,with'
p75886
(F1
F0.00014334862385321102
I1
I0
I1
tp75887
sS'is,little,published'
p75888
(F1
F0.00014334862385321102
I0
I1
I-1
tp75889
sS'sertraline,neutralized,the'
p75890
(F1
F0.00014334862385321102
I0
I1
I-1
tp75891
sS'bromocriptine,mesylate,may'
p75892
(F1
F0.00014334862385321102
I1
I0
I1
tp75893
sS'of,min,before'
p75894
(F1
F0.00014334862385321102
I1
I0
I1
tp75895
sS'cyp3a4,substrates,that'
p75896
(F1
F0.00014334862385321102
I1
I0
I1
tp75897
sS'were,not,altered'
p75898
(F1
F0.00057339449541284407
I0
I4
I-4
tp75899
sS'induce,both,hyperthyroidism'
p75900
(F1
F0.00014334862385321102
I0
I1
I-1
tp75901
sS'tail-flick,inhibition,induced'
p75902
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp75903
sS'as,v,concentrations'
p75904
(F1
F0.00028669724770642203
I0
I2
I-2
tp75905
sS'decrease,in,levels'
p75906
(F1
F0.00014334862385321102
I1
I0
I1
tp75907
sS'threefold,from,to'
p75908
(F1
F0.00014334862385321102
I1
I0
I1
tp75909
sS'oral,antagonists,may'
p75910
(F1
F0.00014334862385321102
I1
I0
I1
tp75911
sS'approximately,mean,sodium'
p75912
(F1
F0.00014334862385321102
I1
I0
I1
tp75913
sS'mg,of,per'
p75914
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp75915
sS'lodine,is,administered'
p75916
(F1
F0.00014334862385321102
I1
I0
I1
tp75917
sS'and,possible,resistance'
p75918
(F1
F0.00028669724770642203
I0
I2
I-2
tp75919
sS'inhibitors,ssris,ssris'
p75920
(F1
F0.00014334862385321102
I1
I0
I1
tp75921
sS'dmpge2,in,cecectomized'
p75922
(F1
F0.00014334862385321102
I0
I1
I-1
tp75923
sS'advantages,over,pi-based'
p75924
(F1
F0.00014334862385321102
I0
I1
I-1
tp75925
sS'with,tuberculosis,showed'
p75926
(F1
F0.00014334862385321102
I1
I0
I1
tp75927
sS'a,pharmacokinetic,study'
p75928
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp75929
sS'acid,has,been'
p75930
(F1
F0.00014334862385321102
I1
I0
I1
tp75931
sS'iressa,may,exacerbate'
p75932
(F1
F0.00014334862385321102
I1
I0
I1
tp75933
sS'co-administration,of,t'
p75934
(F1
F0.00014334862385321102
I1
I0
I1
tp75935
sS'tablets,administration,of'
p75936
(F1
F0.00014334862385321102
I1
I0
I1
tp75937
sS'compounds,eg,and'
p75938
(F1
F0.00014334862385321102
I1
I0
I1
tp75939
sS'ache,activity,appeared'
p75940
(F1
F0.00014334862385321102
I1
I0
I1
tp75941
sS'given,with,because'
p75942
(F1
F0.00043004587155963305
I3
I0
I3
tp75943
sS'suggest,that,coadministration'
p75944
(F1
F0.00028669724770642203
I2
I0
I2
tp75945
sS'kg,day,for'
p75946
(F1
F0.00014334862385321102
I0
I1
I-1
tp75947
sS'anti-arrhythmics,and,anti-depressants'
p75948
(F1
F0.00014334862385321102
I1
I0
I1
tp75949
sS'co-administration,of,a'
p75950
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp75951
sS'omnicef,therapy,omnicef'
p75952
(F1
F0.00028669724770642203
I2
I0
I2
tp75953
sS'per,day,decreases'
p75954
(F1
F0.00014334862385321102
I1
I0
I1
tp75955
sS'trials,the,patients'
p75956
(F1
F0.00014334862385321102
I0
I1
I-1
tp75957
sS'the,tardive,dyskinesia'
p75958
(F1
F0.00014334862385321102
I1
I0
I1
tp75959
sS'in,the,dosage'
p75960
(F1
F0.00014334862385321102
I1
I0
I1
tp75961
sS'once,weekly,reduced'
p75962
(F1
F0.00014334862385321102
I1
I0
I1
tp75963
sS'days,produced,significant'
p75964
(F1
F0.00014334862385321102
I1
I0
I1
tp75965
sS'in,plasma,samples'
p75966
(F1
F0.00014334862385321102
I0
I1
I-1
tp75967
sS'ineffective,in,preventing'
p75968
(F1
F0.00014334862385321102
I0
I1
I-1
tp75969
sS'which,requires,more'
p75970
(F1
F0.00014334862385321102
I0
I1
I-1
tp75971
sS'a,single-dose,study'
p75972
(F1
F0.00014334862385321102
I0
I1
I-1
tp75973
sS'cyp,a,or'
p75974
(F1
F0.00014334862385321102
I0
I1
I-1
tp75975
sS'significant,effect,on'
p75976
(F0.89473684210526316
F0.0024369266055045873
I1
I18
I-17
tp75977
sS'ethinyl,estradiol,concentrations'
p75978
(F1
F0.00014334862385321102
I0
I1
I-1
tp75979
sS'a,weak,inhibitor'
p75980
(F0
F0
I1
I1
I0
tp75981
sS'with,a,low'
p75982
(F1
F0.00014334862385321102
I0
I1
I-1
tp75983
sS'concentrations,of,resulting'
p75984
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp75985
sS'gastrointestinal,secretion,while'
p75986
(F1
F0.00014334862385321102
I1
I0
I1
tp75987
sS'however,preliminary,results'
p75988
(F1
F0.00014334862385321102
I0
I1
I-1
tp75989
sS'mean,cmax,and'
p75990
(F1
F0.0008600917431192661
I6
I0
I6
tp75991
sS'with,camp,whereas'
p75992
(F1
F0.00014334862385321102
I1
I0
I1
tp75993
sS'also,been,reported'
p75994
(F1
F0.00057339449541284407
I0
I4
I-4
tp75995
sS'patients,taking,ace'
p75996
(F1
F0.00014334862385321102
I0
I1
I-1
tp75997
sS'provided,for,any'
p75998
(F1
F0.00014334862385321102
I0
I1
I-1
tp75999
sS'cyclosporine,diclofenac,like'
p76000
(F1
F0.00014334862385321102
I0
I1
I-1
tp76001
sS'cyp3a4,inhibitor,increases'
p76002
(F1
F0.00014334862385321102
I1
I0
I1
tp76003
sS'contribute,to,the'
p76004
(F1
F0.00014334862385321102
I1
I0
I1
tp76005
sS'em,individuals,treated'
p76006
(F1
F0.00014334862385321102
I1
I0
I1
tp76007
sS'of,actions,and'
p76008
(F1
F0.00014334862385321102
I0
I1
I-1
tp76009
sS'cyp3a4,inhibitor,increased'
p76010
(F1
F0.00014334862385321102
I1
I0
I1
tp76011
sS'insp,induced,responses'
p76012
(F0
F0
I1
I1
I0
tp76013
sS'of,two,consecutive'
p76014
(F1
F0.00014334862385321102
I0
I1
I-1
tp76015
sS'and,other,hormonalmethods'
p76016
(F1
F0.00014334862385321102
I1
I0
I1
tp76017
sS'by,up,to'
p76018
(F1
F0.00071674311926605509
I5
I0
I5
tp76019
sS'of,channel,blockers'
p76020
(F1
F0.00014334862385321102
I0
I1
I-1
tp76021
sS'combination,products,should'
p76022
(F1
F0.00014334862385321102
I0
I1
I-1
tp76023
sS'strong,selective,cyp3a4'
p76024
(F1
F0.00028669724770642203
I2
I0
I2
tp76025
sS'monitoring,of,is'
p76026
(F1
F0.00014334862385321102
I1
I0
I1
tp76027
sS'secretion,of,resulting'
p76028
(F1
F0.00014334862385321102
I1
I0
I1
tp76029
sS'any,clinically,significant'
p76030
(F1
F0.00028669724770642203
I0
I2
I-2
tp76031
sS'mg,administered,once'
p76032
(F1
F0.00028669724770642203
I2
I0
I2
tp76033
sS'therapeutic,concentrations,in'
p76034
(F1
F0.00014334862385321102
I0
I1
I-1
tp76035
sS'acid,in,combination'
p76036
(F1
F0.00014334862385321102
I0
I1
I-1
tp76037
sS'doxorubicin,caused,a'
p76038
(F1
F0.00014334862385321102
I1
I0
I1
tp76039
sS'pharmacokinetics,of,the'
p76040
(F1
F0.00071674311926605509
I5
I0
I5
tp76041
sS'a,ten-subject,study'
p76042
(F1
F0.00014334862385321102
I1
I0
I1
tp76043
sS'by,nor,inhibits'
p76044
(F1
F0.00014334862385321102
I0
I1
I-1
tp76045
sS'the,successive,application'
p76046
(F1
F0.00014334862385321102
I1
I0
I1
tp76047
sS'after,or,more'
p76048
(F1
F0.00014334862385321102
I1
I0
I1
tp76049
sS'tid,were,coadministered'
p76050
(F1
F0.00014334862385321102
I0
I1
I-1
tp76051
sS'phosphatase,activity,but'
p76052
(F1
F0.00014334862385321102
I0
I1
I-1
tp76053
sS'an,opposite,way'
p76054
(F1
F0.00014334862385321102
I1
I0
I1
tp76055
sS'doses,may,be'
p76056
(F1
F0.00014334862385321102
I1
I0
I1
tp76057
sS'are,coadministered,the'
p76058
(F1
F0.00014334862385321102
I1
I0
I1
tp76059
sS'intravenous,is,required'
p76060
(F1
F0.00014334862385321102
I1
I0
I1
tp76061
sS'and,inotropic,such'
p76062
(F1
F0.00014334862385321102
I1
I0
I1
tp76063
sS'by,cardiac,enlargement'
p76064
(F1
F0.00014334862385321102
I1
I0
I1
tp76065
sS'pacemaker,activity,can'
p76066
(F1
F0.00014334862385321102
I1
I0
I1
tp76067
sS'mean,minimum,concentration'
p76068
(F1
F0.00014334862385321102
I0
I1
I-1
tp76069
sS'decrease,conduction,through'
p76070
(F1
F0.00014334862385321102
I1
I0
I1
tp76071
sS'of,central,nervous'
p76072
(F1
F0.00028669724770642203
I2
I0
I2
tp76073
sS'normal,and,diabetic'
p76074
(F1
F0.00014334862385321102
I0
I1
I-1
tp76075
sS'been,reported,following'
p76076
(F0.55555555555555558
F0.00071674311926605509
I7
I2
I5
tp76077
sS'systemic,vascular,resistance'
p76078
(F1
F0.00014334862385321102
I1
I0
I1
tp76079
sS'could,be,prevented'
p76080
(F1
F0.00014334862385321102
I1
I0
I1
tp76081
sS'dipstick,test,for'
p76082
(F1
F0.00014334862385321102
I0
I1
I-1
tp76083
sS'other,drugs,in'
p76084
(F1
F0.00028669724770642203
I0
I2
I-2
tp76085
sS'occurred,when,prinivil'
p76086
(F1
F0.00014334862385321102
I0
I1
I-1
tp76087
sS'hepatic,lipid,peroxidation'
p76088
(F1
F0.00014334862385321102
I1
I0
I1
tp76089
sS'in,functional,classes'
p76090
(F1
F0.00028669724770642203
I0
I2
I-2
tp76091
sS'a,month,toxicology'
p76092
(F1
F0.00014334862385321102
I0
I1
I-1
tp76093
sS'containing,or,and'
p76094
(F1
F0.00014334862385321102
I1
I0
I1
tp76095
sS'in,a,ten-subject'
p76096
(F1
F0.00014334862385321102
I1
I0
I1
tp76097
sS'of,of,approximately'
p76098
(F1
F0.00014334862385321102
I1
I0
I1
tp76099
sS'hormonal,co-administration,of'
p76100
(F1
F0.00014334862385321102
I1
I0
I1
tp76101
sS'acarbose,and,should'
p76102
(F1
F0.00014334862385321102
I1
I0
I1
tp76103
sS'directly,to,the'
p76104
(F1
F0.00014334862385321102
I0
I1
I-1
tp76105
sS'release,but,nearly'
p76106
(F1
F0.00014334862385321102
I0
I1
I-1
tp76107
sS'drugs,aeds,phenytoin'
p76108
(F1
F0.00028669724770642203
I0
I2
I-2
tp76109
sS'weight,heparins,as'
p76110
(F1
F0.00014334862385321102
I0
I1
I-1
tp76111
sS'cmax,up,to'
p76112
(F1
F0.00014334862385321102
I1
I0
I1
tp76113
sS'also,the,potential'
p76114
(F1
F0.00014334862385321102
I0
I1
I-1
tp76115
sS'given,the,properties'
p76116
(F1
F0.00014334862385321102
I0
I1
I-1
tp76117
sS'no,alterations,in'
p76118
(F1
F0.00014334862385321102
I0
I1
I-1
tp76119
sS'theophylline-related,adverse,effects'
p76120
(F1
F0.00014334862385321102
I1
I0
I1
tp76121
sS'excessive,concurrent,use'
p76122
(F1
F0.00014334862385321102
I0
I1
I-1
tp76123
sS'heart,rate,or'
p76124
(F1
F0.00014334862385321102
I0
I1
I-1
tp76125
sS'mineral,oil,and'
p76126
(F1
F0.00014334862385321102
I1
I0
I1
tp76127
sS'evaluated,in,a'
p76128
(F1
F0.00028669724770642203
I0
I2
I-2
tp76129
sS'that,with,serial'
p76130
(F1
F0.00014334862385321102
I0
I1
I-1
tp76131
sS'with,oral,and'
p76132
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp76133
sS'the,pharmacodynamics,blood'
p76134
(F1
F0.00014334862385321102
I0
I1
I-1
tp76135
sS'results,in,free'
p76136
(F1
F0.00014334862385321102
I1
I0
I1
tp76137
sS'total,concentrations,of'
p76138
(F1
F0.00014334862385321102
I0
I1
I-1
tp76139
sS'the,availability,of'
p76140
(F1
F0.00014334862385321102
I0
I1
I-1
tp76141
sS'mydriasis,resulting,from'
p76142
(F1
F0.00014334862385321102
I1
I0
I1
tp76143
sS'suspension,can,be'
p76144
(F1
F0.00014334862385321102
I0
I1
I-1
tp76145
sS'lithium-a,interaction,study'
p76146
(F1
F0.00014334862385321102
I0
I1
I-1
tp76147
sS'multiple,doses,of'
p76148
(F0
F0
I5
I5
I0
tp76149
sS'over,in,nucleoside-experienced'
p76150
(F1
F0.00014334862385321102
I0
I1
I-1
tp76151
sS'mg,times,day'
p76152
(F1
F0.00014334862385321102
I0
I1
I-1
tp76153
sS'or,an,levonorgestrol'
p76154
(F1
F0.00014334862385321102
I0
I1
I-1
tp76155
sS'agent,has,on'
p76156
(F1
F0.00014334862385321102
I1
I0
I1
tp76157
sS'by,cyp3a4,eg'
p76158
(F1
F0.00014334862385321102
I1
I0
I1
tp76159
sS'activity,of,other'
p76160
(F1
F0.00014334862385321102
I1
I0
I1
tp76161
sS'was,significantly,decreased'
p76162
(F1
F0.00014334862385321102
I1
I0
I1
tp76163
sS'by,but,had'
p76164
(F1
F0.00014334862385321102
I1
I0
I1
tp76165
sS'mg,m2,basis'
p76166
(F1
F0.00014334862385321102
I1
I0
I1
tp76167
sS'in,patients,n'
p76168
(F1
F0.00014334862385321102
I1
I0
I1
tp76169
sS'with,may,alter'
p76170
(F1
F0.00014334862385321102
I1
I0
I1
tp76171
sS'patients,receiving,intravenous'
p76172
(F1
F0.00014334862385321102
I1
I0
I1
tp76173
sS'of,injection,use'
p76174
(F1
F0.00014334862385321102
I0
I1
I-1
tp76175
sS'nsaid,has,not'
p76176
(F1
F0.00014334862385321102
I0
I1
I-1
tp76177
sS'like,other,ace'
p76178
(F1
F0.00014334862385321102
I1
I0
I1
tp76179
sS'expected,than,when'
p76180
(F1
F0.00014334862385321102
I1
I0
I1
tp76181
sS'given,together,as'
p76182
(F1
F0.00014334862385321102
I0
I1
I-1
tp76183
sS'by,and,suppressed'
p76184
(F1
F0.00014334862385321102
I0
I1
I-1
tp76185
sS'applied,for,other'
p76186
(F1
F0.00014334862385321102
I0
I1
I-1
tp76187
sS'index,digoxin,sonata'
p76188
(F1
F0.00014334862385321102
I0
I1
I-1
tp76189
sS'in,which,eight'
p76190
(F1
F0.00014334862385321102
I0
I1
I-1
tp76191
sS'by,minutes,any'
p76192
(F1
F0.00014334862385321102
I1
I0
I1
tp76193
sS'be,decreased,in'
p76194
(F1
F0.00014334862385321102
I1
I0
I1
tp76195
sS'endorphinergic,system,is'
p76196
(F1
F0.00014334862385321102
I0
I1
I-1
tp76197
sS'auc,of,was'
p76198
(F1
F0.0010034403669724771
I7
I0
I7
tp76199
sS'clinical,studies,where'
p76200
(F1
F0.00014334862385321102
I0
I1
I-1
tp76201
sS'oral,bioavailability,of'
p76202
(F1
F0.00028669724770642203
I2
I0
I2
tp76203
sS'days,after,completion'
p76204
(F1
F0.00014334862385321102
I1
I0
I1
tp76205
sS'systemic,administration,of'
p76206
(F0
F0
I1
I1
I0
tp76207
sS'all,should,be'
p76208
(F1
F0.00014334862385321102
I1
I0
I1
tp76209
sS'or,without,evidence'
p76210
(F1
F0.00014334862385321102
I0
I1
I-1
tp76211
sS'homogenates,supplemented,with'
p76212
(F1
F0.00014334862385321102
I0
I1
I-1
tp76213
sS'administered,with,agents'
p76214
(F1
F0.00014334862385321102
I1
I0
I1
tp76215
sS'with,would,be'
p76216
(F1
F0.00014334862385321102
I1
I0
I1
tp76217
sS'and,agitation,while'
p76218
(F1
F0.00014334862385321102
I0
I1
I-1
tp76219
sS'to,health,if'
p76220
(F0
F0
I1
I1
I0
tp76221
sS'lomefloxacin,is,unlikely'
p76222
(F1
F0.00014334862385321102
I0
I1
I-1
tp76223
sS'of,many,angiotensin-converting'
p76224
(F1
F0.00014334862385321102
I1
I0
I1
tp76225
sS'of,these,peptides'
p76226
(F1
F0.00014334862385321102
I0
I1
I-1
tp76227
sS'known,to,affect'
p76228
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp76229
sS'of,by,fold'
p76230
(F1
F0.00014334862385321102
I1
I0
I1
tp76231
sS'if,used,concomitantly'
p76232
(F1
F0.00014334862385321102
I1
I0
I1
tp76233
sS'will,affect,the'
p76234
(F1
F0.00014334862385321102
I1
I0
I1
tp76235
sS'dose-dependent,fashion,as'
p76236
(F1
F0.00014334862385321102
I1
I0
I1
tp76237
sS'monitored,when,celebrex'
p76238
(F1
F0.00014334862385321102
I1
I0
I1
tp76239
sS'd3,and,tam'
p76240
(F1
F0.00014334862385321102
I1
I0
I1
tp76241
sS'relevant,pharmacokinetic,or'
p76242
(F1
F0.00014334862385321102
I0
I1
I-1
tp76243
sS'a,including,with'
p76244
(F1
F0.00014334862385321102
I1
I0
I1
tp76245
sS'the,beginning,of'
p76246
(F1
F0.00014334862385321102
I0
I1
I-1
tp76247
sS'and,toxicokinetic,studies'
p76248
(F1
F0.00014334862385321102
I0
I1
I-1
tp76249
sS'in,combination,to'
p76250
(F1
F0.00014334862385321102
I1
I0
I1
tp76251
sS'and,minimizes,this'
p76252
(F1
F0.00014334862385321102
I1
I0
I1
tp76253
sS'slower,renal,elimination'
p76254
(F1
F0.00014334862385321102
I1
I0
I1
tp76255
sS'two,clinical,studies'
p76256
(F1
F0.00014334862385321102
I1
I0
I1
tp76257
sS'acidifying,agents,decrease'
p76258
(F1
F0.00014334862385321102
I1
I0
I1
tp76259
sS'patients,taking,concomitantly'
p76260
(F1
F0.00028669724770642203
I2
I0
I2
tp76261
sS'use,of,erection-supporting'
p76262
(F1
F0.00014334862385321102
I0
I1
I-1
tp76263
sS'secondary,to,a'
p76264
(F1
F0.00014334862385321102
I1
I0
I1
tp76265
sS'not,on,overall'
p76266
(F1
F0.00014334862385321102
I0
I1
I-1
tp76267
sS'healthy,volunteers,has'
p76268
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp76269
sS'glycosides,concurrent,use'
p76270
(F1
F0.00014334862385321102
I0
I1
I-1
tp76271
sS'depth,of,involvement'
p76272
(F1
F0.00014334862385321102
I0
I1
I-1
tp76273
sS'should,be,reviewed'
p76274
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp76275
sS'antagonists,the,absorption'
p76276
(F1
F0.00014334862385321102
I1
I0
I1
tp76277
sS'oral,absorption,of'
p76278
(F1
F0.00028669724770642203
I2
I0
I2
tp76279
sS'transit,time,from'
p76280
(F1
F0.00014334862385321102
I1
I0
I1
tp76281
sS'and,or,are'
p76282
(F1
F0.00014334862385321102
I1
I0
I1
tp76283
sS'glycosides,in,a'
p76284
(F1
F0.00014334862385321102
I0
I1
I-1
tp76285
sS'medicine,that,you'
p76286
(F1
F0.00014334862385321102
I1
I0
I1
tp76287
sS'of,t,a'
p76288
(F1
F0.00014334862385321102
I1
I0
I1
tp76289
sS'clearance,values,for'
p76290
(F1
F0.00014334862385321102
I1
I0
I1
tp76291
sS'medicines,including,may'
p76292
(F1
F0.00014334862385321102
I0
I1
I-1
tp76293
sS'of,cardiac,contractility'
p76294
(F1
F0.00014334862385321102
I1
I0
I1
tp76295
sS'or,taking,tarceva'
p76296
(F1
F0.00014334862385321102
I1
I0
I1
tp76297
sS'enzyme,system,responsible'
p76298
(F1
F0.00014334862385321102
I1
I0
I1
tp76299
sS'compared,to,use'
p76300
(F1
F0.00028669724770642203
I2
I0
I2
tp76301
sS'a,history,of'
p76302
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp76303
sS'of,carbimazole,and'
p76304
(F1
F0.00014334862385321102
I1
I0
I1
tp76305
sS'medication,such,as'
p76306
(F1
F0.00014334862385321102
I1
I0
I1
tp76307
sS'as,nuromax,include'
p76308
(F1
F0.00014334862385321102
I1
I0
I1
tp76309
sS'and,after,oral'
p76310
(F1
F0.00014334862385321102
I0
I1
I-1
tp76311
sS'however,interactions,may'
p76312
(F1
F0.00014334862385321102
I1
I0
I1
tp76313
sS'oral,live,typhoid'
p76314
(F1
F0.00014334862385321102
I1
I0
I1
tp76315
sS'your,doctor,or'
p76316
(F1
F0.00014334862385321102
I0
I1
I-1
tp76317
sS'following,table,aed'
p76318
(F1
F0.00014334862385321102
I0
I1
I-1
tp76319
sS'in,dosage,of'
p76320
(F1
F0.00014334862385321102
I1
I0
I1
tp76321
sS'unsteady,gait,or'
p76322
(F1
F0.00014334862385321102
I1
I0
I1
tp76323
sS'week,plasma,levels'
p76324
(F1
F0.00014334862385321102
I1
I0
I1
tp76325
sS'inhibitors,including,acetylsalicylic'
p76326
(F1
F0.00014334862385321102
I0
I1
I-1
tp76327
sS'dependent,labelling,of'
p76328
(F1
F0.00014334862385321102
I0
I1
I-1
tp76329
sS'application,of,or'
p76330
(F1
F0.00014334862385321102
I1
I0
I1
tp76331
sS'earth,and,transition'
p76332
(F1
F0.00014334862385321102
I0
I1
I-1
tp76333
sS'obstipation,even,ileus'
p76334
(F1
F0.00014334862385321102
I1
I0
I1
tp76335
sS'decreased,the,tmax'
p76336
(F1
F0.00014334862385321102
I1
I0
I1
tp76337
sS'agents,for,migraine'
p76338
(F1
F0.00014334862385321102
I1
I0
I1
tp76339
sS'to,indirect-acting,agents'
p76340
(F1
F0.00014334862385321102
I1
I0
I1
tp76341
sS'female,subjects,received'
p76342
(F1
F0.00028669724770642203
I0
I2
I-2
tp76343
sS'hydroxide,hydroxide,and'
p76344
(F1
F0.00014334862385321102
I1
I0
I1
tp76345
sS'and,in,a-chloralose'
p76346
(F1
F0.00014334862385321102
I0
I1
I-1
tp76347
sS'when,flolan,is'
p76348
(F1
F0.00014334862385321102
I1
I0
I1
tp76349
sS'with,other,or'
p76350
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp76351
sS'can,be,anticipated'
p76352
(F1
F0.00014334862385321102
I1
I0
I1
tp76353
sS'serious,cardiovascular,adverse'
p76354
(F1
F0.00014334862385321102
I1
I0
I1
tp76355
sS'mg,sodium,approximately'
p76356
(F1
F0.00014334862385321102
I1
I0
I1
tp76357
sS'inducers,of,cyp3a4'
p76358
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp76359
sS'clinical,interaction,studies'
p76360
(F1
F0.00028669724770642203
I0
I2
I-2
tp76361
sS'study,was,a'
p76362
(F1
F0.00014334862385321102
I0
I1
I-1
tp76363
sS'as,and,maois'
p76364
(F1
F0.00014334862385321102
I1
I0
I1
tp76365
sS'lead,to,elevated'
p76366
(F1
F0.00014334862385321102
I1
I0
I1
tp76367
sS'at,steady-state,were'
p76368
(F1
F0.00014334862385321102
I0
I1
I-1
tp76369
sS'h-spiroperidol,and,low'
p76370
(F1
F0.00014334862385321102
I0
I1
I-1
tp76371
sS'of,cyp3a,compounds'
p76372
(F1
F0.00014334862385321102
I1
I0
I1
tp76373
sS'appropriate,observation,of'
p76374
(F1
F0.00057339449541284407
I4
I0
I4
tp76375
sS'this,observed,increase'
p76376
(F1
F0.00014334862385321102
I1
I0
I1
tp76377
sS'cyp3a4,cyp2d6,cyp2e1'
p76378
(F1
F0.00014334862385321102
I0
I1
I-1
tp76379
sS'suggested,with,phenyl-butazone'
p76380
(F1
F0.00014334862385321102
I0
I1
I-1
tp76381
sS'in,the,appearance'
p76382
(F1
F0.00014334862385321102
I0
I1
I-1
tp76383
sS'urine,volume,and'
p76384
(F1
F0.00014334862385321102
I1
I0
I1
tp76385
sS'posed,by,and'
p76386
(F1
F0.00014334862385321102
I0
I1
I-1
tp76387
sS'fold,of,control'
p76388
(F1
F0.00014334862385321102
I1
I0
I1
tp76389
sS'when,the,use'
p76390
(F1
F0.00014334862385321102
I0
I1
I-1
tp76391
sS'of,hepatic,microsomal'
p76392
(F1
F0.00014334862385321102
I0
I1
I-1
tp76393
sS'fludrocortisone,acetate,because'
p76394
(F1
F0.00014334862385321102
I1
I0
I1
tp76395
sS'of,prinivil,with'
p76396
(F1
F0.00014334862385321102
I1
I0
I1
tp76397
sS'symbol,substitution,test'
p76398
(F1
F0.00014334862385321102
I1
I0
I1
tp76399
sS'subsalicylate,given,concomitantly'
p76400
(F1
F0.00014334862385321102
I1
I0
I1
tp76401
sS'similarly,dialyzed,were'
p76402
(F1
F0.00014334862385321102
I0
I1
I-1
tp76403
sS'and,smx,were'
p76404
(F1
F0.00014334862385321102
I0
I1
I-1
tp76405
sS'with,coronary,artery'
p76406
(F1
F0.00014334862385321102
I0
I1
I-1
tp76407
sS'to,reduced,clearance'
p76408
(F1
F0.00014334862385321102
I0
I1
I-1
tp76409
sS'which,are,very'
p76410
(F1
F0.00014334862385321102
I1
I0
I1
tp76411
sS'auc,and,very'
p76412
(F1
F0.00014334862385321102
I1
I0
I1
tp76413
sS'maximal,decrease,between'
p76414
(F1
F0.00014334862385321102
I0
I1
I-1
tp76415
sS'factive,with,resulted'
p76416
(F1
F0.00014334862385321102
I1
I0
I1
tp76417
sS'in,the,level'
p76418
(F0
F0
I1
I1
I0
tp76419
sS'inhibit,renal,tubular'
p76420
(F1
F0.00014334862385321102
I1
I0
I1
tp76421
sS'alteration,of,either'
p76422
(F1
F0.00014334862385321102
I0
I1
I-1
tp76423
sS'in,a,type'
p76424
(F1
F0.00014334862385321102
I1
I0
I1
tp76425
sS'glutathione,levels,in'
p76426
(F1
F0.00014334862385321102
I1
I0
I1
tp76427
sS'and,severity,of'
p76428
(F1
F0.00014334862385321102
I1
I0
I1
tp76429
sS'coadministration,of,oral'
p76430
(F0.5
F0.00028669724770642203
I3
I1
I2
tp76431
sS'humans,remain,to'
p76432
(F1
F0.00014334862385321102
I0
I1
I-1
tp76433
sS'macrolide,and,other'
p76434
(F1
F0.00014334862385321102
I1
I0
I1
tp76435
sS'withhold,during,dosing'
p76436
(F1
F0.00014334862385321102
I1
I0
I1
tp76437
sS'in,bioavailability,studies'
p76438
(F1
F0.00014334862385321102
I0
I1
I-1
tp76439
sS'when,administered,minutes'
p76440
(F1
F0.00014334862385321102
I0
I1
I-1
tp76441
sS'mask,the,cardiotoxicity'
p76442
(F1
F0.00014334862385321102
I0
I1
I-1
tp76443
sS'hypokalemic,effect,of'
p76444
(F1
F0.00014334862385321102
I1
I0
I1
tp76445
sS'regard,to,the'
p76446
(F1
F0.00014334862385321102
I0
I1
I-1
tp76447
sS'measurable,effect,on'
p76448
(F1
F0.00014334862385321102
I0
I1
I-1
tp76449
sS'be,necessary,when'
p76450
(F0.5
F0.00028669724770642203
I3
I1
I2
tp76451
sS'resistant,strains,of'
p76452
(F1
F0.00014334862385321102
I0
I1
I-1
tp76453
sS'iv,cannot,be'
p76454
(F1
F0.00014334862385321102
I0
I1
I-1
tp76455
sS'a,guide,to'
p76456
(F1
F0.00014334862385321102
I1
I0
I1
tp76457
sS'other,may,inhibit'
p76458
(F1
F0.00014334862385321102
I1
I0
I1
tp76459
sS'being,treated,concurrently'
p76460
(F1
F0.00014334862385321102
I1
I0
I1
tp76461
sS'ironically,are,often'
p76462
(F1
F0.00014334862385321102
I0
I1
I-1
tp76463
sS'study,with,healthy'
p76464
(F1
F0.00014334862385321102
I0
I1
I-1
tp76465
sS'propranolol,in,a'
p76466
(F1
F0.00014334862385321102
I0
I1
I-1
tp76467
sS'not,recommended,due'
p76468
(F1
F0.00043004587155963305
I3
I0
I3
tp76469
sS'a,test,agent'
p76470
(F1
F0.00014334862385321102
I0
I1
I-1
tp76471
sS'as,videx,chewable'
p76472
(F1
F0.00028669724770642203
I2
I0
I2
tp76473
sS'p450,isoforms,cyp3a4'
p76474
(F1
F0.00014334862385321102
I0
I1
I-1
tp76475
sS'associated,with,an'
p76476
(F0.77777777777777779
F0.0010034403669724771
I8
I1
I7
tp76477
sS'demonstrates,some,limited'
p76478
(F1
F0.00014334862385321102
I1
I0
I1
tp76479
sS'antacids,or,substantially'
p76480
(F1
F0.00014334862385321102
I1
I0
I1
tp76481
sS'l-ccg,on,the'
p76482
(F1
F0.00014334862385321102
I0
I1
I-1
tp76483
sS'and,central,nervous'
p76484
(F1
F0.00014334862385321102
I0
I1
I-1
tp76485
sS'with,normal,renal'
p76486
(F1
F0.00014334862385321102
I0
I1
I-1
tp76487
sS'benefit,when,compared'
p76488
(F1
F0.00014334862385321102
I0
I1
I-1
tp76489
sS'duration,of,succinylcholine-induced'
p76490
(F1
F0.00014334862385321102
I0
I1
I-1
tp76491
sS'interactions,have,occurred'
p76492
(F1
F0.00014334862385321102
I1
I0
I1
tp76493
sS'and,mg,a'
p76494
(F1
F0.00014334862385321102
I0
I1
I-1
tp76495
sS'broad-spectrum,augmentin,xr'
p76496
(F1
F0.00014334862385321102
I1
I0
I1
tp76497
sS'administration,and,the'
p76498
(F1
F0.00014334862385321102
I0
I1
I-1
tp76499
sS'and,mg,l'
p76500
(F1
F0.00014334862385321102
I0
I1
I-1
tp76501
sS'inhibitor,can,be'
p76502
(F1
F0.00014334862385321102
I1
I0
I1
tp76503
sS'been,evaluated,but'
p76504
(F1
F0.00028669724770642203
I2
I0
I2
tp76505
sS'in,the,study'
p76506
(F1
F0.00014334862385321102
I0
I1
I-1
tp76507
sS'including,those,contained'
p76508
(F1
F0.00014334862385321102
I1
I0
I1
tp76509
sS'and,mg,q'
p76510
(F1
F0.00014334862385321102
I1
I0
I1
tp76511
sS'action,of,by'
p76512
(F1
F0.00014334862385321102
I1
I0
I1
tp76513
sS'since,may,raise'
p76514
(F1
F0.00014334862385321102
I1
I0
I1
tp76515
sS'suggesting,an,inhibition'
p76516
(F1
F0.00014334862385321102
I1
I0
I1
tp76517
sS'therefore,be,observed'
p76518
(F1
F0.00014334862385321102
I1
I0
I1
tp76519
sS'in,reduced,plasma'
p76520
(F0
F0
I1
I1
I0
tp76521
sS'sympathomimetic,amines,may'
p76522
(F1
F0.00014334862385321102
I1
I0
I1
tp76523
sS'resulting,from,cholinergic'
p76524
(F1
F0.00014334862385321102
I1
I0
I1
tp76525
sS'in,addition,other'
p76526
(F1
F0.00014334862385321102
I1
I0
I1
tp76527
sS'is,adsorption,of'
p76528
(F1
F0.00014334862385321102
I1
I0
I1
tp76529
sS'isoenzymes,cyp1a2,c8'
p76530
(F1
F0.00014334862385321102
I0
I1
I-1
tp76531
sS'the,steady-state,trough'
p76532
(F0
F0
I3
I3
I0
tp76533
sS'the,active,s-isomer'
p76534
(F1
F0.00014334862385321102
I0
I1
I-1
tp76535
sS'several,closely,related'
p76536
(F1
F0.00014334862385321102
I1
I0
I1
tp76537
sS'mg,tid,mg'
p76538
(F1
F0.00014334862385321102
I1
I0
I1
tp76539
sS'increase,in,adults'
p76540
(F1
F0.00014334862385321102
I1
I0
I1
tp76541
sS'and,an,interleukin-1'
p76542
(F1
F0.00014334862385321102
I1
I0
I1
tp76543
sS'following,an,intubating'
p76544
(F1
F0.00014334862385321102
I1
I0
I1
tp76545
sS'to,the,heat'
p76546
(F1
F0.00014334862385321102
I0
I1
I-1
tp76547
sS'acid,using,these'
p76548
(F1
F0.00014334862385321102
I1
I0
I1
tp76549
sS'and,no,potentiation'
p76550
(F1
F0.00014334862385321102
I0
I1
I-1
tp76551
sS'iatrogenic,alterations,caused'
p76552
(F1
F0.00014334862385321102
I1
I0
I1
tp76553
sS'with,are,used'
p76554
(F1
F0.00014334862385321102
I0
I1
I-1
tp76555
sS'effectiveness,is,reported'
p76556
(F1
F0.00014334862385321102
I0
I1
I-1
tp76557
sS'dose,of,intravenously'
p76558
(F1
F0.00014334862385321102
I1
I0
I1
tp76559
sS'increase,or,decrease'
p76560
(F1
F0.00028669724770642203
I2
I0
I2
tp76561
sS'to,the,effects'
p76562
(F0
F0
I1
I1
I0
tp76563
sS'formula,mg,elemental'
p76564
(F1
F0.00014334862385321102
I0
I1
I-1
tp76565
sS'of,to,half'
p76566
(F1
F0.00014334862385321102
I1
I0
I1
tp76567
sS'effective,due,to'
p76568
(F0
F0
I1
I1
I0
tp76569
sS'is,theoretically,possible'
p76570
(F1
F0.00014334862385321102
I1
I0
I1
tp76571
sS'in,ontario,the'
p76572
(F1
F0.00014334862385321102
I0
I1
I-1
tp76573
sS'or,prothrombin,complex'
p76574
(F1
F0.00014334862385321102
I0
I1
I-1
tp76575
sS'weakness,associated,with'
p76576
(F1
F0.00014334862385321102
I0
I1
I-1
tp76577
sS'and,suboxone,should'
p76578
(F1
F0.00014334862385321102
I1
I0
I1
tp76579
sS'of,while,under'
p76580
(F1
F0.00014334862385321102
I1
I0
I1
tp76581
sS'activate,the,renin-angiotensin'
p76582
(F1
F0.00014334862385321102
I0
I1
I-1
tp76583
sS'improves,the,intestinal'
p76584
(F1
F0.00014334862385321102
I0
I1
I-1
tp76585
sS'concomitant,may,decrease'
p76586
(F1
F0.00014334862385321102
I1
I0
I1
tp76587
sS'single,mg,and'
p76588
(F1
F0.00014334862385321102
I0
I1
I-1
tp76589
sS'from,m,v'
p76590
(F1
F0.00014334862385321102
I0
I1
I-1
tp76591
sS'of,and,and'
p76592
(F0.42857142857142855
F0.00043004587155963305
I5
I2
I3
tp76593
sS'will,depend,on'
p76594
(F1
F0.00071674311926605509
I5
I0
I5
tp76595
sS'corrected,qt,intervals'
p76596
(F1
F0.00028669724770642203
I0
I2
I-2
tp76597
sS'when,is,coadministered'
p76598
(F1
F0.00028669724770642203
I2
I0
I2
tp76599
sS'serotonergic,agents,co-administration'
p76600
(F1
F0.00014334862385321102
I0
I1
I-1
tp76601
sS'general,although,there'
p76602
(F1
F0.00014334862385321102
I0
I1
I-1
tp76603
sS'and,nsaids,affect'
p76604
(F1
F0.00014334862385321102
I1
I0
I1
tp76605
sS'cautiously,in,patients'
p76606
(F1
F0.00014334862385321102
I1
I0
I1
tp76607
sS'observed,when,videx'
p76608
(F1
F0.00014334862385321102
I1
I0
I1
tp76609
sS'on,gabitril,carbamazepine'
p76610
(F1
F0.00014334862385321102
I1
I0
I1
tp76611
sS'been,reported,when'
p76612
(F1
F0.0011467889908256881
I8
I0
I8
tp76613
sS'developed,increased,bun'
p76614
(F1
F0.00014334862385321102
I1
I0
I1
tp76615
sS'antagonism,has,the'
p76616
(F1
F0.00014334862385321102
I1
I0
I1
tp76617
sS'with,an,inhibition'
p76618
(F1
F0.00014334862385321102
I1
I0
I1
tp76619
sS'of,a,sensitive'
p76620
(F1
F0.00014334862385321102
I1
I0
I1
tp76621
sS'safely,coadministered,with'
p76622
(F1
F0.00014334862385321102
I0
I1
I-1
tp76623
sS'of,a,known'
p76624
(F1
F0.00043004587155963305
I3
I0
I3
tp76625
sS'increased,approximately,with'
p76626
(F1
F0.00014334862385321102
I1
I0
I1
tp76627
sS'infarction,in,ephesus'
p76628
(F1
F0.00014334862385321102
I0
I1
I-1
tp76629
sS'platelet,inhibitors,including'
p76630
(F1
F0.00014334862385321102
I0
I1
I-1
tp76631
sS'lowered,blood,levels'
p76632
(F1
F0.00014334862385321102
I1
I0
I1
tp76633
sS'observed,when,they'
p76634
(F1
F0.00014334862385321102
I1
I0
I1
tp76635
sS'is,added,of'
p76636
(F1
F0.00014334862385321102
I1
I0
I1
tp76637
sS'with,plus,without'
p76638
(F1
F0.00014334862385321102
I0
I1
I-1
tp76639
sS'single-dose,administration,of'
p76640
(F1
F0.00014334862385321102
I0
I1
I-1
tp76641
sS'and,general,have'
p76642
(F1
F0.00014334862385321102
I1
I0
I1
tp76643
sS'reactions,patients,with'
p76644
(F1
F0.00014334862385321102
I1
I0
I1
tp76645
sS'since,there,is'
p76646
(F1
F0.00014334862385321102
I0
I1
I-1
tp76647
sS'for,injection,concentrate'
p76648
(F1
F0.00014334862385321102
I1
I0
I1
tp76649
sS'of,tmp,and'
p76650
(F1
F0.00014334862385321102
I0
I1
I-1
tp76651
sS'gastrointestinal,adverse,experiences'
p76652
(F1
F0.00014334862385321102
I0
I1
I-1
tp76653
sS'd6,many,other'
p76654
(F1
F0.00071674311926605509
I0
I5
I-5
tp76655
sS'in,cyclosporine-induced,toxicity'
p76656
(F1
F0.00028669724770642203
I2
I0
I2
tp76657
sS'synergism,has,been'
p76658
(F1
F0.00014334862385321102
I1
I0
I1
tp76659
sS'concomitant,therapy,with'
p76660
(F0.33333333333333331
F0.00028669724770642203
I2
I4
I-2
tp76661
sS'pretreatment,period,with'
p76662
(F1
F0.00014334862385321102
I0
I1
I-1
tp76663
sS'stavudine,and,zidovudine'
p76664
(F1
F0.00014334862385321102
I1
I0
I1
tp76665
sS'exacerbate,the,neutropenic'
p76666
(F1
F0.00014334862385321102
I1
I0
I1
tp76667
sS'except,for,increased'
p76668
(F1
F0.00014334862385321102
I0
I1
I-1
tp76669
sS'a,slight,decrease'
p76670
(F1
F0.00028669724770642203
I2
I0
I2
tp76671
sS'secondary,to,its'
p76672
(F1
F0.00014334862385321102
I1
I0
I1
tp76673
sS'describing,patients,with'
p76674
(F1
F0.00014334862385321102
I1
I0
I1
tp76675
sS'patients,reveiving,phenytoin'
p76676
(F1
F0.00014334862385321102
I1
I0
I1
tp76677
sS'both,agents,demonstrated'
p76678
(F1
F0.00014334862385321102
I0
I1
I-1
tp76679
sS'with,iv,such'
p76680
(F1
F0.00014334862385321102
I0
I1
I-1
tp76681
sS'cholestyramine,increases,enterohepatic'
p76682
(F1
F0.00014334862385321102
I0
I1
I-1
tp76683
sS'be,unlikely,to'
p76684
(F1
F0.00014334862385321102
I0
I1
I-1
tp76685
sS'with,viracept,resulted'
p76686
(F0.59999999999999998
F0.00043004587155963305
I4
I1
I3
tp76687
sS'electrocardiographic,abnormalities,and'
p76688
(F1
F0.00014334862385321102
I1
I0
I1
tp76689
sS'cascade,impactor,for'
p76690
(F1
F0.00014334862385321102
I0
I1
I-1
tp76691
sS'are,taking,while'
p76692
(F1
F0.00014334862385321102
I1
I0
I1
tp76693
sS'should,be,co-administered'
p76694
(F1
F0.00014334862385321102
I1
I0
I1
tp76695
sS'susceptible,patients,and'
p76696
(F1
F0.00014334862385321102
I1
I0
I1
tp76697
sS'nnrtis,nevirapine,may'
p76698
(F1
F0.00014334862385321102
I1
I0
I1
tp76699
sS'rapid,contraction,followed'
p76700
(F1
F0.00014334862385321102
I0
I1
I-1
tp76701
sS'are,cytochrome,p450'
p76702
(F1
F0.00014334862385321102
I1
I0
I1
tp76703
sS'be,considered,prior'
p76704
(F1
F0.00014334862385321102
I1
I0
I1
tp76705
sS'vivo,animal,studies'
p76706
(F1
F0.00014334862385321102
I1
I0
I1
tp76707
sS'clinically,relevant,interactions'
p76708
(F1
F0.00014334862385321102
I0
I1
I-1
tp76709
sS'iressa,and,therefore'
p76710
(F1
F0.00014334862385321102
I1
I0
I1
tp76711
sS'by,that,of'
p76712
(F1
F0.00014334862385321102
I1
I0
I1
tp76713
sS'a,prolongation,of'
p76714
(F1
F0.00028669724770642203
I2
I0
I2
tp76715
sS'renal,failure,as'
p76716
(F0
F0
I1
I1
I0
tp76717
sS'with,caution,as'
p76718
(F1
F0.00028669724770642203
I2
I0
I2
tp76719
sS'flolan,to,increase'
p76720
(F1
F0.00014334862385321102
I1
I0
I1
tp76721
sS'also,not,be'
p76722
(F1
F0.00014334862385321102
I1
I0
I1
tp76723
sS'treatment,in,renal'
p76724
(F1
F0.00014334862385321102
I1
I0
I1
tp76725
sS'and,some,resulting'
p76726
(F1
F0.00014334862385321102
I1
I0
I1
tp76727
sS'shock,in,a'
p76728
(F1
F0.00014334862385321102
I0
I1
I-1
tp76729
sS'oral,agents,pharmacokinetic'
p76730
(F1
F0.00014334862385321102
I0
I1
I-1
tp76731
sS'were,studied,following'
p76732
(F1
F0.00014334862385321102
I0
I1
I-1
tp76733
sS'such,a,potential'
p76734
(F1
F0.00014334862385321102
I1
I0
I1
tp76735
sS'tissues,of,mice'
p76736
(F1
F0.00014334862385321102
I0
I1
I-1
tp76737
sS'particular,importance,sufficient'
p76738
(F1
F0.00014334862385321102
I1
I0
I1
tp76739
sS'of,hypoglycemia,secondary'
p76740
(F1
F0.00014334862385321102
I1
I0
I1
tp76741
sS'with,the,clearance'
p76742
(F1
F0.00014334862385321102
I1
I0
I1
tp76743
sS'that,concurrent,use'
p76744
(F1
F0.00014334862385321102
I1
I0
I1
tp76745
sS'article,reported,that'
p76746
(F1
F0.00014334862385321102
I1
I0
I1
tp76747
sS'or,prolong,both'
p76748
(F1
F0.00014334862385321102
I0
I1
I-1
tp76749
sS'and,and,higher'
p76750
(F1
F0.00014334862385321102
I1
I0
I1
tp76751
sS'verified,by,equilibrium'
p76752
(F1
F0.00014334862385321102
I0
I1
I-1
tp76753
sS'morning,dose,of'
p76754
(F1
F0.00014334862385321102
I0
I1
I-1
tp76755
sS'concentrations,of,a'
p76756
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp76757
sS'which,eight,hiv-infected'
p76758
(F1
F0.00014334862385321102
I0
I1
I-1
tp76759
sS'reviewed,and,the'
p76760
(F1
F0.00014334862385321102
I1
I0
I1
tp76761
sS'of,to,induce'
p76762
(F1
F0.00014334862385321102
I1
I0
I1
tp76763
sS'concentrations,of,m'
p76764
(F1
F0.00028669724770642203
I2
I0
I2
tp76765
sS'of,about,when'
p76766
(F1
F0.00014334862385321102
I1
I0
I1
tp76767
sS'inhibitors,as,anorexia'
p76768
(F1
F0.00014334862385321102
I1
I0
I1
tp76769
sS'xanthine,derivatives,or'
p76770
(F1
F0.00014334862385321102
I1
I0
I1
tp76771
sS'or,pharmacodynamics,of'
p76772
(F1
F0.00028669724770642203
I0
I2
I-2
tp76773
sS'concomitant,n,hypotension'
p76774
(F1
F0.00014334862385321102
I1
I0
I1
tp76775
sS'want,to,know'
p76776
(F1
F0.00014334862385321102
I0
I1
I-1
tp76777
sS'the,antidepressant,single'
p76778
(F1
F0.00014334862385321102
I1
I0
I1
tp76779
sS'survanta,also,increased'
p76780
(F1
F0.00014334862385321102
I0
I1
I-1
tp76781
sS'ci,of,the'
p76782
(F1
F0.00014334862385321102
I0
I1
I-1
tp76783
sS'interval,certain,or'
p76784
(F1
F0.00014334862385321102
I1
I0
I1
tp76785
sS'inhibited,the,absorption'
p76786
(F1
F0.00014334862385321102
I1
I0
I1
tp76787
sS'only,bodyweight,gain'
p76788
(F1
F0.00014334862385321102
I0
I1
I-1
tp76789
sS'important,determinant,of'
p76790
(F1
F0.00028669724770642203
I2
I0
I2
tp76791
sS'proleukin,and,antineoplastic'
p76792
(F1
F0.00014334862385321102
I1
I0
I1
tp76793
sS'severe,high,blood'
p76794
(F1
F0.00014334862385321102
I1
I0
I1
tp76795
sS'ibogaine,attenuates,but'
p76796
(F1
F0.00014334862385321102
I1
I0
I1
tp76797
sS'edema,it,has'
p76798
(F1
F0.00014334862385321102
I1
I0
I1
tp76799
sS'naflu,and,the'
p76800
(F1
F0.00014334862385321102
I0
I1
I-1
tp76801
sS'hydrochlorothiazide,hctz,alone'
p76802
(F1
F0.00014334862385321102
I0
I1
I-1
tp76803
sS'or,oral,regular'
p76804
(F1
F0.00014334862385321102
I0
I1
I-1
tp76805
sS'study,with,concomitant'
p76806
(F1
F0.00014334862385321102
I0
I1
I-1
tp76807
sS'methotrexate,renal,tubular'
p76808
(F1
F0.00014334862385321102
I1
I0
I1
tp76809
sS'increase,the,marrow'
p76810
(F1
F0.00014334862385321102
I0
I1
I-1
tp76811
sS'metabolized,by,multiple'
p76812
(F1
F0.00028669724770642203
I0
I2
I-2
tp76813
sS'to,alpha,interferons'
p76814
(F1
F0.00014334862385321102
I0
I1
I-1
tp76815
sS'increased,metabolic,clearance'
p76816
(F1
F0.00014334862385321102
I1
I0
I1
tp76817
sS'encouraged,to,enroll'
p76818
(F1
F0.00014334862385321102
I0
I1
I-1
tp76819
sS'only,to,slower'
p76820
(F1
F0.00014334862385321102
I1
I0
I1
tp76821
sS'levels,carbamazepine,levels'
p76822
(F1
F0.00014334862385321102
I1
I0
I1
tp76823
sS'reports,of,skeletal'
p76824
(F1
F0.00014334862385321102
I0
I1
I-1
tp76825
sS'taking,to,whom'
p76826
(F1
F0.00014334862385321102
I1
I0
I1
tp76827
sS'lithium,ibuprofen,produced'
p76828
(F1
F0.00014334862385321102
I1
I0
I1
tp76829
sS'possibly,increasing,the'
p76830
(F1
F0.00014334862385321102
I1
I0
I1
tp76831
sS'p,the,possibility'
p76832
(F1
F0.00014334862385321102
I1
I0
I1
tp76833
sS'argatroban,g,kg'
p76834
(F1
F0.00014334862385321102
I0
I1
I-1
tp76835
sS'concentration,of,other'
p76836
(F1
F0.00014334862385321102
I0
I1
I-1
tp76837
sS'mucosa,caused,an'
p76838
(F1
F0.00014334862385321102
I1
I0
I1
tp76839
sS'and,mg,once'
p76840
(F1
F0.00014334862385321102
I1
I0
I1
tp76841
sS'of,multipledose,treatment'
p76842
(F1
F0.00014334862385321102
I0
I1
I-1
tp76843
sS'complete,heart,block'
p76844
(F1
F0.00014334862385321102
I0
I1
I-1
tp76845
sS'immobilised,cmc-cys7,from'
p76846
(F1
F0.00014334862385321102
I0
I1
I-1
tp76847
sS'antiprothrombinemic,effect,of'
p76848
(F1
F0.00014334862385321102
I0
I1
I-1
tp76849
sS'by,multiple,enzyme'
p76850
(F1
F0.00014334862385321102
I0
I1
I-1
tp76851
sS'similar,affinities,for'
p76852
(F1
F0.00014334862385321102
I0
I1
I-1
tp76853
sS'of,unchanged,accounts'
p76854
(F1
F0.00014334862385321102
I0
I1
I-1
tp76855
sS'but,not,the'
p76856
(F1
F0.00028669724770642203
I2
I0
I2
tp76857
sS'of,mg,qd'
p76858
(F0
F0
I1
I1
I0
tp76859
sS'hypoparathyroid,patients,who'
p76860
(F1
F0.00028669724770642203
I2
I0
I2
tp76861
sS'with,co-administration,leading'
p76862
(F1
F0.00014334862385321102
I1
I0
I1
tp76863
sS'not,show,a'
p76864
(F1
F0.00028669724770642203
I0
I2
I-2
tp76865
sS'activity,of,mixed-function'
p76866
(F1
F0.00014334862385321102
I0
I1
I-1
tp76867
sS'eszopiclone,mg,administered'
p76868
(F1
F0.00014334862385321102
I0
I1
I-1
tp76869
sS'small,quantities,of'
p76870
(F1
F0.00014334862385321102
I0
I1
I-1
tp76871
sS'myocardial,infarction,vs'
p76872
(F1
F0.00014334862385321102
I1
I0
I1
tp76873
sS'oxide,donor,compounds'
p76874
(F1
F0.00014334862385321102
I1
I0
I1
tp76875
sS'be,reserved,for'
p76876
(F1
F0.00014334862385321102
I0
I1
I-1
tp76877
sS'increases,the,mean'
p76878
(F1
F0.00014334862385321102
I1
I0
I1
tp76879
sS'orally,min,before'
p76880
(F1
F0.00014334862385321102
I0
I1
I-1
tp76881
sS'minutes,following,alfenta'
p76882
(F1
F0.00014334862385321102
I1
I0
I1
tp76883
sS'with,other,members'
p76884
(F1
F0.00028669724770642203
I2
I0
I2
tp76885
sS'administration,of,robinul'
p76886
(F1
F0.00014334862385321102
I1
I0
I1
tp76887
sS'of,about,mm'
p76888
(F1
F0.00014334862385321102
I1
I0
I1
tp76889
sS'either,the,or'
p76890
(F1
F0.00028669724770642203
I0
I2
I-2
tp76891
sS'administered,concomitantly,with'
p76892
(F0.58333333333333337
F0.0020068807339449542
I19
I5
I14
tp76893
sS'by,about,and'
p76894
(F1
F0.00028669724770642203
I2
I0
I2
tp76895
sS'or,retinyl,acetate'
p76896
(F1
F0.00028669724770642203
I2
I0
I2
tp76897
sS'inhibition,of,cholinesterase'
p76898
(F1
F0.00014334862385321102
I1
I0
I1
tp76899
sS'the,following,acetaminophen'
p76900
(F1
F0.00028669724770642203
I2
I0
I2
tp76901
sS'predisposing,to,a'
p76902
(F1
F0.00014334862385321102
I1
I0
I1
tp76903
sS'inhibitors,simvastatin,cyp3a4'
p76904
(F1
F0.00014334862385321102
I0
I1
I-1
tp76905
sS'day,or,placebo'
p76906
(F1
F0.00014334862385321102
I0
I1
I-1
tp76907
sS'elevated,serum,concentrations'
p76908
(F1
F0.00014334862385321102
I1
I0
I1
tp76909
sS'long,acting,triclofos'
p76910
(F1
F0.00014334862385321102
I1
I0
I1
tp76911
sS'celebrex,is,not'
p76912
(F1
F0.00014334862385321102
I0
I1
I-1
tp76913
sS'guardians,of,children'
p76914
(F1
F0.00014334862385321102
I0
I1
I-1
tp76915
sS'observed,to,occasionally'
p76916
(F1
F0.00014334862385321102
I1
I0
I1
tp76917
sS'or,concurrent,with'
p76918
(F1
F0.00028669724770642203
I2
I0
I2
tp76919
sS'increased,auc,values'
p76920
(F1
F0.00014334862385321102
I1
I0
I1
tp76921
sS'subjects,the,auc'
p76922
(F1
F0.00014334862385321102
I1
I0
I1
tp76923
sS'prothrombin,time,measured'
p76924
(F1
F0.00028669724770642203
I2
I0
I2
tp76925
sS'the,urine,using'
p76926
(F1
F0.00014334862385321102
I0
I1
I-1
tp76927
sS'to,co-administer,and'
p76928
(F1
F0.00014334862385321102
I1
I0
I1
tp76929
sS'in,normal,male'
p76930
(F1
F0.00014334862385321102
I1
I0
I1
tp76931
sS'have,additive,hypotensite'
p76932
(F1
F0.00014334862385321102
I1
I0
I1
tp76933
sS'minimizes,this,decrease'
p76934
(F1
F0.00014334862385321102
I1
I0
I1
tp76935
sS'as,and,some'
p76936
(F1
F0.00014334862385321102
I1
I0
I1
tp76937
sS'to,a,clinically'
p76938
(F1
F0.00014334862385321102
I0
I1
I-1
tp76939
sS'the,data,suggest'
p76940
(F1
F0.00014334862385321102
I0
I1
I-1
tp76941
sS'converting,enzyme,inhibitors'
p76942
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp76943
sS'tablets,simultaneous,administration'
p76944
(F1
F0.00014334862385321102
I1
I0
I1
tp76945
sS'ace,inhibitor,mg'
p76946
(F1
F0.00014334862385321102
I1
I0
I1
tp76947
sS'taxol,a,substrate'
p76948
(F1
F0.00014334862385321102
I0
I1
I-1
tp76949
sS'fat,and,like'
p76950
(F1
F0.00014334862385321102
I0
I1
I-1
tp76951
sS'nalfon,has,not'
p76952
(F1
F0.00014334862385321102
I1
I0
I1
tp76953
sS'human,in,vitro'
p76954
(F1
F0.00014334862385321102
I0
I1
I-1
tp76955
sS'those,observed,when'
p76956
(F1
F0.00014334862385321102
I1
I0
I1
tp76957
sS'following,infusions,of'
p76958
(F1
F0.00014334862385321102
I0
I1
I-1
tp76959
sS'additional,interaction,studies'
p76960
(F1
F0.00028669724770642203
I0
I2
I-2
tp76961
sS'some,other,nondepolarizing'
p76962
(F1
F0.00014334862385321102
I1
I0
I1
tp76963
sS'enhance,nutrient,absorption'
p76964
(F1
F0.00014334862385321102
I1
I0
I1
tp76965
sS'been,reported,from'
p76966
(F1
F0.00014334862385321102
I1
I0
I1
tp76967
sS'by,administration,of'
p76968
(F0
F0
I1
I1
I0
tp76969
sS'from,to,took'
p76970
(F1
F0.00014334862385321102
I1
I0
I1
tp76971
sS'or,other,suitable'
p76972
(F1
F0.00043004587155963305
I3
I0
I3
tp76973
sS'in,rat,brain'
p76974
(F1
F0.00014334862385321102
I1
I0
I1
tp76975
sS'cautiously,with,careful'
p76976
(F1
F0.00014334862385321102
I1
I0
I1
tp76977
sS'an,hydroxide,hydroxide'
p76978
(F1
F0.00014334862385321102
I1
I0
I1
tp76979
sS'and,the,deaths'
p76980
(F1
F0.00014334862385321102
I0
I1
I-1
tp76981
sS'anaphylactic,shock,can'
p76982
(F1
F0.00014334862385321102
I1
I0
I1
tp76983
sS'by,administration,or'
p76984
(F1
F0.00014334862385321102
I0
I1
I-1
tp76985
sS'the,unbound,by'
p76986
(F1
F0.00014334862385321102
I1
I0
I1
tp76987
sS'and,intravenous,mg'
p76988
(F1
F0.00028669724770642203
I0
I2
I-2
tp76989
sS'may,increase,the'
p76990
(F0.55172413793103448
F0.0045871559633027525
I45
I13
I32
tp76991
sS'for,signs,of'
p76992
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp76993
sS'pharmacokinetics,of,cmax'
p76994
(F1
F0.00014334862385321102
I0
I1
I-1
tp76995
sS'who,become,pregnant'
p76996
(F1
F0.00014334862385321102
I0
I1
I-1
tp76997
sS'be,tested,more'
p76998
(F1
F0.00014334862385321102
I0
I1
I-1
tp76999
sS'dose,adjustment,is'
p77000
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp77001
sS'diarrhea,would,be'
p77002
(F1
F0.00014334862385321102
I1
I0
I1
tp77003
sS'glyburide,in,a'
p77004
(F1
F0.00014334862385321102
I0
I1
I-1
tp77005
sS'the,antitumour,activity'
p77006
(F0
F0
I1
I1
I0
tp77007
sS'agents,of,class'
p77008
(F1
F0.00014334862385321102
I0
I1
I-1
tp77009
sS'sensipar,may,be'
p77010
(F1
F0.00014334862385321102
I1
I0
I1
tp77011
sS'higher,when,and'
p77012
(F1
F0.00014334862385321102
I1
I0
I1
tp77013
sS'than,have,not'
p77014
(F1
F0.00014334862385321102
I0
I1
I-1
tp77015
sS'wide,interindividual,variability'
p77016
(F1
F0.00014334862385321102
I1
I0
I1
tp77017
sS'steady-state,serum,concentrations'
p77018
(F1
F0.00057339449541284407
I4
I0
I4
tp77019
sS'been,rarely,reported'
p77020
(F1
F0.00028669724770642203
I2
I0
I2
tp77021
sS'amphotericin,foscarnet,and'
p77022
(F1
F0.00014334862385321102
I1
I0
I1
tp77023
sS'in,higher,increases'
p77024
(F1
F0.00014334862385321102
I1
I0
I1
tp77025
sS'the,patient,for'
p77026
(F1
F0.00014334862385321102
I0
I1
I-1
tp77027
sS'presence,of,and'
p77028
(F1
F0.00028669724770642203
I0
I2
I-2
tp77029
sS'patients,if,dosage'
p77030
(F1
F0.00014334862385321102
I1
I0
I1
tp77031
sS'see,contraindications,significant'
p77032
(F1
F0.00014334862385321102
I0
I1
I-1
tp77033
sS'vitamin,d,dosage'
p77034
(F1
F0.00043004587155963305
I3
I0
I3
tp77035
sS'did,not,change'
p77036
(F1
F0.00043004587155963305
I0
I3
I-3
tp77037
sS'and,or,some'
p77038
(F1
F0.00014334862385321102
I1
I0
I1
tp77039
sS'use,of,hivid'
p77040
(F1
F0.00014334862385321102
I1
I0
I1
tp77041
sS'of,alfenta,my'
p77042
(F1
F0.00014334862385321102
I0
I1
I-1
tp77043
sS'when,combining,with'
p77044
(F1
F0.00014334862385321102
I0
I1
I-1
tp77045
sS'development,of,a'
p77046
(F1
F0.00014334862385321102
I0
I1
I-1
tp77047
sS'sites,for,on'
p77048
(F1
F0.00014334862385321102
I0
I1
I-1
tp77049
sS'the,short-acting,adrenergic'
p77050
(F1
F0.00014334862385321102
I0
I1
I-1
tp77051
sS'the,longterm,treatment'
p77052
(F1
F0.00014334862385321102
I0
I1
I-1
tp77053
sS'with,or,innovar'
p77054
(F1
F0.00014334862385321102
I1
I0
I1
tp77055
sS'nonlethal,dose,of'
p77056
(F0
F0
I1
I1
I0
tp77057
sS'in,the,us'
p77058
(F1
F0.00014334862385321102
I0
I1
I-1
tp77059
sS'mechanism,of,interaction'
p77060
(F1
F0.00014334862385321102
I1
I0
I1
tp77061
sS'with,monoamine,oxidase'
p77062
(F1
F0.00057339449541284407
I4
I0
I4
tp77063
sS'and,at,periodic'
p77064
(F1
F0.00014334862385321102
I1
I0
I1
tp77065
sS'liver,function,tests'
p77066
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp77067
sS'triclofos,sodium,unreliable'
p77068
(F1
F0.00014334862385321102
I1
I0
I1
tp77069
sS'were,similar,with'
p77070
(F1
F0.00014334862385321102
I0
I1
I-1
tp77071
sS'to,and,should'
p77072
(F1
F0.00014334862385321102
I1
I0
I1
tp77073
sS'medicines,may,make'
p77074
(F1
F0.00014334862385321102
I0
I1
I-1
tp77075
sS'the,same,degree'
p77076
(F1
F0.00014334862385321102
I0
I1
I-1
tp77077
sS'receiving,n,n'
p77078
(F1
F0.00014334862385321102
I0
I1
I-1
tp77079
sS'subcortical,structures,of'
p77080
(F1
F0.00014334862385321102
I0
I1
I-1
tp77081
sS'and,cmax,respectively'
p77082
(F1
F0.00014334862385321102
I0
I1
I-1
tp77083
sS'smaller,doses,of'
p77084
(F1
F0.00014334862385321102
I1
I0
I1
tp77085
sS'butyrophenones,such,as'
p77086
(F1
F0.00014334862385321102
I1
I0
I1
tp77087
sS'aprepitant,has,been'
p77088
(F1
F0.00014334862385321102
I1
I0
I1
tp77089
sS'long,half-lives,to'
p77090
(F1
F0.00014334862385321102
I0
I1
I-1
tp77091
sS'of,neuromuscular,block'
p77092
(F0.5
F0.00028669724770642203
I3
I1
I2
tp77093
sS'produce,any,interaction'
p77094
(F1
F0.00014334862385321102
I0
I1
I-1
tp77095
sS'a,dose-dependent,fashion'
p77096
(F1
F0.00014334862385321102
I1
I0
I1
tp77097
sS'further,in,clinical'
p77098
(F1
F0.00014334862385321102
I0
I1
I-1
tp77099
sS'nanm,were,compared'
p77100
(F1
F0.00014334862385321102
I0
I1
I-1
tp77101
sS'supplied,aerolizertm,inhalation'
p77102
(F1
F0.00014334862385321102
I0
I1
I-1
tp77103
sS'triglycerides,mg,dl'
p77104
(F1
F0.00014334862385321102
I0
I1
I-1
tp77105
sS'time,window,is'
p77106
(F1
F0.00014334862385321102
I1
I0
I1
tp77107
sS'six,volunteers,received'
p77108
(F1
F0.00014334862385321102
I0
I1
I-1
tp77109
sS'antiepileptic,potential,interactions'
p77110
(F1
F0.00014334862385321102
I0
I1
I-1
tp77111
sS'adrenergic,antagonism,has'
p77112
(F1
F0.00014334862385321102
I1
I0
I1
tp77113
sS'oral,increased,the'
p77114
(F1
F0.00014334862385321102
I1
I0
I1
tp77115
sS'receptors,mc,has'
p77116
(F1
F0.00014334862385321102
I0
I1
I-1
tp77117
sS'normal,volunteers,had'
p77118
(F1
F0.00014334862385321102
I1
I0
I1
tp77119
sS'recommended,and,if'
p77120
(F1
F0.00014334862385321102
I0
I1
I-1
tp77121
sS'superiority,over,in'
p77122
(F1
F0.00014334862385321102
I0
I1
I-1
tp77123
sS'excretion,of,by'
p77124
(F1
F0.00014334862385321102
I1
I0
I1
tp77125
sS'mg,tablets,administered'
p77126
(F1
F0.00014334862385321102
I0
I1
I-1
tp77127
sS'co-administration,of,myobloc'
p77128
(F1
F0.00014334862385321102
I1
I0
I1
tp77129
sS'the,diabetics,and'
p77130
(F1
F0.00014334862385321102
I0
I1
I-1
tp77131
sS'receptor,antagonists,hypertension'
p77132
(F1
F0.00014334862385321102
I1
I0
I1
tp77133
sS'with,highly,protein-bound'
p77134
(F1
F0.00014334862385321102
I0
I1
I-1
tp77135
sS'losartan,bosentan,has'
p77136
(F1
F0.00014334862385321102
I0
I1
I-1
tp77137
sS'of,congestive,heart'
p77138
(F1
F0.00014334862385321102
I1
I0
I1
tp77139
sS'active,metabolite,n-desmethyldiazepam'
p77140
(F1
F0.00014334862385321102
I1
I0
I1
tp77141
sS'be,exceeded,in'
p77142
(F1
F0.00014334862385321102
I1
I0
I1
tp77143
sS'index,fici,was'
p77144
(F1
F0.00014334862385321102
I0
I1
I-1
tp77145
sS'and,reduce,its'
p77146
(F0
F0
I1
I1
I0
tp77147
sS'monoamine,oxidase,inhibitory'
p77148
(F1
F0.00014334862385321102
I0
I1
I-1
tp77149
sS'the,cytochrome,p450'
p77150
(F0.59999999999999998
F0.0008600917431192661
I2
I8
I-6
tp77151
sS'monoamine,oxidase,inhibitors'
p77152
(F0.90000000000000002
F0.0025802752293577983
I19
I1
I18
tp77153
sS'are,taking,certain'
p77154
(F1
F0.00014334862385321102
I0
I1
I-1
tp77155
sS'and,copegus,should'
p77156
(F1
F0.00014334862385321102
I0
I1
I-1
tp77157
sS'cancidas,mg,daily'
p77158
(F1
F0.00014334862385321102
I1
I0
I1
tp77159
sS'enzymes,were,investigated'
p77160
(F1
F0.00014334862385321102
I0
I1
I-1
tp77161
sS'subjects,did,not'
p77162
(F1
F0.00014334862385321102
I0
I1
I-1
tp77163
sS'of,is,moderately'
p77164
(F1
F0.00014334862385321102
I0
I1
I-1
tp77165
sS'be,decreased,when'
p77166
(F1
F0.00014334862385321102
I1
I0
I1
tp77167
sS'these,subjects,did'
p77168
(F1
F0.00014334862385321102
I0
I1
I-1
tp77169
sS'electrophysiologic,interactions,have'
p77170
(F1
F0.00014334862385321102
I0
I1
I-1
tp77171
sS'hypotension,and,profound'
p77172
(F1
F0.00014334862385321102
I1
I0
I1
tp77173
sS'treated,with,zyvox'
p77174
(F1
F0.00014334862385321102
I1
I0
I1
tp77175
sS'of,by,approximately'
p77176
(F1
F0.00043004587155963305
I3
I0
I3
tp77177
sS'combination,with,and'
p77178
(F1
F0.00071674311926605509
I0
I5
I-5
tp77179
sS'acetylcholinesterase,ache,activity'
p77180
(F1
F0.00014334862385321102
I1
I0
I1
tp77181
sS'total,auc,increased'
p77182
(F1
F0.00014334862385321102
I1
I0
I1
tp77183
sS'steady-state,plasma,concentration'
p77184
(F1
F0.00014334862385321102
I0
I1
I-1
tp77185
sS'such,as,garlic'
p77186
(F1
F0.00014334862385321102
I1
I0
I1
tp77187
sS'ca,and,current'
p77188
(F1
F0.00014334862385321102
I1
I0
I1
tp77189
sS'doubling,in,a'
p77190
(F1
F0.00014334862385321102
I1
I0
I1
tp77191
sS'of,a,tnf'
p77192
(F1
F0.00014334862385321102
I1
I0
I1
tp77193
sS'heart,failure,where'
p77194
(F1
F0.00014334862385321102
I0
I1
I-1
tp77195
sS'nalidixic,acid,oxolinic'
p77196
(F1
F0.00014334862385321102
I1
I0
I1
tp77197
sS'microm,inhibited,insp'
p77198
(F1
F0.00014334862385321102
I1
I0
I1
tp77199
sS'of,known,to'
p77200
(F1
F0.00014334862385321102
I1
I0
I1
tp77201
sS'alcohol,although,lexapro'
p77202
(F1
F0.00014334862385321102
I1
I0
I1
tp77203
sS'other,nonsteroidal,that'
p77204
(F1
F0.00014334862385321102
I1
I0
I1
tp77205
sS'amines,may,reduce'
p77206
(F1
F0.00014334862385321102
I1
I0
I1
tp77207
sS'cholestyramine,may,interfere'
p77208
(F1
F0.00014334862385321102
I1
I0
I1
tp77209
sS'during,the,period'
p77210
(F1
F0.00014334862385321102
I1
I0
I1
tp77211
sS'coly-mycin,m,parenteral'
p77212
(F1
F0.00014334862385321102
I1
I0
I1
tp77213
sS'in,and,addicts'
p77214
(F1
F0.00014334862385321102
I1
I0
I1
tp77215
sS'may,exhibit,a'
p77216
(F1
F0.00014334862385321102
I1
I0
I1
tp77217
sS'mechanisms,of,action'
p77218
(F1
F0.00014334862385321102
I0
I1
I-1
tp77219
sS'been,studied,but'
p77220
(F1
F0.00028669724770642203
I2
I0
I2
tp77221
sS'of,the,physician'
p77222
(F1
F0.00014334862385321102
I1
I0
I1
tp77223
sS'average,increase,in'
p77224
(F1
F0.00014334862385321102
I1
I0
I1
tp77225
sS'to,but,it'
p77226
(F1
F0.00014334862385321102
I1
I0
I1
tp77227
sS'can,attenuate,loss'
p77228
(F1
F0.00028669724770642203
I2
I0
I2
tp77229
sS'thus,leading,to'
p77230
(F1
F0.00014334862385321102
I1
I0
I1
tp77231
sS'with,eg,rt-pa'
p77232
(F1
F0.00014334862385321102
I0
I1
I-1
tp77233
sS'such,as,ophthalmic'
p77234
(F0
F0
I1
I1
I0
tp77235
sS'because,they,reduce'
p77236
(F1
F0.00057339449541284407
I4
I0
I4
tp77237
sS'and,no,additional'
p77238
(F1
F0.00028669724770642203
I2
I0
I2
tp77239
sS'who,has,received'
p77240
(F1
F0.00014334862385321102
I1
I0
I1
tp77241
sS'the,mechanism,under'
p77242
(F1
F0.00014334862385321102
I1
I0
I1
tp77243
sS'however,there,were'
p77244
(F1
F0.00014334862385321102
I0
I1
I-1
tp77245
sS'device,and,how'
p77246
(F1
F0.00014334862385321102
I0
I1
I-1
tp77247
sS'with,a,separate'
p77248
(F1
F0.00014334862385321102
I1
I0
I1
tp77249
sS'potent,parental,such'
p77250
(F1
F0.00014334862385321102
I1
I0
I1
tp77251
sS'survive,in,and'
p77252
(F1
F0.00014334862385321102
I0
I1
I-1
tp77253
sS'or,another,such'
p77254
(F1
F0.00014334862385321102
I1
I0
I1
tp77255
sS'drugs,which,may'
p77256
(F1
F0.00028669724770642203
I2
I0
I2
tp77257
sS'additive,hypotensive,effect'
p77258
(F1
F0.00014334862385321102
I1
I0
I1
tp77259
sS'well,as,to'
p77260
(F0
F0
I1
I1
I0
tp77261
sS'squirrel,monkeys,responding'
p77262
(F1
F0.00014334862385321102
I0
I1
I-1
tp77263
sS'an,encephalopathic,syndrome'
p77264
(F1
F0.00014334862385321102
I1
I0
I1
tp77265
sS'urine,samples,for'
p77266
(F1
F0.00014334862385321102
I0
I1
I-1
tp77267
sS'times,a,day'
p77268
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp77269
sS'efficacy,benefit,when'
p77270
(F1
F0.00014334862385321102
I0
I1
I-1
tp77271
sS'd,were,co-administered'
p77272
(F1
F0.00014334862385321102
I1
I0
I1
tp77273
sS'to,is,expected'
p77274
(F1
F0.00014334862385321102
I1
I0
I1
tp77275
sS'tell,your,doctor'
p77276
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp77277
sS'prednisolone,ethinyl,estradiol'
p77278
(F1
F0.00014334862385321102
I1
I0
I1
tp77279
sS'can,antagonize,the'
p77280
(F1
F0.00028669724770642203
I2
I0
I2
tp77281
sS'therapy,and,overuse'
p77282
(F1
F0.00014334862385321102
I0
I1
I-1
tp77283
sS'adjustment,of,dosages'
p77284
(F1
F0.00014334862385321102
I0
I1
I-1
tp77285
sS'always,seen,in'
p77286
(F1
F0.00014334862385321102
I0
I1
I-1
tp77287
sS'significantly,fewer,extrapyramidal'
p77288
(F1
F0.00014334862385321102
I0
I1
I-1
tp77289
sS'effects,and,the'
p77290
(F1
F0.00028669724770642203
I2
I0
I2
tp77291
sS'may,be,ineffective'
p77292
(F1
F0.00014334862385321102
I1
I0
I1
tp77293
sS'therapy,if,diminished'
p77294
(F1
F0.00014334862385321102
I1
I0
I1
tp77295
sS'h2,blockers,proton'
p77296
(F1
F0.00014334862385321102
I1
I0
I1
tp77297
sS'than,with,based'
p77298
(F1
F0.00014334862385321102
I0
I1
I-1
tp77299
sS'period,will,affect'
p77300
(F1
F0.00014334862385321102
I1
I0
I1
tp77301
sS'low,dietary,concentration'
p77302
(F1
F0.00014334862385321102
I0
I1
I-1
tp77303
sS'of,aerosol,particles'
p77304
(F1
F0.00028669724770642203
I0
I2
I-2
tp77305
sS'as,the,effect'
p77306
(F1
F0.00028669724770642203
I2
I0
I2
tp77307
sS'per,day,or'
p77308
(F1
F0.00014334862385321102
I0
I1
I-1
tp77309
sS'starlix,mg,in'
p77310
(F1
F0.00014334862385321102
I0
I1
I-1
tp77311
sS'presence,of,that'
p77312
(F1
F0.00014334862385321102
I1
I0
I1
tp77313
sS'phenobarbital,or,primidone'
p77314
(F1
F0.00014334862385321102
I0
I1
I-1
tp77315
sS'use,of,argatroban'
p77316
(F1
F0.00028669724770642203
I2
I0
I2
tp77317
sS'infusion,rate,requirements'
p77318
(F1
F0.00014334862385321102
I1
I0
I1
tp77319
sS'or,other,central'
p77320
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp77321
sS'types,of,adrenocortical'
p77322
(F1
F0.00014334862385321102
I1
I0
I1
tp77323
sS'for,any,interaction'
p77324
(F1
F0.00014334862385321102
I0
I1
I-1
tp77325
sS'presence,of,than'
p77326
(F1
F0.00014334862385321102
I1
I0
I1
tp77327
sS'necessitate,an,adjustment'
p77328
(F1
F0.00014334862385321102
I0
I1
I-1
tp77329
sS'are,the,following'
p77330
(F1
F0.00043004587155963305
I3
I0
I3
tp77331
sS'shown,that,administration'
p77332
(F1
F0.00014334862385321102
I1
I0
I1
tp77333
sS'can,follow,the'
p77334
(F1
F0.00014334862385321102
I1
I0
I1
tp77335
sS'that,the,conversion'
p77336
(F1
F0.00014334862385321102
I0
I1
I-1
tp77337
sS'increase,in,a'
p77338
(F1
F0.00014334862385321102
I0
I1
I-1
tp77339
sS'despite,reduction,in'
p77340
(F1
F0.00014334862385321102
I0
I1
I-1
tp77341
sS'other,on,sensipar'
p77342
(F1
F0.00014334862385321102
I0
I1
I-1
tp77343
sS'drugs,drugs,metabolized'
p77344
(F1
F0.00014334862385321102
I0
I1
I-1
tp77345
sS'in,patients,using'
p77346
(F0
F0
I1
I1
I0
tp77347
sS'should,be,the'
p77348
(F1
F0.00014334862385321102
I0
I1
I-1
tp77349
sS'of,and,by'
p77350
(F1
F0.00028669724770642203
I2
I0
I2
tp77351
sS'a,slower,absorption'
p77352
(F1
F0.00014334862385321102
I1
I0
I1
tp77353
sS'pharmacokinetics,but,significantly'
p77354
(F1
F0.00014334862385321102
I1
I0
I1
tp77355
sS'in,separate,single'
p77356
(F1
F0.00014334862385321102
I0
I1
I-1
tp77357
sS'been,established,and'
p77358
(F1
F0.00014334862385321102
I0
I1
I-1
tp77359
sS'thus,lower,the'
p77360
(F1
F0.00014334862385321102
I1
I0
I1
tp77361
sS'qd,did,not'
p77362
(F1
F0.00014334862385321102
I0
I1
I-1
tp77363
sS'are,not,recommended'
p77364
(F0
F0
I1
I1
I0
tp77365
sS'eg,have,occasionally'
p77366
(F1
F0.00014334862385321102
I0
I1
I-1
tp77367
sS'inhibitors,or,known'
p77368
(F1
F0.00014334862385321102
I1
I0
I1
tp77369
sS'ethanolysis,reaction,may'
p77370
(F1
F0.00014334862385321102
I1
I0
I1
tp77371
sS'concomitantly,any,reduction'
p77372
(F1
F0.00014334862385321102
I1
I0
I1
tp77373
sS'k,antagonists,should'
p77374
(F1
F0.00014334862385321102
I1
I0
I1
tp77375
sS'when,or,its'
p77376
(F1
F0.00014334862385321102
I1
I0
I1
tp77377
sS'or,other,significantly'
p77378
(F1
F0.00014334862385321102
I1
I0
I1
tp77379
sS'of,to,existing'
p77380
(F1
F0.00014334862385321102
I0
I1
I-1
tp77381
sS'u937,and,molt-4'
p77382
(F1
F0.00014334862385321102
I1
I0
I1
tp77383
sS'pra,induced,by'
p77384
(F1
F0.00014334862385321102
I0
I1
I-1
tp77385
sS'treatment,ataxia,a'
p77386
(F1
F0.00014334862385321102
I0
I1
I-1
tp77387
sS'following,acetaminophen,oral'
p77388
(F1
F0.00014334862385321102
I1
I0
I1
tp77389
sS'most,significant,interactions'
p77390
(F1
F0.00014334862385321102
I0
I1
I-1
tp77391
sS'to,result,from'
p77392
(F1
F0.00014334862385321102
I1
I0
I1
tp77393
sS'metabolism,of,may'
p77394
(F1
F0.00028669724770642203
I2
I0
I2
tp77395
sS'carried,out,to'
p77396
(F1
F0.00014334862385321102
I0
I1
I-1
tp77397
sS'side,effects,including'
p77398
(F1
F0.00014334862385321102
I1
I0
I1
tp77399
sS'ip,injections,of'
p77400
(F1
F0.00014334862385321102
I0
I1
I-1
tp77401
sS'about,one-third,as'
p77402
(F1
F0.00014334862385321102
I1
I0
I1
tp77403
sS'and,elicit,their'
p77404
(F1
F0.00014334862385321102
I0
I1
I-1
tp77405
sS'and,and,potent'
p77406
(F1
F0.00014334862385321102
I0
I1
I-1
tp77407
sS'and,brain,edema'
p77408
(F1
F0.00014334862385321102
I1
I0
I1
tp77409
sS'of,and,following'
p77410
(F1
F0.00014334862385321102
I0
I1
I-1
tp77411
sS'amount,of,hydroxylated'
p77412
(F1
F0.00014334862385321102
I1
I0
I1
tp77413
sS'from,protein,binding'
p77414
(F1
F0.00014334862385321102
I1
I0
I1
tp77415
sS'followed,by,mg'
p77416
(F0
F0
I1
I1
I0
tp77417
sS'since,hydrochloride,is'
p77418
(F1
F0.00014334862385321102
I0
I1
I-1
tp77419
sS'auc,and,a'
p77420
(F1
F0.0012901376146788992
I9
I0
I9
tp77421
sS'with,containing,may'
p77422
(F1
F0.00014334862385321102
I1
I0
I1
tp77423
sS'although,combining,these'
p77424
(F1
F0.00014334862385321102
I0
I1
I-1
tp77425
sS'cerebri,benign,intracranial'
p77426
(F1
F0.00014334862385321102
I1
I0
I1
tp77427
sS'to,induce,hypercalcemia'
p77428
(F1
F0.00043004587155963305
I0
I3
I-3
tp77429
sS'data,in,kidney'
p77430
(F1
F0.00014334862385321102
I0
I1
I-1
tp77431
sS'could,increase,the'
p77432
(F1
F0.00014334862385321102
I1
I0
I1
tp77433
sS'of,toxic,action'
p77434
(F1
F0.00014334862385321102
I0
I1
I-1
tp77435
sS'salt,intake,prior'
p77436
(F1
F0.00057339449541284407
I4
I0
I4
tp77437
sS'exposure,were,assessed'
p77438
(F1
F0.00014334862385321102
I0
I1
I-1
tp77439
sS'pharmacological,actions,via'
p77440
(F1
F0.00014334862385321102
I0
I1
I-1
tp77441
sS'of,additive,negative'
p77442
(F1
F0.00014334862385321102
I1
I0
I1
tp77443
sS'possibility,of,hypotensive'
p77444
(F1
F0.00071674311926605509
I5
I0
I5
tp77445
sS'current,responses,in'
p77446
(F1
F0.00014334862385321102
I1
I0
I1
tp77447
sS'effect,on,either'
p77448
(F1
F0.00057339449541284407
I0
I4
I-4
tp77449
sS'clinical,studies,of'
p77450
(F0.5
F0.00028669724770642203
I3
I1
I2
tp77451
sS'channel,blockers,isolated'
p77452
(F1
F0.00014334862385321102
I1
I0
I1
tp77453
sS'report,l-glutamine,at'
p77454
(F1
F0.00014334862385321102
I1
I0
I1
tp77455
sS'reactions,to,and'
p77456
(F1
F0.00014334862385321102
I0
I1
I-1
tp77457
sS'doses,of,have'
p77458
(F1
F0.00014334862385321102
I0
I1
I-1
tp77459
sS'levels,and,symptoms'
p77460
(F1
F0.00043004587155963305
I3
I0
I3
tp77461
sS'of,serious,sometimes'
p77462
(F1
F0.00028669724770642203
I2
I0
I2
tp77463
sS'and,zdv,has'
p77464
(F1
F0.00014334862385321102
I0
I1
I-1
tp77465
sS'kg,body,weight'
p77466
(F0.66666666666666663
F0.00057339449541284407
I1
I5
I-4
tp77467
sS'index,apoptotic,index'
p77468
(F1
F0.00014334862385321102
I0
I1
I-1
tp77469
sS'lower,maintenance,doses'
p77470
(F1
F0.00014334862385321102
I1
I0
I1
tp77471
sS'or,minutes,following'
p77472
(F1
F0.00014334862385321102
I1
I0
I1
tp77473
sS'also,be,approached'
p77474
(F1
F0.00014334862385321102
I1
I0
I1
tp77475
sS'not,been,investigated'
p77476
(F1
F0.00014334862385321102
I1
I0
I1
tp77477
sS'in,the,management'
p77478
(F1
F0.00028669724770642203
I0
I2
I-2
tp77479
sS'expect,that,a'
p77480
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp77481
sS'and,to,broadly'
p77482
(F1
F0.00014334862385321102
I0
I1
I-1
tp77483
sS'an,effect,may'
p77484
(F1
F0.00028669724770642203
I2
I0
I2
tp77485
sS'eldepryl,and,parnate'
p77486
(F1
F0.00014334862385321102
I0
I1
I-1
tp77487
sS'or,are,taken'
p77488
(F1
F0.00014334862385321102
I1
I0
I1
tp77489
sS'bactericidal,action,of'
p77490
(F1
F0.00028669724770642203
I2
I0
I2
tp77491
sS'a,possible,increase'
p77492
(F1
F0.00014334862385321102
I1
I0
I1
tp77493
sS'because,of,reduced'
p77494
(F1
F0.00014334862385321102
I0
I1
I-1
tp77495
sS'in,transferring,the'
p77496
(F1
F0.00014334862385321102
I0
I1
I-1
tp77497
sS'hcl,no,greater'
p77498
(F1
F0.00014334862385321102
I1
I0
I1
tp77499
sS'be,increased,an'
p77500
(F1
F0.00014334862385321102
I1
I0
I1
tp77501
sS'drugs,whose,efficacy'
p77502
(F1
F0.00014334862385321102
I1
I0
I1
tp77503
sS'clinical,trial,in'
p77504
(F1
F0.00014334862385321102
I0
I1
I-1
tp77505
sS'oral,may,interfere'
p77506
(F1
F0.00014334862385321102
I1
I0
I1
tp77507
sS'doses,of,up'
p77508
(F1
F0.00014334862385321102
I0
I1
I-1
tp77509
sS'of,see,clinical'
p77510
(F1
F0.00014334862385321102
I0
I1
I-1
tp77511
sS'ml,the,binding'
p77512
(F1
F0.00014334862385321102
I1
I0
I1
tp77513
sS'concentrations,were,above'
p77514
(F1
F0.00014334862385321102
I1
I0
I1
tp77515
sS'and,negative,symptoms'
p77516
(F1
F0.00043004587155963305
I0
I3
I-3
tp77517
sS'assessed,by,electrocardiographic'
p77518
(F1
F0.00028669724770642203
I0
I2
I-2
tp77519
sS'via,this,route'
p77520
(F1
F0.00014334862385321102
I1
I0
I1
tp77521
sS'toxicity,than,when'
p77522
(F1
F0.00014334862385321102
I1
I0
I1
tp77523
sS'the,phase,study'
p77524
(F1
F0.00014334862385321102
I0
I1
I-1
tp77525
sS'not,effected,by'
p77526
(F1
F0.00014334862385321102
I0
I1
I-1
tp77527
sS'alone,and,concomitantly'
p77528
(F1
F0.00014334862385321102
I1
I0
I1
tp77529
sS'pressure,after,initiation'
p77530
(F1
F0.00057339449541284407
I4
I0
I4
tp77531
sS'in,peripheral,blood'
p77532
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp77533
sS'its,pharmacologically,active'
p77534
(F1
F0.00014334862385321102
I0
I1
I-1
tp77535
sS'additional,benefit,compared'
p77536
(F1
F0.00028669724770642203
I2
I0
I2
tp77537
sS'mg,l,to'
p77538
(F1
F0.00014334862385321102
I1
I0
I1
tp77539
sS'trials,currently,exist'
p77540
(F1
F0.00014334862385321102
I0
I1
I-1
tp77541
sS'by,chloral,hydrate'
p77542
(F1
F0.00014334862385321102
I0
I1
I-1
tp77543
sS'that,concomitant,administration'
p77544
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp77545
sS'a,potentially,toxic'
p77546
(F0
F0
I1
I1
I0
tp77547
sS'disturbances,and,left'
p77548
(F1
F0.00014334862385321102
I1
I0
I1
tp77549
sS'these,medications,have'
p77550
(F1
F0.00014334862385321102
I0
I1
I-1
tp77551
sS'cyp,inducers,that'
p77552
(F1
F0.00014334862385321102
I1
I0
I1
tp77553
sS'be,formed,with'
p77554
(F1
F0.00014334862385321102
I1
I0
I1
tp77555
sS'mg,tid,the'
p77556
(F1
F0.00014334862385321102
I1
I0
I1
tp77557
sS'and,for,and'
p77558
(F1
F0.00028669724770642203
I0
I2
I-2
tp77559
sS'agonists,in,induction'
p77560
(F1
F0.00014334862385321102
I1
I0
I1
tp77561
sS'concentrations,increase,when'
p77562
(F1
F0.00014334862385321102
I1
I0
I1
tp77563
sS'slight,decrease,in'
p77564
(F1
F0.00014334862385321102
I1
I0
I1
tp77565
sS'dosing,by,at'
p77566
(F1
F0.00014334862385321102
I0
I1
I-1
tp77567
sS'duodenum,and,no'
p77568
(F1
F0.00014334862385321102
I0
I1
I-1
tp77569
sS'steadystate,cmin,to'
p77570
(F1
F0.00014334862385321102
I1
I0
I1
tp77571
sS'weakness,may,be'
p77572
(F1
F0.00014334862385321102
I1
I0
I1
tp77573
sS'are,substrates,of'
p77574
(F1
F0.00014334862385321102
I0
I1
I-1
tp77575
sS'case,were,the'
p77576
(F1
F0.00014334862385321102
I0
I1
I-1
tp77577
sS'not,only,to'
p77578
(F1
F0.00014334862385321102
I1
I0
I1
tp77579
sS'single,enzyme,may'
p77580
(F1
F0.00014334862385321102
I0
I1
I-1
tp77581
sS'that,reportedly,may'
p77582
(F1
F0.00028669724770642203
I2
I0
I2
tp77583
sS'more,potent,than'
p77584
(F1
F0.00028669724770642203
I0
I2
I-2
tp77585
sS'hemabate,may,augment'
p77586
(F1
F0.00014334862385321102
I1
I0
I1
tp77587
sS'was,evaluated,using'
p77588
(F1
F0.00014334862385321102
I0
I1
I-1
tp77589
sS'inhibitor,maoi,such'
p77590
(F1
F0.00014334862385321102
I0
I1
I-1
tp77591
sS'that,have,significant'
p77592
(F1
F0.00014334862385321102
I1
I0
I1
tp77593
sS'increase,when,the'
p77594
(F1
F0.00014334862385321102
I1
I0
I1
tp77595
sS'in,systemic,levels'
p77596
(F1
F0.00014334862385321102
I1
I0
I1
tp77597
sS'of,cyp3a4,inhibitors'
p77598
(F1
F0.00014334862385321102
I0
I1
I-1
tp77599
sS'absorption,can,be'
p77600
(F1
F0.00014334862385321102
I1
I0
I1
tp77601
sS'patient,on,phenytoin'
p77602
(F1
F0.00014334862385321102
I1
I0
I1
tp77603
sS'with,an,increase'
p77604
(F0.5
F0.00028669724770642203
I3
I1
I2
tp77605
sS'is,initiated,to'
p77606
(F1
F0.00014334862385321102
I1
I0
I1
tp77607
sS'ethinyl,estradiol,and'
p77608
(F0.14285714285714285
F0.00014334862385321102
I4
I3
I1
tp77609
sS'inhibitor,to,prevent'
p77610
(F1
F0.00014334862385321102
I0
I1
I-1
tp77611
sS'effect,of,carbimazole'
p77612
(F1
F0.00014334862385321102
I1
I0
I1
tp77613
sS'ventricular,fibrillation,and'
p77614
(F1
F0.00014334862385321102
I0
I1
I-1
tp77615
sS'more,pronounced,than'
p77616
(F1
F0.00014334862385321102
I0
I1
I-1
tp77617
sS'oral,containing,may'
p77618
(F1
F0.00014334862385321102
I1
I0
I1
tp77619
sS'coat-core,formulation,of'
p77620
(F1
F0.00014334862385321102
I1
I0
I1
tp77621
sS'bid,decreased,the'
p77622
(F1
F0.00014334862385321102
I1
I0
I1
tp77623
sS'deaths,reveal,frequent'
p77624
(F1
F0.00014334862385321102
I1
I0
I1
tp77625
sS'therapeutic,index,digoxin'
p77626
(F1
F0.00028669724770642203
I0
I2
I-2
tp77627
sS'actions,or,side'
p77628
(F1
F0.00014334862385321102
I0
I1
I-1
tp77629
sS'serotonergic,agents,including'
p77630
(F1
F0.00014334862385321102
I1
I0
I1
tp77631
sS'performed,in,which'
p77632
(F1
F0.00014334862385321102
I0
I1
I-1
tp77633
sS'results,during,treatment'
p77634
(F1
F0.00014334862385321102
I1
I0
I1
tp77635
sS'infusion,of,had'
p77636
(F1
F0.00014334862385321102
I0
I1
I-1
tp77637
sS'suspending,use,of'
p77638
(F1
F0.00014334862385321102
I1
I0
I1
tp77639
sS'a,large,number'
p77640
(F1
F0.00014334862385321102
I0
I1
I-1
tp77641
sS'or,clinical,effects'
p77642
(F1
F0.00014334862385321102
I0
I1
I-1
tp77643
sS'between,toradol,and'
p77644
(F1
F0.00014334862385321102
I1
I0
I1
tp77645
sS'possibly,other,cause'
p77646
(F1
F0.00028669724770642203
I2
I0
I2
tp77647
sS'cancer,cells,in'
p77648
(F1
F0.00014334862385321102
I0
I1
I-1
tp77649
sS'be,continuously,observed'
p77650
(F1
F0.00014334862385321102
I1
I0
I1
tp77651
sS'nimbex,before,to'
p77652
(F1
F0.00014334862385321102
I0
I1
I-1
tp77653
sS'this,regimen,did'
p77654
(F1
F0.00014334862385321102
I1
I0
I1
tp77655
sS'capsules,mg,with'
p77656
(F1
F0.00014334862385321102
I1
I0
I1
tp77657
sS'pharmacokinetics,auc,c'
p77658
(F1
F0.00014334862385321102
I0
I1
I-1
tp77659
sS'increases,in,their'
p77660
(F0
F0
I1
I1
I0
tp77661
sS'consistent,with,the'
p77662
(F1
F0.00014334862385321102
I0
I1
I-1
tp77663
sS'etodolac-treated,patients,receiving'
p77664
(F1
F0.00014334862385321102
I1
I0
I1
tp77665
sS'hydrochloride,and,therapy'
p77666
(F1
F0.00014334862385321102
I0
I1
I-1
tp77667
sS'used,in,chemotherapy'
p77668
(F1
F0.00014334862385321102
I0
I1
I-1
tp77669
sS'in,humans,can'
p77670
(F1
F0.00014334862385321102
I1
I0
I1
tp77671
sS'affect,the,blood'
p77672
(F1
F0.00014334862385321102
I0
I1
I-1
tp77673
sS'channel,blockers,could'
p77674
(F1
F0.00014334862385321102
I1
I0
I1
tp77675
sS'this,pharmacological,interaction'
p77676
(F1
F0.00014334862385321102
I1
I0
I1
tp77677
sS'subset,of,patients'
p77678
(F1
F0.00014334862385321102
I0
I1
I-1
tp77679
sS'the,chemical,resemblance'
p77680
(F1
F0.00014334862385321102
I1
I0
I1
tp77681
sS'cns,depressant,should'
p77682
(F1
F0.00028669724770642203
I2
I0
I2
tp77683
sS'skeletal,muscle,relaxants'
p77684
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp77685
sS'and,mc,ameliorate'
p77686
(F1
F0.00014334862385321102
I0
I1
I-1
tp77687
sS'or,with,changes'
p77688
(F1
F0.00014334862385321102
I0
I1
I-1
tp77689
sS'not,affected,significantly'
p77690
(F1
F0.00014334862385321102
I0
I1
I-1
tp77691
sS'of,gabitril,with'
p77692
(F1
F0.00028669724770642203
I0
I2
I-2
tp77693
sS'may,produce,excessive'
p77694
(F1
F0.00014334862385321102
I1
I0
I1
tp77695
sS'acquisition,of,goal-directed'
p77696
(F1
F0.00014334862385321102
I0
I1
I-1
tp77697
sS'no,differential,effects'
p77698
(F1
F0.00014334862385321102
I0
I1
I-1
tp77699
sS'd2,vitamin,d3'
p77700
(F1
F0.00043004587155963305
I3
I0
I3
tp77701
sS'or,is,receiving'
p77702
(F1
F0.00014334862385321102
I1
I0
I1
tp77703
sS'the,first,sixty'
p77704
(F1
F0.00014334862385321102
I1
I0
I1
tp77705
sS'xigris,have,not'
p77706
(F1
F0.00014334862385321102
I0
I1
I-1
tp77707
sS'lower,with,than'
p77708
(F1
F0.00014334862385321102
I0
I1
I-1
tp77709
sS'clinical,effects,prolonged'
p77710
(F1
F0.00014334862385321102
I1
I0
I1
tp77711
sS'brain,levels,of'
p77712
(F1
F0.00014334862385321102
I0
I1
I-1
tp77713
sS'the,lipid-lowering,activity'
p77714
(F1
F0.00014334862385321102
I0
I1
I-1
tp77715
sS'channel,and,omega-conotoxin'
p77716
(F1
F0.00014334862385321102
I0
I1
I-1
tp77717
sS'of,the,ace'
p77718
(F1
F0.00014334862385321102
I1
I0
I1
tp77719
sS'prothrombin,times,should'
p77720
(F0
F0
I1
I1
I0
tp77721
sS'in,the,general'
p77722
(F1
F0.00014334862385321102
I0
I1
I-1
tp77723
sS'adjustments,of,agents'
p77724
(F1
F0.00014334862385321102
I1
I0
I1
tp77725
sS'decrease,serum,concentrations'
p77726
(F1
F0.00014334862385321102
I1
I0
I1
tp77727
sS'of,deficit,and'
p77728
(F1
F0.00014334862385321102
I0
I1
I-1
tp77729
sS'elevated,in,serum'
p77730
(F1
F0.00028669724770642203
I0
I2
I-2
tp77731
sS'of,block,is'
p77732
(F1
F0.00014334862385321102
I1
I0
I1
tp77733
sS'placebo-controlled,study,with'
p77734
(F1
F0.00014334862385321102
I0
I1
I-1
tp77735
sS'species,of,the'
p77736
(F1
F0.00043004587155963305
I3
I0
I3
tp77737
sS'days,in,healthy'
p77738
(F1
F0.00014334862385321102
I1
I0
I1
tp77739
sS'antagonists,and,alpha-adrenergic'
p77740
(F1
F0.00014334862385321102
I1
I0
I1
tp77741
sS'gross,motor,skills'
p77742
(F1
F0.00014334862385321102
I0
I1
I-1
tp77743
sS'aluminum-containing,products,containing'
p77744
(F1
F0.00014334862385321102
I1
I0
I1
tp77745
sS'with,or,to'
p77746
(F1
F0.00014334862385321102
I0
I1
I-1
tp77747
sS'concomitantly,with,angiotensin-'
p77748
(F1
F0.00014334862385321102
I0
I1
I-1
tp77749
sS'the,cumulative,incidence'
p77750
(F1
F0.00014334862385321102
I0
I1
I-1
tp77751
sS'and,the,combination'
p77752
(F1
F0.00014334862385321102
I1
I0
I1
tp77753
sS'in,plasma,levels'
p77754
(F1
F0.0015768348623853212
I11
I0
I11
tp77755
sS'pgf2alpha,produced,significantly'
p77756
(F1
F0.00014334862385321102
I1
I0
I1
tp77757
sS'da,sh,fa'
p77758
(F1
F0.00014334862385321102
I0
I1
I-1
tp77759
sS'severe,toxicity,including'
p77760
(F1
F0.00014334862385321102
I1
I0
I1
tp77761
sS'reports,of,increased'
p77762
(F0.5
F0.00028669724770642203
I3
I1
I2
tp77763
sS'anabolic,hormones,and'
p77764
(F1
F0.00014334862385321102
I1
I0
I1
tp77765
sS'tambocor,and,on'
p77766
(F1
F0.00014334862385321102
I1
I0
I1
tp77767
sS'and,other,drugs'
p77768
(F1
F0.00014334862385321102
I1
I0
I1
tp77769
sS'and,intravenous,may'
p77770
(F1
F0.00014334862385321102
I1
I0
I1
tp77771
sS'higher,doses,may'
p77772
(F1
F0.00014334862385321102
I1
I0
I1
tp77773
sS'amoxicillin,an,increase'
p77774
(F1
F0.00014334862385321102
I1
I0
I1
tp77775
sS'available,data,from'
p77776
(F1
F0.00014334862385321102
I1
I0
I1
tp77777
sS'cytochrome,p450,system'
p77778
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp77779
sS'ventricular,tachycardia,ventricular'
p77780
(F1
F0.00014334862385321102
I1
I0
I1
tp77781
sS'their,need,for'
p77782
(F1
F0.00014334862385321102
I0
I1
I-1
tp77783
sS'patients,concomitantly,taking'
p77784
(F1
F0.00014334862385321102
I0
I1
I-1
tp77785
sS'ibuprofen,l-arginine,may'
p77786
(F1
F0.00014334862385321102
I1
I0
I1
tp77787
sS'receiving,low,therapeutic'
p77788
(F1
F0.00014334862385321102
I0
I1
I-1
tp77789
sS'of,concomitant,medications'
p77790
(F1
F0.00014334862385321102
I0
I1
I-1
tp77791
sS'increased,plasma,concentrations'
p77792
(F0.27272727272727271
F0.00043004587155963305
I7
I4
I3
tp77793
sS'inhibited,by,combination'
p77794
(F1
F0.00014334862385321102
I1
I0
I1
tp77795
sS'mg,capsules,or'
p77796
(F1
F0.00014334862385321102
I1
I0
I1
tp77797
sS'the,combined,use'
p77798
(F1
F0.00071674311926605509
I5
I0
I5
tp77799
sS'this,did,not'
p77800
(F1
F0.00014334862385321102
I0
I1
I-1
tp77801
sS'of,complicated,or'
p77802
(F1
F0.00014334862385321102
I0
I1
I-1
tp77803
sS'and,agents,may'
p77804
(F1
F0.00014334862385321102
I1
I0
I1
tp77805
sS'once,monthly,was'
p77806
(F1
F0.00014334862385321102
I0
I1
I-1
tp77807
sS'oxypurines,in,patients'
p77808
(F1
F0.00014334862385321102
I0
I1
I-1
tp77809
sS'taken,and,hours'
p77810
(F1
F0.00014334862385321102
I1
I0
I1
tp77811
sS'clorazepate,dipotassium,prolongs'
p77812
(F1
F0.00014334862385321102
I1
I0
I1
tp77813
sS'multiple-dose,administration,of'
p77814
(F0
F0
I1
I1
I0
tp77815
sS'increase,of,to'
p77816
(F1
F0.00028669724770642203
I2
I0
I2
tp77817
sS'of,four,chemotherapeutic'
p77818
(F1
F0.00014334862385321102
I0
I1
I-1
tp77819
sS'the,soluble,to'
p77820
(F1
F0.00014334862385321102
I0
I1
I-1
tp77821
sS'on,a,are'
p77822
(F1
F0.00014334862385321102
I0
I1
I-1
tp77823
sS'clinically,important,potentiation'
p77824
(F1
F0.00014334862385321102
I0
I1
I-1
tp77825
sS'has,been,suggested'
p77826
(F0.5
F0.00028669724770642203
I1
I3
I-2
tp77827
sS'clinical,studies,and'
p77828
(F1
F0.00014334862385321102
I0
I1
I-1
tp77829
sS'containing,gram,of'
p77830
(F1
F0.00014334862385321102
I1
I0
I1
tp77831
sS'infant,formula,mg'
p77832
(F1
F0.00014334862385321102
I0
I1
I-1
tp77833
sS'muscle,relaxing,effect'
p77834
(F1
F0.00014334862385321102
I1
I0
I1
tp77835
sS'disulfiram,should,be'
p77836
(F1
F0.00014334862385321102
I1
I0
I1
tp77837
sS'healthy,volunteers,with'
p77838
(F1
F0.00014334862385321102
I1
I0
I1
tp77839
sS'with,cyp3a4,inhibitors'
p77840
(F1
F0.00014334862385321102
I0
I1
I-1
tp77841
sS'volunteers,the,pharmacokinetics'
p77842
(F0
F0
I1
I1
I0
tp77843
sS'suppression,by,and'
p77844
(F1
F0.00014334862385321102
I1
I0
I1
tp77845
sS'potentiate,sulfate,neuromuscular'
p77846
(F1
F0.00014334862385321102
I0
I1
I-1
tp77847
sS'mg,sodium,and'
p77848
(F1
F0.00014334862385321102
I1
I0
I1
tp77849
sS'in,the,within'
p77850
(F1
F0.00014334862385321102
I1
I0
I1
tp77851
sS'synergism,in,two'
p77852
(F1
F0.00014334862385321102
I1
I0
I1
tp77853
sS'oral,and,through'
p77854
(F1
F0.00014334862385321102
I0
I1
I-1
tp77855
sS'of,the,non-depolarizing'
p77856
(F1
F0.00014334862385321102
I1
I0
I1
tp77857
sS'plasma,concentrations,cyp3a4'
p77858
(F1
F0.00028669724770642203
I0
I2
I-2
tp77859
sS'amount,absorbed,when'
p77860
(F1
F0.00014334862385321102
I0
I1
I-1
tp77861
sS'drug-metabolizing,enzymes,inducers'
p77862
(F1
F0.00014334862385321102
I0
I1
I-1
tp77863
sS'from,cholinergic,blockade'
p77864
(F1
F0.00014334862385321102
I1
I0
I1
tp77865
sS'indicate,that,or'
p77866
(F1
F0.00014334862385321102
I1
I0
I1
tp77867
sS'healthy,volunteers,exjade'
p77868
(F1
F0.00014334862385321102
I0
I1
I-1
tp77869
sS'one,of,these'
p77870
(F0
F0
I1
I1
I0
tp77871
sS'observed,in,this'
p77872
(F1
F0.00014334862385321102
I1
I0
I1
tp77873
sS'pharmacodynamic,drug-drug,interactions'
p77874
(F1
F0.00014334862385321102
I0
I1
I-1
tp77875
sS'mean,trough,concentrations'
p77876
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp77877
sS'n,n-diethyl,m-toluamide'
p77878
(F1
F0.00014334862385321102
I1
I0
I1
tp77879
sS'fibrillation,and,cardiovascular'
p77880
(F1
F0.00014334862385321102
I0
I1
I-1
tp77881
sS'concentrations,drugs,that'
p77882
(F1
F0.00014334862385321102
I1
I0
I1
tp77883
sS'data,from,several'
p77884
(F1
F0.00014334862385321102
I0
I1
I-1
tp77885
sS'either,mg,every'
p77886
(F1
F0.00014334862385321102
I0
I1
I-1
tp77887
sS'pharmacokinetics,or,renal'
p77888
(F1
F0.00014334862385321102
I0
I1
I-1
tp77889
sS'intraperitoneal,doses,of'
p77890
(F1
F0.00014334862385321102
I1
I0
I1
tp77891
sS'egf-,or,insulin-induced'
p77892
(F1
F0.00014334862385321102
I1
I0
I1
tp77893
sS'the,reports,that'
p77894
(F1
F0.00014334862385321102
I1
I0
I1
tp77895
sS'on,thiazide,and'
p77896
(F1
F0.00028669724770642203
I2
I0
I2
tp77897
sS'volunteers,hormone,replacement'
p77898
(F1
F0.00014334862385321102
I0
I1
I-1
tp77899
sS'protease,inhibitors,and'
p77900
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp77901
sS'coadministered,in,de'
p77902
(F1
F0.00014334862385321102
I0
I1
I-1
tp77903
sS'metabolite,of,were'
p77904
(F1
F0.00014334862385321102
I0
I1
I-1
tp77905
sS'between,folic,acid'
p77906
(F1
F0.00014334862385321102
I0
I1
I-1
tp77907
sS'peptides,in,mice'
p77908
(F1
F0.00014334862385321102
I0
I1
I-1
tp77909
sS'coumarin,anticoagulants,altered'
p77910
(F1
F0.00014334862385321102
I1
I0
I1
tp77911
sS'levels,or,altering'
p77912
(F1
F0.00014334862385321102
I0
I1
I-1
tp77913
sS'study,with,co-administered'
p77914
(F1
F0.00014334862385321102
I0
I1
I-1
tp77915
sS'monitored,and,its'
p77916
(F1
F0.00014334862385321102
I1
I0
I1
tp77917
sS'lotensin,has,been'
p77918
(F1
F0.00014334862385321102
I0
I1
I-1
tp77919
sS'beta,blocker,should'
p77920
(F1
F0.00014334862385321102
I1
I0
I1
tp77921
sS'taking,since,the'
p77922
(F1
F0.00014334862385321102
I1
I0
I1
tp77923
sS'study,dosed,subjects'
p77924
(F1
F0.00014334862385321102
I0
I1
I-1
tp77925
sS'significant,and,no'
p77926
(F1
F0.00014334862385321102
I0
I1
I-1
tp77927
sS'for,converting,difluoro-2'
p77928
(F1
F0.00014334862385321102
I1
I0
I1
tp77929
sS'coadministered,orally,as'
p77930
(F1
F0.00014334862385321102
I1
I0
I1
tp77931
sS'respectively,of,those'
p77932
(F1
F0.00014334862385321102
I1
I0
I1
tp77933
sS'of,and,require'
p77934
(F1
F0.00014334862385321102
I1
I0
I1
tp77935
sS'of,there,is'
p77936
(F1
F0.00014334862385321102
I1
I0
I1
tp77937
sS'the,potentiating,action'
p77938
(F1
F0.00014334862385321102
I1
I0
I1
tp77939
sS'vasoconstrictors,d,h'
p77940
(F1
F0.00014334862385321102
I1
I0
I1
tp77941
sS'of,an,aluminum-containing'
p77942
(F1
F0.00014334862385321102
I0
I1
I-1
tp77943
sS'professional,know,if'
p77944
(F1
F0.00014334862385321102
I1
I0
I1
tp77945
sS'preceded,by,an'
p77946
(F1
F0.00014334862385321102
I0
I1
I-1
tp77947
sS'corticosteroids,may,also'
p77948
(F1
F0.00014334862385321102
I1
I0
I1
tp77949
sS'inhibitors,felodipine,is'
p77950
(F1
F0.00014334862385321102
I0
I1
I-1
tp77951
sS'mg,of,subjects'
p77952
(F1
F0.00028669724770642203
I2
I0
I2
tp77953
sS'kineret,when,the'
p77954
(F1
F0.00014334862385321102
I0
I1
I-1
tp77955
sS'p-450iie1,in,the'
p77956
(F1
F0.00014334862385321102
I1
I0
I1
tp77957
sS'fatal,adverse,events'
p77958
(F1
F0.00014334862385321102
I0
I1
I-1
tp77959
sS'been,reported,that'
p77960
(F0.7142857142857143
F0.00071674311926605509
I6
I1
I5
tp77961
sS'on,the,translocation'
p77962
(F1
F0.00014334862385321102
I0
I1
I-1
tp77963
sS'cns,depressants,may'
p77964
(F0
F0
I2
I2
I0
tp77965
sS'had,no,influence'
p77966
(F1
F0.00014334862385321102
I0
I1
I-1
tp77967
sS'products,should,be'
p77968
(F1
F0.00014334862385321102
I0
I1
I-1
tp77969
sS'been,reported,itraconazole'
p77970
(F1
F0.00014334862385321102
I0
I1
I-1
tp77971
sS'daily,mcg,twice'
p77972
(F1
F0.00014334862385321102
I0
I1
I-1
tp77973
sS'plasma,levels,mcg'
p77974
(F1
F0.00014334862385321102
I1
I0
I1
tp77975
sS'between,the,two'
p77976
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp77977
sS'understand,how,to'
p77978
(F1
F0.00014334862385321102
I0
I1
I-1
tp77979
sS'lithium,serum,concentrations'
p77980
(F1
F0.00014334862385321102
I1
I0
I1
tp77981
sS'cell,accumulation,of'
p77982
(F1
F0.00014334862385321102
I0
I1
I-1
tp77983
sS'indinavir-based,regimens,has'
p77984
(F1
F0.00014334862385321102
I0
I1
I-1
tp77985
sS'glaucoma,or,systemic'
p77986
(F1
F0.00014334862385321102
I1
I0
I1
tp77987
sS'terminated,the,b-blocking'
p77988
(F1
F0.00014334862385321102
I1
I0
I1
tp77989
sS'may,have,either'
p77990
(F1
F0.00014334862385321102
I0
I1
I-1
tp77991
sS'inhibitors,coadministration,of'
p77992
(F1
F0.00014334862385321102
I1
I0
I1
tp77993
sS'illustrated,by,six'
p77994
(F1
F0.00014334862385321102
I0
I1
I-1
tp77995
sS'bombesin-enhanced,peritoneal,metastasis'
p77996
(F1
F0.00014334862385321102
I1
I0
I1
tp77997
sS'sodium,from,the'
p77998
(F1
F0.00014334862385321102
I1
I0
I1
tp77999
sS'group,of,subjects'
p78000
(F1
F0.00014334862385321102
I1
I0
I1
tp78001
sS'increases,in,concentrations'
p78002
(F1
F0.00014334862385321102
I1
I0
I1
tp78003
sS'thus,when,nsaids'
p78004
(F1
F0.00028669724770642203
I2
I0
I2
tp78005
sS'be,taken,during'
p78006
(F1
F0.00043004587155963305
I3
I0
I3
tp78007
sS'these,on,the'
p78008
(F1
F0.00014334862385321102
I0
I1
I-1
tp78009
sS'noninsulin,dependent,diabetic'
p78010
(F1
F0.00014334862385321102
I0
I1
I-1
tp78011
sS'low,measurement,of'
p78012
(F1
F0.00014334862385321102
I0
I1
I-1
tp78013
sS'proteins,and,related'
p78014
(F1
F0.00014334862385321102
I1
I0
I1
tp78015
sS'even,experienced,users'
p78016
(F1
F0.00014334862385321102
I1
I0
I1
tp78017
sS'in,renal,and'
p78018
(F1
F0.00014334862385321102
I1
I0
I1
tp78019
sS'interaction,studies,when'
p78020
(F1
F0.00014334862385321102
I0
I1
I-1
tp78021
sS'and,were,also'
p78022
(F1
F0.00014334862385321102
I0
I1
I-1
tp78023
sS'between,and,a'
p78024
(F1
F0.00014334862385321102
I1
I0
I1
tp78025
sS'higher,absolute,but'
p78026
(F1
F0.00014334862385321102
I0
I1
I-1
tp78027
sS'by,and,increased'
p78028
(F1
F0.00043004587155963305
I3
I0
I3
tp78029
sS'highly,protein-bound,such'
p78030
(F1
F0.00014334862385321102
I0
I1
I-1
tp78031
sS'the,antagonism,of'
p78032
(F1
F0.00014334862385321102
I1
I0
I1
tp78033
sS'in,patients,treated'
p78034
(F0.25
F0.00028669724770642203
I5
I3
I2
tp78035
sS'possibly,related,to'
p78036
(F1
F0.00014334862385321102
I1
I0
I1
tp78037
sS'endothelial,function,is'
p78038
(F1
F0.00014334862385321102
I0
I1
I-1
tp78039
sS'unlikely,to,compete'
p78040
(F1
F0.00014334862385321102
I0
I1
I-1
tp78041
sS'combinations,of,gl'
p78042
(F0
F0
I1
I1
I0
tp78043
sS'normal,volunteers,there'
p78044
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp78045
sS'prostatic,hyperplasia,bph'
p78046
(F1
F0.00014334862385321102
I0
I1
I-1
tp78047
sS'c19,the,enzymes'
p78048
(F1
F0.00014334862385321102
I0
I1
I-1
tp78049
sS'angiomax,with,or'
p78050
(F1
F0.00014334862385321102
I1
I0
I1
tp78051
sS'be,delayed,for'
p78052
(F1
F0.00014334862385321102
I1
I0
I1
tp78053
sS'to,premature,ventricular'
p78054
(F1
F0.00014334862385321102
I0
I1
I-1
tp78055
sS'is,needed,should'
p78056
(F1
F0.00014334862385321102
I0
I1
I-1
tp78057
sS'neuromuscular,blockade,associated'
p78058
(F1
F0.00014334862385321102
I0
I1
I-1
tp78059
sS'rating,scales,and'
p78060
(F1
F0.00014334862385321102
I0
I1
I-1
tp78061
sS'the,electrocardiographic,parameters'
p78062
(F1
F0.00014334862385321102
I0
I1
I-1
tp78063
sS'regulation,of,tyrosine'
p78064
(F1
F0.00014334862385321102
I0
I1
I-1
tp78065
sS'proves,to,be'
p78066
(F1
F0.00014334862385321102
I1
I0
I1
tp78067
sS'single-dose,interaction,study'
p78068
(F1
F0.00014334862385321102
I0
I1
I-1
tp78069
sS'with,angina,pectoris'
p78070
(F1
F0.00014334862385321102
I1
I0
I1
tp78071
sS'while,it,is'
p78072
(F1
F0.00014334862385321102
I0
I1
I-1
tp78073
sS'when,proquin,xr'
p78074
(F1
F0.00014334862385321102
I0
I1
I-1
tp78075
sS'the,hmg-coa,reductase'
p78076
(F1
F0.00014334862385321102
I1
I0
I1
tp78077
sS'narrow,therapeutic,window'
p78078
(F1
F0.00014334862385321102
I1
I0
I1
tp78079
sS'of,with,the'
p78080
(F1
F0.00014334862385321102
I1
I0
I1
tp78081
sS'in,the,experiments'
p78082
(F1
F0.00014334862385321102
I0
I1
I-1
tp78083
sS'a,bile,acid'
p78084
(F1
F0.00028669724770642203
I2
I0
I2
tp78085
sS'retention,in,the'
p78086
(F1
F0.00014334862385321102
I0
I1
I-1
tp78087
sS'potential,for,drug-induced'
p78088
(F1
F0.00014334862385321102
I0
I1
I-1
tp78089
sS'injection,with,other'
p78090
(F1
F0.00014334862385321102
I1
I0
I1
tp78091
sS'an,can,not'
p78092
(F1
F0.00014334862385321102
I1
I0
I1
tp78093
sS'by,glucuronidation,is'
p78094
(F1
F0.00014334862385321102
I0
I1
I-1
tp78095
sS'strongly,support,the'
p78096
(F1
F0.00014334862385321102
I0
I1
I-1
tp78097
sS'a,wax,matrix'
p78098
(F1
F0.00014334862385321102
I1
I0
I1
tp78099
sS'treated,with,tikosyn'
p78100
(F1
F0.00014334862385321102
I0
I1
I-1
tp78101
sS'interferons,such,as'
p78102
(F1
F0.00014334862385321102
I0
I1
I-1
tp78103
sS'augmented,by,antihypertensive'
p78104
(F1
F0.00028669724770642203
I2
I0
I2
tp78105
sS'kinetics,of,a'
p78106
(F1
F0.00014334862385321102
I0
I1
I-1
tp78107
sS'recommended,for,use'
p78108
(F1
F0.00043004587155963305
I3
I0
I3
tp78109
sS'lithium,toxicity,was'
p78110
(F1
F0.00014334862385321102
I1
I0
I1
tp78111
sS'maximum,human,therapeutic'
p78112
(F1
F0.00014334862385321102
I1
I0
I1
tp78113
sS'vardenafil,mg,when'
p78114
(F1
F0.00014334862385321102
I0
I1
I-1
tp78115
sS'increase,cyp,metabolism'
p78116
(F1
F0.00014334862385321102
I1
I0
I1
tp78117
sS'sulfoxide,concentrations,in'
p78118
(F1
F0.00014334862385321102
I1
I0
I1
tp78119
sS'nsaids,have,been'
p78120
(F1
F0.00028669724770642203
I2
I0
I2
tp78121
sS'bioavailability,of,may'
p78122
(F1
F0.00014334862385321102
I1
I0
I1
tp78123
sS'injections,of,trimethyl'
p78124
(F1
F0.00014334862385321102
I0
I1
I-1
tp78125
sS'time,may,occur'
p78126
(F1
F0.00014334862385321102
I1
I0
I1
tp78127
sS'not,affect,subjective'
p78128
(F1
F0.00014334862385321102
I0
I1
I-1
tp78129
sS'is,advised,especially'
p78130
(F1
F0.00014334862385321102
I0
I1
I-1
tp78131
sS'it,is,considered'
p78132
(F1
F0.00014334862385321102
I0
I1
I-1
tp78133
sS'a,sharp,fall'
p78134
(F1
F0.00014334862385321102
I1
I0
I1
tp78135
sS'was,prevented,by'
p78136
(F1
F0.00028669724770642203
I2
I0
I2
tp78137
sS'a,resulting,in'
p78138
(F1
F0.00014334862385321102
I1
I0
I1
tp78139
sS'have,been,some'
p78140
(F1
F0.00014334862385321102
I1
I0
I1
tp78141
sS'physiological,behavioral,or'
p78142
(F1
F0.00014334862385321102
I0
I1
I-1
tp78143
sS'prothrombin,time,of'
p78144
(F1
F0.00014334862385321102
I0
I1
I-1
tp78145
sS'if,or,other'
p78146
(F1
F0.00014334862385321102
I1
I0
I1
tp78147
sS'when,subjects,were'
p78148
(F1
F0.00014334862385321102
I0
I1
I-1
tp78149
sS'the,maximum,recommended'
p78150
(F1
F0.00014334862385321102
I1
I0
I1
tp78151
sS'the,ability,to'
p78152
(F1
F0.00014334862385321102
I0
I1
I-1
tp78153
sS'natriuretic,effect,of'
p78154
(F1
F0.0008600917431192661
I6
I0
I6
tp78155
sS'significant,drug-drug,pharmacokinetic'
p78156
(F1
F0.00028669724770642203
I0
I2
I-2
tp78157
sS'and,toxicity,in'
p78158
(F1
F0.00014334862385321102
I1
I0
I1
tp78159
sS'symptoms,should,be'
p78160
(F1
F0.00014334862385321102
I0
I1
I-1
tp78161
sS'with,oral,treatment'
p78162
(F1
F0.00014334862385321102
I1
I0
I1
tp78163
sS'when,inspra,and'
p78164
(F1
F0.00014334862385321102
I1
I0
I1
tp78165
sS'investigated,in,vivo'
p78166
(F1
F0.00014334862385321102
I0
I1
I-1
tp78167
sS'ssris,may,increase'
p78168
(F1
F0.00014334862385321102
I1
I0
I1
tp78169
sS'patients,on,diuretic'
p78170
(F1
F0.00043004587155963305
I3
I0
I3
tp78171
sS'exaggerate,the,depression'
p78172
(F1
F0.00014334862385321102
I1
I0
I1
tp78173
sS'and,are,co'
p78174
(F1
F0.00014334862385321102
I1
I0
I1
tp78175
sS'the,pharmacologically,predictable'
p78176
(F1
F0.00014334862385321102
I1
I0
I1
tp78177
sS'tested,in,man'
p78178
(F1
F0.00028669724770642203
I0
I2
I-2
tp78179
sS'indicating,no,change'
p78180
(F1
F0.00014334862385321102
I0
I1
I-1
tp78181
sS'drugs,that,are'
p78182
(F1
F0.00014334862385321102
I0
I1
I-1
tp78183
sS'diuretics,diclofenac,and'
p78184
(F1
F0.00014334862385321102
I1
I0
I1
tp78185
sS'but,presumably,to'
p78186
(F1
F0.00014334862385321102
I0
I1
I-1
tp78187
sS'detect,an,effect'
p78188
(F1
F0.00014334862385321102
I0
I1
I-1
tp78189
sS'to,vehicle-,progesterone-'
p78190
(F1
F0.00014334862385321102
I1
I0
I1
tp78191
sS'when,administered,in'
p78192
(F1
F0.00014334862385321102
I1
I0
I1
tp78193
sS'literature,suggest,that'
p78194
(F1
F0.00014334862385321102
I1
I0
I1
tp78195
sS'of,hydrochloride,on'
p78196
(F1
F0.00014334862385321102
I1
I0
I1
tp78197
sS'cytoprotective,properties,of'
p78198
(F1
F0.00014334862385321102
I0
I1
I-1
tp78199
sS'and,hydroxides,and'
p78200
(F1
F0.00014334862385321102
I0
I1
I-1
tp78201
sS'patients,who,take'
p78202
(F1
F0.00014334862385321102
I0
I1
I-1
tp78203
sS'in,humans,have'
p78204
(F1
F0.00043004587155963305
I0
I3
I-3
tp78205
sS'does,affect,the'
p78206
(F1
F0.00014334862385321102
I0
I1
I-1
tp78207
sS'ns,absorbed,is'
p78208
(F1
F0.00014334862385321102
I0
I1
I-1
tp78209
sS'supplements,use,of'
p78210
(F1
F0.00014334862385321102
I1
I0
I1
tp78211
sS'kg,ip,or'
p78212
(F1
F0.00014334862385321102
I1
I0
I1
tp78213
sS'case,of,severe'
p78214
(F1
F0.00014334862385321102
I1
I0
I1
tp78215
sS'receiving,these,who'
p78216
(F1
F0.00014334862385321102
I0
I1
I-1
tp78217
sS'of,zyvox,and'
p78218
(F1
F0.00014334862385321102
I1
I0
I1
tp78219
sS'to,be,drawn'
p78220
(F1
F0.00014334862385321102
I0
I1
I-1
tp78221
sS'and,initiation,of'
p78222
(F1
F0.00028669724770642203
I2
I0
I2
tp78223
sS'cimetidine,co-administration,of'
p78224
(F1
F0.00028669724770642203
I0
I2
I-2
tp78225
sS'clinically,relevant,elevation'
p78226
(F1
F0.00014334862385321102
I1
I0
I1
tp78227
sS'quinidine,and,raise'
p78228
(F1
F0.00014334862385321102
I1
I0
I1
tp78229
sS'non-steroidal,and,herbs'
p78230
(F1
F0.00014334862385321102
I1
I0
I1
tp78231
sS'may,bind,and'
p78232
(F1
F0.00014334862385321102
I1
I0
I1
tp78233
sS'administration,may,result'
p78234
(F1
F0.00014334862385321102
I1
I0
I1
tp78235
sS'a,dose,decrease'
p78236
(F1
F0.00014334862385321102
I1
I0
I1
tp78237
sS'and,fold,respectively'
p78238
(F1
F0.00014334862385321102
I1
I0
I1
tp78239
sS'that,in,patients'
p78240
(F0.33333333333333331
F0.00014334862385321102
I2
I1
I1
tp78241
sS'when,multiple,doses'
p78242
(F1
F0.00028669724770642203
I2
I0
I2
tp78243
sS'safety,however,its'
p78244
(F1
F0.00014334862385321102
I0
I1
I-1
tp78245
sS'of,with,potent'
p78246
(F1
F0.00014334862385321102
I0
I1
I-1
tp78247
sS'by,electrocardiographic,parameters'
p78248
(F1
F0.00028669724770642203
I0
I2
I-2
tp78249
sS'antihypertensive,medications,other'
p78250
(F1
F0.00014334862385321102
I0
I1
I-1
tp78251
sS'may,result,from'
p78252
(F1
F0.00014334862385321102
I1
I0
I1
tp78253
sS'may,have,elevated'
p78254
(F1
F0.00014334862385321102
I1
I0
I1
tp78255
sS'or,metabolic,responses'
p78256
(F1
F0.00014334862385321102
I0
I1
I-1
tp78257
sS'worse,and,prevent'
p78258
(F1
F0.00014334862385321102
I0
I1
I-1
tp78259
sS'prostaglandin,synthase,inhibiting'
p78260
(F1
F0.00014334862385321102
I1
I0
I1
tp78261
sS'excessive,reduction,of'
p78262
(F1
F0.00071674311926605509
I5
I0
I5
tp78263
sS'decrease,first,pass'
p78264
(F1
F0.00014334862385321102
I0
I1
I-1
tp78265
sS'infusion,reactions,compared'
p78266
(F1
F0.00014334862385321102
I0
I1
I-1
tp78267
sS'the,therapeutic,efficacy'
p78268
(F1
F0.00028669724770642203
I2
I0
I2
tp78269
sS'diazepam,valium,is'
p78270
(F1
F0.00014334862385321102
I0
I1
I-1
tp78271
sS'relative,to,the'
p78272
(F0
F0
I1
I1
I0
tp78273
sS'fi,or,fr'
p78274
(F1
F0.00014334862385321102
I1
I0
I1
tp78275
sS'the,serum,sex'
p78276
(F1
F0.00014334862385321102
I1
I0
I1
tp78277
sS'demonstrated,an,association'
p78278
(F1
F0.00014334862385321102
I1
I0
I1
tp78279
sS'amphetamines,may,counteract'
p78280
(F1
F0.00028669724770642203
I2
I0
I2
tp78281
sS'a,statistically,significant'
p78282
(F0
F0
I2
I2
I0
tp78283
sS'of,exogenous,on'
p78284
(F1
F0.00014334862385321102
I0
I1
I-1
tp78285
sS'in,the,doses'
p78286
(F1
F0.00014334862385321102
I1
I0
I1
tp78287
sS'antibiotics-broad,spectrum,may'
p78288
(F1
F0.00014334862385321102
I0
I1
I-1
tp78289
sS'agents,with,proleukin'
p78290
(F1
F0.00014334862385321102
I1
I0
I1
tp78291
sS'hyperkalemia,in,patients'
p78292
(F1
F0.00014334862385321102
I1
I0
I1
tp78293
sS'in,man,include'
p78294
(F0
F0
I1
I1
I0
tp78295
sS'and,were,studied'
p78296
(F1
F0.00014334862385321102
I0
I1
I-1
tp78297
sS'recovery,from,neuromuscular'
p78298
(F1
F0.00014334862385321102
I0
I1
I-1
tp78299
sS'be,required,if'
p78300
(F1
F0.00028669724770642203
I0
I2
I-2
tp78301
sS'constipation,blurred,vision'
p78302
(F1
F0.00014334862385321102
I1
I0
I1
tp78303
sS'nonsteroidal,can,interfere'
p78304
(F1
F0.00014334862385321102
I1
I0
I1
tp78305
sS'other,antiepilepsy,drugs'
p78306
(F0
F0
I1
I1
I0
tp78307
sS'of,isosorbide,dinitrate'
p78308
(F1
F0.00014334862385321102
I1
I0
I1
tp78309
sS'the,same,cytochrome'
p78310
(F1
F0.00014334862385321102
I0
I1
I-1
tp78311
sS'discontinuation,of,which'
p78312
(F1
F0.00014334862385321102
I1
I0
I1
tp78313
sS'cyp3a4,metabolized,should'
p78314
(F1
F0.00014334862385321102
I1
I0
I1
tp78315
sS'a,daily,dose'
p78316
(F0
F0
I1
I1
I0
tp78317
sS'with,on,performance'
p78318
(F1
F0.00014334862385321102
I0
I1
I-1
tp78319
sS'tsh,levels,generally'
p78320
(F1
F0.00014334862385321102
I0
I1
I-1
tp78321
sS'of,the,other'
p78322
(F1
F0.00028669724770642203
I0
I2
I-2
tp78323
sS'of,precedex,for'
p78324
(F1
F0.00014334862385321102
I0
I1
I-1
tp78325
sS'also,using,a'
p78326
(F1
F0.00014334862385321102
I1
I0
I1
tp78327
sS'with,transient,elevations'
p78328
(F1
F0.00028669724770642203
I2
I0
I2
tp78329
sS'nsaids,concomitant,use'
p78330
(F1
F0.00014334862385321102
I1
I0
I1
tp78331
sS'methyltetrahydro-folate,and,in'
p78332
(F1
F0.00014334862385321102
I0
I1
I-1
tp78333
sS'dosages,of,the'
p78334
(F1
F0.00014334862385321102
I0
I1
I-1
tp78335
sS'these,results,together'
p78336
(F1
F0.00014334862385321102
I0
I1
I-1
tp78337
sS'tubular,secretion,of'
p78338
(F1
F0.0011467889908256881
I8
I0
I8
tp78339
sS'showed,a,loss'
p78340
(F1
F0.00014334862385321102
I0
I1
I-1
tp78341
sS'two,of,four'
p78342
(F1
F0.00014334862385321102
I1
I0
I1
tp78343
sS'and,the,leukopenic'
p78344
(F1
F0.00014334862385321102
I1
I0
I1
tp78345
sS'effects,may,induce'
p78346
(F1
F0.00014334862385321102
I1
I0
I1
tp78347
sS'of,our,patient'
p78348
(F1
F0.00014334862385321102
I1
I0
I1
tp78349
sS'resulted,in,additive'
p78350
(F1
F0.00014334862385321102
I1
I0
I1
tp78351
sS'lessen,its,efficacy'
p78352
(F1
F0.00014334862385321102
I0
I1
I-1
tp78353
sS'used,when,administering'
p78354
(F1
F0.00043004587155963305
I3
I0
I3
tp78355
sS'smx,such,as'
p78356
(F1
F0.00014334862385321102
I0
I1
I-1
tp78357
sS'pathways,which,are'
p78358
(F1
F0.00014334862385321102
I0
I1
I-1
tp78359
sS'pretreatment,with,cgs'
p78360
(F1
F0.00014334862385321102
I1
I0
I1
tp78361
sS'oil,interferes,with'
p78362
(F1
F0.00014334862385321102
I1
I0
I1
tp78363
sS'that,patients,take'
p78364
(F1
F0.00014334862385321102
I0
I1
I-1
tp78365
sS'fasting,conditions,or'
p78366
(F1
F0.00014334862385321102
I0
I1
I-1
tp78367
sS'as,a,result'
p78368
(F0
F0
I1
I1
I0
tp78369
sS'and,indanedione,including'
p78370
(F1
F0.00014334862385321102
I0
I1
I-1
tp78371
sS'inhibits,the,ermbt'
p78372
(F1
F0.00014334862385321102
I0
I1
I-1
tp78373
sS'between,mentax,butenafine'
p78374
(F1
F0.00014334862385321102
I0
I1
I-1
tp78375
sS'this,effect,on'
p78376
(F1
F0.00014334862385321102
I1
I0
I1
tp78377
sS'ethinyl,estradiol,mg'
p78378
(F1
F0.00014334862385321102
I0
I1
I-1
tp78379
sS'of,because,the'
p78380
(F1
F0.00014334862385321102
I0
I1
I-1
tp78381
sS'approached,with,caution'
p78382
(F1
F0.00028669724770642203
I2
I0
I2
tp78383
sS'lung,survanta,on'
p78384
(F1
F0.00014334862385321102
I0
I1
I-1
tp78385
sS'this,effect,of'
p78386
(F1
F0.00014334862385321102
I0
I1
I-1
tp78387
sS'reaction,and,lead'
p78388
(F1
F0.00014334862385321102
I1
I0
I1
tp78389
sS'veratrum,alkaloids,may'
p78390
(F1
F0.00014334862385321102
I1
I0
I1
tp78391
sS'of,day-old,chick'
p78392
(F1
F0.00014334862385321102
I1
I0
I1
tp78393
sS'be,increased,when'
p78394
(F1
F0.00028669724770642203
I2
I0
I2
tp78395
sS'hydrochloride,on,the'
p78396
(F1
F0.00014334862385321102
I1
I0
I1
tp78397
sS'concomitant,serotonergic,agents'
p78398
(F1
F0.00014334862385321102
I1
I0
I1
tp78399
sS'formation,from,combined'
p78400
(F1
F0.00014334862385321102
I1
I0
I1
tp78401
sS'by,competing,for'
p78402
(F1
F0.00028669724770642203
I2
I0
I2
tp78403
sS'at,steady-state,in'
p78404
(F1
F0.00014334862385321102
I0
I1
I-1
tp78405
sS'diethyl,pyrocarbonate,revealed'
p78406
(F1
F0.00014334862385321102
I0
I1
I-1
tp78407
sS'the,bile-acidsequestering,agent'
p78408
(F1
F0.00014334862385321102
I0
I1
I-1
tp78409
sS'not,systematically,studied'
p78410
(F1
F0.00014334862385321102
I1
I0
I1
tp78411
sS'the,mean,steady-state'
p78412
(F1
F0.00014334862385321102
I0
I1
I-1
tp78413
sS'in,no,clinically'
p78414
(F1
F0.00014334862385321102
I0
I1
I-1
tp78415
sS'dose,and,the'
p78416
(F1
F0.00014334862385321102
I0
I1
I-1
tp78417
sS'effects,and,therefore'
p78418
(F1
F0.00014334862385321102
I0
I1
I-1
tp78419
sS'receiving,and,can'
p78420
(F1
F0.00014334862385321102
I0
I1
I-1
tp78421
sS'both,and,creatinine'
p78422
(F1
F0.00014334862385321102
I1
I0
I1
tp78423
sS'as,a,single'
p78424
(F1
F0.00028669724770642203
I0
I2
I-2
tp78425
sS'with,a,narrow'
p78426
(F1
F0.00028669724770642203
I0
I2
I-2
tp78427
sS'over,a,period'
p78428
(F1
F0.00014334862385321102
I0
I1
I-1
tp78429
sS'immune,response,to'
p78430
(F1
F0.00014334862385321102
I0
I1
I-1
tp78431
sS'inotropic,effects,of'
p78432
(F1
F0.00028669724770642203
I2
I0
I2
tp78433
sS'was,measured,from'
p78434
(F1
F0.00014334862385321102
I0
I1
I-1
tp78435
sS'led,to,elevated'
p78436
(F1
F0.00014334862385321102
I1
I0
I1
tp78437
sS'healthy,subjects,was'
p78438
(F1
F0.00014334862385321102
I1
I0
I1
tp78439
sS'which,promote,absorption'
p78440
(F1
F0.00043004587155963305
I3
I0
I3
tp78441
sS'of,or,and'
p78442
(F1
F0.00014334862385321102
I0
I1
I-1
tp78443
sS'evening,meal,resulted'
p78444
(F1
F0.00014334862385321102
I1
I0
I1
tp78445
sS'deaths,from,severe'
p78446
(F1
F0.00014334862385321102
I1
I0
I1
tp78447
sS'additive,effects,and'
p78448
(F1
F0.00043004587155963305
I3
I0
I3
tp78449
sS'by,the,cyp2d6'
p78450
(F1
F0.00014334862385321102
I0
I1
I-1
tp78451
sS'not,been,definitively'
p78452
(F1
F0.00014334862385321102
I1
I0
I1
tp78453
sS'antagonist,eg,and'
p78454
(F1
F0.00014334862385321102
I1
I0
I1
tp78455
sS'containing,may,lead'
p78456
(F1
F0.00014334862385321102
I0
I1
I-1
tp78457
sS'fluorescein,naflu,and'
p78458
(F1
F0.00014334862385321102
I0
I1
I-1
tp78459
sS'compared,pharmacokinetics,and'
p78460
(F1
F0.00014334862385321102
I0
I1
I-1
tp78461
sS'vasopressor,and,of'
p78462
(F1
F0.00014334862385321102
I0
I1
I-1
tp78463
sS'anticoagulants,potentiation,of'
p78464
(F1
F0.00014334862385321102
I0
I1
I-1
tp78465
sS'on,the,digit'
p78466
(F1
F0.00014334862385321102
I1
I0
I1
tp78467
sS'days,of,multipledose'
p78468
(F1
F0.00014334862385321102
I0
I1
I-1
tp78469
sS'potentiate,the,neuromuscular'
p78470
(F1
F0.00014334862385321102
I1
I0
I1
tp78471
sS'the,dose,reduced'
p78472
(F1
F0.00014334862385321102
I1
I0
I1
tp78473
sS'severe,reactions,such'
p78474
(F1
F0.00014334862385321102
I0
I1
I-1
tp78475
sS'clozapine,may,potentiate'
p78476
(F1
F0.00014334862385321102
I1
I0
I1
tp78477
sS'likely,will,interfere'
p78478
(F1
F0.00014334862385321102
I1
I0
I1
tp78479
sS'for,relief,of'
p78480
(F1
F0.00014334862385321102
I0
I1
I-1
tp78481
sS'exposure,auc0-12,of'
p78482
(F1
F0.00014334862385321102
I0
I1
I-1
tp78483
sS'locomotor,and,or'
p78484
(F1
F0.00014334862385321102
I0
I1
I-1
tp78485
sS'in,vitro,on'
p78486
(F1
F0.00014334862385321102
I0
I1
I-1
tp78487
sS'inhibit,platelet,function'
p78488
(F1
F0.00014334862385321102
I1
I0
I1
tp78489
sS'if,any,clinically'
p78490
(F1
F0.00014334862385321102
I0
I1
I-1
tp78491
sS'the,to,nonopioid'
p78492
(F1
F0.00014334862385321102
I0
I1
I-1
tp78493
sS'when,is,co-administered'
p78494
(F1
F0.00028669724770642203
I2
I0
I2
tp78495
sS'allegra,should,not'
p78496
(F1
F0.00014334862385321102
I1
I0
I1
tp78497
sS'before,meals,for'
p78498
(F1
F0.00028669724770642203
I0
I2
I-2
tp78499
sS'therapy,with,vitamin'
p78500
(F1
F0.00043004587155963305
I3
I0
I3
tp78501
sS'tachycardia,ventricular,fibrulation'
p78502
(F1
F0.00014334862385321102
I1
I0
I1
tp78503
sS'because,the,action'
p78504
(F1
F0.00043004587155963305
I3
I0
I3
tp78505
sS'macrolide,and,azoles'
p78506
(F1
F0.00014334862385321102
I0
I1
I-1
tp78507
sS'components,are,representations'
p78508
(F1
F0.00014334862385321102
I0
I1
I-1
tp78509
sS'ph,is,an'
p78510
(F1
F0.00028669724770642203
I2
I0
I2
tp78511
sS'arecoline,eproxindine,ethanol'
p78512
(F1
F0.00014334862385321102
I1
I0
I1
tp78513
sS'and,for,the'
p78514
(F1
F0.00028669724770642203
I0
I2
I-2
tp78515
sS'interaction,studies,other'
p78516
(F1
F0.00014334862385321102
I0
I1
I-1
tp78517
sS'interaction,studies,no'
p78518
(F1
F0.00014334862385321102
I0
I1
I-1
tp78519
sS'these,three,products'
p78520
(F1
F0.00014334862385321102
I1
I0
I1
tp78521
sS'may,cause,changes'
p78522
(F1
F0.00028669724770642203
I2
I0
I2
tp78523
sS'have,been,reported'
p78524
(F0.80000000000000004
F0.008027522935779817
I63
I7
I56
tp78525
sS'a,beta,blocker'
p78526
(F1
F0.00014334862385321102
I1
I0
I1
tp78527
sS'to,repeated,exposure'
p78528
(F1
F0.00014334862385321102
I0
I1
I-1
tp78529
sS'cns,depressants,or'
p78530
(F1
F0.00014334862385321102
I1
I0
I1
tp78531
sS'advised,to,avoid'
p78532
(F1
F0.00014334862385321102
I1
I0
I1
tp78533
sS'is,ordinarily,a'
p78534
(F1
F0.00014334862385321102
I0
I1
I-1
tp78535
sS'reportedly,are,increased'
p78536
(F1
F0.00014334862385321102
I1
I0
I1
tp78537
sS'reported,to,cause'
p78538
(F1
F0.00071674311926605509
I5
I0
I5
tp78539
sS'recommended,when,sustiva'
p78540
(F0
F0
I1
I1
I0
tp78541
sS'the,bile,caution'
p78542
(F1
F0.00014334862385321102
I0
I1
I-1
tp78543
sS'likelihood,of,congestive'
p78544
(F1
F0.00014334862385321102
I1
I0
I1
tp78545
sS'of,a,cyp2c9'
p78546
(F1
F0.00014334862385321102
I1
I0
I1
tp78547
sS'passages,increasing,the'
p78548
(F1
F0.00014334862385321102
I1
I0
I1
tp78549
sS'and,animal,studies'
p78550
(F1
F0.00028669724770642203
I2
I0
I2
tp78551
sS'cases,in,which'
p78552
(F1
F0.00014334862385321102
I1
I0
I1
tp78553
sS'folic,acid,and'
p78554
(F1
F0.00028669724770642203
I0
I2
I-2
tp78555
sS'on,resistance,arteries'
p78556
(F1
F0.00014334862385321102
I0
I1
I-1
tp78557
sS'human,immunodeficiency,virus-related'
p78558
(F1
F0.00014334862385321102
I0
I1
I-1
tp78559
sS'activity,of,both'
p78560
(F1
F0.00014334862385321102
I1
I0
I1
tp78561
sS'can,cause,increased'
p78562
(F1
F0.00014334862385321102
I1
I0
I1
tp78563
sS'and,mg,single'
p78564
(F1
F0.00028669724770642203
I0
I2
I-2
tp78565
sS'fewer,interactions,and'
p78566
(F1
F0.00014334862385321102
I0
I1
I-1
tp78567
sS'who,received,angiomax'
p78568
(F1
F0.00014334862385321102
I0
I1
I-1
tp78569
sS'd-penicillamine,or,did'
p78570
(F1
F0.00014334862385321102
I0
I1
I-1
tp78571
sS'when,and,cerebyx'
p78572
(F1
F0.00014334862385321102
I0
I1
I-1
tp78573
sS'than,two-second,increase'
p78574
(F1
F0.00014334862385321102
I1
I0
I1
tp78575
sS'rats,in,a'
p78576
(F1
F0.00014334862385321102
I1
I0
I1
tp78577
sS'blocking,agents,without'
p78578
(F1
F0.00014334862385321102
I0
I1
I-1
tp78579
sS'once,daily,brovana'
p78580
(F1
F0.00014334862385321102
I0
I1
I-1
tp78581
sS'metab-olizers,resemble,poor'
p78582
(F1
F0.00014334862385321102
I0
I1
I-1
tp78583
sS'hypoglycemia,oral,products'
p78584
(F1
F0.00014334862385321102
I0
I1
I-1
tp78585
sS'interval,for,coadministration'
p78586
(F1
F0.00014334862385321102
I0
I1
I-1
tp78587
sS'sugar,concentrations,during'
p78588
(F1
F0.00014334862385321102
I1
I0
I1
tp78589
sS'dose,of,theophylline'
p78590
(F1
F0.00014334862385321102
I0
I1
I-1
tp78591
sS'reduced,clearance,a'
p78592
(F1
F0.00014334862385321102
I1
I0
I1
tp78593
sS'with,schizophrenia,or'
p78594
(F1
F0.00028669724770642203
I0
I2
I-2
tp78595
sS'greater,than,fold'
p78596
(F1
F0.00014334862385321102
I1
I0
I1
tp78597
sS'reported,both,weight'
p78598
(F1
F0.00014334862385321102
I1
I0
I1
tp78599
sS'antiinflammatory,agents,and'
p78600
(F1
F0.00014334862385321102
I1
I0
I1
tp78601
sS'that,a,combination'
p78602
(F1
F0.00014334862385321102
I0
I1
I-1
tp78603
sS'vitamin,d,the'
p78604
(F1
F0.00043004587155963305
I0
I3
I-3
tp78605
sS'symptomatic,orthostatic,hypotension'
p78606
(F1
F0.00028669724770642203
I2
I0
I2
tp78607
sS'of,nimbex,and'
p78608
(F0
F0
I1
I1
I0
tp78609
sS'of,fade,hoof'
p78610
(F1
F0.00014334862385321102
I1
I0
I1
tp78611
sS'now,available,in'
p78612
(F1
F0.00014334862385321102
I0
I1
I-1
tp78613
sS'antagonists,angiotensin,converting'
p78614
(F1
F0.00014334862385321102
I0
I1
I-1
tp78615
sS'aggression,and,agitation'
p78616
(F1
F0.00014334862385321102
I0
I1
I-1
tp78617
sS'possibility,that,the'
p78618
(F1
F0.00014334862385321102
I1
I0
I1
tp78619
sS'inr,elevations,and'
p78620
(F1
F0.00014334862385321102
I1
I0
I1
tp78621
sS'altered,coagulation,parameters'
p78622
(F1
F0.00014334862385321102
I1
I0
I1
tp78623
sS'administered,a,single'
p78624
(F1
F0.00028669724770642203
I2
I0
I2
tp78625
sS'well,as,pure'
p78626
(F1
F0.00014334862385321102
I1
I0
I1
tp78627
sS'procedures,during,or'
p78628
(F1
F0.00014334862385321102
I1
I0
I1
tp78629
sS'blood,area,under'
p78630
(F1
F0.00014334862385321102
I1
I0
I1
tp78631
sS'may,produce,aucs'
p78632
(F1
F0.00014334862385321102
I1
I0
I1
tp78633
sS'patients,with,maximum'
p78634
(F1
F0.00014334862385321102
I0
I1
I-1
tp78635
sS'either,had,no'
p78636
(F1
F0.00014334862385321102
I1
I0
I1
tp78637
sS'inhibitor,or,channel'
p78638
(F1
F0.00014334862385321102
I0
I1
I-1
tp78639
sS'increase,the,severity'
p78640
(F1
F0.00014334862385321102
I1
I0
I1
tp78641
sS'template,bleeding,time'
p78642
(F1
F0.00014334862385321102
I0
I1
I-1
tp78643
sS'light,zone,and'
p78644
(F1
F0.00014334862385321102
I1
I0
I1
tp78645
sS'controlled,study,in'
p78646
(F1
F0.00014334862385321102
I0
I1
I-1
tp78647
sS'levels,and,adjustment'
p78648
(F1
F0.00014334862385321102
I1
I0
I1
tp78649
sS'female,rats,was'
p78650
(F1
F0.00014334862385321102
I0
I1
I-1
tp78651
sS'investigated,in,a'
p78652
(F1
F0.00014334862385321102
I0
I1
I-1
tp78653
sS'although,consistent,with'
p78654
(F1
F0.00014334862385321102
I0
I1
I-1
tp78655
sS'their,effectiveness,when'
p78656
(F1
F0.00014334862385321102
I0
I1
I-1
tp78657
sS'concerning,have,been'
p78658
(F1
F0.00014334862385321102
I1
I0
I1
tp78659
sS'is,contraindicated,and'
p78660
(F1
F0.00014334862385321102
I1
I0
I1
tp78661
sS'anion,plasma,levels'
p78662
(F1
F0.00014334862385321102
I1
I0
I1
tp78663
sS'cholinesterase,inhibitors,such'
p78664
(F1
F0.00014334862385321102
I1
I0
I1
tp78665
sS'is,administered,concomitantly'
p78666
(F1
F0.00071674311926605509
I5
I0
I5
tp78667
sS'development,of,spontaneous'
p78668
(F1
F0.00014334862385321102
I1
I0
I1
tp78669
sS'regulation,of,its'
p78670
(F1
F0.00014334862385321102
I0
I1
I-1
tp78671
sS'the,patients,as'
p78672
(F1
F0.00014334862385321102
I0
I1
I-1
tp78673
sS'mycophenolate,mofetil,ml'
p78674
(F1
F0.00014334862385321102
I0
I1
I-1
tp78675
sS'cardiovascular,adverse,effects'
p78676
(F1
F0.00014334862385321102
I1
I0
I1
tp78677
sS'cmax,by,and'
p78678
(F1
F0.00014334862385321102
I1
I0
I1
tp78679
sS'edetate,disodium,in'
p78680
(F1
F0.00014334862385321102
I1
I0
I1
tp78681
sS'equivalent,amount,of'
p78682
(F1
F0.00014334862385321102
I0
I1
I-1
tp78683
sS'with,atacand,so'
p78684
(F1
F0.00014334862385321102
I1
I0
I1
tp78685
sS'pharmacodynamic,interaction,between'
p78686
(F1
F0.00028669724770642203
I0
I2
I-2
tp78687
sS'was,bioequivalent,to'
p78688
(F1
F0.00014334862385321102
I0
I1
I-1
tp78689
sS'levels,of,other'
p78690
(F1
F0.00014334862385321102
I1
I0
I1
tp78691
sS'about,x,m'
p78692
(F1
F0.00014334862385321102
I1
I0
I1
tp78693
sS'an,adequate,and'
p78694
(F1
F0.00014334862385321102
I0
I1
I-1
tp78695
sS'wshow,that,given'
p78696
(F1
F0.00014334862385321102
I1
I0
I1
tp78697
sS'after,the,dose'
p78698
(F1
F0.00014334862385321102
I1
I0
I1
tp78699
sS'changes,in,gene'
p78700
(F1
F0.00014334862385321102
I0
I1
I-1
tp78701
sS'been,compared,to'
p78702
(F1
F0.00014334862385321102
I0
I1
I-1
tp78703
sS'well-controlled,studies,was'
p78704
(F1
F0.00014334862385321102
I0
I1
I-1
tp78705
sS'vs,when,plasma'
p78706
(F1
F0.00014334862385321102
I1
I0
I1
tp78707
sS'diamox,may,decrease'
p78708
(F1
F0.00014334862385321102
I1
I0
I1
tp78709
sS'smaller,initial,dose'
p78710
(F1
F0.00014334862385321102
I1
I0
I1
tp78711
sS'furthermore,caution,should'
p78712
(F1
F0.00014334862385321102
I0
I1
I-1
tp78713
sS'a,critical,role'
p78714
(F1
F0.00014334862385321102
I0
I1
I-1
tp78715
sS'than,those,receiving'
p78716
(F1
F0.00014334862385321102
I1
I0
I1
tp78717
sS'increased,gastric,ph'
p78718
(F1
F0.00014334862385321102
I0
I1
I-1
tp78719
sS'initiated,at,the'
p78720
(F1
F0.00014334862385321102
I1
I0
I1
tp78721
sS'some,like,monoamine'
p78722
(F1
F0.00014334862385321102
I1
I0
I1
tp78723
sS'blockers,calcium,channel'
p78724
(F1
F0.00014334862385321102
I0
I1
I-1
tp78725
sS'for,hydroxy-iso,by'
p78726
(F1
F0.00014334862385321102
I1
I0
I1
tp78727
sS'brain,edema,it'
p78728
(F1
F0.00014334862385321102
I1
I0
I1
tp78729
sS'administered,to,treated'
p78730
(F1
F0.00014334862385321102
I0
I1
I-1
tp78731
sS'increased,steady-state,levels'
p78732
(F1
F0.00014334862385321102
I0
I1
I-1
tp78733
sS'as,and,would'
p78734
(F1
F0.00014334862385321102
I1
I0
I1
tp78735
sS'for,colazal,however'
p78736
(F1
F0.00014334862385321102
I0
I1
I-1
tp78737
sS'cancidas,reduced,the'
p78738
(F1
F0.00014334862385321102
I1
I0
I1
tp78739
sS'altered,by,concomitant'
p78740
(F1
F0.00014334862385321102
I1
I0
I1
tp78741
sS'a,that,has'
p78742
(F1
F0.00014334862385321102
I0
I1
I-1
tp78743
sS'patient,who,was'
p78744
(F1
F0.00014334862385321102
I0
I1
I-1
tp78745
sS'complex,and,or'
p78746
(F1
F0.00014334862385321102
I1
I0
I1
tp78747
sS'monomeric,disintegrins,and'
p78748
(F1
F0.00014334862385321102
I0
I1
I-1
tp78749
sS'to,minutes,of'
p78750
(F1
F0.00014334862385321102
I0
I1
I-1
tp78751
sS'oral,the,coagulation'
p78752
(F1
F0.00014334862385321102
I0
I1
I-1
tp78753
sS'on,pregnancy,and'
p78754
(F1
F0.00014334862385321102
I0
I1
I-1
tp78755
sS'volunteers,n,resulted'
p78756
(F1
F0.00014334862385321102
I1
I0
I1
tp78757
sS'inhibit,cyp3a,may'
p78758
(F1
F0.00014334862385321102
I0
I1
I-1
tp78759
sS'been,too,little'
p78760
(F1
F0.00014334862385321102
I0
I1
I-1
tp78761
sS'activity,may,result'
p78762
(F0.33333333333333331
F0.00014334862385321102
I1
I2
I-1
tp78763
sS'enhanced,and,excretion'
p78764
(F1
F0.00014334862385321102
I1
I0
I1
tp78765
sS'of,the,fischer-344'
p78766
(F1
F0.00014334862385321102
I0
I1
I-1
tp78767
sS'whereas,it,had'
p78768
(F1
F0.00014334862385321102
I1
I0
I1
tp78769
sS'secretion,of,when'
p78770
(F1
F0.00014334862385321102
I1
I0
I1
tp78771
sS'or,decrease,the'
p78772
(F1
F0.00014334862385321102
I1
I0
I1
tp78773
sS'careful,adjustment,of'
p78774
(F0
F0
I2
I2
I0
tp78775
sS'nacmc,m,v'
p78776
(F1
F0.00028669724770642203
I0
I2
I-2
tp78777
sS'an,additional,effect'
p78778
(F1
F0.00014334862385321102
I1
I0
I1
tp78779
sS'or,s-warfarin,with'
p78780
(F1
F0.00014334862385321102
I0
I1
I-1
tp78781
sS'safety,and,efficacy'
p78782
(F0.20000000000000001
F0.00014334862385321102
I2
I3
I-1
tp78783
sS'concentration,may,prolong'
p78784
(F1
F0.00014334862385321102
I1
I0
I1
tp78785
sS'use,may,be'
p78786
(F0
F0
I1
I1
I0
tp78787
sS'epoxide,steady-state,cmin'
p78788
(F1
F0.00014334862385321102
I0
I1
I-1
tp78789
sS'distribution,of,with'
p78790
(F1
F0.00014334862385321102
I0
I1
I-1
tp78791
sS'individuals,receiving,zyvox'
p78792
(F1
F0.00014334862385321102
I1
I0
I1
tp78793
sS'coadministration,of,with'
p78794
(F0.41176470588235292
F0.0010034403669724771
I12
I5
I7
tp78795
sS'tablets,with,and'
p78796
(F1
F0.00014334862385321102
I0
I1
I-1
tp78797
sS'taking,mg,and'
p78798
(F1
F0.00014334862385321102
I1
I0
I1
tp78799
sS'agents,include,medications'
p78800
(F1
F0.00014334862385321102
I0
I1
I-1
tp78801
sS'of,this,study'
p78802
(F1
F0.00043004587155963305
I0
I3
I-3
tp78803
sS'between,wellbutrin,and'
p78804
(F1
F0.00014334862385321102
I1
I0
I1
tp78805
sS'irrational,behavior,has'
p78806
(F1
F0.00014334862385321102
I1
I0
I1
tp78807
sS'clinically,significant,adverse'
p78808
(F1
F0.00014334862385321102
I0
I1
I-1
tp78809
sS'to,prolong,further'
p78810
(F1
F0.00014334862385321102
I1
I0
I1
tp78811
sS'are,encouraged,to'
p78812
(F1
F0.00014334862385321102
I0
I1
I-1
tp78813
sS'in,the,half-'
p78814
(F1
F0.00043004587155963305
I0
I3
I-3
tp78815
sS'exposed,to,high'
p78816
(F1
F0.00014334862385321102
I1
I0
I1
tp78817
sS'determine,whether,would'
p78818
(F1
F0.00014334862385321102
I0
I1
I-1
tp78819
sS'course,of,in'
p78820
(F1
F0.00014334862385321102
I1
I0
I1
tp78821
sS'nondepolarizing,agents,such'
p78822
(F1
F0.00028669724770642203
I2
I0
I2
tp78823
sS'of,hypotension,or'
p78824
(F1
F0.00014334862385321102
I0
I1
I-1
tp78825
sS'substrate,and,r-warfarin'
p78826
(F1
F0.00014334862385321102
I1
I0
I1
tp78827
sS'carbamazepine,felbatol,causes'
p78828
(F1
F0.00014334862385321102
I1
I0
I1
tp78829
sS'results,do,not'
p78830
(F1
F0.00014334862385321102
I1
I0
I1
tp78831
sS'are,all,associated'
p78832
(F1
F0.00014334862385321102
I1
I0
I1
tp78833
sS'if,you,are'
p78834
(F0.20000000000000001
F0.00014334862385321102
I3
I2
I1
tp78835
sS'protease,inhibitors,the'
p78836
(F1
F0.00014334862385321102
I0
I1
I-1
tp78837
sS'the,biotransformation,system'
p78838
(F1
F0.00028669724770642203
I2
I0
I2
tp78839
sS'drug,interaction,information'
p78840
(F1
F0.00014334862385321102
I0
I1
I-1
tp78841
sS'to,reduce,intestinal'
p78842
(F1
F0.00043004587155963305
I3
I0
I3
tp78843
sS'of,competitive,renal'
p78844
(F1
F0.00014334862385321102
I1
I0
I1
tp78845
sS'of,to,modify'
p78846
(F1
F0.00014334862385321102
I0
I1
I-1
tp78847
sS'capsule,within,minutes'
p78848
(F1
F0.00014334862385321102
I1
I0
I1
tp78849
s.